-DOCSTART- -X- O O 6885201

Pharmacokinetics NNS N
of IN N
naproxen NN N
after IN N
oral JJ N
administration NN N
of IN N
two CD N
tablet NN N
formulations NNS N
in IN N
healthy JJ N
volunteers NNS N
The DT N
pharmacokinetics NNS N
of IN N
two CD N
naproxen JJ N
tablet NN N
formulations NNS N
were VBD N
compared VBN N
after IN N
oral JJ N
administration NN N
The DT N
250-mg JJ N
naproxen JJ N
tablets NNS N
, , N
tablet NN N
I PRP N
from IN N
AFI NNP N
, , N
Oslo NNP N
, , N
Norway NNP N
, , N
and CC N
tablet NN N
II NNP N
Naprosyn NNP N
, , N
Astra-Syntex NNP N
, , N
were VBD N
taken VBN N
by IN N
12 CD 3_p
healthy JJ N
volunteers NNS N
in IN N
a DT N
randomized JJ N
two-period NN N
crossover NN N
study NN N
Plasma NNP N
levels NNS N
of IN N
naproxen NN N
were VBD N
measured VBN N
by IN N
a DT N
sensitive JJ N
and CC N
specific JJ N
HPLC NNP N
method NN N
The DT N
data NNS N
were VBD N
analyzed VBN N
by IN N
means NNS N
of IN N
two-way JJ N
analysis NN N
of IN N
variance NN N
to TO N
test VB N
for IN N
significant JJ N
differences NNS N
between IN N
tablet NN N
formulation NN N
and CC N
differences NNS N
between IN N
the DT N
first JJ N
and CC N
second JJ N
trial NN N
periods NNS N
Rapid JJ N
absorption NN N
, , N
with IN N
most JJS N
Cmax NNP N
values NNS N
from IN N
50-60 JJ N
micrograms/ml NN N
reached VBD N
within IN N
1.5-3 JJ N
h NN N
, , N
was VBD N
found VBN N
for IN N
both DT N
tablet JJ N
formulations NNS N
No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
rate NN N
and CC N
extent NN N
of IN N
absorption NN N
between IN N
the DT N
two CD N
formulations NNS N
: : N
the DT N
relative JJ N
bioavailability NN N
of IN N
tablet NN N
I PRP N
compared VBN N
to TO N
tablet VB N
II NNP N
was VBD N
1.05 CD N
+/- JJ N
0.21 CD N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
The DT N
naproxen JJ N
concentration NN N
2 CD N
h NN N
after IN N
ingestion NN N
and CC N
the DT N
Cmax NNP N
were VBD N
higher JJR N
on IN N
the DT N
second JJ N
occasion NN N
, , N
regardless RB N
of IN N
preparation NN N
, , N
suggesting VBG N
that IN N
the DT N
subjects NNS N
were VBD N
clinically RB N
different JJ N
on IN N
the DT N
two CD N
occasions NNS N
-DOCSTART- -X- O O 23838727

The DT N
impact NN N
of IN N
parent-delivered JJ N
intervention NN N
on IN N
parents NNS N
of IN N
very RB N
young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
This DT N
study NN N
investigated VBD N
the DT N
impact NN N
of IN N
a DT N
parent-coaching JJ N
intervention NN N
based VBN N
on IN N
the DT N
Early JJ N
Start NNP N
Denver NNP N
Model NNP N
( ( N
P-ESDM NNP N
) ) N
on IN N
parenting-related JJ N
stress NN N
and CC N
sense NN N
of IN N
competence NN N
This DT N
was VBD N
part NN N
of IN N
a DT N
multisite NN N
, , N
randomized VBN N
trial NN N
comparing VBG N
P-ESDM NNP N
( ( N
n JJ N
= NNP N
49 CD 3_p
) ) N
with IN N
community NN N
intervention NN N
( ( N
n JJ N
= NNP N
49 CD 3_p
) ) N
for IN N
children NNS 1_p
aged VBN 1_p
12 CD 1_p
and CC 1_p
24 CD 1_p
months NNS 1_p
The DT N
P-ESDM NNP N
group NN N
reported VBD N
no DT N
increase NN N
in IN N
parenting VBG N
stress NN N
, , N
whereas IN N
the DT N
Community NNP N
group NN N
experienced VBD N
an DT N
increase NN N
over IN N
the DT N
same JJ N
3-month JJ N
period NN N
Parental JJ N
sense NN N
of IN N
competence NN N
did VBD N
not RB N
differ VB N
Number NNP N
of IN N
negative JJ N
life NN N
events NNS N
was VBD N
a DT N
significant JJ N
predictor NN N
of IN N
parenting VBG N
stress NN N
and CC N
sense NN N
of IN N
competence NN N
across IN N
both DT N
groups NNS N
This DT N
suggests VBZ N
that IN N
a DT N
parent-coaching JJ N
intervention NN N
may MD N
help VB N
maintain VB N
parental JJ N
adjustment NN N
directly RB N
after IN N
a DT N
child NN N
is VBZ N
diagnosed VBN N
with IN N
ASD NNP N
-DOCSTART- -X- O O 10832772

Secretin NNP N
and CC N
autism NN N
: : N
a DT N
two-part JJ N
clinical JJ N
investigation NN N
Recent JJ N
anecdotal JJ N
reports NNS N
have VBP N
touted VBN N
the DT N
gastrointestinal NN N
( ( N
GI NNP N
) ) N
hormone NN N
secretin NN N
as IN N
a DT N
treatment NN N
modality NN N
for IN N
autism NN N
, , N
though IN N
there EX N
is VBZ N
little JJ N
clinical JJ N
evidence NN N
or CC N
literature NN N
to TO N
support VB N
its PRP$ N
viability NN N
We PRP N
undertook VBD N
a DT N
two-part JJ N
clinical JJ N
trial NN N
to TO N
investigate VB N
these DT N
claims NNS N
Fifty-six JJ 3_p
patients NNS N
( ( N
49 CD 3_p
boys NNS 4_p
, , N
7 CD 3_p
girls NNS 4_p
, , N
mean JJ 1_p
age NN 1_p
= VBD 1_p
6.4 CD 1_p
years NNS 1_p
, , 1_p
SD NNP 1_p
= NNP 1_p
2.7 CD 1_p
) ) N
enrolled VBN N
in IN N
an DT N
open-label JJ N
trial NN N
of IN N
secretin NN N
, , N
during IN N
which WDT N
they PRP N
received VBD N
one CD N
injection NN N
of IN N
the DT N
hormone NN N
( ( N
2 CD N
IU/kg NNP N
) ) N
All DT N
subjects NNS N
were VBD N
evaluated VBN N
by IN N
their PRP$ N
parents NNS N
at IN N
baseline NN N
and CC N
follow-up JJ N
visits NNS N
( ( N
3-6 JJ N
weeks NNS N
later RB N
, , N
M NNP N
= NNP N
3.7 CD N
, , N
SD NNP N
= VBZ N
1.4 CD N
weeks NNS N
) ) N
with IN N
Childhood NNP N
Autism NNP N
Rating NNP N
Scales NNP N
( ( N
CARS NNP N
) ) N
Thirty-four JJ 3_p
patients NNS N
were VBD N
labeled VBN N
with IN N
Pervasive NNP 4_p
Developmental NNP 4_p
Disorder NNP 4_p
Not RB N
Otherwise NNP N
Specified NNP N
, , N
and CC N
22 CD 3_p
met VBD N
diagnostic JJ N
criteria NNS N
for IN N
Autistic JJ 4_p
Disorder NNP 4_p
Forty-five JJ 3_p
patients NNS N
were VBD N
concurrently RB N
on IN N
other JJ N
drug NN 4_p
treatments NNS 4_p
At IN N
follow-up NN N
, , N
some DT N
reported VBD N
minimal JJ N
but CC N
potentially RB N
significant JJ N
improvements NNS N
including VBG N
changes NNS N
in IN N
GI NNP N
symptoms NNS N
, , N
expressive JJ N
and/or NN N
receptive JJ N
language NN N
function NN N
, , N
and CC N
improved JJ N
awareness NN N
and CC N
social JJ N
interactions NNS N
No DT N
adverse JJ N
effects NNS N
were VBD N
reported VBN N
or CC N
observed VBN N
Subsequently NNP N
, , N
17 CD N
of IN N
the DT N
most RBS N
responsive JJ N
patients NNS N
from IN N
Study NNP N
1 CD N
began VBD N
a DT N
double-blind JJ N
trial NN N
that WDT N
also RB N
included VBD N
8 CD N
newly RB N
enrolled VBN N
patients NNS N
Patients NNS N
in IN N
this DT N
second JJ N
study NN N
were VBD N
alternatively RB N
entered VBN N
into IN N
one CD N
of IN N
two CD N
groups NNS N
and CC N
received VBD N
injections NNS N
of IN N
secretin NN N
or CC N
placebo NN N
with IN N
crossover NN N
at IN N
4 CD N
weeks NNS N
Patients NNS N
from IN N
Study NNP N
1 CD N
entered VBD N
into IN N
Study NNP N
2 CD N
at IN N
an DT N
average NN N
of IN N
6.5 CD N
( ( N
SD NNP N
= NNP N
0.8 CD N
) ) N
weeks NNS N
after IN N
beginning VBG N
Study NNP N
1 CD N
Results NNS N
of IN N
both DT N
inquiries NNS N
indicate VBP N
that IN N
although IN N
treatment NN N
with IN N
secretin NN N
was VBD N
reported VBN N
to TO N
cause VB N
transient JJ N
changes NNS N
in IN N
speech NN N
and CC N
behavior NN N
in IN N
some DT N
children NNS N
, , N
overall JJ N
it PRP N
produced VBD N
few JJ N
clinically RB N
meaningful JJ N
changes NNS N
when WRB N
compared VBN N
to TO N
children NNS N
given VBN N
placebo JJ N
injections NNS N
-DOCSTART- -X- O O 8222739

A DT N
double-blind JJ N
comparison NN N
of IN N
oral JJ N
ketoprofen NN N
'controlled VBD N
release NN N
' '' N
and CC N
indomethacin JJ N
suppository NN N
in IN N
the DT N
treatment NN N
of IN N
rheumatoid JJ N
arthritis NN N
with IN N
special JJ N
regard NN N
to TO N
morning NN N
stiffness NN N
and CC N
pain NN N
on IN N
awakening VBG N
A DT N
double-blind JJ N
, , N
double-dummy JJ N
, , N
crossover NN N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
8 CD N
centres NNS N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
'controlled-release NNP N
' POS N
ketoprofen NN N
tablets NNS N
( ( N
200 CD N
mg NN N
) ) N
with IN N
that DT N
of IN N
indomethacin NN N
suppositories NNS N
( ( N
100 CD N
mg NN N
) ) N
in IN N
out-patients NNS 4_p
with IN 4_p
definite NN 4_p
or CC 4_p
classical JJ 4_p
rheumatoid NN 4_p
arthritis NN 4_p
Patients NNS N
were VBD N
allocated VBN N
at IN N
random NN N
to TO N
receive VB N
a DT N
daily JJ N
bedtime NN N
dose NN N
of IN N
either CC N
1 CD N
ketoprofen JJ N
tablet NN N
or CC N
1 CD N
indomethacin JJ N
suppository NN N
plus CC N
the DT N
dummy NN N
of IN N
the DT N
other JJ N
formulation NN N
for IN N
a DT N
period NN N
of IN N
3 CD N
weeks NNS N
They PRP N
were VBD N
then RB N
crossed VBN N
over IN N
to TO N
the DT N
alternative JJ N
treatment NN N
for IN N
a DT N
further JJ N
3 CD N
weeks NNS N
Daily JJ N
diary JJ N
records NNS N
were VBD N
kept VBN N
by IN N
patients NNS N
of IN N
the DT N
number NN N
of IN N
night-time JJ N
awakenings NNS N
due JJ N
to TO N
pain VB N
, , N
pain VB N
severity NN N
at IN N
awakening VBG N
in IN N
the DT N
morning NN N
and CC N
the DT N
duration NN N
of IN N
early JJ N
morning NN N
stiffness NN N
Treatment NNP N
efficacy NN N
was VBD N
also RB N
assessed VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
trial NN N
period NN N
by IN N
means NNS N
of IN N
an DT N
articular JJ N
index NN N
and CC N
by IN N
physician NN N
's POS N
and CC N
patient NN N
's POS N
overall JJ N
evaluation NN N
of IN N
response NN N
Adverse JJ N
effects NNS N
spontaneously RB N
mentioned VBN N
by IN N
the DT N
patients NNS N
or CC N
elicited VBN N
by IN N
direct JJ N
questioning VBG N
using VBG N
a DT N
symptom JJ N
check-list NN N
were VBD N
recorded VBN N
Statistical JJ N
analysis NN N
of IN N
the DT N
results NNS N
from IN N
83 CD N
evaluable JJ N
patients NNS N
showed VBD N
that IN N
the DT N
'controlled-release NNP N
' POS N
tablet NN N
formulation NN N
of IN N
200 CD N
mg NNS N
ketoprofen NN N
was VBD N
equally RB N
as RB N
effective JJ N
as IN N
the DT N
100 CD N
mg NN N
indomethacin NN N
suppository NN N
in IN N
the DT N
treatment NN N
of IN N
rheumatoid NN N
arthritis NN N
, , N
especially RB N
with IN N
regard NN N
to TO N
pain VB N
at IN N
awakening NN N
and CC N
morning NN N
stiffness NN N
Side-effects NNS N
in IN N
both DT N
groups NNS N
were VBD N
those DT N
commonly JJ N
seen VBN N
with IN N
non-steroidal JJ N
anti-inflammatory JJ N
drugs NNS N
and CC N
, , N
as IN N
expected VBN N
, , N
gastro-intestinal JJ N
and CC N
CNS NNP N
disturbances NNS N
predominated VBD N
Overall JJ N
, , N
side-effects NNS N
were VBD N
fewer JJR N
with IN N
ketoprofen NN N
than IN N
with IN N
indomethacin NN N
-DOCSTART- -X- O O 8159300

Cyclosporin NNP N
versus NN N
cyclophosphamide NN N
for IN N
patients NNS N
with IN N
steroid-dependent JJ 4_p
and CC 4_p
frequently RB 4_p
relapsing VBG 4_p
idiopathic JJ 4_p
nephrotic JJ 4_p
syndrome NN 4_p
: : N
a DT N
multicentre NN N
randomized VBN N
controlled VBN N
trial NN N
OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
( ( N
maintenance NN N
of IN N
remission NN N
) ) N
, , N
safety NN N
and CC N
tolerability NN N
of IN N
cyclosporin NN N
( ( N
CsA NNP N
) ) N
with IN N
those DT N
of IN N
cyclophosphamide NN N
in IN N
patients NNS N
with IN N
steroid-dependent JJ 4_p
or CC 4_p
frequently RB 4_p
relapsing VBG 4_p
nephrotic JJ 4_p
syndrome NN 4_p
( ( N
NS NNP 4_p
) ) N
DESIGN NNP N
Open NNP N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
multicentre FW N
, , N
controlled VBD N
study NN N
for IN N
parallel JJ N
groups NNS N
, , N
stratified VBN N
for IN N
adults NNS 1_p
and CC 1_p
children NNS 1_p
The DT N
setting NN N
was VBD N
in IN N
nephrological JJ N
departments NNS N
in IN N
Italy NNP N
SUBJECTS NNP N
AND CC N
INTERVENTIONS NNP N
Seventy-three JJ 3_p
patients NNS N
with IN 4_p
steroid-sensitive JJ 4_p
idiopathic JJ 4_p
NS NNP 4_p
admitted VBD N
to TO N
the DT N
study NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
cyclophosphamide VB N
( ( N
2.5 CD N
mg/kg/day NN N
) ) N
for IN N
8 CD N
weeks NNS N
or CC N
CsA NNP N
( ( N
5 CD N
mg/kg/day NN N
in IN N
adults NNS N
, , N
6 CD N
mg/kg/day NN N
in IN N
children NNS N
) ) N
for IN N
9 CD N
months NNS N
, , N
tapered VBD N
off RP N
by IN N
25 CD N
% NN N
every DT N
month NN N
until IN N
complete JJ N
discontinuation NN N
at IN N
month NN N
12 CD N
Seven CD N
patients NNS N
lost VBN N
to TO N
follow VB N
up RP N
were VBD N
not RB N
considered VBN N
in IN N
the DT N
analysis NN N
The DT N
remaining VBG N
66 CD N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
3-24 JJ N
months NNS N
after IN N
randomization NN N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Relapse-free NNP N
survival NN N
; : N
number NN N
of IN N
N.S NNP N
relapses/patient/year NN N
; : N
cumulative JJ N
dose NN N
of IN N
prednisone/patient NN N
; : N
laboratory JJ N
investigations NNS N
( ( N
kidney NN N
and CC N
liver NN N
functions NNS N
, , N
haematological JJ N
parameters NNS N
) ) N
; : N
incidence NN N
of IN N
adverse JJ N
events NNS N
RESULTS NNP N
At IN N
month NN N
9 CD N
, , N
26 CD N
of IN N
35 CD N
CsA-treated JJ N
patients NNS N
were VBD N
still RB N
in IN N
complete JJ N
remission NN N
and CC N
a DT N
further JJ N
five CD N
patients NNS N
were VBD N
in IN N
partial JJ N
remission NN N
; : N
18 CD N
of IN N
28 CD N
cyclophosphamide-treated JJ N
patients NNS N
were VBD N
in IN N
complete JJ N
remission NN N
, , N
and CC N
one CD N
in IN N
partial JJ N
remission NN N
( ( N
P NNP N
= NNP N
NS NNP N
) ) N
No DT N
difference NN N
between IN N
adults NNS N
and CC N
children NNS N
was VBD N
seen VBN N
with IN N
either DT N
treatment NN N
The DT N
risk NN N
of IN N
relapse NN N
was VBD N
similar JJ N
between IN N
frequent JJ N
relapsers NNS N
( ( N
19 CD N
of IN N
22 CD N
) ) N
and CC N
steroid-dependent JJ N
patients NNS N
( ( N
8 CD N
of IN N
14 CD N
) ) N
given VBN N
CsA NNP N
, , N
and CC N
those DT N
given VBN N
cyclophosphamide NN N
( ( N
5 CD N
of IN N
15 CD N
and CC N
6 CD N
of IN N
15 CD N
) ) N
The DT N
mean JJ N
number NN N
of IN N
relapses NNS N
per IN N
year NN N
and CC N
the DT N
mean NN N
dose NN N
of IN N
prednisone NN N
per IN N
year NN N
were VBD N
significantly RB N
less JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
both DT N
groups NNS N
for IN N
the DT N
experimental JJ N
year NN N
than IN N
for IN N
the DT N
year NN N
before IN N
randomization NN N
At IN N
2 CD N
years NNS N
, , N
25 CD N
% NN N
of IN N
the DT N
patients NNS N
given VBN N
CsA NNP N
( ( N
50 CD N
% NN N
adults NNS N
and CC N
20 CD N
% NN N
children NNS N
) ) N
and CC N
63 CD N
% NN N
of IN N
those DT N
given VBN N
cyclophosphamide NN N
( ( N
40 CD N
% NN N
adults NNS N
and CC N
68 CD N
% NN N
children NNS N
) ) N
had VBD N
not RB N
had VBN N
any DT N
relapse NN N
of IN N
NS NNP N
Tolerance NN N
to TO N
the DT N
two CD N
drugs NNS N
was VBD N
generally RB N
good JJ N
The DT N
CsA-related JJ N
side-effects NNS N
were VBD N
mild JJ N
and CC N
disappeared VBD N
after IN N
drug NN N
discontinuation NN N
CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
that IN N
both DT N
treatments NNS N
are VBP N
effective JJ N
and CC N
well RB N
tolerated VBD N
; : N
more RBR N
patients NNS N
given VBN N
cyclophosphamide JJ N
had VBD N
stable JJ N
remissions NNS N
-DOCSTART- -X- O O 3825543

Parietal NNP N
cell NN N
density NN N
in IN N
duodenal JJ 4_p
ulcer NN 4_p
patients NNS N
after IN N
short-term JJ N
treatment NN N
with IN N
cimetidine NN N
and CC N
antacids NNS N
In IN N
a DT N
prospective JJ N
study NN N
, , N
20 CD N
patients NNS N
with IN N
endoscopically RB 4_p
proven JJ 4_p
duodenal JJ 4_p
ulcers NNS 4_p
were VBD N
randomised VBN N
to TO N
be VB N
treated VBN N
with IN N
cimetidine NN N
1 CD N
g JJ N
daily JJ N
or CC N
with IN N
antacids NNS N
350 CD N
mmol JJ N
daily RB N
The DT N
duration NN N
of IN N
treatment NN N
was VBD N
30 CD N
days NNS N
, , N
but CC N
this DT N
was VBD N
extended VBN N
to TO N
three CD N
months NNS N
in IN N
3 CD N
patients NNS N
in IN N
the DT N
cimetidine NN N
group NN N
and CC N
4 CD N
patients NNS N
in IN N
the DT N
antacid NN N
group NN N
A DT N
morphological JJ N
study NN N
of IN N
biopsies NNS N
taken VBN N
via IN N
a DT N
gastroscope NN N
from IN N
the DT N
corpus NN N
mucosa NN N
showed VBD N
no DT N
change NN N
in IN N
mucosal NN N
height NN N
, , N
parietal JJ N
cell NN N
density NN N
per IN N
unit NN N
volume NN N
or CC N
changes NNS N
in IN N
cellular JJ N
infiltration NN N
after IN N
30 CD N
and CC N
90 CD N
days NNS N
treatment NN N
in IN N
the DT N
two CD N
groups NNS N
Neither CC N
H-2 JJ N
receptor NN N
blockers NNS N
nor CC N
antacids NNS N
alter NN N
mucosal NN N
height VBD N
or CC N
parietal JJ N
cell NN N
density NN N
Treatment NNP N
was VBD N
not RB N
found VBN N
to TO N
induce VB N
gastritic JJ N
changes NNS N
in IN N
the DT N
mucosa NN N
-DOCSTART- -X- O O 3132778

[ JJ N
Total NNP N
parenteral JJ N
nutrition NN N
in IN N
colon NN 4_p
surgery NN 4_p
] NN 4_p
-DOCSTART- -X- O O 15307010

Once-daily JJ N
versus NN N
twice-daily RB N
lamivudine NN N
, , N
in IN N
combination NN N
with IN N
zidovudine NN N
and CC N
efavirenz NN N
, , N
for IN N
the DT N
treatment NN N
of IN N
antiretroviral-naive JJ 4_p
adults NNS 1_p
with IN N
HIV NNP 4_p
infection NN 4_p
: : N
a DT N
randomized JJ N
equivalence NN N
trial NN N
A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
controlled VBN N
, , N
multicenter RBR N
trial NN N
was VBD N
conducted VBN N
that IN N
involved VBD N
554 CD 3_p
antiretroviral-naive JJ N
human JJ 4_p
immunodeficiency NN 4_p
virus-infected JJ 4_p
adults NNS 1_p
( ( N
plasma JJ N
HIV NNP N
type NN N
1 CD N
[ JJ N
HIV-1 NNP N
] NNP N
RNA NNP N
level NN N
, , N
> NNP N
or=400 VBZ N
copies/mL NN N
; : N
CD4 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
, , N
> VBZ N
100 CD N
cells/mm NN N
( ( N
3 CD N
) ) N
) ) N
and CC N
compared VBN N
a DT N
300-mg JJ N
once-daily JJ N
( ( N
q.d JJ N
) ) N
regimen NNS N
of IN N
lamivudine NN N
( ( N
3TC CD N
) ) N
versus NN N
a DT N
150-mg JJ N
twice-daily JJ N
( ( N
b.i.d NN N
) ) N
regimen NNS N
of IN N
3TC CD N
, , N
combined VBN N
with IN N
zidovudine NN N
( ( N
300 CD N
mg NN N
b.i.d NN N
) ) N
and CC N
efavirenz $ N
( ( N
600 CD N
mg NN N
q.d NN N
) ) N
, , N
during IN N
a DT N
48-week JJ N
period NN N
Treatments NNS N
were VBD N
considered VBN N
equivalent JJ N
if IN N
the DT N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
for IN N
the DT N
difference NN N
in IN N
proportions NNS N
of IN N
patients NNS N
achieving VBG N
an DT N
HIV-1 JJ N
RNA NNP N
level NN N
of IN N
< $ N
400 CD N
copies/mL NN N
was VBD N
within IN N
the DT N
bound NN N
of IN N
-12 NN N
% NN N
to TO N
12 CD N
% NN N
At IN N
week NN N
48 CD N
of IN N
the DT N
study NN N
, , N
an DT N
intent-to-treat JJ N
analysis NN N
in IN N
which WDT N
patients NNS N
with IN N
missing VBG N
data NNS N
were VBD N
considered VBN N
to TO N
have VB N
experienced VBN N
treatment NN N
failure NN N
showed VBD N
that IN N
the DT N
3TC CD N
q.d NN N
and CC N
3TC CD N
b.i.d NN N
regimens NNS N
were VBD N
equivalent JJ N
( ( N
HIV-1 NNP N
RNA NNP N
level NN N
< VBD N
400 CD N
copies/mL NN N
, , N
178 CD N
[ JJ N
64 CD N
% NN N
] NN N
of IN N
278 CD N
vs. FW N
174 CD N
[ $ N
63 CD N
% NN N
] NN N
of IN N
276 CD N
; : N
treatment NN N
difference NN N
, , N
1 CD N
% NN N
[ JJ N
95 CD N
% NN N
CI NNP N
, , N
-7.1 NNP N
% NN N
to TO N
8.9 CD N
% NN N
] NN N
; : N
HIV-1 NNP N
RNA NNP N
level NN N
< VBD N
50 CD N
copies/mL NN N
, , N
165 CD N
[ JJ N
59 CD N
% NN N
] NN N
of IN N
278 CD N
vs. FW N
168 CD N
[ $ N
61 CD N
% NN N
] NN N
of IN N
276 CD N
; : N
treatment NN N
difference NN N
, , N
1.7 CD N
% NN N
[ JJ N
95 CD N
% NN N
CI NNP N
, , N
-9.7 NNP N
% NN N
to TO N
6.6 CD N
% NN N
] NN N
) ) N
Median JJ N
increase NN N
above IN N
baseline NN N
in IN N
CD4 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
was VBD N
similar JJ N
( ( N
q.d JJ N
group NN N
, , N
+144 NNP N
cells/mm NN N
( ( N
3 CD N
) ) N
; : N
b.i.d NN N
group NN N
, , N
+146 NNP N
cells/mm NN N
( ( N
3 CD N
) ) N
) ) N
, , N
and CC N
the DT N
incidences NNS N
of IN N
adverse JJ N
events NNS N
, , N
disease NN N
progression NN N
, , N
and CC N
HIV-associated JJ N
conditions NNS N
were VBD N
comparable JJ N
-DOCSTART- -X- O O 11228756

Effect NN N
of IN N
acarbose NN N
on IN N
additional JJ N
insulin NN N
therapy NN N
in IN N
type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS N
with IN N
late JJ 4_p
failure NN 4_p
of IN N
sulphonylurea JJ 4_p
therapy NN 4_p
AIM VB N
The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
acarbose NN N
on IN N
insulin NN N
requirements NNS N
and CC N
glycaemic JJ N
control NN N
in IN N
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
receiving VBG N
exogenous JJ 4_p
insulin NN 4_p
due JJ N
to TO N
secondary JJ N
failure NN 4_p
of IN N
maximum NN N
dose JJ N
sulphonylurea JJ 4_p
therapy NN 4_p
METHODS VB N
A DT N
single-centre JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
study NN N
was VBD N
performed VBN N
in IN N
48 CD 3_p
type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS N
with IN N
late-term JJ 4_p
failure NN 4_p
following VBG N
at IN N
least JJS N
3 CD N
years NNS N
of IN N
sulphonylurea JJ 4_p
therapy NN 4_p
requiring VBG N
additional JJ N
insulin NN 4_p
therapy NN 4_p
to TO N
determine VB N
the DT N
impact NN N
of IN N
acarbose NN N
on IN N
glycaemic JJ N
control NN N
and CC N
insulin NN N
requirements NNS N
The DT N
primary JJ N
end NN N
points NNS N
were VBD N
glycaemic JJ N
response NN N
rate NN N
( ( N
responders NNS N
being VBG N
predefined VBN N
as IN N
patients NNS N
who WP N
achieve VBP N
a DT N
decrease NN N
in IN N
HbA1c NNP N
to TO N
less JJR N
than IN N
8 CD N
% NN N
or CC N
a DT N
reduction NN N
by IN N
at IN N
least JJS N
15 CD N
% NN N
as IN N
compared VBN N
to TO N
the DT N
baseline NN N
values NNS N
) ) N
and CC N
the DT N
daily JJ N
insulin NN N
dose NN N
at IN N
6 CD N
months NNS N
Secondary JJ N
parameters NNS N
assessed VBD N
included VBN N
postprandial JJ N
changes NNS N
in IN N
blood NN N
glucose NN N
, , N
serum JJ N
insulin NN N
and CC N
C-peptide NNP N
during IN N
the DT N
treatment NN N
period NN N
RESULTS CC N
There EX N
were VBD N
significantly RB N
more JJR N
responders NNS N
in IN N
the DT N
acarbose-treated JJ N
group NN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
20/24 CD N
patients NNS N
vs. FW N
10/19 CD N
patients NNS N
; : N
p VB N
< $ N
0.05 CD N
) ) N
The DT N
mean JJ N
daily JJ N
insulin NN N
dose NN N
after IN N
24 CD N
weeks NNS N
of IN N
treatment NN N
was VBD N
16.4 CD N
+/- JJ N
10.1 CD N
IU NNP N
in IN N
the DT N
acarbose JJ N
group NN N
and CC N
22.4 CD N
+/- JJ N
12.2 CD N
IU NNP N
in IN N
the DT N
placebo NN N
group NN N
( ( N
mean JJ N
+/- JJ N
s.d NN N
; : N
p JJ N
< NNP N
0.07 CD N
) ) N
Postprandial JJ N
increases NNS N
in IN N
blood NN N
glucose NN N
, , N
insulin NN N
and CC N
C-peptide NNP N
were VBD N
consistently RB N
lower JJR N
in IN N
the DT N
acarbose-treated JJ N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
For IN N
example NN N
, , N
the DT N
mean JJ N
increase NN N
in IN N
2-h JJ N
postprandial JJ N
serum NN N
insulin NN N
remained VBD N
almost RB N
unchanged JJ N
in IN N
the DT N
acarbose JJ N
group NN N
at IN N
the DT N
end NN N
of IN N
24 CD N
weeks NNS N
of IN N
treatment NN N
compared VBN N
to TO N
an DT N
increase NN N
to TO N
43 CD N
+/- JJ N
29 CD N
microU/ml NN N
( ( N
mean JJ N
+/- JJ N
s.d NN N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
period NN N
for IN N
the DT N
placebo NN N
group NN N
CONCLUSIONS VB N
The DT N
findings NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
the DT N
addition NN N
of IN N
acarbose NN N
to TO N
sulphonylurea/insulin VB N
combination NN N
therapy NN N
can MD N
improve VB N
glycaemic JJ N
control NN N
in IN N
type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS N
Acarbose NNP N
may MD N
also RB N
reduce VB N
insulin NN N
resistance NN N
and CC N
hyperinsulinaemia NN N
-DOCSTART- -X- O O 21740578

The DT N
IDvIP NNP N
trial NN N
: : N
a DT N
two-centre JJ N
randomised JJ N
double-blind NN N
controlled VBD N
trial NN N
comparing VBG N
intramuscular JJ N
diamorphine NN N
and CC N
intramuscular JJ N
pethidine NN N
for IN N
labour JJ N
analgesia NN N
BACKGROUND NNP N
Intramuscular NNP N
pethidine NN N
is VBZ N
routinely RB N
used VBN N
throughout IN N
the DT N
UK NNP N
for IN N
labour JJ N
analgesia NN N
Studies NNS N
have VBP N
suggested VBN N
that IN N
pethidine NN N
provides VBZ N
little JJ N
pain NN N
relief NN N
in IN N
labour NN N
and CC N
has VBZ N
a DT N
number NN N
of IN N
side JJ N
effects NNS N
affecting VBG N
mother NN N
and CC N
neonate NN N
It PRP N
can MD N
cause VB N
nausea NN N
, , N
vomiting VBG N
and CC N
dysphoria NNS N
in IN N
mothers NNS N
and CC N
can MD N
cause VB N
reduced VBN N
fetal JJ N
heart NN N
rate NN N
variability NN N
and CC N
accelerations NNS N
Neonatal JJ N
effects NNS N
include VBP N
respiratory JJ N
depression NN N
and CC N
impaired JJ N
feeding NN N
There EX N
are VBP N
few JJ N
large JJ N
studies NNS N
comparing VBG N
the DT N
relative JJ N
side NN N
effects NNS N
and CC N
efficacy NN N
of IN N
different JJ N
opioids NNS N
in IN N
labour NN N
A DT N
small JJ N
trial NN N
comparing VBG N
intramuscular JJ N
pethidine NN N
with IN N
diamorphine NN N
, , N
showed VBD N
diamorphine NN N
to TO N
have VB N
some DT N
benefits NNS N
over IN N
pethidine NN N
when WRB N
used VBN N
for IN N
labour JJ N
analgesia NN N
but CC N
the DT N
study NN N
did VBD N
not RB N
investigate VB N
the DT N
adverse JJ N
effects NNS N
of IN N
either DT N
opioid NN N
METHODS NNP N
The DT N
Intramuscular NNP N
Diamorphine NNP N
versus IN N
Intramuscular NNP N
Pethidine NNP N
( ( N
IDvIP NNP N
) ) N
trial NN N
is VBZ N
a DT N
randomised JJ N
double-blind NN N
two CD N
centre NN N
controlled VBD N
trial NN N
comparing VBG N
intramuscular JJ N
diamorphine NN N
and CC N
pethidine NN N
regarding VBG N
their PRP$ N
analgesic JJ N
efficacy NN N
in IN N
labour NN N
and CC N
their PRP$ N
side NN N
effects NNS N
in IN N
mother NN N
, , N
fetus NN N
and CC N
neonate NN N
Information NN N
about IN N
the DT N
trial NN N
will MD N
be VB N
provided VBN N
to TO N
women NNS N
in IN N
the DT N
antenatal JJ N
period NN N
or CC N
in IN N
early JJ N
labour NN N
Consent NN N
and CC N
recruitment NN N
to TO N
the DT N
trial NN N
will MD N
be VB N
obtained VBN N
when WRB N
the DT N
mother NN N
requests VBZ N
opioid JJ N
analgesia NN N
The DT N
sample NN N
size NN N
requirement NN N
is VBZ N
406 CD 4_p
women NNS 4_p
with IN 4_p
data NNS 4_p
on IN 4_p
primary JJ 4_p
outcomes NNS 4_p
The DT N
maternal JJ N
primary NN N
outcomes NNS N
are VBP N
pain JJ N
relief NN N
during IN N
the DT N
first JJ N
3 CD N
hours NNS N
after IN N
trial NN N
analgesia NN N
and CC N
specifically RB N
pain VBP N
relief NN N
after IN N
60 CD N
minutes NNS N
The DT N
neonatal JJ N
primary JJ N
outcomes NNS N
are VBP N
need VBN N
for IN N
resuscitation NN N
and CC N
Apgar NNP N
Score NNP N
< VBD N
7 CD N
at IN N
1 CD N
minute NN N
The DT N
secondary JJ N
outcomes NNS N
are VBP N
an DT N
additional JJ N
measure NN N
of IN N
pain NN N
relief NN N
, , N
maternal JJ N
sedation NN N
, , N
nausea NN N
and CC N
vomiting NN N
, , N
maternal JJ N
oxygen NN N
saturation NN N
, , N
satisfaction NN N
with IN N
analgesia NN N
, , N
whether IN N
method NN N
of IN N
analgesia NN N
would MD N
be VB N
used VBN N
again RB N
, , N
use NN N
of IN N
Entonox NNP N
, , N
umbilical JJ N
arterial NN N
and CC N
venous JJ N
pH NN N
, , N
fetal JJ N
heart NN N
rate NN N
, , N
meconium NN N
staining NN N
, , N
time NN N
from IN N
delivery NN N
to TO N
first JJ N
breath NN N
, , N
Apgar NNP N
scores VBZ N
at IN N
5 CD N
mins NNS N
, , N
naloxone JJ N
requirement NN N
, , N
transfer NN N
to TO N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
, , N
neonatal JJ N
haemoglobin NN N
oxygen NN N
saturation NN N
at IN N
30 CD N
, , N
60 CD N
, , N
90 CD N
, , N
and CC N
120 CD N
mins NNS N
after IN N
delivery NN N
, , N
and CC N
neonatal JJ N
sedation NN N
and CC N
feeding VBG N
behaviour NN N
during IN N
first JJ N
2 CD N
hours NNS N
DISCUSSION NNP N
If IN N
the DT N
trial NN N
demonstrates VBZ N
that IN N
diamorphine NN N
provides VBZ N
better RBR N
analgesia NN N
with IN N
fewer JJR N
side NN N
effects NNS N
in IN N
mother NN N
and CC N
neonate NN N
this DT N
could MD N
lead VB N
to TO N
a DT N
change NN N
in IN N
national JJ N
practice NN N
and CC N
result NN N
in IN N
diamorphine NN N
becoming VBG N
the DT N
preferred JJ N
intramuscular JJ N
opioid NN N
for IN N
analgesia NN N
in IN N
labour NN N
TRIAL NNP N
REGISTRATION NNP N
ISRCTN14898678Eudra NNP N
No NNP N
: : N
2006-003250-18 JJ N
, , N
REC NNP N
Reference NNP N
No NNP N
: : N
06/Q1702/95 CD N
, , N
MHRA NNP N
Authorisation NNP N
No NNP N
: : N
1443/0001/001-0001 JJ N
, , N
NIHR NNP N
UKCRN NNP N
reference NN N
6895 CD N
, , N
RfPB NNP N
grant NN N
PB-PG-0407-13170_IR5 NNP N
-DOCSTART- -X- O O 6108264

A DT N
double JJ N
blind JJ N
trial NN N
of IN N
terfenadine NN N
and CC N
placebo NN N
in IN N
hay NN N
fever NN N
using VBG N
a DT N
substitution NN N
technique NN N
for IN N
non-responders NNS N
A DT N
double-blind JJ N
study NN N
of IN N
terfenadine NN N
and CC N
placebo NN N
in IN N
110 CD 3_p
patients NNS N
suffering VBG N
from IN N
hay NN 4_p
fever NN 4_p
( ( N
confirmed VBN N
by IN N
skin NN N
tests NNS N
) ) N
was VBD N
conducted VBN N
A DT N
novel JJ N
technique NN N
was VBD N
applied VBN N
using VBG N
an DT N
escape NN N
envelope NN N
containing VBG N
a DT N
reference NN N
drug NN N
which WDT N
could MD N
be VB N
taken VBN N
under IN N
controlled JJ N
conditions NNS N
if IN N
, , N
after IN N
48 CD N
hours NNS N
, , N
the DT N
patient NN N
experienced VBD N
no DT N
relief NN N
Significantly RB N
more JJR N
patients NNS N
on IN N
placebo NN N
opened VBD N
the DT N
envelope NN N
than IN N
patients NNS N
taking VBG N
the DT N
active JJ N
drug NN N
Terfenadine NNP N
was VBD N
demonstrated VBN N
to TO N
be VB N
an DT N
effective JJ N
drug NN N
in IN N
hay NN N
fever NN N
and CC N
produced VBD N
no DT N
more RBR N
drowsiness NN N
than IN N
placebo NN N
-DOCSTART- -X- O O 25912520

Effects NNS N
of IN N
the DT N
Quest NNP N
to TO N
Lava NNP N
Mountain NNP N
Computer NNP N
Game NNP N
on IN N
Dietary NNP N
and CC N
Physical NNP N
Activity NNP N
Behaviors NNP N
of IN N
Elementary NNP N
School NNP N
Children NNP 1_p
: : N
A DT N
Pilot NNP N
Group-Randomized NNP N
Controlled NNP N
Trial NNP N
BACKGROUND NNP N
Computer-based JJ N
educational JJ N
games NNS N
present VBP N
an DT N
opportunity NN N
for IN N
health NN N
education NN N
in IN N
school NN N
; : N
however RB N
, , N
their PRP$ N
feasibility NN N
in IN N
school NN N
settings NNS N
and CC N
effectiveness NN N
in IN N
changing VBG N
behavior NN N
are VBP N
poorly RB N
understood JJ N
OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
feasibility NN N
, , N
acceptability NN N
, , N
and CC N
effects NNS N
of IN N
the DT N
Quest NNP N
to TO N
Lava NNP N
Mountain NNP N
( ( N
QTLM NNP N
) ) N
computer NN N
game NN N
on IN N
dietary JJ N
behaviors NNS N
, , N
physical JJ N
activity NN N
behaviors NNS N
, , N
and CC N
psychosocial JJ N
factors NNS N
among IN N
ethnically RB N
diverse JJ N
children NNS 1_p
in IN N
Texas NNP N
DESIGN NNP N
Quasi-experimental JJ N
group-randomized JJ N
controlled VBN N
trial NN N
conducted VBN N
during IN N
the DT N
2012-2013 JJ N
school NN N
year NN N
PARTICIPANTS/SETTING CC N
A DT N
total NN N
of IN N
107 CD 3_p
children NNS 1_p
in IN N
fourth JJ N
and CC N
fifth JJ N
grade NN N
consented VBN N
There EX N
was VBD N
an DT N
attrition NN N
rate NN N
of IN N
8.8 CD N
% NN N
with IN N
a DT N
final JJ N
sample NN N
size NN N
of IN N
44 CD 3_p
children NNS 1_p
in IN N
three CD N
intervention NN N
schools NNS N
, , N
and CC N
a DT N
sample NN N
of IN N
50 CD 3_p
children NNS 1_p
in IN N
three CD N
comparison NN N
schools NNS N
Dietary NNP N
intake NN N
was VBD N
measured VBN N
using VBG N
two CD N
random JJ N
24-hour JJ N
recalls NNS N
, , N
whereas JJ N
child NN N
self-report JJ N
surveys NNS N
measured VBN N
diet JJ N
, , N
physical JJ N
activity NN N
, , N
and CC N
psychosocial JJ N
factors NNS N
before IN N
and CC N
after IN N
the DT N
intervention NN N
Process NNP N
data NN N
on IN N
QTLM NNP N
usability NN N
and CC N
back-end JJ N
server NN N
data NNS N
on IN N
QTLM NNP N
exposure NN N
and CC N
progress NN N
achieved VBN N
were VBD N
collected VBN N
INTERVENTION NNP N
QTLM NNP N
was VBD N
implemented VBN N
as IN N
part NN N
of IN N
the DT N
in-school NN N
or CC N
afterschool JJ N
program NN N
Recommended JJ N
game NN N
exposure NN N
duration NN N
was VBD N
90 CD N
min/wk NN N
for IN N
6 CD N
weeks NNS N
STATISTICAL JJ N
ANALYSIS NNP N
Analysis NNP N
of IN N
covariance NN N
or CC N
logistic JJ N
regression NN N
models NNS N
evaluated VBN N
effects NNS N
of IN N
QTLM NNP N
on IN N
diet JJ N
, , N
physical JJ N
activity NN N
, , N
and CC N
psychosocial JJ N
factors NNS N
Post NNP N
hoc JJ N
exploratory NN N
analysis NN N
examined VBD N
the DT N
changes NNS N
before IN N
and CC N
after IN N
the DT N
intervention NN N
in IN N
outcome JJ N
variables NNS N
among IN N
children NNS N
in IN N
the DT N
intervention NN N
group NN N
Significance NN N
was VBD N
set VBN N
at IN N
P NNP N
< NNP N
0.05 CD N
RESULTS NNP N
Children NNP N
played VBD N
an DT N
average NN N
of IN N
274±110 CD N
minutes NNS N
( ( N
approximately RB N
4.6 CD N
hours NNS N
) ) N
of IN N
QTLM NNP N
during IN N
the DT N
6 CD N
weeks NNS N
( ( N
51 CD N
% NN N
of IN N
recommended JJ N
dosage NN N
) ) N
Compared VBN N
with IN N
the DT N
comparison NN N
group NN N
, , N
children NNS N
in IN N
the DT N
intervention NN N
group NN N
reported VBD N
decreased JJ N
sugar NN N
consumption NN N
( ( N
P=0.021 NNP N
) ) N
and CC N
higher JJR N
nutrition/physical JJ N
activity NN N
attitudes NNS N
( ( N
P=0.041 NNP N
) ) N
pre- NN N
to TO N
postintervention NN N
There EX N
were VBD N
no DT N
significant JJ N
effects NNS N
of IN N
QTLM NNP N
on IN N
physical JJ N
activity NN N
However RB N
, , N
post NN N
hoc NN N
analysis NN N
showed VBD N
that IN N
higher JJR N
QTLM NNP N
exposure NN N
and CC N
gaming VBG N
progress NN N
was VBD N
associated VBN N
with IN N
increased JJ N
frequency NN N
of IN N
physical JJ N
activity NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
CONCLUSIONS NNP N
QTLM NNP N
has VBZ N
some DT N
promising JJ N
acceptability NN N
and CC N
initial JJ N
effects NNS N
on IN N
diet JJ N
and CC N
physical JJ N
activity NN N
behaviors NNS N
among IN N
children NNS N
in IN N
elementary JJ N
school NN N
-DOCSTART- -X- O O 10509459

Tactile NNP N
feedback NN N
is VBZ N
present JJ N
during IN N
minimally RB N
invasive JJ N
surgery NN N
BACKGROUND IN N
The DT N
applications NNS N
of IN N
minimally RB N
invasive JJ N
surgery NN N
( ( N
MIS NNP N
) ) N
and CC N
laparoscopy $ N
are VBP N
rapidly RB N
expanding VBG N
Despite IN N
this DT N
expansion NN N
, , N
our PRP$ N
understanding NN N
of IN N
the DT N
importance NN N
of IN N
haptic JJ N
feedback NN N
during IN N
laparoscopic NN N
surgery NN N
is VBZ N
incomplete JJ N
Although IN N
many JJ N
surgeons NNS N
believe VBP N
that IN N
the DT N
use NN N
of IN N
minimally RB N
invasive JJ N
techniques NNS N
eliminates VBZ N
force VBP N
feedback NN N
and CC N
tactile JJ N
sensation NN N
( ( N
haptics NNS N
) ) N
, , N
the DT N
importance NN N
of IN N
haptics NNS N
in IN N
MIS NNP N
has VBZ N
not RB N
been VBN N
fully RB N
evaluated VBN N
There EX N
is VBZ N
considerable JJ N
interest NN N
in IN N
the DT N
development NN N
of IN N
simulators NNS N
for IN N
MIS NNP N
even RB N
though IN N
the DT N
importance NN N
of IN N
force NN N
feedback NN N
remains VBZ N
poorly RB N
understood JJ N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
the DT N
ability NN N
of IN N
experienced JJ N
surgeons NNS N
to TO N
interpret VB N
haptic JJ N
feedback NN N
with IN N
respect NN N
to TO N
texture NN N
, , N
shape NN N
, , N
and CC N
consistency NN N
of IN N
an DT N
object NN N
STUDY NNP N
DESIGN NNP N
A NNP N
randomized JJ N
, , N
single-blinded JJ N
study NN N
was VBD N
designed VBN N
Twenty CD 3_p
surgeons NNS N
were VBD N
presented VBN N
objects NNS N
in IN N
a DT N
random NN N
order NN N
, , N
with IN N
participants NNS N
blinded VBN N
as IN N
to TO N
their PRP$ N
identity NN N
Inspection NN N
by IN N
direct JJ N
palpation NN N
, , N
conventional JJ N
instruments NNS N
, , N
and CC N
laparoscopic JJ N
instruments NNS N
was VBD N
performed VBN N
on IN N
all DT N
objects NNS N
Statistic JJ N
analysis NN N
of IN N
the DT N
data NN N
was VBD N
performed VBN N
using VBG N
chi-square JJ N
analysis NN N
and CC N
, , N
when WRB N
appropriate NN N
, , N
a DT N
Fischer NNP N
exact JJ N
probability NN N
test NN N
RESULTS NNP N
Direct NNP N
palpation NN N
was VBD N
associated VBN N
with IN N
the DT N
highest JJS N
accuracy NN N
for IN N
shape NN N
identification NN N
and CC N
was VBD N
superior VBN N
to TO N
both DT N
conventional JJ N
instruments NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
laparoscopic JJ N
instruments NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
Fine JJ N
texture NN N
analysis NN N
with IN N
either CC N
a DT N
conventional JJ N
instrument NN N
or CC N
a DT N
laparoscopic JJ N
instrument NN N
was VBD N
superior JJ N
to TO N
direct JJ N
palpation NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
Finally RB N
, , N
the DT N
three CD N
methods NNS N
of IN N
analysis NN N
were VBD N
comparable JJ N
for IN N
consistency NN N
analysis NN N
CONCLUSIONS NNP N
These DT N
data NNS N
indicate VBP N
that IN N
laparoscopic NN N
instruments NNS N
do VBP N
, , N
in IN N
fact NN N
, , N
provide VB N
surgeons NNS N
with IN N
haptic JJ N
feedback NN N
Interpretation NN N
of IN N
the DT N
texture NN N
, , N
shape NN N
, , N
and CC N
consistency NN N
of IN N
objects NNS N
can MD N
be VB N
performed VBN N
In IN N
some DT N
situations NNS N
, , N
laparoscopic JJ N
instruments NNS N
appear VBP N
to TO N
amplify VB N
the DT N
haptic JJ N
information NN N
available JJ N
Our PRP$ N
ongoing JJ N
work NN N
is VBZ N
directed VBN N
at IN N
further JJ N
defining VBG N
force NN N
interactions NNS N
-DOCSTART- -X- O O 23275644

A DT N
phase NN N
III NNP N
study NN N
of IN N
laparoscopy-assisted JJ N
versus NN N
open JJ N
distal JJ N
gastrectomy NN N
with IN N
nodal JJ N
dissection NN N
for IN N
clinical JJ N
stage NN N
IA/IB NNP N
gastric JJ N
Cancer NNP N
( ( N
JCOG0912 NNP N
) ) N
A DT N
Phase NNP N
III NNP N
study NN N
was VBD N
started VBN N
in IN N
Japan NNP N
to TO N
evaluate VB N
the DT N
non-inferiority NN N
of IN N
overall JJ N
survival NN N
of IN N
laparoscopy-assisted JJ N
distal JJ N
gastrectomy NN N
with IN N
open JJ 4_p
distal JJ 4_p
gastrectomy NN 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
clinical JJ 4_p
IA NNP 4_p
( ( 4_p
T1N0 NNP 4_p
) ) 4_p
or CC 4_p
IB NNP 4_p
[ NNP 4_p
T1N1 NNP 4_p
or CC N
T2 NNP 4_p
( ( 4_p
MP NNP 4_p
) ) 4_p
N0 NNP 4_p
] NNP 4_p
gastric JJ 4_p
cancer NN 4_p
This DT N
study NN N
followed VBD N
the DT N
previous JJ N
Phase NNP N
II NNP N
study NN N
to TO N
confirm VB N
the DT N
safety NN N
of IN N
laparoscopy-assisted JJ N
distal JJ N
gastrectomy NN N
( ( N
JCOG0703 NNP N
) ) N
and CC N
began VBD N
in IN N
March NNP N
2010 CD N
A DT N
total NN N
of IN N
920 CD 3_p
patients NNS 3_p
will MD N
be VB N
accrued VBN N
from IN N
33 CD N
institutions NNS N
within IN N
5 CD N
years NNS N
The DT N
primary JJ N
endpoint NN N
is VBZ N
overall JJ N
survival NN N
The DT N
secondary JJ N
endpoints NNS N
are VBP N
relapse-free JJ N
survival NN N
, , N
proportion NN N
of IN N
laparoscopy-assisted JJ N
distal JJ N
gastrectomy NN N
completion NN N
, , N
proportion NN N
of IN N
conversion NN N
to TO N
open VB N
surgery NN N
, , N
adverse JJ N
events NNS N
, , N
short-term JJ N
clinical JJ N
outcomes NNS N
, , N
postoperative JJ N
quality NN N
of IN N
life NN N
Only RB N
a DT N
credentialed JJ N
surgeon NN N
can MD N
be VB N
responsible JJ N
for IN N
both DT N
open JJ N
distal NN N
gastrectomy NN N
and CC N
laparoscopy-assisted JJ N
distal JJ N
gastrectomy NN N
-DOCSTART- -X- O O 15968406

Anti-Xa JJ N
effect NN N
of IN N
a DT N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
dalteparin NN N
) ) N
does VBZ N
not RB N
accumulate VB N
in IN N
extended JJ N
duration NN N
therapy NN N
for IN N
venous JJ 4_p
thromboembolism NN 4_p
in IN N
cancer NN 4_p
patients NNS N
Many JJ N
patients NNS N
with IN N
venous JJ 4_p
thromboembolism NN 4_p
are VBP N
being VBG N
treated VBN N
with IN N
low JJ N
molecular JJ N
weight NN N
heparin NN N
for IN N
extended JJ N
periods NNS N
of IN N
time NN N
It PRP N
is VBZ N
not RB N
certain JJ N
if IN N
it PRP N
is VBZ N
necessary JJ N
to TO N
assess VB N
anti-Xa JJ N
levels NNS N
for IN N
extended VBN N
treatment NN N
periods NNS N
This DT N
study NN N
is VBZ N
a DT N
prospective JJ N
assessment NN N
of IN N
anti-Xa JJ N
levels NNS N
in IN N
patients NNS N
on IN N
long-term JJ N
therapy NN N
for IN N
acute JJ 4_p
venous JJ 4_p
thromboembolism NN 4_p
who WP N
have VBP N
active JJ 4_p
cancer NN 4_p
Consecutive JJ N
consenting VBG N
patients NNS N
from IN N
one CD N
center NN N
in IN N
a DT N
multicenter NN N
trial NN N
that WDT N
compared VBN N
6 CD N
months NNS N
of IN N
low JJ N
molecular JJ N
weight NN N
heparin NN N
with IN N
oral JJ N
anticoagulant JJ N
therapy NN N
were VBD N
treated VBN N
with IN N
therapeutic JJ N
doses NNS N
of IN N
dalteparin NN N
( ( N
200 CD N
IU NNP N
per IN N
kilogram NN N
) ) N
subcutaneously RB N
daily JJ N
Anti-Xa JJ N
levels NNS N
were VBD N
assessed VBN N
at IN N
the DT N
end NN N
of IN N
weeks NNS N
1 CD N
and CC N
4,4-6 JJ N
hours NNS N
after IN N
injection NN N
of IN N
dalteparin NN N
Patients NNS N
were VBD N
followed VBN N
for IN N
bleeding NN N
and CC N
recurrent NN N
venous JJ N
thromboembolism NN N
There EX N
were VBD N
24 CD 3_p
patients NNS 3_p
who WP N
had VBD N
anti-Xa JJ 4_p
levels NNS 4_p
measured VBN N
at IN N
weeks NNS N
1 CD N
and CC N
4 CD N
Two CD N
other JJ N
patients NNS N
had VBD N
week NN N
1 CD N
measurements NNS N
performed VBN N
but CC N
died VBD N
before IN N
the DT N
week NN N
4 CD N
sample NN N
was VBD N
collected VBN N
due JJ N
to TO N
their PRP$ N
underlying JJ N
cancer NN N
The DT N
mean JJ N
anti-Xa JJ N
levels NNS N
at IN N
weeks NNS N
1 CD N
and CC N
4 CD N
were VBD N
1.11 CD N
and CC N
1.03 CD N
anti-Xa JJ N
units/ml NN N
respectively RB N
( ( N
P=0.13 NNP N
) ) N
These DT N
results NNS N
suggest VBP N
that IN N
for IN N
patients NNS N
with IN N
active JJ 4_p
cancer NN 4_p
receiving VBG N
extended VBN N
duration NN N
therapy NN N
with IN N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
dalteparin NN N
) ) N
there EX N
is VBZ N
no DT N
accumulation NN N
of IN N
anti-Xa JJ N
effect NN N
over IN N
the DT N
first JJ N
month NN N
of IN N
therapy NN N
Monitoring NN N
of IN N
anti-Xa JJ N
levels NNS N
in IN N
this DT N
situation NN N
is VBZ N
usually RB N
not RB N
required VBN N
-DOCSTART- -X- O O 9735531

Behavioral JJ N
changes NNS N
in IN N
autistic JJ N
individuals NNS N
as IN N
a DT N
result NN N
of IN N
wearing VBG N
ambient JJ N
transitional JJ N
prism NN N
lenses NNS N
A DT N
double-blind JJ N
crossover NN N
design NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
wearing VBG N
ambient JJ N
lenses NNS N
to TO N
reduce VB N
the DT N
behavioral JJ N
symptoms NNS N
of IN N
autism NN N
Eighteen NNP N
autistic JJ N
individuals NNS N
, , N
ranging VBG N
in IN N
age NN N
from IN N
7 CD N
to TO N
18 CD N
years NNS N
, , N
participated VBD N
in IN N
the DT N
study NN N
Behavior NNP N
, , N
attention NN N
, , N
and CC N
orientation NN N
were VBD N
evaluated VBN N
at IN N
1 CD N
1/2 CD N
months NNS N
, , N
2 CD N
months NNS N
, , N
3 CD N
months NNS N
, , N
and CC N
4 CD N
months NNS N
Compared VBN N
to TO N
the DT N
placebo NN N
condition NN N
, , N
the DT N
results NNS N
showed VBD N
a DT N
decrease NN N
in IN N
behavior JJ N
problems NNS N
at IN N
the DT N
1 CD N
1/2 CD N
and CC N
2 CD N
month NN N
assessment NN N
periods NNS N
and CC N
a DT N
slight JJ N
loss NN N
of IN N
these DT N
benefits NNS N
at IN N
the DT N
3 CD N
and CC N
4 CD N
month NN N
assessment NN N
periods NNS N
These DT N
findings NNS N
support VBP N
the DT N
prediction NN N
that WDT N
ambient JJ N
lenses NNS N
, , N
worn VBN N
without IN N
engaging VBG N
in IN N
visual-motor NN N
exercises NNS N
, , N
have VBP N
positive JJ N
effects NNS N
on IN N
autistic JJ N
individuals NNS N
-DOCSTART- -X- O O 23510581

Effects NNS N
of IN N
intranasal NN N
oxytocin NN N
on IN N
the DT N
neural JJ N
basis NN N
of IN N
face NN N
processing NN N
in IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
BACKGROUND NNP N
Autism NNP 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
is VBZ N
associated VBN N
with IN N
altered JJ N
face NN N
processing NN N
and CC N
decreased JJ N
activity NN N
in IN N
brain NN N
regions NNS N
involved VBN N
in IN N
face NN N
processing NN N
The DT N
neuropeptide JJ N
oxytocin NN N
has VBZ N
been VBN N
shown VBN N
to TO N
promote VB N
face NN N
processing NN N
and CC N
modulate NN N
brain NN N
activity NN N
in IN N
healthy JJ N
adults NNS 1_p
The DT N
present JJ N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
oxytocin NN N
on IN N
the DT N
neural JJ N
basis NN N
of IN N
face NN N
processing NN N
in IN N
adults NNS 1_p
with IN N
Asperger NNP 4_p
syndrome NN 4_p
( ( 4_p
AS IN 4_p
) ) 4_p
METHODS NNP N
A NNP N
group NN N
of IN N
14 CD 3_p
individuals NNS 3_p
with IN N
AS NNP N
and CC N
a DT N
group NN N
of IN N
14 CD 3_p
neurotypical JJ N
control NN N
participants NNS N
performed VBD N
a DT N
face-matching JJ N
and CC N
a DT N
house-matching JJ N
task NN N
during IN N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
The DT N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
24 CD N
IU NNP N
intranasally RB N
administered VBD N
oxytocin NNS N
were VBD N
tested VBN N
in IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
within-subject JJ N
, , N
cross-over JJ N
design NN N
RESULTS NNP N
Under IN N
placebo NN N
, , N
the DT N
AS NNP N
group NN N
showed VBD N
decreased JJ N
activity NN N
in IN N
the DT N
right JJ N
amygdala NN N
, , N
fusiform NN N
gyrus NN N
, , N
and CC N
inferior JJ N
occipital JJ N
gyrus NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
during IN N
face NN N
processing NN N
After IN N
oxytocin JJ N
treatment NN N
, , N
right JJ N
amygdala NN N
activity NN N
to TO N
facial JJ N
stimuli NNS N
increased VBN N
in IN N
the DT N
AS NNP N
group NN N
CONCLUSIONS NNP N
These DT N
findings NNS N
indicate VBP N
that IN N
oxytocin NN N
increases VBZ N
the DT N
saliency NN N
of IN N
social JJ N
stimuli NNS N
and CC N
in IN N
ASD NNP 4_p
and CC N
suggest VBP N
that IN N
oxytocin NN N
might MD N
promote VB N
face NN N
processing NN N
and CC N
eye NN N
contact NN N
in IN N
individuals NNS N
with IN N
ASD NNP 4_p
as IN N
prerequisites NNS N
for IN N
neurotypical JJ N
social JJ N
interaction NN N
-DOCSTART- -X- O O 15198767

Needle NNP N
versus NN N
loop NN N
diathermy NN N
excision NN N
of IN N
the DT N
transformation NN N
zone NN N
for IN N
the DT N
treatment NN N
of IN N
cervical JJ 4_p
intraepithelial JJ 4_p
neoplasia NN 4_p
: : 4_p
a DT N
randomised JJ N
controlled VBN N
trial NN N
OBJECTIVE NN N
To TO N
determine VB N
whether IN N
lower JJR N
rates NNS N
or CC N
incomplete JJ N
resection NN N
of IN N
cervical JJ 4_p
intraepithelial JJ 4_p
neoplasia NN 4_p
( ( 4_p
CIN NNP 4_p
) ) 4_p
may MD N
be VB N
achieved VBN N
by IN N
needle JJ N
excision NN N
of IN N
the DT N
transformation NN N
zone NN N
( ( N
NETZ NNP N
) ) N
than IN N
with IN N
loop JJ N
excision NN N
( ( N
LLETZ NNP N
) ) N
DESIGN VB N
A DT N
prospective JJ N
randomised VBN N
controlled VBN N
trial NN N
SETTING VB N
A DT N
gynaecological JJ N
oncology NN N
centre NN N
and CC N
a DT N
teaching JJ N
hospital NN N
in IN N
West NNP N
London NNP N
POPULATION NNP N
Four CD N
hundred VBD N
and CC N
four CD N
women NNS N
due JJ N
to TO N
receive VB N
treatment NN N
for IN N
suspected JJ N
CIN NNP N
METHODS NNP N
Women NNP N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
LLETZ NNP N
or CC N
NETZ NNP N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
study NN N
was VBD N
designed VBN N
to TO N
demostrate VB N
a DT N
difference NN N
in IN N
the DT N
proportion NN N
of IN N
women NNS N
with IN N
clear JJ N
histological JJ N
margins NNS N
of IN N
82 CD N
% NN N
for IN N
LLETZ NNP N
compared VBN N
to TO N
94 CD N
% NN N
for IN N
NETZ NNP N
with IN N
90 CD N
% NN N
power NN N
at IN N
a DT N
5 CD N
% NN N
significance NN N
level NN N
, , N
allowing VBG N
for IN N
absence NN N
of IN N
CIN NNP N
in IN N
the DT N
treatment NN N
specimen NNS N
in IN N
15 CD N
% NN N
RESULTS NNP N
Four NNP N
randomised VBD N
women NNS N
were VBD N
excluded VBN N
from IN N
the DT N
analysis NN N
, , N
as IN N
they PRP N
were VBD N
ineligible JJ N
for IN N
the DT N
study NN N
Three CD N
hundred VBD N
and CC N
forty-seven JJ N
( ( N
87 CD N
% NN N
) ) N
had VBD N
CIN NNP N
in IN N
the DT N
treatment NN N
specimen NNS N
and CC N
could MD N
be VB N
included VBN N
in IN N
the DT N
analysis NN N
of IN N
excision NN N
margins NNS N
More JJR N
women NNS N
in IN N
the DT N
NETZ NNP N
arm NN N
had VBD N
clear JJ N
histological JJ N
margins NNS N
( ( N
84.8 CD N
% NN N
vs JJ N
75 CD N
% NN N
, , N
( ( N
P= NNP N
0.03 CD N
) ) N
The DT N
median JJ N
volume NN N
of IN N
specimens NNS N
in IN N
the DT N
NETZ NNP N
arm NN N
was VBD N
739 CD N
mm NN N
( ( N
3 CD N
) ) N
larger JJR N
( ( N
P= NNP N
0.33 CD N
) ) N
and CC N
they PRP N
were VBD N
less RBR N
likely JJ N
to TO N
be VB N
removed VBN N
in IN N
multiple JJ N
pieces NNS N
( ( N
2.5 CD N
% NN N
vs JJ N
29.5 CD N
% NN N
, , N
RR NNP N
0.09 CD N
, , N
95 CD N
% NN N
CI NNP N
0.04 CD N
to TO N
0.20 CD N
) ) N
Needle NNP N
excision NN N
took VBD N
longer JJR N
to TO N
perform VB N
( ( N
median JJ N
treatment NN N
time NN N
210 CD N
vs NN N
90 CD N
seconds NNS N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
surgeons NNS N
more RBR N
often RB N
reported VBD N
the DT N
procedure NN N
as IN N
'difficult NN N
' '' N
( ( N
9.5 CD N
% NN N
vs JJ N
3.0 CD N
% NN N
, , N
RR NNP N
= VBD N
3.17 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
1.33 CD N
to TO N
7.58 CD N
) ) N
No DT N
difference NN N
in IN N
peri-operative JJ N
or CC N
post-operative JJ N
complication NN N
rates NNS N
could MD N
be VB N
demonstrated VBN N
between IN N
the DT N
two CD N
groups NNS N
CONCLUSION NNP N
NETZ NNP N
is VBZ N
more RBR N
likely JJ N
to TO N
produce VB N
a DT N
specimen NNS N
in IN N
one CD N
piece NN N
and CC N
with IN N
clear JJ N
margins NNS N
compared VBN N
to TO N
LLETZ NNP N
-DOCSTART- -X- O O 10437192

Clinical JJ N
observation NN N
on IN N
treatment NN N
of IN N
obstinate JJ 4_p
heart NN 4_p
failure NN 4_p
by IN N
supplementing VBG N
qi NN N
and CC N
activating VBG N
blood NN N
flow NN N
-DOCSTART- -X- O O 8453557

Adjuvant NNP N
cyclophosphamide NN N
, , N
doxorubicin NN N
, , N
vincristine NN N
, , N
and CC N
prednisone NN N
chemotherapy NN N
after IN N
radiation NN N
therapy NN N
in IN N
stage NN 4_p
I PRP 4_p
low-grade JJ 4_p
and CC 4_p
intermediate-grade JJ 4_p
non-Hodgkin JJ 4_p
lymphoma NN 4_p
Results NNS N
of IN N
a DT N
prospective JJ N
randomized NN N
study NN N
BACKGROUND NNP N
In IN N
a DT N
prospective JJ N
randomized NN N
manner NN N
, , N
this DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
adjuvant JJ N
chemotherapy NN N
( ( N
cyclophosphamide NN N
, , N
doxorubicin NN N
, , N
vincristine NN N
, , N
and CC N
prednisone NN N
; : N
CHOP NNP N
) ) N
in IN N
patients NNS 4_p
with IN 4_p
Stage NNP 4_p
I PRP 4_p
non-Hodgkin JJ 4_p
lymphoma NN 4_p
( ( 4_p
NHL NNP 4_p
) ) 4_p
who WP 4_p
have VBP 4_p
achieved VBN 4_p
a DT 4_p
complete JJ 4_p
response NN 4_p
( ( 4_p
CR NNP 4_p
) ) 4_p
after IN 4_p
radiation NN 4_p
therapy NN 4_p
( ( 4_p
RT NNP 4_p
) ) 4_p
METHODS NNP N
Forty-four JJ N
patients NNS N
with IN N
clinical JJ N
or CC N
pathologic JJ N
Stage NN N
I PRP N
intermediate-grade VBP N
or CC N
low-grade JJ N
NHL NNP N
were VBD N
randomized VBN N
to TO N
receive VB N
regional JJ N
RT NNP N
alone RB N
( ( N
median JJ N
dose NN N
, , N
40 CD N
Gy NNP N
) ) N
or CC N
regional JJ N
RT NNP N
followed VBN N
by IN N
six CD N
cycles NNS N
of IN N
CHOP NNP N
chemotherapy NN N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
clinical JJ N
and CC N
pathologic JJ N
characteristics NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
RESULTS VB N
The DT N
median JJ N
follow-up NN N
was VBD N
7 CD N
years NNS N
( ( N
range NN N
, , N
2-10 JJ N
years NNS N
) ) N
The DT N
actuarial JJ N
relapse-free JJ N
survival NN N
( ( N
RFS NNP N
) ) N
rate NN N
for IN N
the DT N
RT NNP N
plus CC N
CHOP NNP N
group NN N
at IN N
7 CD N
years NNS N
was VBD N
83 CD N
% NN N
compared VBN N
with IN N
47 CD N
% NN N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
for IN N
the DT N
RT-alone NNP N
group NN N
The DT N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
for IN N
the DT N
two CD N
groups NNS N
was VBD N
88 CD N
% NN N
and CC N
66 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.2 CD N
) ) N
In IN N
patients NNS N
with IN N
intermediate-grade JJ N
NHL NNP N
, , N
the DT N
7-year JJ N
actuarial JJ N
RFS NNP N
for IN N
RT NNP N
and CC N
CHOP NNP N
was VBD N
86 CD N
% NN N
compared VBN N
with IN N
20 CD N
% NN N
for IN N
RT NNP N
alone RB N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
The DT N
corresponding JJ N
actuarial JJ N
survival NN N
rates NNS N
were VBD N
92 CD N
% NN N
and CC N
47 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.08 CD N
) ) N
In IN N
patients NNS N
with IN N
low-grade JJ N
histologic JJ N
findings NNS N
, , N
the DT N
addition NN N
of IN N
adjuvant JJ N
CHOP NNP N
did VBD N
not RB N
improve VB N
RFS NNP N
( ( N
P NNP N
= NNP N
0.6 CD N
) ) N
or CC N
OS NNP N
All DT N
relapses VBZ N
in IN N
this DT N
study NN N
were VBD N
at IN N
sites NNS N
remote VBP N
from IN N
the DT N
initially RB N
involved JJ N
areas NNS N
, , N
and CC N
in IN N
5 CD N
of IN N
11 CD N
patients NNS N
( ( N
45 CD N
% NN N
) ) N
, , N
there EX N
were VBD N
recurrences NNS N
5 CD N
years NNS N
or CC N
longer JJR N
after IN N
initial JJ N
treatment NN N
CONCLUSIONS VB N
This DT N
study NN N
showed VBD N
that IN N
adjuvant JJ N
CHOP NNP N
chemotherapy NN N
significantly RB N
improves VBZ N
RFS NNP N
in IN N
patients NNS N
with IN N
Stage NNP N
I PRP N
intermediate-grade VBP N
NHL NNP N
who WP N
achieve VBP N
a DT N
CR NNP N
after IN N
regional-field JJ N
RT NNP N
The DT N
chemotherapeutic JJ N
regimen NNS N
favorably RB N
affected VBD N
their PRP$ N
probability NN N
of IN N
survival NN N
-DOCSTART- -X- O O 24027014

Effectiveness NN N
of IN N
a DT N
theory-based JJ N
intervention NN N
to TO N
increase VB N
colorectal JJ 4_p
cancer NN 4_p
screening VBG 4_p
among IN N
Iranian JJ N
health NN N
club NN N
members NNS 3_p
: : N
a DT N
randomized JJ N
trial NN N
Colorectal JJ N
cancer NN N
is VBZ N
the DT N
third JJ N
most RBS N
commonly RB N
diagnosed JJ N
cancer NN N
and CC N
the DT N
fourth JJ N
leading VBG N
cause NN N
of IN N
death NN N
in IN N
the DT N
world NN N
There EX N
are VBP N
few JJ N
published VBN N
studies NNS N
that WDT N
have VBP N
used VBN N
theory-based JJ N
interventions NNS N
designed VBN N
to TO N
increase VB N
colorectal JJ N
cancer NN N
screening VBG N
in IN N
community NN N
lay VBP N
health NN N
organizations NNS N
The DT N
present JJ N
study NN N
was VBD N
guided VBN N
by IN N
the DT N
theoretical JJ N
concepts NNS N
of IN N
the DT N
preventive JJ N
health NN N
model NN N
Twelve NNP 3_p
health NN N
clubs NNS N
of IN N
a DT N
municipal JJ N
district NN N
in IN N
Tehran NNP N
were VBD N
randomized VBN N
to TO N
two CD N
study NN N
groups NNS N
with IN N
equal JJ N
ratio NN N
The DT N
control NN N
group NN N
received VBD N
usual JJ N
services NNS N
throughout IN N
the DT N
study NN N
while IN N
the DT N
intervention NN N
group NN N
also RB N
received VBD N
a DT N
theory-based JJ N
educational JJ N
program NN N
on IN N
colorectal JJ N
cancer NN N
screening VBG N
plus CC N
a DT N
reminder NN N
call NN N
Screening VBG N
behavior NN N
, , N
the DT N
main JJ N
outcome NN N
, , N
was VBD N
assessed VBN N
4 CD N
months NNS N
after IN N
randomization NN N
A DT N
total NN 3_p
of IN 3_p
360 CD 3_p
members NNS 3_p
aged VBN 1_p
50 CD 1_p
and CC 1_p
older JJR 1_p
from IN N
12 CD 3_p
health NN N
clubs NNS N
completed VBD N
a DT N
baseline NN N
survey NN N
Participants NNS N
in IN N
the DT N
intervention NN N
group NN N
reported VBD N
increased JJ N
knowledge NN N
of IN N
colorectal JJ N
cancer NN N
and CC N
screening NN N
tests NNS N
at IN N
4 CD N
months NNS N
follow-up JJ N
( ( N
p NN N
's POS N
< NNP N
.001 NNP N
) ) N
Moreover RB N
, , N
exposure NN N
to TO N
the DT N
theory-based JJ N
intervention NN N
significantly RB N
improved VBN N
self-efficacy NN N
, , N
perceived VBN N
susceptibility NN N
, , N
efficacy NN N
of IN N
screening NN N
, , N
social JJ N
support NN N
, , N
and CC N
intention NN N
to TO N
be VB N
screened VBN N
for IN N
colorectal JJ N
cancer NN N
, , N
from IN N
baseline NN N
to TO N
4 CD N
months NNS N
follow-up JJ N
( ( N
p NN N
's POS N
< NNP N
.001 NNP N
) ) N
The DT N
screening NN N
rate NN N
for IN N
colorectal JJ N
cancer NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
( ( N
odds NNS N
ratio VBP N
= JJ N
15.93 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
5.57 CD N
, , N
45.53 CD N
) ) N
Our PRP$ N
theory-based JJ N
intervention NN N
was VBD N
found VBN N
to TO N
have VB N
a DT N
significant JJ N
effect NN N
on IN N
colorectal JJ N
cancer NN N
screening VBG N
use NN N
as IN N
measured VBN N
by IN N
self-report NN N
The DT N
findings NNS N
could MD N
have VB N
implications NNS N
for IN N
colorectal JJ N
cancer NN N
screening VBG N
program NN N
development NN N
and CC N
implementation NN N
in IN N
primary JJ N
health NN N
care NN N
settings NNS N
and CC N
through IN N
other JJ N
community NN N
organizations NNS N
-DOCSTART- -X- O O 2177746

Behavioral JJ N
effects NNS N
of IN N
Org NNP N
2766 CD N
, , N
a DT N
synthetic JJ N
analog NN N
of IN N
the DT N
adrenocorticotrophic JJ N
hormone NN N
( ( N
4-9 JJ N
) ) N
, , N
in IN N
14 CD 3_p
outpatient JJ 4_p
autistic JJ 4_p
children NNS N
Fourteen NNP 3_p
children NNS N
( ( N
12 CD 3_p
infantile NN 4_p
autism NN 4_p
full JJ 4_p
syndrome NN 4_p
present NN N
, , N
2 CD 3_p
atypical JJ 4_p
pervasive JJ 4_p
developmental JJ 4_p
disorder NN 4_p
) ) N
between IN N
5 CD 1_p
and CC 1_p
13 CD 1_p
years NNS N
of IN N
age NN N
participated VBN N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
cross-over JJ N
trial NN N
Each DT N
child NN N
received VBD N
20 CD N
mg NNS N
Org JJ N
2766 CD N
( ( N
synthetic JJ N
analog NN N
of IN N
ACTH NNP N
4-9 JJ N
) ) N
/day NN N
during IN N
4 CD N
weeks NNS N
, , N
or CC N
placebo NN N
in IN N
a DT N
randomly NN N
assigned VBN N
sequence NN N
Drug JJ N
effects NNS N
were VBD N
monitored VBN N
by IN N
ethological JJ N
playroom NN N
observation NN N
and CC N
by IN N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
ratings NNS N
by IN N
parents NNS N
and CC N
teachers NNS N
Data NNP N
of IN N
the DT N
playroom NN N
observation NN N
pointed VBD N
to TO N
an DT N
activating VBG N
influence NN N
of IN N
Org NNP N
2766 CD N
, , N
as IN N
revealed VBN N
by IN N
a DT N
significant JJ N
decrease NN N
of IN N
stereotypic NN N
behavior NN N
and CC N
significant JJ N
increases NNS N
in IN N
" JJ N
change NN N
toys NNS N
, , N
" NNP N
" NNP N
locomote NN N
, , N
" NNP N
and CC N
" NNP N
talk NN N
" JJ N
Checklist NNP N
ratings NNS N
did VBD N
not RB N
show VB N
significant JJ N
changes NNS N
The DT N
clinical JJ N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
-DOCSTART- -X- O O 25450124

Differences NNS N
in IN N
quality NN N
of IN N
life NN N
outcomes NNS N
among IN N
depressed JJ 4_p
spinal JJ 4_p
cord NN 4_p
injury NN 4_p
trial NN N
participants NNS N
OBJECTIVE NN N
To TO N
assess VB N
the DT N
role NN N
that WDT N
treatment NN N
response NN N
plays VBZ N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
an DT N
antidepressant JJ N
among IN N
people NNS N
with IN N
spinal JJ 4_p
cord NN 4_p
injury NN 4_p
( ( 4_p
SCI NNP 4_p
) ) 4_p
diagnosed VBD N
with IN N
major JJ 4_p
depressive JJ 4_p
disorder NN 4_p
( ( 4_p
MDD NNP 4_p
) ) N
in IN N
explaining VBG N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
, , N
assessed VBD N
both DT N
globally RB N
as IN N
life NN N
satisfaction NN N
and CC N
in IN N
terms NNS N
of IN N
physical JJ N
and CC N
mental JJ N
health-related JJ N
QOL NNP N
DESIGN NNP N
Multivariable JJ N
analyses NNS N
were VBD N
conducted VBN N
, , N
controlling VBG N
for IN N
demographic JJ N
, , N
neurologic JJ N
, , N
and CC N
participatory JJ N
factors NNS N
and CC N
perceived VBD N
functional JJ N
limitations NNS N
SETTING NN N
Rehabilitation NN N
centers NNS N
PARTICIPANTS NNS N
Of IN N
the DT N
133 CD 3_p
persons NNS N
who WP N
were VBD N
randomized VBN N
into IN N
the DT N
Project NN N
to TO N
Improve VB N
Symptoms NNP N
and CC N
Mood NNP N
after IN N
Spinal NNP 4_p
Cord NNP 4_p
Injury NNP 4_p
randomized VBD N
controlled VBN N
trial NN N
, , N
124 CD 3_p
participated VBN N
in IN N
this DT N
study NN N
All DT N
participants NNS N
were VBD N
between IN N
the DT N
ages NNS N
of IN N
18 CD 1_p
and CC N
64 CD 1_p
years NNS N
, , N
at IN N
least JJS N
1 CD N
month NN N
post-SCI NN N
, , N
met VBD N
the DT N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
4th CD N
edition NN N
, , N
criteria NNS N
for IN N
MDD NNP N
, , N
and CC N
completed VBD N
the DT N
core NN N
measures NNS N
used VBN N
in IN N
this DT N
study NN N
INTERVENTIONS NNP N
Not RB N
applicable JJ N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
Satisfaction NNP N
with IN N
Life NNP N
Scale NNP N
and CC N
the DT N
physical JJ N
and CC N
mental JJ N
component NN N
summary JJ N
scores NNS N
of IN N
the DT N
Medical NNP N
Outcomes NNP N
Study NNP N
12-Item JJ N
Short-Form NNP N
Health NNP N
Survey NNP N
RESULTS NNP N
Reduction NNP N
in IN N
depressive JJ N
symptoms NNS N
over IN N
the DT N
course NN N
of IN N
a DT N
12-week JJ N
trial NN N
was VBD N
predictive JJ N
of IN N
increased JJ N
QOL NNP N
, , N
which WDT N
was VBD N
measured VBN N
as IN N
life NN N
satisfaction NN N
and CC N
mental JJ N
well-being NN N
, , N
within IN N
the DT N
context NN N
of IN N
other JJ N
explanatory JJ N
factors NNS N
However RB N
, , N
reduction NN N
in IN N
symptoms NNS N
did VBD N
not RB N
explain VB N
differences NNS N
in IN N
physical JJ N
well-being NN N
among IN N
those DT N
with IN N
MDD NNP N
Perceived NNP N
functional JJ N
disability NN N
explained VBD N
all DT N
3 CD N
indices NNS N
of IN N
QOL NNP N
CONCLUSIONS NNP N
Greater NNP N
recognition NN N
has VBZ N
been VBN N
given VBN N
to TO N
QOL NNP N
outcomes RB N
as IN N
endpoints NNS N
of IN N
clinical JJ N
trials NNS N
because IN N
these DT N
often RB N
reflect VBP N
participants NNS N
' POS N
reported VBN N
outcomes NNS N
Our PRP$ N
findings NNS N
support VB N
the DT N
association NN N
of IN N
QOL NNP N
to TO N
the DT N
reduction NN N
of IN N
depression NN N
symptoms NNS N
among IN N
trial NN N
participants NNS N
This DT N
association NN N
differs VBZ N
depending VBG N
on IN N
how WRB N
QOL NNP N
is VBZ N
defined VBN N
and CC N
measured VBN N
, , N
with IN N
stronger JJR N
relations NNS N
observed VBN N
with IN N
life NN N
satisfaction NN N
and CC N
mental JJ N
well-being NN N
among IN N
those DT N
diagnosed VBN N
with IN N
MDD NNP N
The DT N
lack NN N
of IN N
association NN N
between IN N
depression NN N
and CC N
physical JJ N
well-being NN N
may MD N
be VB N
explained VBN N
by IN N
participants NNS N
' POS N
subjective JJ N
interpretation NN N
of IN N
physical JJ N
well-being NN N
after IN N
SCI NNP N
and CC N
their PRP$ N
expectations NNS N
and CC N
perceptions NNS N
of IN N
improved JJ N
physical JJ N
health-related JJ N
QOL NNP N
based VBN N
on IN N
the DT N
use NN N
of IN N
assistive JJ N
technology NN N
Consistent JJ N
with IN N
our PRP$ N
findings NNS N
, , N
pain NN N
is VBZ N
likely JJ N
to TO N
play VB N
a DT N
role NN N
in IN N
decreasing VBG N
physical JJ N
QOL NNP N
among IN N
those DT N
with IN N
incomplete JJ 4_p
injuries NNS 4_p
Practicing VBG N
caution NN N
is VBZ N
suggested VBN N
in IN N
using VBG N
physical JJ N
well-being NN N
as IN N
an DT N
endpoint NN N
in IN N
trials NNS N
among IN N
people NNS N
with IN N
SCI NNP 4_p
-DOCSTART- -X- O O 23075031

The DT N
effects NNS N
of IN N
moderate JJ N
to TO N
vigorous JJ N
aerobic JJ N
exercise NN N
on IN N
the DT N
sleep JJ 4_p
need NN 4_p
of IN 4_p
sedentary JJ 4_p
young JJ 4_p
adults NNS 4_p
Exercise NN N
has VBZ N
been VBN N
recommended VBN N
for IN N
enhancing VBG N
sleep NN N
; : N
a DT N
claim NN N
linked VBN N
to TO N
the DT N
belief NN N
that IN N
sleep VBP N
need MD N
- : N
defined VBN N
by IN N
sleep JJ N
duration NN N
and CC N
depth NN N
- : N
is VBZ N
increased VBN N
post-exercise NN N
to TO N
allow VB N
tissue NN N
recovery NN N
Objective JJ N
studies NNS N
investigating VBG N
exercise-sleep JJ N
responses NNS N
have VBP N
produced VBN N
mixed JJ N
outcomes NNS N
, , N
and CC N
the DT N
disparity NN N
in IN N
results NNS N
between IN N
studies NNS N
may MD N
be VB N
due JJ N
to TO N
differences NNS N
in IN N
individual JJ N
characteristics NNS N
and/or VBP N
exercise NN N
protocol NN N
, , N
emphasising VBG N
the DT N
importance NN N
of IN N
carefully RB N
controlled VBN N
trials NNS N
We PRP N
investigated VBD N
the DT N
role NN N
of IN N
exercise NN N
on IN N
the DT N
sleep JJ N
need NN N
of IN N
sedentary JJ 4_p
adults NNS 4_p
, , N
after IN N
controlling VBG N
for IN N
exercise NN N
mode NN N
, , N
timing NN N
and CC N
duration NN N
Twelve NNP N
healthy JJ N
volunteers NNS N
( ( N
25.2 CD N
± RB N
4.0 CD N
years NNS N
, , N
9 CD N
females NNS N
, , N
[ NNP N
Vdot NNP N
] NNP N
O NNP N
( ( N
2 CD N
) ) N
max NN N
35.4 CD N
± NN N
8.8 CD N
ml· NN N
kg NN N
( ( N
-1 NNP N
) ) N
· VBP N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
were VBD N
randomised VBN N
to TO N
no-exercise NN N
or CC N
to TO N
a DT N
bout NN N
of IN N
treadmill NN N
exercise NN N
at IN N
45 CD N
% NN N
, , N
55 CD N
% NN N
, , N
65 CD N
% NN N
or CC N
75 CD N
% NN N
[ JJ N
Vdot NNP N
] NNP N
O NNP N
( ( N
2 CD N
) ) N
max NN N
in IN N
a DT N
crossover NN N
design NN N
Sleep VB N
on IN N
no-exercise NN N
and CC N
exercise NN N
nights NNS N
were VBD N
assessed VBN N
by IN N
polysomnography NN N
Participants NNS N
spent VBD N
a DT N
greater JJR N
proportion NN N
of IN N
sleep NN N
in IN N
light JJ N
sleep NN N
( ( N
stage NN N
1 CD N
+ JJ N
stage NN N
2 CD N
) ) N
after IN N
exercise NN N
at IN N
both DT N
65 CD N
% NN N
and CC N
75 CD N
% NN N
[ JJ N
Vdot NNP N
] NNP N
O NNP N
( ( N
2 CD N
) ) N
max NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
than IN N
the DT N
no-exercise JJ N
condition NN N
There EX N
was VBD N
a DT N
trend NN N
of IN N
a DT N
reduced JJ N
proportion NN N
of IN N
rapid JJ N
eye NN N
movement NN N
sleep JJ N
with IN N
increased JJ N
exercise NN N
intensity NN N
( ( N
P NNP N
= NNP N
0.067 CD N
) ) N
No UH N
other JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
any DT N
other JJ N
sleep JJ N
variables NNS N
Two CD N
findings NNS N
emerged VBD N
: : N
vigorous JJ N
exercise NN N
did VBD N
not RB N
increase VB N
sleep JJ N
need NN N
; : N
however RB N
, , N
this DT N
level NN N
of IN N
exercise NN N
increased VBN N
light JJ N
sleep NN N
-DOCSTART- -X- O O 11134799

A DT N
randomized JJ N
trial NN N
in IN N
simultaneous JJ 4_p
pancreas-kidney JJ 4_p
transplantation NN 4_p
: : N
portal JJ N
versus NN N
systemic JJ N
venous JJ N
drainage NN N
of IN N
the DT N
pancreas NN N
allograft NN N
-DOCSTART- -X- O O 4448416

Coagulation NNP N
factor NN N
concentrate NN N
in IN N
the DT N
treatment NN N
of IN N
the DT N
haemorrhagic JJ 4_p
diathesis NN 4_p
of IN 4_p
fulminant JJ 4_p
hepatic JJ 4_p
failure NN 4_p
To TO N
assess VB N
the DT N
value NN N
of IN N
clotting VBG N
factor NN N
concentrate NN N
infusions NNS N
in IN N
fulminant JJ 4_p
hepatic JJ 4_p
failure NN 4_p
, , N
a DT N
controlled JJ N
trial NN N
was VBD N
performed VBN N
in IN N
which WDT N
nine CD N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
with IN N
either DT N
concentrate NN N
alone RB N
or CC N
concentrate VB N
plus CC N
heparin VB N
The DT N
five CD N
patients NNS N
receiving VBG N
concentrate VB N
alone RB N
all DT N
died VBD N
, , N
with IN N
major JJ N
bleeding VBG N
as IN N
the DT N
direct JJ N
cause NN N
of IN N
death NN N
in IN N
three CD N
, , N
whereas NNS N
in IN N
the DT N
four CD N
receiving VBG N
heparin NN N
as RB N
well RB N
there EX N
was VBD N
only RB N
one CD N
instance NN N
of IN N
bleeding NN N
and CC N
one CD N
patient NN N
survived VBD N
Clinical JJ N
evidence NN N
of IN N
intravascular JJ N
coagulation NN N
appeared VBD N
in IN N
two CD N
patients NNS N
treated VBD N
with IN N
concentrate NN N
alone RB N
and CC N
the DT N
laboratory JJ N
evidence NN N
of IN N
this DT N
progressed VBN N
during IN N
the DT N
period NN N
of IN N
infusions NNS N
in IN N
all DT N
patients NNS N
in IN N
both DT N
treatment NN N
groups NNS N
, , N
although IN N
to TO N
a DT N
lesser JJR N
extent NN N
in IN N
those DT N
receiving VBG N
heparin NN N
Additional JJ N
evidence NN N
for IN N
intravascular JJ N
coagulation NN N
came VBD N
from IN N
the DT N
changes NNS N
observed VBN N
in IN N
factor NN N
VIII NNP N
levels NNS N
which WDT N
, , N
although IN N
initially RB N
high JJ N
in IN N
all DT N
patients NNS N
, , N
fell VBD N
subsequently RB N
, , N
particularly RB N
in IN N
those DT N
given VBN N
concentrate VBP N
alone RB N
There EX N
was VBD N
some DT N
improvement NN N
in IN N
the DT N
prothrombin NN N
ratio NN N
in IN N
both DT N
groups NNS N
of IN N
patients NNS N
but CC N
not RB N
complete JJ N
correction NN N
, , N
and CC N
serial JJ N
assays NNS N
of IN N
clotting VBG N
factors NNS N
showed VBD N
that IN N
although IN N
factor NN N
II NNP N
rose VBD N
to TO N
high JJ N
levels NNS N
during IN N
treatment NN N
, , N
factors NNS N
IX NNP N
and CC N
X NNP N
showed VBD N
little JJ N
response NN N
Thus RB N
, , N
the DT N
use NN N
of IN N
concentrate NN N
of IN N
factor NN N
IX NNP N
in IN N
this DT N
trial NN N
, , N
as RB N
well RB N
as IN N
potentiating VBG N
intravascular JJ N
coagulation NN N
, , N
was VBD N
inadequate JJ N
as IN N
replacement NN N
for IN N
the DT N
clotting NN N
factor NN N
deficiencies NNS N
-DOCSTART- -X- O O 22631032

Evaluation NN N
of IN N
the DT N
pharmacodynamics NNS N
of IN N
acetylsalicylic JJ N
acid NN N
81 CD N
mg NN N
with IN N
or CC N
without IN N
esomeprazole JJ N
20 CD N
mg NN N
in IN N
healthy JJ 4_p
volunteers NNS 4_p
BACKGROUND IN N
The DT N
absence NN N
of IN N
a DT N
pharmacokinetic JJ N
interaction NN N
between IN N
the DT N
proton NN N
pump NN N
inhibitor NN N
esomeprazole NN N
( ( N
40 CD N
mg NN N
) ) N
and CC N
acetylsalicylic JJ N
acid NN N
( ( N
aspirin JJ N
, , N
ASA NNP N
; : N
325 CD N
mg NN N
) ) N
has VBZ N
previously RB N
been VBN N
established VBN N
OBJECTIVE VB N
This DT N
study NN N
set VBD N
out RP N
to TO N
investigate VB N
the DT N
potential NN N
for IN N
pharmacodynamic JJ N
interaction NN N
between IN N
low-dose JJ N
ASA NNP N
and CC N
esomeprazole VB N
in IN N
healthy JJ N
volunteers NNS N
, , N
by IN N
measuring VBG N
ASA NNP N
antiplatelet NN N
activity NN N
STUDY NNP N
DESIGN NNP N
This DT N
was VBD N
a DT N
single-center JJ N
, , N
open-label JJ N
, , N
two-period JJ N
, , N
randomized VBN N
crossover NN N
study NN N
PARTICIPANTS NNP N
Healthy NNP 1_p
male NN 1_p
and CC 1_p
female JJ 1_p
volunteers NNS 1_p
aged VBN 1_p
18-75 CD 1_p
years NNS 1_p
were VBD 1_p
included VBN 1_p
All DT N
volunteers NNS N
received VBD N
ASA NNP N
81 CD N
mg NN N
once RB N
daily JJ N
for IN N
5 CD N
days NNS N
prior RB N
to TO N
the DT N
study NN N
( ( N
pre-screen JJ N
) ) N
Subjects NNS N
were VBD N
eligible JJ N
for IN N
inclusion NN N
if IN N
they PRP N
had VBD N
aspirin VBN N
reactivity NN N
units NNS N
( ( N
ARU NNP N
, , N
as IN N
measured VBN N
by IN N
the DT N
VerifyNow NNP N
ASA NNP N
assay VBP N
) ) N
of IN N
< $ N
550 CD N
on IN N
Day NNP N
6 CD N
INTERVENTION NN N
After IN N
pre-screening NN N
and CC N
a DT N
washout JJ N
period NN N
of IN N
at IN N
least JJS N
14 CD N
days NNS N
, , N
eligible JJ N
volunteers NNS N
received VBD N
ASA NNP N
81 CD N
mg NN N
with IN N
or CC N
without IN N
esomeprazole JJ N
20 CD N
mg NN N
once RB N
daily JJ N
for IN N
5 CD N
days NNS N
in IN N
randomized JJ N
order NN N
, , N
with IN N
a DT N
14-day JJ N
washout NN N
between IN N
treatments NNS N
MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
antiplatelet NN N
activity NN N
of IN N
ASA NNP N
, , N
as IN N
assessed VBN N
by IN N
ARU NNP N
ratio NN N
relative NN N
to TO N
baseline VB N
in IN N
the DT N
VerifyNow NNP N
ASA NNP N
assay VBP N
; : N
suppression NN N
of IN N
serum NN N
thromboxane NN N
B NNP N
( ( N
2 CD N
) ) N
( ( N
TXB NNP N
( ( N
2 CD N
) ) N
) ) N
was VBD N
a DT N
secondary JJ N
endpoint NN N
Statistical JJ N
comparisons NNS N
were VBD N
made VBN N
using VBG N
linear JJ N
mixed JJ N
models NNS N
RESULTS VB N
A DT N
total NN N
of IN N
29 CD N
volunteers NNS N
( ( N
19 CD N
aged VBN N
≥50 CD N
years NNS N
; : N
8 CD N
women NNS N
; : N
21 CD N
men NNS N
) ) N
were VBD N
evaluable JJ N
for IN N
pharmacodynamic JJ N
analysis NN N
( ( N
per IN N
protocol NN N
) ) N
All DT N
volunteers NNS N
on IN N
both DT N
treatments NNS N
achieved VBN N
ARU NNP N
< $ N
550 CD N
at IN N
Day NNP N
6 CD N
The DT N
geometric JJ N
mean NN N
ratio NN N
of IN N
Day NNP N
6 CD N
to TO N
Day NNP N
1 CD N
( ( N
baseline NN N
) ) N
platelet NN N
aggregation NN N
was VBD N
0.70 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
0.68 CD N
, , N
0.72 CD N
) ) N
with IN N
ASA NNP N
alone RB N
and CC N
0.71 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.69 CD N
, , N
0.74 CD N
) ) N
with IN N
ASA NNP N
+ NNP N
esomeprazole NN N
The DT N
ratio NN N
of IN N
platelet NN N
aggregation NN N
( ( N
ASA NNP N
+ NNP N
esomeprazole/ASA NN N
) ) N
was VBD N
1.02 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.99 CD N
, , N
1.05 CD N
) ) N
ASA NNP N
administered VBD N
alone RB N
or CC N
with IN N
esomeprazole JJ N
reduced VBN N
serum NN N
TXB NNP N
( ( N
2 CD N
) ) N
by IN N
more JJR N
than IN N
99.5 CD N
% NN N
The DT N
ratio NN N
of IN N
suppression NN N
of IN N
serum NN N
TXB NNP N
( ( N
2 CD N
) ) N
levels NNS N
( ( N
ASA NNP N
+ NNP N
esomeprazole/ASA NN N
) ) N
was VBD N
1.06 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.88 CD N
, , N
1.29 CD N
) ) N
The DT N
combination NN N
of IN N
ASA NNP N
and CC N
esomeprazole NN N
was VBD N
well RB N
tolerated VBN N
CONCLUSION NNP N
No NNP N
pharmacodynamic JJ N
interaction NN N
between IN N
low-dose JJ N
ASA NNP N
and CC N
esomeprazole NN N
was VBD N
found VBN N
with IN N
regard NN N
to TO N
platelet VB N
function NN N
TRIAL NNP N
REGISTRATION NNP N
Registered NNP N
at IN N
ClinicalTrials NNP N
gov NN N
as IN N
NCT01199328 NNP N
-DOCSTART- -X- O O 8394956

The DT N
relative JJ N
contributions NNS N
of IN N
medication NN N
adherence NN N
and CC N
AA NNP N
meeting NN N
attendance NN N
to TO N
abstinent VB N
outcome NN N
for IN N
chronic JJ N
alcoholics NNS 4_p
Our PRP$ N
preliminary JJ N
studies NNS N
of IN N
the DT N
efficacy NN N
of IN N
lithium NN N
carbonate NN N
therapy NN N
for IN N
alcoholism NN N
under IN N
double-blind NN N
, , N
placebo-controlled JJ N
conditions NNS N
demonstrated VBD N
that IN N
alcoholics NNS 4_p
who WP N
took VBD N
their PRP$ N
assigned JJ N
medication NN N
( ( N
lithium NN N
or CC N
placebo NN N
) ) N
for IN N
the DT N
first JJ N
6 CD N
months NNS N
after IN N
discharge NN N
from IN N
an DT N
inpatient JJ N
rehabilitation NN N
program NN N
were VBD N
more RBR N
likely JJ N
to TO N
abstain VB N
from IN N
any DT N
alcohol NN N
use NN N
for IN N
18 CD N
months NNS N
following VBG N
discharge NN N
than IN N
were VBD N
alcoholics NNS 4_p
who WP N
took VBD N
their PRP$ N
medication NN N
erratically RB N
or CC N
not RB N
at IN N
all DT N
Attendance NN N
at IN N
Alcoholics NNP 4_p
Anonymous NNP N
( ( N
AA NNP N
) ) N
meetings NNS N
was VBD N
also RB N
associated VBN N
with IN N
medication NN N
adherence NN N
We PRP N
applied VBD N
a DT N
structural JJ N
equation NN N
model NN N
to TO N
data NNS N
on IN N
the DT N
relationships NNS N
between IN N
medication NN N
adherence NN N
, , N
AA NNP N
meeting NN N
attendance NN N
and CC N
abstinent JJ N
outcome NN N
to TO N
clarify VB N
whether IN N
medication NN N
adherence NN N
or CC N
AA NNP N
meeting NN N
attendance NN N
better RBR N
explains VBZ N
the DT N
positive-outcome JJ N
" NN N
adherence NN N
effect NN N
" IN N
we PRP N
observed VBD N
Both DT N
medication NN N
adherence NN N
and CC N
AA NNP N
meeting NN N
attendance NN N
evidenced VBD N
direct JJ N
and CC N
independent JJ N
influences NNS N
on IN N
abstinent JJ N
outcome NN N
: : N
medication NN N
adherence NN N
showed VBD N
a DT N
small JJ N
direct JJ N
influence NN N
, , N
and CC N
AA NNP N
meeting NN N
attendance NN N
showed VBD N
a DT N
much RB N
larger JJR N
, , N
independent JJ N
influence NN N
-DOCSTART- -X- O O 20646286

Predictors NNS N
of IN N
stable JJ N
return-to-work NN N
in IN N
non-acute JJ N
, , N
non-specific JJ N
spinal JJ N
pain NN N
: : N
low JJ N
total JJ N
prior JJ N
sick-listing NN N
, , N
high JJ N
self NN N
prediction NN N
and CC N
young JJ N
age NN N
A DT N
two-year JJ N
prospective JJ N
cohort NN N
study NN N
BACKGROUND NNP N
Non-specific JJ 4_p
spinal JJ 4_p
pain NN 4_p
( ( 4_p
NSP NNP 4_p
) ) 4_p
, , N
comprising VBG N
back RP 4_p
and/or JJ 4_p
neck NN 4_p
pain NN 4_p
, , N
is VBZ N
one CD N
of IN N
the DT N
leading VBG N
disorders NNS N
in IN N
long-term JJ N
sick-listing NN N
During IN N
2000-2004 JJ N
, , N
125 CD 3_p
Swedish JJ N
primary-care JJ N
patients NNS N
with IN N
non-acute JJ 4_p
NSP NNP 4_p
, , N
full-time JJ N
sick-listed JJ N
6 CD N
weeks-2 JJ N
years NNS N
, , N
were VBD N
included VBN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
to TO N
compare VB N
a DT N
cognitive-behavioural JJ N
programme NN N
with IN N
traditional JJ N
primary JJ N
care NN N
This DT N
prospective JJ N
cohort NN N
study NN N
is VBZ N
a DT N
re-assessment NN N
of IN N
the DT N
data NN N
from IN N
the DT N
randomized VBN N
trial NN N
with IN N
the DT N
2 CD N
treatment NN N
groups NNS N
considered VBN N
as IN N
a DT N
single JJ N
cohort NN N
The DT N
aim NN N
was VBD N
to TO N
investigate VB N
which WDT N
baseline NN N
variables NNS N
predict VBP N
a DT N
stable JJ N
return-to-work NN N
during IN N
a DT N
2-year JJ N
period NN N
after IN N
baseline NN N
: : N
objective JJ N
variables NNS N
from IN N
function NN N
tests NNS N
, , N
socioeconomic JJ N
, , N
subjective JJ N
and/or NN N
treatment NN N
variables NNS N
Stable JJ N
return-to-work NN N
was VBD N
a DT N
return-to-work JJ N
lasting NN N
for IN N
at IN N
least JJS N
1 CD N
month NN N
from IN N
the DT N
start NN N
of IN N
follow-up NN N
METHODS NNP N
Stable JJ N
return-to-work NN N
was VBD N
the DT N
outcome NN N
variable NN N
, , N
the DT N
above-mentioned JJ N
factors NNS N
were VBD N
the DT N
predictive JJ N
variables NNS N
in IN N
multiple-logistic JJ N
regression NN N
models NNS N
, , N
one CD N
per IN N
follow-up NN N
at IN N
6 CD N
, , N
12 CD N
, , N
18 CD N
and CC N
24 CD N
months NNS N
after IN N
baseline NN N
The DT N
factors NNS N
from IN N
univariate JJ N
analyzes NNS N
with IN N
a DT N
p-value NN N
of IN N
at IN N
most JJS N
.10 NNS N
were VBD N
included VBN N
The DT N
non-significant JJ N
variables NNS N
were VBD N
excluded VBN N
stepwise NN N
to TO N
yield VB N
models NNS N
comprising VBG N
only RB N
significant JJ N
factors NNS N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
As IN N
the DT N
comparatively RB N
few JJ N
cases NNS N
made VBD N
it PRP N
risky JJ N
to TO N
associate VB N
certain JJ N
predictors NNS N
with IN N
certain JJ N
time-points NNS N
, , N
we PRP N
finally RB N
considered VBD N
the DT N
predictors NNS N
which WDT N
were VBD N
represented VBN N
in IN N
at IN N
least JJS N
3 CD N
follow-ups NNS N
They PRP N
are VBP N
presented VBN N
with IN N
odds NNS N
ratios NNS N
( ( N
OR NNP N
) ) N
and CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
RESULTS NNP N
Three CD N
variables NNS N
qualified VBN N
, , N
all DT N
of IN N
them PRP N
represented VBN N
in IN N
3 CD N
follow-ups NNS N
: : N
Low NNP N
total JJ N
prior RB N
sick-listing NN N
( ( N
including VBG N
all DT N
diagnoses NNS N
) ) N
was VBD N
the DT N
strongest JJS N
predictor NN N
in IN N
2 CD N
follow-ups NNS N
, , N
18 CD N
and CC N
24 CD N
months NNS N
, , N
OR NNP N
4.8 CD N
[ JJ N
1.9-12.3 JJ N
] NN N
and CC N
3.8 CD N
[ JJ N
1.6-8.7 JJ N
] NN N
respectively RB N
, , N
High NNP N
self NN N
prediction NN N
( ( N
the DT N
patients NNS N
' POS N
own JJ N
belief NN N
in IN N
return-to-work NN N
) ) N
was VBD N
the DT N
strongest JJS N
at IN N
12 CD N
months NNS N
, , N
OR NNP N
5.2 CD N
[ JJ N
1.5-17.5 JJ N
] NN N
and CC N
Young NNP N
age NN N
( ( N
max JJ N
44 CD N
years NNS N
) ) N
the DT N
second JJ N
strongest NN N
at IN N
18 CD N
months NNS N
, , N
OR NNP N
3.5 CD N
[ JJ N
1.3-9.1 JJ N
] NN N
CONCLUSIONS NNP N
In IN N
primary-care JJ N
patients NNS N
with IN N
non-acute JJ 4_p
NSP NNP 4_p
, , N
the DT N
strong JJ N
predictors NNS N
of IN N
stable JJ N
return-to-work NN N
were VBD N
2 CD N
socioeconomic JJ N
variables NNS N
, , N
Low NNP N
total JJ N
prior JJ N
sick-listing NN N
and CC N
Young NNP N
age NN N
, , N
and CC N
1 CD N
subjective JJ N
variable NN N
, , N
High NNP N
self-prediction NN N
Objective JJ N
variables NNS N
from IN N
function NN N
tests NNS N
and CC N
treatment NN N
variables NNS N
were VBD N
non-predictors NNS N
Except IN N
for IN N
Young NNP N
age NN N
, , N
the DT N
predictors NNS N
have VBP N
previously RB N
been VBN N
insufficiently RB N
studied VBN N
, , N
and CC N
so RB N
our PRP$ N
study NN N
should MD N
widen VB N
knowledge NN N
within IN N
clinical JJ N
practice NN N
-DOCSTART- -X- O O 20431081

Stroke NNP N
team NN N
remote NN N
evaluation NN N
using VBG N
a DT N
digital JJ N
observation NN N
camera NN N
in IN N
Arizona NNP 4_p
: : N
the DT N
initial JJ N
mayo NN N
clinic JJ N
experience NN N
trial NN N
BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Telemedicine NNP N
techniques NNS N
can MD N
be VB N
used VBN N
to TO N
address VB N
the DT N
rural-metropolitan JJ N
disparity NN N
in IN N
acute JJ N
stroke NN N
care NN N
The DT N
Stroke NNP N
Team NNP N
Remote NNP N
Evaluation NNP N
Using VBG N
a DT N
Digital NNP N
Observation NNP N
Camera NNP N
( ( N
STRokE NNP N
DOC NNP N
) ) N
trial NN N
reported VBD N
more RBR N
accurate JJ N
decision NN N
making NN N
for IN N
telemedicine JJ N
consultations NNS N
compared VBN N
with IN N
telephone-only JJ N
and CC N
that IN N
the DT N
California-based JJ N
research NN N
network NN N
facilitated VBD N
a DT N
high JJ N
rate NN N
of IN N
thrombolysis NN N
use NN N
, , N
improved VBN N
data NNS N
collection NN N
, , N
low JJ N
risk NN N
of IN N
complications NNS N
, , N
low JJ N
technical JJ N
complications NNS N
, , N
and CC N
favorable JJ N
assessment NN N
times NNS N
The DT N
main JJ N
objective NN N
of IN N
the DT N
STRokE NNP N
DOC NNP N
Arizona NNP N
TIME NNP N
( ( N
The DT N
Initial NNP N
Mayo NNP N
Clinic NNP N
Experience NNP N
) ) N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
feasibility NN N
of IN N
establishing VBG N
, , N
de FW N
novo FW N
, , N
a DT N
single-hub JJ N
, , N
multirural JJ N
spoke VBD N
hospital JJ N
telestroke NN N
research NN N
network NN N
across IN N
a DT N
large JJ N
geographical JJ N
area NN N
in IN N
Arizona NNP N
by IN N
replicating VBG N
the DT N
STRokE NNP N
DOC NNP N
protocol NN N
METHODS NNP N
Methods NNP N
included VBD N
prospective JJ N
, , N
single-hub JJ N
, , N
2-spoke JJ N
, , N
randomized VBN N
, , N
blinded VBD N
, , N
controlled VBD N
trial NN N
of IN N
a DT N
2-way JJ N
, , N
site-independent JJ N
, , N
audiovisual JJ N
telemedicine NN N
system NN N
designed VBN N
for IN N
remote JJ N
examination NN N
of IN N
adult NN 1_p
patients NNS 1_p
with IN N
acute JJ 4_p
stroke NN 4_p
versus IN N
telephone NN N
consultation NN N
to TO N
assess VB N
eligibility NN N
for IN N
treatment NN N
with IN N
intravenous JJ N
thrombolysis NN N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
whether IN N
the DT N
decision NN N
to TO N
give VB N
thrombolysis NN N
was VBD N
correct JJ N
Secondary JJ N
outcomes NNS N
were VBD N
rate NN N
of IN N
thrombolytic JJ N
use NN N
, , N
90-day JJ N
functional JJ N
outcomes NNS N
, , N
incidence NN N
of IN N
intracerebral JJ N
hemorrhages NNS N
, , N
and CC N
technical JJ N
observations NNS N
RESULTS NN N
From IN N
December NNP N
2007 CD N
to TO N
October NNP N
2008 CD N
, , N
54 CD 3_p
patients NNS 3_p
were VBD N
assessed VBN N
, , N
27 CD N
of IN N
whom WP N
were VBD N
randomized VBN N
to TO N
each DT N
arm NN N
Mean JJ N
National NNP N
Institutes NNPS N
of IN N
Health NNP N
Stroke NNP N
Scale NNP N
score NN N
at IN N
presentation NN N
was VBD N
7.3 CD N
( ( N
SD NNP N
6.2 CD N
) ) N
points NNS N
No DT N
consultations NNS N
were VBD N
aborted VBN N
; : N
however RB N
, , N
technical JJ N
problems NNS N
( ( N
74 CD N
% NN N
) ) N
were VBD N
prevalent JJ N
in IN N
the DT N
telemedicine NN N
arm NN N
Overall JJ N
, , N
the DT N
correct JJ N
treatment NN N
decision NN N
was VBD N
established VBN N
in IN N
87 CD N
% NN N
of IN N
the DT N
consultations NNS N
Both DT N
modalities NNS N
, , N
telephone NN N
( ( N
89 CD N
% NN N
correct NN N
) ) N
and CC N
telemedicine NN N
( ( N
85 CD N
% NN N
correct NN N
) ) N
, , N
performed VBN N
well RB N
Intravenous JJ N
thrombolytic JJ N
treatment NN N
was VBD N
used VBN N
in IN N
30 CD N
% NN N
of IN N
the DT N
telemedicine NN N
and CC N
telephone NN N
consultations NNS N
Good JJ N
functional JJ N
outcomes NNS N
at IN N
90 CD N
days NNS N
were VBD N
not RB N
significantly RB N
different JJ N
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
mortality NN N
( ( N
4 CD N
% NN N
in IN N
telemedicine NN N
and CC N
11 CD N
% NN N
in IN N
telephone NN N
) ) N
or CC N
rates NNS N
of IN N
intracerebral JJ N
hemorrhage NN N
( ( N
4 CD N
% NN N
in IN N
telemedicine NN N
and CC N
0 CD N
% NN N
in IN N
telephone NN N
) ) N
CONCLUSIONS VB N
It PRP N
is VBZ N
feasible JJ N
to TO N
extend VB N
the DT N
original JJ N
STRokE NNP N
DOC NNP N
trial NN N
protocol NN N
to TO N
a DT N
new JJ N
state NN N
and CC N
establish VB N
an DT N
operational JJ N
single-hub NN N
, , N
multispoke VBD N
rural JJ N
hospital NN N
telestroke VBD N
research NN N
network NN N
in IN N
Arizona NNP N
The DT N
trial NN N
was VBD N
not RB N
designed VBN N
to TO N
have VB N
sufficient JJ N
power NN N
to TO N
detect VB N
a DT N
difference NN N
between IN N
the DT N
2 CD N
consultative JJ N
modes NNS N
: : N
telemedicine NN N
and CC N
telephone-only RB N
Whether CC N
by IN N
telemedicine NN N
or CC N
telephone NN N
consultative JJ N
modalities NNS N
, , N
there EX N
were VBD N
appropriate JJ N
treatment NN N
decisions NNS N
, , N
high JJ N
rates NNS N
of IN N
thrombolysis NN N
use NN N
, , N
improved VBN N
data NNS N
collection NN N
, , N
low JJ N
rates NNS N
of IN N
intracerebral JJ N
hemorrhage NN N
, , N
and CC N
equally RB N
favorable JJ N
time NN N
requirements NNS N
The DT N
learning VBG N
curve NN N
was VBD N
steep JJ N
for IN N
the DT N
hub NN N
and CC N
spoke VBD N
personnel NNS N
of IN N
the DT N
new JJ N
telestroke NN N
network NN N
, , N
as IN N
reflected VBN N
by IN N
frequent JJ N
technical JJ N
problems NNS N
Overall NNP N
, , N
the DT N
results NNS N
support VBD N
the DT N
effectiveness NN N
of IN N
highly RB N
organized VBN N
and CC N
structured VBN N
stroke NN N
telemedicine NN N
networks NNS N
for IN N
extending VBG N
expert JJ N
stroke NN N
care NN N
into IN N
rural JJ N
remote JJ N
communities NNS N
lacking VBG N
sufficient JJ N
neurological JJ N
expertise NN N
-DOCSTART- -X- O O 20708275

Changes NNS N
in IN N
sleep JJ N
quality NN N
, , N
but CC N
not RB N
hormones VB N
predict JJ N
time NN N
to TO N
postpartum VB N
depression NN N
recurrence NN N
BACKGROUND NNP N
Poor NNP N
sleep JJ N
quality NN N
, , N
dysregulation NN N
of IN N
hormones NNS N
and CC N
increased VBD N
inflammatory JJ N
cytokines NNS N
are VBP N
all DT N
associated VBN N
with IN N
the DT N
risk NN N
for IN N
postpartum NN N
major JJ N
depression NN N
( ( N
PPMD NNP N
) ) N
We PRP N
evaluated VBD N
change NN N
over IN N
time NN N
in IN N
sleep JJ N
quality NN N
and CC N
hormones NNS N
during IN N
the DT N
first JJ N
17 CD N
weeks NNS N
postpartum RB N
, , N
as RB N
well RB N
as IN N
a DT N
single JJ N
cytokine NN N
measure NN N
, , N
and CC N
their PRP$ N
association NN N
with IN N
PPMD NNP N
recurrence NN N
METHODS JJ N
Participants NNS N
were VBD N
pregnant JJ 4_p
women NNS 2_p
( ( 3_p
N=56 NNP 3_p
) ) 3_p
, , N
with IN N
past JJ N
histories NNS N
of IN N
MDD/PPMD NNP 4_p
but CC 4_p
not RB 4_p
depressed VBN 4_p
in IN 4_p
their PRP$ 4_p
current JJ 4_p
pregnancy NN 4_p
The DT N
Pittsburgh NNP N
Sleep NNP N
Quality NNP N
Index NNP N
( ( N
PSQI NNP N
) ) N
and CC N
blood NN N
samples NNS N
were VBD N
collected VBN N
8 CD N
times NNS N
during IN N
the DT N
first JJ N
17 CD N
weeks NNS N
postpartum NN N
Estradiol NNP N
, , N
prolactin NN N
and CC N
cortisol NN N
, , N
and CC N
a DT N
single JJ N
measure NN N
of IN N
IL-6 NNP N
were VBD N
assayed VBN N
Recurrence NN N
was VBD N
determined VBN N
by IN N
two CD N
consecutive JJ N
21-item JJ N
Hamilton NNP N
Rating NNP N
Scale NNP N
for IN N
Depression NNP N
( ( N
HRSD NNP N
) ) N
scores≥15 NN N
and CC N
clinician JJ N
interview NN N
RESULTS NNP N
In IN N
the DT N
analyses NNS N
of IN N
time NN N
to TO N
PPMD NNP N
recurrence NN N
, , N
poor JJ N
sleep JJ N
quality NN N
, , N
but CC N
none NN N
of IN N
the DT N
hormones NNS N
, , N
was VBD N
associated VBN N
with IN N
PPMD NNP N
recurrence NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
after IN N
controlling VBG N
for IN N
medication NN N
assignment NN N
With IN N
every DT N
one CD N
point NN N
increase NN N
in IN N
PSQI NNP N
scores NNS N
across IN N
time NN N
, , N
a DT N
woman NN N
's POS N
risk NN N
for IN N
recurrence NN N
increased VBN N
by IN N
approximately RB N
25 CD N
% NN N
There EX N
was VBD N
no DT N
significant JJ N
association NN N
between IN N
PSQI NNP N
scores NNS N
and CC N
IL-6 NNP N
concentrations NNS N
in IN N
early JJ N
postpartum NN N
( ( N
χ NNP N
( ( N
2 CD N
) ) N
=0.98 NN N
, , N
p=.32 NN N
) ) N
CONCLUSIONS NNP N
Poor NNP N
sleep VBP N
quality NN N
across IN N
the DT N
first JJ N
17 CD N
weeks NNS N
post-delivery JJ N
increases NNS N
the DT N
risk NN N
for IN N
recurrent JJ N
PPMD NNP N
among IN N
women NNS 2_p
with IN N
a DT N
history NN N
of IN N
MDD NNP 4_p
Changes NNS N
in IN N
the DT N
hormonal JJ N
milieu NN N
were VBD N
not RB N
associated VBN N
with IN N
recurrence NN N
Further JJ N
exploration NN N
of IN N
the DT N
degree NN N
to TO N
which WDT N
poor JJ N
sleep NN N
contributes NNS N
to TO N
hormonal JJ N
and CC N
cytokine JJ N
dysregulation NN N
and CC N
how WRB N
they PRP N
are VBP N
involved VBN N
in IN N
the DT N
pathophysiology NN N
of IN N
PPMD NNP N
is VBZ N
warranted VBN N
-DOCSTART- -X- O O 8104273

Citalopram NNP N
for IN N
post-stroke JJ N
pathological JJ N
crying NN N
Post-stroke NNP N
pathological JJ N
crying NN N
is VBZ N
a DT N
distressing VBG N
condition NN N
in IN N
which WDT N
episodes VBZ N
occur VBP N
in IN N
response NN N
to TO N
minor VB N
stimuli NNS N
without IN N
associated VBN N
mood NN N
changes NNS N
There EX N
is VBZ N
preliminary JJ N
evidence NN N
of IN N
disturbed JJ N
serotoninergic JJ N
neurotransmission NN N
in IN N
such JJ N
cases NNS N
We PRP N
investigated VBD N
the DT N
effect NN N
of IN N
the DT N
selective JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
citalopram NN N
on IN N
uncontrolled JJ N
crying NN N
in IN N
stroke NN 4_p
patients NNS N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
crossover NN N
study NN N
16 CD 3_p
consecutive JJ N
patients NNS N
( ( N
median JJ N
age NN N
58.5 CD 1_p
years NNS 1_p
, , 1_p
range VB 1_p
40-83 JJ 1_p
) ) N
entered VBD N
the DT N
9-week JJ N
study NN N
a DT N
median NN N
of IN N
168 CD N
days NNS N
( ( N
range VB N
6-913 NNP N
) ) N
post NN N
stroke NN N
and CC N
were VBD N
treated VBN N
with IN N
citalopram JJ N
10-20 JJ N
mg NNS N
daily RB N
for IN N
3 CD N
weeks NNS N
Crying VBG 4_p
history NN 4_p
was VBD N
determined VBN N
from IN N
semistructured VBN N
interviews NNS N
and CC N
from IN N
diaries NNS N
kept VBN N
by IN N
the DT N
patients NNS N
Psychiatric NNP N
assessment NN N
was VBD N
made VBN N
with IN N
the DT N
Hamilton NNP N
depression NN N
scale NN N
( ( N
HDS NNP N
) ) N
, , N
and CC N
unwanted JJ N
effects NNS N
were VBD N
measured VBN N
with IN N
the DT N
UKU NNP N
side-effect JJ N
scale NN N
In IN N
13 CD 3_p
patients NNS N
in IN N
whom WP N
frequency NN N
of IN N
crying NN 4_p
could MD N
be VB N
assessed VBN N
, , N
the DT N
number NN N
of IN N
daily JJ N
crying VBG N
episodes NNS N
decreased VBN N
by IN N
at IN N
least JJS N
50 CD N
% NN N
in IN N
all DT N
cases NNS N
during IN N
citalopram JJ N
treatment NN N
vs NN N
2 CD N
patients NNS N
during IN N
placebo JJ N
treatment NN N
( ( N
p JJ N
< NN N
0.005 CD N
, , N
McNemar NNP N
's POS N
test NN N
) ) N
, , N
the DT N
effect NN N
being VBG N
rapid JJ N
( ( N
1-3 JJ N
days NNS N
) ) N
and CC N
pronounced VBN N
in IN N
11 CD N
( ( N
73 CD N
% NN N
) ) N
There EX N
was VBD N
a DT N
concomitant JJ N
significant JJ N
decrease NN N
in IN N
depression NN N
rating NN N
from IN N
HDS NNP N
8.9 CD N
to TO N
5.3 CD N
( ( N
p NN N
< VBZ N
0.005 CD N
, , N
Wilcoxon NNP N
's POS N
test NN N
) ) N
Citalopram NNP N
was VBD N
well RB N
tolerated VBN N
, , N
the DT N
few JJ N
side-effects NNS N
being VBG N
mild JJ N
and CC N
transient JJ N
We PRP N
conclude VBP N
that IN N
serotoninergic JJ N
neurotransmission NN N
plays VBZ N
an DT N
important JJ N
part NN N
in IN N
post-stroke JJ N
pathological JJ N
crying NN N
and CC N
that DT N
citalopram NN N
is VBZ N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
treatment NN N
-DOCSTART- -X- O O 12108617

Double-blind JJ N
placebo-controlled JJ N
trial NN N
of IN N
secretin NN N
: : N
effects NNS N
on IN N
aberrant JJ N
behavior NN N
in IN N
children NNS 4_p
with IN 4_p
autism NN 4_p
Secretin NNP N
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
treatment NN N
alternative NN N
for IN N
autistic JJ N
spectrum NN N
disorders NNS N
, , N
but CC N
empirical JJ N
support NN N
is VBZ N
lacking VBG N
A DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
synthetic JJ N
human JJ N
secretin NN N
on IN N
aberrant JJ N
behavior NN N
Parent NN N
and CC N
teacher NN N
data NNS N
from IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
for IN N
eight CD N
male JJ N
children NNS N
were VBD N
analyzed VBN N
for IN N
reliable JJ N
change NN N
in IN N
a DT N
clinical JJ N
replication NN N
series NN N
By IN N
parent NN N
and CC N
teacher NN N
report NN N
, , N
the DT N
majority NN N
of IN N
change NN N
occurred VBD N
either CC N
on IN N
the DT N
placebo NN N
trial NN N
or CC N
reflected VBN N
deterioration NN N
subsequent NN N
to TO N
secretin VB N
infusion NN N
Repeated-measures JJ N
multivariate JJ N
analysis NN N
of IN N
variance NN N
results NNS N
were VBD N
similar JJ N
Results NNS N
are VBP N
consistent JJ N
with IN N
other JJ N
studies NNS N
, , N
suggesting VBG N
that IN N
secretin NN N
may MD N
not RB N
be VB N
an DT N
effective JJ N
treatment NN N
option NN N
-DOCSTART- -X- O O 8960488

Dental JJ N
bacteremia NN N
in IN 1_p
children NNS 1_p
Bacteremia NNP N
resulting VBG N
from IN N
dental JJ N
extraction NN N
is VBZ N
regarded VBN N
as IN N
an DT N
important JJ N
cause NN N
of IN N
bacterial JJ N
endocarditis NN N
, , N
and CC N
it PRP N
is VBZ N
therefore RB N
recommended JJ N
that IN N
patients NNS 4_p
undergoing VBG 4_p
tooth DT 4_p
extraction NN 4_p
be VB N
given VBN N
prophylactic JJ N
antibiotics NNS N
As IN N
dental JJ N
procedures NNS N
other JJ N
than IN N
extractions NNS N
may MD N
also RB N
cause VB N
bacteremias NN N
, , N
we PRP N
studied VBD N
a DT N
variety NN N
of IN N
dental JJ N
procedures NNS N
routinely RB N
used VBN N
in IN N
pediatric JJ N
dentistry NN N
Blood NNP N
samples NNS N
for IN N
cultures NNS N
were VBD N
obtained VBN N
30 CD N
s NNS N
after IN N
each DT N
of IN N
13 CD N
dental JJ N
operative JJ N
procedures NNS N
in IN N
735 CD 3_p
anesthetized JJ N
children NNS 1_p
aged VBN 1_p
2-16 CD 1_p
years NNS 1_p
Four CD N
procedures NNS N
used VBN N
for IN N
conservative JJ N
dentistry NN N
caused VBD N
bacteremias NNS N
significantly RB N
more RBR N
often RB N
than IN N
the DT N
baseline JJ N
value NN N
of IN N
9.4 CD N
% NN N
: : N
polishing NN N
teeth VBZ N
24.5 CD N
% NN N
, , N
intraligamental JJ N
injection NN N
96.6 CD N
% NN N
, , N
rubber VB N
dam JJ N
placement NN N
29.4 CD N
% NN N
, , N
and CC N
matrix NNS N
band VBP N
with IN N
wedge NN N
placement NN N
32.1 CD N
% NN N
In IN N
comparison NN N
, , N
toothbrushing VBG N
alone RB N
caused VBD N
a DT N
bacteremia NN N
on IN N
38.5 CD N
% NN N
of IN N
occasions NNS N
The DT N
organisms NNS N
isolated VBN N
were VBD N
typical JJ N
of IN N
odontogenic JJ N
bacteremias NN N
in IN N
that DT N
50 CD N
% NN N
of IN N
the DT N
isolates NNS N
were VBD N
identified VBN N
as IN N
varieties NNS N
of IN N
viridans NNS N
streptococci VBP N
These DT N
data NNS N
show VBP N
that IN N
a DT N
wider JJR N
variety NN N
of IN N
dental NN N
procedures NNS N
than IN N
was VBD N
previously RB N
documented VBN N
cause NN N
bacteremia NN N
-DOCSTART- -X- O O 17357577

[ JJ N
Effect NNP N
of IN N
alpha JJ N
dihydroergocryptine NN N
in IN N
patients NNS 4_p
with IN 4_p
fibrocystic JJ 4_p
breast NN 4_p
disease NN 4_p
] NNP N
OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
alpha JJ N
dihidroergocriptine NN N
in IN N
patients NNS 4_p
with IN 4_p
fibrocystic JJ 4_p
mastopathy NN 4_p
PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
with IN N
diagnosis NN N
of IN N
fibrocystic JJ 4_p
breast NN 4_p
disease NN 4_p
were VBD N
included VBN N
in IN N
a DT N
prospective JJ N
longitudinal JJ N
blind NN N
double NN N
, , N
controlled VBN N
with IN N
placebo NN N
study NN N
Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
treatment NN N
groups NNS N
: : N
of IN N
treatment NN N
group NN N
A DT N
: : N
Alpha NNP N
dihidroergocriptine VBP N
tablets NNS N
of IN N
10 CD N
mg NNS N
, , N
group NN N
B NNP N
: : N
Placebo NN N
, , N
during IN N
6 CD N
months NNS N
After IN N
to TO N
basal VB N
evaluation NN N
, , N
the DT N
patients NNS N
were VBD N
revised VBN N
in IN N
a DT N
monthly JJ N
way NN N
evaluating VBG N
the DT N
following NN N
symptoms NNS N
and CC N
signs NNS N
: : N
mastalgia NN N
, , N
mammary JJ N
tension NN N
, , N
presence NN N
of IN N
nodules NNS N
, , N
nipple JJ N
secretion NN N
, , N
and CC N
the DT N
presence NN N
of IN N
adverse JJ N
events NNS N
RESULTS NNP N
39 CD 3_p
patients NNS N
with IN N
alpha JJ 4_p
dihidroergocriptine NN 4_p
and CC N
38 CD 3_p
with IN N
placebo NN 4_p
Mastodinia NNP N
, , N
a DT N
satisfactory JJ N
response NN N
was VBD N
observed VBN N
in IN N
100 CD N
% NN N
of IN N
alpha JJ N
dihidroergocriptine NN N
group NN N
vs VBD N
61.11 CD N
% NN N
of IN N
placebo NN N
group NN N
( ( N
p JJ N
= NNP N
0.0002 CD N
) ) N
Mastalgia NNP N
responded VBD N
in IN N
100 CD N
% NN N
of IN N
alpha JJ N
dihidroergocriptine NN N
group NN N
vs VBD N
64.86 CD N
% NN N
of IN N
placebo NN N
group NN N
( ( N
p JJ N
= NNP N
0.0003 CD N
) ) N
Galactorrea NNP N
responded VBD N
100 CD N
% NN N
of IN N
alpha JJ N
dihidroergocriptine NN N
group NN N
vs VBD N
93.33 CD N
% NN N
of IN N
the DT N
placebo NN N
The DT N
nodules NNS N
in IN N
the DT N
group NN N
alpha VBZ N
dihidroergocriptine NN N
disappeared VBD N
in IN N
23.1 CD N
% NN N
and CC N
in IN N
21.1 CD N
% NN N
of IN N
the DT N
placebo NN N
group NN N
Ultrasound IN N
evaluation NN N
of IN N
the DT N
nodules NNS N
did VBD N
not RB N
show VB N
significant JJ N
differences NNS N
between IN N
both DT N
groups NNS N
Prolactin NNP N
levels NNS N
showed VBD N
a DT N
decrease NN N
in IN N
the DT N
group NN N
treated VBD N
with IN N
alpha JJ N
dihidroergocriptine NN N
with IN N
an DT N
important JJ N
difference NN N
between IN N
both DT N
groups NNS N
at IN N
the DT N
end NN N
of IN N
the DT N
6 CD N
months NNS N
study JJ N
period NN N
There EX N
were VBD N
not RB N
differences NNS N
in IN N
the DT N
presence NN N
of IN N
adverse JJ N
events NNS N
between IN N
groups NNS N
CONCLUSIONS NNP N
Alpha NNP N
dihidroergocriptine NN N
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
fribrocystic JJ 4_p
breast NN 4_p
disease NN 4_p
with IN N
minimum JJ N
adverse JJ N
events NNS N
when WRB N
compared VBN N
with IN N
similar JJ N
drugs NNS N
-DOCSTART- -X- O O 9828635

[ JJ N
Radiotherapy NNP N
for IN N
choroidal JJ N
neovascularization NN N
in IN N
age-related JJ N
macular JJ N
degeneration NN N
A DT N
pilot NN N
study NN N
using VBG N
low- JJ N
versus NN N
high-dose JJ N
photon NN N
bean NN N
radiation NN N
] NN N
PURPOSE NNP N
Several JJ N
pilot NN N
studies NNS N
have VBP N
indicated VBN N
that IN N
low-dose JJ N
radiation NN N
therapy NN N
might MD N
have VB N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
course NN N
of IN N
choroidal JJ N
neovascularization NN N
( ( N
CNV NNP N
) ) N
in IN N
age-related JJ 4_p
macular JJ 4_p
degeneration NN 4_p
( ( 4_p
AMD NNP 4_p
) ) 4_p
This DT N
study NN N
aimed VBD N
to TO N
ascertain VB N
whether IN N
such JJ N
treatment NN N
might MD N
halt VB N
the DT N
progression NN N
of IN N
neovascular JJ N
AMD NNP N
and CC N
whether IN N
a DT N
low JJ N
or CC N
a DT N
high JJ N
radiation NN N
dose NN N
should MD N
be VB N
applied VBN N
PATIENTS VB N
The DT N
patients NNS 4_p
comprised VBD 4_p
some DT 4_p
randomized VBN 4_p
to TO 4_p
0 CD 4_p
vs NNS 4_p
10 CD 4_p
vs NNS 4_p
36 CD 4_p
Gy NNP 4_p
of IN 4_p
radiation NN 4_p
and CC 4_p
( ( 4_p
after IN 4_p
a DT 4_p
change NN 4_p
of IN 4_p
the DT 4_p
study NN 4_p
protocol NN 4_p
became VBD 4_p
necessary JJ 4_p
) ) 4_p
others NNS 4_p
who WP 4_p
participated VBD 4_p
in IN 4_p
a DT 4_p
prospective JJ 4_p
, , 4_p
controlled VBD 4_p
non-randomized JJ 4_p
pilot NN 4_p
study NN 4_p
Enclosed VBN N
were VBD N
eyes NNS N
with IN N
visual JJ N
acuity NN N
of IN N
> NN N
or CC N
= VB N
0.1 CD N
and CC N
< NNP N
or CC N
= $ N
0.6 CD N
revealing VBG N
a DT N
juxta-subfoveal JJ N
CNV NNP N
either NN N
of IN N
the DT N
occult NN N
type NN N
( ( N
type JJ N
1 CD N
) ) N
or CC N
the DT N
classic JJ N
type NN N
( ( N
isolated JJ N
or CC N
as IN N
part NN N
of IN N
a DT N
predominantly RB N
occult JJ N
lesion NN N
) ) N
RESULTS NNP N
Eyes NNP N
treated VBD N
with IN N
10 CD N
Gy NNP N
for IN N
occult NN N
CNV NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
were VBD N
subject JJ N
to TO N
severe JJ N
visual JJ N
loss NN N
in IN N
41.6 CD N
% NN N
of IN N
the DT N
cases NNS N
compared VBN N
to TO N
38.5 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
at IN N
12 CD N
months NNS N
of IN N
follow-up NN N
For IN N
eyes NNS N
treated VBN N
with IN N
10 CD N
Gy NNP N
because IN N
of IN N
classic JJ N
CNV NNP N
, , N
the DT N
corresponding JJ N
figures NNS N
were VBD N
33 CD N
% NN N
( ( N
n JJ N
= NNP N
18 CD N
) ) N
and CC N
57 CD N
% NN N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
respectively RB N
At IN N
18 CD N
months NNS N
of IN N
follow-up NN N
, , N
the DT N
percentages NNS N
were VBD N
63 CD N
% NN N
and CC N
75 CD N
% NN N
respectively RB N
Fluorescein NNP N
angiographic JJ N
growth NN N
of IN N
classic JJ N
and CC N
occult NN N
CNV NNP N
could MD N
not RB N
be VB N
halted VBN N
by IN N
10 CD N
Gy NNP N
, , N
while IN N
a DT N
temporary JJ N
growth NN N
retardation NN N
was VBD N
observed VBN N
in IN N
cases NNS N
irradiated VBN N
with IN N
36 CD N
Gy NNP N
CONCLUSION NNP N
In IN N
the DT N
study NN N
presented VBD N
, , N
the DT N
natural JJ N
course NN N
of IN N
occult NN N
CNV NNP N
could MD N
not RB N
be VB N
improved VBN N
by IN N
irradiation NN N
with IN N
10 CD N
or CC N
36 CD N
Gy NNP N
In IN N
cases NNS N
of IN N
classic JJ N
CNV NNP N
, , N
low-dose JJ N
irradiation NN N
with IN N
10 CD N
Gy NNP N
postponed VBD N
severe JJ N
visual JJ N
loss NN N
by IN N
a DT N
maximum NN N
of IN N
18 CD N
months NNS N
A DT N
positive JJ N
treatment NN N
effect NN N
was VBD N
also RB N
observed VBN N
in IN N
cases NNS N
irradiated VBN N
with IN N
36 CD N
Gy NNP N
; : N
however RB N
, , N
a DT N
25 CD N
% NN N
incidence NN N
of IN N
radiation NN N
retinopathy NN N
seems VBZ N
unacceptable JJ N
-DOCSTART- -X- O O 11683967

Equivalent JJ N
efficacy NN N
of IN N
mitomycin NN N
C NNP N
plus CC N
doxorubicin JJ N
instillation NN N
to TO N
bacillus VB N
Calmette-Guerin NNP N
therapy NN N
for IN N
carcinoma NN N
in IN N
situ NN N
of IN N
the DT N
bladder NN N
BACKGROUND NNP N
To TO N
elucidate VB N
the DT N
most RBS N
efficient JJ N
topical JJ N
therapy NN N
for IN N
carcinoma NN N
in IN N
situ NN N
of IN N
the DT N
bladder NN N
, , N
the DT N
efficacy NN N
of IN N
intravesical JJ N
mitomycin NN N
C NNP N
plus CC N
doxorubicin JJ N
therapy NN N
was VBD N
compared VBN N
with IN N
bacillus JJ N
Calmette-Guerin NNP N
( ( N
BCG NNP N
) ) N
therapy NN N
The DT N
clinical JJ N
behavior NN N
of IN N
the DT N
tumor NN N
was VBD N
analysed VBN N
according VBG N
to TO N
the DT N
histological JJ N
grade NN N
METHODS NNP N
Forty-two JJ N
patients NNS N
with IN N
carcinoma NN 4_p
in IN N
situ NN N
of IN N
the DT N
bladder NN N
were VBD N
randomized VBN N
to TO N
intravesical JJ N
BCG NNP N
( ( N
21 CD N
patients NNS N
) ) N
or CC N
mitomycin JJ N
C NNP N
plus CC N
doxorubicin JJ N
sequential JJ N
therapy NN N
( ( N
21 CD N
patients NNS N
) ) N
as IN N
first JJ N
line NN N
treatment NN N
The DT N
non-responders JJ N
underwent NN N
the DT N
subsequent JJ N
instillation NN N
of IN N
the DT N
other JJ N
intravesical JJ N
therapy NN N
alternately RB N
Of IN N
the DT N
patients NNS N
, , N
27 CD N
had VBD N
grade VBN N
2 CD N
and CC N
15 CD N
had VBD N
grade VBN N
3 CD N
cancer NN N
RESULTS NNP N
Both NNP N
topical JJ N
therapies NNS N
were VBD N
equally RB N
effective JJ N
with IN N
initial JJ N
response NN N
rates NNS N
of IN N
86 CD N
% NN N
( ( N
18/21 CD N
) ) N
for IN N
BCG NNP N
and CC N
81 CD N
% NN N
( ( N
17/21 CD N
) ) N
for IN N
mitomycin NN N
C NNP N
plus CC N
doxorubicin NN N
, , N
irrespective NN N
of IN N
the DT N
tumor NN N
grade NN N
Of IN N
seven CD N
initial JJ N
non-responders NNS N
, , N
five CD N
patients NNS N
achieved VBD N
a DT N
complete JJ N
response NN N
by IN N
subsequent JJ N
instillation NN N
, , N
resulting VBG N
in IN N
a DT N
total JJ N
response NN N
rate NN N
of IN N
95 CD N
% NN N
After IN N
a DT N
mean JJ N
follow-up NN N
of IN N
47 CD N
months NNS N
, , N
five CD N
patients NNS N
( ( N
12 CD N
% NN N
) ) N
developed VBD N
disease JJ N
progression NN N
The DT N
progression NN N
rates NNS N
were VBD N
not RB N
different JJ N
between IN N
the DT N
topical JJ N
therapies NNS N
, , N
but CC N
were VBD N
significantly RB N
higher JJR N
in IN N
grade NN N
3 CD N
than IN N
in IN N
grade JJ N
2 CD N
cases NNS N
CONCLUSION VB N
It PRP N
appears VBZ N
likely JJ N
that IN N
mitomycin VBZ N
C NNP N
plus CC N
doxorubicin JJ N
instillation NN N
has VBZ N
an DT N
equivalent JJ N
efficacy NN N
to TO N
BCG NNP N
as IN N
the DT N
initial JJ N
therapy NN N
of IN N
carcinoma NN N
in IN N
situ NN N
and CC N
the DT N
combination NN N
of IN N
them PRP N
would MD N
be VB N
the DT N
most RBS N
efficient JJ N
treatment NN N
for IN N
the DT N
disease NN N
Moreover RB N
, , N
histological JJ N
grading NN N
would MD N
be VB N
clinically RB N
useful JJ N
in IN N
defining VBG N
the DT N
tumor NN N
characteristics NNS N
and CC N
behavior NN N
of IN N
carcinoma NN N
in IN N
situ NN N
of IN N
the DT N
bladder NN N
-DOCSTART- -X- O O 24371832

Effects NNS N
of IN N
water NN N
extracts NNS N
of IN N
Graptopetalum NNP N
paraguayense NN N
on IN N
blood NN N
pressure NN N
, , N
fasting VBG N
glucose NN N
, , N
and CC N
lipid JJ N
profiles NNS N
of IN N
subjects NNS 4_p
with IN 4_p
metabolic JJ 4_p
syndrome NN 4_p
This DT N
study NN N
was VBD N
aimed VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
water NN N
extracts NNS N
of IN N
Graptopetalum NNP N
paraguayense NN N
( ( N
WGP NNP N
, , N
4 CD N
g/d NN N
) ) N
on IN N
blood NN N
pressure NN N
, , N
blood NN N
glucose JJ N
level NN N
, , N
and CC N
lipid JJ N
profiles NNS N
in IN N
subjects NNS 4_p
with IN 4_p
metabolic JJ 4_p
syndrome NN 4_p
( ( 4_p
MS NNP 4_p
) ) 4_p
Participants NNS 4_p
with IN 4_p
MS NNP 4_p
( ( N
n JJ 3_p
= NNP 3_p
54 CD 3_p
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
placebo NN N
( ( N
n JJ N
= NNP N
28 CD N
) ) N
and CC N
WGP NNP N
groups NNS N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
, , N
and CC N
the DT N
intervention NN N
was VBD N
administered VBN N
for IN N
12 CD N
weeks NNS N
Systolic NNP N
blood NN N
pressure NN N
( ( N
SBP NNP N
) ) N
, , N
diastolic JJ N
blood NN N
pressure NN N
( ( N
DBP NNP N
) ) N
, , N
fasting VBG N
glucose NN N
( ( N
FG NNP N
) ) N
, , N
lipid JJ N
profiles NNS N
( ( N
total JJ N
cholesterol NN N
( ( N
TC NNP N
) ) N
, , N
triglyceride RB N
( ( N
TG NNP N
) ) N
, , N
low JJ N
density NN N
lipoprotein NN N
cholesterol NN N
( ( N
LDL-C NNP N
) ) N
, , N
and CC N
high JJ N
density NN N
lipoprotein NN N
( ( N
HDL-C NNP N
) ) N
) ) N
, , N
and CC N
antioxidant JJ N
enzymes NNS N
activities NNS N
( ( N
catalase NN N
( ( N
CAT NNP N
) ) N
, , N
superoxide JJ N
dismutase NN N
( ( N
SOD NNP N
) ) N
, , N
and CC N
glutathione NN N
peroxidase NN N
( ( N
GPx NNP N
) ) N
) ) N
were VBD N
measured VBN N
Forty-two JJ 3_p
subjects NNS 3_p
completed VBD N
the DT N
study NN N
( ( N
placebo NN N
, , N
n JJ 3_p
= VBP 3_p
19 CD 3_p
; : N
WGP NNP N
, , N
n JJ 3_p
= NNP 3_p
23 CD 3_p
) ) N
FG NNP N
, , N
SBP NNP N
, , N
and CC N
LDL-C JJ N
levels NNS N
were VBD N
significantly RB N
lower JJR N
and CC N
HDL-C NNP N
level NN N
and CC N
antioxidant JJ N
enzymes NNS N
activities NNS N
( ( N
CAT NNP N
and CC N
SOD NNP N
) ) N
were VBD N
significantly RB N
higher JJR N
after IN N
WGP NNP N
supplementation NN N
Blood NNP N
pressure NN N
, , N
FG NNP N
, , N
and CC N
lipid JJ N
profiles NNS N
were VBD N
significantly RB N
correlated VBN N
with IN N
antioxidant JJ N
enzymes NNS N
activities NNS N
after IN N
supplementation NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
The DT N
present JJ N
study NN N
demonstrated VBD N
a DT N
significant JJ N
reduction NN N
in IN N
blood NN N
pressure NN N
, , N
blood NN N
glucose NN N
, , N
and CC N
lipid JJ N
profiles NNS N
and CC N
an DT N
increase NN N
in IN N
antioxidant JJ N
enzymes NNS N
activities NNS N
in IN N
subjects NNS 4_p
with IN 4_p
MS NNP 4_p
after IN N
WGP NNP N
supplementation NN N
Taken VB N
together RB N
, , N
the DT N
antioxidative JJ N
capacity NN N
of IN N
WGP NNP N
might MD N
exert VB N
a DT N
beneficial JJ N
effect NN N
on IN N
MS NNP N
This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
NCT01463748 NNP N
-DOCSTART- -X- O O 20020319

Randomized VBN N
controlled JJ N
trial NN N
for IN N
early JJ N
intervention NN N
for IN N
autism NN N
: : N
a DT N
pilot NN N
study NN N
of IN N
the DT N
Autism NNP N
1-2-3 JJ N
Project NNP N
We PRP N
piloted VBD N
a DT N
2-week JJ N
" JJ N
Autism-1-2-3 NNP N
" NNP N
early JJ N
intervention NN N
for IN N
children NNS 1_p
with IN N
autism NN 4_p
and CC N
their PRP$ N
parents NNS N
immediately RB N
after IN N
diagnosis NN N
that WDT N
targeted VBD N
at IN N
( ( N
1 CD N
) ) N
eye NN N
contact NN N
, , N
( ( N
2 CD N
) ) N
gesture NN N
and CC N
( ( N
3 CD N
) ) N
vocalization/words NNS N
Seventeen JJ 3_p
children NNS N
were VBD N
randomized VBN N
into IN N
the DT N
Intervention NNP N
( ( N
n JJ N
= NNP N
9 CD 3_p
) ) N
and CC N
Control NNP N
( ( N
n JJ N
= NNP N
8 CD 3_p
) ) N
groups NNS N
Outcome NNP N
measures NNS N
included VBD N
the DT N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
, , N
Ritvo-Freeman NNP N
Real NNP N
Life NNP N
Rating NNP N
Scale NNP N
, , N
Symbolic NNP N
Play NNP N
Test NNP N
, , N
and CC N
Parenting NNP N
Stress NNP N
Index NNP N
Children NNP N
with IN N
autism NN N
improved VBN N
in IN N
language/communication NN N
, , N
reciprocal JJ N
social JJ N
interaction NN N
, , N
and CC N
symbolic JJ N
play NN N
Parents NNS N
perceived VBD N
significant JJ N
improvement NN N
in IN N
their PRP$ N
children NNS N
's POS N
language NN N
, , N
social JJ N
interaction NN N
, , N
and CC N
their PRP$ N
own JJ N
stress NN N
level NN N
This DT N
intervention NN N
can MD N
serve VB N
as IN N
short-term JJ N
training NN N
on IN N
communication NN N
and CC N
social JJ N
interaction NN N
for IN N
children NNS N
with IN N
autism NN N
, , N
and CC N
reduce VB N
the DT N
stress NN N
of IN N
their PRP$ N
parents NNS N
during IN N
the DT N
long JJ N
waiting NN N
time NN N
for IN N
public JJ N
health NN N
services NNS N
-DOCSTART- -X- O O 3550340

The DT N
effects NNS N
of IN N
delay NN N
in IN N
standard JJ N
treatment NN N
due JJ N
to TO N
induction VB N
chemotherapy NN N
in IN N
two CD N
randomized JJ N
prospective JJ N
studies NNS N
It PRP N
is VBZ N
often RB N
suggested VBN N
that IN N
tumors NNS N
will MD N
respond VB N
to TO N
induction VB N
chemotherapy NN N
and CC N
result NN N
in IN N
improved JJ N
survival NN N
for IN N
patients NNS 4_p
with IN 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
Two CD N
regimens NNS N
of IN N
induction NN N
chemotherapy NN N
were VBD N
studied VBN N
in IN N
separate JJ N
randomized VBN N
, , N
prospective JJ N
trials NNS N
over IN N
the DT N
last JJ N
6 CD N
years NNS N
Eighty-three JJ N
patients NNS N
with IN N
advanced JJ N
disease NN N
were VBD N
entered VBN N
into IN N
the DT N
first JJ N
study NN N
( ( N
43/chemotherapy CD N
; : N
40/control CD N
) ) N
, , N
and CC N
60 CD N
into IN N
the DT N
second JJ N
( ( N
27/chemotherapy CD N
; : N
33/control CD N
) ) N
Patient JJ N
randomization NN N
was VBD N
stratified VBN N
by IN N
stage NN N
( ( N
III/IV NNP N
) ) N
and CC N
site NN N
( ( N
oral JJ N
cavity NN N
, , N
oropharynx NN N
, , N
nasopharynx RB N
, , N
hypopharynx NN N
, , N
larynx NN N
, , N
paranasal NN N
sinuses NNS N
) ) N
The DT N
first JJ N
study NN N
utilized JJ N
bleomycin NN N
, , N
Cytoxan NNP N
, , N
methotrexate NN N
and CC N
5-fluorouracil JJ N
in IN N
two CD N
cycles NNS N
( ( N
one CD N
cycle NN N
if IN N
no DT N
tumor NN N
response NN N
) ) N
, , N
followed VBN N
by IN N
standard NN N
treatment NN N
which WDT N
consisted VBD N
of IN N
combined JJ N
irradiation NN N
and CC N
surgery NN N
or CC N
, , N
in IN N
some DT N
instances NNS N
, , N
primary JJ N
irradiation NN N
alone RB N
The DT N
second JJ N
study NN N
utilized VBD N
cisplatin NN N
and CC N
5-fluorouracil NN N
in IN N
three CD N
cycles NNS N
prior RB N
to TO N
standard VB N
treatment NN N
An DT N
objective JJ N
tumor NN N
response NN N
to TO N
chemotherapy NN N
was VBD N
observed VBN N
in IN N
68 CD N
% NN N
in IN N
the DT N
first JJ N
study NN N
and CC N
85 CD N
% NN N
in IN N
the DT N
second JJ N
The DT N
patient NN N
survival NN N
in IN N
both DT N
studies NNS N
( ( N
at IN N
24 CD N
months NNS N
in IN N
the DT N
first JJ N
; : N
at IN N
19 CD N
in IN N
the DT N
second JJ N
) ) N
was VBD N
better RBR N
in IN N
the DT N
control NN N
than IN N
that DT N
in IN N
the DT N
experimental JJ N
groups NNS N
( ( N
43 CD N
% NN N
to TO N
31 CD N
% NN N
; : N
69 CD N
% NN N
to TO N
46 CD N
% NN N
) ) N
In IN N
the DT N
second JJ N
study NN N
, , N
the DT N
average JJ N
length NN N
of IN N
delay NN N
of IN N
standard JJ N
treatment NN N
was VBD N
longer JJR N
than IN N
in IN N
the DT N
first JJ N
study NN N
( ( N
95 CD N
days NNS N
vs. FW N
66 CD N
days NNS N
; : N
P NNP N
less JJR N
than IN N
.02 NN N
) ) N
Results CC N
combining VBG N
the DT N
P-values NNS N
of IN N
both DT N
studies NNS N
indicate VBP N
that IN N
the DT N
relative JJ N
risk NN N
of IN N
having VBG N
persistent JJ N
disease NN N
was VBD N
2.9 CD N
times NNS N
greater JJR N
for IN N
patients NNS N
who WP N
received VBD N
chemotherapy NN N
While IN N
toxicity NN N
to TO N
chemotherapy VB N
was VBD N
not RB N
a DT N
factor NN N
in IN N
survival NN N
, , N
the DT N
number NN N
of IN N
patients NNS N
who WP N
withdrew VBP N
from IN N
the DT N
studies NNS N
and CC N
those DT N
who WP N
did VBD N
not RB N
comply VB N
with IN N
treatment NN N
were VBD N
greater JJR N
in IN N
the DT N
chemotherapy NN N
groups NNS N
Except IN N
for IN N
new JJ N
drug NN N
regimens NNS N
of IN N
exceptional JJ N
promise NN N
, , N
it PRP N
is VBZ N
recommended VBN N
that IN N
future JJ N
studies NNS N
be VB N
designed VBN N
so RB N
that IN N
chemotherapy NN N
is VBZ N
given VBN N
concurrent NN N
with IN N
, , N
or CC N
following VBG N
the DT N
completion NN N
of IN N
standard JJ N
treatment NN N
-DOCSTART- -X- O O 16266472

[ IN N
The DT N
comparison NN N
of IN N
the DT N
effect NN N
of IN N
enalapril NN N
and CC N
indapamide NN N
on IN N
the DT N
peripheral JJ N
blood NN N
pressure NN N
and CC N
central JJ N
blood NN N
pressure NN N
through IN N
pulse JJ N
wave NN N
analysis NN N
] NNP N
OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
the DT N
angiotensin-converting JJ N
enzyme NN N
( ( N
ACE NNP N
) ) N
inhibitor NN N
enalapril NN N
and CC N
diuretic JJ N
indapamide NN N
on IN N
the DT N
peripheral JJ N
blood NN N
pressure NN N
and CC N
the DT N
central JJ N
blood NN N
pressure NN N
in IN N
Chinese JJ 4_p
patients NNS 4_p
with IN 4_p
essential JJ 4_p
hypertension NN 4_p
METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
double JJ N
blind NN N
, , N
randomized VBN N
study NN N
Informed VBN N
consent NN N
were VBD N
given VBN N
by IN N
all DT N
patients NNS N
After IN N
2 CD N
weeks NNS N
of IN N
placebo JJ N
run-in JJ N
period NN N
, , N
105 CD 4_p
patients NNS 4_p
with IN 4_p
mild JJ 4_p
or CC 4_p
moderate JJ 4_p
essential JJ 4_p
hypertension NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
enalapril NN N
( ( N
10 CD N
mg NNS N
per IN N
day NN N
) ) N
or CC N
indapamide NN N
( ( N
2.5 CD N
mg NNS N
per IN N
day NN N
) ) N
for IN N
8 CD N
weeks NNS N
Radial JJ N
pulse JJ N
wave NN N
recordings NNS N
were VBD N
performed VBN N
in IN N
all PDT N
the DT N
patients NNS N
before IN N
the DT N
active JJ N
treatments NNS N
were VBD N
given VBN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
Only RB N
those DT N
patients NNS N
who WP N
have VBP N
finished VBN N
8 CD N
weeks NNS N
of IN N
active JJ N
treatment NN N
in IN N
both DT N
groups NNS N
were VBD N
included VBN N
into IN N
the DT N
final JJ N
analysis NN N
RESULTS NNP N
One CD N
hundred VBD N
one CD N
patients NNS N
( ( N
51 CD N
in IN N
enalapril NN N
group NN N
and CC N
50 CD N
in IN N
indapamide JJ N
group NN N
) ) N
completed VBD N
the DT N
study NN N
No DT N
significant JJ N
difference NN N
( ( N
all DT N
P NNP N
values NNS N
> VBP N
0.05 CD N
) ) N
was VBD N
found VBN N
in IN N
baseline NN N
data NNS N
between IN N
the DT N
two CD N
groups NNS N
After IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
, , N
all PDT N
the DT N
parameters NNS N
of IN N
pulse JJ N
wave NN N
( ( N
except IN N
heart NN N
rates NNS N
in IN N
both DT N
groups NNS N
and CC N
augmentation NN N
index NN N
in IN N
indapamide JJ N
group NN N
) ) N
decreased VBD N
significantly RB N
Comparison NNP N
of IN N
the DT N
2 CD N
groups NNS N
showed VBD N
that IN N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
( ( N
all DT N
P NNP N
values NNS N
> VBP N
0.05 CD N
) ) N
in IN N
all PDT N
the DT N
parameters NNS N
of IN N
pulse JJ N
wave NN N
except IN N
that IN N
the DT N
central JJ N
systolic JJ N
blood NN N
pressure NN N
, , N
augmentation NN N
and CC N
augmentation NN N
index NN N
were VBD N
significantly RB N
lower JJR N
in IN N
enalapril NN N
group NN N
than IN N
in IN N
indapamide JJ N
group NN N
In IN N
enalapril JJ N
group NN N
, , N
the DT N
reduced JJ N
values NNS N
of IN N
systolic JJ N
blood NN N
pressure NN N
and CC N
pulse JJ N
pressure NN N
in IN N
central JJ N
aorta NNS N
were VBD N
significantly RB N
larger JJR N
than IN N
those DT N
in IN N
brachial JJ N
artery NN N
However RB N
, , N
the DT N
difference NN N
was VBD N
not RB N
observed VBN N
in IN N
indapamide JJ N
group NN N
CONCLUSIONS NNP N
Enalapril NNP N
and CC N
indapamide NN N
are VBP N
both DT N
similarly RB N
effective JJ N
in IN N
reducing VBG N
peripheral JJ N
arterial JJ N
blood NN N
pressure NN N
Moreover RB N
, , N
enalapril NN N
is VBZ N
more RBR N
effective JJ N
in IN N
reducing VBG N
central JJ N
systolic JJ N
pressure NN N
and CC N
augmentation NN N
index NN N
than IN N
indapamide NN N
The DT N
difference NN N
is VBZ N
probably RB N
due JJ N
to TO N
the DT N
reduction NN N
of IN N
wave NN N
reflection NN N
caused VBN N
by IN N
enalapril NN N
-DOCSTART- -X- O O 10665129

Bronchodilatory JJ N
responses NNS N
to TO N
formoterol VB N
, , N
ipratropium NN N
, , N
and CC N
their PRP$ N
combination NN N
in IN N
patients NNS 4_p
with IN 4_p
stable JJ 4_p
COPD NNP 4_p
We PRP N
studied VBD N
27 CD N
patients NNS N
with IN N
stable JJ N
chronic JJ N
obstuctive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
in IN N
a DT N
randomised JJ N
, , N
single-blind JJ N
, , N
within-patient JJ N
, , N
placebo-controlled JJ N
clinical JJ N
study NN N
Each DT N
patient NN N
was VBD N
assigned VBN N
on IN N
six CD N
separate JJ N
days NNS N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
drug NN N
regimens NNS N
in IN N
random JJ N
order NN N
: : N
A DT N
40 CD N
micrograms JJ N
ipratropium NN N
bromide NN N
( ( N
Atrovent NNP N
MDI NNP N
, , N
20 CD N
micrograms/puff NN N
) ) N
plus CC N
2 CD N
puffs NNS N
placebo NN N
; : N
B NNP N
12 CD N
micrograms NNS N
formoterol JJ N
fumarate NN N
( ( N
Foradil NNP N
MDI NNP N
, , N
12 CD N
micrograms/puff NN N
) ) N
plus CC N
3 CD N
puffs NNS N
placebo VBP N
; : N
C. NNP N
80 CD N
micrograms NNS N
ipratropium NN N
; : N
D. NNP N
24 CD N
micrograms NNS N
formoterol JJ N
plus CC N
2 CD N
puffs NNS N
placebo VBP N
; : N
E. NNP N
12 CD N
micrograms NNS N
formoterol JJ N
plus CC N
40 CD N
micrograms NNS N
ipratropium JJ N
plus CC N
1 CD N
puff NN N
placebo NN N
; : N
F. NNP N
4 CD N
puffs NNS N
placebo NN N
On IN N
each DT N
study NN N
day NN N
, , N
spirometric JJ N
indices NNS N
and CC N
vital JJ N
signs NNS N
were VBD N
measured VBN N
at IN N
5 CD N
, , N
10 CD N
, , N
15 CD N
and CC N
60 CD N
minutes NNS N
, , N
and CC N
hourly RB N
thereafter RB N
up IN N
to TO N
and CC N
including VBG N
12 CD N
hours NNS N
after IN N
study JJ N
drug NN N
administration NN N
Mean NNP N
peak JJ N
FEV1 NNP N
change NN N
( ( N
primary JJ N
endpoint NN N
) ) N
was VBD N
maximum JJ N
with IN N
the DT N
administration NN N
of IN N
the DT N
combination NN N
of IN N
ipratropium NN N
and CC N
formoterol NN N
( ( N
335.2 CD N
ml NN N
, , N
SE NNP N
24.6 CD N
) ) N
, , N
and CC N
it PRP N
differed VBD N
significantly RB N
from IN N
the DT N
observed JJ N
peak NN N
changes NNS N
following VBG N
single JJ N
administration NN N
of IN N
the DT N
two CD N
tested VBD N
doses NNS N
of IN N
ipratropium NN N
( ( N
p JJ N
< NN N
0.05 CD N
and CC N
p VB N
< JJ N
0.05 CD N
respectively RB N
) ) N
Safety NN N
and CC N
tolerability NN N
were VBD N
satisfactory JJ N
throughout IN N
the DT N
study NN N
-DOCSTART- -X- O O 8383874

Sodium-potassium JJ N
pump NN N
activity NN N
in IN N
white JJ N
blood NN N
cells NNS N
from IN N
children NNS 1_p
with IN N
an DT N
increased VBN N
risk NN N
of IN N
developing VBG N
hypertension NN 4_p
-- : N
The DT N
Odense NNP N
Schoolchild NNP N
Study NNP N
We PRP N
have VBP N
measured VBN N
the DT N
capacity NN N
of IN N
the DT N
sodium-potassium JJ N
pump NN N
, , N
as IN N
assessed VBN N
by IN N
86rubidium CD N
uptake NN N
and CC N
the DT N
number NN N
of IN N
[ $ N
3H CD N
] NNP N
-ouabain NN N
binding VBG N
sites NNS N
on IN N
white JJ N
blood NN N
cells NNS N
, , N
in IN N
children NNS 1_p
aged VBN N
9-11 CD 1_p
years NNS N
, , N
partly RB N
cross-sectionally RB N
and CC N
partly RB N
longitudinally RB N
after IN N
a DT N
physical JJ N
training NN N
programme NN N
Children NNP 1_p
from IN N
a DT N
hypertensive JJ 4_p
subgroup NN N
comprising VBG N
the DT N
upper JJ N
5 CD N
% NN N
of IN N
the DT N
blood NN N
pressure NN N
distribution NN N
and CC N
children NNS 1_p
from IN N
a DT N
randomly RB N
selected VBN N
normotensive JJ N
subgroup NN N
were VBD N
eligible JJ N
for IN N
the DT N
study NN N
In IN N
the DT N
cross-sectional JJ N
study NN N
40 CD 3_p
children NNS 1_p
from IN N
the DT N
hypertensive JJ 4_p
subgroup NN N
and CC N
40 CD 3_p
children NNS N
from IN N
the DT N
normotensive JJ N
subgroup NN N
were VBD N
evaluated VBN N
A DT N
significant JJ N
increase NN N
in IN N
86rubidium CD N
uptake NN N
was VBD N
present JJ N
in IN N
boys NN N
as IN N
compared VBN N
to TO N
girls NNS N
After IN N
adjustment NN N
for IN N
differences NNS N
in IN N
sexual JJ N
maturation NN N
the DT N
observed JJ N
significant JJ N
difference NN N
disappeared VBD N
Important NNP N
correlates NNS N
of IN N
pump NN N
activity NN N
were VBD N
height VBN N
, , N
plasma FW N
glucose NN N
, , N
and CC N
physical JJ N
fitness NN N
In IN N
the DT N
training NN N
study NN N
10 CD 3_p
boys NNS 2_p
from IN N
the DT N
hypertensive JJ 4_p
subgroup NN N
and CC N
10 CD 3_p
boys NNS 2_p
from IN N
the DT N
normotensive JJ N
subgroup NN N
were VBD N
also RB N
evaluated VBN N
after IN N
eight CD N
months NNS N
of IN N
physical JJ N
training NN N
A DT N
significant JJ N
fall NN N
in IN N
86rubidium CD N
uptake NN N
was VBD N
observed VBN N
No DT N
control NN N
group NN N
was VBD N
examined VBN N
and CC N
probably RB N
the DT N
changes NNS N
reflect VBP N
some DT N
effects NNS N
of IN N
sexual JJ N
maturation NN N
on IN N
cation NN N
handling NN N
of IN N
cells NNS N
These DT N
results NNS N
indicate VBP N
a DT N
significant JJ N
effect NN N
of IN N
sexual JJ N
maturation NN N
in IN N
capacity NN N
of IN N
sodium-potassium JJ N
pump NN N
in IN N
children NNS 1_p
-DOCSTART- -X- O O 15534261

Impact NN N
of IN N
antioxidants NNS N
, , N
zinc NN N
, , N
and CC N
copper NN N
on IN N
cognition NN N
in IN N
the DT N
elderly JJ N
: : N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
Participants NNS N
in IN N
the DT N
Age-Related JJ N
Eye NNP N
Disease NNP N
Study NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
daily JJ N
antioxidants NNS N
( ( N
vitamin JJ N
C NNP N
, , N
500 CD N
mg NN N
; : N
vitamin CC N
E NNP N
, , N
400 CD N
IU NNP N
; : N
beta NN N
carotene NN N
, , N
15 CD N
mg NN N
) ) N
, , N
zinc NN N
and CC N
copper NN N
( ( N
zinc NN N
, , N
80 CD N
mg NN N
; : N
cupric JJ N
oxide NN N
, , N
2 CD N
mg NN N
) ) N
, , N
antioxidants NNS N
plus CC N
zinc NN N
and CC N
copper NN N
, , N
or CC N
placebo NN N
A DT N
cognitive JJ N
battery NN N
was VBD N
administered VBN N
to TO N
2,166 CD N
elderly JJ N
persons NNS N
after IN N
a DT N
median NN N
of IN N
6.9 CD N
years NNS N
of IN N
treatment NN N
Treatment NNP N
groups NNS N
did VBD N
not RB N
differ VB N
on IN N
any DT N
of IN N
the DT N
six CD N
cognitive JJ N
tests NNS N
( ( N
p JJ N
> VBP N
0.05 CD N
for IN N
all DT N
) ) N
These DT N
results NNS N
do VBP N
not RB N
support VB N
a DT N
beneficial JJ N
or CC N
harmful JJ N
effect NN N
of IN N
antioxidants NNS N
or CC N
zinc NN N
and CC N
copper NN N
on IN N
cognition NN N
in IN N
older JJR N
adults NNS N
-DOCSTART- -X- O O 17201277

[ IN N
The DT N
effects NNS N
of IN N
mexicor NN N
on IN N
thrombocyte JJ N
aggregation NN N
, , N
blood NN N
viscosity NN N
, , N
hemodynamics NNS N
, , N
and CC N
the DT N
clinical JJ N
course NN N
of IN N
coronary JJ N
artery NN N
disease NN N
] NNP N
The DT N
authors NNS N
analyze VBP N
their PRP$ N
experience NN N
in IN N
the DT N
application NN N
of IN N
mexicor NN N
, , N
a DT N
Russian JJ N
cytoprotector NN N
, , N
in IN N
50patients CD 3_p
with IN N
chronic JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
( ( 4_p
CAD NNP 4_p
) ) 4_p
and CC N
51 CD 3_p
patients NNS 3_p
with IN N
acute JJ 4_p
coronary JJ 4_p
syndrome NN 4_p
In IN N
additional JJ N
to TO N
cytoprotective JJ N
action NN N
, , N
the DT N
use NN N
of IN N
mexidor NN N
in IN N
complex JJ N
therapy NN N
of IN N
CAD NNP N
lowers VBZ N
the DT N
functional JJ N
activity NN N
of IN N
thrombocytes NNS N
, , N
eliminates VBZ N
high JJ N
blood NN N
viscosity NN N
syndrome NN N
, , N
and CC N
lowers NNS N
low JJ N
density NN N
lipoprotein NN N
cholesterol NN N
level NN N
These DT N
favorable JJ N
changes NNS N
in IN N
hemorheological JJ N
parameters NNS N
improves VBZ N
myocardial JJ N
perfusion NN N
, , N
lowers VBZ N
the DT N
strength NN N
and CC N
frequency NN N
of IN N
coronary JJ N
pain NN N
attacks NNS N
, , N
retards NNS N
postinfarction NN N
left VBD N
ventricular JJ N
remodeling NN N
, , N
and CC N
increases VBZ N
the DT N
quality NN N
of IN N
life NN N
of IN N
patients NNS N
with IN N
various JJ N
CAD NNP N
forms NNS N
-DOCSTART- -X- O O 7007454

Effects NNS N
of IN N
topical JJ N
and CC N
systemic JJ N
folic JJ N
acid NN N
supplementation NN N
on IN N
gingivitis NN N
in IN N
pregnancy NN N
A DT N
double-blind JJ N
study NN N
evaluated VBD N
the DT N
effects NNS N
of IN N
systemic JJ N
and CC N
topical JJ N
folate NN N
on IN N
gingival JJ 4_p
inflammation NN 4_p
during IN 4_p
the DT 4_p
fourth JJ 4_p
and CC 4_p
eighth JJ 4_p
months NNS 4_p
of IN 4_p
pregnancy NN 4_p
Thirty JJ N
women NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
three CD N
groups NNS N
Group NNP N
A NNP N
received VBD N
placebo JJ N
mouthwash NN N
and CC N
tablets NNS N
; : N
Group NNP N
B NNP N
; : N
placebo NN N
mouthwash NN N
and CC N
5 CD N
mg NN N
folate JJ N
tablets NNS N
; : N
Group NNP N
C NNP N
: : N
folate NN N
mouthwash NN N
and CC N
placebo NN N
tablets NNS N
Supplementation NNP N
lasted VBD N
for IN N
14 CD N
days NNS N
during IN N
months NNS N
4 CD N
and CC N
8 CD N
Subjects NNS N
took VBD N
one CD N
tablet NN N
daily NN N
and CC N
rinsed JJ N
twice RB N
daily RB N
for IN N
1 CD N
min NN N
with IN N
the DT N
mouthwash NN N
At IN N
the DT N
start NN N
and CC N
finish NN N
of IN N
each DT N
14-day JJ N
period NN N
, , N
fasting VBG N
serum NN N
and CC N
red JJ N
cell NN N
folate NN N
levels NNS N
were VBD N
estimated VBN N
and CC N
oral JJ N
status NN N
assessed VBN N
by IN N
a DT N
plaque NN N
index NN N
( ( N
P1I NNP N
) ) N
, , N
a DT N
gingival JJ N
index NN N
( ( N
GI NNP N
) ) N
, , N
and CC N
gingival JJ N
exudate NN N
flow NN N
meter NN N
( ( N
GEF NNP N
) ) N
Subjects NNS N
completed VBD N
1-week JJ N
diet JJ N
sheets NNS N
which WDT N
were VBD N
analysed VBN N
for IN N
dietary JJ N
folate NN N
All DT N
groups NNS N
were VBD N
similar JJ N
in IN N
each DT N
parameter NN N
at IN N
the DT N
start NN N
Correlation NN N
was VBD N
demonstrated VBN N
between IN N
GI NNP N
and CC N
P1I NNP N
, , N
and CC N
between IN N
GI NNP N
and CC N
GEF NNP N
GI NNP N
tended VBD N
to TO N
increase VB N
throughout IN N
pregnancy NN N
in IN N
all DT N
groups NNS N
except IN N
Group NNP N
C NNP N
, , N
when WRB N
in IN N
the DT N
eighth JJ N
month NN N
there EX N
was VBD N
a DT N
highly RB N
significant JJ N
improvement NN N
( ( N
0.001 CD N
less JJR N
than IN N
P NNP N
0.01 CD N
) ) N
despite IN N
no DT N
significant JJ N
change NN N
in IN N
P1I NNP N
Although IN N
dietary JJ N
intake NN N
of IN N
folate NN N
was VBD N
significantly RB N
higher JJR N
during IN N
the DT N
eighth JJ N
month NN N
in IN N
Group NNP N
C NNP N
as IN N
compared VBN N
with IN N
Groups NNP N
A NNP N
and CC N
B NNP N
, , N
( ( N
0.001 CD N
less JJR N
than IN N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
, , N
the DT N
folate NN N
mouthwash NN N
produced VBD N
highly RB N
significantly RB N
improvement NN N
in IN N
gingival JJ N
health NN N
in IN N
pregnancy NN N
-DOCSTART- -X- O O 12553591

Lack NN N
of IN N
benefit NN N
of IN N
intravenous JJ N
synthetic JJ N
human NN N
secretin NN N
in IN N
the DT N
treatment NN N
of IN N
autism NN 4_p
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
an DT N
intravenous JJ N
infusion NN N
of IN N
synthetic JJ N
human JJ N
secretin NN N
improves VBZ N
language NN N
and CC N
behavioral JJ N
symptoms NNS N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
Forty-two JJ 3_p
children NNS 1_p
with IN N
the DT N
diagnosis NN N
of IN N
autism NN 4_p
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
in IN N
this DT N
double-blind JJ N
cross-over JJ N
trial NN N
One CD N
group NN N
received VBD N
2 CD N
IU/kg NNP N
of IN N
intravenous JJ N
synthetic JJ N
human NN N
secretin NN N
at IN N
the DT N
first JJ N
visit NN N
, , N
followed VBN N
by IN N
an DT N
equal JJ N
volume NN N
of IN N
intravenous JJ N
saline NN N
placebo NN N
at IN N
week NN N
6 CD N
The DT N
other JJ N
group NN N
received VBD N
treatments NNS N
in IN N
the DT N
reverse NN N
order NN N
All DT N
children NNS N
were VBD N
evaluated VBN N
at IN N
weeks NNS N
1 CD N
, , N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
with IN N
standardized JJ N
assessments NNS N
of IN N
language NN N
, , N
behavior NN N
, , N
and CC N
autism NN N
symptomatology NN N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
mean JJ N
scores NNS N
on IN N
any DT N
measure NN N
of IN N
language NN N
, , N
behavior NN N
, , N
or CC N
autism NN N
symptom JJ N
severity NN N
after IN N
treatment NN N
with IN N
secretin NN N
compared VBN N
to TO N
treatment NN N
with IN N
placebo NN N
The DT N
results NNS N
of IN N
this DT N
study NN N
do VBP N
not RB N
support VB N
secretin NN N
as IN N
a DT N
treatment NN N
for IN N
autism NN N
-DOCSTART- -X- O O 23838275

Contrast NNP N
, , N
motion NN N
, , N
perceptual JJ N
integration NN N
, , N
and CC N
neurocognition NN N
in IN N
schizophrenia NN N
: : N
the DT N
role NN N
of IN N
fragile-X JJ N
related JJ N
mechanisms NN N
Recent JJ N
studies NNS N
demonstrated VBD N
a DT N
reduced JJ N
expression NN N
of IN N
Fragile NNP N
X NNP N
Mental NNP N
Retardation NNP N
Protein NNP N
( ( N
FMRP NNP N
) ) N
, , N
an DT N
RNA NNP N
binding NN N
protein NN N
and CC N
translation NN N
regulator NN N
, , N
in IN N
the DT N
brain NN N
and CC N
peripheral JJ N
lymphocytes NNS N
of IN N
patients NNS 4_p
with IN 4_p
schizophrenia NN 4_p
Low JJ N
FMRP NNP N
levels NNS N
may MD N
be VB N
related VBN N
to TO N
impaired JJ N
neurodevelopmental JJ N
processes NNS N
and CC N
synaptic JJ N
plasticity NN N
Here RB N
, , N
we PRP N
studied VBD N
the DT N
relationship NN N
between IN N
peripheral JJ N
FMRP NNP N
level NN N
, , N
visual JJ N
perception NN N
( ( N
contrast JJ N
sensitivity NN N
, , N
perceptual JJ N
integration NN N
, , N
motion/form VB N
perception NN N
) ) N
, , N
and CC N
neuropsychological JJ N
functions NNS N
in IN N
schizophrenia NN N
as IN N
measured VBN N
with IN N
the DT N
Repeatable JJ N
Battery NN N
for IN N
the DT N
Assessment NNP N
of IN N
Neuropsychological NNP N
Status NNP N
( ( N
RBANS NNP N
) ) N
Results NNP N
revealed VBD N
that IN N
patients NNS N
with IN N
schizophrenia JJ 4_p
displayed NNS N
lower JJR N
FMRP NNP N
levels NNS N
in IN N
peripheral JJ N
lymphocytes NNS N
as IN N
compared VBN N
to TO N
control VB N
individuals NNS N
We PRP N
found VBD N
significant JJ N
correlations NNS N
between IN N
FMRP NNP N
levels NNS N
and CC N
contrast NN N
sensitivity NN N
at IN N
low JJ N
spatial NN N
and CC N
high JJ N
temporal JJ N
frequencies NNS N
, , N
perceptual JJ N
integration NN N
, , N
and CC N
motion NN N
perception NN N
The DT N
relationship NN N
between IN N
FMRP NNP N
level NN N
and CC N
neuropsychological JJ N
functions NNS N
was VBD N
less RBR N
pronounced JJ N
than IN N
that DT N
seen VBN N
in IN N
the DT N
case NN N
of IN N
visual JJ N
perception NN N
, , N
with IN N
the DT N
greatest JJS N
effect NN N
for IN N
RBANS NNP N
attention NN N
FMRP NNP N
level NN N
was VBD N
not RB N
related VBN N
to TO N
contrast VB N
sensitivity NN N
at IN N
high JJ N
spatial JJ N
and CC N
low JJ N
temporal JJ N
frequencies NNS N
and CC N
form JJ N
perception NN N
This DT N
pattern NN N
of IN N
data NNS N
is VBZ N
reminiscent JJ N
to TO N
that DT N
observed VBN N
in IN N
patients NNS N
with IN N
Fragile NNP N
X NNP N
Syndrome NNP N
( ( N
FXS NNP N
) ) N
These DT N
results NNS N
suggest VBP N
that IN N
FMRP NNP N
may MD N
be VB N
implicated VBN N
in IN N
the DT N
pathogenesis NN N
of IN N
schizophrenia NN N
, , N
possibly RB N
via IN N
the DT N
regulation NN N
of IN N
neurodevelopment NN N
, , N
plasticity NN N
, , N
GABA-ergic NNP N
, , N
and CC N
glutamatergic JJ N
neurotransmission NN N
-DOCSTART- -X- O O 23964752

Efficacy NN N
and CC N
safety NN N
of IN N
diclofenac JJ N
diethylamine JJ N
1.16 CD N
% NN N
gel NN N
in IN N
acute JJ 4_p
neck NN 4_p
pain NN 4_p
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
BACKGROUND NNP N
Neck NNP N
pain NN N
( ( N
NP NNP N
) ) N
is VBZ N
a DT N
common JJ N
musculoskeletal JJ N
disorder NN N
in IN N
primary JJ N
care NN N
that WDT N
frequently RB N
causes VBZ N
discomfort NN N
Non-steroidal JJ N
anti-inflammatory JJ N
drugs NNS N
( ( N
NSAIDs NNP N
) ) N
may MD N
be VB N
used VBN N
to TO N
reduce VB N
neck NN N
pain NN N
and CC N
associated VBN N
inflammation NN N
and CC N
facilitate NN N
earlier RBR N
recovery NN N
Topical JJ N
diclofenac NN N
diethylamine NN N
( ( N
DDEA NNP N
) ) N
1.16 CD N
% NN N
gel NN N
is VBZ N
clinically RB N
proven VBN N
to TO N
be VB N
effective JJ N
and CC N
well RB N
tolerated VBN N
in IN N
acute NN N
and CC N
chronic JJ N
musculoskeletal NN N
conditions NNS N
, , N
but CC N
until IN N
now RB N
no DT N
clinical JJ N
data NNS N
existed VBD N
for IN N
its PRP$ N
use NN N
in IN N
acute JJ N
NP NNP N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
DDEA NNP N
1.16 CD N
% NN N
gel NN N
compared VBN N
with IN N
placebo NN N
gel NN N
in IN N
acute JJ N
NP NNP N
METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
, , N
patients NNS N
with IN N
acute JJ 4_p
NP NNP 4_p
( ( N
n JJ N
= NNP N
72 CD 3_p
) ) N
were VBD N
treated VBN N
with IN N
DDEA NNP N
1.16 CD N
% NN N
gel NN N
( ( N
2 CD N
g NN N
, , N
4x/day CD N
, , N
for IN N
5 CD N
days NNS N
) ) N
or CC N
placebo NN N
Efficacy NN N
assessments NNS N
included VBD N
pain-on-movement NN N
( ( N
POM NNP N
) ) N
, , N
pain-at-rest JJ N
( ( N
PAR NNP N
) ) N
, , N
functional JJ N
neck NN N
disability NN N
index NN N
( ( N
NDI NNP N
) ) N
and CC N
response NN N
to TO N
treatment NN N
( ( N
decrease NN N
in IN N
POM NNP N
by IN N
50 CD N
% NN N
after IN N
48 CD N
h NN N
) ) N
Adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
were VBD N
recorded VBN N
throughout IN N
the DT N
study NN N
RESULTS VB N
The DT N
primary JJ N
outcome NN N
, , N
POM NNP N
at IN N
48 CD N
h NN N
, , N
was VBD N
statistically RB N
significantly RB N
lower JJR N
with IN N
DDEA NNP N
gel NN N
( ( N
19.5 CD N
mm NN N
) ) N
vs. FW N
placebo NN N
( ( N
56.9 CD N
mm NN N
) ) N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
representing VBG N
a DT N
clinically RB N
relevant JJ N
decrease NN N
from IN N
baseline NN N
( ( N
75 CD N
% NN N
vs. FW N
23 CD N
% NN N
, , N
respectively RB N
) ) N
All DT N
POM NNP N
scores NNS N
were VBD N
significantly RB N
lower JJR N
with IN N
DDEA NNP N
gel NN N
vs. FW N
placebo NN N
from IN N
1 CD N
h NN N
, , N
as IN N
were VBD N
PAR NNP N
and CC N
NDI NNP N
scores NNS N
from IN N
first JJ N
assessment NN N
( ( N
24 CD N
h NN N
) ) N
onwards NNS N
( ( N
all DT N
p VBP N
< $ N
0.0001 CD N
) ) N
Response NNP N
to TO N
treatment NN N
was VBD N
significantly RB N
higher JJR N
with IN N
DDEA NNP N
gel NN N
( ( N
94.4 CD N
% NN N
) ) N
vs. FW N
placebo NN N
( ( N
8.3 CD N
% NN N
) ) N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
There EX N
were VBD N
no DT N
AEs NNP N
with IN N
DDEA NNP N
gel NN N
CONCLUSIONS NNP N
DDEA NNP N
1.16 CD N
% NN N
gel NN N
, , N
which WDT N
is VBZ N
available JJ N
over-the-counter JJ N
, , N
was VBD N
effective JJ N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
neck NN N
pain NN N
The DT N
tools NNS N
used VBD N
to TO N
assess VB N
efficacy NN N
suggest VBP N
that IN N
it PRP N
quickly RB N
reduced VBD N
neck NN N
pain NN N
and CC N
improved VBN N
neck NN N
function NN N
However RB N
, , N
questions NNS N
remain VBP N
regarding VBG N
the DT N
comparability NN N
and CC N
validity NN N
of IN N
such JJ N
tools NNS N
Further JJ N
studies NNS N
will MD N
help VB N
ascertain VB N
whether IN N
DDEA NNP N
1.16 CD N
% NN N
gel NN N
offers VBZ N
an DT N
alternative JJ N
treatment NN N
option NN N
in IN N
this DT N
common JJ N
, , N
often RB N
debilitating VBG N
condition NN N
TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT01335724 NNP N
-DOCSTART- -X- O O 26053242

Assessment NN N
from IN N
Functional JJ N
Perspectives NNS N
: : N
Using NNP N
Sensorimotor NNP N
Control NNP N
in IN N
the DT N
Hand NNP N
as IN N
an DT N
Outcome NNP N
Indicator NNP N
in IN N
the DT N
Surgical NNP N
Treatment NNP N
of IN N
Carpal NNP 4_p
Tunnel NNP 4_p
Syndrome NNP 4_p
To TO N
investigate VB N
whether IN N
sensorimotor NN N
control NN N
of IN N
the DT N
hand NN N
could MD N
be VB N
an DT N
outcome NN N
indicator NN N
after IN N
carpal JJ N
tunnel NN N
release NN N
( ( N
CTR NNP N
) ) N
, , N
this DT N
work NN N
examined VBD N
changes NNS N
in IN N
the DT N
results NNS N
of IN N
patients NNS N
' POS N
manual JJ N
tactile NN N
test NN N
( ( N
MTT NNP N
) ) N
, , N
pinch-holding-up JJ N
activity NN N
( ( N
PHUA NNP N
) ) N
, , N
two-point JJ N
discrimination NN N
( ( N
2PD CD N
) ) N
and CC N
Semmes-Weinstein JJ N
monofilament NN N
( ( N
SWM NNP N
) ) N
tests NNS N
Participants NNS N
included VBD N
30 CD 3_p
predominantly RB N
sensory JJ N
neuropathy JJ N
CTS NNP 4_p
patients NNS N
, , N
as IN N
confirmed VBN N
by IN N
a DT N
nerve NN 4_p
conduction NN 4_p
study NN 4_p
The DT N
MTT NNP N
, , N
precision NN N
pinch NN N
performance NN N
in IN N
PHUA NNP N
and CC N
traditional JJ N
sensibility NN N
( ( N
2PD CD N
and CC N
SWM NNP N
) ) N
tests NNS N
were VBD N
used VBN N
to TO N
examine VB N
different JJ N
aspects NNS N
of IN N
sensory JJ N
status NN N
at IN N
the DT N
time-points NNS N
of IN N
two CD N
weeks NNS N
before IN N
operation NN N
and CC N
one CD N
month NN N
post-operation NN N
, , N
with IN N
a DT N
single-blind JJ N
design NN N
The DT N
results NNS N
showed VBD N
significant JJ N
improvements NNS N
in IN N
the DT N
sensory JJ N
function NN N
as IN N
detected VBN N
by IN N
the DT N
2PD CD N
and CC N
SWM NNP N
tests NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
sensorimotor JJ N
function NN N
as IN N
detected VBN N
by IN N
the DT N
MTT NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
PHUA NNP N
test NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
patients NNS N
receiving VBG N
CTR NNP N
The DT N
responsiveness NN N
of IN N
the DT N
SWM NNP N
, , N
MTT NNP N
and CC N
PHUA NNP N
tests NNS N
( ( N
effect NN N
size NN N
> NN N
0.5 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
are VBP N
better JJR N
than IN N
that DT N
of IN N
two-point JJ N
discrimination NN N
test NN N
( ( N
effect NN N
size NN N
< NN N
0.5 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
However RB N
, , N
pinch JJ N
strength NN N
saw VBD N
a DT N
decline NN N
compared VBN N
to TO N
baseline VB N
with IN N
a DT N
moderate JJ N
effect NN N
sizes NNS N
( ( N
effect NN N
size NN N
= NN N
0.7 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
This DT N
cohort NN N
study NN N
found VBD N
that IN N
the DT N
MTT NNP N
and CC N
PHUA NNP N
test NN N
can MD N
both VB N
meet VB N
all PDT N
the DT N
statistical JJ N
criteria NNS N
with IN N
regard NN N
to TO N
assessing VBG N
treatment NN N
outcomes NNS N
for IN N
patients NNS 4_p
with IN 4_p
CTS NNP 4_p
In IN N
addition NN N
, , N
the DT N
results NNS N
of IN N
this DT N
work NN N
provide RB N
clinicians VBZ N
with IN N
the DT N
information NN N
that IN N
the DT N
sensorimotor NN N
functions NNS N
of IN N
the DT N
hands NNS N
, , N
as IN N
assessed VBN N
by IN N
MTT NNP N
and CC N
PHUA NNP N
, , N
are VBP N
responsive JJ N
to TO N
clinical JJ N
changes NNS N
due JJ N
to TO N
CTR NNP N
-DOCSTART- -X- O O 3287999

Transcutaneous JJ N
electrical JJ N
nerve NN N
stimulation NN N
after IN N
thoracotomy NN N
Pain NNP N
relief NN N
and CC N
peak JJ N
expiratory NN N
flow NN N
rate NN N
-- : N
a DT N
trial NN N
of IN N
transcutaneous JJ N
electrical JJ N
nerve NN N
stimulation NN N
Forty NNP 3_p
patients NNS N
scheduled VBN N
to TO N
undergo VB N
thoracotomy NN 4_p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either RB N
transcutaneous JJ N
electrical JJ N
nerve NN N
stimulation NN N
with IN N
intramuscular JJ N
papaveretum NN N
( ( N
20 CD N
patients NNS N
) ) N
or CC N
intramuscular JJ N
papaveretum NN N
alone RB N
( ( N
20 CD N
patients NNS N
) ) N
for IN N
postoperative JJ N
pain NN N
relief NN N
Total JJ N
intramuscular JJ N
analgesic NN N
requirements NNS N
in IN N
the DT N
first JJ N
24 CD N
hours NNS N
, , N
time NN N
to TO N
satisfactory VB N
transfer NN N
to TO N
oral JJ N
analgesia NN N
, , N
antiemetic JJ N
requirements NNS N
and CC N
length NN N
of IN N
stay NN N
in IN N
hospital NN N
postoperatively RB N
were VBD N
noted VBN N
Peak NNP N
expiratory JJ N
flow NN N
rate NN N
was VBD N
compared VBN N
pre- JJ N
and CC N
postoperatively RB N
in IN N
the DT N
two CD N
groups NNS N
Use NNP N
of IN N
nerve NN N
stimulation NN N
did VBD N
not RB N
significantly RB N
alter VB N
the DT N
requirements NNS N
for IN N
analgesia JJ N
although IN N
there EX N
was VBD N
a DT N
reduction NN N
in IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
in IN N
the DT N
nerve NN N
stimulation NN N
group NN N
There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
with IN N
respect NN N
to TO N
changes NNS N
in IN N
peak NN N
expiratory NN N
flow NN N
rate NN N
-DOCSTART- -X- O O 8123267

Recovery NN N
following VBG N
outpatient JJ 4_p
anesthesia NN 4_p
: : N
use NN N
of IN N
enflurane NN N
versus NN N
propofol NN N
STUDY NNP N
OBJECTIVE NNP N
To TO N
compare VB N
the DT N
intraoperative JJ N
conditions NNS N
and CC N
postoperative JJ N
recovery NN N
of IN N
patients NNS N
following VBG N
the DT N
use NN N
of IN N
either DT N
propofol-nitrous JJ N
oxide NN N
( ( N
N2O NNP N
) ) N
or CC N
enflurane-N2O JJ N
for IN N
maintenance NN N
of IN N
outpatient JJ 4_p
anesthesia NN 4_p
DESIGN NNP N
Randomized NNP N
, , N
single-blind NN N
study NN N
SETTING NNP N
University NNP N
hospital NN N
outpatient NN 4_p
surgery NN N
center NN N
PATIENTS CC N
61 CD 3_p
ASA NNP 4_p
physical JJ 4_p
status NN 4_p
I PRP 4_p
and CC 4_p
II NNP 4_p
, , N
healthy JJ 4_p
female NN 2_p
outpatients NNS 4_p
undergoing VBG N
laparoscopic NN 4_p
surgery NN 4_p
INTERVENTIONS JJ N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
anesthetic JJ N
regimens NNS N
Group NNP N
1 CD N
( ( N
control NN N
) ) N
received VBD N
thiopental JJ N
sodium NN N
4 CD N
mg/kg NN N
intravenously RB N
( ( N
i.v JJ N
) ) N
, , N
followed VBN N
by IN N
0.5 CD N
% NN N
to TO N
1.5 CD N
% NN N
enflurane NN N
and CC N
67 CD N
% NN N
N2O NNP N
in IN N
oxygen NN N
( ( N
O2 NNP N
) ) N
Group NNP N
2 CD N
received VBD N
propofol JJ N
2 CD N
mg/kg NN N
i.v. NN N
, , N
followed VBN N
by IN N
0.5 CD N
% NN N
to TO N
1.5 CD N
% NN N
enflurane NN N
and CC N
67 CD N
% NN N
N2O NNP N
in IN N
O2 NNP N
Group NNP N
3 CD N
received VBD N
propofol JJ N
2 CD N
mg/kg NN N
i.v. NN N
, , N
followed VBN N
by IN N
propofol NN N
50 CD N
to TO N
160 CD N
micrograms/kg/min NN N
i.v NN N
and CC N
67 CD N
% NN N
N2O NNP N
in IN N
O2 NNP N
All DT N
patients NNS N
received VBD N
succinylcholine JJ N
1 CD N
mg/kg NN N
i.v NN N
to TO N
facilitate VB N
tracheal JJ N
intubation NN N
and CC N
atracurium NN N
10 CD N
to TO N
20 CD N
mg NN N
i.v NN N
to TO N
provide VB N
adequate JJ N
relaxation NN N
during IN N
the DT N
maintenance NN N
period NN N
MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Recovery NNP N
from IN N
anesthesia NN N
was VBD N
assessed VBN N
by IN N
a DT N
research NN N
nurse NN N
who WP N
was VBD N
unaware NN N
of IN N
the DT N
anesthetic JJ N
technique NN N
used VBN N
The DT N
mean JJ N
+/- JJ N
SD NNP N
time NN N
to TO N
eye NN N
opening NN N
was VBD N
significantly RB N
longer RBR N
in IN N
the DT N
thiopental-enflurane-N2O JJ N
group NN N
( ( N
Group NNP N
1 CD N
) ) N
than IN N
in IN N
the DT N
propofol-propofol-N2O JJ N
group NN N
( ( N
Group NNP N
3 CD N
) ) N
( ( N
6.1 CD N
+/- JJ N
2.5 CD N
minutes NNS N
vs. IN N
3.5 CD N
+/- JJ N
2.8 CD N
minutes NNS N
, , N
respectively RB N
) ) N
In IN N
addition NN N
, , N
the DT N
mean JJ N
time NN N
to TO N
respond VB N
to TO N
verbal VB N
commands NNS N
was VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
propofol NN N
induction NN N
groups NNS N
compared VBN N
with IN N
the DT N
thiopental JJ N
induction NN N
group NN N
However RB N
, , N
the DT N
use NN N
of IN N
enflurane NN N
versus NN N
propofol NN N
for IN N
maintenance NN N
of IN N
anesthesia NN N
did VBD N
not RB N
significantly RB N
prolong IN N
the DT N
time NN N
from IN N
arrival NN N
in IN N
the DT N
recovery NN N
room NN N
to TO N
sitting VBG N
, , N
tolerating VBG N
oral JJ N
fluids NNS N
, , N
walking VBG N
, , N
or CC N
being VBG N
judged VBN N
" NNS N
fit VBP N
for IN N
discharge NN N
" CC N
There EX N
were VBD N
no DT N
differences NNS N
among IN N
the DT N
three CD N
groups NNS N
with IN N
respect NN N
to TO N
postoperative VB N
pain NN N
or CC N
analgesic JJ N
requirements NNS N
Finally RB N
, , N
patients NNS N
who WP N
received VBD N
enflurane NN N
for IN N
maintenance NN N
of IN N
anesthesia NN N
had VBD N
a DT N
significantly RB N
higher JJR N
frequency NN N
of IN N
nausea NN N
and CC N
vomiting NN N
than IN N
the DT N
propofol JJ N
maintenance NN N
group NN N
CONCLUSION NNP N
Induction NNP N
of IN N
anesthesia NN N
with IN N
propofol NN N
is VBZ N
associated VBN N
with IN N
a DT N
more RBR N
rapid JJ N
emergence NN N
from IN N
anesthesia NN N
than IN N
induction NN N
with IN N
thiopental JJ N
Maintenance NN N
of IN N
anesthesia NN N
with IN N
enflurane NN N
did VBD N
not RB N
prolong JJ N
recovery NN N
compared VBN N
with IN N
maintenance NN N
with IN N
propofol NN N
, , N
but CC N
enflurane NN N
was VBD N
associated VBN N
with IN N
increased JJ N
frequency NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
-DOCSTART- -X- O O 16472720

Brain NNP N
mechanisms NNS N
of IN N
expectation NN N
associated VBN N
with IN N
insula NN 4_p
and CC 4_p
amygdala JJ 4_p
response NN N
to TO N
aversive JJ N
taste NN N
: : N
implications NNS N
for IN N
placebo NN N
The DT N
experience NN N
of IN N
aversion NN N
is VBZ N
shaped VBN N
by IN N
multiple JJ N
physiological JJ N
and CC N
psychological JJ N
factors NNS N
including VBG N
one CD N
's POS N
expectations NNS N
Recent JJ N
work NN N
has VBZ N
shown VBN N
that IN N
expectancy NN N
manipulation NN N
can MD N
alter VB N
perceptions NNS N
of IN N
aversive JJ N
events NNS N
and CC N
concomitant JJ N
brain NN N
activation NN N
Accruing VBG N
evidence NN N
indicates VBZ N
a DT N
primary JJ N
role NN N
of IN N
altered JJ N
expectancies NNS N
in IN N
the DT N
placebo NN N
effect NN N
Here RB N
, , N
we PRP N
probed VBD N
the DT N
mechanism NN N
by IN N
which WDT N
expectation NN N
attenuates VBZ N
sensory JJ N
taste NN N
transmission NN N
by IN N
examining VBG N
how WRB N
brain NN 4_p
areas NNS 4_p
activated VBN 4_p
by IN N
misleading VBG N
information NN N
during IN 4_p
an DT 4_p
expectancy NN 4_p
period NN 4_p
modulate NN N
insula NN N
and CC N
amygdala JJ N
activation NN N
to TO N
a DT N
highly RB N
aversive JJ N
bitter NN N
taste NN N
In IN N
a DT N
rapid JJ N
event-related JJ N
fMRI NN N
design NN N
, , N
we PRP N
showed VBD N
that IN N
activations NNS N
in IN N
the DT N
rostral JJ N
anterior JJ N
cingulate NN N
cortex NN N
( ( N
rACC NN N
) ) N
, , N
orbitofrontal JJ N
cortex NN N
( ( N
OFC NNP N
) ) N
, , N
and CC N
dorsolateral JJ N
prefrontal NN N
cortex NN N
to TO N
a DT N
misleading NN N
cue NN N
that IN N
the DT N
taste NN N
would MD N
be VB N
mildly RB N
aversive JJ N
predicted VBN N
decreases NNS N
in IN N
insula NN N
and CC N
amygdala JJ N
activation NN N
to TO N
the DT N
highly RB N
aversive JJ N
taste NN N
OFC NNP N
and CC N
rACC VB N
activation NN N
to TO N
the DT N
misleading NN N
cue NN N
were VBD N
also RB N
associated VBN N
with IN N
less RBR N
aversive JJ N
ratings NNS N
of IN N
that DT N
taste NN N
Additional JJ N
analyses NNS N
revealed VBD N
consistent JJ N
results NNS N
demonstrating VBG N
functional JJ N
connectivity NN N
among IN N
the DT N
OFC NNP N
, , N
rACC NN N
, , N
and CC N
insula NN N
Altering VBG N
expectancies NNS N
of IN N
upcoming VBG N
aversive JJ N
events NNS N
are VBP N
shown VBN N
here RB N
to TO N
depend VB N
on IN N
robust JJ N
functional JJ N
associations NNS N
among IN N
brain NN N
regions NNS N
implicated VBN N
in IN N
prior JJ N
work NN N
on IN N
the DT N
placebo NN N
effect NN N
-DOCSTART- -X- O O 9546119

Amoxicillin/metronidazole/omeprazole/clarithromycin NN N
: : N
a DT N
new JJ N
, , N
short JJ N
quadruple NN N
therapy NN N
for IN N
Helicobacter NNP 4_p
pylori JJ 4_p
eradication NN N
BACKGROUND NNP N
Triple NNP N
therapy NN N
regimens VBZ N
including VBG N
two CD N
antibiotics NNS N
plus CC N
acid JJ N
suppression NN N
have VBP N
become VBN N
the DT N
new JJ N
standard NN N
therapy NN N
in IN N
Helicobacter NNP N
pylori FW N
eradication NN N
because IN N
of IN N
success NN N
rates NNS N
of IN N
about RB N
90 CD N
% NN N
However RB N
, , N
these DT N
regimens NNS N
are VBP N
still RB N
costly JJ N
, , N
duration NN N
is VBZ N
about IN N
one CD N
week NN N
or CC N
less JJR N
, , N
and CC N
side-effects NNS N
are VBP N
not RB N
negligible JJ N
We PRP N
therefore RB N
evaluated VBD N
a DT N
new JJ N
quadruple NN N
therapy NN N
, , N
because IN N
theoretically RB N
a DT N
shorter JJR N
duration NN N
of IN N
treatment NN N
may MD N
result VB N
in IN N
reduced JJ N
costs NNS N
, , N
fewer JJR N
side-effects NNS N
, , N
and CC N
possibly RB N
in IN N
a DT N
lower JJR N
potential NN N
for IN N
antibiotic JJ N
resistances NNS N
METHODS NNP N
Controlled NNP N
, , N
prospective JJ N
pilot NN N
study NN N
including VBG N
H. NNP 4_p
pylori-positive JJ 4_p
patients NNS N
with IN N
gastric JJ 4_p
or CC 4_p
duodenal JJ 4_p
ulcers NNS 4_p
or CC 4_p
erosive JJ 4_p
gastritis NN 4_p
, , N
treated VBN N
after IN N
failure NN N
of IN N
dual JJ N
therapy NN N
( ( N
proton-pump-inhibitors NNS N
or CC N
ranitidine VB N
plus CC N
amoxicillin VB N
) ) N
or CC N
for IN N
the DT N
first JJ N
time NN N
They PRP N
were VBD N
assigned VBN N
to TO N
a DT N
one CD N
week NN N
triple JJ N
standard NN N
therapy NN N
, , N
consisting VBG N
of IN N
metronidazole JJ N
400 CD N
mg JJ N
bid NN N
+ NNP N
omeprazole VBZ N
20 CD N
mg NN N
bid NN N
+ NNP N
clarithromycin VBZ N
250 CD N
mg NN N
bid NN N
, , N
or CC N
a DT N
newly RB N
created VBN N
quadruple-regimen NNS N
, , N
which WDT N
adds VBZ N
amoxicillin NN N
( ( N
1 CD N
g RB N
bid NN N
) ) N
to TO N
the DT N
above JJ N
triple NN N
regimen NNS N
Each DT N
of IN N
the DT N
four CD N
drugs NNS N
was VBD N
given VBN N
for IN N
5 CD N
days NNS N
H. NNP N
pylori NN N
status NN N
was VBD N
checked VBN N
by IN N
13C CD N
urea JJ N
breath NN N
test NN N
before IN N
and CC N
after IN N
four CD N
weeks NNS N
of IN N
therapy NN N
RESULTS VB N
A DT N
total NN N
of IN N
71 CD 3_p
patients NNS N
were VBD N
treated VBN N
by IN N
quadruple JJ N
therapy NN N
, , N
and CC N
42 CD 3_p
patients NNS N
were VBD N
treated VBN N
by IN N
triple JJ N
therapy NN N
The DT N
eradication NN N
rate NN N
of IN N
H. NNP N
pylori NN N
for IN N
patients NNS N
under IN N
quadruple JJ N
treatment NN N
, , N
without IN N
vs. FW N
with IN N
previous JJ N
dual JJ N
therapy NN N
, , N
were VBD N
96 CD N
% NN N
vs. FW N
92 CD N
% NN N
( ( N
42/44 CD N
vs. FW N
22/24 CD N
) ) N
by IN N
per IN N
protocol NN N
and CC N
91 CD N
% NN N
vs. FW N
88 CD N
% NN N
( ( N
42/46 CD N
vs. FW N
22/25 CD N
) ) N
by IN N
intention NN N
to TO N
treat VB N
analysis NN N
( ( N
comparisons NNS N
not RB N
significant JJ N
) ) N
No DT N
major JJ N
side-effects NNS N
were VBD N
reported VBN N
CONCLUSIONS NNP N
Five-day JJ N
quadruple NN N
therapy NN N
( ( N
with IN N
omeprazole NN N
, , N
metronidazole NN N
, , N
clarithromycin NN N
and CC N
amoxicillin NN N
) ) N
represents VBZ N
an DT N
effective JJ N
and CC N
safe JJ N
new JJ N
regimen NNS N
for IN N
H. NNP N
pylori JJ N
eradication NN N
-DOCSTART- -X- O O 4016785

Prospectively RB N
randomized VBN N
toxicity NN N
study NN N
of IN N
high-dose JJ N
versus NN N
low-dose JJ N
treatment NN N
strategies NNS N
for IN N
lymphoblastoid JJ 4_p
interferon NN 4_p
It PRP N
is VBZ N
unclear JJ N
from IN N
preliminary JJ N
laboratory NN N
studies NNS N
whether IN N
a DT N
high- NN N
or CC N
a DT N
low-dose JJ N
interferon NN N
treatment NN N
strategy NN N
is VBZ N
optimal JJ N
As IN N
part NN N
of IN N
an DT N
ongoing JJ N
study NN N
of IN N
mechanisms NNS N
of IN N
interferon NN N
action NN N
, , N
we PRP N
have VBP N
evaluated VBN N
toxicity NN N
in IN N
a DT N
two-arm JJ N
protocol NN N
in IN N
which WDT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
lymphoblastoid JJ N
interferon NN N
by IN N
either CC N
a DT N
low-dose JJ N
treatment NN N
strategy NN N
( ( N
2 CD N
X RB N
10 CD N
( ( N
6 CD N
) ) N
units/m2 JJ N
daily JJ N
X $ N
28 CD N
days NNS N
then RB N
daily JJ N
X NNP N
5 CD N
days NNS N
every DT N
other JJ N
week NN N
by IN N
im JJ N
injection NN N
) ) N
or CC N
a DT N
high-dose JJ N
treatment NN N
strategy NN N
( ( N
5 CD N
X RB N
10 CD N
( ( N
6 CD N
) ) N
units/m2 NN N
by IN N
continuous JJ N
iv JJ N
infusion NN N
over IN N
24 CD N
hours NNS N
, , N
escalating VBG N
by IN N
5 CD N
X NNS N
10 CD N
( ( N
6 CD N
) ) N
units/m2/day NN N
as IN N
tolerated VBN N
over IN N
10 CD N
days NNS N
, , N
repeated VBD N
every DT N
28 CD N
days NNS N
) ) N
The DT N
main JJ N
toxic NN N
effects NNS N
in IN N
both DT N
arms NNS N
were VBD N
fever RB N
, , N
fatigue NN N
, , N
and CC N
anorexia RB N
Marked JJ N
interpatient NN N
differences NNS N
within IN N
each DT N
dose JJ N
arm NN N
were VBD N
greater JJR N
than IN N
differences NNS N
between IN N
arms NNS N
Additional JJ N
significant JJ N
toxic NN N
effects NNS N
included VBD N
nausea NN N
and CC N
vomiting NN N
, , N
hypotension NN N
, , N
leukopenia NN N
, , N
thrombocytopenia NN N
, , N
and CC N
evidence NN N
of IN N
hepatic JJ N
toxicity NN N
Minor JJ N
changes NNS N
in IN N
serum NN N
electrolytes NNS N
were VBD N
noted VBN N
Coagulation NNP N
studies NNS N
were VBD N
normal JJ N
The DT N
dose-limiting JJ N
toxic NN N
effect NN N
for IN N
the DT N
high-dose JJ N
arm NN N
was VBD N
myelosuppression NN N
Median JJ N
maximum NN N
tolerated VBD N
dose JJ N
among IN N
high-dose JJ N
strategy NN N
patients NNS N
was VBD N
18 CD N
X JJ N
10 CD N
( ( N
6 CD N
) ) N
units/m2 NN N
, , N
but CC N
there RB N
was VBD N
marked VBN N
interpatient JJ N
variation NN N
We PRP N
conclude VBP N
that IN N
both DT N
dose JJ N
schedules NNS N
were VBD N
relatively RB N
well-tolerated JJ N
Because IN N
of IN N
individual JJ N
variation NN N
in IN N
tolerance NN N
, , N
high-dose JJ N
treatment NN N
should MD N
include VB N
a DT N
dose JJ N
escalation NN N
strategy NN N
-DOCSTART- -X- O O 23477890

The DT N
addition NN N
of IN N
amifostine NN N
to TO N
carboplatin VB N
and CC N
paclitaxel VB N
based VBN N
chemoradiation NN N
in IN N
locally RB 4_p
advanced JJ 4_p
non-small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
: : 4_p
long-term JJ N
follow-up NN N
of IN N
Radiation NNP N
Therapy NNP N
Oncology NNP N
Group NNP N
( ( N
RTOG NNP N
) ) N
randomized VBD N
trial NN N
9801 CD N
INTRODUCTION NNP N
We PRP N
report VBP N
the DT N
long-term JJ N
results NNS N
of IN N
RTOG NNP N
9801 CD N
, , N
a DT N
randomized JJ N
trial NN N
investigating VBG N
the DT N
ability NN N
of IN N
amifostine NN N
, , N
a DT N
radioprotector NN N
, , N
to TO N
reduce VB N
chemoradiation-induced JJ N
esophagitis NN N
METHODS NNP N
Patients NNPS 4_p
with IN 4_p
stages NNS 4_p
II NNP 4_p
and CC 4_p
IIIA/B NNP 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
received VBD N
induction NN N
paclitaxel NN N
225 CD N
mg/m2 NN N
intravenously RB N
( ( N
IV NNP N
) ) N
and CC N
carboplatin JJ N
area NN N
under IN N
the DT N
curve NN N
( ( N
AUC NNP N
) ) N
6 CD N
both DT N
days NNS N
1 CD N
and CC N
22 CD N
, , N
followed VBN N
by IN N
concurrent JJ N
weekly JJ N
paclitaxel NN N
( ( N
50 CD N
mg/m2 NN N
) ) N
and CC N
carboplatin NN N
( ( N
AUC NNP N
2 CD N
) ) N
, , N
with IN N
hyperfractionated VBN N
radiation NN N
therapy NN N
( ( N
69.6 CD N
Gy NNP N
at IN N
1.2 CD N
Gy NNP N
BID NNP N
) ) N
Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
amifostine VB N
( ( N
AM NNP N
) ) N
500 CD N
mg JJ N
IV NNP N
four CD N
times NNS N
per IN N
week NN N
or CC N
no-AM JJ N
during IN N
chemoradiotherapy NN N
Stratification NN N
factors NNS N
included VBD N
age NN N
( ( N
< JJ N
70 CD N
vs. FW N
≥70 CD N
years NNS N
) ) N
, , N
stage NN N
and CC N
performance NN N
status NN N
RESULTS VB N
243 CD N
patients NNS N
( ( N
pts NNS N
) ) N
were VBD N
enrolled VBN N
; : N
120 CD N
received VBD N
AM NNP N
, , N
123 CD N
received VBD N
no-AM JJ N
Two CD N
pts NNS N
on IN N
each DT N
arm NN N
were VBD N
found VBN N
ineligible JJ N
Overall JJ N
, , N
85 CD N
% NN N
of IN N
patients NNS N
were VBD N
≤70 JJ N
years NNS N
; : N
75 CD N
% NN N
had VBD N
a DT N
KPS NNP N
≥90 NNP N
34 CD N
% NN N
had VBD N
squamous JJ N
histology NN N
With IN N
median JJ N
follow-up NN N
of IN N
96.3 CD N
months NNS N
( ( N
for IN N
patients NNS N
still RB N
alive JJ N
) ) N
, , N
overall JJ N
survival NN N
was VBD N
identical JJ N
( ( N
hazard JJ N
ratio NN N
1.03 CD N
( ( N
0.79-1.34 NN N
) ) N
, , N
NS NNP N
) ) N
: : N
five-year JJ N
survival JJ N
17 CD N
% NN N
in IN N
both DT N
arms NNS N
The DT N
incidence NN N
of IN N
late JJ N
grade NN N
3-5 JJ N
toxicities NNS N
was VBD N
16 CD N
% NN N
in IN N
the DT N
AM NNP N
arm NN N
and CC N
19 CD N
% NN N
in IN N
the DT N
control NN N
arm NN N
( ( N
hazard JJ N
ratio NN N
1.24 CD N
( ( N
0.66-2.32 NN N
) ) N
, , N
NS NNP N
) ) N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
arms NNS N
regarding VBG N
overall JJ N
survival NN N
, , N
disease-free JJ N
survival NN N
or CC N
long-term JJ N
toxicity NN N
CONCLUSION VB N
The DT N
chemoradiation NN N
regimen NNS N
of IN N
carboplatin NN N
and CC N
paclitaxel NN N
produced VBN N
long-term JJ N
results NNS N
in IN N
the DT N
multi-institutional JJ N
setting NN N
comparable JJ N
to TO N
other JJ N
regimens NNS N
Amifostine NNP N
did VBD N
not RB N
appear VB N
to TO N
compromise VB N
survival NN N
As IN N
done VBN N
in IN N
RTOG NNP N
9801 CD N
, , N
more RBR N
consistent JJ N
reporting NN N
of IN N
long JJ N
term NN N
toxicity NN N
is VBZ N
needed VBN N
for IN N
comparison NN N
of IN N
different JJ N
chemoradiation NN N
regimens NNS N
-DOCSTART- -X- O O 22456820

Are NNP N
prenatal JJ N
ultrasound JJ N
scans NNS N
associated VBN N
with IN N
the DT N
autism NN N
phenotype NN N
? . N
Follow-up NNP N
of IN N
a DT N
randomised VBN N
controlled VBN N
trial NN N
An DT N
existing VBG N
randomised VBD N
controlled VBN N
trial NN N
was VBD N
used VBN N
to TO N
investigate VB N
whether IN N
multiple JJ N
ultrasound JJ N
scans NNS N
may MD N
be VB N
associated VBN N
with IN N
the DT N
autism NN N
phenotype NN N
From IN N
2,834 CD N
single JJ N
pregnancies NNS N
, , N
1,415 CD N
were VBD N
selected VBN N
at IN N
random NN N
to TO N
receive VB N
ultrasound JJ N
imaging NN N
and CC N
continuous JJ N
wave NN N
Doppler NNP N
flow NN N
studies NNS N
at IN N
five CD N
points NNS N
throughout IN N
pregnancy NN N
( ( N
Intensive NNP N
) ) N
and CC N
1,419 CD N
to TO N
receive VB N
a DT N
single JJ N
imaging NN N
scan NN N
at IN N
18 CD N
weeks NNS N
( ( N
Regular NNP N
) ) N
, , N
with IN N
further JJ N
scans NNS N
only RB N
as RB N
indicated VBN N
on IN N
clinical JJ N
grounds NNS N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN N
of IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
between IN N
the DT N
Regular NNP N
( ( N
9/1,125 CD N
, , N
0.8 CD N
% NN N
) ) N
and CC N
Intensive NNP N
( ( N
7/1,167 CD N
, , N
0.6 CD N
% NN N
) ) N
groups NNS N
, , N
nor CC N
a DT N
difference NN N
between IN N
groups NNS N
in IN N
the DT N
level NN N
of IN N
autistic-like JJ N
traits NNS N
in IN N
early JJ N
adulthood NN N
There EX N
is VBZ N
no DT N
clear JJ N
link NN N
between IN N
the DT N
frequency NN N
and CC N
timing NN N
of IN N
prenatal JJ N
ultrasound JJ N
scans NNS N
and CC N
the DT N
autism NN N
phenotype NN N
-DOCSTART- -X- O O 10759619

Pharmacokinetic JJ N
interaction NN N
between IN N
proton NN N
pump NN N
inhibitors NNS N
and CC N
roxithromycin NN N
in IN N
volunteers NNS 4_p
BACKGROUND NNP N
Triple NNP N
therapy NN N
including VBG N
two CD N
antibiotics NNS N
and CC N
a DT N
proton NN N
pump NN N
inhibitor NN N
is VBZ N
a DT N
rational JJ N
approach NN N
to TO N
the DT N
treatment NN N
of IN N
Helicobacter NNP N
pylori NN N
induced VBD N
peptic JJ N
ulcer JJ N
disease NN N
The DT N
interaction NN N
of IN N
antimicrobial JJ N
therapy NN N
and CC N
acid JJ N
suppression NN N
is VBZ N
not RB N
yet RB N
well RB N
elucidated VBN N
AIMS NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
proton NN N
pump NN N
inhibitors NNS N
on IN N
roxithromycin NN N
levels NNS N
in IN N
plasma NN N
and CC N
gastric JJ N
tissue NN N
under IN N
steady-state JJ N
conditions NNS N
in IN N
volunteers NNS N
METHODS NNP N
In IN N
two CD N
crossover NN N
studies NNS N
omeprazole VBP N
20 CD N
mg NN N
b.d. NN N
, , N
lansoprazole JJ N
30 CD N
mg NN N
b.d. NN N
, , N
roxithromycin VBZ N
300 CD N
mg NN N
b.d. NN N
, , N
and CC N
the DT N
combination NN N
of IN N
roxithromycin NN N
with IN N
either DT N
omeprazole NN N
or CC N
lansoprazole NN N
were VBD N
administered VBN N
to TO N
12 CD 3_p
healthy JJ 4_p
volunteers NNS N
over IN N
6 CD N
days NNS N
Blood NNP N
plasma NN N
levels NNS N
of IN N
the DT N
drugs NNS N
were VBD N
measured VBN N
In IN N
addition NN N
, , N
roxithromycin JJ N
concentrations NNS N
were VBD N
also RB N
determined VBN N
in IN N
gastric JJ N
juice NN N
and CC N
gastric JJ N
tissue NN N
obtained VBN N
during IN N
endoscopy NN N
RESULTS VB N
The DT N
proton NN N
pump NN N
inhibitors NNS N
and CC N
roxithromycin NN N
did VBD N
not RB N
alter VB N
the DT N
blood NN N
plasma NN N
pharmacokinetics NNS N
of IN N
each DT N
other JJ N
When WRB N
compared VBN N
to TO N
roxithromycin VB N
administered JJ N
alone RB N
, , N
its PRP$ N
combination NN N
with IN N
a DT N
proton NN N
pump NN N
inhibitor NN N
significantly RB N
increased VBD N
the DT N
roxithromycin NN N
concentrations NNS N
in IN N
gastric JJ N
juice NN N
( ( N
3.0-5.0 JJ N
microg/mL NN N
vs. IN N
0.3-0.4 NNP N
microg/mL NN N
) ) N
and CC N
gastric JJ N
tissue NN N
( ( N
antrum NN N
: : N
3.8-4.0 JJ N
vs. FW N
2.8 CD N
microg/g NN N
, , N
fundus NN N
: : N
5.9-7.4 JJ N
vs. IN N
4.2-4.4 JJ N
microg/g NN N
) ) N
CONCLUSIONS NNP N
Proton NNP N
pump NN N
inhibitors NNS N
and CC N
roxithromycin VB N
do VBP N
not RB N
alter VB N
the DT N
systemic JJ N
bioavailability NN N
of IN N
each DT N
other JJ N
However RB N
, , N
proton VBP N
pump NN N
inhibitors NNS N
increase VBP N
the DT N
local JJ N
concentration NN N
of IN N
roxithromycin NN N
in IN N
the DT N
stomach NN N
which WDT N
may MD N
contribute VB N
to TO N
the DT N
clinically RB N
proven JJ N
synergic JJ N
beneficial JJ N
action NN N
in IN N
eradication NN N
therapy NN N
of IN N
H. NNP N
pylori NN N
-DOCSTART- -X- O O 7893582

Angiotensin NNP N
converting VBG N
enzyme JJ N
inhibition NN N
does VBZ N
not RB N
affect VB N
the DT N
response NN N
to TO N
exogenous JJ N
angiotensin NN N
II NNP N
in IN N
the DT N
human JJ N
forearm NN N
Suppression NN N
of IN N
endogenous JJ N
levels NNS N
of IN N
angiotensin NN N
II NNP N
by IN N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibition NN N
, , N
may MD N
result VB N
in IN N
up-regulation NN N
of IN N
vascular JJ N
AT1 NNP N
receptors NNS N
We PRP N
have VBP N
evaluated VBN N
the DT N
effects NNS N
of IN N
orally RB N
administered VBN N
enalapril NN N
on IN N
angiotensin NN N
II NNP N
induced VBD N
vasoconstriction NN N
in IN N
the DT N
human JJ N
forearm NN N
Subjects VBZ N
received VBN N
in IN N
random JJ N
order NN N
, , N
enalapril NN N
( ( N
20 CD N
mg NN N
) ) N
or CC N
matched VBN N
placebo JJ N
daily JJ N
for IN N
2 CD N
weeks NNS N
Forearm NNP N
blood NN N
flow NN N
response NN N
to TO N
increasing VBG N
doses NNS N
of IN N
angiotensin NN N
II NNP N
was VBD N
measured VBN N
using VBG N
venous JJ N
occlusion NN N
plethysmography NN N
at IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
and CC N
at IN N
the DT N
end NN N
of IN N
each DT N
2 CD N
week NN N
treatment NN N
period NN N
Treatment NN N
with IN N
enalapril NN N
significantly RB N
reduced VBN N
plasma NN N
angiotensin NN N
II NNP N
levels NNS N
and CC N
supine VB N
blood NN N
pressure NN N
compared VBN N
with IN N
placebo NN N
The DT N
percentage NN N
reductions NNS N
in IN N
forearm NN N
blood NN N
flow NN N
in IN N
the DT N
infused JJ N
arm NN N
, , N
in IN N
response NN N
to TO N
the DT N
maximum JJ N
dose NN N
of IN N
angiotensin NN N
II NNP N
( ( N
50,000 CD N
fmol RB N
min-1 NN N
) ) N
were VBD N
48.1 CD N
+/- JJ N
3.6 CD N
% NN N
at IN N
baseline NN N
, , N
57.5 CD N
+/- JJ N
3.6 CD N
% NN N
on IN N
placebo NN N
and CC N
54.5 CD N
+/- JJ N
4.2 CD N
% NN N
on IN N
enalapril NN N
The DT N
differences NNS N
were VBD N
not RB N
significantly RB N
different JJ N
This DT N
demonstrates VBZ N
that IN N
suppression NN N
of IN N
plasma NN N
angiotensin NN N
II NNP N
for IN N
a DT N
14 CD N
day NN N
period NN N
does VBZ N
not RB N
enhance VB N
the DT N
response NN N
to TO N
exogenous JJ N
intra-arterial JJ N
angiotensin NN N
II NNP N
in IN N
the DT N
human JJ N
forearm NN N
of IN N
healthy JJ 4_p
salt NN 4_p
replete JJ 4_p
subjects NNS N
-DOCSTART- -X- O O 2068469

Aztreonam NNP N
versus NN N
gentamicin NN N
for IN N
short-term JJ N
prophylaxis NN N
in IN N
biliary JJ N
and CC N
gastric JJ N
surgery NN N
Short-term NNP N
antibiotic JJ N
prophylaxis NN N
was VBD N
studied VBN N
in IN N
80 CD 3_p
patients NNS N
undergoing JJ N
biliary JJ N
or CC N
gastric JJ N
surgery NN N
The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
1 CD N
g NN N
of IN N
aztreonam NN N
or CC N
80 CD N
mg NN N
of IN N
gentamicin NN N
intravenously RB N
30 CD N
minutes NNS N
before IN N
surgery NN N
and CC N
8 CD N
and CC N
16 CD N
hours NNS N
after IN N
surgery NN N
Of IN N
samples NNS N
taken VBN N
from IN N
the DT N
abdominal JJ N
cavity NN N
for IN N
bacteriologic NN N
study NN N
, , N
53 CD N
% NN N
were VBD N
culture NN N
positive JJ N
Wound IN N
infections NNS N
developed VBN N
in IN N
two CD N
( ( N
4.5 CD N
% NN N
) ) N
of IN N
44 CD N
patients NNS N
receiving VBG N
aztreonam NN N
and CC N
in IN N
seven CD N
( ( N
19.4 CD N
% NN N
) ) N
of IN N
36 CD N
patients NNS N
treated VBN N
with IN N
gentamicin NN N
Staphylococcus NNP N
epidermidis NN N
and CC N
Enterobacter NNP N
species NNS N
were VBD N
isolated VBN N
from IN N
sites NNS N
of IN N
wound JJ N
infection NN N
in IN N
the DT N
aztreonam JJ N
group NN N
; : N
Escherichia NNP N
coli NNS N
( ( N
two CD N
isolates NNS N
) ) N
, , N
Pseudomonas NNP N
aeruginosa NN N
( ( N
two CD N
isolates NNS N
) ) N
, , N
Enterobacter NNP N
species NNS N
, , N
Klebsiella NNP N
species NNS N
, , N
Enterococcus NNP N
faecalis NN N
, , N
and CC N
Aeromonas NNP N
hydrophila NN N
were VBD N
isolated VBN N
from IN N
the DT N
gentamicin NN N
group NN N
Our PRP$ N
data NNS N
indicate VBP N
that IN N
aztreonam NN N
is VBZ N
safe JJ N
and CC N
effective JJ N
for IN N
the DT N
prevention NN N
of IN N
infections NNS N
following VBG N
biliary JJ N
and CC N
gastric JJ N
surgery NN N
-DOCSTART- -X- O O 14636372

Prophylactic JJ N
effect NN N
of IN N
phenytoin NN N
in IN N
bipolar JJ 4_p
disorder NN 4_p
: : N
a DT N
controlled VBN N
study NN N
OBJECTIVE NNP N
Phenytoin NNP N
is VBZ N
an DT N
effective JJ N
anticonvulsant NN N
that WDT N
has VBZ N
not RB N
previously RB N
been VBN N
studied VBN N
prophylactically RB N
in IN N
bipolar NN 4_p
( ( N
BP NNP 4_p
) ) N
patients NNS N
Thus VB N
a DT N
study NN N
of IN N
phenytoin NN N
prophylaxis NN N
was VBD N
undertaken JJ N
and CC N
is VBZ N
herein RB N
reported VBN N
METHOD NNP N
Bipolar JJ 4_p
patients NNS N
were VBD N
studied VBN N
who WP N
had VBD 4_p
at IN 4_p
least JJS 4_p
one CD 4_p
episode NN 4_p
per IN 4_p
year NN 4_p
in IN N
the DT N
previous JJ N
2 CD N
years NNS N
despite IN N
ongoing VBG 4_p
prophylaxis NN 4_p
Patients NNS N
were VBD N
stable JJ 4_p
for IN 4_p
a DT 4_p
mean NN 4_p
of IN 4_p
4 CD 4_p
months NNS 4_p
( ( 4_p
range VB 4_p
1-13 NNS 4_p
) ) 4_p
before IN 4_p
entering VBG 4_p
the DT 4_p
study NN 4_p
Phenytoin NNP N
or CC N
placebo NN N
was VBD N
added VBN N
to TO N
their PRP$ N
current JJ N
therapy NN N
in IN N
a DT N
double-blind JJ N
cross-over NN N
design NN N
for IN N
6 CD N
months NNS N
in IN N
each DT N
phase NN N
Thirty NNP N
observation NN N
periods NNS N
of IN N
6 CD N
months NNS N
each DT N
were VBD N
studied VBN N
for IN N
23 CD 3_p
patients NNS N
RESULTS NNP N
Three CD N
patients NNS N
had VBD N
relapse VBN N
on IN N
phenytoin NN N
and CC N
nine CD N
had VBD N
relapse VBN N
on IN N
placebo NN N
There EX N
was VBD N
a DT N
significant JJ N
prophylactic JJ N
effect NN N
of IN N
phenytoin NN N
in IN N
BP NNP N
disorder NN N
[ NNP N
Cox NNP N
's POS N
F-test NNP N
for IN N
comparing VBG N
survival NN N
in IN N
two CD N
groups NNS N
: : N
F NNP N
( ( N
6 CD N
, , N
18 CD N
) ) N
= NN N
3.44 CD N
, , N
p NN N
= VBD N
0.02 CD N
] NN N
CONCLUSIONS VB N
This DT N
study NN N
suggests VBZ N
prophylactic JJ N
effects NNS N
of IN N
add-on JJ N
phenytoin NN N
in IN N
BP NNP N
illness NN N
However RB N
, , N
the DT N
number NN N
of IN N
patients NNS N
was VBD N
small JJ N
and CC N
confirmation NN N
is VBZ N
necessary JJ N
-DOCSTART- -X- O O 17113685

B-vitamins NNS N
reduce VB N
plasma NN N
levels NNS N
of IN N
beta NN N
amyloid NN N
Elevated VBN N
plasma JJ N
homocysteine NN N
( ( N
tHcy NN N
) ) N
is VBZ N
a DT N
risk NN N
factor NN N
for IN N
Alzheimer NNP N
's POS N
disease NN N
( ( N
AD NNP N
) ) N
, , N
and CC N
thus RB N
B NNP N
vitamins NNS N
may MD N
have VB N
a DT N
role NN N
in IN N
the DT N
prevention NN N
of IN N
AD NNP N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
tHcy JJ N
lowering NN N
vitamins NNS N
decrease VBP N
the DT N
circulating NN N
levels NNS N
of IN N
A-beta NNP N
protein NN N
1-40 JJ N
( ( N
A NNP N
beta RB N
40 CD N
) ) N
We PRP N
randomized VBD N
299 CD N
older JJR N
men NNS N
to TO N
treatment NN N
with IN N
2mg CD N
of IN N
folate NN N
, , N
plus CC N
25mg CD N
of IN N
B6 NNP N
and CC N
400 CD N
microg NN N
of IN N
B12 NNP N
, , N
or CC N
placebo NN N
After IN N
2 CD N
years NNS N
of IN N
treatment NN N
the DT N
mean NN N
( ( N
S.E NNP N
) ) N
increase NN N
of IN N
A NNP N
beta NN N
40 CD N
was VBD N
7.0 CD N
pg/ml NN N
( ( N
8.4 CD N
) ) N
in IN N
the DT N
vitamin NN N
group NN N
( ( N
4.9 CD N
% NN N
) ) N
, , N
and CC N
26.8 CD N
pg/ml NN N
( ( N
7.7 CD N
) ) N
( ( N
18.5 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
We PRP N
conclude VBP N
that IN N
B NNP N
vitamins NNS N
may MD N
decrease VB N
the DT N
plasma JJ N
level NN N
of IN N
A NNP N
beta NN N
40 CD N
and CC N
have VBP N
a DT N
role NN N
in IN N
the DT N
prevention NN N
of IN N
AD NNP N
-DOCSTART- -X- O O 5575706

Triamcinolone CD N
acetonide NN N
in IN N
the DT N
treatment NN N
of IN N
bursitis NN 4_p
and CC 4_p
other JJ 4_p
foot NN 4_p
disorders NNS 4_p
-DOCSTART- -X- O O 24460069

A DT N
randomized JJ N
pilot NN N
study NN N
with IN N
daily JJ N
walking VBG N
during IN N
adjuvant JJ N
chemotherapy NN N
for IN N
patients NNS 4_p
with IN 4_p
breast NN 4_p
and CC 4_p
colorectal JJ 4_p
cancer NN 4_p
BACKGROUND NNP N
Physical NNP N
activity NN N
during IN N
chemotherapy NN N
has VBZ N
been VBN N
shown VBN N
in IN N
several JJ N
studies NNS N
to TO N
reduce VB N
fatigue NN N
, , N
improve VB N
symptoms NNS N
and CC N
impact NN N
positively RB N
on IN N
health-related JJ N
quality NN N
of IN N
life NN N
( ( N
HRQoL NNP N
) ) N
Challenges NNS N
associated VBN N
with IN N
intervention NN N
studies NNS N
on IN N
physical JJ N
activity NN N
during IN N
cancer NN N
treatment NN N
relate NN N
to TO N
consistent JJ N
adherence NN N
The DT N
primary JJ N
objective NN N
was VBD N
to TO N
study VB N
feasibility NN N
and CC N
adherence NN N
of IN N
physical JJ N
activity NN N
intervention NN N
among IN N
patients NNS 4_p
with IN 4_p
cancer NN 4_p
during IN 4_p
adjuvant JJ 4_p
chemotherapy NN 4_p
treatment NN 4_p
The DT N
secondary JJ N
objective NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
physical JJ N
activity NN N
on IN N
health NN N
aspects NNS N
, , N
including VBG N
HRQoL NNP N
, , N
symptoms NNS N
and CC N
surrogate JJ N
markers NNS N
for IN N
cardiovascular JJ N
disease NN N
MATERIAL NNP N
AND CC N
METHODS NNP N
This DT N
randomized VBD N
controlled JJ N
trial NN N
included VBD N
patients NNS 4_p
with IN 4_p
breast NN 4_p
cancer NN 4_p
( ( 4_p
BRCA NNP 4_p
) ) 4_p
and CC 4_p
colorectal JJ 4_p
cancer NN 4_p
( ( 4_p
CRC NNP 4_p
) ) 4_p
during IN 4_p
adjuvant JJ 4_p
chemotherapy NN 4_p
The DT N
intervention NN N
continued VBD N
for IN N
10 CD N
weeks NNS N
and CC N
included VBD N
daily JJ N
walks NNS N
of IN N
10 CD N
000 CD N
steps NNS N
and CC N
a DT N
weekly JJ N
supervised VBN N
group NN N
walk NN N
Adherence NNP N
was VBD N
assessed VBN N
by IN N
a DT N
pedometer NN N
and CC N
the DT N
number NN N
of IN N
participants NNS N
who WP N
reported VBD N
step NN N
counts NNS N
every DT N
week NN N
and CC N
percentage NN N
of IN N
participants NNS N
who WP N
achieved VBD N
the DT N
target NN N
steps NNS N
every DT N
week NN N
RESULTS NNP N
Adherence NNP N
average JJ N
reached VBD N
91 CD N
% NN N
during IN N
the DT N
intervention NN N
period NN N
; : N
in IN N
total JJ N
74 CD N
% NN N
completed VBD N
the DT N
exercise NN N
intervention NN N
The DT N
majority NN N
of IN N
the DT N
participants NNS N
achieved VBD N
an DT N
average NN N
of IN N
83 CD N
% NN N
of IN N
the DT N
target NN N
of IN N
10 CD N
000 CD N
steps NNS N
per IN N
day NN N
for IN N
10 CD N
weeks NNS N
There EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
daily JJ N
physical JJ N
activity NN N
( ( N
p JJ N
= NNP N
0.016 CD N
) ) N
in IN N
the DT N
intervention NN N
group NN N
Significant JJ N
differences NNS N
were VBD N
also RB N
found VBN N
for IN N
some DT N
breast NN N
cancer-specific JJ N
symptoms NNS N
[ MD N
swelling VBG N
, , N
mobility NN N
and CC N
pain NN N
( ( N
p JJ N
= NNP N
0.045 CD N
) ) N
] NN N
The DT N
study NN N
showed VBD N
a DT N
relatively RB N
small JJ N
weight NN N
gain NN N
an DT N
average NN N
of IN N
0.9 CD N
kg NNS N
in IN N
the DT N
intervention NN N
group NN N
and CC N
1.3 CD N
kg NN N
in IN N
the DT N
control NN N
group NN N
CONCLUSION NNP N
Physical NNP N
activity NN N
in IN N
the DT N
form NN N
of IN N
walking NN N
is VBZ N
feasible JJ N
during IN N
adjuvant JJ N
chemotherapy NN N
treatment NN N
despite IN N
increasing VBG N
symptoms NNS N
The DT N
physical JJ N
activity NN N
increased VBN N
in IN N
the DT N
intervention NN N
group NN N
during IN N
the DT N
study NN N
time NN N
and CC N
had VBD N
a DT N
positive JJ N
impact NN N
on IN N
breast NN N
symptoms NNS N
and CC N
the DT N
weight NN N
gain NN N
was VBD N
lower JJR N
in IN N
comparison NN N
to TO N
previous JJ N
studies NNS N
-DOCSTART- -X- O O 24375082

Effect NN N
of IN N
camel NN N
milk NN N
on IN N
thymus NN N
and CC N
activation-regulated JJ N
chemokine NN N
in IN N
autistic JJ 4_p
children NNS 1_p
: : N
double-blind NN N
study NN N
BACKGROUND NNP N
This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
role NN N
of IN N
the DT N
effectiveness NN N
of IN N
camel NN N
milk NN N
( ( N
CM NNP N
) ) N
( ( N
raw JJ N
and CC N
boiled VBN N
) ) N
on IN N
thymus NN N
and CC N
activation-regulated JJ N
chemokine NN N
( ( N
TARC NNP N
) ) N
serum NN N
levels NNS N
and CC N
childhood NN 1_p
autism NN 4_p
rating NN N
scale NN N
( ( N
CARS NNP N
) ) N
score NN N
in IN N
subjects NNS N
with IN N
autism NN 4_p
and CC N
compared VBN N
to TO N
placebo VB N
group NN N
( ( N
cow JJ N
milk NN N
) ) N
METHODS NNP N
Forty-five JJ 3_p
subjects NNS N
diagnosed VBN N
with IN N
autism NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
boiled VBN N
CM NNP N
for IN N
group NN N
I PRP N
( ( N
n JJ N
= NNP N
15 CD 3_p
) ) N
, , N
raw JJ N
CM NNP N
for IN N
group NN N
II NNP N
( ( N
n JJ N
= NNP N
15 CD 3_p
) ) N
, , N
and CC N
placebo NN N
for IN N
group NN N
III NNP N
( ( N
n JJ N
= NNP N
15 CD 3_p
) ) N
for IN N
2 CD N
wk NN N
Measures NNS N
included VBD N
changes NNS N
in IN N
professionally RB N
completed VBN N
CARS NNP N
score NN N
and CC N
blood NN N
samples NNS N
for IN N
TARC NNP N
serum NN N
level NN N
were VBD N
taken VBN N
before RB N
and CC N
after IN N
milk NN N
consumption NN N
of IN N
500 CD N
ml NNS N
per IN N
day NN N
in IN N
children NNS N
's POS N
regular JJ N
daily JJ N
diet NN N
RESULTS VB N
The DT N
serum NN N
levels NNS N
of IN N
TARC NNP N
decreased VBD N
significantly RB N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
in IN N
boiled VBN N
CM NNP N
and CC N
in IN N
raw JJ N
CM NNP N
group NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
too RB N
, , N
but CC N
no DT N
effect NN N
was VBD N
observed VBN N
( ( N
P NNP N
= NNP N
0.68 CD N
) ) N
in IN N
placebo NN N
group NN N
Furthermore RB N
, , N
significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
CARS NNP N
score NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
in IN N
raw JJ N
CM NNP N
group NN N
only RB N
There EX N
were VBD N
no DT N
significant JJ N
relationships NNS N
between IN N
the DT N
serum NN N
of IN N
TARC NNP N
level NN N
and CC N
the DT N
CARS NNP N
score NN N
, , N
age NN N
, , N
or CC N
gender VB N
for IN N
any DT N
group NN N
CONCLUSION NNP N
CM NNP N
administered VBD N
for IN N
2 CD N
wk NNS N
significantly RB N
improved VBN N
clinical JJ N
measurements NNS N
of IN N
autism NN N
severity NN N
and CC N
decreased VBD N
serum JJR N
level NN N
of IN N
TARC NNP N
in IN N
autistic JJ N
children NNS N
, , N
but CC N
subsequent JJ N
studies NNS N
are VBP N
recommended VBN N
-DOCSTART- -X- O O 21629200

A DT N
prospective JJ N
double-blind NN N
, , N
randomized VBD N
clinical JJ N
trial NN N
of IN N
levocarnitine NN N
to TO N
treat VB N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
BACKGROUND NNP N
L-carnitine NNP N
was VBD N
proposed VBN N
as IN N
a DT N
potential JJ N
treatment NN N
for IN N
patients NNS 4_p
diagnosed VBN 4_p
with IN 4_p
an DT 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
to TO N
improve VB N
mitochondrial JJ N
dysfunction NN N
, , N
but CC N
no DT N
prior JJ N
randomized VBN N
controlled VBN N
trials NNS N
have VBP N
been VBN N
conducted VBN N
MATERIAL/METHODS NNP N
Thirty NNP 4_p
subjects NNS 4_p
diagnosed VBD 4_p
with IN 4_p
an DT 4_p
ASD NNP 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
standardized JJ N
regimen NN N
( ( N
50 CD N
mg RB N
L-carnitine/kg NNP N
bodyweight/day NN N
) ) N
of IN N
liquid JJ N
L-carnitine NNP N
( ( N
n=19 NN N
) ) N
or CC N
placebo NN N
( ( N
n=11 JJ N
) ) N
for IN N
3-months JJ N
Measures NNS N
included VBD N
changes NNS N
in IN N
professionally RB N
completed VBN N
Childhood NNP N
Autism NNP N
Rating NNP N
Scale NNP N
( ( N
CARS NNP N
) ) N
, , N
hand NN N
muscle NN N
testing NN N
, , N
and CC N
modified VBD N
clinical JJ N
global JJ N
impression NN N
( ( N
CGI NNP N
) ) N
forms VBZ N
; : N
parent NN N
completed VBD N
Autism NNP N
Treatment NNP N
Evaluation NNP N
Checklist NNP N
( ( N
ATEC NNP N
) ) N
, , N
treatment NN N
adherence NN N
measurement NN N
( ( N
TAM NNP N
) ) N
, , N
frequency NN N
and CC N
intensity NN N
of IN N
side JJ N
effect NN N
rating NN N
( ( N
FISER NNP N
) ) N
/global VBD N
rating NN N
of IN N
side JJ N
effect NN N
burden NN N
( ( N
GRSEB NNP N
) ) N
/patient VBD N
report NN N
of IN N
incidence NN N
of IN N
side NN N
effects NNS N
( ( N
PRISE NNP N
) ) N
forms NNS N
; : N
and CC N
lab VB N
testing VBG N
RESULTS NNP N
Significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
CARS NNP N
( ( N
-2.03 NNP N
, , N
95 CD N
% NN N
CI=-3.7 NNP N
to TO N
-0.31 VB N
) ) N
, , N
CGI NNP N
( ( N
-0.69 NNP N
, , N
95 CD N
% NN N
CI=-1.1 NNP N
to TO N
-0.06 VB N
) ) N
, , N
and CC N
ATEC NNP N
scores NNS N
Significant JJ N
correlations NNS N
between IN N
changes NNS N
in IN N
serum JJ N
free-carnitine JJ N
levels NNS N
and CC N
positive JJ N
clinical JJ N
changes NNS N
were VBD N
observed VBN N
for IN N
hand NN N
muscle NN N
strength NN N
( ( N
R2=0.23 NNP N
, , N
P=0.046 NNP N
) ) N
, , N
cognitive JJ N
scores NNS N
( ( N
R2=0.27 NNP N
, , N
P=0.019 NNP N
) ) N
, , N
and CC N
CARS NNP N
scores NNS N
( ( N
R2=0.20 NNP N
, , N
P=0.047 NNP N
) ) N
Study NNP N
subjects NNS N
were VBD N
protocol-compliant JJ N
( ( N
average JJ N
adherence NN N
was VBD N
> JJ N
85 CD N
% NN N
) ) N
and CC N
generally RB N
well-tolerated VBD N
the DT N
L-carnitine JJ N
therapy NN N
given VBN N
CONCLUSIONS NNP N
L-carnitine JJ N
therapy NN N
( ( N
50 CD N
mg/kilogram-bodyweight/day NN N
) ) N
administered VBD N
for IN N
3-months JJ N
significantly RB N
improved VBN N
several JJ N
clinical JJ N
measurements NNS N
of IN N
ASD NNP N
severity NN N
, , N
but CC N
subsequent JJ N
studies NNS N
are VBP N
recommended VBN N
-DOCSTART- -X- O O 15745138

Online NNP N
conductivity NN N
monitoring NN N
: : N
validation NN N
and CC N
usefulness NN N
in IN N
a DT N
clinical JJ N
trial NN N
of IN N
reduced JJ N
dialysate NN N
conductivity NN N
Relatively RB N
low JJ N
dialysate NN N
conductivity NN N
( ( N
Cndi NNP N
) ) N
may MD N
improve VB N
outcomes NNS N
by IN N
reducing VBG N
the DT N
overall JJ N
sodium NN N
burden NN N
in IN N
dialysis NN 4_p
patients NNS N
Excess NNP N
sodium NN N
removal NN N
, , N
however RB N
, , N
could MD N
lead VB N
to TO N
hemodynamic JJ N
instability NN N
We PRP N
performed VBD N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
reduction NN N
of IN N
Cndi NNP N
For IN N
the DT N
study NN N
, , N
28 CD 3_p
patients NNS N
were VBD N
randomized VBN N
to TO N
maintenance NN N
of IN N
Cndi NNP N
at IN N
13.6 CD N
mS/cm NNS N
( ( N
equivalent JJ N
to TO N
135 CD N
mmol/L NN N
of IN N
Na+ NNP N
) ) N
or CC N
serial JJ N
reduction NN N
of IN N
Cndi NNP N
in IN N
steps NNS N
of IN N
0.2 CD N
mS/cm NNS N
, , N
guided VBN N
by IN N
symptoms NNS N
and CC N
blood NN N
pressure NN N
Sodium NNP N
removal NN N
estimated VBN N
from IN N
pre- NN N
and CC N
postplasma JJ N
concentrations NNS N
correlated VBN N
well RB N
with IN N
removal NN N
measured VBN N
by IN N
conductivity NN N
monitoring NN N
as IN N
ionic JJ N
mass NN N
balance NN N
( ( N
R2 NNP N
0.66 CD N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
Of IN N
the DT N
16 CD N
patients NNS N
randomized VBN N
to TO N
reduction NN N
of IN N
Cndi NNP N
, , N
6 CD N
achieved VBD N
Cndi NNP N
13.4 CD N
mS/cm NN N
, , N
6 CD N
achieved VBD N
13.2 CD N
mS/cm NN N
, , N
and CC N
4 CD N
achieved VBD N
13.0 CD N
mS/cm NN N
No DT N
episodes NNS N
of IN N
disequilibrium NN N
occurred VBD N
Interdialytic JJ N
weight NN N
gain NN N
was VBD N
reduced VBN N
from IN N
2.34 CD N
+/- JJ N
0.10 CD N
kg NN N
to TO N
1.57 CD N
+/- JJ N
0.11 CD N
kg NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
Predialysis NNP N
systolic JJ N
blood NN N
pressure NN N
fell VBD N
from IN N
144 CD N
+/- JJ N
3 CD N
mm NN N
Hg NNP N
to TO N
137 CD N
+/- JJ N
4 CD N
mm NN N
Hg NNP N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
The DT N
reduction NN N
in IN N
convective JJ N
sodium NN N
removal NN N
was VBD N
balanced VBN N
by IN N
an DT N
increase NN N
in IN N
diffusive JJ N
sodium NN N
removal NN N
( ( N
95 CD N
+/- JJ N
9 CD N
mmol NN N
cf NN N
175 CD N
+/- JJ N
14 CD N
mmol NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
Reduction NN N
in IN N
Cndi NNP N
monitored VBN N
by IN N
IMB NNP N
is VBZ N
safe JJ N
and CC N
practical JJ N
and CC N
leads VBZ N
to TO N
improved VBN N
interdialytic JJ N
weight NN N
gains NNS N
and CC N
blood NN N
pressure NN N
control NN N
, , N
while IN N
avoiding VBG N
excessive JJ N
sodium NN N
removal NN N
-DOCSTART- -X- O O 15922817

Results NNS N
of IN N
a DT N
multicenter NN N
, , N
8-week JJ N
, , N
parallel-group JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
Phase NNP N
III NNP N
clinical JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
amlodipine JJ N
maleate NN N
versus NN N
amlodipine NN N
besylate NN N
in IN N
Korean JJ N
patients NNS N
with IN N
mild JJ 4_p
to TO 4_p
moderate VB 4_p
hypertension NN 4_p
BACKGROUND NNP N
Recently RB N
, , N
amlodipine JJ N
maleate NN N
was VBD N
developed VBN N
and CC N
tested VBN N
in IN N
preclinical JJ N
and CC N
Phase NNP N
I PRP N
clinical JJ N
trials NNS N
in IN N
Korea NNP N
The DT N
studies NNS N
found VBD N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
similar JJ N
to TO N
those DT N
of IN N
amlodipine JJ N
besylate NN N
OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
amlodipine JJ N
maleate NN N
with IN N
those DT N
of IN N
amlodipine JJ N
besylate NN N
in IN N
Korean JJ 4_p
patients NNS 4_p
with IN N
mild JJ 4_p
to TO 4_p
moderate VB 4_p
hypertension NN 4_p
METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
8-week JJ N
, , N
parallel-group JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
Phase NNP N
III NNP N
clinical JJ N
trial NN N
Eligible JJ N
patients NNS N
were VBD N
Korean NNP N
, , N
aged VBD 1_p
18 CD 1_p
to TO 1_p
75 CD 1_p
years NNS 1_p
, , N
had VBD N
hypertension NN 4_p
, , N
and CC N
were VBD 4_p
either RB 4_p
taking VBG 4_p
antihypertensive JJ 4_p
medications NNS 4_p
or CC 4_p
had VBD 4_p
a DT 4_p
documented VBN 4_p
sitting VBG 4_p
diastolic JJ 4_p
blood NN 4_p
pressure NN 4_p
of IN 4_p
90 CD 4_p
to TO 4_p
109 CD 4_p
mm NN 4_p
Hg NNP 4_p
After IN N
a DT N
washout JJ N
period NN N
of IN N
2 CD N
weeks NNS N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
amlodipine VB N
maleate NN N
or CC N
amlodipine NN N
besylate NN N
for IN N
8 CD N
weeks NNS N
In IN N
both DT N
groups NNS N
, , N
the DT N
medications NNS N
were VBD N
initiated VBN N
at IN N
5 CD N
mg NN N
QD NNP N
At IN N
day NN N
29 CD N
, , N
the DT N
medication NN N
dose NN N
was VBD N
increased VBN N
to TO N
10 CD N
mg NNS N
QD NNP N
if IN N
sitting VBG N
diastolic JJ N
blood NN N
pressure NN N
( ( N
SiDBP NNP N
) ) N
was VBD N
> JJ N
or CC N
= JJ N
90 CD N
mm NN N
Hg NNP N
RESULTS NNP N
One CD 3_p
hundred VBD 3_p
eighteen JJ 3_p
patients NNS N
were VBD N
enrolled VBN N
Fifty-seven JJ N
patients NNS N
received VBD N
amlodipine JJ N
maleate NN N
( ( N
29 CD N
men NNS N
, , N
28 CD N
women NNS N
; : N
mean VB N
[ NNP N
SD NNP N
] NNP N
age NN N
, , N
49.0 CD N
[ NN N
11.4 CD N
] CD N
years NNS N
) ) N
and CC N
61 CD N
received VBD N
amlodipine JJ N
besylate NN N
( ( N
35 CD N
men NNS N
, , N
26 CD N
women NNS N
; : N
mean VB N
[ NNP N
SD NNP N
] NNP N
age NN N
, , N
51.6 CD N
[ NN N
9.4 CD N
] CD N
years NNS N
) ) N
Baseline JJ N
mean NN N
( ( N
SD NNP N
) ) N
values NNS N
for IN N
sitting VBG N
systolic JJ N
blood NN N
pressure NN N
and CC N
SiDBP NNP N
were VBD N
152.0 CD N
( ( N
12.2 CD N
) ) N
mm NN N
Hg NNP N
and CC N
98.1 CD N
( ( N
5.6 CD N
) ) N
mm NN N
Hg NNP N
, , N
respectively RB N
, , N
for IN N
the DT N
amlodipine JJ N
maleate NN N
group NN N
and CC N
153.4 CD N
( ( N
14.0 CD N
) ) N
mm NN N
Hg NNP N
and CC N
98.1 CD N
( ( N
5.5 CD N
) ) N
mm NN N
Hg NNP N
, , N
respectively RB N
, , N
for IN N
the DT N
amlodipine JJ N
besylate NN N
group NN N
In IN N
this DT N
population NN N
, , N
amlodipine JJ N
maleate NN N
was VBD N
not RB N
inferior JJ N
to TO N
amlodipine VB N
besylate NN N
: : N
the DT N
lower JJR N
limit NN N
of IN N
the DT N
2-sided JJ N
95 CD N
% NN N
CI NNP N
for IN N
the DT N
treatment NN N
difference NN N
in IN N
SiDBP NNP N
was VBD N
greater JJR N
than IN N
-4 JJR N
mm NN N
Hg NNP N
The DT N
between-group JJ N
difference NN N
in IN N
SiDBP NNP N
response NN N
rate NN N
( ( N
the DT N
proportion NN N
of IN N
patients NNS N
who WP N
experienced VBD N
adequate JJ N
SiDBP NNP N
reductions NNS N
) ) N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
: : N
85.7 CD N
% NN N
( ( N
42/49 CD N
) ) N
for IN N
the DT N
amlodipine JJ N
maleate NN N
group NN N
and CC N
91.8 CD N
% NN N
( ( N
45/49 CD N
) ) N
for IN N
the DT N
amlodipine JJ N
besylate NN N
group NN N
Compliance NN N
rates NNS N
were VBD N
similar JJ N
between IN N
groups NNS N
, , N
with IN N
mean NN N
( ( N
SD NNP N
) ) N
compliance NN N
rates NNS N
of IN N
97.4 CD N
% NN N
( ( N
2.8 CD N
% NN N
) ) N
and CC N
97.1 CD N
% NN N
( ( N
3.6 CD N
% NN N
) ) N
in IN N
the DT N
amlodipine NN N
maleate NN N
and CC N
amlodipine JJ N
besylate NN N
groups NNS N
, , N
respectively RB N
Also RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
incidences NNS N
of IN N
drug-related JJ N
clinical JJ N
and CC N
laboratory JJ N
adverse JJ N
events NNS N
; : N
the DT N
most RBS N
common JJ N
were VBD N
headache NN N
, , N
flushing NN N
, , N
facial JJ N
edema NN N
, , N
and CC N
paresthesia NN N
CONCLUSION NN N
In IN N
this DT N
population NN N
, , N
the DT N
efficacy NN N
and CC N
tolerability NN N
observed VBN N
with IN N
amlodipine JJ N
maleate NN N
were VBD N
similar JJ N
to TO N
those DT N
seen VBN N
with IN N
amlodipine JJ N
besylate NN N
-DOCSTART- -X- O O 12738312

Comparison NNP N
of IN N
the DT N
comet NN N
assay NN N
and CC N
the DT N
oxygen NN N
microelectrode NN N
for IN N
measuring VBG N
tumor NN N
oxygenation NN N
in IN N
head-and-neck JJ 4_p
cancer NN 4_p
patients NNS N
PURPOSE NNP N
To TO N
compare VB N
the DT N
Eppendorf NNP N
PO2 NNP N
histograph NN N
and CC N
the DT N
alkaline NN N
comet NN N
assay VBP N
as IN N
methods NNS N
of IN N
measuring VBG N
tumor NN N
hypoxia NN N
in IN N
patients NNS N
with IN N
head-and-neck JJ 4_p
squamous JJ 4_p
cell NN 4_p
carcinomas NN 4_p
MATERIALS NNP N
AND CC N
METHODS NNP N
As IN N
part NN N
of IN N
a DT N
larger JJR N
clinical JJ N
trial NN N
, , N
65 CD 3_p
patients NNS 3_p
with IN N
head-and-neck JJ 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
nodal JJ N
metastasis NN N
underwent JJ N
tumor NN N
oxygenation NN N
measurements NNS N
with IN N
Eppendorf NNP N
PO2 NNP N
histographs NN N
and CC N
comet NN N
assays NNS N
, , N
performed VBN N
on IN N
fine-needle JJ N
aspirates NNS N
at IN N
1 CD N
and CC N
2 CD N
min NN N
after IN N
5 CD N
Gy NNP N
Fifty-four CD 3_p
patients NNS 3_p
had VBD N
sufficient JJ N
tumor NN N
cells NNS N
for IN N
comet JJ N
analysis NN N
at IN N
1 CD N
min NN N
and CC N
26 CD N
at IN N
both DT N
1 CD N
and CC N
2 CD N
min NN N
Individual JJ N
cells NNS N
were VBD N
examined VBN N
for IN N
DNA NNP N
single-strand NN N
breaks NNS N
by IN N
alkaline JJ N
gel NN N
electrophoresis NN N
, , N
and CC N
the DT N
distribution NN N
of IN N
values NNS N
was VBD N
quantified VBN N
using VBG N
median JJ N
tail NN N
moment NN N
( ( N
MTM NNP N
) ) N
Nonirradiated VBN N
tumor NN N
cells NNS N
from IN N
pretreatment JJ N
fine-needle JJ N
aspirates NNS N
received VBD N
5 CD N
Gy NNP N
in IN N
vitro NN N
to TO N
establish VB N
the DT N
oxygenated JJ N
response NN N
RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
correlation NN N
between IN N
the DT N
1- JJ N
and CC N
2-min JJ N
MTM NNP N
( ( N
slope VBP N
= RB N
0.77 CD N
+/- JJ N
0.03 CD N
) ) N
There EX N
was VBD N
no DT N
relationship NN N
between IN N
DNA NNP N
damage NN N
in IN N
tumor NN N
cells NNS N
irradiated VBN N
in IN N
vitro NN N
and CC N
in IN N
vivo NN N
No DT N
correlation NN N
was VBD N
found VBN N
between IN N
Eppendorf NNP N
PO2 NNP N
measurements NNS N
and CC N
comet VBD N
MTM NNP N
There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
correlation NN N
between IN N
the DT N
treatment NN N
response NN N
in IN N
the DT N
node NN N
studied VBD N
and CC N
comet VBD N
MTMs NNP N
, , N
whereas VBZ N
no DT N
correlation NN N
was VBD N
observed VBN N
between IN N
treatment NN N
response NN N
and CC N
Eppendorf NNP N
measurements NNS N
CONCLUSIONS NNP N
Comet NNP N
assays NNS N
are VBP N
reproducible JJ N
, , N
as IN N
shown VBN N
by IN N
biopsies NNS N
at IN N
1 CD N
and CC N
2 CD N
min NN N
Intertumor NNP N
variation NN N
in IN N
the DT N
MTM NNP N
is VBZ N
not RB N
a DT N
result NN N
of IN N
intrinsic JJ N
radiosensitivity NN N
but CC N
of IN N
tumor NN N
hypoxia NN N
There EX N
was VBD N
no DT N
correlation NN N
between IN N
Eppendorf NNP N
PO2 NNP N
measurements NNS N
and CC N
comet VBD N
MTM NNP N
Comet NNP N
assays NNS N
were VBD N
better JJR N
than IN N
Eppendorf NNP N
in IN N
predicting VBG N
treatment NN N
response NN N
as IN N
an DT N
end NN N
point NN N
for IN N
short-term JJ N
outcome NN N
Longer JJR N
follow-up NN N
is VBZ N
needed VBN N
to TO N
determine VB N
the DT N
role NN N
of IN N
the DT N
comet NN N
assay NN N
as IN N
a DT N
predictor NN N
for IN N
locoregional JJ N
tumor NN N
control NN N
and CC N
survivals NNS N
-DOCSTART- -X- O O 19562475

Brief JJ N
report NN N
: : N
effects NNS N
of IN N
cognitive JJ N
behavioral JJ N
therapy NN N
on IN N
parent-reported JJ N
autism NN 4_p
symptoms NNS 4_p
in IN N
school-age JJ 1_p
children NNS 1_p
with IN N
high-functioning JJ N
autism NN 4_p
This DT N
pilot NN N
study NN N
tested VBD N
the DT N
effect NN N
of IN N
cognitive JJ N
behavioral JJ N
therapy NN N
( ( N
CBT NNP N
) ) N
on IN N
parent-reported JJ N
autism NN 4_p
symptoms NNS N
Nineteen JJ 3_p
children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
and CC N
an DT N
anxiety NN N
disorder NN N
( ( 1_p
7-11 CD 1_p
years NNS 1_p
old JJ 1_p
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
16 CD N
sessions NNS N
of IN N
CBT NNP N
or CC N
a DT N
waitlist JJ N
condition NN N
The DT N
CBT NNP N
program NN N
emphasized VBN N
in IN N
vivo NN N
exposure NN N
supported VBN N
by IN N
parent NN N
training NN N
and CC N
school NN N
consultation NN N
to TO N
promote VB N
social JJ N
communication NN N
and CC N
emotion NN N
regulation NN N
skills NNS N
Parents NNS N
completed VBD N
a DT N
standardized JJ N
autism NN N
symptom JJ N
checklist NN N
at IN N
baseline NN N
and CC N
posttreatment/postwaitlist NN N
and CC N
3-month JJ N
follow-up JJ N
assessments NNS N
CBT NNP N
outperformed VBD N
the DT N
waitlist JJ N
condition NN N
at IN N
posttreatment/postwaitlist NN N
on IN N
total JJ N
parent-reported JJ N
autism NN N
symptoms NNS N
( ( N
Cohen NNP N
's POS N
d JJ N
effect NN N
size NN N
= NNP N
.77 NNP N
) ) N
Treatment NN N
gains NNS N
were VBD N
maintained VBN N
at IN N
3-month JJ N
follow-up NN N
Further JJ N
investigation NN N
of IN N
this DT N
intervention NN N
modality NN N
with IN N
larger JJR N
samples NNS N
and CC N
broader JJR N
outcome NN N
measures NNS N
appears VBZ N
to TO N
be VB N
indicated VBN N
-DOCSTART- -X- O O 484261

A DT N
controlled VBN N
study NN N
of IN N
early JJ N
discharge NN N
after IN N
uncomplicated JJ N
myocardial JJ 4_p
infarction NN 4_p
Out IN N
of IN N
383 CD 3_p
myocardial JJ 4_p
infarction NN 4_p
( ( 4_p
MI NNP 4_p
) ) 4_p
patients NNS N
aged VBN N
below IN N
70 CD 1_p
years NNS N
, , N
252 CD 3_p
( ( N
66 CD N
% NN N
) ) N
were VBD N
judged VBN N
after IN N
the DT N
third JJ N
day NN N
in IN N
hospital NN N
to TO N
have VB N
had VBN N
uncomplicated VBN 4_p
infarctions NNS 4_p
These DT N
patients NNS N
were VBD N
allocated VBN N
at IN N
random NN N
to TO N
two CD N
groups NNS N
, , N
one CD N
of IN N
which WDT N
was VBD N
given VBN N
treatment NN N
for IN N
8 CD N
days NNS N
and CC N
the DT N
other JJ N
for IN N
15 CD N
days NNS N
No DT N
significant JJ N
differences NNS N
in IN N
mortality NN N
, , N
morbidity NN N
or CC N
incapacity NN N
for IN N
work NN N
could MD N
be VB N
detected VBN N
during IN N
the DT N
three-month JJ N
period NN N
of IN N
follow-up NN N
The DT N
findings NNS N
thus RB N
support VBP N
previous JJ N
conclusions NNS N
that WDT N
early RB N
discharge VBP N
from IN N
hospital NN N
after IN N
uncomplicated JJ N
MI NNP N
is VBZ N
not RB N
associated VBN N
with IN N
greater JJR N
risk NN N
for IN N
the DT N
patient NN N
than IN N
later RB N
discharge NN N
-DOCSTART- -X- O O 8434135

Effects NNS N
of IN N
reducing VBG N
dietary JJ N
[ NN N
( ( N
Na+ NNP N
+ NNP N
K+ NNP N
) ) N
- : N
( ( N
Cl- JJ N
+ NNP N
SO4= NNP N
) ) N
] NN N
on IN N
the DT N
rate NN N
of IN N
calcium NN N
mobilisation NN N
by IN N
dairy NN 4_p
cows NNS 4_p
at IN 4_p
parturition NN 4_p
The DT N
effects NNS N
of IN N
feeding VBG N
diets NNS N
with IN N
different JJ N
milliequivalents NNS N
( ( N
meq NN N
) ) N
of IN N
dietary JJ N
[ NNP N
( ( N
Na+ NNP N
+ NNP N
K+ NNP N
) ) N
- : N
( ( N
Cl- JJ N
+ NNP N
SO4= NNP N
) ) N
] VBP N
to TO N
dairy VB 4_p
cows NNS 4_p
during IN 4_p
the DT 4_p
last JJ 4_p
seven CD 4_p
weeks NNS 4_p
of IN 4_p
pregnancy NN 4_p
on IN N
their PRP$ N
acid-base JJ N
status NN N
and CC N
calcium NN N
mobilisation NN N
rate NN N
around IN N
parturition NN N
were VBD N
studied VBN N
Ten CD N
monozygotic JJ N
twin NN N
pairs NNS N
of IN N
pregnant JJ N
cows NNS N
( ( N
five CD N
pairs NNS N
of IN N
parity NN N
1 CD N
or CC N
2 CD N
, , N
and CC N
five CD N
pairs NNS N
of IN N
parity NN N
3 CD N
or CC N
more JJR N
) ) N
were VBD N
allocated VBN N
to TO N
two CD N
diets NNS N
which WDT N
were VBD N
formulated VBN N
to TO N
provide VB N
either RB N
-4 JJ N
meq NN N
( ( N
anion NN N
diet NN N
) ) N
or CC N
+572.5 JJ N
meq NN N
( ( N
cation NN N
diet NN N
) ) N
of IN N
[ NN N
( ( N
Na+ NNP N
+ NNP N
K+ NNP N
) ) N
- : N
( ( N
Cl- JJ N
+ NNP N
SO4= NNP N
) ) N
] VBD N
kg-1 JJ N
dietary JJ N
dry JJ N
matter NN N
( ( N
DM NNP N
) ) N
The DT N
daily JJ N
rations NNS N
consisted VBD N
of IN N
4 CD N
kg NNS N
grass NN N
hay NN N
and CC N
7 CD N
kg NN N
concentrates NNS N
Changes NNS N
in IN N
meq NN N
of IN N
dietary JJ N
[ NNP N
( ( N
Na+ NNP N
+ NNP N
K+ NNP N
) ) N
- : N
( ( N
Cl- JJ N
+ NNP N
SO4= NNP N
) ) N
] NN N
were VBD N
achieved VBN N
by IN N
adding VBG N
KCl NNP N
, , N
K2SO4 NNP N
and CC N
( ( N
NH4 NNP N
) ) N
2SO4 CD N
( ( N
anion NN N
diet NN N
) ) N
or CC N
K2CO3 NNP N
( ( N
cation NN N
diet NN N
) ) N
to TO N
basal VB N
concentrates NNS N
Plasma NNP N
calcium NN N
concentration NN N
and CC N
blood NN N
acid-base JJ N
parameters NNS N
were VBD N
not RB N
affected VBN N
by IN N
dietary JJ N
treatment NN N
However RB N
, , N
urinary JJ N
calcium NN N
excretion NN N
was VBD N
markedly RB N
higher JJR N
and CC N
urinary JJ N
pH NN N
and CC N
bicarbonate NN N
excretion NN N
significantly RB N
lower JJR N
in IN N
cows NNS N
fed VBP N
the DT N
anion NN N
diet NN N
than IN N
in IN N
cows NNS N
fed VBP N
the DT N
cation NN N
diet NN N
The DT N
responses NNS N
to TO N
hypocalcaemia VB N
induced VBN N
by IN N
an DT N
intravenous JJ N
infusion NN N
of IN N
EDTA NNP N
solution NN N
were VBD N
similar JJ N
in IN N
the DT N
cows NNS N
fed VBP N
either DT N
diet NN N
-DOCSTART- -X- O O 10439497

Treatment NN N
of IN N
hypertensive JJ N
and CC N
hypercholesterolaemic JJ N
patients NNS N
in IN N
general JJ N
practice NN N
The DT N
effect NN N
of IN N
captopril NN N
, , N
atenolol NN N
and CC N
pravastatin NN N
combined VBN N
with IN N
life NN N
style NN N
intervention NN N
OBJECTIVE UH N
To TO N
elucidate VB N
the DT N
effect NN N
on IN N
blood NN N
pressure NN N
and CC N
blood NN N
lipids NNS N
of IN N
an DT N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitor NN N
( ( N
captopril NN N
) ) N
, , N
and CC N
a DT N
beta-receptor NN N
blocking NN N
agent NN N
( ( N
atenolol NN N
) ) N
, , N
given VBN N
alone RB N
or CC N
in IN N
combination NN N
with IN N
a DT N
cholesterol NN N
reducing VBG N
drug NN N
, , N
the DT N
beta-hydroxy-methylglutaryl-coenzyme NN N
A DT N
reductase NN N
inhibitor NN N
pravastatin NN N
, , N
in IN N
patients NNS N
who WP N
were VBD N
also RB N
encouraged VBN N
to TO N
improve VB N
their PRP$ N
lifestyle NN N
DESIGN VB N
A DT N
longitudinal JJ N
study NN N
consisting VBG N
of IN N
three CD N
phases NNS N
I PRP N
: : N
Lifestyle JJ N
intervention NN N
alone RB N
II NN N
: : N
Continued JJ N
lifestyle JJ N
intervention NN N
combined VBN N
with IN N
captopril NN N
or CC N
atenolol NN N
III NN N
: : N
Continued JJ N
lifestyle JJ N
intervention NN N
combined VBN N
with IN N
the DT N
same JJ N
drugs NNS N
as IN N
in IN N
phase NN N
II NNP N
and CC N
in IN N
addition NN N
pravastatin NN N
or CC N
placebo NN N
SETTING CC N
Fifty-four JJ N
general JJ N
practice NN N
surgeries NNS N
in IN N
Norway NNP N
PARTICIPANTS NNP N
Hypertensive JJ N
patients NNS N
, , N
210 CD N
females NNS N
and CC N
160 CD N
males NNS N
, , N
treated VBD N
or CC N
untreated JJ N
with IN N
antihypertensive JJ N
drugs NNS N
with IN N
a DT N
sitting VBG N
diastolic JJ N
blood NN N
pressure NN N
between IN N
95 CD N
and CC N
115 CD N
mmHg NN N
and CC N
a DT N
serum JJ N
total NN N
cholesterol NN N
between IN N
6.5 CD N
mmol/l NNS N
( ( N
7.0 CD N
for IN N
those DT N
age NN N
60-67 JJ N
years NNS N
) ) N
and CC N
9.0 CD N
mmol/l NN N
RESULTS VB N
The DT N
antihypertensive JJ N
effect NN N
of IN N
captopril NN N
and CC N
atenolol NN N
was VBD N
not RB N
influenced VBN N
by IN N
concurrent JJ N
administration NN N
of IN N
pravastatin NN N
The DT N
effect NN N
of IN N
pravastatin NN N
was VBD N
not RB N
limited VBN N
by IN N
concurrent JJ N
medication NN N
with IN N
captopril NN N
or CC N
atenolol NN N
Improvement NN N
in IN N
lifestyle NN N
seemed VBD N
to TO N
reduce VB N
the DT N
need NN N
for IN N
supplementary JJ N
treatment NN N
with IN N
diuretics NNS N
CONCLUSION NNP N
Pravastatin NNP N
can MD N
be VB N
used VBN N
in IN N
combination NN N
with IN N
captopril NN N
or CC N
atenolol NN N
in IN N
the DT N
treatment NN N
of IN N
hypertensive JJ N
and CC N
hypercholesterolaemic JJ N
patients NNS N
-DOCSTART- -X- O O 15897822

Cost-effectiveness NN N
of IN N
combined JJ N
manipulation NN N
, , N
stabilizing VBG N
exercises NNS N
, , N
and CC N
physician JJ N
consultation NN N
compared VBN N
to TO N
physician JJ N
consultation NN N
alone RB N
for IN N
chronic JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
: : 4_p
a DT N
prospective JJ N
randomized VBN N
trial NN N
with IN N
2-year JJ N
follow-up NN N
STUDY NNP N
DESIGN NNP N
A NNP N
prospective JJ N
, , N
randomized VBD N
controlled VBN N
trial NN N
OBJECTIVE UH N
To TO N
examine VB N
long-term JJ N
effects NNS N
and CC N
costs NNS N
of IN N
combined JJ N
manipulative JJ N
treatment NN N
, , N
stabilizing VBG N
exercises NNS N
, , N
and CC N
physician JJ N
consultation NN N
compared VBN N
with IN N
physician JJ N
consultation NN N
alone RB N
for IN N
chronic JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
( ( 4_p
cLBP NN 4_p
) ) N
SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
An DT N
obvious JJ N
gap NN N
exists NNS N
in IN N
knowledge NN N
concerning VBG N
long-term JJ N
efficacy NN N
and CC N
cost-effectiveness NN N
of IN N
manipulative JJ N
treatment NN N
methods NNS N
METHODS NNP N
Of IN N
204 CD 3_p
patients NNS N
with IN N
cLBP NNS N
whose WP$ N
Oswestry NNP N
Disability NNP N
Index NNP N
( ( N
ODI NNP N
) ) N
was VBD N
at IN N
least JJS N
16 CD N
% NN N
, , N
102 CD N
were VBD N
randomized VBN N
into IN N
a DT N
combined JJ N
manipulative JJ N
treatment NN N
, , N
exercise NN N
, , N
and CC N
physician JJ N
consultation NN N
group NN N
( ( N
i.e. FW N
, , N
a DT N
combination NN N
group NN N
) ) N
, , N
and CC N
102 CD N
to TO N
a DT N
consultation NN N
alone RB N
group NN N
All DT N
patients NNS N
were VBD N
clinically RB N
examined VBN N
, , N
informed VBN N
about IN N
their PRP$ N
back NN N
pain NN N
, , N
and CC N
encouraged VBD N
to TO N
stay VB N
active JJ N
and CC N
exercise NN N
according VBG N
to TO N
specific JJ N
instructions NNS N
based VBN N
on IN N
clinical JJ N
evaluation NN N
Treatment NNP N
included VBD N
4 CD N
sessions NNS N
of IN N
manual JJ N
therapy NN N
and CC N
stabilizing NN N
exercises NNS N
aimed VBN N
at IN N
correcting VBG N
the DT N
lumbopelvic JJ N
rhythm NN N
Questionnaires VBZ N
inquired VBN N
about IN N
pain NN N
( ( N
visual JJ N
analog NN N
scale NN N
( ( N
VAS NNP N
) ) N
) ) N
, , N
disability NN N
( ( N
ODI NNP N
) ) N
, , N
health-related JJ N
quality NN N
of IN N
life NN N
( ( N
15D CD N
Quality NN N
of IN N
Life NNP N
Instrument NNP N
) ) N
, , N
satisfaction NN N
with IN N
care NN N
, , N
and CC N
costs NNS N
RESULTS NNP N
Significant NNP N
improvement NN N
occurred VBD N
in IN N
both DT N
groups NNS N
on IN N
every DT N
self-rated JJ N
outcome NN N
measurement NN N
Within IN N
2 CD N
years NNS N
, , N
the DT N
combination NN N
group NN N
showed VBD N
only RB N
a DT N
slightly RB N
more RBR N
significant JJ N
reduction NN N
in IN N
VAS NNP N
( ( N
P NNP N
= NNP N
0.01 CD N
, , N
analysis NN N
of IN N
variance NN N
) ) N
but CC N
clearly RB N
higher JJR N
patient JJ N
satisfaction NN N
( ( N
P NNP N
= NNP N
0.001 CD N
, , N
Pearson NNP N
chi2 NN N
) ) N
as IN N
compared VBN N
to TO N
the DT N
consultation NN N
group NN N
Incremental JJ N
analysis NN N
showed VBD N
that IN N
for IN N
combined JJ N
group NN N
compared VBN N
to TO N
consultation NN N
group NN N
, , N
a DT N
one-point JJ N
change NN N
in IN N
VAS NNP N
scale NN N
cost NN N
$ $ N
512 CD N
CONCLUSIONS NNP N
Physician JJ N
consultation NN N
alone RB N
was VBD N
more RBR N
cost-effective JJ N
for IN N
both DT N
health NN N
care NN N
use NN N
and CC N
work NN N
absenteeism NN N
, , N
and CC N
led VBD N
to TO N
equal JJ N
improvement NN N
in IN N
disability NN N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
It PRP N
seems VBZ N
obvious JJ N
that IN N
encouraging VBG N
information NN N
and CC N
advice NN N
are VBP N
major JJ N
elements NNS N
for IN N
the DT N
treatment NN N
of IN N
patients NNS N
with IN N
cLBP NN 4_p
-DOCSTART- -X- O O 10685722

Efficacy NN N
and CC N
safety NN N
of IN N
a DT N
fixed JJ N
low-dose JJ N
perindopril/indapamide NN N
combination NN N
in IN N
essential JJ 4_p
hypertension NN 4_p
A DT N
randomised JJ N
controlled VBN N
study NN N
This DT N
multicenter NN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
study NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
the DT N
safety NN N
of IN N
fixed JJ N
low JJ N
dose NN N
combination NN N
perindopril VBD N
2 CD N
mg/indapamide RB N
0.625 CD N
mg NN N
( ( N
Per/Ind NNP N
) ) N
versus NN N
atenolol $ N
50 CD N
mg NN N
( ( N
Ate NNP N
) ) N
After IN N
a DT N
4-week JJ N
placebo NN N
run-in NN N
, , N
446 CD 3_p
hypertensive JJ 4_p
patients NNS N
( ( N
mean JJ 1_p
age NN 1_p
: : 1_p
55.8 CD 1_p
+/- JJ 1_p
11.0 CD 1_p
years NNS 1_p
) ) N
were VBD N
randomised VBN N
to TO N
receive VB N
Per/Ind NNP N
or CC N
Ate NNP N
for IN N
12 CD N
weeks NNS N
The DT N
primary JJ N
outcome NN N
measures NNS N
were VBD N
the DT N
changes NNS N
in IN N
trough JJ N
supine NN N
systolic NN N
and CC N
diastolic JJ N
blood NN N
pressure NN N
( ( N
sSBP NN N
, , N
sDBP NN N
) ) N
between IN N
baseline NN N
and CC N
the DT N
last JJ N
observation NN N
Equivalence NN N
was VBD N
assessed VBN N
in IN N
an DT N
intention-to-treat JJ N
analysis NN N
using VBG N
a DT N
two CD N
one-sided JJ N
tests NNS N
procedure NN N
Per/Ind NNP N
and CC N
Ate NNP N
decreased VBD N
sSBP NN N
by IN N
-20.5 NNP N
mmHg NN N
and CC N
-20.1 NNP N
mmHg NN N
, , N
respectively RB N
; : N
the DT N
90 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
-2.3 NNP N
; : N
1.5 CD N
] NN N
of IN N
the DT N
intertreatment NN N
difference NN N
( ( N
-0.4 JJ N
mmHg NN N
) ) N
fell VBD N
within IN N
the DT N
predefined JJ N
equivalence NN N
interval NN N
[ NNP N
-8 NNP N
; : N
+8 NNP N
mmHg FW N
] NNP N
Similarly RB N
, , N
the DT N
sDBP NN N
decreased VBN N
by IN N
-15.1 NNP N
mmHg NN N
( ( N
Per/Ind NNP N
) ) N
and CC N
-16.2 $ N
mmHg NN N
( ( N
Ate NNP N
) ) N
with IN N
an DT N
intertreatment JJ N
difference NN N
of IN N
1.1 CD N
mmHg NNS N
whose WP$ N
90 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
-0.1 NNP N
; : N
2.2 CD N
mmHg NN N
] NN N
fell VBD N
within IN N
the DT N
predefined JJ N
equivalence NN N
interval NN N
[ NNP N
-4 NNP N
; : N
+4 NNP N
mmHg VBZ N
] NNP N
; : N
thus RB N
antihypertensive JJ N
efficacy NN N
of IN N
Per/Ind NNP N
and CC N
Ate NNP N
were VBD N
equivalent JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
In IN N
patients NNS N
older JJR N
than IN N
65 CD N
, , N
Per/Ind NNP N
induces VBZ N
a DT N
statistically RB N
greater JJR N
decrease NN N
in IN N
sSBP NN N
than IN N
Ate NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
Per/Ind NNP N
was VBD N
well RB N
tolerated VBN N
Further RBR N
controlled JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
confirm VB N
these DT N
results NNS N
on IN N
a DT N
long-term JJ N
period NN N
-DOCSTART- -X- O O 23084676

Hemostasis NN N
by IN N
bipolar JJ N
coagulation NN N
versus NN N
suture NN N
after IN N
surgical JJ N
stripping NN N
of IN N
bilateral JJ N
ovarian JJ N
endometriomas NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
STUDY NNP N
OBJECTIVE NNP N
To TO N
estimate VB N
whether IN N
the DT N
suture NN N
of IN N
the DT N
ovary JJ N
is VBZ N
superior JJ N
to TO N
bipolar JJ N
coagulation NN N
in IN N
preserving VBG N
ovarian JJ N
reserve NN N
in IN N
infertile JJ 4_p
women NNS 4_p
undergoing VBG 4_p
laparoscopic JJ 4_p
stripping NN 4_p
of IN 4_p
bilateral JJ 4_p
endometriomas NN 4_p
DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
( ( N
Canadian JJ N
Task NNP N
Force NNP N
classification NN N
I PRP N
) ) N
SETTING NN N
University NNP 4_p
teaching NN 4_p
hospital NN 4_p
PATIENTS CC N
100 CD N
patients NNS N
with IN N
bilateral JJ N
endometriomas NN N
INTERVENTIONS NNP N
Patients NNPS N
underwent JJ N
stripping NN N
of IN N
bilateral JJ N
endometriomas NNS N
and CC N
were VBD N
randomized VBN N
to TO N
undergo VB N
hemostasis NN N
by IN N
use NN N
of IN N
either DT N
laparoscopic NN N
suturing NN N
( ( N
LS NNP N
group NN N
) ) N
or CC N
bipolar JJ N
coagulation NN N
( ( N
BC NNP N
group NN N
) ) N
Changes NNS N
in IN N
ovarian JJ N
reserve NN N
were VBD N
investigated VBN N
by IN N
measuring VBG N
the DT N
levels NNS N
of IN N
anti-Mullerian JJ N
hormone NN N
( ( N
AMH NNP N
) ) N
and CC N
basal JJ N
follicle-stimulating JJ N
hormone NN N
( ( N
FSH NNP N
) ) N
before IN N
surgery NN N
and CC N
at IN N
3 CD N
, , N
6 CD N
and CC N
12 CD N
months NNS N
from IN N
surgery NN N
MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
At IN N
3-month JJ N
, , N
6-month JJ N
, , N
and CC N
12-month JJ N
follow-up NN N
, , N
in IN N
both DT N
study NN N
groups NNS N
, , N
postsurgical JJ N
AMH NNP N
levels NNS N
were VBD N
significantly RB N
lower JJR N
and CC N
basal VB N
FSH NNP N
levels NNS N
were VBD N
significantly RB N
higher JJR N
than IN N
before RB N
surgery NN N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
mean JJ N
percentage NN N
decrease NN N
of IN N
AMH NNP N
levels NNS N
in IN N
the DT N
BC NNP N
group NN N
and CC N
LS NNP N
group NN N
at IN N
3- JJ N
, , N
6- JJ N
, , N
and CC N
12-month JJ N
follow-up NN N
The DT N
mean JJ N
percentage NN N
increase NN N
in IN N
basal JJ N
FSH NNP N
was VBD N
higher RBR N
in IN N
the DT N
BC NNP N
group NN N
than IN N
in IN N
the DT N
LS NNP N
group NN N
at IN N
both DT N
3-month JJ N
( ( N
p JJ N
= NNP N
.023 NNP N
) ) N
and CC N
6-month JJ N
follow-up NN N
( ( N
p JJ N
= NNP N
.029 NNP N
) ) N
, , N
but CC N
not RB N
at IN N
12-month JJ N
follow-up NN N
Pregnancy NNP N
rate NN N
, , N
time NN N
to TO N
conception NN N
, , N
and CC N
rate NN N
of IN N
endometrioma NN N
recurrence NN N
was VBD N
similar JJ N
in IN N
the DT N
2 CD N
study NN N
groups NNS N
CONCLUSION NNP N
Laparoscopic NNP N
stripping NN N
of IN N
ovarian JJ N
endometriotic JJ N
cyst NN N
significantly RB N
decreases VBZ N
serum JJ N
AMH NNP N
levels NNS N
and CC N
increases VBZ N
basal JJ N
FSH NNP N
levels NNS N
independent JJ N
from IN N
the DT N
method NN N
used VBN N
to TO N
obtain VB N
hemostasis NN N
on IN N
the DT N
ovarian JJ N
tissue NN N
-DOCSTART- -X- O O 6984358

Tolfenamic NNP N
acid NN N
and CC N
caffeine NN N
: : N
a DT N
useful JJ N
combination NN N
in IN N
migraine NN 4_p
Tolfenamic NNP N
acid NN N
is VBZ N
a DT N
potent JJ N
inhibitor NN N
of IN N
prostaglandin JJ N
biosynthesis NN N
, , N
which WDT N
has VBZ N
been VBN N
proved VBN N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
migraine NN 4_p
attacks NNS N
The DT N
usefulness NN N
of IN N
caffeine NN N
, , N
metoclopramide NN N
and CC N
pyridoxine NN N
as IN N
adjuncts NNS N
to TO N
tolfenamic VB N
acid NN N
was VBD N
tested VBN N
in IN N
acute JJ N
migraine NN N
attacks NNS N
in IN N
ten JJ N
patients NNS N
A DT N
combination NN N
of IN N
tolfenamic JJ N
acid NN N
( ( N
200 CD N
mg NN N
) ) N
with IN N
either DT N
caffeine NN N
( ( N
100 CD N
mg NN N
) ) N
, , N
metoclopramide RB N
( ( N
10 CD N
mg NN N
) ) N
or CC N
pyridoxine NN N
( ( N
300 CD N
mg NN N
) ) N
was VBD N
given VBN N
twice RB N
to TO N
each DT N
patient NN N
in IN N
random JJ N
order NN N
Thus RB N
60 CD N
attacks NNS N
were VBD N
treated VBN N
The DT N
tolfenamic JJ N
acid-caffeine JJ N
combination NN N
proved VBD N
the DT N
most RBS N
effective JJ N
as IN N
judged VBN N
by IN N
duration NN N
and CC N
intensity NN N
of IN N
attacks NNS N
, , N
working VBG N
ability NN N
, , N
vigilance NN N
, , N
and CC N
overall JJ N
evaluation NN N
of IN N
the DT N
drugs NNS N
by IN N
the DT N
patients NNS N
Metoclopramide NNP N
was VBD N
somewhat RB N
better JJR N
than IN N
pyridoxine NN N
as IN N
an DT N
additive NN N
-DOCSTART- -X- O O 9697788

Comparison NNP N
of IN N
prostate-specific JJ N
antigen NN N
corrected VBN N
for IN N
total JJ N
prostate NN N
volume NN N
and CC N
transition NN N
zone NN N
volume NN N
in IN N
a DT N
population-based JJ N
screening NN N
study NN N
OBJECTIVES NNP N
To TO N
compare VB N
the DT N
discriminatory JJ N
potential NN N
between IN N
prostate NN 4_p
cancer NN 4_p
and CC 4_p
benign JJ 4_p
conditions NNS 4_p
of IN 4_p
the DT 4_p
prostate NN 4_p
in IN N
a DT N
population-based JJ N
screening NN N
study NN N
, , N
of IN N
serum JJ N
prostate-specific JJ N
antigen NN N
levels NNS N
( ( N
PSA NNP N
) ) N
and CC N
PSA NNP N
corrected VBD N
for IN N
both DT N
the DT N
total JJ N
prostate NN N
volume NN N
( ( N
PSA-D NNP N
) ) N
and CC N
the DT N
transition NN N
zone NN N
volume NN N
( ( N
PSA-T NNP N
) ) N
METHODS NNP N
In IN N
a DT N
randomized JJ N
population-based JJ N
screening NN N
study NN N
( ( N
Rotterdam NNP N
section NN N
of IN N
the DT N
European NNP N
Randomized NNP N
Study NNP N
of IN N
Screening NNP N
for IN N
Prostate NNP N
Cancer NNP N
) ) N
, , N
in IN N
which WDT N
10,865 CD N
men NNS N
have VBP N
been VBN N
screened VBN N
, , N
the DT N
biopsy NN N
results NNS N
of IN N
1202 CD N
men NNS N
with IN N
PSA NNP 4_p
levels NNS 4_p
of IN N
4 CD N
ng/mL NNS N
or CC N
more JJR N
were VBD N
evaluated VBN N
Planimetric NNP N
and CC N
prolate VB N
ellipsoid JJ N
volumes NNS N
of IN N
the DT N
total JJ N
prostate NN N
as RB N
well RB N
as IN N
of IN N
the DT N
transition NN N
zone NN N
were VBD N
measured VBN N
The DT N
measured JJ N
volumes NNS N
were VBD N
compared VBN N
with IN N
the DT N
volumes NNS N
of IN N
57 CD N
radical JJ N
prostatectomy NN N
specimens NNS N
through IN N
Spearman NNP N
's POS N
rank NN N
correlation NN N
coefficient NN N
and CC N
agreement NN N
tests NNS N
A DT N
receiver NN N
operating VBG N
characteristic JJ N
( ( N
ROC NNP N
) ) N
curve VBP N
analysis NN N
was VBD N
done VBN N
of IN N
sensitivity NN N
and CC N
specificity NN N
of IN N
biopsy NN N
indications NNS N
through IN N
PSA NNP N
and CC N
PSA NNP N
corrected VBD N
for IN N
the DT N
volumes NNS N
measured VBN N
with IN N
transrectal JJ N
ultrasound NN N
RESULTS NNP N
In IN N
the DT N
1202 CD 3_p
men NNS N
studied VBD N
, , N
361 CD N
cases NNS N
of IN N
prostate NN N
cancer NN N
were VBD N
diagnosed VBN N
Both DT N
PSA-D NNP N
and CC N
PSA-T NNP N
showed VBD N
a DT N
significantly RB N
higher JJR N
area NN N
under IN N
the DT N
ROC NNP N
curve NN N
( ( N
0.77 CD N
and CC N
0.79 CD N
, , N
respectively RB N
) ) N
than IN N
PSA NNP N
alone RB N
( ( N
area NN N
0.65 CD N
) ) N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
PSA-D NNP N
and CC N
PSA-T NNP N
The DT N
use NN N
of IN N
a DT N
PSA-D NNP N
threshold JJ N
value NN N
of IN N
0 CD N
10 CD N
ng/mL/cc NN N
would MD N
have VB N
avoided VBN N
28 CD N
% NN N
of IN N
biopsies NNS N
at IN N
the DT N
cost NN N
of IN N
10 CD N
% NN N
of IN N
detectable JJ N
cancers NNS N
A DT N
PSA-D JJ N
threshold NN N
of IN N
0.15 CD N
ng/mL/cc NNS N
would MD N
have VB N
avoided VBN N
73.8 CD N
% NN N
of IN N
biopsies NNS N
at IN N
the DT N
cost NN N
of IN N
not RB N
diagnosing VBG N
43.8 CD N
% NN N
of IN N
detectable JJ N
cancers NNS N
CONCLUSIONS VB N
The DT N
planimetrically RB N
obtained JJ N
prostate NN N
volume NN N
showed VBD N
a DT N
more RBR N
favorable JJ N
agreement NN N
with IN N
the DT N
radical JJ N
prostatectomy NN N
volume NN N
than IN N
the DT N
prolate JJ N
ellipsoid NN N
volume NN N
The DT N
discriminatory JJ N
potential NN N
of IN N
the DT N
corrected VBN N
PSA NNP N
value NN N
is VBZ N
better JJR N
at IN N
predicting VBG N
the DT N
results NNS N
of IN N
needle JJ N
biopsy NN N
of IN N
the DT N
prostate NN N
when WRB N
compared VBN N
with IN N
PSA NNP N
alone RB N
The DT N
use NN N
of IN N
the DT N
transition NN N
zone NN N
volume NN N
for IN N
this DT N
correction NN N
results NNS N
in IN N
a DT N
higher JJR N
discriminatory JJ N
potential NN N
when WRB N
compared VBN N
to TO N
the DT N
use NN N
of IN N
the DT N
total JJ N
prostate NN N
volume NN N
; : N
however RB N
, , N
the DT N
observed JJ N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
-DOCSTART- -X- O O 22921159

Interventional NNP N
study NN N
to TO N
strengthen VB N
the DT N
health NN N
promoting VBG N
behaviours NNS N
of IN N
pregnant JJ N
women NNS 2_p
to TO N
prevent VB N
anaemia NN N
in IN N
southern JJ 4_p
India NNP 4_p
OBJECTIVES NNP N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
a DT N
health NN N
information NN N
package NN N
in IN N
terms NNS N
of IN N
empowering VBG N
the DT N
pregnant JJ N
women NNS N
to TO N
modify VB N
their PRP$ N
health-care JJ N
behaviour NN N
and CC N
take VB N
appropriate JJ N
action NN N
to TO N
combat VB N
anaemia NN N
in IN N
pregnancy NN N
DESIGN VB N
the DT N
study NN N
was VBD N
conceptualized VBN N
based VBN N
on IN N
Rosenstock NNP N
and CC N
Becker NNP N
's POS N
health NN N
belief NN N
model NN N
A DT N
quasi-experimental JJ N
pretest-posttest JJ N
control NN N
group NN N
design NN N
was VBD N
used VBN N
The DT N
sample NN N
consists VBZ N
of IN N
225 CD N
anaemic JJ N
pregnant JJ N
women NNS N
randomly RB N
allocated VBN N
in IN N
experimental JJ N
( ( N
n=75 JJ N
) ) N
, , N
control NN N
group NN N
A NNP N
( ( N
n=75 NN N
) ) N
and CC N
control NN N
group NN N
B NNP N
( ( N
n=75 NN N
) ) N
The DT N
health NN N
seeking VBG N
behaviour NN N
outcome NN N
measure NN N
included VBD N
knowledge NN N
regarding VBG N
anaemia NN N
, , N
food NN N
selection NN N
ability NN N
, , N
increase NN N
in IN N
haemoglobin JJ N
level NN N
and CC N
compliance NN N
to TO N
iron VB N
supplementation NN N
Intervention NN N
was VBD N
a DT N
validated JJ N
planned JJ N
educational JJ N
programme NN N
with IN N
visual JJ N
aids NNS N
and CC N
iron NN N
supplementation NN N
FINDINGS IN N
the DT N
results NNS N
show VBP N
the DT N
mean JJ N
gain NN N
of IN N
knowledge NN N
scores NNS N
of IN N
experimental JJ N
group NN N
was VBD N
comparatively RB N
higher JJR N
and CC N
control VB N
groups NNS N
A NNP N
and CC N
B NNP N
showed VBD N
that IN N
F NNP N
ratio NN N
was VBD N
( ( N
F NNP N
( ( N
2,190 CD N
) ) N
=11.910 NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
indicating NN N
that IN N
the DT N
pregnant JJ N
women NNS N
learned VBD N
more RBR N
about IN N
anaemia NN N
prevention NN N
than IN N
others NNS N
With IN N
regard NN N
to TO N
food NN N
selection NN N
ability NN N
scores NNS N
of IN N
experimental JJ N
, , N
control NN N
groups NNS N
A NNP N
and CC N
B NNP N
the DT N
F NNP N
ratio NN N
was VBD N
also RB N
significant JJ N
( ( N
F NNP N
( ( N
2,190 CD N
) ) N
=20.92 NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
Nearly RB N
61.2 CD N
% NN N
of IN N
the DT N
subjects NNS N
in IN N
experimental JJ N
group NN N
became VBD N
non-anaemic JJ N
after IN N
the DT N
intervention NN N
when WRB N
compared VBN N
to TO N
control VB N
group NN N
A NNP N
This DT N
indicated VBD N
that IN N
inspite NN N
of IN N
iron NN N
supplementation NN N
received VBN N
by IN N
the DT N
three CD N
groups NNS N
health NN N
education NN N
contributed VBD N
significantly RB N
in IN N
modifying VBG N
their PRP$ N
health NN N
seeking VBG N
behaviour NN N
and CC N
their PRP$ N
perception NN N
about IN N
significance NN N
of IN N
anaemia NN N
has VBZ N
a DT N
problem NN N
CONCLUSION NNP N
developing VBG N
countries NNS N
still RB N
face VBP N
the DT N
critical JJ N
problem NN N
of IN N
anaemia NN N
in IN N
pregnancy NN N
These DT N
are VBP N
the DT N
socio-cultural JJ N
priority NN N
problems NNS N
that WDT N
demand VBP N
immediate JJ N
attention NN N
by IN N
the DT N
policy NN N
makers NNS N
and CC N
health NN N
professionals NNS N
The DT N
national JJ N
anaemia NN N
control NN N
programme NN N
focuses VBZ N
on IN N
iron NN N
supplementation NN N
, , N
but CC N
nutritional JJ N
education NN N
and CC N
supervision NN N
of IN N
iron NN N
supplementation NN N
has VBZ N
failed VBN N
in IN N
different JJ N
regions NNS N
The DT N
study NN N
implies VBZ N
that IN N
economic JJ N
empowerment NN N
; : N
strengthening VBG N
health NN N
literacy NN N
through IN N
planned VBN N
educational JJ N
programs NNS N
will MD N
definitely RB N
improve VB N
the DT N
health NN N
behaviour NN N
of IN N
individual JJ N
and CC N
community NN N
at IN N
large JJ N
-DOCSTART- -X- O O 23680243

Pregnancy NNP N
outcome NN N
and CC N
glycemic JJ N
control NN N
in IN N
women NNS 2_p
with IN N
type JJ 4_p
1 CD 4_p
diabetes NNS 4_p
: : N
a DT N
retrospective JJ N
comparison NN N
between IN N
CSII NNP N
and CC N
MDI NNP N
treatment NN N
AIM NNP N
Present NNP N
study NN N
was VBD N
aimed VBN N
to TO N
evaluate VB N
glycemic JJ N
control NN N
and CC N
maternal-fetal JJ N
outcome NN N
in IN 4_p
pregnant JJ 4_p
type NN 4_p
1 CD 4_p
diabetic JJ 4_p
patient NN 4_p
treated VBN N
with IN N
continuous JJ N
subcutaneous JJ N
insulin NN N
infusion NN N
( ( N
CSII NNP N
) ) N
or CC N
multiple JJ N
daily JJ N
injections NNS N
of IN N
insulin NN N
( ( N
MDI NNP N
) ) N
PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
retrospective JJ N
observational NN N
study NN N
included VBD N
thirty-four JJ 3_p
pregnant JJ 4_p
type NN 4_p
1 CD 4_p
diabetic JJ 4_p
patients NNS 4_p
Patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
group NN N
, , N
CSII NNP N
treated VBD N
group NN N
( ( N
n=14 CC 3_p
) ) N
and CC N
MDI NNP N
treated VBD N
group NN N
( ( N
n=20 RB 3_p
) ) N
The DT N
HbA1c NNP N
level NN N
and CC N
maternal-fetal JJ N
outcome NN N
were VBD N
evaluated VBN N
in IN N
both DT N
the DT N
treatment NN N
group NN N
Outcome NNP N
parameters NNS N
such JJ N
as IN N
glycemic JJ N
control NN N
( ( N
HbA1c NNP N
) ) N
, , N
hypoglycemic JJ N
events NNS N
, , N
time NN N
and CC N
mode NN N
of IN N
delivery NN N
and CC N
labor NN N
results NNS N
( ( N
abortion NN N
, , N
premature NN N
labor NN N
, , N
perinatal JJ N
mortality NN N
, , N
neonatal JJ N
weight NN N
, , N
Apgar NNP N
score NN N
, , N
neonatal JJ N
hypoglycaemia NN N
, , N
presence NN N
of IN N
congenital JJ N
abnormalities NNS N
) ) N
were VBD N
analyzed VBN N
RESULTS NNP N
Pregnancy NNP N
outcome NN N
and CC N
glycemic JJ N
control NN N
in IN N
pregnant JJ N
type NN N
1 CD N
diabetic JJ N
patients NNS N
treated VBN N
with IN N
CSII NNP N
and CC N
MDI NNP N
were VBD N
evaluated VBN N
and CC N
compared VBN N
Two CD N
groups NNS N
were VBD N
compared VBN N
for IN N
their PRP$ N
epidemiological JJ N
parameters NNS N
, , N
although IN N
patients NNS N
on IN N
CSII NNP N
treatment NN N
had VBD N
longer JJR N
duration NN N
of IN N
diabetes NNS N
compared VBN N
to TO N
MDI NNP N
treated VBD N
group NN N
Reduction NN N
in IN N
HbA1c NNP N
level NN N
was VBD N
higher RBR N
in IN N
CSII NNP N
treated VBD N
patients NNS N
at IN N
first JJ N
( ( N
CSII NNP N
: : N
0.9 CD N
% NN N
vs JJ N
MDI NNP N
: : N
0.46 CD N
% NN N
) ) N
, , N
second JJ N
( ( N
CSII NNP N
: : N
1.58 CD N
% NN N
vs JJ N
MDI NNP N
: : N
0.78 CD N
% NN N
) ) N
and CC N
third JJ N
trimester NN N
( ( N
CSII NNP N
: : N
1.74 CD N
% NN N
vs JJ N
MDI NNP N
: : N
1.09 CD N
% NN N
) ) N
of IN N
pregnancy NN N
compared VBN N
to TO N
MDI NNP N
treated VBD N
patients NNS N
Duration NNP N
of IN N
pregnancy NN N
and CC N
new JJ N
born VBN N
baby NN N
weight NN N
were VBD N
founded VBN N
similar JJ N
in IN N
both DT N
group NN N
Moreover RB N
, , N
the DT N
rate NN N
of IN N
abortion NN N
, , N
preterm JJ N
labor NN N
, , N
cesarean JJ N
section NN N
and CC N
hypoglycemia NN N
in IN N
new JJ N
born NNS N
were VBD N
founded VBN N
less RBR N
in IN N
CSII NNP N
treated VBD N
group NN N
compared VBN N
to TO N
MDI NNP N
treated VBN N
group NN N
and CC N
Apgar NNP N
score NN N
was VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
higher JJR N
in IN N
CSII NNP N
treated VBD N
group NN N
compared VBN N
to TO N
MDI NNP N
treated VBD N
group NN N
CONCLUSION NNP N
Results NNP N
of IN N
present JJ N
study NN N
revealed VBD N
that IN N
the DT N
CSII NNP N
gives VBZ N
better JJR N
glycemic JJ N
control NN N
and CC N
pregnancy NN N
outcome NN N
in IN N
pregnant JJ 4_p
type NN 4_p
1 CD 4_p
diabetic JJ 4_p
patients NNS N
compared VBN N
to TO N
MDI NNP N
treatment NN N
CSII NNP N
also RB N
decreases VBZ N
the DT N
daily JJ N
insulin NN N
requirement NN N
compared VBN N
MDI NNP N
-DOCSTART- -X- O O 15948916

Lessons NNS N
learnt VBP N
in IN N
conducting VBG N
a DT N
clinical JJ N
drug NN N
trial NN N
in IN N
children NNS 1_p
with IN N
Asperger NNP 4_p
Syndrome NNP 4_p
OBJECTIVE NNP N
To TO N
describe VB N
the DT N
authors NNS N
' POS N
experience NN N
of IN N
conducting VBG N
a DT N
clinical JJ N
drug NN N
trial NN N
in IN N
children NNS 1_p
with IN N
Asperger NNP 4_p
Syndrome NNP 4_p
, , N
including VBG N
the DT N
pitfalls NNS N
encountered VBD N
and CC N
lessons NNS N
learnt VBP N
CONCLUSIONS VB N
The DT N
main JJ N
barrier NN N
encountered VBD N
was VBD N
in IN N
the DT N
recruitment NN N
of IN N
children NNS N
: : N
it PRP N
was VBD N
not RB N
possible JJ N
to TO N
recruit VB N
the DT N
target NN N
of IN N
60 CD 3_p
patients NNS N
The DT N
recruitment NN N
of IN N
children NNS N
is VBZ N
often RB N
the DT N
major JJ N
barrier NN N
to TO N
the DT N
progress NN N
of IN N
a DT N
successful JJ N
clinical JJ N
trial NN N
Conducting VBG N
the DT N
clinical JJ N
drug NN N
trial NN N
was VBD N
greatly RB N
facilitated VBN N
by IN N
the DT N
appropriate JJ N
setting NN N
and CC N
experienced VBD N
clinical JJ N
pharmacology NN N
staff NN N
-DOCSTART- -X- O O 16454975

XS0601 NN N
reduces VBZ N
the DT N
incidence NN N
of IN N
restenosis NN N
: : N
a DT N
prospective JJ N
study NN N
of IN N
335 CD 3_p
patients NNS N
undergoing VBG N
percutaneous JJ 4_p
coronary JJ 4_p
intervention NN 4_p
in IN N
China NNP N
BACKGROUND NNP N
XS0601 NNP N
, , N
consisting VBG N
of IN N
active JJ N
ingredients NNS N
( ( N
Chuangxiongol NNP N
and CC N
paeoniflorin NN N
) ) N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
inhibit VB N
arterial JJ N
neointimal JJ N
hyperplasia NN N
in IN N
animal JJ N
models NNS N
and CC N
in IN N
preliminary JJ N
human JJ N
studies NNS N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
XS0601 NNP N
in IN N
preventing VBG N
restenosis NN N
following VBG N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
METHODS VB N
A DT N
multi-center NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
was VBD N
conducted VBN N
A DT N
total NN N
of IN N
335 CD 3_p
patients NNS N
were VBD N
randomized VBN N
into IN N
treatment NN N
with IN N
the DT N
oral JJ N
administration NN N
of IN N
XS0601 NNP N
, , N
or CC N
a DT N
placebo NN N
for IN N
6 CD N
months NNS N
after IN N
successful JJ N
PCI NNP N
Angiographic NNP N
follow-up NN N
was VBD N
scheduled VBN N
at IN N
6 CD N
months NNS N
, , N
and CC N
clinical JJ N
follow-ups NNS N
performed VBN N
at IN N
1 CD N
, , N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
PCI NNP N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
angiographic JJ N
restenosis NN N
The DT N
secondary JJ N
end NN N
points NNS N
were VBD N
the DT N
combined JJ N
incidence NN N
of IN N
death NN N
, , N
target NN N
lesion NN N
nonfatal JJ N
myocardial JJ N
infarction NN N
, , N
repeat NN N
angioplasty NN N
, , N
and CC N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
RESULTS VB N
A DT N
total NN N
of IN N
308 CD 3_p
patients NNS N
( ( N
91.9 CD N
% NN N
) ) N
completed VBD N
the DT N
study NN N
and CC N
145 CD 3_p
cases NNS N
( ( N
47.1 CD N
% NN N
) ) N
received VBD N
angiographic JJ N
follow-up NN N
The DT N
restenosis NN N
rates NNS N
were VBD N
significantly RB N
reduced VBN N
in IN N
the DT N
XS0601 NNP N
group NN N
as IN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
26.0 CD N
% NN N
vs. FW N
47.2 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
the DT N
minimum JJ N
lumen NNS N
diameter NN N
( ( N
MLD NNP N
) ) N
was VBD N
greater JJR N
[ NNP N
( ( N
2.08 CD N
+/- JJ N
0.89 CD N
) ) N
mm NN N
for IN N
XS0601 NNP N
vs. FW N
( ( N
1.73 CD N
+/- JJ N
0.94 CD N
) ) N
mm NN N
for IN N
placebo NN N
, , N
P NNP N
< VBZ N
0.05 CD N
] NN N
XS0601 NN N
also RB N
significantly RB N
reduced VBD N
the DT N
combined JJ N
incidence NN N
of IN N
major JJ N
adverse JJ N
cardiac NN N
event NN N
( ( N
10.4 CD N
% NN N
in IN N
the DT N
XS0601 NNP N
group NN N
vs. FW N
22.7 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
The DT N
incidence NN N
of IN N
recurrent JJ N
angina NN N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
PCI NNP N
was VBD N
also RB N
significantly RB N
reduced VBN N
in IN N
XS0601 NNP N
group NN N
( ( N
7.1 CD N
% NN N
and CC N
11.0 CD N
% NN N
) ) N
as IN N
compared VBN N
with IN N
those DT N
in IN N
placebo JJ N
group NN N
( ( N
19.5 CD N
% NN N
and CC N
42.9 CD N
% NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
No DT N
significant JJ N
side NN N
effects NNS N
occurred VBD N
within IN N
the DT N
6-month JJ N
follow-up JJ N
period NN N
in IN N
the DT N
XS0601 NNP N
group NN N
CONCLUSION NNP N
Administration NNP N
of IN N
XS0601 NNP N
for IN N
6 CD N
months NNS N
is VBZ N
demonstrated VBN N
to TO N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
reducing VBG N
restenosis NN N
in IN N
post-PCI JJ N
patients NNS N
-DOCSTART- -X- O O 24315548

Randomized NNP N
clinical JJ N
trial NN N
of IN N
cutting VBG N
balloon NN N
angioplasty JJ N
versus NN N
high-pressure NN N
balloon NN N
angioplasty NN N
in IN N
hemodialysis NN 4_p
arteriovenous JJ 4_p
fistula NN 4_p
stenoses VBZ 4_p
resistant JJ 4_p
to TO 4_p
conventional JJ 4_p
balloon NN 4_p
angioplasty NN 4_p
PURPOSE NNP N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
cutting VBG N
balloon NN N
angioplasty NN N
( ( N
CBA NNP N
) ) N
versus IN N
high-pressure NN N
balloon NN N
angioplasty NN N
( ( N
HPBA NNP N
) ) N
for IN N
the DT N
treatment NN N
of IN N
hemodialysis NN 4_p
autogenous JJ 4_p
fistula NN 4_p
stenoses VBZ 4_p
resistant JJ 4_p
to TO 4_p
conventional JJ 4_p
percutaneous JJ 4_p
transluminal JJ 4_p
angioplasty NN 4_p
( ( 4_p
PTA NNP 4_p
) ) 4_p
MATERIALS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
involving VBG N
patients NNS N
with IN N
dysfunctional JJ 4_p
, , 4_p
stenotic JJ 4_p
hemodialysis NN 4_p
arteriovenous JJ 4_p
fistulas NNS 4_p
( ( 4_p
AVFs NNP 4_p
) ) 4_p
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
CBA NNP N
or CC N
HPBA NNP N
if IN N
conventional JJ N
PTA NNP N
had VBD N
suboptimal JJ N
results NNS N
( ( N
ie JJ N
, , N
residual JJ N
stenosis NN N
> VBD N
30 CD N
% NN N
) ) N
A DT N
total NN N
of IN N
516 CD 3_p
patients NNS N
consented VBN N
to TO N
participate VB N
in IN N
the DT N
study NN N
from IN N
October NNP N
2008 CD N
to TO N
September NNP N
2011 CD N
, , N
85 CD N
% NN N
of IN N
whom WP N
( ( N
n JJ N
= NNP N
439 CD 3_p
) ) N
had VBD N
technically RB N
successful JJ N
conventional JJ N
PTA NNP N
The DT N
remaining VBG N
71 CD 3_p
patients NNS N
( ( N
mean JJ 1_p
age NN 1_p
, , 1_p
60 CD 1_p
y NN 1_p
; : N
49 CD 3_p
men NNS N
) ) N
with IN N
suboptimal JJ N
PTA NNP N
results NNS N
were VBD N
eventually RB N
randomized VBN N
: : N
36 CD N
to TO N
the DT N
CBA NNP N
arm NN N
and CC N
35 CD N
to TO N
the DT N
HPBA NNP N
arm NN N
Primary JJ N
and CC N
secondary JJ N
target NN N
lesion NN N
patencies NNS N
were VBD N
determined VBN N
by IN N
Kaplan-Meier NNP N
analysis NN N
RESULTS NNP N
Clinical JJ N
success NN N
rates NNS N
were VBD N
100 CD N
% NN N
in IN N
both DT N
arms NNS N
Primary JJ N
target NN N
lesion NN N
patency NN N
rates NNS N
at IN N
6 CD N
months NNS N
were VBD N
66.4 CD N
% NN N
and CC N
39.9 CD N
% NN N
for IN N
CBA NNP N
and CC N
HPBA NNP N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
Secondary JJ N
target NN N
lesion NN N
patency NN N
rates NNS N
at IN N
6 CD N
months NNS N
were VBD N
96.5 CD N
% NN N
for IN N
CBA NNP N
and CC N
80.0 CD N
% NN N
for IN N
HPBA NNP N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
There EX N
was VBD N
a DT N
single JJ N
major JJ N
complication NN N
of IN N
venous JJ N
perforation NN N
following VBG N
CBA NNP N
The DT N
30-day JJ N
mortality NN N
rate NN N
was VBD N
1.4 CD N
% NN N
, , N
with IN N
one CD N
non-procedure-related JJ N
death NN N
in IN N
the DT N
HPBA NNP N
group NN N
CONCLUSIONS NNP N
Primary NNP N
and CC N
secondary JJ N
target NN N
lesion NN N
patency NN N
rates NNS N
of IN N
CBA NNP N
were VBD N
statistically RB N
superior JJ N
to TO N
those DT N
of IN N
HPBA NNP N
following VBG N
suboptimal JJ N
conventional JJ N
PTA NNP N
For IN N
AVF NNP N
stenoses VBZ N
resistant JJ N
to TO N
conventional JJ N
PTA NNP N
, , N
CBA NNP N
may MD N
be VB N
a DT N
better JJR N
second-line JJ N
treatment NN N
given VBN N
its PRP$ N
superior JJ N
patency NN N
rates NNS N
-DOCSTART- -X- O O 21639907

Infliximab NNP N
in IN N
ankylosing VBG N
spondylitis NN N
: : N
alone RB N
or CC N
in IN N
combination NN N
with IN N
methotrexate NN N
? . N
A NNP N
pharmacokinetic JJ N
comparative NN N
study NN N
INTRODUCTION NNP N
Methotrexate NNP N
( ( N
MTX NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
modify VB N
infliximab JJ N
pharmacokinetics NNS N
in IN N
rheumatoid JJ N
arthritis NN N
However RB N
, , N
its PRP$ N
combination NN N
with IN N
infliximab NN N
in IN N
the DT N
treatment NN N
of IN N
ankylosing VBG N
spondylitis NN N
( ( N
AS IN N
) ) N
is VBZ N
not RB N
recommended VBN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
influence NN N
of IN N
MTX NNP N
on IN N
infliximab NN N
exposure NN N
in IN N
patients NNS N
with IN N
AS NNP N
METHODS NNP N
Patients NNPS N
with IN N
AS NNP N
patients NNS N
who WP N
had VBD N
predominantly RB N
axial JJ N
symptoms NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
infliximab NN N
alone RB N
( ( N
infusions NNS N
of IN N
5 CD N
mg/kg NNS N
at IN N
weeks NNS N
0 CD N
, , N
2 CD N
, , N
6 CD N
, , N
12 CD N
and CC N
18 CD N
) ) N
or CC N
infliximab JJ N
combined VBN N
with IN N
MTX NNP N
( ( N
10 CD N
mg/week NN N
) ) N
Infliximab JJ N
concentrations NNS N
were VBD N
measured VBN N
before IN N
and CC N
2 CD N
hours NNS N
after IN N
each DT N
infusion NN N
and CC N
at IN N
1 CD N
, , N
3 CD N
, , N
4 CD N
, , N
5 CD N
, , N
8 CD N
, , N
10 CD N
, , N
14 CD N
and CC N
18 CD N
weeks NNS N
We PRP N
estimated VBD N
individual JJ N
cumulative JJ N
area NN N
under IN N
the DT N
concentration NN N
versus NN N
time NN N
curves NNS N
( ( N
AUC NNP N
) ) N
for IN N
infliximab JJ N
concentration NN N
between IN N
baseline NN N
and CC N
week NN N
18 CD N
( ( N
AUC NNP N
( ( N
0-18 NNP N
) ) N
) ) N
Clinical JJ N
and CC N
laboratory JJ N
evaluations NNS N
were VBD N
performed VBN N
at IN N
each DT N
visit NN N
The DT N
Bath NNP N
Ankylosing NNP N
Spondylitis NNP N
Disease NNP N
Activity NNP N
Index NNP N
( ( N
BASDAI NNP N
) ) N
score NN N
was VBD N
the DT N
primary JJ N
end NN N
point NN N
for IN N
clinical JJ N
response NN N
RESULTS NNP N
Twenty-six JJ N
patients NNS N
were VBD N
included VBN N
( ( N
infliximab JJ N
group NN N
: : N
n JJ N
= NN N
12 CD N
, , N
infliximab NN N
+ NNP N
MTX NNP N
group NN N
: : N
n JJ N
= NNP N
14 CD N
) ) N
, , N
and CC N
507 CD N
serum NN N
samples NNS N
were VBD N
available JJ N
for IN N
measurement NN N
of IN N
infliximab JJ N
concentration NN N
The DT N
two CD N
groups NNS N
did VBD N
not RB N
differ VB N
with IN N
regard NN N
to TO N
AUC NNP N
( ( N
0-18 CD N
) ) N
or CC N
evolution NN N
of IN N
BASDAI NNP N
scores NNS N
and CC N
biomarkers NNS N
of IN N
inflammation NN N
CONCLUSIONS VB N
The DT N
combination NN N
of IN N
MTX NNP N
and CC N
infliximab NN N
does VBZ N
not RB N
increase VB N
the DT N
exposure NN N
to TO N
infliximab VB N
over RP N
infliximab JJ N
alone RB N
in IN N
patients NNS N
with IN N
AS NNP N
TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
: : N
NCT00507403 NN N
-DOCSTART- -X- O O 17868242

Injury NNP N
and CC N
illness NN N
costs NNS N
in IN N
the DT N
Certified NNP N
Safe NNP N
Farm NNP N
study NN N
CONTEXT NNP N
The DT N
Certified NNP N
Safe NNP N
Farm NNP N
( ( N
CSF NNP N
) ) N
intervention NN N
program NN N
aims VBZ N
to TO N
reduce VB N
occupational JJ N
injuries NNS N
and CC N
illnesses NNS N
, , N
and CC N
promote VB N
wellness NN N
to TO N
reduce VB N
health NN N
care NN N
and CC N
related JJ N
costs NNS N
to TO N
farmers NNS 4_p
, , 4_p
insurers NNS 4_p
, , 4_p
and CC 4_p
other JJ 4_p
stakeholders NNS 4_p
PURPOSE NNP N
To TO N
evaluate VB N
the DT N
cost NN N
effectiveness NN N
of IN N
CSF NNP N
METHODS NNP N
Farms NNP N
( ( N
316 CD N
) ) N
located VBN N
in IN N
a DT N
9-county JJ N
area NN N
of IN N
northwestern JJ N
Iowa NNP N
were VBD N
recruited VBN N
and CC N
randomized VBN N
into IN N
intervention NN N
and CC N
control NN N
cohorts NNS N
Intervention NN N
farms NNS N
received VBD N
occupational JJ N
health NN N
screenings NNS N
, , N
health NN N
and CC N
wellness NN N
screening NN N
, , N
education NN N
, , N
on-farm JJ N
safety NN N
reviews NNS N
, , N
and CC N
performance NN N
incentives NNS N
For IN N
both DT N
cohorts NNS N
, , N
quarterly JJ N
calls NNS N
over IN N
3 CD N
years NNS N
were VBD N
used VBN N
to TO N
collect VB N
self-reported JJ N
occupational JJ N
injury NN N
and CC N
illness JJ N
information NN N
, , N
including VBG N
costs NNS N
to TO N
the DT N
farmers NNS N
and CC N
their PRP$ N
insurers NNS N
FINDINGS NNP N
Annual NNP N
occupational JJ N
injury NN N
and CC N
illness NN N
costs NNS N
per IN N
farmer NN N
paid VBN N
by IN N
insurers NNS N
were VBD N
45 CD N
% NN N
lower JJR N
in IN N
the DT N
intervention NN N
cohort NN N
( ( N
$ $ N
183 CD N
) ) N
than IN N
in IN N
the DT N
control NN N
cohort NN N
( ( N
$ $ N
332 CD N
) ) N
Although IN N
out-of-pocket NN N
expenses NNS N
were VBD N
similar JJ N
for IN N
both DT N
cohorts NNS N
, , N
combined VBN N
costs NNS N
of IN N
insurance NN N
and CC N
out-of-pocket NN N
expenses NNS N
were VBD N
27 CD N
% NN N
lower JJR N
in IN N
the DT N
intervention NN N
cohort NN N
( ( N
$ $ N
374/year CD N
per IN N
farmer NN N
) ) N
compared VBN N
to TO N
the DT N
control NN N
cohort NN N
( ( N
$ $ N
512/year CD N
per IN N
farmer NN N
) ) N
Within IN N
the DT N
cohort NN N
of IN N
intervention NN N
farmers NNS N
, , N
annual JJ N
occupational JJ N
injury NN N
and CC N
illness NN N
cost NN N
savings NNS N
were VBD N
directly RB N
associated VBN N
with IN N
on-farm JJ N
safety NN N
review NN N
scores NNS N
Reported VBD N
health NN N
care NN N
costs NNS N
were VBD N
$ $ N
237 CD N
per IN N
farmer NN N
in IN N
the DT N
safest NN N
farms NNS N
( ( N
those DT N
farms NNS N
scoring VBG N
in IN N
the DT N
highest JJS N
tertile NN N
) ) N
versus VBD N
$ $ N
485 CD N
per IN N
farmer NN N
in IN N
the DT N
least JJS N
safe JJ N
farms NNS N
( ( N
lowest JJS N
tertile NN N
) ) N
CONCLUSIONS JJ N
Results NNP N
suggest VBP N
that IN N
farmers NNS N
receiving VBG N
the DT N
intervention NN N
had VBD N
lower JJR N
health NN N
care NN N
costs NNS N
for IN N
occupational JJ N
injuries NNS N
and CC N
illnesses NNS N
than IN N
control NN N
farmers NNS N
These DT N
cost NN N
savings NNS N
more JJR N
than IN N
cover VB N
the DT N
cost NN N
of IN N
providing VBG N
CSF NNP N
services NNS N
( ( N
about IN N
$ $ N
100 CD N
per IN N
farm NN N
per IN N
year NN N
) ) N
-DOCSTART- -X- O O 19886920

Sustained JJ N
effect NN N
of IN N
SQ-standardized NNP N
grass NN N
allergy NN N
immunotherapy NN N
tablet NN N
on IN N
rhinoconjunctivitis NN N
quality NN N
of IN N
life NN N
BACKGROUND IN N
The DT N
prevalence NN N
of IN N
allergic JJ N
rhinoconjunctivitis NN N
has VBZ N
increased VBN N
significantly RB N
over IN N
the DT N
past JJ N
decades NNS N
with IN N
grass NN N
pollen NN N
being VBG N
a DT N
common JJ N
trigger NN N
The DT N
impact NN N
of IN N
allergy NN N
on IN N
patient NN N
's POS N
quality NN N
of IN N
life NN N
is VBZ N
substantial JJ N
AIM NNP N
To TO N
investigate VB N
the DT N
sustained JJ N
effect NN N
on IN N
quality NN N
of IN N
life NN N
during IN N
the DT N
grass NN N
pollen NN N
season NN N
1 CD N
year NN N
after IN N
3 CD N
years NNS N
of IN N
treatment NN N
with IN N
the DT N
SQ-standardized JJ N
grass NN N
allergy NN N
immunotherapy NN N
tablet NN N
( ( N
AIT NNP N
) ) N
, , N
Graza NNP N
( ( N
Phleum NNP N
pratense VBZ N
75,000 CD N
SQ-T/2800 JJ N
BAU NNP N
; : N
ALK NNP N
, , N
Denmark NNP N
) ) N
METHODS PDT N
The DT N
trial NN N
was VBD N
a DT N
randomized JJ N
, , N
parallel-group JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
in IN N
adult NN 1_p
subjects NNS N
with IN N
a DT N
history NN N
of IN N
moderate-severe JJ 4_p
grass NN 4_p
pollen NN 4_p
induced VBD 4_p
rhinoconjunctivitis NN 4_p
inadequately RB 4_p
controlled VBN 4_p
by IN 4_p
symptomatic JJ 4_p
medications NNS 4_p
Subjects NNS N
received VBD N
3 CD N
years NNS N
of IN N
grass NN N
AIT NNP N
( ( N
n JJ N
= NNP N
157 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
126 CD N
) ) N
, , N
followed VBN N
by IN N
1 CD N
year NN N
of IN N
follow-up NN N
Quality NN N
of IN N
life NN N
assessments NNS N
were VBD N
based VBN N
on IN N
the DT N
standardized JJ N
rhinoconjunctivitis NN N
quality NN N
of IN N
life NN N
questionnaire NN N
( ( N
RQLQ NNP N
( ( N
S NNP N
) ) N
) ) N
; : N
completed VBN N
weekly JJ N
during IN N
the DT N
entire JJ N
grass NN N
pollen NN N
season NN N
RESULTS NNP N
During IN N
follow-up JJ N
, , N
the DT N
overall JJ N
RQLQ NNP N
( ( N
S NNP N
) ) N
score NN N
for IN N
the DT N
entire JJ N
grass NN N
pollen NN N
season NN N
was VBD N
significantly RB N
improved VBN N
in IN N
the DT N
active JJ N
group NN N
( ( N
relative JJ N
difference NN N
to TO N
placebo VB N
: : N
23 CD N
% NN N
, , N
P NNP N
= NNP N
0.004 CD N
) ) N
The DT N
improvement NN N
was VBD N
higher JJR N
during IN N
the DT N
peak NN N
pollen NN N
season NN N
( ( N
28 CD N
% NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
The DT N
treatment NN N
effect NN N
of IN N
grass NN N
AIT NNP N
during IN N
the DT N
follow-up JJ N
year NN N
and CC N
the DT N
previous JJ N
three CD N
treatment NN N
years NNS N
was VBD N
similar JJ N
Improvements NNS N
were VBD N
found VBN N
in IN N
all DT N
seven CD N
RQLQ NNP N
( ( N
S NNP N
) ) N
domains VBZ N
The DT N
RQLQ NNP N
( ( N
S NNP N
) ) N
as IN N
a DT N
function NN N
of IN N
the DT N
weekly JJ N
average NN N
pollen NN N
counts VBZ N
showed VBD N
a DT N
clear JJ N
separation NN N
between IN N
the DT N
treatment NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
CONCLUSION NNP N
In IN N
subjects NNS N
inadequately RB N
controlled VBN N
by IN N
symptomatic JJ N
medications NNS N
, , N
grass NN N
AIT NNP N
provided VBD N
sustained VBN N
and CC N
clinically RB N
relevant JJ N
improvements NNS N
in IN N
rhinoconjunctivitis NN N
quality NN N
of IN N
life NN N
compared VBN N
to TO N
placebo VB N
The DT N
effect NN N
increased VBD N
with IN N
increasing VBG N
grass NN N
pollen NN N
exposure NN N
-DOCSTART- -X- O O 24280031

A DT N
double-blind NN N
, , N
randomized VBN N
trial NN N
of IN N
deep JJ N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
( ( N
rTMS NN N
) ) N
for IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
BACKGROUND NNP N
Biomedical NNP N
treatment NN N
options NNS N
for IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
are VBP N
extremely RB N
limited JJ N
Repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
( ( N
rTMS NN N
) ) N
is VBZ N
a DT N
safe JJ N
and CC N
efficacious JJ N
technique NN N
when WRB N
targeting VBG N
specific JJ N
areas NNS N
of IN N
cortical JJ N
dysfunction NN N
in IN N
major JJ N
depressive JJ N
disorder NN N
, , N
and CC N
a DT N
similar JJ N
approach NN N
could MD N
yield VB N
therapeutic JJ N
benefits NNS N
in IN N
ASD NNP N
, , N
if IN N
applied VBN N
to TO N
relevant VB N
cortical JJ N
regions NNS N
OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
whether IN N
deep JJ N
rTMS NN N
to TO N
bilateral JJ N
dorsomedial JJ N
prefrontal NN N
cortex NN N
improves VBZ N
social JJ N
relating NN N
in IN N
ASD NNP N
METHODS NNP N
28 CD 3_p
adults NNS 1_p
diagnosed VBN N
with IN N
either DT 4_p
autistic JJ 4_p
disorder NN 4_p
( ( 4_p
high-functioning JJ 4_p
) ) 4_p
or CC 4_p
Asperger NNP 4_p
's POS 4_p
disorder NN 4_p
completed VBD N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
design NN N
with IN N
2 CD N
weeks NNS N
of IN N
daily JJ N
weekday JJ N
treatment NN N
This DT N
involved JJ N
deep JJ N
rTMS NN N
to TO N
bilateral JJ N
dorsomedial JJ N
prefrontal NN N
cortex NN N
( ( N
5 CD N
Hz NNP N
, , N
10-s JJ N
train NN N
duration NN N
, , N
20-s JJ N
inter-train JJ N
interval NN N
) ) N
for IN N
15 CD N
min NN N
( ( N
1500 CD N
pulses VBZ N
per IN N
session NN N
) ) N
using VBG N
a DT N
HAUT-Coil NNP N
The DT N
sham NN N
rTMS NN N
coil NN N
was VBD N
encased VBN N
in IN N
the DT N
same JJ N
helmet NN N
of IN N
the DT N
active JJ N
deep JJ N
rTMS NN N
coil NN N
, , N
but CC N
no DT N
effective JJ N
field NN N
was VBD N
delivered VBN N
into IN N
the DT N
brain NN N
Assessments NNS N
were VBD N
conducted VBN N
before IN N
, , N
after IN N
, , N
and CC N
one CD N
month NN N
following VBG N
treatment NN N
RESULTS JJ N
Participants NNS N
in IN N
the DT N
active JJ N
condition NN N
showed VBD N
a DT N
near JJ N
significant JJ N
reduction NN N
in IN N
self-reported JJ N
social JJ N
relating NN N
symptoms NNS N
from IN N
pre-treatment JJ N
to TO N
one CD N
month NN N
follow-up NN N
, , N
and CC N
a DT N
significant JJ N
reduction NN N
in IN N
social JJ N
relating NN N
symptoms NNS N
( ( N
relative JJ N
to TO N
sham VB N
participants NNS N
) ) N
for IN N
both DT N
post-treatment JJ N
assessments NNS N
Those DT N
in IN N
the DT N
active JJ N
condition NN N
also RB N
showed VBD N
a DT N
reduction NN N
in IN N
self-oriented JJ N
anxiety NN N
during IN N
difficult JJ N
and CC N
emotional JJ N
social JJ N
situations NNS N
from IN N
pre-treatment NN N
to TO N
one CD N
month NN N
follow-up NN N
There EX N
were VBD N
no DT N
changes NNS N
for IN N
those DT N
in IN N
the DT N
sham JJ N
condition NN N
CONCLUSION NNP N
Deep NNP N
rTMS NN N
to TO N
bilateral JJ N
dorsomedial JJ N
prefrontal NN N
cortex NN N
yielded VBD N
a DT N
reduction NN N
in IN N
social JJ N
relating NN N
impairment NN N
and CC N
socially-related JJ N
anxiety NN N
Further NNP N
research NN N
in IN N
this DT N
area NN N
should MD N
employ VB N
extended VBD N
rTMS NN N
protocols NNS N
that WDT N
approximate VBP N
those DT N
used VBN N
in IN N
depression NN N
in IN N
an DT N
attempt NN N
to TO N
replicate VB N
and CC N
amplify VB N
the DT N
clinical JJ N
response NN N
-DOCSTART- -X- O O 9834207

Marginal JJ N
benefit/disadvantage NN N
of IN N
granulocyte JJ N
colony-stimulating JJ N
factor NN N
therapy NN N
after IN N
autologous JJ N
blood NN N
stem NN N
cell NN N
transplantation NN N
in IN N
children NNS 1_p
: : N
results NNS N
of IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
The DT N
Japanese JJ N
Cooperative NNP N
Study NNP N
Group NNP N
of IN N
PBSCT NNP N
In IN N
this DT N
prospective JJ N
trial NN N
, , N
a DT N
total NN N
of IN N
74 CD 3_p
children NNS 1_p
who WP N
were VBD N
scheduled VBN N
to TO N
undergo VB N
high-dose JJ 4_p
chemotherapy NN 4_p
followed VBN N
by IN N
autologous JJ 4_p
peripheral JJ 4_p
blood NN 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
( ( 4_p
PBSCT NNP 4_p
) ) 4_p
were VBD N
prospectively RB N
randomized VBN N
at IN N
diagnosis NN N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
exogenous JJ N
granulocyte JJ N
colony-stimulating JJ N
factor NN N
( ( N
G-CSF NNP N
) ) N
treatment NN N
in IN N
accelerating VBG N
hematopoietic JJ N
recovery NN N
after IN N
PBSCT NNP N
The DT N
diagnosis NN N
included VBD N
acute JJ 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
( ( N
ALL DT N
) ) N
( ( N
n JJ N
= NNP N
27 CD 3_p
) ) N
, , N
neuroblastoma FW 4_p
( ( N
n JJ N
= NNP N
29 CD 3_p
) ) N
, , N
and CC N
miscellaneous JJ 4_p
solid JJ 4_p
tumors NNS 4_p
( ( N
n JJ N
= NNP N
18 CD 3_p
) ) N
Eligibility NNP N
criteria NNS N
included VBD N
( ( N
1 CD N
) ) N
primary NN 4_p
PBSCT NNP 4_p
, , N
( ( N
2 CD N
) ) N
chemotherapy-responsive JJ 4_p
disease NN 4_p
, , N
and CC N
( ( N
3 CD N
) ) N
collected VBN 4_p
cell NN 4_p
number NN 4_p
> $ 4_p
1 CD 4_p
x $ 4_p
10 CD 4_p
( ( 4_p
5 CD 4_p
) ) 4_p
colony-forming NN 4_p
unit-granulocyte-macrophage JJ 4_p
( ( 4_p
CFU-GM NNP 4_p
) ) 4_p
/kg NN 4_p
and CC 4_p
> $ 4_p
1 CD 4_p
x $ 4_p
10 CD 4_p
( ( 4_p
6 CD 4_p
) ) 4_p
CD34 NNP 4_p
( ( 4_p
+ NNP 4_p
) ) 4_p
cells/kg VBP 4_p
patient NN N
's POS N
body NN N
weight NN N
After IN N
applying VBG N
the DT N
above NN N
criteria NN N
, , N
11 CD 3_p
patients NNS N
were VBD N
excluded VBN N
due JJ N
to TO N
disease VB N
progression NN N
before IN N
PBSCT NNP 4_p
( ( N
n JJ N
= NNP N
6 CD 3_p
) ) N
or CC N
a DT N
low JJ N
number NN N
of IN N
harvested JJ N
cells NNS N
( ( N
n JJ N
= NNP N
5 CD N
) ) 3_p
, , N
leaving VBG N
63 CD 3_p
patients NNS N
for IN N
analysis NN N
; : N
32 CD 3_p
patients NNS N
in IN N
the DT N
treatment NN N
group NN N
( ( N
300 CD N
microg/m2 NN N
of IN N
G-CSF NNP N
intravenously RB N
over IN N
1 CD N
hour NN N
from IN N
day NN N
1 CD N
of IN N
PBSCT NNP N
) ) N
and CC N
31 CD N
in IN N
the DT N
control NN N
group NN N
without IN N
treatment NN N
Two CD N
distinct JJ N
disease-oriented JJ N
high-dose JJ N
regimens NNS N
without IN N
total JJ N
body NN N
irradiation NN N
consisted VBD N
of IN N
the DT N
MCVAC NNP N
regimen NNS N
using VBG N
ranimustine NN N
( ( N
MCNU NNP N
, , N
450 CD N
mg/m2 NN N
) ) N
, , N
cytosine JJ N
arabinoside NN N
( ( N
16 CD N
g/m2 NN N
) ) N
, , N
etoposide RB N
( ( N
1.6 CD N
g/m2 NN N
) ) N
, , N
and CC N
cyclophosphamide NN N
( ( N
100 CD N
mg/kg NN N
) ) N
for IN N
patients NNS N
with IN N
ALL NNP N
, , N
and CC N
the DT N
Hi-MEC NNP N
regimen NNS N
using VBG N
melphalan NN N
( ( N
180 CD N
mg/m2 NN N
) ) N
, , N
etoposide RB N
( ( N
1.6 CD N
g/m2 NN N
) ) N
, , N
and CC N
carboplatinum NN N
( ( N
1.6 CD N
g/m2 NN N
) ) N
for IN N
those DT N
with IN N
solid JJ N
tumors NNS N
Five CD 3_p
patients NNS N
( ( N
two CD 3_p
in IN N
the DT N
treatment NN N
group NN N
and CC N
three CD 3_p
in IN N
the DT N
control NN N
group NN N
) ) N
were VBD N
subsequently RB N
removed VBN N
due JJ N
to TO N
protocol VB N
violations NNS N
All DT N
patients NNS N
survived VBD N
PBSCT NNP N
The DT N
median JJ N
numbers NNS N
of IN N
transfused JJ N
mononuclear JJ N
cells NNS N
( ( N
MNC NNP N
) ) N
, , N
CD34 NNP N
( ( N
+ NNP N
) ) N
cells NNS N
, , N
and CC N
CFU-GM NNP N
were VBD N
, , N
respectively RB N
, , N
4.5 CD N
( ( N
range NN N
, , N
1 CD N
to TO N
19 CD N
) ) N
x NN N
10 CD N
( ( N
8 CD N
) ) N
/kg NN N
, , N
8.0 CD N
( ( N
1.1 CD N
to TO N
25 CD N
) ) N
x NN N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
, , N
and CC N
3.7 CD N
( ( N
1.2 CD N
to TO N
23 CD N
) ) N
x NN N
10 CD N
( ( N
5 CD N
) ) N
/kg NN N
in IN N
the DT N
treatment NN N
group NN N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
and CC N
2.9 CD N
( ( N
0.8 CD N
to TO N
21 CD N
) ) N
x NN N
10 CD N
( ( N
8 CD N
) ) N
/kg NN N
, , N
6.3 CD N
( ( N
1.1 CD N
to TO N
34 CD N
) ) N
x NN N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
, , N
and CC N
5.5 CD N
( ( N
1.3 CD N
to TO N
37 CD N
) ) N
x NN N
10 CD N
( ( N
5 CD N
) ) N
/kg NN N
, , N
respectively RB N
, , N
in IN N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
28 CD N
) ) N
, , N
with IN N
no DT N
significant JJ N
difference NN N
After IN N
PBSCT NNP N
, , N
the DT N
time NN N
to TO N
achieve VB N
an DT N
absolute JJ N
neutrophil NN N
count NN N
( ( N
ANC NNP N
) ) N
of IN N
> $ N
0.5 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
in IN N
the DT N
treatment NN N
group NN N
was VBD N
less JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
median JJ N
, , N
11 CD N
v NN N
12 CD N
days NNS N
; : N
the DT N
log-rank JJ N
test NN N
, , N
P NNP N
=.046 NNP N
) ) N
, , N
although IN N
the DT N
last JJ N
day NN N
of IN N
red JJ N
blood NN N
cell NN N
( ( N
RBC NNP N
) ) N
transfusion NN N
( ( N
day NN N
11 CD N
v NN N
day NN N
10 CD N
) ) N
and CC N
the DT N
duration NN N
of IN N
febrile JJ N
days NNS N
( ( N
> JJ N
38 CD N
degrees NNS N
C NNP N
) ) N
after IN N
PBSCT NNP N
( ( N
4 CD N
v RB N
4 CD N
days NNS N
) ) N
were VBD N
identical JJ N
in IN N
both DT N
groups NNS N
However RB N
, , N
platelet JJ N
recovery NN N
to TO N
> VB N
20 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
was VBD N
significantly RB N
longer RBR N
in IN N
treatment NN N
group NN N
than IN N
control NN N
group NN N
( ( N
26 CD N
v RB N
16 CD N
days NNS N
; : N
P NNP N
=.009 NNP N
) ) N
and CC N
> $ N
50 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
tended VBD N
to TO N
take VB N
longer JJR N
in IN N
the DT N
treatment NN N
group NN N
( ( N
29 CD N
v RB N
26 CD N
days NNS N
; : N
P NNP N
=.126 NNP N
) ) N
, , N
with IN N
significantly RB N
more JJR N
platelet JJ N
transfusion-dependent JJ N
days NNS N
( ( N
27 CD N
v RB N
13 CD N
days NNS N
; : N
t-test JJ N
, , N
P NNP N
=.037 NNP N
) ) N
When WRB N
patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
different JJ N
disease NN N
cohorts NNS N
, , N
ALL DT N
patients NNS N
showed VBD N
no DT N
difference NN N
in IN N
engraftment JJ N
kinetics NNS N
between IN N
the DT N
G-CSF NNP N
treatment NN N
and CC N
control NN N
groups NNS N
, , N
while IN N
differences NNS N
were VBD N
seen VBN N
in IN N
those DT N
with IN N
solid JJ N
tumors NNS N
We PRP N
concluded VBD N
that IN N
the DT N
marginal JJ N
clinical JJ N
benefit NN N
of IN N
1 CD N
day NN N
earlier RBR N
recovery NN N
of IN N
granulocytes NNS N
could MD N
be VB N
offset VBN N
by IN N
the DT N
delayed JJ N
recovery NN N
of IN N
platelets NNS N
We PRP N
recommend VBP N
that IN N
the DT N
routine JJ N
application NN N
of IN N
costly JJ N
G-CSF NNP N
therapy NN N
in IN N
children NNS 1_p
undergoing VBG N
PBSCT NNP 4_p
should MD N
be VB N
seriously RB N
reconsidered VBN N
-DOCSTART- -X- O O 15463829

Creon NNP N
10,000 CD N
Minimicrospheres NNP N
vs. FW N
Creon NNP N
8,000 CD N
microspheres NNS N
-- : N
an DT N
open JJ N
randomised VBN N
crossover NN N
preference NN N
study NN N
Creon NNP N
10,000 CD N
Minimicrospherestrade NNP N
mark NN N
( ( N
Creon NNP N
) ) N
10,000 CD N
MMS NNP N
) ) N
is VBZ N
a DT N
pancreatic JJ N
enzyme NN N
formulation NN N
that IN N
contains VBZ N
smaller JJR N
spheres NNS N
of IN N
pancreatin NN N
in IN N
a DT N
50 CD N
% NN N
smaller JJR N
capsule NN N
than IN N
conventional JJ N
microspheres NNS N
( ( N
Creon NNP N
) ) N
8,000 CD N
) ) N
This DT N
three-centre JJ N
study NN N
investigated VBD N
the DT N
preference NN N
of IN N
cystic JJ 4_p
fibrosis NN 4_p
( ( 4_p
CF NNP 4_p
) ) 4_p
patients NNS N
for IN N
these DT N
products NNS N
In IN N
one CD N
centre NN N
, , N
72 CD N
h NN N
stool NN N
fat JJ N
excretion NN N
and CC N
coefficient NN N
of IN N
fat JJ N
absorption NN N
( ( N
CFA NNP N
) ) N
were VBD N
also RB N
compared VBN N
Fifty-nine JJ 3_p
patients NNS N
with IN N
a DT N
mean JJ 1_p
age NN 1_p
10 CD 1_p
years NNS 1_p
( ( 1_p
range VB 1_p
3-17 NNP 1_p
) ) 1_p
took VBD N
Creon NNP N
8,000 CD N
ms NN N
for IN N
14 CD N
days NNS N
and CC N
were VBD N
then RB N
randomised VBN N
to TO N
28 CD N
days NNS N
of IN N
Creon NNP N
8,000 CD N
ms NN N
followed VBN N
by IN N
28 CD N
days NNS N
of IN N
Creon NNP N
10,000 CD N
MMS NNP N
, , N
or CC N
vice NN N
versa NN N
Dosing NNP N
was VBD N
lipase NN N
for IN N
lipase NN N
according VBG N
to TO N
the DT N
labelled VBN N
declaration NN N
At IN N
the DT N
end NN N
of IN N
the DT N
second JJ N
treatment NN N
period NN N
, , N
51 CD 3_p
of IN 3_p
54 CD 3_p
patients NNS N
who WP N
completed VBD N
the DT N
study NN N
expressed VBD N
a DT N
preference NN N
, , N
with IN N
a DT N
statistically RB N
significant JJ N
preference NN N
in IN N
favour NN N
of IN N
Creon NNP N
10,000 CD N
MMS NNP N
( ( N
47/51 CD N
; : N
87 CD N
% NN N
) ) N
vs. FW N
Creon NNP N
8,000 CD N
ms NN N
( ( N
4/51 CD N
; : N
7.4 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
Stool NNP N
fat NN N
( ( N
g/day NN N
) ) N
and CC N
CFA NNP N
( ( N
% NN N
) ) N
were VBD N
measured VBN N
in IN N
24 CD N
patients NNS N
at IN N
the DT N
end NN N
of IN N
each DT N
treatment NN N
period NN N
: : N
the DT N
products NNS N
were VBD N
therapeutically RB N
equivalent JJ N
( ( N
Creon JJ N
10,000 CD N
: : N
8.4 CD N
g/day NN N
, , N
91.3 CD N
% NN N
CFA NNP N
; : N
Creon NNP N
8,000 CD N
: : N
6.7 CD N
g/day NN N
, , N
93.5 CD N
% NN N
CFA NNP N
) ) N
Both DT N
products NNS N
were VBD N
well RB N
tolerated VBN N
In IN N
conclusion NN N
, , N
in IN N
CF NNP 4_p
children NNS 1_p
we PRP N
found VBD N
a DT N
clear JJ N
preference NN N
for IN N
Creon NNP N
10,000 CD N
MMS NNP N
compared VBN N
with IN N
Creon NNP N
8,000 CD N
ms NN N
with IN N
no DT N
difference NN N
in IN N
fat JJ N
absorption NN N
between IN N
the DT N
two CD N
products NNS N
Creon NNP N
10,000s CD N
smaller JJR N
capsules NNS N
are VBP N
easier JJR N
to TO N
take VB N
and CC N
should MD N
aid VB N
patient NN N
compliance NN N
-DOCSTART- -X- O O 25594611

Exploring VBG N
the DT N
role NN N
of IN N
tanezumab NN N
as IN N
a DT N
novel JJ N
treatment NN N
for IN N
the DT N
relief NN N
of IN N
neuropathic JJ 4_p
pain NN 4_p
OBJECTIVE NNP N
Evaluate NNP N
efficacy NN N
and CC N
safety NN N
of IN N
tanezumab NN N
, , N
a DT N
humanized JJ N
monoclonal JJ N
antibody NN N
against IN N
nerve NN N
growth NN N
factor NN N
, , N
in IN N
neuropathic JJ 4_p
pain NN 4_p
DESIGN NNP N
Two CD N
randomized VBD N
controlled VBN N
trials NNS N
SUBJECTS NNP N
Patients NNPS N
with IN N
pain NN N
due JJ N
to TO N
diabetic JJ 4_p
peripheral JJ 4_p
neuropathy NN 4_p
( ( 4_p
DPN NNP 4_p
) ) N
or CC N
postherpetic JJ N
neuralgia NN N
( ( N
PHN NNP N
) ) N
METHODS NNP N
In IN N
the DT N
DPN NNP N
study NN N
, , N
patients NNS N
received VBD N
subcutaneous JJ N
tanezumab NNS N
20 CD N
mg NN N
or CC N
placebo NN N
on IN N
Day NNP N
1 CD N
and CC N
Week NNP N
8 CD N
Evaluations NNS N
included VBD N
change NN N
from IN N
baseline NN N
in IN N
average JJ N
DPN NNP N
pain NN N
( ( N
primary JJ N
endpoint NN N
) ) N
, , N
Patient NNP N
's POS N
Global NNP N
Assessment NNP N
of IN N
DPN NNP N
, , N
and CC N
safety NN N
( ( N
including VBG N
neuropathy JJ N
assessments NNS N
) ) N
Due NNP N
to TO N
a DT N
partial JJ N
clinical JJ N
hold NN N
limiting VBG N
enrollment NN N
and CC N
treatment NN N
duration NN N
, , N
the DT N
prespecified JJ N
landmark NN N
analysis NN N
was VBD N
modified VBN N
post NN N
hoc NN N
from IN N
Week JJ N
16 CD N
to TO N
Week VB N
8 CD N
In IN N
the DT N
PHN NNP N
study NN N
, , N
patients NNS N
received VBD N
intravenous JJ N
tanezumab NNS N
50 CD N
μg/kg NNS N
, , N
tanezumab EX N
200 CD N
μg/kg NN N
, , N
or CC N
placebo NN N
on IN N
Day NNP N
1 CD N
Evaluations NNS N
included VBD N
change NN N
from IN N
baseline NN N
in IN N
average JJ N
daily JJ N
pain NN N
( ( N
primary JJ N
endpoint NN N
) ) N
, , N
Brief JJ N
Pain NNP N
Inventory-short NNP N
form NN N
, , N
Patient NNP N
's POS N
Global NNP N
Assessment NNP N
of IN N
pain NN N
from IN N
PHN NNP N
, , N
and CC N
safety NN N
RESULTS JJ N
Mean NNP N
DPN NNP N
pain VBP N
reduction NN N
from IN N
baseline NN N
to TO N
Week VB N
8 CD N
was VBD N
greater JJR N
with IN N
tanezumab NN N
vs NN N
placebo NN N
( ( N
P NNP N
= NNP N
0.009 CD N
) ) N
; : N
differences NNS N
in IN N
Patient NNP N
's POS N
Global NNP N
Assessment NNP N
of IN N
DPN NNP N
were VBD N
not RB N
significant JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
Neither CC N
tanezumab NN N
dose NN N
resulted VBD N
in IN N
significant JJ N
differences NNS N
vs VBP N
placebo NN N
in IN N
efficacy NN N
in IN N
PHN NNP N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
, , N
although IN N
tanezumab JJ N
200 CD N
μg/kg NN N
provided VBD N
some DT N
benefit NN N
Neuropathy JJ N
assessments NNS N
showed VBD N
no DT N
meaningful JJ N
changes NNS N
CONCLUSIONS NNP N
Tanezumab NNP N
provided VBD N
effective JJ N
pain NN N
reduction NN N
in IN N
DPN NNP N
In IN N
PHN NNP N
, , N
only RB N
the DT N
highest JJS N
tanezumab NN N
dose NN N
reduced VBD N
pain NN N
; : N
treatment NN N
differences NNS N
were VBD N
not RB N
significant JJ N
No DT N
new JJ N
safety NN N
concerns NNS N
were VBD N
observed VBN N
despite IN 4_p
preexisting VBG 4_p
neuropathy JJ 4_p
-DOCSTART- -X- O O 25617202

Effect NN N
of IN N
self-collection NN N
of IN N
HPV NNP N
DNA NNP N
offered VBN N
by IN N
community NN N
health NN N
workers NNS N
at IN N
home NN N
visits NNS N
on IN N
uptake NN N
of IN N
screening VBG N
for IN N
cervical JJ N
cancer NN N
( ( N
the DT N
EMA NNP N
study NN N
) ) N
: : N
a DT N
population-based JJ N
cluster-randomised JJ N
trial NN N
BACKGROUND NNP N
Control NNP N
of IN N
cervical JJ N
cancer NN N
in IN N
developing VBG N
countries NNS N
has VBZ N
been VBN N
hampered VBN N
by IN N
a DT N
failure NN N
to TO N
achieve VB N
high JJ N
screening VBG N
uptake NN N
HPV NNP N
DNA NNP N
self-collection NN N
could MD N
increase VB N
screening VBG N
coverage NN N
, , N
but CC N
implementation NN N
of IN N
this DT N
technology NN N
is VBZ N
difficult JJ N
in IN N
countries NNS 4_p
of IN 4_p
middle JJ 4_p
and CC 4_p
low JJ 4_p
income NN 4_p
We PRP N
investigated VBD N
whether IN N
offering VBG N
HPV NNP N
DNA NNP N
self-collection NN N
during IN N
routine JJ N
home NN N
visits NNS N
by IN N
community NN N
health NN N
workers NNS N
could MD N
increase VB N
cervical JJ N
screening NN N
METHODS NNP N
We PRP N
did VBD N
a DT N
population-based JJ N
cluster-randomised JJ N
trial NN N
in IN N
the DT N
province NN 4_p
of IN 4_p
Jujuy NNP 4_p
, , 4_p
Argentina NNP 4_p
, , N
between IN N
July NNP N
1 CD N
, , N
2012 CD N
, , N
and CC N
Dec NNP N
31 CD N
, , N
2012 CD N
Community NNP N
health NN N
workers NNS N
were VBD N
eligible JJ N
for IN N
the DT N
study NN N
if IN N
they PRP N
scored VBD N
highly RB N
on IN N
a DT N
performance NN N
score NN N
, , N
and CC N
women NNS 2_p
aged VBN 1_p
30 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
were VBD N
eligible JJ N
for IN N
enrolment NN N
by IN N
the DT N
community NN N
health NN N
worker NN N
200 CD 3_p
community NN N
health NN N
workers NNS N
were VBD N
randomly RB N
allocated VBN N
in IN N
a DT N
1:1 CD N
ratio NN N
to TO N
either CC N
the DT N
intervention NN N
group NN N
( ( N
offered VBN N
women NNS N
the DT N
chance NN N
to TO N
self-collect VB N
a DT N
sample NN N
for IN N
cervical JJ N
screening NN N
during IN N
a DT N
home NN N
visit NN N
) ) N
or CC N
the DT N
control NN N
group NN N
( ( N
advised JJ N
women NNS N
to TO N
attend VB N
a DT N
health NN N
clinic NN N
for IN N
cervical JJ N
screening NN N
) ) N
The DT N
primary JJ N
outcome NN N
was VBD N
screening VBG N
uptake NN N
, , N
measured VBN N
as IN N
the DT N
proportion NN N
of IN N
women NNS N
having VBG N
any DT N
HPV NNP N
screening NN N
test NN N
within IN N
6 CD N
months NNS N
of IN N
the DT N
community NN N
health NN N
worker NN N
visit NN N
Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT02095561 NNP N
FINDINGS NNP N
100 CD N
community NN N
health NN N
workers NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
intervention NN N
group NN N
and CC N
100 CD N
were VBD N
assigned VBN N
to TO N
the DT N
control NN N
group NN N
; : N
nine CD N
did VBD N
not RB N
take VB N
part NN N
191 CD 3_p
participating VBG N
community NN N
health NN N
workers NNS N
( ( N
94 CD 3_p
in IN N
the DT N
intervention NN N
group NN N
and CC N
97 CD 3_p
in IN N
the DT N
control NN N
group NN N
) ) N
initially RB N
contacted JJ N
7650 CD 3_p
women NNS 2_p
; : N
of IN N
3632 CD 3_p
women NNS 2_p
contacted VBN N
by IN N
community NN N
health NN N
workers NNS N
in IN N
the DT N
intervention NN N
group NN N
, , N
3049 CD 3_p
agreed VBD N
to TO N
participate VB N
; : N
of IN N
4018 CD 3_p
women NNS N
contacted VBN N
by IN N
community NN N
health NN N
workers NNS N
in IN N
the DT N
control NN N
group NN N
, , N
2964 CD 3_p
agreed VBD N
to TO N
participate VB N
2618 CD N
( ( N
86 CD N
% NN N
) ) N
of IN N
3049 CD N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
had VBD N
any DT N
HPV NNP N
test NN N
within IN N
6 CD N
months NNS N
of IN N
the DT N
community NN N
health NN N
worker NN N
visit NN N
, , N
compared VBN N
with IN N
599 CD N
( ( N
20 CD N
% NN N
) ) N
of IN N
2964 CD N
in IN N
the DT N
control NN N
group NN N
( ( N
risk NN N
ratio NN N
4·02 CD N
, , N
95 CD N
% NN N
CI NNP N
3·44-4·71 CD N
) ) N
INTERPRETATION JJ N
Offering VBG N
self-collection NN N
of IN N
samples NNS N
for IN N
HPV NNP N
testing VBG N
by IN N
community NN N
health NN N
workers NNS N
during IN N
home NN N
visits NNS N
resulted VBD N
in IN N
a DT N
four-fold JJ N
increase NN N
in IN N
screening VBG N
uptake NN N
, , N
showing VBG N
that IN N
this DT N
strategy NN N
is VBZ N
effective JJ N
to TO N
improve VB N
cervical JJ N
screening NN N
coverage NN N
This DT N
intervention NN N
reduces VBZ N
women NNS N
's POS N
barriers NNS N
to TO N
screening VBG N
and CC N
results NNS N
in IN N
a DT N
substantial JJ N
and CC N
rapid JJ N
increase NN N
in IN N
coverage NN N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
HPV NNP N
testing VBG N
could MD N
be VB N
extended VBN N
throughout IN N
Argentina NNP N
and CC N
in IN N
other JJ N
countries NNS N
to TO N
increase VB N
cervical JJ N
screening NN N
coverage NN N
FUNDING NN N
Instituto NNP N
Nacional NNP N
del FW N
Cáncer NNP N
( ( N
Argentina NNP N
) ) N
-DOCSTART- -X- O O 19772883

Double-blind JJ N
placebo-controlled JJ N
trial NN N
of IN N
pentoxifylline NN N
added VBN N
to TO N
risperidone VB N
: : N
effects NNS N
on IN N
aberrant JJ N
behavior NN N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
BACKGROUND IN N
There EX N
are VBP N
several JJ N
lines NNS N
of IN N
evidence NN N
to TO N
indicate VB N
that IN N
the DT N
immune NN N
system NN N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
the DT N
pathophysiology NN N
of IN N
autism NN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
access NN N
the DT N
effects NNS N
of IN N
pentoxifylline NN N
plus CC N
risperidone NN N
in IN N
the DT N
treatment NN N
of IN N
autistic JJ N
disorder NN N
METHODS NNP N
Forty NNP 3_p
children NNS 1_p
between IN N
the DT N
ages NNS 1_p
4 CD 1_p
and CC 1_p
12 CD 1_p
years NNS 1_p
with IN N
a DT N
DSM NNP N
IV-TR NNP N
clinical JJ N
diagnosis NN N
of IN N
autism NN 4_p
were VBD N
recruited VBN N
The DT N
children NNS 1_p
presented VBN N
with IN N
a DT N
chief JJ N
complaint NN N
of IN N
severely RB N
disruptive JJ N
symptoms NNS N
related VBN N
to TO N
autistic JJ 4_p
disorder NN 4_p
Patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
pentoxifylline+risperidone VB N
or CC N
placebo+risperidone VB N
for IN N
a DT N
10-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
The DT N
dose NN N
of IN N
risperidone NN N
was VBD N
titrated VBN N
up RB N
to TO N
3 CD N
mg/day NN N
, , N
pentoxifylline NN N
was VBD N
titrated VBN N
to TO N
600 CD N
mg/day NN N
Patients NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
and CC N
10 CD N
weeks NNS N
of IN N
starting VBG N
medication NN N
The DT N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist-Community NNP N
( ( N
ABC-C NNP N
) ) N
RESULTS VB N
The DT N
difference NN N
between IN N
the DT N
two CD N
protocols NNS N
was VBD N
significant JJ N
as IN N
the DT N
group NN N
that WDT N
received VBD N
pentoxifylline NN N
had VBD N
greater JJR N
reduction NN N
in IN N
ABC-C NNP N
subscale NN N
scores NNS N
for IN N
Irritability NNP N
, , N
Lethargy/Social NNP N
Withdrawal NNP N
, , N
Stereotypic NNP N
Behavior NNP N
, , N
Hyperactivity/Noncompliance NNP N
and CC N
Inappropriate NNP N
Speech NNP N
CONCLUSION NNP N
The DT N
results NNS N
suggest VBP N
that IN N
combination NN N
of IN N
atypical JJ N
antipsychotic JJ N
medications NNS N
and CC N
pentoxifylline NN N
might MD N
have VB N
synergistic JJ N
effects NNS N
in IN N
treatment NN N
of IN N
behavioral JJ N
problems NNS N
of IN N
children NNS 1_p
with IN N
autism NN 4_p
-DOCSTART- -X- O O 15889546

Automatic JJ N
detection NN N
of IN N
red JJ N
lesions NNS N
in IN N
digital JJ N
color NN N
fundus NN N
photographs NN N
The DT N
robust JJ N
detection NN N
of IN N
red JJ N
lesions NNS N
in IN N
digital JJ N
color NN N
fundus NN N
photographs NN N
is VBZ N
a DT N
critical JJ N
step NN N
in IN N
the DT N
development NN N
of IN N
automated JJ N
screening VBG N
systems NNS N
for IN N
diabetic JJ 4_p
retinopathy NN N
In IN N
this DT N
paper NN N
, , N
a DT N
novel NN N
red JJ N
lesion NN N
detection NN N
method NN N
is VBZ N
presented VBN N
based VBN N
on IN N
a DT N
hybrid JJ N
approach NN N
, , N
combining VBG N
prior JJ N
works NNS N
by IN N
Spencer NNP N
et CC N
al NN N
( ( N
1996 CD N
) ) N
and CC N
Frame NNP N
et NNP N
al NN N
( ( N
1998 CD N
) ) N
with IN N
two CD N
important JJ N
new JJ N
contributions NNS N
The DT N
first JJ N
contribution NN N
is VBZ N
a DT N
new JJ N
red JJ N
lesion NN N
candidate NN N
detection NN N
system NN N
based VBN N
on IN N
pixel JJ N
classification NN N
Using VBG N
this DT N
technique NN N
, , N
vasculature NN N
and CC N
red JJ N
lesions NNS N
are VBP N
separated VBN N
from IN N
the DT N
background NN N
of IN N
the DT N
image NN N
After IN N
removal NN N
of IN N
the DT N
connected JJ N
vasculature NN N
the DT N
remaining VBG N
objects NNS N
are VBP N
considered VBN N
possible JJ N
red JJ N
lesions NNS N
Second NNP N
, , N
an DT N
extensive JJ N
number NN N
of IN N
new JJ N
features NNS N
are VBP N
added VBN N
to TO N
those DT N
proposed VBN N
by IN N
Spencer-Frame NNP N
The DT N
detected JJ N
candidate NN N
objects NNS N
are VBP N
classified VBN N
using VBG N
all DT N
features NNS N
and CC N
a DT N
k-nearest JJ N
neighbor NN N
classifier NN N
An DT N
extensive JJ N
evaluation NN N
was VBD N
performed VBN N
on IN N
a DT N
test NN N
set NN N
composed VBN N
of IN N
images NNS N
representative NN N
of IN N
those DT N
normally RB N
found VBN N
in IN N
a DT N
screening NN N
set NN N
When WRB N
determining VBG N
whether IN N
an DT N
image NN N
contains VBZ N
red JJ N
lesions NNS N
the DT N
system NN N
achieves VBZ N
a DT N
sensitivity NN N
of IN N
100 CD N
% NN N
at IN N
a DT N
specificity NN N
of IN N
87 CD N
% NN N
The DT N
method NN N
is VBZ N
compared VBN N
with IN N
several JJ N
different JJ N
automatic JJ N
systems NNS N
and CC N
is VBZ N
shown VBN N
to TO N
outperform VB N
them PRP N
all DT N
Performance NNP N
is VBZ N
close RB N
to TO N
that DT N
of IN N
a DT N
human JJ N
expert NN N
examining VBG N
the DT N
images NNS N
for IN N
the DT N
presence NN N
of IN N
red JJ N
lesions NNS N
-DOCSTART- -X- O O 23806094

Randomized VBN N
trial NN N
of IN N
tailored JJ N
skin NN 4_p
cancer NN 4_p
prevention NN N
for IN N
children NNS 1_p
: : N
the DT N
Project NNP N
SCAPE NNP N
family NN N
study NN N
This DT N
study NN N
evaluated VBD N
a DT N
tailored VBN N
intervention NN N
to TO N
promote VB N
sun NN N
protection NN N
in IN N
parents NNS 1_p
and CC N
their PRP$ N
children NNS 1_p
, , N
hypothesizing VBG N
that IN N
the DT N
tailored VBN N
intervention NN N
would MD N
lead VB N
to TO N
improved JJ N
skin NN N
cancer NN N
prevention NN N
behaviors NNS N
compared VBN N
to TO N
generic JJ N
materials NNS N
Families NNS N
were VBD N
recruited VBN N
through IN N
schools NNS N
and CC N
community NN N
centers NNS N
and CC N
were VBD N
included VBN N
if IN N
there EX N
was VBD N
1 CD N
child NN N
in IN N
Grades NNP 4_p
1-3 JJ 4_p
at IN 4_p
moderate JJ 4_p
to TO 4_p
high JJ 4_p
risk NN 4_p
for IN 4_p
skin JJ 4_p
cancer NN 4_p
Participants NNS N
were VBD N
randomized VBN N
into IN N
one CD N
of IN N
two CD N
intervention NN N
groups NNS N
: : N
a DT N
tailored JJ N
intervention NN N
, , N
in IN N
which WDT N
they PRP N
received VBD N
personalized JJ N
skin NN N
cancer NN N
education NN N
through IN N
the DT N
mail NN N
; : N
or CC N
a DT N
control NN N
group NN N
who WP N
received VBD N
generic JJ N
skin NN N
cancer NN N
information NN N
materials NNS N
Before IN N
and CC N
after IN N
intervention NN N
, , N
parents NNS N
completed VBD N
questionnaires NNS N
about IN N
their PRP$ N
and CC N
their PRP$ N
children NNS N
's POS N
skin NN N
cancer NN N
risk NN N
and CC N
prevention NN N
knowledge NN N
and CC N
behaviors NNS N
Parents NNS N
also RB N
completed VBD N
4-day JJ N
sun NN N
exposure NN N
and CC N
protection NN N
diaries NNS N
for IN N
their PRP$ N
child NN N
and CC N
themselves PRP N
Tailored VBN N
group NN N
participants NNS N
demonstrated VBD N
significantly RB N
greater JJR N
positive JJ N
changes NNS N
in IN N
prevention NN N
behavior NN N
after IN N
the DT N
intervention NN N
, , N
including VBG N
children NNS N
's POS N
use NN N
of IN N
sunscreen NN N
, , N
shirts NNS N
, , N
and CC N
hats NNS N
, , N
and CC N
parents NNS N
' POS N
use NN N
of IN N
shade NN N
, , N
and CC N
skin JJ N
examinations NNS N
Effect JJ N
sizes NNS N
were VBD N
small JJ N
and CC N
perceived JJ N
benefits NNS N
and CC N
social JJ N
norms NNS N
mediated VBN N
intervention NN N
effects NNS N
Findings NNS N
from IN N
this DT N
study NN N
support VBD N
the DT N
efficacy NN N
of IN N
focusing VBG N
tailored VBN N
communications NNS N
to TO N
families NNS N
in IN N
order NN N
to TO N
change VB N
skin JJ N
cancer NN N
prevention NN N
practices NNS N
in IN N
young JJ 1_p
children NNS 1_p
-DOCSTART- -X- O O 22692114

The DT N
acute JJ N
effects NNS N
of IN N
fluid JJ N
intake NN N
on IN N
urine JJ N
specific JJ N
gravity NN N
and CC N
fluid JJ N
retention NN N
in IN N
a DT N
mildly RB 4_p
dehydrated JJ 4_p
state NN 4_p
Many JJ N
athletes NNS N
arrive VBP N
at IN N
training NN N
sessions NNS N
and CC N
competitions NNS N
in IN N
a DT N
mildly RB N
hypohydrated VBN N
( ( N
HYPO NNP 4_p
) ) N
state NN N
and CC N
are VBP N
instructed VBN N
to TO N
drink VB N
fluids NNS N
before IN N
exercise NN N
to TO N
reach VB N
a DT N
euhydrated JJ N
( ( N
HYD NNP N
) ) N
state NN N
Ten CD 3_p
recreational JJ N
athletes NNS N
( ( N
6 CD 2_p
women NNS 2_p
, , 2_p
4 CD 2_p
men NNS 2_p
; : N
71.9 CD N
± $ N
4.6 CD N
kg NN N
, , N
25.2 CD 1_p
± JJ 1_p
0.9 CD 1_p
years NNS 1_p
) ) N
participated VBD N
in IN N
the DT N
studies NNS N
to TO N
examine VB N
( ( N
a DT N
) ) N
the DT N
day-to-day JJ N
variability NN N
of IN N
morning NN N
urine NN N
specific JJ N
gravity NN N
( ( N
USG NNP N
) ) N
, , N
( ( N
b NN N
) ) N
the DT N
effects NNS N
of IN N
consuming VBG N
600 CD N
ml NN N
of IN N
water NN N
on IN N
the DT N
hydration NN N
status NN N
of IN N
HYD NNP N
and CC N
HYPO NNP N
( ( N
USG NNP N
> NNP N
1.020 CD N
) ) N
subjects NNS N
, , N
and CC N
( ( N
c NN N
) ) N
the DT N
effects NNS N
of IN N
consuming VBG N
water NN N
( ( N
W NNP N
) ) N
, , N
salt-water JJ N
( ( N
SW NNP N
, , N
40 CD N
mM NN N
Na NNP N
) ) N
, , N
a DT N
carbohydrate-electrolyte JJ N
solution NN N
with IN N
3 CD N
% NN N
or CC N
light JJ N
carbohydrate NN N
( ( N
CES-L NNP N
, , N
20 CD N
mM NN N
Na NNP N
) ) N
or CC N
a DT N
CES NN N
with IN N
6 CD N
% NN N
carbohydrate NN N
( ( N
CES NNP N
, , N
20 CD N
mM NN N
Na NNP N
) ) N
on IN N
the DT N
hydration NN N
status NN N
of IN N
HYPO NNP N
subjects NNS N
The DT N
hydration NN N
status NN N
was VBD N
assessed VBN N
with IN N
USG NNP N
and CC N
body NN N
mass NN N
measures NNS N
and CC N
urine JJ N
volume NN N
collections NNS N
The DT N
day-to-day JJ N
variability NN N
in IN N
morning NN N
USG NNP N
( ( N
coefficient NN N
of IN N
variation NN N
= FW N
0.2 CD N
± $ N
0.1 CD N
% NN N
) ) N
was VBD N
low JJ N
and CC N
the DT N
responses NNS N
to TO N
600 CD N
ml NN N
of IN N
W NNP N
ingestion NN N
were VBD N
repeatable JJ N
Pretrial JJ N
USG NNP N
was VBD N
1.022 CD N
± JJ N
0.001 CD N
in IN N
the DT N
HYPO NNP N
trial NN N
and CC N
decreased VBD N
< NNS N
1.020 CD N
by IN N
45 CD N
minutes NNS N
( ( N
1.013 CD N
± RB N
0.003 CD N
) ) N
In IN N
the DT N
CES NNP N
study NN N
, , N
HYPO NNP N
subjects VBZ N
reached VBN N
HYD NNP N
status NN N
at IN N
45 CD N
minutes NNS N
in IN N
all DT N
conditions NNS N
( ( N
W NNP N
1.013 CD N
± NNP N
0.003 CD N
, , N
SW NNP N
1.013 CD N
± NNP N
0.003 CD N
, , N
CES-L NNP N
1.011 CD N
± NNP N
0.003 CD N
, , N
CES NNP N
1.017 CD N
± NNP N
0.004 CD N
) ) N
because IN N
salt NN N
or CC N
CES NNP N
ingestion NN N
did VBD N
not RB N
affect VB N
fluid NN N
retention NN N
( ( N
W NNP N
68 CD N
% NN N
, , N
SW NNP N
72 CD N
% NN N
, , N
CES-L JJ N
68 CD N
% NN N
, , N
CES NNP N
76 CD N
% NN N
) ) N
This DT N
study NN N
demonstrated VBD N
that IN N
mildly RB N
HYPO NNP N
subjects NNS N
could MD N
reach VB N
euhydration NN N
within IN N
45 CD N
minutes NNS N
of IN N
the DT N
ingestion NN N
of IN N
600 CD N
ml NN N
of IN N
W NNP N
or CC N
a DT N
combination NN N
of IN N
salt NN N
and CC N
CES NNP N
solutions NNS N
Following VBG N
this DT N
practice NN N
will MD N
minimize VB N
the DT N
incidence NN N
of IN N
starting VBG N
a DT N
practice NN N
or CC N
competition NN N
hypohydrated VBN N
-DOCSTART- -X- O O 17477785

Can MD N
a DT N
home-visit JJ N
invitation NN N
increase NN N
Pap NNP N
smear JJ N
screening NN N
in IN N
Samliem NNP N
, , N
Khon NNP N
Kaen NNP N
, , N
Thailand NNP N
? . N
Our PRP$ N
objective NN N
was VBD N
to TO N
assess VB N
the DT N
efficiency NN N
of IN N
a DT N
home-visit JJ N
invitation NN N
aimed VBN N
to TO N
increase VB N
uptake NN N
of IN N
cervical JJ 4_p
cancer NN 4_p
screening VBG N
in IN N
women NNS 2_p
between IN N
35 CD 1_p
and CC 1_p
60 CD 1_p
years NNS N
of IN N
age NN N
From NN N
May NNP N
, , N
2006 CD N
, , N
we PRP N
conducted VBD N
a DT N
quasi-randomized JJ N
trial NN N
to TO N
determine VB N
if IN N
an DT N
in-home JJ N
education NN N
and CC N
invitation NN N
intervention NN N
would MD N
increase VB N
uptake NN N
of IN N
cervical JJ N
cancer NN N
screening VBG N
We PRP N
randomly RB N
recruited VBD N
304 CD 3_p
women NNS 2_p
from IN N
the DT N
Samliem NNP N
inner-city NN N
community NN N
, , N
Khon NNP N
Kaen NNP N
, , N
Northeast NNP N
Thailand NNP N
, , N
and CC N
assigned VBD N
participants NNS N
to TO N
either VB N
the DT N
intervention NN N
or CC N
control VB N
zone NN N
Baseline NNP N
screening VBG N
coverage NN N
interviews NNS N
were VBD N
then RB N
performed VBN N
: : N
58 CD 3_p
of IN N
158 CD 3_p
women NNS 2_p
in IN N
the DT N
intervention NN N
zone NN N
and CC N
46 CD 3_p
of IN N
146 CD 3_p
in IN N
the DT N
control NN N
zone NN N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
because IN N
of IN N
having VBG N
had VBD N
a DT N
Pap NNP N
smear NN N
within IN N
5 CD N
years NNS N
, , N
but CC N
these DT N
were VBD N
included VBN N
in IN N
the DT N
final JJ N
analysis NN N
First NNP N
, , N
100 CD 3_p
women NNS 2_p
in IN N
the DT N
intervention NN N
group NN N
were VBD N
visited VBN N
in IN N
their PRP$ N
homes NNS N
by IN N
one CD N
of IN N
the DT N
researchers NNS N
, , N
who WP N
provided VBD N
culturally-sensitive JJ N
health NN N
education NN N
that WDT N
emphasized VBD N
the DT N
need NN N
for IN N
screening VBG N
Four CD N
months NNS N
later RB N
, , N
post-intervention NN N
, , N
screening-coverage JJ N
interviews NNS N
were VBD N
again RB N
performed VBN N
in IN N
both DT N
groups NNS N
, , N
in IN N
combination NN N
with IN N
the DT N
same JJ N
health NN N
education NN N
for IN N
100 CD 3_p
women NNS 2_p
in IN N
the DT N
control NN N
group NN N
for IN N
a DT N
comparison NN N
There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
baseline NN N
Pap NNP N
smear JJ N
screening-coverage NN N
rate NN N
in IN N
the DT N
intervention NN N
vs. FW N
control NN N
zones NNS N
( ( N
36.7 CD N
vs. FW N
31.5 CD N
% NN N
, , N
p=0.339 NN N
) ) N
One CD N
hundred JJ N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
completed VBD N
the DT N
intervention NN N
interviews NNS N
and CC N
after IN N
four CD N
months NNS N
, , N
100 CD N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
and CC N
100 CD N
in IN N
the DT N
control NN N
group NN N
also RB N
completed VBD N
the DT N
post-intervention NN N
interviews NNS N
The DT N
increased JJ N
screening-coverage NN N
rate NN N
in IN N
the DT N
intervention NN N
zone NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
the DT N
control NN N
zone NN N
( ( N
43.6 CD N
vs. FW N
34.9 CD N
% NN N
, , N
p=0.119 NN N
) ) N
; : N
however RB N
, , N
there EX N
was VBD N
a DT N
borderline NN N
significant JJ N
increase NN N
in IN N
the DT N
intervention NN N
zone NN N
compared VBN N
with IN N
baseline NN N
( ( N
36.7 CD N
to TO N
43.6 CD N
% NN N
, , N
p=0.070 NN N
) ) N
Therefore NNP N
, , N
home NN N
visit NN N
education NN N
and CC N
invitation NN N
intervention NN N
produced VBD N
only RB N
a DT N
nominal JJ N
effect NN N
on IN N
increasing VBG N
Pap NNP N
smear JJ N
coverage NN N
within IN N
a DT N
4-month JJ N
study NN N
period NN N
-DOCSTART- -X- O O 19144729

Effect NN N
of IN N
testosterone NN N
and CC N
a DT N
nutritional JJ N
supplement NN N
, , N
alone RB N
and CC N
in IN N
combination NN N
, , N
on IN N
hospital JJ N
admissions NNS N
in IN N
undernourished JJ 4_p
older JJR 1_p
men NNS 2_p
and CC 2_p
women NNS 2_p
BACKGROUND NNP N
In IN N
older JJR N
people NNS N
, , N
undernutrition NN N
is VBZ N
associated VBN N
with IN N
increased JJ N
hospitalization NN N
rates NNS N
and CC N
mortality NN N
Because IN N
weight JJ N
loss NN N
in IN N
older JJR N
people NNS N
often RB N
reflects VBZ N
a DT N
disproportionate JJ N
reduction NN N
of IN N
skeletal JJ N
muscle NN N
, , N
anabolic JJ N
treatments NNS N
may MD N
be VB N
beneficial JJ N
OBJECTIVE NNP N
Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
hypothesis NN N
that WDT N
testosterone NN N
treatment NN N
and CC N
a DT N
nutritional JJ N
supplement NN N
have VBP N
additive JJ N
benefits NNS N
DESIGN NNP N
Oral NNP N
testosterone NN N
undecanoate NN N
( ( N
40 CD N
mg NNS N
daily RB N
for IN N
women NNS N
, , N
80 CD N
mg NN N
twice RB N
daily RB N
for IN N
men NNS N
) ) N
and CC N
an DT N
oral JJ N
nutritional JJ N
supplement NN N
( ( N
475 CD N
kcal/d NN N
) ) N
were VBD N
administered VBN N
, , N
alone RB N
or CC N
combined VBN N
, , N
for IN N
1 CD N
y NNS N
to TO N
49 CD N
community-dwelling NN 4_p
, , N
undernourished JJ 4_p
people NNS 4_p
[ VBP N
Mini NNP 4_p
Nutritional NNP 4_p
Assessment NNP 4_p
score VBD 4_p
< JJ 4_p
24 CD 4_p
and CC 4_p
low JJ 4_p
body NN 4_p
weight NN 4_p
( ( 4_p
body JJ 4_p
mass NN 4_p
index NN 4_p
, , 4_p
in IN 4_p
kg/m NN 4_p
( ( 4_p
2 CD 4_p
) ) 4_p
: : 4_p
< $ 4_p
22 CD 4_p
) ) 4_p
or CC 4_p
recent JJ 4_p
weight JJ 4_p
loss NN 4_p
( ( 4_p
> JJ 4_p
7.5 CD 4_p
% NN 4_p
over IN 4_p
3 CD 4_p
mo NNS 4_p
) ) N
] VBP N
aged VBN 1_p
> $ 1_p
65 CD 1_p
y NN 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
: : 1_p
77 CD 1_p
y NN 1_p
; : 1_p
26 CD 2_p
women NNS 2_p
and CC 2_p
23 CD 2_p
men NNS 2_p
) ) N
Hospital JJ N
admissions NNS N
and CC N
other JJ N
variables NNS N
were VBD N
assessed VBN N
RESULTS NNP N
In IN N
subjects NNS N
receiving VBG N
combined VBN N
testosterone NN N
and CC N
nutritional JJ N
supplements NNS N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
, , N
there EX N
were VBD N
no DT N
hospital NN N
admissions NNS N
, , N
whereas IN N
there EX N
were VBD N
9 CD N
admissions NNS N
( ( N
2 CD N
elective NN N
) ) N
in IN N
13 CD N
subjects NNS N
in IN N
the DT N
no-treatment JJ N
group NN N
, , N
4 CD N
in IN N
the DT N
testosterone-treated JJ N
group NN N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
, , N
and CC N
5 CD N
in IN N
the DT N
supplement-treated JJ N
group NN N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
; : N
P NNP N
= VBD N
0.06 CD N
with IN N
no-treatment JJ N
compared VBN N
with IN N
combined JJ N
treatment NN N
When WRB N
compared VBN N
with IN N
the DT N
no-treatment JJ N
group NN N
, , N
the DT N
combined-treatment JJ N
group NN N
had VBD N
significantly RB N
fewer JJR N
subjects NNS N
admitted VBN N
to TO N
hospital VB N
( ( N
0 CD N
compared VBN N
with IN N
5 CD N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
fewer JJR N
days NNS N
in IN N
hospital NN N
( ( N
0 CD N
compared VBN N
with IN N
74 CD N
, , N
P NNP N
= NNP N
0.041 CD N
) ) N
, , N
and CC N
a DT N
longer JJR N
time NN N
to TO N
hospital VB N
admission NN N
( ( N
P NNP N
= NNP N
0.017 CD N
) ) N
CONCLUSIONS NNP N
In IN N
undernourished JJ N
older JJR 1_p
people NNS N
, , N
combined VBN N
treatment NN N
with IN N
testosterone NN N
and CC N
nutritional JJ N
supplementation NN N
reduced VBD N
the DT N
number NN N
of IN N
people NNS N
hospitalized VBN N
and CC N
the DT N
duration NN N
of IN N
hospital NN N
admissions NNS N
, , N
which WDT N
are VBP N
important JJ N
endpoints NNS N
in IN N
this DT N
group NN N
Larger NNP N
, , N
confirmatory NN N
studies NNS N
are VBP N
now RB N
needed VBN N
This DT N
trial NN N
was VBD N
registered VBN N
before IN N
commencement NN N
at IN N
clinical JJ N
trials.gov NN N
as IN N
NCT00117000 NNP N
-DOCSTART- -X- O O 2240543

Successful JJ N
difficult JJ N
intubation NN N
Tracheal NNP N
tube JJ N
placement NN N
over IN N
a DT N
gum-elastic JJ N
bougie NN N
A DT N
randomised JJ N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
tracheal NN N
tube NN N
rotation NN N
on IN N
the DT N
passage NN N
of IN N
a DT N
tube NN N
over IN N
a DT N
gum-elastic JJ N
bougie NN N
into IN N
the DT N
trachea NN N
in IN N
100 CD N
patients NNS N
The DT N
effect NN N
of IN N
the DT N
presence NN N
or CC N
absence NN N
of IN N
a DT N
laryngoscope NN N
on IN N
successful JJ N
tube NN N
placement NN N
was VBD N
also RB N
assessed VBN N
A DT N
grade JJ N
3 CD N
difficult JJ N
intubation NN N
was VBD N
simulated VBN N
in IN N
patients NNS 4_p
with IN 4_p
a DT 4_p
laryngoscope NN 4_p
There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
rates NNS N
for IN N
successful JJ N
first-time JJ N
intubation NN N
in IN N
those DT N
patients NNS N
with IN N
tube JJ N
orientation NN N
of IN N
-90 NN N
degrees NNS N
( ( N
with IN N
the DT N
bevel NN N
facing VBG N
posteriorly RB N
) ) N
as IN N
compared VBN N
with IN N
a DT N
tube JJ N
orientation NN N
of IN N
0 CD N
degrees NNS N
( ( N
the DT N
normal JJ N
orientation NN N
with IN N
the DT N
bevel NN N
facing NN N
left VBD N
) ) N
The DT N
unsuccessful JJ N
first-time JJ N
intubations NNS N
with IN N
a DT N
0 CD N
degree JJ N
orientation NN N
were VBD N
frequently RB N
converted VBN N
to TO N
successful JJ N
intubations NNS N
with IN N
the DT N
-90 NN N
degrees VBZ N
position NN N
at IN N
a DT N
second JJ N
attempt NN N
The DT N
presence NN N
of IN N
a DT N
laryngoscope NN N
in IN N
the DT N
mouth NN N
while IN N
rail-roading VBG N
a DT N
tube NN N
over IN N
the DT N
bougie NN N
also RB N
made VBD N
a DT N
significant JJ N
difference NN N
to TO N
the DT N
rate NN N
of IN N
successful JJ N
first-time JJ N
intubations NNS N
The DT N
most RBS N
successful JJ N
method NN N
was VBD N
to TO N
leave VB N
the DT N
laryngoscope NN N
in IN N
the DT N
mouth NN N
and CC N
rotate VB N
the DT N
tube NN N
to TO N
-90 VB N
degrees NNS N
-DOCSTART- -X- O O 16329017

Virtual JJ N
reality NN N
colonoscopy NN N
simulation NN N
: : N
a DT N
compulsory NN N
practice NN N
for IN N
the DT N
future JJ N
colonoscopist NN N
? . N
BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIM NNP N
As IN N
for IN N
any DT N
manual JJ N
procedure NN N
, , N
the DT N
learning NN N
curves NNS N
for IN N
medical JJ N
interventions NNS N
can MD N
have VB N
undesirable JJ N
phases NNS N
, , N
occurring VBG N
mostly RB N
in IN N
the DT N
early JJ N
experience NN N
of IN N
applying VBG N
a DT N
technique NN N
There EX N
have VBP N
been VBN N
impressive JJ N
advances NNS N
in IN N
endoscopic JJ N
procedures NNS N
during IN N
recent JJ N
years NNS N
, , N
and CC N
there EX N
is VBZ N
an DT N
emerging VBG N
trend NN N
that IN N
the DT N
number NN N
of IN N
procedures NNS N
is VBZ N
increasing VBG N
in IN N
parallel NN N
with IN N
these DT N
In IN N
addition NN N
, , N
the DT N
introduction NN N
of IN N
screening VBG N
programs NNS N
for IN N
colorectal JJ N
cancer NN N
will MD N
also RB N
increase VB N
the DT N
numbers NNS N
of IN N
procedures NNS N
needed VBN N
Recent JJ N
developments NNS N
in IN N
medical JJ N
simulation NN N
seem VBP N
promising VBG N
with IN N
regard NN N
to TO N
the DT N
possibility NN N
of IN N
" NNP N
training VBG N
out RP N
" NNP N
undesirable JJ N
parts NNS N
of IN N
the DT N
learning VBG N
curve NN N
outside IN N
the DT N
operating NN N
room NN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
use NN N
of IN N
the DT N
AccuTouch NNP N
flexible JJ N
endoscopy NN N
simulator NN N
improves VBZ N
the DT N
early JJ N
part NN N
of IN N
the DT N
learning VBG N
curve NN N
in IN N
colonoscopy NN N
training NN N
METHOD NNP N
12 CD 2_p
endoscopy NN 2_p
trainees NNS 2_p
, , 2_p
10 CD 2_p
surgeons NNS 2_p
and CC 2_p
two CD 2_p
medical JJ 2_p
gastroenterologists NNS 2_p
, , 2_p
all DT 2_p
with IN 2_p
experience NN 2_p
in IN 2_p
gastroscopy NN 2_p
but CC 2_p
with IN 2_p
no DT 2_p
specific JJ 2_p
colonoscopy NN 2_p
experience NN 2_p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
simulator NN N
training NN N
or CC N
to TO N
a DT N
control NN N
group NN N
They PRP N
all DT N
received VBD N
the DT N
same JJ N
theoretical JJ N
study NN N
package NN N
and CC N
the DT N
training NN N
group NN N
practiced VBD N
with IN N
the DT N
AccuTouch NNP N
colonoscopy NN N
simulator NN N
until IN N
a DT N
predefined JJ N
expert JJ N
level NN N
of IN N
performance NN N
was VBD N
reached VBN N
All DT N
trainees NNS N
performed VBD N
their PRP$ N
first JJ N
ten VBN N
individual JJ N
colonoscopies NNS N
described VBN N
in IN N
detail NN N
in IN N
a DT N
separate JJ N
protocol NN N
RESULTS NNP N
Trainees NNP N
in IN N
the DT N
simulator-trained JJ N
group NN N
performed VBD N
significantly RB N
better RBR N
( ( N
P=0.0011 NNP N
) ) N
and CC N
managed VBN N
to TO N
reach VB N
the DT N
cecum NN N
in IN N
52 CD N
% NN N
of IN N
their PRP$ N
cases NNS N
( ( N
vs. FW N
19 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
) ) N
, , N
and CC N
were VBD N
4.53 CD N
times NNS N
more RBR N
likely JJ N
to TO N
succeed VB N
compared VBN N
with IN N
the DT N
controls NNS N
Additionally RB N
, , N
there EX N
was VBD N
a DT N
significantly RB N
shorter JJR N
procedure NN N
time NN N
and CC N
less RBR N
patient JJ N
discomfort NN N
in IN N
the DT N
hands NNS N
of IN N
the DT N
simulator-trained JJ N
group NN N
CONCLUSION NNP N
Skills NNP N
acquired VBD N
using VBG N
the DT N
AccuTouch NNP N
simulator NN N
transfer NN N
well RB N
into IN N
the DT N
clinical JJ N
colonoscopy NN N
environment NN N
The DT N
results NNS N
of IN N
this DT N
trial NN N
clearly RB N
support VB N
the DT N
plan NN N
to TO N
integrate VB N
simulator NN N
training NN N
into IN N
endoscopic JJ N
education NN N
curricula NN N
-DOCSTART- -X- O O 25286703

[ VB N
A DT N
clinical JJ N
trial NN N
of IN N
ultrasound-guided JJ N
facet NNS N
joint JJ N
block NN N
in IN N
the DT N
lumbar NN N
spine NN N
to TO N
treat VB N
facet JJ 4_p
joint NN 4_p
related VBD 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
] NN 4_p
OBJECTIVE UH N
To TO N
determine VB N
the DT N
feasibility NN N
and CC N
clinical JJ N
efficacy NN N
of IN N
ultrasound-guided JJ N
facet NNS N
joint JJ N
injection NN N
and CC N
nerve NN N
block NN N
in IN N
lumbar NN N
facet NN N
joint NN N
for IN N
the DT N
treatment NN N
of IN N
facet-joint NN 4_p
related VBN 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
METHODS NNP N
20 CD 3_p
patients NNS N
with IN N
facet-joint JJ 4_p
pain NN 4_p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
received VBD N
block RB N
blindly RB N
( ( N
B NNP N
group NN N
) ) N
or CC N
guided VBN N
by IN N
ultrasound NN N
( ( N
US NNP N
group NN N
) ) N
respectively RB N
The DT N
location NN N
of IN N
needle JJ N
tip NN N
was VBD N
confirmed VBN N
by IN N
CT NNP N
in IN N
both DT N
groups NNS N
, , N
and CC N
the DT N
accuracy NN N
was VBD N
computed VBN N
afterwards NNS N
VAS NNP N
score NN N
, , N
puncture NN N
time NN N
and CC N
one-time JJ N
puncture NN N
success NN N
rate NN N
( ( N
% NN N
) ) N
were VBD N
recorded VBN N
VAS NNP N
scores NNS N
and CC N
pain VB N
remission NN N
rates NNS N
in IN N
both DT N
groups NNS N
were VBD N
recorded VBN N
at IN N
30 CD N
min NN N
, , N
1 CD N
d NN N
, , N
2 CD N
d NN N
, , N
6 CD N
weeks NNS N
after IN N
the DT N
block NN N
RESULTS VB N
The DT N
VAS NNP N
scores NNS N
were VBD N
3.3 CD N
+/- JJ N
0.4 CD N
in IN N
US NNP N
group NN N
and CC N
1.2 CD N
+/- JJ N
0.3 CD N
in IN N
B NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
The DT N
puncture NN N
time NN N
was VBD N
( ( N
206 CD N
+/- JJ N
27 CD N
) ) N
s NN N
in IN N
US NNP N
group NN N
while IN N
( ( N
397 CD N
+/- JJ N
31 CD N
) ) N
s NN N
in IN N
B NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
There EX N
were VBD N
37 CD N
facet JJ N
joint NN N
blocks NNS N
guided VBN N
by IN N
ultrasound NN N
, , N
in IN N
which WDT N
32 CD N
were VBD N
correctly RB N
targeted VBN N
with IN N
the DT N
first JJ N
puncture NN N
The DT N
success NN N
rate NN N
is VBZ N
86.5 CD N
% NN N
There EX N
were VBD N
35 CD N
facet JJ N
joint NN N
blocks NNS N
blindly RB N
, , N
in IN N
which WDT N
11 CD N
were VBD N
correctly RB N
targeted VBN N
with IN N
the DT N
first JJ N
puncture NN N
The DT N
success NN N
rate NN N
is VBZ N
31.4 CD N
% NN N
The DT N
difference NN N
of IN N
one-time JJ N
puncture NN N
success NN N
rate NN N
between IN N
the DT N
two CD N
groups NNS N
was VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
Differences NNS N
of IN N
VAS NNP N
and CC N
pain VB N
remission NN N
rate NN N
at IN N
half PDT N
an DT N
hour NN N
after IN N
facet JJ N
joint JJ N
injection NN N
between IN N
B NNP N
group NN N
and CC N
US NNP N
group NN N
were VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
There EX N
were VBD N
8 CD N
, , N
9 CD N
, , N
9 CD N
, , N
and CC N
9 CD N
patients NNS N
in IN N
US NNP N
group NN N
obtaining VBG N
a DT N
reduction NN N
in IN N
VAS NNP N
scores NNS N
> VBP N
or CC N
= VBP N
3 CD N
at IN N
30 CD N
min NN N
, , N
1 CD N
d NN N
, , N
2 CD N
d NN N
and CC N
6 CD N
weeks NNS N
after IN N
the DT N
procedure NN N
respectively RB N
, , N
while IN N
the DT N
numbers NNS N
of IN N
such JJ N
patients NNS N
were VBD N
5 CD N
, , N
6 CD N
, , N
5 CD N
, , N
5 CD N
in IN N
B NNP N
group NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
After IN N
6 CD N
weeks NNS N
of IN N
follow-up NN N
, , N
the DT N
overall JJ N
remission NN N
rates NNS N
were VBD N
( ( N
72.3 CD N
+/- JJ N
14.0 CD N
) ) N
% NN N
in IN N
US NNP N
group NN N
, , N
and CC N
( ( N
56.7 CD N
+/- JJ N
11.0 CD N
) ) N
% NN N
in IN N
B NNP N
group NN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
CONCLUSION VB N
The DT N
ultrasound-guided JJ N
lumbar NN N
facet NN N
joint JJ N
injection NN N
technique NN N
had VBD N
a DT N
high JJ N
feasibility NN N
and CC N
accuracy NN N
, , N
and CC N
had VBD N
better RBR N
clinical JJ N
efficacy NN N
than IN N
block NN N
blindly RB N
-DOCSTART- -X- O O 7539544

A DT N
randomized VBN N
study NN N
comparing VBG N
glucagon NN N
and CC N
hyoscine VB N
N-butyl NNP N
bromide NN N
before IN N
endoscopic NN N
retrograde NN N
cholangiopancreatography NN N
BACKGROUND NNP N
This DT N
study NN N
tried VBD N
to TO N
resolve VB N
whether IN N
glucagon NN N
is VBZ N
a DT N
better JJR N
premedication NN N
for IN N
endoscopic NN 4_p
retrograde NN 4_p
cholangiopancreatography NN 4_p
( ( 4_p
ERCP NNP 4_p
) ) 4_p
METHODS NNP N
We PRP N
first RB N
measured VBD N
the DT N
basal NN N
blood NN N
sugar NN N
and CC N
amylase NN N
levels NNS N
Then RB N
an DT N
endoscope NN N
was VBD N
placed VBN N
in IN N
the DT N
duodenum NN N
without IN N
premedication NN N
, , N
and CC N
basal NN N
pulse NN N
and CC N
duodenal JJ N
peristaltic JJ N
rates NNS N
were VBD N
measured VBN N
ERCP NNP N
began VBD N
after IN N
studied JJ N
subjects NNS N
were VBD N
randomly RB N
premedicated VBN N
with IN N
either DT N
1 CD 4_p
mg NN 4_p
glucagon NN 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
38 CD 4_p
) ) 4_p
or CC 4_p
40 CD 4_p
mg JJ 4_p
hyoscine NN 4_p
N-butyl NNP 4_p
bromide NN 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
36 CD 4_p
) ) 4_p
intravenously RB N
Ten CD N
minutes NNS N
later RB N
the DT N
variables NNS N
were VBD N
measured VBN N
again RB N
RESULTS NNP N
Glucagon NNP N
elicited VBD N
hyperglycemia NN N
whereas NNS N
hyoscine VBP N
N-butyl NNP N
bromide NN N
manifested VBD N
an DT N
anticholinergic JJ N
effect NN N
No DT N
difference NN N
was VBD N
found VBN N
between IN N
these DT N
two CD N
groups NNS N
with IN N
regard NN N
to TO N
the DT N
necessary JJ N
interval NN N
for IN N
ERCP NNP N
( ( N
20.6 CD N
+/- JJ N
14.1 CD N
min NN N
versus NN N
21.4 CD N
+/- JJ N
14.7 CD N
min NN N
; : N
NS NNP N
) ) N
or CC N
the DT N
success NN N
rate NN N
for IN N
cholangiopancreatography NN N
( ( N
92.1 CD N
% NN N
versus IN N
91.7 CD N
% NN N
; : N
NS NNP N
) ) N
Neither CC N
hyperamylasemia JJ N
nor CC N
pancreatitis NN N
was VBD N
preventable JJ N
when WRB N
glucagon NN N
was VBD N
used VBN N
CONCLUSIONS VB N
The DT N
two CD N
premedications NNS N
appear VBP N
equally RB N
effective JJ N
in IN N
the DT N
performance NN N
of IN N
ERCP NNP N
-DOCSTART- -X- O O 23775967

Randomized VBN N
controlled JJ N
trial NN N
of IN N
entecavir NN N
prophylaxis NN N
for IN N
rituximab-associated JJ N
hepatitis NN N
B NNP N
virus NN N
reactivation NN N
in IN N
patients NNS N
with IN N
lymphoma NN N
and CC N
resolved VBD N
hepatitis NN N
B NNP N
PURPOSE NNP N
The DT N
role NN N
of IN N
antiviral JJ N
prophylaxis NN N
in IN N
preventing VBG N
hepatitis NN N
B NNP N
virus NN N
( ( N
HBV NNP N
) ) N
reactivation NN N
before IN N
rituximab-based JJ N
chemotherapy NN N
in IN N
patients NNS N
with IN N
lymphoma NN N
and CC N
resolved VBD N
hepatitis NN N
B NNP N
is VBZ N
unclear JJ N
PATIENTS NNP N
AND CC N
METHODS NNP N
Eighty NNP N
patients NNS N
with IN N
CD20 NNP N
( ( N
+ NNP N
) ) N
lymphoma NN N
and CC N
resolved VBD N
hepatitis NN N
B NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
prophylactic JJ N
entecavir NN N
( ( N
ETV NNP N
) ) N
before IN N
chemotherapy NN N
to TO N
3 CD N
months NNS N
after IN N
completing VBG N
chemotherapy NN N
( ( N
ETV NNP N
prophylactic JJ N
group NN N
, , N
n RB N
= VBZ N
41 CD N
) ) N
or CC N
to TO N
receive VB N
therapeutic JJ N
ETV NNP N
at IN N
the DT N
time NN N
of IN N
HBV NNP N
reactivation NN N
and CC N
hepatitis NN N
B NNP N
surface NN N
antigen NN N
( ( N
HBsAg NNP N
) ) N
reverse NN N
seroconversion NN N
since IN N
chemotherapy NN N
( ( N
control NN N
group NN N
, , N
n RB N
= VBZ N
39 CD N
) ) N
RESULTS JJ N
Fifty-eight JJ N
patients NNS N
( ( N
72.5 CD N
% NN N
) ) N
were VBD N
positive JJ N
for IN N
hepatitis NN N
B NNP N
surface NN N
antibody NN N
, , N
and CC N
HBV NNP N
DNA NNP N
was VBD N
undetectable JJ N
in IN N
50 CD N
patients NNS N
( ( N
62.5 CD N
% NN N
) ) N
During IN N
a DT N
mean JJ N
18-month JJ N
follow-up JJ N
period NN N
, , N
one CD N
patient NN N
( ( N
2.4 CD N
% NN N
) ) N
in IN N
the DT N
ETV NNP N
prophylactic JJ N
group NN N
and CC N
seven CD N
patients NNS N
( ( N
17.9 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
developed VBD N
HBV NNP N
reactivation NN N
( ( N
P NNP N
= NNP N
.027 NNP N
) ) N
The DT N
cumulative JJ N
HBV NNP N
reactivation NN N
rates NNS N
at IN N
months NNS N
6 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
after IN N
chemotherapy NN N
were VBD N
8 CD N
% NN N
, , N
11.2 CD N
% NN N
, , N
and CC N
25.9 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
control NN N
group NN N
, , N
and CC N
0 CD N
% NN N
, , N
0 CD N
% NN N
, , N
and CC N
4.3 CD N
% NN N
in IN N
the DT N
ETV NNP N
prophylactic JJ N
group NN N
( ( N
P NNP N
= NNP N
.019 NNP N
) ) N
Four CD N
patients NNS N
( ( N
50 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
had VBD N
HBsAg NNP N
reverse NN N
seroconversion NN N
after IN N
HBV NNP N
reactivation NN N
The DT N
cumulative JJ N
HBsAg NNP N
reverse NN N
seroconversion NN N
rates NNS N
at IN N
months NNS N
6 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
since IN N
chemotherapy NN N
were VBD N
0 CD N
% NN N
, , N
6.4 CD N
% NN N
, , N
and CC N
16.3 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
, , N
respectively RB N
, , N
which WDT N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
in IN N
the DT N
ETV NNP N
prophylactic JJ N
group NN N
( ( N
P NNP N
= NNP N
.032 NNP N
) ) N
Patients NNS N
with IN N
detectable JJ N
or CC N
undetectable JJ N
viral JJ N
load NN N
could MD N
develop VB N
HBV NNP N
reactivation NN N
and CC N
HBsAg NNP N
reverse NN N
seroconversion NN N
CONCLUSION NNP N
Undetectable JJ N
HBV NNP N
viral JJ N
load NN N
before IN N
chemotherapy NN N
did VBD N
not RB N
confer VB N
reactivation-free JJ N
status NN N
Antiviral NNP N
prophylaxis NN N
can MD N
potentially RB N
prevent VB N
rituximab-associated JJ N
HBV NNP N
reactivation NN N
in IN N
patients NNS N
with IN N
lymphoma NN N
and CC N
resolved VBD N
hepatitis NN N
B NNP N
-DOCSTART- -X- O O 25818246

MDMA-assisted JJ N
therapy NN N
: : N
A DT N
new JJ N
treatment NN N
model NN N
for IN N
social JJ 4_p
anxiety NN 4_p
in IN 4_p
autistic JJ 4_p
adults NNS N
The DT N
first JJ N
study NN N
of IN N
3,4-methylenedioxymethamphetamine NNP N
( ( N
MDMA NNP N
) ) N
-assisted VBD N
therapy NN N
for IN N
the DT N
treatment NN N
of IN N
social JJ 4_p
anxiety NN 4_p
in IN 4_p
autistic JJ 4_p
adults NNS 4_p
commenced VBD 4_p
in IN 4_p
the DT 4_p
spring NN 4_p
of IN 4_p
2014 CD 4_p
The DT N
search NN N
for IN N
psychotherapeutic JJ N
options NNS N
for IN N
autistic JJ N
individuals NNS N
is VBZ N
imperative JJ N
considering VBG N
the DT N
lack NN N
of IN N
effective JJ N
conventional JJ N
treatments NNS N
for IN N
mental JJ N
health NN N
diagnoses NNS N
that WDT N
are VBP N
common JJ N
in IN N
this DT N
population NN N
Serious JJ N
Adverse JJ N
Events NNS N
( ( N
SAEs NNP N
) ) N
involving VBG N
the DT N
administration NN N
of IN N
MDMA NNP N
in IN N
clinical JJ N
trials NNS N
have VBP N
been VBN N
rare JJ N
and CC N
non-life JJ N
threatening NN N
To TO N
date NN N
, , N
MDMA NNP 4_p
has VBZ 4_p
been VBN 4_p
administered VBN 4_p
to TO N
over IN N
1133 CD 3_p
individuals NNS 3_p
for IN N
research NN N
purposes NNS N
without IN N
the DT N
occurrence NN N
of IN N
unexpected JJ N
drug-related JJ N
SAEs NNP N
that IN N
require VBP N
expedited JJ N
reporting NN N
per IN N
FDA NNP N
regulations NNS N
Now RB N
that IN N
safety NN N
parameters NNS N
for IN N
limited JJ N
use NN N
of IN N
MDMA NNP N
in IN N
clinical JJ N
settings NNS N
have VBP N
been VBN N
established VBN N
, , N
a DT N
case NN N
can MD N
be VB N
made VBN N
to TO N
further JJ N
develop VB N
MDMA-assisted JJ N
therapeutic JJ N
interventions NNS N
that WDT N
could MD N
support VB N
autistic JJ N
adults NNS N
in IN N
increasing VBG N
social JJ N
adaptability NN N
among IN N
the DT N
typically RB N
developing VBG N
population NN N
As IN N
in IN N
the DT N
case NN N
with IN N
classic JJ N
hallucinogens NNS N
and CC N
other JJ N
psychedelic JJ N
drugs NNS N
, , N
MDMA NNP N
catalyzes VBZ N
shifts NNS N
toward IN N
openness NN N
and CC N
introspection NN N
that WDT N
do VBP N
not RB N
require VB N
ongoing VBG N
administration NN N
to TO N
achieve VB N
lasting VBG N
benefits NNS N
This DT N
infrequent JJ N
dosing NN N
mitigates NNS N
adverse JJ N
event NN N
frequency NN N
and CC N
improves VBZ N
the DT N
risk/benefit NN N
ratio NN N
of IN N
MDMA NNP N
, , N
which WDT N
may MD N
provide VB N
a DT N
significant JJ N
advantage NN N
over IN N
medications NNS N
that WDT N
require VBP N
daily JJ N
dosing NN N
Consequently RB N
, , N
clinicians NNS N
could MD N
employ VB N
new JJ N
treatment NN N
models NNS N
for IN N
social JJ N
anxiety NN N
or CC N
similar JJ N
types NNS N
of IN N
distress NN N
administering VBG N
MDMA NNP N
on IN N
one CD N
to TO N
several JJ N
occasions NNS N
within IN N
the DT N
context NN N
of IN N
a DT N
supportive JJ N
and CC N
integrative JJ N
psychotherapy NN N
protocol NN N
-DOCSTART- -X- O O 20329618

[ JJ N
Effect NNP N
of IN N
zengjing VBG N
no DT N
1 CD N
capsule NN N
on IN N
morphology NN N
and CC N
motility NN N
of IN N
sperm NN N
in IN N
patients NNS N
with IN N
oligospermia JJ N
] NN N
OBJECTIVE UH N
To TO N
explore VB N
the DT N
effect NN N
of IN N
Zengjing VBG N
Capsule NNP N
No NNP N
1 CD N
( ( N
ZJC1 NNP N
) ) N
on IN N
morphology NN N
and CC N
motility NN N
of IN N
sperm NN N
in IN N
patients NNS N
with IN N
oligospermia NN N
( ( N
OSM NNP N
) ) N
METHODS NNP N
Seventy-two JJ N
OSM NNP N
patients NNS N
were VBD N
assigned VBN N
to TO N
2 CD N
groups NNS N
by IN N
a DT N
randomizing JJ N
digital NN N
table NN N
, , N
the DT N
treated VBN N
group NN N
and CC N
the DT N
control NN N
group NN N
, , N
they PRP N
were VBD N
treated VBN N
respectively RB N
by IN N
ZJC1 NNP N
and CC N
Wuzi NNP N
Yanzong NNP N
Pill NNP N
( ( N
WYP NNP N
) ) N
The DT N
changes NNS N
of IN N
density NN N
, , N
motility NN N
and CC N
morphology NN N
of IN N
sperm NN N
in IN N
patients NNS N
before IN N
and CC N
after IN N
3-month JJ N
treatment NN N
were VBD N
examined VBN N
using VBG N
computerized JJ N
WLJY-9000 CD N
colour JJ N
semen NNS N
analysis NN N
system NN N
with IN N
refined JJ N
Papanicolaou NNP N
's POS N
stain NN N
RESULTS VB N
The DT N
density NN N
, , N
motility NN N
and CC N
morphology NN N
of IN N
sperm NN N
were VBD N
improved VBN N
and CC N
sperm JJ N
deformity NN N
rate NN N
was VBD N
significantly RB N
decreased VBN N
after IN N
treatment NN N
in IN N
both DT N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
the DT N
effects NNS N
in IN N
the DT N
treated JJ N
group NN N
were VBD N
better JJR N
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
CONCLUSION NNP N
ZJC1 NNP N
can MD N
enhance VB N
the DT N
density NN N
and CC N
motility NN N
of IN N
sperm NN N
and CC N
reduce VB N
the DT N
sperm JJ N
deformity NN N
rate NN N
in IN N
patients NNS 4_p
with IN 4_p
OSM NNP 4_p
-DOCSTART- -X- O O 3065176

[ JJ 4_p
Vulvovaginal NNP 4_p
Candida NNP 4_p
mycoses VBZ 4_p
-- : 4_p
treatment NN 4_p
with IN N
clotrimazole NN N
Comparison NNP N
of IN N
single-dose JJ N
treatment NN N
with IN N
6-day JJ N
therapy NN N
] NN N
-DOCSTART- -X- O O 22999292

Memantine NNP N
as IN N
adjunctive JJ N
treatment NN N
to TO N
risperidone VB N
in IN N
children NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
Autism NNP N
is VBZ N
a DT N
neurodevelopmental JJ N
disorder NN N
that WDT N
causes VBZ N
significant JJ N
impairment NN N
in IN N
socialization NN N
and CC N
communication NN N
It PRP N
is VBZ N
also RB N
associated VBN N
with IN N
ritualistic JJ N
and CC N
stereotypical JJ N
behaviour NN N
Recent JJ N
studies NNS N
propose VBP N
both DT N
hyper-and JJ N
hypoglutamatergic NN N
ideologies NNS N
for IN N
autism NN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
memantine NN N
plus CC N
risperidone NN N
in IN N
the DT N
treatment NN N
of IN N
children NNS 1_p
with IN N
autism NN 4_p
Children NNP N
with IN N
autism NN 4_p
were VBD N
randomly RB N
allocated VBN N
to TO N
risperidone VB N
plus JJ N
memantine NN N
or CC N
placebo NN N
plus CC N
risperidone NN N
for IN N
a DT N
10-wk JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
The DT N
dose NN N
of IN N
risperidone NN N
was VBD N
titrated VBN N
up RB N
to TO N
3 CD N
mg/d NNS N
and CC N
memantine NN N
was VBD N
titrated VBN N
to TO N
20 CD N
mg/d NN N
Children NNP N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
and CC N
10 CD N
wk NN N
of IN N
starting VBG N
medication NN N
protocol NN N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
irritability NN N
subscale NN N
of IN N
Aberrant NNP N
Behavior NNP N
Checklist-Community NNP N
( ( N
ABC-C NNP N
) ) N
Difference NN N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
was VBD N
significant JJ N
as IN N
the DT N
group NN N
that WDT N
received VBD N
memantine NN N
had VBD N
greater JJR N
reduction NN N
in IN N
ABC-C NNP N
subscale NN N
scores NNS N
for IN N
irritability NN N
, , N
stereotypic VB N
behaviour NN N
and CC N
hyperactivity NN N
Eight CD N
side-effects NNS N
were VBD N
observed VBN N
over IN N
the DT N
trial NN N
, , N
out IN N
of IN N
the DT N
25 CD N
side-effects NNS N
that IN N
the DT N
checklist NN N
included VBD N
The DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT N
frequency NN N
of IN N
side-effects NNS N
was VBD N
not RB N
significant JJ N
The DT N
present JJ N
study NN N
suggests VBZ N
that IN N
memantine NN N
may MD N
be VB N
a DT N
potential JJ N
adjunctive JJ N
treatment NN N
strategy NN N
for IN N
autism NN N
and CC N
it PRP N
was VBD N
generally RB N
well RB N
tolerated VBN N
This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
the DT N
Iranian JJ N
Clinical NNP N
Trials NNP N
Registry NNP N
( ( N
IRCT1138901151556N10 NNP N
; : N
www.irct.ir NN N
) ) N
-DOCSTART- -X- O O 20584070

Effects NNS N
of IN N
telmisartan NN N
and CC N
enalapril NN N
on IN N
renoprotection NN N
in IN N
patients NNS N
with IN N
mild JJ 4_p
to TO 4_p
moderate VB 4_p
chronic JJ 4_p
kidney NN 4_p
disease NN 4_p
BACKGROUND NNP N
Blocking VBG N
the DT N
renin-angiotensin NN N
system NN N
( ( N
RAS NNP N
) ) N
with IN N
angiotensin NN N
receptor NN N
blockers NNS N
or CC N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
protects VBZ N
against IN N
renal JJ N
injury NN N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
kidney NN 4_p
disease NN 4_p
( ( 4_p
CKD NNP 4_p
) ) 4_p
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
chronic JJ N
effects NNS N
of IN N
telmisartan NN N
and CC N
enalapril NN N
on IN N
proteinuria NN N
, , N
urinary JJ N
liver-type JJ N
fatty JJ N
acid-binding JJ N
protein NN N
( ( N
L-FABP NNP N
) ) N
and CC N
endothelin $ N
( ( N
ET NNP N
) ) N
-1 NN N
levels NNS N
in IN N
patients NNS N
with IN N
mild JJ 4_p
CKD NNP 4_p
MATERIALS NNP N
AND CC N
METHODS NNP N
Thirty NNP 4_p
CKD NNP 4_p
patients NNS 4_p
with IN N
mild JJ 4_p
to TO 4_p
moderate VB 4_p
renal JJ 4_p
insufficiency NN 4_p
( ( N
20 CD 2_p
men NNS 2_p
and CC 2_p
10 CD 2_p
women NNS 2_p
; : N
mean JJ N
age NN N
, , N
37 CD 1_p
years NNS 1_p
; : 1_p
estimated VBN 1_p
glomerular JJ 1_p
filtration NN 1_p
rate NN 1_p
( ( 1_p
eGFR NN 1_p
) ) 1_p
> VBZ 1_p
60 CD 1_p
mL NN 1_p
min NN 1_p
( ( 1_p
-1 NNP 1_p
) ) 1_p
and CC 1_p
blood NN 1_p
pressure NN 1_p
> VBZ 1_p
130/85 CD 1_p
mmHg NN 1_p
) ) 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
telmisartan NN N
at IN N
80 CD N
mg NNS N
day NN N
( ( N
-1 NN N
) ) N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
or CC N
enalapril VBN N
at IN N
10 CD N
mg NNS N
day NN N
( ( N
-1 NN N
) ) N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
We PRP N
measured VBD N
blood NN N
pressure NN N
, , N
serum JJ N
creatinine NN N
, , N
eGFR NN N
, , N
urinary JJ N
protein NN N
, , N
L-FABP NNP N
and CC N
ET-1 NNP N
before IN N
the DT N
start NN N
of IN N
treatment NN N
and CC N
6 CD N
and CC N
12 CD N
months NNS N
after IN N
the DT N
start NN N
of IN N
treatment NN N
RESULTS VB N
The DT N
blood NN N
pressure NN N
reduction NN N
rate NN N
was VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
Urinary JJ N
protein NN N
, , N
L-FABP NNP N
and CC N
ET-1 NNP N
levels NNS N
were VBD N
significantly RB N
reduced VBN N
in IN N
both DT N
groups NNS N
6 CD N
and CC N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
after IN N
treatment NN N
, , N
but CC N
the DT N
reduction NN N
rates NNS N
were VBD N
more RBR N
pronounced JJ N
in IN N
patients NNS N
receiving VBG N
telmisartan NN N
than IN N
in IN N
those DT N
receiving VBG N
enalapril NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
Estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
was VBD N
increased VBN N
similarly RB N
in IN N
both DT N
groups NNS N
at IN N
12 CD N
months NNS N
CONCLUSIONS NNP N
The DT N
study NN N
results NNS N
suggest VBP N
that IN N
telmisartan JJ N
results NNS N
in IN N
a DT N
greater JJR N
reduction NN N
of IN N
urinary JJ N
markers NNS N
than IN N
does VBZ N
enalapril VB N
and CC N
that IN N
this DT N
effect NN N
occurs VBZ N
by IN N
a DT N
mechanism NN N
independent JJ N
of IN N
blood NN N
pressure NN N
reduction NN N
It PRP N
would MD N
be VB N
needed VBN N
to TO N
investigate VB N
whether IN N
the DT N
differences NNS N
may MD N
be VB N
distinct JJ N
or CC N
not RB N
the DT N
same JJ N
when WRB N
other JJ N
dosages NNS N
are VBP N
used VBN N
-DOCSTART- -X- O O 21621992

Lung NNP N
function NN N
and CC N
respiratory NN N
symptoms NNS N
in IN N
a DT N
1-year JJ N
randomized JJ N
smoking NN N
cessation NN N
trial NN N
of IN N
varenicline NN N
in IN N
COPD NNP 4_p
patients NNS 4_p
UNLABELLED IN N
There EX N
are VBP N
few JJ N
data NNS N
concerning VBG N
changes NNS N
in IN N
lung NN N
function NN N
and CC N
respiratory NN N
symptoms NNS N
in IN N
smokers NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
( ( 4_p
COPD NNP 4_p
) ) N
weeks NNS N
to TO N
months NNS N
after IN N
quitting VBG N
smoking NN N
We PRP N
examined VBD N
serial JJ N
changes NNS N
in IN N
spirometry NN N
and CC N
Clinical NNP N
COPD NNP N
Questionnaire NNP N
( ( N
CCQ NNP N
) ) N
scores VBZ N
( ( N
measuring VBG N
respiratory NN N
symptoms NNS N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
) ) N
in IN N
COPD NNP 4_p
participants NNS N
by IN N
smoking VBG N
status NN N
during IN N
a DT N
smoking NN N
cessation NN N
trial NN N
In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
, , N
smokers NNS N
with IN N
mild-to-moderate JJ N
COPD NNP 4_p
were VBD N
treated VBN N
with IN N
varenicline JJ N
1 CD N
mg NN N
b.i.d NN N
or CC N
placebo NN N
for IN N
12 CD N
weeks NNS N
and CC N
followed VBD N
to TO N
Week VB N
52 CD N
Primary JJ N
endpoints NNS N
of IN N
abstinence NN N
were VBD N
previously RB N
reported VBN N
Secondary JJ N
endpoints NNS N
were VBD N
mean JJ N
changes NNS N
from IN N
baseline NN N
in IN N
post-bronchodilator NN N
forced VBN N
expired JJ N
volume NN N
in IN N
1 CD N
s NN N
( ( N
FEV NNP N
( ( N
1 CD N
) ) N
) ) N
and CC N
CCQ NNP N
scores NNS N
Change NN N
from IN N
baseline NN N
in IN N
post-bronchodilator NN N
FEV NNP N
( ( N
1 CD N
) ) N
was VBD N
significantly RB N
improved VBN N
in IN N
continuous JJ N
abstainers NNS N
( ( N
121.8 CD N
mL NN N
) ) N
vs. FW N
continuous JJ N
smokers NNS N
( ( N
37.9 CD N
mL NN N
) ) N
at IN N
Week $ N
12 CD N
( ( N
P NNP N
= NNP N
0.0069 CD N
) ) N
, , N
but CC N
not RB N
at IN N
Weeks NNP N
24 CD N
or CC N
52 CD N
Mean JJ N
change NN N
from IN N
baseline NN N
at IN N
Week NNP N
12 CD N
in IN N
CCQ NNP N
Total NNP N
Score NNP N
was VBD N
significantly RB N
better RBR N
in IN N
continuous JJ N
abstainers NNS N
( ( N
-1.04 NN N
) ) N
vs. FW N
continuous JJ N
smokers NNS N
( ( N
-0.53 NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
: : N
this DT N
improvement NN N
was VBD N
sustained VBN N
at IN N
Weeks NNP N
24 CD N
and CC N
52 CD N
In IN N
a DT N
1-year JJ N
cessation NN N
trial NN N
of IN N
smokers NNS 4_p
with IN 4_p
COPD NNP 4_p
, , N
continuous JJ N
abstinence NN N
compared VBN N
with IN N
continuous JJ N
smoking VBG N
significantly RB N
improved VBN N
post-bronchodilator NN N
FEV NNP N
( ( N
1 CD N
) ) N
at IN N
Week $ N
12 CD N
( ( N
although IN N
the DT N
difference NN N
narrowed VBD N
subsequently RB N
) ) N
and CC N
CCQ NNP N
Total NNP N
Scores NNP N
at IN N
Week NNP N
12 CD N
, , N
with IN N
sustained JJ N
improvement NN N
thereafter RB N
( ( N
TRIAL NNP N
REGISTRY NNP N
http NN N
: : N
//www.clinicaltrials.gov NN N
; : N
trial NN N
identifier NN N
: : N
NCT00285012 NNP N
) ) N
-DOCSTART- -X- O O 12612897

Gastrointestinal NNP N
safety NN N
of IN N
NO-aspirin NNP N
( ( N
NCX-4016 NNP N
) ) N
in IN N
healthy JJ 4_p
human JJ 4_p
volunteers NNS N
: : N
a DT N
proof NN N
of IN N
concept NN N
endoscopic NN N
study NN N
BACKGROUND NNP N
AND CC N
AIMS NNP N
NCX-4016 NNP N
is VBZ N
a DT N
nitric JJ N
oxide-releasing JJ N
derivative NN N
of IN N
aspirin NN N
with IN N
antiplatelet NN N
activity NN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
NCX-4016 NNP N
on IN N
gastrointestinal JJ N
mucosa NN N
and CC N
platelet NN N
functions NNS N
in IN N
healthy JJ 4_p
human JJ 4_p
volunteers NNS N
METHODS NNP N
This DT N
was VBD N
a DT N
parallel-group JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
Forty NNP 3_p
healthy JJ N
subjects NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
7 CD N
days NNS N
of IN N
treatment NN N
with IN N
NCX-4016 NNP N
( ( N
400 CD N
and CC N
800 CD N
mg NN N
twice RB N
daily RB N
) ) N
, , N
equimolar JJ N
doses NNS N
of IN N
aspirin NN N
( ( N
200 CD N
and CC N
420 CD N
mg NN N
twice RB N
daily RB N
) ) N
, , N
or CC N
placebo NN N
Upper IN N
endoscopies NNS N
were VBD N
performed VBN N
before RB N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
period NN N
, , N
and CC N
gastroduodenal JJ N
lesions NNS N
were VBD N
graded VBN N
using VBG N
a DT N
predefined VBN N
scoring NN N
system NN N
Basal NNP N
and CC N
posttreatment JJ N
platelet NN N
aggregation NN N
in IN N
response NN N
to TO N
arachidonic JJ N
acid NN N
( ( N
AA NNP N
) ) N
and CC N
serum JJ N
thromboxane NN N
( ( N
TX NNP N
) ) N
B NNP N
( ( N
2 CD N
) ) N
and CC N
AA-stimulated JJ N
platelet NN N
TXB NNP N
( ( N
2 CD N
) ) N
production NN N
were VBD N
investigated VBN N
RESULTS NNP N
Mucosal NNP N
endoscopic JJ N
injury NN N
score NN N
on IN N
day NN N
7 CD N
was VBD N
0.63 CD N
+/- JJ N
0.16 CD N
in IN N
the DT N
placebo NN N
group NN N
and CC N
11.0 CD N
+/- JJ N
3.0 CD N
and CC N
16.1 CD N
+/- JJ N
1.6 CD N
in IN N
healthy JJ 4_p
volunteers NNS N
treated VBD N
with IN N
200 CD N
and CC N
420 CD N
mg NN N
aspirin JJ N
twice RB N
daily RB N
( ( N
P NNP N
< VBZ N
0.0001 CD N
vs. FW N
placebo NN N
) ) N
NCX-4016 NN N
was VBD N
virtually RB N
devoid JJ N
of IN N
gastric JJ N
and CC N
duodenal JJ N
toxicity NN N
, , N
resulting VBG N
in IN N
a DT N
total JJ N
gastric NN N
and CC N
duodenal JJ N
endoscopic NN N
score NN N
of IN N
1.38 CD N
+/- JJ N
0.3 CD N
and CC N
1.25 CD N
+/- JJ N
0.5 CD N
( ( N
P NNP N
< VBZ N
0.0001 CD N
vs. NN N
aspirin NN N
, , N
not RB N
significant JJ N
vs. FW N
placebo NN N
) ) N
NCX-4016 JJ N
inhibited JJ N
AA-induced JJ N
platelet NN N
aggregation NN N
as RB N
well RB N
as IN N
serum NN N
TXB NNP N
( ( N
2 CD N
) ) N
and CC N
platelet NN N
TXB NNP N
( ( N
2 CD N
) ) N
generation NN N
induced VBN N
by IN N
AA NNP N
to TO N
the DT N
same JJ N
extent NN N
as IN N
aspirin NN N
( ( N
not RB N
significant JJ N
vs. FW N
aspirin NN N
) ) N
CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
we PRP N
have VBP N
proven VBN N
the DT N
concept NN N
that IN N
addition NN N
of IN N
an DT N
NO-donating JJ N
moiety NN N
to TO N
aspirin VB N
results NNS N
in IN N
a DT N
new JJ N
chemical NN N
entity NN N
that WDT N
maintains VBZ N
cyclooxygenase-1 NN N
and CC N
platelet VB N
inhibitory JJ N
activity NN N
while IN N
nearly RB N
avoiding VBG N
gastrointestinal JJ N
damage NN N
-DOCSTART- -X- O O 25644584

A DT N
feasibility NN N
study NN N
for IN N
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
treatment NN N
withdrawal NN N
in IN N
psoriatic JJ 4_p
arthritis NN 4_p
( ( N
REmoval NNP N
of IN N
treatment NN N
for IN N
patients NNS N
in IN N
REmission NNP N
in IN N
psoriatic JJ N
ArThritis NNP N
( ( N
RETREAT NNP N
( ( N
F NNP N
) ) N
) ) N
TNF NNP N
therapy NN N
is VBZ N
effective JJ N
for IN N
all DT N
aspects NNS N
of IN N
psoriatic JJ N
disease NN N
, , N
but CC N
these DT N
drugs NNS N
are VBP N
costly JJ N
and CC N
the DT N
long-term JJ N
effects NNS N
are VBP N
unknown JJ N
Further NNP N
, , N
methotrexate NN N
causes NNS N
concern NN N
with IN N
long-term JJ N
adverse JJ N
events NNS N
The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
test VB N
the DT N
feasibility NN N
of IN N
drug NN N
withdrawal NN N
from IN N
patients NNS 4_p
with IN 4_p
psoriatic JJ 4_p
arthritis NN 4_p
, , 4_p
in IN 4_p
stable JJ 4_p
low JJ 4_p
disease NN 4_p
state NN 4_p
We PRP N
examined VBD N
the DT N
availability NN N
of IN N
patients NNS N
, , N
their PRP$ N
willingness NN N
to TO N
participate VB N
, , N
study NN N
procedures NNS N
, , N
and CC N
the DT N
proportion NN N
of IN N
patients NNS N
in IN N
the DT N
withdrawal NN N
arm NN N
who WP N
relapsed VBD N
during IN N
the DT N
study NN N
Low JJ N
disease NN N
state NN N
was VBD N
defined VBN N
by IN N
minimal JJ N
disease NN N
activity NN N
criteria NNS N
( ( N
MDA NNP N
) ) N
, , N
and CC N
relapse NN N
by IN N
failure NN N
to TO N
achieve VB N
these DT N
criteria NNS N
Patients NNS N
in IN N
the DT N
withdrawal NN N
group NN N
underwent VBD N
a DT N
phased JJ N
withdrawal NN N
of IN N
medication NN N
where WRB N
the DT N
last JJ N
treatment NN N
added VBD N
was VBD N
the DT N
first JJ N
withdrawn NN N
Assessments NNS N
were VBD N
monthly RB N
for IN N
3 CD N
months NNS N
before IN N
study NN N
exit NN N
Seventy-two JJ 3_p
patients NNS N
were VBD N
invited VBN N
to TO N
participate VB N
, , N
of IN N
which WDT N
57 CD 3_p
were VBD N
found VBN N
to TO N
be VB N
eligible JJ N
Twenty-six NNP N
( ( N
36.1 CD N
% NN N
) ) N
subsequently RB N
attended VBD N
the DT N
screening JJ N
visit NN N
but CC N
9 CD N
failed VBD N
eligibility NN N
criteria NNS N
so RB N
that IN N
17 CD N
patients NNS N
( ( N
29.8 CD N
% NN N
of IN N
the DT N
57 CD N
eligible JJ N
patients NNS N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
18.4 CD N
, , N
43.4 CD N
% NN N
) ) N
were VBD N
randomised VBN N
at IN N
a DT N
ratio NN N
of IN N
2:1 CD N
in IN N
favour NN N
of IN N
the DT N
withdrawal NN N
arm NN N
( ( N
11 CD N
withdrawals NNS N
, , N
6 CD N
standard NN N
care NN N
) ) N
Six CD N
patients NNS N
experienced VBD N
a DT N
flare NN N
, , N
all DT N
of IN N
whom WP N
were VBD N
in IN N
the DT N
withdrawal NN N
arm NN N
( ( N
relapse JJ N
rate NN N
54.6 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
23.4 CD N
, , N
83.3 CD N
% NN N
) ) N
Four CD N
of IN N
the DT N
flares NNS N
were VBD N
apparent JJ N
from IN N
visit NN N
3 CD N
( ( N
8 CD N
weeks NNS N
after IN N
starting VBG N
withdrawal NN N
) ) N
Given VBN N
the DT N
high JJ N
relapse NN N
rate NN N
, , N
an DT N
alternative JJ N
trial NN N
design NN N
of IN N
partial JJ N
treatment NN N
withdrawal NN N
, , N
possibly RB N
including VBG N
a DT N
patient JJ N
preference NN N
arm NN N
, , N
is VBZ N
recommended VBN N
-DOCSTART- -X- O O 17393618

Effects NNS N
of IN N
electro-acupuncture NN N
on IN N
T NNP N
cell NN N
subpopulations NNS N
, , N
NK NNP N
activity NN N
, , N
humoral JJ N
immunity NN N
and CC N
leukocyte NN N
count NN N
in IN N
patients NNS N
undergoing JJ N
chemotherapy NN 4_p
OBJECTIVE UH N
To TO N
observe VB N
the DT N
effects NNS N
of IN N
electro-acupuncture NN N
on IN N
T NNP N
cell NN N
subpopulations NNS N
, , N
natural JJ N
killer NN N
cell NN N
( ( N
NK NNP N
) ) N
activity NN N
, , N
humoral JJ N
immunity NN N
and CC N
leukocyte NN N
count NN N
in IN N
patients NNS N
undergoing JJ N
chemotherapy NN 4_p
METHODS NNP N
Electro-acupuncture NN N
was VBD N
added VBN N
for IN N
patients NNS N
undergoing JJ N
chemotherapy NN 4_p
Tests NNS N
were VBD N
done VBN N
on IN N
T NNP N
cell NN N
subpopulations NNS N
, , N
NK NNP N
activity NN N
, , N
humoral JJ N
immunity NN N
and CC N
leukocyte JJ N
count NN N
before IN N
treatment NN N
and CC N
after IN N
4 CD N
courses NNS N
of IN N
treatment NN N
RESULTS NNP N
After IN N
4 CD N
courses NNS N
of IN N
treatment NN N
with IN N
chemotherapy NN N
and CC N
electro-acupuncture NN N
, , N
no DT N
obvious JJ N
changes NNS N
were VBD N
found VBN N
in IN N
T NNP N
cell NN N
subpopulations NNS N
, , N
NK NNP N
activity NN N
, , N
humoral JJ N
immunity NN N
and CC N
leukocyte NN N
count NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
as IN N
compared VBN N
with IN N
those DT N
before IN N
treatment NN N
Patients NNS N
undergoing VBG N
chemotherapy NN N
combined VBN N
with IN N
electro-acupuncture NN N
showed VBD N
obviously RB N
higher JJR N
leukocyte NN N
count NN N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
given VBN N
no DT N
leukogenic JJ N
drugs NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
CONCLUSION NNP N
Electro-acupuncture NN N
may MD N
reduce VB N
immunologic JJ N
damage NN N
caused VBN N
by IN N
chemotherapy NN N
, , N
thus RB N
it PRP N
can MD N
be VB N
used VBN N
as IN N
the DT N
auxiliary JJ N
therapy NN N
for IN N
patients NNS N
undergoing JJ N
chemotherapy NN 4_p
-DOCSTART- -X- O O 9935021

Morphological JJ N
onset NN N
and CC N
early JJ N
diagnosis NN N
in IN N
apical JJ 4_p
hypertrophic JJ 4_p
cardiomyopathy NN 4_p
: : 4_p
a DT N
long JJ N
term NN N
analysis NN N
with IN N
nuclear JJ N
magnetic JJ N
resonance NN N
imaging NN N
OBJECTIVES VB N
A DT N
long-term JJ N
follow-up NN N
study NN N
with IN N
nuclear JJ N
magnetic JJ N
resonance NN N
( ( N
NMR NNP N
) ) N
imaging NN N
was VBD N
undertaken VBN N
to TO N
detect VB N
the DT N
morphological JJ N
onset NN N
and CC N
to TO N
establish VB N
the DT N
early JJ N
diagnosis NN N
in IN N
apical JJ N
hypertrophic JJ N
cardiomyopathy NN N
( ( N
HCM NNP N
) ) N
BACKGROUND VB N
A DT N
spadelike JJ N
configuration NN N
on IN N
left JJ N
ventriculogram NN N
( ( N
LVG NNP N
) ) N
is VBZ N
regarded VBN N
as IN N
a DT N
diagnostic JJ N
criterion NN N
for IN N
the DT N
classical JJ N
apical JJ N
HCM NNP N
There EX N
also RB N
exists VBZ N
a DT N
segmented JJ N
hypertrophy NN N
at IN N
the DT N
apical JJ N
level NN N
without IN N
indicating VBG N
the DT N
spadelike NN N
features NNS N
( ( N
a DT N
nonspade NN N
configuration NN N
) ) N
To TO N
detect VB N
the DT N
hypertrophied JJ N
myocardium NN N
of IN N
the DT N
nonspade JJ N
configuration NN N
, , N
circumferential JJ N
scrutiny NN N
of IN N
the DT N
apex NN N
is VBZ N
required VBN N
Although IN N
both DT N
configurations NNS N
can MD N
be VB N
underlying JJ N
causes NNS N
of IN N
giant JJ N
negative JJ N
T NNP N
waves NNS N
, , N
etiological JJ N
relationship NN N
between IN N
the DT N
two CD N
is VBZ N
not RB N
clarified VBN N
METHODS NNP N
The DT N
criteria NN N
for IN N
the DT N
spadelike NN N
configuration NN N
defined VBN N
on IN N
left JJ N
ventricular JJ N
short-axis JJ N
NMR NNP N
images NNS N
were VBD N
as IN N
follows VBZ N
: : N
( ( N
apical JJ N
maximal NN N
thickness NN N
> NN N
or CC N
= $ N
15 CD N
mm NN N
) ) N
, , N
( ( N
apical JJ N
anterior NN N
thickness NN N
over IN N
basal JJ N
anterior JJ N
thickness NN N
> NN N
or CC N
= VB N
1.3 CD N
) ) N
and CC N
( ( N
apical JJ N
posterior NN N
thickness NN N
over IN N
basal JJ N
posterior JJ N
thickness NN N
> NN N
or CC N
=1.3 NN N
) ) N
Thirteen JJ 4_p
patients NNS 4_p
who WP 4_p
had VBD 4_p
predominant JJ 4_p
hypertrophy NN 4_p
( ( 4_p
> CD 4_p
or CC 4_p
= VB 4_p
15 CD 4_p
mm NN 4_p
) ) 4_p
at IN 4_p
the DT 4_p
apical JJ 4_p
level NN 4_p
without IN 4_p
the DT 4_p
spadelike NN 4_p
configuration NN 4_p
underwent JJ 4_p
NMR NNP 4_p
imaging VBG 4_p
twice RB 4_p
before RB 4_p
and CC 4_p
after IN 4_p
54+/-10 JJ 4_p
months NNS 4_p
' POS 4_p
follow-up NN 4_p
RESULTS NNP N
Apical NNP N
hypertrophy NN N
that WDT N
had VBD N
been VBN N
confined VBN N
to TO N
the DT N
lateral JJ N
wall NN N
in IN N
four CD N
, , N
the DT N
anterior-lateral JJ N
wall NN N
in IN N
two CD N
, , N
and CC N
the DT N
septal-anterior JJ N
wall NN N
in IN N
one CD N
developed NN N
to TO N
become VB N
circumferential JJ N
hypertrophy NN N
that WDT N
fulfilled VBD N
the DT N
criteria NNS N
for IN N
the DT N
spadelike NN N
configuration NN N
after IN N
the DT N
follow-up JJ N
period NN N
CONCLUSIONS VB N
The DT N
spadelike NN N
configuration NN N
can MD N
begin VB N
with IN N
the DT N
nonspade JJ N
configuration NN N
and CC N
therefore NN N
, , N
both DT N
can MD N
constitute VB N
a DT N
single JJ N
disease NN N
entity NN N
of IN N
apical JJ N
HCM NNP N
The DT N
early JJ N
diagnosis NN N
of IN N
apical JJ N
HCM NNP N
can MD N
be VB N
achieved VBN N
by IN N
identifying VBG N
the DT N
hypertrophy NN N
frequently RB N
confined VBN N
to TO N
the DT N
lateral JJ N
wall NN N
at IN N
the DT N
apical JJ N
level NN N
-DOCSTART- -X- O O 19779611

Cost-effectiveness NN N
of IN N
a DT N
telephone-delivered JJ N
intervention NN N
for IN N
physical JJ 4_p
activity NN 4_p
and CC 4_p
diet NN 4_p
BACKGROUND NNP N
Given NNP N
escalating VBG N
rates NNS N
of IN N
chronic JJ N
disease NN N
, , N
broad-reach NN N
and CC N
cost-effective JJ N
interventions NNS N
to TO N
increase VB N
physical JJ N
activity NN N
and CC N
improve VB N
dietary JJ N
intake NN N
are VBP N
needed VBN N
The DT N
cost-effectiveness NN N
of IN N
a DT N
Telephone NNP N
Counselling NNP N
intervention NN N
to TO N
improve VB N
physical JJ N
activity NN N
and CC N
diet NN N
, , N
targeting VBG N
adults NNS 1_p
with IN N
established VBN 4_p
chronic JJ 4_p
diseases NNS 4_p
in IN N
a DT N
low JJ 4_p
socio-economic JJ 4_p
area NN 4_p
of IN 4_p
a DT 4_p
major JJ 4_p
Australian JJ 4_p
city NN 4_p
was VBD N
examined VBN N
METHODOLOGY/PRINCIPAL NNP N
FINDINGS NNP N
A NNP N
cost-effectiveness NN N
modelling NN N
study NN N
using VBG N
data NNS N
collected VBN N
between IN N
February NNP N
2005 CD N
and CC N
November NNP N
2007 CD N
from IN N
a DT N
cluster-randomised JJ N
trial NN N
that WDT N
compared VBN N
Telephone NNP N
Counselling NNP N
with IN N
a DT N
" JJ N
Usual NNP N
Care NNP N
" NNP N
( ( N
brief JJ N
intervention NN N
) ) N
alternative NN N
Economic JJ N
outcomes NNS N
were VBD N
assessed VBN N
using VBG N
a DT N
state-transition NN N
Markov NNP N
model NN N
, , N
which WDT N
predicted VBD N
the DT N
progress NN N
of IN N
participants NNS N
through IN N
five CD N
health NN N
states NNS N
relating VBG N
to TO N
physical JJ N
activity NN N
and CC N
dietary JJ N
improvement NN N
, , N
for IN N
ten CD N
years NNS N
after IN N
recruitment NN N
The DT N
costs NNS N
and CC N
health NN N
benefits NNS N
of IN N
Telephone NNP N
Counselling NNP N
, , N
Usual NNP N
Care NNP N
and CC N
an DT N
existing VBG N
practice NN N
( ( N
Real NNP N
Control NNP N
) ) N
group NN N
were VBD N
compared VBN N
Telephone CD N
Counselling VBG N
compared VBN N
to TO N
Usual NNP N
Care NNP N
was VBD N
not RB N
cost-effective JJ N
( ( N
$ $ N
78,489 CD N
per IN N
quality NN N
adjusted VBN N
life NN N
year NN N
gained VBN N
) ) N
However RB N
, , N
the DT N
Usual NNP N
Care NNP N
group NN N
did VBD N
not RB N
represent VB N
existing VBG N
practice NN N
and CC N
is VBZ N
not RB N
a DT N
useful JJ N
comparator NN N
for IN N
decision NN N
making NN N
Comparing VBG N
Telephone CD N
Counselling VBG N
outcomes NNS N
to TO N
existing VBG N
practice NN N
( ( N
Real NNP N
Control NNP N
) ) N
, , N
the DT N
intervention NN N
was VBD N
found VBN N
to TO N
be VB N
cost-effective JJ N
( ( N
$ $ N
29,375 CD N
per IN N
quality NN N
adjusted VBN N
life NN N
year NN N
gained VBN N
) ) N
Usual JJ N
Care NNP N
( ( N
brief JJ N
intervention NN N
) ) N
compared VBN N
to TO N
existing VBG N
practice NN N
( ( N
Real NNP N
Control NNP N
) ) N
was VBD N
also RB N
cost-effective JJ N
( ( N
$ $ N
12,153 CD N
per IN N
quality NN N
adjusted VBN N
life NN N
year NN N
gained VBN N
) ) N
CONCLUSIONS/SIGNIFICANCE VB N
This DT N
modelling NN N
study NN N
shows VBZ N
that IN N
a DT N
decision NN N
to TO N
adopt VB N
a DT N
Telephone CD N
Counselling VBG N
program NN N
over IN N
existing VBG N
practice NN N
( ( N
Real NNP N
Control NNP N
) ) N
is VBZ N
likely JJ N
to TO N
be VB N
cost-effective JJ N
Choosing VBG N
the DT N
'Usual JJ N
Care NNP N
' POS N
brief NN N
intervention NN N
over IN N
existing VBG N
practice NN N
( ( N
Real NNP N
Control NNP N
) ) N
shows VBZ N
a DT N
lower JJR N
cost NN N
per IN N
quality NN N
adjusted VBN N
life NN N
year NN N
, , N
but CC N
the DT N
lack NN N
of IN N
supporting VBG N
evidence NN N
for IN N
efficacy NN N
or CC N
sustainability NN N
is VBZ N
an DT N
important JJ N
consideration NN N
for IN N
decision NN N
makers NNS N
The DT N
economics NNS N
of IN N
behavioural JJ N
approaches NNS N
to TO N
improving VBG N
health NN N
must MD N
be VB N
made VBN N
explicit JJ N
if IN N
decision NN N
makers NNS N
are VBP N
to TO N
be VB N
convinced VBN N
that IN N
allocating VBG N
resources NNS N
toward IN N
such JJ N
programs NNS N
is VBZ N
worthwhile JJ N
TRIAL NNP N
REGISTRATION NNP N
This DT N
paper NN N
uses VBZ N
data NNS N
collected VBN N
in IN N
a DT N
previous JJ N
clinical JJ N
trial NN N
registered VBD N
at IN N
the DT N
Australian JJ N
Clinical NNP N
Trials NNP N
Registry NNP N
, , N
Australian JJ N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
: : N
Anzcrt.org.au NNP N
ACTRN012607000195459 NNP N
-DOCSTART- -X- O O 24012722

Why WRB N
does VBZ N
lag NN N
affect VB N
the DT N
durability NN N
of IN N
memory-based JJ 4_p
automaticity NN 4_p
: : 4_p
loss NN N
of IN N
memory NN N
strength NN N
or CC N
interference NN N
? . N
In IN N
Rickard NNP N
, , N
Lau NNP N
, , N
and CC N
Pashler NNP N
's POS N
( ( N
2008 CD N
) ) N
investigation NN N
of IN N
the DT N
lag NN N
effect NN N
on IN N
memory-based JJ N
automaticity NN N
, , N
response NN N
times NNS N
were VBD N
faster RBR N
and CC N
proportion NN N
of IN N
trials NNS N
retrieved VBN N
was VBD N
higher JJR N
at IN N
the DT N
end NN N
of IN N
practice NN N
for IN N
short JJ N
lag NN N
items NNS N
than IN N
for IN N
long JJ N
lag NN N
items NNS N
However RB N
, , N
during IN N
testing VBG N
after IN N
a DT N
delay NN N
, , N
response NN N
times NNS N
were VBD N
slower JJR N
and CC N
proportion NN N
of IN N
trials NNS N
retrieved VBN N
was VBD N
lower JJR N
for IN N
short JJ N
lag NN N
items NNS N
than IN N
for IN N
long JJ N
lag NN N
items NNS N
The DT N
current JJ N
study NN N
investigated VBD N
the DT N
extent NN N
to TO N
which WDT N
the DT N
lag NN N
effect NN N
on IN N
the DT N
durability NN N
of IN N
memory-based JJ N
automaticity NN N
is VBZ N
due JJ N
to TO N
interference VB N
or CC N
to TO N
the DT N
loss NN N
of IN N
memory NN N
strength NN N
with IN N
time NN N
Participants NNS 4_p
repeatedly RB N
practiced VBD N
alphabet JJ N
subtraction NN N
items NNS N
in IN N
short JJ N
lag NN N
and CC N
long JJ N
lag NN N
conditions NNS N
After IN N
practice NN N
, , N
half NN N
of IN N
the DT N
participants NNS N
were VBD N
immediately RB N
tested VBN N
and CC N
the DT N
other JJ N
half NN N
were VBD N
tested VBN N
after IN N
a DT N
7-day JJ N
delay NN N
Results VB N
indicate JJ N
that IN N
the DT N
lag NN N
effect NN N
on IN N
the DT N
durability NN N
of IN N
memory-based JJ N
automaticity NN N
is VBZ N
primarily RB N
due JJ N
to TO N
interference VB N
We PRP N
discuss VBP N
potential JJ N
modification NN N
of IN N
current JJ N
memory-based JJ N
processing NN N
theories NNS N
to TO N
account VB N
for IN N
these DT N
effects NNS N
-DOCSTART- -X- O O 23108780

Effects NNS N
of IN N
strontium NN N
on IN N
the DT N
quality NN N
of IN N
bone NN N
apatite JJ N
crystals NNS N
: : N
a DT N
paired JJ N
biopsy NN N
study NN N
in IN N
postmenopausal JJ 4_p
osteoporotic JJ 4_p
women NNS 2_p
UNLABELLED NN N
In IN N
paired JJ N
biopsies NNS 4_p
of IN N
osteoporotic JJ 4_p
women NNS 2_p
treated VBN N
with IN N
either DT N
strontium NN N
ranelate NN N
or CC N
a DT N
placebo NN N
for IN N
36 CD N
months NNS N
, , N
characteristics NNS N
of IN N
bone NN N
apatite JJ N
crystals NNS N
were VBD N
not RB N
influenced VBN N
by IN N
the DT N
presence NN N
of IN N
strontium NN N
The DT N
mean JJ N
rate NN N
of IN N
substitutions NNS N
of IN N
calcium NN N
by IN N
strontium NN N
ions NNS N
was VBD N
4.5 CD N
% NN N
INTRODUCTION NNP N
The DT N
potential JJ N
effect NN N
of IN N
strontium NN N
( ( N
Sr NNP N
) ) N
on IN N
bone NN N
apatite JJ N
crystals NNS N
was VBD N
investigated VBN N
in IN N
paired JJ N
biopsies NNS N
of IN N
osteoporotic JJ 4_p
women NNS 2_p
treated VBN N
with IN N
either DT N
strontium NN N
ranelate NN N
( ( N
SrRan NNP N
) ) N
or CC N
a DT N
placebo NN N
for IN N
36 CD N
months NNS N
METHODS NNP N
In IN N
ten NN 3_p
paired JJ N
biopsies NNS N
, , N
crystallinity NN N
, , N
apparent JJ N
length NN N
and CC N
width/thickness NN N
of IN N
crystals NNS N
, , N
interplanar NN N
distances NNS N
, , N
and CC N
lattice JJ N
parameters NNS N
of IN N
unit NN N
cells NNS N
were VBD N
assessed VBN N
by IN N
X-ray JJ N
diffraction NN N
and CC N
selected VBN N
area NN N
electron NN N
diffraction NN N
RESULTS VB N
All PDT N
these DT N
parameters NNS N
, , N
reflecting VBG N
crystal NN N
and CC N
unit NN N
cell NN N
characteristics NNS N
, , N
were VBD N
not RB N
influenced VBN N
by IN N
the DT N
presence NN N
of IN N
Sr NNP N
and CC N
were VBD N
similar JJ N
in IN N
SrRan NNP N
and CC N
placebo NN N
groups NNS N
after IN N
36 CD N
months NNS N
of IN N
treatment NN N
The DT N
mean JJ N
rate NN N
of IN N
substitutions NNS N
of IN N
calcium NN N
by IN N
Sr NNP N
ions NNS N
was VBD N
4.5 CD N
% NN N
CONCLUSION NNP N
Overall NNP N
, , N
the DT N
quality NN N
of IN N
bone NN N
apatite JJ N
crystals NNS N
was VBD N
maintained VBN N
after IN N
36 CD N
months NNS N
of IN N
treatment NN N
with IN N
SrRan NNP N
-DOCSTART- -X- O O 3602327

The DT N
effects NNS N
of IN N
amantadine NN N
vs. FW N
trihexyphenidyl NN N
on IN N
memory NN N
in IN N
elderly JJ 1_p
normal JJ N
volunteers NNS N
-DOCSTART- -X- O O 2232625

The DT N
influence NN N
of IN N
penbutolol NN N
and CC N
placebo NN N
on IN N
blood NN N
sugar NN N
levels NNS N
and CC N
insulin NN N
consumption NN N
in IN N
the DT N
glucose-controlled JJ N
insulin NN N
infusion NN N
system NN N
( ( N
" JJ N
artificial JJ N
endocrine NN N
pancreas NNS N
" VBP N
) ) N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
influence NN N
of IN N
40 CD N
mg NN N
of IN N
the DT N
beta-blocker NN N
penbutolol NN N
( ( N
Betapressin NNP N
TM NNP N
; : N
Hoechst NNP N
Ltd. NNP N
, , N
Frankfurt/Main NNP N
) ) N
in IN N
comparison NN N
to TO N
placebo VB N
on IN N
the DT N
insulin NN N
consumption NN N
on IN N
the DT N
blood NN N
sugar NN N
profile NN N
in IN N
twelve JJ N
insulin-dependent JJ N
diabetes NNS N
( ( N
IDDM NNP N
) ) N
patients NNS N
The DT N
patients NNS N
were VBD N
treated VBN N
with IN N
penbutolol NN N
and CC N
placebo NN N
for IN N
a DT N
period NN N
of IN N
three CD N
days NNS N
, , N
and CC N
then RB N
were VBD N
examined VBN N
with IN N
the DT N
help NN N
of IN N
the DT N
glucose-controlled JJ N
insulin NN N
infusion NN N
system NN N
The DT N
blood NN N
sugar NN N
profile NN N
and CC N
insulin NN N
consumption NN N
over IN N
a DT N
24 CD N
hour NN N
period NN N
was VBD N
not RB N
affected VBN N
by IN N
either DT N
penbutolol NN N
or CC N
placebo NN N
, , N
nor CC N
could MD N
any DT N
changes NNS N
be VB N
measured VBN N
in IN N
these DT N
parameters NNS N
when WRB N
measured VBN N
after IN N
food NN N
intake NN N
After IN N
a DT N
submaximal JJ N
exercise NN N
load NN N
on IN N
the DT N
bicycle NN N
ergometer NN N
( ( N
1 CD N
watt NN N
per IN N
kg NN N
body NN N
weight VBD N
) ) N
following VBG N
an DT N
evening JJ N
meal NN N
, , N
no DT N
difference NN N
could MD N
be VB N
observed VBN N
between IN N
penbutolol NN N
and CC N
placebo NN N
in IN N
the DT N
above-mentioned JJ N
parameters NNS N
The DT N
same JJ N
was VBD N
also RB N
true JJ N
for IN N
hormonal JJ N
parameters NNS N
as IN N
STH NNP N
, , N
ACTH NNP N
, , N
cortisol NN N
, , N
and CC N
catecholamines NNS N
These DT N
findings NNS N
demonstrated VBD N
that IN N
medication NN N
of IN N
penbutolol NN N
over IN N
a DT N
three-day JJ N
period NN N
has VBZ N
no DT N
influence NN N
on IN N
the DT N
baseline NN N
blood NN N
sugar NN N
profile NN N
and CC N
insulin NN N
consumption NN N
or CC N
on IN N
insulin NN N
consumption NN N
after IN N
food NN N
intake NN N
during IN N
rest NN N
and CC N
physical JJ N
exercise NN N
-DOCSTART- -X- O O 12463729

Pharmacokinetic JJ N
and CC N
safety NN N
assessments NNS N
of IN N
galantamine NN N
and CC N
risperidone NN N
after IN N
the DT N
two CD N
drugs NNS N
are VBP N
administered VBN N
alone RB N
and CC N
together RB N
To TO N
explore VB N
the DT N
steady-state JJ N
pharmacokinetic JJ N
profile NN N
after IN N
coadministration NN N
of IN N
galantamine NN N
and CC N
risperidone NN N
, , N
an DT N
open-label JJ N
, , N
randomized VBN N
, , N
single-center JJ N
, , N
two-way JJ N
crossover NN N
drug-drug JJ N
interaction NN N
study NN N
was VBD N
conducted VBN N
in IN N
16 CD N
healthy JJ N
elderly JJ N
subjects NNS N
, , N
ages VBZ N
60 CD N
years NNS N
and CC N
older JJR N
The DT N
results NNS N
showed VBD N
that IN N
risperidone NN N
, , N
when WRB N
administered VBN N
with IN N
galantamine NN N
, , N
did VBD N
not RB N
change VB N
the DT N
bioavailability NN N
of IN N
galantamine NN N
at IN N
steady JJ N
state NN N
In IN N
addition NN N
, , N
systemic JJ N
exposure NN N
of IN N
risperidone NN N
active JJ N
moiety NN N
( ( N
risperidone JJ N
plus CC N
9-hydroxyrisperidone CD N
) ) N
, , N
the DT N
most RBS N
clinically RB N
relevant JJ N
component NN N
of IN N
risperidone NN N
treatment NN N
, , N
was VBD N
not RB N
affected VBN N
by IN N
galantamine JJ N
coadministration NN N
, , N
while IN N
systemic JJ N
exposure NN N
was VBD N
increased VBN N
by IN N
approximately RB N
10 CD N
% NN N
for IN N
risperidone NN N
and CC N
decreased VBN N
by IN N
about IN N
10 CD N
% NN N
for IN N
9-hydroxyrisperidone CD N
( ( N
active JJ N
metabolite NN N
of IN N
risperidone NN N
) ) N
Galantamine NNP N
and CC N
risperidone NN N
were VBD N
both DT N
safe JJ N
and CC N
well RB N
tolerated VBN N
administered VBN N
either CC N
alone RB N
or CC N
together RB N
Thus NNP N
, , N
no DT N
dose JJ N
adjustment NN N
for IN N
either DT N
risperidone NN N
orgalantamine NN N
is VBZ N
necessary JJ N
when WRB N
these DT N
two CD N
drugs NNS N
are VBP N
administered VBN N
together RB N
in IN N
the DT N
dose JJ N
range NN N
evaluated VBD N
-DOCSTART- -X- O O 21931984

Locomoting-to-reach NN N
: : N
information NN N
variables NNS N
and CC N
control NN N
strategies NNS N
for IN N
nested JJ N
actions NNS N
Locomoting-to-reach NNP N
is VBZ N
a DT N
basic JJ N
perception/action NN N
behavior NN N
that WDT N
requires VBZ N
visual JJ N
information NN N
for IN N
the DT N
control NN N
of IN N
both DT N
locomotion NN N
and CC N
reaching VBG N
components NNS N
We PRP N
investigated VBD N
the DT N
visual JJ N
information NN N
and CC N
the DT N
control NN N
strategies NNS N
used VBN N
to TO N
guide VB N
both PDT N
the DT N
head NN N
and CC N
the DT N
hand NN N
on IN N
approach NN N
to TO N
a DT N
target NN N
in IN N
a DT N
locomotion-to-reach JJ N
task NN N
In IN N
this DT N
study NN N
, , N
participants NNS 4_p
were VBD 4_p
required VBN 4_p
to TO 4_p
locomote VB 4_p
in IN 4_p
the DT 4_p
dark NN 4_p
to TO 4_p
a DT 4_p
lit NN 4_p
target NN 4_p
in IN 4_p
three CD 4_p
different JJ 4_p
conditions NNS 4_p
: : 4_p
monocular JJ 4_p
vision/target NN 4_p
with IN 4_p
image NN 4_p
size NN 4_p
, , 4_p
binocular JJ 4_p
vision/target NN 4_p
with IN 4_p
image NN 4_p
size NN 4_p
, , 4_p
and CC 4_p
binocular JJ 4_p
vision/point-light JJ 4_p
target NN 4_p
( ( 4_p
without IN 4_p
image NN 4_p
size NN 4_p
) ) 4_p
In IN N
task NN N
one CD N
, , N
participants NNS N
brought VBD N
their PRP$ N
eyes NNS N
to TO N
the DT N
target NN N
In IN N
task NN N
two CD N
, , N
participants NNS N
brought VBD N
their PRP$ N
outstretched JJ N
hand NN N
to TO N
the DT N
target NN N
Movement JJ N
trajectories NNS N
for IN N
both DT N
tasks NNS N
were VBD N
analyzed VBN N
Results NNP N
show VBP N
that IN N
participants NNS N
were VBD N
significantly RB N
more RBR N
accurate JJ N
when WRB N
binocular JJ N
information NN N
was VBD N
present JJ N
In IN N
both DT N
tasks NNS N
, , N
participants NNS N
were VBD N
found VBN N
to TO N
use VB N
a DT N
proportional JJ N
rate NN N
control NN N
strategy NN N
rather RB N
than IN N
a DT N
constant JJ N
τ NN N
strategy NN N
In IN N
the DT N
walk-to-reach NN N
task NN N
, , N
they PRP N
used VBD N
monocular JJ N
and/or NN N
binocular JJ N
τ NN N
information NN N
to TO N
guide VB N
the DT N
head NN N
and CC N
then RB N
switched VBD N
to TO N
using VBG N
relative JJ N
disparity NN N
τ NN N
to TO N
guide VB N
the DT N
hand NN N
to TO N
final JJ N
target NN N
acquisition NN N
, , N
switching VBG N
when WRB N
the DT N
hand NN N
centric JJ N
τ NN N
became VBD N
less JJR N
than IN N
the DT N
head NN N
centric JJ N
τ. NNP N
Dynamical NNP N
models NNS N
of IN N
the DT N
information NN N
and CC N
control NN N
strategies NNS N
were VBD N
used VBN N
to TO N
perform VB N
simulations NNS N
that WDT N
were VBD N
found VBN N
to TO N
fit VB N
the DT N
data NN N
well RB N
The DT N
conclusion NN N
is VBZ N
that IN N
proportional JJ N
rate NN N
control NN N
is VBZ N
used VBN N
sequentially RB N
with IN N
head NN N
centric NN N
, , N
then RB N
hand-centric JJ N
τ-based JJ N
information NN N
, , N
using VBG N
at IN N
each DT N
moment NN N
the DT N
τ NN N
with IN N
the DT N
smallest JJS N
value NN N
-DOCSTART- -X- O O 10080319

Masticatory JJ N
performance NN N
and CC N
chewing VBG N
experience NN N
with IN N
implant-retained JJ 4_p
mandibular JJ 4_p
overdentures NNS 4_p
The DT N
relationship NN N
between IN N
masticatory NN N
performance NN N
and CC N
chewing VBG N
experience NN N
has VBZ N
not RB N
yet RB N
been VBN N
explored VBN N
for IN N
patients NNS N
with IN N
implant-retained JJ 4_p
overdentures NNS 4_p
Although IN N
many JJ N
relationships NNS N
have VBP N
been VBN N
found VBN N
between IN N
parameters NNS N
of IN N
objective JJ N
and CC N
subjective JJ N
oral JJ N
function NN N
, , N
the DT N
structure NN N
of IN N
these DT N
relationships NNS N
remain VBP N
unclear JJ N
Therefore RB N
, , N
we PRP N
studied VBD N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
the DT N
relationship NN N
between IN N
the DT N
comminution NN N
of IN N
an DT N
artificial JJ N
test NN N
food NN N
, , N
i.e NN N
masticatory JJ N
performance NN N
, , N
and CC N
the DT N
subjective JJ N
chewing NN N
experience NN N
The DT N
trial NN N
involved VBD N
a DT N
comparison NN N
between IN N
two CD N
groups NNS N
receiving VBG N
implant JJ N
treatment NN N
and CC N
one CD N
group NN N
receiving VBG N
conventional JJ N
complete JJ N
dentures NNS N
( ( N
CD NN N
) ) N
The DT N
implant JJ N
treatment NN N
involved VBN N
either CC N
a DT N
mainly RB N
implant-supported JJ N
mandibular JJ N
overdenture NN N
on IN N
a DT N
transmandibular JJ N
implant NN N
( ( N
TMI NNP N
) ) N
or CC N
an DT N
implant-tissue-supported JJ N
mandibular JJ N
overdenture NN N
on IN N
two CD N
IMZ JJ N
implants NNS N
( ( N
IMZ NNP N
) ) N
Masticatory JJ N
performance NN N
as RB N
well RB N
as IN N
chewing VBG N
experience NN N
were VBD N
substantially RB N
better JJR N
for IN N
the DT N
implant-retained JJ N
overdentures NNS N
compared VBN N
with IN N
the DT N
complete JJ N
denture NN N
group NN N
No DT N
significant JJ N
differences NNS N
emerged VBD N
between IN N
the DT N
TMI NNP N
and CC N
the DT N
IMZ NNP N
group NN N
A DT N
multiple JJ N
regression NN N
analysis NN N
did VBD N
not RB N
provide VB N
any DT N
comprehensibility NN N
in IN N
the DT N
relationship NN N
between IN N
masticatory NN N
performance NN N
and CC N
the DT N
variables NNS N
of IN N
chewing VBG N
experience NN N
In IN N
the DT N
linear JJ N
structural JJ N
relation NN N
analysis NN N
( ( N
LISREL NNP N
) ) N
no DT N
direct JJ N
relationship NN N
was VBD N
found VBN N
between IN N
masticatory JJ N
performance NN N
and CC N
functional JJ N
complaints NNS N
mandibular JJ N
denture NN N
The DT N
results NNS N
show VBP N
that IN N
an DT N
improvement NN N
in IN N
masticatory JJ N
performance NN N
does VBZ N
not RB N
imply VB N
the DT N
same JJ N
improvement NN N
in IN N
chewing VBG N
experience NN N
and CC N
vice NN N
versa NN N
-DOCSTART- -X- O O 11828556

Carpal NNP N
tunnel NN N
release NN N
by IN N
limited JJ N
palmar NN N
incision NN N
vs IN N
traditional JJ N
open JJ N
technique NN N
: : N
randomized VBN N
controlled JJ N
trial NN N
AIM NNP N
To TO N
compare VB N
a DT N
limited JJ N
palmar NN N
incision NN N
for IN N
carpal JJ N
tunnel NN N
release NN N
( ( N
CTR NNP N
) ) N
with IN N
a DT N
traditional JJ N
open JJ N
technique NN N
, , N
which WDT N
is VBZ N
still RB N
considered VBN N
the DT N
gold JJ N
standard NN N
METHODS NNP N
Seventy-two JJ 3_p
patients NNS 3_p
with IN 4_p
a DT 4_p
carpal JJ 4_p
tunnel NN 4_p
syndrome NN 4_p
were VBD 4_p
individually RB 4_p
randomized VBN 4_p
into IN 4_p
the DT 4_p
trial NN 4_p
( ( 4_p
limited JJ 4_p
incision NN 4_p
CTR NNP 4_p
) ) 4_p
( ( 4_p
n=36 JJ 4_p
) ) 4_p
and CC 4_p
control NN 4_p
group NN 4_p
( ( 4_p
traditional JJ 4_p
technique NN 4_p
CTR NNP 4_p
) ) 4_p
( ( 4_p
n=36 JJ 4_p
) ) 4_p
In IN N
the DT N
trial NN 4_p
group NN 4_p
, , 4_p
skin FW 4_p
incision NN 4_p
parallel NN 4_p
to TO 4_p
the DT 4_p
thenar NN 4_p
crease NN 4_p
was VBD 4_p
made VBN 4_p
up RP 4_p
to TO 4_p
2.5 CD 4_p
cm NN 4_p
in IN 4_p
length NN 4_p
, , 4_p
under IN 4_p
an DT 4_p
operating NN 4_p
microscope NN 4_p
and CC 4_p
endoscopic JJ 4_p
transillumination NN 4_p
Skin NNP N
incision NN N
in IN N
the DT N
control NN N
group NN N
began VBD N
at IN N
the DT N
distal JJ N
border NN N
of IN N
the DT N
carpal JJ N
ligament NN N
, , N
followed VBD N
the DT N
longitudinal JJ N
crease NN N
of IN N
the DT N
palm NN N
, , N
and CC N
crossed VBD N
the DT N
base NN N
of IN N
the DT N
palm NN N
in IN N
a DT N
zigzag JJ N
fashion NN N
Three CD N
months NNS N
after IN N
surgery NN N
, , N
the DT N
patients NNS N
were VBD N
asked VBN N
about IN N
symptomatic JJ N
relief NN N
and CC N
intervals NNS N
between IN N
the DT N
operation NN N
and CC N
return NN N
to TO N
their PRP$ N
daily JJ N
activities NNS N
and CC N
work NN N
, , N
and CC N
examined VBD N
for IN N
scar NN N
tenderness NN N
and CC N
esthetic JJ N
outcome NN N
Distal NNP N
motor NN N
latency NN N
, , N
conduction NN N
velocity NN N
, , N
scar NN N
length NN N
, , N
scar NN N
width NN N
, , N
and CC N
operation NN N
time NN N
were VBD N
measured VBN N
RESULTS VB N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
symptomatic JJ N
relief NN N
and CC N
electrophysiological JJ N
parameters NNS N
Intervals NNS N
between IN N
the DT N
operation NN N
and CC N
return NN N
to TO N
daily JJ N
activities NNS N
( ( N
median JJ N
5 CD N
days NNS N
, , N
range VBP N
2-15 JJ N
) ) N
were VBD N
shorter JJR N
in IN N
the DT N
trial NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
median JJ N
10 CD N
days NNS N
, , N
range VBP N
2-21 JJ N
; : N
p VB N
< $ N
0.001 CD N
) ) N
, , N
as RB N
well RB N
as IN N
the DT N
intervals NNS N
between IN N
the DT N
operation NN N
and CC N
return NN N
to TO N
work VB N
( ( N
median JJ N
15 CD N
days NNS N
, , N
range VBP N
5-45 JJ N
vs NN N
median JJ N
30 CD N
days NNS N
, , N
range VBP N
10-60 JJ N
; : N
p VB N
< $ N
0.001 CD N
) ) N
Scar/pillar JJ N
tenderness NN N
, , N
scar NN N
length NN N
and CC N
width NN N
, , N
esthetic JJ N
outcome NN N
, , N
and CC N
operation NN N
time NN N
were VBD N
significantly RB N
better RBR N
in IN N
the DT N
trial NN N
group NN N
CONCLUSION NNP N
Limited NNP N
palmar NN N
incision NN N
CTR NNP N
is VBZ N
as IN N
effective JJ N
and CC N
safe JJ N
as IN N
traditional JJ N
CTR NNP N
technique NN N
, , N
but CC N
with IN N
better JJR N
postoperative JJ N
recovery NN N
and CC N
cosmetic JJ N
results NNS N
-DOCSTART- -X- O O 11748974

Fibrin NNP N
application NN N
for IN N
preventing VBG N
lymphocysts NNS N
after IN N
retroperitoneal JJ N
lymphadenectomy NN N
in IN N
patients NNS N
with IN N
gynecologic JJ 4_p
malignancies NNS 4_p
OBJECTIVE IN N
We PRP N
performed VBD N
a DT N
randomized VBN N
, , N
prospective JJ N
trial NN N
to TO N
assess VB N
the DT N
impact NN N
of IN N
fibrin JJ N
glue NN N
on IN N
the DT N
incidence NN N
of IN N
lymphocysts NNS N
after IN N
systematic JJ N
pelvic NN N
or CC N
pelvic NN N
and CC N
paraaortic JJ N
lymphadenectomy NN N
in IN N
patients NNS N
with IN N
gynecologic JJ 4_p
malignancies NNS 4_p
METHODS NNP N
Ninety-three JJ 3_p
consecutive JJ N
patients NNS N
with IN N
gynecologic JJ 4_p
pelvic JJ 4_p
malignancies NNS 4_p
who WP N
underwent VBP N
surgery NN N
including VBG N
pelvic NN N
or CC N
pelvic NN N
and CC N
paraaortic JJ N
lymphadenectomy NN N
were VBD N
randomized VBN N
during IN N
surgery NN N
to TO N
be VB N
treated VBN N
with IN N
fibrin JJ N
glue NN N
or CC N
not RB N
Serial JJ N
computed JJ N
tomography NN N
( ( N
CT NNP N
) ) N
scans NNS N
were VBD N
performed VBN N
during IN N
follow-up JJ N
CT NNP N
findings NNS N
of IN N
a DT N
smooth JJ N
and CC N
thin-walled JJ N
cavity NN N
filled VBN N
with IN N
a DT N
water-equivalent JJ N
fluid NN N
, , N
sharply RB N
demarcated VBN N
from IN N
its PRP$ N
surroundings NNS N
and CC N
without IN N
signs NNS N
of IN N
infiltration NN N
were VBD N
interpreted VBN N
as IN N
lymphocysts NNS N
RESULTS NNP N
Forty-seven JJ N
patients NNS N
( ( N
51 CD N
% NN N
) ) N
were VBD N
treated VBN N
with IN N
fibrin JJ N
glue NN N
and CC N
46 CD N
( ( N
49 CD N
% NN N
) ) N
were VBD N
not RB N
All DT N
93 CD 3_p
patients NNS N
underwent JJ N
pelvic JJ N
lymphadenectomy NN N
; : N
15 CD N
patients NNS N
( ( N
32 CD N
% NN N
) ) N
of IN N
the DT N
fibrin NN N
group NN N
and CC N
12 CD N
( ( N
26 CD N
% NN N
) ) N
of IN N
the DT N
controls NNS N
also RB N
underwent JJ N
paraaortic JJ N
lymphadenectomy NN N
We PRP N
found VBD N
no DT N
significant JJ N
differences NNS N
between IN N
patients NNS N
who WP N
received VBD N
fibrin JJ N
glue NN N
and CC N
those DT N
who WP N
did VBD N
not RB N
CONCLUSION NNP N
Intraoperative NNP N
application NN N
of IN N
fibrin JJ N
glue NN N
did VBD N
not RB N
reduce VB N
the DT N
rate NN N
of IN N
postoperative JJ N
lymphocysts NNS N
after IN N
lymphadenectomy NN N
and CC N
had VBD N
no DT N
impact NN N
on IN N
any DT N
follow-up JJ N
parameter NN N
Its PRP$ N
use NN N
seems VBZ N
not RB N
to TO N
be VB N
indicated VBN N
in IN N
systematic JJ N
gynecologic NN N
pelvic NN N
or CC N
pelvic NN N
and CC N
paraaortic JJ N
lymphadenectomy NN N
-DOCSTART- -X- O O 10682031

[ JJ N
Administration NNP N
of IN N
tobramycin JJ N
aerosols NNS N
in IN N
patients NNS 4_p
with IN 4_p
nosocomial JJ 4_p
pneumonia NN 4_p
: : N
a DT N
preliminary JJ N
study NN N
] NNP N
OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
renal JJ N
and CC N
respiratory JJ N
tolerance NN N
of IN N
aerosolized JJ N
tobramycin NN N
in IN N
intubated JJ 4_p
and CC 4_p
mechanically RB 4_p
ventilated JJ 4_p
patients NNS 4_p
with IN N
nosocomial JJ 4_p
pneumonia NN 4_p
PATIENTS NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo NN N
controlled VBD N
study NN N
Thirty-eight NNP 3_p
mechanically RB 4_p
ventilated VBD 4_p
patients NNS 4_p
with IN 4_p
documented JJ 4_p
nosocomial JJ 4_p
pneumonia NN 4_p
were VBD N
included VBN N
Patients NNS N
treated VBD N
with IN N
intravenous JJ N
betalactam NNS N
and CC N
tobramycin NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
aerosolized VBN N
tobramycin NN N
( ( N
6 CD N
mg/kg/day NN N
, , N
n JJ N
= NNP N
21 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
The DT N
aerosol NN N
was VBD N
administered VBN N
via IN N
a DT N
pneumatic JJ N
nebulizer NN N
once RB N
a DT N
day NN N
for IN N
5 CD N
days NNS N
RESULTS NNP N
Respiratory NNP N
tolerance NN N
was VBD N
good JJ N
in IN N
all DT N
but CC N
two CD N
patients NNS N
No DT N
acute JJ N
renal JJ N
failure NN N
occurred VBD N
By IN N
day NN N
10 CD N
, , N
7 CD N
patients NNS N
in IN N
the DT N
tobramycin NN N
group NN N
( ( N
35 CD N
% NN N
) ) N
had VBD N
been VBN N
extubated VBN N
versus NN N
3 CD N
in IN N
the DT N
placebo NN N
group NN N
( ( N
18.5 CD N
% NN N
, , N
p NN N
= NNP N
0.18 CD N
) ) N
By IN N
day NN N
28 CD N
, , N
6 CD N
patients NNS N
had VBD N
died VBN N
( ( N
2 CD N
in IN N
the DT N
tobramycin NN N
group NN N
and CC N
4 CD N
in IN N
the DT N
placebo NN N
group NN N
, , N
p VBP N
= RB N
0.23 CD N
) ) N
CONCLUSION NNP N
Aerosolized NNP N
tobramycin NN N
was VBD N
well RB N
tolerated VBN N
in IN N
ventilated JJ 4_p
patients NNS 4_p
with IN 4_p
documented JJ 4_p
nosocomial JJ 4_p
pneumonia NN 4_p
-DOCSTART- -X- O O 22648717

Oral JJ N
magnesium NN N
supplementation NN N
in IN N
children NNS 1_p
with IN N
cystic JJ 4_p
fibrosis NN 4_p
improves VBZ N
clinical JJ N
and CC N
functional JJ N
variables NNS N
: : N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
crossover NN N
trial NN N
BACKGROUND NNP N
Magnesium NNP N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
important JJ N
minerals NNS N
in IN N
the DT N
body NN N
Although IN N
some DT N
studies NNS N
reported VBD N
that IN N
patients NNS N
with IN N
cystic JJ N
fibrosis NN N
( ( N
CF NNP N
) ) N
lack NN N
magnesium NN N
, , N
no DT N
international JJ N
study NN N
has VBZ N
assessed VBN N
the DT N
importance NN N
of IN N
oral JJ N
magnesium NN N
supplementation NN N
in IN N
CF NNP N
patients NNS N
OBJECTIVE IN N
We PRP N
prospectively RB N
investigated VBD N
the DT N
long-term JJ N
effect NN N
of IN N
oral JJ N
magnesium NN N
supplementation NN N
on IN N
respiratory JJ N
muscle NN N
strength NN N
by IN N
using VBG N
manuvacuometry NN N
and CC N
the DT N
Shwachman-Kulczycki NNP N
( ( N
SK NNP N
) ) N
score NN N
among IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN N
CF NNP 4_p
DESIGN NNP N
This DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
included VBD N
44 CD 3_p
CF NNP N
patients NNS N
( ( N
aged VBN 1_p
7-19 CD 1_p
y NN 1_p
; : N
20 CD 2_p
males NNS 2_p
) ) N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
magnesium NN N
( ( N
n JJ N
= VBZ N
22 CD 3_p
; : N
300 CD N
mg/d NN N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
22 CD 3_p
) ) N
for IN N
8 CD N
wk NN N
with IN N
a DT N
4-wk JJ N
washout NN N
period NN N
between IN N
trials NNS N
All DT N
patients NNS N
were VBD N
undergoing JJ N
conventional JJ N
treatment NN N
of IN N
CF NNP N
The DT N
experimental JJ N
protocol NN N
included VBD N
clinical JJ N
evaluation NN N
, , N
assessment NN N
of IN N
urinary JJ N
concentration NN N
of IN N
magnesium NN N
, , N
and CC N
manuvacuometric JJ N
measurements NNS N
[ VBP N
maximal JJ N
inspiratory JJ N
pressure NN N
( ( N
MIP NNP N
) ) N
and CC N
maximal JJ N
expiratory NN N
pressure NN N
( ( N
MEP NNP N
) ) N
] NN N
MIP NNP N
was VBD N
the DT N
primary JJ N
outcome NN N
RESULTS NNP N
Urinary JJ N
magnesium NN N
increased VBD N
after IN N
the DT N
administration NN N
of IN N
magnesium NN N
( ( N
change NN N
: : N
36.38 CD N
mg/d NN N
after IN N
magnesium NN N
compared VBN N
with IN N
0.72 CD N
mg/d NNS N
after IN N
placebo NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
Moreover RB N
, , N
MIP NNP N
and CC N
MEP NNP N
significantly RB N
improved VBD N
only RB N
after IN N
magnesium NN N
administration NN N
( ( N
change NN N
in IN N
MIP NNP N
: : N
11 CD N
% NN N
predicted VBN N
after IN N
magnesium NN N
compared VBN N
with IN N
0.5 CD N
% NN N
predicted VBN N
after IN N
placebo NN N
; : N
change NN N
in IN N
MEP NNP N
: : N
11.9 CD N
% NN N
predicted VBN N
after IN N
magnesium NN N
compared VBN N
with IN N
0.8 CD N
% NN N
predicted VBN N
after IN N
placebo NN N
; : N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
) ) N
Magnesium NNP N
administration NN N
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
clinical JJ N
variables NNS N
assessed VBN N
by IN N
the DT N
SK NNP N
score NN N
( ( N
change NN N
: : N
4.48 CD N
points NNS N
after IN N
magnesium NN N
compared VBN N
with IN N
-1.30 NNP N
points NNS N
after IN N
placebo NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
CONCLUSION NNP N
Oral NNP N
magnesium NN N
supplementation NN N
helped VBD N
improve VB N
both DT N
the DT N
SK NNP N
score NN N
and CC N
respiratory JJ N
muscle NN N
strength NN N
in IN N
pediatric JJ N
patients NNS N
with IN N
CF NNP N
-DOCSTART- -X- O O 3292597

Antihypertensive JJ N
efficacy NN N
of IN N
cetamolol NN N
: : N
a DT N
dose-titrated JJ N
study NN N
This DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
randomized JJ N
multicenter NN N
study NN N
evaluated VBD N
the DT N
antihypertensive JJ N
efficacy NN N
and CC N
safety NN N
of IN N
cetamolol JJ N
hydrochloride NN N
in IN N
108 CD N
patients NNS N
diagnosed VBN N
as IN N
having VBG N
mild NN N
to TO N
moderate VB N
hypertension NN N
After IN N
a DT N
placebo JJ N
lead-in JJ N
period NN N
, , N
patients NNS N
received VBD N
either DT N
cetamolol JJ N
5-10-15 JJ N
mg/d NN N
( ( N
low JJ N
dose NN N
) ) N
, , N
cetamolol JJ N
15-25-50 JJ N
mg/d NN N
( ( N
high JJ N
dose NN N
) ) N
, , N
or CC N
placebo NN N
, , N
once RB N
daily JJ N
for IN N
four CD N
weeks NNS N
Patients NNS N
began VBD N
at IN N
the DT N
lowest JJS N
dose NN N
and CC N
were VBD N
titrated VBN N
to TO N
higher JJR N
doses NNS N
based VBN N
on IN N
the DT N
first JJ N
two CD N
assessments NNS N
of IN N
diastolic JJ N
blood NN N
pressure NN N
and CC N
heart NN N
rate NN N
, , N
which WDT N
were VBD N
conducted VBN N
each DT N
week NN N
after IN N
double-blind JJ N
treatment NN N
was VBD N
dispensed VBN N
After IN N
four CD N
weeks NNS N
of IN N
treatment NN N
82.4 CD N
% NN N
, , N
81.3 CD N
% NN N
, , N
and CC N
93.3 CD N
% NN N
of IN N
the DT N
low-dose JJ N
group NN N
, , N
high-dose JJ N
group NN N
, , N
and CC N
placebo NN N
group NN N
, , N
respectively RB N
, , N
were VBD N
titrated VBN N
to TO N
the DT N
maximum JJ N
dose JJ N
level NN N
After IN N
four CD N
weeks NNS N
of IN N
treatment NN N
and CC N
24 CD N
hours NNS N
since IN N
the DT N
patient NN N
's POS N
last JJ N
dose NN N
, , N
both DT N
cetamolol NN N
groups NNS N
showed VBD N
a DT N
significantly RB N
greater JJR N
( ( N
P NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
.05 VB N
) ) N
reduction NN N
in IN N
supine JJ N
systolic/diastolic JJ N
blood NN N
pressure NN N
( ( N
-18.1 JJ N
+/- JJ N
2.3/-9.2 JJ N
+/- JJ N
1.5 CD N
mm NN N
Hg NNP N
[ NNP N
low JJ N
dose NN N
] NN N
and CC N
-17.3 JJ N
+/- JJ N
2.3/-8.3 JJ N
+/- JJ N
1.6 CD N
mm NN N
Hg NNP N
[ NNP N
high JJ N
dose RB N
] NNP N
) ) N
than IN N
the DT N
placebo NN N
group NN N
( ( N
-9.9 JJ N
+/- JJ N
2.5/-3.5 JJ N
+/- JJ N
1.7 CD N
mm NN N
Hg NNP N
) ) N
In IN N
general JJ N
, , N
the DT N
changes NNS N
in IN N
standing VBG N
( ( N
stabilized VBN N
) ) N
systolic NN N
and CC N
diastolic JJ N
blood NN N
pressure NN N
were VBD N
similar JJ N
to TO N
those DT N
seen VBN N
in IN N
supine JJ N
measurements NNS N
Significantly RB N
more RBR N
patients NNS N
receiving VBG N
cetamolol NN N
than IN N
those DT N
receiving VBG N
placebo NN N
showed VBD N
a DT N
" JJ N
good JJ N
response NN N
" NN N
( ( N
a DT N
decrease NN N
in IN N
diastolic JJ N
blood NN N
pressure NN N
of IN N
10 CD N
mm NNS N
Hg NNP N
or CC N
more JJR N
or CC N
measuring VBG N
less JJR N
than IN N
90 CD N
mm NNS N
Hg NNP N
with IN N
a DT N
decrease NN N
of IN N
at IN N
least JJS N
4 CD N
mm JJ N
Hg NNP N
) ) N
( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 21120480

A DT N
two-part JJ N
phase NN N
II NNP N
study NN N
of IN N
cediranib NN N
in IN N
patients NNS N
with IN N
advanced JJ 4_p
solid JJ 4_p
tumours NN 4_p
: : N
the DT N
effect NN N
of IN N
food NN N
on IN N
single-dose JJ N
pharmacokinetics NNS N
and CC N
an DT N
evaluation NN N
of IN N
safety NN N
, , N
efficacy NN N
and CC N
imaging VBG N
pharmacodynamics NNS N
BACKGROUND NNP N
Cediranib NNP N
( ( N
RECENTIN™ NNP N
) ) N
is VBZ N
an DT N
oral JJ N
, , N
highly RB N
potent JJ N
VEGF NNP N
inhibitor NN N
This DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
food NN N
on IN N
the DT N
pharmacokinetics NNS N
of IN N
cediranib NN N
and CC N
compared VBN N
the DT N
administration NN N
of IN N
continual JJ N
cediranib NN N
via IN N
two CD N
dosing VBG N
strategies NNS N
using VBG N
this DT N
as IN N
a DT N
platform NN N
to TO N
investigate VB N
pharmacodynamic JJ N
imaging NN N
biomarkers NNS N
METHODS NNP N
Sixty NNP 3_p
patients NNS 3_p
were VBD N
randomised VBN N
to TO N
receive VB N
two CD N
single JJ N
doses NNS N
of IN N
cediranib NN N
in IN N
either CC N
fed/fasted VBD N
or CC N
fasted/fed JJ N
state NN N
( ( N
Part NNP N
A NNP N
) ) N
In IN N
continual JJ N
dosage NN N
phase NN N
( ( N
Part NNP N
B NNP N
) ) N
, , N
patients NNS N
were VBD N
randomised VBN N
to TO N
a DT N
fixed-dose JJ N
or CC N
dose-escalation JJ N
arm NN N
Exploratory JJ N
pharmacodynamic JJ N
assessments NNS N
were VBD N
performed VBN N
using VBG N
DCE-MRI NNP N
and CC N
CT NNP N
enhancing VBG N
fraction NN N
( ( N
EnF NNP N
) ) N
RESULTS VBN N
In IN N
part NN N
A NNP N
, , N
plasma NN N
AUC NNP N
and CC N
C NNP N
( ( N
max NN N
) ) N
of IN N
cediranib NN N
were VBD N
lower JJR N
in IN N
the DT N
presence NN N
of IN N
food NN N
by IN N
a DT N
mean NN N
of IN N
24 CD N
and CC N
33 CD N
% NN N
, , N
respectively RB N
( ( N
94 CD N
% NN N
CI NNP N
: : N
AUC NNP N
, , N
12-34 CD N
% NN N
and CC N
C NNP N
( ( N
max NN N
) ) N
, , N
20-43 JJ N
% NN N
) ) N
, , N
indicating VBG N
food NN N
reduces NNS N
cediranib VBP N
plasma JJ N
exposure NN N
In IN N
part NN N
B NNP N
, , N
cediranib VBZ N
30 CD N
mg/day NN N
appeared VBD N
to TO N
be VB N
the DT N
most RBS N
sustainable JJ N
for IN N
chronic JJ N
dosing NN N
Continuous JJ N
cediranib NN N
therapy NN N
was VBD N
associated VBN N
with IN N
sustained JJ N
antivascular JJ N
effects NNS N
up RB N
to TO N
16 CD N
weeks NNS N
, , N
with IN N
significant JJ N
reductions NNS N
in IN N
DCE-MRI NNP N
parameters NNS N
and CC N
CT NNP N
EnF NNP N
CONCLUSIONS VB N
It PRP N
is VBZ N
recommended VBN N
that IN N
cediranib NN N
be VB N
administered VBN N
at IN N
least JJS N
1 CD N
h NN N
before IN N
or CC N
2 CD N
h NN N
after IN N
food NN N
Evidence NN N
of IN N
antitumour JJ N
activity NN N
was VBD N
observed VBN N
, , N
with IN N
significant JJ N
sustained JJ N
effects NNS N
upon IN N
imaging VBG N
vascular JJ N
parameters NNS N
-DOCSTART- -X- O O 24189342

Central JJ N
5-HT4 JJ N
receptor NN N
binding NN N
as IN N
biomarker NN N
of IN N
serotonergic JJ N
tonus NN N
in IN N
humans NNS 4_p
: : 4_p
a DT N
[ $ N
11C CD N
] NNP N
SB207145 NNP N
PET NNP N
study NN N
Identification NNP N
of IN N
a DT N
biomarker NN N
that WDT N
can MD N
inform VB N
on IN N
extracellular JJ N
serotonin NN N
( ( N
5-HT JJ N
) ) N
levels NNS N
in IN N
the DT N
brains NNS N
of IN N
living NN 4_p
humans NNS 4_p
would MD N
enable VB N
greater JJR N
understanding NN N
of IN N
the DT N
way NN N
brain NN N
circuits NNS N
are VBP N
modulated VBN N
by IN N
serotonergic JJ N
neurotransmission NN N
Substantial JJ N
evidence NN N
from IN N
studies NNS N
in IN N
animals NNS N
and CC N
humans NNS N
indicates VBZ N
an DT N
inverse NN N
relationship NN N
between IN N
central JJ N
5-HT JJ N
tonus NN N
and CC N
5-HT JJ N
type NN N
4 CD N
receptor NN N
( ( N
5-HT4R JJ N
) ) N
density NN N
, , N
suggesting VBG N
that IN N
5-HT4R JJ N
receptor NN N
density NN N
may MD N
be VB N
a DT N
biomarker NN N
marker NN N
for IN N
5-HT JJ N
tonus NN N
Here RB N
, , N
we PRP N
investigated VBD N
whether IN N
a DT N
3-week JJ N
administration NN N
of IN N
a DT N
selective JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
, , N
expected VBN N
to TO N
increase VB N
brain NN N
5-HT JJ N
levels NNS N
, , N
is VBZ N
associated VBN N
with IN N
a DT N
decline NN N
in IN N
brain NN N
5-HT4R JJ N
binding NN N
A DT N
total NN N
of IN N
35 CD N
healthy JJ N
men NNS N
were VBD N
studied VBN N
in IN N
a DT N
placebo-controlled JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
Participants NNS N
were VBD N
assigned VBN N
to TO N
receive VB N
3 CD N
weeks NNS N
of IN N
oral JJ N
dosing VBG N
with IN N
placebo NN N
or CC N
fluoxetine NN N
, , N
40 CD N
mg NNS N
per IN N
day NN N
Brain VB N
5-HT4R JJ N
binding NN N
was VBD N
quantified VBN N
at IN N
baseline NN N
and CC N
at IN N
follow-up JJ N
with IN N
[ NNP N
( ( N
11 CD N
) ) N
C NNP N
] NNP N
SB207145 NNP N
positron NN N
emission NN N
tomography NN N
( ( N
PET NNP N
) ) N
Three CD N
weeks NNS N
of IN N
intervention NN N
with IN N
fluoxetine NN N
was VBD N
associated VBN N
with IN N
a DT N
5.2 CD N
% NN N
reduction NN N
in IN N
brain NN N
5-HT4R JJ N
binding NN N
( ( N
P=0.017 NNP N
) ) N
, , N
whereas JJ N
placebo NN N
intervention NN N
did VBD N
not RB N
change VB N
5-HT4R JJ N
binding NN N
( ( N
P=0.52 NNP N
) ) N
Our PRP$ N
findings NNS N
are VBP N
consistent JJ N
with IN N
a DT N
model NN N
, , N
wherein VBP N
the DT N
5-HT4R JJ N
density NN N
adjusts VBZ N
to TO N
changes NNS N
in IN N
the DT N
extracellular JJ N
5-HT JJ N
tonus NN N
Our PRP$ N
data NNS N
demonstrate NN N
for IN N
the DT N
first JJ N
time NN N
in IN N
humans NNS N
that IN N
the DT N
imaging NN N
of IN N
central JJ N
5-HT4R JJ N
binding NN N
may MD N
be VB N
used VBN N
as IN N
an DT N
in IN N
vivo NN N
biomarker NN N
of IN N
the DT N
central JJ N
5-HT JJ N
tonus NN N
-DOCSTART- -X- O O 19109542

Modified VBN N
constraint-induced JJ N
therapy NN N
combined VBN N
with IN N
mental JJ N
practice NN N
: : N
thinking NN N
through IN N
better JJR N
motor NN N
outcomes NNS N
BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Modified NNP N
constraint-induced JJ N
therapy NN N
( ( N
mCIT NN N
) ) N
is VBZ N
an DT N
outpatient JJ N
therapy NN N
encouraging VBG N
repetitive JJ N
, , N
task-specific JJ N
practice NN N
with IN N
the DT N
affected JJ N
arm NN N
mCIT NN N
has VBZ N
shown VBN N
efficacy NN N
in IN N
all DT N
stages NNS N
poststroke VBP N
Given VBN N
its PRP$ N
efficacy NN N
when WRB N
combined VBN N
with IN N
other JJ N
therapy NN N
regimens NNS N
, , N
the DT N
current JJ N
study NN N
examined VBD N
the DT N
efficacy NN N
of IN N
mental JJ N
practice NN N
when WRB N
combined VBN N
with IN N
mCIT JJ N
versus NN N
mCIT NN N
only RB N
using VBG N
randomized VBN N
, , N
controlled VBN N
methods NNS N
METHOD NNP N
Ten CD N
patients NNS N
with IN N
chronic JJ N
stroke NN N
( ( N
7 CD N
males NNS N
; : N
mean JJ N
age NN N
, , N
61.4+/-3.02 JJ N
years NNS N
; : N
age NN N
range NN N
, , N
48 CD N
to TO N
79 CD N
years NNS N
; : N
mean JJ N
time NN N
since IN N
stroke NN N
, , N
28.5 CD N
months NNS N
; : N
range NN N
, , N
13 CD N
to TO N
42 CD N
months NNS N
) ) N
exhibiting VBG N
stable JJ N
, , N
affected JJ N
arm NN N
motor NN N
deficits NNS N
were VBD N
administered VBN N
mCIT NN N
, , N
consisting VBG N
of IN N
: : N
( ( N
1 CD N
) ) N
structured VBD N
therapy NN N
emphasizing VBG N
affected JJ N
arm NN N
use NN N
in IN N
functional JJ N
activities NNS N
3 CD N
days/week NN N
for IN N
10 CD N
weeks NNS N
; : N
and CC N
( ( N
2 CD N
) ) N
less RBR N
affected JJ N
arm NN N
restraint NN N
5 CD N
days/week NN N
for IN N
5 CD N
hours NNS N
Both DT N
of IN N
these DT N
components NNS N
were VBD N
administered VBN N
during IN N
a DT N
10-week JJ N
period NN N
Subjects NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
mCIT+mental JJ N
practice NN N
experimental JJ N
condition NN N
also RB N
received VBD N
30-minute JJ N
mental JJ N
practice NN N
sessions NNS N
provided VBD N
directly RB N
after IN N
therapy NN N
sessions NNS N
These DT N
mental JJ N
practice NN N
sessions NNS N
required VBN N
daily RB N
cognitive JJ N
rehearsal NN N
of IN N
the DT N
activities NNS N
of IN N
daily JJ N
living NN N
practiced VBD N
during IN N
mCIT JJ N
clinical JJ N
sessions NNS N
RESULTS NNP N
No NNP N
pre-existing JJ N
differences NNS N
were VBD N
found VBN N
between IN N
groups NNS N
on IN N
any DT N
demographic JJ N
variable NN N
or CC N
movement NN N
scale NN N
All DT N
subjects NNS N
exhibited VBN N
marked JJ N
reductions NNS N
in IN N
affected JJ N
arm NN N
impairment NN N
and CC N
functional JJ N
limitation NN N
However RB N
, , N
subjects NNS N
in IN N
the DT N
mCIT+mental JJ N
practice NN N
group NN N
exhibited VBD N
significantly RB N
larger JJR N
changes NNS N
on IN N
both DT N
movement NN N
measures NNS N
after IN N
intervention NN N
: : N
Action NNP N
Research NNP N
Arm NNP N
Test NNP N
, , N
+15.4-point JJ N
change NN N
versus IN N
+8.4-point JJ N
change NN N
for IN N
mCIT NN N
only RB N
subjects VBZ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
Fugl-Meyer NNP N
, , N
+7.8-point JJ N
change NN N
versus IN N
+4.1-point JJ N
change NN N
for IN N
the DT N
mCIT NN N
only RB N
subjects VBZ N
( ( N
P=0.01 NNP N
) ) N
These DT N
changes NNS N
were VBD N
sustained VBN N
3 CD N
months NNS N
after IN N
intervention NN N
CONCLUSIONS NNP N
mCIT NN N
remains VBZ N
a DT N
promising JJ N
motor NN N
intervention NN N
However RB N
, , N
its PRP$ N
efficacy NN N
appears VBZ N
to TO N
be VB N
enhanced VBN N
by IN N
use NN N
of IN N
mental JJ N
practice NN N
provided VBD N
directly RB N
after IN N
mCIT JJ N
clinical JJ N
sessions NNS N
-DOCSTART- -X- O O 3260083

[ JJ N
Propofol NNP N
infusion NN N
for IN N
the DT N
maintenance NN N
of IN N
short-term JJ 4_p
anesthesia NN 4_p
] NN 4_p
The DT N
administration NN N
of IN N
propofol NN N
by IN N
infusion NN N
for IN N
maintenance NN N
of IN N
anesthesia NN N
has VBZ N
attracted VBN N
much JJ N
attention NN N
recently RB N
We PRP N
investigated VBD N
the DT N
necessary JJ N
infusion NN N
rate NN N
of IN N
propofol NN N
to TO N
maintain VB N
anesthesia NN N
for IN N
short JJ N
surgical JJ N
procedures NNS N
without IN N
loss NN N
of IN N
the DT N
evident JJ N
advantages NNS N
of IN N
this DT N
substance NN N
Forty NNP 4_p
unpremedicated JJ 4_p
female NN 4_p
patients NNS 4_p
aged VBN 4_p
18-59 JJ 4_p
, , 4_p
scheduled VBN 4_p
for IN 4_p
minor JJ 4_p
gynecological JJ 4_p
procedures NNS 4_p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD N
groups NNS N
Anesthesia NNP N
was VBD N
induced VBN N
with IN N
2.0 CD N
mg/kg NNS N
propofol JJ N
i.v NN N
and CC N
simultaneously RB N
an DT N
infusion NN N
of IN N
0.05 CD N
, , N
0.10 CD N
, , N
0.15 CD N
, , N
or CC N
0.20 CD N
mg NNS N
propofol/kg JJ N
per IN N
minute NN N
was VBD N
started VBN N
The DT N
patients NNS N
were VBD N
breathing VBG N
N2O/O2 NNP N
with IN N
FIO2 NNP N
33 CD N
% NN N
Additional NNP N
propofol NN N
was VBD N
administered VBN N
as IN N
a DT N
bolus NN N
of IN N
10 CD N
to TO N
20 CD N
mg NN N
when WRB N
the DT N
patients NNS N
moved VBD N
With IN N
0.05 CD N
mg NNS N
propofol/kg JJ N
per IN N
minute NN N
all DT N
patients NNS N
required VBN N
additional JJ N
bolus NN N
injections NNS N
of IN N
propofol NN N
; : N
with IN N
0.10 CD N
mg NNS N
8 CD N
patients NNS N
, , N
with IN N
0.15 CD N
mg NNS N
5 CD N
patients NNS N
, , N
and CC N
with IN N
0.20 CD N
mg NNS N
1 CD N
patient NN N
required VBN N
bolus JJ N
injection NN N
Therefore NNP N
, , N
0.15 CD N
mg/kg NN N
per IN N
minute NN N
can MD N
be VB N
considered VBN N
as IN N
an DT N
approximate JJ N
ED50 NNP N
value NN N
The DT N
total JJ N
propofol NN N
consumption NN N
( ( N
infusion NN N
+ NNP N
bolus NN N
) ) N
increased VBD N
from IN N
0.102 CD N
+/- JJ N
0.028 CD N
( ( N
+/- JJ N
SD NNP N
) ) N
with IN N
the DT N
lowest JJS N
infusion NN N
rate NN N
to TO N
0.202 CD N
+/- JJ N
0.006 CD N
mg/kg NNS N
per IN N
minute NN N
with IN N
the DT N
highest JJS N
infusion NN N
rate NN N
and CC N
recovery NN N
time NN N
from IN N
5.2 CD N
+/- JJ N
1.4 CD N
to TO N
9.9 CD N
+/- JJ N
2.6 CD N
min NN N
There EX N
was VBD N
a DT N
significant JJ N
correlation NN N
between IN N
propofol JJ N
consumption NN N
and CC N
recovery NN N
time NN N
After IN N
induction NN N
, , N
arterial JJ N
blood NN N
pressure NN N
decreased VBN N
by IN N
systolic/diastolic JJ N
20/10-15 JJ N
mmHg NN N
With IN N
the DT N
low JJ N
infusion NN N
rate NN N
, , N
arterial JJ N
pressure NN N
increased VBD N
to TO N
its PRP$ N
control NN N
value NN N
during IN N
operation NN N
; : N
it PRP N
remained VBD N
at IN N
the DT N
postinduction NN N
value NN N
with IN N
high JJ N
infusion NN N
rates NNS N
Side-effects NNS N
: : N
10 CD N
patients NNS N
had VBD N
salivation NN N
that IN N
in IN N
some DT N
instances NNS N
lead VBP N
to TO N
coughing VBG N
, , N
9 CD N
reported VBD N
pain NN N
at IN N
the DT N
injection NN N
site NN N
during IN N
induction NN N
, , N
and CC N
9 CD N
reported VBD N
dreams NNS N
of IN N
a DT N
pleasant JJ N
nature NN N
( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 10348763

Amphotericin NNP N
B NNP N
in IN N
children NNS 1_p
with IN N
malignant JJ 4_p
disease NN 4_p
: : 4_p
a DT N
comparison NN N
of IN N
the DT N
toxicities NNS N
and CC N
pharmacokinetics NNS N
of IN N
amphotericin NN N
B NNP N
administered VBN N
in IN N
dextrose JJ N
versus NN N
lipid JJ N
emulsion NN N
In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
, , N
the DT N
toxicity NN N
of IN N
1 CD N
mg NN N
of IN N
amphotericin NN N
B NNP N
( ( N
AmB NNP N
) ) N
per IN N
kg NN N
of IN N
body NN N
weight JJ N
per IN N
day NN N
infused VBN N
in IN N
5 CD N
% NN N
dextrose NN N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
AmB NNP N
infused VBD N
in IN N
lipid JJ N
emulsion NN N
in IN N
children NNS 1_p
with IN N
malignant JJ 4_p
disease NN 4_p
In IN N
an DT N
analysis NN N
of IN N
82 CD 3_p
children NNS N
who WP N
received VBD N
a DT N
full JJ N
course NN N
of IN N
6 CD N
days NNS N
or CC N
more JJR N
of IN N
AmB NNP N
( ( N
117 CD N
courses NNS N
) ) N
, , N
it PRP N
was VBD N
shown VBN N
that IN N
there EX N
were VBD N
significant JJ N
increases NNS N
in IN N
plasma JJ N
urea JJ N
and CC N
creatinine JJ N
concentrations NNS N
and CC N
in IN N
potassium NN N
requirement NN N
after IN N
6 CD N
days NNS N
of IN N
therapy NN N
with IN N
both DT N
AmB NNP N
infused VBN N
in IN N
dextrose NN N
and CC N
AmB NNP N
infused VBD N
in IN N
lipid JJ N
emulsion NN N
, , N
with IN N
there EX N
being VBG N
no DT N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
of IN N
AmB NNP N
administration NN N
An DT N
intent-to-treat JJ N
comparison NN N
of IN N
the DT N
numbers NNS N
of IN N
courses NNS N
affected VBN N
by IN N
acute JJ N
toxicity NN N
( ( N
fever NN N
, , N
rigors NNS N
) ) N
and CC N
chronic JJ N
toxicity NN N
( ( N
nephrotoxicity NN N
) ) N
also RB N
indicated VBD N
that IN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
AmB NNP N
infused VBD N
in IN N
dextrose NN N
( ( N
78 CD N
courses NNS N
) ) N
and CC N
AmB NNP N
infused VBD N
in IN N
lipid JJ N
emulsion NN N
( ( N
84 CD N
courses NNS N
) ) N
The DT N
pharmacokinetics NNS N
of IN N
AmB NNP N
were VBD N
investigated VBN N
in IN N
20 CD N
children NNS N
who WP N
received VBD N
AmB NNP N
in IN N
dextrose NN N
and CC N
15 CD N
children NNS N
who WP N
received VBD N
AmB NNP N
in IN N
lipid JJ N
emulsion NN N
Blood NN N
samples NNS N
were VBD N
collected VBN N
up RB N
to TO N
24 CD N
h NN N
after IN N
administration NN N
of IN N
the DT N
first JJ N
dose NN N
, , N
and CC N
the DT N
concentration NN N
of IN N
AmB NNP N
in IN N
plasma NN N
was VBD N
analyzed VBN N
by IN N
a DT N
high-performance NN N
liquid NN N
chromatography NN N
assay NN N
The DT N
clearance NN N
( ( N
CL NNP N
) ) N
of IN N
AmB NNP N
in IN N
dextrose NN N
( ( N
0.039 CD N
+/- JJ N
0.016 CD N
liter NN N
h-1 NN N
kg-1 NN N
) ) N
was VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
than IN N
the DT N
CL NNP N
of IN N
AmB NNP N
in IN N
lipid JJ N
emulsion NN N
( ( N
0.062 CD N
+/- JJ N
0 CD N
024 CD N
liter NN N
h-1 NN N
kg-1 NN N
) ) N
The DT N
steady-state JJ N
volume NN N
of IN N
distribution NN N
for IN N
AmB NNP N
in IN N
dextrose NN N
( ( N
0.83 CD N
+/- JJ N
0.33 CD N
liter NN N
kg-1 NN N
) ) N
was VBD N
also RB N
significantly RB N
lower JJR N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
than IN N
that DT N
for IN N
AmB NNP N
in IN N
lipid JJ N
emulsion NN N
( ( N
1.47 CD N
+/- JJ N
0.77 CD N
liter NN N
kg-1 NN N
) ) N
Although IN N
AmB NNP N
in IN N
lipid JJ N
emulsion NN N
is VBZ N
apparently RB N
cleared VBN N
faster RBR N
and CC N
distributes VBZ N
more RBR N
widely RB N
than IN N
AmB NNP N
in IN N
dextrose NN N
, , N
this DT N
study NN N
did VBD N
not RB N
reveal VB N
any DT N
significant JJ N
advantage NN N
with IN N
respect NN N
to TO N
safety NN N
and CC N
tolerance NN N
in IN N
the DT N
administration NN N
of IN N
AmB NNP N
in IN N
lipid JJ N
emulsion NN N
compared VBN N
to TO N
its PRP$ N
administration NN N
in IN N
dextrose NN N
in IN N
children NNS 1_p
with IN N
malignant JJ 4_p
disease NN 4_p
-DOCSTART- -X- O O 22696626

Effect NN N
of IN N
whole JJ N
body NN N
vibration NN N
on IN N
stereotypy NN N
of IN N
young JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
The DT N
objective NN N
of IN N
this DT N
case NN N
was VBD N
report NN N
on IN N
the DT N
effects NNS N
of IN N
acute JJ N
whole JJ N
body NN N
vibration NN N
exposure NN N
on IN N
stereotyped JJ N
behaviour NN N
of IN N
young JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
Four CD 4_p
young JJ 4_p
boys NNS 4_p
( ( 4_p
ages IN 4_p
4-5 CD 4_p
years NNS 4_p
) ) 4_p
diagnosed VBD 4_p
with IN 4_p
autism NN 4_p
participated VBN 4_p
The DT N
children NNS N
were VBD N
participants NNS N
in IN N
an DT N
early JJ N
intensive JJ N
behavioural JJ N
intervention NN N
clinic NN N
and CC N
during IN N
downtimes NNS N
stood VBD N
on IN N
a DT N
whole JJ N
body NN N
vibration NN N
platform NN N
with IN N
the DT N
machine NN N
turned VBD N
off RP N
( ( N
control VB N
condition NN N
) ) N
and CC N
on IN N
( ( N
treatment NN N
condition NN N
) ) N
for IN N
three CD N
to TO N
four CD N
, , N
30 CD N
s NN N
periods NNS N
( ( N
frequency=28 JJ N
Hz NNP N
; : N
amplitude VBZ N
0.97 CD N
mm NN N
) ) N
The DT N
outcome NN N
measure NN N
was VBD N
frequency NN N
of IN N
stereotypic NN N
behaviour NN N
, , N
which WDT N
was VBD N
evaluated VBN N
for IN N
5 CD N
min NN N
before IN N
and CC N
after IN N
standing VBG N
on IN N
the DT N
vibration NN N
platform NN N
The DT N
results NNS N
revealed VBD N
that IN N
whole JJ N
body NN N
vibration NN N
was VBD N
not RB N
able JJ N
to TO N
uniformly VB N
decrease VB N
the DT N
rates NNS N
of IN N
all DT N
types NNS N
of IN N
stereotypy NN N
; : N
that WDT N
is VBZ N
, , N
some DT N
stereotypy NNS N
decreased VBN N
while IN N
others NNS N
were VBD N
unchanged JJ N
Subjectively RB N
, , N
the DT N
children NNS N
enjoyed VBD N
whole JJ N
body NN N
vibration NN N
which WDT N
was VBD N
easy JJ N
to TO N
integrate VB N
into IN N
the DT N
behavioural JJ N
programme NN N
-DOCSTART- -X- O O 21416590

An DT N
interactive JJ N
computer NN N
program NN N
can MD N
effectively RB N
educate VB N
potential JJ N
users NNS N
of IN N
cystic JJ 4_p
fibrosis NN 4_p
carrier NN 4_p
tests NNS N
The DT N
demand NN N
for IN N
cystic JJ N
fibrosis NN N
( ( N
CF NNP N
) ) N
carrier NN N
testing VBG N
is VBZ N
steadily RB N
growing VBG N
, , N
not RB N
only RB N
from IN N
individuals NNS N
with IN N
raised VBN 4_p
a DT 4_p
priori FW 4_p
carrier NN 4_p
risk NN 4_p
, , N
but CC N
also RB N
from IN N
the DT N
general JJ N
population NN N
This DT N
trend NN N
will MD N
likely RB N
exceed VB N
the DT N
availability NN N
of IN N
genetic JJ N
counselors NNS N
, , N
making VBG N
it PRP N
impossible JJ N
to TO N
provide VB N
standard JJ N
face-to-face JJ N
genetic JJ N
counseling NN N
to TO N
all PDT N
those DT N
asking VBG N
for IN N
the DT N
test NN N
In IN N
order NN N
to TO N
reduce VB N
the DT N
time NN N
needed VBN N
to TO N
educate VB N
individuals NNS N
on IN N
the DT N
basics NNS N
of IN N
the DT N
disease NN N
, , N
its PRP$ N
genetic JJ N
transmission NN N
, , N
and CC N
carrier NN N
testing VBG N
peculiarities NNS N
, , N
we PRP N
developed VBD N
an DT N
educational JJ N
method NN N
based VBN N
on IN N
an DT N
interactive JJ N
computer NN N
program NN N
( ( N
IC NNP N
) ) N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
this DT N
program NN N
and CC N
to TO N
compare VB N
it PRP N
to TO N
a DT N
classical JJ N
genetic JJ N
counseling NN N
session NN N
, , N
we PRP N
conducted VBD N
a DT N
comparative JJ N
trial NN N
In IN N
a DT N
population NN N
setting NN N
of IN N
people NNS N
undergoing VBG N
assisted JJ N
reproduction NN N
, , N
44 CD 3_p
individuals NNS 3_p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
receiving VBG N
standard JJ N
one-on-one JJ N
genetic JJ N
counseling NN N
or CC N
education NN N
by IN N
the DT N
IC NNP N
program NN N
We PRP N
measured VBD N
pre- JJ N
and CC N
post-intervention NN N
knowledge NN N
about IN N
CF NNP N
genetic JJ N
transmission NN N
and CC N
carrier NN N
testing NN N
Starting VBG N
from IN N
an DT N
equivalent JJ N
baseline NN N
of IN N
correct JJ N
answers NNS N
to TO N
a DT N
specially RB N
designed VBN N
multiple-choice NN N
questionnaire NN N
( ( N
47 CD N
% NN N
in IN N
the DT N
counselor NN N
group NN N
and CC N
45 CD N
% NN N
in IN N
the DT N
computer NN N
group NN N
) ) N
both DT N
groups NNS N
showed VBD N
a DT N
highly RB N
significant JJ N
and CC N
similar JJ N
increase NN N
( ( N
reaching VBG N
84 CD N
% NN N
in IN N
the DT N
counselor NN N
group NN N
and CC N
85 CD N
% NN N
in IN N
the DT N
computer NN N
group NN N
) ) N
The DT N
computer NN N
program NN N
under IN N
evaluation NN N
can MD N
successfully RB N
educate VB N
individuals NNS N
considering VBG N
genetic JJ N
testing NN N
for IN N
CF NNP N
-DOCSTART- -X- O O 20603436

Comorbidity NN N
, , N
age NN N
and CC N
overall JJ N
survival NN N
in IN N
cetuximab-treated JJ N
patients NNS N
with IN N
advanced JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
( ( 4_p
ACRC NNP 4_p
) ) 4_p
-- : N
results NNS N
from IN N
NCIC NNP N
CTG NNP N
CO.17 NNP N
: : N
a DT N
phase NN N
III NNP N
trial NN N
of IN N
cetuximab NN N
versus NN N
best RBS N
supportive JJ N
care NN N
BACKGROUND IN N
the DT N
interplay NN N
between IN N
comorbidity NN N
, , N
age NN N
and CC N
performance NN N
status NN N
( ( N
PS NNP N
) ) N
as IN N
predictors NNS N
of IN N
outcome NN N
in IN N
advanced JJ N
colorectal JJ N
cancer NN N
( ( N
ACRC NNP N
) ) N
is VBZ N
poorly JJ N
understood NN N
We PRP N
examined VBD N
these DT N
factors NNS N
as IN N
predictors NNS N
of IN N
treatment NN N
toxicity NN N
and CC N
outcome NN N
in IN N
cetuximab-treated JJ 4_p
patients NNS 4_p
with IN N
ACRC NNP 4_p
PATIENTS NNP N
AND CC N
METHODS NNP N
comorbidity NN N
was VBD N
independently RB N
evaluated VBN N
using VBG N
the DT N
Charlson NNP N
Comorbidity NNP N
Index NNP N
( ( N
CCI NNP N
) ) N
, , N
a DT N
validated JJ N
measure NN N
of IN N
comorbidity NN N
based VBN N
on IN N
the DT N
presence NN N
of IN N
medical JJ N
conditions NNS N
weighted VBD N
according VBG N
to TO N
their PRP$ N
effect NN N
on IN N
mortality NN N
CCI NNP N
score NN N
was VBD N
correlated VBN N
with IN N
clinical JJ N
and CC N
outcome JJ N
data NNS N
RESULTS NNP N
five CD 3_p
hundred VBD 3_p
and CC 3_p
seventy-two JJ 3_p
patients NNS 3_p
were VBD N
included VBN N
; : N
41 CD 1_p
% NN 1_p
were VBD 1_p
≥ JJ 1_p
65 CD 1_p
years NNS 1_p
and CC N
25 CD N
% NN N
had VBD N
comorbidities NNS N
at IN N
randomization NN N
In IN N
multivariate JJ N
analysis NN N
( ( N
MVA NNP N
) ) N
of IN N
all DT N
covariates NNS N
, , N
only RB N
older JJR N
age NN N
was VBD N
associated VBN N
with IN N
greater JJR N
comorbidity NN N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
Overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
was VBD N
significantly RB N
better JJR N
for IN N
patients NNS N
with IN N
greater JJR N
comorbidity NN N
in IN N
univariate JJ N
analysis NN N
( ( N
P NNP N
= NNP N
0.047 CD N
) ) N
Conversely RB N
, , N
better JJR N
PS NNP N
was VBD N
associated VBN N
with IN N
better JJR N
OS NNP N
in IN N
MVA NNP N
( ( N
hazard JJ N
ratio NN N
1.92 CD N
for IN N
PS NNP N
= NNP N
2 CD N
versus NN N
PS NNP N
= NNP N
0 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
Age NNP N
was VBD N
not RB N
associated VBN N
with IN N
OS NNP N
( ( N
P NNP N
= NNP N
0.13 CD N
) ) N
Elderly JJ 1_p
patients NNS 1_p
had VBD N
significantly RB N
less JJR N
grade JJ N
≥ NN N
3 CD N
vomiting NN N
( ( N
P NNP N
= NNP N
0.034 CD N
) ) N
but CC N
more JJR N
dyspnea NN N
( ( N
P NNP N
= NNP N
0.005 CD N
) ) N
Patients NNS N
with IN N
greater JJR N
comorbidity NN N
had VBD N
significantly RB N
less JJR N
grade JJ N
≥ NN N
3 CD N
vomiting NN N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
but CC N
more JJR N
non-neutropenic JJ N
fever NN N
( ( N
P NNP N
= NNP N
0.005 CD N
) ) N
CONCLUSION NNP N
better JJR N
PS NNP N
was VBD N
associated VBN N
with IN N
improved JJ N
OS NNP N
For IN N
patients NNS N
with IN N
good JJ N
PS NNP N
, , N
restricting VBG N
cetuximab NN N
use NN N
in IN N
the DT N
setting NN N
of IN N
significant JJ N
comorbidity NN N
does VBZ N
not RB N
appear VB N
justified VBN N
-DOCSTART- -X- O O 23306077

Translating VBG N
the DT N
Dietary NNP N
Approaches NNP N
to TO N
Stop VB N
Hypertension NNP N
( ( N
DASH NNP N
) ) N
diet NN N
for IN N
use NN N
in IN N
underresourced JJ 4_p
, , 4_p
urban JJ 4_p
African JJ 4_p
American JJ 4_p
communities NNS 4_p
, , 4_p
2010 CD 4_p
INTRODUCTION NNP N
Randomized NNP N
trials NNS N
have VBP N
demonstrated VBN N
the DT N
effectiveness NN N
of IN N
the DT N
Dietary NNP N
Approaches NNP N
to TO N
Stop VB N
Hypertension NNP N
( ( N
DASH NNP N
) ) N
program NN N
for IN N
lowering VBG N
blood NN N
pressure NN N
; : N
however RB N
, , N
program NN N
participation NN N
has VBZ N
been VBN N
limited VBN N
in IN N
some DT N
populations NNS N
The DT N
objective NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
test VB N
the DT N
feasibility NN N
of IN N
using VBG N
a DT N
culturally RB N
modified VBN N
version NN N
of IN N
DASH NNP N
among IN N
African JJ 4_p
Americans NNPS 4_p
in IN 4_p
an DT 4_p
underresourced JJ 4_p
community NN 4_p
METHODS NNP N
This DT N
randomized VBD N
controlled VBN N
pilot NN N
study NN N
recruited VBD N
African JJ N
Americans NNPS N
in IN N
2 CD N
North NNP N
Carolina NNP N
neighborhoods NNS N
who WP N
had VBD N
high JJ N
blood NN N
pressure NN N
and CC N
used VBD N
fewer JJR N
than IN N
3 CD N
antihypertension NN N
medications NNS N
We PRP N
offered VBD N
2 CD N
individual JJ N
and CC N
9 CD N
group NN N
DASH NNP N
sessions NNS N
to TO N
intervention NN N
participants NNS N
and CC N
1 CD N
individual JJ N
session NN N
and CC N
printed VBD N
DASH NNP N
educational JJ N
materials NNS N
to TO N
control VB N
participants NNS N
We PRP N
collected VBD N
data NNS N
at IN N
baseline NN N
( ( N
March NNP N
2010 CD N
) ) N
and CC N
12 CD N
weeks NNS N
( ( N
June NNP N
2010 CD N
) ) N
RESULTS NNP N
Of IN N
152 CD N
potential JJ N
participants NNS N
, , N
25 CD N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
intervention NN N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
or CC N
the DT N
control NN N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
group NN N
; : N
22 CD N
were VBD N
women NNS N
, , N
and CC N
21 CD N
were VBD N
educated VBN N
beyond IN N
high JJ N
school NN N
At IN N
baseline NN N
, , N
mean JJ N
blood NN N
pressure NN N
was VBD N
130/78 CD N
mm JJ N
Hg NNP N
; : N
19 CD N
participants NNS N
used VBN N
antihypertension NN N
medications NNS N
, , N
and CC N
mean VB N
body NN N
mass NN N
index NN N
was VBD N
35.9 CD N
kg/m NN N
( ( N
2 CD N
) ) N
Intervention NN N
participants NNS N
attended VBD N
7 CD N
of IN N
9 CD N
group NN N
sessions NNS N
on IN N
average NN N
After IN N
12 CD N
weeks NNS N
, , N
we PRP N
observed VBD N
significant JJ N
increases NNS N
in IN N
fruit NN N
and CC N
vegetable JJ N
consumption NN N
and CC N
increases NNS N
in IN N
participants NNS N
' POS N
confidence NN N
in IN N
their PRP$ N
ability NN N
to TO N
reduce VB N
salt NN N
and CC N
fat JJ N
consumption NN N
and CC N
eat NN N
healthier NN N
snacks NNS N
in IN N
intervention NN N
compared VBN N
with IN N
control NN N
participants NNS N
We PRP N
found VBD N
no DT N
significant JJ N
decreases NNS N
in IN N
blood NN N
pressure NN N
CONCLUSION NNP N
Implementation NNP N
of IN N
a DT N
culturally RB N
modified VBN N
, , N
community-based JJ N
DASH NNP N
intervention NN N
was VBD N
feasible JJ N
in IN N
our PRP$ N
small JJ N
sample NN N
of IN N
African JJ N
Americans NNPS N
, , N
which WDT N
included VBD N
people NNS N
being VBG N
treated VBN N
for IN N
high JJ N
blood NN N
pressure NN N
Future JJ N
studies NNS N
should MD N
evaluate VB N
the DT N
long-term JJ N
effect NN N
of IN N
this DT N
program NN N
in IN N
a DT N
larger JJR N
sample NN N
-DOCSTART- -X- O O 23104718

ARIX NN N
: : N
a DT N
randomised JJ N
trial NN N
of IN N
acupuncture NN N
v FW N
oral JJ N
care NN N
sessions NNS N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
xerostomia NN 4_p
following VBG N
treatment NN N
of IN N
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
BACKGROUND NNP N
Radiation NNP N
treatment NN N
of IN N
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
can MD N
cause VB N
chronic JJ 4_p
xerostomia NN 4_p
which WDT N
impairs VBZ N
patients NNS N
' POS N
quality NN N
of IN N
life NN N
The DT N
study NN N
reported VBD N
here RB N
examined VBN N
the DT N
efficacy NN N
of IN N
acupuncture NN N
in IN N
alleviating VBG N
xerostomia NN N
symptoms NNS N
especially RB N
dry JJ N
mouth NN N
PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
total NN N
of IN N
145 CD 3_p
patients NNS N
with IN N
chronic JJ 4_p
radiation-induced JJ 4_p
xerostomia NN 4_p
> $ N
18 CD N
months NNS N
after IN N
treatments NNS N
were VBD N
recruited VBN N
from IN N
seven CD N
UK NNP N
cancer NN N
centres NNS N
The DT N
study NN N
employed VBD N
a DT N
randomised JJ N
crossover NN N
design NN N
with IN N
participants NNS N
receiving VBG N
two CD N
group NN N
sessions NNS N
of IN N
oral JJ N
care NN N
education NN N
and CC N
eight CD N
of IN N
acupuncture NN N
using VBG N
standardised VBN N
methods NNS N
Patient-reported JJ N
outcome NN N
( ( N
PROs NNP N
) ) N
measures NNS N
were VBD N
completed VBN N
at IN N
baseline NN N
and CC N
weeks NNS N
5 CD N
, , N
9 CD N
, , N
13 CD N
, , N
17 CD N
, , N
and CC N
21 CD N
The DT N
primary JJ N
outcome NN N
was VBD N
improvement NN N
in IN N
dry JJ N
mouth NN N
OBJECTIVE NNP N
saliva NN N
measurements NNS N
were VBD N
also RB N
carried VBN N
out RP N
RESULTS JJ N
Acupuncture NNP N
compared VBN N
with IN N
oral JJ N
care NN N
, , N
produced VBD N
significant JJ N
reductions NNS N
in IN N
patient JJ N
reports NNS N
of IN N
severe JJ N
dry JJ N
mouth NN N
( ( N
OR NNP N
= VBZ N
2.01 CD N
, , N
P NNP N
= NNP N
0.031 CD N
) ) N
sticky NN N
saliva NN N
( ( N
OR NNP N
= VBZ N
1.67 CD N
, , N
P NNP N
= NNP N
0.048 CD N
) ) N
, , N
needing VBG N
to TO N
sip VB N
fluids NNS N
to TO N
swallow VB N
food NN N
( ( N
OR NNP N
= VBZ N
2.08 CD N
, , N
P NNP N
= NNP N
0.011 CD N
) ) N
and CC N
in IN N
waking VBG N
up RP N
at IN N
night NN N
to TO N
drink VB N
( ( N
OR NNP N
= VBZ N
1.71 CD N
, , N
P NNP N
= NNP N
0.013 CD N
) ) N
There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
either DT N
stimulated VBD N
or CC N
unstimulated JJ N
saliva NN N
measurements NNS N
over IN N
time NN N
CONCLUSION NNP N
Eight NNP N
sessions NNS N
of IN N
weekly JJ N
group NN N
acupuncture NN N
compared VBN N
with IN N
group NN N
oral JJ N
care NN N
education NN N
provide VBP N
significantly RB N
better JJR N
relief NN N
of IN N
symptoms NNS N
in IN N
patients NNS N
suffering VBG N
from IN N
chronic JJ 4_p
radiation-induced JJ 4_p
xerostomia NN 4_p
-DOCSTART- -X- O O 21787048

A DT N
communication-based JJ N
intervention NN N
for IN N
nonverbal JJ N
children NNS 1_p
with IN N
autism NN N
: : N
what WP N
changes NNS N
? . N
Who WP N
benefits NNS N
? . N
OBJECTIVE IN N
This DT N
article NN N
examines VBZ N
the DT N
form NN N
and CC N
function NN N
of IN N
spontaneous JJ N
communication NN N
and CC N
outcome NN N
predictors NNS N
in IN N
nonverbal JJ N
children NNS 1_p
with IN N
autism NN 4_p
following VBG N
classroom-based JJ N
intervention NN N
( ( N
Picture NNP N
Exchange NNP N
Communication NNP N
System NNP N
[ NNP N
PECS NNP N
] NNP N
training NN N
) ) N
METHOD $ N
84 CD 3_p
children NNS 1_p
from IN N
15 CD N
schools NNS N
participated VBN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
of IN N
PECS NNP N
( ( N
P. NNP N
Howlin NNP N
, , N
R. NNP N
K. NNP N
Gordon NNP N
, , N
G. NNP N
Pasco NNP N
, , N
A NNP N
Wade NNP N
, , N
& CC N
T. NNP N
Charman NNP N
, , N
2007 CD N
) ) N
They PRP N
were VBD N
aged VBN N
4-10 JJ 1_p
years NNS 1_p
( ( N
73 CD 3_p
boys NNS 2_p
) ) N
Primary JJ N
outcome JJ N
measure NN N
was VBD N
naturalistic JJ N
observation NN N
of IN N
communication NN N
in IN N
the DT N
classroom NN N
Multilevel NNP N
Poisson NNP N
regression NN N
was VBD N
used VBN N
to TO N
test VB N
for IN N
intervention NN N
effects NNS N
and CC N
outcome JJ N
predictors NNS N
RESULTS NNP N
Spontaneous JJ N
communication NN N
using VBG N
picture NN N
cards NNS N
, , N
speech NN N
, , N
or CC N
both DT N
increased VBN N
significantly RB N
following VBG N
training NN N
( ( N
rate NN N
ratio NN N
[ NNP N
RR NNP N
] NNP N
=1.90 NNP N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
1.46 CD N
, , N
2.48 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
; : N
RR NNP N
= VBZ N
1.77 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
1.35 CD N
, , N
2.32 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
; : N
RR NNP N
= VBZ N
3.74 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
2.19 CD N
, , N
6.37 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
, , N
respectively RB N
) ) N
Spontaneous JJ N
communication NN N
to TO N
request VB N
objects NNS N
significantly RB N
increased VBD N
( ( N
RR NNP N
= NNP N
2.17 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
1.75 CD N
, , N
2.68 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
) ) N
, , N
but CC N
spontaneous JJ N
requesting NN N
for IN N
social JJ N
purposes NNS N
did VBD N
not RB N
( ( N
RR NNP N
= NNP N
1.34 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
0.83 CD N
, , N
2.18 CD N
] NN N
, , N
p NN N
= NNP N
.237 NNP N
) ) N
Only RB N
the DT N
effect NN N
on IN N
spontaneous JJ N
speech NN N
persisted VBN N
by IN N
follow-up NN N
( ( N
9 CD N
months NNS N
later RB N
) ) N
Less CC N
severe JJ N
baseline NN N
autism NN N
symptomatology NN N
( ( N
lower JJR N
Autism NNP N
Diagnosis NNP N
Observation NNP N
Schedule NNP N
[ NNP N
ADOS NNP N
] NNP N
score NN N
; : N
C. NNP N
Lord NNP N
et VBZ N
al. RB N
, , N
2000 CD N
) ) N
was VBD N
associated VBN N
with IN N
greater JJR N
increase NN N
in IN N
spontaneous JJ N
speech NN N
( ( N
RR NNP N
= NNP N
0.90 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
0.83 CD N
, , N
0.98 CD N
] NN N
, , N
p NN N
= NNP N
.011 NNP N
) ) N
and CC N
less RBR N
severe JJ N
baseline NN N
expressive JJ N
language NN N
impairment NN N
( ( N
lower JJR N
ADOS NNP N
item NN N
A1 NNP N
score NN N
) ) N
, , N
with IN N
larger JJR N
increases NNS N
in IN N
spontaneous JJ N
use NN N
of IN N
speech NN N
and CC N
pictures VBZ N
together RB N
( ( N
RR NNP N
= NNP N
0.62 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
0.44 CD N
, , N
0.88 CD N
] NN N
, , N
p NN N
= NNP N
.008 NNP N
) ) N
CONCLUSION NNP N
Overall NNP N
, , N
PECS NNP N
appeared VBD N
to TO N
enhance VB N
children NNS N
's POS N
spontaneous JJ N
communication NN N
for IN N
instrumental JJ N
requesting VBG N
using VBG N
pictures NNS N
, , N
speech NN N
, , N
or CC N
a DT N
combination NN N
of IN N
both DT N
Some DT N
effects NNS N
of IN N
training NN N
were VBD N
moderated VBN N
by IN N
baseline NN N
factors NNS N
For IN N
example NN N
, , N
PECS NNP N
appears VBZ N
to TO N
have VB N
increased VBN N
spontaneous JJ N
speech NN N
in IN N
children NNS N
who WP N
could MD N
talk VB N
a DT N
little JJ N
at IN N
baseline NN N
-DOCSTART- -X- O O 21811855

The DT N
effect NN N
of IN N
knee NN N
position NN N
on IN N
blood NN N
loss NN N
and CC N
range NN N
of IN N
motion NN N
following VBG N
total JJ N
knee JJ N
arthroplasty NN N
PURPOSE VB N
This DT N
study NN N
prospectively RB N
assessed VBD N
the DT N
effects NNS N
of IN N
knee JJ N
position NN N
on IN N
blood NN N
loss NN N
and CC N
range NN N
of IN N
motion NN N
after IN N
primary JJ N
total JJ N
knee NN N
arthroplasty NN N
( ( N
TKA NNP N
) ) N
METHODS NNP N
One CD N
hundred CD N
and CC N
ten VB N
consecutive JJ N
TKA NNP N
patients NNS N
were VBD N
randomized VBN N
into IN N
flexion NN N
group NN N
and CC N
extension NN N
group NN N
Both DT N
groups NNS N
had VBD N
the DT N
leg NN N
elevated VBD N
30° CD N
at IN N
the DT N
hip NN N
over IN N
an DT N
inactive JJ N
CPM NNP N
for IN N
72 CD N
h NN N
postoperatively RB N
The DT N
flexion NN N
group NN N
had VBD N
the DT N
knee NN N
flexed VBD N
to TO N
30° CD N
during IN N
this DT N
period NN N
The DT N
extension NN N
group NN N
had VBD N
the DT N
knee NN N
extended VBD N
fully RB N
Perioperative JJ N
blood NN N
loss NN N
, , N
hidden JJ N
blood NN N
loss NN N
, , N
knee NN N
swelling NN N
, , N
ecchymosis NN N
, , N
analgesia NN N
requirements NNS N
, , N
range NN N
of IN N
motion NN N
( ( N
ROM NNP N
) ) N
, , N
fixed VBN N
flexion NN N
deformity NN N
( ( N
FFD NNP N
) ) N
, , N
straight-leg JJ N
raising VBG N
action NN N
, , N
and CC N
postoperative JJ N
complications NNS N
within IN N
6 CD N
weeks NNS N
of IN N
surgery NN N
were VBD N
measured VBN N
for IN N
evaluation NN N
and CC N
comparison NN N
RESULTS VB N
The DT N
postoperative JJ N
hidden JJ N
blood NN N
loss NN N
, , N
knee NN N
swelling NN N
, , N
and CC N
scope NN N
of IN N
ecchymosis NN N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
flexion NN N
group NN N
than IN N
in IN N
the DT N
extension NN N
group NN N
, , N
and CC N
ROM NNP N
and CC N
straight-leg JJ N
raising VBG N
action NN N
were VBD N
significantly RB N
higher JJR N
during IN N
the DT N
early JJ N
period NN N
after IN N
operation NN N
No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
perioperative JJ N
blood NN N
loss NN N
, , N
the DT N
amount NN N
of IN N
morphine NN N
used VBN N
, , N
or CC N
FFD NNP N
in IN N
the DT N
early JJ N
postoperative JJ N
period NN N
or CC N
in IN N
ROM NNP N
and CC N
FFD NNP N
at IN N
6 CD N
weeks NNS N
postoperatively RB N
CONCLUSIONS VB N
The DT N
findings NNS N
of IN N
this DT N
study NN N
indicate VBP N
that IN N
flexion NN N
of IN N
the DT N
knee NN N
to TO N
30° CD N
with IN N
the DT N
leg NN N
elevated VBD N
30° CD N
at IN N
the DT N
hip NN N
after IN N
total JJ N
knee NN N
arthroplasty NN N
may MD N
mitigate VB N
knee NN N
swelling VBG N
and CC N
provide VB N
other JJ N
beneficial JJ N
results NNS N
during IN N
the DT N
early JJ N
rehabilitation NN N
following VBG N
TKA NNP N
LEVEL NNP N
OF IN N
EVIDENCE NNP N
Prospective NNP N
comparative NN N
study NN N
, , N
Level NNP N
I PRP N
-DOCSTART- -X- O O 7640140

Comparison NNP N
of IN N
non-invasive JJ N
methods NNS N
for IN N
the DT N
assessment NN N
of IN N
haemodynamic JJ N
drug NN N
effects NNS N
in IN N
healthy JJ N
male NN N
and CC N
female JJ N
volunteers NNS N
: : N
sex NN N
differences NNS N
in IN N
cardiovascular JJ N
responsiveness NN N
1 CD N
The DT N
study NN N
was VBD N
performed VBN N
to TO N
determine VB N
the DT N
sensitivity NN N
and CC N
short-term JJ N
and CC N
day-to-day JJ N
variability NN N
of IN N
a DT N
novel NN N
technique NN N
based VBN N
on IN N
laser NN N
interferometry NN N
of IN N
ocular JJ N
fundus NN N
pulsations NNS N
and CC N
of IN N
non-invasive JJ N
methods NNS N
for IN N
the DT N
quantification NN N
of IN N
haemodynamic JJ N
drug NN N
effects NNS N
An DT N
additional JJ N
aim NN N
was VBD N
to TO N
assess VB N
sex NN N
differences NNS N
in IN N
haemodynamic JJ N
responsiveness NN N
to TO N
cardiovascular VB N
drugs NNS N
in IN N
male NN N
and CC N
female JJ N
healthy JJ N
volunteers NNS N
2 CD N
Ten CD 3_p
males NNS 2_p
and CC N
nine CD 3_p
females NNS 2_p
( ( N
age NN N
range NN N
20-33 CD N
years NNS N
) ) N
were VBD N
studied VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
cross-over JJ N
trial NN N
Simultaneous JJ N
measurements NNS N
from IN N
systemic JJ N
haemodynamics NNS N
, , N
laser JJR N
interferometry NN N
of IN N
ocular JJ N
fundus NN N
pulsations NNS N
, , N
systolic JJ N
time NN N
intervals NNS N
from IN N
mechanocardiography NN N
, , N
a/b VBP N
ratio NN N
from IN N
oxymetric JJ N
fingerplethysmography NN N
and CC N
Doppler NNP N
sonography NN N
of IN N
the DT N
radial JJ N
artery NN N
were VBD N
used VBN N
to TO N
describe VB N
the DT N
haemodynamic JJ N
effects NNS N
of IN N
cumulative JJ N
, , N
stepwise VB N
increasing VBG N
intravenous JJ N
doses NNS N
of IN N
phenylephrine NN N
, , N
isoprenaline NN N
, , N
sodium NN N
nitroprusside NN N
and CC N
of IN N
placebo NN N
3 CD N
Laser NNP N
interferometry NN N
detected VBD N
the DT N
isoprenaline-effects NNS N
at IN N
the DT N
lowest JJS N
dose JJ N
level NN N
of IN N
0.1 CD N
micrograms NNS N
min-1 JJ N
with IN N
a DT N
high JJ N
signal-to-noise NN N
ratio NN N
The DT N
reproducibility NN N
of IN N
measurements NNS N
under IN N
baseline NN N
was VBD N
high JJ N
, , N
no DT N
changes NNS N
were VBD N
observed VBN N
after IN N
systemically RB N
effective JJ N
doses NNS N
of IN N
phenylephrine NN N
or CC N
sodium NN N
nitroprusside RB N
Systolic JJ N
time NN N
intervals NNS N
were VBD N
sensitive JJ N
and CC N
specific JJ N
for IN N
isoprenaline-induced JJ N
effects NNS N
, , N
PEP NNP N
and CC N
QS2c-measurements NNS N
had VBD N
high JJ N
reproducibility NN N
Fingerplethysmography NNP N
proved VBD N
a DT N
sensitive JJ N
measurement NN N
for IN N
the DT N
detection NN N
of IN N
the DT N
vasodilating VBG N
effects NNS N
of IN N
sodium NN N
nitroprusside NN N
, , N
but CC N
was VBD N
not RB N
specific JJ N
, , N
and CC N
showed VBD N
low JJ N
reproducibility NN N
Measurements NNS N
from IN N
Doppler NNP N
sonography NN N
had VBD N
lower JJR N
reproducibility NN N
and CC N
sensitivity NN N
compared VBN N
with IN N
the DT N
other JJ N
applied JJ N
methods NNS N
4 CD N
There EX N
was VBD N
a DT N
significant JJ N
sex NN N
difference NN N
for IN N
several JJ N
of IN N
the DT N
haemodynamic JJ N
parameters NNS N
under IN N
baseline NN N
conditions NNS N
; : N
however RB N
, , N
the DT N
responsiveness NN N
to TO N
the DT N
drugs NNS N
under IN N
study NN N
was VBD N
not RB N
different JJ N
, , N
when WRB N
drug NN N
effects NNS N
were VBD N
expressed VBN N
as IN N
% NN N
-change NN N
from IN N
the DT N
baseline NN N
5 CD N
Laser NNP N
interferometry NN N
is VBZ N
a DT N
valuable JJ N
non-invasive JJ N
, , N
highly RB N
sensitive JJ N
and CC N
specific JJ N
approach NN N
for IN N
the DT N
detection NN N
of IN N
pulse JJ N
pressure NN N
changes NNS N
A DT N
battery NN N
of IN N
non-invasive JJ N
tests NNS N
appears VBZ N
useful JJ N
for IN N
the DT N
characterization NN N
of IN N
cardiovascular JJ N
drugs NNS N
Gender NNP N
differences NNS N
may MD N
not RB N
pose VB N
a DT N
relevant JJ N
problem NN N
for IN N
the DT N
study NN N
of IN N
acute JJ N
haemodynamic JJ N
effects NNS N
of IN N
cardiovascular JJ N
drugs NNS N
-DOCSTART- -X- O O 21433319

[ JJ N
Results NNP N
of IN N
three-year JJ N
clinical JJ N
study NN N
of IN N
prostamol NN N
uno JJ N
efficacy NN N
and CC N
safety NN N
in IN N
patients NNS N
with IN N
initial JJ N
symptoms NNS N
of IN N
prostatic JJ N
adenoma NN N
and CC N
risk NN N
of IN N
its PRP$ N
progression NN N
] NN N
Prostamol NNP N
Uno NNP N
( ( N
PU NNP N
) ) N
efficacy NN N
and CC N
safety NN N
were VBD N
studied VBN N
in IN N
a DT N
multicenter NN N
, , N
open-population NN N
, , N
randomized VBN N
and CC N
comparative JJ N
trial NN N
PU NNP N
was VBD N
given VBN N
in IN N
a DT N
single JJ N
daily JJ N
dose VB N
320 CD N
mg NN N
for IN N
36 CD N
months NNS N
to TO N
50 CD 3_p
patients NNS 3_p
with IN N
initial JJ N
symptoms NNS N
of IN N
prostatic JJ 4_p
adenoma NN 4_p
( ( 4_p
PA NNP 4_p
) ) 4_p
in IN N
comparison NN N
with IN N
50 CD 3_p
matched JJ 3_p
controls NNS 3_p
The DT N
trial NN N
evaluated VBD N
PU NNP N
action NN N
on IN N
the DT N
symptoms NNS N
progression NN N
and CC N
quality NN N
of IN N
life NN N
with IN N
application NN N
of IN N
questionnaires NNS N
IPSS NNP N
and CC N
QoL NNP N
( ( N
BS NNP N
) ) N
It PRP N
was VBD N
found VBN N
that IN N
PU NNP N
treatment NN N
relieved VBD N
PA NNP N
symptoms NNS N
by IN N
IPSS NNP N
, , N
while IN N
these DT N
symptoms NNS N
progressed VBD N
in IN N
the DT N
controls NNS N
QoL NNP N
improved VBD N
in IN N
the DT N
study NN N
group NN N
and CC N
deteriorated VBN N
in IN N
the DT N
control NN N
one CD N
Administration NN N
of IN N
PU NNP N
significantly RB N
increased VBD N
urinary JJ N
flow NN N
rate NN N
though IN N
in IN N
the DT N
controls NNS N
urinary JJ N
flow NN N
rate NN N
decreased VBN N
, , N
size NN N
of IN N
the DT N
prostate NN N
diminished VBD N
and CC N
increased VBD N
, , N
respectively RB N
Changes NNS N
in IN N
the DT N
PSA NNP N
were VBD N
not RB N
seen VBN N
and CC N
were VBD N
insignificant JJ N
, , N
respectively RB N
The DT N
results NNS N
of IN N
the DT N
study NN N
say VBP N
that IN N
prostamol NN N
Uno NNP N
in IN N
a DT N
dose JJ N
320 CD N
mg/day NN N
can MD N
prevent VB N
PA NNP N
progression NN N
without IN N
side JJ N
effects NNS N
-DOCSTART- -X- O O 22133872

Object JJ N
interest NN N
in IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : 4_p
a DT N
treatment NN N
comparison NN N
A DT N
randomized JJ N
control NN N
trial NN N
comparing VBG N
two CD N
social JJ N
communication NN N
treatments NNS N
for IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
examined VBD N
the DT N
effect NN N
of IN N
treatment NN N
on IN N
object JJ N
interest NN N
Thirty-two JJ 3_p
children NNS 1_p
, , 1_p
18-60 JJ 1_p
months NNS 1_p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
Picture NNP N
Exchange NNP N
Communication NNP N
System NNP N
( ( N
PECS NNP N
) ) N
or CC N
Responsive JJ N
Education NN N
and CC N
Prelinguistic NNP N
Milieu NNP N
Teaching NNP N
( ( N
RPMT NNP N
) ) N
condition NN N
Assessment NN N
of IN N
object JJ N
interest NN N
was VBD N
conducted VBN N
in IN N
an DT N
unstructured JJ N
play NN N
session NN N
with IN N
different JJ N
toys NNS N
, , N
activities NNS N
, , N
adult NN N
, , N
and CC N
location NN N
than IN N
experienced VBN N
in IN N
treatment NN N
Results NNS N
indicated VBD N
children NNS N
in IN N
the DT N
RPMT NNP N
condition NN N
showed VBD N
greater JJR N
increases NNS N
in IN N
object JJ N
interest NN N
as IN N
compared VBN N
to TO N
children NNS N
in IN N
the DT N
PECS NNP N
condition NN N
Because IN N
child JJ N
characteristics NNS N
such JJ N
as IN N
interest NN N
in IN N
objects NNS N
may MD N
influence VB N
response NN N
to TO N
interventions NNS N
using VBG N
object JJ N
play NN N
as IN N
contexts NN N
for IN N
treatment NN N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
improve VB N
our PRP$ N
understanding NN N
of IN N
whether IN N
intervention NN N
can MD N
affect VB N
object JJ N
interest NN N
-DOCSTART- -X- O O 16540862

A DT N
randomized JJ N
trial NN N
of IN N
chiropractic JJ N
and CC N
medical JJ N
care NN N
for IN N
patients NNS N
with IN N
low JJ 4_p
back RB 4_p
pain NN 4_p
: : N
eighteen-month JJ N
follow-up JJ N
outcomes NNS N
from IN N
the DT N
UCLA NNP N
low JJ N
back RB N
pain NN N
study NN N
STUDY NNP N
DESIGN NNP N
Randomized NNP N
clinical JJ N
trial NN N
OBJECTIVES UH N
To TO N
compare VB N
the DT N
long-term JJ N
effectiveness NN N
of IN N
medical JJ N
and CC N
chiropractic JJ N
care NN N
for IN N
low JJ 4_p
back RB 4_p
pain NN 4_p
in IN N
managed VBN N
care NN N
and CC N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
physical JJ N
therapy NN N
and CC N
modalities NNS N
among IN N
patients NNS N
receiving VBG N
medical JJ N
or CC N
chiropractic JJ N
care NN N
SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
Evidence NNP N
comparing VBG N
the DT N
long-term JJ N
relative JJ N
effectiveness NN N
of IN N
common JJ N
treatment NN N
strategies NNS N
offered VBD N
to TO N
low VB 4_p
back RB 4_p
pain NN 4_p
patients NNS N
in IN N
managed VBN N
care NN N
is VBZ N
lacking VBG N
METHODS NNP N
A NNP N
total NN N
of IN N
681 CD 3_p
low JJ 4_p
back RB 4_p
pain NN 4_p
patients NNS N
presenting VBG N
to TO N
a DT N
managed-care JJ N
facility NN N
were VBD N
randomized VBN N
to TO N
chiropractic VB N
with IN N
or CC N
without IN N
physical JJ N
modalities NNS N
, , N
or CC N
medical JJ N
care NN N
with IN N
or CC N
without IN N
physical JJ N
therapy NN N
, , N
and CC N
followed VBD N
for IN N
18 CD N
months NNS N
The DT N
primary JJ N
outcome NN N
variables NNS N
are VBP N
low JJ N
back RB N
pain NN N
intensity NN N
, , N
disability NN N
, , N
and CC N
complete JJ N
remission NN N
The DT N
secondary JJ N
outcome NN N
is VBZ N
participants NNS N
' POS N
perception NN N
of IN N
improvement NN N
in IN N
low JJ N
back RB N
symptoms NNS N
RESULTS NNP N
Of IN N
the DT N
681 CD 3_p
patients NNS N
, , N
610 CD 3_p
( ( N
89.6 CD N
% NN N
) ) N
were VBD N
followed VBN N
through IN N
18 CD N
months NNS N
Among IN N
participants NNS N
not RB N
assigned VBN N
to TO N
receive VB N
physical JJ N
therapy NN N
or CC N
modalities NNS N
, , N
the DT N
estimated JJ N
improvements NNS N
in IN N
pain NN N
and CC N
disability NN N
and CC N
18-month JJ N
risk NN N
of IN N
complete JJ N
remission NN N
were VBD N
a DT N
little JJ N
greater JJR N
in IN N
the DT N
chiropractic JJ N
group NN N
than IN N
in IN N
the DT N
medical JJ N
group NN N
( ( N
adjusted VBN N
RR NNP N
of IN N
remission NN N
= NNP N
1.29 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0.80-2.07 NN N
) ) N
Among IN N
participants NNS N
assigned VBN N
to TO N
medical JJ N
care NN N
, , N
mean JJ N
changes NNS N
in IN N
pain NN N
and CC N
disability NN N
and CC N
risk NN N
of IN N
remission NN N
were VBD N
larger JJR N
in IN N
patients NNS N
assigned VBN N
to TO N
receive VB N
physical JJ N
therapy NN N
( ( N
adjusted VBN N
RR NNP N
= NNP N
1.69 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
1.08-2.66 JJ N
) ) N
Among IN N
those DT N
assigned VBN N
to TO N
chiropractic JJ N
care NN N
, , N
however RB N
, , N
assignment NN N
to TO N
methods NNS N
was VBD N
not RB N
associated VBN N
with IN N
improvement NN N
or CC N
remission NN N
( ( N
adjusted VBN N
RR NNP N
= NNP N
0.98 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0.62-1.55 NN N
) ) N
Compared VBN N
with IN N
medical JJ N
care NN N
only RB N
patients NNS N
, , N
chiropractic JJ N
and CC N
physical JJ N
therapy NN N
patients NNS N
were VBD N
much RB N
more RBR N
likely JJ N
to TO N
perceive VB N
improvement NN N
in IN N
their PRP$ N
low JJ N
back RB N
symptoms NNS N
However RB N
, , N
less JJR N
than IN N
20 CD N
% NN N
of IN N
all DT N
patients NNS N
were VBD N
pain-free JJ N
at IN N
18 CD N
months NNS N
CONCLUSIONS NNP N
Differences NNPS N
in IN N
outcomes NNS N
between IN N
medical JJ N
and CC N
chiropractic JJ N
care NN N
without IN N
physical JJ N
therapy NN N
or CC N
modalities NNS N
are VBP N
not RB N
clinically RB N
meaningful JJ N
, , N
although IN N
chiropractic JJ N
may MD N
result VB N
in IN N
a DT N
greater JJR N
likelihood NN N
of IN N
perceived JJ N
improvement NN N
, , N
perhaps RB N
reflecting VBG N
satisfaction NN N
or CC N
lack NN N
of IN N
blinding NN N
Physical JJ N
therapy NN N
may MD N
be VB N
more RBR N
effective JJ N
than IN N
medical JJ N
care NN N
alone RB N
for IN N
some DT N
patients NNS N
, , N
while IN N
physical JJ N
modalities NNS N
appear VBP N
to TO N
have VB N
no DT N
benefit NN N
in IN N
chiropractic JJ N
care NN N
-DOCSTART- -X- O O 12020338

Effect NN N
of IN N
intensive JJ N
therapy NN N
on IN N
the DT N
microvascular JJ N
complications NNS N
of IN N
type NN 4_p
1 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
The DT N
purpose NN N
of IN N
this DT N
report NN N
is VBZ N
to TO N
summarize VB N
and CC N
integrate VB N
the DT N
findings NNS N
of IN N
the DT N
Diabetes NNP N
Control NNP N
and CC N
Complications NNP N
Trial NNP N
( ( N
DCCT NNP N
) ) N
, , N
a DT N
randomized VBN N
controlled JJ N
clinical JJ N
trial NN N
, , N
and CC N
the DT N
succeeding JJ N
observational JJ N
follow-up NN N
of IN N
the DT N
DCCT NNP N
cohort NN N
in IN N
the DT N
Epidemiology NNP N
of IN N
Diabetes NNP N
Interventions NNP N
and CC N
Complications NNP N
( ( N
EDIC NNP N
) ) N
study NN N
, , N
regarding VBG N
the DT N
effects NNS N
of IN N
intensive JJ N
treatment NN N
on IN N
the DT N
microvascular JJ N
complications NNS N
of IN N
type NN 4_p
1 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
The DT N
DCCT NNP N
proved VBD N
that IN N
intensive JJ N
treatment NN N
reduced VBD N
the DT N
risks NNS N
of IN N
retinopathy NN N
, , N
nephropathy JJ N
, , N
and CC N
neuropathy JJ N
by IN N
35 CD N
% NN N
to TO N
90 CD N
% NN N
compared VBN N
with IN N
conventional JJ N
treatment NN N
The DT N
absolute JJ N
risks NNS N
of IN N
retinopathy NN N
and CC N
nephropathy JJ N
were VBD N
proportional JJ N
to TO N
the DT N
mean NN N
glycosylated VBD N
hemoglobin NN N
( ( N
HbA NNP N
( ( N
1c CD N
) ) N
) ) N
level NN N
over IN N
the DT N
follow-up JJ N
period NN N
preceding VBG N
each DT N
event NN N
Intensive JJ N
treatment NN N
was VBD N
most RBS N
effective JJ N
when WRB N
begun VBN N
early RB N
, , N
before IN N
complications NNS N
were VBD N
detectable JJ N
These DT N
risk NN N
reductions NNS N
, , N
achieved VBN N
at IN N
a DT N
median JJ N
HbA NNP N
( ( N
1c CD N
) ) N
level NN N
difference NN N
of IN N
9.1 CD N
% NN N
for IN N
conventional JJ N
treatment NN N
vs RB N
7.3 CD N
% NN N
for IN N
intensive JJ N
treatment NN N
have VBP N
been VBN N
maintained VBN N
through IN N
7 CD N
years NNS N
of IN N
EDIC NNP N
, , N
even RB N
though IN N
the DT N
difference NN N
in IN N
mean JJ N
HbA NNP N
( ( N
1c CD N
) ) N
levels NNS N
of IN N
the DT N
2 CD N
former JJ N
randomized VBN N
treatment NN N
groups NNS N
was VBD N
only RB N
0.4 CD N
% NN N
at IN N
1 CD N
year NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
( ( N
8.3 CD N
% NN N
in IN N
the DT N
former JJ N
conventional JJ N
treatment NN N
group NN N
vs VBD N
7.9 CD N
% NN N
in IN N
the DT N
former JJ N
intensive JJ N
treatment NN N
group NN N
) ) N
, , N
continued VBD N
to TO N
narrow VB N
, , N
and CC N
became VBD N
statistically RB N
nonsignificant JJ N
by IN N
5 CD N
years NNS N
( ( N
8.1 CD N
% NN N
vs JJ N
8.2 CD N
% NN N
, , N
P NNP N
=.09 NNP N
) ) N
The DT N
further JJ N
rate NN N
of IN N
progression NN N
of IN N
complications NNS N
from IN N
their PRP$ N
levels NNS N
at IN N
the DT N
end NN N
of IN N
the DT N
DCCT NNP N
remains VBZ N
less RBR N
in IN N
the DT N
former JJ N
intensive JJ N
treatment NN N
group NN N
Thus RB N
, , N
the DT N
benefits NNS N
of IN N
6.5 CD N
years NNS N
of IN N
intensive JJ N
treatment NN N
extend VBP N
well RB N
beyond IN N
the DT N
period NN N
of IN N
its PRP$ N
most RBS N
intensive JJ N
implementation NN N
Intensive JJ N
treatment NN N
should MD N
be VB N
started VBN N
as RB N
soon RB N
as IN N
is VBZ N
safely RB N
possible JJ N
after IN N
the DT N
onset NN N
of IN N
type NN N
1 CD N
diabetes NNS N
mellitus NN N
and CC N
maintained VBD N
thereafter RB N
, , N
aiming VBG N
for IN N
a DT N
practicable JJ N
target NN N
HbA NNP N
( ( N
1c CD N
) ) N
level NN N
of IN N
7.0 CD N
% NN N
or CC N
less JJR N
-DOCSTART- -X- O O 11932879

Step-down JJ N
approach NN N
using VBG N
either CC N
cyclosporin VB N
A DT N
or CC N
methotrexate NN N
as IN N
maintenance NN N
therapy NN N
in IN N
early JJ N
rheumatoid NN 4_p
arthritis NN 4_p
OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
feasibility NN N
and CC N
outcome NN N
of IN N
the DT N
step-down JJ N
approach NN N
using VBG N
either CC N
cyclosporin VB N
A NNP N
( ( N
CSA NNP N
) ) N
or CC N
methotrexate NN N
( ( N
MTX NNP N
) ) N
as IN N
maintenance NN N
therapy NN N
following VBG N
6 CD N
months NNS N
treatment NN N
with IN N
these DT N
2 CD N
agents NNS N
in IN N
combination NN N
in IN N
early JJ N
, , N
nonerosive JJ N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
METHODS NNP N
Fifty-seven JJ N
patients NNS N
younger JJR N
than IN N
65 CD N
years NNS N
with IN N
early JJ N
, , N
nonerosive JJ 4_p
RA NNP 4_p
were VBD N
first RB N
treated VBN N
with IN N
CSA NNP N
and CC N
MTX NNP N
in IN N
combination NN N
for IN N
6 CD N
months NNS N
They PRP N
were VBD N
then RB N
randomly RB N
stepped VBD N
down RB N
to TO N
single-agent JJ N
maintenance NN N
treatment NN N
for IN N
another DT N
18 CD N
months NNS N
Safety NNP N
, , N
clinical JJ N
efficacy NN N
, , N
survival NN N
on IN N
treatment NN N
, , N
and CC N
radiographic JJ N
progression NN N
were VBD N
evaluated VBN N
RESULTS VB N
When WRB N
being VBG N
treated VBN N
with IN N
combination NN N
therapy NN N
, , N
7 CD 3_p
of IN 3_p
the DT 3_p
57 CD 3_p
patients NNS 3_p
( ( N
12.3 CD N
% NN N
) ) N
withdrew NN N
because IN N
of IN N
adverse JJ N
events NNS N
Of IN N
the DT N
remaining VBG N
50 CD N
patients NNS N
, , N
42 CD N
( ( N
84.0 CD N
% NN N
) ) N
were VBD N
American JJ N
College NNP N
of IN N
Rheumatology NNP N
( ( N
ACR NNP N
) ) N
20 CD N
% NN N
responders NNS N
, , N
30 CD N
( ( N
60.0 CD N
% NN N
) ) N
were VBD N
ACR NNP N
50 CD N
% NN N
responders NNS N
, , N
and CC N
23 CD N
( ( N
46.0 CD N
% NN N
) ) N
were VBD N
ACR NNP N
70 CD N
% NN N
responders NNS N
At IN N
month NN N
6 CD N
, , N
22 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
CSA NNP N
and CC N
27 CD N
to TO N
MTX NNP N
During IN N
this DT N
trial NN N
period NN N
, , N
the DT N
treatment NN N
was VBD N
discontinued VBN N
by IN N
16 CD N
patients NNS N
taking VBG N
CSA NNP N
( ( N
mainly RB N
because IN N
of IN N
loss NN N
of IN N
efficacy NN N
) ) N
and CC N
by IN N
4 CD N
taking VBG N
MTX NNP N
At IN N
month NN N
24 CD N
, , N
the DT N
probability NN N
( ( N
+/- JJ N
SEM NNP N
) ) N
of IN N
survival NN N
on IN N
treatment NN N
was VBD N
0.273 CD N
+/- JJ N
0.09 CD N
for IN N
CSA NNP N
and CC N
0.852 CD N
+/- JJ N
0.07 CD N
for IN N
MTX NNP N
Of IN N
the DT N
6 CD N
CSA NNP N
patients NNS N
who WP N
completed VBD N
the DT N
trial NN N
, , N
4 CD N
( ( N
66.7 CD N
% NN N
) ) N
were VBD N
ACR NNP N
20 CD N
% NN N
responders NNS N
, , N
and CC N
3 CD N
( ( N
50 CD N
% NN N
) ) N
were VBD N
both DT N
ACR NNP N
50 CD N
% NN N
and CC N
ACR NNP N
70 CD N
% NN N
responders NNS N
Of IN N
the DT N
23 CD N
completers NNS N
in IN N
the DT N
MTX NNP N
arm NN N
, , N
21 CD N
( ( N
91.3 CD N
% NN N
) ) N
were VBD N
ACR NNP N
20 CD N
% NN N
responders NNS N
, , N
18 CD N
( ( N
78.3 CD N
% NN N
) ) N
were VBD N
ACR NNP N
50 CD N
% NN N
, , N
and CC N
10 CD N
( ( N
43.5 CD N
% NN N
) ) N
were VBD N
ACR NNP N
70 CD N
% NN N
responders NNS N
The DT N
treatment NN N
was VBD N
not RB N
responsible JJ N
for IN N
severe JJ N
adverse JJ N
events NNS N
Radiography NNP N
showed VBD N
a DT N
slow JJ N
progression NN N
in IN N
the DT N
damage NN N
score NN N
and CC N
number NN N
of IN N
eroded JJ N
joints NNS N
in IN N
both DT N
treatment NN N
groups NNS N
CONCLUSION NNP N
Stepping VBG N
down RP N
to TO N
single JJ N
agent JJ N
maintenance NN N
therapy NN N
following VBG N
6 CD N
months NNS N
of IN N
combination NN N
treatment NN N
with IN N
CSA NNP N
and CC N
MTX NNP N
in IN N
early JJ N
RA NNP N
was VBD N
only RB N
successful JJ N
with IN N
MTX NNP N
Because IN N
this DT N
treatment NN N
did VBD N
not RB N
prevent VB N
some DT N
radiographic JJ N
progression NN N
, , N
other JJ N
approaches NNS N
( ( N
e.g. NN N
, , N
step-up JJ N
approach NN N
) ) N
may MD N
be VB N
more JJR N
appropriate JJ N
in IN N
early JJ 4_p
RA NNP 4_p
-DOCSTART- -X- O O 16202291

[ NN N
Study NNP N
on IN N
classification NN N
and CC N
treatment NN N
of IN N
vulvovaginal JJ 4_p
candidiasis NN 4_p
] NN N
OBJECTIVE UH N
To TO N
determine VB N
the DT N
clinical JJ N
manifestations NNS N
of IN N
vulvovaginal JJ 4_p
candidiasis NN 4_p
( ( 4_p
VVC NNP 4_p
) ) 4_p
and CC N
to TO N
study VB N
the DT N
mycologic JJ N
eradication NN N
rate NN N
of IN N
different JJ N
miconazole JJ N
treatment NN N
courses NNS N
for IN N
VVC NNP N
METHODS NNP N
Three CD 3_p
hundred VBD 3_p
cases NNS N
of IN N
VVC NNP 4_p
were VBD N
recruited VBN N
The DT N
Candidas NNPS N
were VBD N
cultured VBN N
A DT N
prospective JJ N
and CC N
randomized VBD N
study NN N
was VBD N
performed VBN N
to TO N
compare VB N
the DT N
treatment NN N
effect NN N
of IN N
3 CD N
day NN N
miconazole NN N
( ( N
400 CD N
mg/d NN N
) ) N
, , N
6 CD N
day NN N
miconazole NN N
( ( N
400 CD N
mg/d NN N
) ) N
, , N
and CC N
7 CD N
day NN N
miconazole NN N
( ( N
200 CD N
mg/d NN N
) ) N
for IN N
uncomplicated JJ N
and CC N
complicated VBD N
VVC NNP N
RESULTS NNP N
Among IN N
300 CD 3_p
cases NNS N
of IN N
VVC NNP N
, , N
uncomplicated VBD N
, , N
complicated VBN N
and CC N
recurrent JJ N
VVC NNP N
were VBD N
56.0 CD N
% NN N
, , N
44.0 CD N
% NN N
and CC N
9.7 CD N
% NN N
( ( N
29/300 CD N
) ) N
respectively RB N
C. NNP N
albicans NNS N
was VBD N
isolated VBN N
most JJS N
frequently RB N
90.3 CD N
% NN N
( ( N
271/300 CD N
) ) N
, , N
followed VBN N
by IN N
C. NNP N
glabrata NN N
( ( N
7.3 CD N
% NN N
) ) N
, , N
C. NNP N
tropicalis NN N
( ( N
1.3 CD N
% NN N
) ) N
, , N
C. NNP N
krusei NNP N
( ( N
0.7 CD N
% NN N
) ) N
, , N
and CC N
C. NNP N
parapsilosis NN N
( ( N
0.3 CD N
% NN N
) ) N
Mycologic JJ N
eradication NN N
rate NN N
of IN N
3 CD N
day NN N
, , N
6 CD N
day NN N
and CC N
7 CD N
day NN N
miconazole NN N
courses NNS N
for IN N
uncomplicated JJ N
VVC NNP N
at IN N
day NN N
14 CD N
was VBD N
96.0 CD N
% NN N
, , N
93.5 CD N
% NN N
and CC N
98.0 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
Eradication NNP N
rate NN N
of IN N
3 CD N
day NN N
, , N
6 CD N
day NN N
and CC N
7 CD N
day NN N
miconazole NN N
courses NNS N
for IN N
complicated VBN N
VVC NNP N
at IN N
day NN N
14 CD N
was VBD N
86.7 CD N
% NN N
, , N
92.5 CD N
% NN N
, , N
and CC N
86.4 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
Eradication NNP N
rate NN N
of IN N
3 CD N
day NN N
, , N
6 CD N
day NN N
and CC N
7 CD N
day NN N
miconazole NN N
courses NNS N
for IN N
uncomplicated JJ N
VVC NNP N
at IN N
day NN N
35 CD N
was VBD N
93.8 CD N
% NN N
, , N
95.3 CD N
% NN N
, , N
and CC N
89.8 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
Eradication NNP N
rate NN N
of IN N
3 CD N
day NN N
, , N
6 CD N
day NN N
and CC N
7 CD N
day NN N
miconazole NN N
courses NNS N
for IN N
complicated VBN N
VVC NNP N
at IN N
day NN N
35 CD N
was VBD N
89.7 CD N
% NN N
, , N
97.3 CD N
% NN N
and CC N
86.8 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
CONCLUSION NNP N
Treatment NNP N
of IN N
VVC NNP N
should MD N
be VB N
individualized VBN N
, , N
and CC N
women NNS 2_p
with IN N
complicated JJ N
VVC NNP 4_p
achieve VBP N
superior JJ N
mycologic JJ N
eradication NN N
by IN N
a DT N
6 CD N
day NN N
miconazole JJ N
course NN N
-DOCSTART- -X- O O 25978402

Multicomponent NNP N
interdisciplinary JJ N
group NN N
intervention NN N
for IN N
self-management NN N
of IN N
fibromyalgia NN 4_p
: : N
a DT N
mixed-methods NNS N
randomized VBN N
controlled JJ N
trial NN N
BACKGROUND VB N
This DT N
study NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
the DT N
PASSAGE NNP N
Program NNP N
, , N
a DT N
structured JJ N
multicomponent NN N
interdisciplinary JJ N
group NN N
intervention NN N
for IN N
the DT N
self-management NN N
of IN N
FMS NNP 4_p
METHODS NNP N
A DT N
mixed-methods NNS N
randomized VBN N
controlled VBN N
trial NN N
( ( N
intervention NN N
( ( N
INT NNP N
) ) N
vs. FW N
waitlist NN N
( ( N
WL NNP N
) ) N
) ) N
was VBD N
conducted VBN N
with IN N
patients NNS 4_p
suffering VBG 4_p
from IN 4_p
FMS NNP 4_p
Data NNP N
were VBD N
collected VBN N
at IN N
baseline NN N
( ( N
T0 NNP N
) ) N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
( ( N
T1 NNP N
) ) N
, , N
and CC N
3 CD N
months NNS N
later RB N
( ( N
T2 NNP N
) ) N
The DT N
primary JJ N
outcome NN N
was VBD N
change NN N
in IN N
pain NN N
intensity NN N
( ( N
0-10 JJ N
) ) N
Secondary JJ N
outcomes NNS N
were VBD N
fibromyalgia JJ N
severity NN N
, , N
pain NN N
interference NN N
, , N
sleep JJ N
quality NN N
, , N
pain VBP N
coping VBG N
strategies NNS N
, , N
depression NN N
, , N
health-related JJ N
quality NN N
of IN N
life NN N
, , N
patient JJ N
global JJ N
impression NN N
of IN N
change NN N
( ( N
PGIC NNP N
) ) N
, , N
and CC N
perceived VBD N
pain NN N
relief NN N
Qualitative JJ N
group NN N
interviews NNS N
with IN N
a DT N
subset NN N
of IN N
patients NNS N
were VBD N
also RB N
conducted VBN N
Complete NNP N
data NN N
from IN N
T0 NNP N
to TO N
T2 NNP N
were VBD N
available JJ N
for IN N
43 CD 3_p
patients NNS 3_p
RESULTS VB N
The DT N
intervention NN N
had VBD N
a DT N
statistically RB N
significant JJ N
impact NN N
on IN N
the DT N
three CD N
PGIC NNP N
measures NNS N
At IN N
the DT N
end NN N
of IN N
the DT N
PASSAGE NNP N
Program NNP N
, , N
the DT N
percentages NNS N
of IN N
patients NNS N
who WP N
perceived VBD N
overall JJ N
improvement NN N
in IN N
their PRP$ N
pain NN N
levels NNS N
, , N
functioning NN N
and CC N
quality NN N
of IN N
life NN N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
INT NNP N
Group NNP N
( ( N
73 CD N
% NN N
, , N
55 CD N
% NN N
, , N
77 CD N
% NN N
respectively RB N
) ) N
than IN N
in IN N
the DT N
WL NNP N
Group NNP N
( ( N
8 CD N
% NN N
, , N
12 CD N
% NN N
, , N
20 CD N
% NN N
) ) N
The DT N
same JJ N
differences NNS N
were VBD N
observed JJ N
3 CD N
months NNS N
post-intervention NN N
( ( N
Intervention NNP N
group NN N
: : N
62 CD N
% NN N
, , N
43 CD N
% NN N
, , N
38 CD N
% NN N
vs JJ N
Waitlist NNP N
Group NNP N
: : N
13 CD N
% NN N
, , N
13 CD N
% NN N
, , N
9 CD N
% NN N
) ) N
The DT N
proportion NN N
of IN N
patients NNS N
who WP N
reported VBD N
≥ JJ N
50 CD N
% NN N
pain NN N
relief NN N
was VBD N
also RB N
significantly RB N
higher RBR N
in IN N
the DT N
INT NNP N
Group NNP N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
( ( N
36 CD N
% NN N
vs JJ N
12 CD N
% NN N
) ) N
and CC N
3 CD N
months NNS N
post-intervention NN N
( ( N
33 CD N
% NN N
vs JJ N
4 CD N
% NN N
) ) N
Results NNS N
of IN N
the DT N
qualitative JJ N
analysis NN N
were VBD N
in IN N
line NN N
with IN N
the DT N
quantitative JJ N
findings NNS N
regarding VBG N
the DT N
efficacy NN N
of IN N
the DT N
intervention NN N
The DT N
improvement NN N
, , N
however RB N
, , N
was VBD N
not RB N
reflected VBN N
in IN N
the DT N
primary JJ N
outcome NN N
and CC N
other JJ N
secondary JJ N
outcome NN N
measures NNS N
CONCLUSION NNP N
The DT N
PASSAGE NNP N
Program NNP N
was VBD N
effective JJ N
in IN N
helping VBG 4_p
FMS NNP 4_p
patients NNS 4_p
gain VBP N
a DT N
sense NN N
of IN N
control NN N
over IN N
their PRP$ N
symptoms NNS N
We PRP N
suggest VBP N
including VBG N
PGIC NNP N
in IN N
future JJ N
clinical JJ N
trials NNS N
on IN 4_p
FMS NNP 4_p
as IN N
they PRP N
appear VBP N
to TO N
capture VB N
important JJ N
aspects NNS N
of IN N
the DT N
patients NNS N
' POS N
experience NN N
TRIAL NNP N
REGISTRATION NNP N
International NNP N
Standard NNP N
Randomized NNP N
Controlled NNP N
Trial NNP N
Number NNP N
Register NNP N
ISRCTN14526380 NNP N
-DOCSTART- -X- O O 24992750

Comparison NNP N
of IN N
clinical JJ N
effectiveness NN N
of IN N
acupuncture NN N
and CC N
a DT N
Western JJ N
drug NN N
on IN N
allergic JJ 4_p
rhinitis NN 4_p
: : 4_p
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
an DT N
acupuncture NN N
regimen NN N
for IN N
persistent JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
( ( 4_p
PER NNP 4_p
) ) 4_p
, , N
aimed VBN N
at IN N
improving VBG N
a DT N
patient NN N
's POS N
mind NN N
or CC N
Shen NNP N
in IN N
Traditional NNP N
Chinese NNP N
Medicine NNP N
, , N
to TO N
that DT N
of IN N
a DT N
second-generation JJ N
Hi-receptor NNP N
antagonist NN N
, , N
cetirizine JJ N
hydrochloride NN N
METHODS NNP N
This DT N
multicenter NN N
, , N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
on IN N
PER NNP N
will MD N
be VB N
conducted VBN N
at IN N
three CD N
institutions NNS N
in IN N
China NNP N
The DT N
total JJ N
study NN N
period NN N
will MD N
be VB N
9 CD N
weeks NNS N
After IN N
a DT N
1-week JJ N
preparatory NN N
screening VBG N
period NN N
, , N
240 CD 3_p
eligible JJ N
participants NNS N
with IN N
PER NNP N
will MD N
be VB N
randomized VBN N
to TO N
receive VB N
acupuncture NN N
or CC N
pharmacotherapy NN N
( ( N
1:1 CD N
) ) N
for IN N
4 CD N
weeks NNS N
with IN N
a DT N
4-week JJ N
follow-up NN N
The DT N
primary JJ N
outcome NN N
will MD N
be VB N
changes NNS N
in IN N
7-day JJ N
average JJ N
total JJ N
nasal JJ N
symptom NN N
score NN N
Secondary JJ N
outcome NN N
measures NNS N
include VBP N
rhinoconjunctivitis JJ N
quality NN N
of IN N
life NN N
questionnaire NN N
score NN N
and CC N
total JJ N
non-nasal JJ N
symptom NN N
score NN N
RESULTS VB N
The DT N
presence NN N
and CC N
seriousness NN N
of IN N
psychological JJ N
and CC N
emotional JJ N
impairments NNS N
should MD N
be VB N
considered VBN N
in IN N
therapeutic JJ N
programs NNS N
for IN N
allergic JJ N
rhinitis NN N
No DT N
clinical JJ N
trial NN N
for IN N
treating VBG N
allergic JJ N
rhinitis NN N
via IN N
acupuncture NN N
regulation NN N
of IN N
psychological JJ N
and CC N
emotional JJ N
activities NNS N
has VBZ N
been VBN N
reported VBN N
CONCLUSION VB N
The DT N
findings NNS N
of IN N
the DT N
trial NN N
will MD N
allow VB N
us PRP N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
the DT N
mind NN N
( ( N
Shen NNP N
) ) N
-regulation NN N
treatment NN N
approach NN N
We PRP N
will MD N
also RB N
be VB N
able JJ N
to TO N
confirm VB N
if IN N
the DT N
effects NNS N
of IN N
acupuncture NN N
are VBP N
equivalent JJ N
to TO N
those DT N
of IN N
the DT N
conventional JJ N
drug NN N
cetirizine NN N
hydrochloride NN N
-DOCSTART- -X- O O 20837163

A DT N
web-based JJ N
patient NN N
activation NN N
intervention NN N
to TO N
improve VB N
hypertension NN N
care NN N
: : N
study NN N
design NN N
and CC N
baseline NN N
characteristics NNS N
in IN N
the DT N
web NN N
hypertension NN N
study NN N
BACKGROUND NNP N
Despite IN N
the DT N
known JJ N
health NN N
risks NNS N
of IN N
hypertension NN N
, , N
many JJ N
hypertensive JJ 4_p
patients NNS N
still RB N
have VBP N
uncontrolled VBN N
blood NN N
pressure NN N
Clinical JJ N
inertia NN N
, , N
the DT N
tendency NN N
of IN N
physicians NNS N
not RB N
to TO N
intensify VB N
treatment NN N
, , N
is VBZ N
a DT N
common JJ N
barrier NN N
in IN N
controlling VBG N
chronic JJ N
diseases NNS N
This DT N
trial NN N
is VBZ N
aimed VBN N
at IN N
determining VBG N
the DT N
impact NN N
of IN N
activating VBG N
patients NNS N
to TO N
ask VB N
providers NNS N
to TO N
make VB N
changes NNS N
to TO N
their PRP$ N
care NN N
through IN N
tailored VBN N
feedback NN N
METHODS NNP N
Diagnosed VBD N
hypertensive JJ 4_p
patients NNS N
were VBD N
enrolled VBN N
in IN N
this DT N
RCT NNP N
and CC N
randomized VBN N
to TO N
one CD N
of IN N
two CD N
study NN N
groups NNS N
: : N
( ( N
1 CD N
) ) N
the DT N
intervention NN N
condition NN N
-- : N
Web-based JJ N
hypertension NN N
feedback NN N
, , N
based VBN N
on IN N
the DT N
individual JJ N
patient NN N
's POS N
self-report NN N
of IN N
health NN N
variables NNS N
and CC N
previous JJ N
BP NNP N
measurements NNS N
, , N
to TO N
prompt VB N
them PRP N
to TO N
ask VB N
questions NNS N
during IN N
their PRP$ N
next JJ N
physician NN N
's POS N
visit NN N
about IN N
hypertension NN N
care NN N
( ( N
2 CD N
) ) N
the DT N
control NN N
condition NN N
-- : N
Web-based JJ N
preventive JJ N
health NN N
feedback NN N
, , N
based VBN N
on IN N
the DT N
individual NN N
's POS N
self-report NN N
of IN N
receiving VBG N
preventive JJ N
care NN N
( ( N
e.g. UH N
, , N
pap JJ N
testing VBG N
) ) N
, , N
to TO N
prompt VB N
them PRP N
to TO N
ask VB N
questions NNS N
during IN N
their PRP$ N
next JJ N
physician NN N
's POS N
visit NN N
about IN N
preventive JJ N
care NN N
The DT N
primary JJ N
outcome NN N
of IN N
the DT N
study NN N
is VBZ N
change VBN N
in IN N
blood NN N
pressure NN N
and CC N
change NN N
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
in IN N
each DT N
group NN N
with IN N
controlled VBN N
blood NN N
pressure NN N
CONCLUSION NNP N
Five CD 3_p
hundred VBD 3_p
participants NNS N
were VBD N
enrolled VBN N
and CC N
baseline JJ N
characteristics NNS N
include VBP N
a DT N
mean JJ N
age NN N
of IN N
60.0 CD 1_p
years NNS 1_p
; : N
57.6 CD N
% NN N
female NN 2_p
; : N
and CC N
77.6 CD N
% NN N
white JJ N
Overall JJ N
37.7 CD N
% NN N
participants NNS N
had VBD N
uncontrolled VBN 4_p
blood NN 4_p
pressure NN 4_p
; : N
the DT N
mean NN N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
was VBD N
in IN N
the DT N
obese JJ N
range NN N
( ( N
32.4 CD N
) ) N
and CC N
21.8 CD N
% NN N
had VBD N
diabetes NNS 4_p
By IN N
activating VBG N
patients NNS N
to TO N
become VB N
involved VBN N
in IN N
their PRP$ N
own JJ N
care NN N
, , N
we PRP N
believe VBP N
the DT N
addition NN N
of IN N
the DT N
web-based JJ N
intervention NN N
will MD N
improve VB N
blood NN N
pressure NN N
control NN N
compared VBN N
to TO N
a DT N
control NN N
group NN N
who WP N
receive VBP N
web-based JJ N
preventive JJ N
messages NNS N
unrelated VBN N
to TO N
hypertension NN N
-DOCSTART- -X- O O 23205617

An DT N
internet-based JJ N
cognitive-behavioural JJ N
training NN N
for IN N
acute JJ 4_p
tinnitus NN 4_p
: : N
secondary JJ N
analysis NN N
of IN N
acceptance NN N
in IN N
terms NNS N
of IN N
satisfaction NN N
, , N
trial NN N
attrition NN N
and CC N
non-usage JJ N
attrition NN N
OBJECTIVES NNP N
Recent NNP N
studies NNS N
on IN N
tinnitus NN N
have VBP N
focused VBN N
on IN N
the DT N
efficacy NN N
of IN N
Internet-based JJ N
interventions NNS N
Other JJ N
core NN N
features NNS N
of IN N
the DT N
quality NN N
of IN N
service NN N
, , N
e.g NN N
acceptance NN N
and CC N
attrition NN N
, , N
have VBP N
often RB N
been VBN N
overlooked VBN N
This DT N
study NN N
analyses VBZ N
Internet-based JJ N
training NN N
regarding VBG N
acceptance NN N
and CC N
attrition NN N
in IN N
a DT N
trial NN N
on IN N
minimal-contact JJ N
interventions NNS N
for IN N
acute JJ 4_p
tinnitus NN 4_p
Whenever NNP N
possible JJ N
, , N
we PRP N
give VBP N
information NN N
on IN N
other JJ N
forms NNS N
of IN N
training NN N
for IN N
comparison NN N
METHODS NNP N
In IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
with IN N
337 CD 3_p
participants NNS N
, , N
87 CD 3_p
persons NNS N
took VBD N
part NN N
in IN N
the DT N
Internet NNP N
training NN N
RESULTS VB N
The DT N
participants NNS N
were VBD N
as IN N
satisfied JJ N
with IN N
the DT N
Internet-based JJ N
training NN N
as IN N
with IN N
a DT N
face-to-face JJ N
group NN N
training NN N
There EX N
was VBD N
a DT N
34.48 CD N
% NN N
dropout NN N
from IN N
the DT N
Internet-based JJ N
training NN N
( ( N
dropout IN N
attrition NN N
) ) N
The DT N
training NN N
attrition NN N
from IN N
the DT N
Internet-based JJ N
training NN N
was VBD N
even RB N
higher JJR N
at IN N
64.4 CD N
% NN N
CONCLUSIONS NNP N
Two CD N
out IN N
of IN N
three CD N
indicators NNS N
for IN N
acceptance-satisfaction NN N
and CC N
dropout IN N
attrition-provide JJ N
comparable JJ N
results NNS N
between IN N
the DT N
Internet-based JJ N
training NN N
and CC N
a DT N
face-to-face JJ N
group NN N
training NN N
The DT N
third JJ N
indicator NN N
, , N
training VBG N
attrition NN N
, , N
shows VBZ N
a DT N
better JJR N
result NN N
for IN N
the DT N
group NN N
training NN N
Future JJ N
research NN N
should MD N
focus VB N
on IN N
attrition NN N
in IN N
order NN N
to TO N
enhance VB N
the DT N
overall JJ N
effectiveness NN N
of IN N
training NN N
-DOCSTART- -X- O O 21412846

Correlation NN N
of IN N
adenosinergic JJ N
activity NN N
with IN N
superior JJ N
efficacy NN N
of IN N
clozapine NN N
for IN N
treatment NN N
of IN N
chronic JJ N
schizophrenia NN 4_p
: : N
a DT N
double JJ N
blind NN N
randomised VBD N
trial NN N
OBJECTIVE NN N
It PRP N
has VBZ N
been VBN N
proposed VBN N
that IN N
a DT N
deficit NN N
of IN N
adenosinergic JJ N
activity NN N
could MD N
contribute VB N
to TO N
the DT N
pathophysiology NN N
of IN N
schizophrenia NN N
The DT N
authors NNS N
undertook VBP N
this DT N
study NN N
to TO N
further RBR N
evaluate VB N
the DT N
level NN N
of IN N
adenosine JJ N
deaminase NN N
( ( N
ADA NNP N
) ) N
in IN N
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
schizophrenia NN 4_p
treated VBN N
with IN N
monotherapy NN N
of IN N
haloperidol NN N
, , N
risperidone NN N
or CC N
clozapine NN N
and CC N
correlation NN N
between IN N
the DT N
ADA NNP N
level NN N
with IN N
response NN N
to TO N
treatment NN N
METHODS NNP N
The DT N
trial NN N
was VBD N
a DT N
prospective JJ N
, , N
8-week JJ N
, , N
double JJ N
blind NN N
study NN N
of IN N
parallel JJ N
groups NNS N
of IN N
patients NNS N
with IN N
chronic JJ 4_p
schizophrenia NN 4_p
Eligible JJ N
participants NNS N
in IN N
the DT N
study NN N
were VBD N
51 CD 3_p
patients NNS 3_p
with IN N
chronic JJ 4_p
schizophrenia NN 4_p
with IN N
ages NNS 1_p
ranging VBG 1_p
from IN 1_p
20 CD 1_p
to TO 1_p
45 CD 1_p
years NNS 1_p
All DT N
participants NNS N
were VBD N
inpatients NNS 4_p
, , N
in IN 4_p
the DT 4_p
active JJ 4_p
phase NN 4_p
of IN 4_p
illness NN 4_p
, , N
and CC N
met VBD 4_p
DSM-IV-TR NNP 4_p
criteria NNS 4_p
for IN 4_p
schizophrenia NN 4_p
Patients NNS N
were VBD N
randomly RB N
allocated VBN N
( ( N
17 CD N
patients NNS N
in IN N
each DT N
group NN N
) ) N
to TO N
risperidone VB N
( ( N
6 CD N
mg/day NN N
) ) N
or CC N
haloperidol $ N
15 CD N
mg/day NN N
or CC N
clozapine NN N
( ( N
300 CD N
mg/day NN N
) ) N
Serum NNP N
ADA NNP N
activity NN N
was VBD N
measured VBN N
at IN N
baseline NN N
and CC N
week NN N
8 CD N
RESULTS VB N
The DT N
plasma JJ N
levels NNS N
of IN N
ADA NNP N
in IN N
patients NNS N
with IN N
chronic JJ N
schizophrenia NN N
who WP N
received VBD N
clozapine NN N
were VBD N
significantly RB N
higher JJR N
than IN N
patients NNS N
who WP N
received VBD N
haloperidol NN N
In IN N
addition NN N
, , N
response NN N
to TO N
treatment NN N
was VBD N
positively RB N
correlated VBN N
with IN N
plasma NN N
levels NNS N
of IN N
ADA NNP N
only RB N
in IN N
the DT N
clozapine NN N
group NN N
( ( N
r NN N
= VBZ N
0.46 CD N
and CC N
p VB N
= NNP N
0.04 CD N
) ) N
CONCLUSION VB N
The DT N
results NNS N
indicate VBP N
an DT N
increased JJ N
activity NN N
of IN N
the DT N
enzyme NN N
ADA NNP N
in IN N
the DT N
serum NN N
of IN N
schizophrenic JJ N
patients NNS N
being VBG N
treated VBN N
with IN N
clozapine NN N
and CC N
this DT N
increase NN N
may MD N
be VB N
correlated VBN N
with IN N
clozapine NN N
's POS N
superior JJ N
antipsychotic JJ N
efficacy NN N
-DOCSTART- -X- O O 24433230

Goodstart NN N
: : N
a DT N
cluster NN N
randomised VBD N
effectiveness JJ N
trial NN N
of IN N
an DT N
integrated VBN N
, , N
community-based JJ N
package NN N
for IN N
maternal JJ 4_p
and CC 4_p
newborn JJ 4_p
care NN 4_p
, , 4_p
with IN 4_p
prevention NN 4_p
of IN 4_p
mother-to-child JJ 4_p
transmission NN 4_p
of IN 4_p
HIV NNP 4_p
in IN 4_p
a DT 4_p
South JJ 4_p
African JJ 4_p
township NN 4_p
BACKGROUND NNP N
Progress NNP N
towards NNS N
MDG4 NNP N
for IN N
child NN N
survival NN N
in IN N
South NNP N
Africa NNP N
requires VBZ N
effective JJ N
prevention NN N
of IN N
mother-to-child JJ N
transmission NN N
( ( N
PMTCT NNP N
) ) N
of IN N
HIV NNP N
including VBG N
increasing VBG N
exclusive JJ N
breastfeeding NN N
, , N
as RB N
well RB N
as IN N
a DT N
new JJ N
focus NN N
on IN N
reducing VBG N
neonatal JJ N
deaths NNS N
This DT N
necessitates VBZ N
increased JJ N
focus NN N
on IN N
the DT N
pregnancy NN N
and CC N
early JJ N
post-natal JJ N
periods NNS N
, , N
developing VBG N
and CC N
scaling VBG N
up RP N
appropriate JJ N
models NNS N
of IN N
community-based JJ N
care NN N
, , N
especially RB N
to TO N
reach VB N
the DT N
peri-urban JJ 3_p
poor JJ 3_p
METHODS NNP N
We PRP N
used VBD N
a DT N
randomised JJ N
controlled VBN N
trial NN N
with IN N
30 CD 3_p
clusters NNS 3_p
( ( 3_p
15 CD 3_p
in IN 3_p
each DT 3_p
arm NN 3_p
) ) 3_p
to TO 3_p
evaluate VB 3_p
an DT 3_p
integrated VBN 3_p
, , 3_p
scalable JJ 3_p
package NN 3_p
providing VBG 3_p
two CD 3_p
pregnancy NN 3_p
visits NNS 3_p
and CC 3_p
five CD 3_p
post-natal JJ 3_p
home NN 3_p
visits NNS 3_p
delivered VBN 3_p
by IN 3_p
community NN 3_p
health NN 3_p
workers NNS 3_p
in IN 3_p
Umlazi NNP 3_p
, , 3_p
Durban NNP 3_p
, , 3_p
South NNP 3_p
Africa NNP 3_p
Primary NNP N
outcomes NNS N
were VBD N
exclusive JJ N
and CC N
appropriate JJ N
infant NN N
feeding NN N
at IN N
12 CD 4_p
weeks NNS 4_p
post-natally RB 4_p
and CC 4_p
HIV-free JJ 4_p
infant NN 4_p
survival NN 4_p
RESULTS NNP N
At IN N
12 CD 1_p
weeks NNS 1_p
of IN 1_p
infant JJ 1_p
age NN 1_p
, , N
the DT N
intervention NN N
was VBD N
effective JJ N
in IN N
almost RB N
doubling VBG N
the DT N
rate NN N
of IN N
exclusive JJ N
breastfeeding NN N
( ( N
risk NN N
ratio VBP N
1.92 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.59-2.33 JJ N
) ) N
and CC N
increasing VBG N
infant JJ N
weight NN N
and CC N
length-for-age JJ N
z-scores NNS N
( ( N
weight JJ N
difference NN N
0.09 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.00-0.18 JJ N
, , N
length JJ N
difference NN N
0.11 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.03-0.19 NN N
) ) N
No DT N
difference NN N
was VBD N
seen VBN N
between IN N
study NN N
arms NNS N
in IN N
HIV-free JJ N
survival NN N
Women NNS N
in IN N
the DT N
intervention NN N
arm NN N
were VBD N
also RB N
more RBR N
likely JJ N
to TO N
take VB N
their PRP$ N
infant NN N
to TO N
the DT N
clinic NN N
within IN N
the DT N
first JJ N
week NN N
of IN N
life NN N
( ( N
risk NN N
ratio VBP N
1.10 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.04-1.18 JJ N
) ) N
CONCLUSIONS VB N
The DT N
trial NN N
coincided VBD N
with IN N
national JJ N
scale NN N
up IN N
of IN N
ARVs NNP N
for IN N
PMTCT NNP N
, , N
and CC N
this DT N
could MD N
have VB N
diluted VBN N
the DT N
effect NN N
of IN N
the DT N
intervention NN N
on IN N
HIV-free NNP N
survival NN N
We PRP N
have VBP N
demonstrated VBN N
that IN N
implementation NN N
of IN N
a DT N
pro-poor JJ N
integrated JJ N
PMTCT NNP N
and CC N
maternal JJ N
, , N
neonatal JJ N
and CC N
child JJ N
health NN N
home NN N
visiting VBG N
model NN N
is VBZ N
feasible JJ N
and CC N
effective JJ N
This DT N
trial NN N
could MD N
inform VB N
national JJ N
primary NN N
healthcare NN N
reengineering VBG N
strategies NNS N
in IN N
favour NN N
of IN N
home NN N
visits NNS N
The DT N
dose JJ N
effect NN N
on IN N
exclusive JJ N
breastfeeding NN N
is VBZ N
notable JJ N
as IN N
improving VBG N
exclusive JJ N
breastfeeding NN N
has VBZ N
been VBN N
resistant JJ N
to TO N
change VB N
in IN N
other JJ N
studies NNS N
targeting VBG N
urban JJ N
poor JJ N
families NNS N
-DOCSTART- -X- O O 24074927

Early RB N
clinical JJ N
outcomes NNS N
and CC N
toxicity NN N
of IN N
intensity NN N
modulated VBN N
versus IN N
conventional JJ N
pelvic JJ N
radiation NN N
therapy NN N
for IN N
locally RB 4_p
advanced JJ 4_p
cervix NN 4_p
carcinoma NN 4_p
: : 4_p
a DT N
prospective JJ N
randomized NN N
study NN N
PURPOSE NNP N
To TO N
evaluate VB N
the DT N
toxicity NN N
and CC N
clinical JJ N
outcome NN N
in IN N
patients NNS 4_p
with IN 4_p
locally RB 4_p
advanced JJ 4_p
cervical JJ 4_p
cancer NN 4_p
( ( 4_p
LACC NNP 4_p
) ) 4_p
treated VBD N
with IN N
whole JJ N
pelvic JJ N
conventional JJ N
radiation NN N
therapy NN N
( ( N
WP-CRT NNP N
) ) N
versus NN N
intensity NN N
modulated VBN N
radiation NN N
therapy NN N
( ( N
WP-IMRT NNP N
) ) N
METHODS NNP N
AND CC N
MATERIALS NNP N
Between NNP N
January NNP N
2010 CD N
and CC N
January NNP N
2012 CD N
, , N
44 CD N
patients NNS N
with IN N
International NNP N
Federation NNP N
of IN N
Gynecology NNP N
and CC N
Obstetrics NNP N
( ( N
FIGO NNP N
2009 CD N
) ) N
stage NN N
IIB-IIIB NNP N
squamous JJ N
cell NN N
carcinoma NN N
of IN N
the DT N
cervix NN N
were VBD N
randomized VBN N
to TO N
receive VB N
50.4 CD N
Gy NNP N
in IN N
28 CD N
fractions NNS N
delivered VBN N
via IN N
either DT N
WP-CRT JJ N
or CC N
WP-IMRT JJ N
with IN N
concurrent JJ N
weekly JJ N
cisplatin NN N
40 CD N
mg/m NN N
( ( N
2 CD N
) ) N
Acute NNP N
toxicity NN N
was VBD N
graded VBN N
according VBG N
to TO N
the DT N
Common NNP N
Terminology NNP N
Criteria NNP N
for IN N
Adverse NNP N
Events NNP N
, , N
version NN N
3.0 CD N
, , N
and CC N
late JJ N
toxicity NN N
was VBD N
graded VBN N
according VBG N
to TO N
the DT N
Radiation NNP N
Therapy NNP N
Oncology NNP N
Group NNP N
system NN N
The DT N
primary JJ N
and CC N
secondary JJ N
endpoints NNS N
were VBD N
acute JJ N
gastrointestinal JJ N
toxicity NN N
and CC N
disease-free JJ N
survival NN N
, , N
respectively RB N
RESULTS NNP N
Of IN N
44 CD N
patients NNS N
, , N
22 CD N
patients NNS N
received VBD N
WP-CRT NNP N
and CC N
22 CD N
received VBD N
WP-IMRT NNP N
In IN N
the DT N
WP-CRT JJ N
arm NN N
, , N
13 CD N
patients NNS N
had VBD N
stage NN N
IIB NNP N
disease NN N
and CC N
9 CD N
had VBD N
stage NN N
IIIB NNP N
disease NN N
; : N
in IN N
the DT N
IMRT NNP N
arm NN N
, , N
12 CD N
patients NNS N
had VBD N
stage NN N
IIB NNP N
disease NN N
and CC N
10 CD N
had VBD N
stage NN N
IIIB NNP N
disease NN N
The DT N
median JJ N
follow-up JJ N
time NN N
in IN N
the DT N
WP-CRT JJ N
arm NN N
was VBD N
21.7 CD N
months NNS N
( ( N
range NN N
, , N
10.7-37.4 JJ N
months NNS N
) ) N
, , N
and CC N
in IN N
the DT N
WP-IMRT JJ N
arm NN N
it PRP N
was VBD N
21.6 CD N
months NNS N
( ( N
range NN N
, , N
7.7-34.4 JJ N
months NNS N
) ) N
At IN N
27 CD N
months NNS N
, , N
disease-free JJ N
survival NN N
was VBD N
79.4 CD N
% NN N
in IN N
the DT N
WP-CRT NNP N
group NN N
versus VBD N
60 CD N
% NN N
in IN N
the DT N
WP-IMRT NNP N
group NN N
( ( N
P=.651 NNP N
) ) N
, , N
and CC N
overall JJ N
survival NN N
was VBD N
76 CD N
% NN N
in IN N
the DT N
WP-CRT NNP N
group NN N
versus VBD N
85.7 CD N
% NN N
in IN N
the DT N
WP-IMRT NNP N
group NN N
( ( N
P=.645 NNP N
) ) N
Patients NNS N
in IN N
the DT N
WP-IMRT JJ N
arm NN N
experienced VBD N
significantly RB N
fewer JJR N
grade NN N
≥2 NNP N
acute VBZ N
gastrointestinal JJ N
toxicities NNS N
( ( N
31.8 CD N
% NN N
vs JJ N
63.6 CD N
% NN N
, , N
P=.034 NNP N
) ) N
and CC N
grade JJ N
≥3 NNP N
gastrointestinal JJ N
toxicities NNS N
( ( N
4.5 CD N
% NN N
vs JJ N
27.3 CD N
% NN N
, , N
P=.047 NNP N
) ) N
than IN N
did VBD N
patients NNS N
receiving VBG N
WP-CRT NNP N
and CC N
had VBD N
less JJR N
chronic JJ N
gastrointestinal JJ N
toxicity NN N
( ( N
13.6 CD N
% NN N
vs JJ N
50 CD N
% NN N
, , N
P=.011 NNP N
) ) N
CONCLUSION NNP N
WP-IMRT NNP N
is VBZ N
associated VBN N
with IN N
significantly RB N
less JJR N
toxicity NN N
compared VBN N
with IN N
WP-CRT NNP N
and CC N
has VBZ N
a DT N
comparable JJ N
clinical JJ N
outcome NN N
Further JJ N
studies NNS N
with IN N
larger JJR N
sample NN N
sizes NNS N
and CC N
longer JJR N
follow-up JJ N
times NNS N
are VBP N
warranted VBN N
to TO N
justify VB N
its PRP$ N
use NN N
in IN N
routine JJ N
clinical JJ N
practice NN N
-DOCSTART- -X- O O 3089263

Comparison NNP N
of IN N
amiodarone NN N
and CC N
disopyramide NN N
in IN N
the DT N
control NN 4_p
of IN 4_p
paroxysmal JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
and CC 4_p
atrial JJ 4_p
flutter NN 4_p
( ( N
interim JJ N
report NN N
) ) N
-DOCSTART- -X- O O 3370523

Moisture-vapour-permeable JJ N
film NN N
as IN N
an DT N
outpatient JJ N
burn NN 4_p
dressing VBG N
This DT N
study NN N
compares VBZ N
a DT N
moisture-vapour-permeable JJ N
film NN N
( ( N
MVPF NNP N
) ) N
with IN N
silver NN N
sulphadiazine NN N
in IN N
a DT N
randomized JJ N
prospective JJ N
manner NN N
for IN N
the DT N
treatment NN N
of IN N
outpatient NN N
burns NNS 4_p
The DT N
two CD N
treatment NN N
groups NNS N
were VBD N
closely RB N
matched VBN N
in IN N
age NN N
, , N
sex NN N
, , N
per IN N
cent NN N
of IN N
BSA NNP N
burned VBD 4_p
, , N
and CC N
in IN N
burn JJ 4_p
severity NN N
and CC N
locations NNS N
The DT N
MVPF NNP N
group NN N
demonstrated VBD N
a DT N
39.0 CD N
per IN N
cent NN N
greater JJR N
reduction NN N
in IN N
pain NN N
after IN N
application NN N
of IN N
the DT N
dressing NN N
over IN N
the DT N
silver JJ N
sulphadiazine NN N
group NN N
Patients NNS N
in IN N
the DT N
MVPF NNP N
film NN N
group NN N
also RB N
reported VBD N
significantly RB N
less JJR N
difficulty NN N
in IN N
wound NN N
care NN N
and CC N
in IN N
dressing VBG N
interference NN N
with IN N
their PRP$ N
daily JJ N
functions NNS N
The DT N
clinical JJ N
infection NN N
rate NN N
and CC N
time NN N
to TO N
healing VBG N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
In IN N
the DT N
management NN N
of IN N
outpatient NN N
burns NNS 4_p
, , N
MVPF NNP N
was VBD N
found VBN N
to TO N
be VB N
superior JJ N
to TO N
silver VB N
sulphadiazine NN N
-DOCSTART- -X- O O 1616359

Double JJ N
blind NN N
, , N
placebo NN N
controlled VBD N
study NN N
of IN N
metronidazole NN 4_p
as IN 4_p
a DT 4_p
disease NN 4_p
modifying VBG 4_p
agent NN 4_p
in IN 4_p
the DT 4_p
treatment NN 4_p
of IN 4_p
rheumatoid JJ 4_p
arthritis NN 4_p
Anecdotal JJ N
reports NNS N
suggest VBP N
that IN N
metronidazole NN N
may MD N
have VB N
disease NN N
modifying VBG N
activity NN N
in IN N
the DT N
treatment NN N
of IN N
rheumatoid JJ N
arthritis NN N
To TO N
assess VB N
possible JJ N
beneficial JJ N
effects NNS N
a DT N
double JJ N
blind NN N
, , N
comparative JJ N
trial NN N
of IN N
metronidazole NN N
and CC N
placebo NN N
was VBD N
performed VBN N
Fifty JJ N
patients NNS N
with IN N
active JJ N
rheumatoid NN N
arthritis NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
active JJ N
drug NN N
( ( N
n JJ N
= NNP N
24 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
and CC N
reviewed VBN N
at IN N
weeks NNS N
0 CD N
, , N
1 CD N
, , N
4 CD N
, , N
8 CD N
, , N
12 CD N
, , N
16 CD N
, , N
and CC N
24 CD N
Detailed JJ N
assessment NN N
of IN N
drug NN N
safety NN N
, , N
biochemical JJ N
and CC N
haematological JJ N
parameters NNS N
, , N
and CC N
efficacy NN N
was VBD N
made VBN N
at IN N
these DT N
dates NNS N
Dose NNP N
regimen NNS N
was VBD N
400 CD N
mg JJ N
twice RB N
daily RB N
from IN N
weeks NNS N
0 CD N
to TO N
eight CD N
, , N
increasing VBG N
to TO N
400 CD N
mg NNS N
three CD N
times NNS N
a DT N
day NN N
from IN N
weeks NNS N
nine CD N
to TO N
24 CD N
provided VBD N
that IN N
no DT N
adverse JJ N
effects NNS N
were VBD N
recorded VBN N
Most JJS N
patients NNS N
were VBD N
unable JJ N
to TO N
tolerate VB N
metronidazole NN N
because IN N
of IN N
side NN N
effects NNS N
or CC N
lack NN N
of IN N
efficacy NN N
, , N
with IN N
only RB N
five CD N
( ( N
21 CD N
% NN N
) ) N
continuing VBG N
to TO N
take VB N
the DT N
drug NN N
at IN N
24 CD N
weeks NNS N
For IN N
those DT N
patients NNS N
attaining VBG N
12 CD N
weeks NNS N
of IN N
treatment NN N
an DT N
overall JJ N
improvement NN N
in IN N
articular JJ N
index NN N
and CC N
morning NN N
stiffness NN N
was VBD N
found VBN N
No DT N
improvement NN N
in IN N
laboratory JJ N
indices NNS N
of IN N
disease NN N
activity NN N
was VBD N
seen VBN N
, , N
however RB N
In IN N
this DT N
study NN N
metronidazole NN N
did VBD N
not RB N
have VB N
disease NN N
modifying VBG N
properties NNS N
and CC N
was VBD N
unacceptably RB N
toxic JJ N
-DOCSTART- -X- O O 11779598

Metformin NNP N
therapy NN N
improves VBZ N
ovulatory JJ N
rates NNS N
, , N
cervical JJ N
scores NNS N
, , N
and CC N
pregnancy NN N
rates NNS N
in IN N
clomiphene JJ 4_p
citrate-resistant JJ 4_p
women NNS 4_p
with IN 4_p
polycystic JJ 4_p
ovary JJ 4_p
syndrome NN 4_p
OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
metformin NN N
therapy NN N
on IN N
hyperandrogenism NN N
, , N
insulin NN N
resistance NN N
, , N
cervical JJ N
scores NNS N
, , N
ovulation NN N
, , N
and CC N
pregnancy NN N
rates NNS N
in IN N
clomiphene JJ N
citrate-resistant JJ N
women NNS N
with IN N
polycystic JJ N
ovary JJ N
syndrome NN N
( ( N
PCOS NNP N
) ) N
DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
SETTING NNP N
Infertility NNP N
clinic NN N
of IN N
a DT N
tertiary JJ N
referral NN N
center NN N
PATIENT NNP N
( ( N
S NNP N
) ) N
Fifty-six NNP N
women NNS N
with IN N
clomiphene JJ N
citrate-resistant JJ N
PCOS NNP N
INTERVENTION NNP N
( ( N
S NNP N
) ) N
Two CD N
cycles NNS N
of IN N
oral JJ N
metformin NN N
therapy NN N
( ( N
850 CD N
mg NN N
, , N
twice RB N
daily RB N
) ) N
in IN N
group NN N
I PRP N
and CC N
placebo VB N
therapy NN N
( ( N
twice JJ N
daily RB N
) ) N
in IN N
group NN N
II NNP N
Clomiphene NNP N
citrate NN N
( ( N
100 CD N
mg/day NN N
) ) N
on IN N
cycle NN N
days NNS N
3-7 CD N
of IN N
the DT N
second JJ N
cycle NN N
in IN N
both DT N
groups NNS N
MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Insulin NNP N
, , N
T NNP N
, , N
DHEAS NNP N
, , N
FSH NNP N
, , N
LH NNP N
, , N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
, , N
waist-to-hip JJ N
ratio NN N
, , N
endometrial JJ N
thickness NN N
, , N
cervical JJ N
score NN N
, , N
ovulation NN N
, , N
and CC N
pregnancy NN N
rates NNS N
in IN N
clomiphene-induced JJ N
cycles NNS N
after IN N
metformin JJ N
therapy NN N
RESULT NNP N
( ( N
S NNP N
) ) N
Metformin NNP N
therapy NN N
resulted VBD N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
total JJ N
T NNP N
, , N
LH NNP N
level NN N
, , N
LH/FSH NNP N
ratio NN N
, , N
insulin NN N
resistance NN N
, , N
and CC N
mean JJ N
BMI NNP N
No DT N
difference NN N
in IN N
waist-to-hip JJ N
ratio NN N
, , N
DHEAS NNP N
level NN N
, , N
and CC N
fasting VBG N
insulin JJ N
level NN N
was VBD N
observed VBN N
Clomiphene NNP N
citrate JJ N
induction NN N
resulted VBD N
in IN N
higher JJR N
ovulation NN N
rates NNS N
and CC N
thicker NN N
endometrium NN N
in IN N
the DT N
metformin NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
There EX N
was VBD N
higher JJR N
cumulative JJ N
pregnancy NN N
rate NN N
in IN N
the DT N
metformin NN N
group NN N
; : N
however RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
pregnancy NN N
rate NN N
between IN N
the DT N
two CD N
groups NNS N
CONCLUSION NNP N
( ( N
S NNP N
) ) N
Metformin NNP N
therapy NN N
not RB N
only RB N
decreases VBZ N
hyperandrogenism NN N
and CC N
insulin NN N
resistance NN N
but CC N
also RB N
improves VBZ N
ovulation NN N
rates NNS N
, , N
cervical JJ N
scores NNS N
, , N
and CC N
pregnancy NN N
rates NNS N
in IN N
clomiphene JJ N
citrate-resistant JJ N
women NNS N
with IN N
PCOS NNP N
-DOCSTART- -X- O O 19705924

Pharmacokinetic-pharmacodynamic JJ N
modelling NN N
of IN N
the DT N
antihistaminic NN N
( ( N
H1 NNP N
) ) N
effect NN N
of IN N
bilastine NN N
OBJECTIVE UH N
To TO N
model VB N
the DT N
pharmacokinetic JJ N
and CC N
pharmacodynamic JJ N
relationship NN N
of IN N
bilastine NN N
, , N
a DT N
new JJ N
histamine NN N
H NNP N
( ( N
1 CD N
) ) N
receptor NN N
antagonist NN N
, , N
from IN N
single- JJ N
and CC N
multiple-dose JJ N
studies NNS N
in IN N
healthy JJ 4_p
adult NN 1_p
subjects NNS N
METHODS NNP N
The DT N
pharmacokinetic JJ N
model NN N
was VBD N
developed VBN N
from IN N
different JJ N
single-dose JJ N
and CC N
multiple-dose JJ N
studies NNS N
In IN N
the DT N
single-dose JJ N
studies NNS N
, , N
a DT N
total NN N
of IN N
183 CD 3_p
subjects NNS N
received VBD N
oral JJ N
doses NNS N
of IN N
bilastine NN N
2.5 CD N
, , N
5 CD N
, , N
10 CD N
, , N
20 CD N
, , N
50 CD N
, , N
100 CD N
, , N
120 CD N
, , N
160 CD N
, , N
200 CD N
and CC N
220 CD N
mg NN N
In IN N
the DT N
multiple-dose JJ N
studies NNS N
, , N
127 CD 3_p
healthy JJ 4_p
subjects NNS N
received VBD N
bilastine JJ N
10 CD N
, , N
20 CD N
, , N
40 CD N
, , N
50 CD N
, , N
80 CD N
, , N
100 CD N
, , N
140 CD N
or CC N
200 CD N
mg/day NN N
as IN N
multiple JJ N
doses NNS N
during IN N
a DT N
4- JJ N
, , N
7- JJ N
or CC N
14-day JJ N
period NN N
The DT N
pharmacokinetic JJ N
profile NN N
of IN N
bilastine NN N
was VBD N
investigated VBN N
using VBG N
a DT N
simultaneous JJ N
analysis NN N
of IN N
all DT N
concentration-time JJ N
data NNS N
by IN N
means NNS N
of IN N
nonlinear JJ N
mixed-effects NNS N
modelling VBG N
population NN N
pharmacokinetic JJ N
software NN N
NONMEM NNP N
version NN N
6.1 CD N
Plasma JJ N
concentrations NNS N
were VBD N
modelled VBN N
according VBG N
to TO N
a DT N
two-compartment JJ N
open JJ N
model NN N
with IN N
first-order JJ N
absorption NN N
and CC N
elimination NN N
For IN N
the DT N
pharmacodynamic JJ N
analysis NN N
, , N
the DT N
inhibitory JJ N
effect NN N
of IN N
bilastine NN N
( ( N
inhibition NN N
of IN N
histamine-induced JJ N
wheal NN N
and CC N
flare NN N
) ) N
was VBD N
assessed VBN N
on IN N
a DT N
preselected JJ N
time NN N
schedule NN N
, , N
and CC N
the DT N
predicted JJ N
typical JJ N
pharmacokinetic JJ N
profile NN N
( ( N
based VBN N
on IN N
the DT N
pharmacokinetic JJ N
model NN N
previously RB N
developed VBN N
) ) N
was VBD N
used VBN N
An DT N
indirect JJ N
response NN N
model NN N
was VBD N
developed VBN N
to TO N
describe VB N
the DT N
pharmacodynamic JJ N
relationships NNS N
between IN N
flare NN N
or CC N
wheal JJ N
areas NNS N
and CC N
bilastine NN N
plasma NN N
concentrations NNS N
Finally RB N
, , N
once RB N
values NNS N
of IN N
the DT N
concentration NN N
that WDT N
produced VBD N
50 CD N
% NN N
inhibition NN N
( ( N
IC NNP N
( ( N
50 CD N
) ) N
) ) N
had VBD N
been VBN N
estimated VBN N
for IN N
wheal NN N
and CC N
flare NN N
effects NNS N
, , N
simulations NNS N
were VBD N
carried VBN N
out IN N
to TO N
predict VB N
plasma JJ N
concentrations NNS N
for IN N
the DT N
doses NNS N
of IN N
bilastine NN N
5 CD N
, , N
10 CD N
and CC N
20 CD N
mg NN N
at IN N
steady JJ N
state NN N
( ( N
72-96 JJ N
hours NNS N
) ) N
RESULTS VB N
A DT N
non-compartmental JJ N
analysis NN N
resulted VBD N
in IN N
linear JJ N
kinetics NNS N
of IN N
bilastine NN N
in IN N
the DT N
dose JJ N
range NN N
studied VBN N
Bilastine NNP N
was VBD N
characterized VBN N
by IN N
two-compartmental JJ N
kinetics NNS N
with IN N
a DT N
rapid-absorption NN N
phase NN N
( ( N
first-order JJ N
absorption NN N
rate NN N
constant JJ N
= NN N
1.50 CD N
h NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
plasma JJ N
peak NN N
concentrations NNS N
were VBD N
observed VBN N
at IN N
1 CD N
hour NN N
following VBG N
administration NN N
and CC N
the DT N
maximal JJ N
response NN N
was VBD N
observed VBN N
at IN N
approximately RB N
4 CD N
hours NNS N
or CC N
later RB N
Concerning VBG N
the DT N
selected VBN N
pharmacodynamic JJ N
model NN N
to TO N
fit VB N
the DT N
data NN N
( ( N
type NN N
I PRP N
indirect VBP N
response NN N
model NN N
) ) N
, , N
this DT N
selection NN N
is VBZ N
attributable JJ N
to TO N
the DT N
presence NN N
of IN N
inhibitory JJ N
bilastine NN N
plasma NN N
concentrations NNS N
that WDT N
decrease VBP N
the DT N
input NN N
response NN N
function NN N
, , N
i.e NN N
the DT N
production NN N
of IN N
the DT N
skin JJ N
reaction NN N
This DT N
model NN N
resulted VBD N
in IN N
the DT N
best JJS N
fit NN N
of IN N
wheal NN N
and CC N
flare NN N
data NNS N
The DT N
estimates NNS N
( ( N
with IN N
relative JJ N
standard JJ N
errors NNS N
expressed VBD N
in IN N
percentages NNS N
in IN N
parentheses NNS N
) ) N
of IN N
the DT N
apparent JJ N
zero-order NN N
rate NN N
constant NN N
for IN N
flare NN N
or CC N
wheal NN N
spontaneous JJ N
appearance NN N
( ( N
k NN N
( ( N
in IN N
) ) N
) ) N
, , N
the DT N
first-order JJ N
rate NN N
constant NN N
for IN N
flare NN N
or CC N
wheal JJ N
disappearance NN N
( ( N
k NN N
( ( N
out IN N
) ) N
) ) N
and CC N
bilastine JJ N
IC NNP N
( ( N
50 CD N
) ) N
values NNS N
were VBD N
0.44 CD N
ng/mL/h NNS N
( ( N
14.60 CD N
% NN N
) ) N
, , N
1.09 CD N
h NN N
( ( N
-1 NN N
) ) N
( ( N
15.14 CD N
% NN N
) ) N
and CC N
5.15 CD N
ng/mL NN N
( ( N
16.16 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
for IN N
wheal JJ N
inhibition NN N
, , N
and CC N
11.10 CD N
ng/mL/h NN N
( ( N
8.48 CD N
% NN N
) ) N
, , N
1.03 CD N
h NN N
( ( N
-1 NN N
) ) N
( ( N
8.35 CD N
% NN N
) ) N
and CC N
1.25 CD N
ng/mL NN N
( ( N
14.56 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
for IN N
flare JJ N
inhibition NN N
The DT N
simulation NN N
results NNS N
revealed VBD N
that IN N
bilastine NN N
plasma NN N
concentrations NNS N
do VBP N
not RB N
remain VB N
over IN N
the DT N
IC NNP N
( ( N
50 CD N
) ) N
value NN N
throughout IN N
the DT N
inter-dose JJ N
period NN N
for IN N
doses NNS N
of IN N
5 CD N
and CC N
10 CD N
mg NN N
However RB N
, , N
with IN N
a DT N
dose NN N
of IN N
20 CD N
mg NN N
of IN N
bilastine NN N
administered VBN N
every DT N
24 CD N
hours NNS N
, , N
plasma JJ N
concentrations NNS N
remained VBD N
over IN N
the DT N
IC NNP N
( ( N
50 CD N
) ) N
value NN N
during IN N
the DT N
considered JJ N
period NN N
for IN N
the DT N
flare NN N
effect NN N
, , N
and CC N
up RB N
to TO N
20 CD N
hours NNS N
for IN N
the DT N
wheal JJ N
effect NN N
CONCLUSION NNP N
Pharmacokinetic NNP N
and CC N
pharmacodynamic JJ N
relationships NNS N
of IN N
bilastine NN N
were VBD N
reliably RB N
described VBN N
with IN N
the DT N
use NN N
of IN N
an DT N
indirect JJ N
response NN N
pharmacodynamic JJ N
model NN N
; : N
this DT N
led VBD N
to TO N
an DT N
accurate JJ N
prediction NN N
of IN N
the DT N
pharmacodynamic JJ N
activity NN N
of IN N
bilastine NN N
-DOCSTART- -X- O O 21849168

Effect NN N
of IN N
gravity NN N
on IN N
robot-assisted JJ N
motor NN N
training NN N
after IN N
chronic JJ 4_p
stroke NN 4_p
: : N
a DT N
randomized JJ N
trial NN N
OBJECTIVES UH N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
2 CD N
distinct JJ N
6-week JJ N
robot-assisted JJ N
reaching NN N
programs NNS N
compared VBN N
with IN N
an DT N
intensive JJ N
conventional JJ N
arm NN N
exercise NN N
program NN N
( ( N
ICAE NNP N
) ) N
for IN N
chronic NN N
, , N
stroke-related JJ N
upper-extremity NN N
( ( N
UE NNP N
) ) N
impairment NN N
To TO N
examine VB N
whether IN N
the DT N
addition NN N
of IN N
robot-assisted JJ N
training VBG N
out IN N
of IN N
the DT N
horizontal JJ N
plane NN N
leads VBZ N
to TO N
improved VBN N
outcomes NNS N
DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
, , N
single-blinded JJ N
, , N
with IN N
12-week JJ N
follow-up NN N
SETTING NNP N
Research NNP N
setting VBG N
in IN N
a DT N
large JJ N
medical JJ N
center NN N
PARTICIPANTS NNP N
Adults NNP 1_p
( ( N
N=62 NNP 3_p
) ) N
with IN N
chronic JJ 4_p
, , 4_p
stroke-related JJ 4_p
arm NN 4_p
weakness NN 4_p
stratified VBN N
by IN N
impairment JJ 4_p
severity NN N
using VBG N
baseline JJ N
UE NNP N
motor NN N
assessments NNS N
INTERVENTIONS NNP N
Sixty NNP N
minutes NNS N
, , N
3 CD N
times NNS N
a DT N
week NN N
for IN N
6 CD N
weeks NNS N
of IN N
robot-assisted JJ N
planar NN N
reaching NN N
( ( N
gravity NN N
compensated VBN N
) ) N
, , N
combined VBN N
planar NN N
with IN N
vertical JJ N
robot-assisted JJ N
reaching NN N
, , N
or CC N
intensive JJ N
conventional JJ N
arm NN N
exercise NN N
program NN N
MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
UE NNP N
Fugl-Meyer NNP N
Assessment NNP N
( ( N
FMA NNP N
) ) N
mean VBP N
change NN N
from IN N
baseline NN N
to TO N
final JJ N
training NN N
RESULTS NNP N
All DT N
groups NNS N
showed VBD N
modest JJ N
gains NNS N
in IN N
the DT N
FMA NNP N
from IN N
baseline NN N
to TO N
final JJ N
with IN N
no DT N
significant JJ N
between IN N
group NN N
differences NNS N
Most JJS N
change NN N
occurred VBD N
in IN N
the DT N
planar NN N
robot NN N
group NN N
( ( N
mean JJ N
change NN N
± NNP N
SD NNP N
, , N
2.94 CD N
± JJ N
0.77 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
1.40-4.47 JJ N
) ) N
Participants NNS N
with IN N
greater JJR N
motor NN N
impairment NN N
( ( N
n=41 JJ N
) ) N
demonstrated VBD N
a DT N
larger JJR N
difference NN N
in IN N
response NN N
( ( N
mean JJ N
change NN N
± NNP N
SD NNP N
, , N
2.29 CD N
± JJ N
0.72 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.85-3.72 NNP N
) ) N
for IN N
planar JJ N
robot-assisted JJ N
exercise NN N
compared VBN N
with IN N
the DT N
intensive JJ N
conventional JJ N
arm NN N
exercise NN N
program NN N
( ( N
mean JJ N
change NN N
± NNP N
SD NNP N
, , N
0.43 CD N
± JJ N
0.72 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
-1.00 NNP N
to TO N
1.86 CD N
) ) N
CONCLUSIONS NNP N
Chronic NNP N
UE NNP N
deficits NNS N
because IN N
of IN N
stroke NN N
are VBP N
responsive JJ N
to TO N
intensive JJ N
motor NN N
task NN N
training NN N
However RB N
, , N
training VBG N
outside IN N
the DT N
horizontal JJ N
plane NN N
in IN N
a DT N
gravity NN N
present JJ N
environment NN N
using VBG N
a DT N
combination NN N
of IN N
vertical JJ N
with IN N
planar JJ N
robots NNS N
was VBD N
not RB N
superior JJ N
to TO N
training VBG N
with IN N
the DT N
planar NN N
robot NN N
alone RB N
-DOCSTART- -X- O O 12085177

Marimastat NNP N
as IN N
maintenance NN N
therapy NN N
for IN N
patients NNS N
with IN N
advanced JJ 4_p
gastric JJ 4_p
cancer NN 4_p
: : N
a DT N
randomised JJ N
trial NN N
This DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
ability NN N
of IN N
the DT N
orally RB N
administered VBN N
matrix JJ N
metalloproteinase NN N
inhibitor NN N
, , N
marimastat NN N
, , N
to TO N
prolong VB N
survival NN N
in IN N
patients NNS N
with IN N
non-resectable JJ 4_p
gastric JJ 4_p
and CC 4_p
gastro-oesophageal JJ 4_p
adenocarcinoma NN 4_p
Three CD 3_p
hundred VBD 3_p
and CC 3_p
sixty-nine JJ 3_p
patients NNS N
with IN N
histological JJ 4_p
proof NN 4_p
of IN 4_p
adenocarcinoma NN 4_p
, , N
who WP N
had VBD N
received VBN N
no RB N
more RBR N
than IN N
a DT N
single JJ N
regimen NN N
of IN N
5-fluorouracil-based JJ N
chemotherapy NN N
, , N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
marimastat NN N
( ( N
10 CD N
mg NN N
b.d NN N
) ) N
or CC N
placebo NN N
Patients NNS N
were VBD N
treated VBN N
for IN N
as RB N
long RB N
as IN N
was VBD N
tolerable JJ N
The DT N
primary JJ N
endpoint NN N
was VBD N
overall JJ N
survival NN N
with IN N
secondary JJ N
endpoints NNS N
of IN N
time NN N
to TO N
disease VB N
progression NN N
and CC N
quality NN N
of IN N
life NN N
At IN N
the DT N
point NN N
of IN N
protocol-defined JJ N
study NN N
completion NN N
( ( N
85 CD N
% NN N
mortality NN N
in IN N
the DT N
placebo NN N
arm NN N
) ) N
there EX N
was VBD N
a DT N
modest JJ N
difference NN N
in IN N
survival NN N
in IN N
the DT N
intention-to-treat JJ N
population NN N
in IN N
favour NN N
of IN N
marimastat NN N
( ( N
P=0.07 NNP N
log-rank JJ N
test NN N
, , N
hazard NN N
ratio=1.23 NN N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
0.98-1.55 NNP N
) ) N
) ) N
This DT N
survival JJ N
benefit NN N
was VBD N
maintained VBN N
over IN N
a DT N
further JJ N
2 CD N
years NNS N
of IN N
follow-up NN N
( ( N
P=0.024 NNP N
, , N
hazard NN N
ratio=1.27 NN N
( ( N
1.03-1.57 JJ N
) ) N
) ) N
The DT N
median JJ N
survival NN N
was VBD N
138 CD N
days NNS N
for IN N
placebo NN N
and CC N
160 CD N
days NNS N
for IN N
marimastat NN N
, , N
with IN N
2-year JJ N
survival NN N
of IN N
3 CD N
% NN N
and CC N
9 CD N
% NN N
respectively RB N
A DT N
significant JJ N
survival JJ N
benefit NN N
was VBD N
identified VBN N
at IN N
study NN N
completion NN N
in IN N
the DT N
pre-defined JJ N
sub-group NN N
of IN N
123 CD 3_p
patients NNS N
who WP N
had VBD N
received VBN N
prior RB N
chemotherapy NN N
( ( N
P=0.045 NNP N
, , N
hazard NN N
ratio=1.53 NN N
( ( N
1.00-2.34 JJ N
) ) N
) ) N
This DT N
benefit NN N
increased VBD N
with IN N
2 CD N
years NNS N
additional JJ N
follow-up NN N
( ( N
P=0.006 NNP N
, , N
hazard NN N
ratio=1.68 NN N
( ( N
1.16-2.44 JJ N
) ) N
) ) N
, , N
with IN N
2-year JJ N
survival NN N
of IN N
5 CD N
% NN N
and CC N
18 CD N
% NN N
respectively RB N
Progression-free JJ N
survival NN N
was VBD N
also RB N
significantly RB N
longer RBR N
for IN N
patients NNS N
receiving VBG N
marimastat NNS N
compared VBN N
to TO N
placebo VB N
( ( N
P=0.009 NNP N
, , N
hazard NN N
ratio=1.32 NN N
( ( N
1.07-1.63 JJ N
) ) N
) ) N
Marimastat NNP N
treatment NN N
was VBD N
associated VBN N
with IN N
the DT N
development NN N
of IN N
musculoskeletal JJ N
pain NN N
and CC N
inflammation NN N
Events NNS N
of IN N
anaemia NN N
, , N
abdominal JJ N
pain NN N
, , N
jaundice NN N
and CC N
weight JJ N
loss NN N
were VBD N
more JJR N
common JJ N
in IN N
the DT N
placebo NN N
arm NN N
This DT N
is VBZ N
one CD N
of IN N
the DT N
first JJ N
demonstrations NNS N
of IN N
a DT N
therapeutic JJ N
benefit NN N
for IN N
a DT N
matrix JJ N
metalloproteinase NN N
inhibitor NN N
in IN N
cancer NN N
patients NNS N
The DT N
greatest JJS N
benefit NN N
was VBD N
observed VBN N
in IN N
patients NNS N
who WP N
had VBD N
previously RB N
received VBN N
chemotherapy NN N
A DT N
further RB N
randomised VBN N
study NN N
of IN N
marimastat NN N
in IN N
these DT N
patients NNS N
is VBZ N
warranted VBN N
-DOCSTART- -X- O O 10811665

Outcome NN N
of IN N
CNS NNP N
disease NN N
at IN N
diagnosis NN N
in IN N
disseminated JJ 4_p
small JJ 4_p
noncleaved-cell JJ 4_p
lymphoma NN 4_p
and CC N
B-cell NNP 4_p
leukemia NN 4_p
: : N
a DT N
Children NNP 1_p
's POS 1_p
Cancer NNP 4_p
Group NNP N
study NN N
PURPOSE NNP N
To TO N
examine VB N
the DT N
impact NN N
of IN N
initial JJ N
CNS NNP N
involvement NN N
on IN N
outcome NN N
and CC N
patterns NNS N
of IN N
failure NN N
in IN N
patients NNS N
with IN N
disseminated JJ 4_p
small JJ 4_p
noncleaved-cell JJ 4_p
lymphoma NN 4_p
and CC N
B-cell NNP 4_p
leukemia NN 4_p
who WP N
were VBD N
treated VBN N
in IN N
four CD N
successive JJ N
Children NNP 1_p
's POS 1_p
Cancer NNP 4_p
Group NNP N
trials NNS N
PATIENTS NNP N
AND CC N
METHODS NNP N
Of IN N
462 CD 3_p
patients NNS N
with IN N
disseminated JJ 4_p
disease NN 4_p
, , N
49 CD 3_p
( ( N
10.6 CD N
% NN N
) ) N
had VBD N
CNS NNP 4_p
disease NN N
at IN N
diagnosis NN N
( ( N
CNS+ NNP 4_p
) ) N
CNS NNP N
disease NN N
included VBD N
meningeal JJ N
disease NN N
or CC N
CNS NNP N
parenchymal JJ N
masses NNS N
with IN N
or CC N
without IN N
cranial JJ N
neuropathies NNS N
( ( N
CSF+/Mass NNP N
; : N
CNPs NNP N
) ) N
in IN N
36 CD N
patients NNS N
and CC N
isolated JJ N
CNPs NNP N
in IN N
13 CD N
Of IN N
the DT N
CNS+ NNP 4_p
patients NNS N
, , N
28 CD 3_p
had VBD N
M2 NNP N
( ( N
5 CD N
% NN N
to TO N
25 CD N
% NN N
blasts NNS N
) ) N
or CC N
M3 NNP N
( ( N
> VB N
25 CD N
% NN N
blasts NNS N
) ) N
bone NN N
marrow JJ N
involvement NN N
All DT 3_p
patients NNS N
received VBD N
protocol-based JJ N
systemic JJ N
and CC N
intrathecal JJ N
chemotherapy NN N
Thirty-six JJ N
patients NNS N
also RB N
received VBD N
CNS NNP N
irradiation NN N
RESULTS NNP N
Relapses NNPS N
occurred VBD N
in IN N
21 CD N
( ( N
43 CD N
% NN N
) ) N
of IN N
49 CD N
patients NNS N
, , N
predominantly RB N
in IN N
the DT N
CNS NNP N
( ( N
71 CD N
% NN N
) ) N
and CC N
bone NN N
marrow NN N
( ( N
52 CD N
% NN N
) ) N
The DT N
3-year JJ N
event-free JJ N
survival NN N
+/- JJ N
SE NNP N
for IN N
all DT N
patients NNS N
with IN N
CNS+ NNP N
disease NN N
was VBD N
45 CD N
% NN N
+/- JJ N
7 CD N
% NN N
Patients NNS N
with IN N
CSF+/Mass NNP N
had VBD N
a DT N
nominally RB N
higher JJR N
treatment NN N
failure NN N
rate NN N
compared VBN N
with IN N
patients NNS N
with IN N
CNS- NNP N
after IN N
adjusting VBG N
for IN N
marrow NN N
status NN N
and CC N
lactate VB N
dehydrogenase NN N
( ( N
LDH NNP N
) ) N
diagnosis NN N
, , N
with IN N
a DT N
relative JJ N
failure NN N
rate NN N
( ( N
RFR NNP N
) ) N
of IN N
1.52 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.88 CD N
to TO N
2.6 CD N
; : N
P NNP N
=.15 NNP N
) ) N
In IN N
comparison NN N
, , N
the DT N
RFRs NNP N
for IN N
patients NNS N
with IN N
M2 NNP N
or CC N
M3 NNP N
marrow NN N
and CC N
for IN N
those DT N
with IN N
LDH NNP N
levels NNS N
greater JJR N
than IN N
500 CD N
IU/L NNP N
after IN N
adjusting VBG N
for IN N
CNS NNP N
disease NN N
were VBD N
1.4 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.96 CD N
to TO N
2.0 CD N
; : N
P NNP N
=.029 NNP N
) ) N
and CC N
2.2 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.5 CD N
to TO N
3.0 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
respectively RB N
The DT N
RFR NNP N
for IN N
patients NNS N
with IN N
isolated JJ N
CNPs NNP N
was VBD N
0.87 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.36 CD N
to TO N
2.1 CD N
; : N
P NNP N
=.76 NNP N
) ) N
CONCLUSION NNP N
We PRP N
conclude VBP N
that IN N
, , N
with IN N
the DT N
treatments NNS N
used VBN N
during IN N
the DT N
period NN N
covered VBN N
by IN N
these DT N
studies NNS N
, , N
the DT N
presence NN N
of IN N
CSF+/Mass NNP N
CNS NNP N
disease NN N
at IN N
diagnosis NN N
was VBD N
associated VBN N
with IN N
a DT N
nominally RB N
worse JJR N
outcome JJ N
independent JJ N
of IN N
initial JJ N
bone NN N
marrow NN N
status NN N
and CC N
LDH NNP N
level NN N
, , N
but CC N
the DT N
effect NN N
was VBD N
not RB N
statistically RB N
significant JJ N
-DOCSTART- -X- O O 1759534

Long-term JJ N
growth NN N
hormone NN N
treatment NN N
in IN N
growth NN 4_p
hormone NN 4_p
deficient NN 4_p
adults NNS 1_p
Growth NNP N
hormone NN N
treatment NN N
in IN N
GH-deficient NNP 4_p
adults NNS 4_p
has VBZ N
proved VBN N
beneficial JJ N
in IN N
recent JJ N
short-term JJ N
trials NNS N
, , N
but CC N
long-term JJ N
results NNS N
have VBP N
not RB N
yet RB N
been VBN N
reported VBN N
Thirteen JJ 3_p
GH-deficient JJ 4_p
adults NNS 4_p
( ( N
4 CD 3_p
females NNS 2_p
, , N
9 CD 3_p
males NNS 2_p
; : N
mean FW N
( ( N
SEM NNP N
) ) N
age NN N
26.4 CD 1_p
( ( N
1.7 CD N
) ) N
years NNS N
) ) N
, , N
who WP N
had VBD N
completed VBN N
4 CD N
months NNS N
of IN N
GH NNP N
therapy NN N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
cross-over NN N
study NN N
were VBD N
followed VBN N
, , N
for IN N
further JJ N
16.1 CD N
( ( N
0.8 CD N
) ) N
months NNS N
of IN N
uninterrupted JJ N
GH NNP N
therapy NN N
in IN N
an DT N
open JJ N
design NN N
A DT N
significant JJ N
mean JJ N
increase NN N
of IN N
1.3 CD N
cm NN N
in IN N
linear JJ N
height NN N
was VBD N
recorded VBN N
, , N
whereas IN N
body NN N
mass NN N
index NN N
remained VBD N
unchanged JJ N
Mean JJ N
muscle NN N
volume NN N
of IN N
the DT N
thigh NN N
, , N
estimated VBN N
by IN N
computerised JJ N
tomography NN N
, , N
increased VBD N
significantly RB N
compared VBN N
with IN N
that DT N
of IN N
the DT N
initial JJ N
placebo NN N
period NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
, , N
and CC N
a DT N
slight JJ N
decrease NN N
was VBD N
recorded VBN N
in IN N
adipose JJ N
tissue NN N
volume NN N
of IN N
the DT N
thigh NN N
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
and CC N
subscapular JJ N
skinfold NN N
thickness NN N
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
Still RB N
, , N
the DT N
muscle NN N
to TO N
fat VB N
ratio NN N
of IN N
the DT N
thigh NN N
was VBD N
significantly RB N
lower JJR N
compared VBN N
with IN N
that DT N
of IN N
normal JJ 4_p
subjects NNS N
( ( N
72.6/27.4 CD N
vs RB N
77.9/22.1 CD N
) ) N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
The DT N
mean JJ N
isometric JJ N
strength NN N
of IN N
the DT N
quadriceps JJ N
muscles NNS N
increased VBD N
significantly RB N
during IN N
long-term JJ N
GH NNP N
therapy NN N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
, , N
but CC N
remained VBD N
lower JJR N
compared VBN N
with IN N
that DT N
of IN N
normal JJ N
subjects NNS N
( ( N
1.66 CD N
( ( N
0.10 CD N
) ) N
vs NN N
2.13 CD N
( ( N
0.11 CD N
) ) N
Nm/kg NNP N
body NN N
weight NN N
) ) N
Exercise NN N
capacity NN N
performed VBN N
on IN N
a DT N
bicycle NN N
ergometer NN N
increased VBD N
significantly RB N
after IN N
long-term JJ N
therapy NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
but CC N
still RB N
did VBD N
not RB N
reach VB N
the DT N
values NNS N
seen VBN N
in IN N
normal JJ N
subjects NNS N
( ( N
22.5 CD N
( ( N
3.4 CD N
) ) N
vs NN N
37.4 CD N
( ( N
4.2 CD N
) ) N
watt.min.kg-1 NN N
No DT N
adverse JJ N
reactions NNS N
were VBD N
recorded VBN N
during IN N
long-term JJ N
therapy NN N
and CC N
hemoglobin NN N
A1c NNP N
remained VBD N
unchanged JJ N
These DT N
data NNS N
suggest VBP N
that IN N
long-term JJ N
GH NNP N
replacement NN N
therapy NN N
in IN N
GH-deficient NNP N
adults NNS N
has VBZ N
beneficial JJ N
effects NNS N
on IN N
several JJ N
physiological JJ N
features NNS N
which WDT N
are VBP N
subnormal JJ N
in IN N
these DT N
patients NNS N
-DOCSTART- -X- O O 11159256

The DT N
response NN N
of IN N
neuropathic JJ N
pain NN N
and CC N
pain NN N
in IN N
complex JJ 4_p
regional JJ 4_p
pain NN 4_p
syndrome NN 4_p
I PRP N
to TO N
carbamazepine VB N
and CC N
sustained-release JJ N
morphine NN N
in IN N
patients NNS N
pretreated VBN 4_p
with IN 4_p
spinal JJ 4_p
cord NN 4_p
stimulation NN 4_p
: : N
a DT N
double-blinded JJ N
randomized NN N
study NN N
Forty-three JJ 3_p
patients NNS N
with IN N
peripheral JJ 4_p
neuropathic JJ 4_p
pain NN 4_p
, , N
exclusively RB N
pain NN 4_p
reduced VBN 4_p
by IN 4_p
spinal JJ 4_p
cord NN 4_p
stimulation NN 4_p
( ( 4_p
SCS NNP 4_p
) ) 4_p
, , N
were VBD N
switched VBN N
into IN N
a DT N
painful JJ 4_p
state NN 4_p
after IN 4_p
SCS NNP 4_p
inactivation NN 4_p
This DT N
mode NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
pain-relieving JJ N
effect NN N
of IN N
carbamazepine NN N
( ( N
CMZ NNP N
) ) N
and CC N
opioids NNS N
in IN N
a DT N
double-blinded JJ N
, , N
placebo-controlled JJ N
trial NN N
In IN N
Phase NNP N
1 CD N
, , N
the DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
CMZ NNP N
( ( N
600 CD N
mg/d NN N
) ) N
or CC N
placebo NN N
during IN N
an DT N
SCS-free JJ N
period NN N
of IN N
8 CD N
days NNS N
In IN N
Phase NNP N
2 CD N
, , N
after IN N
a DT N
CMZ NNP N
elimination NN N
interval NN N
of IN N
7 CD N
days NNS N
, , N
38 CD N
patients NNS N
received VBD N
either RB N
sustained-release JJ N
morphine NN N
( ( N
90 CD N
mg/d NN N
) ) N
or CC N
placebo NN N
for IN N
8 CD N
days NNS N
In IN N
cases NNS N
of IN N
intolerable JJ N
pain NN N
, , N
the DT N
patients NNS N
were VBD N
authorized VBN N
to TO N
reactivate VB N
their PRP$ N
SCS NNP N
The DT N
pain NN N
intensity NN N
was VBD N
rated VBN N
on IN N
a DT N
numeric JJ N
analog NN N
scale NN N
In IN N
38 CD N
patients NNS N
who WP N
completed VBD N
Phase NNP N
1 CD N
, , N
significant JJ N
delay NN N
in IN N
pain JJ N
increase NN N
was VBD N
observed VBN N
in IN N
the DT N
CMZ NNP N
group NN N
as IN N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
= NNP N
0.038 CD N
) ) N
In IN N
Phase NNP N
2 CD N
, , N
the DT N
trend NN N
observed VBD N
with IN N
morphine NN N
was VBD N
insignificant JJ N
( ( N
P NNP N
= NNP N
0.41 CD N
) ) N
Two CD N
CMZ JJ N
patients NNS N
and CC N
one CD N
morphine NN N
patient NN N
showed VBD N
complete JJ N
pain NN N
relief NN N
and CC N
preferred VBN N
to TO N
continue VB N
the DT N
medication NN N
Thirty-five JJ N
patients NNS N
returned VBN N
to TO N
SCS NNP N
We PRP N
conclude VBP N
that DT N
CMZ NNP N
is VBZ N
effective JJ N
in IN N
peripheral JJ N
neuropathic JJ N
pain NN N
Morphine NNP N
obviously RB N
requires VBZ N
larger JJR N
individually RB N
titrated VBD N
dosages NNS N
than IN N
those DT N
used VBN N
in IN N
this DT N
study NN N
for IN N
results NNS N
to TO N
be VB N
adequately RB N
interpreted VBN N
-DOCSTART- -X- O O 8106772

Primary JJ N
prophylaxis NN N
with IN N
pyrimethamine NN N
for IN N
toxoplasmic JJ N
encephalitis NN N
in IN N
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
human JJ 4_p
immunodeficiency NN 4_p
virus NN 4_p
disease NN 4_p
: : 4_p
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
Terry NNP N
Beirn NNP N
Community NNP N
Programs NNP N
for IN N
Clinical NNP N
Research NNP N
on IN N
AIDS NNP N
Pyrimethamine NNP N
, , N
25 CD N
mg NN N
thrice NN N
weekly RB N
, , N
was VBD N
evaluated VBN N
as IN N
primary JJ N
prophylaxis NN N
for IN N
toxoplasmic JJ N
encephalitis NN N
( ( N
TE NNP N
) ) N
in IN N
a DT N
double-blind NN N
, , N
randomized VBD N
clinical JJ N
trial NN N
in IN N
patients NNS N
with IN N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
disease NN N
, , N
absolute JJ N
CD4 NNP N
lymphocyte NN N
count NN N
of IN N
< $ N
200/microL CD N
( ( N
or CC N
prior RB N
AIDS-defining NNP N
opportunistic JJ N
infection NN N
) ) N
, , N
and CC N
the DT N
presence NN N
of IN N
serum NN N
IgG NNP N
to TO N
Toxoplasma NNP N
gondii NN N
Leucovorin NNP N
was VBD N
coadministered VBN N
only RB N
for IN N
hematologic JJ N
toxicity NN N
There EX N
was VBD N
a DT N
significantly RB N
higher JJR N
death NN N
rate NN N
among IN N
patients NNS N
receiving VBG N
pyrimethamine NN N
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
, , N
2.5 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
1.3-4.8 JJ N
; : N
P NNP N
= NNP N
.006 NNP N
) ) N
, , N
even RB N
after IN N
adjusting VBG N
for IN N
factors NNS N
predictive CD N
of IN N
survival NN N
The DT N
TE NNP N
event NN N
rate NN N
was VBD N
low JJ N
in IN N
both DT N
treatment NN N
groups NNS N
( ( N
not RB N
significant JJ N
) ) N
Only RB N
1 CD N
of IN N
218 CD N
patients NNS N
taking VBG N
trimethoprim-sulfamethoxazole JJ N
but CC N
7 CD N
of IN N
117 CD N
taking VBG N
aerosolized JJ N
pentamidine NN N
for IN N
prophylaxis NN N
against IN N
Pneumocystis NNP N
carinii NN N
pneumonia NN N
developed VBD N
TE NNP N
( ( N
adjusted VBN N
RR NNP N
for IN N
the DT N
trimethoprim-sulfamethoxazole JJ N
group NN N
, , N
0.16 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.01-1.79 NNP N
; : N
P NNP N
= NNP N
.14 NNP N
) ) N
Thus RB N
, , N
for IN N
HIV-infected JJ N
patients NNS N
receiving VBG N
trimethoprim-sulfamethoxazole JJ N
, , N
additional JJ N
prophylaxis NN N
for IN N
TE NNP N
appears VBZ N
unnecessary JJ N
-DOCSTART- -X- O O 6992570

Carbenicillin-trimethoprim/sulfamethoxazole JJ N
versus NN N
carbenicillin-gentamicin NN N
as IN N
empiric JJ N
therapy NN N
of IN N
infection NN N
in IN N
granulocytopenic JJ 4_p
patients NNS N
A DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
The DT N
results NNS N
of IN N
therapy NN N
with IN N
carbenicillin JJ N
plus CC N
trimethoprim-sulfamethoxazole JJ N
( ( N
C-T/S NNP N
) ) N
were VBD N
compared VBN N
to TO N
those DT N
obtained VBN N
with IN N
carbenicillin JJ N
plus CC N
gentamicin JJ N
( ( N
C-G NNP N
) ) N
in IN N
a DT N
prospective JJ N
double-blind NN N
study NN N
of IN N
empiric JJ N
antibiotic JJ N
therapy NN N
in IN N
granulocytopenic JJ 4_p
patients NNS N
Patients NNS N
were VBD N
stratified VBN N
into IN N
two CD 3_p
groups NNS N
: : N
favorable-prognosis NN N
, , N
group NN 3_p
1 CD 3_p
( ( N
carcinoma NN 4_p
, , N
lymphoma NN 4_p
, , N
multiple JJ 4_p
myeloma NN 4_p
) ) N
, , N
or CC N
unfavorable-prognosis NN N
, , N
group NN 3_p
2 CD 3_p
( ( N
acute JJ 4_p
leukemia NN 4_p
, , N
bone NN 4_p
marrow NN 4_p
transplantation NN 4_p
) ) N
, , N
based VBN N
on IN N
anticipated JJ N
duration NN N
of IN N
granulocytopenia NN 4_p
Over-all NN N
, , N
empiric JJ N
antibiotic JJ N
trials NNS N
were VBD N
more RBR N
often RB N
successful JJ N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
in IN N
group NN N
1 CD N
( ( N
55 CD N
of IN N
62 CD N
patients NNS N
or CC N
89 CD N
per IN N
cent NN N
) ) N
than IN N
in IN N
group NN N
2 CD N
( ( N
42 CD N
of IN N
64 CD N
patients NNS N
, , N
66 CD N
per IN N
cent NN N
) ) N
mwithin NN N
group NN N
1 CD N
, , N
there EX N
was VBD N
a DT N
favorable JJ N
outcome NN N
in IN N
30 CD N
of IN N
32 CD N
( ( N
94 CD N
per IN N
cent NN N
) ) N
C-T/S NNP N
trials NNS N
and CC N
in IN N
25 CD N
of IN N
30 CD N
( ( N
83 CD N
per IN N
cent NN N
) ) N
C-G NN N
trials NNS N
( ( N
P NNP N
= NNP N
0.25 CD N
) ) N
; : N
within IN N
group NN N
2 CD N
, , N
there EX N
was VBD N
a DT N
favorable JJ N
outcome NN N
in IN N
23 CD N
of IN N
30 CD N
( ( N
77 CD N
per IN N
cent NN N
) ) N
C-T/S NNP N
trials NNS N
and CC N
in IN N
19 CD N
of IN N
34 CD N
( ( N
56 CD N
per IN N
cent NN N
) ) N
C-G NN N
trials NNS N
( ( N
P NNP N
= NNP N
0.14 CD N
) ) N
, , N
Combined VBN N
results NNS N
in IN N
both DT N
groups NNS N
indicated VBD N
a DT N
higher JJR N
proportion NN N
of IN N
favorable JJ N
outcome NN N
in IN N
C-T/S NNP N
trials NNS N
( ( N
53 CD N
of IN N
62 CD N
, , N
85 CD N
per IN N
cent NN N
) ) N
than IN N
in IN N
C-G JJ N
trials NNS N
( ( N
44 CD N
of IN N
64 CD N
, , N
69 CD N
per IN N
cent NN N
) ) N
Further JJ N
analysis NN N
( ( N
Manetl-Naenszel NNP N
test NN N
) ) N
showed VBD N
the DT N
over-all JJ N
difference NN N
in IN N
outcome NN N
to TO N
be VB N
significant JJ N
( ( N
P NNP N
= NNP N
0.049 CD N
) ) N
, , N
but CC N
the DT N
general JJ N
applicability NN N
of IN N
this DT N
result NN N
may MD N
be VB N
limited VBN N
by IN N
the DT N
rather RB N
low JJ N
incidence NN N
of IN N
gram-negative JJ N
bacterial JJ N
infections NNS N
in IN N
this DT N
study NN N
There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
treatment NN N
regimens VBZ N
in IN N
antibiotic JJ N
toxicity NN N
, , N
and CC N
serious JJ N
superinfection NN N
occurred VBD N
only RB N
in IN N
group NN N
2 CD N
patients NNS N
( ( N
21 CD N
per IN N
cent NN N
of IN N
trials NNS N
) ) N
, , N
equally RB N
divided VBD N
between IN N
treatment NN N
arms NNS N
Initial JJ N
protocol NN N
dosing VBG N
achieved VBN N
target NN N
plasma NN N
levels NNS N
of IN N
trimethoprim NN N
( ( N
3 CD N
to TO N
8 CD N
micrograms/ml NN N
) ) N
or CC N
gentamicin NN N
( ( N
4 CD N
to TO N
10 CD N
micrograms/ml NN N
) ) N
in IN N
57 CD N
of IN N
68 CD N
( ( N
84 CD N
per IN N
cent NN N
) ) N
C-T/S NNP N
trials NNS N
compared VBN N
to TO N
21 CD N
of IN N
60 CD N
( ( N
35 CD N
per IN N
cent NN N
) ) N
C-G NNP N
trials NNS N
-DOCSTART- -X- O O 25252600

The DT N
REFLO-STEMI NNP N
trial NN N
comparing VBG N
intracoronary JJ N
adenosine NN N
, , N
sodium NN N
nitroprusside RB N
and CC N
standard JJ N
therapy NN N
for IN N
the DT N
attenuation NN N
of IN N
infarct JJ N
size NN N
and CC N
microvascular JJ N
obstruction NN N
during IN N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
: : N
study NN N
protocol NN N
for IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
BACKGROUND NNP N
Microvascular NNP N
obstruction NN N
( ( N
MVO NNP N
) ) N
secondary JJ N
to TO N
ischaemic-reperfusion JJ N
injury NN N
is VBZ N
an DT N
important JJ N
but CC N
underappreciated JJ N
determinant NN N
of IN N
short- JJ N
and CC N
longer-term JJ N
outcome NN N
following VBG N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
treatment NN N
of IN N
ST-elevation NNP N
myocardial JJ N
infarction NN N
( ( N
STEMI NNP N
) ) N
Several JJ N
small JJ N
studies NNS N
have VBP N
demonstrated VBN N
a DT N
reduction NN N
in IN N
the DT N
degree NN N
of IN N
MVO NNP N
utilising VBG N
a DT N
variety NN N
of IN N
vasoactive JJ N
agents NNS N
, , N
with IN N
adenosine NN N
and CC N
sodium NN N
nitroprusside NN N
( ( N
SNP NNP N
) ) N
being VBG N
most JJS N
evaluated VBN N
However RB N
, , N
the DT N
evidence NN N
base NN N
remains VBZ N
weak JJ N
as IN N
the DT N
trials NNS N
have VBP N
had VBN N
variable JJ N
endpoints NNS N
, , N
differing VBG N
drug NN N
doses NNS N
and CC N
delivery NN N
As IN N
such JJ N
, , N
the DT N
results NNS N
regarding VBG N
benefit NN N
are VBP N
conflicting VBG N
METHODS NNP N
The DT N
REperfusion NNP N
Facilitated NNP N
by IN N
LOcal NNP N
adjunctive JJ N
therapy NN N
in IN N
STEMI NNP N
( ( N
REFLO-STEMI NNP N
) ) N
trial NN N
is VBZ N
a DT N
multicentre NN N
, , N
prospective JJ N
, , N
randomised VBD N
, , N
controlled VBD N
, , N
open JJ N
label NN N
, , N
study NN N
with IN N
blinded JJ N
endpoint NN N
analysis NN N
: : N
Patients NNS N
presenting VBG N
within IN N
6 CD 4_p
h NN 4_p
of IN 4_p
onset NN 4_p
of IN 4_p
STEMI NNP 4_p
and CC 4_p
undergoing JJ 4_p
planned VBN 4_p
primary JJ 4_p
PCI NNP 4_p
( ( 4_p
P-PCI NNP 4_p
) ) 4_p
with IN 4_p
TIMI NNP 4_p
0/1 CD 4_p
flow NN 4_p
in IN 4_p
the DT 4_p
infarct-related JJ 4_p
artery NN 4_p
( ( 4_p
IRA NNP 4_p
) ) 4_p
and CC N
no DT 4_p
significant JJ 4_p
bystander NN 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
on IN 4_p
angiography NN 4_p
, , 4_p
are VBP 4_p
randomised VBN 4_p
into IN 4_p
one CD 4_p
of IN 4_p
three CD 4_p
groups NNS 4_p
: : 4_p
PCI NNP 4_p
with IN 4_p
adjunctive JJ 4_p
pharmacotherapy NN 4_p
( ( 4_p
intracoronary JJ 4_p
adenosine NN 4_p
or CC 4_p
SNP NNP 4_p
) ) 4_p
or CC 4_p
control NN 4_p
( ( 4_p
standard JJ 4_p
PCI NNP 4_p
) ) 4_p
All DT N
receive VBP N
Bivalirudin NNP 4_p
anticoagulation NN 4_p
and CC N
thrombus JJ 4_p
aspiration NN 4_p
The DT N
primary JJ N
outcome NN N
is VBZ N
infarct JJ N
size NN N
( ( N
IS NNP N
) ) N
( ( N
determined VBN N
as IN N
a DT N
percentage NN N
of IN N
total JJ N
left VBD N
ventricular JJ N
mass NN N
) ) N
measured VBN N
by IN N
cardiac JJ N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
CMRI NNP N
) ) N
undertaken VBP N
at IN N
48 CD N
to TO N
72 CD N
h NNS N
post JJ N
P-PCI NNP N
Secondary NNP N
outcome NN N
measures NNS N
include VBP N
MVO NNP N
( ( N
hypoenhancement NN N
within IN N
infarct JJ N
core NN N
) ) N
on IN N
CMRI NNP N
, , N
angiographic JJ N
markers NNS N
of IN N
microvascular JJ N
perfusion NN N
and CC N
MACE NNP N
during IN N
1-month JJ N
follow-up NN N
The DT N
study NN N
aims VBZ N
to TO N
recruit VB N
240 CD 3_p
patients NNS 3_p
( ( N
powered VBN N
at IN N
80 CD N
% NN N
to TO N
detect VB N
a DT N
5 CD N
% NN N
absolute JJ N
reduction NN N
in IN N
IS NNP N
) ) N
DISCUSSION VB N
The DT N
REFLO-STEMI NNP N
study NN N
has VBZ N
been VBN N
designed VBN N
to TO N
address VB N
the DT N
weaknesses NNS N
of IN N
previous JJ N
trials NNS N
, , N
which WDT N
have VBP N
collectively RB N
failed VBN N
to TO N
demonstrate VB N
whether IN N
adjunctive JJ N
pharmacotherapy NN N
with IN N
adenosine JJ N
and/or NN N
SNP NNP N
can MD N
reduce VB N
measures NNS N
of IN N
myocardial JJ N
injury NN N
( ( N
infarct JJ N
size NN N
and CC N
MVO NNP N
) ) N
and CC N
improve VB N
clinical JJ N
outcome NN N
, , N
despite IN N
good JJ N
basic JJ N
evidence NN N
that IN N
they PRP N
have VBP N
the DT N
potential JJ N
to TO N
attenuate VB N
this DT N
process NN N
The DT N
REFLO-STEMI NNP N
study NN N
will MD N
be VB N
the DT N
most RBS N
scientifically RB N
robust JJ N
trial NN N
to TO N
date NN N
evaluating VBG N
whether IN N
adjunctive JJ N
therapy NN N
( ( N
intracoronary JJ N
adenosine NN N
or CC N
SNP NNP N
following VBG N
thrombus JJ N
aspiration NN N
) ) N
reduces VBZ N
CMRI NNP N
measured VBN N
IS NNP N
and CC N
MVO NNP N
in IN N
patients NNS N
undergoing VBG N
P-PCI NNP N
within IN N
6 CD N
h NN N
of IN N
onset NN N
of IN N
STEMI NNP N
TRIAL NNP N
REGISTRATION NNP N
Trial NNP N
registered VBD N
20th CD N
November NNP N
2012 CD N
: : N
ClinicalTrials.gov NNP N
Identifier NNP N
NCT01747174 NNP N
-DOCSTART- -X- O O 14722336

Effects NNS N
of IN N
a DT N
caregiver NN N
intervention NN N
on IN N
negative JJ N
caregiver NN N
appraisals NNS N
of IN N
behavior NN N
problems NNS N
in IN N
patients NNS N
with IN N
Alzheimer NNP 4_p
's POS 4_p
disease NN 4_p
: : N
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
Behavioral JJ N
problems NNS N
are VBP N
among IN N
the DT N
most RBS N
challenging JJ N
aspects NNS N
of IN N
caring VBG N
for IN N
a DT N
person NN N
with IN N
Alzheimer NNP 4_p
's POS 4_p
disease NN 4_p
A DT N
sample NN N
of IN N
406 CD 3_p
spouses-caregivers NNS N
of IN N
patients NNS N
with IN N
Alzheimer NNP 4_p
's POS 4_p
disease NN 4_p
was VBD N
randomized VBN N
to TO N
an DT N
active JJ N
multicomponent NN N
counseling NN N
and CC N
support NN N
intervention NN N
condition NN N
or CC N
to TO N
a DT N
usual JJ N
care NN N
condition NN N
Caregivers NNS N
reported VBD N
on IN N
the DT N
frequency NN N
of IN N
troublesome JJ N
patient NN N
behaviors NNS N
and CC N
their PRP$ N
reactions NNS N
to TO N
them PRP N
at IN N
baseline NN N
and CC N
at IN N
regular JJ N
follow-up JJ N
interviews NNS N
Random-effects NNS N
regression NN N
models NNS N
over IN N
the DT N
first JJ N
4 CD N
years NNS N
after IN N
randomization NN N
revealed VBD N
that IN N
, , N
although IN N
the DT N
intervention NN N
did VBD N
not RB N
affect VB N
the DT N
frequency NN N
of IN N
patient JJ N
behavioral JJ N
problems NNS N
, , N
it PRP N
did VBD N
significantly RB N
reduce VB N
caregivers NNS N
' POS N
reaction NN N
ratings NNS N
Because IN N
caregiver NN N
appraisals NNS N
have VBP N
been VBN N
found VBN N
to TO N
mediate VB N
the DT N
impact NN N
of IN N
caregiving VBG N
stress NN N
on IN N
depression NN N
and CC N
to TO N
predict VB N
nursing NN N
home NN N
placement NN N
rates NNS N
, , N
they PRP N
deserve VBP N
greater JJR N
attention NN N
as IN N
an DT N
important JJ N
target NN N
of IN N
intervention NN N
services NNS N
-DOCSTART- -X- O O 14713377

Intervention NN N
in IN N
children NNS N
with IN N
Developmental NNP 4_p
Coordination NNP 4_p
Disorder NNP 4_p
: : N
the DT N
role NN N
of IN N
parents NNS N
and CC N
teachers NNS N
BACKGROUND NNP N
Children NNP N
with IN N
Developmental NNP 4_p
Coordination NNP 4_p
Disorder NNP 4_p
( ( 4_p
DCD NNP 4_p
) ) 4_p
are VBP N
a DT N
heterogeneous JJ N
group NN N
who WP N
have VBP N
a DT N
marked JJ N
impairment NN N
in IN N
the DT N
performance NN N
of IN N
functional JJ N
skills NNS N
Provision NN N
for IN N
these DT N
children NNS N
is VBZ N
usually RB N
made VBN N
via IN N
a DT N
paediatrician JJ N
through IN N
occupational JJ N
or CC N
physiotherapy JJ N
though IN N
, , N
with IN N
a DT N
prevalence NN N
rate NN N
of IN N
5 CD N
% NN N
, , N
regular JJ N
provision NN N
is VBZ N
not RB N
possible JJ N
due JJ N
to TO N
limited JJ N
professional JJ N
resources NNS N
AIMS VB N
The DT N
study NN N
aimed VBD N
to TO N
determine VB N
the DT N
extent NN N
to TO N
which WDT N
parents NNS N
and CC N
teachers NNS N
, , N
with IN N
guidance NN N
, , N
can MD N
assist VB N
in IN N
the DT N
management NN N
of IN N
children NNS N
with IN N
DCD NNP N
; : N
whether IN N
children NNS N
with IN N
DCD NNP N
are VBP N
helped VBN N
in IN N
this DT N
way NN N
and CC N
how WRB N
this DT N
may MD N
contribute VB N
to TO N
our PRP$ N
understanding NN N
of IN N
the DT N
condition NN N
SAMPLE NNP N
Thirty-one CD 3_p
children NNS N
with IN N
DCD NNP N
aged VBD N
7 CD 1_p
to TO 1_p
9 CD 1_p
years NNS 1_p
participated VBN N
in IN N
the DT N
study NN N
METHODS NNP N
Following VBG N
assessment NN N
, , N
individual JJ N
profiles NNS N
were VBD N
developed VBN N
and CC N
each DT N
week NN N
teachers NNS N
and CC N
parents NNS N
were VBD N
given VBN N
guidelines NNS N
for IN N
working VBG N
with IN N
the DT N
children NNS N
and CC N
each DT N
child NN N
had VBD N
three CD N
to TO N
four CD N
sessions NNS N
a DT N
week NN N
lasting VBG N
approximately RB N
for IN N
20 CD N
minutes NNS N
In IN N
Phase NNP N
1 CD N
, , N
one CD N
group NN N
of IN N
children NNS N
worked VBN N
with IN N
teachers NNS N
and CC N
the DT N
other JJ N
group NN N
worked VBD N
with IN N
parents NNS N
In IN N
Phase NNP N
2 CD N
, , N
the DT N
two CD N
groups NNS N
of IN N
children NNS N
swapped VBN N
over IN N
The DT N
children NNS N
were VBD N
assessed VBN N
regularly RB N
throughout IN N
the DT N
project NN N
using VBG N
the DT N
Movement NNP N
ABC NNP N
, , N
together RB N
with IN N
diaries NNS N
and CC N
comments NNS N
from IN N
teachers NNS N
and CC N
parents NNS N
RESULTS NN N
At IN N
the DT N
end NN N
of IN N
the DT N
40-week JJ N
study NN N
, , N
27 CD 3_p
children NNS N
showed VBD N
significant JJ N
improvement NN N
in IN N
their PRP$ N
motor NN N
skills NNS N
CONCLUSIONS NNP N
Both NNP N
teachers NNS N
and CC N
parents NNS N
were VBD N
able JJ N
to TO N
provide VB N
effective JJ N
intervention NN N
for IN N
the DT N
majority NN N
of IN N
the DT N
children NNS N
It PRP N
is VBZ N
possible JJ N
that IN N
the DT N
children NNS N
who WP N
did VBD N
not RB N
improve VB N
have VB N
difficulties NNS N
that WDT N
are VBP N
of IN N
a DT N
more RBR N
complex JJ N
type NN N
which WDT N
require VBP N
more JJR N
specialist JJ N
therapy NN N
to TO N
meet VB N
their PRP$ N
need NN N
-DOCSTART- -X- O O 22585469

Effectiveness NN N
and CC N
safety NN N
of IN N
the DT N
Levitan NNP N
FPS NNP N
Scope™ NNP N
for IN N
tracheal JJ 4_p
intubation NN 4_p
under IN N
general JJ 4_p
anesthesia NN 4_p
with IN N
a DT N
simulated JJ N
difficult JJ N
airway NN N
PURPOSE NNP N
Studies NNP N
show VBP N
that IN N
the DT N
Levitan NNP N
FPS NNP N
( ( N
first JJ N
pass NN N
success NN N
) ) N
Scope™ NNP N
( ( N
LFS NNP N
) ) N
is VBZ N
analogous JJ N
to TO N
a DT N
bougie NN N
in IN N
simulated JJ N
difficult JJ N
airways NNS N
with IN N
comparable JJ N
tracheal JJ N
intubation NN N
success NN N
rates NNS N
In IN N
this DT N
study NN N
, , N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
tracheal JJ N
intubation NN N
with IN N
the DT N
LFS NNP N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
the DT N
Macintosh NNP N
laryngoscope NN N
utilizing VBG N
manual JJ N
in-line JJ N
stabilization NN N
( ( N
MILS NNP N
) ) N
to TO N
simulate VB N
difficult JJ N
airways NNS N
METHODS NNP N
Ninety-four JJ 3_p
subjects NNS N
successfully RB N
completed VBD N
the DT N
trial NN N
Manual JJ N
in-line JJ N
stabilization NN N
of IN N
the DT N
cervical JJ N
spine NN N
was VBD N
applied VBN N
and CC N
the DT N
initial JJ N
laryngoscopy NN N
was VBD N
performed VBN N
using VBG N
either CC N
the DT N
Macintosh NNP N
or CC N
the DT N
LFS NNP N
in IN N
conjunction NN N
with IN N
the DT N
Macintosh NNP N
Following VBG N
the DT N
initial JJ N
grading NN N
, , N
a DT N
second JJ N
laryngoscopy NN N
was VBD N
repeated VBN N
using VBG N
the DT N
second JJ N
randomized JJ N
technique NN N
Cormack-Lehane NNP N
grades NNS N
, , N
percentage NN N
of IN N
glottic JJ N
opening NN N
( ( N
POGO NNP N
) ) N
scores VBZ N
, , N
time NN N
to TO N
intubate VB N
, , N
number NN N
of IN N
intubation NN N
attempts NNS N
, , N
and CC N
the DT N
use NN N
of IN N
alternate NN N
techniques NNS N
were VBD N
recorded VBN N
The DT N
anesthesiologist NN N
rated VBD N
the DT N
subjective JJ N
difficulty NN N
in IN N
using VBG N
each DT N
technique NN N
with IN N
a DT N
numeric JJ N
rating NN N
scale NN N
and CC N
a DT N
visual JJ N
rating NN N
scale NN N
RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
primary JJ N
outcome NN N
" NNP N
good JJ N
laryngoscopic NN N
views NNS N
" NNP N
( ( N
Cormack-Lehane NNP N
grade VBD N
1 CD N
and CC N
2 CD N
) ) N
compared VBN N
with IN N
" NNP N
poor JJ N
laryngoscopic NN N
views NNS N
" NNP N
( ( N
Cormack-Lehane NNP N
grade VBD N
3 CD N
and CC N
4 CD N
) ) N
between IN N
the DT N
LFS NNP N
and CC N
the DT N
Macintosh NNP N
There EX N
were VBD N
higher JJR N
POGO NNP N
scores NNS N
with IN N
the DT N
LFS NNP N
compared VBN N
with IN N
the DT N
Macintosh NNP N
( ( N
80 CD N
% NN N
vs JJ N
20 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
but CC N
this DT N
did VBD N
not RB N
translate VB N
to TO N
easier JJR N
intubations NNS N
, , N
as IN N
documented VBN N
by IN N
the DT N
need NN N
for IN N
an DT N
alternate JJ N
intubation NN N
technique NN N
or CC N
time NN N
to TO N
intubate VB N
( ( N
< JJ N
30 CD N
and CC N
< $ N
60 CD N
sec NN N
, , N
respectively RB N
) ) N
The DT N
incidence NN N
of IN N
mucosal NN N
trauma NN N
, , N
sore RB N
throat NN N
, , N
and CC N
hemodynamic JJ N
responses NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
techniques NNS N
CONCLUSION VB N
The DT N
LFS NNP N
in IN N
conjunction NN N
with IN N
the DT N
Macintosh NNP N
laryngoscope NN N
does VBZ N
not RB N
improve VB N
the DT N
efficacy NN N
or CC N
safety NN N
of IN N
tracheal JJ N
intubation NN N
in IN N
a DT N
simulated JJ N
difficult JJ N
airway NN N
-DOCSTART- -X- O O 8780837

The DT N
effects NNS N
of IN N
chronic JJ N
naltrexone NN N
treatment NN N
in IN N
young JJ 4_p
autistic JJ 4_p
children NNS 1_p
: : 4_p
a DT N
double-blind JJ N
placebo-controlled JJ N
crossover NN N
study NN N
In IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
crossover NN N
trial NN N
23 CD 4_p
autistic JJ 4_p
children NNS 1_p
, , 4_p
aged VBN 4_p
3-7 CD 4_p
years NNS 4_p
, , N
were VBD N
treated VBN N
with IN N
a DT N
mean JJ N
daily JJ N
dosage NN N
of IN N
1 CD N
mg/kg NNS N
naltrexone RB N
for IN N
4 CD N
weeks NNS N
Drug JJ N
effects NNS N
were VBD N
monitored VBN N
with IN N
behavior JJ N
checklists NNS N
rated VBN N
by IN N
parents NNS N
and CC N
teachers NNS N
, , N
and CC N
ethological JJ N
playroom NN N
observations NNS N
On IN N
average NN N
, , N
parents NNS N
' POS N
checklists NNS N
and CC N
playroom NN N
data NNS N
could MD N
not RB N
differentiate VB N
between IN N
naltrexone JJ N
treatment NN N
and CC N
placebo NN N
treatment NN N
; : N
however RB N
, , N
teachers NNS N
significantly RB N
favored VBD N
naltrexone JJ N
treatment NN N
They PRP N
reported VBD N
a DT N
decrease NN N
in IN N
hyperactivity NN N
and CC N
irritability NN N
No DT N
effects NNS N
of IN N
naltrexone NN N
on IN N
social JJ N
and CC N
stereotypic JJ N
behavior NN N
could MD N
be VB N
demonstrated VBN N
-DOCSTART- -X- O O 19564877

A DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
of IN N
the DT N
long-term JJ N
efficacy NN N
and CC N
safety NN N
of IN N
diethylpropion NN N
in IN N
the DT N
treatment NN N
of IN N
obese JJ 4_p
subjects NNS N
OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
diethylpropion NN N
on IN N
a DT N
long-term JJ N
basis NN N
, , N
with IN N
emphasis NN N
in IN N
cardiovascular JJ N
and CC N
psychiatric JJ N
safety NN N
aspects NNS N
DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
MEASUREMENTS NNP N
Following VBG N
a DT N
2-week JJ N
screening NN N
period NN N
, , N
69 CD 3_p
obese JJ 3_p
healthy JJ 3_p
adults NNS 3_p
received VBD N
a DT N
hypocaloric JJ 4_p
diet NN 4_p
and CC N
were VBD N
randomized VBN N
to TO N
diethylpropion VB N
50 CD N
mg NNS N
BID NNP N
( ( N
n=37 NN N
) ) N
or CC N
placebo NN N
( ( N
n=32 JJ N
) ) N
for IN N
6 CD N
months NNS N
After IN N
this DT N
period NN N
, , N
all DT N
participants NNS N
received VBN N
diethylpropion NN N
in IN N
an DT N
open-label JJ N
extension NN N
for IN N
an DT N
additional JJ N
6 CD N
months NNS N
The DT N
primary JJ N
outcome NN N
was VBD N
percentage NN N
change NN N
in IN N
body NN N
weight NN N
Electrocardiogram NNP N
( ( N
ECG NNP N
) ) N
, , N
echocardiography NN N
and CC N
clinical JJ N
chemistry NN N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
every DT N
6 CD N
months NNS N
Psychiatric NNP N
evaluation NN N
and CC N
application NN N
of IN N
Hamilton NNP N
rating NN N
scales NNS N
for IN N
depression NN N
and CC N
anxiety NN N
were VBD N
also RB N
performed VBN N
by IN N
experienced JJ N
psychiatrists NNS N
at IN N
baseline NN N
and CC N
every DT N
3 CD N
months NNS N
RESULTS NNP N
After IN N
6 CD N
months NNS N
, , N
the DT N
diethylpropion NN N
group NN N
lost VBD N
an DT N
average NN N
of IN N
9.8 CD N
% NN N
( ( N
s.d NN N
6.9 CD N
% NN N
) ) N
of IN N
initial JJ N
body NN N
weight VBD N
vs RB N
3.2 CD N
% NN N
( ( N
3.7 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
From IN N
baseline NN N
to TO N
month NN N
12 CD N
, , N
the DT N
mean JJ N
weight NN N
loss NN N
produced VBN N
by IN N
diethylpropion NN N
was VBD N
10.6 CD N
% NN N
( ( N
8.3 CD N
% NN N
) ) N
Participants NNS N
in IN N
the DT N
placebo NN N
group NN N
who WP N
were VBD N
switched VBN N
to TO N
diethylpropion NN N
after IN N
6 CD N
months NNS N
lost VBN N
an DT N
average NN N
of IN N
7.0 CD N
% NN N
( ( N
7.7 CD N
% NN N
) ) N
of IN N
initial JJ N
body NN N
weight NN N
The DT N
difference NN N
between IN N
groups NNS N
at IN N
month NN N
12 CD N
was VBD N
not RB N
significant JJ N
( ( N
P=0.07 NNP N
) ) N
No DT N
differences NNS N
in IN N
blood NN N
pressure NN N
, , N
pulse JJ N
rate NN N
, , N
ECG NNP N
and CC N
psychiatric JJ N
evaluation NN N
were VBD N
observed VBN N
Dry NNP N
mouth NN N
and CC N
insomnia NN N
were VBD N
the DT N
most RBS N
frequent JJ N
adverse JJ N
events NNS N
CONCLUSION NNP N
Diethylpropion NNP N
plus CC N
diet JJ N
produced VBN N
sustained VBN N
and CC N
clinically RB N
significant JJ N
weight JJ N
loss NN N
over IN N
1 CD N
year NN N
It PRP N
seems VBZ N
to TO N
be VB N
safe JJ N
in IN N
relation NN N
to TO N
cardiovascular VB N
and CC N
psychiatric JJ N
aspects NNS N
in IN N
a DT N
well-selected JJ N
population NN N
-DOCSTART- -X- O O 7963648

The DT N
degrees NNS N
of IN N
UVB-induced NNP N
erythema NN N
and CC N
pigmentation NN N
correlate VBP N
linearly RB N
and CC N
are VBP N
reduced VBN N
in IN N
a DT N
parallel JJ N
manner NN N
by IN N
topical JJ N
anti-inflammatory JJ N
agents NNS N
To TO N
examine VB N
whether IN N
it PRP N
is VBZ N
possible JJ N
to TO N
evaluate VB N
the DT N
degree NN N
of IN N
ultraviolet NN N
B NNP N
( ( N
UVB NNP N
) ) N
-induced VBD N
inflammation NN N
by IN N
measuring VBG N
the DT N
degree NN N
of IN N
hyperpigmentation NN N
, , N
we PRP N
investigated VBD N
the DT N
relationship NN N
between IN N
UVB-induced NNP N
erythema NN N
and CC N
the DT N
subsequent JJ N
pigmentation NN N
quantitatively RB N
At IN N
24 CD N
h NN N
and CC N
7 CD N
d NN N
after IN N
irradiation NN N
with IN N
erythemogenic JJ N
doses NNS N
of IN N
UVB NNP N
to TO N
the DT N
backs NNS N
of IN N
16 CD N
Japanese JJ N
subjects NNS N
, , N
the DT N
degree NN N
of IN N
induced JJ N
erythema NN N
( ( N
delta JJ N
erythema VBP N
index NN N
) ) N
and CC N
that IN N
of IN N
pigmentation NN N
( ( N
delta JJ N
melanin NN N
index NN N
) ) N
were VBD N
examined VBN N
by IN N
an DT N
image NN N
analytic JJ N
method NN N
using VBG N
a DT N
videomicroscope NN N
interfaced VBN N
with IN N
a DT N
computer NN N
The DT N
relationship NN N
between IN N
two CD N
indices NNS N
was VBD N
linear JJ N
in IN N
each DT N
subject NN N
, , N
and CC N
the DT N
correlation NN N
coefficient NN N
was VBD N
0.83 CD N
when WRB N
evaluated VBN N
using VBG N
whole JJ N
data NNS N
The DT N
slope NN N
of IN N
the DT N
regression NN N
line NN N
for IN N
the DT N
delta NN N
melanin NN N
index NN N
against IN N
delta NN N
erythema NN N
index NN N
tended VBD N
to TO N
become VB N
steeper JJ N
as IN N
non-irradiated JJ N
skin NN N
color NN N
became VBD N
darker NN N
( ( N
r JJ N
= NNP N
0.63 CD N
) ) N
, , N
suggesting VBG N
that IN N
more RBR N
efficient JJ N
melanogenesis NN N
takes VBZ N
place NN N
after IN N
the DT N
same JJ N
level NN N
of IN N
inflammation NN N
in IN N
the DT N
subject NN N
with IN N
darker NN N
skin NN N
Both DT N
erythema NN N
and CC N
hyperpigmentation NN N
were VBD N
suppressed VBN N
significantly RB N
and CC N
in IN N
a DT N
parallel JJ N
manner NN N
by IN N
corticosteroids NNS N
and CC N
indomethacin NN N
applied VBN N
topically RB N
immediately RB N
after IN N
UVB NNP N
irradiation NN N
These DT N
results NNS N
imply VBP N
that IN N
the DT N
post-inflammatory JJ N
hyperpigmentation NN N
correlates NNS N
closely RB N
with IN N
the DT N
severity NN N
of IN N
the DT N
prior JJ N
inflammation NN N
and CC N
that DT N
chemical NN N
mediators NNS N
released VBN N
in IN N
the DT N
inflammatory NN N
process NN N
have VBP N
considerable JJ N
influence NN N
on IN N
the DT N
melanogenesis NN N
We PRP N
conclude VBP N
that IN N
the DT N
measurement NN N
of IN N
UVB-induced JJ N
hyperpigmentation NN N
can MD N
be VB N
utilized VBN N
for IN N
the DT N
assessment NN N
of IN N
topical JJ N
anti-inflammatory JJ N
agents NNS N
, , N
unless IN N
these DT N
have VBP N
direct JJ N
actions NNS N
on IN N
the DT N
tyrosinase NN N
activity NN N
of IN N
melanocytes NNS N
-DOCSTART- -X- O O 7148967

A DT N
comparison NN N
of IN N
dorsal NN N
and CC N
volar JJ N
resting NN N
hand NN N
splints NNS N
in IN N
the DT N
reduction NN N
of IN N
hypertonus NN 4_p
Ten CD 3_p
adults NNS 1_p
with IN N
hypertonic JJ 4_p
wrist NN N
flexors NNS N
volunteered VBD N
as IN N
subjects NNS N
in IN N
an DT N
experiment NN N
comparing VBG N
the DT N
effectiveness NN N
of IN N
dorsal NN N
and CC N
volar JJ N
resting NN N
hand NN N
splints NNS N
in IN N
the DT N
reduction NN N
of IN N
abnormal JJ N
muscle NN N
tone NN N
Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
of IN N
five CD N
each DT N
Individuals NNS N
in IN N
one CD N
group NN N
were VBD N
fitted VBN N
with IN N
dorsal NN N
splints NNS N
, , N
and CC N
individuals NNS N
in IN N
a DT N
second JJ N
group NN N
with IN N
volar JJ N
splints NNS N
Measurements NNS N
by IN N
spring-weighted JJ N
scales NNS N
were VBD N
taken VBN N
to TO N
assess VB N
the DT N
efficiency NN N
of IN N
each DT N
splint NN N
design NN N
in IN N
the DT N
reduction NN N
of IN N
hypertonus NN N
Results NNP N
demonstrated VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
volar NN N
and CC N
dorsal NN N
splints NNS N
in IN N
reducing VBG N
hypertonus NN 4_p
However RB N
, , N
the DT N
age NN N
of IN N
the DT N
subjects NNS N
was VBD N
found VBN N
to TO N
be VB N
an DT N
intervening VBG N
variable NN N
: : N
The DT N
older JJR 1_p
subjects NNS N
of IN N
both DT N
groups NNS N
demonstrated VBD N
a DT N
gradual JJ N
but CC N
not RB N
significant JJ N
decline NN N
in IN N
hypertonus NN N
, , N
whereas IN N
the DT N
younger JJR 1_p
adults NNS 1_p
demonstrated VBD N
a DT N
significant JJ N
decline NN N
in IN N
hypertonus NN N
over IN N
a DT N
6-week JJ N
period NN N
-DOCSTART- -X- O O 25915138

Indicators NNS N
for IN N
Cervical JJ N
Length NNP N
in IN N
Twin NNP N
Pregnancies NNP N
OBJECTIVE NNP N
Cervical NNP N
length NN N
( ( N
CL NNP N
) ) N
is VBZ N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
preterm JJ N
birth NN N
( ( N
PTB NNP N
) ) N
in IN N
multiple JJ N
pregnancies NNS N
However RB N
, , N
the DT N
position NN N
of IN N
CL NNP N
within IN N
the DT N
pathophysiological JJ N
pathway NN N
of IN N
PTB NNP N
is VBZ N
unclear JJ N
, , N
and CC N
it PRP N
is VBZ N
unknown JJ N
which WDT N
factors NNS N
are VBP N
predictive JJ N
for IN N
CL NNP N
This DT N
study NN N
aims VBZ N
to TO N
investigate VB N
whether IN N
in IN N
twin JJ N
pregnancies NNS N
baseline VBP N
maternal JJ N
and CC N
obstetrical JJ N
characteristics NNS N
are VBP N
potential JJ N
indicators NNS N
for IN N
CL NNP N
, , N
to TO N
improve VB N
insight NN N
in IN N
the DT N
pathophysiological JJ N
pathway NN N
of IN N
PTB NNP N
STUDY NNP N
DESIGN NNP N
Secondary NNP N
analysis NN N
of IN N
data NNS N
on IN N
twin NN 4_p
pregnancies NNS 4_p
and CC N
CL NNP N
measurement NN N
between IN N
16 CD N
and CC N
22 CD N
weeks NNS N
A DT N
set NN N
of IN N
10 CD N
potential JJ N
indicators NNS N
, , N
known VBN N
to TO N
be VB N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
PTB NNP N
and/or NN N
which WDT N
have VBP N
a DT N
plausible JJ N
mechanism NN N
resulting VBG N
in IN N
a DT N
change NN N
of IN N
CL NNP N
were VBD N
selected VBN N
We PRP N
used VBD N
multivariable JJ N
linear JJ N
regression NN N
with IN N
backward JJ N
selection NN N
to TO N
identify VB N
independent JJ N
indicators NNS N
for IN N
CL NNP N
RESULTS VB N
A DT N
total NN N
of IN N
1,447 CD 3_p
women NNS 2_p
with IN N
twin JJ 4_p
pregnancies NNS 4_p
were VBD N
included VBN N
Mean NNP N
CL NNP N
was VBD N
43.7 CD N
( ( N
±8.9 NN N
) ) N
mm NN N
In IN N
multivariable JJ N
analysis NN N
, , N
age NN N
( ( N
0.27 CD N
mm/y NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] VBD N
0.16 CD N
to TO N
0.39 CD N
) ) N
, , N
use NN N
of IN N
assisted JJ N
reproductive JJ N
technologies NNS N
( ( N
ART NNP N
) ) N
( ( N
-1.42 JJ N
mm NN N
, , N
95 CD N
% NN N
CI NNP N
-2.6 NNP N
to TO N
-0.25 VB N
) ) N
, , N
and CC N
having VBG N
delivered VBN N
at IN N
term NN N
in IN N
a DT N
previous JJ N
pregnancy NN N
( ( N
1.32 CD N
mm NN N
, , N
95 CD N
% NN N
CI NNP N
0.25 CD N
to TO N
2.39 CD N
) ) N
were VBD N
significantly RB N
associated VBN N
with IN N
CL NNP N
CONCLUSION NNP N
This DT N
study NN N
shows VBZ N
that IN 4_p
in IN 4_p
twin NN 4_p
pregnancies NNS 4_p
, , N
age NN N
, , N
use NN N
of IN N
ART NNP N
and CC N
having VBG N
delivered VBN N
term NN N
in IN N
a DT N
previous JJ N
pregnancy NN N
has VBZ N
an DT N
association NN N
with IN N
CL NNP N
-DOCSTART- -X- O O 9660035

Zolmitriptan NNP N
( ( N
311C90 CD N
) ) N
does VBZ N
not RB N
interact VB N
with IN N
fluoxetine NN N
in IN N
healthy JJ N
volunteers NNS N
Zolmitriptan NNP N
( ( N
Zomig NNP N
, , N
formerly RB N
311C90 CD N
) ) N
is VBZ N
a DT N
selective JJ N
5-hydroxytryptamine JJ N
( ( N
5-HT JJ N
) ) N
1B/1D-receptor JJ N
agonist NN N
with IN N
central JJ N
and CC N
peripheral JJ N
activity NN N
for IN N
the DT N
acute JJ N
treatment NN N
of IN N
migraine NN N
This DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
investigated VBD N
the DT N
effects NNS N
of IN N
fluoxetine JJ N
administration NN N
on IN N
the DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
zolmitriptan NN N
Twenty CD 3_p
volunteers NNS N
were VBD N
given VBN N
single JJ N
doses NNS N
of IN N
fluoxetine JJ N
20 CD N
mg NN N
or CC N
an DT N
identical JJ N
placebo NN N
daily RB N
for IN N
28 CD N
days NNS N
prior RB N
to TO N
receiving VBG N
a DT N
single JJ N
10 CD N
mg JJ N
oral JJ N
dose NN N
of IN N
zolmitriptan NN N
Sixteen JJ 3_p
volunteers NNS N
completed VBD N
the DT N
two CD N
treatment NN N
phases NNS N
The DT N
pharmacokinetic JJ N
parameters NNS N
of IN N
zolmitriptan NN N
and CC N
its PRP$ N
metabolites NNS N
were VBD N
not RB N
significantly RB N
affected VBN N
by IN N
fluoxetine JJ N
pretreatment NN N
The DT N
pharmacodynamic JJ N
effects NNS N
of IN N
zolmitriptan NN N
were VBD N
also RB N
unaffected VBN N
by IN N
fluoxetine JJ N
pretreatment NN N
There EX N
were VBD N
small JJ N
, , N
clinically RB N
insignificant JJ N
increases NNS N
in IN N
blood NN N
pressure NN N
following VBG N
zolmitriptan NN N
which WDT N
were VBD N
unaltered VBN N
by IN N
fluoxetine NN N
Zolmitriptan NNP N
was VBD N
well RB N
tolerated VBN N
when WRB N
given VBN N
alone RB N
or CC N
concomitantly RB N
with IN N
fluoxetine NN N
These DT N
results NNS N
indicate VBP N
that IN N
there EX N
is VBZ N
no DT N
contraindication NN N
to TO N
the DT N
use NN N
of IN N
zolmitriptan NN N
in IN N
patients NNS N
treated VBN N
concurrently RB N
with IN N
selective JJ N
serotonin NNS 4_p
reuptake VBP 4_p
inhibitors NNS 4_p
and CC N
that IN N
no DT N
adjustment NN N
of IN N
the DT N
zolmitriptan NN N
dose NN N
is VBZ N
required VBN N
in IN N
these DT N
circumstances NNS N
-DOCSTART- -X- O O 2228570

Enhancing VBG N
the DT N
self-esteem NN N
of IN N
inpatient JJ 4_p
alcoholics NNS 4_p
This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
pairing VBG N
inpatient JJ 4_p
alcoholics NNS 4_p
with IN 4_p
nursing NN 4_p
home NN 4_p
residents NNS 4_p
( ( 4_p
NHRs NNP 4_p
) ) 4_p
on IN N
the DT N
alcoholics NNS N
' POS N
self-esteem NN N
In IN N
this DT N
PALS NNP N
program NN N
, , N
the DT N
alcoholic JJ N
inpatients NNS N
assumed VBD N
a DT N
helping-companion NN N
relationship NN N
with IN N
the DT N
NHRs NNP N
for IN N
2 CD N
hr NNS N
per IN N
day NN N
during IN N
their PRP$ N
last JJ N
2 CD N
weeks NNS N
of IN N
treatment NN N
Fifty NNP 3_p
alcoholic JJ 3_p
inpatients NNS 4_p
were VBD 4_p
randomly RB 4_p
assigned VBN 4_p
to TO 4_p
the DT 4_p
PALS NNP 4_p
program NN 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
25 CD 4_p
) ) 4_p
or CC 4_p
to TO 4_p
the DT 4_p
library NN 4_p
for IN 4_p
free JJ 4_p
reading NN 4_p
time NN 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
25 CD 4_p
) ) 4_p
The DT N
Tennessee NNP N
Self-Concept NNP N
Scale NNP N
( ( N
TSCS NNP N
) ) N
was VBD N
administered VBN N
to TO N
all DT N
subjects NNS N
in IN N
both DT N
groups NNS N
before IN N
and CC N
after IN N
the DT N
interventions NNS N
Of IN N
the DT N
nine CD N
TSCS NNP N
scales NNS N
, , N
the DT N
improvement NN N
on IN N
the DT N
Moral-Ethical JJ N
scale NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
PALS NNP N
group NN N
Because IN N
the DT N
alcoholic JJ N
inpatients NNS N
in IN N
the DT N
PALS NNP N
group NN N
engaged VBD N
in IN N
altruistic JJ N
( ( N
moral JJ N
) ) N
behavior NN N
, , N
this DT N
study NN N
provides VBZ N
a DT N
logical JJ N
link NN N
between IN N
the DT N
intervention NN N
and CC N
the DT N
outcome NN N
, , N
which WDT N
has VBZ N
been VBN N
a DT N
prevalent JJ N
weakness NN N
in IN N
previous JJ N
studies NNS N
of IN N
self-esteem NN N
in IN N
alcoholics NNS N
-DOCSTART- -X- O O 22079088

Safety NN N
and CC N
efficacy NN N
of IN N
sitaxsentan JJ N
50 CD N
and CC N
100 CD N
mg NNS N
in IN N
patients NNS N
with IN 4_p
pulmonary JJ 4_p
arterial JJ 4_p
hypertension NN 4_p
OBJECTIVE UH N
To TO N
assess VB N
safety NN N
and CC N
efficacy NN N
of IN N
sitaxsentan JJ N
50 CD N
and CC N
100 CD N
mg NNS N
in IN N
patients NNS N
with IN 4_p
pulmonary JJ 4_p
arterial JJ 4_p
hypertension NN 4_p
( ( 4_p
PAH NNP 4_p
) ) 4_p
BACKGROUND NNP N
Sitaxsentan NNP N
is VBZ N
a DT N
highly RB N
selective JJ N
endothelin-A JJ N
receptor NN N
antagonist NN N
that WDT N
was VBD N
recently RB N
withdrawn VBN N
by IN N
the DT N
manufacturer NN N
because IN N
of IN N
a DT N
pattern NN N
of IN N
idiosyncratic JJ N
liver JJ N
injury NN N
METHODS NNP N
Before IN N
sitaxsentan NN N
withdrawal NN N
, , N
this DT N
18-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
randomized VBD N
patients NNS N
with IN N
PAH NNP N
to TO N
receive VB N
placebo NN N
or CC N
sitaxsentan VB N
50 CD N
or CC N
100 CD N
mg NNS N
once RB N
daily RB N
The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
change NN N
from IN N
baseline NN N
in IN N
6-min JJ N
walk NN N
distance NN N
( ( N
6MWD CD N
) ) N
at IN N
week NN N
18 CD N
Changes NNS N
in IN N
World NNP N
Health NNP N
Organization NNP N
( ( N
WHO NNP N
) ) N
functional JJ N
class NN N
and CC N
time NN N
to TO N
clinical JJ N
worsening NN N
( ( N
TTCW NNP N
) ) N
were VBD N
secondary JJ N
endpoints NNS N
The DT N
primary JJ N
efficacy NN N
analysis NN N
was VBD N
powered VBN N
for IN N
sitaxsentan JJ N
100 CD N
mg NN N
versus NN N
placebo NN N
RESULTS NNP N
Of IN N
98 CD 3_p
randomized JJ N
patients NNS N
, , N
61 CD 3_p
% NN 3_p
were VBD N
WHO NNP N
functional JJ N
class NN N
II NNP N
at IN N
baseline NN 4_p
Improvement NN N
from IN N
baseline NN N
to TO N
week NN N
18 CD N
in IN N
6MWD CD N
occurred VBD N
with IN N
sitaxsentan JJ N
100 CD N
but CC N
not RB N
50 CD N
mg NNS N
; : N
a DT N
strong JJ N
placebo NN N
effect NN N
was VBD N
observed VBN N
At IN N
week NN N
18 CD N
, , N
WHO NNP N
functional VBP N
class NN N
was VBD N
improved VBN N
or CC N
maintained VBN N
in IN N
more RBR N
patients NNS N
receiving VBG N
sitaxsentan JJ N
100 CD N
mg NN N
than IN N
placebo NN N
( ( N
P NNP N
= NNP N
0.038 CD N
) ) N
; : N
0 CD N
% NN N
versus IN N
12 CD N
% NN N
of IN N
patients NNS N
deteriorated VBN N
, , N
respectively RB N
TTCW NNP N
was VBD N
not RB N
significantly RB N
different JJ N
for IN N
100-mg JJ N
sitaxsentan NN N
patients NNS N
than IN N
placebo NN N
( ( N
P NNP N
= NNP N
0.090 CD N
) ) N
Adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
occurring VBG N
more RBR N
frequently RB N
with IN N
sitaxsentan NN N
( ( N
50 CD N
or CC N
100 CD N
mg NN N
) ) N
included VBD N
headache NN N
, , N
peripheral JJ N
edema NN N
, , N
dizziness NN N
, , N
nausea NN N
, , N
extremity NN N
pain NN N
, , N
and CC N
fatigue NN N
; : N
most JJS N
AEs NNP N
were VBD N
of IN N
mild NN N
or CC N
moderate JJ N
severity NN N
CONCLUSION NNP N
Sitaxsentan NNP N
100 CD N
mg NN N
improved VBD N
functional JJ N
class NN N
but CC N
not RB 4_p
6MWD CD 4_p
in IN 4_p
PAH NNP 4_p
patients NNS 4_p
who WP 4_p
were VBD 4_p
mostly RB 4_p
WHO NNP 4_p
functional JJ 4_p
class NN 4_p
II NNP 4_p
at IN 4_p
baseline NN N
No DT N
patient NN N
receiving VBG N
sitaxsentan JJ N
100 CD N
mg NN N
experienced VBD N
clinical JJ N
worsening NN N
; : N
sitaxsentan NN N
was VBD N
well RB N
tolerated VBN N
-DOCSTART- -X- O O 7635420

Synthesis NN N
of IN N
interleukin-1 JJ N
beta NN N
in IN N
primary JJ 4_p
biliary JJ 4_p
cirrhosis NN 4_p
: : N
relationship NN N
to TO N
treatment NN N
with IN N
methotrexate NN N
or CC N
colchicine NN N
and CC N
disease NN N
progression NN N
Primary JJ 4_p
biliary JJ 4_p
cirrhosis NN 4_p
( ( 4_p
PBC NNP 4_p
) ) 4_p
is VBZ N
a DT N
chronic JJ N
, , N
progressive JJ N
, , N
cholestatic JJ N
liver NN 4_p
disease NN 4_p
Interleukin-1 JJ N
beta NN N
( ( N
IL-1 NNP N
beta NN N
) ) N
may MD N
play VB N
a DT N
role NN N
in IN N
the DT N
pathogenesis NN N
of IN N
PBC NNP N
by IN N
contributing VBG N
to TO N
altered VBN N
immune JJ N
function NN N
and CC N
fibrosis NN N
Colchicine NNP N
or CC N
methotrexate NN N
has VBZ N
some DT N
beneficial JJ N
effects NNS N
in IN N
the DT N
treatment NN N
of IN N
PBC NNP N
, , N
and CC N
also RB N
affects VBZ N
interleukin-1 JJ N
( ( N
IL-1 NNP N
) ) N
Therefore RB N
, , N
we PRP N
prospectively RB N
studied VBD N
the DT N
synthesis NN N
of IN N
IL-1 NNP N
beta NN N
by IN N
peripheral JJ N
blood NN N
mononuclear NN N
cells NNS N
( ( N
PBMC NNP N
) ) N
from IN N
42 CD 3_p
patients NNS N
with IN N
PBC NNP 4_p
entered VBD N
into IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
controlled VBD N
trial NN N
of IN N
colchicine NN N
and CC N
methotrexate NN N
PBMC NNP N
obtained VBD N
at IN N
entry NN N
, , N
6 CD N
, , N
12 CD N
, , N
18 CD N
, , N
and CC N
24 CD N
months NNS N
were VBD N
stimulated VBN N
to TO N
produce VB N
IL-1 NNP N
beta NN N
with IN N
phytohemagglutinin NN N
( ( N
PHA NNP N
) ) N
, , N
lipopolysaccharide RB N
( ( N
LPS NNP N
) ) N
, , N
Staphylococcus NNP N
epidermidis NN N
, , N
recombinant JJ N
IL-2 NNP N
, , N
or CC N
mitochondrial JJ N
antigen NN N
Patients NNS N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
did VBD N
not RB N
differ VB N
at IN N
entry NN N
in IN N
biochemical JJ N
measures NNS N
or CC N
liver VB N
histological JJ N
stage NN N
Over IN N
24 CD N
months NNS N
in IN N
both DT N
groups NNS N
, , N
serum JJ N
bilirubin NN N
and CC N
histologic JJ N
stage NN N
remained VBD N
stable JJ N
and CC N
alkaline JJ N
phosphatase NN N
decreased VBN N
significantly RB N
For IN N
all DT N
patients NNS N
, , N
synthesis NN N
of IN N
IL-1 NNP N
beta NN N
increased VBD N
constitutively RB N
and CC N
in IN N
response NN N
to TO N
immune-mediated JJ N
stimulants NNS N
( ( N
PHA NNP N
, , N
IL-2 NNP N
, , N
and CC N
mitochondrial JJ N
antigen NN N
) ) N
but CC N
not RB N
the DT N
bacterial JJ N
stimulants NNS N
LPS NNP N
or CC N
S NNP N
epidermidis NN N
Compared VBN N
with IN N
levels NNS N
of IN N
IL-1 NNP N
beta NN N
at IN N
entry NN N
, , N
PHA NNP N
induced VBD N
increases NNS N
for IN N
patients NNS N
treated VBN N
with IN N
methotrexate NN N
( ( N
12 CD N
, , N
18 CD N
, , N
and CC N
24 CD N
months NNS N
) ) N
or CC N
colchicine NN N
( ( N
18 CD N
and CC N
24 CD N
months NNS N
) ) N
At IN N
24 CD N
months NNS N
, , N
IL-2-induced NNP N
IL-1 NNP N
beta NN N
synthesis NN N
was VBD N
increased VBN N
in IN N
patients NNS N
treated VBN N
with IN N
methotrexate NN N
, , N
whereas JJ N
S NNP N
epidermidis-induced JJ N
IL-1 NNP N
beta NN N
was VBD N
enhanced VBN N
in IN N
colchicine-treated JJ N
patients NNS N
Before IN N
treatment NN N
, , N
IL-1 NNP N
beta NN N
production NN N
did VBD N
not RB N
relate VB N
to TO N
severity NN N
of IN N
disease NN N
except IN N
in IN N
response NN N
to TO N
S NNP N
epidermidis NN N
( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 12151468

Risperidone NN N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
and CC N
serious JJ N
behavioral JJ 4_p
problems NNS 4_p
BACKGROUND NNP N
Atypical NNP N
antipsychotic JJ N
agents NNS N
, , N
which WDT N
block VBP N
postsynaptic JJ N
dopamine NN N
and CC N
serotonin NN N
receptors NNS N
, , N
have VBP N
advantages NNS N
over IN N
traditional JJ N
antipsychotic JJ N
medications NNS N
in IN N
the DT N
treatment NN N
of IN N
adults NNS N
with IN N
schizophrenia NN N
and CC N
may MD N
be VB N
beneficial JJ N
in IN N
children NNS N
with IN N
autistic JJ N
disorder NN N
who WP N
have VBP N
serious JJ N
behavioral JJ N
disturbances NNS N
However RB N
, , N
data NNS N
on IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
atypical JJ N
antipsychotic JJ N
agents NNS N
in IN N
children NNS N
are VBP N
limited VBN N
METHODS NNP N
We PRP N
conducted VBD N
a DT N
multisite NN N
, , N
randomized VBN N
, , N
double-blind JJ N
trial NN N
of IN N
risperidone NN N
as IN N
compared VBN N
with IN N
placebo NN N
for IN N
the DT N
treatment NN N
of IN N
autistic JJ 4_p
disorder NN 4_p
accompanied VBN N
by IN N
severe JJ N
tantrums NNS N
, , N
aggression NN N
, , N
or CC N
self-injurious JJ N
behavior NN N
in IN N
children NNS 1_p
5 CD N
to TO N
17 CD N
years NNS N
old JJ N
The DT N
primary JJ N
outcome NN N
measures NNS N
were VBD N
the DT N
score NN N
on IN N
the DT N
Irritability NNP N
subscale NN N
of IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
and CC N
the DT N
rating NN N
on IN N
the DT N
Clinical NNP N
Global NNP N
Impressions NNP N
- : N
Improvement NN N
( ( N
CGI-I NNP N
) ) N
scale NN N
at IN N
eight CD N
weeks NNS N
RESULTS VB N
A DT N
total NN N
of IN N
101 CD 3_p
children NNS N
( ( N
82 CD 3_p
boys NNS N
and CC N
19 CD 3_p
girls NNS N
; : N
mean VB N
[ IN N
+/-SD JJ N
] NNP N
age NN N
, , N
8.8+/-2.7 CD N
years NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
risperidone NN N
( ( N
49 CD 3_p
children NNS N
) ) N
or CC N
placebo NN N
( ( N
52 CD N
) ) N
Treatment NN N
with IN N
risperidone NN N
for IN N
eight CD N
weeks NNS N
( ( N
dose JJ N
range NN N
, , N
0.5 CD N
to TO N
3.5 CD N
mg NNS N
per IN N
day NN N
) ) N
resulted VBD N
in IN N
a DT N
56.9 CD N
percent NN N
reduction NN N
in IN N
the DT N
Irritability NNP N
score NN N
, , N
as IN N
compared VBN N
with IN N
a DT N
14.1 CD N
percent NN N
decrease NN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
The DT N
rate NN N
of IN N
a DT N
positive JJ N
response NN N
, , N
defined VBD N
as IN N
at IN N
least JJS N
a DT N
25 CD N
percent NN N
decrease NN N
in IN N
the DT N
Irritability NNP N
score NN N
and CC N
a DT N
rating NN N
of IN N
much JJ N
improved VBN N
or CC N
very RB N
much JJ N
improved VBN N
on IN N
the DT N
CGI-I NNP N
scale NN N
, , N
was VBD N
69 CD N
percent NN N
in IN N
the DT N
risperidone NN N
group NN N
( ( N
34 CD N
of IN N
49 CD N
children NNS N
had VBD N
a DT N
positive JJ N
response NN N
) ) N
and CC N
12 CD N
percent NN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
6 CD N
of IN N
52 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
Risperidone NNP N
therapy NN N
was VBD N
associated VBN N
with IN N
an DT N
average JJ N
weight JJ N
gain NN N
of IN N
2.7+/-2.9 JJ N
kg NN N
, , N
as IN N
compared VBN N
with IN N
0.8+/-2.2 JJ N
kg NN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
Increased VBN N
appetite RB N
, , N
fatigue NN N
, , N
drowsiness NN N
, , N
dizziness NN N
, , N
and CC N
drooling VBG N
were VBD N
more JJR N
common JJ N
in IN N
the DT N
risperidone NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
for IN N
each DT N
comparison NN N
) ) N
In IN N
two CD N
thirds NNS N
of IN N
the DT N
children NNS N
with IN N
a DT N
positive JJ N
response NN N
to TO N
risperidone VB N
at IN N
eight CD N
weeks NNS N
( ( N
23 CD N
of IN N
34 CD N
) ) N
, , N
the DT N
benefit NN N
was VBD N
maintained VBN N
at IN N
six CD N
months NNS N
CONCLUSIONS NNP N
Risperidone NNP N
was VBD N
effective JJ N
and CC N
well RB N
tolerated VBN N
for IN N
the DT N
treatment NN N
of IN N
tantrums NNS N
, , N
aggression NN N
, , N
or CC N
self-injurious JJ N
behavior NN N
in IN N
children NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
The DT N
short JJ N
period NN N
of IN N
this DT N
trial NN N
limits VBZ N
inferences NNS N
about IN N
adverse JJ N
effects NNS N
such JJ N
as IN N
tardive JJ N
dyskinesia NN N
-DOCSTART- -X- O O 3123115

Serum NNP N
C-peptide NNP N
after IN N
6 CD N
months NNS N
on IN N
glibenclamide NN N
remains VBZ N
higher JJR N
than IN N
during IN N
insulin JJ N
treatment NN N
Serum NNP N
C-peptide NNP N
was VBD N
measured VBN N
fasting NN N
and CC N
6 CD N
minutes NNS N
after IN N
glucagon NN N
( ( N
1 CD N
mg NN N
given VBN N
intravenously RB N
) ) N
in IN N
49 CD 3_p
patients NNS N
with IN N
non-insulin-dependent JJ 4_p
diabetes NNS 4_p
mellitus NNS 4_p
, , N
after IN N
4 CD N
and CC N
6 CD N
months NNS N
of IN N
successive JJ N
periods NNS N
of IN N
treatment NN N
with IN N
insulin NN N
and CC N
oral JJ N
hypoglycaemics NNS N
( ( N
glibenclamide NN N
and CC N
metformin NN N
) ) N
, , N
given VBN N
in IN N
random JJ N
order NN N
Glycaemic NNP N
control NN N
was VBD N
not RB N
significantly RB N
different JJ N
on IN N
the DT N
two CD N
treatments NNS N
, , N
but CC N
C-peptide NNP N
was VBD N
much RB N
higher JJR N
while IN N
the DT N
patients NNS N
were VBD N
on IN N
glibenclamide NN N
We PRP N
conclude VBP N
that IN N
glibenclamide NN N
stimulates VBZ N
pancreatic JJ N
insulin NN N
production NN N
even RB N
after IN N
6 CD N
months NNS N
treatment NN N
-DOCSTART- -X- O O 18035192

Results NNS N
of IN N
a DT N
phase NN N
III NNP N
, , N
8-week JJ N
, , N
multicenter NN N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
clinical JJ N
trial NN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
amlodipine JJ N
camsylate NN N
versus NN N
amlodipine NN N
besylate NN N
in IN N
Korean JJ N
adults NNS 1_p
with IN N
mild NN N
to TO N
moderate VB N
hypertension NN 4_p
BACKGROUND NNP N
Amlodipine NNP N
besylate NN N
has VBZ N
been VBN N
used VBN N
in IN N
Korea NNP N
for IN N
the DT N
treatment NN N
of IN N
hypertension NN N
for IN N
> $ N
17 CD N
years NNS N
, , N
with IN N
well-established JJ N
efficacy NN N
and CC N
tolerability NN N
Amlodipine NNP N
camsylate NN N
is VBZ N
a DT N
newer JJR N
formulation NN N
developed VBD N
for IN N
generic JJ N
use NN N
It PRP N
has VBZ N
been VBN N
assessed VBN N
in IN N
terms NNS N
of IN N
physical JJ N
stability NN N
and CC N
pharmacokinetic JJ N
and CC N
pharmacodynamic JJ N
properties NNS N
and CC N
been VBN N
found VBN N
to TO N
be VB N
effective JJ N
in IN N
lowering VBG N
blood NN N
pressure NN N
in IN N
preclinical JJ N
and CC N
Phase NNP N
I PRP N
and CC N
II NNP N
trials NNS N
However RB N
, , N
to TO N
date NN N
, , N
no DT N
studies NNS N
have VBP N
compared VBN N
the DT N
clinical JJ N
effectiveness NN N
of IN N
amlodipine JJ N
camsylate NN N
and CC N
amlodipine JJ N
besylate NN N
in IN N
treating VBG N
hypertension NN N
OBJECTIVE CC N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
the DT N
effectiveness NN N
and CC N
tolerability NN N
of IN N
amlodipine JJ N
camsylate NN N
compared VBN N
with IN N
amlodipine JJ N
besylate NN N
in IN N
Korean JJ N
patients NNS N
with IN N
mild JJ 4_p
to TO 4_p
moderate VB 4_p
hypertension NN 4_p
METHODS NNP N
This DT N
Phase NNP N
III NNP N
, , N
8-week JJ N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
study NN N
was VBD N
conducted VBN N
in IN N
13 CD 3_p
cardiology NN N
centers NNS N
across IN N
the DT N
Republic NNP N
of IN N
Korea NNP N
Male NNP 2_p
and CC N
female JJ 2_p
Korean JJ N
patients NNS N
aged VBD 1_p
18 CD 1_p
to TO 1_p
75 CD 1_p
years NNS N
having VBG N
uncomplicated JJ N
, , N
mild JJ N
to TO N
moderate VB N
, , N
essential JJ N
hypertension NN 4_p
( ( N
sitting VBG N
diastolic JJ N
blood NN N
pressure NN N
[ NNP N
SiDBP NNP N
] NNP N
90- CD N
< NNP N
110 CD N
mm NN N
Hg NNP N
) ) N
and CC N
receiving VBG N
no DT N
antihypertensives NNS N
in IN N
the DT N
2 CD N
weeks NNS N
before IN N
randomization NN N
were VBD N
eligible JJ N
Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
oral JJ N
treatment NN N
with IN N
amlodipine JJ N
camsylate NN N
or CC N
amlodipine JJ N
besylate NN N
For IN N
the DT N
first JJ N
4 CD N
weeks NNS N
, , N
patients NNS N
received VBD N
amlodipine JJ N
5 CD N
mg NN N
QD NNP N
( ( N
morning NN N
) ) N
After IN N
4 CD N
weeks NNS N
, , N
if IN N
either DT N
blood NN N
pressure NN N
was VBD N
> JJ N
or CC N
=140/ JJ N
> NN N
or CC N
=90 VB N
mm JJ N
Hg NNP N
or CC N
SiDBP NNP N
had VBD N
not RB N
decreased VBN N
by IN N
> NN N
or CC N
=10 VB N
mm JJ N
Hg NNP N
from IN N
baseline NN N
, , N
the DT N
dose NN N
of IN N
amlodipine NN N
was VBD N
increased VBN N
to TO N
10 CD N
mg NNS N
QD NNP N
for IN N
4 CD N
weeks NNS N
Trough NNP N
blood NN N
pressure NN N
and CC N
heart NN N
rate NN N
were VBD N
measured VBN N
in IN N
duplicate NN N
with IN N
the DT N
patient NN N
in IN N
the DT N
sitting VBG N
position NN N
at IN N
each DT N
clinic JJ N
visit NN N
( ( N
baseline JJ N
[ NNP N
week NN N
0 CD N
] NN N
and CC N
weeks NNS N
4 CD N
and CC N
8 CD N
of IN N
treatment NN N
) ) N
; : N
mean JJ N
values NNS N
were VBD N
calculated VBN N
and CC N
recorded VBN N
At IN N
weeks NNS N
4 CD N
and CC N
8 CD N
, , N
tolerability NN N
was VBD N
assessed VBN N
using VBG N
history NN N
taking NN N
and CC N
laboratory NN N
analysis NN N
, , N
and CC N
compliance NN N
was VBD N
assessed VBN N
using VBG N
pill NN N
counts NNS N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
change NN N
from IN N
baseline NN N
in IN N
SiDBP NNP N
at IN N
week NN N
8 CD N
Secondary JJ N
end NN N
points NNS N
were VBD N
change NN N
from IN N
baseline NN N
in IN N
sitting VBG N
systolic JJ N
blood NN N
pressure NN N
( ( N
SiSBP NNP N
) ) N
at IN N
week NN N
8 CD N
in IN N
the DT N
total JJ N
population NN N
and CC N
in IN N
the DT N
subgroup NN N
of IN N
patients NNS N
who WP N
had VBD N
previously RB N
received VBN N
antihypertensive JJ N
treatment NN N
versus IN N
those DT N
who WP N
had VBD N
not RB N
RESULTS VB N
A DT N
total NN N
of IN N
189 CD 3_p
patients NNS N
were VBD N
enrolled VBN N
( ( N
mean JJ 1_p
age NN 1_p
, , 1_p
53 CD 1_p
years NNS 1_p
; : N
105 CD 3_p
women NNS 2_p
, , N
84 CD 3_p
men NNS 2_p
; : N
mean VB N
body NN N
weight NN N
, , N
65.8 CD N
kg NN N
) ) N
One CD N
patient NN N
in IN N
the DT N
amlodipine JJ N
camsylate NN N
group NN N
dropped VBD N
out IN N
of IN N
the DT N
study NN N
at IN N
week NN N
0 CD N
of IN N
treatment NN N
( ( N
this DT N
patient NN N
did VBD N
not RB N
use VB N
any DT N
study NN N
medication NN N
) ) N
and CC N
was VBD N
excluded VBN N
from IN N
the DT N
modified VBN N
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
analysis NN N
Thus RB N
, , N
188 CD 3_p
patients NNS N
were VBD N
treated VBN N
and CC N
included VBN N
in IN N
the DT N
ITT NNP N
analysis NN N
( ( N
94 CD N
patients NNS N
per IN N
treatment NN N
group NN N
; : N
ITT NNP N
analysis NN N
) ) N
; : N
161 CD N
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
perprotocol NN N
( ( N
PP NNP N
) ) N
analysis NN N
( ( N
n JJ N
= VBP N
80 CD N
for IN N
amlodipine NN N
camsylate NN N
, , N
n JJ N
= VBP N
81 CD N
for IN N
amlodipine JJ N
besylate NN N
) ) N
( ( N
14 CD N
patients NNS N
in IN N
the DT N
amlodipine JJ N
camsylate NN N
group NN N
and CC N
13 CD N
patients NNS N
in IN N
the DT N
amlodipine JJ N
besylate NN N
group NN N
were VBD N
excluded VBN N
from IN N
the DT N
PP NNP N
analysis NN N
due JJ N
to TO N
consistent JJ N
withdrawal NN N
or CC N
protocol JJ N
violation NN N
) ) N
Mean NNP N
( ( N
SD NNP N
) ) N
SiSBP NNP N
and CC N
SiDBP NNP N
were VBD N
significantly RB N
decreased VBN N
from IN N
baseline NN N
in IN N
both DT N
groups NNS N
( ( N
amlodipine JJ N
camsylate NN N
, , N
from IN N
146.7 CD N
[ $ N
12.3 CD N
] NNP N
/96.6 NNP N
[ VBD N
5.4 CD N
] NN N
to TO N
127.9 CD N
[ NNS N
14.8 CD N
] JJ N
/83.4 NNP N
[ NNP N
7.7 CD N
] NNP N
mm NN N
Hg NNP N
[ NNP N
both DT N
, , N
P NNP N
< VBZ N
0.001 CD N
] NN N
; : N
amlodipine JJ N
besylate NN N
, , N
from IN N
146.8 CD N
[ $ N
12.8 CD N
] NNP N
/96.7 NNP N
[ VBD N
5.1 CD N
] NN N
to TO N
128.0 CD N
[ NNS N
10.1 CD N
] JJ N
/83.8 NNP N
[ NNP N
7.5 CD N
] NNP N
mm NN N
Hg NNP N
[ NNP N
both DT N
, , N
P NNP N
< VBZ N
0.001 CD N
] NN N
) ) N
The DT N
differences NNS N
in IN N
SiSBP/SiDBP NNP N
between IN N
the DT N
2 CD N
groups NNS N
at IN N
week NN N
8 CD N
were VBD N
not RB N
significant JJ N
The DT N
SiDBP NNP N
response NN N
rates NNS N
in IN N
the DT N
subgroups NNS N
that WDT N
had VBD N
and CC N
had VBD N
not RB N
been VBN N
previously RB N
treated VBN N
with IN N
antihypertensives NNS N
were VBD N
statistically RB N
similar JJ N
( ( N
56/69 CD N
[ RB N
81.2 CD N
% NN N
] NN N
and CC N
83/92 CD N
[ JJ N
90.2 CD N
% NN N
] NN N
, , N
respectively RB N
) ) N
The DT N
prevalences NNS N
of IN N
clinical JJ N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
2 CD N
treatment NN N
groups NNS N
( ( N
amlodipine JJ N
camsylate NN N
, , N
27.3 CD N
% NN N
; : N
amlodipine JJ N
besylate NN N
, , N
28.7 CD N
% NN N
) ) N
The DT N
most RBS N
common JJ N
AEs NNP N
were VBD N
dizziness JJ N
and CC N
dyspnea NN N
( ( N
both DT N
in IN N
3/94 CD N
[ JJ N
3.2 CD N
% NN N
] NN N
and CC N
1/94 CD N
[ JJ N
1.1 CD N
% NN N
] JJ N
patients NNS N
who WP N
received VBD N
amlodipine JJ N
camsylate NN N
and CC N
amlodipine NN N
besylate NN N
, , N
respectively RB N
) ) N
CONCLUSION VB N
The DT N
effectiveness NN N
and CC N
tolerability NN N
of IN N
amlodipine JJ N
camsylate NN N
were VBD N
not RB N
significantly RB N
different JJ N
from IN N
those DT N
of IN N
amlodipine JJ N
besylate NN N
in IN N
these DT N
Korean JJ N
adults NNS 1_p
with IN N
mild NN 4_p
to TO 4_p
moderate VB 4_p
hypertension NN 4_p
-DOCSTART- -X- O O 15098782

Improved VBN N
intraoperative JJ N
management NN N
of IN N
anastomotic JJ 4_p
bleeding NN 4_p
during IN N
aortic JJ N
reconstruction NN N
: : N
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
the DT N
effectiveness NN N
of IN N
a DT N
polymeric JJ N
surgical JJ N
sealant NN N
( ( N
CoSeal NNP N
) ) N
was VBD N
compared VBN N
to TO N
Gelfoam/thrombin NNP N
for IN N
managing VBG N
anastomotic JJ 4_p
bleeding NN 4_p
after IN N
implantation NN N
of IN N
Dacron NNP N
grafts NNS N
during IN N
aortic JJ N
reconstruction NN N
for IN N
nonruptured JJ 4_p
aneurysms NNS 4_p
Each DT N
treatment NN N
was VBD N
directly RB N
applied VBN N
to TO N
the DT N
suture NN N
line NN N
after IN N
confirmation NN N
of IN N
anastomotic JJ N
bleeding NN N
The DT N
proportion NN N
of IN N
suture NN N
line NN N
sites VBZ N
that IN N
achieved VBD N
immediate JJ N
sealing NN N
and CC N
the DT N
proportion NN N
sealed VBD N
within IN N
5 CD N
minutes NNS N
were VBD N
determined VBN N
among IN N
37 CD 3_p
experimental JJ N
( ( N
59 CD N
sites NNS N
) ) N
and CC N
17 CD 3_p
control NN N
subjects NNS N
( ( N
27 CD N
sites NNS N
) ) N
A DT N
significantly RB N
greater JJR N
proportion NN N
of IN N
bleeding VBG N
suture NN N
line NN N
sites NNS N
treated VBD N
with IN N
the DT N
polymeric JJ N
sealant NN N
achieved VBN N
immediate JJ N
sealing NN N
following VBG N
reestablishment NN N
of IN N
blood NN N
flow NN N
compared VBN N
with IN N
control-treated JJ N
sites NNS N
[ VBP N
48 CD N
of IN N
59 CD N
( ( N
81 CD N
% NN N
) ) N
vs VBZ N
10 CD N
of IN N
27 CD N
( ( N
37 CD N
% NN N
) ) N
; : N
P NNP N
= VBD N
0.002 CD N
] NN N
The DT N
difference NN N
between IN N
treatment NN N
groups NNS N
was VBD N
maintained VBN N
after IN N
5 CD N
minutes NNS N
with IN N
approximately RB N
85 CD N
per IN N
cent NN N
( ( N
50 CD N
of IN N
59 CD N
) ) N
of IN N
CoSeal NNP N
sites NNS N
compared VBN N
to TO N
just RB N
over IN N
one-half JJ N
( ( N
14 CD N
of IN N
27 CD N
) ) N
of IN N
control NN N
sites VBZ N
demonstrating VBG N
ultimate JJ N
sealing NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
There EX N
were VBD N
no DT N
adverse JJ N
events NNS N
related VBN N
to TO N
the DT N
use NN N
of IN N
the DT N
polymeric JJ N
sealant NN N
in IN N
this DT N
study NN N
These DT N
results NNS N
support VBP N
the DT N
use NN N
of IN N
this DT N
novel JJ N
sealant NN N
for IN N
the DT N
intraoperative JJ N
management NN N
of IN N
anastomotic JJ 4_p
bleeding NN 4_p
during IN N
aortic JJ N
reconstruction NN N
procedures NNS N
-DOCSTART- -X- O O 24256459

Randomized VBN N
controlled VBD N
effectiveness JJ N
trial NN N
of IN N
executive NN N
function NN N
intervention NN N
for IN N
children NNS N
on IN N
the DT N
autism NN 4_p
spectrum NN 4_p
BACKGROUND NNP N
Unstuck NNP N
and CC N
On IN N
Target NNP N
( ( N
UOT NNP N
) ) N
is VBZ N
an DT N
executive JJ N
function NN N
( ( N
EF NNP N
) ) N
intervention NN N
for IN N
children NNS 1_p
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
targeting VBG N
insistence NN N
on IN N
sameness NN N
, , N
flexibility NN N
, , N
goal-setting NN N
, , N
and CC N
planning VBG N
through IN N
a DT N
cognitive-behavioral JJ N
program NN N
of IN N
self-regulatory JJ N
scripts NNS N
, , N
guided/faded VBD N
practice NN N
, , N
and CC N
visual/verbal JJ N
cueing NN N
UOT NNP N
is VBZ N
contextually-based JJ N
because IN N
it PRP N
is VBZ N
implemented VBN N
in IN N
school NN N
and CC N
at IN N
home NN N
, , N
the DT N
contexts NN N
in IN N
which WDT N
a DT N
child NN N
uses VBZ N
EF NNP N
skills NNS N
METHODS NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
UOT NNP N
compared VBN N
with IN N
a DT N
social JJ N
skills NNS N
intervention NN N
( ( N
SS NNP N
) ) N
, , N
3rd-5th JJ 1_p
graders NNS 1_p
with IN N
ASD NNP N
( ( N
mean JJ N
IQ NNP N
= NNP N
108 CD N
; : N
UOT NNP N
n VBD N
= JJ N
47 CD N
; : N
SS NNP N
n VBD 3_p
= NNP 3_p
20 CD 3_p
) ) N
received VBD N
interventions NNS N
delivered VBN N
by IN N
school NN N
staff NN N
in IN N
small JJ N
group NN N
sessions NNS N
Students NNS 1_p
were VBD N
matched VBN N
for IN N
gender NN N
, , N
age NN N
, , N
race NN N
, , N
IQ NNP N
, , N
ASD NNP N
symptomotolgy NN N
, , N
medication NN N
status NN N
, , N
and CC N
parents NNS N
' POS N
education NN N
Interventions NNS N
were VBD N
matched VBN N
for IN N
'dose NNP N
' POS N
of IN N
intervention NN N
and CC N
training NN N
Measures NNS N
of IN N
pre-post NN N
change NN N
included VBD N
classroom NN N
observations NNS N
, , N
parent/teacher CC N
report NN N
, , N
and CC N
direct JJ N
child NN N
measures NNS N
of IN N
problem-solving NN N
, , N
EF NNP N
, , N
and CC N
social JJ N
skills NNS N
Schools NNS N
were VBD N
randomized VBN N
and CC N
evaluators NNS N
, , N
but CC N
not RB N
parents NNS N
or CC N
teachers NNS N
, , N
were VBD N
blinded VBN N
to TO N
intervention VB N
type NN N
RESULTS JJ N
Interventions NNPS N
were VBD N
administered VBN N
with IN N
high JJ N
fidelity NN N
Children NNP N
in IN N
both DT N
groups NNS N
improved VBN N
with IN N
intervention NN N
, , N
but CC N
mean JJ N
change NN N
scores NNS N
from IN N
pre- NN N
to TO N
postintervention NN N
indicated VBN N
significantly RB N
greater JJR N
improvements NNS N
for IN N
UOT NNP N
than IN N
SS NNP N
groups NNS N
in IN N
: : N
problem-solving NN N
, , N
flexibility NN N
, , N
and CC N
planning/organizing VBG N
Also RB N
, , N
classroom NN N
observations NNS N
revealed VBD N
that IN N
participants NNS N
in IN N
UOT NNP N
made VBD N
greater JJR N
improvements NNS N
than IN N
SS NNP N
participants NNS N
in IN N
their PRP$ N
ability NN N
to TO N
follow VB N
rules NNS N
, , N
make VBP N
transitions NNS N
, , N
and CC N
be VB N
flexible JJ N
Children NNP N
in IN N
both DT N
groups NNS N
made VBD N
equivalent JJ N
improvements NNS N
in IN N
social JJ N
skills NNS N
CONCLUSIONS NNP N
These DT N
data NNS N
support NN N
the DT N
effectiveness NN N
of IN N
the DT N
first JJ N
contextually-based JJ N
EF NNP N
intervention NN N
for IN N
children NNS 1_p
with IN N
ASD NNP N
UOT NNP N
improved VBD N
classroom NN N
behavior NN N
, , N
flexibility NN N
, , N
and CC N
problem-solving NN N
in IN N
children NNS 1_p
with IN N
ASD NNP N
Individuals NNS N
with IN N
variable JJ N
background/training NN N
in IN N
ASD NNP N
successfully RB N
implemented VBD N
UOT NNP N
in IN N
mainstream JJ N
educational JJ N
settings NNS N
-DOCSTART- -X- O O 1370735

Different NNP N
aprotinin NN N
applications NNS N
influencing VBG N
hemostatic JJ N
changes NNS N
in IN N
orthotopic NN 4_p
liver NN 4_p
transplantation NN 4_p
The DT N
effect NN N
of IN N
different JJ N
aprotinin NN N
applications NNS N
on IN N
hemostatic JJ N
changes NNS N
and CC N
blood NN N
product NN N
requirements NNS N
in IN N
orthotopic JJ N
liver NN N
transplantation NN N
was VBD N
investigated VBN N
in IN N
a DT N
prospective JJ N
, , N
open JJ N
, , N
and CC N
randomized VBD N
study NN N
From IN N
November NNP N
1989 CD N
to TO N
June NNP N
1990 CD N
, , N
13 CD 3_p
patients NNS N
received VBD N
aprotinin RB N
as IN N
a DT N
bolus NN N
of IN N
0.5 CD N
Mill NNP N
Kallikrein NNP N
inactivator JJ N
units NNS N
( ( N
KIU NNP N
) ) N
on IN N
three CD N
occasions NNS N
in IN N
the DT N
course NN N
of IN N
an DT N
OLT NNP N
, , N
whereas RB N
10 CD N
other JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
continuous JJ N
aprotinin JJ N
infusion NN N
of IN N
0.1-0.4 JJ N
Mill NNP N
KIU/hr NNP N
Before IN N
and CC N
after IN N
reperfusion NN N
of IN N
the DT N
graft NN N
liver NN N
, , N
signs NNS N
of IN N
hyperfibrinolysis NN N
, , N
measured VBN N
by IN N
thrombelastography NN N
, , N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
infusion NN N
group NN N
Tissue-type JJ N
plasminogen NN N
activator NN N
( ( N
t-PA JJ N
) ) N
activity NN N
increased VBD N
during IN N
the DT N
anhepatic JJ N
phase NN N
but CC N
to TO N
a DT N
significantly RB N
lesser JJR N
extent NN N
in IN N
the DT N
infusion NN N
group NN N
Blood NNP N
product NN N
requirements NNS N
during IN N
OLT NNP N
were VBD N
tendentiously RB N
higher JJR N
in IN N
the DT N
bolus NN N
group NN N
but CC N
not RB N
significantly RB N
so RB N
However RB N
, , N
the DT N
use NN N
of IN N
packed JJ N
red JJ N
blood NN N
cells NNS N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
postoperative JJ N
period NN N
, , N
whereas IN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
fresh JJ N
frozen NN N
plasma NN N
requirements NNS N
between IN N
the DT N
two CD N
groups NNS N
All DT N
23 CD 3_p
patients NNS N
have VBP N
survived VBN N
, , N
and CC N
only RB N
one CD N
woman NN N
of IN N
each DT N
group NN N
required VBN N
retransplantation NN N
due JJ N
to TO N
severe VB N
host-versus-graft JJ N
reactions NNS N
Furthermore RB N
, , N
we PRP N
investigated VBD N
the DT N
perfusate NN N
of IN N
the DT N
graft NN N
liver NN N
in IN N
both DT N
groups NNS N
and CC N
detected JJ N
signs NNS N
of IN N
a DT N
decreased JJ N
t-PA JJ N
release NN N
in IN N
the DT N
infusion NN N
group NN N
Our PRP$ N
results NNS N
demonstrate VBP N
an DT N
advantage NN N
of IN N
aprotinin NN N
given VBN N
as IN N
continuous JJ N
infusion NN N
over IN N
bolus JJ N
application NN N
in IN N
OLT NNP N
-DOCSTART- -X- O O 12660676

Sustained VBN N
ventricular JJ N
arrhythmias NNS N
and CC N
mortality NN N
among IN N
patients NNS 4_p
with IN 4_p
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
: : N
results NNS N
from IN N
the DT N
GUSTO-III NNP N
trial NN N
BACKGROUND NNP N
In IN N
many JJ N
patients NNS N
, , N
ventricular JJ N
arrhythmias NN N
will MD N
develop VB N
early JJ N
after IN N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
We PRP N
studied VBD N
the DT N
incidence NN N
, , N
timing NN N
, , N
and CC N
outcomes NNS N
of IN N
such JJ N
arrhythmias NNS N
in IN N
the DT N
international JJ N
Global NNP N
Utilization NNP N
of IN N
Streptokinase NNP N
and CC N
TPA NNP N
( ( N
alteplase NN N
) ) N
for IN N
Occluded NNP N
Coronary NNP N
Arteries NNP N
( ( N
GUSTO NNP N
) ) N
-III VBP N
trial NN N
METHODS NNP N
We PRP N
identified VBD N
independent JJ N
predictors NNS N
of IN N
inhospital JJ N
ventricular JJ N
fibrillation NN N
( ( N
VF NNP N
) ) N
and CC N
ventricular JJ N
tachycardia NN N
( ( N
VT NNP N
) ) N
and CC N
compared VBN N
30-day JJ N
and CC N
1-year JJ N
mortality NN N
rates NNS N
of IN N
patients NNS N
who WP N
did VBD N
( ( N
n VB N
= NNP N
1121 CD N
) ) N
and CC N
did VBD N
not RB N
( ( N
n JJ N
= NNP N
13,921 CD N
) ) N
have VBP N
these DT N
arrhythmias NNS N
during IN N
the DT N
index NN N
hospitalization NN N
RESULTS NNP N
Significant NNP N
independent JJ N
predictors NNS N
of IN N
inhospital JJ N
VF NNP N
were VBD N
higher JJR N
Killip NNP N
class NN N
, , N
lower JJR N
baseline NN N
systolic JJ N
pressure NN N
, , N
intravenous JJ N
preenrollment NN N
lidocaine NN N
use NN N
, , N
shorter JJR N
time NN N
to TO N
thrombolysis VB N
, , N
and CC N
beta-blocker NN N
use NN N
< VBZ N
2 CD N
weeks NNS N
before IN N
enrollment NN N
; : N
independent JJ N
predictors NNS N
of IN N
inhospital JJ N
VT NNP N
were VBD N
lower JJR N
baseline NN N
systolic JJ N
pressure NN N
, , N
intravenous JJ N
lidocaine NN N
use NN N
before IN N
enrollment NN N
, , N
higher JJR N
Killip NNP N
class NN N
, , N
faster JJR N
baseline JJ N
heart NN N
rate NN N
, , N
and CC N
advanced JJ N
age NN N
The DT N
30-day JJ N
mortality NN N
rate NN N
was VBD N
31 CD N
% NN N
in IN N
patients NNS N
with IN N
VF NNP N
, , N
24 CD N
% NN N
in IN N
those DT N
with IN N
VT NNP N
, , N
44 CD N
% NN N
in IN N
those DT N
with IN N
both DT N
, , N
and CC N
6 CD N
% NN N
in IN N
those DT N
with IN N
neither DT N
( ( N
P NNP N
=.001 NNP N
) ) N
The DT N
corresponding JJ N
1-year JJ N
mortality NN N
rates NNS N
were VBD N
34 CD N
% NN N
, , N
29 CD N
% NN N
, , N
49 CD N
% NN N
, , N
and CC N
9 CD N
% NN N
( ( N
P NNP N
=.001 NNP N
) ) N
The DT N
30-day JJ N
and CC N
1-year JJ N
mortality NN N
rates NNS N
were VBD N
higher JJR N
for IN N
patients NNS N
with IN N
late JJ N
( ( N
> JJ N
48 CD N
hours NNS N
after IN N
enrollment NN N
) ) N
versus FW N
early JJ N
arrhythmias NN N
( ( N
< CD N
or CC N
=48 VB N
hours NNS N
after IN N
enrollment NN N
) ) N
CONCLUSIONS NNP N
Despite IN N
thrombolysis NN N
, , N
inhospital JJ N
ventricular NN N
arrhythmias NNS N
are VBP N
associated VBN N
with IN N
higher JJR N
30-day JJ N
and CC N
1-year JJ N
mortality NN N
rates NNS N
after IN N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
, , N
particularly RB N
when WRB N
occurring VBG N
later RB N
during IN N
the DT N
initial JJ N
hospitalization NN N
Better JJR N
therapies NNS N
are VBP N
needed VBN N
to TO N
improve VB N
outcomes NNS N
of IN N
these DT N
arrhythmias NNS N
-DOCSTART- -X- O O 25612845

Pharmacokinetic JJ N
study NN N
between IN N
a DT N
bilayer NN N
matrix NN N
fentalyl NN N
patch NN N
and CC N
a DT N
monolayer NN N
matrix NN N
fentanyl JJ N
patch NN N
: : N
single JJ N
dose JJ N
administration NN N
in IN N
healthy JJ N
volunteers NNS N
AIMS NNP N
Transdermal NNP N
fentanyl NN N
is VBZ N
a DT N
well RB N
established VBN N
treatment NN N
for IN N
cancer NN N
pain NN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
is VBZ N
to TO N
assess VB N
the DT N
relative JJ N
bioavailability NN N
of IN N
fentanyl NN N
from IN N
two CD N
different JJ N
transdermal JJ N
systems NNS N
by IN N
evaluating VBG N
plasma JJ N
drug NN N
concentrations NNS N
after IN N
single JJ N
administration NN N
of IN N
Fentalgon® NNP N
( ( N
test NN N
) ) N
, , N
a DT N
novel JJ N
bilayer NN N
matrix NN N
type NN N
patch NN N
, , N
and CC N
Durogesic NNP N
SMAT NNP N
( ( N
reference NN N
) ) N
, , N
a DT N
monolayer NN N
matrix NN N
type NN N
patch NN N
In IN N
the DT N
Fentalgon NNP N
patch VB N
the DT N
upper JJ N
6 CD N
% NN N
fentanyl JJ N
reservoir NN N
layer NN N
maintains VBZ N
a DT N
stable JJ N
concentration NN N
gradient NN N
between IN N
the DT N
lower JJR N
4 CD N
% NN N
donor NN N
layer NN N
and CC N
the DT N
skin NN N
The DT N
system NN N
provides VBZ N
a DT N
constant JJ N
drug NN N
delivery NN N
over IN N
72 CD N
h. JJ N
METHODS NNP N
This DT N
was VBD N
an DT N
open JJ N
label NN N
, , N
single JJ N
centre NN N
, , N
randomized VBN N
, , N
single JJ N
dose NN N
, , N
two CD N
period NN N
crossover VBD N
clinical JJ N
trial NN N
, , N
that WDT N
included VBD N
36 CD 3_p
healthy JJ N
male NN 2_p
volunteers NNS 2_p
The DT N
patches NNS N
were VBD N
applied VBN N
to TO N
non-irritated JJ N
and CC N
non-irradiated JJ N
skin NN N
on IN N
the DT N
intraclavicular JJ N
pectoral JJ N
area NN N
Blood NN N
samples NNS N
were VBD N
collected VBN N
at IN N
different JJ N
time NN N
points NNS N
( ( N
from IN N
baseline NN N
to TO N
120 CD N
h JJ N
post-removal NN N
of IN N
the DT N
devices NNS N
) ) N
and CC N
fentanyl JJ N
concentrations NNS N
were VBD N
determined VBN N
using VBG N
a DT N
validated JJ N
LC/MS/MS NNP N
method NN N
Bioequivalence NNP N
was VBD N
to TO N
be VB N
claimed VBN N
if IN N
the DT N
90 CD N
% NN N
confidence NN N
interval NN N
of IN N
AUC NNP N
( ( N
0 CD N
, , N
t NN N
) ) N
and CC N
C NNP N
( ( N
max NN N
) ) N
ratios NNS N
( ( N
test NN N
: : N
reference NN N
) ) N
were VBD N
within IN N
the DT N
acceptance NN N
range NN N
of IN N
80-125 CD N
% NN N
and CC N
75-133 CD N
% NN N
, , N
respectively RB N
RESULTS VB N
The DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
of IN N
the DT N
AUC NNP N
( ( N
0 CD N
, , N
t NN N
) ) N
ratio NN N
( ( N
116.3 CD N
% NN N
[ JJ N
109.6 CD N
, , N
123.4 CD N
% NN N
] NN N
) ) N
and CC N
C NNP N
( ( N
max NN N
) ) N
ratio NN N
( ( N
114.4 CD N
% NN N
[ JJ N
105.8 CD N
, , N
123.8 CD N
% NN N
] NN N
were VBD N
well RB N
included VBN N
in IN N
the DT N
acceptance NN N
range NN N
and CC N
the DT N
C NNP N
( ( N
max NN N
) ) N
ratio NN N
also RB N
met VBD N
the DT N
narrower JJR N
bounds NNS N
of IN N
80-125 CD N
% NN N
There EX N
was VBD N
no DT N
relevant JJ N
difference NN N
in IN N
overall JJ N
safety NN N
profiles NNS N
of IN N
the DT N
two CD N
preparations NNS N
investigated VBD N
, , N
which WDT N
were VBD N
adequately RB N
tolerated VBN N
, , N
as IN N
expected VBN N
for IN N
opioid-naïve JJ N
subjects NNS N
CONCLUSIONS VB N
The DT N
new JJ N
bilayer NN N
matrix NN N
type NN N
patch NN N
, , N
Fentalgon® NNP N
, , N
is VBZ N
bioequivalent JJ N
to TO N
the DT N
monolayer NN N
matrix NN N
type NN N
Durogesic NNP N
SMAT NNP N
fentanyl VBD N
patch NN N
with IN N
respect NN N
to TO N
the DT N
rate NN N
and CC N
extent NN N
of IN N
exposure NN N
of IN N
fentanyl NN N
( ( N
Eudra/CT NNP N
no DT N
2005-000046-36 JJ N
) ) N
-DOCSTART- -X- O O 25622776

Using VBG N
behavioral JJ N
economics NNS N
to TO N
predict VB N
opioid JJ N
use NN N
during IN 4_p
prescription NN 4_p
opioid JJ 4_p
dependence NN 4_p
treatment NN 4_p
BACKGROUND NNP N
Research NNP N
grounded VBD N
in IN N
behavioral JJ N
economics NNS N
has VBZ N
previously RB N
linked VBN N
addictive JJ N
behavior NN N
to TO N
disrupted VBN N
decision-making NN N
and CC N
reward-processing NN N
, , N
but CC N
these DT N
principles NNS N
have VBP N
not RB N
been VBN N
examined VBN N
in IN N
prescription NN N
opioid JJ N
addiction NN N
, , N
which WDT N
is VBZ N
currently RB N
a DT N
major JJ N
public JJ N
health NN N
problem NN N
This DT N
study NN N
examined VBD N
whether IN N
pre-treatment JJ N
drug NN N
reinforcement NN N
value NN N
predicted VBD N
opioid JJ N
use NN N
during IN N
outpatient JJ N
treatment NN N
of IN N
prescription NN N
opioid JJ N
addiction NN N
METHODS NNP N
Secondary JJ N
analyses NNS N
examined VBD N
participants NNS 4_p
with IN 4_p
prescription NN 4_p
opioid JJ 4_p
dependence NN 4_p
who WP 4_p
received VBD 4_p
12 CD 4_p
weeks NNS 4_p
of IN 4_p
buprenorphine-naloxone NN 4_p
and CC 4_p
counseling NN 4_p
in IN 4_p
a DT 4_p
multi-site JJ 4_p
clinical JJ 4_p
trial NN 4_p
( ( N
N=353 NNP 3_p
) ) N
Baseline NNP N
measures NNS N
assessed VBD N
opioid JJ N
source NN N
and CC N
indices NNS N
of IN N
drug NN N
reinforcement NN N
value NN N
, , N
including VBG N
the DT N
total JJ N
amount NN N
and CC N
proportion NN N
of IN N
income NN N
spent VBN N
on IN N
drugs NNS N
Weekly JJ N
urine JJ N
drug NN N
screens NNS N
measured VBN N
opioid JJ N
use NN N
RESULTS NNP N
Obtaining VBG N
opioids NNS N
from IN N
doctors NNS N
was VBD N
associated VBN N
with IN N
lower JJR N
pre-treatment JJ N
drug NN N
spending NN N
, , N
while IN N
obtaining VBG N
opioids NNS N
from IN N
dealers/patients NNS N
was VBD N
associated VBN N
with IN N
greater JJR N
spending NN N
Controlling VBG N
for IN N
demographics NNS N
, , N
opioid JJ N
use NN N
history NN N
, , N
and CC N
opioid JJ N
source NN N
frequency NN N
, , N
patients NNS N
who WP N
spent VBD N
a DT N
greater JJR N
total JJ N
amount NN N
( ( N
OR=1.30 NNP N
, , N
p NN N
< NNP N
.001 NNP N
) ) N
and CC N
a DT N
greater JJR N
proportion NN N
of IN N
their PRP$ N
income NN N
on IN N
drugs NNS N
( ( N
OR=1.31 NNP N
, , N
p NN N
< NNP N
.001 NNP N
) ) N
were VBD N
more RBR N
likely JJ N
to TO N
use VB N
opioids NNS N
during IN N
treatment NN N
CONCLUSIONS NNP N
Individual NNP N
differences NNS N
in IN N
drug NN N
reinforcement NN N
value NN N
, , N
as IN N
indicated VBN N
by IN N
pre-treatment JJ N
allocation NN N
of IN N
economic JJ N
resources NNS N
to TO N
drugs NNS N
, , N
reflects VBZ N
propensity NN N
for IN N
continued JJ N
opioid JJ N
use NN N
during IN N
treatment NN N
among IN N
individuals NNS 4_p
with IN 4_p
prescription NN 4_p
opioid JJ 4_p
addiction NN 4_p
Future JJ N
studies NNS N
should MD N
examine VB N
disrupted VBN N
decision-making JJ N
and CC N
reward-processing JJ N
in IN N
prescription NN N
opioid NN N
users NNS N
more RBR N
directly RB N
and CC N
test VB N
whether IN N
reinforcer NN N
pathology NN N
can MD N
be VB N
remediated VBN N
in IN N
this DT N
population NN N
-DOCSTART- -X- O O 6836750

Pilot NN N
study NN N
with IN N
adjuvant JJ N
hormone NN N
therapy NN N
in IN N
FIGO NNP 4_p
stage NN 4_p
I PRP 4_p
endometrial JJ 4_p
carcinoma NN 4_p
with IN N
myometrial JJ 4_p
invasion NN 4_p
A DT N
pilot NN N
study NN N
with IN N
adjuvant JJ N
hormone NN N
therapy NN N
in IN N
FIGO NNP 4_p
stage NN 4_p
I PRP 4_p
endometrial JJ 4_p
carcinoma NN 4_p
with IN N
myometrial JJ 4_p
invasion NN 4_p
was VBD N
carried VBN N
out RP N
All DT N
patients NNS N
received VBD N
total JJ N
abdominal JJ N
hysterectomy NN N
and CC N
bilateral JJ N
salpingo-oophorectomy JJ N
plus CC N
complementary JJ N
radium NN N
therapy NN N
on IN N
the DT N
vaginal JJ N
stump NN N
After IN N
the DT N
conventional JJ N
treatment NN N
, , N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
adjuvant VB N
hormone NN N
therapy NN N
or CC N
no DT N
further JJ N
treatment NN N
Hormone NNP N
therapy NN N
consisted VBD N
of IN N
gestonorone NN N
caproate NN N
( ( N
17 CD N
alpha-hydroxy-19-norpregn-4-en JJ N
3 CD N
, , N
20 CD N
dione NN N
caproate NN N
) ) N
administered VBD N
i.m NN N
at IN N
the DT N
dose NN N
of IN N
200 CD N
mg/week NN N
for IN N
1 CD N
year NN N
Of IN N
the DT N
62 CD 3_p
patients NNS N
who WP N
entered VBD N
the DT N
study NN N
, , N
51 CD N
were VBD N
considered VBN N
evaluable JJ N
( ( N
24 CD N
with IN N
adjuvant JJ N
hormone NN N
therapy NN N
and CC N
27 CD N
with IN N
no DT N
further JJ N
treatment NN N
) ) N
Five CD N
patients NNS N
had VBD N
a DT N
relapse NN N
: : N
four CD N
of IN N
these DT N
were VBD N
in IN N
the DT N
group NN N
with IN N
no DT N
further JJ N
treatment NN N
Actuarial JJ N
relapse-free JJ N
survival NN N
analysis NN N
at IN N
5 CD N
years NNS N
was VBD N
95.7 CD N
% NN N
in IN N
the DT N
group NN N
of IN N
adjuvant-treated JJ N
patients NNS N
and CC N
82.8 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
Although IN N
there EX N
is VBZ N
no DT N
statistical JJ N
significance NN N
, , N
adjuvant JJ N
therapy NN N
appears VBZ N
to TO N
result VB N
in IN N
an DT N
increase NN N
in IN N
relapse-free JJ N
survival NN N
in IN N
the DT N
group NN N
of IN N
patients NNS N
with IN N
deep JJ N
myometrial JJ N
invasion NN N
and CC N
undifferentiated JJ N
carcinoma NN N
Further JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
hormone NN N
adjuvant JJ N
treatment NN N
in IN N
FIGO NNP 4_p
stage NN 4_p
I PRP 4_p
endometrial JJ 4_p
carcinoma NN 4_p
with IN N
myometrial JJ 4_p
invasion NN 4_p
-DOCSTART- -X- O O 15446660

Faulty NNP N
Japanese JJ N
sentences NNS N
are VBP N
judged VBN N
more RBR N
grammatical JJ N
when WRB N
punctuation NN N
is VBZ N
used VBN N
: : N
negative JJ N
implications NNS N
for IN N
Chomsky NNP N
's POS N
principle NN N
of IN N
Full NNP N
Interpretation NNP N
88 CD 3_p
adult JJ 1_p
Japanese JJ 4_p
speakers NNS N
judged VBD N
the DT N
grammaticality NN N
of IN N
isolated JJ N
simple JJ N
bitransitive JJ N
sentences NNS N
involving VBG N
an DT N
uninterpretable JJ N
extra JJ N
argument NN N
in IN N
addition NN N
to TO N
three CD N
legitimate JJ N
arguments NNS N
The DT N
sentences NNS N
thus RB N
violated VBD N
Chomsky NNP N
's POS N
principle NN N
of IN N
Full NNP N
Interpretation NNP N
which WDT N
prohibits VBZ N
the DT N
structure NN N
building NN N
of IN N
a DT N
sentence NN N
including VBG N
uninterpretable JJ N
elements NNS N
The DT N
primary JJ N
variable NN N
of IN N
interest NN N
was VBD N
the DT N
presence NN N
or CC N
absence NN N
of IN N
punctuation NN N
, , N
i.e. FW N
, , N
commas NN N
, , N
which WDT N
enclosed VBD N
the DT N
extra JJ N
argument NN N
Findings NNS N
showed VBD N
that IN N
sentences NNS N
with IN N
punctuation NN N
were VBD N
judged VBN N
more RBR N
grammatical JJ N
than IN N
the DT N
ones NNS N
without IN N
punctuation NN N
, , N
with IN N
an DT N
average JJ N
score NN N
of IN N
judged JJ N
grammaticality NN N
exceeding VBG N
3 CD N
on IN N
a DT N
7-point JJ N
scale NN N
( ( N
1 CD N
=least RB N
grammatical JJ N
; : N
7=most CD N
grammatical NN N
) ) N
This DT N
score NN N
would MD N
not RB N
be VB N
expected VBN N
if IN N
the DT N
speakers NNS N
possess NN N
and CC N
judge NN N
the DT N
sentences NNS N
in IN N
conformity NN N
with IN N
the DT N
principle NN N
of IN N
Full NNP N
Interpretation NNP N
-DOCSTART- -X- O O 15929820

[ VB N
A DT N
multicenter NN N
, , N
randomized VBD N
clinical JJ N
trial NN N
of IN N
intravenous JJ N
diltiazem NNS N
in IN N
treatment NN N
of IN N
unstable JJ N
angina NN 4_p
] NNP N
OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
safety NN N
of IN N
intravenous JJ N
diltiazem NNS N
compared VBN N
with IN N
nitroglycerin NN N
in IN N
the DT N
patients NNS N
with IN N
unstable JJ 4_p
angina JJ 4_p
pectoris NN 4_p
METHODS NNP N
A NNP N
multicenter NN N
, , N
randomized VBN N
, , N
open-label JJ N
, , N
parallel JJ N
group NN N
trial NN N
was VBD N
conducted VBN N
A DT N
total NN N
of IN N
213 CD 3_p
eligible JJ N
patients NNS N
were VBD N
enrolled VBN N
They PRP N
were VBD N
randomized VBN N
either RB N
to TO N
diltiazem VB N
or CC N
nitroglycerin VB N
treatment NN N
The DT N
diltiazem NN N
was VBD N
administered VBN N
from IN N
100 CD N
microg/min NN N
at IN N
the DT N
initiation NN N
of IN N
treatment NN N
, , N
the DT N
largest JJS N
dosage NN N
was VBD N
200 CD N
- : N
300 CD N
microg/min NN N
; : N
the DT N
nitroglycerin NN N
was VBD N
administered VBN N
from IN N
20 CD N
microg/min NN N
at IN N
the DT N
initiation NN N
of IN N
treatment NN N
The DT N
largest JJS N
dosage NN N
was VBD N
80 CD N
- : N
100 CD N
microg/min NN N
Intravenous JJ N
infusion NN N
was VBD N
kept VBN N
over IN N
48 CD N
hours NNS N
The DT N
endpoints NNS N
included VBD N
refractory JJ N
angina NN N
pectoris NN N
, , N
acute JJ N
myocardial JJ N
infarction NN N
, , N
death NN N
, , N
emergency NN N
PTCA NNP N
and CC N
CABG NNP N
RESULTS NNP N
( ( N
1 CD N
) ) N
Intravenous NNP N
diltiazem NN N
was VBD N
effective JJ N
on IN N
the DT N
improvement NN N
of IN N
symptom NN N
and CC N
electrocardiogram NN N
, , N
and CC N
its PRP$ N
effects NNS N
were VBD N
similar JJ N
to TO N
intravenous JJ N
nitroglycerin NN N
( ( N
2 CD N
) ) N
Compared VBN N
with IN N
nitroglycerin NN N
, , N
intravenous JJ N
diltiazem NN N
lowered VBD N
heart NN N
rate NN N
and CC N
myocardial JJ N
oxygen NN N
consumption NN N
index NN N
( ( N
systolic JJ N
pressure NN N
x JJ N
heart NN N
rate NN N
) ) N
to TO N
more RBR N
extent JJ N
significantly RB N
( ( N
3 CD N
) ) N
After IN N
treatment NN N
, , N
the DT N
onsets NNS N
of IN N
refractory JJ N
angina NNS N
pectoris NN N
were VBD N
reduced VBN N
more RBR N
significantly RB N
in IN N
the DT N
diltiazem NN N
group NN N
than IN N
in IN N
nitroglycerin JJ N
group NN N
[ VBD N
4 CD N
( ( N
3.8 CD N
% NN N
) ) N
vs NN N
13 CD N
( ( N
11.9 CD N
% NN N
) ) N
, , N
RR NNP N
0.32 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.11 CD N
- : N
0.96 CD N
) ) N
, , N
P NNP N
< VBZ N
0.05 CD N
] NN N
( ( N
4 CD N
) ) N
The DT N
patients NNS N
whose WP$ N
heart NN N
rate NN N
were VBD N
reduced VBN N
significantly RB N
( ( N
< JJ N
or= RB N
50 CD N
beats NNS N
per IN N
minute NN N
) ) N
in IN N
the DT N
diltiazem NN N
group NN N
were VBD N
more JJR N
than IN N
in IN N
the DT N
nitroglycerin JJ N
group NN N
[ VBD N
8 CD N
( ( N
7.7 CD N
% NN N
) ) N
vs NN N
0 CD N
( ( N
0 CD N
% NN N
) ) N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
But CC N
these DT N
patients NNS N
could MD N
tolerate VB N
the DT N
lower JJR N
heart NN N
rate NN N
very RB N
well RB N
in IN N
the DT N
diltiazem NN N
group NN N
( ( N
5 CD N
) ) N
The DT N
needs NNS N
of IN N
beta NN N
receptor NN N
blocker NN N
or CC N
calcium NN N
antagonists NNS N
were VBD N
reduced VBN N
more RBR N
significantly RB N
in IN N
the DT N
diltiazem NN N
group NN N
compared VBN N
with IN N
those DT N
in IN N
the DT N
nitroglycerin JJ N
group NN N
[ VBD N
2 CD N
( ( N
1.9 CD N
% NN N
) ) N
vs NN N
13 CD N
( ( N
11.9 CD N
% NN N
) ) N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
CONCLUSION NNP N
Intravenous NNP N
diltiazem NN N
therapy NN N
is VBZ N
effective JJ N
and CC N
safe JJ N
for IN N
patients NNS N
with IN N
unstable JJ N
angina JJ N
pectoris NN N
It PRP N
may MD N
significantly RB N
lower VB N
the DT N
risk NN N
of IN N
refractory JJ N
angina JJ N
pectoris NNS N
compared VBN N
with IN N
intravenous JJ N
nitroglycerin NNS N
-DOCSTART- -X- O O 22459310

Relation NN N
of IN N
improvement NN N
in IN N
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
with IN N
atorvastatin NN N
to TO N
reductions NNS N
in IN N
hospitalizations NNS N
for IN N
heart NN N
failure NN N
( ( N
from IN N
the DT N
Treating NNP 4_p
to TO 4_p
New NNP 4_p
Targets NNP 4_p
[ NNP 4_p
TNT NNP 4_p
] NNP 4_p
study NN 4_p
) ) 4_p
Impaired NNP N
kidney NN N
function NN N
often RB N
accompanies VBZ N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
and CC N
is VBZ N
associated VBN N
with IN N
a DT N
worse JJR N
prognosis NN N
This DT N
post NN N
hoc NN N
analysis NN N
of IN N
the DT N
Treating NNP N
to TO N
New NNP N
Targets NNP N
( ( N
TNT NNP N
) ) N
trial NN N
examined VBD N
whether IN N
the DT N
observed JJ N
decrease NN N
in IN N
HF NNP N
hospitalizations NNS N
with IN N
high- JJ N
compared VBN N
to TO N
low-dose JJ N
atorvastatin NN N
could MD N
be VB N
related VBN N
to TO N
improvements NNS N
in IN N
kidney NN N
function NN N
Of IN N
10,001 CD N
TNT NNP N
participants NNS N
, , N
9,376 CD N
had VBD N
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
( ( N
eGFR NN N
) ) N
measurements NNS N
at IN N
baseline NN N
and CC N
1 CD N
year NN N
and CC N
were VBD N
included VBN N
in IN N
this DT N
analysis NN N
The DT N
association NN N
of IN N
change NN N
in IN N
year-1 JJ N
eGFR NN N
and CC N
subsequent JJ N
HF NNP N
hospitalization NN N
was VBD N
examined VBN N
using VBG N
Cox NNP N
regression NN N
models NNS N
In IN N
total JJ N
218 CD N
participants NNS N
developed VBD N
subsequent JJ N
HF NNP N
hospitalization NN N
Little JJ N
change NN N
in IN N
eGFR NN N
occurred VBD N
over IN N
1 CD N
year NN N
in IN N
the DT N
atorvastatin JJ N
10-mg JJ N
group NN N
, , N
whereas IN N
eGFR NN N
improved VBN N
in IN N
the DT N
80-mg JJ N
group NN N
by IN N
1.48 CD N
ml/min/1.73 NNS N
m NN N
( ( N
2 CD N
) ) N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
1.29 CD N
to TO N
1.67 CD N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
Subsequent JJ N
HF NNP N
was VBD N
preceded VBN N
by IN N
a DT N
decrease NN N
in IN N
eGFR NN N
over IN N
1 CD N
year NN N
compared VBN N
to TO N
modest JJ N
improvement NN N
in IN N
those DT N
without IN N
subsequent JJ N
HF NNP N
( ( N
-0.09 NNP N
± VBZ N
7.89 CD N
vs NN N
0.81 CD N
± NN N
6.90 CD N
ml/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
, , N
p JJ N
= NNP N
0.0015 CD N
) ) N
After IN N
adjusting VBG N
for IN N
baseline NN N
eGFR NN N
, , N
each DT N
5-ml/min/1.73 JJ N
m NN N
( ( N
2 CD N
) ) N
increase NN N
in IN N
eGFR NN N
at IN N
1 CD N
year NN N
was VBD N
associated VBN N
with IN N
a DT N
lower JJR N
risk NN N
of IN N
subsequent JJ N
HF NNP N
hospitalization NN N
( ( N
hazard JJ N
ratio NN N
0.85 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.77 CD N
to TO N
0.94 CD N
, , N
p NN N
= NNP N
0.002 CD N
) ) N
This DT N
relation NN N
was VBD N
independent JJ N
of IN N
treatment NN N
effect NN N
or CC N
change NN N
in IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
level NN N
at IN N
1 CD N
year NN N
In IN N
conclusion NN N
, , N
treatment NN N
with IN N
high- JJ N
compared VBN N
to TO N
low-dose JJ N
atorvastatin NN N
was VBD N
associated VBN N
with IN N
improvement NN N
in IN N
eGFR NN N
at IN N
1 CD N
year NN N
, , N
which WDT N
was VBD N
related VBN N
to TO N
a DT N
decrease NN N
in IN N
subsequent JJ N
HF NNP N
hospitalization NN N
This DT N
suggests VBZ N
that WDT N
improvement NN N
in IN N
kidney NN N
function NN N
may MD N
be VB N
related VBN N
to TO N
the DT N
beneficial JJ N
effect NN N
of IN N
high-dose JJ N
atorvastatin NN N
on IN N
HF NNP N
hospitalization NN N
-DOCSTART- -X- O O 11284463

Oral JJ N
rizatriptan NN N
versus IN N
oral JJ N
sumatriptan NN N
: : N
a DT N
direct JJ N
comparative NN N
study NN N
in IN N
the DT N
acute JJ 4_p
treatment NN 4_p
of IN 4_p
migraine NN 4_p
Rizatriptan NNP N
030 CD N
Study NNP N
Group NNP N
Rizatriptan NNP N
is VBZ N
a DT N
potent NN N
, , N
oral JJ N
, , N
5-HT1B/1D JJ N
agonist NN N
with IN N
more RBR N
rapid JJ N
absorption NN N
and CC N
higher JJR N
bioavailability NN N
than IN N
oral JJ N
sumatriptan NN N
It PRP N
was VBD N
postulated VBN N
that IN N
this DT N
would MD N
result VB N
in IN N
more RBR N
rapid JJ N
onset NN N
of IN N
effect NN N
This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
triple-dummy JJ N
, , N
parallel-groups JJ N
study NN N
compared VBN N
rizatriptan VBZ N
5 CD N
mg NN N
, , N
rizatriptan VBZ N
10 CD N
mg NN N
, , N
sumatriptan JJ N
100 CD N
mg NN N
, , N
and CC N
placebo NN N
in IN N
1268 CD 4_p
outpatients NNS 4_p
treating VBG 4_p
a DT 4_p
single JJ 4_p
migraine NN 4_p
attack NN 4_p
Headache NNP N
relief NN N
rates NNS N
after IN N
rizatriptan JJ N
10 CD N
mg NNS N
were VBD N
consistently RB N
higher JJR N
than IN N
sumatriptan JJR N
at IN N
all DT N
time NN N
points VBZ N
up IN N
to TO N
2 CD N
hours NNS N
, , N
with IN N
significance NN N
at IN N
1 CD N
hour NN N
( ( N
37 CD N
% NN N
versus IN N
28 CD N
% NN N
, , N
P NNP N
= NNP N
0.010 CD N
) ) N
All DT N
active JJ N
agents NNS N
were VBD N
significantly RB N
superior JJ N
to TO N
placebo VB N
with IN N
regard NN N
to TO N
headache VB N
relief NN N
and CC N
pain NN N
freedom NN N
at IN N
2 CD N
hours NNS N
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.001 CD N
) ) N
The DT N
primary JJ N
efficacy NN N
endpoint NN N
of IN N
time NN N
to TO N
pain VB N
relief NN N
through IN N
2 CD N
hours NNS N
demonstrated VBD N
that IN N
, , N
after IN N
adjustment NN N
for IN N
age NN N
imbalance NN N
, , N
rizatriptan VBZ N
10 CD N
mg NN N
had VBD N
earlier RBR N
onset VBN N
than IN N
sumatriptan JJ N
100 CD N
mg NN N
( ( N
P NNP N
= NNP N
0.032 CD N
; : N
hazard NN N
ratio VBZ N
1.21 CD N
) ) N
Rizatriptan $ N
10 CD N
mg NN N
was VBD N
also RB N
superior JJ N
to TO N
sumatriptan VB N
on IN N
pain-free JJ N
response NN N
( ( N
P NNP N
= NNP N
0.032 CD N
) ) N
, , N
reduction NN N
in IN N
functional JJ N
disability NN N
( ( N
P NNP N
= NNP N
0.015 CD N
) ) N
, , N
and CC N
relief NN N
of IN N
nausea NN N
at IN N
2 CD N
hours NNS N
( ( N
P NNP N
= NNP N
0.010 CD N
) ) N
Significantly RB N
fewer JJR N
drug-related JJ N
clinical JJ N
adverse JJ N
events NNS N
were VBD N
reported VBN N
after IN N
rizatriptan NN N
10 CD N
mg NN N
( ( N
33 CD N
% NN N
, , N
P NNP N
= NNP N
0.014 CD N
) ) N
compared VBN N
with IN N
sumatriptan JJ N
100 CD N
mg NN N
( ( N
41 CD N
% NN N
) ) N
We PRP N
conclude VBP N
that IN N
rizatriptan VBZ N
10 CD N
mg NN N
has VBZ N
a DT N
rapid JJ N
onset NN N
of IN N
action NN N
and CC N
relieves VBZ N
headache NN N
and CC N
associated VBN N
symptoms NNS N
more RBR N
effectively RB N
than IN N
sumatriptan JJ N
100 CD N
mg NN N
-DOCSTART- -X- O O 22982948

Take VB N
a DT N
walk NN N
in IN N
the DT N
park NN N
? . N
A DT N
cross-over NN N
pilot NN N
trial NN N
comparing VBG N
brisk JJ N
walking VBG N
in IN N
two CD N
different JJ N
environments NNS N
: : N
park NN N
and CC N
urban JJ N
OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
is VBZ N
to TO N
investigate VB N
whether IN N
differences NNS N
exist VBP N
between IN N
a DT N
30 CD N
minute NN N
brisk NN N
walk VBP N
taken VBN N
in IN N
two CD N
different JJ N
environments NNS N
in IN N
order NN N
to TO N
determine VB N
which WDT N
environment NN N
best JJS N
facilitates NNS N
current JJ N
physical JJ N
activity NN N
guidelines NNS N
: : N
park NN N
or CC N
urban JJ N
METHODS NNP N
In IN N
this DT N
randomised JJ N
cross-over NN N
pilot NN N
study NN N
, , N
participants NNS N
performed VBD N
a DT N
self-timed JJ N
30 CD N
minute NN N
brisk NN 4_p
walk VBP 4_p
in IN N
two CD N
different JJ N
environments NNS N
, , N
park NN N
and CC N
urban JJ N
, , N
in IN N
Glasgow NNP N
, , N
Scotland NNP N
( ( N
October NNP N
2009 CD N
to TO N
January NNP N
2010 CD N
) ) N
Cadence NN N
, , N
recorded VBD N
using VBG N
the DT N
activPAL™ NN N
activity NN N
monitor NN N
, , N
was VBD N
used VBN N
to TO N
measure VB N
intensity NN N
Outcome CC N
measures NNS N
were VBD N
: : N
mean JJ N
cadence NN N
; : N
moderate-to-vigorous JJ N
physical JJ N
activity NN N
time NN N
accumulated VBN N
in IN N
bouts NNS N
lasting VBG N
≥ $ N
10 CD N
min NN N
; : N
number NN N
of IN N
walking VBG N
breaks NNS N
; : N
and CC N
duration NN N
RESULTS VB N
A DT N
convenience NN N
sample NN N
of IN N
40 CD 3_p
healthy JJ 4_p
adults NNS 1_p
was VBD N
recruited VBN N
: : N
16 CD 2_p
males NNS 2_p
, , N
24 CD 2_p
females NNS 2_p
, , N
mean JJ 1_p
age NN 1_p
22.9 CD 1_p
( ( 1_p
5.5 CD 1_p
) ) 1_p
years NNS 1_p
The DT N
mean JJ N
cadence NN N
for IN N
the DT N
whole JJ N
walk NN N
was VBD N
higher RBR N
in IN N
the DT N
park NN N
: : N
119.3 CD N
( ( N
8.3 CD N
) ) N
vs. FW N
110.9 CD N
( ( N
8.9 CD N
) ) N
steps/min NN N
Participants NNS N
accumulated VBD N
more RBR N
moderate-to-vigorous JJ N
physical JJ N
activity NN N
in IN N
≥ $ N
10 CD N
minute NN N
bouts NNS N
during IN N
park JJ N
walks NNS N
: : N
25.5 CD N
( ( N
9.6 CD N
) ) N
[ NN N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
] VBZ N
vs. FW N
14.0 CD N
( ( N
20.3 CD N
) ) N
min NN N
There EX N
was VBD N
no DT N
difference NN N
in IN N
self-timed JJ N
duration NN N
between IN N
locations NNS N
CONCLUSION NNP N
Participants NNPS N
accumulated VBD N
more RBR N
moderate-to-vigorous JJ N
physical JJ N
activity NN N
in IN N
bouts NNS N
≥ VBP N
10 CD N
min NN N
in IN N
duration NN N
on IN N
park NN N
walks NNS N
due JJ N
to TO N
the DT N
lack NN N
of IN N
interruptions NNS N
in IN N
walking VBG N
Hence NNP N
the DT N
park NN N
environment NN N
better RBR N
facilitated VBD N
the DT N
achievement NN N
of IN N
current JJ N
physical JJ N
activity NN N
guidelines NNS N
Further JJ N
research NN N
involving VBG N
a DT N
larger JJR N
, , N
more RBR N
heterogeneous JJ N
sample NN N
is VBZ N
recommended VBN N
-DOCSTART- -X- O O 15319704

Ropinirole NNP N
as IN N
a DT N
treatment NN N
of IN N
restless JJ 4_p
legs JJ 4_p
syndrome NN 4_p
in IN 4_p
patients NNS 4_p
on IN 4_p
chronic JJ 4_p
hemodialysis NN 4_p
: : 4_p
an DT N
open JJ N
randomized VBN N
crossover NN N
trial NN N
versus NN N
levodopa NN N
sustained VBD N
release NN N
OBJECTIVE NNP N
Restless NNP N
legs VBZ N
syndrome NN N
( ( N
RLS NNP N
) ) N
is VBZ N
a DT N
common JJ N
neurologic JJ N
condition NN N
characterized VBN N
by IN N
uncomfortable JJ N
and CC N
unpleasant JJ N
sensations NNS N
in IN N
the DT N
legs NN N
, , N
occurring VBG N
primarily RB N
at IN N
rest NN N
, , N
which WDT N
are VBP N
usually RB N
worse JJR N
in IN N
the DT N
evening NN N
and CC N
are VBP N
alleviated VBN N
by IN N
movement NN N
RLS NNP N
is VBZ N
present JJ N
in IN N
20-40 JJ N
% NN N
of IN N
patients NNS N
with IN N
renal JJ 4_p
failure NN 4_p
This DT N
study NN N
was VBD N
a DT N
14-week JJ N
open JJ N
, , N
randomized VBN N
, , N
crossover JJ N
trial NN N
of IN N
ropinirole NN N
vs. FW N
levodopa NN N
sustained VBN N
release NN N
( ( N
SR NNP N
) ) N
in IN N
11 CD 3_p
patients NNS N
with IN N
RLS NNP N
on IN N
chronic JJ N
hemodialysis NN N
METHODS NNP N
Eleven NNP N
patients NNS N
( ( N
7 CD 3_p
men NNS 2_p
, , N
4 CD 3_p
women NNS 2_p
) ) N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
They PRP N
received VBD N
either CC N
levodopa JJ N
SR NNP N
or CC N
ropinirole VB N
for IN N
6 CD N
weeks NNS N
, , N
followed VBN N
by IN N
a DT N
washout NN N
week NN N
, , N
then RB N
the DT N
alternate NN N
treatment NN N
for IN N
6 CD N
weeks NNS N
Patients NNS N
rated VBD N
the DT N
severity NN N
of IN N
RLS NNP N
by IN N
means NNS N
of IN N
a DT N
6-item JJ N
questionnaire NN N
developed VBN N
by IN N
the DT N
International NNP N
Restless NNP N
Legs NNP N
Study NNP N
Group NNP N
( ( N
6-item JJ N
IRLS NNP N
) ) N
, , N
by IN N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
( ( N
CGI NNP N
) ) N
scale NN N
, , N
and CC N
by IN N
sleep JJ N
diaries NNS N
RESULTS NNP N
Under IN N
treatment NN N
with IN N
levodopa JJ N
SR NNP N
, , N
1 CD N
patient NN N
presented VBN N
severe JJ N
vomiting NN N
, , N
leading VBG N
to TO N
study VB N
discontinuation NN N
The DT N
10 CD 3_p
patients NNS N
who WP 4_p
completed VBD 4_p
the DT 4_p
study NN 4_p
reported VBD N
a DT N
33.5 CD N
% NN N
improvement NN N
( ( N
from IN N
16.7 CD N
+/- JJ N
3.2 CD N
to TO N
11.1 CD N
+/- JJ N
4 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
of IN N
the DT N
6-item JJ N
IRLS NNP N
scores NNS N
during IN N
levodopa JJ N
SR NNP N
treatment NN N
and CC N
a DT N
73.5 CD N
% NN N
improvement NN N
( ( N
from IN N
16.6 CD N
+/- JJ N
2.8 CD N
to TO N
4.4 CD N
+/- JJ N
3.8 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
during IN N
ropinirole JJ N
treatment NN N
By IN N
the DT N
end NN N
of IN N
the DT N
study NN N
the DT N
mean JJ N
levodopa NN N
SR NNP N
dosage NN N
was VBD N
190 CD N
mg/d NN N
and CC N
the DT N
mean JJ N
ropinirole NN N
dosage NN N
was VBD N
1.45 CD N
mg/d NN N
Ropinirole NNP N
was VBD N
superior JJ N
to TO N
levodopa VB N
SR NNP N
in IN N
reducing VBG N
6-item JJ N
IRLS NNP N
scores NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
in IN N
increasing VBG N
sleep JJ N
time NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
The DT N
patient NN N
CGI NNP N
scale NN N
showed VBD N
a DT N
significant JJ N
difference NN N
favoring VBG N
ropinirole NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
There EX N
was VBD N
no DT N
significant JJ N
carryover NN N
or CC N
period NN N
effect NN N
for IN N
any DT N
outcome JJ N
measure NN N
Four CD N
patients NNS N
reported VBD N
a DT N
complete JJ N
reversion NN N
of IN N
RLS NNP N
symptoms NNS N
during IN N
ropinirole JJ N
treatment NN N
at IN N
doses NNS N
ranging VBG N
from IN N
0.25-2 JJ N
mg/d NN N
CONCLUSIONS NNP N
These DT N
results NNS N
suggest VBP N
that IN N
ropinirole NN N
is VBZ N
more RBR N
effective JJ N
than IN N
levodopa JJS N
SR NNP N
in IN N
the DT N
treatment NN N
of IN N
RLS NNP N
in IN N
patients NNS N
on IN N
chronic JJ N
hemodialysis NN N
-DOCSTART- -X- O O 21463068

Concurrent NNP N
alcohol NN N
dependence NN N
among IN N
methadone-maintained JJ N
cocaine NN N
abusers NNS N
is VBZ N
associated VBN N
with IN N
greater JJR N
abstinence NN N
Concurrent NNP N
alcohol NN N
dependence NN N
( ( N
AD NNP N
) ) N
among IN N
polysubstance NN N
abusers NNS N
has VBZ N
been VBN N
associated VBN N
with IN N
negative JJ N
consequences NNS N
, , N
although IN N
it PRP N
may MD N
not RB N
necessarily RB N
lead VB N
to TO N
poor JJ N
treatment NN N
outcomes NNS N
One CD N
of IN N
the DT N
most RBS N
efficacious JJ N
treatments NNS N
for IN N
cocaine NN N
abuse NN N
is VBZ N
contingency JJ N
management NN N
( ( N
CM NNP N
) ) N
, , N
but CC N
little JJ N
research NN N
has VBZ N
explored VBN N
the DT N
impact NN N
of IN N
AD NNP N
on IN N
abstinence NN N
outcomes NNS N
, , N
particularly RB N
among IN N
patients NNS N
in IN N
methadone JJ N
maintenance NN N
Using VBG N
data NNS N
from IN N
three CD N
trials NNS N
of IN N
CM NNP N
for IN N
cocaine NN N
use NN N
, , N
we PRP N
compared VBN N
baseline JJ N
characteristics NNS N
and CC N
posttreatment NN N
and CC N
follow-up JJ N
cocaine NN N
outcomes NNS N
between IN N
methadone-maintained JJ N
, , N
cocaine-dependent JJ N
patients NNS N
( ( N
N NNP N
= NNP N
193 CD N
) ) N
with IN N
and CC N
without IN N
concurrent JJ N
AD NNP N
, , N
randomized VBN N
to TO N
standard VB N
care NN N
( ( N
SC NNP N
) ) N
with IN N
or CC N
without IN N
CM NNP N
Patients NNS N
with IN N
and CC N
without IN N
concurrent JJ N
AD NNP N
had VBD N
similar JJ N
baseline NN N
characteristics NNS N
, , N
with IN N
the DT N
exception NN N
that WDT N
AD NNP N
patients NNS N
reported VBD N
more RBR N
alcohol NN N
use NN N
AD NN N
patients NNS N
achieved VBN N
longer JJR N
durations NNS N
of IN N
cocaine NN N
abstinence NN N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
submit VB N
a DT N
cocaine-negative JJ N
sample NN N
at IN N
follow-up JJ N
than IN N
non-AD JJ N
patients NNS N
Patients NNS N
randomized VBD N
to TO N
CM NNP N
achieved VBD N
better RBR N
outcomes NNS N
than IN N
those DT N
randomized VBN N
to TO N
SC NNP N
, , N
but CC N
there EX N
was VBD N
no DT N
interaction NN N
between IN N
treatment NN N
condition NN N
and CC N
AD NNP N
status NN N
These DT N
findings NNS N
suggest VBP N
that IN N
cocaine-using JJ N
methadone NN N
patients NNS N
with IN N
AD NNP N
achieve VBP N
greater JJR N
cocaine NN N
abstinence NN N
than IN N
their PRP$ N
non-AD JJ N
counterparts NNS N
and CC N
should MD N
not RB N
necessarily RB N
be VB N
viewed VBN N
as IN N
more RBR N
difficult JJ N
to TO N
treat VB N
-DOCSTART- -X- O O 18701020

Beneficial JJ N
effects NNS N
of IN N
a DT N
diabetes NN N
specific JJ N
formula NN N
on IN N
insulin NN N
sensitivity NN N
and CC N
free JJ N
fatty NN N
acid NN N
in IN N
patients NNS 4_p
with IN 4_p
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
BACKGROUND VB N
This DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
a DT N
diabetes NN N
specific JJ N
formula NN N
( ( N
Diason NNP N
low JJ N
energy NN N
: : N
313.8 CD N
kJ/100 NNS N
ml NN N
) ) N
, , N
compared VBN N
with IN N
a DT N
standard JJ N
formula NN N
, , N
on IN N
insulin NN N
sensitivity NN N
, , N
serum JJ N
C NNP N
peptide NN N
, , N
serum JJ N
lipids NNS N
and CC N
free JJ N
fatty NN N
acid NN N
( ( N
FFA NNP N
) ) N
in IN N
type NN 4_p
2 CD 4_p
diabetics NNS 4_p
METHODS NNP N
In IN N
total NN N
of IN N
71 CD N
type NN N
2 CD N
diabetics NNS N
completed VBD N
the DT N
study NN N
Enteral NNP N
formulas NNS N
were VBD N
given VBN N
orally RB N
as IN N
the DT N
sole JJ N
source NN N
of IN N
nutrition NN N
to TO N
the DT N
subjects NNS N
for IN N
6 CD N
days NNS N
Venous JJ N
blood NN N
samples NNS N
( ( N
0.5 CD N
, , N
1 CD N
, , N
2 CD N
, , N
3 CD N
hours NNS N
) ) N
were VBD N
collected VBN N
at IN N
day-7 NN N
after IN N
a DT N
75 CD N
g JJ N
oral JJ N
glucose JJ N
tolerance NN N
test NN N
( ( N
OGTT NNP N
) ) N
, , N
day NN N
1 CD N
after IN N
a DT N
standard JJ N
test NN N
meal NN N
( ( N
1673.6 CD N
kJ NN N
) ) N
and CC N
after IN N
6 CD N
days NNS N
of IN N
either CC N
the DT N
test NN N
diabetes VBZ N
specific JJ N
formula NN N
or CC N
a DT N
standard JJ N
formula NN N
Plasma NNP N
glucose NN N
, , N
serum JJ N
insulin NN N
, , N
C NNP N
peptide NN N
and CC N
lipids NNS N
were VBD N
measured VBN N
RESULTS NNP N
After IN N
the DT N
intervention NN N
period NN N
, , N
the DT N
diabetes NNS N
specific JJ N
formula NN N
resulted VBD N
in IN N
a DT N
significantly RB N
lower JJR N
postprandial JJ N
rise NN N
in IN N
blood NN N
glucose JJ N
concentrations NNS N
at IN N
0.5 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
1 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
significantly RB N
lower JJR N
peak JJ N
height NN N
of IN N
plasma NN N
glucose NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
; : N
significantly RB N
lower JJR N
plasma NN N
insulin NN N
concentrations NNS N
at IN N
0.5 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
1 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
2 CD N
hours NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
and CC N
a DT N
significantly RB N
lower JJR N
plasma NN N
insulin NN N
peak NN N
compared VBN N
to TO N
controls NNS N
; : N
both DT N
OGTT NNP N
and CC N
a DT N
standard JJ N
test NN N
meal NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
The DT N
glucose NN N
and CC N
insulin JJ N
area NN N
under IN N
the DT N
curve NN N
after IN N
the DT N
diabetes NNS N
specific JJ N
formula NN N
compared VBN N
to TO N
the DT N
standard JJ N
formula NN N
were VBD N
significantly RB N
lower JJR N
The DT N
C NNP N
peptide NN N
level NN N
was VBD N
lower JJR N
after IN N
6 CD N
days NNS N
of IN N
both DT N
nutrition NN N
formulas NNS N
compare VBP N
to TO N
75 CD N
g NN N
OGTT NNP N
, , N
but CC N
not RB N
different JJ N
from IN N
the DT N
standard NN N
mixed JJ N
meal NN N
Both DT N
formulas NNS N
were VBD N
well RB N
tolerated VBN N
CONCLUSIONS NNP N
In IN N
summary JJ N
the DT N
diabetes NNS N
specific JJ N
formula NN N
with IN N
a DT N
relatively RB N
high JJ N
monounsaturated VBN N
fatty JJ N
acid NN N
and CC N
high JJ N
multi NN N
fiber NN N
proportion NN N
significantly RB N
improved VBN N
glycemic JJ N
control NN N
On IN N
top NN N
of IN N
this DT N
, , N
the DT N
insulin NN N
sensitivity NN N
( ( N
HOMA-IS NNP N
) ) N
was VBD N
significantly RB N
improved VBN N
and CC N
may MD N
therefore VB N
directly RB N
improve VB N
the DT N
impact NN N
on IN N
long JJ N
term NN N
complications NNS N
The DT N
disease NN N
specific JJ N
formula NN N
should MD N
therefore RB N
be VB N
the DT N
preferred JJ N
option NN N
to TO N
be VB N
used VBN N
by IN N
diabetic JJ N
and CC N
hyperglycemic JJ N
patients NNS N
in IN N
need NN N
of IN N
nutritional JJ N
support NN N
-DOCSTART- -X- O O 4752239

Mebendazole NNP N
in IN N
enterobiasis NN 4_p
: : 4_p
a DT N
placebo NN N
-- : N
controlled VBD N
trial NN N
in IN N
a DT N
paediatric JJ 4_p
community NN N
-DOCSTART- -X- O O 20608027

[ JJ N
Assessment NNP N
of IN N
natriuretic JJ N
peptide NN N
indices NNS N
and CC N
oxidative JJ N
stress NN N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
] NNP N
The DT N
authors NNS N
have VBP N
studied VBN N
indices NNS N
of IN N
natriuretic JJ N
peptide NN N
and CC N
oxidative JJ N
stress NN N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
( ( 4_p
CHF NNP 4_p
) ) 4_p
52 CD 3_p
male JJ 2_p
patients NNS N
with IN N
postinfarction NN N
cardiosclerosis NN N
( ( N
PICS NNP N
) ) N
who WP N
have VBP N
developed VBN N
CHF NNP 4_p
have VBP N
been VBN N
observed VBN N
The DT N
age NN N
of IN N
the DT N
patients NNS N
varied VBD N
from IN N
38 CD 1_p
till NN 1_p
60 CD 1_p
It PRP N
was VBD N
established VBN N
that IN N
CHF NNP N
patients NNS N
with IN N
progression NN N
of IN N
the DT N
disease NN N
had VBD N
worsening NN N
of IN N
their PRP$ N
clinical JJ N
condition NN N
together RB N
with IN N
an DT N
increase NN N
of IN N
oxidative JJ N
stress NN N
which WDT N
was VBD N
characterized VBN N
through IN N
decrease NN N
of IN N
NO NNP N
metabolites NNS N
, , N
NADPH NNP N
-- : N
diaphorase NN N
( ( N
eNOS NN N
) ) N
, , N
increase NN N
of IN N
nitrite JJ N
reductase NN N
( ( N
iNOS NN N
) ) N
and CC N
peroxinitrite JJ N
( ( N
ONOO NNP N
) ) N
, , N
correlative JJ N
increase NN N
the DT N
level NN N
of IN N
brain NN N
natriuretic JJ N
peptide NN N
in IN N
blood NN N
plazma NN N
Reliable JJ N
connection NN N
between IN N
considerable JJ N
increase NN N
of IN N
oxidative JJ N
stress NN N
and CC N
the DT N
level NN N
of IN N
NT-pro NNP N
BNP NNP N
was VBD N
noted VBN N
in IN N
CHF NNP 4_p
patients NNS N
, , N
which WDT N
demands VBZ N
necessity NN N
of IN N
correction NN N
of IN N
observed JJ N
disorders NNS N
-DOCSTART- -X- O O 23065117

A DT N
pilot NN N
study NN N
on IN N
the DT N
efficacy NN N
of IN N
melodic NNS N
based VBN N
communication NN N
therapy NN N
for IN N
eliciting VBG N
speech NN N
in IN N
nonverbal JJ 4_p
children NNS 1_p
with IN N
autism NN 4_p
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
melodic NNS N
based VBN N
communication NN N
therapy NN N
( ( N
MBCT NNP N
) ) N
to TO N
traditional JJ N
speech NN N
and CC N
language NN N
therapy NN N
for IN N
eliciting VBG N
speech NN N
in IN N
nonverbal JJ N
children NNS N
with IN N
autism NN N
Participants NNS N
were VBD N
12 CD 3_p
nonverbal JJ 4_p
children NNS 4_p
with IN N
autism NN 4_p
ages NNS 1_p
5 CD 1_p
through IN 1_p
7 CD 1_p
randomly RB N
assigned VBN N
to TO N
either DT N
treatment NN N
group NN N
Both DT N
groups NNS N
made VBD N
significant JJ N
progress NN N
after IN N
treatment NN N
The DT N
MBCT NNP N
group NN N
progressed VBD N
significantly RB N
in IN N
number NN N
of IN N
verbal JJ N
attempts NNS N
after IN N
weeks NNS N
1 CD N
through IN N
4 CD N
and CC N
number NN N
of IN N
correct JJ N
words NNS N
after IN N
weeks NNS N
1 CD N
and CC N
3 CD N
, , N
while IN N
the DT N
traditional JJ N
group NN N
progressed VBD N
significantly RB N
after IN N
weeks NNS N
4 CD N
and CC N
5 CD N
No DT N
significant JJ N
differences NNS N
in IN N
number NN N
of IN N
verbal JJ N
attempts NNS N
or CC N
number NN N
of IN N
correct JJ N
words NNS N
were VBD N
noted VBN N
between IN N
groups NNS N
following VBG N
treatment NN N
A DT N
significant JJ N
number NN N
of IN N
new JJ N
words NNS N
were VBD N
heard VBN N
in IN N
the DT N
home NN N
environment NN N
for IN N
the DT N
MBCT NNP N
group NN N
( ( N
p JJ N
= NNP N
.04 NNP N
) ) N
Participants NNS N
in IN N
the DT N
MBCT NNP N
group NN N
had VBD N
more RBR N
imitative JJ N
attempts NNS N
( ( N
p JJ N
= NNP N
.03 NNP N
) ) N
MBCT NNP N
appears VBZ N
to TO N
be VB N
a DT N
valid JJ N
form NN N
of IN N
intervention NN N
for IN N
children NNS N
with IN N
autism NN N
-DOCSTART- -X- O O 1444872

[ NN N
Unstable JJ N
angina NN N
: : N
comparison NN N
of IN N
the DT N
effects NNS N
of IN N
diltiazem NN N
and CC N
propranolol NN N
] NN N
PURPOSE NNP N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
diltiazem NN N
and CC N
propranolol NN N
in IN N
patients NNS N
with IN N
unstable JJ N
angina NN N
METHODS NNP N
Fifty-six JJ N
patients NNS N
with IN N
unstable JJ N
angina NN N
, , N
mean JJ N
age NN N
of IN N
55.4 CD N
+/- JJ N
8.5 CD N
, , N
41 CD N
men NNS N
and CC N
15 CD N
women NNS N
, , N
were VBD N
evaluated VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
study NN N
of IN N
two CD N
groups NNS N
of IN N
patients NNS N
treated VBN N
with IN N
diltiazem NN N
or CC N
propranolol NN N
at IN N
total JJ N
daily JJ N
doses NNS N
of IN N
180 CD N
mg NNS N
and CC N
120 CD N
mg NN N
respectively RB N
during IN N
the DT N
first JJ N
48 CD N
hours NNS N
After IN N
that IN N
the DT N
total JJ N
daily JJ N
doses NNS N
was VBD N
adjusted VBN N
to TO N
240 CD N
mg NNS N
and CC N
160 CD N
mg NN N
, , N
respectively RB N
, , N
until IN N
the DT N
7th JJ N
day NN N
The DT N
first JJ N
48 CD N
hours NNS N
, , N
four CD N
times NNS N
daily RB N
, , N
clinical JJ N
evaluation NN N
, , N
CKMB NNP N
data NN N
, , N
ECG NNP N
were VBD N
obtained VBN N
and CC N
two CD N
times NNS N
daily RB N
until IN N
7th CD N
day NN N
A DT N
coronary JJ N
arteriography NN N
was VBD N
done VBN N
on IN N
study NN N
entry NN N
RESULTS VB N
A NNP N
significative JJ N
reduction NN N
of IN N
angina NN N
crisis NN N
number NN N
, , N
duration NN N
, , N
intensity NN N
and CC N
the DT N
number NN N
of IN N
sublingual JJ N
nitrates NNS N
doses NNS N
were VBD N
observed VBN N
equally RB N
in IN N
both DT N
groups NNS N
The DT N
SAP NNP N
, , N
DAP NNP N
, , N
HR NNP N
and CC N
RR NNP N
did VBD N
not RB N
show VB N
statistical JJ N
differences NNS N
between IN N
groups NNS N
Individual NNP N
groups NNS N
analysis NN N
showed VBD N
significative JJ N
reductions NNS N
of IN N
SAP NNP N
, , N
DAP NNP N
and CC N
HR NNP N
in IN N
propranolol NN N
group NN N
The DT N
CKMB NNP N
data NNS N
, , N
ECG NNP N
alterations NNS N
and CC N
coronary JJ N
arteriography NN N
characteristics NNS N
were VBD N
similar JJ N
CONCLUSION NNP N
Both NNP N
drugs NNS N
were VBD N
effective JJ N
for IN N
the DT N
unstable JJ N
angina NN N
treatment NN N
-DOCSTART- -X- O O 16596861

Nurse-led JJ N
cardiac NN N
clinics NNS N
for IN N
adults NNS 1_p
with IN N
coronary JJ 4_p
heart NN 4_p
disease NN 4_p
This DT N
information NN N
on IN N
best NN N
practice NN N
is VBZ N
based VBN N
on IN N
a DT N
systematic JJ N
review NN N
of IN N
research NN N
, , N
published VBN N
by IN N
Blackwell NNP N
Publishing NNP N
Asia NNP N
and CC N
conducted VBN N
by IN N
the DT N
Centre NNP N
for IN N
Evidence-based JJ N
Nursing NNP N
South NNP N
Australia NNP N
, , N
a DT N
collaborating VBG N
centre NN N
of IN N
the DT N
Joanna NNP N
Briggs NNP N
Institute NNP N
( ( N
JBI NNP N
) ) N
The DT N
primary JJ N
references NNS N
on IN N
which WDT N
this DT N
information NN N
is VBZ N
based VBN N
are VBP N
provided VBN N
in IN N
the DT N
systematic JJ N
review NN N
report NN N
available JJ N
online JJ N
via IN N
Blackwell NNP N
Synergy NNP N
www.blackwell-synergy.com NN N
and CC N
to TO N
members NNS N
of IN N
the DT N
institute NN N
via IN N
the DT N
web JJ N
site NN N
: : N
www.joannabriggs.edu.au NN N
This DT N
information NN N
sheet NN N
covers VBZ N
the DT N
following JJ N
: : N
Nurse-led JJ N
education NN N
and CC N
self-help NN N
Education NN N
and CC N
motivational JJ N
interview NN N
Audit NNP N
and CC N
recall NN N
Secondary JJ N
prevention NN N
-DOCSTART- -X- O O 22583459

Mapping VBG N
from IN N
disease-specific JJ N
measures NNS N
to TO N
health-state JJ N
utility NN N
values NNS N
in IN N
individuals NNS 4_p
with IN 4_p
migraine NN 4_p
OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
develop VB N
empirical JJ N
algorithms NN N
that WDT N
estimate VBP N
health-state JJ N
utility NN N
values NNS N
from IN N
disease-specific JJ N
quality-of-life JJ N
scores NNS N
in IN N
individuals NNS 4_p
with IN 4_p
migraine NN 4_p
METHODS NNP N
Data NNP N
from IN N
a DT N
cross-sectional JJ N
, , N
multicountry NN N
study NN N
were VBD N
used VBN N
Individuals NNS 4_p
with IN 4_p
episodic NN 4_p
and CC 4_p
chronic JJ 4_p
migraine NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
training NN N
or CC N
validation NN N
samples NNS N
Spearman NNP N
's POS N
correlation NN N
coefficients NNS N
between IN N
paired VBN N
EuroQol NNP N
five-dimensional JJ N
( ( N
EQ-5D NNP N
) ) N
questionnaire NN N
utility NN N
values NNS N
and CC N
both DT N
Headache NNP N
Impact NNP N
Test NNP N
( ( N
HIT-6 NNP N
) ) N
scores NNS N
and CC N
Migraine-Specific NNP N
Quality-of-Life NNP N
Questionnaire NNP N
version NN N
2.1 CD N
( ( N
MSQ NNP N
) ) N
domain NN N
scores NNS N
( ( N
role NN N
restrictive NN N
, , N
role NN N
preventive NN N
, , N
and CC N
emotional JJ N
function NN N
) ) N
were VBD N
examined VBN N
Regression NN N
models NNS N
were VBD N
constructed VBN N
to TO N
estimate VB N
EQ-5D NNP N
questionnaire NN N
utility NN N
values NNS N
from IN N
the DT N
HIT-6 NNP N
score NN N
or CC N
the DT N
MSQ NNP N
domain NN N
scores NNS N
Preferred VBN N
algorithms NNS N
were VBD N
confirmed VBN N
in IN N
the DT N
validation NN N
samples NNS N
RESULTS NNP N
In IN N
episodic JJ N
migraine NN N
, , N
the DT N
preferred JJ N
HIT-6 NNP N
and CC N
MSQ NNP N
algorithms VBP N
explained VBD N
22 CD N
% NN N
and CC N
25 CD N
% NN N
of IN N
the DT N
variance NN N
( ( N
R NNP N
( ( N
2 CD N
) ) N
) ) N
in IN N
the DT N
training NN N
samples NNS N
, , N
respectively RB N
, , N
and CC N
had VBD N
similar JJ N
prediction NN N
errors NNS N
( ( N
root JJ N
mean NN N
square JJ N
errors NNS N
of IN N
0.30 CD N
) ) N
In IN N
chronic JJ N
migraine NN N
, , N
the DT N
preferred JJ N
HIT-6 NNP N
and CC N
MSQ NNP N
algorithms VBP N
explained VBD N
36 CD N
% NN N
and CC N
45 CD N
% NN N
of IN N
the DT N
variance NN N
in IN N
the DT N
training NN N
samples NNS N
, , N
respectively RB N
, , N
and CC N
had VBD N
similar JJ N
prediction NN N
errors NNS N
( ( N
root JJ N
mean NN N
square JJ N
errors NNS N
0.31 CD N
and CC N
0.29 CD N
) ) N
In IN N
episodic JJ N
and CC N
chronic JJ N
migraine NN N
, , N
no DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
mean NN N
observed VBD N
and CC N
the DT N
mean NN N
estimated VBD N
EQ-5D NNP N
questionnaire NN N
utility NN N
values NNS N
for IN N
the DT N
preferred JJ N
HIT-6 NNP N
and CC N
MSQ NNP N
algorithms NN N
in IN N
the DT N
validation NN N
samples NNS N
CONCLUSIONS VB N
The DT N
relationship NN N
between IN N
the DT N
EQ-5D NNP N
questionnaire NN N
and CC N
the DT N
HIT-6 NNP N
or CC N
the DT N
MSQ NNP N
is VBZ N
adequate JJ N
to TO N
use VB N
regression NN N
equations NNS N
to TO N
estimate VB N
EQ-5D NNP N
questionnaire NN N
utility NN N
values NNS N
The DT N
preferred JJ N
HIT-6 NNP N
and CC N
MSQ NNP N
algorithms NN N
will MD N
be VB N
useful JJ N
in IN N
estimating VBG N
health-state JJ N
utilities NNS N
in IN N
migraine NN N
trials NNS N
in IN N
which WDT N
no DT N
preference-based JJ N
measure NN N
is VBZ N
present JJ N
-DOCSTART- -X- O O 20456192

Capsaicin NNP N
jelly RB N
against IN N
migraine NN 4_p
pain NN 4_p
OBJECTIVE NNP N
Recent NNP N
studies NNS N
support VBP N
the DT N
role NN N
of IN N
extracranial JJ N
perivascular JJ N
afferents NNS N
in IN N
a DT N
substantial JJ N
percentage NN N
of IN N
migraineurs NNS N
Perivascular JJ N
afferent JJ N
fibres NNS N
of IN N
the DT N
superficial JJ N
temporal JJ N
artery NN N
contain NN N
peptides NNS N
, , N
like IN N
calcitonin JJ N
gene-related JJ N
peptide NN N
( ( N
CGRP NNP N
) ) N
and CC N
substance NN N
P NNP N
( ( N
SP NNP N
) ) N
CGRP NNP N
and CC N
SP NNP N
are VBP N
considered VBN N
relevant JJ N
in IN N
the DT N
genesis NN N
of IN N
migraine NN N
pain NN N
Capsaicin NNP N
is VBZ N
an DT N
agonist NN N
of IN N
the DT N
transient NN N
receptor NN N
potential JJ N
vanilloid NN N
type NN N
1 CD N
It PRP N
causes VBZ N
membrane JJ N
depolarisation NN N
of IN N
sensory JJ N
neurons NNS N
, , N
which WDT N
release VBP N
CGRP NNP N
, , N
SP NNP N
and CC N
other JJ N
pain NN N
peptides NNS N
; : N
excitation NN N
is VBZ N
followed VBN N
by IN N
a DT N
refractory NN N
state NN N
, , N
causing VBG N
inactivation NN N
Topical JJ N
capsaicin NN N
has VBZ N
been VBN N
found VBN N
to TO N
be VB N
efficacious JJ N
in IN N
several JJ N
types NNS N
of IN N
neuropathic JJ N
pain NN N
We PRP N
attempted VBD N
to TO N
verify VB N
whether IN N
topical JJ N
periarterial JJ N
capsaicin NN N
could MD N
ameliorate VB N
pain NN N
in IN N
absence NN N
of IN N
and CC N
during IN N
a DT N
migraine JJ N
attack NN N
METHODS NNP N
On IN N
23 CD 3_p
migraineurs NNS N
showing VBG N
pain NN N
at IN N
pressure NN N
on IN N
scalp NN N
arteries NNS N
, , N
we PRP N
administered VBD N
topical JJ N
capsaicin NN N
0.1 CD N
% NN N
or CC N
vaseline NN N
jelly RB N
on IN N
painful JJ N
arteries NNS N
in IN N
absence NN N
of IN N
migraine JJ N
attack NN N
In IN N
those DT N
having VBG N
pain NN N
reduction NN N
> VBD N
50 CD N
% NN N
, , N
we PRP N
made VBD N
the DT N
same JJ N
comparison NN N
during IN N
a DT N
migraine JJ N
attack NN N
RESULTS NNP N
Topical NNP N
capsaicin NN N
caused VBD N
> JJ N
50 CD N
% NN N
reduction NN N
of IN N
arterial JJ N
pain NN N
in IN N
absence NN N
of IN N
attack NN N
in IN N
17/23 CD N
patients NNS N
, , N
as IN N
opposed VBN N
to TO N
two CD N
with IN N
vaseline NN N
During IN N
attacks NNS N
of IN N
mild- NN N
to TO N
moderate-intensity NN N
, , N
> VB N
50 CD N
% NN N
improvement NN N
was VBD N
obtained VBN N
in IN N
11/17 CD N
with IN N
capsaicin NN N
and CC N
in IN N
one CD N
with IN N
vaseline NN N
CONCLUSIONS NNP N
Although IN N
referring VBG N
to TO N
a DT N
small JJ N
number NN N
of IN N
patients NNS N
, , N
our PRP$ N
data NNS N
show VBP N
that IN N
topical JJ N
capsaicin NN N
may MD N
relieve VB N
arterial JJ N
pain NN N
in IN N
absence NN N
of IN N
and CC N
during IN N
a DT N
migraine JJ N
attack NN N
in IN N
a DT N
substantial JJ N
number NN N
of IN N
patients NNS N
experiencing VBG N
scalp JJ N
arterial JJ N
tenderness NN N
More RBR N
active JJ N
capsacinoids NNS N
might MD N
be VB N
tried VBN N
in IN N
the DT N
future NN N
and CC N
could MD N
provide VB N
a DT N
new JJ N
method NN N
for IN N
treating VBG N
migraine NN N
attacks NNS N
-DOCSTART- -X- O O 1990041

Treatment NN N
of IN N
beta-hemolytic JJ 4_p
streptococcal JJ 4_p
pharyngitis NN 4_p
with IN N
cefaclor NN N
or CC N
penicillin NN N
Efficacy NN N
and CC N
interaction NN N
with IN N
beta-lactamase-producing JJ N
organisms NNS N
in IN N
the DT N
pharynx NN N
The DT N
recommended JJ N
treatment NN N
for IN N
group NN 4_p
A NNP 4_p
beta-hemolytic JJ 4_p
streptococcal JJ 4_p
pharyngitis NN 4_p
has VBZ N
continued VBN N
to TO N
be VB N
penicillin JJ N
given VBN N
in IN N
parenteral JJ N
or CC N
oral JJ N
form NN N
Treatment NNP N
failures NNS N
, , N
as IN N
determined VBN N
by IN N
the DT N
continued JJ N
presence NN N
of IN N
the DT N
streptococcal JJ N
organism NN N
in IN N
the DT N
pharynx NN N
, , N
however RB N
, , N
do VBP N
occur VB N
in IN N
6 CD N
% NN N
to TO N
25 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
penicillin NN N
Furthermore RB N
, , N
beta-lactamase NN N
produced VBN N
by IN N
other JJ N
bacteria NNS N
in IN N
the DT N
pharynx NN N
could MD N
potentially RB N
inactivate VB N
the DT N
penicillin NN N
, , N
resulting VBG N
in IN N
increased VBN N
treatment NN N
failures NNS N
or CC N
infection NN N
relapses NNS N
A DT N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
cefaclor NN N
, , N
which WDT N
is VBZ N
relatively RB N
resistant JJ N
to TO N
inactivation VB N
by IN N
beta-lactamase NN N
, , N
with IN N
penicillin NN N
for IN N
eradicating VBG N
the DT N
group NN N
A DT N
beta-hemolytic JJ N
streptococcal JJ N
organism NN N
from IN N
the DT N
throats NNS N
of IN N
93 CD N
patients NNS N
with IN N
pharyngitis NN N
Additionally RB N
, , N
extensive JJ N
cultures NNS N
for IN N
potential JJ N
beta-lactamase-producing JJ N
organisms NNS N
were VBD N
conducted VBN N
on IN N
37 CD N
patients NNS N
; : N
27 CD N
% NN N
of IN N
these DT N
had VBD N
one CD N
or CC N
more JJR N
pharyngeal JJ N
organisms NNS N
that WDT N
were VBD N
producing VBG N
beta-lactamase NN N
No DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
clinical JJ N
responses NNS N
or CC N
the DT N
bacteriological JJ N
cure NN N
rates NNS N
of IN N
those DT N
treated VBN N
with IN N
cefaclor NN N
and CC N
those DT N
treated VBN N
with IN N
penicillin NN N
when WRB N
stratified VBN N
by IN N
the DT N
presence NN N
or CC N
absence NN N
of IN N
beta-lactamase-producing JJ N
organisms NNS N
The DT N
prevalence NN N
of IN N
beta-lactamase-producing JJ N
organisms NNS N
in IN N
the DT N
pharynx NN N
, , N
however RB N
, , N
was VBD N
increased VBN N
after IN N
treatment NN N
with IN N
penicillin NN N
, , N
whereas IN N
no DT N
change NN N
was VBD N
noted VBN N
following VBG N
treatment NN N
with IN N
cefaclor NN N
-DOCSTART- -X- O O 6122555

Comparison NNP N
of IN N
the DT N
antihypertensive JJ N
effect NN N
of IN N
metipranolol NN N
, , N
butizide NN N
and CC N
torrat NN N
in IN N
Kenyan NNP 4_p
Africans NNPS 4_p
-DOCSTART- -X- O O 8752181

Prediction NN N
of IN N
the DT N
infarct-related JJ N
artery NN N
in IN N
acute JJ N
myocardial JJ N
infarction NN N
by IN N
a DT N
scoring NN N
system NN N
using VBG N
summary JJ N
ST-segment JJ N
and CC N
T-wave JJ N
changes NNS N
We PRP N
developed VBD N
a DT N
scoring NN N
system NN N
to TO N
predict VB N
the DT N
artery NN N
responsible JJ N
for IN N
an DT N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
using VBG N
ST-segment JJ N
and CC N
T-wave JJ N
changes NNS N
on IN N
the DT N
initial JJ N
electrocardiogram NN N
( ( N
ECG NNP N
) ) N
using VBG N
data NNS N
from IN N
228 CD 3_p
patients NNS N
( ( N
development NN N
set VBN N
) ) N
with IN N
symptoms NNS N
compatible JJ N
with IN N
AMI NNP 4_p
and CC N
tested VBN N
in IN N
a DT N
similar JJ N
group NN N
of IN N
223 CD 3_p
patients NNS N
( ( N
test NN N
set VBN N
) ) N
from IN N
the DT N
Thrombolysis NNP N
and CC N
Angioplasty NNP N
in IN N
Myocardial NNP N
Infarction NNP N
( ( N
TAMI-5 NNP N
) ) N
Trial NNP N
Using VBG N
stepwise JJ N
logistic JJ N
regression NN N
we PRP N
were VBD N
able JJ N
to TO N
accurately RB N
predict VB N
the DT N
left NN N
anterior JJ N
descending NN N
( ( N
LAD NNP N
) ) N
, , N
right JJ N
, , N
or CC N
left VBD N
circumflex NN N
( ( N
LC NNP N
) ) N
coronary JJ N
artery NN N
as IN N
the DT N
infarct-related JJ N
artery NN N
using VBG N
2 CD N
variables NNS N
: : N
( ( N
1 CD N
) ) N
the DT N
summation NN N
of IN N
the DT N
ST-segment JJ N
elevation NN N
in IN N
leads VBZ N
V1 NNP N
to TO N
V4 NNP N
; : N
and CC N
( ( N
2 CD N
) ) N
the DT N
summation NN N
of IN N
the DT N
T-wave NNP N
negativity NN N
in IN N
leads NNS N
I PRP N
, , N
aVL RB N
, , N
and CC N
V5 NNP N
In IN N
the DT N
development NN N
set NN N
, , N
these DT N
2 CD N
variables NNS N
demonstrated VBD N
respective JJ N
sensitivity NN N
and CC N
specificity NN N
of IN N
98 CD N
% NN N
and CC N
90 CD N
% NN N
for IN N
LAD NNP N
lesions NNS N
, , N
82 CD N
% NN N
and CC N
85 CD N
% NN N
for IN N
right JJ N
narrowings NNS N
, , N
and CC N
82 CD N
% NN N
and CC N
84 CD N
% NN N
for IN N
LC NNP N
narrowings NNS N
In IN N
the DT N
test NN N
set NN N
, , N
the DT N
sensitivity NN N
and CC N
specificity NN N
were VBD N
97 CD N
% NN N
and CC N
95 CD N
% NN N
for IN N
LAD NNP N
lesions NNS N
, , N
85 CD N
% NN N
and CC N
86 CD N
% NN N
for IN N
right JJ N
lesions NNS N
, , N
and CC N
73 CD N
% NN N
and CC N
60 CD N
% NN N
for IN N
LC NNP N
coronary JJ N
artery NN N
lesions NNS N
Information NNP N
easily RB N
obtained VBD N
on IN N
the DT N
ECG NNP N
can MD N
accurately RB N
predict VB N
the DT N
likelihood NN N
of IN N
the DT N
LAD NNP N
, , N
right RB N
, , N
or CC N
LC NNP N
artery RB N
as IN N
the DT N
infarct-related JJ N
artery NN N
This DT N
may MD N
be VB N
useful JJ N
in IN N
the DT N
decision NN N
to TO N
administer VB N
thrombolytic JJ N
treatment NN N
-DOCSTART- -X- O O 25822242

Randomized VBN N
comparative JJ N
efficacy NN N
study NN N
of IN N
parent-mediated JJ N
interventions NNS N
for IN N
toddlers NNS 1_p
with IN N
autism NN 4_p
OBJECTIVE CC N
This DT N
study NN N
compared VBN N
effects NNS N
of IN N
two CD N
parent-mediated JJ N
interventions NNS N
on IN N
joint JJ N
engagement NN N
outcomes NNS N
as IN N
augmentations NNS N
of IN N
an DT N
early JJ N
intervention NN N
program NN N
for IN N
toddlers NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
METHOD NNP N
Participants NNP N
included VBD N
86 CD 3_p
toddlers NNS 1_p
( ( 1_p
range VB 1_p
22-36 JJ 1_p
months NNS 1_p
) ) 1_p
with IN N
ASD NNP 4_p
and CC N
their PRP$ N
primary JJ N
caregiver NN N
Caregiver-child JJ N
dyads NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
10 CD N
weeks NNS N
of IN N
hands-on JJ N
parent NN N
training NN N
in IN N
a DT N
naturalistic JJ N
, , N
developmental JJ N
behavioral JJ N
intervention NN N
( ( N
joint JJ N
attention NN N
, , N
symbolic JJ N
play NN N
, , N
engagement NN N
and CC N
regulation-JASPER NN N
) ) N
or CC N
a DT N
parent-only JJ N
psychoeducational JJ N
intervention NN N
( ( N
PEI NNP N
) ) N
Dose NNP N
was VBD N
controlled VBN N
in IN N
terms NNS N
of IN N
researcher-parent JJ N
contact NN N
and CC N
early JJ N
intervention NN N
services NNS N
received VBN N
by IN N
the DT N
child NN N
RESULTS JJ N
Results NNP N
yielded VBD N
significant JJ N
effects NNS N
of IN N
the DT N
JASPER NNP N
intervention NN N
on IN N
the DT N
primary JJ N
outcome NN N
of IN N
joint JJ N
engagement NN N
The DT N
treatment NN N
effect NN N
was VBD N
large JJ N
( ( N
Cohen NNP N
's POS N
f² NN N
= NNP N
.69 NNP N
) ) N
and CC N
maintained VBN N
over IN N
the DT N
6-month JJ N
follow-up NN N
JASPER NNP N
effects NNS N
were VBD N
also RB N
found VBN N
on IN N
secondary JJ N
outcomes NNS N
of IN N
play NN N
diversity NN N
, , N
highest JJS N
play NN N
level NN N
achieved VBN N
, , N
and CC N
generalization NN N
to TO N
the DT N
child NN N
's POS N
classroom NN N
for IN N
child-initiated JJ N
joint JJ N
engagement NN N
The DT N
PEI NNP N
intervention NN N
was VBD N
found VBN N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG N
parenting VBG N
stress NN N
associated VBN N
with IN N
child NN N
characteristics NNS N
All DT N
secondary JJ N
effects NNS N
were VBD N
generally RB N
small JJ N
to TO N
moderate VB N
CONCLUSIONS NNP N
These DT N
data NNS N
highlight VBD N
the DT N
benefit NN N
of IN N
a DT N
brief NN N
, , N
targeted VBN N
, , N
parent-mediated JJ N
intervention NN N
on IN N
child NN N
outcomes NNS N
Future JJ N
studies NNS N
may MD N
consider VB N
the DT N
combination NN N
of IN N
JASPER NNP N
and CC N
PEI NNP N
treatments NNS N
for IN N
optimal JJ N
parent NN N
and CC N
child NN N
outcomes NNS N
Trial JJ N
registry NN N
no DT N
NCT00999778 NNP N
-DOCSTART- -X- O O 17432640

[ JJ N
Clinical NNP N
observation NN N
on IN N
different JJ N
acupuncture NN N
and CC N
moxibustion NN N
therapies NNS N
for IN N
treatment NN N
of IN N
postsurgical JJ 4_p
gastroparesis NN 4_p
syndrome NN 4_p
] NNP 4_p
OBJECTIVE NNP N
To TO N
optimize VB N
therapy NN N
of IN N
acupuncture NN N
and CC N
moxibustion NN N
for IN N
postsurgical JJ 4_p
gastroparesis NN 4_p
syndrome NN 4_p
( ( 4_p
PGS NNP 4_p
) ) 4_p
METHODS NNP N
Forty-one JJ 3_p
cases NNS N
of IN N
PGS NNP 4_p
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
in IN N
order NN N
of IN N
visiting VBG N
Group NNP N
A NNP N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
were VBD N
treated VBN N
by IN N
warming VBG N
needle JJ N
moxibustion NN N
, , N
group NN N
B NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
by IN N
acupuncture NN N
plus CC N
auricular JJ N
point NN N
sticking NN N
, , N
and CC N
group NN N
C NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
by IN N
routine JJ N
acupuncture NN N
Changes NNS N
of IN N
gastric JJ N
drainage NN N
volume NN N
, , N
therapeutic JJ N
times NNS N
and CC N
cured JJ N
rate NN N
were VBD N
investigated VBN N
in IN N
the DT N
3 CD N
groups NNS N
RESULTS NNP N
All PDT N
the DT N
3 CD N
therapeutic JJ N
methods NNS N
could MD N
significantly RB N
decrease VB N
gastric JJ N
drainage NN N
volume NN N
The DT N
cured JJ N
rate NN N
was VBD N
100.0 CD N
% NN N
and CC N
the DT N
therapeutic JJ N
times NNS N
was VBD N
( ( N
7.24 CD N
+/- JJ N
3.87 CD N
) ) N
in IN N
the DT N
group NN N
A NNP N
, , N
66.7 CD N
% NN N
, , N
( ( N
9.83 CD N
+/- JJ N
4.60 CD N
) ) N
times NNS N
in IN N
the DT N
group NN N
B NNP N
and CC N
75.0 CD N
% NN N
, , N
( ( N
15.25 CD N
+/- JJ N
3.81 CD N
) ) N
times NNS N
in IN N
the DT N
group NN N
C NNP N
, , N
with IN N
significant JJ N
differences NNS N
in IN N
the DT N
cured JJ N
rate NN N
and CC N
the DT N
therapeutic JJ N
times NNS N
among IN N
the DT N
3 CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
CONCLUSION NNP N
The DT N
warming VBG N
needle JJ N
moxibustion NN N
is VBZ N
the DT N
best JJS N
method NN N
for IN N
PGS NNP 4_p
, , N
with IN N
less RBR N
therapeutic JJ N
times NNS N
, , N
high JJ N
cured VBN N
rate NN N
and CC N
rapid JJ N
effect NN N
-DOCSTART- -X- O O 6761890

Platelet NNP 4_p
inhibitory NN 4_p
drugs NNS 4_p
: : 4_p
an DT N
in IN N
vivo NN N
method NN N
of IN N
evaluation NN N
in IN N
patients NNS N
The DT N
measurement NN N
of IN N
platelet NN 4_p
deposition NN 4_p
in IN 4_p
human JJ 4_p
thrombi NN 4_p
is VBZ N
essential JJ N
for IN N
the DT N
evaluation NN N
of IN N
platelet-inhibitory JJ N
drugs NNS N
and CC N
prosthetic JJ N
materials NNS N
for IN N
use NN N
in IN N
patients NNS N
The DT N
rate NN N
of IN N
111Indium-labelled JJ N
platelet NN N
accumulation NN N
on IN N
Dacron NNP N
arterial JJ N
grafts NN N
was VBD N
measured VBN N
in IN N
27 CD 3_p
patients NNS 3_p
randomised VBD N
to TO N
take VB N
either DT N
aspirin NN N
and CC N
dipyridamole NN N
( ( N
ASA NNP N
+ NNP N
DPM NNP N
) ) N
or CC N
placebo NN N
Autologous JJ N
platelets NNS N
were VBD N
labelled VBN N
and CC N
re-injected JJ N
seven CD N
days NNS N
following VBG N
surgery NN N
and CC N
the DT N
graft NN N
thrombogenicity NN N
index NN N
calculated VBD N
as IN N
the DT N
daily JJ N
rise NN N
in IN N
the DT N
ratio NN N
of IN N
emissions NNS N
from IN N
the DT N
graft NN N
over IN N
a DT N
reference NN N
site NN N
The DT N
mean NN N
( ( N
+/- JJ N
SD NNP N
) ) N
thrombogenicity NN N
index NN N
in IN N
12 CD N
patients NNS N
undergoing JJ N
femoro-popliteal JJ N
bypass NN N
was VBD N
0.25 CD N
+/- JJ N
0.09 CD N
on IN N
placebo NN N
and CC N
0.16 CD N
+/- JJ N
0.07 CD N
on IN N
ASA NNP N
+ NNP N
DPM NNP N
started VBD N
pre-operatively RB N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
Post-operative JJ N
ASA NNP N
+ NNP N
DPM NNP N
therapy NN N
started VBD N
two CD N
days NNS N
following VBG N
platelet NN N
labelling VBG N
in IN N
15 CD N
patients NNS N
with IN N
aorto-femoral JJ N
grafts NNS N
also RB N
significantly RB N
reduce VB N
thrombogenicity NN N
to TO N
0.12 CD N
+/- JJ N
0.05 CD N
compared VBN N
with IN N
0.25 CD N
+/- JJ N
0.08 CD N
on IN N
placebo NN N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
In IN N
the DT N
latter JJ N
patients NNS N
the DT N
ratio NN N
of IN N
emissions NNS N
from IN N
the DT N
graft NN N
over IN N
reference NN N
fell VBD N
significantly RB N
on IN N
starting VBG N
ASA NNP N
+ NNP N
DPM NNP N
, , N
suggesting VBG N
a DT N
net JJ N
loss NN N
of IN N
platelets NNS N
from IN N
the DT N
graft NN N
These DT N
results NNS N
indicate VBP N
that IN N
the DT N
rate NN N
of IN N
in IN N
vivo JJ N
platelet NN N
accumulation NN N
on IN N
Dacron NNP N
grafts NNS N
can MD N
be VB N
quantitated VBN N
and CC N
that IN N
ASA NNP N
+ NNP N
DPM NNP N
reduced VBD N
this DT N
rate NN N
in IN N
man NN N
-DOCSTART- -X- O O 10889149

Atrophy NNP N
and CC N
intestinal JJ 4_p
metaplasia NN 4_p
one CD N
year NN N
after IN N
cure NN N
of IN N
H. NNP 4_p
pylori FW 4_p
infection NN 4_p
: : N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
BACKGROUND NNP N
& CC N
AIMS NNP N
Helicobacter NNP N
pylori-infected JJ N
gastric JJ N
mucosa NN N
evolves VBZ N
through IN N
stages NNS N
of IN N
chronic JJ N
gastritis NN N
, , N
intestinal JJ N
metaplasia NN N
( ( N
IM NNP N
) ) N
, , N
glandular JJ N
atrophy NN N
( ( N
GA NNP N
) ) N
, , N
and CC N
dysplasia NN N
before IN N
carcinoma NN N
develops NNS N
We PRP N
studied VBD N
if IN N
H. NNP N
pylori FW N
eradication NN N
would MD N
alter VB N
the DT N
course NN N
of IN N
premalignant JJ N
histologic NN N
changes NNS N
in IN N
the DT N
stomach NN N
METHODS NNP N
Volunteers NNPS N
from IN N
the DT N
Yantai NNP N
County NNP N
in IN N
China NNP N
underwent JJ N
upper JJ N
endoscopy NN N
with IN N
biopsy NN N
specimens NNS N
obtained VBN N
from IN N
the DT N
antrum NN N
and CC N
corpus NN N
H. NNP N
pylori-infected JJ N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
a DT N
1-week JJ N
course NN N
of IN N
omeprazole JJ N
, , N
amoxicillin NN N
, , N
and CC N
clarithromycin NN N
( ( N
OAC NNP N
) ) N
or CC N
placebo NN N
At IN N
1 CD N
year NN N
, , N
endoscopies NNS N
with IN N
biopsies NNS N
were VBD N
repeated VBN N
RESULTS VB N
A DT N
total NN N
of IN N
587 CD 3_p
H. NNP N
pylori-infected JJ N
subjects NNS N
were VBD N
randomized VBN N
to TO N
OAC NNP N
( ( N
n JJ N
= NNP N
295 CD N
) ) N
and CC N
placebo NN N
( ( N
n JJ N
= NNP N
292 CD N
) ) N
At IN N
1 CD N
year NN N
, , N
H. NNP N
pylori NN N
was VBD N
eradicated VBN N
in IN N
226 CD N
subjects NNS N
assigned VBN N
to TO N
OAC NNP N
In IN N
the DT N
placebo NN N
group NN N
, , N
245 CD 3_p
patients NNS N
remained VBD N
H. NNP N
pylori NN N
infected VBD N
Analysis NN N
of IN N
paired JJ N
samples NNS N
obtained VBN N
from IN N
the DT N
same JJ N
patients NNS N
showed VBD N
that IN N
acute NN N
and CC N
chronic JJ N
gastritis NN N
decreased VBN N
in IN N
both DT N
the DT N
antrum NN N
and CC N
corpus NN N
after IN N
H. NNP N
pylori FW N
eradication NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
activity NN N
of IN N
IM NNP N
decreased VBD N
in IN N
antrum NN N
( ( N
P NNP N
= NNP N
0.014 CD N
) ) N
In IN N
the DT N
H. NNP N
pylori-infected JJ N
group NN N
, , N
antral JJ N
biopsy NN N
specimens NNS N
had VBD N
more RBR N
pronounced JJ N
acute NN N
gastritis NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
whereas JJ N
corpus NN N
specimens NNS N
showed VBD N
increased VBN N
acute NN N
and CC N
chronic JJ N
gastritis NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
marginal JJ N
increase NN N
in IN N
GA NNP N
( ( N
P NNP N
= NNP N
0.052 CD N
) ) N
When WRB N
histologic JJ N
changes NNS N
were VBD N
compared VBN N
between IN N
the DT N
2 CD N
groups NNS N
, , N
decrease NN N
in IN N
acute NN N
and CC N
chronic JJ N
gastritis NN N
was VBD N
more RBR N
frequent JJ N
after IN N
H. NNP N
pylori FW N
eradication NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
but CC N
changes NNS N
in IN N
IM NNP N
were VBD N
similar JJ N
In IN N
the DT N
H. NNP N
pylori-infected JJ N
group NN N
, , N
increase NN N
in IN N
GA NNP N
was VBD N
seen VBN N
in IN N
the DT N
corpus NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
CONCLUSIONS NNP N
At IN N
1 CD N
year NN N
, , N
H. NNP N
pylori FW N
eradication NN N
is VBZ N
beneficial JJ N
in IN N
preventing VBG N
progression NN N
of IN N
pathologic JJ N
changes NNS N
of IN N
the DT N
gastric JJ N
mucosa NN N
-DOCSTART- -X- O O 7429786

Liquid JJ N
antacids NNS 4_p
: : 4_p
palatability NN N
and CC N
predictability NN N
study NN N
-DOCSTART- -X- O O 19324944

Acute JJ N
effects NNS N
of IN N
decaffeinated JJ N
coffee NN N
and CC N
the DT N
major JJ N
coffee NN N
components NNS N
chlorogenic JJ N
acid NN N
and CC N
trigonelline NN N
on IN N
glucose JJ 4_p
tolerance NN 4_p
OBJECTIVE NNP N
Coffee NNP N
consumption NN N
has VBZ N
been VBN N
associated VBN N
with IN N
lower JJR N
risk NN N
of IN N
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
We PRP N
evaluated VBD N
the DT N
acute JJ N
effects NNS N
of IN N
decaffeinated JJ N
coffee NN N
and CC N
the DT N
major JJ N
coffee NN N
components NNS N
chlorogenic JJ N
acid NN N
and CC N
trigonelline NN N
on IN N
glucose JJ N
tolerance NN N
RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
crossover NN N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
12 CD N
g NN N
decaffeinated VBD N
coffee NN N
, , N
1 CD N
g NN N
chlorogenic JJ N
acid NN N
, , N
500 CD N
mg NN N
trigonelline NN N
, , N
and CC N
placebo NN N
( ( N
1 CD N
g NN N
mannitol NN N
) ) N
on IN N
glucose NN N
and CC N
insulin NN N
concentrations NNS N
during IN N
a DT N
2-h JJ N
oral JJ N
glucose NN N
tolerance NN N
test NN N
( ( N
OGTT NNP N
) ) N
in IN N
15 CD 3_p
overweight JJ 4_p
men NNS 2_p
RESULTS NNP N
Chlorogenic NNP N
acid NN N
and CC N
trigonelline NN N
ingestion NN N
significantly RB N
reduced VBN N
glucose NN N
( ( N
-0.7 JJ N
mmol/l NN N
, , N
P NNP N
= NNP N
0.007 CD N
, , N
and CC N
-0.5 NNP N
mmol/l NN N
, , N
P NNP N
= NNP N
0.024 CD N
, , N
respectively RB N
) ) N
and CC N
insulin NN N
( ( N
-73 JJ N
pmol/l NN N
, , N
P NNP N
= NNP N
0.038 CD N
, , N
and CC N
-117 NNP N
pmol/l NN N
, , N
P NNP N
= NNP N
0.007 CD N
) ) N
concentrations NNS N
15 CD N
min NN N
following VBG N
an DT N
OGTT NNP N
compared VBN N
with IN N
placebo NN N
None NN N
of IN N
the DT N
treatments NNS N
affected VBD N
insulin NN N
or CC N
glucose JJ N
area NN N
under IN N
the DT N
curve NN N
values NNS N
during IN N
the DT N
OGTT NNP N
compared VBN N
with IN N
placebo NN N
CONCLUSIONS NNP N
Chlorogenic NNP N
acid NN N
and CC N
trigonelline NN N
reduced VBD N
early JJ N
glucose NN N
and CC N
insulin NN N
responses NNS N
during IN N
an DT N
OGTT NNP N
-DOCSTART- -X- O O 12233993

Examining VBG N
possible JJ N
gender NN N
differences NNS N
among IN N
cocaine-dependent JJ 4_p
outpatients NNS N
Potential JJ N
differences NNS N
in IN N
sociodemographics NNS N
, , N
drug NN N
use NN N
, , N
and CC N
measures NNS N
of IN N
treatment NN N
outcome NN N
were VBD N
examined VBN N
among IN N
137 CD 3_p
male NN 2_p
and CC N
51 CD 3_p
female JJ 2_p
cocaine-dependent JJ 4_p
outpatients NNS N
More JJR N
women NNS 2_p
than IN N
men NNS 2_p
were VBD N
unemployed JJ N
, , N
received VBD N
public JJ N
assistance NN N
, , N
and CC N
were VBD N
living VBG N
with IN N
their PRP$ N
children NNS N
Women NNP N
reported VBD N
fewer JJR N
years NNS N
of IN N
regular JJ N
cocaine NN N
use NN N
, , N
spending NN N
less JJR N
money NN N
per IN N
week NN N
on IN N
cocaine NN N
, , N
less JJR N
prior JJ N
treatment NN N
for IN N
cocaine NN N
abuse NN N
, , N
and CC N
were VBD N
more RBR N
likely JJ N
than IN N
men NNS N
to TO N
test VB N
positive JJ N
for IN N
cocaine NN N
at IN N
intake NN N
With IN N
respect NN N
to TO N
other JJ N
drug NN N
use NN N
, , N
fewer JJR N
women NNS N
than IN N
men NNS N
reported VBN N
using VBG N
sedatives NNS N
and CC N
tested VBD N
positive JJ N
for IN N
sedatives NNS N
at IN N
intake NN N
Women NNP N
reported VBD N
a DT N
lower JJR N
frequency NN N
of IN N
alcohol NN N
use NN N
before IN N
intake NN N
, , N
and CC N
fewer JJR N
women NNS N
than IN N
men NNS N
met VBD N
criteria NNS N
for IN N
cannabis NN N
dependence NN N
Men NNP N
and CC N
women NNS N
experienced VBD N
comparable JJ N
improvement NN N
during IN N
the DT N
course NN N
of IN N
treatment NN N
and CC N
follow-up NN N
-DOCSTART- -X- O O 2688237

[ NN N
EMLA NNP N
cream NN N
( ( N
lidocaine/prilocaine NN N
) ) N
versus NN N
infiltration NN N
analgesia NN N
with IN N
carbocaine NN N
( ( N
mepivacaine NN N
) ) N
in IN N
vasectomy NN N
] NN N
The DT N
analgesic JJ N
efficacy NN N
of IN N
EMLA NNP N
cream NN N
was VBD N
compared VBN N
with IN N
infiltration NN N
with IN N
1 CD N
% NN N
carbocaine NN N
in IN N
13 CD N
bilateral JJ N
vasectomies NNS N
Twelve CD N
patients NNS N
preferred JJ N
infiltration NN N
analgesia NN N
EMLA NNP N
analgesia NN N
was VBD N
only RB N
effective JJ N
in IN N
the DT N
skin NN N
, , N
and CC N
had VBD N
to TO N
be VB N
supplemented VBN N
as IN N
the DT N
incision NN N
reached VBD N
subcutaneous JJ N
tissue NN N
-DOCSTART- -X- O O 24626980

Short-term JJ N
speech-language NN N
intervention NN N
for IN N
children NNS 1_p
with IN N
disorders NNS 4_p
of IN 4_p
the DT 4_p
autism NN 4_p
spectrum NN 4_p
PURPOSE NNP N
To TO N
assess VB N
any DT N
changes NNS N
in IN N
the DT N
Functional NNP N
Communicative NNP N
Profile NNP N
( ( N
FCP NNP N
) ) N
and CC N
in IN N
the DT N
Social NNP N
Cognitive NNP N
Performance NNP N
( ( N
SCP NNP N
) ) N
of IN N
children NNS N
with IN N
Autism NNP N
Spectrum NNP N
Disorders NNP N
, , N
based VBN N
on IN N
two CD N
short JJ N
periods NNS N
of IN N
intervention NN N
METHODS NNP N
The DT N
study NN N
was VBD N
conducted VBN N
with IN N
21 CD N
children NNS N
with IN N
Autism NNP N
Spectrum NNP 4_p
Disorder NNP N
diagnoses NNS N
, , N
randomly RB N
allocated VBN N
into IN N
two CD N
groups NNS N
, , N
who WP N
received VBD N
the DT N
same JJ N
short-term JJ N
intervention NN N
types NNS N
( ( N
6 CD N
weeks NNS N
with IN N
the DT N
mother NN N
and CC N
6 CD N
weeks NNS N
with IN N
the DT N
support NN N
of IN N
an DT N
educational JJ N
software NN N
program NN N
) ) N
The DT N
intervention NN N
process NN N
was VBD N
conducted VBN N
by IN N
speech-language JJ N
pathologists NNS N
who WP N
were VBD N
part NN N
of IN N
a DT N
graduate NN N
program NN N
in IN N
this DT N
area NN N
RESULTS NNP N
Samples NNP N
of IN N
15-minute JJ N
interaction NN N
sessions NNS N
between IN N
the DT N
child NN N
and CC N
speech-language JJ N
pathologist NN N
were VBD N
used VBN N
to TO N
assess VB N
the DT N
changes NNS N
in IN N
the DT N
FCP NNP N
and CC N
the DT N
SCP NNP N
The DT N
statistic JJ N
analysis NN N
pointed VBD N
out RP N
differences NNS N
only RB N
in IN N
Group NNP N
1 CD N
for IN N
the DT N
variables NNS N
" VBP N
percentage NN N
of IN N
communicative JJ N
space NN N
used VBN N
" NNP N
and CC N
" NNP N
use NN N
of IN N
the DT N
mediating NN N
object JJ N
" NNP N
CONCLUSION NN N
With IN N
the DT N
intervention NN N
sessions NNS N
structured VBD N
over IN N
12 CD N
weeks NNS N
, , N
it PRP N
was VBD N
possible JJ N
to TO N
observe VB N
a DT N
few JJ N
changes NNS N
in IN N
the DT N
children NNS N
's POS N
FCP NNP N
and CC N
in IN N
the DT N
SCP NNP N
Therefore RB N
, , N
we PRP N
point VBP N
out RP N
the DT N
need NN N
for IN N
new JJ N
research NN N
studies NNS N
of IN N
longer JJR N
duration NN N
-DOCSTART- -X- O O 26678641

Efficacy NN N
of IN N
colchicine NN N
versus NN N
placebo NN N
for IN N
the DT N
treatment NN N
of IN N
pericardial JJ 4_p
effusion NN 4_p
after IN N
open-heart JJ 4_p
surgery NN 4_p
: : N
A DT N
randomized JJ N
, , N
placebo-controlled JJ N
trial NN N
BACKGROUND NNP N
Pericardial NNP 4_p
effusion NN 4_p
( ( 4_p
PE NNP 4_p
) ) 4_p
, , N
a DT N
common JJ N
complication NN N
after IN N
open-heart JJ N
surgery NN N
, , N
accounts NNS N
for IN N
50 CD N
% NN N
to TO N
85 CD N
% NN N
of IN N
patients NNS N
Although IN N
reversible JJ N
in IN N
most JJS N
of IN N
the DT N
cases NNS N
, , N
it PRP N
could MD N
be VB N
life NN N
threatening VBG N
in IN N
the DT N
occurrence NN N
of IN N
tamponade NN N
in IN N
large JJ N
effusions NNS N
We PRP N
aimed VBD N
to TO N
determine VB N
the DT N
therapeutic JJ N
efficacy NN N
of IN N
colchicine NN N
on IN N
PE NNP 4_p
after IN N
open-heart JJ 4_p
surgery NN 4_p
METHODS NNP N
The DT N
study NN N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
triple-blind JJ N
, , N
placebo-controlled JJ N
single-center JJ N
trial NN N
at IN N
Tehran NNP N
Heart NNP N
Center NNP N
A NNP N
total NN N
of IN N
149 CD 3_p
patients NNS N
with IN N
mild JJ 4_p
or CC 4_p
moderate JJ 4_p
PE NNP 4_p
in IN N
transthoracic NN N
echocardiography NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
1 CD N
mg/d NNS N
colchicine NN N
( ( N
n JJ N
= NNP N
74 CD N
) ) N
or CC N
1 CD N
tablet NN N
of IN N
placebo NN N
( ( N
n JJ N
= NNP N
75 CD N
) ) N
for IN N
2 CD N
weeks NNS N
and CC N
then RB N
underwent JJ N
follow-up JJ N
echocardiography NN N
RESULTS NNP N
Baseline NNP N
and CC N
clinical JJ N
characteristics NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
2 CD N
study NN N
groups NNS N
except IN N
for IN N
age NN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
and CC N
graft JJ N
numbers NNS N
( ( N
P NNP N
= NNP N
.005 NNP N
) ) N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
pretreatment NN N
and CC N
posttreatment NN N
PE NNP N
sizes VBZ N
between IN N
the DT N
2 CD N
study NN N
groups NNS N
( ( N
P NNP N
= NNP N
.440 NNP N
and CC N
.844 NNP N
, , N
respectively RB N
) ) N
Median JJ N
( ( N
25th-75th JJ N
percentiles NNS N
) ) N
of IN N
effusion NN N
changes NNS N
was VBD N
5 CD N
mm NN N
( ( N
1-7.6 JJ N
mm NN N
) ) N
in IN N
the DT N
colchicine NN N
group NN N
and CC N
5 CD N
mm NN N
( ( N
1-6.6 JJ N
mm NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
= NNP N
.932 NNP N
) ) N
Intervention NNP N
had VBD N
no DT N
significant JJ N
impact NN N
on IN N
pretreatment NN N
and CC N
posttreatment JJ N
effusion NN N
values NNS N
and CC N
changes NNS N
in IN N
isolated JJ N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
patients NNS N
( ( N
P NNP N
= NNP N
.607 NNP N
, , N
.539 NNP N
, , N
and CC N
.628 NNP N
, , N
respectively RB N
) ) N
After IN N
adjustment NN N
for IN N
possible JJ N
confounders NNS N
, , N
there EX N
was VBD N
still RB N
no DT N
significant JJ N
difference NN N
in IN N
postoperative JJ N
PE NNP N
between IN N
the DT N
2 CD N
study NN N
groups NNS N
( ( N
t JJ N
= NNP N
-0.285 NNP N
, , N
P NNP N
= NNP N
.776 NNP N
) ) N
CONCLUSION NNP N
We PRP N
concluded VBD N
that IN N
prescription NN N
of IN N
colchicine NN N
does VBZ N
not RB N
seem VB N
to TO N
be VB N
effective JJ N
in IN N
treatment NN N
of IN N
asymptomatic JJ N
postoperative JJ N
PE NNP 4_p
This DT N
could MD N
be VB N
justified VBN N
in IN N
case NN N
that IN N
the DT N
etiology NN N
of IN N
most JJS N
of IN N
the DT N
PEs NNP 4_p
might MD N
be VB N
contribution NN N
of IN N
noninflammatory JJ N
factors NNS N
which WDT N
are VBP N
better JJR N
to TO N
be VB N
dealt VBN N
with IN N
observational JJ N
approaches NNS N
-DOCSTART- -X- O O 16757200

Clinical JJ N
evaluation NN N
of IN N
the DT N
intraoral JJ N
fluoride NN N
releasing VBG N
system NN N
in IN N
radiation-induced JJ 4_p
xerostomic JJ 4_p
subjects NNS 4_p
Part CC N
2 CD N
: : N
Phase NN N
I PRP N
study VBP N
Radiation-induced JJ N
xerostomia NN N
can MD N
result VB N
in IN N
the DT N
rapid JJ N
onset NN N
and CC N
progression NN N
of IN N
dental JJ N
caries NNS N
in IN N
head NN N
and CC N
neck NN N
cancer NN N
patients NNS N
Topically RB N
applied VBN N
fluorides NNS N
have VBP N
been VBN N
successfully RB N
used VBN N
to TO N
inhibit VB N
the DT N
formation NN N
of IN N
dental JJ N
caries NNS N
in IN N
this DT N
population NN N
However RB N
, , N
because IN N
intensive JJ N
daily JJ N
self-application NN N
is VBZ N
required VBN N
, , N
compliance NN N
is VBZ N
an DT N
issue NN N
The DT N
intraoral JJ N
fluoride-releasing NN N
system NN N
( ( N
IFRS NNP N
) ) N
containing VBG N
a DT N
sodium NN N
fluoride NN N
core NN N
is VBZ N
a DT N
newly RB N
developed VBN N
, , N
sustained-release JJ N
, , N
passive JJ N
drug NN N
delivery NN N
system NN N
that WDT N
does VBZ N
not RB N
require VB N
patient JJ N
involvement NN N
except IN N
for IN N
periodic JJ N
replacement NN N
, , N
thus RB N
reducing VBG N
the DT N
effect NN N
of IN N
patient NN N
compliance NN N
on IN N
its PRP$ N
effectiveness NN N
in IN N
dental JJ N
caries NNS N
prevention NN N
Twenty-two JJ 3_p
head NN 3_p
and CC 3_p
neck NN 3_p
cancer NN 3_p
patients NNS 3_p
from IN 3_p
U. NNP 3_p
T. NNP N
M. NNP N
D. NNP N
Anderson NNP N
Cancer NNP N
Center NNP N
, , N
with IN N
radiation-induced JJ N
xerostomia NN N
, , N
were VBD N
entered VBN N
into IN N
a DT N
pilot NN N
study NN N
to TO N
contrast VB N
the DT N
daily JJ N
home NN N
use NN N
of IN N
a DT N
0.4 CD N
% NN N
stannous JJ N
fluoride-gel-containing JJ N
tray NN N
( ( N
control VB N
group NN N
) ) N
to TO N
IFRS NNP N
( ( N
study VB N
group NN N
) ) N
with IN N
respect NN N
to TO N
tolerability NN N
and CC N
adherence NN N
, , N
and CC N
to TO N
obtain VB N
information NN N
on IN N
relative JJ N
caries NNS N
preventive VBP N
efficacy NN N
Participants NNS N
were VBD N
stratified VBN N
on IN N
the DT N
basis NN N
of IN N
radiation NN N
exposure NN N
and CC N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
either DT N
IFRS NNP N
or CC N
stannous JJ N
fluoride JJ N
gel NN N
Patients NNS 4_p
in IN 4_p
both DT 4_p
groups NNS 4_p
were VBD N
fitted VBN N
with IN N
two CD N
IFRS NNP N
retainers NNS N
and CC N
also RB N
were VBD N
instructed VBN N
to TO N
use VB N
a DT N
1100-ppm JJ N
fluoride JJ N
conventional JJ N
sodium NN N
fluoride NN N
dentifrice NN N
twice RB N
daily RB N
The DT N
study NN N
was VBD N
conducted VBN N
as IN N
a DT N
single-blinded JJ N
, , N
parallel-cell JJ N
trial NN N
Pre-existing NNP N
carious JJ N
lesions NNS N
were VBD N
restored VBN N
prior RB N
to TO N
the DT N
beginning NN N
of IN N
the DT N
study NN N
The DT N
efficacy NN N
variable NN N
was VBD N
determined VBN N
by IN N
the DT N
mean JJ N
number NN N
of IN N
new JJ N
or CC N
recurrent JJ N
decayed JJ N
surfaces NNS N
Patients NNS N
were VBD N
examined VBN N
for IN N
caries NNS N
4 CD N
, , N
8 CD N
, , N
12 CD N
, , N
24 CD N
, , N
36 CD N
, , N
and CC N
48 CD N
weeks NNS N
after IN N
initiation NN N
of IN N
treatment NN N
Reports NNS N
of IN N
adverse JJ N
reactions NNS N
were VBD N
based VBN N
on IN N
information NN N
volunteered VBN N
by IN N
patients NNS N
and CC N
that WDT N
were VBD N
elicited VBN N
during IN N
interviews NNS N
At IN N
baseline NN N
, , N
the DT N
resting NN N
and CC N
stimulated VBD N
salivary JJ N
flow NN N
rates NNS N
( ( N
g/5min NN N
) ) N
were VBD N
significantly RB N
greater JJR N
in IN N
the DT N
control NN N
group NN N
than IN N
in IN N
the DT N
study NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
Patients NNS 4_p
in IN 4_p
the DT 4_p
control NN 4_p
group NN 4_p
had VBD N
received VBN N
significantly RB N
more JJR N
radiation NN N
than IN N
those DT N
in IN N
the DT N
test NN N
group NN N
( ( N
68Gy CD N
vs. IN N
60Gy CD N
; : N
p=0.047 NN N
) ) N
No DT N
marked JJ N
differences NNS N
in IN N
follow-up JJ N
new JJ N
and CC N
recurrent JJ N
caries NNS N
were VBD N
found VBN N
between IN N
the DT N
stannous JJ N
fluoride JJ N
gel NN N
control NN N
and CC N
IFRS NNP N
groups NNS N
during IN N
the DT N
study NN N
period NN N
The DT N
rate NN N
of IN N
new JJ N
or CC N
recurrent JJ N
carious JJ N
lesions NNS N
in IN N
the DT N
group NN N
treated VBD N
with IN N
the DT N
fluoride NN N
gel NN N
was VBD N
slightly RB N
lower JJR N
than IN N
in IN N
the DT N
IFRS NNP N
group NN N
, , N
based VBN N
on IN N
carious JJ N
lesions NNS N
at IN N
the DT N
baseline NN N
examination NN N
( ( N
Poisson NNP N
mean VBP N
number NN N
of IN N
new JJ N
or CC N
recurrent JJ N
carious JJ N
lesions NNS N
for IN N
the DT N
control NN N
group=0.55 NN N
per IN N
year NN N
vs. FW N
0.83 CD N
per IN N
year NN N
for IN N
the DT N
study NN N
group NN N
, , N
p=0.705 NN N
; : N
odds NNS N
ratio NN N
of IN N
the DT N
occurrence NN N
of IN N
any DT N
new JJ N
or CC N
recurrent JJ N
caries NNS N
during IN N
follow-up JJ N
for IN N
control NN N
group NN N
vs. FW N
the DT N
study NN N
group=0.80 NN N
; : N
p=0.781 NN N
) ) N
This DT N
pilot NN N
study NN N
revealed VBD N
that IN N
the DT N
IFRS NNP N
was VBD N
well-tolerated JJ N
and CC N
safe JJ N
in IN N
this DT N
study NN N
population NN N
associated VBN N
with IN N
minimal JJ N
complications NNS N
during IN N
the DT N
duration NN N
of IN N
this DT N
study NN N
and CC N
was VBD N
comparable JJ N
in IN N
efficacy NN N
to TO N
a DT N
SnF NNP N
( ( N
2 CD N
) ) N
gel NN N
in IN N
preventing VBG N
caries NNS N
development NN N
The DT N
IFRS NNP N
provided VBD N
similar JJ N
rates NNS N
of IN N
control NN N
for IN N
caries NNS N
formation NN N
to TO N
a DT N
fluoride-gel-containing JJ N
tray NN N
The DT N
IFRS NNP N
is VBZ N
designed VBN N
to TO N
release VB N
a DT N
daily JJ N
dose NN N
of IN N
0.12mg CD N
of IN N
sodium NN N
fluoride NN N
, , N
which WDT N
can MD N
be VB N
evenly RB N
distributed VBN N
throughout IN N
the DT N
oral JJ N
cavity NN N
for IN N
a DT N
single JJ N
application NN N
of IN N
4 CD N
months NNS N
It PRP N
would MD N
be VB N
more RBR N
convenient JJ N
than IN N
the DT N
daily JJ N
home NN N
application NN N
of IN N
a DT N
tray NN N
of IN N
0.4 CD N
% NN N
stannous JJ N
fluoride NN N
or CC N
1.1 CD N
% NN N
sodium NN N
fluoride NN N
gel NN N
, , N
and CC N
avoids VBZ N
the DT N
problem NN N
of IN N
variable JJ N
patient NN N
compliance NN N
-DOCSTART- -X- O O 25056444

Prior JJ N
experience NN N
with IN N
a DT N
pain NN 4_p
stimulus NN 4_p
as IN N
a DT N
predictor NN N
of IN N
placebo NN N
analgesia NN N
Placebo NNP N
effects NNS N
are VBP N
important JJ N
in IN N
pain NN N
reduction NN N
, , N
but CC N
the DT N
effects NNS N
are VBP N
inconsistent JJ N
Prior JJ N
experience NN N
with IN N
a DT N
pain NN N
stimulus NN N
may MD N
moderate VB N
placebo NN N
analgesia NN N
The DT N
current JJ N
study NN N
tests VBZ N
the DT N
effect NN N
of IN N
prior JJ N
experience NN N
with IN N
a DT N
pain NN N
stimulus NN N
on IN N
placebo NN N
analgesia NN N
during IN N
a DT N
laboratory NN N
pain NN N
task NN N
Healthy NNP N
normotensive JJ N
undergraduates NNS 1_p
( ( N
66 CD 3_p
women NNS 2_p
, , N
68 CD 3_p
men NNS 2_p
) ) N
who WP N
either DT N
did VBD N
or CC N
did VBD N
not RB N
report VB N
prior JJ N
experience NN N
with IN N
pain NN N
from IN N
submerging VBG N
a DT N
limb NN N
in IN N
cold JJ N
water NN N
were VBD N
enrolled VBN N
In IN N
the DT N
laboratory NN N
, , N
an DT N
experimenter NN N
applied VBD N
an DT N
inert NN N
, , N
medicinal-smelling JJ N
cream NN N
to TO N
participants NNS N
' POS N
non-dominant JJ N
hand NN N
Participants NNS N
randomized VBD N
to TO N
the DT N
no-expectation JJ N
group NN N
were VBD N
told VBN N
that IN N
the DT N
cream NN N
was VBD N
a DT N
hand NN N
cleanser NN N
Participants NNS N
randomized VBD N
to TO N
the DT N
placebo NN N
expectation NN N
group NN N
were VBD N
told VBN N
that IN N
the DT N
cream NN N
would MD N
reduce VB N
the DT N
pain NN N
associated VBN N
with IN N
the DT N
cold JJ N
pressor NN N
task NN N
Participants NNS N
then RB N
completed VBD N
the DT N
cold JJ N
pressor NN N
task NN N
and CC N
reported VBD N
their PRP$ N
pain NN N
on IN N
the DT N
short JJ N
form NN N
of IN N
the DT N
McGill NNP N
Pain NNP N
Questionnaire NNP N
Analysis NN N
of IN N
variance NN N
revealed VBD N
a DT N
main JJ N
effect NN N
of IN N
expectation NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
, , N
such JJ N
that IN N
participants NNS N
in IN N
the DT N
placebo NN N
expectation NN N
group NN N
reported VBD N
less JJR N
pain NN N
An DT N
interaction NN N
was VBD N
also RB N
found VBN N
between IN N
expectation NN N
and CC N
prior JJ N
experience NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
, , N
such JJ N
that IN N
participants NNS N
with IN N
prior JJ N
experience NN N
with IN N
pain NN N
from IN N
cold JJ N
water NN N
immersion NN N
showed VBD N
no DT N
difference NN N
in IN N
pain NN N
reports NNS N
between IN N
expectation NN N
groups NNS N
In IN N
a DT N
pain NN N
context NN N
, , N
prior JJ N
experience NN N
with IN N
the DT N
pain NN 4_p
stimulus NN 4_p
may MD N
prevent VB N
a DT N
placebo JJ N
expectation NN N
from IN N
reducing VBG N
the DT N
experience NN N
of IN N
pain NN N
-DOCSTART- -X- O O 19169102

Elastic JJ N
stable JJ N
intramedullary JJ N
nailing VBG N
versus NN N
nonoperative JJ N
treatment NN N
of IN N
displaced JJ 4_p
midshaft NN 4_p
clavicular JJ 4_p
fractures-a JJ 4_p
randomized VBN N
, , N
controlled VBN N
, , N
clinical JJ N
trial NN N
OBJECTIVE UH N
To TO N
compare VB N
elastic JJ N
stable JJ N
intramedullary JJ N
nailing NN N
( ( N
ESIN NNP N
) ) N
with IN N
nonoperative JJ N
treatment NN N
of IN N
fully RB N
displaced VBN N
midshaft NN N
clavicular NN N
fractures NNS N
in IN N
adults NNS N
DESIGN VB N
The DT N
study NN N
was VBD N
a DT N
randomized JJ N
, , N
controlled VBN N
, , N
clinical JJ N
trial NN N
SETTING NNP N
Level NNP 4_p
1 CD 4_p
trauma NN 4_p
center NN N
PATIENTS NNP N
AND CC N
METHODS NNP N
Sixty NNP 3_p
patients NNS N
between IN N
18 CD 1_p
and CC 1_p
65 CD 1_p
years NNS 1_p
of IN N
age NN N
participated VBN N
and CC N
completed VBN N
the DT N
study NN N
They PRP N
were VBD N
randomized VBN N
to TO N
either DT N
operative JJ N
or CC N
nonoperative JJ N
treatment NN N
with IN N
a DT N
2-year JJ N
follow-up NN N
INTERVENTION NNP N
Thirty NNP N
patients NNS N
were VBD N
treated VBN N
with IN N
a DT N
simple JJ N
shoulder NN N
sling NN N
and CC N
30 CD N
patients NNS N
with IN N
ESIN NNP N
within IN N
3 CD N
days NNS N
after IN N
trauma NN N
MAIN NNP N
OUTCOME NNP N
MEASUREMENT NNP N
Complications NNP N
after IN N
operative JJ N
and CC N
nonoperative JJ N
treatments NNS N
, , N
Disabilities NNS N
of IN N
the DT N
Arm NNP N
, , N
Shoulder NNP N
and CC N
Hand NNP N
( ( N
DASH NNP N
) ) N
score NN N
and CC N
Constant JJ N
Shoulder NNP N
Score NNP N
for IN N
outcome JJ N
measurement NN N
, , N
and CC N
clavicular JJ N
shortening NN N
RESULTS NNP N
Fracture NNP N
union NN N
was VBD N
achieved VBN N
in IN N
all DT N
patients NNS N
in IN N
the DT N
operative JJ N
group NN N
, , N
whereas IN N
nonunion NN N
was VBD N
observed VBN N
in IN N
3 CD N
of IN N
30 CD N
patients NNS N
of IN N
the DT N
nonoperative JJ N
group NN N
Two CD N
symptomatic JJ N
malunions NNS N
required VBN N
corrective JJ N
osteotomy NN N
in IN N
the DT N
nonoperative JJ N
group NN N
Medial NNP N
nail JJ N
protrusion NN N
occurred VBD N
in IN N
7 CD N
cases NNS N
in IN N
the DT N
operative JJ N
group NN N
Implant JJ N
failure NN N
with IN N
revision NN N
surgery NN N
was VBD N
necessary JJ N
in IN N
2 CD N
patients NNS N
after IN N
an DT N
additional JJ N
adequate NN N
trauma NN N
DASH NNP N
scores NNS N
were VBD N
lower JJR N
in IN N
the DT N
operative JJ N
group NN N
throughout IN N
the DT N
first JJ N
6 CD N
months NNS N
and CC N
2 CD N
years NNS N
after IN N
trauma NN N
, , N
with IN N
a DT N
significant JJ N
difference NN N
during IN N
the DT N
first JJ N
18 CD N
weeks NNS N
Constant JJ N
scores NNS N
were VBD N
significantly RB N
higher JJR N
after IN N
6 CD N
months NNS N
and CC N
2 CD N
years NNS N
after IN N
intramedullary JJ N
stabilization NN N
Patients NNS N
in IN N
the DT N
operative JJ N
group NN N
showed VBD N
a DT N
significant JJ N
improvement NN N
of IN N
posttraumatic JJ N
clavicular JJ N
shortening NN N
; : N
they PRP N
were VBD N
also RB N
more RBR N
satisfied JJ N
with IN N
cosmetic JJ N
appearance NN N
and CC N
overall JJ N
outcome NN N
CONCLUSIONS NNP N
ESIN NNP N
of IN N
displaced JJ N
midshaft NN N
clavicular NN N
fractures NNS N
resulted VBD N
in IN N
a DT N
lower JJR N
rate NN N
of IN N
nonunion NN N
and CC N
delayed VBN N
union NN N
, , N
a DT N
faster JJR N
return NN N
to TO N
daily JJ N
activities NNS N
, , N
and CC N
a DT N
better JJR N
functional JJ N
outcome NN N
Clavicular JJ N
shortening NN N
was VBD N
significantly RB N
lower JJR N
, , N
and CC N
overall JJ N
satisfaction NN N
was VBD N
higher RBR N
in IN N
the DT N
operative JJ N
group NN N
-DOCSTART- -X- O O 19353317

Bridge NNP N
plate NN N
osteosynthesis NN N
using VBG N
dynamic JJ N
condylar JJ N
screw NN N
( ( N
DCS NNP N
) ) N
or CC N
retrograde VBN N
intramedullary JJ N
supracondylar JJ N
nail NN N
( ( N
RIMSN NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
distal JJ 4_p
femoral JJ 4_p
fractures NNS 4_p
: : N
comparison NN N
of IN N
two CD N
methods NNS N
in IN N
a DT N
prospective JJ N
randomized NN N
study NN N
BACKGROUND NNP N
The DT N
treatment NN N
of IN N
distal JJ 4_p
femoral JJ 4_p
fractures NNS 4_p
remains VBZ N
a DT N
significant JJ N
surgical JJ N
challenge NN N
With IN N
the DT N
rigid JJ N
fixation NN N
of IN N
the DT N
distal JJ N
femoral JJ N
fractures NNS N
, , N
bone NN N
grafting NN N
is VBZ N
frequently RB N
needed VBN N
Biological JJ N
osteosynthesis NN N
using VBG N
dynamic JJ N
condylar JJ N
screw NN N
( ( N
DCS NNP N
) ) N
and CC N
retrograde JJ N
intramedullary JJ N
supracondylar NN N
nail NN N
( ( N
RIMSN NNP N
) ) N
preserve VBP N
the DT N
blood NN N
supply NN N
and CC N
limit NN N
the DT N
need NN N
for IN N
bone NN N
grafting NN N
METHODS NNP N
From IN N
September NNP N
2002 CD N
to TO N
December NNP N
2004 CD N
, , N
68 CD 3_p
closed VBD N
fractures NNS 4_p
of IN 4_p
the DT 4_p
distal JJ 4_p
femur NN 4_p
were VBD N
treated VBN N
by IN N
bridge NN N
plate NN N
osteosynthesis NN N
using VBG N
DCS NNP N
in IN N
31 CD 3_p
and CC N
RIMSN NNP N
in IN N
37 CD 3_p
The DT N
patients NNS N
were VBD N
allocated VBN N
to TO N
one CD N
of IN N
the DT N
two CD N
groups NNS N
randomly RB N
and CC N
followed VBD N
for IN N
24-36 JJ N
months NNS N
( ( N
average JJ N
: : N
30 CD N
months NNS N
) ) N
RESULTS VBN N
With IN N
respect NN N
to TO N
operation NN N
time NN N
, , N
the DT N
DCS NNP N
group NN N
presented VBD N
significantly RB N
better JJR N
results NNS N
than IN N
the DT N
RIMSN NNP N
group NN N
( ( N
p=0.000 NN N
) ) N
However RB N
, , N
the DT N
blood NN N
loss NN N
was VBD N
significantly RB N
more RBR N
in IN N
the DT N
DCS NNP N
group NN N
( ( N
p=0.000 NN N
) ) N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
terms NNS N
of IN N
cumulative JJ N
rate NN N
of IN N
union NN N
( ( N
p=0.855 NN N
) ) N
, , N
range NN N
of IN N
motion NN N
of IN N
the DT N
knee NN N
( ( N
p=0.727 NN N
) ) N
, , N
overall JJ N
results NNS N
( ( N
p=0.925 NN N
) ) N
and CC N
complications NNS N
( ( N
p=0.927 NN N
) ) N
between IN N
the DT N
two CD N
groups NNS N
CONCLUSION NNP N
No NNP N
implant NN N
or CC N
surgical JJ N
technique NN N
is VBZ N
superior JJ N
to TO N
any DT N
other JJ N
under IN N
all DT N
circumstances NNS N
for IN N
distal JJ N
femoral JJ N
fracture NN N
RIMSN NNP N
is VBZ N
standard JJ N
care NN N
, , N
yet RB N
the DT N
biological JJ N
osteosynthesis NN N
using VBG N
DCS NNP N
is VBZ N
a DT N
very RB N
good JJ N
alternative NN N
for IN N
the DT N
treatment NN N
of IN N
distal JJ 4_p
femoral JJ 4_p
fractures NNS 4_p
-DOCSTART- -X- O O 6148879

A DT N
comparison NN N
of IN N
propranolol NN N
and CC N
nadolol JJ N
pharmacokinetics NNS N
and CC N
clinical JJ N
effects NNS N
in IN N
thyrotoxicosis NN 4_p
For IN N
a DT N
comparison NN N
of IN N
propranolol NN N
and CC N
nadolol JJ N
pharmacokinetics NNS N
and CC N
clinical JJ N
effects NNS N
, , N
20 CD 4_p
newly RB 4_p
diagnosed VBN 4_p
patients NNS 4_p
with IN 4_p
thyrotoxicosis NN 4_p
were VBD N
randomly RB N
selected VBN N
to TO N
receive VB N
as IN N
sole JJ N
therapy NN N
, , N
either DT N
propranolol NN N
, , N
40 CD N
mg NN N
every DT N
6 CD N
hours NNS N
for IN N
14 CD N
days NNS N
, , N
or CC N
nadolol RB N
, , N
80 CD N
mg NNS N
each DT N
morning NN N
for IN N
14 CD N
days NNS N
The DT N
study NN N
was VBD N
repeated VBN N
when WRB N
the DT N
patients NNS N
were VBD N
in IN N
the DT N
euthyroid JJ N
state NN N
There EX N
was VBD N
a DT N
similar JJ N
and CC N
highly RB N
significant JJ N
degree NN N
of IN N
beta NN N
blockade NN N
and CC N
amelioration NN N
of IN N
symptoms NNS N
of IN N
thyrotoxicosis NN N
at IN N
the DT N
end NN N
of IN N
the DT N
dosage NN N
interval NN N
( ( N
trough IN N
) ) N
, , N
i.e. FW N
, , N
24 CD N
hours NNS N
after IN N
nadolol NN N
or CC N
6 CD N
to TO N
8 CD N
hours NNS N
after IN N
propranolol NN N
Trough NNP N
and CC N
peak VB N
serum NN N
levels NNS N
of IN N
propranolol NN N
were VBD N
significantly RB N
lower JJR N
when WRB N
the DT N
patients NNS N
were VBD N
in IN N
a DT N
thyrotoxic NN N
state NN N
than IN N
when WRB N
they PRP N
were VBD N
in IN N
a DT N
euthyroid JJ N
state NN N
, , N
whereas IN N
the DT N
pharmacokinetics NNS N
of IN N
nadolol NNS N
were VBD N
not RB N
appreciably RB N
altered VBN N
by IN N
thyrotoxicosis NN N
In IN N
thyrotoxicosis NN N
, , N
trough IN N
levels NNS N
of IN N
propranolol NN N
and CC N
nadolol NN N
were VBD N
significantly RB N
inversely RB N
correlated VBN N
with IN N
derived JJ N
creatinine JJ N
clearance NN N
values NNS N
In IN N
the DT N
symptomatic JJ 4_p
treatment NN 4_p
of IN 4_p
thyrotoxicosis NN 4_p
, , N
nadolol RB N
, , N
a DT N
once-daily JJ N
nonmetabolized JJ N
beta NN N
blocker NN N
, , N
has VBZ N
certain JJ N
advantages NNS N
compared VBN N
with IN N
propranolol NN N
It PRP N
is VBZ N
preferred VBN N
by IN N
patients NNS N
, , N
is VBZ N
more RBR N
convenient JJ N
, , N
and CC N
probably RB N
aids NNS N
compliance NN N
-DOCSTART- -X- O O 20332358

The DT N
role NN N
of IN N
adjunctive JJ N
exenatide NN N
therapy NN N
in IN N
pediatric JJ 1_p
type NN 4_p
1 CD 4_p
diabetes NNS 4_p
OBJECTIVE NNP N
Exenatide NNP N
improves VBZ N
postprandial JJ N
glycemic JJ N
excursions NNS N
in IN N
type NN N
2 CD N
diabetes NNS N
Exenatide NNP N
could MD N
benefit VB N
type JJ N
1 CD N
diabetes NNS N
as RB N
well RB N
We PRP N
aimed VBD N
to TO N
determine VB N
an DT N
effective JJ N
and CC N
safe JJ N
glucose-lowering NN N
adjuvant JJ N
exenatide NN N
dose NN N
in IN N
adolescents NNS 1_p
with IN N
type JJ 4_p
1 CD 4_p
diabetes NNS 4_p
RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Eight NNP 3_p
subjects NNS N
completed VBD N
a DT N
three-part JJ N
double-blinded JJ N
randomized VBN N
controlled VBN N
study NN N
of IN N
premeal JJ N
exenatide NN N
Two CD N
doses NNS N
of IN N
exenatide NN N
( ( N
1.25 CD N
and CC N
2.5 CD N
microg NN N
) ) N
were VBD N
compared VBN N
with IN N
insulin NN N
monotherapy NN N
Prandial JJ N
insulin NN N
dose NN N
was VBD N
reduced VBN N
by IN N
20 CD N
% NN N
Gastric NNP N
emptying VBG N
and CC N
hormones NNS N
were VBD N
analyzed VBN N
for IN N
300 CD N
min JJ N
postmeal NN N
RESULTS NNP N
Treatment NNP N
with IN N
both DT N
doses NNS N
of IN N
exenatide JJ N
versus NN N
insulin NN N
monotherapy NN N
significantly RB N
reduced VBD N
glucose JJ N
excursions NNS N
over IN N
300 CD N
min NNS N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
Exenatide NNP N
administration NN N
failed VBD N
to TO N
suppress VB N
glucagon NN N
but CC N
delayed VBD N
gastric JJ N
emptying NN N
( ( N
P NNP N
< NNP N
0.004 CD N
) ) N
CONCLUSIONS NNP N
Adjunctive NNP N
exenatide NN N
therapy NN N
reduces VBZ N
postprandial JJ N
hyperglycemia NN N
in IN N
adolescents NNS 1_p
with IN N
type JJ N
1 CD N
diabetes NNS N
This DT N
reduction NN N
in IN N
glucose JJ N
excursion NN N
occurs VBZ N
despite IN N
reduction NN N
in IN N
insulin NN N
dose NN N
We PRP N
suggest VBP N
that DT N
exenatide NN N
has VBZ N
therapeutic JJ N
potential NN N
as IN N
adjunctive JJ N
therapy NN N
in IN N
type NN N
1 CD N
diabetes NNS N
-DOCSTART- -X- O O 18328868

Randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
Behavioral NNP N
Family NNP N
Systems NNP N
Therapy NNP N
for IN N
Diabetes NNPS 4_p
: : 4_p
maintenance NN N
and CC N
generalization NN N
of IN N
effects NNS N
on IN N
parent-adolescent JJ N
communication NN N
We PRP N
report VBP N
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
revised JJ N
Behavioral NNP N
Family NNP N
Systems NNP N
Therapy NNP N
for IN N
Diabetes NNP N
( ( N
BFST-D NNP N
) ) N
intervention NN N
Families NNS N
of IN N
104 CD 3_p
adolescents NNS 1_p
with IN N
diabetes NNS 4_p
were VBD N
randomized VBN N
to TO N
standard VB N
care NN N
( ( N
SC NNP N
) ) N
or CC N
to TO N
6 CD N
months NNS N
of IN N
an DT N
educational JJ N
support NN N
group NN N
( ( N
ES NNP N
) ) N
or CC N
BFST-D. JJ N
Family NNP N
communication NN N
and CC N
problem-solving JJ N
skills NNS N
were VBD N
assessed VBN N
at IN N
0 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
months NNS N
by IN N
independent JJ N
rating NN N
of IN N
videotaped JJ N
family NN N
problem-solving JJ N
discussions NNS N
BFST-D NNP N
improved VBD N
individual JJ N
communication NN N
of IN N
adolescents NNS N
and CC N
mothers NNS N
, , N
but CC N
not RB N
fathers NNS N
BFST-D NNP N
significantly RB N
improved VBD N
quality NN N
of IN N
family NN N
interaction NN N
compared VBN N
to TO N
SC NNP N
( ( N
10 CD N
of IN N
12 CD N
comparisons NNS N
) ) N
and CC N
ES NNP N
( ( N
6 CD N
of IN N
12 CD N
comparisons NNS N
) ) N
Changes NNS N
in IN N
family NN N
communication NN N
were VBD N
differentially RB N
associated VBN N
with IN N
changes NNS N
in IN N
glycemic JJ N
control NN N
, , N
adherence NN N
, , N
and CC N
family NN N
conflict NN N
BFST-D NNP N
improved VBD N
family NN N
communication NN N
and CC N
problem NN N
solving VBG N
relative JJ N
to TO N
SC NNP N
and CC N
modestly RB N
relative JJ N
to TO N
ES NNP N
-DOCSTART- -X- O O 8823584

One CD N
quadrant JJ N
sub-Tenon NN N
's POS N
capsule NN N
anesthesia NN N
in IN N
anterior JJ 4_p
segment NN 4_p
surgery NN 4_p
Reports NNS N
of IN N
complications NNS N
associated VBN N
with IN N
local JJ N
anesthesia NN N
in IN N
ophthalmic JJ 4_p
surgery NN 4_p
have VBP N
increased VBN N
conspicuously RB N
in IN N
recent JJ N
years NNS N
Sub-Tenon NNP N
's POS N
capsule NN N
anesthesia NN N
for IN N
anterior JJ N
segment NN N
surgery NN N
avoids IN N
the DT N
risks NNS N
of IN N
retrobulbar NN N
and CC N
peribulbar NN N
injections NNS N
This DT N
study NN N
compared VBN N
sub-Tenon NN N
's POS N
and CC N
retrobulbar NN N
anesthesia NN N
Patients NNS N
undergoing VBG N
various JJ N
anterior JJ 4_p
segment NN 4_p
surgery NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
sub-Tenon NN N
's POS N
or CC N
retrobulbar NN N
anesthesia NN N
; : N
300 CD 3_p
were VBD N
operated VBN N
with IN N
1-quadrant JJ 4_p
sub-Tenon NN 4_p
's POS 4_p
anesthesia NN 4_p
( ( 4_p
1-QST JJ 4_p
) ) 4_p
and CC N
the DT N
results NNS N
were VBD N
compared VBN N
with IN N
270 CD 3_p
patients NNS 3_p
operated VBN N
with IN N
retrobulbar NN 4_p
anesthesia NN 4_p
Retrobulbar NNP N
anesthesia NN N
consisted VBD N
of IN N
a DT N
2.5 CD N
ml NN N
injection NN N
of IN N
a DT N
1:1 CD N
mixture NN N
of IN N
2 CD N
% NN N
lidocaine NN N
without IN N
epinephrine NN N
and CC N
0.5 CD N
% NN N
bupivacaine NN N
Sub-Tenon NNP N
's POS N
anesthesia NN N
involved VBN N
direct JJ N
transconjunctival JJ N
infiltration NN N
of IN N
the DT N
same JJ N
local JJ N
anesthetic JJ N
directly RB N
into IN N
the DT N
sub-Tenon NN N
's POS N
space NN N
, , N
in IN N
the DT N
inferior-nasal JJ N
quadrant NN N
, , N
using VBG N
a DT N
blunt NN N
23-gauge JJ N
cannula NN N
Patients NNS N
undergoing VBG N
various JJ N
anterior JJ 4_p
segment NN 4_p
surgery NN 4_p
procedures NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1-QST CD N
or CC N
retrobulbar VB N
anesthesia NN N
; : N
300 CD N
patients NNS N
were VBD N
operated VBN N
with IN N
1-QST JJ N
and CC N
the DT N
results NNS N
were VBD N
compared VBN N
with IN N
270 CD N
patients NNS N
operated VBN N
with IN N
retrobulbar NN N
anesthesia NN N
Preinjection NN N
mean NN N
( ( N
+/- JJ N
SD NNP N
) ) N
IOP NNP N
wer $ N
12.9 CD N
+/- JJ N
3.7 CD N
mmHg NN N
in IN N
the DT N
retrobulbar NN N
and CC N
13.4 CD N
+/- JJ N
3.2 CD N
mmHg NN N
in IN N
the DT N
1-QST JJ N
patients NNS N
Preoperative JJ N
intraocular JJ N
pressures NNS N
were VBD N
8.7 CD N
+/- JJ N
3.0 CD N
mmHg NN N
in IN N
the DT N
retrobulbar NN N
and CC N
9.2 CD N
+/- JJ N
3.2 CD N
mmHg NN N
in IN N
1-QST JJ N
patients NNS N
Pre- NNP N
and CC N
postinjection NN N
IOP NNP N
for IN N
retrobulbar NN N
and CC N
1-QST JJ N
patients NNS N
were VBD N
similar JJ N
Pain NN N
scores NNS N
for IN N
delivery NN N
of IN N
the DT N
anesthetic JJ N
, , N
using VBG N
a DT N
numerical JJ N
rating NN N
scale NN N
, , N
produced VBD N
a DT N
median JJ N
score NN N
of IN N
1 CD N
for IN N
1-QST JJ N
and CC N
2 CD N
for IN N
the DT N
retrobulbar NN N
technique NN N
For IN N
the DT N
subsequent JJ N
operative JJ N
procedure NN N
, , N
the DT N
median JJ N
score NN N
was VBD N
1 CD N
for IN N
1-QST JJ N
and CC N
2 CD N
for IN N
the DT N
retrobulbar NN N
patients NNS N
Complete JJ N
akinesia NN N
was VBD N
achieved VBN N
in IN N
41 CD N
% NN N
with IN N
1-QST JJ N
and CC N
in IN N
69 CD N
% NN N
of IN N
retrobulbar NN N
patients NNS N
1-QST JJ N
patients NNS N
with IN N
incomplete JJ N
akinesia NN N
most RBS N
often RB N
had VBD N
lateral JJ N
muscle NN N
function NN N
which WDT N
did VBD N
not RB N
interfere VB N
with IN N
the DT N
operation NN N
We PRP N
found VBD N
the DT N
use NN N
of IN N
a DT N
blunt NN N
cannula NN N
to TO N
deliver VB N
anesthetic JJ N
into IN N
the DT N
sub-Tenon NN N
's POS N
space NN N
as IN N
a DT N
simple NN N
, , N
safe JJ N
and CC N
effective JJ N
alternative JJ N
approach NN N
to TO N
traditional JJ N
retrobulbar NN N
anesthesia NN N
in IN N
anterior JJ N
segment NN N
surgery NN N
-DOCSTART- -X- O O 12575712

The DT N
results NNS N
of IN N
a DT N
randomized VBN N
study NN N
on IN N
the DT N
use NN N
of IN N
long-acting JJ N
octreotide NN N
in IN N
hepatocellular JJ 4_p
carcinoma NN 4_p
-DOCSTART- -X- O O 1420057

Prevention NN N
of IN N
acute JJ N
postoperative JJ N
pressure NN N
rises VBZ N
in IN N
glaucoma NN 4_p
patients NNS N
undergoing JJ N
cataract JJ N
extraction NN N
with IN N
posterior JJ 4_p
chamber NN 4_p
lens NNS 4_p
implant VBP 4_p
Acute JJ N
elevations NNS N
in IN N
intraocular JJ N
pressure NN N
( ( N
IOP NNP N
) ) N
commonly RB N
follow VBP N
extracapsular JJ N
cataract NN N
extraction NN N
and CC N
lens VBZ N
implant NN N
in IN N
glaucoma NN N
patients NNS N
Thirty NNP 3_p
six CD 3_p
patients NNS N
with IN N
glaucoma JJ N
undergoing JJ N
cataract NN N
extraction NN N
and CC N
posterior JJ N
chamber NN N
lens VBZ N
implantation NN N
received VBD N
one CD N
of IN N
three CD N
treatments NNS N
Group NNP N
1 CD N
: : N
500 CD N
mg NN N
of IN N
Diamox NNP N
Sustets NNP N
( ( N
acetazolamide RB N
) ) N
1 CD N
hour NN N
preoperatively RB N
( ( N
10 CD N
patients NNS N
) ) N
; : N
Group NNP N
2 CD N
: : N
peroperative JJ N
intracameral JJ N
Miochol NNP N
( ( N
acetylcholine NN N
) ) N
( ( N
11 CD N
patients NNS N
) ) N
; : N
Group NNP N
3 CD N
: : N
the DT N
above IN N
treatments NNS N
combined VBN N
( ( N
15 CD N
patients NNS N
) ) N
IOPs NNP N
were VBD N
measured VBN N
at IN N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
24 CD N
hours NNS N
postoperatively RB N
The DT N
average NN N
of IN N
the DT N
maximum JJ N
pressure NN N
rises VBZ N
above IN N
the DT N
preoperative JJ N
level NN N
over IN N
the DT N
24 CD N
hour NN N
period NN N
was VBD N
greatest JJS N
for IN N
the DT N
group NN N
receiving VBG N
acetazolamide IN N
only RB N
at IN N
8.9 CD N
mm NN N
Hg NNP N
; : N
for IN N
the DT N
acetylcholine NN N
group NN N
the DT N
average NN N
maximum JJ N
rise NN N
was VBD N
6.3 CD N
mm JJ N
Hg NNP N
; : N
while IN N
the DT N
combined JJ N
treatment NN N
group NN N
showed VBD N
a DT N
decrease NN N
of IN N
0.7 CD N
mm NN N
Hg NNP N
IOP NNP N
rises VBZ N
of IN N
> $ N
6 CD N
mm NN N
Hg NNP N
were VBD N
seen VBN N
in IN N
7 CD N
% NN N
of IN N
patients NNS N
( ( N
one CD N
of IN N
15 CD N
) ) N
in IN N
the DT N
combined JJ N
treatment NN N
group NN N
, , N
45 CD N
% NN N
( ( N
five CD N
of IN N
11 CD N
) ) N
of IN N
the DT N
acetylcholine NN N
group NN N
, , N
and CC N
70 CD N
% NN N
( ( N
seven CD N
of IN N
10 CD N
) ) N
of IN N
the DT N
acetazolamide NN N
group NN N
IOP NNP N
rises VBZ N
of IN N
> $ N
10 CD N
mm NN N
Hg NNP N
were VBD N
seen VBN N
in IN N
7 CD N
% NN N
of IN N
the DT N
combined JJ N
treatment NN N
group NN N
, , N
in IN N
18 CD N
% NN N
of IN N
the DT N
acetylcholine NN N
only RB N
group NN N
, , N
and CC N
in IN N
50 CD N
% NN N
of IN N
the DT N
acetazolamide NN N
only RB N
group NN N
A DT N
pressure NN N
rise NN N
> VBZ N
20 CD N
mm NN N
Hg NNP N
was VBD N
seen VBN N
in IN N
one CD N
patient NN N
receiving VBG N
acetazolamide IN N
only RB N
and CC N
one CD N
patient NN N
receiving VBG N
acetylcholine NN N
only RB N
The DT N
difference NN N
between IN N
the DT N
acetylcholine NN N
group NN N
and CC N
the DT N
combined VBN N
group NN N
for IN N
rises NNS N
> VBP N
6 CD N
mm NN N
Hg NNP N
was VBD N
significant JJ N
using VBG N
the DT N
chi NN N
2 CD N
test NN N
while IN N
the DT N
acetazolamide NN N
group NN N
showed VBD N
a DT N
significant JJ N
difference NN N
for IN N
rises NNS N
> VBP N
6 CD N
and CC N
10 CD N
mm NN N
Hg NNP N
compared VBN N
with IN N
the DT N
combined VBN N
group NN N
All DT N
acute JJ N
pressure NN N
rises NNS N
were VBD N
recorded VBN N
before RB N
or CC N
at IN N
9 CD N
hours NNS N
following VBG N
operation NN N
except IN N
in IN N
the DT N
combined JJ N
treatment NN N
patient NN N
where WRB N
the DT N
rise NN N
occurred VBD N
at IN N
24 CD N
hours NNS N
To TO N
prevent VB N
the DT N
acute JJ N
IOP NNP N
rises VBZ N
seen VBN N
following VBG N
cataract NN N
surgery NN N
with IN N
lens NNS N
implant VBP N
in IN N
glaucoma NN N
patients NNS N
we PRP N
recommend VBP N
combined VBN N
ocular JJ N
hypotensive JJ N
therapy NN N
-DOCSTART- -X- O O 25022743

Weighted VBN N
blankets NNS N
and CC N
sleep NN N
in IN N
autistic JJ 4_p
children NNS 4_p
-- : 4_p
a DT 4_p
randomized JJ N
controlled JJ N
trial NN N
OBJECTIVE UH N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
a DT N
weighted-blanket JJ N
intervention NN N
in IN N
treating VBG N
severe JJ 4_p
sleep NN 4_p
problems NNS 4_p
in IN 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
METHODS NNP N
This DT N
phase NN N
III NNP N
trial NN N
was VBD N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
crossover NN N
design NN N
Participants NNS 4_p
were VBD 4_p
aged VBN 4_p
between IN 4_p
5 CD 4_p
years NNS 4_p
and CC 4_p
16 CD 4_p
years NNS 4_p
10 CD 4_p
months NNS 4_p
, , 4_p
with IN 4_p
a DT 4_p
confirmed JJ 4_p
ASD NNP 4_p
diagnosis NN 4_p
and CC 4_p
severe JJ 4_p
sleep NN 4_p
problems NNS 4_p
, , 4_p
refractory NN 4_p
to TO 4_p
community-based JJ 4_p
interventions NNS 4_p
The DT N
interventions NNS N
were VBD N
either RB N
a DT N
commercially RB N
available JJ N
weighted JJ N
blanket NN N
or CC N
otherwise RB N
identical JJ N
usual JJ N
weight NN N
blanket NN N
( ( N
control NN N
) ) N
, , N
introduced VBN N
at IN N
bedtime NN N
; : N
each DT N
was VBD N
used VBN N
for IN N
a DT N
2-week JJ N
period NN N
before IN N
crossover NN N
to TO N
the DT N
other JJ N
blanket NN N
Primary JJ N
outcome NN N
was VBD N
total JJ N
sleep JJ N
time NN N
( ( N
TST NNP N
) ) N
recorded VBN N
by IN N
actigraphy NN N
over IN N
each DT N
2-week JJ N
period NN N
Secondary JJ N
outcomes NNS N
included VBD N
actigraphically RB N
recorded VBN N
sleep-onset JJ N
latency NN N
, , N
sleep JJ N
efficiency NN N
, , N
assessments NNS N
of IN N
child NN N
behavior NN N
, , N
family NN N
functioning NN N
, , N
and CC N
adverse JJ N
events NNS N
Sleep NNP N
was VBD N
also RB N
measured VBN N
by IN N
using VBG N
parent-report JJ N
diaries NNS N
RESULTS NNP N
Seventy-three JJ N
children NNS N
were VBD N
randomized VBN N
and CC N
analysis NN N
conducted VBN N
on IN N
67 CD N
children NNS N
who WP N
completed VBD N
the DT N
study NN N
Using VBG N
objective JJ N
measures NNS N
, , N
the DT N
weighted JJ N
blanket NN N
, , N
compared VBN N
with IN N
the DT N
control NN N
blanket NN N
, , N
did VBD N
not RB N
increase VB N
TST NNP N
as IN N
measured VBN N
by IN N
actigraphy NN N
and CC N
adjusted VBN N
for IN N
baseline NN N
TST NNP N
There EX N
were VBD N
no DT N
group NN N
differences NNS N
in IN N
any DT N
other JJ N
objective NN N
or CC N
subjective JJ N
measure NN N
of IN N
sleep NN N
, , N
including VBG N
behavioral JJ N
outcomes NNS N
On IN N
subjective JJ N
preference NN N
measures NNS N
, , N
parents NNS N
and CC N
children NNS N
favored VBD N
the DT N
weighted JJ N
blanket NN N
CONCLUSIONS VB N
The DT N
use NN N
of IN N
a DT N
weighted JJ N
blanket NN N
did VBD N
not RB N
help VB N
children NNS N
with IN N
ASD NNP N
sleep NN N
for IN N
a DT N
longer JJR N
period NN N
of IN N
time NN N
, , N
fall VB N
asleep RB N
significantly RB N
faster RBR N
, , N
or CC N
wake VB N
less JJR N
often RB N
However RB N
, , N
the DT N
weighted JJ N
blanket NN N
was VBD N
favored VBN N
by IN N
children NNS N
and CC N
parents NNS N
, , N
and CC N
blankets NNS N
were VBD N
well RB N
tolerated VBN N
over IN N
this DT N
period NN N
-DOCSTART- -X- O O 15327617

A DT N
prospective JJ N
randomised JJ N
comparison NN N
of IN N
sublingual JJ 4_p
and CC 4_p
vaginal JJ 4_p
misoprostol NN 4_p
in IN 4_p
second JJ 4_p
trimester NN 4_p
termination NN 4_p
of IN 4_p
pregnancy NN 4_p
OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
, , N
side NN N
effects NNS N
and CC N
acceptability NN N
of IN N
sublingual JJ N
and CC N
vaginal JJ N
misoprostol NN N
for IN N
second JJ 4_p
trimester NN 4_p
medical JJ 4_p
abortion NN 4_p
DESIGN NNP N
Prospective NNP N
randomised VBD N
controlled VBN N
trial NN N
SETTING NN N
Tertiary JJ N
referral JJ N
unit NN N
and CC N
a DT N
teaching JJ N
hospital NN N
POPULATION NNP N
Two CD 3_p
hundred VBD 3_p
and CC 3_p
twenty-four JJ 3_p
women NNS 3_p
at IN N
12 CD N
to TO N
20 CD N
weeks NNS N
of IN N
gestation NN N
METHODS NNP N
The DT N
women NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
sublingual JJ N
or CC N
vaginal JJ N
misoprostol NN N
400 CD N
microg NN N
every DT N
3 CD N
hours NNS N
for IN N
a DT N
maximum NN N
of IN N
five CD N
doses NNS N
The DT N
course NN N
of IN N
misoprostol NN N
was VBD N
repeated VBN N
if IN N
the DT N
woman NN N
did VBD N
not RB N
abort VB N
within IN N
24 CD N
hours NNS N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
success NN N
rate NN N
at IN N
48 CD N
hours NNS N
, , N
induction-to-abortion NN N
interval NN N
and CC N
the DT N
side NN N
effects NNS N
RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
success NN N
rate NN N
at IN N
48 CD N
hours NNS N
( ( N
sublingual JJ N
: : N
91 CD N
% NN N
; : N
vaginal JJ N
: : N
95 CD N
% NN N
) ) N
However RB N
, , N
the DT N
success NN N
rate NN N
at IN N
24 CD N
hours NNS N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
vaginal JJ N
group NN N
( ( N
85 CD N
% NN N
) ) N
compared VBN N
with IN N
the DT N
sublingual JJ N
group NN N
( ( N
64 CD N
% NN N
) ) N
There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
median JJ N
induction-to-abortion NN N
interval NN N
( ( N
sublingual JJ N
: : N
13.8 CD N
hours NNS N
; : N
vaginal JJ N
: : N
12.0 CD N
hours NNS N
) ) N
Significantly RB N
more JJR N
women NNS N
in IN N
the DT N
sublingual JJ N
group NN N
preferred VBD N
the DT N
route NN N
to TO N
which WDT N
they PRP N
were VBD N
assigned VBN N
when WRB N
compared VBN N
with IN N
the DT N
vaginal JJ N
group NN N
The DT N
incidence NN N
of IN N
fever NN N
was VBD N
also RB N
less RBR N
in IN N
the DT N
sublingual JJ N
group NN N
CONCLUSION NNP N
The DT N
use NN N
of IN N
vaginal JJ N
misoprostol NN N
for IN N
second JJ N
trimester NN N
medical JJ N
abortion NN N
resulted VBD N
in IN N
a DT N
higher JJR N
success NN N
rate NN N
than IN N
sublingual JJ N
misoprostol NN N
at IN N
24 CD N
hours NNS N
but CC N
the DT N
abortion NN N
rate NN N
was VBD N
similar JJ N
at IN N
48 CD N
hours NNS N
Vaginal NNP N
misoprostol NN N
should MD N
be VB N
the DT N
regimen NNS N
of IN N
choice NN N
but CC N
sublingual JJ N
misoprostol NN N
is VBZ N
also RB N
an DT N
effective JJ N
alternative NN N
-DOCSTART- -X- O O 24335055

Vitamin NNP N
D NNP N
supplementation NN N
increases NNS N
calcium VBP N
absorption NN N
without IN N
a DT N
threshold JJ N
effect NN N
BACKGROUND IN N
The DT N
maximal JJ N
calcium NN N
absorption NN N
in IN N
response NN N
to TO N
vitamin VB N
D NNP N
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
biomarker NN N
for IN N
vitamin NN N
D NNP N
sufficiency NN N
OBJECTIVE CC N
The DT N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
there EX N
is VBZ N
a DT N
threshold JJ N
beyond IN N
which WDT N
increasing VBG N
doses NNS N
of IN N
vitamin NN N
D NNP N
, , N
or CC N
concentrations NNS N
of IN N
serum JJ N
25-hydroxyvitamin JJ N
D NNP N
[ NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
] NNP N
, , N
no RB N
longer RBR N
increase VB N
calcium NN N
absorption NN N
DESIGN NNP N
This DT N
was VBD N
a DT N
placebo-controlled JJ N
, , N
dose-response JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
of IN N
the DT N
effect NN N
of IN N
vitamin NN N
D NNP N
on IN N
calcium NN N
absorption NN N
in IN N
healthy JJ N
postmenopausal NN 4_p
women NNS 2_p
Seventy-six NNP 3_p
healthy JJ N
postmenopausal NN 4_p
women NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
placebo VB N
or CC N
800 CD N
IU NNP N
( ( N
20 CD N
μg NN N
) ) N
, , N
2000 CD N
IU NNP N
( ( N
50 CD N
μg NN N
) ) N
, , N
or CC N
4000 CD N
IU NNP N
( ( N
100 CD N
μg NN N
) ) N
vitamin NN N
D₃ NNP N
for IN N
8 CD N
wk NN N
The DT N
technique NN N
of IN N
dual JJ N
isotopes NNS N
of IN N
stable JJ N
calcium NN N
was VBD N
used VBN N
with IN N
a DT N
calcium NN N
carrier NN N
to TO N
measure VB N
calcium JJ N
absorption NN N
at IN N
baseline NN N
and CC N
after IN N
8 CD N
wk NN N
RESULTS NNP N
Seventy-one JJ N
women NNS N
with IN N
a DT N
mean JJ N
± NN N
SD NNP N
age NN N
of IN N
58.8 CD N
± JJ N
4.9 CD N
y NN N
completed VBD N
the DT N
study NN N
The DT N
mean JJ N
calcium NN N
intake NN N
was VBD N
1142 CD N
± JJ N
509 CD N
mg/d NN N
and CC N
serum NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
was VBD N
63 CD N
± JJ N
14 CD N
nmol/L NN N
at IN N
baseline NN N
A DT N
statistically RB N
significant JJ N
linear JJ N
trend NN N
of IN N
an DT N
increase NN N
in IN N
calcium JJ N
absorption NN N
adjusted VBN N
for IN N
age NN N
and CC N
body NN N
mass NN N
index NN N
with IN N
increasing VBG N
vitamin NN N
D₃ NNP N
dose NN N
or CC N
serum NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
concentration NN N
was VBD N
observed VBN N
A DT N
6.7 CD N
% NN N
absolute JJ N
increase NN N
in IN N
calcium JJ N
absorption NN N
was VBD N
found VBN N
in IN N
the DT N
highest JJS N
vitamin NN N
D₃ NNP N
group NN N
( ( N
100 CD N
μg NN N
) ) N
No DT N
evidence NN N
of IN N
nonlinearity NN N
was VBD N
observed VBN N
in IN N
the DT N
dose-response JJ N
curve NN N
CONCLUSIONS NNP N
No NNP N
evidence NN N
of IN N
a DT N
threshold NN N
of IN N
calcium NN N
absorption NN N
was VBD N
found VBN N
with IN N
a DT N
serum NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
range NN N
from IN N
40 CD N
to TO N
130 CD N
nmol/L NNS N
Calcium NNP N
absorption NN N
in IN N
this DT N
range NN N
is VBZ N
not RB N
a DT N
useful JJ N
biomarker NN N
to TO N
determine VB N
nutritional JJ N
recommendations NNS N
for IN N
vitamin NN N
D NNP N
-DOCSTART- -X- O O 9001833

Comparison NNP N
of IN N
electromotive JJ N
drug NN N
administration NN N
with IN N
ketorolac NNS N
or CC N
with IN N
placebo NN N
in IN N
patients NNS 4_p
with IN 4_p
pain NN 4_p
from IN 4_p
rheumatic JJ 4_p
disease NN 4_p
: : 4_p
a DT N
double-masked JJ N
study NN N
This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
ketorolac NNS N
compared VBN N
with IN N
placebo NN N
when WRB N
delivered VBN N
by IN N
electromotive JJ N
drug NN N
administration NN N
( ( N
EMDA NNP N
) ) N
in IN N
patients NNS 4_p
with IN 4_p
pain NN 4_p
from IN 4_p
rheumatic JJ 4_p
disease NN 4_p
In IN N
EMDA NNP N
, , N
or CC N
iontophoresis NN N
, , N
a DT N
low-intensity NN N
electric JJ N
current JJ N
is VBZ N
applied VBN N
over IN N
the DT N
skin NN N
to TO N
deliver VB N
medication NN N
into IN N
body NN N
tissues NNS N
Although IN N
EMDA NNP N
has VBZ N
been VBN N
used VBN N
to TO N
treat VB N
patients NNS N
with IN N
various JJ N
diseases NNS N
, , N
controlled VBN N
studies NNS N
are VBP N
lacking VBG N
in IN N
patients NNS 4_p
with IN 4_p
rheumatic JJ 4_p
disease NN 4_p
This DT N
double-masked JJ N
study NN N
included VBD N
60 CD 3_p
patients NNS N
( ( N
43 CD 3_p
women NNS 2_p
and CC N
17 CD 3_p
men NNS 2_p
) ) N
aged VBD 1_p
31 CD 1_p
to TO 1_p
80 CD 1_p
years NNS 1_p
with IN N
the DT N
following JJ N
conditions NNS N
: : N
12 CD N
, , N
epicondylitis NN 4_p
; : N
30 CD N
, , N
scapulohumeral JJ 4_p
periarthritis NN 4_p
; : N
10 CD N
, , N
gonalgia NN N
; : N
and CC N
8 CD N
, , N
metatarsalgia NN N
They PRP N
were VBD N
divided VBN N
randomly RB N
by IN N
a DT N
physician NN N
into IN N
2 CD N
groups NNS N
of IN N
30 CD N
patients NNS N
each DT N
for IN N
5 CD N
sessions NNS N
of IN N
active JJ N
treatment NN N
( ( N
30 CD N
mg NN N
of IN N
ketorolac NN N
) ) N
or CC N
placebo NN N
( ( N
5 CD N
mL NN N
of IN N
normal JJ N
saline NN N
) ) N
Treatment NNP N
took VBD N
place NN N
every DT N
other JJ N
day NN N
for IN N
20 CD N
minutes NNS N
Immediately RB N
before IN N
and CC N
after IN N
the DT N
five CD N
treatment NN N
sessions NNS N
and CC N
7 CD N
days NNS N
after IN N
treatment NN N
ended VBN N
, , N
both DT N
patient NN N
and CC N
physician NN N
measured VBD N
the DT N
degree NN N
of IN N
pain NN N
using VBG N
a DT N
categoric JJ N
scale NN N
( ( N
no DT N
pain NN N
, , N
slight JJ N
pain NN N
, , N
intermediate JJ N
pain NN N
, , N
strong JJ N
pain NN N
, , N
and CC N
very RB N
strong JJ N
pain NN N
) ) N
and CC N
evaluated VBN N
pain NN N
intensity NN N
using VBG N
the DT N
Scott NNP N
and CC N
Huskisson NNP N
Visual NNP N
Analogue NNP N
Scale NNP N
( ( N
VAS NNP N
) ) N
Seven NNP N
days NNS N
after IN N
treatment NN N
ended VBN N
, , N
both DT N
physician JJ N
and CC N
patient JJ N
judged VBD N
the DT N
result NN N
of IN N
treatment NN N
using VBG N
a DT N
second JJ N
categoric JJ N
scale NN N
( ( N
no DT N
improvement NN N
or CC N
intermediate NN N
, , N
good JJ N
, , N
or CC N
very RB N
good JJ N
result NN N
) ) N
Both DT N
ketorolac NN N
and CC N
placebo NN N
provided VBN N
immediate JJ N
, , N
significant JJ N
pain NN N
relief NN N
when WRB N
delivered VBN N
by IN N
EMDA NNP N
, , N
but CC N
only RB N
those DT N
patients NNS N
receiving VBG N
ketorolac NN N
experienced VBD N
a DT N
further JJ N
reduction NN N
in IN N
pain NN N
7 CD N
days NNS N
after IN N
treatment NN N
; : N
those DT N
receiving VBG N
placebo NN N
experienced VBD N
a DT N
slight JJ N
increase NN N
in IN N
pain NN N
VAS NNP N
values NNS N
differed VBD N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
Poor NNP N
results NNS N
( ( N
no DT N
improvement NN N
) ) N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
placebo-treated JJ N
group NN N
, , N
while IN N
good JJ N
results NNS N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
ketorolac-treated JJ N
group NN N
No DT N
patient NN N
reported VBD N
any DT N
adverse JJ N
effects NNS N
during IN N
treatment NN N
This DT N
study NN N
demonstrates VBZ N
that IN N
ketorolac NN N
relieves NNS N
pain VBP N
when WRB N
delivered VBN N
by IN N
EMDA NNP N
and CC N
offers VBZ N
longer-lasting JJ N
pain NN N
relief NN N
than IN N
does VBZ N
placebo VB N
-DOCSTART- -X- O O 9919095

The DT 4_p
preparation NN 4_p
of IN 4_p
patients NNS 4_p
for IN 4_p
cardiac JJ 4_p
surgery NN 4_p
This DT N
study NN N
examines VBZ N
the DT N
impact NN N
of IN N
a DT N
preadmission NN N
telephone NN N
intervention NN N
on IN N
anxiety NN N
, , N
knowledge NN N
, , N
and CC N
readiness NN N
for IN N
discharge NN N
for IN N
patients NNS 4_p
attending VBG 4_p
a DT 4_p
preadmission NN 4_p
teaching VBG 4_p
program NN 4_p
prior RB 4_p
to TO 4_p
cardiac VB 4_p
surgery NN 4_p
The DT N
primary JJ N
goal NN N
of IN N
the DT N
telephone NN N
intervention NN N
was VBD N
to TO N
provide VB N
support NN N
by IN N
giving VBG N
additional JJ N
information NN N
about IN N
individual JJ N
concerns NNS N
The DT N
telephone NN N
intervention NN N
did VBD N
not RB N
have VB N
an DT N
effect NN N
on IN N
anxiety NN N
and CC N
knowledge NN N
A DT N
significantly RB N
higher JJR N
level NN N
of IN N
anxiety NN N
was VBD N
found VBN N
in IN N
the DT N
experimental JJ N
group NN N
on IN N
admission NN N
, , N
but CC N
this DT N
difference NN N
became VBD N
nonsignificant JJ N
when WRB N
baseline NN N
level NN N
and CC N
length NN N
of IN N
waiting VBG N
time NN N
were VBD N
entered VBN N
as IN N
covariates NNS N
The DT N
more RBR N
anxious JJ N
group NN N
rated VBD N
their PRP$ N
perceived JJ N
knowledge NN N
level NN N
lower RBR N
, , N
despite IN N
the DT N
fact NN N
that IN N
both DT N
groups NNS N
had VBD N
similar JJ N
scores NNS N
in IN N
actual JJ N
knowledge NN N
Given VBN N
the DT N
potential JJ N
barrier NN N
that IN N
anxiety NN N
can MD N
pose VB N
for IN N
patient NN N
learning NN N
, , N
nurses NNS N
need VBP N
to TO N
adapt VB N
their PRP$ N
interventions NNS N
to TO N
deal VB N
with IN N
the DT N
patients NNS N
' POS N
feelings NNS N
of IN N
anxiety NN N
that IN N
accompany JJ N
cardiac JJ N
surgery NN N
to TO N
make VB N
the DT N
learning NN N
process NN N
effective JJ N
-DOCSTART- -X- O O 8367775

Early RB N
versus NN N
late JJ N
replacement NN N
of IN N
autotransfused JJ N
blood NN N
in IN N
elective JJ 4_p
spinal JJ 4_p
surgery NN 4_p
A DT N
prospective JJ N
randomized NN N
study NN N
The DT N
use NN N
of IN N
autologous JJ N
blood NN N
is VBZ N
a DT N
well RB N
established VBN N
and CC N
extremely RB N
popular JJ N
technique NN N
to TO N
decrease VB N
the DT N
necessity NN N
for IN N
homologous JJ N
transfusions NNS N
and CC N
the DT N
attendant JJ N
risks NNS N
of IN N
hepatitis NN N
, , N
HIV NNP N
, , N
and CC N
HTLV NNP N
-- : N
I/II NNP N
infections NNS N
The DT N
most RBS N
beneficial JJ N
timing NN N
for IN N
autologous JJ N
reinfusion NN N
of IN N
predonated JJ N
blood NN N
remains VBZ N
unknown JJ N
The DT N
present JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
determine VB N
the DT N
optimal JJ N
timing NN N
of IN N
autologous JJ N
blood NN N
reinfusion NN N
in IN N
elective JJ N
spinal JJ N
surgery NN N
Fifty-seven JJ N
patients NNS N
were VBD N
prospectively RB N
individually RB N
randomly RB N
allocated VBN N
into IN N
early JJ N
versus NN N
delayed VBN N
reinfusion NN N
groups NNS N
prior RB N
to TO N
undergoing VBG 4_p
elective JJ 4_p
spinal JJ 4_p
surgery NN 4_p
by IN N
a DT N
single JJ N
surgeon NN N
Three CD N
surgical JJ N
subgroups NNS N
were VBD N
entered VBN N
into IN N
the DT N
study NN N
: : N
anterior/posterior NN 4_p
( ( 4_p
A/P NNP 4_p
) ) 4_p
spinal JJ 4_p
fusion NN 4_p
patients NNS 4_p
, , 4_p
posterior JJ 4_p
thoracolumbar NN 4_p
scoliosis NN 4_p
fusion NN 4_p
patients NNS 4_p
( ( 4_p
PSF NNP 4_p
) ) 4_p
, , 4_p
and CC 4_p
degenerative JJ 4_p
posterior JJ 4_p
lumbar NN 4_p
fusion NN 4_p
patients NNS 4_p
( ( 4_p
LF NNP 4_p
) ) 4_p
Randomization NN N
was VBD N
successful JJ N
in IN N
that DT N
three CD N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
male NN N
to TO N
female VB N
ratio NN N
, , N
age NN N
, , N
preoperative JJ N
hemoglobin NN N
, , N
or CC N
number NN N
of IN N
units NNS N
predonated VBN N
between IN N
the DT N
early JJ N
and CC N
delayed JJ N
reinfusion NN N
groups NNS N
Likewise NNP N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
details NNS N
of IN N
the DT N
operative JJ N
procedure NN N
when WRB N
compared VBN N
as IN N
a DT N
group NN N
for IN N
the DT N
early JJ N
versus NN N
delayed VBN N
reinfusion NN N
groups NNS N
A DT N
significant JJ N
increase NN N
in IN N
the DT N
postoperative JJ N
day NN N
# # N
1 CD N
, , N
2 CD N
and CC N
3 CD N
hemoglobin NN N
was VBD N
seen VBN N
in IN N
the DT N
early JJ N
reinfusion NN N
group NN N
, , N
while IN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
seen VBN N
in IN N
the DT N
postoperative JJ N
day NN N
# # N
7 CD N
hemoglobin NN N
between IN N
the DT N
early JJ N
versus NN N
delayed VBN N
reinfusion NN N
group NN N
There EX N
was VBD N
no DT N
effect NN N
of IN N
surgical JJ N
grouping NN N
on IN N
these DT N
significant JJ N
comparisons NNS N
Earlier RBR N
patient JJ N
mobilization NN N
was VBD N
also RB N
seen VBN N
in IN N
the DT N
early JJ N
reinfusion NN N
groups NNS N
for IN N
the DT N
A/P NNP N
and CC N
PSF NNP N
groups NNS N
There EX N
was VBD N
no DT N
difference NN N
in IN N
patients NNS N
' POS N
subjective JJ N
evaluation NN N
of IN N
satisfaction NN N
and CC N
discomfort NN N
between IN N
the DT N
early JJ N
or CC N
delayed VBN N
reinfusion NN N
groups NNS N
as IN N
determined VBN N
by IN N
blinded VBN N
interview NN N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
5 CD N
, , N
and CC N
7 CD N
postoperatively RB N
( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 8580292

[ NN N
Evaluating VBG N
an DT N
interactive JJ 4_p
, , 4_p
multi-media JJ 4_p
learning NN 4_p
system NN 4_p
for IN N
the DT N
study NN 4_p
of IN 4_p
primary JJ 4_p
open JJ 4_p
angle NN 4_p
glaucoma NN 4_p
] NNP N
Using VBG N
the DT N
interactive JJ N
multimedia NN N
learning NN N
system NN N
for IN N
studying VBG N
open-angle JJ N
glaucoma NN N
[ $ N
3 CD N
] CC N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
case-controlled JJ N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
determine VB N
the DT N
value NN N
of IN N
this DT N
new JJ N
form NN N
of IN N
learning VBG N
in IN N
terms NNS N
of IN N
acceptance NN N
and CC N
the DT N
imparting NN N
of IN N
knowledge NN N
This DT N
article NN N
describes VBZ N
details NNS N
of IN N
the DT N
study NN N
and CC N
presents NNS N
their PRP$ N
results NNS N
Results NNS N
were VBD N
established VBN N
on IN N
the DT N
basis NN N
of IN N
targeted JJ N
questions NNS N
asked VBD N
prior JJ N
to TO N
and CC N
after IN N
the DT N
learning NN N
phase NN N
, , N
followed VBN N
by IN N
an DT N
analysis NN N
of IN N
frequencies NNS N
and CC N
significance NN N
testing NN N
by IN N
the DT N
Chi NNP N
squared VBD N
method NN N
It PRP N
was VBD N
shown VBN N
that IN N
the DT N
imparting NN N
of IN N
knowledge NN N
is VBZ N
significantly RB N
improved VBN N
when WRB N
this DT N
learning NN N
system NN N
is VBZ N
employed VBN N
In IN N
addition NN N
, , N
after IN N
its PRP$ N
first JJ N
use NN N
, , N
acceptance NN N
of IN N
this DT N
new JJ N
medium NN N
rose VBD N
dramatically RB N
-DOCSTART- -X- O O 23101741

Early JJ N
behavioral JJ N
intervention NN N
is VBZ N
associated VBN N
with IN N
normalized JJ N
brain NN N
activity NN N
in IN N
young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
OBJECTIVE CC N
A DT N
previously RB N
published VBN N
randomized JJ N
clinical JJ N
trial NN N
indicated VBD N
that IN N
a DT N
developmental JJ N
behavioral JJ N
intervention NN N
, , N
the DT N
Early JJ N
Start NNP N
Denver NNP N
Model NNP N
( ( N
ESDM NNP N
) ) N
, , N
resulted VBD N
in IN N
gains NNS N
in IN N
IQ NNP N
, , N
language NN N
, , N
and CC N
adaptive JJ N
behavior NN N
of IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
This DT N
report NN N
describes VBZ N
a DT N
secondary JJ N
outcome NN N
measurement NN N
from IN N
this DT N
trial NN N
, , N
EEG NNP N
activity NN N
METHOD NNP N
Forty-eight JJ 1_p
18- JJ 1_p
to TO 1_p
30-month-old JJ 1_p
children NNS 1_p
with IN N
autism NN N
spectrum NN N
disorder NN N
were VBD N
randomized VBN N
to TO N
receive VB N
the DT N
ESDM NNP N
or CC N
referral JJ N
to TO N
community NN N
intervention NN N
for IN N
2 CD N
years NNS N
After IN N
the DT N
intervention NN N
( ( N
age NN N
48 CD N
to TO N
77 CD N
months NNS N
) ) N
, , N
EEG NNP N
activity NN N
( ( N
event-related JJ N
potentials NNS N
and CC N
spectral JJ N
power NN N
) ) N
was VBD N
measured VBN N
during IN N
the DT N
presentation NN N
of IN N
faces VBZ N
versus JJ N
objects NNS N
Age-matched JJ N
typical JJ N
children NNS N
were VBD N
also RB N
assessed VBN N
RESULTS VB N
The DT N
ESDM NNP N
group NN N
exhibited VBD N
greater JJR N
improvements NNS N
in IN N
autism NN N
symptoms NNS N
, , N
IQ NNP N
, , N
language NN N
, , N
and CC N
adaptive JJ N
and CC N
social JJ N
behaviors NNS N
than IN N
the DT N
community NN N
intervention NN N
group NN N
The DT N
ESDM NNP N
group NN N
and CC N
typical JJ N
children NNS N
showed VBD N
a DT N
shorter NN N
Nc NNP N
latency NN N
and CC N
increased VBD N
cortical JJ N
activation NN N
( ( N
decreased VBN N
α NNP N
power NN N
and CC N
increased VBD N
θ NNP N
power NN N
) ) N
when WRB N
viewing VBG N
faces VBZ N
, , N
whereas IN N
the DT N
community NN N
intervention NN N
group NN N
showed VBD N
the DT N
opposite JJ N
pattern NN N
( ( N
shorter JJ N
latency NN N
event-related JJ N
potential JJ N
[ NN N
ERP NNP N
] NNP N
and CC N
greater JJR N
cortical JJ N
activation NN N
when WRB N
viewing VBG N
objects NNS N
) ) N
Greater NNP N
cortical JJ N
activation NN N
while IN N
viewing VBG N
faces VBZ N
was VBD N
associated VBN N
with IN N
improved VBN N
social JJ N
behavior NN N
CONCLUSIONS VB N
This DT N
was VBD N
the DT N
first JJ N
trial NN N
to TO N
demonstrate VB N
that DT N
early JJ N
behavioral JJ N
intervention NN N
is VBZ N
associated VBN N
with IN N
normalized JJ N
patterns NNS N
of IN N
brain NN N
activity NN N
, , N
which WDT N
is VBZ N
associated VBN N
with IN N
improvements NNS N
in IN N
social JJ N
behavior NN N
, , N
in IN N
young JJ N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
-DOCSTART- -X- O O 23511149

Perioperative JJ N
myocardial JJ N
infarctions NNS N
are VBP N
common JJ N
and CC N
often RB N
unrecognized JJ N
in IN N
patients NNS N
undergoing VBG 4_p
hip JJ 4_p
fracture NN 4_p
surgery NN 4_p
BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
cohort NN N
study NN N
was VBD N
to TO N
assess VB N
the DT N
incidence NN N
and CC N
characteristics NNS N
of IN N
acute JJ N
myocardial JJ N
infarction NN N
in IN N
patients NNS N
undergoing JJ N
surgery NN 4_p
for IN 4_p
acute JJ 4_p
hip NN 4_p
fracture NN 4_p
METHODS NNP N
A NNP N
consecutive JJ N
cohort NN N
of IN N
patients NNS N
( ( N
n JJ N
= NN N
200 CD N
, , N
68 CD N
men NNS N
) ) N
referred VBD N
to TO N
acute VB 4_p
surgical JJ 4_p
correction NN 4_p
of IN 4_p
hip NN 4_p
fracture NN 4_p
was VBD N
studied VBN N
Troponin NNP N
T NNP N
( ( N
TnT NNP N
) ) N
measurements NNS N
and CC N
electrocardiographic JJ N
( ( N
ECG NNP N
) ) N
recordings NNS N
were VBD N
performed VBN N
at IN N
admission NN N
, , N
before IN N
operation NN N
, , N
and CC N
on IN N
the DT N
first JJ N
and CC N
2nd CD N
postoperative JJ N
days NNS N
, , N
which WDT N
were VBD N
used VBN N
for IN N
diagnosis NN N
RESULTS VB N
The DT N
age NN 1_p
of IN 1_p
the DT 1_p
patients NNS 1_p
ranged VBD 1_p
from IN 1_p
32 CD 1_p
to TO 1_p
98 CD 1_p
years NNS 1_p
( ( 1_p
mean NN 1_p
, , 1_p
80.8 CD 1_p
years NNS 1_p
) ) N
, , N
and CC N
65 CD N
patients NNS N
had VBD N
a DT N
history NN 4_p
of IN 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
A DT N
significant JJ N
rise NN N
in IN N
TnT NNP N
as IN N
a DT N
sign NN N
of IN N
myocardial JJ N
infarction NN N
was VBD N
observed VBN N
in IN N
71 CD N
patients NNS N
( ( N
35.5 CD N
% NN N
) ) N
, , N
and CC N
25 CD N
of IN N
them PRP N
had VBD N
a DT N
TnT NNP N
elevation NN N
exceeding VBG N
five CD N
times NNS N
the DT N
upper JJ N
normal JJ N
limit NN N
TnT NNP N
elevation NN N
was VBD N
observed VBN N
in IN N
36 CD N
patients NNS N
( ( N
51 CD N
% NN N
) ) N
already RB N
before RB N
surgery NN N
Seven CD N
patients NNS N
( ( N
10 CD N
% NN N
) ) N
had VBD N
ST NNP N
elevation NN N
myocardial JJ N
infarction NN N
, , N
23 CD N
patients NNS N
( ( N
32 CD N
% NN N
) ) N
had VBD N
new JJ N
ST NNP N
depressions NNS N
, , N
and CC N
21 CD N
patients NNS N
( ( N
30 CD N
% NN N
) ) N
had VBD N
no DT N
new JJ N
ST NNP N
segment NN N
changes NNS N
in IN N
the DT N
serial JJ N
electrocardiographic JJ N
recordings NNS N
In IN N
40 CD N
patients NNS N
( ( N
56 CD N
% NN N
) ) N
, , N
the DT N
perioperative JJ N
myocardial JJ N
infarction NN N
was VBD N
the DT N
first JJ N
manifestation NN N
of IN N
coronary JJ N
artery NN N
disease NN N
Multivariate NNP N
logistic JJ N
regression NN N
revealed VBD N
that IN N
old JJ N
age NN N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
, , N
1.06 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
1.02-1.10 JJ N
; : N
p VB N
= $ N
0.002 CD N
) ) N
, , N
earlier JJR N
revascularization NN N
( ( N
OR NNP N
, , N
3.29 CD N
; : N
95 CD N
% NN N
CI NNP N
1.12-9.73 CD N
; : N
p CC N
= VB N
0.03 CD N
) ) N
, , N
and CC N
heart NN N
failure NN N
( ( N
OR NNP N
, , N
2.42 CD N
; : N
95 CD N
% NN N
CI NNP N
1.04-5.61 CD N
; : N
p CC N
= VB N
0.04 CD N
) ) N
were VBD N
independent JJ N
predictors NNS N
of IN N
TnT NNP N
elevation NN N
Majority NNP N
of IN N
myocardial JJ N
infarctions NNS N
were VBD N
asymptomatic JJ N
or CC N
unrecognized JJ N
Evidence-based JJ N
medications NNS N
of IN N
myocardial JJ N
infarction NN N
were VBD N
seldom RB N
started VBN N
and CC N
cardiologist NN N
was VBD N
consulted VBN N
in IN N
12 CD N
patients NNS N
( ( N
16.9 CD N
% NN N
) ) N
CONCLUSION JJ N
Patients NNS N
with IN N
hip JJ N
fracture NN N
often RB N
develop VBZ N
asymptomatic JJ N
and CC N
clinically RB N
unrecognized JJ N
perioperative JJ N
myocardial JJ N
infarctions NNS N
Earlier JJR N
diagnosis NN N
and CC N
appropriate JJ N
treatment NN N
of IN N
cardiac JJ N
infarction NN N
may MD N
improve VB N
survival NN N
of IN N
hip NN N
fracture NN N
patients NNS N
LEVEL NNP N
OF IN N
EVIDENCE NNP N
Epidemiologic NNP N
study NN N
, , N
level NN N
III NNP N
-DOCSTART- -X- O O 25234481

Measuring VBG N
and CC N
supporting VBG N
language NN N
function NN N
for IN N
children NNS 1_p
with IN N
autism NN 4_p
: : N
evidence NN N
from IN N
a DT N
randomized VBN N
control NN N
trial NN N
of IN N
a DT N
social-interaction-based JJ N
therapy NN N
In IN N
a DT N
report NN N
of IN N
the DT N
effectiveness NN N
of IN N
MEHRIT NNP N
, , N
a DT N
social-interaction-based JJ N
intervention NN N
for IN N
autism NN N
, , N
Casenhiser NNP N
et CC N
al NN N
( ( N
Autism $ N
17 CD N
( ( N
2 CD N
) ) N
:220-241 NN N
, , N
2013 CD N
) ) N
failed VBD N
to TO N
find VB N
a DT N
significant JJ N
advantage NN N
for IN N
language NN N
development NN N
in IN N
the DT N
treatment NN N
group NN N
using VBG N
standardized JJ N
language NN N
assessments NNS N
We PRP N
present VBD N
the DT N
results NNS N
from IN N
a DT N
re-analysis NN N
of IN N
their PRP$ N
results NNS N
to TO N
illustrate VB N
the DT N
importance NN N
of IN N
measuring VBG N
communicative JJ N
language NN N
acts NNS N
( ( N
formally RB N
called VBN N
" NN N
speech NN N
acts VBZ N
" NNP N
) ) N
Reanalysis NN N
confirmed VBD N
that IN N
children NNS N
in IN N
the DT N
MEHRIT NNP N
group NN N
outperformed VBD N
the DT N
community NN N
treatment NN N
group NN N
on IN N
measures NNS N
of IN N
MLUm NNP N
, , N
number NN N
of IN N
utterances NNS N
produced VBN N
, , N
and CC N
various JJ N
speech NN N
act NN N
categories NNS N
The DT N
study NN N
underscores VBZ N
the DT N
importance NN N
of IN N
functional JJ N
language NN N
measures NNS N
in IN N
guiding VBG N
and CC N
evaluating VBG N
treatment NN N
for IN N
children NNS N
with IN N
autism NN 4_p
, , N
and CC N
suggests VBZ N
that DT N
MEHRIT NNP N
is VBZ N
effective JJ N
in IN N
improving VBG N
children NNS N
's POS N
use NN N
of IN N
language NN N
during IN N
parent-child JJ N
interactions NNS N
-DOCSTART- -X- O O 21266651

Factors NNS N
predictive VBP N
of IN N
severe JJ N
hypoglycemia NN N
in IN N
type NN N
1 CD N
diabetes NNS N
: : N
analysis NN N
from IN N
the DT N
Juvenile NNP N
Diabetes NNP N
Research NNP N
Foundation NNP N
continuous JJ N
glucose JJ N
monitoring VBG N
randomized VBN N
control NN N
trial NN N
dataset NN N
OBJECTIVE NNP N
Identify NNP N
factors NNS N
predictive VBP N
of IN N
severe JJ N
hypoglycemia NN N
( ( N
SH NNP N
) ) N
and CC N
assess VB N
the DT N
clinical JJ N
utility NN N
of IN N
continuous JJ N
glucose JJ N
monitoring NN N
( ( N
CGM NNP N
) ) N
to TO N
warn VB N
of IN N
impending VBG N
SH NNP N
RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
multicenter NN N
randomized VBN N
clinical JJ N
trial NN N
, , N
436 CD N
children NNS N
and CC N
adults NNS N
with IN N
type JJ N
1 CD N
diabetes NNS N
were VBD N
randomized VBN N
to TO N
a DT N
treatment NN N
group NN N
that WDT N
used VBD N
CGM NNP N
( ( N
N NNP N
= NNP N
224 CD N
) ) N
, , N
or CC N
a DT N
control NN N
group NN N
that WDT N
used VBD N
standard JJ N
home NN N
blood NN N
glucose JJ N
monitoring NN N
( ( N
N NNP N
= NNP N
212 CD N
) ) N
and CC N
completed VBD N
12 CD N
months NNS N
of IN N
follow-up NN N
After IN N
6 CD N
months NNS N
, , N
the DT N
original JJ N
control NN N
group NN N
initiated VBD N
CGM NNP N
while IN N
the DT N
treatment NN N
group NN N
continued VBD N
use NN N
of IN N
CGM NNP N
for IN N
6 CD N
months NNS N
Baseline NNP N
risk NN N
factors NNS N
for IN N
SH NNP N
were VBD N
evaluated VBN N
over IN N
12 CD N
months NNS N
of IN N
follow-up JJ N
using VBG N
proportional JJ N
hazards NNS N
regression NN N
CGM-derived JJ N
indices NNS N
of IN N
hypoglycemia NN N
were VBD N
used VBN N
to TO N
predict VB N
episodes NNS N
of IN N
SH NNP N
over IN N
a DT N
24-h JJ N
time NN N
horizon NN N
RESULTS VB N
The DT N
SH NNP N
rate NN N
was VBD N
17.9 CD N
per IN N
100 CD N
person-years NNS N
, , N
and CC N
a DT N
higher JJR N
rate NN N
was VBD N
associated VBN N
with IN N
the DT N
occurrence NN N
of IN N
SH NNP N
in IN N
the DT N
prior JJ N
6 CD N
months NNS N
and CC N
female JJ N
sex NN N
SH NNP N
frequency NN N
increased VBD N
eightfold RB N
when WRB N
30 CD N
% NN N
of IN N
CGM NNP N
values NNS N
were VBD N
≤ JJ N
70 CD N
mg/dL NN N
on IN N
the DT N
prior JJ N
day NN N
( ( N
4.5 CD N
vs. FW N
0.5 CD N
% NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
the DT N
positive JJ N
predictive JJ N
value NN N
( ( N
PPV NNP N
) ) N
was VBD N
low JJ N
( ( N
< JJ N
5 CD N
% NN N
) ) N
Results NNS N
were VBD N
similar JJ N
for IN N
hypoglycemic JJ N
area NN N
under IN N
the DT N
curve NN N
and CC N
the DT N
low JJ N
blood NN N
glucose NN N
index NN N
calculated VBN N
by IN N
CGM NNP N
CONCLUSIONS NNP N
SH NNP N
in IN N
the DT N
6 CD N
months NNS N
prior RB N
to TO N
the DT N
study NN N
was VBD N
the DT N
strongest JJS N
predictor NN N
of IN N
SH NNP N
during IN N
the DT N
study NN N
CGM-measured JJ N
hypoglycemia NN N
over IN N
a DT N
24-h JJ N
span NN N
is VBZ N
highly RB N
associated VBN N
with IN N
SH NNP N
the DT N
following JJ N
day NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
the DT N
PPV NNP N
is VBZ N
low JJ N
-DOCSTART- -X- O O 18161643

Improving VBG N
the DT N
transition NN N
from IN N
residential JJ 4_p
to TO 4_p
outpatient JJ 4_p
addiction NN 4_p
treatment NN N
: : N
gender NN N
differences NNS N
in IN N
response NN N
to TO N
supportive VB N
telephone NN N
calls NNS N
Substance NN N
use NN N
relapse NN N
rates NNS N
are VBP N
often RB N
high JJ N
in IN N
the DT N
first JJ N
months NNS N
after IN N
discharge NN N
from IN N
inpatient JJ N
substance NN N
abuse NN N
treatment NN N
, , N
and CC N
patient JJ N
adherence NN N
to TO N
aftercare VB N
plans NNS N
is VBZ N
often RB N
low JJ N
Four CD N
residential JJ N
addiction NN N
treatment NN N
centers NNS N
participated VBD N
in IN N
a DT N
feasibility NN N
study NN N
designed VBN N
to TO N
estimate VB N
the DT N
efficacy NN N
of IN N
a DT N
post-discharge JJ N
telephone NN N
intervention NN N
intended VBN N
to TO N
encourage VB N
compliance NN N
with IN N
aftercare NN N
A DT N
total NN N
of IN N
282 CD 3_p
participants NNS N
( ( N
100 CD 3_p
women NNS 2_p
, , N
182 CD 3_p
men NNS 2_p
) ) N
with IN N
substance NN N
use NN N
disorders NNS N
were VBD N
included VBN N
in IN N
this DT N
secondary JJ N
analysis NN N
The DT N
findings NNS N
revealed VBD N
that IN N
women NNS N
were VBD N
more RBR N
likely JJ N
than IN N
men NNS N
to TO N
attend VB N
aftercare NN N
This DT N
" JJ N
gender NN N
effect NN N
" NNP N
persisted VBD N
after IN N
adjustment NN N
for IN N
a DT N
number NN N
of IN N
potential JJ N
mediators NNS N
-DOCSTART- -X- O O 12045163

Prospective JJ N
study NN N
of IN N
C-reactive NNP N
protein NN N
, , N
homocysteine NN N
, , N
and CC N
plasma VB N
lipid JJ N
levels NNS N
as IN N
predictors NNS N
of IN N
sudden JJ N
cardiac JJ N
death NN N
BACKGROUND NNP N
Sudden NNP N
cardiac JJ N
death NN N
( ( N
SCD NNP N
) ) N
is VBZ N
an DT N
important JJ N
cause NN N
of IN N
mortality NN N
even RB N
among IN N
apparently RB N
healthy JJ N
populations NNS N
However RB N
, , N
our PRP$ N
ability NN N
to TO N
identify VB N
those DT N
at IN N
risk NN N
for IN N
SCD NNP N
in IN N
the DT N
general JJ N
population NN N
is VBZ N
poor JJ N
, , N
and CC N
more RBR N
specific JJ N
markers NNS N
are VBP N
needed VBN N
METHODS NNP N
AND CC N
RESULTS NNP N
To TO N
compare VB N
and CC N
contrast VB N
the DT N
relative JJ N
importance NN N
of IN N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
homocysteine NN N
, , N
and CC N
lipids NNS N
as IN N
long-term JJ N
predictors NNS N
of IN N
SCD NNP N
, , N
we PRP N
performed VBD N
a DT N
prospective JJ N
, , N
nested JJ N
, , N
case-control JJ N
analysis NN N
involving VBG N
97 CD 3_p
cases NNS N
of IN N
SCD NNP 4_p
among IN N
apparently RB 4_p
healthy JJ 4_p
men NNS 2_p
enrolled VBN N
in IN N
the DT N
Physician NNP N
's POS N
Health NNP N
Study NNP N
Of IN N
these DT N
plasma JJ N
markers NNS N
measured VBD N
, , N
only RB N
baseline JJ N
CRP NNP N
levels NNS N
were VBD N
significantly RB N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
SCD NNP N
over IN N
the DT N
ensuing VBG N
17 CD N
years NNS N
of IN N
follow-up NN N
( ( N
P NNP N
for IN N
trend=0.001 NN N
) ) N
The DT N
increase NN N
in IN N
risk NN N
associated VBN N
with IN N
CRP NNP N
levels NNS N
was VBD N
primarily RB N
seen VBN N
among IN N
men NNS N
in IN N
the DT N
highest JJS N
quartile NN N
, , N
who WP N
were VBD N
at IN N
a DT N
2.78-fold JJ N
increased JJ N
risk NN N
of IN N
SCD NNP N
( ( N
95 CD N
% NN N
CI NNP N
1.35 CD N
to TO N
5.72 CD N
) ) N
compared VBN N
with IN N
men NNS N
in IN N
the DT N
lowest JJS N
quartile NN N
These DT N
results NNS N
were VBD N
not RB N
significantly RB N
altered VBN N
in IN N
analyses NNS N
that WDT N
( ( N
in IN N
addition NN N
to TO N
the DT N
matching JJ N
variables NNS N
of IN N
age NN N
and CC N
smoking NN N
status NN N
) ) N
controlled VBD N
for IN N
lipid JJ N
parameters NNS N
, , N
homocysteine NN N
, , N
and CC N
multiple JJ N
cardiac JJ N
risk NN N
factors NNS N
( ( N
relative JJ N
risk NN N
for IN N
highest JJS N
versus NN N
lowest JJS N
quartile NN N
2.65 CD N
, , N
95 CD N
% NN N
CI NNP N
0.79 CD N
to TO N
8.83 CD N
; : N
P NNP N
for IN N
trend=0.03 NN N
) ) N
In IN N
contrast NN N
to TO N
the DT N
positive JJ N
relationship NN N
observed VBD N
for IN N
CRP NNP N
, , N
neither DT N
homocysteine NN N
nor CC N
lipid JJ N
levels NNS N
were VBD N
significantly RB N
associated VBN N
with IN N
risk NN N
of IN N
SCD NNP N
CONCLUSIONS NNP N
These DT N
prospective JJ N
data NNS N
suggest VBP N
that IN N
CRP NNP N
levels NNS N
may MD N
be VB N
useful JJ N
in IN N
identifying VBG N
apparently RB N
healthy JJ N
men NNS N
who WP N
are VBP N
at IN 4_p
an DT 4_p
increased VBN 4_p
long-term JJ 4_p
risk NN 4_p
of IN 4_p
SCD NNP 4_p
-DOCSTART- -X- O O 10602739

Ciprofloxacin NNP N
, , N
lomefloxacin NN N
, , N
or CC N
levofloxacin CC N
as IN N
treatment NN N
for IN N
chronic JJ 4_p
osteomyelitis NN 4_p
The DT N
efficacy NN N
and CC N
safety NN N
of IN N
three CD N
oral JJ N
fluoroquinolones NNS N
( ( N
lomefloxacin NN N
, , N
levofloxacin NN N
, , N
and CC N
ciprofloxacin NN N
) ) N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
osteomyelitis NN N
were VBD N
analyzed VBN N
Twenty-seven JJ 3_p
patients NNS N
had VBD N
documented VBN N
infections NNS 4_p
with IN 4_p
quinolone-sensitive JJ 4_p
organisms NNS 4_p
and CC N
received VBD N
either DT N
lomefloxacin NN N
, , N
levofloxacin NN N
, , N
or CC N
ciprofloxacin NN N
Levofloxacin NNP N
was VBD N
effective JJ N
therapy NN N
for IN N
9 CD N
of IN N
15 CD N
( ( N
60 CD N
% NN N
) ) N
patients NNS N
Lomefloxacin NNP N
was VBD N
effective JJ N
therapy NN N
for IN N
five CD N
of IN N
seven CD N
( ( N
71 CD N
% NN N
) ) N
patients NNS N
, , N
and CC N
ciprofloxacin NN N
was VBD N
effective JJ N
therapy NN N
for IN N
two CD N
of IN N
five CD N
patients NNS N
( ( N
40 CD N
% NN N
) ) N
Average JJ N
follow-up NN N
was VBD N
11.8 CD N
months NNS N
for IN N
patients NNS N
who WP N
completed VBD N
the DT N
course NN N
of IN N
therapy NN N
, , N
and CC N
the DT N
average JJ N
duration NN N
of IN N
therapy NN N
was VBD N
60.6 CD N
days NNS N
Gram-positive JJ N
bacteria NNS N
were VBD N
isolated VBN N
from IN N
18 CD N
patients NNS N
, , N
and CC N
11 CD N
patients NNS N
were VBD N
cured VBN N
Oral JJ N
fluoroquinolones NNS N
can MD N
be VB N
safe JJ N
, , N
effective JJ N
therapy NN N
if IN N
they PRP N
are VBP N
given VBN N
for IN N
a DT N
prolonged JJ N
course NN N
as IN N
treatment NN N
for IN N
infections NNS N
caused VBN N
by IN N
susceptible JJ N
gram-positive JJ N
as RB N
well RB N
as IN N
gram-negative JJ N
organisms NNS N
and CC N
in IN N
combination NN N
with IN N
adequate JJ N
surgical JJ N
debridement NN N
-DOCSTART- -X- O O 20406576

The DT N
ScanBrit NNP N
randomised VBD N
, , N
controlled VBD N
, , N
single-blind JJ N
study NN N
of IN N
a DT N
gluten- JJ N
and CC N
casein-free JJ N
dietary JJ N
intervention NN N
for IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
There EX N
is VBZ N
increasing VBG N
interest NN N
in IN N
the DT N
use NN N
of IN N
gluten- JJ N
and CC N
casein-free JJ N
diets NNS N
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP N
) ) N
We PRP N
report VBP N
results NNS N
from IN N
a DT N
two-stage NN N
, , N
24-month JJ N
, , N
randomised VBN N
, , N
controlled VBN N
trial NN N
incorporating VBG N
an DT N
adaptive JJ N
'catch-up NN N
' POS N
design NN N
and CC N
interim JJ N
analysis NN N
Stage NN N
1 CD N
of IN N
the DT N
trial NN N
saw VBD N
72 CD 3_p
Danish JJ N
children NNS N
( ( N
aged VBN 1_p
4 CD 1_p
years NNS 1_p
to TO 1_p
10 CD 1_p
years NNS 1_p
11 CD 1_p
months NNS 1_p
) ) N
assigned VBD N
to TO N
diet VB N
( ( N
A DT N
) ) N
or CC N
non-diet JJ N
( ( N
B NNP N
) ) N
groups NNS N
by IN N
stratified JJ N
randomisation NN N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
( ( N
ADOS NNP N
) ) N
and CC N
the DT N
Gilliam NNP N
Autism NNP N
Rating NNP N
Scale NNP N
( ( N
GARS NNP N
) ) N
were VBD N
used VBN N
to TO N
assess VB N
core NN N
autism NN N
behaviours NNS N
, , N
Vineland NNP N
Adaptive NNP N
Behaviour NNP N
Scales NNP N
( ( N
VABS NNP N
) ) N
to TO N
ascertain VB N
developmental JJ N
level NN N
, , N
and CC N
Attention-Deficit NNP N
Hyperactivity NNP N
Disorder NNP N
- : N
IV NNP N
scale NN N
( ( N
ADHD-IV NNP N
) ) N
to TO N
determine VB N
inattention NN N
and CC N
hyperactivity NN N
Participants NNS N
were VBD N
tested VBN N
at IN N
baseline NN N
, , N
8 CD N
, , N
and CC N
12 CD N
months NNS N
Based VBN N
on IN N
per IN N
protocol NN N
repeated VBN N
measures NNS N
analysis NN N
, , N
data NNS N
for IN N
26 CD 3_p
diet JJ 3_p
children NNS 3_p
and CC N
29 CD 3_p
controls NNS 3_p
were VBD N
available JJ N
at IN N
12 CD N
months NNS N
At IN N
this DT N
point NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
improvement NN N
to TO N
mean VB N
diet JJ N
group NN N
scores NNS N
( ( N
time*treatment JJ N
interaction NN N
) ) N
on IN N
sub-domains NNS N
of IN N
ADOS NNP N
, , N
GARS NNP N
and CC N
ADHD-IV NNP N
measures NNS N
Surpassing VBG N
of IN N
predefined JJ N
statistical JJ N
thresholds NNS N
as IN N
evidence NN N
of IN N
improvement NN N
in IN N
group NN N
A NNP N
at IN N
12 CD N
months NNS N
sanctioned VBD N
the DT N
re-assignment NN N
of IN N
group NN N
B NNP N
participants NNS N
to TO N
active JJ N
dietary JJ N
treatment NN N
Stage NN N
2 CD N
data NNS N
for IN N
18 CD N
group NN N
A NNP N
and CC N
17 CD N
group NN N
B NNP N
participants NNS N
were VBD N
available JJ N
at IN N
24 CD N
months NNS N
Multiple NNP N
scenario NN N
analysis NN N
based VBN N
on IN N
inter- JJ N
and CC N
intra-group JJ N
comparisons NNS N
showed VBD N
some DT N
evidence NN N
of IN N
sustained JJ N
clinical JJ N
group NN N
improvements NNS N
although IN N
possibly RB N
indicative JJ N
of IN N
a DT N
plateau NN N
effect NN N
for IN N
intervention NN N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
dietary JJ N
intervention NN N
may MD N
positively RB N
affect VB N
developmental JJ N
outcome NN N
for IN N
some DT N
children NNS N
diagnosed VBN N
with IN N
ASD NNP N
In IN N
the DT N
absence NN N
of IN N
a DT N
placebo NN N
condition NN N
to TO N
the DT N
current JJ N
investigation NN N
, , N
we PRP N
are VBP N
, , N
however RB N
, , N
unable JJ N
to TO N
disqualify VB N
potential JJ N
effects NNS N
derived VBN N
from IN N
intervention NN N
outside IN N
of IN N
dietary JJ N
changes NNS N
Further JJ N
studies NNS N
are VBP N
required VBN N
to TO N
ascertain VB N
potential JJ N
best- NN N
and CC N
non-responders NNS N
to TO N
intervention NN N
The DT N
study NN N
was VBD N
registered VBN N
with IN N
ClincialTrials.gov NNP N
, , N
number NN N
NCT00614198 NNP N
-DOCSTART- -X- O O 12823129

The DT N
prevalence NN N
of IN N
IgE NNP N
sensitization NN N
to TO N
formaldehyde VB N
in IN N
asthmatic JJ 4_p
children NNS N
BACKGROUND NNP N
Formaldehyde NNP N
( ( N
FA NNP N
) ) N
is VBZ N
well RB N
documented VBN N
as IN N
a DT N
cause NN N
of IN N
occupational JJ N
asthma NN N
Recently RB N
, , N
attention NN N
has VBZ N
been VBN N
paid VBN N
to TO N
FA NNP N
as IN N
an DT N
allergen NN N
and CC N
a DT N
pollutant NN N
that WDT N
enhances VBZ N
allergic JJ N
sensitization NN N
We PRP N
have VBP N
investigated VBN N
the DT N
prevalence NN N
of IN N
FA-specific NNP N
IgE NNP N
in IN N
asthmatic JJ 4_p
children NNS N
and CC N
the DT N
correlation NN N
between IN N
IgE NNP N
sensitization NN N
to TO N
FA NNP N
and CC N
the DT N
severity NN N
of IN N
asthma NN N
METHODS NNP N
One CD N
hundred CD N
and CC N
fifty-five JJ N
children NNS N
were VBD N
investigated VBN N
, , N
122 CD N
of IN N
them PRP N
asthmatic JJ N
and CC N
33 CD N
nonallergic NN N
Specific JJ N
IgE NNP N
against IN N
FA NNP N
was VBD N
measured VBN N
by IN N
CAP NNP N
RAST NNP N
In IN N
addition NN N
, , N
the DT N
patients NNS N
answered VBD N
a DT N
questionnaire NN N
, , N
containing VBG N
questions NNS N
on IN N
clinical JJ N
features NNS N
of IN N
their PRP$ N
asthma NN N
, , N
their PRP$ N
living NN N
conditions NNS N
, , N
and CC N
symptoms NNS N
of IN N
mucosal JJ N
irritation NN N
RESULTS NNP N
Of IN N
all PDT N
the DT N
subjects NNS N
assessed VBN N
, , N
FA-specific NNP N
IgE NNP N
was VBD N
detected VBN N
in IN N
only RB N
two CD N
asthmatics NNS N
, , N
and CC N
their PRP$ N
IgE NNP N
levels NNS N
of IN N
FA NNP N
were VBD N
low JJ N
( ( N
0.42 CD N
and CC N
0.46 CD N
UA/ml NNP N
) ) N
One CD N
of IN N
the DT N
two CD N
patients NNS N
with IN N
FA-specific NNP N
IgE NNP N
had VBD N
severe JJ N
asthma NN N
and CC N
frequent JJ N
symptoms NNS N
of IN N
mucosal JJ N
irritation NN N
, , N
but CC N
the DT N
other JJ N
had VBD N
mild VBN N
asthma NNS N
and CC N
only RB N
rare JJ N
symptoms NNS N
of IN N
mucosal JJ N
irritation NN N
CONCLUSIONS VB N
The DT N
prevalence NN N
of IN N
IgE NNP N
sensitization NN N
to TO N
FA NNP N
appears VBZ N
very RB N
low JJ N
in IN N
Japanese JJ N
children NNS N
, , N
whether IN N
or CC N
not RB N
they PRP N
have VBP N
asthma VBN N
Therefore RB N
, , N
it PRP N
appears VBZ N
likely JJ N
that IN N
FA NNP N
is VBZ N
not RB N
one CD N
of IN N
the DT N
major JJ N
allergens NNS N
causing VBG N
childhood NN N
asthma NN N
-DOCSTART- -X- O O 2860373

Primary JJ 4_p
hypothyroidism NN 4_p
associated VBN N
with IN N
interferon JJ 4_p
therapy NN 4_p
of IN 4_p
breast NN 4_p
cancer NN 4_p
-DOCSTART- -X- O O 23233021

A DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
bumetanide NN N
in IN N
the DT N
treatment NN N
of IN N
autism NN 1_p
in IN 1_p
children NNS 1_p
Gamma NNP N
aminobutyric JJ N
acid NN N
( ( N
GABA NNP N
) ) N
-mediated VBD N
synapses NNS N
and CC N
the DT N
oscillations NNS N
they PRP N
orchestrate VBP N
are VBP N
altered VBN N
in IN N
autism NN N
GABA-acting JJ N
benzodiazepines NNS N
exert NN N
in IN N
some DT N
patients NNS N
with IN N
autism NN N
paradoxical JJ N
effects NNS N
, , N
raising VBG N
the DT N
possibility NN N
that IN N
like IN N
in IN N
epilepsies NNS N
, , N
GABA NNP N
excites VBZ N
neurons NNS N
because IN N
of IN N
elevated JJ N
intracellular JJ N
concentrations NNS N
of IN N
chloride NN N
Following VBG N
a DT N
successful JJ N
pilot NN N
study NN N
, , N
( ( N
1 CD N
) ) N
we PRP N
have VBP N
now RB N
performed VBN N
a DT N
double-blind JJ N
clinical JJ N
trial NN N
using VBG N
the DT N
diuretic JJ N
, , N
chloride-importer JJ N
antagonist NN N
bumetanide IN N
that DT N
reduces VBZ N
intracellular JJ N
chloride NN N
reinforcing VBG N
GABAergic NNP N
inhibition NN N
Sixty NNP 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
or CC 1_p
Asperger NNP 1_p
syndrome VBP 1_p
( ( 1_p
3-11 CD 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
received VBD N
for IN N
3 CD N
months NNS N
placebo NN N
or CC N
bumetanide NN N
( ( N
1 CD N
mg NNS N
daily RB N
) ) N
, , N
followed VBN N
by IN N
1-month JJ N
wash NN N
out IN N
Determination NN N
of IN N
the DT N
severity NN N
of IN N
autism NN N
was VBD N
made VBN N
with IN N
video JJ N
films NNS N
at IN N
day NN N
0 CD N
( ( N
D0 NNP N
) ) N
and CC N
D90 NNP N
by IN N
blind NN N
, , N
independent JJ N
evaluators NNS N
Bumetanide NNP N
reduced VBD N
significantly RB N
the DT N
Childhood NNP N
Autism NNP N
Rating NNP N
Scale NNP N
( ( N
CARS NNP N
) ) N
( ( N
D90-D0 NNP N
; : N
P NNP N
< VBD N
0.004 CD N
treated JJ N
vs NN N
placebo NN N
) ) N
, , N
Clinical JJ N
Global NNP N
Impressions NNP N
( ( N
P NNP N
< VBZ N
0.017 CD N
treated JJ N
vs NN N
placebo NN N
) ) N
and CC N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
values NNS N
when WRB N
the DT N
most RBS N
severe JJ N
cases NNS N
( ( N
CARS NNPS N
values NNS N
above IN N
the DT N
mean JJ N
± NNP N
s.d NN N
; : N
n=9 CC N
) ) N
were VBD N
removed VBN N
( ( N
Wilcoxon JJ N
test NN N
: : N
P-value=0.031 NN N
; : N
Student NNP N
's POS N
t-test NN N
: : N
P-value=0.017 NN N
) ) N
Side JJ N
effects NNS N
were VBD N
restricted VBN N
to TO N
an DT N
occasional JJ N
mild NN N
hypokalaemia NN N
( ( N
3.0-3.5 JJ N
mM NN N
l NN N
( ( N
-1 NNP N
) ) N
K NNP N
( ( N
+ NNP N
) ) N
) ) N
that WDT N
was VBD N
treated VBN N
with IN N
supplemental JJ N
potassium NN N
In IN N
a DT N
companion NN N
study NN N
, , N
chronic JJ N
bumetanide NN N
treatment NN N
significantly RB N
improved VBN N
accuracy NN N
in IN N
facial JJ N
emotional JJ N
labelling NN N
, , N
and CC N
increased VBD N
brain NN N
activation NN N
in IN N
areas NNS N
involved VBN N
in IN N
social JJ N
and CC N
emotional JJ N
perception NN N
( ( N
Hadjikhani NNP N
et RB N
al. RB N
, , N
submitted VBN N
) ) N
Therefore RB N
, , N
bumetanide NN N
is VBZ N
a DT N
promising JJ N
novel NN N
therapeutic JJ N
agent NN N
to TO N
treat VB N
autism NN N
Larger JJR N
trials NNS N
are VBP N
warranted VBN N
to TO N
better RBR N
determine VB N
the DT N
population NN N
best RB N
suited VBN N
for IN N
this DT N
treatment NN N
-DOCSTART- -X- O O 23688859

Effects NNS N
of IN N
exposure NN N
to TO N
thin-ideal JJ N
media NNS N
images NNS N
on IN N
body NN N
dissatisfaction NN N
: : N
testing VBG N
the DT N
inclusion NN N
of IN N
a DT N
disclaimer NN N
versus NN N
warning VBG N
label NN N
The DT N
current JJ N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
whether IN N
the DT N
inclusion NN N
of IN N
a DT N
disclaimer NN N
( ( N
i.e. FW N
, , N
" FW N
Retouched NNP N
photograph NN N
aimed VBN N
at IN N
changing VBG N
a DT N
person NN N
's POS N
physical JJ N
appearance NN N
" NN N
) ) N
or CC N
warning VBG N
( ( N
i.e. FW N
, , N
" FW N
Warning VBG N
: : N
Trying NN N
to TO N
look VB N
as RB N
thin JJ N
as IN N
this DT N
model NN N
may MD N
be VB N
dangerous JJ N
to TO N
your PRP$ N
health NN N
" NN N
) ) N
added VBD N
to TO N
images NNS N
of IN N
thin/attractive JJ N
models NNS N
would MD N
affect VB N
body NN N
dissatisfaction NN N
and CC N
intent NN N
to TO N
diet VB N
in IN N
female JJ N
undergraduate JJ N
students NNS N
( ( N
n=342 NN N
) ) N
Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD N
groups NNS N
: : N
( ( N
a DT N
) ) N
disclaimer NN N
, , N
( ( N
b NN N
) ) N
warning NN N
, , N
( ( N
c NN N
) ) N
model NN N
control NN N
, , N
or CC N
( ( N
d NN N
) ) N
car NN N
control NN N
Results NNP N
revealed VBD N
a DT N
significant JJ N
interaction NN N
between IN N
group NN N
and CC N
time NN N
, , N
whereby WRB N
only RB N
the DT N
car NN N
control NN N
group NN N
reported VBD N
a DT N
significant JJ N
change NN N
( ( N
i.e. FW N
, , N
decrease NN N
) ) N
in IN N
body NN N
dissatisfaction NN N
over IN N
time NN N
Groups NNP N
did VBD N
not RB N
differ VB N
on IN N
intent NN N
to TO N
diet VB N
measured VBN N
at IN N
post-exposure NN N
The DT N
results NNS N
largely RB N
replicate VBP N
other JJ N
findings NNS N
in IN N
this DT N
area NN N
and CC N
call VB N
into IN N
question NN N
advocacy NN N
efforts NNS N
to TO N
label VB N
media NNS N
images NNS N
as IN N
a DT N
strategy NN N
to TO N
decrease VB N
women NNS N
's POS N
identification NN N
with IN N
the DT N
stimuli NNS N
-DOCSTART- -X- O O 14520769

Analgesic JJ N
efficacy NN N
of IN N
low-dose JJ N
diclofenac NN N
versus NN N
paracetamol NN N
and CC N
placebo NN N
in IN N
postoperative JJ 4_p
dental NN 4_p
pain NN 4_p
AIMS NNP N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
diclofenac-K NN N
( ( N
12.5 CD N
mg NN N
) ) N
vs NN N
paracetamol NN N
( ( N
500 CD N
mg NN N
) ) N
and CC N
placebo VB N
given VBN N
in IN N
a DT N
flexible JJ N
dosage NN N
regimen NNS N
to TO N
treat VB N
pain NN 4_p
resulting VBG N
from IN N
extraction NN 4_p
of IN 4_p
impacted JJ 4_p
third JJ 4_p
molar JJ 4_p
teeth NN 4_p
METHODS NNP N
This DT N
was VBD N
a DT N
2-day JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ N
study NN N
of IN N
diclofenac-K NN N
( ( N
12.5 CD N
mg NN N
) ) N
tablets VBZ N
vs JJ N
paracetamol NN N
( ( N
500 CD N
mg NN N
) ) N
tablets NNS N
and CC N
placebo NN N
in IN N
patients NNS N
with IN N
moderate JJ 4_p
or CC 4_p
severe JJ 4_p
pain NN 4_p
within IN N
8 CD N
hours NNS N
of IN N
extraction NN 4_p
of IN 4_p
impacted JJ 4_p
third JJ 4_p
molars NNS 4_p
RESULTS NNP N
After IN N
the DT N
first JJ N
2-tablet JJ N
dose NN N
, , N
patients NNS N
took VBD N
on IN N
average JJ N
2.5 CD N
additional JJ N
tablets NNS N
of IN N
diclofenac-K NN N
or CC N
2.4 CD N
tablets NNS N
of IN N
paracetamol NN N
, , N
almost RB N
all DT N
as IN N
1-tablet JJ N
doses NNS N
Most JJS N
placebo JJ N
patients NNS N
discontinued VBN N
by IN N
taking VBG N
rescue JJ N
medication NN N
( ( N
ibuprofen JJ N
200 CD N
mg NN N
) ) N
on IN N
the DT N
first JJ N
day NN N
Pain NNP N
relief NN N
after IN N
the DT N
initial JJ N
dose NN N
of IN N
diclofenac-K NN N
( ( N
2 CD N
x RB N
12.5 CD N
mg NN N
) ) N
was VBD N
superior JJ N
to TO N
placebo VB N
( ( N
P NNP N
< NNP N
.01 NNP N
for IN N
all DT N
efficacy NN N
outcomes NNS N
) ) N
and CC N
comparable JJ N
to TO N
paracetamol VB N
( ( N
2 CD N
x RB N
500 CD N
mg NN N
) ) N
About IN N
30 CD N
% NN N
of IN N
patients NNS N
in IN N
each DT N
active JJ N
treatment NN N
group NN N
took VBD N
rescue NN N
medication NN N
during IN N
the DT N
study NN N
, , N
compared VBN N
to TO N
78 CD N
% NN N
on IN N
placebo NN N
About IN N
70 CD N
% NN N
in IN N
each DT N
active JJ N
treatment NN N
group NN N
considered VBD N
the DT N
overall JJ N
pain NN N
relief NN N
to TO N
be VB N
" JJ N
some DT N
, , N
" JJ N
" VBP N
a DT N
lot NN N
, , N
" '' N
or CC N
" VB N
complete JJ N
" NNS N
compared VBN N
to TO N
only RB N
15 CD N
% NN N
on IN N
placebo NN N
The DT N
incidence NN N
of IN N
adverse JJ N
events NNS N
in IN N
each DT N
active JJ N
treatment NN N
group NN N
was VBD N
low JJ N
and CC N
comparable JJ N
between IN N
the DT N
treatments NNS N
CONCLUSION NNP N
An DT N
initial JJ N
double-dose NN N
of IN N
diclofenac-K NN N
( ( N
2 CD N
x RB N
12.5 CD N
mg NN N
) ) N
or CC N
paracetamol NN N
( ( N
2 CD N
x RB N
500 CD N
mg NNS N
) ) N
adequately RB N
relieved VBD N
the DT N
most RBS N
intense JJ N
postoperative NN 4_p
pain NN 4_p
, , N
and CC N
the DT N
flexible JJ N
multiple NN N
dose JJ N
regimen NNS N
( ( N
1 CD N
or CC N
2 CD N
tablets NNS N
) ) N
maintained VBD N
adequate JJ N
pain NN N
relief NN N
thereafter RB N
Most JJS N
patients NNS N
needed VBN N
only RB N
1-tablet JJ N
doses NNS N
following VBG N
the DT N
initial JJ N
2-tablet JJ N
dose NN N
-DOCSTART- -X- O O 24998293

Quality NN N
of IN N
life NN N
and CC N
fatigue NN N
of IN N
patients NNS N
with IN N
spinal JJ 4_p
bone NN 4_p
metastases NNS 4_p
under IN N
combined VBN N
treatment NN N
with IN N
resistance NN N
training NN N
and CC N
radiation NN 4_p
therapy- NN 4_p
a DT N
randomized VBN N
pilot NN N
trial NN N
BACKGROUND VB N
The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
resistance NN N
training NN N
versus IN N
passive JJ N
physical JJ N
therapy NN N
on IN N
quality NN N
of IN N
life NN N
( ( N
QoL NNP N
) ) N
, , N
fatigue NN N
, , N
and CC N
emotional JJ N
distress NN N
outcomes NNS N
during IN N
radiation NN N
therapy NN N
in IN N
patients NNS 4_p
with IN 4_p
spinal JJ 4_p
bone NN 4_p
metastases NNS 4_p
under IN 4_p
radiotherapy NN 4_p
( ( 4_p
RT NNP 4_p
) ) 4_p
METHODS NNP N
In IN N
this DT N
randomized JJ N
trial NN N
, , N
60 CD 3_p
patients NNS N
were VBD N
treated VBN N
from IN N
September NNP N
2011 CD N
until IN N
March NNP N
2013 CD N
into IN N
one CD N
of IN N
the DT N
two CD N
groups NNS N
: : N
isometric JJ N
resistance NN N
training NN N
or CC N
physical JJ N
therapy NN N
with IN N
thirty JJ N
patients NNS N
in IN N
each DT N
group NN N
during IN N
RT NNP N
EORTC NNP N
QLQ-BM22 NNP N
, , N
EORTC NNP N
QLQ-FA13 NNP N
, , N
and CC N
FBK-R10 NNP N
were VBD N
assessed VBN N
at IN N
baseline NN N
, , N
three CD N
months NNS N
, , N
and CC N
six CD N
months NNS N
after IN N
RT NNP N
RESULTS NNP N
Psychosocial JJ N
aspects NNS N
in IN N
resistance NN N
training NN N
group NN N
( ( N
Arm NNP N
A NNP N
) ) N
were VBD N
significantly RB N
improved VBN N
after IN N
three CD N
( ( N
p VB N
= RB N
0.001 CD N
) ) N
and CC N
six CD N
months NNS N
( ( N
p JJ N
= NNP N
0.010 CD N
) ) N
Other JJ N
rated JJ N
items NNS N
of IN N
the DT N
QLQ-BM22 NNP N
painful JJ N
site NN N
, , N
and CC N
pain NN N
characteristics NNS N
were VBD N
without IN N
significant JJ N
differences NNS N
Functional JJ N
interference NN N
showed VBD N
a DT N
positive JJ N
trend NN N
after IN N
six CD N
months NNS N
( ( N
p JJ N
= NNP N
0.081 CD N
) ) N
After IN N
six CD N
months NNS N
, , N
physical JJ N
fatigue NN N
( ( N
p JJ N
= NNP N
0.013 CD N
) ) N
, , N
and CC N
interference NN N
with IN N
daily JJ N
life NN N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
according VBG N
to TO N
the DT N
QLQ-FA13 NNP N
assessment NN N
improved VBN N
in IN N
Arm NNP N
A NNP N
significantly RB N
Emotional JJ N
distress NN N
was VBD N
in IN N
Arm NNP N
A NNP N
lower JJR N
after IN N
six CD N
months NNS N
( ( N
p JJ N
= NNP N
0.016 CD N
) ) N
The DT N
Cohen NNP N
's POS N
effect NN N
size NN N
confirmed VBD N
the DT N
clinically NN N
significant JJ N
improvement NN N
of IN N
these DT N
findings NNS N
CONCLUSIONS NNP N
In IN N
this DT N
group NN N
of IN N
patients NNS N
we PRP N
were VBD N
able JJ N
to TO N
show VB N
that DT N
guided VBD N
isometric JJ N
resistance NN N
training NN N
of IN N
the DT N
paravertebral JJ N
muscles NNS N
can MD N
improve VB N
functional JJ N
capacity NN N
, , N
reduce VB N
fatigue NN N
and CC N
thereby NN N
enhance NN N
QoL NNP N
over IN N
a DT N
6-months JJ N
period NN N
in IN N
patients NNS N
with IN N
stable JJ N
spinal JJ N
metastases NNS N
The DT N
results NNS N
offer VBP N
a DT N
rationale NN N
for IN N
future JJ N
large JJ N
controlled VBN N
investigations NNS N
to TO N
confirm VB N
these DT N
findings NNS N
TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
trial NN N
identifier NN N
NCT01409720 NNP N
-DOCSTART- -X- O O 7706098

The DT N
effect NN N
of IN N
patient JJ N
position NN N
on IN N
the DT N
reproducibility NN N
of IN N
cardiac JJ N
output NN N
measurements NNS N
OBJECTIVE NN N
To TO N
determine VB N
the DT N
effect NN N
of IN N
patient JJ N
position NN N
on IN N
the DT N
reproducibility NN N
of IN N
cardiac JJ N
output NN N
measurements NNS N
DESIGN NNP N
Prospective NNP N
, , N
two-group JJ N
quasi-experimental JJ N
design NN N
Convenience NN N
sample NN N
SETTING CC N
The DT N
study NN N
involved VBD N
two CD N
intensive JJ N
care NN N
units NNS N
in IN N
two CD N
adult NN N
acute NN N
care NN N
hospitals NNS N
PATIENTS NNP N
Thirty NNP 3_p
patients NNS N
admitted VBD N
to TO N
the DT N
intensive JJ N
care NN N
unit NN N
who WP N
had VBD N
a DT N
thermodilution NN 4_p
pulmonary JJ 4_p
artery NN 4_p
catheter NN 4_p
in IN N
place NN N
Ages NNS N
ranged VBD N
from IN N
39 CD 1_p
to TO 1_p
80 CD 1_p
years NNS N
( ( N
mean NN N
of IN N
66.4 CD N
+/- JJ N
11.3 CD N
years NNS N
) ) N
OUTCOME NNP N
MEASURES NNP N
Thermodilution NNP N
cardiac NN N
output NN N
measurements NNS N
INTERVENTION NNP N
The DT N
subjects NNS N
were VBD N
placed VBN N
in IN N
one CD N
of IN N
two CD N
groups NNS N
, , N
initially RB N
by IN N
flipping VBG N
a DT N
coin NN N
then RB N
into IN N
alternate NN N
groups NNS N
Group NNP N
A NNP N
subjects NNS N
were VBD N
placed VBN N
supine NN N
, , N
and CC N
after IN N
5 CD N
minutes NNS N
had VBD N
cardiac JJ N
output NN N
measurements NNS N
performed VBN N
They PRP N
were VBD N
then RB N
placed VBN N
in IN N
the DT N
45-degree JJ N
upright JJ N
position NN N
, , N
and CC N
after IN N
an DT N
additional JJ N
5 CD N
minutes NNS N
had VBD N
cardiac JJ N
output NN N
measurements NNS N
performed VBN N
Group NNP N
B NNP N
subjects NNS N
were VBD N
first RB N
placed VBN N
in IN N
the DT N
45-degree JJ N
upright JJ N
position NN N
, , N
and CC N
after IN N
5 CD N
minutes NNS N
had VBD N
cardiac JJ N
output NN N
measurements NNS N
performed VBN N
They PRP N
were VBD N
then RB N
placed VBN N
in IN N
the DT N
supine NN N
flat JJ N
position NN N
, , N
and CC N
after IN N
an DT N
additional JJ N
5 CD N
minutes NNS N
had VBD N
cardiac JJ N
output NN N
measurements NNS N
performed VBN N
RESULTS NNP N
Seventy NNP N
percent NN N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
of IN N
the DT N
sample JJ N
population NN N
displayed VBD N
a DT N
lower JJR N
cardiac NN N
output NN N
in IN N
the DT N
45-degree JJ N
upright JJ N
position NN N
than IN N
that DT N
obtained VBN N
in IN N
the DT N
supine JJ N
position NN N
, , N
with IN N
the DT N
decrease NN N
ranging VBG N
from IN N
1 CD N
% NN N
to TO N
32 CD N
% NN N
( ( N
mean JJ N
decrease NN N
11 CD N
% NN N
) ) N
Forty CD N
percent NN N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
of IN N
cardiac JJ N
output NN N
measurements NNS N
obtained VBN N
in IN N
the DT N
45-degree JJ N
upright NN N
were VBD N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
10 CD N
% NN N
less JJR N
than IN N
those DT N
obtained VBN N
in IN N
the DT N
supine NN N
flat JJ N
position NN N
The DT N
differences NNS N
in IN N
cardiac JJ N
output NN N
were VBD N
analyzed VBN N
with IN N
the DT N
paired JJ N
t JJ N
test NN N
which WDT N
produced VBD N
a DT N
95 CD N
% NN N
confidence NN N
interval NN N
from IN N
-0.539 NN N
to TO N
-0.083 VB N
The DT N
two-group JJ N
Wilcoxon NNP N
test NN N
was VBD N
used VBN N
to TO N
analyze VB N
the DT N
mean JJ N
cardiac JJ N
output NN N
with IN N
the DT N
patient NN N
in IN N
the DT N
supine NN N
, , N
flat JJ N
position NN N
and CC N
in IN N
the DT N
45-degree JJ N
upright JJ N
position NN N
The DT N
mean JJ N
cardiac JJ N
output NN N
at IN N
0 CD N
degrees NNS N
was VBD N
found VBN N
to TO N
be VB N
statistically RB N
significant JJ N
higher JJR N
( ( N
p JJ N
= NNP N
0.0083 CD N
) ) N
than IN N
the DT N
mean JJ N
cardiac JJ N
output NN N
at IN N
45 CD N
degrees NNS N
The DT N
effect NN N
of IN N
coexisting VBG N
variables NNS N
was VBD N
analyzed VBN N
with IN N
the DT N
Kruskal-Wallis NNP N
The DT N
use NN N
of IN N
vasoconstrictors NNS N
was VBD N
the DT N
only JJ N
variable NN N
that WDT N
had VBD N
a DT N
statistically RB N
significant JJ N
change NN N
in IN N
cardiac JJ N
output NN N
associated VBN N
with IN N
a DT N
change NN N
in IN N
position NN N
CONCLUSIONS NNP N
These DT N
results NNS N
indicate VBP N
that IN N
cardiac JJ N
output NN N
measurements NNS N
are VBP N
affected VBN N
by IN N
alterations NNS N
in IN N
patient JJ N
position NN N
To TO N
ensure VB N
accurate JJ N
comparisons NNS N
between IN N
consecutive JJ N
cardiac JJ N
output NN N
measurements NNS N
, , N
the DT N
researchers NNS N
recommend VBP N
that IN N
the DT N
position NN N
in IN N
which WDT N
the DT N
cardiac NN N
output NN N
measurements NNS N
are VBP N
performed VBN N
be VB N
documented VBN N
and CC N
the DT N
cardiac JJ N
output NN N
measurements NNS N
be VB N
conducted VBN N
in IN N
a DT N
uniform JJ N
position NN N
-DOCSTART- -X- O O 20522464

Effect NN N
of IN N
addition NN N
of IN N
single JJ N
dose NN N
of IN N
oral JJ N
montelukast NN N
to TO N
standard VB N
treatment NN N
in IN N
acute JJ 4_p
moderate NN 4_p
to TO 4_p
severe VB 4_p
asthma NN 4_p
in IN N
children NNS 1_p
between IN N
5 CD 1_p
and CC 1_p
15 CD 1_p
years NNS 1_p
of IN N
age NN N
: : N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo NN N
controlled VBD N
trial NN N
OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
of IN N
the DT N
addition NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
oral JJ N
montelukast NN N
to TO N
standard VB N
therapy NN N
in IN N
acute JJ 4_p
moderate NN 4_p
to TO 4_p
severe VB 4_p
asthma NN 4_p
DESIGN NNP N
Double-blind NNP N
randomised VBD N
controlled VBN N
trial NN N
Setting VBG N
Emergency NNP N
room/outpatient NN N
paediatric NN N
services NNS N
of IN N
a DT N
tertiary JJ N
care NN N
hospital NN N
PATIENTS NNP N
Children NNP 1_p
aged VBD N
5-15 CD 1_p
years NNS 1_p
( ( N
without IN N
prior RB N
use NN N
of IN N
montelukast NN N
) ) N
with IN N
acute JJ 4_p
moderate NN 4_p
to TO 4_p
severe VB 4_p
asthma JJ 4_p
exacerbation NN 4_p
, , N
as IN N
defined VBN N
using VBG N
Modified NNP N
Pulmonary NNP N
Index NNP N
Score NNP N
( ( N
MPIS NNP N
) ) N
> VBD N
or CC N
=9 NNS N
, , N
were VBD N
enrolled VBN N
INTERVENTION NNP N
Children NNP N
received VBD N
montelukast NN N
( ( N
5-12 JJ N
years NNS N
: : N
5 CD N
mg NN N
and CC N
> $ N
12 CD N
years NNS N
: : N
10 CD N
mg NN N
) ) N
or CC N
placebo VBN N
orally RB N
in IN N
addition NN N
to TO N
the DT N
standard JJ N
therapy NN N
MPIS NNP N
and CC N
forced VBD N
expiratory JJ N
volume NN N
in IN N
1 CD N
second JJ N
( ( N
FEV NNP N
( ( N
1 CD N
) ) N
) ) N
were VBD N
recorded VBN N
before IN N
administering VBG N
study NN N
medication NN N
and CC N
thereafter RB N
, , N
hourly RB N
for IN N
4 CD N
hours NNS N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcome NN N
was VBD N
decrease NN N
in IN N
MPIS NNP N
to TO N
less JJR N
than IN N
9 CD N
at IN N
the DT N
end NN N
of IN N
4 CD N
hours NNS N
RESULTS VB N
117 CD 3_p
children NNS 1_p
( ( N
60 CD 3_p
in IN N
montelukast NN N
group NN N
and CC N
57 CD 3_p
in IN N
placebo NN N
group NN N
) ) N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
The DT N
number NN N
of IN N
children NNS N
with IN N
decrease NN N
in IN N
MPIS NNP N
to TO N
less JJR N
than IN N
9 CD N
at IN N
4 CD N
hours NNS N
was VBD N
33 CD N
( ( N
55 CD N
% NN N
) ) N
in IN N
the DT N
montelukast NN N
group NN N
and CC N
36 CD N
( ( N
63.2 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
( ( N
p=0.37 NN N
) ) N
There EX N
was VBD N
significant JJ N
improvement NN N
in IN N
MPIS NNP N
and CC N
FEV NNP N
( ( N
1 CD N
) ) N
within IN N
both CC N
the DT N
groups NNS N
from IN N
baseline NN N
to TO N
the DT N
end NN N
of IN N
4 CD N
hours NNS N
No DT N
differences NNS N
in IN N
side NN N
effects NNS N
and CC N
hospitalisation NN N
rates NNS N
were VBD N
noticed VBN N
between IN N
the DT N
two CD N
groups NNS N
CONCLUSION NNP N
Single NNP N
dose JJ N
oral JJ N
montelukast NN N
added VBD N
to TO N
standard JJ N
therapy NN N
of IN N
inhaled JJ N
bronchodilators NNS N
and CC N
systemic JJ N
glucocorticoids NNS N
did VBD N
not RB N
provide VB N
additional JJ N
clinical JJ N
benefit NN N
in IN N
children NNS 1_p
with IN N
acute JJ 4_p
moderate NN 4_p
to TO 4_p
severe VB 4_p
asthma NN 4_p
Trial JJ N
registration NN N
number NN N
The DT N
trial NN N
was VBD N
registered VBN N
at IN N
the DT N
http NN N
: : N
//clinicaltrials.gov JJ N
site NN N
( ( N
trial NN N
ID NNP N
: : N
NCT00565955 NN N
) ) N
-DOCSTART- -X- O O 11683484

Caffeine NNP N
eliminates VBZ N
psychomotor NN N
vigilance NN N
deficits NNS N
from IN N
sleep JJ N
inertia NN N
STUDY NNP N
OBJECTIVES NNP N
This DT N
study NN N
sought VBD N
to TO N
establish VB N
the DT N
effects NNS N
of IN N
caffeine NN N
on IN N
sleep JJ 4_p
inertia NN 4_p
, , N
which WDT N
is VBZ N
the DT N
ubiquitous JJ N
phenomenon NN N
of IN N
cognitive JJ N
performance NN N
impairment NN N
, , N
grogginess NN N
and CC N
tendency NN N
to TO N
return VB N
to TO N
sleep VB N
immediately RB N
after IN N
awakening VBG N
DESIGN NNP N
28 CD N
normal JJ N
adult NN N
volunteers NNS N
were VBD N
administered VBN N
sustained VBN N
low-dose JJ N
caffeine NN N
or CC N
placebo NN N
( ( N
randomized VBN N
double-blind NN N
) ) N
during IN N
the DT N
last JJ N
66 CD N
hours NNS N
of IN N
an DT N
88-hour JJ N
period NN N
of IN N
extended JJ N
wakefulness NN N
that WDT N
included VBD N
seven CD N
2-hour JJ N
naps NNS N
during IN N
which WDT N
polysomnographical JJ N
recordings NNS N
were VBD N
made VBN N
Every DT N
2 CD N
hours NNS N
of IN N
wakefulness NN N
, , N
and CC N
immediately RB N
after IN N
abrupt JJ N
awakening VBG N
from IN N
the DT N
naps NNS N
, , N
psychomotor NN N
vigilance NN N
performance NN N
was VBD N
tested VBN N
SETTING NN N
N/A NNP N
PARTICIPANTS NNP N
N/A NNP N
INTERVENTIONS NNP N
N/A NNP N
MEASUREMENTS NNP N
AND CC N
RESULTS NNP N
In IN N
the DT N
placebo NN N
condition NN N
, , N
sleep JJ N
inertia NN N
was VBD N
manifested VBN N
as IN N
significantly RB N
impaired JJ N
psychomotor NN N
vigilance NN N
upon IN N
awakening VBG N
from IN N
the DT N
naps NNS N
This DT N
impairment NN N
was VBD N
absent JJ N
in IN N
the DT N
caffeine JJ N
condition NN N
Caffeine NNP N
had VBD N
only RB N
modest JJ N
effects NNS N
on IN N
nap JJ N
sleep NN N
CONCLUSIONS NNP N
Caffeine NNP N
was VBD N
efficacious JJ N
in IN N
overcoming VBG N
sleep JJ N
inertia NN N
This DT N
suggests VBZ N
a DT N
reason NN N
for IN N
the DT N
popularity NN N
of IN N
caffeine-containing NN N
beverages NNS N
after IN N
awakening VBG N
Caffeine NNP N
's POS N
main JJ N
mechanism NN N
of IN N
action NN N
on IN N
the DT N
central JJ N
nervous JJ N
system NN N
is VBZ N
antagonism NN N
of IN N
adenosine JJ N
receptors NNS N
Thus RB N
, , N
increased VBD N
adenosine NN N
in IN N
the DT N
brain NN N
upon IN N
awakening VBG N
may MD N
be VB N
the DT N
cause NN N
of IN N
sleep JJ N
inertia NN N
-DOCSTART- -X- O O 8644688

Effect NN N
of IN N
n-3 JJ N
polyunsaturated JJ N
fatty JJ N
acid NNS N
intake VBP N
on IN N
phospholipid JJ N
fatty JJ N
acid JJ N
composition NN N
in IN N
plasma NN N
and CC N
erythrocytes NNS N
To TO N
characterize VB N
the DT N
time NN N
course NN N
of IN N
plasma NN N
and CC N
red JJ N
blood NN N
cell NN N
( ( N
RBC NNP N
) ) N
changes NNS N
after IN N
n-3 JJ N
polyunsaturated JJ N
fatty JJ N
acid NN N
( ( N
PUFA NNP N
) ) N
supplementation NN N
, , N
20 CD N
healthy JJ N
male NN N
volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
four CD N
1-g JJ N
capsules NNS N
of IN N
n-3 JJ N
PUFA NNP N
ethyl NN N
esters NNS N
or CC N
four CD N
1-g JJ N
capsules NNS N
of IN N
olive JJ N
oil NN N
( ( N
as IN N
placebo NN N
) ) N
for IN N
a DT N
period NN N
of IN N
4 CD N
mo NN N
, , N
followed VBN N
by IN N
a DT N
3-mo JJ N
washout NN N
period NN N
Fatty NNP N
acids NNS N
of IN N
plasma NN N
and CC N
RBC NNP N
phospholipid JJ N
fractions NNS N
were VBD N
analyzed VBN N
at IN N
0 CD N
, , N
2 CD N
, , N
and CC N
4 CD N
mo NN N
of IN N
treatment NN N
and CC N
at IN N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
mo NN N
of IN N
washout NN N
During IN N
n-3 JJ N
PUFA NNP N
supplementation NN N
, , N
accumulations NNS N
of IN N
eicosapentaenoic NN N
( ( N
EPA NNP N
) ) N
, , N
docosapentaenoic FW N
( ( N
DPA NNP N
) ) N
, , N
and CC N
docosahexaenoic NN N
( ( N
DHA NNP N
) ) N
acids NNS N
were VBD N
marked VBN N
after IN N
2 CD N
mo NN N
with IN N
differences NNS N
among IN N
different JJ N
fractions NNS N
of IN N
plasma NN N
and CC N
RBCs NNP N
in IN N
further JJ N
accumulation NN N
up RB N
to TO N
4 CD N
mo NN N
During IN N
the DT N
first JJ N
and CC N
second JJ N
months NNS N
of IN N
the DT N
washout NN N
, , N
slight JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
changes NNS N
of IN N
various JJ N
fatty JJ N
acids NNS N
among IN N
different JJ N
phospholipid JJ N
fractions NNS N
, , N
but CC N
after IN N
3 CD N
mo NN N
of IN N
washout NN N
, , N
only RB N
minor JJ N
alterations NNS N
were VBD N
still RB N
detectable JJ N
with IN N
respect NN N
to TO N
pretreatment VB N
values NNS N
These DT N
data NNS N
confirm VBP N
the DT N
complex JJ N
relations NNS N
among IN N
different JJ N
fatty JJ N
acid NN N
pools NNS N
after IN N
n-3 JJ N
PUFA NNP N
supplementation NN N
-DOCSTART- -X- O O 17491486

Treatment NN N
of IN N
periodontal JJ 4_p
disease NN 4_p
and CC N
the DT N
risk NN N
of IN N
preterm JJ N
birth NN N
-DOCSTART- -X- O O 9757955

Compliance NN N
with IN N
depot NN N
medroxyprogesterone NN N
acetate NN N
: : N
a DT N
randomized NN N
, , N
controlled VBD N
trial NN N
of IN N
intensive JJ N
reminders NNS N
We PRP N
enrolled VBD N
women NNS 2_p
in IN N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
to TO N
determine VB N
whether IN N
an DT N
intensive JJ N
reminder NN N
system NN N
would MD N
improve VB N
compliance NN N
in IN N
women NNS N
receiving VBG N
depot NN 4_p
medroxyprogesterone NN 4_p
injections NNS N
Women NNP N
selecting VBG N
this DT N
treatment NN N
were VBD N
assigned VBN N
to TO N
a DT N
group NN N
that WDT N
received VBD N
both DT N
mail NN N
and CC N
telephone NN N
reminders NNS N
or CC N
to TO N
a DT N
second JJ N
group NN N
that WDT N
received VBD N
only RB N
a DT N
scheduled JJ N
appointment NN N
at IN N
the DT N
time NN N
of IN N
the DT N
previous JJ N
injection NN N
The DT N
rate NN N
of IN N
continuation NN N
and CC N
the DT N
rate NN N
of IN N
on-time JJ N
injections NNS N
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
Women NNS N
who WP N
had VBD N
prolonged VBN N
bleeding NN N
were VBD N
more RBR N
likely JJ N
to TO N
discontinue VB N
depot VB N
medroxyprogesterone JJ N
injections NNS N
-DOCSTART- -X- O O 1911498

Intravenous JJ N
lidocaine NN N
does VBZ N
not RB N
cause VB N
shivering-like JJ N
tremor NN N
or CC N
alter NN N
thermoregulation NN N
We PRP N
tested VBD N
the DT N
hypotheses NNS N
that WDT N
systemic JJ N
absorption NN N
of IN N
epidural JJ N
lidocaine NN N
: : N
( ( N
1 CD N
) ) N
contributes NNS N
to TO N
the DT N
shivering-like JJ N
tremor NN N
seen VBN N
during IN N
epidural JJ N
anesthesia NNS N
by IN N
causing VBG N
central JJ N
nervous JJ N
system NN N
disinhibition NN N
of IN N
spinal JJ N
reflexes NNS N
, , N
or CC N
( ( N
2 CD N
) ) N
activates NNS N
or CC N
alters NNS N
thermoregulatory JJ N
mechanisms NNS N
In IN N
a DT N
double-blind NN N
, , N
placebo NN N
, , N
cross-over NN N
study NN N
, , N
nine CD N
healthy JJ N
volunteers NNS N
were VBD N
given VBN N
intravenous JJ N
lidocaine NN N
( ( N
or CC N
saline NN N
) ) N
to TO N
approximate VB N
the DT N
plasma NN N
levels NNS N
of IN N
lidocaine NN N
achieved VBN N
during IN N
epidural JJ N
anesthesia NN N
for IN N
major JJ 4_p
abdominal JJ 4_p
surgery NN 4_p
Five CD N
volunteers NNS N
were VBD N
studied VBN N
in IN N
a DT N
warm JJ N
room NN N
( ( N
to TO N
test VB N
for IN N
nonthermoregulatory JJ N
tremor NN N
) ) N
, , N
and CC N
four CD N
volunteers NNS N
were VBD N
studied VBN N
in IN N
a DT N
cold JJ N
room NN N
( ( N
to TO N
test VB N
the DT N
effects NNS N
of IN N
lidocaine NN N
on IN N
normal JJ N
thermoregulation NN N
) ) N
Central JJ N
temperatures NNS N
, , N
peripheral JJ N
vasoconstriction NN N
, , N
tremor NN N
and CC N
clonus NN N
were VBD N
unaffected VBN N
by IN N
intravenous JJ N
lidocaine NN N
We PRP N
conclude VBP N
that IN N
the DT N
systemic JJ N
absorption NN N
of IN N
epidural JJ N
lidocaine NN N
does VBZ N
not RB N
contribute VB N
to TO N
tremor VB N
or CC N
shivering VBG N
by IN N
these DT N
mechanisms NNS N
-DOCSTART- -X- O O 24675775

The DT N
effect NN N
of IN N
modified VBN N
eggs NNS N
and CC N
an DT N
egg-yolk NN N
based VBN N
beverage NN N
on IN N
serum NN 4_p
lutein NN 4_p
and CC 4_p
zeaxanthin JJ 4_p
concentrations NNS 4_p
and CC N
macular JJ N
pigment NN N
optical JJ N
density NN N
: : N
results NNS N
from IN N
a DT N
randomized JJ N
trial NN N
UNLABELLED CC N
Increasing VBG N
evidence NN N
suggests VBZ N
a DT N
beneficial JJ N
effect NN N
of IN N
lutein NN N
and CC N
zeaxanthin NN N
on IN N
the DT N
progression NN N
of IN N
age-related JJ N
macular JJ N
degeneration NN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
lutein NN N
or CC N
zeaxanthin NN N
enriched VBN N
eggs NNS N
or CC N
a DT N
lutein JJ N
enriched VBN N
egg-yolk NN N
based VBN N
buttermilk NN N
beverage NN N
on IN N
serum NN N
lutein NN N
and CC N
zeaxanthin JJ N
concentrations NNS N
and CC N
macular JJ N
pigment NN N
levels NNS N
Naturally RB N
enriched VBN N
eggs NNS N
were VBD N
made VBN N
by IN N
increasing VBG N
the DT N
levels NNS N
of IN N
the DT N
xanthophylls NNP N
lutein NN N
and CC N
zeaxanthin NN N
in IN N
the DT N
feed NN N
given VBN N
to TO N
laying VBG N
hens NNS N
One CD 3_p
hundred VBD 3_p
healthy JJ 4_p
volunteers NNS N
were VBD N
recruited VBN N
and CC N
randomized VBN N
into IN N
5 CD N
groups NNS N
for IN N
90 CD N
days NNS N
Group NNP N
one CD N
added VBD N
one CD N
normal JJ N
egg NN N
to TO N
their PRP$ N
daily JJ N
diet NNS N
and CC N
group NN N
two CD N
received VBD N
a DT N
lutein NN N
enriched VBD N
egg-yolk NN N
based VBN N
beverage NN N
Group NNP N
three CD N
added VBD N
one CD N
lutein NN N
enriched VBD N
egg NN N
and CC N
group NN N
four CD N
one CD N
zeaxanthin NN N
enriched VBD N
egg NN N
to TO N
their PRP$ N
diet JJ N
Group NNP N
five CD N
was VBD N
the DT N
control NN N
group NN N
and CC N
individuals NNS N
in IN N
this DT N
group NN N
did VBD N
not RB N
modify VB N
their PRP$ N
daily JJ N
diet NN N
Serum NNP N
lutein NN N
and CC N
zeaxanthin JJ N
concentrations NNS N
and CC N
macular JJ N
pigment NN N
densities NNS N
were VBD N
obtained VBN N
at IN N
baseline NN N
, , N
day NN N
45 CD N
and CC N
day NN N
90 CD N
Macular JJ N
pigment NN N
density NN N
was VBD N
measured VBN N
by IN N
heterochromatic JJ N
flicker NN N
photometry NN N
Serum NNP N
lutein JJ N
concentration NN N
in IN N
the DT N
lutein NN N
enriched VBD N
egg NN N
and CC N
egg NN N
yolk-based JJ N
beverage NN N
groups NNS N
increased VBD N
significantly RB N
( ( N
p JJ N
< NN N
0.001 CD N
, , N
76 CD N
% NN N
and CC N
77 CD N
% NN N
) ) N
A DT N
strong JJ N
increase NN N
in IN N
the DT N
serum NN N
zeaxanthin NN N
concentration NN N
was VBD N
observed VBN N
in IN N
individuals NNS N
receiving VBG N
zeaxanthin NN N
enriched VBN N
eggs NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
430 CD N
% NN N
) ) N
No UH N
changes NNS N
were VBD N
observed VBN N
in IN N
macular JJ N
pigment NN N
density NN N
in IN N
the DT N
various JJ N
groups NNS N
tested VBN N
The DT N
results NNS N
indicate VBP N
that IN N
daily JJ N
consumption NN N
of IN N
lutein NN N
or CC N
zeaxanthin NN N
enriched VBN N
egg NN N
yolks NNS N
as RB N
well RB N
as IN N
an DT N
egg NN N
yolk-based JJ N
beverage NN N
show NN N
increases VBZ N
in IN N
serum NN N
lutein NN N
and CC N
zeaxanthin NN N
levels NNS N
that WDT N
are VBP N
comparable JJ N
with IN N
a DT N
daily JJ N
use NN N
of IN N
5 CD N
mg NN N
supplements NNS N
TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT00527553 NNP N
-DOCSTART- -X- O O 24324379

Using VBG N
the DT N
virtual JJ N
reality-cognitive JJ N
rehabilitation NN N
approach NN N
to TO N
improve VB N
contextual JJ N
processing NN N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
BACKGROUND NNP N
This DT N
pilot NN N
study NN N
investigated VBD N
the DT N
efficacy NN N
of IN N
a DT N
novel JJ N
virtual JJ N
reality-cognitive JJ N
rehabilitation NN N
( ( N
VR-CR NNP N
) ) N
intervention NN N
to TO N
improve VB N
contextual JJ N
processing NN N
of IN N
objects NNS N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
Previous JJ N
research NN N
supports VBZ N
that IN N
children NNS 1_p
with IN N
autism NN 4_p
show NN N
deficits NNS N
in IN N
contextual JJ N
processing NN N
, , N
as RB N
well RB N
as IN N
deficits NNS N
in IN N
its PRP$ N
elementary JJ N
components NNS N
: : N
abstraction NN N
and CC N
cognitive JJ N
flexibility NN N
METHODS NNP N
Four CD 3_p
children NNS 1_p
with IN N
autism NN 4_p
participated VBN N
in IN N
a DT N
multiple-baseline JJ N
, , N
single-subject JJ N
study NN N
The DT N
children NNS 1_p
were VBD N
taught JJ N
how WRB N
to TO N
see VB N
objects NNS N
in IN N
context NN N
by IN N
reinforcing VBG N
attention NN N
to TO N
pivotal JJ N
contextual JJ N
information NN N
RESULTS NNP N
All NNP N
children NNS 1_p
demonstrated VBD N
statistically RB N
significant JJ N
improvements NNS N
in IN N
contextual JJ N
processing NN N
and CC N
cognitive JJ N
flexibility NN N
Mixed JJ N
results NNS N
were VBD N
found VBN N
on IN N
the DT N
control NN N
test NN N
and CC N
changes NNS N
in IN N
context-related JJ N
behaviours NNS N
CONCLUSIONS NNP N
Larger-scale JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
determine VB N
the DT N
effectiveness NN N
and CC N
usability NN N
in IN N
comprehensive JJ N
educational JJ N
programs NNS N
-DOCSTART- -X- O O 16214437

Effects NNS N
of IN N
glucose-insulin-potassium JJ N
infusion NN N
on IN N
ST-elevation NNP 4_p
myocardial JJ 4_p
infarction NN 4_p
in IN N
patients NNS N
treated VBN N
with IN N
thrombolytic JJ N
therapy NN N
The DT N
role NN N
of IN N
glucose-insulin-potassium NN N
( ( N
GIK NNP N
) ) N
infusion NN N
in IN N
the DT N
management NN N
of IN N
acute JJ N
myocardial JJ N
infarction NN N
is VBZ N
not RB N
well RB N
established VBN N
This DT N
prospective JJ N
, , N
randomized VBN N
study NN N
comprised VBD N
120 CD N
patients NNS N
who WP N
had VBD N
ST-elevation NNP 4_p
myocardial JJ 4_p
infarction NN 4_p
that WDT N
was VBD N
treated VBN N
within IN N
12 CD N
hours NNS N
from IN N
symptom JJ N
onset VBN N
with IN N
a DT N
high JJ N
dose NN N
of IN N
GIK NNP N
( ( N
25 CD N
% NN N
glucose NN N
, , N
50 CD N
IU NNP N
of IN N
soluble JJ N
insulin NN N
per IN N
liter NN N
, , N
and CC N
80 CD N
mmol NN N
of IN N
potassium NN N
chloride NN N
per IN N
liter NN N
at IN N
1 CD N
ml/kg/hour NN N
over IN N
24 CD N
hours NNS N
) ) N
as IN N
adjunct NN N
to TO N
thrombolytic JJ N
therapy NN N
( ( N
1.5 CD N
MU NNP N
of IN N
streptokinase/30 NN N
to TO N
60 CD N
minutes NNS N
; : N
GIK NNP N
group NN N
) ) N
or CC N
thrombolytic JJ N
therapy NN N
alone RB N
( ( N
control VB N
group NN N
) ) N
The DT N
primary JJ N
end NN N
point NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
rate NN N
of IN N
major JJ N
adverse JJ N
cardiac NN N
events NNS N
( ( N
MACEs NNP N
) ) N
at IN N
1 CD N
month NN N
, , N
defined VBD N
as IN N
a DT N
composite NN N
of IN N
cardiac JJ N
death NN N
, , N
reinfarction NN N
, , N
serious JJ N
arrhythmias NN N
( ( N
ventricular JJ N
fibrillation NN N
and/or IN N
tachycardia NN N
) ) N
, , N
and CC N
severe JJ N
heart NN N
failure NN N
The DT N
secondary JJ N
end NN N
points NNS N
were VBD N
the DT N
rate NN N
of IN N
MACEs NNP N
at IN N
1 CD N
year NN N
and CC N
improvement NN N
in IN N
left JJ N
ventricular JJ N
systolic JJ N
function NN N
The DT N
incidence NN N
of IN N
MACEs NNP N
at IN N
1 CD N
month NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
GIK NNP N
group NN N
( ( N
10 CD N
% NN N
vs JJ N
32.5 CD N
% NN N
, , N
relative JJ N
risk NN N
0.24 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.09 CD N
to TO N
0.63 CD N
, , N
p NN N
= NNP N
0.0043 CD N
) ) N
Patients NNS N
in IN N
the DT N
GIK NNP N
group NN N
had VBD N
significant JJ N
decreases NNS N
in IN N
ventricular JJ N
tachycardia NN N
and/or NN N
fibrillation NN N
( ( N
1.3 CD N
% NN N
vs JJ N
15.0 CD N
% NN N
, , N
p NN N
= NNP N
0.003 CD N
) ) N
and CC N
severe JJ N
heart NN N
failure NN N
( ( N
3 CD N
% NN N
vs JJ N
12.5 CD N
% NN N
, , N
p NN N
= NNP N
0.031 CD N
) ) N
The DT N
rate NN N
of IN N
MACEs NNP N
at IN N
1 CD N
year NN N
was VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
GIK NNP N
group NN N
( ( N
13 CD N
% NN N
vs JJ N
40.0 CD N
% NN N
, , N
relative JJ N
risk NN N
0.22 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.09 CD N
to TO N
0.55 CD N
, , N
p NN N
= NNP N
0.0012 CD N
) ) N
After IN N
1 CD N
year NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
in IN N
the DT N
GIK NNP N
group NN N
( ( N
from IN N
48 CD N
+/- JJ N
8 CD N
% NN N
to TO N
51 CD N
+/- JJ N
10 CD N
% NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
, , N
which WDT N
was VBD N
not RB N
observed VBN N
in IN N
the DT N
control NN N
group NN N
In IN N
conclusion NN N
, , N
high-dose JJ N
GIK NNP N
, , N
used VBD N
as IN N
an DT N
adjunct NN N
to TO N
thrombolytic JJ N
therapy NN N
, , N
was VBD N
safe JJ N
and CC N
improved JJ N
clinical JJ N
outcome NN N
at IN N
1 CD N
month NN N
The DT N
beneficial JJ N
effect NN N
of IN N
GIK NNP N
infusion NN N
was VBD N
maintained VBN N
up RP N
to TO N
1 CD N
year NN N
-DOCSTART- -X- O O 9474454

Twice-a-day JJ N
versus NN N
four-times-a-day JJ N
ofloxacin JJ N
treatment NN N
of IN N
external JJ N
ocular JJ N
infection NN N
PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacies NNS N
of IN N
0.3 CD N
% NN N
ofloxacin JJ N
eyedrops NNS N
, , N
when WRB N
given VBN N
twice-a-day JJ N
( ( N
BID NNP N
) ) N
versus IN N
four-times-a-day JJ N
( ( N
QID NNP N
) ) N
, , N
for IN N
the DT N
treatment NN N
of IN N
external JJ N
ocular JJ N
disease NN N
METHOD NNP N
Fifty NNP 3_p
patients NNS N
with IN N
blepharitis NN 4_p
, , N
conjuctivitis NN 4_p
, , N
or CC N
blepharoconjunctivitis NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
0.3 CD N
% NN N
ofloxacin JJ N
eyedrops NNS N
, , N
BID NNP N
or CC N
QID NNP N
, , N
for IN N
10 CD N
days NNS N
Signs NNP N
, , N
symptoms NNS N
, , N
and CC N
cultures NNS N
were VBD N
evaluated VBN N
at IN N
the DT N
beginning NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
RESULTS VB N
The DT N
clinical JJ N
outcome NN N
was VBD N
virtually RB N
identical JJ N
in IN N
the DT N
two CD N
groups NNS N
There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
clinical JJ N
scores NNS N
in IN N
the DT N
BID NNP N
and CC N
QID NNP N
groups NNS N
by IN N
days NNS N
3 CD N
to TO N
5 CD N
( ( N
2.6-3.0 JJ N
points NNS N
) ) N
and CC N
a DT N
further JJ N
decrease NN N
by IN N
day NN N
11 CD N
( ( N
4.3-5.0 JJ N
points NNS N
) ) N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
at IN N
any DT N
time NN N
interval NN N
Microbiologic NNP N
studies NNS N
showed VBD N
a DT N
reduction NN N
in IN N
colony-forming JJ N
units NNS N
in IN N
87 CD N
% NN N
of IN N
the DT N
BID NNP N
group NN N
and CC N
in IN N
80 CD N
% NN N
of IN N
the DT N
QID NNP N
group NN N
CONCLUSION NNP N
The DT N
treatment NN N
of IN N
external JJ N
ocular JJ N
disease NN N
with IN N
0.3 CD N
% NN N
ofloxacin JJ N
eyedrops NN N
was VBD N
equally RB N
effective JJ N
when WRB N
given VBN N
BID NNP N
or CC N
QID NNP N
-DOCSTART- -X- O O 10960380

The DT N
anesthetic JJ N
and CC N
recovery NN N
profile NN N
of IN N
two CD N
doses NNS N
( ( N
60 CD N
and CC N
80 CD N
mg NN N
) ) N
of IN N
plain NN N
mepivacaine NN N
for IN N
ambulatory JJ N
spinal JJ 4_p
anesthesia NN 4_p
UNLABELLED JJ N
Reports NNS N
of IN N
transient JJ N
neurological JJ N
symptoms NNS N
with IN N
the DT N
use NN N
of IN N
subarachnoid JJ N
lidocaine NN N
has VBZ N
generated VBN N
interest NN N
in IN N
alternate JJ N
local JJ N
anesthetics NNS N
of IN N
intermediate JJ N
duration NN N
, , N
such JJ N
as IN N
mepivacaine NN N
This DT N
prospective JJ N
randomized NN N
, , N
double-blinded JJ N
, , N
dose-response JJ N
study NN N
examined VBD N
the DT N
anesthetic JJ N
and CC N
recovery NN N
profiles NNS N
of IN N
60- JJ N
and CC N
80-mg JJ N
doses NNS N
of IN N
preservative-free JJ N
plain NN N
mepivacaine NN N
for IN N
ambulatory JJ N
spinal JJ N
anesthesia NN N
Sixty CD 4_p
patients NNS 4_p
undergoing JJ N
ambulatory JJ N
anterior JJ N
cruciate NN N
ligament NN N
repair NN N
of IN N
the DT N
knee NN N
under IN N
spinal JJ 4_p
anesthesia NN 4_p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
; : N
Group NNP N
1 CD N
( ( N
29 CD N
patients NNS N
) ) N
received VBD N
4 CD N
mL NN N
of IN N
1.5 CD N
% NN N
( ( N
60-mg JJ N
dose NN N
) ) N
and CC N
Group NNP N
2 CD N
( ( N
31 CD N
patients NNS N
) ) N
received VBD N
4 CD N
mL NN N
of IN N
2 CD N
% NN N
( ( N
80-mg CD N
dose NN N
) ) N
of IN N
plain NN N
mepivacaine NN N
All DT N
patients NNS N
received VBD N
a DT N
combined JJ N
spinal-epidural JJ N
anesthetic JJ N
technique NN N
The DT N
epidural JJ N
catheter NN N
was VBD N
used VBN N
only RB N
in IN N
the DT N
event NN N
the DT N
surgery NN N
outlasted VBD N
the DT N
duration NN N
of IN N
surgical JJ N
anesthesia NN N
with IN N
subarachnoid JJ N
mepivacaine NN N
Epidural JJ N
supplementation NN N
was VBD N
administered VBN N
in IN N
three CD N
patients NNS N
( ( N
12 CD N
% NN N
) ) N
in IN N
Group NNP N
1 CD N
and CC N
one CD N
patient NN N
( ( N
3 CD N
% NN N
) ) N
in IN N
Group NNP N
2 CD N
when WRB N
the DT N
sensory JJ N
block NN N
regressed VBD N
to TO N
L-1 NNP N
with IN N
surgery NN N
expected VBN N
to TO N
last JJ N
longer JJR N
than IN N
15 CD N
min NN N
The DT N
cephalad JJ N
dermatome JJ N
level NN N
of IN N
the DT N
block NN N
and CC N
degree NN N
of IN N
motor NN N
block NN N
was VBD N
comparable JJ N
in IN N
the DT N
two CD N
groups NNS N
Times NNS N
to TO N
two-segment JJ N
and CC N
T-10 JJ N
regression NN N
were VBD N
comparable JJ N
in IN N
the DT N
two CD N
groups NNS N
( ( N
112 CD N
+/- JJ N
26 CD N
min NN N
in IN N
Group NNP N
1 CD N
versus NN N
122 CD N
+/- JJ N
28 CD N
min NN N
in IN N
Group NNP N
2 CD N
) ) N
Time NN N
to TO N
L-1 NNP N
regression NN N
was VBD N
significantly RB N
longer RBR N
in IN N
Group NNP N
2 CD N
( ( N
146 CD N
+/- JJ N
28 CD N
min NN N
in IN N
Group NNP N
1 CD N
versus NN N
159 CD N
+/- JJ N
19 CD N
min NN N
in IN N
Group NNP N
2 CD N
) ) N
All DT N
of IN N
the DT N
ambulatory JJ N
milestones NNS N
were VBD N
significantly RB N
faster RBR N
in IN N
Group NNP N
1 CD N
Side NN N
effects NNS N
, , N
such JJ N
as IN N
hypotension NN N
and CC N
emesis NN N
were VBD N
negligible JJ N
, , N
severe JJ N
bradycardia NN N
and CC N
urinary JJ N
retention NN N
did VBD N
not RB N
occur VB N
, , N
and CC N
none NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
two CD N
groups NNS N
reported VBD N
transient JJ N
neurological JJ N
symptoms NNS N
over IN N
24 CD N
h. NNS N
In IN N
conclusion NN N
, , N
plain VBP N
mepivacaine NN N
in IN N
a DT N
60- JJ N
or CC N
80-mg JJ N
dose NN N
is VBZ N
a DT N
suitable JJ N
local JJ N
anesthetic JJ N
choice NN N
for IN N
ambulatory JJ N
spinal JJ N
anesthesia NN N
with IN N
respect NN N
to TO N
anesthetic JJ N
, , N
as RB N
well RB N
as IN N
recovery NN N
profiles NNS N
IMPLICATIONS NNP N
We PRP N
evaluated VBD N
the DT N
anesthetic JJ N
and CC N
recovery NN N
profiles NNS N
of IN N
60- JJ N
and CC N
80-mg JJ N
doses NNS N
of IN N
plain NN N
mepivacaine NN N
for IN N
ambulatory JJ N
spinal JJ N
anesthesia NN N
Both DT N
doses NNS N
produced VBD N
comparable JJ N
sensory NN N
and CC N
motor NN N
block NN N
Sensory NNP N
and CC N
motor NN N
regression NN N
and CC N
ambulatory JJ N
milestones NNS N
were VBD N
20-30 JJ N
min NN N
longer RBR N
with IN N
the DT N
80-mg JJ N
dose NN N
Side JJ N
effects NNS N
were VBD N
negligible JJ N
and CC N
transient JJ N
neurological JJ N
symptoms NNS N
were VBD N
not RB N
reported VBN N
during IN N
a DT N
24-h JJ N
follow-up NN N
-DOCSTART- -X- O O 22118062

Making VBG N
the DT N
connection NN N
: : N
randomized VBN N
controlled VBD N
trial NN N
of IN N
social JJ N
skills NNS N
at IN N
school NN N
for IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
BACKGROUND NNP N
This DT N
study NN N
compared VBN N
two CD N
interventions NNS N
for IN N
improving VBG N
the DT N
social JJ N
skills NNS N
of IN N
high JJ 4_p
functioning VBG 4_p
children NNS 4_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
in IN N
general JJ N
education NN N
classrooms NNS N
One CD N
intervention NN N
involved VBN N
a DT N
peer-mediated JJ N
approach NN N
( ( N
PEER NNP N
) ) N
and CC N
the DT N
other JJ N
involved VBD N
a DT N
child-assisted JJ N
approach NN N
( ( N
CHILD NNP N
) ) N
METHOD PDT N
The DT N
two CD N
interventions NNS N
were VBD N
crossed VBN N
in IN N
a DT N
2 CD N
× NN N
2 CD N
factorial JJ N
design NN N
yielding VBG N
control NN N
, , N
PEER NNP N
, , N
CHILD NNP N
, , N
and CC N
both DT N
PEER NNP N
and CC N
CHILD NNP N
conditions NNS N
Sixty NNP N
children NNS N
participated VBD N
from IN N
56 CD N
classrooms NNS N
in IN N
30 CD N
schools NNS N
Interventions NNS N
involved VBD N
12 CD N
sessions NNS N
over IN N
6 CD N
weeks NNS N
, , N
with IN N
a DT N
3-month JJ N
follow-up NN N
Outcome NNP N
measures NNS N
included VBD N
self NN N
, , N
peer NN N
and CC N
teacher JJR N
reports NNS N
of IN N
social JJ N
skills NNS N
and CC N
independent JJ N
weekly JJ N
observations NNS N
of IN N
children NNS N
on IN N
their PRP$ N
school NN N
playground NN N
over IN N
the DT N
course NN N
of IN N
the DT N
intervention NN N
RESULTS NNP N
Significant JJ N
improvements NNS N
were VBD N
found VBN N
in IN N
social JJ N
network NN N
salience NN N
, , N
number NN N
of IN N
friendship JJ N
nominations NNS N
, , N
teacher JJ N
report NN N
of IN N
social JJ N
skills NNS N
in IN N
the DT N
classroom NN N
, , N
and CC N
decreased JJ N
isolation NN N
on IN N
the DT N
playground NN N
for IN N
children NNS N
who WP N
received VBD N
PEER NNP N
interventions NNS N
Changes NNS N
obtained VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
persisted VBD N
to TO N
the DT N
3-month JJ N
follow-up NN N
CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
significant JJ N
improvements NNS N
can MD N
be VB N
made VBN N
in IN N
peer JJ N
social JJ N
connections NNS N
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
in IN N
general JJ N
education NN N
classrooms NNS N
with IN N
a DT N
brief JJ N
intervention NN N
, , N
and CC N
that IN N
these DT N
gains NNS N
persist VBP N
over IN N
time NN N
-DOCSTART- -X- O O 10860330

A DT N
laser-powered JJ N
hydrokinetic JJ N
system NN N
for IN N
caries NNS N
removal NN N
and CC N
cavity NN N
preparation NN N
BACKGROUND NNP N
Laser NNP N
systems NNS N
have VBP N
been VBN N
developed VBN N
for IN N
the DT N
cutting NN N
of IN N
dental JJ N
hard JJ N
tissues NNS N
The DT N
erbium NN N
, , N
chromium NN N
: : N
yttrium-scandium-gallium-garnet NN N
, , N
or CC N
Er NNP N
, , N
Cr NNP N
: : N
YSGG NN N
, , N
laser NN N
system NN N
used VBN N
in IN N
conjunction NN N
with IN N
an DT N
air-water NN N
spray NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
efficacious JJ N
in IN N
vitro NN N
for IN N
cavity NN N
preparation NN N
METHODS NNP N
The DT N
authors NNS N
randomly RB 4_p
selected VBN 4_p
subjects NNS 4_p
for IN N
cavity NN 4_p
preparation NN 4_p
with IN N
conventional JJ N
air NN N
turbine/bur IN N
dental JJ N
surgery NN N
or CC N
an DT N
Er NNP N
, , N
Cr NNP N
: : N
YSGG PRP$ N
laser-powered JJ N
system NN N
using VBG N
a DT N
split-mouth JJ N
design NN N
They PRP N
prepared VBD N
Class NNP N
I PRP N
, , N
III NNP N
and CC N
V NNP N
cavities NNS N
, , N
placed VBD N
resin NN N
restorations NNS N
and CC N
evaluated JJ N
subjects NNS N
on IN N
the DT N
day NN N
of IN N
the DT N
procedure NN N
and CC N
30 CD N
days NNS N
and CC N
six CD N
months NNS N
postoperatively RB N
for IN N
pulp NN N
vitality NN N
, , N
recurrent NN N
caries NNS N
, , N
pain NN N
and CC N
discomfort NN N
, , N
and CC N
restoration NN N
retention NN N
Sixty-seven JJ 3_p
subjects NNS N
completed VBD N
the DT N
study NN N
RESULTS CC N
There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
for IN N
the DT N
parameters NNS N
measured VBD N
with IN N
one CD N
exception NN N
; : N
there EX N
was VBD N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
discomfort NN N
levels NNS N
for IN N
the DT N
laser NN N
system NN N
at IN N
the DT N
time NN N
of IN N
cavity NN N
preparation NN N
for IN N
subjects NNS N
who WP N
declined VBD N
to TO N
receive VB N
local JJ N
anesthetic NN N
CONCLUSIONS VB N
The DT N
Er NNP N
, , N
Cr NNP N
: : N
YSGG NNP N
laser NN N
system NN N
is VBZ N
effective JJ N
for IN N
preparation NN N
of IN N
Class NNP N
I PRP N
, , N
III NNP N
and CC N
V NNP N
cavities NNS N
and CC N
resin NN N
restorations NNS N
are VBP N
retained VBN N
by IN N
lased JJ N
tooth NN N
surfaces NNS N
CLINICAL JJ N
IMPLICATIONS NNP N
Hard-tissue NNP N
cutting VBG N
lasers NNS N
are VBP N
being VBG N
introduced VBN N
for IN N
use NN N
in IN N
operative JJ N
dentistry NN N
In IN N
this DT N
study NN N
, , N
an DT N
Er NNP N
, , N
Cr NNP N
: : N
YSGG NNP N
laser NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
for IN N
cavity NN N
preparation NN N
and CC N
restoration NN N
replacement NN N
-DOCSTART- -X- O O 9793091

The DT N
" NNP N
SPEM NNP N
" NNP N
( ( N
Studio NNP N
Policentrico NNP N
Elettrocateteri NNP N
Membrane NNP N
) ) N
: : N
a DT N
multicenter NN N
study NN N
on IN N
membrane NN 4_p
leads NNS 4_p
SPEM NNP N
is VBZ N
a DT N
multicenter NN N
randomized VBN N
double-blind NN N
study NN N
performed VBD N
to TO N
test VB N
the DT N
acute NN N
and CC N
chronic JJ N
electrophysiological JJ N
behavior NN N
of IN N
three CD N
different JJ N
ventricular JJ 4_p
leads NNS 4_p
: : N
( ( N
1 CD N
) ) N
an DT N
ion NN N
exchange NN N
membrane NN N
with IN N
30-microgram JJ N
dexamethasone NN N
elution NN N
in IN N
a DT N
contoured JJ N
activated JJ N
carbon NN N
tip NN N
lead NN N
( ( N
Membrane NNP N
1400T CD N
, , N
30 CD N
patients NNS N
) ) N
; : N
( ( N
2 CD N
) ) N
the DT N
same JJ N
lead NN N
design NN N
without IN N
steroid NN N
( ( N
Membrane NNP N
1401T CD N
, , N
24 CD N
patients NNS N
) ) N
; : N
and CC N
( ( N
3 CD N
) ) N
the DT N
same JJ N
lead NN N
design NN N
without IN N
steroid NN N
or CC N
membrane NN N
( ( N
control NN N
group NN N
, , N
27 CD N
patients NNS N
) ) N
Twenty-three CD 3_p
of IN N
the DT N
81 CD 3_p
patients NNS N
were VBD N
women NNS 2_p
; : N
the DT N
mean JJ N
age NN N
for IN N
all DT N
patients NNS N
was VBD N
74 CD 1_p
+/- JJ 1_p
10 CD 1_p
years NNS 1_p
Parameters NNS N
are VBP N
calculated VBN N
both DT N
in IN N
uni- JJ N
and CC N
bipolar JJ N
configuration NN N
at IN N
implant JJ N
and CC N
at IN N
follow-up JJ N
after IN N
1 CD N
, , N
5 CD N
, , N
15 CD N
, , N
30 CD N
, , N
90 CD N
, , N
180 CD N
, , N
and CC N
360 CD N
days NNS N
Implant JJ N
threshold NN N
( ( N
chronaxie JJ N
= $ N
0.413 CD N
+/- JJ N
0.280 CD N
ms NN N
, , N
rheobase VB N
= JJ N
0.264 CD N
+/- JJ N
0.099 CD N
V NNP N
) ) N
, , N
signal JJ N
amplitude NN N
( ( N
13.45 CD N
+/- JJ N
5.87 CD N
mV NN N
) ) N
, , N
and CC N
slew JJ N
rate NN N
( ( N
2.05 CD N
+/- JJ N
1.38 CD N
V/s NNP N
) ) N
reveal VBP N
no DT N
significant JJ N
differences NNS N
Pacing VBG N
impedance NN N
values NNS N
both DT N
at IN N
implant NN N
( ( N
unipolar JJ N
571 CD N
+/- JJ N
165 CD N
omega NN N
; : N
bipolar JJ N
605 CD N
+/- JJ N
123 CD N
omega NN N
) ) N
and CC N
at IN N
follow-ups NNS N
( ( N
unipolar JJ N
480 CD N
+/- JJ N
72 CD N
omega NN N
; : N
bipolar JJ N
518 CD N
+/- JJ N
75 CD N
omega NN N
) ) N
are VBP N
slightly RB N
lower JJR N
in IN N
the DT N
unipolar JJ N
configuration NN N
At IN N
15 CD N
and CC N
30-day JJ N
follow-ups NNS N
, , N
control NN N
group NN N
and CC N
nonsteroid JJ N
leads VBZ N
show VB N
a DT N
higher JJR N
threshold JJ N
value NN N
growth NN N
( ( N
in IN N
unipolar NN N
from IN N
0.16 CD N
+/- JJ N
0.11 CD N
to TO N
1.19 CD N
+/- JJ N
0.85 CD N
microJ NN N
; : N
in IN N
bipolar NN N
from IN N
0.18 CD N
+/- JJ N
0.13 CD N
to TO N
1.24 CD N
+/- JJ N
0.88 CD N
microJ NN N
) ) N
than IN N
the DT N
membrane NN N
steroid NN N
leads VBZ N
( ( N
in IN N
unipolar NN N
from IN N
0.13 CD N
+/- JJ N
0.11 CD N
to TO N
0.70 CD N
+/- JJ N
0.39 CD N
microJ NN N
; : N
in IN N
bipolar NN N
from IN N
0.23 CD N
+/- JJ N
0.32 CD N
to TO N
0.76 CD N
+/- JJ N
0.36 CD N
microJ NN N
) ) N
; : N
the DT N
threshold NN N
of IN N
nonsteroid JJ N
leads NNS N
decreases NNS N
after IN N
1-3 JJ N
months NNS N
and CC N
it PRP N
settles VBZ N
at IN N
the DT N
same JJ N
threshold JJ N
level NN N
of IN N
the DT N
leads NNS N
with IN N
membrane NN N
and CC N
steroid NN N
( ( N
in IN N
unipolar JJ N
0.60 CD N
+/- JJ N
0.33 CD N
microJ NN N
; : N
in IN N
bipolar JJ N
0.55 CD N
+/- JJ N
0.26 CD N
microJ NN N
) ) N
, , N
which WDT N
has VBZ N
been VBN N
stable JJ N
since IN N
the DT N
first JJ N
month NN N
The DT N
ion NN N
exchange NN N
membrane NN N
is VBZ N
effective JJ N
in IN N
reducing VBG N
the DT N
chronic JJ N
pacing NN N
threshold NN N
like IN N
acute JJ N
steroid JJ N
elution NN N
at IN N
low JJ N
doses NNS N
, , N
but CC N
membrane FW N
alone RB N
does VBZ N
not RB N
prevent VB N
an DT N
acute JJ N
pacing NN N
threshold JJ N
increase NN N
through IN N
the DT N
first JJ N
month NN N
postimplant NN N
-DOCSTART- -X- O O 20345030

[ JJ N
Observation NNP N
of IN N
curative JJ N
effect NN N
on IN N
fixed-point NN N
spin NN N
reduction NN N
of IN N
spinal JJ N
manipulation NN N
therapy NN N
for IN N
cervical JJ 4_p
vertigo NN 4_p
] NN N
OBJECTIVE UH N
To TO N
explore VB N
the DT N
role NN N
of IN N
fixed-point JJ N
spin JJ N
reduction NN N
of IN N
spinal JJ N
manipulation NN N
therapy NN N
in IN N
the DT N
treatment NN N
of IN N
cervical JJ N
vertigo NN N
and CC N
its PRP$ N
effect NN N
on IN N
cervical JJ N
artery NN N
spasm NN N
index NN N
( ( N
RI NNP N
) ) N
and CC N
atlantoaxial JJ N
displacement NN N
index NN N
( ( N
ADI NNP N
) ) N
METHODS NN N
From IN N
January NNP N
2002 CD N
to TO N
May NNP N
2008 CD N
, , N
168 CD 3_p
patients NNS N
with IN N
cervical JJ 4_p
vertigo NNS 4_p
were VBD N
randomly RB N
divided VBN N
into IN N
treatment NN N
group NN N
( ( N
84 CD 3_p
cases NNS 3_p
) ) N
and CC N
the DT N
control NN N
group NN N
( ( N
84 CD 3_p
cases NNS 3_p
) ) N
, , N
22 CD 2_p
males NNS 2_p
and CC 2_p
62 CD 2_p
females NNS 2_p
in IN N
treatment NN N
group NN N
; : N
24 CD 2_p
males NNS 2_p
and CC 2_p
60 CD 2_p
females NNS 2_p
in IN N
control NN N
group NN N
The DT N
patients NNS N
of IN N
treatment NN N
group NN N
and CC N
control NN N
group NN N
were VBD N
respectively RB N
treated VBN N
with IN N
fixed-point JJ N
spin NN N
reduction NN N
of IN N
spinal JJ N
manipulation NN N
therapy NN N
and CC N
dialectical JJ N
prescription NN N
The DT N
score NN N
of IN N
symptoms NNS N
and CC N
signs NNS N
, , N
RI NNP N
, , N
ADI NNP N
were VBD N
observed VBN N
and CC N
compared VBN N
between IN N
two CD N
groups NNS N
RESULTS VB N
The DT N
score NN N
of IN N
symptoms NNS N
and CC N
signs NNS N
markedly RB N
decreased VBD N
after IN N
treatment NN N
, , N
in IN N
treatment NN N
group NN N
: : N
vertigo NN N
had VBD N
( ( N
2.75 CD N
+/- JJ N
1.01 CD N
) ) N
scores NNS N
, , N
neck-shoulder JJ N
pain NN N
( ( N
1.58 CD N
+/- JJ N
0.36 CD N
) ) N
, , N
headache NN N
( ( N
0.39 CD N
+/- JJ N
0.09 CD N
) ) N
, , N
nausea-vomiting JJ N
( ( N
1.58 CD N
+/- JJ N
1.30 CD N
) ) N
, , N
ear JJ N
noises NNS N
( ( N
0.48 CD N
+/- JJ N
0.32 CD N
) ) N
, , N
positive JJ N
neck NN N
rotation NN N
test NN N
( ( N
0.59 CD N
+/- JJ N
0.21 CD N
) ) N
; : N
and CC N
in IN N
control NN N
group NN N
: : N
vertigo NN N
had VBD N
( ( N
5.68 CD N
+/- JJ N
2.02 CD N
) ) N
scores NNS N
, , N
neck-shoulder JJ N
pain NN N
( ( N
3.12 CD N
+/- JJ N
1.82 CD N
) ) N
, , N
headache NN N
( ( N
1.86 CD N
+/- JJ N
0.65 CD N
) ) N
, , N
nausea-vomiting JJ N
( ( N
3.25 CD N
+/- JJ N
0.69 CD N
) ) N
, , N
ear JJ N
noises NNS N
( ( N
1.64 CD N
+/- JJ N
0.61 CD N
) ) N
, , N
positive JJ N
neck NN N
rotation NN N
test NN N
( ( N
1.79 CD N
+/- JJ N
0.67 CD N
) ) N
Cervical JJ N
artery NN N
spasm NN N
index NN N
and CC N
atlantoaxial JJ N
displacement NN N
index NN N
had VBD N
been VBN N
significantly RB N
improved VBN N
, , N
cervical JJ N
artery NN N
spasm NN N
index NN N
was VBD N
respectively RB N
0.54 CD N
+/- JJ N
0.07 CD N
and CC N
0.52 CD N
+/- JJ N
0.13 CD N
, , N
atlantoaxial JJ N
displacement NN N
index NN N
was VBD N
respectively RB N
2.92 CD N
+/- JJ N
0.82 CD N
and CC N
4.50 CD N
+/- JJ N
1.32 CD N
between IN N
treatment NN N
group NN N
and CC N
control NN N
group NN N
CONCLUSION NNP N
Fixed-point NNP N
spin NN N
reduction NN N
of IN N
spinal JJ N
manipulation NN N
therapy NN N
for IN N
cervical JJ N
vertigo NN N
can MD N
accurately RB N
correct VB N
single JJ N
or CC N
multiple JJ N
vertebral JJ 4_p
body NN 4_p
displacement NN 4_p
, , N
restore VB N
normal JJ N
spinal JJ N
position NN N
, , N
reduce VB N
the DT N
oppression NN N
and CC N
stimulus NN N
of IN N
the DT N
vertebral JJ N
artery NN N
, , N
release NN N
ischemia NN N
of IN N
vestibular JJ N
labyrinth NN N
, , N
eliminate VB N
symptoms NNS N
of IN N
vertigo NN N
-DOCSTART- -X- O O 22595172

Effects NNS N
of IN N
skin-to-skin JJ N
contact NN N
on IN N
autonomic JJ N
pain NN N
responses NNS N
in IN N
preterm JJ N
infants NNS N
UNLABELLED IN N
The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
crossover NN N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
on IN N
autonomic JJ N
responses NNS N
in IN N
preterm JJ 1_p
infants NNS 1_p
of IN N
longer JJR 4_p
Kangaroo NNP 4_p
Care NNP 4_p
( ( 4_p
30 CD 4_p
minutes NNS 4_p
, , 4_p
KC30 NNP 4_p
) ) 4_p
and CC N
shorter JJR 4_p
KC NNP 4_p
( ( 4_p
15 CD 4_p
minutes NNS 4_p
, , 4_p
KC15 NNP 4_p
) ) 4_p
before IN 4_p
and CC 4_p
throughout IN 4_p
heel NN 4_p
stick NNS 4_p
compared VBN 4_p
with IN 4_p
incubator NN 4_p
care NN 4_p
( ( 4_p
IC NNP 4_p
) ) 4_p
Beat-to-beat JJ N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
and CC N
spectral JJ N
power NN N
analysis NN N
of IN N
heart NN N
rate NN N
variability NN N
, , N
low JJ N
frequency NN N
power NN N
( ( N
LF NNP N
) ) N
, , N
high JJ N
frequency NN N
power NN N
( ( N
HF NNP N
) ) N
, , N
and CC N
LF/HF NNP N
ratio NN N
were VBD N
measured VBN N
in IN N
26 CD 3_p
infants NNS 1_p
HR NNP N
changes NNS N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
were VBD N
significantly RB N
less RBR N
in IN N
KC30 NNP N
and CC N
KC15 NNP N
than IN N
in IN N
IC NNP N
, , N
and CC N
more JJR N
infants NNS N
had VBD N
HR NNP N
decrease NN N
in IN N
IC NNP N
than IN N
in IN N
2 CD N
KC NNP N
conditions NNS N
In IN N
IC NNP N
, , N
LF NNP N
and CC N
HF NNP N
significantly RB N
increased VBD N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
and CC N
dropped VBD N
from IN N
Heel NNP N
Stick NNP N
to TO N
Recovery NNP N
; : N
in IN N
2 CD N
KC NNP N
conditions NNS N
, , N
no DT N
changes NNS N
across IN N
study NN N
phases NNS N
were VBD N
found VBN N
During IN N
Heel NNP N
Stick NNP N
, , N
LF NNP N
and CC N
HF NNP N
were VBD N
significantly RB N
higher JJR N
in IN N
IC NNP N
than IN N
in IN N
KC30 NNP N
In IN N
all DT N
3 CD N
conditions NNS N
, , N
LF/HF NNP N
ratio NN N
decreased VBD N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
and CC N
increased VBD N
to TO N
Recovery NNP N
; : N
no DT N
differences NNS N
were VBD N
found VBN N
between IN N
IC NNP N
and CC N
two CD N
KC NNP N
conditions NNS N
Both NNP N
longer JJR N
and CC N
shorter JJR N
KC NNP N
before IN N
and CC N
throughout IN N
heel NN N
stick NN N
can MD N
stabilize VB N
HR NNP N
response NN N
in IN N
preterm JJ N
infants NNS N
, , N
and CC N
longer JJR N
KC NNP N
significantly RB N
affected VBD N
infants NNS N
' POS N
sympathetic JJ N
and CC N
parasympathetic JJ N
responses NNS N
during IN N
heel NN N
stick NNS N
compared VBN N
with IN N
incubator NN N
care NN N
PERSPECTIVE VB N
This DT N
study NN N
showed VBD N
that IN N
KC NNP N
has VBZ N
a DT N
significant JJ N
effect NN N
on IN N
reducing VBG N
autonomic JJ N
pain NN N
responses NNS N
in IN N
preterm JJ 1_p
infants NNS 1_p
The DT N
findings NNS N
support NN N
that IN N
KC NNP N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
pain NN N
intervention NN N
in IN N
the DT N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
-DOCSTART- -X- O O 15955950

TENS NNP N
for IN N
the DT N
treatment NN N
of IN N
writer NN N
's POS N
cramp NN N
dystonia NN N
: : N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
study NN N
Manipulation NNP N
of IN N
afferent NN N
inputs NNS N
may MD N
temporarily RB N
modulate VB N
dystonic JJ N
spasms NNS N
Ten CD N
patients NNS N
with IN N
writer NN N
's POS N
cramp NN N
were VBD N
enrolled VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover NN N
study NN N
in IN N
which WDT N
the DT N
effects NNS N
of IN N
transcutaneous JJ N
electrical JJ N
stimulation NN N
( ( N
TENS NNP N
) ) N
and CC N
placebo JJ N
treatment NN N
were VBD N
compared VBN N
Patients NNS N
were VBD N
evaluated VBN N
using VBG N
four CD N
measures NNS N
of IN N
dystonic JJ N
impairment NN N
The DT N
TENS NNP N
group NN N
showed VBD N
a DT N
significant JJ N
improvement NN N
that WDT N
persisted VBD N
for IN N
3 CD N
weeks NNS N
in IN N
three CD N
of IN N
the DT N
four CD N
measures NNS N
-DOCSTART- -X- O O 17929164

A DT N
double-blind JJ N
placebo NN N
controlled VBD N
trial NN N
of IN N
piracetam NN N
added VBN N
to TO N
risperidone VB N
in IN N
patients NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
It PRP N
has VBZ N
been VBN N
reported VBN N
that IN N
autism NN N
is VBZ N
a DT N
hypoglutamatergic JJ N
disorder NN N
Therefore RB N
, , N
it PRP N
was VBD N
of IN N
interest NN N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
piracetam NN N
, , N
a DT N
positive JJ N
modulator NN N
of IN N
AMPA-sensitive JJ N
glutamate NN N
receptors NNS N
in IN N
autistic JJ N
disorder NN N
About IN N
40 CD 3_p
children NNS 1_p
between IN N
the DT N
ages NNS N
three CD 1_p
and CC 1_p
11 CD 1_p
years NNS 1_p
( ( N
inclusive JJ N
) ) N
with IN N
a DT N
DSM NNP N
IV NNP N
clinical JJ N
diagnosis NN N
of IN N
autism NN 4_p
and CC N
who WP N
were VBD N
outpatients NNS N
from IN N
a DT N
specialty NN N
clinic NN N
for IN N
children NNS 1_p
were VBD N
recruited VBN N
The DT N
children NNS 1_p
presented VBN N
with IN N
a DT N
chief JJ N
complaint NN N
of IN N
severely RB N
disruptive JJ N
symptoms NNS N
related VBN N
to TO N
autistic JJ 4_p
disorder NN 4_p
Patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
piracetam VB N
+ NNP N
risperidone NN N
( ( N
Group NNP N
A NNP N
) ) N
or CC N
placebo JJ N
+ NN N
risperidone NN N
( ( N
Group NNP N
B NNP N
) ) N
for IN N
a DT N
10-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
The DT N
dose NN N
of IN N
risperidone NN N
was VBD N
titrated VBN N
up RB N
to TO N
2 CD N
mg/day NN N
for IN N
children NNS N
between IN N
10 CD N
and CC N
40 CD N
kg NN N
and CC N
3 CD N
mg/day NN N
for IN N
children NNS N
weighting VBG N
above IN N
40 CD N
kg NN N
The DT N
dose NN N
of IN N
piracetam NN N
was VBD N
titrated VBN N
up RB N
to TO N
800 CD N
mg/day NN N
Patients NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
and CC N
10 CD N
weeks NNS N
of IN N
starting VBG N
medication NN N
The DT N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist-Community NNP N
( ( N
ABC-C NNP N
) ) N
Rating VBG N
Scale NNP N
( ( N
total JJ N
score NN N
) ) N
The DT N
ABC-C JJ N
Rating NNP N
Scale NNP N
scores VBZ N
improved VBN N
with IN N
piracetam NN N
The DT N
difference NN N
between IN N
the DT N
two CD N
protocols NNS N
was VBD N
significant JJ N
as IN N
indicated VBN N
by IN N
the DT N
effect NN N
of IN N
group NN N
, , N
the DT N
between IN N
subjects NNS N
factor NN N
( ( N
F NNP N
= NNP N
5.85 CD N
, , N
d.f NN N
= CC N
1 CD N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
The DT N
changes NNS N
at IN N
the DT N
endpoint NN N
compared VBN N
with IN N
baseline NN N
were VBD N
: : N
-11.90 JJ N
+/- JJ N
3.79 CD N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
and CC N
-5.15 JJ N
+/- JJ N
3.04 CD N
for IN N
group NN N
A NNP N
and CC N
B NNP N
respectively RB N
A DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
on IN N
the DT N
change NN N
in IN N
scores NNS N
in IN N
the DT N
ABC-C NNP N
Rating NNP N
Scale NNP N
in IN N
week NN N
10 CD N
compared VBN N
with IN N
baseline NN N
in IN N
the DT N
two CD N
groups NNS N
( ( N
t JJ N
= NN N
6.017 CD N
, , N
d.f NN N
= CC N
38 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
The DT N
results NNS N
suggest VBP N
that IN N
a DT N
combination NN N
of IN N
atypical JJ N
antipsychotic JJ N
medications NNS N
and CC N
a DT N
glutamate JJ N
agent NN N
such JJ N
as IN N
piracetam NNS N
, , N
might MD N
have VB N
increase VBN N
synergistic JJ N
effects NNS N
in IN N
the DT N
treatment NN N
of IN N
autism NN N
-DOCSTART- -X- O O 8561059

Effects NNS N
of IN N
interaction NN N
of IN N
RRR-alpha-tocopheryl NNP N
acetate NN N
and CC N
fish JJ N
oil NN N
on IN N
low-density-lipoprotein JJ N
oxidation NN N
in IN N
postmenopausal JJ 4_p
women NNS 2_p
with IN N
and CC N
without IN N
hormone-replacement JJ 4_p
therapy NN 4_p
We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
RRR-alpha-tocpheryl NNP N
acetate NN N
( ( N
alpha-tocopheryl JJ N
acetate NN N
) ) N
and CC N
hormone-replacement JJ N
therapy NN N
( ( N
HRT NNP N
) ) N
on IN N
the DT N
oxidative JJ N
susceptibility NN N
of IN N
low-density NN N
lipoprotein NN N
( ( N
LDL NNP N
) ) N
in IN N
postmenopausal JJ 4_p
women NNS 2_p
consuming VBG N
a DT N
fish JJ N
oil NN N
supplement NN N
The DT N
independent JJ N
effect NN N
of IN N
fish JJ N
oil NN N
was VBD N
also RB N
assessed VBN N
Forty-eight JJ 3_p
women NNS 4_p
, , N
equally RB N
divided VBD N
between IN N
women NNS 4_p
using VBG N
and CC N
not RB N
using VBG N
HRT NNP 4_p
, , N
participated VBD N
in IN N
a DT N
double-blind JJ N
crossover NN N
trial NN N
Each DT N
of IN N
the DT N
four CD N
periods NNS N
lasted VBD N
5 CD N
wk NN N
and CC N
was VBD N
followed VBN N
by IN N
a DT N
4-wk JJ N
washout NN N
interval NN N
During IN N
each DT N
period NN N
all DT N
subjects NNS N
were VBD N
given VBN N
a DT N
15-g JJ N
supplement NN N
of IN N
fish JJ N
oil NN N
and CC N
either RB N
0 CD N
( ( N
placebo NN N
) ) N
, , N
100 CD N
, , N
200 CD N
, , N
or CC N
400 CD N
mg JJ N
alpha-tocopheryl JJ N
acetate JJ N
daily JJ N
LDL NNP N
resistance NN N
to TO N
oxidative VB N
modification NN N
was VBD N
assessed VBN N
by IN N
calculating VBG N
lag NN N
time NN N
, , N
propagation NN N
rate NN N
, , N
and CC N
maximum JJ N
production NN N
of IN N
conjugated JJ N
dienes NNS N
Supplementation NN N
with IN N
fish JJ N
oil NN N
and CC N
placebo NN N
shortened VBN N
lag JJ N
time NN N
and CC N
slowed VBN N
propagation NN N
rate NN N
in IN N
women NNS N
both DT N
using VBG N
and CC N
not RB N
using VBG N
HRT NNP N
After IN N
subjects NNS N
consumed VBD N
fish JJ N
oil NN N
, , N
supplementation NN N
with IN N
alpha-tocopheryl JJ N
acetate NN N
increased VBD N
plasma NN N
and CC N
LDL NNP N
alpha-tocopherol NN N
contents NNS N
significantly RB N
and CC N
lengthened VBD N
lag NN N
time NN N
( ( N
at IN N
even RB N
the DT N
lowest JJS N
concentration NN N
) ) N
but CC N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
propagation NN N
rate NN N
or CC N
maximum JJ N
production NN N
compared VBN N
with IN N
values NNS N
measured VBN N
after IN N
consumption NN N
of IN N
fish JJ N
oil NN N
alone RB N
Women NNP N
not RB N
using VBG N
HRT NNP N
had VBD N
faster JJR N
propagation NN N
rates NNS N
and CC N
higher JJR N
maximum NN N
production NN N
than IN N
women NNS N
using VBG N
HRT NNP N
; : N
after IN N
supplementation NN N
with IN N
fish JJ N
oil NN N
and CC N
alpha-tocopheryl JJ N
acetate NN N
these DT N
differences NNS N
prevailed VBD N
Supplements NNS N
as RB N
low JJ N
as IN N
100 CD N
mg JJ N
alpha-tocopheryl JJ N
acetate/d NN N
increase VB N
the DT N
resistance NN N
of IN N
LDL NNP N
to TO N
oxidation VB N
when WRB N
fish JJ N
oil NN N
supplements NNS N
are VBP N
used VBN N
HRT NNP N
and CC N
fish JJ N
oil NN N
supplements NNS N
may MD N
independently RB N
affect VB N
LDL NNP N
oxidative JJ N
susceptibility NN N
-DOCSTART- -X- O O 23323659

Divergence NN N
in IN N
student NN 4_p
and CC 4_p
educator NN 4_p
conceptual JJ 4_p
structures NNS 4_p
during IN N
auscultation NN 4_p
training NN 4_p
CONTEXT NNP N
Simulation-based JJ N
medical JJ N
education NN N
allows VBZ N
trainees NNS N
to TO N
engage VB N
in IN N
self-regulated JJ N
learning NN N
( ( N
SRL NNP N
) ) N
, , N
yet RB N
research NN N
aimed VBN N
at IN N
elucidating VBG N
the DT N
mechanisms NN N
of IN N
SRL NNP N
in IN N
this DT N
context NN N
is VBZ N
relatively RB N
absent JJ N
We PRP N
compared VBN N
'unguided VBD N
' POS N
SRL NNP N
with IN N
'directed NNP N
' POS N
SRL NNP N
( ( N
DSRL NNP N
) ) N
, , N
wherein JJ N
learners NNS N
followed VBD N
an DT N
expert-designed JJ N
booklet NN N
METHODS NNP N
Year $ N
1 CD N
medical JJ N
students NNS N
( ( N
n JJ 3_p
= NNP 3_p
37 CD 3_p
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
practise VB N
identifying VBG N
seven CD N
cardiac JJ N
murmurs NNS N
using VBG N
a DT N
simulator NN N
and CC N
video NN N
only RB N
( ( N
SRL NNP N
group NN N
) ) N
or CC N
a DT N
simulator NN N
and CC N
video NN N
plus CC N
the DT N
booklet NN N
( ( N
DSRL NNP N
group NN N
) ) N
All DT N
participants NNS N
completed VBD N
a DT N
22-item JJ N
test NN N
3 CD N
weeks NNS N
later RB N
To TO N
compare VB N
interventions NNS N
, , N
we PRP N
analysed VBD N
students NNS N
' POS N
diagnostic JJ N
accuracy NN N
As IN N
a DT N
novel JJ N
source NN N
of IN N
evidence NN N
, , N
we PRP N
documented VBD N
how WRB N
participants NNS N
autonomously RB N
sequenced VBD N
the DT N
seven CD N
murmurs NNS N
during IN N
initial JJ N
and CC N
delayed JJ N
practice NN N
sessions NNS N
In IN N
addition NN N
, , N
we PRP N
surveyed VBD N
clinical JJ N
educators NNS N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
to TO N
find VB N
out RP N
how WRB N
they PRP N
would MD N
sequence VB N
their PRP$ N
teaching NN N
of IN N
these DT N
murmurs NNS N
RESULTS VB N
The DT N
DSRL NNP N
group NN N
used VBD N
50 CD N
% NN N
more JJR N
training NN N
time NN N
than IN N
the DT N
SRL NNP N
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
The DT N
groups NNS N
' POS N
diagnostic JJ N
accuracy NN N
, , N
however RB N
, , N
did VBD N
not RB N
differ VB N
significantly RB N
on IN N
the DT N
post-test NN N
, , N
retention NN N
test NN N
or CC N
transfer VB N
test NN N
items NNS N
( ( N
p VB N
> RB N
0.12 CD N
) ) N
Despite IN N
practising VBG N
with IN N
the DT N
expert-defined JJ N
'timing-based JJ N
' POS N
approach NN N
to TO N
murmur VB N
diagnosis NN N
( ( N
i.e JJ N
systolic JJ N
versus IN N
diastolic NN N
) ) N
, , N
84 CD N
% NN N
of IN N
DSRL NNP N
participants NNS N
implemented VBD N
a DT N
location-based JJ N
approach NN N
( ( N
i.e JJ N
practising VBG N
aortic JJ N
murmurs NNS N
separately RB N
from IN N
mitral JJ N
murmurs NNS N
) ) N
during IN N
a DT N
second JJ N
, , N
unguided JJ N
practice NN N
session NN N
Notably RB N
, , N
most JJS N
SRL JJ N
participants NNS N
used VBD N
that IN N
same JJ N
approach NN N
spontaneously RB N
By IN N
contrast NN N
, , N
clinical JJ N
educators NNS N
were VBD N
split VBN N
in IN N
their PRP$ N
use NN N
of IN N
the DT N
timing-based JJ N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
and CC N
the DT N
location-based JJ N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
approaches NNS N
Chi-squared JJ N
analyses NNS N
suggested VBD N
educators NNS N
' POS N
conceptions NNS N
for IN N
organising VBG N
murmurs NNS N
differed VBN N
significantly RB N
from IN N
students NNS N
' POS N
conceptions NNS N
CONCLUSIONS NNP N
Contrary NNP N
to TO N
our PRP$ N
predictions NNS N
, , N
directing VBG N
students NNS N
' POS N
SRL NNP N
produced VBD N
no DT N
additional JJ N
benefit NN N
and CC N
increased VBD N
their PRP$ N
practice NN N
time NN N
Our PRP$ N
findings NNS N
suggest VBP N
one CD N
potential JJ N
source NN N
of IN N
these DT N
results NNS N
was VBD N
a DT N
divergence NN N
between IN N
student NN N
and CC N
educator NN N
conceptions NNS N
for IN N
structuring VBG N
the DT N
practice NN N
of IN N
cardiac JJ N
auscultation NN N
skills NNS N
This DT N
phenomenon NN N
has VBZ N
not RB N
been VBN N
well RB N
articulated VBN N
in IN N
the DT N
medical JJ N
education NN N
literature NN N
, , N
and CC N
may MD N
have VB N
important JJ N
implications NNS N
in IN N
many JJ N
( ( N
especially RB N
technology-mediated VBN N
) ) N
educational JJ N
contexts NN N
-DOCSTART- -X- O O 8467286

Use NNP N
of IN N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
and CC N
erythropoietin NN N
in IN N
combination NN N
after IN 4_p
autologous JJ 4_p
marrow NN 4_p
transplantation NN 4_p
The DT N
toxicities NNS N
and CC N
possible JJ N
utility NN N
of IN N
the DT N
combination NN N
of IN N
recombinant JJ N
human JJ N
granulocyte-macrophage NN N
colony-stimulating NN N
factor NN N
( ( N
rhGM-CSF NN N
) ) N
and CC N
recombinant JJ N
human JJ N
erythropoietin NN N
( ( N
rHuEPO NN N
) ) N
given VBN N
after IN N
autologous JJ N
BMT NNP N
were VBD N
evaluated VBN N
in IN N
this DT N
pilot NN N
trial NN N
Eighteen JJ 3_p
patients NNS N
received VBD N
the DT N
combination NN N
and CC N
were VBD N
compared VBN N
with IN N
six CD 3_p
concurrent NN N
control NN N
and CC N
65 CD 3_p
historical JJ N
control NN N
patients NNS N
treated VBN N
with IN N
rhGM-CSF JJ N
alone NN N
Patients NNS N
treated VBD N
with IN N
the DT N
combination NN N
tended VBD N
to TO N
have VB N
more RBR N
rapid JJ N
recovery NN N
to TO N
an DT N
absolute JJ N
neutrophil NN N
count NN N
of IN N
500 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
/l NN N
( ( N
median JJ N
= NN N
12.5 CD N
vs NN N
18 CD N
days NNS N
for IN N
concurrent NN N
and CC N
19 CD N
days NNS N
for IN N
historical JJ N
control NN N
patients NNS N
) ) N
There EX N
was VBD N
no DT N
apparent JJ N
impact NN N
on IN N
red JJ N
cell NN N
transfusion NN N
requirements NNS N
, , N
platelet JJ N
recovery NN N
or CC N
duration NN N
of IN N
hospitalization NN N
Patients NNS N
treated VBD N
in IN N
the DT N
current JJ N
study NN N
with IN N
rhGM-CSF JJ N
plus CC N
either CC N
rHuEPO NN N
or CC N
with IN N
placebo NN N
had VBD N
a DT N
higher JJR N
incidence NN N
of IN N
rash NN N
than IN N
seen VBN N
in IN N
our PRP$ N
historical JJ N
experience NN N
using VBG N
rhGM-CSF NN N
This DT N
difference NN N
may MD N
reflect VB N
changes NNS N
in IN N
the DT N
source NN N
of IN N
rhGM-CSF NN N
or CC N
in IN N
the DT N
infusion NN N
schedule NN N
Erythropoietin NN N
can MD N
be VB N
combined VBN N
safely RB N
with IN N
rhGM-CSF NN N
after IN N
autologous JJ N
transplantation NN N
Larger NNP N
controlled VBD N
trials NNS N
will MD N
be VB N
necessary JJ N
to TO N
detect VB N
possible JJ N
therapeutic JJ N
effects NNS N
-DOCSTART- -X- O O 22038501

Standard NNP N
versus NN N
extended VBD N
lymphadenectomy NN N
in IN N
radical JJ N
pancreatoduodenectomy NN N
for IN N
ductal JJ N
adenocarcinoma NN N
of IN N
the DT N
head NN N
of IN N
the DT N
pancreas NNS N
: : N
long-term JJ N
results NNS N
of IN N
a DT N
Japanese JJ N
multicenter NN N
randomized VBD N
controlled VBN N
trial NN N
BACKGROUND IN N
The DT N
value NN N
of IN N
pancreatoduodenectomy NN N
( ( N
PD NNP N
) ) N
with IN N
extended VBN N
lymphadenectomy NN N
for IN N
pancreatic JJ N
cancer NN N
has VBZ N
been VBN N
evaluated VBN N
by IN N
many JJ N
retrospective JJ N
studies NNS N
and CC N
3 CD N
randomized VBN N
controlled VBN N
trials NNS N
( ( N
RCT NNP N
) ) N
However RB N
, , N
the DT N
protocols NNS N
used VBN N
and CC N
the DT N
results NNS N
found VBD N
in IN N
the DT N
3 CD N
RCTs NNP N
were VBD N
diverse JJ N
Therefore RB N
, , N
a DT N
multicenter NN N
RCT NNP N
was VBD N
proposed VBN N
in IN N
1998 CD N
to TO N
evaluate VB N
the DT N
primary JJ N
end NN N
point NN N
of IN N
long-term JJ N
survival NN N
and CC N
the DT N
secondary JJ N
end NN N
points NNS N
of IN N
morbidity NN N
, , N
mortality NN N
and CC N
quality NN N
of IN N
life NN N
of IN N
patients NNS N
undergoing VBG N
standard JJ N
versus NN N
extended VBD N
lymphadenectomy NN N
in IN N
radical JJ 4_p
PD NNP 4_p
for IN N
pancreatic JJ 4_p
cancer NN 4_p
METHODS NNP N
From IN N
March NNP N
2000 CD N
to TO N
May NNP N
2003 CD N
, , N
112 CD 3_p
patients NNS N
with IN N
potentially RB N
curable JJ N
pancreatic JJ 4_p
head NN 4_p
cancer NN 4_p
were VBD N
enrolled VBN N
and CC N
intraoperatively RB N
randomized VBN N
to TO N
a DT N
standard NN N
or CC N
extended JJ N
lymphadenectomy NN N
group NN N
No RB N
resected JJ N
patients NNS N
received VBD N
any DT N
adjuvant JJ N
treatments NNS N
RESULTS VB N
A DT 3_p
hundred CD 3_p
and CC 3_p
one CD 3_p
eligible JJ N
patients NNS N
were VBD N
analyzed VBN N
Demographic NNP N
and CC N
histopathological JJ N
characteristics NNS N
of IN N
the DT N
two CD N
groups NNS N
were VBD N
similar JJ N
The DT N
mean NN N
operating NN N
time NN N
, , N
intraoperative JJ N
blood NN N
loss NN N
and CC N
number NN N
of IN N
retrieved JJ N
lymph NN N
nodes NNS N
were VBD N
greater JJR N
in IN N
the DT N
extended JJ N
group NN N
, , N
but CC N
the DT N
other JJ N
operative JJ N
results NNS N
were VBD N
comparable JJ N
CONCLUSIONS NNP N
Although IN N
this DT N
multicenter NN N
RCT NNP N
was VBD N
conducted VBN N
in IN N
a DT N
strict JJ N
setting NN N
, , N
extended VBD N
lymphadenectomy NN N
in IN N
radical JJ N
PD NNP N
did VBD N
not RB N
benefit VB N
long-term JJ N
survival NN N
in IN N
patients NNS N
with IN N
resectable JJ 4_p
pancreatic JJ 4_p
head NN 4_p
cancer NN 4_p
and CC N
led VBD N
to TO N
levels NNS N
of IN N
morbidity NN N
, , N
mortality NN N
and CC N
quality NN N
of IN N
life NN N
comparable JJ N
to TO N
those DT N
found VBN N
after IN N
standard JJ N
lymphadenectomy NN N
-DOCSTART- -X- O O 8908288

Final JJ N
report NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
study NN N
with IN N
streptococcal JJ N
preparation NN N
OK-432 NNP N
as IN N
a DT N
supplementary JJ N
immunopotentiator NN N
for IN N
laryngeal JJ N
cancer NN N
We PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
study NN N
of IN N
streptococcal JJ N
preparation NN N
OK-432 NNP N
on IN N
120 CD N
newly RB N
identified VBN N
cases NNS N
of IN N
laryngeal JJ N
squamous JJ N
cell NN N
carcinoma NN N
who WP N
were VBD N
registered VBN N
at IN N
10 CD N
participating VBG N
institutions NNS N
between IN N
November NNP N
1984 CD N
and CC N
October NNP N
1989 CD N
The DT N
patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
those DT N
in IN N
early JJ N
stages NNS N
( ( N
stage NN N
I PRP N
or CC N
II NNP N
) ) N
and CC N
those DT N
in IN N
advanced JJ N
stages NNS N
( ( N
stage NN N
III NNP N
or CC N
IV NNP N
) ) N
; : N
these DT N
groups NNS N
were VBD N
further RB N
subdivided VBN N
into IN N
an DT N
immunotherapy NN N
group NN N
( ( N
receiving VBG N
OK-432 NNP N
) ) N
and CC N
a DT N
control NN N
group NN N
( ( N
who WP N
did VBD N
not RB N
receive VB N
OK-432 NNP N
) ) N
The DT N
usefulness NN N
of IN N
OK-432 NNP N
was VBD N
studied VBN N
using VBG N
the DT N
sealed VBN N
envelope NN N
method NN N
The DT N
basic JJ N
therapy NN N
for IN N
all DT N
cases NNS N
was VBD N
radiotherapy NN N
and CC N
, , N
when WRB N
required VBN N
, , N
surgery NN N
As IN N
adjuvant JJ N
therapy NN N
, , N
5Fu CD N
or CC N
derivatives NNS N
were VBD N
administered VBN N
to TO N
all DT N
cases NNS N
from IN N
the DT N
beginning NN N
of IN N
the DT N
treatment NN N
period NN N
to TO N
one CD N
year NN N
after IN N
the DT N
basic JJ N
therapy NN N
, , N
with IN N
the DT N
exception NN N
of IN N
cases NNS N
in IN N
whom WP N
side NN N
effects NNS N
were VBD N
serious JJ N
enough RB N
to TO N
contraindicate VB N
use NN N
of IN N
the DT N
drug NN N
The DT N
target NN N
administration NN N
period NN N
was VBD N
5 CD N
years NNS N
Of IN N
the DT N
initial JJ N
120 CD N
cases NNS N
, , N
11 CD N
cases NNS N
were VBD N
disqualified VBN N
( ( N
3 CD N
cases NNS N
of IN N
double JJ N
cancer NN N
and CC N
8 CD N
of IN N
incomplete JJ N
primary JJ N
therapy NN N
) ) N
and CC N
the DT N
remaining VBG N
109 CD N
were VBD N
used VBN N
for IN N
evaluation NN N
The DT N
5-year JJ N
survival NN N
rate NN N
and CC N
the DT N
5-year JJ N
recurrence-free JJ N
rate NN N
were VBD N
76 CD N
% NN N
and CC N
84 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
immunized JJ N
groups NNS N
( ( N
both DT N
the DT N
early JJ N
and CC N
advanced JJ N
groups NNS N
) ) N
, , N
whereas VBP N
the DT N
same JJ N
rates NNS N
for IN N
the DT N
control NN N
groups NNS N
were VBD N
78 CD N
% NN N
and CC N
75 CD N
% NN N
There EX N
was VBD N
a DT N
tendency NN N
for IN N
the DT N
immunized JJ N
groups NNS N
to TO N
enjoy VB N
a DT N
slightly RB N
longer RBR N
recurrence-free JJ N
period NN N
Over IN N
a DT N
24-month JJ N
observation NN N
period NN N
the DT N
immunized JJ N
group NN N
always RB N
had VBD N
higher JJR N
levels NNS N
of IN N
peripheral JJ N
leukocytes NNS N
and CC N
peripheral JJ N
lymphocytes NNS N
; : N
this DT N
difference NN N
was VBD N
significant JJ N
for IN N
the DT N
first JJ N
21 CD N
months NNS N
Inhibition NN N
of IN N
bone NN N
marrow NN N
function NN N
is VBZ N
sometimes RB N
observed VBN N
with IN N
radiotherapy NN N
It PRP N
is VBZ N
hoped VBN N
that IN N
, , N
if IN N
this DT N
inhibition NN N
can MD N
be VB N
mitigated VBN N
, , N
it PRP N
will MD N
be VB N
possible JJ N
to TO N
assist VB N
the DT N
compromised VBN N
immune NN N
system NN N
and CC N
maintain VB N
a DT N
certain JJ N
level NN N
of IN N
immune JJ N
performance NN N
which WDT N
will MD N
prevent VB N
recurrence NN N
and CC N
improve VB N
survival NN N
rate NN N
In IN N
the DT N
present JJ N
study NN N
we PRP N
observed VBD N
a DT N
tendency NN N
of IN N
the DT N
lower JJR N
recurrence NN N
rate NN N
in IN N
the DT N
immunized JJ N
group NN N
, , N
and CC N
we PRP N
hypothesize VBP N
that IN N
OK-432 NNP N
is VBZ N
effective JJ N
in IN N
extending VBG N
the DT N
recurrence-free JJ N
period NN N
-DOCSTART- -X- O O 15774238

Effect NN N
of IN N
a DT N
nutritional JJ N
supplement NN N
containing VBG N
vitamin NN N
E NNP N
, , N
selenium NN N
, , N
vitamin FW N
c NNS N
and CC N
coenzyme JJ N
Q10 NNP N
on IN N
serum NN N
PSA NNP N
in IN N
patients NNS N
with IN N
hormonally RB 4_p
untreated JJ 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
prostate NN 4_p
: : 4_p
a DT N
randomised JJ N
placebo-controlled JJ N
study NN N
OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effect NN N
of IN N
a DT N
nutritional JJ N
supplement NN N
containing VBG N
vitamin NN N
E NNP N
, , N
selenium NN N
, , N
vitamin FW N
C NNP N
and CC N
coenzyme JJ N
Q10 NNP N
on IN N
changes NNS N
in IN N
serum NN N
levels NNS N
of IN N
PSA NNP N
in IN N
patients NNS N
with IN 4_p
hormonally RB 4_p
untreated JJ 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
prostate NN 4_p
and CC N
rising VBG 4_p
serum NN 4_p
PSA NNP 4_p
levels NNS 4_p
METHODS NNP N
Eighty NNP 3_p
patients NNS 3_p
were VBD 3_p
randomised VBN 3_p
to TO N
receive VB N
a DT N
daily JJ N
supplement NN N
with IN N
either DT N
vitamin NN N
E NNP N
, , N
selenium NN N
, , N
vitamin FW N
C NNP N
, , N
coenzyme NN N
Q10 NNP N
( ( N
intervention NN N
group NN N
) ) N
or CC N
placebo NN N
over IN N
21 CD N
weeks NNS N
Serum NNP N
levels NNS N
of IN N
PSA NNP N
were VBD N
assessed VBN N
at IN N
baseline NN N
( ( N
-2 UH N
, , N
-1 NNP N
, , N
0 CD N
weeks NNS N
) ) N
and CC N
after IN N
6 CD N
, , N
13 CD N
, , N
19 CD N
, , N
20 CD N
and CC N
21 CD N
weeks NNS N
Mean JJ N
changes NNS N
in IN N
log NN N
serum JJ N
level NN N
of IN N
PSA NNP N
, , N
testosterone NN N
, , N
dihydrotestosterone NN N
, , N
luteinizing VBG N
hormone NN N
and CC N
sex NN N
hormone NN N
binding VBG N
globulin NN N
over IN N
21 CD N
weeks NNS N
between IN N
the DT N
verum NN N
and CC N
the DT N
placebo NN N
group NN N
were VBD N
compared VBN N
by IN N
analysis NN N
of IN N
covariance NN N
RESULTS NNP N
Seventy NNP 3_p
patients NNS 3_p
completed VBD N
the DT N
study NN N
( ( N
36 CD 3_p
verum NN 3_p
; : N
34 CD 3_p
placebo NN 3_p
) ) 3_p
Compliance NN N
was VBD N
> JJ N
90 CD N
% NN N
in IN N
all DT N
patients NNS N
In IN N
the DT N
intervention NN N
group NN N
, , N
plasma NN N
levels NNS N
of IN N
vitamin NN N
E NNP N
, , N
selenium NN N
and CC N
coenzyme JJ N
Q10 NNP N
increased VBD N
significantly RB N
over IN N
the DT N
21 CD N
weeks NNS N
study JJ N
period NN N
No DT N
significant JJ N
differences NNS N
in IN N
serum NN N
levels NNS N
of IN N
PSA NNP N
, , N
testosterone NN N
, , N
dihydrotestosterone NN N
, , N
luteinizing VBG N
hormone NN N
or CC N
sex NN N
hormone NN N
binding VBG N
globulin NN N
( ( N
p JJ N
> NNP N
0.2 CD N
) ) N
were VBD N
observed VBN N
between IN N
the DT N
intervention NN N
and CC N
control NN N
group NN N
CONCLUSION NNP N
Our PRP$ N
results NNS N
indicate VBP N
that DT N
supplementation NN N
of IN N
a DT N
combination NN N
of IN N
vitamin NN N
E NNP N
, , N
selenium NN N
, , N
vitamin FW N
C NNP N
and CC N
coenzyme-Q10 NN N
does VBZ N
not RB N
affect VB N
serum JJ N
level NN N
of IN N
PSA NNP N
or CC N
hormone NN N
levels NNS N
in IN N
patients NNS N
with IN N
hormonally RB 4_p
untreated JJ 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
prostate NN 4_p
-DOCSTART- -X- O O 19995250

Breast NNP N
reduction NN N
alleviates VBZ N
depression NN N
and CC N
anxiety NN N
and CC N
restores VBZ N
self-esteem NNS N
: : N
a DT N
prospective JJ N
randomised JJ N
clinical JJ N
trial NN N
Of IN N
women NNS 2_p
who WP N
seek VBP N
reduction NN 4_p
mammaplasty NN 4_p
, , N
up RB N
to TO N
a DT N
third JJ N
have VBP N
pathological JJ N
degrees NNS N
of IN N
anxiety NN 4_p
or CC N
depression NN 4_p
, , N
or CC N
both DT N
The DT N
psychological JJ N
aspect NN N
of IN N
reduction NN N
mammaplasty NN N
is VBZ N
therefore RB N
an DT N
important JJ N
consideration NN N
We PRP N
did VBD N
a DT N
prospective NN N
randomised VBN N
clinical JJ N
trial NN N
to TO N
see VB N
how WRB N
reduction NN N
mammaplasty RB N
affected VBD N
macromastia JJ N
patients NNS N
' POS N
depression NN N
, , N
anxiety NN N
, , N
and CC N
self-esteem JJ N
Eighty-two JJ 3_p
patients NNS N
were VBD N
randomised VBN N
, , N
40 CD N
to TO N
have VB N
the DT N
operation NN N
, , N
and CC N
42 CD N
patients NNS N
to TO N
conservative JJ N
treatment NN N
Both DT N
groups NNS N
were VBD N
followed VBN N
for IN N
six CD N
months NNS N
The DT N
patients NNS N
completed VBD N
the DT N
RBDI NNP N
questionnaire NN N
( ( N
Raitasalo NNP N
's POS N
modification NN N
of IN N
the DT N
short JJ N
form NN N
of IN N
the DT N
Beck NNP N
Depression NNP N
Inventory NNP N
) ) N
Twenty-nine JJ N
patients NNS N
in IN N
the DT N
operated JJ N
group NN N
and CC N
35 CD N
patients NNS N
in IN N
the DT N
conservative JJ N
group NN N
completed VBD N
the DT N
study NN N
At IN N
the DT N
second JJ N
examination NN N
, , N
the DT N
patients NNS N
who WP N
had VBD N
been VBN N
operated VBN N
on IN N
, , N
had VBD N
significantly RB N
less JJR N
depression NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
and CC N
better JJR N
self-esteem NN N
( ( N
p=0.03 NN N
) ) N
than IN N
the DT N
conservative JJ N
group NN N
The DT N
proportions NNS N
of IN N
depressed JJ N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
and CC N
anxious JJ N
( ( N
p=0.04 NN N
) ) N
patients NNS N
were VBD N
also RB N
smaller JJR N
in IN N
the DT N
group NN N
who WP N
were VBD N
operated VBN N
on IN N
There EX N
is VBZ N
significantly RB N
less JJR N
depression NN N
and CC N
anxiety NN N
after IN N
reduction NN N
mammaplasty NN N
, , N
and CC N
patients NNS N
' POS N
self-esteem NN N
is VBZ N
restored VBN N
-DOCSTART- -X- O O 17174705

Continuous JJ N
pralidoxime NN N
infusion NN N
versus NN N
repeated VBD N
bolus JJ N
injection NN N
to TO N
treat VB N
organophosphorus JJ 4_p
pesticide NN 4_p
poisoning NN 4_p
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
BACKGROUND IN N
The DT N
role NN N
of IN N
oximes NNS N
for IN N
the DT N
treatment NN N
of IN N
organophosphorus JJ N
pesticide NN N
poisoning NN N
has VBZ N
not RB N
been VBN N
conclusively RB N
established VBN N
We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
a DT N
constant JJ N
pralidoxime NN N
infusion NN N
compared VBN N
with IN N
repeated JJ N
bolus NN N
doses NNS N
to TO N
treat VB N
patients NNS N
with IN N
moderately RB N
severe JJ N
poisoning VBG N
from IN N
organophosphorus JJ N
pesticides NNS N
METHODS NNP N
200 CD 3_p
patients NNS 3_p
were VBD N
recruited VBN N
to TO N
our PRP$ N
single-centre JJ N
, , N
open JJ 4_p
randomised VBD 4_p
controlled VBN 4_p
trial NN 4_p
after IN 4_p
moderately RB 4_p
severe JJ 4_p
poisoning NN 4_p
by IN 4_p
anticholinesterase NN 4_p
pesticide NN 4_p
All DT N
were VBD N
given VBN N
a DT N
2 CD N
g NN N
loading VBG N
dose NN N
of IN N
pralidoxime NN N
over IN N
30 CD N
min NNS N
Patients NNS N
were VBD N
then RB N
randomly RB N
assigned VBN N
to TO N
control VB N
and CC N
study VB N
groups NNS N
Controls NNS N
were VBD N
given VBN N
a DT N
bolus NN N
dose NN N
of IN N
1 CD N
g NN N
pralidoxime NN N
over IN N
1 CD N
h NNS N
every DT N
4 CD N
h NN N
for IN N
48 CD N
h. PDT N
The DT N
study NN N
group NN N
had VBD N
a DT N
constant JJ N
infusion NN N
of IN N
1 CD N
g NN N
over IN N
an DT N
hour NN N
every DT N
hour NN N
for IN N
48 CD N
h. NN N
Thereafter NNP N
, , N
all DT N
patients NNS N
were VBD N
given VBN N
1 CD N
g JJ N
every DT N
4 CD N
h NN N
until IN N
they PRP N
could MD N
be VB N
weaned VBN N
from IN N
ventilators NNS N
Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
Primary NNP N
outcome JJ N
measures NNS N
were VBD N
median JJ N
atropine NN N
dose NN N
needed VBD N
within IN N
24 CD N
h NN N
, , N
proportion NN N
of IN N
patients NNS N
who WP N
needed VBD N
intubation NN N
, , N
and CC N
number NN N
of IN N
days NNS N
on IN N
ventilation NN N
The DT N
study NN N
is VBZ N
registered VBN N
at IN N
http NN N
: : N
//www.clinicaltrials.gov NN N
with IN N
the DT N
identifier NN N
NCT00333944 NNP N
FINDINGS NNP N
100 CD 3_p
patients NNS 3_p
were VBD N
assigned VBN N
the DT N
high-dose JJ N
regimen NNS N
, , N
and CC N
100 CD N
the DT N
control NN N
regimen NN N
There EX N
were VBD N
no DT N
drop-outs JJ N
Patients NNS N
receiving VBG N
the DT N
high-dose JJ N
pralidoxime JJ 4_p
regimen NNS 4_p
required VBD N
less JJR N
atropine JJ N
during IN N
the DT N
first JJ N
24 CD N
h NN N
than IN N
controls NNS N
( ( N
median JJ N
6 CD N
mg NN N
vs NN N
30 CD N
mg NN N
; : N
difference NN N
24 CD N
mg NN N
[ VBD N
95 CD N
% NN N
CI NNP N
24-26 CD N
, , N
p VBZ N
< JJ N
0.0001 CD N
] NN N
) ) N
88 CD N
( ( N
88 CD N
% NN N
) ) N
and CC N
64 CD N
( ( N
64 CD N
% NN N
) ) N
of IN N
controls NNS N
and CC N
high-dose JJ N
patients NNS N
, , N
respectively RB N
, , N
needed VBD N
intubation NN N
during IN N
admission NN N
to TO N
hospital NN N
( ( N
relative JJ N
risk=0.72 NN N
, , N
0.62-0.86 JJ N
, , N
p=0.0001 NN N
) ) N
Control NNP N
patients NNS N
required VBD N
ventilatory JJ N
support NN N
for IN N
longer JJR N
( ( N
median JJ N
10 CD N
days NNS N
vs RB N
5 CD N
days NNS N
; : N
difference NN N
5 CD N
days NNS N
[ RB N
5-6 JJ N
, , N
p JJ N
< FW N
0.0001 CD N
] NN N
) ) N
INTERPRETATION VB N
A DT N
high-dose JJ N
regimen NN N
of IN N
pralidoxime NN N
, , N
consisting VBG N
of IN N
a DT N
constant JJ N
infusion NN N
of IN N
1 CD N
g/h NN N
for IN N
48 CD N
h NN N
after IN N
a DT N
2 CD N
g NN N
loading VBG N
dose NN N
, , N
reduces VBZ N
morbidity NN N
and CC N
mortality NN N
in IN N
moderately RB N
severe JJ N
cases NNS N
of IN N
acute JJ N
organophosphorus-pesticide JJ N
poisoning NN N
-DOCSTART- -X- O O 23716409

The DT N
effectiveness NN N
of IN N
educational JJ N
interventions NNS N
to TO N
enhance VB N
the DT N
adoption NN N
of IN N
fee-based JJ N
arsenic JJ N
testing NN N
in IN N
Bangladesh NNP 4_p
: : N
a DT N
cluster NN N
randomized VBN N
controlled VBN N
trial NN N
Arsenic NNP N
( ( N
As IN N
) ) N
testing NN N
could MD N
help VB N
22 CD N
million CD N
people NNS N
, , N
using VBG N
drinking NN N
water NN N
sources NNS N
that WDT N
exceed VBP N
the DT N
Bangladesh NNP N
As NNP N
standard NN N
, , N
to TO N
identify VB N
safe JJ N
sources NNS N
A DT N
cluster NN N
randomized VBN N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
household NN N
education NN N
and CC N
local JJ N
media NNS N
in IN N
the DT N
increasing VBG N
demand NN N
for IN N
fee-based JJ N
As IN N
testing VBG N
Randomly RB 4_p
selected VBN 4_p
households NNS 4_p
( ( N
N NNP N
= NNP N
452 CD 3_p
) ) N
were VBD N
divided VBN N
into IN N
three CD N
interventions NNS N
implemented VBN N
by IN N
community NN N
workers NNS N
: : N
1 CD N
) ) N
fee-based JJ N
As IN N
testing VBG N
with IN N
household NN N
education NN N
( ( N
HE NNP N
) ) N
; : N
2 CD N
) ) N
fee-based JJ N
As IN N
testing VBG N
with IN N
household NN N
education NN N
and CC N
a DT N
local JJ N
media NNS N
campaign NN N
( ( N
HELM NNP N
) ) N
; : N
and CC N
3 CD N
) ) N
fee-based JJ N
As IN N
testing VBG N
alone RB N
( ( N
Control NNP N
) ) N
The DT N
fee NN N
for IN N
the DT N
As NNP N
test NN N
was VBD N
US NNP N
$ $ N
0.28 CD N
, , N
higher JJR N
than IN N
the DT N
cost NN N
of IN N
the DT N
test NN N
( ( N
US NNP N
$ $ N
0.16 CD N
) ) N
Of IN N
households NNS N
with IN N
untested JJ N
wells NNS N
, , N
93 CD N
% NN N
in IN N
both DT N
intervention NN N
groups NNS N
HE NNP N
and CC N
HELM NNP N
purchased VBD N
an DT N
As IN N
test NN N
, , N
whereas IN N
only RB N
53 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
In IN N
conclusion NN N
, , N
fee-based JJ N
As IN N
testing VBG N
with IN N
household NN N
education NN N
is VBZ N
effective JJ N
in IN N
the DT N
increasing VBG N
demand NN N
for IN N
As IN N
testing VBG N
in IN N
rural JJ 4_p
Bangladesh NNP 4_p
-DOCSTART- -X- O O 7056921

Effects NNS N
of IN N
vicarious JJ N
reinforcement NN N
in IN N
normal JJ 4_p
and CC 4_p
severely RB 4_p
disturbed JJ 4_p
children NNS 1_p
-DOCSTART- -X- O O 9134405

A DT N
randomised JJ N
trial NN N
evaluating VBG N
pain NN N
and CC N
bleeding NN N
after IN N
a DT N
first JJ 4_p
trimester NN 4_p
miscarriage NN 4_p
treated VBD N
surgically RB N
or CC N
medically RB N
Miscarriage NN N
treated VBD N
surgically RB N
and CC N
medically RB N
were VBD N
compared VBN N
in IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
evaluating VBG N
pain NN N
and CC N
bleeding NN N
Surgery NN N
is VBZ N
associated VBN N
with IN N
less JJR N
pain NN N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
and CC N
vaginal JJ N
bleeding NN N
( ( N
duration NN N
and CC N
severity NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
than IN N
medical JJ N
treatment NN N
, , N
fewer JJR N
daily JJ N
hospital NN N
attendances NNS N
( ( N
2.5 CD N
compared VBN N
with IN N
three CD N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
but CC N
a DT N
greater JJR N
drop NN N
in IN N
haemoglobin JJ N
concentration NN N
( ( N
difference NN N
, , N
1 CD N
g/dl NN N
; : N
CI95 NNP N
% NN N
= NNP N
0.3-1.6 NN N
) ) N
-DOCSTART- -X- O O 1562431

Slotted VBN N
versus IN N
non-slotted JJ N
locked JJ N
intramedullary JJ N
nailing NN N
for IN N
femoral JJ N
shaft NN N
fractures NNS N
Experimentally RB N
, , N
two CD N
slotted VBD N
nails NNS N
, , N
the DT N
Grosse-Kempf NNP N
nail NN N
and CC N
the DT N
AO/ASIF NNP N
universal JJ N
femoral JJ N
nail NN N
, , N
were VBD N
compared VBN N
to TO N
the DT N
non-slotted JJ N
Grosse-Kempf NNP N
nail NN N
and CC N
control NN N
bone NN N
using VBG N
a DT N
cadaver JJ 4_p
femoral JJ 4_p
osteotomy NN 4_p
The DT N
stiffnesses NNS N
and CC N
strengths NNS N
of IN N
the DT N
osteotomies NNS N
fixed VBN N
with IN N
slotted JJ N
nails NNS N
in IN N
10-30 JJ N
degrees NNS N
torsion NN N
were VBD N
6-8 CD N
% NN N
and CC N
the DT N
values NNS N
of IN N
non-slotted JJ N
nails NNS N
40 CD N
% NN N
of IN N
control NN N
bone NN N
The DT N
maximal JJ N
moments NNS N
were VBD N
14-18 CD N
% NN N
and CC N
48 CD N
% NN N
, , N
respectively RB N
In IN N
the DT N
" NNP N
clinical JJ N
range NN N
" NN N
of IN N
torsion NN N
, , N
the DT N
implant-bone JJ N
construct NN N
never RB N
failed VBD N
or CC N
was VBD N
deformed VBN N
Clinically NNP N
, , N
46 CD 3_p
femoral JJ 4_p
shaft NN 4_p
fractures NNS 4_p
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
Gross-Kempf NNP N
nails NNS N
, , N
24 CD 3_p
with IN N
slotted VBN 4_p
nails NNS 4_p
and CC N
22 CD 3_p
with IN N
non-slotted JJ 4_p
nails NNS 4_p
Four CD N
complications NNS N
in IN N
the DT N
slotted JJ N
nail NN N
group NN N
and CC N
three CD N
in IN N
the DT N
non-slotted JJ N
nail NN N
group NN N
were VBD N
considered VBN N
to TO N
be VB N
independent JJ N
of IN N
the DT N
choice NN N
of IN N
nail NN N
and CC N
did VBD N
not RB N
affect VB N
the DT N
end NN N
result NN N
Three CD N
splinterings NNS N
of IN N
the DT N
distal JJ N
fragment NN N
, , N
one CD N
resulting NN N
in IN N
a DT N
change NN N
of IN N
the DT N
osteosynthesis NN N
implant NN N
to TO N
a DT N
condylar JJ N
plate NN N
, , N
were VBD N
considered VBN N
to TO N
result VB N
from IN N
the DT N
high JJ N
stiffness NN N
of IN N
the DT N
non-slotted JJ N
nail NN N
Osteosynthesis NN N
of IN N
femoral JJ N
shaft NN N
fractures NNS N
using VBG N
slotted VBN N
nails NNS N
has VBZ N
not RB N
resulted VBN N
in IN N
healing VBG N
disturbances NNS N
, , N
which WDT N
could MD N
be VB N
accounted VBN N
for IN N
by IN N
the DT N
high JJ N
torsional JJ N
elasticity NN N
of IN N
the DT N
nail NN N
; : N
there RB N
seems VBZ N
to TO N
be VB N
no DT N
indication NN N
for IN N
high-stiffness NN N
nails NNS N
in IN N
femoral JJ 4_p
fractures NNS 4_p
-DOCSTART- -X- O O 8849265

Levels NNS N
of IN N
recombinant JJ N
human JJ N
granulocyte NN N
colony-stimulating NN N
factor NN N
in IN N
serum NN N
are VBP N
inversely RB N
correlated VBN N
with IN N
circulating VBG N
neutrophil JJ N
counts NNS N
Recombinant NNP N
human JJ N
granulocyte NN N
colony-stimulating NN N
factor NN N
( ( N
rhG-CSF NN N
) ) N
is VBZ N
effective JJ N
in IN N
countering VBG N
chemotherapy-induced JJ N
neutropenia NN N
However RB N
, , N
serum JJ N
rhG-CSF NN N
levels NNS N
can MD N
not RB N
be VB N
maintained VBN N
throughout IN N
the DT N
course NN N
of IN N
rhG-CSF JJ N
therapy NN N
The DT N
drop NN N
in IN N
serum JJ N
rhG-CSF JJ N
levels NNS N
may MD N
vary VB N
with IN N
the DT N
duration NN N
of IN N
rhG-CSF JJ N
administration NN N
or CC N
with IN N
the DT N
circulating VBG N
neutrophil JJ N
counts NNS N
We PRP N
investigated VBD N
the DT N
relationship NN N
between IN N
serum JJ N
G-CSF NNP N
levels NNS N
and CC N
circulating VBG N
neutrophil JJ N
counts NNS N
and CC N
the DT N
pharmacokinetics NNS N
of IN N
rhG-CSF NN N
for IN N
patients NNS 4_p
with IN 4_p
lung NN 4_p
cancer NN 4_p
who WP 4_p
had VBD 4_p
been VBN 4_p
treated VBN 4_p
with IN 4_p
myelosuppressive JJ 4_p
chemotherapy NN 4_p
and CC 4_p
then RB 4_p
with IN 4_p
subcutaneous JJ 4_p
rhG-CSF NN 4_p
( ( 4_p
lenograstim NN 4_p
, , 4_p
2 CD 4_p
micrograms NNS 4_p
per IN 4_p
kg NN 4_p
of IN 4_p
body NN 4_p
weight JJ 4_p
per IN 4_p
day NN 4_p
) ) 4_p
Twelve CD 3_p
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD N
groups NNS N
with IN N
different JJ N
rhG-CSF JJ N
therapy NN N
schedules NNS N
Serum NNP N
G-CSF JJ N
levels NNS N
were VBD N
measured VBN N
by IN N
an DT N
enzyme JJ N
immunoassay NN N
method NN N
Serum NNP N
G-CSF NNP N
levels NNS N
during IN N
the DT N
rhG-CSF JJ N
therapy NN N
greatly RB N
exceeded VBD N
endogenous JJ N
G-CSF NNP N
levels NNS N
and CC N
were VBD N
mainly RB N
due JJ N
to TO N
the DT N
presence NN N
of IN N
exogenous JJ N
rhG-CSF NN N
rather RB N
than IN N
increased VBN N
levels NNS N
of IN N
endogenous JJ N
G-CSF NNP N
Despite IN N
the DT N
duration NN N
of IN N
rhG-CSF JJ N
administration NN N
, , N
serum JJ N
G-CSF NNP N
levels NNS N
during IN N
rhG-CSF JJ N
therapy NN N
were VBD N
inversely RB N
correlated VBN N
with IN N
circulating VBG N
neutrophil JJ N
counts NNS N
( ( N
r2 VB N
= RB N
0.73 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
The DT N
value NN N
for IN N
the DT N
area NN N
under IN N
the DT N
concentration-time JJ N
curve NN N
of IN N
rhG-CSF NN N
on IN N
the DT N
day NN N
of IN N
neutrophilia NN N
was VBD N
lower JJR N
than IN N
that DT N
on IN N
the DT N
day NN N
of IN N
neutropenia NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
the DT N
fall NN N
in IN N
serum JJ N
G-CSF NNP N
levels NNS N
during IN N
rhG-CSF JJ N
therapy NN N
may MD N
result VB N
from IN N
increased VBN N
clearance NN N
and/or NN N
decreased VBD N
absorption NN N
of IN N
rhG-CSF NN N
, , N
two CD N
processes NNS N
related VBN N
to TO N
circulating VBG N
neutrophil JJ N
counts NNS N
-DOCSTART- -X- O O 22006695

Effects NNS N
of IN N
body NN N
orientation NN N
on IN N
maximum JJ N
voluntary JJ N
arm NN N
torques NNS N
INTRODUCTION NNP N
Increased VBD N
reliance NN N
on IN N
bulbospinal JJ N
motor NN N
systems NNS N
has VBZ N
been VBN N
implicated VBN N
in IN N
individuals NNS N
with IN N
chronic JJ 4_p
stroke NN 4_p
during IN N
maximum JJ N
voluntary JJ N
arm NN N
joint NN N
torque NN N
generation NN N
METHODS NNP N
Maximum NNP N
isometric JJ N
single-joint NN N
and CC N
multi-joint NN N
arm NN N
strength NN N
was VBD N
observed VBN N
in IN N
two CD N
body NN N
orientations NNS N
( ( N
sitting VBG N
and CC N
supine NN N
) ) N
while IN N
maintaining VBG N
identical JJ N
head/neck/trunk/extremity NN N
joint JJ N
configurations NNS N
in IN N
order NN N
to TO N
identify VB N
bulbospinal JJ N
contributions NNS N
to TO N
maximum VB N
joint JJ N
torque NN N
generation NN N
in IN N
11 CD 3_p
individuals NNS N
with IN N
stroke NN 4_p
and CC N
10 CD 3_p
individuals NNS 3_p
without IN 4_p
stroke NN 4_p
RESULTS NNP N
During IN N
sitting VBG N
, , N
shoulder JJR N
flexion NN N
was VBD N
greater JJR N
for IN N
both DT N
groups NNS N
, , N
whereas NNS N
shoulder VBP N
extension NN N
and CC N
elbow JJ N
flexion NN N
, , N
part NN N
of IN N
the DT N
" NNP N
flexion NN N
synergy NN N
, , N
" EX N
were VBD N
greater JJR N
only RB N
in IN N
individuals NNS N
with IN N
stroke NN N
CONCLUSIONS NNP N
Body NNP N
orientation NN N
influenced VBD N
isometric JJ N
arm NN N
strength NN N
, , N
notably RB N
the DT N
constituents NNS N
of IN N
flexion NN N
synergy NN N
in IN N
individuals NNS N
with IN N
stroke NN N
, , N
suggesting VBG N
bulbospinal JJ N
motor NN N
pathway NN N
involvement NN N
From IN N
a DT N
practical JJ N
perspective NN N
, , N
clinical JJ N
evaluation NN N
of IN N
single JJ N
joint JJ N
strength NN N
in IN N
the DT N
supine JJ N
position NN N
may MD N
underestimate VB N
strength NN N
available JJ N
during IN N
activities NNS N
of IN N
daily JJ N
living NN N
that WDT N
are VBP N
performed VBN N
in IN N
an DT N
upright JJ N
orientation NN N
-DOCSTART- -X- O O 15154956

ROMEO NN N
: : N
rethink NN N
organization NN N
to TO N
improve VB N
education NN N
and CC N
outcomes NNS N
AIMS NNP N
Scarcity NNP N
of IN N
resources NNS N
, , N
expertise NN N
and CC N
evidence-based JJ N
models NNS N
have VBP N
so RB N
far RB N
limited JJ N
delivery NN N
of IN N
patient-centred JJ N
diabetes NNS N
education NN N
We PRP N
have VBP N
developed VBN N
and CC N
validated VBD N
a DT N
group NN N
care NN N
approach NN N
that WDT N
is VBZ N
applicable JJ N
to TO N
everyday VB N
clinical JJ N
practice NN N
and CC N
cost-effective JJ N
in IN N
improving VBG N
metabolic JJ N
control NN N
, , N
knowledge NN N
of IN N
diabetes NNS N
, , N
health NN N
behaviours NNS N
, , N
and CC N
quality NN N
of IN N
life NN N
in IN N
Type NNP N
2 CD N
diabetes NNS N
A DT N
clinical JJ N
trial NN N
( ( N
ROMEO NNP N
) ) N
was VBD N
planned VBN N
to TO N
evaluate VB N
applicability NN N
and CC N
reproducibility NN N
of IN N
group NN N
care NN N
in IN N
other JJ N
outpatients NNS N
facilities NNS N
and CC N
assess VB N
its PRP$ N
impact NN N
on IN N
a DT N
larger JJR 4_p
patient JJ 4_p
population NN 4_p
METHODS NNP N
Multicentre NNP N
, , N
randomized VBD N
, , N
controlled VBD N
clinical JJ N
trial NN N
of IN N
group NN N
vs. FW N
individual JJ N
care NN N
in IN N
the DT N
routine JJ N
management NN N
of IN N
Type NNP N
2 CD N
diabetes NNS N
Nine NNP 4_p
hundred VBD 4_p
patient JJ N
aged VBN N
< NN 1_p
80 CD 1_p
, , N
with IN N
diabetes NNS 4_p
of IN N
> NN N
or CC N
=1 JJ N
year NN N
known VBN N
duration NN N
, , N
treated VBN N
by IN N
either DT N
diet JJ N
alone NN N
or CC N
diet JJ N
and CC N
oral JJ N
agents NNS N
, , N
will MD N
be VB N
recruited VBN N
in IN N
15 CD N
centres NNS N
and CC N
followed VBD N
for IN N
4 CD N
years NNS N
Training NN N
of IN N
physicians NNS N
, , N
nurses NNS N
and CC N
dietitians NNS N
included VBD N
preparation NN N
of IN N
operating VBG N
manual JJ N
and CC N
videos NNS N
, , N
interactive JJ N
sessions NNS N
, , N
and CC N
evaluation NN N
of IN N
local JJ N
facilities NNS N
and CC N
resources NNS N
RESULTS NNP N
PRIMARY NNP N
MEASUREMENTS NNP N
3-monthly JJ N
HbA1c NNP N
, , N
fasting VBG N
blood NN N
glucose NN N
, , N
body NN N
weight VBD N
, , N
waist-hip JJ N
ratio NN N
, , N
yearly RB N
blood NN N
lipids NNS N
, , N
and CC N
bi-yearly JJ N
assessment NN N
of IN N
knowledge NN N
of IN N
diabetes NNS N
, , N
health NN N
behaviours NNS N
and CC N
quality NN N
of IN N
life NN N
SECONDARY NNP N
OUTCOMES NNP N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
, , N
evaluation NN N
of IN N
ECG NNP N
for IN N
ischaemia NN N
and CC N
QT NNP N
interval NN N
, , N
hypoglycaemic JJ N
and CC N
anti-hypertensive JJ N
medication NN N
and CC N
cardiovascular JJ N
events NNS N
Analysis NN N
will MD N
be VB N
by IN N
intention-to-treat JJ N
DISCUSSION NNP N
If IN N
ROMEO NNP N
confirms VBZ N
that IN N
group NN N
care NN N
can MD N
be VB N
successfully RB N
implemented VBN N
in IN N
different JJ N
clinics NNS N
, , N
a DT N
novel JJ N
clinico-pedagogic JJ N
tool NN N
will MD N
have VB N
been VBN N
acquired VBN N
to TO N
support VB N
patient-centred JJ N
education NN N
, , N
improve VB N
lifestyle NN N
and CC N
outcomes NNS N
, , N
support NN N
team NN N
work NN N
, , N
enhance NN N
providers NNS N
' POS N
attitudes NNS N
and CC N
competencies NNS N
and CC N
ameliorate VB N
diabetes NNS N
care JJ N
organization NN N
-DOCSTART- -X- O O 22101219

Challenges NNS N
and CC N
potential JJ N
solutions NNS N
to TO N
meeting VBG N
accrual JJ N
goals NNS N
in IN N
a DT N
Phase NNP N
II NNP N
chemoprevention NN N
trial NN N
for IN N
prostate NN 4_p
cancer NN 4_p
OBJECTIVE CC N
The DT N
goal NN N
of IN N
this DT N
report NN N
is VBZ N
to TO N
describe VB N
the DT N
on IN N
going VBG N
strategies NNS N
, , N
successes NNS N
, , N
challenges NNS N
and CC N
solutions NNS N
for IN N
recruitment NN N
in IN N
this DT N
multi-center NN N
, , N
phase NN N
II NNP N
chemoprevention NN N
trial NN N
targeting VBG N
men NNS 2_p
at IN N
high JJ N
risk NN N
for IN N
prostate NN 4_p
cancer NN 4_p
METHODS NNP N
We PRP N
developed VBD N
and CC N
implemented VBD N
a DT N
multi-center JJ N
clinical JJ N
trial NN N
in IN N
institutions NNS N
with IN N
supportive JJ N
infrastructure NN N
, , N
lead NN N
by IN N
a DT N
recruitment NN N
team NN N
of IN N
experienced JJ N
and CC N
committed JJ N
physicians NNS N
and CC N
clinical JJ N
trial NN N
staff NN N
, , N
implementing VBG N
multi-media NN N
and CC N
community NN N
outreach VBP N
strategies NNS N
to TO N
meet VB N
recruitment JJ N
goals NNS N
Screening VBG N
logs NNS N
were VBD N
reviewed VBN N
to TO N
identify VB N
trends NNS N
as RB N
well RB N
as IN N
patient NN N
, , N
protocol NN N
and CC N
infrastructure NN N
-related VBD N
barriers NNS N
impacting VBG N
accrual JJ N
and CC N
revisions NNS N
to TO N
protocol VB N
implemented VBN N
RESULTS NNP N
Between NNP N
January NNP N
2008 CD N
and CC N
February NNP N
2011 CD N
a DT N
total NN N
of IN N
3547 CD 3_p
individuals NNS N
were VBD N
prescreened VBN N
with IN N
94 CD N
% NN N
( ( N
n=3092 JJ 3_p
) ) N
determined VBD N
to TO N
be VB N
ineligible JJ N
based VBN N
on IN N
diagnosis NN N
of IN N
cancer NN N
or CC N
benign JJ N
biopsy NN N
results NNS N
Of IN N
these DT N
, , N
216 CD 3_p
were VBD N
considered VBN N
eligible JJ N
for IN N
further JJ N
screening NN N
with IN N
52 CD N
% NN N
( ( N
n=113 JJ 3_p
) ) N
declining VBG N
to TO N
participate VB N
due JJ N
to TO N
patient VB N
related JJ N
factors NNS N
and CC N
14 CD N
% NN N
( ( N
n=29 JJ 3_p
) ) N
eliminated VBD N
due JJ N
to TO N
protocol-related JJ N
criteria NNS N
for IN N
exclusion NN N
Ninety-four NNP N
( ( 3_p
94 CD 3_p
) ) N
subjects NNS N
consented VBN N
to TO N
participate VB N
with IN N
34 CD N
% NN N
of IN N
these DT N
subjects NNS N
( ( N
n=74 NN N
) ) N
meeting VBG N
all DT N
eligibility NN N
criteria NNS N
to TO N
be VB N
randomized VBN N
to TO N
receive VB N
study NN N
agent NN N
or CC N
placebo NN N
Across IN N
all DT N
sites NNS N
, , N
99 CD N
% NN N
of IN N
the DT N
recruitment NN N
of IN N
subjects NNS N
in IN N
this DT N
clinical JJ N
trial NN N
is VBZ N
via IN N
physician JJ N
recruitment NN N
and CC N
referral JJ N
with IN N
less JJR N
than IN N
1 CD N
% NN N
responding VBG N
to TO N
other JJ N
recruitment NN N
strategies NNS N
CONCLUSION VB N
A DT N
contemporary JJ N
approach NN N
to TO N
subject VB N
recruitment NN N
and CC N
frequent JJ N
evaluation NN N
is VBZ N
needed VBN N
to TO N
assure VB N
responsiveness NN N
to TO N
emerging VBG N
challenges NNS N
to TO N
accrual JJ N
and CC N
the DT N
evolving VBG N
scientific JJ N
literature NN N
A DT N
focus NN N
on IN N
investing VBG N
on IN N
improving VBG N
systems NNS N
for IN N
physician JJ N
recruitment NN N
may MD N
be VB N
key JJ N
to TO N
meeting VBG N
recruitment JJ N
target NN N
in IN N
chemoprevention NN N
trials NNS N
-DOCSTART- -X- O O 12440177

Determinants NNS N
of IN N
serum JJ N
creatinine NN N
trajectory NN N
in IN N
acute JJ N
contrast NN N
nephropathy NN 4_p
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
describe VB N
the DT N
trajectory NN N
of IN N
creatinine NN N
( ( N
Cr NNP N
) ) N
rise NN N
and CC N
its PRP$ N
determinants NNS N
after IN N
exposure NN N
to TO N
radiocontrast VB 4_p
media NNS N
Included VBN N
were VBD N
98 CD 3_p
subjects NNS N
who WP N
underwent VBP N
cardiac JJ 4_p
catheterization NN 4_p
and CC N
were VBD N
randomized VBN N
to TO N
forced VBN N
diuresis NN N
with IN N
i.v NN N
crystalloid NN N
, , N
furosemide RB N
, , N
mannitol NN N
( ( N
if IN N
pulmonary JJ N
capillary JJ N
wedge NN N
pressure NN N
was VBD N
< JJ N
20 CD N
mmHg NN N
) ) N
, , N
and CC N
low JJ N
dose JJ N
dopamine NN N
versus NN N
intravenous JJ N
crystalloid NN N
and CC N
matching VBG N
placebos NNS N
Baseline NNP N
and CC N
postcatheterization NN N
serum NN N
Cr NNP N
levels NNS N
were VBD N
analyzed VBN N
in IN N
a DT N
longitudinal JJ N
fashion NN N
, , N
allowing VBG N
for IN N
differences NNS N
in IN N
the DT N
time NN N
between IN N
blood NN N
draws NNS N
, , N
to TO N
determine VB N
the DT N
different JJ N
critical JJ N
trajectories NNS N
of IN N
serum NN N
Cr NNP N
The DT N
mean JJ N
age NN N
, , N
baseline NN 4_p
serum NN 4_p
Cr NNP 4_p
, , N
and CC N
Cr NNP 4_p
clearance NN 4_p
( ( N
CrCl NNP N
) ) N
were VBD N
69.3 CD 1_p
+/- JJ 1_p
10.8 CD 1_p
years NNS 1_p
, , 1_p
2.5 CD N
+/- JJ N
0.9 CD N
mg/dL NN N
, , N
and CC N
31.4 CD N
+/- JJ N
12.1 CD N
mL/min NN N
, , N
respectively RB N
The DT N
clinically RB N
driven JJ N
postprocedural JJ N
observation NN N
time NN N
was VBD N
5.5 CD N
+/- JJ N
5.1 CD N
days NNS N
( ( N
range VB N
19 CD N
hours NNS N
and CC N
one CD N
Cr NNP N
value NN N
to TO N
25.7 CD N
days NNS N
and CC N
18 CD N
values NNS N
) ) N
The DT N
mean JJ N
maximum NN N
Cr NNP N
was VBD N
3.3 CD N
+/- JJ N
1.4 CD N
, , N
range NN N
1.7-8.7 JJ N
mg/dL NN N
) ) N
Longitudinal JJ N
models NNS N
support VBP N
baseline JJ N
Cr NNP N
clearance NN N
predictions NNS N
for IN N
the DT N
change NN N
in IN N
Cr NNP N
at IN N
24 CD N
hours NNS N
, , N
time NN N
as IN N
the DT N
determinant NN N
of IN N
Cr NNP N
trajectory NN N
, , N
and CC N
requisite JJ N
monitoring NN N
For IN N
any DT N
given VBN N
individual NN N
, , N
a DT N
rise NN N
in IN N
Cr NNP N
of IN N
< NNP N
or CC N
= $ N
0.5 CD N
mg/dL NN N
in IN N
the DT N
first JJ N
24 CD N
hours NNS N
after IN N
contrast NN N
exposure NN N
predicted VBD N
a DT N
favorable JJ N
outcome NN N
Baseline NNP N
renal JJ N
function NN N
is VBZ N
the DT N
major JJ N
determinant NN N
of IN N
the DT N
rate NN N
of IN N
rise NN N
, , N
height NN N
, , N
and CC N
duration NN N
of IN N
Cr NNP N
trajectory NN N
after IN N
contrast NN N
exposure NN N
Length NNP N
of IN N
observation NN N
and CC N
frequency NN N
of IN N
laboratory NN N
measures NNS N
can MD N
be VB N
anticipated VBN N
from IN N
these DT N
models NNS N
-DOCSTART- -X- O O 7859140

Safety NN N
and CC N
efficacy NN N
of IN N
thymopentin NN N
in IN N
zidovudine NN 4_p
( ( 4_p
AZT NNP 4_p
) ) 4_p
-treated VBD 4_p
asymptomatic JJ 4_p
HIV-infected JJ 4_p
subjects NNS 4_p
with IN 4_p
200-500 JJ 4_p
CD4 NNP 4_p
cells/mm3 NN 4_p
: : N
a DT N
double-blind JJ N
placebo-controlled JJ N
trial NN N
Thymopentin NNP N
, , N
50 CD N
mg NN N
subcutaneously RB N
( ( N
s.c. NN N
) ) N
3 CD N
times NNS N
per IN N
week NN N
, , N
was VBD N
evaluated VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
zidovudine NN N
( ( N
AZT NNP N
) ) N
-treated VBD N
asymptomatic JJ N
human JJ 4_p
immunodeficiency NN 4_p
virus NN 4_p
( ( 4_p
HIV NNP 4_p
) ) 4_p
-infected VBD 4_p
subjects NNS N
with IN N
200-500 JJ N
CD4 NNP N
cells/mm3 NN N
at IN N
entry NN N
The DT N
352 CD 3_p
subjects NNS N
were VBD N
prestratified VBN N
by IN N
prior JJ N
AZT NNP N
use NN N
into IN N
stratum NN N
I PRP N
( ( N
235 CD N
subjects NNS N
, , N
> VBZ N
6 CD N
months NNS N
AZT NNP N
at IN N
entry NN N
) ) N
and CC N
stratum JJ N
II NNP N
( ( N
117 CD N
subjects NNS N
, , N
< '' N
or CC N
= VB N
6 CD N
months NNS N
AZT NNP N
at IN N
entry NN N
) ) N
Clinical JJ N
end NN N
points NNS N
, , N
CD4 NNP N
cell NN N
counts NNS N
, , N
serum NN N
p24 NN N
, , N
serum JJ N
immune NN N
complex NN N
dissociated VBD N
( ( N
ICD NNP N
) ) N
p24 NN N
, , N
and CC N
safety NN N
variables NNS N
were VBD N
evaluated VBN N
through IN N
48 CD N
weeks NNS N
, , N
using VBG N
an DT N
intent-to-treat JJ N
analysis NN N
The DT N
two CD N
strata NNS N
were VBD N
analyzed VBN N
individually RB N
because IN N
they PRP N
yielded VBD N
different JJ N
clinical JJ N
outcomes NNS N
, , N
with IN N
a DT N
statistically RB N
significant JJ N
treatment-by-stratum JJ N
interaction NN N
In IN N
stratum NN N
I PRP N
( ( N
mean VB N
, , N
16 CD N
months NNS N
AZT NNP N
at IN N
entry NN N
) ) N
two CD N
AIDS NNP N
or CC N
death NN N
events NNS N
occurred VBD N
in IN N
thymopentin NN N
and CC N
10 CD N
in IN N
placebo NN N
recipients NNS N
( ( N
p JJ N
= VBZ N
0.024 CD N
; : N
relative JJ N
risk NN N
( ( N
RR NNP N
) ) N
estimate NN N
, , N
4.9 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
limit NN N
( ( N
CI NNP N
) ) N
, , N
1.1 CD N
to TO N
22.2 CD N
] NN N
) ) N
There EX N
were VBD N
three CD N
AIDS-related JJ N
complex NN N
( ( N
ARC NNP N
) ) N
, , N
AIDS NNP N
, , N
or CC N
death NN N
events NNS N
in IN N
thymopentin NN N
and CC N
18 CD N
in IN N
placebo NN N
recipients NNS N
[ VBP N
p JJ N
= NNP N
0.001 CD N
; : N
RR NNP N
estimate NN N
, , N
5.9 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.7 CD N
to TO N
20.0 CD N
) ) N
] NN N
In IN N
stratum NN N
II NNP N
( ( N
mean NN N
, , N
3 CD N
months NNS N
AZT NNP N
at IN N
entry NN N
) ) N
, , N
four CD N
AIDS NNP N
or CC N
death NN N
events NNS N
occurred VBD N
in IN N
thymopentin NN N
and CC N
none NN N
in IN N
placebo NN N
recipients NNS N
( ( N
p JJ N
= NNP N
0.11 CD N
) ) N
, , N
and CC N
four CD N
ARC NNP N
, , N
AIDS NNP N
, , N
or CC N
death NN N
events NNS N
occurred VBD N
in IN N
thymopentin NN N
and CC N
two CD N
in IN N
placebo NN N
recipients NNS N
( ( N
p JJ N
= NNP N
0.79 CD N
) ) N
The DT N
treatment NN N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
with IN N
respect NN N
to TO N
changes NNS N
in IN N
CD4 NNP N
counts NNS N
or CC N
p24 VB N
antigen NN N
levels NNS N
or CC N
with IN N
respect NN N
to TO N
clinical JJ N
adverse JJ N
experiences NNS N
or CC N
laboratory NN N
abnormalities NNS N
Thus RB N
, , N
AZT-experienced JJ N
placebo-treated JJ N
subjects NNS N
had VBD N
relatively RB N
high JJ N
progression NN N
rates NNS N
to TO N
AIDS NNP N
or CC N
death NN N
and CC N
to TO N
ARC NNP N
, , N
AIDS NNP N
, , N
or CC N
death NN N
, , N
and CC N
these DT N
rates NNS N
were VBD N
reduced VBN N
by IN N
thymopentin NN N
treatment NN N
In IN N
contrast NN N
, , N
placebo-treated JJ N
subjects NNS N
with IN N
little JJ N
prior JJ N
AZT NNP N
experience NN N
had VBD N
low JJ N
progression NN N
rates NNS N
; : N
these DT N
were VBD N
not RB N
significantly RB N
changed VBN N
by IN N
thymopentin NN N
treatment NN N
There EX N
was VBD N
no DT N
increase NN N
in IN N
the DT N
incidence NN N
of IN N
adverse JJ N
reactions NNS N
with IN N
thymopentin NN N
-DOCSTART- -X- O O 6391269

Fentanyl NNP N
supplementation NN N
to TO N
inhalation NN 4_p
anaesthesia NN 4_p
In IN N
eight CD 3_p
out IN N
of IN N
15 CD 3_p
healthy JJ 4_p
patients NNS N
undergoing VBG N
body NN 4_p
surface NN 4_p
surgery NN 4_p
, , N
the DT N
effect NN N
of IN N
a DT N
fentanyl JJ N
infusion NN N
on IN N
a DT N
conventional JJ N
thiopentone NN N
, , N
nitrous JJ N
oxide NN N
, , N
oxygen NN N
and CC N
halothane NN N
anaesthetic NN N
was VBD N
studied VBN N
The DT N
fentanyl JJ N
infusion NN N
( ( N
2 CD N
micrograms/kg/hour NN N
) ) N
reduced VBD N
the DT N
induction NN N
dose NN N
of IN N
thiopentone NN N
and CC N
caused VBD N
marked JJ N
respiratory JJ N
depression NN N
with IN N
a DT N
reduction NN N
in IN N
the DT N
patients NNS N
' POS N
response NN N
to TO N
surgery NN N
The DT N
mean JJ N
arterial JJ N
pressures NNS N
and CC N
pulse JJ N
rates NNS N
were VBD N
not RB N
significantly RB N
different JJ N
in IN N
each DT N
group NN N
throughout IN N
the DT N
course NN N
of IN N
the DT N
operation NN N
The DT N
fentanyl NN N
made VBD N
no DT N
difference NN N
to TO N
the DT N
patients NNS N
' POS N
postoperative JJ N
analgesic JJ N
requirements NNS N
or CC N
to TO N
their PRP$ N
recovery NN N
in IN N
the DT N
first JJ N
24 CD N
hours NNS N
-DOCSTART- -X- O O 5431057

Para-anaesthetic JJ N
headache NN 4_p
in IN N
female JJ 2_p
patients NNS N
-DOCSTART- -X- O O 23416308

Safety NN N
, , N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
GS-9620 NNP N
, , N
an DT N
oral JJ N
Toll-like NNP N
receptor NN N
7 CD N
agonist NN N
BACKGROUND NNP N
GS-9620 NNP N
is VBZ N
a DT N
novel JJ N
oral JJ N
agonist NN N
of IN N
Toll-like NNP N
receptor NN N
7 CD N
( ( N
TLR7 NNP N
) ) N
in IN N
development NN N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
viral JJ N
hepatitis NN N
TLR7 NNP N
is VBZ N
a DT N
highly RB N
conserved JJ N
innate NN N
immune NN N
receptor NN N
expressed VBD N
primarily RB N
on IN N
plasmacytoid JJ N
dendritic JJ N
cells NNS N
and CC N
B NNP N
lymphocytes NNS N
The DT N
aim NN N
of IN N
this DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
single JJ N
ascending-dose JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
safety NN N
, , N
tolerability NN N
, , N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
GS-9620 NNP N
in IN N
healthy JJ 4_p
volunteers NNS 4_p
METHODS NNP N
In IN N
total JJ N
, , N
75 CD N
healthy JJ N
volunteers NNS N
( ( N
8 CD N
subjects NNS N
in IN N
each DT N
of IN N
the DT N
10 CD N
cohorts NNS N
; : N
5 CD N
subjects NNS N
participated VBN N
in IN N
two CD N
cohorts NNS N
) ) N
were VBD N
randomized VBN N
( ( N
6:2 CD N
) ) N
to TO N
receive VB N
a DT N
single JJ N
dose NN N
of IN N
GS-9620 NNP N
( ( N
0.3 CD N
, , N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
or CC N
12 CD N
mg NN N
) ) N
or CC N
placebo NN N
RESULTS NNP N
GS-9620 NNP N
was VBD N
well-absorbed JJ N
and CC N
well-tolerated JJ N
in IN N
oral JJ N
doses NNS N
up RB N
to TO N
12 CD N
mg NN N
Minimal JJ N
treatment-related JJ N
adverse JJ N
events NNS N
were VBD N
seen VBN N
at IN N
doses NNS N
up RB N
to TO N
8 CD N
mg. NNS N
Serum NNP N
interferon NN N
( ( N
IFN NNP N
) ) N
-α NN N
was VBD N
only RB N
detected VBN N
in IN N
subjects NNS N
who WP N
received VBD N
8 CD N
or CC N
12 CD N
mg NN N
doses NNS N
, , N
and CC N
the DT N
adverse JJ N
event NN N
profile NN N
at IN N
8 CD N
and CC N
12 CD N
mg NN N
doses NNS N
was VBD N
generally RB N
consistent JJ N
with IN N
that DT N
associated VBN N
with IN N
IFN-α NNP N
exposure NN N
( ( N
flu-like JJ N
symptoms NNS N
) ) N
, , N
consistent JJ N
with IN N
the DT N
mechanism NN N
of IN N
TLR7 NNP N
agonism NN N
All DT N
adverse JJ N
events NNS N
resolved VBD N
within IN N
72 CD N
h. JJ N
Induction NNP N
of IN N
chemokines/cytokines NNS N
and CC N
IFN-stimulated JJ N
genes NNS N
were VBD N
seen VBN N
at IN N
GS-9620 NNP N
doses NNS N
≥ VBP N
2 CD N
mg NN N
, , N
well RB N
below IN N
doses NNS N
that WDT N
induced VBD N
serum JJ N
IFN-α NNP N
or CC N
led VBN N
to TO N
clinical JJ N
adverse JJ N
events NNS N
CONCLUSIONS NNP N
GS-9620 NNP N
demonstrates VBZ N
safety NN N
and CC N
pharmacodynamic JJ N
activity NN N
at IN N
doses VBZ N
up RB N
to TO N
12 CD N
mg. NNS N
Pharmacodynamic NNP N
activity NN N
is VBZ N
seen VBN N
before IN N
adverse JJ N
events NNS N
, , N
suggesting VBG N
the DT N
potential NN N
for IN N
induction NN N
of IN N
an DT N
antiviral JJ N
response NN N
without IN N
systemic JJ N
adverse JJ N
events NNS N
in IN N
subjects NNS N
with IN N
chronic JJ N
viral JJ N
hepatitis NN N
-DOCSTART- -X- O O 9474450

Influence NN N
of IN N
special-effect JJ N
contact NN N
lenses NNS N
( ( N
Crazy NNP N
Lenses NNP N
) ) N
on IN N
visual JJ N
function NN N
PURPOSE NNP N
Special-effect JJ N
contact NN N
lenses NNS N
( ( N
opaque NN N
, , N
tinted VBD N
soft JJ N
contact NN N
lenses VBZ N
that IN N
incorporate JJ N
decorative JJ N
images NNS N
such JJ N
as IN N
" JJ N
cateyes NNS N
, , N
" NNP N
stars VBZ N
, , N
or CC N
hearts NNS N
to TO N
alter VB N
eye NN N
color NN N
and CC N
structure NN N
) ) N
have VBP N
become VBN N
increasingly RB N
popular JJ N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
such JJ N
lenses NNS N
impair VBP N
visual JJ N
function NN N
METHODS NNP N
A DT N
clear JJ N
soft JJ N
contact NN N
lens NNS N
and CC N
a DT N
special-effect JJ N
soft JJ N
contact NN N
lens NNS N
( ( N
Crazy NNP N
lens VBZ N
, , N
) ) N
were VBD N
fit JJ N
in IN N
changing VBG N
sequence NN N
in IN N
nine CD 3_p
healthy JJ 4_p
subjects NNS N
The DT N
parameters NNS N
studied VBD N
included VBN N
: : N
visual JJ N
acuity NN N
, , N
contrast NN N
sensitivity NN N
( ( N
with IN N
and CC N
without IN N
glare NN N
) ) N
, , N
visual JJ N
field NN N
, , N
and CC N
mesopic NN N
vision NN N
( ( N
with IN N
and CC N
without IN N
glare NN N
) ) N
RESULTS VB N
The DT N
following JJ N
parameters NNS N
displayed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
Visual JJ N
acuity NN N
was VBD N
decreased VBN N
to TO N
0.9 CD N
+/- JJ N
0.23 CD N
in IN N
the DT N
Crazy NNP N
lens VBZ N
group NN N
as IN N
compared VBN N
with IN N
1.2 CD N
+/- JJ N
0.13 CD N
in IN N
the DT N
clear JJ N
lens NNS N
group NN N
Goldmann NNP N
visual JJ N
field NN N
displayed VBD N
a DT N
significant JJ N
constriction NN N
of IN N
the DT N
isopters NNS N
: : N
III/4 NNP N
, , N
I/4 NNP N
, , N
and CC N
I/3 NNP N
Mesopic NNP N
vision NN N
without IN N
glare NN N
was VBD N
reduced VBN N
from IN N
1:2.5 CD N
to TO N
1:7.4 CD N
Contrast NNP N
sensitivity NN N
was VBD N
significantly RB N
reduced VBN N
in IN N
a DT N
photopic JJ N
condition NN N
with IN N
and CC N
without IN N
glare NN N
and CC N
in IN N
a DT N
scotopic JJ N
condition NN N
without IN N
glare NN N
Furthermore RB N
, , N
the DT N
special-effect JJ N
lenses NNS N
were VBD N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
lens NNS N
wearing VBG N
comfort NN N
CONCLUSIONS NNP N
Special-effect JJ N
contact NN N
lenses NNS N
were VBD N
associated VBN N
with IN N
a DT N
reduction NN N
of IN N
many JJ N
visual JJ N
functions NNS N
, , N
including VBG N
visual JJ N
acuity NN N
and CC N
contrast NN N
sensitivity NN N
For IN N
some DT N
wearers NNS N
this DT N
may MD N
interfere VB N
with IN N
activities NNS N
where WRB N
excellent JJ N
vision NN N
is VBZ N
crucial JJ N
, , N
such JJ N
as IN N
driving VBG N
a DT N
car NN N
-DOCSTART- -X- O O 20881754

Multicenter NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
to TO N
assess VB N
the DT N
acute JJ N
prokinetic JJ N
efficacy NN N
of IN N
nizatidine-controlled JJ N
release NN N
( ( N
150 CD N
and CC N
300 CD N
mg NN N
) ) N
in IN N
patients NNS N
with IN N
gastroesophageal JJ 4_p
reflux JJ 4_p
disease NN 4_p
INTRODUCTION VBZ N
The DT N
aim NN N
of IN N
the DT N
study NN N
is VBZ N
to TO N
test VB N
whether IN N
nizatidine NN N
delivered VBN N
via IN N
a DT N
unique JJ N
bimodal JJ N
pulsatile-controlled JJ N
release NN N
system NN N
, , N
nizatidine NN N
controlled VBN N
release NN N
( ( N
CR NNP N
) ) N
, , N
accelerates VBZ N
gastric JJ N
emptying VBG N
in IN N
patients NNS N
with IN N
gastroesophageal JJ 4_p
reflux NN 4_p
disease NN 4_p
( ( 4_p
GERD NNP 4_p
) ) 4_p
METHODS NNP N
Combined NNP N
data NNS N
were VBD N
analyzed VBN N
on IN N
39 CD 3_p
patients NNS N
with IN N
delayed JJ 4_p
gastric NN 4_p
emptying NN 4_p
( ( 4_p
DGE NNP 4_p
) ) 4_p
from IN N
2 CD N
studies NNS N
( ( N
n JJ 3_p
= NNP 3_p
84 CD 3_p
) ) N
assessing VBG N
the DT N
prokinetic JJ N
effect NN N
of IN N
nizatidine JJ N
CR NNP N
A DT N
single-blind JJ N
placebo NN N
baseline NN N
was VBD N
followed VBN N
by IN N
double-blind JJ N
nizatidine JJ N
CR NNP N
( ( N
150 CD N
and CC N
300 CD N
mg NN N
) ) N
in IN N
randomized VBN N
sequence NN N
, , N
2 CD N
to TO N
5 CD N
days NNS N
apart RB N
Each DT N
dose NN N
was VBD N
followed VBN N
1 CD N
hour NN N
later RB N
by IN N
an DT N
egg-beater JJ N
meal NN N
, , N
labeled VBN N
with IN N
Tc99m NNP N
Gamma NNP N
camera NN N
images NNS N
were VBD N
obtained VBN N
at IN N
meal JJ N
completion NN N
, , N
1- JJ N
, , N
2- JJ N
, , N
3- JJ N
and CC N
4-hour JJ N
postmeal NN N
All PDT N
the DT N
84 CD 3_p
patients NNS N
were VBD N
classified VBN N
at IN N
baseline NN N
with IN N
DGE NNP 4_p
( ( N
gastric JJ N
retention NN N
> VBD N
6.3 CD N
% NN N
at IN N
4 CD N
hours NNS N
) ) N
or CC N
normal JJ 4_p
gastric JJ 4_p
emptying NN 4_p
RESULTS NNP N
In IN N
the DT N
39 CD N
patients NNS N
identified VBN N
with IN N
DGE NNP N
, , N
change NN N
from IN N
placebo NN N
baseline NN N
( ( N
CFB NNP N
) ) N
for IN N
percent NN N
gastric JJ N
retention NN N
at IN N
4-hour JJ N
postmeal NN N
with IN N
nizatidine JJ N
CR NNP N
( ( N
150 CD N
and CC N
300 CD N
mg NN N
) ) N
was VBD N
each DT N
improved VBN N
and CC N
statistically RB N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
In IN N
a DT N
subgroup NN N
of IN N
diabetic JJ 4_p
patients NNS N
with IN N
DGE NNP 4_p
( ( N
n JJ N
= NNP N
10 CD 3_p
) ) N
, , N
the DT N
CFB NNP N
with IN N
nizatidine JJ N
CR NNP N
( ( N
300 CD N
mg NN N
) ) N
was VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
at IN N
3- JJ N
and CC N
4-hour JJ N
postmeal NN N
CONCLUSIONS NNP N
Nizatidine NNP N
CR NNP N
( ( N
150 CD N
and CC N
300 CD N
mg NN N
) ) N
significantly RB N
enhanced VBN N
gastric JJ N
emptying NN N
of IN N
a DT N
standard JJ N
meal NN N
in IN N
patients NNS N
with IN N
GERD NNP 4_p
with IN N
DGE NNP 4_p
-DOCSTART- -X- O O 23205521

Exposure NN N
to TO N
the DT N
self-face NN N
facilitates VBZ N
identification NN N
of IN N
dynamic JJ N
facial JJ N
expressions NNS N
: : N
influences NNS N
on IN N
individual JJ N
differences NNS N
A DT N
growing VBG N
literature NN N
suggests VBZ N
that IN N
the DT N
self-face NN N
is VBZ N
involved VBN N
in IN N
processing VBG N
the DT N
facial JJ N
expressions NNS N
of IN N
others NNS N
The DT N
authors NNS N
experimentally RB N
activated VBD N
self-face JJ N
representations NNS N
to TO N
assess VB N
its PRP$ N
effects NNS N
on IN N
the DT N
recognition NN N
of IN N
dynamically RB N
emerging VBG N
facial JJ N
expressions NNS N
of IN N
others NNS N
They PRP N
exposed VBD N
participants NNS N
to TO N
videos NNS N
of IN N
either DT N
their PRP$ N
own JJ N
faces VBZ N
( ( N
self-face JJ N
prime NN N
) ) N
or CC N
faces VBZ N
of IN N
others NNS N
( ( N
nonself-face JJ N
prime NN N
) ) N
prior RB N
to TO N
a DT N
facial JJ N
expression NN N
judgment NN N
task NN N
Their PRP$ N
results NNS N
show VBP N
that IN N
experimentally RB N
activating VBG N
self-face JJ N
representations NNS N
results NNS N
in IN N
earlier JJR N
recognition NN N
of IN N
dynamically RB N
emerging VBG N
facial JJ N
expression NN N
As IN N
a DT N
group NN N
, , N
participants NNS N
in IN N
the DT N
self-face JJ N
prime JJ N
condition NN N
recognized VBD N
expressions NNS N
earlier RBR N
( ( N
when WRB N
less RBR N
affective JJ N
perceptual JJ N
information NN N
was VBD N
available JJ N
) ) N
compared VBN N
to TO N
participants NNS N
in IN N
the DT N
nonself-face JJ N
prime JJ N
condition NN N
There EX N
were VBD N
individual JJ N
differences NNS N
in IN N
performance NN N
, , N
such JJ N
that IN N
poorer JJR N
expression NN N
identification NN N
was VBD N
associated VBN N
with IN N
higher JJR N
autism NN 4_p
traits NNS N
( ( N
in IN N
this DT N
neurocognitively RB 4_p
healthy JJ 4_p
sample NN 4_p
) ) N
However RB N
, , N
when WRB N
randomized VBN N
into IN N
the DT N
self-face JJ N
prime JJ N
condition NN N
, , N
participants NNS N
with IN N
high JJ 4_p
autism NN 4_p
traits NNS 4_p
performed VBN N
as RB N
well RB N
as IN N
those DT N
with IN N
low JJ 4_p
autism NN 4_p
traits NNS 4_p
Taken VB N
together RB N
, , N
these DT N
data NNS N
suggest VBP N
that IN N
the DT N
ability NN N
to TO N
recognize VB N
facial JJ N
expressions NNS N
in IN N
others NNS N
is VBZ N
linked VBN N
with IN N
the DT N
internal JJ N
representations NNS N
of IN N
our PRP$ N
own JJ N
faces VBZ N
-DOCSTART- -X- O O 23000125

The DT N
role NN N
of IN N
nasal JJ N
IgA NNP N
in IN N
children NNS N
vaccinated VBN N
with IN N
live JJ N
attenuated VBN N
influenza JJ N
vaccine NN N
BACKGROUND NNP N
Immunoglobulin NNP N
A NNP N
( ( N
IgA NNP N
) ) N
is VBZ N
the DT N
predominant JJ N
antibody NN N
produced VBN N
in IN N
response NN N
to TO N
mucosal VB N
infections NNS N
The DT N
role NN N
of IN N
IgA NNP N
in IN N
providing VBG N
protection NN N
against IN N
influenza NN N
in IN N
children NNS N
vaccinated VBN N
with IN N
live JJ N
attenuated VBN N
influenza JJ N
vaccine NN N
( ( N
LAIV NNP N
) ) N
has VBZ N
not RB N
been VBN N
well RB N
described VBN N
METHODS NNP N
Nasal NNP N
IgA NNP N
responses NNS N
were VBD N
assessed VBN N
using VBG N
data NNS N
from IN N
3 CD N
prospective JJ N
, , N
2-year JJ N
, , N
randomized JJ N
studies NNS N
comparing VBG N
LAIV NNP N
with IN N
placebo NN N
in IN N
children NNS N
6-36 JJ N
months NNS N
of IN N
age NN N
In IN N
each DT N
study NN N
, , N
samples NNS N
were VBD N
collected VBN N
in IN N
a DT N
subset NN N
of IN N
patients NNS N
; : N
a DT N
new JJ N
cohort NN N
was VBD N
enrolled VBN N
each DT N
year NN N
Ratios NNP N
of IN N
strain-specific JJ N
nasal JJ N
IgA NNP N
to TO N
total VB N
nasal JJ N
IgA NNP N
were VBD N
calculated VBN N
and CC N
prevaccination NN N
to TO N
postvaccination NN N
geometric JJ N
mean JJ N
fold-rises NNS N
( ( N
GMFRs NNP N
) ) N
were VBD N
evaluated VBN N
Mean JJ N
postvaccination NN N
IgA NNP N
ratios NNS N
were VBD N
compared VBN N
for IN N
subjects NNS N
with IN N
and CC N
without IN N
confirmed VBN N
influenza NN N
illness NN N
by IN N
study NN N
and CC N
in IN N
pooled JJ N
analyses NNS N
RESULTS NNP N
Across NNP N
studies NNS N
, , N
a DT N
higher JJR N
percentage NN N
of IN N
children NNS N
receiving VBG N
LAIV NNP N
had VBD N
a DT N
≥ JJ N
2-fold JJ N
increase NN N
in IN N
strain-specific JJ N
IgA NNP N
ratio NN N
compared VBN N
with IN N
placebo NN N
recipients NNS N
GMFRs NNP N
after IN N
LAIV NNP N
in IN N
years NNS N
1 CD N
and CC N
2 CD N
ranged VBD N
from IN N
1.2 CD N
to TO N
6.2 CD N
, , N
compared VBN N
with IN N
0.5-2.2 JJ N
among IN N
placebo JJ N
recipients NNS N
Similar JJ N
responses NNS N
were VBD N
observed VBN N
in IN N
subjects NNS N
who WP N
were VBD N
baseline JJ N
seronegative JJ N
and CC N
seropositive JJ N
based VBN N
on IN N
serum JJ N
hemagglutination NN N
inhibition NN N
antibody NN N
titers NNS N
In IN N
years NNS N
1 CD N
and CC N
2 CD N
, , N
the DT N
mean JJ N
postvaccination NN N
strain-specific NN N
to TO N
total JJ N
IgA NNP N
ratio NN N
was VBD N
3.1-fold JJ N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
2.0-fold JJ N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
higher JJR N
among IN N
LAIV JJ N
recipients NNS N
with IN N
no DT N
evidence NN N
of IN N
culture-confirmed JJ N
influenza NN N
illness NN N
compared VBN N
with IN N
LAIV NNP N
recipients NNS N
who WP N
developed VBD N
culture-confirmed JJ N
influenza NN N
illness NN N
; : N
a DT N
similar JJ N
and CC N
consistent JJ N
trend NN N
was VBD N
observed VBN N
for IN N
each DT N
individual NN N
study NN N
and CC N
type/subtype NN N
CONCLUSIONS VB N
The DT N
current JJ N
analysis NN N
demonstrates VBZ N
that IN N
nasal JJ N
IgA NNP N
contributes VBZ N
to TO N
the DT N
efficacy NN N
of IN N
LAIV NNP N
and CC N
can MD N
provide VB N
evidence NN N
of IN N
vaccine-induced JJ N
immunity NN N
However RB N
, , N
the DT N
inherent JJ N
heterogeneity NN N
in IN N
nasal JJ N
antibody NN N
levels NNS N
and CC N
variability NN N
in IN N
nasal JJ N
specimen NNS N
collection NN N
hinders VBZ N
the DT N
precise JJ N
evaluation NN N
of IN N
mucosal NN N
antibody NN N
responses NNS N
Other JJ N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
LAIV-induced NNP N
immunity NN N
is VBZ N
also RB N
partially RB N
explained VBN N
by IN N
T-cell NNP N
immunity NN N
, , N
serum NN N
antibody NN N
responses NNS N
, , N
and CC N
innate JJ N
immunity NN N
, , N
consistent JJ N
with IN N
the DT N
multi-faceted JJ N
nature NN N
of IN N
immunity NN N
induced VBN N
by IN N
wild-type JJ N
influenza JJ N
infection NN N
and CC N
other JJ N
live JJ N
virus NN N
vaccines NNS N
-DOCSTART- -X- O O 23905378

[ NN N
Treating VBG N
rheumatoid JJ N
arthritis NN N
patients NNS N
of IN N
Shen NNP N
deficiency NN N
and CC N
cold JJ N
invading NN N
syndrome NN N
by IN N
bushen NN N
quhan NN N
zhiwang CD N
decoction NN N
combined VBN N
methotrexate NN N
: : N
an DT N
evaluation NN N
of IN N
clinical JJ N
efficacy NN N
and CC N
safety NN N
] NN N
OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
safety NN N
of IN N
bushen NN N
quhan NN N
zhiwang CD N
decoction NN N
( ( N
BQZD NNP N
) ) N
combined VBN N
methotrexate NN N
( ( N
MTX NNP N
) ) N
in IN N
treating VBG N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
METHODS CC N
A DT N
prospective JJ N
, , N
randomized VBN N
controlled VBD N
study NN N
was VBD N
carried VBN N
out RP N
RA NNP N
patients NNS N
of IN N
Shen NNP N
deficiency NN N
and CC N
cold JJ N
invading NN N
syndrome NN N
in IN N
the DT N
treatment NN N
group NN N
( ( N
120 CD N
cases NNS N
) ) N
were VBD N
treated VBN N
with IN N
BQZD NNP N
and CC N
MTX NNP N
( ( N
10 CD N
mg/week NN N
) ) N
, , N
while IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
120 CD N
cases NNS N
) ) N
were VBD N
treated VBN N
with IN N
MTX NNP N
( ( N
10 CD N
mg/week NN N
) ) N
alone RB N
The DT N
therapeutic JJ N
course NN N
for IN N
all DT N
was VBD N
24 CD N
weeks NNS N
The DT N
efficacy NN N
and CC N
safety NN N
indices NNS N
were VBD N
evaluated VBN N
at IN N
the DT N
baseline NN N
and CC N
24 CD N
weeks NNS N
after IN N
treatment NN N
, , N
including VBG N
clinical JJ N
signs NNS N
and CC N
symptoms NNS N
, , N
condition NN N
assessment NN N
, , N
Health NNP N
Assessment NNP N
Questionnaire NNP N
( ( N
HAQ NNP N
) ) N
, , N
disease NN N
activity NN N
index NN N
28 CD N
( ( N
DAS28 NNP N
) ) N
, , N
laboratory JJ N
parameters NNS N
of IN N
erythrocyte JJ N
sedimentation NN N
rate NN N
( ( N
ESR NNP N
) ) N
and CC N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
safety NN N
indicators NNS N
, , N
and CC N
Chinese NNP N
medical JJ N
syndrome NN N
integrals NNS N
RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
was VBD N
80 CD N
0 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
, , N
better JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
( ( N
66.7 CD N
% NN N
) ) N
, , N
showing VBG N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
In IN N
the DT N
two CD N
groups NNS N
significant JJ N
improvement NN N
of IN N
clinical JJ N
signs NNS N
and CC N
symptoms NNS N
, , N
ESR NNP N
, , N
CRP NNP N
, , N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
by IN N
both DT N
physicians NNS N
and CC N
patients NNS N
, , N
HAQ NNP N
, , N
DAS28 NNP N
, , N
and CC N
Chinese NNP N
medical JJ N
syndrome NN N
integrals NNS N
after IN N
treatment NN N
were VBD N
shown VBN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
Better JJR N
effects NNS N
were VBD N
obtained VBN N
in IN N
the DT N
treatment NN N
group NN N
in IN N
lessening VBG N
tender NN N
joint NN N
numbers NNS N
and CC N
swollen JJ N
joint NN N
numbers NNS N
, , N
VAS NNP N
by IN N
both DT N
physicians NNS N
and CC N
patients NNS N
, , N
DAS28 NNP N
, , N
and CC N
Chinese NNP N
medical JJ N
syndrome NN N
integrals NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
Besides NNP N
, , N
adverse JJ N
reactions NNS N
occurred VBD N
less RBR N
in IN N
the DT N
treatment NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
CONCLUSIONS NNP N
BQZD NNP N
had VBD N
roles NNS N
in IN N
relieving VBG N
symptoms NNS N
, , N
improving VBG N
joint JJ N
functions NNS N
, , N
signs NNS N
, , N
ESR NNP N
, , N
and CC N
CRP NNP N
It PRP N
was VBD N
an DT N
effective JJ N
herb NN N
for IN N
RA NNP N
patients NNS N
of IN N
Shen NNP N
deficiency NN N
and CC N
cold JJ N
invading NN N
syndrome NN N
It PRP N
could MD N
enhance VB N
the DT N
efficacy NN N
and CC N
reduce VB N
adverse JJ N
reactions NNS N
of IN N
MTX NNP N
through IN N
synergistic JJ N
effects NNS N
with IN N
MTX NNP N
-DOCSTART- -X- O O 3286673

Pulsatile NNP N
insulin NN N
delivery NN N
is VBZ N
more RBR N
efficient JJ N
than IN N
continuous JJ N
infusion NN N
in IN N
modulating VBG N
islet NN N
cell NN N
function NN N
in IN N
normal JJ 4_p
subjects NNS 4_p
and CC 4_p
patients NNS 4_p
with IN 4_p
type JJ 4_p
1 CD 4_p
diabetes NNS 4_p
The DT N
respective JJ N
modulating NN N
effects NNS N
of IN N
continuous JJ N
and CC N
intermittent JJ N
insulin NN N
delivery NN N
on IN N
pancreatic JJ N
islet NN N
cell NN N
function NN N
were VBD N
studied VBN N
in IN N
seven CD N
normal JJ N
men NNS N
and CC N
nine CD N
insulin-dependent NN N
( ( N
type JJ N
1 CD N
) ) N
diabetic JJ N
patients NNS N
In IN N
the DT N
normal JJ N
men NNS N
, , N
saline NN N
or CC N
continuous JJ N
( ( N
0.8 CD N
mU RB N
kg-1 JJ N
min-1 NN N
) ) N
or CC N
pulsatile NN N
( ( N
5.2 CD N
mU RB N
kg-1 JJ N
min-1 NNS N
, , N
with IN N
a DT N
switching VBG N
on/off RP N
length NN N
of IN N
2/11 CD N
min NN N
) ) N
human JJ N
insulin NN N
were VBD N
delivered VBN N
on IN N
different JJ N
days NNS N
and CC N
in IN N
random JJ N
order NN N
Despite IN N
hyperinsulinemia NN N
, , N
blood NN N
glucose NN N
was VBD N
kept VBN N
close RB N
to TO N
its PRP$ N
basal NN N
value NN N
by IN N
the DT N
glucose JJ N
clamp NN N
technique NN N
The DT N
diabetic JJ N
patients NNS N
also RB N
were VBD N
infused VBN N
in IN N
random JJ N
order NN N
and CC N
on IN N
different JJ N
days NNS N
with IN N
either DT N
saline NN N
or CC N
a DT N
smaller JJR N
amount NN N
of IN N
insulin NN N
delivered VBN N
continuously RB N
( ( N
0.15 CD N
mU RB N
kg-1 JJ N
min-1 NN N
) ) N
or CC N
in IN N
a DT N
pulsatile JJ N
manner NN N
( ( N
0.97 CD N
mU RB N
kg-1 JJ N
min-1 NN N
for IN N
2 CD N
min NN N
, , N
followed VBN N
by IN N
11 CD N
min NNS N
during IN N
which WDT N
no DT N
insulin NN N
was VBD N
infused VBN N
) ) N
In IN N
all DT N
experiments NNS N
, , N
5 CD N
g NN N
arginine NN N
were VBD N
given VBN N
iv NNS N
as IN N
a DT N
bolus NN N
dose JJ N
30 CD N
min NN N
before IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
and CC N
plasma VB N
C-peptide NNP N
and CC N
glucagon NN N
levels NNS N
were VBD N
determined VBN N
to TO N
assess VB N
islet NN N
cell NN N
function NN N
In IN N
the DT N
normal JJ N
men NNS N
, , N
insulin NN N
administration NN N
resulted VBD N
in IN N
a DT N
significant JJ N
decline NN N
of IN N
basal NN N
plasma NN N
glucagon NN N
and CC N
C-peptide JJ N
levels NNS N
and CC N
in IN N
a DT N
clear-cut JJ N
decrease NN N
in IN N
the DT N
arginine-induced JJ N
glucagon NN N
response NN N
These DT N
effects NNS N
of IN N
insulin NN N
were VBD N
significantly RB N
more RBR N
marked JJ N
when WRB N
insulin NN N
was VBD N
delivered VBN N
in IN N
a DT N
pulsatile NN N
rather RB N
than IN N
a DT N
continuous JJ N
manner NN N
In IN N
the DT N
insulin-dependent JJ N
diabetic JJ N
patients NNS N
, , N
the DT N
lower JJR N
dose NN N
of IN N
insulin NN N
infused VBN N
continuously RB N
did VBD N
not RB N
alter VB N
the DT N
basal NN N
or CC N
arginine-stimulated JJ N
glucagon NN N
response NN N
In IN N
contrast NN N
, , N
when WRB N
the DT N
same JJ N
amount NN N
of IN N
insulin NN N
was VBD N
delivered VBN N
intermittently RB N
, , N
arginine-induced JJ N
glucagon NN N
release NN N
was VBD N
greatly RB N
reduced VBN N
Thus RB N
, , N
these DT N
data NNS N
support NN N
the DT N
concept NN N
that WDT N
insulin VBZ N
per IN N
se NN N
is VBZ N
a DT N
potent JJ N
physiological JJ N
modulator NN N
of IN N
islet NN N
A- NNP N
and CC N
B-cell NNP N
function NN N
Furthermore RB N
, , N
they PRP N
suggest VBP N
that IN N
these DT N
effects NNS N
of IN N
insulin NN N
are VBP N
reinforced VBN N
when WRB N
the DT N
hormone NN N
is VBZ N
administered VBN N
in IN N
an DT N
intermittent JJ N
manner NN N
in IN N
an DT N
attempt NN N
to TO N
reproduce VB N
the DT N
pulsatile NN N
physiological JJ N
release NN N
of IN N
insulin NN N
-DOCSTART- -X- O O 16379508

Risperidone-induced JJ N
prolactin NN N
elevation NN N
in IN N
a DT N
prospective JJ N
study NN N
of IN N
children NNS 2_p
, , 2_p
adolescents NNS 2_p
, , 2_p
and CC 2_p
adults NNS 2_p
with IN 2_p
mental JJ 2_p
retardation NN 2_p
and CC 2_p
pervasive JJ 2_p
developmental NN 2_p
disorders NNS 2_p
OBJECTIVE NNP N
Risperidone NNP N
is VBZ N
widely RB N
prescribed VBN N
for IN N
aggression NN N
and CC N
self-injury NN N
in IN N
children NNS 1_p
, , 1_p
adolescents NNS 1_p
, , 1_p
and CC 1_p
adults NNS 1_p
with IN 1_p
mental JJ 1_p
retardation NN 1_p
( ( 1_p
MR NNP 1_p
) ) 1_p
and CC 1_p
pervasive JJ 1_p
developmental NN 1_p
disorders NNS 1_p
( ( 1_p
PDD NNP 1_p
) ) 1_p
Risperidone NNP N
elevates VBZ N
prolactin RB N
more JJR N
than IN N
other JJ N
atypical JJ N
antipsychotic JJ N
medications NNS N
Females NNS N
may MD N
show VB N
greater JJR N
prolactin NN N
elevation NN N
than IN N
males NNS N
METHOD NNP N
In IN N
this DT N
relatively RB N
long-term JJ N
study NN N
of IN N
risperidone NN N
efficacy NN N
and CC N
safety NN N
for IN N
aggression NN N
and CC N
self-injury NN N
in IN N
children NNS 4_p
, , 4_p
adolescents NNS 4_p
, , 4_p
and CC 4_p
adults NNS 4_p
with IN 4_p
MR NNP 4_p
and CC 4_p
PDDs NNP 4_p
, , N
serum NN N
prolactin NN N
was VBD N
measured VBN N
in IN N
a DT N
21-subject JJ 4_p
subset NN 4_p
during IN 4_p
the DT 4_p
course NN 4_p
of IN 4_p
a DT 4_p
double-blind JJ 4_p
, , 4_p
placebo-controlled JJ 4_p
trial NN 4_p
Prolactin NNP N
was VBD N
measured VBN N
in IN N
ng/mL NN N
at IN N
baseline NN N
, , N
once RB N
during IN N
acute JJ N
treatment NN N
, , N
and CC N
once RB N
during IN N
maintenance NN N
RESULTS NNP N
In IN N
children NNS N
and CC N
adolescents NNS N
( ( N
n=10 NN N
) ) N
, , N
mean JJ N
age NN N
of IN N
12.5 CD N
years NNS N
, , N
prolactin NN N
increased VBD N
from IN N
mean JJ N
13.2+/-8.6 CD N
at IN N
baseline NN N
to TO N
31.0+/-11.6 JJ N
acutely RB N
and CC N
remained VBD N
elevated VBN N
at IN N
37.9+/-10.4 JJ N
in IN N
maintenance NN N
In IN N
adults NNS N
, , N
mean JJ N
age NN N
of IN N
35.3 CD N
years NNS N
, , N
prolactin NN N
increased VBD N
more JJR N
markedly RB N
from IN N
11.6+/-7.4 JJ N
baseline NN N
( ( N
n=11 JJ N
) ) N
to TO N
93.3+/-54.2 CD N
acutely RB N
but CC N
decreased VBD N
to TO N
67.8+/-62.9 JJ N
in IN N
maintenance NN N
( ( N
n=7 JJ N
) ) N
Prolactin NNP N
remained VBD N
significantly RB N
elevated VBN N
above IN N
normal JJ N
in IN N
all DT N
subjects NNS N
for IN N
at IN N
least JJS N
26 CD N
weeks NNS N
Mean NNP N
prolactin NN N
of IN N
adult NN N
females NNS N
, , N
while IN N
similar JJ N
to TO N
that DT N
of IN N
adult NN N
males NNS N
at IN N
baseline NN N
, , N
was VBD N
2.2 CD N
times NNS N
male JJ N
levels NNS N
acutely RB N
and CC N
3.7 CD N
times NNS N
greater JJR N
in IN N
maintenance NN N
CONCLUSION NN N
In IN N
this DT N
small JJ N
subset NN N
, , N
mean JJ N
prolactin NN N
elevation NN N
persisted VBD N
for IN N
at IN N
least JJS N
26 CD N
weeks NNS N
In IN N
adults NNS N
, , N
females NNS N
showed VBD N
significantly RB N
greater JJR N
elevations NNS N
than IN N
males NNS N
-DOCSTART- -X- O O 23266440

Reducing VBG N
breast NN 4_p
cancer NN 4_p
recurrence NN N
with IN N
weight JJ N
loss NN N
, , N
a DT N
vanguard JJ N
trial NN N
: : N
the DT N
Exercise NNP N
and CC N
Nutrition NNP N
to TO N
Enhance VB N
Recovery NNP N
and CC N
Good NNP N
Health NNP N
for IN N
You PRP N
( ( N
ENERGY NNP N
) ) N
Trial NNP N
Breast NNP N
cancer NN N
is VBZ N
the DT N
most RBS N
common JJ N
invasive JJ N
cancer NN N
among IN N
women NNS N
in IN N
developed JJ N
countries NNS N
Obesity NN N
is VBZ N
a DT N
major JJ N
risk NN N
factor NN N
for IN N
breast NN N
cancer NN N
recurrence NN N
and CC N
mortality NN N
in IN N
both DT N
pre- JJ 4_p
and CC 4_p
postmenopausal JJ 4_p
women NNS 2_p
Co-morbid NNP N
medical JJ N
conditions NNS N
are VBP N
common JJ N
among IN N
breast JJ N
cancer NN N
survivors NNS N
The DT N
Exercise NN N
and CC N
Nutrition NN N
to TO N
Enhance VB N
Recovery NNP N
and CC N
Good NNP N
Health NNP N
for IN N
You PRP N
( ( N
ENERGY NNP N
) ) N
study NN N
is VBZ N
a DT N
4-year JJ N
randomized JJ N
clinical JJ N
trial NN N
of IN N
693 CD 3_p
overweight/obese JJ 4_p
women NNS 2_p
aged VBN N
≥21years NNS 1_p
diagnosed VBD N
with IN N
any DT N
early JJ 4_p
stage NN 4_p
breast NN 4_p
cancer NN 4_p
( ( N
stages NNS N
I PRP N
[ VBP N
≥1cm JJ N
] NNP N
-III NN N
) ) N
within IN N
the DT N
previous JJ N
five CD N
years NNS N
, , N
designed VBN N
to TO N
demonstrate VB N
the DT N
feasibility NN N
of IN N
achieving VBG N
sustained JJ N
weight JJ N
loss NN N
and CC N
to TO N
examine VB N
the DT N
impact NN N
of IN N
weight JJ N
loss NN N
on IN N
quality NN N
of IN N
life NN N
and CC N
co-morbidities NNS N
, , N
and CC N
to TO N
enable VB N
future JJ N
exploration NN N
of IN N
biochemical JJ N
mechanisms NNS N
linking VBG N
obesity NN N
to TO N
lower JJR N
likelihood NN N
of IN N
disease-free JJ N
survival NN N
This DT N
trial NN N
is VBZ N
strategically RB N
designed VBN N
as IN N
a DT N
vanguard NN N
for IN N
a DT N
fully-powered JJ N
trial NN N
of IN N
women NNS N
who WP N
will MD N
be VB N
evaluated VBN N
for IN N
breast NN N
cancer NN N
recurrence NN N
and CC N
disease-free JJ N
survival NN N
Participants NNS N
were VBD N
recruited VBN N
between IN N
2010 CD N
and CC N
2012 CD N
at IN N
four CD N
sites NNS N
, , N
had VBD N
completed VBN N
initial JJ N
therapies NNS N
, , N
and CC N
had VBD N
a DT N
body NN N
mass NN N
index NN N
between IN N
25 CD N
and CC N
45kg/m CD N
( ( N
2 CD N
) ) N
The DT N
intervention NN N
featured VBD N
a DT N
group-based JJ N
cognitive-behavioral JJ N
weight JJ N
loss NN N
program NN N
with IN N
telephone NN N
counseling NN N
and CC N
tailored VBD N
newsletters NNS N
to TO N
support VB N
initial JJ N
weight NN N
loss NN N
and CC N
subsequent JJ N
maintenance NN N
, , N
with IN N
the DT N
goal NN N
of IN N
7 CD N
% NN N
weight JJ N
loss NN N
at IN N
two CD N
years NNS N
This DT N
study NN N
has VBZ N
high JJ N
potential NN N
to TO N
have VB N
a DT N
major JJ N
impact NN N
on IN N
clinical JJ N
management NN N
and CC N
outcomes NNS N
after IN N
a DT N
breast NN N
cancer NN N
diagnosis NN N
This DT N
trial NN N
initiates VBZ N
the DT N
effort NN N
to TO N
establish VB N
weight NN N
loss NN N
support NN N
for IN N
overweight NN 4_p
or CC 4_p
obese JJ 4_p
breast NN 4_p
cancer NN 4_p
survivors NNS N
as IN N
a DT N
new JJ N
standard NN N
of IN N
clinical JJ N
care NN N
-DOCSTART- -X- O O 11978262

Oat NNP N
ingestion NN N
reduces VBZ N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
in IN N
patients NNS 4_p
with IN 4_p
mild JJ 4_p
or CC 4_p
borderline JJ 4_p
hypertension NN 4_p
: : 4_p
a DT N
pilot NN N
trial NN N
OBJECTIVES IN N
We PRP N
assessed VBD N
the DT N
short-term JJ N
antihypertensive JJ N
effects NNS N
of IN N
soluble JJ N
fiber-rich JJ N
whole JJ N
oat NN N
cereals NNS N
when WRB N
added VBN N
to TO N
a DT N
standard JJ N
American JJ N
diet NN N
In IN N
addition NN N
, , N
multiple JJ N
assessments NNS N
of IN N
insulin NN N
sensitivity NN N
were VBD N
conducted VBN N
STUDY NNP N
DESIGN NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
controlled VBN N
, , N
parallel-group JJ N
pilot NN N
study NN N
designed VBN N
to TO N
compare VB N
an DT N
oat NN N
cereal NN N
group NN N
( ( N
standardized VBN N
to TO N
5.52 CD N
g/day JJ N
beta-glucan JJ N
) ) N
to TO N
a DT N
low-fiber JJ N
cereal NN N
control NN N
group NN N
( ( N
less JJR N
than IN N
1.0 CD N
g/day JJ N
total JJ N
fiber NN N
) ) N
over IN N
6 CD N
weeks NNS N
POPULATION VB N
A DT N
total NN N
of IN N
18 CD N
hypertensive JJ N
and CC N
hyperinsulinemic JJ N
( ( N
= JJ N
10 CD N
U/mL NNP N
or CC N
more JJR N
) ) N
men NNS N
and CC N
women NNS N
completed VBD N
the DT N
trial NN N
OUTCOMES NNP N
MEASURED NNP N
Primary NNP N
study NN N
outcomes NNS N
were VBD N
changes NNS N
in IN N
systolic JJ N
blood NN N
pressure NN N
( ( N
SBP NNP N
) ) N
and CC N
diastolic JJ N
blood NN N
pressure NN N
( ( N
DBP NNP N
) ) N
Secondary JJ N
outcomes NNS N
included VBD N
blood NN N
lipid NN N
, , N
fasting VBG N
glucose NN N
, , N
and CC N
insulin NN N
levels NNS N
and CC N
side NN N
effects NNS N
related VBN N
to TO N
elevated VBN N
blood NN N
pressure NN N
and CC N
increased VBD N
dietary JJ N
fiber NN N
intake NN N
RESULTS VB N
The DT N
oat NN N
cereal NN N
group NN N
experienced VBD N
a DT N
7.5 CD N
mm NN N
Hg NNP N
reduction NN N
in IN N
SBP NNP N
( ( N
P NNP N
& CC N
lt.01 NN N
) ) N
and CC N
a DT N
5.5 CD N
mm NN N
Hg NNP N
reduction NN N
in IN N
DBP NNP N
( ( N
P NNP N
& CC N
lt.02 NN N
) ) N
, , N
while IN N
there EX N
was VBD N
virtually RB N
no DT N
change NN N
in IN N
either DT N
SBP NNP N
or CC N
DBP NNP N
in IN N
the DT N
control NN N
group NN N
In IN N
the DT N
oat NN N
cereal NN N
group NN N
, , N
a DT N
trend NN N
was VBD N
observed VBN N
for IN N
a DT N
lower JJR N
total JJ N
insulin NN N
response NN N
to TO N
a DT N
glucose JJ N
load NN N
, , N
suggesting VBG N
improved VBN N
insulin JJ N
sensitivity NN N
However RB N
, , N
this DT N
could MD N
not RB N
be VB N
confirmed VBN N
using VBG N
estimates NNS N
from IN N
the DT N
Bergman NNP N
Minimal NNP N
Model NNP N
, , N
perhaps RB N
because IN N
of IN N
our PRP$ N
small JJ N
sample NN N
size NN N
The DT N
oats NNS N
group NN N
experienced VBD N
a DT N
significant JJ N
reduction NN N
in IN N
both DT N
total JJ N
cholesterol NN N
( ( N
9 CD N
% NN N
) ) N
and CC N
low-density JJ N
lipoprotein NN N
cholesterol NN N
( ( N
14 CD N
% NN N
) ) N
CONCLUSIONS VB N
The DT N
addition NN N
of IN N
oat NN N
cereals NNS N
to TO N
the DT N
normal JJ N
diet NN N
of IN N
patients NNS N
with IN N
hypertension NN N
significantly RB N
reduces VBZ N
both DT N
SBP NNP N
and CC N
DBP NNP N
Soluble JJ N
fiber-rich JJ N
whole JJ N
oats NNS N
may MD N
be VB N
an DT N
effective JJ N
dietary JJ N
therapy NN N
in IN N
the DT N
prevention NN N
and CC N
adjunct JJ N
treatment NN N
of IN N
hypertension NN N
-DOCSTART- -X- O O 25795413

Selective JJ N
insulin NN N
resistance NN N
in IN N
homeostatic JJ N
and CC N
cognitive JJ N
control NN N
brain NN N
areas NNS N
in IN N
overweight NN 4_p
and CC 4_p
obese JJ 4_p
adults NNS 1_p
OBJECTIVE NNP N
Impaired NNP N
brain NN N
insulin NN N
action NN N
has VBZ N
been VBN N
linked VBN N
to TO N
obesity NN N
, , N
type NN N
2 CD N
diabetes NNS N
, , N
and CC N
neurodegenerative JJ N
diseases NNS N
To TO N
date NN N
, , N
the DT N
central JJ N
nervous JJ N
effects NNS N
of IN N
insulin NN N
in IN N
obese JJ N
humans NNS N
still RB N
remain VBP N
ill JJ N
defined VBN N
, , N
and CC N
no DT N
study NN N
thus RB N
far RB N
has VBZ N
evaluated VBN N
the DT N
specific JJ N
brain NN N
areas NNS N
affected VBN N
by IN N
insulin NN N
resistance NN N
RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
In IN N
25 CD 3_p
healthy JJ N
lean NN N
and CC N
23 CD 3_p
overweight/obese JJ N
participants NNS N
, , N
we PRP N
performed VBD N
magnetic JJ N
resonance NN N
imaging NN N
to TO N
measure VB N
cerebral JJ N
blood NN N
flow NN N
( ( N
CBF NNP N
) ) N
before IN N
and CC N
15 CD N
and CC N
30 CD N
min NN N
after IN N
application NN N
of IN N
intranasal JJ N
insulin NN N
or CC N
placebo NN N
Additionally RB N
, , N
participants NNS N
explicitly RB N
rated VBN N
pictures NNS N
of IN N
high-caloric JJ N
savory NN N
and CC N
sweet VB N
food NN N
60 CD N
min NN N
after IN N
the DT N
spray NN N
for IN N
wanting VBG N
and CC N
liking VBG N
RESULTS NNP N
In IN N
response NN N
to TO N
insulin VB N
compared VBN N
with IN N
placebo NN N
, , N
we PRP N
found VBD N
a DT N
significant JJ N
CBF NNP N
decrease NN N
in IN N
the DT N
hypothalamus NN N
in IN N
both DT N
lean JJ N
and CC N
overweight/obese JJ N
participants NNS N
The DT N
magnitude NN N
of IN N
this DT N
response NN N
correlated VBD N
with IN N
visceral JJ N
adipose JJ N
tissue NN N
independent JJ N
of IN N
other JJ N
fat JJ N
compartments NNS N
Furthermore RB N
, , N
we PRP N
observed VBD N
a DT N
differential JJ N
response NN N
in IN N
the DT N
lean JJ N
compared VBN N
with IN N
the DT N
overweight/obese JJ N
group NN N
in IN N
the DT N
prefrontal JJ N
cortex NN N
, , N
resulting VBG N
in IN N
an DT N
insulin-induced JJ N
CBF NNP N
reduction NN N
in IN N
lean JJ N
participants NNS N
only RB N
This DT N
prefrontal JJ N
cortex NN N
response NN N
significantly RB N
correlated VBN N
with IN N
peripheral JJ N
insulin NN N
sensitivity NN N
and CC N
eating VBG N
behavior JJ N
measures NNS N
such JJ N
as IN N
disinhibition NN N
and CC N
food NN N
craving NN N
Behaviorally NNP N
, , N
we PRP N
were VBD N
able JJ N
to TO N
observe VB N
a DT N
significant JJ N
reduction NN N
for IN N
the DT N
wanting NN N
of IN N
sweet JJ N
foods NNS N
after IN N
insulin JJ N
application NN N
in IN N
lean JJ N
men NNS N
only RB N
CONCLUSIONS NNP N
Brain NNP N
insulin NN N
action NN N
was VBD N
selectively RB N
impaired VBN N
in IN N
the DT N
prefrontal JJ N
cortex NN N
in IN N
overweight NN N
and CC N
obese JJ N
adults NNS N
and CC N
in IN N
the DT N
hypothalamus NN N
in IN N
participants NNS N
with IN N
high JJ N
visceral JJ N
adipose JJ N
tissue NN N
, , N
potentially RB N
promoting VBG N
an DT N
altered JJ N
homeostatic JJ N
set NN N
point NN N
and CC N
reduced JJ N
inhibitory NN N
control NN N
contributing VBG N
to TO N
overeating VBG N
behavior NN N
-DOCSTART- -X- O O 9664917

Diet NNP N
design NN N
for IN N
a DT N
multicenter NN N
controlled VBD N
feeding JJ N
trial NN N
: : N
the DT N
DELTA NNP N
program NN N
Delta NNP N
Research NNP N
Group NNP N
OBJECTIVE NNP N
To TO N
describe VB N
the DT N
process NN N
and CC N
results NNS N
of IN N
diet JJ N
standardization NN N
, , N
diet JJ N
validation NN N
, , N
and CC N
monitoring NN N
of IN N
diet JJ N
composition NN N
, , N
which WDT N
were VBD N
key JJ N
components NNS N
of IN N
protocol JJ N
1 CD N
of IN N
Dietary NNP N
Effects NNPS N
on IN N
Lipoproteins NNS N
and CC N
Thrombogenic NNP N
Activity NNP N
( ( N
DELTA-1 NNP N
) ) N
, , N
the DT N
initial JJ N
protocol NN N
in IN N
a DT N
program NN N
of IN N
multicenter NN N
human JJ N
feeding NN N
studies NNS N
designed VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
amount NN N
and CC N
type NN N
of IN N
fat NN N
on IN N
lipoproteins NNS N
and CC N
hemostasis NN N
parameters NNS N
in IN N
various JJ N
demographic JJ N
groups NNS N
DESIGN NNP N
DELTA-1 NNP N
was VBD N
based VBN N
on IN N
a DT N
randomized VBN N
, , N
blinded VBD N
, , N
crossover JJ N
experimental JJ N
design NN N
Three CD N
diets NNS N
were VBD N
fed VBN N
for IN N
8 CD N
weeks NNS N
to TO N
103 CD 3_p
healthy JJ N
men NNS 2_p
and CC N
women NNS 2_p
aged VBD N
22 CD N
to TO N
67 CD N
years NNS N
at IN N
4 CD N
field NN N
centers NNS N
Diet NNP N
A NNP N
, , N
an DT N
average JJ N
American JJ N
diet NN N
, , N
was VBD N
designed VBN N
to TO N
provide VB N
37 CD N
% NN N
of IN N
energy NN N
from IN N
fat JJ N
, , N
16 CD N
% NN N
of IN N
energy NN N
from IN N
saturated VBN N
fatty JJ N
acids NNS N
( ( N
SFAs NNP N
) ) N
; : N
diet JJ N
B NNP N
( ( N
step NN N
1 CD N
diet NN N
) ) N
was VBD N
designed VBN N
to TO N
provide VB N
30 CD N
% NN N
of IN N
energy NN N
from IN N
fat JJ N
, , N
9 CD N
% NN N
of IN N
energy NN N
from IN N
SFA NNP N
; : N
and CC N
diet JJ N
C NNP N
( ( N
low JJ N
SFA NNP N
diet NN N
) ) N
was VBD N
designed VBN N
to TO N
provide VB N
26 CD N
% NN N
of IN N
energy NN N
from IN N
fat JJ N
, , N
5 CD N
% NN N
of IN N
energy NN N
from IN N
SFA NNP N
Key NNP N
features NNS N
of IN N
diet JJ N
standardization NN N
included VBD N
central JJ N
procurement NN N
of IN N
fat-containing JJ N
foods NNS N
, , N
inclusion NN N
of IN N
standard JJ N
ingredients NNS N
, , N
precision NN N
weighing NN N
of IN N
foods NNS N
-- : N
especially RB N
sources NNS N
of IN N
fat NN N
and CC N
cholesterol NN N
-- : N
and CC N
use NN N
of IN N
standardized JJ N
written VBN N
procedures NNS N
SETTING NN N
For IN N
menu NN N
validation NN N
, , N
a DT N
set NN N
of IN N
12 CD N
menus NNS N
for IN N
each DT N
diet NN N
was VBD N
prepared VBN N
in IN N
duplicate NN N
and CC N
chemically RB N
assayed VBN N
For IN N
monitoring NN N
of IN N
diet JJ N
composition NN N
during IN N
the DT N
study NN N
, , N
an DT N
8-day JJ N
diet JJ N
cycle NN N
( ( N
6 CD N
weekday NN N
and CC N
2 CD N
weekend NN N
menus NN N
) ) N
was VBD N
sampled VBN N
by IN N
every DT N
field NN N
center NN N
twice RB N
during IN N
each DT N
of IN N
3 CD N
feeding VBG N
periods NNS N
STATISTICAL NNP N
ANALYSES NNP N
Means NNP N
( ( N
+/- JJ N
standard NN N
error NN N
) ) N
were VBD N
calculated VBN N
and CC N
compared VBN N
with IN N
target NN N
nutrient JJ N
specifications NNS N
RESULTS NNP N
DELTA-1 NNP N
was VBD N
able JJ N
to TO N
provide VB N
a DT N
standardized JJ N
diet NN N
that WDT N
met VBD N
nutrient JJ N
specifications NNS N
across IN N
4 CD N
field NN N
centers NNS N
over IN N
24 CD N
weeks NNS N
of IN N
participant JJ N
feeding VBG N
spanning VBG N
a DT N
total NN N
of IN N
8 CD N
months NNS N
APPLICATIONS NNP N
Prestudy NNP N
chemical JJ N
validation NN N
of IN N
menus NN N
and CC N
continuous JJ N
sampling NN N
and CC N
assay NN N
of IN N
diets NNS N
throughout IN N
the DT N
study NN N
are VBP N
essential JJ N
to TO N
standardize VB N
experimental JJ N
diets NNS N
and CC N
to TO N
ensure VB N
that DT N
nutrient JJ N
target NN N
goals NNS N
are VBP N
met VBN N
and CC N
maintained VBN N
throughout IN N
a DT N
controlled JJ N
multicenter NN N
feeding NN N
study NN N
-DOCSTART- -X- O O 21327867

Effects NNS N
of IN N
weight JJ N
loss NN N
and CC N
exercise NN N
on IN N
insulin NN 4_p
resistance NN 4_p
, , N
and CC N
intramyocellular JJ N
triacylglycerol NN N
, , N
diacylglycerol NN N
and CC N
ceramide NN N
AIMS/HYPOTHESIS NNP N
Intramyocellular NNP N
lipids NNS N
, , N
including VBG N
diacylglycerol NN N
( ( N
DAG NNP N
) ) N
and CC N
ceramides NNS N
, , N
have VBP N
been VBN N
linked VBN N
to TO N
insulin VB N
resistance NN N
This DT N
randomised VBD N
repeated-measures NNS N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
diet-induced JJ N
weight JJ N
loss NN N
( ( N
DIWL NNP N
) ) N
and CC N
aerobic JJ N
exercise NN N
( ( N
EX NNP N
) ) N
on IN N
insulin NN N
sensitivity NN N
and CC N
intramyocellular JJ N
triacylglycerol NN N
( ( N
IMTG NNP N
) ) N
, , N
DAG NNP N
and CC N
ceramide NN N
METHODS NNP N
Sixteen NNP N
overweight MD N
to TO N
obese VB N
adults NNS N
( ( N
BMI NNP N
30.6 CD N
± NNP N
0.8 CD N
; : N
67.2 CD N
± IN N
4.0 CD N
years NNS N
of IN N
age NN N
) ) N
with IN N
either DT N
impaired JJ N
fasting NN N
glucose NN N
, , N
or CC N
impaired VBD N
glucose JJ N
tolerance NN N
completed VBD N
one CD N
of IN N
two CD N
lifestyle JJ N
interventions NNS N
: : N
DIWL NNP N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
or CC N
EX NNP N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
Insulin NNP N
sensitivity NN N
was VBD N
determined VBN N
using VBG N
hyperinsulinaemic-euglycaemic JJ N
clamps NNS N
Intramyocellular JJ N
lipids NNS N
were VBD N
measured VBN N
in IN N
muscle NN N
biopsies NNS N
using VBG N
histochemistry NN N
and CC N
tandem JJ N
mass NN N
spectrometry NN N
RESULTS NNP N
Insulin NNP N
sensitivity NN N
was VBD N
improved VBN N
with IN N
DIWL NNP N
( ( N
20.6 CD N
± RB N
4.7 CD N
% NN N
) ) N
and CC N
EX NNP N
( ( N
19.2 CD N
± RB N
12.9 CD N
% NN N
) ) N
Body NNP N
weight VBD N
and CC N
body NN N
fat NNS N
were VBD N
decreased VBN N
by IN N
both DT N
interventions NNS N
, , N
with IN N
greater JJR N
decreases NNS N
in IN N
DIWL NNP N
compared VBN N
with IN N
EX NNP N
Muscle NNP N
glycogen NN N
, , N
IMTG NNP N
content NN N
and CC N
oxidative JJ N
capacity NN N
were VBD N
all DT N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
decreased VBN N
with IN N
DIWL NNP N
and CC N
increased VBD N
with IN N
EX NNP N
There EX N
were VBD N
decreases NNS N
in IN N
DAG NNP N
with IN N
DIWL NNP N
( ( N
-12.4 NNP N
± RB N
14.6 CD N
% NN N
) ) N
and CC N
EX NNP N
( ( N
-40.9 NNP N
± RB N
12.0 CD N
% NN N
) ) N
Ceramide NNP N
decreased VBD N
with IN N
EX NNP N
( ( N
-33.7 NNP N
± RB N
11.2 CD N
% NN N
) ) N
, , N
but CC N
not RB N
with IN N
DIWL NNP N
Dihydroceramide NNP N
was VBD N
decreased VBN N
with IN N
both DT N
interventions NNS N
Sphingosine NNP N
was VBD N
decreased VBN N
only RB N
with IN N
EX NNP N
Changes NNS N
in IN N
total JJ N
DAG NNP N
, , N
total JJ N
ceramides NNS N
and CC N
other JJ N
sphingolipids NNS N
did VBD N
not RB N
correlate VB N
with IN N
changes NNS N
in IN N
glucose NN N
disposal NN N
Stearoyl-coenzyme VB N
A DT N
desaturase NN N
1 CD N
( ( N
SCD1 NNP N
) ) N
content NN N
was VBD N
decreased VBN N
with IN N
DIWL NNP N
( ( N
-19.5 NNP N
± RB N
8.5 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
increased VBD N
with IN N
EX NNP N
( ( N
19.6 CD N
± RB N
7.4 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
Diacylglycerol NNP N
acyltransferase VBD N
1 CD N
( ( N
DGAT1 NNP N
) ) N
was VBD N
unchanged JJ N
with IN N
the DT N
interventions NNS N
CONCLUSIONS/INTERPRETATION NNP N
Diet-induced NNP N
weight NN N
loss NN N
and CC N
exercise NN N
training NN N
both DT N
improved JJ N
insulin NN N
resistance NN N
and CC N
decreased VBD N
DAG NNP N
, , N
while IN N
only RB N
exercise NN N
decreased VBD N
ceramides NNS N
, , N
despite IN N
the DT N
interventions NNS N
having VBG N
different JJ N
effects NNS N
on IN N
IMTG NNP N
These DT N
alterations NNS N
may MD N
be VB N
mediated VBN N
through IN N
differential JJ N
changes NNS N
in IN N
skeletal JJ N
muscle NN N
capacity NN N
for IN N
oxidation NN N
and CC N
triacylglycerol NN N
synthesis NN N
TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT00766298 NNP N
-DOCSTART- -X- O O 16940738

A DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
of IN N
oral JJ N
misoprostol NN N
and CC N
intramuscular JJ N
syntometrine NN N
in IN N
the DT N
management NN N
of IN N
the DT N
third JJ 4_p
stage NN 4_p
of IN 4_p
labor NN 4_p
BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
oral JJ N
misoprostol NN N
400 CD N
mug NN N
with IN N
intramuscular JJ N
syntometrine NN N
in IN N
the DT N
management NN N
of IN N
the DT N
third JJ N
stage NN N
of IN N
labor NN N
MATERIAL NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
conducted VBN N
in IN N
a DT N
tertiary JJ N
care NN N
hospital NN N
Three CD 3_p
hundred VBD 3_p
and CC 3_p
fifty-five JJ 3_p
women NNS 2_p
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ N
misoprostol NN N
400 CD N
mug NN N
or CC N
intramuscular JJ N
syntometrine NN N
in IN N
the DT N
third JJ 4_p
stage NN 4_p
of IN 4_p
labor NN 4_p
were VBD N
studied VBN N
The DT N
change NN N
in IN N
hemoglobin JJ N
level NN N
from IN N
before IN N
to TO N
48 CD N
h NN N
after IN N
delivery NN N
, , N
use NN N
of IN N
additional JJ N
oxytocics NNS N
and CC N
treatment NN N
related JJ N
side NN N
effects NNS N
were VBD N
the DT N
main JJ N
outcome NN N
measures NNS N
RESULTS NNP N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
the DT N
change NN N
in IN N
hemoglobin JJ N
level NN N
and CC N
mean JJ N
blood NN N
loss NN N
The DT N
incidence NN N
of IN N
shivering NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
misoprostol NN N
group NN N
whilst VBD N
that IN N
of IN N
vomiting NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
syntometrine NN N
group NN N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
nausea NN N
, , N
headache NN N
, , N
diarrhea NN N
and CC N
pyrexia NN N
between IN N
the DT N
two CD N
groups NNS N
CONCLUSION NNP N
Orally RB N
administered VBD N
misoprostol NN N
at IN N
a DT N
dose NN N
of IN N
400 CD N
mug NN N
is VBZ N
an DT N
acceptable JJ N
alternative NN N
in IN N
preventing VBG N
post-partum JJ N
blood NN N
loss NN N
, , N
as IN N
measured VBN N
by IN N
the DT N
peri-partum JJ N
change NN N
in IN N
hemoglobin JJ N
level NN N
and CC N
was VBD N
not RB N
associated VBN N
with IN N
an DT N
increased JJ N
incidence NN N
of IN N
side NN N
effects NNS N
-DOCSTART- -X- O O 10870534

Clinical JJ N
pathway NN N
for IN N
fractured JJ 4_p
neck NN 4_p
of IN 4_p
femur NN 4_p
: : 4_p
a DT N
prospective JJ N
, , N
controlled VBD N
study NN N
OBJECTIVE NNP N
To TO N
assess VB N
outcomes NNS N
of IN N
using VBG N
a DT N
clinical JJ N
pathway NN N
for IN N
managing VBG N
patients NNS N
with IN N
fractured JJ 4_p
neck NN 4_p
of IN 4_p
femur NN 4_p
DESIGN NNP N
Prospective NNP N
, , N
pseudorandomised VBD N
, , N
controlled VBD N
trial NN N
SETTING NN N
St NNP N
Vincent NNP N
's POS N
Hospital NNP N
, , N
Melbourne NNP N
, , N
Victoria NNP N
( ( N
a DT N
tertiary JJ N
referral NN N
, , N
university NN N
teaching VBG N
hospital NN N
) ) N
, , N
1 CD N
October NNP N
1997 CD N
to TO N
30 CD N
November NNP N
1998 CD N
PARTICIPANTS VB N
111 CD 3_p
patients NNS 3_p
( ( N
80 CD 3_p
women NNS N
and CC N
31 CD 3_p
men NNS N
; : N
mean JJ N
age NN N
, , N
81 CD N
years NNS N
) ) N
admitted VBD N
via IN N
the DT N
emergency NN N
department NN N
with IN N
a DT N
primary JJ N
diagnosis NN N
of IN N
fractured JJ N
neck NN N
of IN N
femur NN N
INTERVENTIONS NNP N
Management NNP N
guided VBN N
by IN N
a DT N
clinical JJ N
pathway NN N
( ( N
55 CD N
patients NNS N
) ) N
or CC N
established VBN N
standard NN N
of IN N
care NN N
( ( N
control NN N
group NN N
, , N
56 CD N
patients NNS N
) ) N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Timing NNP N
of IN N
referrals NNS N
and CC N
discharge NN N
planning NN N
; : N
total JJ N
length NN N
of IN N
stay NN N
; : N
and CC N
complication NN N
and CC N
readmission NN N
rates NNS N
within IN N
28 CD N
days NNS N
of IN N
discharge NN N
RESULTS JJ N
Patients NNS N
managed VBD N
according VBG N
to TO N
the DT N
clinical JJ N
pathway NN N
had VBD N
a DT N
shorter NN N
total JJ N
stay NN N
( ( N
6.6 CD N
versus NN N
8.0 CD N
days NNS N
; : N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
even RB N
if IN N
assessment NN N
for IN N
placement NN N
by IN N
the DT N
Aged NNP N
Care NNP N
Assessment NNP N
Service NNP N
was VBD N
required VBN N
( ( N
9.5 CD N
versus NN N
13.6 CD N
days NNS N
; : N
P NNP N
= NNP N
0.03 CD N
) ) N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
complication NN N
and CC N
readmission NN N
rates NNS N
between IN N
pathway NN N
and CC N
control NN N
patients NNS N
( ( N
complication NN N
rates NNS N
, , N
24 CD N
% NN N
versus IN N
36 CD N
% NN N
; : N
P NNP N
= VBZ N
0.40 CD N
; : N
readmission NN N
rates NNS N
, , N
4 CD N
% NN N
versus IN N
11 CD N
% NN N
; : N
P NNP N
= NNP N
0.28 CD N
) ) N
CONCLUSION NNP N
Coordinated VBD N
multidisciplinary JJ N
care NN N
of IN N
patients NNS N
with IN N
fractured JJ N
neck NN N
of IN N
femur NN N
reduces NNS N
length NN N
of IN N
stay NN N
without IN N
increasing VBG N
complications NNS N
-DOCSTART- -X- O O 23361389

Effects NNS N
of IN N
a DT N
dietetic JJ N
treatment NN N
in IN N
older JJR 1_p
, , N
undernourished JJ 4_p
, , N
community-dwelling JJ N
individuals NNS N
in IN N
primary JJ N
care NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
PURPOSE NNP N
Undernutrition NNP N
is VBZ N
a DT N
prevalent NN N
problem NN N
in IN N
older JJR N
, , N
community-dwelling JJ N
individuals NNS N
Aim NNP N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
a DT N
dietetic JJ N
treatment NN N
in IN N
older JJR N
, , N
undernourished JJ 4_p
, , N
community-dwelling JJ N
individuals NNS N
METHODS NNP N
A NNP N
parallel JJ N
randomized VBN N
controlled JJ N
trial NN N
was VBD N
performed VBN N
in IN N
146 CD 3_p
non-institutionalized JJ 4_p
, , 4_p
undernourished JJ 4_p
individuals NNS N
aged VBN 1_p
≥65 CD 1_p
years NNS 1_p
in IN N
primary JJ N
care NN N
Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
intervention NN N
( ( N
referral JJ N
to TO N
and CC N
treatment NN N
by IN N
a DT N
trained JJ N
dietitian NN N
) ) N
or CC N
control VB N
group NN N
( ( N
no DT N
referral NN N
) ) N
Body NNP N
weight VBD N
, , N
physical JJ N
performance NN N
, , N
handgrip JJ N
strength NN N
, , N
energy NN N
intake NN N
, , N
protein JJ N
intake NN N
and CC N
fat-free JJ N
mass NN N
were VBD N
assessed VBN N
at IN N
baseline NN N
, , N
after IN N
3 CD N
months NNS N
and CC N
after IN N
6 CD N
months NNS N
RESULTS NNP N
All NNP N
randomized VBD N
participants NNS N
( ( N
n JJ N
= NNP N
146 CD N
) ) N
were VBD N
included VBN N
in IN N
the DT N
intention-to-treat JJ N
generalized JJ N
estimating NN N
equations NNS N
analysis NN N
( ( N
72 CD N
in IN N
intervention NN N
and CC N
74 CD N
in IN N
control NN N
group NN N
) ) N
No DT N
treatment NN N
effect NN N
was VBD N
found VBN N
on IN N
the DT N
primary JJ N
outcomes NNS N
body NN N
weight NN N
( ( N
β JJ N
= $ N
0.49 CD N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
-0.15-1.12 NN N
) ) N
, , N
physical JJ N
performance NN N
( ( N
β JJ N
= RB N
0.15 CD N
points NNS N
, , N
95 CD N
% NN N
CI NNP N
: : N
-0.33-0.64 NN N
) ) N
and CC N
handgrip JJ N
strength NN N
( ( N
β JJ N
= $ N
0.49 CD N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
-0.62-1.60 NN N
) ) N
Furthermore NNP N
, , N
no DT N
treatment NN N
effect NN N
was VBD N
found VBN N
for IN N
the DT N
secondary JJ N
outcomes NNS N
Predefined VBN N
subgroup NN N
analyses VBZ N
showed VBD N
a DT N
treatment NN N
effect NN N
on IN N
body NN N
weight NN N
in IN N
physically RB N
active JJ N
participants NNS N
( ( N
β JJ N
= $ N
1.25 CD N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.70-2.11 NN N
) ) N
and CC N
not RB N
in IN N
inactive JJ N
participants NNS N
( ( N
β JJ N
= NNP N
-0.20 NNP N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
-1.16-0.75 NN N
) ) N
CONCLUSIONS NNP N
After IN N
6 CD N
months NNS N
, , N
a DT N
dietetic JJ N
treatment NN N
by IN N
trained JJ N
dietitians NNS N
does VBZ N
not RB N
lead VB N
to TO N
increases NNS N
in IN N
body NN N
weight NN N
and CC N
physical JJ N
functioning NN N
in IN N
older JJR N
, , N
undernourished JJ N
, , N
community-dwelling JJ N
individuals NNS N
-DOCSTART- -X- O O 8437833

Diode NNP N
laser NN N
photocoagulation NN N
for IN N
threshold JJ 4_p
retinopathy NN 4_p
of IN 4_p
prematurity NN 4_p
A DT N
randomized JJ N
study NN N
BACKGROUND NNP N
Although IN N
peripheral JJ N
cryotherapy NN N
decreases VBZ N
the DT N
incidence NN N
of IN N
unfavorable JJ N
anatomic JJ N
outcomes NNS N
in IN N
threshold JJ N
retinopathy NN 4_p
of IN 4_p
prematurity NN 4_p
( ( N
ROP NNP 4_p
) ) N
, , N
apnea RB N
, , N
bradycardia NN N
, , N
and CC N
lid JJ N
edema NN N
can MD N
occur VB N
Argon NNP N
laser NN N
indirect JJ N
ophthalmoscope NN N
photocoagulation NN N
has VBZ N
been VBN N
used VBN N
as IN N
an DT N
alternative NN N
to TO N
cryotherapy VB N
, , N
with IN N
fewer JJR N
adverse JJ N
effects NNS N
Retinal JJ N
lesions NNS N
placed VBN N
with IN N
diode NN N
lasers NNS N
are VBP N
deeper JJR N
than IN N
similar JJ N
argon NN N
laser NN N
lesions NNS N
, , N
and CC N
it PRP N
is VBZ N
not RB N
known VBN N
whether IN N
this DT N
difference NN N
could MD N
influence VB N
the DT N
response NN N
to TO N
ablative JJ N
therapy NN N
METHODS JJ N
Patients NNPS N
were VBD N
enrolled VBN N
under IN N
a DT N
prospective JJ N
, , N
randomized VBN N
protocol NN N
One CD N
eye NN N
of IN N
each DT N
patient NN N
with IN N
symmetric JJ N
, , N
threshold JJ N
ROP NNP N
was VBD N
treated VBN N
with IN N
an DT N
814/815 CD N
nm JJ N
diode NN N
laser NN N
, , N
while IN N
the DT N
other JJ N
eye NN N
was VBD N
treated VBN N
with IN N
cryotherapy NN N
Patients NNS N
with IN N
asymmetric JJ N
diseases NNS N
also RB N
were VBD N
randomized VBN N
for IN N
treatment NN N
in IN N
the DT N
threshold NN N
eye NN N
RESULTS NNP N
Nineteen JJ 3_p
infants NNS 3_p
( ( 3_p
33 CD 3_p
eyes NNS 3_p
) ) 3_p
were VBD N
treated VBN N
, , N
ranging VBG N
from IN N
485 CD N
to TO N
863 CD N
g NNS N
birth JJ N
weight NN N
( ( N
23 CD N
to TO N
27 CD N
weeks NNS N
gestational JJ N
age NN N
) ) N
; : N
18 CD 3_p
patients NNS 3_p
( ( 3_p
32 CD 3_p
eyes NNS 3_p
) ) 3_p
were VBD N
followed VBN N
for IN N
3 CD N
months NNS N
or CC N
longer JJR N
Four CD 3_p
patients NNS 3_p
( ( 3_p
8 CD 3_p
eyes NNS 3_p
) ) 3_p
had VBD N
bilateral JJ N
zone CD N
1 CD N
disease NN N
Postconceptional JJ N
age NN N
was VBD N
36 CD 1_p
to TO 1_p
45 CD 1_p
weeks NNS 1_p
at IN N
the DT N
time NN N
of IN N
treatment NN N
The DT N
diode NN N
laser NN N
treatment NN N
was VBD N
better RBR N
tolerated VBN N
than IN N
cryotherapy NN N
, , N
and CC N
the DT N
treatment NN N
apparatus NN N
was VBD N
more RBR N
easily RB N
transported VBN N
Apneic NNP N
episodes VBZ N
requiring VBG N
intubation NN N
resulted VBD N
from IN N
two CD N
cryotherapy NN N
sessions NNS N
but CC N
no DT N
diode NN N
laser NN N
sessions NNS N
Five CD N
cryotherapy-treated JJ N
eyes NNS N
required VBN N
retreatment NN N
because IN N
of IN N
persistent JJ N
disease NN N
with IN N
adjacent JJ N
skip NN N
areas NNS N
In IN N
the DT N
group NN N
followed VBD N
for IN N
3 CD N
to TO N
15 CD N
months NNS N
, , N
1 CD N
cryotherapy-treated JJ N
eye NN N
and CC N
1 CD N
diode NN N
laser-treated JJ N
eye NN N
progressed VBD N
to TO N
stage VB N
5 CD N
retinal JJ N
detachment NN N
CONCLUSION NNP N
Compared NNP N
with IN N
cryotherapy NN N
, , N
the DT N
diode NN N
laser NN N
was VBD N
more RBR N
convenient JJ N
, , N
technically RB N
easier JJR N
to TO N
administer VB N
, , N
and CC N
better RB N
tolerated VBN N
by IN N
the DT N
patient NN N
Although IN N
the DT N
number NN N
of IN N
patients NNS N
was VBD N
too RB N
small JJ N
for IN N
meaningful JJ N
statistical JJ N
analysis NN N
of IN N
outcome NN N
, , N
diode VB N
laser RBR N
peripheral JJ N
retinal JJ N
ablation NN N
appeared VBD N
to TO N
be VB N
as RB N
effective JJ N
as IN N
cryotherapy NN N
for IN N
the DT N
treatment NN N
of IN N
threshold JJ N
ROP NNP N
-DOCSTART- -X- O O 20221773

The DT N
limit NN N
to TO N
exercise VB N
tolerance NN N
in IN N
humans NNS N
: : N
mind NN N
over IN N
muscle NN N
? . N
In IN N
exercise NN N
physiology NN N
, , N
it PRP N
has VBZ N
been VBN N
traditionally RB N
assumed VBN N
that IN N
high-intensity NN N
aerobic JJ N
exercise NN N
stops NNS N
at IN N
the DT N
point NN N
commonly RB N
called VBD N
exhaustion NN N
because IN N
fatigued VBN N
subjects NNS N
are VBP N
no RB N
longer RBR N
able JJ N
to TO N
generate VB N
the DT N
power NN N
output NN N
required VBN N
by IN N
the DT N
task NN N
despite IN N
their PRP$ N
maximal JJ N
voluntary JJ N
effort NN N
We PRP N
tested VBD N
the DT N
validity NN N
of IN N
this DT N
assumption NN N
by IN N
measuring VBG N
maximal JJ N
voluntary JJ N
cycling VBG N
power NN N
before IN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
1,075 CD N
+/- JJ N
214 CD N
W NNP N
) ) N
and CC N
immediately RB N
after IN N
( ( N
731 CD N
+/- JJ N
206 CD N
W NNP N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
exhaustive VBP N
cycling VBG N
exercise NN N
at IN N
242 CD N
+/- JJ N
24 CD N
W NNP N
( ( N
80 CD N
% NN N
of IN N
peak NN N
aerobic JJ N
power NN N
measured VBN N
during IN N
a DT N
preliminary JJ N
incremental NN N
exercise NN N
test NN N
) ) N
in IN N
ten JJ N
fit JJ N
male NN N
human JJ N
subjects NNS N
Perceived NNP N
exertion NN N
during IN N
exhaustive JJ N
cycling NN N
exercise NN N
was VBD N
strongly RB N
correlated VBN N
( ( N
r JJ N
= NNP N
-0.82 NNP N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
with IN N
time NN N
to TO N
exhaustion NN N
( ( N
10.5 CD N
+/- JJ N
2.1 CD N
min NN N
) ) N
These DT N
results NNS N
challenge VBP N
the DT N
long-standing JJ N
assumption NN N
that IN N
muscle NN N
fatigue NN N
causes VBZ N
exhaustion NN N
during IN N
high-intensity NN N
aerobic JJ N
exercise NN N
, , N
and CC N
suggest VBP N
that IN N
exercise NN N
tolerance NN N
in IN N
highly RB N
motivated JJ N
subjects NNS N
is VBZ N
ultimately RB N
limited VBN N
by IN N
perception NN N
of IN N
effort NN N
-DOCSTART- -X- O O 8561526

A DT N
community-based JJ N
randomized JJ N
trial NN N
of IN N
praziquantel NN N
to TO N
control VB N
schistosomiasis NN N
morbidity NN N
in IN N
schoolchildren NN 1_p
in IN N
Zambia NNP N
A DT N
community-based JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
trial NN N
of IN N
praziquantel NN N
was VBD N
carried VBN N
out RP N
in IN N
an DT N
area NN N
of IN N
Zambia NNP N
endemic FW N
for IN N
schistosomiasis NN 4_p
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
impact NN N
of IN N
the DT N
treatment NN N
on IN N
Schistosoma NNP N
mansoni NNP N
morbidity NN N
A DT N
total NN N
of IN N
377 CD N
infected JJ N
children NNS 1_p
, , 1_p
aged VBD 1_p
seven CD 1_p
to TO 1_p
19 CD 1_p
years NNS 1_p
, , N
was VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
one CD N
of IN N
190 CD N
( ( N
group NN N
A NNP N
) ) N
and CC N
one CD N
of IN N
187 CD N
( ( N
group NN N
B NNP N
) ) N
All DT N
children NNS 1_p
were VBD N
treated VBN N
with IN N
40 CD N
mg NNS N
praziquantel/kg NN N
at IN N
the DT N
start NN N
of IN N
the DT N
study NN N
Six CD N
months NNS N
later RB N
, , N
the DT N
children NNS N
in IN N
group NN N
A NNP N
were VBD N
re-treated JJ N
with IN N
the DT N
same JJ N
dose NN N
of IN N
praziquantel NN N
, , N
while IN N
the DT N
children NNS 1_p
in IN N
group NN N
B NNP N
were VBD N
given VBN N
placebos NNS N
All DT N
children NNS 1_p
were VBD N
followed VBN N
up RP N
three CD N
, , N
six CD N
and CC N
12 CD N
months NNS N
after IN N
the DT N
initial JJ N
treatment NN N
, , N
morbidity NN N
being VBG N
clinically RB N
evaluated VBN N
at IN N
the DT N
six- JJ N
and CC N
12-month JJ N
follow-ups NNS N
The DT N
results NNS N
show VBP N
that IN N
, , N
in IN N
both DT N
groups NNS N
of IN N
children NNS 1_p
, , N
there EX N
were VBD N
significant JJ N
reductions NNS N
in IN N
splenomegaly NN N
, , N
hepatomegaly NN N
, , N
and CC N
subjective JJ N
symptoms NNS N
of IN N
morbidity NN N
six CD N
and CC N
12 CD N
months NNS N
after IN N
initial JJ N
treatment NN N
However RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
, , N
between IN N
the DT N
two CD N
groups NNS N
, , N
in IN N
the DT N
prevalences NNS N
of IN N
these DT N
symptoms NNS N
of IN N
morbidity NN N
It PRP N
therefore RB N
appears VBZ N
that IN N
once-yearly JJ N
treatment NN N
of IN N
children NNS 1_p
, , N
in IN N
this DT N
and CC N
similar JJ N
endemic JJ N
areas NNS N
, , N
is VBZ N
sufficient JJ N
to TO N
reduce VB N
schistosomiasis NN N
morbidity NN N
to TO N
, , N
and CC N
maintain VB N
it PRP N
at IN N
, , N
a DT N
tolerable JJ N
level NN N
-DOCSTART- -X- O O 8363113

Use NNP N
of IN N
activated JJ N
charcoal NN N
in IN N
a DT N
simulated JJ N
poisoning NN 4_p
with IN 4_p
acetaminophen NN 4_p
: : N
a DT N
new JJ N
loading NN N
dose NN N
for IN N
N-acetylcysteine NNP N
? . N
STUDY NNP N
OBJECTIVES NNP N
To TO N
investigate VB N
the DT N
ability NN N
of IN N
a DT N
supranormal JJ N
dose NN N
of IN N
N-acetylcysteine NNP N
to TO N
overcome VB N
the DT N
effects NNS N
of IN N
activated JJ N
charcoal NN N
on IN N
N-acetylcysteine NNP N
bioavailability NN N
and CC N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
activated JJ N
charcoal NN N
on IN N
serum NN N
acetaminophen NN N
levels NNS N
DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Ten NNP 3_p
healthy JJ N
adult NN 1_p
volunteers NNS 1_p
participated VBD N
in IN N
a DT N
controlled JJ N
cross-over JJ N
experiment NN N
During IN N
phase NN N
I PRP N
( ( N
control NN N
) ) N
, , N
subjects VBZ N
ingested JJ N
3 CD N
g NN N
acetaminophen NN N
, , N
followed VBD N
one CD N
hour NN N
later RB N
by IN N
the DT N
normal JJ N
loading VBG N
dose NN N
of IN N
N-acetylcysteine NNP N
( ( N
140 CD N
mg/kg NN N
) ) N
During IN N
phase NN N
II NNP N
( ( N
charcoal NN N
) ) N
, , N
subjects VBZ N
ingested JJ N
3 CD N
g NN N
acetaminophen NN N
, , N
followed VBD N
one CD N
hour NN N
later RB N
by IN N
60 CD N
g NNS N
activated VBN N
charcoal NN N
and CC N
a DT N
supranormal JJ N
loading NN N
dose NN N
of IN N
N-acetylcysteine NNP N
( ( N
235 CD N
mg/kg NN N
) ) N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Serum NNP N
levels NNS N
of IN N
N-acetylcysteine NNP N
were VBD N
measured VBN N
every DT N
30 CD N
minutes NNS N
for IN N
six CD N
hours NNS N
A DT N
serum NN N
acetaminophen NN N
level NN N
was VBD N
measured VBN N
at IN N
four CD N
hours NNS N
RESULTS VB N
The DT N
area NN N
under IN N
the DT N
curve NN N
for IN N
N-acetylcysteine NNP N
was VBD N
significantly RB N
higher JJR N
for IN N
phase NN N
II NNP N
than IN N
phase NN N
I PRP N
( ( N
P NNP N
< NNP N
.05 NNP N
, , N
two-tailed JJ N
paired VBD N
t-test NN N
) ) N
Peak VB N
N-acetylcysteine JJ N
and CC N
time NN N
to TO N
peak VB N
were VBD N
not RB N
significantly RB N
different JJ N
The DT N
four-hour JJ N
serum NN N
acetaminophen NN N
level NN N
was VBD N
significantly RB N
lower JJR N
for IN N
phase NN N
II NNP N
than IN N
phase NN N
I PRP N
( ( N
P NNP N
< NNP N
.05 NNP N
, , N
two-tailed JJ N
paired VBD N
t-test NN N
) ) N
Diarrhea NNP N
occurred VBD N
during IN N
both DT N
phases NNS N
, , N
but CC N
N-acetylcysteine NNP N
was VBD N
otherwise RB N
well RB N
tolerated VBN N
CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
activated JJ N
charcoal NN N
can MD N
be VB N
used VBN N
safely RB N
for IN N
victims NNS N
of IN N
acetaminophen NN 4_p
overdose NN 4_p
A DT N
beneficial JJ N
effect NN N
in IN N
preventing VBG N
acetaminophen JJ N
absorption NN N
can MD N
be VB N
expected VBN N
if IN N
it PRP N
is VBZ N
given VBN N
within IN N
one CD N
hour NN N
after IN N
ingestion NN N
If IN N
N-acetylcysteine NNP N
is VBZ N
needed VBN N
because IN N
of IN N
a DT N
toxic JJ N
serum NN N
acetaminophen NN N
level NN N
, , N
bioavailability NN N
can MD N
be VB N
ensured VBN N
by IN N
increasing VBG N
the DT N
N-acetylcysteine JJ N
loading NN N
dose NN N
from IN N
140 CD N
mg/kg NNS N
to TO N
235 CD N
mg/kg NNS N
-DOCSTART- -X- O O 15943172

A DT N
short-term JJ N
cognitive JJ N
group NN N
treatment NN N
program NN N
gives VBZ N
substantial JJ N
weight NN N
reduction NN N
up RB N
to TO N
18 CD N
months NNS N
from IN N
the DT N
end NN N
of IN N
treatment NN N
A DT N
randomized JJ N
controlled JJ N
trial NN N
OBJECTIVE UH N
To TO N
describe VB N
and CC N
evaluate VB N
long-term JJ N
efficacy NN N
( ( N
18 CD N
months NNS N
from IN N
the DT N
end NN N
of IN N
treatment NN N
) ) N
of IN N
a DT N
new JJ N
cognitive JJ N
short-term JJ N
weight NN N
reducing VBG N
treatment NN N
program NN N
for IN N
obese JJ N
patients NNS N
SUBJECTS NNP N
One CD N
hundred CD N
and CC N
five CD N
obese JJ N
[ NN N
Body NNP N
Mass NNP N
Index NNP N
( ( N
BMI NNP N
) ) N
> VBD N
or CC N
= $ N
30 CD N
] JJ N
patients NNS N
participated VBN N
in IN N
the DT N
study NN N
Of IN N
these DT N
, , N
62 CD N
took VBD N
part NN N
in IN N
the DT N
treatment NN N
program NN N
and CC N
43 CD N
served VBD N
as IN N
controls NNS N
METHOD NNP N
From IN N
an DT N
obesity NN 4_p
unit NN 4_p
's POS 4_p
waiting VBG 4_p
list NN 4_p
, , N
the DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
treatment NN N
group NN N
or CC N
remained VBN N
in IN N
the DT N
waiting VBG N
list NN N
to TO N
serve VB N
as IN N
a DT N
control NN N
group NN N
The DT N
treatment NN N
group NN N
participated VBD N
in IN N
a DT N
10-week JJ N
( ( N
30 CD N
hours NNS N
) ) N
cognitive VBP N
group NN N
treatment NN N
program NN N
All DT N
participants NNS N
were VBD N
weighed VBN N
at IN N
the DT N
outset NN N
of IN N
the DT N
study NN N
, , N
directly RB N
after IN N
treatment NN N
and CC N
at IN N
a DT N
6- JJ N
, , N
12- JJ N
and CC N
18-month JJ N
post-treatment JJ N
follow-up NN N
without IN N
any DT N
booster NN N
treatment NN N
after IN N
the DT N
10-week JJ N
program NN N
RESULTS NNP N
Fifty-seven NNP N
( ( N
92 CD N
% NN N
) ) N
patients NNS N
completed VBN N
treatment NN N
For IN N
the DT N
34 CD N
( ( N
60 CD N
% NN N
) ) N
patients NNS N
who WP N
participated VBD N
in IN N
the DT N
study NN N
18 CD N
months NNS N
after IN N
treatment NN N
was VBD N
terminated VBN N
, , N
the DT N
mean JJ N
weight NN N
loss NN N
at IN N
treatment NN N
's POS N
end NN N
was VBD N
8.5 CD N
kg NN N
( ( N
SD=16.1 NNP N
) ) N
Eighteen JJ N
months NNS N
later RB N
their PRP$ N
mean JJ N
weight NN N
loss NN N
was VBD N
10.4 CD N
kg NN N
( ( N
SD=10.8 NNP N
) ) N
The DT N
control NN N
patients NNS N
( ( N
n=31.72 JJ N
% NN N
) ) N
that WDT N
participated VBD N
in IN N
the DT N
study NN N
during IN N
the DT N
same JJ N
period NN N
increased VBD N
in IN N
weight NN N
by IN N
2.3 CD N
kg NNS N
( ( N
SD=7.0 NNP N
) ) N
The DT N
weight NN N
difference NN N
between IN N
the DT N
treatment NN N
and CC N
control NN N
group NN N
at IN N
the DT N
18-month JJ N
follow-up NN N
was VBD N
highly RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
CONCLUSION VB N
The DT N
cognitive JJ N
group NN N
treatment NN N
program NN N
was VBD N
highly RB N
acceptable JJ N
among IN N
the DT N
participants NNS N
and CC N
was VBD N
completed VBN N
by IN N
nearly RB N
all PDT N
the DT N
patients NNS N
The DT N
10-week JJ N
treatment NN N
program NN N
resulted VBD N
in IN N
satisfactory JJ N
weight JJ N
loss NN N
The DT N
weight NN N
difference NN N
between IN N
the DT N
treatment NN N
group NN N
and CC N
controls NNS N
was VBD N
nearly RB N
the DT N
same JJ N
at IN N
18 CD N
months NNS N
after IN N
end NN N
of IN N
treatment NN N
as IN N
at IN N
six CD N
months NNS N
The DT N
study NN N
, , N
therefore RB N
, , N
does VBZ N
not RB N
provide VB N
support NN N
for IN N
the DT N
contention NN N
that IN N
a DT N
lengthy JJ N
therapy NN N
for IN N
obesity NN N
is VBZ N
necessary JJ N
if IN N
treatment NN N
results NNS N
are VBP N
lasting VBG N
-DOCSTART- -X- O O 16595217

Conventional JJ N
in IN N
vitro JJ N
fertilization NN N
versus IN N
intracytoplasmic JJ N
sperm JJ N
injection NN N
in IN 4_p
patients NNS 4_p
with IN 4_p
borderline JJ 4_p
semen NNS 4_p
: : 4_p
a DT N
randomized JJ N
study NN N
using VBG N
sibling VBG N
oocytes NNS N
OBJECTIVE NN N
To TO N
determine VB N
whether IN N
patients NNS 4_p
with IN 4_p
borderline JJ 4_p
semen NNS 4_p
should MD N
be VB N
treated VBN N
with IN N
conventional JJ N
IVF NNP N
or CC N
intracytoplasmic JJ N
sperm JJ N
injection NN N
( ( N
ICSI NNP N
) ) N
DESIGN NNP N
Randomized NNP N
study NN N
SETTING VB N
A DT N
university NN N
medical JJ N
center NN N
in IN N
The DT N
Netherlands NNP N
PATIENT NNP N
( ( N
S NNP N
) ) N
One CD 3_p
hundred VBN 3_p
six CD 3_p
couples NNS 3_p
with IN N
borderline JJ 4_p
semen NNS 4_p
who WP N
were VBD N
undergoing VBG N
IVF NNP N
and CC N
ICSI NNP N
on IN N
sibling VBG N
oocytes NNS N
INTERVENTION NNP N
( ( N
S NNP N
) ) N
Performing VBG N
IVF NNP N
and CC N
ICSI NNP N
on IN N
sibling VBG N
oocytes NNS N
MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Fertilization NNP N
and CC N
pregnancy NN N
rates NNS N
RESULT NNP N
( ( N
S NNP N
) ) N
One CD N
thousand CD N
five CD N
hundred VBN N
eighteen NN N
oocytes NNS N
were VBD N
collected VBN N
in IN N
106 CD N
oocyte JJ N
retrievals NNS N
: : N
849 CD N
oocytes NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
ICSI NNP N
, , N
of IN N
which WDT N
761 CD N
were VBD N
microinjected VBN N
, , N
and CC N
669 CD N
oocytes NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
IVF NNP N
In IN N
26 CD N
of IN N
the DT N
106 CD N
patients NNS N
, , N
there EX N
was VBD N
fertilization NN N
only RB N
after IN N
ICSI NNP N
and CC N
not RB N
after IN N
IVF NNP N
( ( N
IVF- NNP N
group NN N
) ) N
The DT N
fertilization NN N
rate NN N
was VBD N
51 CD N
% NN N
( ( N
92/182 CD N
oocytes NNS N
) ) N
In IN 3_p
78 CD 3_p
patients NNS 3_p
, , N
there EX N
was VBD N
fertilization NN N
after IN N
both DT N
IVF NNP N
and CC N
ICSI NNP N
( ( N
IVF+ NNP N
group NN N
) ) N
; : N
the DT N
fertilization NN N
rate NN N
was VBD N
51 CD N
% NN N
for IN N
both DT N
the DT N
IVF- NNP N
and CC N
ICSI-treated NNP N
oocytes NNS N
( ( N
271/528 CD N
oocytes NNS N
and CC N
334/658 CD N
oocytes NNS N
, , N
respectively RB N
) ) N
In IN N
2 CD 3_p
patients NNS 3_p
, , N
there EX N
was VBD N
no DT N
fertilization NN N
after IN N
either DT N
IVF NNP N
( ( N
0/6 CD N
oocytes NNS N
) ) N
or CC N
ICSI NNP N
( ( N
0/9 CD N
oocytes NNS N
) ) N
Patients NNS N
of IN N
the DT N
IVF+ NNP N
group NN N
had VBD N
a DT N
higher JJR N
total JJ N
motile JJ N
sperm NN N
count NN N
after IN N
preparation NN N
than IN N
did VBD N
those DT N
of IN N
the DT N
IVF- NNP N
group NN N
More JJR N
high-quality JJ N
embryos NN N
were VBD N
obtained VBN N
after IN N
ICSI NNP N
in IN N
patients NNS N
of IN N
the DT N
IVF+ NNP N
group NN N
In IN N
101 CD 3_p
patients NNS 3_p
, , N
embryo FW N
transfer NN N
was VBD N
performed VBN N
: : N
26 CD N
in IN N
the DT N
IVF- NNP N
group NN N
and CC N
75 CD N
in IN N
the DT N
IVF+ NNP N
group NN N
No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
with IN N
regard NN N
to TO N
pregnancy VB N
rates NNS N
between IN N
those DT N
two CD N
groups NNS N
: : N
pregnancy NN N
rates NNS N
were VBD N
54 CD N
% NN N
in IN N
the DT N
IVF- NNP N
group NN N
and CC N
48 CD N
% NN N
in IN N
the DT N
IVF+ NNP N
group NN N
CONCLUSION NNP N
( ( N
S NNP N
) ) N
Performing VBG N
ICSI NNP N
on IN N
at IN N
least JJS N
some DT N
of IN N
the DT N
oocytes NNS N
will MD N
avoid VB N
unnecessary JJ N
fertilization NN N
failure NN N
in IN N
patients NNS 4_p
with IN 4_p
borderline JJ 4_p
semen NNS 4_p
: : N
in IN N
this DT N
study NN N
, , N
26 CD N
of IN N
104 CD N
cycles NNS N
( ( N
25 CD N
% NN N
) ) N
were VBD N
rescued VBN N
by IN N
ICSI NNP N
-DOCSTART- -X- O O 1984893

Unstable JJ 4_p
angina NN 4_p
Quality NN N
of IN N
life NN N
-DOCSTART- -X- O O 1412152

Desmopressin NNP N
has VBZ N
no DT N
beneficial JJ N
effect NN N
on IN N
excessive JJ N
postoperative JJ N
bleeding NN 4_p
or CC N
blood NN 4_p
product NN 4_p
requirements NNS 4_p
associated VBN N
with IN N
cardiopulmonary JJ 4_p
bypass NN 4_p
Cardiopulmonary JJ N
bypass NN N
during IN N
open-heart JJ N
surgery NN N
is VBZ N
sometimes RB N
associated VBN N
with IN N
excessive JJ N
perioperative JJ N
bleeding NN N
Following VBG N
a DT N
non-randomized JJ N
study NN N
suggesting VBG N
that IN N
desmopressin NN N
acetate NN N
( ( N
desmopressin NN N
) ) N
reduced VBD N
blood NN N
product NN N
requirements NNS N
in IN N
these DT N
patients NNS N
, , N
we PRP N
conducted VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
randomized JJ N
trial NN N
of IN N
desmopressin NN N
( ( N
0.3 CD N
micrograms/kg NN N
, , N
i. JJ N
v. NN N
) ) N
in IN N
92 CD 3_p
patients NNS N
with IN N
overt JJ 4_p
bleeding NN 4_p
and CC N
a DT N
prolonged JJ 4_p
bleeding NN 4_p
time NN 4_p
Mean JJ N
blood NN N
loss NN N
during IN N
the DT N
first JJ N
24 CD N
h JJ N
post-treatment NN N
was VBD N
similar JJ N
in IN N
the DT N
desmopressin NN N
and CC N
placebo NN N
groups NNS N
( ( N
582 CD N
vs RB N
465 CD N
ml NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.15 CD N
) ) N
Red-cell NNP N
( ( N
p JJ N
= NNP N
0.76 CD N
) ) N
, , N
fresh JJ N
frozen JJ N
plasma NN N
( ( N
r JJ N
= NNP N
0.66 CD N
) ) N
and CC N
platelet JJ N
unit NN N
( ( N
p JJ N
= NNP N
0.74 CD N
) ) N
requirements NNS N
were VBD N
also RB N
similar JJ N
The DT N
haemostatic JJ N
effect NN N
of IN N
desmopressin NN N
has VBZ N
been VBN N
attributed VBN N
to TO N
the DT N
release NN N
of IN N
von JJ N
Willebrand NNP N
factor NN N
( ( N
vWF NN N
) ) N
and CC N
a DT N
reduced JJ N
bleeding NN N
time NN N
In IN N
our PRP$ N
study NN N
, , N
vWF NN N
and CC N
factor NN N
VIII NNP N
: : N
C NNP N
levels NNS N
increased VBN N
while IN N
the DT N
bleeding NN N
time NN N
decreased VBN N
significantly RB N
at IN N
90 CD N
min NN N
and CC N
24 CD N
h NN N
in IN N
both DT N
groups NNS N
and CC N
, , N
although IN N
vWF NN N
and CC N
factor NN N
VIII NNP N
: : N
C NN N
levels NNS N
were VBD N
slightly RB N
higher JJR N
in IN N
desmopressin-treated JJ N
patients NNS N
at IN N
90 CD N
min NN N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
Thrombin-antithrombin JJ N
III NNP N
complex NN N
, , N
fibrinogen NN N
degradation NN N
product NN N
and CC N
tissue NN N
plasminogen NN N
activator NN N
levels NNS N
, , N
reflecting VBG N
activation NN N
of IN N
the DT N
coagulation NN N
and CC N
fibrinolytic JJ N
systems NNS N
, , N
respectively RB N
, , N
decreased VBD N
uniformly RB N
in IN N
both DT N
groups NNS N
We PRP N
conclude VBP N
that DT N
desmopressin NN N
is VBZ N
not RB N
useful JJ N
in IN N
reducing VBG N
blood NN N
loss NN N
or CC N
blood NN N
product NN N
requirements NNS N
in IN N
patients NNS N
with IN N
excessive JJ N
immediate JJ N
postoperative JJ N
bleeding NN N
-DOCSTART- -X- O O 1634173

[ JJ N
Local NNP N
therapy NN N
of IN N
grade NN 4_p
1 CD 4_p
and CC N
2 CD 4_p
hemorrhoids NNS 4_p
Effectiveness NN N
of IN N
a DT N
combination NN N
preparation NN N
with IN N
standardized JJ N
blood NN N
leech NN N
extract NN N
] NNP N
AIMS NNP N
Testing VBG N
the DT N
effectiveness NN N
of IN N
a DT N
topical JJ N
combination NN N
preparation NN N
containing VBG N
standardized VBN N
leech JJ N
extract NN N
, , N
polidocanol NN N
and CC N
allantoin NN N
STUDY NNP N
DESIGN NNP N
Placebo-controlled NNP N
, , N
double-blind NN N
study NN N
in IN N
80 CD 3_p
patients NNS N
with IN N
first JJ N
and CC N
second JJ N
degree NN N
hemorrhoids NNS N
; : N
duration NN N
of IN N
treatment NN N
one CD N
week NN N
; : N
examinations NNS N
performed VBD N
on IN N
admission NN N
and CC N
on IN N
days NNS N
3 CD N
, , N
4 CD N
, , N
5 CD N
and CC N
8 CD N
RESULTS VB N
Both DT N
the DT N
subjective NN N
and CC N
objective JJ N
symptoms NNS N
and CC N
signs NNS N
improved VBN N
during IN N
the DT N
one CD N
week NN N
of IN N
treatment NN N
statistically RB N
significantly RB N
more RBR N
rapidly RB N
under IN N
the DT N
test NN N
preparation NN N
as IN N
compared VBN N
with IN N
placebo NN N
Histologically NNP N
demonstrable JJ N
signs NNS N
of IN N
inflammation NN N
were VBD N
more JJR N
clearly RB N
improved VBN N
in IN N
the DT N
preparation NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
No DT N
side NN N
effects NNS N
were VBD N
observed VBN N
CONCLUSIONS VB N
The DT N
good JJ N
efficacy NN N
and CC N
tolerability NN N
of IN N
a DT N
topical JJ N
therapeutic JJ N
preparation NN N
in IN N
first JJ 4_p
and CC 4_p
second JJ 4_p
degree NN 4_p
hemorrhoids NNS 4_p
have VBP N
been VBN N
convincingly RB N
demonstrated VBN N
-DOCSTART- -X- O O 9351754

Postoperative JJ N
pain NN N
relief NN N
following VBG N
laparoscopic NN 4_p
tubal JJ 4_p
sterilization NN 4_p
with IN N
silastic JJ N
bands NNS N
OBJECTIVE NNP N
To TO N
evaluate VB N
postoperative JJ N
pain NN N
relief NN N
of IN N
intramuscular JJ N
ketorolac NN N
, , N
topical JJ N
bupivacaine NN N
, , N
and CC N
placebo NN N
in IN N
patients NNS N
undergoing VBG N
laparoscopic JJ 4_p
tubal JJ 4_p
sterilization NN 4_p
with IN N
silastic JJ N
bands NNS N
METHODS NNP N
One CD 3_p
hundred VBD 3_p
five CD 3_p
women NNS 2_p
undergoing VBG N
laparoscopic NN 4_p
tubal JJ 4_p
sterilization NN 4_p
with IN N
silastic JJ N
bands NNS N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
one CD N
received VBD N
intramuscular JJ N
ketorolac NN N
and CC N
topical JJ N
placebo NN N
applied VBN N
to TO N
the DT N
fallopian JJ N
tubes NN N
, , N
the DT N
second JJ N
received VBD N
intramuscular JJ N
placebo NN N
and CC N
topical JJ N
bupivacaine NN N
, , N
and CC N
the DT N
third JJ N
received VBD N
intramuscular JJ N
placebo NN N
and CC N
topical JJ N
placebo NN N
Surgical JJ N
procedures NNS N
, , N
anesthesia NN N
, , N
and CC N
recovery NN N
were VBD N
conducted VBN N
with IN N
standardized JJ N
protocols NNS N
Postoperative JJ N
pain NN N
perception NN N
was VBD N
graded VBN N
using VBG N
the DT N
modified VBN N
McGill NNP N
pain VBP N
intensity NN N
scale NN N
at IN N
30 CD N
minutes NNS N
postoperatively RB N
, , N
at IN N
discharge NN N
from IN N
the DT N
recovery NN N
room NN N
, , N
and CC N
the DT N
next JJ N
morning NN N
by IN N
telephone NN N
interview NN N
Other JJ N
measured VBD N
variables NNS N
included VBD N
postoperative JJ N
vomiting NN N
, , N
additional JJ N
analgesia NN N
requirement NN N
, , N
and CC N
length NN N
of IN N
time NN N
spent VBN N
in IN N
the DT N
recovery NN N
room NN N
RESULTS NNP N
Only RB N
topical JJ N
bupivacaine NN N
was VBD N
found VBN N
to TO N
decrease VB N
postoperative JJ N
pain NN N
scores NNS N
significantly RB N
over IN N
those DT N
with IN N
placebo NN N
, , N
at IN N
30 CD N
minutes NNS N
postoperatively RB N
( ( N
median JJ N
score NN N
2 CD N
compared VBN N
with IN N
4 CD N
, , N
P NNP N
= NNP N
.002 NNP N
) ) N
and CC N
at IN N
discharge NN N
from IN N
the DT N
recovery NN N
room NN N
( ( N
median JJ N
score NN N
2 CD N
compared VBN N
with IN N
3 CD N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
There EX N
was VBD N
no DT N
significant JJ N
decrease NN N
in IN N
pain NN N
scores NNS N
with IN N
intramuscular JJ N
ketorolac NNS N
compared VBN N
with IN N
placebo NN N
No DT N
differences NNS N
in IN N
pain NN N
scores NNS N
were VBD N
found VBN N
between IN N
the DT N
three CD N
groups NNS N
at IN N
the DT N
next JJ N
morning NN N
phone NN N
call NN N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
three CD N
groups NNS N
with IN N
respect NN N
to TO N
requirements NNS N
for IN N
supplemental JJ N
pain NN N
medications NNS N
in IN N
the DT N
recovery NN N
room NN N
, , N
incidence NN N
of IN N
postoperative JJ N
vomiting NN N
, , N
or CC N
length NN N
of IN N
time NN N
spent VBN N
in IN N
the DT N
recovery NN N
room NN N
CONCLUSION NNP N
Topical NNP N
bupivacaine NN N
decreases VBZ N
postoperative JJ N
pain NN N
scores NNS N
significantly RB N
compared VBN N
with IN N
placebo NN N
in IN N
women NNS N
undergoing VBG N
laparoscopic NN N
tubal JJ N
sterilization NN N
with IN N
silastic JJ N
bands NNS N
-DOCSTART- -X- O O 10593347

Cholesterol-lowering JJ N
effect NN N
of IN N
stanol NN N
ester NN N
in IN N
a DT N
US NNP N
population NN N
of IN N
mildly RB 4_p
hypercholesterolemic JJ 4_p
men NNS 2_p
and CC N
women NNS 2_p
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
OBJECTIVE NN N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
stanol NN N
esters NNS N
in IN N
lowering VBG N
cholesterol NN N
in IN N
a DT N
US NNP N
population NN N
SUBJECTS NNP N
AND NNP N
METHODS NNP N
After IN N
a DT N
run-in JJ N
phase NN N
, , N
318 CD 3_p
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
margarine-like JJ N
spreads NNS N
containing VBG N
stanol JJ N
ester NN N
or CC N
placebo NN N
for IN N
8 CD N
weeks NNS N
: : N
EU NNP N
3 CD N
G NNP N
: : N
1 CD N
g NN N
of IN N
stanol NN N
( ( N
ester JJ N
form NN N
) ) N
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
European JJ N
formula NN N
3 CD N
times NNS N
a DT N
day NN N
; : N
US PRP N
3 CD N
G NNP N
: : N
1 CD N
g NN N
of IN N
stanol NN N
( ( N
ester JJ N
form NN N
) ) N
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
US NNP N
reformulation NN N
3 CD N
times NNS N
a DT N
day NN N
; : N
US PRP N
2 CD N
G NNP N
: : N
0.67 CD N
g NN N
of IN N
stanol NN N
( ( N
ester JJ N
form NN N
) ) N
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
US NNP N
reformulation NN N
3 CD N
times NNS N
a DT N
day NN N
; : N
or CC N
placebo VB N
spread NN N
RESULTS JJ N
Mean JJ N
+/- JJ N
SD NNP N
baseline NN N
total NN N
cholesterol NN N
( ( N
TC NNP N
) ) N
and CC N
low-density JJ N
lipoprotein NN N
cholesterol NN N
( ( N
LDL-C NNP N
) ) N
levels NNS N
were VBD N
233+/-20 JJ N
and CC N
153+21 CD N
mg+/-dL NN N
, , N
respectively RB N
In IN N
the DT N
US NNP N
3 CD N
G NNP N
group NN N
, , N
3 CD N
g JJ N
daily NN N
of IN N
stanol JJ N
esters NNS N
lowered VBD N
TC NNP N
and CC N
LDL-C NNP N
levels NNS N
by IN N
6.4 CD N
% NN N
and CC N
10.1 CD N
% NN N
, , N
respectively RB N
There EX N
was VBD N
a DT N
dose-dependent JJ N
response NN N
compared VBN N
with IN N
2 CD N
g NNS N
daily RB N
( ( N
US PRP N
2 CD N
G NNP N
) ) N
Triglyceride NNP N
and CC N
high-density NN N
lipoprotein NNS N
cholesterol NN N
levels NNS N
were VBD N
unchanged JJ N
The DT N
incidence NN N
of IN N
adverse JJ N
effects NNS N
was VBD N
not RB N
different JJ N
from IN N
placebo NN N
Serum NNP N
vitamin VBD N
A DT N
and CC N
25-hydroxyvitamin JJ N
D NNP N
levels NNS N
were VBD N
not RB N
affected VBN N
CONCLUSIONS NNP N
Stanol NNP N
esters NNS N
lowered VBD N
TC NNP N
and CC N
LDL-C NNP N
levels NNS N
in IN N
a DT N
mildly RB 4_p
hypercholesterolemic JJ 4_p
US NNP N
population NN N
without IN N
evidence NN N
of IN N
adverse JJ N
effects NNS N
It PRP N
may MD N
be VB N
a DT N
useful JJ N
dietary JJ N
adjunct NN N
to TO N
lower VB N
cholesterol NN N
-DOCSTART- -X- O O 23045243

Association NNP N
of IN N
severity NN N
of IN N
coexisting VBG N
patellofemoral JJ N
disease NN N
with IN N
increased JJ N
impairments NNS N
and CC N
functional JJ N
limitations NNS N
in IN N
patients NNS N
with IN N
knee JJ N
osteoarthritis NN N
OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
association NN N
between IN N
severity NN N
of IN N
coexisting VBG N
patellofemoral JJ N
( ( N
PF NNP N
) ) N
disease NN N
with IN N
lower JJR N
extremity NN N
impairments NNS N
and CC N
functional JJ N
limitations NNS N
in IN N
patients NNS N
with IN N
tibiofemoral JJ N
( ( N
TF NNP N
) ) N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
METHODS NNP N
Radiographic NNP N
views NNS N
of IN N
the DT N
TF NNP N
and CC N
PF NNP N
compartments NNS N
, , N
knee VB N
extension NN N
strength NN N
, , N
and CC N
knee VB N
range NN N
of IN N
motion NN N
were VBD N
obtained VBN N
for IN N
167 CD N
patients NNS N
with IN N
knee JJ N
OA NNP N
Additionally RB N
, , N
knee-specific JJ N
symptoms NNS N
and CC N
functional JJ N
limitations NNS N
were VBD N
assessed VBN N
using VBG N
the DT N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
Osteoarthritis NNP N
Index NNP N
( ( N
WOMAC NNP N
) ) N
and CC N
the DT N
Activities NNS N
of IN N
Daily NNP N
Living NNP N
Scale NNP N
( ( N
ADLS NNP N
) ) N
RESULTS NNP N
Moderate/severe NNP N
PFOA NNP N
was VBD N
associated VBN N
with IN N
lower JJR N
knee NN N
extension NN N
strength NN N
( ( N
mean JJ N
± NNP N
SD NNP N
1.4 CD N
± VBD N
0.5 CD N
Nm/body NNP N
weight VBD N
[ NNP N
BW NNP N
] NNP N
) ) N
compared VBN N
to TO N
no DT N
PFOA NNP N
( ( N
mean JJ N
± NNP N
SD NNP N
1.8 CD N
± VBD N
0.5 CD N
Nm/BW NNP N
) ) N
Additionally RB N
, , N
total JJ N
knee NN N
range NN N
of IN N
motion NN N
was VBD N
significantly RB N
lower JJR N
for IN N
patients NNS N
with IN N
moderate/severe JJ N
PFOA NNP N
( ( N
mean JJ N
± NNP N
SD NNP N
120.8° CD N
± NNP N
14.4° CD N
) ) N
compared VBN N
to TO N
no DT N
PFOA NNP N
( ( N
mean JJ N
± NNP N
SD NNP N
133.5° CD N
± NNP N
10.7° CD N
) ) N
and CC N
mild JJ N
PFOA NNP N
( ( N
mean JJ N
± NNP N
SD NNP N
125.8° CD N
± NNP N
13.0° CD N
) ) N
Moderate/severe NNP N
PFOA NNP N
and CC N
mild JJ N
PFOA NNP N
were VBD N
also RB N
associated VBN N
with IN N
less JJR N
pain NN N
while IN N
standing VBG N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] $ N
0.2 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ VBD N
95 CD N
% NN N
CI NNP N
] NNP N
0.1-0.7 JJ N
and CC N
OR NNP N
0.2 CD N
, , N
95 CD N
% NN N
CI NNP N
0.1-0.6 CD N
, , N
respectively RB N
) ) N
on IN N
the DT N
WOMAC NNP N
, , N
and CC N
moderate/severe RB N
PFOA NNP N
was VBD N
associated VBN N
with IN N
greater JJR N
difficulty NN N
with IN N
going VBG N
downstairs NNS N
( ( N
OR NNP N
2.9 CD N
, , N
95 CD N
% NN N
CI NNP N
1.0-8.1 CD N
) ) N
on IN N
the DT N
ADLS NNP N
CONCLUSION VB N
It PRP N
appears VBZ N
that IN N
knees NNS N
with IN N
more RBR N
severe JJ N
coexisting VBG N
PF NNP N
disease NN N
demonstrate NN N
features NNS N
distinct VBP N
from IN N
those DT N
observed VBN N
in IN N
TFOA NNP N
in IN N
isolation NN N
or CC N
in IN N
combination NN N
with IN N
mild JJ N
PF NNP N
disease NN N
Treatment NNP N
strategies VBZ N
targeting VBG N
the DT N
PF NNP N
joint NN N
may MD N
be VB N
warranted VBN N
to TO N
mitigate VB N
the DT N
specific JJ N
lower JJR N
extremity NN N
impairments NNS N
and CC N
functional JJ N
problems NNS N
present JJ N
in IN N
this DT N
patient JJ N
population NN N
-DOCSTART- -X- O O 9315428

Design NN N
of IN N
a DT N
cost-effectiveness NN N
study NN N
within IN N
a DT N
randomized JJ N
trial NN N
: : N
the DT N
LIPID NNP N
Trial NNP N
for IN N
Secondary NNP N
Prevention NNP N
of IN N
IHD NNP 4_p
Long-term JJ N
Intervention NN N
with IN N
Pravastatin NNP N
in IN N
Ischemic NNP N
Heart NNP N
disease NN N
The DT N
Long-term JJ N
Intervention NN N
with IN N
Pravastatin NNP N
in IN N
Ischemic NNP N
Heart NNP N
Disease NNP N
( ( N
LIPID NNP N
) ) N
trial NN N
is VBZ N
a DT N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
trial NN N
evaluating VBG N
the DT N
long-term JJ N
effect NN N
of IN N
pravastatin NN N
on IN N
coronary JJ N
mortality NN N
in IN N
patients NNS N
with IN N
a DT N
previous JJ N
myocardial JJ N
infarction NN N
or CC N
unstable JJ N
angina-ischemic JJ N
heart NN N
disease NN N
( ( N
IHD NNP N
) ) N
It PRP N
is VBZ N
planned VBN N
to TO N
run VB N
for IN N
at IN N
least JJS N
five CD N
years NNS N
with IN N
9014 CD N
patients NNS N
from IN N
85 CD N
centers NNS N
in IN N
Australia NNP N
and CC N
New NNP N
Zealand NNP N
The DT N
trial NN N
will MD N
monitor VB N
cause-specific JJ N
mortality NN N
and CC N
major JJ N
clinical JJ N
events NNS N
associated VBN N
with IN N
each DT N
treatment NN N
Running VBG N
in IN N
parallel NN N
with IN N
the DT N
main JJ N
study NN N
is VBZ N
a DT N
prospective JJ N
economic JJ N
analysis NN N
, , N
the DT N
objectives NNS N
of IN N
which WDT N
are VBP N
( ( N
1 CD N
) ) N
to TO N
estimate VB N
the DT N
effectiveness NN N
of IN N
pravastatin NN N
compared VBN N
with IN N
placebo NN N
in IN N
terms NNS N
of IN N
survival NN N
, , N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
, , N
and CC N
quality-adjusted JJ N
life-years NNS N
( ( N
QALY NNP N
) ) N
; : N
( ( N
2 CD N
) ) N
to TO N
estimate VB N
the DT N
resource NN N
usage NN N
associated VBN N
with IN N
pravastatin NNS N
compared VBN N
with IN N
placebo-in JJ N
particular JJ N
, , N
to TO N
study VB N
whether IN N
it PRP N
alters VBZ N
resource JJ N
usage NN N
through IN N
prevention NN N
of IN N
disease NN N
progression NN N
; : N
and CC N
( ( N
3 CD N
) ) N
to TO N
use VB N
this DT N
information NN N
for IN N
a DT N
cost-utility JJ N
analysis NN N
with IN N
cost NN N
per IN N
quality-adjusted JJ N
life-year JJ N
as IN N
the DT N
unit NN N
of IN N
analysis NN N
A DT N
novel JJ N
aspect NN N
of IN N
the DT N
design NN N
is VBZ N
the DT N
use NN N
of IN N
a DT N
preliminary JJ N
cost-effectiveness NN N
analysis NN N
, , N
based VBN N
on IN N
" JJ N
best-guess JJ N
" NN N
values NNS N
, , N
and CC N
a DT N
sensitivity NN N
analysis NN N
over IN N
plausible JJ N
ranges NNS N
to TO N
guide VB N
the DT N
choice NN N
of IN N
subsample JJ N
size NN N
Some DT N
data NNS N
, , N
such PDT N
a DT N
mortality NN N
, , N
days NNS N
spent VBD N
in IN N
hospital NN N
, , N
major JJ N
clinical JJ N
events NNS N
, , N
and CC N
drug NN N
use NN N
, , N
are VBP N
being VBG N
collected VBN N
within IN N
the DT N
main JJ N
LIPID NNP N
trial NN N
However RB N
, , N
additional JJ N
subsamples NNS N
for IN N
the DT N
cost-effectiveness NN N
study NN N
will MD N
include VB N
information NN N
on IN N
quality NN N
of IN N
life NN N
, , N
time NN N
off RP N
work NN N
, , N
and CC N
resources NNS N
used VBN N
, , N
such JJ N
as IN N
time NN N
in IN N
hospital NN N
, , N
procedures NNS N
, , N
and CC N
medications NNS N
taken VBN N
The DT N
methods NNS N
and CC N
sample NN N
sizes NNS N
for IN N
these DT N
substudies NNS N
have VBP N
been VBN N
a DT N
crucial JJ N
issue NN N
in IN N
validity NN N
and CC N
feasibility NN N
-DOCSTART- -X- O O 22079469

Evaluation NN N
of IN N
oral JJ N
beclomethasone NN N
dipropionate NN N
for IN N
prevention NN N
of IN N
acute JJ N
graft-versus-host JJ N
disease NN N
Results NNS N
from IN N
two CD N
randomized JJ N
trials NNS N
have VBP N
shown VBN N
that IN N
oral JJ N
beclomethasone NN N
dipropionate NN N
( ( N
BDP NNP N
) ) N
is VBZ N
effective JJ N
for IN N
treatment NN N
of IN N
acute JJ N
gastrointestinal JJ N
graft-versus-host NN N
disease NN N
Here RB N
, , N
we PRP N
report VBP N
results NNS N
of IN N
a DT N
double-blind NN N
, , N
randomized VBN N
placebo-controlled JJ N
phase NN N
II NNP N
study NN N
designed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
acute VBZ N
graft-versus-host JJ N
disease NN N
could MD N
be VB N
prevented VBN N
by IN N
administration NN N
of IN N
oral JJ N
BDP NNP N
, , N
beginning VBG N
before IN N
hematopoietic JJ N
cell NN N
transplantation NN N
and CC N
continuing VBG N
until IN N
day NN N
75 CD N
after IN N
hematopoietic JJ N
cell NN N
transplantation NN N
after IN N
myeloablative JJ N
conditioning NN N
Study NNP N
drug NN N
( ( N
BDP NNP N
or CC N
placebo NN N
) ) N
was VBD N
administered VBN N
as IN N
1-mg JJ N
immediate-release JJ N
formulation NN N
plus IN N
1-mg JJ N
delayed-release JJ N
formulation NN N
orally RB N
four CD N
times NNS N
daily RB N
According VBG N
to TO N
the DT N
primary JJ N
endpoint NN N
, , N
systemic JJ N
glucocorticoid NN N
treatment NN N
for IN N
graft-versus-host JJ N
disease NN N
was VBD N
given VBN N
to TO N
60 CD N
of IN N
the DT N
92 CD N
participants NNS N
( ( N
65 CD N
% NN N
) ) N
in IN N
the DT N
BDP NNP N
arm NN N
, , N
versus NN N
31 CD N
of IN N
46 CD N
participants NNS N
( ( N
67 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
arm NN N
The DT N
secondary JJ N
efficacy NN N
endpoints NNS N
showed VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
arms NNS N
The DT N
proportion NN N
of IN N
participants NNS N
who WP N
took VBD N
at IN N
least JJS N
90 CD N
% NN N
of IN N
the DT N
prescribed JJ N
study JJ N
drug NN N
during IN N
the DT N
first JJ N
4 CD N
weeks NNS N
after IN N
hematopoietic JJ N
cell NN N
transplantation NN N
was VBD N
54 CD N
% NN N
overall JJ N
Lower JJR N
severity NN N
of IN N
mucositis NN N
strongly RB N
correlated VBN N
with IN N
higher JJR N
adherence NN N
to TO N
the DT N
schedule NN N
of IN N
study JJ N
drug NN N
administration NN N
Inconsistent JJ N
adherence NN N
related VBN N
to TO N
mucositis VB N
during IN N
recovery NN N
after IN N
myeloablative JJ N
conditioning NN N
may MD N
have VB N
obscured VBN N
a DT N
beneficial JJ N
therapeutic JJ N
effect NN N
in IN N
the DT N
current JJ N
study NN N
-DOCSTART- -X- O O 11867842

Effect NN N
of IN N
delayed JJ N
cord NN N
clamping VBG N
on IN N
iron NN N
stores NNS N
in IN N
infants NNS 1_p
born VBN 4_p
to TO 4_p
anemic JJ 4_p
mothers NNS 4_p
: : 4_p
a DT N
randomized NN N
controlled VBN N
trial NN N
OBJECTIVE UH N
To TO N
study VB N
the DT N
effects NNS N
of IN N
cord NN N
clamping VBG N
on IN N
iron NN N
stores NNS N
of IN N
infants NNS N
born VBN N
to TO N
anemic VB N
mothers NNS N
at IN N
3 CD N
months NNS N
of IN N
age NN N
DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
SETTING NN N
Teaching NNP N
hospital NN N
METHODS NNP N
Infants NNPS N
born VBN N
to TO N
mothers NNS N
with IN N
hemoglobin NN N
( ( N
Hb NNP N
) ) N
< VBD N
100 CD N
g/L NNS N
were VBD N
randomized VBN N
at IN N
delivery NN N
to TO N
either DT N
immediate JJ N
cord NN N
clamping NN N
( ( N
early JJ N
group NN N
) ) N
or CC N
cord NN N
clamping VBG N
delayed VBN N
till JJ N
descent NN N
of IN N
placenta NN N
into IN N
vagina NN N
( ( N
delayed VBN N
group NN N
) ) N
The DT N
outcome NN N
measures NNS N
were VBD N
infant NN N
's POS N
hemoglobin NN N
and CC N
serum NN N
ferritin VBP N
3 CD N
months NNS N
after IN N
delivery NN N
RESULTS CC N
There EX N
were VBD N
102 CD N
neonates NNS N
randomized VBN N
to TO N
early JJ N
( ( N
n JJ N
= NNP N
43 CD N
) ) N
or CC N
delayed VBN N
cord NN N
clamping NN N
( ( N
n JJ N
= NNP N
59 CD N
) ) N
The DT N
groups NNS N
were VBD N
comparable JJ N
for IN N
maternal JJ N
age NN N
, , N
parity NN N
, , N
weight NN N
and CC N
supplemental JJ N
iron NN N
intake NN N
, , N
infant JJ N
s NN N
birth NN N
weight NN N
, , N
gestation NN N
and CC N
sex NN N
The DT N
mean JJ N
infant NN N
ferritin NN N
and CC N
Hb NNP N
at IN N
3 CD N
months NNS N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
delayed JJ N
clamping NN N
group NN N
( ( N
118.4 CD N
microg/L NN N
and CC N
99 CD N
g/L NN N
) ) N
than IN N
in IN N
the DT N
early JJ N
clamping NN N
group NN N
( ( N
73 CD N
microg/L NN N
and CC N
88 CD N
g/L NN N
) ) N
The DT N
mean JJ N
decrease NN N
in IN N
Hb NNP N
( ( N
g/L NN N
) ) N
at IN N
3 CD N
months NNS N
adjusted VBN N
for IN N
co-variates NNS N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
delayed JJ N
clamping NN N
group NN N
compared VBN N
to TO N
the DT N
early JJ N
clamping NN N
group NN N
( ( N
-1.09 NNP N
, , N
95 CD N
% NN N
CI-1.58 NNP N
to TO N
-0.62 VB N
, , N
p VB N
> NNP N
0.001 CD N
) ) N
The DT N
odds NNS N
for IN N
anemia NN N
( ( N
< JJ N
100 CD N
g/L NN N
) ) N
at IN N
3 CD N
months NNS N
was VBD N
7.7 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.84-34.9 CD N
) ) N
times NNS N
higher RBR N
in IN N
the DT N
early JJ N
compared VBN N
to TO N
the DT N
delayed JJ N
clamping NN N
group NN N
CONCLUSION NNP N
Iron NNP N
stores NNS N
and CC N
Hb NNP N
in IN N
infancy NN N
can MD N
be VB N
improved VBN N
in IN N
neonates NNS N
born VBN N
to TO N
anemic VB N
mothers NNS N
by IN N
delaying VBG N
cord NN N
clamping NN N
at IN N
birth NN N
-DOCSTART- -X- O O 3812946

Intravenous JJ N
regional JJ N
anaesthesia NN N
below IN N
the DT N
knee NN N
A DT N
cross-over JJ N
study NN N
with IN N
prilocaine NN N
in IN N
volunteers NNS N
The DT N
quality NN N
of IN N
anaesthesia NN N
provided VBN N
by IN N
three CD N
dosages NNS N
of IN N
prilocaine NN N
, , N
40 CD N
ml VBD N
0.5 CD N
% NN N
, , N
20 CD N
ml VBD N
1 CD N
% NN N
, , N
or CC N
40 CD N
ml JJ N
1 CD N
% NN N
, , N
administered VBN N
in IN N
random NN N
order NN N
, , N
for IN N
intravenous JJ N
regional JJ N
anaesthesia NN N
of IN N
the DT N
lower JJR N
extremity NN N
below IN N
the DT N
knee NN N
was VBD N
compared VBN N
in IN N
six CD 3_p
volunteers NNS N
Limited JJ N
sensory NN N
blockade NN N
was VBD N
achieved VBN N
in IN N
the DT N
groups NNS N
with IN N
40 CD N
ml NNS N
0.5 CD N
% NN N
and CC N
20 CD N
ml NNS N
1 CD N
% NN N
during IN N
the DT N
30-minute JJ N
test NN N
period NN N
One CD N
subject NN N
was VBD N
not RB N
fully RB N
anaesthetised VBN N
with IN N
any DT N
of IN N
the DT N
dosages NNS N
used VBN N
Recovery NNP N
was VBD N
rapid JJ N
( ( N
mean JJ N
12-13 CD N
minutes NNS N
) ) N
in IN N
these DT N
two CD N
groups NNS N
In IN N
two CD N
subjects NNS N
given VBN N
40 CD N
ml NN N
of IN N
1 CD N
% NN N
, , N
complete JJ N
recovery NN N
took VBD N
90 CD N
minutes NNS N
At IN N
30 CD N
minutes NNS N
, , N
the DT N
degree NN N
of IN N
flexion NN N
remaining VBG N
in IN N
the DT N
great JJ N
toe NN N
( ( N
control VB N
100 CD N
% NN N
) ) N
was VBD N
4 CD N
% NN N
in IN N
the DT N
groups NNS N
who WP N
received VBD N
40 CD N
ml NN N
of IN N
0.5 CD N
% NN N
and CC N
1 CD N
% NN N
, , N
but CC N
34 CD N
% NN N
in IN N
those DT N
who WP N
received VBD N
20 CD N
ml NN N
of IN N
1 CD N
% NN N
respectively RB N
Full NNP N
motor NN N
recovery NN N
was VBD N
achieved VBN N
in IN N
8-9 JJ N
minutes NNS N
Five CD N
of IN N
six CD N
volunteers NNS N
who WP N
received VBD N
the DT N
400-mg JJ N
dose NN N
experienced VBD N
subjective JJ N
signs NNS N
of IN N
central JJ N
nervous JJ N
system NN N
side NN N
effects NNS N
when WRB N
the DT N
cuff NN N
was VBD N
released VBN N
In IN N
this DT N
group NN N
, , N
the DT N
mean JJ N
plasma JJ N
level NN N
of IN N
prilocaine NN N
at IN N
2 CD N
minutes NNS N
was VBD N
1.22 CD N
micrograms/ml NN N
, , N
maximum JJ N
2.12 CD N
micrograms/ml NN N
In IN N
a DT N
radiological JJ N
examination NN N
, , N
no DT N
leak NN N
of IN N
contrast NN N
medium NN N
under IN N
the DT N
tourniquet NN N
cuff NN N
( ( N
300 CD N
mmHg NN N
) ) N
was VBD N
detected VBN N
The DT N
development NN N
of IN N
anaesthesia NN N
was VBD N
fastest JJS N
following VBG N
the DT N
largest JJS N
dose NN N
, , N
but CC N
the DT N
large JJ N
number NN N
of IN N
central JJ N
side NN N
effects NNS N
makes VBZ N
that IN N
dosage NN N
less RBR N
suitable JJ N
for IN N
clinical JJ N
work NN N
-DOCSTART- -X- O O 2205798

Reduced VBN N
mortality NN N
among IN N
children NNS 4_p
in IN 4_p
southern JJ 4_p
India NNP 4_p
receiving VBG 4_p
a DT 4_p
small JJ 4_p
weekly JJ 4_p
dose NN 4_p
of IN 4_p
vitamin NN 4_p
A NNP 4_p
BACKGROUND NNP N
Clinical NNP N
vitamin VBD N
A DT N
deficiency NN N
affects VBZ N
millions NNS N
of IN N
children NNS N
worldwide IN N
, , N
and CC N
subclinical JJ N
deficiency NN N
is VBZ N
even RB N
more RBR N
common JJ N
Supplemental JJ N
vitamin NN N
A NNP N
has VBZ N
been VBN N
reported VBN N
to TO N
reduce VB N
mortality NN N
among IN N
these DT N
children NNS N
, , N
but CC N
the DT N
results NNS N
have VBP N
been VBN N
questioned VBN N
METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
controlled VBN N
, , N
masked VBD N
clinical JJ N
trial NN N
for IN N
one CD N
year NN N
in IN N
southern JJ N
India NNP N
involving VBG N
15,419 CD N
preschool-age JJ N
children NNS N
who WP N
received VBD N
either CC N
8.7 CD N
mumol NN N
( ( N
8333 CD N
IU NNP N
) ) N
of IN N
vitamin NN N
A NNP N
and CC N
46 CD N
mumol NN N
( ( N
20 CD N
mg NN N
) ) N
of IN N
vitamin NN N
E NNP N
( ( N
the DT N
treated VBN N
group NN N
) ) N
or CC N
vitamin JJ N
E NNP N
alone RB N
( ( N
the DT N
control NN N
group NN N
) ) N
Vitamin JJ N
supplements NNS N
were VBD N
delivered VBN N
weekly JJ N
by IN N
community NN N
health NN N
volunteers NNS N
who WP N
also RB N
recorded VBD N
mortality NN N
and CC N
morbidity NN N
Weekly JJ N
contact NN N
was VBD N
made VBN N
with IN N
at IN N
least JJS N
88 CD N
percent NN N
of IN N
the DT N
children NNS N
in IN N
both DT N
study NN N
groups NNS N
The DT N
base-line JJ N
characteristics NNS N
of IN N
the DT N
children NNS N
were VBD N
similar JJ N
and CC N
documented VBD N
a DT N
high JJ N
prevalence NN N
of IN N
vitamin NN N
A NNP N
deficiency NN N
and CC N
undernutrition NN N
RESULTS NNP N
One CD N
hundred VBD N
twenty-five JJ N
deaths NNS N
occurred VBD N
, , N
of IN N
which WDT N
117 CD N
were VBD N
not RB N
accidental JJ N
The DT N
risk NN N
of IN N
death NN N
in IN N
the DT N
group NN N
treated VBD N
with IN N
vitamin NN N
A NNP N
was VBD N
less JJR N
than IN N
half NN N
that IN N
in IN N
the DT N
control NN N
group NN N
( ( N
relative JJ N
risk NN N
, , N
0.46 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.30 CD N
to TO N
0.71 CD N
) ) N
The DT N
risk NN N
was VBD N
most RBS N
reduced JJ N
among IN N
children NNS N
under IN N
3 CD N
years NNS N
of IN N
age NN N
( ( N
6 CD N
to TO N
11 CD N
months NNS N
-- : N
relative JJ N
risk NN N
, , N
0.28 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.09 CD N
to TO N
0.85 CD N
; : N
12 CD N
to TO N
35 CD N
months NNS N
-- : N
relative JJ N
risk NN N
, , N
0.46 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.26 CD N
to TO N
0.81 CD N
) ) N
and CC N
among IN N
those DT N
who WP N
were VBD N
chronically RB N
undernourished JJ N
, , N
as IN N
manifested VBN N
by IN N
stunting VBG N
( ( N
relative JJ N
risk NN N
, , N
0.11 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.03 CD N
to TO N
0.36 CD N
) ) N
The DT N
symptom-specific JJ N
risk NN N
of IN N
mortality NN N
was VBD N
significantly RB N
associated VBN N
with IN N
diarrhea NN N
, , N
convulsions NNS N
, , N
and CC N
other JJ N
infection-related JJ N
symptoms NNS N
CONCLUSIONS VB N
The DT N
regular JJ N
provision NN N
of IN N
a DT N
supplement NN N
of IN N
vitamin NN N
A NNP N
to TO N
children NNS N
, , N
at IN N
a DT N
level NN N
potentially RB N
obtainable JJ N
from IN N
foods NNS N
, , N
in IN N
an DT N
area NN N
where WRB N
vitamin NN N
A DT N
deficiency NN N
and CC N
under-nutrition NN N
are VBP N
documented VBN N
public JJ N
health NN N
problems NNS N
contributed VBD N
substantially RB N
to TO N
children NNS N
's POS N
survival NN N
; : N
mortality NN N
was VBD N
reduced VBN N
on IN N
average NN N
by IN N
54 CD N
percent NN N
-DOCSTART- -X- O O 11085402

Use NNP N
of IN N
World NNP N
Wide NNP N
Web-based JJ N
directories NNS N
for IN N
tracing VBG N
subjects NNS 4_p
in IN 4_p
epidemiologic JJ 4_p
studies NNS 4_p
The DT N
recent JJ N
availability NN N
of IN N
World NNP N
Wide NNP N
Web-based JJ N
directories NNS N
has VBZ N
opened VBN N
up RP N
a DT N
new JJ N
approach NN N
for IN N
tracing VBG N
subjects NNS N
in IN N
epidemiologic JJ N
studies NNS N
The DT N
completeness NN N
of IN N
two CD N
World NNP N
Wide NNP N
Web-based JJ N
directories NNS N
( ( N
Canada411 NNP N
and CC N
InfoSpace NNP N
Canada NNP N
) ) N
for IN N
subject JJ N
tracing NN N
was VBD N
evaluated VBN N
by IN N
using VBG N
a DT N
randomized VBN N
crossover NN N
design NN N
for IN N
346 CD 3_p
adults NNS 1_p
randomly RB N
selected VBN N
from IN N
respondents NNS N
in IN N
an DT N
ongoing JJ N
cohort NN N
study NN N
About IN N
half NN N
( ( N
56.4 CD N
% NN N
) ) N
of IN N
the DT N
subjects NNS N
were VBD N
successfully RB N
located VBN N
by IN N
using VBG N
either CC N
Canada411 NNP N
or CC N
InfoSpace NNP N
Of IN N
the DT N
43.6 CD N
% NN N
of IN N
the DT N
subjects NNS N
who WP N
could MD N
not RB N
be VB N
located VBN N
using VBG N
either CC N
directory NN N
, , N
the DT N
majority NN N
( ( N
73.5 CD N
% NN N
) ) N
were VBD N
female JJ N
Overall JJ N
, , N
there EX N
was VBD N
no DT N
clear JJ N
advantage NN N
of IN N
one CD N
directory NN N
over IN N
the DT N
other JJ N
Although IN N
Canada411 NNP N
could MD N
find VB N
significantly RB N
more RBR N
subjects NNS N
than IN N
InfoSpace NNP N
, , N
the DT N
number NN N
of IN N
potential JJ N
matches NNS N
returned VBN N
by IN N
Canada411 NNP N
was VBD N
also RB N
higher JJR N
, , N
which WDT N
meant VBD N
that IN N
a DT N
longer RBR N
list NN N
of IN N
potential JJ N
matches NNS N
had VBD N
to TO N
be VB N
examined VBN N
before IN N
a DT N
true JJ N
match NN N
could MD N
be VB N
found VBN N
One CD N
strategy NN N
to TO N
minimize VB N
the DT N
number NN N
of IN N
potential JJ N
matches NNS N
per IN N
true JJ N
match NN N
is VBZ N
to TO N
first JJ N
search NN N
by IN N
InfoSpace NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
name NN N
, , N
then RB N
by IN N
Canada411 NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
name NN N
, , N
and CC N
finally RB N
by IN N
InfoSpace NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
initial JJ N
Internet-based JJ N
searches NNS N
represent VBP N
a DT N
potentially RB N
useful JJ N
approach NN N
to TO N
tracing VBG N
subjects NNS N
in IN N
epidemiologic JJ N
studies NNS N
-DOCSTART- -X- O O 10807619

Randomised VBN N
, , N
double JJ N
blind NN N
, , N
placebo NN N
controlled VBD N
study NN N
of IN N
fluticasone NN N
propionate NN N
in IN N
patients NNS N
with IN N
moderate JJ 4_p
to TO 4_p
severe VB 4_p
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
: : N
the DT N
ISOLDE NNP N
trial NN N
OBJECTIVES UH N
To TO N
determine VB N
the DT N
effect NN N
of IN N
long JJ N
term NN N
inhaled VBN N
corticosteroids NNS N
on IN N
lung NN N
function NN N
, , N
exacerbations NNS N
, , N
and CC N
health NN N
status NN N
in IN N
patients NNS N
with IN N
moderate JJ 4_p
to TO 4_p
severe VB 4_p
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
DESIGN NNP N
Double NNP N
blind NN N
, , N
placebo NN N
controlled VBD N
study NN N
SETTING NNP N
Eighteen NNP N
UK NNP N
hospitals NNS N
PARTICIPANTS VB N
751 CD N
men NNS 2_p
and CC N
women NNS 2_p
aged VBD 1_p
between IN 1_p
40 CD 1_p
and CC 1_p
75 CD 1_p
years NNS 1_p
with IN N
mean NN N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
( ( N
FEV NNP N
( ( N
1 CD N
) ) N
) ) N
50 CD N
% NN N
of IN N
predicted VBN N
normal JJ N
INTERVENTIONS NNP N
Inhaled VBD N
fluticasone NN N
propionate NN N
500 CD N
microgram NN N
twice RB N
daily RB N
from IN N
a DT N
metered VBN N
dose JJ N
inhaler NN N
or CC N
identical JJ N
placebo NN N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Efficacy NNP N
measures NNS N
: : N
rate NN N
of IN N
decline NN N
in IN N
FEV NNP N
( ( N
1 CD N
) ) N
after IN N
the DT N
bronchodilator NN N
and CC N
in IN N
health NN N
status NN N
, , N
frequency NN N
of IN N
exacerbations NNS N
, , N
respiratory JJ N
withdrawals NNS N
Safety NN N
measures NNS N
: : N
morning NN N
serum NN N
cortisol NN N
concentration NN N
, , N
incidence NN N
of IN N
adverse JJ N
events NNS N
RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
annual JJ N
rate NN N
of IN N
decline NN N
in IN N
FEV NNP N
( ( N
1 CD N
) ) N
( ( N
P=0.16 NNP N
) ) N
Mean JJ N
FEV NNP N
( ( N
1 CD N
) ) N
after IN N
bronchodilator NN N
remained VBD N
significantly RB N
higher JJR N
throughout IN N
the DT N
study NN N
with IN N
fluticasone NN N
propionate NN N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
Median JJ N
exacerbation NN N
rate NN N
was VBD N
reduced VBN N
by IN N
25 CD N
% NN N
from IN N
1.32 CD N
a DT N
year NN N
on IN N
placebo NN N
to TO N
0.99 CD N
a DT N
year NN N
on IN N
with IN N
fluticasone NN N
propionate NN N
( ( N
P=0.026 NNP N
) ) N
Health NNP N
status NN N
deteriorated VBN N
by IN N
3.2 CD N
units NNS N
a DT N
year NN N
on IN N
placebo NN N
and CC N
2.0 CD N
units NNS N
a DT N
year NN N
on IN N
fluticasone NN N
propionate NN N
( ( N
P=0.0043 NNP N
) ) N
Withdrawals NNS N
because IN N
of IN N
respiratory NN N
disease NN N
not RB N
related VBN N
to TO N
malignancy NN N
were VBD N
higher JJR N
in IN N
the DT N
placebo NN N
group NN N
( ( N
25 CD N
% NN N
v JJ N
19 CD N
% NN N
, , N
P=0.034 NNP N
) ) N
CONCLUSIONS NNP N
Fluticasone NNP N
propionate NN N
500 CD N
microgram NN N
twice RB N
daily RB N
did VBD N
not RB N
affect VB N
the DT N
rate NN N
of IN N
decline NN N
in IN N
FEV NNP N
( ( N
1 CD N
) ) N
but CC N
did VBD N
produce VB N
a DT N
small JJ N
increase NN N
in IN N
FEV NNP N
( ( N
1 CD N
) ) N
Patients NNS N
on IN N
fluticasone NN N
propionate NN N
had VBD N
fewer JJR N
exacerbations NNS N
and CC N
a DT N
slower JJR N
decline NN N
in IN N
health NN N
status NN N
These DT N
improvements NNS N
in IN N
clinical JJ N
outcomes NNS N
support VBP N
the DT N
use NN N
of IN N
this DT N
treatment NN N
in IN N
patients NNS N
with IN N
moderate JJ 4_p
to TO 4_p
severe VB 4_p
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
-DOCSTART- -X- O O 18561117

Onset NNP N
of IN N
action NN N
of IN N
ciclesonide NN N
once RB N
daily RB N
in IN N
the DT N
treatment NN N
of IN N
seasonal JJ N
allergic JJ N
rhinitis NN N
Ciclesonide NNP N
is VBZ N
an DT N
intranasal JJ N
corticosteroid NN N
approved VBD N
for IN N
the DT N
treatment NN N
of IN N
allergic JJ N
rhinitis NN N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ N
study NN N
to TO N
evaluate VB N
the DT N
time NN N
to TO N
onset VB N
of IN N
action NN N
of IN N
ciclesonide NN N
200 CD N
microg NN N
once RB N
daily RB N
in IN N
502 CD 3_p
adults NNS N
with IN N
seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
of IN N
at IN N
least JJS N
2 CD N
years NNS N
' POS N
duration NN N
To TO N
trigger VB N
immunologic JJ N
priming NN N
, , N
patients NNS N
underwent VBP N
between IN N
one CD N
and CC N
five CD N
priming NN N
sessions NNS N
with IN N
exposure NN N
to TO N
3,500 CD N
grains/m NN N
( ( N
3 CD N
) ) N
( ( N
+/-500 JJ N
) ) N
of IN N
ragweed NN N
pollen NN N
in IN N
an DT N
environmental JJ N
exposure NN N
chamber NN N
The DT N
criteria NN N
for IN N
a DT N
successful JJ N
priming NN N
session NN N
were VBD N
a DT N
patient-assessed JJ N
instantaneous JJ N
total NN N
nasal NN N
symptom VBD N
score NN N
of IN N
at IN N
least JJS N
6 CD N
( ( N
of IN N
a DT N
possible JJ N
12 CD N
) ) N
and CC N
a DT N
nasal JJ N
congestion NN N
or CC N
rhinorrhea VB N
score NN N
of IN N
at IN N
least JJS N
2 CD N
( ( N
of IN N
a DT N
possible JJ N
3 CD N
) ) N
90 CD N
minutes NNS N
after IN N
allergen NN N
exposure NN N
during IN N
at IN N
least JJS N
two CD N
consecutive JJ N
priming NN N
sessions NNS N
Patients NNS N
were VBD N
then RB N
randomly RB N
assigned VBN N
to TO N
receive VB N
either CC N
a DT N
single JJ N
dose NN N
of IN N
ciclesonide JJ N
200 CD N
microg NN N
( ( N
n JJ N
= NNP N
251 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
251 CD N
) ) N
administered VBN N
intranasally RB N
The DT N
difference NN N
in IN N
the DT N
change NN N
from IN N
baseline NN N
total JJ N
nasal JJ N
symptom NN N
scores NNS N
in IN N
the DT N
two CD N
groups NNS N
was VBD N
assessed VBN N
hourly RB N
for IN N
12 CD N
hours NNS N
after IN N
administration NN N
Onset NNP N
of IN N
action NN N
was VBD N
determined VBN N
to TO N
have VB N
taken VBN N
place NN N
the DT N
first JJ N
time NN N
that IN N
the DT N
effects NNS N
of IN N
ciclesonide NN N
, , N
as IN N
reflected VBN N
in IN N
the DT N
total JJ N
nasal JJ N
symptom NN N
score NN N
, , N
were VBD N
significantly RB N
greater JJR N
than IN N
those DT N
of IN N
placebo NN N
at IN N
a DT N
particular JJ N
hourly JJ N
assessment NN N
, , N
provided VBD N
that IN N
the DT N
subsequent JJ N
hourly NN N
assessment NN N
also RB N
showed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
The DT N
onset NN N
of IN N
action NN N
of IN N
ciclesonide NN N
occurred VBD N
within IN N
1 CD N
hour NN N
of IN N
administration NN N
( ( N
p JJ N
= $ N
0.01 CD N
vs. FW N
placebo NN N
) ) N
, , N
and CC N
the DT N
significant JJ N
difference NN N
in IN N
total JJ N
nasal JJ N
symptom NN N
scores NNS N
between IN N
ciclesonide NN N
and CC N
placebo NN N
was VBD N
maintained VBN N
through IN N
post-treatment JJ N
hour NN N
12 CD N
( ( N
p NN N
= RB N
0.018 CD N
) ) N
-DOCSTART- -X- O O 18339525

Pentoxifylline NN N
to TO N
treat VB N
radiation NN 4_p
proctitis NN 4_p
: : N
a DT N
small JJ N
and CC N
inconclusive JJ N
randomised VBN N
trial NN N
This DT N
prospective JJ N
randomised VBN N
controlled VBN N
study NN 3_p
of IN 3_p
40 CD 3_p
patients NNS 3_p
could MD N
not RB N
show VB N
a DT N
statistically RB N
significant JJ N
advantage NN N
with IN N
6 CD N
months NNS N
of IN N
pentoxifylline NN N
compared VBN N
with IN N
standard JJ N
measures NNS N
for IN N
late JJ N
radiation-induced JJ N
rectal NN N
bleeding NN N
However RB N
, , N
a DT N
modest JJ N
benefit NN N
can MD N
not RB N
be VB N
excluded VBN N
and CC N
larger JJR N
randomised VBD N
placebo-controlled JJ N
trials NNS N
with IN N
longer JJR N
durations NNS N
of IN N
pentoxifylline JJ N
treatment NN N
may MD N
be VB N
justified VBN N
-DOCSTART- -X- O O 11396751

A DT N
comparative JJ N
study NN N
of IN N
caudal JJ N
bupivacaine NN N
and CC N
midazolam-bupivacaine JJ N
mixture NN N
for IN N
post-operative JJ N
analgesia NN N
in IN N
children NNS 4_p
undergoing VBG 4_p
genitourinary JJ 4_p
surgery NN 4_p
OBJECTIVE CC N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
analgesic JJ N
efficacy NN N
of IN N
caudal JJ N
midazolam-bupivacaine JJ N
combination NN N
in IN N
providing VBG N
post-operative JJ N
pain NN N
relief NN N
in IN N
children NNS N
undergoing VBG N
genitourinary JJ N
surgery NN N
and CC N
to TO N
study VB N
the DT N
occurrence NN N
of IN N
adverse JJ N
effects NNS N
SUBJECTS NNP N
AND NNP N
METHODS NNP N
Thirty NNP N
children NNS N
, , N
aged VBD N
2 CD N
to TO N
8 CD N
years NNS N
, , N
scheduled VBN N
for IN N
genitourinary JJ N
surgery NN N
were VBD N
allocated VBN N
randomly RB N
to TO N
receive VB N
either RB N
0.25 CD N
% NN N
bupivacaine NN N
0.5 CD N
ml/kg NN N
( ( N
group NN N
B NNP N
; : N
n CC N
= VB N
15 CD N
) ) N
or CC N
0.25 CD N
% NN N
bupivacaine NN N
0.5 CD N
ml/kg NN N
with IN N
50 CD N
microg/kg NNS N
midazolam NN N
( ( N
group NN N
BM NNP N
; : N
n CC N
= VB N
15 CD N
) ) N
by IN N
the DT N
caudal JJ N
route NN N
immediately RB N
after IN N
induction NN N
of IN N
general JJ N
anesthesia NN N
Heart NNP N
rate NN N
, , N
arterial JJ N
blood NN N
pressure NN N
and CC N
oxygen NN N
saturation NN N
were VBD N
monitored VBN N
throughout IN N
the DT N
study NN N
period NN N
Postoperative JJ N
pain NN N
was VBD N
assessed VBN N
at IN N
regular JJ N
intervals NNS N
for IN N
12 CD N
hours NNS N
using VBG N
an DT N
objective JJ N
pain NN N
score NN N
Analgesia NNP N
was VBD N
supplemented VBN N
whenever IN N
the DT N
pain NN N
score NN N
was VBD N
> JJ N
or CC N
= JJ N
4 CD N
Duration NN N
of IN N
analgesia NN N
, , N
as RB N
well RB N
as IN N
the DT N
requirement NN N
of IN N
additional JJ N
analgesics NNS N
, , N
were VBD N
noted VBN N
RESULTS NNP N
Lowest NNP N
pain NN N
scores NNS N
were VBD N
observed VBN N
with IN N
the DT N
addition NN N
of IN N
midazolam NN N
to TO N
caudal VB N
bupivacaine NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
Duration NN N
of IN N
analgesia NN N
was VBD N
longer RBR N
in IN N
group NN N
BM NNP N
( ( N
11 CD N
+/- JJ N
0.5 CD N
h NN N
) ) N
as IN N
compared VBN N
to TO N
group NN N
B NNP N
( ( N
7.4 CD N
+/- JJ N
2.1 CD N
hours NNS N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
Fewer JJR N
children NNS N
( ( N
26.6 CD N
% NN N
) ) N
required VBD N
additional JJ N
analgesia NN N
in IN N
the DT N
combination NN N
group NN N
whereas VBZ N
in IN N
group NN N
B NNP N
, , N
60 CD N
% NN N
of IN N
the DT N
children NNS N
received VBD N
analgesic JJ N
supplements NNS N
within IN N
6 CD N
hours NNS N
after IN N
surgery NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
heart NN N
rate NN N
, , N
blood NN N
pressure NN N
and CC N
oxygen NN N
saturation NN N
in IN N
both DT N
groups NNS N
We PRP N
observed VBD N
no DT N
untoward JJ N
event NN N
in IN N
either DT N
of IN N
the DT N
groups NNS N
CONCLUSION NNP N
Caudal NNP N
administration NN N
of IN N
bupivacaine-midazolam JJ N
mixture NN N
prolongs NNS N
post-operative JJ N
analgesia NNS N
compared VBN N
to TO N
bupivacaine VB N
alone RB N
without IN N
causing VBG N
any DT N
adverse JJ N
effects NNS N
-DOCSTART- -X- O O 2116385

Cost NNP N
effectiveness NN N
of IN N
training VBG N
incontinent JJ 4_p
elderly RB 1_p
in IN 4_p
nursing VBG 4_p
homes NNS 4_p
: : 4_p
a DT N
randomized JJ N
clinical JJ N
trial NN N
This DT N
study NN N
used VBD N
a DT N
randomized JJ N
clinical JJ N
trial NN N
with IN N
133 CD N
incontinent JJ 4_p
elderly RB 1_p
in IN N
seven CD N
nursing NN N
homes NNS N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
behavioral JJ N
training NN N
therapy NN N
and CC N
its PRP$ N
cost NN N
implications NNS N
The DT N
training NN N
program NN N
lasted VBD N
three CD N
months NNS N
, , N
and CC N
a DT N
22-week JJ N
follow-up JJ N
period NN N
examined VBD N
the DT N
durability NN N
of IN N
the DT N
treatment NN N
effect NN N
The DT N
therapy NN N
became VBD N
effective JJ N
after IN N
six CD N
weeks NNS N
of IN N
training NN N
By IN N
the DT N
final JJ N
months NNS N
of IN N
training NN N
, , N
the DT N
treatment NN N
participants NNS N
' POS N
wet NN N
episodes NNS N
had VBD N
been VBN N
reduced VBN N
by IN N
0.6 CD N
episode NNS N
per IN N
day NN N
, , N
or CC N
a DT N
26 CD N
percent NN N
reduction NN N
over IN N
baseline NN N
, , N
and CC N
improvement NN N
was VBD N
maintained VBN N
during IN N
the DT N
follow-up JJ N
period NN N
Trainees NNS N
with IN N
a DT N
high JJ N
frequency NN N
of IN N
incontinence NN 4_p
during IN N
baseline NN N
, , N
relatively RB N
more RBR N
cognitive JJ N
residents NNS N
, , N
and CC N
residents NNS N
with IN N
a DT N
normal JJ N
bladder NN N
capacity NN N
responded VBD N
better JJR N
to TO N
this DT N
behavioral JJ N
program NN N
The DT N
cost NN N
of IN N
training NN N
was VBD N
the DT N
equivalent NN N
of IN N
about IN N
one CD N
hour NN N
of IN N
nursing VBG N
aide JJ N
time NN N
per IN N
patient JJ N
day NN N
The DT N
reduction NN N
in IN N
incontinence NN N
during IN N
the DT N
follow-up JJ N
period NN N
resulted VBD N
in IN N
some DT N
small JJ N
savings NNS N
in IN N
laundry NN N
costs NNS N
and CC N
supplies NNS N
used VBN N
, , N
and CC N
some DT N
quantitatively RB N
unmeasurable JJ N
but CC N
detectable JJ N
improvement NN N
in IN N
psychosocial JJ N
well-being NN N
among IN N
the DT N
trainees NNS N
Since IN N
the DT N
central JJ N
figure NN N
in IN N
implementing VBG N
this DT N
training NN N
protocol NN N
is VBZ N
the DT N
nursing NN N
aide NN N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
find VB N
an DT N
organizational JJ N
management NN N
scheme NN N
that WDT N
will MD N
stimulate VB N
nursing NN N
aides NNS N
to TO N
reduce VB N
incontinence NN N
among IN N
nursing JJ N
home NN N
residents NNS N
-DOCSTART- -X- O O 19368912

What WP N
is VBZ N
the DT N
optimum JJ N
maximal JJ N
gonadotropin NN N
dosage NN N
used VBN N
in IN N
microdose JJ 4_p
flare-up JJ 4_p
cycles NNS 4_p
in IN 4_p
poor JJ 4_p
responders NNS 4_p
? . N
OBJECTIVE NNP N
To TO N
find VB N
out RP N
the DT N
optimum JJ N
maximal JJ N
dosage NN N
of IN N
recombinant JJ N
follicle NN N
stimulating VBG N
hormone NN N
( ( N
rFSH NN N
) ) N
in IN N
microdose JJ N
gonadotropin-releasing JJ N
hormone NN N
analog NN N
( ( N
GnRH-a NNP N
) ) N
flare NN N
cycles NNS N
in IN N
poor JJ N
responders NNS N
DESIGN NNP N
Prospective NNP N
randomized VBD N
study NN N
SETTING NNP N
Private NNP N
infertility NN N
clinic NN N
PATIENT NNP N
( ( N
S NNP N
) ) N
A NNP N
total NN N
of IN N
119 CD N
women NNS N
were VBD N
taken VBN N
into IN N
the DT N
study NN N
INTERVENTION NNP N
( ( N
S NNP N
) ) N
The DT N
study NN N
group NN N
underwent VBD N
a DT N
microdose JJ N
protocol NN N
with IN N
a DT N
GnRH-agonist JJ N
followed VBN N
by IN N
rFSH JJ N
administration NN N
On IN N
the DT N
third JJ N
day NN N
of IN N
GnRH-a NNP N
administration NN N
, , N
119 CD N
patients NNS N
were VBD N
randomized VBN N
in IN N
three CD N
groups NNS N
to TO N
receive VB N
daily JJ N
fixed VBN N
doses NNS N
of IN N
300 CD N
IU NNP N
of IN N
rFSH NN N
( ( N
group NN N
A NNP N
, , N
n JJ N
= NNP N
38 CD N
) ) N
, , N
or CC N
450 CD N
IU NNP N
of IN N
rFSH NN N
( ( N
group NN N
B NNP N
, , N
n JJ N
= NNP N
39 CD N
) ) N
, , N
or CC N
600 CD N
IU NNP N
of IN N
rFSH NN N
( ( N
group NN N
C NNP N
, , N
n JJ N
= NNP N
42 CD N
) ) N
MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Peak NNP N
E NNP N
( ( N
2 CD N
) ) N
levels NNS N
, , N
days NNS N
of IN N
stimulation NN N
with IN N
rFSH NN N
, , N
total JJ N
rFSH NN N
dosage NN N
, , N
total JJ N
number NN N
of IN N
oocytes NNS N
retrieved VBN N
, , N
M2 NNP N
oocytes VBZ N
retrieved VBN N
, , N
total JJ N
number NN N
of IN N
embryos NN N
, , N
number NN N
of IN N
embryos NN N
transferred VBN N
, , N
number NN N
of IN N
Grade-1 NNP N
embryos NN N
transferred VBD N
, , N
clinical JJ N
pregnancy NN N
rate NN N
( ( N
positive JJ N
fetal JJ N
cardiac JJ N
activity NN N
) ) N
, , N
and CC N
cancellation NN N
rates NNS N
of IN N
stimulation NN N
and CC N
embryo NN N
transfer NN N
RESULT NNP N
( ( N
S NNP N
) ) N
Clinical NNP N
pregnancy NN N
rates NNS N
were VBD N
13.1 CD N
% NN N
, , N
15.3 CD N
% NN N
, , N
and CC N
16.1 CD N
% NN N
for IN N
group NN N
A NNP N
, , N
group NN N
B NNP N
, , N
and CC N
group NN N
C NNP N
, , N
respectively RB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
age NN N
, , N
peak JJ N
serum NN N
E NNP N
( ( N
2 CD N
) ) N
concentration NN N
, , N
days NNS N
of IN N
stimulation NN N
with IN N
rFSH NN N
, , N
total JJ N
number NN N
of IN N
M2 NNP N
oocytes VBZ N
retrieved VBN N
, , N
number NN N
of IN N
embryos NN N
transferred VBN N
, , N
clinical JJ N
pregnancy NN N
rates NNS N
, , N
and CC N
cancellation NN N
rates NNS N
of IN N
stimulation NN N
and CC N
embryo NN N
transfer NN N
between IN N
the DT N
three CD N
groups NNS N
except IN N
for IN N
total JJ N
rFSH JJ N
dosage NN N
CONCLUSION NNP N
( ( N
S NNP N
) ) N
There EX N
is VBZ N
no DT N
need NN N
to TO N
use VB N
doses NNS N
above IN N
300 CD N
IU NNP N
of IN N
rFSH NN N
to TO N
increase VB N
the DT N
pregnancy NN N
rate NN N
in IN N
microdose JJ N
cycles NNS N
In IN N
addition NN N
, , N
because IN N
the DT N
duration NN N
of IN N
stimulation NN N
does VBZ N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
, , N
the DT N
usage NN N
of IN N
300 CD N
IU NNP N
rFSH NN N
in IN N
microdose JJ N
cycles NNS N
results NNS N
in IN N
less JJR N
total JJ N
amount NN N
of IN N
rFSH NN N
consumed VBN N
in IN N
a DT N
cycle NN N
compared VBN N
with IN N
higher JJR N
dosages NNS N
, , N
and CC N
this DT N
would MD N
obviously RB N
cost VB N
less JJR N
money NN N
to TO N
the DT N
patients NNS N
-DOCSTART- -X- O O 11746070

Evaluating VBG N
the DT N
impact NN N
of IN N
peer NN N
, , N
nurse JJ N
case-managed JJ N
, , N
and CC N
standard JJ N
HIV NNP N
risk-reduction NN N
programs NNS N
on IN N
psychosocial JJ N
and CC N
health-promoting JJ N
behavioral JJ N
outcomes NNS N
among IN N
homeless JJ N
women NNS 2_p
Investigators NNS N
examined VBD N
the DT N
6-month JJ N
impact NN N
of IN N
three CD N
cognitive-behavioral JJ N
HIV NNP N
risk-reduction NN N
programs NNS N
on IN N
behavioral JJ N
factors NNS N
( ( N
substance NN N
use NN N
and CC N
sexual JJ N
risk NN N
behaviors NNS N
) ) N
and CC N
cognitive JJ N
and CC N
psychological JJ N
resources NNS N
of IN N
325 CD 3_p
women NNS 2_p
who WP N
resided VBD N
in IN N
emergency NN N
or CC N
sober-living NN N
shelters NNS N
and CC N
their PRP$ N
308 CD 3_p
intimate JJ N
sexual JJ N
partners NNS N
Participants NNS N
were VBD N
randomized VBN N
by IN N
shelter NN N
to TO N
a DT N
peer-mentored JJ N
, , N
a DT N
nurse JJ N
case-managed JJ N
, , N
or CC N
a DT N
standard JJ N
care NN N
HIV NNP N
risk-reduction NN N
program NN N
Significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
all DT N
groups NNS N
in IN N
all DT N
behavioral JJ N
factors NNS N
and CC N
cognitive JJ N
and CC N
psychological JJ N
resources NNS N
except IN N
for IN N
self-esteem NN N
Participants NNS N
in IN N
the DT N
peer-mentored JJ N
and CC N
nurse JJ N
case-managed JJ N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
from IN N
the DT N
standard JJ N
group NN N
in IN N
self-esteem NN N
, , N
life NN N
satisfaction NN N
, , N
psychological JJ N
well-being NN N
, , N
use NN N
of IN N
noninjection NN N
drugs NNS N
, , N
sex NN N
with IN N
multiple JJ N
partners NNS N
, , N
and CC N
unprotected JJ N
sex NN N
at IN N
6 CD N
months NNS N
( ( N
n JJ N
= NNP N
633 CD N
) ) N
It PRP N
was VBD N
concluded VBN N
that IN N
a DT N
standard JJ N
approach NN N
by IN N
health NN N
care NN N
professionals NNS N
appears VBZ N
to TO N
effectively RB N
modify VB N
HIV NNP N
risk NN N
behaviors NNS N
for IN N
a DT N
majority NN N
of IN N
homeless JJ 4_p
participants NNS N
and CC N
may MD N
have VB N
important JJ N
economic JJ N
and CC N
policy NN N
implications NNS N
Further NNP N
, , N
the DT N
impact NN N
of IN N
short-term JJ N
programs NNS N
that WDT N
address VBP N
psychological JJ N
vulnerabilities NNS N
of IN N
impoverished JJ 4_p
populations NNS N
needs NNS N
to TO N
be VB N
studied VBN N
further JJ N
-DOCSTART- -X- O O 9129469

Effects NNS N
of IN N
age NN N
at IN N
introduction NN N
of IN N
complementary JJ N
foods NNS N
to TO N
breast-fed JJ N
infants NNS N
on IN N
duration NN N
of IN N
lactational JJ N
amenorrhea NN N
in IN N
Honduran NNP N
women NNS N
Lactational JJ N
amenorrhea NN N
( ( N
LA NNP N
) ) N
is VBZ N
associated VBN N
with IN N
postpartum NN N
infertility NN N
and CC N
is VBZ N
known VBN N
to TO N
be VB N
related VBN N
to TO N
breast-feeding JJ N
frequency NN N
and CC N
duration NN N
, , N
but CC N
the DT N
exact JJ N
role NN N
of IN N
complementary JJ N
feeding NN N
of IN N
the DT N
infant NN N
has VBZ N
not RB N
been VBN N
clearly RB N
defined VBN N
Data NNS N
on IN N
LA NNP N
were VBD N
collected VBN N
during IN N
and CC N
after IN N
a DT N
2-mo JJ N
intervention NN N
trial NN N
in IN N
which WDT N
low-income JJ N
Honduran NNP N
women NNS N
who WP N
had VBD N
breast-fed VBN N
fully RB N
for IN N
4 CD N
mo NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
continued VBN N
full JJ N
breast-feeding NN N
until IN N
6 CD N
mo NNS N
( ( N
FBF NNP N
, , N
n JJ N
= NNP N
50 CD N
) ) N
, , N
introduction NN N
of IN N
complementary JJ N
foods NNS N
at IN N
4 CD N
mo NN N
with IN N
ad NN N
libitum NN N
breast-feeding NN N
from IN N
4 CD N
to TO N
6 CD N
mo NN N
( ( N
SF NNP N
, , N
n JJ N
= NNP N
47 CD N
) ) N
, , N
or CC N
introduction NN N
of IN N
complementary JJ N
foods NNS N
at IN N
4 CD N
mo NN N
with IN N
maintenance NN N
of IN N
baseline JJ N
breast-feeding JJ N
frequency NN N
from IN N
4 CD N
to TO N
6 CD N
mo NNS N
( ( N
SF-M NNP N
, , N
n JJ N
= NNP N
44 CD N
) ) N
Women NNS N
were VBD N
followed VBN N
up RP N
until IN N
the DT N
infant NN N
was VBD N
12 CD N
mo NN N
of IN N
age NN N
, , N
or CC N
later RB N
if IN N
menses NNS N
had VBD N
not RB N
occurred VBN N
by IN N
then RB N
All DT N
but CC N
six CD N
of IN N
the DT N
women NNS N
continued VBD N
to TO N
breast-feed VB N
for IN N
> NN N
or CC N
= $ N
12 CD N
mo NN N
With IN N
the DT N
exclusion NN N
of IN N
those DT N
whose WP$ N
menses NNS N
returned VBD N
before IN N
18 CD N
wk NN N
postpartum NN N
( ( N
which WDT N
could MD N
not RB N
have VB N
been VBN N
due JJ N
to TO N
the DT N
intervention NN N
) ) N
, , N
the DT N
proportion NN N
of IN N
women NNS N
who WP N
were VBD N
amenorrheic VBN N
at IN N
6 CD N
mo NN N
was VBD N
64.5 CD N
% NN N
in IN N
the DT N
SF NNP N
group NN N
, , N
80.0 CD N
% NN N
in IN N
the DT N
FBF NNP N
group NN N
, , N
and CC N
85.7 CD N
% NN N
in IN N
the DT N
SF-M NNP N
group NN N
( ( N
chi-square JJ N
test NN N
= NN N
4.13 CD N
, , N
P NNP N
= NNP N
0.02 CD N
; : N
one-tailed JJ N
test NN N
with IN N
the DT N
latter JJ N
two CD N
groups NNS N
combined VBN N
) ) N
The DT N
total JJ N
duration NN N
of IN N
LA NNP N
did VBD N
not RB N
differ VB N
significantly RB N
among IN N
groups NNS N
The DT N
most RBS N
significant JJ N
determinant NN N
of IN N
LA NNP N
was VBD N
time NN N
spent VBN N
breast-feeding NN N
( ( N
min/d NN N
) ) N
, , N
which WDT N
was VBD N
in IN N
turn NN N
negatively RB N
associated VBN N
( ( N
P NNP N
= NNP N
0.06 CD N
) ) N
with IN N
the DT N
infant NN N
's POS N
energy NN N
intake NN N
from IN N
complementary JJ N
foods NNS N
in IN N
regression NN N
analyses NNS N
These DT N
results NNS N
indicate VBP N
that IN N
there EX N
is VBZ N
a DT N
significant JJ N
effect NN N
of IN N
introducing VBG N
foods NNS N
at IN N
4 CD N
mo NN N
on IN N
the DT N
likelihood NN N
of IN N
amenorrhea NN N
at IN N
6 CD N
mo NN N
postpartum NN N
, , N
but CC N
not RB N
thereafter RB N
, , N
and CC N
that IN N
this DT N
effect NN N
is VBZ N
not RB N
seen VBN N
in IN N
mothers NNS N
who WP N
maintain VBP N
breast-feeding JJ N
frequency NN N
-DOCSTART- -X- O O 8060436

A DT N
comparison NN N
of IN N
albuterol JJ N
solution NN N
nebulized VBN N
versus NN N
albuterol NN N
powder NN N
given VBN N
by IN N
breath NN N
activated VBN N
metered VBD N
dose JJ N
inhaler NN N
The DT N
goal NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
nebulized JJ N
vs NN N
powdered VBD N
albuterol NN N
in IN N
patients NNS N
with IN N
exacerbated JJ 4_p
bronchial JJ 4_p
asthma NN 4_p
who WP 4_p
required VBD 4_p
hospitalization NN 4_p
From IN 4_p
January NNP 4_p
to TO 4_p
May NNP 4_p
1990 CD 4_p
known NN N
asthmatics NNS N
admitted VBN N
with IN N
acute JJ 4_p
exacerbation NN 4_p
were VBD N
included VBN N
by IN N
established VBN N
criteria NNS N
Two CD N
groups NNS N
were VBD N
randomized VBN N
Group NNP N
I PRP N
for IN N
Albuterol NNP N
powder NN N
200 CD N
micrograms NNS N
inhaled VBD N
q RB N
4 CD N
hours NNS N
Group NNP N
II NNP N
with IN N
Albuterol NNP N
nebulized JJ N
solution NN N
2.5 CD N
mg NN N
inhaled VBD N
q RB N
4 CD N
hrs NN N
Force NNP N
Vital NNP N
Capacity NNP N
and CC N
Force NNP N
Expiratory NNP N
Volume NN N
in IN N
one CD N
second NN N
were VBD N
measured VBN N
with IN N
a DT N
pressure NN N
differential JJ N
transducer NN N
upon IN N
admission NN N
, , N
30 CD N
minutes NNS N
and CC N
24-hours JJ N
following NN N
therapies NNS N
Absolute NNP N
FEV1 NNP N
improvement NN N
was VBD N
calculated VBN N
Statistical JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
student NN N
's POS N
T-Test NNP N
and CC N
Fisher NNP N
's POS N
exact JJ N
Test NNP N
with IN N
significance NN N
established VBN N
at IN N
p NN N
> VBP N
0.01 CD N
% NN N
Fifteen JJ 3_p
patients NNS N
enrolled VBN N
in IN N
both DT N
groups NNS N
, , N
two CD N
patients NNS N
of IN N
group NN N
I PRP N
were VBD N
excluded VBN N
from IN N
the DT N
statistic JJ N
analysis NN N
due JJ N
to TO N
refusal VB N
to TO N
continue VB N
with IN N
the DT N
therapy NN N
Both DT N
groups NNS N
were VBD N
comparable JJ N
with IN N
respect NN N
to TO N
sex NN N
, , N
asthma JJ N
exacerbations/year NN N
, , N
smoking VBG N
history NN N
and CC N
hospital JJ N
length NN N
of IN N
stay NN N
FVC NNP N
and CC N
FEV1 NNP N
were VBD N
comparable JJ N
also RB N
In IN N
contrast NN N
, , N
there EX N
were VBD N
significant JJ N
difference NN N
when WRB N
the DT N
absolute NN N
improvement NN N
were VBD N
compared VBN N
The DT N
mean JJ N
+/- JJ N
SE NNP N
for IN N
FEV1 NNP N
absolute JJ N
improvement NN N
at IN N
the DT N
first JJ N
30 CD N
min NN N
was VBD N
0.42 CD N
+/- JJ N
0.08 CD N
lts NNS N
for IN N
the DT N
Group NNP N
I PRP N
versus VBP N
0.65 CD N
+/- JJ N
0.6 CD N
lts NNS N
in IN N
the DT N
Group NNP N
II NNP N
In IN N
the DT N
next JJ N
24 CD N
hours NNS N
, , N
Group NNP N
I PRP N
was VBD N
0.16 CD N
+/- JJ N
0.2 CD N
lts NNS N
versus JJ N
0.30 CD N
+/- JJ N
0.7 CD N
lts NNS N
in IN N
Group NNP N
II NNP N
( ( N
p JJ N
> NNP N
.01 NNP N
) ) N
We PRP N
conclude VBP N
that IN N
although IN N
the DT N
dose JJ N
equivalence NN N
of IN N
both DT N
delivery NN N
systems NNS N
have VBP N
not RB N
been VBN N
established VBN N
in IN N
our PRP$ N
study NN N
, , N
the DT N
nebulized JJ N
solution NN N
was VBD N
more RBR N
effective JJ N
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
of IN N
hospitalization NN N
than IN N
the DT N
dry JJ N
powder NN N
-DOCSTART- -X- O O 8260242

The DT N
effects NNS N
of IN N
a DT N
24-h JJ N
psychological JJ N
training NN N
program NN N
on IN N
attitudes NNS N
, , N
communication NN N
skills NNS N
and CC N
occupational JJ N
stress NN N
in IN N
oncology NN N
: : N
a DT N
randomised JJ N
study NN N
The DT N
usefulness NN N
of IN N
psychological JJ N
training NN N
programs NNS N
( ( N
P.T.P NNP N
) ) N
in IN N
health NN N
care NN N
settings NNS N
devoted VBN N
to TO N
cancer NN N
care NN N
is VBZ N
beginning VBG N
to TO N
be VB N
recognised VBN N
but CC N
their PRP$ N
content NN N
, , N
form NN N
and CC N
effectiveness VB N
need NN N
further JJ N
investigation NN N
Seventy-two JJ 3_p
oncology NN 4_p
nurses NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
24-h JJ N
P.T.P NNP N
or CC N
to TO N
a DT N
waiting VBG N
list NN N
period NN N
Attitudes NNS N
were VBD N
assessed VBN N
by IN N
a DT N
semantic JJ N
differential NN N
questionnaire NN N
, , N
occupational JJ N
stress NN N
was VBD N
assessed VBN N
by IN N
the DT N
Nursing NNP N
Stress NNP N
Scale NNP N
and CC N
communication NN N
skills NNS N
were VBD N
assessed VBN N
by IN N
standardised JJ N
videotaped VBD N
role-playing NN N
exercises NNS N
These DT N
were VBD N
used VBN N
to TO N
compare VB N
trained JJ N
( ( N
T.S NNP N
) ) N
and CC N
control NN N
subjects NNS N
( ( N
C.S. NNP N
) ) N
The DT N
results NNS N
show VBP N
a DT N
significant JJ N
training NN N
effect NN N
on IN N
attitudes NNS N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
, , N
especially RB N
on IN N
those DT N
related VBN N
to TO N
self VB N
concept NN N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
, , N
and CC N
on IN N
the DT N
level NN N
of IN N
occupational JJ N
stress NN N
related VBN N
to TO N
inadequate VB N
preparation NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
Limited VBN N
changes NNS N
were VBD N
found VBN N
regarding VBG N
post-training JJ N
communication NN N
skills NNS N
T.S NNP N
were VBD N
significantly RB N
more RBR N
in IN N
control NN N
of IN N
the DT N
interview NN N
than IN N
C.S NNP N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
The DT N
results NNS N
indicate VBP N
that IN N
24-h JJ N
P.T.P NNP N
assessed VBN N
here RB N
are VBP N
effective JJ N
The DT N
data NN N
also RB N
demonstrate VBP N
the DT N
need NN N
to TO N
consolidate VB N
the DT N
skills NNS N
acquired VBN N
by IN N
regular JJ N
post-training JJ N
sessions NNS N
-DOCSTART- -X- O O 16198776

Pulse NNP N
versus NN N
continuous JJ N
terbinafine NN N
for IN N
onychomycosis NN 4_p
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
controlled JJ N
trial NN N
BACKGROUND NNP N
Effective NNP N
treatments NNS N
for IN N
onychomycosis NN N
are VBP N
expensive JJ N
Previous JJ N
studies NNS N
suggest VBP N
that IN N
less JJR N
costly JJ N
, , N
pulsed JJ N
doses NNS N
of IN N
antifungal JJ N
medications NNS N
may MD N
be VB N
as RB N
effective JJ N
as IN N
standard NN N
, , N
continuous JJ N
doses NNS N
Terbinafine NNP N
is VBZ N
the DT N
current JJ N
treatment NN N
of IN N
choice NN N
for IN N
toenail JJ N
onychomycosis NN N
OBJECTIVE CC N
Our PRP$ N
purpose NN N
was VBD N
to TO N
determine VB N
whether IN N
pulse-dose JJ N
terbinafine NN N
is VBZ N
as RB N
effective JJ N
as IN N
standard JJ N
continuous-dose JJ N
terbinafine NN N
for IN N
treatment NN N
of IN N
toenail JJ N
onychomycosis NN N
METHODS NNP N
We PRP N
conducted VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
noninferiority NN N
, , N
clinical JJ N
intervention NN N
trial NN N
in IN N
the DT N
Minneapolis NNP N
Veterans NNP N
Affairs NNP N
Medical NNP N
Center NNP N
The DT N
main JJ N
inclusion NN N
criteria NNS N
for IN N
participants NNS N
were VBD N
a DT N
positive JJ 4_p
dermatophyte NN 4_p
culture NN 4_p
and CC 4_p
at IN 4_p
least JJS 4_p
25 CD 4_p
% NN 4_p
distal JJ 4_p
subungual JJ 4_p
clinical JJ 4_p
involvement NN 4_p
Six CD 3_p
hundred VBD 3_p
eighteen JJ 3_p
volunteers NNS N
were VBD N
screened VBN N
; : N
306 CD 3_p
were VBD N
randomized VBN N
Terbinafine NNP N
, , N
250 CD N
mg NNS N
daily RB N
for IN N
3 CD N
months NNS N
( ( N
continuous JJ N
) ) N
or CC N
terbinafine NN N
, , N
500 CD N
mg NNS N
daily RB N
for IN N
1 CD N
week NN N
per IN N
month NN N
for IN N
3 CD N
months NNS N
( ( N
pulse NN N
) ) N
was VBD N
administered VBN N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
mycological JJ N
cure NN N
of IN N
the DT N
target NN N
toenail NN N
at IN N
18 CD N
months NNS N
Secondary JJ N
outcome NN N
measures NNS N
included VBD N
clinical JJ N
cure NN N
and CC N
complete JJ N
( ( N
clinical JJ N
plus CC N
mycological JJ N
) ) N
cure NN N
of IN N
the DT N
target NN N
toenail NN N
and CC N
complete JJ N
cure NN N
of IN N
all DT N
10 CD N
toenails NNS N
RESULTS NNP N
Results NNP N
of IN N
an DT N
intent-to-treat JJ N
analysis NN N
did VBD N
not RB N
meet VB N
the DT N
prespecified JJ N
criterion NN N
for IN N
noninferiority NN N
but CC N
did VBD N
demonstrate VB N
the DT N
superiority NN N
of IN N
continuous-dose JJ N
terbinafine NN N
for IN N
: : N
mycological JJ N
cure NN N
of IN N
the DT N
target NN N
toenail NN N
( ( N
70.9 CD N
% NN N
[ CC N
105/148 CD N
] JJ N
vs RB N
58.7 CD N
% NN N
[ CC N
84/143 CD N
] NN N
; : N
P NNP N
=.03 NNP N
, , N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
of IN N
1.21 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
1.02-1.43 JJ N
] NN N
) ) N
; : N
clinical JJ N
cure NN N
of IN N
the DT N
target NN N
toenail NN N
( ( N
44.6 CD N
% NN N
[ CC N
66/148 CD N
] JJ N
vs RB N
29.3 CD N
% NN N
[ CC N
42/143 CD N
] NN N
; : N
P NNP N
=.007 NNP N
, , N
RR NNP N
=1.52 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
1.11-2.07 JJ N
) ) N
; : N
complete JJ N
cure NN N
of IN N
the DT N
target NN N
toenail NN N
( ( N
40.5 CD N
% NN N
[ CC N
60/148 CD N
] JJ N
vs RB N
28.0 CD N
% NN N
[ CC N
40/143 CD N
] NN N
; : N
P NNP N
=.02 NNP N
, , N
RR=1.45 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
1.04-2.01 JJ N
) ) N
; : N
and CC N
complete JJ N
cure NN N
of IN N
all DT N
10 CD N
toenails NNS N
( ( N
25.2 CD N
% NN N
[ CC N
36/143 CD N
] JJ N
vs RB N
14.7 CD N
% NN N
[ CC N
21/143 CD N
] NN N
; : N
P NNP N
=.03 NNP N
, , N
RR NNP N
=1.71 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
1.05-2.79 JJ N
) ) N
Tolerability NN N
of IN N
the DT N
regimens NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
( ( N
chi2 JJ N
=1.63 NN N
; : N
P NNP N
=.65 NNP N
) ) N
LIMITATIONS VB N
The DT N
study NN N
population NN N
primarily RB N
consisted VBN N
of IN 1_p
older JJR 1_p
men NNS 2_p
with IN N
severe JJ 4_p
onychomycosis NN 4_p
CONCLUSIONS VB N
This DT N
study NN N
demonstrated VBD N
the DT N
superiority NN N
of IN N
continuous- NN N
over IN N
pulse-dose JJ N
terbinafine NN N
We PRP N
also RB N
found VBD N
this DT N
expensive JJ N
therapy NN N
to TO N
be VB N
much RB N
less RBR N
effective JJ N
than IN N
previously RB N
believed VBN N
, , N
particularly RB N
for IN N
achieving VBG N
complete JJ N
cure NN N
of IN N
all DT N
10 CD N
toenails NNS N
-DOCSTART- -X- O O 8884623

Effects NNS N
of IN N
perioperative JJ N
indomethacin NN N
on IN N
intracranial JJ N
pressure NN N
, , N
cerebral JJ N
blood NN N
flow NN N
, , N
and CC N
cerebral JJ N
metabolism NN N
in IN N
patients NNS N
subjected VBN N
to TO N
craniotomy VB 4_p
for IN 4_p
cerebral JJ 4_p
tumors NNS 4_p
This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
perioperative JJ N
indomethacin NN N
on IN N
intracranial JJ N
pressure NN N
( ( N
ICP NNP N
) ) N
, , N
cerebral JJ N
blood NN N
flow NN N
( ( N
CBF NNP N
) ) N
, , N
and CC N
cerebral JJ N
metabolism NN N
Twenty CD 3_p
patients NNS N
subjected VBN N
to TO N
craniotomy VB 4_p
for IN 4_p
supratentorial JJ 4_p
cerebral JJ 4_p
tumors NNS 4_p
were VBD N
anesthetized VBN N
with IN N
thiopental JJ N
, , N
fentanyl JJ N
, , N
nitrous JJ N
oxide NN N
, , N
and CC N
isoflurane NN N
A DT N
PaCO2 NNP N
level NN N
averaging VBG N
4.8 CD N
kPa NN N
( ( N
median JJ N
) ) N
was VBD N
achieved VBN N
The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
intravenous JJ N
indomethacin JJ N
50 CD N
mg NN N
or CC N
placebo NN N
administrated VBN N
after IN N
exposure NN N
of IN N
the DT N
dura NN N
ICP NNP N
was VBD N
measured VBN N
continuously RB N
subdurally RB N
with IN N
a DT N
22-gauge JJ N
canula NN N
connected VBN N
to TO N
a DT N
transducer NN N
CBF NNP N
and CC N
the DT N
arteriovenous JJ N
difference NN N
of IN N
oxygen NN N
( ( N
AVDO2 NNP N
) ) N
were VBD N
measured VBN N
twice RB N
, , N
before IN N
and CC N
after IN N
indomethacin/placebo JJ N
administration NN N
A DT N
significant JJ N
decrease NN N
in IN N
ICP NNP N
from IN N
6.5 CD N
to TO N
1.5 CD N
mm NNS N
Hg NNP N
( ( N
median JJ N
) ) N
was VBD N
found VBN N
after IN N
indomethacin JJ N
administration NN N
This DT N
decrease NN N
was VBD N
caused VBN N
by IN N
a DT N
significant JJ N
decrease NN N
in IN N
CBF NNP N
associated VBD N
with IN N
a DT N
significant JJ N
increase NN N
in IN N
AVDO2 NNP N
Indomethacin NNP N
did VBD N
not RB N
affect VB N
the DT N
cerebral JJ N
metabolic JJ N
rate NN N
of IN N
oxygen NN N
, , N
the DT N
arteriovenous JJ N
difference NN N
of IN N
lactate NN N
, , N
or CC N
the DT N
lactate/oxygen NN N
index NN N
, , N
suggesting VBG N
that IN N
indomethacin NN N
did VBD N
not RB N
provoke VB N
global JJ N
cerebral JJ N
ischemia NN N
In IN N
the DT N
indomethacin NN N
group NN N
, , N
dura NN N
was VBD N
sufficiently RB N
relaxed VBN N
in IN N
eight CD N
of IN N
nine CD N
patients NNS N
and CC N
dura NN N
was VBD N
opened VBN N
without IN N
the DT N
occurrence NN N
of IN N
cerebral JJ N
swelling VBG N
In IN N
one CD N
patient NN N
, , N
mannitol FW N
treatment NN N
was VBD N
necessary JJ N
to TO N
prevent VB N
dural JJ N
tightness NN N
In IN N
the DT N
placebo NN N
group NN N
, , N
mannitol RB N
supplemented VBN N
with IN N
hypocapnia NN N
was VBD N
applied VBN N
in IN N
five CD 3_p
patients NNS N
These DT N
findings NNS N
suggest VBP N
that IN N
perioperative JJ N
treatment NN N
with IN N
indomethacin NN N
is VBZ N
an DT N
excellent JJ N
treatment NN N
of IN N
intracranial JJ N
hypertension NN N
during IN N
normocapnic JJ N
isoflurane NN N
anesthesia NN N
for IN N
craniotomy NN N
-DOCSTART- -X- O O 16671415

Decompressive JJ N
craniectomy NN N
in IN N
traumatic JJ N
brain NN N
injury NN N
: : N
the DT N
randomized JJ N
multicenter NN N
RESCUEicp NNP N
study NN N
( ( N
www.RESCUEicp.com NN N
) ) N
The DT N
RESCUEicp NNP N
( ( N
Randomized NNP N
Evaluation NNP N
of IN N
Surgery NNP N
with IN N
Craniectomy NNP N
for IN N
Uncontrollable JJ N
Elevation NN N
of IN N
intracranial JJ N
pressure NN N
) ) N
study NN N
has VBZ N
been VBN N
established VBN N
to TO N
determine VB N
whether IN N
decompressive JJ N
craniectomy NN N
has VBZ N
a DT N
role NN N
in IN N
the DT N
management NN N
of IN N
patients NNS N
with IN N
traumatic JJ N
brain NN N
injury NN N
and CC N
raised VBD N
intracranial JJ N
pressure NN N
that WDT N
does VBZ N
not RB N
respond VB N
to TO N
initial JJ N
treatment NN N
measures NNS N
We PRP N
describe VBP N
the DT N
concept NN N
of IN N
decompressive JJ N
craniectomy NN N
in IN N
traumatic JJ N
brain NN N
injury NN N
and CC N
the DT N
rationale NN N
and CC N
protocol NN N
of IN N
the DT N
RESCUEicp NNP N
study NN N
-DOCSTART- -X- O O 23463854

Developing VBG N
the DT N
Ho'ouna NNP N
Pono NNP N
substance NN N
use NN N
prevention NN N
curriculum NN N
: : N
collaborating NN N
with IN N
Hawaiian JJ 4_p
youth NN 4_p
and CC 4_p
communities NNS 4_p
This DT N
article NN N
briefly NN N
outlines VBZ N
a DT N
collaboration NN N
among IN N
communities NNS N
on IN N
Hawai'i NNP N
Island NNP N
and CC N
a DT N
university-based JJ N
research NN N
team NN N
to TO N
develop VB N
, , N
implement NN N
, , N
and CC N
evaluate VB N
a DT N
school-based JJ 4_p
substance NN 4_p
use NN 4_p
prevention NN 4_p
curriculum NN 4_p
called VBN N
Ho'ouna NNP N
Pono NNP N
In IN N
addition NN N
to TO N
providing VBG N
a DT N
rationale NN N
for IN N
the DT N
project NN N
, , N
the DT N
goal NN N
of IN N
this DT N
paper NN N
is VBZ N
fourfold JJ N
First NNP N
, , N
an DT N
overview NN N
of IN N
the DT N
Ho'ouna NNP N
Pono NNP N
research NN N
results NNS N
to TO N
date NN N
( ( N
2007-2013 JJ N
) ) N
is VBZ N
provided VBN N
Second JJ N
, , N
within IN N
this DT N
overview NN N
, , N
the DT N
ways NNS N
in IN N
which WDT N
selected VBD N
results NNS N
informed JJ N
program NN N
development NN N
are VBP N
highlighted VBN N
Third NNP N
, , N
the DT N
curriculum NN N
is VBZ N
briefly JJ N
described VBN N
, , N
and CC N
finally RB N
, , N
the DT N
role NN N
of IN N
the DT N
students NNS N
and CC N
community NN N
in IN N
the DT N
video NN N
production NN N
is VBZ N
described VBN N
-DOCSTART- -X- O O 15002089

Retrograde NNP N
tracing NN N
and CC N
electrophysiological JJ N
findings NNS N
of IN N
collateral NN N
sprouting NN N
after IN 4_p
end-to-side JJ 4_p
neurorrhaphy NN 4_p
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
seek VB N
more RBR N
potent JJ N
evidences NNS N
of IN N
collateral NN N
sprouting NN N
for IN N
both DT N
motor NN N
and CC N
sensory JJ N
nerve NN N
fibres NNS N
after IN 4_p
end-to-side JJ 4_p
neurorrhaphy NN 4_p
using VBG N
a DT N
modified VBN N
double-labelling NN N
retrograde NN N
tracing VBG N
method NN N
and CC N
to TO N
investigate VB N
the DT N
function NN N
of IN N
regenerated JJ N
motor NN N
axons NNS N
with IN N
electrophysiological JJ N
evaluation NN N
Four CD N
groups NNS N
( ( N
n=4 JJ N
for IN N
each DT N
group NN N
) ) N
were VBD N
used VBN N
: : N
end-to-end JJ N
coaptation NN N
( ( N
six CD N
months NNS N
postoperatively RB N
) ) N
, , N
end-to-side JJ N
coaptation NN N
( ( N
four CD N
months NNS N
and CC N
six CD N
months NNS N
postoperatively RB N
) ) N
and CC N
normal JJ N
control NN N
Two CD N
fluorescent JJ N
tracers NNS N
( ( N
true JJ N
blue NN N
and CC N
diamidino NN N
yellow NN N
) ) N
were VBD N
applied VBN N
to TO N
the DT N
proximal JJ N
ends NNS N
of IN N
tibial JJ N
and CC N
common JJ N
peroneal NN N
nerves NNS N
, , N
respectively RB N
after IN N
four CD N
or CC N
six CD N
months NNS N
of IN N
nerve DT N
coaptation NN N
Five CD N
days NNS N
later RB N
, , N
we PRP N
only RB N
found VBD N
single-labelled JJ N
motor NN N
and CC N
sensory JJ N
neurons NNS N
in IN N
the DT N
normal JJ N
and CC N
end-to-end JJ N
coaptation NN N
groups NNS N
, , N
while IN N
some DT N
dual-labelled JJ N
neurons NNS N
can MD N
be VB N
identified VBN N
in IN N
end-to-side JJ N
coaptation NN N
groups NNS N
Four CD N
months NNS N
after IN N
surgery NN N
, , N
the DT N
motor NN N
nerve NN N
conduction NN N
velocity NN N
in IN N
end-to-side JJ N
coaptation NN N
was VBD N
significantly RB N
slower JJR N
than IN N
in IN N
the DT N
normal JJ N
control NN N
But CC N
no DT N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
sixth JJ N
month NN N
These DT N
results NNS N
suggest VBP N
that IN N
end-to-side JJ N
neurorrhaphy NN N
can MD N
induce VB N
the DT N
functional JJ N
collateral NN N
sprouting NN N
of IN N
both DT N
motor NN N
and CC N
sensory JJ N
axons NNS N
in IN N
the DT N
peripheral JJ N
nerve NN N
-DOCSTART- -X- O O 2139523

Sequential JJ N
alternate JJ N
administration NN N
of IN N
tamoxifen NN N
and CC N
medroxyprogesterone NN N
acetate NN N
in IN N
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
: : N
clinical-biological JJ N
randomized NN N
study NN N
From IN N
January NNP N
1985 CD N
to TO N
September NNP N
1988 CD N
, , N
60 CD 3_p
women NNS 2_p
with IN N
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
were VBD N
randomized VBN N
in IN N
two CD N
arms NNS N
to TO N
receive VB N
: : N
A DT N
) ) N
tamoxifen NN N
( ( N
TAM NNP N
) ) N
( ( N
20 CD N
mg/die NN N
) ) N
until IN N
progression NN N
or CC N
B NNP N
) ) N
TAM NNP N
( ( N
20 CD N
mg/die NN N
for IN N
14 CD N
days NNS N
) ) N
then RB N
medroxyprogesterone NN N
acetate NN N
( ( N
MPA NNP N
) ) N
( ( N
1500 CD N
mg/die NN N
p.o NN N
for IN N
14 CD N
days NNS N
) ) N
followed VBN N
by IN N
7 CD N
days NNS N
of IN N
wash-out NN N
before IN N
repeating VBG N
the DT N
TAM/MPA NNP N
treatment NN N
All DT N
patients NNS N
were VBD N
post-menopausal JJ 4_p
, , N
previously RB N
untreated VBN N
with IN N
hormone NN N
therapy NN N
, , N
and CC N
with IN N
tumor NN N
receptor NN N
status NN N
determined VBD N
immediately RB N
before IN N
randomization NN N
; : N
all DT N
had VBD N
objectively RB N
evaluable JJ 4_p
lesions NNS 4_p
In IN N
order NN N
to TO N
verify VB N
hormone NN N
receptor NN N
variations NNS N
due JJ N
to TO N
the DT N
antiestrogen NN N
, , N
when WRB N
possible JJ N
a DT N
second JJ N
biopsy NN N
was VBD N
performed VBN N
after IN N
the DT N
initial JJ N
14 CD N
day NN N
cycle NN N
of IN N
TAM NNP N
Thirty-one NN 3_p
and CC N
29 CD 3_p
patients NNS N
were VBD N
included VBN N
respectively RB N
in IN N
arms NNS N
A NNP N
and CC N
B NNP N
Objective JJ N
regression NN N
( ( N
CR NNP N
+ NNP N
PR NNP N
) ) N
was VBD N
observed VBN N
in IN N
58 CD N
% NN N
of IN N
group NN N
A NNP N
and CC N
75 CD N
% NN N
of IN N
group NN N
B NNP N
, , N
with IN N
CR NNP N
in IN N
11 CD N
% NN N
and CC N
23 CD N
% NN N
, , N
respectively RB N
Differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
Median JJ N
time NN N
to TO N
progression NN N
was VBD N
12 CD N
months NNS N
for IN N
group NN N
A NNP N
and CC N
9 CD N
for IN N
group NN N
B NNP N
Overall NNP N
survival NN N
has VBZ N
not RB N
yet RB N
been VBN N
reached VBN N
in IN N
group NN N
A NNP N
while IN N
it PRP N
was VBD N
34 CD N
months NNS N
for IN N
patients NNS N
of IN N
group NN N
B. NNP N
Metrorrhagia NNP N
was VBD N
observed VBN N
in IN N
two CD N
cases NNS N
of IN N
group NN N
A NNP N
and CC N
in IN N
6 CD N
of IN N
group NN N
B NNP N
, , N
and CC N
thrombophlebitis NN N
in IN N
1 CD N
and CC N
3 CD N
cases NNS N
, , N
respectively RB N
The DT N
second JJ N
biopsy NN N
confirmed VBD N
a DT N
clear JJ N
increase NN N
of IN N
PgR NNP N
content NN N
in IN N
8/11 CD N
cases NNS N
( ( N
75 CD N
% NN N
) ) N
Plasma NNP N
level JJ N
variations NNS N
of IN N
TAM NNP N
, , N
N-desmethyl NNP N
TAM NNP N
and CC N
MPA NNP N
were VBD N
checked VBN N
at IN N
various JJ N
intervals NNS N
on IN N
3 CD N
patients NNS N
of IN N
group NN N
B NNP N
, , N
and CC N
confirmed VBD N
that IN N
our PRP$ N
schedule NN N
is VBZ N
able JJ N
to TO N
produce VB N
a DT N
drug NN N
wash-out NN N
period NN N
for IN N
tumor NN N
cells NNS N
In IN N
conclusion NN N
, , N
our PRP$ N
study NN N
demonstrated VBD N
that IN N
while IN N
the DT N
manipulation NN N
of IN N
hormone NN N
receptors NNS N
seems VBZ N
possible JJ N
, , N
results NNS N
indicating VBG N
better JJR N
overall JJ N
survival NN N
and CC N
time NN N
to TO N
progression NN N
were VBD N
not RB N
obtained VBN N
with IN N
alternate JJ N
sequential JJ N
TAM-MPA NNP N
therapy NN N
-DOCSTART- -X- O O 22587862

Effect NN N
of IN N
a DT N
mobile JJ N
safety NN N
alarm NN N
on IN N
going VBG N
outside JJ N
, , N
feeling JJ N
safe JJ N
, , N
fear NN N
of IN N
falling VBG N
, , N
and CC N
quality NN N
of IN N
life NN N
in IN N
community-living JJ N
older NN 1_p
persons NNS 1_p
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
-DOCSTART- -X- O O 3903063

Hodgkin NNP 4_p
's POS 4_p
disease NN 4_p
in IN N
childhood NN 1_p
and CC N
adolescence NN 1_p
: : N
results NNS N
of IN N
chemotherapy-radiotherapy NN N
in IN N
clinical JJ N
stages NNS N
IA-IIB NNP N
From IN N
April NNP N
1972 CD N
to TO N
May NNP N
1980 CD N
, , N
72 CD 3_p
children NNS 1_p
and CC N
adolescents NNS 1_p
( ( N
aged VBN N
5 CD N
to TO N
19 CD N
years NNS N
old JJ N
, , N
median JJ N
16 CD N
) ) N
with IN N
Hodgkin NNP 4_p
's POS 4_p
disease NN 4_p
, , N
clinical JJ N
stages NNS N
IA-IIB NNP N
( ( N
IA NNP N
, , N
18 CD N
; : N
II2A NNP N
, , N
two CD N
areas NNS N
involved VBN N
on IN N
the DT N
same JJ N
side NN N
of IN N
the DT N
diaphragm NN N
, , N
23 CD N
; : N
II3+A NNP N
, , N
three CD N
areas NNS N
or CC N
more JJR N
, , N
16 CD N
; : N
IIB NNP N
, , N
15 CD N
) ) N
were VBD N
prospectively RB N
treated VBN N
in IN N
two CD N
successive JJ N
clinical JJ N
trials NNS N
( ( N
H NNP N
72 CD N
and CC N
H NNP N
77 CD N
) ) N
Clinical JJ N
stages NNS N
IA NNP N
and CC N
II2A NNP N
received VBD N
three CD N
courses NNS N
of IN N
mechlorethamine NN N
, , N
Oncovin NNP N
, , N
procarbazine NN N
, , N
and CC N
prednisone NN N
( ( N
MOPP NNP N
) ) N
and CC N
supradiaphragmatic JJ N
radiotherapy NN N
( ( N
40 CD N
Gy NNP N
) ) N
, , N
and CC N
no DT N
laparotomy NN N
was VBD N
performed VBN N
Clinical JJ N
stages NNS N
II3+A NNP N
and CC N
IIB NNP N
received VBD N
either DT N
six CD N
cycles NNS N
of IN N
MOPP NNP N
( ( N
H NNP N
72 CD N
) ) N
, , N
three CD N
cycles NNS N
of IN N
MOPP NNP N
, , N
or CC N
three CD N
cycles NNS N
of IN N
CCNU NNP N
, , N
vinblastine NN N
, , N
procarbazine NN N
, , N
and CC N
prednisone NN N
( ( N
CVPP NNP N
) ) N
( ( N
H $ N
77 CD N
) ) N
and CC N
subsequently RB N
had VBD N
a DT N
laparotomy NN N
followed VBN N
by IN N
supradiaphragmatic JJ N
radiotherapy NN N
and CC N
a DT N
lumboaortic JJ N
field NN N
if IN N
results NNS N
of IN N
laparotomy NN N
were VBD N
positive JJ N
Patients NNS N
without IN N
evidence NN N
of IN N
mediastinal JJ 4_p
involvement NN 4_p
did VBD N
not RB N
have VB N
mediastinal JJ N
radiotherapy NN N
At IN N
the DT N
completion NN N
of IN N
therapy NN N
, , N
the DT N
disease NN N
in IN N
70 CD N
of IN N
72 CD N
patients NNS N
was VBD N
in IN N
complete JJ N
remission NN N
( ( N
one CD N
failure NN N
, , N
one CD N
death NN N
during IN N
treatment NN N
) ) N
Eight CD N
patients NNS N
relapsed VBN N
( ( N
in IN N
situ NN N
, , N
1 CD N
; : N
marginal JJ N
, , N
1 CD N
; : N
nonirradiated VBN N
subdiaphragmatic JJ N
area NN N
, , N
6 CD N
) ) N
after IN N
three CD N
to TO N
57 CD N
months NNS N
of IN N
complete JJ N
remission NN N
( ( N
median JJ N
20 CD N
months NNS N
) ) N
; : N
one CD N
patient NN N
died VBD N
after IN N
relapse NN N
There EX N
were VBD N
three CD N
deaths NNS N
after IN N
complete JJ N
remission NN N
of IN N
the DT N
disease NN N
( ( N
infection NN N
, , N
two CD N
; : N
acute CC N
nonlymphocytic JJ N
leukemia NN N
[ NNP N
ANLL NNP N
] NNP N
, , N
one CD N
) ) N
As IN N
of IN N
June NNP N
1984 CD N
the DT N
median JJ N
follow-up NN N
was VBD N
82 CD N
months NNS N
( ( N
range NN N
, , N
49 CD N
to TO N
145 CD N
months NNS N
) ) N
, , N
the DT N
actuarial JJ N
probabilities NNS N
for IN N
survival NN N
and CC N
freedom NN N
from IN N
relapse NN N
for IN N
all DT N
patients NNS N
being VBG N
91.6 CD N
% NN N
and CC N
87.6 CD N
% NN N
, , N
respectively RB N
There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
according VBG N
to TO N
clinical JJ N
stage NN N
, , N
age NN N
( ( N
greater JJR N
than IN N
15 CD N
or CC N
less JJR N
than IN N
15 CD N
years NNS N
) ) N
, , N
sex NN N
, , N
or CC N
number NN N
of IN N
cycles NNS N
of IN N
chemotherapy NN N
( ( N
six CD N
or CC N
three CD N
) ) N
Bone NNP N
growth NN N
defects NNS N
related VBN N
to TO N
radiotherapy VB N
were VBD N
reduced VBN N
particularly RB N
in IN N
the DT N
29 CD N
patients NNS N
who WP N
did VBD N
not RB N
receive VB N
mediastinal JJ N
radiotherapy NN N
None NN N
of IN N
these DT N
patients NNS N
had VBD N
a DT N
mediastinal JJ N
relapse NN N
Azoospermia NNP N
was VBD N
the DT N
rule NN N
for IN N
the DT N
male NN N
patients NNS N
studied VBN N
, , N
but CC N
young JJ N
girls NNS N
and CC N
young JJ N
women NNS N
retained VBD N
reproductive JJ N
integrity NN N
-DOCSTART- -X- O O 25224595

Caphosol NNP N
( ( N
® NNP N
) ) N
mouthwash VBP N
gives VBZ N
no DT N
additional JJ N
protection NN N
against IN N
oral JJ N
mucositis NN N
compared VBN N
to TO N
cryotherapy VB N
alone RB N
in IN 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
A DT N
pilot NN N
study NN N
PURPOSE NNP N
To TO N
investigate VB N
if IN N
adding VBG N
Caphosol NNP N
( ( N
® NNP N
) ) N
, , N
a DT N
mouthwash JJ N
solution NN N
, , N
to TO N
oral JJ N
cryotherapy NN N
( ( N
OC NNP N
) ) N
further RBR N
protects NNS N
against IN N
oral JJ N
mucositis NN N
( ( N
OM NNP N
) ) N
, , N
a DT N
toxic JJ N
painful JJ N
complication NN N
to TO N
high VB N
dose JJ N
chemotherapy NN N
METHOD NNP N
The DT N
study NN N
was VBD N
a DT N
randomised JJ N
, , N
controlled VBN N
, , N
study NN N
design NN 4_p
Patients NNS 1_p
≥16 JJ 1_p
years NNS 1_p
scheduled VBN N
for IN N
allogeneic JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
were VBD N
included VBN N
consecutively RB N
and CC N
randomised VBD N
to TO N
experimental VB N
group NN N
receiving VBG N
OC NNP N
combined VBN N
with IN N
Caphosol NNP N
( ( N
® NNP N
) ) N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
or CC N
control VB 3_p
group NN 3_p
receiving VBG N
OC NNP N
only RB N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
OC NNP N
was VBD N
given VBN N
from IN N
start NN N
to TO N
end VB N
of IN N
HDCT NNP N
Caphosol NNP N
( ( N
® NNP N
) ) N
, , N
from IN N
day NN N
0 CD N
to TO N
day NN N
21 CD N
RESULT VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
regarding VBG N
age NN N
or CC N
gender NN N
between IN N
the DT N
groups NNS N
Mucositis NNP N
was VBD N
assessed VBN N
with IN N
the DT N
World NNP N
Health NNP N
Organisation NNP N
( ( N
WHO NNP N
) ) N
grading VBG N
scale NN N
Pain NN N
was VBD N
assessed VBN N
with IN N
a DT N
10 CD N
cm NN N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
from IN N
0 CD N
= JJ N
no DT N
pain NN N
to TO N
10 CD N
= NNS N
worst RBR N
imaginable JJ N
pain NN N
Start NNP N
and CC N
duration NN N
of IN N
therapy NN N
with IN N
pain NN N
relieving VBG N
drugs NNS N
, , N
serum VBD N
C-reactive JJ N
protein NN N
values NNS N
, , N
and CC N
number NN N
of IN N
days NNS N
of IN N
hospitalisation NN N
were VBD N
collected VBN N
from IN N
the DT N
medical JJ N
records NNS N
Data NNS N
on IN N
OM NNP N
, , N
oral JJ N
pain NN N
, , N
use NN N
of IN N
i.v NN N
opioids NNS N
and CC N
total JJ N
parenteral JJ N
nutrition NN N
were VBD N
collected VBN N
during IN N
22 CD N
days NNS N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
on IN N
OM NNP N
, , N
oral JJ N
pain NN N
, , N
use NN N
of IN N
i.v NN N
opioids NNS N
or CC N
TPN NNP N
between IN N
the DT N
groups NNS N
CONCLUSION NNP N
The DT N
study NN N
showed VBD N
no DT N
additional JJ N
effect NN N
of IN N
combining VBG N
Caphosol NNP N
( ( N
® NNP N
) ) N
with IN N
OC NNP N
-DOCSTART- -X- O O 25865864

Fall NN N
rates NNS N
in IN N
hospital JJ 4_p
rehabilitation NN 4_p
units NNS 4_p
after IN N
individualised JJ N
patient NN N
and CC N
staff NN N
education NN N
programmes NNS N
: : N
a DT N
pragmatic JJ N
, , N
stepped-wedge JJ N
, , N
cluster-randomised JJ N
controlled VBN N
trial NN N
BACKGROUND NNP N
Falls NNP N
are VBP N
the DT N
most RBS N
frequent JJ N
adverse JJ N
events NNS N
that WDT N
are VBP N
reported VBN N
in IN N
hospitals NNS N
We PRP N
examined VBD N
the DT N
effectiveness NN N
of IN N
individualised JJ N
falls-prevention NN N
education NN N
for IN N
patients NNS N
, , N
supported VBN N
by IN N
training NN N
and CC N
feedback NN N
for IN N
staff NN N
, , N
delivered VBN N
as IN N
a DT N
ward-level JJ N
programme NN N
METHODS NNP N
Eight NNP 3_p
rehabilitation NN N
units NNS N
in IN N
general JJ N
hospitals NNS N
in IN N
Australia NNP N
participated VBD N
in IN N
this DT N
stepped-wedge NN N
, , N
cluster-randomised JJ N
study NN N
, , N
undertaken JJ N
during IN N
a DT N
50 CD N
week NN N
period NN N
Units NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
intervention VB N
or CC N
control VB N
groups NNS N
by IN N
use NN N
of IN N
computer-generated JJ N
, , N
random JJ N
allocation NN N
sequences NNS N
We PRP N
included VBD N
patients NNS N
admitted VBN N
to TO N
the DT N
unit NN N
during IN N
the DT N
study NN N
with IN N
a DT N
Mini-Mental JJ 4_p
State NNP 4_p
Examination NNP 4_p
( ( 4_p
MMSE NNP 4_p
) ) N
score NN N
of IN N
more JJR N
than IN N
23/30 CD N
to TO N
receive VB N
individualised JJ N
education NN N
that WDT N
was VBD N
based VBN N
on IN N
principles NNS N
of IN N
changes NNS N
in IN N
health NN N
behaviour NN N
from IN N
a DT N
trained JJ N
health NN N
professional NN N
, , N
in IN N
addition NN N
to TO N
usual JJ N
care NN N
We PRP N
provided VBD N
information NN N
about IN N
patients NNS N
' POS N
goals NNS N
, , N
feedback NN N
about IN N
the DT N
ward NN N
environment NN N
, , N
and CC N
perceived VBD N
barriers NNS N
to TO N
engagement VB N
in IN N
falls-prevention NN N
strategies NNS N
to TO N
staff NN N
who WP N
were VBD N
trained VBN N
to TO N
support VB N
the DT N
uptake NN N
of IN N
strategies NNS N
by IN N
patients NNS N
The DT N
coprimary JJ N
outcome NN N
measures NNS N
were VBD N
patient JJ N
rate NN N
of IN N
falls NNS N
per IN N
1000 CD N
patient-days NNS N
and CC N
the DT N
proportion NN N
of IN N
patients NNS N
who WP N
were VBD N
fallers NNS N
All DT N
analyses NNS N
were VBD N
by IN N
intention NN N
to TO N
treat VB N
This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
the DT N
Australian JJ N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
registry NN N
, , N
number NN N
ACTRN12612000877886 NNP N
) ) N
FINDINGS NNP N
Between NNP N
Jan NNP N
13 CD N
, , N
and CC N
Dec NNP N
27 CD N
, , N
2013 CD N
, , N
3606 CD 3_p
patients NNS N
were VBD N
admitted VBN N
to TO N
the DT N
eight CD N
units NNS N
( ( N
n=1983 JJ 3_p
control NN N
period NN N
; : N
n=1623 CC 3_p
intervention NN N
period NN N
) ) N
There EX N
were VBD N
fewer JJR N
falls NNS N
( ( N
n=196 NN N
, , N
7·80/1000 CD N
patient-days JJ N
vs NN N
n=380 NN N
, , N
13·78/1000 CD N
patient-days NNS N
, , N
adjusted VBN N
rate NN N
ratio NN N
0·60 CD N
[ NN N
robust JJ N
95 CD N
% NN N
CI NNP N
0·42-0·94 CD N
] NNP N
, , N
p=0·003 NN N
) ) N
, , N
injurious JJ N
falls NNS N
( ( N
n=66 NN N
, , N
2·63/1000 CD N
patient-days JJ N
vs NN N
131 CD N
, , N
4·75/1000 CD N
patient-days NNS N
, , N
0·65 CD N
[ NN N
robust JJ N
95 CD N
% NN N
CI NNP N
0·42-0·88 CD N
] NNP N
, , N
p=0·006 NN N
) ) N
, , N
and CC N
fallers NNS N
( ( N
n=136 JJ N
[ RB N
8·38 CD N
% NN N
] JJ N
vs NN N
n=248 NN N
[ VBD N
12·51 CD N
% NN N
] NN N
adjusted VBN N
odds NNS N
ratio VBP N
0·55 CD N
[ NNP N
robust JJ N
95 CD N
% NN N
CI NNP N
0·38 CD N
to TO N
0·81 CD N
] NNS N
, , N
p=0·003 NN N
) ) N
in IN N
the DT N
intervention NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
length NN N
of IN N
stay NN N
( ( N
intervention NN N
median RB N
11 CD N
days NNS N
[ JJ N
IQR NNP N
7-19 JJ N
] NNP N
, , N
control NN N
10 CD N
days NNS N
[ RB N
6-18 JJ N
] NN N
) ) N
INTERPRETATION NNP N
Individualised VBD N
patient JJ N
education NN N
programmes NNS N
combined VBN N
with IN N
training NN N
and CC N
feedback NN N
to TO N
staff NN N
added VBN N
to TO N
usual JJ N
care NN N
reduces VBZ N
the DT N
rates NNS N
of IN N
falls NNS N
and CC N
injurious JJ 4_p
falls NNS 4_p
in IN 4_p
older JJR 4_p
patients NNS 4_p
in IN 4_p
rehabilitation NN 4_p
hospital-units NNS N
FUNDING NN N
State NNP N
Health NNP N
Research NNP N
Advisory NNP N
Council NNP N
, , N
Department NNP N
of IN N
Health NNP N
, , N
Government NNP N
of IN N
Western NNP N
Australia NNP N
-DOCSTART- -X- O O 22723176

The DT N
in IN N
vitro JJ N
effects NNS N
of IN N
verbascoside NN N
on IN N
human JJ 4_p
platelet NN 4_p
aggregation NN 4_p
Preliminary NNP N
in IN N
vitro NN N
and CC N
animal NN N
studies NNS N
have VBP N
shown VBN N
that IN N
verbascoside NN N
, , N
a DT N
phenolic JJ N
compound NN N
, , N
may MD N
have VB N
several JJ N
favourable JJ N
biological JJ N
activities NNS N
, , N
including VBG N
an DT N
influence NN N
on IN N
endothelial JJ N
function NN N
and CC N
on IN N
platelet NN N
aggregation NN N
We PRP N
sought VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
verbascoside NN N
, , N
biotechnologically RB N
produced VBN N
from IN N
plant NN N
cell NN N
cultures NNS N
, , N
on IN N
human JJ N
platelet NN N
aggregation NN N
( ( N
PA NNP N
) ) N
The DT N
blood NN N
from IN N
40 CD N
aspirin-naïve JJ N
volunteers NNS N
with IN N
at IN N
least JJS N
one CD N
cardiovascular NN N
risk NN N
factor NN N
was VBD N
preincubated VBN N
in IN N
vitro NN N
with IN N
verbascoside NN N
( ( N
1 CD N
and CC N
2 CD N
mg/dL NN N
) ) N
and CC N
aspirin NN N
( ( N
100 CD N
μM NN N
) ) N
The DT N
blood NN N
from IN N
20 CD N
patients NNS N
with IN N
a DT N
prior JJ N
diagnosis NN N
of IN N
coronary JJ N
heart NN N
disease NN N
who WP N
were VBD N
chronically RB N
assuming VBG N
aspirin NN N
was VBD N
preincubated VBN N
in IN N
vitro NN N
with IN N
verbascoside NN N
( ( N
1 CD N
and CC N
2 CD N
mg/dL NN N
) ) N
PA NNP N
is VBZ N
measured VBN N
with IN N
a DT N
light JJ N
transmission NN N
aggregometry NN N
and CC N
multiplate NN N
analyzer NN N
As IN N
compared VBN N
to TO N
reference VB N
, , N
preincubation NN N
with IN N
verbascoside NN N
resulted VBD N
in IN N
a DT N
significant JJ N
inhibition NN N
of IN N
adenosine JJ N
diphosphate NN N
( ( N
ADP NNP N
) ) N
and CC N
arachidonic JJ N
acid NN N
( ( N
AA NNP N
) ) N
-induced VBD N
PA NNP N
( ( N
p VB N
< $ N
0.01 CD N
for IN N
both DT N
) ) N
Verbascoside $ N
2 CD N
mg/dL NN N
did VBD N
not RB N
show VB N
a DT N
stronger JJR N
effect NN N
as IN N
compared VBN N
to TO N
verbascoside VB N
1 CD N
mg/dL NN N
( ( N
p JJ N
= NNP N
0.4 CD N
) ) N
As IN N
expected VBN N
, , N
the DT N
in IN N
vitro JJ N
addition NN N
of IN N
aspirin NN N
reduced VBN N
AA NNP N
induced JJ N
PA NNP N
( ( N
p VB N
< RB N
0.01 CD N
) ) N
, , N
but CC N
not RB N
that IN N
induced VBN N
by IN N
ADP NNP N
( ( N
p JJ N
= NNP N
0.5 CD N
) ) N
The DT N
addition NN N
of IN N
verbascoside NN N
to TO N
the DT N
blood NN N
of IN N
aspirin-treated JJ N
patients NNS N
did VBD N
not RB N
improve VB N
the DT N
values NNS N
of IN N
PA NNP N
after IN N
AA NNP N
stimulus NN N
( ( N
p JJ N
= NNP N
0.8 CD N
) ) N
, , N
whereas IN N
it PRP N
ensured VBD N
a DT N
stronger JJR N
inhibition NN N
after IN N
ADP NNP N
stimulus NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
Verbascoside NNP N
in IN N
vitro JJ N
affects NNS N
PA VBN N
by IN N
mildly RB N
inhibiting VBG N
aggregation NN N
, , N
triggered VBD N
both DT N
by IN N
ADP NNP N
and CC N
AA NNP N
These DT N
preliminary JJ N
data NNS N
, , N
while IN N
intriguing NN N
, , N
require VBP N
confirmation NN N
in IN N
subjects NNS N
receiving VBG N
verbascoside NN N
orally RB N
in IN N
order NN N
to TO N
determine VB N
whether IN N
these DT N
findings NNS N
are VBP N
clinically RB N
relevant JJ N
-DOCSTART- -X- O O 19264972

Acute NNP N
and CC N
short-term JJ N
effects NNS N
of IN N
secondhand NN N
smoke NN N
on IN N
lung NN N
function NN N
and CC N
cytokine NN N
production NN N
RATIONALE VB N
The DT N
acute JJ N
effect NN N
of IN N
secondhand NN N
smoke NN N
( ( N
SHS NNP N
) ) N
on IN N
lung NN N
function NN N
and CC N
the DT N
duration NN N
of IN N
system NN N
disruption NN N
remain VBP N
unknown JJ N
OBJECTIVES NNP N
To TO N
assess VB N
the DT N
SHS NNP N
effects NNS N
and CC N
their PRP$ N
duration NN N
on IN N
lung NN N
function NN N
and CC N
inflammatory JJ N
markers NNS N
METHODS NNP N
In IN N
a DT N
randomized JJ N
single-blind NN N
crossover NN N
experiment NN N
data NNS N
were VBD N
obtained VBN N
from IN N
16 CD 3_p
( ( N
8 CD 3_p
women NNS 2_p
) ) N
nonsmoking VBG N
adults NNS 1_p
at IN N
baseline NN N
and CC N
at IN N
0 CD N
, , N
1 CD N
, , N
and CC N
3 CD N
hours NNS N
after IN N
a DT N
1-hour JJ N
SHS NNP N
exposure NN N
set VBN N
at IN N
bar/restaurant JJ N
SHS NNP N
levels NNS N
MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Serum NNP N
and CC N
urine JJ N
cotinine NN N
, , N
lung NN N
function NN N
, , N
and CC N
cytokines NNS N
IL-4 NNP N
, , N
IL-5 NNP N
, , N
IL-6 NNP N
, , N
tumor NN N
necrosis NN N
factor NN N
( ( N
TNF NNP N
) ) N
-alpha NN N
, , N
and CC N
IFN-gamma NNP N
At IN N
0 CD N
hours NNS N
most RBS N
lung JJ N
function NN N
parameters NNS N
were VBD N
significantly RB N
reduced VBN N
( ( N
indicative JJ N
: : N
FEV NNP N
( ( N
1 CD N
) ) N
, , N
4.3 CD N
+/- JJ N
0.4 CD N
vs. FW N
3.8 CD N
+/- JJ N
0.3 CD N
L NNP N
; : N
FEV NNP N
( ( N
1 CD N
) ) N
/FVC NN N
, , N
0.9 CD N
+/- JJ N
0.1 CD N
vs. FW N
0.8 CD N
+/- JJ N
0.1 CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
but CC N
at IN N
3 CD N
hours NNS N
they PRP N
were VBD N
at IN N
baseline NN N
levels NNS N
In IN N
contrast NN N
, , N
cotinine NN N
( ( N
serum NN N
, , N
8.9 CD N
+/- JJ N
3.2 CD N
vs. FW N
35.5 CD N
+/- JJ N
10.2 CD N
ng JJ N
x NN N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
IL-4 NNP N
( ( N
41.3 CD N
+/- JJ N
5.8 CD N
vs. FW N
44.2 CD N
+/- JJ N
4.5 CD N
pg NN N
x NN N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
IL-5 NNP N
( ( N
36.1 CD N
+/- JJ N
3.2 CD N
vs. FW N
60.1 CD N
+/- JJ N
7.0 CD N
pg NN N
x NN N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
IL-6 NNP N
( ( N
2.5 CD N
+/- JJ N
0.3 CD N
vs. FW N
7.6 CD N
+/- JJ N
1.4 CD N
pg NN N
x NN N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
and CC N
IFN-gamma NNP N
( ( N
0.3 CD N
+/- JJ N
0.2 CD N
vs. FW N
0.6 CD N
+/- JJ N
0.2 CD N
IU NNP N
x NNP N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
at IN N
3 CD N
hours NNS N
were VBD N
higher JJR N
than IN N
at IN N
baseline NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
IL-4 JJ N
and CC N
TNF-alpha NNP N
increased VBD N
only RB N
in IN N
men NNS N
, , N
whereas IN N
IL-5 NNP N
, , N
IL-6 NNP N
, , N
and CC N
IFN-gamma NNP N
were VBD N
different JJ N
between IN N
sexes NNS N
after IN N
exposure NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
Regression NN N
analyses VBZ N
revealed JJ N
inverse JJ N
associations NNS N
of IN N
FEV NNP N
( ( N
1 CD N
) ) N
and CC N
FEV NNP N
( ( N
1 CD N
) ) N
/FVC NN N
ratio NN N
with IN N
IL-5 NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
men NNS N
and CC N
with IN N
IL-5 NNP N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
IL-6 NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
IFN-gamma NNP N
( ( N
P NNP N
= NNP N
0.034 CD N
) ) N
and CC N
serum JJ N
cotinine NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
women NNS N
CONCLUSIONS NNP N
We PRP N
conclude VBP N
that IN N
1 CD N
hour NN N
of IN N
SHS NNP N
exposure NN N
at IN N
bar/restaurant NN N
levels NNS N
is VBZ N
accompanied VBN N
by IN N
significant JJ N
decrements NNS N
on IN N
lung NN N
function NN N
and CC N
marked JJ N
increases NNS N
in IN N
inflammatory JJ N
cytokines NNS N
, , N
particularly RB N
in IN N
men NNS N
More RBR N
importantly RB N
, , N
whereas IN N
most JJS N
smoke-induced JJ N
effects NNS N
on IN N
lung NN N
function NN N
appear VBP N
to TO N
recede VB N
within IN N
60 CD N
minutes NNS N
, , N
inflammatory JJ N
cytokines NNS N
remain VBP N
elevated JJ N
for IN N
at IN N
least JJS N
3 CD N
hours NNS N
after IN N
exposure NN N
to TO N
SHS NNP N
-DOCSTART- -X- O O 1451242

A DT N
prospective JJ N
, , N
placebo-controlled JJ N
, , N
randomized JJ N
trial NN N
of IN N
intravenous JJ N
streptokinase NN N
and CC N
angioplasty JJ N
versus NN N
lone NN N
angioplasty JJ N
therapy NN N
of IN N
acute JJ N
myocardial JJ N
infarction NN N
BACKGROUND IN N
The DT N
value NN N
of IN N
routine JJ N
administration NN N
of IN N
intravenous JJ N
thrombolytic JJ N
agents NNS N
during IN N
percutaneous JJ N
transluminal JJ N
coronary NN N
angioplasty NN N
( ( N
PTCA NNP N
) ) N
therapy NN N
of IN N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
MI NNP N
) ) N
has VBZ N
not RB N
been VBN N
determined VBN N
Therefore RB N
, , N
we PRP N
prospectively RB N
randomized VBD N
122 CD N
patients NNS N
with IN N
evolving VBG 4_p
MI NNP 4_p
to TO 4_p
PTCA NNP 4_p
therapy NN 4_p
with IN N
or CC N
without IN N
adjunctive JJ N
intravenous JJ N
streptokinase NN N
therapy NN N
METHODS NNP N
AND CC N
RESULTS NNP N
Patients NNP N
with IN N
ECG NNP 4_p
ST NNP 4_p
segment NN 4_p
elevation NN 4_p
who WP N
presented VBD N
within IN N
4 CD N
hours NNS N
of IN N
symptom JJ N
onset NN N
, , N
had VBD N
no DT N
contraindication NN N
to TO N
thrombolytic JJ N
therapy NN N
, , N
and CC N
were VBD N
not RB N
in IN N
cardiogenic JJ N
shock NN N
were VBD N
enrolled VBN N
They PRP N
were VBD N
treated VBN N
immediately RB N
with IN N
intravenous JJ N
heparin NNS N
( ( N
10,000 CD N
units NNS N
) ) N
and CC N
oral JJ N
aspirin NN N
( ( N
325 CD N
mg NN N
) ) N
and CC N
randomized VBN N
to TO N
treatment NN N
with IN N
placebo NN N
or CC N
streptokinase NN N
( ( N
1.5 CD N
M NNP N
units NNS N
) ) N
administered VBD N
intravenously RB N
over IN N
30 CD N
minutes NNS N
Patients NNS N
then RB N
were VBD N
taken VBN N
immediately RB N
to TO N
the DT N
catheterization NN N
laboratory NN N
, , N
and CC N
those DT N
with IN N
suitable JJ N
coronary JJ N
anatomy NN N
underwent JJ N
immediate JJ N
PTCA NNP N
Subsequent NNP N
clinical JJ N
course NN N
, , N
serial JJ N
radionuclide NN N
ventriculography NN N
, , N
and CC N
6-month JJ N
repeat NN N
angiography NN N
were VBD N
analyzed VBN N
A DT N
total NN N
of IN N
106 CD N
patients NNS N
were VBD N
treated VBN 4_p
with IN 4_p
PTCA NNP 4_p
Use NNP N
of IN N
PTCA NNP N
was VBD N
similar JJ N
for IN N
placebo NN N
( ( N
92 CD N
% NN N
) ) N
and CC N
streptokinase NNP N
( ( N
83 CD N
% NN N
) ) N
groups NNS N
Angioplasty NNP N
was VBD N
successful JJ N
in IN N
95 CD N
% NN N
of IN N
patients NNS N
, , N
with IN N
no DT N
difference NN N
in IN N
placebo NN N
( ( N
93 CD N
% NN N
) ) N
and CC N
streptokinase NNP N
( ( N
98 CD N
% NN N
) ) N
groups NNS N
Serial JJ N
radionuclide NN N
ventriculography NN N
demonstrated VBD N
no DT N
difference NN N
in IN N
24-hour JJ N
( ( N
52 CD N
+/- JJ N
12 CD N
% NN N
versus NN N
50 CD N
+/- JJ N
12 CD N
% NN N
) ) N
or CC N
6-week JJ N
( ( N
51 CD N
+/- JJ N
12 CD N
% NN N
versus NN N
51 CD N
+/- JJ N
13 CD N
% NN N
) ) N
ejection NN N
fraction NN N
values NNS N
for IN N
placebo NN N
and CC N
streptokinase NN N
groups NNS N
, , N
respectively RB N
Contrast NNP N
ventriculography NN N
demonstrated VBD N
improvement NN N
in IN N
immediate NN N
( ( N
54 CD N
+/- JJ N
12 CD N
% NN N
) ) N
versus NN N
6-month JJ N
( ( N
60 CD N
+/- JJ N
15 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
values NNS N
for IN N
the DT N
overall JJ N
group NN N
No DT N
differences NNS N
in IN N
6-month JJ N
values NNS N
were VBD N
present JJ N
( ( N
58 CD N
+/- JJ N
15 CD N
% NN N
versus NN N
62 CD N
+/- JJ N
15 CD N
% NN N
, , N
p NN N
= NNP N
NS NNP N
) ) N
for IN N
placebo NN N
and CC N
streptokinase NN N
groups NNS N
, , N
respectively RB N
Coronary JJ N
angiography NN N
was VBD N
performed VBN N
in IN N
75 CD N
% NN N
of IN N
the DT N
90 CD N
patients NNS N
eligible JJ N
for IN N
restudy NN N
Arterial JJ N
patency NN N
was VBD N
87 CD N
% NN N
at IN N
6 CD N
months NNS N
, , N
and CC N
coronary JJ N
restenosis NN N
was VBD N
present JJ N
in IN N
38 CD N
% NN N
of IN N
patients NNS N
No DT N
differences NNS N
in IN N
chronic JJ N
patency NN N
or CC N
restenosis NN N
were VBD N
detected VBN N
for IN N
the DT N
two CD N
treatment NN N
groups NNS N
Although IN N
adjunctive JJ N
intravenous JJ N
streptokinase NN N
therapy NN N
did VBD N
not RB N
improve VB N
outcome NN N
, , N
it PRP N
did VBD N
complicate VB N
the DT N
hospital NN N
course NN N
Hospitalization NNP N
was VBD N
longer JJR N
( ( N
9.3 CD N
+/- JJ N
5.0 CD N
versus NN N
7.7 CD N
+/- JJ N
4.4 CD N
days NNS N
, , N
p VBP N
= RB N
0.046 CD N
) ) N
and CC N
more RBR N
costly JJ N
( ( N
$ $ N
25,191 CD N
+/- JJ N
15,368 CD N
versus IN N
$ $ N
19,643 CD N
+/- JJ N
7,250 CD N
, , N
p NN N
< NNP N
0.02 CD N
) ) N
Transfusion NN N
rate NN N
was VBD N
higher JJR N
( ( N
39 CD N
% NN N
versus IN N
8 CD N
% NN N
, , N
p NN N
= NNP N
0.0001 CD N
) ) N
and CC N
need VBP N
for IN N
emergency NN N
coronary JJ N
bypass NN N
surgery NN N
was VBD N
greater JJR N
( ( N
10.3 CD N
% NN N
versus IN N
1.6 CD N
% NN N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
for IN N
the DT N
streptokinase-treated JJ N
patients NNS N
CONCLUSIONS NNP N
Adjunctive NNP N
intravenous JJ N
streptokinase NN N
therapy NN N
does VBZ N
not RB N
enhance VB N
early JJ N
preservation NN N
of IN N
ventricular JJ N
function NN N
, , N
improve VB N
arterial JJ N
patency NN N
rates NNS N
, , N
or CC N
lower JJR N
restenosis NN N
rates NNS N
after IN N
PTCA NNP N
therapy NN N
of IN N
acute JJ N
MI NNP N
Hospital NNP N
course NN N
is VBZ N
longer JJR N
, , N
more RBR N
expensive JJ N
, , N
and CC N
more RBR N
complicated JJ N
For IN N
these DT N
reasons NNS N
, , N
PTCA NNP N
therapy NN N
of IN N
acute JJ N
MI NNP N
should MD N
not RB N
be VB N
routinely RB N
performed VBN N
with IN N
adjunctive JJ N
intravenous JJ N
streptokinase NN N
therapy NN N
-DOCSTART- -X- O O 21090563

Blockade NN N
of IN N
cytotoxic JJ N
T-lymphocyte JJ N
antigen-4 NN N
by IN N
ipilimumab JJ N
results NNS N
in IN N
dysregulation NN N
of IN N
gastrointestinal JJ N
immunity NN N
in IN N
patients NNS N
with IN N
advanced JJ N
melanoma NN 4_p
Blockade NNP N
of IN N
cytotoxic JJ N
T-lymphocyte JJ N
antigen-4 NN N
( ( N
CTLA-4 NNP N
) ) N
by IN N
ipilimumab NN N
leads NNS N
to TO N
immune-mediated JJ N
tumor NN N
regression NN N
and CC N
immune-related JJ N
adverse JJ N
events NNS N
( ( N
irAEs NN N
) ) N
, , N
including VBG N
diarrhea NN N
and CC N
colitis NN N
The DT N
current JJ N
analyses NNS N
were VBD N
undertaken JJ N
to TO N
promote VB N
an DT N
understanding NN N
of IN N
the DT N
underlying VBG N
mechanism NN N
of IN N
action NN N
and CC N
to TO N
identify VB N
potential JJ N
biomarkers NNS N
that WDT N
could MD N
help VB N
in IN N
the DT N
prediction NN N
and CC N
management NN N
of IN N
ipilimumab-induced JJ N
gastrointestinal JJ N
irAEs NN N
Treatment-naïve CD N
or CC N
previously RB N
treated VBN N
patients NNS N
with IN N
unresectable JJ N
stage NN N
III/IV NNP N
melanoma NN N
( ( N
n JJ N
= NNP N
115 CD N
) ) N
received VBD N
open-label JJ N
ipilimumab NN N
( ( N
10 CD N
mg/kg NN N
every DT N
3 CD N
weeks NNS N
for IN N
four CD N
doses NNS N
) ) N
and CC N
were VBD N
randomized VBN N
to TO N
receive VB N
concomitant NN N
blinded VBN N
prophylactic JJ N
oral JJ N
budesonide NN N
( ( N
9 CD N
mg/d NN N
with IN N
gradual JJ N
taper NN N
through IN N
week NN N
16 CD N
) ) N
or CC N
placebo NN N
Outcome NNP N
measures NNS N
included VBD N
histologic JJ N
assessment NN N
of IN N
bowel NN N
biopsies NNS N
and CC N
assessment NN N
of IN N
serologic JJ N
markers NNS N
of IN N
inflammatory JJ N
bowel NN N
disease NN N
( ( N
IBD NNP N
) ) N
, , N
fecal JJ N
calprotectin NN N
levels NNS N
, , N
and CC N
polymorphisms NNS N
in IN N
immune-related JJ N
genes NNS N
Ipilimumab NNP N
resulted VBD N
in IN N
dysregulation NN N
of IN N
gastrointestinal JJ N
mucosal NN N
immunity NN N
as IN N
evidenced VBN N
by IN N
altered JJ N
antibody NN N
levels NNS N
to TO N
enteric VB N
flora NNS N
, , N
inflammatory NN N
cell NN N
infiltration NN N
into IN N
gastrointestinal JJ N
mucosa NN N
, , N
and CC N
increased VBD N
fecal JJ N
calprotectin NN N
associated VBN N
with IN N
diarrhea NN N
and CC N
clinical JJ N
evidence NN N
of IN N
colitis NN N
The DT N
pattern NN N
of IN N
ipilimumab-induced JJ N
antibody NN N
titers NNS N
to TO N
microbial JJ N
flora NN N
and CC N
the DT N
histologic NN N
features NNS N
and CC N
location NN N
of IN N
the DT N
inflammation NN N
were VBD N
distinct JJ N
from IN N
classic JJ N
IBD NNP N
Prophylactic NNP N
budesonide NN N
did VBD N
not RB N
prevent VB N
ipilimumab-induced JJ N
bowel NN N
inflammation NN N
Despite IN N
an DT N
observed JJ N
association NN N
between IN N
colonic JJ N
inflammation NN N
and CC N
grade VB N
2 CD N
or CC N
higher JJR N
diarrhea NN N
, , N
no DT N
baseline NN N
biomarkers NNS N
could MD N
reliably RB N
predict VB N
development NN N
of IN N
gastrointestinal JJ N
toxicity NN N
Although IN N
classic JJ N
IBD NNP N
and CC N
ipilimumab-related JJ N
gastrointestinal JJ N
toxicity NN N
are VBP N
both DT N
immune JJ N
mediated VBN N
, , N
the DT N
observed JJ N
pattern NN N
of IN N
biomarkers NNS N
suggests VBZ N
ipilimumab-related JJ N
gastrointestinal JJ N
toxicity NN N
may MD N
be VB N
a DT N
distinct JJ N
clinicopathologic NN N
entity NN N
-DOCSTART- -X- O O 17977295

Effect NN N
of IN N
a DT N
dental JJ N
cream NN N
containing VBG N
amorphous JJ N
cream NN N
phosphate NN N
complexes NNS N
on IN N
white JJ N
spot NN N
lesion NN N
regression NN N
assessed VBN N
by IN N
laser NN N
fluorescence NN N
PURPOSE NNP N
To TO N
investigate VB N
and CC N
compare VB N
the DT N
effects NNS N
of IN N
a DT N
dental JJ N
cream NN N
containing VBG N
complexes NNS N
of IN N
casein JJ N
phosphoprotein-amorphous JJ N
calcium NN N
phosphate NN N
( ( N
CPP-ACP NNP N
) ) N
and CC N
fluoride JJ N
mouthwashes NNS N
on IN N
the DT N
regression NN N
of IN N
white JJ N
spot NN N
lesions NNS N
( ( N
WSL NNP N
) ) N
MATERIALS NNP N
AND CC N
METHODS NNP N
The DT N
study NN N
group NN N
consisted VBD N
of IN N
26 CD N
healthy JJ N
adolescents NNS N
( ( N
mean JJ N
age NN N
14.6 CD N
years NNS N
) ) N
exhibiting VBG N
60 CD N
teeth NNS N
with IN N
152 CD N
visible JJ N
WSL NNP N
sites NNS N
on IN N
incisors NNS N
and CC N
canines NNS N
immediately RB N
after IN N
debonding VBG N
of IN N
fixed VBN N
orthodontic JJ N
appliances NNS N
After IN N
bracket NN N
removal NN N
, , N
professional JJ N
tooth NN N
cleaning NN N
and CC N
drying NN N
, , N
a DT N
visual JJ N
scoring NN N
( ( N
0-4 JJ N
) ) N
and CC N
laser JJR N
fluorescence NN N
( ( N
LF NNP N
) ) N
readings NNS N
were VBD N
carried VBN N
out RP N
The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
different JJ N
treatment NN N
protocols NNS N
with IN N
the DT N
aim NN N
of IN N
remineralising VBG N
the DT N
lesions NNS N
: : N
A DT N
) ) N
daily RB N
topical JJ N
applications NNS N
of IN N
a DT N
dental JJ N
cream NN N
containing VBG N
CPP-ACP NNP N
( ( N
Topacal NNP N
) ) N
for IN N
3 CD N
months NNS N
followed VBN N
by IN N
a DT N
3-month JJ N
period NN N
of IN N
daily JJ N
toothbrushing VBG N
with IN N
fluoridated JJ N
dentifrice NN N
, , N
or CC N
B NNP N
) ) N
daily RB N
0.05 CD N
% NN N
sodium NN N
fluoride NN N
mouthwash NN N
combined VBN N
with IN N
fluoridated JJ N
dentifrice NN N
for IN N
6 CD N
months NNS N
The DT N
registrations NNS N
were VBD N
repeated VBN N
after IN N
1 CD N
, , N
3 CD N
, , N
6 CD N
and CC N
12 CD N
months NNS N
and CC N
follow-up JJ N
data NNS N
were VBD N
compared VBN N
with IN N
baseline NN N
with IN N
aid NN N
of IN N
chi-square NN N
and CC N
paired VBD N
t-tests NNS N
RESULTS VB N
A DT N
significant JJ N
improvement NN N
of IN N
the DT N
clinical JJ N
WSL-scores NNS N
was VBD N
found VBN N
over IN N
time NN N
in IN N
both DT N
groups NNS N
, , N
but CC N
there RB N
was VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
concerning VBG N
the DT N
number NN N
of IN N
sites NNS N
that WDT N
totally RB N
disappeared VBD N
after IN N
12 CD N
months NNS N
in IN N
favour NN N
of IN N
the DT N
CPP-ACP NNP N
regime NN N
, , N
63 CD N
% NN N
compared VBN N
with IN N
25 CD N
% NN N
respectively RB N
The DT N
clinical JJ N
registrations NNS N
were VBD N
mirrored VBN N
by IN N
a DT N
statistically RB N
significant JJ N
decrease NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
LF NNP N
readings NNS N
at IN N
the DT N
6- JJ N
and CC N
12-month JJ N
follow-ups NNS N
compared VBN N
with IN N
baseline NN N
No DT N
significant JJ N
differences NNS N
were VBD N
displayed VBN N
between IN N
the DT N
groups NNS N
CONCLUSIONS NNP N
Clinical NNP N
scoring NN N
and CC N
LF NNP N
assessment NN N
suggested VBD N
that IN N
both DT N
regimens NNS N
could MD N
promote VB N
regression NN N
of IN N
WSL NNP N
after IN N
debonding VBG N
of IN N
fixed VBN N
orthodontic JJ N
appliances NNS N
The DT N
visual JJ N
evaluation NN N
suggested VBD N
an DT N
aesthetically RB N
more RBR N
favourable JJ N
outcome NN N
of IN N
the DT N
amorphous JJ N
calcium NN N
phosphate NN N
treatments NNS N
-DOCSTART- -X- O O 6958487

Budesonide NNP N
and CC N
beclomethasone NN N
dipropionate NN N
in IN N
hay NN 4_p
fever NN 4_p
- : N
a DT N
single JJ N
blind NN N
comparison NN N
93 CD 3_p
patients NNS N
with IN N
seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
took VBD N
part NN N
in IN N
a DT N
single JJ N
blind NN N
randomized VBD N
clinical JJ N
comparison NN N
of IN N
budesonide NN N
and CC N
beclomethasone NN N
dipropionate NN N
( ( N
Becotide NNP N
Nasal NNP N
) ) N
All DT N
patients NNS N
were VBD N
sensitive JJ N
to TO N
either DT N
birch NN N
or CC N
grass NN N
pollen NN N
, , N
their PRP$ N
sensitivity NN N
being VBG N
confirmed VBN N
by IN N
a DT N
skin NN N
prick NN N
test NN N
The DT N
total JJ N
daily JJ N
dose NN N
was VBD N
400 CD N
micrograms NNS N
for IN N
both DT N
drugs NNS N
Budesonide NNP N
was VBD N
administered VBN N
twice RB N
a DT N
day NN N
and CC N
Becotide NNP N
Nasal NNP N
four CD N
times NNS N
a DT N
day NN N
Symptoms NNS N
were VBD N
assessed VBN N
over IN N
a DT N
four-week JJ N
period NN N
starting VBG N
with IN N
a DT N
run-in JJ N
period NN N
of IN N
one CD N
week NN N
There EX N
was VBD N
no DT N
placebo NN N
control NN N
group NN N
Daily NNP N
pollen NN N
counts NNS N
were VBD N
measured VBN N
throughout IN N
the DT N
trial NN N
The DT N
patients NNS N
' POS N
diary JJ N
cards NNS N
revealed VBD N
that IN N
both DT N
drugs NNS N
had VBD N
a DT N
beneficial JJ N
therapeutic JJ N
effect NN N
, , N
and CC N
that IN N
budesonide NN N
was VBD N
significantly RB N
more RBR N
active JJ N
than IN N
Becotide NNP N
Nasal NNP N
The DT N
side NN N
effects NNS N
of IN N
both DT N
drugs NNS N
were VBD N
few JJ N
and CC N
transient NN N
-DOCSTART- -X- O O 9322632

A DT N
comparison NN N
of IN N
intermittent JJ N
vaginal JJ N
administration NN N
of IN N
misoprostol NN N
with IN N
continuous JJ N
dinoprostone NN N
for IN N
cervical JJ N
ripening NN N
and CC N
labor NN N
induction NN N
OBJECTIVE CC N
Our PRP$ N
purpose NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
vaginal JJ N
administration NN N
of IN N
misoprostol NN N
( ( N
Cytotec NNP N
) ) N
with IN N
that DT N
of IN N
dinoprostone NN N
( ( N
Cervidil NNP N
) ) N
on IN N
cervical JJ N
ripening NN N
and CC N
labor NN N
induction NN N
STUDY NNP N
DESIGN NNP N
Two CD 3_p
hundred VBD 3_p
patients NNS 3_p
with IN N
indications NNS 4_p
for IN 4_p
induction NN 4_p
of IN 4_p
labor NN 4_p
and CC 4_p
unfavorable JJ 4_p
cervical JJ 4_p
examinations NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
vaginally RB N
administered VBN N
misoprostol NN N
( ( N
prostaglandin JJ N
E1 NNP N
) ) N
or CC N
the DT N
dinoprostone NN N
( ( N
prostaglandin JJ N
E2 NNP N
) ) N
vaginal NN N
insert NN N
Twenty-five JJ N
microgram JJ N
tablets NNS N
of IN N
misoprostol NN N
were VBD N
placed VBN N
in IN N
the DT N
posterior JJ N
vaginal JJ N
fornix NN N
every DT N
4 CD N
hours NNS N
for IN N
a DT N
maximum NN N
of IN N
six CD N
doses NNS N
Additional NNP N
misoprostol NN N
was VBD N
not RB N
given VBN N
after IN N
either DT N
spontaneous JJ N
rupture NN N
of IN N
membranes NNS N
, , N
adequate JJ N
cervical JJ N
ripening NN N
( ( N
Bishop NNP N
score NN N
of IN N
> NN N
or CC N
= VB N
8 CD N
or CC N
cervical JJ N
dilatation NN N
of IN N
> NN N
or CC N
= $ N
3 CD N
cm NN N
) ) N
, , N
or CC N
beginning NN N
of IN N
active JJ N
labor NN N
The DT N
vaginal JJ N
insert NN N
, , N
Cervidil NNP N
, , N
containing VBG N
10 CD N
mg NN N
of IN N
dinoprostone NN N
in IN N
a DT N
timed-release JJ N
preparation NN N
was VBD N
placed VBN N
in IN N
the DT N
posterior JJ N
vaginal JJ N
formix NN N
for IN N
a DT N
maximum JJ N
period NN N
of IN N
24 CD N
hours NNS N
The DT N
vaginal JJ N
insert NN N
was VBD N
removed VBN N
for IN N
spontaneous JJ N
rupture NN N
of IN N
membranes NNS N
, , N
entry NN N
into IN N
active JJ N
labor NN N
, , N
adequate JJ N
cervical JJ N
ripening NN N
, , N
or CC N
abnormality NN N
of IN N
uterine JJ N
contractile NN N
pattern NN N
or CC N
fetal JJ N
cardiac JJ N
activity NN N
RESULTS NN N
Of IN N
the DT N
200 CD 3_p
patients NNS N
enrolled VBD N
, , N
99 CD 3_p
were VBD N
randomized VBN N
to TO N
misoprostol VB 3_p
and CC N
101 CD 3_p
to TO N
dinoprostone VB 3_p
The DT N
average JJ N
interval NN N
from IN N
start NN N
of IN N
induction NN N
to TO N
vaginal JJ N
delivery NN N
was VBD N
1 CD N
hour NN N
shorter NN N
in IN N
the DT N
misoprostol NN N
group NN N
( ( N
1296.7 CD N
+/- JJ N
722.1 CD N
minutes NNS N
) ) N
than IN N
in IN N
the DT N
dinoprostone NN N
group NN N
( ( N
1360.0 CD N
+/- JJ N
792.0 CD N
minutes NNS N
) ) N
, , N
but CC N
this DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.97 CD N
) ) N
Oxytocin NNP N
augmentation NN N
of IN N
labor NN N
was VBD N
used VBN N
in IN N
50 CD N
( ( N
50.5 CD N
% NN N
) ) N
misoprostol-treated JJ N
patients NNS N
and CC N
43 CD N
( ( N
43.5 CD N
% NN N
) ) N
dinoprostone-treated JJ N
patients NNS N
( ( N
relative JJ N
risk NN N
1.14 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.86 CD N
to TO N
1.51 CD N
, , N
p NN N
= NNP N
0.35 CD N
) ) N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
routes NNS N
of IN N
delivery NN N
with IN N
misoprostol NN N
or CC N
dinoprostone NN N
Overall NNP N
, , N
38 CD N
patients NNS N
( ( N
19.3 CD N
% NN N
) ) N
had VBD N
cesarean JJ 4_p
deliveries NNS 4_p
There EX N
was VBD N
a DT N
significantly RB N
lower JJR N
prevalence NN N
of IN N
tachysystole NN N
( ( N
six CD N
or CC N
more JJR N
uterine JJ N
contractions NNS N
in IN N
a DT N
10-minute JJ N
window NN N
for IN N
two CD N
consecutive JJ N
10-minute JJ N
periods NNS N
) ) N
in IN N
the DT N
misoprostol NN N
group NN N
( ( N
7.1 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
dinoprostone NN N
group NN N
( ( N
18.4 CD N
% NN N
) ) N
( ( N
relative JJ N
risk NN N
0.52 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.31 CD N
to TO N
0.89 CD N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
frequency NN N
of IN N
uterine JJ N
hyperstimulation NN N
or CC N
hypertonus NN N
Abnormal NNP N
fetal JJ N
heart NN N
rate NN N
tracings NNS N
were VBD N
found VBN N
in IN N
23 CD N
( ( N
23.2 CD N
% NN N
) ) N
of IN N
misoprostol-treated JJ N
patients NNS N
and CC N
35 CD N
( ( N
35.7 CD N
% NN N
) ) N
of IN N
dinoprostone-treated JJ N
patients NNS N
( ( N
relative JJ N
risk NN N
0.73 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.52 CD N
to TO N
1.01 CD N
, , N
p NN N
= NNP N
0.0546 CD N
) ) N
No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
meconium NN N
passage NN N
, , N
1- JJ N
or CC N
5-minute JJ N
Apgar NNP N
scores NNS N
< VBP N
7 CD N
, , N
neonatal JJ N
resuscitations NNS N
, , N
or CC N
admissions NNS N
to TO N
the DT N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
between IN N
the DT N
two CD N
groups NNS N
CONCLUSIONS NNP N
Vaginally NNP N
administered VBD N
misoprostol NN N
is VBZ N
as RB N
effective JJ N
as IN N
dinoprostone NN N
for IN N
cervical JJ N
ripening NN N
and CC N
the DT N
induction NN N
of IN N
labor NN N
Mean JJ N
time NN N
intervals NNS N
to TO N
delivery NN N
, , N
need NN N
for IN N
oxytocin JJ N
augmentation NN N
, , N
and CC N
routes NNS N
of IN N
delivery NN N
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
Incidence NN N
of IN N
uterine JJ N
tachysystole NN N
with IN N
misoprostol NN N
every DT N
4 CD N
hours NNS N
was VBD N
significantly RB N
less JJR N
than IN N
with IN N
dinoprostone NN N
-DOCSTART- -X- O O 14690574

[ NN N
Combined VBD N
preoperative JJ N
xeloda NN N
and CC N
radiotherapy NN N
for IN N
lower JJR 4_p
rectal NN 4_p
cancer NN 4_p
] NNP N
OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
combined JJ N
preoperative JJ N
xeloda NN N
and CC N
pelvic JJ N
radiotherapy NN N
on IN N
locally RB 4_p
advanced VBN 4_p
lower JJR 4_p
rectal JJ 4_p
cancer NN 4_p
METHODS NNP N
Sixty NNP 3_p
lower JJR N
rectal JJ N
cancer NN N
patients NNS N
were VBD N
divided VBN N
randomly RB N
into IN N
two CD N
groups NNS N
30 CD 3_p
patients NNS N
( ( N
Group NNP N
A NNP N
) ) N
were VBD N
treated VBN N
with IN N
operation NN N
alone RB N
and CC N
30 CD N
patients NNS N
( ( N
Group NNP N
B NNP N
) ) N
were VBD N
treated VBN N
with IN N
xeloda NNP N
and CC N
radiotherapy NN N
before IN N
operation NN N
RESULTS VB N
The DT N
operative JJ N
resection NN N
, , N
anal JJ N
preservation NN N
and CC N
local JJ N
recurrence NN N
rates NNS N
were VBD N
86.66 CD N
% NN N
, , N
33.33 CD N
% NN N
, , N
15.38 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
100 CD N
% NN N
, , N
83.33 CD N
% NN N
, , N
0 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
and CC N
P NNP N
< NNP N
0.01 CD N
) ) N
CONCLUSION NNP N
Combined VBD N
preoperative JJ N
xeloda NN N
and CC N
radiotherapy NN N
for IN N
lower JJR N
rectal NN N
cancer NN N
is VBZ N
able JJ N
to TO N
significantly RB N
improve VB N
the DT N
operative JJ N
resection NN N
, , N
anal JJ N
preservation NN N
and CC N
decrease VB N
the DT N
local JJ N
recurrence NN N
rates NNS N
-DOCSTART- -X- O O 7554709

Pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
the DT N
monoamine NN N
oxidase NN N
B NNP N
inhibitor NN N
mofegiline NN N
assessed VBN N
during IN N
a DT N
phase NN N
I PRP N
dose VBP N
tolerance JJ N
trial NN N
The DT N
safety NN N
, , N
pharmacokinetics NNS N
, , N
and CC N
pharmacodynamics NNS N
of IN N
single JJ N
oral JJ N
doses NNS N
of IN N
up IN N
to TO N
48 CD N
mg NNS N
and CC N
daily JJ N
( ( N
for IN N
28 CD N
days NNS N
) ) N
doses NNS N
of IN N
up IN N
24 CD N
mg NNS N
mofegiline NN N
were VBD N
investigated VBN N
in IN N
healthy JJ N
male NN N
volunteers NNS N
Plasma NNP N
pharmacokinetics NNS N
indicated VBD N
rapid JJ N
absorption NN N
and CC N
elimination NN N
: : N
time NN N
to TO N
reach VB N
maximum JJ N
concentration NN N
occurred VBD N
at IN N
about IN N
1 CD N
hour NN N
; : N
half-life JJ N
ranged VBD N
from IN N
1 CD N
to TO N
3 CD N
hours NNS N
Maximal NNP N
plasma JJ N
concentration NN N
and CC N
area NN N
under IN N
the DT N
plasma JJ N
concentration-time JJ N
curve NN N
increased VBD N
and CC N
oral JJ N
clearance NN N
decreased VBD N
disproportionately RB N
with IN N
dose JJ N
Mofegiline NNP N
rapidly RB N
and CC N
markedly RB N
inhibited JJ N
platelet NN N
monoamine NN N
oxidase NN N
B NNP N
( ( N
MAOB NNP N
) ) N
activity NN N
, , N
which WDT N
returned VBD N
to TO N
baseline VB N
within IN N
14 CD N
days NNS N
Urinary JJ N
excretion NN N
of IN N
phenylethylamine NN N
increased VBN N
proportionately RB N
with IN N
doses NNS N
up RB N
to TO N
24 CD N
mg. NN N
No NNP N
changes NNS N
in IN N
urinary JJ N
elimination NN N
of IN N
catecholamines NNS N
, , N
blood NN N
pressure NN N
, , N
heart NN N
rate NN N
, , N
or CC N
ECG NNP N
were VBD N
observed VBN N
A DT N
classic JJ N
maximum NN N
tolerated VBD N
dose NN N
was VBD N
not RB N
achieved VBN N
in IN N
these DT N
studies NNS N
However RB N
, , N
the DT N
48 CD N
mg NN N
single JJ N
dose NN N
and CC N
the DT N
24 CD N
mg NN N
multiple JJ N
daily JJ N
dose NN N
far RB N
exceeded VBD N
the DT N
dose NN N
( ( N
1 CD N
mg NN N
) ) N
that WDT N
was VBD N
associated VBN N
with IN N
> JJ N
90 CD N
% NN N
platelet NN N
MAOB NNP N
inhibition NN N
-DOCSTART- -X- O O 20726255

[ NN N
Study NNP N
on IN N
safety NN N
and CC N
immunogenicity NN N
of IN N
oral JJ N
poliomyelitis NN N
attenuated VBD N
live JJ N
vaccine NN N
( ( N
human JJ N
diploid NN N
cell NN N
) ) N
] NN N
OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
safety NN N
and CC N
Immunogenicity NNP N
of IN N
the DT N
Poliomyelitis NNP N
vaccine NN N
( ( N
Human NNP N
Diploid NNP N
Cell NNP N
) ) N
in IN N
> NN N
or CC N
=2 VB 1_p
month-old JJ 1_p
children NNS N
METHODS NNP N
A NNP N
random NN N
, , N
blind NN N
and CC N
control NN N
trial NN N
, , N
1200 CD 3_p
healthy JJ N
children NNS 1_p
of IN N
2-5 JJ 1_p
months NNS 1_p
old JJ 1_p
in IN N
Jiangsu NNP N
province NN N
were VBD N
administered VBN N
OPV NNP 4_p
( ( 4_p
HDC NNP 4_p
) ) 4_p
vaccine NN 4_p
and CC N
control NN N
vaccines NNS N
The DT N
antibody NN N
was VBD N
tested VBN N
by IN N
neutralization NN N
test NN N
RESULTS NNP N
After IN N
3 CD N
doses NNS N
of IN N
the DT N
OPV NNP N
( ( N
HDC NNP N
) ) N
vaccine NN N
, , N
the DT N
systemic JJ N
reactions NNS N
were VBD N
mild JJ N
After IN N
1 CD N
month NN N
of IN N
vaccination NN N
with IN N
3 CD N
doses NNS N
of IN N
the DT N
OPV NNP N
( ( N
HDC NNP N
) ) N
vaccine NN N
, , N
the DT N
immune JJ N
success NN N
rates NNS N
of IN N
I PRP N
, , N
II NNP N
, , N
III NNP N
type NN N
were VBD N
98.28 CD N
% NN N
, , N
99.45 CD N
% NN N
, , N
and CC N
95.71 CD N
% NN N
respectively RB N
, , N
the DT N
GMTs NNP N
of IN N
I PRP N
, , N
II NNP N
, , N
III NNP N
type NN N
in IN N
susceptible JJ N
children NNS N
were VBD N
1:1243.72 CD N
, , N
1:234.38 CD N
and CC N
1:273.10 CD N
respectively RB N
CONCLUSIONS VB N
The DT N
OPV NNP N
( ( N
HDC NNP N
) ) N
vaccine NN N
was VBD N
safe JJ N
and CC N
immunogenicity NN N
for IN N
the DT N
children NNS N
> VBP N
or CC N
=2 JJ N
months NNS N
old JJ N
-DOCSTART- -X- O O 8512622

Ethanol-induced JJ N
alterations NNS N
in IN N
electroencephalographic JJ N
activity NN N
in IN N
adult NN 4_p
males NNS 4_p
The DT N
present JJ N
investigation NN N
examined VBD N
the DT N
effects NNS N
of IN N
placebo NN N
( ( N
P NNP N
) ) N
, , N
low-dose JJ N
( ( N
LD NNP N
) ) N
, , N
and CC N
high-dose JJ N
( ( N
HD NNP N
) ) N
ethanol VBP N
on IN N
electroencephalographic JJ N
( ( 4_p
EEG NNP 4_p
) ) 4_p
activity NN 4_p
in IN 4_p
21 CD 4_p
healthy JJ 4_p
, , 4_p
adult JJ 4_p
males NNS 4_p
( ( 4_p
X NNP 4_p
= VBZ 4_p
22.7 CD 4_p
years NNS 4_p
) ) 4_p
Only RB N
one CD N
condition NN N
( ( N
P NNP N
, , N
LD NNP N
, , N
or CC N
HD NNP N
) ) N
was VBD N
presented VBN N
per IN N
day NN N
and CC N
the DT N
condition NN N
order NN N
was VBD N
randomized VBN N
For IN N
each DT N
subject NN N
, , N
blood-alcohol NN N
levels NNS N
measured VBN N
via IN N
breathalyzer NN N
and CC N
EEG NNP N
activity NN N
, , N
using VBG N
the DT N
entire JJ N
10/20 CD N
International NNP N
System NNP N
, , N
were VBD N
recorded VBN N
both DT N
prior JJ N
to TO N
and CC N
at IN N
intervals NNS N
of IN N
35 CD N
, , N
70 CD N
, , N
105 CD N
, , N
and CC N
140 CD N
minutes NNS N
after IN N
P NNP N
, , N
LD NNP N
, , N
or CC N
HD NNP N
administration NN N
The DT N
Fast NNP N
Fourier NNP N
Transform NNP N
was VBD N
used VBN N
to TO N
calculate VB N
power NN N
spectral JJ N
densities NNS N
for IN N
each DT N
EEG NNP N
recording NN N
Measures NNS N
of IN N
the DT N
relative JJ N
areas NNS N
under IN N
the DT N
power NN N
spectral JJ N
curve NN N
were VBD N
made VBN N
for IN N
each DT N
of IN N
the DT N
following JJ N
frequency NN N
bands NNS N
: : N
slow VB N
alpha NN N
( ( N
7.5 CD N
to TO N
10 CD N
Hz NNP N
) ) N
; : N
fast VBN N
alpha NN N
( ( N
10.5 CD N
to TO N
13.0 CD N
Hz NNP N
) ) N
; : N
slow JJ N
beta NN N
( ( N
13.5 CD N
to TO N
19.5 CD N
Hz NNP N
) ) N
; : N
and CC N
fast VB N
beta NN N
( ( N
20 CD N
to TO N
26 CD N
Hz NNP N
) ) N
at IN N
electrodes NNS N
F3 NNP N
, , N
F4 NNP N
, , N
C3 NNP N
, , N
C4 NNP N
, , N
P3 NNP N
, , N
P4 NNP N
, , N
O1 NNP N
, , N
and CC N
O2 NNP N
Repeated-measures NNS N
multivariate JJ N
analysis NN N
of IN N
variance NN N
performed VBN N
on IN N
normalized JJ N
relative JJ N
area NN N
values NNS N
revealed VBD N
that IN N
ethanol NN N
had VBD N
significant JJ N
effects NNS N
on IN N
EEG NNP N
activity NN N
at IN N
anterior JJ N
sites NNS N
: : N
frontal NN N
( ( N
F3 NNP N
, , N
F4 NNP N
) ) N
and CC N
central JJ N
( ( N
C3 NNP N
, , N
C4 NNP N
) ) N
that WDT N
presented VBD N
as IN N
increased JJ N
activity NN N
in IN N
the DT N
slow JJ N
alpha NN N
frequency NN N
band NN N
These DT N
results NNS N
suggest VBP N
a DT N
differential JJ N
responsivity NN N
of IN N
both DT N
cortical JJ N
region NN N
and CC N
EEG NNP N
frequency NN N
band NN N
to TO N
the DT N
effects NNS N
of IN N
ethanol JJ N
ingestion NN N
-DOCSTART- -X- O O 20647058

Rationale NNP N
and CC N
design NN N
of IN N
a DT N
randomized JJ N
trial NN N
to TO N
evaluate VB N
an DT N
evidence-based JJ N
prescription NN N
drug NN N
label NN N
on IN N
actual JJ N
medication NN N
use NN N
BACKGROUND NNP N
Medication NNP N
errors NNS N
are VBP N
an DT N
important JJ N
public JJ N
health NN N
concern NN N
, , N
and CC N
poor JJ N
understanding NN N
of IN N
medication NN N
labels NNS N
are VBP N
a DT N
root NN N
cause NN N
Research NN N
shows VBZ N
that IN N
labels NNS N
are VBP N
variable JJ N
, , N
of IN N
poor JJ N
quality NN N
, , N
and CC N
not RB N
patient-centered JJ N
No DT N
real-world JJ N
trials NNS N
have VBP N
evaluated VBN N
whether IN N
improved JJ N
medication NN N
labels NNS N
can MD N
affect VB N
appropriate JJ N
medication NN N
use NN N
, , N
adherence NN N
or CC N
health NN N
outcomes NNS N
TRIAL NNP N
DESIGN NNP N
We PRP N
developed VBD N
an DT N
evidence-based JJ N
prescription NN N
label NN N
that WDT N
addresses VBZ N
both DT N
content NN N
and CC N
format NN N
The DT N
enhanced JJ N
label NN N
includes VBZ N
a DT N
universal JJ N
medication NN N
schedule NN N
( ( N
UMS NNP N
) ) N
that WDT N
standardizes VBZ N
the DT N
directions NNS N
for IN N
use NN N
incorporating VBG N
1 CD N
) ) N
standard NN N
time NN N
periods NNS N
for IN N
administration NN N
( ( N
morning NN N
, , N
noon NN N
, , N
evening NN N
, , N
and CC N
bedtime NN N
) ) N
, , N
2 CD N
) ) N
numeric JJ N
vs. FW N
alpha NN N
characters NNS N
, , N
3 CD N
) ) N
'carriage NN N
returns NNS N
' POS N
to TO N
separate VB N
daily JJ N
dose NN N
and CC N
4 CD N
) ) N
a DT N
graphic JJ N
aid NN N
to TO N
visually RB N
depict VB N
dose NN N
and CC N
frequency NN N
We PRP N
will MD N
evaluate VB N
the DT N
effect NN N
of IN N
providing VBG N
this DT N
label NN N
to TO N
randomly VB N
sampled VBN N
patients NNS 4_p
who WP 4_p
receive VBP 4_p
their PRP$ 4_p
care NN 4_p
from IN 4_p
free JJ 4_p
clinics NNS 4_p
, , 4_p
mobile JJ 4_p
vans NNS 4_p
and CC 4_p
federally RB 4_p
qualified JJ 4_p
health NN 4_p
centers NNS 4_p
( ( N
FQHCs NNP N
) ) N
in IN N
Northern NNP N
Virginia NNP N
We PRP N
will MD N
recruit VB N
patients NNS 4_p
with IN 4_p
diabetes NNS 4_p
or CC 4_p
hypertension NN 4_p
; : N
these DT N
patients NNS N
will MD N
be VB N
randomly RB N
assigned VBN N
to TO N
receive VB N
all DT N
of IN N
their PRP$ N
medications NNS N
with IN N
improved JJ N
labels NNS N
or CC N
to TO N
receive VB N
prescriptions NNS N
with IN N
standard JJ N
labels NNS N
The DT N
primary JJ N
outcome NN N
will MD N
be VB N
the DT N
patient NN N
's POS N
ability NN N
to TO N
correctly RB N
demonstrate VB N
dosing VBG N
instructions NNS N
Other JJ N
outcomes NNS N
include VBP N
adherence NN N
, , N
error NN N
rates NNS N
and CC N
health NN N
outcomes NNS N
CONCLUSION NN N
To TO N
our PRP$ N
knowledge NN N
, , N
this DT N
trial NN N
is VBZ N
the DT N
first JJ N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
prescription NN N
label NN N
improvement NN N
on IN N
understanding NN N
, , N
medication NN N
use NN N
and CC N
outcomes NNS N
in IN N
a DT N
clinical JJ N
setting NN N
If IN N
successful JJ N
, , N
these DT N
findings NNS N
could MD N
be VB N
implemented VBN N
broadly RB N
to TO N
promote VB N
safe JJ N
and CC N
appropriate JJ N
medication NN N
use NN N
and CC N
to TO N
support VB N
evidence-based JJ N
standards NNS N
in IN N
the DT N
development NN N
of IN N
labels NNS N
-DOCSTART- -X- O O 1835619

Clinical JJ N
outcome NN N
of IN N
postoperative JJ N
adjuvant JJ N
immunochemotherapy NN N
with IN N
sizofiran NN N
for IN N
patients NNS N
with IN N
resectable JJ N
gastric JJ N
cancer NN N
: : N
a DT N
randomised VBN N
controlled VBN N
study NN N
Adjuvant NNP N
immunochemotherapy NN N
using VBG N
the DT N
antitumour JJ N
polysaccharide NN N
sizofiran NN N
( ( N
SPG NNP N
) ) N
, , N
an DT N
extract NN N
from IN N
the DT N
culture NN N
broth NN N
of IN N
Schizophyllum NNP N
commune NN N
Fries NNS N
, , N
was VBD N
prescribed VBN N
randomly RB N
for IN N
386 CD 4_p
Japanese JJ 4_p
patients NNS 4_p
with IN 4_p
resectable JJ 4_p
gastric JJ 4_p
cancer NN 4_p
Although IN N
the DT N
overall JJ N
survival NN N
probability NN N
for IN N
5 CD N
years NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
SPG NNP N
and CC N
control NN N
groups NNS N
, , N
in IN N
264 CD N
patients NNS N
with IN N
curatively RB N
resected VBN N
cancer NN N
, , N
the DT N
probability NN N
to TO N
5 CD N
year NN N
survival NN N
and CC N
to TO N
recurrence VB N
in IN N
the DT N
sizofiran-administered JJ N
patients NNS N
was VBD N
better JJR N
than IN N
in IN N
the DT N
controls NNS N
In IN N
the DT N
multivariate NN N
analysis NN N
, , N
four CD N
of IN N
six CD N
prognostic JJ N
factors NNS N
correlated VBD N
with IN N
the DT N
prognosis NN N
of IN N
the DT N
264 CD N
patients NNS N
who WP N
underwent VBP N
curative JJ N
surgery NN N
, , N
that WDT N
is VBZ N
, , N
nodal JJ N
involvement NN N
( ( N
chi JJ N
2 CD N
= JJ N
21.426 CD N
, , N
P NNP N
= NNP N
less JJR N
than IN N
0.0001 CD N
) ) N
, , N
age NN N
distribution NN N
( ( N
chi JJ N
2 CD N
= JJ N
9.262 CD N
, , N
P NNP N
= NNP N
0.010 CD N
) ) N
, , N
sizofiran JJ N
administration NN N
( ( N
chi JJ N
2 CD N
= JJ N
6.507 CD N
, , N
P NNP N
= NNP N
0.011 CD N
) ) N
, , N
and CC N
primary JJ N
tumour NN N
size NN N
( ( N
chi JJ N
2 CD N
= JJ N
9.345 CD N
, , N
P NNP N
= NNP N
0.025 CD N
) ) N
Thus RB N
, , N
patients NNS N
with IN N
a DT N
curatively RB N
resected VBN N
gastric JJ N
cancer NN N
had VBD N
a DT N
better JJR N
prognosis NN N
when WRB N
sizofiran NN N
was VBD N
prescribed VBN N
in IN N
combination NN N
with IN N
antitumour JJ N
drugs NNS N
-DOCSTART- -X- O O 23128568

The DT N
effect NN N
of IN N
values NNS N
affirmation VBP N
on IN N
race-discordant JJ N
patient-provider JJ N
communication NN N
BACKGROUND NNP N
Communication NNP N
between IN N
African JJ N
American JJ N
patients NNS N
and CC N
white JJ N
health NN N
care NN N
providers NNS N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
of IN N
poorer JJR N
quality NN N
when WRB N
compared VBN N
with IN N
race-concordant JJ N
patient-provider JJ N
communication NN N
Fear NN N
on IN N
the DT N
part NN N
of IN N
patients NNS N
that WDT N
providers NNS N
stereotype VBP N
them PRP N
negatively RB N
might MD N
be VB N
one CD N
cause NN N
of IN N
this DT N
poorer JJR N
communication NN N
This DT N
stereotype JJ N
threat NN N
may MD N
be VB N
lessened VBN N
by IN N
a DT N
values-affirmation NN N
intervention NN N
METHODS NNP N
In IN N
a DT N
blinded JJ N
experiment NN N
, , N
we PRP N
randomized VBD N
99 CD 3_p
African JJ N
American JJ N
patients NNS N
with IN N
hypertension NN 4_p
to TO N
perform VB N
a DT N
values-affirmation NN N
exercise NN N
or CC N
a DT N
control NN N
exercise NN N
before IN N
a DT N
visit NN N
with IN N
their PRP$ N
primary JJ N
care NN N
provider NN N
We PRP N
compared VBN N
patient-provider JJ N
communication NN N
for IN N
the DT N
2 CD N
groups NNS N
using VBG N
audio JJ N
recordings NNS N
of IN N
the DT N
visit NN N
analyzed VBN N
with IN N
the DT N
Roter NNP N
Interaction NNP N
Analysis NNP N
System NNP N
We PRP N
also RB N
evaluated VBD N
visit JJ N
satisfaction NN N
, , N
trust NN N
, , N
stress NN N
, , N
and CC N
mood NN N
after IN N
the DT N
visit NN N
by IN N
means NNS N
of IN N
a DT N
questionnaire NN N
RESULTS JJ N
Patients NNPS N
in IN N
the DT N
intervention NN N
group NN N
requested VBD N
and CC N
provided VBD N
more JJR N
information NN N
about IN N
their PRP$ N
medical JJ N
condition NN N
( ( N
mean JJ N
[ NNP N
SE NNP N
] NNP N
number NN N
of IN N
utterances NNS N
, , N
66.3 CD N
[ NN N
6.8 CD N
] NN N
in IN N
the DT N
values-affirmation NN N
group NN N
vs VBD N
48.1 CD N
[ JJ N
5.9 CD N
] NN N
in IN N
the DT N
control NN N
group NN N
[ NNP N
P NNP N
= NNP N
.03 NNP N
] NNP N
) ) N
Patient-provider JJ N
communication NN N
in IN N
the DT N
intervention NN N
group NN N
was VBD N
characterized VBN N
as IN N
being VBG N
more RBR N
interested JJ N
, , N
friendly JJ N
, , N
responsive JJ N
, , N
interactive JJ N
, , N
and CC N
respectful JJ N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
and CC N
less JJR N
depressed JJ N
and CC N
distressed JJ N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
Patient JJ N
questionnaires NNS N
did VBD N
not RB N
detect VB N
differences NNS N
in IN N
visit NN N
satisfaction NN N
, , N
trust NN N
, , N
stress NN N
, , N
or CC N
mood NN N
Mean NNP N
visit NN N
duration NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
( ( N
19.2 CD N
minutes NNS N
in IN N
the DT N
control NN N
group NN N
vs VBD N
20.5 CD N
minutes NNS N
in IN N
the DT N
intervention NN N
group NN N
[ NNP N
P NNP N
= NNP N
.29 NNP N
] NNP N
) ) N
CONCLUSIONS VB N
A DT N
values-affirmation NN N
exercise NN N
improves VBZ N
aspects NNS N
of IN N
patient-provider JJ N
communication NN N
in IN N
race-discordant JJ N
primary JJ N
care NN N
visits NNS N
The DT N
clinical JJ N
impact NN N
of IN N
the DT N
intervention NN N
must MD N
be VB N
defined VBN N
before IN N
widespread JJ N
implementation NN N
can MD N
be VB N
recommended VBN N
-DOCSTART- -X- O O 17617281

Codeine/acetaminophen NNP N
and CC N
hydrocodone/acetaminophen JJ N
combination NN N
tablets NNS N
for IN N
the DT N
management NN N
of IN N
chronic JJ 4_p
cancer NN 4_p
pain NN 4_p
in IN N
adults NNS 1_p
: : N
a DT N
23-day JJ N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
study NN N
BACKGROUND NNP N
Analgesics NNPS N
are VBP N
an DT N
essential JJ N
component NN N
of IN N
the DT N
treatment NN N
of IN N
cancer-associated JJ N
pain NN N
Pharmacologic NNP N
treatment NN N
is VBZ N
usually RB N
begun VBN N
with IN N
nonopioid JJ N
analgesics NNS N
, , N
most JJS N
frequently RB N
acetaminophen VBP N
If IN N
pain JJ N
relief NN N
is VBZ N
not RB N
achieved VBN N
, , N
the DT N
so-called JJ N
" NNP N
weak JJ N
" NNP N
opioids NNS N
, , N
such JJ N
as IN N
codeine NN N
and CC N
hydrocodone NN N
, , N
may MD N
be VB N
used VBN N
in IN N
combination NN N
with IN N
acetaminophen NN N
Adverse JJ N
effects NNS N
( ( N
AEs NNP N
) ) N
of IN N
the DT N
opioids NNS N
include VBP N
constipation NN N
, , N
somnolence NN N
, , N
nausea NN N
, , N
and CC N
vomiting VBG N
Based VBN N
on IN N
the DT N
results NNS N
of IN N
a DT N
literature NN N
search NN N
, , N
data NNS N
comparing VBG N
the DT N
effects NNS N
of IN N
the DT N
opioids NNS N
are VBP N
lacking VBG N
OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
analgesic JJ N
efficacy NN N
and CC N
tolerability NN N
of IN N
codeine NN N
phosphate NN N
versus IN N
hydrocodone NN N
bitartrate NN N
in IN N
combination NN N
with IN N
acetaminophen NN N
in IN N
the DT N
relief NN N
of IN N
cancer-related JJ N
pain NN N
METHODS NNP N
This DT N
23-day JJ N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
study NN N
was VBD N
conducted VBN N
at IN N
3 CD N
Colombian JJ N
centers NNS N
: : N
University NNP N
Libre NNP N
, , N
Social NNP N
Security NNP N
Institute NNP N
, , N
and CC N
General NNP N
Hospital NNP N
of IN N
Medellín NNP N
, , N
Cali NNP N
, , N
Colombia NNP N
Outpatients NNS N
with IN N
cancer NN N
were VBD N
eligible JJ N
for IN N
the DT N
study NN N
if IN N
they PRP N
were VBD N
aged VBN N
> JJ 1_p
-18 CD 1_p
years NNS 1_p
and CC N
had VBD N
chronic VBN N
( ( N
duration NN N
, , N
> NNP N
/= VBZ N
3 CD N
months NNS N
) ) N
moderate VBP N
to TO N
severe VB N
cancer-related JJ N
pain NN N
( ( N
score NN N
on IN N
10-cm JJ N
visual JJ N
analog NN N
scale NN N
[ NNP N
VAS NNP N
] NNP N
, , N
> VBD N
3 CD N
cm NN N
[ NN N
moderate JJ N
] NN N
; : N
score NN N
on IN N
a DT N
4-point JJ N
verbal JJ N
pain-intensity NN N
scale NN N
, , N
> VBZ N
1 CD N
[ NN N
moderate JJ N
] NN N
) ) N
Eligible JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
1 CD N
tablet NN N
of IN N
codeine/acetaminophen NN N
( ( N
C/A NNP N
) ) N
30/500 CD N
mg NN N
or CC N
hydrocodone/acetaminophen NN N
( ( N
H/A NNP N
) ) N
5/500 CD N
mg NN N
PO NNP N
q4h NN N
( ( N
total JJ N
daily JJ N
doses NNS N
, , N
150/2500 CD N
and CC N
25/2500 CD N
mg NN N
, , N
respectively RB N
) ) N
for IN N
23 CD N
days NNS N
In IN N
both DT N
groups NNS N
, , N
if IN N
pain JJ N
intensity NN N
was VBD N
rated VBN N
as IN N
> JJ N
3 CD N
on IN N
the DT N
VAS NNP N
at IN N
week NN N
1 CD N
or CC N
2 CD N
, , N
the DT N
dosage NN N
was VBD N
doubled VBN N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
proportion NN N
of IN N
patients NNS N
who WP N
achieved VBD N
pain NN N
relief NN N
( ( N
defined VBN N
as IN N
a DT N
score NN N
of IN N
> $ N
1 CD N
on IN N
a DT N
5-point JJ N
verbal NN N
rating NN N
scale NN N
[ NNP N
VRS NNP N
] NNP N
( ( N
0 CD N
= NNP N
none NN N
; : N
1 CD N
= IN N
a DT N
little JJ N
; : N
2 CD N
= IN N
some DT N
; : N
3 CD N
= IN N
a DT N
lot NN N
; : N
and CC N
4 CD N
= NNP N
complete JJ N
) ) N
on IN N
study NN N
days NNS N
1 CD N
and CC N
2 CD N
and CC N
weeks NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
The DT N
secondary JJ N
end NN N
point NN N
was VBD N
the DT N
proportion NN N
of IN N
patients NNS N
in IN N
whom WP N
pain NN N
was VBD N
decreased VBN N
( ( N
VAS NNP N
score RB N
, , N
< NNP N
- : N
3 CD N
cm NN N
) ) N
AEs $ N
were VBD N
self-reported VBN N
on IN N
a DT N
4-point JJ N
VRS NNP N
( ( N
0 CD N
= NNP N
absent NN N
; : N
1 CD N
= NNP N
mild NN N
; : N
2 CD N
= NN N
moderate NN N
; : N
and CC N
3 CD N
= NNP N
severe RB N
) ) N
RESULTS NNP N
Of IN N
the DT N
121 CD 3_p
patients NNS N
who WP N
participated VBD N
, , N
59 CD N
received VBD N
C/A NNP N
and CC N
62 CD N
received VBD N
H/A NNP N
Of IN N
the DT N
total JJ N
number NN N
of IN N
cases NNS N
, , N
59 CD N
% NN N
were VBD N
aged VBN 1_p
60 CD 1_p
to TO 1_p
89 CD 1_p
years NNS 1_p
, , N
and CC N
55 CD N
% NN N
were VBD N
men NNS 2_p
At IN N
baseline NN N
, , N
88 CD N
% NN N
of IN N
the DT N
patients NNS N
described VBD N
their PRP$ N
pain NN N
intensity NN N
as IN N
moderate JJ N
; : N
12 CD N
% NN N
, , N
severe JJ N
Of IN N
the DT N
patients NNS N
who WP N
received VBD N
C/A NNP N
, , N
58 CD N
% NN N
responded VBD N
to TO N
the DT N
initial JJ N
dosage NN N
of IN N
150/2500 CD N
mg/d NN N
, , N
and CC N
8 CD N
% NN N
of IN N
the DT N
patients NNS N
responded VBD N
to TO N
the DT N
double JJ N
dosage NN N
; : N
34 CD N
% NN N
did VBD N
not RB N
experience VB N
pain NN N
relief NN N
In IN N
patients NNS N
with IN N
H/A NNP N
, , N
pain NN N
was VBD N
reported VBN N
as IN N
absent NN N
or CC N
mild NN N
in IN N
56 CD N
% NN N
of IN N
patients NNS N
at IN N
the DT N
starting VBG N
dosage NN N
of IN N
25/2500 CD N
mg/d NN N
; : N
an DT N
additional JJ N
15 CD N
% NN N
of IN N
the DT N
patients NNS N
responded VBD N
to TO N
the DT N
double JJ N
dosage NN N
; : N
the DT N
remaining VBG N
29 CD N
% NN N
of IN N
patients NNS N
did VBD N
not RB N
experience VB N
any DT N
pain NN N
relief NN N
None NN N
of IN N
the DT N
between-group JJ N
differences NNS N
in IN N
response NN N
rates NNS N
were VBD N
significant JJ N
The DT N
most RBS N
common JJ N
AEs NNP N
in IN N
the DT N
C/A NNP N
and CC N
H/A NNP N
groups NNS N
were VBD N
constipation NN N
( ( N
36 CD N
% NN N
and CC N
29 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
dizziness NN N
( ( N
24 CD N
% NN N
and CC N
19 CD N
% NN N
) ) N
, , N
vomiting VBG N
( ( N
24 CD N
% NN N
and CC N
16 CD N
% NN N
) ) N
, , N
and CC N
dry JJ N
mouth NN N
( ( N
15 CD N
% NN N
and CC N
18 CD N
% NN N
) ) N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
CONCLUSION NNP N
In IN N
this DT N
study NN N
, , N
efficacy NN N
and CC N
tolerability NN N
were VBD N
comparable JJ N
between IN N
C/A NNP N
and CC N
H/A NNP N
over IN N
23 CD N
days NNS N
of IN N
treatment NN N
in IN N
these DT N
patients NNS N
with IN N
moderate JJ N
or CC N
severe JJ N
, , N
chronic JJ N
, , N
cancer-related JJ N
pain NN N
-DOCSTART- -X- O O 18278302

Microtensile NNP N
bond NN N
strength NN N
of IN N
a DT N
repair NN N
composite JJ N
to TO N
leucite-reinforced JJ N
feldspathic JJ N
ceramic NN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
microtensile NN N
bond NN N
strength NN N
of IN N
a DT N
repair NN N
composite JJ N
resin NN N
to TO N
a DT N
leucite-reinforced JJ N
feldspathic JJ N
ceramic NN N
( ( N
Omega NNP N
900 CD N
, , N
VITA NNP N
) ) N
submitted VBD N
to TO N
two CD N
surface NN N
conditionings NNS N
methods NNS N
: : N
1 CD N
) ) N
etching VBG N
with IN N
hydrofluoric JJ N
acid NN N
+ NNP N
silane NN N
application NN N
or CC N
2 CD N
) ) N
tribochemical NN N
silica NN N
coating NN N
The DT N
null JJ N
hypothesis NN N
is VBZ N
that IN N
both DT N
surface NN N
treatments NNS N
can MD N
generate VB N
similar JJ N
bond NN N
strengths NNS N
Ten CD 3_p
ceramic JJ 3_p
blocks NNS 3_p
( ( 3_p
6x6x6 CD 3_p
mm NN 3_p
) ) 3_p
were VBD 3_p
fabricated VBN 3_p
and CC 3_p
randomly RB 3_p
assigned VBN 3_p
to TO 3_p
2 CD 3_p
groups NNS 3_p
( ( 3_p
n=5 NN 3_p
) ) 3_p
, , 3_p
according VBG 3_p
to TO 3_p
the DT 3_p
conditioning NN 3_p
method NN 3_p
: : 3_p
G1- JJ 3_p
10 CD 3_p
% NN 3_p
hydrofluoric JJ 3_p
acid NN 3_p
application NN 3_p
for IN 3_p
2 CD 3_p
min NN 3_p
plus CC 3_p
rinsing NN 3_p
and CC 3_p
drying NN 3_p
, , 3_p
followed VBN 3_p
by IN 3_p
silane NN 3_p
application NN 3_p
for IN 3_p
30 CD 3_p
s NNS N
; : N
G2- NNP N
airborne JJ N
particle NN N
abrasion NN N
with IN N
30 CD N
microm NNS N
silica JJ N
oxide IN N
particles NNS N
( ( N
CoJet-Sand NNP N
) ) N
for IN N
20 CD N
s NNS N
using VBG N
a DT N
chairside JJ N
air-abrasion NN N
device NN N
( ( N
CoJet NNP N
System NNP N
) ) N
, , N
followed VBN N
by IN N
silane NN N
application NN N
for IN N
5 CD N
min NN N
Single NNP N
Bond NNP N
adhesive JJ N
system NN N
was VBD N
applied VBN N
to TO N
the DT N
surfaces NNS N
and CC N
light NN N
cured VBN N
( ( N
40 CD N
s NN N
) ) N
Z-250 JJ N
composite JJ N
resin NN N
was VBD N
placed VBN N
incrementally RB N
on IN N
the DT N
treated JJ N
ceramic JJ N
surface NN N
to TO N
build VB N
a DT N
6x6x6 CD N
mm NN N
block NN N
Bar NNP N
specimens VBZ N
with IN N
an DT N
adhesive JJ N
area NN N
of IN N
approximately RB N
1 CD N
+/- JJ N
0.1 CD N
mm NN N
( ( N
2 CD N
) ) N
were VBD N
obtained VBN N
from IN N
the DT N
composite-ceramic JJ N
blocks NNS N
( ( N
6 CD N
per IN N
block NN N
and CC N
30 CD N
per IN N
group NN N
) ) N
for IN N
microtensile NN N
testing VBG N
No DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
G1 NNP N
( ( N
10.19 CD N
+/- JJ N
3.1 CD N
MPa NNP N
) ) N
and CC N
G2 NNP N
( ( N
10.17 CD N
+/- JJ N
3.1 CD N
MPa NNP N
) ) N
( ( N
p=0.982 NN N
) ) N
( ( N
Student NNP N
's POS N
t JJ N
test NN N
; : N
á CC N
= VB N
0.05 CD N
) ) N
The DT N
null JJ N
hypothesis NN N
was VBD N
, , N
therefore RB N
, , N
accepted VBD N
In IN N
conclusion NN N
, , N
both DT N
surface VBP N
conditioning VBG N
methods NNS N
provided VBD N
similar JJ N
microtensile NN N
bond NN N
strengths NNS N
between IN N
the DT N
repair NN N
composite JJ N
resin NN N
and CC N
the DT N
ceramic NN N
Further JJ N
studies NNS N
using VBG N
long-term JJ N
aging NN N
procedures NNS N
should MD N
be VB N
conducted VBN N
-DOCSTART- -X- O O 17276748

Developmental JJ N
disabilities NNS N
modification NN N
of IN N
the DT N
Children NNP N
's POS N
Global NNP N
Assessment NNP N
Scale NNP N
BACKGROUND NNP N
Interventions NNP N
for IN N
pervasive JJ N
developmental NN N
disorders NNS N
( ( N
PDD NNP N
) ) N
aim NN N
to TO N
alleviate VB N
symptoms NNS N
and CC N
improve VB N
functioning NN N
To TO N
measure VB N
global JJ N
functioning NN N
in IN N
treatment NN N
studies NNS N
, , N
the DT N
Children NNP N
's POS N
Global NNP N
Assessment NNP N
Scale NNP N
was VBD N
modified VBN N
and CC N
psychometric JJ N
properties NNS N
of IN N
the DT N
revised VBN N
version NN N
( ( N
DD-CGAS NNP N
) ) N
were VBD N
assessed VBN N
in IN N
children NNS N
with IN N
PDD NNP N
METHODS NNP N
Developmental NNP N
disabilities-relevant JJ N
descriptors NNS N
were VBD N
developed VBN N
for IN N
the DT N
DD-CGAS NNP N
, , N
and CC N
administration NN N
procedures NNS N
were VBD N
established VBN N
to TO N
enhance VB N
rater NN N
consistency NN N
Ratings NNS N
of IN N
clinical JJ N
case NN N
vignettes NNS N
were VBD N
used VBN N
to TO N
assess VB N
inter-rater JJ N
reliability NN N
and CC N
temporal JJ N
stability NN N
Validity NNP N
was VBD N
assessed VBN N
by IN N
correlating VBG N
the DT N
DD-CGAS NNP N
with IN N
measures NNS N
of IN N
functioning NN N
and CC N
symptoms NNS N
in IN N
83 CD N
youngsters NNS N
with IN N
PDD NNP N
Sensitivity NNP N
to TO N
change VB N
was VBD N
assessed VBN N
by IN N
comparing VBG N
change NN N
from IN N
baseline NN N
to TO N
post-treatment JJ N
with IN N
change NN N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist-Irritability NNP N
and CC N
Clinical NNP N
Global NNP N
Impressions-Improvement NNP N
subscale JJ N
scores NNS N
in IN N
a DT N
subset NN N
of IN N
14 CD N
children NNS N
RESULTS NNP N
Inter-rater JJ N
reliability NN N
( ( N
intraclass JJ N
correlation NN N
coefficient NN N
[ NNP N
ICC NNP N
] NNP N
= NNP N
.79 NNP N
) ) N
and CC N
temporal JJ N
stability NN N
( ( N
average JJ N
ICC NNP N
= NNP N
.86 NNP N
) ) N
were VBD N
excellent JJ N
The DT N
DD-CGAS JJ N
scores NNS N
correlated VBN N
with IN N
measures NNS N
of IN N
functioning NN N
and CC N
symptoms NNS N
with IN N
moderate JJ N
to TO N
large JJ N
effect NN N
sizes VBZ N
Changes NNS N
on IN N
the DT N
DD-CGAS NNP N
correlated VBD N
with IN N
changes NNS N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist-I NNP N
( ( N
r NN N
= NNP N
-.71 NNP N
) ) N
and CC N
Global JJ N
Impressions NNP N
Scale-I NNP N
( ( N
r NN N
= NNP N
-.52 NNP N
) ) N
The DT N
pre-post JJ N
DD-CGAS NNP N
change NN N
had VBD N
an DT N
effect NN N
size NN N
of IN N
.72 NNP N
CONCLUSIONS VB N
The DT N
DD-CGAS NNP N
is VBZ N
a DT N
reliable JJ N
instrument NN N
with IN N
apparent JJ N
convergent NN N
validity NN N
for IN N
measuring VBG N
global JJ N
functioning NN N
of IN N
children NNS N
with IN N
PDD NNP N
in IN N
treatment NN N
studies NNS N
-DOCSTART- -X- O O 24119994

Entomological JJ N
determinants NNS N
of IN N
insecticide-treated JJ N
bed JJ N
net JJ N
effectiveness NN N
in IN N
Western JJ N
Myanmar NNP N
BACKGROUND NNP N
In IN N
a DT N
large JJ N
cluster NN N
randomized VBD N
control JJ N
trial NN N
of IN N
insecticide-treated JJ N
bed NN N
nets NNS N
( ( N
ITN NNP N
) ) N
in IN N
Western JJ N
Myanmar NNP N
the DT N
malaria NN N
protective JJ N
effect NN N
of IN N
ITN NNP N
was VBD N
found VBN N
to TO N
be VB N
highly RB N
variable JJ N
and CC N
, , N
in IN N
aggregate NN N
, , N
the DT N
effect NN N
was VBD N
not RB N
statistically RB N
significant JJ N
A DT N
coincident JJ N
entomological JJ N
investigation NN N
measured VBD N
malaria NNS N
vector NN N
abundance NN N
and CC N
biting VBG N
behaviour NN N
and CC N
the DT N
human JJ N
population NN N
sleeping VBG N
habits NNS N
, , N
factors NNS N
relevant VBP N
to TO N
ITN NNP N
effectiveness NN N
METHODS NNP N
Entomological JJ N
surveys NNS N
were VBD N
carried VBN N
out RP N
using VBG N
different JJ N
catching VBG N
methods NNS N
to TO N
identify VB N
potential JJ N
malaria NNS N
vector NN N
species NNS N
and CC N
characterise VB N
their PRP$ N
biting NN N
habits NNS N
The DT N
salivary JJ N
glands NNS N
were VBD N
dissected VBN N
from IN N
all DT N
female JJ N
anophelines NNS N
caught VBD N
to TO N
identify VB N
sporozoites NNS N
by IN N
microscopy NN N
FINDINGS NNP N
Between NNP N
1995 CD N
and CC N
2000 CD N
a DT N
total NN N
of IN N
4,824 CD 3_p
female JJ 2_p
anopheline NN N
mosquitoes NNS N
were VBD N
caught VBN N
with IN N
various JJ N
catching VBG N
methods NNS N
A DT N
total NN N
of IN N
916 CD 3_p
person NN 3_p
nights NNS N
yielded VBD N
3,009 CD N
female JJ N
anopheline NN N
mosquitoes NNS N
between IN N
6 CD N
pm NNS N
and CC N
6 CD N
am VBP N
Except IN N
for IN N
Anopheles NNP N
annularis NN N
, , N
which WDT N
showed VBD N
no DT N
apparent JJ N
preference NN N
( ( N
51 CD N
% NN N
outdoor JJ N
biting NN N
) ) N
, , N
all DT N
major JJ N
species NNS N
showed VBD N
a DT N
strong JJ N
preference NN N
for IN N
outdoor JJ N
biting NN N
; : N
Anopheles NNP N
epiroticus FW N
( ( N
79 CD N
% NN N
) ) N
, , N
Anopheles NNP N
subpictus NN N
( ( N
72 CD N
% NN N
) ) N
, , N
Anopheles NNP N
maculatus NNP N
( ( N
92 CD N
% NN N
) ) N
, , N
Anopheles NNP N
aconitus NN N
( ( N
85 CD N
% NN N
) ) N
and CC N
Anopheles NNP N
vagus NNP N
( ( N
72 CD N
% NN N
) ) N
Most JJS N
human JJ N
biting NN N
occurred VBD N
in IN N
the DT N
early JJ N
evening NN N
with IN N
the DT N
peak NN N
biting VBG N
time NN N
between IN N
6 CD N
pm NNS N
and CC N
7 CD N
pm NN N
( ( N
35 CD N
% NN N
) ) N
Overall JJ N
51 CD N
% NN N
( ( N
1447/2837 CD N
) ) N
of IN N
all DT N
bites NNS N
recorded VBN N
were VBD N
between IN N
6 CD N
pm NNS N
and CC N
8 CD N
pm NN N
A DT N
large JJ N
proportion NN N
of IN N
children NNS 1_p
were VBD N
not RB N
sleeping VBG N
under IN N
an DT N
ITN NNP N
during IN N
peak NN N
biting VBG N
times NNS N
Only RB N
one CD N
An DT N
annularis NN N
mosquito NN N
( ( N
0.02 CD N
% NN N
) ) N
had VBD N
malaria VBN N
sporozoites NNS N
identified VBN N
in IN N
the DT N
salivary JJ N
glands NNS N
CONCLUSIONS NNP N
Peak NNP N
vector NN N
biting NN N
occurred VBD N
early RB N
in IN N
the DT N
evening NN N
and CC N
mainly RB N
occurred VBD N
outdoors NNS N
The DT N
limited JJ N
efficacy NN N
of IN N
ITN NNP N
in IN N
this DT N
area NN N
of IN N
Western JJ N
Myanmar NNP N
may MD N
be VB N
explained VBN N
by IN N
the DT N
biting VBG N
behaviour NN N
of IN N
the DT N
prevalent NN N
Anopheles NNP N
mosquito NN N
vectors NNS N
in IN N
this DT N
area NN N
-DOCSTART- -X- O O 18341602

A DT N
double-blind JJ N
randomized JJ N
clinical JJ N
evaluation NN N
of IN N
enamel JJ N
matrix NNS N
derivative JJ N
proteins NNS N
for IN N
the DT N
treatment NN N
of IN N
proximal JJ N
class-II JJ N
furcation NN N
involvements NNS N
OBJECTIVE IN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
randomized VBN N
, , N
double-blind JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
clinical JJ N
response NN N
of IN N
proximal JJ N
furcations NNS N
treated VBN N
with IN N
enamel JJ N
matrix NNS N
derivative JJ N
proteins NNS N
( ( N
EMD NNP N
) ) N
MATERIAL NNP N
AND NNP N
METHODS NNP N
Fifteen NNP 3_p
patients NNS 3_p
, , N
each DT N
with IN N
a DT N
pair NN N
of IN N
contralateral JJ 4_p
class-II JJ 4_p
proximal JJ 4_p
furcation NN 4_p
involvements NNS 4_p
, , N
presenting VBG 4_p
probing VBG 4_p
depths NNS 4_p
( ( 4_p
PDs NNP 4_p
) ) 4_p
> VBP 4_p
/=5 JJ 4_p
mm NN 4_p
and CC N
bleeding NN 4_p
on IN 4_p
probing VBG 4_p
( ( 4_p
BOP NNP 4_p
) ) 4_p
were VBD N
selected VBN N
The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
: : N
control NN N
group NN N
( ( N
n=15 NN N
) ) N
- : N
open JJ N
flap NN N
debridement NN N
( ( N
OFD NNP N
) ) N
+24 CD N
% NN N
ethylenediaminetetraacetic JJ N
acid NN N
( ( N
EDTA NNP N
) ) N
conditioning NN N
; : N
test CC N
group NN N
( ( N
n=15 NN N
) ) N
- : N
OFD+24 CD N
% NN N
EDTA NNP N
conditioning+EMD NN N
application NN N
Plaque NNP N
index NN N
( ( N
PI NNP N
) ) N
, , N
BOP NNP N
, , N
PD NNP N
, , N
gingival NN N
margin NN N
position NN N
( ( N
GMP NNP N
) ) N
, , N
relative JJ N
vertical NN N
and CC N
horizontal JJ N
clinical JJ N
attachment NN N
level NN N
( ( N
RVCAL NNP N
and CC N
RHCAL NNP N
) ) N
, , N
vertical JJ N
and CC N
horizontal JJ N
bone NN N
level NN N
( ( N
VBL NNP N
and CC N
HBL NNP N
) ) N
and CC N
furcation JJ N
closure NN N
were VBD N
evaluated VBN N
immediately RB N
before IN N
and CC N
2 CD N
, , N
4 CD N
and CC N
6 CD N
months NNS N
after IN N
the DT N
surgeries NNS N
RESULTS NNP N
At IN N
6 CD N
months NNS N
, , N
the DT N
RVCAL NNP N
gains NNS N
of IN N
the DT N
control NN N
and CC N
test NN N
group NN N
were VBD N
0.39 CD N
+/- JJ N
1.00 CD N
and CC N
0.54 CD N
+/- JJ N
0.95 CD N
mm NN N
, , N
while IN N
the DT N
RHCAL NNP N
gains NNS N
were VBD N
1.21 CD N
+/- JJ N
2.28 CD N
and CC N
1.36 CD N
+/- JJ N
1.26 CD N
mm NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
The DT N
VBL NNP N
and CC N
HBL NNP N
gains NNS N
of IN N
the DT N
control NN N
group NN N
were VBD N
1.04 CD N
+/- JJ N
1.12 CD N
and CC N
1.00 CD N
+/- JJ N
1.79 CD N
mm NN N
, , N
and CC N
0.82 CD N
+/- JJ N
1.82 CD N
and CC N
1.17 CD N
+/- JJ N
1.38 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
In IN N
addition NN N
, , N
a DT N
statistical JJ N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
number NN N
of IN N
the DT N
remaining VBG N
class-II JJ N
furcations NNS N
between IN N
the DT N
test NN N
and CC N
control NN N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
this DT N
period NN N
CONCLUSION VB N
It PRP N
may MD N
be VB N
concluded VBN N
that IN N
the DT N
use NN N
of IN N
EMD NNP N
in IN N
proximal JJ N
furcations NNS N
did VBD N
not RB N
promote VB N
a DT N
superior JJ N
reduction NN N
in IN N
PD NNP N
or CC N
a DT N
gain NN N
in IN N
clinical JJ N
and CC N
osseous JJ N
attachment NN N
levels NNS N
, , N
but CC N
resulted VBD N
in IN N
a DT N
higher JJR N
rate NN N
of IN N
class-II NN N
to TO N
class-I JJ N
furcation NN N
conversion NN N
-DOCSTART- -X- O O 16740812

A DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
clinician JJ N
feedback NN N
to TO N
improve VB N
quality NN N
of IN N
care NN N
for IN N
inner-city JJ N
children NNS N
with IN N
asthma NN 4_p
CONTEXT NNP N
Barriers NNP N
impede VBP N
translating VBG N
recommendations NNS N
for IN N
asthma JJ N
treatment NN N
into IN N
practice NN N
, , N
particularly RB N
in IN N
inner NN N
cities NNS N
where WRB N
asthma JJ N
morbidity NN N
is VBZ N
highest JJS N
METHODS VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
effectiveness NN N
of IN N
timely JJ N
patient JJ N
feedback NN N
in IN N
the DT N
form NN N
of IN N
a DT N
letter NN N
providing VBG N
recent JJ N
patient-specific JJ N
symptoms NNS N
, , N
medication NN N
, , N
and CC N
health NN N
service NN N
use NN N
combined VBN N
with IN N
guideline-based JJ N
recommendations NNS N
for IN N
changes NNS N
in IN N
therapy NN N
on IN N
improving VBG N
the DT N
quality NN N
of IN N
asthma NN N
care NN N
by IN N
inner-city NN N
primary NN N
care NN N
providers NNS N
and CC N
on IN N
resultant JJ N
asthma JJ N
morbidity NN N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
controlled VBD N
clinical JJ N
trial NN N
in IN N
5- JJ 1_p
to TO 1_p
11-year-old JJ 1_p
children NNS N
( ( N
n JJ N
= NNP N
937 CD 3_p
) ) N
with IN N
moderate JJ N
to TO N
severe VB N
asthma RB N
receiving VBG N
health NN N
care NN N
in IN N
hospital- JJ N
and CC N
community-based JJ N
clinics NNS N
and CC N
private JJ N
practices NNS N
in IN N
7 CD N
inner-city JJ N
urban JJ N
areas NNS N
The DT N
caretaker NN N
of IN N
each DT N
child NN N
received VBD N
a DT N
bimonthly JJ N
telephone NN N
call NN N
to TO N
collect VB N
clinical JJ N
information NN N
about IN N
the DT N
child NN N
's POS N
asthma NN N
For IN N
a DT N
full JJ N
year NN N
, , N
the DT N
providers NNS N
of IN N
intervention NN N
group NN N
children NNS N
received VBD N
bimonthly RB N
computer-generated JJ N
letters NNS N
based VBN N
on IN N
these DT N
calls NNS N
summarizing VBG N
the DT N
child NN N
's POS N
asthma NN N
symptoms NNS N
, , N
health NN N
service NN N
use NN N
, , N
and CC N
medication NN N
use NN N
with IN N
a DT N
corresponding JJ N
recommendation NN N
to TO N
step VB N
up RP N
or CC N
step VB N
down RP N
medications NNS N
We PRP N
measured VBD N
the DT N
number NN N
and CC N
proportion NN N
of IN N
scheduled JJ N
visits NNS N
resulting VBG N
in IN N
stepping VBG N
up IN N
of IN N
medications NNS N
, , N
asthma NN N
symptoms NNS N
( ( N
2-week JJ N
recall NN N
) ) N
, , N
and CC N
health NN N
care NN N
use NN N
( ( N
2-month JJ N
recall NN N
) ) N
RESULTS VBN N
In IN N
this DT N
population NN N
, , N
only RB N
a DT N
modest JJ N
proportion NN N
of IN N
children NNS N
whose WP$ N
symptoms NNS N
warranted VBD N
a DT N
medication NN N
increase NN N
actually RB N
had VBD N
a DT N
scheduled JJ N
visit NN N
to TO N
reevaluate VB N
their PRP$ N
asthma JJ N
treatment NN N
However RB N
, , N
in IN N
the DT N
2-month JJ N
interval NN N
after IN N
receipt NN N
of IN N
a DT N
step-up JJ N
letter NN N
, , N
17.1 CD N
% NN N
of IN N
the DT N
letters NNS N
were VBD N
followed VBN N
by IN N
scheduled JJ N
visits NNS N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
scheduled JJ N
visits NNS N
12.3 CD N
% NN N
of IN N
the DT N
time NN N
by IN N
the DT N
control NN N
children NNS N
with IN N
comparable JJ N
clinical JJ N
symptoms NNS N
Asthma NNP N
medications NNS N
were VBD N
stepped VBN N
up RP N
when WRB N
indicated VBN N
after IN N
46.0 CD N
% NN N
of IN N
these DT N
visits NNS N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
35.6 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
, , N
and CC N
when WRB N
asthma NN N
symptoms NNS N
warranted VBD N
a DT N
step NN N
up RB N
in IN N
therapy NN N
, , N
medication NN N
changes NNS N
occurred VBD N
earlier RBR N
among IN N
the DT N
intervention NN N
children NNS N
Among IN N
children NNS N
whose WP$ N
medications NNS N
were VBD N
stepped VBN N
up RP N
at IN N
any DT N
time NN N
during IN N
the DT N
12-month JJ N
study NN N
period NN N
, , N
those DT N
in IN N
the DT N
intervention NN N
group NN N
experienced VBD N
22.1 CD N
% NN N
fewer JJR N
symptom JJ N
days NNS N
and CC N
37.9 CD N
% NN N
fewer JJR N
school NN N
days NNS N
missed VBN N
The DT N
intention-to-treat JJ N
analysis NN N
showed VBD N
no DT N
difference NN N
over IN N
the DT N
intervention NN N
year NN N
in IN N
the DT N
number NN N
of IN N
symptom JJ N
days NNS N
, , N
yet RB N
there EX N
was VBD N
a DT N
trend NN N
toward IN N
fewer JJR N
days NNS N
of IN N
limited JJ N
activity NN N
and CC N
a DT N
significant JJ N
decrease NN N
in IN N
emergency NN N
department NN N
visits NNS N
by IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
controls NNS N
This DT N
24 CD N
% NN N
drop NN N
in IN N
emergency NN N
department NN N
visits NNS N
resulted VBD N
in IN N
an DT N
intervention NN N
that WDT N
was VBD N
cost VBN N
saving NN N
in IN N
its PRP$ N
first JJ N
year NN N
CONCLUSIONS NNP N
Patient-specific JJ N
feedback NN N
to TO N
inner-city JJ N
providers NNS N
increased VBD N
scheduled VBN N
asthma RB N
visits NNS N
, , N
increased VBD N
asthma JJ N
visits NNS N
in IN N
which WDT N
medications NNS N
were VBD N
stepped VBN N
up RP N
when WRB N
clinically RB N
indicated VBN N
, , N
and CC N
reduced JJ N
emergency NN N
department NN N
visits NNS N
-DOCSTART- -X- O O 8458681

Hypotensive JJ N
effects NNS N
and CC N
influence NN N
on IN N
serum NN N
lipids NNS N
of IN N
SQ29,852 NNP N
, , N
a DT N
new JJ N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitor NN N
, , N
in IN N
patients NNS 4_p
with IN 4_p
essential JJ 4_p
hypertension NN 4_p
: : 4_p
a DT N
comparison NN N
with IN N
atenolol NN N
The DT N
effects NNS N
of IN N
SQ29,852 NNP N
( ( N
n JJ N
= NNP N
24 CD N
) ) N
, , N
a DT N
new JJ N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitor NN N
, , N
and CC N
atenolol NN N
( ( N
n JJ N
= NNP N
22 CD N
) ) N
, , N
monotherapies NNS N
were VBD N
compared VBN N
in IN N
46 CD N
patients NNS N
with IN N
mild JJ N
to TO N
moderate VB N
essential JJ N
hypertension NN N
Both DT N
SQ29,852 NNP N
( ( N
mean VBP N
dose RB N
15.0 CD N
+/- JJ N
5.1 CD N
mg/day NN N
) ) N
and CC N
atenolol $ N
( ( N
mean VB N
dose RB N
37.5 CD N
+/- JJ N
18.5 CD N
mg/day NN N
) ) N
significantly RB N
decreased VBN N
both DT N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressures NNS N
There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
serum NN N
lipids NNS N
, , N
apolipoproteins NNS N
, , N
lipoproteins VBZ N
or CC N
atherosclerotic JJ N
indices NNS N
after IN N
both DT N
SQ29,852 NNP N
and CC N
atenolol RB N
There EX N
were VBD N
also RB N
no DT N
significant JJ N
inter-group JJ N
differences NNS N
There EX N
were VBD N
no DT N
serious JJ N
side NN N
effects NNS N
or CC N
abnormal JJ N
laboratory NN N
tests NNS N
in IN N
both DT N
treatment NN N
groups NNS N
It PRP N
is VBZ N
concluded VBN N
that IN N
SQ29,852 NNP N
is VBZ N
an DT N
effective JJ N
antihypertensive JJ N
drug NN N
without IN N
adverse JJ N
effect NN N
on IN N
lipid JJ N
metabolism NN N
-DOCSTART- -X- O O 11392343

Double-blind NNP N
, , N
placebo-controlled JJ N
study NN N
of IN N
amantadine JJ N
hydrochloride NN N
in IN N
the DT N
treatment NN N
of IN N
children NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
OBJECTIVE UH N
To TO N
test VB N
the DT N
hypothesis NN N
that WDT N
amantadine JJ N
hydrochloride NN N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
treatment NN N
for IN N
behavioral JJ N
disturbances NNS N
-- : N
for IN N
example NN N
, , N
hyperactivity NN N
and CC N
irritability NN N
-- : N
in IN N
children NNS N
with IN N
autism NN 4_p
METHOD NNP N
Thirty-nine JJ 3_p
subjects NNS 3_p
( ( N
intent NN N
to TO N
treat VB N
; : N
5-19 CD N
years NNS N
old JJ N
; : N
IQ NNP N
> NNP N
35 CD N
) ) N
had VBD N
autism NN 4_p
diagnosed VBN 4_p
according VBG 4_p
to TO 4_p
DSM-IV NNP 4_p
and CC 4_p
ICD-10 NNP 4_p
criteria NNS 4_p
using VBG 4_p
the DT 4_p
Autism NNP 4_p
Diagnostic NNP 4_p
Interview-Revised JJ 4_p
and CC 4_p
the DT 4_p
Autism NNP 4_p
Diagnostic NNP 4_p
Observation NNP 4_p
Schedule-Generic NNP 4_p
The DT N
Aberrant JJ N
Behavior NNP N
Checklist-Community NNP N
Version NNP N
( ( N
ABC-CV NNP N
) ) N
and CC N
Clinical JJ N
Global NNP N
Impressions NNP N
( ( N
CGI NNP N
) ) N
scale NN N
were VBD N
used VBN N
as IN N
outcome JJ N
variables NNS N
After IN N
a DT N
1-week JJ N
, , N
single-blind JJ N
placebo NN N
run-in NN N
, , N
patients NNS N
received VBD N
a DT N
single JJ N
daily JJ N
dose NN N
of IN N
amantadine NN N
( ( N
2.5 CD N
mg/kg NNS N
per IN N
day NN N
) ) N
or CC N
placebo NN N
for IN N
the DT N
next JJ N
week NN N
, , N
and CC N
then RB N
bid VB N
dosing VBG N
( ( N
5.0 CD N
mg/kg NNS N
per IN N
day NN N
) ) N
for IN N
the DT N
subsequent JJ N
3 CD N
weeks NNS N
RESULTS VB N
When WRB N
assessed VBN N
on IN N
the DT N
basis NN N
of IN N
parent-rated JJ N
ABC-CV NNP N
ratings NNS N
of IN N
irritability NN N
and CC N
hyperactivity NN N
, , N
the DT N
mean JJ N
placebo NN N
response NN N
rate NN N
was VBD N
37 CD N
% NN N
versus NN N
amantadine NN N
at IN N
47 CD N
% NN N
( ( N
not RB N
significant JJ N
) ) N
However RB N
, , N
in IN N
the DT N
amantadine-treated JJ N
group NN N
there EX N
were VBD N
statistically RB N
significant JJ N
improvements NNS N
in IN N
absolute JJ N
changes NNS N
in IN N
clinician-rated JJ N
ABC-CVs NNP N
for IN N
hyperactivity NN N
( ( N
amantadine JJ N
-6.4 NNP N
versus NN N
placebo NN N
-2.1 NNP N
; : N
p CC N
= NNP N
.046 NNP N
) ) N
and CC N
inappropriate JJ N
speech NN N
( ( N
-1.9 JJ N
versus NN N
0.4 CD N
; : N
p NN N
= NNP N
.008 NNP N
) ) N
CGI NNP N
scale JJ N
ratings NNS N
were VBD N
higher JJR N
in IN N
the DT N
amantadine NN N
group NN N
: : N
53 CD N
% NN N
improved JJ N
versus NN N
25 CD N
% NN N
( ( N
p JJ N
= NNP N
.076 NNP N
) ) N
Amantadine NNP N
was VBD N
well RB N
tolerated VBN N
CONCLUSIONS NNP N
Parents NNPS N
did VBD N
not RB N
report VB N
statistically RB N
significant JJ N
behavioral JJ N
change NN N
with IN N
amantadine NN N
However RB N
, , N
clinician-rated JJ N
improvements NNS N
in IN N
behavioral JJ N
ratings NNS N
following VBG N
treatment NN N
with IN N
amantadine JJ N
suggest VBP N
that IN N
further JJ N
studies NNS N
with IN N
this DT N
or CC N
other JJ N
drugs NNS N
acting VBG N
on IN N
the DT N
glutamatergic NN N
system NN N
are VBP N
warranted VBN N
The DT N
design NN N
of IN N
these DT N
and CC N
similar JJ N
drug NN N
trials NNS N
in IN N
children NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
must MD N
take VB N
into IN N
account NN N
the DT N
possibility NN N
of IN N
a DT N
large JJ N
placebo NN N
response NN N
-DOCSTART- -X- O O 23812665

Measuring VBG N
the DT N
plasticity NN N
of IN N
social JJ N
approach NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
the DT N
PEERS NNP N
intervention NN N
on IN N
EEG NNP N
asymmetry NN N
in IN N
adolescents NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
This DT N
study NN N
examined VBD N
whether IN N
the DT N
Program NNP N
for IN N
the DT N
Education NNP N
and CC N
Enrichment NNP N
of IN N
Relational NNP N
Skills NNP N
( ( N
PEERS NNS N
: : N
Social NNP N
skills NNS N
for IN N
teenagers NNS 1_p
with IN N
developmental JJ N
and CC N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
The DT N
PEERS NNP N
treatment NN N
manual NN N
, , N
Routledge NNP N
, , N
New NNP N
York NNP N
, , N
2010a CD N
) ) N
affected VBD N
neural JJ N
function NN N
, , N
via IN N
EEG NNP N
asymmetry NN N
, , N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
adolescents NNS 1_p
with IN N
Autism NNP 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
and CC N
a DT N
group NN N
of IN N
typically RB N
developing VBG N
adolescents NNS 1_p
Adolescents NNS 1_p
with IN N
ASD NNP 4_p
in IN 4_p
PEERS NNP 4_p
shifted VBD N
from IN N
right-hemisphere JJ N
gamma-band NN N
EEG NNP N
asymmetry NN N
before IN N
PEERS NNS N
to TO N
left-hemisphere JJ N
EEG NNP N
asymmetry NN N
after IN N
PEERS NNP N
, , N
versus VBZ N
a DT N
waitlist JJ N
ASD NNP N
group NN N
Left-hemisphere JJ N
EEG NNP N
asymmetry NN N
was VBD N
associated VBN N
with IN N
more RBR N
social JJ N
contacts NNS N
and CC N
knowledge NN N
, , N
and CC N
fewer JJR N
symptoms NNS N
of IN N
autism NN N
Adolescents NNS 1_p
with IN N
ASD NNP N
in IN N
PEERS NNP N
no RB N
longer RB N
differed VBN N
from IN N
typically RB N
developing VBG N
adolescents NNS N
in IN N
left-dominant JJ N
EEG NNP N
asymmetry NN N
at IN N
post-test NN N
These DT N
findings NNS N
are VBP N
discussed VBN N
via IN N
the DT N
Modifier NNP N
Model NNP N
of IN N
Autism NNP N
( ( N
Mundy NNP N
et RB N
al RB N
in IN N
Res NNP N
Pract NNP N
Persons NNP N
Severe NNP N
Disabl NNP N
32 CD N
( ( N
2 CD N
) ) N
:124 NN N
, , N
2007 CD N
) ) N
, , N
with IN N
emphasis NN N
on IN N
remediating VBG N
isolation/withdrawal NN N
in IN N
ASD NNP N
-DOCSTART- -X- O O 3896455

A DT N
randomized JJ N
comparative JJ N
trial NN N
of IN N
combined JJ N
versus NN N
alternating VBG N
therapy NN N
with IN N
cytostatic JJ N
drugs NNS N
and CC N
high-dose JJ N
medroxyprogesteron NN N
acetate NN N
in IN N
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
A DT N
prospective JJ N
multicenter NN N
trial NN N
was VBD N
conducted VBN N
in IN N
155 CD 3_p
consecutive JJ N
patients NNS N
with IN N
Stage NNP N
IV NNP N
breast NN N
cancer NN N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
( ( N
1 CD N
) ) N
vincristin NN N
( ( N
V NNP N
) ) N
1.2 CD N
mg/m2 NN N
( ( N
maximum JJ N
dose NN N
, , N
2 CD N
mg NN N
) ) N
, , N
Adriamycin NNP N
( ( N
A NNP N
) ) N
( ( N
doxorubicin NN N
) ) N
40 CD N
mg/m2 NN N
, , N
and CC N
cyclophosphamide NN N
( ( N
C NNP N
) ) N
500 CD N
mg/m2 NN N
, , N
all DT N
intravenously RB N
on IN N
day NN N
1 CD N
, , N
every DT N
4 CD N
weeks NNS N
, , N
in IN N
combination NN N
with IN N
medroxyprogesteron NN N
acetate NN N
( ( N
MPA NNP N
) ) N
600 CD N
mg NN N
orally RB N
on IN N
days NNS N
1 CD N
through IN N
14 CD N
, , N
500 CD N
mg NNS N
intramuscularly RB N
on IN N
days NNS N
1 CD N
through IN N
28 CD N
, , N
and CC N
twice RB N
weekly JJ N
afterwards NNS N
( ( N
combined VBN N
chemoendocrine NN N
approach NN N
) ) N
or CC N
( ( N
2 CD N
) ) N
the DT N
same JJ N
combination NN N
chemotherapy NN N
( ( N
VAC NNP N
) ) N
for IN N
three CD N
cycles NNS N
alternating VBG N
with IN N
MPA NNP N
in IN N
the DT N
above-mentioned JJ N
dosage NN N
during IN N
8 CD N
weeks NNS N
( ( N
alternating VBG N
chemoendocrine VB N
approach NN N
) ) N
Results NNP N
show VBP N
an DT N
overall JJ N
response NN N
rate NN N
of IN N
73 CD N
% NN N
with IN N
26 CD N
% NN N
complete JJ N
responses NNS N
in IN N
the DT N
combined JJ N
treatment NN N
arm NN N
, , N
whereas NNS N
in IN N
the DT N
alternating NN N
arm NN N
, , N
an DT N
overall JJ N
response NN N
rate NN N
of IN N
76 CD N
% NN N
with IN N
20 CD N
% NN N
complete JJ N
responses NNS N
was VBD N
observed VBN N
In IN N
patients NNS N
with IN N
more JJR N
than IN N
one CD N
metastatic JJ N
site NN N
, , N
response NN N
rate NN N
was VBD N
higher RBR N
in IN N
the DT N
combination NN N
treatment NN N
, , N
and CC N
only RB N
in IN N
this DT N
arm NN N
were VBD N
complete JJ N
responses NNS N
observed VBN N
in IN N
these DT N
patients NNS N
Although IN N
the DT N
median JJ N
duration NN N
of IN N
response NN N
was VBD N
long RB N
in IN N
both DT N
treatment NN N
arms NNS N
( ( N
combination NN N
, , N
19 CD N
months NNS N
versus IN N
alternating VBG N
, , N
21 CD N
months NNS N
) ) N
, , N
the DT N
median JJ N
overall JJ N
survival NN N
in IN N
both DT N
groups NNS N
was VBD N
not RB N
definitely RB N
prolonged VBN N
( ( N
22 CD N
versus NN N
24 CD N
months NNS N
, , N
respectively RB N
) ) N
However RB N
, , N
results NNS N
in IN N
subsets NNS N
of IN N
patients NNS N
suggest VBP N
that IN N
the DT N
alternating VBG N
chemoendocrine JJ N
approach NN N
may MD N
be VB N
better JJR N
for IN N
estrogen NN N
receptor NN N
( ( N
ER NNP N
) ) N
-negative JJ N
patients NNS N
, , N
for IN N
patients NNS N
younger JJR N
than IN N
51 CD N
years NNS N
of IN N
age NN N
, , N
and CC N
for IN N
patients NNS N
with IN N
a DT N
disease-free JJ N
interval NN N
of IN N
1 CD N
year NN N
or CC N
less JJR N
Patients NNS N
with IN N
these DT N
parameters NNS N
probably RB N
belong RB N
to TO N
the DT N
same JJ N
population NN N
It PRP N
is VBZ N
concluded VBN N
that IN N
combination NN N
of IN N
chemotherapy NN N
and CC N
high-dose JJ N
MPA NNP N
may MD N
be VB N
indicated VBN N
in IN N
ER-positive JJ N
patients NNS N
when WRB N
a DT N
clinical JJ N
response NN N
is VBZ N
urgently RB N
needed VBN N
In IN N
ER-negative JJ N
patients NNS N
, , N
the DT N
alternating VBG N
use NN N
of IN N
both DT N
treatment NN N
modalities VBZ N
deserves VBZ N
further JJ N
investigation NN N
-DOCSTART- -X- O O 8656171

Effectiveness NN N
of IN N
erythromycin NN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
bronchitis NN N
BACKGROUND NNP N
Clinical NNP N
trials NNS N
have VBP N
not RB N
shown VBN N
a DT N
consistent JJ N
benefit NN N
of IN N
treating VBG N
bronchitis NN N
with IN N
antibiotics NNS N
Many JJ N
physicians NNS N
, , N
however RB N
, , N
treat VB N
acute JJ N
bronchitis NN N
with IN N
antibiotics NNS N
because IN N
of IN N
the DT N
possibility NN N
of IN N
Mycoplasma NNP N
pneumoniae NN N
or CC N
other JJ N
pathogens NNS N
The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
erythromycin JJ N
treatment NN N
in IN N
patients NNS N
with IN N
acute JJ N
bronchitis NN N
and CC N
to TO N
determine VB N
whether IN N
a DT N
newly RB N
developed VBN N
rapid JJ N
M NNP N
pneumoniae NN N
antibody NN N
test NN N
is VBZ N
useful JJ N
in IN N
predicting VBG N
which WDT N
patients NNS N
will MD N
respond VB N
to TO N
therapy VB N
METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
at IN N
three CD N
primary JJ N
care NN N
centers NNS N
in IN N
North NNP N
Carolina NNP N
A DT N
convenience NN N
sample NN N
of IN N
140 CD N
patients NNS N
presenting VBG N
with IN N
acute JJ N
bronchitis NN N
were VBD N
tested VBN N
for IN N
M NNP N
pneumoniae NN N
, , N
91 CD N
of IN N
whom WP N
were VBD N
treated VBN N
with IN N
either DT N
erythromycin JJ N
250 CD N
mg RB N
four CD N
times NNS N
daily RB N
for IN N
10 CD N
days NNS N
or CC N
an DT N
identical-appearing JJ N
placebo NN N
RESULTS JJ N
Patients NNS N
treated VBN N
with IN N
erythromycin NN N
missed VBD N
an DT N
average NN N
of IN N
only JJ N
0.81 CD N
+/- JJ N
1.1 CD N
days NNS N
of IN N
work NN N
compared VBN N
with IN N
2.16 CD N
+/- JJ N
3.2 CD N
days NNS N
for IN N
placebo-treated JJ N
patients NNS N
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
cough NN N
, , N
use NN N
of IN N
cough JJ N
medicine NN N
, , N
general JJ N
feeling NN N
of IN N
well-being NN N
, , N
or CC N
chest JJS N
congestion NN N
between IN N
the DT N
erythromycin NN N
and CC N
placebo NN N
groups NNS N
Twenty-five JJ N
percent NN N
of IN N
the DT N
patients NNS N
tested VBD N
positive JJ N
for IN N
M NNP N
pneumoniae NN N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
response NN N
to TO N
erythromycin VB N
based VBN N
on IN N
whether IN N
the DT N
patient NN N
had VBD N
a DT N
positive JJ N
test NN N
for IN N
M NNP N
pneumoniae NN N
CONCLUSIONS NNP N
Erythromycin NNP N
is VBZ N
effective JJ N
in IN N
significantly RB N
reducing VBG N
lost VBN N
time NN N
from IN N
work NN N
, , N
but CC N
it PRP N
is VBZ N
not RB N
effective JJ N
in IN N
reducing VBG N
cough NN N
or CC N
other JJ N
symptoms NNS N
in IN N
patients NNS N
with IN N
acute JJ N
bronchitis NN N
, , N
regardless RB N
of IN N
the DT N
outcome NN N
of IN N
the DT N
M NNP N
pneumoniae NN N
antibody NN N
test NN N
-DOCSTART- -X- O O 7608801

A DT N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
the DT N
efficacy NN N
of IN N
a DT N
heparin NN N
and CC N
vancomycin JJ N
solution NN N
in IN N
preventing VBG N
central JJ 4_p
venous JJ 4_p
catheter NN 4_p
infections NNS 4_p
in IN N
children NNS 1_p
OBJECTIVE NN N
To TO N
determine VB N
whether IN N
adding VBG N
vancomycin NN N
to TO N
central JJ N
venous JJ N
catheter NN N
( ( N
CVC NNP N
) ) N
flush NN N
solution NN N
would MD N
significantly RB N
reduce VB N
the DT N
incidence NN N
of IN N
bacteremia NN N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
STUDY NNP N
DESIGN NNP N
Fifty-five JJ 3_p
children NNS 1_p
with IN N
cancer NN 4_p
and CC N
eight CD 3_p
children NNS 1_p
given VBN N
total JJ 4_p
parenteral JJ 4_p
nutrition NN 4_p
by IN 4_p
the DT 4_p
surgery NN 4_p
or CC 4_p
nutrition NN 4_p
support NN 4_p
services NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
heparin NN N
CVC NNP N
flush JJ N
solution NN N
( ( N
n JJ N
= NNP N
31 CD N
) ) N
or CC N
a DT N
heparin-vancomycin JJ N
CVC NNP N
flush NN N
solution NN N
( ( N
n JJ N
= NNP N
32 CD N
) ) N
RESULTS NNP N
During IN N
9158 CD N
catheter NN N
days NNS N
, , N
6.5 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
heparin NN N
group NN N
and CC N
15.6 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
heparin-vancomycin JJ N
group NN N
had VBD N
bacteremia VBN N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
( ( N
p JJ N
= NNP N
0.43 CD N
) ) N
The DT N
mean JJ N
rates NNS N
of IN N
bacteremia NN N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
were VBD N
0.6/1000 CD N
catheter NN N
days NNS N
in IN N
the DT N
heparin NN N
group NN N
and CC N
1.4/1000 CD N
catheter NN N
days NNS N
in IN N
the DT N
heparin-vancomycin JJ N
group NN N
( ( N
p JJ N
= NNP N
0.25 CD N
) ) N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
when WRB N
the DT N
time NN N
to TO N
the DT N
first JJ N
episode NN N
of IN N
bacteremia NN N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
a DT N
vancomycin-susceptible JJ N
organism NN N
was VBD N
compared VBN N
by IN N
means NNS N
of IN N
Kaplan-Meier NNP N
survival NN N
estimates NNS N
Streptococcus NNP N
viridans NNPS N
infection NN N
was VBD N
not RB N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
CONCLUSION VB N
The DT N
addition NN N
of IN N
vancomycin NN N
to TO N
heparin VB N
CVC NNP N
flush JJ N
solution NN N
did VBD N
not RB N
reduce VB N
bacteremia NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
Bacteremia NNP N
with IN N
Streptococcus NNP N
viridans NNS N
was VBD N
not RB N
related VBN N
to TO N
the DT N
use NN N
of IN N
a DT N
CVC NNP N
-DOCSTART- -X- O O 7449282

Cardiac NNP N
and CC N
haemodynamic JJ N
measurements NNS N
in IN N
hypertensive JJ 4_p
pregnancy NN 4_p
1 CD N
Haemodynamic NNP N
and CC N
left VBD N
ventricular JJ N
variables NNS N
were VBD N
determined VBN N
by IN N
M-mode NNP N
echocardiography NN N
in IN N
21 CD 3_p
normotensive JJ 4_p
and CC N
36 CD 3_p
hypertensive JJ 4_p
patients NNS N
during IN N
the DT N
last JJ N
trimester NN N
of IN N
pregnancy NN N
2 CD N
Blood NNP N
pressure NN N
of IN N
hypertensive JJ 4_p
patients NNS N
was VBD N
lowered VBN N
by IN N
bed NN N
rest NN N
only RB N
, , N
or CC N
by IN N
oxprenolol JJ N
or CC N
methyldopa NN N
, , N
but CC N
remained VBD N
elevated VBN N
3 CD N
Cardiac NNP N
output NN N
was VBD N
raised VBN N
in IN N
the DT N
last JJ N
trimester NN N
of IN N
pregnancy NN N
in IN N
both DT N
normotensive JJ 4_p
and CC N
hypertensive JJ 4_p
patients NNS N
4 CD N
Left VBN N
ventricular JJ N
mass NN N
was VBD N
increased VBN N
in IN N
normal JJ N
pregnancy NN N
, , N
but CC N
displayed VBD N
an DT N
exaggerated JJ N
increase NN N
in IN N
hypertensive JJ 4_p
patients NNS N
5 CD N
Total JJ N
peripheral JJ N
resistance NN N
was VBD N
inappropriately RB N
elevated VBN N
in IN N
hypertensive JJ N
pregnancy NN N
, , N
except IN N
in IN N
the DT N
oxprenolol-treated JJ N
group NN N
6 CD N
There EX N
ws VBZ N
no DT N
reduction NN N
in IN N
heart NN N
rate NN N
or CC N
cardiac JJ N
output NN N
in IN N
the DT N
group NN N
treated VBD N
with IN N
beta-adrenoreceptor NN N
blocking VBG N
agents NNS N
These DT N
factors NNS N
, , N
in IN N
combination NN N
with IN N
normal JJ N
peripheral JJ N
resistance NN N
, , N
may MD N
contribute VB N
to TO N
the DT N
improvement NN N
in IN N
foetal JJ N
outcome NN N
described VBN N
in IN N
maternal JJ N
hypertension NN N
of IN N
pregnancy NN N
treated VBN N
with IN N
oxprenolol NN N
-DOCSTART- -X- O O 21788433

Effect NN N
of IN N
shearing VBG N
on IN N
water NN N
turnover NN N
and CC N
thermobiological JJ N
variables NNS N
in IN N
German JJ N
Blackhead NNP N
mutton NN N
sheep NN N
Current JJ N
equations NNS N
for IN N
estimating VBG N
water NN N
requirements NNS N
in IN N
sheep JJ N
do VBP N
not RB N
differentiate VB N
between IN N
shorn JJ N
and CC N
unshorn JJ N
sheep NN N
Furthermore RB N
, , N
the DT N
effect NN N
of IN N
shearing VBG N
on IN N
thermoregulative JJ N
responses NNS N
in IN N
sheep NN N
has VBZ N
not RB N
been VBN N
adequately RB N
studied VBN N
under IN N
temperate JJ N
environmental JJ N
conditions NNS N
Therefore RB N
, , N
the DT N
present JJ N
study NN N
was VBD N
conducted VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
wool NN N
coverage NN N
on IN N
water NN N
turnover NN N
in IN N
relation NN N
to TO N
thermoregulation NN N
in IN N
sheep NN N
by IN N
using VBG N
the DT N
deuterium NN N
dilution NN N
technique NN N
to TO N
predict VB N
total JJ N
water NN N
intake NN N
before IN N
and CC N
after IN N
shearing VBG N
Physiological JJ N
responses NNS N
, , N
such JJ N
as IN N
water NN N
turnover NN N
, , N
surface NN N
temperature NN N
, , N
and CC N
rectal JJ N
temperature NN N
, , N
as RB N
well RB N
as IN N
drinking VBG N
behavior NN N
of IN N
sheep NN N
were VBD N
also RB N
evaluated VBN N
Fourteen NNP 3_p
nonlactating JJ 4_p
German JJ N
Blackhead NNP N
mutton NN N
ewes NN N
were VBD N
randomly RB N
allocated VBN N
into IN N
2 CD N
groups NNS N
: : N
a DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
that WDT N
was VBD N
already RB N
shorn VBN N
, , N
and CC N
a DT N
treatment NN N
group NN N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
that WDT N
was VBD N
left VBN N
unshorn JJ N
( ( N
wool JJ N
length NN N
: : N
10.6 CD N
± $ N
1.2 CD N
cm NN N
) ) N
Individual NNP N
feed NN N
and CC N
water NN N
intakes NNS N
were VBD N
recorded VBN N
throughout IN N
the DT N
experiment NN N
( ( N
d JJ N
1 CD N
to TO N
71 CD N
) ) N
Two CD N
weeks NNS N
after IN N
measurements NNS N
commenced VBD N
( ( N
d JJ N
15 CD N
) ) N
, , N
treatment NN N
sheep NN N
were VBD N
shorn VBN N
Water NNP N
intake NN N
was VBD N
estimated VBN N
twice RB N
for IN N
2 CD N
consecutive JJ N
weeks NNS N
by IN N
using VBG N
deuterium JJ N
dilution NN N
techniques NNS N
( ( N
d VB N
1 CD N
to TO N
15 CD N
and CC N
d VB N
57 CD N
to TO N
71 CD N
) ) N
Ambient JJ N
temperature NN N
( ( N
T NNP N
( ( N
a DT N
) ) N
) ) N
, , N
relative JJ N
humidity NN N
, , N
and CC N
respiratory JJ N
rate NN N
were VBD N
measured VBN N
daily RB N
, , N
whereas JJ N
BW NNP N
, , N
rectal NN N
and CC N
animal JJ N
surface NN N
temperatures NNS N
( ( N
using VBG N
infrared VBN N
thermography NN N
) ) N
, , N
and CC N
wool JJ N
length NN N
were VBD N
measured VBN N
weekly RB N
In IN N
the DT N
first JJ N
2 CD N
wk NN N
, , N
when WRB N
treatment NN N
sheep NN N
were VBD N
unshorn JJ N
, , N
treatment NN N
and CC N
control NN N
ewes NN N
differed VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
DMI NNP N
( ( N
52 CD N
± RB N
4 CD N
vs. FW N
59 CD N
± $ N
4 CD N
g·kg NN N
( ( N
-0.75 NNP N
) ) N
·d NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
water NN N
intake NN N
( ( N
165 CD N
± RB N
17 CD N
vs. FW N
134 CD N
± $ N
18 CD N
g·kg NN N
( ( N
-0.75 NNP N
) ) N
·d NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
respiratory JJ N
rate NN N
( ( N
66 CD N
± RB N
5 CD N
vs. FW N
31 CD N
± $ N
4 CD N
breath/min NN N
) ) N
, , N
rectal JJ N
temperature NN N
( ( N
39.3 CD N
± RB N
0.2 CD N
vs. FW N
38.8 CD N
± $ N
0.1°C CD N
) ) N
, , N
and CC N
surface NN N
temperatures NNS N
( ( N
body JJ N
side NN N
: : N
19.3 CD N
± $ N
0.3 CD N
vs. FW N
24.5 CD N
± $ N
0.6°C CD N
; : N
leg NN N
: : N
25.8 CD N
± $ N
2.4 CD N
vs. FW N
27.4 CD N
± $ N
1.6°C CD N
) ) N
However RB N
, , N
after IN N
shearing VBG N
, , N
these DT N
differences NNS N
partly RB N
disappeared VBD N
The DT N
same JJ N
trend NN N
in IN N
water NN N
intake NN N
between IN N
groups NNS N
was VBD N
confirmed VBN N
using VBG N
the DT N
isotope NN N
dilution NN N
technique NN N
We PRP N
found VBD N
a DT N
significant JJ N
relationship NN N
between IN N
T NNP N
( ( N
a DT N
) ) N
and CC N
water NN N
intake NN N
, , N
respiratory NN N
rate NN N
, , N
and CC N
body NN N
surface NN N
temperatures NNS N
Even RB N
under IN N
temperate NN N
conditions NNS N
( ( N
T NNP N
( ( N
a DT N
) ) N
< $ N
28°C CD N
) ) N
, , N
shearing VBG N
significantly RB N
reduced VBN N
core NN N
body NN N
temperature NN N
, , N
water NN N
intake NN N
, , N
and CC N
respiratory NN N
rate NN N
in IN N
German JJ N
Blackhead NNP N
mutton NN N
sheep NN N
, , N
thus RB N
indicating VBG N
heat NN N
stress NN N
in IN N
fleeced JJ N
animals NNS N
, , N
which WDT N
should MD N
be VB N
considered VBN N
when WRB N
determining VBG N
the DT N
optimal JJ N
shearing NN N
time NN N
in IN N
sheep NN N
as RB N
well RB N
as IN N
when WRB N
estimating VBG N
water NN N
requirements NNS N
-DOCSTART- -X- O O 17434069

Comparison NNP N
of IN N
three CD N
methods NNS N
to TO N
increase VB N
knowledge NN N
about IN N
breast NN N
cancer NN N
and CC N
breast NN N
cancer NN N
screening VBG N
in IN N
screening VBG 4_p
mammography NN 4_p
patients NNS 4_p
RATIONALE NNP N
AND CC N
OBJECTIVES NNP N
The DT N
specific JJ N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
which WDT N
of IN N
several JJ N
cost-effective JJ N
interventions NNS N
is VBZ N
best RBS N
able JJ N
to TO N
improve VB N
the DT N
breast NN N
cancer NN N
knowledge NN N
of IN N
women NNS 4_p
who WP 4_p
present VBP 4_p
for IN 4_p
screening VBG 4_p
mammography NN 4_p
MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
198 CD 3_p
English-speaking JJ 3_p
women NNS 3_p
, , N
with IN N
no DT N
personal JJ N
or CC N
family NN N
history NN N
of IN N
breast NN 4_p
cancer NN 4_p
, , N
were VBD N
recruited VBN N
and CC N
randomized VBN N
to TO N
four CD N
groups NNS N
when WRB N
they PRP N
presented VBD N
to TO N
the DT N
clinic NN N
for IN N
a DT N
screening NN 4_p
mammogram NN 4_p
All DT N
women NNS N
filled VBN N
in IN N
a DT N
demographic JJ N
data NN N
form NN N
and CC N
answered VBD N
a DT N
questionnaire NN N
containing VBG N
nine CD N
questions NNS N
about IN N
breast NN N
cancer NN N
, , N
risk NN N
, , N
and CC N
screening VBG N
to TO N
assess VB N
their PRP$ N
knowledge NN N
and CC N
perception NN N
Three CD N
educational JJ N
interventions NNS N
were VBD N
tested VBN N
in IN N
this DT N
study NN N
The DT N
first JJ N
consisted VBN N
of IN N
a DT N
brochure NN N
, , N
which WDT N
provided VBD N
answers NNS N
to TO N
the DT N
questionnaire NN N
items NNS N
and CC N
addressed VBD N
the DT N
issues NNS N
in IN N
more JJR N
depth NN N
The DT N
second JJ N
intervention NN N
was VBD N
an DT N
educational JJ N
conversation NN N
with IN N
a DT N
specially RB N
trained JJ N
mammography NN N
technologist NN N
She PRP N
reviewed VBD N
the DT N
subject NN N
's POS N
answers NNS N
to TO N
the DT N
questionnaire NN N
items NNS N
correcting VBG N
and/or NN N
clarifying VBG N
them PRP N
The DT N
third JJ N
intervention NN N
consisted VBD N
of IN N
the DT N
brochure NN N
together RB N
with IN N
the DT N
conversation NN N
with IN N
a DT N
trained JJ N
technologist NN N
There EX N
was VBD N
also RB N
a DT N
control NN N
group NN N
that WDT N
just RB N
filled VBN N
in IN N
the DT N
study NN N
questionnaire NN N
but CC N
did VBD N
not RB N
receive VB N
an DT N
educational JJ N
intervention NN N
The DT N
same JJ N
questionnaire NN N
was VBD N
administered VBN N
by IN N
telephone NN N
4 CD N
to TO N
6 CD N
weeks NNS N
after IN N
the DT N
screening NN N
experience NN N
to TO N
all DT N
study NN N
subjects NNS N
Changes NNS N
in IN N
their PRP$ N
knowledge NN N
and CC N
perceptions NNS N
of IN N
breast NN N
cancer NN N
were VBD N
measured VBN N
and CC N
compared VBN N
RESULTS VB N
A NNP N
statistically RB N
significant JJ N
increase NN N
in IN N
knowledge NN N
was VBD N
found VBN N
in IN N
all DT N
of IN N
the DT N
three CD N
investigated VBD N
groups NNS N
compared VBN N
to TO N
the DT N
control NN N
group NN N
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
amount NN N
of IN N
increase NN N
between IN N
women NNS N
who WP N
underwent VBP N
different JJ N
interventions NNS N
CONCLUSIONS NNP N
All NNP N
three CD N
interventions NNS N
resulted VBD N
in IN N
increased VBN N
knowledge NN N
about IN N
breast NN N
cancer NN N
and CC N
screening NN N
No DT N
differences NNS N
in IN N
the DT N
amount NN N
of IN N
knowledge NN N
increase NN N
were VBD N
found VBN N
between IN N
three CD N
interventions NNS N
tested VBN N
The DT N
educational JJ N
brochure NN N
seems VBZ N
to TO N
represent VB N
the DT N
most RBS N
convenient JJ N
and CC N
least JJS N
costly JJ N
method NN N
to TO N
increase VB N
knowledge NN N
about IN N
breast NN N
cancer NN N
and CC N
screening VBG N
among IN N
women NNS N
who WP N
present VBP N
for IN N
screening VBG N
mammography NN N
-DOCSTART- -X- O O 20386431

Weight-adjusted JJ N
dalteparin NN N
for IN N
prevention NN N
of IN N
vascular JJ N
thromboembolism NN N
in IN N
advanced JJ 4_p
pancreatic JJ 4_p
cancer NN 4_p
patients NNS 4_p
decreases VBZ N
serum JJ N
tissue NN N
factor NN N
and CC N
serum-mediated JJ N
induction NN N
of IN N
cancer NN N
cell NN N
invasion NN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
role NN N
of IN N
tissue NN N
factor NN N
and CC N
serum-induced JJ N
cell NN N
invasion NN N
in IN N
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
pancreatic JJ 4_p
cancer NN 4_p
( ( 4_p
APC NNP 4_p
) ) 4_p
A DT N
cohort NN N
of IN N
39 CD 3_p
patients NNS 3_p
with IN N
APC NNP N
, , N
without IN N
thrombosis NN 4_p
, , 4_p
receiving VBG 4_p
chemotherapy NN 4_p
, , N
were VBD N
entered VBN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
( ( N
ISRCTN NNP N
= NNP N
76464767 CD N
) ) N
of IN N
thromboprevention NN N
with IN N
weight-adjusted JJ N
dalteparin NN N
( ( N
WAD NNP N
) ) N
A DT N
total NN N
of IN N
19 CD N
patients NNS N
received VBD N
WAD NNP N
, , N
the DT N
remaining VBG N
20 CD N
acting VBG N
as IN N
a DT N
control NN N
group NN N
Serum NNP N
from IN N
baseline NN N
and CC N
week NN N
8 CD N
was VBD N
analysed VBN N
for IN N
circulating-tissue JJ N
factor NN N
antigen NN N
using VBG N
ELISA NNP N
Circulating-tissue NNP N
factor NN N
antigen NN N
rose VBD N
from IN N
324 CD N
pg/ml NN N
, , N
[ NNP N
interquartile NN N
range NN N
( ( N
IQR NNP N
) ) N
282-347 CD N
pg/ml NN N
] NN N
to TO N
356 CD N
pg/ml NN N
, , N
( ( N
IQR NNP N
319-431 NNP N
pg/ml NN N
) ) N
in IN N
controls NNS N
( ( N
C NNP N
) ) N
, , N
and CC N
decreased VBN N
in IN N
the DT N
dalteparin-treated JJ N
group NN N
( ( N
D NNP N
) ) N
from IN N
336 CD N
pg/ml NN N
( ( N
IQR NNP N
281-346 CD N
pg/ml NN N
) ) N
to TO N
303 CD N
pg/ml NN N
( ( N
IQR NNP N
274-339 CD N
pg/ml NN N
) ) N
The DT N
difference NN N
in IN N
median JJ N
percentage NN N
change NN N
between IN N
D NNP N
and CC N
C NNP N
was VBD N
statistically RB N
significant JJ N
[ JJ N
-4.0 NN N
( ( N
D NNP N
) ) N
vs. FW N
4.7 CD N
( ( N
C NNP N
) ) N
; : N
P NNP N
= VBZ N
0.005 CD N
, , N
n RB N
= VBZ N
39 CD N
] NN N
Serum-induced JJ N
cellular JJ N
invasion NN N
of IN N
MIA-Paca-2 NNP N
cells NNS N
in IN N
response NN N
to TO N
patient VB N
serum NN N
was VBD N
studied VBN N
using VBG N
a DT N
Boyden NNP N
chamber NN N
assay NN N
in IN N
30 CD N
patients NNS N
( ( N
14 CD N
WAD NNP N
and CC N
16 CD N
C NNP N
) ) N
The DT N
median JJ N
percentage NN N
change NN N
between IN N
C NNP N
and CC N
D NNP N
was VBD N
significant JJ N
[ JJ N
+54.9 NN N
( ( N
C NNP N
) ) N
vs. FW N
-21.9 FW N
( ( N
D NNP N
) ) N
P NNP N
= $ N
0.025 CD N
, , N
n RB N
= VBZ N
30 CD N
] NN N
There EX N
was VBD N
a DT N
weak JJ N
correlation NN N
between IN N
BB-tissue NNP N
factor NN N
reduction NN N
and CC N
cellular JJ N
invasion NN N
reduction NN N
( ( N
Spearman NNP N
) ) N
[ VBZ N
0.384 CD N
( ( N
P NNP N
= NNP N
0.037 CD N
, , N
n RB N
= VBZ N
30 CD N
) ) N
] NN N
APC NNP 4_p
patients NNS 4_p
treated VBD 4_p
with IN N
WAD NNP N
have VBP N
lower JJR N
tissue NN N
factor NN N
antigen NN N
levels NNS N
and CC N
attenuated JJ N
induction NN N
of IN N
cellular JJ N
invasion NN N
in IN N
their PRP$ N
blood NN N
These DT N
assays NNS N
may MD N
provide VB N
useful JJ N
markers NNS N
to TO N
guide VB N
appropriate JJ N
dalteparin NN N
( ( N
and CC N
other JJ N
low-molecular JJ N
weight NN N
heparin NN N
) ) N
dosing VBG N
schedules NNS N
to TO N
optimize VB N
anticancer JJ N
effects NNS N
of IN N
dalteparin NN N
in IN N
APC NNP N
-DOCSTART- -X- O O 22160347

The DT N
home NN N
TEACCHing NNP N
program NN N
for IN N
toddlers NNS 1_p
with IN N
autism NN 4_p
The DT N
study NN N
evaluated VBD N
the DT N
efficacy NN N
a DT N
parent NN N
training NN N
intervention NN N
for IN N
children NNS 1_p
with IN N
autism NN 4_p
based VBN N
on IN N
the DT N
TEACCH NNP N
model NN N
Twenty JJ 3_p
families NNS 3_p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN N
or CC N
waitlist NN N
group NN N
All DT N
families NNS N
were VBD N
compared VBN N
at IN N
pre- JJ N
and CC N
post-treatment JJ N
on IN N
formal JJ N
dependent NN N
measures NNS N
Direct JJ N
measures NNS N
of IN N
behavior NN N
were VBD N
compared VBN N
across IN N
six CD N
matched VBD N
pairs NNS N
using VBG N
a DT N
multiple JJ N
baseline NN N
probe NN N
design NN N
The DT N
results NNS N
of IN N
the DT N
multiple JJ N
baseline NN N
design NN N
showed VBD N
robust JJ N
support NN N
for IN N
improvement NN N
in IN N
child NN 1_p
and CC N
parent NN N
behavior NN N
Due NNP N
to TO N
the DT N
sample NN N
size NN N
and CC N
short JJ N
time NN N
frame NN N
, , N
results NNS N
of IN N
a DT N
repeated JJ N
measures NNS N
analysis NN N
of IN N
variance NN N
did VBD N
not RB N
reach VB N
significance NN N
-DOCSTART- -X- O O 11536065

[ JJ N
Comparison NNP N
between IN N
anterior JJ N
rhinomanometry NN N
and CC N
impulse-oscillometric JJ N
rhinometry NN N
found VBD N
within IN N
nasal JJ 4_p
allergen JJ 4_p
provocation NN N
] NNP N
UNLABELLED NNP N
Besides IN N
the DT N
standard JJ N
method NN N
of IN N
anterior JJ N
rhinomanometry NN N
( ( N
aR NN N
) ) N
, , N
the DT N
impulse-oscillometric JJ N
rhinometry NN N
( ( N
IOS NNP N
) ) N
is VBZ N
available JJ N
for IN N
measurements NNS N
of IN N
the DT N
nasal JJ N
resistance NN N
The DT N
aR NN N
is VBZ N
a DT N
procedure NN N
dependent NN N
on IN N
the DT N
cooperation NN N
of IN N
the DT N
patient NN N
, , N
whereas JJ N
IOS NNP N
is VBZ N
measured VBN N
regardless RB N
from IN N
the DT N
breathing NN N
activities NNS N
of IN N
the DT N
patient NN N
We PRP N
examined VBD N
weather RP N
the DT N
resistance-measurement NN N
by IN N
means NNS N
of IN N
IOS NNP N
in IN N
comparison NN N
to TO N
the DT N
aR NN N
is VBZ N
a DT N
more RBR N
suitable JJ N
method NN N
for IN N
nasal JJ N
allergic JJ N
provocation NN N
METHOD NNP N
17 CD 3_p
patients NNS N
with IN N
anamnestic JJ N
known VBN N
rhinokonjunktivitis NN 4_p
( ( N
6 CD N
f NN N
, , N
11 CD N
m NN N
) ) N
had VBD N
a DT N
pricktest NN N
and CC N
then RB N
a DT N
nasal JJ N
provocation NN N
testing VBG N
with IN N
an DT N
allergen NN N
which WDT N
provoked VBD N
a DT N
reaction NN N
on IN N
the DT N
skin NN N
The DT N
complete JJ N
resistance NN N
of IN N
the DT N
nose NN N
was VBD N
measured VBN N
in IN N
a DT N
randomized JJ N
order NN N
by IN N
means NNS N
of IN N
aR NN N
and CC N
IOS NNP N
RESULTS VB N
The DT N
complete JJ N
resistance NN N
showed VBD N
neither CC N
in IN N
the DT N
basic JJ N
measurement NN N
( ( N
aR JJ N
0,38 CD N
+/- JJ N
0,14 CD N
kPa/l/s NN N
; : N
IOS NNP N
0,38 CD N
+/- JJ N
0,11 CD N
kPa/l/s NN N
) ) N
nor CC N
in IN N
the DT N
control NN N
solution NN N
( ( N
aR JJ N
0,38 CD N
+/- JJ N
0,14 CD N
; : N
IOS NNP N
0,39 CD N
+/- JJ N
0,14 CD N
) ) N
nor CC N
after IN N
application NN N
of IN N
the DT N
allergenic JJ N
solution NN N
( ( N
15 CD N
min NN N
: : N
aR JJ N
0,69 CD N
+/- JJ N
0,27 CD N
; : N
IOS NNP N
0,77 CD N
+/- JJ N
0,42 CD N
; : N
30 CD N
min NN N
: : N
aR JJ N
0,65 CD N
+/- JJ N
0,29 CD N
; : N
IOS NNP N
0,6 CD N
+/- JJ N
0,38 CD N
) ) N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
The DT N
results NNS N
of IN N
the DT N
measurement NN N
of IN N
aR NN N
and CC N
IOS NNP N
after IN N
the DT N
allergenic JJ N
solution NN N
showed VBD N
a DT N
positive JJ N
correlation NN N
( ( N
15 CD N
min NN N
: : N
r NN N
= VBZ N
0,63 CD N
, , N
p NN N
< VBD N
0,01 CD N
; : N
30 CD N
min NN N
: : N
r NN N
= VBZ N
0,67 CD N
, , N
p NN N
< NNP N
0,01 CD N
) ) N
We PRP N
found VBD N
by IN N
means NNS N
of IN N
clinic NN N
and CC N
measurement NN N
methods NNS N
in IN N
the DT N
aR NN N
of IN N
7 CD 3_p
patients NNS N
a DT N
positive JJ N
reaction NN N
, , N
within IN N
7 CD N
patient NN N
a DT N
negative JJ N
reaction NN N
, , N
3 CD N
patients NNS N
had VBD N
a DT N
unspecific JJ N
nasal NN N
hyperreactivity NN N
There EX N
was VBD N
a DT N
correspondence NN N
in IN N
6 CD N
of IN N
the DT N
7 CD N
patients NNS N
with IN N
positive JJ N
reaction NN N
in IN N
aR NN N
between IN N
both DT N
methods NNS N
4 CD N
of IN N
the DT N
7 CD N
results NNS N
with IN N
negative JJ N
reaction NN N
in IN N
the DT N
aR NN N
would MD N
have VB N
been VBN N
positive JJ N
then RB N
underlying VBG N
the DT N
same JJ N
criteria NNS N
in IN N
the DT N
IOS NNP N
without IN N
announcing VBG N
the DT N
symptomscore NN N
a DT N
relevant JJ N
clinical JJ N
symptomatic NN N
while IN N
testing VBG N
CONCLUSION NNP N
IOS NNP N
is VBZ N
a DT N
suitable JJ N
procedure NN N
for IN N
nasal JJ N
provocation NN N
testing VBG N
and CC N
provides VBZ N
results NNS N
similar JJ N
to TO N
the DT N
aR NN N
In IN N
comparison NN N
to TO N
aR VB N
IOS NNP N
is VBZ N
not RB N
dependent JJ N
on IN N
the DT N
patients NNS N
cooperation NN N
Due NNP N
to TO N
its PRP$ N
higher JJR N
sensitivity NN N
the DT N
valid JJ N
limits NNS N
of IN N
the DT N
aR NN N
at IN N
provocation NN N
testings NNS N
can MD N
not RB N
be VB N
transferred VBN N
to TO N
IOS NNP N
to TO N
avoid VB N
a DT N
false JJ N
positive JJ N
reaction NN N
-DOCSTART- -X- O O 11956614

Endometrial JJ N
cytodiagnosis NN N
using VBG N
a DT N
new JJ N
softcyte NN N
versus NN N
a DT N
conventional JJ N
endocyte NN N
A DT N
new JJ N
endometrial JJ N
cytologic NN N
sampling VBG N
device NN N
, , N
softcyte NN N
, , N
was VBD N
used VBN N
in IN N
cytological JJ N
screening NN N
for IN N
endometrial JJ N
cancer NN N
, , N
and CC N
was VBD N
compared VBN N
with IN N
the DT N
endocyte NN N
with IN N
regard NN N
to TO N
manipulability NN N
, , N
adverse JJ N
effects NNS N
( ( N
including VBG N
pain NN N
and CC N
hemorrhage NN N
) ) N
, , N
and CC N
cellular JJ N
findings NNS N
( ( N
including VBG N
the DT N
quantity NN N
of IN N
cells NNS N
collected VBN N
, , N
the DT N
success NN N
rate NN N
, , N
cell NN N
freshness NN N
, , N
and CC N
cellular JJ N
clumping NN N
) ) N
A DT N
total NN N
of IN N
315 CD 3_p
women NNS 3_p
( ( N
premenopause IN N
251 CD 3_p
, , N
postmenopause RB N
64 CD 3_p
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
who WP N
underwent VBP N
the DT N
endometrial JJ N
cytological JJ N
screening NN N
with IN N
either CC N
the DT N
softcyte NN N
or CC N
the DT N
endocyte NN N
To TO N
assess VB N
the DT N
value NN N
of IN N
the DT N
softcyte NN N
we PRP N
compared VBN N
it PRP N
with IN N
the DT N
endocyte NN N
Endometrial NNP N
cytology NN N
using VBG N
a DT N
softcyte NN N
or CC N
an DT N
endocyte NN N
achieved VBN N
high JJ N
correct JJ N
diagnosis NN N
rate NN N
for IN N
cancer NN N
, , N
and CC N
both DT N
instruments NNS N
are VBP N
valuable JJ N
as IN N
endometrial JJ N
cytologic NN N
sample NN N
devices NNS N
The DT N
softcyte NN N
causes VBZ N
only RB N
mild JJ N
pain NN N
on IN N
introduction NN N
and CC N
during IN N
collection NN N
, , N
and CC N
a DT N
large JJ N
quantity NN N
of IN N
cells NNS N
could MD N
be VB N
harvested VBN N
These DT N
results NNS N
suggest VBP N
that IN N
the DT N
softcyte NN N
is VBZ N
a DT N
useful JJ N
cytologic NN N
sampling VBG N
device NN N
in IN N
screening VBG N
for IN N
endometrial JJ N
cancer NN N
-DOCSTART- -X- O O 10052279

Pre-operative JJ N
short-term JJ N
pulmonary JJ N
rehabilitation NN N
for IN N
patients NNS N
of IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
undergoing VBG N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
The DT N
role NN N
of IN N
pre-operative JJ N
short-term JJ N
pulmonary JJ N
rehabilitation NN N
in IN N
patients NNS N
with IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
who WP N
undergo VBP N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
has VBZ N
been VBN N
assessed VBN N
for IN N
the DT N
first JJ N
time NN N
prospectively RB N
Forty-five JJ 3_p
patients NNS N
posted VBD N
for IN N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
short-term JJ N
pulmonary JJ N
rehabilitation NN N
( ( N
group NN N
I PRP N
) ) N
or CC N
no DT N
such JJ N
programme NN N
( ( N
group NN N
II NNP N
) ) N
Patients NNS N
of IN N
both DT N
the DT N
groups NNS N
were VBD N
evenly RB N
matched VBN N
with IN N
respect NN N
to TO N
age NN N
, , N
sex NN N
, , N
body NN N
surface JJ N
area NN N
, , N
duration NN N
and CC N
severity NN N
of IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
and CC N
coronary JJ N
artery NN N
disease NN N
Normal JJ N
individuals NNS N
who WP N
evenly RB N
matched VBD N
with IN N
the DT N
study NN N
group NN N
were VBD N
assessed VBN N
for IN N
normal JJ N
respiratory JJ N
function NN N
parameters NNS N
Pre-operative JJ N
and CC N
post-operative JJ N
peak NN N
expiratory NN N
flow NN N
rate NN N
, , N
inspiratory NN N
capacity NN N
, , N
post-operative JJ N
ventilation NN N
time NN N
, , N
post-operative JJ N
pulmonary JJ N
complication NN N
and CC N
hospital NN N
stay NN N
were VBD N
determined VBN N
in IN N
both CC N
the DT N
groups NNS N
Peak NNP N
expiratory JJ N
flow NN N
rate NN N
( ( N
220.0 CD N
+/- JJ N
12.9 CD N
and CC N
324.3 CD N
+/- JJ N
84.3 CD N
in IN N
group NN N
I PRP N
, , N
218.0 CD N
+/- JJ N
16.4 CD N
and CC N
260.5 CD N
+/- JJ N
35.2 CD N
in IN N
group NN N
II NNP N
) ) N
and CC N
inspiratory JJ N
capacity NN N
( ( N
844.0 CD N
+/- JJ N
147.4 CD N
and CC N
1100.0 CD N
+/- JJ N
158.1 CD N
in IN N
group NN N
I PRP N
, , N
830.0 CD N
+/- JJ N
117.4 CD N
and CC N
1090 CD N
+/- JJ N
137 CD N
in IN N
group NN N
II NNP N
) ) N
were VBD N
significantly RB N
lower JJR N
before IN N
and CC N
after IN N
surgery NN N
respectively RB N
in IN N
both DT N
groups NNS N
compared VBN N
to TO N
normal JJ N
values NNS N
Even RB N
though IN N
both DT N
groups NNS N
showed VBD N
a DT N
significant JJ N
rise NN N
in IN N
post-operative JJ N
peak JJ N
expiratory NN N
flow NN N
rate NN N
and CC N
inspiratory NN N
capacity NN N
after IN N
surgery NN N
, , N
the DT N
post-operative JJ N
peak NN N
expiratory NN N
flow NN N
rate NN N
and CC N
inspiratory NN N
capacity NN N
in IN N
group NN N
I PRP N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
group NN N
II NNP N
In IN N
group NN N
I PRP N
, , N
the DT N
post-operative JJ N
ventilation NN N
time NN N
( ( N
24.5 CD N
+/- JJ N
6.00 CD N
hours NNS N
) ) N
, , N
post-operative JJ N
complications NNS N
( ( N
n JJ N
= NNP N
4 CD N
) ) N
and CC N
hospital JJ N
stay NN N
( ( N
12.4 CD N
+/- JJ N
3.6 CD N
days NNS N
) ) N
were VBD N
significantly RB N
lower JJR N
than IN N
in IN N
group NN N
II NNP N
( ( N
35.2 CD N
+/- JJ N
22.3 CD N
hours NNS N
, , N
n JJ N
= NN N
11 CD N
, , N
18.8 CD N
+/- JJ N
6.6 CD N
days NNS N
respectively RB N
) ) N
These DT N
data NNS N
suggest VBP N
that IN N
short-term JJ N
pulmonary JJ N
rehabilitation NN N
is VBZ N
feasible JJ N
and CC N
effective JJ N
in IN N
improving VBG N
pulmonary JJ N
functions NNS N
before IN N
and CC N
after IN N
surgery NN N
and CC N
in IN N
reducing VBG N
surgical JJ N
morbidity NN N
and CC N
cost NN N
of IN N
medical JJ N
care NN N
significantly RB N
-DOCSTART- -X- O O 1492408

Effects NNS N
of IN N
a DT N
combination NN N
of IN N
evening VBG N
primrose JJ N
oil NN N
( ( N
gamma NN N
linolenic RB N
acid NN N
) ) N
and CC N
fish JJ N
oil NN N
( ( N
eicosapentaenoic JJ N
+ NNP N
docahexaenoic NN N
acid NN N
) ) N
versus NN N
magnesium NN N
, , N
and CC N
versus NN N
placebo NN N
in IN N
preventing VBG N
pre-eclampsia NN 4_p
In IN N
a DT N
placebo NN N
controlled VBN N
, , N
partially RB N
double-blinded JJ N
, , N
clinical JJ N
trial NN N
, , N
a DT N
combination NN N
of IN N
evening VBG N
primrose JJ N
oil NN N
and CC N
fish JJ N
oil NN N
was VBD N
compared VBN N
to TO N
Magnesium NNP N
Oxide NNP N
, , N
and CC N
to TO N
a DT N
Placebo NNP N
in IN N
preventing VBG N
Pre-Eclampsia NNP N
of IN N
Pregnancy NNP N
All DT N
were VBD N
given VBN N
as IN N
nutritional JJ N
supplements NNS N
for IN N
six CD N
months NNS N
to TO N
a DT N
group NN N
of IN N
primiparous JJ N
and CC N
multiparous JJ N
pregnant JJ N
women NNS N
Some DT 4_p
of IN 4_p
these DT 4_p
women NNS 4_p
had VBD 4_p
personal JJ 4_p
or CC 4_p
family NN 4_p
histories NNS 4_p
of IN 4_p
hypertension NN 4_p
( ( 4_p
21 CD 4_p
% NN 4_p
) ) 4_p
Only RB N
those DT N
patients NNS N
who WP N
received VBD N
prenatal JJ N
care NN N
at IN N
the DT N
Central NNP N
Maternity NNP N
Hospital NNP N
for IN N
Luanda NNP N
were VBD N
included VBN N
in IN N
the DT N
study NN N
Compared VBN N
to TO N
the DT N
Placebo NNP N
group NN N
( ( N
29 CD N
% NN N
) ) N
, , N
the DT N
group NN N
receiving VBG N
the DT N
mixture NN N
of IN N
evening VBG N
primrose JJ N
oil NN N
and CC N
fish JJ N
oil NN N
containing VBG N
Gamma-linolenic JJ N
acid NN N
( ( N
GLA NNP N
) ) N
, , N
Eicosapentaenoic NNP N
acid NN N
( ( N
EPA NNP N
) ) N
, , N
and CC N
Docosahexaenoic NNP N
acid NN N
( ( N
DHA NNP N
) ) N
had VBD N
a DT N
significantly RB N
lower JJR N
incidence NN N
of IN N
edema NN N
( ( N
13 CD N
% NN N
, , N
p NN N
= NNP N
0.004 CD N
) ) N
The DT N
group NN N
receiving VBG N
Magnesium NNP N
Oxide NNP N
had VBD N
statistically RB N
significant JJ N
fewer JJR N
subjects NNS N
who WP N
developed VBD N
hypertension NN N
of IN N
pregnancy NN N
There EX N
were VBD N
3 CD N
cases NNS N
of IN N
eclampsia NN N
, , N
all DT N
in IN N
the DT N
Placebo NNP N
group NN N
-DOCSTART- -X- O O 16709205

Late JJ 4_p
miscarriage NN 4_p
and CC N
preterm JJ 4_p
birth NN 4_p
after IN N
treatment NN N
with IN N
clindamycin NN N
: : N
a DT N
randomised JJ N
consent NN N
design NN N
study NN N
according VBG N
to TO N
Zelen NNP N
OBJECTIVE NNP N
To TO N
screen VB N
for IN N
bacterial JJ 4_p
vaginosis NN 4_p
( ( 4_p
BV NNP 4_p
) ) 4_p
and CC N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
treatment NN N
with IN N
vaginal JJ N
clindamycin NN N
in IN N
order NN N
to TO N
observe VB N
the DT N
effect NN N
on IN N
late JJ N
miscarriage NN N
and CC N
delivery NN N
prior RB N
to TO N
37 CD N
completed VBN N
weeks NNS N
( ( N
primary JJ N
outcome NN N
) ) N
DESIGN NNP N
Randomised VBD N
consent NN N
design NN N
for IN N
clinical JJ N
trials NNS N
according VBG N
to TO N
Zelen NNP N
SETTING NNP N
Southeast NNP N
region NN N
of IN N
Sweden NNP N
POPULATION VB N
A DT N
total NN N
of IN N
9025 CD 3_p
women NNS 2_p
were VBD N
screened VBN N
in IN N
early JJ N
pregnancy NN N
METHODS NNP N
A NNP N
total NN N
of IN N
819 CD 3_p
women NNS N
with IN N
a DT N
Nugent NNP N
score NN N
of IN N
6 CD N
and CC N
above VB N
were VBD N
considered VBN N
to TO N
have VB N
BV NNP N
and CC N
treated VBD N
according VBG N
to TO N
Zelen NNP N
allocation NN N
The DT N
incidence NN N
of IN N
late JJ N
miscarriage NN N
and CC N
spontaneous JJ N
( ( N
noniatrogenic JJ N
) ) N
preterm FW N
birth NN N
was VBD N
assessed VBN N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Late NNP N
miscarriage NN N
and CC N
spontaneous JJ N
preterm NNS N
delivery NN N
before IN N
37 CD N
weeks NNS N
RESULTS NNP N
Therapy NNP N
with IN N
vaginal JJ N
clindamycin NN N
had VBD N
no DT N
significant JJ N
impact NN N
on IN N
the DT N
incidence NN N
of IN N
spontaneous JJ N
preterm JJ N
delivery NN N
prior RB N
to TO N
37 CD N
completed VBN N
weeks NNS N
; : N
OR CC N
0.90 CD N
, , N
95 CD N
% NN N
CI NNP N
0.40-2.02 NN N
( ( N
primary JJ N
outcome NN N
variable NN N
) ) N
However RB N
, , N
only RB N
1 CD N
of IN N
11 CD N
women NNS N
in IN N
the DT N
treatment NN N
group NN N
versus VBD N
5 CD N
of IN N
12 CD N
in IN N
the DT N
control NN N
group NN N
delivered VBD N
prior RB N
to TO N
33 CD N
completed VBN N
weeks NNS N
; : N
OR CC N
0.14 CD N
, , N
95 CD N
% NN N
CI NNP N
0.02-0.95 NN N
Treatment NN N
was VBD N
associated VBN N
with IN N
32 CD N
days NNS N
longer JJR N
gestation NN N
for IN N
the DT N
23 CD 3_p
participants NNS N
who WP N
had VBD N
late JJ N
miscarriage NN N
or CC N
spontaneous JJ 4_p
preterm NNS 4_p
birth NN 4_p
( ( N
P= NNP N
0.024 CD N
, , N
Mann-Whitney NNP N
U NNP N
test NN N
) ) N
and CC N
significantly RB N
fewer JJR N
infants NNS N
had VBD N
a DT N
birthweight NN N
below IN N
2,500 CD N
g NN N
( ( N
secondary JJ N
outcome NN N
) ) N
A DT N
follow JJ N
up NN N
of IN N
infants NNS N
born JJ N
preterm VBP N
4 CD N
years NNS N
postnatally RB N
indicated VBD N
that IN N
extending VBG N
gestational JJ N
age NN N
did VBD N
not RB N
increase VB N
the DT N
number NN N
of IN N
sequelae NN N
CONCLUSIONS NNP N
Clindamycin NNP N
vaginal JJ N
cream NN N
therapy NN N
was VBD N
associated VBN N
with IN N
significantly RB N
prolonged VBN N
gestation NN N
and CC N
reduced JJ N
cost NN N
of IN N
neonatal JJ N
care NN N
in IN N
women NNS N
with IN N
BV NNP 4_p
Early JJ N
screening NN N
for IN N
BV NNP N
and CC N
treatment NN N
with IN N
clindamycin NN N
saved VBD N
approximately RB N
27 CD N
euro JJ N
per IN N
woman NN N
-DOCSTART- -X- O O 21978765

Phase NNP N
III NNP N
trial NN N
of IN N
induction NN N
gemcitabine NN N
or CC N
paclitaxel NN N
plus CC N
carboplatin NN N
followed VBN N
by IN N
paclitaxel JJ N
consolidation NN N
in IN N
ovarian JJ 4_p
cancer NN 4_p
OBJECTIVE CC N
The DT N
safety NN N
and CC N
efficacy NN N
of IN N
gemcitabine JJ N
plus CC N
carboplatin NN N
( ( N
GC NNP N
) ) N
or CC N
paclitaxel JJ N
plus CC N
carboplatin NN N
( ( N
TC NNP N
) ) N
induction NN N
regimens VBZ N
with IN N
or CC N
without IN N
paclitaxel JJ N
consolidation NN N
therapy NN N
were VBD N
assessed VBN N
in IN N
ovarian JJ 4_p
cancer NN 4_p
( ( 4_p
OC NNP 4_p
) ) 4_p
METHODS JJ N
Patients NNPS 4_p
with IN 4_p
stage JJ 4_p
IC-IV JJ 4_p
OC NNP 4_p
were VBD N
randomized VBN N
to TO N
either DT N
GC NNP N
( ( N
gemcitabine JJ N
1,000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
days NNS N
1 CD N
and CC N
8 CD N
, , N
plus CC N
carboplatin JJ N
area NN N
under IN N
the DT N
curve NN N
[ NNP N
AUC NNP N
] NNP N
5 CD N
, , N
day NN N
1 CD N
) ) N
or CC N
TC NNP N
( ( N
paclitaxel JJ N
175 CD N
mg/m NN N
( ( N
2 CD N
) ) N
plus CC N
carboplatin JJ N
AUC NNP N
6 CD N
, , N
day NN N
1 CD N
) ) N
every DT N
21 CD N
days NNS N
for IN N
up IN N
to TO N
six CD N
cycles NNS N
Patients NNS 4_p
with IN 4_p
complete JJ 4_p
response NN 4_p
( ( 4_p
CR NNP 4_p
) ) 4_p
were VBD N
allowed VBN N
optional JJ N
consolidation NN N
with IN N
paclitaxel JJ N
135 CD N
mg/m NN N
( ( N
2 CD N
) ) N
every DT N
28 CD N
days NNS N
for IN N
≤ JJ N
12 CD N
months NNS N
Patients NNS N
without IN N
CR NNP N
received VBD N
single-agent JJ N
crossover NN N
therapy NN N
at IN N
induction NN N
doses/schedules NNS N
until IN N
CR NNP N
, , N
disease NN N
progression NN N
( ( N
PD NNP N
) ) N
, , N
or CC N
unacceptable JJ N
toxicity NN 4_p
PD NNP N
or CC N
death NN N
in IN N
636 CD 3_p
patients NNS N
was VBD N
required VBN N
to TO N
compare VB N
induction NN N
arms NNS N
with IN N
80 CD N
% NN N
statistical JJ N
power NN N
for IN N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
, , N
the DT N
primary JJ N
endpoint NN N
RESULTS NNP N
Randomized NNP N
induction NN N
therapy NN N
was VBD N
received VBN N
by IN N
820 CD 3_p
of IN N
919 CD 3_p
patients NNS N
enrolled VBD N
; : N
352 CD 3_p
patients NNS N
with IN N
CR NNP N
received VBD N
paclitaxel JJ N
consolidation NN N
whereas NNS N
155 CD 3_p
patients NNS N
without IN N
CR NNP N
received VBD N
single-agent JJ N
crossover NN N
therapy NN N
PFS NNP N
was VBD N
similar JJ N
for IN N
GC NNP N
and CC N
TC NNP N
( ( N
median JJ N
, , N
20.0 CD N
and CC N
22.2 CD N
months NNS N
, , N
respectively RB N
; : N
P=.199 NNP N
) ) N
Despite IN N
high JJ N
censoring NN N
rates NNS N
( ( N
> VB N
52 CD N
% NN N
) ) N
, , N
overall JJ N
survival NN N
was VBD N
longer JJR N
for IN N
TC NNP N
( ( N
median JJ N
, , N
57.3 CD N
versus NN N
43.8 CD N
months NNS N
for IN N
GC NNP N
; : N
P=.013 NNP N
) ) N
Controlling VBG N
for IN N
patient JJ N
characteristics NNS N
including VBG N
performance NN N
status NN N
, , N
residual JJ N
tumor NN N
size NN N
, , N
and CC N
tumor NN N
stage NN N
, , N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
a DT N
multivariate NN N
analysis NN N
( ( N
HR=1.22 NNP N
; : N
95 CD N
% NN N
CI=0.99-1.52 NNP N
; : N
P=.067 NNP N
) ) N
CONCLUSIONS NNP N
GC NNP N
does VBZ N
not RB N
improve VB N
PFS NNP N
over RB N
TC NNP N
as IN N
first-line JJ N
induction NN N
chemotherapy NN N
in IN N
OC NNP N
Although IN N
favoring VBG N
TC NNP N
, , N
overall JJ N
survival NN N
analyses NNS N
were VBD N
limited VBN N
by IN N
the DT N
study NN N
design NN N
and CC N
high JJ N
censoring NN N
rates NNS N
-DOCSTART- -X- O O 1682643

Specific JJ N
immunoglobulin NN N
for IN N
treatment NN N
of IN N
whooping JJ 4_p
cough NN 4_p
Immunoglobulin NNP N
treatment NN N
for IN N
whooping JJ N
cough NN N
( ( N
pertussis NN N
) ) N
is VBZ N
widely RB N
believed VBN N
to TO N
be VB N
ineffective JJ N
although IN N
there EX N
are VBP N
sound JJ N
reasons NNS N
for IN N
regarding VBG N
the DT N
condition NN N
as IN N
a DT N
toxin-induced JJ N
disease NN N
We PRP N
wondered VBD N
whether IN N
the DT N
lack NN N
of IN N
success NN N
with IN N
pertussis NN N
immunoglobulins NNS N
might MD N
be VB N
attributable JJ N
to TO N
inadequate VB N
dose NN N
, , N
so IN N
we PRP N
designed VBD N
a DT N
randomised VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
two CD N
immunoglobulin JJ N
preparations NNS N
The DT N
study NN N
was VBD N
conducted VBN N
at IN N
three CD N
Swedish JJ N
hospitals NNS N
We PRP N
enrolled VBD N
73 CD 3_p
children NNS 1_p
aged VBD 1_p
less JJR 1_p
than IN 1_p
36 CD 1_p
months NNS 1_p
who WP N
were VBD N
admitted VBN N
with IN N
a DT N
clinical JJ N
diagnosis NN N
of IN N
whooping JJ 4_p
cough NN 4_p
On IN N
admission NN N
they PRP N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
( ( N
a DT N
) ) N
monocomponent NN N
pertussis NN N
toxoid JJ N
vaccine NN N
; : N
( ( N
b NN N
) ) N
two-component NN N
acellular JJ N
vaccine NN N
also RB N
containing VBG N
filamentous JJ N
haemagglutinin NN N
; : N
or CC N
( ( N
c NN N
) ) N
20 CD N
% NN N
albumin JJ N
solution NN N
( ( N
placebo NN N
) ) N
The DT N
immunoglobulins NNS N
had VBD N
a DT N
high JJ N
antitoxin NN N
content NN N
and CC N
had VBD N
been VBN N
raised VBN N
with IN N
acellular JJ N
pertussis NN N
vaccines NNS N
Diagnosis NN N
of IN N
pertussis NN N
was VBD N
confirmed VBN N
by IN N
laboratory NN N
tests NNS N
and CC N
the DT N
follow-up NN N
was VBD N
completed VBN N
in IN N
67 CD N
children NNS N
The DT N
main JJ N
study NN N
group NN N
consisted VBD N
of IN N
47 CD 3_p
children NNS 1_p
with IN N
less JJR 4_p
than IN 4_p
or CC 4_p
equal JJ 4_p
to TO 4_p
14 CD 4_p
days NNS 4_p
of IN 4_p
disease NN 4_p
before IN 4_p
therapy NN 4_p
Duration NN N
of IN N
whoops JJ N
post-treatment NN N
was VBD N
8.7 CD N
days NNS N
( ( N
95 CD N
% NN N
Cl NNP N
4.8 CD N
, , N
12.6 CD N
) ) N
in IN N
the DT N
33 CD N
children NNS N
receiving VBG N
immunoglobulin NN N
vs NN N
20.6 CD N
( ( N
95 CD N
% NN N
Cl NNP N
11.9 CD N
, , N
29.3 CD N
) ) N
in IN N
the DT N
14 CD N
receiving NN N
placebo NN N
( ( N
p JJ N
= NNP N
0.0041 CD N
) ) N
Mean JJ N
number NN N
of IN N
whoops NNS N
during IN N
the DT N
first JJ N
week NN N
of IN N
follow-up NN N
was VBD N
also RB N
significantly RB N
reduced VBN N
( ( N
p JJ N
= NNP N
0.0196 CD N
) ) N
We PRP N
found VBD N
that IN N
early JJ N
treatment NN N
was VBD N
important JJ N
, , N
since IN N
the DT N
effect NN N
on IN N
duration NN N
of IN N
whoops NNS N
was VBD N
most RBS N
pronounced JJ N
when WRB N
disease NN N
duration NN N
before IN N
treatment NN N
was VBD N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
7 CD N
days NNS N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
immunoglobulin NN N
preparations NNS N
High-dose JJ N
specific JJ N
pertussis NN N
immunoglobulin NN N
with IN N
a DT N
high JJ N
antitoxin NN N
concentration NN N
has VBZ N
a DT N
beneficial JJ N
effect NN N
in IN N
the DT N
treatment NN N
of IN N
whooping JJ N
cough NN N
-DOCSTART- -X- O O 24564346

Are NNP N
'leaky NNP N
gut NN N
' '' N
and CC N
behavior RB N
associated VBN N
with IN N
gluten NNS N
and CC N
dairy NN N
containing VBG N
diet NN N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
? . N
OBJECTIVES NNP N
Studies NNPS N
have VBP N
suggested VBN N
a DT N
link NN N
between IN N
diet JJ N
and CC N
behavior NN N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASDs NNP 4_p
) ) 4_p
Parental JJ N
reports NNS N
of IN N
behavioral JJ N
changes NNS N
upon IN N
exposure NN N
to TO N
gluten VB N
and/or JJ N
casein NN N
are VBP N
common JJ N
in IN N
clinical JJ N
practice NN N
An DT N
association NN N
between IN N
diet JJ N
type NN N
, , N
intestinal JJ N
permeability NN N
( ( N
IP NNP N
) ) N
( ( N
'leaky JJ N
gut NN N
' '' N
) ) N
, , N
and CC N
behavior NN N
has VBZ N
been VBN N
long RB N
proposed VBN N
but CC N
not RB N
substantiated VBN N
We PRP N
explored VBD N
this DT N
possible JJ N
association NN N
in IN N
this DT N
trial NN N
METHODS NNP N
This DT N
randomized JJ N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
explored VBD N
the DT N
effects NNS N
of IN N
gluten NNS N
and CC N
milk NN N
on IN N
IP NNP N
and CC N
behavior NN N
in IN N
children NNS 1_p
with IN N
ASDs NNP 4_p
over IN N
a DT N
period NN N
of IN N
4 CD N
weeks NNS N
IP NNP N
assessed VBN N
by IN N
lactulose NN N
: : N
mannitol NN N
( ( N
L/M NNP N
) ) N
sugar NN N
permeability NN N
test NN N
and CC N
behavior NN N
assessed VBN N
by IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
and CC N
Conners NNP N
Parent NNP N
Rating NNP N
were VBD N
measured VBN N
Gastrointestinal NNP N
symptoms NNS N
in IN N
both DT N
groups NNS N
were VBD N
also RB N
monitored VBN N
RESULTS NNP N
Neither CC N
the DT N
L/M NNP N
ratio NN N
nor CC N
behavioral JJ N
scores NNS N
were VBD N
different JJ N
between IN N
groups NNS N
exposed VBN N
to TO N
gluten/dairy VB N
or CC N
placebo VB N
The DT N
changes NNS N
observed VBN N
were VBD N
noted VBN N
to TO N
be VB N
small JJ N
and CC N
not RB N
clinically RB N
significant JJ N
DISCUSSION NNP N
Our PRP$ N
study NN N
although IN N
underpowered JJ N
to TO N
show VB N
small JJ N
differences NNS N
does VBZ N
not RB N
support VB N
an DT N
association NN N
between IN N
dietary JJ N
gluten/milk NN N
, , N
IP NNP N
, , N
and CC N
behavioral JJ N
changes NNS N
in IN N
subjects NNS N
with IN N
ASD NNP 4_p
-DOCSTART- -X- O O 2468745

Randomized NNP N
clinical JJ N
trial NN N
comparing VBG N
mitoxantrone NN N
with IN N
doxorubicin NN N
in IN N
previously RB 4_p
treated VBN 4_p
patients NNS 4_p
with IN 4_p
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
Three CD N
hundred VBD N
twenty-five JJ N
women NNS N
with IN N
metastatic JJ N
adenocarcinoma NN N
of IN N
the DT N
breast NN N
who WP N
had VBD N
failed VBN N
one CD N
prior JJ N
chemotherapeutic JJ N
regimen NNS N
for IN N
advanced JJ N
disease NN N
were VBD N
randomized VBN N
to TO N
receive VB N
14 CD N
mg/m2 NN N
of IN N
mitoxantrone NN N
or CC N
75 CD N
mg/m2 NN N
of IN N
doxorubicin NN N
intravenously RB N
( ( N
IV NNP N
) ) N
every DT N
3 CD N
weeks NNS N
Enrollment NN N
was VBD N
closed VBN N
on IN N
October NNP N
31 CD N
, , N
1984 CD N
, , N
after IN N
165 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
mitoxantrone VB N
and CC N
160 CD N
patients NNS N
to TO N
doxorubicin VB N
Patients NNS N
randomized VBD N
to TO N
the DT N
two CD N
treatment NN N
groups NNS N
were VBD N
compared VBN N
for IN N
response NN N
rate NN N
, , N
duration NN N
of IN N
response NN N
, , N
time NN N
to TO N
progression NN N
or CC N
death NN N
, , N
time NN N
to TO N
treatment NN N
failure NN N
( ( N
TTF NNP N
) ) N
, , N
and CC N
survival NN N
The DT N
response NN N
rate NN N
to TO N
mitoxantrone NN N
was VBD N
20.6 CD N
% NN N
, , N
to TO N
doxorubicin VB N
29.3 CD N
% NN N
( ( N
P NNP N
= NNP N
.07 NNP N
) ) N
The DT N
median JJ N
response NN N
duration NN N
was VBD N
151 CD N
days NNS N
for IN N
the DT N
mitoxantrone NN N
group NN N
and CC N
126 CD N
days NNS N
for IN N
the DT N
doxorubicin NN N
group NN N
( ( N
P NNP N
= NNP N
.16 NNP N
) ) N
The DT N
median JJ N
TTF NNP N
was VBD N
70 CD N
days NNS N
in IN N
the DT N
mitoxantrone NN N
group NN N
and CC N
104 CD N
days NNS N
in IN N
the DT N
doxorubicin NN N
group NN N
( ( N
P NNP N
= NNP N
.36 NNP N
) ) N
The DT N
median JJ N
survival NN N
of IN N
patients NNS N
initially RB N
randomized VBN N
to TO N
receive VB N
mitoxantrone NN N
was VBD N
273 CD N
days NNS N
; : N
for IN N
doxorubicin NN N
268 CD N
days NNS N
( ( N
P NNP N
= NNP N
.40 NNP N
) ) N
There EX N
were VBD N
three CD N
responses NNS N
among IN N
77 CD N
patients NNS N
crossed VBN N
over IN N
to TO N
mitoxantrone VB N
after IN N
initial JJ N
treatment NN N
with IN N
doxorubicin NN N
The DT N
major JJ N
dose-limiting JJ N
toxicity NN N
for IN N
both DT N
drugs NNS N
was VBD N
leukopenia RB N
There EX N
was VBD N
significantly RB N
less JJR N
severe JJ N
and CC N
less RBR N
frequent JJ N
toxicity NN N
with IN N
mitoxantrone JJ N
administration NN N
Severe NNP N
nausea NN N
and CC N
vomiting NN N
occurred VBD N
in IN N
9.5 CD N
% NN N
of IN N
mitoxantrone NN N
patients NNS N
and CC N
25.3 CD N
% NN N
of IN N
doxorubicin NN N
patients NNS N
( ( N
P NNP N
less JJR N
than IN N
.001 NN N
) ) N
The DT N
incidence NN N
of IN N
severe JJ N
stomatitis NN N
and CC N
mucositis NN N
was VBD N
0.6 CD N
% NN N
in IN N
the DT N
mitoxantrone NN N
group NN N
and CC N
8.4 CD N
% NN N
in IN N
the DT N
doxorubicin NN N
group NN N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
Severe JJ N
alopecia NN N
occurred VBD N
in IN N
5.1 CD N
% NN N
of IN N
mitoxantrone NN N
patients NNS N
and CC N
61.0 CD N
% NN N
of IN N
doxorubicin NN N
patients NNS N
( ( N
P NNP N
less JJR N
than IN N
.001 NN N
) ) N
A DT N
life-table JJ N
comparison NN N
of IN N
the DT N
cumulative JJ N
dose NN N
to TO N
the DT N
development NN N
of IN N
a DT N
cardiac JJ N
event NN N
showed VBD N
that IN N
mitoxantrone NN N
had VBD N
significantly RB N
less JJR N
cardiotoxicity NN N
than IN N
doxorubicin NN N
( ( N
P NNP N
= NNP N
.0005 NNP N
) ) N
This DT N
study NN N
demonstrates VBZ N
that IN N
mitoxantrone NN N
is VBZ N
active JJ N
as IN N
a DT N
single JJ N
agent NN N
in IN N
the DT N
treatment NN N
of IN N
metastatic JJ N
breast NN N
cancer NN N
Compared VBN N
with IN N
doxorubicin NN N
it PRP N
appears VBZ N
to TO N
be VB N
marginally RB N
less RBR N
active JJ N
and CC N
significantly RB N
less JJR N
toxic JJ N
We PRP N
conclude VBP N
that IN N
mitoxantrone NN N
can MD N
be VB N
used VBN N
alone RB N
or CC N
with IN N
other JJ N
standard NN N
drugs NNS N
to TO N
palliate VB N
the DT N
symptoms NNS N
of IN N
metastatic JJ N
breast NN N
cancer NN N
, , N
especially RB N
in IN N
settings NNS N
where WRB N
drug NN N
toxicity NN N
is VBZ N
an DT N
important JJ N
consideration NN N
-DOCSTART- -X- O O 23257173

Simvastatin NNP N
reduces VBZ N
sympathetic JJ N
outflow NN N
and CC N
augments NNS N
endothelium-independent JJ N
dilation NN N
in IN N
non-hyperlipidaemic JJ 4_p
primary JJ 4_p
hypertension NN 4_p
OBJECTIVES NNP N
Previous JJ N
reports NNS N
, , N
involving VBG N
hypercholesterolaemic JJ 4_p
hypertensive JJ 4_p
subjects NNS N
, , N
that IN N
statins VBZ N
reduce VB N
muscle NN N
sympathetic JJ N
nerve NN N
activity NN N
( ( N
MSNA NNP N
) ) N
did VBD N
not RB N
investigate VB N
potential JJ N
neural JJ N
sites NNS N
of IN N
such JJ N
sympathoinhibition NN N
or CC N
determine VB N
its PRP$ N
consequences NNS N
for IN N
endothelial JJ N
function NN N
or CC N
insulin NN N
resistance NN N
This DT N
study NN N
of IN N
hypertensive JJ 4_p
subjects NNS N
with IN N
lower JJR 4_p
plasma NN 4_p
cholesterol NN 4_p
tested VBD N
the DT N
hypotheses NNS N
that WDT N
lipophilic JJ N
simvastatin NN N
would MD N
attenuate VB N
resting VBG N
sympathoexcitation NN N
and CC N
augment NN N
baroreflex JJ N
modulation NN N
of IN N
MSNA NNP N
and CC N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
, , N
flow-mediated JJ N
vasodilation NN N
and CC N
insulin NN N
sensitivity NN N
DESIGN NNP N
Prospective NNP N
, , N
randomised VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
SETTING NNP N
Academic NNP N
hospital-based JJ N
study NN N
PATIENTS NNP N
Fourteen JJ N
non-hyperlipidaemic JJ N
primary JJ N
hypertensive JJ N
subjects NNS N
( ( N
10 CD 2_p
men NNS 2_p
; : N
overall JJ N
mean±SD NN 1_p
age NN 1_p
58±12 CD 1_p
years NNS 1_p
) ) N
INTERVENTIONS NNP N
Four NNP N
weeks NNS N
of IN N
simvastatin NN N
( ( N
80 CD N
mg/day NN N
) ) N
or CC N
placebo NN N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Resting NNP N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
, , N
HR NNP N
, , N
MSNA NNP N
, , N
spontaneous JJ N
arterial JJ N
baroreflex NN N
MSNA NNP N
and CC N
HR NNP N
modulation NN N
, , N
endothelium-dependent JJ N
and CC N
endothelium-independent JJ N
vasodilation NN N
, , N
and CC N
the DT N
homoeostatic JJ N
model NN N
assessment NN N
of IN N
insulin NN N
resistance NN N
( ( N
HOMA-IR NNP N
) ) N
RESULTS NNP N
Simvastatin NNP N
lowered VBD N
MSNA NNP N
burst JJ N
frequency NN N
( ( N
from IN N
32±12 CD N
to TO N
25±9 CD N
bursts/min NN N
) ) N
and CC N
MSNA NNP N
burst NN N
incidence NN N
( ( N
from IN N
55±23 CD N
% NN N
to TO N
43±17 CD N
% NN N
; : N
all DT N
p VBP N
< $ N
0.01 CD N
) ) N
without IN N
affecting VBG N
BP NNP N
, , N
HR NNP N
, , N
baroreflex JJ N
modulation NN N
of IN N
either DT N
MSNA NNP N
or CC N
HR NNP N
, , N
or CC N
HR NNP N
variability NN N
( ( N
all DT N
p VBP N
> $ N
0.05 CD N
) ) N
Plasma NNP N
glucose NN N
, , N
insulin NN N
, , N
HOMA-IR NNP N
and CC N
endothelium-dependent JJ N
vasodilation NN N
( ( N
all DT N
p VBP N
> $ N
0.05 CD N
) ) N
were VBD N
unchanged JJ N
, , N
whereas JJ N
endothelium-independent JJ N
vasodilation NN N
increased VBD N
( ( N
7.1±3.8 CD N
% NN N
to TO N
9.7±3.9 CD N
% NN N
, , N
n=13 RB N
; : N
p VB N
< $ N
0.01 CD N
) ) N
The DT N
fall NN N
in IN N
MSNA NNP N
was VBD N
unrelated JJ N
to TO N
the DT N
decrease NN N
in IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
r=0.41 NN N
, , N
p=0.14 NN N
) ) N
CONCLUSIONS NNP N
These DT N
findings NNS N
are VBP N
consistent JJ N
with IN N
the DT N
concept NN N
that IN N
, , N
in IN N
non-hyperlipidaemic JJ N
subjects NNS N
with IN N
primary JJ N
hypertension NN N
, , N
simvastatin JJ N
causes VBZ N
a DT N
cholesterol-independent JJ N
reduction NN N
in IN N
an DT N
elevated JJ N
central JJ N
set-point NN N
for IN N
MSNA NNP N
, , N
without IN N
affecting VBG N
arterial JJ N
baroreflex JJ N
modulation NN N
of IN N
either DT N
MSNA NNP N
or CC N
HR NNP N
There EX N
may MD N
be VB N
less JJR N
neurogenic JJ N
constraint NN N
on IN N
endothelium-independent JJ N
vasodilation NN N
as IN N
a DT N
consequence NN N
-DOCSTART- -X- O O 3124456

Prospective NNP N
controlled VBD N
study NN N
of IN N
androgen NN N
therapy NN N
in IN N
the DT N
anemia NN 4_p
of IN N
chronic JJ 4_p
renal JJ 4_p
disease NN 4_p
: : N
effects NNS N
on IN N
iron NN N
kinetics NNS N
Ferrokinetic NNP N
and CC N
RBC NNP N
mass NN N
determinations NNS N
were VBD N
made VBN N
at IN N
3-month JJ N
intervals NNS N
in IN N
iron-replete JJ N
hemodialysis NN N
patients NNS N
randomized VBN N
to TO N
a DT N
control NN N
group NN N
or CC N
to TO N
nandrolone CD N
decanoate NN N
therapy NN N
After IN N
3 CD N
months NNS N
, , N
RBC NNP N
mass NN N
increased VBD N
in IN N
two CD N
of IN N
4 CD N
androgen-treated JJ N
patients NNS N
Erythron NNP N
iron NN N
turnover NN N
, , N
an DT N
index NN N
of IN N
RBC NNP N
production NN N
, , N
increased VBN N
in IN N
the DT N
one CD N
responder NN N
studied VBD N
but CC N
not RB N
in IN N
the DT N
two CD N
nonresponders NNS N
Similarly RB N
, , N
in IN N
a DT N
fifth NN N
subject NN N
, , N
who WP N
was VBD N
not RB N
restudied VBN N
until IN N
6 CD N
months NNS N
of IN N
androgen NN N
therapy NN N
were VBD N
completed VBN N
, , N
an DT N
increase NN N
in IN N
RBC NNP N
mass NN N
was VBD N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
erythron NNP N
iron NN N
turnover NN N
However RB N
, , N
between IN N
3 CD N
and CC N
6 CD N
months NNS N
, , N
RBC NNP N
mass NN N
increased VBD N
in IN N
all DT N
4 CD 3_p
androgen-treated JJ N
patients NNS N
studied VBD N
even RB N
though IN N
erythron NN N
iron NN N
turnovers NNS N
remained VBD N
unchanged JJ N
and CC N
dialysis-associated JJ N
blood NN N
losses NNS N
did VBD N
not RB N
decrease VB N
Thus RB N
, , N
at IN N
least JJS N
two CD N
androgen-treated JJ N
patients NNS N
had VBD N
increases NNS N
in IN N
RBC NNP N
mass NN N
without IN N
ever RB N
increasing VBG N
their PRP$ N
erythron NN N
iron NN N
turnover NN N
Two CD N
of IN N
three CD N
control NN N
subjects NNS N
also RB N
had VBD N
increased VBN N
erythron RB N
iron NN N
turnovers NNS N
, , N
which WDT N
in IN N
one CD N
case NN N
was VBD N
related VBN N
to TO N
increased VBN N
dialysis-associated JJ N
blood NN N
losses NNS N
Changes NNS N
in IN N
RBC NNP N
mass NN N
were VBD N
not RB N
consistently RB N
paralleled VBN N
by IN N
changes NNS N
in IN N
Hb NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
increases NNS N
in IN N
RBC NNP N
mass NN N
during IN N
nandrolone JJ N
decanoate NN N
therapy NN N
result NN N
from IN N
two CD N
mechanisms NNS N
: : N
increased VBN N
erythropoiesis NN N
( ( N
shown VBN N
by IN N
simultaneous JJ N
increases NNS N
in IN N
RBC NNP N
mass NN N
and CC N
erythron NN N
iron NN N
turnover NN N
) ) N
and CC N
increased JJ N
RBC NNP N
survival NN N
( ( N
indirectly RB N
shown VBN N
by IN N
increases NNS N
in IN N
RBC NNP N
mass NN N
without IN N
increases NNS N
in IN N
erythron NN N
iron NN N
turnover NN N
) ) N
The DT N
importance NN N
of IN N
control NN N
groups NNS N
, , N
RBC NNP N
mass NN N
determinations NNS N
and CC N
the DT N
monitoring NN N
of IN N
dialysis-associated JJ N
blood NN N
losses NNS N
in IN N
studying VBG N
the DT N
effects NNS N
of IN N
androgens NNS N
on IN N
erythropoiesis NN N
in IN N
chronic JJ N
hemodialysis NN N
patients NNS N
is VBZ N
also RB N
demonstrated VBN N
-DOCSTART- -X- O O 20356587

Metformin NNP N
, , N
naltrexone NN N
, , N
or CC N
the DT N
combination NN N
of IN N
prednisolone NN N
and CC N
antiandrogenic JJ N
oral JJ N
contraceptives NNS N
as IN N
first-line JJ N
therapy NN N
in IN N
hyperinsulinemic JJ N
women NNS 2_p
with IN N
polycystic JJ 4_p
ovary JJ 4_p
syndrome NN 4_p
To TO N
compare VB N
the DT N
short-term JJ N
effects NNS N
of IN N
metformin NN N
( ( N
M NNP N
) ) N
, , N
naltrexone RB N
( ( N
N NNP N
) ) N
, , N
and CC N
a DT N
combination NN N
of IN N
OC NNP N
and CC N
prednisolone NN N
( ( N
OC/Pr NNP N
) ) N
on IN N
the DT N
metabolic JJ N
state NN N
and CC N
the DT N
ovarian JJ N
function NN N
of IN N
PCOS NNP 4_p
women NNS N
, , N
we PRP N
randomized VBD N
29 CD 3_p
women NNS 2_p
to TO N
a DT N
3-month JJ N
course NN N
of IN N
therapy NN N
We PRP N
observed VBD N
significant JJ N
improvements NNS N
in IN N
hyperandrogenemia NN N
and CC N
ovulation NN N
rates NNS N
in IN N
PCOS NNP N
women NNS 2_p
of IN N
all DT N
three CD N
groups NNS N
, , N
in IN N
the DT N
absence NN N
of IN N
changes NNS N
in IN N
the DT N
metabolic JJ N
state NN N
, , N
suggesting VBG N
that IN N
insulin NN N
resistance NN N
in IN N
PCOS NNP 4_p
patients NNS N
is VBZ N
only RB N
one CD N
of IN N
several JJ N
factors NNS N
leading VBG N
to TO N
hyperandrogenemic VB N
ovarian JJ N
failure NN N
-DOCSTART- -X- O O 2586565

Peritoneovenous JJ N
shunting VBG N
as IN N
compared VBN N
with IN N
medical JJ N
treatment NN N
in IN N
patients NNS 4_p
with IN 4_p
alcoholic JJ 4_p
cirrhosis NN 4_p
and CC 4_p
massive JJ 4_p
ascites NNS 4_p
Veterans NNPS N
Administration NNP N
Cooperative NNP N
Study NNP N
on IN N
Treatment NNP N
of IN N
Alcoholic NNP N
Cirrhosis NNP N
with IN N
Ascites NNP N
The DT N
optimal JJ N
management NN N
of IN N
severe JJ N
ascites NNS N
in IN N
patients NNS 4_p
with IN 4_p
alcoholic JJ 4_p
cirrhosis NN 4_p
has VBZ N
not RB N
been VBN N
defined VBN N
in IN N
a DT N
5 CD N
1/2-year JJ N
study NN N
, , N
we PRP N
randomly VBP N
assigned VBN N
299 CD N
men NNS N
with IN N
alcoholic JJ N
cirrhosis NN N
, , N
who WP N
had VBD N
persistent NN N
or CC N
recurrent NN N
severe JJ N
ascites VBZ N
despite IN N
a DT N
standard JJ N
medical JJ N
regimen NNS N
, , N
to TO N
receive VB N
either RB N
intensive JJ N
medical JJ N
treatment NN N
or CC N
peritoneovenous JJ N
( ( N
LeVeen NNP N
) ) N
shunting VBG N
We PRP N
identified VBD N
three CD N
risk NN N
groups NNS N
: : N
Group NNP N
1 CD N
had VBD N
normal JJ N
or CC N
mildly RB N
abnormal JJ N
results NNS N
on IN N
liver-function NN N
tests NNS N
, , N
Group NNP N
2 CD N
had VBD N
more RBR N
severe JJ N
liver NN N
dysfunction NN N
or CC N
previous JJ N
complications NNS N
, , N
and CC N
Group NNP N
3 CD N
had VBD N
severe JJ N
prerenal JJ N
azotemia NN N
without IN N
kidney NN N
disease NN N
For IN N
the DT N
patients NNS N
who WP N
received VBD N
the DT N
medical JJ N
treatment NN N
and CC N
those DT N
who WP N
received VBD N
the DT N
surgical JJ N
treatment NN N
combined VBN N
, , N
the DT N
median JJ N
survival NN N
times NNS N
were VBD N
1093 CD N
days NNS N
in IN N
Group NNP N
1 CD N
, , N
222 CD N
days NNS N
in IN N
Group NNP N
2 CD N
, , N
and CC N
37 CD N
days NNS N
in IN N
Group NNP N
3 CD N
( ( N
P NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.01 CD N
) ) N
for IN N
all DT N
comparisons NNS N
) ) N
For IN N
all PDT N
the DT N
groups NNS N
combined VBN N
, , N
the DT N
median JJ N
time NN N
to TO N
the DT N
resolution NN N
of IN N
ascites NNS N
was VBD N
5.4 CD N
weeks NNS N
for IN N
medical JJ N
patients NNS N
and CC N
3.0 CD N
weeks NNS N
for IN N
surgical JJ N
patients NNS N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
Within IN N
each DT N
risk NN N
group NN N
, , N
mortality NN N
during IN N
the DT N
initial JJ N
hospitalization NN N
and CC N
median JJ N
long-term JJ N
survival NN N
were VBD N
similar JJ N
among IN N
patients NNS N
receiving VBG N
either DT N
treatment NN N
However RB N
, , N
the DT N
median JJ N
time NN N
to TO N
the DT N
recurrence NN N
of IN N
ascites NNS N
in IN N
Group NNP N
1 CD N
was VBD N
4 CD N
months NNS N
in IN N
medical JJ N
patients NNS N
, , N
as IN N
compared VBN N
with IN N
18 CD N
months NNS N
in IN N
surgical JJ N
patients NNS N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
; : N
in IN N
Group NNP N
2 CD N
it PRP N
was VBD N
3 CD N
months NNS N
in IN N
medical JJ N
patients NNS N
as IN N
compared VBN N
with IN N
12 CD N
months NNS N
in IN N
surgical JJ N
patients NNS N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
The DT N
median JJ N
duration NN N
of IN N
hospitalization NN N
was VBD N
longer RBR N
in IN N
medical JJ N
patients NNS N
than IN N
in IN N
surgical JJ N
patients NNS N
( ( N
6.1 CD N
vs. RB N
2.4 CD N
weeks NNS N
in IN N
Group NNP N
1 CD N
[ NNP N
P NNP N
less JJR N
than IN N
0.001 CD N
] NNS N
and CC N
5.0 CD N
vs. FW N
3.1 CD N
weeks NNS N
in IN N
Group NNP N
2 CD N
[ NNP N
P NNP N
less JJR N
than IN N
0.01 CD N
] NN N
) ) N
Group NNP N
3 CD N
was VBD N
too RB N
small JJ N
to TO N
permit VB N
a DT N
meaningful JJ N
comparison NN N
During IN N
the DT N
initial JJ N
hospitalization NN N
, , N
the DT N
incidence NN N
of IN N
infections NNS N
, , N
gastrointestinal JJ N
bleeding NN N
, , N
and CC N
encephalopathy NN N
was VBD N
similar JJ N
among IN N
the DT N
medical JJ N
and CC N
surgical JJ N
patients NNS N
We PRP N
conclude VBP N
that DT N
peritoneovenous JJ N
shunting NN N
alleviated VBD N
disabling VBG N
ascites NNS N
more RBR N
rapidly RB N
than IN N
medical JJ N
management NN N
However RB N
, , N
survival NN N
was VBD N
closely RB N
related VBN N
to TO N
the DT N
severity NN N
of IN N
the DT N
illness NN N
at IN N
the DT N
time NN N
of IN N
randomization NN N
and CC N
was VBD N
not RB N
altered VBN N
by IN N
shunting VBG N
-DOCSTART- -X- O O 8268649

Deficiency NN N
of IN N
serum NN N
ionized JJ N
magnesium NN N
in IN N
patients NNS 4_p
receiving VBG 4_p
hemodialysis NN 4_p
or CC 4_p
peritoneal JJ 4_p
dialysis NN 4_p
Serum NNP N
total JJ N
magnesium NN N
( ( N
TMg NNP N
) ) N
measurements NNS N
in IN N
dialysis NN 4_p
patients NNS N
are VBP N
variable JJ N
, , N
with IN N
some DT N
groups NNS N
reporting VBG N
hypermagnesemia NN N
and CC N
some DT N
hypomagnesemia NN N
It PRP N
had VBD N
not RB N
been VBN N
possible JJ N
to TO N
measure VB N
the DT N
biologically RB N
active JJ N
fraction NN N
, , N
ionized JJ N
magnesium NN N
( ( N
IMg2+ NNP N
) ) N
The DT N
authors NNS N
utilized VBD N
an DT N
ion-selective JJ N
electrode NN N
to TO N
measure VB N
IMg NNP N
in IN N
26 CD 3_p
hemodialysis NN 4_p
patients NNS N
and CC N
10 CD 3_p
peritoneal JJ 4_p
dialysis NN 4_p
( ( 4_p
CAPD NNP 4_p
) ) 4_p
patients NNS N
and CC N
compared VBN N
the DT N
results NNS N
with IN N
those DT N
from IN N
66 CD 3_p
age NN N
matched VBD N
control NN N
subjects NNS N
Dialysate NNP N
magnesium NN N
was VBD N
0.375 CD N
mM/L NN N
for IN N
the DT N
hemodialysis NN N
and CC N
0.25 CD N
mM/L NN N
for IN N
the DT N
CAPD NNP N
patients NNS N
When WRB N
compared VBN N
with IN N
control NN N
subjects NNS N
, , N
both DT N
hemodialysis NN N
and CC N
CAPD NNP N
patients NNS N
had VBD N
significantly RB N
lower JJR N
IMg2+ NNP N
( ( N
0.55 CD N
+/- JJ N
0.02 CD N
and CC N
0.50 CD N
+/- JJ N
0.02 CD N
vs. FW N
0.60 CD N
+/- JJ N
0.004 CD N
mM/L NN N
; : N
p CC N
< VB N
0.05 CD N
) ) N
and CC N
greater JJR N
or CC N
normal JJ N
TMg NNP N
values NNS N
( ( N
0.99 CD N
+/- JJ N
0.04 CD N
, , N
different JJ N
at IN N
the DT N
p NN N
< VBZ N
0.001 CD N
level NN N
, , N
and CC N
0.85 CD N
+/- JJ N
0.04 CD N
vs. FW N
0.84 CD N
+/- JJ N
0.008 CD N
) ) N
Ionized VBN N
calcium NN N
( ( N
ICa2+ NNP N
) ) N
values NNS N
were VBD N
similar JJ N
for IN N
all DT N
three CD N
groups NNS N
( ( N
1.15 CD N
+/- JJ N
0.02 CD N
and CC N
1.21 CD N
+/- JJ N
0.04 CD N
vs. FW N
1.17 CD N
+/- JJ N
0.01 CD N
) ) N
, , N
resulting VBG N
in IN N
increased VBN N
mean NN N
ICa2+/IMg2+ NNP N
ratios NNS N
( ( N
2.14 CD N
+/- JJ N
0.07 CD N
and CC N
2.42 CD N
+/- JJ N
0.06 CD N
vs. FW N
1.95 CD N
+/- JJ N
0.02 CD N
for IN N
the DT N
control NN N
subjects VBZ N
; : N
p VB N
< $ N
0.05 CD N
) ) N
The DT N
percent NN N
of IN N
total JJ N
magnesium NN N
that WDT N
was VBD N
ionized VBN N
( ( N
% NN N
IMg2+ NNP N
) ) N
was VBD N
low JJ N
in IN N
both DT N
the DT N
hemodialysis NN N
and CC N
CAPD NNP N
patients NNS N
( ( N
55.6 CD N
+/- JJ N
0.93 CD N
and CC N
59.2 CD N
+/- JJ N
1.05 CD N
) ) N
compared VBN N
with IN N
that DT N
of IN N
control NN N
subjects NNS N
( ( N
72 CD N
+/- JJ N
0.61 CD N
; : N
p NN N
< VBZ N
0.05 CD N
) ) N
IMg2+ NNP N
values NNS N
correlated VBN N
with IN N
TMg NNP N
values NNS N
in IN N
both DT N
hemodialysis NN N
( ( N
r JJ N
= VBZ N
0.93 CD N
; : N
p NN N
< VBZ N
0.0001 CD N
) ) N
and CC N
CAPD NNP N
( ( N
r VB N
= RB N
0.92 CD N
; : N
p NN N
< VBZ N
0.0001 CD N
) ) N
patients NNS N
did VBD N
not RB N
correlate VB N
with IN N
age NN N
, , N
time NN N
on IN N
dialysis NN N
, , N
weight NN N
, , N
fasting VBG N
cholesterol NN N
or CC N
triglyceride NN N
, , N
albumin NN N
, , N
blood NN N
urea JJ N
nitrogen NN N
( ( N
BUN NNP N
) ) N
, , N
creatinine NN N
, , N
hematocrit NN N
, , N
phosphate NN N
, , N
or CC N
PTH NNP N
values NNS N
( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 21048092

Dopexamine NNP N
has VBZ N
no DT N
additional JJ N
benefit NN N
in IN N
high-risk JJ N
patients NNS N
receiving VBG N
goal-directed JJ N
fluid NN N
therapy NN N
undergoing VBG N
major JJ N
abdominal JJ N
surgery NN N
BACKGROUND NNP N
Dopexamine NNP N
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
both DT N
mortality NN N
and CC N
morbidity NN N
in IN N
major JJ N
surgery NN N
when WRB N
it PRP N
is VBZ N
used VBN N
as IN N
part NN N
of IN N
a DT N
protocol NN N
to TO N
increase VB N
oxygen NN N
delivery NN N
in IN N
the DT N
perioperative JJ N
period NN N
A DT N
European JJ N
multicenter NN N
study NN N
has VBZ N
examined VBN N
the DT N
use NN N
of IN N
dopexamine NN N
in IN N
patients NNS N
undergoing VBG N
major JJ N
abdominal JJ N
surgery NN N
, , N
showing VBG N
a DT N
trend NN N
toward IN N
improved VBN N
survival NN N
and CC N
reduced JJ N
complications NNS N
in IN N
high-risk JJ N
patients NNS N
when WRB N
receiving VBG N
low-dose JJ N
dopexamine NN N
( ( N
0.5 CD N
μg NNP N
· NNP N
kg NNP N
( ( N
-1 NNP N
) ) N
· VBP N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
A DT N
reduced JJ N
oxygen NN N
uptake NN N
at IN N
the DT N
anaerobic JJ N
threshold NN N
( ( N
AT NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
confer VB N
a DT N
significant JJ N
risk NN N
of IN N
mortality NN N
in IN N
patients NNS N
undergoing VBG N
major JJ N
abdominal JJ N
surgery NN N
and CC N
allows VBZ N
objective JJ N
identification NN N
of IN N
a DT N
high-risk JJ N
operative JJ N
group NN N
In IN N
this DT N
study NN N
, , N
we PRP N
assessed VBD N
the DT N
effects NNS N
of IN N
low-dose JJ N
dopexamine NN N
on IN N
morbidity NN N
after IN N
major JJ N
abdominal JJ N
surgery NN N
in IN N
patients NNS N
who WP N
were VBD N
at IN N
increased VBN N
risk NN N
by IN N
virtue NN N
of IN N
a DT N
reduced VBN N
AT NNP N
METHODS NNP N
Patients NNPS N
undergoing VBG N
elective JJ N
major JJ N
colorectal NN N
or CC N
urological JJ N
surgery NN N
who WP N
had VBD N
an DT N
AT NNP N
of IN N
< NNP N
11 CD N
mL NN N
· NN N
kg NN N
( ( N
-1 NNP N
) ) N
· VBP N
min NN N
( ( N
-1 JJ N
) ) N
or CC N
an DT N
AT NNP N
of IN N
11 CD N
to TO N
14 CD N
mL NNS N
· JJ N
kg NN N
( ( N
-1 NNP N
) ) N
· VBP N
min NN N
( ( N
-1 NNP N
) ) N
with IN N
a DT N
history NN N
of IN N
ischemic JJ N
heart NN N
disease NN N
were VBD N
recruited VBN N
Before IN N
surgery NN N
, , N
a DT N
radial JJ N
arterial JJ N
cannula NN N
was VBD N
placed VBN N
and CC N
attached VBN N
to TO N
an DT N
Edwards NNP N
Lifesciences NNP N
FloTrac/Vigileo NNP N
system NN N
for IN N
measuring VBG N
cardiac JJ N
output NN N
Patients NNS N
were VBD N
given VBN N
a DT N
250-mL JJ N
bolus NN N
of IN N
Voluven NNP N
( ( N
6 CD N
% NN N
hydroxyethyl NN N
starch NN N
130/0.4 CD N
in IN N
0.9 CD N
% NN N
sodium NN N
chloride NN N
) ) N
until IN N
the DT N
stroke NN N
volume NN N
no RB N
longer RBR N
increased VBN N
by IN N
10 CD N
% NN N
, , N
then RB N
received VBD N
either CC N
dopexamine NN N
( ( N
0.5 CD N
μg NNP N
· NNP N
kg NNP N
( ( N
-1 NNP N
) ) N
· VBP N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
or CC N
saline VB N
0.9 CD N
% NN N
for IN N
24 CD N
hours NNS N
During IN N
surgery NN N
, , N
fluid NN N
boluses NNS N
of IN N
Voluven NNP N
were VBD N
given VBN N
if IN N
the DT N
stroke NN N
volume NN N
variation NN N
was VBD N
> JJ N
10 CD N
% NN N
No DT N
crystalloid NN N
was VBD N
given VBN N
during IN N
surgery NN N
A DT N
standardized JJ N
postoperative JJ N
fluid NN N
regime NN N
with IN N
Hartmann NNP N
solution NN N
was VBD N
prescribed VBN N
at IN N
1.5 CD N
mL NN N
· NN N
kg NN N
( ( N
-1 NNP N
) ) N
· NN N
h NN N
( ( N
-1 NNP N
) ) N
for IN N
24 CD N
hours NNS N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
postoperative JJ N
morbidity NN N
measured VBN N
by IN N
the DT N
Postoperative NNP N
Morbidity NNP N
Survey NNP N
RESULTS NNP N
One CD N
hundred VBD N
twenty-four JJ N
patients NNS N
were VBD N
recruited VBN N
over IN N
a DT N
23-month JJ N
period NN N
The DT N
incidence NN N
of IN N
morbidity NN N
as IN N
measured VBN N
by IN N
the DT N
Postoperative NNP N
Morbidity NNP N
Survey NNP N
on IN N
day NN N
5 CD N
was VBD N
55 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
versus VBD N
47 CD N
% NN N
in IN N
the DT N
dopexamine NN N
group NN N
( ( N
P NNP N
= NNP N
0.14 CD N
) ) N
There EX N
was VBD N
no DT N
significant JJ N
reduction NN N
in IN N
morbidity NN N
on IN N
any DT N
measured JJ N
postoperative JJ N
day NN N
Complication NN N
rates NNS N
, , N
mortality NN N
, , N
and CC N
hospital JJ N
length NN N
of IN N
stay NN N
were VBD N
similar JJ N
between IN N
the DT N
2 CD N
groups NNS N
; : N
however RB N
, , N
administration NN N
of IN N
dopexamine NN N
was VBD N
associated VBN N
with IN N
earlier JJR N
return NN N
of IN N
tolerating VBG N
an DT N
enteral JJ N
diet NN N
CONCLUSION NN N
With IN N
the DT N
effective JJ N
use NN N
of IN N
goal-directed JJ N
fluid NN N
therapy NN N
in IN N
elective JJ N
surgical JJ N
patients NNS N
, , N
the DT N
routine JJ N
use NN N
of IN N
dopexamine NN N
does VBZ N
not RB N
confer VB N
an DT N
additional JJ N
clinical JJ N
benefit NN N
-DOCSTART- -X- O O 12568856

Carbon NNP N
dioxide RB N
versus VBZ N
normal JJ N
saline NN N
as IN N
a DT N
uterine JJ N
distension NN N
medium NN N
for IN N
diagnostic JJ N
vaginoscopic NN N
hysteroscopy NN N
in IN N
infertile JJ 4_p
patients NNS N
: : N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter NN N
study NN N
OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
satisfaction NN N
rate NN N
, , N
efficacy NN N
, , N
and CC N
complication NN N
rate NN N
of IN N
carbon NN N
dioxide NN N
( ( N
CO NNP N
( ( N
2 CD N
) ) N
) ) N
versus NN N
normal JJ N
saline NN N
as IN N
a DT N
uterine JJ N
distension NN N
medium NN N
for IN N
outpatient JJ N
diagnostic JJ N
vaginoscopic NN N
hysteroscopy NN N
in IN N
infertile JJ N
patients NNS N
DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
multicenter NN N
study NN N
SETTING NNP N
Hysteroscopy NNP N
units NNS N
in IN N
two CD N
university NN N
hospitals NNS N
and CC N
in IN N
a DT N
private JJ N
center NN N
PATIENT NNP N
( ( N
S NNP N
) ) N
One CD 3_p
hundred VBN 3_p
eighty-nine JJ 3_p
infertile JJ 4_p
women NNS 2_p
undergoing VBG N
outpatient JJ N
hysteroscopy NN N
INTERVENTION NNP N
( ( N
S NNP N
) ) N
Outpatient NNP N
hysteroscopy NN N
was VBD N
performed VBN N
with IN N
CO NNP N
( ( N
2 CD N
) ) N
( ( N
group NN N
A NNP N
) ) N
or CC N
normal JJ N
saline NN N
( ( N
group NN N
B NNP N
) ) N
and CC N
with IN N
endometrial JJ N
biopsy NN N
when WRB N
indicated VBN N
MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Quality NN N
of IN N
the DT N
visualization NN N
of IN N
the DT N
uterine JJ N
cavity NN N
, , N
procedure NN N
time NN N
, , N
complications NNS N
, , N
patient JJ N
discomfort NN N
, , N
and CC N
satisfaction NN N
rate NN N
RESULT NNP N
( ( N
S NNP N
) ) N
Significantly NNP N
lower JJR N
abdominal NN N
and CC N
shoulder NN N
tip NN N
pain NN N
and CC N
a DT N
lower JJR N
incidence NN N
of IN N
vasovagal JJ N
reactions NNS N
were VBD N
observed VBN N
in IN N
group NN N
B NNP N
in IN N
comparison NN N
with IN N
group NN N
A NNP N
A NNP N
higher JJR N
satisfaction NN N
rate NN N
and CC N
a DT N
lower JJR N
operative JJ N
time NN N
were VBD N
obtained VBN N
in IN N
the DT N
normal JJ N
saline NN N
group NN N
in IN N
comparison NN N
with IN N
the DT N
CO NNP N
( ( N
2 CD N
) ) N
group NN N
Moreover RB N
, , N
group NN N
A NNP N
required VBD N
significantly RB N
more RBR N
analgesics NNS N
after IN N
the DT N
procedure NN N
than IN N
group NN N
B NNP N
CONCLUSION NNP N
( ( N
S NNP N
) ) N
Uterine NNP N
distension NN N
with IN N
normal JJ N
saline NN N
seems VBZ N
to TO N
have VB N
less JJR N
adverse JJ N
effects NNS N
and CC N
is VBZ N
better RBR N
tolerated VBN N
by IN N
patients NNS N
Moreover RB N
, , N
it PRP N
allows VBZ N
operative JJ N
procedures NNS N
to TO N
be VB N
performed VBN N
with IN N
the DT N
new JJ N
bipolar JJ N
instruments NNS N
-DOCSTART- -X- O O 15509083

Sustained VBN N
oral JJ 4_p
health NN 4_p
improvement NN 4_p
and CC N
use NN N
of IN N
toothbrushes NNS N
and CC N
dentifrice NN N
by IN N
previous JJ N
users NNS N
of IN N
traditional JJ N
materials NNS N
in IN N
a DT N
rural JJ N
population NN N
in IN N
Andhra NNP N
Pradesh NNP N
, , N
India NNP N
AIM NNP N
To TO N
follow-up NN N
, , N
one CD N
year NN N
later RB N
, , N
a DT N
double-blind NN N
, , N
randomised VBN N
study NN N
, , N
which WDT N
investigated VBD N
the DT N
effect NN N
of IN N
regular JJ N
brushing NN N
with IN N
dentifrices NNS N
on IN N
the DT N
oral JJ 4_p
health NN 4_p
of IN N
an DT N
economically RB N
disadvantaged JJ N
rural JJ N
population NN N
in IN N
Andhra NNP N
Pradesh NNP N
, , N
India NNP N
who WP N
were VBD N
primarily RB N
users NNS N
of IN N
traditional JJ N
materials NNS N
SUBJECTS NNP N
150 CD 3_p
of IN N
the DT N
original JJ N
study NN N
population NN N
METHOD NNP N
Examination NNP N
to TO N
determine VB N
whether IN N
the DT N
improvements NNS N
in IN N
oral JJ N
health NN N
status NN N
and CC N
oral JJ N
health NN N
behaviour NN N
( ( N
use NN N
of IN N
toothbrush NN N
and CC N
dentifrice NN N
) ) N
, , N
being VBG N
unsupported JJ N
, , N
had VBD N
been VBN N
sustained VBN N
since IN N
completion NN N
of IN N
the DT N
original JJ N
study NN N
RESULTS NNP N
Data NNP N
analysis NN N
showed VBD N
sustained VBN N
, , N
statistically RB N
significant JJ N
improvements NNS N
in IN N
gingival JJ N
health NN N
as IN N
measured VBN N
by IN N
gingival NN N
bleeding NN N
and CC N
plaque NN N
indices NNS N
( ( N
GBI NNP N
and CC N
PI NNP N
) ) N
comparing VBG N
users NNS N
and CC N
non-users NNS N
of IN N
toothbrushes NNS N
and CC N
dentifrice NN N
in IN N
the DT N
original JJ N
study NN N
( ( N
PI NNP N
: : N
p NN N
= VBZ N
0.04 CD N
; : N
GBI NNP N
: : N
p NN N
= VBZ N
0.03 CD N
) ) N
and CC N
sustained VBN N
use NN N
of IN N
toothbrushes NNS N
and CC N
dentifrice NN N
by IN N
60 CD N
% NN N
of IN N
the DT N
subjects NNS N
at IN N
follow-up JJ N
one CD N
year NN N
later RB N
CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
a DT N
beneficial JJ N
effect NN N
on IN N
oral JJ N
hygiene NN N
indices NNS N
following VBG N
the DT N
introduction NN N
of IN N
toothbrushes NNS N
and CC N
dentifrices NNS N
to TO N
a DT N
community NN N
using VBG N
traditional JJ N
oral JJ N
hygiene NN N
materials NNS N
and CC N
sustainability NN N
of IN N
use NN N
of IN N
these DT N
materials NNS N
with IN N
motivation NN N
and CC N
support NN N
It PRP N
may MD N
therefore RB N
be VB N
concluded VBN N
that IN N
it PRP N
is VBZ N
feasible JJ N
to TO N
achieve VB N
significant JJ N
use NN N
of IN N
conventional JJ N
toothbrushes NNS N
and CC N
toothpastes NNS N
, , N
with IN N
consequent JJ N
major JJ N
and CC N
sustained JJ N
improvements NNS N
in IN N
plaque NN N
control NN N
and CC N
gingival JJ N
health NN N
in IN N
a DT N
disadvantaged JJ N
population NN N
hitherto NN N
often RB N
considered VBN N
as IN N
not RB N
amenable JJ N
to TO N
conventional JJ N
oral JJ N
hygiene NN N
for IN N
cultural JJ N
or CC N
economic JJ N
reasons NNS N
-DOCSTART- -X- O O 23061531

The DT N
effect NN N
of IN N
prethrombolytic JJ N
cyclosporine-A JJ N
injection NN N
on IN N
clinical JJ N
outcome NN N
of IN N
acute JJ 4_p
anterior JJ 4_p
ST-elevation NNP 4_p
myocardial JJ 4_p
infarction NN 4_p
INTRODUCTION NNP N
Reperfusion NNP N
injury NN N
reduces VBZ N
the DT N
benefits NNS N
of IN N
early JJ N
reperfusion NN N
therapies NNS N
after IN N
acute JJ N
ST-elevation NNP N
myocardial JJ N
infarction NN N
( ( N
STEMI NNP N
) ) N
Cyclosporine-A NNP N
( ( N
CsA NNP N
) ) N
is VBZ N
a DT N
potent JJ N
inhibitor NN N
of IN N
opening NN N
of IN N
the DT N
mitochondrial JJ N
permeability NN N
transition NN N
pore NN N
, , N
which WDT N
has VBZ N
been VBN N
shown VBN N
to TO N
play VB N
a DT N
key JJ N
role NN N
in IN N
myocardial JJ N
reperfusion NN N
injury NN N
The DT N
impact NN N
of IN N
this DT N
treatment NN N
on IN N
clinical JJ N
outcomes NNS N
of IN N
acute JJ N
STEMI NNP N
remains VBZ N
unknown JJ N
Our PRP$ N
aim NN N
was VBD N
to TO N
investigate VB N
the DT N
clinical JJ N
outcomes NNS N
of IN N
using VBG N
this DT N
drug NN N
in IN N
patients NNS 4_p
with IN 4_p
acute JJ 4_p
anterior JJ 4_p
STEMI NNP 4_p
receiving VBG 4_p
thrombolytic JJ 4_p
treatment NN 4_p
( ( 4_p
TLT NNP 4_p
) ) 4_p
METHODS NNP N
In IN N
this DT N
double-blinded JJ N
randomized JJ N
clinical JJ N
trial NN N
, , N
101 CD N
patients NNS N
with IN N
acute JJ N
anterior JJ N
STEMI NNP N
who WP N
were VBD N
candidate NN N
for IN N
TLT NNP N
, , N
were VBD N
enrolled VBN N
and CC N
randomly RB N
assigned VBN N
into IN N
treatment NN N
or CC N
control NN N
groups NNS N
Patients NNS N
in IN N
the DT N
treatment NN N
group NN N
received VBD N
an DT N
intravenous JJ N
bolus NN N
injection NN N
of IN N
2.5 CD N
mg/kg NN N
of IN N
CsA NNP N
immediately RB N
before IN N
TLT NNP N
The DT N
patients NNS N
in IN N
the DT N
control NN N
group NN N
received VBD N
an DT N
equivalent JJ N
volume NN N
of IN N
normal JJ N
saline NN N
Infarct NNP N
size NN N
, , N
occurrence NN N
of IN N
major JJ N
arrhythmias NNS N
, , N
heart NN N
failure NN N
, , N
left VBD N
ventricular JJ N
ejection NN N
fraction NN N
( ( N
LVEF NNP N
) ) N
, , N
TLT-related JJ N
complications NNS N
, , N
in-hospital JJ N
and CC N
6-month JJ N
mortality NN N
rates NNS N
were VBD N
investigated VBN N
RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
among IN N
the DT N
demographics NNS N
, , N
myocardial JJ N
enzyme NN N
release NN N
, , N
occurrence NN N
of IN N
major JJ N
arrhythmias NNS N
[ VBP N
9 CD N
( ( N
18 CD N
% NN N
) ) N
vs. FW N
12 CD N
( ( N
23.5 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.80 CD N
] NN N
, , N
heart NN N
failure NN N
[ VBZ N
18 CD N
( ( N
36 CD N
% NN N
) ) N
vs. FW N
19 CD N
( ( N
38.3 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.83 CD N
] NN N
, , N
LVEF NNP N
at IN N
first JJ N
day NN N
[ VB N
34.7 CD N
± JJ N
9.9 CD N
% NN N
vs. FW N
33.5 CD N
± $ N
8.1 CD N
% NN N
, , N
P NNP N
= VBZ N
0.50 CD N
] NN N
or CC N
at IN N
discharge NN N
[ $ N
37.7 CD N
± JJ N
10 CD N
% NN N
vs. FW N
36.1 CD N
± $ N
8.2 CD N
% NN N
, , N
P NNP N
= VBZ N
0.43 CD N
] NN N
, , N
and CC N
in-hospital JJ N
[ NN N
4 CD N
( ( N
8 CD N
% NN N
) ) N
vs. FW N
6 CD N
( ( N
11.8 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.74 CD N
] NN N
or CC N
6-month JJ N
mortality NN N
rates NNS N
[ VBP N
9 CD N
( ( N
18 CD N
% NN N
) ) N
vs. FW N
10 CD N
( ( N
19.6 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.99 CD N
] NN N
between IN N
the DT N
CsA NNP N
vs. IN N
the DT N
control NN N
group NN N
CONCLUSION NNP N
In IN N
this DT N
study NN N
, , N
the DT N
prethrombolytic JJ N
administration NN N
of IN N
CsA NNP N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
the DT N
infarct JJ N
size NN N
or CC N
any DT N
improvement NN N
in IN N
clinical JJ N
outcomes NNS N
-DOCSTART- -X- O O 24785600

Hysteroscopic NNP N
morcellation NN N
compared VBN N
with IN N
electrical JJ N
resection NN N
of IN N
endometrial JJ N
polyps NNS N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
OBJECTIVE UH N
To TO N
evaluate VB N
whether IN N
hysteroscopic JJ N
morcellation NN N
or CC N
bipolar JJ N
electrosurgical JJ N
resection NN N
is VBZ N
more RBR N
favorable JJ N
for IN N
removing VBG N
endometrial JJ 4_p
polyps NNS 4_p
in IN N
an DT N
office NN N
setting NN N
in IN N
terms NNS N
of IN N
feasibility NN N
, , N
speed NN N
, , N
pain NN N
, , N
and CC N
acceptability NN N
METHODS NNP N
A NNP N
multicenter NN N
, , N
single-blind NN N
, , N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
office NN N
hysteroscopic NN N
morcellation NN N
compared VBN N
with IN N
electrosurgical JJ N
resection NN N
was VBD N
conducted VBN N
A DT N
total NN N
of IN N
121 CD N
women NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
polyp VB N
removal NN N
by IN N
one CD N
of IN N
the DT N
two CD N
methods NNS N
in IN N
an DT N
office NN N
setting NN N
The DT N
outcomes NNS N
assessed VBN N
were VBD N
time NN N
taken VBN N
to TO N
complete VB N
the DT N
endometrial JJ N
polypectomy NN N
, , N
defined VBD N
as IN N
the DT N
time NN N
from IN N
insertion NN N
to TO N
removal NN N
of IN N
vaginal JJ N
instrumentation NN N
, , N
completeness NN N
of IN N
polyp NN N
removal NN N
, , N
acceptability NN N
, , N
and CC N
pain NN N
measured VBN N
on IN N
a DT N
100-mm JJ N
visual JJ N
analog NN N
scale NN N
RESULTS VB N
The DT N
median JJ N
time NN N
taken VBN N
to TO N
complete VB N
the DT N
procedure NN N
was VBD N
5 CD N
minutes NNS N
and CC N
28 CD N
seconds NNS N
for IN N
morcellation NN N
compared VBN N
with IN N
10 CD N
minutes NNS N
and CC N
12 CD N
seconds NNS N
for IN N
electrosurgical JJ N
resection NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
The DT N
polyps NNS N
were VBD N
completely RB N
removed VBN N
in IN N
61 CD N
out IN N
of IN N
62 CD N
( ( N
98 CD N
% NN N
) ) N
women NNS N
assigned VBN N
to TO N
morcellation VB N
compared VBN N
with IN N
49 CD N
out IN N
of IN N
59 CD N
( ( N
83 CD N
% NN N
) ) N
women NNS N
treated VBN N
with IN N
electrosurgical JJ N
resection NN N
( ( N
odds NNS N
ratio VBP N
12.5 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
1.5-100.6 CD N
; : N
P=.02 NNP N
) ) N
The DT N
mean JJ N
pain NN N
scores NNS N
during IN N
the DT N
procedure NN N
favored VBN N
morcellation NN N
by IN N
16.1 CD N
points NNS N
on IN N
average NN N
( ( N
35.9 CD N
compared VBN N
with IN N
52.0 CD N
; : N
95 CD N
% NN N
CI NNP N
for IN N
difference NN N
, , N
-24.7 NN N
to TO N
-7.6 VB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
Overall JJ N
, , N
99 CD N
% NN N
of IN N
women NNS N
found VBN N
office NN N
polypectomy NN N
to TO N
be VB N
acceptable JJ N
, , N
with IN N
only RB N
one CD N
woman NN N
in IN N
the DT N
electrosurgical JJ N
resection NN N
group NN N
considering VBG N
the DT N
procedure NN N
unacceptable JJ N
CONCLUSION NNP N
In IN N
comparison NN N
to TO N
electrosurgical JJ N
resection NN N
during IN N
hysteroscopic NN N
polypectomy NN N
, , N
morcellation NN N
was VBD N
significantly RB N
quicker JJR N
, , N
less RBR N
painful JJ N
, , N
more RBR N
acceptable JJ N
to TO N
women NNS N
, , N
and CC N
more RBR N
likely JJ N
to TO N
completely RB N
remove VB N
endometrial JJ N
polyps NNS N
compared VBN N
with IN N
electrosurgical JJ N
resection NN N
CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
, , N
www.clinicaltrials.gov NN N
, , N
NCT01509313 NNP N
-DOCSTART- -X- O O 18208642

Comparison NNP N
of IN N
the DT N
therapeutic JJ N
effects NNS N
of IN N
epoetin NN N
zeta NN N
to TO N
epoetin VB N
alfa NN N
in IN N
the DT N
maintenance NN N
phase NN N
of IN N
renal JJ 4_p
anaemia NN 4_p
treatment NN N
OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
therapeutic JJ N
efficacy NN N
and CC N
safety NN N
of IN N
epoetin JJ N
zeta NN N
, , N
compared VBN N
with IN N
epoetin NN N
alfa NN N
, , N
in IN N
maintaining VBG N
target NN N
haemoglobin NN N
( ( N
Hb NNP N
) ) N
concentrations NNS N
in IN N
patients NNS N
with IN N
anaemia NN 4_p
and CC 4_p
chronic JJ 4_p
kidney NN 4_p
disease NN 4_p
( ( 4_p
CKD NNP 4_p
) ) 4_p
maintained VBD N
on IN N
haemodialysis NN N
METHODS NNP N
Patients NNPS N
received VBD N
epoetin JJ N
zeta NN N
or CC N
epoetin NN N
alfa NN N
intravenously RB N
, , N
1-3 JJ N
times/week NN N
for IN N
12 CD N
weeks NNS N
, , N
then RB N
the DT N
alternative JJ N
treatment NN N
for IN N
12 CD N
weeks NNS N
, , N
in IN N
this DT N
double-blind NN N
, , N
crossover NN N
, , N
phase NN N
III NNP N
trial NN N
Eligible JJ N
patients NNS N
were VBD N
18-75 CD 1_p
years NNS 1_p
old JJ 1_p
with IN N
CKD NNP 4_p
stage NN 4_p
5 CD 4_p
maintained VBN N
on IN N
haemodialysis NN N
Patients NNS N
had VBD N
received VBN N
epoetin NN N
for IN N
> NN N
or CC N
= $ N
3 CD N
months NNS N
upon IN N
study NN N
entry NN N
and CC N
had VBD N
achieved VBN N
a DT N
target NN N
Hb NNP N
level NN N
of IN N
10.5-12.5 JJ N
g/dL NN N
with IN N
a DT N
stable JJ N
epoetin NN N
dose NN N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
efficacy NN N
endpoints NNS N
were VBD N
intra-individual JJ N
differences NNS N
( ( N
test-reference NN N
) ) N
in IN N
mean JJ N
Hb NNP N
levels NNS N
and CC N
mean JJ N
weekly JJ N
dose/kg NN N
of IN N
body NN N
weight NN N
Safety NN N
endpoints NNS N
included VBD N
occurrence NN N
of IN N
neutralizing VBG N
anti-erythro JJ N
poietin NN N
antibodies NNS N
, , N
tolerability NN N
, , N
and CC N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
RESULTS NNP N
In IN N
total JJ N
, , N
313 CD 3_p
patients NNS 3_p
were VBD N
randomized VBN N
to TO N
receive VB N
epoetin NN N
zeta NN N
( ( N
n JJ N
= NNP N
155 CD N
) ) N
or CC N
epoetin JJ N
alfa NN N
( ( N
n JJ N
= NNP N
158 CD N
) ) N
; : N
146 CD N
and CC N
145 CD N
patients NNS N
( ( N
respectively RB N
) ) N
switched VBD N
treatment NN N
after IN N
12 CD N
weeks NNS N
Mean NNP N
( ( N
range NN N
) ) N
Hb NNP N
levels NNS N
were VBD N
11.35 CD N
( ( N
8.96-14.22 CD N
) ) N
g/dL NN N
and CC N
11.54 CD N
( ( N
8.74-13.84 CD N
) ) N
g/dL NN N
for IN N
patients NNS N
receiving VBG N
epoetin JJ N
zeta NN N
and CC N
epoetin NN N
alfa NN N
, , N
respectively RB N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
[ NNP N
test-reference NN N
] NN N
: : N
0.09-0.28 JJ N
g/dL NN N
, , N
within IN N
the DT N
predefined JJ N
equivalence NN N
range NN N
of IN N
+/-0.6 NNP N
g/dL NN N
) ) N
Mean NNP N
( ( N
range NN N
) ) N
weekly JJ N
doses NNS N
were VBD N
92.68 CD N
( ( N
12.74-398.41 JJ N
) ) N
IU/kg/wk NNP N
and CC N
92.58 CD N
( ( N
10.53-393.07 JJ N
) ) N
IU/kg/wk NNP N
for IN N
patients NNS N
receiving VBG N
epoetin JJ N
zeta NN N
and CC N
epoetin NN N
alfa NN N
, , N
respectively RB N
( ( N
95 CD N
% NN N
CI NNP N
[ NNP N
test-reference NN N
] NN N
: : N
-4.67 NN N
and CC N
4.29 CD N
IU/kg/wk NNP N
, , N
within IN N
the DT N
equivalence NN N
range NN N
of IN N
+/-45.00 NNP N
IU/kg/wk NNP N
) ) N
Patients NNPS N
underwent JJ N
minor JJ N
nominal JJ N
dose NN N
adjustments NNS N
during IN N
treatment NN N
crossover NN N
AE NNP N
profile NN N
was VBD N
similar JJ N
for IN N
both DT N
products NNS N
; : N
the DT N
most RBS N
commonly RB N
reported VBD N
AEs NNP N
were VBD N
infections NNS N
and CC N
infestations NNS N
( ( N
in IN N
26.5 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
epoetin JJ N
zeta NN N
and CC N
23.6 CD N
% NN N
receiving VBG N
epoetin JJ N
alfa NN N
) ) N
No UH N
patients NNS N
developed VBD N
neutralizing VBG N
anti-erythropoietin JJ N
antibodies NNS N
CONCLUSIONS NNP N
Epoetin NNP N
zeta NN N
is VBZ N
therapeutically RB N
equivalent JJ N
to TO N
epoetin VB N
alfa NN N
in IN N
the DT N
maintenance NN N
of IN N
target NN N
Hb NNP N
levels NNS N
in IN N
patients NNS N
with IN N
renal JJ 4_p
anaemia NN 4_p
No DT N
unexpected JJ N
AEs NNP N
were VBD N
seen VBN N
-DOCSTART- -X- O O 12951131

Observational NNP N
learning NN N
and CC N
the DT N
formation NN N
of IN N
classes NNS N
of IN N
reading VBG N
skills NNS N
by IN N
individuals NNS N
with IN N
autism NN 4_p
and CC N
other JJ N
developmental JJ N
disabilities NNS N
We PRP N
investigated VBD N
whether IN N
individuals NNS 4_p
with IN 4_p
developmental JJ 4_p
disabilities NNS 4_p
will MD N
demonstrate VB N
stimulus NN N
classes NNS N
after IN N
observing VBG N
another DT N
individual JJ N
demonstrate NN N
the DT N
prerequisite JJ N
conditional JJ N
discriminations NNS N
In IN N
Experiment JJ N
1 CD N
, , N
participants NNS N
learned VBD N
conditional JJ N
discriminations NNS N
among IN N
dictated JJ N
words NNS N
, , N
pictures NNS N
, , N
and CC N
printed VBD N
words NNS N
They PRP N
also RB N
observed VBD N
a DT N
model NN N
without IN N
disabilities NNS N
demonstrate VBP N
conditional JJ N
discriminations NNS N
among IN N
a DT N
different JJ N
set NN N
of IN N
dictated JJ N
words NNS N
, , N
pictures NNS N
, , N
and CC N
printed VBD N
words NNS N
The DT N
classes NNS N
assigned VBD N
to TO N
each DT N
participant NN N
belonged VBD N
to TO N
a DT N
larger JJR N
superordinate JJ N
category NN N
, , N
as IN N
did VBD N
the DT N
classes NNS N
assigned VBD N
to TO N
each DT N
model NN N
The DT N
superordinate JJ N
categories NNS N
were VBD N
different JJ N
for IN N
participants NNS N
and CC N
models NNS N
All DT N
participants NNS N
subsequently RB N
demonstrated VBD N
full JJ N
stimulus NN N
classes NNS N
with IN N
the DT N
stimuli NNS N
involved VBN N
in IN N
direct JJ N
training NN N
: : N
They PRP N
named VBD N
pictures NNS N
, , N
read VBP N
printed VBN N
words NNS N
, , N
and CC N
matched VBD N
pictures NNS N
and CC N
words NNS N
to TO N
one CD N
another DT N
However RB N
, , N
based VBN N
on IN N
observing VBG N
a DT N
model NN N
, , N
none NN N
of IN N
the DT N
participants NNS N
demonstrated VBD N
full JJ N
stimulus NN N
classes NNS N
In IN N
Experiment JJ N
2 CD N
, , N
participants NNS N
learned VBD N
conditional JJ N
discriminations NNS N
among IN N
the DT N
stimuli NNS N
in IN N
three CD N
sets NNS N
, , N
and CC N
observed VBD N
a DT N
model NN N
's POS N
training NN N
with IN N
the DT N
stimuli NNS N
in IN N
three CD N
different JJ N
sets NNS N
The DT N
classes NNS N
assigned VBD N
to TO N
each DT N
participant NN N
belonged VBD N
to TO N
the DT N
same JJ N
larger JJR N
superordinate JJ N
category NN N
as IN N
did VBD N
those DT N
assigned VBN N
to TO N
their PRP$ N
respective JJ N
model NN N
All DT N
participants NNS N
subsequently RB N
demonstrated VBD N
full JJ N
stimulus NN N
classes NNS N
with IN N
the DT N
stimuli NNS N
involved VBN N
in IN N
direct JJ N
training NN N
They PRP N
also RB N
demonstrated VBD N
full JJ N
classes NNS N
with IN N
at IN N
least JJS N
one CD N
of IN N
their PRP$ N
model NN N
's POS N
sets NNS N
of IN N
training NN N
stimuli NNS N
When WRB N
full JJ N
stimulus NN N
classes NNS N
did VBD N
not RB N
occur VB N
from IN N
observing VBG N
a DT N
model NN N
, , N
participants NNS N
named VBD N
the DT N
model NN N
's POS N
pictures NNS N
, , N
read VBD N
the DT N
model NN N
's POS N
printed JJ N
words NNS N
, , N
or CC N
matched VBD N
the DT N
model NN N
's POS N
pictures NNS N
and CC N
words NNS N
Stimulus CC N
class NN N
technology NN N
, , N
coupled VBN N
with IN N
the DT N
opportunity NN N
to TO N
observe VB N
another DT N
individual JJ N
perform NN N
a DT N
skill NN N
, , N
may MD N
be VB N
an DT N
economical JJ N
and CC N
efficient JJ N
means NNS N
of IN N
teaching VBG N
persons NNS 4_p
with IN 4_p
developmental JJ 4_p
disabilities NNS 4_p
-DOCSTART- -X- O O 8858230

Prospective JJ N
comparison NN N
of IN N
nasal JJ N
versus IN N
oral JJ N
insertion NN N
of IN N
a DT N
thin JJ N
video NN N
endoscope NN N
in IN N
healthy JJ 4_p
volunteers NNS 4_p
BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIMS NNP N
Attempts NNP N
have VBP N
been VBN N
made VBN N
to TO N
improve VB N
patient NN N
's POS N
tolerance NN N
of IN N
upper JJ N
gastrointestinal JJ N
endoscopy NN N
and CC N
to TO N
decrease VB N
the DT N
need NN N
for IN N
sedation NN N
, , N
using VBG N
thinner NN N
endoscopes NNS N
and CC N
a DT N
nasal JJ N
introduction NN N
route NN N
We PRP N
prospectively RB N
compared VBN N
the DT N
oral JJ N
and CC N
nasal JJ N
routes NNS N
in IN N
volunteers NNS N
, , N
using VBG N
a DT N
thin JJ N
prototype NN N
video NN N
endoscope NN N
METHODS NNP N
Ten NNP 4_p
healthy JJ 4_p
volunteers NNS 4_p
underwent JJ 4_p
two CD 4_p
upper JJ 4_p
gastrointestinal JJ 4_p
endoscopies NNS 4_p
in IN 4_p
a DT 4_p
random JJ 4_p
order NN 4_p
on IN 4_p
two CD 4_p
different JJ 4_p
days NNS 4_p
, , 4_p
with IN 4_p
the DT 4_p
procedure NN 4_p
being VBG 4_p
carried VBN 4_p
out RP 4_p
by IN 4_p
a DT 4_p
single JJ 4_p
experienced JJ 4_p
endoscopist NN 4_p
Parameters NNS N
assessed VBD N
were VBD N
the DT N
tolerance NN N
of IN N
scope NN N
insertion NN N
and CC N
the DT N
assessment NN N
of IN N
the DT N
entire JJ N
procedure NN N
( ( N
0-10 JJ N
scale NN N
) ) N
, , N
the DT N
method NN N
of IN N
insertion NN N
preferred VBN N
by IN N
the DT N
volunteers NNS N
, , N
the DT N
completeness NN N
of IN N
the DT N
examination NN N
( ( N
assessed VBN N
by IN N
an DT N
independent JJ N
endoscopist NN N
) ) N
, , N
and CC N
the DT N
time NN N
required VBN N
for IN N
the DT N
procedure NN N
RESULTS NNP N
In IN N
one CD N
patient NN N
, , N
nasal JJ N
insertion NN N
failed VBD N
, , N
and CC N
she PRP N
was VBD N
excluded VBN N
from IN N
further JJ N
analysis NN N
The DT N
insertion NN N
of IN N
the DT N
scope NN N
was VBD N
easier JJR N
via IN N
the DT N
oral JJ N
route NN N
, , N
as IN N
reflected VBN N
in IN N
a DT N
shorter JJR N
examination NN N
time NN N
( ( N
mean JJ N
165 CD N
vs. FW N
210 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.017 CD N
) ) N
and CC N
patients NNS N
' POS N
tolerance NN N
for IN N
the DT N
scope NN N
insertion NN N
( ( N
mean JJ N
score NN N
: : N
8 CD N
for IN N
oral JJ N
vs. FW N
4 CD N
for IN N
nasal JJ N
route NN N
; : N
p CC N
= VB N
0.03 CD N
) ) N
On IN N
the DT N
other JJ N
hand NN N
, , N
gagging VBG N
occurred VBD N
more RBR N
frequently RB N
during IN N
oral JJ N
endoscopy NN N
( ( N
6/9 CD N
vs NN N
1/9 CD N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
Three CD N
of IN N
the DT N
volunteers NNS N
in IN N
each DT N
case NN N
preferred VBD N
the DT N
oral JJ N
or CC N
the DT N
nasal JJ N
route NN N
, , N
and CC N
three CD N
were VBD N
not RB N
decided VBN N
, , N
in IN N
case NN N
of IN N
a DT N
repeated JJ N
endoscopy NN N
Similarly RB N
, , N
the DT N
overall JJ N
tolerance NN N
for IN N
the DT N
procedure NN N
did VBD N
not RB N
between IN N
the DT N
two CD N
groups NNS N
CONCLUSION NNP N
Thin-diameter NNP N
gastroscopes NNS N
seem VBP N
to TO N
improve VB N
patient NN N
's POS N
tolerance NN N
In IN N
this DT N
small JJ N
study NN N
in IN N
volunteers NNS N
, , N
nasal JJ N
introduction NN N
showed VBD N
no DT N
overall JJ N
benefit NN N
over IN N
oral JJ N
introduction NN N
Modifications NNS N
of IN N
the DT N
scope NN N
to TO N
achieve VB N
better JJR N
nasal NN N
passage NN N
are VBP N
necessary JJ N
-DOCSTART- -X- O O 22682024

Effectiveness NN N
and CC N
durability NN N
of IN N
Interceptor® NNP N
long-lasting JJ N
insecticidal JJ N
nets NNS 4_p
in IN 4_p
a DT 4_p
malaria NN 4_p
endemic JJ 4_p
area NN 4_p
of IN 4_p
central JJ 4_p
India NNP 4_p
BACKGROUND NNP N
In IN N
the DT N
present JJ N
study NN N
, , N
Interceptor® NNP N
, , N
long-lasting JJ N
polyester NN N
net NN N
, , N
75 CD N
denier NN N
and CC N
bursting VBG N
strength NN N
of IN N
minimum JJ N
250 CD N
kPa NN N
coated VBN N
with IN N
alpha-cypermethrin JJ N
@ NNS N
200 CD N
mg/m² NN N
was VBD N
evaluated VBN N
for IN N
its PRP$ N
efficacy NN N
in IN N
reducing VBG N
the DT N
mosquito NN N
density NN N
, , N
blood NN N
feeding NN N
inhibition NN N
and CC N
malaria NN N
incidence NN N
in IN N
a DT N
tribal NN N
dominated VBN N
malaria NNS 3_p
endemic JJ 3_p
area NN 4_p
in IN N
Chhattisgarh NNP N
state NN N
, , N
central JJ N
India NNP N
Its PRP$ N
durability NN N
, , N
washing VBG N
practices NNS N
and CC N
usage JJ N
pattern NN N
by IN N
the DT 3_p
community NN 3_p
was VBD N
also RB N
assessed VBN N
up RP N
to TO N
a DT N
period NN N
of IN N
three CD N
years NNS N
METHODS PDT N
The DT N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
two CD N
phases NNS N
In IN N
the DT N
first JJ N
phase NN N
( ( N
September NNP N
2006 CD N
to TO N
August NNP N
2007 CD N
) ) N
, , N
16 CD 3_p
malaria NNS 3_p
endemic JJ 3_p
villages NNS 3_p
in IN N
district NN N
Kanker NNP N
were VBD N
randomized VBN N
into IN N
three CD N
groups NNS N
, , N
viz NN N
Interceptor JJ N
net JJ N
( ( N
LN NNP N
) ) N
, , N
untreated JJ N
polyester NN N
net NN N
( ( N
100 CD N
denier NN N
) ) N
and CC N
without IN N
net NN N
Malaria NNP N
cases NNS N
were VBD N
detected VBN N
by IN N
undertaking VBG N
fortnightly RB N
surveillance VBN N
by IN N
home NN N
visits NNS N
and CC N
treated VBD N
as IN N
per IN N
the DT N
national JJ N
drug NN N
policy NN N
Mosquito NNP N
collections NNS N
were VBD N
made VBN N
by IN N
hand NN N
catch NN N
and CC N
pyrethrum JJ N
space NN N
spray NN N
methods NNS N
from IN N
human JJ N
dwellings NNS N
once RB N
every DT N
month NN N
Slide NNP N
positivity NN N
rate NN N
( ( N
SPR NNP N
) ) N
and CC N
malaria $ N
incidence NN N
per IN N
1000 CD N
population NN N
( ( N
PI NNP N
) ) N
were VBD N
compared VBN N
between IN N
the DT N
three CD N
study NN N
arms NNS N
to TO N
assess VB N
the DT N
impact NN N
of IN N
use NN N
of IN N
Interceptor NNP N
nets NNS N
Simultaneously RB N
, , N
wash JJ N
resistance NN N
studies NNS N
were VBD N
carried VBN N
out RP N
in IN N
the DT N
laboratory NN N
by IN N
doing VBG N
cone NN N
bioassays NNS N
on IN N
Interceptor NNP N
LNs NNP N
washed VBD N
up RB N
to TO N
20 CD N
times NNS N
Activities NNS N
undertaken VBP N
in IN N
second JJ N
Phase NNP N
( ( N
April NNP N
2008 CD N
to TO N
October NNP N
2009 CD N
) ) N
after IN N
an DT N
interval NN N
of IN N
about IN N
18 CD N
months NNS N
post-net JJ N
distribution NN N
included VBD N
questionnaire NN N
based VBN N
surveys NNS N
at IN N
every DT N
six CD N
months NNS N
, , N
i.e NN N
18 CD N
, , N
24 CD N
, , N
30 CD N
and CC N
36 CD N
months NNS N
to TO N
observe VB N
durability NN N
, , N
usage JJ N
pattern NN N
of IN N
LNs NNP N
and CC N
washing VBG N
practices NNS N
by IN N
the DT N
community NN 3_p
After IN N
36 CD N
months NNS N
of IN N
field NN N
use NN N
, , N
30 CD N
nets NNS N
were VBD N
retrieved VBN N
and CC N
sampled VBN N
destructively RB N
for IN N
chemical NN N
analysis NN N
RESULTS NNP N
Interceptor NNP N
nets NNS N
were VBD N
found VBN N
effective JJ N
in IN N
reducing VBG N
the DT N
density NN N
, , N
parity NN N
rate NN N
and CC N
blood NN N
feeding NN N
success NN N
rate NN N
of IN N
main JJ N
malaria NNS N
vector NN N
Anopheles NNP N
culicifacies NNS N
as IN N
compared VBN N
to TO N
that DT N
in IN N
untreated JJ N
net NN N
and CC N
no DT N
net JJ N
villages NNS N
SPR NNP N
in IN N
LN NNP N
villages NNS N
was VBD N
3.7 CD N
% NN N
as IN N
compared VBN N
to TO N
6.5 CD N
% NN N
in IN N
untreated JJ N
and CC N
11 CD N
% NN N
in IN N
no DT N
net JJ N
villages NNS N
PI NNP N
in IN N
LN NNP N
villages NNS N
was VBD N
16.4 CD N
in IN N
comparison NN N
to TO N
24.8 CD N
and CC N
44.2 CD N
in IN N
untreated JJ N
polyester NN N
net NN N
and CC N
no DT N
net JJ N
villages NNS N
respectively RB N
In IN N
surveys NNS N
carried VBD N
out RP N
after IN N
three CD N
years NNS N
of IN N
initial JJ N
distribution NN N
, , N
78.7 CD N
% NN N
( ( N
737/936 CD N
) ) N
nets NNS N
were VBD N
still RB N
in IN N
possession NN N
with IN N
the DT N
households NNS N
, , N
of IN N
which WDT N
68 CD N
% NN N
were VBD N
used VBN N
every DT N
night NN N
An DT N
culicifacies NNS N
mortality NN N
was VBD N
> JJ N
80 CD N
% NN N
in IN N
cone NN N
bioassays NNS N
done VBN N
on IN N
LNs NNP N
washed VBD N
up RB N
to TO N
20 CD N
times NNS N
in IN N
laboratory NN N
Mean JJ N
alpha-cypermethrin JJ N
content NN N
was VBD N
43.5 CD N
± JJ N
31.7 CD N
mg/m² NN N
on IN N
Interceptor NNP N
LNs NNP N
withdrawn NN N
after IN N
three CD N
years NNS N
of IN N
household NN N
use NN N
against IN N
the DT N
baseline JJ N
specification NN N
of IN N
200 CD N
mg/m² NN N
A DT N
gradual JJ N
increase NN N
in IN N
the DT N
proportion NN N
of IN N
holed JJ N
nets NNS N
was VBD N
observed VBN N
with IN N
the DT N
increased JJ N
period NN N
of IN N
usage NN N
CONCLUSION NNP N
Interceptor NNP N
nets NNS N
were VBD N
highly RB N
effective JJ N
in IN N
reducing VBG N
vector NN N
densities NNS N
as RB N
well RB N
as IN N
malaria NNS N
incidence NN N
in IN N
the DT N
study NN N
villages NNS N
Availability NNP N
of IN N
78 CD N
% NN N
nets NNS N
with IN N
the DT N
households NNS N
in IN N
usable JJ N
condition NN N
clearly RB N
indicated JJ N
durability NN N
of IN N
Interceptor NNP N
LNs NNP N
up RB N
to TO N
three CD N
years NNS N
in IN N
the DT N
rural JJ N
setting NN N
of IN N
India NNP N
The DT N
nets NNS N
were VBD N
found VBN N
to TO N
contain VB N
an DT N
effective JJ N
concentration NN N
of IN N
alpha-cypermethrin JJ N
against IN N
malaria NNS N
vector NN N
after IN N
three CD N
years NNS N
of IN N
household NN N
use NN N
-DOCSTART- -X- O O 23870440

The DT N
influence NN N
of IN N
fidelity NN N
of IN N
implementation NN N
on IN N
teacher-student JJ 4_p
interaction NN 4_p
quality NN N
in IN N
the DT N
context NN N
of IN N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
the DT N
Responsive NNP N
Classroom NNP N
approach NN N
This DT N
study NN N
examined VBD N
the DT N
direct JJ N
and CC N
indirect JJ N
effects NNS N
between IN N
training NN N
in IN N
the DT N
Responsive NNP N
Classroom® NNP N
( ( N
RC NNP N
) ) N
approach NN N
, , N
teachers NNS N
' POS N
uptake NN N
of IN N
RC NNP N
practices NNS N
, , N
and CC N
teacher-student JJ N
interaction NN N
quality NN N
, , N
using VBG N
a DT N
structural JJ N
equation NN N
modeling VBG N
framework NN N
A DT N
total NN N
of IN N
24 CD 3_p
schools NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
experimental VB N
or CC N
control VB N
conditions NNS N
Third- CD N
and CC N
fourth-grade JJ N
teachers NNS N
in IN N
treatment NN N
schools NNS N
( ( N
n=132 NN 3_p
) ) N
received VBD N
training NN N
in IN N
the DT N
RC NNP N
approach NN N
, , N
whereas JJ N
teachers NNS N
in IN N
control NN N
schools NNS N
( ( N
n=107 NN 3_p
) ) N
continued VBD N
" JJ N
business NN N
as IN N
usual JJ N
" JJ N
Observers NNPS N
rated VBD N
teachers NNS N
' POS N
fidelity NN N
of IN N
implementation NN N
( ( N
FOI NNP N
) ) N
of IN N
RC NNP N
practices NNS N
5 CD N
times NNS N
throughout IN N
the DT N
year NN N
using VBG N
the DT N
Classroom NNP N
Practices NNPS N
Observation NNP N
Measure NNP N
In IN N
addition NN N
, , N
teachers NNS N
completed VBD N
self-report JJ N
measures NNS N
of IN N
FOI NNP N
, , N
the DT N
Classroom NNP N
Practices NNPS N
Teacher NNP N
Survey NNP N
and CC N
Classroom NNP N
Practices NNP N
Frequency NNP N
Survey NNP N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
school NN N
year NN N
Teacher-student JJ N
interactions NNS N
were VBD N
rated VBN N
during IN N
classroom NN N
observations NNS N
using VBG N
the DT N
Classroom NNP N
Assessment NNP N
Scoring NNP N
System NNP N
Controlling VBG N
for IN N
teachers NNS N
' POS N
grade NN N
level NN N
and CC N
teacher-student JJ N
interaction NN N
quality NN N
at IN N
pretest JJS N
, , N
RC NNP N
training NN N
was VBD N
expected VBN N
to TO N
predict VB N
posttest JJS N
teacher-student JJ N
interaction NN N
quality NN N
directly RB N
and CC N
indirectly RB N
through IN N
FOI NNP N
Results NNP N
supported VBD N
only RB N
a DT N
significant JJ N
indirect JJ N
effect NN N
, , N
β=0.85 NNP N
, , N
p=.002 NN N
Specifically RB N
, , N
RC NNP N
teachers NNS N
had VBD N
higher JJR N
levels NNS N
of IN N
FOI NNP N
of IN N
RC NNP N
practices NNS N
, , N
β=1.62 NNP N
, , N
p NN N
< NNP N
.001 NNP N
, , N
R2=.69 NNP N
In IN N
turn NN N
, , N
FOI NNP N
related VBD N
to TO N
greater JJR N
improvement NN N
in IN N
teacher-student JJ N
interaction NN N
quality NN N
, , N
β=0.52 NNP N
, , N
p=.001 NN N
, , N
R2=.32 NNP N
Discussion NNP N
highlights NNS N
factors NNS N
contributing VBG N
to TO N
variability NN N
in IN N
FOI NNP N
and CC N
school NN N
administrators NNS N
roles NNS N
in IN N
supporting VBG N
FOI NNP N
-DOCSTART- -X- O O 20726258

[ JJ N
Effect NNP N
analysis NN N
on IN N
non-and-low JJ N
response NN N
infants NNS 1_p
after IN N
revaccinated VBN N
hepatitis NN 4_p
B NNP 4_p
vaccine NN N
] NN N
OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
booster NN N
immunization NN N
effect NN N
to TO N
non-and-low JJ N
response NN N
children NNS N
after IN N
3 CD N
doses NNS N
HepB NNP N
immunization NN N
METHODS NNP N
Non-and-low JJ N
response NN N
infants NNS 1_p
born VBN N
in IN N
2004 CD 1_p
2005 CD 1_p
administered VBD N
3 CD N
doses NNS N
of IN N
HepB NNP N
at IN N
0 CD N
, , N
1 CD N
, , N
6 CD N
months NNS N
in IN N
Guangzhou NNP N
, , N
Beijing NNP N
and CC N
Zhejiang NNP N
were VBD N
divided VBN N
into IN N
4 CD N
groups NNS N
randomly RB N
, , N
and CC N
boosted VBD N
3 CD N
dose NN N
of IN N
4 CD N
different JJ N
types NNS N
of IN N
HepB NNP N
at IN N
0 CD N
, , N
1 CD N
, , N
6 CD N
months NNS N
RESULTS VB N
The DT N
GMC NNP N
of IN N
non-and-low JJ N
response NN N
children NNS N
in IN N
group NN N
A NNP N
( ( N
before IN N
booster NN N
) ) N
, , N
group NN N
B NNP N
( ( N
after IN N
1 CD N
dose JJ N
booster NN N
) ) N
and CC N
group NN N
C NNP N
( ( N
after IN N
3 CD N
dose JJ N
booster NN N
) ) N
were VBD N
18.66 CD N
mIUml NN N
, , N
88.82 CD N
mIU/ml NN N
, , N
178.24 CD N
mIU/ml NN N
respectively RB N
; : N
the DT N
proportion NN N
of IN N
non-responders NNS N
in IN N
three CD N
groups NNS N
were VBD N
20.4 CD N
% NN N
, , N
9.1 CD N
% NN N
, , N
1.9 CD N
% NN N
respectively RB N
In IN N
103 CD 3_p
non-and-low JJ N
response NN N
children NNS 1_p
, , N
proportion NN N
of IN N
titers NNS N
of IN N
more JJR N
than IN N
100 CD N
mIU/ml NN N
of IN N
group NN N
B NNP N
and CC N
group NN N
C NNP N
were VBD N
61.2 CD N
% NN N
and CC N
84.5 CD N
% NN N
, , N
and CC N
there RB N
was VBD N
statistical JJ N
significant JJ N
difference NN N
( ( N
chi2 JJ N
= NN N
14.13 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
The DT N
GMC NNP N
after IN N
3 CD N
doses NNS N
revaccination NN N
with IN N
four CD N
kinds NNS N
of IN N
HepB NNP N
, , N
included VBD N
5 CD N
microg NN N
HepB-Y NNP N
, , N
10 CD N
microg NN N
HepB-Y NNP N
, , N
l0 JJ N
microg NN N
HepB-CHO NNP N
, , N
10 CD N
microg JJ N
HepB-HY NNP N
were VBD N
168.8 CD N
mJU/ml NN N
, , N
174.7 CD N
mIU/ml NN N
, , N
184.9 CD N
mIU/ml NN N
, , N
182.9 CD N
mIU/ml NN N
respectively RB N
Proportion NN N
of IN N
titers NNS N
of IN N
more JJR N
than IN N
100 CD N
mIU/ml NNS N
for IN N
four CD N
kinds NNS N
HepB NNP N
were VBD N
79.0 CD N
% NN N
, , N
85.7 CD N
% NN N
, , N
88.2 CD N
% NN N
and CC N
84.6 CD N
% NN N
respectively RB N
, , N
and CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
( ( N
chi2 JJ N
= NN N
0.75 CD N
, , N
0.05 CD N
) ) N
CONCLUSION NN N
There EX N
were VBD N
no DT N
different JJ N
of IN N
seroconversion NN N
rate NN N
between IN N
study NN N
population NN N
received VBD N
1 CD N
dose NN N
and CC N
3 CD N
dose JJ N
booster NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
, , N
but CC N
high JJ N
titer NN N
was VBD N
observed VBN N
after IN N
3 CD N
dose JJ N
booster NN N
The DT N
four CD N
kinds NNS N
of IN N
HepB NNP N
, , N
including VBG N
5 CD N
microg JJ N
HepB-Y,10 NNP N
microg NN N
HepB-Y NNP N
, , N
10 CD N
microg NN N
HepB-CHO NNP N
, , N
10 CD N
microg NN N
HepB-HY NNP N
had VBD N
the DT N
same JJ N
immunization NN N
effect NN N
after IN N
3 CD N
doses NNS N
revaccination NN N
at IN N
0 CD N
, , N
1 CD N
, , N
6 CD N
months NNS N
to TO N
non-and-low JJ N
response NN N
children NNS N
-DOCSTART- -X- O O 9437974

The DT N
accuracy NN N
of IN N
clinical JJ N
neurosensory NN N
testing VBG N
for IN N
nerve JJ N
injury NN N
diagnosis NN N
PURPOSE VB N
The DT N
accuracy NN N
of IN N
the DT N
clinical JJ N
neurosensory JJ N
test NN N
to TO N
diagnose VB N
trigeminal JJ N
nerve NN N
injuries NNS N
has VBZ N
never RB N
been VBN N
statistically RB N
evaluated VBN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
statistical JJ N
efficacy NN N
of IN N
the DT N
clinical JJ N
neurosensory JJ N
test NN N
using VBG N
surgical JJ N
findings NNS N
as IN N
the DT N
" NNP N
gold NN N
" NNP N
standard NN N
, , N
and CC N
to TO N
determine VB N
whether IN N
a DT N
correlation NN N
existed VBN N
between IN N
the DT N
sensory JJ N
impairment NN N
score NN N
obtained VBN N
by IN N
preoperative JJ N
testing NN N
and CC N
the DT N
degree NN N
of IN N
nerve NN N
injury NN N
found VBD N
at IN N
surgery NN N
MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
multisite NN N
, , N
randomized VBN N
, , N
prospective JJ N
, , N
blinded VBD N
, , N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
on IN N
130 CD N
patients NNS N
with IN N
inferior JJ N
alveolar JJ N
nerve NN N
( ( N
IAN NNP N
) ) N
and CC N
lingual JJ N
nerve NN N
( ( N
LN NNP N
) ) N
injuries NNS N
Preoperatively RB N
, , N
patients NNS N
were VBD N
provided VBN N
a DT N
sensory JJ N
impairment NN N
score NN N
using VBG N
a DT N
three-level JJ N
drop-out JJ N
clinical JJ N
neurosensory NN N
test NN N
( ( N
NST NNP N
) ) N
, , N
and CC N
blind IN N
comparisons NNS N
were VBD N
made VBN N
with IN N
the DT N
surgical JJ N
findings NNS N
postoperatively RB N
RESULTS VB N
The DT N
positive JJ N
predictive NN N
and CC N
negative JJ N
predictive NN N
values NNS N
for IN N
LN-injured JJ N
patients NNS N
were VBD N
95 CD N
% NN N
and CC N
100 CD N
% NN N
, , N
respectively RB N
The DT N
positive JJ N
predictive NN N
and CC N
negative JJ N
predictive NN N
values NNS N
for IN N
IAN NNP N
patients NNS N
were VBD N
77 CD N
% NN N
and CC N
60 CD N
% NN N
, , N
respectively RB N
There EX N
were VBD N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
distribution NN N
of IN N
age NN N
, , N
duration NN N
of IN N
injury NN N
, , N
cause NN N
of IN N
injury NN N
, , N
presence NN N
of IN N
neuropathic JJ N
pain NN N
, , N
presence NN N
of IN N
trigger NN N
pain NN N
, , N
and CC N
degree NN N
of IN N
injury NN N
between IN N
the DT N
IAN NNP N
and CC N
LN NNP N
patient JJ N
populations NNS N
There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
positive JJ N
relationship NN N
found VBD N
between IN N
the DT N
sensory JJ N
impairment NN N
score NN N
and CC N
the DT N
degree NN N
of IN N
nerve NN N
injury NN N
CONCLUSIONS VB N
The DT N
NST NNP N
is VBZ N
a DT N
clinically RB N
useful JJ N
method NN N
to TO N
diagnose VB N
IAN NNP N
and CC N
LN NNP N
injuries NNS N
However RB N
, , N
the DT N
NST NNP N
results NNS N
are VBP N
less RBR N
efficient JJ N
for IN N
IAN NNP N
injuries NNS N
than IN N
LN NNP N
injuries NNS N
, , N
and CC N
have VBP N
a DT N
high JJ N
incidence NN N
of IN N
false-positive JJ N
( ( N
23 CD N
% NN N
) ) N
and CC N
false-negative JJ N
( ( N
40 CD N
% NN N
) ) N
results NNS N
when WRB N
testing VBG N
patients NNS 4_p
with IN 4_p
IAN NNP 4_p
injuries NNS 4_p
The DT N
different JJ N
rates NNS N
of IN N
statistical JJ N
efficiency NN N
between IN N
the DT N
two CD N
groups NNS N
of IN N
patients NNS N
may MD N
be VB N
attributable JJ N
to TO N
differences NNS N
in IN N
prevalence NN N
and CC N
biologic NN N
covariates NNS N
-DOCSTART- -X- O O 20932687

Late JJ N
patient-reported JJ N
toxicity NN N
after IN N
preoperative JJ N
radiotherapy NN N
or CC N
chemoradiotherapy NN N
in IN N
nonresectable JJ 4_p
rectal JJ 4_p
cancer NN 4_p
: : N
results NNS N
from IN N
a DT N
randomized JJ N
Phase NNP N
III NNP N
study NN N
PURPOSE NNP N
Preoperative NNP N
chemoradiotherapy NN N
( ( N
CRT NNP N
) ) N
is VBZ N
superior JJ N
to TO N
radiotherapy VB N
( ( N
RT NNP N
) ) N
in IN N
locally RB 4_p
advanced JJ 4_p
rectal JJ 4_p
cancer NN 4_p
, , N
but CC N
the DT N
survival JJ N
gain NN N
is VBZ N
limited JJ N
Late JJ N
toxicity NN N
is VBZ N
, , N
therefore RB N
, , N
important JJ N
The DT N
aim NN N
was VBD N
to TO N
compare VB N
late JJ N
bowel NN N
, , N
urinary JJ N
, , N
and CC N
sexual JJ N
functions NNS N
after IN N
CRT NNP N
or CC N
RT NNP N
METHODS NNP N
AND CC N
MATERIALS NNP N
Patients NNP N
( ( N
N NNP N
= NNP N
207 CD 3_p
) ) N
with IN N
nonresectable JJ 4_p
rectal JJ 4_p
cancer NN 4_p
were VBD N
randomized VBN N
to TO N
preoperative VB N
CRT NNP N
or CC N
RT NNP N
( ( N
2 CD N
Gy NNP N
× VBD N
25 CD N
± NNP N
5-fluorouracil/leucovorin JJ N
) ) N
Extended VBN N
surgery NN N
was VBD N
often RB N
required VBN N
Self-reported JJ N
late JJ N
toxicity NN N
was VBD N
scored VBN N
according VBG N
to TO N
the DT N
LENT NNP N
SOMA NNP N
criteria NNS N
in IN N
a DT N
structured JJ N
telephone NN N
interview NN N
and CC N
with IN N
questionnaires NNS N
European JJ N
Organisation NNP N
for IN N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
( ( N
EORTC NNP N
) ) N
Quality NN N
of IN N
Life NNP N
Questionnaire NNP N
( ( N
QLQ-C30 NNP N
) ) N
, , N
International NNP N
Index NNP N
of IN N
Erectile NNP N
Function NNP N
( ( N
IIEF NNP N
) ) N
, , N
and CC N
sexual JJ N
function-vaginal JJ N
changes NNS N
questionnaire VBP N
( ( N
SVQ NNP N
) ) N
RESULTS NNP N
Of IN N
the DT N
105 CD 3_p
patients NNS N
alive JJ N
in IN N
Norway NNP N
and CC N
Sweden NNP N
after IN N
4 CD N
to TO N
12 CD N
years NNS N
of IN N
follow-up NN N
, , N
78 CD N
( ( N
74 CD N
% NN N
) ) N
responded VBD N
More JJR N
patients NNS N
in IN N
the DT N
CRT NNP N
group NN N
had VBD N
received VBN N
a DT N
stoma NN N
( ( N
73 CD N
% NN N
vs. FW N
52 CD N
% NN N
, , N
p NN N
= NNP N
0.09 CD N
) ) N
Most JJS N
patients NNS N
without IN N
a DT N
stoma NN N
( ( N
7 CD N
of IN N
12 CD N
in IN N
CRT NNP N
group NN N
and CC N
9 CD N
of IN N
16 CD N
in IN N
RT NNP N
group NN N
) ) N
had VBD N
incontinence NN N
for IN N
liquid NN N
stools NNS N
or CC N
gas NN N
No DT N
stoma NN N
and CC N
good JJ N
anal JJ N
function NN N
were VBD N
seen VBN N
in IN N
5 CD N
patients NNS N
( ( N
11 CD N
% NN N
) ) N
in IN N
the DT N
CRT NNP N
group NN N
and CC N
in IN N
11 CD N
( ( N
30 CD N
% NN N
) ) N
in IN N
the DT N
RT NNP N
group NN N
( ( N
p JJ N
= NNP N
0.046 CD N
) ) N
Of IN N
44 CD N
patients NNS N
in IN N
the DT N
CRT NNP N
group NN N
, , N
12 CD N
( ( N
28 CD N
% NN N
) ) N
had VBD N
had VBN N
bowel VBN N
obstruction NN N
compared VBN N
with IN N
5 CD N
of IN N
33 CD N
( ( N
15 CD N
% NN N
) ) N
in IN N
the DT N
RT NNP N
group NN N
( ( N
p JJ N
= NNP N
0.27 CD N
) ) N
One-quarter NN N
of IN N
the DT N
patients NNS N
reported VBD N
urinary JJ N
incontinence NN N
The DT N
majority NN N
of IN N
men NNS N
had VBD N
severe JJ N
erectile JJ N
dysfunction NN N
Few JJ N
women NNS N
reported VBD N
sexual JJ N
activity NN N
during IN N
the DT N
previous JJ N
month NN N
However RB N
, , N
the DT N
majority NN N
did VBD N
not RB N
have VB N
concerns NNS N
about IN N
their PRP$ N
sex NN N
life NN N
CONCLUSIONS NNP N
Fecal NNP N
incontinence NN N
and CC N
erectile JJ N
dysfunction NN N
are VBP N
frequent JJ N
after IN N
combined JJ N
treatment NN N
for IN N
locally RB N
advanced JJ N
rectal JJ N
cancer NN N
There EX N
was VBD N
a DT N
clear JJ N
tendency NN N
for IN N
the DT N
problems NNS N
to TO N
be VB N
more JJR N
common JJ N
after IN N
CRT NNP N
than IN N
after IN N
RT NNP N
-DOCSTART- -X- O O 22572567

Roles NNS N
of IN N
adapalene NN N
in IN N
the DT N
treatment NN N
of IN N
pityriasis NN 4_p
versicolor NN 4_p
BACKGROUND NNP N
Ketoconazole NNP N
is VBZ N
a DT N
typical JJ N
treatment NN N
available JJ N
for IN N
pityriasis NN 4_p
versicolor NN 4_p
; : N
tretinoin CC N
cream NN N
is VBZ N
effective JJ N
, , N
too RB N
Adapalene NNP N
gel NN N
is VBZ N
a DT N
tretinoin JJ N
derivative NN N
and CC N
has VBZ N
a DT N
lower JJR N
incidence NN N
of IN N
irritation NN N
compared VBN N
with IN N
other JJ N
topical JJ N
retinoid NN N
products NNS N
However RB N
, , N
there EX N
are VBP N
no DT N
reports NNS N
on IN N
adapalene NN N
gel NN N
for IN N
the DT N
treatment NN N
of IN N
pityriasis NN 4_p
versicolor NN 4_p
OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
of IN N
adapalene NN N
gel NN N
comparing VBG N
the DT N
treatment NN N
with IN N
adapalene JJ N
gel NNS N
and CC N
2 CD N
% NN N
ketoconazole JJ N
cream NN N
in IN N
pityriasis NN 4_p
versicolor NN 4_p
METHODS NNP N
Eighty NNP 3_p
patients NNS N
suffering VBG N
from IN N
pityriasis NN 4_p
versicolor NN 4_p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
; : N
one CD N
group NN N
were VBD N
treated VBN N
with IN N
2 CD N
% NN N
ketoconazole JJ N
cream NN N
topically RB N
twice JJ N
daily RB N
for IN N
2 CD N
weeks NNS N
, , N
adapalene JJ N
gel NN N
was VBD N
used VBN N
for IN N
the DT N
other JJ N
group NN N
in IN N
a DT N
similar JJ N
fashion NN N
RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
efficacy NN N
between IN N
the DT N
two CD N
groups NNS N
No DT N
major JJ N
side NN N
effects NNS N
were VBD N
noted VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
either CC N
CONCLUSION NNP N
Adapalene NNP N
was VBD N
the DT N
favorable JJ N
option NN N
in IN N
the DT N
treatment NN N
of IN N
pityriasis NN 4_p
versicolor NN 4_p
The DT N
probable JJ N
therapeutic JJ N
mechanism NN N
of IN N
adapalene NN N
is VBZ N
also RB N
discussed VBN N
-DOCSTART- -X- O O 8657237

Comparison NNP N
of IN N
coronary JJ N
bypass NN N
surgery NN N
with IN N
angioplasty NN N
in IN N
patients NNS 4_p
with IN 4_p
multivessel JJ 4_p
disease NN 4_p
The DT N
Bypass NNP N
Angioplasty NNP N
Revascularization NNP N
Investigation NNP N
( ( N
BARI NNP N
) ) N
Investigators NNPS N
BACKGROUND NNP N
Coronary-artery JJ N
bypass NN N
grafting NN N
( ( N
CABG NNP N
) ) N
and CC N
percutaneous JJ N
transluminal JJ N
coronary NN N
angioplasty NN N
( ( N
PTCA NNP N
) ) N
are VBP N
alternative JJ N
methods NNS N
of IN N
revascularization NN N
in IN N
patients NNS 4_p
with IN 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
We PRP N
tested VBD N
the DT N
hypothesis NN N
that IN N
in IN N
selected JJ N
patients NNS N
with IN N
multivessel JJ N
disease NN N
suitable JJ N
for IN N
treatment NN N
with IN N
either DT N
procedure NN N
, , N
an DT N
initial JJ N
strategy NN N
of IN N
PTCA NNP N
does VBZ N
not RB N
result VB N
in IN N
a DT N
poorer JJR N
five-year JJ N
clinical JJ N
outcome NN N
than IN N
CABG NNP N
METHODS NNP N
Patients NNPS N
with IN N
multivessel JJ N
disease NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
initial JJ N
treatment NN N
strategy NN N
of IN N
CABG NNP N
( ( N
n JJ N
= NNP N
914 CD N
) ) N
or CC N
PTCA NNP N
( ( N
n JJ N
= NNP N
915 CD N
) ) N
and CC N
were VBD N
followed VBN N
for IN N
an DT N
average NN N
of IN N
5.4 CD N
years NNS N
Analysis NN N
of IN N
outcome JJ N
events NNS N
was VBD N
performed VBN N
according VBG N
to TO N
the DT N
intention NN N
to TO N
treat VB N
RESULTS VB N
The DT N
respective JJ N
in-hospital JJ N
event NN N
rates NNS N
for IN N
CABG NNP N
and CC N
PTCA NNP N
were VBD N
1.3 CD N
percent NN N
and CC N
1.1 CD N
percent NN N
for IN N
mortality NN N
, , N
4.6 CD N
percent NN N
and CC N
2.1 CD N
percent NN N
for IN N
Q-wave NNP N
myocardial JJ N
infarction NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
0.8 CD N
percent NN N
and CC N
0.2 CD N
percent NN N
for IN N
stroke NN N
The DT N
five-year JJ N
survival NN N
rate NN N
was VBD N
89.3 CD N
percent NN N
for IN N
those DT N
assigned VBN N
to TO N
CABG NNP N
and CC N
86.3 CD N
percent NN N
for IN N
those DT N
assigned VBN N
to TO N
PTCA NNP N
( ( N
P NNP N
= NNP N
0.19 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
of IN N
the DT N
difference NN N
in IN N
survival NN N
, , N
-0.2 JJ N
percent NN N
to TO N
6.0 CD N
percent NN N
) ) N
The DT N
respective JJ N
five-year JJ N
survival NN N
rates NNS N
free VBP N
from IN N
Q-wave NNP N
myocardial JJ N
infarction NN N
were VBD N
80.4 CD N
percent NN N
and CC N
78.7 CD N
percent NN N
By IN N
five CD N
years NNS N
after IN N
study NN N
entry NN N
, , N
8 CD N
percent NN N
of IN N
the DT N
patients NNS N
assigned VBD N
to TO N
CABG NNP N
had VBD N
undergone JJ N
additional JJ N
revascularization NN N
procedures NNS N
, , N
as IN N
compared VBN N
with IN N
54 CD N
percent NN N
of IN N
those DT N
assigned VBN N
to TO N
PTCA NNP N
; : N
69 CD N
percent NN N
of IN N
those DT N
assigned VBN N
to TO N
PTCA NNP N
did VBD N
not RB N
subsequently RB N
undergo JJ N
CABG NNP N
Among IN 4_p
diabetic JJ 4_p
patients NNS 4_p
who WP 4_p
were VBD 4_p
being VBG 4_p
treated VBN 4_p
with IN 4_p
insulin NN 4_p
or CC 4_p
oral JJ 4_p
hypoglycemic JJ 4_p
agents NNS 4_p
at IN 4_p
base NN 4_p
line NN 4_p
, , N
a DT N
subgroup NN N
not RB N
specified VBN N
by IN N
the DT N
protocol NN N
, , N
five-year JJ N
survival NN N
was VBD N
80.6 CD N
percent NN N
for IN N
the DT N
CABG NNP N
group NN N
as IN N
compared VBN N
with IN N
65.5 CD N
percent NN N
for IN N
the DT N
PTCA NNP N
group NN N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
CONCLUSIONS NNP N
As IN N
compared VBN N
with IN N
CABG NNP N
, , N
an DT N
initial JJ N
strategy NN N
of IN N
PTCA NNP N
did VBD N
not RB N
significantly RB N
compromise VB N
five-year JJ N
survival NN N
in IN N
patients NNS N
with IN N
multivessel JJ N
disease NN N
, , N
although IN N
subsequent JJ N
revascularization NN N
was VBD N
required VBN N
more RBR N
often RB N
with IN N
this DT N
strategy NN N
For IN N
treated JJ N
diabetics NNS N
, , N
five-year JJ N
survival NN N
was VBD N
significantly RB N
better JJR N
after IN N
CABG NNP N
than IN N
after IN N
PTCA NNP N
-DOCSTART- -X- O O 24898574

Changes NNS N
in IN N
motor NN N
cortex NN N
excitability NN N
associated VBN N
with IN N
temporal JJ N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
in IN N
tinnitus NN 4_p
: : N
hints NNS N
for IN N
cross-modal JJ N
plasticity NN N
? . N
BACKGROUND NNP N
Motor NNP N
cortex VBP N
excitability NN N
was VBD N
found VBN N
to TO N
be VB N
changed VBN N
after IN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
( ( N
rTMS NN N
) ) N
of IN N
the DT N
temporal JJ N
cortex NN N
highlighting VBG N
the DT N
occurrence NN N
of IN N
cross-modal JJ N
plasticity NN N
in IN N
non-invasive JJ N
brain NN N
stimulation NN N
Here RB N
, , N
we PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
temporal JJ N
low-frequency NN N
rTMS NN N
on IN N
motor NN N
cortex NN N
plasticity NN N
in IN N
a DT N
large JJ N
sample NN N
of IN N
tinnitus NN 4_p
patients NNS N
In IN N
116 CD 3_p
patients NNS N
with IN N
chronic JJ N
tinnitus NN 4_p
different JJ N
parameters NNS N
of IN N
cortical JJ N
excitability NN N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
ten JJ N
rTMS JJ N
treatment NN N
sessions NNS N
Patients NNS N
received VBD N
one CD N
of IN N
three CD N
different JJ N
protocols NNS N
all DT N
including VBG N
1 CD N
Hz NNP N
rTMS NN N
over IN N
the DT N
left JJ N
temporal JJ N
cortex NN N
Treatment NNP N
response NN N
was VBD N
defined VBN N
as IN N
improvement NN N
by IN N
at IN N
least JJS N
five CD N
points NNS N
in IN N
the DT N
tinnitus NN N
questionnaire NN N
( ( N
TQ NNP N
) ) N
Variables NNS N
of IN N
interest NN N
were VBD N
resting VBG N
motor NN N
threshold NN N
( ( N
RMT NNP N
) ) N
, , N
short-interval JJ N
intra-cortical JJ N
inhibition NN N
( ( N
SICI NNP N
) ) N
, , N
intracortical JJ N
facilitation NN N
( ( N
ICF NNP N
) ) N
, , N
and CC N
cortical JJ N
silent JJ N
period NN N
( ( N
CSP NNP N
) ) N
RESULTS NNP N
After IN N
rTMS JJ N
treatment NN N
RMT NNP N
was VBD N
decreased VBN N
by IN N
about IN N
1 CD N
% NN N
of IN N
stimulator NN N
output NN N
near-significantly RB N
in IN N
the DT N
whole JJ N
group NN N
of IN N
patients NNS N
SICI NNP N
was VBD N
associated VBN N
with IN N
significant JJ N
changes NNS N
with IN N
respect NN N
to TO N
treatment NN N
response NN N
The DT N
group NN N
of IN N
treatment NN N
responders NNS N
showed VBD N
a DT N
decrease NN N
of IN N
SICI NNP N
over IN N
the DT N
course NN N
of IN N
treatment NN N
, , N
the DT N
group NN N
of IN N
non-responders NNS N
the DT N
reverse NN N
pattern NN N
CONCLUSIONS NNP N
Minor NNP N
RMT NNP N
changes NNS N
during IN N
rTMS NN N
treatment NN N
do VBP N
not RB N
necessarily RB N
suggest VB N
the DT N
need NN N
for IN N
systematic JJ N
re-examination NN N
of IN N
the DT N
RMT NNP N
for IN N
safety NN N
and CC N
efficacy NN N
issues NNS N
Treatment NNP N
response NN N
to TO N
rTMS VB N
was VBD N
shown VBN N
to TO N
be VB N
related VBN N
to TO N
changes NNS N
in IN N
SICI NNP N
that WDT N
might MD N
reflect VB N
modulation NN N
of IN N
GABAergic NNP N
mechanisms FW N
directly RB N
or CC N
indirectly RB N
related VBN N
to TO N
rTMS VB N
treatment NN N
effects NNS N
-DOCSTART- -X- O O 161652

Aortic JJ N
valve NN N
replacement NN N
A DT N
randomized JJ N
study NN N
comparing VBG N
the DT N
Björk-Shiley NNP N
and CC N
Lillehei-Kaster NNP N
disc NN N
valves NNS N
Late JJ N
haemodynamics NNS N
related VBN N
to TO N
clinical JJ N
results NNS N
In IN N
this DT N
study NN N
, , N
78 CD 3_p
randomized VBD N
patients NNS N
with IN N
either DT N
Björk-Shiley NNP N
( ( N
B-S NNP N
) ) N
or CC N
Lillehei-Kaster JJ N
( ( N
L-K NNP N
) ) N
aortic JJ N
disc NN N
valve NN N
prostheses NNS N
were VBD N
re-admitted JJ N
for IN N
clinical JJ N
and CC N
haemodynamic JJ N
evaluation NN N
The DT N
patients NNS N
were VBD N
selected VBN N
that IN N
those DT N
with IN N
narrow JJ N
aortic JJ N
roots NNS N
were VBD N
over-represented JJ N
Cine-aortography NN N
was VBD N
carried VBN N
out RP N
in IN N
75 CD 3_p
patients NNS N
and CC N
left VBD N
ventricular JJ N
catheterisation NN N
via IN N
the DT N
transseptal JJ N
approach NN N
was VBD N
performed VBN N
in IN N
42 CD 3_p
The DT N
clinical JJ N
improvement NN N
was VBD N
striking VBG N
, , N
although IN N
the DT N
number NN N
of IN N
patients NNS N
still RB N
incapacitated VBN N
was VBD N
relatively RB N
large JJ N
in IN N
patients NNS N
with IN N
the DT N
small JJ N
L-K JJ N
valves NNS N
( ( N
Nos NNP N
14 CD N
& CC N
16 CD N
) ) N
Peak-to-peak JJ N
and CC N
mean JJ N
systolic JJ N
pressure NN N
differences NNS N
across IN N
the DT N
valves NNS N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
B-S NNP N
than IN N
in IN N
the DT N
L-K NNP N
valves NNS N
, , N
particularly RB N
when WRB N
the DT N
small JJ N
valve NN N
sizes NNS N
were VBD N
compared VBN N
Left NNP N
ventricular JJ N
end-diastolic JJ N
pressure NN N
( ( N
LVEDP NNP N
) ) N
, , N
which WDT N
was VBD N
elevated VBN N
in IN N
most JJS N
patients NNS N
before IN N
operation NN N
, , N
decreased VBN N
significantly RB N
to TO N
normal JJ N
levels NNS N
in IN N
the DT N
B-S NNP N
group NN N
In IN N
the DT N
L-K NNP N
group NN N
, , N
LVEDP NNP N
did VBD N
not RB N
decrease VB N
significantly RB N
and CC N
was VBD N
on IN N
the DT N
average NN N
still RB N
above IN N
the DT N
normal JJ N
level NN N
after IN N
operation NN N
, , N
probably RB N
due JJ N
to TO N
the DT N
relatively RB N
large JJ N
pressure NN N
gradients NNS N
The DT N
study NN N
indicates VBZ N
that IN N
the DT N
L-K NNP N
valves NNS N
Nos NNP N
14 CD N
& CC N
16 CD N
in IN N
particular JJ N
represents VBZ N
a DT N
resistance NN N
to TO N
flow VB N
that DT N
is VBZ N
too RB N
large JJ N
to TO N
be VB N
acceptable JJ N
in IN N
clinical JJ N
practice NN N
-DOCSTART- -X- O O 12478408

A DT N
randomized JJ N
prospective NN N
controlled VBN N
trial NN N
of IN N
oral JJ N
ganciclovir NN N
versus IN N
oral JJ N
valacyclovir NN N
for IN N
prophylaxis NN N
of IN N
cytomegalovirus NN N
disease NN N
after IN N
renal JJ 4_p
transplantation NN 4_p
Oral NNP N
ganciclovir NN N
and CC N
valacyclovir NN N
reduce VB N
the DT N
incidence NN N
of IN N
cytomegalovirus NN N
( ( N
CMV NNP N
) ) N
disease NN N
after IN N
renal JJ N
transplantation NN N
( ( N
RTx NNP N
) ) N
Our PRP$ N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
efficacy NN N
, , N
costs NNS N
, , N
and CC N
safety NN N
of IN N
oral JJ N
ganciclovir NN N
and CC N
valacyclovir NN N
in IN N
the DT N
prophylaxis NN N
of IN N
CMV NNP N
disease NN N
over IN N
the DT N
first JJ N
6 CD N
months NNS N
after IN N
RTx NNP N
A NNP N
total NN N
of IN N
38 CD N
patients NNS N
was VBD N
randomized VBN N
to TO N
3-month JJ N
treatment NN N
with IN N
either DT N
oral JJ N
ganciclovir NN N
( ( N
1 CD N
g NN N
t.i.d. NN N
, , N
n=14 RB N
, , N
GAN NNP N
group NN N
) ) N
or CC N
oral JJ N
valacyclovir NN N
( ( N
2 CD N
g NN N
q.i.d. NN N
, , N
n=12 RB N
, , N
VAL NNP N
group NN N
) ) N
A DT N
third JJ N
group NN N
( ( N
C NNP N
, , N
n=12 NN N
) ) N
received VBD N
no DT N
prophylaxis NN N
The DT N
patients NNS N
were VBD N
monitored VBN N
by IN N
CMV-nested JJ N
PCR NNP N
in IN N
whole JJ N
blood NN N
No DT N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
in IN N
their PRP$ N
demographic JJ N
characteristics NNS N
, , N
immunosuppressive JJ N
protocols NNS N
, , N
or CC N
donor NN N
and CC N
recipient NN N
CMV NNP N
serology NN N
Thirty-six CD N
out IN N
of IN N
38 CD N
( ( N
94.7 CD N
% NN N
) ) N
recipients NNS N
were VBD N
CMV-seropositive JJ N
Over IN N
the DT N
6-month JJ N
post-RTx JJ N
period NN N
, , N
there EX N
were VBD N
13 CD N
episodes NNS N
of IN N
CMV NNP N
disease NN N
in IN N
eight CD N
( ( N
66.7 CD N
% NN N
) ) N
patients NNS N
of IN N
the DT N
C NNP N
group NN N
compared VBN N
with IN N
none NN N
in IN N
the DT N
GAN NNP N
and CC N
VAL NNP N
groups NNS N
( ( N
P=0.0005 NNP N
, , N
GAN NNP N
vs NNP N
C NNP N
; : N
P=0.001 NNP N
, , N
VAL NNP N
vs NNP N
C NNP N
) ) N
The DT N
incidence NN N
of IN N
CMV NNP N
viremia NN N
was VBD N
30.8 CD N
% NN N
, , N
50.0 CD N
% NN N
, , N
and CC N
91.7 CD N
% NN N
in IN N
the DT N
GAN NNP N
, , N
VAL NNP N
, , N
and CC N
C NNP N
groups NNS N
, , N
respectively RB N
( ( N
P=0.004 NNP N
, , N
GAN NNP N
vs NNP N
C NNP N
; : N
P=0.07 NNP N
, , N
VAL NNP N
vs NNP N
C NNP N
; : N
P=NS NNP N
, , N
GAN NNP N
vs NNP N
VAL NNP N
) ) N
Treatment JJ N
failure NN N
( ( N
death NN N
, , N
graft NN N
loss NN N
, , N
CMV NNP N
disease NN N
, , N
or CC N
withdrawal NN N
from IN N
study NN N
) ) N
occurred VBD N
in IN N
14.3 CD N
% NN N
, , N
0 CD N
% NN N
and CC N
66.7 CD N
% NN N
in IN N
the DT N
GAN NNP N
, , N
VAL NNP N
, , N
and CC N
C NNP N
groups NNS N
, , N
respectively RB N
( ( N
P=0.014 NNP N
, , N
GAN NNP N
vs NNP N
C NNP N
; : N
P=0.001 NNP N
, , N
VAL NNP N
vs NNP N
C NNP N
; : N
P=NS NNP N
, , N
GAN NNP N
vs NNP N
VAL NNP N
) ) N
The DT N
average JJ N
CMV-associated JJ N
costs NNS N
per IN N
patient NN N
( ( N
in IN N
2001 CD N
euros NN N
) ) N
were VBD N
2,449+/-1,178 JJ N
, , N
2,485+/-581 JJ N
, , N
and CC N
4,259+/-4,616 JJ N
in IN N
the DT N
GAN NNP N
, , N
VAL NNP N
, , N
and CC N
C NNP N
groups NNS N
, , N
respectively RB N
Ganciclovir NNP N
and CC N
valacyclovir NN N
were VBD N
well RB N
tolerated VBN N
, , N
with IN N
ganciclovir JJ N
having VBG N
had VBD N
to TO N
be VB N
withdrawn VBN N
shortly RB N
in IN N
one CD N
patient NN N
only RB N
because IN N
of IN N
thrombocytopenia NN N
In IN N
conclusion NN N
, , N
oral JJ N
ganciclovir NN N
and CC N
valacyclovir NN N
are VBP N
equally RB N
safe JJ N
and CC N
effective JJ N
in IN N
the DT N
prophylaxis NN N
of IN N
CMV NNP N
disease NN N
after IN N
RTx NNP N
Both DT N
are VBP N
cost-effective JJ N
and CC N
help VB N
reduce VB N
CMV-associated JJ N
costs NNS N
by IN N
some DT N
40 CD N
% NN N
compared VBN N
with IN N
patients NNS N
without IN N
prophylaxis NN N
-DOCSTART- -X- O O 1411449

[ JJ N
Physical NNP N
performance NN N
and CC N
sedation NN N
: : N
comparative JJ N
study NN N
of IN N
the DT N
effects NNS N
of IN N
a DT N
benzodiazepine NN N
( ( N
temazepam NN N
) ) N
and CC N
of IN N
a DT N
non-benzodiazepine JJ N
hypnotic NN N
( ( N
zolpidem NN N
) ) N
] NN N
It PRP N
is VBZ N
well-known JJ N
that IN N
many JJ N
athletes NNS N
experience VBP N
some DT N
form NN N
of IN N
precompetition NN N
stress NN N
that WDT N
may MD N
result VB N
in IN N
insomnia NN N
during IN N
the DT N
night NN N
before IN N
their PRP$ N
competition NN N
Yet CC N
, , N
sleep VBP N
withdrawal NN N
even RB N
if IN N
only RB N
partial JJ N
, , N
has VBZ N
a DT N
negative JJ N
influence NN N
on IN N
performance NN N
, , N
particularly RB N
when WRB N
the DT N
type NN N
of IN N
exercise NN N
requires VBZ N
good JJ N
psychomotor NN N
performance NN N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
intake NN N
of IN N
a DT N
hypnotic JJ N
drug NN N
would MD N
have VB N
negative JJ N
effects NNS N
on IN N
physical JJ N
performance NN N
capacity NN N
The DT N
authors NNS N
have VBP N
compared VBN N
the DT N
effects NNS N
of IN N
oral JJ N
temazepam NN N
, , N
a DT N
medium NN N
half-life JJ N
benzodiazepine NN N
vs IN N
oral JJ N
zolpidem NN N
, , N
a DT N
short JJ N
half-life JJ N
non-benzodiazepine JJ N
drug NN N
, , N
vs NN N
placebo NN N
A DT N
randomized JJ N
double-blind JJ N
trial NN N
was VBD N
used VBN N
to TO N
assess VB N
endurance NN N
, , N
resistance NN N
, , N
strength NN N
and CC N
coordination NN N
in IN N
26 CD 3_p
athletes NNS 3_p
The DT N
results NNS N
did VBD N
not RB N
show VB N
any DT N
differences NNS N
between IN N
the DT N
three CD N
groups NNS N
, , N
neither CC N
in IN N
physical JJ N
performance NN N
characteristic JJ N
nor CC N
in IN N
coordination NN N
It PRP N
is VBZ N
concluded VBN N
that IN N
as IN N
regards NNS N
the DT N
performance NN N
capacity NN N
, , N
there EX N
is VBZ N
no DT N
risk NN N
for IN N
stressed JJ 4_p
athletes NNS N
to TO N
use VB N
sleep JJ N
inducers NNS N
the DT N
night NN N
before IN N
their PRP$ N
competition NN N
-DOCSTART- -X- O O 1751081

Is VBZ N
Na+ NNP N
modeling VBG N
necessary JJ N
in IN N
high JJ N
flux NN N
dialysis NN N
? . N
One CD N
important JJ N
pathogenic JJ N
factor NN N
in IN N
dialysis NN N
hypotension NN N
is VBZ N
the DT N
drop NN N
in IN N
plasma JJ N
osmolality NN N
Increasing VBG N
the DT N
dialysate NN N
Na+ NNP N
concentration NN N
decreases VBZ N
hypotensive JJ N
episodes NNS N
The DT N
authors NNS N
studied VBD N
39 CD N
patients NNS N
being VBG N
treated VBN N
with IN N
high JJ N
flux JJ N
dialysis NN N
During IN N
a DT N
9 CD N
week NN N
period NN N
, , N
the DT N
patients NNS N
were VBD N
on IN N
a DT N
standard JJ N
Na+ NNP N
dialysate NN N
( ( N
Na+ NNP N
= VBZ N
140 CD N
meq/L NN N
) ) N
basal NN N
period NN N
( ( N
B NNP N
) ) N
; : N
9 CD N
% NN N
( ( N
Na+ NNP N
= VBZ N
149 CD N
meq/L NN N
) ) N
linear NN N
( ( N
L NNP N
) ) N
; : N
step VBN N
drop NN N
( ( N
S NNP N
) ) N
; : N
and CC N
exponential JJ N
drop NN N
( ( N
E NNP N
) ) N
The DT N
Na+ NNP N
program NN N
was VBD N
changed VBN N
weekly RB N
at IN N
random NN N
The DT N
results NNS N
obtained VBD N
with IN N
the DT N
three CD N
Na+ NNP N
modeling VBG N
programs NNS N
were VBD N
similar JJ N
We PRP N
compared VBN N
the DT N
periods NNS N
with IN N
and CC N
without IN N
Na+ NNP N
modeling NN N
: : N
no DT N
differences NNS N
were VBD N
found VBN N
in IN N
weight NN N
gained VBN N
interdialysis NN N
, , N
mean JJ N
blood NN N
pressure NN N
predialysis NN N
and CC N
postdialysis NN N
, , N
and CC N
hemoconcentration NN N
Serum NNP N
Na+ NNP N
levels NNS N
were VBD N
significantly RB N
higher JJR N
predialysis NN N
and CC N
postdialysis NN N
for IN N
those DT N
patients NNS N
on IN N
Na+ NNP N
modeling VBG N
Hypotensive NNP N
episodes NNS N
and CC N
cramps NNS N
decreased VBD N
50 CD N
% NN N
with IN N
Na+ NNP N
modeling VBG N
The DT N
amount NN N
of IN N
hypertonic JJ N
and CC N
normal JJ N
saline NN N
given VBN N
during IN N
dialysis NN N
was VBD N
markedly RB N
reduced VBN N
Na+ NNP N
modeling VBG N
should MD N
always RB N
be VB N
used VBN N
in IN N
patients NNS N
being VBG N
maintained VBN N
on IN N
high JJ N
flux JJ N
dialysis NN N
-DOCSTART- -X- O O 18989547

Comparison NNP N
between IN N
intermittent JJ N
mandatory JJ N
ventilation NN N
and CC N
synchronized JJ N
intermittent NN N
mandatory JJ N
ventilation NN N
with IN N
pressure NN N
support NN N
in IN N
children NNS 1_p
OBJECTIVE NN N
To TO N
compare VB N
intermittent JJ N
mandatory JJ N
ventilation NN N
( ( N
IMV NNP N
) ) N
with IN N
synchronized JJ N
intermittent JJ N
mandatory NN N
ventilation NN N
plus CC N
pressure NN N
support NN N
( ( N
SIMV+PS NNP N
) ) N
in IN N
terms NNS N
of IN N
time NN N
on IN N
mechanical JJ N
ventilation NN N
, , N
duration NN N
of IN N
weaning VBG N
and CC N
length NN N
of IN N
stay NN N
in IN N
a DT N
pediatric JJ N
intensive JJ N
care NN N
unit NN N
( ( N
PICU NNP N
) ) N
METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
clinical JJ N
trial NN N
that WDT N
enrolled VBD N
children NNS 1_p
aged VBN 1_p
28 CD 1_p
days NNS 1_p
to TO 1_p
4 CD 1_p
years NNS 1_p
who WP N
were VBD N
admitted VBN N
to TO N
a DT N
PICU NNP 4_p
between IN N
October NNP N
of IN N
2005 CD N
and CC N
June NNP N
of IN N
2007 CD N
and CC N
put VB N
on IN N
mechanical JJ N
ventilation NN N
( ( N
MV NNP N
) ) N
for IN N
more JJR N
than IN N
48 CD N
hours NNS N
These DT N
patients NNS N
were VBD N
allocated VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
by IN N
drawing VBG N
lots NNS N
: : N
IMV NNP N
group NN N
( ( N
IMVG NNP N
; : N
n CC N
= VB N
35 CD N
) ) N
and CC N
SIMV+PS NNP N
group NN N
( ( N
SIMVG NNP N
; : N
n CC N
= VB N
35 CD N
) ) N
Children NNP 1_p
were VBD N
excluded VBN N
if IN N
they PRP N
had VBD N
undergone JJ N
tracheotomy NN N
or CC N
had VBD N
chronic JJ 4_p
respiratory NN 4_p
diseases NNS 4_p
Data NNS N
on IN N
oxygenation NN N
and CC N
ventilation NN N
were VBD N
recorded VBN N
at IN N
admission NN N
and CC N
at IN N
the DT N
start NN N
of IN N
weaning VBG N
RESULTS CC N
There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
terms NNS N
of IN N
age NN N
, , N
sex NN N
, , N
indication NN N
for IN N
MV NNP N
, , N
PRISM NNP N
score NN N
, , N
Comfort NNP N
scale NN N
, , N
use NN N
of IN N
sedatives NNS N
or CC N
ventilation NN N
and CC N
oxygenation NN N
parameters NNS N
The DT N
median JJ N
time NN N
on IN N
MV NNP N
was VBD N
5 CD N
days NNS N
for IN N
both DT N
groups NNS N
( ( N
p JJ N
= NNP N
0.120 CD N
) ) N
There EX N
were VBD N
also RB N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
for IN N
duration NN N
of IN N
weaning VBG N
[ JJ N
IMVG NNP N
: : N
1 CD N
day NN N
( ( N
1-6 JJ N
) ) N
vs. FW N
SIMVG NNP N
: : N
1 CD N
day NN N
( ( N
1-6 JJ N
) ) N
; : N
p CC N
= $ N
0.262 CD N
] NN N
or CC N
length NN N
of IN N
hospital NN N
stay NN N
[ JJ N
IMVG NNP N
: : N
8 CD N
days NNS N
( ( N
2-22 JJ N
) ) N
vs. FW N
SIMVG NNP N
: : N
6 CD N
days NNS N
( ( N
3-20 JJ N
) ) N
; : N
p CC N
= $ N
0.113 CD N
] NNP N
CONCLUSION NNP N
Among IN N
the DT N
children NNS 1_p
studied VBN N
here RB N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
IMV NNP N
and CC N
SIMV+PS NNP N
in IN N
terms NNS N
of IN N
time NN N
on IN N
MV NNP N
, , N
duration NN N
of IN N
weaning VBG N
or CC N
time NN N
spent VBN N
in IN N
the DT N
PICU NNP N
ClinicalTrials.govID NN N
: : N
NCT00549809 NNP N
-DOCSTART- -X- O O 24242260

Testing VBG N
the DT N
efficacy NN N
of IN N
an DT N
HIV NNP N
stigma NN N
reduction NN N
intervention NN N
with IN N
medical JJ N
students NNS N
in IN N
Puerto NNP N
Rico NNP N
: : N
the DT N
SPACES NNP N
project NN N
INTRODUCTION NNP N
Stigma NNP N
associated VBD N
with IN N
HIV NNP N
has VBZ N
been VBN N
documented VBN N
as IN N
a DT N
barrier NN N
for IN N
accessing VBG N
quality NN N
health-related JJ N
services NNS N
When WRB N
the DT N
stigma NN N
manifests NNS N
in IN N
the DT N
health NN N
care NN N
setting VBG N
, , N
people NNS N
living VBG N
with IN N
HIV NNP N
receive VBP N
substandard NN N
services NNS N
or CC N
even RB N
be VB N
denied VBN N
care NN N
altogether RB N
Although IN N
the DT N
consequences NNS N
of IN N
HIV NNP N
stigma NN N
have VBP N
been VBN N
documented VBN N
extensively RB N
, , N
efforts NNS N
to TO N
reduce VB N
these DT N
negative JJ N
attitudes NNS N
have VBP N
been VBN N
scarce JJ N
Interventions NNS N
to TO N
reduce VB N
HIV NNP N
stigma NN N
should MD N
be VB N
implemented VBN N
as IN N
part NN N
of IN N
the DT N
formal JJ N
training NN N
of IN N
future JJ N
health NN N
care NN N
professionals NNS N
The DT N
interventions NNS N
that WDT N
have VBP N
been VBN N
tested VBN N
with IN N
health NN N
care NN N
professionals NNS N
and CC N
published VBN N
have VBP N
several JJ N
limitations NNS N
that WDT N
must MD N
be VB N
surpassed VBN N
( ( N
i.e NN N
lack NN N
of IN N
comparison NN N
groups NNS N
in IN N
research NN N
designs NNS N
and CC N
longitudinal JJ N
follow-up JJ N
data NNS N
) ) N
Furthermore UH N
, , N
Latino NNP N
health NN N
care NN N
professionals NNS N
have VBP N
been VBN N
absent JJ N
from IN N
these DT N
intervention NN N
efforts NNS N
even RB N
though IN N
the DT N
epidemic NN N
has VBZ N
affected VBN N
this DT N
population NN N
disproportionately RB N
METHODS NNP N
In IN N
this DT N
article NN N
, , N
we PRP N
describe VBP N
an DT N
intervention NN N
developed VBD N
to TO N
reduce VB N
HIV NNP N
stigma NN N
among IN N
medical JJ N
students NNS N
in IN N
Puerto NNP N
Rico NNP N
A NNP N
total NN N
of IN N
507 CD 3_p
medical JJ N
students NNS N
were VBD N
randomly RB N
introduced VBN N
into IN N
our PRP$ N
intervention NN N
and CC N
control NN N
conditions NNS N
RESULTS VB N
The DT N
results NNS N
show VBP N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
; : N
intervention NN N
group NN N
participants NNS N
had VBD N
lower JJR N
HIV NNP N
stigma NN N
levels NNS N
than IN N
control NN N
participants NNS N
after IN N
the DT N
intervention NN N
In IN N
addition NN N
, , N
differences NNS N
in IN N
HIV NNP N
stigma NN N
levels NNS N
between IN N
the DT N
groups NNS N
were VBD N
sustained VBN N
for IN N
a DT N
12-month JJ N
period NN N
CONCLUSION VB N
The DT N
results NNS N
of IN N
our PRP$ N
study NN N
demonstrate VB N
the DT N
efficacy NN N
of IN N
the DT N
modes NNS N
of IN N
intervention NN N
developed VBN N
by IN N
us PRP N
and CC N
serve VB N
as IN N
a DT N
new JJ N
training NN N
tool NN N
for IN N
future JJ N
health NN N
care NN N
professionals NNS N
with IN N
regard NN N
to TO N
stigma VB N
reduction NN N
-DOCSTART- -X- O O 24898318

Improving VBG N
adolescent JJ 1_p
social JJ N
competence NN N
and CC N
behavior NN N
: : N
a DT N
randomized JJ N
trial NN N
of IN N
an DT N
11-week JJ N
equine NN N
facilitated VBN N
learning JJ N
prevention NN N
program NN N
There EX N
is VBZ N
growing VBG N
evidence NN N
that IN N
promoting VBG N
social JJ N
competence NN N
in IN N
youth NN 1_p
is VBZ N
an DT N
effective JJ N
strategy NN N
to TO N
prevent VB N
mental JJ N
, , N
emotional JJ N
, , N
and CC N
behavioral JJ N
disorders NNS N
in IN N
adulthood NN N
Research NNP N
suggests VBZ N
that IN N
programs NNS N
delivered VBN N
in IN N
collaboration NN N
with IN N
schools NNS N
are VBP N
particularly RB N
effective JJ N
when WRB N
they PRP N
target VBP N
social JJ N
and CC N
emotional JJ N
skill NN N
building NN N
, , N
utilize VB N
an DT N
interactive JJ N
instructional JJ N
style NN N
, , N
provide VB N
opportunities NNS N
for IN N
youth NN N
participation NN N
and CC N
self-direction NN N
, , N
and CC N
include VBP N
explicit JJ N
attempts NNS N
to TO N
enhance VB N
youth RB N
social JJ N
competence NN N
A NNP N
relatively RB N
new JJ N
but CC N
popular JJ N
approach NN N
that WDT N
incorporates VBZ N
these DT N
characteristics NNS N
is VBZ N
human JJ N
animal JJ N
interaction NN N
, , N
which WDT N
can MD N
be VB N
implemented VBN N
in IN N
educational JJ N
settings NNS N
We PRP N
report VBP N
the DT N
results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
examining VBG N
the DT N
effects NNS N
of IN N
an DT N
11-week JJ N
equine NN N
facilitated VBN N
learning NN N
( ( N
EFL NNP N
) ) N
program NN N
on IN N
the DT N
social JJ N
competence NN N
and CC N
behavior NN N
of IN N
5th-8th JJ 1_p
grade NN 1_p
children NNS 1_p
Children NNP 1_p
( ( N
N NNP N
= NNP N
131 CD 3_p
) ) N
were VBD N
recruited VBN N
through IN N
referral JJ N
by IN N
school NN N
counselors NNS N
and CC N
school-based JJ N
recruitment NN N
and CC N
then RB N
screened VBD N
for IN N
low JJ N
social JJ N
competence NN N
Researchers NNP N
randomly RB N
assigned VBD N
children NNS N
to TO N
an DT N
experimental JJ N
( ( N
n JJ N
= NNP N
53 CD N
) ) N
or CC N
waitlisted VBN N
control NN N
group NN N
( ( N
n JJ N
= NNP N
60 CD N
) ) N
Children NNP N
in IN N
the DT N
experimental JJ N
group NN N
participated VBD N
in IN N
an DT N
11-week JJ N
EFL NNP N
program NN N
consisting NN N
of IN N
once-weekly JJ N
, , N
90-min JJ N
sessions NNS N
of IN N
individual JJ N
and CC N
team-focused JJ N
activities NNS N
, , N
whereas NNS N
children NNS N
in IN N
the DT N
control NN N
group NN N
served VBD N
as IN N
a DT N
wait-listed JJ N
control NN N
and CC N
participated VBD N
16 CD N
weeks NNS N
later RB N
Parents NNS N
of IN N
children NNS N
in IN N
both DT N
groups NNS N
rated VBN N
child JJ N
social JJ N
competence NN N
at IN N
pretest NN N
and CC N
posttest NN N
Three CD N
independent JJ N
raters NNS N
observed VBD N
and CC N
reported VBD N
children NNS N
's POS N
positive JJ N
and CC N
negative JJ N
behavior NN N
using VBG N
a DT N
validated JJ N
checklist NN N
during IN N
each DT N
weekly JJ N
session NN N
Results NNS N
indicated VBD N
that IN N
program NN N
participation NN N
had VBD N
a DT N
moderate JJ N
treatment NN N
effect NN N
( ( N
d JJ N
= NNP N
.55 NNP N
) ) N
on IN N
social JJ N
competence NN N
( ( N
p JJ N
= NNP N
.02 NNP N
) ) N
that WDT N
was VBD N
independent JJ N
of IN N
pretest NN N
levels NNS N
, , N
age NN N
, , N
gender NN N
, , N
and CC N
referral JJ N
status NN N
Results NNS N
showed VBD N
that IN N
higher JJR N
levels NNS N
of IN N
program NN N
attendance NN N
predicted VBD N
children NNS N
's POS N
trajectories NNS N
of IN N
observed JJ N
positive JJ N
( ( N
β JJ N
= NNP N
.500 NNP N
; : N
p CC N
= NNP N
.003 NNP N
) ) N
and CC N
negative JJ N
behavior NN N
( ( N
β JJ N
= NNP N
-.062 NNP N
; : N
p CC N
< NNP N
.001 NNP N
) ) N
over IN N
the DT N
11-week JJ N
program NN N
-DOCSTART- -X- O O 15275765

Gabapentin NNP N
for IN N
the DT N
prevention NN N
of IN N
postoperative JJ 4_p
pain NN 4_p
after IN N
vaginal JJ 4_p
hysterectomy NN 4_p
Gabapentin NNP N
alleviates VBZ N
and/or JJ N
prevents NNS N
acute JJ N
nociceptive JJ N
and CC N
inflammatory JJ N
pain NN N
both DT N
in IN N
animals NNS N
and CC N
volunteers NNS N
, , N
especially RB N
when WRB N
given VBN N
before IN N
trauma NN N
Gabapentin NNP N
might MD N
also RB N
reduce VB N
postoperative JJ N
pain NN N
To TO N
test VB N
the DT N
hypothesis NN N
that WDT N
gabapentin NN N
reduces VBZ N
the DT N
postoperative JJ N
need NN N
for IN N
additional JJ N
pain NN N
treatment NN N
( ( N
postoperative JJ N
opioid NN N
sparing VBG N
effect NN N
of IN N
gabapentin NN N
in IN N
humans NNS N
) ) N
, , N
we PRP N
gave VBD N
1200 CD N
mg NN N
of IN N
gabapentin NN N
or CC N
15 CD N
mg NN N
of IN N
oxazepam NN N
( ( N
active JJ N
placebo NN N
) ) N
2.5 CD N
h NN N
prior RB N
to TO N
induction NN N
of IN N
anaesthesia NN N
to TO N
patients NNS N
undergoing VBG N
elective JJ N
vaginal JJ N
hysterectomy NN N
in IN N
an DT N
active JJ N
placebo-controlled JJ N
, , N
double JJ N
blind NN N
, , N
randomised VBD N
study NN N
Gabapentin NNP N
reduced VBD N
the DT N
need NN N
for IN N
additional JJ N
postoperative JJ N
pain NN N
treatment NN N
( ( N
PCA NNP N
boluses NNS N
of IN N
50 CD N
microg NN N
of IN N
fentanyl NN N
) ) N
by IN N
40 CD N
% NN N
during IN N
the DT N
first JJ N
20 CD N
postoperative JJ N
hours NNS N
During IN N
the DT N
first JJ N
2 CD N
postoperative JJ N
hours NNS N
pain VBP N
scores NNS N
at IN N
rest NN N
and CC N
worst JJS N
pain NN N
score NN N
( ( N
VAS NNP N
0-100 NNP N
mm NN N
) ) N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
active JJ N
placebo NN N
group NN N
compared VBN N
to TO N
the DT N
gabapentin-treated JJ N
patients NNS N
Additionally RB N
, , N
pretreatment NN N
with IN N
gabapentin NN N
reduced VBD N
the DT N
degree NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
incidence NN N
of IN N
vomiting/retching VBG N
possibly RB N
either RB N
due JJ N
to TO N
the DT N
diminished JJ N
need NN N
for IN N
postoperative JJ N
pain NN N
treatment NN N
with IN N
opioids NNS N
or CC N
because IN N
of IN N
an DT N
anti-emetic JJ N
effect NN N
of IN N
gabapentin NN N
itself PRP N
No DT N
preoperative JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
encountered VBN N
with IN N
respect NN N
to TO N
the DT N
side NN N
effects NNS N
of IN N
the DT N
premedication NN N
However RB N
, , N
15 CD N
mg NN N
oxazepam NN N
was VBD N
more RBR N
effective JJ N
in IN N
relieving VBG N
preoperative JJ N
anxiety NN N
than IN N
1200 CD N
mg NN N
gabapentin NN N
-DOCSTART- -X- O O 14984440

Delayed VBN N
genomic JJ N
and CC N
acute JJ N
nongenomic JJ N
action NN N
of IN N
glucocorticosteroids NNS N
in IN N
seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
BACKGROUND NNP N
Glucocorticosteroids NNP N
are VBP N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
allergic JJ 4_p
rhinitis NN 4_p
, , N
a DT N
disease NN N
characterized VBN N
by IN N
a DT N
variety NN N
of IN N
symptoms NNS N
, , N
e.g NN N
rhinorrhea NN N
and CC N
itching NN N
The DT N
time NN N
course NN N
of IN N
symptomatic JJ N
relief NN N
for IN N
allergic JJ N
rhinitis NN N
by IN N
steroids NNS N
has VBZ N
not RB N
been VBN N
examined VBN N
in IN N
detail NN N
to TO N
date NN N
, , N
although IN N
the DT N
onset NN N
of IN N
steroid JJ N
action NN N
is VBZ N
one CD N
of IN N
the DT N
main JJ N
discriminations NNS N
between IN N
genomic JJ N
and CC N
nongenomic JJ N
actions NNS N
of IN N
steroids NNS N
We PRP N
therefore RB N
investigated VBD N
the DT N
time NN N
course NN N
of IN N
subjective JJ N
and CC N
objective JJ N
measures NNS N
of IN N
nasal JJ N
affection NN N
after IN N
steroid JJ N
administration NN N
in IN N
patients NNS N
with IN N
allergic JJ N
rhinitis NN N
following VBG N
specific JJ N
allergen NN N
challenge NN N
METHODS NNP N
Six NNP 3_p
female NN 2_p
and CC N
18 CD 3_p
male NN 2_p
volunteers NNS N
( ( N
median JJ N
age NN N
26 CD 1_p
years NNS 1_p
) ) N
with IN N
a DT N
history NN N
of IN N
allergic JJ 4_p
rhinitis NN 4_p
but CC N
currently RB N
free JJ N
of IN N
symptoms NNS N
were VBD N
included VBN N
in IN N
this DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
, , N
three-period JJ N
crossover NN N
study NN N
A DT N
single JJ N
dose NN N
of IN N
either CC N
betamethasone NN N
( ( N
60 CD N
mg NN N
) ) N
, , N
methylprednisolone NN N
( ( N
400 CD N
mg NN N
) ) N
or CC N
placebo NN N
was VBD N
given VBN N
intravenously RB N
, , N
5 CD N
min NN N
after IN N
intranasal JJ N
allergen JJ N
provocation NN N
After IN N
10 CD N
, , N
20 CD N
, , N
60 CD N
, , N
150 CD N
and CC N
240 CD N
min NN N
, , N
nasal JJ N
itching NN N
and CC N
nasal JJ N
obstruction NN N
were VBD N
assessed VBN N
using VBG N
a DT N
standardized JJ N
visual JJ N
analogue NN N
scale NN N
In IN N
addition NN N
, , N
nasal RB N
airflow NN N
was VBD N
measured VBN N
by IN N
anterior JJ N
rhinomanometry NN N
RESULTS NNP N
Nasal NNP N
itching NN N
was VBD N
markedly RB N
reduced VBN N
following VBG N
either NN N
of IN N
the DT N
two CD N
steroids NNS N
within IN N
10 CD N
min NNS N
after IN N
administration NN N
of IN N
study JJ N
drug NN N
Itching NNP N
was VBD N
depressed VBN N
by IN N
38 CD N
% NN N
following VBG N
betamethasone NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
by IN N
18 CD N
% NN N
following VBG N
methylprednisolone NN N
( ( N
P=0.07 NNP N
) ) N
compared VBN N
with IN N
placebo NN N
Nasal NNP N
airflow JJ N
and CC N
nasal JJ N
obstruction NN N
were VBD N
not RB N
significantly RB N
altered VBN N
by IN N
steroids NNS N
during IN N
the DT N
first JJ N
2 CD N
h NN N
of IN N
the DT N
study NN N
However RB N
, , N
after IN N
150 CD N
min NN N
, , N
nasal RB N
airflow NN N
was VBD N
21 CD N
% NN N
rsp NN N
19 CD N
% NN N
higher JJR N
after IN N
methylprednisolone NN N
and CC N
betamethasone NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
compared VBN N
with IN N
placebo NN N
After IN N
240 CD N
min NN N
, , N
nasal RB N
airflow JJ N
was VBD N
increased VBN N
by IN N
20 CD N
% NN N
following VBG N
betamethasone NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
by IN N
19 CD N
% NN N
following VBG N
methylprednisolone NN N
Nasal NNP N
obstruction NN N
was VBD N
also RB N
beneficially RB N
affected VBN N
by IN N
both DT N
steroids NNS N
150 CD N
and CC N
240 CD N
min NN N
after IN N
administration NN N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
for IN N
both DT N
time NN N
points NNS N
following VBG N
betamethasone NN N
) ) N
CONCLUSION VB N
This DT N
study NN N
for IN N
the DT N
first JJ N
time NN N
shows NNS N
rapid VBP N
in IN N
vivo JJ N
effects NNS N
of IN N
external JJ N
glucocorticosteroids NNS N
in IN N
humans NNS N
Itching NNP N
, , N
a DT N
pathophysiologically RB N
complex JJ N
sensation NN N
, , N
is VBZ N
favourably RB N
influenced VBN N
by IN N
steroids NNS N
within IN N
10 CD N
min NNS N
, , N
therefore RB N
presumably RB N
via IN N
nongenomic JJ N
mechanisms NN N
Though IN N
no DT N
detailed JJ N
mechanisms NNS N
can MD N
be VB N
derived VBN N
from IN N
this DT N
study NN N
, , N
steroid JJ N
interaction NN N
with IN N
receptors NNS N
in IN N
the DT N
central JJ N
nervous JJ N
system NN N
may MD N
play VB N
an DT N
important JJ N
role NN N
in IN N
mediating VBG N
this DT N
effect NN N
-DOCSTART- -X- O O 24928832

A DT N
randomized VBN N
, , N
phase VB N
II NNP N
study NN N
of IN N
afatinib JJ N
versus NN N
cetuximab NN N
in IN N
metastatic JJ 4_p
or CC 4_p
recurrent JJ 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
BACKGROUND NNP N
Afatinib NNP N
is VBZ N
an DT N
oral JJ N
, , N
irreversible JJ N
ErbB NNP N
family NN N
blocker NN N
that WDT N
has VBZ N
shown VBN N
activity NN N
in IN N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
( ( N
EGFR NNP N
) ) N
-mutated VBD N
lung NN N
cancer NN N
We PRP N
hypothesized VBD N
that IN N
the DT N
agent NN N
would MD N
have VB N
greater JJR N
antitumor NN N
activity NN N
compared VBN N
with IN N
cetuximab NN N
in IN N
recurrent NN 4_p
or CC 4_p
metastatic JJ 4_p
( ( 4_p
R/M NNP 4_p
) ) 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
( ( 4_p
HNSCC NNP 4_p
) ) 4_p
patients NNS 4_p
, , N
whose WP$ N
disease NN 4_p
has VBZ 4_p
progressed VBN 4_p
after IN 4_p
platinum-containing JJ 4_p
therapy NN 4_p
PATIENTS NNP N
AND CC N
METHODS NNP N
An DT N
open-label JJ N
, , N
randomized VBN N
, , N
phase VB N
II NNP N
trial NN N
was VBD N
conducted VBN N
in IN N
43 CD N
centers NNS N
; : N
124 CD 3_p
patients NNS 3_p
were VBD N
randomized VBN N
( ( N
1 CD N
: : N
1 CD N
) ) N
to TO N
either DT N
afatinib NN N
( ( N
50 CD N
mg/day NN N
) ) N
or CC N
cetuximab NN N
( ( N
250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/week NN N
) ) N
until IN N
disease JJ N
progression NN N
or CC N
intolerable JJ N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
( ( N
stage NN N
I PRP N
) ) N
, , N
with IN N
optional JJ N
crossover NN N
( ( N
stage JJ N
II NNP N
) ) N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
tumor JJ N
shrinkage NN N
before IN N
crossover NN N
assessed VBN N
by IN N
investigator NN N
( ( N
IR NNP N
) ) N
and CC N
independent JJ N
central JJ N
review NN N
( ( N
ICR NNP N
) ) N
RESULTS VB N
A DT N
total NN N
of IN N
121 CD 3_p
patients NNS 3_p
were VBD N
treated VBN N
( ( N
61 CD 3_p
afatinib NN 3_p
, , N
60 CD 3_p
cetuximab NN 3_p
) ) N
and CC N
68 CD 3_p
crossed VBN 3_p
over IN 3_p
to TO 3_p
stage VB 3_p
II NNP 3_p
( ( N
32 CD 3_p
and CC N
36 CD 3_p
respectively RB N
) ) N
In IN N
stage NN N
I PRP N
, , N
mean JJ N
tumor NN N
shrinkage NN N
by IN N
IR/ICR NNP N
was VBD N
10.4 CD N
% NN N
/16.6 CD N
% NN N
with IN N
afatinib NN N
and CC N
5.4 CD N
% NN N
/10.1 CD N
% NN N
with IN N
cetuximab NN N
( ( N
P NNP N
= NNP N
0.46/0.30 CD N
) ) N
Objective JJ N
response NN N
rate NN N
was VBD N
16.1 CD N
% NN N
/8.1 CD N
% NN N
with IN N
afatinib NN N
and CC N
6.5 CD N
% NN N
/9.7 CD N
% NN N
with IN N
cetuximab NN N
( ( N
IR/ICR NNP N
) ) N
Comparable JJ N
disease NN N
control NN N
rates NNS N
were VBD N
observed VBN N
with IN N
afatinib NN N
( ( N
50 CD N
% NN N
) ) N
and CC N
cetuximab NN N
( ( N
56.5 CD N
% NN N
) ) N
by IN N
IR NNP N
; : N
similar JJ N
results NNS N
were VBD N
seen VBN N
by IN N
ICR NNP N
Most JJS N
common JJ N
grade NN N
≥3 JJ N
drug-related JJ N
AEs NNP N
( ( N
DRAEs NNP N
) ) N
were VBD N
rash/acne VBN N
( ( N
18 CD N
% NN N
versus IN N
8.3 CD N
% NN N
) ) N
, , N
diarrhea NN N
( ( N
14.8 CD N
% NN N
versus IN N
0 CD N
% NN N
) ) N
, , N
and CC N
stomatitis/mucositis NN N
( ( N
11.5 CD N
% NN N
versus IN N
0 CD N
% NN N
) ) N
with IN N
afatinib NN N
and CC N
cetuximab NN N
, , N
respectively RB N
Patients NNS N
with IN N
DRAEs NNP N
leading VBG N
to TO N
treatment NN N
discontinuation NN N
were VBD N
23 CD N
% NN N
with IN N
afatinib NN N
and CC N
5 CD N
% NN N
with IN N
cetuximab NN N
In IN N
stage NN N
II NNP N
, , N
disease VB N
control NN N
rate NN N
( ( N
IR/ICR NNP N
) ) N
was VBD N
38.9 CD N
% NN N
/33.3 CD N
% NN N
with IN N
afatinib NN N
and CC N
18.8 CD N
% NN N
/18.8 CD N
% NN N
with IN N
cetuximab NN N
CONCLUSION NNP N
Afatinib NNP N
showed VBD N
antitumor JJ N
activity NN N
comparable JJ N
to TO N
cetuximab VB N
in IN N
R/M NNP N
HNSCC NNP N
in IN N
this DT N
exploratory JJ N
phase NN N
II NNP N
trial NN N
, , N
although IN N
more JJR N
patients NNS N
on IN N
afatinib JJ N
discontinued VBN N
treatment NN N
due JJ N
to TO N
AEs NNP N
Sequential NNP N
EGFR/ErbB NNP N
treatment NN N
with IN N
afatinib NN N
and CC N
cetuximab NN N
provided VBD N
sustained JJ N
clinical JJ N
benefit NN N
in IN N
patients NNS N
after IN N
crossover NN N
, , N
suggesting VBG N
a DT N
lack NN N
of IN N
cross-resistance NN N
-DOCSTART- -X- O O 7551999

Abdominoperineal NNP N
resection NN N
and CC N
anterior JJ N
resection NN N
in IN N
the DT N
treatment NN N
of IN N
rectal JJ 4_p
cancer NN 4_p
: : N
results NNS N
in IN N
relation NN N
to TO N
adjuvant VB N
preoperative JJ N
radiotherapy NN N
The DT N
outcome NN N
of IN N
patients NNS N
with IN N
rectal JJ N
cancer NN N
treated VBN N
by IN N
abdominoperineal NN N
or CC N
anterior JJ N
resection NN N
, , N
with IN N
or CC N
without IN N
preoperative JJ N
radiotherapy NN N
, , N
was VBD N
assessed VBN N
to TO N
detect VB N
any DT N
differences NNS N
attributable JJ N
to TO N
the DT N
operative JJ N
method NN N
and CC N
interactions NNS N
between IN N
radiotherapy NN N
and CC N
type NN N
of IN N
surgery NN N
The DT N
study NN N
was VBD N
based VBN N
on IN N
1292 CD 3_p
patients NNS N
included VBN N
in IN N
two CD N
consecutive JJ N
controlled VBN N
randomized JJ N
trials NNS N
of IN N
preoperative JJ N
radiotherapy NN N
in IN N
operable JJ N
rectal JJ N
carcinoma NN N
The DT N
outcome NN N
was VBD N
not RB N
related VBN N
to TO N
surgical JJ N
method NN N
Radiotherapy NNP N
increased VBD N
postoperative JJ N
mortality NN N
and CC N
complications NNS N
and CC N
reduced JJ N
local JJ N
and CC N
distant JJ N
recurrence NN N
, , N
but CC N
had VBD N
no DT N
effect NN N
on IN N
overall JJ N
survival NN N
Effects NNS N
of IN N
radiotherapy NN N
were VBD N
similar JJ N
irrespective NN N
of IN N
the DT N
type NN N
of IN N
surgery NN N
, , N
except IN N
that IN N
the DT N
increase NN N
in IN N
postoperative JJ N
mortality NN N
in IN N
irradiated JJ N
patients NNS N
was VBD N
greater JJR N
in IN N
those DT N
treated VBN N
with IN N
abdominoperineal JJ N
resection NN N
Sphincter-saving JJ N
procedures NNS N
appear VBP N
to TO N
have VB N
no DT N
adverse JJ N
effects NNS N
on IN N
outcome NN N
of IN N
rectal JJ N
cancer NN N
, , N
but CC N
the DT N
optimum JJ N
use NN N
of IN N
radiotherapy NN N
is VBZ N
still RB N
to TO N
be VB N
defined VBN N
-DOCSTART- -X- O O 25180722

Impact NN N
of IN N
early JJ N
mobilization NN N
on IN N
glycemic JJ N
control NN N
and CC N
ICU-acquired NNP N
weakness NN N
in IN N
critically RB 4_p
ill JJ 4_p
patients NNS 4_p
who WP 4_p
are VBP 4_p
mechanically RB 4_p
ventilated VBN 4_p
BACKGROUND NNP N
ICU-acquired JJ N
weakness NN N
( ( N
ICU-AW NNP N
) ) N
has VBZ N
immediate JJ N
and CC N
long-term JJ N
consequences NNS N
for IN N
critically RB 4_p
ill JJ 4_p
patients NNS 4_p
Strategies NNS N
for IN N
the DT N
prevention NN N
of IN N
weakness NN N
include VBP N
modification NN N
of IN N
known VBN N
risk NN N
factors NNS N
, , N
such JJ N
as IN N
hyperglycemia NN N
and CC N
immobility NN N
Intensive JJ N
insulin NN N
therapy NN N
( ( N
IIT NNP N
) ) N
has VBZ N
been VBN N
proposed VBN N
to TO N
prevent VB N
critical JJ N
illness NN N
polyneuropathy NN N
However RB N
, , N
the DT N
effect NN N
of IN N
insulin NN N
and CC N
early JJ N
mobilization NN N
on IN N
clinically RB N
apparent JJ N
weakness NN N
is VBZ N
not RB N
well RB N
known VBN N
METHODS NNP N
This DT N
is VBZ N
a DT N
secondary JJ N
analysis NN N
of IN N
all DT 4_p
patients NNS 4_p
with IN 4_p
mechanical JJ 4_p
ventilation NN 4_p
( ( 3_p
N NNP 3_p
= NNP 3_p
104 CD 3_p
) ) N
previously RB 4_p
enrolled VBN 4_p
in IN 4_p
a DT 4_p
randomized NN 4_p
controlled VBN 4_p
trial NN 4_p
of IN 4_p
early JJ 4_p
occupational JJ 4_p
and CC 4_p
physical JJ 4_p
therapy NN 4_p
vs JJ 4_p
conventional JJ 4_p
therapy NN 4_p
, , 4_p
which WDT 4_p
evaluated VBD 4_p
the DT 4_p
end NN 4_p
point NN 4_p
of IN 4_p
functional JJ 4_p
independence NN 4_p
Every NNP 4_p
patient NN 4_p
had VBD 4_p
IIT NNP 4_p
and CC 4_p
blinded VBD 4_p
muscle NN 4_p
strength NN 4_p
testing VBG 4_p
on IN 4_p
hospital NN 4_p
discharge NN 4_p
to TO N
determine VB N
the DT N
incidence NN N
of IN N
clinically RB N
apparent JJ N
weakness NN N
The DT N
effects NNS N
of IN N
insulin NN N
dose NN N
and CC N
early JJ N
mobilization NN N
on IN N
the DT N
incidence NN N
of IN N
ICU-AW NNP N
were VBD N
assessed VBN N
RESULTS VB N
On IN N
logistic JJ N
regression NN N
analyses NNS N
, , N
early JJ N
mobilization NN N
and CC N
increasing VBG N
insulin NN N
dose NN N
prevented VBD N
the DT N
incidence NN N
of IN N
ICU-AW NNP N
( ( N
OR NNP N
, , N
0.18 CD N
, , N
P NNP N
= NNP N
.001 NNP N
; : N
OR NNP N
, , N
0.001 CD N
, , N
P NNP N
= NNP N
.011 NNP N
; : N
respectively RB N
) ) N
independent JJ N
of IN N
known VBN N
risk NN N
factors NNS N
for IN N
weakness NN N
Early JJ N
mobilization NN N
also RB N
significantly RB N
reduced VBN N
insulin NN N
requirements NNS N
to TO N
achieve VB N
similar JJ N
glycemic JJ N
goals NNS N
as IN N
compared VBN N
with IN N
control NN N
patients NNS N
( ( N
0.07 CD N
units/kg/d RB N
vs JJ N
0.2 CD N
units/kg/d NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
CONCLUSIONS VB N
The DT N
duel NN N
effect NN N
of IN N
early JJ N
mobilization NN N
in IN N
reducing VBG N
clinically RB N
relevant JJ N
ICU-AW NNP N
and CC N
promoting VBG N
euglycemia JJ N
suggests VBZ N
its PRP$ N
potential JJ N
usefulness NN N
as IN N
an DT N
alternative NN N
to TO N
IIT NNP N
-DOCSTART- -X- O O 20378181

Effects NNS N
of IN N
10 CD N
Hz NNP N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
( ( N
rTMS NN N
) ) N
on IN N
clinical JJ N
global JJ N
impression NN N
in IN N
chronic JJ 4_p
schizophrenia NN 4_p
UNLABELLED IN N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
sham-controlled JJ N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
( ( N
rTMS NN N
) ) N
study NN N
in IN N
chronic JJ 4_p
schizophrenia NN 4_p
in-patients NNS N
( ( N
n=35 NN 3_p
) ) N
to TO N
evaluate VB N
the DT N
therapeutic JJ N
efficacy NN N
of IN N
10 CD N
Hz NNP N
stimulation NN N
Patients NNS N
, , N
who WP N
were VBD N
on IN N
stable JJ 4_p
antipsychotic JJ 4_p
treatment NN 4_p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
active JJ N
or CC N
sham JJ N
condition NN N
In IN N
the DT N
active JJ N
rTMS NN N
group NN N
, , N
ten JJ N
sessions NNS N
with IN N
a DT N
total NN N
of IN N
10,000 CD N
stimuli NNS N
were VBD N
applied VBN N
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal JJ N
cortex NN N
at IN N
110 CD N
% NN N
of IN N
motor NN N
threshold NN N
The DT N
sham NN N
group NN N
received VBD N
corresponding VBG N
sham JJ N
stimulation NN N
Clinical JJ N
improvement NN N
was VBD N
measured VBN N
by IN N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
scale NN N
( ( N
primary JJ N
outcome NN N
measure NN N
) ) N
, , N
the DT N
Global NNP N
Assessment NNP N
of IN N
Functioning NNP N
Scale NNP N
( ( N
GAF NNP N
) ) N
and CC N
the DT N
Positive NNP N
and CC N
Negative NNP N
Symptom NNP N
Scale NNP N
( ( N
PANSS NNP N
; : N
secondary JJ N
outcome NN N
measures NNS N
) ) N
Between-group JJ N
comparisons NNS N
revealed VBD N
no DT N
significant JJ N
differences NNS N
in IN N
clinical JJ N
outcome NN N
variables NNS N
Only RB N
a DT N
subgroup NN N
of IN N
patients NNS N
with IN N
pronounced JJ N
negative JJ N
symptoms NNS N
developed VBD N
some DT N
clinical JJ N
improvement NN N
as IN N
indicated VBN N
by IN N
significant JJ N
changes NNS N
in IN N
the DT N
GAF-scale NNP N
Besides IN N
there EX N
is VBZ N
some DT N
evidence NN N
for IN N
a DT N
more RBR N
favourable JJ N
clinical JJ N
outcome NN N
within IN N
this DT N
subgroup NN N
after IN N
rTMS NN N
in IN N
the DT N
CGI-S NNP N
and CC N
PANSS NNP N
negative JJ N
scale NN N
, , N
too RB N
In IN N
line NN N
with IN N
earlier JJR N
investigations NNS N
, , N
our PRP$ N
results NNS N
suggest VBP N
a DT N
moderate JJ N
- : N
potentially RB N
clinically RB N
relevant JJ N
- : N
treatment NN N
effect NN N
of IN N
prefrontal JJ N
10 CD N
Hz NNP N
rTMS NN N
stimulation NN N
in IN N
chronic JJ 4_p
patients NNS N
However RB N
, , N
in IN N
our PRP$ N
study NN N
this DT N
beneficial JJ N
effect NN N
was VBD N
restricted VBN N
to TO N
subjects NNS N
with IN N
pronounced JJ N
negative JJ N
symptoms NNS N
CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
INFORMATION NNP N
ClinicalTrial.gov NNP N
Identifier NNP N
: : N
NCT00169689 NNP N
, , N
http NN N
: : N
//www.clinicaltrials.gov NN N
-DOCSTART- -X- O O 7489845

Cholesterol-lowering JJ N
therapy NN N
may MD N
retard VB N
the DT N
progression NN N
of IN N
diabetic JJ 4_p
nephropathy NN 4_p
There EX N
is VBZ N
experimental JJ N
evidence NN N
to TO N
suggest VB N
that IN N
hypercholesterolaemia NN N
may MD N
play VB N
a DT N
pathogenetic JJ N
role NN N
in IN N
progressive JJ 4_p
glomerular JJ 4_p
injury NN 4_p
We PRP N
investigated VBD N
the DT N
effect NN N
of IN N
cholesterol-lowering JJ N
therapy NN N
on IN N
the DT N
progression NN N
of IN N
diabetic JJ N
nephropathy NN N
in IN N
34 CD 3_p
patients NNS N
with IN N
non-insulin-dependent JJ 4_p
diabetes NNS 4_p
mellitus NNS 4_p
Patients NNS N
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
single-blind JJ N
fashion NN N
to TO N
treatment NN N
with IN N
either DT N
lovastatin NN N
, , N
an DT N
HMG NNP N
CoA NNP N
reductase NN N
inhibitor NN N
( ( N
n JJ N
= VBZ N
16 CD N
; : N
mean VB N
dose JJ N
30.0 CD N
+/- JJ N
12.6 CD N
mg/day NN N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
18 CD N
) ) N
for IN N
2 CD N
years NNS N
Renal JJ N
function NN N
was VBD N
assessed VBN N
by IN N
serially RB N
measuring VBG N
the DT N
serum NN N
creatinine NN N
, , N
glomerular JJ N
filtration NN N
rate NN N
( ( N
using VBG N
Cr51-EDTA NNP N
) ) N
, , N
and CC N
24-h JJ N
urinary JJ N
protein NN N
excretion NN N
Lovastatin NNP N
treatment NN N
was VBD N
associated VBN N
with IN N
significant JJ N
reductions NNS N
in IN N
total JJ N
cholesterol NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
LDL-cholesterol NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
apo JJ N
B NNP N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
the DT N
reductions NNS N
at IN N
24 CD N
months NNS N
being VBG N
26 CD N
, , N
30 CD N
and CC N
18 CD N
% NN N
, , N
respectively RB N
Beneficial JJ N
effects NNS N
on IN N
serum NN N
triglyceride NN N
, , N
HDL-cholesterol NNP N
and CC N
apo VB N
A1 NNP N
levels NNS N
were VBD N
also RB N
observed VBN N
Lp NNP N
( ( N
a DT N
) ) N
showed VBD N
no DT N
significant JJ N
change NN N
in IN N
both DT N
groups NNS N
Glomerular JJ N
filtration NN N
rate NN N
deteriorated VBN N
significantly RB N
in IN N
the DT N
placebo NN N
group NN N
after IN N
24 CD N
months NNS N
( ( N
p JJ N
< NNP N
0.025 CD N
) ) N
but CC N
showed VBD N
no DT N
significant JJ N
change NN N
in IN N
the DT N
lovastatin-treated JJ N
patients NNS N
The DT N
increase NN N
in IN N
serum JJ N
creatinine NN N
was VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
in IN N
placebo-treated JJ N
patients NNS N
at IN N
12 CD N
and CC N
24 CD N
months NNS N
, , N
and CC N
in IN N
the DT N
lovastatin NN N
group NN N
after IN N
24 CD N
months NNS N
Twenty-four CD N
hour NN N
urinary JJ N
protein NN N
excretion NN N
increased VBN N
in IN N
both DT N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
Lovastatin NNP N
treatment NN N
was VBD N
not RB N
associated VBN N
with IN N
significant JJ N
elevations NNS N
in IN N
liver NN N
or CC N
muscle NN N
enzymes NNS N
We PRP N
conclude VBP N
that IN N
effective JJ N
normalisation NN N
of IN N
hypercholesterolaemia NN N
may MD N
retard VB N
the DT N
progression NN N
of IN N
diabetic JJ N
nephropathy NN N
-DOCSTART- -X- O O 21574725

On IN N
the DT N
benign JJ N
qualities NNS N
of IN N
behavioral JJ 4_p
disinhibition NN 4_p
: : N
because IN N
of IN N
the DT N
prosocial JJ 4_p
nature NN 4_p
of IN 4_p
people NNS 4_p
, , N
behavioral JJ N
disinhibition NN N
can MD N
weaken VB N
pleasure NN N
with IN N
getting VBG N
more JJR N
than IN N
you PRP N
deserve VBP N
This DT N
article NN N
focuses VBZ N
on IN N
social JJ N
situations NNS N
in IN N
which WDT N
people NNS N
are VBP N
surprised VBN N
about IN N
what WP N
is VBZ N
happening VBG N
and CC N
inhibited VBN N
about IN N
how WRB N
to TO N
respond VB N
to TO N
the DT N
situation NN N
at IN N
hand NN N
We PRP N
study VBP N
these DT N
situations NNS N
by IN N
examining VBG N
a DT N
classic JJ N
topic NN N
in IN N
social JJ N
psychology NN N
: : N
how WRB N
people NNS 4_p
respond VBP 4_p
to TO 4_p
receiving VBG 4_p
better JJR 4_p
outcomes NNS 4_p
than IN 4_p
are VBP 4_p
deserved VBN 4_p
In IN N
these DT N
situations NNS N
, , N
the DT N
actions NNS N
of IN N
an DT N
authority NN N
or CC N
a DT N
coworker NN N
push NN N
in IN N
the DT N
direction NN N
of IN N
accepting VBG N
and CC N
enjoying VBG N
the DT N
unfair JJ N
outcome NN N
, , N
whereas JJ N
personal JJ N
values NNS N
for IN N
most JJS N
people NNS N
push VBP N
in IN N
the DT N
direction NN N
of IN N
rejecting VBG N
or CC N
being VBG N
displeased VBN N
with IN N
the DT N
outcome NN N
This DT N
conflict NN N
may MD N
inhibit VB N
people NNS N
's POS N
response NN N
to TO N
the DT N
advantageous JJ N
but CC N
unfair JJ N
outcomes NNS N
If IN N
people NNS N
are VBP N
indeed RB N
inhibited VBN N
about IN N
how WRB N
to TO N
respond VB N
to TO N
these DT N
kinds NNS N
of IN N
outcomes NNS N
, , N
then RB N
lowering VBG N
behavioral JJ N
inhibition NN N
by IN N
reminding VBG N
people NNS N
of IN N
having VBG N
acted VBN N
in IN N
the DT N
past NN N
without IN N
inhibitions NNS N
( ( N
in IN N
a DT N
manner NN N
that WDT N
is VBZ N
unrelated JJ N
to TO N
the DT N
outcomes NNS N
participants NNS N
subsequently RB N
receive VBP N
) ) N
should MD N
affect VB N
reactions NNS N
to TO N
the DT N
outcomes NNS N
Specifically RB N
, , N
we PRP N
hypothesize VBP N
that IN N
because IN N
many JJ N
people NNS N
are VBP N
prosocial JJ N
and CC N
want VBP N
to TO N
adhere VB N
to TO N
principles NNS N
of IN N
fairness NN N
, , N
reminders NNS N
of IN N
behavioral JJ N
disinhibition NN N
will MD N
lead VB N
to TO N
less JJR N
pleasure NN N
with IN N
the DT N
unfairly RB N
obtained VBN N
outcomes RB N
The DT N
results NNS N
of IN N
8 CD N
experiments NNS N
( ( N
conducted VBN N
both DT N
inside IN N
and CC N
outside IN N
the DT N
psychology NN N
laboratory NN N
) ) N
revealed VBD N
evidence NN N
for IN N
this DT N
benign JJ N
disinhibition NN N
effect NN N
on IN N
various JJ N
reactions NNS N
to TO N
outcomes NNS N
that WDT N
are VBP N
better JJR N
than IN N
deserved VBN N
In IN N
further JJ N
accordance NN N
with IN N
our PRP$ N
line NN N
of IN N
reasoning NN N
, , N
the DT N
effect NN N
is VBZ N
particularly RB N
pronounced VBN N
among IN N
those DT N
who WP N
adhere VBP N
to TO N
a DT N
prosocial JJ N
orientation NN N
or CC N
who WP N
have VBP N
adopted VBN N
a DT N
prosocial JJ N
mindset NN N
and CC N
is VBZ N
not RB N
observed VBN N
among IN N
those DT N
with IN N
proself JJ N
orientations NNS N
or CC N
mindsets NNS N
-DOCSTART- -X- O O 24393553

Population NNP N
pharmacokinetic/pharmacodynamic JJ N
analysis NN N
of IN N
the DT N
DPP-4 NNP N
inhibitor NN N
linagliptin NN N
in IN N
Japanese JJ N
patients NNS N
with IN 4_p
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
OBJECTIVES NNP N
Linagliptin NNP N
is VBZ N
a DT N
novel JJ N
, , N
highly RB N
selective JJ N
and CC N
long JJ N
acting VBG N
DPP-4 NNP N
inhibitor NN N
for IN N
the DT N
treatment NN N
of IN N
type NN N
2 CD N
diabetes NNS N
mellitus FW N
( ( N
T2DM NNP N
) ) N
Linagliptin JJ N
exhibits VBZ N
non-linear JJ N
pharmacokinetics NNS N
( ( N
PK NNP N
) ) N
due JJ N
to TO N
saturable JJ N
binding NN N
to TO N
plasma VB N
and CC N
tissue VB N
DPP-4 NNP N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
characterize VB N
the DT N
PK NNP N
and CC N
PK/DPP-4 NNP N
inhibition NN N
relationship NN N
of IN N
linagliptin NN N
in IN N
Japanese JJ N
patients NNS N
with IN N
T2DM NNP 4_p
using VBG N
a DT N
population NN N
PK/DPP-4 NNP N
model NN N
and CC N
to TO N
support VB N
the DT N
rationale NN N
for IN N
the DT N
therapeutic JJ N
dose NN N
in IN N
Japanese JJ N
patients NNS N
by IN N
simulation NN N
METHODS NNP N
Linagliptin NNP N
plasma NN N
concentration NN N
and CC N
DPP-4 NNP N
inhibition NN N
measurements NNS N
from IN N
a DT N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
multiple NN N
( ( N
28 CD N
days NNS N
) ) N
dose VBP N
trial NN N
that WDT N
included VBD N
36 CD 3_p
T2DM NNP N
patients NNS N
( ( N
18 CD 3_p
patients NNS N
each DT N
in IN N
2.5 CD N
mg NN N
and CC N
10 CD N
mg NNS N
dose JJ N
group NN N
) ) N
were VBD N
used VBN N
for IN N
analysis NN N
Modeling NNP N
was VBD N
performed VBN N
using VBG N
FOCE NNP N
INTERACTION NNP N
estimation NN N
method NN N
implemented VBN N
in IN N
NONMEM NNP N
V. NNP N
The DT N
linagliptin JJ N
plasma JJ N
concentration- NN N
and CC N
DPP-4 NNP N
inhibition- JJ N
time NN N
profiles NNS N
were VBD N
simulated VBN N
for IN N
Japanese JJ N
patients NNS N
receiving VBG N
5 CD N
mg JJ N
linagliptin NN N
once RB N
daily JJ N
by IN N
the DT N
model NN N
established VBN N
RESULTS NNP N
Nonlinear NNP N
PK NNP N
of IN N
linagliptin NN N
in IN N
T2DM NNP N
patients NNS N
were VBD N
well RB N
described VBN N
by IN N
a DT N
2-compartment JJ N
model NN N
assuming VBG N
concentration-dependent JJ N
binding NN N
to TO N
DPP-4 NNP N
in IN N
the DT N
central JJ N
and CC N
peripheral JJ N
compartment NN N
Plasma NNP N
DPP-4 NNP N
inhibition NN N
was VBD N
integrated VBN N
in IN N
the DT N
model NN N
by IN N
relating VBG N
the DT N
model-predicted JJ N
DPP-4 NNP N
occupancy NN N
with IN N
linagliptin JJ N
linearly JJ N
to TO N
DPP-4 JJ N
inhibition NN N
The DT N
simulation NN N
predicted VBD N
that IN N
for IN N
the DT N
5 CD N
mg NN N
dose NN N
group NN N
the DT N
trough JJ N
DPP-4 JJ N
inhibition NN N
at IN N
steady-state NN N
was VBD N
84.2 CD N
% NN N
, , N
which WDT N
is VBZ N
higher JJR N
than IN N
the DT N
target NN N
inhibition NN N
( ( N
≥80 CD N
% NN N
) ) N
for IN N
an DT N
effective JJ N
dose NN N
of IN N
DPP-4 NNP N
inhibitor NN N
In IN N
2.5 CD N
mg NNS N
dose JJ N
group NN N
, , N
steady-state JJ N
DPP-4 NNP N
inhibition NN N
of IN N
> $ N
80 CD N
% NN N
was VBD N
not RB N
maintained VBN N
over IN N
24 CD N
hours NNS N
( ( N
observed VBN N
and CC N
simulated VBN N
) ) N
CONCLUSIONS VB N
The DT N
nonlinear JJ N
PK NNP N
of IN N
linagliptin NN N
and CC N
its PRP$ N
plasma JJ N
DPP-4 JJ N
inhibition NN N
in IN N
patients NNS N
were VBD N
well RB N
characterized VBN N
by IN N
a DT N
target-mediated JJ N
drug NN N
disposition NN N
model NN N
relating VBG N
DPP-4 NNP N
occupancy NN N
with IN N
linagliptin NN N
to TO N
DPP-4 NNP N
inhibition NN N
Simulations NNS N
of IN N
plasma JJ N
DPP-4 NNP N
inhibition NN N
suggest VBP N
that IN N
5 CD N
mg NNS N
linagliptin JJ N
once RB N
daily JJ N
is VBZ N
an DT N
appropriate JJ N
therapeutic JJ N
dose NN N
for IN N
Japanese JJ N
patients NNS N
with IN N
T2DM NNP N
-DOCSTART- -X- O O 15681940

A DT N
phase NN N
III NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
, , N
multicenter NN N
study NN N
on IN N
the DT N
efficacy NN N
of IN N
recombinant JJ N
human JJ N
antithrombin NN N
in IN N
heparin-resistant JJ N
patients NNS N
scheduled VBN 4_p
to TO 4_p
undergo VB 4_p
cardiac JJ 4_p
surgery NN 4_p
necessitating VBG 4_p
cardiopulmonary JJ 4_p
bypass NN 4_p
BACKGROUND IN N
The DT N
study NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
recombinant JJ N
human JJ N
antithrombin NN N
( ( N
rhAT NN N
) ) N
for IN N
restoring VBG N
heparin NN N
responsiveness NN N
in IN N
heparin NN N
resistant JJ N
patients NNS N
undergoing VBG N
cardiac JJ N
surgery NN N
METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
in IN N
heparin-resistant JJ N
patients NNS N
undergoing VBG N
cardiac JJ 4_p
surgery NN 4_p
with IN N
cardiopulmonary JJ N
bypass NN N
Heparin NNP N
resistance NN N
was VBD N
diagnosed VBN N
when WRB N
the DT N
activated VBN N
clotting NN N
time NN N
was VBD N
less JJR N
than IN N
480 CD N
s NNS N
after IN N
400 CD N
U/kg NNP N
heparin NN N
Fifty-four JJ 3_p
heparin-resistant JJ N
patients NNS N
were VBD N
randomized VBN N
One CD N
cohort NN N
received VBD N
75 CD N
U/kg NNP N
rhAT NN N
, , N
and CC N
the DT N
other JJ N
received VBD N
normal JJ N
saline NN N
If IN N
the DT N
activated JJ N
clotting NN N
time NN N
remained VBD N
less JJR N
than IN N
480 CD N
s NN N
, , N
this DT N
was VBD N
considered VBN N
treatment NN N
failure NN N
, , N
and CC N
2 CD N
units NNS N
fresh JJ N
frozen JJ N
plasma NN N
was VBD N
transfused VBN N
Patients NNS N
were VBD N
monitored VBN N
for IN N
adverse JJ N
events NNS N
RESULTS NNP N
Only RB N
19 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
rhAT NN N
group NN N
received VBD N
fresh JJ N
frozen JJ N
plasma NN N
, , N
compared VBN N
with IN N
81 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
During IN N
their PRP$ N
hospitalization NN N
, , N
48 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
rhAT NN N
group NN N
received VBD N
fresh JJ N
frozen JJ N
plasma NN N
, , N
compared VBN N
with IN N
85 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
= NNP N
0.009 CD N
) ) N
Patients NNS N
in IN N
the DT N
placebo NN N
group NN N
required VBD N
higher JJR N
heparin NN N
doses NNS N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
for IN N
anticoagulation NN N
There EX N
was VBD N
no DT N
increase NN N
in IN N
serious JJ N
adverse JJ N
events NNS N
associated VBN N
with IN N
rhAT NN N
There EX N
was VBD N
increased VBN N
blood NN N
loss NN N
12 CD N
h NN N
postoperatively RB N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
with IN N
a DT N
trend NN N
toward IN N
increased VBN N
24-h JJ N
bleeding NN N
in IN N
the DT N
rhAT NN N
group NN N
( ( N
P NNP N
= NNP N
0.06 CD N
) ) N
There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
blood NN N
and CC N
platelet NN N
transfusions NNS N
CONCLUSION NNP N
Treatment NNP N
with IN N
75 CD N
U/kg NNP N
rhAT NN N
is VBZ N
effective JJ N
in IN N
restoring VBG N
heparin NN N
responsiveness NN N
and CC N
promoting VBG N
therapeutic JJ N
anticoagulation NN N
in IN N
the DT N
majority NN N
of IN N
heparin-resistant JJ N
patients NNS N
Treating VBG N
heparin-resistant JJ N
patients NNS N
with IN N
rhAT NN N
may MD N
decrease VB N
the DT N
requirement NN N
for IN N
heparin NN N
and CC N
fresh JJ N
frozen JJ N
plasma NN N
-DOCSTART- -X- O O 6721970

General NNP N
anaesthesia NN N
for IN N
caesarean JJ 4_p
section NN 4_p
in IN 4_p
severe JJ 4_p
pre-eclampsia NN 4_p
Comparison NNP N
of IN N
the DT N
renal JJ N
and CC N
hepatic JJ N
effects NNS N
of IN N
enflurane NN N
and CC N
halothane NN N
In IN N
a DT N
randomized JJ N
study NN N
of IN N
patients NNS 4_p
undergoing VBG 4_p
Caesarean JJ 4_p
section NN 4_p
, , 4_p
either CC 4_p
enflurane NN 4_p
( ( 4_p
mean JJ 4_p
0.24 CD 4_p
MAC-h NN 4_p
) ) 4_p
or CC 4_p
halothane NN 4_p
( ( 4_p
mean JJ 4_p
0.23 CD 4_p
MAC-h NN 4_p
) ) 4_p
and CC 4_p
50 CD 4_p
% NN 4_p
nitrous JJ 4_p
oxide NN 4_p
in IN 4_p
oxygen NN 4_p
were VBD N
administered VBN N
to TO N
women NNS 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
12 CD 4_p
) ) 4_p
with IN 4_p
severe JJ 4_p
pre-eclampsia-eclampsia NN 4_p
and CC 4_p
to TO 4_p
16 CD 4_p
healthy JJ 4_p
pregnant JJ 4_p
patients NNS 4_p
with IN 4_p
normal JJ 4_p
renal JJ 4_p
and CC 4_p
hepatic JJ 4_p
function NN 4_p
No DT N
evidence NN N
of IN N
nephrotoxicity NN N
was VBD N
found VBN N
in IN N
any DT N
pre-eclamptic JJ N
or CC N
normal JJ N
patient NN N
Metabolism NN N
of IN N
enflurane NN N
resulted VBD N
in IN N
plasma NN N
inorganic JJ N
fluoride NN N
concentrations NNS N
( ( N
max $ N
15 CD N
mumol NN N
litre NN N
-1 NNP N
) ) N
which WDT N
were VBD N
well RB N
below IN N
the DT N
toxic NN N
value NN N
Postoperative JJ N
liver NN N
function NN N
tests NNS N
showed VBD N
no DT N
important JJ N
changes NNS N
from IN N
preoperative JJ N
values NNS N
, , N
although IN N
reductive JJ N
metabolites NNS N
of IN N
halothane NN N
were VBD N
not RB N
measured VBN N
In IN N
patients NNS N
with IN N
severe JJ N
pre-eclampsia NN N
there EX N
appears VBZ N
no DT N
contraindication NN N
to TO N
enflurane VB N
or CC N
, , N
probably RB N
, , N
halothane NN N
as IN N
volatile JJ N
supplements NNS N
during IN N
general JJ N
anaesthesia NN N
-DOCSTART- -X- O O 24104511

Correlation NN N
of IN N
cognitive JJ N
and CC N
social JJ N
outcomes NNS N
among IN N
children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
behavioral JJ N
intervention NN N
Although IN N
social JJ N
impairments NNS N
are VBP N
considered VBN N
the DT N
hallmark NN N
deficit NN N
of IN N
autism NN N
, , N
many JJ N
behavioral JJ N
intervention NN N
studies NNS N
rely VBP N
on IN N
cognitive JJ N
functioning NN N
as IN N
a DT N
primary JJ N
outcome NN N
Fewer JJR N
studies NNS N
have VBP N
examined VBN N
whether IN N
changes NNS N
in IN N
cognition NN N
are VBP N
associated VBN N
with IN N
changes NNS N
in IN N
social JJ N
functioning NN N
This DT N
study NN N
examined VBD N
whether IN N
cognitive JJ N
gains NNS N
among IN N
192 CD 3_p
students NNS 3_p
from IN 3_p
47 CD 3_p
kindergarten-through-second-grade JJ 3_p
autism NN N
support NN 3_p
classrooms NNS 3_p
participating VBG N
in IN N
a DT N
year-long JJ N
behavioral JJ N
intervention NN N
study NN N
were VBD N
associated VBN N
with IN N
gains NNS N
in IN N
social JJ N
functioning NN N
Children NNP 1_p
's POS 1_p
gains NNS N
in IN N
cognitive JJ N
ability NN N
were VBD N
modestly RB N
associated VBN N
with IN N
independent JJ N
assessors NNS N
' POS N
and CC N
teachers NNS N
' POS N
evaluations NNS N
of IN N
social JJ N
functioning NN N
but CC N
were VBD N
not RB N
associated VBN N
with IN N
changes NNS N
in IN N
parent NN N
ratings NNS N
Observed VBN N
social JJ N
gains NNS N
were VBD N
not RB N
commensurate JJ N
with IN N
gains NNS N
in IN N
cognition NN N
, , N
suggesting VBG N
the DT N
need NN N
both DT N
for IN N
interventions NNS N
that WDT N
directly RB N
target VBP N
social JJ N
functioning NN N
and CC N
relevant JJ N
field NN N
measures NNS N
of IN N
social JJ N
functioning NN N
-DOCSTART- -X- O O 8331682

Low-dose JJ N
aspirin NN N
and CC N
incidence NN N
of IN N
colorectal JJ N
tumors NNS N
in IN N
a DT N
randomized JJ N
trial NN N
BACKGROUND NNP N
Laboratory NNP N
, , N
clinical JJ N
, , N
and CC N
epidemiologic JJ N
studies NNS N
have VBP N
recently RB N
suggested VBN N
that IN N
regular JJ N
use NN N
of IN N
aspirin NN N
can MD N
reduce VB N
colorectal JJ N
cancer NN N
incidence NN N
or CC N
mortality NN N
However RB N
, , N
observational JJ N
epidemiologic NN N
analyses NNS N
have VBP N
had VBN N
limited VBN N
opportunity NN N
to TO N
control VB N
for IN N
confounding VBG N
bias NN N
or CC N
to TO N
specify VB N
aspirin JJ N
doses NNS N
used VBN N
PURPOSE VB N
Our PRP$ N
purpose NN N
was VBD N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
regular JJ N
use NN N
of IN N
low-dose JJ N
aspirin NN N
and CC N
incidence NN N
of IN N
invasive JJ N
and CC N
noninvasive JJ N
colorectal NN N
tumors NNS N
by IN N
utilizing VBG N
data NNS N
from IN N
the DT N
Physicians NNPS N
' POS N
Health NNP N
Study NNP N
, , N
a DT N
randomized VBN N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
aspirin NN N
and CC N
beta NN N
carotene NN N
We PRP N
also RB N
attempted VBD N
to TO N
determine VB N
whether IN N
invasive JJ N
cancers NNS N
among IN N
aspirin JJ N
users NNS N
were VBD N
associated VBN N
with IN N
rectal JJ N
bleeding NN N
and CC N
early JJ N
stage NN N
at IN N
diagnosis NN N
METHODS NNP N
The DT N
Physicians NNPS N
' POS N
Health NNP N
Study NNP N
includes VBZ N
22071 CD 3_p
U.S. NNP N
male JJ 2_p
physicians NNS N
The DT N
aspirin JJ N
arm NN N
was VBD N
terminated VBN N
in IN N
1988 CD N
after IN N
a DT N
mean JJ N
follow-up NN N
of IN N
5 CD N
years NNS N
Stage NN N
at IN N
diagnosis NN N
and CC N
signs NNS N
and/or VBP N
symptoms NNS N
during IN N
presentation NN N
were VBD N
abstracted VBN N
from IN N
medical JJ N
records NNS N
Cox NNP N
proportional JJ N
hazards NNS N
models NNS N
were VBD N
used VBN N
to TO N
estimate VB N
relative JJ N
risk NN N
( ( N
RR NNP N
) ) N
, , N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
, , N
and CC N
the DT N
association NN N
between IN N
aspirin NN N
and CC N
bleeding NN N
Differences NNS N
between IN N
aspirin NN N
and CC N
placebo NN N
groups NNS N
in IN N
tumor NN N
risk NN N
over IN N
time NN N
were VBD N
visualized VBN N
with IN N
Kaplan-Meier NNP N
curves NNS N
We PRP N
assessed VBD N
the DT N
association NN N
between IN N
aspirin NN N
and CC N
stage NN N
at IN N
diagnosis NN N
with IN N
a DT N
Mann-Whitney NNP N
rank NN N
sum NN N
statistic NN N
for IN N
non-parametric JJ N
comparison NN N
of IN N
two CD N
ordinal JJ N
distributions NNS N
RESULTS VB N
The DT N
RR NNP N
of IN N
developing VBG N
colorectal JJ N
cancer NN N
for IN N
aspirin NNS N
compared VBN N
with IN N
placebo NN N
was VBD N
1.15 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
0.80-1.65 NN N
) ) N
For IN N
in IN N
situ NN N
cancers NNS N
and CC N
polyps NNS N
, , N
the DT N
RR NNP N
was VBD N
0.86 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
0.68-1.10 NN N
) ) N
There EX N
was VBD N
no DT N
significant JJ N
trend NN N
for IN N
decreasing VBG N
RR NNP N
by IN N
year NN N
of IN N
follow-up NN N
for IN N
invasive JJ N
cancers NNS N
( ( N
P NNP N
= NNP N
.09 NNP N
) ) N
or CC N
noninvasive JJ N
tumors NNS N
( ( N
P NNP N
= NNP N
.96 NNP N
) ) N
Aspirin NNP N
and CC N
placebo NN N
groups NNS N
did VBD N
not RB N
differ VB N
in IN N
stage NN N
or CC N
prevalence NN N
of IN N
rectal JJ N
bleeding NN N
at IN N
diagnosis NN N
CONCLUSIONS NNP N
Regular NNP N
aspirin NN N
use NN N
, , N
at IN N
a DT N
dose JJ N
adequate NN N
for IN N
preventing VBG N
myocardial JJ N
infarction NN N
, , N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
substantial JJ N
reduction NN N
in IN N
the DT N
incidence NN N
of IN N
colorectal JJ N
cancer NN N
during IN N
5 CD N
years NNS N
of IN N
randomized JJ N
treatment NN N
and CC N
follow-up NN N
A DT N
small JJ N
decrease NN N
in IN N
polyps NNS N
in IN N
the DT N
aspirin NN N
group NN N
could MD N
not RB N
be VB N
reliably RB N
distinguished VBN N
from IN N
a DT N
chance NN N
association NN N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
among IN N
low-dose JJ N
aspirin NN N
users NNS N
, , N
( ( N
a DT N
) ) N
colorectal NN N
cancer NN N
mortality NN N
is VBZ N
not RB N
likely JJ N
to TO N
be VB N
reduced VBN N
by IN N
earlier JJR N
detection NN N
and CC N
( ( N
b NN N
) ) N
incidence NN N
is VBZ N
not RB N
likely JJ N
to TO N
be VB N
increased VBN N
due JJ N
to TO N
aspirin-induced JJ N
gastrointestinal JJ N
bleeding NN N
IMPLICATIONS VBZ N
The DT N
potential NN N
for IN N
a DT N
benefit NN N
from IN N
higher JJR N
doses NNS N
of IN N
aspirin NN N
or CC N
longer JJR N
duration NN N
of IN N
use NN N
should MD N
be VB N
addressed VBN N
by IN N
more JJR N
detailed JJ N
observational JJ N
epidemiologic NN N
studies NNS N
and CC N
prevention NN N
trials NNS N
with IN N
longer JJR N
follow-up NN N
of IN N
randomized JJ N
participants NNS N
-DOCSTART- -X- O O 24146455

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
of IN N
Cappra® NNP N
for IN N
the DT N
treatment NN N
of IN N
mild NN 4_p
or CC 4_p
mild NN 4_p
to TO 4_p
moderate VB 4_p
erectile JJ 4_p
dysfunction NN 4_p
in IN 4_p
Thai NNP 4_p
male NN 2_p
Erectile JJ N
dysfunction NN N
( ( N
ED NNP N
) ) N
is VBZ N
one CD N
of IN N
the DT N
major JJ N
health NN N
concerns NNS N
affects VBZ N
the DT N
quality NN N
of IN N
life NN N
among IN N
Thai NNP N
male NN 2_p
The DT N
treatment NN N
of IN N
ED NNP N
by IN N
the DT N
first-line JJ N
drugs NNS N
is VBZ N
limited VBN N
to TO N
a DT N
certain JJ N
group NN N
of IN N
patients NNS N
due JJ N
to TO N
their PRP$ N
side NN N
effects NNS N
and CC N
costs NNS N
Alternative JJ N
medicine NN N
can MD N
be VB N
beneficial JJ N
for IN N
the DT N
treatment NN N
of IN N
ED NNP N
This DT N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
aimed VBN N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
Cappra NNP N
( ( N
® NNP N
) ) N
, , N
a DT N
traditional JJ N
herbal NN N
medicine NN N
which WDT N
was VBD N
used VBN N
in IN N
Thailand NNP N
for IN N
decades NNS N
, , N
for IN N
the DT N
treatment NN N
of IN 4_p
mild NN 4_p
and CC 4_p
mild NN 4_p
to TO 4_p
moderate VB 4_p
ED NNP 4_p
in IN 4_p
Thai NNP 4_p
patients NNS 4_p
A DT N
total NN N
of IN N
63 CD 3_p
patients NNS 3_p
with IN N
mild JJ 4_p
or CC 4_p
mild JJ 4_p
to TO 4_p
moderate VB 4_p
ED NNP 4_p
were VBD 4_p
randomized VBN 4_p
to TO N
receive VB N
Cappra NNP N
( ( N
® NNP N
) ) N
or CC N
placebo NN N
for IN N
two CD N
weeks NNS N
in IN N
the DT N
first JJ N
period NN N
, , N
followed VBN N
by IN N
one CD N
week NN N
washout NN N
period NN N
The DT N
patients NNS N
were VBD N
switched VBN N
to TO N
the DT N
alternative JJ N
treatment NN N
in IN N
the DT N
second JJ N
period NN N
The DT N
efficacy NN N
was VBD N
assessed VBN N
by IN N
the DT N
International NNP N
Index NNP N
of IN N
Erectile NNP N
Function NNP N
( ( N
IIEF NNP N
) ) N
questionnaire NN N
and CC N
adverse JJ N
events NNS N
Sixty NNP N
one CD N
patients NNS N
completed VBD N
the DT N
study NN N
There EX N
was VBD N
an DT N
improvement NN N
of IN N
IIEF NNP N
score NN N
for IN N
all DT N
domains NNS N
in IN N
Cappra NNP N
( ( N
® NNP N
) ) N
group NN N
compared VBN N
with IN N
placebo NN N
group NN N
The DT N
mean JJ N
change NN N
of IN N
IIEF NNP N
score NN N
from IN N
baseline NN N
for IN N
erectile JJ N
function NN N
domain NN N
of IN N
Cappra NNP N
( ( N
® NNP N
) ) N
was VBD N
significantly RB N
higher JJR N
than IN N
placebo NN N
( ( N
4.87 CD N
vs NN N
3.44 CD N
, , N
p NN N
= NNP N
0.032 CD N
) ) N
The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
were VBD N
dizziness NN N
( ( N
13.3 CD N
% NN N
Cappra NNP N
( ( N
® NNP N
) ) N
, , N
9.6 CD N
% NN N
placebo NN N
) ) N
, , N
face NN N
numbness NN N
( ( N
1.6 CD N
% NN N
Cappra NNP N
( ( N
® NNP N
) ) N
, , N
0 CD N
% NN N
placebo NN N
) ) N
, , N
and CC N
tachycardia NN N
( ( N
1.6 CD N
% NN N
Cappra NNP N
( ( N
® NNP N
) ) N
, , N
0 CD N
% NN N
placebo NN N
) ) N
The DT N
results NNS N
from IN N
this DT N
study NN N
demonstrated VBD N
that IN N
Cappra NNP N
( ( N
® NNP N
) ) N
is VBZ N
effective JJ N
and CC N
well-tolerated JJ N
and CC N
can MD N
be VB N
used VBN N
as IN N
alternative JJ N
therapy NN N
for IN N
mild NN N
and CC N
mild NN N
to TO N
moderate VB N
ED NNP N
-DOCSTART- -X- O O 2374275

Nicotinic JJ N
acid NN N
as IN N
therapy NN N
for IN N
dyslipidemia NN N
in IN N
non-insulin-dependent JJ 4_p
diabetes NNS 4_p
mellitus NN 4_p
Recently RB N
, , N
nicotinic JJ N
acid NN N
has VBZ N
been VBN N
recommended VBN N
as IN N
a DT N
first-line JJ N
hypolipidemic JJ N
drug NN N
To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
nicotinic JJ N
acid NN N
in IN N
dyslipidemic JJ 4_p
patients NNS 4_p
with IN 4_p
non-insulin-dependent JJ 4_p
diabetes NNS 4_p
mellitus VBP 4_p
, , 4_p
13 CD 4_p
patients NNS 4_p
were VBD 4_p
treated VBN 4_p
in IN 4_p
a DT 4_p
randomized JJ 4_p
crossover NN 4_p
trial NN 4_p
Patients NNS N
received VBD N
either RB N
nicotinic JJ N
acid NN N
( ( N
1.5 CD N
g NN N
three CD N
times NNS N
daily RB N
) ) N
or CC N
no DT N
therapy NN N
( ( N
control JJ N
period NN N
) ) N
for IN N
8 CD N
weeks NNS N
each DT N
Compared VBN N
with IN N
the DT N
control NN N
period NN N
, , N
nicotinic JJ N
acid NN N
therapy NN N
reduced VBD N
the DT N
plasma NN N
total JJ N
cholesterol NN N
level NN N
by IN N
24 CD N
% NN N
, , N
plasma JJ N
triglyceride IN N
level NN N
by IN N
45 CD N
% NN N
, , N
very-low-density NN N
lipoprotein NN N
cholesterol NN N
level NN N
by IN N
58 CD N
% NN N
, , N
and CC N
low-density NN N
lipoprotein NN N
cholesterol NN N
level NN N
by IN N
15 CD N
% NN N
, , N
and CC N
it PRP N
increased VBD N
the DT N
high-density NN N
lipoprotein NN N
cholesterol NN N
level NN N
by IN N
34 CD N
% NN N
However RB N
, , N
nicotinic JJ N
acid NN N
therapy NN N
resulted VBD N
in IN N
the DT N
deterioration NN N
of IN N
glycemic JJ N
control NN N
, , N
as IN N
evidenced VBN N
by IN N
a DT N
16 CD N
% NN N
increase NN N
in IN N
mean JJ N
plasma NN N
glucose JJ N
concentrations NNS N
, , N
a DT N
21 CD N
% NN N
increase NN N
in IN N
glycosylated JJ N
hemoglobin NN N
levels NNS N
, , N
and CC N
the DT N
induction NN N
of IN N
marked JJ N
glycosuria NN N
in IN N
some DT N
patients NNS N
Furthermore NNP N
, , N
a DT N
consistent JJ N
increase NN N
in IN N
plasma JJ N
uric JJ N
acid NN N
levels NNS N
was VBD N
observed VBN N
Therefore RB N
, , N
despite IN N
improvement NN N
in IN N
lipid JJ N
and CC N
lipoprotein JJ N
concentrations NNS N
, , N
because IN N
of IN N
worsening VBG N
hyperglycemia NN N
and CC N
the DT N
development NN N
of IN N
hyperuricemia NN N
, , N
nicotinic JJ N
acid NN N
must MD N
be VB N
used VBN N
with IN N
caution NN N
in IN N
patients NNS N
with IN N
non-insulin-dependent JJ N
diabetes NNS N
mellitus VBP N
with IN N
dyslipidemia NN N
We PRP N
suggest VBP N
that IN N
the DT N
drug NN N
not RB N
be VB N
used VBN N
as IN N
a DT N
first-line JJ N
hypolipidemic JJ N
drug NN N
in IN N
patients NNS N
with IN N
non-insulin-dependent JJ N
diabetes NNS N
mellitus NN N
-DOCSTART- -X- O O 25453593

A DT N
step-by-step JJ N
introduction NN N
to TO N
vegetables NNS N
at IN N
the DT N
beginning NN N
of IN N
complementary JJ N
feeding NN N
The DT N
effects NNS N
of IN N
early JJ N
and CC N
repeated JJ N
exposure NN N
Breastfeeding NNP 4_p
( ( 4_p
BF NNP 4_p
) ) 4_p
is VBZ N
associated VBN N
with IN N
willingness NN N
to TO N
accept VB N
vegetables NNS N
This DT N
may MD N
be VB N
due JJ N
to TO N
the DT N
variety NN N
of IN N
flavours NNS N
delivered VBN N
via IN N
breast NN N
milk NN N
Some DT N
mothers NNS 2_p
add VBP N
vegetables NNS N
to TO N
milk VB N
during IN N
complementary JJ N
feeding NN N
( ( N
CF NNP N
) ) N
to TO N
enhance VB N
acceptance NN N
The DT N
present JJ N
study NN N
tested VBD N
a DT N
step-by-step JJ N
exposure NN N
to TO N
vegetables NNS N
in IN N
milk NN N
then RB N
rice NN N
during IN N
CF NNP N
, , N
on IN N
intake NN N
and CC N
liking NN N
of IN N
vegetables NNS N
Just NNP N
before IN N
CF NNP N
, , N
enrolled VBD N
mothers NNS 2_p
were VBD N
randomised VBN N
to TO N
an DT N
intervention NN N
( ( N
IG NNP N
, , N
n JJ N
= VBP N
18 CD 3_p
; : N
6 CD N
BF NNP N
) ) N
or CC N
control VB N
group NN N
( ( N
CG NNP N
, , N
n JJ N
= VBP N
18 CD N
; : N
6 CD N
BF NNP N
) ) N
IG JJ N
infants NNS N
received VBD N
12 CD N
daily JJ N
exposures NNS N
to TO N
vegetable JJ N
puree NN N
added VBD N
to TO N
milk VB N
( ( N
days NNS N
1-12 RB N
) ) N
, , N
then RB N
12 CD N
× NNS N
2 CD N
daily JJ N
exposures NNS N
to TO N
vegetable JJ N
puree NN N
added VBD N
to TO N
rice VB N
at IN N
home NN N
( ( N
days NNS N
13-24 RB N
) ) N
Plain NNP N
milk NN N
and CC N
rice NN N
were VBD N
given VBN N
to TO N
CG NNP N
Then RB N
both DT N
received VBD N
11 CD N
daily JJ N
exposures NNS N
to TO N
vegetable JJ N
puree NN N
Intake NNP N
was VBD N
weighed VBN N
and CC N
liking VBG N
rated VBN N
on IN N
days NNS N
25-26 JJ N
and CC N
33-35 JJ N
after IN N
the DT N
start NN N
of IN N
CF NNP N
in IN N
the DT N
laboratory NN N
, , N
supplemented VBN N
by IN N
the DT N
same JJ N
data NN N
recorded VBD N
at IN N
home NN N
Vegetables NNS N
were VBD N
rotated VBN N
daily RB N
( ( N
carrots NNS N
, , N
green JJ N
beans NNS N
, , N
spinach NN N
, , N
broccoli NN N
) ) N
Intake NNP N
, , N
liking VBG N
and CC N
pace NN N
of IN N
eating VBG N
were VBD N
greater JJR N
for IN N
IG NNP N
than IN N
CG NNP N
infants NNS N
Intake NNP N
and CC N
liking NN N
of IN N
carrots NNS N
were VBD N
greater JJR N
than IN N
green JJ N
beans NNS N
However RB N
, , N
at IN N
6m CD N
then RB N
18m CD N
follow VBP N
up RB N
, , N
vegetable JJ N
( ( N
carrot JJ N
> NN N
green JJ N
beans NNS N
) ) N
but CC N
not RB N
group NN N
differences NNS N
were VBD N
observed VBN N
Mothers NNS N
reported VBD N
appreciation NN N
of IN N
the DT N
structure NN N
and CC N
guidance NN N
of IN N
this DT N
systematic JJ N
approach NN N
Early JJ N
exposure NN N
to TO N
vegetables NNS N
in IN N
a DT N
step-by-step JJ N
method NN N
could MD N
be VB N
included VBN N
in IN N
CF NNP N
guidelines NNS N
and CC N
longer JJR N
term NN N
benefits NNS N
assessed VBN N
by IN N
extending VBG N
the DT N
exposure NN N
period NN N
-DOCSTART- -X- O O 9261669

High-dose JJ N
pyridoxine NN N
and CC N
magnesium NN N
administration NN N
in IN N
children NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
: : N
an DT N
absence NN N
of IN N
salutary JJ N
effects NNS N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
Several JJ N
reports NNS N
have VBP N
described VBN N
salutary JJ N
effects NNS N
such JJ N
as IN N
decreased JJ N
physical JJ N
aggression NN N
and CC N
improved VBN N
social JJ N
responsiveness NN N
being VBG N
associated VBN N
with IN N
the DT N
administration NN N
of IN N
high JJ N
doses NNS N
of IN N
pyridoxine NN N
and CC N
magnesium NN N
( ( N
HDPM NNP N
) ) N
in IN N
open-labeled JJ N
and CC N
controlled JJ N
studies NNS N
of IN N
patients NNS N
with IN N
autism NN 4_p
Despite IN N
this DT N
fact NN N
, , N
this DT N
intervention NN N
remains VBZ N
controversial JJ N
A DT N
10-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
examine VB N
both DT N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
HDPM NNP N
in IN N
autism NN N
Twelve CD 3_p
patients NNS N
were VBD N
enrolled VBN N
, , N
and CC N
10 CD 3_p
patients NNS N
( ( N
mean JJ N
age NN N
6 CD 1_p
years NNS 1_p
3 CD 1_p
months NNS 1_p
) ) N
were VBD N
able JJ N
to TO N
complete VB N
the DT N
study NN N
HDPM NNP N
at IN N
an DT N
average JJ N
dose NN N
of IN N
638.9 CD N
mg NN N
of IN N
pyridoxine NN N
and CC N
216.3 CD N
mg NN N
of IN N
magnesium NN N
oxide NN N
was VBD N
ineffective JJ N
in IN N
ameliorating VBG N
autistic JJ N
behaviors NNS N
as IN N
assessed VBN N
by IN N
the DT N
Children NNP N
's POS N
Psychiatric NNP N
Rating NNP N
Scale NNP N
( ( N
CPRS NNP N
) ) N
, , N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
Scale NNP N
, , N
and CC N
the DT N
NIMH NNP N
Global NNP N
Obsessive NNP N
Compulsive NNP N
Scale NNP N
Furthermore NNP N
, , N
no DT N
clinically RB N
significant JJ N
side NN N
effects NNS N
were VBD N
noted VBN N
during IN N
HDPM NNP N
administration NN N
A DT N
trend NN N
for IN N
a DT N
transient JJ N
change NN N
on IN N
the DT N
CPRS NNP N
was VBD N
found VBN N
that IN N
was VBD N
possibly RB N
due JJ N
to TO N
a DT N
placebo NN N
response NN N
This DT N
study NN N
raises VBZ N
doubts NNS N
about IN N
the DT N
clinical JJ N
effectiveness NN N
of IN N
HDPM NNP N
in IN N
autistic JJ N
disorder NN N
-DOCSTART- -X- O O 21389925

Role NNP N
of IN N
oxidized VBN N
regenerated VBN N
cellulose NN N
in IN N
preventing VBG N
infections NNS N
at IN N
the DT N
surgical JJ N
site NN N
: : N
prospective JJ N
, , N
randomized VBN N
study NN N
in IN N
98 CD 4_p
patients NNS 4_p
affected VBN 4_p
by IN 4_p
a DT 4_p
dirty NN 4_p
wound NN 4_p
AIM IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
oxidized JJ N
regenerated VBN N
cellulose NN N
( ( N
ORC NNP N
) ) N
, , N
applied VBN N
to TO N
" VB N
dirty JJ N
" NNP N
surgical JJ N
wounds NNS N
, , N
is VBZ N
able JJ N
to TO N
reduce VB N
the DT N
microbial JJ N
load NN N
and CC N
, , N
consequently RB N
, , N
the DT N
infection NN N
rate NN N
as IN N
compared VBN N
to TO N
conventional JJ N
local JJ N
wound NN N
treatment NN N
METHODS NNP N
The DT N
study NN N
included VBD N
98 CD N
patients NNS N
who WP N
underwent VBP N
intestinal JJ N
recanalization NN N
procedures NNS N
between IN N
December NNP N
2003 CD N
and CC N
December NNP N
2008 CD N
, , N
with IN N
the DT N
stoma NN N
as IN N
the DT N
surgical JJ N
site NN N
Authors NNS N
considered VBD N
several JJ N
risk NN N
factors NNS N
for IN N
SSI NNP N
The DT N
patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
In IN N
group NN N
A NNP N
( ( N
50 CD N
patients NNS N
) ) N
, , N
the DT N
surgical JJ N
wound NN N
, , N
previous JJ N
site NN N
of IN N
the DT N
stoma NN N
, , N
was VBD N
packed VBN N
with IN N
ORC NNP N
, , N
whereas RB N
in IN N
group NN N
B NNP N
( ( N
48 CD N
patients NNS N
) ) N
gauze VBP N
soaked VBN N
in IN N
iodine NN N
was VBD N
used VBN N
Microbial JJ N
contamination NN N
was VBD N
evaluated VBN N
with IN N
three CD N
swabs NNS N
( ( N
in IN N
subcutaneous JJ N
tissue NN N
and CC N
the DT N
dermis NN N
) ) N
, , N
in IN N
the DT N
operating NN N
room NN N
before IN N
wound NN N
packing NN N
and CC N
on IN N
the DT N
2nd CD N
and CC N
3rd CD N
postoperative JJ N
day NN N
( ( N
before IN N
suturing VBG N
the DT N
skin NN N
) ) N
RESULTS CC N
There EX N
were VBD N
no DT N
cases NNS N
of IN N
wound NN N
dehiscence NN N
and CC N
no DT N
clinically RB N
evident JJ N
superficial NN N
or CC N
deep JJ N
surgical JJ N
site NN N
infections NNS N
in IN N
either DT N
group NN N
Analysis NN N
of IN N
all DT N
data NNS N
revealed VBD N
that IN N
there EX N
was VBD N
no DT N
or CC N
reduced VBN N
bacterial JJ N
contamination NN N
in IN N
the DT N
second JJ N
and CC N
third JJ N
swab NN N
in IN N
33 CD N
patients NNS N
( ( N
66 CD N
% NN N
) ) N
of IN N
Group NNP N
A NNP N
versus NN N
12 CD N
patients NNS N
( ( N
25 CD N
% NN N
) ) N
of IN N
Group NNP N
B NNP N
CONCLUSION NNP N
Although IN N
it PRP N
is VBZ N
necessary JJ N
to TO N
consider VB N
all DT N
factors NNS N
which WDT N
can MD N
have VB N
an DT N
influence NN N
on IN N
SSI NNP N
and CC N
use VB N
all PDT N
the DT N
means NNS N
shown VBN N
to TO N
be VB N
effective JJ N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
SSI NNP N
, , N
there EX N
is VBZ N
a DT N
rationale NN N
for IN N
using VBG N
ORC NNP N
to TO N
prevent VB N
this DT N
kind NN N
of IN N
infection NN N
, , N
especially RB N
in IN N
patients NNS N
who WP N
undergo VBP N
" NNP N
dirty NN N
" NN N
surgery NN N
-DOCSTART- -X- O O 19035420

Efficacy NN N
of IN N
wrist NN N
working VBG N
splints NNS N
in IN N
patients NNS N
with IN N
rheumatoid JJ N
arthritis NN N
: : N
a DT N
randomized NN N
controlled VBN N
study NN N
OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
efficacy NN N
of IN N
wrist NN N
working VBG N
splints NNS N
after IN N
a DT N
period NN N
of IN N
splinting VBG N
in IN N
patients NNS N
with IN N
rheumatoid JJ N
arthritis NN N
( ( N
RA NNP N
) ) N
METHODS NNP N
We PRP N
performed VBD N
a DT N
4-week JJ N
randomized NN N
controlled VBN 4_p
trial NN 4_p
among IN 4_p
33 CD 3_p
RA NNP 3_p
patients NNS 3_p
with IN 4_p
wrist JJ 4_p
arthritis NN 4_p
Patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
splinting VBG N
group NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
or CC N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
Patients NNS 4_p
in IN 4_p
the DT 4_p
splinting NN 4_p
group NN 4_p
received VBD N
a DT N
prefabricated JJ N
wrist NN N
working VBG N
splint NN N
and CC N
were VBD N
instructed VBN N
to TO N
use VB N
this DT N
splint NN N
as RB N
much RB N
as IN N
possible JJ N
during IN N
the DT N
day NN N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
average JJ N
wrist JJ N
pain NN N
during IN N
the DT N
past JJ N
week NN N
, , N
measured VBN N
using VBG N
a DT N
visual JJ N
analog NN N
scale NN N
( ( N
VAS NNP N
) ) N
Secondary JJ N
outcome NN N
measures NNS N
were VBD N
grip JJ N
strength NN N
and CC N
functional JJ N
ability NN N
The DT N
latter NN N
was VBD N
measured VBN N
using VBG N
the DT N
Disabilities NNPS N
of IN N
the DT N
Arm NNP N
, , N
Shoulder NNP N
, , N
and CC N
Hand NNP N
questionnaire NN N
and CC N
the DT N
short JJ N
version NN N
of IN N
the DT N
Sequential NNP N
Occupational NNP N
Dexterity NNP N
Assessment NNP N
Measurements NNS N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
after IN N
4 CD N
weeks NNS N
Performance NN N
tests NNS N
were VBD N
performed VBN N
without IN N
splint NN N
Differences NNS N
in IN N
change NN N
scores NNS N
between IN N
the DT N
splinting NN N
and CC N
the DT N
control NN N
group NN N
were VBD N
analyzed VBN N
using VBG N
analysis NN N
of IN N
covariance NN N
To TO N
indicate VB N
the DT N
magnitude NN N
of IN N
the DT N
treatment NN N
effects NNS N
, , N
effect NN N
sizes NNS N
were VBD N
calculated VBN N
RESULTS VB N
A DT N
large JJ N
and CC N
highly RB N
significant JJ N
treatment NN N
effect NN N
on IN N
wrist NN N
pain NN N
was VBD N
found VBN N
VAS NNP N
pain NN N
scores NNS N
decreased VBN N
by IN N
32 CD N
% NN N
in IN N
the DT N
splinting NN N
group NN N
and CC N
increased VBN N
by IN N
17 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
Small NNP N
and CC N
nonsignificant JJ N
treatment NN N
effects NNS N
were VBD N
found VBN N
with IN N
regard NN N
to TO N
nonsplinted VBN N
grip NN N
strength NN N
and CC N
functional JJ N
ability NN N
CONCLUSION NNP N
Prefabricated NNP N
wrist NN N
working VBG N
splints NNS N
are VBP N
highly RB N
effective JJ N
in IN N
reducing VBG N
wrist NN N
pain NN N
after IN N
4 CD N
weeks NNS N
of IN N
splint NN N
wearing NN N
in IN N
RA NNP N
patients NNS N
with IN N
wrist JJ N
arthritis NN N
-DOCSTART- -X- O O 3556337

Effects NNS N
of IN N
nifedipine NN N
on IN N
gastric JJ 4_p
acid JJ 4_p
secretion NN 4_p
and CC N
gastrin NN 4_p
release NN 4_p
in IN N
man NN 2_p
As IN N
calcium NN N
is VBZ N
important JJ N
in IN N
the DT N
regulation NN N
of IN N
gastric JJ N
acid JJ N
secretion NN N
and CC N
gastrin NN N
release NN N
, , N
we PRP N
have VBP N
examined VBN N
the DT N
effect NN N
of IN N
the DT N
calcium NN N
antagonist NN N
nifedipine NN N
on IN N
these DT N
processes NNS N
in IN N
man NN N
Nifedipine CC N
30 CD N
mg NNS N
orally RB N
inhibited VBN N
basal NN N
acid NN N
output NN N
by IN N
37 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.025 CD N
) ) N
and CC N
that IN N
stimulated VBN N
by IN N
low JJ N
infusion NN N
rates NNS N
of IN N
pentagastrin NN N
-- : N
that WDT N
is VBZ N
, , N
0.031 CD N
and CC N
0.062 CD N
microgram/kg/h NN N
by IN N
44 CD N
% NN N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
and CC N
39 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
respectively RB N
On IN N
increasing VBG N
the DT N
pentagastrin JJ N
infusion NN N
rate NN N
the DT N
inhibition NN N
was VBD N
surmounted VBN N
suggesting VBG N
it PRP N
was VBD N
competitive JJ N
in IN N
type NN N
Nifedipine NNP N
did VBD N
not RB N
affect VB N
basal NN N
or CC N
Oxo NNP N
meal NN N
stimulated VBD N
gastrin JJ N
concentrations NNS N
in IN N
normal JJ N
volunteers NNS N
nor CC N
did VBD N
it PRP N
affect VB N
resting VBG N
serum JJ N
gastrin NN N
or CC N
calcium NN N
stimulated JJ N
increase NN N
in IN N
gastrin NN N
in IN N
a DT N
single JJ N
patient NN N
with IN N
Zollinger-Ellison NNP 4_p
syndrome NN 4_p
These DT N
findings NNS N
are VBP N
consistent JJ N
with IN N
the DT N
transmembrane NN N
flux NN N
of IN N
calcium NN N
ions NNS N
being VBG N
involved VBN N
in IN N
basal NN N
and CC N
pentagastrin NN 4_p
stimulated VBD 4_p
acid JJ 4_p
secretion NN 4_p
in IN N
man NN N
-DOCSTART- -X- O O 20562617

Hematologic NNP 4_p
patients NNS N
' POS N
clinical JJ N
and CC N
psychosocial JJ N
experiences NNS N
with IN N
implanted JJ N
long-term JJ N
central JJ 4_p
venous JJ 4_p
catheter NN 4_p
: : N
self-management JJ N
versus NN N
professionally RB N
controlled VBN N
care NN N
BACKGROUND VB N
A DT N
significant JJ N
decrease NN N
in IN N
catheter-related JJ N
infections NNS N
was VBD N
demonstrated VBN N
in IN N
our PRP$ N
earlier JJR N
randomized VBN N
controlled JJ N
trial NN N
of IN N
central JJ N
venous JJ N
catheter NN N
( ( N
CVC NNP N
) ) N
care NN N
in IN N
hematologic JJ 4_p
patients NNS N
OBJECTIVE IN N
This DT N
article NN N
focuses VBZ N
on IN N
patients NNS N
' POS N
clinical JJ N
and CC N
psychosocial JJ N
experiences NNS N
with IN N
CVC NNP N
self-care NN N
compared VBN N
with IN N
professionally RB N
controlled VBN N
CVC NNP N
care NN N
METHODS NNP N
Eighty-two JJ 3_p
patients NNS N
with IN N
tunneled JJ N
CVCs NNP 4_p
were VBD N
enrolled VBN N
in IN N
the DT N
randomized NN N
controlled VBD N
trial NN N
The DT N
intervention NN N
group NN N
( ( N
n JJ N
= NNP N
42 CD N
) ) N
was VBD N
trained VBN N
to TO N
perform VB N
CVC NNP N
self-care NN N
The DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
40 CD N
) ) N
followed VBD N
standard JJ N
CVC NNP N
procedure NN N
provided VBN N
by IN N
nurses NNS N
Eighteen JJ N
patients NNS N
were VBD N
selected VBN N
for IN N
semistructured JJ N
interviews NNS N
focusing VBG N
on IN N
patients NNS N
' POS N
clinical JJ N
and CC N
psychosocial JJ N
experiences NNS N
with IN N
CVCs NNP N
RESULTS NNP N
Methods NNP N
of IN N
CVC NNP N
care NN N
have VBP N
different JJ N
influences NNS N
on IN N
the DT N
patients NNS N
' POS N
clinical JJ N
and CC N
psychosocial JJ N
outcomes NNS N
, , N
depending VBG N
on IN N
whether IN N
they PRP N
were VBD N
hospitalized VBN N
or CC N
outpatients NNS N
Central NNP N
venous JJ N
catheter NN N
was VBD N
viewed VBN N
as IN N
important JJ N
because IN N
it PRP N
was VBD N
the DT N
main JJ N
port NN N
of IN N
treatment NN N
toward IN N
a DT N
cure NN N
, , N
although IN N
patients NNS N
constantly RB N
fear VBP N
complications NNS N
Central NNP N
venous JJ N
catheter NN N
self-care NN N
increased VBD N
patients NNS N
' POS N
independence NN N
from IN N
health NN N
professionals NNS N
and CC N
supported VBD N
perceived VBN N
self-efficacy NN N
and CC N
control NN N
Central NNP N
venous JJ N
catheters NNS N
cause VBP N
psychosocial JJ N
problems NNS N
including VBG N
altered VBD N
body NN N
perception NN N
, , N
sexual JJ N
activity NN N
avoidance NN N
, , N
and CC N
feeling VBG N
stigmatized VBN N
CONCLUSIONS JJ N
Patients NNPS N
experience NN N
increased VBD N
perceived VBN N
self-control NN N
and CC N
independence NN N
when WRB N
individually RB N
supervised VBN N
and CC N
trained VBN N
in IN N
CVC NNP N
self-management NN N
Assuming VBG N
ownership NN N
of IN N
CVC NNP N
care NN N
can MD N
encourage VB N
patients NNS N
to TO N
feel VB N
less RB N
inhibited VBN N
about IN N
sexual JJ N
activity NN N
and CC N
socialization NN N
IMPLICATIONS NNP N
FOR NNP N
PRACTICE NNP N
Placement NNP N
of IN N
a DT N
tunneled JJ N
CVC NNP N
should MD N
engage VB N
nurses NNS N
to TO N
organize VB N
individualized JJ N
structured VBN N
and CC N
supervised VBN N
patient JJ N
education NN N
Stigma NNP N
originating VBG N
from IN N
CVCs NNP N
should MD N
be VB N
carefully RB N
considered VBN N
by IN N
health NN N
professionals NNS N
when WRB N
maintaining VBG N
CVC NNP N
insertion NN N
for IN N
longer JJR N
periods NNS N
Central NNP N
venous JJ N
catheters NNS N
should MD N
be VB N
removed VBN N
whenever WRB N
the DT N
potential JJ N
risks NNS N
exceed VBP N
the DT N
catheter NN N
's POS N
functional JJ N
necessity NN N
-DOCSTART- -X- O O 18501909

Penetration NN N
and CC N
accumulation NN N
of IN N
moxifloxacin NN N
in IN N
uterine JJ N
tissue NN N
OBJECTIVE NN N
To TO N
determine VB N
whether IN N
moxifloxacin NN N
penetrates VBZ N
the DT N
uterine JJ N
tissue NN N
and CC N
accumulates NNS N
at IN N
levels NNS N
sufficient JJ N
to TO N
eradicate VB N
the DT N
major JJ N
pathogens NNS N
causing VBG N
pelvic JJ 4_p
inflammatory JJ 4_p
disease NN 4_p
( ( 4_p
PID NNP 4_p
) ) 4_p
METHOD NNP N
In IN N
a DT N
prospective JJ N
, , N
multicenter NN N
, , N
open-label JJ N
, , N
parallel-group JJ N
study NN N
we PRP N
determined VBD N
the DT N
concentration NN N
of IN N
moxifloxacin NN N
in IN N
plasma NN N
and CC N
uterine JJ N
tissue NN N
after IN N
a DT N
single JJ N
, , N
400-mg JJ N
intravenous JJ N
dose NN N
of IN N
moxifloxacin NN N
Study NN N
participants NNS N
were VBD N
randomized VBN N
for IN N
time NN N
of IN N
tissue NN N
sampling NN N
, , N
which WDT N
was VBD N
performed VBN N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
7 CD N
, , N
or CC N
24 CD N
hours NNS N
following VBG N
the DT N
moxifloxacin JJ N
infusion NN N
RESULTS NNP N
Of IN N
43 CD 3_p
participants NNS N
, , N
40 CD 3_p
were VBD N
randomized VBN N
to TO N
tissue VB N
sampling VBG N
Moxifloxacin NNP N
accumulated VBD N
in IN N
uterine JJ N
tissue NN N
and CC N
concentrations NNS N
were VBD N
highest JJS N
1 CD N
hour NN N
after IN N
infusion NN N
in IN N
both DT N
plasma NN N
and CC N
tissue NN N
Tissue NN N
to TO N
plasma VB N
ratios NNS N
remained VBD N
between IN N
1.7 CD N
and CC N
2.1 CD N
for IN N
24 CD N
hours NNS N
Moxifloxacin NNP N
was VBD N
found VBN N
to TO N
be VB N
safe JJ N
and CC N
well RB N
tolerated VBN N
CONCLUSION NNP N
Based VBD N
on IN N
known VBN N
minimum JJ N
inhibitory JJ N
concentration NN N
data NNS N
, , N
the DT N
uterine JJ N
tissue NN N
concentrations NNS N
of IN N
moxifloxacin NN N
achieved VBN N
over IN N
24 CD N
hours NNS N
would MD N
be VB N
sufficient JJ N
to TO N
eradicate VB N
the DT N
range NN N
of IN N
bacterial JJ N
pathogens NNS N
responsible JJ N
for IN N
PID NNP 4_p
-DOCSTART- -X- O O 26742304

Effect NN N
of IN N
direct JJ N
current JJ N
pulse NN N
stimulating VBG N
acupoints NNS N
of IN N
JiaJi NNP N
( ( N
T10-13 NNP N
) ) N
and CC N
Ciliao NNP N
( ( N
BL NNP N
32 CD N
) ) N
with IN N
Han NNP N
's POS N
Acupoint NNP N
Nerve NNP N
Stimulator NNP N
on IN N
labour NN 4_p
pain NN 4_p
in IN N
women NNS 2_p
: : N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
study NN N
OBJECTIVE NNP N
To TO N
assess VB N
the DT N
clinical JJ N
effect NN N
and CC N
safety NN N
of IN N
direct JJ N
current JJ N
( ( N
DC NNP N
) ) N
pulse NN N
produced VBN N
by IN N
Han NNP N
's POS N
Acupoint NNP N
Nerve NNP N
Stimulator NNP N
in IN N
reduction NN N
( ( N
HANS NNP N
) ) N
of IN N
labor NN N
pain NN N
METHODS NNP N
Totally RB N
120 CD 3_p
participants NNS N
were VBD N
enrolled VBN N
in IN N
this DT N
clinical JJ N
trial NN N
, , N
and CC N
were VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
groups NNS N
including VBG N
: : N
HANS NNP N
group NN N
, , N
patient NN N
controlled VBD N
intravenous JJ N
analgesia NN N
( ( N
PCIA NNP N
) ) N
group NN N
, , N
patient-controlled JJ N
epidural JJ N
analgesia NN N
( ( N
PCEA NNP N
) ) N
group NN N
and CC N
control NN N
group NN N
The DT N
HANS NNP N
group NN N
was VBD N
treated VBN N
by IN N
stimulating VBG N
the DT N
acupoints NNS N
of IN N
JiaJi NNP N
( ( N
T10-L3 NNP N
) ) N
and CC N
Ciliao NNP N
( ( N
BL NNP N
32 CD N
) ) N
with IN N
DC NNP N
pulse NN N
of IN N
100 CD N
Hz NNP N
and CC N
15-30 JJ N
mA NN N
produced VBN N
by IN N
a DT N
portable JJ N
battery-powered JJ N
Han NNP N
's POS N
Acupoint NNP N
Nerve NNP N
Stimulator NNP N
for IN N
30 CD N
min NN N
The DT N
PCIA NNP N
group NN N
was VBD N
intravenously RB N
infused VBN N
Ondansetron NNP N
( ( N
8 CD N
mg NN N
) ) N
for IN N
5 CD N
min NNS N
, , N
then RB N
tramadol VB N
injection NN N
( ( N
1.5 CD N
mg/kg NN N
) ) N
was VBD N
slowly RB N
dripped VBN N
by IN N
using VBG N
BaxterAP NNP N
II NNP N
electronic JJ N
pump NN N
with IN N
50 CD N
mL NNS N
tramadol NN N
( ( N
0.70 CD N
% NN N
) ) N
+ NN N
ondansetron NN N
( ( N
8 CD N
mg NN N
) ) N
, , N
background JJ N
infusion NN N
2 CD N
mL/h NN N
, , N
PCA NNP N
dose NN N
of IN N
2 CD N
mL NNS N
, , N
lockout IN N
interval NN N
of IN N
10 CD N
min NN N
In IN N
PCEA NNP N
group NN N
, , N
women NNS N
received VBD N
intrathecal JJ N
injection NN N
ropivacaine NN N
( ( N
3 CD N
mg NN N
) ) N
in IN N
L2-3 NNP N
, , N
and CC N
epidural JJ N
catheter NN N
was VBD N
connected VBN N
to TO N
BaxterAP NNP N
II NNP N
electronic JJ N
pump NN N
, , N
with IN N
100 CD N
mL NNS N
Ropivacaine NNP N
( ( N
0.1 CD N
% NN N
) ) N
and CC N
Sufentanil NNP N
( ( N
50 CD N
ug NN N
) ) N
, , N
background JJ N
infusion NN N
5 CD N
mL NN N
, , N
Patient NNP N
controlled VBD N
analgesia NN N
( ( N
PCA NNP N
) ) N
dose NN N
of IN N
5 CD N
mL NNS N
, , N
lockout IN N
interval NN N
of IN N
10 CD N
min NN N
The DT N
control NN N
group NN N
was VBD N
not RB N
received VBN N
analgesia NN N
The DT N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
, , N
stage NN N
and CC N
manner NN N
of IN N
labor NN N
, , N
Apgar NNP N
score NN N
of IN N
newborn JJ N
, , N
neonatal JJ N
weights NNS N
, , N
oxytocin JJ N
dosage NN N
, , N
postpartum NN N
hemorrhage NN N
and CC N
side NN N
effects NNS N
were VBD N
monitored VBN N
in IN N
all DT N
groups NNS N
RESULTS VB N
The DT N
vital JJ N
signs NNS N
were VBD N
all DT N
stable JJ N
in IN N
the DT N
four CD N
analgesic JJ N
groups NNS N
After IN N
analgesia NN N
, , N
there EX N
was VBD N
statistical JJ N
difference NN N
in IN N
VAS NNP N
score NN N
between IN N
HANS NNP N
group NN N
and CC N
control NN N
group NN N
, , N
between IN N
PCEA NNP N
group NN N
and CC N
the DT N
control NN N
group NN N
, , N
between IN N
PCIA NNP N
group NN N
and CC N
control NN N
group NN N
The DT N
analgesic JJ N
effect NN N
in IN N
the DT N
PCEA NNP N
group NN N
was VBD N
significantly RB N
better JJR N
than IN N
that DT N
of IN N
other JJ N
two CD N
groups NNS N
The DT N
second JJ N
stage NN N
of IN N
labor NN N
in IN N
the DT N
PCEA NNP N
group NN N
was VBD N
longer JJR N
than IN N
the DT N
other JJ N
three CD N
groups NNS N
, , N
showing VBG N
significant JJ N
difference NN N
between IN N
them PRP N
The DT N
Apgar NNP N
score NN N
of IN N
newborn JJ N
1 CD N
min NN N
after IN N
birth NN N
in IN N
the DT N
PCIA NNP N
group NN N
was VBD N
slightly RB N
lower JJR N
than IN N
that DT N
of IN N
the DT N
other JJ N
two CD N
groups NNS N
, , N
showing VBG N
significant JJ N
difference NN N
between IN N
them PRP N
The DT N
neonatal JJ N
weights NNS N
between IN N
four CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
The DT N
rate NN N
of IN N
cesarean JJ N
section NN N
in IN N
the DT N
control NN N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
of IN N
the DT N
labor NN N
analgesia NN N
group NN N
, , N
there EX N
was VBD N
statistically RB N
difference NN N
in IN N
four CD N
groups NNS N
The DT N
number NN N
of IN N
PCIA NNP N
group NN N
that WDT N
used VBD N
oxytocin NN N
was VBD N
lower JJR N
than IN N
that DT N
of IN N
other JJ N
three CD N
groups NNS N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
postpartum JJ N
hemorrhage NN N
between IN N
four CD N
groups NNS N
The DT N
side NN N
effects NNS N
of IN N
the DT N
PCEA NNP N
group NN N
were VBD N
itching VBG N
, , N
uroschesis NN N
and CC N
neonatal JJ N
asphyxia NN N
and CC N
PCIA NNP N
group NN N
were VBD N
nausea RB N
and CC N
vomiting VBG N
and CC N
neonatal JJ N
asphyxia NN N
However RB N
, , N
fewer JJR N
side-effects NNS N
were VBD N
observed VBN N
in IN N
the DT N
HANS NNP N
group NN N
CONCLUSION NNP N
The DT N
DC NNP N
pulse NN N
produced VBN N
by IN N
HANS NNP N
may MD N
be VB N
a DT N
non-pharmacological JJ N
alternative NN N
to TO N
labor NN N
pain NN N
with IN N
fewer JJR N
side NN N
effects NNS N
-DOCSTART- -X- O O 17762804

Are NNP N
back RB N
supports VBZ N
plus CC N
education NN N
more RBR N
effective JJ N
than IN N
education NN N
alone RB N
in IN N
promoting VBG N
recovery NN N
from IN N
low JJ 4_p
back RB 4_p
pain NN 4_p
? . N
: : N
Results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
STUDY NNP N
DESIGN NNP N
Randomized NNP N
clinical JJ N
trial NN N
OBJECTIVES UH N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
back JJ N
support NN N
plus CC N
education NN N
versus IN N
education NN N
alone RB N
in IN N
promoting VBG N
recovery NN N
from IN N
a DT N
work-related JJ 4_p
low JJ 4_p
back RB 4_p
disorder NN 4_p
( ( N
WR-LBD NNP 4_p
) ) N
while IN N
simultaneously RB N
considering VBG N
personal JJ N
, , N
health NN N
, , N
and CC N
occupational JJ N
factors NNS N
and CC N
the DT N
impact NN N
of IN N
occupational JJ N
factors NNS N
on IN N
recovery NN N
SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
No NNP N
randomized JJ N
studies NNS N
of IN N
active JJ 4_p
industrial JJ 4_p
workers NNS 4_p
with IN N
low JJ 4_p
back RB 4_p
disorders NNS 4_p
exist VBP N
regarding VBG N
the DT N
effectiveness NN N
of IN N
back JJ N
supports NNS N
plus CC N
education NN N
METHODS NNP N
A NNP N
total NN N
of IN N
433 CD 3_p
actively RB N
employed VBN N
hourly RB N
union NN N
workers NNS N
who WP N
had VBD N
a DT N
recent JJ N
diagnosis NN N
of IN N
a DT N
WR-LBD JJ N
: : N
1 CD N
) ) N
those DT N
who WP N
wore VBP N
a DT N
specially RB N
designed VBN N
back RP N
support NN N
plus CC N
received JJ N
education NN N
on IN N
back JJ N
health NN N
; : N
and CC N
2 CD N
) ) N
those DT N
who WP N
received VBD N
education NN N
on IN N
back JJ N
health NN N
only RB N
Demographic NNP N
, , N
health NN N
, , N
medical JJ N
, , N
and CC N
occupational JJ N
factors NNS N
were VBD N
obtained VBN N
through IN N
interview NN N
or CC N
abstraction NN N
of IN N
computer NN N
files NNS N
; : N
individual JJ N
ergonomic JJ N
exposures NNS N
were VBD N
measured VBN N
with IN N
a DT N
lumbar NN N
motion NN N
monitor NN N
Outcomes CC N
evaluated VBD N
over IN N
a DT N
12-month JJ N
period NN N
included VBD N
: : N
self-reported JJ N
measures NNS N
of IN N
back RB N
pain NN N
, , N
back RB N
pain NN N
disability NN N
level NN N
, , N
physical JJ N
health NN N
, , N
mental JJ N
health NN N
, , N
and CC N
administrative JJ N
measures NNS N
of IN N
recurrence NN N
, , N
lost VBN N
work NN N
time NN N
, , N
and CC N
medical JJ N
care NN N
utilization NN N
RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
study NN N
groups NNS N
with IN N
respect NN N
to TO N
mental VB N
or CC N
physical JJ N
health NN N
, , N
low JJ N
back RB N
pain NN N
, , N
back RB N
pain NN N
disability NN N
, , N
neurogenic JJ N
symptoms NNS N
, , N
lost VBN N
work NN N
time NN N
, , N
likelihood NN N
of IN N
recurrence NN N
of IN N
an DT N
episode NN N
of IN N
a DT N
back JJ N
disorder NN N
, , N
or CC N
other JJ N
administrative JJ N
measures NNS N
of IN N
healthcare JJ N
utilization NN N
or CC N
lost VBN N
work NN N
time NN N
However RB N
, , N
significant JJ N
decreases NNS N
in IN N
low JJ N
back RB N
pain NN N
, , N
low JJ N
back RB N
pain NN N
disability NN N
, , N
neurogenic JJ N
symptoms NNS N
, , N
and CC N
an DT N
increase NN N
in IN N
physical JJ N
health NN N
were VBD N
observed VBN N
over IN N
the DT N
12 CD N
months NNS N
of IN N
observation NN N
in IN N
both DT N
study NN N
groups NNS N
The DT N
only JJ N
occupational JJ N
variable NN N
found VBD N
to TO N
influence VB N
was VBD N
plant NN N
group NN N
whereby WRB N
service NN N
parts NNS N
operations NNS N
workers NNS N
in IN N
the DT N
back JJ N
support NN N
plus CC N
education NN N
group NN N
experienced VBD N
a DT N
lower JJR N
likelihood NN N
of IN N
WR-LBD NNP N
recurrence NN N
CONCLUSION NNP N
Although IN N
there EX N
was VBD N
no DT N
overall JJ N
effect NN N
on IN N
self-reported JJ N
recovery NN N
or CC N
administrative JJ N
measures NNS N
or CC N
lost VBN N
work NN N
time NN N
between IN N
the DT N
study NN N
groups NNS N
, , N
a DT N
back JJ N
support NN N
plus CC N
health NN N
education NN N
may MD N
have VB N
some DT N
value NN N
in IN N
preventing VBG N
recurrent JJ N
WR-LBD NNP N
in IN N
industrial JJ N
workers NNS N
who WP N
work VBP N
in IN N
psychosocial JJ N
environments NNS N
and CC N
perform VB N
manual JJ N
material NN N
handling VBG N
tasks NNS N
similar JJ N
to TO N
those DT N
found VBN N
in IN N
parts NNS N
distribution NN N
centers NNS N
-DOCSTART- -X- O O 19081412

Three-year JJ N
clinical JJ N
outcome NN N
after IN N
primary JJ N
stenting NN N
of IN N
totally RB N
occluded JJ 4_p
native JJ 4_p
coronary JJ 4_p
arteries NNS 4_p
: : N
a DT N
randomized JJ N
comparison NN N
of IN N
bare-metal JJ N
stent JJ N
implantation NN N
with IN N
sirolimus-eluting JJ N
stent NN N
implantation NN N
for IN N
the DT N
treatment NN N
of IN N
total JJ 4_p
coronary JJ 4_p
occlusions NNS 4_p
( ( N
Primary JJ N
Stenting NNP N
of IN N
Totally NNP N
Occluded NNP N
Native NNP N
Coronary NNP N
Arteries NNP N
[ NNP N
PRISON NNP N
] NNP N
II NNP N
study NN N
) ) N
BACKGROUND IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
3-year JJ N
clinical JJ N
outcome NN N
in IN N
patients NNS N
enrolled VBN N
in IN N
the DT N
Primary NNP N
Stenting NNP N
of IN N
Totally NNP 4_p
Occluded NNP 4_p
Native NNP 4_p
Coronary NNP 4_p
Arteries NNP 4_p
II NNP N
study NN N
METHODS NNP N
Patients NNPS N
with IN N
totally RB 4_p
occluded JJ 4_p
coronary JJ 4_p
arteries NNS 4_p
randomized VBN N
to TO N
either DT N
sirolimus-eluting JJ N
Cypher NNP N
stents NNS N
( ( N
SESs NNP N
) ) N
( ( N
Cordis NNP N
, , N
a DT N
Johnson NNP N
& CC N
Joshson NNP N
Company NNP N
, , N
Miami NNP N
Lakes NNP N
, , N
FL NNP N
) ) N
( ( N
100 CD 3_p
patients NNS N
) ) N
or CC N
bare-metal JJ N
BxVelocity NNP N
stents NNS N
( ( N
BMSs NNP N
) ) N
( ( N
Cordis NNP N
) ) N
( ( N
100 CD 3_p
patients NNS N
) ) N
were VBD N
followed VBN N
clinically RB N
for IN N
3 CD N
years NNS N
RESULTS NNP N
Between NNP N
1 CD N
and CC N
3 CD N
years NNS N
, , N
there EX N
were VBD N
infrequent JJ N
additional JJ N
clinical JJ N
events NNS N
that WDT N
were VBD N
equally RB N
distributed VBN N
between IN N
the DT N
SES NNP N
and CC N
the DT N
BMS NNP N
group NN N
After IN N
3 CD N
years NNS N
, , N
target NN N
lesion NN N
revascularization NN N
was VBD N
7 CD N
% NN N
in IN N
the DT N
SES NNP N
group NN N
versus VBD N
27 CD N
% NN N
in IN N
the DT N
BMS NNP N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
; : N
and CC N
target VB N
vessel JJ N
revascularization NN N
was VBD N
seen VBN N
in IN N
11 CD N
% NN N
in IN N
the DT N
SES NNP N
group NN N
versus VBD N
30 CD N
% NN N
in IN N
the DT N
BMS NNP N
group NN N
( ( N
P NNP N
= NNP N
.002 NNP N
) ) N
Major JJ N
adverse JJ N
cardiac NN N
events NNS N
were VBD N
noted VBN N
in IN N
10 CD N
% NN N
of IN N
the DT N
SES NNP N
group NN N
versus VBD N
34 CD N
% NN N
in IN N
the DT N
BMS NNP N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
death NN N
, , N
myocardial JJ N
infarction NN N
, , N
and CC N
stent JJ N
thrombosis NN N
according VBG N
to TO N
the DT N
Academic NNP N
Research NNP N
Consortium NNP N
criteria NNS N
between IN N
the DT N
2 CD N
groups NNS N
CONCLUSIONS NNP N
Clinical NNP N
outcome VBD N
up RB N
to TO N
3 CD N
years NNS N
after IN N
implantation NN N
of IN N
SESs NNP N
for IN N
total JJ N
coronary JJ N
occlusions NNS N
continues VBZ N
to TO N
demonstrate VB N
a DT N
significant JJ N
reduction NN N
in IN N
adverse JJ N
clinical JJ N
events NNS N
compared VBN N
with IN N
BMSs NNP N
without IN N
the DT N
evidence NN N
for IN N
either DT N
disproportionate NN N
late JJ N
restenosis NN N
or CC N
late JJ N
stent JJ N
thrombosis NN N
-DOCSTART- -X- O O 18249478

Evaluation NN N
of IN N
the DT N
effects NNS N
of IN N
human JJ N
leukocyte JJ N
IFN-alpha NN N
on IN N
the DT N
immune JJ N
response NN N
to TO N
the DT N
HBV NNP N
vaccine NN N
in IN N
healthy JJ N
unvaccinated JJ N
individuals NNS N
HBV NNP N
vaccine NN N
needs VBZ N
3 CD N
injections NNS N
over IN N
6 CD N
months NNS N
to TO N
induce VB N
immunity NN N
Thus RB N
, , N
the DT N
use NN N
of IN N
adjuvants NNS N
capable JJ N
of IN N
inducing VBG N
earlier JJR N
immune JJ N
protection NN N
would MD N
be VB N
highly RB N
desirable JJ N
Most JJS N
adjuvants NNS N
may MD N
act VB N
by IN N
inducing VBG N
cytokines NNS N
, , N
and CC N
among IN N
them PRP N
, , N
type NN N
I PRP N
interferons NNS N
( ( N
IFNs NNP N
) ) N
, , N
deserve VB N
a DT N
special JJ N
attention NN N
in IN N
view NN N
of IN N
the DT N
potent JJ N
immunomostimulatory NN N
activity NN N
observed VBN N
in IN N
mouse NN N
models NNS N
and CC N
on IN N
dendritic JJ N
cell NN N
functions NNS N
The DT N
aim NN N
of IN N
the DT N
present JJ N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
IFN-alpha NNP N
administered VBD N
as IN N
an DT N
adjuvant NN N
of IN N
HBV NNP N
vaccine NN N
in IN N
healthy JJ 4_p
unvaccinated JJ 4_p
individuals NNS 4_p
No DT N
significant JJ N
enhancing VBG N
effect NN N
on IN N
the DT N
antibody NN N
response NN N
was VBD N
observed VBN N
, , N
in IN N
spite NN N
of IN N
an DT N
early JJ N
and CC N
transient JJ N
upregulation NN N
of IN N
costimulatory NN N
molecule NN N
expression NN N
on IN N
peripheral JJ N
blood NN N
mononuclear NN N
cells NNS N
, , N
which WDT N
may MD N
be VB N
suggestive JJ N
of IN N
an DT N
IFN-mediated JJ N
activation NN N
of IN N
antigen NN N
presenting VBG N
cells NNS N
We PRP N
conclude VBP N
that IN N
, , N
under IN N
the DT N
conditions NNS N
used VBN N
in IN N
this DT N
trial NN N
, , N
natural JJ N
IFN-alpha NNP N
does VBZ N
not RB N
act VB N
as IN N
an DT N
adjuvant NN N
of IN N
the DT N
HBV NNP N
vaccine NN N
in IN N
healthy JJ N
unvaccinated JJ N
individuals NNS N
-DOCSTART- -X- O O 1255322

Variance NN N
in IN N
albumin NN N
loading NN N
in IN N
exchange NN N
transfusions NNS N
To TO N
assess VB N
the DT N
rationale NN N
of IN N
albumin NN N
priming VBG N
prior RB N
to TO N
exchange NN N
transfusions NNS N
, , N
42 CD 4_p
hyperbilirubinemic JJ 4_p
infants NNS 4_p
who WP 4_p
required VBD 4_p
exchange NN 4_p
transfusions NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
Group NNP N
I PRP N
consisted VBD N
of IN N
15 CD 1_p
infants NNS 1_p
who WP N
were VBD N
given VBN N
intravenously RB N
1 CD N
gm/kg NN N
of IN N
salt-poor JJ N
human JJ N
serum NN N
albumin IN N
one CD N
hour NN N
before IN N
the DT N
exchanges NNS N
Group NNP N
II NNP N
, , N
which WDT N
consisted VBD N
of IN N
27 CD N
infants NNS N
, , N
received VBD N
simple JJ N
exchanges NNS N
No DT N
statistical JJ N
differences NNS N
were VBD N
found VBN N
in IN N
variations NNS N
in IN N
reserve NN N
albumin-binding JJ N
capacity NN N
, , N
bilirubin NN N
, , N
albumin NN N
, , N
or CC N
red JJ N
cell NN N
bilirubin NN N
at IN N
pre NN N
and CC N
one-hour JJ N
post NN N
albumin NN N
infusion NN N
in IN N
the DT N
primed JJ N
infants NNS N
The DT N
amount NN N
of IN N
bilirubin NN N
removed VBN N
per IN N
kilogram NN N
is VBZ N
directly RB N
correlated VBN N
to TO N
plasma VB N
bilirubin JJ N
concentration NN N
( ( N
r=0.87 NN N
) ) N
No DT N
significant JJ N
difference NN N
in IN N
efficiency NN N
on IN N
bilirubin NN N
removal NN N
was VBD N
seen VBN N
between IN N
the DT N
two CD N
groups NNS N
Beneficial JJ N
effects NNS N
of IN N
albumin JJ N
therapy NN N
was VBD N
apparent JJ N
only RB N
in IN N
those DT N
infants NNS N
with IN N
low JJ N
RABC NNP N
as IN N
determined VBN N
by IN N
the DT N
sephadex NN N
gel JJ N
filtration NN N
technique NN N
-DOCSTART- -X- O O 10735900

Use NNP N
of IN N
recombinant JJ N
human JJ N
granulocyte NN N
colony-stimulating NN N
factor NN N
to TO N
increase VB N
chemotherapy JJ N
dose-intensity NN N
: : N
a DT N
randomized JJ N
trial NN N
in IN N
very RB N
high-risk JJ N
childhood NN 4_p
acute NN 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
PURPOSE NNP N
To TO N
determine VB N
whether IN N
the DT N
use NN N
of IN N
a DT N
recombinant JJ N
human JJ N
granulocyte NN N
colony-stimulating NN N
factor NN N
( ( N
[ JJ N
G-CSF NNP N
] NNP N
lenogastrim NN N
) ) N
can MD N
increase VB N
the DT N
chemotherapy JJ N
dose-intensity NN N
( ( N
CDI NNP N
) ) N
delivered VBD N
during IN N
consolidation NN N
chemotherapy NN N
of IN N
childhood NN 1_p
acute NN 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
( ( N
ALL DT 4_p
) ) N
PATIENTS NNP N
AND CC N
METHODS NNP N
Sixty-seven NNP 3_p
children NNS 1_p
with IN N
very RB N
high-risk JJ N
ALL NNP N
were VBD N
randomized VBN N
( ( N
slow JJ N
early JJ N
response NN N
to TO N
therapy VB N
, , N
55 CD N
patients NNS N
; : N
translocation NN N
t NN N
( ( N
9 CD N
; : N
22 CD N
) ) N
or CC N
t NN N
( ( N
4 CD N
; : N
11 CD N
) ) N
, , N
12 CD N
patients NNS N
) ) N
Consolidation NNP N
consisted VBD N
of IN N
six CD N
courses NNS N
of IN N
chemotherapy NN N
; : N
the DT N
first JJ N
, , N
third JJ N
, , N
and CC N
fifth JJ N
courses NNS N
were VBD N
a DT N
combination NN N
of IN N
high-dose JJ N
cytarabine NN N
, , N
etoposide RB N
, , N
and CC N
dexamethasone NN N
( ( N
R3 NNP N
) ) N
, , N
whereas VBD N
the DT N
second JJ N
, , N
fourth JJ N
, , N
and CC N
sixth JJ N
courses NNS N
included VBD N
vincristine NN N
, , N
prednisone NN N
, , N
cyclophosphamide NN N
, , N
doxorubicin NN N
, , N
and CC N
methotrexate NN N
( ( N
COPADM NNP N
) ) N
G-CSF NNP N
was VBD N
given VBN N
after IN N
each DT N
course NN N
, , N
and CC N
the DT N
next JJ N
scheduled JJ N
course NN N
was VBD N
started VBN N
as RB N
soon RB N
as IN N
neutrophil JJ N
count NN N
was VBD N
> JJ N
1 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
and CC N
platelet NN N
count NN N
was VBD N
> JJ N
100 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
CDI NNP N
was VBD N
calculated VBN N
using VBG N
the DT N
interval NN N
from IN N
day NN N
1 CD N
of IN N
the DT N
first JJ N
course NN N
to TO N
hematologic VB N
recovery NN N
after IN N
the DT N
fifth JJ N
course NN N
( ( N
100 CD N
% NN N
CDI NNP N
= NNP N
105-day JJ N
interval NN N
) ) N
RESULTS NNP N
CDI NNP N
was VBD N
significantly RB N
increased VBN N
in IN N
the DT N
G-CSF NNP N
group NN N
compared VBN N
with IN N
the DT N
non-G-CSF JJ N
group NN N
( ( N
mean JJ N
+/- JJ N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
105 CD N
+/- JJ N
5 CD N
% NN N
v JJ N
91 CD N
+/- JJ N
4 CD N
% NN N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
This DT N
higher JJR N
intensity NN N
was VBD N
a DT N
result NN N
of IN N
shorter JJR N
post-R3 NN N
intervals NNS N
in IN N
the DT N
G-CSF NNP N
group NN N
, , N
whereas IN N
the DT N
post-COPADM JJ N
intervals NNS N
were VBD N
not RB N
statistically RB N
reduced VBN N
After IN N
the DT N
R3 NNP N
courses NNS N
, , N
the DT N
number NN N
of IN N
days NNS N
with IN N
fever NN N
and CC N
intravenous JJ N
antibiotics NNS N
and CC N
duration NN N
of IN N
hospitalization NN N
were VBD N
significantly RB N
decreased VBN N
by IN N
G-CSF NNP N
, , N
whereas JJ N
reductions NNS N
observed VBD N
after IN N
COPADM NNP N
were VBD N
not RB N
statistically RB N
significant JJ N
Duration NN N
of IN N
granulocytopenia NN N
was VBD N
reduced VBN N
in IN N
the DT N
G-CSF NNP N
group NN N
, , N
but CC N
thrombocytopenia NN N
was VBD N
prolonged VBN N
, , N
and CC N
the DT N
number NN N
of IN N
platelet NN N
transfusions NNS N
was VBD N
increased VBN N
Finally RB N
, , N
the DT N
3-year JJ N
probability NN N
of IN N
event-free JJ N
survival NN N
was VBD N
not RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
CONCLUSION NNP N
G-CSF NNP N
can MD N
increase VB N
CDI NNP N
in IN N
high-risk JJ 4_p
childhood NN 4_p
ALL NNP 4_p
Its PRP$ N
effects NNS N
depend VBP N
on IN N
the DT N
chemotherapy NN N
regimen NNS N
given VBN N
before IN N
G-CSF NNP N
administration NN N
In IN N
our PRP$ N
study NN N
, , N
a DT N
higher JJR N
CDI NNP N
did VBD N
not RB N
improve VB N
disease NN N
control NN N
-DOCSTART- -X- O O 11210885

Alternative JJ N
voice NN N
after IN N
laryngectomy NN 4_p
using VBG N
a DT N
sound-producing JJ N
voice NN N
prosthesis NN N
OBJECTIVE UH N
To TO N
improve VB N
the DT N
voice NN N
quality NN N
of IN N
female JJ 2_p
laryngectomees NNS 4_p
and/or VBP N
laryngectomees NNS 4_p
with IN 4_p
a DT 4_p
hypotonic JJ 4_p
pharyngoesophageal NN 4_p
( ( 4_p
PE NNP 4_p
) ) 4_p
segment NN 4_p
by IN N
means NNS N
of IN N
a DT N
pneumatic JJ N
artificial JJ N
source NN N
of IN N
voice NN N
incorporated VBN N
in IN N
a DT N
regular JJ N
tracheoesophageal NN N
( ( N
TE NNP N
) ) N
shunt NN N
valve NN N
STUDY NNP N
DESIGN NNP N
Experimental NNP N
, , N
randomized VBD N
, , N
crossover JJ N
trial NN N
METHODS NNP N
The DT N
new JJ N
sound NN N
source NN N
consists VBZ N
of IN N
a DT N
single JJ N
silicone NN N
lip NN N
, , N
which WDT N
performs VBZ N
an DT N
oscillatory JJ N
movement NN N
driven VBN N
by IN N
expired JJ N
pulmonary JJ N
air NN N
flowing VBG N
along IN N
the DT N
outward-striking JJ N
lip NN N
through IN N
the DT N
TE NNP N
shunt NN N
valve NN N
A DT N
prototype NN N
of IN N
this DT N
pneumatic JJ N
sound NN N
source NN N
is VBZ N
evaluated VBN N
in IN N
vitro NN N
and CC N
in IN N
six CD 3_p
laryngectomees NNS 4_p
In IN N
vivo JJ N
evaluation NN N
includes VBZ N
speech JJ N
rate NN N
, , N
maximal JJ N
phonation NN N
time NN N
, , N
perceptual JJ N
voice NN N
evaluation NN N
of IN N
read-aloud JJ N
prose NN N
by IN N
an DT N
expert NN N
listener NN N
, , N
speech JJ 4_p
intelligibility NN 4_p
measurements NNS 4_p
with IN N
12 CD N
listeners NNS N
, , N
and CC N
self-assessment JJ N
by IN N
the DT N
patients NNS N
Moreover RB N
, , N
extensive JJ N
acoustical JJ N
and CC N
aerodynamic JJ N
in IN N
vivo JJ N
registrations NNS N
are VBP N
performed VBN N
using VBG N
a DT N
newly RB N
developed VBN N
data NNS N
acquisition NN N
system NN N
RESULTS VB N
The DT N
current JJ N
prototype NN N
seems VBZ N
beneficial JJ N
in IN N
female JJ 2_p
laryngectomees NNS 4_p
with IN 4_p
a DT 4_p
hypotonic JJ 4_p
PE NNP 4_p
segment NN 4_p
only RB N
For IN N
them PRP N
the DT N
sound-producing JJ N
voice NN N
prosthesis NN N
improves VBZ N
voice JJ N
quality NN N
and CC N
increases VBZ N
the DT N
average JJ N
pitch NN N
of IN N
voice NN N
, , N
without IN N
decreasing VBG N
intelligibility NN N
or CC N
necessitating VBG N
other JJ N
pressure NN N
and CC N
airflow NN N
rates NNS N
than IN N
regular JJ N
TE NNP N
shunt NN N
speech NN N
Pitch NNP N
regulation NN N
of IN N
this DT N
prosthetic JJ N
voice NN N
is VBZ N
possible JJ N
, , N
yet RB N
limited VBN N
CONCLUSIONS VB N
The DT N
mechanism NN N
is VBZ N
feasible JJ N
and CC N
does VBZ N
not RB N
result VB N
in IN N
unacceptable JJ N
airflow JJ N
resistance NN N
For IN N
this DT N
new JJ N
mechanism NN N
of IN N
alaryngeal JJ N
voice NN N
to TO N
become VB N
an DT N
established JJ N
technique NN N
for IN N
postlaryngectomy JJ N
voice NN N
restoration NN N
, , N
a DT N
voice NN N
suitably RB N
pitched VBN N
for IN N
male NN 2_p
laryngectomees NNS 4_p
has VBZ N
to TO N
be VB N
generated VBN N
and CC N
a DT N
large JJ N
part NN N
of IN N
the DT N
melodic NN N
and CC N
dynamic JJ N
range NN N
of IN N
the DT N
sound NN N
source NN N
has VBZ N
to TO N
be VB N
attainable JJ N
within IN N
physiological JJ N
airflow JJ N
rates NNS N
-DOCSTART- -X- O O 8540453

Effect NN N
of IN N
dietary JJ N
supplementation NN N
with IN N
n-3 JJ N
fatty JJ N
acids NNS N
on IN N
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
graft NN 4_p
patency NN N
Epidemiologic NNP N
and CC N
experimental JJ N
data NNS N
suggest VBP N
that IN N
a DT N
high JJ N
dietary JJ N
intake NN N
of IN N
long-chain JJ N
polyunsaturated JJ N
n-3 JJ N
fatty JJ N
acids NNS N
may MD N
reduce VB N
the DT N
risk NN N
of IN N
atherothrombotic JJ N
disease NN N
In IN N
a DT N
randomized NN N
, , N
controlled VBD N
study NN N
, , N
610 CD 3_p
patients NNS N
undergoing JJ N
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
grafting VBG 4_p
were VBD N
assigned VBN N
either RB N
to TO N
a DT N
fish JJ N
oil NN N
group NN N
, , N
receiving VBG N
4 CD N
g/day NN N
of IN N
fish JJ N
oil NN N
concentrate NN N
, , N
or CC N
to TO N
a DT N
control NN N
group NN N
All DT N
patients NNS N
received VBD N
antithrombotic JJ 4_p
treatment NN 4_p
, , N
either CC N
aspirin NN N
or CC N
warfarin NN N
Their PRP$ N
diet JJ N
and CC N
serum JJ N
phospholipid JJ N
fatty JJ N
acid NN N
profiles NNS N
were VBD N
monitored VBN N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
1-year JJ N
graft NN N
patency NN N
, , N
which WDT N
was VBD N
assessed VBN N
by IN N
angiography NN N
in IN N
95 CD N
% NN N
of IN N
patients NNS N
Vein NNP N
graft JJ N
occlusion NN N
rates NNS N
per IN N
distal JJ N
anastomoses NNS N
were VBD N
27 CD N
% NN N
in IN N
the DT N
fish JJ N
oil NN N
group NN N
and CC N
33 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
odds NNS N
ratio VBP N
0.77 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.60 CD N
to TO N
0.99 CD N
, , N
p NN N
= NNP N
0.034 CD N
) ) N
In IN N
the DT N
fish JJ N
oil NN N
group NN N
, , N
43 CD N
% NN N
of IN N
the DT N
patients NNS N
had VBD N
> VBN N
or CC N
= $ N
1 CD N
occluded VBN N
vein NN N
graft NN N
( ( N
s PRP N
) ) N
compared VBN N
with IN N
51 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
odds NNS N
ratio VBP N
0.72 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.51 CD N
to TO N
1.01 CD N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
Moreover RB N
, , N
in IN N
the DT N
entire JJ N
patient NN N
group NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
trend NN N
to TO N
fewer JJR N
patients NNS N
with IN N
vein JJ N
graft NN N
occlusions NNS N
with IN N
increasing VBG N
relative JJ N
change NN N
in IN N
serum JJ N
phospholipid JJ N
n-3 JJ N
fatty JJ N
acids NNS N
during IN N
the DT N
study NN N
period NN N
( ( N
p NN N
for IN N
linear JJ N
trend NN N
= VBZ N
0.0037 CD N
) ) N
Thus RB N
, , N
in IN N
patients NNS N
undergoing VBG N
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
grafting NN 4_p
, , N
dietary JJ N
supplementation NN N
with IN N
n-3 JJ N
fatty JJ N
acids NNS N
reduced VBD N
the DT N
incidence NN N
of IN N
vein NN N
graft NN N
occlusion NN N
, , N
and CC N
an DT N
inverse JJ N
relation NN N
between IN N
relative JJ N
change NN N
in IN N
serum JJ N
phospholipid JJ N
n-3 JJ N
fatty JJ N
acids NNS N
and CC N
vein NN N
graft NN N
occlusions NNS N
was VBD N
observed VBN N
-DOCSTART- -X- O O 25840599

Prolonged NNP N
sirolimus NN N
administration NN N
after IN N
allogeneic JJ 4_p
hematopoietic JJ 4_p
cell NN 4_p
transplantation NN 4_p
is VBZ N
associated VBN N
with IN N
decreased JJ N
risk NN N
for IN N
moderate-severe JJ N
chronic JJ N
graft-versus-host NN N
disease NN N
Effective JJ N
pharmacological JJ N
strategies NNS N
employed VBN N
in IN N
allogeneic JJ 4_p
hematopoietic JJ 4_p
cell NN 4_p
transplantation NN 4_p
should MD N
prevent VB N
serious JJ N
chronic JJ N
graft-versus-host NN N
disease NN N
and CC N
facilitate VB N
donor-recipient JJ N
immune JJ N
tolerance NN N
Based VBN N
on IN N
demonstrated JJ N
pro-tolerogenic JJ N
activity NN N
, , N
sirolimus NN N
( ( N
rapamycin NN N
) ) N
is VBZ N
an DT N
agent NN N
with IN N
promise NN N
to TO N
achieve VB N
these DT N
goals NNS N
In IN N
a DT N
long-term JJ N
follow-up JJ N
analysis NN N
of IN N
a DT N
randomized JJ N
phase NN N
II NNP N
trial NN N
comparing VBG N
sirolimus/tacrolimus JJ N
versus NN N
methotrexate/tacrolimus NN N
for IN N
graft-versus-host JJ N
disease NN N
prevention NN N
in IN N
matched JJ N
sibling NN N
or CC N
unrelated JJ N
donor NN N
transplant NN N
, , N
we PRP N
examined VBD N
the DT N
impact NN N
of IN N
prolonged JJ N
sirolimus NN N
administration NN N
( ( N
≥ $ N
1 CD N
year NN N
post-transplant NN N
) ) N
Median JJ N
follow-up JJ N
time NN N
for IN N
surviving VBG N
patients NNS N
at IN N
time NN N
of IN N
this DT N
analysis NN N
was VBD N
41 CD N
months NNS N
( ( N
range VB N
27-60 CD N
) ) N
for IN N
sirolimus/tacrolimus NN N
and CC N
49 CD N
months NNS N
( ( N
range VB N
29-63 CD N
) ) N
for IN N
methotrexate/tacrolimus NN N
Sirolimus/tacrolimus NNP N
patients NNS N
had VBD N
significantly RB N
lower JJR N
National NNP N
Institutes NNPS N
of IN N
Health NNP N
Consensus NNP N
moderate-severe JJ N
chronic JJ N
graft-versus-host NN N
disease NN N
( ( N
34 CD N
% NN N
vs. FW N
65 CD N
% NN N
; : N
P=0.004 NNP N
) ) N
and CC N
late JJ N
acute NN N
graft-versus-host JJ N
disease NN N
( ( N
20 CD N
% NN N
vs. FW N
43 CD N
% NN N
; : N
P=0.04 NNP N
) ) N
While IN N
sirolimus/tacrolimus JJ N
patients NNS N
had VBD N
lower JJR N
prednisone NN N
exposure NN N
and CC N
earlier JJR N
discontinuation NN N
of IN N
tacrolimus NN N
( ( N
median JJ N
time NN N
to TO N
tacrolimus VB N
discontinuation NN N
368 CD N
days NNS N
vs. FW N
821 CD N
days NNS N
; : N
P=0.002 NNP N
) ) N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
complete JJ N
immune JJ N
suppression NN N
discontinuation NN N
( ( N
60-month JJ N
estimate NN N
: : N
43 CD N
% NN N
vs. FW N
31 CD N
% NN N
; : N
P=0.78 NNP N
) ) N
Prolonged VBN N
sirolimus JJ N
administration NN N
represents VBZ N
a DT N
viable JJ N
approach NN N
to TO N
mitigate VB N
risk NN N
for IN N
moderate-severe JJ N
chronic JJ N
and CC N
late JJ N
acute NN N
graft-versus-host JJ N
disease NN N
Further NNP N
study NN N
of IN N
determinants NNS N
of IN N
successful JJ N
immune JJ N
suppression NN N
discontinuation NN N
is VBZ N
needed VBN N
-DOCSTART- -X- O O 3653128

Deleterious JJ N
effects NNS N
of IN N
low-dose JJ N
oestrogen NN N
therapy NN N
on IN N
coronary JJ N
status NN N
in IN N
patients NNS 4_p
with IN 4_p
prostatic JJ 4_p
cancer NN 4_p
The DT N
effects NNS N
of IN N
oestrogen NN N
therapy NN N
and CC N
of IN N
orchidectomy NN N
on IN N
coronary JJ N
status NN N
, , N
as IN N
reflected VBN N
by IN N
exercise NN N
ECG-testing NN N
before IN N
and CC N
after IN N
one CD N
year NN N
of IN N
treatment NN N
, , N
were VBD N
assessed VBN N
in IN N
a DT N
randomized JJ N
study NN N
of IN N
patients NNS N
( ( N
N NNP 3_p
= NNP 3_p
100 CD 3_p
) ) N
with IN N
prostatic JJ 4_p
cancer NN 4_p
Oestrogen NNP N
was VBD N
given VBN N
as IN N
polyestradiol NN N
phosphate NN N
80 CD N
mg NN N
i.m NN N
per IN N
month NN N
in IN N
combination NN N
with IN N
150 CD N
micrograms NNS N
ethinylestradiol JJ N
p.o NN N
per IN N
day NN N
There EX N
were VBD N
no DT N
significant JJ N
inter-group JJ N
differences NNS N
in IN N
conventional JJ N
risk NN N
factors NNS N
or CC N
in IN N
pre-treatment JJ N
exercise NN N
test NN N
results NNS N
Twelve NNP N
months NNS N
after IN N
the DT N
start NN N
of IN N
therapy NN N
the DT N
oestrogen NN N
group NN N
showed VBD N
a DT N
significantly RB N
greater JJR N
depression NN N
of IN N
the DT N
ST-segment NNP N
during IN N
maximal JJ N
exercise NN N
in IN N
leads NNS N
CH2 NNP N
( ( N
P NNP N
less JJR N
than IN N
0.0005 CD N
) ) N
and CC N
CH5 NNP N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
compared VBN N
with IN N
the DT N
pre-treatment JJ N
depression NN N
Twenty-five JJ N
per IN N
cent NN N
( ( N
N NNP N
= NNP N
13 CD N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
oestrogen NN N
group NN N
suffered VBD N
cardiovascular JJ N
complications NNS N
during IN N
the DT N
year NN N
of IN N
therapy NN N
, , N
whereas JJ N
no DT N
such JJ N
complications NNS N
were VBD N
observed VBN N
in IN N
the DT N
orchidectomy NN N
group NN N
However RB N
, , N
even RB N
the DT N
patients NNS N
in IN N
the DT N
oestrogen NN N
group NN N
who WP N
had VBD N
not RB N
suffered VBN N
cardiovascular JJ N
complications NNS N
had VBD N
significantly RB N
greater JJR N
depressions NNS N
of IN N
the DT N
ST-segment NNP N
during IN N
exercise NN N
both DT N
in IN N
lead NN N
CH2 NNP N
( ( N
P NNP N
less JJR N
than IN N
0.0005 CD N
) ) N
and CC N
in IN N
CH5 NNP N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
There EX N
was VBD N
no DT N
significant JJ N
change NN N
in IN N
the DT N
ST-segment JJ N
level NN N
in IN N
the DT N
orchidectomy NN N
group NN N
twelve VBD N
months NNS N
after IN N
surgery NN N
In IN N
summary JJ N
, , N
we PRP N
found VBD N
evidence NN N
of IN N
an DT N
induction NN N
of IN N
myocardial JJ N
ischaemia NN N
during IN N
treatment NN N
with IN N
exogenous JJ N
oestrogens NNS N
at IN N
low JJ N
dosage NN N
in IN N
patients NNS N
with IN N
prostatic JJ N
cancer NN N
This DT N
deleterious JJ N
effect NN N
of IN N
oestrogen NN N
on IN N
the DT N
coronary JJ N
status NN N
argues NNS N
against IN N
oestrogen NN N
therapy NN N
, , N
since IN N
oestrogen NN N
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
be VB N
more RBR N
beneficial JJ N
than IN N
orchidectomy NN N
against IN N
prostatic JJ N
carcinoma NN N
-DOCSTART- -X- O O 11323998

Comparative JJ N
evaluation NN N
of IN N
calcium NN N
hydroxide NN N
and CC N
zinc NN N
oxide RB N
eugenol RB N
as IN N
root JJ 4_p
canal JJ 4_p
filling NN 4_p
materials NNS N
for IN N
primary JJ 4_p
molars NNS 4_p
: : N
a DT N
clinical JJ N
and CC N
radiographic JJ N
study NN N
Calcium NNP N
hydroxide NN N
, , N
a DT N
material NN N
widely RB N
used VBN N
for IN N
the DT N
treatment NN N
of IN N
permanent JJ N
teeth NN N
has VBZ N
not RB N
been VBN N
used VBN N
frequently RB N
for IN N
pulpectomy NN N
in IN N
primary JJ N
teeth NNS N
A DT N
comparative JJ N
evaluation NN N
of IN N
calcium NN N
hydroxide NN N
and CC N
zinc NN N
oxide NN N
eugenol NN N
used VBN N
as IN N
root JJ N
canal JJ N
filling NN N
materials NNS N
in IN N
primary JJ 4_p
molars NNS 4_p
is VBZ N
presented VBN N
-DOCSTART- -X- O O 6146112

Comparison NNP N
between IN N
the DT N
central JJ N
effects NNS N
of IN N
camazepam NN N
and CC N
temazepam NN N
Computerized JJ N
analysis NN N
of IN N
sleep JJ N
recordings NNS N
The DT N
effects NNS N
of IN N
acute JJ N
administration NN N
per IN N
os NN N
of IN N
30 CD N
mg NNS N
camazepam NN N
and CC N
the DT N
same JJ N
dose NN N
of IN N
temazepam NN N
, , N
were VBD N
compared VBN N
with IN N
placebo NN N
in IN N
8 CD N
young JJ N
male NN N
volunteers NNS N
, , N
fully RB N
adapted VBN N
to TO N
the DT N
laboratory NN N
environment NN N
by IN N
6 CD N
nights NNS N
of IN N
adaptation NN N
The DT N
study NN N
was VBD N
double-blind JJ N
, , N
in IN N
a DT N
random NN N
order NN N
, , N
10 CD N
days NNS N
separating VBG N
each DT N
session NN N
Spectral JJ N
analysis NN N
was VBD N
performed VBN N
on IN N
the DT N
all-night JJ N
records NNS N
( ( N
1-min JJ N
epochs NN N
) ) N
, , N
and CC N
the DT N
relative JJ N
power NN N
of IN N
six CD N
frequency NN N
bands NNS N
calculated VBN N
Concerning VBG N
sleep JJ N
parameters NNS N
, , N
temazepam NN N
induces NNS N
a DT N
statistically RB N
significant JJ N
reduction NN N
of IN N
: : N
phase NN N
shifts NNS N
; : N
number NN N
of IN N
awakenings NNS N
; : N
percent JJ N
duration NN N
of IN N
sleep JJ N
stages NNS N
I PRP N
and CC N
IV NNP N
A NNP N
significant JJ N
increase NN N
of IN N
the DT N
percent NN N
duration NN N
of IN N
stage NN N
II NNP N
and CC N
sleep JJ N
efficiency NN N
was VBD N
also RB N
found VBN N
Camazepam NNP N
shows VBZ N
modification NN N
, , N
with IN N
the DT N
same JJ N
trend NN N
, , N
but CC N
not RB N
reaching VBG N
statistical JJ N
significance NN N
Concerning VBG N
spectral JJ N
analysis NN N
, , N
temazepam NN N
induces NNS N
a DT N
light JJ N
increase NN N
of IN N
the DT N
relative JJ N
power NN N
of IN N
the DT N
slowest JJS N
frequencies NNS N
, , N
paralleled VBN N
by IN N
an DT N
increase NN N
of IN N
the DT N
fast JJ N
bands NNS N
, , N
while IN N
major JJ N
effects NNS N
are VBP N
found VBN N
on IN N
the DT N
characteristic JJ N
periodicity NN N
of IN N
delta NN N
activities NNS N
, , N
which WDT N
appear VBP N
disrupted VBN N
by IN N
the DT N
drug NN N
These DT N
effects NNS N
are VBP N
not RB N
evident JJ N
with IN N
camazepam NN N
, , N
which WDT N
does VBZ N
not RB N
seem VB N
to TO N
distort VB N
the DT N
normal JJ N
sleep JJ N
pattern NN N
-DOCSTART- -X- O O 20500784

Effects NNS N
of IN N
a DT N
leisure NN N
programme NN N
on IN N
quality NN N
of IN N
life NN N
and CC N
stress NN N
of IN N
individuals NNS N
with IN N
ASD NNP 4_p
BACKGROUND NNP N
Even RB N
though IN N
there EX N
is VBZ N
research NN N
demonstrating VBG N
a DT N
positive JJ N
relationship NN N
between IN N
leisure NN N
participation NN N
and CC N
the DT N
two CD N
constructs NNS N
of IN N
quality NN N
of IN N
life NN N
and CC N
stress NN N
reduction NN N
, , N
current JJ N
conceptualisation NN N
of IN N
leisure NN N
as IN N
a DT N
contributor NN N
to TO N
quality NN N
of IN N
life NN N
is VBZ N
limited VBN N
In IN N
addition NN N
, , N
in IN N
spite NN N
of IN N
improvements NNS N
in IN N
accurate JJ N
diagnosis NN N
of IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
at IN N
increasingly RB N
earlier JJR N
ages NNS N
and CC N
proliferation NN N
of IN N
interventions NNS N
, , N
research NN N
associated VBN N
with IN N
leisure NN N
and CC N
quality NN N
of IN N
life NN N
for IN N
people NNS N
with IN N
ASD NNP 4_p
is VBZ N
lacking VBG N
METHODS NNP N
Therefore NNP N
, , N
a DT N
study NN N
using VBG N
a DT N
repeated JJ N
measures NNS N
design NN N
was VBD N
used VBN N
to TO N
measure VB N
effects NNS N
of IN N
a DT N
1-year JJ N
group NN N
leisure NN N
programme NN N
intended VBN N
to TO N
facilitate VB N
interaction NN N
with IN N
media NNS N
, , N
engagement NN N
in IN N
exercise NN N
, , N
playing VBG N
games NNS N
and CC N
doing VBG N
crafts NNS N
, , N
attending VBG N
events NNS N
, , N
and CC N
participating VBG N
in IN N
other JJ N
recreation NN N
activities NNS N
on IN N
quality NN N
of IN N
life NN N
and CC N
stress NN N
of IN N
37 CD 3_p
participants NNS N
( ( N
22 CD 2_p
male NN 2_p
, , 2_p
15 CD 2_p
female NN 2_p
) ) N
, , N
ages VBZ 1_p
17-39 JJ 1_p
( ( 1_p
M NNP 1_p
= NNP 1_p
31.49 CD 1_p
) ) 1_p
years NNS 1_p
at IN N
the DT N
beginning NN N
of IN N
the DT N
programme NN N
) ) N
diagnosed VBD N
with IN N
an DT N
ASD NNP 4_p
and CC N
a DT N
group NN N
of IN N
34 CD 3_p
adults NNS 3_p
with IN N
ASD NNP 4_p
as IN N
control NN N
group NN N
( ( N
waiting VBG N
list NN N
) ) N
( ( N
19 CD 2_p
male NN 2_p
, , 2_p
15 CD 2_p
female NN 2_p
) ) N
, , N
ages VBZ 1_p
24-38 JJ 1_p
( ( N
M NNP N
= VBZ N
30 CD N
at IN N
programme JJ N
initiation NN N
) ) N
years NNS N
RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
overall JJ N
scores NNS N
of IN N
stress NN N
levels NNS N
for IN N
participants NNS N
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
and CC N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
four CD N
factors NNS N
of IN N
quality NN N
of IN N
life NN N
that WDT N
were VBD N
measured VBN N
( ( N
satisfaction NN N
, , N
independence NN N
, , N
competence NN N
and CC N
social JJ N
interaction NN N
) ) N
as RB N
well RB N
as IN N
the DT N
total JJ N
score NN N
for IN N
quality NN N
of IN N
life NN N
from IN N
baseline NN N
to TO N
the DT N
end NN N
of IN N
the DT N
intervention NN N
12 CD N
months NNS N
later RB N
In IN N
contrast NN N
, , N
the DT N
control NN N
group NN N
demonstrated VBD N
no DT N
significant JJ N
improvements NNS N
related VBN N
to TO N
stress VB N
or CC N
quality NN N
of IN N
life NN N
Implications NNS N
of IN N
these DT N
findings NNS N
to TO N
leisure VB N
services NNS N
and CC N
the DT N
quality NN N
of IN N
life NN N
of IN N
individuals NNS N
with IN N
ASD NNP 4_p
are VBP N
discussed VBN N
CONCLUSION NNP N
Findings NNP N
support NN N
the DT N
contention NN N
that WDT N
participation NN N
in IN N
recreation NN N
activities NNS N
positively RB N
influenced VBD N
the DT N
stress NN N
and CC N
quality NN N
of IN N
life NN N
of IN N
adults NNS 1_p
with IN N
ASD NNP 4_p
-DOCSTART- -X- O O 11429349

The DT N
clinical JJ N
and CC N
biochemical JJ N
effects NNS N
of IN N
propofol JJ N
infusion NN N
with IN N
and CC N
without IN N
EDTA NNP N
for IN N
maintenance NN N
anesthesia NN N
in IN N
healthy JJ N
children NNS 1_p
undergoing VBG N
ambulatory NN 4_p
surgery NN 4_p
UNLABELLED IN N
We PRP N
conducted VBD N
this DT N
randomized VBN N
, , N
double-blinded JJ N
, , N
comparative JJ N
, , N
parallel-group JJ N
study NN N
to TO N
determine VB N
whether IN N
adding VBG N
EDTA NNP N
to TO N
propofol VB N
would MD N
affect VB N
the DT N
clinical JJ N
profile NN N
, , N
calcium NN N
and CC N
magnesium NN N
homeostasis NN N
, , N
or CC N
renal JJ N
function NN N
in IN N
healthy JJ N
children NNS 1_p
After IN N
the DT N
induction NN N
of IN N
anesthesia NN N
with IN N
halothane NN N
, , N
69 CD 3_p
ambulatory JJ 4_p
surgical JJ 4_p
patients NNS N
( ( N
1 CD 1_p
mo NN 1_p
to TO 1_p
< VB 1_p
17 CD 1_p
yr NNP 1_p
old JJ 1_p
) ) N
, , N
received VBD N
propofol NN N
without IN N
EDTA NNP N
( ( N
n JJ N
= NNP N
33 CD N
) ) N
or CC N
propofol NN N
with IN N
EDTA NNP N
( ( N
n JJ N
= NNP N
36 CD N
) ) N
Blood NN N
samples NNS N
were VBD N
obtained VBN N
for IN N
the DT N
measurement NN N
of IN N
ionized JJ N
calcium NN N
, , N
ionized JJ N
magnesium NN N
, , N
and CC N
laboratory JJ N
indicators NNS N
of IN N
renal JJ N
function NN N
Hemodynamic NNP N
measurements NNS N
, , N
recovery NN N
, , N
and CC N
adverse JJ N
events NNS N
were VBD N
recorded VBN N
Propofol NNP N
with IN N
EDTA NNP N
produced VBD N
no DT N
significant JJ N
effects NNS N
on IN N
clinical JJ N
efficacy NN N
or CC N
renal JJ N
function NN N
Propofol NNP N
and CC N
propofol JJ N
EDTA NNP N
produced VBD N
a DT N
statistically RB N
significant JJ N
decrease NN N
from IN N
baseline NN N
in IN N
serum JJ N
concentrations NNS N
of IN N
ionized JJ N
calcium NN N
and CC N
magnesium NN N
during IN N
infusion NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
with IN N
no DT N
apparent JJ N
clinical JJ N
effect NN N
Hemodynamic NNP N
measurements NNS N
generally RB N
remained VBD N
stable JJ N
and CC N
were VBD N
similar JJ N
for IN N
both DT N
groups NNS N
Statistically NNP N
significant JJ N
changes NNS N
in IN N
systolic JJ N
blood NN N
pressure NN N
, , N
mean JJ N
arterial JJ N
pressure NN N
, , N
and CC N
heart NN N
rate NN N
were VBD N
not RB N
considered VBN N
clinically RB N
significant JJ N
Adverse JJ N
events NNS N
were VBD N
mild JJ N
or CC N
moderate JJ N
The DT N
addition NN N
of IN N
EDTA NNP N
does VBZ N
not RB N
alter VB N
the DT N
clinical JJ N
profile NN N
of IN N
propofol NN N
in IN N
pediatric JJ N
ambulatory JJ 4_p
surgical JJ 4_p
patients NNS N
With IN N
or CC N
without IN N
EDTA NNP N
, , N
propofol NN N
is VBZ N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
ionized JJ N
calcium NN N
with IN N
no DT N
apparent JJ N
clinical JJ N
effect NN N
IMPLICATIONS VBZ N
The DT N
addition NN N
of IN N
EDTA NNP N
does VBZ N
not RB N
alter VB N
the DT N
clinical JJ N
profile NN N
of IN N
propofol NN N
in IN N
pediatric JJ N
ambulatory JJ 4_p
surgical JJ 4_p
patients NNS N
With IN N
or CC N
without IN N
EDTA NNP N
, , N
propofol NN N
is VBZ N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
ionized JJ N
calcium NN N
with IN N
no DT N
apparent JJ N
clinical JJ N
effect NN N
-DOCSTART- -X- O O 22434360

Pemetrexed NNP N
in IN N
combination NN N
with IN N
cisplatin JJ N
versus NN N
cisplatin NN N
monotherapy NN N
in IN N
patients NNS N
with IN N
recurrent NN N
or CC N
metastatic JJ N
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
: : N
final JJ N
results NNS N
of IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
phase VB N
3 CD N
study NN N
BACKGROUND NNP N
Recurrent NNP N
or CC N
metastatic JJ N
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
of IN N
the DT N
head NN N
and CC N
neck NN N
( ( N
SCCHN NNP N
) ) N
is VBZ N
associated VBN N
with IN N
poor JJ N
survival NN N
Platinum-based JJ N
chemotherapy NN N
is VBZ N
often RB N
a DT N
first-line JJ N
treatment NN N
Pemetrexed NNP N
has VBZ N
shown VBN N
single-agent JJ N
activity NN N
in IN N
SCCHN NNP N
and CC N
in IN N
combination NN N
with IN N
cisplatin NN N
for IN N
other JJ N
tumors NNS N
This DT N
trial NN N
examined VBD N
the DT N
efficacy NN N
of IN N
pemetrexed-cisplatin NN N
for IN N
SCCHN NNP N
METHODS NNP N
In IN N
a DT N
double-blind JJ N
phase NN N
3 CD N
trial NN N
, , N
patients NNS N
with IN N
recurrent NN N
or CC N
metastatic JJ N
SCCHN NNP 4_p
and CC N
no DT N
prior JJ N
systemic JJ N
therapy NN N
for IN N
metastatic JJ N
disease NN N
were VBD N
randomized VBN N
to TO N
pemetrexed VB N
( ( N
500 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
plus CC N
cisplatin NN N
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
; : N
n CC N
= VB N
398 CD N
) ) N
or CC N
placebo JJ N
plus CC N
cisplatin NN N
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
; : N
n CC N
= VB N
397 CD N
) ) N
to TO N
assess VB N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
and CC N
secondary JJ N
endpoints NNS N
RESULTS NNP N
Median JJ N
OS NNP N
was VBD N
7.3 CD N
months NNS N
in IN N
the DT N
pemetrexed-cisplatin JJ N
arm NN N
and CC N
6.3 CD N
months NNS N
in IN N
the DT N
placebo-cisplatin JJ N
arm NN N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.87 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.75-1.02 NNP N
; : N
P NNP N
= NNP N
.082 NNP N
) ) N
Median JJ N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
, , N
months NNS N
) ) N
was VBD N
similar JJ N
in IN N
both DT N
treatment NN N
arms NNS N
( ( N
pemetrexed-cisplatin NN N
, , N
3.6 CD N
; : N
placebo-cisplatin NN N
, , N
2.8 CD N
; : N
HR NNP N
, , N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.76-1.03 NNP N
; : N
P NNP N
= NNP N
.166 NNP N
) ) N
Among IN N
patients NNS N
with IN N
performance NN N
status NN N
0 CD N
or CC N
1 CD N
, , N
pemetrexed-cisplatin NN N
( ( N
n JJ N
= NNP N
347 CD N
) ) N
led VBD N
to TO N
longer JJR N
OS NNP N
and CC N
PFS NNP N
than IN N
placebo-cisplatin NN N
( ( N
n JJ N
= VBZ N
343 CD N
; : N
8.4 CD N
vs IN N
6.7 CD N
months NNS N
; : N
HR NNP N
, , N
0.83 CD N
; : N
P NNP N
= NNP N
.026 NNP N
; : N
4.0 CD N
vs IN N
3.0 CD N
months NNS N
; : N
HR NNP N
, , N
0.84 CD N
; : N
P NNP N
= NNP N
.044 NNP N
, , N
respectively RB N
) ) N
Among IN N
patients NNS N
with IN N
oropharyngeal JJ 4_p
cancers NNS 4_p
, , N
pemetrexed-cisplatin NN N
( ( N
n JJ N
= NNP N
86 CD N
) ) N
resulted VBD N
in IN N
longer JJR N
OS NNP N
and CC N
PFS NNP N
than IN N
placebo-cisplatin NN N
( ( N
n JJ N
= VBZ N
106 CD N
; : N
9.9 CD N
vs IN N
6.1 CD N
months NNS N
; : N
HR NNP N
, , N
0.59 CD N
; : N
P NNP N
= NNP N
.002 NNP N
; : N
4.0 CD N
vs IN N
3.4 CD N
months NNS N
; : N
HR NNP N
, , N
0.73 CD N
; : N
P NNP N
= NNP N
.047 NNP N
, , N
respectively RB N
) ) N
Pemetrexed-cisplatin JJ N
toxicity NN N
was VBD N
consistent JJ N
with IN N
studies NNS N
in IN N
other JJ N
tumors NNS N
CONCLUSIONS NNP N
Pemetrexed-cisplatin NNP N
compared VBN N
with IN N
placebo-cisplatin NN N
did VBD N
not RB N
significantly RB N
improve VB N
survival NN N
for IN N
the DT N
intent-to-treat JJ N
population NN N
However RB N
, , N
in IN N
a DT N
prespecified JJ N
subgroup NN N
analysis NN N
, , N
pemetrexed-cisplatin NN N
showed VBD N
OS NNP N
and CC N
PFS NNP N
advantage NN N
for IN N
patients NNS N
with IN N
performance NN N
status NN N
0 CD N
or CC N
1 CD N
or CC N
oropharyngeal JJ N
cancers NNS N
-DOCSTART- -X- O O 26388532

Skin NNP N
antisepsis NN N
with IN N
chlorhexidine-alcohol JJ N
versus NN N
povidone NN N
iodine-alcohol NN N
, , N
with IN N
and CC N
without IN N
skin JJ N
scrubbing NN N
, , N
for IN N
prevention NN N
of IN N
intravascular-catheter-related JJ 4_p
infection NN 4_p
( ( N
CLEAN NNP N
) ) N
: : N
an DT N
open-label JJ N
, , N
multicentre NN N
, , N
randomised VBN N
, , N
controlled VBN N
, , N
two-by-two JJ N
factorial JJ N
trial NN N
BACKGROUND NNP N
Intravascular-catheter-related JJ N
infections NNS N
are VBP N
frequent JJ N
life-threatening JJ N
events NNS N
in IN N
health NN N
care NN N
, , N
but CC N
incidence NN N
can MD N
be VB N
decreased VBN N
by IN N
improvements NNS N
in IN N
the DT N
quality NN N
of IN N
care NN N
Optimisation NN N
of IN N
skin JJ N
antisepsis NN N
is VBZ N
essential JJ N
to TO N
prevent VB N
short-term JJ N
catheter-related JJ N
infections NNS N
We PRP N
hypothesised VBD N
that IN N
chlorhexidine-alcohol NN N
would MD N
be VB N
more RBR N
effective JJ N
than IN N
povidone RB N
iodine-alcohol NN N
as IN N
a DT N
skin JJ N
antiseptic NN N
to TO N
prevent VB N
intravascular-catheter-related JJ N
infections NNS N
METHODS NNP N
In IN N
this DT N
open-label JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
with IN N
a DT N
two-by-two JJ N
factorial JJ N
design NN N
, , N
we PRP N
enrolled VBD N
consecutive JJ N
adults NNS 1_p
( ( N
age NN 1_p
≥18 CD 1_p
years NNS 1_p
) ) 1_p
admitted VBD N
to TO N
one CD N
of IN N
11 CD N
French JJ N
intensive-care JJ N
units NNS N
and CC N
requiring VBG N
at IN N
least JJS N
one CD N
of IN N
central-venous JJ 4_p
, , 4_p
haemodialysis NN 4_p
, , 4_p
or CC 4_p
arterial JJ 4_p
catheters NNS 4_p
Before IN N
catheter JJ N
insertion NN N
, , N
we PRP N
randomly VBP N
assigned VBN N
( ( N
1:1:1:1 CD N
) ) N
patients NNS N
via IN N
a DT N
secure JJ N
web-based JJ N
random-number JJ N
generator NN N
( ( N
permuted JJ N
blocks NNS N
of IN N
eight CD N
, , N
stratified VBN N
by IN N
centre NN N
) ) N
to TO N
have VB N
all DT N
intravascular JJ N
catheters NNS N
prepared VBD N
with IN N
2 CD N
% NN N
chlorhexidine-70 JJ N
% NN N
isopropyl NN N
alcohol NN N
( ( N
chlorhexidine-alcohol NN N
) ) N
or CC N
5 CD N
% NN N
povidone JJ N
iodine-69 JJ N
% NN N
ethanol NN N
( ( N
povidone JJ N
iodine-alcohol NN N
) ) N
, , N
with IN N
or CC N
without IN N
scrubbing VBG N
of IN N
the DT N
skin NN N
with IN N
detergent NN N
before IN N
antiseptic JJ N
application NN N
Physicians NNPS N
and CC N
nurses NNS N
were VBD N
not RB N
masked VBN N
to TO N
group NN N
assignment NN N
but CC N
microbiologists NNS N
and CC N
outcome JJ N
assessors NNS N
were VBD N
The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
incidence NN N
of IN N
catheter-related JJ N
infections NNS N
with IN N
chlorhexidine-alcohol JJ N
versus NN N
povidone NN N
iodine-alcohol NN N
in IN N
the DT N
intention-to-treat JJ N
population NN N
This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT01629550 NNP N
and CC N
is VBZ N
closed VBN N
to TO N
new JJ N
participants NNS N
FINDINGS NNP N
Between NNP N
Oct NNP N
26 CD N
, , N
2012 CD N
, , N
and CC N
Feb NNP N
12 CD N
, , N
2014 CD N
, , N
2546 CD 3_p
patients NNS 3_p
were VBD N
eligible JJ N
to TO N
participate VB N
in IN N
the DT N
study NN N
We PRP N
randomly RB N
assigned VBD N
1181 CD 3_p
patients NNS 3_p
( ( N
2547 CD 3_p
catheters NNS 3_p
) ) N
to TO N
chlorhexidine-alcohol NN N
( ( N
594 CD N
patients NNS N
with IN N
scrubbing NN N
, , N
587 CD N
without IN N
) ) N
and CC N
1168 CD N
( ( N
2612 CD N
catheters NNS N
) ) N
to TO N
povidone VB N
iodine-alcohol NN N
( ( N
580 CD N
patients NNS N
with IN N
scrubbing NN N
, , N
588 CD N
without IN N
) ) N
Chlorhexidine-alcohol NN N
was VBD N
associated VBN N
with IN N
lower JJR N
incidence NN N
of IN N
catheter-related JJ N
infections NNS N
( ( N
0·28 CD N
vs RB N
1·77 CD N
per IN N
1000 CD N
catheter-days NNS N
with IN N
povidone JJ N
iodine-alcohol NN N
; : N
hazard CC N
ratio VB N
0·15 CD N
, , N
95 CD N
% NN N
CI NNP N
0·05-0·41 CD N
; : N
p=0·0002 NN N
) ) N
Scrubbing VBG N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
significant JJ N
difference NN N
in IN N
catheter NN N
colonisation NN N
( ( N
p=0·3877 NN N
) ) N
No UH N
systemic JJ N
adverse JJ N
events NNS N
were VBD N
reported VBN N
, , N
but CC N
severe JJ N
skin NN N
reactions NNS N
occurred VBD N
more RBR N
frequently RB N
in IN N
those DT N
assigned VBN N
to TO N
chlorhexidine-alcohol NN N
( ( N
27 CD N
[ RB N
3 CD N
% NN N
] JJ N
patients NNS N
vs JJ N
seven CD N
[ $ N
1 CD N
% NN N
] NN N
with IN N
povidone JJ N
iodine-alcohol NN N
; : N
p=0·0017 CC N
) ) N
and CC N
led VBN N
to TO N
chlorhexidine VB N
discontinuation NN N
in IN N
two CD N
patients NNS N
INTERPRETATION NNP N
For IN N
skin JJ N
antisepsis NN N
, , N
chlorhexidine-alcohol NN N
provides VBZ N
greater JJR N
protection NN N
against IN N
short-term JJ N
catheter-related JJ N
infections NNS N
than IN N
does VBZ N
povidone VB N
iodine-alcohol NN N
and CC N
should MD N
be VB N
included VBN N
in IN N
all DT N
bundles NNS N
for IN N
prevention NN N
of IN N
intravascular JJ N
catheter-related JJ N
infections NNS N
FUNDING NN N
University NNP N
Hospital NNP N
of IN N
Poitiers NNP N
, , N
CareFusion NNP N
-DOCSTART- -X- O O 1730427

Stage NN 4_p
II NNP 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
ovary JJ 4_p
: : N
an DT N
analysis NN N
of IN N
survival NN N
after IN N
comprehensive JJ N
surgical JJ N
staging NN N
and CC N
adjuvant JJ N
therapy NN N
Ninety-three JJ 3_p
women NNS 2_p
with IN N
FIGO NNP 4_p
stage NN 4_p
II NNP 4_p
epithelial JJ 4_p
ovarian JJ 4_p
carcinoma NN 4_p
underwent JJ N
comprehensive JJ N
surgical JJ N
staging NN N
and CC N
were VBD N
randomized VBN N
prospectively RB N
to TO N
therapy VB N
consisting NN N
of IN N
either DT N
intraperitoneal JJ N
radioactive JJ N
phosphorus NN N
or CC N
oral JJ N
melphalan NN N
No DT N
patient NN N
had VBD N
gross JJ N
residual JJ N
disease NN N
at IN N
the DT N
time NN N
of IN N
randomization NN N
Ten CD N
of IN N
the DT N
forty-five JJ 3_p
women NNS 2_p
treated VBN N
with IN N
melphalan NN N
experienced VBN N
severe JJ N
bone NN N
marrow NN N
depression NN N
at IN N
some DT N
time NN N
during IN N
therapy NN N
and CC N
two CD N
women NNS N
expired VBD N
from IN N
leukemia NN N
Four CD N
of IN N
the DT N
forty-eight JJ 3_p
women NNS 2_p
treated VBN 4_p
with IN 4_p
intraperitoneal JJ 4_p
phosphorus NN 4_p
required VBN N
surgical JJ N
reexploration NN N
for IN N
intestinal JJ N
obstruction NN N
or CC N
bowel NN N
injury NN N
Twenty-one JJ N
women NNS N
died VBD N
of IN N
their PRP$ N
disease NN N
Survival NNP N
was VBD N
not RB N
statistically RB N
different JJ N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
The DT N
5-year JJ N
actuarial JJ N
survival NN N
was VBD N
78 CD N
% NN N
-DOCSTART- -X- O O 26382998

Oxygen NNP N
saturation NN N
targets NNS N
in IN N
infants NNS 1_p
with IN N
bronchiolitis NN 4_p
( ( 4_p
BIDS NNP 4_p
) ) 4_p
: : N
a DT N
double-blind NN N
, , N
randomised VBN N
, , N
equivalence JJ N
trial NN N
BACKGROUND VB N
The DT N
American JJ N
Academy NNP N
of IN N
Pediatrics NNP N
recommends VBZ N
a DT N
permissive JJ N
hypoxaemic JJ N
target NN N
for IN N
an DT N
oxygen NN N
saturation NN N
of IN N
90 CD N
% NN N
for IN N
children NNS N
with IN N
bronchiolitis NN N
, , N
which WDT N
is VBZ N
consistent JJ N
with IN N
the DT N
WHO NNP N
recommendations NNS N
for IN N
targets NNS N
in IN N
children NNS 1_p
with IN N
lower JJR 4_p
respiratory NN 4_p
tract JJ 4_p
infections NNS 4_p
No DT N
evidence NN N
exists VBZ N
to TO N
support VB N
this DT N
threshold NN N
We PRP N
aimed VBD N
to TO N
assess VB N
whether IN N
the DT N
90 CD N
% NN N
or CC N
higher JJR N
target NN N
for IN N
management NN N
of IN N
oxygen NN N
supplementation NN N
was VBD N
equivalent JJ N
to TO N
a DT N
normoxic JJ N
94 CD N
% NN N
or CC N
higher JJR N
target NN N
for IN N
infants NNS N
admitted VBN N
to TO N
hospital VB N
with IN N
viral JJ N
bronchiolitis NN N
METHODS NNP N
We PRP N
did VBD N
a DT N
parallel-group NN N
, , N
randomised VBN N
, , N
controlled VBN N
, , N
equivalence NN N
trial NN N
of IN N
infants NNS 1_p
aged VBN 1_p
6 CD 1_p
weeks NNS 1_p
to TO 1_p
12 CD 1_p
months NNS 1_p
of IN 1_p
age NN 1_p
with IN N
physician-diagnosed JJ N
bronchiolitis NN 4_p
newly RB N
admitted VBN N
into IN N
eight CD N
paediatric JJ N
hospital NN N
units NNS N
in IN N
the DT N
UK NNP N
( ( N
the DT N
Bronchiolitis NNP N
of IN N
Infancy NNP N
Discharge NNP N
Study NNP N
[ NNP N
BIDS NNP N
] NNP N
) ) N
A DT N
central JJ N
computer NN N
randomly RB N
allocated VBD N
( ( N
1:1 CD N
) ) N
infants NNS N
, , N
in IN N
varying VBG N
length NN N
blocks NNS N
of IN N
four CD N
and CC N
six CD N
and CC N
without IN N
stratification NN N
, , N
to TO N
be VB N
clipped VBN N
to TO N
standard VB N
oximeters NNS N
( ( N
patients NNS N
treated VBN N
with IN N
oxygen NN N
if IN N
pulse JJ N
oxygen NN N
saturation NN N
[ NNP N
SpO2 NNP N
] NNP N
< VBD N
94 CD N
% NN N
) ) N
or CC N
modified VBN N
oximeters NNS N
( ( N
displayed VB N
a DT N
measured JJ N
value NN N
of IN N
90 CD N
% NN N
as IN N
94 CD N
% NN N
, , N
therefore RB N
oxygen IN N
not RB N
given VBN N
until IN N
SpO2 NNP N
< VBD N
90 CD N
% NN N
) ) N
All DT N
parents NNS N
, , N
clinical JJ N
staff NN N
, , N
and CC N
outcome JJ N
assessors NNS N
were VBD N
masked VBN N
to TO N
allocation NN N
The DT N
primary JJ N
outcome NN N
was VBD N
time NN N
to TO N
resolution NN N
of IN N
cough NN N
( ( N
prespecified JJ N
equivalence NN N
limits NNS N
of IN N
plus CC N
or CC N
minus CC N
2 CD N
days NNS N
) ) N
in IN N
the DT N
intention-to-treat JJ N
population NN N
This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ISRCTN NNP N
, , N
number NN N
ISRCTN28405428 NNP N
FINDINGS NNP N
Between NNP N
Oct NNP N
3 CD N
, , N
and CC N
March NNP N
30 CD N
, , N
2012 CD N
, , N
and CC N
Oct NNP N
1 CD N
, , N
and CC N
March NNP N
29 CD N
, , N
2013 CD N
, , N
we PRP N
randomly VBP N
assigned VBD N
308 CD 3_p
infants NNS 3_p
to TO N
standard VB N
oximeters NNS N
and CC N
307 CD N
infants NNS N
to TO N
modified JJ N
oximeters NNS N
Cough NNP N
resolved VBN N
by IN N
15·0 CD N
days NNS N
( ( N
median JJ N
) ) N
in IN N
both DT N
groups NNS N
( ( N
95 CD N
% NN N
CI NNP N
for IN N
difference NN N
-1 NN N
to TO N
2 CD N
) ) N
and CC N
so RB N
oxygen JJ N
thresholds NNS N
were VBD N
equivalent JJ N
We PRP N
recorded VBD N
35 CD N
serious JJ N
adverse JJ N
events NNS N
in IN N
32 CD N
infants NNS N
in IN N
the DT N
standard NN N
care NN N
group NN N
and CC N
25 CD N
serious JJ N
adverse JJ N
events NNS N
in IN N
24 CD N
infants NNS N
in IN N
the DT N
modified NNP N
care NN N
group NN N
In IN N
the DT N
standard NN N
care NN N
group NN N
, , N
eight CD N
infants NNS N
transferred VBN N
to TO N
a DT N
high-dependency NN N
unit NN N
, , N
23 CD N
were VBD N
readmitted VBN N
, , N
and CC N
one CD N
had VBD N
a DT N
prolonged JJ N
hospital NN N
stay NN N
In IN N
the DT N
modified NNP N
care NN N
group NN N
, , N
12 CD N
infants NNS N
were VBD N
transferred VBN N
to TO N
a DT N
high-dependency NN N
unit NN N
and CC N
12 CD N
were VBD N
readmitted VBN N
to TO N
hospital NN N
Recorded VBN N
adverse JJ N
events NNS N
did VBD N
not RB N
differ VB N
significantly RB N
INTERPRETATION NNP N
Management NNP N
of IN N
infants NNS 1_p
with IN N
bronchiolitis NN 4_p
to TO N
an DT N
oxygen NN N
saturation NN N
target NN N
of IN N
90 CD N
% NN N
or CC N
higher JJR N
is VBZ N
as IN N
safe JJ N
and CC N
clinically RB N
effective JJ N
as IN N
one CD N
of IN N
94 CD N
% NN N
or CC N
higher JJR N
Future JJ N
research NN N
should MD N
assess VB N
the DT N
benefits NNS N
and CC N
risks NNS N
of IN N
different JJ N
oxygen NN N
saturation NN N
targets NNS N
in IN N
acute JJ N
respiratory NN N
infection NN N
in IN N
older JJR N
children NNS N
, , N
particularly RB N
in IN N
developing VBG N
nations NNS N
where WRB N
resources NNS N
are VBP N
scarce JJ N
FUNDING NNP N
National NNP N
Institute NNP N
for IN N
Health NNP N
Research NNP N
, , N
Health NNP N
Technology NNP N
Assessment NNP N
programme NN N
-DOCSTART- -X- O O 21996342

Epicutaneous JJ N
allergen-specific JJ N
immunotherapy NN N
ameliorates VBZ N
grass JJ N
pollen-induced JJ N
rhinoconjunctivitis NN N
: : N
A DT N
double-blind NN N
, , N
placebo-controlled JJ N
dose NN N
escalation NN N
study NN N
BACKGROUND NNP N
Epicutaneous NNP N
allergen NN N
administration NN N
using VBG N
a DT N
patch NN N
may MD N
be VB N
an DT N
alternative JJ N
to TO N
subcutaneous JJ N
or CC N
sublingual JJ N
immunotherapy NN N
OBJECTIVE UH N
To TO N
optimize VB N
treatment NN N
dose NN N
and CC N
to TO N
demonstrate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
epicutaneous JJ N
immunotherapy NN N
METHODS NNP N
This DT N
monocentric JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
included VBD N
132 CD 3_p
patients NNS N
with IN N
grass JJ 4_p
pollen-induced JJ 4_p
rhinoconjunctivitis NN 4_p
In IN N
February NNP N
2008 CD N
, , N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
placebo NN N
or CC N
3 CD N
different JJ N
doses NNS N
of IN N
allergen NN N
Before IN N
and CC N
during IN N
the DT N
pollen NN N
season NN N
2008 CD N
, , N
patients NNS N
received VBD N
6 CD N
weekly JJ N
patches NNS N
Efficacy NN N
was VBD N
assessed VBN N
4 CD N
to TO N
5 CD N
months NNS N
later RB N
( ( N
n JJ N
= NNP N
110 CD N
) ) N
and CC N
during IN N
the DT N
pollen NN N
season NN N
of IN N
the DT N
treatment-free JJ N
follow-up JJ N
year NN N
in IN N
2009 CD N
( ( N
n JJ N
= NNP N
93 CD N
) ) N
The DT N
primary JJ N
outcome NN N
was VBD N
patient-reported JJ N
changes NNS N
in IN N
hay NN N
fever NN N
symptoms NNS N
assessed VBN N
by IN N
a DT N
visual JJ N
analog NN N
scale NN N
Secondary JJ N
outcome NN N
measures NNS N
were VBD N
weekly JJ N
visual JJ N
analog NN N
scale JJ N
symptom NN N
scores NNS N
during IN N
pollen NN N
season NN N
, , N
use NN N
of IN N
rescue NN N
medication NN N
, , N
changes NNS N
in IN N
conjunctival NN N
and CC N
skin NN N
reactivity NN N
, , N
as RB N
well RB N
as IN N
safety NN N
RESULTS NNP N
Hay NNP N
fever NN N
symptoms NNS N
during IN N
the DT N
pollen NN N
season NN N
were VBD N
reduced VBN N
by IN N
more JJR N
than IN N
30 CD N
% NN N
in IN N
2008 CD N
and CC N
by IN N
24 CD N
% NN N
in IN N
2009 CD N
in IN N
the DT N
high-dose JJ N
group NN N
as IN N
compared VBN N
with IN N
that DT N
in IN N
the DT N
placebo NN N
group NN N
, , N
and CC N
the DT N
alleviation NN N
of IN N
symptoms NNS N
in IN N
the DT N
follow-up JJ N
year NN N
was VBD N
dependent JJ N
on IN N
the DT N
treatment NN N
dose NN N
Higher JJR N
allergen NN N
doses NNS N
were VBD N
associated VBN N
with IN N
drug-related JJ N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
, , N
predominantly RB N
manifested VBN N
by IN N
pruritus NN N
, , N
erythema NN N
, , N
wheal NN N
, , N
or CC N
eczema NN N
Eleven NNP N
systemic JJ N
AEs NNP N
of IN N
grades NNS N
1 CD N
to TO N
2 CD N
required VBN N
treatment NN N
and CC N
led VBD N
to TO N
study VB N
exclusion NN N
The DT N
dropout NN N
rate NN N
due JJ N
to TO N
AEs NNP N
was VBD N
8.3 CD N
% NN N
No DT N
drug-related JJ N
serious JJ N
AE NNP N
was VBD N
recorded VBN N
CONCLUSION NNP N
Epicutaneous NNP N
immunotherapy NN N
is VBZ N
safe JJ N
and CC N
efficacious JJ N
in IN N
a DT N
dose-dependent JJ N
manner NN N
after IN N
6 CD N
patches NNS N
only RB N
-DOCSTART- -X- O O 16508555

Minimal NNP N
clinically RB N
important JJ N
change NN N
for IN N
pain NN N
intensity NN N
, , N
functional JJ N
status NN N
, , N
and CC N
general JJ N
health NN N
status NN N
in IN N
patients NNS N
with IN N
nonspecific JJ N
low JJ 4_p
back RB 4_p
pain NN 4_p
STUDY NNP N
DESIGN NNP N
Cohort NNP N
study NN N
OBJECTIVES NNP N
To TO N
estimate VB N
the DT N
Minimal NNP N
Clinically NNP N
Important NNP N
Change NNP N
( ( N
MCIC NNP N
) ) N
of IN N
the DT N
pain NN N
intensity NN N
numerical JJ N
rating NN N
scale NN N
( ( N
PI-NRS NNP N
) ) N
, , N
the DT N
Quebec NNP N
Back NNP N
Pain NNP N
Disability NNP N
Scale NNP N
( ( N
QBPDS NNP N
) ) N
, , N
and CC N
the DT N
Euroqol NNP N
( ( N
EQ NNP N
) ) N
in IN N
patients NNS N
with IN N
low JJ 4_p
back RB 4_p
pain NN 4_p
SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
MCIC NNP N
can MD N
provide VB N
valuable JJ N
information NN N
for IN N
researchers NNS N
, , N
healthcare NN N
providers NNS N
, , N
and CC N
policymakers NNS N
METHODS NNP N
Data NNP N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
with IN N
442 CD 3_p
patients NNS N
with IN N
low JJ 4_p
back RB 4_p
pain NN 4_p
were VBD N
used VBN N
The DT N
MCIC NNP N
was VBD N
estimated VBN N
over IN N
a DT N
12-week JJ N
period NN N
, , N
and CC N
three CD N
different JJ N
methods NNS N
were VBD N
used VBN N
: : N
1 CD N
) ) N
mean NN N
change NN N
scores NNS N
, , N
2 CD N
) ) N
minimal NN N
detectable JJ N
change NN N
, , N
and CC N
3 CD N
) ) N
optimal VBD N
cutoff NN N
point NN N
in IN N
receiver NN N
operant JJ N
curves NNS N
The DT N
global JJ N
perceived JJ N
effect NN N
scale NN N
( ( N
GPE NNP N
) ) N
was VBD N
used VBN N
as IN N
an DT N
external JJ N
criterion NN N
The DT N
effect NN N
of IN N
initial JJ N
scores NNS N
on IN N
the DT N
MCIC NNP N
was VBD N
also RB N
assessed VBN N
RESULTS VB N
The DT N
MCIC NNP N
of IN N
the DT N
PI-NRS NNP N
ranged VBD N
from IN N
3.5 CD N
to TO N
4.7 CD N
points NNS N
in IN N
( ( N
sub NN N
) ) N
acute NN N
patients NNS N
and CC N
2.5 CD N
to TO N
4.5 CD N
points NNS N
in IN N
chronic JJ N
patients NNS N
with IN N
low JJ N
back RB N
pain NN N
The DT N
MCIC NNP N
of IN N
the DT N
QBPDS NNP N
was VBD N
estimated VBN N
between IN N
17.5 CD N
to TO N
32.9 CD N
points NNS N
and CC N
8.5 CD N
to TO N
24.6 CD N
points NNS N
for IN N
( ( N
sub NN N
) ) N
acute NN N
and CC N
chronic JJ N
patients NNS N
with IN N
low JJ 4_p
back RB 4_p
pain NN 4_p
The DT N
MCIC NNP N
for IN N
the DT N
EQ NNP N
ranged VBD N
from IN N
0.07 CD N
to TO N
0.58 CD N
in IN N
( ( N
sub NN N
) ) N
acute NN N
patients NNS N
and CC N
0.09 CD N
to TO N
0.28 CD N
in IN N
patients NNS N
with IN N
chronic JJ N
low JJ N
back RB N
pain NN N
CONCLUSION NNP N
Reporting VBG N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
have VBP N
made VBN N
a DT N
MCIC NNP N
adds VBZ N
to TO N
the DT N
interpretability NN N
of IN N
study NN N
results NNS N
We PRP N
present VBD N
a DT N
range NN N
of IN N
MCIC NNP N
values NNS N
and CC N
advocate VB N
the DT N
choice NN N
of IN N
a DT N
single JJ N
MCIC NNP N
value NN N
according VBG N
to TO N
the DT N
specific JJ N
context NN N
-DOCSTART- -X- O O 10208073

Clinical JJ N
hypnosis NN N
versus NN N
cognitive JJ N
behavioral JJ N
training NN N
for IN N
pain NN N
management NN N
with IN N
pediatric JJ 1_p
cancer NN 4_p
patients NNS 4_p
undergoing VBG 4_p
bone NN 4_p
marrow NN 4_p
aspirations NNS 4_p
A DT N
randomized JJ N
controlled JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
clinical JJ N
hypnosis NN N
versus NN N
cognitive JJ N
behavioral NN N
( ( N
CB NNP N
) ) N
coping VBG N
skills NNS N
training VBG N
in IN N
alleviating VBG N
the DT N
pain NN N
and CC N
distress NN N
of IN N
30 CD 3_p
pediatric JJ N
cancer NN 4_p
patients NNS N
( ( N
age NN 1_p
5 CD 1_p
to TO 1_p
15 CD 1_p
years NNS 1_p
) ) N
undergoing VBG N
bone NN N
marrow NN N
aspirations NNS N
Patients NNS N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
hypnosis NN N
, , N
a DT N
package NN N
of IN N
CB NNP N
coping VBG N
skills NNS N
, , N
and CC N
no DT N
intervention NN N
Patients NNS N
who WP N
received VBD N
either CC N
hypnosis NN N
or CC N
CB NNP N
reported VBD N
less JJR N
pain NN N
and CC N
pain-related JJ N
anxiety NN N
than IN N
did VBD N
control VB N
patients NNS N
and CC N
less JJR N
pain NN N
and CC N
anxiety NN N
than IN N
at IN N
their PRP$ N
own JJ N
baseline NN N
Hypnosis NNP N
and CC N
CB NNP N
were VBD N
similarly RB N
effective JJ N
in IN N
the DT N
relief NN N
of IN N
pain NN N
Results NNP N
also RB N
indicated VBD N
that IN N
children NNS N
reported VBD N
more RBR N
anxiety NN N
and CC N
exhibited VBD N
more RBR N
behavioral JJ N
distress NN N
in IN N
the DT N
CB NNP N
group NN N
than IN N
in IN N
the DT N
hypnosis NN N
group NN N
It PRP N
is VBZ N
concluded VBN N
that IN N
hypnosis NN N
and CC N
CB NNP N
coping VBG N
skills NNS N
are VBP N
effective JJ N
in IN N
preparing VBG N
pediatric JJ N
oncology NN N
patients NNS N
for IN N
bone NN N
marrow NN N
aspiration NN N
-DOCSTART- -X- O O 7072873

Memory NN N
aids NNS N
in IN N
longitudinal JJ N
health NN N
surveys NNS N
: : N
results NNS N
from IN N
a DT N
field NN N
experiment NN N
The DT N
use NN N
of IN N
memory NN N
aids NNS N
to TO N
improve VB N
respondent NN N
recall NN N
is VBZ N
becoming VBG N
increasingly RB N
popular JJ N
in IN N
health NN N
surveys NNS N
In IN N
a DT N
one-year JJ N
field NN N
experiment NN N
involving VBG N
over IN 4_p
1,200 CD 4_p
respondents NNS 4_p
, , 4_p
people NNS 4_p
assigned VBD 4_p
memory NN 4_p
aids NNS 4_p
reported VBD 4_p
over IN 4_p
50 CD 4_p
per IN 4_p
cent NN 4_p
more JJR 4_p
symptom JJ 4_p
episodes NNS 4_p
than IN 4_p
those DT 4_p
not RB 4_p
assigned JJ 4_p
memory NN 4_p
aids NNS 4_p
Differences NNS N
in IN N
reporting NN N
levels NNS N
were VBD N
particularly RB N
striking VBG N
during IN N
the DT N
first JJ N
six CD N
to TO N
12 CD N
weeks NNS N
of IN N
the DT N
survey NN N
, , N
for IN N
symptoms NNS N
related VBN N
to TO N
acute VB N
, , N
transitory NN N
illness NN N
, , N
and CC N
among IN N
minorities NNS N
and CC N
the DT N
lower JJR N
socioeconomic JJ N
groups NNS N
Respondents NNS N
assigned VBD N
memory NN N
aids NNS N
were VBD N
also RB N
more RBR N
likely JJ N
to TO N
report VB N
a DT N
doctor NN N
contact NN N
-- : N
especially RB N
during IN N
the DT N
fall/winter JJ N
months NNS N
Among IN N
respondent NN N
who WP N
used VBD N
their PRP$ N
memory NN N
aids NNS N
at IN N
least JJS N
once RB N
( ( N
N NNP N
= NNP N
252 CD N
) ) N
, , N
nearly RB N
35 CD N
per IN N
cent NN N
said VBD N
they PRP N
were VBD N
influenced VBN N
by IN N
the DT N
information NN N
recorded VBN N
in IN N
their PRP$ N
memory NN N
aids NNS N
, , N
and CC N
most JJS N
of IN N
those DT N
who WP N
were VBD N
influenced VBN N
said VBD N
that IN N
they PRP N
became VBD N
more RBR N
aware JJ N
of IN N
their PRP$ N
health NN N
Ten CD N
of IN N
these DT N
people NNS N
said VBD N
that IN N
they PRP N
became VBD N
more RBR N
worried JJ N
or CC N
depressed JJ N
because IN N
of IN N
the DT N
information NN N
recorded VBN N
in IN N
their PRP$ N
memory NN N
aids NNS N
This DT N
constitutes VBZ N
about IN N
a DT N
four CD N
per IN N
cent NN N
risk NN N
among IN N
those DT N
people NNS N
who WP N
reported VBD N
using VBG N
their PRP$ N
memory NN N
aids NNS N
at IN N
least JJS N
once RB N
There EX N
was VBD N
no DT N
evidence NN N
to TO N
suggest VB N
that IN N
the DT N
memory NN N
aids NNS N
influenced VBD N
perceptions NNS N
of IN N
health NN N
status NN N
-DOCSTART- -X- O O 17321529

Misoprostol NNP N
versus NN N
oxytocin NN N
for IN N
the DT N
reduction NN N
of IN N
postpartum NN 4_p
blood NN N
loss NN N
OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
400 CD N
mug NN N
of IN N
oral JJ N
misoprostol NN N
with IN N
5 CD N
U NNP N
of IN N
intravenous JJ N
oxytocin NNS N
in IN N
the DT N
reduction NN N
of IN N
postpartum NN N
blood NN N
loss NN N
and CC N
prevention NN N
of IN N
postpartum NN N
hemorrhage NN N
METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
controlled VBN N
trial NN N
conducted VBN N
in IN N
a DT N
tertiary JJ N
maternity NN N
hospital NN N
622 CD 3_p
women NNS 2_p
received VBD N
either RB N
400 CD N
mug NN N
of IN N
oral JJ N
misoprostol NN N
or CC N
5 CD N
U NNP N
of IN N
intravenous JJ N
oxytocin NNS N
after IN N
delivery NN N
of IN N
the DT N
anterior JJ N
shoulder NN N
or CC N
within IN N
1 CD N
min NNS N
of IN N
delivery NN N
The DT N
primary JJ N
outcome NN N
was VBD N
a DT N
hematocrit JJ N
drop NN N
of IN N
10 CD N
% NN N
or CC N
greater JJR N
24 CD N
h NN N
postpartum NN N
The DT N
secondary JJ N
outcomes NNS N
were VBD N
a DT N
hemoglobin JJ N
drop NN N
of IN N
30 CD N
mg/L NN N
or CC N
greater JJR N
, , N
the DT N
use NN N
of IN N
additional JJ N
oxytocin NN N
, , N
an DT N
estimated VBN N
blood NN N
loss NN N
greater JJR N
than IN N
1000 CD N
mL NN N
, , N
manual JJ N
removal NN N
of IN N
the DT N
placenta NN N
, , N
a DT N
blood NN N
transfusion NN N
, , N
and CC N
shivering VBG N
and CC N
fever NN N
( ( N
> JJ N
or=38 NN N
degrees NNS N
C NNP N
) ) N
as IN N
adverse JJ N
effects NNS N
of IN N
misoprostol NN N
RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
regarding VBG N
the DT N
primary JJ N
outcome NN N
( ( N
a DT N
> NN N
or=10 NN N
% NN N
hematocrit JJ N
drop NN N
occurred VBD N
in IN N
3.4 CD N
% NN N
and CC N
3.7 CD N
% NN N
of IN N
the DT N
participants NNS N
in IN N
the DT N
oxytocin NN N
and CC N
misoprostol NN N
groups NNS N
, , N
P=0.98 NNP N
) ) N
The DT N
rate NN N
of IN N
use NN N
of IN N
additional JJ N
oxytocin NN N
was VBD N
higher RBR N
in IN N
the DT N
misoprostol NN N
group NN N
( ( N
51 CD N
% NN N
versus IN N
40.5 CD N
% NN N
, , N
P=0.01 NNP N
) ) N
Shivering VBG N
was VBD N
confined VBN N
to TO N
the DT N
misoprostol NN N
group NN N
( ( N
6.8 CD N
% NN N
) ) N
, , N
and CC N
fever RB N
occurred VBD N
in IN N
12.5 CD N
% NN N
of IN N
the DT N
women NNS N
in IN N
the DT N
misoprostol NN N
group NN N
and CC N
0.3 CD N
% NN N
of IN N
the DT N
women NNS N
in IN N
the DT N
oxytocin NN N
group NN N
CONCLUSION NNP N
The DT N
routine JJ N
use NN N
of IN N
400 CD N
microg NN N
of IN N
oral JJ N
misoprostol NN N
was VBD N
no DT N
less RBR N
effective JJ N
than IN N
5 CD N
U NNP N
of IN N
intravenous JJ N
oxytocin NNS N
in IN N
reducing VBG N
blood NN N
loss NN N
after IN N
delivery NN N
, , N
as IN N
assessed VBN N
by IN N
change NN N
in IN N
postpartum NN N
hematocrit NN N
The DT N
adverse JJ N
effects NNS N
of IN N
misoprostol NN N
were VBD N
mild JJ N
and CC N
self-limiting JJ N
-DOCSTART- -X- O O 21220480

Gefitinib NNP N
or CC N
placebo NN N
in IN N
combination NN N
with IN N
tamoxifen NN N
in IN N
patients NNS N
with IN N
hormone JJ N
receptor-positive JJ N
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
: : N
a DT N
randomized JJ N
phase NN N
II NNP N
study NN N
PURPOSE NNP N
Increased VBD N
growth NN N
factor NN N
signaling VBG N
may MD N
contribute VB N
to TO N
tamoxifen VB N
resistance NN N
This DT N
randomized JJ N
phase NN N
II NNP N
trial NN N
assessed VBD N
tamoxifen JJ N
plus CC N
placebo NN N
or CC N
the DT N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
inhibitor NN N
gefitinib NN N
in IN N
estrogen NN N
receptor NN N
( ( N
ER NNP N
) ) N
-positive VBP N
metastatic JJ N
breast NN N
cancer NN N
EXPERIMENTAL NNP N
DESIGN NNP N
Patients NNPS N
with IN N
newly RB N
metastatic JJ 4_p
disease NN 4_p
or CC N
recurred VBN N
after IN N
adjuvant JJ N
tamoxifen NN N
( ( N
stratum JJ N
1 CD N
) ) N
, , N
or CC N
recurred VBD N
during/after NN N
adjuvant JJ N
aromatase NN N
inhibitor NN N
( ( N
AI NNP N
) ) N
or CC N
after IN N
failed VBN N
first-line NN N
AI NNP N
( ( N
stratum JJ N
2 CD N
) ) N
, , N
were VBD N
eligible JJ N
Primary JJ N
variables NNS N
were VBD N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
; : N
stratum VBZ N
1 CD N
) ) N
and CC N
clinical JJ N
benefit NN N
rate NN N
( ( N
CBR NNP N
; : N
stratum VBZ N
2 CD N
) ) N
A DT N
5 CD N
% NN N
or CC N
more JJR N
improvement NN N
in IN N
response NN N
variables NNS N
with IN N
gefitinib NN N
was VBD N
considered VBN N
to TO N
warrant VB N
further JJ N
investigation NN N
Outcome NNP N
was VBD N
correlated VBN N
with IN N
biomarkers NNS N
measured VBN N
on IN N
the DT N
primary JJ N
tumor NN N
RESULTS NNP N
In IN N
stratum JJ N
1 CD N
( ( N
n JJ N
= NNP N
206 CD N
) ) N
, , N
the DT N
PFS NNP N
HR NNP N
( ( N
gefitinib NN N
: : N
placebo NN N
) ) N
was VBD N
0.84 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.59-1.18 NNP N
; : N
median JJ N
PFS NNP N
10.9 CD N
versus NN N
8.8 CD N
months NNS N
) ) N
In IN N
the DT N
stratum NN N
1 CD N
endocrine JJ N
therapy-naïve JJ N
subset NN N
( ( N
n JJ N
= NNP N
158 CD N
) ) N
the DT N
HR NNP N
was VBD N
0.78 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.52-1.15 NNP N
) ) N
, , N
and CC N
the DT N
prior JJ N
endocrine-treated JJ N
subgroup NN N
( ( N
n JJ N
= NNP N
48 CD N
) ) N
1.47 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.63-3.45 NN N
) ) N
In IN N
stratum NN N
1 CD N
, , N
CBRs NNP N
were VBD N
50.5 CD N
% NN N
with IN N
gefitinib NN N
and CC N
45.5 CD N
% NN N
with IN N
placebo NN N
In IN N
stratum NN N
2 CD N
( ( N
n JJ N
= NNP N
84 CD N
) ) N
, , N
CBRs NNP N
were VBD N
29.2 CD N
% NN N
with IN N
gefitinib NN N
and CC N
31.4 CD N
% NN N
with IN N
placebo NN N
Biomarker NNP N
analysis NN N
suggested VBD N
that IN N
in IN N
stratum NN N
1 CD N
there EX N
was VBD N
greater JJR N
benefit NN N
with IN N
gefitinib NN N
in IN N
patients NNS N
who WP N
were VBD N
ER-negative JJ N
or CC N
had VBD N
lower JJR N
levels NNS N
of IN N
ER NNP N
protein NN N
CONCLUSIONS NNP N
In IN N
stratum NN N
1 CD N
, , N
the DT N
improved JJ N
PFS NNP N
with IN N
gefitinib JJ N
plus CC N
tamoxifen JJ N
met VBD N
the DT N
protocol NN N
criteria NNS N
to TO N
warrant VB N
further JJ N
investigation NN N
of IN N
this DT N
strategy NN N
In IN N
stratum NN N
2 CD N
, , N
there EX N
was VBD N
a DT N
numerical JJ N
disadvantage NN N
for IN N
gefitinib NN N
; : N
additional JJ N
investigation NN N
after IN N
AI NNP N
therapy NN N
is VBZ N
not RB N
warranted VBN N
Studies NNS N
of IN N
predictive JJ N
biomarkers NNS N
are VBP N
needed VBN N
to TO N
subset VB N
appropriate JJ N
patients NNS N
-DOCSTART- -X- O O 24930383

Elevation NN N
of IN N
HDL-C NNP N
in IN N
response NN N
to TO N
statin VB N
treatment NN N
is VBZ N
involved VBN N
in IN N
the DT N
regression NN N
of IN N
carotid JJ 4_p
atherosclerosis NN 4_p
AIM NNP N
Atherosclerosis NNP N
is VBZ N
strongly RB N
associated VBN N
with IN N
an DT N
increased VBN N
mortality NN N
in IN N
subjects NNS N
with IN N
diabetes NNS 4_p
The DT N
carotid JJ N
intima-media JJ N
thickness NN N
( ( N
IMT NNP N
) ) N
is VBZ N
commonly RB N
measured VBN N
as IN N
a DT N
surrogate NN N
marker NN N
for IN N
cardiovascular JJ N
risk NN N
Statins NNS N
are VBP N
well-established JJ N
protective JJ N
agents NNS N
against IN N
atherosclerosis NN N
and CC N
reportedly RB N
suppress JJ N
IMT NNP N
progression NN N
in IN N
subjects NNS N
with IN N
diabetes NNS N
To TO N
clarify VB N
the DT N
effects NNS N
of IN N
statins NNS N
on IN N
subclinical JJ N
atherosclerosis NN N
, , N
we PRP N
herein VBP N
investigated JJ N
changes NNS N
in IN N
the DT N
carotid NN N
IMT NNP N
and CC N
lipid JJ N
profiles NNS N
in IN N
a DT N
multi-center NN N
, , N
prospective JJ N
, , N
randomized JJ N
trial NN N
METHODS NNP N
Hypercholesterolemic NNP N
subjects VBZ N
with IN N
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
open-label JJ N
treatment NN N
with IN N
either DT N
pravastatin NN N
or CC N
pitavastatin NN N
The DT N
primary JJ N
endpoint NN N
of IN N
this DT N
study NN N
was VBD N
the DT N
IMT NNP N
change NN N
after IN N
36 CD N
months NNS N
of IN N
statin JJ N
treatment NN N
RESULTS VB N
A DT N
total NN N
of IN N
97 CD 3_p
subjects NNS N
( ( N
51 CD 3_p
pitavastatin NN N
; : N
46 CD 3_p
pravastatin NN N
) ) N
completed VBD N
this DT N
36-month JJ N
study NN N
The DT N
LDL-C NNP N
decreased VBD N
significantly RB N
from IN N
163.4 CD N
± $ N
27.9 CD N
mg/dl NN N
at IN N
baseline NN N
to TO N
100.4 CD N
± NNS N
19.6 CD N
mg/dl NN N
at IN N
36 CD N
months NNS N
in IN N
the DT N
pitavastatin NN N
group NN N
and CC N
from IN N
159.7 CD N
± $ N
25.6 CD N
mg/dl NN N
to TO N
118.5 CD N
± NNS N
22.1 CD N
mg/dl NN N
in IN N
the DT N
pravastatin NN N
group NN N
The DT N
mean NN N
IMT NNP N
showed VBD N
moderate JJ N
regression NN N
in IN N
both CC N
the DT N
pitavastatin NN N
( ( N
-0.070 JJ N
± $ N
0.215 CD N
mm NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
the DT N
pravastatin NN N
( ( N
-0.067 JJ N
± $ N
0.260 CD N
mm NN N
) ) N
group NN N
However RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
IMT NNP N
change NN N
between IN N
the DT N
two CD N
groups NNS N
When WRB N
the DT N
two CD N
groups NNS N
were VBD N
combined VBN N
, , N
the DT N
36-month JJ N
change NN N
in IN N
the DT N
mean JJ N
IMT NNP N
was VBD N
significantly RB N
associated VBN N
with IN N
HDL-C NNP N
change NN N
( ( N
r=-0.24 JJ N
, , N
P= NNP N
0.03 CD N
) ) N
Multiple JJ N
linear JJ N
regression NN N
analysis NN N
revealed VBD N
the DT N
change NN N
in IN N
HDL-C NNP N
to TO N
be VB N
an DT N
independent JJ N
variable JJ N
showing VBG N
a DT N
positive JJ N
correlation NN N
with IN N
the DT N
carotid NN N
IMT NNP N
reduction NN N
CONCLUSION NNP N
The DT N
administration NN N
of IN N
statins NNS N
for IN N
3 CD N
years NNS N
to TO N
subjects NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
resulted VBD N
in IN N
a DT N
significant JJ N
regression NN N
of IN N
the DT N
carotid NN N
IMT NNP N
An DT N
elevation NN N
of IN N
the DT N
plasma JJ N
HDL-C NNP N
with IN N
statin JJ N
treatment NN N
was VBD N
closely RB N
related VBN N
to TO N
a DT N
regression NN N
of IN N
atherosclerosis NN N
-DOCSTART- -X- O O 15353873

A DT N
double JJ N
blind NN N
randomized VBD N
trial NN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
eprosartan NN N
and CC N
enalapril NN N
on IN N
blood NN N
pressure NN N
, , N
platelets NNS N
, , N
and CC N
endothelium NN N
function NN N
in IN N
patients NNS N
with IN N
essential JJ 4_p
hypertension NN 4_p
The DT N
renin-angiotensin JJ N
system NN N
is VBZ N
the DT N
major JJ N
contributor NN N
to TO N
development NN N
of IN N
hypertension NN N
, , N
atherosclerosis NN N
, , N
and CC N
many JJ N
other JJ N
cardiovascular JJ N
diseases NNS N
Angiotensin NNP N
II NNP N
, , N
one CD N
of IN N
the DT N
main JJ N
effectors NNS N
of IN N
this DT N
system NN N
, , N
contributes VBZ N
to TO N
the DT N
pathogenesis NN N
of IN N
hypertension NN N
and CC N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
monocyte NN N
, , N
platelet NN N
, , N
and CC N
endothelium NN N
interactions NNS N
The DT N
effects NNS N
on IN N
platelet NN N
and CC N
endothelial JJ N
function NN N
, , N
either RB N
by IN N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitors NNS N
or CC N
angiotensin NN N
receptor NN N
antagonists NNS N
, , N
are VBP N
still RB N
not RB N
well RB N
understood RB N
A DT N
double-blind NN N
, , N
randomized VBN N
, , N
prospective JJ N
trial NN N
of IN N
either DT N
enalapril NN N
( ( N
10-20 JJ N
mg NNS N
daily RB N
) ) N
or CC N
eprosartan JJ N
( ( N
400-800 JJ N
mg NNS N
daily RB N
) ) N
over IN N
a DT N
10-week JJ N
period NN N
was VBD N
conducted VBN N
in IN N
42 CD 3_p
patients NNS N
( ( N
27 CD 3_p
males NNS 2_p
, , N
15 CD 3_p
females NNS 2_p
) ) N
Platelet NNP N
activation NN N
was VBD N
evaluated VBN N
by IN N
measuring VBG N
platelet NN N
factor NN N
4 CD N
( ( N
PF-4 NNP N
) ) N
, , N
beta-thromboglobulin JJ N
( ( N
beta-TG JJ N
) ) N
, , N
the DT N
ratio NN N
of IN N
platelet NN N
factor NN N
4 CD N
to TO N
beta-thromboglobulin NN N
, , N
and CC N
endothelial JJ N
function NN N
by IN N
measuring VBG N
total JJ N
plasma JJ N
nitrate NN N
levels NNS N
, , N
von FW N
Willebrand NNP N
factor NN N
( ( N
vWF NN N
) ) N
levels NNS N
, , N
and CC N
blood NN N
flow NN N
using VBG N
venous JJ N
occlusive JJ N
plethysmography NN N
After IN N
a DT N
10-week JJ N
treatment NN N
with IN N
enalapril NN N
or CC N
eprosartan NN N
, , N
the DT N
sitting VBG N
blood NN N
pressure NN N
in IN N
both DT N
the DT N
enalapril NN N
group NN N
( ( N
from IN N
152.2 CD N
+/- JJ N
18.7 CD N
mmHg NN N
to TO N
141.9 CD N
+/- JJ N
23.5 CD N
mmHg NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
eprosartan JJ N
group NN N
( ( N
from IN N
151 CD N
+/- JJ N
10.0 CD N
mmHg NN N
to TO N
142.3 CD N
+/- JJ N
12.9 CD N
mmHg NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
was VBD N
significantly RB N
reduced VBN N
Significant NNP N
diastolic JJ N
blood NN N
pressure NN N
( ( N
DPB NNP N
) ) N
reduction NN N
( ( N
from IN N
94 CD N
+/- JJ N
8.7 CD N
to TO N
84.5 CD N
+/- JJ N
9.6 CD N
mmHg NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
a DT N
greater JJR N
DBP NNP N
reduction NN N
response NN N
were VBD N
found VBN N
in IN N
the DT N
eprosartan NN N
group NN N
( ( N
63 CD N
% NN N
in IN N
eprosartan JJ N
versus NN N
25 CD N
% NN N
in IN N
enalapril NN N
) ) N
Additionally RB N
, , N
dose-dependent JJ N
reductions NNS N
in IN N
the DT N
indices NNS N
of IN N
platelet NN N
activation NN N
and CC N
endothelial JJ N
dysfunction NN N
were VBD N
observed VBN N
in IN N
patients NNS N
administered VBN N
high JJ N
dose JJ N
treatments NNS N
of IN N
eprosartan NN N
and CC N
enalapril NN N
, , N
and CC N
the DT N
beneficial JJ N
effects NNS N
of IN N
these DT N
agents NNS N
were VBD N
not RB N
correlated VBN N
with IN N
the DT N
reduction NN N
of IN N
blood NN N
pressure NN N
using VBG N
both DT N
agents NNS N
Eprosartan NNP N
is VBZ N
effective JJ N
and CC N
well-tolerated JJ N
in IN N
the DT N
treatment NN N
of IN N
mid-to-moderate JJ N
hypertension NN N
, , N
and CC N
the DT N
DBP NNP N
response NN N
reduction NN N
to TO N
eprosartin VB N
was VBD N
better JJR N
than IN N
that DT N
to TO N
enalapril VB N
A DT N
high JJ N
dose NN N
of IN N
either DT N
eprosartan NN N
or CC N
enalapril VB N
significantly RB N
decreased VBN N
the DT N
indices NNS N
of IN N
platelet NN N
activation NN N
and CC N
endothelial JJ N
dysfunction NN N
in IN N
hypertensive JJ 4_p
patients NNS N
The DT N
benefits NNS N
of IN N
both DT N
agents NNS N
can MD N
not RB N
be VB N
explained VBN N
solely RB N
by IN N
their PRP$ N
antihypertensive JJ N
effects NNS N
and CC N
possibly RB N
may MD N
be VB N
mediated VBN N
through IN N
their PRP$ N
unique JJ N
effect NN N
on IN N
angiotensin NN N
blockade NN N
-DOCSTART- -X- O O 10770979

Lack NN N
of IN N
effect NN N
of IN N
a DT N
low-fat JJ N
, , N
high-fiber JJ N
diet NN N
on IN N
the DT N
recurrence NN N
of IN N
colorectal JJ N
adenomas NN N
Polyp NNP N
Prevention NNP N
Trial NNP N
Study NNP N
Group NNP N
BACKGROUND NNP N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
dietary JJ N
intervention NN N
can MD N
inhibit VB N
the DT N
development NN N
of IN N
recurrent NN N
colorectal NN N
adenomas NN N
, , N
which WDT N
are VBP N
precursors NNS N
of IN N
most JJS N
large-bowel JJ N
cancers NNS N
METHODS NNP N
We PRP N
randomly RB N
assigned VBD N
2079 CD 3_p
men NNS 2_p
and CC N
women NNS 2_p
who WP N
were VBD N
35 CD 1_p
years NNS N
of IN N
age NN N
or CC N
older JJR N
and CC N
who WP N
had VBD N
had VBN N
one CD N
or CC N
more JJR N
histologically RB N
confirmed VBN N
colorectal JJ 4_p
adenomas NN 4_p
removed VBD N
within IN N
six CD N
months NNS N
before IN N
randomization NN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
: : N
an DT N
intervention NN N
group NN N
given VBN N
intensive JJ N
counseling NN N
and CC N
assigned VBD N
to TO N
follow VB N
a DT N
diet NN N
that WDT N
was VBD N
low JJ N
in IN N
fat NN N
( ( N
20 CD N
percent NN N
of IN N
total JJ N
calories NNS N
) ) N
and CC N
high JJ N
in IN N
fiber NN N
( ( N
18 CD N
g NN N
of IN N
dietary JJ N
fiber NN N
per IN N
1000 CD N
kcal NN N
) ) N
and CC N
fruits NNS N
and CC N
vegetables NNS N
( ( N
3.5 CD N
servings NNS N
per IN N
1000 CD N
kcal NN N
) ) N
, , N
and CC N
a DT N
control NN N
group NN N
given VBN N
a DT N
standard JJ N
brochure NN N
on IN N
healthy JJ N
eating NN N
and CC N
assigned VBD N
to TO N
follow VB N
their PRP$ N
usual JJ N
diet NN N
Subjects NNS N
entered VBD N
the DT N
study NN N
after IN N
undergoing VBG N
complete JJ N
colonoscopy NN N
and CC N
removal NN N
of IN N
adenomatous JJ N
polyps NNS N
; : N
they PRP N
remained VBD N
in IN N
the DT N
study NN N
for IN N
approximately RB N
four CD N
years NNS N
, , N
undergoing VBG N
colonoscopy NN N
one CD N
and CC N
four CD N
years NNS N
after IN N
randomization NN N
RESULTS VB N
A DT N
total NN N
of IN N
1905 CD 3_p
of IN N
the DT N
randomized JJ N
subjects NNS N
( ( N
91.6 CD N
percent NN N
) ) N
completed VBD N
the DT N
study NN N
Of IN N
the DT N
958 CD N
subjects NNS N
in IN N
the DT N
intervention NN N
group NN N
and CC N
the DT N
947 CD N
in IN N
the DT N
control NN N
group NN N
who WP N
completed VBD N
the DT N
study NN N
, , N
39.7 CD N
percent NN N
and CC N
39.5 CD N
percent NN N
, , N
respectively RB N
, , N
had VBD N
at IN N
least JJS N
one CD N
recurrent NN N
adenoma NN N
; : N
the DT N
unadjusted JJ N
risk NN N
ratio NN N
was VBD N
1.00 CD N
( ( N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.90 CD N
to TO N
1.12 CD N
) ) N
Among IN N
subjects NNS N
with IN N
recurrent NN N
adenomas NN N
, , N
the DT N
mean NN N
( ( N
+/-SE JJ N
) ) N
number NN N
of IN N
such JJ N
lesions NNS N
was VBD N
1.85+/-0.08 JJ N
in IN N
the DT N
intervention NN N
group NN N
and CC N
1.84+/-0.07 NNS N
in IN N
the DT N
control NN N
group NN N
The DT N
rate NN N
of IN N
recurrence NN N
of IN N
large JJ N
adenomas NNS N
( ( N
with IN N
a DT N
maximal JJ N
diameter NN N
of IN N
at IN N
least JJS N
1 CD N
cm NN N
) ) N
and CC N
advanced JJ N
adenomas NN N
( ( N
defined VBN N
as IN N
lesions NNS N
that WDT N
had VBD N
a DT N
maximal JJ N
diameter NN N
of IN N
at IN N
least JJS N
1 CD N
cm NN N
or CC N
at IN N
least JJS N
25 CD N
percent NN N
villous JJ N
elements NNS N
or CC N
evidence NN N
of IN N
high-grade JJ N
dysplasia NN N
, , N
including VBG N
carcinoma NN N
) ) N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
CONCLUSIONS NNP N
Adopting VBG N
a DT N
diet NN N
that WDT N
is VBZ N
low JJ N
in IN N
fat NN N
and CC N
high JJ N
in IN N
fiber NN N
, , N
fruits NNS N
, , N
and CC N
vegetables NNS N
does VBZ N
not RB N
influence VB N
the DT N
risk NN N
of IN N
recurrence NN N
of IN N
colorectal JJ N
adenomas NN N
-DOCSTART- -X- O O 3166942

Psoriasis NN 4_p
of IN 4_p
the DT 4_p
scalp NN 4_p
treated VBD N
with IN N
Grenz NNP N
rays NNS N
or CC N
topical JJ N
corticosteroid NN N
combined VBN N
with IN N
Grenz NNP N
rays NNS N
A DT N
comparative JJ N
randomized VBN N
trial NN N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
Grenz NNP N
ray NN N
therapy NN N
alone RB N
compared VBN N
with IN N
Grenz NNP N
rays NNS N
combined VBN N
with IN N
a DT N
topical JJ N
corticosteroid NN N
( ( N
betamethasone JJ N
dipropionate NN N
) ) N
in IN N
psoriasis NN N
of IN N
the DT N
scalp NN N
, , N
40 CD 3_p
patients NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
One CD N
group NN N
received VBD N
4 CD N
Gy NNP N
of IN N
Grenz NNP N
rays NNS N
administered VBD N
on IN N
six CD N
occasions NNS N
at IN N
intervals NNS N
of IN N
1 CD N
week NN N
and CC N
the DT N
other JJ N
group NN N
was VBD N
given VBN N
the DT N
same JJ N
Grenz NNP N
ray NN N
treatment NN N
plus CC N
topical JJ N
corticosteroid NN N
The DT N
patients NNS N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
Grenz NNP N
ray NN N
therapy NN N
and CC N
were VBD N
followed-up NNS N
for IN N
6 CD N
months NNS N
Of IN N
the DT N
37 CD 3_p
patients NNS N
who WP N
completed VBD N
the DT N
trial NN N
16 CD N
out IN N
of IN N
19 CD N
( ( N
84 CD N
% NN N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
Grenz NNP N
ray NN N
group NN N
, , N
and CC N
13 CD N
out IN N
of IN N
18 CD N
( ( N
72 CD N
% NN N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
combination NN N
group NN N
healed VBD N
The DT N
remission NN N
time NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
Of IN N
the DT N
patients NNS N
who WP N
healed VBD N
, , N
5 CD N
of IN N
16 CD N
patients NNS N
in IN N
the DT N
Grenz NNP N
ray NN N
only RB N
group NN N
and CC N
4 CD N
of IN N
13 CD N
patients NNS N
in IN N
the DT N
combination NN N
group NN N
remained VBD N
healed VBN N
at IN N
6 CD N
months NNS N
We PRP N
conclude VBP N
that IN N
Grenz NNP N
ray NN N
therapy NN N
is VBZ N
a DT N
useful JJ N
treatment NN N
modality NN N
for IN N
scalp JJ N
psoriasis NN N
, , N
but CC N
that IN N
the DT N
addition NN N
of IN N
a DT N
topical JJ N
corticosteroid NN N
has VBZ N
only RB N
a DT N
minor JJ N
effect NN N
-DOCSTART- -X- O O 11863211

Effect NN N
of IN N
oxolamine NN N
on IN N
cough JJ N
sensitivity NN N
in IN N
COPD NNP 4_p
patients NNS 4_p
-DOCSTART- -X- O O 12810472

Treatment NN N
of IN N
recurrent NN 4_p
chronic JJ 4_p
hyperplastic JJ 4_p
sinusitis NN 4_p
with IN 4_p
nasal JJ 4_p
polyposis NN 4_p
OBJECTIVE UH N
To TO N
demonstrate VB N
the DT N
long-term JJ N
efficacy NN N
of IN N
intranasal JJ N
furosemide NN N
, , N
an DT N
inhibitor NN N
of IN N
the DT N
sodium NN N
chloride NN N
cotransporter NN N
channel NN N
at IN N
the DT N
basolateral JJ N
surface NN N
of IN N
the DT N
respiratory JJ N
epithelial JJ N
cell NN N
, , N
vs VBZ N
no DT N
therapeutic JJ N
intervention NN N
vs NN N
intranasal NN N
mometasone NN N
furoate NN N
, , N
a DT N
corticosteroid NN N
, , N
in IN N
preventing VBG N
relapses NNS N
of IN N
chronic JJ N
hyperplastic JJ N
sinusitis NN N
with IN N
nasal JJ N
polyposis NN N
DESIGN NNP N
Randomized NNP N
prospective NN N
controlled VBD N
study NN N
Patients NNS N
were VBD N
examined VBN N
every DT N
6 CD N
months NNS N
during IN N
follow-up NN N
( ( N
range NN N
, , N
1-9 JJ N
years NNS N
) ) N
PATIENTS VB N
One CD 4_p
hundred JJ 4_p
seventy NN 4_p
patients NNS 4_p
with IN 4_p
bilateral JJ 4_p
obstructive CD 4_p
or CC 4_p
minimally RB 4_p
obstructive JJ 4_p
chronic JJ 4_p
hyperplastic JJ 4_p
sinusitis NN 4_p
with IN 4_p
nasal JJ 4_p
polyposis NN 4_p
INTERVENTION NNP N
All DT N
patients NNS N
were VBD N
surgically RB N
treated VBN N
in IN N
the DT N
ENT NNP N
Department NNP N
, , N
University NNP N
of IN N
Siena NNP N
Medical NNP N
School NNP N
One CD N
month NN N
after IN N
surgery NN N
, , N
group NN N
1 CD N
patients NNS N
( ( N
n JJ N
= NNP N
97 CD N
) ) N
started VBD N
treatment NN N
with IN N
intranasal JJ N
furosemide NN N
, , N
group NN N
2 CD N
( ( N
n JJ N
= NNP N
40 CD N
) ) N
received VBD N
no DT N
therapeutic JJ N
treatment NN N
, , N
and CC N
group NN N
3 CD N
( ( N
n JJ N
= NNP N
33 CD N
) ) N
were VBD N
treated VBN N
with IN N
mometasone NN N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Clinical NNP N
and CC N
instrumental JJ N
evaluation NN N
of IN N
postoperative JJ N
outcomes NNS N
RESULTS NNP N
Seventeen NNP N
( ( N
17.5 CD N
% NN N
) ) N
of IN N
97 CD N
patients NNS N
in IN N
group NN N
1 CD N
, , N
12 CD N
( ( N
30.0 CD N
% NN N
) ) N
of IN N
40 CD N
patients NNS N
in IN N
group NN N
2 CD N
, , N
and CC N
8 CD N
( ( N
24.2 CD N
% NN N
) ) N
of IN N
33 CD N
patients NNS N
in IN N
group NN N
3 CD N
experienced VBD N
nasal JJ N
polyposis NN N
relapses NNS N
We PRP N
noted VBD N
a DT N
prevalence NN N
of IN N
early-stage JJ N
relapse NN N
in IN N
patients NNS N
treated VBN N
with IN N
furosemide NN N
or CC N
mometasone NN N
, , N
whereas JJ N
patients NNS N
who WP N
did VBD N
not RB N
receive VB N
any DT N
treatment NN N
experienced VBD N
more JJR N
severe JJ N
grades NNS N
of IN N
chronic JJ N
hyperplastic JJ N
sinusitis NN N
with IN N
nasal JJ N
polyposis NN N
( ( N
P NNP N
< NNP N
.005 NNP N
) ) N
CONCLUSION NNP N
Use NNP N
of IN N
intranasal NN N
furosemide JJ N
represents VBZ N
a DT N
valid JJ N
therapeutic JJ N
treatment NN N
in IN N
the DT N
prevention NN N
of IN N
chronic JJ N
hyperplastic JJ N
sinusitis NN N
with IN N
nasal JJ N
polyposis NN N
-DOCSTART- -X- O O 8655293

Pentoxifylline NNP N
therapy NN N
in IN N
HIV NNP 4_p
seropositive JJ 4_p
subjects NNS N
with IN N
elevated JJ N
TNF NNP N
Tumor NNP N
necrosis IN N
factor-alpha JJ N
( ( N
TNF-alpha NNP N
) ) N
is VBZ N
thought VBN N
to TO N
induce VB N
cachexia NN N
in IN N
subjects NNS N
infected VBN N
with IN N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
, , N
and CC N
it PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
HIV-seropositive JJ 4_p
patients NNS N
would MD N
benefit VB N
from IN N
treatment NN N
with IN N
pentoxifylline NN N
, , N
a DT N
known VBN N
suppressor NN N
of IN N
TNF-alpha NNP N
production NN N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
examine VB N
how WRB N
pentoxifylline NN N
at IN N
a DT N
dose NN N
of IN N
800 CD N
mg JJ N
thrice JJ N
daily RB N
would MD N
influence VB N
the DT N
cellular JJ N
immune NN N
system NN N
in IN N
HIV-seropositive JJ N
persons NNS N
with IN N
elevated JJ N
TNF-alpha NNP N
Six NNP 3_p
HIV-seropositive JJ 4_p
subjects NNS N
with IN N
elevated JJ N
amounts NNS N
of IN N
TNF-alpha NNP N
in IN N
plasma NN N
at IN N
least JJS N
at IN N
two CD N
occasions NNS N
were VBD N
included VBN N
in IN N
an DT N
open JJ N
, , N
controlled VBN N
, , N
randomized VBN N
, , N
cross-over JJ N
study NN N
consisting VBG N
of IN N
a DT N
6 CD N
week NN N
treatment NN N
period NN N
and CC N
a DT N
6 CD N
week NN N
control NN N
period NN N
Blood NN N
samples NNS N
were VBD N
collected VBN N
before RB N
and CC N
at IN N
the DT N
end NN N
of IN N
each DT N
period NN N
Pentoxifylline NNP N
treatment NN N
did VBD N
not RB N
influence VB N
the DT N
concentration NN N
of IN N
plasma-TNF-alpha NN N
, , N
subpopulations NNS N
of IN N
blood NN N
mononuclear NN N
cells NNS N
, , N
the DT N
proliferative JJ N
responses NNS N
nor CC N
the DT N
natural JJ N
killer NN N
( ( N
NK NNP N
) ) N
, , N
and CC N
lymphokine NN N
activated VBN N
killer NN N
( ( N
LAK NNP N
) ) N
cell NN N
activities NNS N
Furthermore RB N
, , N
pentoxifylline JJ N
treatment NN N
did VBD N
not RB N
influence VB N
the DT N
weight NN N
, , N
temperature NN N
, , N
well RB N
being VBG N
, , N
or CC N
tiredness NN N
of IN N
the DT N
subjects NNS N
However RB N
, , N
the DT N
patients NNS N
frequently RB N
reported VBD N
gastrointestinal JJ N
side NN N
effects NNS N
In IN N
vitro NN N
, , N
however RB N
, , N
pentoxifylline NN N
at IN N
suprapharmacological JJ N
concentrations NNS N
inhibited VBD N
the DT N
blood NN N
mononuclear NN N
cell NN N
( ( N
BMNC NNP N
) ) N
proliferative NN N
responses NNS N
, , N
NK NNP N
, , N
and CC N
LAK NNP N
cell NN N
activities NNS N
-DOCSTART- -X- O O 7010662

[ JJ N
Biological NNP N
and CC N
clinical JJ N
effects NNS N
of IN N
oral JJ N
magnesium NN N
and CC N
associated VBN N
magnesium-vitamin JJ N
B6 NNP N
administration NN N
on IN N
certain JJ 4_p
disorders NNS 4_p
observed VBN 4_p
in IN 4_p
infantile JJ 4_p
autism NN 4_p
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
-DOCSTART- -X- O O 6131800

The DT N
effect NN N
of IN N
Naftidrofuryl NNP N
on IN N
ethanol-induced JJ N
liver NN N
damage NN N
in IN N
chronic JJ 4_p
alcoholic JJ 4_p
patients NNS N
A DT N
prospective JJ N
double-blind JJ N
placebo-controlled JJ N
trial NN N
of IN N
intramuscular JJ N
Naftidrofuryl NNP N
was VBD N
carried VBN N
out RP N
on IN N
32 CD 3_p
randomly RB N
selected VBN N
hospitalized VBN N
male JJ 2_p
alcoholic JJ 4_p
patients NNS N
with IN N
clinical JJ N
, , N
biochemical JJ N
and CC N
histological JJ N
evidence NN N
of IN N
hepatic JJ 4_p
damage NN 4_p
Seventeen JJ N
patients NNS N
received VBD N
the DT N
drug NN N
( ( N
40 CD N
mg NN N
in IN N
5 CD N
ml NN N
i.m NN N
three CD N
times NNS N
daily RB N
for IN N
6 CD N
days NNS N
) ) N
and CC N
15 CD N
patients NNS N
received VBD N
a DT N
placebo NN N
( ( N
5 CD N
ml NN N
in IN N
normal JJ N
saline JJ N
i.m NN N
three CD N
times NNS N
daily RB N
for IN N
6 CD N
days NNS N
) ) N
The DT N
drug NN N
was VBD N
well RB N
tolerated VBN N
and CC N
there EX N
were VBD N
no DT N
adverse JJ N
side-effects NNS N
Naftidrofuryl NNP N
significantly RB N
improved VBD N
the DT N
physiological JJ N
function NN N
of IN N
the DT N
liver NN N
cells NNS N
as IN N
reflected VBN N
by IN N
indocyanine NN N
green NN N
( ( N
ICG NNP N
) ) N
clearance NN N
by IN N
the DT N
liver NN N
( ( N
t JJ N
= VBZ N
2.61 CD N
; : N
p NN N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.02 CD N
) ) N
and CC N
also RB N
caused VBD N
a DT N
larger JJR N
fall NN N
in IN N
raised VBN N
serum NN N
levels NNS N
of IN N
gamma NN N
glutamyl NN N
transpeptidase NN N
( ( N
GGT NNP N
) ) N
than IN N
did VBD N
the DT N
placebo NN N
injections NNS N
Overall JJ N
clinical JJ N
improvement NN N
( ( N
e.g NN N
appetite NN N
, , N
body NN N
weight NN N
, , N
reduced VBD N
liver JJ N
size NN N
, , N
general JJ N
sense NN N
of IN N
well-being NN N
) ) N
was VBD N
more RBR N
clearly RB N
evident JJ N
in IN N
patients NNS N
of IN N
the DT N
treated VBN N
group NN N
than IN N
in IN N
those DT N
of IN N
the DT N
placebo NN N
group NN N
Naftidrofuryl NNP N
, , N
therefore RB N
, , N
appears VBZ N
to TO N
be VB N
of IN N
benefit NN N
in IN N
ethanol-induced JJ 4_p
liver NN 4_p
damage NN 4_p
and CC N
more RBR N
extensive JJ N
long-term JJ N
trials NNS N
are VBP N
suggested VBN N
in IN N
patients NNS N
with IN N
alcoholic JJ 4_p
liver NN 4_p
disease NN 4_p
( ( 4_p
ALD NNP 4_p
) ) 4_p
-DOCSTART- -X- O O 12816740

Antiinflammatory JJ N
effects NNS N
of IN N
the DT N
phosphodiesterase-4 JJ N
inhibitor NN N
cilomilast NN N
( ( N
Ariflo NNP N
) ) N
in IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
Cilomilast NNP N
( ( N
Ariflo NNP N
) ) N
, , N
a DT N
new JJ N
oral JJ N
phosphodiesterase-4 JJ N
selective JJ N
inhibitor NN N
, , N
improves VBZ N
lung JJ N
function NN N
in IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
We PRP N
have VBP N
evaluated VBN N
its PRP$ N
antiinflammatory JJ N
effects NNS N
in IN N
59 CD 3_p
patients NNS N
with IN N
COPD NNP 4_p
randomized VBD N
to TO N
receive VB N
cilomilast NN N
, , N
15 CD N
mg NN N
two CD N
times NNS N
a DT N
day NN N
, , N
or CC N
placebo NN N
for IN N
12 CD N
weeks NNS N
Induced NNP N
sputum JJ N
differential NN N
cell NN N
counts NNS N
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
at IN N
five CD N
further JJ N
visits NNS N
Interleukin-8 NNP N
and CC N
neutrophil JJ N
elastase NN N
were VBD N
measured VBN N
in IN N
sputum NN N
supernatant NN N
Bronchial JJ N
biopsies NNS N
obtained VBN N
at IN N
baseline NN N
and CC N
at IN N
Week NNP N
10 CD N
were VBD N
immunostained VBN N
and CC N
counted VBN N
for IN N
neutrophils NNS N
, , N
CD8+ NNP N
and CC N
CD4+ NNP N
T-lymphocyte NNP N
subsets NNS N
, , N
and CC N
CD68+ NNP N
macrophages NNS N
Cells NNP N
expressing VBG N
the DT N
genes NNS N
for IN N
interleukin-8 NN N
and CC N
tumor NN N
necrosis NN N
factor-alpha NN N
were VBD N
identified VBN N
by IN N
in IN N
situ JJ N
hybridization NN N
and CC N
quantified VBD N
Compared VBN N
with IN N
placebo NN N
, , N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
of IN N
the DT N
change NN N
from IN N
baseline NN N
showed VBD N
that IN N
cilomilast NN N
did VBD N
not RB N
alter VB N
any DT N
sputum JJ N
endpoint NN N
or CC N
FEV1 NNP N
However RB N
, , N
bronchial JJ N
biopsies NNS N
demonstrated VBD N
that IN N
cilomilast NN N
treatment NN N
was VBD N
associated VBN N
with IN N
reductions NNS N
in IN N
CD8+ NNP N
( ( N
p JJ N
= VBZ N
0.001 CD N
; : N
ANOVA NNP N
) ) N
and CC N
CD68+ NNP N
cells NNS N
( ( N
p JJ N
< VBZ N
0.05 CD N
; : N
ANOVA NNP N
) ) N
In IN N
addition NN N
, , N
by IN N
Poisson NNP N
analysis NN N
, , N
comparison NN N
of IN N
cell NN N
counts NNS N
analyzed VBN N
as IN N
a DT N
ratio NN N
of IN N
active JJ N
to TO N
placebo VB N
demonstrated JJ N
reductions NNS N
of IN N
CD8+ NNP N
( ( N
48 CD N
% NN N
p NN N
< NNP N
0.01 CD N
) ) N
and CC N
CD68+ NNP N
( ( N
47 CD N
% NN N
p NN N
= NNP N
0.001 CD N
) ) N
cells NNS N
This DT N
is VBZ N
the DT N
first JJ N
demonstration NN N
of IN N
reduction NN N
by IN N
any DT N
agent NN N
of IN N
airway JJ N
tissue NN N
inflammatory NN N
cells NNS N
characteristic JJ N
of IN N
COPD NNP N
Phosphodiesterase-4 JJ N
inhibitors NNS N
represent VBP N
a DT N
promising JJ N
new JJ N
class NN N
of IN N
substances NNS N
for IN N
use NN N
in IN N
antiinflammatory JJ N
treatment NN N
of IN N
this DT N
disease NN N
-DOCSTART- -X- O O 11476129

Clomipramine NNP N
versus NN N
haloperidol NN N
in IN N
the DT N
treatment NN N
of IN N
autistic JJ 4_p
disorder NN 4_p
: : 4_p
a DT N
double-blind NN N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
Clomipramine NNP N
, , N
haloperidol NN N
, , N
and CC N
placebo NN N
were VBD N
compared VBN N
with IN N
baseline NN N
in IN N
the DT N
treatment NN N
of IN N
autism NN 4_p
, , N
and CC N
overall JJ N
outcome NN N
, , N
specific JJ N
symptoms NNS N
, , N
and CC N
side JJ N
effects NNS N
were VBD N
examined VBN N
It PRP N
was VBD N
hypothesized VBN N
that IN N
clomipramine NN N
would MD N
be VB N
better RB N
tolerated VBN N
than IN N
haloperidol NN N
and CC N
prove VB N
superior JJ N
on IN N
a DT N
measure NN N
of IN N
stereotypy NN N
Individuals NNS N
with IN N
a DT N
DSM-IV JJ N
diagnosis NN N
of IN N
autistic JJ N
disorder NN N
( ( N
mean JJ N
age NN N
, , N
16.3 CD N
years NNS N
; : N
range NN N
, , N
10-36 JJ N
years NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
, , N
by IN N
using VBG N
a DT N
Latin NNP N
square NN N
design NN N
, , N
to TO N
the DT N
following JJ N
7-week JJ N
trials NNS N
: : N
placebo NN N
, , N
clomipramine NN N
( ( N
mean JJ N
daily RB N
dose RB N
, , N
128.4 CD N
mg NN N
; : N
range NN N
, , N
100-150 JJ N
mg NN N
) ) N
, , N
or CC N
haloperidol NN N
( ( N
mean JJ N
daily RB N
dose RB N
, , N
1.3 CD N
mg NN N
; : N
range NN N
, , N
1-1.5 JJ N
mg NN N
) ) N
Data NNP N
on IN N
36 CD 3_p
subjects NNS N
were VBD N
analyzed VBN N
and CC N
taken VBN N
together RB N
; : N
the DT N
results NNS N
favored VBD N
haloperidol NN N
In IN N
those DT N
patients NNS N
who WP N
were VBD N
able JJ N
to TO N
complete VB N
a DT N
full JJ N
therapeutic JJ N
trial NN N
, , N
clomipramine NN N
proved VBD N
comparable JJ N
to TO N
haloperidol VB N
in IN N
terms NNS N
of IN N
improvement NN N
compared VBN N
with IN N
baseline NN N
However RB N
, , N
significantly RB N
fewer JJR N
individuals NNS N
receiving VBG N
clomipramine NN N
versus NN N
haloperidol NN N
were VBD N
able JJ N
to TO N
complete VB N
the DT N
trial NN N
( ( N
37.5 CD N
% NN N
vs. FW N
69.7 CD N
% NN N
, , N
respectively RB N
) ) N
for IN N
reasons NNS N
related VBN N
to TO N
both DT N
side NN N
effects NNS N
and CC N
efficacy NN N
or CC N
behavior NN N
problems NNS N
In IN N
the DT N
intent-to-treat JJ N
sample NN N
, , N
which WDT N
is VBZ N
perhaps RB N
more RBR N
clinically RB N
relevant JJ N
, , N
only RB N
haloperidol VBZ N
proved VBN N
superior JJ N
to TO N
baseline VB N
on IN N
a DT N
global JJ N
measure NN N
of IN N
autistic JJ N
symptom NN N
severity NN N
, , N
as RB N
well RB N
as IN N
specific JJ N
measures NNS N
for IN N
irritability NN N
and CC N
hyperactivity NN N
Clomipramine NNP N
did VBD N
not RB N
seem VB N
more RBR N
effective JJ N
on IN N
a DT N
measure NN N
of IN N
stereotypy NN N
, , N
nor CC N
was VBD N
it PRP N
better RBR N
tolerated VBN N
-DOCSTART- -X- O O 15965438

Montelukast NNP N
treatment NN N
of IN N
moderate JJ N
to TO N
severe VB 4_p
atopic NN 4_p
dermatitis NN 4_p
in IN 4_p
adults NNS 4_p
: : 4_p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
4-week JJ N
trial NN N
, , N
59 CD N
patients NNS N
with IN N
moderate JJ N
to TO N
severe VB N
atopic NN N
dermatitis NN N
were VBD N
treated VBN N
orally RB N
with IN N
10 CD N
mg NN N
of IN N
the DT N
leukotriene JJ N
antagonist NN N
montelukast NN N
Forty-seven JJ N
patients NNS N
completed VBD N
the DT N
study NN N
No DT N
difference NN N
in IN N
efficacy NN N
was VBD N
seen VBN N
among IN N
patients NNS N
who WP N
received VBD N
montelukast NN N
and CC N
the DT N
group NN N
given VBN N
a DT N
placebo NN N
-DOCSTART- -X- O O 3548803

A DT N
randomized JJ N
study NN N
of IN N
fetal JJ N
abdominal JJ N
diameter NN N
and CC N
fetal JJ N
weight NN N
estimation NN N
for IN N
detection NN N
of IN N
light-for-gestation NN 4_p
infants NNS 1_p
in IN N
low-risk JJ 4_p
pregnancies NNS 4_p
A DT N
total NN N
of IN N
2771 CD 3_p
pregnant JJ 4_p
women NNS 2_p
with IN N
gestational JJ N
age NN N
estimated VBN N
by IN N
ultrasound JJ N
measurement NN N
of IN N
the DT N
fetal JJ N
biparietal JJ N
diameter NN N
( ( N
BPD NNP N
) ) N
before IN N
the DT N
22nd CD N
week NN N
of IN N
gestation NN N
were VBD N
re-examined VBN N
by IN N
ultrasound NN N
in IN N
the DT N
32nd CD 4_p
and CC 4_p
37th CD 4_p
week NN 4_p
of IN 4_p
pregnancy NN 4_p
at IN N
which WDT N
time NN N
the DT N
fetal JJ N
BPD NNP N
and CC N
abdominal JJ N
diameter NN N
( ( N
AD NNP N
) ) N
were VBD N
measured VBN N
An DT N
additional JJ N
examination NN N
was VBD N
performed VBN N
at IN N
34 CD N
weeks NNS N
if IN N
the DT N
fetal JJ N
weight NN N
in IN N
the DT N
32nd CD N
week NN N
was VBD N
estimated VBN N
to TO N
be VB N
less JJR N
than IN N
95 CD N
% NN N
of IN N
the DT N
expected JJ N
mean JJ N
weight NN N
Light-for-gestational JJ N
age NN N
( ( N
LGA NNP N
) ) N
was VBD N
suspected VBN N
if IN N
the DT N
estimated VBN N
birth-weight NN N
was VBD N
less JJR N
than IN N
85 CD N
% NN N
of IN N
the DT N
expected JJ N
mean NN N
birthweight NN N
This DT N
applied VBD N
to TO N
186 CD N
uncomplicated JJ N
pregnancies NNS N
in IN N
which WDT N
there EX N
was VBD N
no DT N
clinical JJ N
suspicion NN N
of IN N
poor JJ N
intrauterine JJ N
growth NN N
These DT N
pregnancies NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
treatment NN N
group NN N
( ( N
AD NNP N
and CC N
estimated VBN N
weight NN N
reported VBN N
) ) N
or CC N
to TO N
a DT N
control NN N
group NN N
( ( N
AD NNP N
and CC N
estimated VBN N
weight JJ N
withheld NN N
) ) N
Induction NN N
of IN N
labour NN N
was VBD N
significantly RB N
more JJR N
common JJ N
in IN N
the DT N
treatment NN N
group NN N
( ( N
41 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
15 CD N
% NN N
) ) N
No DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
use NN N
of IN N
instrumental JJ N
vaginal JJ N
delivery NN N
or CC N
caesarean JJ N
section NN N
There EX N
was VBD N
a DT N
suggestion NN N
of IN N
marginal JJ N
benefit NN N
in IN N
terms NNS N
of IN N
neonatal JJ N
morbidity NN N
but CC N
this DT N
was VBD N
not RB N
statistically RB N
significant JJ N
-DOCSTART- -X- O O 8129324

Topical JJ N
anesthesia NN N
during IN N
infant JJ N
eye NN N
examinations NNS N
: : N
does VBZ N
it PRP N
reduce VB N
stress NN N
? . N
We PRP N
studied VBD N
the DT N
effect NN N
of IN N
topical JJ N
anesthesia NN N
on IN N
infant JJ N
stress NN N
and CC N
corneal NN N
haze NN N
during IN N
the DT N
routine JJ N
eye NN N
examination NN N
for IN N
retinopathy NN N
of IN N
prematurity NN N
Using VBG N
a DT N
double-blind JJ N
protocol NN N
, , N
55 CD N
premature NN N
infants NNS N
weighing VBG N
less JJR N
than IN N
1501 CD N
g NN N
at IN N
birth NN N
were VBD N
selected VBN N
randomly RB N
to TO N
receive VB N
normal JJ N
saline NN N
or CC N
proparacaine NN N
HCl NNP N
0.5 CD N
% NN N
eye NN N
drops VBZ N
as IN N
a DT N
corneal NN N
wetting VBG N
agent NN N
at IN N
their PRP$ N
initial JJ N
eye NN N
examination NN N
Before IN N
, , N
during IN N
, , N
and CC N
after IN N
the DT N
procedure NN N
, , N
infant JJ N
stress NN N
was VBD N
evaluated VBN N
by IN N
heart NN N
rate NN N
, , N
respiration NN N
rate NN N
, , N
blood NN N
pressure NN N
, , N
and CC N
transcutaneous JJ N
oxygen NN N
saturation NN N
Subjective JJ N
assessment NN N
of IN N
the DT N
infant NN N
's POS N
cry NN N
intensity NN N
and CC N
corneal NN N
haze NN N
also RB N
were VBD N
recorded VBN N
Adequate NNP N
data NNS N
were VBD N
collected VBN N
on IN N
42 CD N
patients NNS N
Using VBG N
analysis NN N
of IN N
variance NN N
and CC N
chi-square NN N
tests NNS N
, , N
we PRP N
found VBD N
no DT N
difference NN N
in IN N
any DT N
of IN N
these DT N
parameters NNS N
between IN N
the DT N
two CD N
patients NNS N
groups NNS N
These DT N
data NNS N
suggest VBP N
that IN N
topical JJ N
anesthetic JJ N
agents NNS N
offer VBP N
no DT N
advantage NN N
over IN N
normal JJ N
saline JJ N
eye NN N
drops NNS N
during IN N
the DT N
examination NN N
of IN N
premature JJ N
infants NNS N
-DOCSTART- -X- O O 16887481

Left NNP N
thoracoabdominal JJ N
approach NN N
versus IN N
abdominal-transhiatal JJ N
approach NN N
for IN N
gastric JJ N
cancer NN N
of IN N
the DT N
cardia NN N
or CC N
subcardia NN N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
BACKGROUND NNP N
Because IN N
of IN N
the DT N
inaccessibility NN N
of IN N
mediastinal JJ N
nodal JJ N
metastases NNS N
, , N
the DT N
left JJ N
thoracoabdominal JJ N
approach NN N
( ( N
LTA NNP N
) ) N
has VBZ N
often RB N
been VBN N
used VBN N
to TO N
treat VB N
gastric JJ N
cancer NN N
of IN N
the DT N
cardia NN N
or CC N
subcardia NN N
In IN N
a DT N
randomised JJ N
phase NN N
III NNP N
study NN N
, , N
we PRP N
aimed VBD N
to TO N
compare VB N
LTA NNP N
with IN N
the DT N
abdominal-transhiatal JJ N
approach NN N
( ( N
TH NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
these DT N
tumours NNS N
METHODS NNP N
Between NNP N
July NNP N
, , N
1995 CD N
, , N
and CC N
December NNP N
, , N
2003 CD N
, , N
167 CD N
patients NNS N
were VBD N
enrolled VBN N
from IN N
27 CD N
Japanese JJ N
hospitals NNS N
and CC N
randomly RB N
assigned VBN N
to TO N
TH NNP N
( ( N
n=82 NN N
) ) N
or CC N
LTA NNP N
( ( N
n=85 NN N
) ) N
The DT N
primary JJ N
endpoint NN N
was VBD N
overall JJ N
survival NN N
, , N
and CC N
secondary JJ N
endpoints NNS N
were VBD N
disease-free JJ N
survival NN N
, , N
postoperative JJ N
morbidity NN N
and CC N
hospital NN N
mortality NN N
, , N
and CC N
postoperative JJ N
symptoms NNS N
and CC N
change NN N
of IN N
respiratory NN N
function NN N
The DT 4_p
projected JJ 4_p
sample NN 4_p
size NN 4_p
was VBD 4_p
302 CD 4_p
After IN 4_p
the DT 4_p
first JJ 4_p
interim JJ 4_p
analysis NN 4_p
, , 4_p
the DT 4_p
predicted JJ 4_p
probability NN 4_p
of IN 4_p
LTA NNP 4_p
having VBG 4_p
a DT 4_p
significantly RB 4_p
better RBR 4_p
overall JJ 4_p
survival NN 4_p
than IN 4_p
TH NNP 4_p
at IN 4_p
the DT 4_p
final JJ 4_p
analysis NN 4_p
was VBD 4_p
only RB 4_p
3.65 CD 4_p
% NN 4_p
, , 4_p
and CC 4_p
the DT 4_p
trial NN 4_p
was VBD 4_p
closed VBN 4_p
immediately RB 4_p
Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
This DT N
study NN N
is VBZ N
registered VBN N
with IN N
, , N
number NN N
NCT00149266 NNP N
FINDINGS NNP N
5-year JJ N
overall JJ N
survival NN N
was VBD N
52.3 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
40.4-64.1 CD N
) ) N
in IN N
the DT N
TH NNP N
group NN N
and CC N
37.9 CD N
% NN N
( ( N
26.1-49.6 JJ N
) ) N
in IN N
the DT N
LTA NNP N
group NN N
The DT N
hazard NN N
ratio NN N
of IN N
death NN N
for IN N
LTA NNP N
compared VBN N
with IN N
TH NNP N
was VBD N
1.36 CD N
( ( N
0.89-2.08 CD N
, , N
p=0.92 NN N
) ) N
Three CD N
patients NNS N
died VBD N
in IN N
hospital NN N
after IN N
LTA NNP N
but CC N
none NN N
after IN N
TH NNP N
Morbidity NNP N
was VBD N
worse JJR N
after IN N
LTA NNP N
than IN N
after IN N
TH NNP N
INTERPRETATION NNP N
Because IN N
LTA NNP N
does VBZ N
not RB N
improve VB N
survival NN N
after IN N
TH NNP N
and CC N
leads VBZ N
to TO N
increased VBN N
morbidity NN N
in IN N
patients NNS 4_p
with IN 4_p
cancer NN 4_p
of IN 4_p
the DT 4_p
cardia NN 4_p
or CC 4_p
subcardia NN 4_p
, , N
LTA NNP N
can MD N
not RB N
be VB N
justified VBN N
to TO N
treat VB N
these DT N
tumours NNS N
-DOCSTART- -X- O O 1527133

The DT N
A-V NNP N
Impulse NNP N
System NNP N
reduces VBZ N
deep-vein JJ 4_p
thrombosis NN 4_p
and CC N
swelling NN N
after IN N
hemiarthroplasty NN 4_p
for IN 4_p
hip NN 4_p
fracture NN 4_p
We PRP N
performed VBD N
a DT N
prospective JJ N
randomised VBN N
controlled JJ N
trial NN N
of IN N
the DT N
A-V NNP N
Impulse NNP N
System NNP N
in IN N
82 CD 3_p
patients NNS N
treated VBN 4_p
by IN 4_p
hemiarthroplasty NN 4_p
for IN 4_p
subcapital JJ 4_p
fracture NN 4_p
of IN 4_p
the DT 4_p
femoral JJ 4_p
neck NN 4_p
The DT N
incidence NN N
of IN N
proximal JJ N
deep-vein JJ N
thrombosis NN N
as IN N
assessed VBN N
by IN N
Doppler NNP N
ultrasonography NN N
was VBD N
23 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
and CC N
0 CD N
% NN N
in IN N
those DT N
using VBG N
the DT N
device NN N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
Calf NNP N
and CC N
thigh JJ N
circumferences NNS N
were VBD N
measured VBN N
in IN N
both DT N
groups NNS N
at IN N
seven CD N
to TO N
ten VB N
days NNS N
after IN N
operation NN N
In IN N
the DT N
treatment NN N
group NN N
there EX N
was VBD N
a DT N
mean JJ N
relative JJ N
reduction NN N
of IN N
postoperative JJ N
swelling NN N
of IN N
the DT N
thigh NN N
by IN N
3.27 CD N
cm NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
of IN N
the DT N
calf NN N
by IN N
1.55 CD N
cm NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
The DT N
A-V NNP N
Impulse NNP N
System NNP N
appears VBZ N
to TO N
be VB N
a DT N
safe JJ N
and CC N
effective JJ N
method NN N
of IN N
reducing VBG N
the DT N
incidence NN N
of IN N
proximal JJ N
deep-vein JJ N
thrombosis NN N
, , N
and CC N
of IN N
postoperative JJ N
swelling NN N
-DOCSTART- -X- O O 15175435

Bevacizumab NNP N
plus CC N
irinotecan JJ N
, , N
fluorouracil NN N
, , N
and CC N
leucovorin NN N
for IN N
metastatic JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
BACKGROUND NNP N
Bevacizumab NNP N
, , N
a DT N
monoclonal JJ N
antibody NN N
against IN N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
, , N
has VBZ N
shown VBN N
promising JJ N
preclinical JJ N
and CC N
clinical JJ N
activity NN N
against IN N
metastatic JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
, , N
particularly RB N
in IN N
combination NN N
with IN N
chemotherapy NN N
METHODS NNP N
Of IN N
813 CD 3_p
patients NNS N
with IN N
previously RB N
untreated VBN 4_p
metastatic JJ 4_p
colorectal NN 4_p
cancer NN 4_p
, , N
we PRP N
randomly VBP N
assigned VBD N
402 CD N
to TO N
receive VB N
irinotecan JJ N
, , N
bolus JJ N
fluorouracil NN N
, , N
and CC N
leucovorin NN N
( ( N
IFL NNP N
) ) N
plus CC N
bevacizumab NN N
( ( N
5 CD N
mg NN N
per IN N
kilogram NN N
of IN N
body NN N
weight JJ N
every DT N
two CD N
weeks NNS N
) ) N
and CC N
411 CD N
to TO N
receive VB N
IFL NNP N
plus CC N
placebo NN N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
overall JJ N
survival NN N
Secondary JJ N
end NN N
points NNS N
were VBD N
progression-free JJ N
survival NN N
, , N
the DT N
response NN N
rate NN N
, , N
the DT N
duration NN N
of IN N
the DT N
response NN N
, , N
safety NN N
, , N
and CC N
the DT N
quality NN N
of IN N
life NN N
RESULTS VB N
The DT N
median JJ N
duration NN N
of IN N
survival NN N
was VBD N
20.3 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP N
plus CC N
bevacizumab NN N
, , N
as IN N
compared VBN N
with IN N
15.6 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP N
plus CC N
placebo NN N
, , N
corresponding VBG N
to TO N
a DT N
hazard NN N
ratio NN N
for IN N
death NN N
of IN N
0.66 CD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
The DT N
median JJ N
duration NN N
of IN N
progression-free JJ N
survival NN N
was VBD N
10.6 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP N
plus CC N
bevacizumab NN N
, , N
as IN N
compared VBN N
with IN N
6.2 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP N
plus CC N
placebo NN N
( ( N
hazard JJ N
ratio NN N
for IN N
disease NN N
progression NN N
, , N
0.54 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
the DT N
corresponding JJ N
rates NNS N
of IN N
response NN N
were VBD N
44.8 CD N
percent NN N
and CC N
34.8 CD N
percent NN N
( ( N
P=0.004 NNP N
) ) N
The DT N
median JJ N
duration NN N
of IN N
the DT N
response NN N
was VBD N
10.4 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP N
plus CC N
bevacizumab NN N
, , N
as IN N
compared VBN N
with IN N
7.1 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP N
plus CC N
placebo NN N
( ( N
hazard JJ N
ratio NN N
for IN N
progression NN N
, , N
0.62 CD N
; : N
P=0.001 NNP N
) ) N
Grade $ N
3 CD N
hypertension NN N
was VBD N
more RBR N
common JJ N
during IN N
treatment NN N
with IN N
IFL NNP N
plus CC N
bevacizumab NN N
than IN N
with IN N
IFL NNP N
plus CC N
placebo NN N
( ( N
11.0 CD N
percent NN N
vs. FW N
2.3 CD N
percent NN N
) ) N
but CC N
was VBD N
easily RB N
managed VBN N
CONCLUSIONS VB N
The DT N
addition NN N
of IN N
bevacizumab NN N
to TO N
fluorouracil-based JJ N
combination NN N
chemotherapy NN N
results NNS N
in IN N
statistically RB N
significant JJ N
and CC N
clinically RB N
meaningful JJ N
improvement NN N
in IN N
survival NN N
among IN N
patients NNS N
with IN N
metastatic JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
-DOCSTART- -X- O O 23292082

HOXB13 NNP N
G84E NNP N
mutation NN N
in IN N
Finland NNP 4_p
: : N
population-based JJ N
analysis NN N
of IN N
prostate NN 4_p
, , 4_p
breast NN 4_p
, , 4_p
and CC 4_p
colorectal JJ 4_p
cancer NN 4_p
risk NN 4_p
BACKGROUND VB N
A DT N
recently RB N
identified VBN N
germline NN N
mutation NN N
G84E NNP N
in IN N
HOXB13 NNP N
was VBD N
shown VBN N
to TO N
increase VB N
the DT N
risk NN N
of IN N
prostate NN N
cancer NN N
In IN N
a DT N
family-based JJ N
analysis NN N
by IN N
The DT N
International NNP N
Consortium NNP N
for IN N
Prostate NNP N
Cancer NNP N
Genetics NNP N
( ( N
ICPCG NNP N
) ) N
, , N
the DT N
G84E NNP N
mutation NN N
was VBD N
most RBS N
prevalent JJ N
in IN N
families NNS N
from IN N
the DT N
Nordic NNP N
countries NNS N
of IN N
Finland NNP N
( ( N
22.4 CD N
% NN N
) ) N
and CC N
Sweden NNP N
( ( N
8.2 CD N
% NN N
) ) N
METHODS NNP N
To TO N
further VB N
investigate VB N
the DT N
importance NN N
of IN N
G84E NNP N
in IN N
the DT N
Finns NNP N
, , N
we PRP N
determined VBD N
its PRP$ N
frequency NN N
in IN N
more JJR N
than IN N
4,000 CD 3_p
prostate JJ N
cancer NN N
cases NNS N
and CC N
5,000 CD 3_p
controls NNS N
In IN N
addition NN N
, , N
986 CD 3_p
breast NN N
cancer NN N
and CC N
442 CD 3_p
colorectal JJ N
cancer NN N
( ( N
CRC NNP N
) ) N
cases NNS N
were VBD N
studied VBN N
Genotyping VBG N
was VBD N
conducted VBN N
using VBG N
TaqMan NNP N
, , N
MassARRAY NNP N
iPLEX NN N
, , N
and CC N
sequencing VBG N
Statistical JJ N
analyses NNS N
were VBD N
conducted VBN N
using VBG N
Fisher NNP N
exact JJ N
test NN N
, , N
and CC N
overall JJ N
survival NN N
was VBD N
analyzed VBN N
using VBG N
Cox NNP N
modeling NN N
RESULTS VB N
The DT N
frequency NN N
of IN N
the DT N
G84E NNP N
mutation NN N
was VBD N
significantly RB N
higher JJR N
among IN N
patients NNS N
with IN N
prostate JJ N
cancer NN N
and CC N
highest JJS N
among IN N
patients NNS N
with IN N
a DT N
family NN N
history NN N
of IN N
the DT N
disease NN N
, , N
hereditary JJ N
prostate NN N
cancer NN N
[ VBZ N
8.4 CD N
% NN N
vs. FW N
1.0 CD N
% NN N
in IN N
controls NNS N
; : N
OR CC N
8.8 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
4.9-15.7 JJ N
] NN N
The DT N
mutation NN N
contributed VBD N
significantly RB N
to TO N
younger JJR N
age NN N
( ( N
≤55 CD N
years NNS N
) ) N
at IN N
onset NN N
and CC N
high JJ N
prostate-specific JJ N
antigen NN N
( ( N
PSA NNP N
; : N
≥20 NNP N
ng/mL NN N
) ) N
at IN N
diagnosis NN N
An DT N
association NN N
with IN N
increased JJ N
prostate NN N
cancer NN N
risk NN N
in IN N
patients NNS N
with IN N
prior JJ N
benign NN N
prostate NN N
hyperplasia NN N
( ( N
BPH NNP N
) ) N
diagnosis NN N
was VBD N
also RB N
revealed VBN N
No DT N
statistically RB N
significant JJ N
evidence NN N
for IN N
a DT N
contribution NN N
in IN N
CRC NNP N
risk NN N
was VBD N
detected VBN N
, , N
but CC N
a DT N
suggestive JJ N
role NN N
for IN N
the DT N
mutation NN N
was VBD N
observed VBN N
in IN N
familial JJ N
BRCA1/2-negative JJ N
breast NN N
cancer NN N
CONCLUSIONS NNP N
These DT N
findings NNS N
confirm VBP N
an DT N
increased JJ N
cancer NN N
risk NN N
associated VBN N
with IN N
the DT N
G84E NNP N
mutation NN N
in IN N
the DT N
Finnish JJ N
population NN N
, , N
particularly RB N
for IN N
early-onset JJ N
prostate NN N
cancer NN N
and CC N
cases NNS N
with IN N
substantially RB N
elevated VBN N
PSA NNP N
IMPACT NNP N
This DT N
study NN N
confirms VBZ N
the DT N
overall JJ N
importance NN N
of IN N
the DT N
HOXB13 NNP N
G84E NNP N
mutation NN N
in IN N
prostate NN N
cancer NN N
susceptibility NN N
-DOCSTART- -X- O O 10643677

The DT N
effect NN N
of IN N
body NN N
weight JJ N
changes NNS N
and CC N
endurance NN N
training NN N
on IN N
24h CD N
substrate JJ N
oxidation NN N
OBJECTIVE UH N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
exercise NN N
training NN N
and CC N
dietary JJ N
macronutrient NN N
composition NN N
on IN N
24 CD N
h NN N
substrate JJ N
oxidation NN N
in IN N
male NN 2_p
, , N
obese JJ 4_p
subjects NNS N
DESIGN VB N
A DT N
16 CD N
month NN N
exercise NN N
intervention NN N
study NN N
was VBD N
executed VBN N
, , N
including VBG N
a DT N
weight JJ N
loss NN N
period NN N
with IN N
a DT N
very RB N
low JJ N
energy NN N
diet NN N
( ( N
VLED NNP N
) ) N
for IN N
2 CD N
months NNS N
at IN N
the DT N
start NN N
of IN N
the DT N
study NN N
SUBJECTS NNP N
Twelve NNP 3_p
male NN 2_p
, , N
obese JJ 4_p
subjects NNS N
( ( N
age NN N
36.3+/-5.1 CD 1_p
y NN N
; : N
body NN N
weight VBD N
94.6+/-13.9 CD N
kg NN N
; : N
body NN N
mass NN N
index NN N
, , N
BMI NNP N
30.8+/-3.0 NNP N
kg/m2 NN N
) ) N
and CC N
in IN N
an DT N
additional JJ N
study NN N
15 CD 3_p
lean JJ N
, , N
well-trained JJ N
subjects NNS N
( ( N
age NN N
36.2+/-7.2 CD 1_p
y NN N
; : N
body NN N
weight VBD N
72.2+/-5.9 JJ N
kg NN N
; : N
BMI NNP N
22.3+/-1.7 CD N
kg/m2 NN N
) ) N
participated VBD N
MEASUREMENTS NNP N
Substrate NNP N
oxidation NN N
was VBD N
measured VBN N
during IN N
a DT N
standardized JJ N
36 CD N
h NN N
stay NN N
in IN N
the DT N
respiration NN N
chamber NN N
at IN N
the DT N
start NN N
of IN N
the DT N
study NN N
( ( N
0 CD N
months NNS N
) ) N
, , N
and CC N
at IN N
4 CD N
, , N
10 CD N
and CC N
16 CD N
months NNS N
In IN N
the DT N
respiration NN N
chamber NN N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
high-fat NN N
( ( N
Hi.F NNP N
) ) N
diet NN N
( ( N
60 CD N
% NN N
of IN N
energy NN N
( ( N
En NNP N
% NN N
) ) N
fat NN N
) ) N
or CC N
a DT N
reduced-fat JJ N
( ( N
Red.F NNP N
) ) N
diet NN N
( ( N
30 CD N
En NNP N
% NN N
fat NN N
) ) N
The DT N
well-trained JJ N
group NN N
was VBD N
measured VBN N
once RB N
in IN N
the DT N
respiration NN N
chamber NN N
for IN N
36 CD N
h NN N
according VBG N
to TO N
the DT N
same JJ N
protocol NN N
RESULTS NNP N
At IN N
any DT N
time NN N
point NN N
, , N
independent JJ N
of IN N
the DT N
diet NN N
consumed VBD N
, , N
the DT N
24 CD N
h NN N
carbohydrate NN N
( ( N
CHO NNP N
) ) N
balances NNS N
in IN N
the DT N
chamber NN N
were VBD N
mostly RB N
negative JJ N
( ( N
means NNS N
ranging VBG N
from IN N
+31 NN N
to TO N
-98 VB N
g/d NN N
) ) N
and CC N
the DT N
fat JJ N
balances NNS N
mostly RB N
positive JJ N
( ( N
means NNS N
ranging VBG N
from IN N
-26 NN N
to TO N
+38 VB N
g/d NN N
) ) N
for IN N
the DT N
obese NN N
a DT N
well RB N
as IN N
for IN N
the DT N
lean JJ N
, , N
well-trained JJ N
group NN N
For IN N
both DT N
diets NNS N
an DT N
increased JJ N
shortage NN N
of IN N
70 CD N
g NN N
of IN N
CHO NNP N
was VBD N
found VBN N
at IN N
16 CD N
months NNS N
compared VBN N
with IN N
4 CD N
months NNS N
, , N
and CC N
an DT N
increase NN N
in IN N
fat JJ N
balance NN N
of IN N
33 CD N
g NN N
during IN N
the DT N
same JJ N
time NN N
period NN N
in IN N
the DT N
obese JJ N
subjects NNS N
, , N
indicating VBG N
that IN N
CHO NNP N
oxidation NN N
had VBD N
increased VBN N
with IN N
12 CD N
months NNS N
endurance RB N
training VBG N
In IN N
the DT N
well-trained JJ N
group NN N
the DT N
24h CD N
CHO NNP N
balance NN N
was VBD N
even RB N
more RBR N
negative JJ N
for IN N
both DT N
types NNS N
of IN N
diet NN N
( ( N
-103 UH N
to TO N
-185 VB N
g/d NN N
for IN N
the DT N
Red.F NNP N
and CC N
Hi.F NNP N
diet NN N
, , N
respectively RB N
) ) N
under IN N
similar JJ N
conditions NNS N
compared VBN N
with IN N
the DT N
trained JJ N
obese JJ N
group NN N
CONCLUSION NNP N
The DT N
changes NNS N
in IN N
24 CD N
h NN N
substrate JJ N
utilization NN N
in IN N
the DT N
obese JJ N
, , N
as RB N
well RB N
as IN N
in IN N
the DT N
well-trained JJ N
group NN N
, , N
suggest VBP N
that IN N
endurance NN N
training NN N
increased VBD N
the DT N
reliance NN N
on IN N
carbohydrate NN N
oxidation NN N
and CC N
therefore RB N
did VBD N
not RB N
increase VB N
24 CD N
fat JJ N
oxidation NN N
-DOCSTART- -X- O O 10742359

Impact NN N
of IN N
an DT N
encounter-based JJ N
prompting NN N
system NN N
on IN N
resident JJ 4_p
vaccine JJ 4_p
administration NN 4_p
performance NN 4_p
and CC 4_p
immunization NN 4_p
knowledge NN 4_p
OBJECTIVES NNP N
To TO N
evaluate VB N
an DT N
encounter-based JJ N
immunization NN N
prompting VBG N
system NN N
on IN N
resident JJ N
performance NN N
in IN N
administering VBG N
vaccines NNS N
and CC N
knowledge NN N
of IN N
immunization NN N
guidelines NNS N
DESIGN/METHODS NNP N
Prospective NNP N
randomized VBD N
, , N
controlled VBD N
trial NN N
Subjects NNS N
were VBD N
first- JJ N
and CC N
second-year JJ N
pediatric JJ N
residents NNS N
in IN N
a DT N
hospital-based JJ N
continuity NN N
clinic NN N
The DT N
intervention NN N
group NN N
received VBD N
manual JJ N
prompts NNS N
of IN N
immunizations NNS N
due JJ N
Postclinic NNP N
chart NN N
review NN N
compared VBN N
immunizations NNS N
due JJ N
with IN N
those DT N
administered VBN N
Acceptable JJ N
and CC N
unacceptable JJ N
reasons NNS N
for IN N
not RB N
administering VBG N
vaccines NNS N
were VBD N
assigned VBN N
Resident NNP N
knowledge NN N
was VBD N
measured VBN N
by IN N
a DT N
70-item JJ N
examination NN N
RESULTS VB N
The DT N
intervention NN N
group NN N
had VBD N
significantly RB N
less RBR N
missed JJ N
opportunities/vaccine JJ N
administration NN N
errors NNS N
( ( N
11.4 CD N
% NN N
vs JJ N
21.6 CD N
% NN N
) ) N
The DT N
most RBS N
common JJ N
reason NN N
for IN N
unacceptable JJ N
errors NNS N
in IN N
the DT N
intervention NN N
group NN N
: : N
vaccine NN N
was VBD N
given VBN N
too RB N
early JJ N
; : N
in IN N
the DT N
control NN N
group NN N
: : N
vaccine NN N
was VBD N
postponed VBN N
to TO N
next JJ N
visit NN N
Pre- NNP N
and CC N
postintervention NN N
knowledge NN N
scores NNS N
were VBD N
similar JJ N
: : N
intervention NN N
group NN N
( ( N
75.5 CD N
% NN N
vs JJ N
80.7 CD N
% NN N
, , N
control NN N
group NN N
; : N
76.5 CD N
% NN N
vs JJ N
81.3 CD N
% NN N
) ) N
CONCLUSION NNP N
An DT N
immunization NN N
prompting VBG N
system NN N
in IN N
a DT N
hospital-based JJ N
pediatric JJ N
resident NN N
continuity NN N
clinic NN N
reduced VBD N
missed JJ N
opportunities/vaccine JJ N
administration NN N
errors NNS N
without IN N
significantly RB N
impacting VBG N
resident JJ N
knowledge NN N
of IN N
immunization NN N
guidelines.immunization NN N
schedule NN N
, , N
vaccination NN N
, , N
immunization NN N
, , N
prompting VBG N
systems NNS N
, , N
resident JJ N
education NN N
-DOCSTART- -X- O O 9632036

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
nefazodone NN N
in IN N
the DT N
treatment NN N
of IN N
patients NNS N
hospitalized VBN N
for IN N
major JJ 4_p
depression NN 4_p
BACKGROUND IN N
There EX N
are VBP N
few JJ N
published VBN N
placebo-controlled JJ N
clinical JJ N
trials NNS N
demonstrating VBG N
the DT N
efficacy NN N
of IN N
the DT N
newer NN N
antidepressants NNS N
in IN N
markedly RB N
or CC N
severely RB 4_p
depressed JJ 4_p
hospitalized JJ N
patients NNS N
This DT N
study NN N
demonstrates VBZ N
the DT N
efficacy NN N
of IN N
nefazodone NN N
compared VBN N
with IN N
placebo NN N
in IN N
the DT N
treatment NN N
of IN N
patients NNS N
hospitalized VBN N
for IN N
major JJ 4_p
depression NN 4_p
METHOD NNP N
Nefazodone NNP N
and CC N
placebo VB N
treatment NN N
were VBD N
compared VBN N
in IN N
a DT N
6-week JJ N
trial NN N
of IN N
120 CD N
patients NNS N
hospitalized VBN N
for IN N
DSM-III-R NNP N
diagnosed VBD N
major JJ N
depression NN N
( ( N
without IN N
psychosis NN N
) ) N
at IN N
2 CD N
study NN N
centers NNS N
Efficacy NN N
was VBD N
evaluated VBN N
using VBG N
standard JJ N
psychiatric NN N
rating NN N
scales NNS N
, , N
and CC N
patients NNS N
were VBD N
monitored VBN N
for IN N
safety NN N
RESULTS NNP N
Nefazodone NNP N
treatment NN N
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
of IN N
the DT N
17-item JJ N
Hamilton NNP N
Rating NNP N
Scale NNP N
for IN N
Depression NNP N
( ( N
HAM-D-17 NNP N
) ) N
total NN N
score NN N
compared VBN N
with IN N
placebo NN N
from IN N
the DT N
end NN N
of IN N
the DT N
first JJ N
treatment NN N
week NN N
through IN N
the DT N
end NN N
of IN N
the DT N
study NN N
( ( N
-12.2 NNP N
nefazodone RB N
vs. FW N
-7.7 NNP N
placebo NN N
) ) N
At IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
, , N
significantly RB N
more RBR N
nefazodone-treated JJ N
patients NNS N
( ( N
50 CD N
% NN N
) ) N
than IN N
placebo-treated JJ N
patients NNS N
( ( N
29 CD N
% NN N
) ) N
had VBD N
responded VBN N
, , N
as IN N
indicated VBN N
by IN N
their PRP$ N
Clinical JJ N
Global NNP N
Impressions-Improvement NN N
score NN N
( ( N
p JJ N
= NNP N
.021 NNP N
) ) N
or CC N
by IN N
a DT N
> NN N
or CC N
= VB N
50 CD N
% NN N
reduction NN N
in IN N
their PRP$ N
HAM-D-17 JJ N
scores NNS N
( ( N
p VB N
= NNP N
.017 NNP N
) ) N
Significantly RB N
more RBR N
patients NNS N
treated VBN N
with IN N
nefazodone NN N
( ( N
36 CD N
% NN N
) ) N
than IN N
placebo-treated JJ N
patients NNS N
( ( N
14 CD N
% NN N
) ) N
had VBD N
a DT N
HAM-D-17 NNP N
score NN N
< NN N
or CC N
= VB N
10 CD N
at IN N
the DT N
end NN N
of IN N
treatment NN N
( ( N
p JJ N
= NNP N
.004 NNP N
) ) N
Significant JJ N
treatment NN N
differences NNS N
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
in IN N
favor NN N
of IN N
nefazodone NN N
were VBD N
also RB N
seen VBN N
in IN N
the DT N
Montgomery-Asberg NNP N
Depression NNP N
Rating NNP N
Scale NNP N
; : N
the DT N
HAM-D NNP N
retardation NN N
, , N
anxiety NN N
, , N
and CC N
sleep JJ N
disturbance NN N
factors NNS N
; : N
and CC N
HAM-D NNP N
item NN N
1 CD N
( ( N
depressed JJ N
mood NN N
) ) N
Patients NNS N
with IN N
dysthymia NN 4_p
in IN N
addition NN N
to TO N
major JJ 4_p
depression NN 4_p
also RB N
showed VBD N
significant JJ N
improvement NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
when WRB N
treated VBN N
with IN N
nefazodone NN N
, , N
with IN N
significant JJ N
differences NNS N
in IN N
response NN N
rates NNS N
seen VBN N
as RB N
early RB N
as IN N
week NN N
2 CD N
and CC N
through IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
The DT N
mean JJ N
nefazodone NN N
dose NN N
was VBD N
491 CD N
mg/day NN N
at IN N
the DT N
end NN N
of IN N
week NN N
2 CD N
and CC N
503 CD N
mg/day NN N
at IN N
the DT N
end NN N
of IN N
treatment NN N
Nefazodone NN N
was VBD N
well RB N
tolerated VBN N
, , N
and CC N
the DT N
number NN N
of IN N
patients NNS N
discontinuing VBG N
owing VBG N
to TO N
adverse JJ N
events NNS N
was VBD N
small JJ N
, , N
with IN N
no DT N
significant JJ N
safety NN N
issues NNS N
noted VBN N
in IN N
either DT N
treatment NN N
group NN N
Fewer JJR N
nefazodone-treated JJ N
than IN N
placebo-treated JJ N
patients NNS N
discontinued VBN N
owing VBG N
to TO N
lack VB N
of IN N
efficacy NN N
CONCLUSION NNP N
Nefazodone NNP N
was VBD N
superior JJ N
to TO N
placebo VB N
in IN N
the DT N
treatment NN N
of IN N
marked VBN N
to TO N
severe VB N
major JJ 4_p
depression NN 4_p
in IN N
patients NNS N
requiring VBG N
hospitalization NN N
The DT N
clinical JJ N
benefit NN N
of IN N
nefazodone NN N
was VBD N
evident JJ N
as RB N
early RB N
as IN N
the DT N
first JJ N
week NN N
of IN N
treatment NN N
as IN N
judged VBN N
by IN N
several JJ N
measures NNS N
of IN N
efficacy NN N
, , N
with IN N
significant JJ N
differences NNS N
from IN N
placebo NN N
sustained VBN N
throughout IN N
the DT N
trial NN N
-DOCSTART- -X- O O 2204661

Long-term JJ N
oral JJ N
branched-chain NN N
amino NN N
acid NN N
treatment NN N
in IN N
chronic JJ 4_p
hepatic JJ 4_p
encephalopathy NN 4_p
A DT N
randomized JJ N
double-blind JJ N
casein-controlled JJ N
trial NN N
The DT N
Italian JJ N
Multicenter NNP N
Study NNP N
Group NNP N
In IN N
a DT N
double JJ N
blind NN N
randomized VBN N
study NN N
, , N
branched-chain JJ N
amino NN N
acids NNS N
and CC N
placebo NN N
( ( N
casein NN N
) ) N
were VBD N
compared VBN N
as IN N
a DT N
treatment NN N
for IN N
chronic JJ 4_p
hepatic JJ 4_p
encephalopathy NN 4_p
in IN N
cirrhosis NN 4_p
After IN N
a DT N
15-day JJ N
run-in JJ N
period NN N
with IN N
controlled JJ N
diet JJ N
( ( N
45-65 JJ N
g NN N
protein NN N
) ) N
, , N
the DT N
patients NNS N
were VBD N
administered VBN N
, , N
in IN N
addition NN N
to TO N
their PRP$ N
diet JJ N
, , N
branched-chain JJ N
amino NN N
acids NNS N
( ( N
0.24 CD N
g/kg NN N
, , N
30 CD N
patients NNS N
) ) N
or CC N
an DT N
equinitrogenous JJ N
amount NN N
of IN N
casein NN N
( ( N
34 CD N
patients NNS N
) ) N
One CD N
patient NN N
on IN N
branched-chain NN N
amino NN N
acids NNS N
and CC N
two CD N
on IN N
casein NNS N
were VBD N
lost VBN N
to TO N
the DT N
study NN N
After IN N
3 CD N
months NNS N
, , N
the DT N
index NN N
of IN N
portal-systemic JJ N
encephalopathy NN N
significantly RB N
improved VBN N
in IN N
patients NNS N
on IN N
active JJ N
treatment NN N
( ( N
from IN N
40 CD N
[ JJ N
S.D NNP N
14 CD N
] CD N
% NN N
to TO N
21 CD N
[ NNS N
17 CD N
] NN N
) ) N
, , N
but CC N
was VBD N
not RB N
in IN N
subjects NNS N
receiving VBG N
casein NN N
( ( N
from IN N
37 CD N
[ $ N
13 CD N
] NNP N
% NN N
to TO N
36 CD N
[ NNS N
12 CD N
] NN N
) ) N
Two CD N
or CC N
more JJR N
parameters NNS N
of IN N
the DT N
index NN N
improved VBD N
in IN N
24 CD N
patients NNS N
treated VBN N
with IN N
amino JJ N
acids NNS N
( ( N
80 CD N
% NN N
; : N
confidence NN N
limits NNS N
, , N
61-92 CD N
% NN N
) ) N
, , N
and CC N
only RB N
in IN N
12 CD N
receiving VBG N
casein NN N
( ( N
35 CD N
% NN N
; : N
confidence NN N
limits NNS N
, , N
20-54 JJ N
% NN N
; : N
p CC N
less JJR N
than IN N
0.001 CD N
) ) N
Patients NNS N
who WP N
did VBD N
not RB N
improve VB N
were VBD N
given VBN N
an DT N
alternative JJ N
treatment NN N
for IN N
3 CD N
more JJR N
months NNS N
Casein-treated JJ N
patients NNS N
given VBN N
branched-chain JJ N
amino NN N
acids NNS N
rapidly RB N
improved VBN N
The DT N
changes NNS N
in IN N
neuropsychologic JJ N
function NN N
were VBD N
associated VBN N
with IN N
an DT N
improvement NN N
in IN N
semiquantitative JJ N
nitrogen NN N
balance NN N
, , N
which WDT N
became VBD N
consistently RB N
positive JJ N
in IN N
amino JJ N
acid-treated JJ N
subjects NNS N
; : N
there EX N
was VBD N
also RB N
a DT N
mild JJ N
improvement NN N
in IN N
nutritional JJ N
parameters NNS N
and CC N
in IN N
liver JJ N
function NN N
tests NNS N
The DT N
supplementation NN N
of IN N
oral JJ N
branched-chain NN N
amino NN N
acids NNS N
to TO N
the DT N
diet NN N
is VBZ N
superior JJ N
to TO N
casein VB N
as IN N
a DT N
treatment NN N
for IN N
providing VBG N
adequate JJ N
nitrogen JJ N
supply NN N
and CC N
improving VBG N
the DT N
mental JJ N
state NN N
of IN N
cirrhotic JJ 3_p
patients NNS 3_p
with IN N
chronic JJ 4_p
encephalopathy NN 4_p
-DOCSTART- -X- O O 10757579

Ropivacaine-clonidine JJ N
combination NN N
for IN N
caudal NN 4_p
blockade NN 4_p
in IN N
children NNS 1_p
BACKGROUND NNP N
Adding NNP N
clonidine NN N
to TO N
weak JJ N
ropivacaine JJ N
solutions NNS N
( ( N
< VB N
0.2 CD N
% NN N
) ) N
could MD N
potentially RB N
enhance VB N
analgesia NN N
as RB N
well RB N
as IN N
further JJ N
reduce VB N
the DT N
risk NN N
for IN N
unwanted JJ N
motor NN N
blockade NN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
postoperative JJ N
pain-relieving JJ N
quality NN N
of IN N
a DT N
ropivacaine JJ N
0.1 CD N
% NN N
-clonidine JJ N
mixture NN N
to TO N
that DT N
of IN N
plain NN N
ropivacaine VBP N
0.2 CD N
% NN N
following VBG N
caudal JJ N
administration NN N
in IN N
children NNS N
METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
observer-blinded JJ N
fashion NN N
, , N
40 CD 3_p
ASA NNP N
1 CD N
paediatric JJ 1_p
patients NNS 1_p
undergoing VBG N
subumbilical JJ 4_p
surgery NN 4_p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
a DT N
caudal JJ N
injection NN N
of IN N
either DT N
plain NN N
ropivacaine VBP N
0.2 CD N
% NN N
( ( N
1 CD N
ml/kg NN N
) ) N
( ( N
R0.2 NNP N
) ) N
or CC N
a DT N
mixture NN N
of IN N
ropivacaine JJ N
0.1 CD N
% NN N
with IN N
clonidine JJ N
2 CD N
microg/kg NN N
( ( N
1 CD N
ml/kg NN N
) ) N
( ( N
R0.1C NNP N
) ) N
Objective JJ N
pain NN N
scale NN N
score NN N
and CC N
need NN N
for IN N
supplemental JJ N
analgesia NN N
were VBD N
used VBN N
to TO N
evaluate VB N
analgesia NN N
during IN N
the DT N
first JJ N
24 CD N
h NN N
postoperatively RB N
Residual JJ N
postoperative JJ N
sedation NN N
was VBD N
also RB N
assessed VBN N
RESULTS VB N
A DT N
significantly RB N
higher JJR N
number NN N
of IN N
patients NNS N
in IN N
the DT N
R0.1C NNP N
group NN N
( ( N
18/20 CD N
) ) N
could MD N
be VB N
managed VBN N
without IN N
supplemental JJ N
analgesia NN N
during IN N
the DT N
first JJ N
24 CD N
h NN N
postoperatively RB N
compared VBN N
to TO N
the DT N
R0.2 NNP N
group NN N
( ( N
11/20 CD N
) ) N
( ( N
P=0.034 NNP N
) ) N
Both CC N
the DT N
degree NN N
and CC N
the DT N
duration NN N
of IN N
postoperative JJ N
sedation NN N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
No DT N
signs NNS N
of IN N
postoperative JJ N
motor NN N
blockade NN N
were VBD N
observed VBN N
CONCLUSIONS VB N
The DT N
combination NN N
of IN N
clonidine NN N
( ( N
2 CD N
microg/kg NN N
) ) N
and CC N
ropivacaine VB N
0.1 CD N
% NN N
is VBZ N
associated VBN N
with IN N
an DT N
improved JJ N
quality NN N
of IN N
postoperative JJ N
analgesia NN N
compared VBN N
to TO N
plain VB N
0.2 CD N
% NN N
ropivacaine NN N
The DT N
improved JJ N
analgesic JJ N
quality NN N
of IN N
the DT N
clonidine-ropivacaine JJ N
mixture NN N
is VBZ N
achieved VBN N
without IN N
causing VBG N
any DT N
significant JJ N
degree NN N
of IN N
postoperative JJ N
sedation NN N
-DOCSTART- -X- O O 16253098

Oral NNP N
health NN N
impacts NNS N
on IN N
daily JJ N
living NN N
related VBN N
to TO N
four CD N
different JJ N
treatment NN N
protocols NNS N
for IN N
chronic JJ 4_p
periodontitis NN 4_p
BACKGROUND IN N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
evaluate VB N
the DT N
oral JJ N
health NN N
impacts NNS N
perceived VBN N
by IN N
patients NNS N
submitted VBN N
to TO N
different JJ N
treatments NNS N
of IN N
chronic JJ 4_p
periodontitis NN 4_p
and CC N
their PRP$ N
association NN N
with IN N
clinical JJ N
parameters NNS N
METHODS NNP N
Sixty NNP 3_p
patients NNS N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
therapeutic JJ N
groups NNS N
: : N
control NN N
, , N
treated VBN N
with IN N
full-mouth JJ N
scaling NN N
and CC N
root NN N
planing NN N
( ( N
SRP NNP N
) ) N
; : N
test $ N
1 CD N
, , N
treated VBN N
with IN N
SRP NNP N
and CC N
400 CD N
mg NNS N
systemically RB N
administered VBN N
metronidazole NN N
( ( N
MET NNP N
) ) N
three CD N
times NNS N
per IN N
day NN N
for IN N
10 CD N
days NNS N
; : N
test JJS N
2 CD N
, , N
treated VBN N
with IN N
SRP NNP N
and CC N
professional JJ N
supragingival NN N
plaque NN N
removal NN N
( ( N
PP NNP N
) ) N
every DT N
week NN N
for IN N
3 CD N
months NNS N
; : N
and CC N
test VB N
3 CD N
, , N
treated VBN N
with IN N
SRP NNP N
and CC N
MET NNP N
plus CC N
PP NNP N
Clinical NNP N
periodontal JJ N
measurements NNS N
and CC N
data NNS N
regarding VBG N
patients NNS N
' POS N
oral JJ N
health NN N
impacts NNS N
( ( N
perceived VBN N
impacts NNS N
on IN N
bleeding VBG N
gums NNS N
, , N
gingival JJ N
recession NN N
, , N
sensitivity NN N
to TO N
cold VB N
, , N
packing VBG N
foods NNS N
, , N
aesthetics NNS N
, , N
bad JJ N
breath NN N
, , N
and CC N
tooth DT N
mobility NN N
) ) N
were VBD N
collected VBN N
at IN N
baseline NN N
and CC N
3 CD N
months NNS N
after IN N
therapy NN N
RESULTS NNP N
All NNP N
groups NNS N
presented VBD N
significant JJ N
improvement NN N
in IN N
oral JJ N
health NN N
perceived VBD N
impacts NNS N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
improvement NN N
of IN N
oral JJ N
health NN N
impacts NNS N
among IN N
groups NNS N
subjected VBN N
to TO N
different JJ N
treatments NNS N
The DT N
clinical JJ N
data NNS N
of IN N
percentage NN N
of IN N
deep JJ N
probing VBG N
depth NN N
, , N
deep JJ N
clinical JJ N
attachment NN N
level NN N
, , N
and CC N
bleeding VBG N
on IN N
probing VBG N
were VBD N
found VBN N
to TO N
be VB N
correlated VBN N
significantly RB N
with IN N
oral JJ N
health NN N
impacts NNS N
CONCLUSIONS NNP N
Periodontal NNP N
treatment NN N
leads VBZ N
to TO N
a DT N
significant JJ N
reduction NN N
of IN N
self-perceived JJ N
impacts NNS N
regardless RB N
of IN N
the DT N
non-surgical JJ N
treatment NN N
protocol NN N
employed VBN N
Most JJS N
of IN N
the DT N
clinical JJ N
data NNS N
were VBD N
associated VBN N
with IN N
oral JJ N
health NN N
impacts NNS N
-DOCSTART- -X- O O 8624384

Antibiotic JJ N
strategy NN N
after IN N
the DT N
empiric JJ N
phase NN N
in IN N
patients NNS N
treated VBN N
for IN N
a DT N
hematological JJ 4_p
malignancy NN 4_p
Empiric JJ N
broad-spectrum JJ N
antibiotic JJ N
therapy NN N
has VBZ N
become VBN N
a DT N
generally RB N
accepted VBN N
strategy NN N
in IN N
the DT N
treatment NN N
of IN N
febrile JJ 4_p
neutropenic JJ 4_p
patients NNS N
Particularly NNP N
in IN N
patients NNS N
with IN N
prolonged JJ 4_p
neutropenia NN 4_p
, , N
subsequent JJ N
adaptation NN N
of IN N
such JJ N
a DT N
regimen NNS N
will MD N
be VB N
the DT N
rule NN N
rather RB N
than IN N
exception NN N
Since IN N
there EX N
are VBP N
no DT N
uniformly RB N
accepted VBN N
guidelines NNS N
for IN N
the DT N
modification NN N
of IN N
antibiotic JJ N
therapy NN N
during IN N
the DT N
post-empiric JJ N
phase NN N
, , N
we PRP N
assessed VBD N
the DT N
impact NN N
of IN N
a DT N
set NN N
of IN N
rules NNS N
that WDT N
evolved VBD N
during IN N
the DT N
first JJ N
randomized JJ N
trials NNS N
Evaluation NN N
of IN N
the DT N
clinician NN N
's POS N
compliance NN N
with IN N
these DT N
rules NNS N
in IN N
1951 CD N
febrile NN N
neutropenic JJ N
episodes NNS N
was VBD N
the DT N
subject NN N
of IN N
the DT N
present JJ N
analysis NN N
Treatment NNP N
was VBD N
modified VBN N
in IN N
761 CD N
( ( N
39 CD N
% NN N
) ) N
cases NNS N
, , N
and CC N
these DT N
changes NNS N
were VBD N
made VBN N
according VBG N
to TO N
the DT N
rules NNS N
in IN N
76 CD N
% NN N
For IN N
75 CD N
% NN N
of IN N
the DT N
alterations NNS N
in IN N
treatment NN N
during IN N
the DT N
evening NN N
and CC N
night NN N
shifts NNS N
, , N
no DT N
reasonable JJ N
explanation NN N
was VBD N
established VBN N
, , N
while IN N
93 CD N
% NN N
of IN N
the DT N
modifications NNS N
during IN N
the DT N
normal JJ N
working JJ N
hours NNS N
were VBD N
made VBN N
for IN N
objective JJ N
reasons NNS N
The DT N
empiric JJ N
regimen NN N
was VBD N
more RBR N
frequently RB N
changed VBN N
in IN N
patients NNS N
with IN N
a DT N
clinical JJ N
focus NN N
of IN N
infection NN N
at IN N
the DT N
onset NN N
of IN N
fever NN N
than IN N
in IN N
patients NNS N
who WP N
showed VBD N
fever RB N
as IN N
the DT N
only JJ N
symptom NN N
of IN N
a DT N
possible JJ N
infection NN N
The DT N
perceived JJ N
need NN N
for IN N
modification NN N
amounted VBD N
to TO N
69 CD N
% NN N
in IN N
pulmonary JJ N
infections NNS N
, , N
to TO N
51 CD N
% NN N
in IN N
skin NN N
and CC N
soft-tissue NN N
infections NNS N
, , N
to TO N
44 CD N
% NN N
in IN N
patients NNS N
with IN N
abdominal JJ N
complaints NNS N
, , N
and CC N
to TO N
37 CD N
% NN N
in IN N
upper JJ N
respiratory NN N
tract NN N
infections NNS N
Glycopeptides NNP N
constituted VBD N
22 CD N
% NN N
of IN N
modifications NNS N
, , N
particularly RB N
in IN N
patients NNS N
with IN N
a DT N
central JJ N
venous JJ N
catheter NN N
, , N
and CC N
systemically RB N
active JJ N
antifungals NNS N
were VBD N
administered VBN N
in IN N
16 CD N
% NN N
of IN N
cases NNS N
Especially RB N
inexperienced JJ N
clinicians NNS N
tend VBP N
to TO N
adjust VB N
antibiotic JJ N
therapy NN N
, , N
in IN N
spite NN N
of IN N
the DT N
fact NN N
that IN N
persistence NN N
of IN N
fever NN N
alone RB N
seldom JJ N
reflects VBZ N
inadequate JJ N
treatment NN N
when WRB N
the DT N
clinical JJ N
condition NN N
of IN N
the DT N
patient NN N
is VBZ N
stable JJ N
or CC N
improving VBG N
On IN N
the DT N
other JJ N
hand NN N
, , N
the DT N
development NN N
of IN N
subsequent JJ N
infectious JJ N
events NNS N
emphasizes VBZ N
that IN N
a DT N
genuine JJ N
need NN N
for IN N
modification NN N
does VBZ N
frequently RB N
exist VB N
-DOCSTART- -X- O O 22476876

Impact NN N
of IN N
the DT N
quantity NN N
and CC N
flavonoid JJ N
content NN N
of IN N
fruits NNS N
and CC N
vegetables NNS N
on IN N
markers NNS N
of IN N
intake NN N
in IN N
adults NNS 1_p
with IN 4_p
an DT 4_p
increased VBN 4_p
risk NN 4_p
of IN 4_p
cardiovascular JJ 4_p
disease NN 4_p
: : N
the DT N
FLAVURS NNP N
trial NN N
PURPOSE NNP N
Limited NNP N
robust NN N
randomised VBD N
controlled VBN N
trials NNS N
investigating VBG N
fruit NN N
and CC N
vegetable JJ N
( ( N
F NNP N
& CC N
V NNP N
) ) N
intake VBP N
in IN N
people NNS 4_p
at IN 4_p
risk NN 4_p
of IN 4_p
cardiovascular JJ 4_p
disease NN 4_p
( ( 4_p
CVD NNP 4_p
) ) 4_p
exist VBP N
We PRP N
aimed VBD N
to TO N
design VB N
and CC N
validate VB N
a DT N
dietary JJ N
strategy NN N
of IN N
increasing VBG N
flavonoid-rich JJ N
versus NN N
flavonoid-poor JJ N
F NNP N
& CC N
V NNP N
consumption NN N
on IN N
nutrient JJ N
biomarker NN N
profile NN N
METHODS NNP N
A NNP N
parallel NN N
, , N
randomised VBN N
, , N
controlled VBN N
, , N
dose-response JJ N
dietary JJ N
intervention NN N
study NN N
Participants NNS 4_p
with IN 4_p
a DT 4_p
CVD NNP 4_p
relative JJ 4_p
risk NN 4_p
of IN 4_p
1.5 CD 4_p
assessed VBN 4_p
by IN 4_p
risk NN 4_p
scores NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
3 CD N
groups NNS N
: : N
habitual JJ N
( ( N
control NN N
, , N
CT NNP N
) ) N
, , N
high-flavonoid JJ N
( ( N
HF NNP N
) ) N
or CC N
low-flavonoid JJ N
( ( N
LF NNP N
) ) N
diets NNS N
While IN N
the DT N
CT NNP N
group NN N
( ( N
n JJ N
= NNP N
57 CD N
) ) N
consumed VBD N
their PRP$ N
habitual JJ N
diet NN N
throughout IN N
, , N
the DT N
HF NNP N
( ( N
n JJ N
= NNP N
58 CD N
) ) N
and CC N
LF NNP N
( ( N
n JJ N
= NNP N
59 CD N
) ) N
groups NNS N
sequentially RB N
increased VBD N
their PRP$ N
daily JJ N
F NNP N
& CC N
V NNP N
intake NN N
by IN N
an DT N
additional JJ N
2 CD N
, , N
4 CD N
and CC N
6 CD N
portions NNS N
for IN N
6-week JJ N
periods NNS N
during IN N
the DT N
18-week JJ N
study NN N
RESULTS NNP N
Compliance NNP N
to TO N
target VB N
numbers NNS N
and CC N
types NNS N
of IN N
F NNP N
& CC N
V NNP N
was VBD N
broadly RB N
met VBN N
and CC N
verified VBN N
by IN N
dietary JJ N
records NNS N
, , N
and CC N
plasma NN N
and CC N
urinary JJ N
biomarkers NNS N
Mean NNP N
( ( N
± NNP N
SEM NNP N
) ) N
number NN N
of IN N
F NNP N
& CC N
V NNP N
portions/day NN N
consumed VBN N
by IN N
the DT N
HF NNP N
and CC N
LF NNP N
groups NNS N
at IN N
baseline NN N
( ( N
3.8 CD N
± RB N
0.3 CD N
and CC N
3.4 CD N
± NNS N
0.3 CD N
) ) N
, , N
6 CD N
weeks NNS N
( ( N
6.3 CD N
± RB N
0.4 CD N
and CC N
5.8 CD N
± NNS N
0.3 CD N
) ) N
, , N
12 CD N
weeks NNS N
( ( N
7.0 CD N
± RB N
0.3 CD N
and CC N
6.8 CD N
± NNS N
0.3 CD N
) ) N
and CC N
18 CD N
weeks NNS N
( ( N
7.6 CD N
± RB N
0.4 CD N
and CC N
8.1 CD N
± NNS N
0.4 CD N
) ) N
, , N
respectively RB N
, , N
was VBD N
similar JJ N
at IN N
baseline NN N
yet RB N
higher JJR N
than IN N
the DT N
CT NNP N
group NN N
( ( N
3.9 CD N
± RB N
0.3 CD N
, , N
4.3 CD N
± NN N
0.3 CD N
, , N
4.6 CD N
± NN N
0.4 CD N
, , N
4.5 CD N
± $ N
0.3 CD N
) ) N
( ( N
P NNP N
= NNP N
0.015 CD N
) ) N
There EX N
was VBD N
a DT N
dose-dependent JJ N
increase NN N
in IN N
dietary JJ N
and CC N
urinary JJ N
flavonoids NNS N
in IN N
the DT N
HF NNP N
group NN N
, , N
with IN N
no DT N
change NN N
in IN N
other JJ N
groups NNS N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
Significantly RB N
higher JJR N
dietary JJ N
intakes NNS N
of IN N
folate NN N
( ( N
P NNP N
= NNP N
0.035 CD N
) ) N
, , N
non-starch JJ N
polysaccharides NNS N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
vitamin FW N
C NNP N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
and CC N
carotenoids NNS N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
were VBD N
observed VBN N
in IN N
both DT N
intervention NN N
groups NNS N
compared VBN N
with IN N
CT NNP N
, , N
which WDT N
were VBD N
broadly RB N
supported VBN N
by IN N
nutrient JJ N
biomarker NN N
analysis NN N
CONCLUSIONS VB N
The DT N
success NN N
of IN N
improving VBG N
nutrient JJ N
profile NN N
by IN N
active JJ N
encouragement NN N
of IN N
F NNP N
& CC N
V NNP N
intake NN N
in IN N
an DT N
intervention NN N
study NN N
implies VBZ N
the DT N
need NN N
for IN N
a DT N
more RBR N
hands-on JJ N
public JJ N
health NN N
approach NN N
-DOCSTART- -X- O O 17947724

Comparison NNP N
of IN N
menopausal NN N
symptoms NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
adjuvant JJ N
therapy NN N
with IN N
either DT N
exemestane NN N
or CC N
tamoxifen NN N
in IN N
early JJ N
breast NN 4_p
cancer NN 4_p
: : N
report NN N
of IN N
a DT N
Tamoxifen NNP N
Exemestane NNP N
Adjuvant NNP N
Multicenter NNP N
trial NN N
substudy NN N
PURPOSE NNP N
Hormonal NNP N
breast NN N
cancer NN N
treatment NN N
increases NNS N
menopausal VBP N
symptoms NNS N
in IN N
women NNS 2_p
This DT N
study NN N
investigated VBD N
differences NNS N
between IN N
the DT N
symptoms NNS N
associated VBN N
with IN N
either DT N
adjuvant JJ N
tamoxifen NN N
or CC N
exemestane NN N
PATIENTS NNP N
AND CC N
METHODS NNP N
Ten NNP N
common JJ N
symptoms NNS N
were VBD N
assessed VBN N
by IN N
self-report JJ N
questionnaire NN N
administered VBD N
to TO N
1,614 CD 3_p
consecutive JJ N
patients NNS N
at IN N
baseline NN N
and CC N
every DT N
3 CD N
months NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
a DT N
double-blind NN N
, , N
randomized VBN N
trial NN N
of IN N
postmenopausal JJ 4_p
women NNS 2_p
with IN N
early JJ 4_p
hormone NN 4_p
receptor-positive JJ 4_p
breast NN 4_p
cancer NN 4_p
Symptoms NNS N
were VBD N
categorized VBN N
as IN N
none NN N
, , N
mild NN N
, , N
moderate JJ N
, , N
or CC N
severe RB N
A DT N
hot JJ N
flash NN N
score NN N
was VBD N
calculated VBN N
at IN N
each DT N
time NN N
point NN N
Symptoms NNS N
were VBD N
analyzed VBN N
by IN N
repeated-measures NNS N
analysis NN N
of IN N
variance NN N
Each DT N
time NN N
period NN N
was VBD N
tested VBN N
repeatedly RB N
against IN N
the DT N
baseline NN N
; : N
an DT N
overall JJ N
P NNP N
value NN N
was VBD N
assigned VBN N
for IN N
each DT N
reported VBN N
symptom NN N
RESULTS NNP N
Compliance NNP N
was VBD N
excellent JJ N
, , N
with IN N
7,286 CD N
questionnaires NNS N
analyzed VBN N
Baseline NNP N
symptom JJ N
prevalence NN N
ranged VBD N
from IN N
2 CD N
% NN N
( ( N
vaginal JJ N
bleeding NN N
) ) N
to TO N
60 CD N
% NN N
to TO N
70 CD N
% NN N
( ( N
bone/muscle NN N
aches NNS N
and CC N
low JJ N
energy NN N
) ) N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
vaginal JJ N
bleeding NN N
, , N
mood NN N
alteration NN N
, , N
or CC N
low JJ N
energy NN N
Patients NNS N
receiving VBG N
tamoxifen NN N
had VBD N
significantly RB N
more RBR N
vaginal JJ N
discharge NN N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
Exemestane NN N
patients NNS N
reported VBD N
more RBR N
bone/muscle NN N
aches NNS N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
vaginal JJ N
dryness NN N
( ( N
P NNP N
= NNP N
.0004 NNP N
) ) N
, , N
and CC N
difficulty NN N
sleeping NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
In IN N
both DT N
groups NNS N
, , N
the DT N
hot JJ N
flash NN N
score NN N
peaked VBD N
at IN N
3 CD N
months NNS N
and CC N
decreased JJ N
thereafter NN N
At IN N
12 CD N
months NNS N
, , N
patients NNS N
receiving VBG N
tamoxifen NN N
had VBD N
a DT N
significantly RB N
higher JJR N
mean JJ N
hot JJ N
flash NN N
score NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
, , N
with IN N
daily JJ N
hot JJ N
flashes NNS N
increasing VBG N
from IN N
baseline NN N
by IN N
33 CD N
% NN N
compared VBN N
with IN N
a DT N
7 CD N
% NN N
increase NN N
from IN N
baseline NN N
with IN N
exemestane NN N
CONCLUSION NNP N
At IN N
12 CD N
months NNS N
, , N
exemestane NN N
was VBD N
associated VBN N
with IN N
fewer JJR N
hot JJ N
flashes NNS N
and CC N
less JJR N
vaginal JJ N
discharge NN N
than IN N
tamoxifen NN N
, , N
but CC N
with IN N
more JJR N
vaginal JJ N
dryness NN N
, , N
bone/muscle NN N
aches NNS N
, , N
and CC N
difficulty NN N
sleeping NN N
Symptoms NNS N
were VBD N
common JJ N
in IN N
both DT N
groups NNS N
-DOCSTART- -X- O O 12505565

Treatment JJ N
effects NNS N
of IN N
eptifibatide NN N
in IN N
planned JJ N
coronary JJ N
stent NN N
implantation NN N
in IN N
patients NNS N
with IN N
chronic JJ N
kidney NN N
disease NN N
( ( N
ESPRIT NNP N
Trial NNP N
) ) N
The DT N
role NN N
of IN N
platelet NN N
glycoprotein NN N
IIb/IIIa NNP N
inhibitor NN N
therapy NN N
in IN N
patients NNS N
with IN N
mild JJ N
renal JJ N
impairment NN N
is VBZ N
not RB N
well RB N
characterized VBN N
Our PRP$ N
objective NN N
was VBD N
to TO N
explore VB N
the DT N
associations NNS N
of IN N
creatinine JJ N
clearance NN N
( ( N
CrCl NNP N
) ) N
with IN N
outcomes NNS N
in IN N
a DT N
trial NN N
of IN N
eptifibatide JJ N
therapy NN N
in IN N
patients NNS N
who WP N
underwent VBP N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
We PRP N
analyzed VBD N
48-hour CD N
and CC N
30-day JJ N
outcomes NNS N
of IN N
patients NNS N
enrolled VBN N
in IN N
the DT N
Enhanced NNP N
Suppression NNP N
of IN N
the DT N
Platelet NNP N
IIb/IIIa NNP N
Receptor NNP N
with IN N
Integrilin NNP N
Therapy NNP N
( ( N
ESPRIT NNP N
) ) N
trial NN N
Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
placebo VB N
or CC N
eptifibatide VB N
as IN N
an DT N
adjunct NN N
to TO N
stent VB N
implantation NN N
( ( N
1,755 CD N
with IN N
CrCl NNP N
> NNP N
or CC N
=60 NNP N
ml/min NN N
and CC N
289 CD N
with IN N
CrCl NNP N
< NNP N
60 CD N
ml/min NN N
) ) N
CrCl NNP N
was VBD N
calculated VBN N
using VBG N
the DT N
Cockcroft NNP N
and CC N
Gault NNP N
formula NN N
, , N
and CC N
the DT N
associations NNS N
of IN N
CrCl NNP N
with IN N
outcomes NNS N
were VBD N
evaluated VBN N
using VBG N
logistic JJ N
regression NN N
models NNS N
Patients NNS N
with IN N
CrCl NNP N
< NNP N
60 CD N
ml/min NN N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
older JJR N
, , N
women NNS N
, , N
hypertensive JJ N
, , N
and CC N
have VBP N
a DT N
history NN N
of IN N
coronary JJ N
artery NN N
bypass NN N
surgery NN N
, , N
stroke NN N
, , N
or CC N
peripheral JJ N
vascular JJ N
disease NN N
The DT N
interaction NN N
of IN N
eptifibatide NN N
with IN N
CrCl NNP N
had VBD N
borderline JJ N
significance NN N
for IN N
the DT N
30-day JJ N
outcome NN N
( ( N
p JJ N
= NNP N
0.109 CD N
) ) N
Treatment JJ N
effect NN N
trended VBD N
toward IN N
a DT N
greater JJR N
magnitude NN N
in IN N
patients NNS N
with IN N
lower JJR N
CrCl NNP N
( ( N
60 CD N
ml/min NN N
) ) N
( ( N
odds NNS N
ratio VBP N
0.53 CD N
, , N
confidence NN N
interval NN N
0.34 CD N
to TO N
0.83 CD N
) ) N
compared VBN N
with IN N
those DT N
with IN N
higher JJR N
CrCl NNP N
( ( N
90 CD N
ml/min NN N
) ) N
( ( N
odds NNS N
ratio VBP N
0.68 CD N
, , N
confidence NN N
interval NN N
0.49 CD N
to TO N
0.94 CD N
) ) N
An DT N
accompanying VBG N
increase NN N
in IN N
bleeding VBG N
risk NN N
also RB N
was VBD N
not RB N
apparent JJ N
with IN N
lower JJR N
CrCl NNP N
The DT N
treatment NN N
effect NN N
of IN N
eptifibatide NN N
is VBZ N
realized VBN N
regardless RB N
of IN N
renal JJ N
function NN N
and CC N
trends VBZ N
toward IN N
being VBG N
greater JJR N
in IN N
patients NNS N
with IN N
mild JJ N
renal JJ N
impairment NN N
-DOCSTART- -X- O O 8297739

Granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
( ( N
GM-CSF NNP N
) ) N
allows VBZ N
acceleration NN N
and CC N
dose JJ N
intensity NN N
increase NN N
of IN N
CEF NNP N
chemotherapy NN N
: : N
a DT N
randomised JJ N
study NN N
in IN N
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
A DT N
randomised JJ N
study NN N
was VBD N
conducted VBN N
in IN N
62 CD 3_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
to TO N
assess VB N
whether IN N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
( ( N
GM-CSF NNP N
) ) N
would MD N
yield VB N
an DT N
increase NN N
in IN N
the DT N
dose JJ N
intensity NN N
of IN N
a DT N
standard-dose JJ N
CEF NNP N
regimen NNS N
through IN N
an DT N
acceleration NN N
of IN N
chemotherapy JJ N
administration NN N
Patients NNS N
received VBD N
CEF NNP N
( ( N
cyclophosphamide VB N
600 CD N
mg JJ N
m-2 NN N
, , N
epidoxorubicin VBZ N
60 CD N
mg NN N
m-2 NN N
and CC N
fluorouracil NN N
600 CD N
mg JJ N
m-2 NN N
) ) N
i.v NN N
on IN N
day NN N
1 CD N
or CC N
the DT N
same JJ N
chemotherapy NN N
, , N
plus CC N
GM-CSF NNP N
10 CD N
micrograms NNS N
kg-1 JJ N
s.c. NNS N
starting VBG N
from IN N
day NN N
4 CD N
, , N
repeated VBN N
as RB N
soon RB N
as IN N
haematopoietic JJ N
recovery NN N
from IN N
nadir NN N
occurred VBD N
Patients NNS N
in IN N
the DT N
CEF NNP N
+ NNP N
GM-CSF NNP N
group NN N
received VBD N
chemotherapy NN N
at IN N
a DT N
median JJ N
interval NN N
of IN N
16 CD N
days NNS N
compared VBN N
with IN N
20 CD N
days NNS N
in IN N
the DT N
control NN N
group NN N
This DT N
led VBD N
to TO N
a DT N
significant JJ N
increase NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
in IN N
the DT N
dose JJ N
intensity NN N
actually RB N
administered VBN N
in IN N
the DT N
third JJ N
, , N
fourth JJ N
and CC N
sixth JJ N
cycles NNS N
: : N
+28 CD N
% NN N
, , N
+25 CD N
% NN N
, , N
+20 CD N
% NN N
respectively RB N
Non-haematological JJ N
toxicity NN N
was VBD N
mild JJ N
GM-CSF NNP N
had VBD N
to TO N
be VB N
reduced VBN N
or CC N
suspended VBN N
in IN N
50 CD N
% NN N
of IN N
patients NNS N
because IN N
of IN N
toxicity NN N
Haematological JJ N
toxicity NN N
, , N
mainly RB N
cumulative JJ N
anaemia NN N
and CC N
thrombocytopenia NN N
, , N
was VBD N
manageable JJ N
An DT N
increase NN N
in IN N
response NN N
rate NN N
for IN N
patients NNS N
with IN N
measurable JJ N
disease NN N
, , N
of IN N
borderline JJ N
statistical JJ N
significance NN N
( ( N
P NNP N
= NNP N
0.088 CD N
, , N
P NNP N
for IN N
trend NN N
= NNP N
0.018 CD N
) ) N
, , N
from IN N
42 CD N
% NN N
in IN N
the DT N
CEF NNP N
group NN N
to TO N
69 CD N
% NN N
in IN N
the DT N
CEF NNP N
+ NNP N
GM-CSF NNP N
group NN N
, , N
was VBD N
observed VBN N
This DT N
randomised JJ N
trial NN N
indicates VBZ N
that IN N
GM-CSF NNP N
is VBZ N
useful JJ N
for IN N
chemotherapy NN N
acceleration NN N
Accelerated NNP N
CEF NNP N
+ NNP N
GM-CSF NNP N
is VBZ N
a DT N
moderately RB N
dose-intensive JJ N
regimen NNS N
that WDT N
can MD N
be VB N
administered VBN N
in IN N
an DT N
outpatient NN N
clinic NN N
and CC N
is VBZ N
associated VBN N
with IN N
a DT N
high JJ N
objective JJ N
response NN N
-DOCSTART- -X- O O 10213554

Isradipine NNP N
, , N
raised VBD N
glycosylated VBN N
haemoglobin NN N
, , N
and CC N
risk NN 4_p
of IN 4_p
cardiovascular JJ 4_p
events NNS 4_p
-DOCSTART- -X- O O 19833962

Direct JJ N
evidence NN N
for IN N
spinal JJ N
cord NN N
involvement NN N
in IN N
placebo NN N
analgesia NN N
Placebo NNP N
analgesia NN N
is VBZ N
a DT N
prime JJ N
example NN N
of IN N
the DT N
impact NN N
that WDT N
psychological JJ N
factors NNS N
have VBP N
on IN N
pain NN N
perception NN N
We PRP N
used VBD N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
of IN N
the DT N
human JJ N
spinal JJ N
cord NN N
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
placebo VBZ N
analgesia JJ N
results NNS N
in IN N
a DT N
reduction NN N
of IN N
nociceptive JJ N
processing NN N
in IN N
the DT N
spinal JJ N
cord NN N
In IN N
line NN N
with IN N
behavioral JJ N
data NNS N
that WDT N
show VBP N
decreased VBN N
pain NN N
responses NNS N
under IN N
placebo NN N
, , N
pain-related JJ N
activity NN N
in IN N
the DT N
spinal JJ N
cord NN N
is VBZ N
strongly RB N
reduced VBN N
under IN N
placebo NN N
These DT N
results NNS N
provide VBP N
direct JJ N
evidence NN N
for IN N
spinal JJ N
inhibition NN N
as IN N
one CD N
mechanism NN N
of IN N
placebo NN N
analgesia NN N
and CC N
highlight NN N
that WDT N
psychological JJ N
factors NNS N
can MD N
act VB N
on IN N
the DT N
earliest JJS N
stages NNS N
of IN N
pain NN N
processing NN N
in IN N
the DT N
central JJ N
nervous JJ N
system NN N
-DOCSTART- -X- O O 26068086

Improvement NN N
in IN N
Patient-Reported NNP 4_p
Visual NNP 4_p
Function NNP 4_p
After IN 4_p
Ocriplasmin NNP 4_p
for IN 4_p
Vitreomacular NNP 4_p
Adhesion NNP 4_p
: : N
Results NNS N
of IN N
the DT N
Microplasmin NNP N
for IN N
Intravitreous NNP N
Injection-Traction NNP N
Release NNP N
Without NNP N
Surgical NNP N
Treatment NNP N
( ( N
MIVI-TRUST NNP N
) ) N
Trials NNPS N
IMPORTANCE VB N
The DT N
impact NN N
of IN N
vitreomacular JJ N
adhesion NN N
( ( N
VMA NNP N
) ) N
resolution NN N
on IN N
patient-reported JJ 4_p
visual JJ 4_p
function NN 4_p
in IN 4_p
symptomatic JJ 4_p
VMA/vitreomacular NNP 4_p
traction NN 4_p
( ( 4_p
VMT NNP 4_p
) ) 4_p
has VBZ N
not RB N
yet RB N
been VBN N
documented VBN N
, , N
to TO N
our PRP$ N
knowledge NN N
OBJECTIVE UH N
To TO N
determine VB N
the DT N
impact NN N
of IN N
intravitreal JJ N
ocriplasmin NNS N
on IN N
patient-reported JJ N
visual JJ N
function NN N
using VBG N
the DT N
25-item JJ N
National NNP N
Eye NNP N
Institute NNP N
Visual NNP N
Function NNP N
Questionnaire NNP N
( ( N
NEI NNP N
VFQ-25 NNP N
) ) N
during IN N
a DT N
6-month JJ N
follow-up NN N
in IN N
patients NNS 4_p
with IN 4_p
symptomatic JJ 4_p
VMA NNP 4_p
DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Two CD N
multicenter NN N
, , N
randomized VBN N
, , N
masked VBN N
, , N
phase VB N
3 CD N
clinical JJ N
trials NNS N
( ( N
studies NNS N
TG-MV-006 NNP N
[ NN N
between IN N
December NNP N
2008 CD N
and CC N
April NNP N
2010 CD N
] NNP N
and CC N
TG-MV-007 NNP N
[ NNP N
between IN N
December NNP N
2008 CD N
and CC N
July NNP N
2010 CD N
] NN N
) ) N
at IN N
clinic-based JJ N
centers NNS N
in IN N
the DT N
United NNP N
States NNPS N
and CC N
Europe NNP N
A NNP N
total NN N
of IN N
652 CD 3_p
patients NNS 3_p
with IN N
symptomatic JJ 4_p
VMA/VMT NNP 4_p
, , N
including VBG N
when WRB N
associated VBN N
with IN N
a DT N
macular JJ N
hole NN N
400 CD N
μm NN N
or CC N
smaller JJR N
, , N
were VBD N
studied VBN N
Analysis NN N
was VBD N
by IN N
intent-to-treat JJ N
population NN N
and CC N
performed VBN N
in IN N
May NNP N
2013 CD N
INTERVENTIONS JJ N
Patients NNS N
with IN N
symptomatic JJ N
VMA/VMT NNP N
were VBD N
randomly RB N
assigned VBN N
( ( N
2:1 CD N
or CC N
3:1 CD N
in IN N
study NN N
TG-MV-006 NNP N
and CC N
study VB N
TG-MV-007 NNP N
, , N
respectively RB N
) ) N
to TO N
receive VB N
a DT N
single JJ N
intravitreal NN N
injection NN N
of IN N
ocriplasmin NN N
, , N
125 CD N
μg NN N
, , N
or CC N
placebo-injected JJ N
vehicle NN N
( ( N
placebo NN N
) ) N
The DT N
NEI NNP N
VFQ-25 NNP N
was VBD N
administered VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
following VBG N
ocriplasmin JJ N
injection NN N
MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Mean NNP N
changes NNS N
between IN N
baseline NN N
and CC N
6-month JJ N
follow-up JJ N
NEI NNP N
VFQ-25 NNP N
composite JJ N
and CC N
subscale JJ N
scores NNS N
and CC N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
a DT N
clinically RB N
meaningful JJ N
change NN N
( ( N
≥5 JJ N
points NNS N
) ) N
in IN N
scores NNS N
RESULTS NNP N
Across IN N
the DT N
2 CD N
studies NNS N
, , N
464 CD 3_p
patients NNS 3_p
received VBN N
ocriplasmin JJ N
and CC N
188 CD 3_p
received VBD 3_p
placebo NN N
At IN N
6 CD N
months NNS N
, , N
the DT N
ocriplasmin NN N
group NN N
reported VBD N
greater JJR N
mean JJ N
improvements NNS N
from IN N
baseline NN N
in IN N
the DT N
NEI NNP N
VFQ-25 NNP N
composite JJ N
score NN N
than IN N
the DT N
placebo NN N
group NN N
( ( N
mean JJ N
change NN N
, , N
3.4 CD N
vs NN N
0.7 CD N
, , N
respectively RB N
; : N
P NNP N
= NNP N
.005 NNP N
) ) N
Improvements NNS N
were VBD N
also RB N
noted VBN N
in IN N
subscale JJ N
scores NNS N
, , N
with IN N
the DT N
following VBG N
respective JJ N
mean JJ N
changes NNS N
for IN N
the DT N
ocriplasmin NN N
vs NN N
placebo NN N
groups NNS N
: : N
vision-related JJ N
dependency NN N
, , N
1.7 CD N
vs NN N
-2.1 NNP N
( ( N
P NNP N
= NNP N
.009 NNP N
) ) N
; : N
driving VBG N
difficulty NN N
, , N
2.7 CD N
vs NN N
-1.5 NNP N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
; : N
distance NN N
vision NN N
activities NNS N
, , N
4.1 CD N
vs NN N
0.8 CD N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
; : N
and CC N
general JJ N
vision NN N
, , N
6.1 CD N
vs NN N
2.1 CD N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
A DT N
higher JJR N
proportion NN N
of IN N
the DT N
ocriplasmin NN N
group NN N
had VBD N
a DT N
clinically RB N
meaningful JJ N
( ( N
≥5-point JJ N
) ) N
improvement NN N
in IN N
NEI NNP N
VFQ-25 NNP N
composite JJ N
score NN N
from IN N
baseline NN N
than IN N
the DT N
placebo NN N
group NN N
( ( N
36.0 CD N
% NN N
vs JJ N
27.2 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
Fewer JJR N
ocriplasmin-treated JJ N
patients NNS N
had VBD N
a DT N
clinically RB N
meaningful JJ N
worsening VBG N
in IN N
their PRP$ N
visual JJ N
function NN N
than IN N
the DT N
placebo NN N
group NN N
( ( N
15.0 CD N
% NN N
vs JJ N
24.3 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
.005 NNP N
) ) N
Changes NNS N
in IN N
NEI NNP N
VFQ-25 NNP N
composite JJ N
score NN N
and CC N
various JJ N
subscale JJ N
scores NNS N
were VBD N
observed VBN N
in IN N
ocriplasmin-treated JJ N
patients NNS N
who WP N
achieved VBD N
VMA NNP N
resolution NN N
at IN N
day NN N
28 CD N
CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
Ocriplasmin NNP N
produces VBZ N
clinically RB N
meaningful JJ N
improvement NN N
in IN N
patient-reported JJ N
visual JJ N
function NN N
in IN N
symptomatic JJ N
VMA/VMT NNP N
TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifiers NNS N
: : N
NCT00781859 NNP N
and CC N
NCT00798317 NNP N
-DOCSTART- -X- O O 23760519

Ultrasonography-guided JJ N
bilateral JJ N
rectus NN N
sheath NN N
block NN N
vs NN N
local JJ N
anesthetic JJ N
infiltration NN N
after IN N
pediatric JJ N
umbilical JJ N
hernia NN N
repair NN N
: : N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
IMPORTANCE NNP N
Regional NNP N
anesthetic JJ N
techniques NNS N
can MD N
be VB N
used VBN N
to TO N
alleviate VB N
postoperative JJ N
pain NN N
in IN N
children NNS N
undergoing VBG N
pediatric JJ N
surgical JJ N
procedures NNS N
Use NNP N
of IN N
ultrasonographic JJ N
guidance NN N
for IN N
bilateral JJ N
rectus NN N
sheath NN N
block NN N
( ( N
BRSB NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
improve VB N
immediate JJ N
pain NN N
scores NNS N
and CC N
reduce VB N
use NN N
of IN N
postoperative JJ N
analgesia NN N
in IN N
the DT N
postanesthesia NN N
care NN N
unit NN N
( ( N
PACU NNP N
) ) N
OBJECTIVE UH N
To TO N
compare VB N
efficacy NN N
of IN N
ultrasonography-guided JJ N
BRSB NNP N
and CC N
local JJ N
anesthetic JJ N
infiltration NN N
( ( N
LAI NNP N
) ) N
in IN N
providing VBG N
postoperative JJ N
analgesia NN N
after IN N
pediatric JJ N
umbilical JJ N
hernia NN N
repair NN N
DESIGN NNP N
Prospective NNP N
, , N
observer-blinded JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
SETTING CC N
Tertiary-referral JJ 4_p
urban JJ 4_p
children NNS 4_p
's POS 4_p
hospital NN 4_p
PARTICIPANTS NNP N
Eligible JJ N
children NNS N
3 CD N
to TO N
12 CD N
years NNS N
of IN N
age NN N
undergoing JJ N
elective JJ N
umbilical JJ N
hernia NN N
repair NN N
from IN N
November NNP N
16 CD N
, , N
2009 CD N
, , N
through IN N
May NNP N
31 CD N
, , N
2011 CD N
INTERVENTIONS NNP N
Ropivacaine NNP N
hydrochloride NN N
administered VBD N
at IN N
the DT N
conclusion NN N
of IN N
surgery NN N
as IN N
LAI NNP N
by IN N
the DT N
surgeon NN N
( ( N
n JJ N
= NNP N
25 CD N
) ) N
or CC N
as IN N
ultrasonography-guided JJ N
BRSB NNP N
by IN N
the DT N
anesthesiologist NN N
( ( N
n JJ N
= NNP N
27 CD N
) ) N
MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Scores NNP N
on IN N
the DT N
FACES NNP N
Pain NNP N
Rating NNP N
Scale NNP N
measured VBD N
at IN N
10-minute JJ N
intervals NNS N
and CC N
all DT N
use NN N
of IN N
analgesic JJ N
medications NNS N
in IN N
the DT N
PACU NNP N
RESULTS NNP N
Median JJ N
FACES NNP N
scores NNS N
in IN N
the DT N
PACU NNP N
were VBD N
lower JJR N
in IN N
the DT N
BRSB NNP N
group NN N
compared VBN N
with IN N
the DT N
LAI NNP N
group NN N
at IN N
10 CD N
minutes NNS N
( ( N
0 CD N
vs RB N
1 CD N
; : N
P NNP N
= NNP N
.04 NNP N
) ) N
, , N
30 CD N
minutes NNS N
( ( N
0 CD N
vs RB N
1 CD N
; : N
P NNP N
= NNP N
.01 NNP N
) ) N
, , N
and CC N
40 CD N
minutes NNS N
or CC N
later RB N
( ( N
0 CD N
vs RB N
1 CD N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
Fewer JJR N
doses NNS N
of IN N
opioid NN N
and CC N
nonopioid JJ N
medications NNS N
were VBD N
given VBN N
to TO N
the DT N
BRSB NNP N
group NN N
compared VBN N
with IN N
the DT N
LAI NNP N
group NN N
( ( N
5 CD N
vs RB N
11 CD N
doses NNS N
for IN N
opioids NNS N
; : N
5 CD N
vs NN N
10 CD N
for IN N
nonopioids NNS N
) ) N
CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
In IN N
the DT N
PACU NNP N
, , N
ultrasonography-guided JJ N
BRSB NNP N
after IN N
umbilical JJ N
hernia NN N
repair NN N
in IN N
children NNS N
is VBZ N
associated VBN N
with IN N
lower JJR N
median JJ N
FACES NNP N
scores NNS N
and CC N
decreased VBN N
use NN N
of IN N
opioid NN N
and CC N
nonopioid JJ N
medications NNS N
compared VBN N
with IN N
LAI NNP N
Future NNP N
studies NNS N
could MD N
examine VB N
the DT N
use NN N
of IN N
longer-acting JJ N
anesthetic JJ N
agents NNS N
with IN N
ultrasonography-guided JJ N
BRSB NNP N
TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT01015053 NN N
-DOCSTART- -X- O O 18073312

Short-term JJ N
aerobic JJ N
exercise NN N
training NN N
in IN N
obese JJ N
humans NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
mellitus JJ N
improves VBZ N
whole-body JJ N
insulin NN N
sensitivity NN N
through IN N
gains NNS N
in IN N
peripheral JJ N
, , N
not RB N
hepatic JJ N
insulin NN N
sensitivity NN N
CONTEXT NNP N
Short-term JJ N
aerobic JJ N
exercise NN N
training NN N
can MD N
improve VB N
whole-body JJ N
insulin NN N
sensitivity NN N
in IN N
humans NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
mellitus VBP N
; : N
however RB N
, , N
the DT N
contributions NNS N
of IN N
peripheral JJ N
and CC N
hepatic JJ N
tissues NNS N
to TO N
these DT N
improvements NNS N
are VBP N
not RB N
known VBN N
OBJECTIVE VB N
Our PRP$ N
objective NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
7-d JJ N
aerobic JJ N
exercise NN N
training NN N
on IN N
peripheral JJ N
and CC N
hepatic JJ N
insulin NN N
sensitivity NN N
during IN N
isoglycemic/hyperinsulinemic JJ N
clamp NN N
conditions NNS N
DESIGN NNP N
Subjects NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
The DT N
energy NN N
balance NN N
group NN N
consumed VBD N
an DT N
isocaloric JJ N
diet JJ N
consisting NN N
of IN N
50 CD N
% NN N
carbohydrate NN N
, , N
30 CD N
% NN N
fat NN N
, , N
and CC N
20 CD N
% NN N
protein NN N
for IN N
15 CD N
d. NN N
The DT N
energy NN N
balance NN N
plus CC N
exercise NN N
group NN N
consumed VBD N
a DT N
similar JJ N
diet NN N
over IN N
the DT N
15 CD N
d NN N
and CC N
performed VBD N
50-min CD N
of IN N
treadmill NN N
walking VBG N
at IN N
70 CD N
% NN N
of IN N
maximum JJ N
oxygen NN N
consumption NN N
maximum NN N
during IN N
the DT N
second JJ N
7 CD N
d NN N
of IN N
the DT N
15-d JJ N
study NN N
period NN N
Each DT N
subject NN N
underwent VBD N
an DT N
initial JJ N
isoglycemic/hyperinsulinemic JJ N
clamp NN N
after IN N
1-wk JJ N
dietary JJ N
control NN N
and CC N
a DT N
second JJ N
clamp NN N
after IN N
completing VBG N
the DT N
study NN N
SETTING CC N
The DT N
study NN N
was VBD N
performed VBN N
at IN N
Ohio NNP N
State NNP N
University NNP N
's POS N
General NNP N
Clinical NNP N
Research NNP N
Center NNP N
PARTICIPANTS CC N
There EX N
were VBD N
18 CD N
obese JJ N
, , N
mildly RB N
diabetic JJ N
humans NNS N
included VBD N
in IN N
the DT N
study NN N
INTERVENTION NNP N
Aerobic NNP N
exercise NN N
training NN N
was VBD N
performed VBN N
for IN N
7 CD N
d. NN N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Whole-body NNP N
, , N
peripheral JJ N
, , N
and CC N
hepatic JJ N
insulin NN N
sensitivity NN N
were VBD N
measured VBN N
RESULTS NNP N
Exercise NNP N
training NN N
did VBD N
not RB N
have VB N
an DT N
impact NN N
on IN N
peripheral JJ N
glucose JJ N
uptake NN N
or CC N
endogenous JJ N
glucose JJ N
production NN N
during IN N
the DT N
basal NN N
state NN N
or CC N
low-dose JJ N
insulin NN N
Likewise NNP N
, , N
it PRP N
did VBD N
not RB N
alter RB N
endogenous JJ N
glucose JJ N
production NN N
during IN N
high-dose JJ N
insulin NN N
However RB N
, , N
1-wk CD N
of IN N
exercise NN N
training NN N
increased VBD N
both DT N
whole-body NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
peripheral JJ N
insulin NN N
sensitivity NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
during IN N
high-dose JJ N
insulin NN N
CONCLUSION NNP N
Improvements NNPS N
to TO N
whole VB N
body NN N
insulin JJ N
sensitivity NN N
after IN N
short-term JJ N
aerobic JJ N
exercise NN N
training NN N
are VBP N
due JJ N
to TO N
gains NNS N
in IN N
peripheral JJ N
, , N
not RB N
heptic JJ N
insulin NN N
sensitivity NN N
-DOCSTART- -X- O O 22330261

Bilateral NNP N
transversus NN N
abdominis NN N
plane NN N
block NN N
does VBZ N
not RB N
decrease VB N
postoperative JJ N
pain NN N
after IN N
laparoscopic NN N
cholecystectomy NN N
when WRB N
compared VBN N
with IN N
local JJ N
anesthetic JJ N
infiltration NN N
of IN N
trocar NN N
insertion NN N
sites NNS N
BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Transversus NNP N
abdominis NN N
plane NN N
( ( N
TAP NNP N
) ) N
block NN N
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
pain NN N
and CC N
analgesic JJ N
requirements NNS N
after IN N
abdominal JJ N
surgery NN N
Our PRP$ N
hypothesis NN N
was VBD N
that IN N
bilateral JJ N
TAP NNP N
blocks NNS N
decrease NN N
pain NN N
after IN N
laparoscopic NN N
cholecystectomy NN N
when WRB N
compared VBN N
with IN N
local JJ N
anesthetic JJ N
infiltration NN N
of IN N
trocar NN N
insertion NN N
sites NNS N
METHODS NNP N
Eighty NNP 3_p
patients NNS 3_p
undergoing VBG N
laparoscopic JJ 4_p
cholecystectomy NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
bilateral JJ N
TAP NNP N
blocks NNS N
or CC N
local JJ N
anesthetic JJ N
infiltration NN N
of IN N
trocar NN N
insertion NN N
sites VBZ N
with IN N
ropivacaine JJ N
0.5 CD N
% NN N
Postoperative JJ N
pain NN N
scores NNS N
and CC N
analgesic JJ N
use NN N
for IN N
the DT N
first JJ N
24 CD N
hrs NN N
were VBD N
recorded VBN N
RESULTS NNP N
Eighty NNP 3_p
patients NNS 3_p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
After IN N
exclusions NNS N
, , N
data NNS N
were VBD N
analyzed VBN N
on IN N
39 CD N
patients NNS N
in IN N
group NN N
T NNP N
( ( N
bilateral JJ N
TAP NNP N
block NN N
) ) N
and CC N
35 CD N
patients NNS N
in IN N
group NN N
I PRP N
( ( N
infiltration NN N
) ) N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
pain NN N
scores NNS N
on IN N
the DT N
numeric JJ N
analog NN N
scale NN N
( ( N
0-10 JJ N
) ) N
between IN N
the DT N
groups NNS N
at IN N
4 CD N
hrs NN N
after IN N
surgery NN N
( ( N
P NNP N
= NNP N
0.18 CD N
) ) N
or CC N
during IN N
the DT N
24 CD N
hrs NN N
after IN N
surgery NN N
( ( N
P NNP N
= NNP N
0.23 CD N
) ) N
The DT N
time NN N
interval NN N
from IN N
anesthesia JJ N
start NN N
to TO N
surgery VB N
start NN N
was VBD N
greater JJR N
in IN N
group NN N
T NNP N
than IN N
group NN N
I PRP N
( ( N
48 CD N
vs RB N
35 CD N
mins NNS N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
found VBD N
in IN N
analgesic JJ N
use NN N
during IN N
the DT N
first JJ N
24 CD N
hrs NN N
after IN N
surgery NN N
CONCLUSIONS NNP N
Bilateral NNP N
ultrasound-guided JJ N
TAP NNP N
block NN N
is VBZ N
equivalent JJ N
to TO N
local JJ N
anesthetic JJ N
infiltration NN N
of IN N
trocar NN N
insertion NN N
sites VBZ N
for IN N
overall JJ N
postoperative JJ N
pain NN N
in IN N
a DT N
heterogeneous JJ N
group NN N
of IN N
patients NNS N
undergoing VBG N
laparoscopic JJ N
cholecystectomy NN N
-DOCSTART- -X- O O 24266796

Stimulus JJ N
over-selectivity NN N
in IN N
temporal JJ N
brain NN N
injury NN N
: : N
mindfulness NN N
as IN N
a DT N
potential JJ N
intervention NN N
OBJECTIVE IN N
The DT N
current JJ N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
impact NN N
of IN N
brief JJ N
mindfulness JJ N
training NN N
on IN N
the DT N
performance NN N
of IN N
a DT N
sample NN N
of IN N
patients NNS N
with IN N
TBI NNP N
in IN N
an DT N
over-selectivity JJ N
task NN N
PARTICIPANTS VB N
Twenty-four JJ N
patients NNS N
who WP N
had VBD N
suffered VBN N
TBI NNP N
and CC N
reported VBD N
problems NNS N
with IN N
focused JJ N
or CC N
sustained JJ N
attention NN N
METHOD NNP N
The DT N
study NN N
was VBD N
a DT N
between-subjects JJ N
design NN N
( ( N
mindfulness JJ N
intervention NN N
vs NNS N
control NN N
) ) N
with IN N
difference NN N
between IN N
number NN N
of IN N
most JJS N
and CC N
least JJS N
chosen JJ N
stimulus JJ N
selections NNS N
on IN N
an DT N
over-selectivity JJ N
task NN N
as IN N
the DT N
dependent JJ N
measure NN N
RESULTS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
indicated VBD N
that IN N
stimulus JJ N
over-selectivity NN N
was VBD N
present JJ N
in IN N
a DT N
group NN N
of IN N
patients NNS N
with IN N
TBI NNP N
However RB N
, , N
the DT N
level NN N
of IN N
emergent JJ N
over-selectivity NN N
was VBD N
significantly RB N
reduced VBN N
by IN N
a DT N
mindfulness NN N
induction NN N
when WRB N
compared VBN N
to TO N
a DT N
no- JJ N
intervention NN N
control NN N
group NN N
CONCLUSIONS VB N
The DT N
findings NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
the DT N
efficacy NN N
of IN N
mindfulness NN N
training NN N
in IN N
reducing VBG N
TBI-related JJ N
cognitive JJ N
deficits NNS N
-DOCSTART- -X- O O 17954768

Lactoferrin NNP N
supplementation NN N
to TO N
Holstein NNP N
calves NNS N
during IN N
the DT N
preweaning NN N
and CC N
postweaning NN N
phases NNS N
Sixty NNP N
Holstein NNP N
calves VBZ N
( ( 4_p
30 CD 4_p
bulls NNS 4_p
, , 4_p
30 CD 4_p
heifers NNS 4_p
) ) 4_p
were VBD N
used VBN N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
supplemental JJ N
lactoferrin NN N
on IN N
feed NN N
intake NN N
, , N
growth NN N
, , N
and CC N
health NN N
during IN N
the DT N
preweaning NN N
and CC N
postweaning NN N
periods NNS N
One CD N
of IN N
3 CD N
levels NNS N
of IN N
lactoferrin NN N
was VBD N
supplemented VBN N
from IN N
3 CD N
to TO N
56 CD N
d NN N
in IN N
either DT N
whole JJ N
milk NN N
or CC N
water NN N
to TO N
produce VB N
3 CD N
dietary JJ N
treatments NNS N
: : N
1 CD N
) ) N
0 CD N
g/d NN N
, , N
2 CD N
) ) N
0.5 CD N
g/d NN N
, , N
and CC N
3 CD N
) ) N
1 CD N
g/d NN N
Whole JJ N
milk NN N
( ( N
3.8 CD N
L/d NNP N
) ) N
containing VBG N
lactoferrin JJ N
supplements NNS N
was VBD N
fed VBN N
from IN N
bottles NNS N
until IN N
weaning VBG N
at IN N
35 CD N
d. NN N
From NNP N
d VBZ N
36 CD N
to TO N
56 CD N
, , N
lactoferrin JJ N
supplements NNS N
were VBD N
added VBN N
to TO N
water NN N
( ( N
15 CD N
to TO N
25 CD N
mL NN N
) ) N
and CC N
fed VBN N
from IN N
bottles NNS N
Lactoferrin NNP N
supplementation NN N
had VBD N
no DT N
effect NN N
on IN N
feed NN N
intake NN N
, , N
body NN N
weight NN N
, , N
average JJ N
daily JJ N
gain NN N
, , N
heart NN N
girth NN N
, , N
body NN N
temperature NN N
, , N
fecal JJ N
scores NNS N
, , N
respiratory NN N
scores NNS N
, , N
or CC N
haptoglobin JJ N
concentrations NNS N
Calves NNS N
were VBD N
housed VBN N
in IN N
individual JJ N
pens NNS N
in IN N
either DT N
an DT N
open-sided JJ N
barn NN N
or CC N
hutches NNS N
Calves NNS N
raised VBD N
in IN N
the DT N
barn NN N
consumed VBD N
more JJR N
calf JJ N
starter NN N
and CC N
therefore RB N
grew VBD N
better JJR N
than IN N
calves NNS N
raised VBN N
in IN N
hutches NNS N
Under IN N
the DT N
conditions NNS N
of IN N
this DT N
study NN N
, , N
lactoferrin JJ N
supplementation NN N
was VBD N
not RB N
beneficial JJ N
Further NNP N
research NN N
is VBZ N
needed VBN N
to TO N
fully RB N
elucidate VB N
the DT N
role NN N
of IN N
lactoferrin NN N
, , N
and CC N
possible JJ N
benefits NNS N
during IN N
different JJ N
feeding VBG N
conditions NNS N
or CC N
milk NN N
sources NNS N
-DOCSTART- -X- O O 7801065

Low JJ N
power NN N
Ga-Al-As NNP N
laser NN N
treatment NN N
of IN N
painful JJ N
osteoarthritis NN N
of IN N
the DT N
knee NN N
A DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
The DT N
aim NN N
of IN N
this DT N
double-blind NN N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
low JJ N
power NN N
Ga-Al-As NNP N
laser NN N
treatment NN N
on IN N
chronic JJ N
pain NN N
related VBN N
to TO N
osteoarthritis NN N
of IN N
the DT N
knee NN N
with IN N
periarticular JJ N
tender NN N
points NNS N
Twenty-nine JJ N
out-patients NNS N
with IN N
uni- JJ N
or CC N
bilateral JJ N
osteoarthritis NN N
of IN N
the DT N
knee NN N
were VBD N
included VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
either DT N
laser NN N
or CC N
placebo NN N
laser NN N
Fourteen JJ N
patients NNS N
received VBD N
active JJ N
laser NN N
treatment NN N
and CC N
all DT N
patients NNS N
included VBD N
completed VBN N
the DT N
study NN N
The DT N
effect NN N
variables NNS N
were VBD N
daily JJ N
levels NNS N
of IN N
pain NN N
, , N
analgesic JJ N
requirements NNS N
, , N
palpation NN N
tenderness NN N
and CC N
isokinetic JJ N
quadriceps NNS N
strength NN N
Each DT N
patient NN N
participated VBN N
in IN N
the DT N
study NN N
for IN N
9 CD N
weeks NNS N
and CC N
registered VBD N
daily JJ N
level NN N
of IN N
pain NN N
and CC N
consumption NN N
of IN N
analgesics NNS N
In IN N
weeks NNS N
4 CD N
, , N
5 CD N
and CC N
6 CD N
the DT N
patients NNS N
received VBD N
a DT N
total NN N
of IN N
nine CD N
treatments NNS N
, , N
each DT N
of IN N
15 CD N
min NNS N
and CC N
administered VBN N
to TO N
periarticular VB N
tender NN N
points NNS N
The DT N
dose JJ N
per IN N
treatment NN N
was VBD N
22.5 CD N
joule NN N
No DT N
significant JJ N
differences NNS N
in IN N
any DT N
of IN N
the DT N
effect NN N
variables NNS N
were VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
before IN N
, , N
during IN N
or CC N
after IN N
treatment NN N
With IN N
regard NN N
to TO N
the DT N
patients NNS N
' POS N
overall JJ N
assessment NN N
there EX N
was VBD N
a DT N
clearly RB N
demonstrable JJ N
positive JJ N
effect NN N
of IN N
treatment NN N
in IN N
both DT N
groups NNS N
This DT N
is VBZ N
likely JJ N
to TO N
be VB N
due JJ N
to TO N
a DT N
placebo NN N
effect NN N
-DOCSTART- -X- O O 12402011

Preliminary JJ N
findings NNS N
from IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
two CD N
palatal JJ N
operations NNS N
for IN N
sleep-disordered JJ N
breathing NN N
OBJECTIVES IN N
We PRP N
compared VBN N
the DT N
efficacy NN N
of IN N
2 CD N
palatal JJ N
surgical JJ N
procedures NNS N
in IN N
the DT N
treatment NN N
of IN N
patients NNS 4_p
with IN 4_p
mild JJ 4_p
sleep-disordered JJ 4_p
breathing NN 4_p
( ( 4_p
SDB NNP 4_p
) ) 4_p
STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
crossover RB N
surgical JJ N
trial NN N
at IN N
a DT N
university NN N
hospital NN N
METHODS NNP N
Twenty NNP 3_p
patients NNS N
with IN 4_p
mild JJ 4_p
SDB NNP 4_p
for IN 4_p
whom WP 4_p
conservative JJ 4_p
treatment NN 4_p
failed VBD 4_p
were VBD N
identified VBN N
and CC N
consecutively RB N
enrolled VBD N
into IN N
an DT N
institutional JJ N
review NN N
board-approved JJ N
surgical JJ N
protocol NN N
They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
either DT N
radiofrequency NN N
ablation NN N
of IN N
the DT N
palate NN N
( ( N
RFAP NNP N
) ) N
for IN N
a DT N
planned JJ N
3-stage JJ N
treatment NN N
or CC N
laser-assisted JJ N
uvulopalatoplasty JJ N
( ( N
LAUP NNP N
) ) N
, , N
also RB N
for IN N
3 CD N
stages NNS N
of IN N
treatment NN N
, , N
using VBG N
a DT N
CO NNP N
( ( N
2 CD N
) ) N
laser NN N
Parameters NNS N
assessed VBD N
included JJ N
severity NN N
of IN N
SDB NNP N
( ( N
polysomnography NN N
) ) N
, , N
subjective JJ N
and CC N
objective JJ N
loudness NN N
of IN N
snoring VBG N
( ( N
visual JJ N
analog NN N
scale NN N
and CC N
SNAP NNP N
recording NN N
) ) N
, , N
sleepiness NN N
( ( N
Epworth NNP N
Sleepiness NNP N
Scale NNP N
) ) N
, , N
and CC N
anatomic JJ N
changes NNS N
( ( N
upper JJ N
airway RB N
endoscopy NN N
) ) N
, , N
as RB N
well RB N
as IN N
demographic JJ N
factors NNS N
Patients NNS N
not RB N
achieving VBG N
satisfactory JJ N
improvement NN N
in IN N
their PRP$ N
condition NN N
were VBD N
crossed VBN N
over IN N
to TO N
the DT N
alternative JJ N
surgical JJ N
therapy NN N
for IN N
attempted JJ N
salvage NN N
RESULTS NNP N
Seventeen NNP N
of IN N
the DT N
enrolled JJ N
patients NNS N
have VBP N
completed VBN N
the DT N
protocol NN N
Ten CD N
of IN N
these DT N
were VBD N
randomized VBN N
to TO N
the DT N
RFAP NNP N
group NN N
, , N
and CC N
7 CD N
to TO N
the DT N
LAUP NNP N
group NN N
Six CD N
of IN N
the DT N
RFAP NNP N
patients NNS N
( ( N
60 CD N
% NN N
) ) N
achieved VBD N
a DT N
satisfactory JJ N
resolution NN N
of IN N
their PRP$ N
snoring NN N
, , N
and CC N
4 CD N
failed VBD N
and CC N
were VBD N
salvaged VBN N
with IN N
LAUP NNP N
Six NNP N
of IN N
the DT N
LAUP NNP N
patients NNS N
( ( N
86 CD N
% NN N
) ) N
achieved VBD N
a DT N
satisfactory JJ N
resolution NN N
of IN N
their PRP$ N
snoring NN N
, , N
and CC N
1 CD N
patient NN N
failed VBD N
and CC N
was VBD N
salvaged VBN N
with IN N
nasal JJ N
surgery NN N
One CD N
patient NN N
who WP N
was VBD N
initially RB N
cured VBN N
had VBD N
a DT N
relapse NN N
after IN N
9 CD N
months NNS N
and CC N
was VBD N
successfully RB N
salvaged VBN N
with IN N
RFA NNP N
CONCLUSION NNP N
Prospective NNP N
, , N
randomized VBD N
trials NNS N
of IN N
surgery NN N
for IN N
SDB NNP N
are VBP N
possible JJ N
Preliminary JJ N
findings NNS N
from IN N
the DT N
current JJ N
protocol NN N
reveal NN N
a DT N
slight JJ N
advantage NN N
of IN N
LAUP NNP N
over IN N
RFAP NNP N
but CC N
with IN N
a DT N
greater JJR N
degree NN N
of IN N
discomfort NN N
postoperatively RB N
-DOCSTART- -X- O O 22728026

Phase NNP N
II NNP N
trial NN N
of IN N
nab-paclitaxel JJ N
compared VBN N
with IN N
docetaxel NN N
as IN N
first-line JJ N
chemotherapy NN N
in IN N
patients NNS N
with IN N
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
: : N
final JJ N
analysis NN N
of IN N
overall JJ N
survival NN N
BACKGROUND VB N
A DT N
randomized JJ N
phase NN N
II NNP N
study NN N
in IN N
first-line JJ N
MBC NNP N
demonstrated VBD N
superior JJ N
efficacy NN N
and CC N
safety NN N
of IN N
weekly JJ N
nab-paclitaxel NNS N
compared VBN N
with IN N
docetaxel NN N
Final NNP N
survival NN N
analyses NNS N
and CC N
updated JJ N
safety NN N
results NNS N
are VBP N
reported VBN N
PATIENTS NNS N
AND CC N
METHODS NNP N
Three NNP 3_p
hundred VBD 3_p
two CD 3_p
patients NNS N
with IN 4_p
no DT 4_p
previous JJ 4_p
chemotherapy NN 4_p
for IN N
MBC NNP 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
nab-paclitaxel JJ N
300 CD N
mg/m NN N
( ( N
2 CD N
) ) N
q3w NN N
, , N
nab-paclitaxel JJ N
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
or CC N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
the DT N
first JJ N
3 CD N
of IN N
4 CD N
weeks NNS N
( ( N
qw VB N
3/4 CD N
) ) N
, , N
or CC N
docetaxel VB N
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
q3w NN N
The DT N
trial NN N
was VBD N
powered VBN N
for IN N
analyses NNS N
of IN N
antitumor NN N
activity NN N
and CC N
safety NN N
RESULTS NNP N
Treatment NNP N
with IN N
nab-paclitaxel JJ N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
qw NN N
3/4 CD N
resulted VBD N
in IN N
a DT N
median JJ N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
of IN N
33.8 CD N
months NNS N
compared VBN N
with IN N
22.2 CD N
, , N
27.7 CD N
, , N
and CC N
26.6 CD N
months NNS N
for IN N
nab-paclitaxel JJ N
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
qw NN N
3/4 CD N
, , N
nab-paclitaxel JJ N
300 CD N
mg/m NN N
( ( N
2 CD N
) ) N
q3w NN N
, , N
and CC N
docetaxel NN N
, , N
respectively RB N
( ( N
overall JJ N
P NNP N
= NNP N
.047 NNP N
) ) N
Patients NNPS N
receiving VBG N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
nab-paclitaxel NN N
had VBD N
prolonged VBN N
median JJ N
OS NNP N
compared VBN N
with IN N
those DT N
in IN N
the DT N
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
nab-paclitaxel JJ N
arm NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.575 CD N
; : N
P NNP N
= NNP N
.008 NNP N
) ) N
A DT N
trend NN N
toward IN N
a DT N
longer JJR N
OS NNP N
was VBD N
noted VBN N
in IN N
the DT N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
nab-paclitaxel JJ N
arm NN N
versus NN N
docetaxel NN N
arm NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.688 CD N
) ) N
Grade $ N
3 CD N
or CC N
4 CD N
fatigue NN N
, , N
neutropenia NN N
, , N
and CC N
febrile JJ N
neutropenia NN N
were VBD N
less JJR N
frequent JJ N
in IN N
all DT N
nab-paclitaxel JJ N
arms NNS N
compared VBN N
with IN N
docetaxel NN N
CONCLUSIONS NNP N
Consistent NNP N
with IN N
previously RB N
published VBN N
efficacy NN N
results NNS N
, , N
these DT N
data NNS N
suggest VBP N
that IN N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
qw NN N
3/4 CD N
may MD N
represent VB N
the DT N
most RBS N
clinically RB N
efficacious JJ N
nab-paclitaxel JJ N
dosing VBG N
regimen NNS N
for IN N
patients NNS N
with IN N
no DT N
previous JJ N
chemotherapy NN N
for IN N
MBC NNP N
A DT N
phase NN N
III NNP N
trial NN N
confirming VBG N
these DT N
results NNS N
would MD N
be VB N
necessary JJ N
and CC N
prudent JJ N
before RB N
widespread JJ N
adoption NN N
of IN N
the DT N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
dose NN N
in IN N
clinical JJ N
practice NN N
-DOCSTART- -X- O O 8686245

[ JJ N
Effectiveness NNP N
of IN N
adjuvant JJ N
hormone NN N
therapy NN N
in IN N
breast NN N
cancer NN N
] NNP N
A NNP N
third JJ N
series NN N
of IN N
randomized JJ N
tests NNS N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
postoperative JJ N
adjuvant JJ N
hormone NN N
therapy NN N
( ( N
tamoxifen NN N
, , N
diethylstilbestrol NN N
, , N
orimethen VBP N
amino JJ N
glutethymide NN N
) ) N
in IN N
breast NN 4_p
cancer NN 4_p
patients NNS N
Tamoxifen NNP N
was VBD N
studied VBN N
in IN N
176 CD 3_p
patients NNS 4_p
with IN 4_p
T1-2N0M0 NNP 4_p
tumors NNS 4_p
Five-year JJ N
recurrence-free JJ N
survival NN N
was VBD N
registered VBN N
in IN N
85.2 CD N
% NN N
of IN N
menopausal NN N
patients NNS N
treated VBN N
with IN N
tamoxifen JJ N
versus NN N
71.1 CD N
% NN N
in IN N
control NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
Five-year JJ N
recurrence-free JJ N
survival NN N
in IN N
menopausal NN N
females NNS N
with IN N
breast NN N
tumors NNS N
, , N
stage NN N
IIb NNP N
, , N
was VBD N
71.1 CD N
% NN N
among IN N
those DT N
treated VBN N
with IN N
diethylstilbestrol NN N
and CC N
as RB N
low JJ N
as IN N
57.4 CD N
% NN N
in IN N
the DT N
tamoxifen NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
Untoward NNP N
side-effect JJ N
incidence NN N
was VBD N
much JJ N
higher JJR N
in IN N
the DT N
diethylstilbestrol NN N
group NN N
( ( N
30.4 CD N
% NN N
) ) N
as IN N
compared VBN N
with IN N
tamoxifen NN N
( ( N
3.5 CD N
% NN N
) ) N
No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
for IN N
the DT N
relationship NN N
between IN N
orimethen NN N
and CC N
tamoxifen JJ N
treatment NN N
with IN N
respect NN N
to TO N
5-year JJ N
survival NN N
and CC N
recurrence-free JJ N
survival NN N
-DOCSTART- -X- O O 8966003

[ JJ N
Drug NNP N
therapy NN N
of IN N
condylomata NN N
acuminata NNS N
] RB N
This DT N
study NN N
seeks VBZ N
to TO N
evaluate VB N
two CD N
candidate NN N
regimens NNS N
( ( N
5-fluorouracil JJ N
and CC N
interferon NN N
) ) N
as IN N
adjuvants NNS N
to TO N
optimally RB N
performed VBN N
laser NN N
surgery NN N
in IN N
the DT N
treatment NN N
of IN N
condylomata NN 4_p
acuminata NNS 4_p
Skillful NNP N
laser NN N
ablation NN N
can MD N
remove VB N
any DT N
volume NN N
of IN N
human JJ N
papillomavirus-associated JJ N
vulvar NN N
disease NN N
but CC N
can MD N
not RB N
prevent VB N
reactivation NN N
of IN N
the DT N
surrounding VBG N
latent JJ N
viral JJ N
reservoir NN N
during IN N
postoperative JJ N
healing NN N
Conversely RB N
, , N
interferon NN N
and CC N
5-fluorouracil JJ N
are VBP N
relatively RB N
ineffective JJ N
as IN N
primary JJ N
therapies NNS N
This DT N
study NN N
involves VBZ N
118 CD 3_p
evaluable JJ N
patients NNS N
: : N
32 CD 3_p
in IN N
the DT N
laser-CO2 JJ N
group NN N
, , N
34 CD 3_p
in IN N
the DT N
5-fluorouracil JJ N
group NN N
and CC N
52 CD 3_p
in IN N
the DT N
interferon NN N
group NN N
At IN N
assessment NN N
of IN N
final JJ N
outcome NN N
, , N
it PRP N
was VBD N
found VBN N
that IN N
43 CD N
of IN N
52 CD N
( ( N
82 CD N
% NN N
) ) N
assessable JJ N
patients NNS N
in IN N
the DT N
adjuvant JJ N
interferon NN N
arm NN N
were VBD N
controlled VBN N
by IN N
a DT N
single JJ N
laser NN N
ablation NN N
as IN N
compared VBN N
with IN N
only RB N
17 CD N
of IN N
34 CD N
( ( N
50 CD N
% NN N
) ) N
in IN N
the DT N
5-fluorouracil JJ N
group NN N
and CC N
13 CD N
of IN N
32 CD N
( ( N
40 CD N
% NN N
) ) N
in IN N
the DT N
laser NN N
alone RB N
group NN N
There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
outcome NN N
within IN N
the DT N
5-fluorouracil JJ N
and CC N
laser VBZ N
only RB N
arms NNS N
Conversely RB N
, , N
a DT N
relatively RB N
low JJ N
dose NN N
of IN N
recombinant JJ N
interferon NN N
, , N
used VBN N
in IN N
combination NN N
with IN N
effective JJ N
surgical JJ N
deleulking NN N
, , N
can MD N
markedly RB N
reduce VB N
the DT N
risk NN N
of IN N
postoperative JJ N
recurrence NN N
-DOCSTART- -X- O O 20851499

Early JJ N
treatment NN N
of IN N
cold JJ N
sores NNS N
with IN N
topical JJ N
ME-609 NNP N
decreases VBZ N
the DT N
frequency NN N
of IN N
ulcerative JJ N
lesions NNS N
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
patient-initiated JJ N
clinical JJ N
trial NN N
BACKGROUND NNP N
Prior NNP N
pilot NN N
studies NNS N
support VBP N
the DT N
use NN N
of IN N
antiviral JJ N
medications NNS N
with IN N
topical JJ N
corticosteroids NNS N
for IN N
herpes NNS 4_p
simplex JJ 4_p
labialis NN 4_p
( ( N
HSL NNP N
) ) N
ME-609 NNP N
( ( N
Xerese JJ N
, , N
Xerclear NNP N
) ) N
is VBZ N
a DT N
combination NN N
of IN N
5 CD N
% NN N
acyclovir NN N
and CC N
1 CD N
% NN N
hydrocortisone NN N
developed VBD N
for IN N
the DT N
topical JJ N
treatment NN N
of IN N
HSL NNP N
OBJECTIVES NNP N
The DT N
primary NN N
study VBD N
end JJ N
point NN N
was VBD N
the DT N
prevention NN N
of IN N
ulcerative JJ N
HSL NNP N
lesions NNS N
METHODS NNP N
In IN N
all DT N
, , N
2437 CD 3_p
patients NNS N
with IN N
a DT N
history NN 4_p
of IN 4_p
HSL NNP 4_p
were VBD N
randomized VBN N
to TO N
self-initiate JJ N
treatment NN N
with IN N
ME-609 NNP N
, , N
5 CD N
% NN N
acyclovir NN N
in IN N
ME-609 NNP N
vehicle NN N
, , N
or CC N
ME-609 JJ N
vehicle NN N
( ( N
placebo NN N
) ) N
at IN N
the DT N
earliest JJS N
sign NN N
of IN N
a DT N
cold JJ N
sore NN N
recurrence NN N
Cream NNP N
was VBD N
applied VBN N
5 CD N
times/d NN N
for IN N
5 CD N
days NNS N
A DT N
total NN N
of IN N
1443 CD N
patients NNS N
experienced VBD N
a DT N
recurrence NN N
and CC N
initiated JJ N
treatment NN N
with IN N
ME-609 NNP N
( ( N
n JJ N
= NNP N
601 CD N
) ) N
, , N
acyclovir FW N
( ( N
n JJ N
= NNP N
610 CD N
) ) N
, , N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
232 CD N
) ) N
RESULTS NNP N
Of IN N
patients NNS N
receiving VBG N
ME-609 NNP N
, , N
42 CD N
% NN N
did VBD N
not RB N
develop VB N
an DT N
ulcerative JJ N
lesion NN N
compared VBN N
with IN N
35 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
acyclovir NN N
in IN N
ME-609 NNP N
vehicle NN N
( ( N
P NNP N
= NNP N
.014 NNP N
) ) N
and CC N
26 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
placebo NN N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
In IN N
patients NNS N
with IN N
ulcerative JJ N
lesions NNS N
, , N
healing VBG N
times NNS N
were VBD N
reduced VBN N
in IN N
the DT N
ME-609 NNP N
and CC N
acyclovir NN N
groups NNS N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
.01 NNP N
for IN N
both DT N
) ) N
The DT N
cumulative JJ N
lesion NN N
area NN N
for IN N
all DT N
lesions NNS N
was VBD N
reduced VBN N
50 CD N
% NN N
in IN N
patients NNS N
receiving VBG N
ME-609 NNP N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
There EX N
were VBD N
no DT N
differences NNS N
among IN N
groups NNS N
in IN N
the DT N
number NN N
of IN N
patients NNS N
with IN N
positive JJ N
herpes NNS N
simplex JJ N
virus NN N
cultures NNS N
The DT N
side-effect JJ N
profile NN N
was VBD N
similar JJ N
among IN N
treatments NNS N
LIMITATIONS VB N
The DT N
study NN N
did VBD N
not RB N
contain VB N
a DT N
group NN N
treated VBD N
with IN N
a DT N
topical JJ N
corticosteroid NN N
alone RB N
CONCLUSIONS NNP N
ME-609 NNP N
prevented VBD N
progression NN N
of IN N
cold JJ N
sores NNS N
to TO N
ulcerative JJ N
lesions NNS N
and CC N
significantly RB N
reduced VBD N
the DT N
cumulative JJ N
lesion NN N
area NN N
compared VBN N
with IN N
acyclovir NN N
and CC N
placebo NN N
ME-609 NNP N
treatment NN N
offers NNS N
additional JJ N
therapeutic JJ N
benefit NN N
compared VBN N
with IN N
therapy NN N
with IN N
topical JJ N
acyclovir NN N
alone RB N
-DOCSTART- -X- O O 21189767

In IN N
vitro JJ N
determination NN N
of IN N
the DT N
chromatic JJ N
effect NN N
of IN N
a DT N
silver NN N
nanoparticles VBZ N
solution NN N
linked VBN N
to TO N
the DT N
gantrez JJ N
S-97 NNP N
copolymer NN N
on IN N
tooth DT 4_p
enamel NN 4_p
Silver NNP N
nanoparticles NNS N
( ( N
NNPs NNP N
) ) N
, , N
alone RB N
or CC N
in IN N
combination NN N
with IN N
the DT N
bioadhesive JJ N
Gantrez NNP N
S-97 NNP N
, , N
have VBP N
demonstrated VBN N
their PRP$ N
efficacy NN N
against IN N
Streptococcus NNP N
mutans NNS N
; : N
however RB N
, , N
it PRP N
is VBZ N
not RB N
known VBN N
if IN N
this DT N
combination NN N
changes VBZ N
the DT N
color NN N
of IN N
teeth NN N
The DT N
aim NN N
of IN N
this DT N
work NN N
was VBD N
to TO N
measure VB N
the DT N
color NN N
changes NNS N
occurring VBG N
after IN N
the DT N
use NN N
of IN N
a DT N
Gantrez-NNP JJ N
combination NN N
on IN N
enamel JJ N
tooth NN N
blocks NNS N
Two CD N
study NN N
groups NNS N
were VBD N
randomly RB N
formed VBN N
: : N
enamel NN 4_p
blocks NNS 4_p
brushed VBN N
with IN N
( ( N
a DT N
) ) N
the DT N
Gantrez-NNP JJ N
combination NN N
and CC N
( ( N
b NN N
) ) N
conventional JJ N
toothpaste NN N
, , N
for IN N
1 CD N
minute NN N
once RB N
daily JJ N
for IN N
4 CD N
weeks NNS N
, , N
then RB N
rinsed VBD N
with IN N
distilled JJ N
water NN N
and CC N
placed VBN N
in IN N
thymol JJ N
solution NN N
Color NN N
changes NNS N
in IN N
the DT N
enamel NN N
blocks NNS N
were VBD N
measured VBN N
using VBG N
a DT N
Minolta NNP N
colorimeter NN N
CR300 NNP N
Analysis NN N
of IN N
mixed JJ N
models NNS N
was VBD N
performed VBN N
with IN N
R NNP N
2.10.1 CD N
at IN N
a DT N
95 CD N
% NN N
confidence NN N
level NN N
, , N
using VBG N
the DT N
nonlinear JJ N
mixed JJ N
effects NNS N
( ( N
NLME NNP N
) ) N
package NN N
The DT N
results NNS N
showed VBD N
that IN N
there EX N
were VBD N
no DT N
color NN N
changes VBZ N
over IN N
time NN N
, , N
only RB N
a DT N
high JJ N
luminosity NN N
equal JJ N
in IN N
both DT N
groups NNS N
Our PRP$ N
study NN N
showed VBD N
that IN N
the DT N
use NN N
of IN N
the DT N
Gantrez-NNP NNP N
combination NN N
is VBZ N
safe JJ N
with IN N
respect NN N
to TO N
dental JJ 4_p
esthetics NNS 4_p
in IN N
the DT N
control NN N
of IN N
S. NNP N
mutans NNS N
-DOCSTART- -X- O O 9850026

BEACOPP NNP N
, , N
a DT N
new JJ N
dose-escalated JJ N
and CC N
accelerated JJ N
regimen NNS N
, , N
is VBZ N
at IN N
least JJS N
as RB N
effective JJ N
as IN N
COPP/ABVD NNP N
in IN N
patients NNS 4_p
with IN 4_p
advanced-stage JJ 4_p
Hodgkin NNP 4_p
's POS 4_p
lymphoma NN 4_p
: : 4_p
interim JJ N
report NN N
from IN N
a DT N
trial NN N
of IN N
the DT N
German JJ N
Hodgkin NNP N
's POS N
Lymphoma NNP N
Study NNP N
Group NNP N
PURPOSE NNP N
The DT N
HD9 NNP N
trial NN N
aims NNS N
to TO N
evaluate VB N
whether IN N
moderate JJ N
dose JJ N
escalation NN N
and/or IN N
acceleration NN N
of IN N
standard JJ N
polychemotherapy NN N
is VBZ N
beneficial JJ N
for IN N
advanced-stage JJ N
Hodgkin NNP N
's POS N
disease NN N
( ( N
HD NNP 4_p
) ) N
Two CD N
variants NNS N
of IN N
a DT N
novel JJ N
bleomycin NN N
, , N
etoposide RB N
, , N
doxorubicin NN N
, , N
cyclophosphamide NN N
, , N
vincristine NN N
, , N
procarbazine NN N
, , N
and CC N
prednisone NN N
( ( N
BEACOPP NNP N
) ) N
scheme NN N
( ( N
standard JJ N
and CC N
escalated VBD N
dose NN N
) ) N
are VBP N
compared VBN N
with IN N
cyclophosphamide NN N
, , N
vincristine NN N
, , N
procarbazine NN N
, , N
and CC N
prednisone NN N
( ( N
COPP NNP N
) ) N
/doxorubicin NN N
, , N
bleomycin NN N
, , N
vinblastine NN N
, , N
and CC N
dacarbazine NN N
( ( N
ABVD NNP N
) ) N
PATIENTS NNP N
AND CC N
METHODS NNP N
The DT N
randomized VBN N
, , N
three-arm JJ N
trial NN N
recruited VBD N
patients NNS N
in IN N
stages NNS N
IIB NNP N
and CC N
IIIA NNP N
with IN N
risk NN N
factors NNS N
and CC N
stages NNS N
IIIB NNP N
and CC N
IV NNP N
BEACOPP NNP N
in IN N
baseline NN N
dose NN N
contains VBZ N
all DT N
drug NN N
dosages NNS N
of IN N
COPP/ABVD NNP N
( ( N
except IN N
vincristine NN N
and CC N
procarbazine NN N
) ) N
rearranged VBD N
in IN N
a DT N
shorter NN N
, , N
3-week JJ N
cycle NN N
Escalated VBN N
BEACOPP NNP N
uses VBZ N
higher JJR N
doses NNS N
of IN N
cyclophosphamide NN N
, , N
doxorubicin NN N
, , N
and CC N
etoposide RB N
with IN N
granulocyte JJ N
colony-stimulating JJ N
factor NN N
( ( N
G-CSF NNP N
) ) N
support NN N
After IN N
eight CD N
chemotherapy NN N
cycles NNS N
, , N
initial JJ N
bulky NN N
and CC N
residual JJ N
disease NN N
is VBZ N
irradiated VBN N
The DT N
trial NN N
is VBZ N
monitored VBN N
and CC N
analyzed VBN N
by IN N
means NNS N
of IN N
a DT N
sequential JJ N
strategy NN N
RESULTS NNP N
An DT N
interim JJ N
analysis NN N
with IN N
505 CD 3_p
assessable JJ N
patients NNS N
and CC N
a DT N
median JJ N
follow-up NN N
of IN N
23 CD N
months NNS N
showed VBD N
a DT N
significant JJ N
inferiority NN N
( ( N
according VBG N
to TO N
sequential JJ N
monitoring NN N
strategy NN N
) ) N
of IN N
the DT N
COPP/ABVD NNP N
regimen NNS N
in IN N
progression NN N
rate NN N
and CC N
freedom NN N
from IN N
treatment NN N
failure NN N
( ( N
FFTF NNP N
) ) N
compared VBN N
with IN N
the DT N
pooled JJ N
results NNS N
of IN N
both DT N
BEACOPP NNP N
variants NNS N
The DT N
24-month JJ N
FFTF NNP N
rate NN N
was VBD N
75 CD N
% NN N
for IN N
COPP/ABVD NNP N
and CC N
84 CD N
% NN N
for IN N
BEACOPP NNP N
pooled VBD N
( ( N
P NNP N
= NNP N
.034 NNP N
) ) N
There EX N
was VBD N
12 CD N
% NN N
progressive JJ N
disease NN N
with IN N
COPP/ABVD NNP N
and CC N
6 CD N
% NN N
with IN N
BEACOPP NNP N
pooled VBD N
Differences NNS N
in IN N
survival NN N
were VBD N
not RB N
significant JJ N
in IN N
sequential JJ N
analysis NN N
The DT N
acute JJ N
toxicity NN N
of IN N
baseline NN N
BEACOPP NNP N
resembled VBD N
that IN N
of IN N
COPP/ABVD NNP N
; : N
escalated VBD N
BEACOPP NNP N
showed VBD N
increased VBN N
but CC N
manageable JJ N
hematologic JJ N
toxicity NN N
CONCLUSION NNP N
Combined VBD N
with IN N
local JJ N
irradiation NN N
, , N
BEACOPP NNP N
in IN N
one CD N
or CC N
both DT N
variants NNS N
shows VBZ N
superior JJ N
disease NN N
control NN N
compared VBN N
with IN N
COPP/ABVD NNP N
, , N
with IN N
acceptable JJ N
acute JJ N
toxicity NN N
Further JJ N
follow-up NN N
is VBZ N
required VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
dosage NN N
and CC N
the DT N
effect NN N
on IN N
survival NN N
and CC N
late JJ N
toxicities NNS N
-DOCSTART- -X- O O 7559252

Effect NN N
of IN N
perception NN N
of IN N
mechanical JJ N
loading NN N
on IN N
human JJ N
respiratory NN N
pattern NN N
regulation NN N
We PRP N
applied VBD N
external JJ N
flow NN N
resistive NN N
( ( N
R NNP N
) ) N
and CC N
elastic JJ N
( ( N
E NNP N
) ) N
mechanical JJ N
loads NNS N
over IN N
the DT N
entire JJ N
respiratory NN N
cycle NN N
to TO N
five CD 3_p
normal JJ 4_p
subjects NNS N
by IN N
using VBG N
a DT N
pseudorandom NN N
loading VBG N
protocol NN N
Loads NNP N
ranged VBD N
in IN N
magnitude NN N
from IN N
imperceptible JJ N
( ( N
R0/E0 NNP N
) ) N
through IN N
just RB N
perceptible JJ N
( ( N
R1/E1 NNP N
) ) N
to TO N
large JJ N
( ( N
R2/E2 NNP N
) ) N
and CC N
resulted VBN N
in IN N
respiratory NN N
pattern NN N
responses NNS N
that WDT N
were VBD N
due JJ N
to TO N
reflex JJ N
responses NNS N
alone RB N
( ( N
R0/E0 NNP N
) ) N
or CC N
to TO N
a DT N
combination NN N
of IN N
reflex JJ N
responses NNS N
and CC N
behavioral JJ N
reactions NNS N
to TO N
the DT N
perception NN N
of IN N
impeded JJ N
breathing NN N
( ( N
R1/E1 NNP N
and CC N
R2/E2 NNP N
) ) N
Pattern NNP N
regulation NN N
dynamics NNS N
were VBD N
estimated VBN N
from IN N
the DT N
computed VBN N
impulse JJ N
responses NNS N
of IN N
tidal JJ N
volume NN N
and CC N
inspiratory NN N
and CC N
expiratory JJ N
durations NNS N
We PRP N
anticipated VBD N
that IN N
emergence NN N
of IN N
behavioral JJ N
contributions NNS N
would MD N
be VB N
marked VBN N
by IN N
increased JJ N
variability NN N
in IN N
response NN N
strategies NNS N
and CC N
by IN N
increased JJ N
nonlinearity NN N
in IN N
the DT N
observed JJ N
responses NNS N
Regarding VBG N
the DT N
immediate JJ N
pattern NN N
response NN N
to TO N
loading NN N
, , N
there EX N
was VBD N
a DT N
tendency NN N
for IN N
increased JJ N
qualitative JJ N
variation NN N
across NN N
subjects NNS N
as IN N
the DT N
load NN N
size NN N
increased VBD N
, , N
but CC N
the DT N
within-subject JJ N
variability NN N
( ( N
coefficient NN N
of IN N
variation NN N
) ) N
was VBD N
unaffected JJ N
We PRP N
found VBD N
no DT N
evidence NN N
for IN N
increased JJ N
nonlinearity NN N
as IN N
loads NNS N
became VBD N
perceptible JJ N
The DT N
emergence NN N
of IN N
behavioral JJ N
control NN N
in IN N
some DT N
instances NNS N
seemed VBD N
to TO N
be VB N
marked VBN N
by IN N
reduction NN N
of IN N
complexity NN N
of IN N
the DT N
impulse JJ N
response NN N
to TO N
one CD N
dominated VBN N
by IN N
the DT N
zeroth-order NN N
lag NN N
, , N
leading VBG N
to TO N
dynamically RB N
simpler VB N
responses NNS N
compared VBN N
to TO N
control VB N
-DOCSTART- -X- O O 3954130

Response NN N
to TO N
tubular VB N
airway RP N
resistance NN N
in IN N
normal JJ 4_p
subjects NNS N
and CC N
postoperative JJ N
patients NNS N
Critically NNP 4_p
ill JJ 4_p
patients NNS N
must MD N
often RB N
breathe VB N
spontaneously RB N
through IN N
an DT N
endotracheal JJ N
tube NN N
that WDT N
acts VBZ N
as IN N
a DT N
fixed JJ N
inspiratory NN N
and CC N
expiratory JJ N
tubular JJ N
airway NN N
resistor NN N
Although IN N
this DT N
practice NN N
is VBZ N
common JJ N
, , N
its PRP$ N
effect NN N
on IN N
the DT N
pattern NN N
of IN N
breathing NN N
is VBZ N
not RB N
known VBN N
The DT N
mean JJ N
breathing NN N
patterns NNS N
of IN N
seven CD 3_p
normal JJ 4_p
, , 4_p
healthy JJ 4_p
male NN 2_p
subjects NNS N
and CC N
eight CD 3_p
male NN 2_p
patients NNS N
who WP N
had VBD N
undergone JJ N
upper JJ N
abdominal JJ N
surgery NN N
2-4 JJ N
days NNS N
previously RB N
were VBD N
studied VBN N
breathing VBG N
through IN N
a DT N
mouthpiece NN N
fitted VBN N
in IN N
random JJ N
order NN N
with IN N
a DT N
5 CD N
, , N
6 CD N
, , N
7 CD N
, , N
8 CD N
, , N
or CC N
15 CD N
mm NNS N
diameter NN N
( ( N
17 CD N
mm RB N
long RB N
) ) N
resistor NN N
These DT N
diameters NNS N
were VBD N
selected VBN N
because IN N
they PRP N
simulate VBP N
the DT N
pressure-flow JJ N
relationships NNS N
of IN N
adult NN N
endotracheal NN N
tubes NNS N
With IN N
the DT N
15 CD N
mm NN N
aperture NN N
, , N
the DT N
patients NNS N
had VBD N
a DT N
greater JJR N
breathing NN N
frequency NN N
( ( N
f NN N
) ) N
than IN N
did VBD N
the DT N
normal JJ N
subjects NNS N
( ( N
21 CD N
+/- JJ N
5 CD N
[ JJ N
SD NNP N
] NNP N
vs. IN N
14 CD N
+/- JJ N
4 CD N
breaths/min NN N
, , N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
as RB N
well RB N
as IN N
a DT N
smaller JJR N
mean JJ N
tidal NN N
volume NN N
( ( N
VT NNP N
) ) N
In IN N
both DT N
groups NNS N
, , N
minute JJ N
ventilation NN N
( ( N
VE NNP N
) ) N
and CC N
f $ N
progressively RB N
decreased VBN N
as IN N
resistance NN N
was VBD N
increased VBN N
by IN N
decreasing VBG N
the DT N
aperture NN N
size NN N
from IN N
15 CD N
to TO N
16 CD N
mm NN N
In IN N
the DT N
normal JJ N
subjects NNS N
but CC N
not RB N
the DT N
patients NNS N
, , N
VT NNP N
also RB N
progressively RB N
decreased VBN N
When WRB N
the DT N
diameter NN N
was VBD N
decreased VBN N
from IN N
6 CD N
mm NNS N
to TO N
5 CD N
mm NN N
, , N
there EX N
were VBD N
increases NNS N
in IN N
VT NNP N
and CC N
decreases NNS N
in IN N
f NN N
that WDT N
were VBD N
more JJR N
marked VBN N
in IN N
the DT N
normal JJ N
subjects NNS N
In IN N
both DT N
groups NNS N
, , N
the DT N
changes NNS N
in IN N
VE NNP N
were VBD N
accompanied VBN N
by IN N
decreases NNS N
in IN N
mean NN N
and CC N
peak JJ N
inspiratory NN N
and CC N
expiratory NN N
flow NN N
rates NNS N
Throughout IN N
the DT N
study NN N
, , N
oxygen NN N
consumption NN N
( ( N
VO2 NNP N
) ) N
and CC N
carbon NN N
dioxide NN N
production NN N
( ( N
VCO2 NNP N
) ) N
did VBD N
not RB N
change VB N
This DT N
, , N
coupled VBN N
with IN N
the DT N
decreases NNS N
in IN N
VE NNP N
resulted VBD N
in IN N
decreases NNS N
in IN N
the DT N
ventilatory NN N
equivalents NNS N
to TO N
CO2 NNP N
and CC N
O2 NNP N
( ( N
VE/VCO2 NNP N
, , N
VE/VO2 NNP N
) ) N
( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 8619354

Iobitridol NNP N
300 CD N
compared VBN N
to TO N
iopromide VB N
300 CD N
-- : N
a DT N
double-blind JJ N
randomized JJ N
phase-III NN N
study NN N
of IN N
clinical JJ N
tolerance NN N
in IN N
total JJ 4_p
body NN 4_p
CT. NNP 4_p
UNLABELLED NNP N
PURPOSE NNP N
, , N
MATERIAL NNP N
AND NNP N
METHODS NNP N
: : N
The DT N
clinical JJ N
safety NN N
of IN N
iobitriodol JJ N
300 CD N
mg NN N
I/ml NNP N
and CC N
iopromide RB N
300 CD N
mg NNS N
I/ml NNP N
were VBD N
compared VBN N
in IN N
a DT N
randomized JJ N
double JJ N
blind IN N
phase-III JJ N
study NN N
conducted VBD N
on IN N
60 CD N
patients NNS N
undergoing JJ N
abdominal JJ N
CT NNP N
for IN N
a DT N
variety NN N
of IN N
indications NNS N
Each DT N
examination NN N
was VBD N
rated VBN N
as IN N
diagnostic JJ N
or CC N
nondiagnostic JJ N
and CC N
the DT N
image NN N
quality NN N
was VBD N
noted VBN N
Nature NN N
, , N
onset NN N
, , N
intensity NN N
as RB N
well RB N
as IN N
outcome NN N
of IN N
each DT N
adverse JJ N
reaction NN N
were VBD N
recorded VBN N
RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
imaging VBG N
quality NN N
and CC N
side NN N
effects NNS N
between IN N
the DT N
contrast NN N
media NNS N
In IN N
this DT N
study NN N
, , N
both DT N
iobitridol NNS N
and CC N
iopromide NN N
provided VBD N
excellent JJ N
image NN N
quality NN N
and CC N
a DT N
low JJ N
rate NN N
of IN N
side NN N
effects NNS N
CONCLUSION NNP N
Iobitridol NNP N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
nonionic JJ N
contrast NN N
agent NN N
for IN N
contrast-enhanced JJ N
body NN N
CT NNP N
-DOCSTART- -X- O O 7761011

[ RB N
Postoperative JJ N
analgesia NN N
: : N
peridural JJ N
morphine NN N
versus NN N
sublingual JJ N
buprenorphine NN N
Comparative NNP N
clinical JJ N
study NN N
] NNP N
The DT N
authors NNS N
herein VBP N
present JJ N
their PRP$ N
personal JJ N
series NN N
on IN N
the DT N
clinical JJ N
evaluation NN N
of IN N
the DT N
analgesic JJ N
efficacy NN N
of IN N
2 CD N
opiodes NNS N
, , N
peridural JJ N
morphine NN N
hydrochloride NN N
( ( N
0.5 CD N
mg/kg NN N
) ) N
administered VBD N
to TO N
group NN N
A NNP N
patients NNS N
, , N
and CC N
sublingual JJ N
buprenorphine NN N
( ( N
0.4 CD N
mg NN N
) ) N
administered VBD N
to TO N
group NN N
B NNP N
patients NNS N
in IN N
the DT N
management NN N
of IN N
post-operative JJ N
pain NN N
in IN N
major JJ N
abdominal JJ N
surgery NN N
The DT N
study NN N
was VBD N
conducted VBN N
on IN N
44 CD 3_p
patients NNS N
, , N
both DT N
male NN 2_p
and CC N
female NN 2_p
, , N
classified VBD N
as IN N
ASA NNP N
II NNP N
and CC N
III NNP N
Statistical JJ N
analysis NN N
of IN N
cardiovascular JJ N
parameters NNS N
( ( N
BP NNP N
and CC N
cardiac JJ N
frequency NN N
) ) N
, , N
respiratory JJ N
frequency NN N
and CC N
pain NN N
score NN N
showed VBD N
an DT N
overlapping JJ N
progression NN N
among IN N
the DT N
two CD N
groups NNS N
Spontaneous JJ N
pain NN N
decreased VBD N
significantly RB N
to TO N
zero CD N
at IN N
T6 NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
However RB N
, , N
the DT N
necessity NN N
to TO N
administer VB N
buprenorphine NN N
more RBR N
frequently RB N
after IN N
the DT N
sixth JJ N
hour NN N
and CC N
the DT N
consequent JJ N
increase NN N
in IN N
side JJ N
effects NNS N
, , N
lead VBP N
us PRP N
to TO N
believe VB N
that IN N
the DT N
method NN N
used VBN N
for IN N
group NN N
A NNP N
patients NNS N
is VBZ N
more RBR N
advantageous JJ N
-DOCSTART- -X- O O 11701101

The DT N
role NN N
of IN N
radiography NN N
in IN N
primary JJ 4_p
care NN 4_p
patients NNS 4_p
with IN 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
of IN 4_p
at IN 4_p
least JJS 4_p
6 CD 4_p
weeks NNS 4_p
duration NN 4_p
: : N
a DT N
randomised JJ N
( ( N
unblinded JJ N
) ) N
controlled VBD N
trial NN N
OBJECTIVES UH N
To TO N
test VB N
the DT N
hypotheses NNS N
that WDT N
: : N
( ( N
1 CD N
) ) N
Lumbar NNP N
spine NN N
radiography NN N
in IN N
primary JJ N
care NN N
patients NNS N
with IN N
low JJ N
back RB N
pain NN N
is VBZ N
not RB N
associated VBN N
with IN N
improved JJ N
patient NN N
outcomes NNS N
, , N
including VBG N
pain NN N
, , N
disability NN N
, , N
health NN N
status NN N
, , N
sickness NN N
absence NN N
, , N
reassurance NN N
, , N
and CC N
patient JJ N
satisfaction NN N
or CC N
belief NN N
in IN N
the DT N
value NN N
of IN N
radiography NN N
( ( N
2 CD N
) ) N
Lumbar NNP N
spine NN N
radiography NN N
in IN N
primary JJ N
care NN N
patients NNS N
with IN N
low JJ N
back RB N
pain NN N
is VBZ N
not RB N
associated VBN N
with IN N
changes NNS N
in IN N
patient JJ N
management NN N
, , N
including VBG N
medication NN N
use NN N
, , N
and CC N
the DT N
use NN N
of IN N
primary JJ N
and CC N
secondary JJ N
care NN N
services NNS N
, , N
physical JJ N
therapies NNS N
and CC N
complementary JJ N
therapies NNS N
( ( N
3 CD N
) ) N
Participants NNS N
choosing VBG N
their PRP$ N
treatment NN N
group NN N
( ( N
i.e NN N
radiography NN N
or CC N
no DT N
radiography NN N
) ) N
do VBP N
not RB N
have VB N
better JJR N
outcomes NNS N
than IN N
those DT N
randomised VBN N
to TO N
a DT N
treatment NN N
group NN N
( ( N
4 CD N
) ) N
Lumbar NNP N
spine NN N
radiography NN N
is VBZ N
not RB N
cost-effective JJ N
compared VBN N
with IN N
usual JJ N
care NN N
without IN N
lumbar NN N
spine NN N
radiography NN N
DESIGN VB N
A DT N
randomised JJ N
unblinded JJ N
controlled VBN N
trial NN N
SETTING CC N
Seventy-three JJ 3_p
general JJ N
practices NNS N
in IN N
Nottingham NNP N
, , N
North NNP N
Nottinghamshire NNP N
, , N
Southern NNP N
Derbyshire NNP N
, , N
North NNP N
Lincolnshire NNP N
and CC N
North NNP N
Leicestershire NNP N
Fifty-two NNP 3_p
practices NNS N
recruited VBD N
participants NNS N
to TO N
the DT N
trial NN N
SUBJECTS NNP N
Randomised VBD N
arm NN N
: : N
421 CD 3_p
participants NNS N
with IN N
low JJ 4_p
back RB 4_p
pain NN 4_p
, , 4_p
with IN 4_p
median JJ 4_p
duration NN 4_p
of IN 4_p
10 CD 4_p
weeks NNS 4_p
Patient JJ N
preference NN N
arm NN N
: : N
55 CD 3_p
participants NNS N
with IN N
low JJ N
back RB N
pain NN N
, , N
with IN N
median JJ N
duration NN N
of IN N
11 CD N
weeks NNS N
INTERVENTION NNP N
Lumbar NNP N
spine NN N
radiography NN N
and CC N
usual JJ N
care NN N
versus NN N
usual JJ N
care NN N
without IN N
radiography NN N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Roland NNP N
adaptation NN N
of IN N
the DT N
Sickness NNP N
Impact NNP N
Profile NNP N
, , N
visual JJ N
analogue NN N
pain NN N
scale NN N
, , N
health NN N
status NN N
scale NN N
, , N
EuroQol NNP N
, , N
use NN N
of IN N
primary JJ N
and CC N
secondary JJ N
care NN N
services NNS N
, , N
and CC N
physical JJ N
and CC N
complementary JJ N
therapies NNS N
, , N
sickness JJ N
absence NN N
, , N
medication NN N
use NN N
, , N
patient JJ N
satisfaction NN N
, , N
reassurance NN N
and CC N
belief NN N
in IN N
value NN N
of IN N
radiography NN N
at IN N
3 CD N
and CC N
9 CD N
months NNS N
post-randomisation NN N
RESULTS JJ N
Participants NNS N
randomised VBD N
to TO N
receive VB N
an DT N
X-ray NN N
were VBD N
more RBR N
likely JJ N
to TO N
report VB N
low JJ N
back RB N
pain NN N
at IN N
3 CD N
months NNS N
( ( N
odds NNS N
ratio NN N
( ( N
OR NNP N
) ) N
= VBZ N
1.56 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
1.02 CD N
to TO N
2.40 CD N
) ) N
and CC N
had VBD N
a DT N
lower JJR N
overall JJ N
health NN N
status NN N
score NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
health NN N
or CC N
functional JJ N
status NN N
at IN N
9 CD N
months NNS N
A DT N
higher JJR N
proportion NN N
of IN N
participants NNS N
consulted VBN N
the DT N
general JJ N
practitioner NN N
( ( N
GP NNP N
) ) N
in IN N
the DT N
3 CD N
months NNS N
following VBG N
an DT N
X-ray JJ N
( ( N
OR NNP N
= VBZ N
2.72 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.80 CD N
to TO N
4.10 CD N
) ) N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
use NN N
of IN N
any DT N
other JJ N
services NNS N
, , N
medication NN N
use NN N
or CC N
sickness NN N
absence NN N
at IN N
3 CD N
or CC N
9 CD N
months NNS N
No DT N
serious JJ N
spinal JJ N
pathology NN N
was VBD N
identified VBN N
in IN N
either DT N
group NN N
The DT N
commonest JJS N
X-ray JJ N
reports NNS N
were VBD N
of IN N
discovertebral JJ N
degeneration NN N
and CC N
normal JJ N
findings NNS N
Many JJ N
patients NNS N
did VBD N
not RB N
perceive VB N
their PRP$ N
information NN N
needs NNS N
were VBD N
met VBN N
within IN N
the DT N
consultation NN N
Satisfaction NN N
with IN N
care NN N
was VBD N
greater JJR N
in IN N
the DT N
group NN N
receiving VBG N
radiography NN N
at IN N
9 CD N
months NNS N
Participants NNS N
randomised VBD N
to TO N
receive VB N
an DT N
X-ray NN N
were VBD N
not RB N
less RBR N
worried JJ N
, , N
or CC N
more JJR N
reassured JJ N
about IN N
serious JJ N
disease NN N
causing VBG N
their PRP$ N
low JJ N
back RB N
pain NN N
Satisfaction NN N
was VBD N
associated VBN N
with IN N
meeting NN N
participants NNS N
' POS N
information NN N
needs NNS N
and CC N
reduced JJ N
belief NN N
in IN N
the DT N
necessity NN N
for IN N
investigations NNS N
for IN N
low JJ N
back RB N
pain NN N
, , N
including VBG N
X-rays NNS N
and CC N
blood NN N
tests NNS N
In IN N
both DT N
groups NNS N
, , N
at IN N
3 CD N
and CC N
9 CD N
months NNS N
80 CD N
% NN N
of IN N
participants NNS N
would MD N
choose VB N
to TO N
have VB N
an DT N
X-ray JJ N
if IN N
the DT N
choice NN N
was VBD N
available JJ N
Participants NNS N
in IN N
the DT N
patient JJ N
preference NN N
group NN N
achieved VBD N
marginally RB N
better JJR N
outcomes NNS N
than IN N
those DT N
randomised VBN N
to TO N
a DT N
treatment NN N
group NN N
, , N
but CC N
the DT N
clinical JJ N
significance NN N
of IN N
these DT N
differences NNS N
is VBZ N
unclear JJ N
Lumbar NNP N
spine NN N
radiography NN N
was VBD N
associated VBN N
with IN N
a DT N
net JJ N
economic JJ N
loss NN N
at IN N
3 CD N
and CC N
9 CD N
months NNS N
CONCLUSIONS NNP N
Lumbar NNP N
spine NN N
radiography NN N
in IN N
primary JJ N
care NN N
patients NNS N
with IN N
low JJ N
back RB N
pain NN N
of IN N
at IN N
least JJS N
6 CD N
weeks NNS N
duration NN N
is VBZ N
not RB N
associated VBN N
with IN N
improved JJ N
functioning NN N
, , N
severity NN N
of IN N
pain NN N
or CC N
overall JJ N
health NN N
status NN N
, , N
and CC N
is VBZ N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
GP NNP N
workload NN N
Participants NNS N
receiving VBG N
X-rays NNS N
are VBP N
more RBR N
satisfied JJ N
with IN N
their PRP$ N
care NN N
, , N
but CC N
are VBP N
not RB N
less RBR N
worried JJ N
or CC N
more RBR N
reassured JJ N
about IN N
serious JJ N
disease NN N
causing VBG N
their PRP$ N
low JJ N
back RB N
pain NN N
CONCLUSIONS NNP N
- : N
RECOMMENDATIONS NN N
FOR IN N
FURTHER JJ N
RESEARCH NN N
: : N
Further JJ N
work NN N
is VBZ N
required VBN N
to TO N
develop VB N
and CC N
test VB N
an DT N
educational JJ N
package NN N
that WDT N
educates VBZ N
patients NNS N
and CC N
GPs NNP N
about IN N
the DT N
utility NN N
of IN N
radiography NN N
and CC N
provides VBZ N
strategies NNS N
for IN N
identifying VBG N
and CC N
meeting VBG N
the DT N
information NN N
needs NNS N
of IN N
patients NNS N
, , N
and CC N
the DT N
needs NNS N
of IN N
patients NNS N
and CC N
GPs NNP N
to TO N
be VB N
reassured VBN N
about IN N
missing VBG N
serious JJ N
disease NN N
Guidelines NNS N
on IN N
the DT N
management NN N
of IN N
low JJ N
back RB N
pain NN N
in IN N
primary JJ N
care NN N
should MD N
be VB N
consistent JJ N
about IN N
not RB N
recommending VBG N
lumbar NN N
spine NN N
radiography NN N
in IN N
patients NNS N
with IN N
low JJ N
back RB N
pain NN N
in IN N
the DT N
absence NN N
of IN N
red JJ N
flags NNS N
for IN N
serious JJ N
spinal JJ N
pathology NN N
, , N
even RB N
if IN N
the DT N
pain NN N
has VBZ N
persisted VBN N
for IN N
at IN N
least JJS N
6 CD N
weeks NNS N
-DOCSTART- -X- O O 20486273

Efficacy NN N
and CC N
safety NN N
of IN N
routine JJ N
blood NN N
pressure NN N
lowering VBG N
in IN N
older JJR 1_p
patients NNS N
with IN N
diabetes NNS 4_p
: : N
results NNS N
from IN N
the DT N
ADVANCE NNP N
trial NN N
OBJECTIVE CC N
The DT N
efficacy NN N
and CC N
safety NN N
of IN N
blood NN N
pressure NN N
lowering VBG N
in IN N
elderly JJ 1_p
patients NNS N
have VBP N
not RB N
been VBN N
sufficiently RB N
investigated VBN N
in IN N
patients NNS N
with IN N
diabetes NNS N
Using VBG N
data NNS N
from IN N
the DT N
Action NNP N
in IN N
Diabetes NNP N
and CC N
Vascular NNP N
disease NN N
: : N
preterAx NN N
and CC N
diamicroN-MR NN N
Controlled NNP N
Evaluation NNP N
study NN N
, , N
we PRP N
assessed VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
routine JJ N
blood NN N
pressure NN N
lowering VBG N
to TO N
prevent VB N
major JJ N
clinical JJ N
outcomes NNS N
in IN N
elderly JJ 1_p
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
METHODS NNP N
Eleven NNP 3_p
thousand VBP 3_p
one CD 3_p
hundred CD 3_p
and CC 3_p
forty JJ 3_p
patients NNS N
aged VBN 1_p
at IN 1_p
least JJS 1_p
55 CD 1_p
years NNS 1_p
with IN N
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
( ( N
mean JJ 1_p
66+/-6 CD 1_p
years NNS 1_p
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
perindopril-indapamide JJ N
or CC N
placebo NN N
The DT N
primary JJ N
endpoint NN N
was VBD N
a DT N
composite NN N
of IN N
major JJ N
macrovascular NN N
and CC N
microvascular JJ N
disease NN N
The DT N
effects NNS N
of IN N
active JJ N
treatment NN N
on IN N
outcomes NNS N
were VBD N
estimated VBN N
in IN N
subgroups NNS N
according VBG N
to TO N
age NN N
: : N
below IN N
65 CD N
, , N
65-74 JJ N
and CC N
at IN N
least JJS N
75 CD N
years NNS N
RESULTS NNP N
During IN N
a DT N
mean JJ N
4.3-year JJ N
follow-up NN N
, , N
1799 CD N
( ( N
16.1 CD N
% NN N
) ) N
patients NNS N
experienced VBD N
a DT N
major JJ N
event NN N
Active JJ N
treatment NN N
produced VBD N
similar JJ N
relative JJ N
risk NN N
reductions NNS N
for IN N
the DT N
primary JJ N
outcome NN N
, , N
major JJ N
macrovascular JJ N
disease NN N
, , N
death NN N
and CC N
renal JJ N
events NNS N
across IN N
age NN N
groups NNS N
( ( N
all DT N
P NNP N
heterogeneity NN N
> NNP N
0.3 CD N
) ) N
Over IN N
5 CD N
years NNS N
, , N
active JJ N
treatment NN N
was VBD N
estimated VBN N
to TO N
prevent VB N
one CD N
primary JJ N
outcome NN N
in IN N
every DT N
21 CD N
, , N
71 CD N
and CC N
118 CD N
patients NNS N
of IN N
at IN N
least JJS N
75 CD N
, , N
65-74 JJ N
and CC N
below IN N
65 CD N
years NNS N
, , N
respectively RB N
Similar JJ N
patterns NNS N
of IN N
benefits NNS N
were VBD N
observed VBN N
for IN N
secondary JJ N
outcomes NNS N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
tolerability NN N
between IN N
randomized VBN N
allocations NNS N
across IN N
age NN N
groups NNS N
( ( N
all DT N
P NNP N
heterogeneity NN N
> NNP N
0.6 CD N
) ) N
CONCLUSION NNP N
Routine NNP N
administration NN N
of IN N
perindopril-indapamide JJ N
lowers NNS N
blood NN N
pressure NN N
safely RB N
and CC N
reduces VBZ N
the DT N
risk NN N
of IN N
major JJ N
clinical JJ N
outcomes NNS N
in IN N
patients NNS N
of IN N
at IN N
least JJS N
75 CD N
years NNS N
with IN N
type NN N
2 CD N
diabetes NNS N
The DT N
greater JJR N
absolute JJ N
benefits NNS N
in IN N
older JJR N
patients NNS N
in IN N
this DT N
age NN N
group NN N
were VBD N
not RB N
offset VBN N
by IN N
an DT N
increased VBN N
risk NN N
of IN N
side NN N
effects NNS N
-DOCSTART- -X- O O 12407485

Lamivudine NNP N
300 CD N
mg NN N
QD NNP N
versus NN N
continued VBD N
lamivudine JJ N
150 CD N
mg NNS N
BID NNP N
with IN N
stavudine NN N
and CC N
a DT N
protease NN N
inhibitor NN N
in IN N
suppressed JJ 4_p
patients NNS N
PURPOSE NNP N
To TO N
compare VB N
the DT N
efficacy NN N
( ( N
sustained VBN N
virologic IN N
suppression NN N
) ) N
and CC N
safety/tolerability NN N
of IN N
a DT N
switch NN N
to TO N
lamivudine VB N
300 CD N
mg NNS N
once RB N
daily JJ N
( ( N
QD NNP N
) ) N
versus NN N
continued VBD N
lamivudine JJ N
150 CD N
mg JJ N
twice RB N
daily RB N
( ( N
BID NNP N
) ) N
in IN N
virologically RB 4_p
suppressed VBN 4_p
patients NNS N
( ( N
HIV-1 NNP N
RNA NNP N
< NNP N
400 CD N
copies/mL NN N
for IN N
> NN N
or CC N
=3 JJ N
months NNS N
) ) N
on IN N
stable JJ N
( ( N
> JJ N
or CC N
=6 JJ N
months NNS N
) ) N
therapy NN N
with IN N
lamivudine JJ N
150 CD N
mg NN N
BID NNP N
plus CC N
stavudine NN N
and CC N
either DT N
indinavir NN N
or CC N
nelfinavir NN N
METHOD NNP N
Eighty-nine NNP N
suppressed VBD 4_p
patients NNS N
> CD N
or CC N
=18 CD N
years NNS N
old JJ N
with IN N
CD4 NNP 4_p
counts VBZ 4_p
> JJ 4_p
50 CD 4_p
cells/mm NN 4_p
( ( 4_p
3 CD 4_p
) ) 4_p
were VBD N
enrolled VBN N
in IN N
this DT N
phase NN N
II NNP N
, , N
open-label NN N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
stratified VBN N
( ( N
by IN N
pretrial JJ N
protease NN N
inhibitor NN N
[ NNP N
PI NNP N
] NNP N
) ) N
, , N
parallel-group JJ N
clinical JJ N
trial NN N
Eighty-one JJ N
patients NNS N
received VBD N
either RB N
lamivudine JJ N
300 CD N
mg NN N
QD NNP N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
or CC N
150 CD N
mg NNS N
BID NNP N
( ( N
n JJ N
= NNP N
42 CD N
) ) N
with IN N
their PRP$ N
pretrial JJ N
stavudine/PI NN N
regimens NNS N
for IN N
24 CD N
weeks NNS N
RESULTS VB N
A DT N
high JJ N
rate NN N
of IN N
virologic JJ N
suppression NN N
was VBD N
sustained VBN N
with IN N
both DT N
regimens NNS N
throughout IN N
the DT N
trial NN N
At IN N
week NN N
24 CD N
, , N
intent-to-treat NN N
: : N
exposed VBN N
( ( N
missing VBG N
= NNP N
failure NN N
) ) N
analyses VBZ N
showed VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
with IN N
HIV-1 NNP N
RNA NNP N
< NNP N
400 CD N
copies/mL NN N
( ( N
95 CD N
% NN N
[ JJ N
QD NNP N
] NNP N
vs. IN N
90 CD N
% NN N
[ JJ N
BID NNP N
] NNP N
) ) N
or CC N
< $ N
50 CD N
copies/mL NN N
( ( N
82 CD N
% NN N
[ JJ N
QD NNP N
] NNP N
vs. IN N
81 CD N
% NN N
[ JJ N
BID NNP N
] NNP N
) ) N
or CC N
in IN N
the DT N
median JJ N
change NN N
from IN N
baseline NN N
in IN N
CD4 NNP N
counts NNS N
( ( N
+42 JJ N
cells/mm NN N
( ( N
3 CD N
) ) N
[ NN N
QD NNP N
] NNP N
vs. FW N
+22 NNP N
cells/mm NN N
( ( N
3 CD N
) ) N
[ FW N
BID NNP N
] NNP N
) ) N
Both DT N
regimens NNS N
were VBD N
well RB N
tolerated VBN N
No DT N
patient NN N
experienced VBD N
virologic JJ N
failure NN N
, , N
clinical JJ N
disease NN N
progression NN N
, , N
or CC N
a DT N
drug-related JJ N
serious JJ N
adverse JJ N
event NN N
during IN N
the DT N
trial NN N
Self-reported JJ N
medication NN N
adherence NN N
was VBD N
high JJ N
in IN N
both DT N
groups NNS N
CONCLUSION NNP N
Patients NNPS N
who WP N
experience VBP N
virologic JJ 4_p
suppression NN 4_p
with IN N
a DT N
regimen NNS N
of IN N
lamivudine JJ N
150 CD N
mg NN N
BID NNP N
in IN N
combination NN N
with IN N
stavudine/PI NN N
can MD N
maintain VB N
that DT N
suppression NN N
by IN N
continuing VBG N
their PRP$ N
regimen NNS N
or CC N
switching VBG N
to TO N
lamivudine VB N
300 CD N
mg NN N
QD NNP N
and CC N
continuing VBG N
the DT N
other JJ N
components NNS N
Adverse JJ N
event NN N
profiles NNS N
were VBD N
comparable JJ N
among IN N
treatment NN N
regimens NNS N
, , N
and CC N
no DT N
new JJ N
safety NN N
concerns NNS N
were VBD N
raised VBN N
-DOCSTART- -X- O O 21909698

Randomised VBN N
multicentre JJ N
trial NN N
of IN N
circular JJ N
stapling NN N
devices NNS N
PURPOSE NNP N
In IN N
a DT N
register NN N
study NN N
, , N
the DT N
risk NN N
of IN N
anastomotic JJ N
leakage NN N
correlated VBD N
to TO N
the DT N
choice NN N
of IN N
circular JJ N
stapling VBG N
device NN N
with IN N
a DT N
4 CD N
% NN N
difference NN N
between IN N
the DT N
two CD N
brands NNS N
used VBN N
Based VBN N
on IN N
those DT N
data NNS N
, , N
a DT N
randomised JJ N
multicentre NN N
study NN N
was VBD N
started VBN N
to TO N
explore VB N
the DT N
risk NN N
of IN N
an DT N
anastomotic JJ N
leakage NN N
based VBN N
upon IN N
the DT N
surgical JJ N
device NN N
METHODS NNP N
Patients NNPS N
above IN N
18 CD 1_p
years NNS 1_p
with IN N
a DT N
rectal JJ 4_p
cancer NN 4_p
, , N
able JJ 4_p
to TO 4_p
give VB 4_p
informed JJ 4_p
consent NN 4_p
, , N
and CC N
scheduled VBD 4_p
for IN 4_p
an DT 4_p
anterior JJ 4_p
resection NN 4_p
were VBD N
eligible JJ N
for IN N
the DT N
study NN N
Perioperative JJ N
randomisation NN N
was VBD N
to TO N
Ethicon™ NNP N
PROXIMATE™ NNP N
ILS™ NNP N
or CC N
Autosuture™ NNP N
Premium NNP N
Plus NNP N
CEEA™ NNP N
Anastomotic JJ N
leakage NN N
was VBD N
defined VBN N
as IN N
a DT N
clinically RB N
manifest JJS N
leak NN 4_p
RESULTS NNP N
Five CD 3_p
hundred VBD 3_p
twenty-nine NN 3_p
patients NNS N
were VBD N
randomised VBN N
( ( N
58 CD N
% NN N
male NN N
) ) N
A DT N
leak NN N
occurred VBD N
in IN N
8.3 CD N
% NN N
The DT N
anastomoses NNS N
created VBN N
by IN N
PROXIMATE™ NNP N
ILS™ NNP N
leaked VBD N
in IN N
25/265 CD N
( ( N
9.4 CD N
% NN N
) ) N
anastomoses VBZ N
, , N
and CC N
the DT N
Premium NNP N
Plus NNP N
CEEA™ NNP N
leaked VBD N
in IN N
19/260 CD N
( ( N
7.3 CD N
% NN N
) ) N
, , N
p JJ N
= NNP N
.419 NNP N
CONCLUSION NNP N
No DT N
difference NN N
in IN N
the DT N
leak NN N
rate NN N
could MD N
be VB N
revealed VBN N
Several JJ N
centres NNS N
replaced VBD N
one CD N
of IN N
the DT N
staplers NNS N
by IN N
a DT N
new JJ N
product NN N
, , N
and CC N
the DT N
study NN N
was VBD N
ended VBN N
before IN N
the DT N
stipulated JJ N
number NN N
of IN N
patients NNS N
was VBD N
reached VBN N
In IN N
the DT N
future NN N
, , N
surgical JJ N
devices NNS N
may MD N
have VB N
to TO N
prove VB N
superiority NN N
in IN N
randomised JJ N
trials NNS N
or CC N
be VB N
monitored VBN N
in IN N
quality NN N
registers NNS N
before IN N
they PRP N
can MD N
be VB N
introduced VBN N
into IN N
day NN N
to TO N
day NN N
surgical JJ N
practice NN N
The DT N
study NN N
was VBD N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
: : N
NCT00399009 NN N
-DOCSTART- -X- O O 9917050

Effects NNS N
of IN N
atropine NN N
and CC N
scopolamine NN N
on IN N
bradycardia NN 4_p
and CC N
emetic JJ 4_p
symptoms NNS 4_p
in IN N
otoplasty NN N
OBJECTIVE UH N
To TO N
assess VB N
the DT N
effects NNS N
of IN N
unilateral JJ N
or CC N
bilateral JJ N
otoplasty NN N
on IN N
bradycardia NN N
and CC N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
( ( N
PONV NNP N
) ) N
and CC N
the DT N
efficiency NN N
of IN N
transdermal JJ N
scopolamine NN N
in IN N
the DT N
prophylaxis NN N
of IN N
PONV NNP N
STUDY NNP N
DESIGN NNP N
Post NNP N
hoc JJ N
assessment NN N
of IN N
the DT N
data NNS N
from IN N
a DT N
double-blind NN N
, , N
randomized VBN N
study NN N
METHODS NNP N
Fifty NNP 3_p
otoplasty JJ 4_p
patients NNS N
were VBD N
studied VBN N
; : N
half NN N
of IN N
them PRP N
received VBD N
randomly RB N
and CC N
in IN N
double-blind JJ N
fashion NN N
a DT N
transdermal JJ N
therapeutic JJ N
system NN N
( ( N
patch NN N
) ) N
of IN N
scopolamine NN N
( ( N
TTS-scopolamine NNP N
) ) N
as IN N
prophylaxis NN N
against IN N
PONV NNP N
before IN N
general JJ N
anesthesia NN N
The DT N
placebo NN N
group NN N
received VBD N
atropine JJ N
10 CD N
microg NN N
x NN N
kg NN N
( ( N
-1 NNP N
) ) N
intravenously RB N
during IN N
induction NN N
RESULTS VB N
The DT N
scopolamine-treated JJ N
patients NNS N
suffered VBD N
more RBR N
from IN N
moderate JJ N
peroperative JJ N
bradycardia NN N
( ( N
8/25 CD N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
than IN N
the DT N
atropine-treated JJ N
patients NNS N
( ( N
1/25 CD N
) ) N
Two CD N
patients NNS N
wearing VBG N
a DT N
half NN N
of IN N
the DT N
TTS-scopolamine NNP N
patch NN N
needed VBD N
intravenous JJ N
atropine NN N
After IN N
unilateral JJ N
otoplasty NN N
, , N
none NN N
of IN N
the DT N
TTS-scopolamine-treated JJ N
patients NNS N
and CC N
50 CD N
% NN N
of IN N
the DT N
atropine-treated JJ N
patients NNS N
suffered VBD N
from IN N
PONV NNP N
After IN N
bilateral JJ N
operation NN N
, , N
the DT N
respective JJ N
incidences NNS N
were VBD N
39 CD N
% NN N
and CC N
81 CD N
% NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
After IN N
unilateral JJ N
otoplasty JJ N
no DT N
patient NN N
needed VBD N
droperidol NN N
, , N
but CC N
after IN N
bilateral JJ N
otoplasty NN N
, , N
12 CD N
of IN N
19 CD N
of IN N
the DT N
atropine-treated JJ N
and CC N
4 CD N
of IN N
18 CD N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
of IN N
the DT N
scopolamine-treated JJ N
patients NNS N
needed VBN N
droperidol NN N
The DT N
mean JJ N
numbers NNS N
of IN N
doses NNS N
of IN N
droperidol NN N
were VBD N
0.8+/-0.9 JJ N
and CC N
0.3+/-0.6 JJ N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
, , N
respectively RB N
Two CD N
additional JJ N
patients NNS N
, , N
wearing VBG N
half NN N
of IN N
the DT N
TTS-scopolamine NNP N
patch NN N
, , N
suffered VBD N
from IN N
mild JJ N
central JJ N
anticholinergic JJ N
syndrome NN N
CONCLUSION NNP N
TTS-scopolamine JJ N
offers NNS N
effective JJ N
prophylaxis NN N
against IN N
PONV NNP N
( ( N
auriculoemetic JJ N
reflex NN N
) ) N
, , N
but CC N
does VBZ N
not RB N
protect VB N
from IN N
bradycardia NN N
( ( N
auriculocardiac JJ N
reflex NN N
) ) N
in IN N
otoplasty NN N
Cutting NNP N
of IN N
the DT N
TTS-scopolamine NNP N
patch NN N
may MD N
lead VB N
to TO N
undesirable JJ N
side NN N
effects NNS N
-DOCSTART- -X- O O 11374137

[ JJ N
Advantages NNP N
of IN N
video NN N
assisted VBN N
thoracic NN N
surgery NN N
in IN N
the DT N
treatment NN N
of IN N
spontaneous JJ 4_p
pneumothorax NN 4_p
] NNP 4_p
Spontaneous JJ N
pneumothorax NN N
( ( N
SP NNP N
) ) N
is VBZ N
a DT N
disabling VBG N
condition NN N
mostly RB N
affecting VBG N
young JJ N
, , N
thin JJ N
and CC N
otherwise RB N
healthy JJ N
males NNS N
It PRP N
is VBZ N
usually RB N
caused VBN N
by IN N
ruptured JJ N
pleural JJ N
blebs NN N
The DT N
first JJ N
treatment NN N
is VBZ N
the DT N
insertion NN N
of IN N
a DT N
chest NN N
tube NN N
( ( N
ICT NNP N
) ) N
but CC N
in IN N
a DT N
great JJ N
number NN N
of IN N
patients NNS N
there EX N
is VBZ N
recurrence NN N
of IN N
the DT N
disease NN N
We PRP N
believe VBP N
that IN N
the DT N
video NN N
assisted VBN N
thoracoscopy NN N
( ( N
VATS NNP N
) ) N
is VBZ N
the DT N
best JJS N
treatment NN N
possible JJ N
because IN N
it PRP N
allows VBZ N
us PRP N
to TO N
treat VB N
the DT N
ruptured JJ N
bleb NN N
radically RB N
avoiding VBG N
any DT N
recurrence NN N
In IN N
order NN N
to TO N
prove VB N
it PRP N
, , N
40 CD N
patients NNS N
admitted VBN N
in IN N
a DT N
five-year JJ N
period NN N
, , N
with IN N
a DT N
SP NNP N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
be VB N
treated VBN N
by IN N
ICT NNP N
or CC N
VATS NNP N
The DT N
ICT JJ N
patients NNS N
were VBD N
in IN N
the DT N
hospital NN N
a DT N
mean JJ N
time NN N
of IN N
7.5 CD N
( ( N
4 CD N
to TO N
15 CD N
) ) N
days NNS N
and CC N
the DT N
VATS NNP N
patients NNS N
, , N
5.3 CD N
( ( N
2 CD N
to TO N
7 CD N
) ) N
days NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
ICT JJ N
patients NNS N
required VBN N
analgesic JJ N
drugs NNS N
during IN N
76.8 CD N
+/- JJ N
31 CD N
hours NNS N
and CC N
VATS NNP N
patients NNS N
38.4 CD N
+/- JJ N
13 CD N
hours NNS N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
From IN N
the DT N
ICT NNP N
group NN N
, , N
8 CD N
( ( N
53 CD N
% NN N
) ) N
patients NNS N
had VBD N
recurrence NN N
of IN N
the DT N
disease NN N
and CC N
6 CD N
( ( N
40 CD N
% NN N
) ) N
had VBD N
a DT N
prolonged JJ N
air NN N
leak NN N
, , N
while IN N
none NN N
of IN N
the DT N
patients NNS N
of IN N
the DT N
VATS NNP N
group NN N
had VBD N
any DT N
complication NN N
( ( N
< NNP N
.001 NNP N
) ) N
Cost NN N
of IN N
ICT NNP N
and CC N
VATS NNP N
were VBD N
$ $ N
850 CD N
and CC N
$ $ N
1730 CD N
, , N
respectively RB N
According VBG N
to TO N
these DT N
results NNS N
, , N
VATS NNP N
should MD N
be VB N
the DT N
treatment NN N
of IN N
choice NN N
in IN N
SP NNP N
patients NNS N
It PRP N
treats VBZ N
the DT N
cause NN N
of IN N
the DT N
disease NN N
It PRP N
also RB N
reduces VBZ N
the DT N
hospitalization NN N
time NN N
, , N
the DT N
use NN N
of IN N
analgesic JJ N
drugs NNS N
post NN N
surgery NN N
, , N
decreases VBZ N
recurrence NN N
of IN N
the DT N
disease NN N
and CC N
the DT N
cost NN N
of IN N
the DT N
treatment NN N
Moreover RB N
, , N
the DT N
patients NNS N
were VBD N
back RB N
to TO N
work VB N
in IN N
less JJR N
than IN N
10 CD N
days NNS N
-DOCSTART- -X- O O 1707797

The DT N
instruction NN N
to TO N
refrain VB N
from IN N
blinking VBG N
affects NNS N
auditory JJ N
P3 NNP N
and CC N
N1 NNP N
amplitudes NNS N
Often NNP N
subjects VBZ N
have VBP N
been VBN N
instructed VBN N
to TO N
refrain VB N
from IN N
blinking VBG N
lest JJS N
their PRP$ N
evoked JJ N
EEG NNP N
potentials NNS N
should MD N
be VB N
distorted VBN N
We PRP N
studied VBD N
whether IN N
these DT N
very RB N
instructions NNS N
have VBP N
any DT N
impact NN N
on IN N
P3 NNP N
amplitude NN N
Two CD N
tones NNS N
were VBD N
presented VBN N
in IN N
random JJ N
order NN N
, , N
and CC N
subjects NNS N
had VBD N
to TO N
count VB N
the DT N
high-pitched JJ N
tones NNS N
Half PDT N
the DT N
subjects NNS N
were VBD N
instructed VBN N
not RB 4_p
to TO 4_p
blink VB 4_p
, , N
whereas IN N
this DT N
instruction NN N
was VBD N
omitted VBN N
for IN N
the DT N
other JJ N
subjects NNS N
Target NNP N
tones NNS N
evoked VBD N
larger JJR N
P3s NNP N
than IN N
non-targets NNS N
in IN N
the DT N
latter JJ N
group NN N
but CC N
not RB N
in IN N
the DT N
former JJ N
, , N
in IN N
particular JJ N
not RB N
in IN N
those DT N
subjects NNS N
that WDT N
actually RB N
blinked VBD N
rarely RB N
The DT N
groups NNS N
also RB N
differed VBN N
in IN N
their PRP$ N
N1 NNP N
amplitudes NNS N
These DT N
findings NNS N
might MD N
be VB N
relevant JJ N
to TO N
P3 NNP N
studies NNS N
working VBG N
with IN N
patients NNS N
and CC N
controls NNS N
: : N
the DT N
harder NN N
some DT N
frequently RB N
blinking JJ N
subjects NNS N
try VBP N
to TO N
refrain VB N
from IN N
blinking NN N
, , N
the DT N
smaller JJR N
might MD N
become VB N
their PRP$ N
P3 NNP N
amplitudes NNS N
Omitting VBG N
the DT N
instruction NN N
and CC N
using VBG N
off-line JJ N
blink NN N
subtraction NN N
procedures NNS N
seems VBZ N
a DT N
viable JJ N
alternative NN N
This DT N
study NN N
was VBD N
actually RB N
motivated VBN N
by IN N
discrepant JJ N
findings NNS N
on IN N
the DT N
effects NNS N
of IN N
the DT N
preceding VBG N
tone NN N
sequence NN N
on IN N
P3 NNP N
These DT N
discrepancies NNS N
could MD N
be VB N
largely RB N
resolved VBN N
by IN N
the DT N
instructional JJ N
variable NN N
, , N
in IN N
conjunction NN N
with IN N
different JJ N
tone NN N
intensities NNS N
It PRP N
is VBZ N
suggested VBN N
that IN N
subjects NNS N
who WP N
are VBP N
discouraged VBN N
from IN N
blinking VBG N
try NN N
to TO N
protect VB N
themselves PRP N
against IN N
the DT N
arousing JJ N
effects NNS N
of IN N
stimuli NN N
-DOCSTART- -X- O O 20661580

A DT N
comparison NN N
of IN N
the DT N
effect NN N
of IN N
short-term JJ N
aromatase NN N
inhibitor NN N
( ( N
letrozole JJ N
) ) N
and CC N
GnRH NNP N
agonist NN N
( ( N
triptorelin NN N
) ) N
versus NN N
case NN N
control NN N
on IN N
pregnancy NN N
rate NN N
and CC N
symptom NN N
and CC N
sign NN N
recurrence NN N
after IN N
laparoscopic JJ N
treatment NN N
of IN N
endometriosis NN N
PURPOSE NNP N
To TO N
compare VB N
the DT N
role NN N
of IN N
an DT N
aromatase NN N
inhibitor NN N
( ( N
letrozole JJ N
) ) N
with IN N
a DT N
GnRH NNP N
agonist NN N
( ( N
triptorelin NN N
) ) N
versus NN N
case NN N
control NN N
on IN N
the DT N
pregnancy NN N
rate NN N
and CC N
recurrence NN N
of IN N
symptoms NNS N
and CC N
signs NNS N
in IN N
patients NNS N
with IN N
endometriosis NN 4_p
METHODS NNP N
In IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
, , N
after IN N
treatment NN N
of IN N
144 CD 3_p
infertile JJ 4_p
women NNS 2_p
in IN N
their PRP$ N
reproductive JJ N
age NN N
by IN N
laparoscopy NN N
( ( N
whose WP$ N
endometriosis NN N
was VBD N
confirmed VBN N
by IN N
prior JJ N
laparoscopy NN N
) ) N
, , N
they PRP N
were VBD N
divided VBN N
into IN N
3 CD N
groups NNS N
: : N
group NN N
1 CD N
( ( N
47 CD 3_p
cases NNS N
) ) N
who WP N
received VBD N
letrozole NN N
for IN N
2 CD N
months NNS N
, , N
group NN N
2 CD N
( ( N
40 CD N
patients NNS N
) ) N
who WP N
were VBD N
prescribed VBN N
triptorelin NN N
for IN N
2 CD N
months NNS N
and CC N
group NN N
3 CD N
who WP N
were VBD N
57 CD N
patients NNS N
in IN N
the DT N
control NN N
group NN N
and CC N
did VBD N
not RB N
receive VB N
any DT N
medication NN N
We PRP N
followed VBD N
up RP N
each DT N
group NN N
at IN N
least JJS N
for IN N
12 CD N
months NNS N
after IN N
their PRP$ N
restoration NN N
of IN N
regular JJ N
cycle NN N
RESULTS JJ N
Pregnancy NNP N
rate NN N
was VBD N
23.4 CD N
% NN N
in IN N
group NN N
1 CD N
, , N
27.5 CD N
% NN N
in IN N
group NN N
2 CD N
, , N
and CC N
28.1 CD N
% NN N
in IN N
group NN N
3 CD N
The DT N
results NNS N
did VBD N
not RB N
show VB N
significant JJ N
differences NNS N
among IN N
the DT N
3 CD N
groups NNS N
Recurrence NNP N
rate NN N
of IN N
endometriosis NN N
was VBD N
6.4 CD N
% NN N
in IN N
group NN N
1 CD N
, , N
5 CD N
% NN N
group NN N
2 CD N
and CC N
5.3 CD N
% NN N
in IN N
group NN N
3 CD N
, , N
which WDT N
was VBD N
not RB N
statistically RB N
significantly RB N
different JJ N
as RB N
well RB N
CONCLUSION NNP N
Pregnancy NNP N
rate NN N
and CC N
endometriosis NN N
recurrence NN N
rate NN N
are VBP N
comparable JJ N
among IN N
the DT N
3 CD N
groups NNS N
-DOCSTART- -X- O O 17014731

Nordic NNP N
walking NN N
and CC N
chronic JJ N
low JJ N
back RB N
pain NN N
: : N
design NN N
of IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
BACKGROUND NNP N
Low NNP N
Back NNP N
Pain NNP N
is VBZ N
a DT N
major JJ N
public JJ N
health NN N
problem NN N
all DT N
over IN N
the DT N
western JJ N
world NN N
Active JJ N
approaches NNS N
including VBG N
exercise NN N
in IN N
the DT N
treatment NN N
of IN N
low JJ N
back RB N
pain NN N
results NNS N
in IN N
better JJR N
outcomes NNS N
for IN N
patients NNS N
, , N
but CC N
it PRP N
is VBZ N
not RB N
known VBN N
exactly RB N
which WDT N
types NNS N
of IN N
back NN N
exercises NNS N
are VBP N
most RBS N
beneficial JJ N
or CC N
whether IN N
general JJ N
physical JJ N
activity NN N
provide VBP N
similar JJ N
benefits NNS N
Nordic NNP N
Walking NNP N
is VBZ N
a DT N
popular JJ N
and CC N
fast JJ N
growing VBG N
type NN N
of IN N
exercise NN N
in IN N
Northern NNP N
Europe NNP N
Initial NNP N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
persons NNS N
performing VBG N
Nordic NNP N
Walking NNP N
are VBP N
able JJ N
to TO N
exercise VB N
longer JJR N
and CC N
harder RBR N
compared VBN N
to TO N
normal JJ N
walking VBG N
thereby RB N
increasing VBG N
their PRP$ N
cardiovascular JJ N
metabolism NN N
Until IN N
now RB N
no DT N
studies NNS N
have VBP N
been VBN N
performed VBN N
to TO N
investigate VB N
whether IN N
Nordic NNP N
Walking NNP N
has VBZ N
beneficial JJ N
effects NNS N
in IN N
relation NN N
to TO N
low VB N
back RB N
pain NN N
The DT N
primary JJ N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
investigate VB N
whether IN N
supervised JJ N
Nordic NNP N
Walking NNP N
can MD N
reduce VB N
pain NN N
and CC N
improve VB N
function NN N
in IN 4_p
a DT 4_p
population NN 4_p
of IN 4_p
chronic JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
patients NNS 4_p
when WRB N
compared VBN N
to TO N
unsupervised JJ N
Nordic NNP N
Walking NNP N
and CC N
advice NN N
to TO N
stay VB N
active JJ N
In IN N
addition NN N
we PRP N
investigate VBP N
whether IN N
there EX N
is VBZ N
an DT N
increase NN N
in IN N
the DT N
cardiovascular JJ N
metabolism NN N
in IN N
persons NNS N
performing VBG N
supervised VBD N
Nordic NNP N
Walking NNP N
compared VBN N
to TO N
persons NNS N
who WP N
are VBP N
advised VBN N
to TO N
stay VB N
active JJ N
Finally RB N
, , N
we PRP N
investigate VBP N
whether IN N
there EX N
is VBZ N
a DT N
difference NN N
in IN N
compliance NN N
between IN N
persons NNS N
receiving VBG N
supervised VBD N
Nordic NNP N
Walking NNP N
and CC N
persons NNS N
doing VBG N
unsupervised JJ N
Nordic NNP N
Walking NNP N
METHODS NNP N
One CD 4_p
hundred CD 4_p
and CC 4_p
fifty JJ 4_p
patients NNS 4_p
with IN 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
for IN 4_p
at IN 4_p
least JJS 4_p
eight CD 4_p
weeks NNS 4_p
and CC 4_p
referred VBD 4_p
to TO 4_p
a DT 4_p
specialized JJ 4_p
secondary JJ 4_p
sector NN 4_p
outpatient NN 4_p
back RB 4_p
pain NN 4_p
clinic NN 4_p
are VBP 4_p
included VBN 4_p
in IN 4_p
the DT 4_p
study NN 4_p
After IN N
completion NN N
of IN N
the DT N
standard NN N
back RB N
centre JJ N
treatment NN N
patients NNS N
are VBP N
randomized VBN N
into IN N
one CD N
of IN N
three CD N
groups NNS N
: : N
A DT N
) ) N
Nordic NNP N
Walking NNP N
twice RB N
a DT N
week NN N
for IN N
eight CD N
weeks NNS N
under IN N
supervision NN N
of IN N
a DT N
specially RB N
trained JJ N
instructor NN N
; : N
B NNP N
) ) N
Unsupervised VBD N
Nordic NNP N
Walking NNP N
for IN N
eight CD N
weeks NNS N
after IN N
one CD N
training NN N
session NN N
with IN N
an DT N
instructor NN N
; : N
C NNP N
) ) N
A DT N
one CD N
hour NN N
motivational JJ N
talk NN N
including VBG N
advice NN N
to TO N
stay VB N
active JJ N
Outcome NN N
measures NNS N
are VBP N
pain NN N
, , N
function NN N
, , N
overall JJ N
health NN N
, , N
cardiovascular JJ N
ability NN N
and CC N
activity NN N
level NN N
RESULTS NNP N
No NNP N
results NNS N
available JJ N
at IN N
this DT N
point NN N
DISCUSSION NNP N
This DT N
study NN N
will MD N
investigate VB N
the DT N
effect NN N
of IN N
Nordic NNP N
Walking VBG N
on IN N
pain NN N
and CC N
function NN N
in IN N
a DT N
population NN N
of IN N
people NNS N
with IN N
chronic JJ N
LBP NNP N
-DOCSTART- -X- O O 23811316

Arm-cranking JJ N
exercise NN N
reduced VBN N
oxidative JJ N
damage NN N
in IN N
adults NNS N
with IN N
chronic JJ N
spinal JJ N
cord NN N
injury NN N
OBJECTIVE UH N
To TO N
assess VB N
the DT N
effect NN N
of IN N
a DT N
12-week JJ N
arm-cranking JJ N
exercise NN N
program NN N
on IN N
reducing VBG N
oxidative JJ N
damage NN N
in IN N
untrained JJ N
adults NNS N
with IN N
chronic JJ N
spinal JJ N
cord NN N
injury NN N
( ( N
SCI NNP N
) ) N
DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
SETTING CC N
Community-based JJ N
supervised JJ N
intervention NN N
PARTICIPANTS NNP N
Male NNP N
adults NNS N
with IN N
complete JJ N
SCI NNP N
at IN N
or CC N
below IN N
the DT N
fifth JJ N
thoracic NN N
level NN N
( ( N
T5 NNP N
) ) N
( ( N
N=17 NNP N
) ) N
volunteered VBD N
for IN N
this DT N
study NN N
Participants NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
intervention NN N
( ( N
n=9 JJ N
) ) N
or CC N
control NN N
( ( N
n=8 JJ N
) ) N
group NN N
using VBG N
a DT N
concealed JJ N
method NN N
INTERVENTION VB N
A DT N
12-week JJ N
arm-cranking JJ N
exercise NN N
program NN N
, , N
3 CD N
sessions/wk NN N
, , N
consisting VBG N
of IN N
warming-up JJ N
( ( N
10-15min JJ N
) ) N
followed VBN N
by IN N
a DT N
main JJ N
part NN N
in IN N
arm-crank JJ N
( ( N
20-30min JJ N
[ NN N
increasing VBG N
2min CD N
and CC N
30s CD N
every DT N
3wk CD N
] NN N
) ) N
at IN N
a DT N
moderate JJ N
work NN N
intensity NN N
of IN N
50 CD N
% NN N
to TO N
65 CD N
% NN N
of IN N
the DT N
heart NN N
rate NN N
reserve NN N
( ( N
starting VBG N
at IN N
50 CD N
% NN N
and CC N
increasing VBG N
5 CD N
% NN N
every DT N
3 CD N
weeks NNS N
) ) N
and CC N
by IN N
a DT N
cooling-down JJ N
period NN N
( ( N
5-10min JJ N
) ) N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Plasmatic NNP N
levels NNS N
of IN N
total JJ N
antioxidant JJ N
status NN N
as RB N
well RB N
as IN N
erythrocyte NN N
glutathione NN N
peroxidase NN N
activity NN N
were VBD N
measured VBN N
Lipid NNP N
and CC N
protein JJ N
oxidation NN N
were VBD N
determined VBN N
as IN N
malondialdehyde NN N
and CC N
carbonyl NN N
group NN N
levels NNS N
, , N
respectively RB N
Furthermore NNP N
, , N
physical JJ N
fitness NN N
and CC N
body NN N
composition NN N
were VBD N
assessed VBN N
RESULTS VB N
When WRB N
compared VBN N
with IN N
baseline NN N
results NNS N
, , N
maximum JJ N
oxygen NN N
consumption NN N
was VBD N
significantly RB N
increased VBN N
( ( N
P=.031 NNP N
) ) N
, , N
suggesting VBG N
an DT N
improvement NN N
in IN N
physical JJ N
fitness NN N
in IN N
the DT N
intervention NN N
group NN N
Regarding VBG N
the DT N
antioxidant NN N
defense NN N
system NN N
, , N
it PRP N
was VBD N
found VBN N
that IN N
both DT N
total JJ N
antioxidant NN N
status NN N
( ( N
P=.014 NNP N
) ) N
and CC N
erythrocyte $ N
glutathione NN N
peroxidase NN N
activity NN N
( ( N
P=.027 NNP N
) ) N
were VBD N
significantly RB N
increased VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
training NN N
program NN N
As IN N
a DT N
consequence NN N
, , N
plasmatic JJ N
levels NNS N
of IN N
malondialdehyde NN N
( ( N
P=.008 NNP N
) ) N
and CC N
carbonyl JJ N
groups NNS N
( ( N
P=.022 NNP N
) ) N
were VBD N
significantly RB N
reduced VBN N
CONCLUSION VB N
A DT N
12-week JJ N
arm-cranking JJ N
exercise NN N
program NN N
improved VBD N
the DT N
antioxidant NN N
defense NN N
system NN N
in IN N
adults NNS N
with IN N
chronic JJ N
SCI NNP N
, , N
which WDT N
may MD N
finally RB N
attenuate VB N
both DT N
lipid JJ N
and CC N
protein JJ N
oxidation NN N
in IN N
this DT N
population NN N
-DOCSTART- -X- O O 8131429

Videofluoroscopic NNP N
evidence NN N
of IN N
aspiration NN N
predicts NNS N
pneumonia NN N
and CC N
death NN N
but CC N
not RB N
dehydration NN N
following VBG N
stroke NN N
In IN N
order NN N
to TO N
assess VB N
the DT N
risk NN N
of IN N
pneumonia NN N
, , N
dehydration NN N
, , N
and CC N
death NN N
associated VBN N
with IN N
videofluoroscopic JJ N
evidence NN N
of IN N
aspiration NN N
following VBG N
stroke NN 4_p
, , N
the DT N
clinical JJ N
records NNS N
of IN N
26 CD 3_p
patients NNS 3_p
with IN N
aspiration NN N
and CC N
33 CD 3_p
randomly RB N
selected VBN N
, , N
case-matched JJ N
, , N
dysphagic JJ 4_p
controls NNS 4_p
without IN 4_p
videofluoroscopic JJ 4_p
evidence NN 4_p
of IN 4_p
aspiration NN 4_p
were VBD N
reviewed VBN N
The DT N
videofluoroscopic NN N
modified VBD N
barium NN N
swallow NN N
technique NN N
included VBD N
5 CD N
ml-thin JJ N
and CC N
thick JJ N
liquid NN N
barium NN N
, , N
5 CD N
ml NN N
barium NN N
pudding NN N
, , N
and CC N
1/4 CD N
cookie NN N
coated VBN N
with IN N
barium NN N
, , N
plus CC N
additional JJ N
20 CD N
and CC N
30 CD N
ml NN N
of IN N
thin JJ N
liquid JJ N
barium NN N
Patients NNS N
were VBD N
assessed VBN N
a DT N
mean NN N
of IN N
2 CD N
+/- JJ N
1 CD N
SD NNP N
months NNS N
poststroke NN 4_p
and CC N
were VBD N
followed VBN N
for IN N
a DT N
mean NN N
of IN N
16 CD N
+/- JJ N
8 CD N
SD NNP N
months NNS N
poststroke RB 4_p
The DT N
odds NNS N
ratio NN N
for IN N
developing VBG N
pneumonia NN N
was VBD N
7.6 CD N
times NNS N
greater JJR N
for IN N
those DT N
who WP N
aspirated VBD N
any DT N
amount NN N
of IN N
barium NN N
irrespective NN N
of IN N
its PRP$ N
consistency NN N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
The DT N
odds NNS N
ratio NN N
for IN N
developing VBG N
pneumonia NN N
was VBD N
5.6 CD N
times NNS N
greater JJR N
for IN N
those DT N
who WP N
aspirated VBD N
thickened JJ N
liquids NNS N
or CC N
more JJR N
solid JJ N
consistencies NNS N
compared VBN N
with IN N
those DT N
who WP N
did VBD N
not RB N
aspirate VB N
, , N
or CC N
who WP N
aspirated VBD N
thin JJ N
liquids NNS N
only RB N
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
Dehydration NN N
was VBD N
unrelated JJ N
to TO N
the DT N
presence NN N
or CC N
absence NN N
of IN N
aspiration NN N
The DT N
odds NNS N
ratio NN N
for IN N
death NN N
was VBD N
9.2 CD N
times NNS N
greater JJR N
for IN N
those DT N
aspirating VBG N
thickened JJ N
liquids NNS N
or CC N
more JJR N
solid JJ N
consistencies NNS N
compared VBN N
with IN N
those DT N
who WP N
did VBD N
not RB N
aspirate VB N
or CC N
who WP N
aspirated VBD N
thin JJ N
liquids NNS N
only RB N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
Aspiration NNP N
documented VBN N
by IN N
modified JJ N
videofluoroscopic NN N
barium NN N
swallow NN N
technique NN N
is VBZ N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN N
in IN N
risk NN N
of IN N
pneumonia NN N
and CC N
death NN N
but CC N
not RB N
dehydration NN N
following VBG N
stroke NN N
-DOCSTART- -X- O O 12830748

Clinic JJ N
visit NN N
and CC N
waiting NN N
: : N
patient JJ N
education NN N
and CC N
satisfaction NN N
Patients NNS N
who WP N
were VBD N
taught VBN N
about IN N
their PRP$ N
health NN 4_p
problems NNS 4_p
while IN N
waiting VBG N
in IN N
the DT N
clinic NN N
( ( N
n JJ N
= NNP N
104 CD 3_p
) ) N
were VBD N
significantly RB N
more RBR N
satisfied JJ N
with IN N
the DT N
education NN N
received VBD N
during IN N
that DT N
visit NN N
than IN N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
101 CD 3_p
) ) N
The DT N
longer JJR N
patients NNS N
waited VBD N
in IN N
the DT N
clinic NN N
to TO N
see VB N
their PRP$ N
providers NNS N
, , N
the DT N
less JJR N
satisfied JJ N
they PRP N
were VBD N
with IN N
the DT N
clinic JJ N
visit NN N
-DOCSTART- -X- O O 19159477

An DT N
emergency NN N
clinical JJ N
pathway NN N
for IN N
stroke NN N
patients NNS N
-- : N
results NNS N
of IN N
a DT N
cluster NN N
randomised VBN N
trial NN N
( ( N
isrctn41456865 NN N
) ) N
BACKGROUND NNP N
Emergency NNP N
Clinical NNP N
Pathways NNP N
( ( N
ECP NNP N
) ) N
for IN N
stroke NN N
have VBP N
never RB N
been VBN N
tested VBN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
( ( N
RCTs NNP N
) ) N
OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
an DT N
ECP NNP N
for IN N
stroke NN N
patients NNS N
in IN N
Latium NNP N
( ( N
Italy NNP N
) ) N
emergency NN N
system NN N
METHODS NNP N
cluster-RCT NN N
designed VBN N
to TO N
compare VB N
stroke JJ N
patient JJ N
referrals NNS N
by IN N
Emergency NNP N
Medical NNP N
Service NNP N
( ( N
EMS NNP N
) ) N
and CC N
Emergency NNP N
Room NNP N
( ( N
ER NNP N
) ) N
health NN N
professionals NNS N
trained VBN N
in IN N
the DT N
ECP NNP N
, , N
with IN N
those DT N
of IN N
non-trained JJ N
EMS NNP N
and CC N
ER NNP N
controls NNS N
Primary NNP N
outcome JJ N
measure NN N
was VBD N
the DT N
proportion NN N
of IN N
eligible JJ 4_p
( ( 4_p
aged VBN 4_p
< NNP 4_p
/= $ 4_p
80 CD 4_p
and CC 4_p
symptom JJ 4_p
onset NN 4_p
< NNP 4_p
/= VBZ 4_p
6 CD 4_p
hours NNS 4_p
) ) 4_p
stroke VBD 4_p
patients NNS 4_p
referred VBN 4_p
to TO 4_p
a DT 4_p
stroke NN 4_p
unit NN 4_p
( ( 4_p
SU NNP 4_p
) ) 4_p
Intention NN N
to TO N
treat VB N
( ( N
ITT NNP N
) ) N
and CC N
per-protocol JJ N
( ( N
PP NNP N
) ) N
analyses NNS N
were VBD N
performed VBN N
, , N
and CC N
risk NN N
ratios NNS N
( ( N
RR NNP N
) ) N
adjusted VBN N
by IN N
age NN N
, , N
gender NN N
and CC N
area NN N
, , N
were VBD N
calculated VBN N
RESULTS JJ N
2656 CD N
patients NNS N
in IN N
the DT N
intervention NN N
arm NN N
and CC N
2239 CD N
in IN N
the DT N
control NN N
arm NN N
required VBN N
assistance NN N
; : N
78.3 CD N
% NN N
of IN N
the DT N
former JJ N
and CC N
80.6 CD N
% NN N
of IN N
the DT N
latter NN N
were VBD N
admitted VBN N
to TO N
hospitals NNS N
, , N
and CC N
respectively RB N
74.8 CD N
% NN N
and CC N
78.3 CD N
% NN N
were VBD N
confirmed VBN N
strokes NNS N
Of IN N
the DT N
eligible JJ N
confirmed JJ N
strokes NNS N
, , N
106/434 CD N
( ( N
24.4 CD N
% NN N
) ) N
in IN N
the DT N
intervention NN N
arm NN N
and CC N
43/328 CD N
( ( N
13.1 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
arm NN N
were VBD N
referred VBN N
to TO N
the DT N
SU NNP N
in IN N
the DT N
ITT NNP N
analysis NN N
( ( N
RR NNP N
= NNP N
2.01 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.79-4.00 NN N
) ) N
, , N
and CC N
respectively RB N
105/243 CD N
( ( N
43.2 CD N
% NN N
) ) N
and CC N
43/311 CD N
( ( N
13.8 CD N
% NN N
) ) N
in IN N
the DT N
PP NNP N
analysis NN N
( ( N
RR NNP N
= NNP N
3.21 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.62-4.98 JJ N
) ) N
Of IN N
patients NNS N
suitable JJ N
for IN N
i.v NN N
thrombolysis NN N
, , N
15/175 CD N
( ( N
8.6 CD N
% NN N
) ) N
in IN N
the DT N
intervention NN N
arm NN N
and CC N
2/115 CD N
( ( N
1.7 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
arm NN N
received VBN N
thrombolysis NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
in IN N
the DT N
ITT NNP N
analysis NN N
, , N
and CC N
respectively RB N
15/99 CD N
( ( N
15.1 CD N
% NN N
) ) N
and CC N
2/107 CD N
( ( N
1.9 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
in IN N
the DT N
PP NNP N
analysis NN N
CONCLUSION NNP N
Our PRP$ N
data NNS N
suggest VBP N
potenti JJ N
efficiency NN N
and CC N
feasibility NN N
of IN N
an DT N
ECP NNP N
The DT N
integration NN N
of IN N
EMS NNP N
and CC N
ERs NNP N
with IN N
SU NNP N
networks NNS N
for IN N
organised JJ N
acute NN N
stroke NN N
care NN N
is VBZ N
feasible JJ N
and CC N
may MD N
ameliorate VB N
the DT N
quality NN N
of IN N
care NN N
for IN N
stroke NN N
patients NNS N
TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
( ( N
ISRCTN41456865 NNP N
) ) N
-DOCSTART- -X- O O 24488157

A DT N
parent-mediated JJ N
intervention NN N
that WDT N
targets VBZ N
responsive JJ N
parental JJ N
behaviors NNS N
increases VBZ N
attachment JJ N
behaviors NNS N
in IN N
children NNS 1_p
with IN N
ASD NNP 4_p
: : N
results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
The DT N
current JJ N
study NN N
is VBZ N
a DT N
randomized JJ N
clinical JJ N
trial NN N
evaluating VBG N
the DT N
efficacy NN N
of IN N
Focused JJ N
Playtime NNP N
Intervention NNP N
( ( N
FPI NNP N
) ) N
in IN N
a DT N
sample NN N
of IN N
70 CD 3_p
children NNS 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
This DT N
parent-mediated JJ N
intervention NN N
has VBZ N
previously RB N
been VBN N
shown VBN N
to TO N
significantly RB N
increase VB N
responsive JJ N
parental JJ N
communication NN N
( ( N
Siller NNP N
et RB N
al RB N
in IN N
J NNP N
Autism NNP N
Dev NNP N
Disord NNP N
43:540-555 CD N
, , N
2013a CD N
) ) N
The DT N
current JJ N
analyses NNS N
focus VBP N
on IN N
children NNS N
's POS N
attachment NN N
related VBN N
outcomes NNS N
Results NNS N
revealed VBD N
that IN N
children NNS N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
FPI NNP N
showed VBD N
bigger JJR N
increases NNS N
in IN N
attachment-related JJ N
behaviors NNS N
, , N
compared VBN N
to TO N
children NNS N
assigned VBN N
to TO N
the DT N
control NN N
condition NN N
Significant JJ N
treatment NN N
effects NNS N
of IN N
FPI NNP N
were VBD N
found VBN N
for IN N
both DT N
an DT N
observational JJ N
measure NN N
of IN N
attachment-related JJ N
behaviors NNS N
elicited VBD N
during IN N
a DT N
brief JJ N
separation-reunion JJ N
episode NN N
and CC N
a DT N
questionnaire JJ N
measure NN N
evaluating VBG N
parental JJ N
perceptions NNS N
of IN N
child JJ N
attachment NN N
The DT N
theoretical JJ N
and CC N
clinical JJ N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
-DOCSTART- -X- O O 24732169

Effect NN N
of IN N
a DT N
mixed JJ N
kinesio JJ N
taping-compression NN N
technique NN N
on IN N
quality NN N
of IN N
life NN N
and CC N
clinical JJ N
and CC N
gait JJ N
parameters NNS N
in IN N
postmenopausal JJ 4_p
women NNS 2_p
with IN N
chronic JJ 4_p
venous JJ 4_p
insufficiency NN 4_p
: : N
double-blinded JJ N
, , N
randomized VBN N
controlled VBN N
trial NN N
OBJECTIVE UH N
To TO N
investigate VB N
the DT N
short-term JJ N
effect NN N
of IN N
a DT N
mixed JJ N
Kinesio NNP N
taping NN N
( ( N
KT NNP N
) ) N
model NN N
on IN N
range NN N
of IN N
ankle JJ N
motion NN N
( ( N
ROAM NNP N
) ) N
, , N
gait NN N
, , N
pain NN N
, , N
perimeter NN N
of IN N
lower JJR N
limbs NN N
, , N
and CC N
quality NN N
of IN N
life NN N
in IN N
postmenopausal JJ 4_p
women NNS N
with IN N
chronic JJ 4_p
venous JJ 4_p
insufficiency NN 4_p
( ( 4_p
CVI NNP 4_p
) ) 4_p
DESIGN NNP N
Double-blinded JJ N
, , N
randomized VBN N
controlled VBN N
trial NN N
SETTING NNP N
Clinical JJ N
setting NN N
PARTICIPANTS NNP N
Consecutive JJ N
postmenopausal NN N
women NNS N
( ( N
N=130 NNP N
; : N
mean JJ N
age NN N
± NNP N
SD NNP N
, , N
65.44±14.7y CD N
) ) N
with IN N
mild JJ N
CVI NNP N
No NNP N
participant NN N
withdrew VBD N
because IN N
of IN N
adverse JJ N
effects NNS N
INTERVENTION NN N
Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
( ( N
1 CD N
) ) N
an DT N
experimental JJ N
group NN N
to TO N
receive VB N
a DT N
mixed JJ N
KT-compression NNP N
treatment NN N
following VBG N
KT NNP N
recommendations NNS N
for IN N
gastrocnemius JJ N
muscle NN N
enhancement NN N
and CC N
functional JJ N
correction NN N
of IN N
the DT N
ankle NN N
, , N
and CC N
adding VBG N
2 CD N
tapes NNS N
to TO N
simulate VB N
traditional JJ N
compression NN N
bandages NNS N
( ( N
no DT N
KT NNP N
guidelines NNS N
) ) N
; : N
or CC N
( ( N
2 CD N
) ) N
a DT N
placebo NN N
control NN N
group NN N
for IN N
sham NN N
KT NNP N
Both DT N
interventions NNS N
were VBD N
performed VBN N
3 CD N
times NNS N
a DT N
week NN N
during IN N
a DT N
4-week JJ N
period NN N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
ROAM NNP N
, , N
gait NN N
, , N
pain NN N
, , N
perimeter NN N
of IN N
right NN N
and CC N
left VBD N
lower JJR N
limb NN N
, , N
and CC N
quality NN N
of IN N
life NN N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
48 CD N
hours NNS N
posttreatment NN N
RESULTS NNP N
Quality NNP N
of IN N
life NN N
was VBD N
better RBR N
in IN N
the DT N
intervention NN N
group NN N
by IN N
a DT N
mean NN N
of IN N
8.76 CD N
points NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
4.96-12.55 JJ N
) ) N
The DT N
experimental JJ N
group NN N
also RB N
showed VBD N
significant JJ N
pre-/posttreatment JJ N
improvements NNS N
in IN N
both DT N
lower JJR N
limbs NN N
in IN N
gait JJ N
dorsiflexion NN N
ROAM NNP N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.02-2.49 JJ N
) ) N
, , N
cadence NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
3.45-1.47 NNP N
) ) N
, , N
stride JJ N
length NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
21.48-10.83 JJ N
) ) N
, , N
step JJ N
length NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.68-6.61 JJ N
) ) N
, , N
stance NN N
phase NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
61-107 JJ N
) ) N
, , N
and CC N
foot NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
.56-.92 NNP N
) ) N
and CC N
malleolus $ N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.15-1.63 JJ N
) ) N
circumference NN N
None NN N
of IN N
these DT N
variables NNS N
were VBD N
significantly RB N
modified VBN N
in IN N
the DT N
placebo NN N
group NN N
Both DT N
groups NNS N
reported VBD N
a DT N
significant JJ N
reduction NN N
in IN N
pain NN N
CONCLUSIONS NNP N
Ankle NNP N
dorsiflexion NN N
during IN N
gait NN N
, , N
walking VBG N
parameters NNS N
, , N
peripheral JJ N
edema NN N
, , N
venous JJ N
pain NN N
, , N
and CC N
quality NN N
of IN N
life NN N
remain VBP N
improved VBN N
in IN N
patients NNS N
with IN N
CVI NNP N
at IN N
1 CD N
month NN N
after IN N
mixed JJ N
KT-compression NNP N
therapy NN N
KT NNP N
may MD N
have VB N
a DT N
placebo NN N
effect NN N
on IN N
pain NN N
perception NN N
-DOCSTART- -X- O O 25455414

Reducing VBG N
iodine JJ N
load NN N
in IN N
hepatic JJ N
CT NNP N
for IN N
patients NNS N
with IN N
chronic JJ 4_p
liver NN 4_p
disease NN 4_p
with IN N
a DT N
combination NN N
of IN N
low-tube-voltage NN N
and CC N
adaptive JJ N
statistical JJ N
iterative JJ N
reconstruction NN N
PURPOSE NNP N
To TO N
prospectively RB N
assess VB N
the DT N
effect NN N
of IN N
reduced JJ N
iodine JJ N
load NN N
to TO N
contrast VB N
enhancement NN N
, , N
image NN N
quality NN N
, , N
and CC N
detectability NN N
of IN N
hepatocellular JJ N
carcinomas NN N
( ( N
HCCs NNP N
) ) N
in IN N
hepatic JJ N
CT NNP N
with IN N
a DT N
combination NN N
of IN N
80 CD N
kVp NNS N
tube JJ N
voltage NN N
setting NN N
and CC N
adaptive JJ N
statistical JJ N
iterative JJ N
reconstruction NN N
( ( N
ASIR NNP N
) ) N
technique NN N
in IN N
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
liver NN 4_p
disease NN 4_p
MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
HIPAA-compliant NNP N
study NN N
was VBD N
approved VBN N
by IN N
our PRP$ N
institutional JJ N
review NN N
board NN N
and CC N
written VBN N
informed JJ N
consent NN N
was VBD N
obtained VBN N
in IN N
all DT N
patients NNS N
During IN N
a DT N
recent JJ N
9-month JJ N
period NN N
, , N
170 CD 3_p
consecutive JJ N
patients NNS N
( ( N
114 CD 3_p
men NNS 2_p
and CC N
56 CD 3_p
women NNS 2_p
; : N
age NN N
range NN N
, , N
40-85 JJ 1_p
years NNS 1_p
; : N
mean VB N
, , N
67.7 CD N
years NNS N
) ) N
with IN N
suspected VBN N
chronic JJ N
liver NN N
diseases NNS N
were VBD N
randomized VBN N
into IN N
three CD N
CT NNP N
groups NNS N
according VBG N
to TO N
the DT N
following JJ N
iodine-load NN N
and CC N
tube-voltage NN N
protocols NNS N
: : N
600 CD N
milligram NN N
per IN N
kilogram NN N
body NN N
weight NN N
( ( N
mg/kg NN N
) ) N
iodine NN N
load NN N
and CC N
120 CD N
peak NN N
kilovolt NN N
( ( N
kVp NN N
) ) N
tube NN N
voltage NN N
setting VBG N
( ( N
600-120 JJ N
group NN N
) ) N
, , N
500 CD N
mg/kg NN N
and CC N
80 CD N
kVp NN N
( ( N
500-80 JJ N
group NN N
) ) N
, , N
and CC N
400mg/kg CD N
and CC N
80 CD N
kVp NN N
( ( N
400-80 JJ N
group NN N
) ) N
Analysis NN N
of IN N
variance NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
differences NNS N
in IN N
CT NNP N
number NN N
, , N
background NN N
noise NN N
, , N
signal-to-noise JJ N
ratio NN N
( ( N
SNR NNP N
) ) N
, , N
effective JJ N
dose NN N
, , N
HCC-to-liver NNP N
contrast-to-noise NN N
ratio NN N
( ( N
CNR NNP N
) ) N
, , N
and CC N
figure NN N
of IN N
merit NN N
( ( N
FOM NNP N
) ) N
Sensitivity NNP N
, , N
specificity NN N
, , N
and CC N
area NN N
under IN N
the DT N
receiver-operating-characteristic JJ N
curve NN N
( ( N
AUC NNP N
) ) N
were VBD N
compared VBN N
to TO N
assess VB N
the DT N
detectability NN N
of IN N
HCCs NNP N
RESULTS NNP N
Vascular NNP N
and CC N
hepatic JJ N
enhancement NN N
in IN N
the DT N
400-80 JJ N
and CC N
500-80 JJ N
groups NNS N
was VBD N
comparable JJ N
to TO N
or CC N
greater JJR N
than IN N
that DT N
in IN N
the DT N
600-120 JJ N
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
Subjective JJ N
image NN N
quality NN N
was VBD N
comparable JJ N
among IN N
the DT N
three CD N
groups NNS N
Sensitivity NNP N
, , N
specificity NN N
, , N
and CC N
AUC NNP N
for IN N
detecting VBG N
HCCs NNP N
were VBD N
comparable JJ N
among IN N
the DT N
groups NNS N
The DT N
effective JJ N
dose NN N
was VBD N
kept VBN N
low JJ N
( ( N
3.3-4.1 JJ N
mSv NN N
) ) N
in IN N
all DT N
three CD N
groups NNS N
CONCLUSION NNP N
Iodine NNP N
load NN N
can MD N
be VB N
reduced VBN N
by IN N
33 CD N
% NN N
in IN N
CT NNP N
of IN N
the DT N
liver NN N
with IN N
a DT N
combination NN N
of IN N
80 CD N
kVp NNS N
tube JJ N
voltage NN N
setting NN N
and CC N
ASIR NNP N
technique NN N
, , N
without IN N
compromising VBG N
the DT N
contrast NN N
enhancement NN N
, , N
image NN N
quality NN N
, , N
and CC N
detection NN N
of IN N
HCCs NNP N
-DOCSTART- -X- O O 17450704

Women NNP 4_p
's POS 4_p
responses NNS 4_p
to TO 4_p
information NN 4_p
on IN 4_p
mammographic JJ 4_p
breast NN 4_p
density NN 4_p
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
negative JJ N
and CC N
positive JJ N
outcomes NNS N
of IN N
providing VBG N
mammographic JJ N
breast NN N
density NN N
( ( N
MBD NNP N
) ) N
information NN N
to TO N
participants NNS N
of IN N
a DT N
screening JJ N
program NN N
A DT N
randomized JJ N
experiment NN N
was VBD N
conducted VBN N
with IN N
a DT N
sample NN N
of IN N
618 CD N
women NNS N
50 CD N
years NNS N
or CC N
older JJR N
with IN N
MBD NNP N
greater JJR N
than IN N
50 CD N
% NN N
of IN N
breast NN N
volume NN N
The DT N
intervention NN N
consisted VBD N
of IN N
reporting VBG N
the DT N
presence NN N
of IN N
MBD NNP N
in IN N
the DT N
screening NN N
mammography NN N
results NNS N
letter NN N
that WDT N
was VBD N
sent VBN N
along IN N
with IN N
an DT N
information NN N
pamphlet NN N
Compared VBN N
to TO N
the DT N
controls NNS N
, , N
more JJR N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
described VBD N
the DT N
term NN N
breast NN N
density NN N
correctly RB N
and CC N
recognized VBD N
it PRP N
as IN N
a DT N
risk NN N
factor NN N
for IN N
breast NN N
cancer NN N
Although IN N
at IN N
the DT N
4-week JJ N
follow-up NN N
the DT N
intervention NN N
group NN N
indicated VBD N
that IN N
they PRP N
were VBD N
" JJ N
very RB N
likely JJ N
" NN N
to TO N
have VB N
an DT N
annual JJ N
clinical JJ N
breast NN N
examination NN N
more RBR N
frequently RB N
than IN N
controls NNS N
, , N
no DT N
differences NNS N
were VBD N
detected VBN N
at IN N
6 CD N
months NNS N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
on IN N
other JJ N
behavioural JJ N
or CC N
psychological JJ N
measures NNS N
, , N
although IN N
at IN N
the DT N
4-week JJ N
follow-up JJ N
the DT N
control NN N
group NN N
perceived VBD N
their PRP$ N
risk NN N
for IN N
breast NN N
cancer NN N
, , N
relative VBP N
to TO N
other JJ N
women NNS N
their PRP$ N
age NN N
, , N
as IN N
" PDT N
a DT N
lot NN N
lower JJR N
" NN N
than IN N
did VBD N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
The DT N
results NNS N
demonstrate VBP N
a DT N
feasible JJ N
and CC N
non-threatening JJ N
way NN N
to TO N
provide VB N
women NNS N
with IN N
important JJ N
personalized VBN N
information NN N
about IN N
breast NN N
cancer NN N
risk NN N
-DOCSTART- -X- O O 8091822

[ VB N
The DT N
anti-ischemic JJ N
effect NN N
of IN N
phosphodiesterase NN N
III NNP N
inhibitors NNS N
] NNP N
When WRB N
enoximone NN N
is VBZ N
acutely RB N
administered VBN N
to TO N
patients NNS 4_p
with IN 4_p
stable JJ 4_p
angina NNS 4_p
and CC 4_p
angiographically RB 4_p
proven JJ 4_p
relevant JJ 4_p
coronary JJ 4_p
stenosis NN 4_p
i.v NN 4_p
application NN 4_p
of IN 4_p
0.75 CD 4_p
mg/kg NN 4_p
exhibits NNS N
pronounced VBD N
antiischemic JJ N
effects NNS N
This DT N
could MD N
be VB N
observed VBN N
in IN N
patients NNS N
during IN N
exercise NN N
and CC N
in IN N
those DT N
in IN N
whom WP N
the DT N
ischemia NN N
was VBD N
provoked VBN N
by IN N
rapid JJ N
cardiac JJ N
stimulation NN N
The DT N
antiischemic JJ N
effects NNS N
were VBD N
documented VBN N
by IN N
relief NN N
of IN N
symptoms NNS N
, , N
reduction NN N
of IN N
ST-depression NNP N
, , N
improvement NN N
of IN N
impaired JJ N
myocardial JJ N
wall NN N
motion NN N
, , N
decrease NN N
to TO N
normalization NN N
of IN N
pathologically RB N
elevated VBN N
filling JJ N
pressure NN N
, , N
amelioration NN N
of IN N
coronary JJ N
blood NN N
flow NN N
as IN N
evidenced VBN N
by IN N
myocard NN N
scintigraphy NN N
and CC N
washout NN N
time NN N
of IN N
an DT N
intracoronarily JJ N
injected VBN N
echo-contrast JJ N
medium NN N
There EX N
was VBD N
also RB N
a DT N
definite JJ N
improvement NN N
of IN N
ischemia-caused JJ N
mitral JJ N
regurgitation NN N
Similar JJ N
observations NNS N
were VBD N
found VBN N
when WRB N
the DT N
drug NN N
was VBD N
injected VBN N
in IN N
the DT N
diseased JJ N
coronary JJ N
arteries NNS N
in IN N
a DT N
small JJ N
dose NN N
( ( N
0.075 CD N
mg/kg NN N
) ) N
so IN N
that DT N
peripheral JJ N
effects NNS N
were VBD N
not RB N
present JJ N
In IN N
comparison NN N
to TO N
the DT N
Ca NNP N
( ( N
++ NNP N
) ) N
-blocker NN N
Gallopamil NNP N
the DT N
antiischemic JJ N
effects NNS N
of IN N
Enoximone NNP N
were VBD N
more RBR N
pronounced JJ N
, , N
a DT N
synergistic JJ N
action NN N
was VBD N
, , N
however RB N
, , N
observed JJ N
Negative JJ N
dromotropic JJ N
effects NNS N
of IN N
Gallopamil NNP N
could MD N
be VB N
abolished VBN N
by IN N
Enoximone NNP N
With IN N
oral JJ N
administration NN N
of IN N
the DT N
drug NN N
over IN N
a DT N
period NN N
of IN N
one CD N
week NN N
antiischemic JJ N
effects NNS N
could MD N
also RB N
be VB N
documented VBN N
with IN N
Holter NNP N
monitoring NN N
as RB N
well RB N
as IN N
during IN N
exercise NN N
There EX N
was VBD N
a DT N
reduction NN N
of IN N
ST-depression NNP N
both DT N
at IN N
spontaneously RB N
occurring VBG N
ischemic JJ N
episodes NNS N
and CC N
during IN N
exercise NN N
, , N
in IN N
the DT N
number NN N
and CC N
duration NN N
of IN N
episodes NNS N
of IN N
silent JJ N
ischemia NN N
, , N
particularly RB N
, , N
however RB N
, , N
a DT N
decrease NN N
in IN N
symptomatic JJ N
episodes NNS N
In IN N
none NN N
of IN N
the DT N
patients NNS N
under IN N
study NN N
proarrhythmic JJ N
effects NNS N
were VBD N
observed VBN N
-DOCSTART- -X- O O 16904970

Patient-reported JJ N
outcomes NNS N
after IN N
inguinal JJ N
herniorrhaphy NN N
BACKGROUND NNP N
Patient-reported JJ N
outcomes NNS N
( ( N
PRO NNP N
) ) N
reflect VBP N
the DT N
functional JJ N
outcomes NNS N
of IN N
inguinal JJ N
herniorrhaphy NN N
We PRP N
studied VBD N
the DT N
effect NN N
of IN N
hernia NN N
recurrence NN N
and CC N
complications NNS N
on IN N
PRO NNP N
for IN N
participants NNS N
in IN N
the DT N
Veterans NNP N
Affairs NNPS N
trial NN N
of IN N
Open NNP N
or CC N
Laparoscopic NNP N
Repair NNP N
of IN N
Inguinal NNP N
Hernia NNP N
METHODS NNP N
Analyzed NNP N
PRO NNP N
included VBD N
( ( N
1 CD N
) ) N
the DT N
Medical NNP N
Outcomes NNP N
Study NNP N
Short NNP N
Form NNP N
36 CD N
, , N
version NN N
2 CD N
, , N
( ( N
2 CD N
) ) N
the DT N
Surgical NNP N
Pain NNP N
Scale NNP N
, , N
( ( N
3 CD N
) ) N
the DT N
Activities NNPS N
Assessment NNP N
Scale NNP N
, , N
and CC N
( ( N
4 CD N
) ) N
patient NN N
satisfaction NN N
Recurrences NNS N
and CC N
complications NNS N
were VBD N
recorded VBN N
at IN N
follow-up JJ N
visits NNS N
Complications NNS N
were VBD N
categorized VBN N
by IN N
( ( N
1 CD N
) ) N
hematoma/seroma NN N
, , N
( ( N
2 CD N
) ) N
orchitis NN N
, , N
( ( N
3 CD N
) ) N
neuralgia NN N
, , N
and CC N
( ( N
4 CD N
) ) N
other JJ N
Univariate NNP N
and CC N
multivariable JJ N
regression NN N
analyses NNS N
identified VBD N
variables NNS N
significantly RB N
associated VBN N
with IN N
postoperative JJ N
PRO NNP N
RESULTS NNP N
Of IN N
the DT N
1603 CD N
patients NNS N
with IN N
PRO NNP N
data NNS N
, , N
105 CD N
had VBD N
a DT N
recurrence NN N
and CC N
342 CD N
had VBD N
a DT N
complication NN N
at IN N
2 CD N
years NNS N
Multivariable JJ N
analyses NNS N
showed VBD N
neuralgia JJ N
( ( N
P NNP N
< NNP N
.0005 NNP N
) ) N
adversely RB N
affected VBD N
all DT N
PRO NNP N
, , N
and CC N
recurrence NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
affected VBD N
patient-reported JJ N
pain NN N
, , N
activity NN N
, , N
and CC N
satisfaction NN N
, , N
but CC N
not RB N
the DT N
score NN N
for IN N
the DT N
Medical NNP N
Outcomes NNP N
Study NNP N
Short NNP N
Form NNP N
3 CD N
Patients NNS N
with IN N
a DT N
recurrence NN N
after IN N
open JJ N
repair NN N
had VBD N
more RBR N
pain NN N
than IN N
those DT N
with IN N
a DT N
recurrence NN N
after IN N
laparoscopic JJ N
repair NN N
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
Patients NNS N
with IN N
other JJ N
complications NNS N
after IN N
laparoscopic NN N
repair NN N
reported VBD N
more JJR N
pain NN N
and CC N
less JJR N
activity NN N
than IN N
those DT N
with IN N
other JJ N
complications NNS N
after IN N
open JJ N
repair NN N
( ( N
P NNP N
= NNP N
.003 NNP N
and CC N
P NNP N
= NNP N
.009 NNP N
, , N
respectively RB N
) ) N
CONCLUSIONS VB N
The DT N
effectiveness NN N
of IN N
inguinal JJ N
herniorrhaphy NN N
should MD N
be VB N
measured VBN N
by IN N
the DT N
rate NN N
of IN N
recurrence NN N
and CC N
neuralgia NN N
Postoperative JJ N
neuralgias NNS N
have VBP N
a DT N
deleterious JJ N
effect NN N
on IN N
all DT N
patient-reported JJ N
outcomes NNS N
-DOCSTART- -X- O O 18592368

The DT N
effects NNS N
of IN N
improvisational JJ N
music NN N
therapy NN N
on IN N
joint JJ N
attention NN N
behaviors NNS N
in IN N
autistic JJ 4_p
children NNS 1_p
: : N
a DT N
randomized NN N
controlled VBN N
study NN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
improvisational JJ N
music NN N
therapy NN N
on IN N
joint JJ N
attention NN N
behaviors NNS N
in IN N
pre-school JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
It PRP N
was VBD N
a DT N
randomized VBN N
controlled VBN N
study NN N
employing VBG N
a DT N
single JJ N
subject NN N
comparison NN N
design NN N
in IN N
two CD N
different JJ N
conditions NNS N
, , N
improvisational JJ N
music NN N
therapy NN N
and CC N
play NN N
sessions NNS N
with IN N
toys NNS N
, , N
and CC N
using VBG N
standardized JJ N
tools NNS N
and CC N
DVD NNP N
analysis NN N
of IN N
sessions NNS N
to TO N
evaluate VB N
behavioral JJ N
changes NNS N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
The DT N
overall JJ N
results NNS N
indicated VBD N
that IN N
improvisational JJ N
music NN N
therapy NN N
was VBD N
more RBR N
effective JJ N
at IN N
facilitating VBG N
joint JJ N
attention NN N
behaviors NNS N
and CC N
non-verbal JJ N
social JJ N
communication NN N
skills NNS N
in IN N
children NNS N
than IN N
play NN N
Session NN N
analysis NN N
showed VBD N
significantly RB N
more RBR N
and CC N
lengthier JJR N
events NNS N
of IN N
eye NN N
contact NN N
and CC N
turn-taking NN N
in IN N
improvisational JJ N
music NN N
therapy NN N
than IN N
play NN N
sessions NNS N
The DT N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
further RBR N
-DOCSTART- -X- O O 20229169

PSK NNP N
may MD N
suppress VB N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
to TO N
improve VB N
survival NN N
of IN N
advanced JJ N
gastric JJ N
cancer NN N
patients NNS N
BACKGROUND NNP N
A NNP N
recent JJ N
report NN N
showed VBD N
that IN N
oral JJ N
adjuvant JJ N
immunochemotherapy NN N
with IN N
protein-bound JJ N
polysaccharide NN N
K NNP N
( ( N
PSK NNP N
) ) N
and CC N
tegafur/uracil NN N
( ( N
UFT NNP N
) ) N
for IN N
stage NN N
II NNP N
and CC N
III NNP N
colorectal JJ N
cancer NN N
improves VBZ N
overall JJ N
survival NN N
compared VBN N
with IN N
UFT NNP N
alone RB N
PSK NNP N
has VBZ N
been VBN N
supposed VBN N
to TO N
improve VB N
survival NN N
through IN N
immunological JJ N
mechanisms NNS N
such JJ N
as IN N
induction NN N
of IN N
cytokines NNS N
, , N
regulation NN N
of IN N
Th1/Th2 NNP N
balance NN N
, , N
and CC N
inhibition NN N
of IN N
immunosuppressive JJ N
molecules NNS N
METHODS NNP N
We PRP N
investigated VBD N
the DT N
mechanisms NNS N
by IN N
which WDT N
PSK NNP N
influences VBZ N
immunological JJ N
parameters NNS N
such JJ N
as IN N
Th1 NNP N
cells NNS N
( ( N
IFN-gamma-positive JJ N
CD4 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
) ) N
, , N
Th2 NNP N
cells NNS N
( ( N
IL-4-positive JJ N
CD4 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
) ) N
, , N
Th1/Th2 NNP N
ratio NN N
, , N
NKT NNP N
cells NNS N
( ( N
CD56 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
and CC N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
) ) N
, , N
NK NNP N
cells NNS N
, , N
and CC N
CD25 NNP N
( ( N
+ NNP N
) ) N
CD4 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
in IN N
stage NN N
III NNP N
gastric JJ N
cancer NN N
patients NNS N
Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
3 CD N
g NN N
PSK NNP N
plus CC N
300 CD N
mg NN N
UFT NNP N
( ( N
PSK NNP N
group NN N
) ) N
or CC N
300 CD N
mg JJ N
UFT NNP N
alone RB N
( ( N
control NN N
) ) N
orally RB N
each DT N
day NN N
for IN N
at IN N
least JJS N
1 CD N
year NN N
following VBG N
their PRP$ N
operation NN N
RESULTS NNP N
Twenty-one CD N
registered VBD N
patients NNS N
with IN N
stage NN N
III NNP N
gastric JJ N
cancer NN N
were VBD N
analyzed VBN N
The DT N
3-year JJ N
overall JJ N
survival NN N
was VBD N
62.2 CD N
% NN N
in IN N
the DT N
PSK NNP N
group NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
and CC N
12.5 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
( ( N
P NNP N
= NNP N
0.038 CD N
) ) N
Before IN N
operation NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
proportions NNS N
of IN N
Th1 NNP N
cells NNS N
, , N
Th2 NNP N
cells NNS N
, , N
Th1/Th2 NNP N
ratio NN N
, , N
CD56 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
, , N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
, , N
NK NNP N
cells NNS N
, , N
and CC N
CD4 NNP N
( ( N
+ NNP N
) ) N
CD25 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
between IN N
PSK NNP N
and CC N
control NN N
groups NNS N
However RB N
, , N
after IN N
operation NN N
, , N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
decreased VBD N
significantly RB N
in IN N
the DT N
PSK NNP N
group NN N
compared VBN N
to TO N
the DT N
control NN N
( ( N
P NNP N
= NNP N
0.0486 CD N
) ) N
When WRB N
all DT N
patients NNS N
were VBD N
analyzed VBN N
, , N
patients NNS N
with IN N
increased JJ N
proportion NN N
( ( N
> JJ N
18 CD N
% NN N
) ) N
of IN N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
showed VBD N
worse JJR N
survival NN N
than IN N
those DT N
with IN N
lower JJR N
( ( N
< CD N
or CC N
= VB N
18 CD N
% NN N
) ) N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
( ( N
3-year JJ N
survival NN N
, , N
25.0 CD N
and CC N
45.7 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.046 CD N
) ) N
, , N
consistent JJ N
with IN N
our PRP$ N
previous JJ N
report NN N
that WDT N
high JJ N
CD57 NNP N
( ( N
+ NNP N
) ) N
is VBZ N
an DT N
indicator NN N
of IN N
poor JJ N
prognosis NN N
in IN N
patients NNS N
with IN N
advanced JJ N
gastric JJ N
cancer NN N
However RB N
, , N
in IN N
the DT N
group NN N
treated VBD N
with IN N
PSK NNP N
+ NNP N
UFT NNP N
, , N
3-year JJ N
survival NN N
of IN N
CD57-high JJ N
patients NNS N
was VBD N
as RB N
great JJ N
as IN N
that DT N
of IN N
CD57-low JJ N
patients NNS N
( ( N
66.7 CD N
and CC N
51.4 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.67 CD N
) ) N
CONCLUSION VB N
The DT N
present JJ N
findings NNS N
suggest VBP N
that IN N
PSK NNP N
improves VBZ N
overall JJ N
survival NN N
of IN N
stage NN N
III NNP N
gastric JJ N
cancer NN N
patients NNS N
partly RB N
by IN N
inhibiting VBG N
CD57 NNP N
( ( N
+ NNP N
) ) N
T NNP N
cells NNS N
, , N
a DT N
proven JJ N
poor JJ N
prognostic JJ N
factor NN N
in IN N
advanced JJ N
gastric JJ N
cancer NN N
-DOCSTART- -X- O O 25791707

Magnetic JJ N
resonance NN N
imaging NN N
in IN N
the DT N
evaluation NN N
of IN N
clinical JJ N
treatment NN N
of IN N
otospongiosis NN 4_p
: : 4_p
a DT N
pilot NN N
study NN N
OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
applicability NN N
of IN N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
MRI NNP N
) ) N
as IN N
a DT N
method NN N
for IN N
monitoring VBG N
the DT N
activity NN N
of IN N
otospongiotic JJ N
lesions NNS N
before IN N
and CC N
after IN N
clinical JJ N
treatment NN N
STUDY NNP N
DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
controlled VBD N
, , N
double-blind NN N
study NN N
SETTING CC N
One CD N
single JJ N
tertiary NN N
care NN N
institution NN N
in IN N
a DT N
large JJ N
, , N
cosmopolitan JJ N
city NN N
METHODS NNP N
Twenty-six JJ 3_p
patients NNS N
( ( N
n JJ 3_p
= $ 3_p
42 CD 3_p
ears NNS 3_p
) ) N
with IN N
clinical JJ N
, , N
audiometric JJ N
, , N
and CC N
tomographic JJ N
diagnosis NN N
of IN N
otosclerosis NN 4_p
were VBD N
enrolled VBN N
If IN N
computed VBN N
tomography NN N
( ( N
CT NNP N
) ) N
demonstrated VBD N
active JJ N
lesions NNS N
, , N
these DT N
patients NNS N
underwent VBD N
MRI NNP N
to TO N
detect VB N
otospongiotic JJ N
foci NN N
, , N
seen VBN N
as IN N
areas NNS N
of IN N
gadolinium NN N
enhancement NN N
Patients NNS N
were VBD N
divided VBN N
into IN N
3 CD N
groups NNS N
and CC N
received VBN N
treatment NN N
with IN N
placebo NN N
, , N
sodium NN N
alendronate NN N
, , N
or CC N
sodium NN N
fluoride NN N
for IN N
6 CD N
months NNS N
After IN N
this DT N
period NN N
, , N
clinical JJ N
and CC N
audiometric JJ N
evaluations NNS N
and CC N
a DT N
second JJ N
MRI NNP N
were VBD N
performed VBN N
Each DT N
MRI NNP N
was VBD N
evaluated VBN N
by IN N
both DT N
a DT N
neuroradiologist NN N
and CC N
an DT N
otolaryngologist NN N
in IN N
a DT N
subjective JJ N
( ( N
visual JJ N
) ) N
and CC N
objective JJ N
( ( N
using VBG N
specific JJ N
eFilm JJ N
Workstation NNP N
software NN N
) ) N
manner NN N
RESULTS NNP N
Otospongiosis NNP N
was VBD N
most JJS N
predominantly RB N
identified VBN N
in IN N
the DT N
region NN N
anterior RB N
to TO N
the DT N
oval NN N
window NN N
, , N
and CC N
this DT N
site NN N
was VBD N
reliable JJ N
for IN N
comparing VBG N
pre- JJ N
and CC N
posttreatment JJ N
scans NNS N
The DT N
patients NNS N
in IN N
the DT N
alendronate NN N
and CC N
sodium NN N
fluoride NN N
groups NNS N
had VBD N
MRI NNP N
findings NNS N
that WDT N
suggested VBD N
a DT N
decrease NN N
in IN N
activity NN N
of IN N
otospongiotic JJ N
lesions NNS N
, , N
more RBR N
relevant JJ N
in IN N
the DT N
alendronate NN N
group NN N
These DT N
findings NNS N
were VBD N
statistically RB N
significant JJ N
for IN N
both DT N
subjective JJ N
and CC N
objective JJ N
MRI NNP N
evaluations NNS N
CONCLUSIONS NNP N
MRI NNP N
shows VBZ N
higher JJR N
sensitivity NN N
than IN N
clinical JJ N
or CC N
audiometric JJ N
assessment NN N
for IN N
detecting VBG N
reduction NN N
in IN N
activity NN N
of IN N
otospongiosis NN N
The DT N
objective JJ N
MRI NNP N
evaluation NN N
based VBN N
on IN N
software NN N
analysis NN N
was VBD N
the DT N
most RBS N
accurate JJ N
method NN N
of IN N
monitoring VBG N
clinical JJ N
treatment NN N
response NN N
in IN N
otospongiosis NN N
-DOCSTART- -X- O O 9039228

Marginal NNP N
zone NN N
B NNP N
cell NN N
lymphoma NN N
of IN N
the DT N
parotid JJ N
glands NNS N
: : N
results NNS N
of IN N
a DT N
randomised JJ N
trial NN N
comparing VBG N
radiotherapy NN N
to TO N
combined VBN N
therapy NN N
39 CD 3_p
patients NNS N
with IN N
marginal JJ 4_p
zone NN 4_p
B NNP 4_p
cell NN 4_p
lymphoma NN 4_p
( ( 4_p
MZBCL NNP 4_p
) ) 4_p
of IN N
the DT N
parotid NN N
glands NNS N
( ( N
stages NNS N
I PRP N
or CC N
II NNP N
) ) N
were VBD N
studied VBN N
They PRP N
were VBD N
randomized VBN N
to TO N
be VB N
treated VBN N
with IN N
either DT N
radiotherapy NN N
alone RB N
( ( N
extended JJ N
fields NNS N
, , N
4500 CD N
cGy NN N
) ) N
or CC N
radiotherapy NN N
( ( N
the DT N
same JJ N
schedule NN N
) ) N
plus CC N
adjuvant JJ N
chemotherapy NN N
( ( N
cyclophosphamide NN N
, , N
vincristine NN N
and CC N
prednisone NN N
) ) N
The DT N
end NN N
points NNS N
were VBD N
survival JJ N
and CC N
time NN N
to TO N
treatment NN N
failure NN N
( ( N
TTF NNP N
) ) N
Patients NNPS N
who WP N
received VBD N
radiotherapy VB N
alone RB N
had VBD N
a DT N
complete JJ N
remission NN N
rate NN N
of IN N
100 CD N
% NN N
, , N
the DT N
TTF NNP N
was VBD N
90 CD N
% NN N
at IN N
5 CD N
years NNS N
and CC N
overall JJ N
survival NN N
at IN N
5 CD N
years NNS N
was VBD N
90 CD N
% NN N
with IN N
no DT N
statistical JJ N
difference NN N
when WRB N
compared VBN N
with IN N
patients NNS N
who WP N
received VBD N
combined JJ N
therapy NN N
[ NN N
100 CD N
, , N
80 CD N
and CC N
95 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.5 CD N
) ) N
] NN N
Although IN N
adjuvant JJ N
chemotherapy NN N
was VBD N
well RB N
tolerated VBN N
, , N
the DT N
use NN N
of IN N
this DT N
therapeutic JJ N
approach NN N
in IN N
patients NNS N
with IN N
early JJ N
stage NN N
MZBCL NNP N
did VBD N
not RB N
offer VB N
any DT N
advantage NN N
over IN N
radiotherapy NN N
alone RB N
as IN N
the DT N
initial JJ N
treatment NN N
Until IN N
now RB N
, , N
radiotherapy NN N
was VBD N
considered VBN N
the DT N
treatment NN N
of IN N
choice NN N
in IN N
this DT N
clinical JJ N
setting NN N
of IN N
patients NNS N
-DOCSTART- -X- O O 9532999

The DT N
reliability NN N
of IN N
catheter-tip JJ N
transducers NNS N
for IN N
the DT N
measurement NN N
of IN N
intrauterine JJ N
pressure NN N
in IN N
the DT N
third JJ N
stage NN N
of IN N
labour NN N
In IN N
order NN N
to TO N
assess VB N
the DT N
reliability NN N
of IN N
intrauterine JJ N
pressure NN N
measurements NNS N
in IN N
the DT N
third JJ N
stage NN N
of IN N
labour NN N
, , N
catheter-tip JJ N
transducers NNS N
were VBD N
used VBN N
in IN N
20 CD 1_p
women NNS 1_p
randomly RB 1_p
allocated VBN 1_p
into IN 1_p
two CD 1_p
groups NNS 1_p
of IN 1_p
10 CD 1_p
In IN N
each DT N
case NN N
in IN N
the DT N
first JJ N
group NN N
two CD N
catheters NNS N
were VBD N
tied VBN N
together RB N
and CC N
introduced VBN N
transcervically RB N
into IN N
the DT N
uterine JJ N
cavity NN N
after IN N
delivery NN N
of IN N
the DT N
placenta NN N
In IN N
each DT N
case NN N
in IN N
the DT N
second JJ N
group NN N
two CD N
catheters NNS N
were VBD N
inserted VBN N
independently RB N
into IN N
the DT N
same JJ N
uterine JJ N
cavity NN N
The DT N
active JJ N
and CC N
cumulative JJ N
active JJ N
pressures NNS N
recorded VBN N
from IN N
the DT N
pairs NNS N
of IN N
catheters NNS N
within IN N
each DT N
uterine JJ N
cavity NN N
were VBD N
compared VBN N
Comparison NNP N
of IN N
individual JJ N
active JJ N
pressure NN N
readings NNS N
from IN N
separate JJ N
transducers NNS N
revealed VBD N
good JJ N
agreement NN N
whether IN N
the DT N
catheters NNS N
were VBD N
tied VBN N
together RB N
or CC N
were VBD N
separate JJ N
Cumulative JJ N
active JJ N
pressure NN N
was VBD N
very RB N
similar JJ N
when WRB N
assessed VBN N
by IN N
each DT N
catheter NN N
in IN N
the DT N
same JJ N
uterus NN N
Intrauterine NNP N
catheter-tip JJ N
transducers NNS N
can MD N
be VB N
used VBN N
reliably RB N
to TO N
measure VB N
uterine JJ N
activity NN N
in IN N
the DT N
third JJ N
stage NN N
of IN N
labour JJ N
although IN N
there EX N
may MD N
be VB N
minor JJ N
contraction NN N
by IN N
contraction NN N
differences NNS N
in IN N
recordings NNS N
of IN N
individual JJ N
active JJ N
pressures NNS N
-DOCSTART- -X- O O 184069

Effect NN N
of IN N
radiotherapy NN N
on IN N
blood NN 4_p
lymphocyte JJ 4_p
population NN 4_p
in IN 4_p
mammary JJ 4_p
carcinoma NN 4_p
-DOCSTART- -X- O O 3307623

Oral JJ N
ribavirin NN N
treatment NN N
of IN N
influenza NN N
A NNP N
and CC N
B NNP N
A NNP N
loading VBG N
dose JJ N
and CC N
short-term JJ N
administration NN N
of IN N
oral JJ N
ribavirin NN N
significantly RB N
improved VBN N
symptoms NNS N
and CC N
signs NNS N
of IN N
influenza NN 4_p
type NN 4_p
A DT 4_p
or CC 4_p
B NNP 4_p
infection NN 4_p
in IN 4_p
25 CD 4_p
patients NNS 4_p
The DT N
antiviral JJ N
effect NN N
was VBD N
not RB N
significant JJ N
No DT N
adverse JJ N
clinical JJ N
effects NNS N
or CC N
significant JJ N
laboratory NN N
values NNS N
were VBD N
observed VBN N
Oral JJ N
treatment NN N
of IN N
patients NNS N
with IN N
influenza NN N
A NNP N
or CC N
B NNP N
infection NN N
might MD N
be VB N
possible JJ N
with IN N
ribavirin NN N
-DOCSTART- -X- O O 11384820

Rehabilitation NNP N
outcomes VBZ N
following VBG N
percutaneous JJ N
coronary JJ N
interventions NNS N
( ( N
PCI NNP N
) ) N
This DT N
prospective JJ N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
an DT N
individualized JJ N
, , N
comprehensive JJ N
, , N
home-based JJ N
cardiac JJ N
rehabilitation NN N
program NN N
combining NN N
exercise NN N
training NN N
with IN N
risk NN N
factor NN N
modification NN N
and CC N
psychosocial JJ N
counseling NN N
on IN N
risk NN N
factors NNS N
, , N
psychological JJ N
well-being NN N
, , N
functional JJ N
capacity NN N
, , N
and CC N
work NN N
resumption NN N
in IN N
99 CD N
post-percutaneous JJ N
coronary JJ N
interventions NNS N
( ( N
PCI NNP N
) ) N
patients NNS N
randomized VBN N
to TO N
control VB N
( ( N
standard JJ N
care NN N
plus CC N
telephone NN N
follow-up NN N
, , N
n=49 NN N
) ) N
or CC N
intervention NN N
( ( N
individualized VBN N
, , N
comprehensive JJ N
, , N
home-based JJ N
cardiac JJ N
rehabilitation NN N
, , N
n=50 NN N
) ) N
groups NNS N
Data NNS N
were VBD N
collected VBN N
at IN N
time NN N
1 CD N
( ( N
T NNP N
( ( N
1 CD N
) ) N
) ) N
during IN N
hospital JJ N
admission NN N
, , N
time NN N
2 CD N
( ( N
T NNP N
( ( N
2 CD N
) ) N
) ) N
approximately RB N
2 CD N
months NNS N
post-PCI JJ N
, , N
and CC N
time NN N
3 CD N
( ( N
T NNP N
( ( N
3 CD N
) ) N
) ) N
approximately RB N
12 CD N
months NNS N
post-PCI JJ N
Results VB N
suggest JJS N
that IN N
the DT N
allocation NN N
to TO N
an DT N
individualized VBN N
, , N
comprehensive JJ N
, , N
home-based JJ N
cardiac JJ N
rehabilitation NN N
program NN N
provided VBD N
more RBR N
advantageous JJ N
outcomes NNS N
At IN N
both DT N
follow-ups NNS N
, , N
the DT N
intervention NN N
group NN N
showed VBD N
within-group JJ N
improvement NN N
in IN N
serum NN N
cholesterol NN N
levels NNS N
( ( N
P NNP N
< NNP N
0.02 CD N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
exercise JJ N
participation NN N
( ( N
P NNP N
< NNP N
0.001 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
with IN N
differences NNS N
in IN N
exercise NN N
participation NN N
favoring VBG N
the DT N
intervention NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
at IN N
T NNP N
( ( N
2 CD N
) ) N
Repeated VBN N
measures NNS N
ANOVA NNP N
showed VBD N
significant JJ N
improvements NNS N
over IN N
time NN N
in IN N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
psychological JJ N
well-being NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
functional JJ N
capacity NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
for IN N
both DT N
groups NNS N
More JJR N
patients NNS N
in IN N
the DT N
intervention NN N
group NN N
had VBD N
returned VBN N
to TO N
work VB N
at IN N
T NNP N
( ( N
2 CD N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
did VBD N
so RB N
more RBR N
quickly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
These DT N
findings NNS N
suggest VBP N
that IN N
an DT N
individualized JJ N
, , N
comprehensive JJ N
, , N
home-based JJ N
cardiac JJ N
rehabilitation NN N
program NN N
improves VBZ N
risk NN N
factor NN N
profiles NNS N
and CC N
work NN N
resumption NN N
patterns NNS N
for IN N
patients NNS N
following VBG N
PCI NNP N
-DOCSTART- -X- O O 25760553

A DT N
possible JJ N
link NN N
between IN N
early JJ N
probiotic JJ N
intervention NN N
and CC N
the DT N
risk NN N
of IN N
neuropsychiatric JJ 4_p
disorders NNS 4_p
later RB N
in IN N
childhood NN 1_p
: : N
a DT N
randomized JJ N
trial NN N
BACKGROUND NNP N
Recent NNP N
experimental JJ N
evidence NN N
suggests VBZ N
that IN N
gut NN N
microbiota NN N
may MD N
alter VB N
function NN N
within IN N
the DT N
nervous JJ N
system NN N
providing VBG N
new JJ N
insight NN N
on IN N
the DT N
mechanism NN N
of IN N
neuropsychiatric JJ N
disorders NNS N
METHODS NNP N
Seventy-five JJ 3_p
infants NNS 1_p
who WP N
were VBD N
randomized VBN 4_p
to TO 4_p
receive VB 4_p
Lactobacillus NNP 4_p
rhamnosus NN 4_p
GG NNP 4_p
( ( 4_p
ATCC NNP 4_p
53103 CD 4_p
) ) N
or CC 4_p
placebo NN 4_p
during IN 4_p
the DT 4_p
first JJ 4_p
6 CD N
mo NN N
of IN N
life NN N
were VBD N
followed-up JJ N
for IN N
13 CD N
y NN N
Gut NNP N
microbiota NN N
was VBD N
assessed VBN N
at IN N
the DT N
age NN N
of IN N
3 CD N
wk NN N
, , N
3 CD N
, , N
6 CD N
, , N
12 CD N
, , N
18 CD N
, , N
24 CD N
mo NN N
, , N
and CC N
13 CD N
y NN N
using VBG N
fluorescein NN N
in IN N
situ JJ N
hybridization NN N
( ( N
FISH NNP N
) ) N
and CC N
qPCR $ N
, , N
and CC N
indirectly RB N
by IN N
determining VBG N
the DT N
blood NN N
group NN N
secretor NN N
type NN N
at IN N
the DT N
age NN N
of IN N
13 CD N
y NN N
The DT N
diagnoses NNS N
of IN N
attention NN N
deficit NN N
hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
and CC N
Asperger NNP N
syndrome VBP N
( ( N
AS IN N
) ) N
by IN N
a DT N
child JJ N
neurologist NN N
or CC N
psychiatrist NN N
were VBD N
based VBN N
on IN N
ICD-10 NNP N
diagnostic JJ N
criteria NNS N
RESULTS NN N
At IN N
the DT N
age NN N
of IN N
13 CD N
y NNS N
, , N
ADHD NNP N
or CC N
AS NNP N
was VBD N
diagnosed VBN N
in IN N
6/35 CD N
( ( N
17.1 CD N
% NN N
) ) N
children NNS N
in IN N
the DT N
placebo NN N
and CC N
none NN N
in IN N
the DT N
probiotic JJ N
group NN N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
The DT N
mean NN N
( ( N
SD NNP N
) ) N
numbers NNS N
of IN N
Bifidobacterium NNP N
species NNS N
bacteria VBP N
in IN N
feces NNS N
during IN N
the DT N
first JJ N
6 CD N
mo NN N
of IN N
life NN N
was VBD N
lower JJR N
in IN N
affected JJ N
children NNS N
8.26 CD N
( ( N
1.24 CD N
) ) N
log NN N
cells/g NN N
than IN N
in IN N
healthy JJ N
children NNS N
9.12 CD N
( ( N
0.64 CD N
) ) N
log NN N
cells/g NN N
; : N
P NNP N
= VBD N
0.03 CD N
CONCLUSION NNP N
Probiotic NNP N
supplementation NN N
early RB N
in IN N
life NN N
may MD N
reduce VB N
the DT N
risk NN N
of IN N
neuropsychiatric JJ N
disorder NN N
development NN N
later RB N
in IN N
childhood NN 1_p
possible JJ N
by IN N
mechanisms NNS N
not RB N
limited VBN N
to TO N
gut VB N
microbiota JJ N
composition NN N
-DOCSTART- -X- O O 12423984

Effect NN N
of IN N
nitazoxanide NN N
on IN N
morbidity NN N
and CC N
mortality NN N
in IN N
Zambian JJ 4_p
children NNS 1_p
with IN N
cryptosporidiosis NN 4_p
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
BACKGROUND NNP N
Cryptosporidiosis NNP 4_p
in IN N
children NNS 1_p
in IN N
developing VBG 4_p
countries NNS 4_p
causes VBZ N
persistent JJ N
diarrhoea NN N
and CC N
malnutrition NN N
and CC N
is VBZ N
associated VBN N
with IN N
increased JJ N
mortality NN N
, , N
but CC N
there EX N
is VBZ N
no DT N
effective JJ N
treatment NN N
We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
effect NN N
of IN N
nitazoxanide-a JJ N
new JJ N
broad-spectrum JJ N
antiparasitic JJ N
drug-on JJ N
morbidity NN N
and CC N
mortality NN N
in IN N
Zambian JJ 4_p
children NNS 1_p
with IN N
diarrhoea NN 4_p
due JJ 4_p
to TO 4_p
Cryptosporidium NNP 4_p
parvum NN 4_p
METHODS NNP N
Children NNP 1_p
with IN N
cryptosporidial JJ 4_p
diarrhoea NNS 4_p
who WP N
were VBD N
admitted VBN N
to TO N
the DT N
University NNP N
Teaching NNP N
Hospital NNP N
, , N
Lusaka NNP N
, , N
Zambia NNP N
, , N
between IN N
November NNP N
, , N
2000 CD N
, , N
and CC N
July NNP N
, , N
2001 CD N
, , N
and CC N
whose WP$ N
parents NNS N
consented VBD N
to TO N
their PRP$ N
having VBG N
an DT N
HIV JJ N
test NN N
were VBD N
randomly RB N
assigned VBN N
nitazoxanide RB N
( ( N
100 CD N
mg NN N
twice RB N
daily RB N
orally RB N
for IN N
3 CD N
days NNS N
) ) N
or CC N
placebo NN N
The DT N
primary JJ N
endpoint NN N
was VBD N
clinical JJ N
response NN N
on IN N
day NN N
7 CD N
after IN N
the DT N
start NN N
of IN N
treatment NN N
Secondary JJ N
endpoints NNS N
included VBD N
parasitological JJ N
response NN N
by IN N
day NN N
10 CD N
and CC N
mortality NN N
at IN N
day NN N
8 CD N
Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
, , N
with IN N
exclusion NN N
of IN N
patients NNS N
subsequently RB N
found VBN N
to TO N
be VB N
negative JJ N
for IN N
C NNP 4_p
parvum NN 4_p
or CC N
co-infected JJ N
at IN N
baseline NN N
The DT N
trial NN N
was VBD N
stratified VBN N
by IN N
HIV NNP N
serology NN N
FINDINGS CD N
50 CD 3_p
HIV-seropositive JJ N
and CC N
50 CD 3_p
HIV-seronegative JJ N
children NNS 1_p
were VBD N
recruited VBN N
for IN N
the DT N
study NN N
, , N
four CD N
of IN N
whom WP N
were VBD N
subsequently RB N
excluded VBN N
In IN N
HIV-seronegative JJ N
children NNS N
, , N
diarrhoea NN N
resolved VBD N
in IN N
14 CD N
( ( N
56 CD N
% NN N
) ) N
of IN N
25 CD N
receiving VBG N
nitazoxanide RB N
and CC N
5 CD N
( ( N
23 CD N
% NN N
) ) N
of IN N
22 CD N
receiving VBG N
placebo NN N
( ( N
difference NN N
33 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
7-59 CD N
; : N
p=0.037 NN N
) ) N
C NNP N
parvum NN N
was VBD N
eradicated VBN N
from IN N
stool NN N
in IN N
13 CD N
( ( N
52 CD N
% NN N
) ) N
of IN N
25 CD N
receiving VBG N
nitazoxanide NN N
and CC N
three CD N
( ( N
14 CD N
% NN N
) ) N
of IN N
22 CD N
receiving VBG N
placebo NN N
( ( N
38 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
14-63 CD N
; : N
p=0.007 NN N
) ) N
Four CD N
children NNS N
( ( N
18 CD N
% NN N
) ) N
of IN N
22 CD N
in IN N
the DT N
placebo NN N
group NN N
had VBD N
died VBN N
by IN N
day NN N
8 CD N
, , N
compared VBN N
with IN N
none NN N
of IN N
25 CD N
in IN N
the DT N
nitazoxanide JJ N
group NN N
( ( N
-18 CD N
% NN N
, , N
-34 NN N
to TO N
2 CD N
; : N
p=0.041 NN N
) ) N
HIV-seropositive JJ N
children NNS N
did VBD N
not RB N
benefit VB N
from IN N
nitazoxanide RB N
Nitazoxanide NNP N
was VBD N
not RB N
significantly RB N
associated VBN N
with IN N
adverse JJ N
events NNS N
in IN N
either DT N
stratum NN N
INTERPRETATION VB N
A DT N
3-day JJ N
course NN N
of IN N
nitazoxanide JJ N
significantly RB N
improved VBN N
the DT N
resolution NN N
of IN N
diarrhoea NN N
, , N
parasitological JJ N
eradication NN N
, , N
and CC N
mortality NN N
in IN N
HIV-seronegative NNP N
, , N
but CC N
not RB N
HIV-seropositive NNP N
, , N
children NNS N
-DOCSTART- -X- O O 18161677

Effect NN N
of IN N
upper JJ N
arm NN N
brachial NN N
basilic NN N
and CC N
prosthetic JJ N
forearm NN N
arteriovenous JJ N
fistula NN N
on IN N
left JJ N
ventricular JJ N
hypertrophy NN N
BACKGROUND NNP N
Creation NNP N
of IN N
an DT N
arteriovenous JJ N
fistula NN N
( ( N
AVF NNP N
) ) N
may MD N
increase VB N
left VBD N
ventricular JJ N
hypertrophy NN N
in IN N
the DT N
hemodialysis NN 4_p
population NN 4_p
Aim NNP N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
a DT N
brachial-basilic JJ N
( ( N
BB NNP N
) ) N
AVF NNP N
and CC N
the DT N
prosthetic JJ N
brachial-antecubital JJ N
forearm NN N
loop NN N
access NN N
( ( N
PTFE NNP N
) ) N
on IN N
cardiac JJ N
performance NN N
METHODS JJ N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
receive VB N
BB-AVF NNP N
or CC N
prosthetic JJ N
brachial-antecubital JJ N
forearm NN N
loop NN N
access NN N
Before IN N
and CC N
three CD N
months NNS N
after IN N
AVF NNP 4_p
creation NN 4_p
patients NNS 4_p
underwent VBD N
an DT N
echocardiographic JJ N
examination NN N
Mann-Whitney JJ N
U-test NNP N
was VBD N
used VBN N
to TO N
compare VB N
relative JJ N
increase NN N
between IN N
the DT N
measured JJ N
cardiac JJ N
parameters NNS N
for IN N
the DT N
two CD N
groups NNS N
RESULTS NNP N
Twenty-seven JJ 3_p
patients NNS 3_p
participated VBN 3_p
in IN 3_p
the DT 3_p
study NN 3_p
The DT N
relative JJ N
increase NN N
in IN N
left JJ N
ventricular JJ N
parameters NNS N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
Only RB N
left VBD N
ventricular JJ N
end-diastolic JJ N
diameter NN N
tended VBD N
to TO N
be VB N
of IN N
significance NN N
Mean NNP N
blood NN N
flow NN N
through IN N
the DT N
brachial JJ N
artery NN N
was VBD N
1680+/-156 JJ N
and CC N
1450+/-221 JJ N
mL/min NNS N
three CD N
months NNS N
after IN N
surgery NN N
for IN N
the DT N
PTFE NNP N
and CC N
the DT N
BB-AVF NNP N
group NN N
, , N
respectively RB N
CONCLUSION NN N
After IN N
three CD N
months NNS N
of IN N
follow-up NN N
, , N
changes NNS N
in IN N
cardiac JJ N
structure NN N
were VBD N
comparable JJ N
between IN N
patients NNS 4_p
with IN 4_p
BB NNP 4_p
and CC 4_p
PTFE NNP 4_p
AVFs NNP 4_p
Also RB N
access NN N
flow NN N
was VBD N
comparable JJ N
at IN N
this DT N
time NN N
In IN N
general JJ N
, , N
the DT N
effects NNS N
of IN N
creation NN N
of IN N
a DT N
fistula NN N
on IN N
LV NNP N
structure NN N
were VBD N
limited VBN N
Longer RBR N
follow VB N
up RP N
time NN N
may MD N
be VB N
needed VBN N
to TO N
explore VB N
the DT N
long JJ N
term NN N
effects NNS N
of IN N
different JJ N
vascular JJ N
accesses NNS N
on IN N
cardiac JJ N
function NN N
-DOCSTART- -X- O O 16730335

Effects NNS N
of IN N
short- JJ N
and CC N
long-term JJ N
risperidone NN N
treatment NN N
on IN N
prolactin NN N
levels NNS N
in IN N
children NNS N
with IN N
autism NN N
BACKGROUND IN N
The DT N
effects NNS N
of IN N
short- JJ N
and CC N
long-term JJ N
risperidone NN N
treatment NN N
on IN N
serum NN N
prolactin NN N
were VBD N
assessed VBN N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
METHODS NNP N
Patients NNPS N
with IN N
autism NN N
( ( N
N NNP N
= NNP N
101 CD N
, , N
5-17 CD N
years NNS N
of IN N
age NN N
) ) N
were VBD N
randomized VBN N
to TO N
an DT N
8-week JJ N
trial NN N
of IN N
risperidone NN N
or CC N
placebo NN N
and CC N
63 CD N
then RB N
took VBD N
part NN N
in IN N
a DT N
4-month JJ N
open-label JJ N
follow-up JJ N
phase NN N
Serum NNP N
samples NNS N
were VBD N
obtained VBN N
at IN N
Baseline NNP N
and CC N
Week-8 NNP N
( ( N
N NNP N
= NNP N
78 CD N
) ) N
, , N
and CC N
at IN N
6-month JJ N
( ( N
N NNP N
= NNP N
43 CD N
) ) N
and CC N
22-month JJ N
( ( N
N NNP N
= NNP N
30 CD N
) ) N
follow-up NN N
Serum NNP N
prolactin NN N
was VBD N
determined VBN N
by IN N
immunoradiometric JJ N
assay NN N
; : N
dopamine JJ N
type-2 JJ N
receptor NN N
( ( N
DRD2 NNP N
) ) N
polymorphisms NNS N
were VBD N
genotyped VBN N
RESULTS NNP N
Baseline NNP N
prolactin NN N
levels NNS N
were VBD N
similar JJ N
in IN N
the DT N
risperidone NN N
( ( N
N NNP N
= NNP N
42 CD N
) ) N
and CC N
placebo NN N
( ( N
N NNP N
= NNP N
36 CD N
) ) N
groups NNS N
( ( N
9.3 CD N
+/- JJ N
7.5 CD N
and CC N
9.3 CD N
+/- JJ N
7.6 CD N
ng/ml NN N
, , N
respectively RB N
) ) N
After IN N
8 CD N
weeks NNS N
of IN N
risperidone NN N
, , N
prolactin NN N
increased VBD N
to TO N
39.0 CD N
+/- JJ N
19.2 CD N
ng/ml NN N
, , N
compared VBN N
with IN N
10.1 CD N
+/- JJ N
8.8 CD N
ng/ml NN N
for IN N
placebo NN N
( ( N
p JJ N
< NNP N
.0001 NNP N
) ) N
Prolactin NN N
levels NNS N
were VBD N
also RB N
significantly RB N
increased VBN N
at IN N
6 CD N
months NNS N
( ( N
32.4 CD N
+/- JJ N
17.8 CD N
ng/ml NN N
; : N
N NNP N
= VBZ N
43 CD N
, , N
p NN N
< NNP N
.0001 NNP N
) ) N
and CC N
at IN N
22 CD N
months NNS N
( ( N
N NNP N
= NNP N
30 CD N
, , N
25.3 CD N
+/- JJ N
15.6 CD N
ng/ml NN N
, , N
p NN N
< NNP N
.0001 NNP N
) ) N
Prolactin NN N
levels NNS N
were VBD N
not RB N
associated VBN N
with IN N
adverse JJ N
effects NNS N
and CC N
DRD2 NNP N
alleles NNS N
( ( N
Taq1A NNP N
, , N
-141C NNP N
Ins/Del NNP N
, , N
C957T NNP N
) ) N
did VBD N
not RB N
significantly RB N
influence VB N
baseline NN N
levels NNS N
or CC N
risperidone-induced JJ N
increases NNS N
in IN N
prolactin NN N
CONCLUSIONS NNP N
Risperidone NNP N
treatment NN N
was VBD N
associated VBN N
with IN N
two- JJ N
to TO N
four-fold JJ N
mean NN N
increases NNS N
in IN N
serum NN N
prolactin NN N
in IN N
children NNS N
with IN N
autism NN N
Although IN N
risperidone-induced JJ N
increases NNS N
tended VBD N
to TO N
diminish VB N
with IN N
time NN N
, , N
further JJ N
research NN N
on IN N
the DT N
consequences NNS N
of IN N
long-term JJ N
prolactin NN N
elevations NNS N
in IN N
children NNS N
and CC N
adolescents NNS N
is VBZ N
needed VBN N
-DOCSTART- -X- O O 21869698

Symptomatic JJ N
and CC N
functional JJ N
improvement NN N
in IN N
employed NNS N
depressed JJ 4_p
patients NNS N
: : N
a DT N
double-blind JJ N
clinical JJ N
trial NN N
of IN N
desvenlafaxine NN N
versus NN N
placebo NN N
OBJECTIVE VB N
This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
desvenlafaxine NN N
( ( N
administered VBN N
as IN N
desvenlafaxine JJ N
succinate NN N
) ) N
for IN N
improving VBG N
depressive JJ N
symptoms NNS N
and CC N
functioning VBG N
exclusively RB N
in IN N
employed JJ N
patients NNS N
with IN N
major JJ 4_p
depressive JJ 4_p
disorder NN 4_p
( ( 4_p
MDD NNP 4_p
) ) 4_p
METHODS NNP N
Gainfully NNP N
employed VBD N
( ( N
≥20 NNP N
h/wk NN N
) ) N
male NN N
and CC N
female JJ N
outpatients NNS N
with IN N
MDD NNP N
were VBD N
randomly RB N
assigned VBN N
( ( N
2:1 CD N
ratio NN N
) ) N
to TO N
12 CD N
weeks NNS N
of IN N
double-blind JJ N
treatment NN N
with IN N
desvenlafaxine JJ N
50 CD N
mg/d NN N
or CC N
placebo NN N
Analysis NN N
of IN N
covariance NN N
was VBD N
used VBN N
to TO N
compare VB N
differences NNS N
in IN N
week NN N
12 CD N
adjusted VBN N
mean JJ N
changes NNS N
from IN N
baseline NN N
on IN N
the DT N
17-item JJ N
Hamilton NNP N
Depression NNP N
Rating NNP N
Scale NNP N
( ( N
HAM-D₁₇ NNP N
) ) N
( ( N
primary JJ N
outcome NN N
) ) N
and CC N
Sheehan NNP N
Disability NNP N
Scale NNP N
( ( N
SDS NNP N
) ) N
( ( N
key JJ N
secondary JJ N
outcome NN N
) ) N
in IN N
the DT N
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
population NN N
A DT N
predefined JJ N
, , N
modified VBD N
ITT NNP N
population NN N
( ( N
ie JJ N
, , N
those DT N
in IN N
the DT N
ITT NNP N
population NN N
with IN N
baseline JJ N
HAM-D₁₇ NNP N
≥20 NN N
) ) N
was VBD N
also RB N
analyzed VBN N
Tolerability NNP N
was VBD N
assessed VBN N
by IN N
recording VBG N
adverse JJ N
events NNS N
and CC N
change NN N
on IN N
the DT N
Arizona NNP N
Sexual NNP N
Experience NNP N
Scale NNP N
RESULTS NNP N
Baseline NNP N
HAM-D₁₇ NNP N
scores NNS N
for IN N
desvenlafaxine NN N
( ( N
n JJ N
= NNP N
285 CD N
) ) N
and CC N
placebo NN N
( ( N
n JJ N
= NNP N
142 CD N
) ) N
were VBD N
22.0 CD N
and CC N
21.8 CD N
, , N
whereas NNS N
baseline VBP N
SDS NNP N
scores NNS N
were VBD N
19.8 CD N
and CC N
20.4 CD N
Adjusted VBN N
mean JJ N
differences NNS N
between IN N
desvenlafaxine NN N
and CC N
placebo NN N
were VBD N
2.1 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.78-3.46 NNP N
; : N
P NNP N
= NNP N
0.002 CD N
) ) N
on IN N
the DT N
HAM-D₁₇ NNP N
and CC N
1.3 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-0.09 NNP N
to TO N
2.76 CD N
; : N
P NNP N
= NNP N
0.067 CD N
) ) N
on IN N
the DT N
SDS NNP N
For IN N
the DT N
modified JJ N
ITT NNP N
sample NN N
, , N
desvenlafaxine NN N
( ( N
n JJ N
= NNP N
208 CD N
) ) N
and CC N
placebo NN N
( ( N
n JJ N
= NNP N
102 CD N
) ) N
, , N
baseline JJ N
HAM-D₁₇ JJ N
scores NNS N
were VBD N
23.8 CD N
and CC N
23.9 CD N
; : N
the DT N
SDS NNP N
baseline NN N
scores NNS N
were VBD N
20.1 CD N
and CC N
20.8 CD N
Mean JJ N
differences NNS N
were VBD N
2.6 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.93-4.22 NNP N
; : N
P NNP N
= NNP N
0.002 CD N
) ) N
on IN N
the DT N
HAM-D₁₇ NNP N
and CC N
2.1 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.36-3.76 NNP N
; : N
P NNP N
= NNP N
0.017 CD N
) ) N
on IN N
the DT N
SDS NNP N
Adverse JJ N
events NNS N
and CC N
Arizona NNP N
Sexual NNP N
Experience NNP N
Scale NNP N
scores NNS N
were VBD N
comparable JJ N
between IN N
groups NNS N
CONCLUSIONS NNP N
Desvenlafaxine NNP N
50 CD N
mg/d NN N
was VBD N
efficacious JJ N
for IN N
treating VBG N
MDD NNP N
in IN N
gainfully RB N
employed VBN N
adults NNS N
Between-group NNP N
differences NNS N
on IN N
the DT N
SDS NNP N
narrowly RB N
missed VBD N
statistical JJ N
significance NN N
in IN N
the DT N
ITT NNP N
population NN N
alone RB N
, , N
but CC N
the DT N
totality NN N
of IN N
data NNS N
suggests NNS N
functional JJ N
improvements NNS N
with IN N
active JJ N
treatment NN N
-DOCSTART- -X- O O 12135593

Limited JJ N
effects NNS N
of IN N
micronutrient JJ N
supplementation NN N
on IN N
strength NN N
and CC N
physical JJ N
function NN N
after IN N
abdominal JJ 4_p
aortic JJ 4_p
aneurysmectomy NN 4_p
BACKGROUND NNP N
Tissue NNP N
injury NN N
following VBG N
ischemia-reperfusion NN N
is VBZ N
mediated VBN N
in IN N
part NN N
by IN N
free JJ N
oxygen NN N
radicals NNS N
We PRP N
hypothesized VBD N
that IN N
perioperative JJ N
micronutrient NN N
supplementation NN N
would MD N
augment VB N
antioxidant JJ N
defenses NNS N
, , N
minimize VB N
muscle NN N
injury NN N
, , N
and CC N
minimize VB N
postoperative JJ N
decreases NNS N
in IN N
muscle NN N
strength NN N
and CC N
physical JJ N
function NN N
following VBG N
abdominal JJ N
aortic JJ N
aneurysmectomy NN N
SETTING VB N
A DT N
university-affiliated JJ N
hospital NN N
and CC N
regional JJ N
referral JJ N
center NN N
DESIGN VB N
A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
supplementation NN N
with IN N
beta-carotene NN N
, , N
vitamins VBZ N
C NNP N
and CC N
E NNP N
, , N
zinc NN N
, , N
and CC N
selenium NN N
for IN N
a DT N
period NN N
of IN N
2-3 JJ N
weeks NNS N
prior RB N
to TO N
surgery NN N
and CC N
1 CD N
week NN N
thereafter RB N
STUDY NNP N
POPULATION NNP N
Patients NNP N
undergoing VBG N
elective JJ N
abdominal JJ 4_p
aortic JJ 4_p
aneurysmectomy NN 4_p
( ( N
n=18 JJ 3_p
per IN N
group NN N
) ) N
PRINCIPAL JJ N
MEASUREMENTS NNP N
Handgrip NNP N
and CC N
other JJ N
measures NNS N
of IN N
strength NN N
and CC N
physical JJ N
function NN N
RESULTS NNP N
Handgrip NNP N
and CC N
quadriceps JJ N
strength NN N
decreased VBD N
following VBG N
surgery NN N
, , N
but CC N
not RB N
to TO N
a DT N
significantly RB N
different JJ N
extent NN N
in IN N
the DT N
placebo NN N
and CC N
supplemented VBD N
groups NNS N
Self-rated JJ N
physical JJ N
function NN N
decreased VBD N
following VBG N
surgery NN N
in IN N
the DT N
placebo NN N
group NN N
and CC N
was VBD N
preserved VBN N
in IN N
the DT N
supplemented JJ N
group NN N
CONCLUSIONS NNP N
Perioperative NNP N
supplementation NN N
with IN N
micronutrients NNS N
with IN N
antioxidant JJ N
properties NNS N
has VBZ N
limited VBN N
effects NNS N
on IN N
strength NN N
and CC N
physical JJ N
function NN N
following VBG N
major JJ N
elective JJ N
surgery NN N
-DOCSTART- -X- O O 16299669

Comparative JJ N
speed NN N
of IN N
kill NN N
of IN N
selamectin NN N
, , N
imidacloprid JJ N
, , N
and CC N
fipronil- NN N
( ( N
S NNP N
) ) N
-methoprene VBD N
spot-on JJ N
formulations NNS N
against IN N
fleas NNS 4_p
on IN N
cats NNS 4_p
The DT N
speed NN N
of IN N
kill NN N
of IN N
selamectin NN N
, , N
imidacloprid JJ N
, , N
and CC N
fipronil- NN N
( ( N
S NNP N
) ) N
-methoprene NN N
against IN N
Ctenocephalides NNP N
felis JJ N
infestations NNS N
on IN N
cats NNS N
for IN N
one CD N
month NN N
following VBG N
a DT N
single JJ N
treatment NN N
was VBD N
evaluated VBN N
Eighty NNP 3_p
cats NNS N
were VBD N
randomly RB N
allocated VBN N
so RB N
that IN N
there EX N
were VBD N
20 CD N
cats NNS N
in IN N
four CD N
different JJ N
treatment NN N
groups NNS N
On IN N
Days NNPS N
-2 NNP N
, , N
7 CD N
, , N
14 CD N
, , N
21 CD N
, , N
and CC N
28 CD N
, , N
each DT N
cat NN N
was VBD N
infested VBN N
with IN N
100 CD N
adult NN N
C. NNP N
felis NN N
from IN N
the DT N
Kansas NNP 4_p
1 CD 4_p
flea NN 4_p
strain NN N
Following VBG N
initial JJ N
application NN N
only RB N
imidacloprid JJ N
had VBD N
caused VBN N
a DT N
significant JJ N
reduction NN N
in IN N
adult NN N
fleas NNS N
on IN N
treated JJ N
cats NNS N
within IN N
6 CD N
hours NNS N
, , N
but CC N
by IN N
24 CD N
hours NNS N
all DT N
three CD N
formulations NNS N
had VBD N
killed VBN N
96.7 CD N
% NN N
of IN N
the DT N
fleas NNS N
At IN N
7 CD N
days NNS N
post NN N
treatment NN N
, , N
all DT N
three CD N
formulations NNS N
reduced VBD N
flea JJ N
populations NNS N
within IN N
6 CD N
and CC N
24 CD N
hours NNS N
by IN N
68.4 CD N
% NN N
and CC N
99.4 CD N
% NN N
, , N
respectively RB N
At IN N
21 CD N
and CC N
28 CD N
days NNS N
after IN N
treatment NN N
, , N
none NN N
of IN N
the DT N
formulations NNS N
killed VBD N
significant JJ N
numbers NNS N
of IN N
fleas NNS N
as IN N
compared VBN N
to TO N
controls NNS N
within IN N
6 CD N
hours NNS N
of IN N
infestation NN N
At IN N
28 CD N
days NNS N
after IN N
treatment NN N
, , N
selamectin NN N
, , N
fipronil- JJ N
( ( N
S NNP N
) ) N
-methoprene NN N
, , N
and CC N
imidacloprid VB N
had VBD N
killed VBN N
99.0 CD N
% NN N
, , N
86.4 CD N
% NN N
, , N
and CC N
72.6 CD N
% NN N
of IN N
the DT N
fleas NNS N
within IN N
48 CD N
hours NNS N
of IN N
infestation NN N
, , N
respectively RB N
This DT N
study NN N
demonstrates VBZ N
that IN N
the DT N
speed NN N
of IN N
kill NN N
of IN N
residual JJ N
flea NN N
products NNS N
on IN N
cats NN N
decreases NNS N
throughout IN N
the DT N
month NN N
following VBG N
application NN N
It PRP N
also RB N
demonstrated VBD N
that IN N
selamectin NN N
provided VBD N
the DT N
highest JJS N
level NN N
of IN N
residual JJ N
activity NN N
on IN N
cats NNS N
against IN N
the DT N
Kansas NNP N
1 CD N
flea NN N
strain NN N
-DOCSTART- -X- O O 22782459

Celecoxib NNP N
as IN N
adjunctive JJ N
treatment NN N
to TO N
risperidone VB N
in IN N
children NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
: : 4_p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
RATIONAL JJ N
Autism NNP N
is VBZ N
associated VBN N
with IN N
activation NN N
of IN N
the DT N
inflammatory NN N
response NN N
system NN N
OBJECTIVE VB N
This DT N
study NN N
aims VBZ N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
a DT N
cyclooxygenase-2 JJ N
inhibitor NN N
, , N
celecoxib NN N
, , N
as IN N
adjunctive JJ N
therapy NN N
in IN N
the DT N
treatment NN N
of IN N
autism NN N
METHODS NNP N
In IN N
a DT N
10-week JJ N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
, , N
40 CD 3_p
outpatient JJ 3_p
children NNS 3_p
with IN N
a DT N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
fourth JJ N
edition NN N
, , N
text JJ N
revision NN N
clinical JJ N
diagnosis NN N
of IN N
autism NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
celecoxib VB N
plus CC N
risperidone VB N
or CC N
placebo VB N
plus CC N
risperidone VB N
The DT N
dose NN N
of IN N
risperidone NN N
and CC N
celecoxib NN N
were VBD N
titrated VBN N
up RB N
to TO N
3 CD N
and CC N
300 CD N
mg/day NN N
, , N
respectively RB N
Patients NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
and CC N
10 CD N
weeks NNS N
of IN N
starting VBG N
medication NN N
using VBG N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist-Community NNP N
( ( N
ABC-C NNP N
) ) N
Rating VBG N
Scale NNP N
Primary NNP N
outcome JJ N
measure NN N
was VBD N
the DT N
change NN N
in IN N
irritability NN N
subscale NN N
of IN N
ABC-C NNP N
RESULTS NNP N
Significant JJ N
time NN N
× NNP N
treatment NN N
interaction NN N
was VBD N
observed VBN N
for IN N
Irritability NNP N
( ( N
F NNP N
( ( N
1.658 CD N
, , N
63.021 CD N
) ) N
= NN N
13.580 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
Lethargy/Social NNP N
Withdrawal NNP N
( ( N
F NNP N
( ( N
1.948 CD N
, , N
74.032 CD N
) ) N
= NN N
16.811 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
Stereotypic NNP N
Behavior NNP N
( ( N
F NNP N
( ( N
1.742 CD N
, , N
66.198 CD N
) ) N
= NN N
12.104 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
for IN N
Hyperactivity/Noncompliance NNP N
( ( N
F NNP N
( ( N
2.564 CD N
, , N
97.424 CD N
) ) N
= NN N
1.469 CD N
, , N
P NNP N
= NNP N
0.232 CD N
) ) N
, , N
and CC N
Inappropriate NNP N
Speech NNP N
subscales NNS N
( ( N
F NNP N
( ( N
1.607 CD N
, , N
61.075 CD N
) ) N
= NN N
0.173 CD N
, , N
P NNP N
= NNP N
0.794 CD N
) ) N
By IN N
week NN N
10 CD N
, , N
patients NNS N
in IN N
the DT N
celecoxib NN N
group NN N
showed VBD N
significantly RB N
greater JJR N
improvement NN N
in IN N
the DT N
Irritability NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
Lethargy/Social NNP N
Withdrawal NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
Stereotypic NNP N
Behavior NNP N
( ( N
P NNP N
< NNP N
0.00 CD N
) ) N
but CC N
not RB N
in IN N
Hyperactivity/Noncompliance NNP N
( ( N
P NNP N
= NNP N
0.202 CD N
) ) N
and CC N
Inappropriate NNP N
Speech NNP N
( ( N
P NNP N
= NNP N
0.802 CD N
) ) N
subscales NNS N
than IN N
the DT N
placebo NN N
group NN N
Complete JJ N
response NN N
was VBD N
achieved VBN N
by IN N
four CD N
( ( N
20 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
and CC N
11 CD N
( ( N
55 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
celecoxib NN N
group NN N
( ( N
χ NNP N
( ( N
2 CD N
) ) N
( ( N
1 CD N
) ) N
= NN N
5.227 CD N
, , N
P NNP N
= NNP N
0.022 CD N
) ) N
Frequency NN N
of IN N
side NN N
effects NNS N
was VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
CONCLUSIONS NNP N
Combination NNP N
of IN N
risperidone NN N
and CC N
celecoxib NN N
was VBD N
superior JJ N
to TO N
risperidone VB 4_p
alone RB 4_p
in IN 4_p
treating VBG 4_p
irritability NN N
, , N
social JJ N
withdrawal NN N
, , N
and CC N
stereotypy NN N
of IN N
children NNS N
with IN N
autism NN N
( ( N
Registration NNP N
, , N
www.irct.ir NN N
; : N
IRCT138711091556N2 NNP N
) ) N
-DOCSTART- -X- O O 19716589

Treatment NN N
of IN N
sperm NN N
with IN N
platelet-activating JJ N
factor NN N
does VBZ N
not RB N
improve VB N
intrauterine JJ N
insemination NN N
outcome NN N
in IN N
unselected JJ N
cases NNS N
of IN N
mild JJ N
male JJ N
factor NN N
infertility NN N
: : N
a DT N
prospective JJ N
double-blind NN N
randomized VBN N
crossover NN N
study NN N
OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
sperm JJ N
treatment NN N
with IN N
exogenous JJ N
platelet-activating JJ N
factor NN N
( ( N
PAF NNP N
) ) N
on IN N
intrauterine JJ N
insemination NN N
( ( N
IUI NNP N
) ) N
clinical JJ N
pregnancy NN N
rate NN N
in IN N
cases NNS N
of IN N
mild JJ N
male JJ N
factor NN N
infertility NN N
PAF NNP N
is VBZ N
a DT N
phospholipid JJ N
mediator NN N
, , N
which WDT N
is VBZ N
present JJ N
in IN N
human JJ N
sperm NN N
METHODS NNP N
The DT N
study NN N
was VBD N
performed VBN N
in IN N
the DT N
Assisted NNP N
Reproduction NNP N
Unit NNP N
of IN N
the DT N
2nd CD N
Department NNP N
of IN N
Obstetrics NNP N
and CC N
Gynecology NNP N
, , N
University NNP N
of IN N
Athens NNP N
, , N
Aretaieion NNP N
Hospital NNP N
, , N
Athens NNP N
, , N
Greece NNP N
, , N
and CC N
included VBD N
92 CD N
couples NNS N
who WP N
presented VBD N
with IN N
mild JJ N
male JJ N
factor NN N
infertility-all JJ N
candidates NNS N
for IN N
IUI NNP N
A NNP N
maximum NN N
of IN N
4 CD N
IUI NNP N
cycles NNS N
per IN N
couple NN N
with IN N
or CC N
without IN N
exogenous JJ N
PAF NNP N
treatment NN N
were VBD N
performed VBN N
and CC N
the DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
clinical JJ N
pregnancy NN N
rate NN N
( ( N
pregnancies NNS N
confirmed VBN N
by IN N
ultrasonography NN N
per IN N
100 CD N
cycles NNS N
) ) N
RESULTS VB N
The DT N
overall JJ N
clinical JJ N
pregnancy NN N
rate NN N
after IN N
a DT N
maximum NN N
of IN N
4 CD N
IUI NNP N
cycles NNS N
was VBD N
comparable JJ N
in IN N
cases NNS N
with IN N
and CC N
without IN N
sperm JJ N
treatment NN N
with IN N
PAF NNP N
( ( N
12.24 CD N
% NN N
vs JJ N
11.11 CD N
% NN N
) ) N
Addition NN N
or CC N
exclusion NN N
of IN N
PAF NNP N
sperm FW N
treatment NN N
in IN N
the DT N
same JJ N
patients NNS N
did VBD N
not RB N
significantly RB N
alter VB N
the DT N
outcome NN N
CONCLUSIONS VB N
The DT N
generalized JJ N
use NN N
of IN N
exogenous JJ N
PAF NNP N
for IN N
the DT N
preparation NN N
of IN N
sperm NN N
in IN N
unselected JJ N
cases NNS N
of IN N
mild JJ N
male JJ N
infertility NN N
does VBZ N
not RB N
improve VB N
the DT N
clinical JJ N
outcome NN N
of IN N
IUI NNP N
-DOCSTART- -X- O O 8904679

Impact NN N
of IN N
triiodothyronine NN N
on IN N
the DT N
survival NN N
of IN N
high-risk JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
open JJ 4_p
heart NN 4_p
surgery NN 4_p
Experimental NNP N
and CC N
clinical JJ N
studies NNS N
have VBP N
shown VBN N
the DT N
beneficial JJ N
effects NNS N
of IN N
triiodothyronine NN N
( ( N
T3 NNP N
) ) N
following VBG N
myocardial JJ N
revascularization NN N
on IN N
cardiopulmonary JJ N
bypass NN N
( ( N
CPB NNP N
) ) N
In IN N
this DT N
study NN N
, , N
open-label JJ N
T3 NNP N
was VBD N
administered VBN N
to TO N
68 CD 3_p
high-risk JJ N
patients NNS N
undergoing VBG 4_p
open JJ 4_p
heart NN 4_p
surgery NN 4_p
The DT N
New NNP N
Jersey NNP N
Risk NNP N
Assessment NNP N
was VBD N
used VBN N
to TO N
calculate VB N
the DT N
preoperative NN N
estimated VBD N
surgical JJ N
mortality NN N
A DT N
loading VBG N
dose NN N
of IN N
T3 NNP N
was VBD N
administered VBN N
: : N
( ( N
a DT N
) ) N
at IN N
release NN N
of IN N
the DT N
aortic JJ N
cross-clamp NN N
, , N
( ( N
b NN N
) ) N
whenever WRB N
the DT N
patient NN N
became VBD N
CPB NNP N
dependent NN N
, , N
( ( N
c NN N
) ) N
if IN N
the DT N
patient NN N
exhibited VBD N
low JJ N
cardiac NN N
output NN N
after IN N
discontinuing VBG N
CPB NNP N
and CC N
( ( N
d NN N
) ) N
as IN N
pretreatment NN N
before IN N
initiating VBG N
CPB NNP N
All NNP N
therapeutic JJ N
modalities NNS N
were VBD N
followed VBN N
by IN N
a DT N
continuous JJ N
T3 NNP N
infusion NN N
Following VBG N
T3 NNP N
therapy NN N
, , N
CPB NNP N
was VBD N
discontinued VBN N
in IN N
all DT N
patients NNS N
Based VBN N
upon IN N
discriminant JJ N
analysis NN N
, , N
a DT N
total NN N
of IN N
26 CD N
deaths NNS N
were VBD N
expected VBN N
from IN N
the DT N
entire JJ N
group NN N
, , N
but CC N
only RB N
7 CD N
patients NNS N
died VBD N
, , N
therefore RB N
, , N
the DT N
observed JJ N
mortality NN N
was VBD N
reduced VBN N
by IN N
72 CD N
% NN N
( ( N
p JJ N
< NNP N
0.007 CD N
) ) N
The DT N
use NN N
of IN N
T3 NNP N
had VBD N
a DT N
major JJ N
impact NN N
on IN N
reducing VBG N
surgical JJ N
mortality NN N
, , N
and CC N
may MD N
be VB N
advocated VBN N
as IN N
a DT N
new JJ N
therapeutic JJ N
modality NN N
in IN N
patients NNS N
with IN N
high JJ N
estimated VBN N
mortality NN N
undergoing VBG N
open JJ 4_p
heart NN 4_p
surgery NN 4_p
-DOCSTART- -X- O O 10077140

Switching VBG N
patients NNS N
with IN N
asthma NN N
from IN N
chlorofluorocarbon NN N
( ( N
CFC NNP N
) ) N
albuterol NN N
to TO N
hydrofluoroalkane-134a NN N
( ( N
HFA NNP N
) ) N
albuterol NN N
Chlorofluorocarbon NNP N
( ( N
CFC NNP N
) ) N
propellants VBZ N
deplete JJ N
stratospheric JJ N
ozone NN N
Production NN N
and CC N
use NN N
of IN N
CFCs NNS N
, , N
except IN N
for IN N
certain JJ N
critical JJ N
exemptions NNS N
, , N
has VBZ N
been VBN N
prohibited VBN N
by IN N
the DT N
Montreal NNP N
Protocol NNP N
Use NNP N
of IN N
CFCs NNPS N
as IN N
propellants NNS N
in IN N
metered-dose JJ N
inhalers NNS N
( ( N
MDIs NNP N
) ) N
is VBZ N
still RB N
allowed VBN N
, , N
but CC N
the DT N
U.S. NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
is VBZ N
planning VBG N
the DT N
transition NN N
to TO N
alternative JJ N
propellants NNS N
for IN N
use NN N
in IN N
MDIs NNP N
Hydrofluoroalkane-134a NNP N
( ( N
HFA NNP N
) ) N
, , N
a DT N
non-ozone-depleting JJ N
propellant NN N
, , N
has VBZ N
been VBN N
used VBN N
to TO N
reformulate VB N
albuterol NN N
( ( N
HFA NNP N
albuterol NN N
) ) N
This DT N
study NN N
evaluates VBZ N
whether IN N
comparable JJ N
safety NN N
and CC N
efficacy NN N
continues VBZ N
for IN N
12 CD N
weeks NNS N
after IN N
patients NNS N
with IN N
asthma NNS N
are VBP N
switched VBN N
from IN N
CFC NNP N
albuterol NN N
to TO N
HFA NNP N
albuterol NN N
Patients NNS N
with IN N
asthma JJ N
stabilized VBN N
on IN N
CFC NNP N
albuterol NN N
during IN N
a DT N
12-week JJ N
safety NN N
and CC N
efficacy NN N
trial NN N
were VBD N
randomized VBN N
to TO N
either DT N
continue NN N
receiving VBG N
CFC NNP N
albuterol NN N
or CC N
to TO N
be VB N
switched VBN N
to TO N
receive VB N
HFA NNP N
albuterol NN N
in IN N
a DT N
yearlong JJ N
safety NN N
and CC N
efficacy NN N
trial NN N
Safety NN N
and CC N
efficacy NN N
were VBD N
compared VBN N
over IN N
the DT N
first JJ N
12 CD N
weeks NNS N
of IN N
the DT N
yearlong JJ N
trial NN N
between IN N
patients NNS N
who WP N
had VBD N
remained VBN N
on IN N
CFC NNP N
albuterol NN N
and CC N
those DT N
who WP N
had VBD N
been VBN N
switched VBN N
to TO N
HFA NNP N
albuterol NN N
Bronchodilator NNP N
efficacy NN N
was VBD N
evaluated VBN N
by IN N
serial JJ N
spirometry NN N
for IN N
6 CD N
hr NN N
after IN N
the DT N
patients NNS N
self-administered VBD N
the DT N
study NN N
drug NN N
in IN N
the DT N
clinic NN N
Safety NNP N
was VBD N
assessed VBN N
by IN N
measuring VBG N
changes NNS N
in IN N
pulse JJ N
rate NN N
, , N
blood NN N
pressure NN N
, , N
and CC N
electrocardiogram NN N
( ( N
ECG NNP N
) ) N
intervals NNS N
after IN N
dosing VBG N
with IN N
study JJ N
drug NN N
, , N
monitoring VBG N
adverse JJ N
events NNS N
, , N
and CC N
performing VBG N
prestudy NN N
and CC N
poststudy NN N
laboratory NN N
testing NN N
and CC N
physical JJ N
examinations NNS N
No DT N
significant JJ N
differences NNS N
in IN N
bronchodilator NN N
efficacy NN N
between IN N
the DT N
patients NNS N
continuing VBG N
to TO N
receive VB N
CFC NNP N
albuterol NN N
and CC N
those DT N
switched VBN N
to TO N
HFA NNP N
albuterol NN N
were VBD N
found VBN N
in IN N
the DT N
12 CD N
weeks NNS N
after IN N
the DT N
switch NN N
No DT N
differences NNS N
between IN N
the DT N
two CD N
products NNS N
were VBD N
found VBN N
for IN N
changes NNS N
in IN N
pulse JJ N
rate NN N
, , N
blood NN N
pressure NN N
, , N
and CC N
ECG NNP N
intervals NNS N
Adverse JJ N
event NN N
profiles NNS N
were VBD N
similar JJ N
for IN N
the DT N
two CD N
products NNS N
, , N
except IN N
the DT N
patients NNS N
remaining VBG N
on IN N
CFC NNP N
albuterol NN N
reported VBD N
increased JJ N
asthma NN N
symptoms NNS N
and CC N
rhinitis VB N
significantly RB N
more RBR N
often RB N
than IN N
the DT N
patients NNS N
switched VBD N
to TO N
HFA NNP N
albuterol NN N
No DT N
clinically RB N
meaningful JJ N
changes NNS N
in IN N
laboratory NN N
tests NNS N
or CC N
physical JJ N
examinations NNS N
were VBD N
found VBN N
in IN N
either DT N
treatment NN N
group NN N
Patients NNS N
with IN N
asthma JJ N
switched VBN N
from IN N
CFC NNP N
albuterol NN N
to TO N
HFA NNP N
albuterol NN N
receive VBP N
comparable JJ N
bronchodilation NN N
with IN N
a DT N
similar JJ N
safety NN N
profile NN N
as IN N
those DT N
continuing VBG N
to TO N
receive VB N
CFC NNP N
albuterol NN N
-DOCSTART- -X- O O 11348533

Clinical JJ N
description NN N
of IN N
encephalopathic JJ N
syndromes NNS N
and CC N
risk NN N
factors NNS N
for IN N
their PRP$ N
occurrence NN N
and CC N
outcome NN N
during IN N
melarsoprol NN N
treatment NN N
of IN N
human JJ 4_p
African JJ 4_p
trypanosomiasis NN 4_p
Encephalopathies NNS N
are VBP N
the DT N
most RBS N
feared JJ N
complications NNS N
of IN N
sleeping VBG N
sickness JJ N
treatment NN N
with IN N
melarsoprol NN N
To TO N
investigate VB N
the DT N
existence NN N
of IN N
risk NN N
factors NNS N
, , N
the DT N
incidence NN N
of IN N
encephalopathic JJ N
syndromes NNS N
and CC N
the DT N
relationship NN N
between IN N
the DT N
development NN N
of IN N
different JJ N
types NNS N
of IN N
encephalopathies NNS N
and CC N
the DT N
clinical JJ N
outcome NN N
was VBD N
studied VBN N
in IN N
a DT N
clinical JJ N
trial NN N
with IN N
588 CD N
patients NNS N
under IN N
treatment NN N
with IN N
melarsoprol NN N
The DT N
38 CD N
encephalopathy JJ N
cases NNS N
were VBD N
classified VBN N
into IN N
three CD N
types NNS N
according VBG N
to TO N
the DT N
leading VBG N
clinical JJ N
picture NN N
: : N
coma NN N
type NN N
, , N
convulsion NN N
type NN N
and CC N
psychotic JJ N
reactions NNS N
Nine JJ N
patients NNS N
were VBD N
attributed VBN N
to TO N
the DT N
convulsion NN N
type NN N
, , N
defined VBD N
as IN N
a DT N
transient JJ N
event NN N
of IN N
short JJ N
duration NN N
with IN N
convulsions NNS N
followed VBN N
by IN N
a DT N
post-ictal JJ N
phase NN N
, , N
without IN N
signs NNS N
of IN N
a DT N
generalized JJ N
disease NN N
None NN N
of IN N
these DT N
patients NNS N
died VBD N
from IN N
the DT N
reaction NN N
Febrile JJ N
reactions NNS N
in IN N
the DT N
48 CD N
h NN N
preceding VBG N
the DT N
reaction NN N
were VBD N
generally RB N
not RB N
observed VBN N
in IN N
this DT N
group NN N
Twenty-five JJ N
patients NNS N
were VBD N
attributed VBN N
to TO N
the DT N
coma NN N
type NN N
, , N
which WDT N
is VBZ N
a DT N
progredient JJ N
coma NN N
lasting VBG N
several JJ N
days NNS N
Those DT N
patients NNS N
often RB N
had VBD N
signs NNS N
of IN N
a DT N
generalized JJ N
disease NN N
such JJ N
as IN N
fever NN N
( ( N
84 CD N
% NN N
) ) N
, , N
headache NN N
( ( N
72 CD N
% NN N
) ) N
or CC N
bullous JJ N
skin NN N
( ( N
8 CD N
% NN N
) ) N
reactions NNS N
The DT N
risk NN N
of IN N
mortality NN N
was VBD N
high JJ N
in IN N
this DT N
group NN N
( ( N
52 CD N
% NN N
) ) N
About IN N
14/16 CD N
patients NNS N
with IN N
encephalopathic JJ N
syndrome NN N
of IN N
the DT N
coma NN N
type NN N
were VBD N
infected VBN N
with IN N
malaria NNS N
Patients NNS N
with IN N
psychotic JJ N
reactions NNS N
or CC N
abnormal JJ N
psychiatric JJ N
behaviour NN N
( ( N
3/38 CD N
) ) N
and CC N
one CD N
patient NN N
who WP N
died VBD N
after IN N
alcohol NN N
intake NN N
were VBD N
excluded VBN N
from IN N
the DT N
analysis NN N
The DT N
overall JJ N
rate NN N
of IN N
encephalopathic JJ N
syndromes NNS N
in IN N
the DT N
cases NNS N
analysed VBD N
( ( N
n=34 NN N
) ) N
was VBD N
5.8 CD N
% NN N
, , N
of IN N
which WDT N
38.2 CD N
% NN N
died VBD N
We PRP N
did VBD N
not RB N
find VB N
any DT N
parameters NNS N
of IN N
predictive JJ N
value NN N
for IN N
the DT N
risk NN N
of IN N
developing VBG N
an DT N
encephalopathic JJ N
syndrome NN N
based VBN N
on IN N
the DT N
symptoms NNS N
and CC N
signs NNS N
before IN N
treatment NN N
initiation NN N
The DT N
appearance NN N
during IN N
treatment NN N
of IN N
febrile JJ N
reactions NNS N
( ( N
RR NNP N
11.5 CD N
) ) N
, , N
headache NN N
( ( N
RR NNP N
2.5 CD N
) ) N
, , N
bullous JJ N
eruptions NNS N
( ( N
RR NNP N
4.5 CD N
) ) N
and CC N
systolic JJ N
hypotension NN N
( ( N
RR NNP N
2.6 CD N
) ) N
were VBD N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
for IN N
the DT N
occurrence NN N
of IN N
encephalopathic JJ N
syndromes NNS N
especially RB N
of IN N
the DT N
coma NN N
type NN N
-DOCSTART- -X- O O 6849742

Changes NNS N
in IN N
heart NN N
rate NN N
and CC N
forearm NN N
blood NN N
flow NN N
following VBG N
intravenous JJ N
boluses NNS N
of IN N
isoprenaline NN N
in IN N
the DT N
presence NN N
of IN N
practolol NN N
and CC N
propranolol NN N
1 CD N
Increases NNS N
in IN N
heart NN N
rate NN N
and CC N
forearm NN N
blood NN N
flow NN N
following VBG N
graded VBD N
intravenous JJ N
bolus JJ N
injections NNS N
of IN N
isoprenaline JJ N
sulphate NN N
, , N
were VBD N
measured VBN N
in IN N
a DT N
double-blind NN N
randomised VBN N
study NN N
of IN N
six CD 3_p
subjects NNS N
who WP N
received VBD N
either DT N
placebo NN N
, , N
practolol VBP N
50 CD N
mg NN N
, , N
practolol VBP N
200 CD N
mg NN N
, , N
propranolol VBP N
10 CD N
mg NN N
or CC N
propranolol VB N
40 CD N
mg. NN N
2 CD N
Dose NNP N
related JJ N
increases NNS N
in IN N
forearm NN N
blood NN N
flow NN N
were VBD N
produced VBN N
by IN N
the DT N
graded JJ N
boluses NNS N
of IN N
isoprenaline JJ N
sulphate NN N
3 CD N
Practolol NNP N
50 CD N
mg NN N
attenuated VBD N
the DT N
heart NN N
rate NN N
response NN N
to TO N
isoprenaline VB N
but CC N
did VBD N
not RB N
significantly RB N
affect VB N
the DT N
changes NNS N
in IN N
forearm NN N
blood NN N
flow NN N
Practolol CC N
200 CD N
mg NN N
further RB N
attenuated VBD N
the DT N
heart NN N
rate NN N
responses NNS N
but CC N
also RB N
decreased VBD N
the DT N
forearm NN N
blood NN N
flow NN N
responses NNS N
4 CD N
Propranolol NNP N
10 CD N
mg NN N
and CC N
propranolol NN N
40 CD N
mg NN N
significantly RB N
attenuated VBD N
both DT N
the DT N
heart NN N
rate NN N
and CC N
forearm NN N
blood NN N
flow NN N
responses NNS N
The DT N
effect NN N
on IN N
forearm NN N
blood NN N
flow NN N
tended VBD N
to TO N
be VB N
greater JJR N
than IN N
the DT N
effect NN N
on IN N
heart NN N
rate NN N
5 CD N
Practolol NNP N
200 CD N
mg NN N
had VBD N
the DT N
same JJ N
effect NN N
on IN N
heart NN N
rate NN N
responses NNS N
as IN N
propranolol NN N
10 CD N
mg NN N
but CC N
a DT N
significantly RB N
smaller JJR N
effect NN N
on IN N
the DT N
forearm NN N
blood NN N
flow NN N
responses NNS N
6 CD N
The DT N
measurement NN N
of IN N
forearm NN N
blood NN N
flow NN N
following VBG N
intravenous JJ N
bolus JJ N
injections NNS N
of IN N
isoprenaline NN N
provides VBZ N
useful JJ N
information NN N
about IN N
the DT N
beta NN N
2-adrenoceptor JJ N
antagonism NN N
of IN N
propranolol NN N
and CC N
practolol NN N
However RB N
, , N
application NN N
of IN N
the DT N
technique NN N
may MD N
be VB N
limited VBN N
by IN N
the DT N
magnitude NN N
of IN N
the DT N
heart NN N
rate NN N
response NN N
and CC N
by IN N
the DT N
short-lived JJ N
nature NN N
of IN N
the DT N
increase NN N
in IN N
forearm JJ N
blood NN N
flow NN N
-DOCSTART- -X- O O 25973096

Comparison NNP N
of IN N
the DT N
neuroprotective JJ N
effects NNS N
and CC N
recovery NN N
profiles NNS N
of IN N
isoflurane NN N
, , N
sevoflurane NN N
and CC N
desflurane NN N
as IN N
neurosurgical JJ N
pre-conditioning NN N
on IN N
ischemia/reperfusion NN 4_p
cerebral JJ 4_p
injury NN 4_p
BACKGROUND IN N
There EX N
are VBP N
a DT N
few JJ N
reports NNS N
regarding VBG N
the DT N
comparison NN N
of IN N
these DT N
anesthetic JJ N
agents NNS N
, , N
but CC N
previous JJ N
studies NNS N
mainly RB N
focus VBP N
on IN N
the DT N
veterinary JJ N
anesthesiology NN N
Less NNP N
attention NN N
has VBZ N
been VBN N
focused VBN N
comparing VBG N
the DT N
effectiveness NN N
of IN N
these DT N
inhalational JJ N
anesthetic JJ N
agents NNS N
in IN N
neurosurgery NN 4_p
This DT N
lack NN N
of IN N
interest NN N
is VBZ N
regretful JJ N
particularly RB N
considering VBG N
the DT N
fact NN N
that IN N
anesthetics NNS N
during IN N
neurosurgery NN N
are VBP N
an DT N
issue NN N
of IN N
extreme JJ N
sensitivity NN N
and CC N
subtlety NN N
, , N
where WRB N
the DT N
cerebral JJ N
oxygenation NN N
process NN N
plays VBZ N
a DT N
significant JJ N
role NN N
in IN N
the DT N
neuroprotective JJ N
mechanisms NN N
OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
retrospective JJ N
study NN N
is VBZ N
to TO N
contribute VB N
to TO N
the DT N
existing VBG N
knowledge NN N
of IN N
the DT N
comparative JJ N
studies NNS N
of IN N
the DT N
volatile JJ N
anesthetic JJ N
agents NNS N
such JJ N
as IN N
isoflurane NN N
, , N
sevoflurane NN N
and CC N
desflurane NN N
by IN N
evaluating VBG N
the DT N
maintenance NN N
and CC N
emergence NN N
characteristics NNS N
after IN N
volatile JJ N
anesthetics-induced JJ N
preconditioning NN N
with IN N
isoflurane NN N
, , N
sevoflurane NN N
or CC N
desflurane NN N
for IN N
inpatient JJ N
ischemia/reperfusion NN 4_p
cerebral JJ 4_p
injury NN 4_p
during IN N
cerebral JJ N
or CC N
neural JJ N
surgeries NNS N
METHODS NNP N
The DT N
aim NN N
was VBD N
to TO N
investigate VB N
their PRP$ N
neuroprotective JJ N
mechanisms NNS N
and CC N
effects NNS N
by IN N
analyzing VBG N
and CC N
comparing VBG N
the DT N
superiority NN N
of IN N
each DT N
agent NN N
in IN N
a DT N
Chinese JJ N
patient NN N
population NN N
, , N
in IN N
terms NNS N
of IN N
faster NN N
emergence NN N
, , N
and CC N
early RB N
and CC N
intermediate JJ N
recovery NN N
The DT N
intraoperative JJ N
haemodynamic JJ N
profiles NNS N
and CC N
postoperative JJ N
adverse JJ N
effects NNS N
of IN N
these DT N
three CD N
agents NNS N
were VBD N
also RB N
systematically RB N
analyzed VBN N
RESULTS NNP N
We PRP N
found VBD N
that IN N
sevoflurane NN N
, , N
when WRB N
compared VBN N
with IN N
isoflurane NN N
and CC N
desflurane NN N
, , N
provided VBN N
anesthesia NN N
with IN N
similar JJ N
hemodynamic JJ N
stability NN N
but CC N
allowed VBN N
for IN N
a DT N
smoother NN N
, , N
more RBR N
rapid JJ N
emergence NN N
and CC N
better JJR N
quality NN N
of IN N
induction NN N
and CC N
recovery NN N
to TO N
surgical JJ N
patients NNS N
under IN N
clinical JJ N
conditions NNS N
, , N
particularly RB N
to TO N
those DT N
who WP N
were VBD N
experiencing VBG N
substantial JJ 4_p
cerebral JJ 4_p
vasodilation NN 4_p
CONCLUSION NNP N
Sevoflurane NNP N
offers VBZ N
several JJ N
advantages NNS N
, , N
including VBG N
a DT N
relative JJ N
lack NN N
of IN N
airway JJ N
irritation NN N
, , N
a DT N
more RBR N
rapid JJ N
onset NN N
and CC N
recovery NN N
, , N
and CC N
greater JJR N
hemodynamic JJ N
stability NN N
than IN N
other JJ N
potent NN N
inhaled JJ N
agents NNS N
These DT N
properties NNS N
would MD N
appear VB N
to TO N
afford VB N
sevoflurane NN N
significant JJ N
clinical JJ N
potential NN N
-DOCSTART- -X- O O 21087288

A DT N
placebo-controlled JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
using VBG N
testosterone NN N
undecanoate NN N
with IN N
injectable JJ N
norethisterone JJ N
enanthate NN N
: : N
effect NN N
on IN N
anthropometric NN 4_p
, , 4_p
metabolic JJ 4_p
and CC 4_p
biochemical JJ 4_p
parameters NNS 4_p
Testosterone CD N
administered VBD N
alone RB N
or CC N
in IN N
combination NN N
with IN N
progestogens NNS N
in IN N
male JJ N
contraception NN N
induces NNS N
reversible JJ N
oligo-azoospermia JJ N
, , N
but CC N
its PRP$ N
effects NNS N
on IN N
body NN N
composition NN N
and CC N
metabolism NN N
are VBP N
less RBR N
known JJ N
We PRP N
analysed VBD N
anthropometric JJ N
and CC N
metabolic JJ N
parameters NNS N
in IN N
five CD N
groups NNS N
of IN N
10 CD N
males NNS N
: : N
four CD N
receiving VBG N
testosterone NN N
undecanoate NN N
( ( N
TU NNP N
: : N
1000 CD N
mg NN N
) ) N
plus CC N
norethisterone JJ N
enanthate NN N
( ( N
NETE NNP N
: : N
200 CD N
mg NN N
) ) N
at IN N
different JJ N
intervals NNS N
( ( N
every DT N
8 CD N
weeks NNS N
: : N
NETE-8 JJ N
; : N
every DT N
12 CD N
weeks NNS N
: : N
NETE-12 NN N
; : N
every DT N
6 CD N
weeks NNS N
for IN N
12 CD N
weeks NNS N
and CC N
then RB N
every DT N
12 CD N
weeks NNS N
: : N
NETE-6/12 JJ N
; : N
every DT N
6 CD N
weeks NNS N
for IN N
12 CD N
weeks NNS N
and CC N
then RB N
TU NNP N
plus CC N
placebo JJ N
every DT N
12 CD N
weeks NNS N
: : N
NETE-6/12/0 NNP N
) ) N
and CC N
one CD N
placebo NN N
( ( N
NETE-0/0 NNP N
) ) N
for IN N
a DT N
total NN N
of IN N
48 CD N
weeks NNS N
Body NNP N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
and CC N
waist JJ N
circumference NN N
did VBD N
not RB N
change VB N
in IN N
any DT N
groups NNS N
except IN N
for IN N
the DT N
NETE-8 NNP N
in IN N
which WDT N
BMI NNP N
increased VBD N
significantly RB N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
period NN N
Lean JJ N
body NN N
mass NN N
( ( N
MAMC NNP N
or CC N
AMA NNP N
) ) N
increased VBD N
significantly RB N
in IN N
the DT N
highest JJS N
hormonal JJ N
dose NN N
groups NNS N
( ( N
p JJ N
= NN N
0.04 CD N
, , N
NETE-6/12 NNP N
; : N
p VBZ N
= $ N
0.004 CD N
, , N
NETE-8 NNP N
) ) N
No UH N
differences NNS N
were VBD N
observed VBN N
in IN N
glucose JJ N
levels NNS N
, , N
insulin NN N
sensitivity NN N
index NN N
and CC N
lipid JJ N
profile NN N
as RB N
well RB N
as IN N
in IN N
biochemical JJ N
and CC N
cell NN N
count NN N
parameters NNS N
in IN N
any DT N
groups NNS N
In IN N
conclusion NN N
, , N
NETE NNP N
and CC N
TU NNP N
for IN N
48 CD N
weeks NNS N
were VBD N
not RB N
accompanied VBN N
by IN N
any DT N
metabolic JJ N
changes NNS N
and CC N
any DT N
adverse JJ N
effects NNS N
The DT N
weight JJ N
gain NN N
of IN N
the DT N
highest JJS N
NETE JJ N
plus CC N
TU JJ N
dosage NN N
was VBD N
mainly RB N
because IN N
of IN N
gain NN N
in IN N
muscle NN N
mass NN N
-DOCSTART- -X- O O 17625432

Efficacy NN N
of IN N
amantadine NN N
on IN N
quality NN N
of IN N
life NN N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
hepatitis NN 4_p
C NNP 4_p
treated VBD N
with IN N
interferon-alpha JJ N
and CC N
ribavirin NN N
: : N
results NNS N
from IN N
a DT N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
AIM VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
amantadine JJ N
reduces NNS N
deterioration NN N
of IN N
quality NN N
of IN N
life NN N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
hepatitis NN 4_p
C NNP 4_p
during IN N
and CC N
after IN N
treatment NN N
with IN N
interferon-alpha JJ N
( ( N
IFN-alpha NNP N
) ) N
and CC N
ribavirin NN N
PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
randomized VBN N
, , N
prospective JJ N
, , N
placebo-controlled JJ N
, , N
multicenter JJ N
trial NN N
, , N
previously RB 4_p
untreated JJ 4_p
patients NNS 4_p
with IN N
chronic JJ 4_p
hepatitis NN 4_p
C NNP 4_p
were VBD N
treated VBN N
with IN N
IFN-alpha NNP N
plus CC N
ribavirin JJ N
[ NN N
17 CD N
] NN N
and CC N
randomized VBN N
for IN N
treatment NN N
with IN N
amantadine NN N
( ( N
200 CD N
mg/day NN N
, , N
orally RB N
, , N
n=136 NN N
) ) N
or CC N
placebo NN N
( ( N
n=131 JJ N
) ) N
Quality NN N
of IN N
life NN N
was VBD N
assessed VBN N
with IN N
the DT N
'Profile NN N
of IN N
Mood NNP N
States NNPS N
' POS N
scale NN N
and CC N
the DT N
'Everyday JJ N
Life NNP N
' POS N
questionnaire NN N
at IN N
baseline NN N
, , N
treatment NN N
week NN N
( ( N
TW NNP N
) ) N
8 CD N
, , N
TW24 NNP N
, , N
TW48 NNP N
, , N
and CC N
at IN N
follow-up JJ N
RESULTS VB N
Early JJ N
during IN N
treatment NN N
at IN N
TW8 NNP N
, , N
quality NN N
of IN N
life NN N
was VBD N
not RB N
different JJ N
between IN N
patients NNS N
in IN N
the DT N
control NN N
and CC N
the DT N
amantadine NN N
group NN N
At IN N
TW24 NNP N
, , N
the DT N
control NN N
group NN N
but CC N
not RB N
the DT N
amantadine NN N
group NN N
, , N
however RB N
, , N
showed VBD N
significant JJ N
deterioration NN N
of IN N
the DT N
modalities NNS N
depression NN N
, , N
fatigue NN N
, , N
and CC N
vigor NN N
compared VBN N
with IN N
baseline NN N
Especially RB N
, , N
nonresponders NNS N
in IN N
the DT N
amantadine NN N
group NN N
showed VBD N
significantly RB N
lower JJR N
deterioration NN N
of IN N
depression NN N
, , N
anger NN N
, , N
mind NN N
function NN N
, , N
everyday JJ N
life NN N
, , N
and CC N
zest JJS N
for IN N
life NN N
than IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
After IN N
treatment NN N
, , N
the DT N
beneficial JJ N
effects NNS N
of IN N
amantadine NN N
disappeared VBN N
CONCLUSION VB N
The DT N
addition NN N
of IN N
amantadine NN N
to TO N
IFN-alpha NNP N
plus CC N
ribavirin JJ N
combination NN N
therapy NN N
may MD N
reduce VB N
deterioration NN N
of IN N
depression NN N
, , N
fatigue NN N
, , N
and CC N
vigor NN N
during IN N
treatment NN N
but CC N
does VBZ N
not RB N
affect JJ N
quality NN N
of IN N
life NN N
after IN N
treatment NN N
-DOCSTART- -X- O O 11718681

Relationship NN N
between IN N
endogenous JJ N
estrogen NN N
concentrations NNS N
and CC N
serum NN N
cholesteryl NN N
ester NN N
transfer NN N
protein NN N
concentrations NNS N
in IN N
Chinese JJ 4_p
women NNS 2_p
BACKGROUND NNP N
CETP NNP N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
HDL NNP N
metabolism NN N
and CC N
in IN N
the DT N
reverse NN N
cholesterol NN N
transport NN N
pathway NN N
METHODS NNP N
The DT N
relationship NN N
between IN N
the DT N
changes NNS N
of IN N
endogenous JJ N
estrogen NN N
and CC N
the DT N
concentration NN N
of IN N
cholesteryl NN N
ester NN N
transfer NN N
protein NN N
( ( N
CETP NNP N
) ) N
in IN N
the DT N
serum NN N
of IN N
Chinese JJ N
women NNS N
was VBD N
investigated VBN N
Serum NNP N
concentrations NNS N
of IN N
estradiol NN N
( ( N
E NNP N
( ( N
2 CD N
) ) N
) ) N
, , N
follicle-stimulating JJ N
hormone NN N
( ( N
FSH NNP N
) ) N
, , N
CETP NNP N
and CC N
lipid JJ N
profile NN N
were VBD N
determined VBN N
in IN N
196 CD 3_p
Chinese JJ 4_p
women NNS 2_p
( ( N
52 CD 3_p
premenopausal NN 4_p
with IN N
ages NNS 1_p
ranging VBG 1_p
from IN 1_p
18 CD 1_p
to TO 1_p
40 CD 1_p
years NNS 1_p
, , N
57 CD 3_p
perimenopausal NN 4_p
from IN N
41 CD 1_p
to TO 1_p
60 CD 1_p
years NNS 1_p
, , N
and CC N
87 CD 3_p
postmenopausal NN 4_p
from IN N
61 CD 1_p
to TO 1_p
81 CD 1_p
years NNS 1_p
) ) N
RESULTS NNP N
Serum NNP N
CETP NNP N
concentration NN N
was VBD N
significantly RB N
lower JJR N
in IN N
postmenopausal JJ N
women NNS N
compared VBN N
with IN N
those DT N
in IN N
perimenopausal NN N
and CC N
premenopausal JJ N
women NNS N
( ( N
1.39+/-1.06 JJ N
, , N
2.36+/-1.50 JJ N
and CC N
2.31+/-1.25 JJ N
mg/l NN N
, , N
respectively RB N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
Even RB N
in IN N
the DT N
women NNS N
around IN N
the DT N
menopausal NN N
, , N
CETP NNP N
concentration NN N
in IN N
postmenopause NN N
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
in IN N
premenopause NN N
( ( N
1.93+/-1.33 JJ N
vs. IN N
3.42+/-1.35 JJ N
mg/l NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
In IN N
addition NN N
, , N
CETP NNP N
concentration NN N
had VBD N
a DT N
highly RB N
positive JJ N
correlation NN N
with IN N
serum JJ N
concentration NN N
of IN N
E NNP N
( ( N
2 CD N
) ) N
( ( N
r=0.243 NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
while IN N
negative JJ N
correlation NN N
of IN N
CETP NNP N
concentration NN N
with IN N
serum JJ N
concentration NN N
of IN N
FSH NNP N
was VBD N
found VBN N
( ( N
r=-0.273 JJ N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
CONCLUSIONS NNP N
Estrogen NNP N
may MD N
affect VB N
the DT N
concentration NN N
of IN N
CETP NNP N
-DOCSTART- -X- O O 12591004

Bioavailability NN N
of IN N
omega-3 JJ 4_p
essential JJ 4_p
fatty JJ 4_p
acids NNS 4_p
from IN 4_p
perilla NN 4_p
seed NN 4_p
oil NN 4_p
Increased VBD N
dietary JJ N
intake NN N
of IN N
fish JJ N
oil NN N
omega-3 JJ N
fatty NN N
acids NNS N
, , N
eicosapentanoic JJ N
acid NN N
and CC N
docosohexanoic NN N
acid NN N
, , N
and CC N
their PRP$ N
precursor NN N
, , N
alpha-linolenic JJ N
acid NN N
( ( N
ALA NNP N
) ) N
, , N
is VBZ N
associated VBN N
with IN N
various JJ N
health NN N
benefits NNS N
Enteric-coating NNP N
( ( N
Entrox NNP N
) ) N
, , N
which WDT N
improves VBZ N
stability NN N
of IN N
omega-3 JJ N
capsules NNS N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
facilitate VB N
fish JJ N
oil NN N
absorption NN N
after IN N
chronic JJ N
treatment NN N
To TO N
assess VB N
the DT N
effect NN N
of IN N
Entrox NNP N
coating VBG N
on IN N
the DT N
short-term JJ N
bioavailability NN N
of IN N
ALA NNP N
administered VBD N
in IN N
the DT N
form NN N
of IN N
ALA-rich NNP N
Perilla NNP N
seed NN N
oil NN N
, , N
12 CD 4_p
healthy JJ 4_p
subjects NNS 4_p
( ( 4_p
6 CD 4_p
males NNS 4_p
and CC 4_p
6 CD 4_p
females NNS 4_p
) ) 4_p
received VBN N
in IN N
a DT N
random JJ N
order NN N
Entrox-coated JJ N
and CC N
non-coated JJ N
ALA NNP N
formulations NNS N
, , N
each DT N
as IN N
a DT N
single JJ N
6g CD N
dose NN N
separated VBN N
by IN N
a DT N
3-week JJ N
washout NN N
period NN N
Measurements NNS N
of IN N
plasma NN N
ALA NNP N
concentrations NNS N
from IN N
0 CD N
to TO N
24h CD N
showed VBD N
no DT N
difference NN N
in IN N
ALA NNP N
pharmacokinetics NNS N
between IN N
the DT N
two CD N
formulations NNS N
However RB N
, , N
significantly RB N
greater JJR N
increases NNS N
in IN N
plasma JJ N
ALA NNP N
levels NNS N
from IN N
baseline NN N
to TO N
24h CD N
were VBD N
observed VBN N
after IN N
ingestion NN N
of IN N
Entrox NNP N
vs. IN N
non-coated JJ N
product NN N
, , N
suggesting VBG N
a DT N
possible JJ N
benefit NN N
of IN N
Entrox NNP N
with IN N
long-term JJ N
treatment NN N
-DOCSTART- -X- O O 19884541

Comparison NNP N
of IN N
neurocognitive JJ N
functioning NN N
in IN N
children NNS N
previously RB N
randomly RB N
assigned VBN N
to TO N
intrathecal JJ N
methotrexate NN N
compared VBN N
with IN N
triple JJ N
intrathecal JJ N
therapy NN N
for IN N
the DT N
treatment NN N
of IN N
childhood NN N
acute NN N
lymphoblastic JJ 4_p
leukemia NN 4_p
PURPOSE NNP N
For IN N
the DT N
majority NN N
of IN N
children NNS 1_p
with IN N
acute JJ 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
( ( 4_p
ALL NNP 4_p
) ) 4_p
, , N
CNS NNP N
prophylaxis NN N
consists VBZ N
of IN N
either DT N
intrathecal JJ N
( ( N
IT NNP N
) ) N
methotrexate NN N
or CC N
triple VB N
IT NNP N
therapy NN N
( ( N
ie JJ N
, , N
methotrexate NN N
with IN N
both DT N
cytarabine NN N
and CC N
hydrocortisone NN N
) ) N
The DT N
long-term JJ N
neurotoxicities NNS N
of IN N
these DT N
two CD N
IT NNP N
strategies NNS N
have VBP N
not RB N
yet RB N
been VBN N
directly RB N
compared VBN N
PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
multisite NN N
study NN N
, , N
171 CD 3_p
children NNS 1_p
with IN N
standard-risk JJ N
ALL NNP N
, , N
age NN 1_p
1 CD 1_p
to TO 1_p
9.99 CD 1_p
years NNS 1_p
at IN N
diagnosis NN N
, , N
previously RB N
randomly RB N
assigned VBN N
to TO N
IT NNP N
methotrexate NNP N
( ( N
n JJ N
= NNP N
82 CD N
) ) N
or CC N
to TO N
triple VB N
IT NNP N
therapy NN N
( ( N
n JJ N
= NNP N
89 CD N
) ) N
on IN N
CCG NNP N
1952 CD N
, , N
underwent JJ N
neurocognitive JJ N
evaluation NN N
by IN N
a DT N
licensed JJ N
psychologist NN N
at IN N
a DT N
mean NN N
of IN N
5.9 CD N
years NNS N
after IN N
random JJ N
assignment NN N
RESULTS JJ N
Patients NNPS N
who WP N
received VBD N
IT NNP N
methotrexate NNP N
had VBD N
a DT N
mean JJ N
Processing NNP N
Speed NNP N
Index NNP N
that WDT N
was VBD N
3.6 CD N
points NNS N
lower JJR N
, , N
about IN N
one CD N
fourth JJ N
of IN N
a DT N
standard JJ N
deviation NN N
, , N
than IN N
those DT N
who WP N
received VBD N
triple JJ N
IT NNP N
therapy NN N
( ( N
P NNP N
= NNP N
.04 NNP N
) ) N
after IN N
analysis NN N
was VBD N
adjusted VBN N
for IN N
age NN N
, , N
sex NN N
, , N
and CC N
time NN N
since IN N
diagnosis NN N
Likewise NNP N
, , N
19.5 CD N
% NN N
of IN N
children NNS N
in IN N
the DT N
IT NNP N
methotrexate NNP N
group NN N
had VBD N
a DT N
Processing NNP N
Speed NNP N
Index NNP N
score NN N
in IN N
the DT N
below-average NN N
range NN N
compared VBN N
with IN N
6.9 CD N
% NN N
in IN N
the DT N
triple NN N
IT NNP N
therapy NN N
group NN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
Otherwise UH N
, , N
the DT N
groups NNS N
performed VBD N
similarly RB N
on IN N
tests NNS N
of IN N
full-scale JJ N
intelligence NN N
quotient NN N
, , N
academic JJ N
achievement NN N
, , N
attention/concentration NN N
, , N
memory NN N
, , N
and CC N
visual JJ N
motor NN N
integration NN N
The DT N
association NN N
of IN N
treatment NN N
with IN N
measures NNS N
of IN N
cognitive JJ N
functioning NN N
was VBD N
not RB N
modified VBN N
by IN N
sex NN N
or CC N
age NN N
at IN N
diagnosis NN N
In IN N
the DT N
post-therapy JJ N
period NN N
, , N
there EX N
were VBD N
no DT N
group NN N
differences VBZ N
in IN N
special JJ N
education NN N
services NNS N
, , N
neurologic JJ N
events NNS N
, , N
or CC N
use NN N
of IN N
psychotropic NN N
medications NNS N
CONCLUSION NNP N
This DT N
study NN N
did VBD N
not RB N
show VB N
any DT N
clinically RB N
meaningful JJ N
differences NNS N
in IN N
neurocognitive JJ N
functioning NN N
between IN N
patients NNS N
previously RB N
randomly RB N
assigned VBN N
to TO N
IT NNP N
methotrexate NN N
or CC N
triple VB N
IT NNP N
therapy NN N
except IN N
for IN N
a DT N
small JJ N
difference NN N
in IN N
processing VBG N
speed NN N
in IN N
the DT N
IT NNP N
methotrexate NNP N
group NN N
-DOCSTART- -X- O O 9788685

Efficacy NN N
and CC N
safety NN N
relative VBP N
to TO N
placebo VB N
of IN N
an DT N
oral JJ N
formulation NN N
of IN N
cetirizine NN N
and CC N
sustained-release JJ N
pseudoephedrine NN N
in IN N
the DT N
management NN N
of IN N
nasal JJ 4_p
congestion NN 4_p
BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
clinical JJ N
efficacy NN N
of IN N
an DT N
oral JJ N
formulation NN N
of IN N
cetirizine NN N
5 CD N
mg NN N
with IN N
sustained-release JJ N
pseudoephedrine NN N
( ( N
PSE NNP N
) ) N
120 CD N
mg JJ N
relative NN N
to TO N
placebo VB N
in IN N
patients NNS 4_p
with IN 4_p
nasal JJ 4_p
congestion NN 4_p
METHODS NNP N
Twenty-four JJ 3_p
patients NNS N
with IN N
perennial JJ N
rhinitis NN N
due JJ N
to TO N
house-dust-mite JJ N
( ( N
HDM NNP N
) ) N
allergy NN N
were VBD N
recruited VBN N
in IN N
this DT N
crossover NN N
study NN N
A DT N
treatment NN N
period NN N
of IN N
1 CD N
week NN N
, , N
in IN N
which WDT N
cetirizine/PSE NN N
was VBD N
administered VBN N
twice RB N
daily RB N
, , N
was VBD N
followed VBN N
by IN N
a DT N
washout JJ N
period NN N
of IN N
at IN N
least JJS N
2 CD N
weeks NNS N
and CC N
a DT N
further JJ N
period NN N
of IN N
1 CD N
week NN N
in IN N
which WDT N
the DT N
alternative NN N
treatment NN N
was VBD N
given VBN N
to TO N
each DT N
patient NN N
Immediately RB N
after IN N
the DT N
first JJ N
dose NN N
of IN N
each DT N
medication NN N
( ( N
day NN N
1 CD N
) ) N
, , N
nasal JJ N
congestion NN N
and CC N
related VBN N
symptoms NNS N
were VBD N
assessed VBN N
during IN N
a DT N
7-h JJ N
challenge NN N
with IN N
HDM NNP N
feces NNS N
, , N
with IN N
the DT N
Vienna NNP N
Challenge NNP N
Chamber NNP N
( ( N
VCC NNP N
) ) N
, , N
to TO N
investigate VB N
onset NN N
of IN N
action NN N
of IN N
the DT N
preparation NN N
A DT N
second JJ N
challenge NN N
of IN N
3-h JJ N
duration NN N
, , N
carried VBD N
out RP N
at IN N
least JJS N
12 CD N
h NN N
after IN N
the DT N
final JJ N
dose NN N
, , N
was VBD N
undertaken VBN N
after IN N
1 CD N
week NN N
( ( N
mean JJ N
) ) N
of IN N
twice-daily JJ N
treatment NN N
to TO N
assess VB N
residual JJ N
effects NNS N
of IN N
the DT N
formulation NN N
after IN N
achievement NN N
of IN N
steady JJ N
state NN N
RESULTS VB N
The DT N
oral JJ N
formulation NN N
of IN N
cetirizine/PSE NN N
was VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
superior NN N
to TO N
placebo VB N
in IN N
improving VBG N
nasal JJ N
obstruction NN N
during IN N
both DT N
challenges NNS N
The DT N
improvement NN N
in IN N
nasal JJ N
airflow NN N
and CC N
nasal JJ N
patency NN N
was VBD N
significantly RB N
greater JJR N
with IN N
cetirizine/PSE NN N
than IN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
In IN N
addition NN N
, , N
subjective JJ N
assessment NN N
of IN N
nasal NN N
symptoms NNS N
showed VBD N
that IN N
cetirizine/PSE NN N
was VBD N
significantly RB N
superior JJ N
to TO N
placebo VB N
in IN N
both DT N
challenges NNS N
for IN N
the DT N
sum NN N
of IN N
nasal JJ N
obstruction NN N
scores NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
Both DT N
medications NNS N
were VBD N
well RB N
tolerated VBN N
, , N
and CC N
no DT N
serious JJ N
adverse JJ N
events NNS N
occurred VBD N
during IN N
the DT N
study NN N
CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
cetirizine/PSE NN N
relieved VBD N
nasal JJ N
congestion NN N
and CC N
other JJ N
objective JJ N
and CC N
subjective JJ N
symptoms NNS N
to TO N
a DT N
significantly RB N
greater JJR N
extent NN N
than IN N
placebo NN N
No DT N
serious JJ N
adverse JJ N
events NNS N
occurred VBD N
, , N
and CC N
both DT N
regimens NNS N
were VBD N
equally RB N
well RB N
tolerated VBN N
-DOCSTART- -X- O O 10618526

Early JJ N
immunisation NN N
with IN N
hepatitis NN N
B NNP N
vaccine NN N
: : N
a DT N
five-year JJ N
study NN N
We PRP N
evaluated VBD N
the DT N
response NN N
to TO N
the DT N
recombinant NN N
Hepatitis NNP N
B NNP N
vaccine NN N
using VBG N
an DT N
accelerated JJ N
schedule NN N
versus IN N
the DT N
traditional JJ N
schedule NN N
by IN N
studying VBG N
the DT N
immunologic JJ N
memory NN N
induced VBN N
in IN N
200 CD 3_p
children NNS 1_p
with IN N
HBs-Ag NNP 4_p
negative JJ N
mothers NNS N
At IN N
seroconversion NN N
, , N
the DT N
traditional JJ N
schedule NN N
presented VBD N
a DT N
higher JJR N
percentage NN N
of IN N
children NNS N
with IN N
serum JJ N
HBs-Ag JJ N
concentrations NNS N
over IN N
100 CD N
mIU/ml NNS N
than IN N
the DT N
accelerated JJ N
schedule NN N
After IN N
five CD N
years NNS N
this DT N
difference NN N
was VBD N
no RB N
longer RBR N
statistically RB N
significant JJ N
and CC N
children NNS N
who WP N
presented VBD N
anti-HBsAg JJ N
concentrations NNS N
below IN N
10 CD N
mUI/ml NN N
received VBD N
an DT N
additional JJ N
booster NN N
dose NN N
which WDT N
stimulated VBD N
the DT N
antibody NN N
concentration NN N
to TO N
exceed VB N
100 CD N
mIU/ml NNS N
in IN N
all DT N
cases NNS N
Recombinant JJ N
HBV NNP N
vaccine NN N
induced VBD N
better JJR N
long JJ N
term NN N
immunologic JJ N
memory NN N
when WRB N
it PRP N
was VBD N
administered VBN N
earlier RBR N
-DOCSTART- -X- O O 11710599

Absence NN N
of IN N
cervical JJ N
radiation NN N
myelitis NN N
after IN N
hyperfractionated VBN N
radiation NN N
therapy NN N
with IN N
and CC N
without IN N
concurrent JJ N
chemotherapy NN N
for IN N
locally RB 4_p
advanced JJ 4_p
, , 4_p
unresectable JJ 4_p
, , 4_p
nonmetastatic JJ 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
PURPOSE NNP N
To TO N
evaluate VB N
the DT N
risk NN N
of IN N
developing VBG N
radiation NN N
myelitis NN N
after IN N
a DT N
cervical JJ N
spinal NN N
cord NN N
dose NN N
of IN N
50.6 CD N
Gy NNP N
given VBN N
via IN N
1.1 CD N
Gy NNP N
b.i.d NN N
fractionation NN N
during IN N
a DT N
prospective JJ N
, , N
randomised JJ N
trial NN N
of IN N
hyperfractionated JJ N
radiation NN N
therapy NN N
( ( N
HFX NNP N
RT NNP N
) ) N
to TO N
a DT N
total JJ N
dose NN N
of IN N
77 CD N
Gy NNP N
given VBN N
in IN N
70 CD N
fractions NNS N
of IN N
1.1 CD N
Gy NNP N
b.i.d. NN N
, , N
with IN N
and CC N
without IN N
concurrent JJ N
low-dose JJ N
, , N
daily JJ N
cisplatin NN N
( ( N
CDDP NNP N
) ) N
for IN N
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
METHODS NNP N
Of IN N
130 CD 3_p
patients NNS N
with IN N
locally RB N
advanced VBN N
, , N
unresectable JJ N
, , N
nonmetastatic JJ N
squamous JJ N
cell NN N
carcinoma NN N
of IN N
the DT N
head NN N
and CC N
neck NN N
( ( N
SCC NNP N
H NNP N
& CC N
N NNP N
) ) N
who WP N
entered VBD N
a DT N
prospective JJ N
, , N
randomised JJ N
trial NN N
, , N
101 CD N
patients NNS N
received VBD N
50.6 CD N
Gy NNP N
to TO N
a DT N
portion NN N
of IN N
their PRP$ N
spinal JJ N
cord NN N
and CC N
survived VBD N
> NNS N
1 CD N
year NN N
following VBG N
the DT N
beginning NN N
of IN N
therapy NN N
Forty-five JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
HFX NNP N
RT NNP N
alone RB N
and CC N
fifty-six JJ N
patients NNS N
also RB N
received VBD N
CDDP NNP N
RESULTS NNP N
None NN N
of IN N
these DT N
101 CD N
patients NNS N
developed VBD N
cervical JJ N
radiation NN N
myelitis NN N
Therefore RB N
, , N
it PRP N
was VBD N
not RB N
possible JJ N
to TO N
investigate VB N
the DT N
influence NN N
of IN N
potentially RB N
contributing VBG N
factors NNS N
on IN N
the DT N
occurrence NN N
of IN N
radiation NN N
myelitis NN N
, , N
such JJ N
as IN N
interfraction NN N
interval NN N
, , N
cord NN N
length NN N
, , N
and CC N
administration NN N
of IN N
concurrent JJ N
CDDP NNP N
CONCLUSIONS NNP N
Given NNP N
the DT N
increasing VBG N
number NN N
of IN N
studies NNS N
with IN N
both DT N
altered VBN N
fractionated VBN N
regimens NNS N
and CC N
concurrent JJ N
radio-chemotherapy NN N
in IN N
SCC NNP N
H NNP N
& CC N
N NNP N
, , N
new JJ N
studies NNS N
with IN N
more JJR N
patients NNS N
are VBP N
needed VBN N
to TO N
gain VB N
better JJR N
insight NN N
into IN N
the DT N
risks NNS N
of IN N
developing VBG N
cervical JJ N
radiation NN N
myelitis NN N
-DOCSTART- -X- O O 20048611

Evaluation NN N
of IN N
a DT N
new JJ N
wound NN N
closure NN N
device NN N
for IN N
linear JJ N
surgical JJ N
incisions NNS N
: : N
3M CD N
Steri-Strip JJ N
S NNP N
Surgical NNP N
Skin NNP N
Closure NNP N
versus IN N
subcuticular JJ N
closure NN N
BACKGROUND NNP N
Technological JJ N
innovations NNS N
are VBP N
often RB N
adopted VBN N
before IN N
scientific JJ N
comparison NN N
to TO N
an DT N
accepted JJ N
standard NN N
The DT N
authors NNS N
' POS N
study NN N
compared VBN N
suture NN N
with IN N
a DT N
new JJ N
coaptive JJ N
film NN N
device NN N
, , N
3M CD N
Steri-Strip JJ N
S NNP N
Surgical NNP N
Skin NNP N
Closure NNP N
, , N
on IN N
linear JJ N
incisions NNS N
METHODS NNP N
Patients NNPS N
undergoing VBG N
Wise-pattern JJ 4_p
breast NN 4_p
reduction NN 4_p
or CC 4_p
abdominal JJ 4_p
procedures NNS 4_p
had VBD N
paired VBN N
incisions NNS N
randomly RB N
assigned VBN N
to TO N
Steri-Strip NNP N
S NNP N
or CC N
suture JJ N
closure NN N
Key NNP N
outcome JJ N
measures NNS N
were VBD N
closure JJ N
time NN N
, , N
patient JJ N
comfort NN N
, , N
and CC N
scar NN N
quality NN N
at IN N
6 CD N
months NNS N
by IN N
patients NNS N
and CC N
surgeons NNS N
using VBG N
a DT N
new JJ N
scar NN N
evaluation NN N
tool NN N
, , N
visual JJ N
assessment NN N
of IN N
linear JJ N
scars NNS N
Statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
closure NN N
techniques NNS N
were VBD N
assessed VBN N
by IN N
Wilcoxon NNP N
signed VBD N
rank JJ N
test NN N
RESULTS NNP N
Of IN N
59 CD 3_p
patients NNS N
, , N
eight CD N
were VBD N
excluded VBN N
from IN N
randomization NN N
( ( N
a DT N
surgeon NN N
judged VBN N
Steri-Strip NNP N
S NNP N
to TO N
be VB N
a DT N
nonviable JJ N
closure NN N
technique NN N
for IN N
mismatched VBN N
wound NN N
edges NNS N
) ) N
Fifty-one CD 3_p
patients NNS N
( ( N
breast NN N
, , N
n JJ N
= VBP N
24 CD N
; : N
abdomen NNS N
, , N
n JJ N
= NNP N
27 CD N
) ) N
were VBD N
randomized VBN N
Operative JJ N
time NN N
with IN N
Steri-Strip NNP N
S NNP N
for IN N
breast NN N
was VBD N
2.0 CD N
minutes NNS N
( ( N
SD NNP N
= NNP N
1.1 CD N
) ) N
versus NN N
suture NN N
closure NN N
at IN N
4.6 CD N
minutes NNS N
( ( N
SD NNP N
= NNP N
1.5 CD N
; : N
p NN N
< VBZ N
0.001 CD N
) ) N
Similarly RB N
, , N
Steri-Strip NNP N
S NNP N
versus NN N
suture NN N
for IN N
the DT N
abdomen NNS N
was VBD N
faster RBR N
( ( N
p JJ N
< VBZ N
0.001 CD N
; : N
4.9 CD N
minutes NNS N
, , N
SD NNP N
= VBZ N
2.3 CD N
versus NN N
10.1 CD N
minutes NNS N
, , N
SD NNP N
= NNP N
3.4 CD N
) ) N
Comfort NNP N
scores NNS N
did VBD N
not RB N
differ VB N
between IN N
closures NNS N
[ VBP N
5.8 CD N
( ( N
SD NNP N
= NNP N
2.7 CD N
) ) N
versus NN N
6.9 CD N
( ( N
SD NNP N
= NNP N
2.0 CD N
) ) N
, , N
respectively RB N
, , N
on IN N
breast NN N
( ( N
p JJ N
= NNP N
0.142 CD N
) ) N
and CC N
7.7 CD N
( ( N
SD NNP N
= NNP N
1.8 CD N
) ) N
versus NN N
7.7 CD N
( ( N
SD NNP N
= NNP N
2.3 CD N
) ) N
on IN N
abdomen NNS N
( ( N
p JJ N
= NNP N
0.903 CD N
) ) N
] NN N
Complication NN N
rates NNS N
did VBD N
not RB N
differ VB N
between IN N
closure NN N
types NNS N
Patients NNS N
' POS N
visual JJ N
assessment NN N
of IN N
linear JJ N
scars NNS N
rating NN N
of IN N
breasts NNS N
was VBD N
3.8 CD N
( ( N
SD NNP N
= NNP N
2.9 CD N
) ) N
for IN N
Steri-Strip NNP N
S NNP N
and CC N
better JJR N
at IN N
2.6 CD N
( ( N
SD NNP N
= NNP N
2.9 CD N
) ) N
for IN N
suture NN N
( ( N
p JJ N
= NNP N
0.008 CD N
) ) N
One CD N
surgeon NN N
rated VBN N
breast IN N
Steri-Strip NNP N
S NNP N
scars VBZ N
worse JJR N
than IN N
suture NN N
scars NNS N
( ( N
4.3 CD N
versus NN N
3.7 CD N
; : N
p NN N
= VBZ N
0.014 CD N
) ) N
For IN N
abdominal JJ N
scars NNS N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
patient NN N
or CC N
surgeon NN N
ratings NNS N
CONCLUSIONS NNP N
Steri-Strip NNP N
S NNP N
permits VBZ N
faster JJR N
wound IN N
closure NN N
than IN N
suture NN N
On IN N
the DT N
basis NN N
of IN N
patient JJ N
reports NNS N
of IN N
comfort NN N
and CC N
scar NN N
quality NN N
, , N
surgeons NNS N
increase VBP N
efficiency NN N
and CC N
maintain VBP N
quality NN N
with IN N
the DT N
use NN N
of IN N
Steri-Strip NNP N
S NNP N
on IN N
abdominal JJ N
wounds NNS N
but CC N
not RB N
on IN N
breast NN N
wounds NNS N
-DOCSTART- -X- O O 16335132

Phytase NNP N
and CC N
1alpha-hydroxycholecalciferol JJ N
supplementation NN N
of IN N
broiler NN 4_p
chickens NNS 4_p
during IN N
the DT N
starting NN N
and CC N
growing/finishing NN N
phases NNS N
Supplemental JJ N
1alpha-hydroxycholecalciferol JJ N
( ( N
1alpha-OHD3 JJ N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
have VB N
qualitatively RB N
similar JJ N
and CC N
quantitatively RB N
additive JJ N
effects NNS N
to TO N
exogenous JJ N
phytase NN N
Two CD N
experiments NNS N
were VBD N
conducted VBN N
from IN N
0 CD N
to TO N
35 CD N
d NN N
in IN N
floor NN N
pens NNS N
to TO N
determine VB N
the DT N
additive JJ N
effect NN N
of IN N
phytase NN N
and CC N
1alpha-OHD3 JJ N
when WRB N
supplemented VBN N
to TO N
Ca- NNP N
and CC N
P-deficient NNP N
diets NNS N
In IN N
both DT N
experiments NNS N
, , N
at IN 4_p
least JJS 4_p
4 CD N
replicates NNS N
per IN N
treatment NN N
( ( N
50 CD N
chicks NNS N
per IN N
replicate NN N
) ) 4_p
were VBD 4_p
used VBN 4_p
Corn-soybean-meal-and JJ 4_p
soybean-oil-based JJ 4_p
diets NNS 4_p
were VBD N
fed VBN N
and CC N
birds NNS N
were VBD N
raised VBN N
in IN N
a DT N
house NN 4_p
impervious JJ 4_p
to TO 4_p
ultraviolet VB 4_p
light NN 4_p
During IN N
the DT N
starter JJ N
phase NN N
( ( N
ST NNP N
) ) N
, , N
from IN N
0 CD N
to TO N
18 CD N
d NN N
, , N
chicks NNS N
were VBD N
fed VBN N
a DT N
23 CD N
% NN N
CP NNP N
diet JJ N
containing VBG N
0.60 CD N
% NN N
Ca NNP N
and CC N
0.47 CD N
% NN N
total JJ N
P NNP N
( ( N
tP NN N
) ) N
During IN N
the DT N
grower/finisher NN N
phase NN N
( ( N
GF NNP N
) ) N
, , N
from IN N
19 CD N
to TO N
35 CD N
d NN N
, , N
birds NNS N
were VBD N
fed VBN N
a DT N
19 CD N
% NN N
CP NNP N
diet JJ N
containing VBG N
0.30 CD N
% NN N
Ca NNP N
and CC N
0.37 CD N
% NN N
tP NN N
A DT N
combination NN N
of IN N
1,000 CD N
phytase NN N
units/kg NN N
of IN N
Natuphos NNP N
phytase NN N
and CC N
5 CD N
microg/kg NN N
of IN N
1alpha-OHD3 JJ N
( ( N
P+1A NNP N
) ) N
was VBD N
supplemented VBN N
to TO N
some DT N
of IN N
the DT N
feed NN N
during IN N
the DT N
ST NNP N
and CC N
GF NNP N
Diets NNS N
containing VBG N
adequate NN N
Ca NNP N
and CC N
P NNP N
were VBD N
also RB N
fed VBN N
during IN N
the DT N
ST NNP N
( ( N
0.90 CD N
% NN N
Ca NNP N
, , N
0.68 CD N
% NN N
tP NN N
) ) N
and CC N
GF NNP N
( ( N
0.80 CD N
% NN N
Ca NNP N
, , N
0.67 CD N
% NN N
tP NN N
) ) N
Performance NN N
characteristics NNS N
and CC N
the DT N
incidence NN N
of IN N
rickets NNS N
and CC N
tibial JJ N
dyschondroplasia NN N
were VBD N
measured VBN N
at IN N
18 CD N
and CC N
35 CD N
d. NN N
In IN N
experiment JJ N
1 CD N
, , N
unsupplemented JJ N
chicks NNS N
performed VBN N
well RB N
but CC N
had VBD N
considerable JJ N
leg JJ N
problems NNS N
Chicks NNP N
fed VBD N
P+1A NNP N
during IN N
the DT N
ST NNP N
or CC N
GF NNP N
did VBD N
not RB N
perform VB N
as RB N
well RB N
as IN N
birds NNS N
fed VBN N
P+1A NNP N
throughout IN N
Birds NNS N
fed VBD N
P+1A NNP N
throughout IN N
performed VBN N
as IN N
well RB N
birds NNS N
fed VBD N
the DT N
adequate JJ N
diets NNS N
without IN N
any DT N
indication NN N
of IN N
leg NN N
problems NNS N
In IN N
experiment JJ N
2 CD N
, , N
unsupplemented JJ N
birds NNS N
performed VBD N
similarly RB N
to TO N
unsupplemented JJ N
birds NNS 4_p
in IN N
experiment JJ N
1 CD N
However RB N
, , N
chicks NNS N
fed VBP N
the DT N
supplements NNS N
or CC N
the DT N
control JJ N
diets NNS N
did VBD N
not RB N
perform VB N
as RB N
well RB N
or CC N
accumulate VB N
as IN N
much JJ N
bone NN N
ash NN N
as IN N
birds NNS 4_p
in IN N
experiment JJ N
1 CD N
, , N
although IN N
the DT N
diets NNS N
were VBD N
formulated VBN N
identically RB N
in IN N
both DT N
experiments NNS N
Diets NNS N
with IN N
as RB N
little JJ N
as IN N
0.30 CD N
% NN N
Ca NNP N
and CC N
0.37 CD N
% NN N
tP NN N
appear VBP N
to TO N
be VB N
adequate JJ N
for IN N
broilers NNS N
older JJR N
than IN N
18 CD N
d NN N
if IN N
supplemented VBN N
with IN N
the DT N
correct JJ N
amounts NNS N
of IN N
phytase NN N
and CC N
1alpha-OHD3 JJ N
However RB N
, , N
there EX N
are VBP N
unknown JJ N
variables NNS N
that WDT N
may MD N
limit VB N
the DT N
potential NN N
of IN N
broilers NNS N
in IN N
terms NNS N
of IN N
bone NN N
mineralization NN N
and CC N
bone NN N
pathology NN N
, , N
even RB N
when WRB N
adequate JJ N
diets NNS N
are VBP N
fed VBN N
-DOCSTART- -X- O O 11237545

Comparison NNP N
of IN N
provocative JJ N
tests NNS N
for IN N
unexplained JJ N
syncope NN N
: : N
isoprenaline NN N
and CC N
glyceryl NN N
trinitrate NN N
for IN N
diagnosing VBG N
vasovagal JJ N
syncope NN N
AIMS NNP N
To TO N
compare VB N
the DT N
sensitivity NN N
, , N
specificity NN N
and CC N
adverse JJ N
event NN N
profile NN N
of IN N
glyceryl JJ N
trinitrate JJ N
head-up NN N
tilt NN N
with IN N
isoprenaline JJ N
head-up JJ N
tilt NN N
in IN N
the DT N
diagnosis NN N
of IN N
vasovagal JJ N
syncope NN N
in IN N
patients NNS N
with IN N
unexplained JJ N
syncope NN N
and CC N
healthy JJ N
controls NNS N
METHODS NNP N
AND CC N
RESULTS NNP N
Forty-eight NNP N
patients NNS N
with IN N
unexplained JJ N
syncope NN N
and CC N
negative JJ N
passive JJ N
head-up NN N
tilt NN N
at IN N
70 CD N
degrees NNS N
for IN N
40 CD N
min NN N
, , N
and CC N
14 CD N
healthy JJ N
controls NNS N
underwent JJ N
glyceryl JJ N
trinitrate NN N
head-up NN N
tilt NN N
and CC N
isoprenaline JJ N
head-up NN N
tilt NN N
( ( N
maximum JJ N
dose RB N
5 CD N
microg NNS N
x JJ N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
one CD N
week NN N
apart RB N
in IN N
random JJ N
order NN N
Outcome CC N
measures NNS N
were VBD N
production NN N
of IN N
symptoms NNS N
( ( N
syncope NN N
, , N
pre-syncope NN N
) ) N
with IN N
development NN N
of IN N
hypotension NN N
In IN N
those DT N
with IN N
negative JJ N
passive JJ N
head-up NN N
tilt NN N
, , N
the DT N
sensitivity NN N
of IN N
glyceryl NN N
trinitrate NN N
for IN N
diagnosing VBG N
vasovagal JJ N
syncope NN N
was VBD N
48 CD N
% NN N
and CC N
the DT N
specificity NN N
was VBD N
71 CD N
% NN N
Glyceryl NNP N
trinitrate NN N
was VBD N
well RB N
tolerated VBN N
Isoprenaline NNP N
sensitivity NN N
was VBD N
21 CD N
% NN N
with IN N
specificity NN N
64 CD N
% NN N
Side-effects NNS N
prevented JJ N
completion NN N
of IN N
the DT N
test NN N
in IN N
68 CD N
% NN N
Commonest NNP N
adverse JJ N
events NNS N
were VBD N
the DT N
development NN N
of IN N
hypertension NN N
or CC N
tachycardia NN N
and CC N
intolerable JJ N
flushing NN N
or CC N
nausea NN N
CONCLUSIONS NNP N
Glyceryl NNP N
trinitrate VB N
head-up JJ N
tilt NN N
is VBZ N
as RB N
effective JJ N
as IN N
isoprenaline JJ N
head-up JJ N
tilt NN N
as IN N
a DT N
provocative JJ N
agent NN N
for IN N
vasovagal JJ N
syncope NN N
and CC N
has VBZ N
a DT N
lower JJR N
incidence NN N
of IN N
adverse JJ N
events NNS N
-DOCSTART- -X- O O 9180065

Randomised VBN N
controlled JJ N
trial NN N
of IN N
graded JJ N
exercise NN N
in IN N
patients NNS N
with IN N
the DT N
chronic JJ 4_p
fatigue NN 4_p
syndrome NN 4_p
OBJECTIVE UH N
To TO N
test VB N
the DT N
efficacy NN N
of IN N
a DT N
graded JJ N
aerobic JJ N
exercise NN N
programme NN N
in IN N
the DT N
chronic JJ 4_p
fatigue NN 4_p
syndrome NN 4_p
DESIGN NNP N
Randomised VBD N
controlled VBN N
trial NN N
with IN N
control NN N
treatment NN N
crossover NN N
after IN N
the DT N
first JJ N
follow VB N
up RP N
examination NN N
SETTING NN N
Chronic NNP N
fatigue NN N
clinic NN N
in IN N
a DT N
general JJ N
hospital NN N
department NN N
of IN N
psychiatry NN N
SUBJECTS NNP N
66 CD 3_p
patients NNS N
with IN N
the DT N
chronic JJ 4_p
fatigue NN 4_p
syndrome NN 4_p
who WP N
had VBD N
neither CC N
a DT N
psychiatric JJ 4_p
disorder NN 4_p
nor CC N
appreciable JJ 4_p
sleep JJ 4_p
disturbance NN 4_p
INTERVENTIONS NNP N
Random NNP N
allocation NN N
to TO N
12 CD N
weeks NNS N
of IN N
either DT N
graded VBN N
aerobic NN N
exercise NN N
or CC N
flexibility NN N
exercises NNS N
and CC N
relaxation NN N
therapy NN N
Patients NNS N
who WP N
completed VBD N
the DT N
flexibility NN N
programme NN N
were VBD N
invited VBN N
to TO N
cross VB N
over IN N
to TO N
the DT N
exercise NN N
programme NN N
afterwards NNS N
MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
self NN N
rated VBN N
clinical JJ N
global JJ N
impression NN N
change NN N
score NN N
, , N
" VB N
very RB N
much RB N
better RBR N
" NN N
or CC N
" VB N
much JJ N
better JJR N
" NN N
being VBG N
considered VBN N
as IN N
clinically RB N
important JJ N
RESULTS VB N
Four CD N
patients NNS N
receiving VBG N
exercise NN N
and CC N
three CD N
receiving VBG N
flexibility NN N
treatment NN N
dropped VBD N
out RP N
before IN N
completion NN N
15 CD N
of IN N
29 CD N
patients NNS N
rated VBN N
themselves PRP N
as IN N
better JJR N
after IN N
completing VBG N
exercise NN N
treatment NN N
compared VBN N
with IN N
eight CD N
of IN N
30 CD N
patients NNS N
who WP N
completed VBD N
flexibility NN N
treatment NN N
Analysis NN N
by IN N
intention NN N
to TO N
treat VB N
gave VBD N
similar JJ N
results NNS N
( ( N
17/33 CD N
v RB N
9/33 CD N
patients NNS N
better RBR N
) ) N
Fatigue NNP N
, , N
functional JJ N
capacity NN N
, , N
and CC N
fitness NN N
were VBD N
significantly RB N
better RBR N
after IN N
exercise NN N
than IN N
after IN N
flexibility NN N
treatment NN N
12 CD N
of IN N
22 CD N
patients NNS N
who WP N
crossed VBD N
over IN N
to TO N
exercise VB N
after IN N
flexibility NN N
treatment NN N
rated VBN N
themselves PRP N
as IN N
better JJR N
after IN N
completing VBG N
exercise NN N
treatment NN N
32 CD N
of IN N
47 CD N
patients NNS N
rated VBN N
themselves PRP N
as IN N
better JJR N
three CD N
months NNS N
after IN N
completing VBG N
supervised JJ N
exercise NN N
treatment NN N
35 CD N
of IN N
47 CD N
patients NNS N
rated VBN N
themselves PRP N
as IN N
better JJR N
one CD N
year NN N
after IN N
completing VBG N
supervised JJ N
exercise NN N
treatment NN N
CONCLUSION NNP N
These DT N
findings NNS N
support VBP N
the DT N
use NN N
of IN N
appropriately RB N
prescribed VBN N
graded VBN N
aerobic JJ N
exercise NN N
in IN N
the DT N
management NN N
of IN N
patients NNS N
with IN N
the DT N
chronic JJ 4_p
fatigue NN 4_p
syndrome NN 4_p
-DOCSTART- -X- O O 11360574

[ JJ N
Clinical NNP N
and CC N
experimental JJ N
research NN N
of IN N
Epimedium NNP N
brevicornum NN N
in IN N
relieving VBG N
neuroendocrino-immunological JJ 4_p
effect NN 4_p
inhibited VBN N
by IN N
exogenous JJ N
glucocorticoid NN N
] NN N
OBJECTIVE UH N
To TO N
study VB N
protective JJ N
effect NN N
of IN N
Epimedium NNP N
brevicornum NN N
( ( N
EB NNP N
) ) N
on IN N
hypothalamus-pituitary-adrenal-thymus NN N
( ( N
HPAT NNP N
) ) N
axis NN N
inhibited VBN N
by IN N
exogenous JJ N
glucocorticoid NN N
METHODS NNP N
In IN N
clinical JJ N
research NN N
, , N
variation NN N
of IN N
cortisol NN N
, , N
adrenocorticotrophin NN N
( ( N
ACTH NNP N
) ) N
, , N
lymphocyte JJ N
proliferative JJ N
reaction NN N
were VBD N
observed VBN N
before IN N
and CC N
after IN N
medication NN N
in IN N
65 CD 3_p
patients NNS N
took VBD N
prednisone NN N
, , N
and CC N
were VBD N
randomly RB N
divided VBN N
into IN N
Fufang NNP N
prednisone NN N
group NN N
( ( N
mixture NN N
of IN N
prednisone NN N
and CC N
EB NNP N
) ) N
and CC N
prednisone NN N
group NN N
An DT N
experimental JJ N
model NN N
of IN N
HPAT NNP N
axis NN N
inhibited VBN N
by IN N
corticosterone NN N
( ( N
CORT NNP N
) ) N
was VBD N
established VBN N
to TO N
observe VB N
the DT N
effect NN N
of IN N
EB NNP N
on IN N
relevant JJ N
indices NNS N
of IN N
HPAT NNP N
axis NN N
RESULTS VB N
The DT N
level NN N
of IN N
ACTH NNP N
and CC N
CORT NNP N
in IN N
plasma NN N
decreased VBN N
and CC N
lymphocyte JJ N
proliferative JJ N
reaction NN N
reduced VBN N
in IN N
patients NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
In IN N
experimental JJ N
study NN N
, , N
monoaminic JJ N
transmitters NNS N
activated VBN N
in IN N
hypothalamus NN N
; : N
weight NN N
of IN N
pituitary JJ N
, , N
adrenal JJ N
and CC N
thymus NN N
decreased VBN N
; : N
number NN N
of IN N
CRH NNP N
positive JJ N
neurons NNS N
in IN N
hypothalamic JJ N
paraventricular JJ N
nucleus NN N
, , N
CRH NNP N
positive JJ N
neurofibrilin NN N
median JJ N
eminence NN N
and CC N
anterior JJ N
pituitary JJ N
ACTH NNP N
positive JJ N
secretory NN N
cells NNS N
decreased VBD N
; : N
adrenal JJ N
fasciculate NN N
zone NN N
and CC N
thymus NN N
cortex NN N
atrophies NNS N
; : N
NK NNP N
cell VBP N
cytotoxicity NN N
and CC N
the DT N
level NN N
of IN N
IL-2 NNP N
and CC N
gamma-IFN NN N
which WDT N
were VBD N
produced VBN N
by IN N
lymphocytes NNS N
reduced VBN N
in IN N
CORT-rats NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
There EX N
were VBD N
significant JJ N
difference NN N
between IN N
Fufang NNP N
prednisone NN N
group NN N
( ( N
clinical JJ N
research NN N
) ) N
or CC N
EB NNP N
group NN N
( ( N
experimental JJ N
research NN N
) ) N
and CC N
CORT NNP N
control NN N
groups NNS N
, , N
P NNP N
< VBZ N
0.05 CD N
CONCLUSION NNP N
EB NNP N
could MD N
relieve VB N
neuroendocrino-immunological JJ N
effect NN N
inhibited VBN N
by IN N
exogenous JJ N
glucocorticoid NN N
-DOCSTART- -X- O O 2148830

A DT N
randomized VBN N
study NN N
on IN N
hormone-resistant JJ N
prostatic JJ N
cancer NN N
: : N
estramustine JJ N
phosphate NN N
versus NN N
low JJ N
dose JJ N
epirubicin NN N
with IN N
or CC N
without IN N
medroxyprogesterone JJ N
acetate NN N
A DT N
Norwegian JJ N
multicenter NN N
study NN N
A DT N
prospective JJ N
randomized NN N
study NN N
has VBZ N
been VBN N
carried VBN N
out RP N
in IN N
order NN N
to TO N
compare VB N
three CD N
different JJ N
treatment NN N
modalities NNS N
for IN N
symptomatic JJ N
metastatic JJ N
hormone-resistant JJ N
prostatic JJ N
cancer NN N
A DT N
total NN 4_p
of IN 4_p
79 CD 4_p
patients NNS 4_p
were VBD 4_p
included VBN 4_p
One CD N
group NN N
was VBD N
treated VBN N
with IN N
estramustine JJ N
phosphate NN N
, , N
another DT N
with IN N
Epirubicin NNP N
plus CC N
Medroxyprogesterone NNP N
acetate NN N
( ( N
MPA NNP N
) ) N
, , N
while IN N
the DT N
third JJ N
arm NN N
consisted VBD N
of IN N
Epirubicin NNP N
plus CC N
placebo NN N
Best JJS N
palliation NN N
was VBD N
obtained VBN N
by IN N
the DT N
combination NN N
of IN N
Epirubicin NNP N
and CC N
MPA NNP N
This DT N
combination NN N
also RB N
seemed VBD N
to TO N
be VB N
associated VBN N
with IN N
the DT N
longest JJS N
response NN N
duration NN N
-DOCSTART- -X- O O 9413463

Randomised VBN N
trial NN N
of IN N
efficacy NN N
and CC N
safety NN N
of IN N
oral JJ N
ganciclovir NN N
in IN N
the DT N
prevention NN N
of IN N
cytomegalovirus NN N
disease NN N
in IN N
liver-transplant JJ 4_p
recipients NNS N
The DT N
Oral NNP N
Ganciclovir NNP N
International NNP N
Transplantation NNP N
Study NNP N
Group NNP N
[ NNP N
corrected VBD N
] NNP N
BACKGROUND NNP N
Cytomegalovirus NNP N
( ( N
CMV NNP N
) ) N
disease NN N
is VBZ N
a DT N
frequent JJ N
cause NN N
of IN N
serious JJ N
morbidity NN N
after IN N
solid-organ JJ N
transplantation NN N
The DT N
prophylactic JJ N
regimens NNS N
used VBN N
to TO N
prevent VB N
CMV NNP N
infection NN N
and CC N
disease NN N
have VBP N
shown VBN N
limited JJ N
benefit NN N
in IN N
seronegative JJ N
recipients NNS N
We PRP N
studied VBD N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
oral JJ N
ganciclovir NN N
in IN N
the DT N
prevention NN N
of IN N
CMV NNP N
disease NN N
following VBG N
orthotopic NN N
liver JJ N
transplantation NN N
METHODS NNP N
Between NNP N
December NNP N
, , N
1993 CD N
, , N
and CC N
April NNP N
, , N
1995 CD N
, , N
304 CD 3_p
liver-transplant JJ N
recipients NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
oral JJ N
ganciclovir NN N
1000 CD N
mg NN N
or CC N
matching VBG N
placebo NN N
three CD N
times NNS N
a DT N
day NN N
Seronegative JJ N
recipients NNS N
of IN N
seronegative JJ 4_p
livers NNS 4_p
were VBD N
excluded VBN N
Study NNP N
drug NN N
was VBD N
administered VBN N
as RB N
soon RB N
as IN N
the DT N
patient NN N
was VBD N
able JJ N
to TO N
take VB N
medication NN N
by IN N
mouth NN N
( ( N
no DT N
later RB N
than IN N
day NN N
10 CD N
) ) N
until IN N
the DT N
98th CD N
day NN N
after IN N
transplantation NN N
Patients NNS N
were VBD N
assessed VBN N
at IN N
specified VBN N
times NNS N
throughout IN N
the DT N
first JJ N
6 CD N
months NNS N
after IN N
surgery NN N
for IN N
evidence NN N
of IN N
CMV NNP N
infection NN N
, , N
CMV NNP N
disease NN N
, , N
rejection NN N
, , N
opportunistic JJ N
infections NNS N
, , N
and CC N
possible JJ N
drug NN N
toxicity NN N
FINDINGS IN N
The DT N
Kaplan-Meier NNP N
estimate NN N
of IN N
the DT N
6-month JJ N
incidence NN N
of IN N
CMV NNP N
disease NN N
was VBD N
29 CD N
( ( N
18.9 CD N
% NN N
) ) N
of IN N
154 CD N
in IN N
the DT N
placebo NN N
group NN N
, , N
compared VBN N
with IN N
seven CD N
( ( N
4.8 CD N
% NN N
) ) N
of IN N
150 CD N
in IN N
the DT N
ganciclovir NN N
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
In IN N
the DT N
high-risk JJ N
group NN N
of IN N
seronegative JJ N
recipients NNS N
( ( N
R- NNP N
) ) N
of IN N
seropositive JJ N
livers NNS N
( ( N
D+ NNP N
) ) N
, , N
incidence NN N
of IN N
CMV NNP N
disease NN N
was VBD N
11 CD N
( ( N
44.0 CD N
% NN N
) ) N
of IN N
25 CD N
in IN N
the DT N
placebo NN N
group NN N
, , N
three CD N
( ( N
14.8 CD N
% NN N
) ) N
of IN N
21 CD N
in IN N
the DT N
ganciclovir NN N
group NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
Significant JJ N
benefit NN N
was VBD N
also RB N
observed VBN N
in IN N
those DT N
receiving VBG N
antibodies NNS N
to TO N
lymphocytes NNS N
, , N
where WRB N
the DT N
incidence NN N
of IN N
CMV NNP N
disease NN N
was VBD N
12 CD N
( ( N
32.9 CD N
% NN N
) ) N
of IN N
37 CD N
in IN N
the DT N
placebo NN N
group NN N
and CC N
two CD N
( ( N
4.6 CD N
% NN N
) ) N
of IN N
44 CD N
in IN N
the DT N
ganciclovir NN N
group NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
Oral JJ N
ganciclovir NN N
reduced VBD N
the DT N
incidence NN N
of IN N
CMV NNP N
infection NN N
( ( N
placebo JJ N
79 CD N
[ JJ N
51.5 CD N
% NN N
] NN N
of IN N
154 CD N
; : N
ganciclovir CC N
37 CD N
[ JJ N
24.5 CD N
% NN N
] NN N
of IN N
150 CD N
; : N
p NN N
< VBZ N
0.001 CD N
) ) N
and CC N
also RB N
reduced VBN N
symptomatic JJ N
herpes-simplex JJ N
infections NNS N
( ( N
Kaplan-Meier NNP N
estimates NNS N
: : N
placebo NN N
36 CD N
[ JJ N
23.5 CD N
% NN N
] NN N
of IN N
154 CD N
; : N
ganciclovir JJ N
five CD N
[ JJ N
3.5 CD N
% NN N
] NN N
of IN N
150 CD N
; : N
p NN N
< VBZ N
0.001 CD N
) ) N
INTERPRETATION NNP N
Oral NNP N
ganciclovir NN N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
method NN N
for IN N
the DT N
prevention NN N
of IN N
CMV NNP N
disease NN N
after IN N
orthotopic NN N
liver NN 4_p
transplantation NN 4_p
-DOCSTART- -X- O O 19207781

Esophageal JJ N
damage NN N
during IN N
radiofrequency NN N
ablation NN N
of IN N
atrial JJ N
fibrillation NN N
: : N
impact NN N
of IN N
energy NN N
settings NNS N
, , N
lesion NN N
sets NNS N
, , N
and CC N
esophageal JJ N
visualization NN N
INTRODUCTION NNP N
Atrioesophageal NNP N
fistula NN N
is VBZ N
an DT N
uncommon JJ N
but CC N
often RB N
lethal JJ N
complication NN N
of IN N
atrial JJ 4_p
fibrillation NN 4_p
( ( 4_p
AF NNP 4_p
) ) 4_p
ablation NN 4_p
The DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
prospectively RB N
investigate VB N
the DT N
incidence NN N
of IN N
esophageal JJ N
ulcerations NNS N
( ( N
ESUL NNP N
) ) N
as RB N
well RB N
as IN N
the DT N
impact NN N
of IN N
energy NN N
settings NNS N
, , N
radiofrequency NN N
lesion NN N
sets NNS N
, , N
and CC N
direct JJ N
visualization NN N
of IN N
the DT N
esophagus NN N
on IN N
esophageal NN N
wall JJ N
injury NN N
METHODS NNP N
AND CC N
RESULTS NNP N
One CD 3_p
hundred VBD 3_p
seventy-five JJ 3_p
patients NNS 3_p
, , N
57.1 CD N
% NN N
paroxysmal JJ N
AF NNP N
, , N
78.5 CD N
% NN N
male NN 2_p
, , N
underwent JJ N
AF NNP 4_p
ablation NN 4_p
and CC 4_p
esophagoscopy $ 4_p
24 CD N
hours NNS N
thereafter RB N
We PRP N
performed VBD N
a DT N
2:1:1-randomization JJ N
as IN N
follows VBZ N
: : N
CONTROL NNP N
GROUP NNP N
Ablation NNP N
without IN N
visualization NN N
of IN N
the DT N
esophagus NN N
using VBG N
25 CD N
Watt NNP N
( ( N
W NNP N
) ) N
power NN N
limit NN N
on IN N
the DT N
posterior NN N
wall NN N
, , N
n JJ N
= NN N
70 CD N
Visualization NN N
and CC N
15 CD N
W NNP N
maximum NN N
: : N
Ablation NN N
guided VBN N
by IN N
barium NN N
visualization NN N
of IN N
the DT N
esophageal JJ N
course NN N
using VBG N
a DT N
limit NN N
of IN N
15 CD N
W NNP N
, , N
n JJ N
= NN N
35 CD N
Visualization NN N
and CC N
25 CD N
W NNP N
" NNP N
short JJ N
burns NNS N
" NNS N
: : N
Ablation NN N
guided VBN N
by IN N
barium NN N
visualization NN N
using VBG N
25 CD N
W NNP N
and CC N
" NNP N
short JJ N
burns NNS N
" NNP N
( ( N
max NN N
5 CD N
sec NN N
) ) N
, , N
n JJ N
= NN N
35 CD N
Patients NNS N
performed VBN N
under IN N
general JJ N
anesthesia NN N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
were VBD N
separated VBN N
as IN N
a DT N
nasogastric JJ N
tube NN N
for IN N
visualization NN N
of IN N
the DT N
esophagus NN N
was VBD N
used VBN N
In IN N
total JJ N
, , N
we PRP N
found VBD N
2.9 CD N
% NN N
of IN N
patients NNS N
( ( N
5/175 CD N
) ) N
presenting NN N
ESUL NNP N
Parameters NNS N
discriminating VBG N
the DT N
development NN N
of IN N
ESUL NNP N
in IN N
a DT N
specific JJ N
patient NN N
were VBD N
type NN N
of IN N
AF NNP N
, , N
maximum JJ N
energy NN N
delivered VBN N
, , N
usage NN N
of IN N
a DT N
nasogastric JJ N
tube NN N
, , N
and CC N
additional JJ N
left NN N
atrial JJ N
lines NNS N
Visualization NN N
of IN N
the DT N
esophageal JJ N
course NN N
by IN N
barium NN N
contrast NN N
was VBD N
not RB N
able JJ N
to TO N
prevent VB N
ESUL NNP N
CONCLUSION NNP N
ESUL NNP N
is VBZ N
a DT N
rare JJ N
finding NN N
when WRB N
using VBG N
a DT N
reasonable JJ N
energy NN N
maximum NN N
of IN N
25 CD N
W NNP N
with IN N
open-irrigated JJ N
tip NN N
catheters NNS N
at IN N
the DT N
posterior JJ N
wall NN N
Lower NNP N
energy NN N
settings NNS N
may MD N
increase VB N
safety NN N
without IN N
losing VBG N
efficacy NN N
Additional JJ N
linear JJ N
radiofrequency NN N
lesions NNS N
increase VBP N
the DT N
risk NN N
of IN N
ESUL NNP N
development NN N
-DOCSTART- -X- O O 24689172

Safety NNP N
evaluation NN N
of IN N
lasalocid NN N
use NN N
in IN N
Chinese JJ N
ring-necked JJ N
pheasants NNS N
( ( N
Phasianus NNP N
colchicus NN N
) ) N
Coccidiosis NN N
remains VBZ N
a DT N
significant JJ N
threat NN N
to TO N
the DT N
welfare NN N
of IN N
game NN 4_p
farm-reared JJ 4_p
pheasants NNS 4_p
in IN 4_p
the DT 4_p
United NNP 4_p
States NNPS 4_p
Although IN N
lasalocid NN N
has VBZ N
been VBN N
demonstrated VBN N
to TO N
be VB N
effective JJ N
against IN N
pheasant JJ N
specific JJ N
coccidia NN N
, , N
information NN N
regarding VBG N
its PRP$ N
safety NN N
in IN N
this DT N
species NNS N
is VBZ N
lacking VBG N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
gather VB N
data NNS N
on IN N
the DT N
safety NN N
of IN N
lasalocid NN N
when WRB N
fed NN N
to TO N
Chinese JJ N
ring-necked JJ N
pheasants NNS N
at IN N
one CD N
, , N
two CD N
, , N
and CC N
three CD N
times NNS N
the DT N
recommended JJ N
high JJ N
dose NN N
of IN N
lasalocid NN N
used VBN N
for IN N
prevention NN N
of IN N
coccidiosis NN N
in IN N
other JJ N
poultry NN N
at IN N
three CD N
times NNS N
the DT N
normal JJ N
treatment NN N
period NN N
Pheasant JJ N
chicks NNS N
( ( N
approximately RB N
1 CD N
day-old JJ N
; : N
n CC 3_p
= VB 3_p
160 CD 3_p
) ) N
were VBD N
randomly RB N
blocked VBN N
by IN N
sex NN N
into IN N
four CD N
treatment NN N
groups NNS N
and CC N
given VBN N
their PRP$ N
respective JJ N
diets NNS N
continuously RB N
for IN N
6 CD N
wk NN N
No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
overall JJ N
feed NN N
consumption NN N
, , N
weight NN N
gain NN N
, , N
feed VBN N
conversion NN N
rates NNS N
, , N
clinical JJ N
pathology NN N
measurements NNS N
, , N
or CC N
tissue NN N
gross JJ N
and CC N
histopathologic JJ N
evaluations NNS N
between IN N
controls NNS N
and CC N
treatment NN N
groups NNS N
associated VBN N
with IN N
lasalocid JJ N
administration NN N
Based VBN N
on IN N
the DT N
results NNS N
of IN N
this DT N
study NN N
it PRP N
appears VBZ N
that IN N
lasalocid NN N
fed VBN N
at IN N
the DT N
recommended JJ N
rate NN N
of IN N
125 CD N
ppm NN N
is VBZ N
safe JJ N
in IN N
Chinese JJ N
ring-necked JJ N
pheasants NNS N
-DOCSTART- -X- O O 2208619

[ JJ N
Clinical NNP N
observations NNS N
on IN N
the DT N
treatment NN N
of IN N
hookworm NN 4_p
, , N
Ascaris NNP 4_p
and CC N
Trichuris NNP 4_p
infection NN 4_p
with IN N
oxibendazole JJ N
] NN N
340 CD 3_p
cases NNS N
of IN N
hookworm NN 4_p
infection NN 4_p
, , N
196 CD 3_p
cases NNS N
of IN N
ascariasis NN 4_p
and CC N
178 CD 3_p
cases NNS N
of IN N
trichuriasis NN 4_p
were VBD N
treated VBN N
with IN N
an DT N
anthelmintic JJ N
, , N
oxibendazole JJ N
, , N
15mg/kg.d CD N
x JJ N
3d CD N
; : N
102 CD N
, , N
70 CD N
and CC N
66 CD N
cases NNS N
of IN N
respective JJ 4_p
infections NNS 4_p
were VBD N
treated VBN N
with IN N
pyrantel NN N
10mg/kg.d CD N
x NN N
3d CD N
and CC N
108 CD N
, , N
74 CD N
and CC N
63 CD N
cases NNS N
took VBD N
placebo NN N
for IN N
comparison NN N
and CC N
as IN N
control NN N
under IN N
double-blind JJ N
observations NNS N
Re-examinations NNS N
of IN N
the DT N
stool NN N
were VBD N
performed VBN N
after IN N
the DT N
treatment NN N
Among IN N
the DT N
cases NNS N
treated VBN N
with IN N
oxibendazole NN N
, , N
the DT N
egg NN N
negative JJ N
conversion NN N
rates NNS N
of IN N
hookworm NN N
, , N
Ascaris NNP N
and CC N
Trichuris NNP N
were VBD N
70.3-80.6 CD N
% NN N
, , N
92.5-97.8 CD N
and CC N
67.0-71.0 CD N
% NN N
respectively RB N
The DT N
egg NN N
reduction NN N
rates NNS N
of IN N
hookworm NN N
were VBD N
98.1-98.6 CD N
% NN N
The DT N
larval JJ N
negative JJ N
conversion NN N
rates NNS N
of IN N
Ancylostoma NNP N
duodenale NN N
and CC N
Necator NNP N
americanus VBP N
were VBD N
77.7 CD N
and CC N
83.2 CD N
% NN N
respectively RB N
Among IN N
the DT N
cases NNS N
treated VBN N
with IN N
pyrantel NN N
, , N
the DT N
egg NN N
negative JJ N
conversion NN N
rates NNS N
of IN N
the DT N
three CD N
above IN N
mentioned VBN N
parasites NNS N
were VBD N
73.5 CD N
, , N
90.0 CD N
and CC N
28.8 CD N
% NN N
respectively RB N
The DT N
egg NN N
reduction NN N
rate NN N
of IN N
hookworm NN N
was VBD N
98.8 CD N
% NN N
Among IN N
the DT N
cases NNS N
treated VBN N
with IN N
placebo NN N
, , N
the DT N
egg NN N
negative JJ N
conversion NN N
rates NNS N
of IN N
the DT N
three CD N
above IN N
mentioned VBN N
parasites NNS N
were VBD N
6.5 CD N
, , N
29.7 CD N
and CC N
7.9 CD N
% NN N
No CC N
marked JJ N
adverse JJ N
reactions NNS N
were VBD N
observed VBN N
by IN N
clinical JJ N
and CC N
laboratory JJ N
examinations NNS N
-DOCSTART- -X- O O 17356056

Pathological JJ N
features NNS N
and CC N
inhaled JJ N
corticosteroid NN N
response NN N
of IN N
eosinophilic JJ 4_p
and CC 4_p
non-eosinophilic JJ 4_p
asthma NN 4_p
BACKGROUND NNP N
Non-eosinophilic JJ N
asthma NN N
is VBZ N
a DT N
potentially RB N
important JJ N
clinicopathological JJ N
phenotype NN N
since IN N
there EX N
is VBZ N
evidence NN N
that IN N
it PRP N
responds VBZ N
poorly RB N
to TO N
inhaled VB N
corticosteroid JJ N
therapy NN N
However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
underlying JJ N
airway NN N
immunopathology NN N
and CC N
there EX N
are VBP N
no DT N
data NNS N
from IN N
placebo-controlled JJ N
studies NNS N
examining VBG N
the DT N
effect NN N
of IN N
inhaled JJ N
corticosteroids NNS N
METHODS NNP N
Airway NNP N
immunopathology NN N
was VBD N
investigated VBN N
using VBG N
induced JJ N
sputum NN N
, , N
bronchial JJ N
biopsies NNS N
, , N
bronchial JJ N
wash NN N
and CC N
bronchoalveolar JJ N
lavage NN N
in IN N
12 CD 3_p
patients NNS 3_p
with IN N
symptomatic JJ 4_p
eosinophilic JJ 4_p
asthma NN 4_p
, , N
11 CD 3_p
patients NNS 3_p
with IN N
non-eosinophilic JJ 4_p
asthma NN 4_p
and CC N
10 CD 3_p
healthy JJ 4_p
controls NNS 4_p
The DT N
patients NNS N
with IN N
non-eosinophilic JJ N
asthma NN N
and CC N
6 CD 3_p
different JJ 3_p
patients NNS 3_p
with IN N
eosinophilic JJ N
asthma NN N
entered VBD N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
in IN N
which WDT N
the DT N
effects NNS N
of IN N
inhaled JJ N
mometasone NN N
400 CD N
microg NN N
once RB N
daily JJ N
for IN N
8 CD N
weeks NNS N
on IN N
airway NN N
responsiveness NN N
and CC N
asthma JJ N
quality NN N
of IN N
life NN N
were VBD N
investigated VBN N
RESULTS JJ N
Patients NNS N
with IN N
non-eosinophilic JJ N
asthma NN N
had VBD N
absence NN N
of IN N
eosinophils NNS N
in IN N
the DT N
mucosa NN N
( ( N
median JJ N
4.4 CD N
cells/mm NN N
( ( N
2 CD N
) ) N
vs NN N
23 CD N
cells/mm NN N
( ( N
2 CD N
) ) N
in IN N
eosinophilic JJ N
asthma NN N
and CC N
0 CD N
cells/mm NN N
( ( N
2 CD N
) ) N
in IN N
normal JJ N
controls NNS N
; : N
p VB N
= $ N
0.03 CD N
) ) N
and CC N
normal JJ N
subepithelial JJ N
layer NN N
thickness NN N
( ( N
5.8 CD N
microm NN N
vs NN N
10.3 CD N
microm NN N
in IN N
eosinophilic JJ N
asthma NN N
and CC N
5.1 CD N
microm NN N
in IN N
controls NNS N
, , N
p VBP N
= RB N
0.002 CD N
) ) N
Non-eosinophilic JJ N
and CC N
eosinophilic JJ N
asthma NN N
groups NNS N
had VBD N
increased VBN N
mast RB N
cell NN N
numbers NNS N
in IN N
the DT N
airway NN N
smooth JJ N
muscle NN N
compared VBN N
with IN N
normal JJ N
controls NNS N
( ( N
9 CD N
vs RB N
8 CD N
vs NNS N
0 CD N
cells/mm NN N
( ( N
2 CD N
) ) N
, , N
p JJ N
= NNP N
0.016 CD N
) ) N
Compared VBN N
with IN N
placebo NN N
, , N
8 CD N
weeks NNS N
of IN N
treatment NN N
with IN N
inhaled JJ N
mometasone NN N
led VBD N
to TO N
less RBR N
improvement NN N
in IN N
methacholine JJ N
PC NN N
( ( N
20 CD N
) ) N
( ( N
0.5 CD N
vs RB N
5.5 CD N
doubling VBG N
concentrations NNS N
, , N
95 CD N
% NN N
CI NNP N
of IN N
difference NN N
1.1 CD N
to TO N
9.1 CD N
; : N
p NN N
= VBZ N
0.018 CD N
) ) N
and CC N
asthma JJ N
quality NN N
of IN N
life NN N
( ( N
0.2 CD N
vs RB N
1.0 CD N
points NNS N
, , N
95 CD N
% NN N
CI NNP N
of IN N
difference NN N
0.27 CD N
to TO N
1.43 CD N
; : N
p NN N
= VBZ N
0.008 CD N
) ) N
CONCLUSIONS NNP N
Non-eosinophilic JJ N
asthma NN N
represents VBZ N
a DT N
pathologically RB N
distinct JJ N
disease NN N
phenotype NN N
which WDT N
is VBZ N
characterised VBN N
by IN N
the DT N
absence NN N
of IN N
airway NN N
eosinophilia NNS N
, , N
normal JJ N
subepithelial JJ N
layer NN N
thickness NN N
and CC N
a DT N
poor JJ N
short-term JJ N
response NN N
to TO N
treatment NN N
with IN N
inhaled JJ N
corticosteroids NNS N
-DOCSTART- -X- O O 25542821

Efficacy NN N
and CC N
safety NN N
of IN N
repeated VBN N
use NN N
of IN N
ulipristal JJ N
acetate NN N
in IN N
uterine JJ 4_p
fibroids NNS 4_p
OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
repeated VBN N
12-week JJ N
courses NNS N
of IN N
5 CD N
or CC N
10 CD N
mg JJ N
daily NN N
of IN N
ulipristal JJ N
acetate NN N
for IN N
intermittent JJ N
treatment NN N
of IN N
symptomatic JJ 4_p
uterine JJ 4_p
fibroids NNS 4_p
DESIGN NNP N
Double-blind NNP N
, , N
randomized JJ N
administration NN N
of IN N
two CD N
12-week JJ N
courses NNS N
of IN N
ulipristal JJ N
acetate NN N
SETTING NNP N
Gynecology NNP 4_p
centers NNS 4_p
PATIENT NNP N
( ( N
S NNP N
) ) N
A NNP N
total NN N
of IN N
451 CD 3_p
patients NNS N
with IN N
symptomatic JJ 4_p
uterine JJ 4_p
fibroid NN 4_p
( ( 4_p
s NN 4_p
) ) 4_p
and CC 4_p
heavy JJ 4_p
bleeding NN 4_p
INTERVENTION NNP N
( ( N
S NNP N
) ) N
Two CD N
repeated VBD N
12-week JJ N
treatment NN N
courses NNS N
of IN N
daily JJ N
5 CD N
or CC N
10 CD N
mg NN N
of IN N
ulipristal JJ N
acetate NN N
MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Amenorrhea NNP N
, , N
controlled VBD N
bleeding NN N
, , N
fibroid JJ N
volume NN N
, , N
quality NN N
of IN N
life NN N
( ( N
QoL NNP N
) ) N
, , N
pain NN N
RESULT NNP N
( ( N
S NNP N
) ) N
In IN N
the DT N
5- JJ N
and CC N
10-mg JJ N
treatment NN N
groups NNS N
( ( N
62 CD N
% NN N
and CC N
73 CD N
% NN N
of IN N
patients NNS N
, , N
respectively RB N
) ) N
achieved VBD N
amenorrhea NN N
during IN N
both DT N
treatment NN N
courses NNS N
Proportions NNS N
of IN N
patients NNS N
achieving VBG N
controlled VBD N
bleeding VBG N
during IN N
two CD N
treatment NN N
courses NNS N
were VBD N
> JJ N
80 CD N
% NN N
Menstruation NN N
resumed VBD N
after IN N
each DT N
treatment NN N
course NN N
and CC N
was VBD N
diminished VBN N
compared VBN N
with IN N
baseline NN N
After IN N
the DT N
second JJ N
treatment NN N
course NN N
, , N
median JJ N
reductions NNS N
from IN N
baseline NN N
in IN N
fibroid JJ N
volume NN N
were VBD N
54 CD N
% NN N
and CC N
58 CD N
% NN N
for IN N
the DT N
patients NNS N
receiving VBG N
5 CD N
and CC N
10 CD N
mg NN N
of IN N
ulipristal JJ N
acetate NN N
, , N
respectively RB N
Pain NN N
and CC N
QoL NNP N
improved VBN N
in IN N
both DT N
groups NNS N
Ulipristal JJ N
acetate NN N
was VBD N
well RB N
tolerated VBN N
with IN N
less JJR N
than IN N
5 CD N
% NN N
of IN N
patients NNS N
discontinuing VBG N
treatment NN N
due JJ N
to TO N
adverse JJ N
events NNS N
CONCLUSION NNP N
( ( N
S NNP N
) ) N
Repeated VBD N
12-week JJ N
courses NNS N
of IN N
daily JJ N
oral JJ N
ulipristal JJ N
acetate NN N
( ( N
5 CD N
and CC N
10 CD N
mg NN N
) ) N
effectively RB N
control VBP N
bleeding VBG N
and CC N
pain NN N
, , N
reduce VB N
fibroid JJ N
volume NN N
, , N
and CC N
restore VB N
QoL NNP N
in IN N
patients NNS N
with IN N
symptomatic JJ N
fibroids NNS N
CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
NCT01629563 NNP N
( ( N
PEARL NNP N
IV NNP N
) ) N
-DOCSTART- -X- O O 8421029

Timing NN N
of IN N
antibiotic JJ N
administration NN N
in IN N
knee JJ 4_p
replacement NN 4_p
under IN 4_p
tourniquet NN 4_p
Cephamandole NNP N
levels NNS N
in IN N
serum NN N
and CC N
drain NN N
fluid NN N
were VBD N
measured VBN N
in IN N
32 CD 3_p
knee JJ 4_p
replacement NN 4_p
operations NNS 4_p
to TO N
determine VB N
the DT N
benefit NN N
of IN N
an DT N
intravenous JJ N
dose NN N
of IN N
antibiotic JJ N
at IN N
the DT N
time NN N
of IN N
tourniquet JJ N
deflation NN N
Concentrations NNS N
of IN N
cephamandole NN N
in IN N
drain NN N
fluid NN N
were VBD N
directly RB N
proportional JJ N
to TO N
the DT N
serum NN N
concentration NN N
at IN N
the DT N
time NN N
of IN N
tourniquet JJ N
release NN N
A DT N
'tourniquet-release JJ N
' POS N
dose NN N
of IN N
antibiotic JJ N
increased VBD N
drain NN N
fluid NN N
concentration NN N
threefold NN N
-DOCSTART- -X- O O 5512598

Effects NNS N
of IN N
progressive JJ N
relaxation NN N
on IN N
autonomic JJ 4_p
processes NNS 4_p
-DOCSTART- -X- O O 15793648

Stapled VBN N
hemorrhoidopexy NN N
vs. FW N
Harmonic NNP N
Scalpel NNP N
hemorrhoidectomy NN N
: : N
a DT N
randomized JJ N
trial NN N
PURPOSE VB N
A NNP N
randomized JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
and CC N
compare VB N
stapled VBN N
hemorrhoidopexy NN N
with IN N
excisional JJ N
hemorrhoidectomy NN N
in IN N
which WDT N
the DT N
Harmonic NNP N
Scalpel NNP N
was VBD N
used VBN N
METHODS JJ N
Patients NNS 4_p
with IN 4_p
Grade NNP 4_p
III NNP 4_p
hemorrhoids NNS 4_p
who WP 4_p
were VBD 4_p
employed VBN 4_p
during IN 4_p
the DT 4_p
trial NN 4_p
period NN 4_p
were VBD N
recruited VBN N
and CC N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
Harmonic NNP N
Scalpel NNP N
hemorrhoidectomy NN N
, , N
and CC N
( ( N
2 CD N
) ) N
stapled VBD N
hemorrhoidopexy NN N
All DT N
operations NNS N
were VBD N
performed VBN N
by IN N
a DT N
single JJ N
surgeon NN N
In IN N
the DT N
stapled JJ N
group NN N
, , N
the DT N
doughnut NN N
obtained VBN N
was VBD N
sent VBN N
for IN N
histopathologic JJ N
examination NN N
to TO N
determine VB N
whether IN N
smooth JJ N
muscles NNS N
were VBD N
included VBN N
in IN N
the DT N
specimen NNS N
Operative NNP N
data NN N
and CC N
complications NNS N
were VBD N
recorded VBN N
, , N
and CC N
patients NNS N
were VBD N
followed VBN N
up RP N
through IN N
a DT N
structured JJ N
pro JJ N
forma NN N
protocol NN N
An DT N
independent JJ N
assessor NN N
was VBD N
assigned VBN N
to TO N
obtain VB N
postoperative JJ N
pain NN N
scores NNS N
and CC N
satisfaction NN N
scores NNS N
at IN N
six-month JJ N
follow-up JJ N
Patients NNS N
were VBD N
also RB N
administered VBN N
a DT N
simple JJ N
questionnaire NN N
at IN N
follow-up JJ N
to TO N
assess VB N
continence NN N
functions NNS N
RESULTS NNP N
Over IN N
a DT N
20-month JJ N
period NN N
, , N
88 CD N
patients NNS N
were VBD N
recruited VBN N
The DT N
two CD N
groups NNS N
were VBD N
matched VBN N
for IN N
age NN N
and CC N
gender NN N
distribution NN N
No DT N
significant JJ N
difference NN N
was VBD N
identified VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
operation NN N
time NN N
, , N
blood NN N
loss NN N
, , N
day NN N
of IN N
first JJ N
bowel NN N
movement NN N
after IN N
surgery NN N
, , N
and CC N
complication NN N
rates NNS N
Despite IN N
a DT N
similar JJ N
parenteral NN N
and CC N
oral JJ N
analgesic JJ N
requirement NN N
, , N
the DT N
stapled VBN N
group NN N
had VBD N
a DT N
significantly RB N
better RBR N
pain NN N
score NN N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
; : N
these DT N
patients NNS N
also RB N
had VBD N
a DT N
significantly RB N
shorter JJR N
length NN N
of IN N
stay NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
on IN N
average NN N
resumed VBN N
work NN N
nine CD N
days NNS N
earlier RBR N
than IN N
the DT N
group NN N
treated VBD N
with IN N
the DT N
Harmonic NNP N
Scalpel NNP N
( ( N
6.7 CD N
vs. FW N
15.6 CD N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
Although IN N
88 CD N
percent NN N
of IN N
doughnuts NNS N
obtained VBN N
in IN N
the DT N
stapled JJ N
group NN N
contained VBD N
some DT N
smooth JJ N
muscle NN N
fibers NNS N
, , N
no DT N
association NN N
was VBD N
found VBN N
between IN N
smooth JJ N
muscle NN N
incorporation NN N
and CC N
postoperative JJ N
continence NN N
function NN N
, , N
and CC N
as IN N
a DT N
whole JJ N
the DT N
continence NN N
outcomes NNS N
of IN N
the DT N
stapled VBN N
group NN N
were VBD N
similar JJ N
to TO N
those DT N
after IN N
Harmonic NNP N
Scalpel NNP N
hemorrhoidectomy NN N
Finally RB N
, , N
at IN N
six-month JJ N
follow-up JJ N
, , N
patients NNS N
who WP N
underwent VBP N
the DT N
stapled JJ N
procedure NN N
had VBD N
significantly RB N
better JJR N
satisfaction NN N
scores NNS N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
CONCLUSION NNP N
Stapled NNP N
hemorrhoidopexy NN N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
procedure NN N
for IN N
Grade NNP N
III NNP N
hemorrhoidal JJ N
disease NN N
Patients NNS N
derive JJ N
greater JJR N
short-term JJ N
benefits NNS N
of IN N
reduced JJ N
pain NN N
, , N
shorter JJR N
length NN N
of IN N
stay NN N
, , N
and CC N
earlier JJR N
resumption NN N
to TO N
work VB N
Long-term JJ N
follow-up NN N
is VBZ N
necessary JJ N
to TO N
determine VB N
whether IN N
these DT N
initial JJ N
results NNS N
are VBP N
lasting VBG N
-DOCSTART- -X- O O 7910732

Exposure NN N
reduced VBN N
agoraphobia NNS N
but CC N
not RB N
panic JJ N
, , N
and CC N
cognitive JJ N
therapy NN N
reduced VBD N
panic JJ N
but CC N
not RB N
agoraphobia RB N
Earlier JJR N
studies NNS N
showed VBD N
that IN N
cognitive JJ N
therapy NN N
has VBZ N
anti-panic JJ N
effects NNS N
and CC N
exposure NN N
has VBZ N
anti-agoraphobic JJ N
effects NNS N
while IN N
other JJ N
studies NNS N
suggest VBP N
that IN N
agoraphobia NN N
is VBZ N
a DT N
secondary JJ N
complication NN N
of IN N
panic JJ N
disorder NN N
It PRP N
was VBD N
therefore RB N
hypothesized VBN N
that IN N
cognitive JJ N
therapy NN N
not RB N
only RB N
reduces VBZ N
panic NN N
but CC N
also RB N
agoraphobia JJ N
and CC N
that IN N
it PRP N
potentiates VBZ N
the DT N
effects NNS N
of IN N
exposure NN N
in IN N
vivo NN N
Two CD 4_p
groups NNS 4_p
of IN 4_p
12 CD 3_p
severe JJ 4_p
agoraphobics NNS 4_p
were VBD 4_p
treated VBN 4_p
with IN N
4 CD N
sessions NNS N
of IN N
cognitive JJ N
therapy NN N
followed VBN N
by IN N
8 CD N
sessions NNS N
of IN N
cognitive JJ N
therapy NN N
combined VBN N
with IN N
in IN N
vivo NN N
exposure NN N
The DT N
other JJ N
12 CD 3_p
received VBD N
4 CD N
sessions NNS N
of IN N
'associative JJ N
therapy NN N
' '' N
, , N
a DT N
presumably RB N
inert JJ N
treatment NN N
that WDT N
controls VBZ N
for IN N
therapist NN N
attention NN N
, , N
followed VBN N
by IN N
8 CD N
sessions NNS N
of IN N
in IN N
vivo NN N
exposure NN N
that WDT N
was VBD N
framed VBN N
in IN N
common JJ N
behavioral JJ N
terms NNS N
The DT N
initial JJ N
cognitive JJ N
therapy NN N
produced VBD N
a DT N
significant JJ N
reduction NN N
in IN N
panic JJ N
frequency NN N
, , N
while IN N
associative JJ N
therapy NN N
did VBD N
not RB N
affect VB N
panic NN N
Neither CC N
cognitive JJ N
therapy NN N
alone RB N
, , N
nor CC N
associate JJ N
therapy NN N
alone RB N
significantly RB N
reduced VBN N
depression NN N
, , N
state NN N
or CC N
trait NN N
anxiety NN N
, , N
self-rated JJ N
agoraphobia NN N
or CC N
behavioral JJ N
avoidance NN N
After IN N
adding VBG N
exposure NN N
however RB N
, , N
these DT N
parameters NNS N
were VBD N
clearly RB N
and CC N
significantly RB N
reduced VBN N
Cognitive JJ N
therapy NN N
did VBD N
not RB N
potentiate VB N
exposure NN N
effects NNS N
The DT N
results NNS N
are VBP N
discussed VBN N
-DOCSTART- -X- O O 7218018

Are NNP N
oral JJ N
cathartics NNS N
of IN N
value NN N
in IN N
optimizing VBG N
the DT N
gallium NN N
scan JJ N
? . N
Concise NNP N
communication NN N
The DT N
normal JJ N
intestinal JJ N
secretion NN N
of IN N
9-15 CD N
% NN N
of IN N
an DT N
administered VBN N
dose NN N
of IN N
gallium-67 NN N
may MD N
prevent VB N
early JJ N
detection NN N
of IN N
intra-abdominal JJ N
disease NN N
We PRP N
randomized VBD 4_p
50 CD 3_p
patients NNS N
to TO N
receive VB N
either DT N
no DT N
bowel NN N
preparation NN N
or CC N
30 CD N
cc NN N
of IN N
milk NN N
of IN N
magnesia JJ N
plus CC N
5 CD N
cc NN N
of IN N
cascara NN N
No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
frequency NN N
with IN N
which WDT N
gallium NN N
interfered VBD N
with IN N
readings NNS N
or CC N
time NN N
to TO N
complete VB N
the DT N
study NN N
-DOCSTART- -X- O O 24122191

Characterization NN N
of IN N
early JJ N
thermal JJ N
burns NNS 4_p
and CC N
the DT N
effects NNS N
of IN N
hyperbaric JJ N
oxygen NN N
treatment NN N
: : N
a DT N
pilot NN N
study NN N
BACKGROUND NNP N
AND CC N
AIMS NNP N
Studies NNP N
investigating VBG N
hyperbaric JJ N
oxygen NN N
treatment NN N
( ( N
HBOT NNP N
) ) N
to TO N
improve VB N
outcome NN N
in IN N
burns NNS N
have VBP N
been VBN N
inconclusive JJ N
In IN N
this DT N
study NN N
, , N
we PRP N
aimed VBD N
to TO N
characterize VB N
early JJ 4_p
thermal NN 4_p
burns NNS 4_p
injury NN 4_p
in IN N
adult NN 1_p
patients NNS N
with IN N
< JJ 4_p
40 CD 4_p
% NN 4_p
total JJ 4_p
body NN 4_p
surface NN 4_p
area NN 4_p
( ( 4_p
TBSA NNP 4_p
) ) N
and CC N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
HBOT NNP N
administered VBD N
within IN N
24 CD N
h NN N
to TO N
48 CD N
h NN N
of IN N
a DT N
burn JJ N
injury NN N
METHODS NNP N
Seventeen JJ 3_p
subjects NNS N
were VBD N
randomized VBN N
into IN N
control NN N
( ( N
n JJ N
= NNP N
9 CD 3_p
) ) N
and CC N
HBOT NNP N
treatment NN N
( ( N
n JJ N
= NNP N
8 CD 3_p
) ) N
arms NNS N
Burn NNP N
depth NN N
, , N
measured VBN N
by IN N
laser NN N
Doppler NNP N
imaging NN N
( ( N
LDI NNP N
) ) N
and CC N
histologically RB N
, , N
white JJ N
blood NN N
cell NN N
( ( N
WBC NNP N
) ) N
count NN N
and CC N
plasma JJ N
cytokine NN N
inflammatory NN N
markers NNS N
were VBD N
assessed VBN N
at IN N
24 CD N
h NN N
( ( N
pre JJ N
HBOT NNP N
) ) N
and CC N
48 CD N
h NN N
( ( N
post VB N
HBOT NNP N
) ) N
post NN N
burn NN N
, , N
as IN N
were VBD N
immunohistochemistry NN N
and CC N
microbiology NN N
of IN N
burns NNS N
tissue NN N
samples NNS N
at IN N
48 CD N
h NN N
post NN N
burn NN N
RESULTS NNP N
WBC NNP N
count NN N
and CC N
serum NN N
interleukin NN N
( ( N
IL NNP N
) ) N
-1β NN N
, , N
IL-4 NNP N
, , N
IL-6 NNP N
, , N
IL-10 NNP N
and CC N
interferon-γ NNS N
were VBD N
significantly RB N
elevated VBN N
24 CD N
h NN N
after IN N
burn NN N
, , N
but CC N
no DT N
significant JJ N
changes NNS N
in IN N
any DT N
of IN N
these DT N
parameters NNS N
were VBD N
found VBN N
with IN N
HBOT NNP N
HBOT NNP N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
burn NN N
depth NN N
Two CD N
HBOT NNP N
patients NNS N
and CC N
four CD N
control NN N
patients NNS N
developed VBD N
positive JJ N
bacterial JJ N
cultures NNS N
CONCLUSIONS NNP N
Slower JJR N
than IN N
anticipated VBN N
recruitment NN N
resulted VBD N
in IN N
considerably RB N
fewer JJR N
patients NNS N
than IN N
planned VBN N
being VBG N
studied VBN N
Inflammatory JJ N
markers NNS N
were VBD N
significantly RB N
increased VBN N
at IN N
24 CD N
h NN N
in IN N
patients NNS N
with IN N
< JJ N
40 CD N
% NN N
TBSA NNP N
burn NN N
Early JJ N
HBOT NNP N
had VBD N
no DT N
apparent JJ N
effects NNS N
on IN N
any DT N
of IN N
the DT N
parameters NNS N
measured VBN N
in IN N
this DT N
small JJ N
pilot NN N
study NN N
HBOT NNP N
may MD N
possibly RB N
have VB N
a DT N
broad-spectrum JJ N
antimicrobial JJ N
effect NN N
worthy NN N
of IN N
further JJ N
study NN N
We PRP N
report VBP N
our PRP$ N
methodology NN N
in IN N
detail NN N
as IN N
a DT N
possible JJ N
model NN N
for IN N
future JJ N
burns NNS N
studies NNS N
-DOCSTART- -X- O O 16212446

Intensive JJ N
behavioral JJ N
treatment NN N
for IN N
children NNS 1_p
with IN 1_p
autism NN 4_p
: : N
four-year JJ N
outcome NN N
and CC N
predictors NNS N
Twenty-four JJ 3_p
children NNS 1_p
with IN N
autism NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
clinic-directed JJ N
group NN N
, , N
replicating VBG N
the DT N
parameters NNS N
of IN N
the DT N
early JJ N
intensive JJ N
behavioral JJ N
treatment NN N
developed VBD N
at IN N
UCLA NNP N
, , N
or CC N
to TO N
a DT N
parent-directed JJ N
group NN N
that WDT N
received VBD N
intensive JJ N
hours NNS N
but CC N
less JJR N
supervision NN N
by IN N
equally RB N
well-trained JJ N
supervisors NNS N
Outcome NNP N
after IN N
4 CD N
years NNS N
of IN N
treatment NN N
, , N
including VBG N
cognitive JJ N
, , N
language NN N
, , N
adaptive JJ N
, , N
social JJ N
, , N
and CC N
academic JJ N
measures NNS N
, , N
was VBD N
similar JJ N
for IN N
both DT N
groups NNS N
After IN N
combining VBG N
groups NNS N
, , N
we PRP N
found VBD N
that IN N
48 CD N
% NN N
of IN N
all DT N
children NNS N
showed VBD N
rapid JJ N
learning NN N
, , N
achieved VBN N
average JJ N
posttreatment JJ N
scores NNS N
, , N
and CC N
at IN N
age NN N
7 CD N
, , N
were VBD N
succeeding VBG N
in IN N
regular JJ N
education NN N
classrooms NNS N
Treatment NNP N
outcome NN N
was VBD N
best RB N
predicted VBN N
by IN N
pretreatment JJ N
imitation NN N
, , N
language NN N
, , N
and CC N
social JJ N
responsiveness NN N
These DT N
results NNS N
are VBP N
consistent JJ N
with IN N
those DT N
reported VBN N
by IN N
Lovaas NNP N
and CC N
colleagues NNS N
( ( N
Lovaas NNP N
, , N
1987 CD N
; : N
McEachin NNP N
, , N
Smith NNP N
, , N
& CC N
Lovaas NNP N
, , N
1993 CD N
) ) N
-DOCSTART- -X- O O 17947289

Children NNP 4_p
with IN 4_p
autism NN 4_p
's POS 4_p
response NN N
to TO N
novel VB N
stimuli NNS N
while IN N
participating VBG N
in IN N
interventions NNS N
targeting VBG N
joint JJ N
attention NN N
or CC N
symbolic JJ N
play NN N
skills NNS N
Thirty-five JJ 3_p
children NNS 3_p
diagnosed VBN N
with IN N
autism NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
joint JJ N
attention NN N
or CC N
a DT N
symbolic JJ N
play NN N
intervention NN N
During IN N
the DT N
5-8 JJ N
week NN N
treatment NN N
, , N
three CD N
novel NN N
probes NNS N
were VBD N
administered VBN N
to TO N
determine VB N
mastery NN N
of IN N
joint JJ N
attention NN N
skills NNS N
The DT N
probes NNS N
consisted VBD N
of IN N
auditory NN N
and CC N
visual JJ N
stimuli NN N
, , N
such JJ N
as IN N
a DT N
loud JJ N
spider NN N
crawling NN N
or CC N
a DT N
musical JJ N
ball NN N
bouncing NN N
The DT N
current JJ N
study NN N
examined VBD N
affect JJ N
, , N
gaze JJ N
, , N
joint JJ N
attention NN N
behaviors NNS N
, , N
and CC N
verbalizations NNS N
at IN N
three CD N
different JJ N
time NN N
points NNS N
of IN N
intervention NN N
Results NNS N
revealed VBD N
that IN N
children NNS N
randomized VBN N
to TO N
the DT N
joint JJ N
attention NN N
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
acknowledge VB N
the DT N
probe NN N
and CC N
engage NN N
in IN N
shared VBN N
interactions NNS N
between IN N
intervener NN N
and CC N
probe NN N
upon IN N
termination NN N
of IN N
intervention NN N
Additionally RB N
, , N
the DT N
joint JJ N
attention NN N
group NN N
improved VBD N
in IN N
the DT N
proportion NN N
of IN N
time NN N
spent VBN N
sharing VBG N
coordinated VBN N
joint JJ N
looks NNS N
between IN N
intervener NN N
and CC N
probe NN N
These DT N
results NNS N
suggest VBP N
that IN N
generalization NN N
of IN N
joint JJ N
attention NN N
skills NNS N
to TO N
a DT N
novel JJ N
probe NN N
did VBD N
occur VB N
for IN N
the DT N
group NN N
targeting VBG N
joint JJ N
attention NN N
and CC N
provides VBZ N
further JJ N
evidence NN N
of IN N
the DT N
effectiveness NN N
of IN N
the DT N
joint JJ N
attention NN N
intervention NN N
-DOCSTART- -X- O O 3624669

Disopyramide-pyridostigmine JJ N
interaction NN N
: : N
selective JJ N
reversal NN N
of IN N
anticholinergic NN N
symptoms NNS N
with IN N
preservation NN N
of IN N
antiarrhythmic JJ N
effect NN N
This DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo FW N
crossover NN N
study NN N
was VBD N
used VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
cholinesterase NN N
inhibitor NN N
-- : N
slow-release JJ N
pyridostigmine NN N
( ( N
180 CD N
mg NNS N
orally RB N
every DT N
12 CD N
hours NNS N
) ) N
-- : N
on IN N
the DT N
anticholinergic NN N
and CC N
antiarrhythmic JJ N
properties NNS N
of IN N
disopyramide NN N
Quantitative JJ N
side NN N
effects NNS N
questionnaire VBP N
scores NNS N
were VBD N
used VBN N
to TO N
guide VB N
disopyramide JJ N
administration NN N
in IN N
20 CD 3_p
men NNS 2_p
with IN N
ventricular JJ 4_p
tachycardia NN 4_p
Disopyramide NNP N
was VBD N
given VBN N
to TO N
each DT N
patient NN N
both DT N
with IN N
placebo NN 4_p
and CC N
with IN N
active JJ 4_p
pyridostigmine NN 4_p
The DT N
maximal JJ N
administered VBD N
dose NN N
for IN N
each DT N
regimen NN N
was VBD N
used VBN N
in IN N
conjunction NN N
with IN N
corresponding JJ N
questionnaire NN N
scores NNS N
to TO N
calculate VB N
an DT N
index NN N
or CC N
estimate NN N
of IN N
the DT N
maximal JJ N
tolerable JJ N
dose NN N
of IN N
disopyramide NN N
Additional JJ N
evaluations NNS N
performed VBN N
at IN N
baseline NN N
and CC N
at IN N
each DT N
maximal NN N
administered VBD N
dose JJ N
regimen NNS N
included VBD N
tear JJ N
and CC N
saliva JJ N
quantitation NN N
, , N
24 CD N
hour NN N
electrocardiogram NN N
( ( N
ECG NNP N
) ) N
, , N
exercise VBP N
testing VBG N
and CC N
programmed VBD N
ventricular JJ N
stimulation NN N
Results NNS N
showed VBD N
that IN N
the DT N
maximal NN N
administered VBD N
dose NN N
of IN N
disopyramide NN N
was VBD N
greater JJR N
with IN N
active JJ N
pyridostigmine NN N
than IN N
with IN N
placebo NN N
: : N
295 CD N
+/- JJ N
75 CD N
versus NN N
245 CD N
+/- JJ N
100 CD N
mg NN N
every DT N
6 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
The DT N
calculated JJ N
maximal NN N
tolerable JJ N
dose NN N
was VBD N
substantially RB N
greater JJR N
in IN N
the DT N
presence NN N
of IN N
pyridostigmine NN N
: : N
355 CD N
+/- JJ N
90 CD N
versus NN N
260 CD N
+/- JJ N
115 CD N
mg NN N
every DT N
6 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
Maximal JJ N
side NN N
effects NNS N
questionnaire NN N
scores NNS N
also RB N
reflected VBD N
decreased JJ N
anticholinergic JJ N
activity NN N
in IN N
the DT N
presence NN N
of IN N
pyridostigmine NN N
compared VBN N
with IN N
placebo NN N
: : N
101.9 CD N
+/- JJ N
2.2 CD N
versus NN N
104.6 CD N
+/- JJ N
2.8 CD N
, , N
respectively RB N
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
Baseline NNP N
tear NN N
and CC N
saliva JJ N
production NN N
was VBD N
significantly RB N
reduced VBN N
during IN N
disopyramide JJ N
therapy NN N
, , N
but CC N
was VBD N
restored VBN N
toward IN N
normal JJ N
by IN N
the DT N
addition NN N
of IN N
pyridostigmine NN N
( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 16855475

Divalproex NNP N
versus NN N
placebo NN N
for IN N
the DT N
prevention NN N
of IN N
irritability NN N
associated VBN N
with IN N
fluoxetine JJ N
treatment NN N
in IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
-DOCSTART- -X- O O 20865676

The DT N
effect NN N
of IN N
L-arginine NNP N
and CC N
citrulline NN N
on IN N
endothelial JJ N
function NN N
in IN N
patients NNS 4_p
in IN 4_p
heart NN 4_p
failure NN 4_p
with IN 4_p
preserved JJ 4_p
ejection NN 4_p
fraction NN 4_p
BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
amino JJ N
acids NNS N
L-arginine JJ N
and CC N
citrulline NN N
on IN N
endothelial JJ N
function NN N
in IN N
patients NNS 4_p
in IN 4_p
stable JJ 4_p
diastolic NN 4_p
and CC 4_p
right JJ 4_p
heart NN 4_p
failure NN 4_p
using VBG N
photoplethysmography NN N
METHODS NNP N
Thirty NNP 3_p
patients NNS 3_p
from IN N
the DT N
Heart NNP 4_p
Failure NNP 4_p
Clinic NNP 4_p
of IN 4_p
the DT 4_p
Instituto NNP 4_p
Nacional NNP 4_p
de FW 4_p
Ciencias NNP 4_p
Médicas NNP 4_p
y NNP 4_p
Nutrición NNP 4_p
" NNP 4_p
Salvador NNP 4_p
Zubirán NNP 4_p
" NNP 4_p
underwent JJ 4_p
photoplethysmography NN 4_p
using VBG 4_p
the DT 4_p
hyperemia NN 4_p
technique NN 4_p
Index NNP N
finger VBD N
flow NN N
was VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
ischemia NN N
every DT N
30 CD N
s NN N
by IN N
maximum JJ N
amplitude JJ N
time NN N
( ( N
MAT NNP N
) ) N
, , N
total JJ N
time NN N
of IN N
the DT N
curve NN N
( ( N
TT NNP N
) ) N
and CC N
the DT N
index NN N
of IN N
the DT N
two CD N
( ( N
MAT/TT NNP N
< VBZ N
30 CD N
= NNP N
normal JJ N
) ) N
before IN N
and CC N
after IN N
the DT N
administration NN N
of IN N
L-arginine NNP N
( ( N
8 CD N
g/day NN N
in IN N
two CD N
doses NNS N
, , N
n JJ N
= NNP N
15 CD N
) ) N
or CC N
citrulline NN N
( ( N
3 CD N
g/day NN N
in IN N
one CD N
dose NN N
, , N
n JJ N
= NNP N
15 CD N
) ) N
for IN N
60 CD N
days NNS N
in IN N
addition NN N
to TO N
optimal VB N
pharmacological JJ N
treatment NN N
RESULTS CC N
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
at IN N
baseline NN N
After IN N
the DT N
intervention NN N
, , N
the DT N
MAT/TT NNP N
index NN N
of IN N
all DT N
patients NNS N
normalized VBN N
in IN N
each DT N
evaluation NN N
period NN N
with IN N
statistically RB N
significant JJ N
differences NNS N
Basal NNP N
L-arginine NNP N
group NN N
= VBD N
38.75 CD N
± NN N
11.52 CD N
, , N
final JJ N
23.32 CD N
± JJ N
6.08 CD N
, , N
p NN N
= VBD N
0.007 CD N
and CC N
basal JJ N
citrulline NN N
group NN N
= VBD N
41.4 CD N
± NN N
13.47 CD N
, , N
final JJ N
23.65 CD N
± JJ N
6.74 CD N
, , N
p NN N
= VBD N
0.007 CD N
at IN N
60-90 JJ N
s. JJ N
Post-ischemia NN N
: : N
basal NN N
L-arginine JJ N
36.60 CD N
± JJ N
11.51 CD N
, , N
final JJ N
18.81 CD N
± JJ N
15.13 CD N
, , N
p NN N
= VBD N
0.004 CD N
and CC N
basal JJ N
citrulline NN N
= $ N
49.51 CD N
± NNP N
15.17 CD N
, , N
final JJ N
27.13 CD N
± JJ N
7.87 CD N
, , N
p NN N
= VBD N
0.003 CD N
CONCLUSIONS VB N
The DT N
administration NN N
of IN N
L-arginine NNP N
and CC N
citrulline NN N
has VBZ N
a DT N
beneficial JJ N
effect NN N
on IN N
endothelial JJ N
function NN N
as IN N
shown VBN N
by IN N
the DT N
normalized JJ N
MAT/TT NNP N
index NN N
It PRP N
probably RB N
improves VBZ N
systemic JJ N
and CC N
pulmonary JJ N
hemodynamics NNS N
, , N
which WDT N
could MD N
help VB N
in IN N
the DT N
treatment NN 4_p
of IN 4_p
diastolic JJ 4_p
heart NN 4_p
failure NN N
-DOCSTART- -X- O O 23360819

Influence NN N
of IN N
SNPs NNP N
in IN N
nutrient-sensitive JJ N
candidate NN N
genes NNS N
and CC N
gene-diet JJ N
interactions NNS N
on IN N
blood NN N
lipids NNS N
: : N
the DT N
DiOGenes NNP 4_p
study NN 4_p
Blood NNP N
lipid JJ N
response NN N
to TO N
a DT N
given VBN N
dietary JJ N
intervention NN N
could MD N
be VB N
determined VBN N
by IN N
the DT N
effect NN N
of IN N
diet NN N
, , N
gene NN N
variants NNS N
or CC N
gene-diet JJ N
interactions NNS N
The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
variants NNS N
in IN N
presumed JJ N
nutrient-sensitive JJ N
genes NNS N
involved VBN N
in IN N
lipid JJ N
metabolism NN N
modified VBD N
lipid JJ N
profile NN N
after IN N
weight JJ N
loss NN N
and CC N
in IN N
response NN N
to TO N
a DT N
given VBN N
diet JJ N
, , N
among IN N
overweight JJ 4_p
European JJ N
adults NNS N
participating VBG N
in IN N
the DT N
Diet NNP 4_p
Obesity NNP 4_p
and CC 4_p
Genes NNP 4_p
study NN 4_p
By IN N
multiple JJ N
linear JJ N
regressions NNS N
, , N
240 CD N
SNPs NNP N
in IN N
twenty-four JJ 3_p
candidate NN 3_p
genes NNS 3_p
were VBD 3_p
investigated VBN 3_p
for IN N
SNP NNP N
main JJ N
and CC N
SNP-diet JJ N
interaction NN N
effects NNS N
on IN N
total JJ N
cholesterol NN N
, , N
LDL-cholesterol NNP N
, , N
HDL-cholesterol NNP N
and CC N
TAG NNP N
after IN N
an DT N
8-week JJ N
low-energy JJ N
diet NN N
( ( N
only RB N
main JJ N
effect NN N
) ) N
, , N
and CC N
a DT N
6-month JJ N
ad NN N
libitum NN N
weight VBD N
maintenance NN N
diet NN N
, , N
with IN N
different JJ N
contents NNS N
of IN N
dietary JJ N
protein NN N
or CC N
glycaemic JJ N
index NN N
After IN N
adjusting VBG N
for IN N
multiple JJ N
testing NN N
, , N
a DT N
SNP-dietary JJ N
protein NN N
interaction NN N
effect NN N
on IN N
TAG NNP N
was VBD N
identified VBN N
for IN N
lipin NN N
1 CD N
( ( N
LPIN1 NNP N
) ) N
rs4315495 NN N
, , N
with IN N
a DT N
decrease NN N
in IN N
TAG NNP N
of IN N
20.26 CD N
mmol/l NNS N
per IN N
A-allele/protein NNP N
unit NN N
( ( N
95 CD N
% NN N
CI NNP N
20.38 CD N
, , N
20.14 CD N
, , N
P=0.000043 NNP N
) ) N
In IN N
conclusion NN N
, , N
we PRP N
investigated VBD N
SNP-diet JJ N
interactions NNS N
for IN N
blood NN N
lipid JJ N
profiles NNS N
for IN N
240 CD N
SNPs NNP N
in IN N
twenty-four JJ N
candidate NN N
genes NNS N
, , N
selected VBN N
for IN N
their PRP$ N
involvement NN N
in IN N
lipid JJ N
metabolism NN N
pathways NNS N
, , N
and CC N
identified VBD N
one CD N
significant JJ N
interaction NN N
between IN N
LPIN1 NNP N
rs4315495 NN N
and CC N
dietary JJ N
protein NN N
for IN N
TAG NNP N
concentration NN N
-DOCSTART- -X- O O 14616279

Vaginal JJ N
electrical JJ N
stimulation NN N
of IN N
the DT N
pelvic JJ N
floor NN N
: : N
a DT N
randomized JJ N
feasibility NN N
study NN N
in IN N
urinary JJ N
incontinent NN N
elderly JJ N
women NNS N
BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
intravaginal JJ N
electrical JJ N
stimulation NN N
( ( N
ES NNP N
) ) N
of IN N
the DT N
pelvic JJ N
floor NN N
for IN N
urinary JJ N
incontinence NN N
in IN N
elderly JJ N
women NNS N
, , N
and CC N
to TO N
determine VB N
whether IN N
ES NNP N
of IN N
the DT N
pelvic JJ N
floor NN N
is VBZ N
a DT N
preferable JJ N
treatment NN N
for IN N
urinary JJ N
incontinence NN N
in IN N
elderly JJ N
women NNS N
METHODS NNP N
Postmenopausal NNP N
women NNS N
( ( N
age NN N
65 CD N
years NNS N
or CC N
older JJR N
) ) N
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
and CC N
underwent JJ N
every-other-day JJ N
ES NNP N
of IN N
the DT N
pelvic JJ N
floor NN N
, , N
or CC N
a DT N
daily JJ N
Kegel NNP N
exercise NN N
( ( N
KE NNP N
) ) N
program NN N
Objective NNP N
outcome NN N
variables NNS N
were VBD N
: : N
( ( N
1 CD N
) ) N
Urinary JJ N
leakage NN N
( ( N
during IN N
a DT N
standardized JJ N
PAD NNP N
test NN N
) ) N
, , N
( ( N
2 CD N
) ) N
pelvic NN N
muscle NN N
strength NN N
( ( N
measured VBN N
by IN N
a DT N
perineometer NN N
) ) N
, , N
and CC N
( ( N
3 CD N
) ) N
detrusor NN N
instability NN N
( ( N
on IN N
ambulant NN N
urodynamic JJ N
registration NN N
) ) N
Subjective JJ N
outcome NN N
variables NNS N
were VBD N
women NNS N
's POS N
subjective JJ N
assessment NN N
of IN N
change NN N
in IN N
urinary JJ N
symptoms NNS N
based VBN N
on IN N
the DT N
PRAFAB NNP N
score NN N
Twenty-four JJ N
women NNS N
treated VBN N
with IN N
ES NNP N
and CC N
11 CD N
women NNS N
treated VBN N
with IN N
Kegel NNP N
exercises NNS N
completed VBD N
the DT N
8-week JJ N
study NN N
program NN N
The DT N
Chi-square JJ N
test NN N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
RESULTS NNP N
No NNP N
significant JJ N
improvement NN N
in IN N
objective JJ N
outcome NN N
variables NNS N
was VBD N
observed VBN N
in IN N
the DT N
population NN N
treated VBD N
with IN N
ES NNP N
compared VBN N
with IN N
the DT N
population NN N
treated VBD N
with IN N
KE NNP N
( ( N
with IN N
29.2 CD N
% NN N
vs. FW N
36.4 CD N
% NN N
of IN N
the DT N
women NNS N
showing VBG N
objective JJ N
improvement NN N
in IN N
measured JJ N
urinary JJ N
leakage NN N
) ) N
Neither CC N
was VBD N
subjective JJ N
improvement NN N
significant JJ N
, , N
with IN N
29.2 CD N
% NN N
vs. FW N
27.3 CD N
% NN N
of IN N
the DT N
women NNS N
reporting VBG N
improvement NN N
in IN N
the DT N
amount NN N
of IN N
urinary JJ N
leakage NN N
CONCLUSIONS NNP N
Although IN N
the DT N
number NN N
of IN N
enrolled JJ N
women NNS N
was VBD N
very RB N
small JJ N
this DT N
study NN N
shows VBZ N
that IN N
: : N
1 CD N
Treating VBG N
elderly JJ N
women NNS N
with IN N
vaginal JJ N
ES NNP N
of IN N
the DT N
pelvic JJ N
floor NN N
has VBZ N
a DT N
high JJ N
physical JJ N
and CC N
emotional JJ N
cost NN N
for IN N
the DT N
individual NN N
2 CD N
The DT N
effectiveness NN N
of IN N
ES NNP N
of IN N
the DT N
pelvic JJ N
floor NN N
in IN N
urinary JJ N
incontinent NN N
elderly JJ N
women NNS N
is VBZ N
low JJ N
3 CD N
There EX N
is VBZ N
no DT N
great JJ N
discrepancy NN N
between IN N
objective JJ N
amelioration NN N
( ( N
PAD NNP N
test NN N
) ) N
and CC N
subjective JJ N
amelioration NN N
( ( N
PRAFAB NNP N
score/quantity NN N
of IN N
urinary JJ N
leakage NN N
) ) N
, , N
if IN N
the DT N
objective JJ N
improvement NN N
is VBZ N
adequately RB N
defined VBN N
4 CD N
It PRP N
is VBZ N
not RB N
reasonable JJ N
to TO N
advise VB N
elderly JJ N
women NNS N
with IN N
urinary JJ N
incontinence NN N
to TO N
undertake VB N
this DT N
treatment NN N
procedure NN N
The DT N
effectiveness NN N
of IN N
treatment NN N
does VBZ N
not RB N
compensate VB N
for IN N
the DT N
long-lasting JJ N
and CC N
intense JJ N
treatment NN N
protocol NN N
5 CD N
We PRP N
terminated VBD N
this DT N
study NN N
because IN N
of IN N
the DT N
negative JJ N
outcome NN N
with IN N
ES NNP N
-DOCSTART- -X- O O 24898665

Patients NNS N
with IN 4_p
relapsed JJ 4_p
follicular JJ 4_p
lymphoma NN 4_p
treated VBN N
with IN N
rituximab JJ N
versus NN N
tositumomab NN N
and CC N
iodine JJ N
I-131 NNP N
tositumomab NN N
-DOCSTART- -X- O O 22510874

Osteopontin NNP N
is VBZ N
a DT N
prognostic JJ N
factor NN N
for IN N
survival NN N
of IN N
acute JJ 4_p
myeloid JJ 4_p
leukemia NN 4_p
patients NNS 4_p
Osteopontin NNP N
( ( N
OPN NNP N
) ) N
is VBZ N
a DT N
glycoprotein NN N
that WDT N
is VBZ N
secreted VBN N
by IN N
osteoblasts NNS N
and CC N
hematopoietic JJ N
cells NNS N
OPN NNP N
suppresses VBZ N
the DT N
proliferation NN N
of IN N
hematopoietic JJ N
stem NN N
cells NNS N
in IN N
vitro NN N
and CC N
may MD N
regulate VB N
the DT N
hematopoietic JJ N
stem NN N
cell NN N
pool NN N
Increased VBN N
serum NN N
OPN NNP N
concentrations NNS N
occur VBP N
in IN N
chronic JJ N
myeloid NN N
leukemia NN N
, , N
multiple JJ N
myeloma NN N
, , N
and CC N
acute JJ N
myeloid NN N
leukemia NN N
( ( N
AML NNP N
) ) N
In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
analyzed VBD N
the DT N
prognostic JJ N
impact NN N
of IN N
OPN NNP N
in IN N
AML NNP N
by IN N
investigating VBG N
the DT N
expression NN N
and CC N
relevance NN N
of IN N
OPN NNP N
in IN N
newly RB N
diagnosed VBN N
AML NNP N
patients NNS N
from IN N
2 CD 3_p
large JJ N
study NN N
groups NNS N
( ( N
the DT N
German JJ N
AML NNP N
Cooperative NNP N
Group NNP N
and CC N
the DT N
Dutch-Belgian JJ N
Hematology NNP N
Oncology NNP N
Cooperative NNP N
group NN N
) ) N
IHC NNP N
( ( N
n JJ N
= NNP N
84 CD N
) ) N
, , N
ELISAs NNP N
of IN N
blood/BM NN N
sera NN N
( ( N
n JJ N
= NNP N
41 CD N
) ) N
, , N
and CC N
microarray NN N
data NNS N
for IN N
mRNA NN N
levels NNS N
( ( N
n JJ N
= NNP N
261 CD N
) ) N
were VBD N
performed VBN N
Expression NN N
of IN N
OPN NNP N
protein NN N
was VBD N
increased VBN N
in IN N
AML NNP N
patients NNS N
both DT N
in IN N
BM NNP N
blasts NNS N
( ( N
IHC NNP N
) ) N
and CC N
in IN N
BM NNP N
serum NN N
( ( N
ELISA NNP N
) ) N
compared VBN N
with IN N
healthy JJ N
controls NNS N
Patients NNS N
expressing VBG N
high JJ N
levels NNS N
of IN N
OPN NNP N
within IN N
the DT N
BM NNP N
( ( N
IHC NNP N
) ) N
experienced VBD N
shortened VBN N
overall JJ N
survival NN N
( ( N
OS NNP N
; : N
P NNP N
= NNP N
.025 NNP N
) ) N
Multivariate NNP N
analysis NN N
identified VBD N
karyotype NN N
, , N
blast JJ N
clearance NN N
( ( N
day NN N
16 CD N
) ) N
, , N
and CC N
the DT N
level NN N
of IN N
OPN NNP N
expression NN N
as IN N
independent JJ N
prognostic JJ N
factors NNS N
for IN N
OS NNP N
This DT N
prompted VBD N
us PRP N
to TO N
analyze VB N
microarray NN N
data NNS N
from IN N
261 CD 3_p
patients NNS 3_p
from IN 3_p
a DT 3_p
third JJ 3_p
cohort NN 3_p
The DT N
analysis NN N
confirmed VBD N
OPN NNP N
as IN N
a DT N
prognostic JJ N
marker NN N
In IN N
summary JJ N
, , N
high JJ N
OPN NNP N
mRNA NN N
expression NN N
indicated VBD N
decreased JJ N
event-free JJ N
survival NN N
( ( N
P NNP N
= NNP N
.0002 NNP N
) ) N
and CC N
OS NNP N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
The DT N
prognostic JJ N
role NN N
of IN N
OPN NNP N
was VBD N
most RBS N
prominent JJ N
in IN N
intermediate-risk JJ N
AML NNP N
These DT N
data NNS N
provide VBP N
evidence NN N
that IN N
OPN NNP N
expression NN N
is VBZ N
an DT N
independent JJ N
prognostic JJ N
factor NN N
in IN N
AML NNP N
-DOCSTART- -X- O O 10715372

Study NN N
of IN N
the DT N
vaginal JJ N
tolerance NN N
to TO N
Acidform NNP N
, , N
an DT N
acid-buffering JJ N
, , N
bioadhesive JJ N
gel NN N
Vaginal JJ N
tolerance NN N
tests NNS N
were VBD N
performed VBN N
with IN N
a DT N
new JJ N
potential JJ N
microbicidal NN N
and CC N
spermicidal JJ N
product NN N
, , N
an DT N
acid-buffering JJ N
vaginal JJ N
gel NN N
( ( N
Acidform NNP N
) ) N
without IN N
or CC N
with IN N
nonoxynol-9 JJ N
( ( N
N-9 NNP N
) ) N
The DT N
potential JJ N
advantages NNS N
over IN N
other JJ N
vaginal JJ N
products NNS N
include VBP N
keeping VBG N
a DT N
low JJ N
pH NN N
, , N
decrease NN N
of IN N
the DT N
irritating VBG N
effect NN N
of IN N
N-9 NNP N
on IN N
the DT N
cervix NN N
or CC N
vaginal JJ N
mucosa NN N
associated VBN N
with IN N
greater JJR N
retention NN N
of IN N
the DT N
product NN N
after IN N
application NN N
, , N
and CC N
decreasing VBG N
" NNP N
messiness NN N
" NN N
as IN N
compared VBN N
to TO N
other JJ N
vaginal JJ N
products NNS N
Three CD 3_p
groups NNS 3_p
of IN 3_p
six CD 3_p
women NNS N
were VBD N
admitted VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
use VB N
Acidform NNP N
with IN N
0 CD N
% NN N
, , N
2.5 CD N
% NN N
, , N
and CC N
5 CD N
% NN N
N-9 NNP N
Colposcopic NNP N
evaluation NN N
for IN N
vulvar NN N
, , N
vaginal JJ N
, , N
and CC N
cervical JJ N
signs NNS N
of IN N
irritation NN N
was VBD N
performed VBN N
and CC N
photographs NNS N
were VBD N
taken VBN N
, , N
following VBG N
a DT N
specific JJ N
World NNP N
Health NNP N
Organization NNP N
protocol NN N
, , N
at IN N
time NN N
0 CD N
, , N
and CC N
after IN N
24 CD N
h NN N
and CC N
6 CD N
days NNS N
of IN N
application NN N
of IN N
the DT N
gel NN N
No DT N
irritation NN N
or CC N
symptom NN N
was VBD N
reported VBN N
by IN N
users NNS N
of IN N
Acidform NNP N
without IN N
N-9 NNP N
A NNP N
generalized JJ N
and CC N
intense JJ N
erythema NN N
in IN N
cervix NN N
was VBD N
observed VBN N
in IN N
10 CD N
of IN N
12 CD N
Acidform/N-9 JJ N
users NNS N
and CC N
abrasion NN N
occurred VBD N
in IN N
nine CD N
of IN N
them PRP N
Vulvar NNP N
irritation NN N
was VBD N
seen VBN N
in IN N
seven CD N
of IN N
these DT N
10 CD N
volunteers NNS N
N-9 JJ N
concentration NN N
in IN N
the DT N
gel NN N
( ( N
2.5 CD N
% NN N
or CC N
5.0 CD N
% NN N
) ) N
was VBD N
not RB N
related VBN N
to TO N
the DT N
findings NNS N
No DT N
ulcer NN N
, , N
exulceration NN N
, , N
or CC N
de-epithelialization NN N
was VBD N
observed VBN N
Acidform VB N
without IN N
N-9 NNP N
was VBD N
well RB N
tolerated VBN N
by IN N
volunteers NNS N
, , N
but CC N
it PRP N
was VBD N
unable JJ N
to TO N
protect VB N
the DT N
cervix NN N
, , N
vagina NN N
, , N
and CC N
vulva NN N
from IN N
the DT N
N-9 JJ N
effects NNS N
-DOCSTART- -X- O O 22382875

Infrared NNP N
LED NNP N
irradiation NN N
applied VBD N
during IN N
high-intensity NN N
treadmill NN N
training VBG N
improves NNS N
maximal JJ N
exercise NN N
tolerance NN N
in IN N
postmenopausal JJ N
women NNS N
: : N
a DT N
6-month JJ N
longitudinal JJ N
study NN N
Reduced NNP N
aerobic JJ N
fitness NN N
is VBZ N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
cardiovascular JJ N
diseases NNS N
among IN N
the DT N
older JJR N
population NN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
LED NNP N
irradiation NN N
( ( N
850 CD N
nm RB N
) ) N
applied VBD N
during IN N
treadmill JJ N
training VBG N
on IN N
the DT N
maximal JJ N
exercise NN N
tolerance NN N
in IN N
postmenopausal JJ N
women NNS N
At IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
, , N
45 CD N
postmenopausal JJ N
women NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
three CD N
groups NNS N
, , N
and CC N
30 CD N
women NNS N
completed VBD N
the DT N
entire JJ N
6 CD N
months NNS N
of IN N
the DT N
study NN N
The DT N
groups NNS N
were VBD N
: : N
( ( N
1 CD N
) ) N
the DT N
LED NNP N
group NN N
( ( N
treadmill IN N
training VBG N
associated VBN N
with IN N
phototherapy NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
, , N
( ( N
2 CD N
) ) N
the DT N
exercise NN N
group NN N
( ( N
treadmill IN N
training NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
, , N
and CC N
( ( N
3 CD N
) ) N
the DT N
sedentary JJ N
group NN N
( ( N
neither DT N
physical JJ N
training NN N
nor CC N
phototherapy NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
The DT N
training NN N
was VBD N
performed VBN N
for IN N
45 CD N
min NN N
twice RB N
a DT N
week NN N
for IN N
6 CD N
months NNS N
at IN N
intensities NNS N
between IN N
85 CD N
% NN N
and CC N
90 CD N
% NN N
maximal JJ N
heart NN N
rate NN N
( ( N
HRmax NNP N
) ) N
The DT N
irradiation NN N
parameters NNS N
were VBD N
39 CD N
mW/cm NN N
( ( N
2 CD N
) ) N
, , N
45 CD N
min NN N
and CC N
108 CD N
J/cm NNP N
( ( N
2 CD N
) ) N
The DT N
cardiovascular JJ N
parameters NNS N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
months NNS N
As IN N
expected VBN N
, , N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
sedentary JJ N
group NN N
( ( N
p JJ N
≥ NNP N
0.05 CD N
) ) N
The DT N
maximal JJ N
time NN N
of IN N
tolerance NN N
( ( N
Tlim NNP N
) ) N
, , N
metabolic JJ N
equivalents NNS N
( ( N
METs NNP N
) ) N
and CC N
Bruce NNP N
stage NN N
reached VBD N
significantly RB N
higher JJR N
values NNS N
in IN N
the DT N
LED NNP N
group NN N
and CC N
the DT N
exercise NN N
group NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
Furthermore UH N
, , N
the DT N
HR NNP N
, , N
double JJ N
product NN N
and CC N
Borg NNP N
score NN N
at IN N
isotime NN N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
LED NNP N
group NN N
and CC N
in IN N
the DT N
exercise NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
However RB N
, , N
the DT N
time NN N
of IN N
recovery NN N
showed VBD N
a DT N
significant JJ N
decrease NN N
only RB N
in IN N
the DT N
LED NNP N
group NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
Moreover RB N
, , N
the DT N
differences NNS N
between IN N
before IN N
and CC N
after IN N
training NN N
( ( N
delta JJ N
values NNS N
) ) N
for IN N
the DT N
Tlim NNP N
, , N
METs NNP N
and CC N
HR NNP N
at IN N
isotime NN N
were VBD N
greater JJR N
in IN N
the DT N
LED NNP N
group NN N
than IN N
in IN N
the DT N
exercise NN N
group NN N
with IN N
a DT N
significant JJ N
intergroup NN N
difference NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
Therefore RB N
, , N
the DT N
infrared JJ N
LED NNP N
irradiation NN N
during IN N
treadmill JJ N
training NN N
can MD N
improve VB N
maximal JJ N
performance NN N
and CC N
post-exercise JJ N
recovery NN N
in IN N
postmenopausal JJ N
women NNS N
-DOCSTART- -X- O O 9932558

Videotaped NNP N
training NN N
in IN N
alcohol NN N
counseling NN N
for IN N
obstetric JJ 4_p
care NN 4_p
practitioners NNS 4_p
: : 4_p
a DT N
randomized NN N
controlled VBN N
trial NN N
OBJECTIVE NN N
To TO N
determine VB N
the DT N
feasibility NN N
of IN N
videotaped JJ N
training NN N
for IN N
obstetric JJ 4_p
care NN 4_p
practitioners NNS 4_p
in IN N
motivational JJ N
interviewing NN N
skills NNS N
that WDT N
could MD N
be VB N
used VBN N
in IN N
brief JJ N
patient JJ N
consultations NNS N
on IN N
problem NN N
drinking NN N
METHODS NNP N
Thirty NNP N
health NN N
care NN N
practitioners NNS N
participated VBD N
in IN N
a DT N
clinical JJ N
trial NN N
using VBG N
a DT N
20-minute JJ N
videotape NN N
to TO N
instruct VB N
them PRP N
in IN N
motivational JJ N
interviewing NN N
Participants NNS N
engaged VBN N
in IN N
a DT N
pretest JJ N
roleplay NN N
with IN N
an DT N
actress NN N
playing VBG N
a DT N
drinking NN N
pregnant JJ N
woman NN N
Those DT N
randomly RB N
assigned VBN N
to TO N
the DT N
experimental JJ N
condition NN N
watched VBD N
the DT N
motivational JJ N
interviewing NN N
videotape NN N
Control NNP N
condition NN N
participants NNS N
watched VBD N
a DT N
20-minute JJ N
docudrama NN N
of IN N
a DT N
pregnant JJ N
problem NN N
drinker NN N
Both DT N
groups NNS N
then RB N
engaged VBD N
in IN N
a DT N
post-test JJ N
roleplay NN N
similar JJ N
to TO N
the DT N
pretest NN N
Behavioral JJ N
ratings NNS N
of IN N
the DT N
roleplays NNS N
and CC N
participant JJ N
evaluations NNS N
of IN N
the DT N
motivational JJ N
interviewing NN N
video NN N
constituted VBD N
the DT N
outcome NN N
measures NNS N
RESULTS NNP N
Participant NNP N
evaluations NNS N
indicated VBD N
that IN N
the DT N
training NN N
video NN N
was VBD N
clear JJ N
in IN N
explaining VBG N
and CC N
demonstrating VBG N
the DT N
principles NNS N
and CC N
skills NNS N
of IN N
motivational JJ N
interviewing NN N
Change NN N
in IN N
behavioral JJ N
ratings NNS N
from IN N
pretest NN N
to TO N
post-test NN N
showed VBD N
significant JJ N
differences NNS N
in IN N
motivational JJ N
interviewing NN N
skills NNS N
between IN N
the DT N
experimental JJ N
and CC N
control NN N
groups NNS N
Obstetric NNP N
care NN N
practitioners NNS N
who WP N
viewed VBD N
the DT N
training NN N
video NN N
were VBD N
rated VBN N
as IN N
showing VBG N
greater JJR N
empathy NN N
, , N
minimizing VBG N
patient JJ N
defensiveness NN N
, , N
and CC N
supporting VBG N
women NNS N
's POS N
beliefs NNS N
in IN N
their PRP$ N
ability NN N
to TO N
change VB N
CONCLUSION NNP N
Obstetric NNP N
care NN N
practitioners NNS N
can MD N
improve VB N
their PRP$ N
alcohol NN N
intervention NN N
skills NNS N
through IN N
the DT N
use NN N
of IN N
a DT N
20-minute JJ N
videotaped JJ N
instruction NN N
in IN N
motivational JJ N
interviewing NN N
Clinicians NNPS N
who WP N
improve VBP N
their PRP$ N
skills NNS N
in IN N
motivational JJ N
interviewing NN N
can MD N
intervene VB N
more RBR N
effectively RB N
with IN N
their PRP$ N
drinking NN N
pregnant JJ N
patients NNS N
Using VBG N
motivational JJ N
interviewing NN N
with IN N
this DT N
population NN N
holds VBZ N
promise RB N
for IN N
helping VBG N
prevent JJ N
alcohol-related JJ N
health NN N
problems NNS N
-DOCSTART- -X- O O 25471330

Ranibizumab NNP N
plus CC N
verteporfin JJ N
photodynamic JJ N
therapy NN N
in IN N
neovascular JJ N
age-related JJ N
macular JJ N
degeneration NN N
: : N
12 CD N
months NNS N
of IN N
retreatment NN N
and CC N
vision NN N
outcomes NNS N
from IN N
a DT N
randomized VBN N
study NN N
PURPOSE NNP N
To TO N
investigate VB N
the DT N
injection NN N
frequency NN N
and CC N
visual JJ N
acuity NN N
( ( N
VA NNP N
) ) N
outcomes VBZ N
with IN N
combination NN N
therapy NN N
( ( N
ranibizumab JJ N
plus CC N
verteporfin JJ N
photodynamic JJ N
therapy NN N
, , N
PDT NNP N
) ) N
versus NN N
monotherapy NN N
( ( N
ranibizumab NN N
) ) N
METHODS CC N
A DT N
total NN N
of IN N
40 CD 3_p
patients NNS 3_p
with IN N
exudative JJ 4_p
age-related JJ 4_p
macular JJ 4_p
degeneration NN 4_p
were VBD 4_p
randomized VBN 4_p
1:1 CD N
to TO N
ranibizumab VB N
0.3 CD N
mg JJ N
plus CC N
single JJ N
standard NN N
verteporfin NN N
PDT NNP N
or CC N
ranibizumab VB N
0.3 CD N
mg JJ N
plus CC N
sham JJ N
PDT NNP N
Ranibizumab NNP N
was VBD N
administered VBN N
3 CD N
times NNS N
monthly JJ N
followed VBN N
by IN N
'as NNP N
needed VBD N
' '' N
to TO N
month NN N
12 CD N
based VBN N
on IN N
predetermined JJ N
vision/anatomical JJ N
criteria NNS N
Retreatment NN N
rates NNS N
, , N
VA NNP N
outcomes NNS N
and CC N
safety NN N
were VBD N
assessed VBN N
RESULTS NNP N
During IN N
months NNS N
3-12 CD N
, , N
combination NN N
therapy NN N
patients NNS N
required VBD N
fewer JJR N
ranibizumab JJ N
injections NNS N
( ( N
mean VB N
1.3 CD N
) ) N
compared VBN N
with IN N
monotherapy NN N
patients NNS N
( ( N
2.8 CD N
) ) N
Mean NNP N
VA NNP N
improved VBN N
by IN N
9.0 CD N
letters NNS N
with IN N
combination NN N
therapy NN N
versus NN N
7.5 CD N
letters NNS N
in IN N
the DT N
monotherapy NN N
group NN N
at IN N
month NN N
12 CD N
Both DT N
treatment NN N
regimens NNS N
were VBD N
well RB N
tolerated VBN N
CONCLUSION VB N
The DT N
need NN N
for IN N
ranibizumab JJ N
retreatment NN N
might MD N
be VB N
reduced VBN N
by IN N
administering VBG N
a DT N
single JJ N
verteporfin NN N
PDT NNP N
on IN N
the DT N
same JJ N
day NN N
as IN N
the DT N
first JJ N
ranibizumab NN N
injection NN N
, , N
without IN N
compromising VBG N
VA NNP N
outcomes NNS N
or CC N
safety NN N
-DOCSTART- -X- O O 8852235

An DT N
occupation NN N
based VBN N
physical JJ N
activity NN N
intervention NN N
program NN N
: : N
improving NN N
fitness NN N
and CC N
decreasing VBG N
obesity NN 4_p
The DT N
purpose NN N
of IN N
this DT N
quasi-experimental JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
an DT N
occupation NN N
based VBN N
health NN N
and CC N
fitness NN N
program NN N
Subjects NNS N
were VBD N
1,504 CD 3_p
police NNS N
trainees NNS N
( ( N
85 CD N
% NN N
male NN 2_p
, , N
15 CD N
% NN N
female NN 2_p
) ) N
with IN N
an DT N
ethnic JJ N
distribution NN N
of IN N
82 CD N
% NN N
white JJ N
, , N
16 CD N
% NN N
African JJ N
American NNP N
, , N
and CC N
2 CD N
% NN N
other JJ N
Data NNS N
were VBD N
collected VBN N
at IN N
25 CD N
sites NNS N
across IN N
the DT N
state NN N
of IN N
North NNP N
Carolina NNP N
The DT N
sites NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
experimental JJ N
group NN N
( ( N
implemented VBN N
the DT N
intervention NN N
) ) N
or CC N
the DT N
control NN N
group NN N
( ( N
continued VBN N
usual JJ N
training NN N
) ) N
As IN N
compared VBN N
with IN N
controls NNS N
, , N
subjects NNS N
at IN N
the DT N
experimental JJ N
sites NNS N
improved VBN N
significantly RB N
in IN N
cardiovascular JJ N
fitness NN N
( ( N
aerobic JJ N
power NN N
) ) N
, , N
general JJ N
muscular JJ N
strength NN N
( ( N
number NN N
of IN N
sit NN N
ups NNS N
per IN N
minute NN N
) ) N
, , N
and CC N
flexibility NN N
, , N
and CC N
lowered VBD N
their PRP$ N
body NN N
fat NN N
The DT N
intervention NN N
required VBN N
minimal JJ N
equipment NN N
and CC N
was VBD N
taught VBN N
primarily RB N
by IN N
peers NNS N
who WP N
received VBD N
a DT N
1 CD N
week NN N
training NN N
program NN N
This DT N
occupational JJ N
approach NN N
to TO N
improving VBG N
health NN N
could MD N
be VB N
particularly RB N
useful JJ N
in IN N
occupations NNS N
with IN N
many JJ N
workers NNS N
who WP N
seldom VBP N
engage VB N
in IN N
leisure NN N
time NN N
physical JJ N
activity NN N
-DOCSTART- -X- O O 17114905

A DT N
randomized VBN N
controlled VBN N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
ultrasound-guided JJ N
laser NN N
photocoagulation NN N
for IN N
treatment NN N
of IN N
benign JJ 4_p
thyroid JJ 4_p
nodules NNS 4_p
This DT N
randomized VBD N
controlled VBN N
study NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
percutaneous JJ N
ultrasound NN N
( ( N
US NNP N
) ) N
-guided VBD N
laser NN N
photocoagulation NN N
( ( N
PLP NNP N
) ) N
for IN N
treatment NN N
of IN N
subjects NNS N
with IN N
compressive JJ 4_p
symptoms NNS 4_p
due JJ 4_p
to TO 4_p
benign VB 4_p
thyroid JJ 4_p
nodules NNS 4_p
and/or VBP 4_p
at IN 4_p
high JJ 4_p
surgical JJ 4_p
risk NN 4_p
Twenty NNP 3_p
six CD 3_p
subjects NNS N
were VBD N
randomized VBN N
to TO N
the DT N
intervention NN N
( ( N
no DT N
13 CD 3_p
, , N
age NN N
68+/-3 JJ 1_p
yr NN 1_p
, , N
mean+/-SEM NN N
) ) N
or CC N
observation NN N
( ( N
no DT N
13 CD 3_p
, , N
age NN N
71+/-2 JJ 1_p
yr NN 1_p
) ) N
groups NNS N
In IN N
the DT N
control NN N
group NN N
, , N
the DT N
volume NN N
of IN N
nodules NNS N
did VBD N
not RB N
significantly RB N
change VBP N
over IN N
the DT N
30 CD N
week NN N
period NN N
of IN N
observation NN N
In IN N
the DT N
intervention NN N
group NN N
, , N
median JJ N
nodule NN N
volume NN N
at IN N
baseline NN N
was VBD N
8.2 CD N
ml NN N
( ( N
range VB N
2.8-26.9 JJ N
) ) N
and CC N
was VBD N
not RB N
significantly RB N
different JJ N
from IN N
that DT N
of IN N
the DT N
control NN N
group NN N
Nodules NNS N
decreased VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
by IN N
22 CD N
% NN N
after IN N
2 CD N
weeks NNS N
( ( N
6.5 CD N
ml NN N
; : N
range VB N
2.4-16.7 JJ N
) ) N
and CC N
by IN N
44 CD N
% NN N
after IN N
30 CD N
weeks NNS N
( ( N
4.6 CD N
ml NN N
; : N
range VB N
0.69-14.2 NN N
) ) N
Energy NNP N
given VBN N
was VBD N
correlated VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
with IN N
the DT N
reduction NN N
of IN N
thyroid JJ N
nodule NN N
volume NN N
All DT N
patients NNS N
tolerated VBD N
the DT N
treatment NN N
well RB N
and CC N
reported VBD N
relief NN N
from IN N
compressive JJ N
and CC N
cosmetic JJ N
complaints NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
At IN N
the DT N
time NN N
of IN N
enrolment JJ N
7/13 CD N
( ( N
54 CD N
% NN N
) ) N
and CC N
6/13 CD N
( ( N
46 CD N
% NN N
) ) N
of IN N
patients NNS N
in IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
, , N
respectively RB N
, , N
had VBD N
sub VBN N
clinical JJ N
hyperthyroidism NN N
PLP NNP N
normalized JJ N
thyroid NN N
function NN N
at IN N
6 CD N
and CC N
30 CD N
weeks NNS N
after IN N
treatment NN N
In IN N
conclusion NN N
, , N
PLP NNP N
is VBZ N
a DT N
promising JJ N
safe JJ N
and CC N
effective JJ N
procedure NN N
for IN N
treatment NN N
of IN N
benign JJ 4_p
thyroid JJ 4_p
nodules NNS 4_p
in IN N
patients NNS N
at IN N
high JJ N
surgical JJ N
risk NN N
-DOCSTART- -X- O O 2461017

Safety NN N
and CC N
efficacy NN N
of IN N
a DT N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
Logiparin NNP N
) ) N
versus NN N
dextran NN N
as IN N
prophylaxis NN N
against IN N
thrombosis NN N
after IN N
total JJ 4_p
hip NN 4_p
replacement NN 4_p
In IN N
order NN N
to TO N
study VB N
the DT N
plasma NN N
levels NNS N
of IN N
factor NN N
XaI NNP N
and CC N
IIaI NNP N
activity NN N
an DT N
enzymatically RB N
depolymerized VBN N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
LMW-heparin NNP N
; : N
Logiparin NNP N
) ) N
was VBD N
given VBN N
s.c. NN N
in IN N
a DT N
dose NN N
of IN N
35 CD N
XaI NNP N
mu/kg NN N
b.w NN N
once RB N
daily JJ N
for IN N
7 CD N
days NNS N
to TO N
10 CD 3_p
patients NNS N
undergoing JJ N
total JJ N
hip NN N
replacement NN N
( ( N
THR NNP 4_p
) ) N
in IN N
a DT N
pilot NN N
study NN N
The DT N
XaI NN N
activity NN N
was VBD N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.24 CD N
XaI NNP N
units/ml NN N
and CC N
the DT N
IIaI NNP N
activity NN N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.043 CD N
IIaI NNP N
mu/ml NN N
No DT N
accumulation NN N
of IN N
the DT N
activities NNS N
were VBD N
seen VBN N
No DT N
phlebographically RB N
verified VBN N
thrombi NN N
or CC N
any DT N
bleeding JJ N
complications NNS N
were VBD N
registered VBN N
From IN N
this DT N
study NN N
it PRP N
was VBD N
concluded VBN N
that IN N
the DT N
given VBN N
dose NN N
of IN N
Logiparin NNP N
was VBD N
safe JJ N
with IN N
regard NN N
to TO N
bleeding VBG N
complications NNS N
Based VBN N
on IN N
these DT N
data NNS N
, , N
an DT N
open JJ N
, , N
randomized VBD N
controlled VBN N
trial NN N
was VBD N
started VBN N
In IN N
this DT N
main JJ N
study NN N
the DT N
thromboprophylactic JJ N
effect NN N
of IN N
the DT N
LMW-heparin NNP N
( ( N
Logiparin NNP N
) ) N
in IN N
a DT N
dose NN N
of IN N
35 CD N
XaI NNP N
mu/kg NN N
b.w NN N
once RB N
daily JJ N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
dextran NN N
70 CD N
in IN N
patients NNS N
undergoing JJ 4_p
THR NNP 4_p
100 CD 3_p
patients NNS N
were VBD N
randomized VBN N
The DT N
over-all JJ N
thrombosis NN N
rate NN N
was VBD N
28 CD N
% NN N
in IN N
patients NNS N
treated VBN N
with IN N
LMW-heparin NNP N
and CC N
39 CD N
% NN N
in IN N
those DT N
given VBN N
dextran NN N
, , N
a DT N
non-significant JJ N
difference NN N
No UH N
bleeding VBG N
complications NNS N
, , N
deaths NNS N
or CC N
pulmonary JJ N
embolism NN N
were VBD N
recorded VBN N
in IN N
either DT N
group NN N
Peroperative JJ N
blood NN N
loss NN N
and CC N
transfusion NN N
requirements NNS N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
In IN N
conclusion NN N
, , N
the DT N
investigated JJ N
LMW-heparin NNP N
( ( N
Logiparin NNP N
) ) N
is VBZ N
safe JJ N
and CC N
effective JJ N
in IN N
preventing VBG N
postoperative JJ N
thromboembolism NN N
in IN N
patients NNS N
undergoing JJ N
total JJ N
hip NN N
replacement NN N
, , N
but CC N
the DT N
dosage NN N
can MD N
probably RB N
be VB N
optimized VBN N
-DOCSTART- -X- O O 19272375

A DT N
randomized VBN N
, , N
controlled VBN N
study NN N
on IN N
the DT N
influence NN N
of IN N
acetaminophen NN N
, , N
diclofenac NN N
, , N
or CC N
naproxen RB N
on IN N
aspirin-induced JJ N
inhibition NN N
of IN N
platelet NN N
aggregation NN N
Nonsteroidal NNP N
anti-inflammatory JJ N
drugs NNS N
( ( N
NSAID NNP N
) ) N
may MD N
interfere VB N
with IN N
aspirin NN N
( ( N
acetylsalicylic JJ N
acid NN N
) ) N
and CC N
increase VB N
the DT N
risk NN N
for IN N
cardiovascular JJ N
events NNS N
The DT N
clinical JJ N
relevance NN N
is VBZ N
uncertain JJ N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyse VB N
the DT N
influence NN N
of IN N
a DT N
co-administration NN N
of IN N
aspirin NN N
and CC N
NSAID NNP N
on IN N
platelet NN N
aggregation NN N
In IN N
a DT N
randomized JJ N
, , N
placebo NN N
controlled VBD N
trial NN N
, , N
eleven RB 4_p
healthy JJ 4_p
volunteers NNS 4_p
were VBD N
studied VBN N
during IN N
4 CD N
separate JJ N
study NN N
periods NNS N
of IN N
4 CD N
days NNS N
each DT N
Individuals NNS N
were VBD N
treated VBN N
on IN N
each DT N
occasion NN N
with IN N
100 CD N
mg NNS N
aspirin JJ N
daily RB N
in IN N
combination NN N
with IN N
either DT N
3 CD N
x VBD N
1 CD N
g NN N
acetaminophen NN N
, , N
3 CD N
x NN N
50 CD N
mg NN N
diclofenac NN N
, , N
3 CD N
x NN N
250 CD N
mg NN N
naproxen NN N
, , N
or CC N
3 CD N
x JJ N
1 CD N
placebo NN N
Primary JJ N
hemostasis NN N
was VBD N
assessed VBN N
with IN N
a DT N
platelet NN N
function NN N
analyser NN N
( ( N
PFA-100 NNP N
) ) N
, , N
which WDT N
measures VBZ N
the DT N
closure NN N
time NN N
( ( N
CT NNP N
) ) N
of IN N
a DT N
collagen- JJ N
and CC N
epinephrine-coated JJ N
pore NN N
by IN N
aggregating VBG N
platelets NNS N
in IN N
flowing VBG N
blood NN N
Naproxen NNP N
enhanced VBD N
the DT N
anti-aggregatory JJ N
action NN N
of IN N
aspirin NN N
after IN N
24 CD N
h NN N
( ( N
CT NNP N
rising VBG N
from IN N
104+/-16 JJ N
s NN N
at IN N
baseline NN N
to TO N
212+/-69 JJ N
s NN N
at IN N
24 CD N
h NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
which WDT N
was VBD N
not RB N
seen VBN N
with IN N
any DT N
other JJ N
drug NN N
combination NN N
Diclofenac NNP N
reduced VBD N
the DT N
anti-aggregatory JJ N
action NN N
of IN N
aspirin NN N
in IN N
the DT N
first JJ N
two CD N
days NNS N
, , N
since IN N
the DT N
CT NNP N
did VBD N
not RB N
rise VB N
significantly RB N
( ( N
109+/-19 JJ N
s NN N
, , N
148+/-56 JJ N
s NN N
, , N
and CC N
168+/-66 JJ N
s NN N
at IN N
0 CD N
h NN N
, , N
24 CD N
h NN N
, , N
48 CD N
h NN N
, , N
respectively RB N
, , N
P NNP N
> NNP N
0.05 CD N
) ) N
Acetaminophen NNP N
had VBD N
no DT N
effect NN N
compared VBN N
with IN N
placebo NN N
After IN N
4 CD N
days NNS N
of IN N
treatment NN N
platelet NN N
aggregation NN N
was VBD N
similarly RB N
inhibited VBN N
by IN N
all DT N
combinations NNS N
We PRP N
conclude VBP N
that IN N
a DT N
co-administration NN N
of IN N
NSAID NNP N
and CC N
aspirin NN N
may MD N
interfere VB N
with IN N
platelet NN N
inhibition NN N
at IN N
the DT N
beginning NN N
of IN N
a DT N
treatment NN N
with IN N
an DT N
increase NN N
of IN N
naproxen JJ N
and CC N
a DT N
decrease NN N
of IN N
diclofenac NN N
This DT N
effect NN N
is VBZ N
lost VBN N
after IN N
4 CD N
days NNS N
, , N
suggesting VBG N
that IN N
a DT N
regular JJ N
daily JJ N
co-administration NN N
of IN N
NSAID NNP N
does VBZ N
not RB N
have VB N
an DT N
influence NN N
on IN N
platelet NN N
inhibition NN N
by IN N
aspirin NN N
-DOCSTART- -X- O O 23414585

Ganitumab NNP N
with IN N
either DT N
exemestane NN N
or CC N
fulvestrant NN N
for IN N
postmenopausal JJ N
women NNS N
with IN N
advanced JJ N
, , N
hormone-receptor-positive JJ N
breast NN N
cancer NN N
: : N
a DT N
randomised JJ N
, , N
controlled VBN N
, , N
double-blind NN N
, , N
phase NN N
2 CD N
trial NN N
BACKGROUND NNP N
Insulin-like JJ N
growth NN N
factors NNS N
( ( N
IGF-1 JJ N
and CC N
IGF-2 NNP N
) ) N
bind NN N
to TO N
the DT N
IGF-1 NNP N
receptor NN N
( ( N
IGF-1R NNP N
) ) N
, , N
increasing VBG N
cell NN N
proliferation NN N
and CC N
survival NN N
Ganitumab NNP N
is VBZ N
a DT N
monoclonal JJ N
IgG1 NNP N
antibody NN N
that WDT N
blocks VBZ N
IGF-1R NNP N
We PRP N
tested VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
adding VBG N
ganitumab NN N
to TO N
endocrine VB N
treatment NN N
for IN N
patients NNS N
with IN N
hormone-receptor-positive JJ N
breast NN N
cancer NN N
METHODS NNP N
We PRP N
did VBD N
this DT N
phase NN N
2 CD N
trial NN N
in IN N
outpatient JJ N
clinics NNS N
and CC N
hospitals NNS N
We PRP N
enrolled VBD N
postmenopausal JJ N
women NNS N
with IN N
hormone-receptor-positive JJ N
, , N
locally RB N
advanced VBD N
or CC N
metastatic JJ N
breast NN N
cancer NN N
previously RB N
treated VBN N
with IN N
endocrine JJ N
treatment NN N
They PRP N
were VBD N
randomly RB N
assigned VBN N
( ( N
2:1 CD N
) ) N
with IN N
a DT N
central JJ N
randomisation NN N
schedule NN N
to TO N
receive VB N
intravenous JJ N
ganitumab NNS N
12 CD N
mg NNS N
per IN N
kg NN N
bodyweight NN N
or CC N
placebo NN N
in IN N
combination NN N
with IN N
open-label JJ N
intramuscular JJ N
fulvestrant NN N
( ( N
500 CD N
mg NN N
on IN N
day NN N
1 CD N
, , N
then RB N
250 CD N
mg NNS N
on IN N
days NNS N
15 CD N
, , N
29 CD N
, , N
and CC N
every DT N
28 CD N
days NNS N
) ) N
or CC N
oral JJ N
exemestane NN N
( ( N
25 CD N
mg NN N
once RB N
daily RB N
) ) N
on IN N
a DT N
28-day JJ N
cycle NN N
Patients NNS N
, , N
investigators NNS N
, , N
study NN N
monitors NNS N
, , N
and CC N
the DT N
sponsor JJ N
staff NN N
were VBD N
masked VBN N
to TO N
treatment NN N
allocation NN N
Response NNP N
was VBD N
assessed VBN N
every DT N
8 CD N
weeks NNS N
The DT N
primary JJ N
endpoint NN N
was VBD N
median JJ N
progression-free JJ N
survival NN N
in IN N
the DT N
intention-to-treat JJ N
population NN N
We PRP N
analysed VBD N
overall JJ N
survival NN N
as IN N
one CD N
of IN N
our PRP$ N
secondary JJ N
endpoints NNS N
The DT N
study NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00626106 NNP N
FINDINGS NNP N
We PRP N
screened VBD N
189 CD N
patients NNS N
and CC N
enrolled VBD N
156 CD N
( ( N
106 CD N
in IN N
the DT N
ganitumab NN N
group NN N
and CC N
50 CD N
in IN N
the DT N
placebo NN N
group NN N
) ) N
Median JJ N
progression-free JJ N
survival NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
ganitumab NN N
and CC N
placebo NN N
groups NNS N
( ( N
3·9 CD N
months NNS N
, , N
80 CD N
% NN N
CI NNP N
3·6-5·3 CD N
vs NN N
5·7 CD N
months NNS N
, , N
4·4-7·4 JJ N
; : N
hazard PRP$ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
1·17 CD N
, , N
80 CD N
% NN N
CI NNP N
0·91-1·50 CD N
; : N
p=0·44 NN N
) ) N
However RB N
, , N
overall JJ N
survival NN N
was VBD N
worse RBR N
in IN N
the DT N
the DT N
ganitumab NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
HR NNP N
1·78 CD N
, , N
80 CD N
% NN N
CI NNP N
1·27-2·50 CD N
; : N
p=0·025 NN N
) ) N
With IN N
the DT N
exception NN N
of IN N
hyperglycaemia NN N
, , N
adverse JJ N
events NNS N
were VBD N
generally RB N
similar JJ N
between IN N
groups NNS N
The DT N
most RBS N
common JJ N
grade NN N
3 CD N
or CC N
higher JJR N
adverse JJ N
event NN N
was VBD N
neutropenia-reported JJ N
by IN N
six CD N
of IN N
106 CD N
( ( N
6 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
ganitumab NN N
group NN N
and CC N
one CD N
of IN N
49 CD N
( ( N
2 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
Hyperglycaemia NNP N
was VBD N
reported VBN N
by IN N
12 CD N
of IN N
106 CD N
( ( N
11 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
ganitumab NN N
group NN N
( ( N
with IN N
six CD N
patients NNS N
having VBG N
grade JJ N
3 CD N
or CC N
4 CD N
hyperglycaemia NN N
) ) N
and CC N
none NN N
of IN N
49 CD N
in IN N
the DT N
placebo NN N
group NN N
Serious JJ N
adverse JJ N
events NNS N
were VBD N
reported VBN N
by IN N
27 CD N
of IN N
106 CD N
( ( N
25 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
ganitumab NN N
group NN N
and CC N
nine CD N
of IN N
49 CD N
( ( N
18 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
INTERPRETATION NNP N
Addition NNP N
of IN N
ganitumab NN N
to TO N
endocrine VB N
treatment NN N
in IN N
women NNS N
with IN N
previously RB N
treated VBN N
hormone-receptor-positive JJ N
locally RB N
advanced VBD N
or CC N
metastatic JJ N
breast NN N
cancer NN N
did VBD N
not RB N
improve VB N
outcomes RB N
Our PRP$ N
results NNS N
do VBP N
not RB N
support VB N
further RBR N
study NN N
of IN N
ganitumab NN N
in IN N
this DT N
subgroup NN N
of IN N
patients NNS N
FUNDING NN N
Amgen NNP N
-DOCSTART- -X- O O 21902704

Effects NNS N
of IN N
three CD N
oral JJ N
analgesics NNS N
on IN N
postoperative JJ N
pain NN N
following VBG N
root JJ N
canal JJ N
preparation NN N
: : N
a DT N
controlled JJ N
clinical JJ N
trial NN N
AIM NNP N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
single JJ N
doses NNS N
of IN N
three CD N
oral JJ N
medications NNS N
on IN N
postoperative JJ N
pain NN N
following VBG N
instrumentation NN N
of IN N
root NN N
canals NNS N
in IN N
teeth NN N
with IN N
irreversible JJ N
pulpitis NN N
METHODOLOGY NNP N
In IN N
this DT N
double-blind JJ N
clinical JJ N
trial NN N
, , N
100 CD 3_p
patients NNS N
who WP N
had VBD N
anterior CC 4_p
or CC 4_p
premolar JJ 4_p
teeth NNS 4_p
with IN 4_p
irreversible JJ 4_p
pulpitis NN 4_p
without IN N
any DT N
signs NNS N
and CC N
symptoms NNS N
of IN N
acute NN 4_p
or CC 4_p
chronic JJ 4_p
apical JJ 4_p
periodontitis NN 4_p
and CC N
moderate VB N
to TO N
severe VB N
pain NN N
were VBD N
divided VBN N
by IN N
balanced JJ N
block NN N
random NN N
allocation NN N
into IN N
four CD N
groups NNS N
of IN N
25 CD N
each DT N
, , N
a DT N
control NN N
group NN N
receiving VBG N
a DT N
placebo NN N
medication NN N
, , N
and CC N
three CD N
experimental JJ N
groups NNS N
receiving VBG N
a DT N
single JJ N
dose NN N
of IN N
either DT N
Tramadol NNP N
( ( N
100 CD N
mg NN N
) ) N
, , N
Novafen NNP N
( ( N
325 CD N
mg NN N
of IN N
paracetamol NN N
, , N
200 CD N
mg NN N
ibuprofen NN N
and CC N
40 CD N
mg NNS N
caffeine VBP N
anhydrous JJ N
) ) N
or CC N
Naproxen NNP N
( ( N
500 CD N
mg NN N
) ) N
immediately RB N
after IN N
the DT N
first JJ N
appointment NN N
where WRB N
the DT N
pulp NN N
was VBD N
removed VBN N
, , N
and CC N
the DT N
canals NNS N
were VBD N
fully RB N
prepared VBN N
The DT N
intensity NN N
of IN N
pain NN N
was VBD N
scored VBN N
based VBN N
on IN N
10-point JJ N
VAS NNP N
before IN N
and CC N
after IN N
treatment NN N
for IN N
up IN N
to TO N
24 CD N
h NN N
postoperatively RB N
Data NNS N
were VBD N
submitted VBN N
to TO N
repeated VBN N
analysis NN N
of IN N
variance NN N
RESULTS NNP N
At IN N
the DT N
6 CD N
, , N
12 CD N
and CC N
24 CD N
h NNS N
postoperative JJ N
intervals NNS N
after IN N
drug NN N
administration NN N
, , N
the DT N
intensity NN N
of IN N
pain NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
experimental NN N
groups NNS N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
Tramadol NNP N
was VBD N
significantly RB N
less RBR N
effective JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
than IN N
Naproxen NNP N
, , N
and CC N
Novafen NNP N
that WDT N
were VBD N
similar JJ N
to TO N
each DT N
other JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
CONCLUSION VB N
A DT N
single JJ N
oral JJ N
dose NN N
of IN N
Naproxen NNP N
, , N
Novafen NNP N
and CC N
Tramadol NNP N
taken VBN N
immediately RB N
after IN N
treatment NN N
reduced VBD N
postoperative JJ N
pain NN N
following VBG N
pulpectomy NN N
and CC N
root JJ N
canal JJ N
preparation NN N
of IN N
teeth NNS N
with IN N
irreversible JJ N
pulpitis NN N
-DOCSTART- -X- O O 18054932

Effectiveness NN N
of IN N
cetrorelix NN N
for IN N
the DT N
prevention NN N
of IN N
premature NN N
luteinizing VBG N
hormone NN N
surge NN N
during IN N
controlled JJ N
ovarian JJ N
stimulation NN N
using VBG N
letrozole JJ N
and CC N
gonadotropins NNS N
: : N
a DT N
randomized JJ N
trial NN N
OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
GnRH NNP N
antagonist NN N
in IN N
preventing VBG N
premature NN N
LH NNP N
surge NN N
under IN N
a DT N
letrozole NN N
and CC N
gonadotropin NN N
protocol NN N
DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
clinical JJ N
trial NN N
SETTING VB N
A DT N
teaching JJ N
hospital NN N
and CC N
tertiary JJ N
medical JJ N
center NN N
PATIENT NNP N
( ( N
S NNP N
) ) N
Sixty-one CD 3_p
patients NNS N
were VBD N
randomly RB N
assigned VBN N
into IN N
two CD N
letrozole JJ N
and CC N
gonadotropin-treated JJ N
groups NNS N
These DT N
were VBD N
distinguished VBN N
by IN N
the DT N
absence NN N
( ( N
group NN N
I PRP N
) ) N
or CC N
presence NN N
( ( N
group NN N
II NNP N
) ) N
of IN N
supplementation NN N
with IN N
0.25 CD N
mg NNS N
of IN N
cetrorelix NN N
INTERVENTION NNP N
( ( N
S NNP N
) ) N
Controlled VBD N
ovarian JJ N
stimulation NN N
with IN N
letrozole JJ N
and CC N
gonadotropins NNS N
, , N
cetrorelix NN N
and CC N
intrauterine JJ N
insemination NN N
MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Rate NNP N
of IN N
premature NN N
LH NNP N
surge NN N
RESULT NNP N
( ( N
S NNP N
) ) N
Compared NNP N
with IN N
group NN N
I PRP N
, , N
the DT N
rate NN N
of IN N
premature NN N
LH NNP N
surge NN N
was VBD N
statistically RB N
significantly RB N
lower JJR N
for IN N
group NN N
II NNP N
( ( N
43.4 CD N
% NN N
[ CC N
13/30 CD N
] NN N
vs. FW N
19.4 CD N
% NN N
[ CC N
6/31 CD N
] NN N
) ) N
, , N
but CC N
the DT N
amount NN N
of IN N
gonadotropins NNS N
used VBN N
was VBD N
statistically RB N
significantly RB N
higher JJR N
( ( N
817.5 CD N
+/- JJ N
28.5 CD N
vs. FW N
907.5 CD N
+/- JJ N
27.3 CD N
IU NNP N
) ) N
Patients NNS N
with IN N
premature JJ N
LH NNP N
surge NN N
had VBD N
a DT N
statistically RB N
significantly RB N
lower JJR N
pregnancy NN N
rate NN N
( ( N
21.4 CD N
% NN N
[ CC N
9/42 CD N
] NN N
vs. FW N
0 CD N
[ $ N
0/18 CD N
] NNP N
) ) N
relative VBP N
to TO N
their PRP$ N
unaffected JJ N
counterparts NNS N
CONCLUSION NNP N
( ( N
S NNP N
) ) N
A NNP N
flexible JJ N
protocol NN N
of IN N
0.25 CD N
mg NN N
of IN N
cetrorelix NN N
for IN N
IUI NNP N
cycles NNS N
appears VBZ N
to TO N
suppress VB N
the DT N
rate NN N
of IN N
premature NN N
LH NNP N
surge NN N
during IN N
ovarian JJ N
stimulation NN N
with IN N
letrozole JJ N
and CC N
gonadotropins NNS N
However RB N
, , N
the DT N
incidence NN N
of IN N
premature NN N
LH NNP N
surge NN N
remains VBZ N
too RB N
high JJ N
, , N
and CC N
modification NN N
will MD N
be VB N
necessary JJ N
before IN N
the DT N
application NN N
of IN N
cetrorelix NN N
to TO N
IVF NNP N
treatment NN N
-DOCSTART- -X- O O 24913600

A DT N
brief JJ N
adherence NN N
intervention NN N
that WDT N
improved VBD N
glycemic JJ N
control NN N
: : N
mediation NN N
by IN N
patterns NNS N
of IN N
adherence NN N
This DT N
study NN N
examined VBD N
whether IN N
longitudinal JJ N
adherence NN N
profiles NNS N
mediated VBD N
the DT N
relationship NN N
between IN N
a DT N
brief JJ N
adherence NN N
intervention NN N
and CC N
glycemic JJ N
control NN N
among IN N
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
Adherence NNP N
was VBD N
assessed VBN N
using VBG N
the DT N
Medication NNP N
Event NNP N
Monitoring NNP N
System NNP N
Longitudinal JJ N
analysis NN N
via IN N
growth NN N
curve VBP N
mixture NN N
modeling NN N
was VBD N
carried VBN N
out IN N
to TO N
classify VB N
patients NNS N
according VBG N
to TO N
patterns NNS N
of IN N
adherence NN N
to TO N
oral JJ N
hypoglycemic JJ N
agents NNS N
Hemoglobin NNP N
A1c NNP N
assays NNS N
were VBD N
used VBN N
to TO N
measure VB N
glycemic JJ N
control NN N
as IN N
the DT N
clinical JJ N
outcome NN N
Across IN N
the DT N
whole JJ N
sample NN N
, , N
longitudinal JJ N
adherence NN N
profiles NNS N
mediated VBD N
35.2 CD N
% NN N
( ( N
13.2 CD N
, , N
81.0 CD N
% NN N
) ) N
of IN N
the DT N
effect NN N
of IN N
a DT N
brief JJ N
adherence NN N
intervention NN N
on IN N
glycemic JJ N
control NN N
[ NN N
from IN N
odds NNS N
ratio NN N
( ( N
OR NNP N
) ) N
= VBZ N
8.48 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
( ( N
3.24 CD N
, , N
22.2 CD N
) ) N
to TO N
4.00 CD N
, , N
95 CD N
% NN N
CI NNP N
( ( N
1.34 CD N
, , N
11.93 CD N
) ) N
] NN N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
patients NNS N
in IN N
the DT N
intervention NN N
had VBD N
better JJR N
glycemic JJ N
control NN N
largely RB N
due JJ N
to TO N
their PRP$ N
greater JJR N
likelihood NN N
of IN N
adherence NN N
to TO N
oral JJ N
hypoglycemic JJ N
agents NNS N
-DOCSTART- -X- O O 24291456

Exercise NN N
for IN N
methamphetamine NN 4_p
dependence NN 4_p
: : 4_p
rationale NN N
, , N
design NN N
, , N
and CC N
methodology NN N
BACKGROUND NNP N
Effective NNP N
pharmacotherapies NNS N
to TO N
treat VB N
methamphetamine NN N
( ( N
MA NNP N
) ) N
dependence NN N
have VBP N
not RB N
been VBN N
identified VBN N
, , N
and CC N
behavioral JJ N
therapies NNS N
are VBP N
marginally RB N
effective JJ N
Based VBN N
on IN N
behavioral JJ N
studies NNS N
demonstrating VBG N
the DT N
potential JJ N
efficacy NN N
of IN N
aerobic JJ N
exercise NN N
for IN N
improving VBG N
depressive JJ N
symptoms NNS N
, , N
anxiety NN N
, , N
cognitive JJ N
deficits NNS N
, , N
and CC N
substance NN N
use NN N
outcomes NNS N
, , N
the DT N
study NN N
described VBD N
here RB N
is VBZ N
examining VBG N
exercise NN N
as IN N
a DT N
potential JJ N
treatment NN N
for IN N
MA-dependent JJ 4_p
individuals NNS 4_p
METHODS NNP N
This DT N
study NN N
is VBZ N
randomizing VBG N
150 CD N
participants NNS N
with IN N
MA NNP N
dependence NN N
at IN N
a DT N
residential JJ N
treatment NN N
facility NN N
for IN N
addictive JJ N
disorders NNS N
to TO N
receive VB N
either RB N
a DT N
thrice-weekly JJ N
structured JJ N
aerobic NN N
and CC N
resistance NN N
exercise NN N
intervention NN N
or CC N
a DT N
health NN N
education NN N
condition NN N
Recruitment NNP N
commenced VBD N
in IN N
March NNP N
, , N
2010 CD N
Enrollment NN N
and CC N
follow-up JJ N
phases NNS N
are VBP N
ongoing VBG N
, , N
and CC N
recruitment NN N
is VBZ N
exceeding VBG N
targeted VBN N
enrollment JJ N
rates NNS N
CONCLUSIONS NNP N
Seeking NNP N
evidence NN N
for IN N
a DT N
possibly RB N
effective JJ N
adjunct NN N
to TO N
traditional JJ N
behavioral JJ N
approaches NNS N
for IN N
treatment NN N
of IN N
MA NNP N
dependence NN N
, , N
this DT N
study NN N
is VBZ N
assessing VBG N
the DT N
ability NN N
of IN N
an DT N
8-week JJ N
aerobic NN N
and CC N
resistance NN N
exercise NN N
protocol NN N
to TO N
reduce VB N
relapse NN N
to TO N
MA NNP N
use NN N
during IN N
a DT N
12-week JJ N
follow-up JJ N
period NN N
after IN N
discharge NN N
from IN N
residential-based JJ N
treatment NN N
The DT N
study NN N
also RB N
is VBZ N
evaluating VBG N
improvements NNS N
in IN N
health NN N
and CC N
functional JJ N
outcomes NNS N
during IN N
and CC N
after IN N
the DT N
protocol NN N
This DT N
paper NN N
describes VBZ N
the DT N
design NN N
and CC N
methods NNS N
of IN N
the DT N
study NN N
-DOCSTART- -X- O O 11196013

Spatial JJ N
orientation NN N
adjustments NNS N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
in IN N
Hong NNP N
Kong NNP N
Abnormal NNP N
spatial JJ N
orientation NN N
and CC N
body NN N
postures NNS N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
often RB N
interfere RB N
with IN N
visual JJ N
abilities NNS N
to TO N
attend VB N
tasks NNS N
and CC N
social JJ N
interactions NNS N
Twenty-four JJ 3_p
children NNS 1_p
diagnosed VBN N
with IN N
autism NN 4_p
from IN N
Kowloon NNP N
, , N
Hong NNP N
Kong NNP N
were VBD N
assessed VBN N
for IN N
spatial JJ N
orientation NN N
and CC N
spatial JJ N
management NN N
abilities NNS N
Positive JJ N
changes NNS N
in IN N
spatial JJ N
orientation NN N
were VBD N
evident JJ N
when WRB N
the DT N
children NNS N
wore VBD N
ambient JJ N
prism NN N
lenses NNS N
and CC N
included VBD N
changes NNS N
in IN N
posture NN N
from IN N
slanted VBN N
to TO N
erect VB N
Adjustments NNS N
in IN N
spatial JJ N
management NN N
were VBD N
evident JJ N
in IN N
improved JJ N
ball NN N
catching VBG N
ability NN N
, , N
a DT N
task NN N
requiring VBG N
visual JJ N
tracking NN N
and CC N
eye-hand JJ N
coordination NN N
The DT N
findings NNS N
suggest VBP N
that IN N
alterations NNS N
to TO N
the DT N
sensory JJ N
systems NNS N
may MD N
lead VB N
to TO N
behavioral JJ N
change NN N
in IN N
some DT N
children NNS N
-DOCSTART- -X- O O 15781531

A DT N
comparison NN N
of IN N
the DT N
efficacy NN N
of IN N
heparinized VBN N
and CC N
nonheparinized JJ N
solutions NNS N
for IN N
maintenance NN N
of IN N
perioperative JJ 4_p
radial JJ 4_p
arterial JJ 4_p
catheter NN 4_p
patency NN N
and CC N
subsequent JJ N
occlusion NN N
In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
controlled VBD N
study NN N
, , N
we PRP N
compared VBN N
heparinized VBN N
and CC N
nonheparinized VBN N
infusions NNS N
for IN N
the DT N
maintenance NN N
of IN N
perioperative JJ N
arterial JJ N
catheter NN N
patency NN N
and CC N
the DT N
incidence NN N
of IN N
subsequent JJ N
radial JJ N
arterial JJ N
occlusion NN N
Two-hundred JJ N
patients NNS N
were VBD N
randomized VBN N
into IN N
2 CD N
groups NNS N
to TO N
receive VB N
heparinized VBN N
( ( N
group NN N
H NNP N
, , N
n JJ N
= NNP N
100 CD N
) ) N
or CC N
nonheparinized VBN N
( ( N
group NN N
S NNP N
, , N
n JJ N
= NNP N
100 CD N
) ) N
flush NN N
solutions NNS N
Radial NNP N
and CC N
ulnar JJ N
blood NN N
flows NNS N
were VBD N
assessed VBN N
using VBG N
Doppler NNP N
probe NN N
and CC N
pulse JJ N
oximetry NN N
before IN N
, , N
just RB N
after IN N
, , N
and CC N
24 CD N
h NN N
after IN N
decannulation NN N
by IN N
the DT N
same JJ N
investigator NN N
The DT N
cannulation NN N
site NN N
was VBD N
examined VBN N
for IN N
complications NNS N
such JJ N
as IN N
hematoma NN N
, , N
nerve JJ N
injury NN N
, , N
and CC N
infection NN N
The DT N
mean JJ N
duration NN N
of IN N
cannulations NNS N
was VBD N
378 CD N
+/- JJ N
159.0 CD N
min NN N
in IN N
group NN N
H NNP N
and CC N
332 CD N
+/- JJ N
154.6 CD N
min NN N
in IN N
group NN N
S. NNP N
The DT N
mean JJ N
number NN N
of IN N
corrective JJ N
interventions NNS N
caused VBN N
by IN N
dampening VBG N
of IN N
the DT N
pressure NN N
wave NN N
( ( N
mean JJ N
number NN N
of IN N
positional JJ N
changes NNS N
[ VBP N
group NN N
S NNP N
, , N
1.5 CD N
+/- JJ N
2.0 CD N
; : N
group NN N
H NNP N
, , N
1.4 CD N
+/- JJ N
3.8 CD N
] NN N
and CC N
mean JJ N
number NN N
of IN N
manual JJ N
flushes NNS N
[ VBP N
group NN N
S NNP N
, , N
1.3 CD N
+/- JJ N
1.7 CD N
; : N
group NN N
H NNP N
, , N
1.2 CD N
+/- JJ N
1.2 CD N
] NN N
) ) N
was VBD N
not RB N
significantly RB N
different JJ N
in IN N
both DT N
groups NNS N
After IN N
decannulation NN N
, , N
partial JJ N
or CC N
total JJ N
occlusion NN N
developed VBD N
in IN N
20 CD N
group NN N
H NNP N
patients NNS N
and CC N
16 CD N
group NN N
S NNP N
patients NNS N
( ( N
not RB N
significant JJ N
) ) N
The DT N
incidence NN N
of IN N
occlusion NN N
was VBD N
correlated VBN N
to TO N
the DT N
presence NN N
of IN N
hematoma NN N
at IN N
the DT N
puncture NN N
site NN N
after IN N
decannulation NN N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
, , N
long JJ N
duration NN N
of IN N
cannulation NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
and CC N
age NN N
< VBP N
65 CD N
yr NN N
( ( N
P NNP N
= NNP N
0.009 CD N
) ) N
In IN N
conclusion NN N
, , N
there EX N
is VBZ N
no DT N
significant JJ N
difference NN N
between IN N
heparinized VBN N
and CC N
nonheparinized VBN N
flush JJ N
solutions NNS N
for IN N
the DT N
maintenance NN N
of IN N
perioperative JJ N
radial JJ N
artery NN N
catheter NN N
patency NN N
-DOCSTART- -X- O O 20113305

Hunter NNP N
DBT NNP N
project NN N
: : N
randomized VBN N
controlled VBD N
trial NN N
of IN N
dialectical JJ N
behaviour NN N
therapy NN N
in IN N
women NNS 4_p
with IN 4_p
borderline JJ 4_p
personality NN 4_p
disorder NN 4_p
OBJECTIVE JJ N
Deliberate NNP N
self-harm NN N
( ( N
DSH NNP N
) ) N
, , N
general JJ N
hospital NN N
admission NN N
and CC N
psychiatric JJ N
hospital NN N
admission NN N
are VBP N
common JJ N
in IN N
women NNS 4_p
meeting VBG 4_p
criteria NNS 4_p
for IN 4_p
borderline NN 4_p
personality NN 4_p
disorder NN 4_p
( ( 4_p
BPD NNP 4_p
) ) 4_p
Dialectical JJ N
behaviour NN N
therapy NN N
( ( N
DBT NNP N
) ) N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG N
DSH NNP N
and CC N
hospitalization NN N
METHOD NNP N
A NNP N
randomized VBD N
controlled JJ N
trial NN N
of IN N
73 CD N
female JJ N
subjects NNS N
meeting VBG N
criteria NNS N
for IN N
BPD NNP N
was VBD N
carried VBN N
out RP N
with IN N
intention-to-treat JJ N
analyses NNS N
and CC N
per-protocol JJ N
analyses NNS N
The DT N
intervention NN N
was VBD N
DBT NNP N
and CC N
the DT N
control NN N
condition NN N
was VBD N
treatment NN N
as IN N
usual JJ N
plus CC N
waiting JJ N
list NN N
for IN N
DBT NNP N
( ( N
TAU+WL NNP N
) ) N
, , N
with IN N
outcomes NNS N
measured VBN N
after IN N
6 CD N
months NNS N
Primary JJ N
outcomes NNS N
were VBD N
differences NNS N
in IN N
proportions NNS N
and CC N
event NN N
rates NNS N
of IN N
: : N
any DT N
DSH NNP N
; : N
general JJ N
hospital NN N
admission NN N
for IN N
DSH NNP N
and CC N
any DT N
psychiatric JJ N
admission NN N
; : N
and CC N
mean VB N
difference NN N
in IN N
length NN N
of IN N
stay NN N
for IN N
any DT N
hospitalization NN N
Secondary JJ N
outcomes NNS N
were VBD N
disability NN N
and CC N
quality NN N
of IN N
life NN N
measures NNS N
RESULTS NNP N
Both NNP N
groups NNS N
showed VBD N
a DT N
reduction NN N
in IN N
DSH NNP N
and CC N
hospitalizations NNS N
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
DSH NNP N
, , N
hospital JJ N
admissions NNS N
or CC N
length NN N
of IN N
stay NN N
in IN N
hospital NN N
between IN N
groups NNS N
Disability NNP N
( ( N
days NNS N
spent VBN N
in IN N
bed NN N
) ) N
and CC N
quality NN N
of IN N
life NN N
( ( N
Physical NNP N
, , N
Psychological NNP N
and CC N
Environmental NNP N
domains NNS N
) ) N
were VBD N
significantly RB N
improved VBN N
for IN N
the DT N
DBT NNP N
group NN N
CONCLUSION NNP N
DBT NNP N
produced VBD N
non-significant JJ N
reductions NNS N
in IN N
DSH NNP N
and CC N
hospitalization NN N
when WRB N
compared VBN N
to TO N
the DT N
TAU+WL NNP N
control NN N
, , N
due JJ N
in IN N
part NN N
to TO N
the DT N
lower JJR N
than IN N
expected VBN N
rates NNS N
of IN N
hospitalization NN N
in IN N
the DT N
control NN N
condition NN N
Nevertheless NNP N
, , N
DBT NNP N
showed VBD N
significant JJ N
benefits NNS N
for IN N
the DT N
secondary JJ N
outcomes NNS N
of IN N
improved JJ N
disability NN N
and CC N
quality NN N
of IN N
life NN N
scores NNS N
, , N
a DT N
clinically RB N
useful JJ N
result NN N
that WDT N
is VBZ N
also RB N
in IN N
keeping VBG N
with IN N
the DT N
theoretical JJ N
constructs NNS N
of IN N
the DT N
benefits NNS N
of IN N
DBT NNP N
-DOCSTART- -X- O O 23107353

Acceleration NN N
of IN N
insulin NN N
pharmacodynamic JJ N
profile NN N
by IN N
a DT N
novel JJ N
insulin NN N
infusion NN N
site NN N
warming VBG N
device NN N
BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Subcutaneously NNP N
injected VBD N
rapid-acting JJ N
insulin NN N
analogs NNS N
do VBP N
not RB N
replicate VB N
physiologic JJ N
insulin NN N
action NN N
due JJ N
to TO N
delays NNS N
in IN N
their PRP$ N
onset NN N
and CC N
peak JJ N
action NN N
resulting VBG N
in IN N
postprandial JJ N
glucose JJ N
excursions NNS N
The DT N
InsuPatch NNP N
( ( N
IP NNP N
) ) N
is VBZ N
a DT N
novel JJ N
insulin NN N
infusion NN N
site NN N
warming VBG N
device NN N
developed VBD N
to TO N
accelerate VB N
insulin NN N
action NN N
by IN N
increasing VBG N
blood NN N
flow NN N
to TO N
the DT N
area NN N
of IN N
insulin NN N
absorption NN N
Thirteen JJ 3_p
adolescents NNS 1_p
with IN N
type JJ 4_p
1 CD 4_p
diabetes NNS 4_p
( ( N
T1D NNP N
, , N
mean JJ 1_p
age NN 1_p
14 CD 1_p
± NN 1_p
4 CD 1_p
yr NN 1_p
) ) 1_p
were VBD N
enrolled VBN N
in IN N
this DT N
study NN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
the DT N
IP NNP N
on IN N
the DT N
pharmacodynamics NNS N
and CC N
pharmacokinetics NNS N
of IN N
a DT N
0.2 CD N
unit/kg JJ N
bolus NN N
dose NN N
of IN N
aspart JJ N
insulin NN N
using VBG N
the DT N
euglycemic JJ N
clamp NN N
technique NN N
RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Each DT N
subject JJ N
underwent JJ N
two CD N
euglycemic JJ N
clamp NN N
procedures NNS N
on IN N
separate JJ N
occasions NNS N
: : N
one CD N
with IN N
IP NNP N
and CC N
one CD N
without IN N
IP NNP N
activation NN N
in IN N
random JJ N
order NN N
RESULTS VB N
When WRB N
the DT N
insulin NN N
bolus NN N
was VBD N
given VBN N
with IN N
IP NNP N
activation NN N
as IN N
compared VBN N
to TO N
without IN N
IP NNP N
activation NN N
, , N
time NN N
to TO N
reach VB N
maximum JJ N
insulin JJ N
action NN N
( ( N
T NNP N
( ( N
GIRmax NNP N
) ) N
) ) N
and CC N
to TO N
reach VB N
50 CD N
% NN N
maximum JJ N
action NN N
( ( N
T NNP N
( ( N
50 CD N
% NN N
GIRmax NNP N
) ) N
) ) N
were VBD N
35 CD N
and CC N
18 CD N
min NNS N
earlier RB N
( ( N
125 CD N
± RB N
8 CD N
min NNS N
vs. FW N
90 CD N
± $ N
6 CD N
min NN N
, , N
p NN N
= VBD N
0.002 CD N
and CC N
58 CD N
± NNS N
5 CD N
min NN N
vs. FW N
40 CD N
± $ N
3 CD N
min NN N
, , N
p NN N
= VBD N
0.01 CD N
, , N
respectively RB N
) ) N
, , N
and CC N
the DT N
area NN N
under IN N
curve NN N
, , N
AUC NNP N
( ( N
GIR NNP N
0-90 NNP N
min NN N
) ) N
, , N
reflecting VBG N
early JJ N
glucodynamic JJ N
action NN N
, , N
was VBD N
significantly RB N
greater JJR N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
IP NNP N
activation NN N
also RB N
accelerated VBD N
the DT N
rise NN N
in IN N
plasma JJ N
insulin NN N
levels NNS N
after IN N
the DT N
bolus NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
and CC N
resulted VBN N
in IN N
a DT N
higher JJR N
peak NN N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
and CC N
greater JJR N
overall JJ N
increase NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
in IN N
plasma JJ N
insulin NN N
levels NNS N
CONCLUSIONS NNP N
Our PRP$ N
results NNS N
show VBP N
that IN N
insulin NN N
infusion NN N
site NN N
warming VBG N
with IN N
IP NNP N
activation NN N
accelerates VBZ N
the DT N
time NN N
action NN N
profile NN N
of IN N
aspart NN N
insulin NN N
which WDT N
may MD N
be VB N
of IN N
benefit NN N
to TO N
current JJ N
open-loop JJ N
and CC N
future JJ N
closed-loop JJ N
insulin NN N
delivery NN N
in IN N
patients NNS N
with IN N
T1D NNP N
-DOCSTART- -X- O O 10719133

Blood NNP N
pressure NN N
biofeedback NN N
treatment NN N
of IN N
white-coat JJ N
hypertension NN N
OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
biofeedback NN N
treatment NN N
( ( N
BF NNP N
) ) N
effects NNS N
between IN N
white-coat JJ N
hypertension NN N
and CC N
essential JJ N
hypertension NN N
METHODS NNP N
Fifteen NNP 3_p
white-coat JJ 4_p
hypertensive JJ 4_p
out-patients NNS N
and CC N
23 CD 3_p
essential JJ 4_p
hypertensive JJ 4_p
out-patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
groups NNS N
A NNP N
or CC N
B NNP N
Subjects NNS N
in IN N
group NN N
A NNP N
underwent NN N
BF NNP N
once RB N
a DT N
week NN N
for IN N
a DT N
total NN N
of IN N
four CD N
sessions NNS N
Those DT N
in IN N
group NN N
B NNP N
visited VBD N
the DT N
clinic NN N
only RB N
to TO N
measure VB N
BP NNP N
and CC N
later RB N
underwent VBD N
the DT N
same JJ N
BF NNP N
RESULTS NNP N
In IN N
group NN N
A NNP N
, , N
BPs NNP N
of IN N
white-coat JJ N
hypertensives NNS N
and CC N
essential JJ N
hypertensives NNS N
were VBD N
significantly RB N
reduced VBN N
by IN N
22/11 CD N
and CC N
14/8 CD N
mmHg NN N
, , N
respectively RB N
In IN N
group NN N
B NNP N
, , N
they PRP N
were VBD N
unchanged JJ N
during IN N
the DT N
same JJ N
period NN N
but CC N
later RB N
suppressed VBN N
by IN N
BF NNP N
Under IN N
BF NNP N
, , N
pulse NN N
and CC N
respiratory NN N
rates NNS N
were VBD N
significantly RB N
higher JJR N
, , N
and CC N
elevation NN N
of IN N
diastolic JJ N
BP NNP N
due JJ N
to TO N
mental JJ N
stress NN N
testing NN N
was VBD N
better RBR N
suppressed VBN N
in IN N
white-coat NN N
hypertensives NNS N
than IN N
in IN N
essential JJ N
hypertensives NNS N
CONCLUSION VB N
This DT N
treatment NN N
was VBD N
effective JJ N
in IN N
both DT N
types NNS N
of IN N
hypertension NN N
, , N
and CC N
pressor NN N
response NN N
to TO N
stress VB N
seems VBZ N
to TO N
be VB N
important JJ N
in IN N
the DT N
differentiated JJ N
BF NNP N
effect NN N
-DOCSTART- -X- O O 15606733

5 CD N
% NN N
imiquimod JJ N
cream NN N
and CC N
reflectance-mode JJ N
confocal JJ N
microscopy NN N
as IN N
adjunct JJ N
modalities NNS N
to TO N
Mohs NNP N
micrographic JJ N
surgery NN N
for IN N
treatment NN N
of IN N
basal NN N
cell NN N
carcinoma NN N
BACKGROUND NNP N
Imiquimod NNP N
is VBZ N
an DT N
immune JJ N
response NN N
modifier NN N
that IN N
up-regulates JJ N
cytokines NNS N
and CC N
has VBZ N
been VBN N
shown VBN N
in IN N
clinical JJ N
studies NNS N
to TO N
reduce VB N
or CC N
clear VB N
basal NN N
cell NN N
carcinoma NN N
tumors NNS N
when WRB N
applied VBN N
topically RB N
OBJECTIVE CC N
The DT N
objectives NNS N
were VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
5 CD N
% NN N
imiquimod JJ N
cream NN N
in IN N
treating VBG N
basal NN N
cell NN N
carcinoma NN N
preceding VBG N
excision NN N
by IN N
Mohs NNP N
micrographic JJ N
surgery NN N
and CC N
to TO N
determine VB N
if IN N
reflectance-mode JJ N
confocal JJ N
microscopy NN N
is VBZ N
useful JJ N
to TO N
establish VB N
the DT N
need NN N
for IN N
surgical JJ N
intervention NN N
after IN N
imiquimod JJ N
treatment NN N
METHODS NNP N
Subjects NNP N
applied VBD N
study NN N
cream NN N
to TO N
one CD N
biopsy-confirmed JJ N
basal NN N
cell NN N
carcinoma NN N
tumor NN N
5 CD N
x/week NN N
for IN N
2 CD N
, , N
4 CD N
, , N
or CC N
6 CD N
weeks NNS N
in IN N
this DT N
vehicle-controlled JJ N
, , N
double-blind JJ N
study NN N
Confocal NNP N
microscopy NN N
was VBD N
used VBN N
for IN N
the DT N
6-week JJ N
treatment NN N
group NN N
to TO N
examine VB N
the DT N
target NN N
tumor NN N
area NN N
at IN N
each DT N
interval JJ N
visit NN N
and CC N
immediately RB N
before IN N
Mohs NNP N
micrographic JJ N
surgery NN N
After IN N
the DT N
Mohs NNP N
micrographic JJ N
surgery NN N
excision NN N
, , N
the DT N
tissue NN N
was VBD N
evaluated VBN N
histologically RB N
, , N
and CC N
the DT N
excision NN N
area NN N
was VBD N
measured VBN N
Confocal JJ N
microscopy NN N
readings NNS N
were VBD N
correlated VBN N
to TO N
the DT N
histologic JJ N
diagnosis NN N
RESULTS NNP N
Tumors NNPS N
cleared VBD N
or CC N
the DT N
target NN N
tumor NN N
area NN N
was VBD N
reduced VBN N
in IN N
subjects NNS N
in IN N
the DT N
4- JJ N
and CC N
6-week JJ N
dosing NN N
regimens NNS N
Confocal JJ N
microscopy NN N
assessments NNS N
correlated VBN N
well RB N
with IN N
the DT N
histologic JJ N
diagnosis NN N
CONCLUSION NNP N
Imiquimod NNP N
improved VBD N
excision NN N
results NNS N
relative JJ N
to TO N
vehicle NN N
when WRB N
used VBN N
for IN N
treating VBG N
basal NN N
cell NN N
carcinoma NN N
before IN N
Mohs NNP N
micrographic JJ N
surgery NN N
Confocal JJ N
microscopy NN N
assessments NNS N
correlated VBN N
well RB N
with IN N
tumor NN N
response NN N
to TO N
therapy VB N
, , N
suggesting VBG N
that IN N
confocal JJ N
microscopy NN N
may MD N
help VB N
determine VB N
the DT N
need NN N
for IN N
surgery NN N
-DOCSTART- -X- O O 18271235

[ JJ N
Effects NNS N
of IN N
early JJ N
acupuncture NN N
on IN N
motor NN N
function NN N
of IN N
the DT N
limb NN N
in IN N
the DT N
severe JJ N
head NN 4_p
injury NN 4_p
patients NNS N
] VBP N
UNLABELLED NNP N
OBJECTIVE NNP N
; : N
To TO N
observe VB N
the DT N
effects NNS N
of IN N
early JJ N
acupuncture NN N
on IN N
motor NN N
function NN N
of IN N
the DT N
limb NN N
in IN N
the DT N
severe JJ N
head NN N
injury NN N
patients NNS N
METHODS NNP N
Ninety-six JJ 4_p
patients NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
an DT N
observation NN N
group NN N
and CC N
a DT N
control NN N
group NN N
, , N
48 CD 4_p
cases NNS N
in IN N
each DT N
group NN N
The DT N
patient NN N
in IN N
the DT N
control NN N
group NN N
were VBD N
treated VBN N
by IN N
routine JJ N
treatment NN N
of IN N
neurosurgical JJ N
operation NN N
and CC N
drug NN N
treatment NN N
( ( N
Mannitol NNP N
, , N
Citioline NNP N
Sodium NNP N
, , N
Cefeazidime NNP N
, , N
etc. NN N
) ) N
While IN N
the DT N
patient NN N
in IN N
the DT N
observation NN N
group NN N
were VBD N
treated VBN N
by IN N
the DT N
routine JJ N
treatment NN N
and CC N
acupuncture NN N
treatment NN N
48 CD N
h NN N
( ( N
-1 NNP N
) ) N
week NN N
after IN N
operation NN N
in IN N
different JJ N
stages NNS N
with IN N
different JJ N
acupoints NNS N
selected VBN N
when WRB N
the DT N
situation NN N
was VBD N
stable JJ N
The DT N
selected VBN N
main JJ N
points NNS N
were VBD N
Neiguan NNP N
( ( N
PC NNP N
6 CD N
) ) N
, , N
Qu-chi NNP N
( ( N
LI NNP N
11 CD N
) ) N
, , N
Waiguan NNP N
( ( N
TE NNP N
5 CD N
) ) N
, , N
Hegu NNP N
( ( N
LI NNP N
4 CD N
) ) N
, , N
Binao NNP N
( ( N
LI NNP N
14 CD N
) ) N
, , N
Jianyu NNP N
( ( N
LI NNP N
15 CD N
) ) N
, , N
Fengshi NNP N
( ( N
GB NNP N
31 CD N
) ) N
, , N
Xuehai NNP N
( ( N
SP NNP N
10 CD N
) ) N
, , N
Yinlingquan NNP N
( ( N
SP NNP N
9 CD N
) ) N
, , N
Sanyinjiao NNP N
( ( N
SP NNP N
6 CD N
) ) N
, , N
Taichong NNP N
( ( N
LR NNP N
3 CD N
) ) N
, , N
etc.. VBZ N
The DT N
limb NN N
motor NN N
function NN N
was VBD N
evaluated VBN N
with IN N
Fugl-Meyer NNP N
Assessment NNP N
( ( N
FMA NNP N
) ) N
scale NN N
before IN N
treatment NN N
and CC N
after IN N
10-week JJ N
treatment NN N
RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
FMA NNP N
score NN N
in IN N
the DT N
two CD N
groups NNS N
after IN N
the DT N
treatment NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
The DT N
comparison NN N
between IN N
the DT N
two CD N
groups NNS N
after IN N
the DT N
treatment NN N
showed VBD N
that IN N
the DT N
improvement NN N
of IN N
FMA NNP N
score NN N
in IN N
the DT N
observation NN N
group NN N
was VBD N
significantly RB N
better JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
CONCLUSION NNP N
Early JJ N
acupuncture NN N
can MD N
improve VB N
the DT N
limb NN N
motor NN N
function NN N
in IN N
the DT N
severe JJ N
head NN N
injury NN N
patients NNS N
-DOCSTART- -X- O O 16108781

Economic JJ N
evaluation NN N
of IN N
a DT N
nursing-led JJ N
inpatient JJ N
unit NN N
: : N
the DT N
impact NN N
of IN N
findings NNS N
on IN N
management NN N
decisions NNS N
of IN N
service NN N
utility NN N
and CC N
sustainability NN N
AIMS IN N
The DT N
nursing-led JJ N
inpatient NN N
unit NN N
is VBZ N
designed VBN N
to TO N
substitute VB N
for IN N
a DT N
period NN N
of IN N
care NN N
in IN N
acute JJ N
hospital NN N
wards NNS N
and CC N
to TO N
improve VB N
patient NN N
outcome NN N
prior RB N
to TO N
discharge VB N
to TO N
the DT N
community NN N
This DT N
paper NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
cost NN N
, , N
from IN N
the DT N
UK NNP N
National NNP N
Health NNP N
Service NNP N
perspective NN N
, , N
of IN N
transfer NN N
to TO N
a DT N
nursing-led JJ N
inpatient NN N
unit NN N
for IN N
intermediate JJ N
care NN N
and CC N
to TO N
discuss VB N
the DT N
impact NN N
of IN N
these DT N
findings NNS N
to TO N
the DT N
future NN N
development NN N
and CC N
sustainability NN N
of IN N
the DT N
nursing-led JJ N
inpatient NN N
unit NN N
BACKGROUND NNP N
Recent NNP N
economic JJ N
analyses NNS N
have VBP N
showed VBN N
that IN N
nursing-led JJ N
inpatient JJ N
units NNS N
are VBP N
associated VBN N
with IN N
increased JJ N
costs NNS N
of IN N
care NN N
with IN N
length NN N
of IN N
stay NN N
as IN N
the DT N
main JJ N
driver NN N
of IN N
inpatient NN N
costs NNS N
METHOD VB N
The DT N
cost-effectiveness JJ N
analysis NN N
was VBD N
part NN N
of IN N
a DT N
randomized-controlled JJ N
trial NN N
with IN N
a DT N
sample JJ 4_p
size NN 4_p
of IN 4_p
175 CD 4_p
, , 4_p
of IN 4_p
which WDT 4_p
89 CD 4_p
were VBD 4_p
in IN 4_p
the DT 4_p
nursing-led JJ 4_p
inpatient NN 4_p
unit NN 4_p
arm NN 4_p
and CC 4_p
86 CD 4_p
in IN 4_p
the DT 4_p
control NN 4_p
arm NN 4_p
Resource NNP N
use NN N
data NNS N
included VBD N
length NN N
of IN N
stay NN N
, , N
investigations NNS N
performed VBD N
, , N
multiprofessional JJ N
input NN N
and CC N
nursing NN N
input NN N
Clinical JJ N
outcome NN N
was VBD N
measured VBN N
using VBG N
Barthel NNP N
Index NNP N
, , N
a DT N
functional JJ N
status NN N
measure NN N
RESULTS NNP N
Cost NNP N
per IN N
day NN N
was VBD N
lower JJR N
on IN N
the DT N
nursing-led JJ N
inpatient NN N
unit NN N
although IN N
cost NN N
per IN N
hospital NN N
stay NN N
was VBD N
higher JJR N
due JJ N
to TO N
significantly RB N
increased JJ N
length NN N
of IN N
stay NN N
Postdischarge NNP N
community NN N
care NN N
costs NNS N
were VBD N
lower JJR N
The DT N
incremental JJ N
cost-effectiveness JJ N
ratio NN N
of IN N
the DT N
treatment NN N
was VBD N
1044 CD N
pounds NNS N
sterling JJ N
per IN N
point NN N
improvement NN N
of IN N
the DT N
Barthel NNP N
Index NNP N
CONCLUSIONS VB N
The DT N
nursing-led JJ N
inpatient NN N
unit NN N
was VBD N
associated VBN N
with IN N
higher JJR N
costs NNS N
however RB N
, , N
the DT N
question NN N
of IN N
whether IN N
the DT N
nursing-led JJ N
inpatient NN N
unit NN N
is VBZ N
cost-effective JJ N
has VBZ N
not RB N
been VBN N
clearly RB N
answered VBN N
because IN N
of IN N
the DT N
limited JJ N
follow-up JJ N
period NN N
of IN N
the DT N
study NN N
The DT N
increased JJ N
cost NN N
of IN N
care NN N
on IN N
the DT N
nursing-led JJ N
inpatient NN N
unit NN N
was VBD N
not RB N
a DT N
major JJ N
factor NN N
in IN N
local JJ N
management NN N
decisions NNS N
about IN N
the DT N
future NN N
of IN N
the DT N
unit NN N
The DT N
changes NNS N
in IN N
the DT N
context NN N
of IN N
service NN N
provision NN N
within IN N
which WDT N
the DT N
nursing-led JJ N
inpatient NN N
unit NN N
operated VBD N
as IN N
a DT N
result NN N
of IN N
substantial JJ N
investment NN N
in IN N
intermediate JJ N
care NN N
did VBD N
have VB N
a DT N
major JJ N
impact NN N
-DOCSTART- -X- O O 7799030

Cytokine NN N
levels NNS N
and CC N
systemic JJ N
toxicity NN N
in IN N
patients NNS N
undergoing VBG 4_p
isolated JJ 4_p
limb NN 4_p
perfusion NN 4_p
with IN 4_p
high-dose JJ 4_p
tumor NN 4_p
necrosis NN 4_p
factor NN 4_p
, , 4_p
interferon NN 4_p
gamma NN 4_p
, , 4_p
and CC 4_p
melphalan NN 4_p
PURPOSE NNP N
Isolated NNP N
limb NN N
perfusion NN N
( ( N
ILP NNP N
) ) N
with IN N
tumor NN N
necrosis NN N
factor NN N
( ( N
TNF NNP N
) ) N
, , N
interferon JJ N
gamma NN N
, , N
and CC N
melphalan NN N
( ( N
M NNP N
) ) N
has VBZ N
been VBN N
reported VBN N
to TO N
result VB N
in IN N
high JJ N
response NN N
rates NNS N
for IN N
extremity NN N
melanoma NN N
and CC N
sarcoma NN N
We PRP N
have VBP N
evaluated VBN N
the DT N
relationship NN N
of IN N
systemic JJ N
TNF NNP N
exposure NN N
to TO N
induction NN N
of IN N
several JJ N
secondary JJ N
mediators NNS N
and CC N
incidence NN N
of IN N
systemic JJ N
toxicity NN N
PATIENTS NNP N
AND CC N
METHODS NNP N
Nineteen NNP 3_p
patients NNS N
with IN N
extremity NN 4_p
melanoma NN 4_p
( ( N
n JJ N
= NNP N
16 CD N
) ) N
or CC N
sarcoma NN 4_p
( ( N
n JJ N
= NNP N
3 CD N
) ) N
, , N
underwent JJ N
90-minute JJ N
ILP NNP N
with IN N
TNF-alpha NNP N
, , N
interferon NN N
gamma NN N
( ( N
0.2 CD N
mg NN N
) ) N
, , N
and CC N
M NNP N
( ( N
10 CD N
to TO N
13 CD N
mg/L NN N
of IN N
limb NN N
volume NN N
) ) N
( ( N
TNF/IFN/M NNP N
) ) N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
, , N
or CC N
M NNP N
alone RB N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
Continuous JJ N
intraoperative JJ N
monitoring NN N
( ( N
CIM NNP N
) ) N
for IN N
systemic JJ N
leak NN N
from IN N
the DT N
perfusion NN N
circuit NN N
was VBD N
performed VBN N
using VBG N
radioactive JJ N
iodine-131 JJ N
albumin NN N
Cytokine NN N
levels NNS N
in IN N
the DT N
perfusate NN N
and CC N
systemic JJ N
circulation NN N
during IN N
and CC N
after IN N
ILP NNP N
were VBD N
measured VBN N
by IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
RESULTS NNP N
Systemic NNP N
leaks VBZ N
> CD N
or CC N
= VB N
1 CD N
% NN N
from IN N
the DT N
perfusion NN N
circuit NN N
occurred VBD N
in IN N
six CD N
patients NNS N
who WP N
received VBD N
TNF/IFN/M NNP N
and CC N
in IN N
four CD N
who WP N
received VBD N
M NNP N
alone RB N
Hypotension NNP N
that IN N
required VBD N
vasopressor NN N
support NN N
occurred VBD N
in IN N
six CD N
of IN N
six CD N
patients NNS N
with IN N
evidence NN N
of IN N
a DT N
leak NN N
( ( N
> CD N
or CC N
= VB N
1 CD N
% NN N
) ) N
and CC N
zero CD N
of IN N
six CD N
patients NNS N
without IN N
a DT N
leak NN N
( ( N
< JJ N
1 CD N
% NN N
) ) N
These DT N
six CD N
patients NNS N
had VBD N
significantly RB N
higher JJR N
peak JJ N
systemic JJ N
TNF NNP N
levels NNS N
during IN N
and CC N
after IN N
perfusion NN N
than IN N
patients NNS N
without IN N
a DT N
leak NN N
( ( N
2.8 CD N
and CC N
8.2 CD N
ng/mL JJ N
v NN N
0.7 CD N
and CC N
2.0 CD N
ng/mL NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
All PDT N
patients NNS N
who WP N
received VBD N
TNF/IFN/M NNP N
had VBD N
significantly RB N
greater JJR N
increases NNS N
in IN N
systemic JJ N
interleukin-6 JJ N
( ( N
IL-6 NNP N
) ) N
levels NNS N
than IN N
in IN N
patients NNS N
with IN N
M NNP N
alone RB N
( ( N
12,395 CD N
+/- JJ N
10,374 CD N
pg/mL NN N
v NN N
79.4 CD N
+/- JJ N
7.2 CD N
pg/mL NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
Intracellular JJ N
adhesion NN N
molecule NN N
( ( N
ICAM NNP N
) ) N
, , N
IL-8 NNP N
, , N
and CC N
TNF-R JJ N
levels NNS N
were VBD N
also RB N
increased VBN N
after IN N
ILP NNP N
with IN N
TNF/IFN/M NNP N
CONCLUSION NNP N
ILP NNP N
with IN N
TNF/IFN/M NNP N
can MD N
be VB N
safely RB N
performed VBN N
, , N
as IN N
I131 NNP N
albumin VBP N
provides VBZ N
a DT N
sensitive JJ N
measure NN N
of IN N
systemic JJ N
leakage NN N
from IN N
the DT N
perfusion NN N
circuit NN N
Patients NNS N
with IN N
a DT N
measured JJ N
leak NN N
of IN N
> NN N
or CC N
= VB N
1 CD N
% NN N
develop NN N
mild NN N
and CC N
transient JJ N
postoperative JJ N
hypotension NN N
with IN N
significantly RB N
higher JJR N
systemic JJ N
TNF NNP N
levels NNS N
and CC N
lower JJR N
perfusate NN N
TNF NNP N
levels NNS N
than IN N
in IN N
patients NNS N
without IN N
leaks NNS N
-DOCSTART- -X- O O 17331237

Cost-effectiveness NN N
of IN N
collaborative JJ N
care NN N
including VBG N
PST NNP N
and CC N
an DT N
antidepressant JJ N
treatment NN N
algorithm NN N
for IN N
the DT N
treatment NN N
of IN N
major JJ 4_p
depressive JJ 4_p
disorder NN 4_p
in IN N
primary JJ N
care NN N
; : N
a DT N
randomised JJ N
clinical JJ N
trial NN N
BACKGROUND NNP N
Depressive NNP N
disorder NN N
is VBZ N
currently RB N
one CD N
of IN N
the DT N
most RBS N
burdensome JJ N
disorders NNS N
worldwide VBP N
Evidence-based JJ N
treatments NNS N
for IN N
depressive JJ N
disorder NN N
are VBP N
already RB N
available JJ N
, , N
but CC N
these DT N
are VBP N
used VBN N
insufficiently RB N
, , N
and CC N
with IN N
less JJR N
positive JJ N
results NNS N
than IN N
possible JJ N
Earlier RBR N
research NN N
in IN N
the DT N
USA NNP N
has VBZ N
shown VBN N
good JJ N
results NNS N
in IN N
the DT N
treatment NN N
of IN N
depressive JJ N
disorder NN N
based VBN N
on IN N
a DT N
collaborative JJ N
care NN N
approach NN N
with IN N
Problem NNP N
Solving NNP N
Treatment NNP N
and CC N
an DT N
antidepressant JJ N
treatment NN N
algorithm NN N
, , N
and CC N
research NN N
in IN N
the DT N
UK NNP N
has VBZ N
also RB N
shown VBN N
good JJ N
results NNS N
with IN N
Problem NNP N
Solving VBG N
Treatment NNP N
These DT N
treatment NN N
strategies NNS N
may MD N
also RB N
work VB N
very RB N
well RB N
in IN N
the DT N
Netherlands NNP N
too RB N
, , N
even RB N
though IN N
health NN N
care NN N
systems NNS N
differ VBP N
between IN N
countries NNS N
METHODS/DESIGN NNP N
This DT N
study NN N
is VBZ N
a DT N
two-armed JJ N
randomised JJ N
clinical JJ N
trial NN N
, , N
with IN N
randomization NN N
on IN N
patient-level NN N
The DT N
aim NN N
of IN N
the DT N
trial NN N
is VBZ N
to TO N
evaluate VB N
the DT N
treatment NN N
of IN N
depressive JJ N
disorder NN N
in IN N
primary JJ N
care NN N
in IN N
the DT N
Netherlands NNP N
by IN N
means NNS N
of IN N
an DT N
adapted JJ N
collaborative NN N
care NN N
framework NN N
, , N
including VBG N
contracting NN N
and CC N
adherence-improving JJ N
strategies NNS N
, , N
combined VBN N
with IN N
Problem NNP N
Solving NNP N
Treatment NNP N
and CC N
antidepressant JJ N
medication NN N
according VBG N
to TO N
a DT N
treatment NN N
algorithm NN N
Forty NNP 3_p
general JJ N
practices NNS N
will MD N
be VB N
randomised VBN N
to TO N
either CC N
the DT N
intervention NN N
group NN N
or CC N
the DT N
control NN N
group NN N
Included VBN N
will MD N
be VB N
patients NNS N
who WP N
are VBP N
diagnosed VBN N
with IN N
moderate JJ N
to TO N
severe JJ N
depression NN N
, , N
based VBN N
on IN N
DSM-IV NNP N
criteria NNS N
, , N
and CC N
stratified VBD N
according VBG N
to TO N
comorbid VB N
chronic JJ N
physical JJ N
illness NN N
Patients NNS N
in IN N
the DT N
intervention NN N
group NN N
will MD N
receive VB N
treatment NN N
based VBN N
on IN N
the DT N
collaborative JJ N
care NN N
approach NN N
, , N
and CC N
patients NNS N
in IN N
the DT N
control NN N
group NN N
will MD N
receive VB N
care NN N
as IN N
usual JJ N
Baseline NN N
measurements NNS N
and CC N
follow VB N
up RP N
measures NNS N
( ( N
3 CD N
, , N
6 CD N
, , N
9 CD N
and CC N
12 CD N
months NNS N
) ) N
are VBP N
assessed VBN N
using VBG N
questionnaires NNS N
and CC N
an DT N
interview NN N
The DT N
primary JJ N
outcome JJ N
measure NN N
is VBZ N
severity NN N
of IN N
depressive JJ N
symptoms NNS N
, , N
according VBG N
to TO N
the DT N
PHQ9 NNP N
Secondary NNP N
outcome NN N
measures NNS N
are VBP N
remission NN N
as IN N
measured VBN N
with IN N
the DT N
PHQ9 NNP N
and CC N
the DT N
IDS-SR NNP N
, , N
and CC N
cost-effectiveness NN N
measured VBN N
with IN N
the DT N
TiC-P NNP N
, , N
the DT N
EQ-5D NNP N
and CC N
the DT N
SF-36 NNP N
DISCUSSION NNP N
In IN N
this DT N
study NN N
, , N
an DT N
American JJ N
model NN N
to TO N
enhance VB N
care NN N
for IN N
patients NNS N
with IN N
a DT N
depressive JJ N
disorder NN N
, , N
the DT N
collaborative JJ N
care NN N
model NN N
, , N
will MD N
be VB N
evaluated VBN N
for IN N
effectiveness NN N
in IN N
the DT N
primary JJ N
care NN N
setting VBG N
If IN N
effective JJ N
across IN N
the DT N
Atlantic NNP N
and CC N
across IN N
different JJ N
health NN N
care NN N
systems NNS N
, , N
it PRP N
is VBZ N
also RB N
likely JJ N
to TO N
be VB N
an DT N
effective JJ N
strategy NN N
to TO N
implement VB N
in IN N
the DT N
treatment NN N
of IN N
major JJ N
depressive JJ N
disorder NN N
in IN N
the DT N
Netherlands NNP N
-DOCSTART- -X- O O 17623816

The DT N
peroxisome JJ N
proliferator-activated JJ N
receptor-gamma JJ N
agonist NN N
pioglitazone NN N
increases VBZ N
number NN N
and CC N
function NN N
of IN N
endothelial JJ N
progenitor NN N
cells NNS N
in IN N
patients NNS N
with IN N
coronary JJ N
artery NN N
disease NN N
and CC N
normal JJ N
glucose JJ N
tolerance NN N
OBJECTIVE CC N
Peroxisome JJ N
proliferator-activated JJ N
receptor-gamma NN N
( ( N
PPAR NNP N
gamma NN N
) ) N
agonists VBZ N
( ( N
thiazolidinediones NNS N
[ NNP N
TZDs NNP N
] NNP N
) ) N
are VBP N
used VBN N
for IN N
the DT N
treatment NN N
of IN N
diabetes NNS N
Bone CD N
marrow-derived JJ N
endothelial JJ N
progenitor NN N
cells NNS N
( ( N
EPCs NNP N
) ) N
improve VB N
vascular JJ N
function NN N
and CC N
predict NN N
cardiovascular NN N
risk NN N
The DT N
effect NN N
of IN N
pioglitazone NN N
therapy NN N
on IN N
EPCs NNP N
was VBD N
examined VBN N
RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
AND NNP N
RESULTS NNP N
We PRP N
performed VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
on IN N
patients NNS 4_p
with IN 4_p
documented JJ 4_p
stable JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
and CC 4_p
normal JJ 4_p
glucose JJ 4_p
tolerance NN 4_p
Of IN N
54 CD 4_p
patients NNS 4_p
with IN 4_p
normal JJ 4_p
fasting VBG 4_p
glucose JJ 4_p
levels NNS 4_p
, , 4_p
18 CD 4_p
showed VBD 4_p
impaired JJ 4_p
glucose JJ 4_p
tolerance NN 4_p
and CC 4_p
36 CD 4_p
patients NNS 4_p
with IN 4_p
normal JJ 4_p
glucose JJ 4_p
tolerance NN 4_p
were VBD 4_p
randomized VBN 4_p
to TO N
30-day JJ N
treatment NN N
with IN N
pioglitazone NN N
( ( N
45 CD N
mg NN N
) ) N
or CC N
placebo NN N
in IN N
addition NN N
to TO N
optimal VB N
medical JJ N
therapy NN N
All DT N
patients NNS N
in IN N
the DT N
TZD NNP N
group NN N
showed VBD N
an DT N
increase NN N
of IN N
adiponectin JJ N
levels NNS N
as IN N
an DT N
indicator NN N
of IN N
compliance NN N
( ( N
11.4 CD N
+/- JJ N
1.1 CD N
to TO N
36.8 CD N
+/- JJ N
2.1 CD N
microg/ml NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
TZD NNP N
, , N
but CC N
not RB N
placebo VB N
, , N
decreased VBN N
mean JJ N
high-sensitivity NN N
C-reactive JJ N
protein NN N
to TO N
43 CD N
+/- JJ N
19 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
Pioglitazone NN N
increased VBD N
CD34 NNP N
( ( N
+ NNP N
) ) N
/kinase NN N
insert JJ N
domain NN N
receptor NN N
( ( N
+ NNP N
) ) N
EPCs NNP N
to TO N
142 CD N
+/- JJ N
9 CD N
% NN N
and CC N
cultured VBD N
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled JJ N
acetylated JJ N
LDL NNP N
( ( N
+ NNP N
) ) N
/lectin NN N
( ( N
+ NNP N
) ) N
EPCs NNP N
to TO N
180 CD N
+/- JJ N
3 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
EPC JJ N
numbers NNS N
were VBD N
not RB N
changed VBN N
in IN N
the DT N
placebo NN N
group NN N
TZD NNP N
increased VBD N
the DT N
SDF-1-induced NNP N
migratory NN N
capacity NN N
to TO N
146 CD N
+/- JJ N
9 CD N
% NN N
per IN N
EPC NNP N
number NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
upregulated VBD N
the DT N
clonogenic JJ N
potential NN N
of IN N
EPCs NNP N
, , N
increasing VBG N
the DT N
colony-forming JJ N
units NNS N
to TO N
172 CD N
+/- JJ N
12 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
In IN N
cultured JJ N
human JJ N
EPCs NNP N
, , N
TZD NNP N
increased VBD N
EPC NNP N
numbers NNS N
and CC N
migration NN N
and CC N
reduced JJ N
NADPH-oxidase NNP N
activity NN N
The DT N
TZD NNP N
effect NN N
was VBD N
reversed VBN N
by IN N
the DT N
PPAR NNP N
gamma NN N
antagonist NN N
GW9662 NNP N
and CC N
mimicked VBN N
by IN N
treatment NN N
with IN N
adiponectin NN N
CONCLUSIONS VB N
The DT N
PPAR NNP N
gamma NN N
agonist NN N
pioglitazone NN N
increases VBZ N
the DT N
number NN N
and CC N
function NN N
of IN N
EPCs NNP N
in IN N
patients NNS N
with IN N
coronary JJ N
artery NN N
disease NN N
The DT N
effect NN N
represents VBZ N
a DT N
potential JJ N
regenerative NN N
mechanism NN N
in IN N
atherosclerosis NN N
and CC N
is VBZ N
observed VBN N
in IN N
normoglycemic JJ 4_p
individuals NNS 4_p
with IN 4_p
stable JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
-DOCSTART- -X- O O 24939380

Electrothermal JJ N
arthroscopic NN N
capsulorrhaphy NN N
: : N
old JJ N
technology NN N
, , N
new JJ N
evidence NN N
A DT N
multicenter NN N
randomized VBN N
clinical JJ N
trial NN N
BACKGROUND NNP N
Radiofrequency NNP N
technology NN N
for IN N
shoulder JJR 4_p
instability NN 4_p
was VBD N
rapidly RB N
adopted VBN N
despite IN N
limited JJ N
clinical JJ N
evidence NN N
and CC N
a DT N
poor JJ N
understanding NN N
of IN N
its PRP$ N
indications NNS N
Reports NNS N
of IN N
serious JJ N
adverse JJ N
events NNS N
followed VBD N
, , N
leading VBG N
to TO N
its PRP$ N
abandonment NN N
This DT N
paper NN N
presents VBZ N
findings NNS N
from IN N
a DT N
multicenter NN N
randomized VBN N
clinical JJ N
trial NN N
evaluating VBG N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
electrothermal JJ N
arthroscopic NN N
capsulorrhaphy NN N
( ( N
ETAC NNP N
) ) N
compared VBN N
with IN N
open JJ N
inferior JJ N
capsular JJ N
shift NN N
( ( N
ICS NNP N
) ) N
and CC N
reviews VBZ N
the DT N
role NN N
of IN N
randomized JJ N
trials NNS N
in IN N
adopting VBG N
new JJ N
technology NN N
METHODS NNP N
Patients NNPS 1_p
( ( 1_p
> JJ 1_p
14 CD 1_p
years NNS 1_p
) ) 1_p
diagnosed VBD N
with IN N
multidirectional JJ 4_p
instability NN 4_p
or CC N
multidirectional JJ 4_p
laxity NN 4_p
with IN 4_p
anteroinferior JJ 4_p
instability NN 4_p
and CC 4_p
failed VBD 4_p
nonoperative JJ 4_p
treatment NN 4_p
were VBD N
enrolled VBN N
Patients NNS N
with IN N
bone JJ N
lesions NNS N
or CC N
labral JJ N
, , N
biceps JJ N
anchor NN N
, , N
or CC N
full-thickness JJ N
rotator NN N
cuff NN N
tears NNS N
were VBD N
excluded VBN N
intraoperatively RB N
Outcomes NNP N
included VBD N
Western NNP N
Ontario NNP N
Shoulder NNP N
Instability NNP N
Index NNP N
, , N
function NN N
and CC N
recurrent JJ N
instability NN N
at IN N
2 CD N
years NNS N
postoperatively RB N
, , N
and CC N
surgical JJ N
times NNS N
RESULTS NNP N
Fifty-four JJ 3_p
subjects NNS N
( ( N
mean JJ 1_p
age NN 1_p
, , 1_p
23 CD 1_p
years NNS 1_p
; : N
37 CD N
women NNS 2_p
) ) N
were VBD N
randomized VBN N
to TO N
ETAC NNP N
( ( N
n JJ N
= NNP N
28 CD N
) ) N
or CC N
open JJ N
ICS NNP N
( ( N
n JJ 3_p
= NNP 3_p
26 CD 3_p
) ) N
The DT N
groups NNS N
were VBD N
comparable JJ N
at IN N
baseline NN N
, , N
except IN N
for IN N
external JJ N
rotation NN N
at IN N
the DT N
side NN N
At IN N
2 CD N
years NNS N
postoperatively RB N
, , N
there EX N
were VBD N
no DT N
statistically RB N
or CC N
clinically RB N
significant JJ N
differences NNS N
between IN N
groups NNS N
for IN N
the DT N
Western NNP N
Ontario NNP N
Shoulder NNP N
Instability NNP N
Index NNP N
( ( N
P NNP N
= NNP N
.71 NNP N
) ) N
, , N
American NNP N
Shoulder NNP N
and CC N
Elbow NNP N
Surgeons NNP N
score NN N
( ( N
P NNP N
= NNP N
.43 NNP N
) ) N
, , N
Constant JJ N
score NN N
( ( N
P NNP N
= NNP N
.43 NNP N
) ) N
, , N
and CC N
active JJ N
range NN N
of IN N
motion NN N
Recurrent NNP N
instability NN N
was VBD N
not RB N
statistically RB N
different JJ N
( ( N
ETAC NNP N
, , N
2 CD N
; : N
open JJ N
, , N
4 CD N
; : N
P NNP N
= NNP N
.41 NNP N
) ) N
ETAC NNP N
( ( N
23 CD N
minutes NNS N
) ) N
was VBD N
significantly RB N
shorter JJR N
than IN N
open JJ N
ICS NNP N
( ( N
59 CD N
minutes NNS N
) ) N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
surgery NN N
Three CD N
subjects NNS N
( ( N
1 CD N
ETAC NNP N
, , N
2 CD N
open JJ N
) ) N
had VBD N
stiff JJ N
shoulders NNS N
CONCLUSIONS NNP N
At IN N
2 CD N
years NNS N
postoperatively RB N
, , N
quality NN N
of IN N
life NN N
and CC N
functional JJ N
outcomes NNS N
between IN N
groups NNS N
were VBD N
not RB N
clinically RB N
different JJ N
ETAC NNP N
had VBD N
fewer JJR N
complications NNS N
and CC N
episodes NNS N
of IN N
recurrence NN N
compared VBN N
with IN N
open JJ N
surgery NN N
This DT N
evidence NN N
reinforces VBZ N
the DT N
need NN N
to TO N
critically VB N
evaluate VB N
new JJ N
technology NN N
before IN N
widespread JJ N
clinical JJ N
use NN N
-DOCSTART- -X- O O 9170524

[ VB N
A DT N
randomized JJ N
comparative NN N
study NN N
of IN N
surgical JJ N
adjuvant NN N
chemotherapy NN N
using VBG N
5-fluorouracil JJ N
and CC N
dl-leucovorin JJ N
with IN N
CDDP NNP N
5-FU JJ N
and CC N
dl-leucovorin JJ N
for IN N
colorectal JJ 4_p
cancer NN 4_p
] NNP N
A NNP N
randomized JJ N
comparative NN N
study NN N
of IN N
surgical JJ N
adjuvant NN N
chemotherapy NN N
using VBG N
dl-leucovorin JJ N
( ( N
dl-LV JJ N
) ) N
and CC N
5-fluorouracil JJ N
( ( N
5-FU JJ N
) ) N
( ( N
FL-therapy NNP N
) ) N
with IN N
CDDP NNP N
, , N
5-FU JJ N
, , N
and CC N
dl-LV JJ N
( ( N
PFL-therapy NNP N
) ) N
was VBD N
conducted VBN N
The DT N
following VBG N
were VBD N
the DT N
administration NN N
schedules NNS N
: : N
Arm VB N
A DT N
was VBD N
13 CD N
mg/m2 NN N
of IN N
CDDP NNP N
, , N
300 CD N
mg/m2 NN N
of IN N
5-FU JJ N
, , N
and CC N
30 CD N
mg/body NN N
of IN N
dl-LV NN N
for IN N
5 CD N
consecutive JJ N
days NNS N
and CC N
arm NN N
B NNP N
was VBD N
300 CD N
mg/m2 NN N
of IN N
5-FU JJ N
and CC N
30 CD N
mg/body NN N
of IN N
dl-LV NN N
for IN N
5 CD N
consecutive JJ N
days NNS N
Both DT N
regimens NNS N
were VBD N
followed VBN N
by IN N
biweekly JJ N
administration NN N
of IN N
the DT N
same JJ N
dose NN N
of IN N
dl-LV JJ N
and CC N
5-FU JJ N
in IN N
outpatients NNS N
Arm VB N
A DT N
was VBD N
started VBN N
at IN N
the DT N
26th CD N
postoperative JJ N
day NN N
and CC N
arm NN N
B NNP N
at IN N
the DT N
21st CD N
day NN N
on IN N
average NN N
Some DT N
26 CD 3_p
cases NNS N
composed VBN N
of IN N
11 CD 3_p
cases NNS N
of IN N
arm NN N
A NNP N
and CC N
15 CD 3_p
cases NNS N
of IN N
arm NN N
B NNP N
completed VBD N
the DT N
administration NN N
schedules NNS N
Only RB N
one CD N
case NN N
in IN N
arm NN N
A NN N
was VBD N
complicated VBN N
by IN N
local JJ N
recurrence NN N
around IN N
35 CD N
months NNS N
after IN N
operation NN N
Major JJ N
toxicities NNS N
were VBD N
anorexia JJ N
and CC N
neutropenia NN N
Both CC N
toxicities NNS N
were VBD N
seen VBN N
more RBR N
in IN N
arm NN N
A NN N
than IN N
in IN N
arm NN N
B NNP N
, , N
showing VBG N
complete JJ N
recovery NN N
in IN N
all DT N
cases NNS N
These DT N
data NNS N
suggest VBP N
that IN N
PFL-therapy NNP N
and CC N
FL-therapy NNP N
seem VBP N
to TO N
be VB N
possible JJ N
and CC N
promising JJ N
surgical JJ N
adjuvant NN N
therapies NNS N
for IN N
advanced JJ 4_p
colorectal JJ 4_p
carcinoma NN 4_p
-DOCSTART- -X- O O 1409770

The DT N
cumulative JJ N
dose NN N
response NN N
effect NN N
of IN N
eicosapentaenoic NN N
and CC N
docosahexaenoic JJ N
acid NN N
on IN N
blood NN N
pressure NN N
, , N
plasma NN N
lipid JJ N
profile NN N
and CC N
diet JJ N
pattern NN N
in IN N
mild NN 4_p
to TO 4_p
moderate VB 4_p
essential JJ 4_p
hypertensive JJ 4_p
black JJ 4_p
patients NNS 4_p
In IN N
this DT N
study NN N
eicosapentaenoic VBZ N
acid NNS N
( ( N
EPA NNP N
) ) N
and CC N
docosahexaenoic JJ N
acid NN N
( ( N
DHA NNP N
) ) N
were VBD N
given VBN N
in IN N
a DT N
cumulative JJ N
manner NN N
, , N
every DT N
6 CD N
weeks NNS N
, , N
starting VBG N
with IN N
10 CD N
mg NNS N
, , N
then RB N
100 CD N
mg NNS N
, , N
1000 CD N
mg NN N
and CC N
10,000 CD N
mg NNS N
EPA NNP N
daily RB N
to TO N
mild VB N
to TO N
moderate VB N
essential JJ N
hypertensive JJ N
black JJ N
patients NNS N
The DT N
corresponding JJ N
DHA NNP N
doses NNS N
were VBD N
3 CD N
, , N
33 CD N
, , N
333 CD N
and CC N
3333 CD N
mg. NN N
A NNP N
control NN N
group NN N
was VBD N
given VBN N
olive JJ N
oil NN N
as IN N
placebo NN N
for IN N
the DT N
entire JJ N
24 CD N
weeks NNS N
The DT N
placebo NN N
group NN N
had VBD N
lower JJR N
diastolic NN N
and CC N
systolic JJ N
blood NN N
pressures NNS N
after IN N
24 CD N
weeks NNS N
than IN N
the DT N
EPA NNP N
and CC N
DHA NNP N
group NN N
No DT N
effect NN N
was VBD N
seen VBN N
on IN N
plasma NN N
triglycerides NNS N
, , N
cholesterol NN N
, , N
HDL-cholesterol NNP N
and CC N
gamma-glutamyltranspeptidase NN N
at IN N
any DT N
stage NN N
of IN N
the DT N
trial NN N
In IN N
the DT N
EPA NNP N
group NN N
plasma VBD N
free-EPA NN N
increased VBN N
significantly RB N
from IN N
1000 CD N
mg NN N
onwards NNS N
and CC N
plasma JJ N
free-arachidonic JJ N
acid NN N
( ( N
AA NNP N
) ) N
decreased VBD N
after IN N
1000 CD N
mg NN N
EPA NNP N
No DT N
other JJ N
plasma NN N
free JJ N
essential JJ N
fatty NN N
acid RB N
changed VBD N
during IN N
the DT N
trial NN N
, , N
although IN N
the DT N
HDL NNP N
: : N
cholesterol NN N
increased VBD N
slightly RB N
but CC N
non-significantly RB N
with IN N
an DT N
increase NN N
in IN N
EPA NNP N
and CC N
DHA NNP N
No NNP N
significant JJ N
changes NNS N
in IN N
diet JJ N
pattern NN N
or CC N
body NN N
mass NN N
was VBD N
observed VBN N
It PRP N
is VBZ N
therefore RB N
concluded JJ N
that IN N
EPA NNP N
and CC N
DHA NNP N
supplementation NN N
had VBD N
no DT N
beneficial JJ N
effects NNS N
in IN N
mild NN N
to TO N
moderate VB N
essential JJ N
hypertensive JJ N
black JJ N
patients NNS N
except IN N
for IN N
a DT N
lowering NN N
of IN N
plasma NN N
AA NNP N
-DOCSTART- -X- O O 20865678

Influence NN N
of IN N
exercise NN N
training NN N
on IN N
leptin NN N
levels NNS N
in IN N
patients NNS 4_p
with IN 4_p
stable JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
: : N
A DT N
pilot NN N
study NN N
BACKGROUND NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
examine VB N
the DT N
influence NN N
of IN N
exercise NN N
training NN N
on IN N
leptin NN N
levels NNS N
in IN N
patients NNS N
with IN N
stable JJ N
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
( ( N
CAD NNP N
) ) N
METHODS NNP N
Sixty-four JJ 3_p
male NN 2_p
patients NNS N
, , N
mean JJ 1_p
age NN 1_p
55.6 CD 1_p
± JJ 1_p
6.0 CD 1_p
years NNS 1_p
, , N
were VBD N
randomized VBN N
either RB N
to TO N
six CD N
weeks NNS N
of IN N
aerobic JJ N
training NN N
, , N
three CD N
times NNS N
a DT N
week NN N
, , N
at IN N
60-80 CD N
% NN N
of IN N
maximal JJ N
heart NN N
rate NN N
( ( N
training VBG N
group NN N
, , N
Ex NNP N
, , N
n JJ N
= NNP N
32 CD N
) ) N
or CC N
to TO N
a DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
32 CD N
) ) N
Exercise NNP N
stress JJ N
test NN N
was VBD N
performed VBN N
and CC N
body JJ N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
, , N
waist-to-hip JJ N
ratio NN N
( ( N
WHR NNP N
) ) N
, , N
waist JJ N
circumference NN N
and CC N
plasma NN N
leptin NN N
levels NNS N
were VBD N
measured VBN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
study NN N
RESULTS NNP N
Physical JJ N
capacity NN N
increased VBD N
significantly RB N
only RB N
in IN N
Ex NNP N
patients NNS N
( ( N
max JJ N
workload NN N
in IN N
METs NNP N
from IN N
7.7 CD N
± $ N
1.4 CD N
to TO N
8.2 CD N
± NNS N
1.4 CD N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
initial JJ N
and CC N
final JJ N
results NNS N
in IN N
either DT N
group NN N
in IN N
terms NNS N
of IN N
BMI NNP N
, , N
WHR NNP N
or CC N
waist JJ N
circumference NN N
Although IN N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
leptin NN N
levels NNS N
did VBD N
not RB N
change VB N
in IN N
Ex NNP N
patients NNS N
( ( N
6.7 CD N
± RB N
3.2 CD N
vs NNS N
6.9 CD N
± $ N
3.6 CD N
ng/mL NN N
, , N
NS NNP N
) ) N
, , N
they PRP N
did VBD N
increase VB N
significantly RB N
in IN N
the DT N
control NN N
group NN N
( ( N
8.0 CD N
± RB N
4.0 CD N
vs NNS N
9.3 CD N
± $ N
5.2 CD N
ng/mL NN N
, , N
p NN N
< NNP N
0.02 CD N
) ) N
CONCLUSIONS VB N
A DT N
short JJ N
period NN N
of IN N
exercise NN N
training NN N
in IN N
CAD NNP 4_p
patients NNS N
improved VBD N
their PRP$ N
physical JJ N
capacity NN N
, , N
but CC N
did VBD N
not RB N
influence VB N
BMI NNP N
, , N
WHR NNP N
and CC N
waist JJ N
circumference NN N
Exercise NN N
training NN N
prevented VBD N
an DT N
increase NN N
in IN N
leptin JJ N
levels NNS N
during IN N
the DT N
study NN N
period NN N
-DOCSTART- -X- O O 25912590

Peritonsillar JJ N
infiltration NN N
with IN N
levobupivacaine NN N
for IN N
posttonsillectomy NN 4_p
pain NN 4_p
relief NN N
: : N
does VBZ N
concentration NN N
have VB N
any DT N
effect NN N
? . N
A DT N
double-blind JJ N
randomized NN N
controlled VBD N
clinical JJ N
study NN N
OBJECTIVE NNP N
Post-tonsillectomy JJ 4_p
pain NN 4_p
is VBZ N
believed VBN N
to TO N
be VB N
mediated VBN N
by IN N
noxious JJ N
stimulation NN N
of IN N
C-fiber NNP N
afferents NNS N
located VBN N
in IN N
the DT N
peritonsillary JJ N
space NN N
, , N
and CC N
local JJ N
anesthetic JJ N
infiltration NN N
to TO N
this DT N
area NN N
may MD N
decrease VB N
pain NN N
by IN N
blocking VBG N
the DT N
sensory JJ N
pathways NNS N
and CC N
thus RB N
preventing VBG N
the DT N
nociceptive JJ N
impulses NNS N
We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
different JJ N
concentrations NNS N
of IN N
preincisional JJ N
peritonsillar JJ N
levobupivacaine NN N
( ( N
0.25 CD N
% NN N
and CC N
0.5 CD N
% NN N
) ) N
infiltration NN N
on IN N
postoperative JJ N
pain NN N
and CC N
bleeding NN N
in IN N
a DT N
placebo-controlled JJ N
design NN N
PATIENTS NNP N
AND CC N
METHODS NNP N
After IN N
obtaining VBG N
Institutional NNP N
Ethics NNP N
Committee NNP N
approval NN N
, , N
72 CD 3_p
ASA NNP N
I-II JJ N
patients NNS N
between IN 1_p
3 CD 1_p
and CC 1_p
12 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , N
scheduled VBN N
to TO N
undergo VB N
tonsillectomy NN N
were VBD N
enrolled VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
three CD N
groups NNS N
using VBG N
the DT N
sealed VBN N
envelope NN N
technique NN N
, , N
as IN N
Group NNP N
I PRP N
( ( N
Control NNP N
group NN N
) ) N
, , N
Group NNP N
II NNP N
, , N
and CC N
Group NNP N
III NNP N
receiving VBG N
preincisional JJ N
bilateral JJ N
peritonsillar JJ N
infiltration NN N
with IN N
saline NN N
, , N
0.25 CD N
% NN N
levobupivacaine NN N
and CC N
0.5 CD N
% NN N
levobupivacaine NN N
, , N
respectively RB N
( ( N
3 CD N
mL NN N
to TO N
each DT N
tonsil NN N
) ) N
Pain NNP N
, , N
fever NN N
, , N
dysphagia NN N
; : N
nausea-vomiting JJ N
and CC N
hemorrhage NN N
were VBD N
evaluated VBN N
at IN N
postoperative JJ N
0 CD N
, , N
30 CD N
, , N
and CC N
60 CD N
minutes NNS N
and CC N
2 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
hours NNS N
Oral NNP N
paracetamol NN N
was VBD N
administered VBN N
at IN N
a DT N
dose NN N
of IN N
15 CD N
mg/kg NN N
when WRB N
FLACC NNP N
score NN N
was VBD N
> JJ N
4 CD N
The DT N
number NN N
of IN N
paracetamol JJ N
administrations NNS N
within IN N
the DT N
first JJ N
24 CD N
hours NNS N
were VBD N
recorded VBN N
RESULTS VB N
The DT N
patients NNS N
in IN N
Groups NNP N
I PRP N
, , N
II NNP N
and CC N
III NNP N
defined VBD N
pain NN N
( ( N
FLACC NNP N
> NNP N
4 CD N
) ) N
at IN N
a DT N
rate NN N
of IN N
87 CD N
% NN N
, , N
60.9 CD N
% NN N
, , N
and CC N
54.2 CD N
% NN N
within IN N
the DT N
postoperative JJ N
first JJ N
24 CD N
hours NNS N
, , N
respectively RB N
The DT N
total JJ N
number NN N
of IN N
additional JJ N
analgesic JJ N
requirements NNS N
was VBD N
significantly RB N
low JJ N
in IN N
Group NNP N
II NNP N
and CC N
III NNP N
when WRB N
compared VBN N
with IN N
Group NNP N
I PRP N
There EX N
was VBD N
no DT N
difference NN N
between IN N
groups NNS N
in IN N
terms NNS N
of IN N
fever NN N
, , N
dysphagia NN N
, , N
nausea-vomiting JJ N
, , N
hemorrhage NN N
CONCLUSIONS NNP N
Both NNP N
concentrations NNS N
( ( N
0.50 CD N
% NN N
and CC N
0.25 CD N
% NN N
) ) N
of IN N
levobupivacaine NN N
were VBD N
found VBN N
to TO N
be VB N
equally RB N
safe JJ N
and CC N
effective JJ N
during IN N
preincisional JJ N
peritonsillar JJ N
infiltration NN N
in IN N
children NNS 1_p
NCT NNP N
number NN N
: : N
02322346 CD N
-DOCSTART- -X- O O 22007005

Use NNP N
of IN N
an DT N
Internet NNP N
portal NN N
to TO N
improve VB N
community-based JJ N
pediatric JJ 1_p
ADHD NNP 4_p
care NN N
: : N
a DT N
cluster NN N
randomized VBN N
trial NN N
OBJECTIVE NN N
To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
a DT N
quality NN N
improvement NN N
program NN N
to TO N
improve VB N
pediatricians NNS N
' POS N
adherence NN N
to TO N
existing VBG N
, , N
evidence-based JJ N
, , N
attention-deficit/hyperactivity JJ N
disorder NN N
( ( N
ADHD NNP N
) ) N
practice NN N
guidelines NNS N
METHODS NNP N
Forty-nine JJ 3_p
community-based JJ N
pediatricians NNS N
at IN N
8 CD N
practices NNS N
participated VBN N
in IN N
a DT N
cluster-randomized JJ N
trial NN N
Practices NNS N
were VBD N
matched VBN N
according VBG N
to TO N
the DT N
numbers NNS N
of IN N
pediatricians NNS N
and CC N
the DT N
proportions NNS N
of IN N
patients NNS N
receiving VBG N
Medicaid NNP N
The DT N
medical JJ N
charts NNS N
for IN N
a DT N
random JJ N
sample NN N
of IN N
patients NNS N
with IN N
ADHD NNP N
for IN N
each DT N
of IN N
the DT N
participating VBG N
pediatricians NNS N
were VBD N
examined VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
All DT N
practices NNS N
participated VBN N
in IN N
4 CD N
sessions NNS N
of IN N
training NN N
, , N
including VBG N
didactic JJ N
lectures NNS N
and CC N
office NN N
flow NN N
modification NN N
workshops NNS N
Practices NNS N
were VBD N
then RB N
given VBN N
access NN N
to TO N
an DT N
ADHD NNP N
Internet NNP N
portal NN N
that WDT N
allowed VBD N
parents NNS N
, , N
teachers NNS N
, , N
and CC N
pediatricians NNS N
to TO N
input VB N
information NN N
( ( N
eg NN N
, , N
rating NN N
scales NNS N
) ) N
about IN N
patients NNS N
, , N
after IN N
which WDT N
information NN N
was VBD N
scored VBN N
, , N
interpreted VBN N
, , N
and CC N
formatted VBN N
in IN N
a DT N
report NN N
style NN N
that WDT N
was VBD N
helpful JJ N
for IN N
assessment NN N
and CC N
treatment NN N
of IN N
patients NNS N
with IN N
ADHD NNP N
Physicians NNPS N
evaluated VBD N
their PRP$ N
practice NN N
behaviors NNS N
quarterly RB N
and CC N
addressed VBD N
underperforming JJ N
areas NNS N
RESULTS NNP N
Pediatricians NNPS N
in IN N
the DT N
intervention NN N
group NN N
, , N
compared VBN N
with IN N
those DT N
in IN N
the DT N
control NN N
group NN N
, , N
demonstrated VBD N
significantly RB N
higher JJR N
rates NNS N
of IN N
many JJ N
American JJ N
Academy NNP N
of IN N
Pediatrics-recommended NNP N
ADHD NNP N
care NN N
practices NNS N
, , N
including VBG N
collection NN N
of IN N
parent NN N
( ( N
Cohen NNP N
's POS N
d NN N
= VBZ N
0.69 CD N
) ) N
and CC N
teacher $ N
( ( N
d JJ N
= NNP N
0.68 CD N
) ) N
rating NN N
scales NNS N
for IN N
assessment NN N
of IN N
children NNS N
with IN N
ADHD NNP N
, , N
use NN N
of IN N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
, , N
criteria NNS N
( ( N
d VB N
= RB N
0.85 CD N
) ) N
, , N
and CC N
use NN N
of IN N
teacher NN N
rating NN N
scales NNS N
to TO N
monitor VB N
treatment NN N
responses NNS N
( ( N
d VB N
= RB N
1.01 CD N
) ) N
CONCLUSION VB N
A DT N
quality NN N
improvement NN N
intervention NN N
that WDT N
can MD N
be VB N
widely RB N
disseminated VBN N
by IN N
using VBG N
Internet-based JJ N
information NN N
technology NN N
significantly RB N
improved VBD N
the DT N
quality NN N
of IN N
ADHD NNP N
care NN N
in IN N
community-based JJ N
pediatric JJ N
settings NNS N
-DOCSTART- -X- O O 23312881

Intravenous JJ N
aflibercept NN N
administered VBN N
in IN N
combination NN N
with IN N
irinotecan JJ N
, , N
5-fluorouracil JJ N
and CC N
leucovorin JJ N
in IN N
patients NNS N
with IN N
advanced JJ 4_p
solid JJ 4_p
tumours NNS 4_p
: : N
results NNS N
from IN N
the DT N
expansion NN N
cohort NN N
of IN N
a DT N
phase NN N
I PRP N
study VBP N
BACKGROUND NNP N
Following VBG N
the DT N
dose-escalation NN N
stage NN N
, , N
this DT N
double-blind JJ N
expansion NN N
stage NN N
of IN N
the DT N
phase NN N
I PRP N
study VBP N
evaluated VBD N
the DT N
safety NN N
, , N
pharmacodynamics NNS N
, , N
pharmacokinetics NNS N
, , N
anti-vascular JJ N
effects NNS N
and CC N
antitumour JJ N
activity NN N
of IN N
aflibercept $ N
4 CD N
mg/kg NN N
with IN N
irinotecan JJ N
, , N
5-fluorouracil JJ N
and CC N
leucovorin JJ N
( ( N
LV5FU2 NNP N
) ) N
PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNP N
with IN N
advanced JJ 4_p
solid JJ 4_p
tumours NNS 4_p
were VBD N
randomised VBN N
at IN N
cycle-1 NN N
to TO N
placebo VB N
or CC N
aflibercept VB N
( ( N
4 CD N
mg/kg NN N
) ) N
on IN N
day NN N
1 CD N
then RB N
irinotecan-LV5FU2 NN N
on IN N
days NNS N
1 CD N
and CC N
2 CD N
Subsequently RB N
, , N
all DT N
patients NNS N
received VBD N
aflibercept JJ N
with IN N
irinotecan-LV5FU2 JJ N
every DT N
2 CD N
weeks NNS N
Anti-vascular JJ N
effects NNS N
were VBD N
assessed VBN N
using VBG N
dynamic JJ N
contrast-enhanced JJ N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
DCE-MRI NNP N
) ) N
RESULTS JJ N
Twenty-seven JJ 3_p
patients NNS N
were VBD N
treated VBN N
; : N
14 CD N
received VBD N
placebo NN N
in IN N
cycle-1 NN N
followed VBN N
by IN N
aflibercept NN N
in IN N
later JJ N
cycles NNS N
and CC N
13 CD N
received VBD N
aflibercept JJ N
4 CD N
mg/kg NN N
upfront NN N
The DT N
median JJ N
number NN N
of IN N
aflibercept JJ N
cycles NNS N
was VBD N
16 CD N
( ( N
range VB N
1-44 CD N
) ) N
, , N
12 CD N
patients NNS N
received VBD N
≥20 JJ N
cycles NNS N
Most JJS N
frequent JJ N
grade NN N
3/4 CD N
adverse JJ N
events NNS N
were VBD N
neutropenia RB N
( ( N
37 CD N
% NN N
) ) N
, , N
fatigue NN N
( ( N
33 CD N
% NN N
) ) N
and CC N
hypertension NN N
( ( N
30 CD N
% NN N
) ) N
No DT N
anti-aflibercept JJ N
antibodies NNS N
were VBD N
detected VBN N
Four CD N
patients NNS N
achieved VBN N
partial JJ N
responses NNS N
and CC N
17 CD N
had VBD N
stable JJ N
disease NN N
, , N
lasting VBG N
> JJ N
3 CD N
months NNS N
in IN N
14 CD N
patients NNS N
Plasma NNP N
levels NNS N
of IN N
free JJ N
over IN N
vascular JJ N
endothelial JJ N
growth NN N
factor-bound JJ N
aflibercept NN N
were VBD N
adequate JJ N
, , N
with IN N
steady-state JJ N
achieved VBN N
from IN N
cycle-3 NN N
Exploratory JJ N
DCE-MRI NNP N
showed VBD N
no DT N
significant JJ N
perfusion NN N
changes NNS N
with IN N
aflibercept NN N
CONCLUSION NNP N
Aflibercept IN N
4 CD N
mg/kg JJ N
plus CC N
irinotecan-LV5FU2 JJ N
every DT N
2 CD N
weeks NNS N
had VBD N
acceptable JJ N
toxicity NN N
and CC N
pharmacokinetics NNS N
, , N
and CC N
showed VBD N
promising JJ N
antitumour JJ N
activity NN N
-DOCSTART- -X- O O 15249792

Effect NN N
of IN N
the DT N
dietary JJ N
approaches NNS N
to TO N
stop VB N
hypertension NN N
diet NN N
and CC N
reduced JJ N
sodium NN N
intake NN N
on IN N
blood NN N
pressure NN N
control NN N
The DT N
authors NNS N
hypothesized VBD N
that IN N
the DT N
Dietary NNP N
Approaches NNP N
to TO N
Stop VB N
Hypertension NNP N
( ( N
DASH NNP N
) ) N
diet NN N
and CC N
reduced JJ N
sodium NN N
intake NN N
would MD N
control VB N
stage NN N
1 CD N
hypertension NN N
and CC N
reduce VB N
high-normal JJ N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
to TO N
optimal JJ N
levels NNS N
Adults NNS 1_p
with IN N
systolic JJ 4_p
BP NNP 4_p
120-159 JJ 4_p
mm NN 4_p
Hg NNP 4_p
and CC 4_p
diastolic JJ 4_p
BP NNP 4_p
80-95 JJ 4_p
mm NN 4_p
Hg NNP 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
the DT N
DASH NNP N
diet NN N
or CC N
a DT N
typical JJ N
American NNP N
( ( N
control NN N
) ) N
diet NN N
, , N
consuming VBG N
three CD N
different JJ N
sodium NN N
intakes NNS N
( ( N
higher=142 JJ N
mmol/d NN N
, , N
intermediate=107 NN N
mmol/d NN N
, , N
and CC N
lower=65 JJ N
mmol/d NN N
) ) N
for IN N
30 CD N
days NNS N
each DT N
BP NNP N
control NN N
was VBD N
defined VBN N
as IN N
systolic JJ N
BP NNP N
< NNP N
140 CD N
mm NN N
Hg NNP N
and CC N
diastolic JJ N
BP NNP N
< NNP N
90 CD N
mm NN N
Hg NNP N
Among IN N
subjects NNS N
with IN N
hypertension NN 4_p
at IN N
baseline NN N
, , N
at IN N
higher JJR N
sodium NN N
intake VBP N
the DT N
DASH NNP N
diet NN N
increased VBD N
BP NNP N
control NN N
two-fold NN N
over IN N
control NN N
( ( N
63 CD N
% NN N
vs. FW N
32 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.4-2.9 JJ N
) ) N
Reducing VBG N
sodium JJ N
intake NN N
in IN N
the DT N
control NN N
diet JJ N
group NN N
increased VBD N
BP NNP N
control NN N
2.3-fold JJ N
( ( N
74 CD N
% NN N
vs. FW N
32 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.7-3.2 JJ N
) ) N
The DT N
maximum JJ N
BP NNP N
control NN N
rate NN N
( ( N
84 CD N
% NN N
) ) N
was VBD N
achieved VBN N
with IN N
the DT N
DASH/lower NNP N
sodium NN N
diet NN N
BP NNP N
became VBD N
normal JJ N
or CC N
optimal JJ N
in IN N
71 CD N
% NN N
of IN N
persons NNS N
consuming VBG N
the DT N
control/lower NN N
sodium NN N
diet NN N
and CC N
77 CD N
% NN N
of IN N
persons NNS N
consuming VBG N
the DT N
DASH/lower NNP N
sodium NN N
diet NN N
Both CC N
the DT N
DASH NNP N
diet NN N
and CC N
reduced JJ N
sodium NN N
intake NN N
improved VBD N
BP NNP N
control NN N
-DOCSTART- -X- O O 25246602

Fluticasone CD N
or CC N
montelukast VB N
in IN N
preschool NN 4_p
wheeze NN 4_p
: : 4_p
a DT N
randomized NN N
controlled VBN N
trial NN N
INTRODUCTION NNP N
Approximately RB N
30 CD N
% NN N
of IN N
children NNS 1_p
younger JJR 1_p
than IN 1_p
3 CD 1_p
years NNS 1_p
experience RB N
at IN N
least JJS N
1 CD N
episode NN N
of IN N
wheezing VBG N
Antiasthmatic JJ N
medication NN N
is VBZ N
routinely RB N
prescribed JJ N
, , N
but CC N
its PRP$ N
effectiveness NN N
remains VBZ N
unclear JJ N
Our PRP$ N
study NN N
was VBD N
aimed VBN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
anti-inflammatory JJ N
treatment NN N
on IN N
frequency NN N
and CC N
severity NN N
of IN N
preschool NN 4_p
wheeze NN 4_p
episodes NNS 4_p
( ( 4_p
PWEs NNP 4_p
) ) 4_p
METHODS NNP N
Children NNP 1_p
aged VBD 1_p
6 CD 1_p
to TO 1_p
36 CD 1_p
months NNS 1_p
with IN 1_p
the DT 1_p
first JJ 1_p
up RB 1_p
to TO 1_p
the DT 1_p
third JJ 1_p
PWE NNP 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
montelukast NN N
, , N
fluticasone NN N
, , N
or CC N
no DT N
treatment NN N
for IN N
12 CD N
weeks NNS N
The DT N
outcome NN N
measures NNS N
were VBD N
the DT N
number NN N
of IN N
PWEs NNP N
, , N
the DT N
number NN N
of IN N
hospitalizations NNS N
due JJ N
to TO N
PWE NNP N
, , N
and CC N
the DT N
severity NN N
of IN N
respiratory NN N
symptoms NNS N
results NNS N
: : N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
outcome JJ N
measures NNS N
between IN N
the DT N
groups NNS N
However RB N
, , N
tobacco-exposed JJ N
children NNS N
treated VBN N
with IN N
fluticasone NN N
had VBD N
significantly RB N
fewer JJR N
PWEs NNP N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
CONCLUSION NNP N
Neither NNP N
montelukast NN N
nor CC N
fluticasone NN N
has VBZ N
proven VBN N
effective JJ N
in IN N
the DT N
prevention NN N
of IN N
PWE NNP N
recurrence NN N
Children NNP 1_p
of IN 1_p
smoking VBG 1_p
parents NNS 1_p
may MD N
benefit VB N
from IN N
fluticasone NN N
treatment NN N
after IN N
PWE NNP N
This DT N
observation NN N
requires VBZ N
confirmation NN N
in IN N
larger JJR N
studies NNS N
-DOCSTART- -X- O O 24214189

QT/QTc NNP N
study NN N
conducted VBD N
in IN N
Japanese JJ 4_p
adult NN 1_p
healthy JJ 4_p
subjects NNS 4_p
: : 4_p
a DT N
novel JJ N
xanthine NN N
oxidase NN N
inhibitor NN N
topiroxostat NN N
was VBD N
not RB N
associated VBN N
with IN N
QT NNP N
prolongation NN N
A DT N
QT/QTc NNP N
study NN N
was VBD N
conducted VBN N
in IN N
compliance NN N
with IN N
ICH NNP N
E14 NNP N
guideline NN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
new JJ N
xanthine JJ N
oxidase NN N
inhibitor NN N
topiroxostat NN N
in IN N
Japanese JJ 4_p
healthy JJ 4_p
subjects NNS 4_p
Forty-eight JJ N
Japanese JJ N
healthy JJ N
subjects NNS N
( ( N
males NNS N
24 CD N
; : N
females NNS N
24 CD N
) ) N
received VBD N
a DT N
single JJ N
oral JJ N
dose NN N
of IN N
topiroxostat NN N
( ( N
60 CD N
or CC N
180 CD N
mg NN N
) ) N
, , N
moxifloxacin FW N
( ( N
400 CD N
mg NN N
) ) N
or CC N
placebo NN N
in IN N
a DT N
single-center JJ N
, , N
double-blind JJ N
, , N
four-period JJ N
crossover NN N
design NN N
Fridericia NNP N
's POS N
formula NN N
( ( N
QTcF NNP N
= NNP N
QT/RR NNP N
( ( N
0.33 CD N
) ) N
) ) N
was VBD N
used VBN N
as IN N
a DT N
primary JJ N
method NN N
for IN N
QT-interval JJ N
correction NN N
The DT N
mean JJ N
QTcF NNP N
was VBD N
prolonged VBN N
by IN N
moxifloxacin NN N
, , N
of IN N
which WDT N
largest JJS N
time-matched JJ N
difference NN N
from IN N
placebo JJ N
administration NN N
was VBD N
13.6 CD N
milliseconds NNS N
with IN N
90 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
of IN N
11.2 CD N
and CC N
15.9 CD N
milliseconds NNS N
at IN N
4 CD N
hours NNS N
post-dose JJ N
The DT N
mean JJ N
QTcF NNP N
was VBD N
hardly RB N
affected VBN N
by IN N
either DT N
dose NN N
of IN N
topiroxostat NN N
, , N
of IN N
which WDT N
largest JJS N
time-matched JJ N
difference NN N
from IN N
placebo JJ N
administration NN N
was VBD N
2.9 CD N
milliseconds NNS N
with IN N
90 CD N
% NN N
CI NNP N
of IN N
0.6 CD N
and CC N
5.3 CD N
milliseconds NNS N
at IN N
4 CD N
hours NNS N
post-dose JJ N
for IN N
60 CD N
mg NN N
, , N
and CC N
2.3 CD N
milliseconds NNS N
with IN N
90 CD N
% NN N
CI NNP N
of IN N
0 CD N
and CC N
4.7 CD N
milliseconds NNS N
at IN N
1 CD N
hour NN N
post-dose NN N
for IN N
180 CD N
mg NN N
The DT N
results NNS N
were VBD N
essentially RB N
the DT N
same JJ N
in IN N
the DT N
sex NN N
subgroup NN N
analysis NN N
Moxifloxacin NNP N
can MD N
be VB N
used VBN N
as IN N
a DT N
positive JJ N
control NN N
for IN N
QT/QTc NNP N
studies NNS N
in IN N
Japanese JJ N
subjects NNS N
; : N
and CC N
topiroxostat VB N
may MD N
not RB N
cause VB N
QT-interval JJ N
prolongation NN N
in IN N
males NNS N
as RB N
well RB N
as IN N
females NNS N
-DOCSTART- -X- O O 17579182

Use NNP N
of IN N
a DT N
DNAemia NNP N
cut-off NN N
for IN N
monitoring VBG N
human JJ N
cytomegalovirus NN N
infection NN N
reduces VBZ N
the DT N
number NN N
of IN N
preemptively RB N
treated VBN N
children NNS N
and CC N
young JJ N
adults NNS N
receiving VBG N
hematopoietic JJ N
stem-cell JJ N
transplantation NN N
compared VBN N
with IN N
qualitative JJ N
pp65 NN N
antigenemia NN N
We PRP N
performed VBD N
a DT N
randomized JJ N
trial NN N
comparing VBG N
the DT N
use NN N
of IN N
quantitative JJ N
DNAemia NNP N
versus NN N
positive JJ N
antigenemia NN N
for IN N
starting VBG N
preemptive JJ N
antihuman NN N
cytomegalovirus NN N
( ( N
HCMV NNP N
) ) N
therapy NN N
in IN N
hematopoietic JJ N
stem-cell JJ N
transplantation NN N
( ( N
HSCT NNP N
) ) N
recipients NNS N
In IN N
the DT N
DNAemia NNP N
arm NN N
, , N
antiviral JJ N
therapy NN N
was VBD N
initiated VBN N
on IN N
reaching VBG N
a DT N
DNAemia NNP N
cut-off NN N
of IN N
10 CD N
000 CD N
DNA NNP N
copies/mL NN N
of IN N
whole JJ N
blood NN N
, , N
whereas NNS N
in IN N
the DT N
antigenemia NN N
arm NN N
, , N
therapy NN N
was VBD N
started VBN N
in IN N
the DT N
presence NN N
of IN N
a DT N
positive JJ N
antigenemia NN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
number NN N
of IN N
patients NNS N
treated VBN N
in IN N
the DT N
2 CD N
arms NNS N
On IN N
the DT N
whole NN N
, , N
178 CD N
patients NNS N
( ( N
89 CD N
in IN N
each DT N
arm NN N
) ) N
, , N
receiving VBG N
unmanipulated JJ N
HSCT NNP N
from IN N
either CC N
a DT N
relative NN N
or CC N
an DT N
unrelated JJ N
donor NN N
, , N
completed VBD N
the DT N
study NN N
Although IN N
the DT N
incidence NN N
of IN N
HCMV NNP N
infection NN N
was VBD N
comparable JJ N
in IN N
DNAemia NNP N
and CC N
antigenemia NN N
arms NNS N
( ( N
34 CD N
% NN N
vs JJ N
42 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
= NNP N
.259 NNP N
) ) N
, , N
the DT N
number NN N
of IN N
patients NNS N
treated VBN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
DNAemia NNP N
arm NN N
( ( N
18 CD N
% NN N
vs JJ N
31 CD N
% NN N
, , N
P NNP N
= NNP N
.026 NNP N
) ) N
No DT N
patient NN N
developed VBD N
HCMV NNP N
disease NN N
The DT N
use NN N
of IN N
a DT N
DNAemia NNP N
cut-off NN N
avoids NNS N
unnecessary JJ N
antiviral JJ N
treatment NN N
-DOCSTART- -X- O O 11500608

Does VBZ N
short-term JJ N
treatment NN N
with IN N
proton NN N
pump NN N
inhibitors NNS N
cause VBP N
rebound JJ N
aggravation NN N
of IN N
symptoms NNS N
? . N
BACKGROUND NNP N
Rebound NNP N
acid VBZ N
hypersecretion NN N
might MD N
occur VB N
after IN N
treatment NN N
with IN N
proton NN N
pump NN N
inhibitors NNS N
This DT N
study NN N
looks VBZ N
for IN N
a DT N
rebound JJ N
aggravation NN N
of IN N
symptoms NNS N
after IN N
short-term JJ N
treatment NN N
with IN N
lansoprazole NN N
STUDY NNP N
Sixty-two JJ 4_p
patients NNS 4_p
( ( 4_p
19 CD 4_p
men NNS 4_p
and CC 4_p
43 CD 4_p
women NNS 4_p
; : 4_p
mean JJ 4_p
age NN 4_p
, , 4_p
54 CD 4_p
years NNS 4_p
; : 4_p
range NN 4_p
, , 4_p
32-77 CD 4_p
years NNS 4_p
) ) 4_p
with IN 4_p
heartburn NN 4_p
and CC 4_p
regurgitation NN 4_p
and CC 4_p
normal JJ 4_p
upper JJ 4_p
endoscopy NN 4_p
findings NNS 4_p
were VBD N
studied VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
with IN N
a DT N
crossover NN N
design NN N
There EX N
were VBD N
two CD N
5-day JJ N
treatment NN N
periods NNS N
with IN N
lansoprazole JJ N
60 CD N
mg NN N
once RB N
daily JJ N
or CC N
placebo NN N
in IN N
random JJ N
order NN N
, , N
separated VBN N
by IN N
a DT N
9-day JJ N
washout NN N
period NN N
Reflux NNP N
, , N
total JJ N
, , N
and CC N
antacid JJ N
scores NNS N
were VBD N
calculated VBN N
for IN N
each DT N
of IN N
the DT N
treatment NN N
periods NNS N
Higher JJR N
scores NNS N
during IN N
the DT N
placebo JJ N
period NN N
in IN N
the DT N
group NN N
given VBN N
lansoprazole VBZ N
first RB N
than IN N
in IN N
the DT N
group NN N
given VBN N
placebo VBP N
first RB N
indicated VBN N
a DT N
rebound NN N
aggravation NN N
of IN N
symptoms NNS N
RESULTS VB N
The DT N
mean JJ N
symptom NN N
scores NNS N
during IN N
the DT N
placebo JJ N
period NN N
in IN N
the DT N
groups NNS N
given VBN N
lansoprazole VBP N
first JJ N
and CC N
placebo NN N
first RB N
were VBD N
as IN N
follows VBZ N
: : N
reflux NN N
score NN N
, , N
21.5 CD N
and CC N
17.6 CD N
, , N
respectively RB N
( ( N
not RB N
significant JJ N
) ) N
; : N
total JJ N
score NN N
, , N
11.2 CD N
and CC N
10.3 CD N
, , N
respectively RB N
( ( N
not RB N
significant JJ N
) ) N
; : N
and CC N
antacid VB N
score NN N
, , N
8.2 CD N
and CC N
7.2 CD N
, , N
respectively RB N
( ( N
not RB N
significant JJ N
) ) N
CONCLUSIONS NNP N
There EX N
is VBZ N
no DT N
indication NN N
of IN N
a DT N
rebound JJ N
aggravation NN N
of IN N
symptoms NNS N
12 CD N
to TO N
14 CD N
days NNS N
after IN N
a DT N
5-day JJ N
treatment NN N
with IN N
lansoprazole JJ N
60 CD N
mg NN N
once RB N
daily JJ N
in IN N
patients NNS 4_p
with IN 4_p
reflux NN 4_p
symptoms NNS 4_p
-DOCSTART- -X- O O 18328090

Long-term JJ N
retention NN N
on IN N
treatment NN N
with IN N
lumiracoxib JJ N
100 CD N
mg NN N
once RB N
or CC N
twice RB N
daily RB N
compared VBN N
with IN N
celecoxib NN N
200 CD N
mg NN N
once RB N
daily JJ N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
in IN N
patients NNS 4_p
with IN 4_p
osteoarthritis NN 4_p
BACKGROUND IN N
The DT N
efficacy NN N
, , N
safety NN N
and CC N
tolerability NN N
of IN N
lumiracoxib NN N
, , N
a DT N
novel JJ N
selective JJ N
cyclooxygenase-2 NN N
( ( N
COX-2 NNP N
) ) N
inhibitor NN N
, , N
has VBZ N
been VBN N
demonstrated VBN N
in IN N
previous JJ N
studies NNS N
of IN N
patients NNS 1_p
with IN 1_p
osteoarthritis NN 1_p
( ( 1_p
OA NNP 1_p
) ) 1_p
As IN N
it PRP N
is VBZ N
important JJ N
to TO N
establish VB N
the DT N
long-term JJ N
safety NN N
and CC N
efficacy NN N
of IN N
treatments NNS N
for IN N
a DT N
chronic JJ N
disease NN N
such JJ N
as IN N
OA NNP N
, , N
the DT N
present JJ N
study NN N
compared VBN N
the DT N
effects NNS N
of IN N
lumiracoxib NN N
at IN N
doses NNS N
of IN N
100 CD N
mg NNS N
once RB N
daily JJ N
( ( N
o.d JJ N
) ) N
and CC N
100 CD N
mg NN N
twice RB N
daily RB N
( ( N
b.i.d NN N
) ) N
with IN N
those DT N
of IN N
celecoxib JJ N
200 CD N
mg NN N
o.d NN N
on IN N
retention NN N
on IN N
treatment NN N
over IN N
1 CD N
year NN N
METHODS NNP N
In IN N
this DT N
52-week JJ N
, , N
multicentre NN N
, , N
randomised VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
study NN N
, , N
male NN N
and CC N
female JJ N
patients NNS N
( ( N
aged VBN N
at IN N
least JJS N
40 CD N
years NNS N
) ) N
with IN N
symptomatic JJ N
primary JJ N
OA NNP N
of IN N
the DT N
hip NN N
, , N
knee NN N
, , N
hand NN N
or CC N
spine NN N
were VBD N
randomised VBN N
( ( N
1:2:1 CD N
) ) N
to TO N
lumiracoxib VB N
100 CD N
mg NN N
o.d NN N
( ( N
n JJ N
= NNP N
755 CD N
) ) N
, , N
lumiracoxib $ N
100 CD N
mg NN N
b.i.d NN N
( ( N
n JJ N
= NNP N
1,519 CD N
) ) N
or CC N
celecoxib $ N
200 CD N
mg NN N
o.d NN N
( ( N
n JJ N
= NNP N
758 CD N
) ) N
The DT N
primary JJ N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
demonstrate VB N
non-inferiority NN N
of IN N
lumiracoxib NN N
at IN N
either CC N
dose VB N
compared VBN N
with IN N
celecoxib NN N
200 CD N
mg NN N
o.d NN N
with IN N
respect NN N
to TO N
the DT N
1-year JJ N
retention NN N
on IN N
treatment NN N
rate NN N
Secondary JJ N
outcome NN N
variables NNS N
included VBD N
OA NNP N
pain NN N
in IN N
the DT N
target NN N
joint NN N
, , N
patient NN N
's POS N
and CC N
physician NN N
's POS N
global JJ N
assessments NNS N
of IN N
disease NN N
activity NN N
, , N
Short NNP N
Arthritis NNP N
assessment JJ N
Scale NNP N
( ( N
SAS NNP N
) ) N
total NN N
score NN N
, , N
rescue NN N
medication NN N
use NN N
, , N
and CC N
safety NN N
and CC N
tolerability NN N
RESULTS JJ N
Retention NN N
rates NNS N
at IN N
1 CD N
year NN N
were VBD N
similar JJ N
for IN N
the DT N
lumiracoxib NN N
100 CD N
mg NN N
o.d. NN N
, , N
lumiracoxib VBZ N
100 CD N
mg NN N
b.i.d NN N
and CC N
celecoxib JJ N
200 CD N
mg NN N
o.d NN N
groups NNS N
( ( N
46.9 CD N
% NN N
vs JJ N
47.5 CD N
% NN N
vs JJ N
45.3 CD N
% NN N
, , N
respectively RB N
) ) N
It PRP N
was VBD N
demonstrated VBN N
that IN N
retention NN N
on IN N
treatment NN N
with IN N
lumiracoxib NN N
at IN N
either CC N
dose VB N
was VBD N
non-inferior JJ N
to TO N
celecoxib VB N
200 CD N
mg NN N
o.d NN N
Similarly RB N
, , N
Kaplan-Meier NNP N
curves VBZ N
for IN N
the DT N
probability NN N
of IN N
premature JJ N
discontinuation NN N
from IN N
the DT N
study NN N
for IN N
any DT N
reason NN N
were VBD N
similar JJ N
across IN N
the DT N
treatment NN N
groups NNS N
All DT N
three CD N
treatments NNS N
generally RB N
yielded VBN N
comparable JJ N
results NNS N
for IN N
the DT N
secondary JJ N
efficacy NN N
variables NNS N
and CC N
all DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN N
CONCLUSION NNP N
Long-term JJ N
treatment NN N
with IN N
lumiracoxib JJ N
100 CD N
mg NN N
o.d. NN N
, , N
the DT N
recommended VBN N
dose NN N
for IN N
OA NNP N
, , N
was VBD N
as IN N
effective JJ N
and CC N
well RB N
tolerated VBN N
as IN N
celecoxib NN N
200 CD N
mg NN N
o.d NN N
in IN N
patients NNS N
with IN N
OA NNP N
TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
NCT00145301 NNP N
-DOCSTART- -X- O O 18606053

Dexamethasone NN N
phosphate NN N
in IN N
antibiotic JJ N
ear NN N
drops NNS N
for IN N
the DT N
treatment NN N
of IN N
acute JJ 4_p
bacterial JJ 4_p
otitis NN 4_p
externa NN 4_p
OBJECTIVES NNP N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
polymyxin NN N
sulfate NN N
7500 CD N
IU/neomycin NNP N
sulfate NN N
3500 CD N
IU/dexamethasone NNP N
phosphate VB N
0.1 CD N
% NN N
( ( N
PN+Dx NNP N
) ) N
otic JJ N
solution NN N
with IN N
polymyxin NN N
sulfate NN N
7500 CD N
IU/neomycin NNP N
sulfate NN N
3500 CD N
IU NNP N
( ( N
PN-Dx NNP N
) ) N
in IN N
patients NNS 4_p
with IN 4_p
acute JJ 4_p
bacterial JJ 4_p
otitis NN 4_p
externa NN 4_p
( ( 4_p
AOE NNP 4_p
) ) 4_p
, , N
in IN N
order NN N
to TO N
determine VB N
the DT N
possible JJ N
benefit NN N
of IN N
the DT N
addition NN N
of IN N
dexamethasone NN N
RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Active NNP N
controlled VBD N
, , N
double-blind NN N
, , N
randomized VBN N
, , N
parallel JJ N
group NN N
, , N
multi-center JJ 4_p
clinical JJ 4_p
trial NN 4_p
in IN 4_p
ear NN 4_p
, , 4_p
nose RB 4_p
, , 4_p
and CC 4_p
throat NN 4_p
( ( 4_p
ENT NNP 4_p
) ) 4_p
specialist NN 4_p
practices NNS 4_p
with IN N
a DT N
planned VBN N
interim NN N
analysis NN N
for IN N
sample JJ N
size NN N
adaptation NN N
In IN N
total JJ N
, , N
338 CD 3_p
patients NNS N
aged VBN 1_p
18-76 NNS 1_p
who WP N
had VBD N
a DT N
previous JJ N
episode NN 4_p
of IN 4_p
otitis NN 4_p
externa NN 4_p
within IN N
the DT N
last JJ N
year NN N
were VBD N
randomized VBN N
to TO N
receive VB N
10 CD N
+/- JJ N
2 CD N
days NNS N
of IN N
treatment NN N
with IN N
two CD N
drops NNS N
, , N
three CD N
times NNS N
daily RB N
, , N
of IN N
either DT N
PN+Dx NNP N
or CC N
PN-Dx NNP N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Change NNP N
in IN N
the DT N
clinical JJ N
symptom NN N
score NN N
( ( N
consisting VBG N
of IN N
the DT N
subscores NNS N
redness NN N
, , N
swelling VBG N
, , N
pain NN N
, , N
and CC N
secretion NN N
) ) N
and CC N
of IN N
the DT N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
rating NN N
for IN N
pain NN N
from IN N
Visit NNP N
1 CD N
( ( N
Day NNP N
1 CD N
) ) N
to TO N
Visit VB N
2 CD N
( ( N
Day NNP N
4 CD N
+/- JJ N
1 CD N
) ) N
, , N
patient NN N
's POS N
assessment NN N
of IN N
efficacy NN N
at IN N
Visit NNP N
3 CD N
( ( N
Day NNP N
10 CD N
+/- JJ N
2 CD N
) ) N
, , N
and CC N
the DT N
frequency NN N
and CC N
type NN N
of IN N
adverse JJ N
events NNS N
RESULTS NNP N
There EX N
was VBD N
a DT N
significantly RB N
greater JJR N
reduction NN N
of IN N
swelling VBG N
from IN N
Visit NNP N
1 CD N
to TO N
Visit VB N
2 CD N
with IN N
PN+Dx NNP N
, , N
and CC N
more JJR N
patients NNS N
rated VBD N
the DT N
efficacy NN N
of IN N
PN+Dx NNP N
as IN N
'very RB N
good JJ N
' '' N
or CC N
'good POS N
' '' N
at IN N
Visit NNP N
3 CD N
( ( N
p NN N
= RB N
0.03 CD N
) ) N
There EX N
was VBD N
also RB N
a DT N
significantly RB N
greater JJR N
decrease NN N
in IN N
the DT N
clinical JJ N
symptom NN N
score NN N
from IN N
Visit NNP N
1 CD N
to TO N
Visit VB N
2 CD N
in IN N
the DT N
PN+Dx NNP N
group NN N
in IN N
patients NNS N
who WP N
had VBD N
at IN N
least JJS N
a DT N
moderately RB N
severe JJ N
symptom NN N
score NN N
with IN N
more JJR N
than IN N
seven CD N
points NNS N
at IN N
Visit NNP N
1 CD N
( ( N
p NN N
= RB N
0.01 CD N
) ) N
and CC N
in IN N
patients NNS N
suffering VBG N
from IN N
their PRP$ N
current JJ N
episode NN N
of IN N
otitis NN N
externa NN N
for IN N
more JJR N
than IN N
2 CD N
days NNS N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
In IN N
total JJ N
, , N
14 CD N
adverse JJ N
events NNS N
were VBD N
reported VBN N
during IN N
the DT N
study NN N
period NN N
with IN N
no DT N
related JJ N
adverse JJ N
drug NN N
reactions NNS N
for IN N
PN+Dx NNP N
CONCLUSIONS NNP N
The DT N
addition NN N
of IN N
dexamethasone NN N
phosphate NN N
to TO N
polymyxin VB N
B/neomycin NNP N
significantly RB N
reduces VBZ N
swelling VBG N
in IN N
patients NNS 4_p
with IN 4_p
AOE NNP 4_p
and CC N
leads VBZ N
to TO N
significantly RB N
higher JJR N
patient NN N
's POS N
ratings NNS N
of IN N
treatment NN N
efficacy NN N
It PRP N
especially RB N
leads VBZ N
to TO N
an DT N
overall JJ N
reduction NN N
of IN N
symptoms NNS N
in IN N
cases NNS N
of IN N
moderately RB N
or CC N
more JJR N
severe JJ N
otitis NN N
externa NN N
and CC N
cases NNS N
lasting VBG N
for IN N
more JJR N
than IN N
2 CD N
days NNS N
-DOCSTART- -X- O O 11234566

Phase-dependent JJ N
modulation NN N
of IN N
the DT N
soleus JJ N
H-reflex NNP N
during IN N
rhythmical JJ N
arm NN 4_p
swing NN 4_p
in IN N
humans NNS N
The DT N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
investigate VB N
modulation NN N
of IN N
the DT N
soleus JJ N
H-reflex NNP N
during IN N
rhythmic JJ N
arm NN 4_p
swing NN 4_p
in IN N
humans NNS N
Significant JJ N
depression NN N
of IN N
the DT N
soleus JJ N
H-reflex NNP N
was VBD N
observed VBN N
when WRB N
subjects NNS N
swung VBP N
their PRP$ N
ipsilateral JJ 4_p
arms NNS N
or CC N
both DT N
arms NNS N
reciprocally RB N
during IN N
testing VBG N
The DT N
degree NN N
of IN N
soleus JJ N
H-reflex NNP N
depression NN N
appeared VBD N
directly RB N
proportional JJ N
to TO N
the DT N
speed NN N
of IN N
the DT N
arm NN N
swing NN N
This DT N
depression NN N
was VBD N
observed VBN N
in IN N
the DT N
conditioning-testing JJ N
intervals NNS N
of IN N
400 CD N
, , N
500 CD N
, , N
and CC N
600 CD N
msec NN N
during IN N
the DT N
ipsilateral JJ N
backward NN N
arm NN N
swing NN N
and CC N
at IN N
the DT N
onset NN N
of IN N
the DT N
ipsilateral JJ N
arm NN N
forward NN N
swing NN N
This DT N
phase NN N
of IN N
depression NN N
partially RB N
overlapped VBD N
the DT N
phase NN N
of IN N
depression NN N
of IN N
the DT N
soleus JJ N
H-reflex NNP N
during IN N
walking VBG N
However RB N
, , N
the DT N
pattern NN N
of IN N
modulation NN N
during IN N
arm NN N
swing NN N
was VBD N
not RB N
exactly RB N
the DT N
same JJ N
as IN N
that DT N
during IN N
walking VBG N
Therefore RB N
, , N
we PRP N
concluded VBD N
that IN N
the DT N
ipsilateral JJ N
arm NN N
swing NN N
may MD N
partially RB N
affect VB N
the DT N
depression NN N
of IN N
the DT N
soleus JJ N
H-reflex NNP N
during IN N
the DT N
arm NN N
swing NN N
phase NN N
of IN N
walking VBG N
but CC N
is VBZ N
not RB N
responsible JJ N
for IN N
depression NN N
of IN N
the DT N
soleus NN N
H-reflex NNP N
throughout IN N
the DT N
entire JJ N
walking NN N
cycle NN N
-DOCSTART- -X- O O 12033348

Lack NN N
of IN N
benefit NN N
of IN N
an DT N
active JJ N
pectoral JJ N
pulse NN N
generator NN N
on IN N
atrial JJ N
defibrillation NN N
thresholds NNS N
INTRODUCTION NNP N
Atrial NNP N
defibrillation NN N
can MD N
be VB N
achieved VBN N
with IN N
standard JJ N
implantable JJ N
cardioverter NN N
defibrillator NN N
leads VBZ N
, , N
which WDT N
has VBZ N
led VBN N
to TO N
the DT N
development NN N
of IN N
combined JJ N
atrial JJ N
and CC N
ventricular JJ N
devices NNS N
For IN N
ventricular JJ N
defibrillation NN N
, , N
use NN N
of IN N
an DT N
active JJ N
pectoral JJ N
electrode NN N
( ( N
active JJ N
can MD N
) ) N
in IN N
the DT N
shocking VBG N
pathway RB N
markedly RB N
reduces VBZ N
defibrillation NN N
thresholds NNS N
( ( N
DFTs NNP N
) ) N
However RB N
, , N
the DT N
effect NN N
of IN N
an DT N
active JJ N
pectoral NN N
can MD N
on IN N
atrial JJ N
defibrillation NN N
is VBZ N
unknown JJ N
METHODS NNP N
AND CC N
RESULTS NNP N
This DT N
study NN N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
paired VBD N
comparison NN N
of IN N
two CD N
shock NN N
configurations NNS N
on IN N
atrial JJ N
DFTs NNP N
in IN N
33 CD N
patients NNS N
The DT N
lead NN N
system NN N
evaluated VBD N
was VBD N
a DT N
dual-coil JJ N
transvenous JJ N
defibrillation NN N
lead NN N
with IN N
a DT N
left JJ N
pectoral JJ N
pulse NN N
generator NN N
emulator NN N
Shocks NNS N
were VBD N
delivered VBN N
either RB N
between IN N
the DT N
right JJ N
ventricular NN N
coil NN N
and CC N
proximal JJ N
atrial JJ N
coil NN N
( ( N
lead JJ N
) ) N
or CC N
between IN N
the DT N
right JJ N
ventricular NN N
coil NN N
and CC N
an DT N
active JJ N
can MD N
in IN N
common JJ N
with IN N
the DT N
atrial JJ N
coil NN N
( ( N
active JJ N
can MD N
) ) N
Delivered VBN N
energy NN N
at IN N
DFT NNP N
was VBD N
4.2 CD N
+/- JJ N
4.1 CD N
J NNP N
in IN N
the DT N
lead NN N
configuration NN N
and CC N
5.0 CD N
+/- JJ N
3.7 CD N
J NNP N
in IN N
the DT N
active JJ N
can MD N
configuration NN N
( ( N
P NNP N
= NNP N
NS NNP N
) ) N
Peak NNP N
current JJ N
was VBD N
32 CD N
% NN N
higher JJR N
with IN N
an DT N
active JJ N
can MD N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
whereas JJ N
shock NN N
impedance NN N
was VBD N
18 CD N
% NN N
lower JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
Moreover RB N
, , N
a DT N
low JJ N
threshold NN N
( ( N
< CD N
or CC N
= VB N
3 CD N
J NNP N
) ) N
was VBD N
observed VBN N
in IN N
61 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
lead JJ N
configuration NN N
but CC N
in IN N
only RB N
36 CD N
% NN N
in IN N
the DT N
active JJ N
can MD N
configuration NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
There EX N
were VBD N
no DT N
clinical JJ N
predictors NNS N
of IN N
the DT N
atrial JJ N
DFT NNP N
CONCLUSION NNP N
These DT N
results NNS N
indicate VBP N
that IN N
low JJ N
atrial JJ N
DFTs NN N
can MD N
be VB N
achieved VBN N
using VBG N
a DT N
transvenous JJ N
ventricular JJ N
defibrillation NN N
lead NN N
Because IN N
no DT N
benefit NN N
was VBD N
observed VBN N
with IN N
the DT N
use NN N
of IN N
an DT N
active JJ N
pectoral JJ N
electrode NN N
for IN N
atrial JJ N
defibrillation NN N
, , N
programmable JJ N
shock NN N
vectors NNS N
may MD N
be VB N
useful JJ N
for IN N
dual-chamber JJ N
implantable JJ N
cardioverter NN N
defibrillators NNS N
-DOCSTART- -X- O O 3341795

Topical JJ N
fibronectin NN N
therapy NN N
for IN N
treatment NN N
of IN N
a DT N
patient NN N
with IN N
chronic JJ 4_p
stasis NN 4_p
ulcers NNS 4_p
-DOCSTART- -X- O O 1553169

Use NNP N
of IN N
Interceed NNP N
( ( N
TC7 NNP N
) ) N
absorbable JJ N
adhesion NN N
barrier NN N
to TO N
reduce VB N
postoperative JJ N
adhesion NN N
reformation NN N
in IN N
infertility NN 4_p
and CC N
endometriosis NN 4_p
surgery NN N
The DT N
Obstetrics NNPS N
and CC N
Gynecology NNP N
Adhesion NNP N
Prevention NNP N
Committee NNP N
Interceed NNP N
( ( N
TC7 NNP N
) ) N
is VBZ N
a DT N
fabric NN N
composed VBN N
of IN N
oxidized JJ N
, , N
regenerated VBD N
cellulose NN N
that WDT N
was VBD N
designed VBN N
to TO N
reduce VB N
the DT N
formation NN N
of IN N
postsurgical JJ N
adhesions NNS N
We PRP N
evaluated VBD N
Interceed NNP N
( ( N
TC7 NNP N
) ) N
in IN N
a DT N
randomized JJ N
, , N
multicenter RB N
clinical JJ N
study NN N
Sixty-three JJ 3_p
infertility NN 4_p
patients NNS N
had VBD N
bilateral JJ N
pelvic JJ N
sidewall NN N
adhesions NNS N
removed VBD N
at IN N
laparotomy NN N
One CD N
pelvic NN N
sidewall NN N
was VBD N
covered VBN N
by IN N
Interceed NNP N
( ( N
TC7 NNP N
) ) N
and CC N
the DT N
other JJ N
was VBD N
left VBN N
uncovered JJ N
The DT N
deperitonealized JJ N
areas NNS N
( ( N
N NNP N
= NNP N
205 CD N
) ) N
of IN N
all DT N
sidewalls NNS N
were VBD N
divided VBN N
into IN N
three CD N
groups NNS N
: : N
less JJR N
than IN N
100 CD N
mm2 NN N
, , N
N NNP N
= NNP N
72 CD N
; : N
100-1000 CD N
mm2 NN N
, , N
N NNP N
= NNP N
95 CD N
; : N
and CC N
more JJR N
than IN N
1000 CD N
mm2 NN N
, , N
N NNP N
= VBZ N
38 CD N
The DT N
effectiveness NN N
of IN N
Interceed NNP N
( ( N
TC7 NNP N
) ) N
was VBD N
evaluated VBN N
at IN N
laparoscopy JJ N
10-98 JJ N
days NNS N
after IN N
laparotomy NN N
Significantly RB N
more JJR N
adhesions NNS N
were VBD N
observed VBN N
at IN N
laparoscopy NN N
on IN N
the DT N
control NN N
pelvic JJ N
sidewalls NNS N
( ( N
48 CD N
of IN N
63 CD N
, , N
76 CD N
% NN N
) ) N
than IN N
on IN N
the DT N
treated VBN N
sides NNS N
( ( N
26 CD N
of IN N
63 CD N
, , N
41 CD N
% NN N
) ) N
( ( N
P NNP N
less JJR N
than IN N
.0001 NN N
) ) N
The DT N
Interceed NNP N
( ( N
TC7 NNP N
) ) N
-treated VBD N
sidewalls NNS N
also RB N
had VBD N
significantly RB N
less RBR N
area NN N
involved VBN N
with IN N
adhesions NNS N
at IN N
laparoscopy NN N
( ( N
P NNP N
less JJR N
than IN N
.05 NN N
, , N
P NNP N
less JJR N
than IN N
.001 NN N
, , N
and CC N
P NNP N
less JJR N
than IN N
.001 NN N
in IN N
the DT N
three CD N
groups NNS N
, , N
respectively RB N
) ) N
Twenty-eight JJ N
women NNS N
with IN N
severe JJ N
endometriosis NN N
also RB N
had VBD N
significantly RB N
more JJR N
adhesions NNS N
on IN N
the DT N
control NN N
side NN N
( ( N
23 CD N
of IN N
28 CD N
, , N
82 CD N
% NN N
) ) N
than IN N
on IN N
the DT N
treated JJ N
side NN N
( ( N
14 CD N
of IN N
28 CD N
, , N
50 CD N
% NN N
) ) N
( ( N
P NNP N
less JJR N
than IN N
.05 NN N
) ) N
We PRP N
conclude VBP N
that DT N
Interceed NNP N
( ( N
TC7 NNP N
) ) N
effectively RB N
reduced VBD N
the DT N
incidence NN N
and CC N
extent NN N
of IN N
postoperative JJ N
adhesions NNS N
, , N
even RB N
in IN N
patients NNS N
with IN N
severe JJ N
endometriosis NN N
-DOCSTART- -X- O O 20394631

The DT N
pulsed-dye JJ N
laser NN N
as IN N
an DT N
adjuvant JJ N
treatment NN N
modality NN N
in IN N
acne JJ N
vulgaris NN N
: : N
a DT N
randomized JJ N
controlled VBN N
single-blinded JJ N
trial NN N
BACKGROUND NNP N
Acne NNP N
vulgaris NN N
is VBZ N
the DT N
most RBS N
common JJ N
skin NN N
disease NN N
and CC N
can MD N
pose VB N
a DT N
substantial JJ N
therapeutic JJ N
challenge NN N
Recently RB N
, , N
several JJ N
phototherapeutic JJ N
modalities NNS N
, , N
most JJS N
notably RB N
pulsed-dye JJ N
laser NN N
( ( N
PDL NNP N
) ) N
treatment NN N
, , N
have VBP N
been VBN N
introduced VBN N
, , N
but CC N
the DT N
published VBN N
results NNS N
- : N
albeit IN N
promising VBG N
- : N
are VBP N
controversial JJ N
OBJECTIVES NNP N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
an DT N
adjuvant JJ N
PDL NNP N
treatment NN N
when WRB N
combined VBN N
with IN N
a DT N
proven JJ N
topical JJ N
treatment NN N
[ JJ N
fixed-combination NN N
clindamycin NN N
1 CD N
% NN N
-benzoyl NNP N
peroxide RB N
5 CD N
% NN N
hydrating VBG N
gel NN N
( ( N
C/BPO NNP N
) ) N
] NN N
METHODS NNP N
Eighty NNP 3_p
patients NNS N
( ( N
38 CD 3_p
males NNS 4_p
and CC N
42 CD 3_p
females NNS 4_p
, , N
mean JJ 1_p
+/- JJ 1_p
SD NNP 1_p
age NN 1_p
19.7 CD 1_p
+/- JJ 1_p
5.9 CD 1_p
years NNS 1_p
) ) 1_p
were VBD N
randomized VBN N
in IN N
a DT N
1 CD N
: : N
2 CD N
ratio NN N
to TO N
receive VB N
C/BPO NNP N
alone RB N
or CC N
in IN N
combination NN N
with IN N
PDL NNP N
treatment NN N
( ( N
wavelength JJ N
585 CD N
nm NN N
, , N
energy NN N
fluence NN N
3 CD N
J NNP N
cm NN N
( ( N
-2 NNP N
) ) N
, , N
pulse JJ N
duration NN N
0.35 CD N
ms NN N
, , N
spot NN N
size NN N
7 CD N
mm NN N
) ) N
Patients NNS N
were VBD N
evaluated VBN N
at IN N
baseline NN N
and CC N
at IN N
2 CD N
and CC N
4 CD N
weeks NNS N
after IN N
initial JJ N
treatment NN N
The DT N
primary JJ N
end NN N
points NNS N
were VBD N
the DT N
Investigator NNP N
's POS N
Static JJ N
Global NNP N
Assessment NNP N
( ( N
ISGA NNP N
) ) N
score NN N
and CC N
lesion NN N
count NN N
; : N
the DT N
secondary JJ N
end NN N
point NN N
was VBD N
the DT N
Dermatology NNP N
Life NNP N
Quality NNP N
Index NNP N
( ( N
DLQI NNP N
) ) N
RESULTS NNP N
Both NNP N
groups NNS N
showed VBD N
a DT N
significant JJ N
improvement NN N
during IN N
observation NN N
[ NNP N
ISGA NNP N
27.1 CD N
% NN N
( ( N
C/BPO NNP N
) ) N
and CC N
24.6 CD N
% NN N
( ( N
C/BPO NNP N
+ NNP N
laser NN N
) ) N
, , N
total JJ N
lesion NN N
count NN N
9.2 CD N
% NN N
and CC N
9.0 CD N
% NN N
, , N
inflammatory JJ N
lesion NN N
count NN N
36.3 CD N
% NN N
and CC N
36.9 CD N
% NN N
, , N
DLQI NNP N
54.5 CD N
% NN N
and CC N
42.5 CD N
% NN N
] NN N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
or CC N
otherwise RB N
appreciable JJ N
difference NN N
between IN N
treatment NN N
modalities NNS N
as RB N
far RB N
as IN N
the DT N
extent NN N
of IN N
improvement NN N
was VBD N
concerned VBN N
Patients NNS N
with IN N
more RBR N
severe JJ N
findings NNS N
at IN N
baseline NN N
had VBD N
a DT N
greater JJR N
benefit NN N
from IN N
either CC N
therapy JJ N
regimen NNS N
CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
do VBP N
not RB N
support VB N
the DT N
concept NN N
of IN N
a DT N
substantial JJ N
benefit NN N
of IN N
PDL NNP N
treatment NN N
in IN N
acne JJ N
vulgaris NN N
-DOCSTART- -X- O O 18676757

Combination NNP N
chemotherapy NN N
and CC N
ALVAC-CEA/B7.1 NNP N
vaccine NN N
in IN N
patients NNS N
with IN N
metastatic JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
PURPOSE VB N
The DT N
combination NN N
of IN N
vaccines NNS N
and CC N
chemotherapy NN N
holds VBZ N
promise NN N
for IN N
cancer NN N
therapy NN N
, , N
but CC N
the DT N
effect NN N
of IN N
cytotoxic NN N
chemotherapy NN N
on IN N
vaccine-induced JJ N
antitumor NN N
immunity NN N
is VBZ N
unknown JJ N
This DT N
study NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
systemic JJ N
chemotherapy NN N
on IN N
ALVAC-CEA/B7.1-induced NNP N
T-cell NNP N
immunity NN N
in IN N
patients NNS N
with IN N
metastatic JJ N
colorectal JJ N
cancer NN N
EXPERIMENTAL NNP N
DESIGN NNP N
Patients NNPS N
with IN N
metastatic JJ N
colorectal JJ N
cancer NN N
were VBD N
treated VBN N
with IN N
fluorouracil NN N
, , N
leucovorin NN N
, , N
and CC N
irinotecan JJ N
and CC N
were VBD N
also RB N
given VBN N
ALVAC-CEA/B7.1 NNP N
vaccine NN N
with IN N
or CC N
without IN N
tetanus JJ N
toxoid NN N
adjuvant NN N
Eligible JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
ALVAC NNP N
followed VBN N
by IN N
chemotherapy NN N
and CC N
booster NN N
vaccination NN N
( ( N
group NN N
1 CD N
) ) N
, , N
ALVAC NNP N
and CC N
tetanus NN N
toxoid NN N
followed VBN N
by IN N
chemotherapy NN N
( ( N
group NN N
2 CD N
) ) N
, , N
or CC N
chemotherapy VB N
alone RB N
followed VBN N
by IN N
ALVAC NNP N
in IN N
patients NNS N
without IN N
disease JJ N
progression NN N
( ( N
group NN N
3 CD N
) ) N
Humoral NNP N
immune JJ N
responses NNS N
were VBD N
measured VBN N
by IN N
standard JJ N
ELISA NNP N
assay NN N
, , N
and CC N
carcinoembryonic JJ N
antigen NN N
( ( N
CEA NNP N
) ) N
-specific VBD N
T-cell NNP N
responses NNS N
were VBD N
measured VBN N
by IN N
IFN-gamma NNP N
enzyme-linked JJ N
immunospot NN N
assay NN N
RESULTS NNP N
One CD 3_p
hundred VBD 3_p
eighteen JJ 3_p
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
ALVAC NNP N
before IN N
and CC N
concomitantly RB N
with IN N
chemotherapy NN N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
, , N
ALVAC NNP N
with IN N
tetanus NN N
adjuvant NN N
before IN N
and CC N
concomitantly RB N
with IN N
chemotherapy NN N
( ( N
n JJ N
= NNP N
40 CD N
) ) N
, , N
or CC N
chemotherapy NN N
followed VBN N
by IN N
ALVAC NNP N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
Serious JJ N
adverse JJ N
events NNS N
were VBD N
largely RB N
gastrointestinal JJ N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
and CC N
hematologic $ N
( ( N
n JJ N
= NNP N
24 CD N
) ) N
Overall JJ N
, , N
42 CD N
patients NNS N
( ( N
40.4 CD N
% NN N
) ) N
showed VBD N
objective JJ N
clinical JJ N
responses NNS N
All DT N
patients NNS N
developed VBD N
antibody JJ N
responses NNS N
against IN N
ALVAC NNP N
, , N
but CC N
increased VBD N
anti-CEA JJ N
antibody NN N
titers NNS N
were VBD N
detected VBN N
in IN N
only RB N
three CD N
patients NNS N
Increases NNS N
in IN N
CEA-specific NNP N
T NNP N
cells NNS N
were VBD N
detected VBN N
in IN N
50 CD N
% NN N
, , N
37 CD N
% NN N
, , N
and CC N
30 CD N
% NN N
of IN N
patients NNS N
in IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
, , N
respectively RB N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
clinical JJ N
or CC N
immune JJ N
responses NNS N
between IN N
the DT N
treatment NN N
groups NNS N
CONCLUSION NNP N
The DT N
combination NN N
of IN N
ALVAC-CEA/B7.1 NNP N
vaccine NN N
and CC N
systemic JJ N
chemotherapy NN N
has VBZ N
an DT N
acceptable JJ N
safety NN N
profile NN N
in IN N
patients NNS N
with IN N
metastatic JJ N
colorectal JJ N
cancer NN N
Systemic NNP N
chemotherapy NN N
did VBD N
not RB N
affect VB N
the DT N
generation NN N
of IN N
CEA-specific NNP N
T-cell NNP N
responses NNS N
following VBG N
vaccination NN N
-DOCSTART- -X- O O 20484002

Efficacy NN N
of IN N
TeachTown NNP N
: : N
Basics NNS N
computer-assisted JJ N
intervention NN N
for IN N
the DT N
Intensive NNP N
Comprehensive NNP N
Autism NNP N
Program NNP N
in IN N
Los NNP N
Angeles NNP N
Unified NNP N
School NNP N
District NNP N
Computer NNP N
Assisted NNP N
Instruction NNP N
( ( N
CAI NNP N
) ) N
has VBZ N
shown VBN N
increased VBN N
popularity NN N
recently RB N
and CC N
there EX N
are VBP N
many JJ N
studies NNS N
showing VBG N
promise NN N
for IN N
this DT N
approach NN N
for IN N
children NNS 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorders NNP 4_p
( ( N
ASD NNP 4_p
) ) N
However RB N
, , N
there EX N
are VBP N
no DT N
between-subject JJ N
studies NNS N
to TO N
date NN N
assessing VBG N
the DT N
efficacy NN N
of IN N
CAI NNP N
with IN N
this DT N
population NN N
In IN N
this DT N
study NN N
, , N
47 CD 3_p
preschool NN 1_p
and CC 1_p
K-1 JJ 1_p
students NNS 1_p
in IN N
ASD NNP 4_p
classrooms NNS N
participated VBD N
from IN N
Los NNP N
Angeles NNP N
Unified NNP N
School NNP N
District NNP N
TeachTown NN N
: : N
Basics NNS N
, , N
a DT N
CAI NNP N
program NN N
which WDT N
also RB N
includes VBZ N
supplementary JJ N
off-computer NN N
activities NNS N
, , N
was VBD N
implemented VBN N
over IN N
3 CD N
months NNS N
for IN N
approximately RB N
20 CD N
minutes NNS N
per IN N
day NN N
on IN N
the DT N
computer NN N
and CC N
20 CD N
minutes NNS N
per IN N
day NN N
in IN N
supplementary JJ N
TeachTown NN N
: : N
Basics JJ N
activities NNS N
Compared VBN N
to TO N
the DT N
students NNS N
in IN N
the DT N
control NN N
group NN N
, , N
the DT N
TeachTown NNP N
: : N
Basics NNS N
students NNS N
showed VBD N
more RBR N
improvement NN N
overall JJ N
on IN N
language NN N
and CC N
cognitive JJ N
outcome NN N
measures NNS N
In IN N
addition NN N
, , N
students NNS N
who WP N
used VBD N
TeachTown NNP N
: : N
Basics NNS N
demonstrated VBD N
significant JJ N
progress NN N
overall NN N
in IN N
the DT N
software NN N
and CC N
those DT N
students NNS N
who WP N
used VBD N
the DT N
program NN N
for IN N
more JJR N
time NN N
demonstrated VBD N
larger JJR N
gains NNS N
within IN N
the DT N
software NN N
and CC N
in IN N
outcome JJ N
measures NNS N
Although IN N
not RB N
conclusive JJ N
, , N
these DT N
findings NNS N
offer VBP N
possibilities NNS N
for IN N
the DT N
use NN N
of IN N
CAI NNP N
for IN N
remediating VBG N
many JJ N
deficits NNS N
for IN N
children NNS N
with IN N
ASD NNP 4_p
and CC N
other JJ N
special JJ 4_p
needs NNS 4_p
In IN N
addition NN N
, , N
CAI NNP N
may MD N
offer VB N
solutions NNS N
to TO N
schools NNS N
and CC N
parents NNS N
with IN N
insufficient JJ N
funds NNS N
for IN N
more RBR N
expensive JJ N
treatments NNS N
-DOCSTART- -X- O O 24107284

Enhanced NNP N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
and CC N
inflammatory JJ N
cytokine NN N
removal NN N
with IN N
online JJ N
hemodiafiltration NN N
over IN N
high-flux JJ N
hemodialysis NN N
in IN N
sepsis-related JJ N
acute JJ N
kidney NN N
injury NN N
patients NNS N
Hypercytokinemia NNP N
plays VBZ N
a DT N
central JJ N
role NN N
in IN N
pathogenesis NN N
and CC N
is VBZ N
related VBN N
to TO N
the DT N
high JJ N
mortality NN N
in IN N
sepsis-related JJ N
acute JJ N
kidney NN N
injury NN N
( ( N
AKI NNP N
) ) N
Besides IN N
the DT N
established VBN N
cytokines NNS N
, , N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
is VBZ N
demonstrated VBN N
as IN N
an DT N
important JJ N
factor NN N
in IN N
enhancing VBG N
vascular JJ N
leakage NN N
in IN N
sepsis NN N
This DT N
prospective JJ N
randomized JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
cytokine NN N
removal NN N
between IN N
online JJ N
hemodiafiltration NN N
( ( N
HDF NNP N
) ) N
, , N
which WDT N
combines VBZ N
convective NN N
and CC N
diffusive JJ N
solute NN N
removal NN N
, , N
and CC N
high-flux JJ N
hemodialysis NN N
( ( N
HD NNP N
) ) N
Twenty-eight JJ N
sepsis-related JJ N
AKI NNP N
patients NNS N
were VBD N
included VBN N
and CC N
randomized VBN N
into IN N
online JJ N
HDF NNP N
and CC N
high-flux JJ N
HD NNP N
The DT N
percentages NNS N
of IN N
the DT N
reduction NN N
ratio NN N
in IN N
plasma JJ N
cytokines NNS N
were VBD N
measured VBN N
as IN N
primary JJ N
outcomes NNS N
Other JJ N
clinical JJ N
parameters NNS N
were VBD N
determined VBN N
as IN N
secondary JJ N
outcomes NNS N
When WRB N
compared VBN N
with IN N
high-flux JJ N
HD NNP N
, , N
online JJ N
HDF NNP N
provided VBD N
significantly RB N
greater JJR N
percentages NNS N
of IN N
the DT N
reduction NN N
ratio NN N
in IN N
plasma JJ N
cytokine NN N
levels NNS N
, , N
including VBG N
VEGF NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
IL-6 NNP N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
IL-8 NNP N
( ( N
P NNP N
= NNP N
0.021 CD N
) ) N
, , N
IL-10 NNP N
( ( N
P NNP N
= NNP N
0.011 CD N
) ) N
, , N
and CC N
tumor NN N
necrosis NN N
factor-α NN N
( ( N
P NNP N
= NNP N
0.029 CD N
) ) N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
intradialytic JJ N
blood NN N
pressures NNS N
Online NNP N
HDF NNP N
revealed VBD N
better RBR N
renal JJ N
recovery NN N
and CC N
shorter JJR N
length NN N
of IN N
hospitalization NN N
than IN N
high-flux JJ N
HD NNP N
In IN N
conclusion NN N
, , N
online JJ N
HDF NNP N
in IN N
sepsis-related JJ N
AKI NNP N
could MD N
provide VB N
significantly RB N
better JJR N
removal NN N
of IN N
VEGF NNP N
and CC N
other JJ N
cytokines NNS N
and CC N
these DT N
were VBD N
associated VBN N
with IN N
better JJR N
renal NN N
outcome NN N
than IN N
high-flux JJ N
HD NNP N
Thus NNP N
, , N
online JJ N
HDF NNP N
would MD N
offer VB N
a DT N
potential JJ N
role NN N
in IN N
hypercytokinemic JJ N
state NN N
in IN N
sepsis-related JJ N
AKI NNP N
-DOCSTART- -X- O O 23592849

The DT N
role NN N
of IN N
treatment NN N
fidelity NN N
on IN N
outcomes NNS N
during IN N
a DT N
randomized JJ N
field NN N
trial NN N
of IN N
an DT N
autism NN 4_p
intervention NN N
This DT N
randomized JJ N
field NN N
trial NN N
comparing VBG N
Strategies NNS N
for IN N
Teaching VBG N
based VBN N
on IN N
Autism NNP N
Research NNP N
and CC N
Structured NNP N
Teaching NNP N
enrolled VBD N
educators NNS N
in IN N
33 CD 3_p
kindergarten-through-second-grade JJ 1_p
autism NN 4_p
support NN N
classrooms NNS N
and CC N
119 CD 3_p
students NNS N
, , N
aged VBN 1_p
5-8 CD 1_p
years NNS 1_p
in IN N
the DT N
School NNP N
District NNP N
of IN N
Philadelphia NNP N
Students NNS N
were VBD N
assessed VBN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
academic JJ N
year NN N
using VBG N
the DT N
Differential NNP N
Ability NNP N
Scales NNP N
Program NNP N
fidelity NN N
was VBD N
measured VBN N
through IN N
video NN N
coding NN N
and CC N
use NN N
of IN N
a DT N
checklist NN N
Outcomes CC N
were VBD N
assessed VBN N
using VBG N
linear JJ N
regression NN N
with IN N
random JJ N
effects NNS N
for IN N
classroom NN N
and CC N
student NN N
Average JJ N
fidelity NN N
was VBD N
57 CD N
% NN N
in IN N
Strategies NNP N
for IN N
Teaching NNP N
based VBN N
on IN N
Autism NNP N
Research NNP N
classrooms NNS N
and CC N
48 CD N
% NN N
in IN N
Structured NNP N
Teaching NNP N
classrooms NNS N
There EX N
was VBD N
a DT N
9.2-point JJ N
( ( N
standard JJ N
deviation NN N
= NNP N
9.6 CD N
) ) N
increase NN N
in IN N
Differential NNP N
Ability NNP N
Scales NNP N
score RB N
over IN N
the DT N
8-month JJ N
study NN N
period NN N
, , N
but CC N
no DT N
main JJ N
effect NN N
of IN N
program NN N
There EX N
was VBD N
a DT N
significant JJ N
interaction NN N
between IN N
fidelity NN N
and CC N
group NN N
In IN N
classrooms NNS N
with IN N
either DT N
low JJ N
or CC N
high JJ N
program NN N
fidelity NN N
, , N
students NNS N
in IN N
Strategies NNP N
for IN N
Teaching NNP N
based VBN N
on IN N
Autism NNP 4_p
Research NNP N
experienced VBD N
a DT N
greater JJR N
gain NN N
in IN N
Differential NNP N
Ability NNP N
Scales NNP N
score RB N
than IN N
students NNS N
in IN N
Structured NNP N
Teaching NNP N
( ( N
11.2 CD N
vs. RB N
5.5 CD N
points NNS N
and CC N
11.3 CD N
vs. FW N
8.9 CD N
points NNS N
, , N
respectively RB N
) ) N
In IN N
classrooms NNS N
with IN N
moderate JJ N
fidelity NN N
, , N
students NNS N
in IN N
Structured NNP N
Teaching NNP N
experienced VBD N
a DT N
greater JJR N
gain NN N
than IN N
students NNS N
in IN N
Strategies NNP N
for IN N
Teaching NNP N
based VBN N
on IN N
Autism NNP 4_p
Research NNP N
( ( N
10.1 CD N
vs. RB N
4.4 CD N
points NNS N
) ) N
The DT N
results NNS N
suggest VBP N
significant JJ N
variability NN N
in IN N
implementation NN N
of IN N
evidence-based JJ N
practices NNS N
, , N
even RB N
with IN N
supports NNS N
, , N
and CC N
also RB N
suggest VBP N
the DT N
need NN N
to TO N
address VB N
challenging VBG N
issues NNS N
related VBN N
to TO N
implementation VB N
measurement NN N
in IN N
community NN N
settings NNS N
-DOCSTART- -X- O O 26052790

Environmental JJ N
enrichment NN N
as IN N
a DT N
therapy NN N
for IN N
autism NN 4_p
: : 4_p
A DT N
clinical JJ N
trial NN N
replication NN N
and CC N
extension NN N
Based VBN N
on IN N
work NN N
done VBN N
in IN N
animal NN N
models NNS N
showing VBG N
that IN N
autism-like JJ N
symptoms NNS N
are VBP N
ameliorated VBN N
following JJ N
exposure NN N
to TO N
an DT N
enriched JJ N
sensorimotor NN N
environment NN N
, , N
we PRP N
attempted VBD N
to TO N
develop VB N
a DT N
comparable JJ N
therapy NN N
for IN N
children NNS N
with IN N
autism NN 4_p
In IN N
an DT N
initial JJ N
randomized NN N
controlled VBD N
trial NN N
, , N
children NNS 1_p
with IN N
autism NN 4_p
who WP N
received VBD N
sensorimotor NN N
enrichment NN N
at IN N
home NN N
for IN N
6 CD N
months NNS N
had VBD N
significant JJ N
improvements NNS N
in IN N
both DT N
their PRP$ N
cognitive NN N
ability NN N
and CC N
the DT N
severity NN N
of IN N
their PRP$ N
autism NN 4_p
symptoms NNS N
( ( N
Woo NNP N
& CC N
Leon NNP N
, , N
2013 CD N
) ) N
We PRP N
now RB N
report VBP N
the DT N
outcomes NNS N
of IN N
a DT N
similar JJ N
randomized NN N
controlled VBD N
trial NN N
in IN N
which WDT N
children NNS 1_p
with IN N
autism NN 4_p
, , N
3 CD 1_p
to TO 1_p
6 CD 1_p
years NNS 1_p
old JJ 1_p
, , 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
groups NNS N
that WDT N
received VBD N
either DT N
daily JJ N
sensorimotor NN N
enrichment NN N
, , N
administered VBN N
by IN N
their PRP$ N
parents NNS N
, , N
along IN N
with IN N
standard JJ N
care NN N
, , N
or CC N
they PRP N
received VBD N
standard JJ N
care NN N
alone RB N
After IN N
6 CD N
months NNS N
, , N
enriched VBD N
children NNS N
showed VBD N
statistically RB N
significant JJ N
gains NNS N
in IN N
their PRP$ N
IQ NNP N
scores NNS N
, , N
a DT N
decline NN N
in IN N
their PRP$ N
atypical JJ N
sensory NN N
responses NNS N
, , N
and CC N
an DT N
improvement NN N
in IN N
their PRP$ N
receptive JJ N
language NN N
performance NN N
, , N
compared VBN N
to TO N
controls NNS N
Furthermore NNP N
, , N
after IN N
6 CD N
months NNS N
of IN N
enrichment JJ N
therapy NN N
, , N
21 CD N
% NN N
of IN N
the DT N
children NNS N
who WP N
initially RB N
had VBD N
been VBN N
given VBN N
an DT N
autism NN N
classification NN N
, , N
using VBG N
the DT N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
, , N
improved VBN N
to TO N
the DT N
point NN N
that IN N
, , N
although IN N
they PRP N
remained VBD N
on IN N
the DT N
autism NN N
spectrum NN N
, , N
they PRP N
no RB N
longer RBR N
met VBD N
the DT N
criteria NNS N
for IN N
classic JJ N
autism NN N
None NN N
of IN N
the DT N
standard NN N
care NN N
controls VBZ N
reached VBD N
an DT N
equivalent JJ N
level NN N
of IN N
improvement NN N
Finally RB N
, , N
the DT N
outcome NN N
measures NNS N
for IN N
children NNS N
who WP N
received VBD N
only RB N
a DT N
subset NN N
of IN N
sensory JJ N
stimuli NNS N
were VBD N
similar JJ N
to TO N
those DT N
receiving VBG N
the DT N
full JJ N
complement NN N
of IN N
enrichment NN N
exercises NNS N
Sensorimotor NNP N
enrichment JJ N
therapy NN N
therefore RB N
appears VBZ N
to TO N
be VB N
a DT N
cost-effective JJ N
means NNS N
of IN N
treating VBG N
a DT N
range NN N
of IN N
symptoms NNS N
for IN N
children NNS N
with IN N
autism NN N
-DOCSTART- -X- O O 15915547

Enhancement NN N
of IN N
blood NN N
glucose NN N
lowering VBG N
effect NN N
of IN N
a DT N
sulfonylurea NN N
when WRB N
coadministered VBN N
with IN N
an DT N
ACE NNP N
inhibitor NN N
: : N
results NNS N
of IN N
a DT N
glucose-clamp JJ N
study NN N
BACKGROUND NNP N
To TO N
investigate VB N
if IN N
coadministration NN N
of IN N
enalapril NN N
alters NNS N
the DT N
metabolic JJ N
effect NN N
of IN N
glibenclamide NN N
by IN N
employing VBG N
an DT N
euglycemic JJ N
glucose-clamp NN N
technique NN N
in IN N
healthy JJ N
volunteers NNS N
METHODS VB N
A DT N
double-blind JJ N
crossover NN N
study NN N
with IN N
nine CD N
healthy JJ N
normotensive JJ N
volunteers NNS N
( ( N
age NN 1_p
27 CD 1_p
+/- JJ 1_p
3 CD 1_p
y NN 1_p
, , N
BMI NNP N
23.3 CD N
+/- JJ N
2.0 CD N
kg NN N
m NN N
( ( N
-2 NNP N
) ) N
; : N
mean JJ N
+/- JJ N
SD NNP N
) ) N
-randomly RB N
assigned VBN N
to TO N
a DT N
3-day JJ N
treatment NN N
of IN N
either CC N
5 CD N
mg NN N
enalapril NN N
or CC N
placebo NN N
In IN N
the DT N
morning NN N
of IN N
the DT N
fourth JJ N
day NN N
, , N
volunteers NNS N
orally RB N
received VBD N
3.5 CD N
mg NNS N
glibenclamide RB N
together RB N
with IN N
either DT N
10 CD N
mg NN N
enalapril NN N
or CC N
placebo NN N
Blood NNP N
glucose JJ N
levels NNS N
of IN N
volunteers NNS N
were VBD N
allowed VBN N
to TO N
fall VB N
by IN N
10 CD N
% NN N
from IN N
fasting NN N
levels NNS N
and CC N
were VBD N
kept VBN N
constant JJ N
thereafter NN N
by IN N
employing VBG N
a DT N
Biostator-based JJ N
euglycemic JJ N
glucose NN N
clamp NN N
RESULTS NNP N
Coadministration NNP N
of IN N
enalapril-compared JJ N
with IN N
placebo-resulted JJ N
in IN N
a DT N
temporarily RB N
higher JJR N
metabolic JJ N
effect NN N
of IN N
glibenclamide NN N
( ( N
AUC NNP N
GIR NNP N
( ( N
0-120 NNP N
) ) N
229 CD N
+/- JJ N
173 CD N
vs JJ N
137 CD N
+/- JJ N
44 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
, , N
p JJ N
< VBP N
0.01 CD N
; : N
mean JJ N
+/- JJ N
SD NNP N
) ) N
, , N
which WDT N
lasted VBD N
from IN N
120 CD N
min NNS N
to TO N
240 CD N
min NNS N
after IN N
enalapril DT N
administration NN N
In IN N
parallel NN N
, , N
the DT N
maximal JJ N
metabolic JJ N
effect NN N
of IN N
glibenclamide NN N
tended VBD N
to TO N
be VB N
higher JJR N
with IN N
enalapril NN N
( ( N
GIR NNP N
( ( N
max NN N
) ) N
5.2 CD N
+/- JJ N
1.9 CD N
vs JJ N
4.1 CD N
+/- JJ N
1.3 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
min NN N
( ( N
-1 NNP N
) ) N
; : N
p CC N
= VB N
0.19 CD N
) ) N
However RB N
, , N
the DT N
total JJ N
metabolic JJ N
effect NN N
of IN N
glibenclamide NN N
was VBD N
almost RB N
identical JJ N
between IN N
volunteers NNS N
taking VBG N
enalapril NN N
or CC N
placebo NN N
( ( N
AUC NNP N
GIR NNP N
( ( N
0-600 CD N
) ) N
1267 CD N
+/- JJ N
334 CD N
vs JJ N
1286 CD N
+/- JJ N
249 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
, , N
ns RB N
) ) N
In IN N
contrast NN N
, , N
serum JJ N
insulin NN N
levels NNS N
, , N
C-peptide NNP N
levels NNS N
, , N
and CC N
serum JJ N
glibenclamide NN N
profiles NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
enalapril NN N
and CC N
placebo NN N
CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
may MD N
explain VB N
the DT N
higher JJR N
incidence NN N
of IN N
hypoglycemic JJ N
episodes NNS N
observed VBN N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
when WRB N
taking VBG N
ACE NNP N
inhibitors NNS N
together RB N
with IN N
sulfonylureas NNS N
or CC N
insulin NN N
ACE NNP N
inhibitors NNS N
may MD N
cause VB N
a DT N
temporary JJ N
increase NN N
of IN N
the DT N
insulin NN N
sensitivity NN N
, , N
which WDT N
leads VBZ N
to TO N
an DT N
increased VBN N
risk NN N
of IN N
hypoglycemia NN N
under IN N
these DT N
conditions NNS N
-DOCSTART- -X- O O 4908199

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
ergotamine JJ 4_p
tartrate NN 4_p
-DOCSTART- -X- O O 25580916

N-acetylcysteine NNP N
as IN N
an DT N
adjunctive JJ N
therapy NN N
to TO N
risperidone VB N
for IN N
treatment NN N
of IN N
irritability NN N
in IN 4_p
autism NN 4_p
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
of IN N
efficacy NN N
and CC N
safety NN N
OBJECTIVES NNP N
According VBG N
to TO N
the DT N
proposed VBN N
interference NN N
of IN N
N-acetylcysteine NNP N
( ( N
NAC NNP N
) ) N
with IN N
pathophysiologic JJ N
processes NNS N
of IN N
autistic JJ N
disorders NNS N
( ( N
ADs NNP N
) ) N
, , N
we PRP N
aimed VBD N
to TO N
assess VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
NAC NNP N
as IN N
an DT N
adjunct NN N
to TO N
risperidone VB N
in IN N
the DT N
treatment NN N
of IN N
ADs NNP N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
clinical JJ N
trial NN N
METHODS NNP N
The DT N
participants NNS 1_p
were VBD 1_p
referred VBN 1_p
outpatients NNS 1_p
between IN 1_p
4 CD 1_p
and CC 1_p
12 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN N
the DT 4_p
diagnosis NN 4_p
of IN 4_p
ADs NNP 4_p
and CC N
a DT 4_p
score NN 4_p
of IN 4_p
more JJR 4_p
than IN 4_p
12 CD 4_p
on IN 4_p
Aberrant JJ 4_p
Behavior NNP 4_p
Checklist-Community NNP 4_p
( ( 4_p
ABC-C NNP 4_p
) ) 4_p
Irritability NNP 4_p
subscale NN 4_p
score NN 4_p
The DT N
participants NNS N
were VBD N
randomized VBN N
into IN N
2 CD N
groups NNS N
One CD N
group NN N
received VBD N
risperidone JJ N
plus CC N
NAC NNP N
, , N
and CC N
the DT N
other JJ N
group NN N
received VBD N
risperidone JJ N
plus CC N
placebo NN N
The DT N
dose NN N
of IN N
risperidone NN N
was VBD N
titrated VBN N
between IN N
1 CD N
and CC N
2.0 CD N
mg/d NN N
, , N
and CC N
the DT N
dose NN N
of IN N
NAC NNP N
was VBD N
600 CD N
to TO N
900 CD N
mg/d NN N
The DT N
main JJ N
outcome NN N
was VBD N
mean JJ N
decrease NN N
in IN N
the DT N
ABC-C NNP N
irritability NN N
subscale NN N
score NN N
from IN N
baseline NN N
at IN N
5 CD N
and CC N
10 CD N
weeks NNS N
Changes NNS N
in IN N
other JJ N
subscales NNS N
were VBD N
considered VBN N
as IN N
secondary JJ N
outcome NN N
measures NNS N
RESULTS NNP N
Forty NNP 3_p
patients NNS N
completed VBD N
the DT N
10-week JJ 3_p
trial NN N
Baseline NNP N
characteristics NNS N
including VBG N
age NN N
, , N
sex NN N
and CC N
body NN N
weight NN N
, , N
as RB N
well RB N
as IN N
baseline NN N
scores NNS N
in IN N
5 CD N
subscales NNS N
did VBD N
not RB N
demonstrate VB N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
Repeated-measures NNS N
analysis NN N
showed VBD N
significant JJ N
effect NN N
for IN N
time NN N
× CD N
treatment NN N
interaction NN N
in IN N
irritability NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
and CC N
hyperactivity/noncompliance NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
subscales NNS N
By IN N
week NN N
10 CD N
, , N
the DT N
NAC NNP N
group NN N
showed VBD N
significantly RB N
more JJR N
reduction NN N
in IN N
irritability NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
hyperactivity/noncompliance NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
subscales NNS N
scores NNS N
CONCLUSIONS NNP N
N-acetylcysteine JJ N
can MD N
be VB N
considered VBN N
as IN N
an DT N
adjuvant JJ N
therapy NN N
for IN N
ADs NNP N
with IN N
beneficial JJ N
therapeutic JJ N
outcomes NNS N
-DOCSTART- -X- O O 24973545

Riding VBG N
the DT N
rapids NNS N
: : N
living NN N
with IN N
autism NN N
or CC N
disability NN N
-- : N
an DT N
evaluation NN N
of IN N
a DT N
parenting VBG N
support NN N
intervention NN N
for IN N
parents NNS N
of IN N
disabled JJ 4_p
children NNS 4_p
Evidence NN N
on IN N
the DT N
effectiveness NN N
of IN N
interventions NNS N
to TO N
support VB N
parents NNS N
of IN N
disabled JJ N
children NNS N
to TO N
manage VB N
their PRP$ N
child NN N
's POS N
behaviour NN N
problems NNS N
is VBZ N
limited VBN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
a DT N
group-delivered JJ N
intervention NN N
( ( N
Riding VBG N
the DT N
Rapids NNP N
) ) N
which WDT N
was VBD N
specifically RB N
developed VBN N
for IN N
parents NNS N
of IN N
a DT N
child NN N
with IN N
a DT N
disability NN 4_p
or CC 4_p
autistic JJ 4_p
spectrum NN 4_p
condition NN 4_p
This DT N
programme NN N
has VBZ N
been VBN N
routinely RB N
delivered VBN N
by IN N
a DT N
community-based JJ N
mental JJ N
health NN N
team NN N
across IN N
an DT N
urban JJ N
, , N
multi-ethnic JJ N
locality NN N
for IN N
a DT N
number NN N
of IN N
years NNS N
A DT N
non-randomised JJ N
controlled JJ N
study NN N
design NN N
comprising VBG N
an DT N
intervention NN N
group NN N
( ( N
n=48 CC 3_p
) ) N
and CC N
comparator NN N
( ( N
no DT N
intervention NN N
) ) N
group NN N
( ( N
n=28 RB 3_p
) ) N
was VBD N
used VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
the DT N
intervention NN N
on IN N
child JJ N
behaviour NN N
( ( N
Eyberg NNP N
Child NNP N
Behaviour NNP N
Inventory NNP N
; : N
parent-set JJ N
goals NNS N
) ) N
and CC N
parenting VBG N
efficacy NN N
and CC N
satisfaction NN N
( ( N
Parents NNP N
Sense NNP N
of IN N
Competence NNP N
Scale NNP N
) ) N
at IN N
post-intervention NN N
and CC N
six-month JJ N
follow-up NN N
Data NNS N
on IN N
costs NNS N
to TO N
the DT N
service NN N
provider NN N
of IN N
delivering VBG N
the DT N
intervention NN N
were VBD N
also RB N
collected VBN N
Receipt NNP N
of IN N
the DT N
intervention NN N
was VBD N
associated VBN N
with IN N
significant JJ N
reductions NNS N
in IN N
parent-reported JJ N
behaviour NN N
problems NNS N
and CC N
significant JJ N
improvements NNS N
in IN N
parenting VBG N
efficacy NN N
and CC N
satisfaction NN N
At IN N
six-month JJ N
follow-up NN N
, , N
progress NN N
towards NNS N
achieving VBG N
parent-set JJ N
child NN N
behaviour NN N
goals NNS N
and CC N
parenting VBG N
satisfaction NN N
had VBD N
been VBN N
maintained VBN N
Post NNP N
hoc JJ N
analysis NN N
suggests VBZ N
parents NNS N
who WP N
do VBP N
not RB N
have VB N
English NNP N
as IN N
a DT N
first JJ N
language NN N
may MD N
not RB N
benefit VB N
as RB N
much RB N
as IN N
other JJ N
parents NNS N
from IN N
this DT N
intervention NN N
Findings NNS N
suggest VBP N
this DT N
is VBZ N
a DT N
promising JJ N
intervention NN N
for IN N
parents NNS N
of IN N
a DT N
child NN N
with IN N
a DT N
disability NN N
that WDT N
is VBZ N
likely JJ N
to TO N
be VB N
less JJR N
resource JJ N
intensive NN N
to TO N
service NN N
providers NNS N
than IN N
individually RB N
delivered VBN N
interventions NNS N
Limitations NNS N
and CC N
implications NNS N
for IN N
future JJ N
research NN N
are VBP N
discussed VBN N
-DOCSTART- -X- O O 26317618

High JJ N
Platelet NNP N
Reactivity NNP N
in IN N
Patients NNP 4_p
with IN 4_p
Acute NNP 4_p
Coronary NNP 4_p
Syndromes NNP 4_p
Undergoing NNP 4_p
Percutaneous NNP 4_p
Coronary NNP 4_p
Intervention NN 4_p
: : 4_p
Randomised VBN N
Controlled NNP N
Trial NNP N
Comparing NNP N
Prasugrel NNP N
and CC N
Clopidogrel NNP N
BACKGROUND NNP N
Prasugrel NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
clopidogrel NN N
in IN N
reducing VBG N
platelet NN N
aggregation NN N
in IN N
acute JJ 4_p
coronary JJ 4_p
syndromes NNS 4_p
Data NNP N
available JJ N
on IN N
prasugrel NN N
reloading NN N
in IN N
clopidogrel NN N
treated VBD N
patients NNS N
with IN N
high JJ N
residual JJ N
platelet NN N
reactivity NN N
( ( N
HRPR NNP N
) ) N
i.e NN N
poor JJ N
responders NNS N
, , N
is VBZ N
limited VBN N
OBJECTIVES UH N
To TO N
determine VB N
the DT N
effects NNS N
of IN N
prasugrel NN N
loading VBG N
on IN N
platelet NN N
function NN N
in IN N
patients NNS 4_p
on IN 4_p
clopidogrel NN 4_p
and CC 4_p
high JJ 4_p
platelet NN 4_p
reactivity NN 4_p
undergoing VBG 4_p
percutaneous JJ 4_p
coronary JJ 4_p
intervention NN 4_p
for IN 4_p
acute JJ 4_p
coronary JJ 4_p
syndrome NN 4_p
( ( 4_p
ACS NNP 4_p
) ) 4_p
PATIENTS JJ N
Patients NNS 4_p
with IN 4_p
ACS NNP 4_p
on IN N
clopidogrel NN N
who WP N
were VBD N
scheduled VBN N
for IN N
PCI NNP N
found VBD N
to TO N
have VB N
a DT N
platelet NN N
reactivity NN N
≥40 NNP N
AUC NNP N
with IN N
the DT N
Multiplate NNP N
Analyzer NNP N
, , N
i.e NN N
" JJ N
poor JJ N
responders NNS N
" VBP N
were VBD N
randomised VBN N
to TO N
prasugrel VB N
( ( N
60 CD N
mg NN N
loading NN N
and CC N
10 CD N
mg JJ N
maintenance NN N
dose NN N
) ) N
or CC N
clopidogrel NN N
( ( N
600 CD N
mg NN N
reloading NN N
and CC N
150 CD N
mg JJ N
maintenance NN N
dose NN N
) ) N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
proportion NN N
of IN N
patients NNS N
with IN N
platelet JJ N
reactivity NN N
< VBP N
40 CD N
AUC NNP N
4 CD N
hours NNS N
after IN N
loading VBG N
with IN N
study NN N
medication NN N
, , N
and CC N
also RB N
at IN N
one CD N
hour NN N
( ( N
secondary JJ N
outcome NN N
) ) N
44 CD 3_p
patients NNS 3_p
were VBD 3_p
enrolled VBN 3_p
and CC N
the DT N
study NN N
was VBD N
terminated VBN N
early RB N
as IN N
clopidogrel NN N
use NN N
decreased VBD N
sharply RB N
due JJ N
to TO N
introduction NN N
of IN N
newer JJR N
P2Y12 NNP N
inhibitors NNS N
RESULTS NNP N
At IN N
4 CD N
hours NNS N
after IN N
study NN N
medication NN N
100 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
prasugrel NN N
compared VBN N
to TO N
91 CD N
% NN N
of IN N
those DT N
treated VBN N
with IN N
clopidogrel NN N
had VBD N
platelet VBN N
reactivity NN N
< VBZ N
40 CD N
AUC NNP N
( ( N
p JJ N
= NNP N
0.49 CD N
) ) N
, , N
while IN N
at IN N
1 CD N
hour NN N
the DT N
proportions NNS N
were VBD N
95 CD N
% NN N
and CC N
64 CD N
% NN N
respectively RB N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
Mean JJ N
platelet NN N
reactivity NN N
at IN N
4 CD N
and CC N
1 CD N
hours NNS N
after IN N
study NN N
medication NN N
in IN N
prasugrel NN N
and CC N
clopidogrel NN N
groups NNS N
respectively RB N
were VBD N
12 CD N
versus NN N
22 CD N
( ( N
p NN N
= RB N
0.005 CD N
) ) N
and CC N
19 CD N
versus NN N
34 CD N
( ( N
p NN N
= RB N
0.01 CD N
) ) N
respectively RB N
CONCLUSIONS NNP N
Routine NNP N
platelet NN N
function NN N
testing VBG N
identifies NNS N
patients NNS N
with IN N
high JJ N
residual JJ N
platelet NN N
reactivity NN N
( ( N
" JJ N
poor JJ N
responders NNS N
" VBP N
) ) N
on IN N
clopidogrel NN N
A DT N
strategy NN N
of IN N
prasugrel NN N
rather RB N
than IN N
clopidogrel VB N
reloading VBG N
results NNS N
in IN N
earlier JJR N
and CC N
more RBR N
sustained JJ N
suppression NN N
of IN N
platelet NN N
reactivity NN N
Future JJ N
trials NNS N
need VBP N
to TO N
identify VB N
if IN N
this DT N
translates VBZ N
into IN N
clinical JJ N
benefit NN N
TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT01339026 NNP N
-DOCSTART- -X- O O 25854713

Visual JJ N
Assessment NNP N
of IN N
Relative NNP N
Apical NNP N
Sparing NNP N
Pattern NNP N
Is VBZ N
More RBR N
Useful JJ N
Than NNP N
Quantitative NNP N
Assessment NNP N
for IN N
Diagnosing NNP N
Cardiac NNP N
Amyloidosis NNP N
in IN N
Borderline NNP 4_p
or CC 4_p
Mildly RB 4_p
Increased VBD 4_p
Left NNP 4_p
Ventricular NNP 4_p
Wall NNP 4_p
Thickness NNP 4_p
BACKGROUND NNP N
Relative NNP N
apical JJ N
sparing VBG N
pattern NN N
of IN N
longitudinal JJ N
strain NN N
( ( N
RapSP-LS NNP N
) ) N
was VBD N
suggested VBN N
in IN N
advanced JJ N
cardiac JJ N
amyloidosis NN N
( ( N
CA NNP N
) ) N
It PRP N
is VBZ N
unclear JJ N
whether IN N
it PRP N
is VBZ N
present JJ N
in IN N
less RBR N
advanced JJ N
CA NNP N
METHODS NNP N
AND CC N
RESULTS NNP N
Patients NNP 4_p
with IN 4_p
presumptive JJ 4_p
diagnosis NN 4_p
of IN 4_p
CA NNP 4_p
and CC 4_p
mean VB 4_p
left JJR 4_p
ventricular NN 4_p
wall NN 4_p
thickness NN 4_p
( ( 4_p
LVWT NNP 4_p
) ) 4_p
≤14 VBP 4_p
mm NNS 4_p
were VBD 4_p
recruited VBN 4_p
Apart RB N
from IN N
RapSP-LS NNP N
visually RB N
identified VBD N
, , N
relative JJ N
apical JJ N
longitudinal NN N
strain NN N
index NN N
( ( N
RapLSI NNP N
) ) N
was VBD N
defined VBN N
as IN N
[ JJ N
average JJ N
apical JJ N
LS/ NNP N
( ( N
average JJ N
basal NN N
LS+average NNP N
mid-ventricle NN N
LS NNP N
) ) N
] NN N
Among IN N
119 CD 3_p
patients NNS N
included VBD N
, , N
47 CD 3_p
were VBD N
finally RB N
diagnosed VBN N
with IN N
CA NNP 4_p
RapLSI NNP N
was VBD N
higher RBR N
in IN N
the DT N
CA NNP N
group NN N
compared VBN N
to TO N
other JJ N
causes NNS N
of IN N
increased JJ N
mean NN N
LVWT NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
with IN N
a DT N
significant JJ N
range NN N
of IN N
overlap NN N
noted VBN N
In IN N
contrast NN N
, , N
RapSP-LS NNP N
visually RB N
assessed VBD N
was VBD N
noted VBN N
in IN N
most JJS N
CA JJ N
patients NNS N
( ( N
31/47 CD N
, , N
66.0 CD N
% NN N
) ) N
except IN N
in IN N
those DT N
with IN N
preserved JJ N
LV NNP N
ejection NN N
fraction NN N
, , N
normal JJ N
LVWT NNP N
, , N
and CC N
mildly RB N
decreased VBD N
global JJ N
LS NNP N
, , N
suggesting VBG N
least JJS N
advanced JJ N
CA NNP N
On IN N
multivariate JJ N
analysis NN N
of IN N
the DT N
added JJ N
diagnostic JJ N
role NN N
of IN N
RapSP-LS NNP N
or CC N
RapLSI NNP N
on IN N
top NN N
of IN N
clinical JJ N
, , N
electrocardiographic JJ N
, , N
and CC N
conventional JJ N
echocardiographic JJ N
parameters NNS N
, , N
addition NN N
of IN N
RapLSI NNP N
produced VBD N
only RB N
borderline JJ N
increase NN N
in IN N
area NN N
under IN N
the DT N
curve NN N
of IN N
the DT N
multivariate NN N
model NN N
( ( N
P=0.05 NNP N
) ) N
, , N
whereas JJ N
addition NN N
of IN N
RapSP-LS NNP N
significantly RB N
increased VBD N
it PRP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
CONCLUSIONS NNP N
Visual NNP N
identification NN N
of IN N
RapSP-LS NNP N
is VBZ N
useful JJ N
in IN N
terms NNS N
of IN N
added VBN N
diagnostic JJ N
value NN N
compared VBN N
with IN N
quantitative JJ N
calculation NN N
of IN N
RapLSI NNP N
Its PRP$ N
clinical JJ N
application NN N
, , N
however RB N
, , N
should MD N
be VB N
used VBN N
with IN N
caution NN N
in IN 4_p
patients NNS 4_p
with IN 4_p
less JJR 4_p
advanced JJ 4_p
CA NNP 4_p
-DOCSTART- -X- O O 9172668

[ JJ N
Initial NNP N
nuclear JJ N
magnetic JJ N
resonance NN N
tomography NN N
results NNS N
of IN N
the DT N
treatment NN N
course NN N
of IN N
avascular JJ 4_p
femur NNS 4_p
head VBP 4_p
necrosis NN 4_p
after IN N
femoral JJ 4_p
core NN 4_p
decompression NN 4_p
] NNP N
The DT N
vascular JJ 4_p
femoral JJ 4_p
head NN 4_p
necrosis NN 4_p
is VBZ N
a DT N
serious JJ N
illness NN N
, , N
especially RB N
when WRB N
appearing VBG N
in IN N
patients NNS N
aged VBD N
30 CD 1_p
to TO 1_p
50 CD 1_p
years NNS 1_p
Many JJ N
etiologic JJ N
factors NNS N
cause VBP N
a DT N
femoral JJ N
head NN N
necrosis NN N
such JJ N
as IN N
, , N
for IN N
example NN N
, , N
high-dose JJ N
steroids NNS N
, , N
abuse NN N
of IN N
alcohol NN N
, , N
defect NN 4_p
of IN 4_p
bone NN 4_p
marrow NN 4_p
and CC N
trauma NN 4_p
of IN 4_p
the DT 4_p
hip NN 4_p
Often VB N
the DT N
X-ray JJ N
photograph NN N
leads VBZ N
to TO N
the DT N
diagnosis NN N
in IN N
the DT N
second JJ N
stage NN N
( ( N
ARCO NNP N
1992 CD N
) ) N
or CC N
in IN N
the DT N
third JJ N
stage NN N
, , N
when WRB N
the DT N
femoral JJ N
head NN N
has VBZ N
begun VBN N
to TO N
collapse VB N
The DT N
stage NN N
IIc NNP N
and CC N
III NNP N
shows VBZ N
an DT N
evident JJ N
enhancement NN N
in IN N
contrast NN N
media NNS N
in IN N
MRI NNP N
Contrast NNP N
enhancement NN N
is VBZ N
demonstrated VBN N
by IN N
STIR NNP N
, , N
FATSAT NNP N
, , N
T1-weighted NNP N
and CC N
dynamic JJ N
screening NN N
sequence NN N
The DT N
characteristics NNS N
of IN N
the DT N
contrast NN N
media NNS N
enhancement VBP N
argue NN N
for IN N
an DT N
active JJ N
concomitant NN N
process NN N
of IN N
destruction NN N
and CC N
regeneration NN N
This DT N
stage NN N
has VBZ N
the DT N
best JJS N
chances NNS N
for IN N
a DT N
drug NN N
or CC N
a DT N
surgical JJ N
therapy NN N
The DT N
evaluation NN N
of IN N
the DT N
signal JJ N
intensity NN N
by IN N
the DT N
dynamic JJ N
screening NN N
sequence NN N
is VBZ N
considered VBN N
as IN N
an DT N
objective JJ N
contribution NN N
for IN N
the DT N
staging NN N
of IN N
the DT N
femoral JJ N
head NN N
necrosis NN N
This DT N
enables VBZ N
one CD N
to TO N
differentiate VB N
between IN N
the DT N
curable JJ N
stage NN N
IIc NNP N
and CC N
the DT N
stage NN N
III NNP N
, , N
showing VBG N
the DT N
beginning NN N
of IN N
breakdown NN 4_p
of IN 4_p
the DT 4_p
femoral JJ 4_p
head NN 4_p
-DOCSTART- -X- O O 12121427

Walking VBG N
trials NNS N
in IN N
postmenopausal JJ 4_p
women NNS 2_p
: : N
effect NN N
of IN N
one CD N
vs NN N
two CD N
daily JJ N
bouts NNS N
on IN N
aerobic JJ N
fitness NN N
We PRP N
compared VBN N
the DT N
effects NNS N
of IN N
one CD N
vs NN N
two CD N
daily JJ N
bouts NNS N
of IN N
walking VBG N
on IN N
aerobic JJ N
fitness NN N
and CC N
body NN N
composition NN N
in IN N
postmenopausal JJ 4_p
women NNS 2_p
One CD 3_p
hundred CD 3_p
and CC 3_p
thirty-four JJ 3_p
subjects NNS N
were VBD N
randomized VBN N
into IN N
exercise NN N
groups NNS N
or CC N
a DT N
control NN N
group NN N
and CC N
130 CD 3_p
completed VBD N
the DT N
study NN N
The DT N
subjects NNS N
walked VBD N
5 CD N
d/week NN N
for IN N
15 CD N
weeks NNS N
at IN N
65 CD N
% NN N
of IN N
their PRP$ N
maximal NN N
aerobic JJ N
power NN N
expending VBG N
300 CD N
kcal JJ N
( ( N
1255 CD N
kJ NN N
) ) N
in IN N
exercise NN N
in IN N
one CD N
( ( N
Group NNP N
S1 NNP N
) ) N
or CC N
two CD N
daily JJ N
sessions NNS N
( ( N
Group NNP N
S2 NNP N
) ) N
VO NNP N
( ( N
2max CD N
) ) N
was VBD N
measured VBN N
in IN N
a DT N
direct JJ N
maximal NN N
treadmill NN N
test NN N
Body NNP N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
was VBD N
calculated VBN N
and CC N
the DT N
percentage NN N
of IN N
body NN N
fat NN N
( ( N
fat JJ N
% NN N
) ) N
estimated VBN N
using VBG N
skinfold JJ N
measurements NNS N
The DT N
net JJ N
change NN N
in IN N
the DT N
VO NNP N
( ( N
2max CD N
) ) N
was VBD N
2.5 CD N
mL NN N
min/kg NN N
( ( N
95 CD N
% NN N
CI NNP N
1.5 CD N
, , N
3.5 CD N
) ) N
( ( N
8.7 CD N
% NN N
) ) N
in IN N
Group NNP N
S1 NNP N
and CC N
2.5 CD N
mL NN N
min/kg NN N
( ( N
95 CD N
% NN N
CI NNP N
1.5 CD N
, , N
3.5 CD N
) ) N
( ( N
8.8 CD N
% NN N
) ) N
in IN N
Group NNP N
S2 NNP N
The DT N
net JJ N
change NN N
in IN N
body NN N
mass NN N
was VBD N
-1.2 JJ N
kg NN N
( ( N
95 CD N
% NN N
CI-1.9 NNP N
, , N
-0.5 NNP N
) ) N
in IN N
Group NNP N
S1 NNP N
and CC N
-1.1 NNP N
kg NNP N
( ( N
95 CD N
% NN N
CI NNP N
-1.8 NNP N
, , N
-0.4 NNP N
) ) N
in IN N
Group NNP N
S2 NNP N
The DT N
net JJ N
fat NN N
% NN N
change NN N
was VBD N
-2.1 JJ N
% NN N
( ( N
95 CD N
% NN N
CI-2.7 NNP N
, , N
-1.4 NNP N
) ) N
in IN N
Group NNP N
S1 NNP N
and CC N
-1.7 NNP N
% NN N
( ( N
95 CD N
% NN N
CI-2.3 NNP N
, , N
-1.0 NNP N
) ) N
in IN N
Group NNP N
S2 NNP N
Exercise NN N
improved VBD N
the DT N
maximal NN N
aerobic JJ N
power NN N
and CC N
body NN N
composition NN N
equally RB N
when WRB N
walking NN N
was VBD N
performed VBN N
in IN N
one CD N
or CC N
two CD N
daily JJ N
bouts NNS N
-DOCSTART- -X- O O 24839884

Internet-based JJ N
, , N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
omega-3 JJ N
fatty JJ N
acids NNS N
for IN N
hyperactivity NN 4_p
in IN 4_p
autism NN 4_p
OBJECTIVE NNP N
Preliminary NNP N
evidence NN N
suggests VBZ N
that IN N
omega-3 JJ N
fatty JJ N
acids NNS N
may MD N
reduce VB N
hyperactivity NN N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
We PRP N
sought VBD N
to TO N
examine VB N
the DT N
feasibility NN N
of IN N
a DT N
novel NN N
, , N
Internet-based JJ N
clinical JJ N
trial NN N
design NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
this DT N
supplement NN N
METHOD NNP N
E-mail JJ N
invitations NNS N
were VBD N
sent VBN N
to TO N
parents NNS N
of IN N
children NNS 1_p
aged VBN 1_p
5 CD 1_p
to TO 1_p
8 CD 1_p
years NNS 1_p
enrolled VBN N
in IN N
the DT N
Interactive NNP N
Autism NNP N
Network NNP N
All DT N
study NN N
procedures NNS N
, , N
including VBG N
screening NN N
, , N
informed JJ N
consent NN N
, , N
and CC N
collection NN N
of IN N
outcome NN N
measures NNS N
took VBD N
place NN N
over IN N
the DT N
Internet NNP N
The DT N
primary JJ N
outcome NN N
measures NNS N
were VBD N
parent- JJ N
and CC N
teacher-rated JJ N
changes NNS N
in IN N
hyperactivity NN N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
( ( N
ABC-H NNP N
) ) N
RESULTS NNP N
During IN N
the DT N
6-week JJ N
recruitment NN N
period NN N
, , N
57 CD 3_p
children NNS 1_p
from IN N
28 CD N
states NNS N
satisfied VBD N
all DT N
eligibility NN N
criteria NNS N
and CC N
were VBD N
randomly RB N
assigned VBN N
to TO N
1.3 CD N
grams NNS N
of IN N
omega-3 JJ N
fatty JJ N
acids NNS N
or CC N
an DT N
identical JJ N
placebo NN N
daily RB N
for IN N
6 CD N
weeks NNS N
Outcome JJ N
assessments NNS N
were VBD N
obtained VBN N
from IN N
all DT N
57 CD N
participants NNS N
and CC N
57 CD N
teachers NNS N
, , N
and CC N
the DT N
study NN N
was VBD N
completed VBN N
in IN N
3 CD N
months NNS N
Children NNP N
in IN N
the DT N
omega-3 JJ N
fatty JJ N
acid NN N
group NN N
had VBD N
a DT N
greater JJR N
reduction NN N
in IN N
hyperactivity NN N
( ( N
-5.3 JJ N
points NNS N
) ) N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
( ( N
-2.6 CD N
points NNS N
) ) N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
1.9-point JJ N
greater JJR N
improvement NN N
in IN N
the DT N
omega-3 JJ N
group NN N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
-2.2 NNP N
to TO N
5.2 CD N
) ) N
Adverse JJ N
events NNS N
were VBD N
rare JJ N
and CC N
not RB N
associated VBN N
with IN N
omega-3 JJ N
fatty JJ N
acids NNS N
Participant NNP N
feedback NN N
was VBD N
positive JJ N
CONCLUSION NNP N
Internet-based JJ N
, , N
randomized VBN N
controlled JJ N
trials NNS N
of IN N
therapies NNS N
in IN N
children NNS 1_p
with IN N
ASD NNP 4_p
are VBP N
feasible JJ N
and CC N
may MD N
lead VB N
to TO N
marked JJ N
reductions NNS N
in IN N
the DT N
time NN N
and CC N
cost NN N
of IN N
completing VBG N
trials NNS N
A NNP N
larger JJR N
sample NN N
size NN N
is VBZ N
required VBN N
to TO N
definitively RB N
determine VB N
the DT N
efficacy NN N
of IN N
omega-3 JJ N
fatty JJ N
acids NNS N
Clinical JJ N
trial NN N
registration NN N
information-Omega-3 JJ N
Fatty NNP N
Acids NNP N
for IN N
Hyperactivity NNP N
Treatment NNP N
in IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
; : N
http NN N
: : N
//clinicaltrials.gov NN N
; : N
NCT01694667 NNP N
-DOCSTART- -X- O O 8279616

A DT N
workplace NN N
intervention NN N
for IN N
increasing VBG N
outdoor JJ N
workers NNS N
' POS N
use NN N
of IN N
solar JJ N
protection NN N
OBJECTIVES NNP N
Outdoor NNP N
workers NNS N
are VBP N
at IN N
high JJ N
risk NN N
of IN N
developing VBG N
skin JJ N
cancer NN N
Primary JJ N
prevention NN N
in IN N
this DT N
group NN N
can MD N
potentially RB N
reduce VB N
the DT N
incidence NN N
of IN N
skin NN N
cancer NN N
, , N
and CC N
also RB N
potentiates VBZ N
the DT N
spontaneous JJ N
remission NN N
of IN N
existing VBG N
solar JJ N
keratoses NNS N
A DT N
randomized JJ N
controlled JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
a DT N
solar JJ N
protection NN N
intervention NN N
targeting VBG N
outdoor JJ N
workers NNS N
METHODS NNP N
Outdoor NNP N
workers NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
an DT N
intervention NN N
( ( N
n JJ N
= NNP N
65 CD 3_p
) ) N
or CC N
control VB N
group NN N
( ( N
n JJ N
= NNP N
77 CD 3_p
) ) N
The DT N
intervention NN N
group NN N
received VBD N
individual JJ N
skin NN N
screening NN N
by IN N
a DT N
dermatologist NN N
and CC N
participated VBD N
in IN N
an DT N
education NN N
session NN N
Pre- NNP N
and CC N
posttest JJS N
outcome NN N
measures NNS N
included VBD N
solar JJ N
protection NN N
behavior NN N
( ( N
assessed VBN N
using VBG N
a DT N
validated JJ N
diary NN N
) ) N
, , N
knowledge NN N
, , N
and CC N
attitudes NNS N
RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
increase NN N
( ( N
16 CD N
% NN N
) ) N
in IN N
the DT N
percentage NN N
of IN N
outdoor JJ N
workers NNS N
who WP N
were VBD N
using VBG N
a DT N
high JJ N
level NN N
of IN N
solar JJ N
protection NN N
at IN N
posttest NN N
compared VBN N
to TO N
pretest VB N
in IN N
the DT N
intervention NN N
group NN N
, , N
but CC N
there EX N
was VBD N
no DT N
change NN N
in IN N
the DT N
control NN N
group NN N
Although IN N
both DT N
groups NNS N
improved VBN N
in IN N
their PRP$ N
knowledge NN N
score NN N
, , N
the DT N
intervention NN N
group NN N
showed VBD N
a DT N
significantly RB N
greater JJR N
improvement NN N
at IN N
posttest JJS N
No DT N
changes NNS N
in IN N
attitudes NNS N
were VBD N
detected VBN N
CONCLUSIONS VB N
The DT N
findings NNS N
suggest VBP N
that IN N
changes NNS N
in IN N
solar JJ N
protection NN N
are VBP N
achievable JJ N
with IN N
outdoor JJ N
workers NNS N
-DOCSTART- -X- O O 7881703

Absolute NNP N
bioavailability NN N
of IN N
a DT N
new JJ N
high JJ N
dose NN N
methylprednisolone NN N
tablet NN N
formulation NN N
This DT N
was VBD N
a DT N
single-blind JJ N
, , N
single-dose JJ N
, , N
randomized VBN N
crossover NN N
study NN N
to TO N
determine VB N
the DT N
absolute JJ N
bioavailability NN N
of IN N
Medrol NNP N
, , N
a DT N
new JJ N
high JJ N
dose NN N
( ( N
100 CD N
mg NN N
) ) N
methylprednisolone NN N
tablet NN N
product NN N
, , N
by IN N
comparing VBG N
it PRP N
with IN N
100 CD N
mg NNS N
methylprednisolone NN N
from IN N
an DT N
intravenous JJ N
formulation NN N
, , N
Solu-Medrol NNP N
Fourteen NNP 3_p
healthy JJ N
, , N
non-smoking JJ N
, , N
Caucasian JJ N
male NN 2_p
volunteers NNS N
took VBD N
part NN N
On IN N
treatment NN N
days NNS N
volunteers NNS N
remained VBD N
recumbent NN N
for IN N
4 CD N
hours NNS N
after IN N
drug NN N
administration NN N
, , N
with IN N
food NN N
and CC N
fluid NN N
intake VBP N
standardized VBN N
over IN N
this DT N
period NN N
Serial JJ N
blood NN N
samples NNS N
were VBD N
drawn VBN N
over IN N
a DT N
14-hour JJ N
period NN N
after IN N
drug NN N
administration NN N
Plasma NNP N
methylprednisolone NN N
concentrations NNS N
were VBD N
determined VBN N
by IN N
high JJ N
performance NN N
liquid NN N
chromatography NN N
The DT N
geometric JJ N
means NNS N
of IN N
AUCi.v NNP N
and CC N
AUCtablet NNP N
were VBD N
4,049 CD N
and CC N
3,334 CD N
ng.h/ml NN N
, , N
respectively RB N
The DT N
absolute JJ N
bioavailability NN N
of IN N
the DT N
tablet NN N
product NN N
was VBD N
82 CD N
% NN N
, , N
which WDT N
is VBZ N
in IN N
agreement NN N
with IN N
published VBN N
data NNS N
for IN N
other JJ N
oral JJ N
dosage NN N
forms NNS N
of IN N
methylprednisolone NN N
Volunteers NNS N
displayed VBD N
the DT N
expected VBN N
rise NN N
in IN N
peripheral JJ N
blood NN N
neutrophil NN N
count NN N
, , N
but CC N
no DT N
other JJ N
clinically RB N
relevant JJ N
changes NNS N
in IN N
hematology NN N
or CC N
clinical JJ N
chemistry NN N
were VBD N
observed VBN N
No DT N
adverse JJ N
drug NN N
reactions NNS N
were VBD N
recorded VBN N
It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
tablet NN N
product NN N
can MD N
be VB N
used VBN N
as IN N
a DT N
substitute NN N
for IN N
parenteral JJ N
methylprednisolone NN N
in IN N
situations NNS N
requiring VBG N
high-dose JJ N
therapy NN N
-DOCSTART- -X- O O 17935144

Supportive-expressive JJ N
group NN N
therapy NN N
for IN N
primary JJ 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
: : 4_p
a DT N
randomized JJ N
prospective JJ N
multicenter NN N
trial NN N
OBJECTIVE CC N
The DT N
aim NN N
is VBZ N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
manualized JJ N
12-week JJ N
supportive-expressive JJ N
group NN N
therapy NN N
program NN N
among IN N
primary JJ 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
treated VBN 4_p
in IN 4_p
community NN 4_p
settings NNS 4_p
, , N
to TO N
determine VB N
whether IN N
highly RB N
distressed JJ N
patients NNS N
were VBD N
most RBS N
likely JJ N
to TO N
benefit VB N
and CC N
whether IN N
therapist NN N
's POS N
training NN N
or CC N
experience NN N
was VBD N
related VBN N
to TO N
outcome VB N
METHOD NNP N
Three CD N
hundred VBD N
and CC N
fifty-three JJ N
women NNS N
within IN N
one CD N
year NN N
of IN N
diagnosis NN N
with IN N
primary JJ N
breast NN N
cancer NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
supportive-expressive JJ N
group NN N
therapy NN N
or CC N
to TO N
an DT N
education NN N
control NN N
condition NN N
Participants NNS N
were VBD N
recruited VBN N
from IN N
two CD N
academic JJ N
centers NNS N
and CC N
nine CD N
oncology NN N
practices NNS N
, , N
which WDT N
were VBD N
members NNS N
of IN N
NCI NNP N
's POS N
Community NNP N
Clinical NNP N
Oncology NNP N
Program NNP N
( ( N
CCOP NNP N
) ) N
and CC N
were VBD N
followed VBN N
over IN N
2 CD N
years NNS N
RESULTS VB N
A DT N
2x2x19 CD N
analysis NN N
of IN N
variance NN N
was VBD N
conducted VBN N
with IN N
main JJ N
effects NNS N
of IN N
treatment NN N
condition NN N
, , N
cohort NN N
, , N
and CC N
baseline NN N
distress NN N
and CC N
their PRP$ N
interactions NNS N
There EX N
was VBD N
no DT N
main JJ N
effect NN N
for IN N
treatment NN N
condition NN N
after IN N
removing VBG N
one CD N
subject NN N
with IN N
an DT N
extreme JJ N
score NN N
Highly NNP 4_p
distressed JJ 4_p
women NNS 4_p
did VBD N
not RB N
derive VB N
a DT N
greater JJR N
benefit NN N
from IN N
treatment NN N
Therapist VB N
training NN N
and CC N
psychotherapy NN N
experience NN N
were VBD N
not RB N
associated VBN N
with IN N
a DT N
treatment NN N
effect NN N
CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
no DT N
evidence NN N
of IN N
reduction NN N
in IN N
distress NN N
as IN N
the DT N
result NN N
of IN N
a DT N
brief JJ N
supportive-expressive JJ N
intervention NN N
for IN N
women NNS N
with IN N
primary JJ 4_p
breast NN N
cancer NN N
Future NNP N
studies NNS N
might MD N
productively RB N
focus VB N
on IN N
women NNS 4_p
with IN 4_p
higher JJR 4_p
initial JJ 4_p
levels NNS 4_p
of IN 4_p
distress NN 4_p
-DOCSTART- -X- O O 21054362

Antimigraine NNP N
efficacy NN N
of IN N
telcagepant NN N
based VBN N
on IN N
patient NN N
's POS N
historical JJ N
triptan NN N
response NN N
OBJECTIVE UH N
To TO N
evaluate VB N
whether IN N
the DT N
same JJ N
or CC N
different JJ N
patients NNS 4_p
respond NN 4_p
to TO 4_p
triptans NNS 4_p
and CC 4_p
telcagepant NN 4_p
BACKGROUND NNP N
Telcagepant NNP N
is VBZ N
an DT N
oral JJ N
calcitonin NN N
gene-related JJ N
peptide NN N
receptor NN N
antagonist NN N
with IN N
acute JJ N
antimigraine NN N
efficacy NN N
comparable JJ N
to TO N
oral JJ N
triptans NNS N
It PRP N
is VBZ N
currently RB N
unknown JJ N
whether IN N
migraine NN N
patients NNS N
who WP N
can MD N
not RB N
be VB N
adequately RB N
helped VBN N
with IN N
triptans NNS N
might MD N
benefit VB N
from IN N
treatment NN N
with IN N
telcagepant NN N
METHODS NNP N
Post-hoc JJ N
analysis NN N
of IN N
data NNS N
from IN N
a DT N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
telcagepant NN N
( ( N
150 CD N
mg NN N
, , N
300 CD N
mg NN N
) ) N
zolmitriptan VBZ N
5 CD N
mg NN N
, , N
or CC N
placebo NN N
for IN N
a DT N
moderate/severe JJ N
migraine NN N
Responder VB N
rates NNS N
were VBD N
analyzed VBN N
according VBG N
to TO N
patients NNS N
' POS N
self-reported JJ N
historical JJ N
triptan NN N
response NN N
( ( N
HTR NNP N
) ) N
: : N
( ( N
1 CD N
) ) N
good JJ N
HTR NNP N
( ( N
N NNP N
= NNP N
660 CD N
) ) N
: : N
response NN N
in IN N
75-100 CD N
% NN N
of IN N
attacks NNS N
; : N
( ( N
2 CD N
) ) N
intermediate NN N
HTR NNP N
( ( N
N NNP N
= NNP N
248 CD N
) ) N
: : N
response NN N
in IN N
25-74 JJ N
% NN N
of IN N
attacks NNS N
; : N
( ( N
3 CD N
) ) N
poor JJ N
HTR/no NNP N
use NN N
( ( N
N NNP N
= NNP N
407 CD N
) ) N
: : N
response NN N
in IN N
< JJ N
25 CD N
% NN N
of IN N
attacks NNS N
, , N
or CC N
patient NN N
did VBD N
not RB N
take VB N
triptans NNS N
A DT N
limitation NN N
of IN N
the DT N
analysis NN N
is VBZ N
that IN N
the DT 4_p
last JJ 4_p
subgroup NN 4_p
comprised VBD 4_p
mainly RB 4_p
( ( 4_p
91 CD 4_p
% NN 4_p
) ) 4_p
patients NNS 4_p
who WP 4_p
reported VBD 4_p
that IN 4_p
they PRP 4_p
did VBD 4_p
not RB 4_p
take VB 4_p
triptans NNS 4_p
, , 4_p
but CC 4_p
it PRP 4_p
was VBD 4_p
not RB 4_p
known VBN 4_p
whether IN 4_p
these DT 4_p
patients NNS 4_p
were VBD 4_p
triptan-naïve JJ 4_p
or CC 4_p
had VBD 4_p
previously RB 4_p
used VBN 4_p
triptans NNS 4_p
and CC 4_p
stopped VBD 4_p
taking VBG 4_p
them PRP 4_p
RESULTS VB N
For IN N
zolmitriptan JJ N
, , N
2-hour JJ N
pain NN N
relief NN N
rates NNS N
were VBD N
higher JJR N
in IN N
the DT N
good JJ N
HTR NNP N
subgroup NN N
( ( N
116/162 CD N
, , N
72 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
intermediate NN N
( ( N
29/62 CD N
, , N
47 CD N
% NN N
) ) N
and CC N
poor/no NN N
use NN N
( ( N
44/111 CD N
, , N
40 CD N
% NN N
) ) N
HTR NNP N
subgroups NNS N
The DT N
2-hour JJ N
pain NN N
relief NN N
rates NNS N
were VBD N
similar JJ N
across IN N
HTR NNP N
subgroups NNS N
for IN N
telcagepant JJ N
150 CD N
mg NN N
( ( N
48-58 CD N
% NN N
) ) N
, , N
300 CD N
mg NN N
( ( N
52-58 CD N
% NN N
) ) N
, , N
and CC N
placebo NN N
( ( N
26-31 CD N
% NN N
) ) N
In IN N
the DT N
poor/no NN N
use NN N
HTR NNP N
subgroup NN N
, , N
more JJR N
patients NNS N
receiving VBG N
telcagepant JJ N
300 CD N
mg NN N
( ( N
56/98 CD N
, , N
57.1 CD N
% NN N
) ) N
had VBD N
2-hour JJ N
pain NN N
relief NN N
than IN N
those DT N
receiving VBG N
zolmitriptan NN N
( ( N
44/111 CD N
, , N
39.6 CD N
% NN N
; : N
odds NNS N
ratio VBP N
= $ N
2.11 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
: : N
1.20,3.71 CD N
] NN N
, , N
P NNP N
= NNP N
.009 NNP N
) ) N
; : N
the DT N
percentage NN N
for IN N
telcagepant JJ N
150 CD N
mg NN N
( ( N
57/119 CD N
, , N
47.9 CD N
% NN N
) ) N
was VBD N
not RB N
significantly RB N
different JJ N
from IN N
zolmitriptan NN N
( ( N
odds NNS N
ratio VBP N
= $ N
1.41 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
: : N
0.82 CD N
, , N
2.40 CD N
] NN N
, , N
P NNP N
= NNP N
.211 NNP N
) ) N
CONCLUSIONS VB N
This DT N
suggests VBZ N
that IN N
different JJ N
patients NNS N
may MD N
respond VB N
to TO N
triptans NNS N
or CC N
telcagepant JJ N
300 CD N
mg NN N
Caution NN N
should MD N
be VB N
exercised VBN N
in IN N
interpreting VBG N
the DT N
results NNS N
because IN N
of IN N
the DT N
post-hoc JJ N
nature NN N
of IN N
the DT N
analysis NN N
( ( N
clinical JJ N
trial NN N
registry NN N
: : N
NCT00442936 NNP N
) ) N
-DOCSTART- -X- O O 23965288

Assessment NN N
of IN N
global JJ N
functioning NN N
in IN N
adolescents NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
utility NN N
of IN N
the DT N
Developmental NNP N
Disability-Child NNP N
Global NNP N
Assessment NNP N
Scale NNP N
Assessment NN N
of IN N
global JJ N
functioning NN N
is VBZ N
an DT N
important JJ N
consideration NN N
in IN N
treatment NN N
outcome NN N
research NN N
; : N
yet RB N
, , N
there EX N
is VBZ N
little JJ N
guidance NN N
on IN N
its PRP$ N
evidence-based JJ N
assessment NN N
for IN N
children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
This DT N
study NN N
investigated VBD N
the DT N
utility NN N
and CC N
validity NN N
of IN N
clinician-rated JJ N
global JJ N
functioning NN N
using VBG N
the DT N
Developmental NNP N
Disability-Child NNP N
Global NNP N
Assessment NNP N
Scale NNP N
in IN N
a DT N
sample NN N
of IN N
higher JJR N
functioning NN N
adolescents NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
and CC 4_p
comorbid NN 4_p
anxiety NN 4_p
disorders NNS 4_p
enrolled VBD N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
Pretreatment JJ N
Developmental JJ N
Disability-Child JJ N
Global NNP N
Assessment NNP N
Scale NNP N
scores NNS N
correlated VBD N
with IN N
severity NN N
of IN N
autism NN N
spectrum NN N
disorders NNS N
core VBP N
symptoms NNS N
( ( N
r VB N
= NNP N
-.388 NNP N
, , N
p NN N
= NNP N
.034 NNP N
) ) N
, , N
pragmatic JJ N
communication NN N
( ( N
r JJ N
= NNP N
.407 NNP N
, , N
p NN N
= NNP N
.032 NNP N
) ) N
, , N
and CC N
verbal JJ N
ability NN N
( ( N
r JJ N
= NNP N
.449 NNP N
, , N
p NN N
= NNP N
.013 NNP N
) ) N
and CC N
did VBD N
not RB N
correlate VB N
with IN N
severity NN N
of IN N
anxiety NN N
symptoms NNS N
or CC N
with IN N
parent-reported JJ N
adaptive JJ N
behavior NN N
Change NN N
in IN N
Developmental NNP N
Disability-Child NNP N
Global NNP N
Assessment NNP N
Scale NNP N
scores VBZ N
during IN N
treatment NN N
was VBD N
associated VBN N
with IN N
autism NN N
spectrum NN N
disorders NNS N
symptomatic JJ N
improvement NN N
( ( N
r JJ N
= NNP N
.414 NNP N
, , N
p NN N
= NNP N
.040 NNP N
) ) N
and CC N
with IN N
improved JJ N
general JJ N
communication NN N
( ( N
r JJ N
= NNP N
.499 NNP N
, , N
p NN N
= NNP N
.013 NNP N
) ) N
Results JJ N
support NN N
the DT N
importance NN N
of IN N
assessing VBG N
global JJ N
functioning NN N
in IN N
addition NN N
to TO N
symptom VB N
change NN N
and CC N
treatment NN N
response NN N
in IN N
clinical JJ N
trials NNS N
-DOCSTART- -X- O O 22050040

Once-daily RB N
topical JJ N
brimonidine NN N
tartrate NN N
gel VBD N
0·5 CD N
% NN N
is VBZ N
a DT N
novel JJ N
treatment NN N
for IN N
moderate JJ N
to TO N
severe VB N
facial JJ N
erythema NN N
of IN N
rosacea NN N
: : N
results NNS N
of IN N
two CD N
multicentre NNS N
, , N
randomized VBN N
and CC N
vehicle-controlled JJ N
studies NNS N
BACKGROUND NNP N
Erythema NNP 4_p
of IN 4_p
rosacea NN 4_p
is VBZ N
thought VBN N
to TO N
result VB N
from IN N
abnormal JJ N
cutaneous JJ N
vasomotor NN N
activity NN N
Brimonidine NNP N
tartrate NN N
( ( N
BT NNP N
) ) N
is VBZ N
a DT N
highly RB N
selective JJ N
α NN N
( ( N
2 CD N
) ) N
-adrenergic NN N
receptor NN N
agonist NN N
with IN N
vasoconstrictive JJ N
activity NN N
OBJECTIVE NN N
To TO N
determine VB N
the DT N
optimal JJ N
concentration NN N
and CC N
dose JJ N
regimen NNS N
of IN N
topical JJ N
BT NNP N
gel NN N
for IN N
the DT N
treatment NN N
of IN N
erythema NN N
of IN N
rosacea NN N
and CC N
to TO N
evaluate VB N
its PRP$ N
efficacy NN N
and CC N
safety NN N
METHODS NNP N
In IN N
study NN N
A NNP N
, , N
122 CD 3_p
subjects NNS 3_p
were VBD N
randomized VBN N
to TO N
receive VB N
a DT N
single JJ N
application NN N
of IN N
BT NNP N
0·07 CD N
% NN N
, , N
0·18 CD N
% NN N
, , N
0·5 CD N
% NN N
or CC N
vehicle NN N
In IN N
study NN N
B NNP N
( ( N
4-week JJ N
treatment NN N
and CC N
4-week JJ N
follow-up NN N
) ) N
, , N
269 CD 3_p
subjects NNS 3_p
were VBD N
randomized VBN N
to TO N
receive VB N
BT NNP N
0·5 CD N
% NN N
once RB N
daily JJ N
, , N
BT NNP N
0·18 CD N
% NN N
once RB N
daily JJ N
, , N
vehicle NN N
once RB N
daily RB N
, , N
BT NNP N
0·18 CD N
% NN N
twice JJ N
daily RB N
or CC N
vehicle NN N
twice RB N
daily RB N
Evaluations NNS N
included VBD N
Clinician NNP N
's POS N
Erythema NNP N
Assessment NNP N
( ( N
CEA NNP N
) ) N
, , N
Patient NNP N
's POS N
Self-Assessment JJ N
( ( N
PSA NNP N
) ) N
, , N
Chroma NNP N
Meter NNP N
measurements NNS N
and CC N
adverse JJ N
events NNS N
RESULTS NNP N
In IN N
study NN N
A NNP N
, , N
a DT N
single JJ N
application NN N
of IN N
topical JJ N
BT NNP N
gel NN N
reduced VBD N
facial JJ N
erythema NN N
in IN N
a DT N
dose-dependent JJ N
fashion NN N
A DT N
significant JJ N
difference NN N
between IN N
BT NNP N
0·5 CD N
% NN N
and CC N
vehicle NN N
in IN N
Chroma NNP N
Meter NNP N
redness NN N
value NN N
was VBD N
observed VBN N
from IN N
30min CD N
to TO N
12h CD N
after IN N
application NN N
In IN N
study NN N
B NNP N
, , N
BT NNP N
0·5 CD N
% NN N
once RB N
daily JJ N
had VBD N
a DT N
statistically RB N
superior JJ N
success NN N
profile NN N
( ( N
defined VBN N
as IN N
a DT N
two-grade JJ N
improvement NN N
on IN N
both DT N
CEA NNP N
and CC N
PSA NNP N
over IN N
12h CD N
) ) N
compared VBN N
with IN N
vehicle NN N
once RB N
daily RB N
on IN N
days NNS N
1 CD N
, , N
15 CD N
and CC N
29 CD N
( ( N
all DT N
P NNP N
< NNP N
0·001 CD N
) ) N
No DT N
tachyphylaxis NN N
, , N
rebound NN N
of IN N
erythema NN N
or CC N
aggravation NN N
of IN N
other JJ N
disease NN N
signs NNS N
( ( N
telangiectasia NN N
, , N
inflammatory JJ N
lesions NNS N
) ) N
was VBD N
observed VBN N
All DT N
regimens NNS N
were VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
with IN N
similarly RB N
low JJ N
incidence NN N
of IN N
adverse JJ N
events NNS N
CONCLUSIONS NNP N
Once-daily JJ N
BT NNP N
gel VBD N
0·5 CD N
% NN N
is VBZ N
well RB N
tolerated JJ N
and CC N
provides VBZ N
significantly RB N
greater JJR N
efficacy NN N
than IN N
vehicle NN N
gel NN N
for IN N
the DT N
treatment NN N
of IN N
moderate JJ N
to TO N
severe VB N
erythema NN N
of IN N
rosacea NN N
-DOCSTART- -X- O O 2405107

Randomized VBN N
study NN N
of IN N
continuous JJ N
infusion NN N
fluorouracil NN N
versus NN N
fluorouracil NN N
plus CC N
cisplatin NN N
in IN N
patients NNS N
with IN N
metastatic JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
One CD 3_p
hundred VBD 3_p
twenty-two JJ 3_p
chemotherapy-naive JJ N
patients NNS N
with IN N
histologically RB N
confirmed VBN N
colorectal JJ 4_p
adenocarcinoma NN 4_p
were VBD N
entered VBN N
into IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
infusional JJ N
fluorouracil NN N
( ( N
FU NNP N
) ) N
versus NN N
cisplatin NN N
( ( N
CDDP NNP N
) ) N
and CC N
FU NNP N
In IN N
both DT N
groups NNS N
, , N
patients NNS N
received VBD N
continuous JJ N
infusion NN N
FU NNP N
1,000 CD N
mg/m2/d NN N
for IN N
5 CD N
consecutive JJ N
days NNS N
every DT N
4 CD N
weeks NNS N
Patients NNS N
randomized VBD N
to TO N
CDDP/FU NNP N
also RB N
received VBD N
CDDP NNP N
20 CD N
mg/m2 NN N
intravenous JJ N
( ( N
IV NNP N
) ) N
bolus NN N
on IN N
days NNS N
1 CD N
to TO N
5 CD N
of IN N
each DT N
cycle NN N
Patients NNS N
were VBD N
comparable JJ N
in IN N
terms NNS N
of IN N
age NN N
, , N
performance NN N
status NN N
, , N
baseline VB N
laboratory NN N
values NNS N
, , N
dominant JJ N
sites NNS N
of IN N
measurable JJ N
disease NN N
, , N
and CC N
percent NN N
of IN N
liver JJ N
involvement NN N
The DT N
partial JJ N
response NN N
rate NN N
was VBD N
significantly RB N
greater JJR N
in IN N
patients NNS N
who WP N
received VBD N
CDDP/FU NNP N
versus NN N
FU NNP N
alone RB N
( ( N
25 CD N
% NN N
v JJ N
3 CD N
% NN N
, , N
P NNP N
= NNP N
.001 NNP N
) ) N
Patients NNPS N
who WP N
received VBD N
CDDP/FU NNP N
experienced VBD N
significantly RB N
greater JJR N
toxicity NN N
compared VBN N
with IN N
FU NNP N
alone RB N
: : N
grades NNS N
3 CD N
and CC N
4 CD N
hematologic JJ N
toxicity NN N
occurred VBD N
in IN N
22 CD N
% NN N
and CC N
0 CD N
% NN N
of IN N
patients NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
; : N
grades VBZ N
2 CD N
to TO N
4 CD N
nausea NN N
and CC N
vomiting NN N
occurred VBD N
in IN N
80 CD N
% NN N
and CC N
15 CD N
% NN N
of IN N
patients NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
either CC N
the DT N
duration NN N
of IN N
response NN N
( ( N
median JJ N
, , N
6 CD N
and CC N
4.7 CD N
months NNS N
for IN N
CDDP/FU NNP N
and CC N
FU NNP N
groups NNS N
, , N
respectively RB N
) ) N
or CC N
survival NN N
( ( N
median JJ N
10 CD N
, , N
and CC N
12 CD N
months NNS N
, , N
respectively RB N
) ) N
Compared VBN N
with IN N
infusional JJ N
FU NNP N
alone RB N
, , N
CDDP/FU NNP N
provided VBD N
a DT N
significantly RB N
greater JJR N
partial JJ N
response NN N
rate NN N
with IN N
increased JJ N
toxicity NN N
, , N
but CC N
it PRP N
did VBD N
not RB N
improve VB N
overall JJ N
survival NN N
in IN N
patients NNS N
with IN N
advanced JJ 4_p
colorectal JJ 4_p
carcinoma NN 4_p
Therefore RB N
, , N
the DT N
use NN N
of IN N
CDDP/FU NNP N
as IN N
routine JJ N
therapy NN N
for IN N
the DT N
treatment NN N
of IN N
colorectal JJ N
carcinoma NN N
can MD N
not RB N
be VB N
recommended VBN N
-DOCSTART- -X- O O 10939601

5-fluorouracil JJ N
plus CC N
folinic JJ N
acid NN N
with IN N
or CC N
without IN N
ifosfamide NN N
in IN N
advanced JJ N
colorectal JJ N
cancer NN N
: : N
a DT N
phase NN N
II NNP N
randomized VBD N
trial NN N
AIM VB N
This DT N
phase NN N
II NNP N
trial NN N
evaluated VBD N
the DT N
biomodulation NN N
of IN N
5-fluorouracil JJ N
( ( N
5-FU JJ N
) ) N
plus CC N
folinic JJ N
acid NN N
( ( N
FA NNP N
) ) N
with IN N
or CC N
without IN N
ifosfamide JJ N
( ( N
IFO NNP N
) ) N
in IN N
chemotherapy-naive JJ N
patients NNS N
with IN N
colorectal JJ 4_p
cancer NN 4_p
PATIENTS NNP N
AND CC N
METHODS NNP N
Forty-eight NNP 3_p
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
: : N
FA NNP N
( ( N
25 CD N
mg/m2 NN N
iv NN N
bolus JJ N
days NNS N
1 CD N
to TO N
3 CD N
) ) N
, , N
followed VBN N
by IN N
5-FU JJ N
( ( N
750 CD N
mg/m2 NN N
iv NN N
bolus JJ N
days NNS N
1 CD N
to TO N
3 CD N
) ) N
, , N
arm VBZ N
A NNP N
; : N
or CC N
FA NNP N
( ( N
25 CD N
mg/m2 NN N
iv NN N
bolus JJ N
days NNS N
1 CD N
to TO N
3 CD N
) ) N
, , N
followed VBN N
by IN N
5-FU JJ N
( ( N
750 CD N
mg/m2 NN N
iv NN N
bolus JJ N
days NNS N
1 CD N
to TO N
3 CD N
) ) N
plus CC N
IFO NNP N
( ( N
2,000 CD N
mg/m2 NN N
in IN N
1000 CD N
mL JJ N
5 CD N
% NN N
dextrose NN N
in IN N
a DT N
2-hr JJ N
infusion NN N
, , N
days NNS N
1 CD N
to TO N
3 CD N
) ) N
, , N
arm JJ N
B. NNP N
Mesna NNP N
was VBD N
added VBN N
during IN N
and CC N
after IN N
IFO NNP N
to TO N
prevent VB N
hemorrhagic JJ N
cystitis NN N
Treatment NNP N
was VBD N
repeated VBN N
every DT N
21 CD N
days NNS N
in IN N
both DT N
arms NNS N
RESULTS JJ N
Forty-five JJ 3_p
patients NNS N
were VBD N
assessable JJ N
for IN N
response NN N
: : N
in IN N
arm NN N
A NNP N
, , N
5 CD N
patients NNS N
achieved VBD N
a DT N
partial JJ N
response NN N
( ( N
overall JJ N
response NN N
, , N
25 CD N
% NN N
) ) N
, , N
and CC N
in IN N
arm NN N
B NNP N
, , N
2 CD N
patients NNS N
achieved VBD N
a DT N
complete JJ N
and CC N
1 CD N
a DT N
partial JJ N
response NN N
( ( N
overall JJ N
response NN N
, , N
12 CD N
% NN N
) ) N
Time NN N
to TO N
failure NN N
was VBD N
3.5 CD N
months NNS N
( ( N
range NN N
, , N
1-38 JJ N
) ) N
in IN N
patients NNS N
treated VBN N
with IN N
5-FU JJ N
plus CC N
FA NNP N
, , N
and CC N
3 CD N
months NNS N
( ( N
range NN N
, , N
1-21 JJ N
) ) N
in IN N
patients NNS N
treated VBN N
with IN N
the DT N
IFO NNP N
combination NN N
The DT N
median JJ N
survival NN N
time NN N
was VBD N
13.5 CD N
months NNS N
( ( N
range NN N
, , N
1-49 JJ N
months NNS N
) ) N
in IN N
arm NN N
A NN N
and CC N
16 CD N
months NNS N
( ( N
range NN N
, , N
1-43 JJ N
months NNS N
) ) N
in IN N
arm NN N
B NNP N
Diarrhea NNP N
, , N
stomatitis NN N
and CC N
vomiting NN N
were VBD N
the DT N
most RBS N
common JJ N
nonhematologic JJ N
toxicities NNS N
in IN N
both DT N
arms NNS N
The DT N
most RBS N
notable JJ N
hematologic JJ N
toxicity NN N
was VBD N
leukopenia VBN N
; : N
15 CD N
% NN N
and CC N
20 CD N
% NN N
of IN N
patients NNS N
experienced JJ N
grade VBD N
4 CD N
in IN N
arm NN N
A NN N
and CC N
arm NN N
B NNP N
, , N
respectively RB N
CONCLUSIONS NNP N
IFO NNP N
does VBZ N
not RB N
increase VB N
the DT N
activity NN N
of IN N
the DT N
5-FU JJ N
plus CC N
FA JJ N
combination NN N
in IN N
advanced JJ N
colorectal JJ N
cancer NN N
-DOCSTART- -X- O O 12410073

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
porcine NN N
versus NN N
synthetic JJ N
secretin NN N
for IN N
reducing VBG N
symptoms NNS N
of IN N
autism NN 4_p
OBJECTIVE UH N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
biologic NN N
and CC N
synthetic JJ N
porcine NN N
secretin NN N
to TO N
placebo VB N
on IN N
a DT N
variety NN N
of IN N
autism NN 4_p
symptoms NNS N
METHOD NNP N
Eighty-five JJ 3_p
children NNS 3_p
with IN N
autism NN N
without IN N
other JJ N
medical JJ N
conditions NNS N
and CC N
not RB N
taking VBG N
other JJ N
psychotropic NN N
medications NNS N
participated VBD N
( ( N
ages NNS 1_p
between IN 1_p
3 CD 1_p
and CC 1_p
12 CD 1_p
years NNS 1_p
, , N
mean JJ N
IQ NNP N
= NNP N
55 CD N
) ) N
Children NNP N
were VBD N
grouped VBN N
into IN N
trios NNS N
matched VBN N
by IN N
age NN N
and CC N
communication NN N
level NN N
and CC N
then RB N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatment NN N
groups NNS N
: : N
biologic NN N
secretin NN N
( ( N
2 CD N
CU/kg NNP N
) ) N
, , N
synthetic JJ N
secretin NN N
( ( N
0.4 CD N
microg/kg NN N
) ) N
, , N
and CC N
placebo NN N
Measures NNS N
collected VBD N
1 CD N
week NN N
before RB N
and CC N
4 CD N
weeks NNS N
after IN N
infusion NN N
included VBD N
autism NN N
symptoms NNS N
, , N
language NN N
skills NNS N
, , N
and CC N
problem NN N
behaviors NNS N
, , N
gathered VBN N
from IN N
parents NNS N
, , N
teachers NNS N
, , N
and CC N
investigators NNS N
, , N
who WP N
were VBD N
all DT N
blind NNS N
to TO N
treatment NN N
Two-factor NN N
, , N
repeated-measures JJ N
analyses NNS N
of IN N
variance NN N
( ( N
3 CD N
treatment NN N
levels NNS N
by IN N
2 CD N
repeated JJ N
measures NNS N
, , N
pre- NN N
and CC N
postinfusion NN N
) ) N
were VBD N
used VBN N
to TO N
examine VB N
efficacy NN N
RESULTS NNP N
Direct JJ N
observation NN N
measures NNS N
did VBD N
not RB N
show VB N
change NN N
over IN N
time NN N
related VBN N
to TO N
secretin VB N
Parent NN N
reports NNS N
showed VBD N
an DT N
overall JJ N
reduction NN N
of IN N
symptom JJ N
severity NN N
for IN N
all DT N
treatment NN N
groups NNS N
, , N
including VBG N
the DT N
placebo NN N
group NN N
One CD N
teacher-report NN N
measure NN N
showed VBD N
decreases NNS N
in IN N
autism NN N
symptoms NNS N
in IN N
the DT N
placebo NN N
and CC N
synthetic JJ N
secretin NN N
groups NNS N
CONCLUSIONS NNP N
No NNP N
evidence NN N
that IN N
either DT N
biologic NN N
or CC N
synthetic JJ N
secretin NN N
provided VBD N
amelioration NN N
of IN N
symptoms NNS N
beyond IN N
placebo NN N
was VBD N
observed VBN N
This DT N
held VBD N
true JJ N
when WRB N
children NNS 1_p
with IN N
and CC N
without IN N
gastrointestinal JJ 4_p
problems NNS 4_p
were VBD N
examined VBN N
separately RB N
-DOCSTART- -X- O O 19691092

A DT N
randomized JJ N
trial NN N
of IN N
external JJ N
beam NN N
radiotherapy NN N
versus NN N
cryoablation NN N
in IN N
patients NNS N
with IN N
localized JJ 4_p
prostate NN 4_p
cancer NN 4_p
: : N
quality NN N
of IN N
life NN N
outcomes NNS N
BACKGROUND VB N
A DT N
recent JJ N
randomized JJ N
trial NN N
to TO N
compare VB N
external JJ N
beam NN N
radiation NN N
therapy NN N
( ( N
EBRT NNP N
) ) N
to TO N
cryoablation NN N
for IN N
localized JJ N
disease NN N
showed VBD N
cryoablation NN N
to TO N
be VB N
noninferior JJ N
to TO N
external JJ N
beam NN N
EBRT NNP N
in IN N
disease NN N
progression NN N
and CC N
overall JJ N
and CC N
disease-specific JJ N
survival NN N
We PRP N
report VBP N
on IN N
the DT N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
outcomes VBZ N
for IN N
this DT N
trial NN N
METHODS NN N
From IN N
December NNP N
1997 CD N
through IN N
February NNP N
2003 CD N
, , N
244 CD 3_p
men NNS 3_p
with IN N
newly RB N
diagnosed VBN N
localized JJ 4_p
prostate NN 4_p
cancer NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
cryoablation NN N
or CC N
EBRT NNP N
( ( N
median JJ N
dose NN N
68 CD N
Gy NNP N
) ) N
All DT N
patients NNS N
received VBD N
neoadjuvant JJ N
antiandrogen NN N
therapy NN N
Patients NNS N
completed VBD N
the DT N
EORTC NNP N
QLQ NNP N
C30 NNP N
and CC N
the DT N
Prostate NNP N
Cancer NNP N
Index NNP N
( ( N
PCI NNP N
) ) N
before IN N
treatment NN N
and CC N
at IN N
1.5 CD N
, , N
3 CD N
, , N
6 CD N
, , N
12 CD N
, , N
18 CD N
, , N
24 CD N
, , N
and CC N
36 CD N
months NNS N
post-treatment JJ N
RESULTS NNP N
Regardless NNP N
of IN N
treatment NN N
arm NN N
, , N
participants NNS N
reported VBD N
high JJ N
levels NNS N
of IN N
QOL NNP N
with IN N
few JJ N
exceptions NNS N
cryoablation NN N
was VBD N
associated VBN N
with IN N
more RBR N
acute JJ N
urinary JJ N
dysfunction NN N
( ( N
mean JJ N
PCI NNP N
urinary JJ N
function NN N
cryoablation=69.4 NN N
; : N
mean JJ N
EBRT=90.7 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
which WDT N
resolved VBD N
over IN N
time NN N
No DT N
late JJ N
arising NN N
QOL NNP N
issues NNS N
were VBD N
observed VBN N
Both DT N
EBRT NNP N
and CC N
cryoablation NN N
participants NNS N
reported VBD N
decreases NNS N
in IN N
sexual JJ N
function NN N
at IN N
3 CD N
months NNS N
with IN N
the DT N
cryoablation NN N
patients NNS N
reporting VBG N
poorer NN N
functioning NN N
( ( N
mean JJ N
cryoablation=7.2 NN N
: : N
mean JJ N
EBRT=32.9 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
Mean JJ N
sexual JJ N
function NN N
score NN N
was VBD N
15 CD N
points NNS N
lower JJR N
at IN N
3 CD N
years NNS N
for IN N
the DT N
cryoablation NN N
group NN N
and CC N
13 CD N
% NN N
more JJR N
of IN N
the DT N
cryoablation NN N
men NNS N
said VBD N
that IN N
sexuality NN N
was VBD N
a DT N
moderate JJ N
or CC N
big JJ N
problem NN N
CONCLUSIONS NNP N
In IN N
this DT N
randomized JJ N
trial NN N
, , N
no DT N
long-term JJ N
QOL NNP N
advantage NN N
for IN N
either DT N
treatment NN N
was VBD N
apparent JJ N
with IN N
the DT N
exception NN N
of IN N
poorer JJR N
sexual JJ N
function NN N
reported VBN N
by IN N
those DT N
treated VBN N
with IN N
cryoablation NN N
Men NN N
who WP N
wish VBZ N
to TO N
increase VB N
their PRP$ N
odds NNS N
of IN N
retaining VBG N
sexual JJ N
function NN N
might MD N
be VB N
counseled VBN N
to TO N
choose VB N
EBRT NNP N
over IN N
cryoablation NN N
-DOCSTART- -X- O O 6740101

A DT N
comparison NN N
of IN N
the DT N
serologic JJ N
responses NNS N
to TO N
oral JJ N
and CC N
injectable JJ N
trivalent NN N
poliovirus NN N
vaccines NNS N
United NNP N
States NNPS N
children NNS 1_p
two CD 1_p
months NNS 1_p
of IN N
age NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
that WDT N
received VBD N
either RB N
the DT N
commercially RB N
available JJ N
oral JJ N
trivalent NN N
poliovirus NN N
vaccine NN N
( ( N
OPV NNP N
) ) N
or CC N
an DT N
injectable JJ N
( ( N
inactivated VBN N
) ) N
trivalent NN N
poliovirus NN N
vaccine NN N
( ( N
IPV NNP N
) ) N
with IN N
a DT N
confirmed JJ N
minimum JJ N
D-antigen NNP N
content NN N
of IN N
27 CD N
, , N
3.5 CD N
, , N
and CC N
29 CD N
units NNS N
for IN N
poliovirus NN N
types NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
, , N
respectively RB N
Vaccine NNP N
was VBD N
given VBN N
at IN N
two CD N
, , N
four CD N
, , N
and CC N
18 CD N
months NNS N
of IN N
age NN N
Sera NN N
obtained VBN N
from IN N
439 CD 3_p
children NNS 1_p
at IN 1_p
two CD 1_p
, , 1_p
four CD 1_p
, , 1_p
and CC 1_p
six CD 1_p
months NNS 1_p
of IN 1_p
age NN 1_p
and CC N
from IN N
85 CD 3_p
children NNS 1_p
at IN 1_p
18 CD 1_p
and CC 1_p
20 CD 1_p
months NNS 1_p
of IN 1_p
age NN 1_p
were VBD N
examined VBN N
for IN N
neutralizing VBG N
antibodies NNS N
The DT N
percentage NN N
of IN N
children NNS N
with IN N
detectable JJ N
antibodies NNS N
and CC N
the DT N
reciprocal JJ N
geometric JJ N
mean NN N
titers NNS N
were VBD N
similar JJ N
for IN N
both DT N
groups NNS N
at IN N
two CD N
months NNS N
of IN N
age NN N
for IN N
antibodies NNS N
to TO N
all DT N
three CD N
poliovirus NN N
types NNS N
At IN N
20 CD N
months NNS N
of IN N
age NN N
, , N
all DT N
children NNS N
but CC N
one CD N
had VBD N
detectable JJ N
antibodies NNS N
to TO N
all DT N
three CD N
poliovirus NN N
types NNS N
Significantly RB N
higher JJR N
geometric JJ N
mean NN N
titers NNS N
against IN N
types NNS N
2 CD N
and CC N
3 CD N
were VBD N
noted VBN N
at IN N
20 CD N
months NNS N
of IN N
age NN N
for IN N
the DT N
IPV NNP N
group NN N
-DOCSTART- -X- O O 3385217

Actions NNS N
of IN N
platelet NN N
activating VBG N
factor NN N
( ( N
PAF NNP N
) ) N
homologues NNS N
and CC N
their PRP$ N
combinations NNS N
on IN N
neutrophil JJ 4_p
chemokinesis NN 4_p
and CC N
cutaneous JJ 4_p
inflammatory NN 4_p
responses NNS 4_p
in IN N
man NN 2_p
The DT N
inflammatory JJ N
actions NNS N
of IN N
synthetic JJ N
C16:0 NNP N
and CC N
C18:0 NNP N
platelet NN N
activating VBG N
factor NN N
( ( N
PAF NNP N
) ) N
homologues NNS N
, , N
both DT N
alone RB N
and CC N
in IN N
combination NN N
, , N
have VBP N
been VBN N
compared VBN N
in IN N
an DT N
in IN N
vitro JJ N
human JJ N
neutrophil JJ 4_p
chemokinesis NN 4_p
assay NN N
and CC N
by IN N
intradermal JJ N
injection NN N
in IN N
human JJ N
skin NN N
In IN N
the DT N
chemokinesis NN N
assay NN N
, , N
the DT N
maximum JJ N
distance NN N
moved VBN N
by IN N
neutrophils NNS N
in IN N
the DT N
presence NN N
of IN N
C18:0 NNP N
PAF NNP N
was VBD N
significantly RB N
greater JJR N
than IN N
that DT N
seen VBN N
with IN N
the DT N
C16:0 NNP N
compound NN N
A DT N
mixture NN N
of IN N
C16:0 NNP N
and CC N
C18:0 NNP N
PAFs NNP N
in IN N
a DT N
ratio NN N
of IN N
1:9 CD N
appeared VBD N
to TO N
be VB N
more RBR N
active JJ N
than IN N
in IN N
a DT N
ratio NN N
of IN N
3:1 CD N
Intradermal JJ N
injection NN N
of IN N
the DT N
C16:0 NNP N
and CC N
C18:0 NNP N
PAF NNP N
homologues NNS N
induced VBD N
dose-dependent JJ N
increases NNS N
in IN N
weal JJ N
volume NN N
and CC N
flare JJ N
area NN N
responses NNS N
which WDT N
were VBD N
not RB N
significantly RB N
different JJ N
Combination NN N
of IN N
these DT N
phospholipids NNS N
in IN N
a DT N
ratio NN N
of IN N
3:1 CD N
or CC N
1:9 CD N
of IN N
C16:0 NN N
: : N
C18:0 NN N
did VBD N
not RB N
significantly RB N
alter VB N
the DT N
dose JJ N
response NN N
curves NNS N
Thus RB N
, , N
changes NNS N
in IN N
the DT N
chain NN N
length NN N
of IN N
the DT N
alkyl JJ N
substituent NN N
of IN N
synthetic JJ N
PAF NNP N
homologues NNS N
and CC N
combination NN N
of IN N
these DT N
homologues NNS N
, , N
in IN N
ratios NNS N
found VBN N
in IN N
vivo NN N
or CC N
formed VBN N
by IN N
leukocytes NNS N
in IN N
vitro NN N
, , N
did VBD N
not RB N
alter VB N
the DT N
cutaneous JJ 4_p
inflammatory NN 4_p
responses NNS 4_p
to TO N
PAF NNP N
in IN N
man NN 2_p
The DT N
C18:0 NNP N
homologue NN N
was VBD N
, , N
however RB N
, , N
more RBR N
active JJ N
as IN N
a DT N
human JJ N
neutrophil NN N
chemoattractant NN N
in IN N
vitro NN N
-DOCSTART- -X- O O 19928389

The DT N
effect NN N
of IN N
posture NN N
on IN N
Cheyne-Stokes NNP N
respirations NNS N
and CC N
hemodynamics NNS N
in IN N
patients NNS N
with IN N
heart NN 4_p
failure NN 4_p
STUDY NNP N
OBJECTIVES NNP N
Cheyne-Stokes NNP N
respirations NNS N
occur VBP N
in IN N
40 CD N
% NN N
of IN N
patients NNS N
with IN N
heart NN N
failure NN N
Orthopnea NNP N
is VBZ N
a DT N
cardinal JJ N
symptom NN N
of IN N
heart NN N
failure NN N
and CC N
may MD N
affect VB N
the DT N
patient NN N
's POS N
sleeping VBG N
angle NN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
respiratory NN N
and CC N
hemodynamic JJ N
response NN N
to TO N
sleeping VBG N
angle NN N
in IN N
a DT N
group NN N
of IN N
subjects NNS N
with IN N
stable JJ N
heart NN 4_p
failure NN 4_p
DESIGN NNP N
Twenty-five JJ 3_p
patients NNS N
underwent JJ N
overnight JJ N
polysomnography NN N
with IN N
simultaneous JJ N
and CC N
continuous JJ N
impedance NN N
cardiographic JJ N
monitoring NN N
Sleeping VBG N
polysomnographic JJ N
and CC N
impedance JJ N
cardiographic JJ N
data NNS N
were VBD N
recorded VBN N
SETTING VBG N
The DT N
study NN N
was VBD N
conducted VBN N
in IN N
a DT N
sleep JJ N
center NN N
PATIENTS VB N
All DT N
25 CD 3_p
patients NNS N
had VBD N
clinically RB 4_p
stable JJ 4_p
heart NN 4_p
failure NN 4_p
and CC N
left VBD N
ventricular JJ 4_p
ejection NN 4_p
fractions NNS 4_p
< VBP 4_p
40 CD 4_p
% NN 4_p
INTERVENTIONS NNP N
The DT N
patients NNS N
slept VBD N
at IN N
0 CD N
degrees NNS N
, , N
15 CD N
degrees NNS N
, , N
30 CD N
degrees NNS N
, , N
and CC N
45 CD N
degrees NNS N
in IN N
random JJ N
order NN N
MEASUREMENTS NNS N
AND CC N
RESULTS NNP N
Seventeen NNP N
patients NNS N
had VBD N
Cheyne-Stokes NNP N
apneas NNS N
( ( N
index NN N
> RB N
5/h CD N
) ) N
and CC N
23 CD N
patients NNS N
had VBD N
hypopneas NNS N
( ( N
index NN N
> RB N
5/h CD N
) ) N
The DT N
hypopnea NN N
index NN N
showed VBD N
no DT N
response NN N
to TO N
sleeping VBG N
angle NN N
The DT N
Cheyne-Stokes NNP N
apnea NN N
index NN N
decreased VBD N
with IN N
increasing VBG N
sleeping VBG N
angle NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
This DT N
effect NN N
was VBD N
seen VBN N
only RB N
during IN N
supine JJ N
sleep NN N
and CC N
non-rapid JJ N
eye NN N
movement NN N
sleep NN N
and CC N
was VBD N
absent VBN N
in IN N
non-supine JJ N
sleep NN N
, , N
rapid JJ N
eye NN N
movement NN N
sleep NN N
, , N
and CC N
during IN N
periods NNS N
of IN N
wakefulness NN N
Thoracic NNP N
fluid NN N
content NN N
index NN N
and CC N
left VBD N
ventricular JJ N
hemodynamics NNS N
measured VBN N
by IN N
impedance NN N
cardiography NN N
showed VBD N
no DT N
response NN N
to TO N
sleeping VBG N
angle NN N
CONCLUSIONS NNP N
Changing VBG N
the DT N
heart NN N
failure NN N
patient NN N
's POS N
sleeping VBG N
angle NN N
from IN N
0 CD N
degrees NNS N
to TO N
45 CD N
degrees NNS N
results NNS N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
Cheyne-Stokes NNP N
apneas NN N
This DT N
decrease NN N
occurs VBZ N
on IN N
a DT N
constant JJ N
base NN N
of IN N
hypopneas NNS N
The DT N
changes NNS N
in IN N
Cheyne-Stokes NNP N
apneas NNS N
are VBP N
not RB N
related VBN N
to TO N
changes NNS N
in IN N
lung NN N
congestion NN N
and CC N
left VBD N
ventricular JJ N
hemodynamics NNS N
-DOCSTART- -X- O O 19763803

Azelnidipine NNP N
and CC N
amlodipine VB N
anti-coronary JJ N
atherosclerosis NN N
trial NN N
in IN N
hypertensive JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
coronary JJ 4_p
intervention NN 4_p
by IN 4_p
serial JJ 4_p
volumetric JJ 4_p
intravascular NN 4_p
ultrasound NN 4_p
analysis NN 4_p
in IN 4_p
Juntendo NNP 4_p
university NN 4_p
( ( 4_p
ALPS-J NNP 4_p
) ) 4_p
PURPOSE NNP N
Many JJ N
trials NNS N
have VBP N
shown VBN N
that IN N
calcium NN N
channel NN N
blockers NNS N
( ( N
CCBs NNP N
) ) N
can MD N
reduce VB N
the DT N
cardiovascular NN N
( ( N
CV NNP N
) ) N
events NNS N
in IN N
patients NNS N
with IN N
coronary JJ N
artery NN N
disease NN N
( ( N
CAD NNP N
) ) N
The DT N
mechanisms NN N
of IN N
this DT N
effect NN N
could MD N
be VB N
associated VBN N
with IN N
plaque JJ N
regression NN N
due JJ N
to TO N
the DT N
anti-atherosclerotic JJ N
properties NNS N
of IN N
CCBs NNP N
The DT N
goal NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
CCB NNP N
on IN N
volumetric JJ N
quantitative JJ N
changes NNS N
of IN N
coronary JJ N
plaques NNS N
accessed VBN N
by IN N
intravascular JJ N
ultrasound NN N
( ( N
IVUS NNP N
) ) N
To TO N
confirm VB N
this DT N
hypothesis NN N
, , N
a DT N
multicenter NN N
randomized VBN N
trial NN N
of IN N
CCBs NNP N
treatment NN N
with IN N
azelnidipine NN N
or CC N
amlodipine NN N
will MD N
be VB N
conducted VBN N
in IN N
hypertensive JJ 4_p
CAD NNP 4_p
patients NNS 4_p
undergoing VBG 4_p
elective JJ 4_p
percutaneous JJ 4_p
coronary JJ 4_p
intervention NN 4_p
( ( 4_p
PCI NNP 4_p
) ) 4_p
METHODS NNP N
AND CC N
RESULTS NNP N
Patients NNPS 1_p
who WP 1_p
have VBP 1_p
hypertension NN 1_p
and CC 1_p
are VBP 1_p
scheduled VBN 1_p
for IN 1_p
PCI NNP 1_p
will MD 1_p
be VB 1_p
enrolled VBN 1_p
Subjects NNS N
will MD N
be VB N
randomized VBN N
to TO N
azelnidipine VB N
or CC N
amlodipine VB N
and CC N
observed VB N
for IN N
48 CD N
weeks NNS N
The DT N
primary JJ N
endpoint NN N
will MD N
be VB N
the DT N
percent NN N
change NN N
of IN N
coronary JJ N
plaque NN N
volume NN N
The DT N
secondary JJ N
endpoint NN N
will MD N
include VB N
inflammatory JJ N
markers NNS N
, , N
antioxidant JJ N
activity NN N
, , N
and CC N
incidence NN N
of IN N
composite JJ N
cardiovascular JJ N
events NNS N
CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
we PRP N
will MD N
investigate VB N
the DT N
improvement NN N
of IN N
coronary JJ N
plaque NN N
with IN N
IVUS NNP N
by IN N
treatment NN N
with IN N
two CD N
dihydropyridine NN N
CCBs NNP N
in IN N
hypertensive JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
elective JJ 4_p
PCI NNP 4_p
This DT N
result NN N
will MD N
lead VB N
to TO N
the DT N
discovery NN N
of IN N
more RBR N
effective JJ N
drug NN N
therapy NN N
for IN N
inhibition NN N
of IN N
coronary JJ N
events NNS N
-DOCSTART- -X- O O 8873520

The DT N
tension-free JJ N
hernioplasty NN N
in IN N
a DT N
randomized JJ N
trial NN N
BACKGROUND VB N
The DT N
tension-free JJ N
hernioplasty NN N
as IN N
introduced VBN N
by IN N
Lichtenstein NNP N
has VBZ N
gained VBN N
increasing VBG N
acceptance NN N
during IN N
the DT N
last JJ N
decade NN N
although IN N
the DT N
technique NN N
has VBZ N
not RB N
been VBN N
evaluated VBN N
in IN N
a DT N
randomized JJ N
trial NN N
METHODS NNP N
This DT N
randomized VBN N
study NN N
compares VBZ N
the DT N
2-year JJ N
follow-up JJ N
results NNS N
after IN N
102 CD 3_p
tension-free JJ N
hernioplasties NNS 4_p
with IN N
implantation NN N
of IN N
a DT N
prolene NN N
mesh NN N
in IN N
all DT N
groin NN 4_p
hernias VBD 4_p
to TO N
53 CD 3_p
Cooper NNP N
ligament NN N
repairs NNS N
in IN N
direct JJ 4_p
hernias NN 4_p
and CC N
53 CD 3_p
abdominal JJ N
ring NN N
repairs NNS N
in IN N
indirect JJ 4_p
hernias NN 4_p
RESULTS NNP N
After IN N
tension-free JJ N
repairs NNS N
five CD N
hernias NNS N
recurred VBN N
( ( N
5 CD N
% NN N
) ) N
, , N
and CC N
after IN N
either DT N
Cooper NNP N
ligament NN N
or CC N
abdominal JJ N
ring NN N
repair NN N
, , N
16 CD N
recurrences NNS N
were VBD N
found VBN N
( ( N
15 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.025 CD N
) ) N
No UH N
indirect JJ N
hernias NN N
recurred VBD N
after IN N
a DT N
tension-free JJ N
repair NN N
; : N
2 CD N
recurred VBD N
after IN N
abdominal JJ N
ring NN N
repair NN N
( ( N
4 CD N
% NN N
; : N
NS NNP N
) ) N
The DT N
recurrence NN N
rate NN N
after IN N
tension-free JJ N
repairs NNS N
for IN N
primary JJ N
direct JJ N
inguinal JJ N
hernias NN N
was VBD N
7 CD N
% NN N
as IN N
compared VBN N
with IN N
30 CD N
% NN N
after IN N
Cooper NNP N
ligament NN N
repair NN N
( ( N
P NNP N
= NNP N
0.0081 CD N
) ) N
No DT N
difference NN N
in IN N
complication NN N
rate NN N
between IN N
the DT N
tested JJ N
methods NNS N
was VBD N
found VBN N
CONCLUSION JJ N
Recurrence NNP N
rate NN N
is VBZ N
reduced VBN N
to TO N
one-third JJ N
after IN N
tension-free JJ 4_p
herniotomies NNS 4_p
as IN N
compared VBN N
with IN N
the DT N
conventionel NN N
herniotomies NNS N
without IN N
increase NN N
in IN N
complication NN N
rate NN N
-DOCSTART- -X- O O 1291393

An DT N
in IN N
vitro NN N
comparative JJ N
analysis NN N
: : N
scanning NN N
electron NN N
microscopy NN N
of IN N
dentin/restoration NN N
interfaces NNS N
One CD 3_p
hundred VBD 3_p
maxillary JJ N
premolar JJ N
teeth NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
ten VB N
groups NNS N
Each DT N
group NN N
was VBD N
restored VBN N
with IN N
one CD N
of IN N
ten JJ N
different JJ N
restorative NN N
techniques NNS N
The DT N
teeth NNS N
were VBD N
stored VBN N
in IN N
deionized JJ N
water NN N
for IN N
7d CD N
prior JJ N
to TO N
longitudinal JJ N
sectioning NN N
in IN N
a DT N
mesio-distal JJ N
plane NN N
Following VBG N
sectioning NN N
, , N
ten JJ N
specimens NNS N
from IN N
each DT N
group NN N
were VBD N
chosen VBN N
at IN N
random NN N
from IN N
the DT N
20 CD N
available JJ N
sections NNS N
The DT N
sectioned JJ N
surfaces NNS N
were VBD N
polished VBN N
using VBG N
600-grit JJ N
SiC NNP N
abrasive JJ N
paper NN N
and CC N
etched VBD N
for IN N
10 CD N
s NN N
with IN N
50 CD N
% NN N
phosphoric JJ N
acid NN N
to TO N
remove VB N
the DT N
smear JJ N
layer NN N
produced VBN N
by IN N
sectioning VBG N
Five CD N
tooth JJ N
sections NNS N
from IN N
the DT N
dentin NN N
bonding VBG N
resin NN N
groups NNS N
were VBD N
allowed VBN N
to TO N
dry VB N
at IN N
20 CD N
degrees NNS N
C NNP N
for IN N
24h CD N
The DT N
glass NN N
ionomer-based JJ N
groups NNS N
were VBD N
reimmersed VBN N
in IN N
deionized JJ N
water NN N
during IN N
this DT N
period NN N
The DT N
remaining VBG N
five CD N
sections NNS N
from IN N
each DT N
group NN N
were VBD N
replicated VBN N
using VBG N
an DT N
addition-cure JJ N
vinyl NN N
polysiloxane NN N
impression NN N
material NN N
and CC N
an DT N
epoxy JJ N
resin NN N
A DT N
comparison NN N
was VBD N
made VBN N
of IN N
the DT N
sections NNS N
and CC N
the DT N
replicas NN N
All DT N
tooth JJ N
specimens NNS N
were VBD N
sputter-coated JJ N
with IN N
gold NN N
for IN N
4 CD N
min NNS N
and CC N
examined VBD N
using VBG N
a DT N
scanning VBG N
electron NN N
microscope NN N
Replicas NNPS N
were VBD N
gold-coated JJ N
for IN N
3 CD N
min NN N
Different JJ N
tooth/restoration NN N
interfaces NNS N
, , N
associated VBN N
with IN N
different JJ N
materials NNS N
, , N
were VBD N
observed VBN N
A DT N
marked JJ N
difference NN N
between IN N
the DT N
replicas NN N
and CC N
tooth JJ N
sections NNS N
was VBD N
observed VBN N
for IN N
glass NN N
ionomer-based JJ N
restorations NNS N
but CC N
not RB N
for IN N
resin-based JJ N
bonding NN N
systems NNS N
Representative JJ N
samples NNS N
of IN N
replicas NN N
and CC N
specimens NNS N
are VBP N
shown VBN N
, , N
and CC N
the DT N
significance NN N
of IN N
the DT N
observed JJ N
differences NNS N
is VBZ N
discussed VBN N
-DOCSTART- -X- O O 23118244

Effects NNS N
of IN N
a DT N
standardized JJ N
pamphlet NN N
on IN N
insomnia NN 4_p
in IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
OBJECTIVE NNP N
Sleep NNP N
difficulties NNS N
are VBP N
common JJ N
reasons NNS N
why WRB N
parents NNS N
seek VBP N
medical JJ N
intervention NN N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP 4_p
) ) N
We PRP N
determined VBD N
whether IN N
a DT N
pamphlet NN N
alone RB N
could MD N
be VB N
used VBN N
by IN N
parents NNS N
to TO N
help VB N
their PRP$ N
child NN N
's POS N
insomnia NN N
METHODS NNP N
Thirty-six JJ 3_p
children NNS 1_p
with IN N
ASD NNP 4_p
, , N
ages VBZ 1_p
2 CD 1_p
to TO 1_p
10 CD 1_p
years NNS 1_p
, , N
were VBD N
enrolled VBN N
All DT N
had VBD N
prolonged VBN N
sleep JJ N
latency NN N
confirmed VBN N
by IN N
actigraphy NN N
showing VBG N
a DT N
mean JJ N
sleep JJ N
latency NN N
of IN N
30 CD N
minutes NNS N
or CC N
more JJR N
Parents NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
the DT N
sleep JJ N
education NN N
pamphlet NN N
or CC N
no DT N
intervention NN N
Children NNP N
wore VBD N
an DT N
actigraphy NN N
device NN N
to TO N
record VB N
baseline NN N
sleep JJ N
parameters NNS N
, , N
with IN N
the DT N
primary JJ N
outcome NN N
variable JJ N
being VBG N
change NN N
in IN N
sleep JJ N
latency NN N
Actigraphy NNP N
data NNS N
were VBD N
collected VBN N
a DT N
second JJ N
time NN N
2 CD N
weeks NNS N
after IN N
the DT N
parent NN N
received VBD N
the DT N
randomization NN N
assignment NN N
and CC N
analyzed VBN N
by IN N
using VBG N
Student NNP N
's POS N
t JJ N
test NN N
Parents NNS N
were VBD N
also RB N
asked VBN N
a DT N
series NN N
of IN N
questions NNS N
to TO N
gather VB N
information NN N
about IN N
the DT N
pamphlet NN N
and CC N
its PRP$ N
usefulness NN N
RESULTS NNP N
Although IN N
participants NNS N
randomized VBN N
to TO N
the DT N
2 CD N
arms NNS N
did VBD N
not RB N
differ VB N
statistically RB N
in IN N
age NN N
, , N
gender NN N
, , N
socioeconomic JJ N
status NN N
, , N
total JJ N
Children NNP N
's POS N
Sleep NNP N
Habits NNP N
Questionnaire NNP N
score NN N
, , N
or CC N
actigraphy NN N
parameters NNS N
, , N
some DT N
differences NNS N
may MD N
be VB N
large JJ N
enough RB N
to TO N
affect VB N
results NNS N
Mean JJ N
change NN N
in IN N
sleep-onset JJ N
latency NN N
did VBD N
not RB N
differ VB N
between IN N
the DT N
randomized VBN N
groups NNS N
( ( N
pamphlet VB N
versus NN N
no DT N
pamphlet NN N
) ) N
Parents NNS N
commented VBD N
that IN N
the DT N
pamphlet NN N
contained VBD N
good JJ N
information NN N
, , N
but CC N
indicated VBD N
that IN N
it PRP N
would MD N
have VB N
been VBN N
more RBR N
useful JJ N
to TO N
be VB N
given VBN N
specific JJ N
examples NNS N
of IN N
how WRB N
to TO N
take VB N
the DT N
information NN N
and CC N
put VB N
it PRP N
into IN N
practice NN N
CONCLUSIONS VB N
A DT N
sleep JJ N
education NN N
pamphlet NN N
did VBD N
not RB N
appear VB N
to TO N
improve VB N
sleep JJ N
latency NN N
in IN N
children NNS N
with IN N
ASDs NNP N
-DOCSTART- -X- O O 25623276

The DT N
effects NNS N
of IN N
stimulation NN N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
via IN N
perioperative JJ N
nutrition NN N
on IN N
postoperative JJ N
ileus NN N
and CC N
anastomotic JJ N
leakage NN N
following VBG N
colorectal JJ N
surgery NN N
( ( N
SANICS NNP N
II NNP N
trial NN N
) ) N
: : N
a DT N
study NN N
protocol NN N
for IN N
a DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
BACKGROUND NNP N
Postoperative NNP N
ileus NN N
and CC N
anastomotic JJ N
leakage NN N
are VBP N
important JJ N
complications NNS N
following VBG N
colorectal JJ N
surgery NN N
associated VBN N
with IN N
short-term JJ N
morbidity NN N
and CC N
mortality NN N
Previous JJ N
experimental JJ N
and CC N
preclinical JJ N
studies NNS N
have VBP N
shown VBN N
that IN N
a DT N
short JJ N
intervention NN N
with IN N
enriched JJ N
enteral JJ N
nutrition NN N
dampens VBZ N
inflammation NN N
via IN N
stimulation NN N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
and CC N
thereby RB N
reduces NNS N
postoperative JJ N
ileus NN N
Furthermore RB N
, , N
early JJ N
administration NN N
of IN N
enteral JJ N
nutrition NN N
reduced VBD N
anastomotic JJ N
leakage NN N
This DT N
study NN N
will MD N
investigate VB N
the DT N
effect NN N
of IN N
nutritional JJ N
stimulation NN N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
just RB N
before RB N
, , N
during IN N
and CC N
early RB N
after IN N
colorectal JJ N
surgery NN N
on IN N
inflammation NN N
, , N
postoperative JJ N
ileus NN N
and CC N
anastomotic JJ N
leakage NN N
METHODS/DESIGN NNP N
This DT N
multicenter NN N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
controlled VBN N
trial NN N
will MD N
include VB N
280 CD 3_p
patients NNS 3_p
undergoing JJ N
colorectal JJ 4_p
surgery NN 4_p
All DT N
patients NNS N
will MD N
receive VB N
a DT N
selfmigrating JJ N
nasojejunal JJ N
tube NN N
that WDT N
will MD N
be VB N
connected VBN N
to TO N
a DT N
specially RB N
designed VBN N
blinded VBN N
tubing NN N
system NN N
Patients NNS N
will MD N
be VB N
allocated VBN N
either DT N
to TO N
the DT N
intervention NN N
group NN N
, , N
receiving VBG N
perioperative JJ N
nutrition NN N
, , N
or CC N
to TO N
the DT N
control NN N
group NN N
, , N
receiving VBG N
no DT N
nutrition NN N
The DT N
primary JJ N
endpoint NN N
is VBZ N
postoperative JJ N
ileus NN N
Secondary JJ N
endpoints NNS N
include VBP N
anastomotic JJ N
leakage NN N
, , N
local JJ N
and CC N
systemic JJ N
inflammation NN N
, , N
( ( N
aspiration NN N
) ) N
pneumonia NN N
, , N
surgical JJ N
complications NNS N
classified VBD N
according VBG N
to TO N
Clavien-Dindo NNP N
, , N
quality NN N
of IN N
life NN N
, , N
gut FW N
barrier JJR N
integrity NN N
and CC N
time NN N
until IN N
functional JJ N
recovery NN N
Furthermore NNP N
, , N
a DT N
cost-effectiveness JJ N
analysis NN N
will MD N
be VB N
performed VBN N
DISCUSSION NNP N
Activation NNP N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
via IN N
perioperative JJ N
enteral JJ N
feeding NN N
is VBZ N
expected VBN N
to TO N
dampen VB N
the DT N
local JJ N
and CC N
systemic JJ N
inflammatory NN N
response NN N
Consequently RB N
, , N
postoperative JJ N
ileus NN N
will MD N
be VB N
reduced VBN N
as RB N
well RB N
as IN N
anastomotic JJ N
leakage NN N
The DT N
present JJ N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
enriched JJ N
nutrition NN N
given VBN N
shortly RB N
before RB N
, , N
during IN N
and CC N
after IN N
surgery NN N
in IN N
a DT N
clinical JJ N
setting NN N
TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
: : N
NCT02175979 NNP N
- : N
date NN N
of IN N
registration NN N
: : N
25 CD N
June NNP N
2014 CD N
Dutch VB N
Trial JJ N
Registry NN N
: : N
NTR4670 NNP N
- : N
date NN N
of IN N
registration NN N
: : N
1 CD N
August NNP N
2014 CD N
-DOCSTART- -X- O O 9926538

Network NNP N
support NN N
for IN N
drinking NN N
, , N
Alcoholics NNP N
Anonymous NNP N
and CC N
long-term JJ N
matching NN N
effects NNS N
AIMS NNP N
( ( N
1 CD N
) ) N
To TO N
examine VB N
the DT N
matching JJ N
hypothesis NN N
that WDT N
Twelve NNP N
Step NNP N
Facilitation NNP N
Therapy NNP N
( ( N
TSF NNP N
) ) N
is VBZ N
more RBR N
effective JJ N
than IN N
Motivational NNP N
Enhancement NNP N
Therapy NNP N
( ( N
MET NNP N
) ) N
for IN N
alcohol-dependent JJ 4_p
clients NNS N
with IN N
networks NNS N
highly RB N
supportive JJ N
of IN N
drinking VBG N
3 CD N
years NNS N
following VBG N
treatment NN N
; : N
( ( N
2 CD N
) ) N
to TO N
test VB N
a DT N
causal NN N
chain NN N
providing VBG N
the DT N
rationale NN N
for IN N
this DT N
effect NN N
DESIGN NN N
Outpatients NNPS 4_p
were VBD N
re-interviewed JJ N
3 CD N
years NNS N
following VBG N
treatment NN N
ANCOVAs NNP N
tested VBD N
the DT N
matching JJ N
hypothesis NN N
SETTING NN N
Outpatients NNS N
from IN N
five CD N
clinical JJ N
research NN N
units NNS N
distributed VBN N
across IN N
the DT N
United NNP N
States NNPS N
PARTICIPANTS NNP N
Eight NNP 3_p
hundred VBD 3_p
and CC 3_p
six CD 3_p
alcohol-dependent JJ 4_p
clients NNS N
INTERVENTION JJ N
Clients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
12-week JJ N
, , N
manually-guided JJ N
, , N
individual JJ N
treatments NNS N
: : N
TSF NNP N
, , N
MET NNP N
or CC N
Cognitive NNP N
Behavioral NNP N
Coping NNP N
Skills NNP N
Therapy NNP N
( ( N
CBT NNP N
) ) N
MEASUREMENTS NNP N
Network NNP N
support NN N
for IN N
drinking VBG N
prior JJ N
to TO N
treatment NN N
, , N
Alcoholics NNP N
Anonymous NNP N
( ( N
AA NNP N
) ) N
involvement NN N
during IN N
and CC N
following VBG N
treatment NN N
, , N
percentage NN N
of IN N
days NNS N
abstinent JJ N
and CC N
drinks NNS N
per IN N
drinking NN N
day NN N
during IN N
months NNS N
37-39 JJ N
FINDINGS NNP N
( ( N
1 CD N
) ) N
The DT N
a DT N
priori JJ N
matching NN N
hypothesis NN N
that IN N
TSF NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
MET NNP N
for IN N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
was VBD N
supported VBN N
at IN N
the DT N
3 CD N
year NN N
follow-up NN N
; : N
( ( N
2 CD N
) ) N
AA NNP N
involvement NN N
was VBD N
a DT N
partial JJ N
mediator NN N
of IN N
this DT N
effect NN N
; : N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
assigned VBN N
to TO N
TSF VB N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
involved VBN N
in IN N
AA NNP N
; : N
AA NNP N
involvement NN N
was VBD N
associated VBN N
with IN N
better JJR N
3-year JJ N
drinking NN N
outcomes NNS N
for IN N
such JJ N
clients NNS N
CONCLUSIONS NNP N
( ( N
1 CD N
) ) N
In IN N
the DT N
long-term JJ N
TSF NNP N
may MD N
be VB N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
alcohol-dependent JJ N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
; : N
( ( N
2 CD N
) ) N
involvement NN N
in IN N
AA NNP N
should MD N
be VB N
given VBN N
special JJ N
consideration NN N
for IN N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
, , N
irrespective NN N
of IN N
the DT N
therapy NN N
they PRP N
will MD N
receive VB N
-DOCSTART- -X- O O 18429536

Evaluation NN N
of IN N
a DT N
device NN N
to TO N
facilitate VB N
female JJ 2_p
urethral JJ N
catheterization NN N
Urethral JJ N
catheterization NN N
is VBZ N
a DT N
skilled JJ N
procedure NN N
that WDT N
nurses VBZ N
in IN N
hospital JJ N
settings NNS N
perform VBP N
routinely RB N
The DT N
opening NN N
of IN N
the DT N
female JJ N
urethra NN N
is VBZ N
located VBN N
within IN N
the DT N
vulvar NN N
vestibule NN N
, , N
making VBG N
insertion NN N
of IN N
urinary JJ N
catheters NNS N
into IN N
females NNS 2_p
a DT N
greater JJR N
technical JJ N
challenge NN N
than IN N
in IN N
males NNS N
Researchers NNS N
evaluated VBD N
whether IN N
a DT N
new JJ N
device NN N
might MD N
decrease VB N
the DT N
time NN N
required VBN N
for IN N
catheter NN N
insertion NN N
, , N
increase VB N
the DT N
likelihood NN N
of IN N
inserting VBG N
the DT N
catheter NN N
on IN N
the DT N
first JJ N
attempt NN N
( ( N
improved VBN N
accuracy NN N
) ) N
, , N
and CC N
reduce VB N
patient JJ N
discomfort NN N
Comments NNS N
about IN N
the DT N
device NN N
from IN N
both DT N
patients NNS N
and CC N
nurses NNS N
also RB N
are VBP N
reported VBN N
-DOCSTART- -X- O O 1659236

A DT N
randomized JJ N
trial NN N
of IN N
an DT N
interim JJ N
methadone NN N
maintenance NN N
clinic NN N
BACKGROUND NNP N
Interim NNP N
methadone NN N
maintenance NN N
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
method NN N
of IN N
providing VBG N
clinically RB N
effective JJ N
services NNS N
to TO N
heroin VB 4_p
addicts NNS 4_p
waiting VBG N
for IN N
treatment NN N
in IN N
standard JJ N
comprehensive JJ N
methadone NN N
maintenance NN N
programs NNS N
METHODS NNP N
A NNP N
clinic NN N
that WDT N
provided VBD N
initial JJ N
medical JJ N
evaluation NN N
, , N
methadone NN N
medication NN N
, , N
and CC N
AIDS NNP N
education NN N
, , N
but CC N
did VBD N
not RB N
include VB N
formal JJ N
drug NN N
abuse NN N
counseling NN N
or CC N
other JJ N
social JJ N
support NN N
services NNS N
was VBD N
established VBN N
in IN N
New NNP N
York NNP N
City NNP N
A NNP N
sample NN N
of IN N
301 CD 3_p
volunteer NN N
subjects NNS N
recruited VBN N
from IN N
the DT N
waiting VBG N
list NN N
for IN N
treatment NN N
in IN N
the DT N
Beth NNP N
Israel NNP N
methadone NN N
program NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
immediate VB N
entry NN N
into IN N
the DT N
interim JJ N
clinic NN N
or CC N
a DT N
control NN N
group NN N
RESULTS CC N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
initial JJ N
levels NNS N
of IN N
illicit JJ N
drug NN N
use NN N
across IN N
the DT N
experimental JJ N
and CC N
control NN N
groups NNS N
One-month JJ N
urinalysis JJ N
follow-up NN N
data NNS N
showed VBD N
a DT N
significant JJ N
reduction NN N
in IN N
heroin NN N
use NN N
in IN N
the DT N
experimental JJ N
group NN N
( ( N
from IN N
63 CD N
% NN N
positive JJ N
at IN N
intake NN N
to TO N
29 CD N
% NN N
positive JJ N
) ) N
with IN N
no DT N
change NN N
in IN N
the DT N
control NN N
group NN N
( ( N
62 CD N
% NN N
to TO N
60 CD N
% NN N
positive JJ N
) ) N
No DT N
significant JJ N
change NN N
was VBD N
observed VBN N
in IN N
cocaine NN N
urinalyses NNS N
( ( N
approximately RB N
70 CD N
% NN N
positive JJ N
for IN N
both DT N
groups NNS N
at IN N
intake NN N
and CC N
follow-up NN N
) ) N
A DT N
higher JJR N
percentage NN N
of IN N
the DT N
experimental JJ N
group NN N
were VBD N
in IN N
treatment NN N
at IN N
16-month JJ N
follow-up NN N
( ( N
72 CD N
% NN N
vs JJ N
56 CD N
% NN N
) ) N
CONCLUSIONS NNP N
Limited NNP N
services NNS N
interim VBP N
methadone JJ N
maintenance NN N
can MD N
reduce VB N
heroin NNS N
use VBP N
among IN N
persons NNS N
awaiting VBG N
entry NN N
into IN N
comprehensive JJ N
treatment NN N
and CC N
increase VB N
the DT N
percentage NN N
entering VBG N
treatment NN N
-DOCSTART- -X- O O 2694356

Low JJ N
power NN N
laser NN N
therapy NN N
of IN N
shoulder NN 4_p
tendonitis NN 4_p
30 CD 3_p
patients NNS N
with IN 4_p
supraspinatus NN 4_p
or CC 4_p
bicipital JJ 4_p
tendonitis NN 4_p
were VBD N
randomly RB N
allocated VBN N
to TO N
active JJ N
infrared VBN N
laser NN N
therapy NN N
at IN N
904 CD N
nm JJ N
three CD N
times NNS N
weekly RB N
for IN N
2 CD N
weeks NNS N
, , N
dummy JJ N
laser NN N
or CC N
drug NN N
treatment NN N
for IN N
2 CD N
weeks NNS N
Objectively RB N
maximum JJ N
active JJ N
extension NN N
, , N
flexion NN N
and CC N
abduction NN N
of IN N
the DT N
shoulder NN N
, , N
and CC N
subjectively RB N
pain VB N
stiffness JJ N
movement NN N
and CC N
function NN N
were VBD N
measured VBN N
at IN N
0 CD N
and CC N
2 CD N
weeks NNS N
Significant JJ N
improvement NN N
of IN N
active JJ N
over IN N
dummy JJ N
laser NN N
was VBD N
noted VBN N
for IN N
all DT N
seven CD N
assessments NNS N
Active NNP N
laser NN N
therapy NN N
produced VBD N
significant JJ N
improvement NN N
over IN N
drug NN N
therapy NN N
for IN N
all DT N
three CD N
objective JJ N
measures NNS N
and CC N
pain NN N
Naproxen NNP N
sodium NN N
significantly RB N
improved VBN N
only RB N
movement NN N
and CC N
function NN N
compared VBN N
to TO N
dummy VB N
laser NN N
These DT N
results NNS N
demonstrate VBP N
the DT N
effectiveness NN N
of IN N
laser NN N
therapy NN N
in IN N
tendonitis NN N
of IN N
the DT N
shoulder NN N
-DOCSTART- -X- O O 6841763

Modifying VBG N
the DT N
Type NN 4_p
A DT 4_p
coronary-prone JJ 4_p
behavior NN 4_p
pattern NN N
-DOCSTART- -X- O O 11453509

Ipratropium NNP N
bromide NN N
nasal NN N
spray NN N
for IN N
treatment NN N
of IN N
rhinorrhea NN 4_p
in IN N
the DT N
laryngectomized JJ 4_p
patient NN 4_p
: : N
a DT N
pilot NN N
study NN N
Many NNP N
who WP N
have VBP N
had VBD N
a DT N
total JJ N
laryngectomy NN N
complain NN N
of IN N
unrelenting VBG N
rhinorrhea NN N
that WDT N
is VBZ N
often RB N
very RB N
difficult JJ N
to TO N
control VB N
This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
ipratropium NN N
bromide NN N
( ( N
IB NNP N
) ) N
, , N
an DT N
anticholinergic JJ N
nasal NN N
spray NN N
, , N
on IN N
rhinorrhea NN N
in IN N
these DT N
patients NNS N
This DT N
was VBD N
designed VBN N
as IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
crossover NN N
pilot NN N
study NN N
Participants NNS N
were VBD N
selected VBN N
if IN N
they PRP N
had VBD N
a DT N
total JJ 4_p
laryngectomy NN 4_p
and CC N
complained VBD N
of IN N
rhinorrhea NN 4_p
They PRP N
were VBD N
asked VBN N
to TO N
rate NN N
the DT N
severity NN N
and CC N
duration NN N
of IN N
their PRP$ N
rhinorrhea JJ N
each DT N
day NN N
throughout IN N
the DT N
study NN N
on IN N
a DT N
scale NN N
from IN N
zero CD N
to TO N
six CD N
Each DT N
participant NN N
was VBD N
initially RB N
given VBN N
a DT N
saline NN N
nasal NN N
spray NN N
for IN N
one CD N
week NN N
They PRP N
were VBD N
then RB N
randomized VBN N
to TO N
use VB N
either DT N
IB NNP N
or CC N
saline NN N
for IN N
the DT N
double-blinded JJ N
portion NN N
of IN N
the DT N
study NN N
Two CD N
sprays NNS N
of IN N
IB NNP N
at IN N
a DT N
dose NN N
of IN N
42 CD N
micrograms/spray NN N
( ( N
0.06 CD N
% NN N
) ) N
, , N
or CC N
saline NN N
, , N
were VBD N
administered VBN N
intranasally RB N
twice JJ N
daily RB N
for IN N
two CD N
weeks NNS N
, , N
after IN N
which WDT N
time NN N
the DT N
participants NNS N
were VBD N
given VBN N
another DT N
nasal NN N
spray NN N
( ( N
either CC N
IB NNP N
or CC N
saline NN N
) ) N
for IN N
the DT N
crossover NN N
portion NN N
of IN N
the DT N
study NN N
Six CD 3_p
patients NNS N
entered VBD N
and CC N
completed VBD N
the DT N
study NN N
Those DT N
patients NNS N
using VBG N
the DT N
IB NNP N
recorded VBD N
a DT N
mean JJ N
55 CD N
% NN N
decline NN N
in IN N
severity NN N
and CC N
a DT N
mean JJ N
51 CD N
% NN N
decline NN N
in IN N
duration NN N
of IN N
the DT N
rhinorrhea NN N
as IN N
compared VBN N
to TO N
placebo VB N
The DT N
relief NN N
in IN N
both DT N
severity NN N
and CC N
duration NN N
of IN N
rhinorrhea NN N
obtained VBN N
by IN N
patients NNS N
was VBD N
analyzed VBN N
using VBG N
the DT N
Wilcoxon NNP N
signed-rank JJ N
test NN N
and CC N
found VBN N
to TO N
be VB N
highly RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
Despite IN N
the DT N
limitations NNS N
of IN N
a DT N
small JJ N
sample NN N
size NN N
in IN N
this DT N
study NN N
, , N
ipratropium NN N
bromide NN N
nasal NN N
spray NN N
significantly RB N
reduced VBD N
both DT N
the DT N
severity NN N
and CC N
duration NN N
of IN N
rhinorrhea NN N
in IN N
laryngectomized JJ N
patients NNS N
We PRP N
suggest VBP N
ipratropium JJ N
nasal NN N
spray NN N
as IN N
a DT N
safe JJ N
, , N
effective JJ N
way NN N
to TO N
treat VB N
chronic JJ N
rhinorrhea NN N
in IN N
laryngectomized JJ N
patients NNS N
, , N
improving VBG N
their PRP$ N
quality NN N
of IN N
life NN N
-DOCSTART- -X- O O 7814306

Vigorous JJ N
, , N
aerobic JJ N
exercise NN N
versus NN N
general JJ N
motor NN N
training NN N
activities NNS N
: : N
effects NNS N
on IN N
maladaptive JJ N
and CC N
stereotypic JJ N
behaviors NNS N
of IN N
adults NNS 4_p
with IN 4_p
both DT 4_p
autism NN 4_p
and CC 4_p
mental JJ 4_p
retardation NN 4_p
Examined VBD N
the DT N
effects NNS N
of IN N
antecedent JJ N
exercise NN N
conditions NNS N
on IN N
maladaptive NN N
and CC N
stereotypic NN N
behaviors NNS N
in IN N
6 CD 4_p
adults NNS 4_p
with IN 4_p
both DT 4_p
autism NN 4_p
and CC 4_p
moderate VB 4_p
to TO 4_p
profound VB 4_p
mental JJ 4_p
retardation NN 4_p
The DT N
behaviors NNS N
were VBD N
observed VBN N
in IN N
a DT N
controlled JJ N
environment NN N
before IN N
and CC N
after IN N
2 CD N
exercise NN N
and CC N
1 CD N
non-exercise JJ N
conditions NNS N
From IN N
the DT N
original JJ N
group NN N
of IN N
6 CD N
participants NNS N
, , N
2 CD N
were VBD N
selected VBN N
subsequently RB N
to TO N
participate VB N
in IN N
aerobic JJ N
exercise NN N
immediately RB N
before IN N
performing VBG N
a DT N
community-integrated JJ N
vocational JJ N
task NN N
Only RB N
antecedent JJ N
aerobic JJ N
exercise NN N
significantly RB N
reduced VBD N
maladaptive JJ N
and CC N
stereotypic JJ N
behaviors NNS N
in IN N
the DT N
controlled JJ N
setting NN N
Neither CC N
of IN N
the DT N
less RBR N
vigorous JJ N
antecedent JJ N
conditions NNS N
did VBD N
When WRB N
aerobic JJ N
exercise NN N
preceded VBD N
the DT N
vocational JJ N
task NN N
, , N
similar JJ N
reductions NNS N
were VBD N
observed VBN N
There EX N
were VBD N
individual JJ N
differences NNS N
in IN N
response NN N
to TO N
antecedent JJ N
exercise NN N
Use NN N
of IN N
antecedent NN N
aerobic JJ N
exercise NN N
to TO N
reduce VB N
maladaptive JJ N
and CC N
stereotypic JJ N
behaviors NNS N
of IN N
adults NNS N
with IN N
both DT N
autism NN N
and CC N
mental JJ N
retardation NN N
is VBZ N
supported VBN N
-DOCSTART- -X- O O 26573368

A DT N
randomised JJ N
double-blind JJ N
placebo-controlled JJ N
trial NN N
investigating VBG N
the DT N
behavioural JJ N
effects NNS N
of IN N
vitamin NN N
, , N
mineral JJ N
and CC N
n-3 JJ N
fatty JJ N
acid JJ N
supplementation NN N
in IN N
typically RB N
developing VBG N
adolescent JJ 1_p
schoolchildren NN 1_p
Nutrient JJ N
deficiencies NNS N
have VBP N
been VBN N
implicated VBN N
in IN N
anti-social JJ N
behaviour NN N
in IN N
schoolchildren NN N
; : N
hence NN N
, , N
correcting VBG N
them PRP N
may MD N
improve VB N
sociability NN N
We PRP N
therefore RB N
tested VBD N
the DT N
effects NNS N
of IN N
vitamin NN N
, , N
mineral JJ N
and CC N
n-3 JJ N
supplementation NN N
on IN N
behaviour NN N
in IN N
a DT N
12-week JJ N
double-blind NN N
randomised VBD N
placebo-controlled JJ N
trial NN N
in IN N
typically RB N
developing VBG N
UK NNP N
adolescents NNS 1_p
aged VBN 1_p
13-16 CD 1_p
years NNS 1_p
( ( N
n RB 3_p
196 CD 3_p
) ) N
Changes NNS N
in IN N
erythrocyte JJ N
n-3 JJ N
and CC N
6 CD N
fatty JJ N
acids NNS N
and CC N
some DT N
mineral NN N
and CC N
vitamin NN N
levels NNS N
were VBD N
measured VBN N
and CC N
compared VBN N
with IN N
behavioural JJ N
changes NNS N
, , N
using VBG N
Conners NNP N
' POS N
teacher NN N
ratings NNS N
and CC N
school NN N
disciplinary JJ N
records NNS N
At IN N
baseline NN N
, , N
the DT N
children NNS N
's POS N
PUFA NNP N
( ( N
n-3 JJ N
and CC N
n-6 JJ N
) ) N
, , N
vitamin FW N
and CC N
mineral JJ N
levels NNS N
were VBD N
low JJ N
, , N
but CC N
they PRP N
improved VBD N
significantly RB N
in IN N
the DT N
group NN N
treated VBD N
with IN N
n-3 JJ N
, , N
vitamins NNS N
and CC N
minerals NNS N
( ( N
P=0·0005 NNP N
) ) N
On IN N
the DT N
Conners NNP N
disruptive JJ N
behaviour NN N
scale NN N
, , N
the DT N
group NN N
given VBN N
the DT N
active JJ N
supplements NNS N
improved VBN N
, , N
whereas IN N
the DT N
placebo NN N
group NN N
worsened VBD N
( ( N
F=5·555 NNP N
, , N
d=0·35 NN N
; : N
P=0·02 NNP N
) ) N
The DT N
general JJ N
level NN N
of IN N
disciplinary JJ N
infringements NNS N
was VBD N
low JJ N
, , N
thus RB N
making VBG N
it PRP N
difficult JJ N
to TO N
obtain VB N
improvements NNS N
However RB N
, , N
throughout IN N
the DT N
school NN N
term NN N
school NN N
disciplinary JJ N
infringements NNS N
increased VBN N
significantly RB N
( ( N
by IN N
25 CD N
% NN N
; : N
Bayes NNP N
factor=115 NN N
) ) N
in IN N
both CC N
the DT N
treated VBN N
and CC N
untreated JJ N
groups NNS N
However RB N
, , N
when WRB N
the DT N
subjects NNS N
were VBD N
split VBN N
into IN N
high JJ N
and CC N
low JJ N
baseline NN N
infringements NNS N
, , N
the DT N
low JJ N
subset NN N
increased VBD N
their PRP$ N
offences NNS N
, , N
whereas IN N
the DT N
high-misbehaviour JJ N
subset NN N
appeared VBD N
to TO N
improve VB N
after IN N
treatment NN N
But CC N
it PRP N
was VBD N
not RB N
possible JJ N
to TO N
determine VB N
whether IN N
this DT N
was VBD N
merely RB N
a DT N
statistical JJ N
artifact NN N
Thus RB N
, , N
when WRB N
assessed VBN N
using VBG N
the DT N
validated JJ N
and CC N
standardised JJ N
Conners NNP N
teacher NN N
tests NNS N
( ( N
but CC N
less JJR N
clearly RB N
when WRB N
using VBG N
school NN N
discipline NN N
records NNS N
in IN N
a DT N
school NN N
where WRB N
misbehaviour NN N
was VBD N
infrequent NN N
) ) N
, , N
supplementary JJ N
nutrition NN N
might MD N
have VB N
a DT N
protective JJ N
effect NN N
against IN N
worsening VBG N
behaviour NN N
-DOCSTART- -X- O O 10379020

Vitamin NNP N
A DT N
supplementation NN N
for IN N
extremely-low-birth-weight JJ 4_p
infants NNS N
National NNP N
Institute NNP N
of IN N
Child NNP N
Health NNP N
and CC N
Human NNP N
Development NNP N
Neonatal NNP N
Research NNP N
Network NNP N
BACKGROUND NNP N
Vitamin NNP N
A NNP N
supplementation NN N
may MD N
reduce VB N
the DT N
risk NN N
of IN N
chronic JJ N
lung NN N
disease NN N
and CC N
sepsis NN N
in IN N
extremely-low-birth-weight JJ N
infants NNS 1_p
The DT N
results NNS N
of IN N
our PRP$ N
pilot NN N
study NN N
suggested VBD N
that IN N
a DT N
dose NN N
of IN N
5000 CD N
IU NNP N
administered VBD N
intramuscularly RB N
three CD N
times NNS N
per IN N
week NN N
for IN N
four CD N
weeks NNS N
was VBD N
more RBR N
effective JJ N
than IN N
the DT N
lower JJR N
doses NNS N
given VBN N
in IN N
past JJ N
trials NNS N
METHODS NNP N
We PRP N
performed VBD N
a DT N
multicenter NN N
, , N
blinded VBD N
, , N
randomized VBN N
trial NN N
to TO N
assess VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
this DT N
regimen NN N
as IN N
compared VBN N
with IN N
sham JJ N
treatment NN N
in IN N
807 CD 3_p
infants NNS N
in IN N
need NN N
of IN N
respiratory JJ N
support NN N
24 CD N
hours NNS N
after IN N
birth NN N
The DT N
mean JJ N
birth NN N
weight NN N
was VBD N
770 CD N
g NN N
in IN N
the DT N
vitamin NN N
A NNP N
group NN N
and CC N
769 CD N
g NN N
in IN N
the DT N
control NN N
group NN N
, , N
and CC N
the DT N
respective JJ N
gestational JJ N
ages NNS N
were VBD N
26.8 CD N
and CC N
26.7 CD N
weeks NNS N
RESULTS VBN N
By IN N
36 CD N
weeks NNS N
' POS N
postmenstrual JJ N
age NN N
, , N
59 CD N
of IN N
the DT N
405 CD N
infants NNS N
( ( N
15 CD N
percent NN N
) ) N
in IN N
the DT N
vitamin NN N
A NNP N
group NN N
and CC N
55 CD N
of IN N
the DT N
402 CD N
infants NNS N
( ( N
14 CD N
percent NN N
) ) N
in IN N
the DT N
control NN N
group NN N
had VBD N
died VBN N
The DT N
primary JJ N
outcome NN N
- : N
death NN N
or CC N
chronic JJ N
lung NN N
disease NN N
at IN N
36 CD N
weeks NNS N
' POS N
postmenstrual JJ N
age NN N
- : N
occurred VBD N
in IN N
significantly RB N
fewer JJR N
infants NNS N
in IN N
the DT N
vitamin NN N
A NNP N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
55 CD N
percent NN N
vs. FW N
62 CD N
percent NN N
; : N
relative JJ N
risk NN N
, , N
0.89 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.80 CD N
to TO N
0.99 CD N
) ) N
Overall JJ N
, , N
1 CD N
additional JJ N
infant NN N
survived VBD N
without IN N
chronic JJ N
lung NN N
disease NN N
for IN N
every DT N
14 CD N
to TO N
15 CD N
infants NNS N
who WP N
received VBD N
vitamin VBP N
A DT N
supplements NNS N
The DT N
proportions NNS N
of IN N
infants NNS N
in IN N
the DT N
vitamin NN N
A NNP N
group NN N
and CC N
the DT N
control NN N
group NN N
who WP N
had VBD N
signs NNS N
of IN N
potential JJ N
vitamin NN N
A DT N
toxicity NN N
were VBD N
similar JJ N
The DT N
proportion NN N
of IN N
infants NNS N
with IN N
serum JJ N
retinol NN N
values NNS N
below IN N
20 CD N
microg NNS N
per IN N
deciliter NN N
( ( N
0.70 CD N
micromol NN N
per IN N
liter NN N
) ) N
was VBD N
lower JJR N
in IN N
the DT N
vitamin NN N
A NNP N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
25 CD N
percent NN N
vs. FW N
54 CD N
percent NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
CONCLUSIONS NNP N
Intramuscular NNP N
administration NN N
of IN N
5000 CD N
IU NNP N
of IN N
vitamin NN N
A NNP N
three CD N
times NNS N
per IN N
week NN N
for IN N
four CD N
weeks NNS N
reduced VBD N
biochemical JJ N
evidence NN N
of IN N
vitamin NN N
A NNP N
deficiency NN N
and CC N
slightly RB N
decreased VBD N
the DT N
risk NN N
of IN N
chronic JJ N
lung NN N
disease NN N
in IN N
extremely-low-birth-weight JJ N
infants NNS N
-DOCSTART- -X- O O 25542620

Crohn NNP N
's POS N
disease NN N
management NN N
after IN N
intestinal JJ N
resection NN N
: : N
a DT N
randomised JJ N
trial NN N
BACKGROUND NNP N
Most JJS N
patients NNS 4_p
with IN 4_p
Crohn NNP 4_p
's POS 4_p
disease NN 4_p
need VBD N
an DT N
intestinal JJ N
resection NN N
, , N
but CC N
a DT N
majority NN N
will MD N
subsequently VB N
experience VB N
disease NN N
recurrence NN N
and CC N
require VB N
further JJ N
surgery NN N
This DT N
study NN N
aimed VBD N
to TO N
identify VB N
the DT N
optimal JJ N
strategy NN N
to TO N
prevent VB N
postoperative JJ N
disease NN N
recurrence NN N
METHODS NNP N
In IN N
this DT N
randomised JJ N
trial NN N
, , N
consecutive JJ N
patients NNS N
from IN N
17 CD N
centres NNS N
in IN N
Australia NNP N
and CC N
New NNP N
Zealand NNP N
undergoing JJ N
intestinal JJ N
resection NN N
of IN N
all DT N
macroscopic NNP N
Crohn NNP 4_p
's POS 4_p
disease NN 4_p
, , N
with IN N
an DT N
endoscopically RB N
accessible JJ N
anastomosis NN N
, , N
received VBD N
3 CD N
months NNS N
of IN N
metronidazole JJ N
therapy NN N
Patients NNS 4_p
at IN 4_p
high JJ 4_p
risk NN 4_p
of IN 4_p
recurrence NN 4_p
also RB N
received VBD N
a DT N
thiopurine NN N
, , N
or CC N
adalimumab RB N
if IN N
they PRP N
were VBD N
intolerant JJ N
to TO N
thiopurines NNS N
Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
parallel VB N
groups NNS N
: : N
colonoscopy NN N
at IN N
6 CD N
months NNS N
( ( N
active JJ N
care NN N
) ) N
or CC N
no DT N
colonoscopy NN N
( ( N
standard JJ N
care NN N
) ) N
We PRP N
used VBD N
computer-generated JJ N
block NN N
randomisation NN N
to TO N
allocate VB N
patients NNS N
in IN N
each DT N
centre NN N
to TO N
active JJ N
or CC N
standard JJ N
care NN N
in IN N
a DT N
2:1 CD N
ratio NN N
For IN N
endoscopic JJ N
recurrence NN N
( ( N
Rutgeerts NNP N
score RB N
≥i2 VBD N
) ) N
at IN N
6 CD N
months NNS N
, , N
patients NNS N
stepped-up VBP N
to TO N
thiopurine VB N
, , N
fortnightly RB N
adalimumab VBZ N
with IN N
thiopurine NN N
, , N
or CC N
weekly JJ N
adalimumab NN N
The DT N
primary JJ N
endpoint NN N
was VBD N
endoscopic JJ N
recurrence NN N
at IN N
18 CD N
months NNS N
Patients NNS N
and CC N
treating VBG N
physicians NNS N
were VBD N
aware JJ N
of IN N
the DT N
patient NN N
's POS N
study NN N
group NN N
and CC N
treatment NN N
, , N
but CC N
central JJ N
reading NN N
of IN N
the DT N
endoscopic NN N
findings NNS N
was VBD N
undertaken JJ N
blind NN N
to TO N
the DT N
study NN N
group NN N
and CC N
treatment NN N
Analysis NN N
included VBD N
all DT N
patients NNS N
who WP N
received VBD N
at IN N
least JJS N
one CD N
dose NN N
of IN N
study JJ N
drug NN N
This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00989560 NNP N
FINDINGS NNP N
Between NNP N
Oct NNP N
13 CD N
, , N
2009 CD N
, , N
and CC N
Sept NNP N
28 CD N
, , N
2011 CD N
, , N
174 CD N
( ( N
83 CD N
% NN N
high JJ N
risk NN N
across IN N
both DT N
active JJ N
and CC N
standard JJ N
care NN N
groups NNS N
) ) N
patients NNS N
were VBD N
enrolled VBN N
and CC N
received VBN N
at IN N
least JJS N
one CD N
dose NN N
of IN N
study JJ N
drug NN N
Of IN N
122 CD 3_p
patients NNS 3_p
in IN 3_p
the DT 3_p
active JJ 3_p
care NN 3_p
group NN 3_p
, , N
47 CD N
( ( N
39 CD N
% NN N
) ) N
stepped-up NN N
treatment NN N
At IN N
18 CD N
months NNS N
, , N
endoscopic FW N
recurrence NN N
occurred VBD N
in IN N
60 CD N
( ( N
49 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
active JJ N
care NN N
group NN N
and CC N
35 CD N
( ( N
67 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
standard NN N
care NN N
group NN N
( ( N
p=0.03 NN N
) ) N
Complete JJ N
mucosal NN N
normality NN N
was VBD N
maintained VBN N
in IN N
27 CD N
( ( N
22 CD N
% NN N
) ) N
of IN N
122 CD N
patients NNS N
in IN N
the DT N
active JJ N
care NN N
group NN N
versus IN N
four CD N
( ( N
8 CD N
% NN N
) ) N
in IN N
the DT N
standard NN N
care NN N
group NN N
( ( N
p=0.03 NN N
) ) N
In IN N
the DT N
active JJ N
care NN N
arm NN N
, , N
of IN N
those DT N
with IN N
6 CD N
months NNS N
recurrence NN N
who WP N
stepped VBD N
up RB N
treatment NN N
, , N
18 CD N
( ( N
38 CD N
% NN N
) ) N
of IN N
47 CD N
patients NNS N
were VBD N
in IN N
remission NN N
12 CD N
months NNS N
later RB N
; : N
conversely RB N
, , N
of IN N
those DT N
in IN N
remission NN N
at IN N
6 CD N
months NNS N
who WP N
did VBD N
not RB N
change VB N
therapy NN N
recurrence NN N
occurred VBD N
in IN N
31 CD N
( ( N
41 CD N
% NN N
) ) N
of IN N
75 CD N
patients NNS N
12 CD N
months NNS N
later RB N
Smoking NNP N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] $ N
2.4 CD N
, , N
95 CD N
% NN N
CI NNP N
1.2-4.8 CD N
, , N
p=0.02 NN N
) ) N
and CC N
the DT N
presence NN N
of IN N
two CD N
or CC N
more JJR N
clinical JJ N
risk NN N
factors NNS N
including VBG N
smoking NN N
( ( N
OR CC N
2.8 CD N
, , N
95 CD N
% NN N
CI NNP N
1.01-7.7 CD N
, , N
p=0.05 NN N
) ) N
increased VBD N
the DT N
risk NN N
of IN N
endoscopic JJ N
recurrence NN N
The DT N
incidence NN N
and CC N
type NN N
of IN N
adverse JJ N
and CC N
severe JJ N
adverse JJ N
events NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
patients NNS N
in IN N
the DT N
active JJ N
care NN N
and CC N
standard NN N
care NN N
groups NNS N
( ( N
100 CD N
[ RB N
82 CD N
% NN N
] NN N
of IN N
122 CD N
vs NNS N
45 CD N
[ JJ N
87 CD N
% NN N
] NN N
of IN N
52 CD N
; : N
p=0.51 NN N
) ) N
and CC N
( ( N
33 CD N
[ RB N
27 CD N
% NN N
] NN N
of IN N
122 CD N
vs NNS N
18 CD N
[ JJ N
35 CD N
% NN N
] NN N
of IN N
52 CD N
; : N
p=0.36 NN N
) ) N
, , N
respectively RB N
INTERPRETATION NNP N
Treatment NNP N
according VBG N
to TO N
clinical JJ N
risk NN N
of IN N
recurrence NN N
, , N
with IN N
early JJ N
colonoscopy NN N
and CC N
treatment NN N
step-up NN N
for IN N
recurrence NN N
, , N
is VBZ N
better JJR N
than IN N
conventional JJ N
drug NN N
therapy NN N
alone RB N
for IN N
prevention NN N
of IN N
postoperative JJ N
Crohn NNP N
's POS N
disease NN N
recurrence NN N
Selective JJ N
immune JJ N
suppression NN N
, , N
adjusted VBN N
for IN N
early JJ N
recurrence NN N
, , N
rather RB N
than IN N
routine VB N
use NN N
, , N
leads VBZ N
to TO N
disease VB N
control NN N
in IN N
most JJS N
patients NNS N
Clinical JJ N
risk NN N
factors NNS N
predict VBP N
recurrence NN N
, , N
but CC N
patients NNS N
at IN N
low JJ N
risk NN N
also RB N
need VBP N
monitoring VBG N
Early JJ N
remission NN N
does VBZ N
not RB N
preclude VB N
the DT N
need NN N
for IN N
ongoing VBG N
monitoring NN N
FUNDING NN N
AbbVie NNP N
, , N
Gutsy NNP N
Group NNP N
, , N
Gandel NNP N
Philanthropy NNP N
, , N
Angior NNP N
Foundation NNP N
, , N
Crohn NNP N
's POS N
Colitis NNP N
Australia NNP N
, , N
and CC N
the DT N
National NNP N
Health NNP N
and CC N
Medical NNP N
Research NNP N
Council NNP N
-DOCSTART- -X- O O 7806134

Lipoprotein NNP N
( ( N
a DT N
) ) N
serum NN N
levels NNS N
in IN N
post-menopausal JJ 4_p
women NNS 4_p
treated VBN 4_p
with IN 4_p
oral JJ 4_p
estrogens NNS 4_p
administered VBN 4_p
at IN 4_p
different JJ 4_p
times NNS 4_p
The DT N
different JJ N
effects NNS N
on IN N
serum NN N
lipoprotein NN N
( ( N
a DT N
) ) N
[ NN N
Lp NNP N
( ( N
a DT N
) ) N
] NN N
levels NNS N
by IN N
administering VBG N
estrogens NNS N
at IN N
different JJ N
times NNS N
of IN N
the DT N
day NN N
( ( N
8 CD N
a.m. RB N
and CC N
8 CD N
p.m. NN N
) ) N
were VBD N
evaluated VBN N
in IN N
twenty-four JJ 4_p
post-menopausal JJ 4_p
women NNS 4_p
Patients NNS N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
two CD N
treatment NN N
groups NNS N
by IN N
random JJ N
sampling VBG N
numbers NNS N
Patients NNS N
of IN N
both DT N
groups NNS N
received VBD N
0.625 CD N
mg NNS N
conjugated VBN N
equine JJ N
estrogens NNS N
daily JJ N
per IN N
os NN N
for IN N
21 CD N
days NNS N
Group NNP N
A NNP N
patients NNS N
( ( N
n JJ N
: : N
9 CD N
) ) N
received VBD N
the DT N
pill NN N
at IN N
8 CD N
a.m. NN N
, , N
and CC N
group NN N
B NNP N
patients NNS N
( ( N
n JJ N
: : N
12 CD N
) ) N
received VBD N
the DT N
pill NN N
at IN N
8 CD N
p.m NN N
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
as IN N
regards NNS N
the DT N
anthropometric JJ N
characteristics NNS N
, , N
the DT N
basal NN N
values NNS N
of IN N
the DT N
Lp NNP N
( ( N
a DT N
) ) N
, , N
the DT N
sex NN N
steroid NN N
and CC N
pituitary JJ N
hormone NN N
levels NNS N
Administration NN N
of IN N
conjugated JJ N
equine NN N
estrogens NNS N
resulted VBD N
in IN N
decreased JJ N
levels NNS N
of IN N
Lp NNP N
( ( N
a DT N
) ) N
only RB N
in IN N
group NN N
B NNP N
after IN N
treatment NN N
The DT N
different JJ N
Lp NNP N
( ( N
a DT N
) ) N
behaviour NN N
in IN N
the DT N
two CD N
groups NNS N
and CC N
in IN N
the DT N
presence NN N
of IN N
the DT N
same JJ N
serum JJ N
hormonal NN N
levels NNS N
, , N
seems VBZ N
to TO N
be VB N
dependent JJ N
on IN N
the DT N
existence NN N
of IN N
a DT N
circadian JJ N
rhythm NN N
of IN N
the DT N
hepatic JJ N
responsiveness NN N
to TO N
estrogens VB N
, , N
whose WP$ N
expression NN N
is VBZ N
higher JJR N
during IN N
evening NN N
hours NNS N
-DOCSTART- -X- O O 25963425

The DT N
SOFT JJ N
trial NN N
: : N
a DT N
Phase NNP N
III NNP N
study NN N
of IN N
the DT N
dihydropyrimidine NN N
dehydrogenase NN N
inhibitory JJ N
fluoropyrimidine JJ N
S-1 NNP N
and CC N
oxaliplatin NN N
( ( N
SOX NNP N
) ) N
plus CC N
bevacizumab JJ N
as IN N
first-line JJ N
chemotherapy NN N
for IN N
metastatic JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
A DT N
combination NN N
of IN N
oxaliplatin NN N
, , N
leucovorin NN N
and CC N
5-fluorouracil JJ N
( ( N
FOLFOX NNP N
) ) N
plus CC N
bevacizumab NN N
has VBZ N
been VBN N
widely RB N
used VBN N
for IN N
the DT N
first-line JJ N
chemotherapy NN N
of IN N
metastatic JJ 4_p
colorectal NN 4_p
cancer NN 4_p
( ( 4_p
mCRC NN 4_p
) ) 4_p
S-1 NNP N
is VBZ N
an DT N
oral JJ N
fluoropyrimidine NN N
preparation NN N
that IN N
combines VBZ N
tegafur NN N
, , N
a DT N
prodrug NN N
of IN N
5-fluorouracil JJ N
, , N
with IN N
two CD N
modulators NNS N
Several JJ N
studies NNS N
of IN N
combination NN N
chemotherapy NN N
with IN N
oxaliplatin JJ N
plus CC N
S-1 JJ N
( ( N
SOX NNP N
) ) N
conducted VBD N
in IN N
Asia NNP N
have VBP N
reported VBN N
promising JJ N
efficacy NN N
and CC N
safety NN N
in IN N
patients NNS 4_p
with IN 4_p
mCRC NN 4_p
, , N
suggesting VBG N
the DT N
potential JJ N
to TO N
replace VB N
mFOLFOX6 NN N
The DT N
SOFT JJ N
trial NN N
( ( N
JapicCTI-090699 NNP N
) ) N
was VBD N
a DT N
randomized JJ N
Phase NNP N
III NNP N
trial NN N
designed VBN N
to TO N
evaluate VB N
the DT N
noninferiority NN N
of IN N
SOX NNP N
plus CC N
bevacizumab NN N
to TO N
mFOLFOX6 VB N
plus JJ N
bevacizumab NN N
in IN N
patients NNS 4_p
with IN 4_p
mCRC NN 4_p
This DT N
review NN N
summarizes VBZ N
the DT N
drug NN N
concept NN N
of IN N
S-1 NNP N
and CC N
the DT N
results NNS N
of IN N
clinical JJ N
trials NNS N
of IN N
S-1 NNP N
and CC N
SOX NNP N
in IN N
CRC NNP N
and CC N
presents VBZ N
an DT N
overview NN N
of IN N
the DT N
SOFT NNP N
trial NN N
-DOCSTART- -X- O O 2527542

The DT N
influence NN N
of IN N
prostaglandin NN N
inhibition NN N
by IN N
indomethacin NN N
on IN N
blood NN N
pressure NN N
and CC N
renal JJ N
function NN N
in IN N
hypertensive JJ 4_p
patients NNS N
treated VBN N
with IN N
cilazapril NN N
1 CD N
In IN N
a DT N
placebo-controlled JJ N
double-blind JJ N
cross-over NN N
study NN N
lasting VBG N
6 CD N
weeks NNS N
, , N
twenty JJ 3_p
patients NNS N
with IN N
essential JJ 4_p
hypertension NN 4_p
were VBD N
treated VBN N
with IN N
placebo NN N
for IN N
2 CD N
weeks NNS N
followed VBN N
by IN N
oral JJ N
cilazapril NN N
2.5 CD N
mg NN N
once RB N
a DT N
day NN N
or CC N
oral JJ N
indomethacin NN N
50 CD N
mg NN N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
Afterwards NNS N
they PRP N
received VBD N
the DT N
combination NN N
of IN N
both DT N
drugs NNS N
for IN N
a DT N
further JJ N
2 CD N
weeks NNS N
2 CD N
Cilazapril NNP N
significantly RB N
lowered VBD N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
for IN N
a DT N
period NN N
of IN N
24 CD N
h NNS N
post JJ N
administration NN N
3 CD N
Indomethacin NNP N
significantly RB N
attenuated VBD N
the DT N
antihypertensive JJ N
activity NN N
of IN N
cilazapril NN N
This DT N
was VBD N
more RBR N
pronounced JJ N
in IN N
those DT N
patients NNS N
who WP N
were VBD N
treated VBN N
for IN N
the DT N
initial JJ N
2 CD N
weeks NNS N
with IN N
indomethacin JJ N
plus CC N
placebo NN N
( ( N
and CC N
subsequently RB N
with IN N
cilazapril NN N
in IN N
addition NN N
) ) N
than IN N
in IN N
the DT N
subjects NNS N
who WP N
first RB N
received VBD N
cilazapril JJ N
plus CC N
placebo NN N
and CC N
then RB N
the DT N
combination NN N
4 CD N
Correspondingly VB N
the DT N
decrease NN N
of IN N
plasma JJ N
renin NN N
activity NN N
( ( N
PRA NNP N
) ) N
and CC N
urinary JJ N
prostaglandin NN N
excretion NN N
( ( N
PGE2 NNP N
) ) N
was VBD N
more RBR N
pronounced JJ N
in IN N
those DT N
patients NNS N
treated VBD N
initially RB N
with IN N
indomethacin NN N
5 CD N
The DT N
effect NN N
of IN N
indomethacin NN N
on IN N
the DT N
antihypertensive JJ N
effect NN N
of IN N
cilazapril NN N
appears VBZ N
to TO N
depend VB N
upon IN N
the DT N
sequence NN N
of IN N
drug NN N
administration NN N
-DOCSTART- -X- O O 8932546

Inhibition NN N
of IN N
histamine-induced JJ N
skin NN N
wheal NN N
and CC N
flare NN N
after IN N
5 CD N
days NNS N
of IN N
mizolastine NN N
Mizolastine NNP N
is VBZ N
a DT N
new JJ N
, , N
nonsedating JJ N
antihistamine NN N
providing VBG N
satisfactory JJ N
symptomatic JJ N
relief NN N
in IN N
allergic JJ 4_p
rhinitis NN 4_p
and CC 4_p
urticaria NN 4_p
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
use VB N
inhibition NN N
of IN N
wheal NN N
and CC N
flare NN N
formation NN N
after IN N
2-mu JJ N
g NN N
intradermal JJ N
histamine NN N
injections NNS N
as IN N
a DT N
measure NN N
of IN N
the DT N
antihistamine JJ N
effect NN N
of IN N
repeated JJ N
doses NNS N
of IN N
mizolastine NN N
Eight CD 3_p
volunteers NNS 4_p
were VBD N
enrolled VBN N
in IN N
this DT N
four-arm JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
, , N
randomized VBN N
study NN N
Three CD N
dose JJ N
levels NNS N
of IN N
once-daily JJ N
mizolastine NN N
( ( N
5 CD N
mg NN N
, , N
10 CD N
mg NN N
, , N
and CC N
15 CD N
mg NN N
) ) N
were VBD N
compared VBN N
with IN N
placebo NN N
during IN N
5-day JJ N
dose JJ N
periods NNS N
Histamine NN N
tests NNS N
were VBD N
performed VBN N
before IN N
drug NN N
intake NN N
on IN N
days NNS N
1 CD N
and CC N
5 CD N
, , N
and CC N
then RB N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
, , N
10 CD N
, , N
12 CD N
, , N
14 CD N
, , N
and CC N
24 CD N
hours NNS N
after IN N
drug NN N
intake NN N
on IN N
day NN N
5 CD N
All DT N
3 CD N
doses NNS N
of IN N
mizolastine NN N
were VBD N
more RBR N
effective JJ N
than IN N
placebo NN N
in IN N
suppressing VBG N
wheal NN N
and CC N
flare NN N
reactions NNS N
, , N
and CC N
the DT N
antihistamine NN N
activity NN N
was VBD N
highest JJS N
at IN N
both DT N
the DT N
10- JJ N
and CC N
15-mg JJ N
dose NN N
levels NNS N
The DT N
effect NN N
on IN N
the DT N
flare JJ N
reaction NN N
appeared VBD N
within IN N
1 CD N
hour NN N
, , N
reached VBD N
a DT N
maximum JJ N
effect NN N
4 CD N
hours NNS N
after IN N
administration NN N
, , N
and CC N
persisted VBD N
for IN N
as RB N
long RB N
as IN N
24 CD N
hours NNS N
The DT N
relative JJ N
changes NNS N
in IN N
wheal NN N
and CC N
flare JJ N
areas NNS N
were VBD N
correlated VBN N
with IN N
mizolastine NN N
trough IN N
plasma NN N
levels NNS N
on IN N
day NN N
5 CD N
Safety NN N
was VBD N
satisfactory JJ N
in IN N
all DT N
groups NNS N
This DT N
study NN N
confirms VBZ N
that IN N
mizolastine NN N
is VBZ N
a DT N
rapid JJ N
and CC N
potent JJ N
antihistamine NN N
; : N
and CC N
its PRP$ N
long-lasting JJ N
effectiveness NN N
indicates VBZ N
that IN N
a DT N
once-daily JJ N
regimen NN N
is VBZ N
acceptable JJ N
for IN N
clinical JJ N
use NN N
-DOCSTART- -X- O O 393286

A DT N
comparative JJ N
study NN N
of IN N
methyldopa NN N
and CC N
labetalol NN N
in IN N
the DT N
treatment NN N
of IN N
hypertension NN 4_p
1 CD N
Twenty CD 3_p
patients NNS N
with IN N
essential JJ N
hypertension NN N
completed VBD N
a DT N
double-blind JJ N
, , N
dose-tritrated JJ N
, , N
cross-over JJ N
comparison NN N
of IN N
methyldopa NN N
and CC N
labetalol NN N
2 CD N
Average JJ N
lying VBG N
BPs NNP N
( ( N
systolic/diastolic JJ N
) ) N
were VBD N
reduced VBN N
by IN N
28/15 CD N
mmHg NNS N
with IN N
methyldopa NN N
and CC N
by IN N
23/15 CD N
mmHg NNS N
with IN N
labetalol NN N
3 CD N
Average JJ N
standing VBG N
BPs NNP N
( ( N
systolic/diastolic JJ N
) ) N
were VBD N
reduced VBN N
by IN N
29/14 CD N
mmHg NNS N
with IN N
methyldopa NN N
and CC N
by IN N
29/15 CD N
mmHg NNS N
with IN N
labetalol NN N
4 CD N
Both DT N
lying NN N
and CC N
standing VBG N
heart NN N
rates NNS N
were VBD N
reduced VBN N
with IN N
labetalol NN N
5 CD N
It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
antihypertensive JJ N
properties NNS N
of IN N
labetalol NN N
and CC N
methyldopa NN N
are VBP N
similar JJ N
but CC N
that IN N
larger JJR N
patient NN N
populations NNS N
are VBP N
needed VBN N
to TO N
study VB N
the DT N
relative JJ N
incidence NN N
of IN N
subjective JJ N
adverse JJ N
effects NNS N
-DOCSTART- -X- O O 17410213

Effects NNS N
of IN N
application NN N
in IN N
spring NN N
of IN N
urea JJ N
fertiliser NN N
on IN N
aspects NNS N
of IN N
reproductive JJ N
performance NN N
of IN N
pasture-fed JJ 4_p
dairy NN N
cows NNS N
AIMS NNP N
To TO N
assess VB N
if IN N
raising VBG N
concentrations NNS N
of IN N
crude NN N
protein NN N
( ( N
CP NNP N
) ) N
in IN N
pasture NN N
in IN N
spring NN N
by IN N
the DT N
frequent JJ N
application NN N
of IN N
urea JJ N
fertiliser NN N
would MD N
affect VB N
ovarian JJ N
follicular JJ N
dynamics NNS N
, , N
luteal JJ N
function NN N
, , N
onset NN N
of IN N
oestrus NN N
and CC N
reproductive JJ N
performance NN N
of IN N
dairy NN N
cows NNS N
under IN N
farming VBG N
conditions NNS N
in IN N
New NNP N
Zealand NNP N
METHODS NNP N
Spring-calved JJ N
dairy NN N
cows NNS N
were VBD N
grazed VBN N
for IN N
101 CD N
days NNS N
in IN N
paddocks NNS N
that WDT N
were VBD N
either RB N
not RB N
fertilised VBN N
( ( N
Control NNP N
; : N
n=20 CC 3_p
) ) N
during IN N
the DT N
course NN N
of IN N
the DT N
study NN N
, , N
or CC N
were VBD N
fertilised VBN N
with IN N
40-50 JJ N
kg NNS N
nitrogen NN N
( ( N
N NNP N
) ) N
/ha VBP N
every DT N
4-6 JJ N
weeks NNS N
( ( N
High-N NNP N
; : N
n=20 NN 3_p
) ) N
Similar JJ N
generous JJ N
pasture NN N
allowances NNS N
were VBD N
offered VBN N
to TO N
both DT N
groups NNS N
Concentrations NNS N
of IN N
CP NNP N
in IN N
pasture NN N
, , N
urea JJ N
in IN N
serum NN N
and CC N
progesterone NN N
in IN N
milk NN N
were VBD N
measured VBN N
Ovarian JJ N
follicular NN N
and CC N
luteal JJ N
dynamics NNS N
were VBD N
determined VBN N
using VBG N
ultrasonography NN N
Oestrous JJ N
behaviour NN N
and CC N
the DT N
number NN N
, , N
time NN N
and CC N
outcome NN N
of IN N
inseminations NNS N
were VBD N
also RB N
recorded VBN N
RESULTS JJ N
Mean JJ N
concentrations NNS N
of IN N
CP NNP N
in IN N
pasture NN N
and CC N
urea NN N
in IN N
serum NN N
was VBD N
higher RBR N
in IN N
the DT N
High-N NNP N
than IN N
the DT N
Control NNP N
group NN N
( ( N
25.2 CD N
vs NN N
21.6 CD N
and CC N
8.3 CD N
vs NN N
5.4 CD N
mmol/L NN N
for IN N
CP NNP N
and CC N
urea JJ N
, , N
respectively RB N
; : N
p VB N
< $ N
0.001 CD N
) ) N
Intervals NNS N
between IN N
calving VBG N
and CC N
first JJ N
oestrus NN N
, , N
first JJ N
insemination NN N
and CC N
conception NN N
, , N
the DT N
time NN N
of IN N
first JJ N
emergence NN N
of IN N
a DT N
dominant JJ N
follicle NN N
, , N
milk NN N
progesterone NN N
concentration NN N
, , N
and CC N
the DT N
diameter NN N
of IN N
the DT N
corpus NN N
luteum NN N
( ( N
CL NNP N
) ) N
in IN N
the DT N
first JJ N
luteal JJ N
phase NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
groups NNS N
The DT N
interval NN N
from IN N
calving VBG N
to TO N
first JJ N
ovulation NN N
tended VBN N
( ( N
p=0.10 NN N
) ) N
to TO N
be VB N
lower JJR N
and CC N
the DT N
diameter NN N
of IN N
the DT N
dominant JJ N
follicle NN N
of IN N
the DT N
oestrous JJ N
cycle NN N
at IN N
which WDT N
cows VBZ N
conceived VBN N
was VBD N
greater JJR N
( ( N
p=0.02 NN N
) ) N
in IN N
Control NNP N
than IN N
High-N NNP N
cows NNS N
CONCLUSIONS VB N
The DT N
use NN N
of IN N
large JJ N
amounts NNS N
of IN N
urea JJ N
fertiliser NN N
during IN N
spring NN N
and CC N
the DT N
consequent NN N
increases NNS N
in IN N
concentrations NNS N
of IN N
CP NNP N
in IN N
pasture NN N
and CC N
urea NN N
in IN N
serum NN N
did VBD N
not RB N
negatively RB N
affect JJ N
any DT N
of IN N
the DT N
parameters NNS N
of IN N
reproductive JJ N
performance NN N
of IN N
pasture-fed JJ N
dairy NN N
cows NNS N
that WDT N
were VBD N
assessed VBN N
in IN N
this DT N
study NN N
-DOCSTART- -X- O O 17362495

Immediately RB N
restored VBN N
, , N
single-tapered JJ N
implants NNS 4_p
in IN 4_p
the DT 4_p
anterior JJ 4_p
maxilla NN 4_p
: : N
prosthodontic JJ N
and CC N
aesthetic JJ N
outcomes NNS N
after IN N
1 CD N
year NN N
BACKGROUND NNP N
Conventional NNP N
implant JJ N
protocols NNS N
advocate VBP N
a DT N
two-stage NN N
technique NN N
with IN N
a DT N
load-free JJ N
, , N
submerged VBD N
healing JJ N
period NN N
Recent JJ N
studies NNS N
suggest VBP N
that IN N
immediate JJ N
restoration NN N
of IN N
single JJ N
implants NNS N
may MD N
be VB N
a DT N
viable JJ N
treatment NN N
option NN N
PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
prosthodontic JJ 4_p
and CC N
aesthetic JJ 4_p
peri-implant JJ 4_p
mucosal NN N
outcomes NNS N
of IN N
immediately RB N
restored VBN N
, , N
Southern JJ 4_p
single-tapered JJ 4_p
implants NNS 4_p
in IN 4_p
the DT 4_p
anterior JJ 4_p
maxilla NN 4_p
after IN N
1 CD N
year NN N
MATERIALS NNP N
AND CC N
METHODS NNP N
Participants NNP N
( ( N
mean JJ N
age NN N
: : N
43.25 CD 1_p
years NNS N
; : N
range NN N
: : N
23-71 JJ 1_p
years NNS N
) ) N
satisfying VBG N
specified VBN N
inclusion NN N
criteria NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
conventional JJ N
two-stage JJ N
restoration NN N
( ( N
control NN N
group NN N
; : N
n=14 CC N
) ) N
and CC N
immediate JJ N
restoration NN N
groups NNS N
( ( N
test NN N
group NN N
; : N
n CC N
=14 NN N
) ) N
in IN N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
Tapered VBN N
, , N
roughened-surface JJ N
Southern JJ N
implants NNS N
were VBD N
placed VBN N
using VBG N
a DT N
standardized JJ N
technique NN N
, , N
and CC N
implant JJ N
level NN N
bone NN N
impressions NNS N
were VBD N
made VBN N
Provisional JJ N
screw-retained JJ N
crowns NNS N
, , N
out IN N
of IN N
occlusion NN N
, , N
were VBD N
placed VBN N
at IN N
second-stage NN N
surgery NN N
after IN N
26 CD N
weeks NNS N
for IN N
the DT N
conventional JJ N
restoration NN N
group NN N
, , N
and CC N
within IN N
4 CD N
hours NNS N
of IN N
implant JJ N
placement NN N
for IN N
the DT N
immediate JJ N
restoration NN N
group NN N
Both DT N
groups NNS N
had VBD N
definitive JJ N
screw-retained JJ N
metal-ceramic JJ N
crowns NNS N
placed VBN N
in IN N
occlusion NN N
8 CD N
weeks NNS N
later RB N
Peri-implant JJ N
mucosal NN N
response NN N
and CC N
papilla NN N
index NN N
were VBD N
recorded VBN N
4 CD N
weeks NNS N
after IN N
definitive JJ N
crown JJ N
placement NN N
to TO N
allow VB N
for IN N
mucosal JJ N
maturation NN N
and CC N
at IN N
1 CD N
year NN N
Prosthodontic NNP N
and CC N
aesthetic JJ N
outcomes NNS N
were VBD N
assessed VBN N
using VBG N
established VBN N
criteria NNS N
RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
within IN N
, , N
or CC N
between IN N
, , N
the DT N
control NN N
and CC N
test NN N
groups NNS N
for IN N
age NN N
, , N
gender NN N
, , N
bone NN N
quality NN N
or CC N
quantity NN N
, , N
implant JJ N
stability NN N
measurements NNS N
at IN N
surgery NN N
, , N
or CC N
implant JJ N
length NN N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
implant JJ N
success NN N
rate NN N
as IN N
determined VBN N
by IN N
radiographic JJ N
bone NN N
loss NN N
and CC N
stability NN N
tests NNS N
after IN N
1 CD N
year NN N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
prosthodontic JJ N
maintenance NN N
, , N
peri-implant JJ N
mucosal NN N
response NN N
, , N
and CC N
papilla NN N
index NN N
between IN N
the DT N
two CD N
groups NNS N
over IN N
1 CD N
year NN N
CONCLUSIONS NNP N
Tapered NNP N
, , N
roughened-surface JJ N
implants NNS N
immediately RB N
restored VBN N
with IN N
single JJ N
provisional JJ N
crowns NNS N
at IN N
surgery NN N
and CC N
definitive JJ N
crowns NNS N
8 CD N
weeks NNS N
later RB N
were VBD N
as IN N
prosthodontically RB N
and CC N
aesthetically RB N
successful JJ N
as IN N
conventionally RB N
restored VBN N
two-stage JJ N
implants NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
service NN N
Restoring VBG N
single JJ N
implants NNS N
immediately RB N
with IN N
screw-retained JJ N
crowns NNS N
is VBZ N
an DT N
efficient JJ N
procedure NN N
, , N
but CC N
the DT N
short-term JJ N
outcome NN N
is VBZ N
by IN N
no DT N
means NNS N
superior VBP N
to TO N
a DT N
conventional JJ N
two-stage JJ N
approach NN N
-DOCSTART- -X- O O 16864164

Long-term JJ N
follow-up NN N
of IN N
the DT N
Stockholm NNP N
randomized VBD N
trials NNS N
of IN N
postoperative JJ N
radiation NN N
therapy NN N
versus NN N
adjuvant JJ N
chemotherapy NN N
among IN N
'high JJ N
risk NN N
' POS N
pre- NN N
and CC N
postmenopausal NN N
breast NN N
cancer NN N
patients NNS N
For IN N
many JJ N
years NNS N
, , N
loco-regional JJ N
radiotherapy NN N
was VBD N
the DT N
standard JJ N
postoperative JJ N
treatment NN N
for IN N
node JJ 4_p
positive JJ 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
in IN 4_p
Sweden NNP 4_p
Because IN N
of IN N
encouraging VBG N
results NNS N
from IN N
trials NNS N
of IN N
adjuvant JJ N
chemotherapy NN N
in IN N
the DT N
mid NN N
1970s CD N
, , N
the DT N
Stockholm NNP N
Breast NNP N
Cancer NNP N
Study NNP N
Group NNP N
decided VBD N
to TO N
directly RB N
compare VB N
postoperative JJ N
radiation NN N
( ( N
RT NNP N
) ) N
with IN N
adjuvant JJ N
CMF-type JJ N
chemotherapy NN N
( ( N
CT NNP N
) ) N
Long-term JJ N
results NNS N
are VBP N
presented VBN N
from IN N
two CD N
randomized JJ N
trials NNS N
of IN N
RT NNP N
versus NN N
CT NNP N
in IN N
pre- NN N
( ( N
n JJ N
= NNP N
547 CD N
) ) N
and CC N
postmenopausal NN N
( ( N
n JJ N
= NNP N
679 CD N
) ) N
patients NNS N
, , N
respectively RB N
, , N
with IN N
node JJ N
positive JJ N
disease NN N
or CC N
a DT N
tumour JJ N
diameter NN N
> VBD N
30 CD N
mm NN N
RT NNP N
substantially RB N
reduced VBD N
loco-regional JJ N
recurrences NNS N
among IN N
both DT N
pre- JJ N
and CC N
postmenopausal JJ N
patients NNS N
( ( N
relative JJ N
hazard NN N
RT NNP N
versus NN N
CT NNP N
: : N
0.67 CD N
and CC N
0.43 CD N
, , N
respectively RB N
) ) N
Among IN N
premenopausal JJ N
patients NNS N
distant JJ N
metastases NNS N
occurred VBD N
less RBR N
frequently RB N
in IN N
the DT N
CT NNP N
group NN N
( ( N
relative JJ N
hazard NN N
: : N
1.68 CD N
, , N
p NN N
> NNP N
0.001 CD N
) ) N
resulting VBG N
in IN N
an DT N
improved JJ N
recurrence-free JJ N
survival NN N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
Overall JJ N
survival NN N
was VBD N
also RB N
better RB N
with IN N
CT NNP N
( ( N
cumulative JJ N
survival NN N
at IN N
15 CD N
years NNS N
: : N
50 CD N
% NN N
and CC N
44 CD N
% NN N
in IN N
the DT N
CT NNP N
and CC N
RT NNP N
groups NNS N
, , N
respectively RB N
) ) N
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
Among IN N
the DT N
postmenopausal NN N
patients NNS N
there EX N
were VBD N
no DT N
substantial JJ N
differences NNS N
in IN N
terms NNS N
of IN N
recurrence-free NN N
or CC N
overall JJ N
survival NN N
between IN N
the DT N
treatment NN N
groups NNS N
The DT N
risk NN N
of IN N
a DT N
second JJ N
primary JJ N
malignancy NN N
, , N
however RB N
, , N
was VBD N
doubled VBN N
in IN N
the DT N
RT NNP N
group NN N
( ( N
p JJ N
> NNP N
0.01 CD N
) ) N
The DT N
most RBS N
pronounced JJ N
excess NN N
concerned JJ N
second JJ N
lung NN N
cancers NNS N
occurring VBG N
after IN N
10 CD N
years NNS N
The DT N
cumulative JJ N
incidence NN N
at IN N
20 CD N
years NNS N
was VBD N
estimated VBN N
at IN N
0.3 CD N
% NN N
and CC N
3.7 CD N
% NN N
in IN N
the DT N
CT NNP N
and CC N
RT NNP N
groups NNS N
, , N
respectively RB N
The DT N
trials NNS N
illustrate VBP N
the DT N
role NN N
of IN N
radiotherapy NN N
in IN N
preventing VBG N
loco-regional JJ N
recurrences NNS N
among IN N
high-risk JJ N
patients NNS N
, , N
as RB N
well RB N
as IN N
the DT N
need NN N
for IN N
systemic JJ N
treatment NN N
to TO N
control VB N
the DT N
disease NN N
systemically RB N
-DOCSTART- -X- O O 23727103

Anxiolytics NNS N
in IN N
patients NNS N
suffering VBG N
a DT N
suspected JJ N
acute JJ 4_p
coronary JJ 4_p
syndrome NN 4_p
: : N
multi-centre NN N
randomised VBD N
controlled VBN N
trial NN N
in IN N
Emergency NNP N
Medical NNP N
Service NNP N
BACKGROUND NNP N
The DT N
prehospital JJ N
treatment NN N
of IN N
pain NN N
and CC N
discomfort NN N
among IN N
patients NNS 4_p
who WP 4_p
suffer VBP 4_p
from IN 4_p
acute JJ 4_p
coronary JJ 4_p
syndrome NN 4_p
( ( 4_p
ACS NNP 4_p
) ) 4_p
needs VBZ N
a DT N
treatment NN N
strategy NN N
which WDT N
combines VBZ N
relief NN N
of IN N
pain NN N
with IN N
relief NN N
of IN N
anxiety NN N
AIM IN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
impact NN N
on IN N
pain NN N
and CC N
anxiety NN N
of IN N
the DT N
combination NN N
of IN N
an DT N
anxiolytic JJ N
and CC N
an DT N
analgesic JJ N
as IN N
compared VBN N
with IN N
an DT N
analgesic JJ N
alone NN N
in IN N
the DT N
prehospital JJ N
setting NN N
of IN N
suspected JJ N
ACS NNP N
METHODS NNP N
A DT N
multi-centre NN N
randomised VBN N
controlled VBN N
trial NN N
compared VBN N
the DT N
combination NN N
of IN N
Midazolam NNP N
( ( N
Mi NNP N
) ) N
+Morphine NN N
( ( N
Mo NNP N
) ) N
and CC N
Mo NNP N
alone RB N
All DT N
measures NNS N
took VBD N
part NN N
: : N
Prior NNP N
to TO N
randomisation NN N
, , N
15 CD N
min NN N
thereafter RB N
and CC N
on IN N
admission NN N
to TO N
a DT N
hospital NN N
Inclusion NN N
criteria NNS N
were VBD N
: : N
1 CD N
) ) N
pain NN N
raising VBG N
suspicion NN N
of IN N
ACS NNP N
and CC N
2 CD N
) ) N
pain NN N
score NN N
≥4 NN N
PRIMARY NNP N
ENDPOINT NNP N
Pain NNP N
score NN N
after IN N
15 CD N
min NN N
RESULTS NNP N
In IN N
all DT N
, , N
890 CD 3_p
patients NNS 3_p
were VBD N
randomised VBN N
to TO N
Mi+Mo NNP N
and CC N
873 CD N
to TO N
Mo NNP N
alone RB N
Pain NN N
was VBD N
reduced VBN N
from IN N
a DT N
median NN N
of IN N
6 CD N
to TO N
4 CD N
and CC N
finally RB N
to TO N
3 CD N
in IN N
both DT N
groups NNS N
The DT N
mean JJ N
dose NN N
of IN N
Mo NNP N
was VBD N
5.3 CD N
mg NN N
in IN N
Mi+Mo NNP N
and CC N
6.0 CD N
mg NN N
in IN N
Mo NNP N
alone RB N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
Anxiety NN N
was VBD N
reported VBN N
in IN N
66 CD N
% NN N
in IN N
Mi+Mo NNP N
and CC N
in IN N
64 CD N
% NN N
in IN N
Mo NNP N
alone RB N
at IN N
randomisation NN N
( ( N
NS NNP N
) ) N
; : N
15 CD N
min NN N
thereafter RB N
in IN N
31 CD N
% NN N
and CC N
39 CD N
% NN N
( ( N
p=0.002 NN N
) ) N
and CC N
finally RB N
in IN N
12 CD N
% NN N
and CC N
26 CD N
% NN N
respectively RB N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
On IN N
admission NN N
to TO N
a DT N
hospital NN N
nausea NN N
or CC N
vomiting NN N
was VBD N
reported VBN N
in IN N
9 CD N
% NN N
in IN N
Mi+Mo NNP N
and CC N
in IN N
13 CD N
% NN N
in IN N
Mo NNP N
alone RB N
( ( N
p=0.003 NN N
) ) N
Drowsiness NNP N
differed VBD N
; : N
15 CD N
% NN N
and CC N
14 CD N
% NN N
were VBD N
drowsy VBN N
in IN N
Mi+Mo NNP N
versus VBP N
2 CD N
% NN N
and CC N
3 CD N
% NN N
in IN N
Mo NNP N
alone RB N
respectively RB N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
CONCLUSION NNP N
Despite IN N
the DT N
fact NN N
that IN N
the DT N
combination NN N
of IN N
anxiolytics NNS N
and CC N
analgesics NNS N
as IN N
compared VBN N
with IN N
analgesics NNS N
alone RB N
reduced VBN N
anxiety NN N
and CC N
the DT N
requirement NN N
of IN N
Morphine NNP N
in IN N
the DT N
prehospital JJ N
setting NN N
of IN N
acute JJ N
coronary JJ N
syndrome NN N
, , N
this DT N
strategy NN N
did VBD N
not RB N
reduce VB N
patients NNS N
' POS N
estimation NN N
of IN N
pain NN N
( ( N
primary JJ N
endpoint NN N
) ) N
More RBR N
effective JJ N
pain NN N
relief NN N
among IN N
these DT N
patients NNS N
is VBZ N
warranted VBN N
-DOCSTART- -X- O O 7826791

Co-administration NN N
of IN N
pethidine NN N
and CC N
clonidine NN N
: : N
a DT N
spinal JJ N
anaesthetic JJ N
technique NN N
for IN N
total JJ N
hip NN N
replacement NN N
Co-administration NN N
of IN N
pethidine NN N
0.75 CD N
mg NN N
kg-1 NN N
and CC N
clonidine NN N
75 CD N
micrograms NNS N
intrathecally RB N
provided VBD N
good JJ N
intraoperative JJ N
anaesthesia NN N
for IN N
total JJ N
hip NN N
replacement NN N
, , N
similar JJ N
to TO N
that DT N
obtained VBN N
using VBG N
0.5 CD N
% NN N
isobaric JJ N
bupivacaine NN N
Sensory NNP N
and CC N
motor NN N
block NN N
were VBD N
of IN N
shorter JJR N
duration NN N
than IN N
that DT N
after IN N
0.5 CD N
% NN N
isobaric JJ N
bupivacaine NN N
and CC N
0.5 CD N
% NN N
isobaric JJ N
bupivacaine NN N
with IN N
morphine JJ N
0.5 CD N
mg NN N
( ( N
P NNP N
< VBZ N
0.001 CD N
sensory JJ N
block NN N
, , N
P NNP N
< VBZ N
0.001 CD N
motor NN N
block NN N
) ) N
Postoperative JJ N
morphine NN N
consumption NN N
, , N
measured VBN N
using VBG N
a DT N
patient-controlled JJ N
system NN N
, , N
was VBD N
similar JJ N
to TO N
that DT N
in IN N
patients NNS N
in IN N
the DT N
bupivacaine NN N
only RB N
group NN N
( ( N
pethidine-clonidine JJ N
: : N
median JJ N
39 CD N
mg/24 NN N
h NN N
; : N
bupivacaine NN N
: : N
median JJ N
34 CD N
mg/24 NN N
h NN N
) ) N
but CC N
greater JJR N
than IN N
that DT N
in IN N
the DT N
bupivacaine-morphine JJ N
group NN N
( ( N
median JJ N
8 CD N
mg/24 NN N
h NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
Visual JJ N
analogue NN N
pain NN N
scores NNS N
after IN N
operation NN N
were VBD N
similar JJ N
to TO N
those DT N
with IN N
bupivacaine JJ N
alone NN N
at IN N
all DT N
but CC N
one CD N
of IN N
the DT N
recording NN N
times NNS N
but CC N
were VBD N
greater JJR N
than IN N
those DT N
in IN N
patients NNS N
who WP N
received VBD N
bupivacaine NN N
and CC N
morphine NN N
at IN N
4 CD N
, , N
6 CD N
and CC N
10 CD N
h NN N
after IN N
operation NN N
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
P NNP N
< NNP N
0.04 CD N
, , N
P NNP N
< NNP N
0.02 CD N
) ) N
The DT N
combination NN N
did VBD N
not RB N
offer VB N
any DT N
major JJ N
advantage NN N
over IN N
conventional JJ N
agents NNS N
-DOCSTART- -X- O O 17572835

Effect NN N
of IN N
low-intensity NN N
back RB N
exercise NN N
on IN N
quality NN N
of IN N
life NN N
and CC N
back RB N
extensor JJ N
strength NN N
in IN N
patients NNS N
with IN N
osteoporosis NN 4_p
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
UNLABELLED NNP N
Randomized NNP N
controlled VBD N
study NN N
in IN N
80 CD 3_p
postmenopausal JJ 4_p
women NNS N
with IN N
osteoporosis NN 4_p
was VBD N
conducted VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
a DT N
home-based JJ N
, , N
simple JJ N
, , N
low-intensity JJ N
exercise NN N
Low-intensity JJ N
back-strengthening JJ N
exercise NN N
was VBD N
effective JJ N
in IN N
improving VBG N
the DT N
quality NN N
of IN N
life NN N
and CC N
back RB N
extensor JJ N
strength NN N
INTRODUCTION NNP N
AND CC N
HYPOTHESIS NNP N
Back-strengthening NNP N
exercise NN N
is VBZ N
effective JJ N
in IN N
increasing VBG N
back RB N
extensor NN N
strength NN N
and CC N
decreasing VBG N
risk NN N
of IN N
vertebral JJ N
fractures NNS N
We PRP N
hypothesized VBD N
that IN N
a DT N
home-based JJ N
, , N
simple JJ N
, , N
low-intensity JJ N
exercise NN N
could MD N
enhance VB N
back RB N
extensor JJ N
strength NN N
and CC N
improve VB N
the DT N
quality NN N
of IN N
life NN N
and/or IN N
spinal JJ N
range NN N
of IN N
motion NN N
in IN N
postmenopausal JJ 4_p
women NNS N
in IN N
a DT N
short-term JJ N
follow-up NN N
METHODS NNP N
Eighty NNP 3_p
postmenopausal JJ 4_p
women NNS N
with IN N
osteoporosis NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
38 CD 3_p
) ) N
or CC N
an DT N
exercise NN N
group NN N
( ( N
n JJ N
= NNP N
42 CD 3_p
) ) N
Subjects NNS N
were VBD N
instructed VBN N
to TO N
lift VB N
their PRP$ N
upper JJ N
trunk NN N
from IN N
a DT N
prone NN N
position NN N
antigravity NN N
and CC N
maintain VB N
the DT N
neutral JJ N
position NN N
Isometric NNP N
back RB N
extensor NN N
strength NN N
, , N
spinal JJ N
range NN N
of IN N
motion NN N
, , N
and CC N
scores NNS N
for IN N
quality NN N
of IN N
life NN N
were VBD N
evaluated VBN N
at IN N
baseline NN N
and CC N
4 CD N
months NNS N
RESULTS NNP N
Back NNP N
extensor NN N
strength NN N
significantly RB N
increased VBD N
both DT N
in IN N
the DT N
exercise NN N
group NN N
( ( N
26 CD N
% NN N
) ) N
and CC N
in IN N
the DT N
control NN N
group NN N
( ( N
11 CD N
% NN N
) ) N
Scores NNS N
for IN N
quality NN N
of IN N
life NN N
increased VBN N
in IN N
the DT N
exercise NN N
group NN N
( ( N
7 CD N
% NN N
) ) N
, , N
whereas IN N
it PRP N
remained VBD N
unchanged JJ N
in IN N
the DT N
control NN N
group NN N
( ( N
0 CD N
% NN N
) ) N
There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
quality NN N
of IN N
life NN N
score NN N
between IN N
the DT N
groups NNS N
( ( N
p JJ N
= NNP N
0.012 CD N
) ) N
CONCLUSIONS JJ N
Low-intensity JJ N
back-strengthening NN N
exercise NN N
was VBD N
effective JJ N
in IN N
improving VBG N
the DT N
quality NN N
of IN N
life NN N
and CC N
back RB N
extensor JJ N
strength NN N
in IN N
patients NNS N
with IN N
osteoporosis NN N
-DOCSTART- -X- O O 12384805

Randomized VBN N
trial NN N
of IN N
adoptive JJ N
transfer NN N
of IN N
melanoma JJ N
tumor-infiltrating JJ N
lymphocytes NNS N
as IN N
adjuvant JJ N
therapy NN N
for IN N
stage NN 4_p
III NNP 4_p
melanoma NN 4_p
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
demonstrate VB N
the DT N
interest NN N
of IN N
using VBG N
tumor-infiltrating JJ N
lymphocytes NNS N
( ( N
TIL NNP N
) ) N
as IN N
adjuvant JJ N
therapy NN N
for IN N
stage NN 4_p
III NNP 4_p
( ( 4_p
regional JJ 4_p
lymph NN 4_p
nodes NNS 4_p
) ) 4_p
melanoma NN 4_p
After IN N
lymph JJ N
node JJ N
excision NN N
, , N
patients NNS N
without IN N
any DT N
detectable JJ N
metastases NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
TIL NNP N
plus CC N
interleukin-2 JJ N
( ( N
IL-2 NNP N
) ) N
for IN N
2 CD N
months NNS N
, , N
or CC N
IL-2 NNP N
only RB N
The DT N
primary JJ N
endpoint NN N
was VBD N
determination NN N
of IN N
the DT N
duration NN N
of IN N
the DT N
relapse-free JJ N
interval NN N
Eighty-eight JJ 3_p
patients NNS N
determined VBD N
as IN N
eligible JJ N
for IN N
treatment NN N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
After IN N
a DT N
median JJ N
follow-up NN N
of IN N
46.9 CD N
months NNS N
, , N
for IN N
the DT N
study NN N
population NN N
the DT N
analysis NN N
did VBD N
not RB N
show VB N
a DT N
significant JJ N
extension NN N
of IN N
the DT N
relapse-free JJ N
interval NN N
or CC N
overall JJ N
survival NN N
However RB N
, , N
a DT N
significant JJ N
interaction NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
was VBD N
found VBN N
between IN N
the DT N
treatment NN N
and CC N
the DT N
number NN N
of IN N
invaded JJ N
lymph NN N
nodes NNS N
In IN N
the DT N
group NN N
with IN N
only RB N
one CD N
invaded VBD N
lymph NN N
node NN N
, , N
the DT N
estimated VBN N
relapse NN N
rate NN N
was VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
( ( N
adjusted VBN N
) ) N
=0.0285 NN N
) ) N
and CC N
the DT N
overall JJ N
survival NN N
was VBD N
increased VBN N
( ( N
P NNP N
( ( N
adjusted VBN N
) ) N
=0.039 NN N
) ) N
in IN N
the DT N
TIL+IL-2 NNP N
arm NN N
compared VBN N
with IN N
the DT N
IL-2 NNP N
only JJ N
arm NN N
No DT N
differences NNS N
between IN N
the DT N
two CD N
arms NNS N
, , N
either CC N
as IN N
regards NNS N
the DT N
duration NN N
of IN N
disease-free JJ N
survival NN N
or CC N
overall JJ N
survival NN N
, , N
were VBD N
noted VBN N
in IN N
the DT N
group NN N
with IN N
more JJR N
than IN N
one CD N
invaded JJ N
lymph NN N
node NN N
whatever IN N
the DT N
number NN N
of IN N
invaded JJ N
lymph NN N
nodes NNS N
Treatment NN N
was VBD N
compatible JJ N
with IN N
normal JJ N
daily JJ N
activity NN N
This DT N
study NN N
demonstrates VBZ N
for IN N
the DT N
first JJ N
time NN N
that IN N
the DT N
efficiency NN N
of IN N
TIL NNP N
in IN N
stage NN N
III NNP N
melanoma NN N
( ( N
AJCC NNP N
) ) N
is VBZ N
directly RB N
related VBN N
to TO N
the DT N
number NN N
of IN N
invaded JJ N
lymph NN N
nodes NNS N
, , N
indicating VBG N
that IN N
tumor NN N
burden NN N
might MD N
be VB N
a DT N
crucial JJ N
factor NN N
in IN N
the DT N
efficacy NN N
and/or NN N
in IN N
vitro JJ N
expansion NN N
of IN N
T NNP N
cells NNS N
specific JJ N
for IN N
autologous JJ N
tumor NN N
antigen NN N
, , N
a DT N
finding NN N
which WDT N
could MD N
be VB N
of IN N
value NN N
in IN N
future JJ N
vaccine NN N
development NN N
for IN N
the DT N
treatment NN N
of IN N
melanoma NN N
-DOCSTART- -X- O O 24011178

Benefits NNS N
and CC N
costs NNS N
of IN N
home-based JJ N
pulmonary JJ N
rehabilitation NN N
in IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
- : N
a DT N
multi-centre JJ N
randomised VBN N
controlled VBN N
equivalence NN N
trial NN N
BACKGROUND NNP N
Pulmonary NNP N
rehabilitation NN N
is VBZ N
widely RB N
advocated VBN N
for IN N
people NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
( ( N
COPD NNP 4_p
) ) N
to TO N
improve VB N
exercise NN N
capacity NN N
, , N
symptoms NNS N
and CC N
quality NN N
of IN N
life NN N
, , N
however RB N
only RB N
a DT N
minority NN N
of IN N
individuals NNS N
with IN N
COPD NNP N
are VBP N
able JJ N
to TO N
participate VB N
Travel NNP N
and CC N
transport NN N
are VBP N
frequently RB N
cited VBN N
as IN N
barriers NNS N
to TO N
uptake VB N
of IN N
centre-based JJ N
programs NNS N
Other JJ N
models NNS N
of IN N
pulmonary JJ N
rehabilitation NN N
, , N
including VBG N
home-based JJ N
programs NNS N
, , N
have VBP N
been VBN N
proposed VBN N
in IN N
order NN N
to TO N
improve VB N
access NN N
to TO N
this DT N
important JJ N
treatment NN N
Previous JJ N
studies NNS N
of IN N
home-based JJ N
pulmonary JJ N
rehabilitation NN N
in IN N
COPD NNP N
have VBP N
demonstrated VBN N
improvement NN N
in IN N
exercise NN N
capacity NN N
and CC N
quality NN N
of IN N
life NN N
, , N
but CC N
not RB N
all DT N
elements NNS N
of IN N
the DT N
program NN N
were VBD N
conducted VBN N
in IN N
the DT N
home NN N
environment NN N
It PRP N
is VBZ N
uncertain JJ N
whether IN N
a DT N
pulmonary JJ N
rehabilitation NN N
program NN N
delivered VBN N
in IN N
its PRP$ N
entirety NN N
at IN N
home NN N
is VBZ N
cost VBN N
effective JJ N
and CC N
equally RB N
capable JJ N
of IN N
producing VBG N
benefits NNS N
in IN N
exercise NN N
capacity NN N
, , N
symptoms NNS N
and CC N
quality NN N
of IN N
life NN N
as IN N
a DT N
hospital-based JJ N
program NN N
The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
compare VB N
the DT N
costs NNS N
and CC N
benefits NNS N
of IN N
home-based JJ N
and CC N
hospital-based JJ N
pulmonary JJ N
rehabilitation NN N
for IN N
people NNS N
with IN N
COPD NNP 4_p
METHODS/DESIGN NNP N
This DT N
randomised VBD N
, , N
controlled VBD N
, , N
equivalence NN N
trial NN N
conducted VBN N
at IN N
two CD N
centres NNS N
will MD N
recruit VB N
166 CD 3_p
individuals NNS N
with IN N
spirometrically RB N
confirmed VBN N
COPD NNP 4_p
Participants NNS N
will MD N
be VB N
randomly RB N
allocated VBN N
to TO N
hospital-based JJ N
or CC N
home-based JJ N
pulmonary JJ N
rehabilitation NN N
Hospital JJ N
programs NNS N
will MD N
follow VB N
the DT N
traditional JJ N
outpatient NN N
model NN N
consisting VBG N
of IN N
twice JJ N
weekly NNS N
supervised VBD N
exercise NN N
training NN N
and CC N
education NN N
for IN N
eight CD N
weeks NNS N
Home-based JJ N
programs NNS N
will MD N
involve VB N
one CD N
home NN N
visit NN N
followed VBN N
by IN N
seven CD N
weekly JJ N
telephone NN N
calls NNS N
, , N
using VBG N
a DT N
motivational JJ N
interviewing NN N
approach NN N
to TO N
enhance VB N
exercise NN N
participation NN N
and CC N
facilitate VB N
self JJ N
management NN N
The DT N
primary JJ N
outcome NN N
is VBZ N
change VBN N
in IN N
6-minute JJ N
walk NN N
distance NN N
immediately RB N
following VBG N
intervention NN N
Measurements NNS N
of IN N
exercise NN N
capacity NN N
, , N
physical JJ N
activity NN N
, , N
symptoms NNS N
and CC N
quality NN N
of IN N
life NN N
will MD N
be VB N
taken VBN N
at IN N
baseline NN N
, , N
immediately RB N
following VBG N
the DT N
intervention NN N
and CC N
at IN N
12 CD N
months NNS N
, , N
by IN N
a DT N
blinded JJ N
assessor NN N
Completion NN N
rates NNS N
will MD N
be VB N
compared VBN N
between IN N
programs NNS N
Direct NNP N
healthcare NN N
costs NNS N
and CC N
indirect JJ N
( ( N
patient-related JJ N
) ) N
costs NNS N
will MD N
be VB N
measured VBN N
to TO N
compare VB N
the DT N
cost-effectiveness NN N
of IN N
each DT N
program NN N
DISCUSSION NNP N
This DT N
trial NN N
will MD N
identify VB N
whether IN N
home-based JJ N
pulmonary JJ N
rehabilitation NN N
can MD N
deliver VB N
equivalent JJ N
benefits NNS N
to TO N
centre-based JJ N
pulmonary JJ N
rehabilitation NN N
in IN N
a DT N
cost NN N
effective JJ N
manner NN N
The DT N
results NNS N
of IN N
this DT N
study NN N
will MD N
contribute VB N
new JJ N
knowledge NN N
regarding VBG N
alternative JJ N
models NNS N
of IN N
pulmonary JJ N
rehabilitation NN N
and CC N
will MD N
inform VB N
pulmonary JJ N
rehabilitation NN N
guidelines NNS N
for IN N
COPD NNP N
-DOCSTART- -X- O O 17985004

Cost-effectiveness NN N
of IN N
clopidogrel NN N
in IN N
acute JJ 4_p
coronary JJ 4_p
syndromes NNS 4_p
in IN N
Canada NNP N
: : N
a DT N
long-term JJ N
analysis NN N
based VBN N
on IN N
the DT N
CURE NNP N
trial NN N
BACKGROUND NNP N
Cardiovascular NNP N
diseases VBZ N
account NN N
for IN N
nearly RB N
20 CD N
% NN N
of IN N
all DT N
hospitalizations NNS N
in IN N
Canada NNP N
and CC N
consume VB N
12 CD N
% NN N
of IN N
the DT N
total JJ N
cost NN N
of IN N
all DT N
illnesses NNS N
With IN N
increasing VBG N
trends NNS N
of IN N
cardiovascular JJ N
disease NN N
and CC N
increasing VBG N
costs NNS N
of IN N
care NN N
, , N
development NN N
of IN N
cost-effective JJ N
strategies NNS N
is VBZ N
vital JJ N
The DT N
Clopidogrel NNP N
in IN N
Unstable NNP N
angina NN N
to TO N
prevent VB N
Recurrent JJ N
Events NNS N
( ( N
CURE NNP N
) ) N
trial NN N
demonstrated VBD N
the DT N
effectiveness NN N
of IN N
clopidogrel NN N
plus CC N
acetylsalicylic JJ N
acid NN N
( ( N
ASA NNP N
) ) N
compared VBN N
with IN N
ASA NNP N
alone RB N
in IN N
reducing VBG N
cardiovascular JJ N
events NNS N
in IN N
patients NNS N
with IN N
acute JJ N
coronary JJ N
syndromes NNS N
and CC N
, , N
in IN N
addition NN N
, , N
patients NNS N
undergoing VBG N
percutaneous JJ N
coronary JJ 4_p
intervention NN 4_p
in IN N
the DT N
Percutaneous NNP N
Coronary NNP N
Intervention NNP N
in IN N
CURE NNP N
( ( N
PCI-CURE NNP N
) ) N
trial NN N
OBJECTIVE UH N
To TO N
assess VB N
the DT N
cost-effectiveness NN N
of IN N
clopidogrel NN N
in IN N
the DT N
Canadian NNP N
health NN N
care NN N
system NN N
METHODS NNP N
Estimates NNS N
of IN N
hospitalization NN N
costs NNS N
were VBD N
based VBN N
on IN N
the DT N
2003 CD N
cost NN N
schedules NNS N
released VBN N
by IN N
the DT N
Health NNP N
Funding NNP N
and CC N
Costing NNP N
Branch NNP N
of IN N
the DT N
Alberta NNP N
Health NNP N
and CC N
Wellness NNP N
, , N
as RB N
well RB N
as IN N
on IN N
the DT N
Case NNP N
Mix NNP N
Group NNP N
classification NN N
system NN N
Life NNP N
expectancy NN N
beyond IN N
the DT N
trial NN N
was VBD N
estimated VBN N
from IN N
the DT N
Saskatchewan NNP N
Health NNP N
Database NNP N
Cost-effectiveness NNP N
was VBD N
expressed VBN N
as IN N
the DT N
incremental JJ N
cost-effectiveness NN N
ratio NN N
, , N
and CC N
bootstrap NN N
methods NNS N
were VBD N
used VBN N
to TO N
estimate VB N
the DT N
joint JJ N
distribution NN N
of IN N
costs NNS N
and CC N
effectiveness NN N
RESULTS NNP N
Clopidogrel NNP N
was VBD N
shown VBN N
to TO N
be VB N
cost-effective JJ N
, , N
with IN N
incremental JJ N
cost-effectiveness JJ N
ratios NNS N
less JJR N
than IN N
$ $ N
10,000 CD N
per IN N
event NN N
prevented VBN N
and CC N
less JJR N
than IN N
$ $ N
4,000 CD N
per IN N
life-year NN N
gained VBN N
The DT N
probability NN N
of IN N
clopidogrel NN N
resulting VBG N
in IN N
cost NN N
per IN N
life-year JJ N
gained VBN N
of IN N
less JJR N
than IN N
$ $ N
20,000 CD N
was VBD N
0.975 CD N
for IN N
CURE NNP N
patients NNS N
and CC N
0.904 CD N
for IN N
PCI-CURE JJ N
patients NNS N
CONCLUSIONS NNP N
The DT N
economic JJ N
analysis NN N
demonstrated VBD N
that IN N
clopidogrel NN N
combination NN N
therapy NN N
is VBZ N
not RB N
only RB N
cost-effective JJ N
as IN N
antiplatelet NN N
therapy NN N
compared VBN N
with IN N
ASA NNP N
alone RB N
, , N
but CC N
it PRP N
is VBZ N
also RB N
cost-effective JJ N
compared VBN N
with IN N
other JJ N
commonly RB N
used VBN N
and CC N
openly RB N
reimbursed VBD N
cardiovascular JJ N
therapies NNS N
in IN N
the DT N
Canadian NNP N
health NN N
care NN N
system NN N
-DOCSTART- -X- O O 3895875

Prophylactic JJ N
lidocaine NN N
in IN N
the DT N
early JJ N
phase NN N
of IN N
suspected JJ N
myocardial JJ N
infarction NN N
Four CD 3_p
hundred VBD 3_p
two CD 3_p
patients NNS N
with IN N
suspected JJ N
myocardial JJ 4_p
infarction NN 4_p
seen VBN N
within IN N
6 CD N
hours NNS N
of IN N
the DT N
onset NN N
of IN N
symptoms NNS N
entered VBD N
a DT N
double-blind JJ N
randomized JJ N
trial NN N
of IN N
lidocaine NN N
vs NN N
placebo NN N
During IN N
the DT N
1 CD N
hour NN N
after IN N
administration NN N
of IN N
the DT N
drug NN N
the DT N
incidence NN N
of IN N
ventricular JJ N
fibrillation NN N
or CC N
sustained VBN N
ventricular JJ N
tachycardia NN N
among IN N
the DT N
204 CD 3_p
patients NNS N
with IN N
acute JJ N
myocardial JJ N
infarction NN N
was VBD N
low JJ N
, , N
1.5 CD N
% NN N
Lidocaine NNP N
, , N
given VBN N
in IN N
a DT N
300 CD N
mg NN N
dose VBD N
intramuscularly RB N
followed VBN N
by IN N
100 CD N
mg NN N
intravenously RB N
, , N
did VBD N
not RB N
prevent VB N
sustained JJ N
ventricular JJ N
tachycardia NN N
, , N
although IN N
there EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN N
of IN N
patients NNS N
with IN N
warning VBG N
arrhythmias NNS N
between IN N
15 CD N
and CC N
45 CD N
minutes NNS N
after IN N
the DT N
administration NN N
of IN N
lidocaine NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
The DT N
average JJ N
plasma JJ N
lidocaine JJ N
level NN N
10 CD N
minutes NNS N
after IN N
administration NN N
for IN N
patients NNS N
without IN N
a DT N
myocardial JJ N
infarction NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
for IN N
patients NNS N
with IN N
an DT N
acute JJ N
infarction NN N
The DT N
mean JJ N
plasma NN N
lidocaine JJ N
level NN N
of IN N
patients NNS N
on IN N
beta-blocking JJ N
agents NNS N
was VBD N
no DT N
different JJ N
from IN N
that DT N
in IN N
patients NNS N
not RB N
on IN N
beta NN N
blocking VBG N
agents NNS N
During IN N
the DT N
1-hour JJ N
study NN N
period NN N
, , N
the DT N
incidence NN N
of IN N
central JJ N
nervous JJ N
system NN N
side NN N
effects NNS N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
lidocaine NN N
group NN N
, , N
hypotension NN N
occurred VBD N
in IN N
11 CD N
patients NNS N
, , N
nine CD N
of IN N
whom WP N
had VBD N
received VBN N
lidocaine NN N
, , N
and CC N
four CD N
patients NNS N
died VBD N
from IN N
asystole NN N
, , N
three CD N
of IN N
whom WP N
had VBD N
had VBN N
lidocaine NN N
We PRP N
can MD N
not RB N
advocate VB N
the DT N
administration NN N
of IN N
lidocaine JJ N
prophylactically RB N
in IN N
the DT N
early JJ N
hours NNS N
of IN N
suspected JJ N
myocardial JJ N
infarction NN N
-DOCSTART- -X- O O 24982504

Tacrolimus/sirolimus NNP N
vs NN N
tacrolimus/methotrexate NN N
as IN N
GVHD NNP N
prophylaxis NN N
after IN N
matched VBN N
, , N
related VBN N
donor NN 4_p
allogeneic NN 4_p
HCT NNP 4_p
Grades NNP N
2-4 JJ N
acute JJ N
graft-versus-host JJ N
disease NN N
( ( N
GVHD NNP N
) ) N
occurs VBZ N
in IN N
approximately RB N
35 CD N
% NN N
of IN N
matched VBN N
, , N
related VBN N
donor NN N
( ( N
MRD NNP N
) ) N
allogeneic VBZ N
hematopoietic JJ N
cell NN N
transplantation NN N
( ( N
HCT NNP N
) ) N
recipients NNS N
We PRP N
sought VBD N
to TO N
determine VB N
if IN N
the DT N
combination NN N
of IN N
tacrolimus NN N
and CC N
sirolimus NN N
( ( N
Tac/Sir NNP N
) ) N
was VBD N
more RBR N
effective JJ N
than IN N
tacrolimus NN N
and CC N
methotrexate NN N
( ( N
Tac/Mtx NNP N
) ) N
in IN N
preventing VBG N
acute JJ N
GVHD NNP N
and CC N
early JJ N
mortality NN N
after IN N
allogeneic JJ N
MRD NNP N
HCT NNP N
in IN N
a DT N
phase NN N
3 CD N
, , N
multicenter JJR N
trial NN N
The DT N
primary JJ N
end NN N
point NN N
of IN N
the DT N
trial NN N
was VBD N
to TO N
compare VB N
114-day JJ N
grades NNS N
2-4 JJ N
acute JJ N
GVHD-free NNP N
survival NN N
using VBG N
an DT N
intention-to-treat JJ N
analysis NN N
of IN N
304 CD 3_p
randomized JJ N
subjects NNS N
There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
probability NN N
of IN N
day NN N
114 CD N
grades NNS N
2-4 JJ N
acute JJ N
GVHD-free JJ N
survival NN N
( ( N
67 CD N
% NN N
vs JJ N
62 CD N
% NN N
, , N
P NNP N
= NNP N
.38 NNP N
) ) N
Grades NNP N
2-4 JJ N
GVHD NNP N
was VBD N
similar JJ N
in IN N
the DT N
Tac/Sir NNP N
and CC N
Tac/Mtx NNP N
arms NNS N
( ( N
26 CD N
% NN N
vs JJ N
34 CD N
% NN N
, , N
P NNP N
= NNP N
.48 NNP N
) ) N
Neutrophil NNP N
and CC N
platelet VB N
engraftment NN N
were VBD N
more RBR N
rapid JJ N
in IN N
the DT N
Tac/Sir NNP N
arm NN N
( ( N
14 CD N
vs RB N
16 CD N
days NNS N
, , N
P NNP N
< NNP N
.001 NNP N
; : N
16 CD N
vs IN N
19 CD N
days NNS N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
Oropharyngeal NNP N
mucositis NN N
was VBD N
less RBR N
severe JJ N
in IN N
the DT N
Tac/Sir NNP N
arm NN N
( ( N
peak JJ N
Oral NNP N
Mucositis NNP N
Assessment NNP N
Scale NNP N
score VBD N
0.70 CD N
vs NN N
0.96 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
but CC N
otherwise RB N
toxicity NN N
was VBD N
similar JJ N
Chronic NNP N
GVHD NNP N
, , N
relapse-free JJ N
survival NN N
, , N
and CC N
overall JJ N
survival NN N
at IN N
2 CD N
years NNS N
were VBD N
no DT N
different JJ N
between IN N
study NN N
arms NNS N
( ( N
53 CD N
% NN N
vs JJ N
45 CD N
% NN N
, , N
P NNP N
= NNP N
.06 NNP N
; : N
53 CD N
% NN N
vs JJ N
54 CD N
% NN N
, , N
P NNP N
= NNP N
.77 NNP N
; : N
and CC N
59 CD N
% NN N
vs JJ N
63 CD N
% NN N
, , N
P NNP N
= NNP N
.36 NNP N
) ) N
Based VBN N
on IN N
similar JJ N
long-term JJ N
outcomes NNS N
, , N
more RBR N
rapid JJ N
engraftment NN N
, , N
and CC N
less JJR N
oropharyngeal JJ N
mucositis NN N
, , N
the DT N
combination NN N
of IN N
Tac/Sir NNP N
is VBZ N
an DT N
acceptable JJ N
alternative NN N
to TO N
Tac/Mtx NNP N
after IN N
MRD NNP N
HCT NNP N
This DT N
study NN N
was VBD N
funded VBN N
by IN N
the DT N
National NNP N
Heart NNP N
, , N
Lung NNP N
, , N
and CC N
Blood NNP N
Institute NNP N
and CC N
the DT N
National NNP N
Cancer NNP N
Institute NNP N
; : N
and CC N
the DT N
trial NN N
was VBD N
registered VBN N
at IN N
www.clinicaltrials.gov NN N
as IN N
# # N
NCT00406393 NNP N
-DOCSTART- -X- O O 9101850

[ RB N
Restorative NNP N
proctectomy NN N
, , N
reconstruction NN N
of IN N
continuity NN N
with IN N
or CC N
without IN N
colon NN N
J NNP N
pouch JJ N
] NNP N
Of IN N
63 CD 3_p
patients NNS N
undergoing JJ N
deep JJ 4_p
anterior JJ 4_p
resection NN 4_p
of IN 4_p
the DT 4_p
rectum NN 4_p
, , N
39 CD 3_p
patients NNS N
received VBD N
a DT N
straight JJ N
colo-anal JJ N
anastomosis NN N
( ( N
CAA NNP N
) ) N
, , N
24 CD N
additionally RB N
had VBD N
a DT N
colon-j-pouch JJ N
( ( N
CPA NNP N
) ) N
constructed VBD N
Local NNP N
septic JJ N
complications NNS N
occurred VBD N
in IN N
12.5 CD N
% NN N
of IN N
patients NNS N
after IN N
pouch-anal JJ N
anastomosis NN N
compared VBN N
to TO N
20.5 CD N
% NN N
after IN N
colo-anal JJ N
anastomosis NN N
: : N
stool NN N
frequency NN N
, , N
after IN N
pouch-anal JJ N
anastomosis NN N
was VBD N
3.3 CD N
per IN N
24 CD N
h NN N
compared VBN N
to TO N
5.2 CD N
per IN N
24 CD N
h NN N
after IN N
straight JJ N
anastomosis NN N
within IN N
the DT N
first JJ N
year NN N
after IN N
ileostomy JJ N
closure NN N
( ( N
p JJ N
= NNP N
0.053 CD N
) ) N
; : N
continence NN N
was VBD N
slightly RB N
better RBR N
in IN N
the DT N
pouch JJ N
group NN N
( ( N
n.s RB N
) ) N
; : N
and CC N
anal JJ N
manometry NN N
showed VBD N
a DT N
significant JJ N
postoperative JJ N
decrease NN N
only RB N
in IN N
resting VBG N
pressure NN N
after IN N
straight JJ N
colo-anal JJ N
anastomosis NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
Pouch JJ N
construction NN N
should MD N
be VB N
considered VBN N
after IN N
deep JJ N
rectal JJ N
resection NN N
, , N
as IN N
it PRP N
seems VBZ N
to TO N
improve VB N
functional JJ N
outcome NN N
and CC N
has VBZ N
fewer JJR N
local JJ N
septic NN N
complications NNS N
than IN N
straight JJ N
anastomosis NN N
-DOCSTART- -X- O O 7491394

A DT N
comparison NN N
of IN N
live JJ N
and CC N
videotape JJ N
ratings NNS N
: : N
clomipramine NN 4_p
and CC N
haloperidol NN 4_p
in IN 4_p
autism NN 4_p
This DT N
study NN N
compared VBN N
live JJ N
ratings NNS N
with IN N
ratings NNS N
of IN N
videotapes NNS N
and CC N
compared VBN N
response NN N
to TO N
clomipramine VB N
with IN N
response NN N
to TO N
haloperidol VB N
in IN N
8 CD 3_p
subjects NNS N
, , N
mean JJ N
age NN N
5.62 CD 1_p
years NNS 1_p
, , N
who WP N
met VBD N
criteria NNS N
for IN N
autism NN N
They PRP N
were VBD N
consecutive JJ N
admissions NNS N
to TO N
a DT N
pilot NN N
study NN N
of IN N
clomipramine NN N
( ( N
n JJ N
= NNP N
4 CD N
) ) N
or CC N
a DT N
double-blind JJ N
, , N
placebo NN N
controlled VBD N
study NN N
of IN N
haloperidol NN N
( ( N
n JJ N
= NNP N
4 CD N
) ) N
Live JJ N
ratings NNS N
were VBD N
performed VBN N
by IN N
two CD N
raters NNS N
at IN N
the DT N
end NN N
of IN N
the DT N
pre-treatment JJ N
placebo NN N
baseline NN N
period NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
drug NN N
treatment NN N
period NN N
on IN N
the DT N
CPRS NNP N
and CC N
the DT N
CGI NNP N
and CC N
were VBD N
videotaped VBN N
Employing VBG N
the DT N
same JJ N
instruments NNS N
, , N
these DT N
videotapes NNS N
were VBD N
rated VBN N
by IN N
two CD N
raters NNS N
who WP N
did VBD N
not RB N
know VB N
the DT N
subjects NNS N
and CC N
were VBD N
blind NNS N
to TO N
study VB N
design NN N
, , N
treatment NN N
, , N
and CC N
study NN N
phase NN N
Ratings NNS N
of IN N
videotapes NNS N
significantly RB N
differed VBN N
from IN N
live JJ N
ratings NNS N
A DT N
treatment NN N
effect NN N
for IN N
haloperidol NN N
was VBD N
detected VBN N
only RB N
on IN N
live JJ N
ratings NNS N
and CC N
not RB N
on IN N
ratings NNS N
of IN N
videotapes NNS N
No DT N
treatment NN N
effect NN N
was VBD N
detected VBN N
for IN N
clomipramine NN N
in IN N
either CC N
live JJ N
or CC N
videotape JJ N
ratings NNS N
-DOCSTART- -X- O O 24768960

To TO N
excise VB N
or CC N
ablate VB N
endometriosis NN 4_p
? . N
A DT N
prospective JJ N
randomized VBN N
double-blinded JJ N
trial NN N
after IN N
5-year JJ N
follow-up NN N
STUDY NNP N
OBJECTIVE NNP N
To TO N
compare VB N
reduction NN N
of IN N
pain NN N
after IN N
laparoscopy NN N
for IN N
ablation NN N
or CC N
excision NN N
of IN N
endometriosis NN N
DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
double-blind JJ N
study NN N
( ( N
Canadian JJ N
Task NNP N
Force NNP N
classification NN N
I PRP N
) ) N
SETTING CC N
Endometriosis NNP 4_p
and CC N
pelvic JJ 4_p
pain NN 4_p
clinic NN N
at IN N
a DT N
university NN N
teaching VBG N
hospital NN N
PATIENTS NNP N
Women NNP 2_p
of IN N
reproductive JJ N
age NN N
with IN N
pelvic JJ 4_p
pain NN 4_p
and CC N
visually RB N
proved JJ N
endometriosis NN 4_p
INTERVENTIONS NNP N
Subjects NNPS N
completed VBD N
a DT N
questionnaire NN N
rating NN N
various JJ N
kinds NNS N
of IN N
pain NN N
using VBG N
visual JJ N
analog NN N
scales NNS N
( ( N
VAS NNP N
) ) N
After IN N
visual JJ N
identification NN N
subjects NNS N
were VBD N
randomized VBN N
to TO N
treatment NN N
via IN N
ablation NN N
or CC N
excision NN N
by IN N
supervised JJ N
training NN N
gynecologists NNS N
as IN N
primary JJ N
surgeons NNS N
Follow-up JJ N
questionnaires NNS N
documented VBN N
pain NN N
levels NNS N
every DT N
3 CD N
months NNS N
for IN N
1 CD N
year NN N
and CC N
then RB N
every DT N
6 CD N
months NNS N
for IN N
5 CD N
years NNS N
MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Change NNP N
in IN N
pain NN N
VAS NNP N
scores VBZ N
during IN N
5 CD N
years NNS N
after IN N
the DT N
operation NN N
and CC N
rates NNS N
of IN N
pregnancy NN N
, , N
repeat NN N
surgery NN N
, , N
and CC N
use NN N
of IN N
hormone NN N
therapy NN N
were VBD N
evaluated VBN N
There EX N
was VBD N
a DT N
reduction NN N
in IN N
all DT N
pain NN N
scores NNS N
over IN N
the DT N
5-year JJ N
follow-up NN N
in IN N
both DT N
treatment NN N
groups NNS N
A DT N
significantly RB N
greater JJR N
reduction NN N
in IN N
dyspareunia NN N
VAS NNP N
scores NNS N
was VBD N
observed VBN N
in IN N
the DT N
excision NN N
group NN N
at IN N
5 CD N
years NNS N
( ( N
p JJ N
= NN N
.03 NN N
at IN N
univariate JJ N
analysis NN N
, , N
and CC N
p NN N
= NN N
.007 NN N
at IN N
multivariate JJ N
analysis NN N
) ) N
More JJR N
women NNS N
in IN N
the DT N
ablation NN N
group NN N
continued VBD N
to TO N
receive VB N
medical JJ N
treatment NN N
of IN N
endometriosis NN N
at IN N
5 CD N
years NNS N
( ( N
p JJ N
= NNP N
.004 NNP N
) ) N
CONCLUSIONS NNP N
Surgical NNP N
treatment NN N
of IN N
endometriosis NN N
provides VBZ N
symptom JJ N
reduction NN N
for IN N
up IN N
to TO N
5 CD N
years NNS N
In IN N
some DT N
limited JJ N
areas NNS N
such JJ N
as IN N
deep JJ N
dyspareunia NN N
, , N
excision NN N
is VBZ N
more RBR N
effective JJ N
than IN N
ablation NN N
-DOCSTART- -X- O O 21048041

Pharmacogenetic JJ N
interaction NN N
analysis NN N
for IN N
the DT N
efficacy NN N
of IN N
systemic JJ N
treatment NN N
in IN N
metastatic JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
BACKGROUND NNP N
Pharmacogenetic NNP N
markers NNS N
related VBN N
to TO N
drug NN N
metabolism NN N
and CC N
mechanisms NNS N
of IN N
action NN N
could MD N
help VB N
to TO N
better VB N
select JJ N
patients NNS N
with IN N
metastatic JJ 4_p
colorectal NN 4_p
cancer NN 4_p
( ( 4_p
mCRC NN 4_p
) ) 4_p
for IN N
treatment NN N
Genetic JJ N
interaction NN N
analysis NN N
is VBZ N
used VBN N
as IN N
a DT N
rational JJ N
tool NN N
to TO N
study VB N
the DT N
contribution NN N
of IN N
polygenic JJ N
variation NN N
in IN N
relation NN N
to TO N
drug NN N
response NN N
PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
selection NN N
of IN N
17 CD N
polymorphisms NNS N
in IN N
genes NNS N
encoding VBG N
drug NN N
targets NNS N
, , N
pathway NN N
molecules NNS N
and CC N
detoxification NN N
enzymes NNS N
was VBD N
analyzed VBN N
in IN N
279 CD 3_p
previously RB 4_p
untreated JJ 4_p
mCRC NN 4_p
patients NNS N
treated VBN N
with IN N
capecitabine NN N
, , N
oxaliplatin NN N
and CC N
bevacizumab NN N
( ( N
CAPOX-B NNP N
) ) N
Multifactor NNP N
dimensionality NN N
reduction NN N
analysis NN N
was VBD N
used VBN N
to TO N
identify VB N
a DT N
genetic JJ N
interaction NN N
profile NN N
for IN N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
RESULTS NNP N
Median JJ N
PFS NNP N
was VBD N
10.9 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
9.4-12.4 CD N
] JJ N
months NNS N
A NNP N
genetic JJ N
interaction NN N
profile NN N
consisting VBG N
of IN N
the DT N
TYMS NNP N
enhancer NN N
region NN N
and CC N
VEGF NNP N
+405G NNP N
> NNP N
C NNP N
polymorphisms NN N
was VBD N
significantly RB N
associated VBN N
with IN N
PFS NNP N
Median JJ N
PFS NNP N
was VBD N
13.3 CD N
( ( N
95 CD N
% NN N
CI NNP N
11.4-15.3 CD N
) ) N
and CC N
9.7 CD N
( ( N
95 CD N
% NN N
CI NNP N
7.6-11.8 CD N
) ) N
months NNS N
for IN N
the DT N
beneficial JJ N
and CC N
unfavorable JJ N
genetic JJ N
profiles NNS N
, , N
respectively RB N
, , N
corresponding VBG N
to TO N
a DT N
hazards NNS N
ratio NN N
for IN N
PFS NNP N
of IN N
1.58 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.14-2.19 CD N
) ) N
None NN N
of IN N
the DT N
studied JJ N
polymorphisms NNS N
were VBD N
individually RB N
associated VBN N
with IN N
PFS NNP N
CONCLUSIONS NNP N
Our PRP$ N
results NNS N
support VB N
a DT N
genetic JJ N
interaction NN N
between IN N
the DT N
TYMS NNP N
enhancer NN N
region NN N
and CC N
VEGF NNP N
+405G NNP N
> NNP N
C NNP N
polymorphisms NN N
as IN N
a DT N
predictor NN N
of IN N
the DT N
efficacy NN N
of IN N
CAPOX-B NNP N
in IN N
mCRC NN 4_p
patients NNS N
-DOCSTART- -X- O O 15845130

Outcome NN N
at IN N
7 CD N
years NNS N
of IN N
children NNS 1_p
diagnosed VBN N
with IN N
autism NN 4_p
at IN N
age NN 1_p
2 CD 1_p
: : N
predictive JJ N
validity NN N
of IN N
assessments NNS N
conducted VBN N
at IN N
2 CD 1_p
and CC 1_p
3 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
and CC N
pattern NN N
of IN N
symptom JJ N
change NN N
over IN N
time NN N
OBJECTIVE UH N
To TO N
examine VB N
the DT N
predictive JJ N
validity NN N
of IN N
symptom JJ N
severity NN N
, , N
cognitive JJ N
and CC N
language NN N
measures NNS N
taken VBN N
at IN N
ages NNS N
2 CD N
and CC N
3 CD N
years NNS N
to TO N
outcome VB N
at IN N
age NN N
7 CD N
in IN N
a DT N
sample NN N
of IN N
children NNS 1_p
diagnosed VBN N
with IN N
autism NN 4_p
at IN N
age NN 1_p
2 CD 1_p
METHOD NNP N
Twenty-six JJ 3_p
children NNS 1_p
diagnosed VBN N
with IN N
autism NN 4_p
at IN N
age NN 1_p
2 CD 1_p
were VBD N
re-assessed VBN N
at IN N
ages NNS N
3 CD N
and CC N
7 CD N
years NNS N
At IN N
each DT N
age NN N
symptom JJ N
severity NN N
, , N
cognitive JJ N
and CC N
language NN N
assessments NNS N
were VBD N
completed VBN N
RESULTS VB N
The DT N
pattern NN N
of IN N
autistic JJ N
symptom NN N
severity NN N
varied VBN N
over IN N
time NN N
by IN N
domain NN N
Across IN N
time NN N
, , N
children NNS N
moved VBD N
across IN N
diagnostic JJ N
boundaries NNS N
both DT N
in IN N
terms NNS N
of IN N
clinical JJ N
diagnosis NN N
and CC N
in IN N
terms NNS N
of IN N
instrument NN N
diagnosis NN N
on IN N
the DT N
Autism NNP N
Diagnostic NNP N
Interview-Revised JJ N
( ( N
ADI-R NNP N
) ) N
On IN N
all DT N
measures NNS N
group NN N
variability NN N
in IN N
scores NNS N
increased VBN N
with IN N
age NN N
Although IN N
non-verbal JJ N
IQ NNP N
( ( N
NVIQ NNP N
) ) N
for IN N
the DT N
group NN N
as IN N
a DT N
whole NN N
was VBD N
stable JJ N
across IN N
the DT N
3 CD N
assessments NNS N
, , N
this DT N
masked VBD N
considerable JJ N
individual JJ N
instability NN N
Standard JJ N
assessments NNS N
at IN N
age NN N
2 CD N
did VBD N
not RB N
predict VB N
outcome NN N
at IN N
age NN N
7 CD N
even RB N
within IN N
the DT N
same JJ N
domain NN N
of IN N
functioning VBG N
In IN N
contrast NN N
, , N
standard JJ N
assessments NNS N
at IN N
age NN N
3 CD N
did VBD N
predict JJ N
outcome NN N
However RB N
, , N
a DT N
measure NN N
of IN N
rate NN N
of IN N
non-verbal JJ N
communicative JJ N
acts NNS N
taken VBN N
from IN N
an DT N
interactive JJ N
play-based JJ N
assessment NN N
at IN N
age NN N
2 CD N
was VBD N
significantly RB N
associated VBN N
with IN N
language NN N
, , N
communication NN N
and CC N
social JJ N
outcomes NNS N
at IN N
age NN N
7 CD N
CONCLUSIONS VB N
The DT N
trajectory NN N
of IN N
autism NN N
symptoms NNS N
over IN N
time NN N
differed VBN N
in IN N
different JJ N
domains NNS N
, , N
suggesting VBG N
that IN N
they PRP N
may MD N
be VB N
, , N
at IN N
least JJS N
in IN N
part NN N
, , N
separable JJ N
Variability NN N
in IN N
language NN N
, , N
NVIQ NNP N
and CC N
symptom JJ N
severity NN N
increased VBD N
over IN N
time NN N
Caution NN N
is VBZ N
required VBN N
when WRB N
interpreting VBG N
the DT N
findings NNS N
from IN N
assessments NNS N
of IN N
children NNS 1_p
with IN N
autism NN 4_p
at IN N
age NN 1_p
2 CD 1_p
years NNS 1_p
At IN N
this DT N
age NN N
measures VBZ N
of IN N
rate NN N
of IN N
non-verbal JJ N
communication NN N
might MD N
be VB N
more RBR N
informative JJ N
than IN N
scores NNS N
on IN N
standard JJ N
psychometric NN N
tests NNS N
Predictive JJ N
validity NN N
of IN N
assessments NNS N
at IN N
age NN N
3 CD N
years NNS N
was VBD N
greater JJR N
-DOCSTART- -X- O O 16648775

The DT N
double-blind JJ N
sham-controlled JJ N
study NN N
of IN N
high-frequency NN N
rTMS NN N
( ( N
20 CD N
Hz NNP N
) ) N
for IN N
negative JJ N
symptoms NNS N
in IN N
schizophrenia NN 4_p
: : N
negative JJ N
results NNS N
The DT N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
( ( N
HF-rTMS NNP N
) ) N
over IN N
the DT N
prefrontal JJ N
cortex NN N
is VBZ N
a DT N
promising JJ N
method NN N
for IN N
the DT N
treatment NN N
of IN N
negative JJ N
symptoms NNS N
of IN N
schizophrenia NN 4_p
Using VBG N
double-blind JJ N
sham-controlled JJ N
parallel NN N
design NN N
, , N
we PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
HF-rTMS NNP N
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal NN N
cortex NN N
( ( N
DLPFC NNP N
) ) N
on IN N
negative JJ N
symptoms NNS N
in IN N
patients NNS N
with IN N
schizophrenia NN 4_p
Sixteen NNP 3_p
schizophrenia NN 4_p
patients NNS N
with IN N
predominantly RB N
negative JJ N
symptoms NNS N
on IN N
stable JJ N
antipsychotic JJ N
medication NN N
were VBD N
treated VBN N
with IN N
20 CD N
Hz NNP N
rTMS NN N
( ( N
90 CD N
% NN N
of IN N
motor NN N
threshold NN N
, , N
2000 CD N
stimuli NN N
per IN N
session NN N
) ) N
over IN N
ten JJ N
days NNS N
within IN N
2 CD N
weeks NNS N
with IN N
six CD N
weeks NNS N
follow-up RB N
The DT N
effect NN N
was VBD N
assessed VBN N
using VBG N
PANSS NNP N
, , N
CGI NNP N
, , N
MADRS NNP N
and CC N
neuropsychological JJ N
tests NNS N
We PRP N
failed VBD N
to TO N
find VB N
any DT N
significant JJ N
effect NN N
of IN N
active JJ N
rTMS NN N
Sham NNP N
rTMS NN N
showed VBD N
a DT N
trend NN N
for IN N
improvement NN N
over IN N
time NN N
on IN N
positive JJ N
and CC N
negative JJ N
subscales NNS N
of IN N
PANSS NNP N
and CC N
MADRS NNP N
Between-group NNP N
comparisons NNS N
failed VBD N
to TO N
reveal VB N
any DT N
significant JJ N
differences NNS N
on IN N
any DT N
rating NN N
scales NNS N
except IN N
a DT N
positive JJ N
subscale NN N
of IN N
PANSS NNP N
after IN N
8 CD N
weeks NNS N
Results NNS N
from IN N
our PRP$ N
study NN N
did VBD N
not RB N
confirm VB N
that IN N
HF-rTMS NNP N
over IN N
the DT N
left JJ N
DLPCF NNP N
affects VBZ N
the DT N
negative JJ N
symptoms NNS N
of IN N
schizophrenia NN N
and CC N
alternative JJ N
rTMS NN N
approaches NNS N
are VBP N
discussed VBN N
-DOCSTART- -X- O O 25871593

Feasibility NN N
of IN N
a DT N
sensory-adapted JJ N
dental NN N
environment NN N
for IN N
children NNS 1_p
with IN N
autism NN 4_p
OBJECTIVE UH N
To TO N
provide VB N
an DT N
example NN N
of IN N
an DT N
occupational JJ N
therapy NN N
feasibility NN N
study NN N
and CC N
evaluate VB N
the DT N
implementation NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
pilot NN N
and CC N
feasibility NN N
trial NN N
examining VBG N
the DT N
impact NN N
of IN N
a DT N
sensory-adapted JJ N
dental NN N
environment NN N
( ( N
SADE NNP N
) ) N
to TO N
enhance VB N
oral JJ N
care NN N
for IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
METHOD NNP N
Twenty-two JJ 3_p
children NNS N
with IN N
ASD NNP 4_p
and CC N
22 CD N
typically RB N
developing VBG N
children NNS 1_p
, , N
ages VBZ 1_p
6-12 JJ 1_p
yr NN 1_p
, , N
attended VBD N
a DT N
dental JJ N
clinic NN N
in IN N
an DT N
urban JJ N
hospital NN N
Participants NNS N
completed VBD N
two CD N
dental JJ N
cleanings NNS N
, , N
3-4 JJ N
mo NN N
apart RB N
, , N
one CD N
in IN N
a DT N
regular JJ N
environment NN N
and CC N
one CD N
in IN N
a DT N
SADE NNP N
Feasibility NNP N
outcome JJ N
measures NNS N
were VBD N
recruitment NN N
, , N
retention NN N
, , N
accrual JJ N
, , N
dropout NN N
, , N
and CC N
protocol NN N
adherence NN N
Intervention NNP N
outcome JJ N
measures NNS N
were VBD N
physiological JJ N
stress NN N
, , N
behavioral JJ N
distress NN N
, , N
pain NN N
, , N
and CC N
cost NN N
RESULTS NNP N
We PRP N
successfully RB N
recruited VBD N
and CC N
retained VBD N
participants NNS N
Parents NNS N
expressed VBD N
satisfaction NN N
with IN N
research NN N
study NN N
participation NN N
Dentists NNS N
stated VBD N
that IN N
the DT N
intervention NN N
could MD N
be VB N
incorporated VBN N
in IN N
normal JJ N
practice NN N
Intervention NNP N
outcome NN N
measures NNS N
favored VBD N
the DT N
SADE NNP N
condition NN N
CONCLUSION NNP N
Preliminary NNP N
positive JJ N
benefit NN N
of IN N
SADE NNP N
in IN N
children NNS 1_p
with IN N
ASD NNP 4_p
warrants NNS N
moving VBG N
forward RB N
with IN N
a DT N
large-scale JJ N
clinical JJ N
trial NN N
-DOCSTART- -X- O O 22092038

Activator NNP N
protein-1 NN N
( ( N
AP-1 NNP N
) ) N
signalling VBG N
in IN N
human JJ N
atherosclerosis NN 4_p
: : N
results NNS N
of IN N
a DT N
systematic JJ N
evaluation NN N
and CC N
intervention NN N
study NN N
Animal NNP N
studies NNS N
implicate VBP N
the DT N
AP-1 NNP N
( ( N
activator IN N
protein-1 NN N
) ) N
pro-inflammatory NN N
pathway NN N
as IN N
a DT N
promising NN N
target NN N
in IN N
the DT N
treatment NN N
of IN N
atherosclerotic JJ 4_p
disease NN 4_p
It PRP N
is VBZ N
, , N
however RB N
, , N
unclear JJ N
whether IN N
these DT N
observations NNS N
apply VBP N
to TO N
human JJ N
atherosclerosis NN 4_p
Therefore IN N
we PRP N
evaluated VBD N
the DT N
profile NN N
of IN N
AP-1 NNP N
activation NN N
through IN N
histological JJ N
analysis NN N
and CC N
tested VBD N
the DT N
potential JJ N
benefit NN N
of IN N
AP-1 NNP N
inhibition NN N
in IN N
a DT N
clinical JJ N
trial NN N
AP-1 JJ N
activation NN N
was VBD N
quantified VBN N
by IN N
phospho-c-Jun JJ N
nuclear JJ N
translocation NN N
( ( N
immunohistochemistry NN N
) ) N
on IN N
a DT N
biobank NN N
of IN N
aortic JJ 4_p
wall NN 4_p
samples NNS N
from IN N
organ JJ N
donors NNS N
The DT N
effect NN N
of IN N
AP-1 NNP N
inhibition NN N
on IN N
vascular JJ N
parameters NNS N
was VBD N
tested VBN N
through IN N
a DT N
double JJ N
blind JJ N
placebo-controlled JJ N
cross-over NN N
study NN N
of IN N
28 CD N
days NNS N
doxycycline NN N
or CC N
placebo NN N
in IN N
patients NNS N
with IN N
symptomatic JJ N
peripheral JJ N
artery NN N
disease NN N
Vascular JJ N
function NN N
was VBD N
assessed VBN N
by IN N
brachial JJ N
dilation NN N
as RB N
well RB N
as IN N
by IN N
plasma NN N
samples NNS N
analysed VBN N
for IN N
hs-CRP NN N
( ( N
high-sensitivity JJ N
C-reactive NNP N
protein NN N
) ) N
, , N
IL-6 NNP N
( ( N
interleukin-6 NN N
) ) N
, , N
IL-8 NNP N
, , N
ICAM-1 NNP N
( ( N
intercellular JJ N
adhesion NN N
molecule-1 NN N
) ) N
, , N
vWF FW N
( ( N
von FW N
Willebrand NNP N
factor NN N
) ) N
, , N
MCP-1 NNP N
( ( N
monocyte JJ N
chemoattractant NN N
protein-1 NN N
) ) N
, , N
PAI-1 NNP N
( ( N
plasminogen JJ N
activator NN N
inhibitor-1 NN N
) ) N
and CC N
fibrinogen NN N
Histological JJ N
evaluation NN N
of IN N
human JJ N
atherosclerosis NN N
showed VBD N
minimal JJ N
AP-1 NNP N
activation NN N
in IN N
non-diseased JJ N
arterial JJ N
wall NN N
( ( N
i.e JJ N
vessel NN N
wall NN N
without IN N
any DT N
signs NNS N
of IN N
atherosclerotic JJ N
disease NN N
) ) N
A DT N
gradual JJ N
increase NN N
of IN N
AP-1 NNP N
activation NN N
was VBD N
found VBN N
in IN N
non-progressive JJ N
and CC N
progressive JJ N
phases NNS N
of IN N
atherosclerosis NN N
respectively RB N
( ( N
P NNP N
< NNP N
0.044 CD N
) ) N
No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
progressive JJ N
and CC N
vulnerable JJ N
lesions NNS N
The DT N
expression NN N
of IN N
phospho-c-Jun JJ N
diminished VBN N
as IN N
the DT N
lesion NN N
stabilized VBN N
( ( N
P NNP N
< NNP N
0.016 CD N
) ) N
and CC N
does VBZ N
not RB N
significantly RB N
differ VBP N
from IN N
the DT N
normal JJ N
aortic JJ N
wall NN N
( ( N
P NNP N
< NNP N
0.33 CD N
) ) N
Evaluation NN N
of IN N
the DT N
doxycycline NN N
intervention NN N
only RB N
revealed VBD N
a DT N
borderline-significant JJ N
reduction NN N
of IN N
circulating VBG N
hs-CRP JJ N
levels NNS N
( ( N
-0.51 NNP N
μg/ml NNP N
, , N
P=0.05 NNP N
) ) N
and CC N
did VBD N
not RB N
affect VB N
any DT N
of IN N
the DT N
other JJ N
markers NNS N
of IN N
systemic JJ N
inflammation NN N
and CC N
vascular JJ N
function NN N
Our PRP$ N
studies NNS N
do VBP N
not RB N
characterize VB N
AP-1 NNP N
as IN N
a DT N
therapeutic JJ N
target NN N
for IN N
progressive JJ N
human JJ N
atherosclerotic JJ N
disease NN N
-DOCSTART- -X- O O 24138011

Aripiprazole NNP N
treatment NN N
of IN N
irritability NN N
associated VBN N
with IN N
autistic JJ 4_p
disorder NN 4_p
and CC N
the DT N
relationship NN N
between IN N
prior JJ N
antipsychotic JJ N
exposure NN N
, , N
adverse JJ N
events NNS N
, , N
and CC N
weight VBD N
change NN N
OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
prior JJ N
antipsychotic JJ N
exposure NN N
( ( N
PAE NNP N
) ) N
on IN N
safety NN N
and CC N
tolerability NN N
outcomes NNS N
in IN N
pediatric JJ 4_p
subjects NNS 4_p
receiving VBG 4_p
aripiprazole JJ 4_p
treatment NN 4_p
METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
post-hoc JJ N
analysis NN N
of IN N
pooled VBN N
data NNS N
from IN N
two CD N
8-week JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
studies NNS N
evaluating VBG N
aripiprazole NN N
for IN N
the DT N
treatment NN N
of IN N
irritability NN N
in IN N
pediatric JJ N
subjects NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
, , N
aged VBN 1_p
6-17 CD 1_p
years NNS 1_p
Subjects NNS N
were VBD N
stratified VBN N
by IN N
PAE NNP N
; : N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
, , N
and CC N
changes NNS N
in IN N
weight NN N
, , N
and CC N
metabolic JJ N
measures NNS N
were VBD N
evaluated VBN N
For IN N
subjects NNS N
receiving VBG N
aripiprazole NN N
, , N
regardless RB N
of IN N
PAE NNP N
, , N
baseline NN N
weight NN N
, , N
age NN N
, , N
gender NN N
, , N
and CC N
symptom JJ N
severity NN N
were VBD N
evaluated VBN N
in IN N
a DT N
regression NN N
model NN N
predicting VBG N
body NN N
weight JJ N
change NN N
RESULTS NNP N
Of IN N
316 CD 3_p
randomized JJ 3_p
subjects NNS 3_p
, , N
259 CD 3_p
( ( 3_p
82.0 CD 3_p
% NN 3_p
) ) N
were VBD N
antipsychotic JJ N
naïve NN N
( ( N
AN NNP N
) ) N
and CC N
57 CD 3_p
( ( 3_p
18.0 CD 3_p
% NN 3_p
) ) 3_p
had VBD N
a DT N
PAE NNP N
Aripiprazole-treated NNP N
AN NNP N
subjects NNS N
were VBD N
more RBR N
likely JJ N
than IN N
PAE NNP N
subjects NNS N
to TO N
report VB N
somnolence NN N
( ( N
11.9 CD N
% NN N
vs. FW N
2.8 CD N
% NN N
) ) N
, , N
sedation NN N
( ( N
22.7 CD N
% NN N
vs. FW N
11.1 CD N
% NN N
) ) N
, , N
or CC N
fatigue NN N
( ( N
17.0 CD N
% NN N
vs. FW N
13.9 CD N
% NN N
) ) N
Rates NNS N
of IN N
extrapyramidal JJ N
disorder NN N
and CC N
drooling NN N
, , N
but CC N
not RB N
akathisia VB N
or CC N
tremor VB N
, , N
were VBD N
marginally RB N
higher JJR N
in IN N
AN NNP N
subjects NNS N
Overall NNP N
, , N
10.8 CD N
% NN N
of IN N
aripiprazole-treated JJ N
AN NNP N
subjects NNS N
had VBD N
at IN N
least JJS N
one CD N
AE NNP N
leading VBG N
to TO N
discontinuation NN N
compared VBN N
with IN N
8.3 CD N
% NN N
of IN N
aripiprazole-treated JJ N
PAE NNP N
subjects NNS N
AN NNP N
subjects VBZ N
receiving VBG N
aripiprazole NN N
had VBD N
a DT N
larger JJR N
change NN N
in IN N
weight NN N
from IN N
baseline NN N
to TO N
endpoint VB N
compared VBN N
with IN N
those DT N
receiving VBG N
placebo NN N
( ( N
1.9 CD N
vs. FW N
0.7 CD N
kg NN N
; : N
treatment NN N
difference NN N
1.2 CD N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.5 CD N
, , N
1.9 CD N
) ) N
than IN N
PAE NNP N
subjects NNS N
receiving VBG N
aripiprazole JJ N
compared VBN N
with IN N
subjects NNS N
receiving VBG N
placebo NN N
( ( N
0.4 CD N
vs. FW N
-0.4 NNP N
kg NN N
; : N
treatment NN N
difference NN N
0.9 CD N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
-0.6 NN N
, , N
2.4 CD N
) ) N
Regression NN N
analysis NN N
identified VBD N
that IN 1_p
younger JJR 1_p
subjects NNS 1_p
with IN N
higher JJR N
baseline NN N
weight VBD N
z-score NN N
were VBD N
at IN N
highest JJS N
risk NN N
for IN N
weight JJ N
gain NN N
There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
metabolic JJ N
measures NNS N
compared VBN N
with IN N
placebo NN N
in IN N
either DT N
group NN N
CONCLUSIONS NNP N
Weight NNP N
gain NN N
was VBD N
more RBR N
pronounced JJ N
in IN N
AN NNP N
subjects NNS N
and CC N
more RBR N
likely JJ N
to TO N
occur VB N
in IN N
younger JJR 1_p
subjects NNS 1_p
with IN N
a DT N
higher JJR N
baseline NN N
weight VBD N
z-score RB N
AN JJ N
subjects NNS N
were VBD N
more RBR N
likely JJ N
to TO N
experience VB N
AEs NNP N
related VBN N
to TO N
somnolence NN N
However RB N
, , N
based VBN N
on IN N
discontinuations NNS N
rates NNS N
from IN N
AEs NNP N
, , N
overall JJ N
tolerability NN N
was VBD N
good JJ N
for IN N
both DT N
AN NNP N
and CC N
PAE NNP N
groups NNS N
CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
Study NNP N
of IN N
aripiprazole NN N
in IN N
the DT N
treatment NN N
of IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
Registry NN N
: : N
www.clinicaltrials.gov NN N
Identifiers NNS N
: : N
NCT00332241 NNP N
and CC N
NCT00337571 NNP N
-DOCSTART- -X- O O 17501728

The DT N
effectiveness NN N
of IN N
Picture NNP N
Exchange NNP N
Communication NNP N
System NNP N
( ( N
PECS NNP N
) ) N
training NN N
for IN N
teachers NNS 4_p
of IN 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
: : 4_p
a DT N
pragmatic JJ N
, , N
group NN N
randomised VBD N
controlled VBN N
trial NN N
OBJECTIVE UH N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
expert JJ N
training NN N
and CC N
consultancy NN N
for IN N
teachers NNS 4_p
of IN 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
in IN N
the DT N
use NN N
of IN N
the DT N
Picture NNP N
Exchange NNP N
Communication NNP N
System NNP N
( ( N
PECS NNP N
) ) N
METHOD NNP N
DESIGN NNP N
Group NNP N
randomised VBD N
, , N
controlled VBN N
trial NN N
( ( N
3 CD N
groups NNS N
: : N
immediate JJ N
treatment NN N
, , N
delayed VBN N
treatment NN N
, , N
no DT N
treatment NN N
) ) N
PARTICIPANTS $ N
84 CD 3_p
elementary JJ 1_p
school NN 1_p
children NNS 1_p
, , 1_p
mean JJ 1_p
age NN 1_p
6.8 CD 1_p
years NNS 1_p
TREATMENT VB N
A DT N
2-day JJ N
PECS NNP N
workshop NN N
for IN N
teachers NNS N
plus CC N
6 CD N
half-day JJ N
, , N
school-based JJ N
training NN N
sessions NNS N
with IN N
expert JJ N
consultants NNS N
over IN N
5 CD N
months NNS N
OUTCOME NNP N
MEASURES NNP N
Rates NNPS N
of IN N
: : N
communicative JJ N
initiations NNS N
, , N
use NN N
of IN N
PECS NNP N
, , N
and CC N
speech NN N
in IN N
the DT N
classroom NN N
; : N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule-Generic NNP N
( ( N
ADOS-G NNP N
) ) N
domain NN N
scores NNS N
for IN N
Communication NNP N
and CC N
Reciprocal NNP N
Social NNP N
Interaction NNP N
; : N
scores NNS N
on IN N
formal JJ N
language NN N
tests NNS N
RESULTS NNP N
Controlling VBG N
for IN N
baseline NN N
age NN N
, , N
developmental JJ N
quotient NN N
( ( N
DQ NNP N
) ) N
and CC N
language NN N
; : N
rates NNS N
of IN N
initiations NNS N
and CC N
PECS NNP N
usage NN N
increased VBD N
significantly RB N
immediately RB N
post-treatment JJ N
( ( N
Odds NNP N
Ratio NNP N
( ( N
OR NNP N
) ) N
of IN N
being VBG N
in IN N
a DT N
higher JJR N
ordinal JJ N
rate NN N
category NN N
2.72 CD N
, , N
95 CD N
% NN N
confidence NN N
interval JJ N
1.22-6.09 JJ N
, , N
p JJ N
< NNP N
.05 NNP N
and CC N
OR NNP N
3.90 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.75-8.68 CD N
) ) N
, , N
p JJ N
< NNP N
.001 NNP N
, , N
respectively RB N
) ) N
There EX N
were VBD N
no DT N
increases NNS N
in IN N
frequency NN N
of IN N
speech NN N
, , N
or CC N
improvements NNS N
in IN N
ADOS-G NNP N
ratings NNS N
or CC N
language NN N
test NN N
scores NNS N
CONCLUSIONS VB N
The DT N
results NNS N
indicate VBP N
modest JJ N
effectiveness NN N
of IN N
PECS NNP N
teacher NN N
training/consultancy NN N
Rates NNS N
of IN N
pupils NNS N
' POS N
initiations NNS N
and CC N
use NN N
of IN N
symbols NNS N
in IN N
the DT N
classroom NN N
increased VBD N
, , N
although IN N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
improvement NN N
in IN N
other JJ N
areas NNS N
of IN N
communication NN N
TREATMENT NNP N
effects NNS N
were VBD N
not RB N
maintained VBN N
once RB N
active JJ N
intervention NN N
ceased VBD N
-DOCSTART- -X- O O 12202662

Randomized VBN N
comparative JJ N
study NN N
of IN N
tegafur/uracil NN N
and CC N
oral JJ N
leucovorin NN N
versus IN N
parenteral JJ N
fluorouracil NN N
and CC N
leucovorin NN N
in IN N
patients NNS N
with IN N
previously RB N
untreated VBN N
metastatic JJ 4_p
colorectal NN 4_p
cancer NN 4_p
PURPOSE VB N
This DT N
phase NN N
III NNP N
study NN N
compared VBN N
the DT N
time NN N
to TO N
progression NN N
( ( N
TTP NNP N
) ) N
of IN N
an DT N
oral JJ N
regimen NNS N
of IN N
dihydropyrimidine JJ N
dehydrogenase NN N
inhibitory NN N
fluoropyrimidine NN N
composed VBN N
of IN N
a DT N
fixed JJ N
combination NN N
of IN N
tegafur NN N
and CC N
uracil NN N
in IN N
a DT N
1:4 CD N
molar JJ N
ratio NN N
( ( N
UFT NNP N
) ) N
and CC N
leucovorin $ N
( ( N
LV NNP N
) ) N
to TO N
intravenous JJ N
( ( N
IV NNP N
) ) N
fluorouracil NN N
( ( N
5-FU JJ N
) ) N
and CC N
LV NNP N
in IN N
previously RB 4_p
untreated VBN 4_p
metastatic JJ 4_p
colorectal NN 4_p
carcinoma NN 4_p
( ( 4_p
CRC NNP 4_p
) ) 4_p
patients NNS 4_p
Secondary JJ N
end NN N
points NNS N
were VBD N
survival JJ N
, , N
tumor JJ N
response NN N
, , N
safety NN N
, , N
and CC N
quality NN N
of IN N
life NN N
PATIENTS NNP N
AND CC N
METHODS NNP N
Between NNP N
May NNP N
1996 CD N
and CC N
July NNP N
1997 CD N
, , N
380 CD 3_p
patients NNS 3_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
UFT NNP N
( ( N
300 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
) ) N
and CC N
LV NNP N
( ( N
90 CD N
mg/d NN N
) ) N
, , N
administered VBN N
for IN N
28 CD N
days NNS N
every DT N
35 CD N
days NNS N
, , N
or CC N
5-FU JJ N
( ( N
425 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
) ) N
and CC N
LV NNP N
( ( N
20 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
) ) N
, , N
given VBN N
IV NNP N
for IN N
5 CD N
days NNS N
every DT N
35 CD N
days NNS N
RESULTS NNP N
No NNP N
statistically RB N
significant JJ N
difference NN N
in IN N
TTP NNP N
was VBD N
observed VBN N
between IN N
treatments NNS N
With IN N
320 CD N
events NNS N
assessed VBN N
, , N
the DT N
median JJ N
TTP NNP N
was VBD N
3.4 CD N
months NNS N
( ( N
95 CD N
% NN N
Confidence NNP N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
2.6 CD N
to TO N
3.8 CD N
) ) N
on IN N
UFT/LV NNP N
and CC N
3.3 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
2.5 CD N
to TO N
3.7 CD N
) ) N
on IN N
5-FU/LV JJ N
( ( N
P NNP N
=.591 NNP N
, , N
stratified VBD N
log-rank JJ N
test NN N
) ) N
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
survival NN N
, , N
tumor NN N
response NN N
, , N
duration NN N
of IN N
response NN N
, , N
and CC N
time NN N
to TO N
response NN N
Substantial NNP N
safety NN N
benefits NNS N
were VBD N
observed VBN N
in IN N
patients NNS N
treated VBN N
with IN N
UFT/LV NNP N
They PRP N
experienced VBD N
significantly RB N
less JJR N
stomatitis/mucositis NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
myelosuppression NN N
, , N
resulting VBG N
in IN N
fewer JJR N
episodes NNS N
of IN N
febrile JJ N
neutropenia NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
less RBR N
documented JJ N
infection NN N
( ( N
P NNP N
=.04 NNP N
) ) N
Concomitant JJ N
medication NN N
usage NN N
was VBD N
significantly RB N
greater JJR N
on IN N
5-FU/LV JJ N
( ( N
P NNP N
=.010 NNP N
) ) N
With IN N
respect NN N
to TO N
quality NN N
of IN N
life NN N
, , N
after IN N
correcting VBG N
for IN N
baseline NN N
imbalances NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
treatments NNS N
for IN N
any DT N
scale NN N
, , N
except IN N
diarrhea NN N
CONCLUSION VB N
The DT N
oral JJ N
UFT/LV NNP N
regimen NNS N
failed VBD N
to TO N
achieve VB N
improved JJ N
TTP NNP N
; : N
however RB N
, , N
the DT N
study NN N
confirms VBZ N
significant JJ N
safety NN N
improvements NNS N
compared VBN N
with IN N
bolus JJ N
IV NNP N
5-FU/LV NN N
for IN N
the DT N
first-line JJ N
treatment NN N
of IN N
metastatic JJ N
CRC NNP N
-DOCSTART- -X- O O 20689977

Cost-effectiveness NN N
of IN N
cognitive-behavioral JJ N
group NN N
therapy NN N
for IN N
dysfunctional JJ N
fear NN N
of IN N
progression NN N
in IN N
cancer NN N
patients NNS N
Anxiety NNP N
and CC N
fear NN N
are VBP N
often RB N
associated VBN N
with IN N
chronic JJ N
conditions NNS N
such JJ N
as IN N
cancer NN N
This DT N
paper NN N
targets VBZ N
the DT N
cost-effectiveness JJ N
analysis NN N
of IN N
a DT N
cognitive-behavioral JJ N
group NN N
therapy NN N
( ( N
CBT NNP N
) ) N
in IN N
comparison NN N
to TO N
a DT N
client-centered JJ N
, , N
supportive-experiential JJ N
group NN N
therapy NN N
( ( N
SET NNP N
) ) N
in IN N
cancer NN N
patients NNS N
with IN N
dysfunctional JJ N
fear NN N
of IN N
progression NN N
An DT N
incremental JJ N
cost-effectiveness JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
data NNS N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
among IN N
cancer NN N
patients NNS N
receiving VBG N
inpatient JJ N
rehabilitation NN N
The DT N
means NNPS N
, , N
95 CD N
% NN N
confidence NN N
intervals NNS N
[ VBP N
95 CD N
% NN N
CI NNP N
] NNP N
, , N
incremental JJ N
cost-effectiveness JJ N
graphic NN N
and CC N
acceptability NN N
curve NN N
were VBD N
obtained VBN N
from IN N
1,000 CD N
bootstrap NN N
replications NNS N
A DT N
total NN N
of IN N
174 CD N
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
economic JJ N
evaluation NN N
The DT N
estimated JJ N
means VBZ N
[ JJ N
95 CD N
% NN N
CI NNP N
] NNP N
of IN N
direct JJ N
costs NNS N
and CC N
reduction NN N
of IN N
fear NN N
of IN N
progression NN N
were VBD N
< JJ N
euro JJ N
> NN N
9,045.03 CD N
[ JJ N
6,359.07 CD N
; : N
12,091.87 CD N
] NN N
and CC N
1.41 CD N
[ JJ N
0.93 CD N
; : N
1.92 CD N
] NN N
for IN N
patients NNS N
in IN N
the DT N
SET NNP N
and CC N
< NNP N
euro VBP N
> $ N
6,682.78 CD N
[ JJ N
4,998.09 CD N
; : N
8,440.95 CD N
] NN N
and CC N
1.44 CD N
[ JJ N
1.02 CD N
; : N
1.09 CD N
] NN N
for IN N
patients NNS N
in IN N
the DT N
CBT NNP N
The DT N
incremental JJ N
cost-effectiveness JJ N
ratio NN N
[ VBD N
95 CD N
% NN N
CI NNP N
] NNP N
amounts NNS N
to TO N
minus NNS N
< NNP N
euro VBP N
> $ N
78,741.66 CD N
[ NNP N
-154,987.20 NNP N
; : N
110,486.32 CD N
] NN N
for IN N
an DT N
additional JJ N
unit NN N
of IN N
effect NN N
Given VBN N
the DT N
acceptability NN N
curve NN N
, , N
there EX N
is VBZ N
a DT N
92.4 CD N
% NN N
chance NN N
that IN N
the DT N
CBT NNP N
, , N
compared VBN N
with IN N
the DT N
SET NNP N
, , N
is VBZ N
cost-effective JJ N
without IN N
the DT N
need NN N
of IN N
additional JJ N
costs NNS N
to TO N
payers NNS N
Our PRP$ N
main JJ N
result NN N
is VBZ N
the DT N
superior JJ N
cost-effectiveness NN N
of IN N
the DT N
cognitive-behavioral JJ N
intervention NN N
program NN N
in IN N
comparison NN N
to TO N
the DT N
non-directive JJ N
encounter NN N
group NN N
for IN N
our PRP$ N
sample NN N
of IN N
cancer NN N
patients NNS N
with IN N
high JJ N
levels NNS N
of IN N
anxiety NN N
-DOCSTART- -X- O O 17445928

A DT N
randomised JJ N
trial NN N
of IN N
radiotherapy NN N
compared VBN N
with IN N
cisplatin JJ N
chemo-radiotherapy NN N
in IN N
patients NNS N
with IN N
unresectable JJ 4_p
squamous JJ 4_p
cell NN 4_p
cancer NN 4_p
of IN 4_p
the DT 4_p
esophagus NN 4_p
BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Following NNP N
our PRP$ N
phase NN N
II NNP N
experience NN N
, , N
a DT N
randomised JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
adding VBG N
chemotherapy NN N
to TO N
radiotherapy VB N
in IN N
patients NNS N
with IN N
unresectable JJ 4_p
squamous JJ 4_p
cell NN 4_p
cancer NN 4_p
of IN 4_p
the DT 4_p
esophagus NN 4_p
PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNS N
randomised VBD N
to TO N
the DT N
RT NNP N
group NN N
received VBD N
50 CD N
Gy/25 NNP N
fx/5 JJ N
weeks NNS N
of IN N
teletherapy NN N
followed VBD N
1-2 JJ N
weeks NNS N
later RB N
with IN N
12 CD N
Gy/2 NNP N
fx NN N
of IN N
high-dose-rate JJ N
intra-lumenal JJ N
brachytherapy NN N
spaced VBD N
a DT N
week NN N
apart RB N
Following VBG N
the DT N
first JJ N
3 CD N
years NNS N
of IN N
recruitment NN N
, , N
due JJ N
to TO N
unexpected JJ N
late JJ N
morbidity NN N
, , N
brachytherapy NN N
was VBD N
excluded VBN N
and CC N
the DT N
protocol NN N
modified VBD N
to TO N
66 CD N
Gy/33 NNP N
fx/6.5 JJ N
weeks NNS N
The DT N
CRT NNP N
group NN N
received VBD N
identical JJ N
radiotherapy NN N
with IN N
concurrent JJ N
weekly JJ N
cisplatin NN N
at IN N
35 CD N
mg/m NN N
( ( N
2 CD N
) ) N
for IN N
6-7 JJ N
cycles NNS N
RESULTS NNP N
Between NNP N
April NNP N
1999 CD N
and CC N
December NNP N
2005 CD N
, , N
125 CD 3_p
patients NNS N
were VBD N
randomised VBN N
to TO N
a DT N
RT NNP N
( ( N
n=60 NN N
) ) N
or CC N
CRT NNP N
group NN N
( ( N
n=65 RB N
) ) N
Radiotherapy NNP N
treatment NN N
was VBD N
completed VBN N
in IN N
78 CD N
% NN N
( ( N
47/60 CD N
) ) N
of IN N
the DT N
RT NNP N
group NN N
and CC N
89 CD N
% NN N
( ( N
58/65 CD N
) ) N
of IN N
the DT N
CRT NNP N
group NN N
( ( N
P=0.10 NNP N
) ) N
Six CD N
or CC N
more JJR N
cycles NNS N
of IN N
cisplatin NN N
could MD N
be VB N
delivered VBN N
in IN N
63 CD N
% NN N
( ( N
41/65 CD N
) ) N
, , N
which WDT N
resulted VBD N
in IN N
RTOG NNP N
grade VBD N
3 CD N
neutropenia NN N
of IN N
3 CD N
% NN N
Late JJ N
morbidity NN N
in IN N
the DT N
form NN N
of IN N
ulcers NNS N
( ( N
5 CD N
% NN N
vs. FW N
15 CD N
% NN N
odds NNS N
ratio VBP N
0.29 CD N
, , N
95 CD N
% NN N
CI NNP N
0.08-1.11 CD N
, , N
P=0.08 NNP N
) ) N
and CC N
strictures NNS N
( ( N
13 CD N
% NN N
vs. FW N
28 CD N
% NN N
, , N
odds NNS N
ratio VBP N
0.40 CD N
, , N
95 CD N
% NN N
CI NNP N
0.16-1.01 CD N
, , N
P=0.05 NNP N
) ) N
was VBD N
observed VBN N
in IN N
the DT N
RT NNP N
and CC N
CRT NNP N
groups NNS N
, , N
respectively RB N
At IN N
a DT N
median NN N
follow VBP N
up IN N
of IN N
23 CD N
months NNS N
of IN N
all DT N
patients NNS N
alive JJ N
( ( N
range JJ N
6-82 JJ N
months NNS N
) ) N
and CC N
with IN N
95/125 CD N
events NNS N
, , N
the DT N
median NN N
, , N
1 CD N
, , N
2 CD N
and CC N
5 CD N
year NN N
projected VBD N
survival NN N
was VBD N
7.1 CD N
months NNS N
, , N
32.3 CD N
% NN N
, , N
22.8 CD N
% NN N
and CC N
13.7 CD N
% NN N
vs. FW N
13.4 CD N
months NNS N
, , N
57.6 CD N
% NN N
, , N
38.9 CD N
% NN N
and CC N
24.8 CD N
% NN N
for IN N
the DT N
RT NNP N
and CC N
CRT NNP N
groups NNS N
, , N
respectively RB N
( ( N
hazard JJ N
ratio NN N
0.65 CD N
, , N
95 CD N
% NN N
CI NNP N
0.44-0.98 CD N
, , N
P=0.038 NNP N
) ) N
CONCLUSIONS VB N
The DT N
addition NN N
of IN N
concurrent NN N
cisplatin NN N
to TO N
radiotherapy VB N
resulted VBN N
in IN N
a DT N
modest JJ N
improvement NN N
in IN N
survival NN N
and CC N
was VBD N
associated VBN N
with IN N
manageable JJ N
additional JJ N
acute NN N
and CC N
late JJ N
morbidity NN N
-DOCSTART- -X- O O 23127528

Monitoring NN N
of IN N
CA19-9 NNP N
and CC N
SPan-1 NNP N
can MD N
facilitate VB N
the DT N
earlier JJR N
confirmation NN N
of IN N
progressing VBG N
pancreatic JJ N
cancer NN N
during IN N
chemotherapy NN N
BACKGROUND NNP N
Measurement NNP N
of IN N
objective JJ N
response NN N
to TO N
chemotherapy VB N
using VBG N
imaging VBG N
modalities NNS N
is VBZ N
sometimes RB N
difficult JJ N
in IN N
pancreatic JJ 4_p
cancer NN 4_p
( ( 4_p
PC NN 4_p
) ) 4_p
We PRP N
aimed VBD N
to TO N
verify VB N
whether IN N
monitoring NN N
of IN N
serum JJ N
tumor NN N
markers NNS N
( ( N
TMs NNP N
) ) N
, , N
namely RB N
carcinoembryonic JJ N
antigen NN N
, , N
CA19-9 NNP N
, , N
DUPAN-2 NNP N
, , N
SPan-1 NNP N
, , N
can MD N
facilitate VB N
earlier JJR N
confirmation NN N
of IN N
treatment NN N
failure NN N
METHODS NNP N
Monitoring NNP N
of IN N
serum NN N
TMs NNP N
and CC N
computed VBN N
tomography NN N
were VBD N
performed VBN N
every DT N
4 CD N
weeks NNS N
until IN N
progression NN N
of IN N
disease NN N
in IN N
90 CD 3_p
patients NNS N
with IN N
PC NNP 4_p
undergoing VBG N
gemcitabine JJ 4_p
therapy NN 4_p
In IN N
Group NNP N
A NNP N
( ( N
January NNP N
2006-October NNP N
2007 CD N
) ) N
, , N
we PRP N
analyzed VBD N
the DT N
fluctuation NN N
rates NNS N
of IN N
TMs NNP N
with IN N
high JJ N
pretreatment NN N
positive JJ N
rates NNS N
, , N
and CC N
defined VBD N
the DT N
criteria NNS N
of IN N
progressive JJ N
disease NN N
under IN N
TM NNP N
monitoring NN N
( ( N
TM-PD NNP N
) ) N
In IN N
Group NNP N
B NNP N
( ( N
November NNP N
2007-October JJ N
2008 CD N
) ) N
, , N
we PRP N
calculated VBD N
the DT N
time NN N
to TO N
progression NN N
( ( N
TTP NNP N
) ) N
under IN N
this DT N
TM-PD NNP N
criteria NNS N
, , N
which WDT N
was VBD N
compared VBN N
with IN N
the DT N
TTP NNP N
under IN N
the DT N
RECIST NNP N
criteria NNS N
RESULTS NNP N
CA19-9 JJ N
and CC N
SPan-1 NNP N
had VBD N
the DT N
highest JJS N
pretreatment JJ N
positive JJ N
rates NNS N
: : N
83 CD N
% NN N
and CC N
90 CD N
% NN N
, , N
respectively RB N
In IN N
Group NNP N
A NNP N
( ( N
CA19-9 NNP N
, , N
n JJ N
= VBP N
38 CD N
; : N
SPan-1 NNP N
, , N
n JJ N
= NNP N
36 CD N
) ) N
, , N
TM-PD JJ N
criteria NNS N
were VBD N
defined VBN N
as IN N
follows VBZ N
: : N
fluctuation NN N
rates NNS N
were VBD N
≥25 CD N
% NN N
for IN N
a DT N
month NN N
or CC N
≥10 CD N
% NN N
for IN N
2 CD N
consecutive JJ N
months NNS N
in IN N
CA19-9 NNP N
, , N
and CC N
≥10 CD N
% NN N
for IN N
a DT N
month NN N
in IN N
SPan-1 NNP N
In IN N
Group NNP N
B NNP N
( ( N
CA19-9 NNP N
, , N
n JJ N
= VBP N
18 CD N
; : N
SPan-1 NNP N
, , N
n JJ N
= NNP N
17 CD N
) ) N
, , N
under IN N
these DT N
criteria NNS N
, , N
one-month JJ N
earlier JJR N
confirmation NN N
of IN N
treatment NN N
failure NN N
was VBD N
feasible JJ N
in IN N
61 CD N
% NN N
by IN N
CA19-9 NNP N
and CC N
59 CD N
% NN N
by IN N
SPan-1 NNP N
Furthermore NNP N
, , N
the DT N
combination NN N
could MD N
facilitate VB N
this DT N
determination NN N
in IN N
72 CD N
% NN N
( ( N
35/49 CD N
) ) N
, , N
significantly RB N
better JJR N
than IN N
CA19-9 NNP N
alone RB N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
CONCLUSION NNP N
Monitoring NNP N
of IN N
serum JJ N
CA19-9 NNP N
and CC N
SPan-1 NNP N
is VBZ N
helpful JJ N
for IN N
earlier JJR N
confirmation NN N
of IN N
treatment NN N
failure NN N
during IN N
gemcitabine JJ N
therapy NN N
in IN N
PC NN N
-DOCSTART- -X- O O 2576261

Effect NN N
of IN N
two CD N
monophasic JJ N
oral JJ N
contraceptives NNS N
containing VBG N
gestodene NN N
or CC N
desogestrel NN N
on IN N
serum NN N
lipoprotein NN N
lipid JJ N
levels NNS N
Forty-nine NNP 3_p
healthy JJ N
women NNS 2_p
aged VBN 1_p
20-35 JJ 1_p
years NNS 1_p
who WP N
had VBD N
not RB N
been VBN N
pregnant JJ N
or CC N
using VBG N
an DT N
oral JJ 4_p
contraceptive NN 4_p
( ( N
OC NNP N
) ) N
for IN N
the DT N
previous JJ N
3 CD N
months NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
one CD N
group NN N
taking VBG N
an DT N
OC NNP N
containing VBG N
75 CD N
micrograms NNS N
gestodene NN N
( ( N
GTD NNP N
) ) N
and CC N
30 CD N
micrograms NNS N
ethinyl VBP N
estradiol NN N
( ( N
EE NNP N
) ) N
, , N
and CC N
the DT N
other JJ N
group NN N
using VBG N
an DT N
OC NNP N
with IN N
150 CD N
micrograms NNS N
desogestrel NN N
( ( N
DSG NNP N
) ) N
and CC N
30 CD N
micrograms NNS N
EE NNP N
Fasting VBG N
blood NN N
samples NNS N
were VBD N
taken VBN N
before RB N
treatment NN N
, , N
and CC N
after IN N
cycles NNS N
3 CD N
and CC N
6 CD N
, , N
between IN N
the DT N
18th CD N
and CC N
the DT N
22nd CD N
day NN N
of IN N
the DT N
cycle NN N
Blood NNP N
lipoprotein JJ N
lipid JJ N
levels NNS N
were VBD N
measured VBN N
Serum NNP N
total JJ N
cholesterol NN N
did VBD N
not RB N
change VB N
significantly RB N
in IN N
both DT N
groups NNS N
However RB N
, , N
in IN N
the DT N
first JJ N
three CD N
cycles NNS N
, , N
serum JJ N
triglyceride NN N
increased VBN N
by IN N
46 CD N
% NN N
and CC N
40 CD N
% NN N
and CC N
HDL-cholesterol NNP N
by IN N
14 CD N
% NN N
and CC N
8 CD N
% NN N
in IN N
the DT N
GTD NNP N
and CC N
DSG NNP N
groups NNS N
, , N
respectively RB N
The DT N
serum NN N
LDL NNP N
level NN N
decreased VBN N
by IN N
6.2 CD N
% NN N
and CC N
11.8 CD N
% NN N
, , N
respectively RB N
Between VB N
the DT N
third JJ N
and CC N
sixth JJ N
cycle NN N
, , N
no DT N
further JJ N
significant JJ N
changes NNS N
were VBD N
observed VBN N
, , N
nor CC N
did VBD N
these DT N
changes NNS N
differ VBP N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
In IN N
conclusion NN N
, , N
both DT N
OC NNP N
preparations NNS N
exerted VBD N
small JJ N
and CC N
probably RB N
favorable JJ N
effects NNS N
on IN N
serum NN N
lipoprotein NN N
lipid JJ N
levels NNS N
-DOCSTART- -X- O O 10594393

Ursodeoxycholic JJ N
acid NN N
has VBZ N
no DT N
influence NN N
on IN N
function NN N
after IN N
restorative JJ N
proctocolectomy NN N
in IN N
ulcerative JJ 4_p
colitis NN 4_p
BACKGROUND NNP N
Poor NNP N
pouch JJ N
function NN N
is VBZ N
associated VBN N
with IN N
impaired JJ N
bile NN N
acid NN N
absorption NN N
and CC N
increased VBD N
faecal JJ N
loss NN N
of IN N
bile JJ N
acids NNS N
Bile NNP N
acid JJ N
replacement NN N
therapy NN N
might MD N
therefore RB N
be VB N
of IN N
clinical JJ N
benefit NN N
, , N
provided VBD N
that IN N
diarrhoea NN N
is VBZ N
not RB N
aggravated VBN N
by IN N
therapy NN N
AIM NNP N
To TO N
investigate VB N
the DT N
role NN N
of IN N
exogenous JJ N
bile NN N
acid NN N
therapy NN N
in IN N
patients NNS 4_p
with IN 4_p
poor JJ 4_p
pouch JJ 4_p
function NN 4_p
after IN N
restorative JJ N
proctocolectomy NN N
for IN N
ulcerative JJ N
colitis NN N
PATIENTS NNP N
AND CC N
METHODS NNP N
Twenty NNP 3_p
ulcerative JJ 4_p
colitis NN 4_p
patients NNS N
with IN N
poor JJ 4_p
pouch JJ 4_p
function NN 4_p
( ( N
score NN N
> VBZ N
4 CD N
on IN N
a DT N
12-point JJ N
score NN N
) ) N
were VBD N
recruited VBN N
for IN N
inclusion NN N
to TO N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
crossover NN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
ursodeoxycholic JJ N
acid NN N
( ( N
10 CD N
mg/kg NNS N
per IN N
day NN N
in IN N
two CD N
divided JJ N
doses NNS N
for IN N
1 CD N
month NN N
) ) N
RESULTS VB N
A DT N
total NN N
of IN N
16 CD 3_p
patients NNS N
completed VBD N
the DT N
study NN N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
functional JJ N
score NN N
or CC N
bowel NN N
frequency NN N
following VBG N
treatment NN N
irrespective NN N
of IN N
whether IN N
the DT N
active JJ N
treatment NN N
was VBD N
given VBN N
before IN N
or CC N
after IN N
placebo NN N
CONCLUSIONS NNP N
We PRP N
conclude VBP N
that IN N
ursodeoxycholic JJ N
acid NN N
given VBN N
over IN N
4 CD N
weeks NNS N
had VBD N
no DT N
influence NN N
on IN N
functional JJ N
score NN N
or CC N
bowel NN N
frequency NN N
after IN N
restorative JJ N
proctocolectomy NN N
for IN N
U.C NNP N
-DOCSTART- -X- O O 18541792

Multiple JJ N
sclerosis NN N
risk NN N
after IN N
optic JJ 4_p
neuritis NN 4_p
: : N
final JJ N
optic JJ N
neuritis NN N
treatment NN N
trial NN N
follow-up NN N
OBJECTIVE UH N
To TO N
assess VB N
the DT N
risk NN N
of IN N
developing VBG N
multiple JJ N
sclerosis NN N
( ( N
MS NNP N
) ) N
after IN N
optic JJ 4_p
neuritis NN 4_p
and CC N
the DT N
factors NNS N
predictive VBP N
of IN N
high JJ N
and CC N
low JJ N
risk NN N
DESIGN NNP N
Subjects NNPS N
in IN N
the DT N
Optic NNP N
Neuritis NNP N
Treatment NNP N
Trial NNP N
, , N
who WP N
were VBD N
enrolled VBN N
between IN N
July NNP N
1 CD N
, , N
1988 CD N
, , N
and CC N
June NNP N
30 CD N
, , N
1991 CD N
, , N
were VBD N
followed VBN N
up RP N
prospectively RB N
for IN N
15 CD N
years NNS N
, , N
with IN N
the DT N
final JJ N
examination NN N
in IN N
2006 CD N
SETTING CC N
Neurologic NNP N
and CC N
ophthalmologic JJ N
examinations NNS N
at IN N
13 CD N
clinical JJ N
sites NNS N
PARTICIPANTS NNP N
Three CD 3_p
hundred VBD 3_p
eighty-nine JJ 3_p
subjects NNS N
with IN N
acute JJ 4_p
optic JJ 4_p
neuritis NN 4_p
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Development NNP N
of IN N
MS NNP N
and CC N
neurologic JJ N
disability NN N
assessment NN N
RESULTS VB N
The DT N
cumulative JJ N
probability NN N
of IN N
developing VBG N
MS NNP N
by IN N
15 CD N
years NNS N
after IN N
onset NN N
of IN N
optic JJ N
neuritis NN N
was VBD N
50 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
44 CD N
% NN N
-56 NNP N
% NN N
) ) N
and CC N
strongly RB N
related VBN N
to TO N
presence NN N
of IN N
lesions NNS N
on IN N
a DT N
baseline JJ N
non-contrast-enhanced JJ N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
MRI NNP N
) ) N
of IN N
the DT N
brain NN N
Twenty-five JJ N
percent NN N
of IN N
patients NNS N
with IN N
no DT N
lesions NNS N
on IN N
baseline NN N
brain NN N
MRI NNP N
developed VBD N
MS NNP N
during IN N
follow-up JJ N
compared VBN N
with IN N
72 CD N
% NN N
of IN N
patients NNS N
with IN N
1 CD N
or CC N
more JJR N
lesions NNS N
After IN N
10 CD N
years NNS N
, , N
the DT N
risk NN N
of IN N
developing VBG N
MS NNP N
was VBD N
very RB N
low JJ N
for IN N
patients NNS N
without IN N
baseline JJ N
lesions NNS N
but CC N
remained VBD N
substantial JJ N
for IN N
those DT N
with IN N
lesions NNS N
Among IN N
patients NNS N
without IN N
lesions NNS N
on IN N
MRI NNP N
, , N
baseline NN N
factors NNS N
associated VBN N
with IN N
a DT N
substantially RB N
lower JJR N
risk NN N
for IN N
MS NNP N
included VBD N
male JJ N
sex NN N
, , N
optic JJ N
disc NN N
swelling NN N
, , N
and CC N
certain JJ N
atypical JJ N
features NNS N
of IN N
optic JJ N
neuritis NN N
CONCLUSIONS VB N
The DT N
presence NN N
of IN N
brain NN N
MRI NNP N
abnormalities NNS N
at IN N
the DT N
time NN N
of IN N
an DT N
optic JJ N
neuritis NN N
attack NN N
is VBZ N
a DT N
strong JJ N
predictor NN N
of IN N
the DT N
15-year JJ N
risk NN N
of IN N
MS NNP N
In IN N
the DT N
absence NN N
of IN N
MRI-detected JJ N
lesions NNS N
, , N
male JJ N
sex NN N
, , N
optic JJ N
disc NN N
swelling NN N
, , N
and CC N
atypical JJ N
clinical JJ N
features NNS N
of IN N
optic JJ N
neuritis NN N
are VBP N
associated VBN N
with IN N
a DT N
low JJ N
likelihood NN N
of IN N
developing VBG N
MS NNP N
This DT N
natural JJ N
history NN N
information NN N
is VBZ N
important JJ N
when WRB N
considering VBG N
prophylactic JJ N
treatment NN N
for IN N
MS NNP N
at IN N
the DT N
time NN N
of IN N
a DT N
first JJ N
acute JJ N
onset NN N
of IN N
optic JJ N
neuritis NN N
-DOCSTART- -X- O O 2510260

Rioprostil NNP N
, , N
a DT N
new JJ N
prostaglandin NN N
E1 NNP N
analogue NN N
, , N
in IN N
the DT N
once-daily JJ N
treatment NN N
for IN N
the DT N
prevention NN N
of IN N
duodenal JJ 4_p
ulcer JJ 4_p
recurrence NN N
: : N
a DT N
comparison NN N
with IN N
ranitidine NN N
The DT N
efficacy NN N
of IN N
Rioprostil NNP N
( ( N
a DT N
new JJ N
prostaglandin NN N
E1 NNP N
analogue NN N
) ) N
is VBZ N
compared VBN N
with IN N
that DT N
of IN N
ranitidine NN N
in IN N
the DT N
recurrence NN N
prevention NN N
of IN N
duodenal JJ N
ulcer NN N
( ( N
s NN N
) ) N
Duration NN N
of IN N
treatment NN N
is VBZ N
6 CD N
months NNS N
Ninety-seven JJ 3_p
patients NNS N
received VBD N
rioprostil JJ N
, , N
600 CD N
micrograms NNS N
once-daily RB N
orally RB N
, , N
and CC N
110 CD 3_p
patients NNS N
received JJ N
ranitidine NN N
, , N
150 CD N
mg JJ N
once-daily RB N
orally RB N
On IN N
rioprostil NN N
, , N
14.9 CD N
% NN N
of IN N
patients NNS N
showed VBD N
a DT N
relapse NN N
after IN N
6 CD N
months NNS N
compared VBN N
to TO N
10.1 CD N
% NN N
on IN N
ranitidine NN N
Diarrhoea NNP N
occurred VBD N
in IN N
7 CD N
patients NNS N
on IN N
rioprostil NN N
and CC N
3 CD N
patients NNS N
on IN N
ranitidine NN N
Rioprostil NNP N
given VBN N
600 CD N
micrograms NNS N
daily RB N
in IN N
the DT N
evening NN N
is VBZ N
a DT N
highly RB N
effective JJ N
treatment NN N
for IN N
the DT N
prevention NN N
of IN N
duodenal JJ N
ulcer NN N
relapse NN N
, , N
the DT N
efficacy NN N
not RB N
being VBG N
significantly RB N
different JJ N
from IN N
ranitidine NN N
150 CD N
mg NN N
-DOCSTART- -X- O O 9342133

Effect NN N
of IN N
esmolol JJ N
pretreatment NN N
on IN N
EEG NNP N
seizure NN N
morphology NN N
in IN N
RUL NNP N
ECT NNP N
Intravenous JJ N
beta-blockers NNS N
are VBP N
an DT N
effective JJ N
means NNS N
of IN N
controlling VBG N
heart NN N
rate NN N
and CC N
blood NN N
pressure NN N
during IN N
electroconvulsive JJ N
therapy NN N
( ( N
ECT NNP N
) ) N
, , N
but CC N
have VBP N
been VBN N
shown VBN N
to TO N
decrease VB N
seizure NN N
duration NN N
While IN N
the DT N
importance NN N
of IN N
seizure NN N
duration NN N
to TO N
the DT N
antidepressant JJ N
response NN N
of IN N
ECT NNP N
grows VBZ N
less JJR N
certain JJ N
, , N
there EX N
is VBZ N
growing VBG N
evidence NN N
that IN N
seizure NN N
morphology NN N
predicts VBZ N
the DT N
antidepressant JJ N
effect NN N
of IN N
ECT NNP N
This DT N
study NN N
examined VBD N
the DT N
impact NN N
of IN N
esmolol JJ N
pretreatment NN N
on IN N
seizure NN N
morphology NN N
Eighteen NNP 3_p
depressed VBD 4_p
patients NNS N
( ( N
6 CD 3_p
men NNS 2_p
, , N
12 CD 3_p
women NNS 2_p
; : N
69 CD 1_p
+/- JJ 1_p
12.8 CD 1_p
years NNS N
old JJ N
) ) N
received VBD N
ECT NNP N
with IN N
and CC N
without IN N
esmolol JJ N
pretreatment NN N
in IN N
a DT N
randomized JJ N
, , N
blinded VBD N
crossover NN N
design NN N
The DT N
seizures NNS N
were VBD N
blindly RB N
rated VBN N
for IN N
duration NN N
of IN N
motor NN N
convulsion NN N
, , N
duration NN N
of IN N
electroencephalogram NN N
( ( N
EEG NNP N
) ) N
seizure NN N
, , N
degree NN N
of IN N
seizure NN N
regularity NN N
, , N
and CC N
degree NN N
of IN N
postictal JJ N
EEG NNP N
suppression NN N
Esmolol NNP N
shortened VBD N
the DT N
duration NN N
of IN N
the DT N
motor NN N
convulsion NN N
and CC N
degraded VBD N
the DT N
quality NN N
of IN N
the DT N
ictal JJ N
regularity NN N
Routine JJ N
administration NN N
of IN N
intravenous JJ N
esmolol NN N
before IN N
ECT NNP N
may MD N
cause VB N
a DT N
decrease NN N
in IN N
ictal JJ N
regularity NN N
Careful JJ N
consideration NN N
should MD N
be VB N
given VBN N
to TO N
the DT N
potential JJ N
benefits NNS N
of IN N
esmolol NN N
versus IN N
the DT N
deleterious JJ N
effect NN N
on IN N
the DT N
electrophysiologic JJ N
process NN N
Esmolol NN N
may MD N
still RB N
be VB N
indicated VBN N
on IN N
a DT N
case-by-case JJ N
basis NN N
for IN N
extreme JJ N
tachycardia NN N
or CC N
hypertension NN N
associated VBN N
with IN N
ECT NNP N
, , N
and CC N
presumably RB N
poses VBZ N
no DT N
problem NN N
for IN N
the DT N
therapeutic JJ N
effect NN N
of IN N
ECT NNP N
if IN N
given VBN N
after IN N
the DT N
seizure NN N
is VBZ N
over IN N
-DOCSTART- -X- O O 19590523

Excimer NNP N
laser NN N
trabeculotomy NN N
vs NN N
180 CD N
degrees NNS N
selective JJ N
laser NN N
trabeculoplasty NN N
in IN N
primary JJ N
open-angle JJ N
glaucoma NN N
A DT N
2-year JJ N
randomized NN N
, , N
controlled VBN N
trial NN N
PURPOSE NNP N
To TO N
compare VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
excimer FW N
laser NN N
trabeculotomy NN N
( ( N
ELT NNP N
) ) N
ab VBP N
interno JJ N
vs NN N
selective JJ N
laser NN N
trabeculoplasty NN N
( ( N
SLT NNP N
) ) N
over IN N
24 CD N
months NNS N
of IN N
follow-up NN N
in IN N
patients NNS 4_p
with IN 4_p
primary JJ 4_p
open-angle JJ 4_p
glaucoma NN 4_p
( ( 4_p
POAG NNP 4_p
) ) 4_p
refractory NN 4_p
to TO 4_p
medical JJ 4_p
therapy NN 4_p
PATIENTS NNP N
AND CC N
METHODS NNP N
This DT N
prospective JJ N
, , N
randomized VBN N
study NN N
included VBD N
30 CD 3_p
consecutive JJ N
eyes NNS N
assigned VBD N
randomly RB N
to TO N
either DT N
ELT NNP N
or CC N
SLT NNP N
group NN N
ELT NNP N
was VBD N
carried VBN N
out RP N
using VBG N
a DT N
XeCl JJ N
Excimer NNP N
Laser NNP N
with IN N
an DT N
emission NN N
wavelength NN N
of IN N
308 CD N
nm NN N
Eight JJ N
spots NNS N
were VBD N
equally RB N
distributed VBN N
at IN N
a DT N
distance NN N
of IN N
500 CD N
microm NN N
from IN N
one CD N
another DT N
over IN N
the DT N
anterior JJ N
trabeculum NN N
The DT N
SLT JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
a DT N
frequency-doubled JJ N
q-switched JJ N
neodymium NN N
: : N
yytrium-aluminum-garnet JJ N
laser NN N
( ( N
wavelength JJ N
532 CD N
nm NN N
) ) N
Approximately RB N
50 CD N
adjacent JJ N
, , N
but CC N
not RB N
overlapping JJ N
, , N
laser JJ N
spots NNS N
were VBD N
distributed VBN N
over IN N
180 CD N
degrees NNS N
of IN N
the DT N
trabecular JJ N
meshwork NN N
, , N
using VBG N
an DT N
energy NN N
level NN N
ranging VBG N
from IN N
0.7 CD N
to TO N
1.0 CD N
mJ NNS N
per IN N
pulse NN N
The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
intraocular JJ N
pressure NN N
( ( N
IOP NNP N
) ) N
lowering NN N
after IN N
ELT NNP N
and CC N
SLT NNP N
Success NNP N
was VBD N
defined VBN N
as IN N
> JJ N
or=20 CD N
% NN N
reduction NN N
in IN N
IOP NNP N
without IN N
further JJ N
glaucoma NN N
intervention NN N
RESULTS NNP N
At IN N
24 CD N
months NNS N
, , N
complete JJ N
success NN N
rates NNS N
were VBD N
53.3 CD N
% NN N
for IN N
the DT N
ELT NNP N
group NN N
and CC N
40 CD N
% NN N
for IN N
the DT N
SLT NNP N
group NN N
( ( N
P=0.35 NNP N
, , N
Fisher NNP N
's POS N
exact JJ N
test NN N
) ) N
; : N
qualified VBN N
success NN N
rates NNS N
were VBD N
33.3 CD N
% NN N
for IN N
the DT N
ELT NNP N
and CC N
26.6 CD N
% NN N
for IN N
the DT N
SLT NNP N
group NN N
( ( N
P=0.5 NNP N
, , N
Fisher NNP N
's POS N
exact JJ N
test NN N
) ) N
.Mean VBP N
IOP NNP N
decreased VBD N
from IN N
25.0+/-1.9 JJ N
to TO N
17.6+/-2.2 JJ N
mmHg NN N
( ( N
-29.6 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
in IN N
the DT N
ELT NNP N
group NN N
and CC N
from IN N
23.9+/-0.9 JJ N
to TO N
19.1+/-1.8 JJ N
mmHg NN N
( ( N
-21 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
in IN N
the DT N
SLT NNP N
group NN N
CONCLUSIONS NNP N
Both NNP N
ELT NNP N
and CC N
SLT NNP N
proved VBD N
to TO N
be VB N
effective JJ N
techniques NNS N
in IN N
the DT N
treatment NN N
of IN N
POAG NNP N
refractory NN N
to TO N
medical JJ N
therapy NN N
-DOCSTART- -X- O O 20965956

Complement JJ N
activation NN N
on IN N
the DT N
surface NN N
of IN N
cell-derived JJ N
microparticles NNS N
during IN N
cardiac JJ N
surgery NN N
with IN N
cardiopulmonary JJ 4_p
bypass NN 4_p
- : N
is VBZ N
retransfusion NN N
of IN N
pericardial JJ N
blood NN N
harmful NN N
? . N
OBJECTIVES UH N
To TO N
investigate VB N
whether IN N
cell-derived JJ N
microparticles NNS N
play VBP N
a DT N
role NN N
in IN N
complement JJ N
activation NN N
in IN N
pericardial JJ N
blood NN N
of IN N
patients NNS N
undergoing VBG N
cardiac JJ 4_p
surgery NN 4_p
with IN 4_p
cardiopulmonary JJ 4_p
bypass NN 4_p
( ( 4_p
CPB NNP 4_p
) ) 4_p
and CC N
whether IN N
microparticles NNS N
in IN N
pericardial JJ N
blood NN N
contribute NN N
to TO N
systemic VB N
complement JJ N
activation NN N
upon IN N
retransfusion NN N
METHODS NNP N
Pericardial NNP N
blood NN N
of IN N
13 CD 3_p
patients NNS N
was VBD N
retransfused VBN N
in IN N
9 CD N
and CC N
discarded VBD N
in IN N
4 CD N
cases NNS N
Microparticles NNS N
were VBD N
isolated VBN N
from IN N
systemic JJ N
blood NN N
collected VBN N
before IN N
anesthesia NN N
( ( N
T1 NNP N
) ) N
and CC N
at IN N
the DT N
end NN N
of IN N
CPB NNP N
( ( N
T2 NNP N
) ) N
, , N
and CC N
from IN N
pericardial JJ N
blood NN N
The DT N
microparticles NNS N
were VBD N
analyzed VBN N
by IN N
flow JJ N
cytometry NN N
for IN N
bound NN N
complement NN N
components NNS N
C1q NNP N
, , N
C4 NNP N
and CC N
C3 NNP N
, , N
and CC N
bound VB N
complement NN N
activator NN N
molecules VBZ N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
serum JJ N
amyloid JJ N
P-component NN N
( ( N
SAP NNP N
) ) N
, , N
immunoglobulin NN N
( ( N
Ig NNP N
) ) N
M NNP N
and CC N
IgG NNP N
Fluid-phase NNP N
complement JJ N
activation NN N
products NNS N
( ( N
C4b/c NNP N
, , N
C3b/c NNP N
) ) N
and CC N
activator JJ N
molecules NNS N
were VBD N
determined VBN N
by IN N
ELISA NNP N
RESULTS NNP N
Compared VBD N
with IN N
systemic JJ N
T1 NNP N
blood NN N
, , N
pericardial JJ N
blood NN N
contained VBD N
increased JJ N
C4b/c NNP N
and CC N
C3b/c NNP N
, , N
and CC N
increased VBD N
levels NNS N
of IN N
microparticles NNS N
with IN N
bound JJ N
complement NN N
components NNS N
In IN N
systemic JJ N
T1 NNP N
samples NNS N
, , N
microparticle-bound JJ N
CRP NNP N
, , N
whereas NN N
in IN N
pericardial JJ N
blood NN N
, , N
microparticle-bound JJ N
SAP NNP N
and CC N
IgM NNP N
were VBD N
associated VBN N
with IN N
complement JJ N
activation NN N
At IN N
the DT N
end NN N
of IN N
CPB NNP N
, , N
increased VBD N
C3b/c NNP N
( ( N
but CC N
not RB N
C4b/c NNP N
) ) N
was VBD N
present JJ N
in IN N
systemic JJ N
T2 NNP N
blood NN N
compared VBN N
with IN N
T1 NNP N
, , N
while IN N
concentrations NNS N
of IN N
microparticles NNS N
binding VBG N
complement JJ N
components NNS N
and CC N
of IN N
those DT N
binding VBG N
complement JJ N
activator NN N
molecules NNS N
were VBD N
similar JJ N
Concentrations NNS N
of IN N
fluid-phase JJ N
complement NN N
activation NN N
products NNS N
and CC N
microparticles NNS N
were VBD N
similar JJ N
in IN N
patients NNS N
whether IN N
or CC N
not RB N
retransfused VBN N
with IN N
pericardial JJ N
blood NN N
CONCLUSIONS NNP N
In IN N
pericardial JJ N
blood NN N
of IN N
patients NNS N
undergoing VBG N
cardiac JJ N
surgery NN N
with IN N
CPB NNP N
, , N
microparticles VBZ N
contribute VBP N
to TO N
activation NN N
of IN N
the DT N
complement NN N
system NN N
via IN N
bound NN N
SAP NNP N
and CC N
IgM NNP N
Retransfusion NN N
of IN N
pericardial JJ N
blood NN N
, , N
however RB N
, , N
does VBZ N
not RB N
contribute VB N
to TO N
systemic VB N
complement JJ N
activation NN N
-DOCSTART- -X- O O 12651635

Single-dose JJ N
tranexamic JJ N
acid NN N
reduces NNS N
postoperative VBP N
bleeding NN N
after IN N
coronary JJ N
surgery NN N
in IN N
patients NNS N
treated VBN N
with IN N
aspirin NN N
until IN N
surgery NN 4_p
UNLABELLED NNP N
Tranexamic NNP N
acid NN N
reduces NNS N
postoperative VBP N
bleeding NN N
after IN N
coronary JJ N
artery NN N
bypass NN N
grafting VBG N
We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
tranexamic JJ N
acid NN N
given VBN N
immediately RB N
before IN N
cardiopulmonary JJ N
bypass NN N
( ( N
CPB NNP N
) ) N
in IN N
patients NNS N
treated VBN N
with IN N
aspirin NN N
until IN N
the DT N
day NN N
before IN N
surgery NN 4_p
The DT N
study NN N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
, , N
parallel-group JJ N
trial NN N
Eighty JJ 3_p
patients NNS 3_p
were VBD N
included VBN N
and CC N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
one CD N
group NN N
received VBD N
tranexamic JJ N
acid NN N
30 CD N
mg/kg NN N
, , N
and CC N
one CD N
group NN N
received VBD N
placebo NN N
( ( N
0.9 CD N
% NN N
NaCl NNP N
) ) N
as IN N
a DT N
bolus JJ N
injection NN N
before IN N
CPB NNP N
Postoperative NNP N
blood NN N
loss NN N
was VBD N
recorded VBN N
for IN N
16 CD N
h. JJ N
Transfusions NNS N
of IN N
blood NN N
products NNS N
were VBD N
recorded VBN N
for IN N
the DT N
whole JJ N
hospital NN N
stay NN N
Transfusions NNS N
of IN N
packed JJ N
red JJ N
cells NNS N
were VBD N
given VBN N
when WRB N
the DT N
hematocrit NN N
value NN N
was VBD N
less JJR N
than IN N
20 CD N
% NN N
during IN N
CPB NNP N
and CC N
less JJR N
than IN N
25 CD N
% NN N
after IN N
surgery NN N
The DT 3_p
patients NNS 3_p
in IN 3_p
the DT 3_p
tranexamic JJ 3_p
acid NN 3_p
group NN 3_p
had VBD N
significantly RB N
less RBR N
postoperative JJ N
bleeding NN N
compared VBN N
with IN N
the DT 3_p
patients NNS 3_p
in IN 3_p
the DT 3_p
placebo NN 3_p
group NN 3_p
( ( N
mean JJ N
[ NNP N
SD NNP N
] NNP N
) ) N
( ( N
475 CD N
[ RB N
274 CD N
] JJ N
mL NN N
versus NN N
713 CD N
[ NN N
243 CD N
] NNP N
mL NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
An DT N
effective JJ N
inhibition NN N
of IN N
fibrinolysis NN N
was VBD N
found VBN N
in IN N
patients NNS N
receiving VBG N
tranexamic JJ N
acid NN N
Tranexamic NNP N
acid NN N
reduces NNS N
postoperative VBP N
bleeding NN N
in IN N
coronary JJ N
artery NN N
bypass NN N
grafting VBG N
patients NNS N
treated VBN N
with IN N
aspirin NN N
until IN N
the DT N
day NN N
before IN N
surgery NN N
IMPLICATIONS NNP N
Continuation NNP N
of IN N
aspirin JJ N
medication NN N
until IN N
the DT N
day NN N
before IN N
coronary JJ N
artery NN N
bypass NN N
grafting NN N
may MD N
increase VB N
postoperative JJ N
bleeding NN N
The DT N
administration NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
tranexamic JJ N
acid NN N
( ( N
30 CD N
mg/kg NN N
) ) N
immediately RB N
before IN N
cardiopulmonary JJ N
bypass NN N
significantly RB N
reduced VBD N
postoperative JJ N
bleeding NN N
and CC N
inhibited JJ N
fibrinolysis NN N
in IN N
these DT N
patients NNS N
-DOCSTART- -X- O O 1515255

Prospective NNP N
randomised VBD N
study NN N
of IN N
double JJ N
hemi-body JJ N
irradiation NN N
with IN N
and CC N
without IN N
subsequent JJ N
maintenance NN N
recombinant NN N
alpha VBD N
2b CD N
interferon NN N
on IN N
survival NN N
in IN N
patients NNS N
with IN N
relapsed JJ N
multiple JJ N
myeloma NN N
Immediately RB N
before IN N
first JJ N
hemi-body NN N
irradiation NN N
, , N
59 CD 3_p
patients NNS N
with IN N
relapsed JJ N
multiple JJ N
myeloma NN N
were VBD N
randomised VBN N
to TO N
receive VB N
or CC N
not RB N
to TO N
receive VB N
subsequent JJ N
alpha-2b JJ N
interferon NN N
maintenance NN N
13 CD N
patients NNS N
( ( N
22 CD N
% NN N
) ) N
[ VBZ N
8 CD N
of IN N
31 CD N
( ( N
26 CD N
% NN N
) ) N
controls VBZ N
, , N
5 CD N
of IN N
28 CD N
( ( N
18 CD N
% NN N
) ) N
in IN N
the DT N
interferon NN N
arm NN N
] NN N
received VBD N
single JJ N
hemi-body JJ N
irradiation NN N
alone RB N
due JJ N
to TO N
progressive JJ N
disease NN N
and/or JJ N
persistent JJ N
cytopoenias NN N
following VBG N
the DT N
initial JJ N
procedure NN N
Mean JJ N
time NN N
between IN N
upper JJ N
and CC N
lower JJR N
hemi-body NN N
irradiation NN N
was VBD N
69 CD N
days NNS N
( ( N
range VB N
35-294 NNP N
) ) N
Of IN N
23 CD N
patients NNS N
randomised VBN N
to TO N
receive VB N
interferon NN N
and CC N
completing VBG N
double JJ N
hemi-body JJ N
irradiation NN N
, , N
15 CD N
( ( N
65 CD N
% NN N
) ) N
achieved VBD N
peripheral JJ N
blood NN N
counts NNS N
adequate VBP N
to TO N
allow VB N
interferon JJ N
administration NN N
as IN N
per IN N
study NN N
criteria NNS N
commencing VBG N
at IN N
a DT N
mean JJ N
116 CD N
days NNS N
( ( N
61-241 JJ N
) ) N
from IN N
time NN N
of IN N
study NN N
entry NN N
The DT N
mean JJ N
period NN N
of IN N
interferon NN N
therapy NN N
, , N
starting VBG N
at IN N
a DT N
mean JJ N
65 CD N
days NNS N
( ( N
26-160 JJ N
) ) N
post NN N
second JJ N
hemi-body NN N
irradiation NN N
, , N
is VBZ N
16.4 CD N
months NNS N
( ( N
2-33.5 JJ N
) ) N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
median JJ N
survival NN N
durations NNS N
( ( N
10 CD N
months NNS N
) ) N
from IN N
time NN N
of IN N
initial JJ N
radiotherapy NN N
between IN N
control NN N
and CC N
interferon NN N
patients NNS N
-DOCSTART- -X- O O 4154124

Bites NNS N
by IN N
the DT N
saw-scaled JJ N
or CC N
carpet NN N
viper NN N
( ( N
Echis NNP N
carinatus NN N
) ) N
: : N
trial NN N
of IN N
two CD N
specific JJ N
antivenoms NNS N
Echis NNP N
carinatus NN N
is VBZ N
the DT N
most RBS N
important JJ N
cause NN N
of IN N
morbidity NN N
and CC N
mortality NN N
from IN N
snake JJ N
bite NN N
in IN N
Nigeria NNP N
and CC N
in IN N
many JJ N
other JJ N
parts NNS N
of IN N
the DT N
world NN N
Forty-six JJ 3_p
patients NNS N
with IN N
systemic JJ 4_p
poisoning NN 4_p
by IN 4_p
this DT 4_p
snake NN 4_p
were VBD N
given VBN N
echis JJ N
antivenom NN N
made VBD N
either CC N
by IN N
the DT N
South JJ N
African NNP N
Institute NNP N
for IN N
Medical NNP N
Research NNP N
( ( N
S.A.I.M.R NNP N
) ) N
or CC N
by IN N
Behringwerke NNP N
( ( N
North NNP N
and CC N
West NNP N
African NNP N
polyvalent NN N
antivenom NN N
) ) N
A DT N
simple JJ N
test NN N
of IN N
blood NN N
coagulability NN N
was VBD N
used VBN N
to TO N
assess VB N
whether IN N
an DT N
adequate JJ N
neutralizing NN N
dose NN N
of IN N
antivenom NN N
had VBD N
been VBN N
given VBN N
An DT N
average NN N
of IN N
15.2 CD N
ml NN N
S.A.I.M.R NNP N
antivenom RB N
restored VBD N
normal JJ N
coagulability NN N
permanently RB N
in IN N
all DT N
23 CD 3_p
patients NNS 4_p
in IN 4_p
one CD 4_p
group NN 4_p
, , N
but CC N
in IN N
the DT N
other JJ N
group NN N
receiving VBG N
an DT N
average JJ N
dose NN N
of IN N
37.9 CD N
ml NNS N
Behringwerke NNP N
antivenom VBP N
normal JJ N
clotting NN N
resulted VBD N
in IN N
only RB N
18 CD N
out IN N
of IN N
23 CD N
patients NNS N
Local JJ N
tissue NN N
swelling NN N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
, , N
but CC N
local JJ N
necrosis NN N
occurred VBD N
in IN N
three CD N
patients NNS N
treated VBN N
with IN N
Behringwerke NNP N
antivenom NN N
and CC N
in IN N
none NN N
given VBN N
S.A.I.M.R NNP N
antivenom NN N
-DOCSTART- -X- O O 19817753

The DT N
effect NN N
of IN N
oral JJ N
steroids NNS N
with IN N
and CC N
without IN N
vitamin JJ N
D3 NNP N
on IN N
early JJ N
efficacy NN N
of IN N
immunotherapy NN N
in IN N
asthmatic JJ 4_p
children NNS 1_p
BACKGROUND NNP N
The DT N
possibility NN N
of IN N
additional JJ N
strategies NNS N
to TO N
enhance VB N
the DT N
effectiveness NN N
of IN N
specific JJ N
immunotherapy NN N
( ( N
SIT NNP N
) ) N
is VBZ N
highly RB N
attractive JJ N
AIM IN N
The DT N
aim NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
influence NN N
of IN N
oral JJ N
corticosteroids NNS N
and CC N
oral JJ N
corticosteroids NNS N
combined VBN N
with IN N
vitamin NN N
D NNP N
( ( N
3 CD N
) ) N
on IN N
the DT N
early JJ N
clinical JJ N
and CC N
immunological JJ N
effects NNS N
of IN N
SIT NNP N
METHODS NNP N
It PRP N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
conducted VBN N
in IN N
54 CD 3_p
asthmatic JJ 4_p
children NNS 1_p
allergic VBP 4_p
to TO 4_p
house NN 4_p
dust NN 4_p
mites NNS 4_p
Intervention NN N
was VBD N
based VBN N
on IN N
receiving VBG N
a DT N
single JJ N
dose NN N
of IN N
oral JJ N
steroid NN N
, , N
with IN N
or CC N
without IN N
vitamin JJ N
D NNP N
( ( N
3 CD N
) ) N
, , N
or CC N
placebo VBZ N
only RB N
on IN N
the DT N
day NN N
of IN N
the DT N
build-up JJ N
phase NN N
of IN N
SIT NNP N
RESULTS NNP N
After IN N
12 CD N
months NNS N
of IN N
SIT NNP N
, , N
the DT N
median JJ N
daily JJ N
inhaled VBN N
corticosteroid NN N
( ( N
ICS NNP N
) ) N
dose NN N
, , N
which WDT N
controls VBZ N
the DT N
symptoms NNS N
of IN N
asthma NN N
, , N
was VBD N
reduced VBN N
by IN N
25 CD N
% NN N
in IN N
the DT N
steroid NN N
group NN N
However RB N
, , N
a DT N
50 CD N
% NN N
reduction NN N
of IN N
the DT N
median JJ N
daily JJ N
ICS NNP N
dose NN N
was VBD N
observed VBN N
in IN N
the DT N
control NN N
group NN N
The DT N
clinical JJ N
effects NNS N
of IN N
SIT NNP N
were VBD N
not RB N
affected VBN N
in IN N
the DT N
steroid+D NN N
( ( N
3 CD N
) ) N
group NN N
Concomitantly RB N
, , N
we PRP N
found VBD N
that IN N
intervention NN N
with IN N
prednisone NN N
significantly RB N
impaired VBD N
the DT N
induction NN N
of IN N
T NNP N
regulatory JJ N
lymphocytes NNS N
Importantly RB N
, , N
the DT N
clinical JJ N
and CC N
immunological JJ N
effects NNS N
of IN N
SIT NNP N
were VBD N
not RB N
affected VBN N
by IN N
intervention NN N
with IN N
steroids NNS N
administered VBN N
with IN N
vitamin NN N
D NNP N
( ( N
3 CD N
) ) N
CONCLUSIONS NNP N
Our PRP$ N
study NN N
failed VBD N
to TO N
show VB N
a DT N
beneficial JJ N
effect NN N
of IN N
oral JJ N
corticosteroids NNS N
on IN N
allergen-specific JJ N
immunotherapy NN N
We PRP N
observed VBD N
that IN N
the DT N
combined JJ N
administration NN N
of IN N
a DT N
corticosteroid JJ N
drug NN N
and CC N
allergen NN N
extract NN N
suppressed VBD N
the DT N
early JJ N
clinical JJ N
and CC N
immunological JJ N
effects NNS N
of IN N
SIT NNP N
and CC N
that IN N
vitamin NN N
D NNP N
( ( N
3 CD N
) ) N
prevented VBD N
this DT N
'adverse NN N
' '' N
influence NN N
of IN N
steroids NNS N
-DOCSTART- -X- O O 21035047

Stepwise NNP N
assessment JJ N
tool NN N
of IN N
operative JJ N
skills NNS N
( ( N
SATOS NNP N
) ) N
: : N
validity NN N
testing VBG N
on IN N
a DT N
porcine JJ N
training NN N
model NN N
of IN N
open JJ N
gastrectomy NN N
BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
study NN N
was VBD N
to TO N
evaluate VB N
and CC N
compare VB N
operative JJ N
performance NN N
and CC N
technical JJ N
improvement NN N
of IN N
surgical JJ N
trainees NNS N
learning VBG N
open JJ N
gastrectomy NN N
using VBG N
an DT N
objective JJ N
structured JJ N
stepwise NN N
assessment JJ N
tool NN N
of IN N
operative JJ N
skills NNS N
( ( N
SATOS NNP N
) ) N
previously RB N
validated VBN N
for IN N
open JJ N
surgery NN N
STUDY NNP N
DESIGN NNP N
Thirty NNP N
residents NNS N
in IN N
general JJ N
surgery NN N
performed VBD N
2 CD N
open JJ N
partial JJ N
gastrectomy NN N
training VBG N
events NNS N
on IN N
a DT N
porcine JJ N
model NN N
Earlier JJR N
instruction NN N
was VBD N
provided VBN N
for IN N
the DT N
critical JJ N
operative JJ N
steps NNS N
, , N
with IN N
additional JJ N
intraoperative JJ N
instruction NN N
when WRB N
required VBN N
Performance NN N
was VBD N
assessed VBN N
by IN N
postgraduate JJ N
year NN N
( ( N
PGY NNP N
) ) N
according VBG N
to TO N
operative JJ N
time NN N
, , N
technical JJ N
skills NNS N
using VBG N
a DT N
23-step JJ N
objective NN N
structured VBD N
tool NN N
, , N
and CC N
error NN N
rate NN N
RESULTS CC N
There EX N
were VBD N
11 CD N
PGY-3 NNP N
, , N
11 CD N
PGY-4 NN N
, , N
and CC N
8 CD N
PGY-5 JJ N
residents NNS N
At IN N
the DT N
initial JJ N
assessment NN N
, , N
performance NN N
significantly RB N
differentiated VBD N
the DT N
3 CD N
PGY NNP N
grades NNS N
according VBG N
to TO N
technical JJ N
skills NNS N
and CC N
error NN N
rate NN N
At IN N
the DT N
second JJ N
assessment NN N
, , N
all DT N
3 CD N
PGY NNP N
classes NNS N
were VBD N
still RB N
significantly RB N
differentiable JJ N
by IN N
technical JJ N
skills NNS N
, , N
with IN N
no DT N
difference NN N
in IN N
error NN N
rate NN N
Comparing NNP N
performances NNS N
, , N
residents NNS N
improved VBD N
operative JJ N
time NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
technical JJ N
skills NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
error NN N
rate NN N
( ( N
p JJ N
= NNP N
0.019 CD N
) ) N
over IN N
the DT N
2 CD N
training NN N
events NNS N
CONCLUSIONS NNP N
SATOS NNP N
demonstrated VBD N
relevant JJ N
and CC N
accurate JJ N
objective JJ N
assessment NN N
of IN N
trainees NNS N
' POS N
operative JJ N
skills NNS N
and CC N
improvement NN N
for IN N
open JJ N
gastrectomy NN N
in IN N
a DT N
porcine JJ N
model NN N
This DT N
tool NN N
may MD N
be VB N
useful JJ N
to TO N
standardize VB N
instruction NN N
, , N
to TO N
expose VB N
weaknesses NNS N
of IN N
trainees NNS N
, , N
and CC N
to TO N
determine VB N
minimal JJ N
technical JJ N
standards NNS N
in IN N
residency NN N
programs NNS N
-DOCSTART- -X- O O 25365653

Topiramate NNP N
impairs NNS N
cognitive JJ N
function NN N
in IN N
methadone-maintained JJ N
individuals NNS N
with IN N
concurrent JJ 4_p
cocaine NN 4_p
dependence NN 4_p
Topiramate NNP N
is VBZ N
being VBG N
investigated VBN N
as IN N
a DT N
potential JJ N
pharmacotherapy NN N
for IN N
the DT N
treatment NN N
of IN N
addictive JJ N
disorders NNS N
However RB N
, , N
its PRP$ N
cognitive JJ N
side NN N
effects NNS N
raise VBP N
concerns NNS N
about IN N
its PRP$ N
use NN N
, , N
especially RB N
in IN N
populations NNS N
with IN N
cognitive JJ N
impairment NN N
, , N
such JJ N
as IN N
persons NNS N
with IN N
chronic JJ 4_p
substance NN 4_p
use NN 4_p
disorders NNS 4_p
This DT N
study NN N
investigated VBD N
topiramate NN N
's POS N
cognitive JJ N
effects NNS N
in IN N
individuals NNS N
dually RB 4_p
dependent VBP 4_p
on IN 4_p
cocaine NN 4_p
and CC 4_p
opioids NNS 4_p
as IN N
part NN N
of IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
topiramate NN N
for IN N
cocaine NN N
dependence NN N
treatment NN N
After IN N
5 CD N
weeks NNS N
of IN N
stabilization NN N
on IN N
daily JJ N
oral JJ N
methadone NN N
( ( N
M NNP N
= VBZ N
96 CD N
mg NN N
) ) N
, , N
participants NNS N
were VBD N
randomized VBN N
to TO N
topiramate VB N
( ( N
n JJ N
= NNP N
18 CD 3_p
) ) 3_p
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
22 CD 3_p
) ) N
Cognitive JJ N
testing VBG N
took VBD N
place NN N
at IN N
2 CD N
time NN N
points NNS N
: : N
study NN N
weeks NNS N
4 CD N
through IN N
5 CD N
to TO N
assess VB N
baseline JJ N
performance NN N
and CC N
10 CD N
to TO N
13 CD N
weeks NNS N
later RB N
to TO N
assess VB N
performance NN N
during IN N
stable JJ N
dosing NN N
( ( N
300 CD N
mg NN N
topiramate NN N
or CC N
placebo NN N
) ) N
All DT N
participants NNS N
were VBD N
maintained VBN N
on IN N
methadone NN N
at IN N
both DT N
testing VBG N
times NNS N
, , N
and CC N
testing VBG N
occurred VBD N
2 CD N
hours NNS N
after IN N
the DT N
daily JJ N
methadone NN N
plus CC N
topiramate/placebo JJ N
administration NN N
The DT N
topiramate NN N
and CC N
placebo NN N
groups NNS N
did VBD N
not RB N
differ VB N
on IN N
sex NN N
, , N
level NN N
of IN N
education NN N
, , N
premorbid JJ N
intelligence NN N
, , N
methadone NN N
dose NN N
, , N
or CC N
illicit JJ N
drug NN N
use NN N
Topiramate NN N
slowed VBD N
psychomotor NN N
and CC N
information NN N
processing NN N
speed NN N
, , N
worsened VBD N
divided JJ N
attention NN N
, , N
reduced VBN N
n-back JJ N
working VBG N
memory NN N
accuracy NN N
, , N
and CC N
increased VBD N
the DT N
false JJ N
alarm NN N
rate NN N
in IN N
recognition NN N
memory NN N
Topiramate NNP N
had VBD N
no DT N
effects NNS N
on IN N
visual JJ N
processing NN N
, , N
other JJ N
measures NNS N
of IN N
psychomotor NN N
function NN N
, , N
risk-taking JJ N
, , N
self-control JJ N
, , N
Sternberg NNP N
working VBG N
memory NN N
, , N
free JJ N
recall NN N
, , N
and CC N
metamemory NN N
These DT N
findings NNS N
indicate VBP N
that IN N
topiramate NN N
may MD N
cause VB N
cognitive JJ N
impairment NN N
in IN N
this DT N
population NN N
This DT N
effect NN N
may MD N
limit VB N
its PRP$ N
acceptability NN N
and CC N
use NN N
as IN N
a DT N
treatment NN N
in IN N
individuals NNS N
with IN N
chronic JJ 4_p
opioid NN 4_p
and CC 4_p
cocaine NN 4_p
use NN 4_p
disorders NNS 4_p
, , N
among IN N
whom WP N
preexisting VBG N
cognitive JJ N
impairments NNS N
are VBP N
common JJ N
( ( N
PsycINFO JJ N
Database NNP N
Record NN N
-DOCSTART- -X- O O 3563413

Fasting VBG N
and CC N
meal-stimulated JJ N
plasma NN N
levels NNS N
of IN N
neurotensin NN N
in IN N
obese JJ 4_p
patients NNS 4_p
after IN 4_p
jejunoileal JJ 4_p
bypass NN 4_p
with IN 4_p
3:1 CD 4_p
or CC 4_p
1:3 CD 4_p
jejunoileal NN 4_p
ratio NN 4_p
The DT N
functional JJ N
role NN N
of IN N
the DT N
jejunum NN N
and CC N
ileum NN N
with IN N
regard NN N
to TO N
peripheral JJ N
plasma NN N
levels NNS N
of IN N
intact JJ N
neurotensin JJ N
and CC N
NH2-terminal JJ N
immunoreactivity NN N
of IN N
neurotensin NN N
was VBD N
studied VBN N
by IN N
using VBG N
jejunoileal JJ N
bypass NN N
as IN N
a DT N
model NN N
Plasma NNP N
levels NNS N
were VBD N
measured VBN N
by IN N
radioimmunoassay NN N
before IN N
and CC N
after IN N
jejunoileal JJ N
bypass NN N
randomized VBN N
to TO N
different JJ N
jejunoileal JJ N
ratios NNS N
Seven CD 3_p
patients NNS 3_p
were VBD N
studied VBN N
before IN N
bypass NN 4_p
surgery NN 4_p
and CC N
28 CD 3_p
were VBD N
examined VBN N
after IN N
end-to-side JJ 4_p
jejunoileal JJ 4_p
bypass NN 4_p
with IN 4_p
50 CD 4_p
cm NNS 4_p
intestine NN 4_p
in IN 4_p
continuity NN 4_p
and CC 4_p
a DT 4_p
3:1 CD 4_p
or CC 4_p
1:3 CD 4_p
ratio NN 4_p
between IN 4_p
the DT 4_p
length NN 4_p
of IN 4_p
the DT 4_p
jejunal NN 4_p
and CC 4_p
ileal JJ 4_p
segments NNS 4_p
Fasting VBG N
levels NNS N
of IN N
intact JJ N
neurotensin NNS N
were VBD N
unchanged JJ N
by IN N
surgery NN N
, , N
whereas JJ N
levels NNS N
of IN N
NH2-terminal JJ N
immunoreactivity NN N
were VBD N
higher JJR N
in IN N
bypass NN N
patients NNS N
with IN N
a DT N
long JJ N
ileal NN N
segment NN N
( ( N
37.5 CD N
cm NN N
) ) N
than IN N
in IN N
unoperated JJ N
patients NNS N
and CC N
in IN N
those DT N
with IN N
a DT N
short JJ N
ileal NN N
segment NN N
( ( N
12.5 CD N
cm NN N
) ) N
Meal-stimulated JJ N
levels NNS N
of IN N
intact JJ N
neurotensin NNS N
were VBD N
higher JJR N
after IN N
1:3 CD N
than IN N
3:1 CD N
jejunoileal JJ N
bypass NN N
The DT N
levels NNS N
of IN N
NH2-terminal JJ N
immunoreactivity NN N
in IN N
patients NNS N
with IN N
a DT N
short JJ N
ileal NN N
segment NN N
and CC N
in IN N
controls NNS N
were VBD N
lower JJR N
than IN N
in IN N
patients NNS N
with IN N
a DT N
long JJ N
ileal NN N
segment NN N
The DT N
results NNS N
show VBP N
that IN N
postprandial JJ N
levels NNS N
of IN N
both DT N
intact JJ N
neurotensin NN N
and CC N
NH2-terminal JJ N
immunoreactivity NN N
are VBP N
related VBN N
to TO N
the DT N
length NN N
of IN N
the DT N
functioning NN N
ileum NN N
and CC N
that IN N
even RB N
a DT N
difference NN N
in IN N
length NN N
of IN N
25 CD N
cm NN N
is VBZ N
reflected VBN N
in IN N
the DT N
circulating NN N
levels NNS N
of IN N
neurotensin NN N
-DOCSTART- -X- O O 7708953

The DT N
influence NN N
of IN N
breast NN N
size NN N
on IN N
late JJ N
radiation NN N
effects NNS N
and CC N
association NN N
with IN N
radiotherapy NN N
dose JJ N
inhomogeneity NN N
A DT N
prospective JJ N
assessment NN N
of IN N
late JJ N
changes NNS N
in IN N
breast NN N
appearance NN N
in IN N
559 CD 3_p
patients NNS N
after IN 4_p
tumour JJ 4_p
excision NN 4_p
and CC 4_p
radiotherapy NN 4_p
for IN N
early JJ 4_p
breast NN 4_p
cancer NN 4_p
noted VBD N
a DT N
strong JJ N
association NN N
with IN N
breast NN N
size NN N
Only RB N
3/48 CD N
( ( N
6 CD N
% NN N
) ) N
patients NNS N
with IN N
small JJ N
breasts NNS N
developed VBD N
moderate JJ N
or CC N
severe JJ N
late JJ N
changes NNS N
compared VBN N
with IN N
94/423 CD N
( ( N
22 CD N
% NN N
) ) N
with IN N
medium NN N
sized VBN N
breasts NNS N
and CC N
34/88 CD N
( ( N
39 CD N
% NN N
) ) N
patients NNS N
with IN N
large JJ N
breasts NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
One CD N
possibility NN N
is VBZ N
that IN N
greater JJR N
radiation NN N
changes NNS N
are VBP N
related VBN N
to TO N
greater JJR N
dose JJ N
inhomogeneity NN N
in IN N
women NNS N
with IN N
large JJ N
breasts NNS N
To TO N
explore VB N
this DT N
hypothesis NN N
, , N
radiation NN N
dose JJ N
distributions NNS N
were VBD N
assessed VBN N
in IN N
a DT N
separate JJ N
group NN N
of IN N
37 CD N
women NNS N
in IN N
whom WP N
three-level JJ N
transverse NN N
computer NN N
tomographic JJ N
images NNS N
of IN N
the DT N
breast NN N
in IN N
the DT N
treatment NN N
position NN N
were VBD N
available JJ N
A DT N
significant JJ N
correlation NN N
was VBD N
found VBN N
between IN N
breast NN N
size NN N
and CC N
dose NN N
inhomogeneity NN N
which WDT N
may MD N
account VB N
for IN N
the DT N
marked JJ N
changes NNS N
in IN N
breast NN N
appearance NN N
reported VBD N
in IN N
women NNS N
with IN N
large JJ N
breasts NNS N
-DOCSTART- -X- O O 19681257

Clinical JJ N
trial NN N
of IN N
tooth NN N
whitening VBG N
with IN N
6 CD N
% NN N
hydrogen NN N
peroxide IN N
whitening VBG N
strips NNS N
and CC N
two CD N
whitening NN N
dentifrices NNS N
PURPOSE NNP N
To TO N
compare VB N
tooth JJ N
whitening VBG N
with IN N
6 CD N
% NN N
hydrogen NN N
peroxide IN N
whitening VBG N
strips NNS N
and CC N
two CD N
whitening VBG N
dentifrices NNS N
in IN N
a DT N
12-week JJ N
randomized NN N
controlled VBD N
trial NN N
at IN N
a DT N
Belgian JJ N
dental JJ N
school NN N
METHODS NNP N
After IN N
informed JJ N
consent NN N
, , N
46 CD 3_p
healthy JJ N
adults NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
strip NN N
+ NNP N
dentifrice NN N
treatment NN N
groups NNS N
Subjects NNS N
received VBD N
either RB N
6 CD N
% NN N
hydrogen NN N
peroxide IN N
whitening VBG N
strips NNS N
( ( N
Crest NNP N
Whitestrips NNP N
) ) N
and CC N
an DT N
anticavity NN N
toothpaste NN N
( ( N
Crest NNP N
Cavity NNP N
Protection NNP N
) ) N
, , N
placebo JJ N
strips NNS N
and CC N
a DT N
sodium NN N
fluoride NN N
( ( N
NaF NNP N
) ) N
whitening VBG N
dentifrice NN N
( ( N
Mentadent NNP N
Whitening NNP N
Toothpaste NNP N
) ) N
or CC N
placebo VBN N
strips NNS N
and CC N
a DT N
sodium NN N
monofluorophosphate NN N
( ( N
MFP NNP N
) ) N
whitening VBG N
dentifrice NN N
( ( N
Rembrandt NNP N
Low NNP N
Abrasion NNP N
Whitening NNP N
Toothpaste NNP N
) ) N
Strip NNP N
use NN N
( ( N
peroxide NN N
or CC N
placebo NN N
) ) N
was VBD N
for IN N
30 CD N
minutes NNS N
, , N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
, , N
while IN N
dentifrice NN N
use NN N
was VBD N
at IN N
least JJS N
twice JJ N
daily RB N
for IN N
12 CD N
weeks NNS N
Efficacy NN N
was VBD N
measured VBN N
from IN N
standardized JJ N
digital JJ N
images NNS N
of IN N
the DT N
maxillary JJ N
facial JJ N
tooth NN N
surfaces NNS N
, , N
while IN N
safety NN N
was VBD N
evaluated VBN N
from IN N
oral JJ N
examination NN N
and CC N
interview NN N
Treatments NNS N
were VBD N
compared VBN N
after IN N
2 CD N
weeks NNS N
( ( N
strip NN N
use NN N
) ) N
and CC N
12 CD N
weeks NNS N
( ( N
dentifrice NN N
use NN N
) ) N
using VBG N
analysis NN N
of IN N
covariance NN N
RESULTS NNP N
All NNP N
subjects VBZ N
completed VBN N
the DT N
12-week JJ N
evaluation NN N
Adjusting VBG N
for IN N
baseline NN N
and CC N
age NN N
, , N
the DT N
peroxide JJ N
strip NN N
group NN N
had VBD N
-2.45 NNP N
Deltab* NNP N
, , N
2.39 CD N
DeltaL* NNP N
, , N
and CC N
-0.96 JJ N
Deltaa* NNP N
at IN N
Week NNP N
2 CD N
Between-group JJ N
comparisons NNS N
demonstrated VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
reductions NNS N
in IN N
yellowness NN N
and CC N
redness NN N
, , N
and CC N
increased VBD N
brightness NN N
favoring VBG N
the DT N
peroxide JJ N
strip NN N
group NN N
The DT N
peroxide JJ N
strip NN N
group NN N
demonstrated VBD N
95 CD N
% NN N
+ NNP N
color NN N
retention NN N
( ( N
Deltab* NNP N
& CC N
DeltaL* NNP N
) ) N
at IN N
Week NNP N
12 CD N
, , N
differing VBG N
significantly RB N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
versus NN N
either DT N
of IN N
the DT N
continuously NN N
used VBN N
whitening NN N
dentifrices NNS N
There EX N
were VBD N
no DT N
significant JJ N
( ( N
P NNP N
> NNP N
0.18 CD N
) ) N
differences NNS N
between IN N
the DT N
whitening VBG N
dentifrice NN N
groups NNS N
at IN N
any DT N
timepoints NNS N
All DT N
treatments NNS N
were VBD N
well-tolerated JJ N
, , N
with IN N
minor JJ N
tooth DT N
sensitivity NN N
and CC N
oral JJ N
irritation NN N
representing VBG N
the DT N
most RBS N
common JJ N
findings NNS N
-DOCSTART- -X- O O 20220293

Efficacy NN N
and CC N
safety NN N
of IN N
two CD N
different JJ N
testosterone NN N
undecanoate JJ N
formulations NNS N
in IN N
hypogonadal JJ 4_p
men NNS 2_p
with IN N
metabolic JJ 4_p
syndrome NN 4_p
AIM NNP N
To TO N
investigate VB N
efficacy NN N
and CC N
safety NN N
of IN N
two CD N
different JJ N
preparations NNS N
of IN N
testosterone NN N
undecanoate NN N
( ( N
TU NNP N
) ) N
in IN N
52 CD 3_p
hypogonadal JJ 4_p
men NNS 2_p
[ VBP N
mean JJ N
age NN 1_p
57 CD 3_p
yr NN 3_p
and CC N
mean VB N
testosterone NN N
( ( N
T NNP N
) ) N
< VBD N
320 CD N
ng/dl JJ N
] NN N
with IN N
metabolic JJ 4_p
syndrome NN 4_p
( ( 4_p
MS NNP 4_p
) ) 4_p
SUBJECTS NNP N
AND NNP N
METHODS NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
double-dummy JJ N
study NN N
with IN N
three CD N
parallel JJ N
treatment NN N
arms NNS N
[ VBP N
oral JJ N
TU NNP N
; : N
transdermal JJ N
placebo NN N
gel NN N
( ( N
P NNP N
) ) N
; : N
im JJ N
TU NNP N
] NNP N
administration NN N
for IN N
12 CD N
months NNS N
( ( N
mo NN N
) ) N
Each DT N
subject NN N
was VBD N
randomized VBN N
( ( N
1:1:3 CD N
) ) N
to TO N
receive VB N
either DT N
oral JJ N
TU NNP N
( ( N
2 CD N
capsules NNS N
of IN N
40 CD N
mg/twice NNS N
per IN N
day NN N
at IN N
breakfast NN N
and CC N
dinner NN N
, , N
equalling VBG N
a DT N
total JJ N
dose NN N
of IN N
160 CD N
mg/day NN N
; : N
no.=10 CC N
) ) N
for IN N
6 CD N
mo NN N
and CC N
continued VBN N
with IN N
im JJ N
TU NNP N
for IN N
further JJ N
6 CD N
mo NN N
, , N
or CC N
P NNP N
( ( N
3-4 JJ N
g/day NN N
; : N
no.=10 CC N
) ) N
and CC N
im JJ N
TU NNP N
( ( N
1000 CD N
mg/12 NN N
weeks NNS N
from IN N
week NN N
6 CD N
; : N
no.=32 NNS N
) ) N
for IN N
12 CD N
mo NNS N
RESULTS NNP N
After IN N
6 CD N
mo NN N
, , N
im JJ N
TU NNP N
increased VBD N
T NNP N
and CC N
free- JJ N
T NNP N
levels NNS N
( ( N
p VB N
< RB N
0.0001 CD N
) ) N
, , N
and CC N
improved VBN N
metabolic JJ N
parameters NNS N
[ VBP N
reduction NN N
in IN N
Homeostasis NNP N
Model NNP N
Assessment NNP N
( ( N
HOMA NNP N
) ) N
index NN N
, , N
p NN N
< VBD N
0.0001 CD N
; : N
waist JJ N
circumference NN N
and CC N
fat JJ N
mass NN N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
] JJ N
, , N
in IN N
International NNP N
Index NNP N
of IN N
Erectile NNP N
Function-5 NNP N
and CC N
Aging NNP N
Males NNP N
' POS N
Symptoms NNP N
scores NNS N
( ( N
p VB N
< RB N
0.01 CD N
, , N
respectively RB N
) ) N
After IN N
12 CD N
months NNS N
, , N
im JJ N
TU NNP N
produced VBD N
further JJ N
increases NNS N
in IN N
T NNP N
and CC N
free- JJ N
T NNP N
levels NNS N
( ( N
p VB N
< RB N
0.0001 CD N
) ) N
and CC N
metabolic JJ N
parameters NNS N
( ( N
reduction NN N
in IN N
HOMA-index NNP N
, , N
p NN N
< VBD N
0.0001 CD N
; : N
waist JJ N
circumference NN N
p NN N
< VBZ N
0.0001 CD N
; : N
fat JJ N
mass NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
No DT N
major JJ N
adverse JJ N
event NN N
due JJ N
to TO N
T NNP N
treatment NN N
occurred VBD N
CONCLUSIONS NNP N
Clinical NNP N
efficacy NN N
of IN N
T NNP N
replacement NN N
therapy NN N
in IN N
hypogonadal JJ 4_p
men NNS 2_p
with IN N
MS NNP 4_p
is VBZ N
reached VBN N
when WRB N
its PRP$ N
plasmatic JJ N
levels NNS N
approach VBP N
into IN N
the DT N
medium-high JJ N
range NN N
of IN N
normality NN N
( ( N
> JJ N
5 CD N
ng/ml NN N
) ) N
, , N
although IN N
subjective JJ N
threshold JJ N
values NNS N
may MD N
be VB N
different JJ N
Administration NN N
of IN N
im JJ N
TU NNP N
was VBD N
more RBR N
effective JJ N
than IN N
oral JJ N
TU NNP N
to TO N
reach VB N
the DT N
target NN N
for IN N
T NNP N
levels NNS N
and CC N
to TO N
improve VB N
MS NNP N
parameters NNS N
TU NNP N
was VBD N
safe JJ N
over IN N
12 CD N
months NNS N
and CC N
discontinuation NN N
rates NNS N
were VBD N
similar JJ N
to TO N
placebo VB N
-DOCSTART- -X- O O 1497159

Rapid-sequence JJ N
intubation NN N
of IN N
head NN 4_p
trauma NN 4_p
patients NNS N
: : N
prevention NN N
of IN N
fasciculations NNS N
with IN N
pancuronium NN N
versus NN N
minidose JJ N
succinylcholine NN N
INTRODUCTION NNP N
Fasciculations NNP N
during IN N
rapid-sequence JJ N
intubation NN N
may MD N
lead VB N
to TO N
increased VBN N
intracranial JJ N
pressure NN N
and CC N
emesis NN N
with IN N
aspiration NN N
Standard NNP N
rapid-sequence NN N
intubation NN N
requires VBZ N
a DT N
nondepolarizing JJ N
blocking NN N
agent NN N
before IN N
succinylcholine JJ N
administration NN N
HYPOTHESIS NNP N
Prevention NNP N
of IN N
fasciculations NNS N
during IN N
rapid-sequence JJ N
intubation NN N
of IN N
head NN N
trauma IN N
patients NNS N
can MD N
be VB N
accomplished VBN N
as IN N
safely RB N
and CC N
effectively RB N
with IN N
minidose JJ N
succinylcholine NN N
as IN N
with IN N
a DT N
defasciculating VBG N
dose NN N
of IN N
pancuronium NN N
DESIGN VB N
A DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
SETTING VBG N
An DT N
inner-city JJ N
county NN N
trauma NN N
center NN N
with IN N
70,000 CD N
patient JJ N
visits NNS N
per IN N
year NN N
PARTICIPANTS NNP N
Sequential NNP N
adult NN 1_p
head NN N
trauma NN N
patients NNS N
requiring VBG N
rapid-sequence JJ N
intubation NN N
who WP N
had VBD N
no DT N
contraindications NNS N
to TO N
succinylcholine VB N
or CC N
pancuronium VB N
INTERVENTIONS NNP N
Each DT N
head NN N
trauma NN N
patient JJ N
requiring VBG N
rapid-sequence NN N
intubation NN N
who WP N
met VBD N
the DT N
inclusion NN N
criteria NNS N
received VBD N
standard JJ N
rapid-sequence NN N
intubation NN N
maneuvers NNS N
and CC N
lidocaine NN N
( ( N
1 CD N
mg/kg NN N
) ) N
IV NNP N
Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
minidose JJ N
succinylcholine NN N
( ( N
0.1 CD N
mg/kg NN N
) ) N
or CC N
pancuronium NN N
( ( N
0.03 CD N
mg/kg NN N
) ) N
IV NNP N
one CD N
minute NN N
prior RB N
to TO N
the DT N
full JJ N
paralytic JJ N
dose NN N
of IN N
succinylcholine NN N
( ( N
1.5 CD N
mg/kg NN N
) ) N
IV NNP N
Fasciculations NNS N
were VBD N
recorded VBN N
using VBG N
a DT N
graded JJ N
visual JJ N
scale NN N
RESULTS NNP N
Of IN N
46 CD 3_p
patients NNS N
, , N
eight CD N
of IN N
19 CD N
( ( N
42 CD N
% NN N
) ) N
in IN N
the DT N
pancuronium NN N
group NN N
and CC N
six CD N
of IN N
27 CD N
( ( N
22 CD N
% NN N
) ) N
in IN N
the DT N
succinylcholine NN N
group NN N
experienced VBD N
fasciculations NNS N
No DT N
statistically RB N
significant JJ N
difference NN N
in IN N
fasciculations NNS N
was VBD N
detected VBN N
between IN N
the DT N
two CD N
groups NNS N
using VBG N
chi JJ N
2 CD N
analysis NN N
Complete JJ N
relaxation NN N
of IN N
the DT N
cords NNS N
was VBD N
present JJ N
in IN N
all DT N
but CC N
two CD N
patients NNS N
, , N
one CD N
in IN N
each DT N
group NN N
No DT N
patient NN N
in IN N
either DT N
group NN N
experienced VBD N
emesis NN N
or CC N
significant JJ N
dysrhythmias NN N
CONCLUSION NNP N
Pretreatment NNP N
with IN N
minidose JJ N
succinylcholine JJ N
causes VBZ N
no DT N
greater JJR N
incidence NN N
of IN N
fasciculations NNS N
than IN N
pancuronium NN N
in IN N
rapid-sequence JJ N
intubation NN N
of IN N
head NN N
trauma NN N
patients NNS N
in IN N
an DT N
ED NNP N
setting NN N
Thus NNP N
succinylcholine NN N
may MD N
be VB N
used VBN N
as IN N
the DT N
sole JJ N
paralytic JJ N
agent NN N
in IN N
rapid-sequence JJ N
intubation NN N
of IN N
head NN N
trauma NN N
patients NNS N
-DOCSTART- -X- O O 24327720

Impact NN N
of IN N
vitamin NN N
D NNP N
supplementation NN N
on IN N
inflammatory JJ N
markers NNS N
in IN N
African JJ N
Americans NNPS N
: : N
results NNS N
of IN N
a DT N
four-arm JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
trial NN N
African JJ N
Americans NNPS N
have VBP N
a DT N
disproportionate JJ N
burden NN N
of IN N
inflammation-associated JJ N
chronic JJ N
diseases NNS N
such JJ N
as IN N
cancer NN N
and CC N
lower JJR N
circulating NN N
levels NNS N
of IN N
25-hydroxyvitamin JJ N
D NNP N
[ NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
] NNP N
The DT N
effect NN N
of IN N
vitamin NN N
D3 NNP N
( ( N
cholecalciferol NN N
) ) N
supplementation NN N
on IN N
inflammatory JJ N
markers NNS N
is VBZ N
uncertain JJ N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
supplemental JJ N
oral JJ N
vitamin NN N
D NNP N
( ( N
placebo NN N
, , N
1,000 CD N
, , N
2,000 CD N
, , N
or CC N
4,000 CD N
IU/day NN N
of IN N
vitamin NN N
D3 NNP N
orally RB N
for IN N
3 CD N
months NNS N
) ) N
in IN N
328 CD N
African JJ N
Americans NNPS N
( ( N
median JJ N
age NN N
, , N
51 CD N
years NNS N
) ) N
of IN N
public JJ N
housing NN N
communities NNS N
in IN N
Boston NNP N
, , N
MA NNP N
, , N
who WP N
were VBD N
enrolled VBN N
over RP N
three CD N
consecutive JJ N
winter NN N
periods NNS N
( ( N
2007-2010 JJ N
) ) N
Change NN N
from IN N
0 CD N
to TO N
3 CD N
months NNS N
of IN N
plasma NN N
levels NNS N
of IN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
, , N
high-sensitivity JJ N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
interleukin FW N
( ( N
IL NNP N
) ) N
-6 NN N
, , N
IL-10 NNP N
, , N
and CC N
soluble JJ N
TNF-α NNP N
receptor NN N
type NN N
2 CD N
( ( N
sTNF-R2 NN N
) ) N
in IN N
292 CD N
( ( N
89 CD N
% NN N
) ) N
participants NNS N
were VBD N
measured VBN N
Overall NNP N
, , N
no DT N
statistically RB N
significant JJ N
changes NNS N
in IN N
CRP NNP N
, , N
IL-6 NNP N
, , N
IL-10 NNP N
, , N
and CC N
sTNF-R2 NNS N
were VBD N
observed VBN N
after IN N
the DT N
vitamin NN N
D NNP N
supplementation NN N
period NN N
Baseline NNP N
CRP NNP N
was VBD N
significantly RB N
inversely RB N
associated VBN N
with IN N
the DT N
baseline NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
level NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
unadjusted JJ N
and CC N
adjusted JJ N
models NNS N
An DT N
interaction NN N
between IN N
baseline NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
and CC N
vitamin NNP N
D NNP N
supplementation NN N
was VBD N
observed VBN N
for IN N
outcome JJ N
change NN N
in IN N
log NN N
CRP NNP N
( ( N
month NN N
3-month RB N
0 CD N
; : N
P NNP N
for IN N
interaction NN N
= NNP N
0.04 CD N
) ) N
Within IN N
an DT N
unselected JJ N
population NN N
of IN N
African JJ N
Americans NNPS N
, , N
short-term JJ N
exposure NN N
to TO N
vitamin VB N
D NNP N
supplementation NN N
produced VBD N
no DT N
change NN N
in IN N
circulating VBG N
inflammatory JJ N
markers NNS N
This DT N
study NN N
confirms VBZ N
the DT N
strong JJ N
independent JJ N
association NN N
of IN N
CRP NNP N
with IN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
status NN N
even RB N
after IN N
adjusting VBG N
for IN N
body NN N
mass NN N
index NN N
Future JJ N
studies NNS N
of IN N
longer JJR N
supplemental JJ N
vitamin NN N
D3 NNP N
duration NN N
are VBP N
necessary JJ N
to TO N
examine VB N
the DT N
complex JJ N
influence NN N
of IN N
vitamin NN N
D3 NNP N
on IN N
CRP NNP N
and CC N
other JJ N
chronic JJ N
inflammatory NN N
cytokines NNS N
for IN N
possible JJ N
reduction NN N
of IN N
cancer NN N
health NN N
disparities NNS N
in IN N
African JJ N
Americans NNPS N
-DOCSTART- -X- O O 19462303

Gamma-hydroxybutyric JJ N
acid NN N
versus NN N
clomethiazole NN N
for IN N
the DT N
treatment NN N
of IN N
alcohol NN 4_p
withdrawal NN 4_p
syndrome NN 4_p
in IN N
a DT N
medical JJ N
intensive JJ N
care NN N
unit NN N
: : N
an DT N
open JJ N
, , N
single-center JJ N
randomized VBN N
study NN N
BACKGROUND NNP N
Clomethiazole NNP N
( ( N
CLO NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
treating VBG N
alcohol NN 4_p
withdrawal NN 4_p
syndrome NN 4_p
( ( 4_p
AWS NNP 4_p
) ) 4_p
Gamma-Hydroxybutyric JJ N
acid NN N
( ( N
GHB NNP N
) ) N
has VBZ N
also RB N
been VBN N
introduced VBN N
in IN N
the DT N
treatment NN N
of IN N
alcoholic JJ N
patients NNS N
and CC N
is VBZ N
effective JJ N
in IN N
surgical JJ N
intensive JJ N
care NN N
unit NN N
( ( N
ICU NNP N
) ) N
patients NNS N
in IN N
preventing VBG N
and CC N
treating VBG N
AWS NNP N
There EX N
are VBP N
no DT N
comparative JJ N
studies NNS N
between IN N
CLO NNP N
and CC N
GHB NNP N
in IN N
a DT N
medical JJ N
ICU NNP N
setting NN N
METHODS NNP N
Twenty-six NNP 3_p
alcoholic JJ 4_p
patients NNS N
with IN N
severe JJ 4_p
AWS NNP 4_p
and CC 4_p
concomitant JJ 4_p
medical JJ 4_p
diseases NNS 4_p
were VBD N
randomally RB N
enrolled VBN N
in IN N
the DT N
study NN N
CLO NNP N
was VBD N
given VBN N
orally RB N
to TO N
12 CD N
patients NNS N
in IN N
a DT N
dosage NN N
of IN N
250 CD N
mg NN N
every DT N
4 CD N
hours NNS N
as IN N
a DT N
liquid NN N
; : N
GHB NNP N
( ( N
initially RB N
30 CD N
mg/kg NNS N
body NN N
weight NN N
( ( N
BW NNP N
) ) N
followed VBN N
by IN N
15 CD N
mg/kg NNS N
BW NNP N
) ) N
was VBD N
administered VBN N
intravenously RB N
to TO N
14 CD N
patients NNS N
Four CD N
major JJ N
AWS NNP N
symptoms NNS N
( ( N
tremor NN N
, , N
sweating VBG N
, , N
nausea NN N
, , N
restlessness NN N
) ) N
were VBD N
scored VBN N
, , N
and CC N
the DT N
administration NN N
of IN N
additional JJ N
medication NN N
was VBD N
registered VBN N
RESULTS NNP N
GHB NNP N
was VBD N
more RBR N
effective JJ N
in IN N
treating VBG N
AWS NNP N
symptoms NNS N
In IN N
the DT N
GHB NNP N
group NN N
, , N
AWS NNP N
score NN N
dropped VBD N
from IN N
6.6 CD N
+/- JJ N
2.6 CD N
to TO N
1.8 CD N
+/- JJ N
2.1 CD N
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
, , N
while IN N
in IN N
the DT N
CLO NNP N
group NN N
, , N
the DT N
score NN N
dropped VBD N
from IN N
6 CD N
+/- JJ N
2.5 CD N
to TO N
4.1 CD N
+/- JJ N
2.4 CD N
( ( N
n. JJ N
s. NN N
) ) N
Differences NNS N
between IN N
groups NNS N
were VBD N
significant JJ N
( ( N
p JJ N
=.021 NN N
, , N
two-way JJ N
ANOVA NNP N
) ) N
The DT N
treatment NN N
did VBD N
not RB N
alter VB N
outcome NN N
or CC N
the DT N
duration NN N
of IN N
ICU NNP N
stay NN N
No DT N
serious JJ N
side NN N
effects NNS N
were VBD N
detected VBN N
CONCLUSION NNP N
GHB NNP N
effectively RB N
controls VBZ N
AWS NNP N
symptoms NNS N
in IN N
medical JJ N
ICU NNP N
patients NNS N
The DT N
rapid JJ N
initial JJ N
treatment NN N
response NN N
of IN N
GHB NNP N
in IN N
contrast NN N
to TO N
CLO NNP N
has VBZ N
no DT N
influence NN N
on IN N
duration NN N
of IN N
patient NN N
withdrawal NN N
-DOCSTART- -X- O O 8237838

Veterans NNS 1_p
Affairs VBP N
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
antiarrhythmic JJ N
trial NN N
CHF NNP N
STAT NNP N
Investigators NNP N
This DT N
is VBZ N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
antiarrhythmic JJ N
drug NN N
therapy NN N
on IN N
mortality NN N
in IN N
patients NNS N
with IN N
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
and CC N
ventricular JJ 4_p
arrhythmia NN 4_p
Patients NNS N
will MD N
be VB N
assigned VBN N
to TO N
receive VB N
either CC N
amiodarone VB N
or CC N
placebo VB N
Eligible JJ N
patients NNS N
include VBP N
those DT N
with IN N
ischemic JJ N
and CC N
nonischemic JJ N
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
and CC N
with IN N
> NNP N
or CC N
= $ N
10 CD N
ventricular JJ 4_p
premature NN 4_p
beats NNS 4_p
per IN N
hour NN N
All DT N
patients NNS N
must MD N
have VB N
shortness NN 4_p
of IN 4_p
breath NN 4_p
with IN N
minimal JJ N
exertion NN N
or CC N
paroxysmal JJ 4_p
nocturnal JJ 4_p
dyspnea NN 4_p
, , N
a DT N
left JJ N
ventricular JJ N
internal JJ N
dimension NN N
( ( N
LVIDd NNP N
) ) N
by IN N
echocardiogram NN N
of IN N
> NN N
or CC N
= $ N
55 CD N
mm NN N
or CC N
a DT N
cardiothoracic JJ N
ratio NN N
of IN N
> $ N
0.5 CD N
and CC N
an DT N
ejection NN N
fraction NN N
of IN N
< NN N
or CC N
= VB N
40 CD N
% NN N
All DT N
patients NNS N
will MD N
receive VB N
vasodilator NN N
therapy NN N
, , N
unless IN N
they PRP N
find VBP N
it PRP N
intolerable JJ N
Patients NNS N
will MD N
be VB N
entered VBN N
into IN N
the DT N
study NN N
for IN N
2.5 CD N
years NNS N
and CC N
followed VBD N
for IN N
an DT N
additional JJ N
2 CD N
years NNS N
Drug NNP N
therapy NN N
will MD N
be VB N
continued VBN N
for IN N
all DT N
patients NNS N
throughout IN N
the DT N
entire JJ N
study NN N
unless IN N
adverse JJ N
reactions NNS N
occur VBP N
that IN N
necessitate JJ N
individualized JJ N
treatment NN N
The DT N
expectation NN N
is VBZ N
that IN N
674 CD N
patients NNS N
will MD N
be VB N
entered VBN N
into IN N
the DT N
study NN N
from IN N
25 CD N
participating VBG N
centers NNS N
This DT N
sample JJ N
size NN N
will MD N
allow VB N
for IN N
the DT N
detection NN N
of IN N
a DT N
33 CD N
% NN N
decrease NN N
in IN N
2-year JJ N
mortality NN N
( ( N
20 CD N
% NN N
vs JJ N
30 CD N
% NN N
) ) N
in IN N
the DT N
treated JJ N
patients NNS N
compared VBN N
with IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
, , N
with IN N
a DT N
power NN N
of IN N
0.90 CD N
and CC N
a DT N
2-sided JJ N
alpha JJ N
level NN N
of IN N
0.05 CD N
Intermittent JJ N
Holter NNP N
monitoring NN N
, , N
radionuclide JJ N
ventriculograms NN N
, , N
pulmonary JJ N
function NN N
tests NNS N
, , N
echocardiograms NNS N
, , N
and CC N
blood NN N
tests NNS N
, , N
including VBG N
arterial JJ N
blood NN N
gases NNS N
, , N
will MD N
be VB N
required VBN N
for IN N
each DT N
patient NN N
( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 10201101

Reduction NN N
of IN N
stimulus JJ N
overselectivity NN N
with IN N
nonverbal JJ N
differential JJ N
observing NN N
responses NNS N
Three CD 3_p
individuals NNS N
with IN N
mental JJ 4_p
retardation NN 4_p
exhibited VBD N
stimulus JJ N
overselectivity NN N
in IN N
a DT N
delayed JJ N
matching-to-sample NN N
task NN N
in IN N
which WDT N
two CD N
sample NN N
stimuli NNS N
were VBD N
displayed VBN N
on IN N
each DT N
trial NN N
Intermediate NNP N
accuracy NN N
scores NNS N
indicated VBD N
that IN N
participants NNS N
could MD N
match VB N
one CD N
of IN N
the DT N
samples NNS N
but CC N
not RB N
both DT N
of IN N
them PRP N
Accuracy NN N
in IN N
a DT N
baseline NN N
condition NN N
was VBD N
compared VBN N
to TO N
accuracy VB N
with IN N
a DT N
differential JJ N
observing NN N
response NN N
procedure NN N
This DT N
procedure NN N
prompted VBD N
participants NNS N
to TO N
make VB N
simultaneous JJ N
identity-matching JJ N
responses NNS N
that WDT N
required VBD N
observation NN N
and CC N
discrimination NN N
of IN N
both DT N
sample JJ N
stimuli NN N
These DT N
observing VBG N
responses NNS N
were VBD N
never RB N
followed VBN N
by IN N
differential JJ N
consequences NNS N
When WRB N
observing VBG N
responses NNS N
were VBD N
prompted VBN N
, , N
participants NNS N
' POS N
accuracy NN N
scores NNS N
improved VBN N
In IN N
a DT N
return NN N
to TO N
the DT N
baseline NN N
condition NN N
, , N
when WRB N
differential JJ N
observing NN N
responses NNS N
were VBD N
no RB N
longer RB N
prompted VBN N
, , N
accuracy NN N
returned VBD N
to TO N
intermediate JJ N
levels NNS N
The DT N
results NNS N
show VBP N
that IN N
stimulus JJ N
overselectivity NN N
can MD N
be VB N
greatly RB N
reduced VBN N
by IN N
a DT N
behavioral JJ N
intervention NN N
that IN N
controls VBZ N
observing VBG N
behavior NN N
and CC N
verifies NNS N
discrimination NN N
, , N
but CC N
that IN N
exposure NN N
to TO N
such JJ N
procedures NNS N
alone VBP N
may MD N
be VB N
insufficient JJ N
for IN N
lasting VBG N
benefits NNS N
-DOCSTART- -X- O O 19371522

Randomized VBN N
evaluation NN N
of IN N
octreotide JJ N
vs FW N
prochlorperazine NN N
for IN N
ED NNP N
treatment NN N
of IN N
migraine NN N
headache NN N
UNLABELLED JJ N
Patients NNS N
with IN N
headaches NNS N
account VBP N
for IN N
approximately RB N
2 CD N
% NN N
of IN N
all DT N
ED NNP N
visits NNS N
, , N
with IN N
migraines NNS N
being VBG N
the DT N
most RBS N
common JJ N
defined VBD N
primary JJ N
headache NN N
syndrome NN N
Our PRP$ N
goals NNS N
were VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
intravenous JJ N
octreotide NN N
( ( N
OC NNP N
) ) N
for IN N
the DT N
treatment NN N
of IN N
migraines NNS N
, , N
when WRB N
compared VBN N
to TO N
standard VB N
therapy NN N
with IN N
prochlorperazine NN N
METHODS NNP N
The DT N
study NN N
was VBD N
conducted VBN N
as IN N
a DT N
double-blinded JJ N
, , N
randomized VBN N
controlled VBN N
trial NN N
Each DT N
subject NN N
received VBD N
either CC N
100 CD N
microg NN N
of IN N
octreotide NN N
or CC N
10 CD N
mg NN N
of IN N
prochlorperazine NN N
intravenously RB N
for IN N
a DT N
2-minute JJ N
period NN N
RESULTS NNP N
Comparison NNP N
of IN N
the DT N
change NN N
in IN N
median JJ N
visual JJ N
analog NN N
scale NN N
scores NNS N
for IN N
60 CD N
minutes NNS N
demonstrated VBD N
that IN N
octreotide NN N
was VBD N
less RBR N
effective JJ N
at IN N
reducing VBG N
pain NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
and CC N
producing VBG N
clinical JJ N
success NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
Restlessness JJ N
consistent JJ N
with IN N
akathisia NN N
was VBD N
noted VBN N
by IN N
35 CD N
% NN N
of IN N
the DT N
PC NN N
group NN N
and CC N
8 CD N
% NN N
of IN N
the DT N
OC NNP N
group NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
At IN N
60 CD N
minutes NNS N
, , N
rescue NN N
medication NN N
was VBD N
required VBN N
by IN N
48 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
OC NNP N
group NN N
, , N
whereas RB N
10 CD N
% NN N
of IN N
the DT N
PC NNP N
group NN N
required VBD N
such JJ N
therapy NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
All DT N
44 CD N
patients NNS N
were VBD N
contacted VBN N
for IN N
follow-up NN N
at IN N
48 CD N
to TO N
72 CD N
hours NNS N
after IN N
enrollment NN N
At IN N
that DT N
time NN N
, , N
10 CD N
% NN N
of IN N
the DT N
prochlorperazine NN N
and CC N
25 CD N
% NN N
of IN N
the DT N
octreotide JJ N
patients NNS N
had VBD N
experienced VBN N
some DT N
headache NN N
recurrence NN N
( ( N
P NNP N
= NNP N
.1 NNP N
) ) N
CONCLUSION NNP N
Prochlorperazine NNP N
was VBD N
statistically RB N
superior JJ N
to TO N
octreotide VB N
in IN N
clinical JJ N
success NN N
rate NN N
and CC N
decrease NN N
in IN N
pain NN N
in IN N
migraine NN N
patients NNS N
but CC N
caused VBD N
more JJR N
restlessness NN N
and CC N
sedation NN N
-DOCSTART- -X- O O 23532629

Erythropoietin NNP N
treatment NN N
in IN N
chemotherapy-induced JJ N
anemia NN N
in IN N
previously RB N
untreated VBN N
advanced JJ 4_p
esophagogastric JJ 4_p
cancer NN 4_p
patients NNS 4_p
BACKGROUND NNP N
The DT N
impact NN N
of IN N
erythropoiesis-stimulating JJ N
agents NNS N
in IN N
chemotherapy-induced JJ N
anemia NN N
has VBZ N
been VBN N
a DT N
constant JJ N
topic NN N
of IN N
debate NN N
over IN N
recent JJ N
years NNS N
We PRP N
prospectively RB N
assessed VBD N
the DT N
efficacy NN N
of IN N
epoetin NN N
beta NN N
( ( N
Epo-b NNP N
) ) N
in IN N
improving VBG N
hemoglobin NN N
( ( N
Hb NNP N
) ) N
levels NNS N
and CC N
outcome NN N
in IN N
patients NNS N
within IN N
an DT N
open JJ N
label NN N
, , N
randomized VBD N
clinical JJ N
phase NN N
II NNP N
trial NN N
with IN N
advanced JJ 4_p
or CC 4_p
metastatic JJ 4_p
gastric/esophagogastric JJ 4_p
cancer NN 4_p
METHODS NNP N
Previously RB 4_p
untreated VBD 4_p
patients NNS 4_p
were VBD 4_p
randomized VBN 4_p
to TO N
receive VB N
3-weekly JJ N
cycles NNS N
of IN N
capecitabine NN N
( ( N
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
bid NN N
) ) N
for IN N
14 CD N
days NNS N
plus CC N
on IN N
day NN N
1 CD N
either CC N
irinotecan JJ N
250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
or CC N
cisplatin $ N
80 CD N
mg/m NN N
( ( N
2 CD N
) ) N
Epo-b NNP N
( ( N
30000 CD N
IU NNP N
once RB N
weekly RB N
) ) N
was VBD N
initiated VBN N
in IN N
patients NNS N
with IN N
Hb NNP N
< NNP N
11 CD N
g/dl NN N
and CC N
continued VBD N
until IN N
Hb NNP N
≥12 NNP N
g/dl NN N
was VBD N
reached VBN N
If IN N
after IN N
4 CD N
weeks NNS N
the DT N
Hb NNP N
increase NN N
was VBD N
< JJ N
0.5 CD N
g/dl NN N
, , N
Epo-b NNP N
was VBD N
increased VBN N
to TO N
30000 CD N
IU NNP N
, , N
twice RB N
weekly RB N
RESULTS NNP N
Of IN N
118 CD 3_p
patients NNS 3_p
enrolled VBD 3_p
, , N
32 CD N
received VBD N
Epo-b NNP N
treatment NN N
; : N
of IN N
these DT N
, , N
65 CD N
% NN N
achieved VBD N
an DT N
increase NN N
in IN N
Hb NNP N
levels NNS N
of IN N
at IN N
least JJS N
2 CD N
g/dl NN N
, , N
with IN N
74 CD N
% NN N
achieving VBG N
the DT N
target NN N
Hb NNP N
of IN N
≥12 NNP N
g/dl NN N
Within IN N
the DT N
study NN N
population NN N
, , N
patients NNS N
receiving VBG N
Epo-b NNP N
showed VBD N
better JJR N
overall JJ N
survival NN N
( ( N
median JJ N
14.5 CD N
vs. FW N
8.0 CD N
months NNS N
, , N
P NNP N
= NNP N
0.056 CD N
) ) N
as RB N
well RB N
as IN N
a DT N
significantly RB N
improved VBN N
disease NN N
control NN N
rate NN N
( ( N
78 CD N
vs. FW N
55 CD N
% NN N
, , N
P NNP N
= NNP N
0.025 CD N
) ) N
Patients NNS N
in IN N
the DT N
irinotecan JJ N
group NN N
profited VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
terms NNS N
of IN N
progression-free JJ N
survival NN N
and CC N
overall JJ N
survival NN N
under IN N
Epo-b NNP N
treatment NN N
( ( N
median JJ N
6.5 CD N
vs JJ N
4.1 CD N
months NNS N
and CC N
median JJ N
15.4 CD N
vs JJ N
8.4 CD N
months NNS N
, , N
respectively RB N
) ) N
CONCLUSIONS NNP N
Epo-b NNP N
was VBD N
effective JJ N
in IN N
raising VBG N
Hb NNP N
levels NNS N
in IN N
patients NNS N
with IN N
advanced JJ N
esophagogastric JJ N
cancer NN N
Patients NNS N
receiving VBG N
Epo-b NNP N
had VBD N
a DT N
significantly RB N
increased VBN N
response NN N
to TO N
chemotherapy VB N
and CC N
a DT N
clear JJ N
trend NN N
to TO N
improved VBN N
survival NN N
-DOCSTART- -X- O O 16772718

Intermittent NNP N
recombinant JJ N
growth NN N
hormone NN N
treatment NN N
in IN N
short JJ 1_p
children NNS 1_p
born VBP 1_p
small JJ 1_p
for IN 1_p
gestational JJ 1_p
age NN 1_p
: : 1_p
four-year JJ N
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
of IN N
two CD N
different JJ N
treatment NN N
regimens NNS N
BACKGROUND NNP N
Treatment NNP N
of IN N
short JJ 1_p
children NNS 1_p
born VBP 1_p
small JJ 1_p
for IN 1_p
gestational JJ 1_p
age NN 1_p
SGA NNP 1_p
with IN N
recombinant JJ N
human JJ N
growth NN N
hormone VBD N
r-hGH JJ N
increases NNS N
growth NN N
velocity NN N
during IN N
childhood NN N
As IN N
in IN N
other JJ N
indications NNS N
, , N
the DT N
growth NN N
velocity NN N
in IN N
these DT N
patients NNS N
is VBZ N
more JJR N
marked JJ N
during IN N
the DT N
first JJ N
year NN N
of IN N
treatment NN N
and CC N
then RB N
decreases VBZ N
This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
different JJ N
r-hGH JJ N
treatment NN N
schedules NNS N
( ( N
67 CD N
microg/kg/day NN N
in IN N
a DT N
discontinuous JJ N
or CC N
continuous JJ N
regimen NNS N
) ) N
during IN N
the DT N
second JJ N
year NN N
of IN N
r-hGH JJ N
treatment NN N
by IN N
comparing VBG N
height JJ N
velocity NN N
changes NNS N
and CC N
total JJ N
gain NN N
of IN N
height NN N
over IN N
a DT N
4-year JJ N
period NN N
METHODS $ N
58 CD 3_p
growth-retarded JJ 1_p
SGA NNP 1_p
children NNS 1_p
aged VBN 1_p
2-5 CD 1_p
years NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO N
a DT N
TOTO NNP N
regimen NN N
( ( N
4 CD N
years NNS N
alternating VBG N
treatment NN N
( ( N
T NNP N
) ) N
and CC N
observation NN N
( ( N
O NNP N
) ) N
, , N
n JJ N
= NNP N
30 CD N
) ) N
or CC N
a DT N
TTOO JJ N
regimen NN N
( ( N
2 CD N
years NNS N
' POS N
treatment NN N
, , N
followed VBN N
by IN N
2 CD N
years NNS N
' POS N
observation NN N
, , N
n JJ N
= NNP N
28 CD N
) ) N
Height NNP N
velocity NN N
HV NNP N
and CC N
total JJ N
height NN N
gain NN N
were VBD N
assessed VBN N
during IN N
the DT N
4-year JJ N
study NN N
RESULTS NNP N
In IN N
both DT N
groups NNS N
, , N
HV NNP N
and CC N
HV NNP N
standard JJ N
deviation NN N
score VBD N
HV-SDSCA NNP N
increased VBD N
during IN N
treatment NN N
and CC N
decreased VBD N
during IN N
observation NN N
periods NNS N
Interruption NN N
of IN N
treatment NN N
in IN N
the DT N
TOTO NNP N
group NN N
did VBD N
not RB N
result VB N
in IN N
a DT N
better JJR N
gain NN N
in IN N
height JJ N
standard NN N
deviation NN N
score VBD N
H-SDSCA NNP N
when WRB N
compared VBN N
with IN N
the DT N
TTOO NNP N
group NN N
After IN N
4 CD N
years NNS N
of IN N
study NN N
, , N
the DT N
gain NN N
in IN N
H-SDSCA NNP N
was VBD N
1.4 CD N
+ NN N
or CC N
- : N
01 CD N
in IN N
the DT N
TOTO NNP N
group NN N
and CC N
1.6 CD N
+ NN N
or CC N
- : N
0.2 CD N
in IN N
the DT N
TTOO NNP N
group NN N
leading VBG N
to TO N
a DT N
mean JJ N
height NN N
of IN N
-2.0 NNP N
+ NNP N
or CC N
- : N
1.0 CD N
SDS NNP N
and CC N
-2.0 NNP N
+ NNP N
or CC N
- : N
0.8 CD N
SDS NNP N
, , N
respectively RB N
The DT N
rate NN N
of IN N
bone NN N
maturation NN N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
CONCLUSIONS NNP N
In IN N
short JJ N
SGA NNP N
children NNS N
, , N
TOTO NNP N
and CC N
TTOO NNP N
regimens NNS N
produced VBD N
significant JJ N
improvements NNS N
in IN N
growth NN N
during IN N
r-hGH JJ N
treatment NN N
However RB N
, , N
treatment NN N
interruption NN N
after IN N
1 CD N
year NN N
did VBD N
not RB N
influence VB N
the DT N
overall JJ N
gain NN N
in IN N
height NN N
SDS NNP N
when WRB N
compared VBN N
with IN N
2 CD N
years NNS N
' POS N
continuous JJ N
treatment NN N
-DOCSTART- -X- O O 6522132

Effects NNS N
of IN N
antihypertensive JJ N
drugs NNS N
on IN N
cognitive JJ N
function NN N
in IN N
adolescents NNS 1_p
The DT N
effects NNS N
of IN N
clonidine NN N
and CC N
hydrochlorothiazide NN N
on IN N
cognitive JJ N
function NN N
were VBD N
studied VBN N
in IN N
hypertensive JJ 4_p
adolescents NNS N
requiring VBG N
pharmacologic JJ N
therapy NN N
for IN N
blood NN N
pressure NN N
control NN N
Twenty-four JJ 3_p
adolescents NNS 1_p
with IN N
persistent JJ 4_p
blood NN 4_p
pressure NN 4_p
elevation NN 4_p
( ( 4_p
greater JJR 4_p
than IN 4_p
95th CD 4_p
% NN 4_p
) ) 4_p
on IN N
placebo NN N
were VBD N
randomized VBN N
double JJ N
blind NN N
to TO N
clonidine VB N
or CC N
hydrochlorothiazide VB N
treatment NN N
A DT N
battery NN N
of IN N
cognitive JJ N
tests NNS N
were VBD N
performed VBN N
during IN N
the DT N
placebo NN N
phase NN N
and CC N
after IN N
16 CD N
weeks NNS N
of IN N
active JJ N
therapy NN N
Antihypertensive JJ N
therapy NN N
resulted VBD N
in IN N
significant JJ N
blood NN N
pressure NN N
reduction NN N
( ( N
p NN N
less JJR N
than IN N
.01 NN N
) ) N
A DT N
slight JJ N
interactive JJ N
effect NN N
was VBD N
observed VBN N
in IN N
arithmetic JJ N
performance NN N
( ( N
p NN N
less JJR N
than IN N
.05 NN N
) ) N
All DT N
other JJ N
parameters NNS N
of IN N
cognitive JJ N
function NN N
were VBD N
not RB N
affected VBN N
by IN N
either DT N
treatment NN N
-DOCSTART- -X- O O 21844080

Comparative JJ N
effectiveness NN N
of IN N
exercise NN N
electrocardiography NN N
with IN N
or CC N
without IN N
myocardial JJ N
perfusion NN N
single JJ N
photon NN N
emission NN N
computed VBD N
tomography NN N
in IN N
women NNS 4_p
with IN 4_p
suspected JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
: : 4_p
results NNS N
from IN N
the DT N
What WP N
Is VBZ N
the DT N
Optimal NNP N
Method NNP N
for IN N
Ischemia NNP N
Evaluation NNP N
in IN N
Women NNP N
( ( N
WOMEN NNP N
) ) N
trial NN N
BACKGROUND NNP N
There EX N
is VBZ N
a DT N
paucity NN N
of IN N
randomized JJ N
trials NNS N
regarding VBG N
diagnostic JJ N
testing NN N
in IN N
women NNS 4_p
with IN 4_p
suspected JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
( ( 4_p
CAD NNP 4_p
) ) 4_p
It PRP N
remains VBZ N
unclear JJ N
whether IN N
the DT N
addition NN N
of IN N
myocardial JJ N
perfusion NN N
imaging NN N
( ( N
MPI NNP N
) ) N
to TO N
the DT N
standard JJ N
ECG NNP N
exercise NN N
treadmill NN N
test NN N
( ( N
ETT NNP N
) ) N
provides VBZ N
incremental JJ N
information NN N
to TO N
improve VB N
clinical JJ N
decision NN N
making NN N
in IN N
women NNS N
with IN N
suspected JJ N
CAD NNP N
METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
randomized VBD N
symptomatic JJ N
women NNS N
with IN N
suspected JJ N
CAD NNP N
, , N
an DT N
interpretable JJ N
ECG NNP N
, , N
and CC N
≥5 NNP N
metabolic JJ N
equivalents NNS N
on IN N
the DT N
Duke NNP N
Activity NNP N
Status NNP N
Index NNP N
to TO N
1 CD N
of IN N
2 CD N
diagnostic JJ N
strategies NNS N
: : N
ETT NNP N
or CC N
exercise NN N
MPI NNP N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
2-year JJ N
incidence NN N
of IN N
major JJ N
adverse JJ N
cardiac NN N
events NNS N
, , N
defined VBN N
as IN N
CAD NNP N
death NN N
or CC N
hospitalization NN N
for IN N
an DT N
acute JJ N
coronary JJ N
syndrome NN N
or CC N
heart NN N
failure NN N
A DT N
total NN N
of IN N
824 CD N
women NNS N
were VBD N
randomized VBN N
to TO N
ETT NNP N
or CC N
exercise NN N
MPI NNP N
For IN N
women NNS N
randomized VBN N
to TO N
ETT NNP N
, , N
ECG NNP N
results NNS N
were VBD N
normal JJ N
in IN N
64 CD N
% NN N
, , N
indeterminate NN N
in IN N
16 CD N
% NN N
, , N
and CC N
abnormal JJ N
in IN N
20 CD N
% NN N
By IN N
comparison NN N
, , N
the DT N
exercise NN N
MPI NNP N
results NNS N
were VBD N
normal JJ N
in IN N
91 CD N
% NN N
, , N
mildly RB N
abnormal JJ N
in IN N
3 CD N
% NN N
, , N
and CC N
moderate VB N
to TO N
severely RB N
abnormal JJ N
in IN N
6 CD N
% NN N
At IN N
2 CD N
years NNS N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
major JJ N
adverse JJ N
cardiac NN N
events NNS N
( ( N
98.0 CD N
% NN N
for IN N
ETT NNP N
and CC N
97.7 CD N
% NN N
for IN N
MPI NNP N
; : N
P=0.59 NNP N
) ) N
Compared VBN N
with IN N
ETT NNP N
, , N
index NN N
testing VBG N
costs NNS N
were VBD N
higher JJR N
for IN N
exercise NN N
MPI NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
whereas JJ N
downstream NN N
procedural NN N
costs NNS N
were VBD N
slightly RB N
lower JJR N
( ( N
P=0.0008 NNP N
) ) N
Overall UH N
, , N
the DT N
cumulative JJ N
diagnostic JJ N
cost NN N
savings NNS N
was VBD N
48 CD N
% NN N
for IN N
ETT NNP N
compared VBN N
with IN N
exercise NN N
MPI NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
CONCLUSIONS NNP N
In IN N
low-risk JJ N
, , N
exercising VBG N
women NNS N
, , N
a DT N
diagnostic JJ N
strategy NN N
that WDT N
uses VBZ N
ETT NNP N
versus NN N
exercise NN N
MPI NNP N
yields NNS N
similar JJ N
2-year JJ N
posttest NN N
outcomes NNS N
while IN N
providing VBG N
significant JJ N
diagnostic JJ N
cost NN N
savings NNS N
The DT N
ETT NNP N
with IN N
selective JJ N
follow-up JJ N
testing NN N
should MD N
be VB N
considered VBN N
as IN N
the DT N
initial JJ N
diagnostic JJ N
strategy NN N
in IN N
symptomatic JJ N
women NNS N
with IN N
suspected JJ N
CAD NNP N
CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
http NN N
: : N
//www.clinicaltrials.gov NN N
Unique NNP N
identifier NN N
: : N
NCT00282711 NNP N
-DOCSTART- -X- O O 21785360

To TO N
share NN N
or CC N
not RB N
to TO N
share NN N
: : N
a DT N
randomized JJ N
trial NN N
of IN N
consent NN N
for IN N
data NNS N
sharing VBG N
in IN N
genome JJ 4_p
research NN 4_p
PURPOSE NNP N
Despite IN N
growing VBG N
concerns NNS N
toward IN N
maintaining VBG N
participants NNS N
' POS N
privacy NN N
, , N
individual JJ N
investigators NNS N
collecting VBG N
tissue NN N
and CC N
other JJ N
biological JJ N
specimens NNS N
for IN N
genomic JJ N
analysis NN N
are VBP N
encouraged VBN N
to TO N
obtain VB N
informed JJ N
consent NN N
for IN N
broad JJ N
data NNS N
sharing VBG N
Our PRP$ N
purpose NN N
was VBD N
to TO N
assess VB N
the DT N
effect NN N
on IN N
research NN N
enrollment NN N
and CC N
data NNS N
sharing VBG N
decisions NNS N
of IN N
three CD N
different JJ N
consent NN N
types NNS N
( ( N
traditional JJ N
, , N
binary JJ N
, , N
or CC N
tiered VBN N
) ) N
with IN N
varying VBG N
levels NNS N
of IN N
control NN N
and CC N
choices NNS N
regarding VBG N
data NNS N
sharing VBG N
METHODS VB N
A DT N
single-blinded JJ N
, , N
randomized VBN N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
with IN N
323 CD 3_p
eligible JJ N
adult NN 1_p
participants NNS N
being VBG N
recruited VBN N
into IN N
one CD N
of IN N
six CD N
genome JJ N
studies NNS N
at IN N
Baylor NNP N
College NNP N
of IN N
Medicine NNP N
in IN N
Houston NNP N
, , N
Texas NNP N
, , N
between IN N
January NNP N
2008 CD N
and CC N
August NNP N
2009 CD N
Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
experimental JJ N
consent NN N
documents NNS N
( ( N
traditional JJ N
, , N
n JJ N
= VBP N
110 CD 3_p
; : N
binary JJ N
, , N
n JJ N
= VBP N
103 CD N
; : N
and CC N
tiered VBD N
, , N
n JJ N
= NNP N
110 CD N
) ) N
Debriefing VBG N
in IN N
follow-up JJ N
visits NNS N
provided VBD N
participants NNS N
a DT N
detailed JJ N
review NN N
of IN N
all DT N
consent NN N
types NNS N
and CC N
the DT N
chance NN N
to TO N
change VB N
data NNS N
sharing VBG N
choices NNS N
or CC N
decline VB N
genome NN N
study NN N
participation NN N
RESULTS NNP N
Before IN N
debriefing VBG N
, , N
83.9 CD N
% NN N
of IN N
participants NNS N
chose JJ N
public JJ N
data NNS N
release NN N
After IN N
debriefing VBG N
, , N
53.1 CD N
% NN N
chose JJ N
public JJ N
data NNS N
release NN N
, , N
33.1 CD N
% NN N
chose NN N
restricted VBN N
( ( N
controlled JJ N
access NN N
database NN N
) ) N
release NN N
, , N
and CC N
13.7 CD N
% NN N
opted VBN N
out IN N
of IN N
data NNS N
sharing VBG N
Only RB N
one CD N
participant NN N
declined VBD N
genome JJ N
study NN N
participation NN N
due JJ N
to TO N
data VB N
sharing NN N
concerns NNS N
CONCLUSION NNP N
Our PRP$ N
findings NNS N
indicate VBP N
that IN N
most JJS N
participants NNS N
are VBP N
willing JJ N
to TO N
publicly RB N
release VB N
their PRP$ N
genomic JJ N
data NNS N
; : N
however RB N
, , N
a DT N
significant JJ N
portion NN N
prefers NNS N
restricted VBD N
release NN N
These DT N
results NNS N
suggest VBP N
discordance NN N
between IN N
existing VBG N
data NNS N
sharing VBG N
policies NNS N
and CC N
participants NNS N
' POS N
judgments NNS N
and CC N
desires NNS N
-DOCSTART- -X- O O 1364154

[ JJ N
Platelet NNP N
serotonin NN N
in IN N
infantile JJ 4_p
autism NN 4_p
Cross-over JJ N
effects NNS N
of IN N
a DT N
dopamine JJ N
agonist NN N
and CC N
an DT N
antagonist JJ N
] NN N
In IN N
infantile JJ 4_p
autism NN 4_p
, , N
the DT N
serotoninergic NN N
( ( N
5-HT JJ N
) ) N
hypothesis NN N
is VBZ N
corroborated VBN N
by IN N
biological JJ N
dosages NNS N
and CC N
therapeutic JJ N
effects NNS N
of IN N
fenfluramine NN N
which WDT N
decrease NN N
blood NN N
serotonin NN N
However RB N
other JJ N
drugs NNS N
, , N
such JJ N
as IN N
dopaminergic JJ N
agonists NNS N
or CC N
antagonists NNS N
, , N
have VBP N
therapeutic JJ N
effects NNS N
Therefore RB N
, , N
we PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
two CD N
dopaminergic NN N
( ( N
DA NNP N
) ) N
drugs NNS N
have VBP N
a DT N
similar JJ N
5-HT JJ N
effect NN N
underlying VBG N
the DT N
therapeutic JJ N
efficiency NN N
We PRP N
evaluated VBD N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
and CC N
cross-over JJ N
study NN N
, , N
the DT N
effects NNS N
of IN N
a DT N
DA NNP N
agonist NN N
( ( N
bromocriptine NN N
) ) N
and CC N
a DT N
DA NNP N
antagonist NN N
( ( N
amisulpride RB N
) ) N
on IN N
platelet NN N
5-HT JJ N
in IN N
infantile JJ 4_p
autism NN 4_p
The DT N
prolactinemia NN N
, , N
reflecting VBG N
the DT N
DA NNP N
action NN N
, , N
has VBZ N
been VBN N
also RB N
measured VBN N
Nine NNP 3_p
children NNS 1_p
, , N
aged VBN N
from IN N
4 CD 1_p
to TO 1_p
13 CD 1_p
years NNS N
, , N
according VBG N
to TO N
the DT N
DSM NNP N
III NNP N
for IN N
infantile JJ 4_p
autism NN 4_p
, , N
received VBD N
either DT N
drug NN N
in IN N
a DT N
random JJ N
order NN N
during IN N
four CD N
weeks NNS N
with IN N
an DT N
in-between JJ N
placebo NN N
period NN N
of IN N
six CD N
weeks NNS N
The DT N
dosages NNS N
of IN N
platelet NN N
5-HT JJ N
and CC N
serum JJ N
prolactin NN N
were VBD N
carried VBN N
out RP N
at IN N
the DT N
beginning NN N
and CC N
at IN N
the DT N
end NN N
of IN N
every DT N
phase NN N
of IN N
treatment NN N
( ( N
active JJ N
or CC N
placebo NN N
) ) N
with IN N
radioenzymology NN N
and CC N
radioimmunoassay VB N
methods NNS N
respectively RB N
The DT N
principal JJ N
results NNS N
on IN N
serum JJ N
prolactin NN N
show NN N
neither DT N
order NN N
x NNP N
treatment NN N
interaction NN N
, , N
nor CC N
order NN N
effect NN N
but CC N
a DT N
significant JJ N
treatment NN N
effect NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
: : N
amisulpride NN N
increases VBZ N
serum JJ N
prolactin NN N
whereas NNS N
bromocriptine VBP N
decreases VBZ N
according VBG N
to TO N
the DT N
usual JJ N
data NN N
About IN N
platelet NN N
5-HT JJ N
, , N
there EX N
is VBZ N
neither DT N
order NN N
x NNP N
treatment NN N
interaction NN N
, , N
nor CC N
treatment NN N
effect NN N
but CC N
a DT N
significant JJ N
order NN N
effect NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
Both DT N
drugs NNS N
increase VBP N
platelet NN N
5-HT JJ N
in IN N
the DT N
first JJ N
phase NN N
of IN N
treatment NN N
This DT N
order NN N
effect NN N
could MD N
be VB N
explained VBN N
by IN N
a DT N
remanent JJ N
effect NN N
of IN N
amisulpride NN N
after IN N
6 CD N
wash-out JJ N
weeks NNS N
( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 20338811

CD4+FOXP3+ NNP N
regulatory JJ N
T NNP N
cell NN N
depletion NN N
by IN N
low-dose JJ N
cyclophosphamide NN N
prevents NNS N
recurrence NN N
in IN N
patients NNS N
with IN N
large JJ N
condylomata NNS N
acuminata NNS N
after IN N
laser NN N
therapy NN N
Condylomata NNP N
acuminata NN N
( ( N
CA NNP N
) ) N
caused VBN N
by IN N
human JJ N
papillomavirus NN N
( ( N
HPV NNP N
) ) N
is VBZ N
a DT N
common JJ N
sexually RB N
transmitted JJ N
disease NN N
with IN N
half PDT N
a DT N
million CD N
new JJ N
cases NNS N
diagnosed VBN N
in IN N
the DT N
United NNP N
States NNPS N
per IN N
year NN N
and CC N
the DT N
annual JJ N
increase NN N
in IN N
incidence NN N
in IN N
China NNP N
Recurrence NNP N
is VBZ N
a DT N
major JJ N
challenge NN N
for IN N
CA NNP N
treatment NN N
Recently RB N
, , N
we PRP N
demonstrated VBD N
that IN N
FOXP3 NNP N
( ( N
+ NNP N
) ) N
regulatory JJ N
T NNP N
( ( N
Treg NNP N
) ) N
cells NNS N
mediate VBP N
the DT N
immunosuppression NN N
in IN N
large JJ N
genital JJ N
warts NNS N
Here RB N
, , N
we PRP N
further VBP N
report VB N
that IN N
low-dose JJ N
cyclophosphamide NN N
( ( N
CY NNP N
) ) N
, , N
a DT N
conventional JJ N
chemotherapy JJ N
drug NN N
, , N
can MD N
effectively RB N
prevent VB N
the DT N
recurrence NN N
of IN N
large JJ N
CA NNP N
in IN N
clinical JJ N
patients NNS N
after IN N
laser NN N
therapy NN N
Surprisingly RB N
, , N
although IN N
9 CD N
out IN N
of IN N
52 CD 3_p
patients NNS N
recur JJ N
six CD N
weeks NNS N
after IN N
the DT N
combination NN N
treatment NN N
, , N
the DT N
re-administration NN N
of IN N
low-dose JJ N
CY NNP N
alone RB N
completely RB N
eliminates VBZ N
most JJS N
recurred JJ N
lesions NNS N
We PRP N
provide VBP N
evidence NN N
that IN N
low-dose JJ N
CY NNP N
not RB N
only RB N
depletes VBZ N
patients NNS N
' POS N
Treg NNP N
cells NNS N
and CC N
enhances NNS N
function NN N
of IN N
HPV-specific NNP N
T NNP N
cells NNS N
and CC N
NK NNP N
cells NNS N
in IN N
the DT N
periphery NN N
, , N
but CC N
also RB N
ameliorates VBZ N
the DT N
immune JJ N
milieu NN N
of IN N
the DT N
lesion NN N
site NN N
, , N
leading VBG N
to TO N
the DT N
elimination NN N
of IN N
remnant JJ N
viruses NNS N
These DT N
findings NNS N
have VBP N
important JJ N
clinical JJ N
significance NN N
, , N
and CC N
potentially RB N
lead JJ N
to TO N
a DT N
therapeutic JJ N
breakthrough NN N
for IN N
the DT N
treatment NN N
of IN N
CA NNP N
-DOCSTART- -X- O O 7955250

Late JJ N
hemodynamic JJ N
effects NNS N
of IN N
the DT N
preserved JJ N
papillary JJ N
muscles NNS N
during IN N
mitral JJ 4_p
valve FW 4_p
replacement NN 4_p
BACKGROUND VB N
The DT N
late JJ N
hemodynamic JJ N
effects NNS N
of IN N
preserving VBG N
the DT N
papillary JJ N
muscles NNS N
during IN N
mitral JJ N
valve FW N
replacement NN N
have VBP N
not RB N
been VBN N
evaluated VBN N
METHODS NNP N
AND CC N
RESULTS NNP N
Sixteen NNP 3_p
patients NNS N
who WP N
had VBD N
chronic JJ 4_p
mitral JJ 4_p
regurgitation NN 4_p
due JJ 4_p
to TO 4_p
myxomatous JJ 4_p
degeneration NN 4_p
were VBD N
randomized VBN N
to TO N
preservation NN 4_p
( ( N
Pres NNP N
group NN N
, , N
n RB N
= VBZ N
8 CD 3_p
) ) N
or CC N
no DT 4_p
preservation NN 4_p
( ( N
No NNP N
Pres NNP N
group NN N
, , N
n RB N
= VBZ N
8 CD 3_p
) ) N
of IN N
the DT N
chordae NN N
tendineae NN N
and CC N
papillary JJ N
muscles NNS N
during IN N
mitral JJ N
valve FW N
replacement NN N
Rest NNP N
and CC N
exercise NN N
nuclear JJ N
ventriculograms NNS N
were VBD N
performed VBN N
early RB N
( ( N
3 CD N
months NNS N
) ) N
and CC N
late JJ N
( ( N
5 CD N
years NNS N
) ) N
after IN N
surgery NN N
Early RB N
after IN N
surgery NN N
, , N
the DT N
No NNP N
Pres NNP N
group NN N
had VBD N
lower JJR N
ejection NN N
fractions NNS N
and CC N
stroke VBD N
work NN N
indexes NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
by IN N
repeated-measures NNS N
[ NNP N
rm NN N
] NNP N
ANOVA NNP N
) ) N
than IN N
the DT N
Pres NNP N
group NN N
did VBD N
at IN N
similar JJ N
end-diastolic JJ N
volume NN N
indexes NNS N
The DT N
No NNP N
Pres NNP N
group NN N
had VBD N
similar JJ N
cardiac NN N
indexes NNS N
after IN N
exercise NN N
because IN N
heart NN N
rate NN N
increased VBD N
( ( N
P NNP N
< NNP N
.005 NNP N
by IN N
rm NN N
ANOVA NNP N
) ) N
Late JJ N
after IN N
surgery NN N
, , N
ejection NN N
fraction NN N
was VBD N
greater JJR N
at IN N
similar JJ N
end-diastolic JJ N
volume NN N
indexes NNS N
( ( N
P NNP N
< NNP N
.005 NNP N
by IN N
rm NN N
ANCOVA NNP N
) ) N
, , N
and CC N
preload NN N
recruitable JJ N
stroke NN N
work NN N
indexes NNS N
( ( N
P NNP N
< NNP N
.001 NNP N
by IN N
rm NN N
ANCOVA NNP N
) ) N
were VBD N
better RBR N
in IN N
the DT N
Pres NNP N
group NN N
CONCLUSIONS NNP N
Preserving VBG N
chordal JJ N
attachments NNS N
enhanced VBD N
the DT N
late JJ N
hemodynamic JJ N
recovery NN N
after IN N
mitral JJ N
valve FW N
replacement NN N
for IN N
mitral JJ N
regurgitation NN N
-DOCSTART- -X- O O 11472320

There EX N
are VBP N
some DT N
benefits NNS N
for IN N
eradicating VBG N
Helicobacter NNP N
pylori NN N
in IN N
patients NNS N
with IN N
non-ulcer JJ 4_p
dyspepsia NN 4_p
BACKGROUND IN N
The DT N
relationship NN N
between IN N
Helicobacter NNP N
pylori CC N
infection NN N
and CC N
non-ulcer JJ N
dyspepsia NN N
is VBZ N
not RB N
established VBN N
AIM NNP N
To TO N
determine VB N
whether IN N
eradication NN N
of IN N
H. NNP N
pylori NN N
might MD N
be VB N
of IN N
benefit NN N
in IN N
non-ulcer JJ 4_p
dyspepsia NN 4_p
patients NNS N
METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
129 CD 3_p
H. NNP N
pylori NN 4_p
infected VBD 4_p
patients NNS N
with IN N
severe JJ 4_p
epigastric JJ 4_p
pain NN 4_p
, , N
without IN 4_p
gastro-oesophageal JJ 4_p
reflux NN 4_p
symptoms NNS N
, , N
to TO N
receive VB N
twice RB N
daily JJ N
treatment NN N
with IN N
300 CD N
mg NNS N
of IN N
ranitidine NN N
, , N
1000 CD N
mg NN N
of IN N
amoxicillin NN N
, , N
and CC N
500 CD N
mg NN N
of IN N
clarithromycin NN N
for IN N
7 CD N
days NNS N
and CC N
124 CD 3_p
such JJ N
patients NNS N
to TO N
receive VB N
identical-appearing JJ N
placebos NNS N
RESULTS NNP N
Treatment NNP N
was VBD N
successful JJ N
( ( N
decrease NN N
of IN N
symptoms NNS N
at IN N
12 CD N
months NNS N
) ) N
in IN N
62 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
active-treatment JJ N
group NN N
and CC N
in IN N
60 CD N
% NN N
of IN N
the DT N
placebo NN N
group NN N
( ( N
N.S. NNP N
) ) N
At IN N
12 CD N
months NNS N
, , N
the DT N
rate NN N
of IN N
eradication NN N
of IN N
H. NNP N
pylori NN N
was VBD N
69 CD N
% NN N
in IN N
the DT N
active-treatment JJ N
group NN N
and CC N
18 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
Complete JJ N
relief NN N
of IN N
symptoms NNS N
occurred VBD N
significantly RB N
more RBR N
frequently RB N
in IN N
patients NNS N
on IN N
the DT N
active JJ N
treatment NN N
( ( N
43 CD N
% NN N
) ) N
than IN N
in IN N
placebo-treated JJ N
patients NNS N
( ( N
31 CD N
% NN N
, , N
P=0.048 NNP N
) ) N
Within IN N
the DT N
active-treatment JJ N
group NN N
, , N
therapeutic JJ N
success NN N
was VBD N
significantly RB N
more RBR N
frequent JJ N
in IN N
the DT N
non-infected JJ 4_p
patients NNS N
( ( N
84 CD N
% NN N
vs. FW N
64 CD N
% NN N
, , N
P=0.04 NNP N
) ) N
CONCLUSIONS NNP N
Although IN N
eradicating VBG N
H. NNP N
pylori NN N
is VBZ N
not RB N
likely JJ N
to TO N
relieve VB N
symptoms NNS N
in IN N
the DT N
majority NN N
of IN N
patients NNS N
with IN N
non-ulcer JJ 4_p
dyspepsia NN 4_p
, , N
a DT N
small JJ N
proportion NN N
of IN N
H. NNP N
pylori-infected JJ 4_p
patients NNS N
may MD N
benefit VB N
from IN N
eradication NN N
treatment NN N
-DOCSTART- -X- O O 8215273

Cefprozil NNP N
versus NN N
penicillin NN N
V NNP N
in IN N
treatment NN N
of IN N
streptococcal JJ 4_p
tonsillopharyngitis NN 4_p
In IN N
a DT N
randomized JJ N
multicenter NN N
study NN N
, , N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
cefprozil NN N
were VBD N
compared VBN N
with IN N
those DT N
of IN N
penicillin NN N
in IN N
the DT N
treatment NN N
of IN N
group NN N
A NNP N
streptococcal JJ N
tonsillopharyngitis NN N
in IN N
children NNS N
Of IN N
the DT N
409 CD 3_p
patients NNS N
enrolled VBD N
, , N
323 CD 3_p
were VBD N
evaluable JJ N
for IN N
their PRP$ N
clinical JJ N
and CC N
bacteriological JJ N
responses NNS N
; : N
of IN N
these DT N
323 CD 3_p
children NNS N
, , N
172 CD N
received VBD N
cefprozil NN N
and CC N
151 CD N
received VBD N
penicillin NN N
V. NNP N
The DT N
clinical JJ N
responses NNS N
in IN N
patients NNS N
treated VBN N
with IN N
cefprozil NNS N
were VBD N
significantly RB N
better JJR N
than IN N
those DT N
in IN N
patients NNS N
who WP N
received VBD N
penicillin NN N
( ( N
95.3 CD N
versus RB N
88.1 CD N
% NN N
; : N
P NNP N
= NNP N
0.023 CD N
) ) N
Eradication NN N
of IN N
the DT N
original JJ N
serotype NN N
of IN N
group NN N
A NNP N
streptococci NN N
was VBD N
achieved VBN N
in IN N
91.3 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
cefprozil NN N
and CC N
87.4 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
penicillin NN N
, , N
the DT N
difference NN N
not RB N
being VBG N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
0.125 CD N
) ) N
However RB N
, , N
there EX N
were VBD N
significantly RB N
more RBR N
symptomatic JJ N
patients NNS N
among IN N
the DT N
bacteriological JJ N
failures NNS N
in IN N
the DT N
penicillin NN N
group NN N
( ( N
68.4 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
cefprozil NN N
group NN N
( ( N
26.7 CD N
% NN N
) ) N
beta-Lactamase-producing JJ N
Staphylococcus NNP N
aureus NN N
was VBD N
more RBR N
frequently RB N
isolated VBN N
from IN N
the DT N
throat NN N
flora NN N
during IN N
penicillin NN N
therapy NN N
than IN N
during IN N
cefprozil JJ N
treatment NN N
No DT N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
adverse JJ N
events NNS N
probably RB N
related VBD N
or CC N
of IN N
unknown JJ N
relationship NN N
to TO N
the DT N
study NN N
drugs NNS N
was VBD N
observed VBN N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
( ( N
5.2 CD N
% NN N
of IN N
those DT N
treated VBN N
with IN N
cefprozil NN N
and CC N
6.0 CD N
% NN N
of IN N
those DT N
treated VBN N
with IN N
penicillin NN N
) ) N
Cefprozil NNP N
can MD N
be VB N
considered VBN N
a DT N
safe JJ N
and CC N
reliable JJ N
drug NN N
for IN N
the DT N
treatment NN N
of IN N
streptococcal JJ 4_p
pharyngitis NN 4_p
in IN N
children NNS N
-DOCSTART- -X- O O 21949005

Learning VBG N
through IN N
interaction NN N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
: : N
preliminary JJ N
data NNS N
from IN N
asocial-communication-based JJ N
intervention NN N
The DT N
study NN N
evaluates VBZ N
a DT N
social-communication-based JJ N
approach NN N
to TO N
autism VB N
intervention NN N
aimed VBN N
at IN N
improving VBG N
the DT N
social JJ N
interaction NN N
skills NNS N
of IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
We PRP N
report VBP N
preliminary JJ N
results NNS N
from IN N
an DT N
ongoing JJ N
randomized NN N
controlled VBD N
trial NN N
of IN N
51 CD 3_p
children NNS 1_p
aged VBN 1_p
2 CD 1_p
years NNS 1_p
0 CD 1_p
months NNS 1_p
to TO 1_p
4 CD 1_p
years NNS 1_p
11 CD 1_p
months NNS 1_p
Participants NNS N
were VBD N
assigned VBN N
to TO N
either VB N
a DT N
target NN N
treatment NN N
or CC N
community NN N
treatment NN N
group NN N
Families NNS N
in IN N
the DT N
target NN N
treatment NN N
group NN N
were VBD N
given VBN N
2 CD N
hours NNS N
of IN N
therapy NN N
and CC N
coaching VBG N
each DT N
week NN N
in IN N
an DT N
intervention NN N
emphasizing VBG N
social-interaction NN N
and CC N
the DT N
parent-child JJ N
relationship NN N
Children NNP N
in IN N
the DT N
community NN N
treatment NN N
group NN N
received VBD N
a DT N
variety NN N
of IN N
services NNS N
averaging VBG N
3.9 CD N
hours NNS N
per IN N
week NN N
After IN N
12 CD N
months NNS N
, , N
outcomes NNS N
were VBD N
measured VBN N
to TO N
determine VB N
changes NNS N
in IN N
the DT N
groups NNS N
in IN N
social JJ N
interaction NN N
and CC N
communication NN N
In IN N
addition NN N
, , N
a DT N
regression NN N
analysis NN N
was VBD N
conducted VBN N
to TO N
determine VB N
whether IN N
changes NNS N
in IN N
social JJ N
interaction NN N
skills NNS N
were VBD N
associated VBN N
with IN N
language NN N
development NN N
Results NNS N
suggest VBP N
that IN N
children NNS N
in IN N
the DT N
treatment NN N
group NN N
made VBD N
significantly RB N
greater JJR N
gains NNS N
in IN N
social JJ N
interaction NN N
skills NNS N
in IN N
comparison NN N
to TO N
the DT N
community NN N
treatment NN N
group NN N
, , N
but CC N
no DT N
between-group JJ N
differences NNS N
were VBD N
found VBN N
for IN N
standard JJ N
language NN N
assessments NNS N
Initiation NN N
of IN N
joint JJ N
attention NN N
, , N
involvement NN N
, , N
and CC N
severity NN N
of IN N
language NN N
delay NN N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
associated VBN N
with IN N
improvement NN N
of IN N
language NN N
skills NNS N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
Finally RB N
caregiver JJ N
skills NNS N
targeted VBN N
by IN N
the DT N
intervention NN N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
associated VBN N
with IN N
changes NNS N
in IN N
children NNS 1_p
's POS 1_p
interaction NN N
skills NNS N
-DOCSTART- -X- O O 23980091

Gefitinib NNP N
versus NN N
placebo NN N
in IN N
completely RB N
resected VBN N
non-small-cell JJ N
lung NN N
cancer NN N
: : N
results NNS N
of IN N
the DT N
NCIC NNP N
CTG NNP N
BR19 NNP N
study NN N
PURPOSE NNP N
Survival NNP N
of IN N
patients NNS N
with IN N
completely RB 4_p
resected VBN 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
( ( 4_p
NSCLC NNP 4_p
) ) 4_p
is VBZ N
unsatisfactory JJ N
, , N
and CC N
in IN N
2002 CD N
, , N
the DT N
benefit NN N
of IN N
adjuvant JJ N
chemotherapy NN N
was VBD N
not RB N
established VBN N
This DT N
phase NN N
III NNP N
study NN N
assessed VBD N
the DT N
impact NN N
of IN N
postoperative JJ N
adjuvant JJ N
gefitinib NN N
on IN N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
with IN N
completely RB N
resected VBN N
( ( N
stage NN N
IB NNP N
, , N
II NNP N
, , N
or CC N
IIIA NNP N
) ) N
NSCLC NNP N
stratified VBN N
by IN N
stage NN N
, , N
histology NN N
, , N
sex NN N
, , N
postoperative JJ N
radiotherapy NN N
, , N
and CC N
chemotherapy NN N
were VBD N
randomly RB N
assigned VBN N
( ( N
1:1 CD N
) ) N
to TO N
receive VB N
gefitinib NN N
250 CD N
mg NN N
per IN N
day NN N
or CC N
placebo NN N
for IN N
2 CD N
years NNS N
Study NNP N
end VBP N
points NNS N
were VBD N
OS NNP N
, , N
disease-free JJ N
survival NN N
( ( N
DFS NNP N
) ) N
, , N
and CC N
toxicity NN N
RESULTS NNP N
As IN N
a DT N
result NN N
of IN N
early JJ N
closure NN N
, , N
503 CD 3_p
of IN 3_p
1,242 CD 3_p
planned JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
( ( N
251 CD N
to TO N
gefitinib VB N
and CC N
252 CD N
to TO N
placebo VB N
) ) N
Baseline JJ N
factors NNS N
were VBD N
balanced VBN N
between IN N
the DT N
arms NNS N
With IN N
a DT N
median NN N
of IN N
4.7 CD N
years NNS N
of IN N
follow-up NN N
( ( N
range NN N
, , N
0.1 CD N
to TO N
6.3 CD N
years NNS N
) ) N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
OS NNP N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
1.24 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.94 CD N
to TO N
1.64 CD N
; : N
P NNP N
= NNP N
.14 NNP N
) ) N
or CC N
DFS NNP N
( ( N
HR NNP N
, , N
1.22 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.93 CD N
to TO N
1.61 CD N
; : N
P NNP N
= NNP N
.15 NNP N
) ) N
between IN N
the DT N
arms NNS N
Exploratory JJ N
analyses NNS N
demonstrated VBD N
no DT N
DFS NNP N
( ( N
HR NNP N
, , N
1.28 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.92 CD N
to TO N
1.76 CD N
; : N
P NNP N
= NNP N
.14 NNP N
) ) N
or CC N
OS NNP N
benefit NN N
( ( N
HR NNP N
, , N
1.24 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.90 CD N
to TO N
1.71 CD N
; : N
P NNP N
= NNP N
.18 NNP N
) ) N
from IN N
gefitinib NN N
for IN N
344 CD 3_p
patients NNS 3_p
with IN N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
( ( N
EGFR NNP N
) ) N
wild-type NN N
tumors NNS N
Similarly RB N
, , N
there EX N
was VBD N
no DT N
DFS NNP N
( ( N
HR NNP N
, , N
1.84 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.44 CD N
to TO N
7.73 CD N
; : N
P NNP N
= NNP N
.395 NNP N
) ) N
or CC N
OS NNP N
benefit NN N
( ( N
HR NNP N
, , N
3.16 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.61 CD N
to TO N
16.45 CD N
; : N
P NNP N
= NNP N
.15 NNP N
) ) N
from IN N
gefitinib NN N
for IN N
the DT N
15 CD N
patients NNS N
with IN N
EGFR NNP N
mutation-positive JJ N
tumors NNS N
Adverse JJ N
events NNS N
were VBD N
those DT N
expected VBN N
with IN N
an DT N
EGFR NNP N
inhibitor NN N
Serious JJ N
adverse JJ N
events NNS N
occurred VBD N
in IN N
≤ NNP N
5 CD N
% NN N
of IN N
patients NNS N
, , N
except IN N
infection NN N
, , N
fatigue NN N
, , N
and CC N
pain NN N
One CD N
patient NN N
in IN N
each DT N
arm NN N
had VBD N
fatal JJ N
pneumonitis NN N
CONCLUSION NNP N
Although IN N
the DT N
trial NN N
closed VBD N
prematurely RB N
and CC N
definitive JJ N
statements NNS N
regarding VBG N
the DT N
efficacy NN N
of IN N
adjuvant JJ N
gefitinib NN N
can MD N
not RB N
be VB N
made VBN N
, , N
these DT N
results NNS N
indicate VBP N
that IN N
it PRP N
is VBZ N
unlikely JJ N
to TO N
be VB N
of IN N
benefit NN N
-DOCSTART- -X- O O 15165532

Mouth NNP N
closing NN N
device NN N
( ( N
chinstrap NN N
) ) N
reduces VBZ N
mouth JJ N
leak NN N
during IN N
nasal JJ N
CPAP NNP N
BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Mouth NNP N
leak VBP N
occasionally RB N
complicates VBZ N
continuous JJ N
positive JJ N
airway NN N
pressure NN N
( ( N
CPAP NNP N
) ) N
therapy NN N
, , N
which WDT N
leads VBZ N
to TO N
discomfort VB N
While IN N
a DT N
chinstrap NN N
prevents VBZ N
the DT N
mouth NN N
from IN N
opening VBG N
during IN N
sleep NN N
, , N
its PRP$ N
efficacy NN N
in IN N
diminishing VBG N
mouth NN N
leak NN N
has VBZ N
not RB N
been VBN N
studied VBN N
PATIENTS NNP N
AND CC N
METHODS NNP N
Fifteen NNP N
patients NNS N
with IN N
mouth JJ N
leak JJ N
complaining NN N
of IN N
mouth NN N
dryness NN N
and CC N
nasal JJ N
obstruction NN N
underwent JJ N
two CD N
consecutive JJ N
overnight JJ N
polysomnographies NNS N
, , N
one CD N
with IN N
a DT N
chinstrap NN N
, , N
in IN N
random JJ N
order NN N
Cephalometry NN N
with IN N
and CC N
without IN N
a DT N
chinstrap NN N
was VBD N
randomly RB N
performed VBN N
on IN N
six CD N
patients NNS N
RESULTS NNP N
With IN N
the DT N
chinstrap NN N
, , N
both DT N
mouth FW N
leak NN N
and CC N
the DT N
arousal NN N
index NN N
decreased VBD N
significantly RB N
, , N
from IN N
( ( N
mean+/-SD JJ N
) ) N
42.9+/-23.5 CD N
to TO N
23.8+/-13.3 CD N
% NN N
of IN N
total JJ N
sleep JJ N
time NN N
( ( N
TST NNP N
) ) N
, , N
and CC N
from IN N
33.4+/-18.6 JJ N
to TO N
23.6+/-9.3/sleep JJ N
hour NN N
, , N
respectively RB N
However RB N
, , N
snoring VBG N
time NN N
showed VBD N
a DT N
concomitant JJ N
increase NN N
from IN N
6.7+/-14.3 JJ N
to TO N
24.0+/-13.2 CD N
% NN N
of IN N
TST NNP N
The DT N
arousal JJ N
index NN N
was VBD N
significantly RB N
higher JJR N
during IN N
leak JJR N
periods NNS N
, , N
and CC N
its PRP$ N
changes NNS N
correlated VBN N
positively RB N
with IN N
changes NNS N
in IN N
mouth NN N
leak NN N
Cephalometric JJ N
measures NNS N
showed VBD N
a DT N
significant JJ N
decrease NN N
in IN N
anterior JJ N
lower JJR N
facial JJ N
height NN N
CONCLUSIONS VB N
The DT N
chinstrap NN N
, , N
by IN N
closing VBG N
the DT N
mouth NN N
during IN N
CPAP NNP N
, , N
reduces VBZ N
mouth JJ N
leak NN N
and CC N
therefore RB N
the DT N
arousal NN N
index NN N
in IN N
most JJS N
patients NNS N
Nevertheless NNP N
, , N
the DT N
indices NNS N
remained VBD N
unacceptably RB N
high JJ N
The DT N
chinstrap NN N
may MD N
also RB N
increase VB N
snoring NN N
and CC N
, , N
in IN N
rare JJ N
cases NNS N
, , N
can MD N
worsen VB N
the DT N
respiratory NN N
disturbance NN N
index NN N
Consideration NN N
of IN N
these DT N
potential JJ N
effects NNS N
is VBZ N
important JJ N
before IN N
instituting VBG N
regular JJ N
home NN N
use NN N
of IN N
the DT N
chinstrap NN N
-DOCSTART- -X- O O 16492716

Perceptual JJ N
wind-up NN N
in IN N
the DT N
human JJ 4_p
oesophagus NN 4_p
is VBZ N
enhanced VBN N
by IN N
central JJ N
sensitisation NN N
BACKGROUND NNP N
Oesophageal NNP N
acid JJ N
infusion NN N
induces NNS N
enhanced VBD N
pain NN N
hypersensitivity NN N
in IN N
non-acid JJ N
exposed JJ N
upper JJ N
oesophagus NN N
( ( N
secondary JJ N
hyperalgesia NN N
) ) N
in IN N
patients NNS N
with IN N
non-cardiac JJ N
chest NN N
pain NN N
, , N
thus RB N
suggesting VBG N
central JJ N
sensitisation NN N
contributes NNS N
to TO N
visceral JJ N
pain NN N
hypersensitivity NN N
in IN N
functional JJ N
gut NN N
disorders NNS N
( ( N
FGD NNP N
) ) N
Perceptual JJ N
wind-up JJ N
( ( N
increased JJ N
pain NN N
perception NN N
to TO N
constant JJ N
intensity NN N
sensory NN N
stimuli NN N
at IN N
frequencies NNS N
> VBP N
or=0.3 JJ N
Hz NNP N
) ) N
is VBZ N
used VBN N
as IN N
a DT N
proxy NN N
for IN N
central JJ N
sensitisation NN N
to TO N
investigate VB N
pain NN N
syndromes NNS N
where WRB N
pain NN N
hypersensitivity NN N
is VBZ N
important JJ N
( ( N
for IN N
example NN N
, , N
fibromyalgia NN N
) ) N
AIMS $ N
Wind-up JJ N
in IN N
central JJ N
sensitisation NN N
induced VBD N
human JJ N
visceral JJ N
pain NN N
hypersensitivity NN N
has VBZ N
not RB N
been VBN N
explored VBN N
We PRP N
hypothesised VBD N
that IN N
if IN N
wind-up NN N
is VBZ N
a DT N
proxy NN N
for IN N
central JJ N
sensitisation NN N
induced VBD N
human JJ N
visceral JJ N
pain NN N
hypersensitivity NN N
, , N
then RB N
oesophageal JJ N
wind-up NN N
should MD N
be VB N
enhanced VBN N
by IN N
secondary JJ N
hyperalgesia NN N
METHODS NNP N
In IN N
eight CD 3_p
healthy JJ 4_p
volunteers NNS N
( ( N
seven CD 3_p
males NNS 2_p
; : N
mean JJ 1_p
age NN 1_p
32 CD 1_p
years NNS 1_p
) ) N
, , N
perception NN N
at IN N
pain NN N
threshold NN N
to TO N
a DT N
train NN N
of IN N
20 CD N
electrical JJ N
stimuli NNS N
applied VBN N
to TO N
the DT N
hand NN N
and CC N
upper JJ N
oesophagus NN N
( ( N
UO NNP N
) ) N
at IN N
either DT N
0.1 CD N
Hz NNP N
( ( N
control NN N
) ) N
or CC N
2 CD N
Hz NNP N
was VBD N
determined VBN N
before IN N
and CC N
one CD N
hour NN N
after IN N
a DT N
30 CD N
minute NN N
lower JJR N
oesophageal NN N
acid JJ N
infusion NN N
RESULTS NNP N
Wind-up JJ N
occurred VBD N
only RB N
with IN N
the DT N
2 CD N
Hz NNP N
train NN N
in IN N
the DT N
UO NNP N
and CC N
hand NN N
( ( N
both DT N
p=0.01 NN N
) ) N
Following VBG N
acid JJ N
infusion NN N
, , N
pain VBP N
threshold JJ N
decreased VBN N
( ( N
17 CD N
( ( N
4 CD N
) ) N
% NN N
; : N
p=0.01 NN N
) ) N
in IN N
the DT N
UO NNP N
, , N
suggesting VBG N
the DT N
presence NN N
of IN N
secondary JJ N
hyperalgesia NN N
Wind-up UH N
to TO N
the DT N
2 CD N
Hz NNP N
train NN N
increased VBD N
in IN N
the DT N
UO NNP N
( ( N
wind-up JJ N
ratio NN N
1.4 CD N
( ( N
0.1 CD N
) ) N
to TO N
1.6 CD N
( ( N
0.1 CD N
) ) N
; : N
p=0.03 NN N
) ) N
but CC N
not RB N
in IN N
the DT N
hand NN N
( ( N
wind-up JJ N
ratio NN N
1.3 CD N
( ( N
0.1 CD N
) ) N
and CC N
1.3 CD N
( ( N
0.1 CD N
) ) N
; : N
p=0.3 NN N
) ) N
CONCLUSION NNP N
Enhanced NNP N
wind-up NN N
after IN N
secondary JJ N
oesophageal NN N
hyperalgesia NN N
suggests VBZ N
that IN N
visceral JJ N
pain NN N
hypersensitivity NN N
induced VBN N
by IN N
central JJ N
sensitisation NN N
results NNS N
from IN N
increased JJ N
central JJ N
neuronal JJ N
excitability NN N
Wind-up JJ N
may MD N
offer VB N
new JJ N
opportunities NNS N
to TO N
investigate VB N
the DT N
contribution NN N
of IN N
central JJ N
neuronal JJ N
changes NNS N
to TO N
symptoms NNS N
in IN N
FGD NNP N
-DOCSTART- -X- O O 23280086

Treatment NN N
of IN N
adults NNS 1_p
with IN N
acute JJ 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
: : N
do VB N
the DT N
specifics NNS N
of IN N
the DT N
regimen NNS N
matter NN N
? . N
: : N
Results NNS N
from IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
BACKGROUND NNP N
Induction NNP N
therapy NN N
for IN N
adults NNS N
with IN N
acute JJ N
lymphoblastic JJ N
leukemia NN N
( ( N
ALL DT N
) ) N
is VBZ N
similar JJ N
across IN N
essentially RB N
all DT N
regimens NNS N
, , N
comprised VBN N
of IN N
vincristine NN N
, , N
corticosteroids NNS N
, , N
and CC N
anthracyclines NNS N
intensified VBN N
with IN N
cyclophosphamide NN N
, , N
asparaginase NN N
, , N
or CC N
both DT N
Given VBN N
the DT N
lack NN N
of IN N
randomized VBN N
data NNS N
, , N
to TO N
date NN N
, , N
no DT N
regimen NN N
has VBZ N
emerged VBN N
as IN N
standard NN N
The DT N
authors NNS N
previously RB N
evaluated VBD N
cytarabine JJ N
3 CD N
g/m NN N
( ( N
2 CD N
) ) N
daily RB N
for IN N
5 CD N
days NNS N
with IN N
mitoxantrone NN N
80 CD N
mg/m NN N
( ( N
2 CD N
) ) N
( ( N
the DT N
ALL-2 NNP N
regimen NNS N
) ) N
as IN N
a DT N
novel JJ N
induction NN N
regimen NNS N
Compared VBN N
with IN N
historic JJ N
controls NNS N
, , N
the DT N
ALL-2 NNP N
regimen NN N
was VBD N
superior JJ N
in IN N
terms NNS N
of IN N
incidence NN N
of IN N
complete JJ N
remission NN N
, , N
failure NN N
with IN N
resistant JJ N
disease NN N
, , N
and CC N
activity NN N
in IN N
patients NNS N
with IN N
Philadelphia NNP N
chromosome NN N
( ( N
Ph NNP N
) ) N
-positive VBP N
ALL NNP N
METHODS NNP N
The DT N
authors NNS N
conducted VBD N
a DT N
multicenter NN N
, , N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
the DT N
ALL-2 NNP N
regimen NNS N
compared VBN N
with IN N
a DT N
standard JJ N
4-drug JJ N
induction NN N
( ( N
the DT N
L-20 NNP N
regimen NNS N
) ) N
Patients NNS N
also RB N
received VBD N
consolidation NN N
, , N
maintenance NN N
therapy NN N
, , N
and CC N
central JJ N
nervous JJ N
system NN N
prophylaxis NN N
The DT N
trial NN N
accrued VBD N
patients NNS N
from IN N
August NNP N
1996 CD N
to TO N
October NNP N
2004 CD N
RESULTS VB N
The DT N
median JJ N
follow-up NN N
for IN N
survivors NNS N
was VBD N
7 CD N
years NNS N
, , N
and CC N
the DT N
median JJ 1_p
patient NN 1_p
age NN 1_p
was VBD 1_p
43 CD 1_p
years NNS 1_p
Responses NNS N
were VBD N
evaluated VBN N
in IN N
164 CD 3_p
patients NNS N
The DT N
treatment NN N
arms NNS N
were VBD N
balanced VBN N
in IN N
terms NNS N
of IN N
pretreatment NN N
characteristics NNS N
The DT N
frequency NN N
of IN N
complete JJ N
remission NN N
for IN N
the DT N
ALL-2 NNP N
regimen NNS N
versus IN N
the DT N
L-20 JJ N
regimen NN N
was VBD N
83 CD N
% NN N
versus IN N
71 CD N
% NN N
( ( N
P NNP N
= NNP N
.06 NNP N
) ) N
More JJR N
patients NNS N
on IN N
the DT N
L-20 NNP N
arm NN N
failed VBD N
with IN N
resistant JJ N
disease NN N
( ( N
21 CD N
% NN N
vs JJ N
8 CD N
% NN N
; : N
P NNP N
= NNP N
.02 NNP N
) ) N
Induction NNP N
deaths NNS N
were VBD N
comparable JJ N
at IN N
9 CD N
% NN N
( ( N
ALL-2 NNP N
) ) N
versus VBD N
7 CD N
% NN N
( ( N
L-20 NNP N
) ) N
The DT N
median JJ N
survival NN N
was VBD N
similar JJ N
; : N
and CC N
, , N
at IN N
5 CD N
years NNS N
, , N
the DT N
survival NN N
rate NN N
was VBD N
33 CD N
% NN N
alive JJ N
on IN N
the DT N
ALL-2 NNP N
arm NN N
versus NN N
27 CD N
% NN N
on IN N
the DT N
L-20 NNP N
CONCLUSIONS NNP N
Despite IN N
superior JJ N
results NNS N
of IN N
induction NN N
therapy NN N
with IN N
the DT N
ALL-2 NNP N
regimen NNS N
, , N
this DT N
treatment NN N
did VBD N
not RB N
improve VB N
long-term JJ N
outcomes NNS N
When WRB N
coupled VBN N
to TO N
the DT N
reported VBN N
experience NN N
of IN N
other JJ N
studies NNS N
in IN N
adults NNS N
with IN N
ALL NNP N
, , N
the DT N
results NNS N
of IN N
this DT N
randomized VBN N
trial NN N
raise NN N
the DT N
possibility NN N
that WDT N
ultimate JJ N
outcomes NNS N
in IN N
adult NN N
ALL NNP N
may MD N
be VB N
independent JJ N
of IN N
the DT N
specific JJ N
regimen NNS N
chosen VBN N
Cancer NN N
2013 CD N
© VB N
2012 CD N
American NNP N
Cancer NNP N
Society NNP N
-DOCSTART- -X- O O 9735623

Conservative JJ N
treatment NN N
of IN N
plantar NN 4_p
fasciitis NN 4_p
A DT N
prospective JJ N
study NN N
A DT N
randomized JJ N
, , N
prospective JJ N
study NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
individual JJ N
effectiveness NN N
of IN N
three CD N
types NNS N
of IN N
conservative JJ N
therapy NN N
in IN N
the DT N
treatment NN N
of IN N
plantar NN N
fasciitis NN N
One CD 3_p
hundred VBD 3_p
three CD 3_p
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatment NN N
categories NNS N
: : N
anti-inflammatory NN N
, , N
accommodative JJ N
, , N
or CC N
mechanical JJ N
Subjects NNS N
were VBD N
treated VBN N
for IN N
3 CD N
months NNS N
, , N
with IN N
follow-up JJ N
visits NNS N
at IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
weeks NNS N
For IN N
the DT N
85 CD 3_p
patients NNS N
who WP N
completed VBD N
the DT N
study NN N
, , N
a DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
noted VBN N
between IN N
groups NNS N
, , N
with IN N
mechanical JJ N
treatment NN N
with IN N
taping VBG N
and CC N
orthoses NNS N
proving VBG N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
either DT N
anti-inflammatory JJ N
or CC N
accommodative JJ N
modalities NNS N
-DOCSTART- -X- O O 20001837

Effects NNS N
of IN N
Thai NNP N
traditional JJ N
massage NN N
on IN N
autistic JJ 4_p
children NNS 1_p
's POS 1_p
behavior NN N
OBJECTIVES CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
access NN N
whether IN N
there EX N
were VBD N
any DT N
therapeutic JJ N
effects NNS N
of IN N
Thai NNP N
Traditional NNP N
Massage NNP N
( ( N
TTM NNP N
) ) N
on IN N
major JJ N
behavioral JJ N
and CC N
emotional JJ N
disturbances NNS N
in IN N
Thai NNP N
autistic JJ N
children NNS N
DESIGN NN N
This DT N
was VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
study NN N
SETTINGS/LOCATION NNP N
The DT N
study NN N
was VBD N
conducted VBN N
at IN N
the DT N
Rehabilitation NNP N
Centre NNP N
of IN N
the DT N
Thai NNP N
Red NNP N
Cross NNP N
Society NNP N
SUBJECTS NNP N
A NNP N
total NN N
of IN N
60 CD 3_p
autistic JJ 4_p
children NNS N
between IN N
the DT N
ages NNS N
of IN N
3 CD 1_p
and CC 1_p
10 CD 1_p
completed VBD N
this DT N
study NN N
INTERVENTIONS NNP N
Standard NNP N
sensory JJ N
integration NN N
therapy NN N
( ( N
SI NNP N
) ) N
was VBD N
compared VBN N
to TO N
the DT N
SI NNP N
with IN N
TTM NNP N
treatments NNS N
OUTCOME NNP N
MEASURES NNP N
Parents NNP N
and CC N
teachers NNS N
assessed VBD N
major JJ N
behavior NN N
disturbances NNS N
using VBG N
the DT N
Conners NNPS N
' POS N
Rating VBG N
Scales NNS N
at IN N
0 CD N
and CC N
8 CD N
weeks NNS N
Sleep JJ N
Diary NNP N
( ( N
SD NNP N
) ) N
, , N
recorded VBN N
by IN N
the DT N
parents NNS N
, , N
assessed VBD N
the DT N
patient NN N
's POS N
sleeping NN N
patterns NNS N
every DT N
week NN N
RESULTS NNP N
Sixty NNP 3_p
( ( 3_p
60 CD 3_p
) ) 3_p
autistic JJ 4_p
children NNS N
, , N
mean JJ N
age NN N
4.67 CD 1_p
+/- JJ 1_p
1.82 CD 1_p
, , N
were VBD N
recruited VBN N
No DT N
statistical JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
the DT N
demographic JJ N
and CC N
baseline JJ N
data NN N
among IN N
both DT N
groups NNS N
From IN N
both CC N
the DT N
Conners NNPS N
' POS N
Teacher NNP N
Questionnaire NNP N
and CC N
SD NNP N
, , N
statistical JJ N
improvement NN N
was VBD N
detected VBN N
for IN N
conduct NN N
problem NN N
, , N
hyperactivity NN N
, , N
inattention-passivity NN N
, , N
hyperactivity NN N
index NN N
, , N
and CC N
sleeping VBG N
behavior NN N
However RB N
, , N
results NNS N
from IN N
the DT N
Conners NNP N
' POS N
Parent NNP N
Questionnaire NNP N
revealed VBD N
an DT N
improvement NN N
only RB N
for IN N
anxiety NN N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
in IN N
the DT N
massage NN N
group NN N
, , N
whereas IN N
when WRB N
both DT N
groups NNS N
were VBD N
compared VBN N
, , N
a DT N
significant JJ N
improvement NN N
in IN N
conduct NN N
problem NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
and CC N
anxiety NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
was VBD N
found VBN N
Results NNS N
indicated VBD N
that IN N
TTM NNP N
may MD N
have VB N
a DT N
positive JJ N
effect NN N
in IN N
improving VBG N
stereotypical JJ N
behaviors NNS N
in IN N
autistic JJ N
children NNS N
CONCLUSIONS NNP N
Over IN N
a DT N
period NN N
of IN N
8 CD N
weeks NNS N
, , N
our PRP$ N
findings NNS N
suggested VBD N
that IN N
TTM NNP N
could MD N
be VB N
used VBN N
as IN N
a DT N
complementary JJ N
therapy NN N
for IN N
autistic JJ N
children NNS N
in IN N
Thailand NNP N
-DOCSTART- -X- O O 11832869

Changes NNS N
in IN N
selected VBN N
fitness NN N
parameters NNS N
following VBG N
six CD N
weeks NNS N
of IN N
snowshoe JJ N
training NN N
BACKGROUND NNP N
Recently RB N
, , N
there EX N
has VBZ N
been VBN N
an DT N
increase NN N
in IN N
popularity NN N
and CC N
participation NN N
in IN N
the DT N
sport NN N
of IN N
snowshoeing VBG N
While IN N
the DT N
sport NN N
has VBZ N
gained VBN N
considerable JJ N
recognition NN N
, , N
to TO N
date NN N
there EX N
is VBZ N
little JJ N
or CC N
no DT N
scientific JJ N
research NN N
regarding VBG N
training NN N
responses NNS N
to TO N
snowshoeing VBG N
as IN N
a DT N
form NN N
of IN N
exercise NN N
Therefore RB N
, , N
the DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
snowshoe JJ N
training NN N
could MD N
improve VB N
fitness NN N
measures NNS N
A DT N
further JJ N
purpose NN N
was VBD N
to TO N
compare VB N
responses NNS N
from IN N
a DT N
snowshoe JJ N
training NN N
program NN N
to TO N
a DT N
similarly RB N
designed VBN N
run RP N
training VBG N
program NN N
METHODS NNP N
This DT N
prospective JJ N
, , N
comparative JJ N
study NN N
was VBD N
conducted VBN N
with IN N
healthy JJ 4_p
males NNS 2_p
and CC N
females NNS 2_p
between IN N
the DT N
ages NNS N
of IN N
19 CD 1_p
and CC 1_p
24 CD 1_p
These DT N
subjects NNS N
were VBD N
recruited VBN N
from IN N
the DT N
University NNP N
of IN N
Vermont NNP N
population NN N
and CC N
surrounding VBG N
community NN N
Following VBG N
baseline NN N
measurements NNS N
in IN N
VO2max NNP N
, , N
running VBG N
time NN N
to TO N
exhaustion NN N
( ( N
RTE NNP N
) ) N
, , N
and CC N
anthropometry NN N
, , N
17 CD 3_p
subjects NNS N
( ( N
10 CD N
snowshoers NNS N
and CC N
7 CD N
runners NNS N
) ) N
participated VBD N
in IN N
a DT N
six CD N
week NN N
conditioning VBG N
program NN N
Both DT N
groups NNS N
exercised VBD N
for IN N
30 CD N
min NNS N
at IN N
75-85 CD N
% NN N
age NN N
predicted VBD N
maximum JJ N
heart NN N
rate NN N
, , N
3-4 JJ N
times NNS N
per IN N
week NN N
, , N
for IN N
a DT N
total NN N
of IN N
18 CD N
sessions NNS N
RESULTS NNP N
VO2max NNP N
improved VBD N
significantly RB N
in IN N
both DT N
running NN N
and CC N
snowshoeing VBG N
groups NNS N
, , N
6.3 CD N
and CC N
8.5 CD N
% NN N
, , N
respectively RB N
Run VB N
time NN N
to TO N
exhaustion NN N
also RB N
improved VBN N
significantly RB N
in IN N
both DT N
groups NNS N
, , N
23.3 CD N
and CC N
33.5 CD N
% NN N
, , N
respectively RB N
There EX N
were VBD N
no DT N
changes NNS N
in IN N
anthropometry NN N
for IN N
either DT N
group NN N
With IN N
the DT N
exception NN N
of IN N
RTE NNP N
, , N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
any DT N
other JJ N
measurements NNS N
at IN N
baseline NN N
CONCLUSIONS NNP N
These DT N
results NNS N
support VBD N
the DT N
acceptability NN N
of IN N
snowshoeing VBG N
as IN N
a DT N
valid JJ N
means NN N
to TO N
improve VB N
or CC N
maintain VB N
cardiovascular JJ N
endurance NN N
-DOCSTART- -X- O O 19502023

Transdermal NNP N
scopolamine NN N
patch NN N
in IN N
addition NN N
to TO N
ondansetron VB N
for IN N
postoperative JJ N
nausea NN N
and CC N
vomiting VBG N
prophylaxis NN N
in IN N
patients NNS N
undergoing VBG 4_p
ambulatory JJ 4_p
cosmetic JJ 4_p
surgery NN 4_p
STUDY NNP N
OBJECTIVE NNP N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
transdermal JJ N
scopolamine NN N
in IN N
addition NN N
to TO N
ondansetron VB N
in IN N
decreasing VBG N
the DT N
incidence NN N
of IN N
postoperative JJ 4_p
nausea NN 4_p
and CC 4_p
vomiting NN 4_p
( ( N
PONV NNP 4_p
) ) N
DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
SETTING NN N
Academic NNP N
hospital NN N
PATIENTS CC N
126 CD 3_p
ASA NNP 4_p
physical JJ 4_p
status NN 4_p
I PRP 4_p
and CC 4_p
II NNP 4_p
patients NNS 4_p
undergoing VBG 4_p
outpatient JJ 4_p
plastic NN 4_p
surgery NN 4_p
with IN N
three CD 4_p
or CC 4_p
more JJR 4_p
risk NN 4_p
factors NNS 4_p
for IN 4_p
PONV NNP 4_p
INTERVENTIONS NNP N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
to TO N
receive VB N
( ( N
Group NNP N
1 CD N
) ) N
a DT N
transdermal JJ N
scopolamine NN N
( ( N
TDS NNP N
) ) N
patch NN N
or CC N
( ( N
Group NNP N
2 CD N
) ) N
, , N
a DT N
placebo JJ N
patch NN N
two CD N
hours NNS N
before IN N
surgery NN N
MEASUREMENTS NNP N
Occurrence NNP N
of IN N
vomiting VBG N
, , N
severity NN N
of IN N
nausea NN N
using VBG N
a DT N
visual JJ N
analog NN N
scale NN N
( ( N
VAS NNP N
) ) N
, , N
rescue JJ N
medication NN N
, , N
pain VBP N
intensity NN N
and CC N
pain NN N
medications NNS N
, , N
and CC N
side JJ N
effects NNS N
were VBD N
recorded VBN N
every DT N
hour NN N
until IN N
discharge NN N
from IN N
hospital NN N
, , N
then RB N
every DT N
4 CD N
hours NNS N
thereafter RB N
for IN N
a DT N
total NN N
of IN N
24 CD N
hours NNS N
MAIN NNP N
RESULTS NNP N
A NNP N
statistically RB N
significant JJ N
reduction NN N
in IN N
postoperative JJ N
nausea NN N
between IN N
8 CD N
and CC N
24 CD N
hours NNS N
in IN N
patients NNS N
receiving VBG N
TDS NNP N
was VBD N
noted VBN N
CONCLUSIONS NNP N
Transdermal NNP N
scopolamine NN N
in IN N
addition NN N
to TO N
ondansetron VB N
benefits NNS N
patients NNS N
at IN N
high JJ N
risk NN N
for IN N
PONV NNP N
undergoing JJ N
outpatient NN N
plastic NN N
surgery NN N
for IN N
up IN N
to TO N
20 CD N
hours NNS N
after IN N
surgery NN N
-DOCSTART- -X- O O 11334068

Comments NNS N
on IN N
" NNP N
Comparison NNP N
of IN N
gastrointestinal JJ N
tolerance NN N
feeding NN N
proctocols NNS N
in IN N
critically RB 4_p
ill JJ 4_p
patients NNS 4_p
: : 4_p
a DT N
prospective JJ N
, , N
randomized VBN 4_p
controlled VBD 4_p
clinical JJ 4_p
trial NN 4_p
" NN 4_p
-DOCSTART- -X- O O 3122275

Effects NNS N
of IN N
misoprostol NN N
on IN N
human JJ 4_p
circulation NN 4_p
Prostaglandins NNP N
( ( N
PGs NNP N
) ) N
of IN N
the DT N
E-type NNP N
are VBP N
potent JJ N
vasodilators NNS N
in IN N
most JJS N
species NNS N
and CC N
in IN N
most JJS N
vascular JJ N
beds NNS N
However RB N
, , N
vasoconstrictor JJ N
effects NNS N
of IN N
PGEs NNP N
have VBP N
also RB N
been VBN N
noted VBN N
at IN N
selected VBN N
sites NNS N
This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
misoprostol NN N
, , N
a DT N
PGE1 NNP N
analog NN N
with IN N
antiulcer NN N
activity NN N
, , N
on IN N
the DT N
human JJ N
cardiovascular NN N
system NN N
Twenty NNP 3_p
healthy JJ N
subjects NNS N
participated VBN N
in IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study NN N
Following VBG N
a DT N
12 CD N
hour NN N
fast NN N
, , N
heart NN N
rate NN N
, , N
arterial JJ N
blood NN N
pressure NN N
, , N
light JJ N
reflex JJ N
plethysmography NN N
of IN N
the DT N
finger NN N
, , N
resting VBG N
blood NN N
flow NN N
volume NN N
in IN N
the DT N
lower JJR N
arm NN N
and CC N
leg NN N
and CC N
peripheral JJ N
vascular JJ N
resistance NN N
were VBD N
measured VBN N
at IN N
10 CD N
min NN N
intervals NNS N
for IN N
1 CD N
hour NN N
prior RB N
to TO N
drug NN N
administration NN N
, , N
to TO N
permit VB N
calculating VBG N
baseline NN N
values NNS N
Misoprostol NNP N
( ( N
400 CD N
mcg NN N
) ) N
or CC N
its PRP$ N
matching JJ N
placebo NN N
were VBD N
administered VBN N
orally RB N
, , N
and CC N
the DT N
measurements NNS N
were VBD N
repeated VBN N
at IN N
10 CD N
min NN N
intervals NNS N
over IN N
the DT N
next JJ N
2 CD N
hours NNS N
A DT N
decrease NN N
in IN N
leg NN N
blood NN N
flow NN N
volume NN N
and CC N
a DT N
corresponding JJ N
increase NN N
in IN N
leg JJ N
peripheral JJ N
vascular JJ N
resistance NN N
were VBD N
noted VBN N
in IN N
the DT N
misoprostol NN N
group NN N
A DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
heart NN N
rate NN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
was VBD N
also RB N
noted VBN N
These DT N
small JJ N
changes NNS N
were VBD N
not RB N
considered VBN N
to TO N
be VB N
of IN N
clinical JJ N
importance NN N
No DT N
adverse JJ N
experiences NNS N
were VBD N
reported VBN N
In IN N
conclusion NN N
, , N
a DT N
single JJ N
dose NN N
of IN N
misoprostol NN N
( ( N
400 CD N
mcg NN N
) ) N
has VBZ N
no DT N
clinically RB N
significant JJ N
vasoconstrictive JJ N
or CC N
vasodilative JJ N
properties NNS N
in IN N
man NN N
-DOCSTART- -X- O O 8197064

[ JJ N
Effects NNS N
of IN N
an DT N
intensive JJ N
therapy NN N
program NN N
for IN N
behaviorally RB 4_p
disordered VBN 4_p
mentally RB 4_p
handicapped JJ 4_p
patients NNS N
on IN N
staff NN N
personnel NNS N
in IN N
residential JJ N
care NN N
] NNP N
This DT N
study NN N
evaluates VBZ N
the DT N
effects NNS N
of IN N
an DT N
intensive JJ N
therapy NN N
program NN N
designed VBN N
for IN N
mentally RB 4_p
handicapped JJ 4_p
persons NNS N
with IN N
severely RB N
disturbed VBN 4_p
or CC 4_p
autistic JJ 4_p
behavior NN 4_p
on IN N
their PRP$ N
staff NN N
personal JJ N
which WDT N
had VBD N
an DT N
active JJ N
role NN N
in IN N
the DT N
program NN N
The DT N
staff NN N
members NNS N
rated VBD N
their PRP$ N
professional JJ N
competence NN N
, , N
quality NN N
of IN N
interaction NN N
with IN N
the DT N
client NN N
, , N
team JJ N
culture NN N
and CC N
work NN N
satisfaction NN N
before IN N
and CC N
after IN N
being VBG N
engaged VBN N
in IN N
the DT N
program NN N
, , N
with IN N
additional JJ N
ratings NNS N
of IN N
their PRP$ N
personal JJ N
aims NNS N
at IN N
the DT N
beginning NN N
of IN N
the DT N
program NN N
Three NNP N
sets NNS N
of IN N
data NNS N
were VBD N
obtained VBN N
with IN N
the DT N
program NN N
being VBG N
conducted VBN N
three CD N
times NNS N
in IN N
a DT N
row NN N
The DT N
testings NNS N
of IN N
the DT N
related VBN N
as RB N
well RB N
as IN N
the DT N
independent JJ N
samples NNS N
show VBP N
differentiated JJ N
program NN N
effects NNS N
The DT N
main JJ N
effect NN N
is VBZ N
an DT N
increase NN N
of IN N
the DT N
professional JJ N
competence NN N
and CC N
quality NN N
of IN N
interaction NN N
, , N
especially RB N
by IN N
the DT N
qualified JJ N
staff NN N
members NNS N
Trainees NNP N
put VBD N
emphasis NN N
on IN N
the DT N
development NN N
of IN N
their PRP$ N
personal JJ N
relationship NN N
with IN N
the DT N
client NN N
The DT N
results NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
the DT N
impact NN N
of IN N
learning VBG N
processes NNS N
specific JJ N
to TO N
the DT N
roles NNS N
of IN N
the DT N
staff NN N
members NNS N
and CC N
motivational JJ N
factors NNS N
on IN N
learning NN N
and CC N
therapy NN N
outcome NN N
, , N
along IN N
with IN N
institutional JJ N
conditions NNS N
influencing VBG N
successful JJ N
learning NN N
Thus VB N
the DT N
program NN N
facilitates VBZ N
the DT N
professional JJ N
and CC N
interpersonal JJ N
learning NN N
process NN N
of IN N
staff NN N
members NNS N
in IN N
a DT N
specific JJ N
way NN N
with IN N
success NN N
as RB N
well RB N
as IN N
with IN N
limitations NNS N
-DOCSTART- -X- O O 20592840

Field NNP N
efficacy NN N
of IN N
an DT N
inactivated JJ N
bivalent NN N
influenza NN N
vaccine NN N
in IN N
a DT N
multi-site JJ 4_p
swine NN 4_p
production NN 4_p
system NN 4_p
during IN 4_p
an DT 4_p
outbreak NN 4_p
of IN 4_p
systemic JJ 4_p
porcine NN 4_p
circovirus NN 4_p
associated VBN 4_p
disease NN 4_p
Swine NNP N
influenza NN N
( ( N
SI NNP N
) ) N
is VBZ N
a DT N
disease NN N
of IN N
significance NN N
for IN N
the DT N
swine NN N
industry NN N
, , N
and CC N
vaccination NN N
is VBZ N
often RB N
recommended VBN N
as IN N
a DT N
way NN N
to TO N
reduce VB N
its PRP$ N
impact NN N
on IN N
production NN N
The DT N
efficacy NN N
of IN N
SI NNP N
vaccines NNS N
is VBZ N
well RB N
established VBN N
under IN N
experimental JJ N
conditions NNS N
, , N
but CC N
information NN N
about IN N
field NN N
efficacy NN N
is VBZ N
scarce JJ N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
commercial JJ N
inactivated JJ N
bivalent NN N
( ( N
H1N1/H3N2 NNP N
) ) N
vaccine NN N
under IN N
conditions NNS N
of IN N
natural JJ N
exposure NN N
to TO N
a DT N
field NN N
SI NNP N
variant NN N
To TO N
accomplish VB N
our PRP$ N
goal NN N
we PRP N
used VBD N
a DT N
randomized JJ N
, , N
blinded VBD N
, , N
field NN N
trial NN N
in IN N
2 CD 3_p
cohorts NNS 3_p
of IN N
finisher NN N
pigs NNS N
in IN N
a DT N
multi-site JJ N
swine NN N
production NN N
system NN N
located VBN N
in IN N
southern JJ N
Ontario NNP N
During IN N
the DT N
trial NN N
, , N
this DT N
herd NN N
experienced VBD N
an DT N
outbreak NN N
of IN N
porcine NN N
circovirus NN N
associated VBN N
disease NN N
( ( N
PCVAD NNP N
) ) N
The DT N
efficacy NN N
of IN N
the DT N
SI NNP N
vaccine NN N
was VBD N
assessed VBN N
through IN N
its PRP$ N
effect NN N
on IN N
average JJ N
daily JJ N
weight NN N
gain NN N
, , N
and CC N
serological JJ N
responses NNS N
to TO N
SI VB N
over IN N
time NN N
The DT N
effect NN N
of IN N
vaccination NN N
on IN N
pig NN N
growth NN N
was VBD N
different JJ N
in IN N
the DT N
2 CD N
cohorts NNS N
Weight NNP N
gain NN N
was VBD N
higher RBR N
in IN N
vaccinated JJ N
pigs NNS N
than IN N
in IN N
control NN N
pigs NNS N
in IN N
Cohort NNP N
1 CD N
, , N
but CC N
was VBD N
numerically RB N
higher JJR N
for IN N
control NN N
pigs NNS N
than IN N
for IN N
vaccinated JJ N
pigs NNS N
in IN N
Cohort NNP N
2 CD N
Vaccination NN N
against IN N
swine NN N
influenza NN N
, , N
in IN N
a DT N
herd NN N
experiencing VBG N
an DT N
outbreak NN N
of IN N
PCVAD NNP N
, , N
was VBD N
of IN N
questionable JJ N
value NN N
-DOCSTART- -X- O O 9648960

Bronchodilator NNP N
response NN N
to TO N
salbutamol VB N
after IN N
spontaneous JJ N
recovery NN N
from IN N
nonspecific JJ N
bronchial JJ N
provocation NN N
tests NNS N
in IN N
asthma NN 4_p
Assessment NN N
of IN N
airway NN N
responsiveness NN N
by IN N
bronchoprovocation NN N
and CC N
bronchodilatation NN N
tests NNS N
is VBZ N
important JJ N
in IN N
the DT N
diagnostic JJ N
work-up JJ N
protocol NN N
of IN N
bronchial JJ 4_p
asthma NN 4_p
and CC N
it PRP N
would MD N
be VB N
convenient JJ N
to TO N
undertake VB N
both DT N
tests NNS N
on IN N
the DT N
same JJ N
occasion NN N
However RB N
, , N
it PRP N
is VBZ N
not RB N
known VBN N
whether IN N
this DT N
can MD N
be VB N
done VBN N
accurately RB N
Therefore RB N
, , N
this DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
a DT N
prior JJ N
bronchial JJ N
provocation NN N
test NN N
on IN N
the DT N
bronchodilator NN N
response NN N
to TO N
salbutamol VB N
after IN N
spontaneous JJ N
recovery NN N
of IN N
the DT N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
( ( N
FEV1 NNP N
) ) N
in IN N
a DT N
group NN N
of IN N
asthmatic JJ N
subjects NNS N
On IN N
two CD N
separate JJ N
occasions NNS N
at IN N
the DT N
same JJ N
time NN N
of IN N
day NN N
, , N
concentration-response JJ N
studies NNS N
with IN N
inhaled JJ N
histamine NN N
or CC N
methacholine NN N
, , N
or CC N
a DT N
sham JJ N
challenge NN N
with IN N
normal JJ N
saline NN N
were VBD N
carried VBN N
out RP N
in IN N
a DT N
blinded JJ N
, , N
randomized JJ N
manner NN N
Changes NNS N
in IN N
airway NN N
calibre NN N
were VBD N
followed VBN N
as IN N
FEV1 NNP N
and CC N
agonist JJ N
responsiveness NN N
expressed VBN N
as IN N
the DT N
provocative JJ N
concentration NN N
causing VBG N
a DT N
20 CD N
% NN N
fall NN N
in IN N
FEV1 NNP N
( ( N
PC20 NNP N
) ) N
After IN N
either DT N
spontaneous JJ N
recovery NN N
or CC N
a DT N
fixed-duration JJ N
wait NN N
of IN N
45 CD N
min NNS N
( ( N
when WRB N
appropriate NN N
) ) N
, , N
the DT N
subjects NNS N
received VBD N
2x100 CD N
microg NN N
of IN N
salbutamol NN N
from IN N
a DT N
metered VBN N
dose NN N
inhaler NN N
with IN N
a DT N
spacer NN N
The DT N
bronchodilator NN N
response NN N
to TO N
salbutamol VB N
was VBD N
expressed VBN N
as IN N
a DT N
percentage NN N
of IN N
initial JJ N
FEV1 NNP N
( ( N
deltaFEV1 CD N
% NN N
init NN N
) ) N
Bronchial JJ N
challenge NN N
with IN N
both DT N
agonists NNS N
failed VBD N
to TO N
alter VB N
significantly RB N
the DT N
airway NN N
response NN N
to TO N
salbutamol VB N
, , N
with IN N
the DT N
deltaFEV1 NN N
% NN N
init JJ N
mean JJ N
value NN N
( ( N
range NN N
) ) N
being VBG N
16.9 CD N
% NN N
( ( N
9.0-31.9 CD N
) ) N
and CC N
17.5 CD N
% NN N
( ( N
11.6-31.2 JJ N
) ) N
on IN N
the DT N
sham NN N
and CC N
histamine/methacholine JJ N
challenge NN N
day NN N
respectively RB N
It PRP N
was VBD N
shown VBN N
that IN N
the DT N
degree NN N
of IN N
bronchodilatation NN N
achieved VBN N
after IN N
salbutamol JJ N
200 CD N
microg NN N
is VBZ N
not RB N
affected VBN N
by IN N
prior JJ N
bronchoprovocation NN N
testing VBG N
when WRB N
enough JJ N
time NN N
is VBZ N
allowed VBN N
for IN N
the DT N
airways NNS N
to TO N
recover VB N
spontaneously RB N
to TO N
baseline VB N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
Thus NNP N
evaluation NN N
of IN N
airway NN N
responsiveness NN N
by IN N
both DT N
bronchial JJ N
provocation NN N
tests NNS N
and CC N
bronchodilator NN N
testing NN N
can MD N
be VB N
assessed VBN N
reliably RB N
within IN N
a DT N
few JJ N
hours NNS N
in IN N
asthmatic JJ N
patients NNS N
-DOCSTART- -X- O O 14996144

Short-term JJ N
fluoxetine NN N
monotherapy NN N
for IN N
bipolar JJ 4_p
type NN 4_p
II NNP 4_p
or CC 4_p
bipolar JJ 4_p
NOS NNP 4_p
major JJ 4_p
depression NN 4_p
- : 4_p
low JJ 4_p
manic JJ 4_p
switch NN 4_p
rate NN 4_p
OBJECTIVES CC N
Current NNP N
guidelines NNS N
for IN N
the DT N
initial JJ N
treatment NN N
of IN N
bipolar JJ 4_p
type NN 4_p
II NNP 4_p
( ( N
BP NNP 4_p
II NNP 4_p
) ) N
major JJ N
depressive JJ N
episode NN N
( ( N
MDE NNP N
) ) N
recommend VBP N
using VBG N
either CC N
a DT N
mood NN N
stabilizer NN N
alone RB N
or CC N
a DT N
combination NN N
of IN N
a DT N
mood NN N
stabilizer NN N
plus CC N
a DT N
selective JJ N
serotonin NN N
re-uptake NN N
inhibitor NN N
( ( N
SSRI NNP N
) ) N
This DT N
recommendation NN N
is VBZ N
the DT N
result NN N
of IN N
concern NN N
over IN N
antidepressant-induced JJ N
manic JJ N
switch NN N
episodes NNS N
However RB N
, , N
recent JJ N
evidence NN N
suggests VBZ N
that IN N
the DT N
manic JJ N
switch NN N
rate NN N
may MD N
be VB N
low JJ N
in IN N
BP NNP N
II NNP N
MDE NNP N
during IN N
SSRI NNP N
therapy NN N
METHODS NNP N
As IN N
part NN N
of IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
relapse-prevention NN N
study NN N
of IN N
fluoxetine JJ N
monotherapy NN N
in IN N
BP NNP 4_p
II NNP 4_p
MDE NNP N
, , N
37 CD 3_p
patients NNS N
received VBD N
open-label JJ N
fluoxetine NN N
20 CD N
mg NN N
every DT N
day NN N
for IN N
up IN N
to TO N
8 CD N
weeks NNS N
Outcome NNP N
measures NNS N
included VBD N
the DT N
Hamilton NNP N
Depression NNP N
Rating NNP N
( ( N
HAM-D NNP N
17 CD N
) ) N
rating NN N
and CC N
the DT N
Young NNP N
Mania NNP N
Rating NNP N
( ( N
YMR NNP N
) ) N
scale NN N
RESULTS NNP N
Eleven NNP N
of IN N
23 CD N
patients NNS N
( ( N
48 CD N
% NN N
) ) N
who WP N
completed VBD N
8 CD N
weeks NNS N
of IN N
fluoxetine NN N
treatment NN N
showed VBD N
a DT N
HAM-D JJ N
17 CD N
reduction NN N
of IN N
> NN N
or CC N
=50 CD N
% NN N
, , N
while IN N
14 CD N
( ( N
38 CD N
% NN N
) ) N
of IN N
all DT N
treated JJ N
patients NNS N
had VBD N
> VBN N
or CC N
=50 CD N
% NN N
reduction NN N
in IN N
baseline JJ N
HAM-D JJ N
17 CD N
score NN N
Using VBG N
a DT N
conservative JJ N
YMR NNP N
score NN N
of IN N
> NN N
or CC N
=8 VB N
to TO N
identify VB N
hypomanic JJ N
symptoms NNS N
, , N
the DT N
frequency NN N
of IN N
patients NNS N
with IN N
YMR NNP N
score NN N
> NN N
or CC N
=8 NN N
during IN N
fluoxetine NN N
did VBD N
not RB N
differ VB N
from IN N
that DT N
seen VBN N
during IN N
the DT N
screen NN N
and CC N
baseline JJ N
period NN N
Only RB N
three CD N
patients NNS N
( ( N
7.3 CD N
% NN N
) ) N
had VBD N
symptoms NNS N
suggestive JJ N
of IN N
hypomania NN N
, , N
and CC N
only RB N
one CD N
patient NN N
stopped VBD N
treatment NN N
because IN N
of IN N
a DT N
rapid JJ N
mood NN N
swing VBG N
into IN N
depression NN N
LIMITATIONS NNP N
Fluoxetine NNP N
was VBD N
given VBN N
at IN N
a DT N
fixed JJ N
dose NN N
of IN N
20 CD N
mg NNS N
everyday JJ N
Fluoxetine NNP N
was VBD N
prescribed VBN N
in IN N
an DT N
open-label JJ N
manner NN N
, , N
and CC N
the DT N
sample NN N
size NN N
was VBD N
limited VBN N
CONCLUSIONS NNP N
These DT N
observations NNS N
support VBP N
the DT N
findings NNS N
of IN N
a DT N
low JJ N
manic JJ N
switch NN N
rate NN N
during IN N
SSRI NNP N
monotherapy NN N
of IN N
BP NNP N
II NNP N
MDE NNP N
, , N
and CC N
suggest VBP N
that IN N
fluoxetine JJ N
monotherapy NN N
may MD N
be VB N
a DT N
safe JJ N
and CC N
effective JJ N
initial JJ N
treatment NN N
of IN N
BP NNP 4_p
II NNP 4_p
MDE NNP 4_p
-DOCSTART- -X- O O 21432861

Quantification NN N
of IN N
cyproheptadine NN N
in IN 4_p
human JJ 4_p
plasma NN 4_p
by IN N
high-performance NN N
liquid NN N
chromatography NN N
coupled VBD N
to TO N
electrospray VB N
tandem JJ N
mass NN N
spectrometry NN N
in IN N
a DT N
bioequivalence NN N
study NN N
A DT N
rapid JJ N
, , N
sensitive JJ N
and CC N
specific JJ N
method NN N
to TO N
quantify VB N
cyproheptadine NN N
in IN N
human JJ N
plasma NN N
using VBG N
amitriptyline NN N
as IN N
the DT N
internal JJ N
standard NN N
( ( N
IS NNP N
) ) N
is VBZ N
described VBN N
The DT N
analyte NN N
and CC N
the DT N
IS NNP N
were VBD N
extracted VBN N
from IN N
plasma NN N
by IN N
liquid-liquid JJ N
extraction NN N
using VBG N
a DT N
diethyl-ether/dichloromethane NN N
( ( N
70/30 CD N
; : N
v/v NN N
) ) N
solvent NN N
After IN N
removing VBG N
and CC N
drying VBG N
the DT N
organic JJ N
phase NN N
, , N
the DT N
extracts NNS N
were VBD N
reconstituted VBN N
with IN N
a DT N
fixed JJ N
volume NN N
of IN N
acetonitrile/water NN N
( ( N
50/50 CD N
v/v NN N
) ) N
+0.1 CD N
% NN N
of IN N
acetic JJ N
acid NN N
The DT N
extracts NNS N
were VBD N
analyzed VBN N
by IN N
high JJ N
performance NN N
liquid NN N
chromatography NN N
coupled VBD N
to TO N
electrospray VB N
tandem JJ N
mass NN N
spectrometry NN N
( ( N
LC-MS/MS NNP N
) ) N
Chromatography NNP N
was VBD N
performed VBN N
isocratically RB N
using VBG N
an DT N
Alltech NNP N
Prevail NNP N
C18 NNP N
5 CD N
µm NNP N
analytical JJ N
column NN N
, , N
( ( N
150 CD N
mm NN N
x VBD N
4.6 CD N
mm NNS N
I.D. NNP N
) ) N
The DT N
method NN N
had VBD N
a DT N
chromatographic JJ N
run NN N
time NN N
of IN N
4 CD N
min NNS N
and CC N
a DT N
linear JJ N
calibration NN N
curve NN N
ranging VBG N
from IN N
0.05 CD N
to TO N
10 CD N
ng/mL NNS N
( ( N
r2 VB N
> RB N
0.99 CD N
) ) N
The DT N
limit NN N
of IN N
quantification NN N
was VBD N
0.05 CD N
ng/mL RB N
This DT N
HPLC/MS/MS NNP N
procedure NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
bioequivalence NN N
of IN N
cyproheptadine NN N
in IN N
two CD N
cyproheptadine NN N
+ NNS N
cobamamide VBP N
( ( N
4 CD N
mg NN N
+ VBD N
1 CD N
mg NN N
) ) N
tablet NN N
formulations NNS N
( ( N
Cobactin® NNP N
[ NNP N
cyproheptadine NN N
+ NNP N
cobamamide NN N
] NNP N
test NN N
formulation NN N
supplied VBN N
from IN N
Zambon NNP N
Laboratórios NNP N
Farmacêuticos NNP N
Ltda NNP N
and CC N
Cobavital® NNP N
from IN N
Solvay NNP N
Farma NNP N
( ( N
standard JJ N
reference NN N
formulation NN N
) ) N
) ) N
A DT N
single JJ N
4 CD N
mg NN N
+ VBD N
1 CD N
mg NN N
[ NNP N
cyproheptadine NN N
+ NNP N
cobamamide NN N
] NNP N
dose NN N
of IN N
each DT N
formulation NN N
was VBD N
administered VBN N
to TO N
healthy JJ N
volunteers NNS N
The DT N
study NN N
was VBD N
conducted VBN N
using VBG N
an DT N
open JJ N
, , N
randomized VBN N
, , N
two-period JJ N
crossover NN N
design NN N
with IN N
a DT N
1-week JJ N
washout NN N
interval NN N
Since IN N
the DT N
90 CD N
% NN N
CI NNP N
for IN N
Cmax NNP N
and CC N
AUCs NNP N
ratios NNS N
were VBD N
all DT N
within IN N
the DT N
80-125 JJ N
% NN N
bioequivalence NN N
limit NN N
proposed VBN N
by IN N
the DT N
US NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
, , N
it PRP N
was VBD N
concluded VBN N
that IN N
the DT N
cyproheptadine JJ N
test NN N
formulation NN N
( ( N
Cobactin® NNP N
) ) N
is VBZ N
bioequivalent JJ N
to TO N
the DT N
Cobavital® NNP N
formulation NN N
for IN N
both DT N
the DT N
rate NN N
and CC N
the DT N
extent NN N
of IN N
absorption NN N
of IN N
cyproheptadine NN N
-DOCSTART- -X- O O 7492158

The DT N
effect NN N
of IN N
iron NN N
in IN N
formula NN N
milk NN N
after IN N
6 CD N
months NNS N
of IN N
age NN N
Ninety NNP 3_p
two CD 3_p
normal JJ 4_p
birthweight JJ 4_p
infants NNS 1_p
aged VBD N
6 CD 1_p
months NNS 1_p
entered VBD N
a DT N
double JJ N
blind NN N
controlled VBD N
trial NN N
which WDT N
compared VBN N
a DT N
follow NN N
on IN N
formula NN N
milk NN N
with IN N
no DT N
added JJ N
iron NN N
against IN N
the DT N
same JJ N
formula NN N
milk NN N
containing VBG N
1.2 CD N
mg NN N
of IN N
iron NN N
per IN N
100 CD N
ml NN N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
social JJ N
class NN N
or CC N
demographic JJ N
characteristics NNS N
of IN N
the DT N
two CD N
treatment NN N
groups NNS N
or CC N
in IN N
the DT N
proportion NN N
of IN N
each DT N
group NN N
completing VBG N
the DT N
trial NN N
There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT N
quantity NN N
of IN N
milk NN N
taken VBN N
but CC N
the DT N
amounts NNS N
taken VBN N
lessened VBD N
between IN N
6 CD N
and CC N
18 CD N
months NNS N
of IN N
age NN N
There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
with IN N
respect NN N
to TO N
mean VB N
haemoglobin NN N
and CC N
median JJ N
serum NN N
ferritin NN N
at IN N
6 CD N
, , N
9 CD N
, , N
12 CD N
, , N
15 CD N
, , N
and CC N
18 CD N
months NNS N
of IN N
age NN N
Very RB N
few JJ N
infants NNS N
developed VBD N
iron NN N
deficiency NN N
anaemia NN N
in IN N
either CC N
group NN N
but CC N
there EX N
was VBD N
a DT N
tendency NN N
for IN N
serum NN N
ferritin NN N
levels NNS N
to TO N
fall VB N
between IN N
6 CD N
and CC N
18 CD N
months NNS N
of IN N
age NN N
in IN N
both DT N
groups NNS N
The DT N
results NNS N
suggest VBP N
that IN N
iron NN N
added VBD N
to TO N
follow VB N
on IN N
milk NN N
was VBD N
not RB N
an DT N
important JJ N
source NN N
of IN N
dietary JJ N
iron NN N
in IN N
the DT N
infants NNS N
studied VBN N
-DOCSTART- -X- O O 3220672

Argon NNP N
laser NN N
trabeculoplasty NN N
in IN N
primary JJ 4_p
open-angle JJ 4_p
glaucoma NN 4_p
-- : N
results NNS N
in IN N
black JJ N
Jamaican JJ N
population NN N
A DT N
controlled JJ N
, , N
randomised VBD N
, , N
prospective JJ N
trial NN N
of IN N
Argon NNP N
laser NN N
trabeculoplasty NN N
( ( N
ALT NNP N
) ) N
was VBD N
carried VBN N
out RP N
on IN N
48 CD N
eyes NNS N
of IN N
30 CD 3_p
black JJ N
Jamaican JJ N
patients NNS N
with IN N
primary JJ 4_p
open-angle JJ 4_p
glaucoma NN 4_p
All DT N
eyes NNS N
had VBD N
uncontrolled VBN 4_p
intra-ocular JJ 4_p
pressures NNS 4_p
( ( 4_p
greater JJR 4_p
than IN 4_p
or CC 4_p
equal JJ 4_p
to TO 4_p
22 CD 4_p
mm NNS 4_p
Hg NNP 4_p
) ) 4_p
despite IN N
medical JJ N
therapy NN N
Treatment NN N
was VBD N
successful JJ N
in IN N
controlling VBG N
intraocular JJ N
pressure NN N
in IN N
68 CD N
% NN N
of IN N
eyes NNS N
after IN N
12 CD N
months NNS N
follow-up JJ N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
The DT N
average JJ N
drop NN N
in IN N
intraocular JJ N
pressure NN N
attributable JJ N
to TO N
ALT NNP N
was VBD N
6.6 CD N
mmHg NN N
Argon NNP N
laser NN N
trabeculoplasty NN N
is VBZ N
an DT N
effective JJ N
adjunct NN N
in IN N
managing VBG N
to TO N
control VB N
intraocular JJ N
pressure NN N
in IN N
black JJ N
Jamaican NNP N
glaucoma NN 4_p
patients NNS N
-DOCSTART- -X- O O 7298122

Changing VBG N
sodium NN N
intake NN N
in IN N
children NNS 1_p
The DT N
Minneapolis NNP N
Children NNP N
's POS N
Blood NNP N
Pressure NN N
Study NNP N
To TO N
assess VB N
the DT N
effects NNS N
of IN N
modifying VBG N
dietary JJ N
sodium NN N
intake NN N
, , N
80 CD 3_p
school NN N
children NNS 1_p
with IN N
blood NN 4_p
pressures NNS 4_p
above IN 4_p
the DT 4_p
95th CD 4_p
percentile NN 4_p
for IN 4_p
age NN 4_p
and CC 4_p
sex NN 4_p
but CC 4_p
below IN 4_p
130/90 CD 4_p
mm NN 4_p
Hg NNP 4_p
at IN N
school NN N
screening VBG N
were VBD N
randomized VBN N
to TO N
a DT N
family NN N
intervention NN N
program NN N
or CC N
a DT N
control NN N
group NN N
Twenty NNP 3_p
children NNS 1_p
aged VBD 1_p
6 CD 1_p
to TO 1_p
9 CD 1_p
years NNS 1_p
and CC N
their PRP$ N
families NNS N
began VBD N
a DT N
program NN N
to TO N
modify VB N
the DT N
family NN N
diet VBZ N
toward IN N
a DT N
goal NN N
of IN N
70 CD N
mEq JJ N
sodium NN N
per IN N
person NN N
per IN N
day NN N
Adherence NNP N
was VBD N
assessed VBN N
by IN N
3-day JJ N
food NN N
records NNS N
and CC N
urine JJ N
collections NNS N
in IN N
children NNS N
and CC N
adults NNS N
The DT N
sodium NN N
intakes NNS N
and CC N
blood NN N
pressures NNS N
of IN N
the DT N
intervention NN N
and CC N
control NN N
group NN N
were VBD N
compared VBN N
1 CD N
year NN N
after IN N
randomization NN N
Sodium NNP N
intake NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
only RB N
in IN N
the DT N
active JJ N
participants NNS N
as IN N
compared VBN N
to TO N
dropouts NNS N
and CC N
controls NNS N
( ( N
87 CD N
vs NN N
130 CD N
and CC N
133 CD N
mmoles/24 NNS N
hr NN N
) ) N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
height NN N
, , N
weight NN N
, , N
or CC N
blood NN N
pressure NN N
-DOCSTART- -X- O O 17175376

No DT N
association NN N
between IN N
dinucleotide JJ N
repeat NN N
polymorphism NN N
in IN N
intron NN N
1 CD N
of IN N
the DT N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
gene NN N
EGFR NNP N
and CC N
risk NN 4_p
of IN 4_p
lung NN 4_p
cancer NN 4_p
The DT N
tyrosine JJ N
kinase NN N
receptor NN N
EGFR NNP N
pathway NN N
is VBZ N
one CD N
of IN N
the DT N
oncogenic JJ N
signaling NN N
cascades NNS N
involved VBN N
in IN N
lung NN N
cancer NN N
, , N
mediating VBG N
the DT N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
gene NN N
EGFR NNP N
First-intron NNP N
polymorphisms NN N
with IN N
greater JJR N
numbers NNS N
of IN N
CA NNP N
dinucleotide NN N
repeats NNS N
tend VBP N
to TO N
downregulate VB N
EGFR NNP N
expression NN N
, , N
which WDT N
suggests VBZ N
that IN N
this DT N
polymorphism NN N
may MD N
modulate VB N
susceptibility NN 4_p
to TO 4_p
lung NN 4_p
cancer NN 4_p
The DT N
present JJ N
hospital-based JJ N
case-control NN N
study NN N
evaluated VBD N
the DT N
possible JJ N
association NN N
of IN N
CA NNP 4_p
repeat NN 4_p
polymorphism NN 4_p
in IN 4_p
the DT 4_p
EGFR NNP 4_p
gene NN 4_p
with IN 4_p
risk NN 4_p
of IN 4_p
lung NN 4_p
cancer NN 4_p
in IN 4_p
a DT 4_p
Korean JJ 4_p
population NN 4_p
A DT N
bimodal JJ N
pattern NN N
appeared VBD N
, , N
with IN N
a DT N
frequency NN N
of IN N
57.1 CD N
% NN N
for IN N
20 CD N
CA NNP N
repeats NNS N
and CC N
18.6 CD N
% NN N
for IN N
16 CD N
CA NNP N
repeats NNS N
There EX N
was VBD N
, , N
however RB N
, , N
no DT N
significant JJ N
difference NN N
in IN N
distribution NN N
of IN N
allele JJ N
genotypes NNS N
between IN N
all DT N
lung NN N
cancer NN N
cases NNS N
and CC N
the DT N
controls NNS N
, , N
nor CC N
among IN N
histological JJ N
types NNS N
for IN N
the DT N
cases NNS N
-DOCSTART- -X- O O 24550145

Two CD N
to TO N
ten CD N
years NNS N
: : N
developmental JJ N
trajectories NNS N
of IN N
joint JJ N
attention NN N
in IN N
children NNS 1_p
with IN N
ASD NNP 4_p
who WP N
received VBD 4_p
targeted VBN 4_p
social JJ 4_p
communication NN 4_p
interventions NNS 4_p
This DT N
study NN N
follows VBZ N
40 CD 3_p
children NNS 1_p
who WP N
were VBD N
participants NNS N
in IN N
a DT N
randomized NN 4_p
controlled VBD 4_p
early JJ 4_p
intervention NN 4_p
trial NN N
( ( N
Kasari NNP N
et RB N
al RB N
) ) N
from IN 1_p
early JJ 1_p
childhood NN 1_p
( ( 1_p
2-5 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
) ) 1_p
to TO 1_p
elementary JJ 1_p
school NN 1_p
age NN 1_p
( ( 1_p
8-10 CD 1_p
years NNS 1_p
) ) 1_p
To TO N
fully RB N
utilize VB N
the DT N
available JJ N
longitudinal JJ N
data NNS N
, , N
the DT N
general JJ N
linear NN N
mixed JJ N
model NN N
was VBD N
the DT N
primary JJ N
analytical JJ N
approach NN N
The DT N
growth NN N
trajectories NNS N
of IN N
joint JJ N
attention NN N
skills NNS N
( ( N
pointing VBG N
, , N
coordinated VBD N
joint JJ N
looking VBG N
, , N
and CC N
showing VBG N
) ) N
and CC N
expressive JJ N
language NN N
outcomes NNS N
in IN N
these DT N
children NNS N
were VBD N
estimated VBN N
based VBN N
on IN N
five CD N
time NN N
points NNS N
during IN N
the DT N
measurement JJ N
period NN N
The DT N
children NNS N
were VBD N
grouped VBN N
by IN N
diagnosis NN N
at IN N
the DT N
last JJ N
follow-up JJ N
( ( N
autism NN N
, , N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
, , N
no DT N
diagnosis NN N
) ) N
and CC N
by IN N
their PRP$ N
original JJ N
treatment NN N
group NN N
assignment NN N
( ( N
joint JJ N
attention NN N
, , N
symbolic JJ N
play NN N
, , N
control NN N
) ) N
, , N
and CC N
differences NNS N
between IN N
these DT N
groups NNS N
were VBD N
evaluated VBN N
Results NNS N
showed VBD N
that IN N
joint JJ N
attention NN N
skills NNS N
of IN N
coordinated VBN N
joint NN N
looking VBG N
and CC N
showing VBG N
increased VBN N
over IN N
time NN N
, , N
and CC N
pointing VBG N
to TO N
share NN N
interest NN N
increased VBN N
over IN N
the DT N
first JJ N
year NN N
measured VBN N
and CC N
decreased VBN N
thereafter RB N
These DT N
trajectories NNS N
were VBD N
influenced VBN N
by IN N
both DT N
original JJ N
treatment NN N
assignment NN N
and CC N
diagnostic JJ N
status NN N
at IN N
follow-up NN N
In IN N
addition NN N
, , N
a DT N
cross-lagged JJ N
panel NN N
analysis NN N
revealed VBD N
a DT N
causal NN N
relationship NN N
between IN N
early JJ N
pointing NN N
and CC N
later RB N
language NN N
development NN N
This DT N
study NN N
highlights VBZ N
the DT N
longitudinal JJ N
and CC N
developmental JJ N
importance NN N
of IN N
measures NNS N
of IN N
early JJ N
core NN N
deficits NNS N
in IN N
autism NN N
, , N
and CC N
suggests VBZ N
that IN N
both DT N
treatment NN N
and CC N
ASD NNP N
symptomatology NN N
may MD N
influence VB N
growth NN N
in IN N
these DT N
skills NNS N
over IN N
time NN N
-DOCSTART- -X- O O 2035777

The DT N
effect NN N
of IN N
prophylactic JJ N
fentanyl NN N
on IN N
shivering VBG 4_p
in IN N
elective JJ 4_p
caesarean JJ 4_p
section NN 4_p
under IN 4_p
epidural JJ 4_p
analgesia NN 4_p
The DT N
aims NNS N
of IN N
this DT N
randomised VBN N
double-blind NN N
study NN N
were VBD N
to TO N
investigate VB N
whether IN N
25 CD N
micrograms NNS N
of IN N
fentanyl NN N
administered VBN N
prophylactically RB N
by IN N
the DT N
epidural JJ N
route NN N
would MD N
influence VB N
the DT N
incidence NN N
of IN N
shivering VBG N
in IN N
parturients NNS 4_p
who WP N
underwent VBP 4_p
elective JJ 4_p
Caesarean JJ 4_p
section NN 4_p
under IN N
epidural JJ 4_p
analgesia NN 4_p
and CC N
whether IN N
it PRP N
would MD N
affect VB N
the DT N
axillary JJ N
and CC N
calf JJ N
temperatures NNS N
There EX N
was VBD N
a DT N
50 CD N
% NN N
reduction NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
in IN N
the DT N
overall JJ N
incidence NN N
of IN N
shivering VBG N
in IN N
patients NNS N
who WP N
received VBD N
fentanyl NN N
and CC N
there EX N
was VBD N
some DT N
evidence NN N
to TO N
suggest VB N
that IN N
low-dose JJ N
epidural JJ N
fentanyl NN N
might MD N
reduce VB N
shivering VBG N
by IN N
an DT N
influence NN N
on IN N
thermoregulation NN N
-DOCSTART- -X- O O 8454478

A DT N
randomized JJ N
trial NN N
of IN N
radiation NN N
therapy NN N
compared VBN N
to TO N
split VB N
course NN N
radiation NN N
therapy NN N
combined VBN N
with IN N
mitomycin JJ N
C NNP N
and CC N
5 CD N
fluorouracil NN N
as IN N
initial JJ N
treatment NN N
for IN N
advanced JJ 4_p
laryngeal NN 4_p
and CC 4_p
hypopharyngeal NN 4_p
squamous JJ 4_p
carcinoma NN 4_p
Two CD 3_p
hundred VBD 3_p
and CC 3_p
twelve JJ 3_p
patients NNS N
with IN N
previously RB 4_p
untreated VBN 4_p
advanced JJ 4_p
squamous JJ 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
larynx NN 4_p
or CC 4_p
hypopharynx NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
initial JJ N
treatment NN N
with IN N
radiotherapy NN N
, , N
50 CD N
Gy NNP N
in IN N
20 CD N
fractions NNS N
in IN N
28 CD N
days NNS N
or CC N
split JJ N
course NN N
radiotherapy NN N
and CC N
concurrent NN N
chemotherapy NN N
, , N
25 CD N
Gy NNP N
in IN N
10 CD N
fractions NNS N
in IN N
14 CD N
days NNS N
followed VBN N
by IN N
a DT N
4 CD N
week NN N
rest NN N
and CC N
a DT N
further JJ N
25 CD N
Gy NNP N
in IN N
10 CD N
fractions NNS N
in IN N
14 CD N
days NNS N
starting VBG N
on IN N
day NN N
43 CD N
; : N
Mitomycin NNP N
C NNP N
was VBD N
given VBN N
on IN N
day NN N
1 CD N
and CC N
day NN N
43 CD N
and CC N
5FU CD N
continuous JJ N
infusions NNS N
on IN N
days NNS N
1 CD N
-- : N
4 CD N
and CC N
days NNS N
43 CD N
-- : N
46 CD N
Surgery NN N
was VBD N
reserved VBN N
for IN N
persistent NN N
or CC N
recurrent JJ N
disease NN N
Two CD N
hundred VBD N
and CC N
nine CD N
of IN N
the DT N
212 CD N
patients NNS N
randomized VBN N
were VBD N
included VBN N
in IN N
the DT N
analyses NNS N
Outcome NN N
analyses NNS N
were VBD N
performed VBN N
at IN N
a DT N
median JJ N
follow-up JJ N
interval NN N
of IN N
4.4 CD N
years NNS N
No DT N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up NN N
No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
arms NNS N
for IN N
the DT N
end NN N
points NNS N
of IN N
local JJ N
relapse-free JJ N
rate NN N
( ( N
p JJ N
= NNP N
0.91 CD N
) ) N
, , N
regional JJ N
relapse-free JJ N
rate NN N
( ( N
p JJ N
= NN N
0.17 CD N
, , N
adjusted VBN N
) ) N
or CC N
overall JJ N
survival NN N
( ( N
p JJ N
= NNP N
0.86 CD N
) ) N
Eight-eight JJ N
patients NNS N
had VBD N
attempted VBN N
surgical JJ N
resection NN N
following VBG N
radiotherapy JJ N
failure NN N
The DT N
contribution NN N
of IN N
salvage NN N
surgery NN N
to TO N
overall JJ N
survival NN N
was VBD N
similar JJ N
for IN N
both DT N
arms NNS N
of IN N
the DT N
study NN N
as IN N
was VBD N
the DT N
surgical JJ N
complication NN N
rate NN N
Serious JJ N
late JJ N
radiation NN N
toxicity NN N
was VBD N
minimal JJ N
( ( N
3 CD N
% NN N
in IN N
the DT N
RT NNP N
group NN N
, , N
0 CD N
% NN N
in IN N
the DT N
radiation NN N
therapy NN N
plus CC N
chemotherapy NN N
group NN N
) ) N
The DT N
result NN N
of IN N
the DT N
trial NN N
shows VBZ N
no DT N
advantage NN N
in IN N
terms NNS N
of IN N
local JJ N
control NN N
or CC N
survival NN N
for IN N
the DT N
experimental JJ N
treatment NN N
arm NN N
of IN N
split NN N
course NN N
radiotherapy NN N
and CC N
concurrent JJ N
chemotherapy NN N
with IN N
Mitomycin NNP N
C NNP N
and CC N
5 CD N
Fluorouracil NNP N
compared VBN N
to TO N
radiotherapy VB N
alone RB N
-DOCSTART- -X- O O 10337657

Effect NN N
of IN N
total JJ N
androgen NN N
ablation NN N
on IN N
pathologic JJ N
stage NN N
and CC N
resection NN N
limit NN N
status NN N
of IN N
prostate NN 4_p
cancer NN 4_p
Initial JJ N
results NNS N
of IN N
the DT N
Italian JJ N
PROSIT NNP N
study NN N
The DT N
likelihood NN N
of IN N
finding VBG N
organ-confined JJ N
untreated JJ N
prostate NN N
cancer NN N
( ( N
PCa NNP N
) ) N
by IN N
pathological JJ N
examination NN N
at IN N
the DT N
time NN N
of IN N
radical JJ N
prostatectomy NN N
( ( N
RP NNP N
) ) N
is VBZ N
only RB N
50 CD N
% NN N
in IN N
patients NNS N
with IN N
clinically RB N
organ-confined JJ N
disease NN N
In IN N
addition NN N
, , N
tumour NN N
is VBZ N
present JJ N
at IN N
the DT N
resection NN N
margin NN N
in IN N
approximately RB N
30 CD N
% NN N
of IN N
clinical JJ N
T2 NNP N
( ( N
clinical JJ N
stage NN N
B NNP N
) ) N
cases NNS N
The DT N
issue NN N
of IN N
clinical JJ N
" NN N
understaging VBG N
" NNP N
and CC N
of IN N
resection NN N
limit NN N
positivity NN N
have VBP N
led VBN N
to TO N
the DT N
development NN N
of IN N
novel JJ N
management NN N
practices NNS N
, , N
including VBG N
" JJ N
neoadjuvant JJ N
" NNP N
hormonal JJ N
therapy NN N
( ( N
NHT NNP N
) ) N
The DT N
optimal JJ N
duration NN N
of IN N
NHT NNP N
is VBZ N
unknown JJ N
We PRP N
undertook VBD N
the DT N
present JJ N
analysis NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
NHT NNP N
on IN N
pathologic JJ N
stage NN N
of IN N
PCa NNP N
and CC N
resection NN N
limit NN N
status NN N
in IN N
patients NNS N
with IN N
prostate JJ N
cancer NN N
and CC N
treated VBN N
with IN N
total JJ N
androgen NN N
ablation NN N
either DT N
for IN N
three CD N
or CC N
six CD N
months NNS N
before IN N
RP NNP N
Between NNP N
January NNP N
1996 CD N
and CC N
February NNP N
1998 CD N
, , N
259 CD N
men NNS N
with IN N
prostate NN N
cancer NN N
underwent JJ N
radical JJ N
retropubic NN N
prostatectomy NN N
and CC N
bilateral JJ N
pelvic JJ N
node NN N
dissection NN N
in IN N
the DT N
26 CD N
centres NNS N
participating VBG N
in IN N
the DT N
Italian JJ N
randomised VBD N
prospective JJ N
PROSIT NNP N
study NN N
Whole NNP N
mount NN N
sectioning NN N
of IN N
the DT N
complete JJ N
RP NNP N
specimens NNS N
was VBD N
adopted VBN N
in IN N
each DT N
centre NN N
for IN N
accurately RB N
evaluating VBG N
the DT N
pathologic JJ N
stage NN N
and CC N
resection NN N
limit NN N
status NN N
By IN N
February NNP N
1998 CD N
, , N
haematoxylin NN N
and CC N
eosin NN N
stained VBD N
sections NNS N
from IN N
155 CD N
RP NNP N
specimens NNS N
had VBD N
been VBN N
received VBN N
and CC N
evaluated VBN N
by IN N
the DT N
reviewing VBG N
pathologist NN N
( ( N
RM NNP N
) ) N
64 CD N
cases NNS N
had VBD N
not RB N
been VBN N
treated VBN N
with IN N
total JJ N
androgen NN N
ablation NN N
( ( N
e.g JJ N
NHT NNP N
) ) N
before IN N
RP NNP N
was VBD N
performed VBN N
, , N
whereas JJ N
58 CD N
and CC N
33 CD N
had VBD N
been VBN N
treated VBN N
for IN N
three CD N
and CC N
six CD N
months NNS N
, , N
respectively RB N
114 CD N
patients NNS N
were VBD N
clinical JJ N
stage NN N
B NNP N
whereas IN N
41 CD N
were VBD N
clinical JJ N
stage NN N
C. NNP N
After IN N
three CD N
months NNS N
of IN N
total JJ N
androgen NN N
ablation NN N
, , N
pathological JJ N
stage NN N
B NNP N
was VBD N
more RBR N
prevalent JJ N
among IN N
patients NNS N
with IN N
clinical JJ N
B NNP N
tumours NN N
, , N
compared VBN N
with IN N
untreated JJ N
patients NNS N
( ( N
57 CD N
% NN N
in IN N
treated JJ N
patients NNS N
vs. FW N
36 CD N
% NN N
in IN N
untreated JJ N
) ) N
The DT N
percentage NN N
of IN N
cancers NNS N
with IN N
negative JJ N
margins NNS N
was VBD N
statistically RB N
significantly RB N
greater JJR N
in IN N
patients NNS N
treated VBN N
with IN N
neoadjuvant JJ N
therapy NN N
than IN N
those DT N
treated VBN N
with IN N
immediate JJ N
surgery NN N
alone RB N
( ( N
69 CD N
% NN N
vs. FW N
42 CD N
% NN N
, , N
respectively RB N
) ) N
After IN N
six CD N
months NNS N
of IN N
NHT NNP N
therapy VBP N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
pathological JJ N
stage NN N
B NNP N
( ( N
67 CD N
% NN N
vs. FW N
36 CD N
% NN N
, , N
respectively RB N
) ) N
and CC N
negative JJ N
margins NNS N
was VBD N
greater JJR N
than IN N
after IN N
3 CD N
months NNS N
( ( N
92 CD N
% NN N
vs. FW N
42 CD N
% NN N
, , N
respectively RB N
) ) N
For IN N
clinical JJ N
C NNP N
tumours NN N
, , N
the DT N
prevalence NN N
of IN N
pathological JJ N
stage NN N
B NNP N
and CC N
negative JJ N
margins NNS N
in IN N
the DT N
patients NNS N
treated VBD N
for IN N
either DT N
3 CD N
or CC N
6 CD N
months NNS N
was VBD N
not RB N
as RB N
high JJ N
as IN N
in IN N
the DT N
clinical JJ N
B NNP N
tumours NN N
, , N
when WRB N
compared VBN N
with IN N
the DT N
untreated JJ N
group NN N
( ( N
pathological JJ N
stage NN N
B NNP N
: : N
31 CD N
% NN N
and CC N
33 CD N
% NN N
vs. FW N
6 CD N
% NN N
in IN N
the DT N
clinical JJ N
C NNP N
cases NNS N
, , N
respectively RB N
Negative JJ N
margins NNS N
: : N
56 CD N
% NN N
and CC N
67 CD N
% NN N
vs. FW N
31 CD N
% NN N
, , N
respectively RB N
) ) N
The DT N
initial JJ N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
total JJ N
androgen NN N
ablation NN N
before IN N
RP NNP N
is VBZ N
beneficial JJ N
in IN N
men NNS N
with IN N
clinical JJ N
stage NN N
B NNP N
because IN N
of IN N
the DT N
significant JJ N
pathological JJ N
downstaging NN N
and CC N
decrease NN N
in IN N
the DT N
number NN N
of IN N
positive JJ N
margins NNS N
in IN N
the DT N
RP NNP N
specimens NNS N
These DT N
two CD N
effects NNS N
are VBP N
more RBR N
pronounced JJ N
after IN N
six CD N
months NNS N
of IN N
NHT NNP N
than IN N
after IN N
three CD N
months NNS N
of IN N
therapy NN N
The DT N
same JJ N
degree NN N
of IN N
beneficial JJ N
effects NNS N
are VBP N
not RB N
observed VBN N
in IN N
clinical JJ N
C NNP N
tumours NN N
-DOCSTART- -X- O O 25342205

Dexmedetomidine NNP N
pretreatment NN N
alleviates VBZ N
propofol JJ 4_p
injection NN 4_p
pain NN 4_p
OBJECTIVE CC N
The DT N
incidence NN N
of IN N
propofol JJ N
injection NN N
pain NN N
during IN N
induction NN N
of IN N
general JJ N
anesthesia NN N
varies NNS N
from IN N
28 CD N
% NN N
to TO N
90 CD N
% NN N
This DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
dexmedetomidine NN N
( ( N
DEX NNP N
) ) N
for IN N
reducing VBG N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
propofol JJ N
injection NN N
pain NN N
METHODS NNP N
Patients NNPS N
undergoing VBG N
elective JJ N
surgical JJ N
procedures NNS N
were VBD N
randomly RB N
allocated VBN N
into IN N
seven CD N
groups NNS N
of IN N
30 CD 3_p
patients NNS N
each DT N
Experimental JJ N
treatments NNS N
were VBD N
intravenously RB N
administered VBN N
over IN N
10 CD N
min NNS N
( ( N
total JJ N
volume NN N
10 CD N
mL NN N
) ) N
prior RB N
to TO N
intravenous JJ N
propofol NN N
injection NN N
, , N
as IN N
follows VBZ N
: : N
group NN N
I PRP N
, , N
the DT N
control NN N
group NN N
, , N
was VBD N
given VBN N
isotonic JJ N
saline NN N
Patients NNS N
in IN N
groups NNS N
II NNP N
, , N
III NNP N
, , N
and CC N
IV NNP N
received VBD N
DEX NNP N
0.25 CD N
µg/kg NNP N
, , N
0.5 CD N
µg/kg NN N
, , N
or CC N
1.0 CD N
µg/kg NNS N
, , N
respectively RB N
, , N
mixed JJ N
with IN N
isotonic JJ N
saline NN N
immediately RB N
before IN N
propofol JJ N
injection NN N
Patients NNS N
in IN N
groups NNS N
V NNP N
, , N
VI NNP N
, , N
and CC N
VII NNP N
received VBD N
DEX NNP N
as IN N
above NN N
, , N
but CC N
5 CD N
minutes NNS N
before IN N
propofol JJ N
injection NN N
Propofol NNP N
consisted VBD N
of IN N
1 CD N
% NN N
long-chain JJ N
triglyceride NN N
propofol NN N
( ( N
2.5 CD N
mg/kg NN N
) ) N
injected VBD N
at IN N
1 CD N
mL/s NNS N
RESULTS NNP N
Median JJ N
propofol NN N
injection NN N
pain NN N
score NN N
was VBD N
0.00 CD N
( ( N
IQR NNP N
0.00-3.00 NN N
) ) N
in IN N
patients NNS N
who WP N
received VBD N
1.0 CD N
µg/kg NNP N
DEX NNP N
5 CD N
min NN N
before IN N
the DT N
propofol NN N
injection NN N
( ( N
group NN N
VII NNP N
) ) N
, , N
and CC N
only RB N
1 CD N
patient NN N
( ( N
of IN N
30 CD N
) ) N
in IN N
this DT N
group NN N
received VBD N
a DT N
pain NN N
score NN N
> VBD N
2 CD N
The DT N
median JJ N
pain NN N
score NN N
and CC N
number NN N
of IN N
patients NNS N
with IN N
pain NN N
scores NNS N
> VBP N
2 CD N
in IN N
group NN N
VII NNP N
were VBD N
both DT N
significantly RB N
less JJR N
than IN N
in IN N
the DT N
control NN N
( ( N
group NN N
I PRP N
; : N
p CC N
= $ N
0.000 CD N
, , N
both DT N
) ) N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
either DT N
mean JJ N
arterial JJ N
pressure NN N
or CC N
heart NN N
rate NN N
at IN N
any DT N
time NN N
point NN N
after IN N
DEX NNP N
injection NN N
among IN N
the DT N
groups NNS N
CONCLUSIONS NNP N
Pretreatment NNP N
with IN N
intravenous JJ N
DEX NNP N
1 CD N
µg/kg VBD N
5 CD N
min NN N
prior RB N
to TO N
injection NN N
of IN N
long-chain JJ N
triglyceride NN N
propofol NN N
is VBZ N
effective JJ N
and CC N
safe JJ N
in IN N
reducing VBG N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
pain NN N
due JJ N
to TO N
propofol VB N
injection NN N
-DOCSTART- -X- O O 11743411

Capsular JJ N
contracture NN N
around IN N
saline-filled JJ N
fine NN N
textured VBN N
and CC N
smooth JJ N
mammary JJ N
implants NNS N
: : N
a DT N
prospective JJ N
7.5-year JJ N
follow-up NN N
In IN N
a DT N
previous JJ N
prospective JJ N
randomized VBN N
clinical JJ N
study NN N
comparing VBG N
in IN N
the DT N
same JJ N
patient NN N
textured VBD N
and CC N
smooth JJ N
saline-filled JJ N
mammary JJ N
implants NNS N
( ( N
Biocell NNP N
) ) N
with IN N
large JJ N
pore NN N
size NN N
( ( N
300 CD N
to TO N
600 CD N
microm NN N
) ) N
, , N
we PRP N
saw VBD N
no DT N
difference NN N
in IN N
capsular JJ N
contracture NN N
This DT N
study NN N
was VBD N
undertaken VBN N
in IN N
a DT N
similar JJ N
way NN N
to TO N
compare VB N
capsular JJ N
contracture NN N
around IN N
smooth JJ N
and CC N
textured VBD N
saline-filled JJ N
prostheses NNS N
with IN N
pores NNS N
of IN N
small JJ N
size NN N
During IN N
a DT N
period NN N
of IN N
7.5 CD N
years NNS N
, , N
the DT N
breast NN N
hardness NN N
was VBD N
followed VBN N
up RP N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
patient JJ N
satisfaction NN N
was VBD N
evaluated VBN N
Twenty NNP 3_p
healthy JJ 4_p
women NNS 2_p
with IN N
a DT N
mean JJ 1_p
age NN 1_p
of IN 1_p
30 CD 1_p
years NNS 1_p
were VBD N
operated VBN N
on IN N
for IN N
breast NN 4_p
augmentation NN 4_p
Two CD N
surgeons NNS N
performed VBD N
all DT N
operations NNS N
in IN N
a DT N
standardized JJ N
way NN N
Each DT N
patient NN N
received VBD N
subglandularly RB N
a DT N
Siltex NNP N
textured VBD N
saline-filled JJ N
prosthesis NN N
with IN N
a DT N
pore NN N
size NN N
of IN N
30 CD N
to TO N
70 CD N
microm NN N
in IN N
one CD N
breast NN N
, , N
and CC N
a DT N
smooth JJ N
saline-filled JJ N
prosthesis NN N
in IN N
the DT N
other JJ N
The DT N
hardness NN N
of IN N
the DT N
breasts NNS N
was VBD N
evaluated VBN N
after IN N
0.5 CD N
, , N
1 CD N
, , N
and CC N
7.5 CD N
years NNS N
using VBG N
Baker NNP N
grading NN N
and CC N
applanation NN N
tonometry NN N
Eighteen JJ 3_p
patients NNS 3_p
completed VBN N
1-year JJ N
and CC N
7.5-year JJ N
follow-up NN N
Two CD N
breasts NNS N
with IN N
smooth JJ N
prostheses NNS N
were VBD N
contracted VBN N
after IN N
6 CD N
months NNS N
( ( N
Baker NNP N
III NNP N
or CC N
IV NNP N
) ) N
After IN N
1 CD N
year NN N
, , N
four CD N
patients NNS N
with IN N
smooth JJ N
prostheses NNS N
and CC N
one CD N
with IN N
a DT N
textured JJ N
prosthesis NN N
had VBD N
capsular JJ N
contracture NN N
( ( N
p JJ N
= NNP N
0.34 CD N
) ) N
Seven CD N
and CC N
one-half JJ N
years NNS N
after IN N
surgery NN N
, , N
six CD N
patents NNS N
with IN N
smooth DT N
and CC N
four CD N
with IN N
textured JJ N
implants NNS N
had VBD N
contracture NN N
( ( N
p JJ N
= NNP N
0.66 CD N
) ) N
On IN N
two CD N
patients NNS N
with IN N
smooth JJ N
prostheses NNS N
and CC N
one CD N
patient NN N
with IN N
a DT N
textured JJ N
prosthesis NN N
, , N
the DT N
capsule NN N
around IN N
the DT N
implant NN N
hardened VBD N
between IN N
6 CD N
and CC N
12 CD N
months NNS N
Between NNP N
1 CD N
year NN N
and CC N
7.5 CD N
years NNS N
, , N
three CD N
breasts NNS N
with IN N
smooth JJ N
and CC N
textured JJ N
implants NNS N
contracted VBD N
and CC N
one CD N
with IN N
a DT N
textured JJ N
implant NN N
softened.The NN N
patients NNS N
reported VBN N
on IN N
a DT N
Visual NNP N
Analogue NNP N
Scale NNP N
( ( N
1 CD N
to TO N
10 CD N
) ) N
the DT N
impact NN N
of IN N
the DT N
augmentation NN N
on IN N
their PRP$ N
quality NN N
of IN N
life NN N
to TO N
be VB N
9 CD N
+/- JJ N
1 CD N
Four CD N
patients NNS N
preferred VBD N
the DT N
breast NN N
with IN N
the DT N
smooth JJ N
prosthesis NN N
, , N
three CD N
preferred VBD N
the DT N
breast NN N
with IN N
the DT N
textured JJ N
prosthesis NN N
, , N
and CC N
the DT N
others NNS N
found VBD N
both DT N
breasts NNS N
equal VBP N
This DT N
study NN N
showed VBD N
no DT N
significant JJ N
difference NN N
of IN N
contracture NN N
with IN N
smooth JJ N
versus FW N
fine JJ N
textured VBN N
implants NNS N
The DT N
majority NN N
of IN N
the DT N
patients NNS N
preferred VBD N
the DT N
smooth JJ N
implants NNS N
The DT N
patients NNS N
reported VBD N
that IN N
the DT N
breast NN N
augmentation NN N
had VBD N
had VBN N
an DT N
extremely RB N
high JJ N
impact NN N
on IN N
their PRP$ N
quality NN N
of IN N
life NN N
-DOCSTART- -X- O O 8255984

A DT N
preliminary JJ N
trial NN N
of IN N
ascorbic JJ N
acid NN N
as IN N
supplemental JJ N
therapy NN N
for IN N
autism NN 4_p
1 CD N
This DT N
study NN N
presents VBZ N
the DT N
results NNS N
of IN N
a DT N
30-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
exploring VBG N
the DT N
effectiveness NN N
of IN N
ascorbic JJ N
acid NN N
( ( N
8g/70kg/day CD N
) ) N
as IN N
a DT N
supplemental JJ N
pharmacological JJ N
treatment NN N
for IN N
autistic JJ 1_p
children NNS 1_p
in IN 1_p
residential JJ 1_p
treatment NN 1_p
2 CD N
Residential JJ 1_p
school NN 1_p
children NNS 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
18 CD 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
ascorbate-ascorbate-placebo JJ N
treatment NN N
order NN N
group NN N
or CC N
ascorbate-placebo-ascorbate JJ N
treatment NN N
order NN N
group NN N
Each DT N
treatment NN N
phase NN N
lasted VBD N
10 CD N
weeks NNS N
and CC N
behaviors NNS N
were VBD N
rated VBN N
weekly JJ N
using VBG N
the DT N
Ritvo-Freeman NNP N
scale NN N
3 CD N
Significant JJ N
group NN N
by IN N
phase NN N
interactions NNS N
were VBD N
found VBN N
for IN N
total JJ N
scores NNS N
and CC N
also RB N
sensory JJ N
motor NN N
scores NNS N
indicating VBG N
a DT N
reduction NN N
in IN N
symptom JJ N
severity NN N
associated VBN N
with IN N
the DT N
ascorbic JJ N
acid NN N
treatment NN N
4 CD N
These DT N
results NNS N
were VBD N
consistent JJ N
with IN N
a DT N
hypothesized VBN N
dopaminergic NN N
mechanism NN N
of IN N
action NN N
of IN N
ascorbic JJ N
acid NN N
-DOCSTART- -X- O O 21704300

Preoperative JJ N
beta-blocker NN N
usage NN N
: : N
is VBZ N
it PRP N
really RB N
worthy JJ N
of IN N
being VBG N
a DT N
quality NN N
indicator NN N
? . N
BACKGROUND NNP N
Since IN N
2007 CD N
, , N
the DT N
use NN N
of IN N
preoperative JJ N
β-blockers NNS N
has VBZ N
been VBN N
used VBN N
as IN N
a DT N
quality NN N
standard NN N
for IN N
patients NNS N
undergoing VBG N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
Recent JJ N
studies NNS N
have VBP N
called VBN N
into IN N
question NN N
of IN N
the DT N
benefit NN N
of IN N
empiric JJ N
preoperative JJ N
β-blocker NN N
use NN N
METHODS NNP N
Data NNP N
were VBD N
extracted VBN N
from IN N
our PRP$ N
Society NN N
of IN N
Thoracic NNP N
Surgeons NNP N
certified VBD N
database NN N
for IN N
patients NNS N
undergoing VBG 4_p
isolated JJ 4_p
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
graft NN 4_p
surgery NN 4_p
from IN N
2000 CD N
to TO N
2008 CD N
We PRP N
compared VBN N
the DT N
outcomes NNS N
for IN N
patients NNS N
who WP N
received VBD N
preoperative JJ N
β-blockers NNS N
with IN N
those DT N
of IN N
patients NNS N
who WP N
did VBD N
not RB N
RESULTS VB N
The DT N
study NN N
group NN N
had VBD N
12,855 CD 3_p
patients NNS N
, , N
of IN N
whom WP N
7,967 CD N
( ( N
62.0 CD N
% NN N
) ) N
were VBD N
treated VBN N
preoperatively RB N
with IN N
β-blockers NNS N
Using VBG N
propensity NN N
matching NN N
, , N
we PRP N
selected VBD N
two CD N
matched JJ N
groups NNS N
of IN N
4,474 CD N
patients NNS N
with IN N
preoperative JJ N
β-blocker NN N
use NN N
and CC N
4,474 CD N
not RB N
using VBG N
preoperative JJ N
β-blockers NNS N
In IN N
the DT N
unmatched JJ N
cohort NN N
, , N
only RB N
deep JJ N
sternal JJ N
infection NN N
( ( N
0.3 CD N
% NN N
versus IN N
0.5 CD N
% NN N
without IN N
β-blockers NNS N
; : N
p=0.032 NN N
) ) N
, , N
pneumonia NN N
( ( N
1.9 CD N
% NN N
versus IN N
2.4 CD N
% NN N
without IN N
β-blockers NNS N
; : N
p=0.039 NN N
) ) N
, , N
and CC N
intraoperative JJ N
blood NN N
usage NN N
( ( N
37.2 CD N
% NN N
versus IN N
34.1 CD N
% NN N
without IN N
β-blockers NNS N
; : N
p VB N
< $ N
0.001 CD N
) ) N
reached VBD N
statistically RB N
significant JJ N
difference NN N
In IN N
the DT N
matched JJ N
groups NNS N
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
adverse JJ N
event NN N
rates NNS N
in IN N
patients NNS N
treated VBN N
with IN N
β-blockers NNS N
and CC N
those DT N
who WP N
were VBD N
not RB N
The DT N
number NN N
of IN N
patients NNS N
requiring VBG N
intraoperative JJ N
blood NN N
product NN N
use NN N
was VBD N
significantly RB N
higher JJR N
among IN N
β-blocker-treated JJ N
patients NNS N
( ( N
p=0.004 NN N
) ) N
Calculating VBG N
the DT N
adjusted VBN N
odds NNS N
ratios NNS N
showed VBD N
that IN N
in IN N
the DT N
matched JJ N
groups NNS N
, , N
the DT N
preoperative JJ N
use NN N
of IN N
β-blockers NNS N
was VBD N
not RB N
an DT N
independent JJ N
predictor NN N
of IN N
mortality NN N
CONCLUSIONS VB N
A DT N
rational NN N
for IN N
preoperative JJ N
β-blockade JJ N
exists NNS N
However RB N
, , N
as IN N
with IN N
any DT N
medical JJ N
intervention NN N
, , N
its PRP$ N
application NN N
should MD N
be VB N
tailored VBN N
to TO N
specific JJ N
clinical JJ N
scenarios NNS N
With IN N
no DT N
differences NNS N
in IN N
mortality NN N
or CC N
morbidity NN N
, , N
our PRP$ N
findings NNS N
do VBP N
not RB N
support VB N
preoperative JJ N
β-blockade NN N
as IN N
a DT N
useful JJ N
quality NN N
indicator NN N
for IN N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
-DOCSTART- -X- O O 23630033

Study NNP N
design NN N
and CC N
rationale NN N
of IN N
a DT N
dose-ranging JJ N
trial NN N
of IN N
LX4211 NNP N
, , N
a DT N
dual JJ N
inhibitor NN N
of IN N
SGLT1 NNP N
and CC N
SGLT2 NNP N
, , N
in IN N
type JJ N
2 CD N
diabetes NNS N
inadequately RB N
controlled VBN N
on IN N
metformin NN N
monotherapy NN N
Sodium-glucose JJ N
cotransporters NNS N
1 CD N
( ( N
SGLT1 NNP N
) ) N
and CC N
2 CD N
( ( N
SGLT2 NNP N
) ) N
are VBP N
the DT N
major JJ N
cellular JJ N
transporters NNS N
responsible JJ N
for IN N
gastrointestinal JJ N
( ( N
GI NNP N
) ) N
glucose VBP N
absorption NN N
and CC N
renal JJ N
glucose NN N
reabsorption NN N
, , N
respectively RB N
LX4211 NNP N
, , N
a DT N
dual JJ N
inhibitor NN N
of IN N
SGLT1 NNP N
and CC N
SGLT2 NNP N
, , N
reduces VBZ N
glucose JJ N
absorption NN N
from IN N
the DT N
GI NNP N
tract NN N
and CC N
enhances NNS N
urinary JJ N
glucose JJ N
excretion NN N
Although IN N
several JJ N
SGLT2-selective JJ N
inhibitors NNS N
have VBP N
been VBN N
tested VBN N
in IN N
large JJ N
phase NN N
2 CD N
studies NNS N
, , N
dual JJ N
inhibition NN N
of IN N
SGLT1 NNP N
and CC N
SGLT2 NNP N
is VBZ N
novel JJ N
at IN N
this DT N
stage NN N
of IN N
drug NN N
development NN N
, , N
and CC N
it PRP N
has VBZ N
implications NNS N
for IN N
clinical-trial JJ N
design NN N
In IN N
this DT N
article NN N
, , N
we PRP N
describe VBP N
the DT N
design NN N
and CC N
rationale NN N
of IN N
a DT N
phase NN N
2 CD N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study NN N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
LX4211 NNP N
in IN N
subjects NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
mellitus NN N
who WP N
have VBP N
inadequate JJ N
glycemic NNS N
control NN N
on IN N
metformin NN N
monotherapy NN N
The DT N
primary JJ N
endpoint NN N
is VBZ N
the DT N
change NN N
in IN N
glycated JJ N
hemoglobin NN N
A1c NNP N
from IN N
baseline NN N
to TO N
week NN N
12 CD N
Secondary JJ N
endpoints NNS N
include VBP N
the DT N
proportion NN N
of IN N
subjects NNS N
achieving VBG N
a DT N
glycated JJ N
hemoglobin NN N
A1c NNP N
value NN N
of IN N
< $ N
7 CD N
% NN N
, , N
change NN N
from IN N
baseline NN N
in IN N
fasting VBG N
plasma NN N
glucose NN N
and CC N
postprandial JJ N
glucose NN N
( ( N
as IN N
part NN N
of IN N
an DT N
oral JJ N
glucose NN N
tolerance NN N
test NN N
) ) N
, , N
body NN N
weight NN N
, , N
and CC N
blood NN N
pressure NN N
Safety NN N
is VBZ N
evaluated VBN N
with IN N
particular JJ N
focus NN N
on IN N
hypoglycemia NN N
, , N
GI NNP N
symptoms NNS N
, , N
and CC N
incidence NN N
of IN N
genitourinary JJ N
tract NN N
infections NNS N
-DOCSTART- -X- O O 23104956

Effect NN N
of IN N
unfractionated JJ N
and CC N
low-molecular-weight JJ N
heparin NN N
on IN N
OPG NNP N
, , N
sRANKL NN N
, , N
and CC N
von JJ N
Willebrand NNP N
factor NN N
concentrations NNS N
during IN N
hemodialysis NN 4_p
BACKGROUND NNP N
Endothelial NNP N
dysfunction NN N
marker NN N
, , N
von FW N
Willebrand NNP N
factor NN N
( ( N
vWF NN N
) ) N
, , N
is VBZ N
physically RB N
connected VBN N
with IN N
osteoprotegerin NN N
( ( N
OPG NNP N
) ) N
in IN N
the DT N
Weibel-Palade JJ N
bodies NNS N
We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
unfractionated JJ N
( ( N
UFH NNP N
) ) N
and CC N
low-molecular-weight JJ N
( ( N
LMWH NNP N
enoxaparin RB N
) ) N
heparin NN N
used VBN N
as IN N
anticoagulants NNS N
during IN N
hemodialysis NN 4_p
( ( 4_p
HD NNP 4_p
) ) 4_p
on IN N
plasma NN N
levels NNS N
and CC N
relationships NNS N
of IN N
OPG NNP N
, , N
soluble JJ N
receptor NN N
activator NN N
of IN N
nuclear JJ N
factor NN N
κB NN N
Ligand NNP N
( ( N
sRANKL NN N
) ) N
, , N
and CC N
vWF NN N
METHODS NNP N
Totally RB 3_p
21 CD 3_p
clinically RB 3_p
stable JJ 3_p
chronic JJ 3_p
HD NNP 3_p
patients NNS 3_p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
enoxaparin NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
or CC N
UFH NNP N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
anticoagulation NN N
and CC N
followed VBD N
prospectively RB N
for IN N
12 CD N
weeks NNS N
before IN N
crossing VBG N
over IN N
to TO N
the DT N
alternate NN N
therapy NN N
for IN N
further JJ N
12 CD N
weeks NNS N
The DT N
OPG NNP N
, , N
RANKL NNP N
, , N
and CC N
vWF NN N
levels NNS N
were VBD N
measured VBN N
at IN N
T0 NNP N
, , N
T10 NNP N
, , N
and CC N
T180 NNP N
of IN N
HD NNP N
session NN N
after IN N
each DT N
period NN N
of IN N
evaluation NN N
RESULTS VB N
The DT N
baseline NN N
sRANKL NN N
level NN N
was VBD N
higher JJR N
under IN N
UFH NNP N
treatment NN N
Its PRP$ N
over-HD JJ N
level NN N
does VBZ N
not RB N
behave VB N
significantly RB N
different JJ N
under IN N
enoxaparin NN N
and CC N
UFH NNP N
treatment NN N
Plasma NNP N
OPG NNP N
levels NNS N
expressly RB N
changed VBN N
during IN N
both DT N
enoxaparin FW N
( ( N
χ NNP N
( ( N
2 CD N
) ) N
analysis NN N
of IN N
variance NN N
[ NNP N
ANOVA NNP N
] NNP N
= NNP N
31.13 CD N
, , N
P NNP N
< NNP N
.016 NNP N
) ) N
and CC N
UFH NNP N
( ( N
χ NNP N
( ( N
2 CD N
) ) N
ANOVA NNP N
= $ N
8.26 CD N
, , N
P NNP N
= NNP N
.016 NNP N
) ) N
anticoagulation NN N
, , N
and CC N
its PRP$ N
increment NN N
at IN N
T10 NNP N
and CC N
T180 NNP N
was VBD N
significantly RB N
different JJ N
between IN N
both DT N
the DT N
heparins NNS N
The DT N
main JJ N
negative JJ N
predictor NN N
of IN N
OPG NNP N
concentration NN N
was VBD N
the DT N
total JJ N
cholesterol NN N
level NN N
( ( N
β JJ N
= NNP N
-.51 NNP N
, , N
P NNP N
= NNP N
.025 NNP N
) ) N
von JJ N
Willebrand NNP N
factor NN N
concentration NN N
remained VBD N
stable JJ N
during IN N
UFH NNP N
anticoagulation NN N
, , N
whereas JJ N
constant NN N
, , N
no DT N
significant JJ N
increments NNS N
were VBD N
noticed VBN N
, , N
under IN N
enoxaparin JJ N
treatment NN N
After IN N
10 CD N
minutes NNS N
of IN N
HD NNP N
, , N
especially RB N
under IN N
enoxaparin NN N
use NN N
, , N
a DT N
positive JJ N
correlation NN N
between IN N
OPG NNP N
and CC N
vWF JJ N
increase NN N
was VBD N
noticed VBN N
( ( N
P NNP N
= NNP N
.03 NNP N
, , N
R NNP N
= NNP N
.45 NNP N
) ) N
CONCLUSIONS NNP N
Impact NNP N
of IN N
heparin NN N
on IN N
endothelial JJ N
cells NNS N
and CC N
simultaneously RB N
on IN N
OPG/RANK/RANKL NNP N
axis NN N
reinforces VBZ N
the DT N
presumption NN N
of IN N
the DT N
pathophysiological JJ N
linkage NN N
between IN N
bone NN N
mineralization NN N
and CC N
endothelial JJ N
dysfunction NN 4_p
in IN 4_p
end-stage JJ 4_p
renal JJ 4_p
disease NN 4_p
-DOCSTART- -X- O O 6148163

Thyroid NNP N
stimulating VBG N
antibodies NNS N
: : N
an DT N
aid NN N
to TO N
the DT N
strategy NN N
of IN N
treatment NN N
of IN N
Graves NNP 4_p
' POS 4_p
disease NN 4_p
? . N
In IN N
1976 CD N
we PRP N
initiated VBD N
a DT N
prospective JJ N
study NN N
to TO N
specify VB N
the DT N
usefulness NN N
of IN N
thyroid JJ N
stimulating VBG N
antibody NN N
( ( N
TSAb NNP N
) ) N
determinations NNS N
in IN N
predicting VBG N
the DT N
outcome NN N
of IN N
post-antithyroid JJ N
drug NN N
treatment NN N
for IN N
Graves NNP N
' POS N
disease NN N
This DT N
study NN N
was VBD N
carried VBN N
out RP N
on IN N
55 CD 3_p
patients NNS N
, , N
who WP N
were VBD N
either RB N
treated VBN N
for IN N
six CD N
( ( N
n JJ N
= NNP N
16 CD 3_p
) ) N
or CC N
18 CD N
months NNS N
( ( N
n JJ N
= NNP N
39 CD 3_p
) ) N
and CC N
followed VBD N
up RP N
for IN N
an DT N
additional JJ N
two-year JJ N
period NN N
TSAb NNP N
was VBD N
determined VBN N
on IN N
whole JJ N
serum NN N
in IN N
29 CD 3_p
patients NNS N
before IN N
and CC N
at IN N
the DT N
end NN N
of IN N
treatment NN N
, , N
and CC N
in IN N
26 CD 3_p
patients NNS N
at IN N
the DT N
end NN N
of IN N
treatment NN N
only RB N
These DT N
determinations NNS N
were VBD N
carried VBN N
out RP N
using VBG N
a DT N
sensitive JJ N
and CC N
reproducible JJ N
microassay NNS N
based VBN N
on IN N
cAMP JJ N
accumulation NN N
in IN N
human JJ N
thyroid NN N
cell NN N
cultures NNS N
Before IN N
treatment NN N
, , N
TSAb NNP N
ranging VBG N
from IN N
170 CD N
to TO N
1529 CD N
% NN N
was VBD N
present JJ N
in IN N
28/29 CD N
patients NNS N
and CC N
reached VBN N
significantly RB N
low JJ N
levels NNS N
at IN N
the DT N
end NN N
of IN N
treatment NN N
whatever WDT N
its PRP$ N
duration NN N
TSAb NNP N
was VBD N
undetectable JJ N
in IN N
24/55 CD N
patients NNS N
at IN N
the DT N
end NN N
of IN N
treatment NN N
8/16 CD N
'short-treated JJ N
' POS N
and CC N
18/39 CD N
'long-treated JJ N
' POS N
patients NNS N
remained VBD N
in IN N
remission NN N
As IN N
expected VBN N
, , N
initial JJ N
TSAb NNP N
levels NNS N
had VBD N
no DT N
predictive JJ N
value NN N
End-treatment JJ N
TSAb NNP N
values NNS N
, , N
when WRB N
low JJ N
( ( N
less JJR N
than IN N
350 CD N
% NN N
) ) N
or CC N
negative JJ N
did VBD N
not RB N
correlate VB N
with IN N
later JJ N
evolution NN N
: : N
in IN N
these DT N
39 CD N
patients NNS N
, , N
relapse NN N
rate NN N
was VBD N
41 CD N
% NN N
In IN N
contrast NN N
, , N
13/16 CD N
patients NNS N
with IN N
end-treatment JJ N
TSAb NNP N
greater JJR N
than IN N
350 CD N
% NN N
relapsed VBN N
Relapses NNS N
tended VBD N
to TO N
occur VB N
earlier RBR N
in IN N
patients NNS N
with IN N
the DT N
highest JJS N
TSAb NN N
levels NNS N
TSAb NNP N
determined VBD N
again RB N
during IN N
follow-up NN N
was VBD N
negative JJ N
in IN N
each DT N
of IN N
the DT N
18 CD 3_p
patients NNS N
in IN N
remission NN N
, , N
and CC N
positive JJ N
in IN N
8/10 CD 3_p
patients NNS N
at IN N
the DT N
time NN N
of IN N
relapse NN N
, , N
whatever WDT N
its PRP$ N
level NN N
at IN N
the DT N
end NN N
of IN N
the DT N
drug NN N
course NN N
This DT N
study NN N
confirms VBZ N
that IN N
only RB N
end-treatment JJ N
TSAb NNP N
levels NNS N
are VBP N
predictive JJ N
of IN N
relapse NN N
( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 22659656

[ JJ N
Effect NNP N
of IN N
probucol NN N
on IN N
serum NN N
malondialdehyde NN N
and CC N
superoxide JJ N
dismutase NN N
in IN N
patients NNS N
with IN N
primary JJ N
hypertension NN N
] NN N
OBJECTIVE UH N
To TO N
observe VB N
the DT N
therapeutic JJ N
effect NN N
of IN N
probucol NN N
on IN N
serum NN N
malondialdehyde NN N
( ( N
MDA NNP N
) ) N
and CC N
superoxide JJ N
dismutase NN N
( ( N
SOD NNP N
) ) N
in IN N
patients NNS 4_p
with IN 4_p
primary JJ 4_p
hypertension NN 4_p
METHODS NNP N
A NNP N
randomized VBD N
study NN N
was VBD N
performed VBN N
on IN N
40 CD N
patients NNS N
with IN N
hypertension NN N
The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
control NN N
( ( N
levamlodipine JJ N
besylate NN N
2.5 CD N
mg/d NN N
plus CC N
benazepril JJ N
10 CD N
mg/d NN N
, , N
n=20 NN N
) ) N
or CC N
probucol VBN N
group NN N
( ( N
levamlodipine JJ N
besylate NN N
2.5 CD N
mg/d NN N
plus CC N
benazepril JJ N
10 CD N
mg/d NN N
plus CC N
probucol JJ N
500 CD N
mg/d NN N
, , N
n=20 NN N
) ) N
An DT N
additional JJ N
twenty NN N
healthy JJ N
people NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
( ( N
normal JJ N
group NN N
) ) N
All DT N
subjects NNS N
were VBD N
followed VBN N
up RP N
for IN N
a DT N
period NN N
of IN N
four CD N
weeks NNS N
Lipids NNS N
and CC N
hepatic/renal JJ N
function NN N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
4 CD N
weeks NNS N
The DT N
levels NNS N
of IN N
serum NN N
MDA NNP N
and CC N
SOD NNP N
activity NN N
were VBD N
assayed VBN N
by IN N
chemical NN N
colorimetry NN N
, , N
and CC N
other JJ N
indices NNS N
, , N
including VBG N
blood NN N
pressure NN N
, , N
lipids NNS N
and CC N
hepatic/renal JJ N
function NN N
, , N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
4 CD N
weeks NNS N
RESULTS NNP N
Compared VBD N
to TO N
the DT N
normal JJ N
group NN N
, , N
the DT N
levels NNS N
of IN N
MDA NNP N
in IN N
all DT N
of IN N
the DT N
hypertension NN N
patient NN N
groups NNS N
were VBD N
higher JJR N
, , N
SOD NNP N
was VBD N
lower JJR N
The DT N
antihypertensive JJ N
treatment NN N
decreased VBD N
serum JJ N
MDA NNP N
levels NNS N
but CC N
increased VBD N
SOD NNP N
content NN N
, , N
and CC N
probucol NN N
treatment NN N
exaggerated VBD N
these DT N
effects NNS N
, , N
with IN N
greater JJR N
reduction NN N
of IN N
serum NN N
MDA NNP N
levels NNS N
and CC N
greater JJR N
increase NN N
of IN N
SOD NNP N
content NN N
CONCLUSION VB N
The DT N
treatment NN N
with IN N
probucol NN N
can MD N
improve VB N
oxidative JJ N
stress NN N
in IN N
hypertension NN 4_p
patients NNS 4_p
, , N
resulting VBG N
in IN N
reduced VBN N
serum NN N
MDA NNP N
levels NNS N
and CC N
improved VBN N
SOD NNP N
activity NN N
, , N
thus RB N
contributing VBG N
agreater RBR N
antihypertensive JJ N
effect NN N
-DOCSTART- -X- O O 3962622

The DT N
effect NN N
of IN N
polyvinylpyrrolidone-iodine NN N
as IN N
an DT N
disinfectant NN N
in IN N
eye NN N
surgery NN N
105 CD 3_p
patients NNS N
admitted VBN N
for IN N
cataract NN 4_p
surgery NN N
were VBD N
treated VBN N
pre-operatively RB N
with IN N
polyvinylpyrrolidone-iodine JJ N
( ( N
PVP-I NNP N
) ) N
as IN N
a DT N
disinfectant NN N
, , N
and CC N
consecutive JJ N
bacterial JJ N
cultures NNS N
were VBD N
obtained VBN N
before IN N
initiating VBG N
surgery NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
operation NN N
A DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
99 CD 3_p
) ) N
only RB N
had VBD N
a DT N
standard JJ N
disinfection NN N
procedure NN N
of IN N
the DT N
eye NN N
( ( N
including VBG N
instillation NN N
of IN N
Terramycin NNP N
cum NN N
polymyxin NN N
B NNP N
cream NN N
in IN N
the DT N
conjunctival NN N
sac VBD N
the DT N
evening NN N
before IN N
surgery NN N
) ) N
The DT N
cultures NNS N
obtained VBN N
from IN N
the DT N
conjunctival NN N
sac NN N
of IN N
the DT N
control NN N
group NN N
principally RB N
showed VBD N
growth NN N
of IN N
Staph NNP N
albus NN N
and CC N
Staph NNP N
aureus NN N
, , N
and CC N
to TO N
a DT N
minor JJ N
degree NN N
diphtheroids NNS N
( ( N
Corynebacterium NNP N
species NNS N
) ) N
Proteus NNP N
mirabilis NN N
, , N
Escherichia NNP N
coli NN N
and CC N
micrococci NN N
There EX N
was VBD N
a DT N
significant JJ N
quantitative JJ N
diminished VBN N
growth NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
of IN N
bacteria NN N
in IN N
the DT N
group NN N
of IN N
patients NNS N
treated VBN N
with IN N
PVP-I NNP N
compared VBN N
to TO N
the DT N
control NN N
group NN N
Concerning VBG N
the DT N
growth NN N
of IN N
Staph NNP N
albus NN N
, , N
this DT N
was VBD N
reduced VBN N
to TO N
almost RB N
one CD N
third JJ N
and CC N
other JJ N
bacteria NNS N
were VBD N
almost RB N
eliminated VBN N
in IN N
the DT N
group NN N
receiving VBG N
PVP-I NNP N
As IN N
we PRP N
disclosed VBD N
no DT N
toxic NN N
or CC N
allergic JJ N
reaction NN N
post-operatively RB N
which WDT N
could MD N
be VB N
related VBN N
to TO N
the DT N
use NN N
of IN N
PVP-I NNP N
as IN N
a DT N
disinfectant NN N
, , N
this DT N
agent NN N
seems VBZ N
to TO N
constitute VB N
an DT N
effective JJ N
pre-operative JJ N
antimicrobial JJ N
treatment NN N
, , N
taking VBG N
into IN N
consideration NN N
the DT N
broad JJ N
antimicrobial JJ N
spectrum NN N
of IN N
PVP-I NNP N
shown VBN N
by IN N
other JJ N
authors NNS N
-DOCSTART- -X- O O 7011331

Preventive JJ N
treatment NN N
of IN N
serotonin-migraine JJ 4_p
with IN N
1,3,4,14b-tetrahydro-2,7-dimethyl-2H-dibenzo JJ N
( ( N
b NN N
, , N
f NN N
) ) N
pyrazino- NN N
( ( N
1,2 CD N
-- : N
d NN N
) ) N
- : N
( ( N
1,4 CD N
) ) N
-oxazepine NN N
hydrogen NN N
maleate NN N
( ( N
Org NNP N
GC NNP N
94 CD N
) ) N
A DT N
double-blind JJ N
study NN N
1,3,4,14b-Tetrahydro-2,7-dimethyl-2H-dibenzo JJ N
( ( N
b NN N
, , N
f NN N
) ) N
pyrazino- NN N
( ( N
1,2-d CD N
) ) N
- : N
( ( N
1,4 CD N
) ) N
-oxazepine NN N
hydrogen NN N
maleate NN N
( ( N
Org NNP N
GC NNP N
94 CD N
) ) N
is VBZ N
an DT N
oral JJ N
" NN N
antamine NN N
" NNP N
preparation NN N
with IN N
anti-serotoninergic JJ N
and CC N
anti-histaminic JJ N
effects NNS N
Its PRP$ N
lack NN N
of IN N
unpleasant JJ N
side-effects NNS N
permits NNS N
protracted VBN N
use NN N
for IN N
the DT N
preventive JJ N
treatment NN N
of IN N
serotonin-migraine NN N
Its PRP$ N
chemical NN N
structure NN N
-- : N
tetracyclic JJ N
ring NN N
, , N
C-beta NNP N
, , N
C-alpha NNP N
, , N
amine NN N
in IN N
a DT N
secondary JJ N
position NN N
-- : N
allows VBZ N
block NN N
of IN N
the DT N
receptors NNS N
for IN N
serotonin NN N
and CC N
histamine NN N
Preventive JJ N
treatment NN N
with IN N
3 CD N
x NNS N
5 CD N
mg/day NN N
of IN N
Org NNP N
GC NNP N
94 CD N
for IN N
a DT N
period NN N
of IN N
3 CD N
months NNS N
can MD N
almost RB N
completely RB N
eliminate JJ N
migraine NN N
attacks NNS N
21 CD N
out IN N
of IN N
30 CD 3_p
patients NNS N
( ( N
70 CD N
% NN N
) ) N
profited VBN N
from IN N
such JJ N
a DT N
treatment NN N
, , N
showing VBG N
a DT N
drop NN N
from IN N
5 CD N
-- : N
30 CD N
attacks NNS N
to TO N
0 CD N
-- : N
1 CD N
attack NN N
per IN N
month NN N
and CC N
normalization NN N
of IN N
high JJ N
urinary JJ N
serotonin NN N
, , N
5-HIAA JJ N
or CC N
histamine JJ N
levels NNS N
However RB N
, , N
30 CD 3_p
patients NNS 3_p
receiving VBG N
3 CD N
x JJ N
0.5 CD N
mg NN N
or CC N
placebo JJ N
daily RB N
reacted VBD N
only RB N
rarely RB N
The DT N
typical JJ N
side-effects NNS N
of IN N
anti-serotonin JJ N
drugs NNS N
, , N
especially RB N
sedation NN N
or CC N
dizziness NN N
and CC N
hyperorexia NN N
were VBD N
hardly RB N
observed VBN N
Randomization NN N
of IN N
the DT N
serotonin-migraine JJ N
cases NNS N
and CC N
double-blind JJ N
methodology NN N
were VBD N
applied VBN N
throughout IN N
the DT N
trial NN N
-DOCSTART- -X- O O 2182521

The DT N
clinician NN N
's POS N
decision NN N
of IN N
whether IN N
CHOP NNP N
chemotherapy NN N
should MD N
be VB N
standard JJ N
therapy NN N
for IN N
treatment NN N
of IN N
patients NNS N
with IN N
diffuse NN 4_p
histiocytic JJ 4_p
lymphoma NN 4_p
-DOCSTART- -X- O O 19911168

Dose-dependent JJ N
effects NNS N
of IN N
the DT N
CRF NNP N
( ( N
1 CD N
) ) N
receptor NN N
antagonist JJ N
R317573 NNP N
on IN N
regional JJ N
brain NN N
activity NN N
in IN N
healthy JJ 4_p
male JJ 4_p
subjects NNS 4_p
BACKGROUND NNP N
Corticotropin-releasing NNP N
factor NN N
receptor NN N
type NN N
1 CD N
( ( N
CRF NNP N
( ( N
1 CD N
) ) N
) ) N
antagonists NNS N
have VBP N
been VBN N
proposed VBN N
as IN N
therapeutic JJ N
agents NNS N
in IN N
the DT N
treatment NN N
of IN N
mood NN N
and CC N
anxiety NN N
disorders NNS N
although IN N
clinical JJ N
evidence NN N
supporting VBG N
their PRP$ N
development NN N
and CC N
understanding NN N
of IN N
a DT N
dose-response JJ N
relationship NN N
has VBZ N
been VBN N
lacking VBG N
METHODS NNP N
We PRP N
tested VBD N
two CD N
doses NNS N
of IN N
the DT N
CRF NNP N
( ( N
1 CD N
) ) N
antagonist NN N
R317573 NNP N
for IN N
effects NNS N
on IN N
regional JJ N
cerebral JJ N
glucose NN N
metabolism NN N
( ( N
rCMglu NN N
) ) N
using VBG N
[ NNP N
( ( N
18 CD N
) ) N
F NNP N
] JJ N
fluoro-2-deoxy-D NN N
: : N
-glucose NN N
( ( N
FDG NNP N
) ) N
positron NN N
emission NN N
tomography NN N
( ( N
PET NNP N
) ) N
following VBG N
single-dose JJ N
challenges NNS N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
cross-over JJ N
design NN N
, , N
in IN N
12 CD 1_p
healthy JJ 1_p
male NN 1_p
volunteers NNS 1_p
RESULTS NNP N
Single NNP N
30- JJ N
and CC N
200-mg JJ N
doses NNS N
of IN N
R317573 NNP N
resulted VBD N
in IN N
dose-related JJ N
changes NNS N
in IN N
rCMglu NN N
Relative JJ N
increases NNS N
in IN N
rCMglu NN N
were VBD N
observed VBN N
in IN N
frontal JJ N
cortical JJ N
regions NNS N
while IN N
relative JJ N
decreases NNS N
occurred VBD N
in IN N
the DT N
putamen NNS N
and CC N
right JJ N
amygdala NN N
after IN N
both DT N
doses NNS N
Relative JJ N
decreases NNS N
occurred VBD N
in IN N
cerebellum NN N
and CC N
right JJ N
parahippocampal NN N
gyrus NN N
following VBG N
the DT N
higher JJR N
dose NN N
CONCLUSIONS NNP N
R317573 NNP N
appears VBZ N
to TO N
produce VB N
acute JJ N
dose-dependent JJ N
changes NNS N
in IN N
rCMglu NN N
Effects NNS N
occurred VBD N
in IN N
regions NNS N
that WDT N
may MD N
be VB N
behaviorally RB N
relevant JJ N
to TO N
mood NN N
and CC N
anxiety NN N
disorders NNS N
In IN N
some DT N
regions NNS N
, , N
these DT N
effects NNS N
may MD N
be VB N
related VBN N
to TO N
the DT N
receptor NN N
( ( N
target NN N
) ) N
density NN N
Measuring VBG N
acute JJ N
effects NNS N
on IN N
rCMglu NN N
with IN N
FDG-PET NNP N
may MD N
offer VB N
a DT N
method NN N
for IN N
defining VBG N
pharmacologically RB N
active JJ N
doses NNS N
for IN N
central JJ N
nervous JJ N
system NN N
targets NNS N
for IN N
which WDT N
selective JJ N
radiotracers NNS N
are VBP N
lacking VBG N
-DOCSTART- -X- O O 17241298

Comparison NNP N
of IN N
7-day JJ N
and CC N
14-day JJ N
proton NN N
pump IN N
inhibitor-containing JJ N
triple JJ N
therapy NN N
for IN N
Helicobacter NNP 4_p
pylori JJ 4_p
eradication NN 4_p
: : N
neither CC N
treatment NN N
duration NN N
provides VBZ N
acceptable JJ N
eradication NN N
rate NN N
in IN N
Korea NNP N
BACKGROUND NNP N
AND CC N
AIMS NNP N
Although IN N
triple JJ N
combination NN N
therapy NN N
containing VBG N
a DT N
proton NN N
pump NN N
inhibitor NN N
( ( N
PPI NNP N
) ) N
and CC N
two CD N
antibiotics NNS N
is VBZ N
considered VBN N
as IN N
a DT N
standard JJ N
regimen NN N
for IN N
the DT N
first-line JJ N
anti-Helicobacter JJ N
pylori NN N
treatment NN N
, , N
there EX N
are VBP N
still RB N
debates NNS N
on IN N
the DT N
ideal JJ N
duration NN N
of IN N
treatment NN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacies NNS N
of IN N
7-day JJ N
and CC N
14-day JJ N
PPI-containing JJ N
triple NN N
therapy NN N
MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
study NN N
was VBD N
performed VBN N
in IN N
a DT N
randomized JJ N
, , N
multicenter NN N
, , N
prospective JJ N
manner NN N
After IN N
upper JJ 4_p
gastrointestinal JJ 4_p
endoscopy NN 4_p
, , N
H. NNP 4_p
pylori-infected JJ 4_p
patients NNS N
with IN N
a DT N
gastric JJ 4_p
ulcer NN 4_p
and/or VBZ 4_p
a DT 4_p
duodenal JJ 4_p
ulcer NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
PAC7 NNP N
group NN N
( ( N
omeprazole JJ N
20 CD N
mg NN N
or CC N
equivalent JJ N
dose NN N
of IN N
other JJ N
PPIs NNP N
, , N
amoxicillin NN N
1000 CD N
mg NN N
, , N
and CC N
clarithromycin VBZ N
500 CD N
mg NN N
twice RB N
daily RB N
for IN N
7 CD N
days NNS N
) ) N
or CC N
to TO N
a DT N
PAC14 NNP N
group NN N
( ( N
the DT N
same JJ N
regimen NN N
as IN N
the DT N
PAC7 NNP N
group NN N
but CC N
for IN N
14 CD N
days NNS N
) ) N
H. NNP N
pylori NN N
status NN N
was VBD N
evaluated VBN N
by IN N
( ( N
13 CD N
) ) N
C NNP N
urea JJ N
breath NN N
test NN N
5 CD N
weeks NNS N
after IN N
anti-ulcer JJ N
treatment NN N
completion NN N
RESULTS VB N
A DT N
total NN N
of IN N
598 CD 3_p
patients NNS N
were VBD N
enrolled VBN N
; : N
337 CD N
were VBD N
randomized VBN N
to TO N
the DT N
PAC7 NNP N
group NN N
and CC N
261 CD N
to TO N
the DT N
PAC14 NNP N
group NN N
The DT N
two CD N
groups NNS N
were VBD N
comparable JJ N
in IN N
terms NNS N
of IN N
baseline NN N
characteristics NNS N
The DT N
eradication NN N
rates NNS N
of IN N
the DT N
PAC7 NNP N
group NN N
were VBD N
not RB N
inferior JJ N
to TO N
those DT N
of IN N
the DT N
PAC14 NNP N
group NN N
in IN N
both DT N
intention-to-treat JJ N
analysis NN N
( ( N
71.2 CD N
% NN N
vs. FW N
75.5 CD N
% NN N
) ) N
and CC N
per-protocol JJ N
analysis NN N
( ( N
83.6 CD N
% NN N
vs. FW N
86.6 CD N
% NN N
) ) N
Incidences NNS N
of IN N
adverse JJ N
events NNS N
were VBD N
comparable JJ N
CONCLUSIONS NNP N
Although IN N
the DT N
7-day JJ N
PPI-containing JJ N
triple JJ N
anti-H. JJ N
pylori NN N
therapy NN N
is VBZ N
not RB N
inferior JJ N
to TO N
the DT N
14-day JJ N
therapy NN N
, , N
neither CC N
treatment NN N
duration NN N
provides VBZ N
acceptable JJ N
eradication NN N
rate NN N
reaching VBG N
90 CD N
% NN N
in IN N
per-protocol JJ N
analysis NN N
New NNP N
combination NN N
regimen NNS N
with IN N
higher JJR N
efficacy NN N
should MD N
be VB N
developed VBN N
as IN N
a DT N
first-line JJ N
eradication NN N
therapy NN N
for IN N
H. NNP 4_p
pylori NN 4_p
in IN N
Korea NNP N
-DOCSTART- -X- O O 20305865

Short-term JJ N
effects NNS N
of IN N
systemic JJ N
antibiotics NNS N
during IN N
periodontal JJ 4_p
healing NN 4_p
OBJECTIVES NNP N
To TO N
investigate VB N
the DT N
short-term JJ N
effects NNS N
of IN N
nonsurgical JJ 4_p
therapy NN 4_p
( ( 4_p
scaling VBG 4_p
and CC 4_p
root NN 4_p
planing NN 4_p
, , 4_p
SRP NNP 4_p
) ) 4_p
on IN 4_p
the DT 4_p
subgingival NN 4_p
microbiota NN 4_p
in IN 4_p
chronic NN 4_p
( ( 4_p
CP NNP 4_p
) ) 4_p
and CC 4_p
aggressive JJ 4_p
( ( 4_p
AP NNP 4_p
) ) 4_p
periodontal JJ 4_p
disease NN 4_p
METHOD NNP N
AND CC N
MATERIALS NNP N
Ninety-seven NNP N
CP NNP N
and CC N
AP NNP N
subjects NNS N
underwent JJ N
full-mouth JJ N
SRP NNP N
on IN N
2 CD N
consecutive JJ N
days NNS N
AP JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
receive JJ N
systemic JJ N
metronidazole NN N
plus CC N
amoxicillin NN N
( ( N
AP+AB NNP N
) ) N
or CC N
were VBD N
treated VBN N
mechanically RB N
alone RB N
( ( N
AP NNP N
) ) N
Pathogens NNS N
were VBD N
identified VBN N
with IN N
16S CD N
rRNA NNS N
oligodeoxynucleotide JJ N
probes NNS N
and CC N
dot-blot JJ N
hybridization NN N
before IN N
and CC N
at IN N
days NNS N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
7 CD N
, , N
10 CD N
, , N
and CC N
21 CD N
of IN N
healing VBG N
CP JJ N
subjects NNS N
were VBD N
treated VBN N
by IN N
scaling VBG N
and CC N
root JJ N
planing NN N
along IN N
with IN N
placebo JJ N
tablets NNS N
RESULTS NNP N
Initially NNP N
, , N
AP NNP N
cell NN N
counts NNS N
were VBD N
69.9- JJ N
( ( N
Porphyromonas NNP N
gingivalis NN N
) ) N
, , N
10.2- JJ N
( ( N
Aggregatibacter NNP N
actinomycetemcomitans NNS N
) ) N
, , N
5.7- JJ N
( ( N
Tannerella NNP N
forsythia NN N
) ) N
, , N
and CC N
3.3-fold JJ N
( ( N
Prevotella NNP N
intermedia NN N
) ) N
enhanced VBD N
compared VBN N
to TO N
CP NNP N
cell NN N
counts NNS N
Following VBG N
SRP NNP N
, , N
immediate JJ N
elimination NN N
occurred VBD N
in IN N
single JJ N
individuals NNS N
of IN N
all DT N
three CD N
treatment NN N
groups NNS N
at IN N
day NN N
2 CD N
After IN N
SRP NNP N
plus CC N
antibiotic JJ N
therapy NN N
( ( N
AP+AB NNP N
) ) N
, , N
the DT N
prevalence NN N
scores NNS N
dropped VBD N
beyond IN N
the DT N
levels NNS N
of IN N
AP NNP N
and CC N
CP NNP N
, , N
beginning VBG N
at IN N
day NN N
7 CD N
, , N
and CC N
remained VBD N
low JJ N
until IN N
day NN N
21 CD N
( ( N
P NNP N
=or NNP N
< NNP N
.05 NNP N
) ) N
Clinical JJ N
healing VBG N
statistically RB N
benefited VBN N
from IN N
SRP NNP N
with IN N
no DT N
differences NNS N
among IN N
the DT N
three CD N
treatment NN N
groups NNS N
CONCLUSION NNP N
Nonsurgical NNP N
therapy NN N
resulted VBD N
in IN N
both DT N
a DT N
suppression NN N
and CC N
early JJ N
elimination NN N
of IN N
single JJ N
taxa NN N
immediately RB N
after IN N
completion NN N
of IN N
active JJ N
treatment NN N
Systemic NNP N
antibiotics NNS N
significantly RB N
accelerate VBP N
the DT N
suppression NN N
of IN N
the DT N
periodontal JJ N
microflora NN N
, , N
but CC N
have VBP N
limited VBN N
effect NN N
on IN N
the DT N
elimination NN N
of IN N
target NN N
isolates NNS N
during IN N
healing NN N
-DOCSTART- -X- O O 17516971

Comparison NNP N
of IN N
self-administered JJ N
vaginal JJ N
misoprostol NN N
versus NN N
placebo NN N
for IN N
cervical JJ N
ripening VBG N
prior JJ N
to TO N
operative JJ N
hysteroscopy NN N
using VBG N
a DT N
sequential JJ N
trial NN N
design NN N
OBJECTIVE UH N
To TO N
compare VB N
the DT N
impact NN N
of IN N
1000-microgram JJ N
self-administered JJ N
vaginal JJ N
misoprostol NN N
versus IN N
self-administered JJ N
vaginal JJ N
placebo NN N
at IN N
home NN N
on IN N
preoperative JJ N
cervical JJ N
ripening NN N
in IN N
both DT N
premenopausal NN 4_p
and CC 4_p
postmenopausal JJ 4_p
women NNS 2_p
prior RB N
to TO N
outpatient VB 4_p
resectoscopy NN 4_p
DESIGN NNP N
Randomised VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
sequential JJ N
trial NN N
SETTING NN N
Norwegian JJ N
university NN N
teaching VBG N
hospital NN N
SAMPLE NNP N
Premenopausal NNP 4_p
and CC 4_p
postmenopausal JJ 4_p
women NNS 2_p
referred VBD N
to TO N
outpatient VB 4_p
resectoscopy NN 4_p
METHODS NNP N
The DT N
women NNS N
were VBD N
randomised VBN N
to TO N
either DT N
1000 CD N
micrograms NNS N
of IN N
self-administered JJ N
vaginal JJ N
misoprostol NN N
or CC N
self-administered JJ N
vaginal JJ N
placebo NN N
the DT N
evening NN N
before IN N
outpatient JJ N
resectoscopy NN N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Preoperative NNP N
cervical JJ N
dilatation NN N
, , N
acceptability NN N
and CC N
complications NNS N
RESULTS NNP N
( ( N
a DT N
) ) N
Intraoperative JJ N
findings NNS N
and CC N
distribution NN N
of IN N
cervical JJ N
dilatation NN N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
Values NNS N
are VBP N
given VBN N
as IN N
median JJ N
( ( N
range NN N
) ) N
or CC N
n JJ N
( ( N
% NN N
) ) N
( ( N
b NN N
) ) N
Acceptability NN N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
Values NNS N
are VBP N
given VBN N
as IN N
completely RB N
acceptable JJ N
, , N
n JJ N
( ( N
% NN N
) ) N
; : N
fairly RB N
acceptable JJ N
, , N
n JJ N
( ( N
% NN N
) ) N
; : N
fairly RB N
unacceptable JJ N
, , N
n JJ N
( ( N
% NN N
) ) N
and CC N
completely RB N
unacceptable JJ N
, , N
n JJ N
( ( N
% NN N
) ) N
( ( N
c NN N
) ) N
Pain NN N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
Pain NNP N
was VBD N
measured VBN N
with IN N
a DT N
visual JJ N
analogue NN N
scale NN N
score NN N
, , N
scale JJ N
ranges NNS N
from IN N
0 CD N
( ( N
no DT N
pain NN N
) ) N
to TO N
10 CD N
( ( N
unbearable JJ N
pain NN N
) ) N
Values NNS N
are VBP N
given VBN N
as IN N
median JJ N
( ( N
range NN N
) ) N
( ( N
d NN N
) ) N
Occurrence NN N
of IN N
adverse JJ N
effects NNS N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
Values NNS N
are VBP N
given VBN N
as IN N
n JJ N
( ( N
% NN N
) ) N
( ( N
e NN N
) ) N
Complications NNPS N
, , N
given VBN N
as IN N
n JJ N
( ( N
% NN N
) ) N
-DOCSTART- -X- O O 15533466

Botulinum NNP N
toxin NN N
a DT N
has VBZ N
antinociceptive JJ N
effects NNS N
in IN N
treating VBG N
interstitial JJ N
cystitis NN N
OBJECTIVES NNP N
To TO N
present VB N
clinical JJ N
evidence NN N
with IN N
botulinum NN N
toxin NN N
A NNP N
( ( N
BTX-A NNP N
) ) N
suggesting VBG N
an DT N
antinociceptive JJ N
role NN N
in IN N
patients NNS N
with IN N
interstitial JJ 4_p
cystitis NN 4_p
( ( 4_p
IC NNP 4_p
) ) 4_p
Intriguing VBG N
evidence NN N
in IN N
a DT N
somatic JJ N
pain NN N
model NN N
has VBZ N
suggested VBN N
that IN N
BTX-A NNP N
injection NN N
may MD N
have VB N
an DT N
antinociceptive JJ N
effect NN N
on IN N
both DT N
acute NN N
and CC N
chronic NN N
( ( N
inflammatory NN N
) ) N
pain NN N
METHODS NNP N
Thirteen NNP 3_p
female JJ 2_p
patients NNS N
( ( N
6 CD 3_p
in IN N
the DT N
United NNP N
States NNPS N
and CC N
7 CD 3_p
in IN N
Poland NNP N
) ) N
with IN N
IC NNP 4_p
according VBG N
to TO N
the DT N
criteria NNS N
of IN N
the DT N
National NNP N
Institute NNP N
of IN N
Diabetes NNP N
, , N
Digestive NNP N
and CC N
Kidney NNP N
Disease NNP N
were VBD N
included VBN N
Under IN N
short JJ N
general JJ N
anesthesia NN N
or CC N
sedation NN N
, , N
100 CD 4_p
to TO 4_p
200 CD 4_p
U NNP 4_p
of IN 4_p
Dysport NNP 4_p
( ( N
Polish JJ N
patients NNS N
) ) N
or CC N
Botox NNP 4_p
( ( N
U.S. NNP N
patients NNS N
) ) N
was VBD N
injected VBN N
through IN N
a DT N
cystoscope NN N
into IN N
20 CD N
to TO N
30 CD N
sites NNS N
submucosally RB N
in IN N
the DT N
trigone NN N
and CC N
floor NN N
of IN N
the DT N
bladder NN N
Patients NNS N
were VBD N
evaluated VBN N
with IN N
the DT N
O'Leary-Sant NNP N
validated VBD N
IC NNP N
questionnaire NN N
or CC N
with IN N
voiding JJ N
charts NNS N
and CC N
a DT N
visual JJ N
analog NN N
pain VBP N
scale JJ N
1 CD N
month NN N
postoperatively RB N
and CC N
at IN N
subsequent JJ N
3-month JJ N
intervals NNS N
The DT N
Polish JJ N
patients NNS N
also RB N
underwent JJ N
pretreatment NN N
and CC N
post-treatment JJ N
urodynamic JJ N
evaluations NNS N
RESULTS NNP N
Overall NNP N
, , N
9 CD N
( ( N
69 CD N
% NN N
) ) N
of IN N
13 CD N
patients NNS N
noted JJ N
subjective JJ N
improvement NN N
after IN N
BTX-A NNP N
treatment NN N
The DT N
Interstitial NNP N
Cystitis NNP N
Symptom NNP N
Index NNP N
and CC N
Interstitial NNP N
Cystitis NNP N
Problem NNP N
Index NNP N
mean NN N
scores NNS N
improved VBN N
by IN N
71 CD N
% NN N
and CC N
69 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
Daytime NNP N
frequency NN N
, , N
nocturia NN N
, , N
and CC N
pain NN N
by IN N
visual JJ N
analog NN N
scale NN N
decreased VBN N
by IN N
44 CD N
% NN N
, , N
45 CD N
% NN N
, , N
and CC N
79 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
The DT N
first JJ N
desire NN N
to TO N
void VB N
and CC N
maximal VB N
cystometric JJ N
capacity NN N
increased VBN N
by IN N
58 CD N
% NN N
and CC N
57 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
BTX-A NNP N
has VBZ N
an DT N
antinociceptive JJ N
effect NN N
on IN N
bladder NN N
afferent NN N
pathways NNS N
in IN N
patients NNS N
with IN N
IC NNP N
, , N
producing VBG N
both DT N
symptomatic JJ N
and CC N
functional JJ N
( ( N
ie JJ N
, , N
urodynamic JJ N
) ) N
improvements NNS N
-DOCSTART- -X- O O 25456370

Everolimus NNP N
for IN N
subependymal JJ N
giant NN N
cell NN N
astrocytoma NN N
in IN N
patients NNS 4_p
with IN 4_p
tuberous JJ 4_p
sclerosis NN 4_p
complex NN 4_p
: : N
2-year JJ N
open-label JJ N
extension NN N
of IN N
the DT N
randomised JJ N
EXIST-1 NNP N
study NN N
BACKGROUND NNP N
In IN N
the DT N
EXIST-1 NNP N
trial NN N
, , N
initiated VBN N
on IN N
Aug NNP N
10 CD N
, , N
2009 CD N
, , N
more JJR N
than IN N
35 CD N
% NN N
of IN N
patients NNS N
with IN N
subependymal JJ 4_p
giant NN 4_p
cell NN 4_p
astrocytoma NN 4_p
( ( 4_p
SEGA NNP 4_p
) ) 4_p
associated VBN N
with IN N
tuberous JJ 4_p
sclerosis NN 4_p
complex NN 4_p
had VBD N
at IN N
least JJS N
50 CD N
% NN N
reduction NN N
in IN N
SEGA NNP N
volume NN N
after IN N
9·6 CD N
months NNS N
of IN N
treatment NN N
with IN N
everolimus NN N
In IN N
this DT N
Article NNP N
, , N
we PRP N
report VBP N
interim JJ N
data NNS N
( ( N
up IN N
to TO N
Jan NNP N
11 CD N
, , N
2013 CD N
) ) N
to TO N
support VB N
longer-term JJ N
tolerability NN N
and CC N
efficacy NN N
of IN N
everolimus NN N
from IN N
the DT N
continuing VBG N
4-year JJ N
extension NN N
phase NN N
of IN N
EXIST-1 NNP N
METHODS NNP N
We PRP N
assessed VBD N
data NNS N
from IN N
a DT N
prospective JJ N
, , N
open-label JJ N
extension NN N
of IN N
a DT N
multicentre NN N
, , N
phase NN N
3 CD N
, , N
randomised VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
in IN N
patients NNS N
with IN N
tuberous JJ 4_p
sclerosis NN 4_p
complex NN 4_p
who WP 4_p
had VBD 4_p
SEGA NNP 4_p
that WDT 4_p
was VBD 4_p
growing VBG 4_p
and CC 4_p
needed VBN 4_p
treatment NN 4_p
In IN N
this DT N
extension NN N
study NN N
, , N
we PRP N
included VBD N
all DT N
patients NNS N
who WP N
had VBD N
been VBN N
assigned VBN N
everolimus RBR N
during IN N
the DT N
double-blind NN N
, , N
randomised VBD N
phase NN N
of IN N
the DT N
trial NN N
and CC N
those DT N
patients NNS N
who WP N
crossed VBD N
over IN N
from IN N
the DT N
placebo NN N
group NN N
to TO N
receive VB N
everolimus NN N
during IN N
the DT N
randomised JJ N
phase NN N
or CC N
at IN N
the DT N
start NN N
of IN N
the DT N
extension NN N
phase NN N
All DT N
patients NNS N
received VBD N
oral JJ N
everolimus NN N
at IN N
a DT N
starting VBG N
dose NN N
of IN N
4·5 CD N
mg/m NN N
( ( N
2 CD N
) ) N
per IN N
day NN N
Everolimus NNP N
dose NN N
was VBD N
subsequently RB N
adjusted VBN N
subject NN N
to TO N
tolerability NN N
to TO N
attain VB N
blood NN N
trough IN N
concentrations NNS N
of IN N
5-15 JJ N
ng/mL NN N
An DT N
independent JJ N
central JJ N
radiology NN N
review NN N
team NN N
assessed VBD N
SEGA NNP N
response NN N
( ( N
at IN N
least JJS N
a DT N
50 CD N
% NN N
reduction NN N
from IN N
baseline NN N
in IN N
total JJ N
volume NN N
of IN N
all DT N
target NN N
SEGAs NNP N
; : N
the DT N
primary JJ N
endpoint NN N
) ) N
by IN N
MRI NNP N
at IN N
12 CD N
, , N
24 CD N
, , N
and CC N
48 CD N
weeks NNS N
, , N
then RB N
every DT N
year NN N
thereafter RB N
in IN N
all DT N
patients NNS N
who WP N
received VBD N
at IN N
least JJS N
one CD N
dose NN N
of IN N
everolimus NN N
This DT N
study NN N
was VBD N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00789828 NNP N
FINDINGS NNP N
Of IN N
the DT N
original JJ N
117 CD 3_p
randomly RB N
assigned VBN N
patients NNS N
, , N
111 CD 3_p
were VBD N
given VBN N
everolimus NNS N
between IN N
Aug NNP N
20 CD N
, , N
2009 CD N
, , N
and CC N
Jan NNP N
11 CD N
, , N
2013 CD N
( ( N
date NN N
of IN N
data NNS N
cutoff NN N
) ) N
; : N
we PRP N
included VBD N
these DT N
patients NNS N
in IN N
our PRP$ N
longer-term JJ N
analysis NN N
Median JJ N
duration NN N
of IN N
everolimus NN N
exposure NN N
was VBD N
29·3 CD N
months NNS N
( ( N
IQR NNP N
19·4-33·8 CD N
) ) N
Median JJ N
follow-up NN N
was VBD N
28·3 CD N
months NNS N
( ( N
IQR NNP N
19·3-33·0 CD N
) ) N
54 CD N
( ( N
49 CD N
% NN N
) ) N
patients NNS N
had VBD N
a DT N
response NN N
of IN N
50 CD N
% NN N
or CC N
greater JJR N
reduction NN N
in IN N
SEGA NNP N
volume NN N
( ( N
95 CD N
% NN N
CI NNP N
39·0-58·3 CD N
) ) N
, , N
and CC N
duration NN N
of IN N
response NN N
was VBD N
between IN N
2·1 CD N
and CC N
31·1 CD N
months NNS N
( ( N
median JJ N
not RB N
reached VBN N
) ) N
SEGA JJ N
volume NN N
was VBD N
reduced VBN N
by IN N
50 CD N
% NN N
or CC N
more JJR N
in IN N
39 CD N
( ( N
37 CD N
% NN N
) ) N
of IN N
105 CD N
patients NNS N
at IN N
24 CD N
weeks NNS N
, , N
48 CD N
( ( N
46 CD N
% NN N
) ) N
of IN N
104 CD N
patients NNS N
at IN N
48 CD N
weeks NNS N
, , N
36 CD N
( ( N
47 CD N
% NN N
) ) N
of IN N
76 CD N
patients NNS N
at IN N
96 CD N
weeks NNS N
, , N
and CC N
11 CD N
( ( N
38 CD N
% NN N
) ) N
of IN N
29 CD N
patients NNS N
at IN N
144 CD N
weeks NNS N
Stomatitis NNP N
( ( N
48 CD N
[ RB N
43 CD N
% NN N
] JJ N
patients NNS N
) ) N
and CC N
mouth JJ N
ulceration NN N
( ( N
33 CD N
[ RB N
30 CD N
% NN N
] JJ N
patients NNS N
) ) N
were VBD N
the DT N
most RBS N
frequent JJ N
treatment-related JJ N
adverse JJ N
events NNS N
; : N
infections NNS N
were VBD N
the DT N
most RBS N
commonly RB N
reported VBD N
treatment-related JJ N
serious JJ N
adverse JJ N
event NN N
, , N
occurring VBG N
in IN N
15 CD N
( ( N
14 CD N
% NN N
) ) N
patients NNS N
35 CD N
( ( N
32 CD N
% NN N
) ) N
patients NNS N
reported VBD N
treatment-related JJ N
grade NN N
3 CD N
or CC N
4 CD N
adverse JJ N
events NNS N
, , N
the DT N
most RBS N
common JJ N
of IN N
which WDT N
were VBD N
stomatitis NN N
( ( N
nine CD N
[ RB N
8 CD N
% NN N
] NN N
) ) N
and CC N
pneumonia NN N
( ( N
nine CD N
[ RB N
8 CD N
% NN N
] NN N
) ) N
18 CD N
( ( N
16 CD N
% NN N
) ) N
patients NNS N
had VBD N
treatment-related JJ N
serious JJ N
adverse JJ N
events NNS N
Six NNP N
( ( N
5 CD N
% NN N
) ) N
patients NNS N
withdrew VBD N
because IN N
of IN N
adverse JJ N
events NNS N
INTERPRETATION NNP N
These DT N
results NNS N
support VBD N
the DT N
longer-term JJ N
use NN N
of IN N
everolimus NN N
in IN N
patients NNS N
who WP N
have VBP N
few JJ N
treatment NN N
options NNS N
and CC N
who WP N
need VBP N
continued VBN N
treatment NN N
for IN N
tuberous JJ 4_p
sclerosis NN 4_p
complex NN N
and CC N
its PRP$ N
varied JJ N
manifestations NNS N
Reduction NN N
or CC N
stabilisation NN N
of IN N
tumour JJ N
volume NN N
with IN N
everolimus NN N
will MD N
hopefully RB N
provide VB N
long-term JJ N
clinical JJ N
benefit NN N
in IN N
patients NNS N
with IN N
SEGA NNP N
FUNDING NN N
Novartis NN N
Pharmaceuticals NNP N
-DOCSTART- -X- O O 9652561

Randomised VBN N
placebo-controlled JJ N
trial NN N
of IN N
rhesus-human JJ N
reassortant JJ N
rotavirus NN N
vaccine NN N
for IN N
prevention NN N
of IN N
severe JJ N
rotavirus NN N
gastroenteritis NN N
BACKGROUND NNP N
Rotavirus NNP N
is VBZ N
the DT N
most RBS N
common JJ N
cause NN N
of IN N
acute JJ N
childhood NN N
gastroenteritis NN N
Vaccination NN N
with IN N
live JJ N
oral JJ N
heterologous JJ N
rotavirus NN N
vaccines NNS N
may MD N
prevent VB N
rotavirus NN N
gastroenteritis NN N
We PRP N
assessed VBD N
the DT N
efficacy NN N
of IN N
rhesus-human JJ N
reassortant JJ N
rotavirus NN N
tetravalent NN N
vaccine NN N
( ( N
RRV-TV NNP N
) ) N
against IN N
severe JJ N
rotavirus NN N
gastroenteritis NN N
in IN N
Finnish JJ N
children NNS 1_p
in IN N
a DT N
randomised JJ N
placebo-controlled JJ N
double-blind JJ N
trial NN N
METHODS NNP N
Placebo NNP N
or CC N
RRV-TV NNP N
( ( N
titre JJ N
4x10 CD N
( ( N
5 CD N
) ) N
plaque-forming JJ N
units NNS N
) ) N
was VBD N
given VBN N
to TO N
infants NNS 1_p
at IN 1_p
ages NNS 1_p
2 CD 1_p
, , 1_p
3 CD 1_p
, , 1_p
and CC 1_p
5 CD 1_p
months NNS 1_p
The DT N
children NNS N
were VBD N
followed VBN N
up RP N
for IN N
one CD N
or CC N
two CD N
rotavirus JJ N
epidemic JJ N
seasons NNS N
The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
protection NN N
against IN N
severe JJ N
rotavirus NN N
gastroenteritis NN N
( ( N
score JJ N
> NN N
or CC N
=11 NN N
on IN N
a DT N
20-point JJ N
severity NN N
scale NN N
) ) N
2398 CD 3_p
children NNS 1_p
were VBD N
enrolled VBN N
and CC N
received VBN N
at IN N
least JJS N
one CD N
dose NN N
of IN N
RRV-TV NNP N
( ( N
n=1191 NN N
) ) N
or CC N
placebo NN N
( ( N
n=1207 JJ N
) ) N
The DT N
primary JJ N
efficacy NN N
analysis NN N
was VBD N
based VBN N
on IN N
children NNS N
who WP N
received VBD N
three CD N
doses NNS N
of IN N
RRV-TV NNP N
( ( N
n=1128 NN N
) ) N
or CC N
placebo NN N
( ( N
n=1145 JJ N
) ) N
FINDINGS $ N
256 CD N
episodes NNS N
of IN N
rotavirus NN N
gastroenteritis NN N
occurred VBD N
at IN N
any DT N
time NN N
during IN N
the DT N
study NN N
; : N
65 CD N
were VBD N
among IN N
1191 CD N
RRV-TV JJ N
recipients NNS N
, , N
and CC N
191 CD N
among IN N
1207 CD N
placebo NN N
recipients NNS N
( ( N
vaccine JJ N
efficacy NN N
66 CD N
% NN N
[ JJ N
95 CD N
% NN N
CI NNP N
55-74 JJ N
] NN N
; : N
intention-to-treat JJ N
analysis NN N
) ) N
226 CD N
episodes NNS N
were VBD N
included VBN N
in IN N
the DT N
primary JJ N
efficacy NN N
analysis NN N
of IN N
fully RB N
vaccinated VBN N
children NNS N
( ( N
54 CD N
among IN N
1128 CD N
RRV-TV JJ N
recipients NNS N
, , N
172 CD N
among IN N
1145 CD N
placebo NN N
recipients NNS N
; : N
vaccine VB N
efficacy NN N
68 CD N
% NN N
[ JJ N
57-76 JJ N
] NN N
) ) N
100 CD N
episodes NNS N
were VBD N
severe JJ N
, , N
eight CD N
in IN N
RRV-TV NNP N
recipients NNS N
and CC N
92 CD N
in IN N
placebo NN N
recipients NNS N
( ( N
vaccine JJ N
efficacy NN N
91 CD N
% NN N
[ JJ N
82-96 JJ N
] NN N
) ) N
INTERPRETATION NNP N
RRV-TV NNP N
vaccine NN N
was VBD N
highly RB N
effective JJ N
against IN N
severe JJ N
rotavirus NN N
gastroenteritis NN N
in IN N
young JJ 1_p
children NNS 1_p
Incorporation NN N
of IN N
this DT N
vaccine NN N
into IN N
routine JJ N
immunisation NN N
schedules NNS N
of IN N
infants NNS N
could MD N
reduce VB N
severe JJ N
rotavirus NN N
gastroenteritis NN N
by IN N
90 CD N
% NN N
and CC N
severe JJ N
gastroenteritis NN N
of IN N
all DT N
causes NNS N
in IN N
young JJ N
children NNS N
by IN N
60 CD N
% NN N
-DOCSTART- -X- O O 7196452

Menstrual JJ N
cycle NN N
symptoms NNS N
in IN N
infertile JJ 4_p
and CC N
control JJ 4_p
subjects NNS N
: : N
a DT N
re-evaluation NN N
of IN N
the DT N
evidence NN N
for IN N
psychological JJ N
changes NNS N
-DOCSTART- -X- O O 8391792

Subcutaneous JJ N
low-molecular-weight JJ N
heparin NN N
compared VBN N
with IN N
continuous JJ N
intravenous JJ N
unfractionated JJ N
heparin NN N
in IN N
the DT N
treatment NN N
of IN N
proximal JJ 4_p
deep JJ 4_p
vein NN 4_p
thrombosis NN 4_p
BACKGROUND VB N
A DT N
low-molecular-weight JJ N
heparin NN N
, , N
enoxaparin JJ N
sodium NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
and CC N
safe JJ N
in IN N
preventing VBG N
deep JJ 4_p
vein NN 4_p
thrombosis NN 4_p
both DT N
in IN N
general JJ N
surgery NN N
and CC N
in IN N
high-risk JJ N
orthopedic JJ N
surgery NN N
We PRP N
conducted VBD N
a DT N
controlled VBN N
, , N
randomized VBN N
trial NN N
with IN N
enoxaparin NN N
in IN N
the DT N
treatment NN N
of IN N
established VBN N
deep JJ N
vein NN N
thrombosis NN N
METHODS NNP N
In IN N
a DT N
multicenter NN N
trial NN N
, , N
we PRP N
compared VBN N
fixed-dose RB N
subcutaneous JJ N
enoxaparin NN N
, , N
given VBN N
twice RB N
daily RB N
, , N
with IN N
adjusted-dose JJ N
intravenous JJ N
unfractionated JJ N
heparin NN N
( ( N
UFH NNP N
) ) N
given VBN N
by IN N
continuous JJ N
intravenous JJ N
infusion NN N
for IN N
the DT N
initial JJ N
10 CD N
days NNS N
of IN N
treatment NN N
of IN N
patients NNS N
with IN N
proximal JJ 4_p
vein NN 4_p
thrombosis NN 4_p
The DT N
primary JJ N
efficacy NN N
outcome NN N
was VBD N
the DT N
change NN N
of IN N
the DT N
size NN N
of IN N
the DT N
thrombus NN N
assessed VBN N
by IN N
repeated JJ N
venograms NNS N
between IN N
day NN N
0 CD N
and CC N
day NN N
10 CD N
The DT N
primary JJ N
analysis NN N
of IN N
safety NN N
was VBD N
based VBN N
on IN N
the DT N
incidence NN N
of IN N
major JJ N
bleeding VBG N
during IN N
10 CD N
days NNS N
of IN N
treatment NN N
RESULTS CC N
There EX N
were VBD N
67 CD 3_p
patients NNS N
in IN N
each DT N
group NN N
Venographic NNP N
assessment NN N
of IN N
clot NN N
size NN N
evolution NN N
between IN N
day NN N
0 CD N
and CC N
day NN N
10 CD N
showed VBD N
a DT N
statistically RB N
significant JJ N
superiority NN N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
of IN N
enoxaparin NN N
over IN N
the DT N
reference NN N
treatment NN N
with IN N
UFH NNP N
Moreover RB N
, , N
the DT N
incidence NN N
of IN N
overall JJ N
recurrent JJ N
thromboembolic JJ N
events NNS N
during IN N
10 CD N
days NNS N
of IN N
treatment NN N
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
in IN N
the DT N
UFH NNP N
group NN N
( ( N
seven CD N
of IN N
67 CD N
) ) N
than IN N
in IN N
the DT N
enoxaparin NN N
group NN N
( ( N
one CD N
of IN N
67 CD N
) ) N
There EX N
were VBD N
no DT N
serious JJ N
bleeding VBG N
complications NNS N
in IN N
either DT N
group NN N
CONCLUSIONS NNP N
Enoxaparin NNP N
is VBZ N
at IN N
least JJS N
as IN N
effective JJ N
and CC N
safe JJ N
as IN N
UFH NNP N
under IN N
the DT N
conditions NNS N
of IN N
this DT N
study NN N
Moreover RB N
, , N
it PRP N
is VBZ N
more RBR N
comfortable JJ N
for IN N
patients NNS N
and CC N
less JJR N
time-consuming NN N
for IN N
nurses NNS N
and CC N
laboratories NNS N
Thus RB N
, , N
our PRP$ N
study NN N
confirmed VBD N
, , N
with IN N
the DT N
use NN N
of IN N
enoxaparin NN N
, , N
other JJ N
observations NNS N
that IN N
low-molecular-weight JJ N
heparin NN N
provides VBZ N
a DT N
real JJ N
therapeutic JJ N
advance NN N
in IN N
the DT N
treatment NN N
of IN N
deep JJ 4_p
vein NN 4_p
thrombosis NN 4_p
-DOCSTART- -X- O O 8208874

Lithium NN N
sustains VBZ N
the DT N
acute NN 4_p
antidepressant JJ 4_p
effects NNS 4_p
of IN N
sleep JJ 4_p
deprivation NN 4_p
: : 4_p
preliminary JJ N
findings NNS N
from IN N
a DT N
controlled VBN N
study NN N
Early JJ N
morning NN N
sleep JJ 4_p
deprivation NN 4_p
( ( N
patient JJ N
awake NN N
from IN N
0200 CD N
to TO N
2200 CD N
hours NNS N
) ) N
produces VBZ N
a DT N
same-day JJ N
antidepressant JJ N
effect NN N
in IN N
approximately RB N
one-half JJ N
of IN N
patients NNS N
with IN N
major JJ 4_p
depression NN 4_p
Unfortunately RB N
, , N
these DT N
antidepressant JJ N
effects NNS N
are VBP N
short-lived JJ N
and CC N
patients NNS N
usually RB N
relapse VBP N
to TO N
baseline VB N
depression NN N
levels NNS N
within IN N
48 CD N
hours NNS N
Recent JJ N
work NN N
suggests VBZ N
, , N
however RB N
, , N
that IN N
the DT N
use NN N
of IN N
lithium NN N
with IN N
early JJ N
morning NN N
sleep JJ N
deprivation NN N
sustains VBZ N
this DT N
rapid JJ N
antidepressant JJ N
effect NN N
and CC N
makes VBZ N
it PRP N
clinically RB N
useful JJ N
In IN N
a DT N
30-day JJ N
study NN N
, , N
we PRP N
compared VBN N
the DT N
abilities NNS N
of IN N
four CD N
different JJ N
treatments NNS N
( ( N
lithium JJ N
plus CC N
early JJ N
morning NN N
sleep NN N
deprivation NN N
, , N
lithium NN N
plus CC N
a DT N
control NN N
sleep JJ N
deprivation NN N
procedure NN N
, , N
and CC N
desipramine NN N
with IN N
either DT N
of IN N
the DT N
two CD N
sleep JJ N
manipulations NNS N
) ) N
to TO N
induce VB N
a DT N
rapid JJ N
( ( N
next-day JJ N
) ) N
and CC N
sustained VBN N
antidepressant JJ N
response NN N
in IN N
16 CD 3_p
depressed JJ 4_p
patients NNS N
Lithium NNP N
plus CC N
early JJ N
morning NN N
sleep JJ N
deprivation NN N
produced VBD N
a DT N
quicker NN N
response NN N
than IN N
lithium NN N
with IN N
the DT N
control NN N
sleep JJ N
deprivation NN N
, , N
and CC N
the DT N
response NN N
was VBD N
sustained VBN N
for IN N
at IN N
least JJS N
30 CD N
days NNS N
In IN N
this DT N
design NN N
, , N
however RB N
, , N
lithium/early RB N
morning NN N
sleep JJ N
deprivation NN N
was VBD N
no DT N
faster JJR N
than IN N
either DT N
of IN N
the DT N
two CD N
desipramine/sleep JJ N
deprivation NN N
conditions NNS N
in IN N
inducing VBG N
remission NN N
These DT N
results NNS N
support VBD N
the DT N
results NNS N
of IN N
previous JJ N
studies NNS N
and CC N
suggest VBP N
further JJ N
investigation NN N
of IN N
this DT N
novel JJ N
sleep/pharmacologic JJ N
intervention NN N
is VBZ N
warranted VBN N
-DOCSTART- -X- O O 4353587

A DT N
study NN N
of IN N
postoperative JJ 4_p
cytostatic JJ 4_p
medication NN 4_p
in IN N
patients NNS N
with IN 4_p
operable JJ 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
lung NN 4_p
-DOCSTART- -X- O O 19660462

Norfloxacin NNP N
modulates VBZ N
the DT N
inflammatory JJ N
response NN N
and CC N
directly RB N
affects VBZ N
neutrophils NNS N
in IN N
patients NNS N
with IN N
decompensated JJ 4_p
cirrhosis NN 4_p
BACKGROUND NNP N
& CC N
AIMS NNP N
Patients NNPS N
with IN N
cirrhosis NN 4_p
undergoing VBG N
selective JJ N
intestinal JJ N
decontamination NN N
with IN N
norfloxacin JJ N
show NN N
a DT N
reduction NN N
in IN N
serum JJ N
cytokine NN N
levels NNS N
, , N
probably RB N
because IN N
of IN N
a DT N
combined JJ N
effect NN N
of IN N
norfloxacin NN N
on IN N
bowel NN N
flora NNS N
and CC N
neutrophils NNS N
METHODS NNP N
Thirty-one CD 3_p
patients NNS N
with IN N
cirrhosis NN 4_p
receiving VBG N
norfloxacin NN N
( ( N
400 CD N
mg/day NN N
) ) N
were VBD N
included VBN N
Blood NNP N
samples NNS N
were VBD N
collected VBN N
at IN N
0.5-4 JJ N
hours NNS N
( ( N
peak JJ N
samples NNS N
group NN N
, , N
n RB N
= VBZ N
47 CD N
) ) N
and CC N
at IN N
22-24 JJ N
hours NNS N
( ( N
trough IN N
samples NNS N
group NN N
, , N
n RB N
= VBZ N
84 CD N
) ) N
after IN N
dose NN N
Fifty-nine JJ N
ascitic JJ N
fluid NN N
samples NNS N
were VBD N
obtained VBN N
Single NNP N
doses NNS N
of IN N
norfloxacin NN N
and CC N
trimethoprim/sulfamethoxazole NN N
were VBD N
administered VBN N
to TO N
13 CD N
and CC N
5 CD N
patients NNS N
, , N
respectively RB N
, , N
( ( N
temporal JJ N
profile NN N
group NN N
) ) N
and CC N
samples NNS N
were VBD N
collected VBN N
at IN N
0 CD N
, , N
0.5 CD N
, , N
1 CD N
, , N
1.5 CD N
, , N
2 CD N
, , N
4 CD N
, , N
and CC N
24 CD N
hours NNS N
Norfloxacin NNP N
, , N
trimethoprim/sulfamethoxazole NN N
, , N
cytokines NNS N
, , N
nitric JJ N
oxide NN N
, , N
expression NN N
levels NNS N
of IN N
nuclear JJ N
factor NN N
( ( N
NF NNP N
) ) N
-kappaB NN N
and CC N
inhibitor NN N
of IN N
NF-kappaB NNP N
( ( N
IkB-alpha NNP N
) ) N
, , N
neutrophil JJ N
oxidative JJ N
burst NN N
, , N
and CC N
rate NN N
of IN N
apoptotic JJ N
events NNS N
were VBD N
determined VBN N
RESULTS NNP N
All NNP N
samples NNS N
were VBD N
bacterial JJ N
DNA NNP N
negative NN N
and CC N
had VBD N
no DT N
significant JJ N
levels NNS N
of IN N
lipopolysaccharide NN N
Serum NNP N
and CC N
ascitic JJ N
levels NNS N
of IN N
tumor NN N
necrosis NN N
factor-alpha JJ N
, , N
interferon-gamma JJ N
, , N
interleukin-12 JJ N
, , N
and CC N
nitric JJ N
oxide NN N
were VBD N
significantly RB N
lower JJR N
in IN N
peak NN N
than IN N
in IN N
trough JJ N
samples NNS N
A DT N
correlation NN N
was VBD N
present JJ N
between IN N
serum NN N
norfloxacins NNS N
concentrations NNS N
and CC N
tumor NN N
necrosis NN N
factor-alpha NN N
( ( N
r JJ N
= NNP N
-0.68 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
interferon-gamma JJ N
( ( N
r JJ N
= NNP N
-0.66 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
interleukin-12 JJ N
( ( N
r JJ N
= NNP N
-0.66 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
nitric JJ N
oxide NN N
( ( N
r JJ N
= NNP N
-0.68 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
Serum NNP N
norfloxacin NN N
's POS N
highest JJS N
concentrations NNS N
( ( N
1 CD N
+/- JJ N
0.5 CD N
microg/mL NN N
) ) N
were VBD N
achieved VBN N
at IN N
1-2 JJ N
hours NNS N
and CC N
concurred VBN N
in IN N
time NN N
with IN N
the DT N
lower JJR N
levels NNS N
of IN N
cytokines NNS N
and CC N
nitric JJ N
oxide NN N
Intracellular NNP N
norfloxacin NN N
's POS N
highest JJS N
levels NNS N
( ( N
2 CD N
+/- JJ N
1 CD N
microg/mL/10 NN N
( ( N
7 CD N
) ) N
cells NNS N
) ) N
were VBD N
observed VBN N
at IN N
2 CD N
hours NNS N
and CC N
concurred VBN N
with IN N
a DT N
lower JJR N
NF-kappaB JJ N
expression NN N
, , N
a DT N
reduced JJ N
anion NN N
superoxide NN N
generation NN N
, , N
and CC N
apoptotic JJ N
rate NN N
in IN N
response NN N
to TO N
phorbol VB N
myristate JJ N
acetate NN N
Trimethoprim/sulfamethoxazole NNP N
did VBD N
not RB N
significantly RB N
modulate VB N
cytokine JJ N
expression NN N
CONCLUSIONS NNP N
Norfloxacin NNP N
but CC N
not RB N
trimethoprim/sulfamethoxazole JJ N
modulates NNS N
inflammatory JJ N
response NN N
and CC N
directly RB N
affects VBZ N
neutrophils NNS N
in IN N
patients NNS N
with IN N
cirrhosis NN 4_p
-DOCSTART- -X- O O 14995965

Skin NNP N
concentrations NNS N
of IN N
thromboxane NN N
synthetase NN N
inhibitor NN N
after IN N
topical JJ N
application NN N
with IN N
bioelastic JJ N
membrane NN N
Elevated VBN N
thromboxane NN N
levels NNS N
are VBP N
associated VBN N
with IN N
a DT N
number NN N
of IN N
disease NN N
states NNS N
, , N
including VBG N
dermal JJ N
pressure NN N
ulcers NNS N
When WRB N
dazmegrel NN N
was VBD N
orally RB N
administered VBN N
to TO N
greyhound VB 4_p
dogs NNS 4_p
wearing VBG 4_p
leg NN 4_p
casts NNS 4_p
, , N
it PRP N
resulted VBD N
in IN N
a DT N
sparring JJ N
effect NN N
on IN N
the DT N
skin JJ N
areas NNS N
of IN N
potential JJ N
pressure NN N
ulcer NN N
development NN N
The DT N
objective NN N
of IN N
this DT N
research NN N
was VBD N
to TO N
determine VB N
if IN N
bioelastic JJ N
matrices NNS N
could MD N
provide VB N
controlled VBD N
release NN N
of IN N
thromboxane NN N
A2 NNP N
synthetase NN N
inhibitor NN N
( ( N
dazmegrel NN N
) ) N
at IN N
tissue NN N
concentrations NNS N
sufficient NN N
for IN N
inhibition NN N
of IN N
thromboxane NN N
synthesis NN N
The DT N
animal NN N
used VBN N
for IN N
these DT N
studies NNS N
was VBD N
the DT N
greyhound NN N
, , N
which WDT N
has VBZ N
thin JJ N
skin NN N
, , N
angular JJ N
conformation NN N
, , N
limited JJ N
body NN N
fat JJ N
and CC N
is VBZ N
predisposed VBN N
to TO N
pressure VB N
ulcers NNS N
similar JJ N
to TO N
those DT N
occurring VBG N
in IN N
humans NNS N
In IN N
vivo JJ N
skin JJ N
penetration NN N
studies NNS N
showed VBD N
that IN N
epidermal JJ N
exposure NN N
to TO N
bioelastic JJ N
thromboxane NN N
synthetase NN N
inhibitor NN N
( ( N
TSI NNP N
) ) N
matrix NN N
resulted VBD N
in IN N
local JJ N
tissue NN N
concentrations NNS N
of IN N
TSI NNP N
sufficient NN N
for IN N
thromboxane NN N
synthetase NN N
inhibition NN N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
dazmegrel NN N
in IN N
the DT N
skin NN N
layers NNS N
( ( N
epidermis NN N
, , N
dermis NN N
and CC N
subcutaneous JJ N
layers NNS N
) ) N
on IN N
1 CD N
, , N
7 CD N
and CC N
14-day JJ N
exposures NNS N
-DOCSTART- -X- O O 17950167

Covariation NN N
of IN N
adolescent JJ 1_p
physical JJ N
activity NN N
and CC N
dietary JJ N
behaviors NNS N
over IN N
12 CD N
months NNS N
PURPOSE VB N
This DT N
study NN N
examined VBD N
covariation NN N
among IN N
changes NNS N
in IN N
dietary JJ N
, , N
physical JJ N
activity NN N
, , N
and CC N
sedentary JJ N
behaviors NNS N
over IN N
12 CD N
months NNS N
among IN N
adolescents NNS N
participating VBG N
in IN N
a DT N
health NN 4_p
behavior NN 4_p
intervention NN 4_p
Evidence NN N
of IN N
covariation NN N
among IN N
behaviors NNS N
would MD N
suggest VB N
multi-behavior JJ N
interventions NNS N
could MD N
have VB N
synergistic JJ N
effects NNS N
METHODS NNP N
Prospective JJ N
analyses NNS N
were VBD N
conducted VBN N
with IN N
baseline NN N
and CC N
12-month JJ N
assessments NNS N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
to TO N
promote VB N
improved JJ N
diet JJ N
, , N
physical JJ N
activity NN N
, , N
and CC N
sedentary JJ N
behaviors NNS N
( ( N
experimental JJ N
condition NN N
) ) N
or CC N
SUN NNP N
protection NN N
behaviors NNS N
( ( N
comparison JJ N
condition NN N
) ) N
Participants NNS N
were VBD N
adolescent JJ N
girls NNS 2_p
and CC N
boys NNS 2_p
( ( N
N NNP N
= NNP N
878 CD 3_p
) ) N
aged VBN N
11-15 CD 1_p
years NNS N
on IN N
entry NN N
The DT N
main JJ N
outcomes NNS N
were VBD N
: : N
diet NN N
, , N
based VBN N
on IN N
multiple JJ N
24-hour JJ N
recalls NNS N
( ( N
total JJ N
fat NN N
, , N
grams NNS N
of IN N
fiber NN N
, , N
servings NNS N
of IN N
fruit NN N
and CC N
vegetables NNS N
, , N
total JJ N
calories NNS N
) ) N
; : N
average JJ N
daily JJ N
energy NN N
expenditure NN N
( ( N
kcals/kg NN N
) ) N
based VBN N
on IN N
7-day JJ N
physical JJ N
activity NN N
recall VBP N
interviews NNS N
; : N
daily JJ N
minutes NNS N
of IN N
moderate-vigorous JJ N
physical JJ N
activity NN N
minutes NNS N
from IN N
accelerometery NN N
; : N
and CC N
self-reported JJ N
daily JJ N
hours NNS N
of IN N
sedentary JJ N
behavior NN N
RESULTS NNP N
Covariation NNP N
was VBD N
found VBN N
between IN N
fat NN N
and CC N
calories NNS N
( ( N
r NN N
= NNP N
.16 NNP N
) ) N
, , N
fiber NN N
and CC N
calories NNS N
( ( N
r NN N
= NNP N
.53 NNP N
) ) N
, , N
fiber NN N
and CC N
fruit/vegetables NNS N
( ( N
r NN N
= NNP N
.53 NNP N
) ) N
, , N
calories NNS N
and CC N
fruit/vegetables NNS N
( ( N
r NN N
= NNP N
.34 NNP N
) ) N
, , N
and CC N
fruit NN N
and CC N
vegetables NNS N
and CC N
sedentary JJ N
behavior NN N
( ( N
r JJ N
= NNP N
-.12 NNP N
) ) N
for IN N
the DT N
total JJ N
sample NN N
( ( N
all DT N
p NN N
values NNS N
< NNP N
.01 NNP N
) ) N
The DT N
pattern NN N
of IN N
findings NNS N
was VBD N
similar JJ N
for IN N
most JJS N
subgroups NNS N
defined VBN N
by IN N
gender NN N
and CC N
study NN N
condition NN N
CONCLUSIONS VB N
The DT N
strongest JJS N
covariation NN N
was VBD N
observed VBN N
for IN N
diet JJ N
variables NNS N
that WDT N
are VBP N
inherently RB N
related VBN N
( ( N
calories NNS N
and CC N
fat NN N
, , N
fiber NN N
, , N
and CC N
fruit/vegetables NNS N
) ) N
Little JJ N
covariation NN N
was VBD N
detected VBN N
within IN N
or CC N
between IN N
other JJ N
diet JJ N
, , N
physical JJ N
activity NN N
and CC N
sedentary JJ N
behavior NN N
domains NNS N
suggesting VBG N
that IN N
interventions NNS N
to TO N
improve VB N
these DT N
behaviors NNS N
in IN N
adolescents NNS N
need VBP N
to TO N
include VB N
specific JJ N
program NN N
components NNS N
for IN N
each DT N
target NN N
behavior NN N
of IN N
interest NN N
-DOCSTART- -X- O O 3976757

Prevention NN N
of IN N
premature JJ N
labor NN N
by IN N
17 CD N
alpha-hydroxyprogesterone JJ N
caproate NN N
Eighty NNP 3_p
pregnant JJ 4_p
women NNS 4_p
at IN N
high JJ 4_p
risk NN 4_p
of IN 4_p
giving VBG 4_p
birth NN 4_p
prematurely RB 4_p
were VBD N
divided VBN N
randomly RB N
into IN N
two CD N
groups NNS N
Treatment NN N
with IN N
either DT N
17 CD N
alpha-hydroxyprogesterone NN N
caproate NN N
, , N
250 CD N
mg NN N
by IN N
intramuscular JJ N
injection NN N
once RB N
a DT N
week NN N
, , N
or CC N
a DT N
placebo NN N
was VBD N
given VBN N
in IN N
a DT N
double-blind JJ N
fashion NN N
Imminent JJ N
premature NN N
labor NN N
occurred VBD N
in IN N
29.0 CD N
% NN N
of IN N
the DT N
treated VBN N
group NN N
and CC N
in IN N
59.4 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.025 CD N
) ) N
The DT N
rate NN N
of IN N
premature NN N
deliveries NNS N
was VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
treated JJ N
group NN N
( ( N
16.1 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
37.82 CD N
% NN N
) ) N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
There EX N
were VBD N
no DT N
cases NNS N
of IN N
perinatal JJ N
death NN N
or CC N
fetal JJ N
malformations NNS N
in IN N
either DT N
group NN N
The DT N
mean JJ N
birth NN N
weight NN N
of IN N
all DT N
infants NNS N
of IN N
the DT N
treated JJ N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
those DT N
of IN N
the DT N
control NN N
group NN N
( ( N
3111.9 CD N
+/- JJ N
905 CD N
gm NN N
versus NN N
2680 CD N
+/- JJ N
813.4 CD N
gm NN N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
The DT N
results NNS N
support VB N
treatment NN N
with IN N
progesterone NN N
caproate NN N
for IN N
the DT N
prevention NN N
of IN N
premature JJ N
labor NN N
-DOCSTART- -X- O O 20367417

Teriparatide NNP N
improves VBZ N
early JJ N
callus NN N
formation NN N
in IN N
distal JJ 4_p
radial JJ 4_p
fractures NNS 4_p
BACKGROUND NNP N
Teriparatide NNP N
( ( N
parathyreoid JJ N
hormone NN N
; : N
PTH NNP N
1-34 CD N
) ) N
increases VBZ N
skeletal JJ N
mass NN N
in IN N
humans NNS N
and CC N
improves VBZ N
fracture NN N
healing VBG N
in IN N
animals NNS N
A DT N
recent JJ N
randomized JJ N
multicenter NN N
trial NN N
of IN N
nonoperated JJ 4_p
distal JJ 4_p
radial NN 4_p
fractures NNS 4_p
showed VBD N
a DT N
moderate JJ N
shortening NN N
of IN N
the DT N
time NN N
to TO N
restoration NN N
of IN N
cortical JJ N
continuity NN N
by IN N
treatment NN N
with IN N
20 CD N
microg NNS N
( ( N
low-dose JJ N
) ) N
teriparatide NN N
per IN N
day NN N
, , N
but CC N
not RB N
with IN N
40 CD N
microg NNS N
( ( N
high-dose JJ N
) ) N
As IN N
radiographic JJ N
cortical JJ N
continuity NN N
appears VBZ N
late RB N
in IN N
the DT N
healing NN N
process NN N
, , N
perhaps RB N
too RB N
late JJ N
for IN N
clinical JJ N
relevance NN N
, , N
we PRP N
studied VBD N
the DT N
qualitative JJ N
appearance NN N
of IN N
the DT N
callus JJ N
5 CD N
weeks NNS N
after IN N
fracture NN N
METHODS NNP N
One CD N
third NN N
of IN N
the DT N
patients NNS N
of IN N
the DT N
international JJ N
trial NN N
were VBD N
treated VBN N
at IN N
Linköping NNP N
University NNP N
Hospital NNP N
The DT N
multicenter NN N
trial NN N
did VBD N
not RB N
evaluate VB N
early JJ N
callus NN N
formation NN N
We PRP N
therefore RB N
made VBD N
a DT N
blinded JJ N
qualitative JJ N
scoring NN N
of IN N
the DT N
callus NN N
at IN N
5 CD N
weeks NNS N
in IN N
our PRP$ N
27 CD N
patients NNS N
Callus NNP N
formation NN N
was VBD N
arbitrarily RB N
classified VBN N
as IN N
rich JJ N
, , N
intermediate JJ N
, , N
or CC N
poor JJ N
RESULTS NNP N
9 CD N
patients NNS N
were VBD N
classified VBN N
as IN N
rich JJ N
( ( N
none NN N
had VBD N
received VBN N
placebo RB N
, , N
3 CD N
low-dose JJ N
teriparatide NN N
, , N
and CC N
6 CD N
high-dose JJ N
teriparatide NN N
) ) N
9 CD N
patients NNS N
were VBD N
classified VBN N
as IN N
intermediate NN N
( ( N
1 CD N
had VBD N
received VBN N
placebo RB N
, , N
5 CD N
low-dose JJ N
, , N
and CC N
3 CD N
high-dose JJ N
) ) N
9 CD N
patients NNS N
were VBD N
classified VBN N
as IN N
poor JJ N
( ( N
7 CD N
had VBD N
received VBN N
placebo RB N
, , N
1 CD N
low-dose JJ N
, , N
and CC N
1 CD N
high-dose NN N
) ) N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
INTERPRETATION NN N
This DT N
is VBZ N
a DT N
post NN N
hoc NN N
subgroup NN N
analysis NN N
of IN N
an DT N
outcome NN N
variable NN N
, , N
which WDT N
was VBD N
not RB N
in IN N
the DT N
official JJ N
protocol NN N
The DT N
results NNS N
must MD N
therefore RB N
be VB N
interpreted VBN N
with IN N
caution NN N
However RB N
, , N
in IN N
combination NN N
with IN N
the DT N
results NNS N
of IN N
the DT N
larger JJR N
trial NN N
, , N
the DT N
data NN N
suggest NN N
that IN N
radiographic JJ N
quality NN N
at IN N
an DT N
early JJ N
time NN N
point NN N
might MD N
be VB N
a DT N
sensitive JJ N
variable NN N
, , N
perhaps RB N
better JJR N
than IN N
time NN N
to TO N
cortical JJ N
continuity NN N
Moreover RB N
, , N
teriparatide RB N
appeared VBD N
to TO N
improve VB N
early JJ N
callus NN N
formation NN N
in IN N
distal JJ N
radial JJ N
fractures NNS N
-DOCSTART- -X- O O 15535495

Gum NNP N
elastic JJ N
bougie-guided JJ N
insertion NN N
of IN N
the DT N
ProSeal NNP N
Laryngeal NNP N
Mask NNP N
Airway NNP N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
gum VBZ N
elastic-bougie-guided JJ N
insertion NN N
of IN N
the DT N
ProSeal NNP N
Laryngeal NNP N
Mask NNP N
Airway NNP N
is VBZ N
more RBR N
frequently RB N
successful JJ N
than IN N
introducer JJ N
tool NN N
guided VBD N
insertion NN N
after IN N
failed VBD N
digital JJ N
insertion NN N
One CD 3_p
hundred VBD 3_p
anaesthetized JJ N
patients NNS N
( ( N
ASA NNP N
1-2 CD N
, , N
aged VBD N
18 CD 1_p
to TO 1_p
80 CD 1_p
years NNS 1_p
) ) N
were VBD N
randomized VBN N
for IN N
the DT N
second JJ N
insertion NN N
attempt NN N
using VBG N
either CC N
the DT N
gum JJ N
elastic JJ N
bougie-guided JJ N
or CC N
introducer JJ N
tool NN N
techniques NNS N
The DT N
bougie-guided JJ N
technique NN N
involved VBN N
priming VBG N
the DT N
drain NN N
tube NN N
with IN N
the DT N
bougie NN N
, , N
placing VBG N
the DT N
bougie NN N
in IN N
the DT N
oesophagus NN N
using VBG N
laryngoscope JJ N
guidance NN N
, , N
digital JJ N
insertion NN N
along IN N
the DT N
palato-pharyngeal JJ N
curve NN N
, , N
and CC N
bougie NN N
removal NN N
The DT N
introducer JJ N
tool NN N
technique NN N
involved VBN N
attaching VBG N
the DT N
introducer NN N
tool NN N
, , N
single-handed JJ N
rotation NN N
along IN N
the DT N
palatopharyngeal NN N
curve NN N
, , N
and CC N
introducer JJ N
tool NN N
removal NN N
Failed VBD N
insertion NN N
was VBD N
classified VBN N
as IN N
( ( N
i NN N
) ) N
failed VBD N
passage NN N
into IN N
the DT N
pharynx NN N
, , N
( ( N
ii NN N
) ) N
malposition NN N
, , N
or CC N
( ( N
iii NN N
) ) N
ineffective JJ N
ventilation NN N
Any DT N
blood NN N
staining NN N
was VBD N
documented VBN N
Insertion NN N
was VBD N
more RBR N
frequently RB N
successful JJ N
( ( N
50/50 CD N
vs NN N
15/50 CD N
, , N
P=0.0002 NNP N
) ) N
and CC N
faster RBR N
( ( N
35+/-17 JJ N
s NN N
vs IN N
54+/-45 JJ N
s NN N
, , N
mean+/-SD NN N
, , N
P=0.006 NNP N
) ) N
with IN N
the DT N
bougie-guided JJ N
technique NN N
All DT N
failed VBD N
insertions NNS N
with IN N
the DT N
introducer NN N
tool NN N
technique NN N
were VBD N
successful JJ N
with IN N
the DT N
bougie-guided JJ N
technique NN N
The DT N
aetiology NN N
of IN N
failed JJ N
insertion NN N
was VBD N
similar JJ N
for IN N
the DT N
digital JJ N
and CC N
introducer JJ N
tool NN N
techniques NNS N
in IN N
94 CD N
% NN N
( ( N
33/35 CD N
) ) N
of IN N
patients NNS N
There EX N
was VBD N
no DT N
blood NN N
staining VBG N
on IN N
the DT N
bougie NN N
, , N
laryngoscope NN N
or CC N
introducer NN N
tool NN N
at IN N
removal NN N
, , N
but CC N
blood VBD N
staining NN N
was VBD N
more RBR N
common JJ N
on IN N
the DT N
ProSeal NNP N
Laryngeal NNP N
Mask NNP N
Airway NNP N
with IN N
the DT N
introducer NN N
tool NN N
technique NN N
( ( N
9/50 CD N
vs NN N
2/50 CD N
, , N
P=0.03 NNP N
) ) N
We PRP N
conclude VBP N
that IN N
the DT N
gum JJ N
elastic JJ N
bougie-guided JJ N
insertion NN N
has VBZ N
a DT N
higher JJR N
success NN N
rate NN N
and CC N
causes VBZ N
less RBR N
trauma JJ N
than IN N
the DT N
insertion NN N
tool NN N
insertion NN N
technique NN N
after IN N
failed VBD N
digital JJ N
insertion NN N
of IN N
the DT N
ProSeal NNP N
Laryngeal NNP N
Mask NNP N
Airway NNP N
-DOCSTART- -X- O O 21802739

MRI NNP N
signal JJ N
hyperintensities NNS N
and CC N
failure NN N
to TO N
remit VB N
following VBG N
antidepressant JJ N
treatment NN N
BACKGROUND NNP N
MRI NNP N
signal JJ N
hyperintensities NNS N
predict VBP N
poor JJ N
remission NN N
to TO N
antidepressant VB N
treatment NN N
Previous JJ N
studies NNS N
using VBG N
volumetrics NNS N
in IN N
outpatient NN N
samples NNS N
have VBP N
relied VBN N
on IN N
total JJ N
lesion NN N
volume NN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
whether IN N
remission NN N
from IN N
geriatric JJ 4_p
depression NN 4_p
depends VBZ N
on IN N
lesion NN N
volume NN N
by IN N
region NN N
of IN N
interest NN N
( ( N
ROI NNP N
) ) N
METHOD NNP N
Thirty-eight JJ 3_p
patients NNS N
received VBD N
baseline JJ N
MRIs NNP N
as IN N
part NN N
of IN N
a DT N
larger JJR N
12-week JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
comparing VBG N
sertraline NN N
and CC N
nortriptyline NN N
in IN N
the DT N
treatment NN N
of IN N
late-life JJ 4_p
depression NN 4_p
MRIcro NNP N
was VBD N
used VBN N
to TO N
quantify VB N
MRI-hyperintensity NNP N
volume NN N
into IN N
total JJ N
hyperintensity NN N
, , N
deep JJ N
white JJ N
matter NN N
hyperintensity NN N
( ( N
DWMH NNP N
) ) N
, , N
and CC N
periventricular JJ N
hyperintensity NN N
( ( N
PVH NNP N
) ) N
volumes NNS N
High NNP N
versus NN N
low JJ N
total NN N
, , N
DWMH NNP N
, , N
and CC N
PVH NNP N
volumes NNS N
were VBD N
defined VBN N
based VBN N
on IN N
the DT N
highest JJS N
quartile NN N
of IN N
their PRP$ N
respective JJ N
distributions NNS N
Remission NN N
from IN N
depression NN N
was VBD N
defined VBN N
as IN N
a DT N
24-item JJ N
Hamilton NNP N
Rating NNP N
Scale NNP N
for IN N
Depression NNP N
score VBD N
≤ JJ N
7 CD N
for IN N
two CD N
consecutive JJ N
weeks NNS N
RESULTS JJ N
Patients NNS N
classified VBD N
as IN N
having VBG N
high JJ N
DWMH NNP N
were VBD N
7.14 CD N
times NNS N
more RBR N
likely JJ N
not RB N
to TO N
remit VB N
following VBG N
antidepressant JJ N
treatment NN N
compared VBN N
to TO N
patients NNS N
classified VBN N
as IN N
having VBG N
low JJ N
DWMH NNP N
( ( N
p=0.02 NN N
) ) N
Similar JJ N
odds NNS N
ratios NNS N
were VBD N
obtained VBN N
for IN N
PVH NNP N
( ( N
OR=4.17 NNP N
, , N
p=0.16 NN N
) ) N
and CC N
total JJ N
volumes NNS N
( ( N
OR=5.00 NNP N
, , N
p=0.05 NN N
) ) N
Importantly RB N
, , N
adjusting VBG N
for IN N
age NN N
did VBD N
not RB N
change VB N
the DT N
magnitude NN N
of IN N
these DT N
effects NNS N
LIMITATIONS VB N
A NNP N
small JJ N
and CC N
predominantly RB N
White NNP N
sample NN N
CONCLUSIONS VB N
This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
test VB N
whether IN N
remission NN N
from IN N
geriatric JJ N
depression NN N
depends VBZ N
on IN N
lesion NN N
volume NN N
by IN N
ROI NNP N
in IN N
an DT N
outpatient JJ N
sample NN N
The DT N
pattern NN N
of IN N
remission NN N
rates NNS N
and CC N
odds JJ N
ratios NNS N
was VBD N
similar JJ N
when WRB N
patients NNS N
were VBD N
classified VBN N
as IN N
having VBG N
high JJ N
DWMH NNP N
, , N
PVH NNP N
or CC N
total JJ N
volume NN N
suggesting VBG N
that IN N
lesion NN N
location NN N
may MD N
not RB N
be VB N
critical JJ N
-DOCSTART- -X- O O 17961229

How WRB N
well RB N
do VB N
blood NN N
folate VB N
concentrations NNS N
predict VBP N
dietary JJ N
folate NN N
intakes NNS N
in IN N
a DT N
sample NN N
of IN N
Canadian JJ N
lactating VBG N
women NNS 2_p
exposed VBN N
to TO N
high JJ N
levels NNS N
of IN N
folate NN 4_p
? . N
An DT N
observational JJ N
study NN N
BACKGROUND NNP N
In IN N
1998 CD N
, , N
mandatory JJ N
folic JJ N
acid JJ N
fortification NN N
of IN N
white JJ N
flour NN N
and CC N
select JJ N
cereal NN N
grain NN N
products NNS N
was VBD N
implemented VBN N
in IN N
Canada NNP N
with IN N
the DT N
intention NN N
to TO N
increase VB N
dietary JJ N
folate JJ N
intakes NNS N
of IN N
reproducing VBG 4_p
women NNS 2_p
Folic NNP N
acid JJ N
fortification NN N
has VBZ N
produced VBN N
a DT N
dramatic JJ N
increase NN N
in IN N
blood NN N
folate JJ N
concentrations NNS N
among IN N
reproductive JJ N
age NN N
women NNS N
, , N
and CC N
a DT N
reduction NN N
in IN N
neural JJ N
tube NN N
defect NN N
( ( N
NTD NNP N
) ) N
-affected VBD N
pregnancies NNS N
In IN N
response NN N
to TO N
improved VBN N
blood NN N
folate NN N
concentrations NNS N
, , N
many JJ N
health NN N
care NN N
professionals NNS N
are VBP N
asking VBG N
whether IN N
a DT N
folic JJ N
acid NN N
supplement NN N
is VBZ N
necessary JJ N
for IN N
NTD NNP N
prevention NN N
among IN N
women NNS 2_p
with IN N
high JJ 4_p
blood NN 4_p
folate NN 4_p
values NNS 4_p
, , N
and CC N
how WRB N
reliably RB N
high JJ N
RBC NNP N
folate NN N
concentrations NNS N
predict VBP N
folate JJ N
intakes NNS N
shown VBN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
to TO N
be VB N
protective JJ N
against IN N
NTDs NNP N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
how WRB N
predictive JJ N
blood NN N
folate NN N
concentrations NNS N
and CC N
folate NN N
intakes NNS N
are VBP N
of IN N
each DT N
other JJ N
in IN N
a DT N
sample NN N
of IN N
well-educated JJ N
lactating VBG N
Canadian JJ N
women NNS 2_p
exposed VBN N
to TO N
high JJ N
levels NNS N
of IN N
synthetic JJ 4_p
folate NN 4_p
METHODS NNP N
The DT N
relationship NN N
between IN N
blood NN N
folate NN N
concentrations NNS N
and CC N
dietary JJ N
folate NN N
intakes NNS N
, , N
determined VBN N
by IN N
weighed VBN N
food NN N
records NNS N
, , N
were VBD N
assessed VBN N
in IN N
a DT N
sample NN N
of IN N
predominantly RB N
university-educated JJ N
lactating VBG N
women NNS 2_p
( ( 1_p
32 CD 1_p
+/- JJ 1_p
4 CD 1_p
yr NN 1_p
) ) 1_p
at IN N
4- JJ N
( ( N
n JJ N
= NNP N
53 CD 3_p
) ) N
and CC N
16-wk JJ N
postpartum NN N
( ( N
n JJ N
= NNP N
55 CD 3_p
) ) N
RESULTS NNP N
Median JJ N
blood NN N
folate NN N
concentrations NNS N
of IN N
all DT N
participants NNS N
were VBD N
well RB N
above IN N
plasma NN N
and CC N
RBC NNP N
folate VBP N
cut-off NN N
levels NNS N
indicative CD N
of IN N
deficiency NN N
( ( N
6.7 CD N
and CC N
317 CD N
nmol/L NN N
, , N
respectively RB N
) ) N
and CC N
all DT N
, , N
except IN N
for IN N
2 CD N
subjects NNS N
, , N
were VBD N
above IN N
the DT N
cut-off NN N
for IN N
NTD-risk NNP N
reduction NN N
( ( N
> $ N
906 CD N
nmol/L NN N
) ) N
Only RB N
modest JJ N
associations NNS N
existed VBD N
between IN N
total JJ N
folate NN N
intakes NNS N
and CC N
plasma NN N
( ( N
r JJ N
= NN N
0.46 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
RBC NNP N
( ( N
r VB N
= RB N
0.36 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
folate NN N
concentrations NNS N
at IN N
16-wk JJ N
postpartum NN N
Plasma NNP N
and CC N
RBC NNP N
folate VBP N
values NNS N
at IN N
16-wk JJ N
postpartum NN N
correctly RB N
identified VBD N
the DT N
quartile NN N
of IN N
folate JJ N
intake NN N
of IN N
only RB N
26 CD N
of IN N
55 CD N
( ( N
47 CD N
% NN N
) ) N
and CC N
18 CD N
of IN N
55 CD N
( ( N
33 CD N
% NN N
) ) N
of IN N
subjects NNS N
, , N
respectively RB N
The DT N
mean JJ N
RBC NNP N
folate NN N
concentration NN N
of IN N
women NNS N
consuming VBG N
151-410 JJ N
microg/d NN N
of IN N
synthetic JJ N
folate NN N
( ( N
2nd CD N
quartile NN N
of IN N
intake NN N
) ) N
did VBD N
not RB N
differ VB N
from IN N
that DT N
of IN N
women NNS N
consuming VBG N
> JJ N
410 CD N
microg/d NN N
( ( N
3rd CD N
and CC N
4th CD N
quartile NN N
) ) N
CONCLUSION NNP N
Folate NNP N
intakes NNS N
, , N
estimated VBN N
by IN N
food NN N
composition NN N
tables NNS N
, , N
and CC N
blood NN N
folate NN N
concentrations NNS N
are VBP N
not RB N
predictive JJ N
of IN N
each DT N
other JJ N
in IN N
Canadian JJ N
lactating VBG N
women NNS N
exposed VBN N
to TO N
high JJ N
levels NNS N
of IN N
folate NN N
Synthetic JJ N
intakes NNS N
> VBP N
151-410 JJ N
microg/d NN N
in IN N
these DT N
women NNS N
produced VBD N
little JJ N
additional JJ N
benefit NN N
in IN N
terms NNS N
of IN N
maximizing VBG N
RBC NNP N
content NN N
More JJR N
studies NNS N
are VBP N
needed VBN N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
blood NN N
folate NN N
concentration NN N
and CC N
NTD NNP N
risk NN N
Until IN N
data NNS N
from IN N
such JJ N
studies NNS N
are VBP N
available JJ N
, , N
women NNS N
planning VBG N
a DT N
pregnancy NN N
should MD N
continue VB N
to TO N
consume VB N
a DT N
daily JJ N
folic JJ N
acid JJ N
supplement NN N
of IN N
400 CD N
microg NN N
-DOCSTART- -X- O O 7080985

[ RB N
Comparative NNP N
study NN N
of IN N
cinoxacin NN N
( ( N
Cinobac NNP N
) ) N
, , N
nitrofurantoin FW N
( ( N
Furadantine NNP N
MC NNP N
) ) N
and CC N
oxolinic JJ N
acid NN N
( ( N
Uritrate NNP N
) ) N
in IN N
urinary JJ N
tract NN N
infections NNS N
Results NNS N
of IN N
a DT N
random NN N
study NN N
of IN N
three CD N
groups NNS N
of IN N
30 CD 3_p
patients NNS N
with IN N
uncomplicated JJ N
urinary JJ 4_p
infections NNS 4_p
] VBP N
-DOCSTART- -X- O O 7036799

Lidocaine NNP N
and CC N
bupivacaine NN N
mixtures NNS N
for IN N
epidural JJ N
blockade NN N
In IN N
a DT N
prospective JJ N
double-blind NN N
clinical JJ N
study NN N
, , N
single-dose JJ N
lumbar NN N
epidural JJ N
blockade NN N
was VBD N
instituted VBN N
in IN N
60 CD 3_p
healthy JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
lower JJR 4_p
abdominal JJ 4_p
surgery NN 4_p
Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
five CD N
groups NNS N
Each DT N
group NN N
received VBD N
treatment NN N
with IN N
a DT N
different JJ N
local JJ N
anesthetic JJ N
solution NN N
containing VBG N
1:200,000 CD N
epinephrine NN N
Local JJ N
anesthetic JJ N
solutions NNS N
used VBN N
were VBD N
0.5 CD N
per IN N
cent NN N
bupivacaine NN N
HCl NNP N
, , N
2 CD N
per IN N
cent NN N
lidocaine NN N
HCl NNP N
, , N
and CC N
lidocaine-bupivacaine JJ N
mixtures NNS N
in IN N
the DT N
ratios NNS N
of IN N
1:3 CD N
, , N
1:1 CD N
or CC N
3:1 CD N
by IN N
volume NN N
Onset NNP N
and CC N
complete JJ N
spread NN N
of IN N
sensory JJ N
blockade NN N
were VBD N
similar JJ N
in IN N
all DT N
five CD N
groups NNS N
Time NNP N
to TO N
regression VB N
to TO N
two CD N
segments NNS N
of IN N
partial JJ N
and CC N
complete JJ N
sensory NN N
blockade NN N
was VBD N
positively RB N
correlated VBN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
with IN N
increasing VBG N
dose NN N
of IN N
bupivacaine NN N
in IN N
the DT N
solutions NNS N
and CC N
ranged VBD N
from IN N
84 CD N
min NN N
( ( N
partial JJ N
) ) N
and CC N
70 CD N
min NN N
( ( N
complete JJ N
) ) N
for IN N
lidocaine NN N
, , N
to TO N
128 CD N
min NN N
( ( N
partial JJ N
) ) N
and CC N
101 CD N
min NN N
( ( N
complete JJ N
) ) N
for IN N
bupivacaine NN N
Using VBG N
skin JJ N
temperature NN N
as IN N
a DT N
criterion NN N
of IN N
sympathetic JJ N
blockade NN N
, , N
all DT N
three CD N
mixtures NNS N
demonstrated VBD N
a DT N
duration NN N
of IN N
action NN N
intermediate NN N
between IN N
the DT N
two CD N
single JJ N
drugs NNS N
, , N
lidocaine NN N
( ( N
124 CD N
+/- JJ N
13 CD N
min NN N
) ) N
and CC N
bupivacaine NN N
( ( N
286 CD N
+/- JJ N
32 CD N
min NN N
) ) N
Onset NNP N
of IN N
complete JJ N
motor NN N
blockade NN N
was VBD N
fastest JJS N
and CC N
the DT N
degree NN N
of IN N
motor NN N
blockade NN N
was VBD N
most RBS N
profound JJ N
with IN N
the DT N
mixture NN N
containing VBG N
equal JJ N
proportions NNS N
of IN N
lidocaine NN N
and CC N
bupivacaine NN N
Pharmacokinetics NNS N
of IN N
individual JJ N
drugs NNS N
were VBD N
unaltered VBN N
in IN N
any DT N
of IN N
the DT N
mixtures NNS N
-DOCSTART- -X- O O 21042930

Intensive JJ N
case NN N
management NN N
before IN N
and CC N
after IN N
prison NN N
release NN N
is VBZ N
no DT N
more RBR N
effective JJ N
than IN N
comprehensive JJ N
pre-release JJ N
discharge NN N
planning NN N
in IN N
linking VBG N
HIV-infected JJ 4_p
prisoners NNS 4_p
to TO N
care VB N
: : N
a DT N
randomized JJ N
trial NN N
Imprisonment NNP N
provides VBZ N
opportunities NNS N
for IN N
the DT N
diagnosis NN N
and CC N
successful JJ N
treatment NN N
of IN N
HIV NNP N
, , N
however RB N
, , N
the DT N
benefits NNS N
of IN N
antiretroviral JJ N
therapy NN N
are VBP N
frequently RB N
lost VBN N
following VBG N
release NN N
due JJ N
to TO N
suboptimal JJ N
access NN N
and CC N
utilization NN N
of IN N
health NN N
care NN N
and CC N
services NNS N
In IN N
response NN N
, , N
some DT N
have VBP N
advocated VBN N
for IN N
development NN N
of IN N
intensive JJ N
case-management JJ N
interventions NNS N
spanning VBG N
incarceration NN N
and CC N
release NN N
to TO N
support VB N
treatment NN N
adherence NN N
and CC N
community NN N
re-entry NN N
for IN N
HIV-infected JJ 4_p
releasees NNS 4_p
We PRP N
conducted VBD N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
motivational JJ N
Strengths NNP N
Model NNP N
bridging VBG N
case NN N
management NN N
intervention NN N
( ( N
BCM NNP N
) ) N
beginning VBG N
approximately RB N
3 CD N
months NNS N
prior RB N
to TO N
and CC N
continuing VBG N
6 CD N
months NNS N
after IN N
release NN N
versus IN N
a DT N
standard NN N
of IN N
care NN N
prison-administered JJ N
discharge NN N
planning VBG N
program NN N
( ( N
SOC NNP N
) ) N
for IN N
HIV-infected JJ N
state NN N
prison NN N
inmates NNS N
The DT N
primary JJ N
outcome NN N
variable NN N
was VBD N
self-reported JJ N
access NN N
to TO N
post-release VB N
medical JJ N
care NN N
Of IN N
the DT N
104 CD N
inmates NNS N
enrolled VBD N
, , N
89 CD N
had VBD N
at IN N
least JJS N
1 CD N
post-release JJ N
study NN N
visit NN N
Of IN N
these DT N
, , N
65.1 CD N
% NN N
of IN N
BCM NNP N
and CC N
54.4 CD N
% NN N
of IN N
SOC NNP N
assigned VBD N
participants NNS N
attended VBD N
a DT N
routine JJ N
medical JJ N
appointment NN N
within IN N
4 CD N
weeks NNS N
of IN N
release NN N
( ( N
P NNP N
> NNP N
0.3 CD N
) ) N
By IN N
week NN N
12 CD N
post-release NN N
, , N
88.4 CD N
% NN N
of IN N
the DT N
BCM NNP N
arm NN N
and CC N
78.3 CD N
% NN N
of IN N
the DT N
SOC NNP N
arm NN N
had VBD N
at IN N
attended VBN N
at IN N
least JJS N
one CD N
medical JJ N
appointment NN N
( ( N
P NNP N
= NNP N
0.2 CD N
) ) N
, , N
increasing VBG N
in IN N
both DT N
arms NNS N
at IN N
week NN N
24-90.7 CD N
% NN N
with IN N
BCM NNP N
and CC N
89.1 CD N
% NN N
with IN N
SOC NNP N
( ( N
P NNP N
> NNP N
0.5 CD N
) ) N
No DT N
participant NN N
without IN N
a DT N
routine JJ N
medical JJ N
visit NN N
by IN N
week NN N
24 CD N
attended VBD N
an DT N
appointment NN N
from IN N
weeks NNS N
24 CD N
to TO N
48 CD N
The DT N
mean JJ N
number NN N
of IN N
clinic JJ N
visits NNS N
during IN N
the DT N
48 CD N
weeks NNS N
post NN N
release NN N
was VBD N
5.23 CD N
( ( N
SD NNP N
= NNP N
3.14 CD N
) ) N
for IN N
BCM NNP N
and CC N
4.07 CD N
( ( N
SD NNP N
= NNP N
3.20 CD N
) ) N
for IN N
SOC NNP N
( ( N
P NNP N
> NNP N
0.5 CD N
) ) N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
arms NNS N
in IN N
social JJ N
service NN N
utilization NN N
and CC N
re-incarceration NN N
rates NNS N
were VBD N
also RB N
similar JJ N
We PRP N
found VBD N
that IN N
a DT N
case NN N
management NN N
intervention NN N
bridging VBG N
incarceration NN N
and CC N
release NN N
was VBD N
no DT N
more RBR N
effective JJ N
than IN N
a DT N
less RBR N
intensive JJ N
pre-release JJ N
discharge NN N
planning VBG N
program NN N
in IN N
supporting VBG N
health NN N
and CC N
social JJ N
service NN N
utilization NN N
for IN N
HIV-infected JJ N
individuals NNS N
released VBN N
from IN N
prison NN N
-DOCSTART- -X- O O 10223244

Allelic JJ N
imbalance NN N
in IN N
the DT N
clonal JJ N
evolution NN N
of IN N
prostate NN 4_p
carcinoma NN 4_p
BACKGROUND NNP N
To TO N
understand VB N
better JJR N
the DT N
genetic JJ N
basis NN N
of IN N
the DT N
clonal JJ N
evolution NN N
of IN N
prostate NN N
carcinoma NN N
, , N
the DT N
authors NNS N
analyzed VBD N
the DT N
pattern NN N
of IN N
allelic JJ N
loss NN N
in IN N
25 CD 3_p
matched JJ N
primary NN 4_p
and CC 4_p
metastatic JJ 4_p
prostate NN 4_p
tumors NNS 4_p
METHODS NNP N
Twenty-five JJ 3_p
cases NNS N
were VBD N
selected VBN N
from IN N
the DT N
surgical JJ N
pathology NN N
files NNS N
of IN N
the DT N
Mayo NNP N
Clinic NNP N
from IN N
patients NNS N
who WP N
had VBD N
undergone JJ N
radical JJ N
retropubic NN N
prostatectomy NN N
and CC N
bilateral JJ N
lymphadenectomy NN N
between IN N
1987-1991 JJ N
All DT N
patients NNS N
had VBD N
regional JJ 4_p
lymph NN 4_p
node NN 4_p
metastases NNS 4_p
at IN N
the DT N
time NN N
of IN N
surgery NN N
DNA NN N
samples NNS N
for IN N
the DT N
analysis NN N
of IN N
allelic JJ N
loss NN N
pattern NN N
were VBD N
prepared VBN N
from IN N
primary JJ N
tumors NNS N
and CC N
matched VBD N
synchronous JJ N
lymph NN N
node NN N
metastases NNS N
by IN N
tissue NN N
microdissection NN N
The DT N
oligonucleotide JJ N
primer NN N
pairs NNS N
for IN N
the DT N
microsatellite JJ N
DNA NN N
markers NNS N
were VBD N
D8S133 NNP N
, , N
D8S136 NNP N
, , N
D8S137 NNP N
, , N
ANK1 NNP N
on IN N
chromosome NN N
8p12-21 CD N
, , N
LPLTET NNP N
on IN N
chromosome NN N
8p22 CD N
, , N
and CC N
D17S855 NNP N
( ( N
intragenic JJ N
to TO N
the DT N
BRCA1 NNP N
gene NN N
) ) N
on IN N
chromosome NN N
17q21 CD N
One CD N
case NN N
was VBD N
not RB N
informative JJ N
at IN N
any DT N
of IN N
the DT N
loci NN N
tested VBD N
and CC N
was VBD N
excluded VBN N
from IN N
further JJ N
analysis NN N
RESULTS VB N
The DT N
overall JJ N
frequency NN N
of IN N
allelic JJ N
imbalance NN N
was VBD N
79 CD N
% NN N
in IN N
primary JJ N
tumors NNS N
and CC N
88 CD N
% NN N
in IN N
paired JJ N
metastases NNS N
Of IN N
24 CD 3_p
informative JJ N
cases NNS N
, , N
14 CD N
patients NNS N
( ( N
58 CD N
% NN N
) ) N
showed VBD N
the DT N
same JJ N
pattern NN N
of IN N
allelic JJ N
loss NN N
or CC N
retention NN N
in IN N
matched JJ N
primary NN N
and CC N
metastatic JJ N
tumors NNS N
at IN N
all DT N
marker NN N
locus NN N
; : N
discordant JJ N
allelic JJ N
loss NN N
was VBD N
observed VBN N
in IN N
the DT N
remaining VBG N
10 CD N
patients NNS N
( ( N
42 CD N
% NN N
) ) N
Four CD N
patients NNS N
showed VBD N
loss NN N
of IN N
the DT N
same JJ N
allele NN N
at IN N
one CD N
or CC N
more JJR N
marker NN N
loci NN N
in IN N
both DT N
primary JJ N
and CC N
metastatic JJ N
tumors NNS N
, , N
but CC N
discordant JJ N
allelic JJ N
loss NN N
was VBD N
observed VBN N
at IN N
other JJ N
marker NN N
loci NN N
Five CD N
patients NNS N
showed VBD N
allelic JJ N
loss NN N
in IN N
at IN N
least JJS N
one CD N
genetic JJ N
marker NN N
in IN N
the DT N
metastatic JJ N
tumor NN N
but CC N
not RB N
in IN N
its PRP$ N
matched JJ N
primary JJ N
tumor NN N
Five CD N
patients NNS N
displayed JJ N
loss NN N
of IN N
one CD N
allele NN N
at IN N
one CD N
or CC N
more JJR N
marker NN N
loci NN N
in IN N
a DT N
primary JJ N
tumor NN N
but CC N
not RB N
in IN N
the DT N
matched JJ N
metastases NNS N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
frequency NN N
of IN N
allelic JJ N
imbalance NN N
between IN N
primary JJ N
and CC N
metastatic JJ N
tumors NNS N
at IN N
any DT N
marker NN N
analyzed VBN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
different JJ N
patterns NNS N
of IN N
allelic JJ N
deletion NN N
may MD N
be VB N
acquired VBN N
during IN N
cancer NN N
progression NN N
to TO N
metastases NNS N
The DT N
differences NNS N
in IN N
genetic JJ N
composition NN N
between IN N
primary JJ N
prostate NN N
carcinoma NN N
and CC N
its PRP$ N
metastases NNS N
may MD N
be VB N
related VBN N
to TO N
intrinsic JJ N
cancer NN N
heterogeneity NN N
, , N
overall JJ N
genetic JJ N
instability NN N
, , N
and CC N
clonal JJ N
divergence NN N
-DOCSTART- -X- O O 7726441

The DT N
antiemetic JJ N
efficacy NN N
of IN N
prophylactic JJ N
granisetron NN N
in IN N
gynecologic JJ 4_p
surgery NN 4_p
Postoperative NNP N
nausea NN N
and CC N
vomiting NN N
are VBP N
common JJ N
after IN N
recovery NN 4_p
from IN 4_p
anesthesia NN 4_p
We PRP N
examined VBD N
the DT N
prophylactic JJ N
effect NN N
of IN N
granisetron NN N
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
in IN N
120 CD 4_p
female JJ 4_p
patients NNS 4_p
( ( 4_p
ASA NNP 4_p
physical JJ 4_p
status NN 4_p
I PRP 4_p
) ) 4_p
undergoing VBG 4_p
gynecologic JJ 4_p
surgery NN 4_p
They PRP N
were VBD N
randomly RB N
allocated VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
( ( N
n JJ N
= VBP N
40 CD N
for IN N
each DT N
) ) N
: : N
saline NN N
( ( N
as IN N
a DT N
control NN N
) ) N
, , N
granisetron $ N
20 CD N
micrograms/kg NN N
, , N
and CC N
granisetron $ N
40 CD N
micrograms/kg NN N
Saline NNP N
or CC N
granisetron NN N
was VBD N
given VBN N
intravenously RB N
( ( N
IV NNP N
) ) N
over IN N
5 CD N
min NNS N
approximately RB N
30 CD N
min NN N
before IN N
the DT N
end NN N
of IN N
anesthesia NN N
Nausea NN N
, , N
vomiting NN N
, , N
and CC N
safety NN N
assessments NNS N
were VBD N
performed VBN N
during IN N
the DT N
24-h JJ N
recovery NN N
period NN N
For IN N
the DT N
24-h JJ N
period NN N
after IN N
surgery NN N
, , N
the DT N
number NN N
of IN N
emesis-free JJ N
patients NNS N
was VBD N
significantly RB N
larger JJR N
in IN N
the DT N
granisetron NN N
groups NNS N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
83 CD N
% NN N
, , N
78 CD N
% NN N
, , N
and CC N
20 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
granisetron NN N
20 CD N
micrograms/kg NN N
and CC N
40 CD N
micrograms/kg NN N
, , N
and CC N
saline NN N
, , N
respectively RB N
) ) N
Granisetron NNP N
at IN N
both DT N
doses NNS N
also RB N
was VBD N
superior JJ N
to TO N
the DT N
control NN N
for IN N
the DT N
prevention NN N
of IN N
nausea NN N
over IN N
the DT N
24-h JJ N
study NN N
period NN N
( ( N
nausea JJ N
visual JJ N
analog NN N
scales NNS N
at IN N
24-h JJ N
postsurgery NN N
: : N
49 CD N
mm NN N
, , N
17 CD N
mm NN N
, , N
and CC N
18 CD N
mm NN N
in IN N
the DT N
control NN N
, , N
granisetron VBP N
20 CD N
micrograms/kg NN N
, , N
and CC N
granisetron $ N
40 CD N
micrograms/kg NN N
groups NNS N
, , N
respectively RB N
) ) N
Fewer JJR N
patients NNS N
received VBD N
" JJ N
rescue NN N
" NN N
antiemetics NNS N
in IN N
the DT N
granisetron NN N
groups NNS N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
10 CD N
% NN N
, , N
10 CD N
% NN N
, , N
and CC N
43 CD N
% NN N
of IN N
patients NNS N
in IN N
granisetron NN N
20 CD N
micrograms/kg NN N
and CC N
40 CD N
micrograms/kg NN N
, , N
and CC N
the DT N
control NN N
groups NNS N
, , N
respectively RB N
) ) N
The DT N
adverse JJ N
events NNS N
in IN N
the DT N
granisetron NN N
groups NNS N
were VBD N
similar JJ N
to TO N
those DT N
in IN N
the DT N
control NN N
group NN N
The DT N
administration NN N
of IN N
granisetron NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
vital JJ N
signs NNS N
or CC N
clinical JJ N
laboratory NN N
test NN N
profiles NNS N
Granisetron NNP N
given VBN N
at IN N
20 CD N
or CC N
40 CD N
micrograms/kg JJ N
i.v NN N
during IN N
anesthesia JJ N
appears VBZ N
to TO N
be VB N
a DT N
simple JJ N
, , N
effective JJ N
, , N
and CC N
safe JJ N
method NN N
for IN N
preventing VBG N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
-DOCSTART- -X- O O 12093332

Bovine NNP N
pericardium NN N
vs NN N
dacron NN N
for IN N
patch NN N
angioplasty NN N
after IN 4_p
carotid JJ 4_p
endarterectomy NN 4_p
: : N
a DT N
prospective JJ N
randomized NN N
study NN N
HYPOTHESIS NNP N
Bovine NNP N
pericardium NN N
( ( N
BP NNP N
) ) N
demonstrates VBZ N
improved JJ N
intraoperative JJ N
hemostasis NN N
and CC N
equivalent JJ N
perioperative JJ N
morbidity NN N
compared VBN N
with IN N
Dacron NNP N
when WRB N
used VBN N
as IN N
patch JJ N
material NN N
for IN N
angioplasty NN N
following VBG N
carotid JJ N
endarterectomy NN N
OBJECTIVE UH N
To TO N
prospectively RB N
compare VB N
BP NNP N
and CC N
Dacron NNP N
patch NN N
angioplasty NN N
after IN N
carotid JJ N
endarterectomy NN N
in IN N
a DT N
randomized JJ N
fashion NN N
METHODS NNP N
Ninety-five JJ N
consecutive JJ N
primary JJ N
carotid NN 4_p
endarterectomies NNS 4_p
were VBD N
performed VBN N
in IN N
a DT N
prospective JJ N
randomized VBN N
fashion NN N
in IN N
92 CD 3_p
patients NNS N
Fifty-one CD N
procedures NNS N
were VBD N
performed VBN N
using VBG N
BP NNP N
and CC N
44 CD N
using VBG N
Dacron NNP N
Intraoperative JJ N
suture NN N
line NN N
bleeding NN N
was VBD N
subjectively RB N
evaluated VBN N
by IN N
observing VBG N
bleeding VBG N
at IN N
3 CD N
and CC N
4 CD N
minutes NNS N
following VBG N
carotid JJ N
cross-clamp JJ N
removal NN N
and CC N
then RB N
objectively RB N
weighing VBG N
the DT N
sponge NN N
used VBN N
to TO N
tamponade VB N
bleeding VBG N
during IN N
these DT N
time NN N
intervals NNS N
Perioperative JJ N
morbidity NN N
, , N
including VBG N
cervical JJ N
wound NN N
hematoma NN N
, , N
transient JJ N
ischemic JJ N
attack NN N
, , N
and CC N
stroke NN N
, , N
and CC N
perioperative JJ N
mortality NN N
were VBD N
recorded VBN N
Statistical JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
paired JJ N
t NN N
tests NNS N
, , N
chi NN N
( ( N
2 CD N
) ) N
analysis NN N
, , N
Fisher NNP N
exact JJ N
test NN N
, , N
or CC N
multiple JJ N
linear JJ N
regression NN N
as IN N
appropriate JJ N
RESULTS JJ N
Suture NNP N
line NN N
bleeding VBG N
at IN N
3 CD N
minutes NNS N
was VBD N
present JJ N
in IN N
7 CD N
( ( N
14 CD N
% NN N
) ) N
of IN N
51 CD N
patients NNS N
in IN N
the DT N
BP NNP N
group NN N
and CC N
24 CD N
( ( N
55 CD N
% NN N
) ) N
of IN N
44 CD N
patients NNS N
in IN N
the DT N
Dacron NNP N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
Suture JJ N
line NN N
bleeding NN N
evaluated VBD N
at IN N
4 CD N
minutes NNS N
was VBD N
present JJ N
in IN N
2 CD N
( ( N
4 CD N
% NN N
) ) N
of IN N
51 CD N
patients NNS N
in IN N
the DT N
BP NNP N
group NN N
and CC N
13 CD N
( ( N
30 CD N
% NN N
) ) N
of IN N
44 CD N
patients NNS N
in IN N
the DT N
Dacron NNP N
group NN N
( ( N
P NNP N
=.001 NNP N
) ) N
Net JJ N
+/- JJ N
SEM NNP N
sponge NN N
weight NN N
( ( N
total JJ N
intraoperative JJ N
suture NN N
line NN N
bleeding VBG N
) ) N
was VBD N
6.25 CD N
+/- JJ N
0.55 CD N
g NN N
in IN N
the DT N
BP NNP N
group NN N
and CC N
16.34 CD N
+/- JJ N
1.85 CD N
g NN N
in IN N
the DT N
Dacron NNP N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
Total JJ N
suture NN N
line NN N
bleeding NN N
was VBD N
significantly RB N
affected VBN N
by IN N
activated JJ N
clotting NN N
time NN N
; : N
however RB N
, , N
multivariate JJ N
analysis NN N
demonstrated VBD N
that IN N
bleeding NN N
was VBD N
significantly RB N
less JJR N
with IN N
BP NNP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
even RB N
after IN N
adjusting VBG N
for IN N
differences NNS N
in IN N
activated JJ N
clotting NN N
time NN N
CONCLUSIONS NNP N
Bovine NNP N
pericardium NN N
demonstrated VBD N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
intraoperative JJ N
suture NN N
line NN N
bleeding VBG N
compared VBN N
with IN N
Dacron NNP N
Handling VBG N
characteristics NNS N
were VBD N
judged VBN N
by IN N
the DT N
surgeons NNS N
to TO N
be VB N
superior JJ N
for IN N
BP NNP N
Therefore RB N
, , N
we PRP N
believe VBP N
BP NNP N
may MD N
be VB N
an DT N
alternative JJ N
to TO N
Dacron NNP N
when WRB N
performing VBG N
patch NN N
angioplasty NN N
of IN N
the DT N
carotid NN N
artery NN N
after IN N
endarterectomy NN N
-DOCSTART- -X- O O 23746205

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
the DT N
effect NN N
of IN N
dried JJ N
purple JJ N
carrot NN N
on IN N
body NN N
mass NN N
, , N
lipids NNS N
, , N
blood NN N
pressure NN N
, , N
body NN N
composition NN N
, , N
and CC N
inflammatory JJ N
markers NNS N
in IN N
overweight NN 4_p
and CC 4_p
obese JJ 4_p
adults NNS 1_p
: : N
the DT N
QUENCH NNP N
trial NN N
Obesity NNP N
is VBZ N
a DT N
significant JJ N
health NN N
issue NN N
worldwide NN N
and CC N
is VBZ N
associated VBN N
with IN N
chronic JJ N
, , N
low-grade JJ N
inflammation NN N
predisposing VBG N
the DT N
individual NN N
to TO N
cardiovascular VB N
disease NN N
and CC N
impaired JJ N
blood NN N
glucose JJ N
homeostasis NN N
Anthocyanins NNS N
and CC N
phenolic JJ N
acids NNS N
from IN N
purple JJ N
carrots NNS N
are VBP N
effective JJ N
at IN N
reversing VBG N
inflammation NN N
and CC N
metabolic JJ N
alterations NNS N
in IN N
animal NN N
models NNS N
, , N
potentially RB N
through IN N
inhibition NN N
of IN N
inflammatory JJ N
pathways NNS N
The DT N
effects NNS N
of IN N
dried JJ N
purple JJ N
carrot NN N
on IN N
body NN N
mass NN N
, , N
body NN N
composition NN N
, , N
blood NN N
pressure NN N
, , N
lipids NNS N
, , N
inflammatory JJ N
markers NNS N
, , N
liver JJ N
function NN N
tests NNS N
, , N
and CC N
appetite RB N
were VBD N
investigated VBN N
in IN N
16 CD 3_p
males NNS 2_p
( ( N
aged VBN 1_p
53.1 CD 1_p
± JJ 1_p
7.6 CD 1_p
years NNS 1_p
and CC N
with IN N
a DT N
mean JJ 4_p
BMI NNP 4_p
of IN 4_p
32.8 CD 4_p
± JJ 4_p
4.6 CD 4_p
kg/m NN 4_p
( ( 4_p
2 CD 4_p
) ) 4_p
) ) 4_p
with IN 4_p
normal JJ 4_p
lipid JJ 4_p
and CC 4_p
inflammatory JJ 4_p
markers NNS 4_p
There EX N
was VBD N
no DT N
evidence NN N
that IN N
118.5 CD N
mg/day NN N
of IN N
anthocyanins NNS N
and CC N
259.2 CD N
mg/day NN N
of IN N
phenolic JJ N
acids NNS N
for IN N
4 CD N
weeks NNS N
resulted VBD N
in IN N
statistically RB N
significant JJ N
changes NNS N
in IN N
body NN N
mass NN N
, , N
body NN N
composition NN N
, , N
appetite RB N
, , N
dietary JJ N
intake NN N
, , N
low JJ N
density NN N
lipoprotein NN N
, , N
total JJ N
cholesterol NN N
, , N
blood NN N
pressure NN N
, , N
or CC N
C-reactive JJ N
protein NN N
in IN N
these DT N
obese JJ N
participants NNS N
at IN N
the DT N
dose NN N
and CC N
length NN N
of IN N
intervention NN N
used VBN N
in IN N
this DT N
trial NN N
High JJ N
density NN N
lipoprotein VBP N
cholesterol NN N
was VBD N
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
Aspartate NNP N
amino NN N
transferase NN N
and CC N
alanine NN N
amino NN N
transferase NN N
did VBD N
not RB N
change NN N
, , N
indicating VBG N
that IN N
the DT N
intervention NN N
was VBD N
safe JJ N
More JJR N
studies NNS N
are VBP N
required VBN N
to TO N
establish VB N
the DT N
bioavailability NN N
and CC N
pharmacokinetic JJ N
effects NNS N
of IN N
purple JJ N
carrot NN N
anthocyanins NNS N
and CC N
phenolic JJ N
acids NNS N
prior RB N
to TO N
further JJ N
trials NNS N
of IN N
efficacy NN N
with IN N
respect NN N
to TO N
treating VBG N
inflammation NN N
and CC N
metabolic JJ N
alterations NNS N
-DOCSTART- -X- O O 9109702

Comparative JJ N
efficacy NN N
and CC N
safety NN N
of IN N
twice JJ N
daily JJ N
fluticasone NN N
propionate NN N
powder NN N
versus NN N
placebo NN N
in IN N
the DT N
treatment NN N
of IN N
moderate JJ 4_p
asthma NN 4_p
BACKGROUND NNP N
Fluticasone NNP N
propionate NN N
, , N
an DT N
inhaled JJ N
corticosteroid NN N
with IN N
negligible JJ N
systemic JJ N
bioavailability NN N
via IN N
the DT N
oral JJ N
route NN N
, , N
is VBZ N
efficacious JJ N
in IN N
the DT N
treatment NN N
of IN N
asthma NN 4_p
when WRB N
administered VBN N
via IN N
metered-dose JJ N
inhaler NN N
OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
inhaled JJ N
fluticasone NN N
propionate NN N
powder NN N
in IN N
patients NNS N
with IN N
moderate JJ 4_p
asthma NNS 4_p
previously RB 4_p
treated VBN 4_p
with IN 4_p
an DT 4_p
inhaled JJ 4_p
corticosteroid NN 4_p
METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel-group JJ N
, , N
multicenter NN N
study NN N
of IN N
342 CD 3_p
adolescent NN 1_p
and CC 1_p
adult NN 1_p
patients NNS N
with IN N
moderate JJ 4_p
asthma NNS 4_p
[ RB N
forced VBD 4_p
expiratory JJ 4_p
volume NN 4_p
in IN 4_p
1 CD 4_p
second JJ 4_p
( ( 4_p
FEV1 NNP 4_p
) ) 4_p
between IN 4_p
50 CD 4_p
% NN 4_p
and CC 4_p
80 CD 4_p
% NN 4_p
of IN 4_p
predicted JJ 4_p
] NNP N
treated VBD N
previously RB N
by IN N
beclomethasone NN N
dipropionate NN N
or CC N
triamcinolone NN N
acetonide RB N
Patients NNS N
received VBD N
fluticasone JJ N
propionate NN N
powder NN N
50 CD N
micrograms NNS N
, , N
100 CD N
micrograms NNS N
, , N
250 CD N
micrograms NNS N
, , N
or CC N
placebo NN N
via IN N
a DT N
breath-actuated JJ N
inhalation NN N
device NN N
, , N
the DT N
Diskhaler NNP N
, , N
twice RB N
daily RB N
for IN N
12 CD N
weeks NNS N
RESULTS JJ N
Patients NNPS N
in IN N
the DT N
fluticasone NN N
propionate NN N
groups NNS N
experienced VBD N
a DT N
mean JJ N
increase NN N
from IN N
baseline NN N
to TO N
endpoint VB N
in IN N
FEV1 NNP N
ranging VBG N
from IN N
0.43 CD N
L NNP N
to TO N
0.47 CD N
L. NNP N
Patients NNPS N
in IN N
the DT N
placebo NN N
group NN N
experienced VBD N
a DT N
mean JJ N
decrease NN N
from IN N
baseline NN N
of IN N
0.22 CD N
L NNP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
The DT N
probability NN N
of IN N
patients NNS N
remaining VBG N
in IN N
the DT N
study NN N
over IN N
time NN N
without IN N
developing VBG N
signs NNS N
of IN N
exacerbating VBG N
asthma NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
fluticasone NN N
propionate NN N
groups NNS N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
Asthma NNP N
symptom NN N
scores NNS N
, , N
supplemental JJ N
rescue NN N
albuterol NN N
use NN N
, , N
and CC N
number NN N
of IN N
nighttime JJ N
awakenings NNS N
due JJ N
to TO N
asthma VB N
requiring VBG N
treatment NN N
also RB N
improved VBN N
significantly RB N
with IN N
all DT N
fluticasone NN N
propionate NN N
treatment NN N
regimens NNS N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
at IN N
endpoint NN N
among IN N
the DT N
three CD N
fluticasone NN N
propionate NN N
groups NNS N
No DT N
serious JJ N
drug-related JJ N
adverse JJ N
events NNS N
occurred VBD N
CONCLUSIONS NNP N
Fluticasone NNP N
propionate NN N
powder NN N
( ( N
50 CD N
, , N
100 CD N
, , N
and CC N
250 CD N
micrograms NNS N
) ) N
was VBD N
well-tolerated JJ N
and CC N
significantly RB N
improved VBN N
lung NN N
function NN N
in IN N
patients NNS N
with IN N
moderate JJ 4_p
asthma NNS 4_p
-DOCSTART- -X- O O 12876178

Children NNP 4_p
with IN 4_p
autistic JJ 4_p
spectrum NN 4_p
disorders NNS 4_p
II NN N
: : N
parents NNS 4_p
are VBP N
unable JJ N
to TO N
distinguish VB N
secretin NN N
from IN N
placebo NN N
under IN N
double-blind JJ N
conditions NNS N
BACKGROUND NNP N
Standardised VBD N
measures NNS N
of IN N
behaviour NNS N
have VBP N
failed VBN N
to TO N
detect VB N
short JJ N
term NN N
improvement NN N
in IN N
children NNS N
with IN N
autism NN N
following VBG N
treatment NN N
with IN N
secretin NN N
However RB N
, , N
it PRP N
is VBZ N
possible JJ N
that IN N
standardised JJ N
measures NNS N
are VBP N
insensitive JJ N
to TO N
dimensions NNS N
of IN N
child NN N
behaviour NN N
that WDT N
are VBP N
nonetheless RB N
detectable JJ N
by IN N
parents NNS N
AIM NNP N
To TO N
determine VB N
the DT N
ability NN N
of IN N
parents NNS N
of IN N
children NNS N
with IN N
autism NN N
to TO N
guess VB N
, , N
under IN N
double JJ N
blind NN N
conditions NNS N
, , N
whether IN N
their PRP$ N
child NN N
had VBD N
received VBN N
secretin NN N
or CC N
placebo NN N
METHODS NNP N
2x2 CD N
crossover NN N
randomised VBD N
blinded VBN N
study NN N
, , N
comparing VBG N
the DT N
effect NN N
of IN N
synthetic JJ N
human JJ N
secretin NN N
2 CD N
U/kg NNP N
to TO N
placebo VB N
( ( N
saline NN N
) ) N
Sixty CD N
two CD N
children NNS N
with IN N
autism NN N
( ( N
aged VBN N
43-103 CD N
months NNS N
) ) N
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
groups NNS N
: : N
group NN N
1 CD N
received VBD N
placebo NN N
, , N
followed VBD N
six CD N
weeks NNS N
later RB N
by IN N
secretin NN N
, , N
and CC N
group NN N
2 CD N
received VBD N
secretin NN N
followed VBN N
by IN N
placebo NN N
At IN N
the DT N
conclusion NN N
of IN N
the DT N
study NN N
, , N
parents NNS N
were VBD N
asked VBN N
to TO N
guess VB N
their PRP$ N
child NN N
's POS N
group NN N
assignment NN N
RESULTS NNP N
Twenty NNP N
seven CD N
families NNS N
guessed VBD N
their PRP$ N
child NN N
's POS N
group NN N
assignment NN N
correctly RB N
and CC N
27 CD N
guessed VBN N
incorrectly RB N
In IN N
48 CD N
instances NNS N
, , N
parents NNS N
based VBN N
their PRP$ N
guess NN N
on IN N
perceived JJ N
improvement NN N
; : N
in IN N
six CD N
cases NNS N
, , N
parents NNS N
based VBN N
their PRP$ N
guess NN N
on IN N
perceived JJ N
deterioration NN N
Six NNP N
families NNS N
saw VBD N
no DT N
difference NN N
after IN N
either DT N
infusion NN N
, , N
and CC N
offered VBD N
no DT N
guess NN N
One CD N
family NN N
dropped VBD N
out RP N
after IN N
the DT N
first JJ N
infusion NN N
, , N
and CC N
one CD N
family NN N
was VBD N
lost VBN N
to TO N
follow VB N
up RP N
after IN N
the DT N
second JJ N
infusion NN N
CONCLUSION NNP N
In IN N
a DT N
controlled JJ N
setting NN N
, , N
parents NNS N
of IN N
young JJ N
children NNS N
with IN N
autism NN N
are VBP N
unable JJ N
to TO N
distinguish VB N
the DT N
short JJ N
term NN N
behavioural JJ N
effects NNS N
of IN N
secretin NN N
from IN N
placebo NN N
-DOCSTART- -X- O O 10734271

Computer-assisted JJ N
instruction NN N
: : N
an DT N
effective JJ N
instructional JJ N
method NN N
for IN N
HIV NNP N
prevention NN N
education NN N
? . N
PURPOSE NNP N
To TO N
compare VB N
the DT N
effectiveness NN N
of IN N
a DT N
computer-assisted JJ N
instruction NN N
( ( N
CAI NNP N
) ) N
-based VBD N
intervention NN N
to TO N
a DT N
more RBR N
traditional JJ N
lecture-based JJ N
intervention NN N
for IN N
influencing VBG N
psychosocial JJ N
correlates NNS N
of IN N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
preventive JJ N
behaviors NNS N
METHODS NNP N
Students NNPS 1_p
enrolled VBD N
in IN N
a DT N
Human NNP N
Sexuality NNP N
course NN N
( ( N
N NNP N
= NNP N
152 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
CAI NNP N
, , N
Lecture NNP N
, , N
or CC N
No DT N
Intervention NNP N
group NN N
Participants NNS N
in IN N
the DT N
CAI NNP N
group NN N
reviewed VBD N
a DT N
1-hour JJ N
long JJ N
CAI NNP N
program NN N
, , N
participants NNS N
in IN N
the DT N
Lecture NNP N
group NN N
were VBD N
presented VBN N
with IN N
a DT N
1-hour JJ N
long JJ N
lecture NN N
, , N
and CC N
participants NNS N
in IN N
the DT N
No NNP N
Intervention NNP N
group NN N
received VBD N
no DT N
intervention NN N
After IN N
completing VBG N
the DT N
respective JJ N
interventions NNS N
, , N
all DT N
participants NNS N
completed VBD N
the DT N
HIV NNP N
questionnaire NN N
, , N
which WDT N
measured VBD N
selected VBN N
Social NNP N
Cognitive NNP N
Theory NNP N
constructs NNS N
associated VBN N
with IN N
HIV NNP N
preventive JJ N
behaviors NNS N
MANCOVA NNP N
, , N
ANCOVA NNP N
and CC N
Post NNP N
Hoc NNP N
analyses NNS N
were VBD N
utilized JJ N
to TO N
test VB N
for IN N
significant JJ N
differences NNS N
among IN N
the DT N
three CD N
groups NNS N
RESULTS VB N
The DT N
analyses NNS N
disclosed VBD N
that IN N
, , N
compared VBN N
to TO N
participants NNS N
in IN N
the DT N
Lecture NNP N
group NN N
, , N
participants NNS N
in IN N
the DT N
CAI NNP N
group NN N
scored VBD N
significantly RB N
higher JJR N
on IN N
the DT N
scales NNS N
measuring VBG N
autoimmune JJ N
deficiency NN N
syndrome NN N
( ( N
AIDS NNP N
) ) N
knowledge NN N
, , N
self-evaluative JJ N
outcome NN N
motivation NN N
, , N
and CC N
intention NN N
to TO N
practice NN N
HIV NNP N
preventive JJ N
behaviors NNS N
with IN N
current JJ N
partner NN N
In IN N
addition NN N
, , N
compared VBN N
to TO N
the DT N
No NNP N
Intervention NNP N
group NN N
, , N
the DT N
CAI NNP N
group NN N
scored VBD N
significantly RB N
higher JJR N
on IN N
the DT N
scales NNS N
measuring VBG N
physical JJ N
outcome NN N
motivation NN N
and CC N
social JJ N
outcome NN N
motivation NN N
CONCLUSIONS NNP N
CAI-based JJ N
programs NNS N
can MD N
be VB N
effective JJ N
for IN N
delivering VBG N
instruction NN N
on IN N
HIV NNP N
prevention NN N
However RB N
, , N
because IN N
of IN N
certain JJ N
limitations NNS N
, , N
this DT N
type NN N
of IN N
program NN N
is VBZ N
best RB N
utilized VBN N
as IN N
part NN N
of IN N
a DT N
more RBR N
comprehensive JJ N
intervention NN N
that WDT N
uses VBZ N
several JJ N
different JJ N
delivery NN N
systems NNS N
-DOCSTART- -X- O O 16684856

Endurance NN N
training NN N
has VBZ N
little JJ N
effect NN N
on IN N
active JJ N
muscle NN N
free JJ N
fatty NN N
acid NN N
, , N
lipoprotein FW N
cholesterol NN N
, , N
or CC N
triglyceride JJ N
net JJ N
balances NNS N
We PRP N
evaluated VBD N
the DT N
hypothesis NN N
that WDT N
net JJ N
leg NN N
total JJ N
FFA NNP N
, , N
LDL-C NNP N
, , N
and CC N
TG NNP N
uptake JJ N
and CC N
HDL-C JJ N
release NN N
during IN N
moderate-intensity NN N
cycling NN N
exercise NN N
would MD N
be VB N
increased VBN N
following VBG N
endurance NN N
training NN N
Eight NNP 3_p
sedentary JJ N
men NNS 2_p
( ( N
26 CD 1_p
+/- JJ 1_p
1 CD 1_p
yr NN 1_p
, , 1_p
77.4 CD N
+/- JJ N
3.7 CD N
kg NN N
) ) N
were VBD N
studied VBN N
in IN N
the DT N
postprandial JJ N
state NN N
during IN N
90 CD N
min NNS N
of IN N
rest NN N
and CC N
60 CD N
min NN N
of IN N
exercise NN N
twice NN N
before IN N
( ( N
45 CD N
% NN N
and CC N
65 CD N
% NN N
V NNP N
( ( N
O2 NNP N
peak NN N
) ) N
) ) N
and CC N
twice RB N
after IN N
9 CD N
wk NN N
of IN N
endurance NN N
training NN N
( ( N
55 CD N
% NN N
and CC N
65 CD N
% NN N
posttraining VBG N
V NNP N
( ( N
O2 NNP N
peak NN N
) ) N
) ) N
Measurements NNS N
across IN N
an DT N
exercising VBG N
leg NN N
were VBD N
taken VBN N
to TO N
be VB N
a DT N
surrogate NN N
for IN N
active JJ N
skeletal JJ N
muscle NN N
To TO N
determine VB N
limb NN N
lipid JJ N
exchange NN N
, , N
femoral JJ N
arterial NN N
and CC N
venous JJ N
blood NN N
samples NNS N
drawn VBP N
simultaneously RB N
at IN N
rest NN N
and CC N
during IN N
exercise NN N
were VBD N
analyzed VBN N
for IN N
total JJ N
and CC N
individual JJ N
FFA NNP N
( ( N
e.g. NN N
, , N
palmitate NN N
, , N
oleate NN N
) ) N
, , N
LDL-C NNP N
, , N
HDL-C NNP N
, , N
and CC N
TG NNP N
concentrations NNS N
, , N
and CC N
limb NN N
blood NN N
flow NN N
was VBD N
determined VBN N
by IN N
thermodilution NN N
The DT N
transition NN N
from IN N
rest NN N
to TO N
exercise VB N
resulted VBN N
in IN N
a DT N
shift NN N
from IN N
net JJ N
leg NN N
total JJ N
FFA NNP N
release NN N
( ( N
-44 JJ N
+/- JJ N
16 CD N
micromol/min NN N
) ) N
to TO N
uptake VB N
( ( N
193 CD N
+/- JJ N
49 CD N
micromol/min NN N
) ) N
that WDT N
was VBD N
unaffected VBN N
by IN N
either DT N
exercise NN N
intensity NN N
or CC N
endurance NN N
training NN N
The DT N
relative JJ N
net NN N
leg NN N
release NN N
and CC N
uptake NN N
of IN N
individual JJ N
FFA NNP N
closely RB N
resembled VBD N
their PRP$ N
relative JJ N
abundances NNS N
in IN N
the DT N
plasma NN N
with IN N
approximately RB N
21 CD N
and CC N
41 CD N
% NN N
of IN N
net JJ N
leg NN N
total JJ N
FFA NNP N
uptake NN N
during IN N
exercise NN N
accounted VBN N
for IN N
by IN N
palmitate NN N
and CC N
oleate NN N
, , N
respectively RB N
Endurance NNP N
training NN N
resulted VBD N
in IN N
significant JJ N
changes NNS N
in IN N
arterial JJ N
concentrations NNS N
of IN N
HDL-C NNP N
( ( N
49 CD N
+/- JJ N
5 CD N
vs. FW N
52 CD N
+/- JJ N
5 CD N
mg/dl NN N
, , N
pre NN N
vs. FW N
post NN N
) ) N
and CC N
LDL-C NNP N
( ( N
82 CD N
+/- JJ N
9 CD N
vs. FW N
76 CD N
+/- JJ N
9 CD N
mg/dl NN N
, , N
pre NN N
vs. FW N
post NN N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
net JJ N
TG NN N
or CC N
LDL-C JJ N
uptake NN N
or CC N
HDL-C JJ N
release NN N
across IN N
the DT N
resting NN N
or CC N
active JJ N
leg NN N
before IN N
or CC N
after IN N
endurance JJ N
training NN N
In IN N
conclusion NN N
, , N
endurance NN N
training NN N
favorably RB N
affects VBZ N
blood NN N
lipoprotein NN N
profiles NNS N
, , N
even RB N
in IN N
young JJ 1_p
, , N
healthy JJ N
normolipidemic JJ N
men NNS 2_p
, , N
but CC N
muscle NN N
contractions NNS N
per IN N
se NN N
have VBP N
little JJ N
effect NN N
on IN N
net JJ N
leg NN N
LDL-C NNP N
, , N
or CC N
TG NNP N
uptake VBP N
or CC N
HDL-C JJ N
release NN N
during IN N
moderate-intensity NN N
cycling NN N
exercise NN N
Therefore RB N
, , N
the DT N
favorable JJ N
effects NNS N
of IN N
physical JJ N
activity NN N
on IN N
the DT N
lipid JJ N
profiles NNS N
of IN N
young JJ 1_p
, , N
healthy JJ N
normolipidemic JJ 4_p
men NNS 2_p
in IN N
the DT N
postprandial JJ N
state NN N
are VBP N
not RB N
attributable JJ N
to TO N
changes NNS N
in IN N
HDL-C NNP N
or CC N
LDL-C NNP N
exchange NN N
across IN N
active JJ N
skeletal JJ N
muscle NN N
-DOCSTART- -X- O O 8733449

A DT N
double-blind JJ N
comparative NN N
study NN N
of IN N
ofloxacin JJ N
otic JJ N
drops NNS N
versus IN N
neomycin-polymyxin JJ N
B-hydrocortisone NNP N
otic JJ N
drops NNS N
in IN N
the DT N
medical JJ N
treatment NN N
of IN N
chronic JJ 4_p
suppurative JJ 4_p
otitis NN 4_p
media NNS 4_p
Active NNP 4_p
chronic JJ 4_p
suppurative NN 4_p
otitis NN 4_p
media NNS 4_p
poses VBZ N
a DT N
management NN N
problem NN N
when WRB N
patients NNS N
are VBP N
being VBG N
considered VBN N
for IN N
surgical JJ N
treatment NN N
Topical JJ N
antibiotics NNS N
have VBP N
demonstrated VBN N
varying VBG N
degrees NNS N
of IN N
success NN N
in IN N
the DT N
management NN N
of IN N
discharging VBG 4_p
ears NNS 4_p
The DT N
introduction NN N
of IN N
quinolones NNS N
has VBZ N
revived VBN N
interest NN N
in IN N
these DT N
topical JJ N
agents NNS N
This DT N
double-blind NN N
study NN N
compares VBZ N
two CD N
antibiotics NNS N
, , N
namely RB N
ofloxacin JJ N
and CC N
neomycin-polymyxin JJ N
B NNP N
, , N
with IN N
similar JJ N
in IN N
vitro JJ N
sensitivities NNS N
to TO N
Gram NNP N
positive JJ N
and CC N
Gram NNP N
negative JJ N
organisms NNS N
Fifty-two JJ 3_p
patients NNS N
were VBD N
selected VBN N
randomly RB N
and CC N
the DT N
results NNS N
show VBP N
that IN N
ofloxacin NN N
eardrops NNS N
have VBP N
marginal JJ N
benefits NNS N
in IN N
symptomatic JJ N
improvement NN N
( ( N
89 CD N
per IN N
cent NN N
versus NN N
79 CD N
per IN N
cent NN N
, , N
p VBP N
= RB N
0.27 CD N
) ) N
and CC N
bacterial JJ N
eradication NN N
( ( N
81 CD N
per IN N
cent NN N
versus NN N
75 CD N
per IN N
cent NN N
, , N
p VBP N
= RB N
0.81 CD N
) ) N
in IN N
active JJ N
chronic JJ 4_p
suppurative NN 4_p
otitis NN 4_p
media NNS 4_p
Significantly RB N
fewer JJR N
patients NNS N
( ( N
seven CD N
per IN N
cent NN N
versus NN N
29 CD N
per IN N
cent NN N
, , N
p VBP N
= RB N
0.04 CD N
) ) N
in IN N
the DT N
ofloxacin NN N
group NN N
had VBD N
active JJ N
disease NN N
at IN N
the DT N
end NN N
of IN N
the DT N
two-week JJ N
treatment NN N
We PRP N
recommend VBP N
the DT N
use NN N
of IN N
ofloxacin JJ N
eardrops NNS N
in IN N
managing VBG N
active JJ 4_p
chronic JJ 4_p
suppurative NN 4_p
otitis NN 4_p
media NNS 4_p
since IN N
it PRP N
has VBZ N
high JJ N
clinical JJ N
efficacy NN N
, , N
contains VBZ N
no DT N
steroid JJ N
component NN N
and CC N
has VBZ N
no DT N
demonstrated VBN N
risk NN N
of IN N
ototoxicity NN N
-DOCSTART- -X- O O 20106358

Comparable JJ N
patencies NNS N
of IN N
the DT N
radial JJ N
artery NN N
and CC N
right JJ N
internal JJ N
thoracic NN N
artery NN N
or CC N
saphenous JJ N
vein NNS N
beyond IN N
5 CD N
years NNS N
: : N
results NNS N
from IN N
the DT N
Radial NNP N
Artery NNP N
Patency NNP N
and CC N
Clinical NNP N
Outcomes NNP N
trial NN N
OBJECTIVE UH N
To TO N
investigate VB N
the DT N
optimum JJ N
conduit NN N
for IN N
coronary JJ N
targets NNS N
other JJ N
than IN N
the DT N
left JJ N
anterior JJ N
descending VBG N
artery NN N
, , N
we PRP N
evaluated VBD N
long-term JJ N
patencies NNS N
and CC N
clinical JJ N
outcomes NNS N
of IN N
the DT N
radial JJ N
artery NN N
, , N
right JJ N
internal JJ N
thoracic NN N
artery NN N
, , N
and CC N
saphenous JJ N
vein NN N
through IN N
the DT N
Radial NNP N
Artery NNP N
Patency NNP N
and CC N
Clinical NNP N
Outcomes NNP N
trial NN N
METHODS NNP N
As IN N
part NN N
of IN N
a DT N
10-year JJ N
prospective JJ N
, , N
randomized VBN N
, , N
single-center JJ N
trial NN N
, , N
patients NNS N
undergoing VBG N
primary JJ 4_p
coronary JJ 4_p
surgery NN 4_p
were VBD N
allocated VBN N
to TO N
the DT N
radial JJ N
artery NN N
( ( N
n JJ N
= NNP N
198 CD 3_p
) ) N
or CC N
free JJ N
right JJ N
internal JJ N
thoracic NN N
artery NN N
( ( N
n JJ N
= NNP N
196 CD 3_p
) ) N
if IN N
aged VBN N
less JJR 1_p
than IN 1_p
70 CD 1_p
years NNS N
( ( N
group NN N
1 CD N
) ) N
, , N
or CC N
radial JJ N
artery NN N
( ( N
n JJ N
= NNP N
113 CD 3_p
) ) N
or CC N
saphenous JJ N
vein NN N
( ( N
n JJ N
= NNP N
112 CD 3_p
) ) N
if IN N
aged VBN N
at IN 1_p
least JJS 1_p
70 CD 1_p
years NNS N
( ( N
group NN N
2 CD N
) ) N
All DT N
patients NNS N
received VBD N
a DT N
left JJ N
internal JJ N
thoracic NN N
artery NN N
to TO N
the DT N
left VBN N
anterior JJ N
descending NN N
, , N
and CC N
the DT N
randomized JJ N
conduit NN N
was VBD N
used VBN N
to TO N
graft VB N
the DT N
second JJ N
largest JJS N
target NN N
Protocol-directed JJ N
angiography NN N
has VBZ N
been VBN N
performed VBN N
at IN N
randomly RB N
assigned VBN N
intervals NNS N
, , N
weighted VBD N
toward IN N
the DT N
end NN N
of IN N
the DT N
study NN N
period NN N
Grafts NNS N
are VBP N
defined VBN N
as IN N
failed JJ N
if IN N
there EX N
was VBD N
occlusion NN N
, , N
string VBG N
sign NN N
, , N
or CC N
greater JJR N
than IN N
80 CD N
% NN N
stenosis NN N
, , N
independently RB N
reported VBN N
by IN N
3 CD N
assessors NNS N
Analysis NN N
is VBZ N
by IN N
intention NN N
to TO N
treat VB N
RESULTS NNP N
At IN N
mean NN N
follow VBP N
up RB N
of IN N
5.5 CD N
years NNS N
, , N
protocol NN N
angiography NN N
has VBZ N
been VBN N
performed VBN N
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
in IN N
237 CD 3_p
and CC N
113 CD 3_p
patients NNS N
, , N
respectively RB N
There EX N
are VBP N
no DT N
significant JJ N
differences NNS N
within IN N
each DT N
group NN N
in IN N
preoperative JJ N
comorbidity NN N
, , N
age NN N
, , N
or CC N
urgency NN N
Patencies NNS N
were VBD N
similar JJ N
for IN N
either DT N
of IN N
the DT N
2 CD N
conduits NNS N
in IN N
each DT N
group NN N
( ( N
log JJ N
rank NN N
analysis NN N
, , N
P NNP N
= NNP N
.06 NNP N
and CC N
P NNP N
= NNP N
.54 NNP N
, , N
respectively RB N
) ) N
The DT N
differences NNS N
in IN N
estimated VBN N
5-year JJ N
patencies NNS N
were VBD N
6.6 CD N
% NN N
( ( N
radial JJ N
minus NN N
right JJ N
internal JJ N
thoracic NN N
artery NN N
) ) N
in IN N
group NN N
1 CD N
and CC N
2.9 CD N
% NN N
( ( N
radial JJ N
minus NN N
saphenous JJ N
vein NN N
graft NN N
) ) N
in IN N
group NN N
2 CD N
CONCLUSION NN N
At IN N
mean JJ N
5-year JJ N
angiography NN N
in IN N
largely RB N
asymptomatic JJ N
patients NNS N
, , N
the DT N
selection NN N
of IN N
arterial JJ N
or CC N
venous JJ N
conduit NN N
for IN N
the DT N
second JJ N
graft NN N
has VBZ N
not RB N
significantly RB N
affected JJ N
patency NN N
This DT N
finding NN N
offers VBZ N
surgeons NNS N
, , N
for IN N
now RB N
, , N
enhanced VBD N
flexibility NN N
in IN N
planning VBG N
revascularization NN N
-DOCSTART- -X- O O 8530236

Laparoscopic NNP 4_p
hysterectomy NN 4_p
: : N
is VBZ N
dissecting VBG N
the DT N
ureter NN N
necessary JJ N
? . N
Laparoscopic NNP N
hysterectomy NN N
has VBZ N
been VBN N
first RB N
reported VBN N
by IN N
Reich NNP N
et CC N
al NN N
in IN N
1989 CD N
, , N
which WDT N
confirmed VBD N
the DT N
possibility NN N
of IN N
laparoscopic JJ N
hysterectomy NN N
being VBG N
employed VBN N
as IN N
a DT N
replacement NN N
of IN N
the DT N
vast JJ N
majority NN N
of IN N
traditional JJ N
abdominal JJ N
hysterectomies NNS N
There EX N
are VBP N
three CD N
critical JJ N
points NNS N
in IN N
laparoscopic JJ N
hysterectomy NN N
The DT N
most RBS N
important JJ N
critical JJ N
point NN N
is VBZ N
to TO N
identify VB N
uterine JJ N
arteries NNS N
from IN N
the DT N
ureter NN N
in IN N
the DT N
paracervical JJ N
area NN N
Several JJ N
ureteral JJ N
injuries NNS N
at IN N
operative JJ N
laparoscopy NN N
have VBP N
been VBN N
reported VBN N
We PRP N
performed VBD N
two CD N
hundred CD N
and CC N
thirty VB N
laparoscopic JJ 4_p
hysterectomies NNS 4_p
during IN N
the DT N
period NN N
from IN N
March NNP N
1991 CD N
to TO N
October NNP N
1993 CD N
Sixty CD 3_p
patients NNS N
were VBD N
later RB N
included VBN N
in IN N
this DT N
study NN N
Thirty NNP N
of IN N
these DT N
applied VBN N
the DT N
technique NN N
of IN N
dissecting VBG N
the DT N
ureter NN N
at IN N
the DT N
initiation NN N
of IN N
laparoscopic JJ N
hysterectomy NN N
Most JJS N
of IN N
the DT N
patients NNS N
were VBD N
discharged VBN N
on IN N
the DT N
second JJ N
postoperative JJ N
day NN N
Although IN N
dissecting VBG N
the DT N
ureter NN N
at IN N
the DT N
beginning NN N
of IN N
the DT N
operation NN N
did VBD N
not RB N
produce VB N
a DT N
significant JJ N
discrepancy NN N
in IN N
operation NN N
time NN N
, , N
blood NN N
loss NN N
, , N
hospitalization NN N
day NN N
and CC N
ureter JJ N
injury NN N
when WRB N
compared VBN N
with IN N
the DT N
control NN N
group NN N
, , N
the DT N
uterine JJ N
arteries NNS N
, , N
however RB N
, , N
may MD N
be VB N
confidently RB N
desiccated VBN N
once RB N
the DT N
path NN N
of IN N
the DT N
ureter NN N
near IN N
the DT N
uterosacral JJ N
ligament NN N
is VBZ N
identified VBN N
-DOCSTART- -X- O O 24972577

Standardized NNP N
treatment NN N
of IN N
Chinese JJ N
medicine NN N
decoction NN N
for IN N
cancer NN 4_p
pain NN 4_p
patients NNS 4_p
with IN 4_p
opioid-induced JJ 4_p
constipation NN 4_p
: : 4_p
a DT N
multi-center JJ N
prospective JJ N
randomized VBN N
controlled VBN N
study NN N
OBJECTIVE NNP N
To TO N
observe VB N
the DT N
efficacy NN N
and CC N
the DT N
influence NN N
on IN N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
of IN N
syndrome JJ N
differentiation NN N
treatment NN N
with IN N
Chinese JJ N
medicine NN N
( ( N
CM NNP N
) ) N
for IN N
opioid-induced JJ 4_p
constipation NN 4_p
as RB N
well RB N
as IN N
the DT N
safety NN N
and CC N
influence NN N
on IN N
analgesic JJ N
effect NN N
of IN N
opioids NNS N
METHODS NNP N
Totally RB N
406 CD 3_p
cases NNS 3_p
enrolled VBD N
from IN N
53 CD N
collaborating VBG N
medical JJ N
centers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
CM NNP N
group NN N
and CC N
a DT N
control NN N
group NN N
The DT N
CM NNP N
group NN N
were VBD N
treated VBN N
with IN N
CM NNP N
decoction NN N
based VBN N
on IN N
syndrome JJ N
differentiation NN N
, , N
and CC N
the DT N
control NN N
group NN N
were VBD N
treated VBN N
with IN N
Phenolphthalein NNP N
Tablet NNP N
Both DT N
groups NNS N
were VBD N
treated VBN N
for IN N
14 CD N
days NNS N
Cleveland NNP N
constipation NN N
score NN N
( ( N
CCS NNP N
) ) N
, , N
numerical JJ N
rating NN N
scale NN N
( ( N
NRS NNP N
) ) N
of IN N
pain NN N
and CC N
Chinese JJ N
version NN N
of IN N
European JJ N
Organisation NNP N
for IN N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
, , N
Quality NNP N
of IN N
Life NNP N
Questionnaire-C30 NNP N
V3.0 NNP N
( ( N
EORTC NNP N
QLQ-C30 NNP N
V3.0 NNP N
) ) N
were VBD N
used VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
, , N
pain NN N
controlled VBD N
and CC N
QOL NNP N
status NN N
RESULTS VB N
The DT N
comparisons NNS N
of IN N
CCS NNP N
score NN N
reduction NN N
and CC N
QOL NNP N
between IN N
the DT N
two CD N
groups NNS N
after IN N
treatment NN N
suggested VBD N
that IN N
the DT N
improvements NNS N
of IN N
constipation NN N
and CC N
QOL NNP N
in IN N
the DT N
CM NNP N
group NN N
were VBD N
better JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
The DT N
total JJ N
efficiency NN N
of IN N
the DT N
CM NNP N
group NN N
was VBD N
better JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
93.5 CD N
% NN N
vs. FW N
86.4 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
NRS NNP N
scores NNS N
between IN N
before IN N
and CC N
after IN N
treatment NN N
in IN N
both DT N
groups NNS N
There EX N
was VBD N
no DT N
serious JJ N
drug-related JJ N
adverse JJ N
event NN N
during IN N
the DT N
course NN N
of IN N
study NN N
CONCLUSION NNP N
CM NNP N
decoction NN N
could MD N
effectively RB N
treat VB N
opioid-induced JJ 4_p
constipation NN 4_p
and CC N
improve VB N
patients NNS N
' POS N
QOL NNP N
at IN N
the DT N
same JJ N
time NN N
It PRP N
is VBZ N
safe JJ N
and CC N
does VBZ N
n't RB N
affect VB N
the DT N
analgesic JJ N
effect NN N
of IN N
opioids NNS N
when WRB N
treating VBG N
constipation NN N
-DOCSTART- -X- O O 12108616

Efficacy NN N
of IN N
porcine NN N
secretin NN N
in IN N
children NNS N
with IN N
autism NN N
and CC N
pervasive JJ N
developmental JJ N
disorder NN N
Secretin NNP N
, , N
a DT N
gastrointestinal JJ N
( ( N
GI NNP N
) ) N
hormone NN N
, , N
was VBD N
reported VBN N
in IN N
a DT N
preliminary JJ N
study NN N
to TO N
improve VB N
language NN N
and CC N
behavior NN N
in IN N
children NNS N
with IN N
autism/pervasive JJ N
developmental JJ N
disorder NN N
( ( N
PDD NNP N
) ) N
and CC N
chronic JJ N
diarrhea NN N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
secretin NN N
, , N
we PRP N
completed VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
crossover NN N
( ( N
3 CD N
weeks NNS N
) ) N
study NN N
in IN N
children NNS N
with IN N
autism/PDD NN N
and CC N
various JJ N
GI NNP N
conditions NNS N
using VBG N
a DT N
single JJ N
dose NN N
of IN N
intravenous JJ N
porcine NN N
secretin NN N
Children NNP N
with IN N
chronic NN N
, , N
active JJ N
diarrhea NN N
showed VBD N
a DT N
reduction NN N
in IN N
aberrant JJ N
behaviors NNS N
when WRB N
treated VBN N
with IN N
the DT N
secretin NN N
but CC N
not RB N
when WRB N
treated VBN N
with IN N
the DT N
placebo NN N
Children NNP N
with IN N
no DT N
GI NNP N
problems NNS N
are VBP N
unaffected VBN N
by IN N
either DT N
secretin NN N
or CC N
placebo NN N
The DT N
improvement NN N
seen VBN N
with IN N
secretin NN N
in IN N
children NNS N
with IN N
autism/PDD NN N
and CC N
chronic JJ N
diarrhea NN N
suggests VBZ N
that IN N
there EX N
may MD N
be VB N
a DT N
subtype NN N
of IN N
children NNS N
with IN N
autism/PDD NN N
who WP N
respond VBZ N
to TO N
secretin VB N
-DOCSTART- -X- O O 8155449

Risk NN N
of IN N
aspiration NN N
with IN N
the DT N
laryngeal NN N
mask NN N
In IN N
order NN N
to TO N
assess VB N
if IN N
the DT N
use NN N
of IN N
the DT N
laryngeal JJ N
mask NN N
airway NN N
is VBZ N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
gastric JJ N
regurgitation NN N
during IN N
mechanical JJ N
ventilation NN N
, , N
we PRP N
studied VBD N
50 CD 3_p
patients NNS N
allocated VBD N
randomly RB N
to TO N
undergo VB N
anaesthesia NN N
with IN N
either DT N
artificial JJ N
ventilation NN N
with IN N
isoflurane NN N
and CC N
nitrous JJ N
oxide NN N
in IN N
oxygen NN N
and CC N
atracurium NN N
( ( N
group NN N
A NNP N
) ) N
or CC N
spontaneous JJ N
ventilation NN N
with IN N
isoflurane NN N
and CC N
nitrous JJ N
oxide NN N
in IN N
oxygen NN N
( ( N
group NN N
B NNP N
) ) N
In IN N
both DT N
groups NNS N
a DT N
laryngeal JJ N
mask NN N
airway NN N
was VBD N
used VBN N
Regurgitation NNP N
was VBD N
assessed VBN N
by IN N
the DT N
patient NN N
ingesting VBG N
a DT N
methylene NN N
blue JJ N
capsule NN N
10 CD N
min NN N
before IN N
induction NN N
of IN N
anaesthesia NN N
and CC N
examining VBG N
the DT N
oropharynx NN N
by IN N
direct JJ N
laryngoscopy NN N
at IN N
the DT N
end NN N
of IN N
surgery NN N
In IN N
one CD N
patient NN N
in IN N
each DT N
group NN N
, , N
there EX N
was VBD N
staining VBG N
of IN N
the DT N
oropharynx NN N
with IN N
blue JJ N
dye NN N
at IN N
the DT N
end NN N
of IN N
surgery NN N
In IN N
the DT N
patient NN N
in IN N
group NN N
A NNP N
, , N
dye NN N
was VBD N
present JJ N
in IN N
the DT N
trachea NN N
and CC N
bronchi NN N
-DOCSTART- -X- O O 6134039

Ceftriaxone NNP N
versus NN N
ampicillin NN N
and CC N
chloramphenicol NN N
for IN N
treatment NN N
of IN N
bacterial JJ 4_p
meningitis NN 4_p
in IN 4_p
children NNS 4_p
78 CD 4_p
patients NNS 4_p
with IN 4_p
bacterial JJ 4_p
meningitis NN 4_p
were VBD 4_p
evaluated VBN 4_p
in IN N
a DT N
prospective JJ N
, , N
randomised VBD N
study NN N
comparing VBG N
twice-daily RB N
ceftriaxone NN N
as IN N
single-drug JJ N
therapy NN N
with IN N
ampicillin NN N
and CC N
chloramphenicol NN N
given VBN N
every DT N
6 CD N
h. PDT N
The DT N
groups NNS N
were VBD N
comparable JJ N
in IN N
age NN N
, , N
sex NN N
, , N
days NNS N
of IN N
illness NN N
before IN N
admission NN N
, , N
and CC N
bacterial JJ N
colony NN N
counts NNS N
in IN N
cerebrospinal JJ N
fluid NN N
( ( N
CSF NNP N
) ) N
The DT N
pathogens NNS N
were VBD N
Haemophilus NNP N
influenzae JJ N
type NN N
b NN N
( ( N
54 CD N
cases NNS N
) ) N
, , N
streptococci NN N
( ( N
9 CD N
cases NNS N
) ) N
, , N
meningococci FW N
( ( N
9 CD N
cases NNS N
) ) N
, , N
and CC N
unknown JJ N
( ( N
6 CD N
cases NNS N
) ) N
In IN N
40 CD N
CSF NNP N
specimens NNS N
obtained VBD N
4-12 CD N
h NN N
after IN N
initiation NN N
of IN N
therapy NN N
, , N
cultures NNS N
were VBD N
negative JJ N
in IN N
57 CD N
% NN N
of IN N
the DT N
ceftriaxone NN N
patients NNS N
and CC N
in IN N
42 CD N
% NN N
of IN N
the DT N
others NNS N
The DT N
mean NN N
falls VBZ N
in IN N
the DT N
CSF NNP N
bacterial JJ N
colony NN N
counts NNS N
were VBD N
4.7 CD N
and CC N
5.0 CD N
log10 JJ N
colony-forming JJ N
units/ml NN N
, , N
respectively RB N
Mean NNP N
bactericidal JJ N
activity NN N
in IN N
CSF NNP N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
ceftriaxone NN N
than IN N
in IN N
the DT N
conventional JJ N
treatment NN N
group NN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
therapy NN N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
clinical JJ N
responses NNS N
or CC N
in IN N
frequency NN N
of IN N
complications NNS N
, , N
except IN N
for IN N
mild JJ N
diarrhoea NN N
, , N
which WDT N
occurred VBD N
in IN N
16 CD N
ceftriaxone NN N
patients NNS N
and CC N
in IN N
8 CD N
in IN N
the DT N
other JJ N
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.05 CD N
) ) N
-DOCSTART- -X- O O 15673894

Spinal JJ N
2-chloroprocaine JJ N
: : N
the DT N
effect NN N
of IN N
added JJ N
clonidine NN N
Preservative-free JJ N
2-chloroprocaine JJ N
( ( N
2-CP JJ N
) ) N
is VBZ N
being VBG N
investigated VBN N
for IN N
short-acting JJ N
spinal JJ N
anesthesia NN N
Clonidine NNP N
improves VBZ N
the DT N
quality NN N
of IN N
spinal JJ N
bupivacaine NN N
and CC N
ropivacaine NN N
, , N
but CC N
in IN N
traditional JJ N
doses NNS N
( ( N
1-2 JJ N
microg/kg NN N
) ) N
it PRP N
produces VBZ N
systemic JJ N
side NN N
effects NNS N
It PRP N
has VBZ N
not RB N
been VBN N
studied VBN N
in IN N
combination NN N
with IN N
2-CP JJ N
In IN N
this DT N
double-blind NN N
, , N
randomized VBN N
crossover NN N
study NN N
, , N
we PRP N
compared VBN N
spinal JJ N
2-CP JJ N
( ( N
30 CD N
mg NN N
) ) N
with IN N
and CC N
without IN N
clonidine NN N
( ( N
15 CD N
microg NN N
) ) N
in IN N
eight CD 3_p
volunteers NNS N
Pinprick NNP N
anesthesia NN N
, , N
motor NN N
strength NN N
, , N
tolerance NN N
to TO N
electrical JJ N
stimulation NN N
and CC N
thigh JJ N
tourniquet NN N
, , N
and CC N
time NN N
to TO N
ambulation NN N
were VBD N
assessed VBN N
Peak NNP N
block NN N
height NN N
was VBD N
similar JJ N
between IN N
2-CP JJ N
( ( N
T8 NNP N
[ NNP N
range NN N
, , N
T6 NNP N
to TO N
L2 NNP N
] NNP N
) ) N
and CC N
2-CP JJ N
with IN N
clonidine NN N
( ( N
T8 NNP N
[ NNP N
range NN N
, , N
T4 NNP N
to TO N
T11 NNP N
] NNP N
) ) N
( ( N
P NNP N
= NNP N
0.57 CD N
) ) N
Sensory JJ N
anesthesia NN N
was VBD N
prolonged VBN N
with IN N
clonidine NN N
at IN N
L1 NNP N
( ( N
51 CD N
+/- JJ N
23 CD N
min NN N
versus NN N
76 CD N
+/- JJ N
11 CD N
min NN N
; : N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
as IN N
was VBD N
complete JJ N
block NN N
regression NN N
( ( N
99 CD N
+/- JJ N
18 CD N
min NN N
versus NN N
131 CD N
+/- JJ N
15 CD N
min NN N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
Lower JJR N
extremity NN N
motor NN N
blockade NN N
was VBD N
increased VBN N
with IN N
clonidine NN N
( ( N
return NN N
to TO N
baseline VB N
Bromage NNP N
score NN N
: : N
65 CD N
+/- JJ N
13 CD N
min NN N
versus NN N
79 CD N
+/- JJ N
19 CD N
min NN N
, , N
P NNP N
= NNP N
0.004 CD N
; : N
return NN N
to TO N
90 CD N
% NN N
gastrocnemius JJ N
strength NN N
: : N
P NNP N
= NNP N
0.003 CD N
) ) N
Clonidine NNP N
increased VBD N
tourniquet JJ N
tolerance NN N
from IN N
33 CD N
to TO N
45 CD N
min NN N
( ( N
P NNP N
= NNP N
0.06 CD N
) ) N
and CC N
increased JJ N
time NN N
to TO N
ambulation NN N
, , N
spontaneous JJ N
voiding NN N
, , N
and CC N
discharge NN N
( ( N
99 CD N
+/- JJ N
18 CD N
min NN N
versus NN N
131 CD N
+/- JJ N
15 CD N
min NN N
for IN N
all DT N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
hemodynamic JJ N
measurements NNS N
, , N
and CC N
no DT N
subject NN N
reported VBD N
transient JJ N
neurologic NN N
symptoms NNS N
We PRP N
conclude VBP N
that IN N
small-dose JJ N
clonidine NN N
increases VBZ N
the DT N
duration NN N
and CC N
improves VBZ N
the DT N
quality NN N
of IN N
2-CP JJ N
spinal JJ N
anesthesia NN N
without IN N
systemic JJ N
side NN N
effects NNS N
-DOCSTART- -X- O O 24277510

Comparative JJ N
evaluation NN N
of IN N
percutaneous JJ N
laser NN N
and CC N
radiofrequency NN N
ablation NN N
in IN N
patients NNS N
with IN N
HCC NNP 4_p
smaller JJR N
than IN N
4 CD N
cm NN N
OBJECTIVE CC N
This DT N
study NN N
was VBD N
done VBN N
to TO N
compare VB N
percutaneous JJ N
laser NN N
ablation NN N
( ( N
PLA NNP N
) ) N
and CC N
radiofrequency NN N
thermoablation NN N
( ( N
RFA NNP N
) ) N
for IN N
the DT N
treatment NN N
of IN N
hepatocellular JJ 4_p
carcinoma NN 4_p
( ( N
HCC NNP N
) ) N
≤ VBD N
4 CD N
cm NN N
, , N
in IN N
patients NNS N
with IN N
liver JJ 4_p
cirrhosis NN 4_p
MATERIALS NNP N
AND CC N
METHODS NNP N
Thirty NNP N
patients NNS N
with IN N
single JJ N
HCC NNP N
≤ NNP N
4 CD N
cm NN N
in IN N
diameter NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
treatments NNS N
: : N
15 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
PLA NNP N
, , N
using VBG N
a DT N
multifibre NN N
system NN N
connected VBN N
to TO N
a DT N
neodymium JJ N
yttrium-aluminium-garnet NN N
laser NN N
source NN N
; : N
15 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
RFA NNP N
, , N
using VBG N
an DT N
expandable JJ N
needle JJ N
electrode NN N
Patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
up RB N
to TO N
12 CD N
months NNS N
RESULTS VB N
A NNP N
complete JJ N
response NN N
was VBD N
obtained VBN N
in IN N
87 CD N
% NN N
lesions NNS N
treated VBN N
with IN N
PLA NNP N
and CC N
in IN N
93 CD N
% NN N
lesions NNS N
treated VBN N
with IN N
RFA NNP N
( ( N
p JJ N
= NNP N
ns NN N
) ) N
The DT N
overall JJ N
local JJ N
recurrence-free JJ N
survival NN N
rates NNS N
at IN N
3 CD N
, , N
6 CD N
and CC N
12 CD N
months NNS N
were VBD N
comparable JJ N
However RB N
, , N
a DT N
higher JJR N
rate NN N
of IN N
recurrence NN N
was VBD N
observed VBN N
in IN N
the DT N
PLA NNP N
group NN N
for IN N
lesions NNS N
≥ VBP N
21 CD N
mm NN N
( ( N
p JJ N
= NNP N
0.0081 CD N
) ) N
A DT N
postablation NN N
syndrome NN N
was VBD N
documented VBN N
in IN N
13 CD N
patients NNS N
( ( N
1 CD N
PLA NNP N
; : N
12 CD N
RFA NNP N
) ) N
Tumour JJ N
necrosis NN N
factor-α NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
RFA NNP N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
CONCLUSIONS NNP N
RFA NNP N
is VBZ N
more RBR N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
HCC NNP N
compared VBN N
to TO N
PLA NNP N
for IN N
lesions NNS N
≥ VBP N
21 CD N
mm NN N
However RB N
, , N
PLA NNP N
should MD N
be VB N
considered VBN N
a DT N
viable JJ N
treatment NN N
option NN N
for IN N
HCC NNP N
≤ NNP N
20 CD N
mm NN N
, , N
in IN N
view NN N
of IN N
the DT N
lower JJR N
incidence NN N
of IN N
complications NNS N
-DOCSTART- -X- O O 17481800

Dissociation NN N
between IN N
cortical JJ N
activation NN N
and CC N
cognitive JJ N
performance NN N
under IN N
pharmacological JJ N
blood NN N
pressure NN N
elevation NN N
in IN N
chronic JJ N
hypotension NN N
The DT N
present JJ N
study NN N
explored VBD N
the DT N
impact NN N
of IN N
pharmacological JJ N
blood NN N
pressure NN N
elevation NN N
on IN N
cortical JJ N
activation NN N
and CC N
reaction NN N
time NN N
in IN N
chronic JJ 4_p
hypotension NN 4_p
Effects NNS N
of IN N
the DT N
sympathomimetic JJ N
etilefrine NN N
were VBD N
investigated VBN N
in IN N
50 CD 3_p
hypotensive JJ 4_p
persons NNS N
based VBN N
on IN N
a DT N
randomized VBN N
, , N
placebo-controlled JJ N
double JJ N
blind NN N
design NN N
As IN N
an DT N
indicator NN N
of IN N
cortical JJ N
excitability NN N
, , N
the DT N
contingent NN N
negative JJ N
variation NN N
( ( N
CNV NNP N
) ) N
, , N
induced VBN N
by IN N
a DT N
constant JJ N
foreperiod NN N
reaction NN N
time NN N
task NN N
, , N
was VBD N
assessed VBN N
at IN N
frontal JJ N
( ( N
F3 NNP N
, , N
Fz NNP N
, , N
F4 NNP N
) ) N
and CC N
central JJ N
( ( N
C3 NNP N
, , N
Cz NNP N
, , N
C4 NNP N
) ) N
scalp NN N
sites NNS N
Etilefrine NNP N
provoked VBD N
a DT N
decrease NN N
in IN N
the DT N
frontal NN N
and CC N
central JJ N
CNV NNP N
In IN N
contrast NN N
, , N
shorter JJR N
reaction NN N
times NNS N
were VBD N
observed JJ N
following JJ N
drug NN N
administration NN N
The DT N
degree NN N
of IN N
pharmacologically RB N
induced VBN N
blood NN N
pressure NN N
elevation NN N
was VBD N
correlated VBN N
to TO N
CNV NNP N
attrition NN N
as RB N
well RB N
as IN N
to TO N
performance NN N
enhancement NN N
Inhibitory JJ N
effects NNS N
of IN N
baroreceptor NN N
activation NN N
on IN N
cortical JJ N
excitability NN N
and CC N
enhanced VBD N
cerebral JJ N
blood NN N
flow NN N
are VBP N
considered VBN N
to TO N
be VB N
involved VBN N
in IN N
mediating VBG N
the DT N
effects NNS N
of IN N
blood NN N
pressure NN N
elevation NN N
on IN N
cerebral JJ N
functioning NN N
Implications NNS N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
hypotension NN N
are VBP N
discussed VBN N
-DOCSTART- -X- O O 1350581

Amisulpride NNP N
versus NN N
bromocriptine NN N
in IN N
infantile JJ 4_p
autism NN 4_p
: : 4_p
a DT N
controlled VBN N
crossover NN N
comparative NN N
study NN N
of IN N
two CD N
drugs NNS N
with IN N
opposite JJ N
effects NNS N
on IN N
dopaminergic JJ N
function NN N
An DT N
alteration NN N
of IN N
dopaminergic NN N
( ( N
DA NNP N
) ) N
function NN N
much RB N
more RBR N
complex JJ N
than IN N
simple JJ N
hyperactivity NN N
has VBZ N
been VBN N
evoked VBN N
in IN N
infantile JJ 4_p
autism NN 4_p
We PRP N
therefore RB N
compared VBN N
the DT N
clinical JJ N
efficacy NN N
of IN N
a DT N
DA NNP N
antagonist NN N
( ( N
amisulpride IN N
) ) N
and CC N
a DT N
DA NNP N
agonist NN N
( ( N
bromocriptine NN N
) ) N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
crossover JJ N
trial NN N
in IN N
9 CD 3_p
children NNS 1_p
with IN N
autism NN 4_p
, , N
likely RB N
severely RB N
mentally RB 4_p
retarded JJ 4_p
Amisulpride NNP N
acts VBZ N
preferentially RB N
on IN N
specific JJ N
autistic JJ N
symptoms NNS N
whereas VBP N
bromocriptine JJ N
acts NNS N
more RBR N
on IN N
motor NN N
hyperactivity NN N
and CC N
attention NN N
symptoms NNS N
These DT N
findings NNS N
raise VBP N
the DT N
specificity NN N
of IN N
these DT N
two CD N
drugs NNS N
which WDT N
appear VBP N
to TO N
act VB N
preferentially RB N
on IN N
some DT N
target NN N
symptoms NNS N
and CC N
are VBP N
consistent JJ N
with IN N
some DT N
clinical JJ N
and CC N
pharmacological JJ N
observations NNS N
showing VBG N
a DT N
sedative JJ N
effect NN N
with IN N
low JJ N
doses NNS N
of IN N
DA NNP N
agonists NNS N
and CC N
a DT N
stimulant JJ N
effect NN N
with IN N
low JJ N
doses NNS N
of IN N
DA NNP N
antagonists NNS N
such JJ N
as IN N
the DT N
benzamides NNS N
-DOCSTART- -X- O O 6343259

A DT N
comparison NN N
of IN N
once RB N
and CC N
twice RB N
daily JJ N
atenolol NN N
for IN N
angina JJ 4_p
pectoris NN 4_p
We PRP N
have VBP N
studied VBN N
the DT N
effects NNS N
of IN N
four CD N
doses NNS N
of IN N
atenolol NN N
in IN N
11 CD 4_p
patients NNS N
with IN N
stable JJ N
angina NNS N
pectoris VBP N
using VBG N
a DT N
symptom-limited JJ N
exercise NN N
test NN N
and CC N
angina NN N
diaries NNS N
The DT N
doses NNS N
100 CD N
mg JJ N
twice RB N
daily RB N
and CC N
50 CD N
mg NN N
, , N
100 CD N
mg NN N
and CC N
200 CD N
mg NN N
once RB N
daily JJ N
were VBD N
given VBN N
double-blind NNS N
and CC N
randomised VBD N
within IN N
patients NNS N
following VBG N
run-in NN N
on IN N
placebo NN N
Measurements NNS N
were VBD N
made VBN N
12 CD N
hours NNS N
after IN N
the DT N
last JJ N
twice JJ N
daily RB N
dose JJ N
and CC N
24 CD N
hours NNS N
after IN N
the DT N
last JJ N
once JJ N
daily JJ N
dose NN N
Exercise NN N
tolerance NN N
was VBD N
improved VBN N
by IN N
40-74 JJ N
% NN N
and CC N
exercise NN N
duration NN N
before IN N
the DT N
onset NN N
of IN N
angina NN N
by IN N
61-94 JJ N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
Maximal JJ N
heart NN N
rate NN N
was VBD N
reduced VBN N
further RB N
by IN N
a DT N
total JJ N
daily JJ N
dose NN N
of IN N
200 CD N
mg NNS N
than IN N
by IN N
lower JJR N
doses NNS N
, , N
but CC N
no DT N
extra JJ N
benefit NN N
was VBD N
derived VBN N
by IN N
giving VBG N
the DT N
drug NN N
twice RB N
daily RB N
The DT N
largest JJS N
increase NN N
in IN N
exercise NN N
tolerance NN N
was VBD N
obtained VBN N
during IN N
treatment NN N
with IN N
50 CD N
mg NNS N
once RB N
daily RB N
Atenolol NNP N
was VBD N
shown VBN N
to TO N
be VB N
an DT N
effective JJ N
anti-anginal JJ N
agent NN N
when WRB N
given VBN N
once RB N
daily JJ N
, , N
and CC N
there EX N
were VBD N
no DT N
major JJ N
differences NNS N
between IN N
the DT N
doses NNS N
studied VBN N
-DOCSTART- -X- O O 25475363

Parents NNS N
' POS N
Adoption NN N
of IN N
Social NNP N
Communication NNP N
Intervention NNP N
Strategies NNS N
: : N
Families NNS N
Including VBG N
Children NNP 1_p
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
Who NNP N
are VBP N
Minimally NNP N
Verbal NNP N
Notably RB N
absent NN N
from IN N
the DT N
intervention NN N
literature NN N
are VBP N
parent JJ N
training VBG N
programs NNS N
targeting VBG N
school-aged JJ N
children NNS 1_p
with IN N
autism NN 4_p
who WP N
have VBP N
limited VBN N
communication NN N
skills NNS N
( ( N
Tager-Flusberg NNP N
and CC N
Kasari NNP N
in IN N
Autism NNP N
Res NNP N
6:468-478 CD N
, , N
2013 CD N
) ) N
Sixty-one JJ 3_p
children NNS N
with IN N
autism NN 4_p
age NN 1_p
5-8 JJ 1_p
with IN N
minimal JJ N
spontaneous JJ N
communication NN N
received VBD N
a DT N
6-month JJ N
social JJ N
communication NN N
intervention NN N
including VBG N
parent NN N
training NN N
Parent-child JJ N
play NN N
interactions NNS N
were VBD N
coded VBN N
for IN N
parents NNS N
' POS N
strategy NN N
implementation NN N
and CC N
children NNS N
's POS N
time NN N
jointly RB N
engaged VBN N
( ( N
Adamson NNP N
et RB N
al RB N
in IN N
J NNP N
Autism NNP N
Dev NNP N
Disord NNP N
39:84-96 CD N
, , N
2009 CD N
) ) N
Parents NNS N
mastered VBD N
an DT N
average NN N
of IN N
70 CD N
% NN N
of IN N
the DT N
strategies NNS N
Further JJ N
analyses NNS N
indicated VBD N
some DT N
gains NNS N
in IN N
implementation NN N
occurred VBD N
from IN N
mere JJ N
observation NN N
of IN N
sessions NNS N
, , N
while IN N
the DT N
greatest JJS N
gains NNS N
occurred VBD N
in IN N
the DT N
first JJ N
month NN N
of IN N
active JJ N
coaching NN N
and CC N
workshops NNS N
Children NNP 1_p
's POS 1_p
joint JJ N
engagement NN N
was VBD N
associated VBN N
with IN N
parents NNS N
' POS N
implementation NN N
success NN N
across IN N
time NN N
demonstrating VBG N
parents NNS N
' POS N
implementation NN N
was VBD N
relevant JJ N
to TO N
children NNS 1_p
's POS 1_p
social JJ N
engagement NN N
-DOCSTART- -X- O O 2085344

Acamprosate NNP N
appears VBZ N
to TO N
decrease VB N
alcohol JJ N
intake NN N
in IN N
weaned JJ N
alcoholics NNS 4_p
Five CD 3_p
hundred JJ 3_p
and CC 3_p
sixty-nine JJ 3_p
alcoholics NNS 4_p
were VBD N
included VBN N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
randomized VBN N
multicenter NN N
study NN N
of IN N
the DT N
effects NNS N
of IN N
Acamprosate NNP N
( ( N
calcium NN N
acetylhomotaurinate NN N
( ( N
CA NNP N
) ) N
, , N
1.3 CD N
g/day NN N
) ) N
on IN N
indicators NNS N
of IN N
alcoholic JJ N
relapse NN N
after IN N
withdrawal NN N
One CD 3_p
hundred CD 3_p
and CC 3_p
eighty-one JJ 3_p
patients NNS N
in IN N
the DT N
CA NNP N
group NN N
versus VBD N
175 CD 3_p
in IN N
the DT N
placebo NN 4_p
group NN 4_p
completed VBD N
the DT N
three-month JJ N
study NN N
The DT N
major JJ N
efficacy NN N
criterion NN N
was VBD N
plasma JJ N
gamma-glutamyl JJ N
transpeptidase NN N
( ( N
GGT NNP N
) ) N
, , N
as IN N
an DT N
indicator NN N
of IN N
recent JJ N
alcohol NN N
ingestion NN N
This DT N
analysis NN N
was VBD N
completed VBN N
by IN N
criteria NNS N
concordance NN N
analysis NN N
on IN N
a DT N
number NN N
of IN N
indicators NNS N
of IN N
alcohol NN N
intake NN N
Patients NNS N
in IN N
both DT N
groups NNS N
were VBD N
similar JJ N
initially RB N
After IN N
3 CD N
months NNS N
of IN N
treatment NN N
, , N
the DT N
patients NNS N
in IN N
the DT N
CA NNP N
group NN N
had VBD N
significantly RB N
lower JJR N
GGT NNP N
( ( N
1.4 CD N
+/- JJ N
1.56 CD N
versus NN N
2.0 CD N
+/- JJ N
3.19 CD N
times NNS N
normal JJ N
, , N
P NNP N
= NNP N
0.016 CD N
) ) N
All DT N
significant JJ N
differences NNS N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
or CC N
trends NNS N
( ( N
0.10 CD N
greater JJR N
than IN N
P NNP N
greater JJR N
than IN N
0.05 CD N
) ) N
were VBD N
in IN N
favor NN N
of IN N
a DT N
superior JJ N
effect NN N
of IN N
CA NNP N
over IN N
placebo NN N
The DT N
major JJ N
side-effect NN N
of IN N
CA NNP N
was VBD N
diarrhea VBN N
( ( N
present JJ N
in IN N
13 CD N
% NN N
of IN N
CA NNP N
patients NNS N
versus VBP N
7 CD N
% NN N
of IN N
placebo NN N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
CA NNP N
proved VBD N
superior JJ N
to TO N
placebo VB N
on IN N
the DT N
evolution NN N
of IN N
markers NNS N
of IN N
alcohol NN N
ingestion NN N
at IN N
three CD N
months NNS N
, , N
in IN N
this DT N
large-scale JJ N
multicenter NN N
study NN N
It PRP N
could MD N
be VB N
a DT N
new JJ N
modality NN N
in IN N
the DT N
drug NN N
therapy NN N
of IN N
alcoholism NN N
, , N
not RB N
involving VBG N
an DT N
antabuse NN N
effect NN N
, , N
an DT N
antidepressant JJ N
action NN N
, , N
or CC N
conditioning NN N
-DOCSTART- -X- O O 15746480

The DT N
overt JJ N
aggression NN N
scale NN N
for IN N
rating NN N
aggression NN N
in IN N
outpatient JJ N
youth NN N
with IN N
autistic JJ N
disorder NN N
: : N
preliminary JJ N
findings NNS N
Aggression NNP N
is VBZ N
a DT N
common JJ N
and CC N
costly JJ N
problem NN N
in IN N
youth NN N
with IN N
developmental JJ N
disabilities NNS N
Rating VBG N
scales NNS N
that WDT N
accurately RB N
capture NN N
and CC N
measure NN N
subtypes NNS N
of IN N
aggression NN N
phenomenology NN N
, , N
frequency NN N
and CC N
severity NN N
are VBP N
urgently RB N
needed VBN N
, , N
in IN N
both DT N
clinical JJ N
practice NN N
and CC N
research NN N
The DT N
authors NNS N
studied VBD N
the DT N
Overt NNP N
Aggression NNP N
Scale NNP N
( ( N
OAS NNP N
) ) N
in IN N
a DT N
preliminary JJ N
sample NN N
of IN N
eight CD 4_p
outpatients NNS 4_p
who WP 4_p
participated VBD 4_p
in IN 4_p
an DT 4_p
ongoing JJ 4_p
placebo-controlled JJ 4_p
study NN 4_p
of IN 4_p
valproate NN 4_p
for IN 4_p
aggression NN 4_p
in IN 4_p
autism NN 4_p
Subjects NNS N
' POS N
OAS NNP N
aggression NN N
scores NNS N
showed VBD N
significant JJ N
correlation NN N
with IN N
the DT N
already RB N
validated VBN N
retrospectively RB N
rated VBN N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
Community NNP N
Scale NNP N
irritability NN N
subscale NN N
Further NNP N
study NN N
of IN N
the DT N
OAS NNP N
in IN N
outpatients NNS N
with IN N
aggression NN N
and CC N
developmental JJ N
disabilities NNS N
is VBZ N
warranted VBN N
-DOCSTART- -X- O O 16911869

Cardiac NNP N
safety NN N
of IN N
formoterol NN N
12 CD N
microg NN N
twice RB N
daily RB N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
BACKGROUND CC N
Some DT N
evidence NN N
suggests VBZ N
an DT N
increased VBN N
risk NN N
of IN N
myocardial JJ N
infarction NN N
and CC N
dysrhythmia NN N
events NNS N
associated VBN N
with IN N
beta NN N
( ( N
2 CD N
) ) N
-agonist NN N
use NN N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
( ( 4_p
COPD NNP 4_p
) ) 4_p
This DT N
prospective JJ N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
compared VBN N
the DT N
cardiac JJ N
safety NN N
of IN N
formoterol NN N
and CC N
placebo NN N
in IN N
patients NNS N
with IN N
COPD NNP 4_p
METHODS NNP N
After IN N
a DT N
3-14-day JJ N
run-in NN N
, , N
204 CD 3_p
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
formoterol NN N
12 CD N
microg NN N
dry JJ N
powder NN N
inhalation NN N
or CC N
matching VBG N
placebo JJ N
twice RB N
daily RB N
for IN N
8 CD N
weeks NNS N
Twenty CD N
four-hour JJ N
continuous JJ N
electrocardiography NN N
( ( N
Holter NNP N
monitoring NN N
) ) N
was VBD N
performed VBN N
at IN N
screening NN N
and CC N
after IN N
2 CD N
and CC N
8 CD N
weeks NNS N
of IN N
treatment NN N
RESULTS NNP N
Only RB N
a DT N
small JJ N
number NN N
of IN N
patients NNS N
met VBD N
the DT N
predefined JJ N
criteria NNS N
for IN N
a DT N
proarrhythmic JJ N
event NN N
( ( N
4 CD N
formoterol NN N
and CC N
2 CD N
placebo NN N
patients NNS N
) ) N
No UH N
patients NNS N
had VBD N
sustained VBN N
postbaseline JJ N
ventricular JJ N
tachycardia NN N
events NNS N
, , N
postbaseline JJ N
run NN N
of IN N
ventricular JJ N
ectopic NN N
beats NNS N
associated VBN N
with IN N
relevant JJ N
symptoms NNS N
( ( N
e.g NN N
hypotension NN N
, , N
syncope NN N
) ) N
, , N
or CC N
an DT N
episode NN N
of IN N
ventricular JJ N
flutter NN N
or CC N
fibrillation NN N
Holter NNP N
monitoring VBG N
data NNS N
were VBD N
variable JJ N
but CC N
showed VBD N
no DT N
clinically RB N
meaningful JJ N
differences NNS N
between IN N
the DT N
formoterol NN N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
, , N
for IN N
variables NNS N
such JJ N
as IN N
( ( N
mean+/-SD NN N
at IN N
end NN N
of IN N
treatment NN N
) ) N
: : N
heart NN N
rate NN N
( ( N
80+/-8.6 JJ N
vs. IN N
80+/-10.6 JJ N
bpm NN N
) ) N
, , N
number NN N
and CC N
rate NN N
of IN N
ventricular JJ N
premature NN N
beats NNS N
( ( N
total JJ N
732+/-2685.4 JJ N
vs. IN N
650+/-2090.6 JJ N
; : N
rate NN N
35+/-131.0 JJ N
vs. IN N
30+/-101.3 JJ N
per IN N
h NN N
) ) N
, , N
ventricular JJ N
tachycardia NN N
events NNS N
( ( N
total JJ N
0.4+/-1.70 JJ N
vs. IN N
1.0+/-9.23 JJ N
; : N
rate NN N
0.02+/-0.082 JJ N
vs. IN N
0.05+/-0.479 JJ N
per IN N
h NN N
) ) N
, , N
and CC N
supraventricular JJ N
premature NN N
beats NNS N
( ( N
total JJ N
504+/-1844.1 JJ N
vs. IN N
823+/-2961.8 JJ N
; : N
rate NN N
22+/-80.6 JJ N
vs. IN N
37+/-129.6 JJ N
per IN N
h NN N
) ) N
Vital JJ N
signs NNS N
and CC N
electrocardiogram NN N
data NNS N
, , N
including VBG N
corrected VBN N
QT NNP N
intervals NNS N
( ( N
Bazett NNP N
and CC N
Fridericia NNP N
) ) N
, , N
were VBD N
similar JJ N
across IN N
treatment NN N
groups NNS N
The DT N
overall JJ N
adverse JJ N
event NN N
experience NN N
was VBD N
similar JJ N
in IN N
the DT N
formoterol NN N
( ( N
n=26 JJ N
[ RB N
27 CD N
% NN N
] NN N
) ) N
and CC N
placebo NN N
( ( N
n=33 JJ N
[ RB N
31 CD N
% NN N
] NN N
) ) N
groups NNS N
The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
, , N
infections NNS N
and CC N
respiratory JJ N
events NNS N
, , N
were VBD N
expected VBN N
for IN N
this DT N
patient JJ N
population NN N
The DT N
incidence NN N
of IN N
cardiac JJ N
adverse JJ N
events NNS N
was VBD N
low JJ N
( ( N
1 CD N
formoterol NN N
and CC N
4 CD N
placebo NN N
patients NNS N
) ) N
CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
confirm VBD N
the DT N
good JJ N
cardiovascular JJ N
safety NN N
profile NN N
of IN N
formoterol NN N
in IN N
patients NNS N
with IN N
COPD NNP 4_p
-DOCSTART- -X- O O 8217692

High JJ N
purity NN N
factor NN N
VIII NNP N
and CC N
immune JJ N
state NN N
in IN N
HIV NNP 4_p
-DOCSTART- -X- O O 1707337

Evolution NN N
of IN N
neuropathy JJ N
and CC N
myopathy JJ N
during IN N
intensive JJ N
vincristine/corticosteroid NNS N
chemotherapy NN N
for IN N
non-Hodgkin NN N
's POS N
lymphoma NN N
Neuropathy NNP N
and CC N
myopathy NN N
are VBP N
common JJ N
sequelae NN N
of IN N
intensive JJ N
chemotherapy NN N
protocols NNS N
that WDT N
contain VBP N
vincristine JJ N
and CC N
corticosteroids NNS N
The DT N
authors NNS N
prospectively RB N
monitored VBD N
the DT N
evolution NN N
of IN N
neuropathy JJ N
and CC N
myopathy JJ N
during IN N
an DT N
intensive JJ N
12-week JJ N
chemotherapy NN N
program NN N
for IN N
patients NNS N
with IN N
intermediate JJ 4_p
and CC 4_p
high-grade JJ 4_p
non-Hodgkin NN 4_p
's POS 4_p
lymphoma NN 4_p
In IN N
this DT N
study NN N
, , N
vincristine NN N
was VBD N
administered VBN N
by IN N
bolus NN N
injection NN N
followed VBN N
by IN N
a DT N
3-day JJ N
continuous JJ N
intravenous JJ N
( ( N
IV NNP N
) ) N
infusion NN N
( ( N
total JJ N
dose NN N
of IN N
2.0 CD N
mg/m2 NNS N
every DT N
other JJ N
week NN N
) ) N
; : N
the DT N
maximum JJ N
dose NN N
of IN N
vincristine NN N
was VBD N
not RB N
arbitrarily RB N
limited VBN N
Cronassial NNP N
, , N
a DT N
mixture NN N
of IN N
four CD N
naturally RB N
occurring VBG N
gangliosides NNS N
, , N
was VBD N
administered VBN N
in IN N
a DT N
randomized JJ N
double-blind JJ N
test NN N
to TO N
evaluate VB N
whether IN N
this DT N
agent NN N
could MD N
prevent VB N
vincristine-induced JJ N
neuropathy NN N
High JJ N
doses NNS N
of IN N
dexamethasone NN N
( ( N
50 CD N
mg/d NN N
for IN N
3 CD N
days NNS N
weekly RB N
or CC N
every DT N
other JJ N
week NN N
) ) N
were VBD N
also RB N
prescribed VBN N
Patients NNS N
were VBD N
monitored VBN N
every DT N
4 CD N
weeks NNS N
with IN N
comprehensive JJ N
physical JJ N
and CC N
neurologic JJ N
examinations NNS N
and CC N
electrophysiologic JJ N
studies NNS N
of IN N
peripheral JJ N
nerve NN N
function NN N
Twenty-seven JJ 3_p
patients NNS N
were VBD N
fully RB N
evaluable JJ N
Weakness NNP N
was VBD N
a DT N
prominent JJ N
adverse JJ N
reaction NN N
in IN N
this DT N
study NN N
, , N
and CC N
all DT N
patients NNS N
had VBD N
moderate JJ N
to TO N
severe VB N
signs NNS N
and CC N
symptoms NNS N
of IN N
neuropathy JJ N
and CC N
myopathy JJ N
Cronassial NNP N
( ( N
100 CD N
mg NN N
) ) N
administered VBN N
by IN N
intramuscular NN N
( ( N
IM NNP N
) ) N
injection NN N
daily RB N
provided VBD N
no DT N
protection NN N
against IN N
the DT N
development NN N
of IN N
neuropathic JJ N
symptoms NNS N
Vincristine NNP N
typically RB N
impaired VBD N
fine-motor JJ N
coordination NN N
initially RB N
, , N
whereas JJ N
corticosteroids NNS N
were VBD N
associated VBN N
with IN N
delayed JJ N
development NN N
of IN N
proximal JJ N
muscle NN N
weakness NN N
Results NNS N
of IN N
electrodiagnostic JJ N
studies NNS N
did VBD N
not RB N
add VB N
to TO N
the DT N
clinical JJ N
examination NN N
results NNS N
The DT N
authors NNS N
conclude VBP N
that IN N
symptomatic JJ N
weakness NN N
due JJ N
to TO N
neuropathy JJ N
or CC N
myopathy JJ N
appears VBZ N
in IN N
a DT N
predictable JJ N
manner NN N
during IN N
intensive JJ N
vincristine/corticosteroid-based JJ N
treatment NN N
protocols NNS N
Simple JJ N
clinical JJ N
tests NNS N
can MD N
be VB N
used VBN N
to TO N
rapidly RB N
distinguish VB N
between IN N
toxic JJ N
effects NNS N
due JJ N
either RB N
to TO N
vincristine VB N
or CC N
corticosteroids NNS N
, , N
and CC N
routine JJ N
implementation NN N
of IN N
these DT N
tests NNS N
can MD N
prevent VB N
inappropriate JJ N
dose JJ N
attenuation NN N
of IN N
these DT N
agents NNS N
-DOCSTART- -X- O O 12974687

Abrasive JJ N
wear NN N
on IN N
eroded JJ 4_p
root NN 4_p
dentine NN 4_p
after IN N
different JJ N
periods NNS N
of IN N
exposure NN N
to TO N
saliva VB N
in IN N
situ NN N
The DT N
effect NN N
of IN N
salivary JJ N
exposure NN N
time NN N
on IN N
the DT N
abrasive JJ N
wear NN N
of IN N
acid-eroded JJ 4_p
dentine NN 4_p
was VBD N
evaluated VBN N
in IN N
situ NN N
One-hundred JJ 3_p
and CC 3_p
twenty JJ 3_p
bovine NN 3_p
root NN 3_p
dentine NN 3_p
slabs NN 3_p
were VBD N
randomly RB N
assigned VBN N
into IN N
six CD N
groups NNS N
( ( N
A-F NNP N
) ) N
and CC N
placed VBN N
in IN N
intraoral JJ N
palatal JJ N
devices NNS N
, , N
which WDT N
were VBD N
worn VBN N
by IN N
10 CD 3_p
volunteers NNS N
for IN N
4 CD N
d. NN N
On IN N
the DT N
first JJ N
day NN N
, , N
no DT N
erosive/abrasive JJ N
procedures NNS N
were VBD N
carried VBN N
out RP N
On IN N
the DT N
following VBG N
3 CD N
d NN N
, , N
erosive JJ N
challenges NNS N
were VBD N
performed VBN N
extraorally RB N
, , N
two CD N
times NNS N
per IN N
day NN N
, , N
by IN N
immersing VBG N
the DT N
device NN N
for IN N
90 CD N
s NN N
in IN N
a DT N
soft JJ N
drink NN N
Subsequently RB N
, , N
the DT N
group NN N
A DT N
specimens NNS N
were VBD N
immediately RB N
brushed VBN N
( ( N
40 CD N
strokes NNS N
) ) N
, , N
and CC N
the DT N
others NNS N
were VBD N
brushed VBN N
after IN N
the DT N
following JJ N
times NNS N
: : N
B NNP N
, , N
20 CD N
min NN N
; : N
C NNP N
, , N
40 CD N
min NN N
; : N
and CC N
D NNP N
, , N
60 CD N
min NN N
Group NNP N
E NNP N
specimens NNS N
were VBD N
only RB N
acid-eroded JJ N
and CC N
those DT N
of IN N
group NN N
F NNP N
were VBD N
only RB N
brushed VBN N
Dentine NNP N
wear NN N
was VBD N
measured VBN N
with IN N
a DT N
profilometer NN N
anova NN N
and CC N
Dunnett NNP N
's POS N
test NN N
showed VBD N
that IN N
groups NNS N
A-D NNP N
did VBD N
not RB N
differ VB N
statistically RB N
from IN N
the DT N
control NN N
group NN N
E NNP N
but CC N
differed VBD N
from IN N
the DT N
control NN N
group NN N
F. NNP N
The DT N
lowest JJS N
mean JJ N
value NN N
was VBD N
found VBN N
for IN N
group NN N
F. NNP N
Regression NNP N
analysis NN N
was VBD N
unable JJ N
to TO N
show VB N
salivary JJ N
effect NN N
on IN N
dentine NN N
wear NN N
reduction NN N
The DT N
data NN N
suggest NN N
that IN N
the DT N
exposure NN N
time NN N
of IN N
saliva NN N
of IN N
up IN N
to TO N
60 CD N
min NN N
has VBZ N
no DT N
effect NN N
on IN N
reducing VBG N
the DT N
eroded JJ N
dentine NN N
wear NN N
by IN N
toothbrushing VBG N
-DOCSTART- -X- O O 17984242

Effects NNS N
of IN N
resistance NN N
versus NN N
endurance NN N
training NN N
on IN N
serum NN N
adiponectin NN N
and CC N
insulin NN N
resistance NN N
index NN N
PURPOSE VB N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
resistance NN N
and CC N
endurance NN N
training NN N
on IN N
serum NN N
adiponectin NN N
and CC N
insulin NN N
resistance NN N
index NN N
( ( N
SI NNP N
) ) N
in IN N
healthy JJ 4_p
men NNS 2_p
METHODS NNP N
Twenty-four CD 2_p
healthy JJ N
males NNS 2_p
( ( N
age NN 1_p
, , 1_p
35-48 CD 1_p
years NNS 1_p
) ) N
participated VBD N
in IN N
the DT N
study NN N
The DT N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
endurance NN N
training NN N
group NN N
( ( N
n=8 NN N
) ) N
, , N
resistance NN N
training NN N
group NN N
( ( N
n=8 CC N
) ) N
and CC N
control NN N
group NN N
( ( N
n=8 RB N
) ) N
Blood NN N
samples NNS N
were VBD N
taken VBN N
in IN N
fasting VBG N
state NN N
from IN N
all DT N
subjects NNS N
The DT N
experimental JJ N
groups NNS N
performed VBD N
either CC N
endurance NN N
or CC N
resistance NN N
training NN N
3 CD N
days NNS N
a DT N
week NN N
for IN N
12 CD N
weeks NNS N
The DT N
endurance NN N
training NN N
programme NN N
included VBD N
continuous JJ N
running VBG N
at IN N
an DT N
intensity NN N
corresponding VBG N
to TO N
75-85 CD N
% NN N
of IN N
maximal JJ N
heart NN N
rate NN N
, , N
while IN N
resistance NN N
training NN N
consisted VBD N
of IN N
four CD N
sets NNS N
of IN N
circuit NN N
weight NN N
training NN N
for IN N
11 CD N
stations NNS N
and CC N
at IN N
an DT N
intensity NN N
corresponding VBG N
to TO N
50-60 CD N
% NN N
of IN N
one-repetition JJ N
maximum NN N
The DT N
maximum JJ N
numbers NNS N
of IN N
repetitions NNS N
in IN N
each DT N
station NN N
was VBD N
12 CD N
RESULTS VB N
There EX N
were VBD N
significant JJ N
negative JJ N
correlations NNS N
between IN N
serum NN N
adiponectin NN N
and CC N
body NN N
fat JJ N
percentage NN N
, , N
waist-to-hip JJ N
ratio NN N
, , N
body NN N
mass NN N
index NN N
and CC N
the DT N
insulin NN N
resistance NN N
index NN N
at IN N
baseline NN N
, , N
whereas JJ N
changes NNS N
in IN N
response NN N
to TO N
training NN N
were VBD N
not RB N
significantly RB N
correlated VBN N
Both DT N
endurance NN N
and CC N
resistance NN N
training NN N
resulted VBD N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
the DT N
SI NNP N
in IN N
comparison NN N
with IN N
the DT N
control NN N
group NN N
However RB N
, , N
serum JJ N
adiponectin NN N
did VBD N
not RB N
change VB N
significantly RB N
in IN N
response NN N
to TO N
resistance NN N
and CC N
endurance NN N
training NN N
CONCLUSION NNP N
Endurance NNP N
and CC N
resistance NN N
training NN N
caused VBD N
an DT N
improvement NN N
in IN N
insulin NN N
resistance NN N
in IN N
healthy JJ 4_p
men NNS 2_p
, , N
but CC N
this DT N
improvement NN N
was VBD N
not RB N
accompanied VBN N
by IN N
increased JJ N
adiponectin NN N
levels NNS N
-DOCSTART- -X- O O 20654755

Effects NNS N
of IN N
two CD N
combined JJ N
hormonal JJ N
contraceptives NNS N
with IN N
the DT N
same JJ N
composition NN N
and CC N
different JJ N
doses NNS N
on IN N
female JJ 4_p
sexual JJ N
function NN N
and CC N
plasma NN N
androgen NN N
levels NNS N
BACKGROUND NNP N
This DT N
study NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
two CD N
contraceptive JJ N
pills NNS N
with IN N
different JJ N
doses NNS N
of IN N
the DT N
same JJ N
components NNS N
, , N
on IN N
plasma JJ N
androgen NN N
levels NNS N
and CC N
female JJ N
sexual JJ N
function NN N
among IN N
women NNS N
without IN N
previous JJ N
sexual JJ N
dysfunction NN N
STUDY NNP N
DESIGN NNP N
The DT N
participants NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
to TO N
receive VB N
pills NNS N
containing VBG N
ethynylestradiol NN N
( ( N
EE NNP N
) ) N
30 CD N
mcg NN N
and CC N
levonorgestrel NN N
( ( N
LNG NNP N
) ) N
150 CD N
mcg NN N
or CC N
EE NNP N
20 CD N
mcg NN N
and CC N
LNG NNP N
100 CD N
mcg NN N
, , N
for IN N
six CD N
cycles NNS N
Sexual JJ N
function NN N
was VBD N
assessed VBN N
using VBG N
a DT N
standardized JJ N
questionnaire NN N
[ NNP N
Female NNP N
Sexual NNP N
Function NNP N
Index NNP N
( ( N
FSFI NNP N
) ) N
] NN N
Hormone NNP N
assays NNS N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
after IN N
the DT N
sixth JJ N
cycle NN N
RESULTS NNP N
Forty-nine JJ N
women NNS N
were VBD N
included VBN N
in IN N
the DT N
EE30/LNG150 NNP N
group NN N
and CC N
48 CD N
in IN N
the DT N
EE20/LNG100 NNP N
group NN N
EE30/LNG150 NNP N
group NN N
presented VBD N
54 CD N
% NN N
and CC N
67 CD N
% NN N
decreases NNS N
of IN N
total JJ N
testosterone NN N
and CC N
free JJ N
androgen NN N
index NN N
, , N
respectively RB N
, , N
with IN N
statistical JJ N
significance NN N
EE20/LNG100 NNP N
presented VBD N
reductions NNS N
of IN N
20 CD N
% NN N
and CC N
42 CD N
% NN N
, , N
respectively RB N
, , N
but CC N
without IN N
statistical JJ N
significance NN N
Both DT N
groups NNS N
showed VBD N
improvements NNS N
in IN N
the DT N
FSFI NNP N
" NNP N
desire NN N
" NN N
score NN N
, , N
but CC N
with IN N
statistical JJ N
significance NN N
only RB N
for IN N
EE20/LNG100 NNP N
group NN N
CONCLUSIONS NNP N
EE30/LNG150 NNP N
decreased VBD N
plasma JJ N
androgen NN N
levels NNS N
, , N
but CC N
there EX N
was VBD N
no DT N
impairment NN N
in IN N
sexual JJ N
desire NN N
, , N
on IN N
the DT N
other JJ N
hand NN N
, , N
sexual JJ N
desire NN N
score NN N
increased VBD N
with IN N
EE20/LNG100 NNP N
formulation NN N
-DOCSTART- -X- O O 16753722

Greater NNP N
knowledge NN N
gain NN N
with IN N
structured VBN N
than IN N
student-directed JJ N
learning NN N
in IN N
Child NNP N
Health NNP 4_p
: : N
cluster NN N
randomized VBD N
trial NN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
detect VB N
a DT N
difference NN N
in IN N
knowledge NN N
gain NN N
between IN N
students NNS 1_p
receiving VBG N
structured JJ N
versus NN N
student-directed JJ N
learning NN N
for IN N
the DT N
two-week JJ N
Child NNP N
Health NNP N
outpatient NN N
module NN N
A DT N
total NN N
of IN N
138 CD 3_p
phase NN N
3 CD N
( ( N
year NN N
4 CD N
) ) N
medical JJ N
students NNS N
in IN N
10 CD N
two-week JJ N
paediatric JJ N
outpatient NN N
blocks NNS N
at IN N
the DT N
Department NNP N
of IN N
Child NNP N
Health NNP N
, , N
University NNP N
of IN N
Dundee NNP N
, , N
Scotland NNP N
, , N
were VBD N
randomized VBN N
to TO N
student-directed JJ N
or CC N
structured VBN N
learning NN N
between IN N
January NNP N
and CC N
December NNP N
2002 CD N
Pre- JJ N
and CC N
post-course JJ N
tests NNS N
were VBD N
administered VBN N
at IN N
the DT N
start NN N
and CC N
the DT N
end NN N
of IN N
the DT N
attachment NN N
; : N
129 CD 3_p
students NNS N
sat VBD N
both DT N
tests NNS N
Results NNS N
are VBP N
presented VBN N
as IN N
mean JJ N
scores NNS N
with IN N
standard JJ N
deviations NNS N
or CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CI NNP N
) ) N
in IN N
parentheses NNS N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
gain NN N
in IN N
knowledge NN N
of IN N
the DT N
Child NNP N
Health NNP N
core NN N
curriculum NN N
that WDT N
is VBZ N
covered VBN N
in IN N
the DT N
outpatient JJ N
setting NN N
Although IN N
pre-course JJ N
scores NNS N
were VBD N
similar JJ N
( ( N
student-directed JJ N
25.3 CD N
( ( N
7.3 CD N
) ) N
; : N
structured VBN N
24.8 CD N
( ( N
7.5 CD N
) ) N
) ) N
the DT N
structured JJ N
approach NN N
resulted VBD N
in IN N
higher JJR N
post-course NN N
scores NNS N
in IN N
comparison NN N
with IN N
the DT N
student-directed JJ N
approach NN N
( ( N
student-directed JJ N
41.8 CD N
( ( N
9.4 CD N
) ) N
; : N
structured VBN N
53.8 CD N
( ( N
8.8 CD N
) ) N
; : N
p CC N
< VB N
0.01 CD N
) ) N
Knowledge NNP N
gain NN N
showed VBD N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
learning NN N
approaches NNS N
( ( N
student-directed JJ N
16.5 CD N
( ( N
3.7 CD N
) ) N
; : N
structured VBN N
29.1 CD N
( ( N
3.8 CD N
) ) N
, , N
difference NN N
= VBD N
12.6 CD N
( ( N
95 CD N
% NN N
CI NNP N
11.3 CD N
to TO N
13.9 CD N
) ) N
) ) N
Low JJ N
pre-course JJ N
scores NNS N
or CC N
gender VB N
did VBD N
not RB N
affect VB N
knowledge NN N
gain NN N
In IN N
the DT N
Child NNP N
Health NNP N
outpatient NN N
setting NN N
, , N
the DT N
'traditional NNP N
' POS N
structured JJ N
approach NN N
led VBD N
to TO N
significantly RB N
greater JJR N
knowledge NN N
gain NN N
in IN N
comparison NN N
with IN N
the DT N
'novel NNP N
' POS N
student-directed JJ N
approach NN N
The DT N
findings NNS N
emphasize VBP N
the DT N
importance NN N
of IN N
careful JJ N
evaluation NN N
of IN N
novel JJ N
medical JJ N
education NN N
strategies NNS N
before IN N
their PRP$ N
implementation NN N
in IN N
medical JJ N
schools NNS N
, , N
and CC N
the DT N
need NN N
for IN N
further JJ N
research NN N
to TO N
define VB N
the DT N
effective JJ N
methods NNS N
for IN N
delivering VBG N
medical JJ N
education NN N
in IN N
Child NNP N
Health NNP N
-DOCSTART- -X- O O 2768768

Cardiovascular JJ N
and CC N
behavioral JJ N
effects NNS N
of IN N
aerobic JJ N
exercise NN N
training NN N
in IN N
healthy JJ N
older JJR 1_p
men NNS 2_p
and CC 2_p
women NNS 2_p
The DT N
cardiovascular JJ N
and CC N
behavioral JJ N
adaptations NNS N
associated VBN N
with IN N
a DT N
4-month JJ N
program NN N
of IN N
aerobic JJ N
exercise NN N
training NN N
were VBD N
examined VBN N
in IN N
101 CD 3_p
older JJR 1_p
men NNS N
and CC N
women NNS N
( ( N
mean JJ N
age NN N
= VBD N
67 CD N
years NNS N
) ) N
Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
Aerobic NNP N
Exercise NNP N
group NN N
, , N
a DT N
Yoga NNP N
and CC N
Flexibility NNP N
control NN N
group NN N
, , N
or CC N
a DT N
Waiting JJ N
List NNP N
control NN N
group NN N
Prior NNP N
to TO N
and CC N
following VBG N
the DT N
4-month JJ N
program NN N
, , N
subjects VBZ N
underwent JJ N
comprehensive JJ N
physiological NN N
and CC N
psychological JJ N
evaluations NNS N
Physiological JJ N
measures NNS N
included VBD N
measurement NN N
of IN N
blood NN N
pressure NN N
, , N
lipids NNS N
, , N
bone NN N
density NN N
, , N
and CC N
cardiorespiratory JJ N
fitness NN N
including VBG N
direct JJ N
measurements NNS N
of IN N
peak NN N
oxygen NN N
consumption NN N
( ( N
VO2 NNP N
) ) N
and CC N
anaerobic JJ N
threshold NN N
Psychological JJ N
measures NNS N
included VBD N
measures NNS N
of IN N
mood NN N
, , N
psychiatric JJ N
symptoms NNS N
, , N
and CC N
neuropsychological JJ N
functioning NN N
This DT N
study NN N
demonstrated VBD N
that IN N
4 CD N
months NNS N
of IN N
aerobic JJ N
exercise NN N
training NN N
produced VBD N
an DT N
overall JJ N
11.6 CD N
% NN N
improvement NN N
in IN N
peak NN N
VO2 NNP N
and CC N
a DT N
13 CD N
% NN N
increase NN N
in IN N
anaerobic JJ N
threshold NN N
In IN N
contrast NN N
, , N
the DT N
Yoga NNP N
and CC N
Waiting NNP N
List NNP N
control NN N
groups NNS N
experienced VBD N
no DT N
change NN N
in IN N
cardiorespiratory NN N
fitness NN N
Other JJ N
favorable JJ N
physiological JJ N
changes NNS N
observed VBN N
among IN N
aerobic JJ N
exercise NN N
participants NNS N
included VBD N
lower JJR N
cholesterol NN N
levels NNS N
, , N
diastolic JJ N
blood NN N
pressure NN N
levels NNS N
, , N
and CC N
for IN N
subjects NNS N
at IN N
risk NN N
for IN N
bone NN N
fracture NN N
, , N
a DT N
trend NN N
toward IN N
an DT N
increase NN N
in IN N
bone JJ N
mineral JJ N
content NN N
Although IN N
few JJ N
significant JJ N
psychological JJ N
changes NNS N
could MD N
be VB N
attributed VBN N
to TO N
aerobic VB N
exercise NN N
training NN N
, , N
participants NNS N
in IN N
the DT N
two CD N
active JJ N
treatment NN N
groups NNS N
perceived VBD N
themselves PRP N
as IN N
improving VBG N
on IN N
a DT N
number NN N
of IN N
psychological JJ N
and CC N
behavioral JJ N
dimensions NNS N
-DOCSTART- -X- O O 21846665

Increasing VBG N
verbal JJ N
responsiveness NN N
in IN N
parents NNS N
of IN N
children NNS N
with IN N
autism NN N
: : N
a DT N
pilot NN N
study NN N
Correlational NNP N
studies NNS N
have VBP N
revealed VBN N
a DT N
positive JJ N
relationship NN N
between IN N
parent NN 4_p
verbal JJ N
responsiveness NN N
and CC N
language NN N
outcomes NNS N
in IN N
children NNS 4_p
with IN 4_p
autism NN 4_p
We PRP N
investigated VBD N
whether IN N
parents NNS 4_p
of IN 4_p
young JJ 4_p
children NNS 4_p
on IN 4_p
the DT 4_p
autism NN 4_p
spectrum NN 4_p
could MD N
learn VB N
and CC N
implement VB N
the DT N
specific JJ N
categories NNS N
of IN N
verbal JJ N
responsiveness NN N
that WDT N
have VBP N
been VBN N
suggested VBN N
to TO N
facilitate VB N
language NN N
development NN N
Parents NNS 4_p
were VBD N
taught VBN N
to TO N
increase VB N
their PRP$ N
verbal JJ N
responsiveness NN N
in IN N
the DT N
context NN N
of IN N
a DT N
short-term JJ N
language NN N
intervention NN N
that WDT N
included VBD N
group NN N
parent NN N
education NN N
sessions NNS N
, , N
as RB N
well RB N
as IN N
individual JJ N
and CC N
small-group JJ N
coaching NN N
sessions NNS N
of IN N
parent-child JJ N
play NN N
interactions NNS N
Parents NNS 4_p
in IN N
the DT N
treatment NN N
group NN N
increased VBD N
their PRP$ N
use NN N
of IN N
comments NNS N
that WDT N
: : N
described VBD N
their PRP$ N
child NN N
's POS N
focus NN N
of IN N
attention NN N
; : N
interpreted VBN N
or CC N
expanded VBN N
child JJ N
communication NN N
acts NNS N
; : N
and CC N
prompted VBD N
child JJ N
communication NN N
Preliminary JJ N
treatment NN N
effects NNS N
were VBD N
also RB N
noted VBN N
in IN N
children NNS N
's POS N
prompted VBN N
and CC N
spontaneous JJ N
communication NN N
These DT N
results NNS N
support VBP N
the DT N
use NN N
of IN N
parent-mediated JJ N
interventions NNS N
targeting VBG N
verbal JJ N
responsiveness NN N
to TO N
facilitate VB N
language NN N
development NN N
and CC N
communication NN N
in IN N
young JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
-DOCSTART- -X- O O 11570966

Benefit NN N
of IN N
FSH NNP N
priming NN N
of IN N
women NNS 2_p
with IN N
PCOS NNP 4_p
to TO N
the DT N
in IN N
vitro JJ N
maturation NN N
procedure NN N
and CC N
the DT N
outcome NN N
: : N
a DT N
randomized JJ N
prospective JJ N
study NN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
the DT N
rates NNS N
of IN N
in IN N
vitro JJ N
oocyte JJ N
maturation NN N
, , N
fertilization NN N
and CC N
cleavage NN N
, , N
as RB N
well RB N
as IN N
implantation NN N
rate NN N
and CC N
pregnancy NN N
rate NN N
, , N
could MD N
be VB N
improved VBN N
by IN N
low-dose JJ N
priming NN N
with IN N
FSH NNP N
in IN N
vivo NN N
before IN N
retrieval NN N
of IN N
immature NN N
oocytes NNS N
in IN N
patients NNS N
with IN N
polycystic JJ 4_p
ovary JJ 4_p
syndrome NN 4_p
( ( 4_p
PCOS NNP 4_p
) ) 4_p
From IN N
March NNP N
1998 CD N
to TO N
June NNP N
2000 CD N
, , N
a DT N
total NN N
of IN N
28 CD 3_p
women NNS 2_p
underwent JJ N
36 CD N
completed VBN N
treatment NN N
cycles NNS N
, , N
randomized VBN N
sequentially RB N
in IN N
one CD N
of IN N
two CD N
groups NNS N
Women NNP N
in IN N
group NN N
1 CD N
( ( N
n JJ N
= $ N
12 CD N
cycles NNS N
) ) N
received VBD N
no DT N
stimulation NN N
and CC N
women NNS N
in IN N
group NN N
2 CD N
( ( N
n JJ N
= $ N
24 CD N
cycles NNS N
) ) N
received VBD N
150 CD N
iu NN N
recombinant JJ N
FSH NNP N
day NN N
( ( N
-1 NNP N
) ) N
for IN N
3 CD N
days NNS N
, , N
initiated VBN N
on IN N
day NN N
3 CD N
after IN N
menstruation NN N
Aspiration NN N
was VBD N
performed VBN N
transvaginally RB N
between IN N
day NN N
9 CD N
and CC N
day NN N
17 CD N
in IN N
the DT N
unstimulated JJ N
group NN N
and CC N
on IN N
day NN N
8 CD N
or CC N
day NN N
9 CD N
in IN N
the DT N
FSH-primed NNP N
group NN N
after IN N
FSH NNP N
deprivation NN N
for IN N
2 CD N
or CC N
3 CD N
days NNS N
All DT N
cumulus-enclosed JJ N
oocytes NNS N
of IN N
healthy JJ N
appearance NN N
were VBD N
matured VBN N
in IN N
culture NN N
medium NN N
( ( N
TCM-199 NNP N
) ) N
in IN N
vitro NN N
for IN N
28-36 JJ N
h NN N
before IN N
intracytoplasmic JJ N
sperm NN N
injection NN N
( ( N
ICSI NNP N
) ) N
After IN N
oocyte JJ N
retrieval NN N
the DT N
women NNS N
were VBD N
given VBN N
oestradiol NNS N
( ( N
6 CD N
mg NNS N
day NN N
( ( N
-1 NNP N
) ) N
) ) N
and CC N
progesterone JJ N
administration NN N
( ( N
300 CD N
mg NNS N
day NN N
( ( N
-1 NNP N
) ) N
) ) N
was VBD N
initiated VBN N
2 CD N
days NNS N
later RB N
Suitable JJ N
embryos NN N
( ( N
maximum JJ N
two CD N
embryos NN N
) ) N
were VBD N
transferred VBN N
on IN N
day NN N
3 CD N
after IN N
ICSI NNP N
The DT N
percentage NN N
of IN N
oocytes NNS N
reaching VBG N
metaphase NN N
II NNP N
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
FSH-primed NNP N
group NN N
( ( N
59 CD N
% NN N
, , N
92/156 CD N
) ) N
compared VBN N
with IN N
the DT N
non-primed JJ N
group NN N
( ( N
44 CD N
% NN N
, , N
36/81 CD N
) ) N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
rates NNS N
of IN N
oocyte JJ N
fertilization NN N
and CC N
cleavage NN N
between IN N
these DT N
groups NNS N
No DT N
pregnancies NNS N
were VBD N
obtained VBN N
in IN N
group NN N
1 CD N
( ( N
0 CD N
% NN N
, , N
0/12 CD N
) ) N
, , N
whereas JJ N
seven CD N
clinical JJ N
pregnancies NNS N
were VBD N
obtained VBN N
in IN N
group NN N
2 CD N
( ( N
29 CD N
% NN N
, , N
7/24 CD N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
In IN N
group NN N
2 CD N
, , N
37 CD N
embryo NN N
transfers NNS N
resulted VBD N
in IN N
eight CD N
implantations NNS N
( ( N
21.6 CD N
% NN N
) ) N
Three CD N
healthy JJ N
singleton NN N
children NNS N
have VBP N
been VBN N
born VBN N
at IN N
term NN N
; : N
the DT N
remaining VBG N
pregnancies NNS N
ended VBN N
with IN N
spontaneous JJ N
abortions NNS N
in IN N
the DT N
first JJ N
trimester NN N
These DT N
results NNS N
indicate VBP N
that IN N
priming VBG N
with IN N
recombinant JJ N
FSH NNP N
before IN N
harvesting NN N
of IN N
immature NN N
oocytes NNS N
from IN N
patients NNS N
with IN N
PCOS NNP 4_p
may MD N
improve VB N
the DT N
maturational JJ N
potential NN N
of IN N
the DT N
oocytes NNS N
and CC N
the DT N
implantation NN N
rate NN N
of IN N
the DT N
cleaved JJ N
embryos NN N
-DOCSTART- -X- O O 2508567

[ RB N
Cooperative NNP N
study NN N
of IN N
surgical JJ N
adjuvant JJ N
chemotherapy NN N
of IN N
colorectal JJ 4_p
carcinoma NN 4_p
( ( N
second JJ N
study NN N
) ) N
: : N
3-year JJ N
survival NN N
after IN N
surgery NN N
of IN N
non-curatively RB 4_p
resected JJ 4_p
patients NNS N
Cooperative NNP N
Study NNP N
Group NNP N
of IN N
Surgical NNP N
Adjuvant NNP N
Chemotherapy NNP N
of IN N
Colorectal NNP N
Cancer NNP N
in IN N
Japan NNP N
] NNP N
A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
surgical JJ N
adjuvant NN N
chemotherapy NN N
for IN N
non-curatively RB 4_p
resected VBN 4_p
colorectal JJ 4_p
carcinoma NN 4_p
patients NNS 4_p
as IN N
a DT N
collaborative JJ 4_p
study NN 4_p
at IN N
428 CD N
institutes NNS N
in IN N
Japan NNP N
from IN N
Jan. NNP N
, , N
1984 CD N
to TO N
Dec. NNP N
, , N
1985 CD N
A DT N
total NN N
of IN N
1,138 CD 3_p
patients NNS N
were VBD N
entered VBN N
in IN N
this DT N
study NN N
All DT N
patients NNS N
were VBD N
divided VBN N
according VBG N
to TO N
disease NN N
location NN N
( ( N
colon NN N
or CC N
rectum NN N
) ) N
and CC N
received VBD N
one CD N
of IN N
two CD N
chemotherapeutic JJ N
regimens NNS N
after IN N
surgery NN N
( ( N
Regimen NNP N
C NNP N
: : N
MMC NNP N
12 CD N
mg/m2 NN N
i.v NN N
at IN N
operation NN N
day NN N
and CC N
6 CD N
mg/m2 NN N
in IN N
every DT N
2 CD N
months NNS N
+UFT RB N
600 CD N
mg/day JJ N
p.o. NN N
, , N
D NNP N
: : N
the DT N
same JJ N
dose NN N
of IN N
MMC NNP N
+ NNP N
UFT NNP N
400 CD N
mg/day NN N
p.o NN N
) ) N
randomly RB N
556 CD 3_p
cases NNS N
( ( N
colon NN N
carcinoma NN N
regimen NNS N
C NNP N
: : N
148 CD 3_p
, , N
D NNP N
: : N
185 CD 3_p
cases NNS N
, , N
rectal JJ N
carcinoma NN N
regimen NNS N
C NNP N
: : N
94 CD 3_p
, , N
D NNP N
: : N
129 CD 3_p
cases NNS N
) ) N
were VBD N
evaluable JJ N
at IN N
this DT N
presentation NN N
Three-year-survival JJ N
rate NN N
of IN N
histologically RB N
confirmed VBN N
non-curatively RB N
resected VBN N
colon NN N
carcinoma NN N
patients NNS N
was VBD N
higher RBR N
in IN N
the DT N
group NN N
receiving VBG N
regimen NNS N
C NNP N
than IN N
in IN N
regimen JJ N
D. NNP N
But CC N
no DT N
significant JJ N
difference NN N
was VBD N
found VBN N
among IN N
the DT N
other JJ N
groups NNS N
-DOCSTART- -X- O O 24708422

An DT N
RCT NNP N
comparing VBG N
patient-centred JJ N
outcome NN N
variables NNS N
of IN N
guided VBN N
surgery NN N
( ( N
bone NN N
or CC N
mucosa NN N
supported VBN N
) ) N
with IN N
conventional JJ N
implant JJ N
placement NN N
AIM NNP N
To TO N
assess VB N
in IN N
a DT N
randomized JJ N
study NN N
the DT N
patient-centred JJ N
outcome NN N
of IN N
two CD N
guided JJ N
surgery NN N
systems NNS N
( ( N
mucosa NN N
or CC N
bone NN N
supported VBN N
) ) N
compared VBN N
to TO N
conventional JJ N
implant JJ N
placement NN N
, , N
in IN N
fully RB 4_p
edentulous JJ 4_p
patients NNS 4_p
MATERIAL NNP N
AND NNP N
METHODS NNP N
Fifty-nine NNP 3_p
patients NNS 3_p
( ( N
72 CD N
jaws NNS N
) ) N
with IN N
edentulous JJ 4_p
maxillas NNS 4_p
and/ VBP 4_p
or CC 4_p
mandibles NNS 4_p
, , 4_p
were VBD N
consecutively RB N
recruited VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
treatment NN N
groups NNS N
Outcome NNP N
measures NNS N
were VBD N
the DT N
Dutch JJ N
version NN N
of IN N
the DT N
McGill NNP N
Pain NNP N
Questionnaire NNP N
( ( N
MPQ-DLV NNP N
) ) N
, , N
the DT N
Health-related JJ N
quality NN N
of IN N
life NN N
instrument NN N
( ( N
HRQOL NNP N
) ) N
, , N
visual JJ N
analogue NN N
scales NNS N
( ( N
VAS NNP N
) ) N
, , N
the DT N
duration NN N
of IN N
the DT N
procedure NN N
, , N
and CC N
the DT N
analgesic JJ N
doses NNS N
taken VBN N
each DT N
day NN N
RESULTS NNP N
Three CD N
hundred VBD N
and CC N
fourteen JJ N
implants NNS N
were VBD N
placed VBN N
successfully RB N
No DT N
statistical JJ N
differences NNS N
could MD N
be VB N
shown VBN N
between IN N
treatment NN N
groups NNS N
on IN N
pain NN N
response NN N
( ( N
MPQ-DLV NNP N
) ) N
, , N
treatment NN N
perception NN N
( ( N
VAS NNP N
) ) N
or CC N
number NN N
or CC N
kind NN N
of IN N
pain NN N
killers NNS N
For IN N
the DT N
HRQOLI-instrument NNP N
, , N
a DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
Materialise NNP N
Mucosa NNP N
and CC N
Materialise NNP N
Bone NNP N
group NN N
at IN N
day NN N
1 CD N
( ( N
p NN N
= RB N
0.02 CD N
) ) N
and CC N
day NN N
2 CD N
( ( N
p NN N
= RB N
0.01 CD N
) ) N
For IN N
the DT N
duration NN N
of IN N
the DT N
surgery NN N
, , N
a DT N
statistical JJ N
difference NN N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
was VBD N
found VBN N
between IN N
the DT N
Materialise NNP N
mucosa NN N
and CC N
the DT N
Mental NNP N
group NN N
, , N
in IN N
favour NN N
of IN N
the DT N
first JJ N
CONCLUSION NN N
In IN N
this DT N
study NN N
little JJ N
difference NN N
could MD N
be VB N
found VBN N
in IN N
the DT N
patient JJ N
outcome NN N
variables NNS N
of IN N
the DT N
different JJ N
treatment NN N
groups NNS N
However RB N
there EX N
was VBD N
a DT N
tendency NN N
for IN N
patients NNS N
treated VBN N
with IN N
conventional JJ N
flapped JJ N
implant JJ N
placement NN N
to TO N
experience VB N
the DT N
pain NN N
for IN N
a DT N
longer JJR N
period NN N
of IN N
time NN N
-DOCSTART- -X- O O 3839157

The DT N
Eastern NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
experience NN N
with IN N
cyclophosphamide NN N
, , N
adriamycin NN N
, , N
and CC N
5-fluorouracil JJ N
( ( N
CAF NNP N
) ) N
in IN N
patients NNS N
with IN N
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
Data NNP N
on IN N
162 CD 3_p
women NNS N
( ( N
90 CD 3_p
premenopausal NN 4_p
and CC N
72 CD 3_p
postmenopausal NN 4_p
) ) N
with IN N
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
randomized VBN N
to TO N
receive VB N
cyclophosphamide NN N
, , N
Adriamycin NNP N
( ( N
doxorubicin NN N
) ) N
and CC N
5-fluorouracil JJ N
( ( N
CAF NNP N
) ) N
on IN N
two CD N
Eastern JJ N
Cooperative NNP N
Oncology NNP N
Group NNP N
( ( N
ECOG NNP N
) ) N
protocols NNS N
were VBD N
analyzed VBN N
Twenty-three JJ N
percent NN N
had VBD N
complete JJ N
remission NN N
; : N
39 CD N
% NN N
had VBD N
partial JJ N
remission NN N
; : N
28 CD N
% NN N
had VBD N
no DT N
change NN N
; : N
and CC N
3 CD N
% NN N
had VBD N
disease VBN N
progression NN N
Of IN N
those DT N
patients NNS N
in IN N
whom WP N
receptors NNS N
were VBD N
known VBN N
, , N
response NN N
rates NNS N
were VBD N
65 CD N
% NN N
for IN N
estrogen NN N
( ( N
ER NNP N
) ) N
-receptor NN N
positive JJ N
and CC N
70 CD N
% NN N
for IN N
ER-negative JJ N
patients NNS N
The DT N
median JJ N
duration NN N
of IN N
response NN N
was VBD N
11.4 CD N
months NNS N
The DT N
median JJ N
survival NN N
time NN N
from IN N
the DT N
start NN N
of IN N
CAF NNP N
was VBD N
20.2 CD N
months NNS N
The DT N
response NN N
rate NN N
, , N
time NN N
to TO N
treatment NN N
failure NN N
( ( N
TTF NNP N
) ) N
, , N
and CC N
median JJ N
survival NN N
time NN N
were VBD N
superior JJ N
in IN N
the DT N
premenopausal JJ N
women NNS N
These DT N
differences NNS N
ceased VBD N
, , N
however RB N
, , N
to TO N
be VB N
statistically RB N
significant JJ N
in IN N
logistic JJ N
models NNS N
Factors NNS N
significantly RB N
associated VBN N
with IN N
longer JJR N
TTF NNP N
and CC N
longer JJR N
survival NN N
were VBD N
as IN N
follows VBZ N
: : N
one CD N
or CC N
two CD N
organs NNS N
with IN N
metastases NNS N
( ( N
TTF NNP N
, , N
P NNP N
less JJR N
than IN N
0.0001 CD N
; : N
survival NN N
, , N
P NNP N
less JJR N
than IN N
0.0001 CD N
) ) N
; : N
dominant JJ N
site NN N
other JJ N
than IN N
soft JJ N
tissue NN N
( ( N
TTF NNP N
, , N
P NNP N
less JJR N
than IN N
0.0001 CD N
; : N
survival NN N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
; : N
and CC N
an DT N
initial JJ N
good JJ N
performance NN N
status NN N
( ( N
TTF NNP N
, , N
P NNP N
= NNP N
0.007 CD N
; : N
survival NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
Patients NNS N
with IN N
ER-positive JJ N
disease NN N
had VBD N
a DT N
significantly RB N
longer RBR N
median JJ N
survival NN N
time NN N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
-DOCSTART- -X- O O 19661796

Preliminary JJ N
evaluation NN N
of IN N
psychoeducational JJ N
support NN N
interventions NNS N
on IN N
quality NN N
of IN N
life NN N
in IN N
rural JJ N
breast NN 4_p
cancer NN 4_p
survivors NNS N
after IN N
primary JJ N
treatment NN N
Although IN N
most JJS N
cancer NN N
survivors NNS N
are VBP N
at IN N
risk NN N
for IN N
being VBG N
lost VBN N
in IN N
the DT N
transition NN N
from IN N
treatment NN N
to TO N
survivorship VB N
, , N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
face VBP N
special JJ N
challenges NNS N
that WDT N
might MD N
place VB N
them PRP N
at IN N
particular JJ N
risk NN N
This DT N
small-scale JJ N
preliminary JJ N
study NN N
had VBD N
2 CD N
specific JJ N
aims NNS N
: : N
( ( N
aim IN N
1 CD N
) ) N
establish VB N
the DT N
feasibility NN N
of IN N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
participation VBP N
in IN N
a DT N
longitudinal JJ N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
intervention NN N
trial NN N
and CC N
( ( N
aim VB N
2 CD N
) ) N
determine VB N
the DT N
effects NNS N
of IN N
the DT N
Breast NNP N
Cancer NNP N
Education NNP N
Intervention NNP N
( ( N
BCEI NNP N
) ) N
on IN N
overall JJ N
QOL NNP N
Fifty-three JJ 3_p
rural JJ N
breast NN N
cancer NN N
survivors NNS N
were VBD N
randomized VBN N
to TO N
either DT N
an DT N
experimental JJ N
( ( N
n JJ N
= NNP N
27 CD N
) ) N
or CC N
a DT N
wait-control JJ N
arm NN N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
Participants NNS N
in IN N
the DT N
experimental JJ N
arm NN N
received VBD N
the DT N
BCEI NNP N
consisting NN N
of IN N
3 CD N
face-to-face JJ N
education NN N
and CC N
support NN N
sessions NNS N
and CC N
2 CD N
face-to-face NN N
and CC N
3 CD N
telephone NN N
follow-up JJ N
sessions NNS N
, , N
along IN N
with IN N
supplemental JJ N
written VBN N
and CC N
audiotape JJ N
materials NNS N
over IN N
a DT N
6-month JJ N
period NN N
Breast NNP N
Cancer NNP N
Education NNP N
Intervention NNP N
modules NNS N
and CC N
interventions NNS N
are VBP N
organized VBN N
within IN N
a DT N
QOL NNP N
framework NN N
To TO N
address VB N
the DT N
possible JJ N
effects NNS N
of IN N
attention NN N
, , N
wait-control JJ N
participants NNS N
received VBD N
3 CD N
face-to-face JJ N
sessions NNS N
and CC N
3 CD N
telephone NN N
sessions NNS N
during IN N
the DT N
first JJ N
6 CD N
months NNS N
of IN N
participation NN N
in IN N
the DT N
study NN N
, , N
but CC N
not RB N
the DT N
BCEI NNP N
intervention NN N
Research NNP N
questions NNS N
addressing VBG N
aim NN N
1 CD N
were VBD N
as IN N
follows VBZ N
: : N
( ( N
a DT N
) ) N
can MD N
rural VB N
breast NN N
cancer NN N
survivors NNS N
be VB N
recruited VBN N
into IN N
a DT N
longitudinal JJ N
intervention NN N
trial NN N
, , N
and CC N
( ( N
b NN N
) ) N
can MD N
their PRP$ N
participation NN N
be VB N
retained VBN N
Research NNP N
questions NNS N
for IN N
aim NN N
2 CD N
were VBD N
as IN N
follows VBZ N
: : N
( ( N
a DT N
) ) N
do VBP N
participants NNS N
who WP N
received VBD N
the DT N
BCEI NNP N
show NN N
improvement NN N
in IN N
overall JJ N
QOL NNP N
, , N
and CC N
( ( N
b NN N
) ) N
is VBZ N
the DT N
QOL NNP N
improvement NN N
sustained VBD N
over IN N
time NN N
Data NNS N
were VBD N
analyzed VBN N
using VBG N
repeated-measures JJ N
general JJ N
linear NN N
mixed JJ N
models NNS N
Results NNS N
demonstrated VBD N
the DT N
ability NN N
to TO N
recruit VB N
and CC N
retain VB N
53 CD N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
, , N
that IN N
the DT N
experimental JJ N
arm NN N
showed VBD N
improvement NN N
in IN N
overall JJ N
QOL NNP N
( ( N
P NNP N
= NNP N
.013 NNP N
) ) N
, , N
and CC N
that IN N
there EX N
were VBD N
significant JJ N
differences NNS N
in IN N
overall JJ N
QOL NNP N
between IN N
the DT N
experimental JJ N
and CC N
wait-control JJ N
groups NNS N
at IN N
both DT N
months NNS N
3 CD N
and CC N
6 CD N
Thus RB N
, , N
it PRP N
appears VBZ N
that IN N
at IN N
least JJS N
some DT N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
can MD N
and CC N
will MD N
participate VB N
in IN N
a DT N
larger JJR N
trial NN N
and CC N
will MD N
maintain VB N
their PRP$ N
participation NN N
and CC N
that IN N
those DT N
that WDT N
do VBP N
participate VB N
experience NN N
significant JJ N
QOL NNP N
benefit NN N
-DOCSTART- -X- O O 17941770

Tubeless NNP N
percutaneous JJ N
nephrolithotomy NN N
: : N
safe JJ N
even RB N
in IN N
supracostal JJ N
access NN N
PURPOSE VB N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
the DT N
outcome NN N
and CC N
safety NN N
of IN N
tubeless NN N
percutaneous JJ N
nephrolithotomy NN N
( ( N
PCNL NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
renal JJ 4_p
calculi NN 4_p
PATIENTS NNP N
AND CC N
METHODS NNP N
Between NNP N
November NNP N
2005 CD N
and CC N
March NNP N
2006 CD N
, , N
48 CD 3_p
patients NNS N
were VBD N
randomized VBN N
to TO N
either DT N
an DT N
18F CD N
Re-entry JJ N
nephrostomy NN N
tube NN N
( ( N
group NN N
1 CD N
) ) N
or CC N
a DT N
6F CD N
Double-J JJ N
stent NN N
( ( N
group NN N
2 CD N
) ) N
The DT N
two CD N
groups NNS N
were VBD N
well RB N
matched VBN N
for IN N
age NN N
, , N
sex NN N
, , N
stone NN N
size NN N
, , N
stone NN N
laterality NN N
, , N
and CC N
number NN N
of IN N
previous JJ N
renal JJ N
procedures NNS N
All DT N
PCNL NNP N
procedures NNS N
were VBD N
performed VBN N
by IN N
the DT N
same JJ N
surgeon NN N
Postoperative JJ N
visual JJ N
analog NN N
pain NN N
scale NN N
( ( N
VAS NNP N
) ) N
scores VBZ N
at IN N
8 CD N
and CC N
24 CD N
hours NNS N
and CC N
14 CD N
days NNS N
after IN N
surgery NN N
, , N
in-hospital JJ N
analgesic JJ N
use NN N
, , N
length NN N
of IN N
hospital NN N
stay NN N
, , N
success NN N
rate NN N
, , N
blood NN N
transfusion NN N
rate NN N
, , N
and CC N
postoperative JJ N
complications NNS N
were VBD N
compared VBN N
for IN N
the DT N
two CD N
groups NNS N
RESULTS VB N
The DT N
mean JJ N
hospital NN N
stays NNS N
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
were VBD N
3.1 CD N
and CC N
1.6 CD N
days NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
The DT N
mean JJ N
VAS NNP N
scores VBZ N
8 CD N
and CC N
24 CD N
hours NNS N
after IN N
surgery NN N
were VBD N
significantly RB N
lower JJR N
in IN N
group NN N
2 CD N
than IN N
in IN N
group NN N
1 CD N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
The DT N
postoperative JJ N
analgesic JJ N
requirement NN N
( ( N
diclofenac JJ N
sodium NN N
) ) N
was VBD N
significantly RB N
higher JJR N
in IN N
group NN N
1 CD N
( ( N
263 CD N
mg NN N
) ) N
than IN N
in IN N
group NN N
2 CD N
( ( N
120 CD N
mg NN N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
The DT N
rate NN N
of IN N
blood NN N
transfusion NN N
in IN N
the DT N
two CD N
groups NNS N
was VBD N
similar JJ N
( ( N
P NNP N
= NNP N
NS NNP N
) ) N
There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
VAS NNP N
scores NNS N
on IN N
postoperative JJ N
day NN N
14 CD N
The DT N
number NN N
of IN N
supracostal JJ N
accesses NNS N
was VBD N
significantly RB N
higher JJR N
in IN N
group NN N
2 CD N
than IN N
in IN N
group NN N
1 CD N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
The DT N
stone-free JJ N
rates NNS N
and CC N
the DT N
numbers NNS N
of IN N
patients NNS N
with IN N
insignificant JJ N
residual JJ N
fragments NNS N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
There EX N
was VBD N
no DT N
urine JJ N
leakage NN N
or CC N
formation NN N
of IN N
urinoma NN N
in IN N
patients NNS N
with IN N
Double-J NNP N
stents NNS N
CONCLUSION NNP N
Tubeless NNP N
PCNL NNP N
is VBZ N
safe JJ N
and CC N
effective JJ N
even RB N
after IN N
supracostal JJ N
access NN N
and CC N
is VBZ N
associated VBN N
with IN N
less RBR N
postoperative JJ N
pain NN N
and CC N
a DT N
shorter JJR N
hospital NN N
stay NN N
-DOCSTART- -X- O O 2225700

Mefloquine NNP 4_p
kinetics NNS 4_p
in IN 4_p
cured JJ 4_p
and CC 4_p
recrudescent JJ 4_p
patients NNS 4_p
with IN 4_p
acute JJ 4_p
falciparum NN 4_p
malaria NN 4_p
and CC 4_p
in IN 4_p
healthy JJ 4_p
volunteers NNS 4_p
Mefloquine NNP N
pharmacokinetics NNS N
were VBD N
compared VBN N
in IN N
a DT N
randomized JJ N
clinical JJ 4_p
trial NN 4_p
in IN 4_p
Thailand NNP 4_p
among IN 4_p
patients NNS 4_p
with IN 4_p
malaria NNS 4_p
and CC 4_p
healthy JJ 4_p
volunteers NNS 4_p
A DT N
single JJ N
oral JJ N
dose NN N
of IN N
1500 CD N
mg NN N
mefloquine NN N
hydrochloride NN N
was VBD N
administered VBN N
to TO N
11 CD N
patients NNS N
and CC N
5 CD N
volunteers NNS N
and CC N
750 CD N
mg NN N
was VBD N
given VBN N
to TO N
16 CD N
patients NNS N
and CC N
5 CD N
volunteers NNS N
Efficacy NNP N
was VBD N
82 CD N
% NN N
for IN N
1500 CD N
mg NN N
and CC N
63 CD N
% NN N
for IN N
750 CD N
mg NN N
In IN N
cured JJ N
patients NNS N
taking VBG N
750 CD N
mg JJ N
mefloquine NN N
, , N
peak JJ N
plasma JJ N
drug NN N
concentration NN N
( ( N
Cmax NNP N
) ) N
and CC N
area NN N
under IN N
the DT N
plasma JJ N
concentration-time JJ N
curve NN N
( ( N
AUC NNP N
) ) N
were VBD N
significantly RB N
greater JJR N
than IN N
in IN N
the DT N
patients NNS N
for IN N
whom WP N
treatment NN N
failed VBD N
( ( N
p NN N
less JJR N
than IN N
0.0005 CD N
and CC N
p RB N
less JJR N
than IN N
0.01 CD N
, , N
respectively RB N
) ) N
, , N
and CC N
plasma JJ N
mefloquine NN N
levels NNS N
were VBD N
significantly RB N
higher JJR N
from IN N
8 CD N
hours NNS N
to TO N
18 CD N
days NNS N
after IN N
treatment NN N
Mefloquine NNP N
AUC NNP N
was VBD N
reduced VBN N
and CC N
variable JJ N
in IN N
the DT N
presence NN N
of IN N
diarrhea NN N
Compared VBN N
with IN N
noninfected JJ N
volunteers NNS N
, , N
clinically RB N
ill JJ N
patients NNS N
displayed VBD N
a DT N
delayed JJ N
time NN N
to TO N
reach VB N
peak JJ N
concentration NN N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
significantly RB N
higher JJR N
mefloquine NN N
plasma NN N
levels NNS N
in IN N
the DT N
first JJ N
2 CD N
days NNS N
after IN N
administration NN N
of IN N
either CC N
the DT N
750 CD N
mg NN N
or CC N
the DT N
1500 CD N
mg NN N
dose NN N
Mefloquine NNP N
AUC NNP N
was VBD N
similar JJ N
in IN N
patients NNS N
with IN N
malaria NNS N
and CC N
healthy JJ N
volunteers NNS N
Because IN N
plasma JJ N
levels NNS N
increased VBN N
in IN N
temporal JJ N
relationship NN N
with IN N
clinical JJ N
illness NN N
, , N
mefloquine JJ N
volume NN N
of IN N
distribution NN N
or CC N
clearance NN N
( ( N
or CC N
both DT N
) ) N
was VBD N
reduced VBN N
during IN N
the DT N
acute JJ N
phase NN N
of IN N
illness NN N
-DOCSTART- -X- O O 701664

Poylmerized VBN N
whole JJ N
ragweed NN N
: : N
an DT N
improved JJ N
method NN N
of IN N
immunotherapy NN N
A DT N
single-blind JJ N
study NN N
compared VBN N
the DT N
effectiveness NN N
of IN N
glutaraldehyde-treated JJ N
polymerized NNS N
ragweed VBP N
with IN N
nonpolymerized JJ N
monomeric JJ N
ragweed NN N
These DT N
studies NNS N
are VBP N
an DT N
extension NN N
of IN N
those DT N
previously RB N
reported VBN N
for IN N
polymerized JJ N
AgE NNP N
using VBG N
a DT N
readily RB N
available JJ N
ragweed NN N
preparation NN N
containing VBG N
all DT N
ragweed NN N
antigens NNS N
Nineteen JJ 3_p
ragweed-sensitive JJ 4_p
patients NNS N
were VBD 4_p
randomized VBN 4_p
into IN 4_p
2 CD 4_p
groups NNS 4_p
; : 4_p
10 CD 3_p
received VBD N
the DT N
polymerized JJ N
form NN N
and CC 4_p
9 CD 3_p
received VBD N
the DT N
monomeric JJ N
form NN N
Four CD N
parameters NNS N
were VBD N
followed VBN N
: : N
serum-specific JJ N
IgE NNP N
against IN N
antigen NN N
E NNP N
, , N
total JJ N
blocking VBG N
antibody NN N
against IN N
antigen NN N
E NNP N
, , N
local JJ N
and CC N
systemic JJ N
reactions NNS N
to TO N
injection NN N
therapy NN N
, , N
and CC N
symptom NN N
score NN N
indices NNS N
Pretreatment NNP N
levels NNS N
of IN N
antigen NN N
E NNP N
-- : N
specific JJ N
IgE NNP N
and CC N
blocking VBG N
antibody NN N
activity NN N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
After IN N
a DT N
total NN N
of IN N
15,000 CD N
protein NNS N
nitrogen JJ N
units NNS N
( ( N
PNU NNP N
) ) N
had VBD N
been VBN N
given VBN N
, , N
blocking VBG N
antibody NN N
activity NN N
in IN N
the DT N
monomer NN N
group NN N
rose VBD N
from IN N
a DT N
mean NN N
of IN N
170 CD N
ng JJ N
AgE NNP N
bound NN N
per IN N
ml NN N
to TO N
a DT N
mean NN N
of IN N
2,813 CD N
The DT N
rise NN N
in IN N
blocking VBG N
antibody NN N
activity NN N
in IN N
the DT N
polymer NN N
group NN N
was VBD N
from IN N
a DT N
mean NN N
of IN N
181 CD N
ng JJ N
AgE NNP N
bound NN N
per IN N
ml NN N
to TO N
1,574 CD N
At IN N
15,000 CD N
PNU NNP N
, , N
blocking VBG N
antibody NN N
activity NN N
levels NNS N
were VBD N
not RB N
statistically RB N
different JJ N
in IN N
the DT N
2 CD N
groups NNS N
After IN N
1 CD N
year NN N
of IN N
treatment NN N
, , N
no DT N
consistent JJ N
decrease NN N
in IN N
postseasonal JJ N
specific JJ N
IgE NNP N
rise NN N
could MD N
be VB N
shown VBN N
in IN N
either DT N
group NN N
Forty NNP N
times NNS N
less RBR N
erythema JJ N
and CC N
15 CD N
times NNS N
less JJR N
induration NN N
were VBD N
found VBN N
with IN N
polymerized JJ N
ragweed NN N
There EX N
were VBD N
7 CD N
systemic JJ N
reactions NNS N
with IN N
the DT N
monomer NN N
and CC N
none NN N
with IN N
the DT N
polymer NN N
Both DT N
groups NNS N
experienced VBD N
symptomatic JJ N
improvement NN N
with IN N
treatment NN N
-DOCSTART- -X- O O 8639070

The DT N
effects NNS N
of IN N
amantadine NN N
and CC N
pemoline NN N
on IN N
cognitive JJ N
functioning NN N
in IN N
multiple JJ N
sclerosis NN N
BACKGROUND NNP N
Amantadine NNP N
hydrochloride NN N
and CC N
pemoline NN N
, , N
both DT N
frequently RB N
used VBN N
to TO N
treat VB N
the DT N
fatigue NN N
of IN N
multiple JJ N
sclerosis NN N
( ( N
MS NNP N
) ) N
, , N
may MD N
also RB N
improve VB N
attention NN N
and CC N
other JJ N
cognitive JJ N
functions NNS N
in IN N
MS. NNP N
To TO N
our PRP$ N
knowledge NN N
, , N
these DT N
agents NNS N
have VBP N
never RB N
been VBN N
compared VBN N
in IN N
a DT N
placebo-controlled JJ N
trial NN N
of IN N
patients NNS 4_p
with IN 4_p
MS NNP 4_p
OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
amantadine NN N
and CC N
pemoline NN N
on IN N
cognitive JJ N
functioning NN N
in IN N
MS. NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
45 CD N
ambulatory JJ N
patients NNS N
with IN N
MS NNP N
and CC N
severe JJ N
fatigue NN N
were VBD N
treated VBN N
for IN N
6 CD N
weeks NNS N
with IN N
amantadine NN N
, , N
pemoline NN N
, , N
or CC N
placebo NN N
using VBG N
a DT N
parallel JJ N
group NN N
design NN N
They PRP N
underwent VBD N
comprehensive JJ N
neuropsychological JJ N
testing NN N
to TO N
determine VB N
treatment NN N
effects NNS N
on IN N
cognitive JJ N
functioning NN N
Primary JJ N
outcome JJ N
measures NNS N
were VBD N
tests NNS N
of IN N
attention NN N
( ( N
Digit NNP N
Span NNP N
, , N
Trail NNP N
Making NNP N
Test NNP N
, , N
and CC N
Symbol NNP N
Digit NNP N
Modalities NNP N
Test NNP N
) ) N
, , N
verbal JJ N
memory NN N
( ( N
Selective JJ N
Reminding NNP N
Test NNP N
) ) N
, , N
nonverbal JJ N
memory NN N
( ( N
Benton NNP N
Visual NNP N
Retention NNP N
Test NNP N
) ) N
, , N
and CC N
motor NN N
speed NN N
( ( N
Finger NNP N
Tapping NNP N
Test NNP N
) ) N
RESULTS NNP N
Fatigue NNP N
did VBD N
not RB N
significantly RB N
correlate VB N
with IN N
any DT N
of IN N
the DT N
neuropsychological JJ N
outcome NN N
measures NNS N
at IN N
baseline NN N
or CC N
after IN N
treatment NN N
All DT N
three CD N
treatment NN N
groups NNS N
improved VBN N
on IN N
tests NNS N
of IN N
attention NN N
( ( N
P NNP N
< NNP N
.003 NNP N
) ) N
, , N
verbal JJ N
memory NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
motor NN N
speed NN N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
amantadine NN N
, , N
pemoline NN N
, , N
and CC N
placebo NN N
CONCLUSIONS NNP N
Cognitive NNP N
functioning NN N
in IN N
MS NNP N
is VBZ N
independent JJ N
of IN N
fatigue NN N
Neither CC N
amantadine JJ N
nor CC N
pemoline JJ N
enhances NNS N
cognitive JJ N
performance NN N
in IN N
MS NNP N
compared VBN N
with IN N
placebo NN N
-DOCSTART- -X- O O 8161002

Anticholinergic NNP N
drugs NNS N
: : N
effects NNS N
on IN N
oxygen NN N
consumption NN N
and CC N
energy NN N
expenditure NN N
Premedication NN N
has VBZ N
been VBN N
shown VBN N
to TO N
affect VB N
both DT N
oxygen NN N
consumption NN N
( ( N
VO2 NNP N
) ) N
and CC N
energy NN N
expenditure NN N
( ( N
EE NNP N
) ) N
The DT N
metabolic JJ N
responses NNS N
to TO N
anticholinergic VB N
drugs NNS N
have VBP N
not RB N
been VBN N
studied VBN N
In IN N
this DT N
study NN N
the DT N
effects NNS N
of IN N
anticholinergic JJ N
drugs NNS N
on IN N
VO2 NNP N
and CC N
EE NNP N
( ( N
calculated VBN N
from IN N
the DT N
measured VBN N
rates NNS N
of IN N
VO2 NNP N
and CC N
carbon NN N
dioxide NN N
production NN N
[ NNP N
VCO2 NNP N
] NN N
: : N
EE NNP N
[ NNP N
kcal/d NNP N
] NNP N
= VBD N
3.581 CD N
x NNP N
VO2 NNP N
[ NNP N
L/d NNP N
] NNP N
+ VBD N
1.448 CD N
x NNP N
VCO2 NNP N
[ NNP N
L/d NNP N
] NNP N
- : N
32.4 CD N
) ) N
were VBD N
measured VBN N
in IN N
six CD 3_p
healthy JJ N
female NN 2_p
volunteers NNS N
They PRP N
were VBD N
given VBN N
intramuscular JJ N
atropine NN N
( ( N
15 CD N
micrograms/kg NN N
) ) N
, , N
glycopyrrolate NN N
( ( N
8 CD N
micrograms/kg NN N
) ) N
, , N
scopolamine NN N
( ( N
8 CD N
micrograms/kg NN N
) ) N
, , N
and CC N
placebo NN N
in IN N
a DT N
random JJ N
double-blind JJ N
cross-over NN N
design NN N
The DT N
consecutive JJ N
sessions NNS N
were VBD N
at IN N
least JJS N
1 CD N
wk JJ N
apart RB N
for IN N
each DT N
subject NN N
VO2 NNP N
and CC N
EE NNP N
were VBD N
measured VBN N
using VBG N
an DT N
indirect JJ N
calorimetry NN N
( ( N
Deltatrac NNP N
) ) N
Cardiovascular JJ N
responses NNS N
were VBD N
assessed VBN N
using VBG N
standard JJ N
noninvasive JJ N
monitoring NN N
Plasma NNP N
drug NN N
concentrations NNS N
were VBD N
analyzed VBN N
using VBG N
a DT N
sensitive JJ N
modification NN N
of IN N
radioreceptor NN N
assay NN N
Subjective JJ N
responses NNS N
were VBD N
measured VBN N
with IN N
visual JJ N
analog NN N
scale NN N
( ( N
VAS NNP N
) ) N
Atropine NNP N
and CC N
glycopyrrolate NN N
induced VBD N
a DT N
significant JJ N
increase NN N
in IN N
heart NN N
rate NN N
with IN N
a DT N
simultaneous JJ N
decrease NN N
in IN N
pressure NN N
rate NN N
quotient NN N
( ( N
PRQ NNP N
) ) N
, , N
while IN N
scopolamine NN N
caused VBD N
a DT N
significant JJ N
decrease NN N
in IN N
heart NN N
rate NN N
with IN N
a DT N
simultaneous JJ N
increase NN N
in IN N
PRQ NNP N
Scopolamine NNP N
significantly RB N
decreased VBD N
both DT N
VO2 NNP N
and CC N
EE NNP N
, , N
whereas JJ N
glycopyrrolate NN N
increased VBD N
VO2 NNP N
Atropine NNP N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
metabolic JJ N
variables NNS N
Only RB N
scopolamine NN N
induced JJ N
sedation NN N
in IN N
this DT N
study NN N
In IN N
conclusion NN N
, , N
atropine NN N
, , N
glycopyrrolate NN N
, , N
and CC N
scopolamine NN N
differ NN N
not RB N
only RB N
in IN N
their PRP$ N
cardiovascular NN N
and CC N
central JJ N
nervous JJ N
system NN N
effects NNS N
, , N
but CC N
also RB N
in IN N
their PRP$ N
effects NNS N
on IN N
metabolism NN N
-DOCSTART- -X- O O 20683712

Sunlight JJ N
exposure NN N
or CC N
vitamin NN N
D NNP N
supplementation NN N
for IN N
vitamin JJ 4_p
D-deficient JJ 4_p
non-western JJ N
immigrants NNS N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
UNLABELLED NNP N
Vitamin NNP N
D NNP N
deficiency NN N
is VBZ N
very RB N
common JJ N
in IN N
non-western JJ N
immigrants NNS N
In IN N
this DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
vitamin NN N
D NNP N
800 CD N
IU/day NNP N
or CC N
100,000 CD N
IU/3 JJ N
months NNS N
were VBD N
compared VBN N
with IN N
advised JJ N
sunlight NN N
exposure NN N
Vitamin NNP N
D NNP N
supplementation NN N
was VBD N
more RBR N
effective JJ N
than IN N
advised JJ N
sunlight JJ N
exposure NN N
in IN N
improving VBG N
vitamin NN N
D NNP N
status NN N
and CC N
lowering VBG N
parathyroid JJ N
hormone NN N
levels NNS N
INTRODUCTION NNP N
Vitamin NNP N
D NNP N
deficiency NN N
( ( N
25-hydroxyvitamin JJ N
D NNP N
[ NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
] NNP N
< VBD N
25 CD N
nmol/l NN N
) ) N
is VBZ N
common JJ N
among IN N
non-western JJ N
immigrants NNS N
It PRP N
can MD N
be VB N
treated VBN N
with IN N
vitamin NN N
D NNP N
supplementation NN N
or CC N
sunlight JJ N
exposure NN N
METHODS NNP N
To TO N
determine VB N
whether IN N
the DT N
effect NN N
of IN N
vitamin NN N
D NNP N
( ( N
3 CD N
) ) N
supplementation NN N
( ( N
daily JJ N
800 CD N
IU NNP N
or CC N
100,000 CD N
IU/3 NNP N
months NNS N
) ) N
or CC N
sunlight JJ N
exposure NN N
advice NN N
is VBZ N
similar JJ N
with IN N
regard NN N
to TO N
serum VB N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
and CC N
parathyroid VB N
hormone NN N
( ( N
PTH NNP N
) ) N
concentrations NNS N
Randomized NNP N
clinical JJ N
trial NN N
in IN N
11 CD N
general JJ N
practices NNS N
in IN N
The DT N
Netherlands NNP N
Non-western JJ N
immigrants NNS N
, , N
aged VBN N
18-65 CD N
years NNS N
( ( N
n JJ N
= NNP N
232 CD N
) ) N
and CC N
serum $ N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
< $ N
25 CD N
nmol/l NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
supplementation NN N
( ( N
daily JJ N
800 CD N
IU NNP N
or CC N
100,000 CD N
IU/3 NNP N
months NNS N
) ) N
or CC N
advice NN N
for IN N
sunlight JJ N
exposure NN N
for IN N
6 CD N
months NNS N
( ( N
March-September NNP N
) ) N
Blood NN N
samples NNS N
were VBD N
collected VBN N
at IN N
baseline NN N
, , N
during IN N
treatment NN N
( ( N
3 CD N
months NNS N
, , N
6 CD N
months NNS N
) ) N
, , N
and CC N
at IN N
follow-up JJ N
( ( N
12 CD N
months NNS N
) ) N
Statistical JJ N
analysis NN N
was VBD N
performed VBN N
with IN N
multilevel JJ N
regression NN N
modelling NN N
RESULTS VB N
The DT N
intention-to-treat JJ N
analysis NN N
included VBD N
211 CD N
persons NNS N
Baseline NNP N
serum NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
was VBD N
22.5 CD N
± JJ N
11.1 CD N
nmol/l NN N
After IN N
6 CD N
months NNS N
, , N
mean VBP N
serum JJ N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
increased VBD N
to TO N
53 CD N
nmol/l NNS N
with IN N
800 CD N
IU/day NNP N
, , N
to TO N
50.5 CD N
nmol/l NNS N
with IN N
100,000 CD N
IU/3 NNP N
months NNS N
, , N
and CC N
to TO N
29.1 CD N
nmol/l NNS N
with IN N
advised JJ N
sunlight NN N
exposure NN N
( ( N
supplementation NN N
vs FW N
sunshine NN N
p NN N
< NNP N
0.001 CD N
) ) N
Serum NNP N
PTH NNP N
decreased VBD N
significantly RB N
in IN N
all DT N
groups NNS N
after IN N
3 CD N
months NNS N
, , N
more RBR N
in IN N
the DT N
supplementation NN N
groups NNS N
than IN N
in IN N
the DT N
advised JJ N
sunlight NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
There EX N
was VBD N
no DT N
significant JJ N
effect NN N
on IN N
physical JJ N
performance NN N
and CC N
functional JJ N
limitations NNS N
CONCLUSION NNP N
Vitamin NNP N
D NNP N
supplementation NN N
is VBZ N
more RBR N
effective JJ N
than IN N
advised JJ N
sunlight JJ N
exposure NN N
for IN N
treating VBG N
vitamin NN N
D NNP N
deficiency NN N
in IN N
non-western JJ N
immigrants NNS N
-DOCSTART- -X- O O 19910815

In-season JJ N
effect NN N
of IN N
short-term JJ N
sprint NN N
and CC N
power NN N
training NN N
programs NNS N
on IN N
elite JJ 4_p
junior JJ 4_p
soccer NN 4_p
players NNS 4_p
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
2 CD N
in-season JJ N
short-term JJ N
sprint NN N
and CC N
power NN N
training NN N
protocols NNS N
on IN N
vertical JJ N
countermovement NN N
jump NN N
height NN N
( ( N
with IN N
or CC N
without IN N
arms NNS N
) ) N
, , N
sprint NN N
( ( N
Sprint-15m NNP N
) ) N
speed NN N
, , N
and CC N
agility NN N
( ( N
Agility-15m NNP N
) ) N
speed NN N
in IN N
male JJ 2_p
elite JJ N
junior JJ N
soccer NN N
players NNS N
Twenty NNP N
highly RB N
trained VBD N
soccer NN N
players NNS N
( ( N
age NN N
18.3 CD 1_p
+/- JJ 1_p
0.6 CD 1_p
years NNS 1_p
, , N
height VBD N
177 CD N
+/- JJ N
4 CD N
cm NN N
, , N
body NN N
mass VBD N
71.4 CD N
+/- JJ N
6.9 CD N
kg NN N
, , N
sum NN N
skinfolds NNS N
48.1 CD N
+/- JJ N
11.4 CD N
mm NN N
) ) N
, , N
members NNS N
of IN N
a DT N
professional JJ N
soccer NN N
academy NN N
, , N
were VBD N
randomly RB N
allocated VBN N
to TO N
either VB N
a DT N
CONTRAST NNP N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
or CC N
SPRINT NNP N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
group NN N
The DT N
training NN N
intervention NN N
consisted VBD N
of IN N
6 CD N
supervised JJ N
training NN N
sessions NNS N
over IN N
7 CD N
weeks NNS N
, , N
targeting VBG N
the DT N
improvement NN N
of IN N
the DT N
players NNS N
' POS N
speed NN N
and CC N
power NN N
CONTRAST NNP N
protocol NN N
consisted VBD N
of IN N
alternating VBG N
heavy-light JJ N
resistance NN N
( ( N
15-50 CD N
% NN N
body NN N
mass NN N
) ) N
with IN N
soccer-specific JJ N
drills NNS N
( ( N
small-sided JJ N
games NNS N
or CC N
technical JJ N
skills NNS N
) ) N
SPRINT NNP N
training NN N
protocol NN N
used VBN N
line NN N
30-m JJ N
sprints NNS N
( ( N
2-4 JJ N
sets NNS N
of IN N
4 CD N
x JJ N
30 CD N
m NN N
with IN N
180 CD N
and CC N
90 CD N
seconds NNS N
of IN N
recovery NN N
, , N
respectively RB N
) ) N
At IN N
baseline JJ N
no DT N
difference NN N
between IN N
physical JJ N
test NN N
performance NN N
was VBD N
evident JJ N
between IN N
the DT N
2 CD N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
No DT N
time NN N
x VBZ N
training VBG N
group NN N
effect NN N
was VBD N
found VBN N
for IN N
any DT N
of IN N
the DT N
vertical JJ N
jump NN N
and CC N
Agility-15m JJ N
variables NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
A DT N
time NN N
x JJ N
training VBG N
group NN N
effect NN N
was VBD N
found VBN N
for IN N
Sprint-15m JJ N
performance NN N
with IN N
the DT N
CONTRAST NNP N
group NN N
showing VBG N
significantly RB N
better JJR N
scores NNS N
than IN N
the DT N
SPRINT NNP N
group NN N
( ( N
7.23 CD N
+/- JJ N
0.18 CD N
vs. FW N
7.09 CD N
+/- JJ N
0.20 CD N
m.s NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
In IN N
light NN N
of IN N
these DT N
findings NNS N
CONTRAST NNP N
training NN N
should MD N
be VB N
preferred VBN N
to TO N
line NN N
sprint NN N
training NN N
in IN N
the DT N
short JJ N
term NN N
in IN N
young JJ N
elite JJ N
soccer NN N
players NNS N
when WRB N
the DT N
aim NN N
is VBZ N
to TO N
improve VB N
soccer-specific JJ N
sprint NN N
performance NN N
( ( N
15 CD N
m NN N
) ) N
during IN N
the DT N
competitive JJ N
season NN N
-DOCSTART- -X- O O 21042763

An DT N
explorative JJ N
study NN N
on IN N
the DT N
clinical JJ N
utility NN N
of IN N
baseline NN N
and CC N
serial JJ N
serum NN N
tumour NN N
marker NN N
measurements NNS N
in IN N
advanced JJ 4_p
upper JJ 4_p
gastrointestinal JJ 4_p
cancer NN 4_p
The DT N
value NN N
of IN N
early JJ N
tumour NN N
marker NN N
changes NNS N
during IN N
palliative JJ N
chemotherapy NN N
in IN N
patients NNS 4_p
with IN 4_p
upper JJ 4_p
gastrointestinal JJ 4_p
adenocarcinoma NN 4_p
( ( 4_p
UGIA NNP 4_p
) ) 4_p
is VBZ N
unclear JJ N
Seventy-three JJ 3_p
patients NNS 3_p
with IN N
advanced JJ 4_p
UGIA NNP 4_p
were VBD N
randomised VBN N
to TO N
receive VB N
45 CD N
mg/m2 NN N
docetaxel NN N
or CC N
180 CD N
mg/m2 NNS N
irinotecan JJ N
with IN N
5-FU/leucovorin JJ N
After IN N
every DT N
2nd CD N
course NN N
the DT N
patients NNS N
were VBD N
crossed VBN N
over IN N
to TO N
the DT N
other JJ N
regimen NNS N
Serum NNP N
was VBD N
sampled VBN N
before IN N
start NN N
of IN N
chemotherapy NN N
and CC N
every DT N
2nd CD N
week NN N
during IN N
8 CD N
weeks NNS N
for IN N
CEA NNP N
, , N
TPA NNP N
, , N
TPS NNP N
, , N
CA72-4 NNP N
, , N
CA19-9 NNP N
and CC N
CA242 NNP N
measurements NNS N
Eighteen JJ N
patients NNS N
( ( N
25 CD N
% NN N
) ) N
had VBD N
partial JJ N
response NN N
( ( N
PR NNP N
) ) N
and CC N
21 CD N
patients NNS N
had VBD N
stable JJ N
disease NN N
for IN N
at IN N
least JJS N
4 CD N
months NNS N
( ( N
SD4 NNP N
) ) N
All DT N
baseline NN N
marker NN N
levels NNS N
, , N
except IN N
CA72-4 NNP N
, , N
correlated VBN N
with IN N
time NN N
to TO N
progression NN N
and CC N
survival NN N
Patients NNS 4_p
with IN 4_p
normal JJ 4_p
levels NNS 4_p
, , 4_p
except IN 4_p
CA72-4 NNP 4_p
, , N
also RB N
had VBD N
more RBR N
clinical JJ N
responses NNS N
( ( N
PR+SD4 NNP N
) ) N
than IN N
patients NNS N
with IN N
elevated JJ N
values NNS N
Tumour CD N
marker NN N
changes NNS N
early RB N
during IN N
treatment NN N
provided VBN N
modest JJ N
predictive JJ N
information NN N
for IN N
tumour NN N
response NN N
and CC N
survival NN N
A DT N
model NN N
combining VBG N
baseline JJ N
level NN N
, , N
the DT N
change NN N
and CC N
the DT N
interaction NN N
between IN N
them PRP N
gave VBD N
the DT N
best JJS N
prediction NN N
of IN N
outcome NN N
, , N
however RB N
, , N
insignificantly RB N
better JJR N
than IN N
baseline JJ N
level NN N
for IN N
all DT N
markers NNS N
except IN N
CA242 NNP N
Baseline NNP N
tumour JJ N
marker NN N
levels NNS N
provide VBP N
prognostic JJ N
information NN N
for IN N
patients NNS 4_p
with IN 4_p
UGIA NNP 4_p
on IN 4_p
palliative JJ 4_p
chemotherapy NN 4_p
Early JJ N
changes NNS N
generally RB N
failed VBD N
to TO N
provide VB N
accurate JJ N
information NN N
for IN N
tumour NN N
response NN N
and CC N
survival NN N
-DOCSTART- -X- O O 25407464

Anthropometric JJ N
indices NNS N
of IN N
Gambian JJ N
children NNS 1_p
after IN N
one CD N
or CC N
three CD N
annual JJ N
rounds NNS N
of IN N
mass JJ N
drug NN N
administration NN N
with IN N
azithromycin NN N
for IN N
trachoma NN 4_p
control NN N
BACKGROUND NNP N
Mass NNP N
drug NN N
administration NN N
( ( N
MDA NNP N
) ) N
with IN N
azithromycin NN N
, , N
carried VBD N
out RP N
for IN N
the DT N
control NN N
of IN N
blinding VBG N
trachoma NN N
, , N
has VBZ N
been VBN N
linked VBN N
to TO N
reduced VBN N
mortality NN N
in IN N
children NNS 1_p
While IN N
the DT N
mechanism NN N
behind IN N
this DT N
reduction NN N
is VBZ N
unclear JJ N
, , N
it PRP N
may MD N
be VB N
due JJ N
, , N
in IN N
part NN N
, , N
to TO N
improved VBN N
nutritional JJ N
status NN N
via IN N
a DT N
potential JJ N
reduction NN N
in IN N
the DT N
community NN N
burden NN N
of IN N
infectious JJ N
disease NN N
To TO N
determine VB N
whether IN N
MDA NNP N
with IN N
azithromycin JJ N
improves NNS N
anthropometric JJ N
indices NNS N
at IN N
the DT N
community NN N
level NN N
, , N
we PRP N
measured VBD N
the DT N
heights NNS N
and CC N
weights NNS N
of IN N
children NNS 1_p
aged VBN 1_p
1 CD 1_p
to TO 1_p
4 CD 1_p
years NNS 1_p
in IN N
communities NNS N
where WRB N
one CD N
( ( N
single JJ N
MDA NNP N
arm NN N
) ) N
or CC N
three CD N
annual JJ N
rounds NNS N
( ( N
annual JJ N
MDA NNP N
arm NN N
) ) N
of IN N
azithromycin NN 4_p
had VBD N
been VBN N
distributed VBN N
METHODS NNP N
Data NNP N
collection NN N
took VBD N
place NN N
three CD N
years NNS N
after IN N
treatment NN N
in IN N
the DT N
single JJ N
MDA NNP N
arm NN N
and CC N
one CD N
year NN N
after IN N
the DT N
final JJ N
round NN N
of IN N
treatment NN N
in IN N
the DT N
annual JJ N
MDA NNP N
arm NN N
Mean JJ N
height-for-age NN N
, , N
weight-for-age NN N
and CC N
weight-for-height JJ N
z NN N
scores NNS N
were VBD N
compared VBN N
between IN N
treatment NN N
arms NNS N
RESULTS NNP N
No NNP N
significant JJ N
differences NNS N
in IN N
mean JJ N
height-for-age NN N
, , N
weight-for-age NN N
or CC N
weight-for-height JJ N
z NN N
scores NNS N
were VBD N
found VBN N
between IN N
the DT N
annual JJ N
MDA NNP N
and CC N
single JJ N
MDA NNP N
arms NNS N
, , N
nor CC N
was VBD N
there EX N
a DT N
significant JJ N
reduction NN N
in IN N
prevalence NN N
of IN N
stunting NN N
, , N
wasting VBG N
or CC N
underweight JJ N
between IN N
arms NNS N
CONCLUSIONS VB N
Our PRP$ N
data NNS N
do VBP N
not RB N
provide VB N
evidence NN N
that IN N
community NN N
MDA NNP N
with IN N
azithromycin NN N
improved VBN N
anthropometric JJ N
outcomes NNS N
of IN N
children NNS 1_p
in IN N
The DT N
Gambia NNP N
This DT N
may MD N
suggest VB N
reductions NNS N
in IN N
mortality NN N
associated VBN N
with IN N
azithromycin JJ N
MDA NNP N
are VBP N
due JJ N
to TO N
a DT N
mechanism NN N
other JJ N
than IN N
improved JJ N
nutritional JJ N
status NN N
-DOCSTART- -X- O O 16850327

Effects NNS N
of IN N
single JJ N
doses NNS N
of IN N
rabeprazole JJ N
20 CD N
mg NN N
and CC N
esomeprazole JJ N
40 CD N
mg NN N
on IN N
24-h JJ 4_p
intragastric JJ 4_p
pH NN 4_p
in IN 4_p
healthy JJ 4_p
subjects NNS 4_p
OBJECTIVE NNP N
To TO N
compare VB N
antisecretory JJ N
effects NNS N
of IN N
single JJ N
doses NNS N
of IN N
rabeprazole NN N
and CC N
esomeprazole NN N
METHODS NNP N
Open NNP N
, , N
randomised VBD N
, , N
2-way JJ N
crossover NN N
, , N
clinical JJ N
pharmacology NN N
study NN N
24 CD 3_p
healthy JJ 3_p
subjects NNS 3_p
( ( 1_p
10 CD 3_p
men NNS 2_p
; : 1_p
mean JJ 1_p
age NN 1_p
26.2 CD 1_p
y NN 1_p
) ) 1_p
received VBD N
a DT N
single JJ N
dose NN N
of IN N
rabeprazole JJ N
20 CD N
mg NN N
or CC N
esomeprazole JJ N
40 CD N
mg NN N
, , N
with IN N
a DT N
14-day JJ N
'washout NN N
' POS N
Intragastric NNP N
pH NN N
was VBD N
recorded VBN N
continuously RB N
from IN N
24 CD N
h NN N
before IN N
to TO N
24 CD N
h NN N
after IN N
dosing VBG N
RESULTS JJ N
Mean NNP N
intragastric JJ N
pH NN N
was VBD N
higher JJR N
after IN N
esomeprazole JJR N
than IN N
rabeprazole NN N
during IN N
0-5 JJ N
h NN N
after IN N
dosing VBG N
( ( N
P=0.0001 NNP N
) ) N
; : N
the DT N
reverse NN N
was VBD N
true JJ N
from IN N
14-24 JJ N
h NN N
( ( N
P=0.0002 NNP N
) ) N
Mean VB N
% NN N
time NN N
pH JJ N
> $ N
3 CD N
and CC N
> $ N
4 CD N
was VBD N
greater JJR N
after IN N
esomeprazole JJR N
than IN N
rabeprazole NN N
during IN N
0-14 JJ N
h NN N
( ( N
P=0.041 NNP N
and CC N
0.044 CD N
) ) N
, , N
but CC N
the DT N
reverse NN N
was VBD N
true JJ N
during IN N
14-24 JJ N
h NN N
( ( N
P=0.0005 NNP N
and CC N
0.001 CD N
) ) N
In IN N
the DT N
0-24 JJ N
h NN N
interval NN N
as IN N
a DT N
whole NN N
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
treatments NNS N
in IN N
mean JJ N
pH NN N
or CC N
% NN N
time NN N
pH JJ N
> JJ N
3 CD N
or CC N
> $ N
4 CD N
CONCLUSION NNP N
Single-dose JJ N
rabeprazole NN N
20 CD N
mg NN N
was VBD N
as RB N
effective JJ N
as IN N
esomeprazole JJ N
40 CD N
mg NN N
in IN N
increasing VBG N
intragastric JJ N
pH NN N
and CC N
maintaining VBG N
pH NN N
> $ N
3 CD N
and CC N
> $ N
4 CD N
, , N
despite IN N
the DT N
2-fold JJ N
difference NN N
in IN N
dose NN N
-DOCSTART- -X- O O 7134226

Inhibition NN N
of IN N
spontaneous JJ N
platelet NN N
aggregation NN N
and CC N
adhesion NN N
by IN N
indobufen NN N
( ( N
K NNP N
3920 CD N
) ) N
A DT N
randomized JJ N
, , N
double-blind JJ N
crossover NN N
study NN N
on IN N
platelet NN N
, , N
coagulation NN N
and CC N
fibrinolysis NN N
function NN N
tests NNS N
In IN N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
study NN N
in IN N
12 CD 3_p
patients NNS N
with IN N
atherosclerotic JJ 4_p
disease NN 4_p
, , N
the DT N
effect NN N
of IN N
2 CD N
dosages NNS N
( ( N
100 CD N
and CC N
200 CD N
mg NN N
twice RB N
daily RB N
) ) N
of IN N
indobufen NN N
, , N
a DT N
new JJ N
synthetic JJ N
inhibition NN N
of IN N
platelet NN N
aggregation NN N
, , N
on IN N
some DT N
platelet NN N
functions NNS N
, , N
coagulation NN N
and CC N
fibrinolysis NN N
tests NNS N
was VBD N
investigated VBN N
Regardless NNP N
of IN N
the DT N
dosage NN N
used VBN N
, , N
indobufen NN N
was VBD N
shown VBN N
to TO N
induce VB N
a DT N
prompt JJ N
normalization NN N
of IN N
the DT N
enhanced JJ N
platelet NN N
aggregation NN N
of IN N
these DT N
patients NNS N
The DT N
effect NN N
lasted VBD N
for IN N
the DT N
entire JJ N
period NN N
of IN N
drug NN N
administration NN N
and CC N
in IN N
50 CD N
% NN N
of IN N
patients NNS N
a DT N
normal JJ N
platelet NN N
aggregation NN N
was VBD N
maintained VBN N
until IN N
the DT N
fourth JJ N
day NN N
after IN N
discontinuation NN N
of IN N
the DT N
drug NN N
Indobufen NNP N
was VBD N
also RB N
able JJ N
to TO N
reduce VB N
platelet NN N
adhesiveness NN N
and CC N
to TO N
lengthen VB N
bleeding NN N
time NN N
, , N
especially RB N
when WRB N
the DT N
higher JJR N
dosage NN N
was VBD N
used VBN N
-DOCSTART- -X- O O 23776270

Long-term JJ N
effects NNS N
of IN N
choline NN N
on IN N
productive JJ N
performance NN N
and CC N
egg NN N
quality NN N
of IN N
brown-egg NN N
laying NN N
hens NNS N
A DT N
total NN N
of IN N
five CD 3_p
hundred JJ 3_p
forty NN 3_p
19-wk-old JJ 1_p
HyLine NNP N
Brown NNP N
hens NNS N
were VBD N
used VBN N
to TO N
study VB N
the DT N
long-term JJ N
effects NNS N
of IN N
increasing VBG N
choline NN N
with IN N
0 CD N
( ( N
control NN N
) ) N
, , N
425 CD N
, , N
850 CD N
, , N
1,700 CD N
, , N
3,400 CD N
, , N
and CC N
6,800 CD N
mg/kg NN N
of IN N
corn-soybean JJ N
meal-based JJ N
diets NNS N
on IN N
productive JJ N
performance NN N
and CC N
egg NN N
quality NN N
Phase VB N
1 CD N
was VBD N
from IN N
19 CD N
to TO N
58 CD N
wk NN N
, , N
and CC N
phase NN N
2 CD N
was VBD N
from IN N
59 CD N
to TO N
68 CD N
wk NN N
During IN N
the DT N
whole JJ N
experimental JJ N
period NN N
, , N
dietary JJ N
choline NN N
had VBD N
no DT N
significant JJ N
effects NNS N
on IN N
feed NN N
intake NN N
, , N
egg NN N
weight NN N
, , N
and CC N
egg NN N
mass NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
During IN N
phase NN N
1 CD N
, , N
egg NN N
production NN N
decreased VBD N
linearly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
feed JJ N
conversion NN N
ratio NN N
( ( N
FCR NNP N
) ) N
tended VBD N
to TO N
increase VB N
linearly RB N
( ( N
P NNP N
= NNP N
0.057 CD N
) ) N
with IN N
increasing VBG N
choline JJ N
level NN N
in IN N
the DT N
diet NN N
Moreover RB N
, , N
BW NNP N
decreased VBD N
both DT N
linearly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
quadratically RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
as IN N
choline NN N
increased VBN N
from IN N
0 CD N
to TO N
6,800 CD N
mg/kg NNS N
No DT N
significant JJ N
treatment NN N
effects NNS N
were VBD N
found VBN N
for IN N
shell NN N
thickness NN N
and CC N
shell NN N
strength NN N
of IN N
eggs NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
However RB N
, , N
albumen NNS N
height VBD N
and CC N
Haugh NNP N
units NNS N
increased VBD N
linearly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
and CC N
P NNP N
< NNP N
0.05 CD N
, , N
respectively RB N
) ) N
as IN N
choline NN N
increased VBD N
during IN N
phase NN N
2 CD N
Compared VBN N
with IN N
the DT N
control NN N
group NN N
, , N
diets NNS N
supplemented VBD N
with IN N
425 CD N
or CC N
850 CD N
mg NN N
of IN N
choline/kg NN N
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
improved VBN N
yolk JJ N
color NN N
during IN N
phase NN N
1 CD N
This DT N
study NN N
indicates VBZ N
that IN N
a DT N
dietary JJ N
choline NN N
level NN N
of IN N
no DT N
more JJR N
than IN N
700 CD N
mg/kg NN N
is VBZ N
sufficient JJ N
to TO N
maintain VB N
egg NN N
production NN N
The DT N
effect NN N
of IN N
choline NN N
on IN N
egg NN N
quality NN N
was VBD N
minimal JJ N
when WRB N
hens NNS N
were VBD N
fed VBN N
a DT N
corn-soybean JJ N
meal-based JJ N
diet NN N
from IN N
19 CD N
to TO N
68 CD N
wk NN N
of IN N
age NN N
-DOCSTART- -X- O O 22214113

Pilot NNP N
study NN N
of IN N
the DT N
effectiveness NN N
of IN N
weighted JJ N
vests NNS N
OBJECTIVE NN N
In IN N
this DT N
pilot NN N
study NN N
, , N
we PRP N
determined VBD N
the DT N
effectiveness NN N
of IN N
a DT N
weighted JJ N
vest NN N
on IN N
attention NN N
to TO N
task VB N
for IN N
second-grade JJ 3_p
general JJ N
education NN N
students NNS N
with IN 4_p
difficulty NN 4_p
attending VBG 4_p
METHOD NNP N
We PRP N
used VBD N
an DT N
intervention NN N
and CC N
a DT N
control NN N
group NN N
and CC N
an DT N
ABA NNP N
design NN N
to TO N
compare VB N
participants NNS N
' POS N
percentage NN N
of IN N
time NN N
on IN N
task NN N
with IN N
and CC N
without IN N
a DT N
vest NN N
Ten CD 3_p
participants NNS N
from IN N
nine CD N
elementary JJ N
schools NNS N
in IN N
a DT N
suburban JJ N
Texas NNP N
school NN N
district NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
intervention NN N
or CC N
a DT N
control NN N
group NN N
Control NNP N
group NN N
participants NNS N
wore VBD N
a DT N
nonweighted JJ N
vest NN N
Participants NNS N
, , N
classroom NN N
teachers NNS N
, , N
and CC N
research NN N
assistants NNS N
who WP N
coded VBD N
the DT N
data NNS N
were VBD N
blind RB N
as IN N
to TO N
the DT N
group NN N
to TO N
which WDT N
the DT N
participants NNS N
were VBD N
assigned VBN N
RESULTS VB N
A NNP N
repeated JJ N
measures NNS N
analysis NN N
of IN N
variance NN N
indicated VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
or CC N
between IN N
baseline NN N
, , N
intervention NN N
, , N
and CC N
withdrawal NN N
conditions NNS N
CONCLUSION NNP N
Our PRP$ N
results NNS N
indicated VBD N
that IN N
the DT N
weighted JJ N
vests NNS N
were VBD N
not RB N
effective JJ N
in IN N
increasing VBG N
time NN N
on IN N
task NN N
These DT N
results NNS N
should MD N
be VB N
generalized VBN N
cautiously RB N
owing VBG N
to TO N
the DT N
small JJ N
sample NN N
size NN N
and CC N
participant JJ N
selection NN N
process NN N
-DOCSTART- -X- O O 20058059

A DT N
randomized VBN N
controlled VBN N
study NN N
of IN N
parent-assisted JJ N
Children NNP N
's POS N
Friendship NNP N
Training NNP N
with IN N
children NNS 1_p
having VBG N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
This DT N
study NN N
evaluated VBD N
Children NNP N
's POS N
Friendship NNP N
Training NNP N
( ( N
CFT NNP N
) ) N
, , N
a DT N
manualized JJ N
parent-assisted JJ N
intervention NN N
to TO N
improve VB N
social JJ N
skills NNS N
among IN N
second JJ 1_p
to TO 1_p
fifth VB 1_p
grade JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
Comparison NNP N
was VBD N
made VBN N
with IN N
a DT N
delayed JJ N
treatment NN N
control NN N
group NN N
( ( N
DTC NNP N
) ) N
Targeted VBN N
skills NNS N
included VBD N
conversational JJ N
skills NNS N
, , N
peer VBP N
entry NN N
skills NNS N
, , N
developing VBG N
friendship JJ N
networks NNS N
, , N
good JJ N
sportsmanship NN N
, , N
good JJ N
host NN N
behavior NN N
during IN N
play NN N
dates NNS N
, , N
and CC N
handling VBG N
teasing NN N
At IN N
post-testing NN N
, , N
the DT N
CFT NNP N
group NN N
was VBD N
superior JJ N
to TO N
the DT N
DTC NNP N
group NN N
on IN N
parent NN N
measures NNS N
of IN N
social JJ N
skill NN N
and CC N
play NN N
date NN N
behavior NN N
, , N
and CC N
child JJ N
measures NNS N
of IN N
popularity NN N
and CC N
loneliness NN N
, , N
At IN N
3-month JJ N
follow-up NN N
, , N
parent NN N
measures NNS N
showed VBD N
significant JJ N
improvement NN N
from IN N
baseline NN N
Post-hoc JJ N
analysis NN N
indicated VBD N
more JJR N
than IN N
87 CD N
% NN N
of IN N
children NNS N
receiving VBG N
CFT NNP N
showed VBD N
reliable JJ N
change NN N
on IN N
at IN N
least JJS N
one CD N
measure NN N
at IN N
post-test NN N
and CC N
66.7 CD N
% NN N
after IN N
3 CD N
months NNS N
follow-up RB N
-DOCSTART- -X- O O 7975860

Correlation NN N
between IN N
in IN N
vivo JJ N
humoral JJ N
and CC N
in IN N
vitro JJ N
cellular JJ N
immune NN N
responses NNS N
following VBG N
immunization NN N
with IN N
hepatitis NN N
B NNP N
surface NN N
antigen NN N
( ( N
HBsAg NNP N
) ) N
vaccines NNS N
To TO N
study VB N
the DT N
regulation NN N
of IN N
the DT N
human JJ 4_p
immune NN 4_p
response NN 4_p
to TO 4_p
hepatitis VB 4_p
B NNP 4_p
surface NN 4_p
antigen NN 4_p
( ( N
HBsAg NNP N
) ) N
we PRP N
have VBP N
carefully RB N
monitored VBN N
the DT N
in IN N
vivo JJ N
humoral JJ N
and CC N
in IN N
vitro JJ N
cellular JJ N
immune NN N
responses NNS N
to TO N
HBsAg NNP N
in IN N
50 CD 3_p
subjects NNS N
receiving VBG 4_p
four CD 4_p
doses NNS 4_p
of IN 4_p
hepatitis NN 4_p
B NNP 4_p
vaccine NN 4_p
according VBG N
to TO N
a DT N
0 CD N
, , N
1 CD N
, , N
2 CD N
, , N
12 CD N
month NN N
vaccination NN N
scheme NN N
Twenty-three JJ N
subjects NNS N
were VBD N
given VBN N
a DT N
plasma-derived JJ N
vaccine NN N
( ( N
Hevac NNP N
B NNP N
) ) N
and CC N
27 CD N
received VBD N
a DT N
recombinant JJ N
HBsAg NNP N
vaccine NN N
( ( N
yeast-derived JJ N
; : N
Engerix-B NNP N
) ) N
The DT N
humoral JJ N
and CC N
cellular JJ N
immune NN N
responses NNS N
were VBD N
measured VBN N
before IN N
vaccination NN N
( ( N
day NN N
0 CD N
) ) N
; : N
6 CD N
days NNS N
after IN N
the DT N
second JJ N
dose NN N
( ( N
day NN N
36 CD N
) ) N
; : N
6 CD N
days NNS N
( ( N
day NN N
66 CD N
) ) N
, , N
2 CD N
months NNS N
( ( N
day NN N
120 CD N
) ) N
and CC N
10 CD N
months NNS N
( ( N
day NN N
365 CD N
) ) N
after IN N
the DT N
third JJ N
dose NN N
and CC N
1 CD N
month NN N
after IN N
the DT N
fourth JJ N
dose NN N
( ( N
day NN N
395 CD N
) ) N
Based VBN N
on IN N
the DT N
kinetics NNS N
of IN N
the DT N
humoral JJ N
immune NN N
responses NNS N
, , N
the DT N
vaccinees NNS N
could MD N
be VB N
classified VBN N
into IN N
fast NN N
, , N
intermediate JJ N
and CC N
slow/non-responders NNS N
Based VBN N
on IN N
the DT N
magnitude NN N
of IN N
the DT N
immune JJ N
response NN N
( ( N
anti-HBs JJ N
titre NN N
) ) N
on IN N
day NN N
395 CD N
, , N
the DT N
vaccinees NNS N
could MD N
be VB N
divided VBN N
into IN N
high JJ N
( ( N
> FW N
or CC N
= VB N
2000 CD N
U NNP N
l-1 NN N
) ) N
and CC N
low JJ N
( ( N
< CD N
or CC N
= VB N
2000 CD N
U NNP N
l-1 NN N
) ) N
responders NNS N
A DT N
close JJ N
correlation NN N
between IN N
the DT N
kinetics NNS N
and CC N
the DT N
magnitude NN N
of IN N
the DT N
humoral JJ N
immune NN N
response NN N
was VBD N
observed VBN N
The DT N
in IN N
vivo JJ N
anti-HBs JJ N
response NN N
was VBD N
measured VBN N
using VBG N
commercially RB N
available JJ N
immunoradiometric JJ N
assays NNS N
The DT N
in IN N
vitro NN N
cellular JJ N
immune JJ N
response NN N
was VBD N
measured VBN N
using VBG N
an DT N
HBsAg-specific JJ N
lymphoproliferation NN N
assay NN N
Because IN N
of IN N
interassay JJ N
variability NN N
the DT N
results NNS N
were VBD N
considered VBN N
as IN N
dichotomous JJ N
variables NNS N
( ( N
proliferation NN N
versus IN N
non-proliferation NN N
) ) N
for IN N
further JJ N
data NNS N
analysis NN N
A DT N
statistically RB N
significant JJ N
correlation NN N
was VBD N
observed VBN N
between IN N
the DT N
kinetics NNS N
and CC N
magnitude NN N
of IN N
the DT N
humoral JJ N
immune JJ N
response NN N
on IN N
the DT N
one CD N
hand NN N
and CC N
the DT N
in IN N
vitro JJ N
anti-HBs JJ N
response NN N
on IN N
the DT N
other JJ N
hand NN N
( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 24101716

The DT N
Autism NNP N
MEAL NNP N
Plan NN N
: : N
a DT N
parent-training JJ N
curriculum NN N
to TO N
manage VB N
eating JJ N
aversions NNS N
and CC N
low JJ N
intake NN N
among IN N
children NNS N
with IN N
autism NN 4_p
Feeding VBG N
problems NNS N
represent VBP N
a DT N
frequent NN N
concern NN N
reported VBN N
by IN N
caregivers NNS N
of IN N
children NNS 1_p
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
, , N
and CC N
growing VBG N
evidence NN N
suggests VBZ N
atypical JJ N
patterns NNS N
of IN N
intake NN N
may MD N
place VB N
this DT N
population NN N
at IN N
risk NN N
of IN N
nutritional JJ N
and/or NN N
related JJ N
medical JJ N
issues NNS N
, , N
including VBG N
chronic JJ N
vitamin NN N
and CC N
mineral JJ N
deficiencies NNS N
, , N
poor JJ N
bone NN N
growth NN N
, , N
and CC N
obesity NN N
This DT N
combination NN N
of IN N
factors NNS N
emphasizes VBZ N
a DT N
clear JJ N
need NN N
to TO N
identify VB N
and CC N
disseminate VB N
evidence-based JJ N
treatment NN N
of IN N
feeding VBG N
problems NNS N
associated VBN N
with IN N
autism NN N
spectrum NN N
disorders NNS N
Behavioral NNP N
intervention NN N
represents VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
chronic JJ N
feeding NN N
concerns NNS N
in IN N
this DT N
population NN N
; : N
however RB N
, , N
evidence NN N
has VBZ N
largely RB N
been VBN N
established VBN N
with IN N
trained JJ N
therapists NNS N
working VBG N
in IN N
highly RB N
structured JJ N
settings NNS N
This DT N
pilot NN N
study NN N
seeks VBZ N
to TO N
fill VB N
this DT N
gap NN N
in IN N
the DT N
literature NN N
by IN N
describing VBG N
and CC N
evaluating VBG N
the DT N
Autism NNP N
MEAL NNP N
Plan NNP N
, , N
a DT N
behaviorally RB N
based VBN N
parent-training NN N
curriculum NN N
to TO N
address VB N
feeding VBG N
problems NNS N
associated VBN N
with IN N
autism NN N
spectrum NN N
disorders NNS N
We PRP N
assessed VBD N
the DT N
feasibility NN N
of IN N
the DT N
intervention NN N
in IN N
terms NNS N
of IN N
program NN N
content NN N
and CC N
study NN N
protocol NN N
( ( N
e.g JJ N
recruitment NN N
and CC N
retention NN N
of IN N
participants NNS N
, , N
assessment NN N
procedures NNS N
) ) N
, , N
as RB N
well RB N
as IN N
efficacy NN N
in IN N
terms NNS N
of IN N
changes NNS N
in IN N
feeding VBG N
behaviors NNS N
A DT N
total NN N
of IN N
10 CD 3_p
families NNS N
participated VBN N
in IN N
the DT N
treatment NN N
condition NN N
, , N
and CC N
the DT N
program NN N
was VBD N
evaluated VBN N
using VBG N
a DT N
waitlist NN N
control NN N
design NN N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
, , N
representing VBG N
the DT N
first JJ N
randomized-control NN N
study NN N
of IN N
a DT N
feeding VBG N
intervention NN N
in IN N
autism NN N
spectrum NN N
disorders NNS N
Results NNS N
provide VBP N
provisional JJ N
support NN N
regarding VBG N
the DT N
utility NN N
of IN N
the DT N
program NN N
, , N
including VBG N
high JJ N
social JJ N
validity NN N
, , N
parent NN N
perception NN N
of IN N
effectiveness NN N
, , N
and CC N
reduced JJ N
levels NNS N
of IN N
caregiver NN N
stress NN N
following VBG N
intervention NN N
Implications NNS N
, , N
limitations NNS N
, , N
and CC N
future JJ N
directions NNS N
for IN N
this DT N
line NN N
of IN N
research NN N
are VBP N
discussed VBN N
-DOCSTART- -X- O O 8549289

Direct JJ N
analysis NN N
of IN N
resistance NN N
in IN N
the DT N
cutaneous JJ N
microflora NN N
during IN N
treatment NN N
of IN N
acne JJ 4_p
vulgaris NN 4_p
with IN N
topical JJ N
1 CD N
% NN N
nadifloxacin NN N
and CC N
2 CD N
% NN N
erythromycin NN N
-DOCSTART- -X- O O 17322624

Dose-response JJ N
effect NN N
of IN N
flecainide NN N
in IN N
patients NNS N
with IN N
symptomatic JJ 4_p
paroxysmal JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
and/or NN 4_p
flutter NN 4_p
monitored VBD N
with IN N
trans-telephonic JJ N
electrocardiography NN N
: : N
a DT N
multicenter NN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
BACKGROUND VB N
A DT N
double-blind NN N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ N
trial NN N
was VBD N
conducted VBN N
in IN N
patients NNS N
with IN N
paroxysmal JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
or CC 4_p
flutter NN 4_p
( ( 4_p
PAF/PAFL NNP 4_p
) ) 4_p
experiencing VBG N
2 CD N
or CC N
more JJR N
episodes NNS N
of IN N
symptomatic JJ 4_p
PAF/PAFL NNP 4_p
during IN N
a DT N
28-day JJ N
observation NN N
period NN N
to TO N
determine VB N
the DT N
dose-response JJ N
effect NN N
and CC N
safety NN N
of IN N
flecainide NN N
METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
143 CD 3_p
patients NNS N
at IN N
30 CD N
centers NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
25 CD N
, , N
50 CD N
, , N
or CC N
100 CD N
mg NN N
of IN N
flecainide NN N
or CC N
placebo VB N
twice JJ N
daily JJ N
( ( N
BID NNP N
) ) N
In IN N
123 CD 3_p
patients NNS N
( ( N
per IN N
protocol NN N
set NN N
) ) N
, , N
those DT N
remaining VBG N
free JJ N
from IN N
PAF/PAFL NNP N
after IN N
the DT N
treatment NN N
were VBD N
3.1 CD N
% NN N
on IN N
placebo NN N
, , N
7.7 CD N
% NN N
on IN N
25 CD N
mg/BID NN N
, , N
9.4 CD N
% NN N
on IN N
50 CD N
mg/BID NN N
, , N
and CC N
39.4 CD N
% NN N
on IN N
100 CD N
mg/BID NN N
of IN N
flecainide NN N
As IN N
a DT N
whole JJ N
group NN N
, , N
a DT N
significant JJ N
linear JJ N
dose-response NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
was VBD N
observed VBN N
and CC N
a DT N
significant JJ N
difference NN N
between IN N
placebo NN N
and CC N
100 CD N
mg/BID NN N
was VBD N
observed VBN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
A DT N
similar JJ N
dose-response NN N
between IN N
the DT N
present JJ N
study NN N
and CC N
Caucasian NNP N
study NN N
was VBD N
demonstrated VBN N
Although IN N
there EX N
were VBD N
5 CD N
patients NNS N
who WP N
needed VBD N
cardioversion NN N
or CC N
ablation NN N
because IN N
of IN N
frequent JJ N
episodes NNS N
of IN N
PAF/PAFL NNP N
( ( N
2 CD N
in IN N
25 CD N
mg/BID NN N
, , N
1 CD N
in IN N
50 CD N
mg/BID NN N
, , N
and CC N
2 CD N
in IN N
100 CD N
mg/BID NN N
of IN N
flecainide NN N
) ) N
, , N
neither CC N
death NN N
nor CC N
ventricular JJ N
proarrhythmic JJ N
event NN N
was VBD N
reported VBN N
CONCLUSIONS VB N
This DT N
study NN N
indicated VBD N
that IN N
flecainide NN N
exerted VBD N
a DT N
significant JJ N
dose-dependent JJ N
effect NN N
on IN N
the DT N
prevention NN N
of IN N
symptomatic JJ N
PAF/PAFL NNP N
recurrence NN N
and CC N
showed VBD N
that IN N
there EX N
was VBD N
no DT N
inter-ethnic JJ N
difference NN N
in IN N
the DT N
clinical JJ N
effect NN N
of IN N
flecainide NN N
in IN N
patients NNS N
with IN N
PAF/PAFL NNP 4_p
-DOCSTART- -X- O O 24799074

Development NNP N
and CC N
in IN N
vitro/in JJ N
vivo JJ N
evaluation NN N
of IN N
immediate JJ N
release NN N
perindopril NN N
tablets NNS N
Perindopril NNP N
erbumine NN N
( ( N
PE NNP N
) ) N
is VBZ N
a DT N
BCS NNP N
( ( N
Biopharmaceutics NNPS N
Classification NNP N
System NNP N
) ) N
class NN N
3 CD N
drug NN N
with IN N
high JJ N
solubility NN N
and CC N
low JJ N
permeability NN N
It PRP N
is VBZ N
an DT N
inhibitor NN N
of IN N
the DT N
enzyme NN N
that WDT N
converts VBZ N
angiotensin NN N
I PRP N
( ( N
Angiotensin NNP N
Converting NNP N
Enzyme NNP N
, , N
ACE NNP N
) ) N
into IN N
angiotensin NN N
II NNP N
as RB N
well RB N
as IN N
causing VBG N
the DT N
degradation NN N
of IN N
the DT N
vasodilator NN N
bradykinin NN N
into IN N
an DT N
inactive JJ N
heptapeptide NN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
develop VB N
an DT N
alternative JJ N
drug NN N
product NN N
by IN N
using VBG N
a DT N
different JJ N
salt NN N
of IN N
perindopril NN N
and CC N
to TO N
evaluate VB N
the DT N
bioequivalence NN N
between IN N
PE NNP N
, , N
not RB N
still RB N
licensed VBN N
, , N
and CC N
perindopril JJ N
arginine NN N
( ( N
PA NNP N
) ) N
, , N
licensed VBD N
in IN N
many JJ N
countries NNS N
, , N
and CC N
to TO N
prepare VB N
PE NNP N
tablets NNS N
by IN N
using VBG N
direct JJ N
compression NN N
method NN N
Many JJ N
different JJ N
formulations NNS N
were VBD N
prepared VBN N
, , N
among IN N
which WDT N
F3-coded NNP N
formulation NN N
was VBD N
only RB N
selected VBN N
due JJ N
to TO N
releasing VBG N
of IN N
98.03 CD N
% NN N
active JJ N
substance NN N
at IN N
45th CD N
minute NN N
Bioequivalence NNP N
study NN N
was VBD N
planned VBN N
as IN N
a DT N
cross-designed JJ N
, , N
randomized VBN N
, , N
open-labeled JJ N
, , N
single-dose JJ N
, , N
single-center JJ N
study NN N
and CC N
conducted VBN N
in IN N
24 CD 3_p
male NN 2_p
healthy JJ 4_p
volunteers NNS 4_p
via IN 4_p
peroral JJ 4_p
route NN 4_p
The DT N
results NNS N
of IN N
bioequivalence NN N
study NN N
were VBD N
evaluated VBN N
for IN N
Perindopril NNP N
and CC N
Perindoprilat NNP N
according VBG N
to TO N
Cmax NNP N
, , N
tmax NN N
and CC N
AUC NNP N
criteria NNS N
The DT N
geometric JJ N
mean JJ N
ratios NNS N
( ( N
90 CD N
% NN N
CI NNP N
) ) N
of IN N
perindopril NN N
and CC N
perindoprilat NN N
followed VBD N
test NN N
and CC N
reference NN N
drug NN N
were VBD N
calculated VBN N
for IN N
AUC0-t NNP N
and CC N
Cmax NNP N
, , N
105.946 CD N
% NN N
( ( N
100.218-112.002 CD N
% NN N
) ) N
and CC N
110.437 CD N
% NN N
( ( N
102.534-118.948 CD N
% NN N
) ) N
; : N
109.542 CD N
% NN N
( ( N
98.364-121.992 CD N
% NN N
) ) N
and CC N
115.729 CD N
% NN N
( ( N
101.031-132.565 CD N
% NN N
) ) N
, , N
respectively RB N
The DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
of IN N
them PRP N
were VBD N
found VBN N
within IN N
the DT N
standard JJ N
bioequivalence NN N
range NN N
( ( N
80-125 CD N
% NN N
) ) N
-DOCSTART- -X- O O 7075499

[ JJ N
Dose-effect NNP N
relationship NN N
of IN N
isosorbide NN N
dinitrate NN N
in IN N
the DT N
treatment NN N
of IN N
angina JJ N
pectoris NN N
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
Fifteen JJ N
males NNS N
with IN N
angiographic JJ N
evidence NN N
of IN N
coronary JJ N
heart NN N
disease NN N
and CC N
stable JJ N
, , N
exercise-induced JJ N
angina NN N
pectoris NN N
were VBD N
given VBN N
placebo NNS N
or CC N
isosorbide VB N
dinitrate NN N
( ( N
ISDN NNP N
) ) N
in IN N
a DT N
dialy NN N
dose NN N
of IN N
30 CD N
mg NNS N
, , N
120 CD N
mg NN N
, , N
240 CD N
mg NN N
and CC N
480 CD N
mg NN N
in IN N
a DT N
randomized JJ N
single-blind JJ N
trial NN N
The DT N
daily JJ N
doses NNS N
were VBD N
given VBN N
as IN N
a DT N
single JJ N
oral JJ N
dose NN N
of IN N
5 CD N
mg NNS N
, , N
20 CD N
mg NN N
, , N
40 CD N
mg NN N
and CC N
80 CD N
mg JJ N
tablets NNS N
Each DT N
dose NN N
and CC N
placebo NN N
was VBD N
given VBN N
for IN N
seven CD N
days NNS N
On IN N
the DT N
seventh JJ N
day NN N
an DT N
exercise NN N
ECG NNP N
of IN N
standardized JJ N
level NN N
and CC N
duration NN N
of IN N
exercise NN N
was VBD N
recorded VBN N
The DT N
ischaemia NN N
response NN N
in IN N
the DT N
ECG NNP N
revealed VBD N
a DT N
dose-dependent JJ N
reduction NN N
by IN N
28 CD N
% NN N
( ( N
5 CD N
mg RB N
ISDN NNP N
) ) N
, , N
43 CD N
% NN N
( ( N
20 CD N
mg NN N
) ) N
, , N
60 CD N
% NN N
( ( N
40 CD N
mg NN N
) ) N
and CC N
73 CD N
% NN N
( ( N
80 CD N
mg NN N
) ) N
The DT N
number NN N
of IN N
anginal JJ N
attacks NNS N
similarly RB N
fell VBD N
parallel RB N
to TO N
dose VB N
Plasma NNP N
level NN N
of IN N
ISDN NNP N
and CC N
the DT N
mononitrates NNS N
, , N
measured VBD N
one CD N
and CC N
four CD N
hours NNS N
after IN N
drug NN N
intake NN N
, , N
rose VBD N
almost RB N
linearly JJ N
in IN N
relation NN N
to TO N
dose VB N
Oral NNP N
ISDN NNP N
thus RB N
has VBZ N
a DT N
dose-dependent JJ N
effect NN N
on IN N
the DT N
frequency NN N
of IN N
angina NN N
and CC N
ischaemia NN N
parameters NNS N
during IN N
ergometric JJ N
exercise NN N
The DT N
protracted JJ N
anti-anginal JJ N
effect NN N
of IN N
ISDN NNP N
is VBZ N
largely RB N
due JJ N
to TO N
its PRP$ N
metabolites NNS N
At IN N
high JJ N
doses NNS N
there EX N
is VBZ N
presumably RB N
an DT N
added JJ N
effect NN N
of IN N
the DT N
high JJ N
blood NN N
level NN N
of IN N
the DT N
basic JJ N
substance.U NN N
-DOCSTART- -X- O O 7820060

Interferon NNP N
treatment NN N
for IN N
hairy NN 4_p
cell NN 4_p
leukemia NN 4_p
An DT N
update NN N
on IN N
a DT N
cohort NN N
of IN N
69 CD 3_p
patients NNS N
treated VBN N
from IN N
1983 CD N
to TO N
1986 CD N
We PRP N
report VBP N
follow-up JJ N
information NN N
on IN N
69 CD 3_p
hairy NN 4_p
cell NN 4_p
leukemia NN 4_p
( ( 4_p
HCL NNP 4_p
) ) 4_p
patients NNS N
treated VBN N
with IN N
interferon JJ N
alfa-2b NN N
( ( N
IFN NNP N
) ) N
as IN N
primary JJ N
treatment NN N
from IN N
1983 CD N
to TO N
1986 CD N
Follow-up NNP N
through IN N
April NNP N
, , N
1993 CD N
shows VBZ N
that IN N
only RB N
14 CD N
patients NNS N
have VBP N
expired VBN N
Forty-seven CD N
of IN N
the DT N
61 CD N
patients NNS N
completing VBG N
the DT N
intended JJ N
12 CD N
or CC N
more JJR N
months NNS N
of IN N
initial JJ N
IFN NNP N
treatment NN N
were VBD N
eventually RB N
considered VBN N
IFN NNP N
failures NNS N
Forty-three CD N
required JJ N
re-treatment NN N
( ( N
41 CD N
received VBD N
a DT N
second JJ N
course NN N
of IN N
IFN NNP N
and CC N
2 CD N
received VBD N
pentostatin NN N
) ) N
Four CD N
patients NNS N
died VBD N
without IN N
further JJ N
therapy NN N
for IN N
HCL NNP N
The DT N
median JJ N
time NN N
to TO N
interferon VB N
failure NN N
was VBD N
31.3 CD N
months NNS N
Fourteen JJ N
patients NNS N
are VBP N
alive JJ N
and CC N
have VBP N
not RB N
required VBN N
further RBR N
treatment NN N
after IN N
completing VBG N
their PRP$ N
initial JJ N
12 CD N
or CC N
more JJR N
months NNS N
of IN N
interferon NN N
Fifteen JJ N
patients NNS N
underwent VBD N
a DT N
third JJ N
course NN N
of IN N
interferon NN N
therapy NN N
at IN N
a DT N
median JJ N
time NN N
after IN N
completion NN N
of IN N
a DT N
second JJ N
course NN N
of IN N
IFN NNP N
of IN N
1.0 CD N
year NN N
Eighteen JJ N
patients NNS N
were VBD N
eventually RB N
treated VBN N
with IN N
pentostatin NN N
and CC N
ten VB N
with IN N
2-chlorodeoxyadenosine JJ N
( ( N
2-CdA JJ N
) ) N
Thirteen JJ N
patients NNS N
developed VBD N
a DT N
second JJ N
malignancy NN N
; : N
six CD N
of IN N
these DT N
patients NNS N
developed VBD N
a DT N
hematologic JJ N
malignancy NN N
between IN N
44.6 CD N
months NNS N
and CC N
99.1 CD N
months NNS N
after IN N
initiation NN N
of IN N
interferon NN N
therapy NN N
We PRP N
conclude VBP N
that IN N
although IN N
interferon NN N
provides VBZ N
excellent JJ N
palliation NN N
, , N
that IN N
most JJS N
patients NNS N
will MD N
eventually RB N
require VB N
further JJ N
treatment NN N
with IN N
interferon NN N
or CC N
chemotherapy NN N
Future JJ N
trials NNS N
in IN N
HCL NNP N
must MD N
be VB N
aware JJ N
of IN N
the DT N
risk NN N
of IN N
second JJ N
malignancies NNS N
-DOCSTART- -X- O O 22275153

The DT N
effect NN N
of IN N
rectal JJ N
distension NN N
on IN N
bladder NN N
function NN N
in IN N
patients NNS 4_p
with IN 4_p
overactive JJ 4_p
bladder NN 4_p
AIMS NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
rectal JJ N
distension NN N
on IN N
bladder NN N
sensation NN N
volumes NNS N
and CC N
the DT N
number NN N
of IN N
detrusor NN N
contractions NNS N
in IN N
patients NNS N
with IN N
overactive JJ N
bladder NN N
( ( N
OAB NNP N
) ) N
symptoms NNS N
METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
study NN N
included VBD N
patients NNS N
with IN N
OAB NNP N
symptoms NNS N
Multichannel NNP N
urodynamic JJ N
studies NNS N
were VBD N
completed VBN N
with IN N
and CC N
without IN N
rectal JJ N
balloon NN N
distension NN N
Bladder NNP N
sensation NN N
volumes NNS N
and CC N
detrusor NN N
contractions NNS N
were VBD N
compared VBN N
RESULTS NNP N
Twenty-six JJ N
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
The DT N
mean JJ N
age NN N
was VBD N
67 CD N
years NNS N
and CC N
mean JJ N
BMI NNP N
was VBD N
28.3 CD N
kg/m NN N
( ( N
2 CD N
) ) N
Bladder NNP N
sensation NN N
volumes NNS N
were VBD N
lower JJR N
with IN N
rectal JJ N
distention NN N
as IN N
follows VBZ N
: : N
normal JJ N
desire NN N
to TO N
void VB N
( ( N
139 CD N
ml NN N
SD NNP N
, , N
±114 NNP N
vs. FW N
197 CD N
ml NN N
SD NNP N
±150 NNP N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
strong JJ N
desire NN N
to TO N
void VB N
( ( N
260 CD N
ml NN N
SD NNP N
±171 NNP N
vs. IN N
330 CD N
ml NNS N
SD NNP N
±172 NNP N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
and CC N
maximum JJ N
cystometric JJ N
capacity NN N
( ( N
326 CD N
ml NN N
SD NNP N
±183 NNP N
vs. IN N
403 CD N
ml NNS N
SD NNP N
±180 NNP N
, , N
P NNP N
= NNP N
0.0001 CD N
) ) N
There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
number NN N
of IN N
detrusor JJ N
contractions NNS N
or CC N
the DT N
bladder NN N
volume NN N
at IN N
which WDT N
the DT N
first JJ N
detrusor NN N
contraction NN N
had VBD N
occurred VBN N
with IN N
and CC N
without IN N
rectal JJ N
distension NN N
CONCLUSION NNP N
Rectal NNP N
distention NN N
in IN N
patients NNS N
with IN N
OAB NNP N
symptoms NNS N
significantly RB N
lowered VBD N
bladder JJR N
sensation NN N
volumes NNS N
( ( N
normal JJ N
desire NN N
, , N
strong JJ N
desire NN N
, , N
and CC N
maximal JJ N
capacity NN N
) ) N
-DOCSTART- -X- O O 18678836

Concurrent NNP N
doxorubicin NN N
plus CC N
docetaxel NN N
is VBZ N
not RB N
more RBR N
effective JJ N
than IN N
concurrent NN N
doxorubicin NN N
plus CC N
cyclophosphamide NN N
in IN N
operable JJ N
breast NN 4_p
cancer NN 4_p
with IN N
0 CD N
to TO N
3 CD N
positive JJ N
axillary JJ N
nodes NNS N
: : N
North JJ N
American JJ N
Breast NNP N
Cancer NNP N
Intergroup NNP N
Trial NNP N
E NNP N
2197 CD N
PURPOSE VB N
The DT N
combination NN N
of IN N
doxorubicin NN N
and CC N
cyclophosphamide NN N
( ( N
AC NNP N
) ) N
is VBZ N
a DT N
standard JJ N
adjuvant JJ N
regimen NNS N
Doxorubicin NNP N
and CC N
docetaxel NN N
( ( N
AT NNP N
) ) N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
active JJ N
cytotoxic NN N
regimens NNS N
for IN N
metastatic JJ N
breast NN N
cancer NN N
The DT N
purpose NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
determine VB N
whether IN N
adjuvant NN N
AT NNP N
improved VBD N
disease-free JJ N
survival NN N
compared VBN N
with IN N
AC NNP N
in IN N
operable JJ 4_p
breast NN 4_p
cancer NN 4_p
PATIENTS NNP N
AND CC N
METHODS NNP N
Women NNP 2_p
with IN N
invasive JJ 4_p
breast NN 4_p
cancer NN 4_p
were VBD N
eligible JJ N
if IN N
there EX N
were VBD N
one CD N
to TO N
three CD N
positive JJ N
lymph NN N
nodes NNS N
or CC N
if IN N
the DT N
node-negative JJ N
tumor NN N
was VBD N
greater JJR N
than IN N
1 CD N
cm NN N
Patients NNS N
were VBD N
randomly RB N
assigned VBN N
after IN N
surgery NN N
to TO N
receive VB N
doxorubicin NN N
( ( N
60 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
plus CC N
either DT N
cyclophosphamide NN N
( ( N
600 CD N
mg/m NN N
( ( N
2 CD N
) ) N
; : N
AC NNP N
) ) N
or CC N
docetaxel NN N
( ( N
60 CD N
mg/m NN N
( ( N
2 CD N
) ) N
; : N
AT NNP N
) ) N
given VBN N
every DT N
3 CD N
weeks NNS N
for IN N
four CD N
cycles NNS N
, , N
followed VBN N
by IN N
hormone NN N
therapy NN N
for IN N
patients NNS N
with IN N
estrogen JJ N
receptor NN N
( ( N
ER NNP N
) ) N
and/or VBP N
progesterone NN N
receptor NN N
( ( N
PR NNP N
) ) N
-positive JJ N
tumors NNS N
RESULTS VB N
There EX N
were VBD N
2,882 CD 3_p
eligible JJ N
patients NNS N
enrolled VBN N
After IN N
a DT N
median JJ N
follow-up NN N
of IN N
79.5 CD N
months NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
disease-free JJ N
survival NN N
( ( N
DFS NNP N
; : N
85 CD N
% NN N
in IN N
both DT N
arms NNS N
) ) N
or CC N
overall JJ N
survival NN N
( ( N
91 CD N
% NN N
v JJ N
92 CD N
% NN N
) ) N
at IN N
5 CD N
years NNS N
The DT N
hazard NN N
ratio NN N
for IN N
AC NNP N
versus NN N
AT NNP N
was VBD N
1.02 CD N
( ( N
95 CD N
% NN N
CI NNP N
for IN N
DFS NNP N
, , N
0.86 CD N
to TO N
1.22 CD N
; : N
P NNP N
= NNP N
.78 NNP N
) ) N
In IN N
an DT N
exploratory JJ N
analysis NN N
of IN N
prespecified JJ N
stratification NN N
factors NNS N
by IN N
ER NNP N
and CC N
PR NNP N
expression NN N
there EX N
were VBD N
trends NNS N
toward IN N
improved JJ N
DFS NNP N
for IN N
AT NNP N
in IN N
ER/PR-negative JJ N
disease NN N
Grade VB N
3 CD N
neutropenia RB N
associated VBN N
with IN N
fever NN N
or CC N
infection NN N
occurred VBD N
more RBR N
often RB N
with IN N
AT NNP N
( ( N
26 CD N
% NN N
v JJ N
10 CD N
% NN N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
CONCLUSION NN N
AT NNP N
did VBD N
not RB N
improve VB N
DFS NNP N
or CC N
overall JJ N
survival NN N
in IN N
this DT N
population NN N
, , N
and CC N
was VBD N
associated VBN N
with IN N
more JJR N
toxicity NN N
-DOCSTART- -X- O O 8582461

Chronopharmacology NN N
of IN N
enalapril NN N
in IN N
hypertensive JJ 4_p
patients NNS 4_p
The DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
enalapril NN N
, , N
an DT N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitor NN N
, , N
are VBP N
reported VBN N
to TO N
vary VB N
with IN N
the DT N
time NN N
of IN N
administration NN N
The DT N
present JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
examine VB N
whether IN N
the DT N
effect NN N
of IN N
enalapril NN N
on IN N
plasma NN N
bradykinin NN N
( ( N
BK NNP N
) ) N
, , N
substance NN N
P NNP N
and CC N
prostaglandin VB N
E2 NNP N
( ( N
PGE2 NNP N
) ) N
, , N
which WDT N
are VBP N
likely JJ N
to TO N
be VB N
involved VBN N
in IN N
the DT N
mechanism NN N
of IN N
enalapril-induced JJ N
cough NN N
, , N
might MD N
also RB N
be VB N
affected VBN N
by IN N
its PRP$ N
time NN N
of IN N
administration NN N
Enalapril NNP N
5 CD N
mg NN N
or CC N
placebo NN N
was VBD N
given VBN N
orally RB N
at IN N
10:00 CD N
h NN N
( ( N
day NN N
trial NN N
) ) N
or CC N
22:00 CD N
h NN N
( ( N
night NN N
trial NN N
) ) N
to TO N
12 CD 4_p
patients NNS 4_p
with IN 4_p
essential JJ 4_p
hypertension NN 4_p
Serum NNP N
concentrations NNS N
of IN N
total JJ N
drug NN N
( ( N
enalapril JJ N
+ NNP N
enalaprilat NN N
, , N
its PRP$ N
active JJ N
metabolite NN N
) ) N
during IN N
the DT N
day NN N
and CC N
night NN N
trials NNS N
did VBD N
not RB N
differ VB N
significantly RB N
at IN N
any DT N
time NN N
However RB N
, , N
serum JJ N
enalaprilat NN N
tended VBD N
to TO N
be VB N
higher JJR N
and CC N
its PRP$ N
maximum JJ N
concentration NN N
greater JJR N
in IN N
the DT N
day NN N
trial NN N
than IN N
in IN N
the DT N
night NN N
trial NN N
Blood NNP N
pressure NN N
24 CD N
h NN N
after IN N
administration NN N
of IN N
enalapril NN N
was VBD N
reduced VBN N
at IN N
22:00 CD N
h NN N
, , N
but CC N
not RB N
at IN N
10:00 CD N
h. NN N
Plasma NNP N
BK NNP N
tended VBD N
to TO N
increase VB N
following VBG N
enalapril JJ N
administration NN N
at IN N
10:00 CD N
h NN N
, , N
but CC N
not RB N
at IN N
22:00 CD N
h. NN N
Remarkable JJ N
increases NNS N
in IN N
plasma NN N
BK NNP N
were VBD N
observed VBN N
in IN N
two CD N
patients NNS N
in IN N
the DT N
day NN N
trial NN N
and CC N
one CD N
of IN N
them PRP N
also RB N
complained VBD N
of IN N
cough NN N
However RB N
, , N
no DT N
such JJ N
increase NN N
in IN N
plasma JJ N
BK NNP N
or CC N
subsequent JJ N
adverse JJ N
effect NN N
were VBD N
recorded VBN N
in IN N
the DT N
night NN N
trial NN N
Plasma NNP N
substance NN N
P NNP N
and CC N
PGE2 NNP N
did VBD N
not RB N
change VB N
significantly RB N
following VBG N
enalapril JJ N
administration NN N
either RB N
in IN N
the DT N
day NN N
or CC N
night NN N
trial NN N
The DT N
results NNS N
suggest VBP N
that IN N
the DT N
response NN N
of IN N
BK NNP N
to TO N
enalapril VB N
is VBZ N
affected VBN N
by IN N
the DT N
time NN N
of IN N
administration NN N
In IN N
patients NNS N
who WP N
complain VBP N
of IN N
cough NN N
during IN N
treatment NN N
with IN N
enalapril NN N
during IN N
the DT N
daytime NN N
, , N
this DT N
adverse JJ N
effect NN N
might MD N
be VB N
diminished VBN N
or CC N
eliminated VBN N
by IN N
a DT N
switch NN N
to TO N
night-time JJ N
administration NN N
-DOCSTART- -X- O O 16483029

Evaluating VBG N
erectile JJ 4_p
dysfunction NN 4_p
: : 4_p
oral JJ N
sildenafil NN N
versus NN N
intracavernosal JJ N
injection NN N
of IN N
papaverine NN N
BACKGROUND NNP N
Intracavernosal NNP N
injection NN N
of IN N
vasoactive JJ N
drugs NNS N
is VBZ N
an DT N
established JJ N
method NN N
of IN N
evaluating VBG N
erectile JJ N
dysfunction NN N
However RB N
, , N
it PRP N
is VBZ N
invasive JJ N
and CC N
may MD N
be VB N
associated VBN N
with IN N
pain NN N
and CC N
priapism NN N
We PRP N
investigated VBD N
the DT N
use NN N
of IN N
oral JJ N
sildenafil NN N
as IN N
a DT N
possible JJ N
substitute NN N
for IN N
intracavernosal JJ N
agents NNS N
METHODS NNP N
Men NNP 2_p
with IN N
erectile JJ 4_p
dysfunction NN 4_p
were VBD N
randomized VBN N
into IN N
two CD 3_p
groups NNS 3_p
of IN 3_p
25 CD 3_p
each DT 3_p
One CD N
group NN N
of IN N
25 CD 3_p
men NNS 2_p
received VBN N
injection NN N
papaverine NN N
initially RB N
followed VBN N
by IN N
oral JJ N
sildenafil NN N
, , N
and CC N
another DT N
25 CD N
received VBD N
oral JJ N
sildenafil NN N
followed VBN N
by IN N
injection NN N
papaverine NN N
Genital JJ N
self-stimulation NN N
was VBD N
used VBN N
in IN N
both DT N
the DT N
groups NNS N
Penile NNP N
length NN N
and CC N
circumference NN N
as RB N
well RB N
as IN N
angle NN N
of IN N
erection NN N
, , N
before IN N
and CC N
after IN N
each DT N
medication NN N
, , N
were VBD N
recorded VBN N
Two CD N
days NNS N
later RB N
, , N
the DT N
intervention NN N
arms NNS N
were VBD N
crossed VBN N
over IN N
Subjective JJ N
responses NNS N
were VBD N
obtained VBN N
The DT N
effect NN N
of IN N
medication NN N
on IN N
each DT N
outcome NN N
variable NN N
was VBD N
studied VBN N
by IN N
using VBG N
analysis NN N
of IN N
variance NN N
models NNS N
in IN N
relation NN N
to TO N
patient VB N
, , N
period NN N
and CC N
medication NN N
RESULTS NNP N
There EX N
was VBD N
statistically RB N
significant JJ N
improvement NN N
from IN N
the DT N
baseline NN N
value NN N
in IN N
both CC N
the DT N
arms NNS N
, , N
i.e JJ N
injection NN N
papaverine NN N
and CC N
oral JJ N
sildenafil NN N
( ( N
p JJ N
< NN N
0.001 CD N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
for IN N
both DT N
penile JJ N
length NN N
and CC N
circumference NN N
No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
medications NNS N
in IN N
the DT N
outcome NN N
measures NNS N
CONCLCUSION NN N
: : N
Oral JJ N
sildenafil NN N
was VBD N
as RB N
effective JJ N
as IN N
injection NN N
papaverine NN N
in IN N
evaluating VBG N
erectile JJ 4_p
dysfunction NN 4_p
-DOCSTART- -X- O O 14650863

Future NNP N
therapeutic JJ N
directions NNS N
for IN N
factor NN N
Xa NNP N
inhibition NN N
in IN N
the DT N
prophylaxis NN N
and CC N
treatment NN N
of IN N
thrombotic JJ 4_p
disorders NNS 4_p
The DT N
targeted JJ N
mechanism NN N
of IN N
factor NN N
Xa NNP N
inhibition NN N
has VBZ N
been VBN N
studied VBN N
extensively RB N
, , N
initially RB N
as IN N
prophylaxis NN N
for IN N
venous JJ 4_p
thromboembolism NN 4_p
( ( 4_p
VTE NNP 4_p
) ) 4_p
in IN N
the DT N
orthopedic JJ N
surgical JJ N
setting NN N
Future NNP N
therapeutic JJ N
directions NNS N
for IN N
selective JJ N
factor NN N
Xa NNP N
inhibition NN N
in IN N
the DT N
management NN N
of IN N
other JJ N
thrombotic JJ N
diseases NNS N
are VBP N
discussed VBN N
Thromboembolic JJ N
diseases NNS N
can MD N
occur VB N
in IN N
the DT N
venous JJ N
or CC N
arterial JJ N
sides NNS N
of IN N
the DT N
circulatory NN N
system NN N
Factor NNP N
Xa NNP N
inhibition NN N
is VBZ N
a DT N
targeted JJ N
approach NN N
to TO N
anticoagulation VB N
that IN N
resulted VBD N
from IN N
significant JJ N
advances NNS N
in IN N
our PRP$ N
understanding NN N
of IN N
the DT N
coagulation NN N
cascade NN N
The DT N
factor NN N
Xa NNP N
inhibitor NN N
fondaparinux NN N
has VBZ N
been VBN N
studied VBN N
extensively RB N
in IN N
the DT N
orthopedic JJ N
surgical JJ N
setting NN N
for IN N
the DT N
prophylaxis NN N
of IN N
VTE NNP N
Current NNP N
investigations NNS N
that WDT N
are VBP N
under IN N
way NN N
or CC N
completed VBN N
evaluate VBP N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
fondaparinux NN N
for IN N
the DT N
management NN N
of IN N
various JJ N
thrombotic JJ N
diseases NNS N
The DT N
future NN N
development NN N
of IN N
fondaparinux NN N
resides NNS N
primarily RB N
in IN N
three CD N
therapeutic JJ N
areas NNS N
: : N
prevention NN N
of IN N
VTE NNP N
, , N
treatment NN N
of IN N
VTE NNP N
, , N
and CC N
treatment NN N
of IN N
acute JJ N
coronary JJ N
syndromes NNS N
For IN N
the DT N
prevention NN N
of IN N
VTE NNP N
, , N
fondaparinux NN N
has VBZ N
been VBN N
studied VBN N
as IN N
extended JJ N
prophylaxis NN N
following VBG N
hip NN N
fracture NN N
surgery NN N
( ( N
PENTHIFRA NNP N
Plus NNP N
) ) N
, , N
for IN N
use NN N
in IN N
high-risk JJ N
abdominal JJ N
surgical JJ N
patients NNS N
( ( N
PEGASUS NNP N
and CC N
APOLLO NNP N
) ) N
, , N
and CC N
for IN N
use NN N
in IN N
medical JJ N
patients NNS N
( ( N
ARTEMIS NNP N
) ) N
Studies NNPS N
evaluating VBG N
fondaparinux NN N
for IN N
the DT N
treatment NN N
of IN N
VTE NNP N
are VBP N
part NN N
of IN N
the DT N
large JJ N
MATISSE NNP N
clinical JJ N
program NN N
( ( N
MATISSE NNP N
DVT NNP N
and CC N
MATISSE NNP N
PE NNP N
) ) N
Fondaparinux NNP N
was VBD N
investigated VBN N
in IN N
phase NN N
2 CD N
studies NNS N
for IN N
the DT N
treatment NN N
of IN N
acute JJ 4_p
coronary JJ 4_p
syndromes NNS 4_p
, , N
including VBG N
acute JJ N
ST-segment JJ N
myocardial JJ N
infarction NN N
( ( N
PENTALYSE NNP N
) ) N
and CC N
unstable JJ N
angina NN N
( ( N
PENTUA NNP N
) ) N
Encouraging VBG N
data NNS N
from IN N
these DT N
trials NNS N
are VBP N
the DT N
basis NN N
for IN N
phase NN N
3 CD N
programs NNS N
in IN N
this DT N
area NN N
( ( N
MICHELANGELO NNP N
) ) N
The DT N
orthopedic JJ N
prophylactic JJ N
and CC N
nonorthopedic JJ N
clinical JJ N
programs NNS N
for IN N
fondaparinux NN N
in IN N
the DT N
management NN N
of IN N
thrombosis NN N
support NN N
the DT N
concept NN N
that WDT N
targeted VBD N
inhibition NN N
of IN N
coagulation NN N
is VBZ N
an DT N
effective JJ N
advance NN N
in IN N
antithrombotic JJ N
therapy NN N
-DOCSTART- -X- O O 18078449

A DT N
randomized JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
controlled JJ N
release NN N
melatonin NN N
treatment NN N
of IN N
delayed JJ 4_p
sleep JJ 4_p
phase NN 4_p
syndrome NN 4_p
and CC N
impaired JJ 4_p
sleep JJ 4_p
maintenance NN 4_p
in IN N
children NNS 1_p
with IN N
neurodevelopmental JJ 4_p
disabilities NNS 4_p
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
controlled-release NN N
( ( N
CR NNP N
) ) N
melatonin NN N
in IN N
the DT N
treatment NN N
of IN N
delayed JJ 4_p
sleep JJ 4_p
phase NN 4_p
syndrome NN 4_p
and CC N
impaired JJ 4_p
sleep JJ 4_p
maintenance NN 4_p
of IN N
children NNS 1_p
with IN N
neurodevelopmental JJ 4_p
disabilities NNS 4_p
including VBG N
autistic JJ 4_p
spectrum NN 4_p
disorders NNS 4_p
A DT N
randomized JJ N
double-blind NN N
, , N
placebo-controlled JJ N
crossover NN N
trial NN N
of IN N
CR NNP N
melatonin NN N
( ( N
5 CD N
mg NN N
) ) N
followed VBN N
by IN N
a DT N
3-month JJ N
open-label NN N
study NN N
was VBD N
conducted VBN N
during IN N
which WDT N
the DT N
dose NN N
was VBD N
gradually RB N
increased VBN N
until IN N
the DT N
therapy NN N
showed VBD N
optimal JJ N
beneficial JJ N
effects NNS N
Sleep JJ N
characteristics NNS N
were VBD N
measured VBN N
by IN N
caregiver NN N
who WP N
completed VBD N
somnologs NNS N
and CC N
wrist JJ N
actigraphs NN N
Clinician JJ N
rating NN N
of IN N
severity NN N
of IN N
the DT N
sleep JJ N
disorder NN N
and CC N
improvement NN N
from IN N
baseline NN N
, , N
along IN N
with IN N
caregiver JJ N
ratings NNS N
of IN N
global JJ N
functioning NN N
and CC N
family NN N
stress NN N
were VBD N
also RB N
obtained VBN N
Fifty-one CD 3_p
children NNS 1_p
( ( 1_p
age NN 1_p
range NN 1_p
2-18 CD 1_p
years NNS 1_p
) ) 1_p
who WP N
did VBD N
not RB N
respond VB N
to TO N
sleep VB N
hygiene NN N
intervention NN N
were VBD N
enrolled VBN N
Fifty JJ N
patients NNS N
completed VBD N
the DT N
crossover NN N
trial NN N
and CC N
47 CD N
completed VBD N
the DT N
open-label JJ N
phase NN N
Recordings NNS N
of IN N
total JJ N
night-time JJ N
sleep NN N
and CC N
sleep JJ N
latency NN N
showed VBD N
significant JJ N
improvement NN N
of IN N
approximately RB N
30 CD N
min NNS N
Similarly RB N
, , N
significant JJ N
improvement NN N
was VBD N
observed VBN N
in IN N
clinician JJ N
and CC N
parent JJ N
ratings NNS N
There EX N
was VBD N
additional JJ N
improvement NN N
in IN N
the DT N
open-label JJ N
somnolog NN N
measures NNS N
of IN N
sleep JJ N
efficiency NN N
and CC N
the DT N
longest JJS N
sleep JJ N
episode NN N
in IN N
the DT N
open-label JJ N
phase NN N
Overall UH N
, , N
the DT N
therapy NN N
improved VBD N
the DT N
sleep NN N
of IN N
47 CD N
children NNS N
and CC N
was VBD N
effective JJ N
in IN N
reducing VBG N
family NN N
stress NN N
Children NNP 1_p
with IN N
neurodevelopmental JJ 4_p
disabilities NNS 4_p
, , N
who WP N
had VBD N
treatment NN 4_p
resistant JJ 4_p
chronic JJ 4_p
delayed VBN 4_p
sleep JJ 4_p
phase NN 4_p
syndrome NN 4_p
and CC N
impaired JJ N
sleep JJ N
maintenance NN N
, , N
showed VBD N
improvement NN N
in IN N
melatonin NN N
therapy NN N
-DOCSTART- -X- O O 18443393

A DT N
pilot NN N
group NN N
therapy NN N
for IN N
functional JJ 4_p
memory NN 4_p
disorder NN 4_p
-DOCSTART- -X- O O 11550726

Is VBZ N
psychotherapy VBN N
more RBR N
effective JJ N
when WRB N
therapists NNS 4_p
disclose VB N
information NN N
about IN N
themselves PRP N
? . N
Theorists NNS N
have VBP N
long RB N
debated VBN N
the DT N
wisdom NN N
of IN N
therapists NNS N
disclosing VBG N
personal JJ N
information NN N
during IN N
psychotherapy NN N
Some DT N
observers NNS N
have VBP N
argued VBN N
that IN N
such JJ N
therapist JJ N
self-disclosure NN N
impedes NNS N
treatment NN N
, , N
whereas IN N
others NNS N
have VBP N
suggested VBN N
that IN N
it PRP N
enhances VBZ N
the DT N
effectiveness NN N
of IN N
therapy NN N
To TO N
test VB N
these DT N
competing VBG N
positions NNS N
, , N
therapists NNS N
at IN N
a DT N
university NN N
counseling NN N
center NN N
were VBD N
instructed VBN N
to TO N
increase VB N
the DT N
number NN N
of IN N
self-disclosures NNS N
they PRP N
made VBD N
during IN N
treatment NN N
of IN N
one CD N
client NN N
and CC N
refrain NN N
from IN N
making VBG N
self-disclosures NNS N
during IN N
treatment NN N
of IN N
another DT N
client NN N
Analyses NNS N
revealed VBD N
that IN N
clients NNS N
receiving VBG N
psychotherapy NN N
under IN N
conditions NNS N
of IN N
heightened VBN N
therapist NN N
disclosure NN N
not RB N
only RB N
reported VBD N
lower JJR N
levels NNS N
of IN N
symptom NN N
distress NN N
but CC N
also RB N
liked VBD N
their PRP$ N
therapist NN N
more RBR N
Such JJ N
findings NNS N
suggest VBP N
that IN N
self-disclosure NN N
by IN N
the DT N
therapist NN N
may MD N
improve VB N
both PDT N
the DT N
quality NN N
of IN N
the DT N
therapeutic JJ N
relationship NN N
and CC N
the DT N
outcome NN N
of IN N
treatment NN N
-DOCSTART- -X- O O 24146058

Comparison NNP N
of IN N
meloxicam NN N
and CC N
a DT N
glucosamine-chondroitin JJ N
supplement NN N
in IN N
management NN N
of IN N
feline NN 4_p
osteoarthritis NN 4_p
A DT N
double-blind NN N
randomised VBN N
, , N
placebo-controlled JJ N
, , N
prospective JJ N
trial NN N
OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
meloxicam NN N
and CC N
a DT N
glucosamine-chondroitin JJ N
( ( N
Glu-Ch NNP N
) ) N
supplement NN N
in IN N
the DT N
management NN N
of IN N
feline NN 4_p
osteoarthritis NN 4_p
( ( 4_p
OA NNP 4_p
) ) 4_p
METHODS NNP N
Prospective NNP N
, , N
blinded VBD N
, , N
randomized VBD N
clinical JJ N
trial NN N
Cats NNPS 1_p
over IN 1_p
eight CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN N
clinical JJ 4_p
signs NNS 4_p
of IN 4_p
chronic JJ 4_p
OA NNP 4_p
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
and CC N
Glu-Ch NNP N
or CC N
meloxicam NN N
was VBD N
administered VBN N
orally RB N
for IN N
70 CD N
days NNS N
, , N
followed VBN N
by IN N
a DT N
placebo NN N
until IN N
day NN N
98 CD N
Cats NNPS N
were VBD N
assessed VBN N
by IN N
a DT N
veterinarian NN N
on IN N
five CD N
occasions NNS N
and CC N
the DT N
owner NN N
completed VBD N
an DT N
assessment JJ N
form NN N
at IN N
the DT N
same JJ N
time NN N
RESULTS NNP N
Data NNP N
were VBD N
collected VBN N
from IN N
thirty NN N
cats NNS N
Pre-treatment JJ N
disease NN N
scores NNS N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
meloxicam NN N
group NN N
for IN N
owner NN N
mobility NN N
( ( N
p=0.01 NN N
) ) N
and CC N
veterinary JJ N
lameness NN N
( ( N
p=0.02 NN N
) ) N
Owner NNP N
mobility NN N
scores NNS N
at IN N
day NN N
14 CD N
( ( N
p=0.01 NN N
) ) N
and CC N
day NN N
42 CD N
( ( N
p=0.002 NN N
) ) N
were VBD N
significantly RB N
improved VBN N
compared VBN N
to TO N
pre-treatment JJ N
scores NNS N
for IN N
the DT N
meloxicam NN N
group NN N
When WRB N
meloxicam NN N
and CC N
Glu-Ch NNP N
were VBD N
discontinued VBN N
and CC N
the DT N
placebo NN N
commenced VBD N
, , N
a DT N
significant JJ N
proportion NN N
of IN N
the DT N
meloxicam NN N
group NN N
showed VBD N
worsening NN N
of IN N
all PDT N
the DT N
owner-assessed JJ N
scores NNS N
between IN N
day NN N
70 CD N
and CC N
day NN N
98 CD N
, , N
when WRB N
compared VBN N
to TO N
the DT N
Glu-Ch NNP N
group NN N
( ( N
mobility NN N
p=0.01 NN N
; : N
activity NN N
p=0.02 NN N
; : N
temperament JJ N
p=0.04 NN N
; : N
lifestyle CC N
p=0.01 NN N
) ) N
CONCLUSIONS NNP N
Treatment NNP N
with IN N
meloxicam NN N
resulted VBN N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
mobility NN N
and CC N
activity NN N
levels NNS N
of IN N
cats NNS N
with IN N
OA NNP N
until IN N
the DT N
placebo NN N
was VBD N
introduced VBN N
A DT N
greater JJR N
proportion NN N
of IN N
cats NNS N
receiving VBG N
meloxicam NN N
medication NN N
showed VBD N
a DT N
significant JJ N
worsening NN N
of IN N
owner NN N
assessment NN N
scores VBZ N
once RB N
the DT N
placed NN N
was VBD N
introduced VBN N
, , N
when WRB N
compared VBN N
to TO N
the DT N
Glu-Ch NNP N
group NN N
-DOCSTART- -X- O O 19523608

Randomized VBN N
placebo NN N
controlled VBN N
human JJ N
volunteer NN 4_p
trial NN 4_p
of IN N
a DT N
live JJ N
oral JJ N
cholera NN N
vaccine NN N
VA1.3 NNP N
for IN N
safety NN N
and CC N
immune JJ N
response NN N
A DT N
live JJ N
oral JJ N
cholera NN N
vaccine NN N
developed VBN N
from IN N
a DT N
non-toxigenic JJ N
Vibrio NNP N
cholerae NN N
O1 NNP N
El NNP N
Tor NNP N
strain NN N
VA1.3 NNP N
was VBD N
tested VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
placebo NN N
controlled VBD N
study NN N
for IN N
safety NN N
and CC N
immunogenicity NN N
in IN N
304 CD 3_p
men NNS N
aged VBN N
between IN N
16 CD N
and CC N
50 CD N
years NNS N
from IN N
Kolkata NNP N
, , N
India NNP N
A NNP N
dose NN N
of IN N
5 CD N
x NNS N
10 CD N
( ( N
9 CD N
) ) N
CFU NNP N
( ( N
n=186 NN N
) ) N
or CC N
a DT N
placebo NN N
( ( N
n=116 JJ N
) ) N
containing VBG N
the DT N
diluent NN N
buffer NN N
was VBD N
administered VBN N
The DT N
vaccine NN N
did VBD N
not RB N
elicit JJ N
adverse JJ N
events NNS N
except IN N
in IN N
two CD N
vaccine NN N
recipients NNS N
with IN N
mild JJ N
diarrhoea NN N
and CC N
vomiting NN N
None NN N
excreted VBD N
the DT N
vaccine NN N
strain NN N
Vibriocidal NNP N
antibody NN N
response NN N
developed VBD N
in IN N
105/186 CD N
( ( N
57 CD N
% NN N
) ) N
and CC N
5/116 CD N
( ( N
4 CD N
% NN N
) ) N
in IN N
vaccine NN N
and CC N
placebo NN N
recipients NNS N
, , N
respectively RB N
In IN N
a DT N
subgroup NN N
, , N
anti-CT JJ N
antibody NN N
rose VBD N
( ( N
> JJ N
or CC N
=2-folds NNS N
) ) N
in IN N
23/30 CD N
( ( N
77 CD N
% NN N
) ) N
and CC N
6/19 CD N
( ( N
32 CD N
% NN N
) ) N
in IN N
vaccine NN N
and CC N
placebo NN N
recipients NNS N
, , N
respectively RB N
These DT N
studies NNS N
demonstrate VBP N
that IN N
VA1.3 NNP N
at IN N
a DT N
dose NN N
of IN N
5 CD N
x NNS N
10 CD N
( ( N
9 CD N
) ) N
is VBZ N
safe JJ N
and CC N
immunogenic JJ N
in IN N
adults NNS N
from IN N
a DT N
cholera NN N
endemic JJ N
region NN N
-DOCSTART- -X- O O 12790985

Stapled JJ N
mucosectomy NN N
for IN N
acute NN N
thrombosed VBN N
circumferentially RB N
prolapsed JJ N
piles NNS N
: : N
a DT N
prospective JJ N
randomized VBN N
comparison NN N
with IN N
conventional JJ N
haemorrhoidectomy NN N
OBJECTIVE NNP N
Stapled NNP N
mucosectomy NN N
has VBZ N
been VBN N
developed VBN N
as IN N
an DT N
alternative NN N
to TO N
conventional JJ N
haemorrhoidectomy NN N
for IN N
the DT N
elective JJ N
treatment NN N
of IN N
haemorrhoids NNS N
, , N
but CC N
has VBZ N
not RB N
been VBN N
assessed VBN N
in IN N
the DT N
emergency NN N
setting VBG N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
this DT N
technique NN N
with IN N
a DT N
conventional JJ N
procedure NN N
for IN N
acute NN N
thrombosed VBN N
circumferential JJ N
prolapsed JJ N
haemorrhoids NNS N
PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
comparison NN N
of IN N
conventional JJ N
Milligan-Morgan JJ N
haemorrhoidectomy NN N
and CC N
stapled VBD N
mucosectomy NN N
was VBD N
carried VBN N
out RP N
on IN N
35 CD 3_p
consecutive JJ N
patients NNS N
presenting VBG N
with IN N
acute NN 4_p
thrombosed VBN 4_p
circumferential JJ 4_p
prolapsed JJ 4_p
haemorrhoids NNS 4_p
Operative NNP N
data NN N
, , N
postoperative JJ N
stay NN N
, , N
pain NN N
assessment NN N
and CC N
persistent NN N
symptoms NNS N
were VBD N
compared VBN N
at IN N
discharge NN N
and CC N
at IN N
2 CD N
week NN N
and CC N
6 CD N
week NN N
review NN N
Additionally RB N
at IN N
6 CD N
week NN N
review VB N
the DT N
time NN N
to TO N
return VB N
to TO N
work VB N
was VBD N
recorded VBN N
and CC N
an DT N
endoanal JJ N
ultrasound NN N
was VBD N
carried VBN N
out RP N
RESULTS NNP N
Thirty NNP 3_p
patients NNS N
were VBD N
randomized VBN N
and CC N
followed VBN N
up RP N
for IN N
six CD N
weeks NNS N
Although IN N
postoperative JJ N
stay NN N
and CC N
in-hospital JJ N
analgesia NN N
were VBD N
the DT N
same JJ N
, , N
patients NNS N
from IN N
the DT N
stapled VBN N
group NN N
reported VBD N
significantly RB N
more RBR N
pain NN N
at IN N
discharge NN N
However RB N
, , N
by IN N
2 CD N
weeks NNS N
the DT N
conventional JJ N
group NN N
reported VBD N
significantly RB N
higher JJR N
pain NN N
scores NNS N
particularly RB N
on IN N
passing VBG N
stool NN N
By IN N
this DT N
stage NN N
over IN N
half PDT N
the DT N
stapled JJ 3_p
group NN 3_p
patients NNS N
reported VBD N
no DT N
pain NN N
at IN N
all DT N
More JJR N
patients NNS N
in IN N
the DT N
conventional JJ 4_p
group NN 4_p
complained VBD N
of IN N
persistent JJ N
symptoms NNS N
of IN N
pain NN N
, , N
bleeding NN N
and CC N
discharge NN N
at IN N
2 CD N
week NN N
and CC N
6 CD N
week NN N
review NN N
with IN N
20 CD N
% NN N
requiring VBG N
readmission NN N
compared VBN N
with IN N
none NN N
in IN N
the DT N
stapled JJ N
group NN N
The DT N
median JJ N
return NN N
to TO N
work VB N
was VBD N
significantly RB N
shorter JJR N
for IN N
the DT N
stapled VBN N
group NN N
( ( N
14 CD N
days NNS N
vs RB N
28 CD N
days NNS N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
Although IN N
all DT N
patients NNS N
claimed VBD N
to TO N
be VB N
continent JJ N
, , N
two CD N
patients NNS N
from IN N
each DT N
group NN N
had VBD N
ultrasonic JJ N
evidence NN N
of IN N
internal JJ N
sphincter NN N
damage NN N
CONCLUSION NNP N
Stapled VBD N
mucosectomy NN N
for IN N
acute NN N
thrombosed VBN N
circumferential JJ N
piles NNS N
is VBZ N
feasible JJ N
and CC N
may MD N
result VB N
in IN N
less JJR N
pain NN N
, , N
a DT N
more RBR N
rapid JJ N
resolution NN N
of IN N
symptoms NNS N
and CC N
an DT N
earlier JJR N
return NN N
to TO N
work VB N
compared VBN N
with IN N
a DT N
conventional JJ N
procedure NN N
-DOCSTART- -X- O O 15914128

Effects NNS N
of IN N
two CD N
combined JJ N
oral JJ N
contraceptives NNS N
containing VBG N
ethinyl NN N
estradiol $ N
20 CD N
microg NN N
combined VBN N
with IN N
either DT N
drospirenone NN N
or CC N
desogestrel NN N
on IN N
lipids NNS N
, , N
hemostatic JJ N
parameters NNS N
and CC N
carbohydrate JJ N
metabolism NN N
OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
ethinyl NN N
estradiol NN N
20 CD N
microg/drospirenone NN N
3 CD N
mg NN N
( ( N
EE NNP N
20 CD N
microg/DRSP NN N
3 CD N
mg NN N
) ) N
administered VBD N
according VBG N
to TO N
a DT N
24/4 JJ N
regimen NN N
with IN N
ethinyl JJ N
estradiol NN N
20 CD N
microg/desogestrel NN N
150 CD N
microg NN N
( ( N
EE NNP N
20 CD N
microg/DSG NN N
150 CD N
microg NN N
) ) N
administered VBD N
according VBG N
to TO N
the DT N
conventional JJ N
21/7 CD N
regimen NNS N
on IN N
lipid JJ N
, , N
carbohydrate NN N
and CC N
hemostatic JJ N
parameters NNS N
STUDY NNP N
DESIGN NNP N
In IN N
this DT N
open-label JJ N
study NN N
, , N
healthy JJ 4_p
women NNS 2_p
were VBD N
randomized VBN N
to TO N
EE VB N
20 CD N
microg/DRSP NN N
3 CD N
mg NN N
or CC N
EE NNP N
20 CD N
microg/DSG NN N
150 CD N
microg NN N
for IN N
seven CD N
cycles NNS N
Mean JJ N
differences NNS N
in IN N
high-density NN N
lipoprotein NN N
( ( N
HDL NNP N
) ) N
- : N
and CC N
low-density JJ N
lipoprotein NN N
( ( N
LDL NNP N
) ) N
-cholesterol NN N
levels NNS N
at IN N
cycle NN N
7 CD N
compared VBN N
to TO N
baseline VB N
were VBD N
assessed VBN N
Secondary JJ N
variables NNS N
included VBD N
changes NNS N
in IN N
other JJ N
lipid JJ N
, , N
hemostatic JJ N
and CC N
carbohydrate JJ N
parameters NNS N
RESULTS NNP N
Both NNP N
treatments NNS N
increased VBD N
HDL-cholesterol NNP N
, , N
but CC N
decreased VBD N
LDL-cholesterol NNP N
by IN N
a DT N
comparable JJ N
extent NN N
Although IN N
slightly RB N
elevated VBN N
in IN N
both DT N
groups NNS N
, , N
blood NN N
glucose NN N
and CC N
C-peptide JJ N
levels NNS N
measured VBN N
during IN N
oral JJ N
glucose JJ N
tolerance NN N
tests NNS N
were VBD N
within IN N
normal JJ N
reference NN N
ranges VBZ N
at IN N
cycle NN N
7 CD N
Overall JJ N
, , N
the DT N
differences NNS N
in IN N
lipid JJ N
, , N
hemostatic JJ N
or CC N
carbohydrate JJ N
parameters NNS N
were VBD N
not RB N
significant JJ N
between IN N
the DT N
two CD N
treatments NNS N
CONCLUSION NNP N
EE NNP N
20 CD N
microg/DRSP NN N
3 CD N
mg NN N
has VBZ N
a DT N
good JJ N
safety NN N
profile NN N
comparable JJ N
with IN N
EE NNP N
20 CD N
microg/DSG NN N
150 CD N
microg NN N
-DOCSTART- -X- O O 16950955

A DT N
controlled VBN N
, , N
randomized VBN N
, , N
double-blind JJ N
trial NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
supplement NN N
of IN N
cocoa NN N
husk NN N
that WDT N
is VBZ N
rich JJ N
in IN N
dietary JJ N
fiber NN N
on IN N
colonic JJ N
transit NN N
in IN N
constipated JJ 4_p
pediatric JJ 1_p
patients NNS 4_p
OBJECTIVE NNP N
Although IN N
a DT N
diet JJ N
that WDT N
is VBZ N
rich JJ N
in IN N
fiber NN N
is VBZ N
widely RB N
recommended VBN N
for IN N
preventing VBG N
and CC N
treating VBG N
constipation NN N
, , N
the DT N
efficacy NN N
of IN N
fiber NN N
supplements NNS N
have VBP N
not RB N
been VBN N
tested VBN N
sufficiently RB N
in IN N
children NNS 1_p
Our PRP$ N
aim NN N
with IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
evaluate VB N
if IN N
fiber JJ N
supplementation NN N
is VBZ N
beneficial JJ N
for IN N
the DT N
treatment NN N
of IN N
children NNS N
with IN N
idiopathic JJ N
chronic JJ N
constipation NN N
METHODS NNP N
Using VBG N
a DT N
parallel NN N
, , N
randomized VBN N
, , N
double-blind NN N
, , N
controlled VBN N
trial NN N
, , N
we PRP N
conducted VBD N
an DT N
interventional JJ N
study NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
supplement NN N
of IN N
cocoa NN N
husk NN N
rich JJ N
in IN N
dietary JJ N
fiber NN N
on IN N
intestinal JJ N
transit NN N
time NN N
and CC N
other JJ N
indices NNS N
of IN N
constipation NN N
in IN N
children NNS 4_p
with IN 4_p
constipation NN 4_p
After IN N
screening VBG N
, , N
the DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
, , N
for IN N
a DT N
period NN N
of IN N
4 CD N
weeks NNS N
, , N
either CC N
a DT N
cocoa NN N
husk NN N
supplement NN N
or CC N
placebo NN N
plus CC N
standardized JJ N
toilet NN N
training NN N
procedures NNS N
Before IN N
and CC N
after IN N
4 CD N
weeks NNS N
of IN N
treatment NN N
, , N
we PRP N
( ( N
1 CD N
) ) N
performed VBD N
anthropometry NN N
, , N
a DT N
physical JJ N
examination NN N
, , N
and CC N
routine JJ N
laboratory NN N
measurements NNS N
, , N
( ( N
2 CD N
) ) N
determined VBN N
total JJ N
and CC N
segmental JJ N
colonic JJ N
transit NN N
time NN N
, , N
( ( N
3 CD N
) ) N
evaluated VBD N
bowel JJ N
movement NN N
habits NNS N
and CC N
stool NN N
consistency NN N
using VBG N
a DT N
diary JJ N
, , N
and CC N
( ( N
4 CD N
) ) N
received VBD N
a DT N
subjective JJ N
evaluation NN N
from IN N
the DT N
parents NNS N
regarding VBG N
the DT N
efficacy NN N
of IN N
the DT N
treatment NN N
The DT N
main JJ N
variable NN N
for IN N
verifying VBG N
the DT N
efficacy NN N
of IN N
the DT N
treatment NN N
was VBD N
the DT N
total JJ N
colonic JJ N
transit NN N
time NN N
RESULTS VB N
Fifty-six NNP 3_p
chronically RB 4_p
constipated VBD 4_p
children NNS 4_p
were VBD 4_p
randomly RB 4_p
assigned VBN 4_p
into IN 4_p
the DT 4_p
study NN 4_p
, , 4_p
but CC 4_p
only RB 4_p
48 CD 3_p
children NNS 4_p
completed VBD 4_p
it PRP 4_p
These DT N
children NNS N
, , N
who WP N
were VBD N
aged VBN N
between IN N
3 CD 1_p
and CC 1_p
10 CD 1_p
years NNS 1_p
, , N
had VBD N
a DT N
diagnosis NN N
of IN N
chronic JJ 4_p
idiopathic JJ 4_p
constipation NN 4_p
With IN N
respect NN N
to TO N
total JJ N
, , N
partial JJ N
colon NN N
, , N
and CC N
rectum VB N
transit NN N
time NN N
, , N
there EX N
seemed VBN N
to TO N
be VB N
a DT N
trend NN N
, , N
although IN N
statistically RB N
nonsignificant JJ N
, , N
toward IN N
faster JJR N
transit NN N
times NNS N
in IN N
the DT N
cocoa NN N
husk NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
When WRB N
we PRP N
analyzed VBD N
the DT N
evolution NN N
of IN N
the DT N
intestinal JJ N
transit NN N
time NN N
throughout IN N
the DT N
study NN N
of IN N
children NNS N
whose WP$ N
total JJ N
basal JJ N
intestinal JJ N
transit NN N
time NN N
was VBD N
> JJ N
50th JJ N
percentile NN N
, , N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
groups NNS N
The DT N
total JJ N
transit NN N
time NN N
decreased VBN N
by IN N
45.4 CD N
+/- JJ N
38.4 CD N
hours NNS N
in IN N
the DT N
cocoa NN N
husk NN N
group NN N
and CC N
by IN N
8.7 CD N
+/- JJ N
28.9 CD N
hours NNS N
in IN N
the DT N
placebo NN N
group NN N
( ( N
-38.1 NNP N
hours NNS N
) ) N
In IN N
the DT N
case NN N
of IN N
the DT N
right JJ N
colon NN N
, , N
changes NNS N
in IN N
transit NN N
time NN N
also RB N
were VBD N
significant JJ N
between IN N
groups NNS N
Mean NNP N
changes NNS N
tended VBD N
toward IN N
faster RBR N
transit NN N
times NNS N
in IN N
the DT N
left NN N
colon NN N
and CC N
the DT N
rectum NN N
, , N
although IN N
the DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
The DT N
children NNS N
who WP N
received VBD N
cocoa NN N
husk NN N
supplements NNS N
tended VBD N
to TO N
increase VB N
the DT N
number NN N
of IN N
bowel NN N
movements NNS N
by IN N
more JJR N
than IN N
that DT N
of IN N
the DT N
children NNS N
of IN N
the DT N
placebo NN N
group NN N
We PRP N
also RB N
observed VBD N
a DT N
reduction NN N
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
reported VBD N
hard JJ N
stools NNS N
( ( N
hard JJ N
scybalous JJ N
or CC N
pebble-like JJ N
stools NNS N
) ) N
, , N
although IN N
this DT N
reduction NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
cocoa NN N
husk NN N
group NN N
At IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
, , N
41.7 CD N
% NN N
and CC N
75.0 CD N
% NN N
of IN N
the DT N
patients NNS N
who WP N
received VBD N
cocoa NN N
husk NN N
supplementation NN N
or CC N
placebo NN N
, , N
respectively RB N
, , N
reported VBD N
having VBG N
hard JJ N
stools NNS N
Moreover RB N
, , N
a DT N
significantly RB N
higher JJR N
number NN N
of IN N
children NNS N
( ( N
or CC N
their PRP$ N
parents NNS N
) ) N
reported VBD N
a DT N
subjective JJ N
improvement NN N
in IN N
stool JJ N
consistency NN N
No DT N
significant JJ N
adverse JJ N
effects NNS N
were VBD N
reported VBN N
during IN N
the DT N
study NN N
CONCLUSIONS NNP N
This DT N
study NN N
confirms VBZ N
the DT N
beneficial JJ N
effect NN N
of IN N
a DT N
supplement NN N
of IN N
cocoa NN N
husk NN N
that WDT N
is VBZ N
rich JJ N
in IN N
dietary JJ N
fiber NN N
on IN N
chronic JJ N
idiopathic JJ N
constipation NN N
in IN N
children NNS N
These DT N
benefits NNS N
seem VBP N
to TO N
be VB N
more RBR N
evident JJ N
in IN N
pediatric JJ N
constipated JJ N
patients NNS N
with IN N
slow JJ N
colonic JJ N
transit NN N
time NN N
-DOCSTART- -X- O O 19713225

Arterial NNP N
cardiovascular JJ N
risk NN N
factors NNS N
and CC N
venous JJ N
thrombosis NN N
: : N
results NNS N
from IN N
a DT N
population-based JJ N
, , N
prospective JJ N
study NN N
( ( N
the DT N
HUNT NNP N
2 CD N
) ) N
BACKGROUND NNP N
An DT N
explanation NN N
for IN N
the DT N
increased VBN N
risk NN N
of IN N
myocardial JJ N
infarction NN N
and CC N
stroke NN N
in IN N
patients NNS 4_p
with IN 4_p
venous JJ 4_p
thrombosis NN 4_p
is VBZ N
lacking VBG N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
risk NN N
factors NNS N
for IN N
arterial JJ N
cardiovascular JJ N
disease NN N
also RB N
increase VBZ N
the DT N
risk NN N
of IN N
venous JJ N
thrombosis NN N
DESIGN NNP N
AND CC N
METHODS NNP N
Cases NNP N
who WP N
had VBD N
a DT N
first JJ N
venous JJ N
thrombosis NN N
( ( N
n=515 JJ N
) ) N
and CC N
matched VBN N
controls NNS N
( ( N
n=1,505 NN N
) ) N
were VBD N
identified VBN N
from IN N
a DT N
population-based JJ N
, , N
nested JJ N
, , N
case-cohort JJ N
study NN N
( ( N
the DT N
HUNT NNP N
2 CD N
study NN N
) ) N
comprising VBG N
71 CD N
% NN N
( ( N
n=66,140 JJ N
) ) N
of IN N
the DT N
adult NN N
residents NNS N
of IN N
Nord-Trøndelag NNP N
County NNP N
in IN N
Norway NNP N
RESULTS VB N
The DT N
age- JJ N
and CC N
sex-adjusted JJ N
odds NNS N
ratio NN N
of IN N
venous JJ N
thrombosis NN N
for IN N
subjects NNS N
with IN N
concentrations NNS N
of IN N
C-reactive JJ N
protein NN N
in IN N
the DT N
highest JJS N
quintile NN N
was VBD N
1.6 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
1.2-2.2 JJ N
) ) N
compared VBN N
to TO N
subjects NNS N
with IN N
C-reactive JJ N
protein NN N
in IN N
the DT N
lowest JJS N
quintile NN N
This DT N
association NN N
was VBD N
strongest VBN N
in IN N
subjects NNS N
who WP N
experienced VBD N
venous JJ N
thrombosis NN N
within IN N
a DT N
year NN N
after IN N
blood NN N
sampling VBG N
with IN N
a DT N
three-fold JJ N
increased JJ N
risk NN N
of IN N
participants NNS N
in IN N
the DT N
highest JJS N
versus NN N
the DT N
lowest JJS N
quintile NN N
Having VBG N
first JJ N
degree JJ N
relatives NNS N
who WP N
had VBD N
a DT N
myocardial JJ N
infarction NN N
before IN N
the DT N
age NN N
of IN N
60 CD N
years NNS N
was VBD N
positively RB N
associated VBN N
with IN N
venous JJ N
thrombosis NN N
compared VBN N
to TO N
not RB N
having VBG N
a DT N
positive JJ N
family NN N
history NN N
[ NNP N
odds VBZ N
ratio NN N
1.3 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
1.1-1.6 JJ N
) ) N
] NN N
Subjects NNS N
with IN N
blood NN N
pressure NN N
in IN N
the DT N
highest JJS N
quintile NN N
had VBD N
half PDT N
the DT N
risk NN N
of IN N
developing VBG N
venous JJ N
thrombosis NN N
compared VBN N
to TO N
subjects NNS N
whose WP$ N
blood NN N
pressure NN N
was VBD N
in IN N
the DT N
lowest JJS N
quintile NN N
There EX N
were VBD N
no DT N
associations NNS N
between IN N
the DT N
risk NN N
of IN N
venous JJ N
thrombosis NN N
and CC N
total JJ N
cholesterol NN N
, , N
low JJ N
density NN N
lipoprotein-cholesterol NN N
, , N
high JJ N
density NN N
lipoprotein-cholesterol NN N
, , N
triglycerides NNS N
, , N
glucose NN N
or CC N
smoking NN N
We PRP N
confirmed VBD N
the DT N
positive JJ N
association NN N
between IN N
obesity NN N
and CC N
venous JJ N
thrombosis NN N
CONCLUSIONS NNP N
C-reactive JJ N
protein NN N
and CC N
a DT N
family NN N
history NN N
of IN N
myocardial JJ N
infarction NN N
were VBD N
positively RB N
associated VBN N
with IN N
subsequent JJ N
venous JJ N
thrombosis NN N
Blood NNP N
pressure NN N
was VBD N
inversely RB N
correlated VBN N
to TO N
venous JJ N
thrombosis NN N
These DT N
findings NNS N
should MD N
be VB N
confirmed VBN N
by IN N
further JJ N
investigations NNS N
-DOCSTART- -X- O O 18855271

The DT N
effect NN N
of IN N
trandolapril NN N
and CC N
its PRP$ N
fixed-dose JJ N
combination NN N
with IN N
verapamil NN N
on IN N
circulating VBG N
adhesion NN N
molecules NNS N
levels NNS N
in IN N
hypertensive JJ 4_p
patients NNS 4_p
with IN 4_p
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
BACKGROUND NNP N
AND NNP N
AIM NNP N
Endothelial NNP N
dysfunction NN N
in IN N
hypertensive JJ 4_p
type-2 JJ 4_p
diabetic JJ 4_p
patients NNS N
is VBZ N
associated VBN N
with IN N
increased JJ N
levels NNS N
of IN N
circulating VBG N
soluble JJ N
adhesion NN N
molecules NNS N
( ( N
SAM NNP N
) ) N
SAM NNP N
participate VB N
in IN N
the DT N
development NN N
of IN N
diabetic JJ N
macroangiopathy NN N
and CC N
microangiopathy NN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
trandolapril NN N
( ( N
T NNP N
) ) N
and CC N
its PRP$ N
fixed-dose JJ N
combination NN N
with IN N
verapamil NN N
( ( N
FDTV NNP N
) ) N
on IN N
SAM NNP N
levels NNS N
in IN N
hypertensive JJ 4_p
type-2 JJ 4_p
diabetic JJ 4_p
patients NNS N
METHODS NNP N
Forty NNP 3_p
type-2 JJ 4_p
diabetic JJ 4_p
patients NNS N
with IN N
never-treated JJ N
hypertension NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
One CD N
group NN N
( ( N
FDTV NNP N
) ) N
received VBD N
2/180 CD N
mg NN N
once RB N
a DT N
day NN N
; : N
the DT N
other JJ N
group NN N
received VBD N
T NNP N
2 CD N
mg NN N
once RB N
a DT N
day NN N
Study NNP N
drugs NNS N
were VBD N
administered VBN N
for IN N
three CD N
months NNS N
in IN N
both DT N
groups NNS N
VCAM-1 NNP N
, , N
ICAM NNP N
, , N
and CC N
E-selectin NNP N
were VBD N
measured VBN N
by IN N
ELISA NNP N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
study NN N
Patients NNS N
were VBD N
evaluated VBN N
monthly RB N
for IN N
blood NN N
pressure NN N
, , N
fasting VBG N
serum NN N
glucose NN N
, , N
and CC N
adverse JJ N
events NNS N
Statistical JJ N
analysis NN N
was VBD N
performed VBN N
with IN N
ANOVA NNP N
RESULTS NNP N
Both NNP N
therapeutics NNS N
regimens NNS N
reduced VBD N
significantly RB N
the DT N
levels NNS N
of IN N
the DT N
SAM NNP N
tested VBD N
When WRB N
both DT N
groups NNS N
were VBD N
compared VBN N
, , N
we PRP N
did VBD N
not RB N
find VB N
a DT N
significant JJ N
difference NN N
in IN N
ICAM NNP N
and CC N
E-selectin NNP N
reduction NN N
However RB N
, , N
VCAM-1 NNP N
presented VBD N
a DT N
significantly RB N
greater JJR N
reduction NN N
( ( N
p JJ N
= NNP N
0.022 CD N
) ) N
in IN N
the DT N
trandolapril-verapamil JJ N
group NN N
No DT N
patient NN N
suffered VBD N
adverse JJ N
events NNS N
CONCLUSION NNP N
Our PRP$ N
results NNS N
show VBP N
that IN N
FDTV NNP N
produces VBZ N
a DT N
greater JJR N
reduction NN N
of IN N
VCAM-1 NNP N
circulating NN N
levels NNS N
than IN N
trandolapril NN N
alone RB N
This DT N
may MD N
explain VB N
some DT N
of IN N
the DT N
beneficial JJ N
effects NNS N
of IN N
this DT N
fixed VBN N
dosed JJ N
combination NN N
that WDT N
are VBP N
non-related JJ N
to TO N
its PRP$ N
antihypertensive JJ N
effects NNS N
-DOCSTART- -X- O O 22527308

Successful JJ N
treatment NN N
of IN N
blepharitis NN 4_p
with IN N
bibrocathol NN N
( ( N
Posiformin® NNP N
2 CD N
% NN N
) ) N
BACKGROUND NNP N
Bibrocathol NNP N
is VBZ N
a DT N
well-established JJ N
antiseptic JJ N
drug NN N
for IN N
the DT N
treatment NN N
of IN N
acute NN N
eyelid JJ N
diseases NNS N
like IN N
blepharitis NN N
Despite IN N
its PRP$ N
frequent JJ N
use NN N
in IN N
clinical JJ N
practice NN N
, , N
no DT N
controlled JJ N
clinical JJ N
trial NN N
on IN N
the DT N
efficacy NN N
of IN N
bibrocathol $ N
2 CD N
% NN N
eye NN N
ointment NN N
has VBZ N
been VBN N
performed VBN N
until IN N
now RB N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
efficacy NN N
, , N
safety NN N
and CC N
tolerability NN N
of IN N
bibrocathol NN N
( ( N
Posiformin® NNP N
2 CD N
% NN N
) ) N
eye NN N
ointment NN N
in IN N
patients NNS N
diagnosed VBN N
with IN N
blepharitis NN N
METHODS NNP N
In IN N
this DT N
multi-center NN N
, , N
randomized VBN N
, , N
double-masked JJ N
, , N
placebo-controlled JJ N
parallel-group NN N
comparison NN N
, , N
the DT N
change NN N
of IN N
signs NNS N
and CC N
symptoms NNS N
( ( N
sum VB N
score NN N
) ) N
of IN N
blepharitis NN N
in IN N
197 CD N
patients NNS N
( ( N
ITT NNP N
( ( N
intention-to-treat-group JJ N
) ) N
; : N
mean JJ N
age NN N
56 CD N
± JJ N
18 CD N
years NNS N
, , N
56 CD N
% NN N
female NN N
, , N
active JJ N
drug NN N
: : N
vehicle NN N
= IN N
97:100 CD N
) ) N
over IN N
2 CD N
weeks NNS N
treatment NN N
with IN N
bibrocathol JJ N
2 CD N
% NN N
eye NN N
ointment NN N
was VBD N
evaluated VBN N
RESULTS JJ N
Patients NNPS N
receiving VBG N
bibrocathol RB N
2 CD N
% NN N
showed VBD N
greater JJR N
improvement NN N
in IN N
the DT N
sum NN N
score NN N
than IN N
the DT N
placebo NN N
patients NNS N
( ( N
p JJ N
< NN N
0.0001 CD N
, , N
Cohen NNP N
's POS N
effect NN N
size NN N
d NN N
= NNP N
0.73 CD N
) ) N
Also RB N
, , N
the DT N
results NNS N
from IN N
further JJ N
efficacy NN N
assessments NNS N
improvement NN N
of IN N
single JJ N
symptoms NNS N
and CC N
ocular JJ N
discomfort NN N
measured VBN N
by IN N
a DT N
VAS NNP N
( ( N
visual JJ N
analogue NN N
scale NN N
) ) N
supported VBD N
treatment NN N
with IN N
bibrocathol NN N
Patients NNS N
and CC N
investigators NNS N
provided VBD N
favorable JJ N
tolerability NN N
ratings NNS N
preferring VBG N
bibrocathol NN N
over IN N
placebo NN N
No DT N
safety NN N
issues NNS N
were VBD N
observed VBN N
with IN N
regard NN N
to TO N
intraocular JJ N
pressure NN N
, , N
visual JJ N
acuity NN N
, , N
or CC N
occurrence NN N
of IN N
adverse JJ N
events NNS N
CONCLUSIONS NNP N
Blepharitis NNP N
therapy NN N
with IN N
the DT N
antiseptic JJ N
bibrocathol NN N
2 CD N
% NN N
in IN N
this DT N
trial NN N
was VBD N
highly RB N
efficacious JJ N
and CC N
safe JJ N
-DOCSTART- -X- O O 2968595

[ JJ N
Effects NNS N
of IN N
simvastatin NN N
on IN N
plasma NN N
lipids NNS N
, , N
lipoproteins NNS N
and CC N
apoproteins NNS N
( ( N
A1 NNP N
and CC N
B NNP N
) ) N
24 CD N
cases NNS N
of IN N
major JJ N
primary JJ N
hypercholesterolemia NN 4_p
] NN N
We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
simvastatin NN N
( ( N
MK NNP N
733 CD N
) ) N
, , N
a DT N
new JJ N
competitive JJ N
inhibitor NN N
of IN N
HMG NNP N
CoA NNP N
reductase NN N
, , N
alone RB N
and CC N
in IN N
combination NN N
with IN N
a DT N
bile JJ N
acid NN N
sequestrant NN N
, , N
cholestyramine NN N
, , N
on IN N
serum NN N
levels NNS N
of IN N
lipoproteins NNS N
and CC N
apoproteins NNS N
A1 NNP N
and CC N
B NNP N
, , N
in IN N
24 CD 3_p
patients NNS N
with IN N
familial JJ 4_p
hypercholesterolemia NN 4_p
After IN N
simvastatin JJ N
treatment NN N
( ( N
40 CD N
mg/day NN N
) ) N
alone RB N
for IN N
12 CD N
weeks NNS N
, , N
serum JJ N
total NN N
and CC N
low JJ N
density NN N
lipoprotein NN N
cholesterol NN N
decreased VBN N
by IN N
31 CD N
and CC N
36 CD N
percent NN N
respectively RB N
With IN N
the DT N
addition NN N
of IN N
cholestyramine NN N
, , N
there EX N
was VBD N
a DT N
41 CD N
per IN N
cent NN N
total JJ N
decrease NN N
in IN N
serum NN N
cholesterol NN N
from IN N
the DT N
control NN N
value NN N
and CC N
a DT N
50 CD N
percent NN N
decrease NN N
in IN N
low JJ N
density NN N
lipoprotein NN N
cholesterol NN N
After IN N
cholestyramine JJ N
treatment NN N
alone RB N
for IN N
12 CD N
weeks NNS N
, , N
serum JJ N
total NN N
and CC N
low JJ N
density NN N
lipoprotein NN N
cholesterol NN N
decreased VBN N
by IN N
20 CD N
percent NN N
and CC N
29 CD N
percent NN N
respectively RB N
With IN N
the DT N
addition NN N
of IN N
simvastatin NN N
( ( N
20 CD N
mg NNS N
per IN N
day NN N
) ) N
, , N
there EX N
was VBD N
a DT N
32 CD N
percent NN N
total JJ N
decrease NN N
in IN N
serum NN N
cholesterol NN N
from IN N
the DT N
control NN N
value NN N
and CC N
a DT N
43 CD N
percent NN N
decrease NN N
in IN N
low JJ N
density NN N
lipoprotein NN N
cholesterol NN N
High JJ N
density NN N
lipoprotein VBP N
cholesterol NN N
remained VBD N
unchanged JJ N
No DT N
major JJ N
adverse JJ N
effect NN N
was VBD N
observed VBN N
If IN N
long JJ N
term NN N
safety NN N
can MD N
be VB N
confirmed VBN N
, , N
the DT N
simvastatin-cholestyramine JJ N
regimen NNS N
may MD N
prove VB N
useful JJ N
in IN N
heterozygous JJ 4_p
familial JJ 4_p
hypercholesterolemia NN 4_p
-DOCSTART- -X- O O 25279666

Dental NNP 4_p
prophylaxis NN 4_p
decreases VBZ 4_p
the DT N
risk NN N
of IN N
esophageal JJ 4_p
cancer NN 4_p
in IN N
males NNS 2_p
; : N
a DT N
nationwide JJ N
population-based JJ N
study NN N
in IN N
Taiwan NNP N
BACKGROUND NNP N
Periodontal NNP N
disease NN N
( ( N
PD NNP N
) ) N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
common JJ N
chronic JJ N
inflammatory NN N
diseases NNS N
Esophageal NN 4_p
cancer NN 4_p
( ( 4_p
EC NNP 4_p
) ) 4_p
is VBZ N
also RB N
a DT N
common JJ N
cause NN N
of IN N
death NN N
due JJ N
to TO N
cancer NN 4_p
among IN N
males NNS 2_p
Systemic NNP N
inflammatory NN N
processes NNS N
have VBP N
been VBN N
shown VBN N
to TO N
increase VB N
the DT N
risk NN N
of IN N
cancer NN N
We PRP N
conducted VBD N
a DT N
retrospective JJ N
cohort NN N
study NN N
to TO N
investigate VB N
the DT N
association NN N
between IN N
PD NNP N
and CC N
EC NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
718,409 CD 3_p
subjects NNS N
were VBD N
recruited VBN N
from IN N
the DT N
Taiwan NNP N
National NNP 4_p
Health NNP 4_p
Insurance NNP 4_p
Research NNP 4_p
Database NNP 4_p
( ( 4_p
NHIRD NNP 4_p
) ) N
and CC N
followed VBN N
from IN N
January NNP N
1 CD N
, , N
2000 CD N
to TO N
December NNP N
31 CD N
, , N
2010 CD N
Of IN N
these DT N
, , N
519,831 CD 3_p
subjects NNS N
were VBD N
diagnosed VBN N
with IN N
PD NNP N
and CC N
were VBD N
grouped VBN N
according VBG N
to TO N
the DT N
most RBS N
advanced JJ N
treatment NN N
they PRP N
received VBD N
: : N
dental JJ N
prophylaxis NN N
, , N
intensive JJ N
treatment NN N
, , N
or CC N
no DT N
treatment NN N
The DT N
IRs NNP N
of IN N
EC NNP N
were VBD N
compared VBN N
among IN N
groups NNS N
RESULTS VB N
A DT N
total NN N
of IN N
682 CD 3_p
patients NNS N
developed VBD N
EC NNP N
, , N
resulting VBG N
in IN N
an DT N
overall JJ N
IR NNP N
of IN N
0.11 CD N
case-number JJ N
per IN N
1000 CD N
person-years NNS N
( ( N
‰/y NN N
) ) N
The DT N
dental JJ N
prophylaxis NN N
group NN N
had VBD N
a DT N
significantly RB N
lower JJR N
IR NNP N
of IN N
EC NNP N
( ( N
0.06‰/y CD N
) ) N
than IN N
other JJ N
groups NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
Multivariable JJ N
Cox NNP N
regression NN N
analysis NN N
further RBR N
revealed VBD N
that IN N
male JJ 2_p
subjects NNS N
[ JJ N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
= VBD N
10.04 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
= VBD N
7.58-13.30 JJ N
] NN N
, , N
as RB N
well RB N
as IN N
a DT N
history NN N
of IN N
esophageal JJ N
ulcers NNS N
( ( N
HR NNP N
= NNP N
7.10 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
5.03-10.01 JJ N
) ) N
, , N
alcohol NN N
abuse NN N
( ( N
HR NNP N
= NNP N
5.46 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
2.26-13.18 JJ N
) ) N
, , N
or CC N
esophageal VB N
reflux NN N
( ( N
HR NNP N
= NNP N
1.86 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
1.02-3.52 JJ N
) ) N
, , N
were VBD N
factors NNS N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
of IN N
EC NNP N
And CC N
the DT N
dental JJ N
prophylaxis NN N
group NN N
showed VBD N
a DT N
significantly RB N
lower JJR N
risk NN N
for IN N
EC NNP N
( ( N
HR NNP N
= NNP N
0.53 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
0.44-0.65 NN N
) ) N
Further NNP N
subgroup NN N
analysis NN N
showed VBD N
that IN N
the DT N
dental JJ N
prophylaxis NN N
group NN N
among IN N
males NNS N
had VBD N
a DT N
significant JJ N
lower JJR N
risk NN N
( ( N
HR NNP N
= NNP N
0.54 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
0.44-0.66 NN N
) ) N
for IN N
EC NNP N
, , N
while IN N
that DT N
of IN N
the DT N
females NNS N
did VBD N
not RB N
has VBZ N
statistically RB N
significant JJ N
difference NN N
CONCLUSION NN N
For IN N
this DT N
cohort NN N
, , N
subjects VBZ N
received VBN N
dental JJ N
prophylaxis NN N
reduced VBD N
the DT N
risk NN N
of IN N
EC NNP N
compared VBN N
to TO N
all DT N
PD NNP N
and CC N
no DT N
PD NNP N
groups NNS N
among IN N
males NNS N
-DOCSTART- -X- O O 20415897

A DT N
phase NN N
III NNP N
study NN N
of IN N
belatacept-based JJ N
immunosuppression NN N
regimens NNS N
versus VBP N
cyclosporine NN N
in IN N
renal JJ 4_p
transplant NN 4_p
recipients NNS 4_p
( ( N
BENEFIT NNP N
study NN N
) ) N
Belatacept NNP N
, , N
a DT N
costimulation NN N
blocker NN N
, , N
may MD N
preserve VB N
renal JJ N
function NN N
and CC N
improve VB N
long-term JJ N
outcomes NNS N
versus IN N
calcineurin JJ N
inhibitors NNS N
in IN N
kidney NN N
transplantation NN N
This DT N
Phase NNP N
III NNP N
study NN N
( ( N
Belatacept NNP N
Evaluation NNP N
of IN N
Nephroprotection NNP N
and CC N
Efficacy NNP N
as IN N
First-line NNP N
Immunosuppression NNP N
Trial NNP N
) ) N
assessed VBD N
a DT N
more RBR N
intensive JJ N
( ( N
MI NNP N
) ) N
or CC N
less RBR N
intensive JJ N
( ( N
LI NNP N
) ) N
regimen NNS N
of IN N
belatacept JJ N
versus NN N
cyclosporine NN N
in IN N
adults NNS 1_p
receiving VBG N
a DT N
kidney NN 4_p
transplant NN 4_p
from IN N
living NN N
or CC N
standard JJ N
criteria NNS N
deceased VBN N
donors NNS N
The DT N
co-primary JJ N
endpoints NNS N
at IN N
12 CD N
months NNS N
were VBD N
patient/graft JJ N
survival NN N
, , N
a DT N
composite JJ N
renal JJ N
impairment NN N
endpoint NN N
( ( N
percent NN N
with IN N
a DT N
measured JJ N
glomerular JJ N
filtration NN N
rate NN N
( ( N
mGFR NN N
) ) N
< VBZ N
60 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
at IN N
Month NNP N
12 CD N
or CC N
a DT N
decrease NN N
in IN N
mGFR JJ N
> NN N
or CC N
=10 VB N
mL/min/1.73 JJ N
m NN N
( ( N
2 CD N
) ) N
Month NNP N
3-Month JJ N
12 CD N
) ) N
and CC N
the DT N
incidence NN N
of IN N
acute JJ N
rejection NN N
At IN N
Month NNP N
12 CD N
, , N
both DT N
belatacept IN N
regimens NNS N
had VBD N
similar JJ N
patient/graft NN N
survival NN N
versus NN N
cyclosporine NN N
( ( N
MI NNP N
: : N
95 CD N
% NN N
, , N
LI NNP N
: : N
97 CD N
% NN N
and CC N
cyclosporine NN N
: : N
93 CD N
% NN N
) ) N
, , N
and CC N
were VBD N
associated VBN N
with IN N
superior JJ N
renal JJ N
function NN N
as IN N
measured VBN N
by IN N
the DT N
composite JJ N
renal JJ N
impairment NN N
endpoint NN N
( ( N
MI NNP N
: : N
55 CD N
% NN N
; : N
LI NNP N
: : N
54 CD N
% NN N
and CC N
cyclosporine NN N
: : N
78 CD N
% NN N
; : N
p CC N
< CD N
or CC N
= VB N
0.001 CD N
MI NNP N
or CC N
LI NNP N
versus IN N
cyclosporine NN N
) ) N
and CC N
by IN N
the DT N
mGFR NN N
( ( N
65 CD N
, , N
63 CD N
and CC N
50 CD N
mL/min NN N
for IN N
MI NNP N
, , N
LI NNP N
and CC N
cyclosporine NN N
; : N
p CC N
< CD N
or CC N
= VB N
0.001 CD N
MI NNP N
or CC N
LI NNP N
versus IN N
cyclosporine NN N
) ) N
Belatacept IN N
patients NNS N
experienced VBD N
a DT N
higher JJR N
incidence NN N
( ( N
MI NNP N
: : N
22 CD N
% NN N
, , N
LI NNP N
: : N
17 CD N
% NN N
and CC N
cyclosporine NN N
: : N
7 CD N
% NN N
) ) N
and CC N
grade NN N
of IN N
acute JJ N
rejection NN N
episodes NNS N
Safety NN N
was VBD N
generally RB N
similar JJ N
between IN N
groups NNS N
, , N
but CC N
posttransplant JJ N
lymphoproliferative JJ N
disorder NN N
was VBD N
more RBR N
common JJ N
in IN N
the DT N
belatacept NN N
groups NNS N
Belatacept NNP N
was VBD N
associated VBN N
with IN N
superior JJ N
renal JJ N
function NN N
and CC N
similar JJ N
patient/graft NN N
survival NN N
versus NN N
cyclosporine NN N
at IN N
1 CD N
year NN N
posttransplant NN N
, , N
despite IN N
a DT N
higher JJR N
rate NN N
of IN N
early JJ N
acute JJ N
rejection NN N
-DOCSTART- -X- O O 14521638

Randomized VBN N
controlled JJ N
trial NN N
of IN N
education NN N
and CC N
feedback NN N
for IN N
implementation NN N
of IN N
guidelines NNS N
for IN N
acute NN N
low JJ N
back RB N
pain NN N
OBJECTIVE CC N
The DT N
effect NN N
of IN N
clinical JJ N
guidelines NNS N
on IN N
resource NN N
utilization NN N
for IN N
complex JJ N
conditions NNS N
with IN N
substantial JJ N
barriers NNS N
to TO N
clinician JJ N
behavior NN N
change NN N
has VBZ N
not RB N
been VBN N
well RB N
studied VBN N
We PRP N
report VBP N
the DT N
impact NN N
of IN N
a DT N
multifaceted JJ N
guideline NN N
implementation NN N
intervention NN N
on IN N
primary JJ N
care NN N
clinician JJ N
utilization NN N
of IN N
radiologic NN N
and CC N
specialty NN N
services NNS N
for IN N
the DT N
care NN N
of IN N
acute NN N
low JJ N
back RB N
pain NN N
DESIGN NNP N
Physician JJ N
groups NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
guideline JJ N
education NN N
and CC N
individual JJ N
feedback NN N
, , N
supporting VBG N
patient JJ N
education NN N
materials NNS N
, , N
both DT N
, , N
or CC N
neither RB N
The DT N
impact NN N
on IN N
guideline NN N
adherence NN N
and CC N
resource NN N
utilization NN N
was VBD N
evaluated VBN N
during IN N
the DT N
12-month JJ N
period NN N
before IN N
and CC N
after IN N
implementation NN N
PARTICIPANTS NNP N
Fourteen NNP 3_p
physician JJ N
groups NNS N
with IN N
120 CD 3_p
primary JJ N
care NN N
physician NN N
and CC N
associate JJ N
practitioners NNS N
from IN N
2 CD 3_p
group NN N
model NN N
HMO NNP N
practices NNS N
INTERVENTIONS NNP N
Guideline NNP N
implementation NN N
utilized VBD N
an DT N
education/audit/feedback NN N
model NN N
with IN N
local JJ N
peer NN N
opinion NN N
leaders NNS N
The DT N
patient JJ N
education NN N
component NN N
included VBD N
written VBN N
and CC N
videotaped VBN N
materials NNS N
on IN N
the DT N
care NN N
of IN N
low JJ N
back RB N
pain NN N
MAIN NNP N
RESULTS NNP N
The DT N
clinician JJ N
intervention NN N
was VBD N
associated VBN N
with IN N
an DT N
absolute JJ N
increase NN N
in IN N
guideline-consistent JJ N
behavior NN N
of IN N
5.4 CD N
% NN N
in IN N
the DT N
intervention NN N
group NN N
versus VBD N
a DT N
decline NN N
of IN N
2.7 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
=.04 NNP N
) ) N
The DT N
patient JJ N
education NN N
intervention NN N
produced VBD N
no DT N
significant JJ N
change NN N
in IN N
guideline-consistent JJ N
behavior NN N
, , N
but CC N
was VBD N
poorly RB N
adopted VBN N
Patient JJ N
characteristics NNS N
including VBG N
duration NN N
of IN N
pain NN N
, , N
prior JJ N
history NN N
of IN N
low JJ N
back RB N
pain NN N
, , N
and CC N
number NN N
of IN N
visits NNS N
during IN N
the DT N
illness JJ N
episode NN N
were VBD N
strong JJ N
predictors NNS N
of IN N
service NN N
utilization NN N
and CC N
guideline-consistent JJ N
behavior NN N
CONCLUSIONS NNP N
Implementation NNP N
of IN N
an DT N
education NN N
and CC N
feedback-supported JJ N
acute NN N
low JJ N
back RB N
pain NN N
care NN N
guideline NN N
for IN N
primary JJ N
care NN N
clinicians NNS N
was VBD N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
guideline-consistent JJ N
behavior NN N
Patient JJ N
education NN N
materials NNS N
did VBD N
not RB N
enhance VB N
guideline NN N
effectiveness NN N
Implementation NNP N
barriers NNS N
could MD N
limit VB N
the DT N
utility NN N
of IN N
this DT N
approach NN N
in IN N
usual JJ N
care NN N
settings NNS N
-DOCSTART- -X- O O 19135235

Probiotics NNS N
prevent VBP N
IgE-associated JJ N
allergy NN N
until IN N
age NN N
5 CD N
years NNS N
in IN 4_p
cesarean-delivered JJ 4_p
children NNS 1_p
but CC N
not RB N
in IN N
the DT N
total JJ N
cohort NN N
BACKGROUND NNP N
Less NNP N
microbial JJ N
exposure NN N
in IN N
early JJ N
childhood NN N
is VBZ N
associated VBN N
with IN N
more RBR N
allergic JJ N
disease NN N
later RB N
Allergic NNP 4_p
children NNS N
have VBP N
a DT N
different JJ N
fecal JJ N
microflora NN N
, , N
with IN N
less JJR N
lactobacilli NN N
and CC N
bifidobacteria NN N
Beneficial JJ N
effects NNS N
regarding VBG N
the DT N
development NN N
of IN N
allergy NNS N
have VBP N
been VBN N
suggested VBN N
to TO N
come VB N
through IN N
probiotic JJ N
supplementation NN N
OBJECTIVE IN N
We PRP N
sought VBD N
to TO N
study VB N
the DT N
effect NN N
of IN N
probiotic JJ N
and CC N
prebiotic JJ N
supplementation NN N
in IN N
preventing VBG N
allergies NNS N
METHODS NNP N
In IN N
a DT N
double-blinded JJ N
, , N
placebo-controlled JJ N
study NN N
we PRP N
randomized VBD N
1223 CD 3_p
mothers NNS 3_p
with IN N
infants NNS 1_p
at IN N
high JJ 4_p
risk NN 4_p
for IN 4_p
allergy NN 4_p
to TO N
receive VB N
a DT N
probiotic JJ N
mixture NN N
( ( N
2 CD N
lactobacilli NN N
, , N
bifidobacteria NN N
, , N
and CC N
propionibacteria NN N
) ) N
or CC N
placebo NN N
during IN N
the DT N
last JJ N
month NN N
of IN N
pregnancy NN N
and CC N
their PRP$ N
infants NNS 1_p
to TO N
receive VB N
it PRP N
from IN N
birth NN N
until IN N
age NN 1_p
6 CD 1_p
months NNS 1_p
Infants NNS N
also RB N
received VBD N
a DT N
prebiotic JJ N
galacto-oligosaccharide NN N
or CC N
placebo NN N
At IN N
5 CD N
years NNS N
, , N
we PRP N
evaluated VBD N
the DT N
cumulative JJ N
incidence NN N
of IN N
allergic JJ N
diseases NNS N
( ( N
eczema NN N
, , N
food NN N
allergy NN N
, , N
allergic JJ N
rhinitis NN N
, , N
and CC N
asthma NN N
) ) N
and CC N
IgE NNP N
sensitization NN N
RESULTS NNP N
Of IN N
the DT N
1018 CD 3_p
intent-to-treat NN 3_p
infants NNS N
, , N
891 CD 3_p
( ( 3_p
88 CD 3_p
% NN 3_p
) ) 3_p
attended VBD 3_p
the DT N
5-year JJ N
visit NN N
Frequencies NNS N
of IN N
allergic JJ N
and CC N
IgE-associated JJ N
allergic JJ N
disease NN N
and CC N
sensitization NN N
in IN N
the DT N
probiotic JJ N
and CC N
placebo JJ N
groups NNS N
were VBD N
similar JJ N
: : N
52.6 CD N
% NN N
versus IN N
54.9 CD N
% NN N
and CC N
29.5 CD N
% NN N
versus IN N
26.6 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
41.3 CD N
% NN N
in IN N
both DT N
No DT N
significant JJ N
difference NN N
appeared VBD N
in IN N
frequencies NNS N
of IN N
eczema NN N
( ( N
39.3 CD N
% NN N
vs JJ N
43.3 CD N
% NN N
) ) N
, , N
atopic JJ N
eczema NN N
( ( N
24.0 CD N
% NN N
vs JJ N
25.1 CD N
% NN N
) ) N
, , N
allergic JJ N
rhinitis NN N
( ( N
20.7 CD N
% NN N
vs JJ N
19.1 CD N
% NN N
) ) N
, , N
or CC N
asthma NN N
( ( N
13.0 CD N
% NN N
vs JJ N
14.1 CD N
% NN N
) ) N
between IN N
groups NNS N
However RB N
, , N
less JJR N
IgE-associated JJ N
allergic JJ N
disease NN N
occurred VBD N
in IN N
cesarean-delivered JJ N
children NNS N
receiving VBG N
probiotics NNS N
( ( N
24.3 CD N
% NN N
vs JJ N
40.5 CD N
% NN N
; : N
odds NNS N
ratio VBP N
, , N
0.47 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.23 CD N
% NN N
to TO N
0.96 CD N
% NN N
; : N
P NNP N
= NNP N
.035 NNP N
) ) N
CONCLUSIONS NNP N
No NNP N
allergy-preventive JJ N
effect NN N
that WDT N
extended VBD N
to TO N
age NN N
5 CD N
years NNS N
was VBD N
achieved VBN N
with IN N
perinatal JJ N
supplementation NN N
of IN N
probiotic JJ N
bacteria NNS N
to TO N
high-risk JJ 4_p
mothers NNS N
and CC N
children NNS N
It PRP N
conferred VBD N
protection NN N
only RB N
to TO N
cesarean-delivered JJ N
children NNS N
-DOCSTART- -X- O O 25119339

Effects NNS N
of IN N
iron NN N
supplements NNS N
and CC N
perinatal JJ N
factors NNS N
on IN N
fetal JJ N
hemoglobin NN N
disappearance NN N
in IN N
LBW NNP 4_p
infants NNS 1_p
BACKGROUND IN N
The DT N
homeostatic JJ N
mechanisms NN N
of IN N
iron NN N
metabolism NN N
and CC N
erythropoiesis NN N
in IN N
infants NNS N
are VBP N
unclear JJ N
Infants NNS N
synthesize VB N
both DT N
fetal JJ N
hemoglobin NN N
( ( N
HbF NNP N
) ) N
and CC N
adult NN N
hemoglobin NN N
( ( N
HbA NNP N
) ) N
, , N
and CC N
it PRP N
is VBZ N
not RB N
known VBN N
how WRB N
the DT N
hemoglobin NN N
switch NN N
is VBZ N
regulated VBN N
We PRP N
hypothesized VBD N
that IN N
iron NN N
supplements NNS N
to TO N
infants NNS N
affect VB N
the DT N
disappearance NN N
of IN N
HbF NNP N
METHODS NNP N
We PRP N
randomized VBD N
285 CD 3_p
low-birth-weight JJ 4_p
infants NNS N
( ( N
2,000-2,500 JJ N
g NN N
) ) N
into IN N
three CD N
intervention NN N
groups NNS N
receiving VBG N
0 CD N
, , N
1 CD N
, , N
or CC N
2 CD N
mg/kg/d NN N
of IN N
iron NN N
supplements NNS N
from IN N
6 CD N
wk NN N
to TO N
6 CD N
mo NN N
of IN N
age NN N
In IN N
the DT N
present JJ N
secondary JJ N
analysis NN N
, , N
we PRP N
analyzed VBD N
iron NN N
status NN N
, , N
total JJ N
hemoglobin NN N
( ( N
Hb NNP N
) ) N
, , N
and CC N
HbF NNP N
fraction NN N
at IN N
6 CD N
wk NN N
, , N
12 CD N
wk NN N
, , N
and CC N
at IN N
6 CD N
mo NN N
and CC N
calculated VBD N
absolute JJ N
levels NNS N
of IN N
HbF NNP N
RESULTS NNP N
We PRP N
observed VBD N
dose-dependent JJ N
increased JJ N
levels NNS N
of IN N
Hb NNP N
in IN N
iron-supplemented JJ N
groups NNS N
at IN N
6 CD N
mo NN N
of IN N
age NN N
However RB N
, , N
for IN N
absolute JJ N
HbF NNP N
concentration NN N
, , N
there EX N
was VBD N
no DT N
similar JJ N
effect NN N
of IN N
intervention NN N
Mean NNP N
( ( N
SD NNP N
) ) N
HbF NNP N
was VBD N
81.2 CD N
( ( N
16.8 CD N
) ) N
, , N
37.0 CD N
( ( N
13.8 CD N
) ) N
, , N
and CC N
8.1 CD N
( ( N
5.6 CD N
) ) N
g/l NN N
at IN N
6 CD N
wk NN N
, , N
12 CD N
wk NN N
, , N
and CC N
6 CD N
mo NN N
, , N
respectively RB N
, , N
similar JJ N
in IN N
all DT N
groups NNS N
In IN N
linear JJ N
regression NN N
analyses NNS N
, , N
postconceptional JJ N
age NN N
turned VBD N
out RP N
as IN N
the DT N
major JJ N
predictor NN N
of IN N
HbF NNP N
, , N
independent JJ N
of IN N
gestational JJ N
age NN N
at IN N
birth NN N
CONCLUSION NNP N
Our PRP$ N
hypothesis NN N
was VBD N
rejected VBN N
Instead RB N
, , N
we PRP N
confirmed VBD N
a DT N
close JJ N
correlation NN N
to TO N
postconceptional JJ N
age NN N
, , N
supporting VBG N
a DT N
genetically RB N
programmed VBN N
switch NN N
, , N
insensitive JJ N
to TO N
most JJS N
environmental JJ N
factors NNS N
including VBG N
birth NN N
-DOCSTART- -X- O O 2653041

Treatments NNS N
of IN N
preterm JJ 4_p
premature JJ 4_p
rupture NN 4_p
of IN 4_p
the DT 4_p
membranes NNS 4_p
: : 4_p
a DT N
meta-analysis NN N
The DT N
objective NN N
of IN N
this DT N
overview NN N
was VBD N
to TO N
critically RB N
evaluate VB N
published VBN N
randomized JJ N
controlled VBN N
trials NNS N
on IN N
treatments NNS N
in IN N
preterm JJ 4_p
premature JJ 4_p
rupture NN 4_p
of IN 4_p
the DT 4_p
membranes NNS 4_p
The DT N
Oxford NNP N
data NN N
base NN N
on IN N
perinatal JJ N
trials NNS N
, , N
MEDLINE NNP N
, , N
Excerpta NNP N
Medica NNP N
, , N
and CC N
Index NNP N
Medicus NNP N
were VBD N
searched VBN N
Through IN N
primary JJ N
and CC N
secondary JJ N
review NN N
with IN N
preset JJ N
inclusion NN N
criteria NNS N
, , N
two CD N
independent JJ N
judges NNS N
identified VBD N
27 CD N
randomized VBN N
controlled VBN N
trials NNS N
, , N
of IN N
which WDT N
13 CD N
met VBD N
inclusion NN N
criteria NNS N
The DT N
quality NN N
of IN N
these DT N
randomized VBN N
controlled VBD N
trials NNS N
was VBD N
scored VBN N
Five CD N
randomized VBN N
controlled VBN N
trials NNS N
regarding VBG N
antenatal JJ N
use NN N
of IN N
corticosteroids NNS N
to TO N
prevent VB N
respiratory JJ N
distress JJ N
syndrome NN N
could MD N
be VB N
combined VBN N
meta-analytically RB N
and CC N
showed VBD N
a DT N
reduction NN N
in IN N
respiratory NN N
distress NN N
syndrome NN N
in IN N
the DT N
treatment NN N
group NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
However RB N
, , N
no DT N
significant JJ N
reduction NN N
in IN N
respiratory NN N
distress NN N
syndrome NN N
( ( N
p JJ N
= NNP N
0.286 CD N
) ) N
was VBD N
found VBN N
after IN N
one CD N
study NN N
, , N
with IN N
the DT N
lowest JJS N
quality NN N
score NN N
, , N
was VBD N
excluded VBN N
A DT N
significant JJ N
increase NN N
in IN N
endometritis NN N
and CC N
a DT N
trend NN N
toward IN N
an DT N
increase NN N
in IN N
neonatal JJ N
infections NNS N
and CC N
cesarean JJ N
section NN N
rates NNS N
were VBD N
noted VBN N
with IN N
treatment NN N
Tocolysis NN N
, , N
prophylactic JJ N
antibiotics NNS N
, , N
and CC N
other JJ N
interventions NNS N
studied VBN N
were VBD N
not RB N
found VBN N
to TO N
be VB N
of IN N
proved JJ N
benefit NN N
and CC N
therefore RB N
should MD N
not RB N
be VB N
used VBN N
outside IN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
-DOCSTART- -X- O O 5322596

Incidence NN N
of IN N
candida NN N
in IN N
hospital JJ N
in-patients NNS N
and CC N
the DT N
effects NNS N
of IN N
antibiotic JJ N
therapy NN N
-DOCSTART- -X- O O 23365106

Supplementation NN N
with IN N
n3 JJ N
fatty JJ N
acid NN N
ethyl NN N
esters NNS N
increases VBZ N
large JJ N
and CC N
small JJ N
artery NN N
elasticity NN N
in IN N
obese JJ 4_p
adults NNS 4_p
on IN 4_p
a DT 4_p
weight JJ 4_p
loss NN 4_p
diet NN 4_p
Increased VBN N
arterial JJ N
stiffness NN N
is VBZ N
associated VBN N
with IN N
enhanced JJ N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
in IN N
obese JJ N
individuals NNS N
Whether NNP N
n3 JJ N
fatty RB N
acid JJ N
ethyl NN N
ester NN N
( ( N
FAEE NNP N
) ) N
supplementation NN N
improves VBZ N
arterial JJ N
stiffness NN N
in IN N
obese JJ N
participants NNS N
on IN N
a DT N
weight JJ N
loss NN N
diet NN N
has VBZ N
not RB N
yet RB N
been VBN N
investigated VBN N
The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
carry VB N
out RP N
a DT N
12-wk JJ N
randomized NN N
, , N
single-blind JJ N
trial NN N
to TO N
test VB N
the DT N
effect NN N
of IN N
a DT N
25 CD N
% NN N
energy NN N
deficit NN N
weight VBD 4_p
loss NN 4_p
diet NN 4_p
alone RB 4_p
( ( 4_p
WL NNP 4_p
) ) 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
12 CD 4_p
) ) 4_p
or CC N
WL NNP N
plus CC N
4 CD N
g/d NN N
Omacor NNP N
( ( N
46 CD N
% NN N
EPA NNP N
and CC N
38 CD N
% NN N
DHA NNP N
) ) N
supplementation NN N
( ( N
WL+FAEE NNP N
) ) N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
on IN N
arterial JJ N
elasticity NN N
in IN N
obese JJ N
adults NNS N
Large NNP N
( ( N
C1 NNP N
) ) N
and CC N
small JJ N
artery NN N
elasticity NN N
( ( N
C2 NNP N
) ) N
were VBD N
measured VBN N
by IN N
pulse JJ N
contour NN N
analysis NN N
of IN N
the DT N
radial JJ N
artery NN N
WL NNP N
alone RB N
reduced VBD N
( ( N
P NNP N
< VBZ N
0.05 CD N
in IN N
all DT N
) ) N
body NN N
weight NN N
( ( N
-3 CD N
% NN N
) ) N
, , N
waist JJ N
circumference NN N
( ( N
-4 CD N
% NN N
) ) N
, , N
systolic JJ N
( ( N
-3 CD N
% NN N
) ) N
and CC N
diastolic JJ N
( ( N
-3 CD N
% NN N
) ) N
blood NN N
pressures NNS N
, , N
cardiac JJ N
output NN N
( ( N
-4 CD N
% NN N
) ) N
, , N
plasma JJ N
TG NNP N
concentration NN N
( ( N
-25 CD N
% NN N
) ) N
, , N
and CC N
the DT N
homeostasis NN N
model NN N
assessment NN N
( ( N
HOMA NNP N
) ) N
score NN N
( ( N
-12 CD N
% NN N
) ) N
and CC N
increased VBD N
plasma NN N
HDL NNP N
cholesterol NN N
( ( N
+9 CD N
% NN N
) ) N
and CC N
adiponectin NN N
( ( N
+18 CD N
% NN N
) ) N
concentrations NNS N
However RB N
, , N
WL NNP N
alone RB N
did VBD N
not RB N
alter VB N
C1 NNP N
and CC N
C2 NNP N
The DT N
WL+FAEE NNP N
intervention NN N
significantly RB N
reduced VBN N
body NN N
weight NN N
( ( N
-4 CD N
% NN N
) ) N
, , N
waist JJ N
circumference NN N
( ( N
-4 CD N
% NN N
) ) N
, , N
systolic JJ N
( ( N
-8 CD N
% NN N
) ) N
and CC N
diastolic JJ N
( ( N
-5 CD N
% NN N
) ) N
blood NN N
pressures NNS N
, , N
pulse JJ N
pressure NN N
( ( N
-5 CD N
% NN N
) ) N
, , N
heart NN N
rate NN N
( ( N
-8 CD N
% NN N
) ) N
, , N
plasma JJ N
TG NNP N
concentration NN N
( ( N
-36 CD N
% NN N
) ) N
, , N
and CC N
HOMA NNP N
score NN N
( ( N
-12 CD N
% NN N
) ) N
and CC N
increased JJ N
stroke NN N
volume NN N
( ( N
+3 CD N
% NN N
) ) N
, , N
plasma JJ N
HDL NNP N
cholesterol NN N
( ( N
+6 CD N
% NN N
) ) N
and CC N
adiponectin JJ N
concentrations NNS N
( ( N
+28 CD N
% NN N
) ) N
, , N
and CC N
C1 NNP N
( ( N
+20 NNP N
% NN N
) ) N
and CC N
C2 NNP N
( ( N
+22 NNP N
% NN N
) ) N
artery NN N
elasticity NN N
The DT N
changes NNS N
in IN N
systolic JJ N
blood NN N
pressure NN N
, , N
heart NN N
rate NN N
, , N
plasma NN N
TGs NNP N
, , N
C1 NNP N
, , N
and CC N
C2 NNP N
were VBD N
significantly RB N
greater JJR N
in IN N
the DT N
WL+FAEE NNP N
group NN N
than IN N
in IN N
the DT N
WL NNP N
group NN N
Supplementation NN N
with IN N
n3 JJ N
FAEEs NNP N
improves VBZ N
C1 NNP N
and CC N
C2 NNP N
independently RB N
of IN N
weight JJ N
loss NN N
in IN N
obese JJ 4_p
adults NNS 4_p
-DOCSTART- -X- O O 24216497

The DT N
cardiovascular JJ N
effects NNS N
of IN N
sevoflurane NN N
and CC N
isoflurane NN N
after IN N
premedication NN N
of IN N
healthy JJ N
dogs NNS N
undergoing VBG N
elective JJ 4_p
surgery NN 4_p
Sevoflurane NNP N
and CC N
isoflurane NN N
are VBP N
commonly RB N
used VBN N
in IN N
veterinary JJ N
anesthesia NN N
The DT N
objective NN N
of IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
open-label JJ N
clinical JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
cardiovascular JJ N
effects NNS N
of IN N
sevoflurane NN N
and CC N
isoflurane NN N
via IN N
direct JJ N
arterial JJ N
blood NN N
pressure NN N
measurements NNS N
and CC N
the DT N
lithium NN N
dilution NN N
cardiac NN N
output NN N
( ( N
LDCO NNP N
) ) N
on IN N
premedicated VBN N
healthy JJ N
dogs NNS N
undergoing VBG N
elective JJ 4_p
tibial JJ 4_p
plateau NN 4_p
leveling VBG 4_p
osteotomy NN 4_p
( ( 4_p
TPLO NNP 4_p
) ) 4_p
Nineteen JJ 3_p
client-owned JJ 3_p
dogs NNS N
were VBD N
included VBN N
All DT N
dogs NNS N
were VBD N
premedicated VBN N
with IN N
hydromorphone NN N
( ( N
0.05 CD N
mg/kg NN N
IV NNP N
and CC N
glycopyrrolate VB N
0.01 CD N
mg/kg NNS N
subcutaneously RB N
) ) N
Ten CD N
dogs NNS N
were VBD N
anesthetized VBN N
with IN N
sevoflurane NN N
and CC N
nine CD N
dogs NNS N
were VBD N
anesthetized VBN N
with IN N
isoflurane NN N
Eighteen JJ N
dogs NNS N
were VBD N
instrumented VBN N
with IN N
a DT N
dorsal NN N
pedal JJ N
arterial JJ N
catheter NN N
, , N
and CC N
one CD N
dog NN N
had VBD N
a DT N
femoral JJ N
arterial JJ N
catheter NN N
All DT N
dogs NNS N
had VBD N
continuous JJ N
, , N
direct JJ N
systolic NN N
( ( N
SAP NNP N
) ) N
, , N
diastolic JJ N
( ( N
DAP NNP N
) ) N
, , N
and CC N
mean JJ N
arterial NN N
( ( N
MAP NNP N
) ) N
blood NN N
pressure NN N
readings NNS N
as RB N
well RB N
as IN N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
, , N
cardiac JJ N
output NN N
( ( N
CO NNP N
) ) N
, , N
cardiac JJ N
index NN N
( ( N
CI NNP N
) ) N
, , N
systemic JJ N
vascular NN N
resistance NN N
( ( N
SVR NNP N
) ) N
, , N
systemic JJ N
vascular NN N
resistance NN N
index NN N
( ( N
SVRI NNP N
) ) N
, , N
stroke VBD N
volume NN N
variation NN N
( ( N
SVV NNP N
) ) N
, , N
and CC N
pulse JJ N
pressure NN N
variation NN N
( ( N
PPV NNP N
) ) N
recorded VBD N
q $ N
5 CD N
min NN N
during IN N
the DT N
surgical JJ N
procedure NN N
There EX N
was VBD N
no DT N
significant JJ N
statistical JJ N
difference NN N
in IN N
all DT N
parameters NNS N
between IN N
the DT N
sevoflurane NN N
and CC N
isoflurane NN N
treatment NN N
groups NNS N
Both DT N
sevoflurane NN N
and CC N
isoflurane NN N
inhalant JJ N
anesthetics NNS N
appear VBP N
to TO N
have VB N
similar JJ N
hemodynamic JJ N
effects NNS N
when WRB N
used VBN N
as IN N
part NN N
of IN N
a DT N
multimodal JJ N
anesthetic JJ N
protocol NN N
in IN N
premedicated VBN N
healthy JJ N
dogs NNS N
undergoing VBG N
an DT N
elective JJ N
surgical JJ N
procedure NN N
-DOCSTART- -X- O O 2142040

Nephrotoxicity NN N
of IN N
cyclosporin NN N
A NNP N
in IN N
patients NNS N
with IN N
newly RB N
diagnosed VBN N
type NN 4_p
1 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
Renal JJ N
function NN N
was VBD N
studied VBN N
in IN N
18 CD 3_p
patients NNS N
with IN N
Type NNP 4_p
1 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
All DT N
were VBD N
participating VBG N
in IN N
the DT N
Canadian-European JJ N
randomized JJ N
placebo-controlled JJ N
cyclosporin NN N
trial NN N
in IN N
newly RB N
diagnosed VBN N
Type NNP N
1 CD 4_p
diabetic JJ 4_p
patients NNS N
, , N
nine CD N
being VBG N
randomized VBN N
to TO N
placebo VB N
, , N
and CC N
nine CD N
to TO N
cyclosporin VB N
A NNP N
During IN N
treatment NN N
for IN N
12 CD N
to TO N
18 CD N
months NNS N
, , N
cyclosporin VBP N
A DT N
caused JJ N
significant JJ N
reductions NNS N
in IN N
the DT N
glomerular JJ N
filtration NN N
rate NN N
( ( N
before IN N
drug NN N
withdrawal NN N
, , N
cyclosporin JJ N
97 CD N
+/- JJ N
18 CD N
vs NN N
placebo NN N
125 CD N
+/- JJ N
16 CD N
ml JJ N
min-1 JJ N
1.73-m-2 JJ N
, , N
p RB N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
renal JJ N
plasma NN N
flow NN N
( ( N
454 CD N
+/- JJ N
83 CD N
vs JJ N
536 CD N
+/- JJ N
70 CD N
ml JJ N
min-1 JJ N
1.73-m-2 JJ N
, , N
p RB N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
and CC N
lithium JJ N
clearance NN N
( ( N
17 CD N
+/- JJ N
3 CD N
vs JJ N
28 CD N
+/- JJ N
5 CD N
ml JJ N
min-1 JJ N
1.73-m-2 JJ N
, , N
p RB N
less JJR N
than IN N
0.05 CD N
) ) N
The DT N
fractional JJ N
proximal JJ N
reabsorption NN N
was VBD N
increased VBN N
( ( N
0.82 CD N
+/- JJ N
0.03 CD N
vs JJ N
0.78 CD N
+/- JJ N
0.03 CD N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
and CC N
the DT N
fractional JJ N
distal JJ N
sodium NN N
reabsorption NN N
reduced VBD N
( ( N
0.88 CD N
+/- JJ N
0.03 CD N
vs JJ N
0.94 CD N
+/- JJ N
0.02 CD N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
These DT N
results NNS N
are VBP N
in IN N
accordance NN N
with IN N
the DT N
hypothesis NN N
that IN N
the DT N
nephrotoxic JJ N
effect NN N
of IN N
cyclosporin NN N
A NNP N
results NNS N
from IN N
a DT N
preferential JJ N
constriction NN N
of IN N
afferent JJ N
glomerular JJ N
vessels NNS N
One CD N
year NN N
after IN N
withdrawal NN N
of IN N
the DT N
drug NN N
, , N
all DT N
variables NNS N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
, , N
except IN N
for IN N
blood NN N
glucose NN N
control NN N
which WDT N
was VBD N
worse RBR N
in IN N
the DT N
cyclosporin NN N
A NNP N
treated VBD N
group NN N
When WRB N
corrected VBN N
for IN N
differences NNS N
in IN N
blood NN N
glucose NN N
control NN N
it PRP N
appeared VBD N
that IN N
in IN N
three CD N
out IN N
of IN N
nine CD N
patients NNS N
glomerular JJ N
filtration NN N
rate NN N
had VBD N
not RB N
completely RB N
returned VBN N
to TO N
the DT N
reference NN N
range NN N
of IN N
the DT N
placebo NN N
group NN N
We PRP N
conclude VBP N
that IN N
the DT N
nephrotoxic JJ N
side-effects NNS N
of IN N
cyclosporin NN N
A NNP N
treatment NN N
for IN N
1 CD N
year NN N
are VBP N
reversible JJ N
There EX N
are VBP N
, , N
however RB N
, , N
signs NNS N
of IN N
minor JJ N
and CC N
perhaps RB N
chronic JJ N
renal JJ N
injury NN N
-DOCSTART- -X- O O 25225698

Methylprednisolone NN N
in IN N
patients NNS 4_p
with IN 4_p
cancer NN 4_p
using VBG 4_p
opioids NNS 4_p
-DOCSTART- -X- O O 9398110

The DT N
effects NNS N
of IN N
the DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
imidapril NN N
on IN N
plasma NN N
plasminogen NN N
activator NN N
inhibitor NN N
activity NN N
in IN N
patients NNS N
with IN N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
This DT N
study NN N
sought VBD N
to TO N
determine VB N
whether IN N
early JJ N
treatment NN N
with IN N
angiotensin-converting JJ N
enzyme NN N
( ( N
ACE NNP N
) ) N
inhibitors NNS N
in IN N
patients NNS N
with IN N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
is VBZ N
useful JJ N
for IN N
the DT N
improvement NN N
of IN N
fibrinolytic JJ N
function NN N
, , N
as RB N
well RB N
as IN N
left VBN N
ventricular JJ N
function NN N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
examine VB N
the DT N
levels NNS N
of IN N
plasma NN N
plasminogen NN N
activator NN N
inhibitor NN N
( ( N
PAI NNP N
) ) N
activity NN N
and CC N
serum JJ N
ACE NNP N
activity NN N
during IN N
the DT N
course NN N
of IN N
2 CD N
weeks NNS N
in IN N
40 CD 3_p
patients NNS N
with IN N
AMI NNP 4_p
within IN N
12 CD N
hours NNS N
after IN N
the DT N
onset NN N
of IN N
the DT N
symptom NN N
and CC N
who WP N
randomly VBP N
received VBN N
early JJ N
treatment NN N
with IN N
either CC N
the DT N
ACE NNP N
inhibitor NN N
imidapril NN N
or CC N
a DT N
placebo NN N
( ( N
20 CD 3_p
patients NNS N
in IN N
the DT N
imidapril NN N
group NN N
and CC N
20 CD 3_p
in IN N
the DT N
placebo NN N
group NN N
) ) N
The DT N
levels NNS N
of IN N
serum JJ N
ACE NNP N
activity NN N
in IN N
the DT N
imidapril NN N
group NN N
decreased VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
8 CD N
hours NNS N
after IN N
the DT N
administration NN N
of IN N
imidapril NN N
, , N
and CC N
the DT N
levels NNS N
24 CD N
hours NNS N
after IN N
administration NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
( ( N
3.6 CD N
+/- JJ N
0.6 CD N
IU/L NNP N
vs VBD N
7.4 CD N
+/- JJ N
0.8 CD N
IU/L NNP N
; : N
p VBZ N
< $ N
0.001 CD N
) ) N
The DT N
plasma JJ N
PAI NNP N
activity NN N
increased VBD N
gradually RB N
to TO N
peak VB N
levels NNS N
16 CD N
hours NNS N
after IN N
the DT N
administration NN N
of IN N
imidapril NN N
and CC N
placebo NN N
The DT N
levels NNS N
in IN N
the DT N
placebo NN N
group NN N
decreased VBD N
gradually RB N
but CC N
remained VBD N
high JJ N
during IN N
the DT N
study NN N
period NN N
On IN N
the DT N
other JJ N
hand NN N
, , N
the DT N
levels NNS N
of IN N
PAI NNP N
activity NN N
in IN N
the DT N
imidapril NN N
group NN N
decreased VBD N
rapidly RB N
and CC N
those DT N
48 CD N
hours NNS N
after IN N
administration NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
( ( N
7.9 CD N
+/- JJ N
1.9 CD N
IU/ml NNP N
vs VBD N
18.4 CD N
+/- JJ N
3.5 CD N
IU/ml NNP N
; : N
p VBZ N
< $ N
0.01 CD N
) ) N
The DT N
levels NNS N
of IN N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
about IN N
2 CD N
weeks NNS N
after IN N
admission NN N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
imidapril NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
65.9 CD N
% NN N
+/- JJ N
2.5 CD N
% NN N
vs JJ N
49.1 CD N
% NN N
+/- JJ N
4.4 CD N
% NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
This DT N
study NN N
showed VBD N
that IN N
imidapril NN N
, , N
an DT N
ACE NNP N
inhibitor NN N
, , N
might MD N
be VB N
useful JJ N
for IN N
the DT N
improvement NN N
of IN N
fibrinolytic JJ N
function NN N
and CC N
left VBD N
ventricular JJ N
function NN N
in IN N
the DT N
acute JJ N
phase NN N
of IN N
myocardial JJ N
infarction NN N
-DOCSTART- -X- O O 22342106

A DT N
randomized VBN N
controlled VBN N
pilot JJ N
trial NN N
of IN N
oral JJ N
N-acetylcysteine NNP N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
BACKGROUND NNP N
An DT N
imbalance NN N
in IN N
the DT N
excitatory/inhibitory JJ N
systems NNS N
with IN N
abnormalities NNS N
in IN N
the DT N
glutamatergic NN N
pathways VBZ N
has VBZ N
been VBN N
implicated VBN N
in IN N
the DT N
pathophysiology NN N
of IN N
autism NN N
Furthermore NNP N
, , N
chronic JJ N
redox NN N
imbalance NN N
was VBD N
also RB N
recently RB N
linked VBN N
to TO N
this DT N
disorder NN N
The DT N
goal NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
assess VB N
the DT N
feasibility NN N
of IN N
using VBG N
oral JJ N
N-acetylcysteine NNP N
( ( N
NAC NNP N
) ) N
, , N
a DT N
glutamatergic JJ N
modulator NN N
and CC N
an DT N
antioxidant NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
behavioral JJ N
disturbance NN N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
METHODS NNP N
This DT N
was VBD N
a DT N
12-week JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
study NN N
of IN N
NAC NNP N
in IN N
children NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
Subjects VBZ N
randomized VBN N
to TO N
NAC NNP N
were VBD N
initiated VBN N
at IN N
900 CD N
mg NNS N
daily RB N
for IN N
4 CD N
weeks NNS N
, , N
then RB N
900 CD N
mg NNS N
twice RB N
daily RB N
for IN N
4 CD N
weeks NNS N
and CC N
900 CD N
mg NN N
three CD N
times NNS N
daily RB N
for IN N
4 CD N
weeks NNS N
The DT N
primary JJ N
behavioral JJ N
measure NN N
( ( N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
[ NNP N
ABC NNP N
] NNP N
irritability NN N
subscale NN N
) ) N
and CC N
safety NN N
measures NNS N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
4 CD N
, , N
8 CD N
, , N
and CC N
12 CD N
weeks NNS N
Secondary JJ N
measures NNS N
included VBD N
the DT N
ABC NNP N
stereotypy NN N
subscale NN N
, , N
Repetitive JJ N
Behavior NNP N
Scale-Revised JJ N
, , N
and CC N
Social NNP N
Responsiveness NNP N
Scale NNP N
RESULTS NNP N
Thirty-three JJ 3_p
subjects NNS N
( ( N
31 CD 3_p
male NN 2_p
subjects NNS N
, , N
2 CD 3_p
female JJ 2_p
subjects NNS N
; : N
aged VBN N
3.2-10.7 CD 1_p
years NNS 1_p
) ) N
were VBD N
randomized VBN N
in IN N
the DT N
study NN N
Follow-up NNP N
data NN N
was VBD N
available JJ N
on IN N
14 CD 3_p
subjects NNS N
in IN N
the DT N
NAC NNP N
group NN N
and CC N
15 CD 3_p
in IN N
the DT N
placebo NN N
group NN N
Oral NNP N
NAC NNP N
was VBD N
well RB N
tolerated VBN N
with IN N
limited JJ N
side NN N
effects NNS N
Compared VBN N
with IN N
placebo NN N
, , N
NAC NNP N
resulted VBD N
in IN N
significant JJ N
improvements NNS N
on IN N
ABC NNP N
irritability NN N
subscale NN N
( ( N
F NNP N
= NNP N
6.80 CD N
; : N
p NN N
< NNP N
.001 NNP N
; : N
d VBZ N
= NNP N
.96 NNP N
) ) N
CONCLUSIONS NNP N
Data NNP N
from IN N
this DT N
pilot NN N
investigation NN N
support NN N
the DT N
potential JJ N
usefulness NN N
of IN N
NAC NNP N
for IN N
treating VBG N
irritability NN N
in IN N
children NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
Large NNP N
randomized VBD N
controlled VBN N
investigations NNS N
are VBP N
warranted VBN N
-DOCSTART- -X- O O 22964266

Mindfulness-based JJ N
therapy NN N
in IN N
adults NNS 1_p
with IN 4_p
an DT 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : 4_p
a DT N
randomized NN N
controlled VBN N
trial NN N
Research NN N
shows VBZ N
that IN N
depression NN N
and CC N
anxiety NN N
disorders NNS N
are VBP N
the DT N
most RBS N
common JJ N
psychiatric JJ N
concern NN N
in IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
Mindfulness-based JJ N
therapy NN N
( ( N
MBT NNP N
) ) N
has VBZ N
been VBN N
found VBN N
effective JJ N
in IN N
reducing VBG N
anxiety NN N
and CC N
depression NN N
symptoms NNS N
, , N
however RB N
research NN N
in IN N
autism NN N
is VBZ N
limited VBN N
Therefore RB N
, , N
we PRP N
examined VBD N
the DT N
effects NNS N
of IN N
a DT N
modified JJ N
MBT NNP N
protocol NN N
( ( N
MBT-AS NNP N
) ) N
in IN N
high-functioning NN 4_p
adults NNS 1_p
with IN N
ASD NNP 4_p
42 CD 3_p
participants NNS N
were VBD N
randomized VBN N
into IN N
a DT N
9-week JJ N
MBT-AS JJ N
training NN N
or CC N
a DT N
wait-list JJ N
control NN N
group NN N
Results NNP N
showed VBD N
a DT N
significant JJ N
reduction NN N
in IN N
depression NN N
, , N
anxiety NN N
and CC N
rumination NN N
in IN N
the DT N
intervention NN N
group NN N
, , N
as IN N
opposed VBN N
to TO N
the DT N
control NN N
group NN N
Furthermore RB N
, , N
positive JJ N
affect NN N
increased VBN N
in IN N
the DT N
intervention NN N
group NN N
, , N
but CC N
not RB N
in IN N
the DT N
control NN N
group NN N
Concluding NNP N
, , N
the DT N
present JJ N
study NN N
is VBZ N
the DT N
first JJ N
controlled VBN N
trial NN N
to TO N
demonstrate VB N
that IN N
adults NNS 1_p
with IN N
ASD NNP N
can MD N
benefit VB N
from IN N
MBT-AS NNP N
-DOCSTART- -X- O O 20796074

Effect NN N
of IN N
thermal JJ N
stress NN N
, , N
restricted VBD N
feeding NN N
and CC N
combined VBN N
stresses NNS N
( ( N
thermal JJ N
stress NN N
and CC N
restricted VBD N
feeding VBG N
) ) N
on IN N
growth NN N
and CC N
plasma VB N
reproductive JJ N
hormone NN N
levels NNS N
of IN N
Malpura NNP N
ewes FW N
under IN N
semi-arid JJ N
tropical JJ N
environment NN N
A DT N
study NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
thermal NN N
, , N
nutritional JJ N
and CC N
combined JJ N
stresses NNS N
( ( N
thermal JJ N
and CC N
nutritional JJ N
) ) N
on IN N
the DT N
growth NN N
, , N
oestradiol NN N
and CC N
progesterone NN N
levels NNS N
during IN N
oestrus NN N
cycles NNS N
in IN N
Malpura NNP N
ewes NN N
Twenty-eight JJ 3_p
adult NN 1_p
Malpura NNP N
ewes NN N
were VBD N
used VBN N
in IN N
the DT N
present JJ N
study NN N
The DT N
ewes NN N
were VBD N
randomly RB N
allocated VBN N
into IN N
four CD N
groups NNS N
, , N
viz. NN N
, , N
GI NNP N
( ( N
n=7 RB N
; : N
control NN N
) ) N
, , N
GII NNP N
( ( N
n=7 RB N
; : N
thermal JJ N
stress NN N
) ) N
, , N
GIII NNP N
( ( N
n=7 RB N
; : N
restricted VBN N
feeding NN N
) ) N
and CC N
GIV NNP N
( ( N
n=7 RB N
; : N
combined VBN N
stress NN N
) ) N
The DT N
animals NNS N
were VBD N
stall JJ N
fed VBN N
with IN N
a DT N
diet JJ N
consisting NN N
of IN N
60 CD N
% NN N
roughage NN N
and CC N
40 CD N
% NN N
concentrate NN N
GI NNP N
and CC N
GII NNP N
ewes NN N
were VBD N
provided VBN N
with IN N
ad NN N
libitum NN N
feeding VBG N
while IN N
GIII NNP N
and CC N
GIV NNP N
ewes NN N
were VBD N
provided VBN N
with IN N
restricted JJ N
feed NN N
( ( N
30 CD N
% NN N
intake NN N
of IN N
GI NNP N
and CC N
GII NNP N
ewes NN N
) ) N
to TO N
induce VB N
nutritional JJ N
insufficiency NN N
GII NNP N
and CC N
GIV NNP N
ewes NN N
were VBD N
kept VBN N
in IN N
climatic JJ N
chamber NN N
at IN N
40°C CD N
and CC N
55 CD N
% NN N
RH NNP N
for IN N
6 CD N
h NNS N
a DT N
day NN N
between IN N
10:00 CD N
and CC N
16:00 CD N
hours NNS N
to TO N
induce VB N
thermal JJ N
stress NN N
for IN N
a DT N
period NN N
of IN N
two CD N
oestrous JJ N
cycles NNS N
Parameters NNS N
studied VBD N
were VBD N
body JJ N
weight NN N
, , N
oestrus NN N
incidences NNS N
, , N
plasma JJ N
oestradiol IN N
17-β JJ N
, , N
plasma JJ N
progesterone NN N
, , N
conception NN N
rate NN N
, , N
gestation NN N
period NN N
, , N
lambing VBG N
rate NN N
, , N
and CC N
birth NN N
weight NN N
of IN N
lambs NN N
The DT N
results NNS N
indicate VBP N
that IN N
combined VBD N
stress NN N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
reduced VBN N
body NN N
weight NN N
, , N
oestrus JJ N
duration NN N
, , N
birth NN N
weight NN N
of IN N
lambs NN N
, , N
and CC N
oestradiol JJ N
17-β JJ N
whereas NNS N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
increased VBD N
oestrus JJ N
cycle NN N
length NN N
and CC N
progesterone NN N
Furthermore RB N
, , N
the DT N
results NNS N
reveal VBP N
that IN N
on IN N
comparative JJ N
basis NN N
, , N
ewes NN N
were VBD N
able JJ N
to TO N
better VB N
adapt NN N
in IN N
terms NNS N
of IN N
growth NN N
and CC N
reproduction NN N
to TO N
restricted VB N
feeding NN N
than IN N
thermal JJ N
stress NN N
However RB N
, , N
when WRB N
restricted VBD N
feeding NN N
was VBD N
coupled VBN N
with IN N
thermal JJ N
stress NN N
it PRP N
had VBD N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
influence NN N
on IN N
body NN N
weight NN N
, , N
average JJ N
daily JJ N
gain NN N
, , N
oestradiol JJ N
17-β JJ N
and CC N
progesterone JJ N
concentrations NNS N
This DT N
showed VBD N
that IN N
combined JJ N
stress NN N
were VBD N
more JJR N
detrimental JJ N
for IN N
these DT N
reproductive JJ N
hormones NNS N
in IN N
Malpura NNP N
ewes NN N
under IN N
a DT N
hot JJ N
semi-arid JJ N
environment NN N
-DOCSTART- -X- O O 25957107

Effect NN N
of IN N
Chinese NNP N
herbal JJ N
medicine NN N
on IN N
vascular JJ N
functions NNS N
during IN N
60-day JJ N
head-down JJ N
bed NN N
rest NN N
PURPOSE NNP N
Chinese JJ N
herbal JJ N
medicine NN N
is VBZ N
a DT N
promising JJ N
countermeasure NN N
against IN N
cardiovascular JJ 4_p
dysfunction NN 4_p
associated VBN N
with IN N
a DT N
sedentary JJ N
lifestyle NN N
We PRP N
examined VBD N
the DT N
impact NN N
of IN N
the DT N
Chinese JJ N
herb NN N
, , N
Taikong NNP N
Yangxin NNP N
, , N
on IN N
the DT N
micro- JJ N
and CC N
macrovascular JJ N
dysfunction NN N
associated VBN N
with IN N
a DT N
60-day JJ N
bed NN N
rest NN N
METHODS NNP N
Fourteen NNP 3_p
healthy JJ N
men NNS 2_p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
those DT N
given VBN N
herbal JJ N
supplement NN N
, , N
and CC N
the DT N
control NN N
group NN N
; : N
the DT N
two CD N
groups NNS N
underwent VBD N
a DT N
60-day JJ N
bed NN N
rest NN N
The DT N
macrovasculature NN N
was VBD N
assessed VBN N
by IN N
sonography NN N
Skin NNP N
microvascular JJ N
functions NNS N
were VBD N
assessed VBN N
with IN N
laser NN N
Doppler NNP N
The DT N
plasma JJ N
level NN N
of IN N
endothelial JJ N
microparticles NNS N
( ( N
EMPs NNP N
) ) N
, , N
markers NNS N
of IN N
endothelial JJ N
injury NN N
, , N
was VBD N
determined VBN N
RESULTS NNP N
Bed NNP N
rest NN N
induced VBD N
a DT N
33 CD N
% NN N
decrease NN N
in IN N
the DT N
femoral JJ N
artery NN N
diameter NN N
and CC N
compliance NN N
whereas NNS N
carotid VBP N
wall NN N
thickness NN N
, , N
diameter NN N
, , N
and CC N
compliance NN N
remained VBD N
unchanged JJ N
The DT N
early JJ N
phase NN N
of IN N
endothelium-dependent JJ N
vasodilation NN N
to TO N
ACh NNP N
was VBD N
unmodified VBN N
by IN N
bed NN N
rest NN N
, , N
while IN N
the DT N
late JJ N
phase NN N
was VBD N
reduced VBN N
by IN N
30 CD N
% NN N
along IN N
with IN N
a DT N
twofold JJ N
increase NN N
in IN N
EMPs NNP N
In IN N
those DT N
given VBN N
Taikong NNP N
Yangxin NNP N
, , N
the DT N
early JJ N
phase NN N
was VBD N
amplified VBN N
by IN N
2.5-fold JJ N
, , N
and CC N
the DT N
effects NNS N
of IN N
bed NN N
rest NN N
on IN N
the DT N
late JJ N
phase NN N
were VBD N
prevented VBN N
CONCLUSION NNP N
These DT N
findings NNS N
indicate VBP N
that IN N
Taikong NNP N
Yangxin NNP N
ameliorates VBZ N
endothelium-dependent JJ N
vasodilation NN N
, , N
likely RB N
by IN N
improving VBG N
the DT N
NO NNP N
pathway NN N
The DT N
study NN N
suggests VBZ N
Taikong NNP N
Yangxin NNP N
as IN N
a DT N
new JJ N
countermeasure NN N
to TO N
prevent VB N
the DT N
changes NNS N
in IN N
microvascular JJ N
function NN N
induced VBN N
by IN N
physical JJ N
inactivity NN N
-DOCSTART- -X- O O 17926617

[ JJ N
Effects NNS N
of IN N
electroacupuncture NN N
combined VBN N
with IN N
behavior JJ N
therapy NN N
on IN N
intelligence NN N
and CC N
behavior NN N
of IN N
children NNS 1_p
of IN N
autism NN 4_p
] NNP N
OBJECTIVE NNP N
To TO N
find VB N
out RP N
an DT N
effective JJ N
therapy NN N
for IN N
autism NN N
METHODS NNP N
Sixty NNP 3_p
children NNS 1_p
of IN N
autism NN 4_p
were VBD N
randomly RB N
divided VBN N
into IN N
an DT N
electroacupuncture NN N
( ( N
EA NNP N
) ) N
plus CC N
behavior JJ N
therapy NN N
group NN N
and CC N
a DT N
behavior JJ N
therapy NN N
group NN N
, , N
30 CD N
cases NNS N
in IN N
each DT N
group NN N
The DT N
patients NNS N
in IN N
the DT N
two CD N
groups NNS N
were VBD N
treated VBN N
with IN N
routine JJ N
behavior NN N
, , N
with IN N
EA NNP N
at IN N
Baihui NNP N
( ( N
GV NNP N
20 CD N
) ) N
, , N
Sishencong NNP N
( ( N
EX-HN NNP N
1 CD N
) ) N
, , N
Shenting NNP N
( ( N
GV NNP N
24 CD N
) ) N
, , N
Benshen NNP N
( ( N
GB NNP N
13 CD N
) ) N
, , N
Yintang NNP N
( ( N
EX-HN NNP N
3 CD N
) ) N
, , N
Naohu NNP N
( ( N
GV NNP N
17 CD N
) ) N
, , N
Naokong NNP N
( ( N
GB NNP N
19 CD N
) ) N
, , N
Neiguan NNP N
( ( N
PC NNP N
6 CD N
) ) N
and CC N
scalp JJ N
acupuncture NN N
at IN N
Speech NNP N
Areas NNP N
I PRP N
, , N
II NNP N
, , N
III NNP N
added VBD N
for IN N
the DT N
EA NNP N
plus CC N
behavior JJ N
therapy NN N
group NN N
Their PRP$ N
therapeutic JJ N
effects NNS N
were VBD N
observed VBN N
, , N
and CC N
the DT N
picture NN N
and CC N
vocabulary JJ N
scale NN N
( ( N
PPVT NNP N
) ) N
and CC N
behavior JJ N
ability NN N
were VBD N
detected VBN N
RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
was VBD N
86.7 CD N
% NN N
in IN N
the DT N
EA NNP N
plus CC N
behavior JJ N
therapy NN N
group NN N
which WDT N
was VBD N
better JJR N
than IN N
56.7 CD N
% NN N
of IN N
the DT N
behavior JJ N
therapy NN N
group NN N
, , N
and CC N
had VBD N
significant JJ N
enhancement NN N
in IN N
sensation NN N
, , N
association NN N
, , N
body NN N
, , N
and CC N
ability NN N
of IN N
self-care NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
was VBD N
better JJR N
than IN N
the DT N
behavior JJ N
therapy NN N
group NN N
in IN N
sensation NN N
, , N
body NN N
and CC N
self-care JJ N
factors NNS N
, , N
with IN N
no DT N
significantly RB N
improvement NN N
in IN N
the DT N
scores NNS N
of IN N
PPVT NNP N
in IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
CONCLUSION NNP N
EA NNP N
combined VBD N
with IN N
behavior JJ N
therapy NN N
can MD N
significantly RB N
improve VB N
clinical JJ N
symptoms NNS N
of IN N
autism NN N
, , N
but CC N
does VBZ N
not RB N
improve VB N
intelligence NN N
-DOCSTART- -X- O O 15509022

Total JJ N
anthelmintic JJ N
failure NN N
to TO N
control VB N
nematode JJ 4_p
parasites NNS 4_p
of IN N
small JJ N
ruminants NNS N
on IN N
government NN N
breeding NN N
farms NNS N
in IN N
Sabah NNP N
, , N
East NNP N
Malaysia NNP N
Government-owned JJ N
small-ruminant JJ N
breeding NN N
farms NNS N
in IN N
Malaysia NNP N
provide VBP N
the DT N
source NN N
of IN N
sheep NN N
and CC N
goats NNS N
to TO N
smallholder VB N
farmers NNS N
in IN N
the DT N
country NN N
In IN N
the DT N
eastern JJ N
Malaysian JJ N
state NN N
of IN N
Sabah NNP N
, , N
high-level JJ N
stock NN N
losses NNS N
have VBP N
been VBN N
recorded VBN N
on IN N
these DT N
farms NNS N
for IN N
several JJ N
years NNS N
, , N
frequently RB N
accompanied VBN N
by IN N
clinical JJ N
signs NNS N
indicating VBG N
pathogenic JJ N
levels NNS N
of IN N
infections NNS N
with IN N
the DT N
nematode JJ 4_p
parasite NN 4_p
Haemonchus NNP 4_p
contortus NN 4_p
This DT N
suggests VBZ N
that IN N
their PRP$ N
dependence NN N
on IN N
chemotherapy NN N
to TO N
control VB N
parasite JJ N
infections NNS N
had VBD N
failed VBN N
Accordingly RB N
, , N
tests NNS N
for IN N
anthelmintic JJ N
efficacy NN N
using VBG N
the DT N
faecal JJ N
egg NN N
count NN N
reduction NN N
test NN N
( ( N
FECRT NNP N
) ) N
on IN N
the DT N
range NN N
of IN N
drugs NNS N
used VBN N
to TO N
control VB N
nematode JJ N
parasites NNS N
were VBD N
carried VBN N
out RP N
on IN N
the DT N
five CD N
government NN N
small-ruminant JJ N
breeding NN N
farms NNS N
in IN N
Sabah NNP N
These DT N
tests NNS N
showed VBD N
a DT N
total JJ N
failure NN N
of IN N
the DT N
benzimidazole NN N
, , N
imidothiazole NN N
, , N
macrocyclic JJ N
lactone NN N
and CC N
salicylanilide JJ N
groups NNS N
of IN N
anthelmintics NNS N
to TO N
control VB N
H. NNP N
contortus JJ N
infections NNS N
of IN N
sheep NN N
and CC N
goats NNS N
on IN N
all DT N
farms NNS N
Drastic JJ N
changes NNS N
in IN N
animal JJ N
management NN N
need NN N
to TO N
be VB N
made VBN N
in IN N
an DT N
attempt NN N
to TO N
deal VB N
with IN N
this DT N
situation NN N
, , N
for IN N
which WDT N
suggestions NNS N
are VBP N
made VBN N
-DOCSTART- -X- O O 21636141

Short-term JJ N
effect NN N
of IN N
pitavastatin NN N
on IN N
the DT N
reactive JJ N
hyperemic JJ N
index NN N
in IN N
post-menopausal JJ 4_p
women NNS 2_p
with IN N
high JJ 4_p
levels NNS 4_p
in IN 4_p
serum JJ 4_p
LDL-cholesterol NNP 4_p
-DOCSTART- -X- O O 7028532

A DT N
controlled VBN N
trial NN N
with IN N
diclofensine NN N
, , N
a DT N
new JJ N
psychoactive JJ N
drug NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
depression NN N
Diclofensine NNP N
inhibits VBZ N
the DT N
uptake NN N
of IN N
serotonin NN N
, , N
noradrenaline NN N
and CC N
dopamine NN N
In IN N
a DT N
controlled JJ N
study NN N
, , N
out-patients NNS 4_p
suffering VBG 4_p
from IN 4_p
moderate JJ 4_p
to TO 4_p
severe JJ 4_p
depression NN 4_p
were VBD N
treated VBN N
with IN N
the DT N
objective NN N
of IN N
assessing VBG N
the DT N
new JJ N
drug NN N
's POS N
therapeutically RB N
effective JJ N
dose NN N
range NN N
Maprotiline NNP N
was VBD N
used VBN N
as IN N
a DT N
reference NN N
drug NN N
: : N
fourteen JJ 3_p
patients NNS N
were VBD N
assigned VBN N
to TO N
receive VB N
diclofensine NN N
and CC N
thirteen NN 3_p
to TO N
receive VB N
maprotiline NN N
in IN N
a DT N
double-blind JJ N
design NN N
Depending VBG N
on IN N
tolerance NN N
and CC N
efficacy NN N
, , N
they PRP N
were VBD N
treated VBN N
for IN N
periods NNS N
ranging VBG N
from IN N
5 CD N
to TO N
150 CD N
days NNS N
Doses NNS N
were VBD N
titrated VBN N
to TO N
the DT N
optimum NN N
Findings NNS N
suggest VBP N
that IN N
a DT N
50 CD N
mg JJ N
daily JJ N
dose NN N
of IN N
diclofensine NN N
would MD N
be VB N
sufficient JJ N
for IN N
the DT N
majority NN N
of IN N
the DT N
patients NNS N
The DT N
dosage NN N
can MD N
be VB N
safely RB N
increased VBN N
up RP N
to TO N
150 CD N
mg NNS N
daily RB N
but CC N
this DT N
offers VBZ N
few JJ N
therapeutic JJ N
advantages NNS N
While IN N
the DT N
efficacy NN N
index NN N
of IN N
the DT N
two CD N
drugs NNS N
was VBD N
similar JJ N
( ( N
approximately RB N
60 CD N
% NN N
) ) N
, , N
they PRP N
differed VBD N
greatly RB N
in IN N
their PRP$ N
profile NN N
of IN N
side-effects NNS N
No DT N
signs NNS N
of IN N
abrupt JJ N
dissipation NN N
of IN N
the DT N
achieved JJ N
clinical JJ N
effects NNS N
were VBD N
observed VBN N
during IN N
continued JJ N
treatment NN N
, , N
and CC N
no DT N
withdrawal NN N
reactions NNS N
were VBD N
observed VBN N
when WRB N
the DT N
treatment NN N
was VBD N
stopped VBN N
The DT N
new JJ N
drug NN N
may MD N
be VB N
more RBR N
effective JJ N
in IN N
treating VBG N
patients NNS N
in IN N
whom WP N
a DT N
psycho-energizing NN N
and CC N
mood NN N
alleviating VBG N
effect NN N
is VBZ N
desired VBN N
-DOCSTART- -X- O O 6839001

Human NNP N
platelet NN N
response NN N
to TO N
three CD N
salicylate NN N
dosage NN N
forms NNS N
Acetylsalicylic NNP N
acid NN N
( ( N
ASA NNP N
) ) N
inhibition NN N
of IN N
platelet NN N
aggregation NN N
as IN N
evaluated VBN N
by IN N
collagen-induced JJ N
14C-serotonin JJ N
release NN N
, , N
has VBZ N
been VBN N
measured VBN N
in IN N
12 CD 3_p
healthy JJ N
male JJ 2_p
subjects NNS N
Each DT N
subject NN N
received VBD N
a DT N
single JJ N
oral JJ N
dose NN N
( ( N
650 CD N
mg NN N
) ) N
of IN N
enteric-coated JJ N
ASA NNP N
( ( N
ecASA NN N
) ) N
and CC N
compressed VBN N
ASA NNP N
tablets NNS N
( ( N
cASA NN N
) ) N
, , N
or CC N
ecASA NN N
and CC N
sodium NN N
salicylate NN N
( ( N
578 CD N
mg NN N
) ) N
separated VBN N
by IN N
a DT N
minimum NN N
of IN N
5 CD N
weeks NNS N
The DT N
platelet NN N
response NN N
was VBD N
related VBN N
to TO N
plasma VB N
ASA NNP N
and CC N
salicyclic JJ N
acid NN N
determined VBN N
by IN N
high-pressure NN N
liquid NN N
chromatography NN N
Both DT N
ecASA JJ N
and CC N
cASA JJ N
inhibited VBN N
14C-serotonin JJ N
release NN N
; : N
no DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
maximum JJ N
effect NN N
between IN N
these DT N
two CD N
products NNS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
No DT N
relationship NN N
was VBD N
found VBN N
between IN N
the DT N
maximum JJ N
observed JJ N
plasma NN N
ASA NNP N
level NN N
and CC N
the DT N
maximum JJ N
effect NN N
Further NNP N
, , N
no DT N
correlation NN N
was VBD N
found VBN N
between IN N
the DT N
maximum JJ N
inhibition NN N
of IN N
14C-serotonin JJ N
release NN N
in IN N
vivo NN N
and CC N
the DT N
release NN N
predicted VBD N
from IN N
in IN N
vitro JJ N
experiments NNS N
wherein VBP N
the DT N
effect NN N
was VBD N
measured VBN N
after IN N
incubating VBG N
plasma NN N
containing VBG N
specified VBN N
ASA NNP N
concentrations NNS N
-DOCSTART- -X- O O 25619686

Three-Arm NNP N
Randomized NNP N
Phase NNP N
III NNP N
Trial NNP N
: : N
Quality NN N
Aloe NNP N
and CC N
Placebo NNP N
Cream NNP N
Versus NNP N
Powder NNP N
as IN N
Skin NNP N
Treatment NNP N
During IN N
Breast NNP 4_p
Cancer NNP 4_p
Radiation NNP N
Therapy NNP N
BACKGROUND NNP N
The DT N
efficacy NN N
of IN N
aloe JJ N
extract NN N
in IN N
reducing VBG N
radiation-induced JJ N
skin JJ N
injury NN N
is VBZ N
controversial JJ N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
3-arm JJ N
randomized VBN N
trial NN N
was VBD N
to TO N
test VB N
the DT N
efficacy NN N
of IN N
quality-tested JJ N
aloe NN N
extract NN N
in IN N
reducing VBG N
the DT N
severity NN N
of IN N
radiation-induced JJ N
skin JJ N
injury NN N
and CC N
, , N
secondarily RB N
, , N
to TO N
examine VB N
the DT N
effect NN N
of IN N
a DT N
moist NN N
cream NN N
versus IN N
a DT N
dry JJ N
powder NN N
skin NN N
care NN N
regimen NNS N
MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
248 CD 3_p
patients NNS N
with IN N
breast JJ 4_p
cancer NN 4_p
were VBD N
randomized VBN N
to TO N
powder VB N
, , N
aloe VB N
cream NN N
, , N
or CC N
placebo NN N
cream NN N
Acute NNP N
skin JJ N
toxicity NN N
was VBD N
scored VBN N
weekly JJ N
and CC N
after IN N
treatment NN N
at IN N
weeks NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
4 CD N
using VBG N
a DT N
modified VBN N
10-point JJ N
Catterall NNP N
scale NN N
The DT N
patients NNS N
scored VBD N
their PRP$ N
symptom JJ N
severity NN N
using VBG N
a DT N
6-point JJ N
Likert NNP N
scale NN N
and CC N
kept VBD N
an DT N
acute JJ N
phase NN N
diary NN N
RESULTS VB N
The DT N
aloe JJ N
formulation NN N
did VBD N
not RB N
reduce VB N
acute JJ N
skin NN N
toxicity NN N
or CC N
symptom JJ N
severity NN N
Patients NNS N
with IN N
a DT N
greater JJR N
body NN N
mass NN N
index NN N
were VBD N
more RBR N
likely JJ N
to TO N
develop VB N
acute JJ N
skin NN N
toxicity NN N
A DT N
similar JJ N
pattern NN N
of IN N
increased VBN N
skin NN N
reaction NN N
toxicity NN N
occurred VBD N
with IN N
both DT N
study NN N
creams NNS N
compared VBN N
with IN N
the DT N
dry JJ N
powder NN N
regimen NNS N
CONCLUSION NNP N
No NNP N
evidence NN N
was VBD N
found VBN N
to TO N
support VB N
prophylactic JJ N
application NN N
of IN N
quality NN N
aloe VBP N
extract NN N
or CC N
cream NN N
to TO N
improve VB N
the DT N
symptoms NNS N
or CC N
reduce VB N
the DT N
skin NN N
reaction NN N
severity NN N
Our PRP$ N
results NNS N
support VB N
a DT N
dry JJ N
skin NN N
care NN N
regimen NNS N
of IN N
powder NN N
during IN N
radiation NN N
therapy NN N
-DOCSTART- -X- O O 19657698

Prognostic JJ N
value NN N
of IN N
postoperative JJ N
CEA NNP N
clearance NN N
in IN N
rectal JJ 4_p
cancer NN 4_p
patients NNS 4_p
with IN 4_p
high JJ 4_p
preoperative JJ 4_p
CEA NNP 4_p
levels NNS 4_p
PURPOSE NNP N
We PRP N
determined VBD N
the DT N
prognostic JJ N
value NN N
of IN N
carcinoembryonic JJ N
antigen NN N
( ( N
CEA NNP N
) ) N
clearance NN N
after IN N
tumor NN N
resection NN N
with IN N
serial JJ N
evaluation NN N
of IN N
postoperative JJ N
CEA NNP N
levels NNS N
in IN N
rectal JJ N
cancer NN N
METHODS NNP N
Between NNP N
1994 CD N
and CC N
2004 CD N
, , N
we PRP N
retrospectively RB N
reviewed VBD N
122 CD 3_p
patients NNS N
with IN N
rectal JJ N
cancer NN N
whose WP$ N
serum JJ N
CEA NNP N
levels NNS N
were VBD N
measured VBN N
on IN N
the DT N
preoperative JJ N
day NN N
and CC N
postoperative JJ N
days NNS N
7 CD N
and CC N
30 CD N
Patients NNS N
with IN N
preoperative JJ N
CEA NNP N
levels NNS N
< VBP N
5.0 CD N
ng/ml NNS N
were VBD N
excluded VBN N
An DT N
exponential JJ N
trend NN N
line NN N
was VBD N
drawn VBN N
using VBG N
the DT N
three CD N
CEA NNP N
values NNS N
Patients NNS N
were VBD N
categorized VBN N
into IN N
three CD N
groups NNS N
based VBN N
on IN N
R NNP N
( ( N
2 CD N
) ) N
values NNS N
calculated VBN N
through IN N
trend NN N
line NN N
, , N
which WDT N
indicates VBZ N
the DT N
correlation NN N
coefficient NN N
between IN N
exponential JJ N
graph NN N
and CC N
measured VBD N
CEA NNP N
values NNS N
: : N
exponential JJ N
decrease NN N
group NN N
( ( N
group NN N
1 CD N
: : N
0.9 CD N
< NN N
R NNP N
( ( N
2 CD N
) ) N
< NN N
or CC N
= VB N
1.0 CD N
) ) N
, , N
nearly RB N
exponential JJ N
decrease NN N
group NN N
( ( N
group NN N
2 CD N
: : N
0.5 CD N
< NN N
R NNP N
( ( N
2 CD N
) ) N
< NN N
or CC N
= VB N
0.9 CD N
) ) N
, , N
and CC N
randomized JJ N
clearance NN N
group NN N
( ( N
group NN N
3 CD N
: : N
0.5 CD N
< NN N
or CC N
= VB N
R NNP N
( ( N
2 CD N
) ) N
) ) N
We PRP N
then RB N
analyzed VBD N
the DT N
CEA NNP N
clearance NN N
pattern NN N
as IN N
a DT N
prognostic JJ N
indicator NN N
RESULTS NNP N
With IN N
a DT N
median JJ N
follow-up NN N
of IN N
57 CD N
months NNS N
, , N
the DT N
5-year JJ N
overall JJ N
survival NN N
was VBD N
62.3 CD N
% NN N
vs. FW N
48.1 CD N
% NN N
vs. FW N
25 CD N
% NN N
and CC N
the DT N
5-year JJ N
disease-free JJ N
survival NN N
was VBD N
58.6 CD N
% NN N
vs. FW N
52.7 CD N
% NN N
vs. FW N
25 CD N
% NN N
among IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
( ( N
P NNP N
= NNP N
0.014 CD N
, , N
P NNP N
= NNP N
0.027 CD N
, , N
respectively RB N
) ) N
in IN N
patients NNS N
with IN N
stage NN N
III NNP N
rectal JJ N
cancer NN N
For IN N
those DT N
with IN N
stage NN N
II NNP N
rectal NN N
cancer NN N
, , N
the DT N
5-year JJ N
overall JJ N
survival NN N
rate NN N
of IN N
group NN N
1 CD N
was VBD N
significantly RB N
better JJR N
than IN N
groups NNS N
2 CD N
and CC N
3 CD N
( ( N
88.8 CD N
% NN N
vs. FW N
74.1 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
= NNP N
0.021 CD N
) ) N
CONCLUSIONS VB N
The DT N
postoperative JJ N
pattern NN N
of IN N
CEA NNP N
clearance NN N
is VBZ N
a DT N
useful JJ N
prognostic JJ N
determinant NN N
in IN N
patients NNS N
with IN N
rectal JJ N
cancer NN N
Patients NNS N
with IN N
a DT N
randomized JJ N
pattern NN N
of IN N
CEA NNP N
clearance NN N
after IN N
tumor NN N
resection NN N
should MD N
be VB N
regarded VBN N
as IN N
having VBG N
the DT N
possibility NN N
of IN N
a DT N
persistent JJ N
CEA NNP N
source NN N
and CC N
may MD N
require VB N
consideration NN N
of IN N
intensive JJ N
follow-up NN N
or CC N
adjuvant JJ N
therapy NN N
-DOCSTART- -X- O O 23611569

Vilazodone NN N
lacks VBZ N
proarrhythmogenic JJ N
potential NN N
in IN N
healthy JJ N
participants NNS N
: : N
a DT N
thorough JJ N
ECG NNP N
study NN N
OBJECTIVE NNP N
Vilazodone NNP N
is VBZ N
a DT N
potent JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
and CC N
5-HT1A JJ N
receptor NN N
partial JJ N
agonist NN N
approved VBD N
for IN N
the DT N
treatment NN N
of IN N
major JJ N
depressive JJ N
disorder NN N
( ( N
MDD NNP N
) ) N
in IN N
adults NNS N
The DT N
effect NN N
of IN N
clinical JJ N
and CC N
supratherapeutic JJ N
doses NNS N
of IN N
vilazodone NN N
on IN N
cardiac JJ N
repolarization NN N
was VBD N
determined VBN N
in IN N
healthy JJ 4_p
volunteers NNS 4_p
METHODS NNP N
In IN N
this DT N
Phase NNP N
1 CD N
, , N
randomized VBN N
, , N
doubleblind VB N
, , N
placebo- JJ N
and CC N
active-controlled JJ N
, , N
3-arm JJ N
, , N
parallel JJ N
, , N
single-center JJ N
study NN N
, , N
healthy JJ N
subjects NNS N
received VBD N
placebo NN N
; : N
moxifloxacin CC N
400 CD N
mg NN N
; : N
or CC N
vilazodone NN N
( ( N
sequentially RB N
escalated VBN N
every DT N
3 CD N
days NNS N
) ) N
10 CD N
, , N
20 CD N
, , N
40 CD N
, , N
60 CD N
, , N
and CC N
80 CD N
mg/day NN N
The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
time-matched JJ N
change NN N
from IN N
baseline NN N
in IN N
the DT N
QT NNP N
interval NN N
corrected VBD N
for IN N
heart NN N
rate NN N
( ( N
QTc NNP N
) ) N
using VBG N
an DT N
individual JJ N
correction NN N
method NN N
( ( N
QTcI NNP N
) ) N
RESULTS JJ N
Placebo-corrected JJ N
time-matched JJ N
analysis NN N
of IN N
the DT N
QTcI NNP N
duration NN N
for IN N
the DT N
vilazodone NN N
treatment NN N
effect NN N
indicated VBD N
that IN N
no DT N
vilazodone NN N
dose NN N
had VBD N
an DT N
upper JJ N
bound NN N
that IN N
approached VBD N
or CC N
exceeded VBD N
10 CD N
ms NN N
, , N
demonstrating VBG N
no DT N
signal NN N
for IN N
a DT N
significant JJ N
vilazodone NN N
effect NN N
on IN N
cardiac JJ N
repolarization NN N
Vilazodone NNP N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
heart NN N
rate NN N
, , N
PR NNP N
, , N
or CC N
QRS NNP N
interval JJ N
duration NN N
The DT N
pharmacokinetic/pharmacodynamic JJ N
model NN N
showed VBD N
that IN N
the DT N
QTcI NNP N
slope NN N
for IN N
vilazodone NN N
was VBD N
not RB N
different JJ N
from IN N
0.0 CD N
and CC N
that IN N
the DT N
predicted JJ N
increase NN N
from IN N
baseline NN N
in IN N
the DT N
QTc NNP N
at IN N
Cmax NNP N
for IN N
the DT N
highest JJS N
therapeutic JJ N
dose NN N
( ( N
156 CD N
ng/ml RB N
after IN N
40 CD N
mg/day NN N
) ) N
was VBD N
< JJ N
1 CD N
ms NN N
The DT N
incidence NN N
of IN N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
was VBD N
higher RBR N
in IN N
the DT N
vilazodone NN N
group NN N
( ( N
57.6 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
moxifloxacin NN N
( ( N
37.0 CD N
% NN N
) ) N
and CC N
placebo NN N
( ( N
35.6 CD N
% NN N
) ) N
groups NNS N
, , N
though IN N
AEs NNP N
were VBD N
generally RB N
mild VBN N
to TO N
moderate VB N
in IN N
severity NN N
and CC N
resulted VBD N
in IN N
few JJ N
discontinuations NNS N
CONCLUSIONS NNP N
Vilazodone NNP N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
cardiac JJ N
repolarization NN N
, , N
heart NN N
rate NN N
, , N
PR NNP N
or CC N
QRS NNP N
interval JJ N
duration NN N
, , N
or CC N
ECG NNP N
morphology NN N
in IN N
healthy JJ 4_p
adult NN 4_p
participants NNS 4_p
-DOCSTART- -X- O O 2008691

[ JJ N
Gluten-free NNP N
diet NN N
in IN N
infantile JJ 4_p
autism NN 4_p
A NNP N
therapeutic JJ N
trial NN N
] NN N
It PRP N
has VBZ N
been VBN N
postulated VBN N
that IN N
there EX N
may MD N
be VB N
a DT N
connection NN N
between IN N
wheat-gluten/milk-casein NN N
and CC N
mental JJ N
disorders NNS N
such JJ N
as IN N
schizophrenia NN N
, , N
hyperactivity NN N
and CC N
autism NN N
In IN N
this DT N
study NN N
seven CD N
patients NNS N
with IN N
infantile JJ N
autism NN N
, , N
three CD N
before IN N
puberty NN N
and CC N
four CD N
after IN N
puberty NN N
, , N
were VBD N
given VBN N
a DT N
gluten-free JJ N
diet NN N
Three CD N
children NNS N
were VBD N
provoked VBN N
with IN N
gluten/placebo NN N
in IN N
a DT N
double-blind NN N
study NN N
Four CD N
young JJ N
patients NNS N
participated VBN N
in IN N
an DT N
open JJ N
study NN N
and CC N
were VBD N
given VBN N
a DT N
gluten-free JJ N
diet NN N
in IN N
six CD N
months NNS N
Behaviour NNP N
was VBD N
registered VBN N
before RB N
, , N
during IN N
and CC N
after IN N
the DT N
period NN N
with IN N
a DT N
gluten-free JJ N
diet NN N
Visual NNP N
Analogue NNP N
Scale NNP N
and CC N
Real NNP N
Life NNP N
Rating NNP N
Scale NNP N
were VBD N
used VBN N
to TO N
register VB N
changes NNS N
in IN N
behaviour NN N
No DT N
connection NN N
was VBD N
observed VBN N
between IN N
gluten NNS N
and CC N
behaviour VB N
typical JJ N
for IN N
these DT N
patients NNS N
On IN N
the DT N
contrary JJ N
, , N
the DT N
gluten-free JJ N
diet NN N
seemed VBD N
to TO N
be VB N
another DT N
negative JJ N
factor NN N
leading VBG N
to TO N
further JJ N
social JJ N
isolation NN N
in IN N
this DT N
group NN N
of IN N
highly RB N
socially RB N
handicapped JJ N
patients NNS N
and CC N
families NNS N
-DOCSTART- -X- O O 9230829

Mortality NN N
in IN N
patients NNS N
with IN N
small JJ N
choroidal NNS N
melanoma NN N
COMS NNP N
report NN N
no DT N
4 CD N
The DT N
Collaborative JJ N
Ocular NNP N
Melanoma NNP N
Study NNP N
Group NNP N
OBJECTIVE NNP N
To TO N
describe VB N
the DT N
clinical JJ N
characteristics NNS N
and CC N
survival JJ N
experience NN N
of IN N
a DT N
prospectively RB N
followed VBN N
up RP N
group NN N
of IN N
patients NNS N
with IN N
small JJ N
choroidal NNS N
melanoma NN N
METHODS NNP N
The DT N
Collaborative NNP N
Ocular NNP N
Melanoma NNP N
Study NNP N
( ( N
COMS NNP N
) ) N
is VBZ N
a DT N
set NN N
of IN N
clinical JJ N
trials NNS N
designed VBN N
to TO N
compare VB N
the DT N
role NN N
of IN N
radiotherapy NN N
and CC N
enucleation NN N
in IN N
the DT N
treatment NN N
of IN N
medium NN N
and CC N
large-size JJ N
choroidal NN N
melanoma NN N
From IN N
December NNP N
1986 CD N
to TO N
August NNP N
1989 CD N
, , N
patients NNS N
with IN N
small JJ N
choroidal NN N
melanoma NN N
, , N
not RB N
large JJ N
enough RB N
to TO N
be VB N
eligible JJ N
for IN N
the DT N
COMS NNP N
clinical JJ N
trials NNS N
, , N
were VBD N
offered VBN N
participation NN N
in IN N
a DT N
nonrandomized JJ N
prospective JJ N
follow-up NN N
study NN N
Small NNP N
choroidal JJ N
melanomas NN N
were VBD N
defined VBN N
as IN N
1.0 CD N
to TO N
3.0 CD N
mm NNS N
in IN N
apical JJ N
height NN N
and CC N
at IN N
least JJS N
5.0 CD N
mm NN N
in IN N
basal NN N
diameter NN N
A DT N
total NN N
of IN N
204 CD N
patients NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
Patients NNS N
were VBD N
followed VBN N
up RP N
annually RB N
through IN N
August NNP N
1989 CD N
Two CD N
additional JJ N
assessments NNS N
of IN N
treatment NN N
status NN N
and CC N
mortality NN N
were VBD N
conducted VBN N
in IN N
1993-1994 JJ N
and CC N
1995-1996 JJ N
The DT N
median JJ N
length NN N
of IN N
follow-up NN N
was VBD N
92 CD N
months NNS N
Eight NNP N
percent NN N
of IN N
patients NNS N
were VBD N
treated VBN N
at IN N
the DT N
time NN N
of IN N
study NN N
enrollment NN N
and CC N
an DT N
additional JJ N
33 CD N
% NN N
were VBD N
treated VBN N
during IN N
follow-up JJ N
RESULTS JJ N
Twenty-seven JJ N
patients NNS N
have VBP N
died VBN N
; : N
6 CD N
deaths NNS N
were VBD N
reported VBN N
by IN N
the DT N
clinical JJ N
center NN N
as IN N
due JJ N
to TO N
metastatic JJ N
melanoma NN N
The DT N
Kaplan-Meier NNP N
estimate NN N
of IN N
5-year JJ N
all-cause JJ N
mortality NN N
was VBD N
6.0 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
2.7 CD N
% NN N
-9.3 NNP N
% NN N
) ) N
and CC N
8-year JJ N
all-cause NN N
mortality NN N
was VBD N
14.9 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
9.6 CD N
% NN N
-20.2 NNP N
% NN N
) ) N
CONCLUSIONS NNP N
Otherwise NNP N
healthy JJ N
patients NNS N
, , N
average JJ N
age NN N
of IN N
60 CD N
years NNS N
, , N
without IN N
a DT N
previous JJ N
diagnosis NN N
of IN N
malignant JJ N
disease NN N
who WP N
have VBP N
small JJ N
choroidal JJ N
lesions NNS N
judged VBD N
to TO N
be VB N
melanoma VBN N
have VBP N
a DT N
low JJ N
risk NN N
of IN N
dying VBG N
within IN N
5 CD N
years NNS N
-DOCSTART- -X- O O 16382035

Albendazole JJ N
trial NN N
at IN N
15 CD N
or CC N
30 CD N
mg/kg/day NN N
for IN N
subarachnoid NN 4_p
and CC 4_p
intraventricular JJ 4_p
cysticercosis NN 4_p
Thirty-six JJ 3_p
patients NNS N
with IN N
subarachnoid JJ 4_p
and CC 4_p
intraventricular JJ 4_p
cysticercosis NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
albendazole NN N
at IN N
15 CD N
or CC N
30 CD N
mg/kg/day JJ N
plus CC N
dexamethasone NN N
for IN N
8 CD N
days NNS N
Results NNS N
favored VBD N
a DT N
higher JJR N
dose NN N
, , N
with IN N
larger JJR N
cyst NN N
reduction NN N
on IN N
MRI NNP N
at IN N
90 CD N
and CC N
180 CD N
days NNS N
and CC N
higher JJR N
albendazole JJ N
sulfoxide NN N
levels NNS N
in IN N
plasma NN N
An DT N
albendazole JJ N
course NN N
at IN N
30 CD N
mg/kg/day NN N
combined VBN N
with IN N
corticosteroids NNS N
is VBZ N
safe JJ N
and CC N
more RBR N
effective JJ N
than IN N
the DT N
usual JJ N
dose NN N
A DT N
single JJ N
treatment NN N
was VBD N
insufficient JJ N
in IN N
intraventricular JJ N
and CC N
giant JJ N
cysts NNS N
-DOCSTART- -X- O O 21224870

Efficient JJ N
tetanus NN 4_p
toxoid JJ 4_p
immunization NN 4_p
on IN N
vitamin NN 4_p
D NNP 4_p
supplementation NN 4_p
BACKGROUND/OBJECTIVES NNP N
Vitamin NNP N
D NNP N
mediates VBZ N
immunomodulatory JJ N
functions NNS N
, , N
and CC N
its PRP$ N
deficiency NN N
has VBZ N
been VBN N
associated VBN N
with IN N
an DT N
increased JJ N
prevalence NN N
of IN N
immunological JJ N
diseases NNS N
The DT N
supplementation NN N
of IN N
vitamin NN N
D NNP N
might MD N
be VB N
therapeutically RB N
beneficial JJ N
, , N
for IN N
example NN N
, , N
in IN N
lupus JJ N
erythematosus NN N
patients NNS N
However RB N
, , N
its PRP$ N
affect NN N
on IN N
established VBN N
recall NN N
immune NN N
responses NNS N
is VBZ N
undefined JJ N
SUBJECTS/METHODS NNP N
In IN N
all DT N
, , N
32 CD 3_p
individuals NNS N
were VBD N
randomized VBN N
in IN N
a DT N
placebo NN N
controlled VBN N
, , N
double-blind JJ N
setting NN N
, , N
and CC N
received VBD N
vitamin NNS N
D NNP N
( ( N
daily JJ N
2000 CD N
IU NNP N
) ) N
for IN N
10 CD N
weeks NNS N
followed VBN N
by IN N
tetanus NN N
toxoid NN N
( ( N
TT NNP N
) ) N
booster NN N
immunization NN N
RESULTS NNP N
During IN N
vitamin JJ N
D NNP N
supplementation NN N
the DT N
median JJ N
25-hydroxyvitamin JJ N
D NNP N
serum NN N
concentration NN N
increased VBD N
to TO N
80.3 CD N
nM NNS N
, , N
which WDT N
as IN N
expected VBN N
decreased VBN N
in IN N
the DT N
placebo NN N
group NN N
to TO N
29.1 CD N
nM NNS N
during IN N
the DT N
ultraviolet-deprived JJ N
winter NN N
months NNS N
The DT N
TT-specific JJ N
immunoglobulin NN N
G NNP N
( ( N
IgG NNP N
) ) N
boost VBD N
efficiency NN N
was VBD N
marginal JJ N
higher JJR N
in IN N
the DT N
vitamin NN N
D NNP N
group NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
The DT N
increase NN N
of IN N
the DT N
25-hydroxyvitamin JJ N
D NNP N
levels NNS N
correlated VBN N
with IN N
the DT N
increase NN N
of IN N
TT-IgG NNP N
serum NN N
concentrations NNS N
The DT N
induction NN N
of IN N
specific JJ N
serum NN N
IgA NNP N
and CC N
specific JJ N
antibody NN N
secreting VBG N
cells NNS N
was VBD N
comparable JJ N
between IN N
both DT N
groups NNS N
Accordingly RB N
, , N
the DT N
TT-specific NNP N
and CC N
polyclonally RB N
triggered VBD N
T-cell NNP N
cytokine NN N
profiles NNS N
were VBD N
stable JJ N
as RB N
well RB N
CONCLUSIONS NNP N
Vitamin NNP N
D NNP N
supplementation NN N
was VBD N
successful JJ N
and CC N
booster JJ N
immunization NN N
induced VBD N
efficiently RB N
specific JJ N
antibodies NNS N
titers NNS N
-DOCSTART- -X- O O 18157013

Minimally RB N
invasive JJ N
treatment NN N
combined VBN N
with IN N
cytokine-induced JJ N
killer NN N
cells NNS N
therapy VBP N
lower JJR N
the DT N
short-term JJ N
recurrence NN N
rates NNS N
of IN N
hepatocellular JJ 4_p
carcinomas NN 4_p
The DT N
recurrence NN N
of IN N
hepatocellular JJ N
carcinoma NN N
( ( N
HCC NNP N
) ) N
after IN N
minimally RB N
invasive JJ N
therapy NN N
is VBZ N
frequent JJ N
Adoptive JJ N
immunotherapy NN N
is VBZ N
thought VBN N
to TO N
be VB N
an DT N
effective JJ N
method NN N
to TO N
lower JJR N
recurrence NN N
and CC N
metastasis NN N
rates NNS N
of IN N
malignant JJ N
tumors NNS N
Therefore RB N
, , N
85 CD 3_p
HCC NNP N
patients NNS N
after IN N
transcatheter JJ N
arterial JJ N
chemoembolization NN N
and CC N
radiofrequency NN N
ablation NN N
therapy NN N
were VBD N
randomized VBN N
to TO N
immunotherapy VB N
group NN N
and CC N
no DT N
adjuvant JJ N
therapy NN N
group NN N
Autologous JJ N
cytokine-induced JJ N
killer NN N
( ( N
CIK NNP N
) ) N
cells NNS N
were VBD N
transfused VBN N
via IN N
hepatic JJ N
artery NN N
to TO N
the DT N
patients NNS N
The DT N
alteration NN N
of IN N
levels NNS N
of IN N
lymphocyte JJ N
subsets NNS N
in IN N
peripheral JJ N
blood NN N
of IN N
patients NNS N
was VBD N
examined VBN N
by IN N
flow JJ N
cytometry NN N
All DT N
patients NNS N
were VBD N
screened VBN N
by IN N
computed JJ N
tomography NN N
every DT N
2 CD N
months NNS N
to TO N
observe VB N
the DT N
tumor NN 4_p
recurrent NN 4_p
conditions NNS 4_p
After IN N
CIK NNP N
cell NN N
infusions NNS N
, , N
the DT N
percentages NNS N
of IN N
CD3+ NNP N
, , N
CD4+ NNP N
, , N
CD56+ NNP N
, , N
CD3+CD56+ NNP N
cells NNS N
, , N
and CC N
CD4+/CD8+ NNP N
ratio VBP N
increased VBN N
from IN N
68.6+/-11.0 CD N
% NN N
, , N
31.1+/-9.0 CD N
% NN N
, , N
15.6+/-7.9 CD N
% NN N
, , N
5.2+/-3.1 CD N
% NN N
, , N
and CC N
1.1+/-0.5 JJ N
to TO N
70.7+/-10.1 CD N
% NN N
, , N
33.5+/-8.0 CD N
% NN N
, , N
18.4+/-9.4 CD N
% NN N
, , N
5.9+/-2.8 CD N
% NN N
, , N
and CC N
1.3+/-0.7 JJ N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
; : N
whereas IN N
the DT N
percentage NN N
of IN N
CD8 NNP N
cells NNS N
decreased VBN N
from IN N
31.1+/-7.8 CD N
% NN N
to TO N
28.6+/-8.3 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
The DT N
1-year JJ N
and CC N
18-month JJ N
recurrence NN N
rates NNS N
of IN N
the DT N
study NN N
group NN N
were VBD N
8.9 CD N
% NN N
and CC N
15.6 CD N
% NN N
, , N
compared VBN N
with IN N
30.0 CD N
% NN N
and CC N
40.0 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
( ( N
both DT N
P NNP N
value NN N
< NNP N
0.05 CD N
) ) N
The DT N
data NN N
suggest NN N
that IN N
CIK NNP N
cell NN N
transfusion NN N
is VBZ N
an DT N
effective JJ N
treatment NN N
It PRP N
can MD N
boost VB N
the DT N
immunologic JJ N
function NN N
in IN N
HCC NNP 4_p
patients NNS N
and CC N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
reducing VBG N
the DT N
recurrence NN N
rate NN N
of IN N
HCC NNP N
-DOCSTART- -X- O O 10663363

Randomized VBN N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
risedronate NN N
on IN N
vertebral JJ N
fractures NNS N
in IN N
women NNS 2_p
with IN N
established VBN N
postmenopausal NN 4_p
osteoporosis NN 4_p
Vertebral JJ N
Efficacy NN N
with IN N
Risedronate NNP N
Therapy NNP N
( ( N
VERT NNP N
) ) N
Study NNP N
Group NNP N
The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
, , N
double-masked JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
risedronate NN N
in IN N
the DT N
prevention NN N
of IN N
vertebral JJ N
fractures NNS N
in IN N
postmenopausal JJ 4_p
women NNS 2_p
with IN N
established VBN 4_p
osteoporosis NN 4_p
The DT N
study NN N
was VBD N
conducted VBN N
at IN N
80 CD N
study NN N
centers NNS N
in IN N
Europe NNP N
and CC N
Australia NNP N
Postmenopausal NNP N
women NNS 2_p
( ( N
n JJ 3_p
= NN 3_p
1226 CD 3_p
) ) N
with IN 4_p
two CD 4_p
or CC 4_p
more JJR 4_p
prevalent JJ 4_p
vertebral JJ 4_p
fractures NNS 4_p
received VBD N
risedronate JJ N
2.5 CD N
or CC N
5 CD N
mg/day NN N
or CC N
placebo NN N
; : N
all DT N
subjects NNS N
also RB N
received VBD N
elemental JJ N
calcium NN N
1000 CD N
mg/day NN N
, , N
and CC N
up RB N
to TO N
500 CD N
IU/day NNP N
vitamin FW N
D NNP N
if IN N
baseline NN N
levels NNS N
were VBD N
low JJ N
The DT N
study NN N
duration NN N
was VBD N
3 CD N
years NNS N
; : N
however RB N
, , N
the DT N
2.5 CD N
mg NN N
group NN N
was VBD N
discontinued VBN N
by IN N
protocol NN N
amendment NN N
after IN N
2 CD N
years NNS N
Lateral JJ N
spinal JJ N
radiographs NN N
were VBD N
taken VBN N
annually RB N
for IN N
assessment NN N
of IN N
vertebral JJ N
fractures NNS N
, , N
and CC N
bone RB N
mineral JJ N
density NN N
was VBD N
measured VBN N
by IN N
dual-energy JJ N
X-ray JJ N
absorptiometry NN N
at IN N
6-month JJ N
intervals NNS N
Risedronate VB N
5 CD N
mg NN N
reduced VBD N
the DT N
risk NN N
of IN N
new JJ N
vertebral JJ N
fractures NNS N
by IN N
49 CD N
% NN N
over IN N
3 CD N
years NNS N
compared VBN N
with IN N
control NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
A DT N
significant JJ N
reduction NN N
of IN N
61 CD N
% NN N
was VBD N
seen VBN N
within IN N
the DT N
first JJ N
year NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
The DT N
fracture NN N
reduction NN N
with IN N
risedronate NN N
2.5 CD N
mg NN N
was VBD N
similar JJ N
to TO N
that DT N
in IN N
the DT N
5 CD N
mg NN N
group NN N
over IN N
2 CD N
years NNS N
The DT N
risk NN N
of IN N
nonvertebral JJ N
fractures NNS N
was VBD N
reduced VBN N
by IN N
33 CD N
% NN N
compared VBN N
with IN N
control NN N
over IN N
3 CD N
years NNS N
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
Risedronate NNP N
significantly RB N
increased VBD N
bone JJ N
mineral JJ N
density NN N
at IN N
the DT N
spine NN N
and CC N
hip NN N
within IN N
6 CD N
months NNS N
The DT N
adverse-event JJ N
profile NN N
of IN N
risedronate NN N
, , N
including VBG N
gastrointestinal JJ N
adverse JJ N
events NNS N
, , N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
control NN N
Risedronate NNP N
5 CD N
mg NN N
provides VBZ N
effective JJ N
and CC N
well-tolerated JJ N
therapy NN N
for IN N
severe JJ 4_p
postmenopausal NN 4_p
osteoporosis NN 4_p
, , N
reducing VBG N
the DT N
incidence NN N
of IN N
vertebral JJ N
fractures NNS N
and CC N
improving VBG N
bone NN N
density NN N
in IN N
women NNS 2_p
with IN 4_p
established VBN 4_p
disease NN 4_p
-DOCSTART- -X- O O 125133

Anabolic JJ N
steroids NNS N
in IN N
athelics NNS N
: : N
crossover RB N
double-blind VBP N
trial NN N
on IN N
weightlifters NNS N
Thirteen NNP 3_p
experienced VBD N
male JJ 2_p
weightlifters NNS N
taking VBG N
high-protein JJ N
diets NNS N
and CC N
regular JJ N
exercise NN N
took VBD N
part NN N
in IN N
a DT N
double-blind JJ N
crossover NN N
trial NN N
of IN N
methandienone NN N
10 CD N
or CC N
25 CD N
mg/day NN N
to TO N
seeif VB N
the DT N
drug NN N
improved VBD N
athletic JJ N
performance NN N
Their PRP$ N
improvemments NNS N
were VBD N
significantly RB N
greater JJR N
on IN N
methandienone NN N
than IN N
on IN N
placebo NN N
; : N
their PRP$ N
body NN N
weights NNS N
rose VBD N
( ( N
though IN N
this DT N
seemed VBD N
to TO N
be VB N
associated VBN N
with IN N
water NN N
retention NN N
) ) N
; : N
and CC N
systolic JJ N
blood NN N
pressure NN N
rose VBD N
significantly RB N
Methandienone NNP N
caused VBD N
many JJ N
side NN N
effects NNS N
, , N
and CC N
three CD N
men NNS N
had VBD N
to TO N
withdraw VB N
because IN N
of IN N
them PRP N
All DT N
side NN N
effects NNS N
disappeared VBD N
after IN N
the DT N
drug NN N
was VBD N
stopped VBN N
Anabolic JJ N
steroids NNS N
are VBP N
effective JJ N
only RB N
when WRB N
given VBN N
combination NN N
with IN N
exercise NN N
and CC N
high-protein JJ N
diet NN N
We PRP N
deprecate VBP N
their PRP$ N
use NN N
in IN N
athletics NNS N
but CC N
can MD N
suggest VB N
no DT N
way NN N
of IN N
stopping VBG N
it PRP N
-DOCSTART- -X- O O 17909199

Phase NNP N
II NNP N
study NN N
of IN N
efficacy NN N
and CC N
safety NN N
of IN N
bevacizumab NN N
in IN N
combination NN N
with IN N
chemotherapy NN N
or CC N
erlotinib NN N
compared VBN N
with IN N
chemotherapy NN N
alone RB N
for IN N
treatment NN N
of IN N
recurrent NN 4_p
or CC 4_p
refractory NN 4_p
non JJ 4_p
small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
PURPOSE NNP N
Bevacizumab NNP N
, , N
a DT N
humanized JJ N
anti-vascular JJ N
endothelial JJ N
growth NN N
factor NN N
monoclonal JJ N
antibody NN N
, , N
and CC N
erlotinib RB N
, , N
a DT N
reversible JJ N
, , N
orally RB N
available JJ N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
tyrosine NN N
kinase NN N
inhibitor NN N
, , N
have VBP N
demonstrated VBN N
evidence NN N
of IN N
a DT N
survival JJ N
benefit NN N
in IN N
the DT N
treatment NN N
of IN N
non-small-cell JJ N
lung NN N
cancer NN N
( ( N
NSCLC NNP N
) ) N
A DT N
single-arm JJ N
phase NN N
I PRP N
and CC N
II NNP N
study NN N
of IN N
bevacizumab NN N
plus CC N
erlotinib NN N
demonstrated VBD N
encouraging JJ N
efficacy NN N
, , N
with IN N
a DT N
favorable JJ N
safety NN N
profile NN N
PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
multicenter NN N
, , N
randomized VBN N
phase NN N
II NNP N
trial NN N
evaluated VBD N
the DT N
safety NN N
of IN N
combining VBG N
bevacizumab NN N
with IN N
either DT N
chemotherapy NN N
( ( N
docetaxel NN N
or CC N
pemetrexed NN N
) ) N
or CC N
erlotinib JJ N
and CC N
preliminarily RB N
assessed VBN N
these DT N
combinations NNS N
versus VBP N
chemotherapy NN N
alone RB N
, , N
as IN N
measured VBN N
by IN N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
All DT N
patients NNS N
had VBD N
histologically RB 4_p
confirmed VBN 4_p
nonsquamous JJ 4_p
NSCLC NNP 4_p
that WDT N
had VBD N
progressed VBN N
during IN N
or CC N
after IN N
one CD N
platinum-based JJ N
regimen NNS N
RESULTS NNP N
One CD 3_p
hundred VBD 3_p
twenty NN 3_p
patients NNS 3_p
were VBD N
randomly RB N
assigned VBN N
and CC N
treated VBN N
No DT N
unexpected JJ N
adverse JJ N
events NNS N
were VBD N
noted VBN N
Fewer JJR N
patients NNS N
( ( N
13 CD N
% NN N
) ) N
in IN N
the DT N
bevacizumab-erlotinib JJ N
arm NN N
discontinued VBN N
treatment NN N
as IN N
a DT N
result NN N
of IN N
adverse JJ N
events NNS N
than IN N
in IN N
the DT N
chemotherapy NN N
alone RB N
( ( N
24 CD N
% NN N
) ) N
or CC N
bevacizumab-chemotherapy NN N
( ( N
28 CD N
% NN N
) ) N
arms NNS N
The DT N
incidence NN N
of IN N
grade NN N
5 CD N
hemorrhage NN N
in IN N
patients NNS N
receiving VBG N
bevacizumab NN N
was VBD N
5.1 CD N
% NN N
Although IN N
not RB N
statistically RB N
significant JJ N
, , N
relative JJ N
to TO N
chemotherapy VB N
alone RB N
, , N
the DT N
risk NN N
of IN N
disease NN N
progression NN N
or CC N
death NN N
was VBD N
0.66 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.38 CD N
to TO N
1.16 CD N
) ) N
among IN N
patients NNS N
treated VBN N
with IN N
bevacizumab-chemotherapy NN N
and CC N
0.72 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.42 CD N
to TO N
1.23 CD N
) ) N
among IN N
patients NNS N
treated VBN N
with IN N
bevacizumab-erlotinib JJ N
One-year JJ N
survival NN N
rate NN N
was VBD N
57.4 CD N
% NN N
for IN N
bevacizumab-erlotinib NN N
and CC N
53.8 CD N
% NN N
for IN N
bevacizumab-chemotherapy NN N
compared VBN N
with IN N
33.1 CD N
% NN N
for IN N
chemotherapy NN N
alone RB N
CONCLUSION NNP N
Results NNP N
for IN N
PFS NNP N
and CC N
overall JJ N
survival NN N
favor NN N
combination NN N
of IN N
bevacizumab NN N
with IN N
either DT N
chemotherapy NN N
or CC N
erlotinib NN N
over IN N
chemotherapy NN N
alone RB N
in IN N
the DT N
second-line JJ N
setting NN N
No DT N
unexpected JJ N
safety NN N
signals NNS N
were VBD N
noted VBN N
The DT N
rate NN N
of IN N
fatal JJ N
pulmonary JJ N
hemorrhage NN N
was VBD N
consistent JJ N
with IN N
previous JJ N
bevacizumab NN N
trials NNS N
The DT N
toxicity NN N
profile NN N
of IN N
the DT N
bevacizumab-erlotinib JJ N
combination NN N
is VBZ N
favorable JJ N
compared VBN N
with IN N
either DT N
chemotherapy-containing JJ N
group NN N
-DOCSTART- -X- O O 18051010

Effect NN N
of IN N
a DT N
ferrule NN N
and CC N
increased VBD N
clinical JJ N
crown NN N
length NN N
on IN N
the DT N
in IN N
vitro JJ N
fracture NN N
resistance NN N
of IN N
premolars NNS N
restored VBN N
using VBG N
two CD N
dowel-and-core JJ N
systems NNS N
This DT N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
a DT N
crown-lengthening JJ N
ferrule NN N
on IN N
the DT N
fracture NN N
resistance NN N
of IN N
endodontically-treated JJ N
teeth NNS N
restored VBN N
with IN N
two CD N
dowel-core JJ N
systems NNS N
Thirty-two NNP 3_p
extracted VBD N
mandibular JJ N
first JJ N
premolars NNS N
were VBD N
sectioned VBN N
perpendicular JJ N
to TO N
the DT N
long JJ N
axis NN N
at IN N
a DT N
point NN N
1.0 CD N
mm NN N
occlusal NN N
to TO N
the DT N
buccal JJ N
cementoenamel NN N
junction NN N
Following VBG N
endodontic JJ N
treatment NN N
, , N
the DT N
teeth NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD N
groups NNS N
: : N
cast VBN N
Ni-Cr JJ N
alloy NN N
dowel-core NN N
with IN N
no DT N
ferrule NN N
( ( N
Group NNP N
A1 NNP N
) ) N
, , N
cast VBD N
Ni-Cr JJ N
alloy NN N
dowel-core NN N
with IN N
2.0 CD N
mm NNS N
ferrule NN N
( ( N
Group NNP N
A2 NNP N
) ) N
, , N
prefabricated VBN N
carbon NN N
fiber-reinforced JJ N
dowel-resin NN N
core NN N
with IN N
no DT N
ferrule NN N
( ( N
Group NNP N
B1 NNP N
) ) N
and CC N
carbon JJ N
fiber-reinforced JJ N
dowel-resin NN N
core NN N
with IN N
2.0 CD N
mm NNS N
ferrule NN N
( ( N
Group NNP N
B2 NNP N
) ) N
Each DT N
specimen NN N
was VBD N
embedded VBN N
in IN N
a DT N
self-cured JJ N
acrylic JJ N
resin NN N
block NN N
from IN N
2.0 CD N
mm JJ N
apical JJ N
to TO N
the DT N
margins NNS N
of IN N
a DT N
cast JJ N
Ni-Cr JJ N
alloy NN N
crown NN N
, , N
then RB N
loaded VBD N
at IN N
150 CD N
degrees NNS N
from IN N
the DT N
long JJ N
axis NN N
in IN N
a DT N
universal JJ N
testing VBG N
machine NN N
at IN N
a DT N
crosshead JJ N
speed NN N
of IN N
1.0 CD N
mm/minute NN N
until IN N
fracture NN N
The DT N
data NNS N
were VBD N
recorded VBN N
and CC N
analyzed VBN N
using VBG N
ANOVA NNP N
and CC N
Fisher NNP N
's POS N
exact NN N
tests NNS N
, , N
with IN N
alpha JJ N
= $ N
0.05 CD N
Mean JJ N
failure NN N
loads NNS N
( ( N
kN NN N
) ) N
for IN N
the DT N
A1 NNP N
, , N
A2 NNP N
, , N
B1 NNP N
and CC N
B2 NNP N
Groups NNP N
were VBD N
: : N
1.46 CD N
( ( N
S.D NNP N
0.45 CD N
) ) N
, , N
1.07 CD N
( ( N
0.21 CD N
) ) N
, , N
1.13 CD N
( ( N
0.30 CD N
) ) N
and CC N
1.02 CD N
( ( N
0.27 CD N
) ) N
The DT N
teeth NNS N
restored VBD N
with IN N
cast JJ N
Ni-Cr JJ N
dowel-cores NNS N
and CC N
2.0 CD N
mm NN N
ferrules NNS N
demonstrated VBD N
significantly RB N
lower JJR N
fracture NN N
strengths NNS N
, , N
p VBP N
= JJ N
0.04 CD N
There EX N
were VBD N
significant JJ N
differences NNS N
in IN N
the DT N
root NN N
fracture NN N
patterns VBZ N
between IN N
the DT N
two CD N
dowel NN N
systems NNS N
, , N
with IN N
the DT N
carbon NN N
fiber-reinforced JJ N
dowel-resin NN N
core NN N
system NN N
, , N
being VBG N
the DT N
less JJS N
severe JJ N
p NN N
< VBD N
0.05 CD N
Crown NNP N
lengthening VBG N
with IN N
a DT N
2.0 CD N
mm NN N
apical JJ N
extended VBD N
ferrule NN N
resulted VBD N
in IN N
reduced JJ N
fracture NN N
strengths NNS N
for IN N
endodontically-treated JJ N
teeth NNS N
restored VBN N
using VBG N
two CD N
dowel-core JJ N
systems NNS N
and CC N
cast JJ N
metal NN N
crowns NNS N
The DT N
carbon NN N
fiber-reinforced JJ N
dowel-resin NN N
core NN N
system NN N
reduced VBD N
the DT N
severity NN N
of IN N
the DT N
root NN 4_p
fractures NNS 4_p
-DOCSTART- -X- O O 10195003

A DT N
comparison NN N
of IN N
a DT N
non-ionic JJ N
dimer NN N
, , N
iodixanol NN N
with IN N
a DT N
non-ionic JJ N
monomer NN N
, , N
iohexol NN N
in IN N
low JJ 4_p
dose VBP 4_p
intravenous JJ 4_p
urography NN 4_p
A DT N
prospective JJ N
, , N
double-blind JJ N
study NN N
of IN N
392 CD N
patients NNS N
randomized VBN N
into IN N
four CD N
groups NNS N
was VBD N
performed VBN N
to TO N
establish VB N
whether IN N
diagnostic JJ N
intravenous JJ N
urograms NNS N
could MD N
be VB N
obtained VBN N
with IN N
a DT N
lower JJR N
dose NN N
of IN N
iodine NN N
when WRB N
using VBG N
the DT N
dimeric NN N
, , N
non-ionic JJ N
contrast NN N
medium NN N
iodixanol NN N
compared VBN N
with IN N
the DT N
monomeric NN N
, , N
non-ionic JJ N
iohexol NN N
Patients NNS N
received VBD N
iodixanol JJ N
or CC N
iohexol JJ N
containing VBG N
either CC N
9 CD N
or CC N
12 CD N
g NN N
of IN N
iodine NN N
( ( N
gI NN N
) ) N
The DT N
primary JJ N
parameter NN N
was VBD N
the DT N
diagnostic JJ N
quality NN N
of IN N
the DT N
6 CD N
min NN N
film NN N
, , N
assessed VBN N
in IN N
a DT N
blinded JJ N
fashion NN N
, , N
by IN N
consensus NN N
, , N
by IN N
four CD N
radiologists NNS N
Iodixanol NN N
at IN N
both DT N
doses NNS N
was VBD N
diagnostic JJ N
in IN N
over IN N
90 CD N
% NN N
of IN N
cases NNS N
Iohexol NNP N
was VBD N
only RB N
diagnostic JJ N
in IN N
74 CD N
% NN N
( ( N
9 CD N
gI NN N
) ) N
and CC N
81.8 CD N
% NN N
( ( N
12 CD N
gI NN N
) ) N
Pairwise VB N
comparisons NNS N
revealed VBD N
that IN N
iodixanol JJ N
9 CD N
gI NN N
was VBD N
significantly RB N
better JJR N
than IN N
both DT N
iohexol JJ N
9 CD N
gI NN N
( ( N
p JJ N
= NNP N
0.0005 CD N
) ) N
and CC N
12 CD N
gI NN N
( ( N
p JJ N
= NNP N
0.014 CD N
) ) N
No DT N
significant JJ N
difference NN N
was VBD N
present JJ N
for IN N
different JJ N
doses NNS N
within IN N
the DT N
same JJ N
contrast NN N
medium NN N
group NN N
Iodixanol NNP N
resulted VBD N
in IN N
poorer NN N
bladder NN N
distension NN N
than IN N
iohexol NN N
Iodixanol NNP N
caused VBD N
significantly RB N
less JJR N
discomfort NN N
than IN N
iohexol NN N
-DOCSTART- -X- O O 24006504

Intravesical JJ N
seeding NN N
of IN N
upper JJ N
urinary JJ N
tract NN N
urothelial JJ N
carcinoma NN N
cells NNS N
during IN N
nephroureterectomy NN 4_p
: : N
an DT N
exploratory JJ N
analysis NN N
from IN N
the DT N
THPMG NNP N
trial NN N
OBJECTIVE CC N
The DT N
Pirarubicin NNP N
Monotherapy NNP N
Study NNP N
Group NNP N
trial NN N
was VBD N
a DT N
randomized JJ N
Phase NNP N
II NNP N
study NN N
that WDT N
evaluated VBD N
the DT N
efficacy NN N
of IN N
intravesical JJ N
instillation NN N
of IN N
pirarubicin NN N
in IN N
the DT N
prevention NN N
of IN N
bladder NN N
recurrence NN N
after IN N
nephroureterectomy NN N
for IN N
upper JJ 4_p
urinary JJ 4_p
tract NN 4_p
urothelial JJ 4_p
carcinoma NN 4_p
This DT N
study NN N
conducted VBD N
further JJ N
analysis NN N
of IN N
the DT N
Pirarubicin NNP N
Monotherapy NNP N
Study NNP N
Group NNP N
cohort NN N
, , N
focusing VBG N
on IN N
intravesical JJ N
seeding NN N
of IN N
cancer NN N
cells NNS N
METHODS NNP N
Using VBG N
the DT N
data NN N
from IN N
the DT N
Pirarubicin NNP N
Monotherapy NNP N
Study NNP N
Group NNP N
trial NN N
, , N
bladder VB N
recurrence-free JJ N
survival NN N
rates NNS N
and CC N
factors NNS N
associated VBN N
with IN N
bladder NN N
recurrence NN N
in IN N
the DT N
control NN N
group NN N
were VBD N
analyzed VBN N
RESULTS NNP N
Of IN N
36 CD 3_p
patients NNS N
in IN N
the DT N
control NN N
group NN N
, , N
14 CD 3_p
with IN N
positive JJ N
urine JJ N
cytology NN N
had VBD N
more RBR N
frequent JJ N
recurrence NN N
when WRB N
compared VBN N
with IN N
the DT N
22 CD 3_p
patients NNS N
with IN N
negative JJ N
cytology NN N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
Based VBN N
on IN N
the DT N
multivariate NN N
analysis NN N
in IN N
the DT N
control NN N
group NN N
, , N
voided VBD N
urine JJ N
cytology NN N
was VBD N
an DT N
independent JJ N
predictive JJ N
factor NN N
of IN N
bladder NN N
recurrence NN N
( ( N
hazard JJ N
ratio NN N
, , N
5.54 CD N
; : N
95 CD N
% NN N
confidence NN N
interval JJ N
1.12-27.5 JJ N
; : N
P NNP N
= NNP N
0.036 CD N
) ) N
Of IN N
72 CD 3_p
patients NNS N
in IN N
the DT N
Pirarubicin NNP N
Monotherapy NNP N
Study NNP N
Group NNP N
trial NN N
, , N
31 CD N
had VBD N
positive JJ N
urine JJ N
cytology NN N
Among IN N
the DT N
31 CD 3_p
patients NNS N
, , N
17 CD 3_p
patients NNS N
who WP N
received VBD N
pirarubicin JJ N
instillation NN N
had VBD N
fewer JJR N
recurrences NNS N
when WRB N
compared VBN N
with IN N
14 CD 3_p
patients NNS N
who WP N
received VBD N
control NN N
treatment NN N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
On IN N
multivariate NN N
analysis NN N
, , N
pirarubicin JJ N
instillation NN N
was VBD N
an DT N
independent JJ N
predictor NN N
of IN N
better JJR N
recurrence-free JJ N
survival NN N
rates NNS N
in IN N
the DT N
patients NNS N
with IN N
positive JJ N
urine JJ N
cytology NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.02 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.00-0.53 JJ N
; : N
P NNP N
= NNP N
0.018 CD N
) ) N
Of IN N
21 CD N
patients NNS N
with IN N
bladder NN N
recurrence NN N
, , N
17 CD N
had VBD N
recurrent JJ N
tumor NN N
around IN N
cystotomy NN N
or CC N
in IN N
the DT N
bladder NN N
neck NN N
compromised VBN N
by IN N
the DT N
urethral JJ N
catheter NN N
, , N
supporting VBG N
the DT N
notion NN N
that IN N
tumor NN N
cells NNS N
seeded VBN N
in IN N
the DT N
injured JJ N
urothelium NN N
CONCLUSIONS NNP N
Intravesical NNP N
instillation NN N
of IN N
pirarubicin NN N
immediately RB N
after IN N
nephroureterectomy NN N
significantly RB N
reduced VBD N
the DT N
bladder NN N
recurrence NN N
rate NN N
in IN N
patients NNS N
with IN N
positive JJ N
voided JJ N
urine JJ N
cytology NN N
The DT N
results NNS N
suggest VBP N
that IN N
intravesical JJ N
seeding NN N
of IN N
upper JJ N
urinary JJ N
tract NN N
urothelial JJ N
carcinoma NN N
occurs VBZ N
during IN N
nephroureterectomy NN N
-DOCSTART- -X- O O 9303285

Dose-response JJ N
and CC N
concentration-response JJ N
relation NN N
of IN N
rocuronium NN N
infusion NN N
during IN N
propofol-nitrous JJ N
oxide NN N
and CC N
isoflurane-nitrous JJ N
oxide NN N
anaesthesia NN N
The DT N
dose-response JJ N
and CC N
concentration-response JJ N
relation NN N
of IN N
rocuronium NN N
infusion NN N
was VBD N
studied VBN N
in IN N
20 CD N
adult NN N
surgical JJ N
patients NNS N
during IN N
propofol-nitrous JJ N
oxide NN N
and CC N
isoflurane NN N
( ( N
1 CD N
MAC NNP N
) ) N
-nitrous JJ N
oxide JJ N
anaesthesia NN N
Neuromuscular JJ N
block NN N
was VBD N
kept VBN N
constant JJ N
, , N
initially RB N
at IN N
90 CD N
% NN N
and CC N
then RB N
at IN N
50 CD N
% NN N
with IN N
a DT N
closed-loop JJ N
feedback NN N
controller NN N
At IN N
90 CD N
% NN N
block NN N
the DT N
steady-state JJ N
infusion NN N
of IN N
rocuronium NN N
was VBD N
0.55 CD N
+/- JJ N
0.16 CD N
mg JJ N
kg-1 JJ N
h-1 NN N
and CC N
the DT N
corresponding JJ N
concentration NN N
1714 CD N
+/- JJ N
281 CD N
ng JJ N
mL-1 NN N
in IN N
patients NNS N
receiving VBG N
propofol NN N
At IN N
50 CD N
% NN N
block NN N
the DT N
corresponding JJ N
infusion NN N
rate NN N
was VBD N
0.27 CD N
+/- JJ N
0.11 CD N
mg JJ N
kg-1 JJ N
h-1 NN N
and CC N
the DT N
concentration NN N
1077 CD N
+/- JJ N
244 CD N
ng JJ N
mL-1 NN N
, , N
respectively RB N
At IN N
50 CD N
% NN N
block NN N
isoflurane NN N
reduced VBD N
the DT N
rate NN N
of IN N
infusion NN N
by IN N
52 CD N
% NN N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
and CC N
the DT N
concentration NN N
by IN N
59 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
at IN N
90 CD N
% NN N
block NN N
both CC N
the DT N
mean JJ N
infusion NN N
rate NN N
and CC N
the DT N
concentration NN N
of IN N
rocuronium NN N
were VBD N
reduced VBN N
by IN N
35 CD N
% NN N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
The DT N
mean JJ N
rocuronium NN N
clearance NN N
at IN N
50 CD N
% NN N
block NN N
was VBD N
unaffected VBN N
by IN N
the DT N
type NN N
of IN N
anaesthesia NN N
; : N
it PRP N
was VBD N
4.1 CD N
+/- JJ N
1.6 CD N
and CC N
4.9 CD N
+/- JJ N
2.7 CD N
mL JJ N
kg-1 JJ N
min-1 NN N
in IN N
the DT N
groups NNS N
receiving VBG N
propofol NN N
and CC N
isoflurane NN N
anaesthesia NN N
, , N
respectively RB N
We PRP N
conclude VBP N
that IN N
isoflurane NN N
reduces VBZ N
the DT N
infusion NN N
requirements NNS N
of IN N
rocuronium NN N
by IN N
changing VBG N
the DT N
pharmacodynamic JJ N
behaviour NN N
-DOCSTART- -X- O O 9332112

Intravenous JJ N
magnesium NN N
sulfate NN N
in IN N
acute NN 4_p
severe JJ 4_p
asthma NN 4_p
not RB 4_p
responding VBG 4_p
to TO 4_p
conventional JJ 4_p
therapy NN 4_p
OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
early JJ N
administration NN N
of IN N
intravenous JJ N
Magnesium NNP N
sulfate NN N
( ( N
i.v JJ N
MgSO4 NNP N
) ) N
in IN N
children NNS 1_p
with IN N
acute NN 4_p
severe JJ 4_p
asthma NN 4_p
not RB 4_p
responding VBG 4_p
to TO 4_p
conventional JJ 4_p
therapy NN 4_p
DESIGN NNP N
Randomized NNP N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
SETTING NN N
Pediatric NNP N
emergency NN N
service NN N
of IN N
a DT N
large JJ N
teaching NN N
hospital NN N
SUBJECTS CC N
47 CD 3_p
children NNS 3_p
aged VBN 1_p
between IN 1_p
1-12 CD 1_p
years NNS 1_p
with IN N
acute NN N
severe JJ N
asthma NN N
showing VBG N
inadequate JJ N
or CC N
poor JJ N
response NN N
to TO N
3 CD N
doses NNS N
of IN N
nebulized JJ N
salbutamol NN N
given VBN N
at IN N
an DT N
interval NN N
of IN N
20 CD N
min NNS N
each DT N
INTERVENTION VBZ N
The DT N
MgSO4 NNP N
group NN N
received VBD N
0.2 CD N
ml/kg NN N
of IN N
50 CD N
% NN N
MgSO4 NNP N
as IN N
intravenous JJ N
( ( N
i.v JJ N
) ) N
infusion NN N
over IN N
35 CD N
minutes NNS N
and CC N
the DT N
placebo NN N
group NN N
received VBD N
normal JJ N
saline JJ N
infusion NN N
in IN N
the DT N
same JJ N
dose NN N
and CC N
at IN N
the DT N
same JJ N
rate NN N
MgSO4 NNP N
solution NN N
and CC N
normal JJ N
saline NN N
were VBD N
coded VBN N
and CC N
dispensed VBN N
in IN N
identical JJ N
containers NNS N
Decoding VBG N
was VBD N
done VBN N
at IN N
the DT N
completion NN N
of IN N
the DT N
study NN N
All PDT N
the DT N
patients NNS N
received VBD N
oxygen NN N
, , N
nebulized JJ N
salbutamol NN N
, , N
i.v NN N
aminophylline NN N
and CC N
corticosteroids NNS N
RESULTS NNP N
MgSO4 NNP N
group NN N
showed VBD N
early JJ N
and CC N
significant JJ N
improvement NN N
as IN N
compared VBN N
to TO N
placebo VB N
group NN N
in IN N
PEFR NNP N
and CC N
SaO2 NNP N
at IN N
30 CD N
min NN N
and CC N
1 CD N
, , N
2 CD N
, , N
3 CD N
and CC N
7 CD N
hours NNS N
after IN N
stopping VBG N
the DT N
infusion NN N
( ( N
p JJ N
ranging VBG N
from IN N
< $ N
0.05 CD N
to TO N
< VB N
0.01 CD N
) ) N
The DT N
clinical JJ N
asthma NN N
score NN N
also RB N
showed VBD N
significant JJ N
improvement NN N
in IN N
the DT N
MgSO4 NNP N
group NN N
1 CD N
, , N
2 CD N
, , N
3 CD N
and CC N
11 CD N
hours NNS N
after IN N
stopping VBG N
the DT N
infusion NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
CONCLUSION NNP N
Addition NNP N
of IN N
MgSO4 NNP N
to TO N
conventional JJ N
therapy NN N
helps VBZ N
in IN N
achieving VBG N
earlier RBR N
improvement NN N
in IN N
clinical JJ N
signs NNS N
and CC N
symptoms NNS N
of IN N
asthma NN N
and CC N
PEFR NNP N
in IN N
patients NNS N
not RB N
responding VBG N
to TO N
conventional JJ N
therapy NN N
alone RB N
-DOCSTART- -X- O O 20697791

Promoting VBG N
imitation NN N
in IN N
young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
: : N
a DT N
comparison NN N
of IN N
reciprocal JJ N
imitation NN N
training NN N
and CC N
video NN N
modeling NN N
The DT N
inability NN N
to TO N
imitate VB N
is VBZ N
a DT N
salient JJ N
diagnostic JJ N
marker NN N
for IN N
autism NN 4_p
It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
for IN N
children NNS 1_p
with IN N
autism NN N
, , N
imitation NN N
may MD N
be VB N
a DT N
prerequisite NN N
skill NN N
that WDT N
can MD N
assist VB N
in IN N
the DT N
development NN N
of IN N
various JJ N
skills NNS N
Using VBG N
a DT N
multiple JJ N
baseline NN N
design NN N
across IN N
subjects NNS N
, , N
the DT N
purpose NN N
of IN N
this DT N
research NN N
was VBD N
to TO N
determine VB N
if IN N
two CD N
interventions NNS N
, , N
reciprocal JJ N
imitation NN N
training NN N
and CC N
video NN N
modeling NN N
were VBD N
effective JJ N
in IN N
promoting VBG N
imitation NN N
acquisition NN N
in IN N
young JJ N
children NNS N
with IN N
autism NN N
Six NNP 3_p
boys NNS 2_p
were VBD N
matched VBN N
across IN N
various JJ N
features NNS N
( ( N
i.e. FW N
, , N
age NN N
, , N
language NN N
, , N
autism NN N
severity NN N
) ) N
and CC N
randomly RB N
placed VBN N
in IN N
a DT N
treatment NN N
condition NN N
Results NNS N
indicated VBD N
that IN N
all DT N
six CD N
participants NNS N
increased VBD N
their PRP$ N
imitation NN N
skills NNS N
to TO N
varying VBG N
degrees NNS N
in IN N
both DT N
conditions NNS N
, , N
and CC N
imitation NN N
maintained VBD N
and CC N
generalized VBD N
at IN N
higher JJR N
than IN N
baseline NN N
levels NNS N
post NN N
treatment NN N
-DOCSTART- -X- O O 3303886

Prognostic JJ N
significance NN N
and CC N
beneficial JJ N
effect NN N
of IN N
diltiazem NN N
on IN N
the DT N
incidence NN N
of IN N
early JJ 4_p
recurrent NN 4_p
ischemia NN 4_p
after IN N
non-Q-wave JJ N
myocardial JJ N
infarction NN N
: : N
results NNS N
from IN N
the DT N
Multicenter NNP N
Diltiazem NNP N
Reinfarction NNP N
Study NNP N
Of IN N
576 CD 3_p
patients NNS N
with IN N
non-Q-wave JJ 4_p
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
enrolled VBN N
in IN N
the DT N
Diltiazem NNP N
Reinfarction NNP N
Study NNP N
, , N
246 CD N
( ( N
43 CD N
% NN N
) ) N
had VBD N
1 CD N
or CC N
more JJR N
episodes NNS N
of IN N
angina NN N
at IN N
rest NN N
or CC N
with IN N
minimal JJ N
effort NN N
during IN N
10.5 CD N
days NNS N
of IN N
treatment NN N
with IN N
either DT N
diltiazem NN N
( ( N
90 CD N
mg NN N
every DT N
6 CD N
hours NNS N
) ) N
or CC N
placebo NN N
Reinfarction NNP N
( ( N
12.2 CD N
% NN N
vs JJ N
3.6 CD N
% NN N
, , N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
or CC N
death NN N
( ( N
6.1 CD N
% NN N
vs JJ N
1.5 CD N
% NN N
, , N
p NN N
= NNP N
0.003 CD N
) ) N
was VBD N
more RBR N
likely JJ N
to TO N
occur VB N
within IN N
2 CD N
weeks NNS N
of IN N
randomization NN N
in IN N
patients NNS N
with IN N
postinfarction NN N
angina NNS N
than IN N
in IN N
those DT N
without IN N
angina NNS N
Based VBN N
on IN N
serial JJ N
electrocardiographic JJ N
data NNS N
, , N
115 CD N
of IN N
the DT N
246 CD N
patients NNS N
with IN N
angina NNS N
had VBD N
transient JJ N
ST-T JJ N
changes NNS N
and CC N
131 CD N
did VBD N
not RB N
Comparison NNP N
of IN N
the DT N
14-day JJ N
event NN N
rates NNS N
in IN N
these DT N
2 CD N
groups NNS N
showed VBD N
that IN N
the DT N
115 CD N
patients NNS N
with IN N
electrocardiographic JJ N
evidence NN N
of IN N
ischemia NN N
had VBD N
a DT N
higher JJR N
frequency NN N
of IN N
reinfarction NN N
( ( N
20 CD N
% NN N
vs JJ N
5.3 CD N
% NN N
, , N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
, , N
more RBR N
extensive JJ N
damage NN N
as IN N
assessed VBN N
by IN N
peak JJ N
MB-creatine JJ N
kinase NN N
levels NNS N
( ( N
91 CD N
+/- JJ N
76 CD N
vs JJ N
37 CD N
+/- JJ N
19 CD N
IU/liter NNP N
, , N
p NN N
= VBD N
0.059 CD N
[ NNP N
Wilcoxon NNP N
rank NN N
sum NN N
] NN N
) ) N
and CC N
a DT N
higher JJR N
mortality NN N
rate NN N
( ( N
11.3 CD N
% NN N
vs JJ N
1.5 CD N
% NN N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
Angina NNP N
associated VBD N
with IN N
transient JJ N
ST-T JJ N
changes NNS N
occurred VBD N
in IN N
70 CD N
of IN N
the DT N
289 CD N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
but CC N
in IN N
only RB N
45 CD N
of IN N
the DT N
287 CD N
patients NNS N
in IN N
the DT N
diltiazem NN N
group NN N
-- : N
a DT N
28 CD N
% NN N
reduction NN N
in IN N
cumulative JJ N
life-table JJ N
incidence NN N
( ( N
p JJ N
= $ N
0.0103 CD N
[ NNP N
2-tail JJ N
, , N
log JJ N
rank NN N
] NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
9.3 CD N
to TO N
53.8 CD N
% NN N
) ) N
It PRP N
is VBZ N
concluded VBN N
that IN N
patients NNS N
with IN N
early JJ 4_p
postinfarction NN 4_p
angina NN 4_p
are VBP N
at IN N
increased JJ N
risk NN N
of IN N
reinfarction NN N
and CC N
death NN N
, , N
and CC N
angina RB N
associated VBN N
with IN N
transient JJ N
electrocardiographic JJ N
changes NNS N
identified VBD N
a DT N
very RB N
high JJ N
risk NN N
subset NN N
This DT N
subset NN N
appeared VBD N
to TO N
have VB N
a DT N
larger JJR N
area NN N
of IN N
viable JJ N
but CC N
jeopardized JJ N
myocardium NN N
and CC N
benefited VBD N
from IN N
prophylactic JJ N
therapy NN N
with IN N
diltiazem NN N
-DOCSTART- -X- O O 22721929

Effect NN N
of IN N
chelation NN N
therapy NN N
on IN N
progressive JJ N
diabetic JJ N
nephropathy NN N
in IN N
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
and CC N
high-normal JJ 4_p
body NN 4_p
lead JJ 4_p
burdens NNS 4_p
BACKGROUND VB N
A DT N
previous JJ N
study NN N
in IN N
type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS N
with IN N
high-normal JJ N
body NN N
lead NN N
burdens VBZ N
showed VBD N
that IN N
EDTA NNP N
chelation NN N
therapy NN N
for IN N
3 CD N
months NNS N
slows VBZ N
progressive JJ N
diabetic JJ N
nephropathy NN N
during IN N
a DT N
12-month JJ N
follow-up NN N
The DT N
effect NN N
of IN N
a DT N
longer JJR N
course NN N
of IN N
therapy NN N
on IN N
kidney NN N
function NN N
decrease NN N
over IN N
a DT N
longer JJR N
follow-up NN N
is VBZ N
not RB N
known VBN N
STUDY NNP N
DESIGN NNP N
A NNP N
12-month JJ N
run-in JJ N
phase NN N
, , N
then RB N
a DT N
randomized VBN N
single-blind NN N
study NN N
with IN N
a DT N
27-month JJ N
intervention NN N
SETTING NNP N
& CC N
PARTICIPANTS NNP N
University NNP N
medical JJ N
center NN N
; : N
50 CD N
patients NNS N
( ( N
serum JJ N
creatinine NN N
, , N
1.5-3.9 JJ N
mg/dL NN N
) ) N
with IN N
high-normal JJ N
body NN N
lead JJ N
burden NN N
( ( N
≥80- JJ N
< NN N
600 CD N
μg NN N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN N
and CC N
control NN N
groups NNS N
INTERVENTION NNP N
The DT N
treatment NN N
group NN N
received VBD N
weekly JJ N
chelation NN N
therapy NN N
for IN N
3 CD N
months NNS N
to TO N
reduce VB N
their PRP$ N
body NN N
lead JJ N
burden NN N
to TO N
< VB N
60 CD N
μg NNS N
and CC N
then RB N
as IN N
needed VBN N
for IN N
24 CD N
months NNS N
to TO N
maintain VB N
this DT N
level NN N
The DT N
control NN N
group NN N
received VBD N
placebo NN N
for IN N
3 CD N
months NNS N
and CC N
then RB N
weekly VB N
for IN N
5 CD N
weeks NNS N
at IN N
6-month JJ N
intervals NNS N
for IN N
24 CD N
months NNS N
OUTCOMES IN N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
change NN N
in IN N
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
( ( N
eGFR NN N
) ) N
over IN N
time NN N
A DT N
secondary JJ N
end NN N
point NN N
was VBD N
a DT N
2-fold JJ N
increase NN N
in IN N
baseline JJ N
serum NN N
creatinine NN N
level NN N
or CC N
the DT N
requirement NN N
for IN N
renal JJ N
replacement NN N
therapy NN N
MEASUREMENTS NNP N
Body NNP N
lead JJ N
burdens NNS N
were VBD N
assessed VBN N
by IN N
EDTA NNP N
mobilization NN N
tests NNS N
and CC N
eGFR NN N
was VBD N
calculated VBN N
using VBG N
the DT N
equation NN N
for IN N
Chinese JJ N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
RESULTS NNP N
Mean NNP N
baseline NN N
eGFRs NN N
in IN N
the DT N
treatment NN N
and CC N
control NN N
groups NNS N
were VBD N
similar JJ N
After IN N
3 CD N
months NNS N
of IN N
chelation NN N
therapy NN N
, , N
the DT N
change NN N
in IN N
eGFR NN N
in IN N
the DT N
treatment NN N
group NN N
( ( N
+1.0 NNP N
± VBZ N
4.8 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
) ) N
differed VBN N
significantly RB N
from IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
-1.5 NNP N
± VBZ N
4.8 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
In IN N
the DT N
subsequent JJ N
24-month JJ N
intervention NN N
, , N
the DT N
yearly JJ N
rate NN N
of IN N
decrease NN N
in IN N
eGFR NN N
( ( N
5.6 CD N
± RB N
5.0 CD N
mL/min/1.73 NNS N
m NN N
( ( N
2 CD N
) ) N
per IN N
year NN N
) ) N
in IN N
the DT N
treatment NN N
group NN N
was VBD N
slower JJR N
than IN N
that DT N
( ( N
9.2 CD N
± RB N
3.6 CD N
mL/min/1.73 NNS N
m NN N
( ( N
2 CD N
) ) N
per IN N
year NN N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
17 CD N
( ( N
68 CD N
% NN N
) ) N
control-group NN N
patients NNS N
and CC N
9 CD N
( ( N
36 CD N
% NN N
) ) N
treatment-group NN N
patients NNS N
achieved VBD N
the DT N
secondary JJ N
end NN N
point NN N
LIMITATIONS NNP N
Small NNP N
sample NN N
size NN N
, , N
not RB N
double JJ N
blind NN N
CONCLUSIONS VB N
A DT N
27-month JJ N
course NN N
of IN N
EDTA NNP N
chelation NN N
therapy NN N
retards VBZ N
the DT N
progression NN N
of IN N
diabetic JJ N
nephropathy NN N
in IN N
type NN N
2 CD N
diabetic JJ N
patients NNS N
with IN N
high-normal JJ N
body NN N
lead JJ N
burdens NNS N
-DOCSTART- -X- O O 7595712

Cisplatin NNP N
plus CC N
etoposide JJ N
with IN N
and CC N
without IN N
ifosfamide NN N
in IN N
extensive JJ N
small-cell NN N
lung NN 4_p
cancer NN 4_p
: : N
a DT N
Hoosier NNP N
Oncology NNP N
Group NNP N
study NN N
PURPOSE NNP N
To TO N
determine VB N
whether IN N
the DT N
addition NN N
of IN N
ifosfamide NN N
to TO N
cisplatin VB N
plus JJ N
etoposide JJ N
improves VBZ N
the DT N
response NN N
rate NN N
, , N
time NN N
to TO N
disease VB N
progression NN N
, , N
or CC N
overall JJ N
survival NN N
in IN N
previously RB N
untreated JJ N
patients NNS N
with IN N
extensive-stage JJ N
small-cell JJ 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
lung NN 4_p
( ( 4_p
SCLC NNP 4_p
) ) 4_p
PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
with IN N
extensive JJ N
SCLC NNP N
with IN N
a DT N
Karnofsky NNP N
performance NN N
score NN N
( ( N
KPS NNP N
) ) N
> VBD N
or CC N
= $ N
50 CD N
and CC N
adequate JJ N
renal JJ N
function NN N
and CC N
bone NN N
marrow NN N
reserve NN N
were VBD N
eligible JJ N
Patients NNS N
with IN N
CNS NNP N
metastases NNS N
were VBD N
eligible JJ N
and CC N
received JJ N
concurrent JJ N
whole-brain JJ N
radiotherapy NN N
Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
cisplatin NN N
( ( N
20 CD N
mg/m2 NN N
) ) N
plus CC N
etoposide JJ N
( ( N
100 CD N
mg/m2 NN N
) ) N
( ( N
VP NNP N
) ) N
both DT N
given VBN N
intravenously RB N
( ( N
i.v JJ N
) ) N
on IN N
days NNS N
1 CD N
to TO N
4 CD N
or CC N
cisplatin NN N
( ( N
20 CD N
mg/m2 NN N
) ) N
, , N
ifosfamide RB N
( ( N
1.2 CD N
g/m2 NN N
) ) N
, , N
and CC N
etoposide RB N
( ( N
75 CD N
mg/m2 NN N
) ) N
( ( N
VIP NNP N
) ) N
all DT N
given VBN N
i.v NNS N
on IN N
days NNS N
1 CD N
to TO N
4 CD N
Cycles NNS N
were VBD N
repeated VBN N
every DT N
3 CD N
weeks NNS N
for IN N
four CD N
cycles NNS N
RESULTS NNP N
From NNP N
May NNP N
1989 CD N
through IN N
March NNP N
1993 CD N
, , N
171 CD 3_p
patients NNS N
were VBD N
randomized VBN N
( ( N
84 CD N
to TO N
VP NNP N
and CC N
87 CD N
to TO N
VIP NNP N
) ) N
The DT N
median JJ N
follow-up JJ N
duration NN N
is VBZ N
26 CD N
months NNS N
All DT N
patients NNS N
were VBD N
assessable JJ N
for IN N
survival NN N
; : N
163 CD 3_p
were VBD N
fully RB N
assessable JJ N
for IN N
response NN N
and CC N
162 CD 3_p
for IN N
toxicity NN N
Myelosuppression NN N
was VBD N
greater JJR N
with IN N
VIP NNP N
Objective JJ N
responses NNS N
were VBD N
observed VBN N
in IN N
55 CD N
of IN N
82 CD N
( ( N
67 CD N
% NN N
) ) N
and CC N
59 CD N
of IN N
81 CD N
( ( N
73 CD N
% NN N
) ) N
assessable JJ N
patients NNS N
treated VBN N
with IN N
VP NNP N
and CC N
VIP NNP N
, , N
respectively RB N
( ( N
difference NN N
not RB N
significant JJ N
) ) N
The DT N
difference NN N
in IN N
the DT N
median JJ N
time NN N
to TO N
progression NN N
was VBD N
statistically RB N
different JJ N
( ( N
P NNP N
= NNP N
.039 NNP N
) ) N
The DT N
median JJ N
survival NN N
times NNS N
on IN N
VP NNP N
and CC N
VIP NNP N
were VBD N
7.3 CD N
months NNS N
and CC N
9.0 CD N
months NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.045 NNP N
for IN N
survival JJ N
curves NNS N
by IN N
stratified JJ N
log-rank JJ N
test NN N
) ) N
with IN N
2-year JJ N
survival JJ N
rates NNS N
of IN N
5 CD N
% NN N
versus IN N
13 CD N
% NN N
, , N
respectively RB N
CONCLUSION NNP N
VIP NNP N
combination NN N
chemotherapy NN N
is VBZ N
associated VBN N
with IN N
an DT N
improved JJ N
time NN N
to TO N
progression NN N
and CC N
overall JJ N
survival NN N
over IN N
VP NNP N
therapy NN N
in IN N
patients NNS N
with IN N
extensive JJ N
SCLC NNP N
-DOCSTART- -X- O O 10470636

Effect NN N
of IN N
spinal JJ N
versus NN N
general JJ N
anesthesia NN N
on IN N
bladder NN N
compliance NN N
and CC N
intraabdominal JJ N
pressure NN N
during IN N
transurethral JJ N
procedures NNS N
STUDY NNP N
OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
influence NN N
of IN N
spinal JJ N
versus NN N
general JJ N
anesthesia NN N
on IN N
bladder NN N
compliance NN N
and CC N
intraabdominal JJ N
pressure NN N
in IN N
elderly JJ 1_p
males NNS 2_p
undergoing VBG 4_p
elective JJ 4_p
transurethral JJ 4_p
resection NN 4_p
of IN 4_p
the DT 4_p
prostate NN 4_p
DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
open-label JJ N
study NN N
SETTING NN N
Teaching NNP N
hospital NN N
PATIENTS CC N
21 CD 3_p
ASA NNP 4_p
physical JJ 4_p
status NN 4_p
I PRP 4_p
, , 4_p
II NNP 4_p
, , 4_p
and CC 4_p
III NNP 4_p
patients NNS 4_p
at IN 1_p
least JJS 1_p
18 CD 1_p
years NNS N
of IN N
age NN N
, , N
undergoing VBG N
transurethral JJ N
surgery NN N
INTERVENTIONS NNP N
According VBG N
to TO N
a DT N
computer-generated JJ N
randomization NN N
schedule NN N
, , N
patients NNS N
were VBD N
allocated VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
In IN N
Group NNP N
Spinal NNP N
( ( N
S NNP N
) ) N
, , N
10 CD N
mg NN N
of IN N
hyperbaric JJ N
tetracaine NN N
was VBD N
administered VBN N
intrathecally RB N
In IN N
Group NNP N
General NNP N
Anesthesia NNP N
( ( N
GA NNP N
) ) N
, , N
patients NNS N
received VBD N
, , N
fentanyl RB N
intravenous JJ N
( ( N
i.v JJ N
1 CD N
to TO N
2 CD N
micrograms/kg NNS N
and CC N
propofol NN N
i.v NN N
1.0 CD N
to TO N
2.0 CD N
mg/kg NN N
for IN N
induction NN N
of IN N
anesthesia NN N
Thereafter NNP N
, , N
a DT N
laryngeal JJ N
mask NN N
airway NN N
was VBD N
inserted VBN N
and CC N
, , N
with IN N
spontaneous JJ N
ventilation NN N
, , N
anesthesia NN N
was VBD N
maintained VBN N
by IN N
administering VBG N
isoflurane NN N
( ( N
end-tidal JJ N
0.7 CD N
% NN N
to TO N
1.2 CD N
% NN N
) ) N
and CC N
70 CD N
% NN N
nitrous JJ N
oxide NN N
( ( N
N2O NNP N
) ) N
in IN N
oxygen NN N
Intraabdominal JJ N
pressure NN N
and CC N
bladder NN N
compliance NN N
were VBD N
recorded VBN N
prior RB N
to TO N
the DT N
induction NN N
of IN N
anesthesia NN N
and CC N
immediately RB N
before IN N
the DT N
onset NN N
of IN N
the DT N
surgical JJ N
procedure NN N
MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
two CD N
groups NNS N
were VBD N
demographically RB N
comparable JJ N
In IN N
Group NNP N
S NNP N
, , N
mean JJ N
bladder NN N
compliance NN N
was VBD N
significantly RB N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
higher JJR N
and CC N
mean JJ N
intraabdominal JJ N
pressure NN N
significantly RB N
lower JJR N
( ( N
p JJ N
= NNP N
0.007 CD N
) ) N
when WRB N
compared VBN N
to TO N
baseline VB N
preanesthetic JJ N
values NNS N
In IN N
Group NNP N
GA NNP N
, , N
mean JJ N
intraabdominal JJ N
pressure NN N
significantly RB N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
decreased VBD N
when WRB N
compared VBN N
to TO N
baseline VB N
preanesthetic JJ N
recordings NNS N
Following VBG N
the DT N
induction NN N
of IN N
general JJ N
anesthesia NN N
, , N
a DT N
small JJ N
change NN N
in IN N
bladder NN N
compliance NN N
was VBD N
noted VBN N
However RB N
, , N
statistical JJ N
significance NN N
was VBD N
not RB N
reached VBN N
Data NNS N
were VBD N
analyzed VBN N
and CC N
compared VBN N
using VBG N
Student NNP N
's POS N
t-test NN N
( ( N
p JJ N
< NN N
0.05 CD N
was VBD N
considered VBN N
statistically RB N
significant JJ N
) ) N
CONCLUSION NNP N
Both NNP N
spinal JJ N
and CC N
general JJ N
anesthesia NN N
induced VBD N
a DT N
significant JJ N
decrease NN N
in IN N
intraabdominal JJ N
pressure NN N
While IN N
both DT N
techniques NNS N
were VBD N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
bladder NN N
compliance NN N
, , N
statistical JJ N
significance NN N
was VBD N
demonstrated VBN N
only RB N
in IN N
the DT N
spinal JJ N
anesthesia NN N
treatment NN N
group NN N
-DOCSTART- -X- O O 9683043

White NNP N
coat NN N
effect NN N
detected VBD N
using VBG N
self-monitoring NN N
of IN N
blood NN N
pressure NN N
at IN N
home NN N
: : N
comparison NN N
with IN N
ambulatory JJ N
blood NN N
pressure NN N
The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
home NN N
blood NN N
pressure NN N
( ( N
HBP NNP N
) ) N
is VBZ N
a DT N
reliable JJ N
alternative NN N
to TO N
ambulatory VB N
blood NN N
pressure NN N
( ( N
ABP NNP N
) ) N
for IN N
the DT N
detection NN N
of IN N
the DT N
white JJ N
coat NN N
effect NN N
( ( N
WCE NNP N
) ) N
Hypertensive JJ 4_p
patients NNS N
were VBD N
randomized VBN N
to TO N
measure VB N
HBP NNP N
for IN N
2 CD N
weeks NNS N
or CC N
ABP NNP N
for IN N
24 CD N
h. PDT N
The DT N
alternative JJ N
measurement NN N
was VBD N
then RB N
performed VBN N
Clinic NNP N
blood NN N
pressure NN N
( ( N
CBP NNP N
) ) N
was VBD N
measured VBN N
in IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
study NN N
Subjects NNS N
with IN N
a DT N
difference NN N
of IN N
> NN N
or CC N
= $ N
20 CD N
mm NN N
Hg NNP N
systolic NN N
or CC N
> NN N
or CC N
= $ N
10 CD N
mm NN N
Hg NNP N
diastolic VBZ N
BP NNP N
between IN N
CBP NNP N
and CC N
awake VB N
ABP NNP N
or CC N
CBP NNP N
and CC N
HBP NNP N
, , N
were VBD N
classified VBN N
as IN N
clinic JJ N
reactors NNS N
A DT N
total NN N
of IN N
189 CD 3_p
patients NNS N
completed VBD N
the DT N
study NN N
( ( N
79 CD 3_p
on IN N
stable JJ N
antihypertensive JJ N
treatment NN N
) ) N
There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
magnitude NN N
of IN N
WCE NNP N
assessed VBD N
using VBG N
the DT N
ABP NNP N
or CC N
the DT N
HBP NNP N
method NN N
( ( N
mean JJ N
discrepancy NN N
, , N
systolic JJ N
BP NNP N
: : N
-1.5 JJ N
+/- JJ N
11.7 CD N
mm NN N
Hg NNP N
, , N
95 CD N
% NN N
CI NNP N
-3.2 NNP N
, , N
0.2 CD N
; : N
diastolic JJ N
BP NNP N
: : N
0.9 CD N
+/- JJ N
7.0 CD N
, , N
95 CD N
% NN N
CI NNP N
-0.1 NNP N
, , N
1.9 CD N
) ) N
A NNP N
strong JJ N
association NN N
existed VBD N
between IN N
WCE NNP N
calculated VBD N
using VBG N
the DT N
HBP NNP N
or CC N
the DT N
ABP NNP N
method NN N
( ( N
r VB N
= RB N
0.64/0.59 CD N
systolic/diastolic JJ N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
The DT N
proportion NN N
of IN N
patients NNS N
classified VBN N
as IN N
clinic JJ N
reactors NNS N
was VBD N
identical JJ N
using VBG N
the DT N
HBP NNP N
or CC N
the DT N
ABP NNP N
method NN N
( ( N
25.9 CD N
% NN N
) ) N
Agreement NN N
between IN N
methods NNS N
in IN N
the DT N
classification NN N
of IN N
clinic JJ N
reactors NNS N
was VBD N
found VBN N
in IN N
147 CD N
patients NNS N
( ( N
78 CD N
% NN N
) ) N
The DT N
sensitivity NN N
and CC N
specificity NN N
of IN N
the DT N
HBP NNP N
method NN N
to TO N
classify VB N
correctly RB N
clinic JJ N
reactors NNS N
( ( N
ABP NNP N
method RB N
used VBD N
as IN N
the DT N
standard NN N
) ) N
were VBD N
57 CD N
% NN N
and CC N
85 CD N
% NN N
, , N
respectively RB N
, , N
whereas VBD N
its PRP$ N
positive JJ N
and CC N
negative JJ N
predictive JJ N
value NN N
were VBD N
57 CD N
% NN N
and CC N
85 CD N
% NN N
These DT N
results NNS N
indicate VBP N
that IN N
HBP NNP N
is VBZ N
not RB N
appropriate JJ N
as IN N
an DT N
alternative NN N
to TO N
ABP NNP N
diagnostic JJ N
testing NN N
in IN N
the DT N
detection NN N
of IN N
WCE NNP N
Nevertheless NNP N
, , N
HBP NNP N
appears VBZ N
useful JJ N
as IN N
a DT N
screening JJ N
test NN N
for IN N
the DT N
detection NN N
of IN N
this DT N
phenomenon NN N
-DOCSTART- -X- O O 23547660

The DT N
Tiotropium NNP N
Safety NNP N
and CC N
Performance NNP N
in IN N
Respimat NNP N
Trial NNP N
( ( N
TIOSPIR NNP N
) ) N
, , N
a DT N
large JJ N
scale NN N
, , N
randomized VBN N
, , N
controlled VBN N
, , N
parallel-group JJ N
trial-design NN N
and CC N
rationale NN N
BACKGROUND NNP N
Tiotropium NNP N
bromide NN N
is VBZ N
an DT N
effective JJ N
therapy NN N
for IN N
COPD NNP N
patients NNS N
Comparing VBG N
across IN N
programs NNS N
tiotropium VBP N
Respimat NNP N
Soft NNP N
Mist NNP N
inhaler NN N
was VBD N
at IN N
least JJS N
as RB N
efficacious JJ N
as IN N
tiotropium NN N
HandiHaler NNP N
, , N
however RB N
, , N
concerns NNS N
have VBP N
been VBN N
raised VBN N
about IN N
tiotropium NN N
's POS N
safety NN N
when WRB N
given VBN N
via IN N
Respimat NNP N
METHODS NNP N
The DT N
TIOSPIR NNP N
trial NN N
( ( N
NCT01126437 NNP N
) ) N
compares VBZ N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
tiotropium NN N
Respimat NNP N
5 CD N
μg NNP N
once RB N
daily RB N
( ( N
marketed VBN N
) ) N
and CC N
2.5 CD N
μg NNS N
once RB N
daily JJ N
( ( N
investigational JJ N
) ) N
with IN N
tiotropium NN N
HandiHaler NNP N
18 CD N
μ NNP N
once RB N
daily RB N
( ( N
marketed VBN N
) ) N
The DT N
hypotheses NNS N
to TO N
be VB N
tested VBN N
are VBP N
1 CD N
) ) N
that IN N
tiotropium NN N
Respimat NNP N
5 CD N
μg NNP N
once RB N
daily RB N
and CC N
Respimat NNP N
2.5 CD N
μg NNP N
once RB N
daily RB N
are VBP N
non-inferior JJ N
to TO N
HandiHaler NNP N
in IN N
terms NNS N
of IN N
all-cause NN N
mortality NN N
, , N
and CC N
2 CD N
) ) N
that IN N
tiotropium NN N
Respimat NNP N
5 CD N
μg NNP N
once RB N
daily RB N
is VBZ N
superior JJ N
to TO N
HandiHaler NNP N
in IN N
terms NNS N
of IN N
time NN N
to TO N
first JJ N
exacerbation NN N
A DT N
spirometry NN N
substudy NN N
evaluates VBZ N
the DT N
bronchodilator NN N
efficacy NN N
The DT N
trial NN N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double JJ N
dummy NN N
, , N
event-driven JJ N
, , N
parallel JJ N
group NN N
study NN N
Participants NNS N
can MD N
use VB N
any DT N
background NN N
treatment NN N
for IN N
COPD NNP N
except IN N
inhaled JJ N
anticholinergic JJ N
agents NNS N
The DT N
study NN N
encompasses VBZ N
a DT N
wide JJ N
range NN N
of IN N
COPD NNP N
patients NNS N
, , N
e.g FW N
patients NNS N
with IN N
stable JJ N
cardiac JJ N
diseases NNS N
including VBG N
arrhythmia NN N
can MD N
be VB N
included VBN N
Clinical JJ N
sites NNS N
are VBP N
international JJ N
and CC N
include VBP N
both DT N
primary JJ N
care NN N
as RB N
well RB N
as IN N
specialists NNS N
RESULTS NNP N
To TO N
date NN N
, , N
over IN N
17,000 CD N
participants NNS N
have VBP N
been VBN N
randomized VBN N
from IN N
over IN N
1200 CD N
sites NNS N
in IN N
50 CD N
countries NNS N
with IN N
an DT N
anticipated JJ N
treatment NN N
duration NN N
of IN N
2-3 JJ N
years NNS N
CONCLUSION NNP N
TIOSPIR NNP N
will MD N
provide VB N
precise JJ N
estimates NNS N
of IN N
the DT N
relative JJ N
safety NN N
and CC N
efficacy NN N
of IN N
the DT N
Respimat NNP N
and CC N
HandiHaler NNP N
formulations NNS N
of IN N
tiotropium NN N
, , N
assess JJ N
potential JJ N
dose-dependence NN N
of IN N
important JJ N
outcomes NNS N
and CC N
provide VB N
information NN N
on IN N
the DT N
clinical JJ N
epidemiology NN N
of IN N
COPD NNP N
in IN N
a DT N
large JJ N
international JJ N
patient NN N
cohort NN N
-DOCSTART- -X- O O 15778725

Prospective JJ N
randomised VBD N
trial NN N
of IN N
amifostine JJ N
cytoprotection NN N
in IN N
myeloma NN N
patients NNS N
undergoing VBG N
high-dose JJ N
melphalan NN N
conditioned VBN N
autologous JJ N
stem NN N
cell NN N
transplantation NN N
In IN N
this DT N
prospective JJ N
multicentre NN N
trial NN N
, , N
90 CD 3_p
patients NNS N
undergoing VBG N
autologous JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
( ( 4_p
ASCT NNP 4_p
) ) 4_p
were VBD N
randomised VBN N
to TO N
receive VB N
( ( N
n=43 NN N
) ) N
or CC N
not RB N
receive JJ N
( ( N
n=47 JJ N
) ) N
amifostine VBP N
910 CD N
mg/m NN N
( ( N
2 CD N
) ) N
prior RB N
to TO N
melphalan VB N
200 CD N
mg/m NN N
( ( N
2 CD N
) ) N
Patients NNS N
were VBD N
monitored VBN N
for IN N
regimen-related JJ N
toxicity NN N
, , N
engraftment NN N
, , N
supportive JJ N
care NN N
, , N
response NN N
and CC N
survival NN N
Both DT N
groups NNS N
underwent VBD N
ASCT NNP N
at IN N
a DT N
median NN N
of IN N
8 CD N
months NNS N
from IN N
diagnosis NN N
and CC N
were VBD N
matched VBN N
for IN N
disease NN N
characteristics NNS N
, , N
prior JJ N
therapy NN N
and CC N
pre-ASCT JJ N
disease NN N
responsiveness NN N
Amifostine NNP N
infusional JJ N
side-effects NNS N
were VBD N
frequent JJ N
, , N
occurring VBG N
in IN N
65 CD N
% NN N
of IN N
patients NNS N
, , N
but CC N
of IN N
mild JJ N
severity NN N
Amifostine NNP N
use NN N
was VBD N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
the DT N
median JJ N
grade NN N
of IN N
oral JJ N
mucositis NN N
( ( N
1 CD N
vs NN N
2 CD N
, , N
P=0.01 NNP N
) ) N
and CC N
the DT N
frequency NN N
of IN N
severe JJ N
( ( N
WHO NNP N
grades VBZ N
3 CD N
or CC N
4 CD N
) ) N
mucositis NN N
( ( N
12 CD N
vs RB N
33 CD N
% NN N
, , N
P=0.02 NNP N
) ) N
, , N
but CC N
no DT N
reduction NN N
in IN N
the DT N
requirement NN N
for IN N
parenteral JJ N
nutrition NN N
or CC N
analgesic JJ N
use NN N
Conversion NN N
to TO N
complete VB N
remission NN N
post-ASCT NN N
occurred VBD N
in IN N
30 CD N
and CC N
14 CD N
% NN N
of IN N
the DT N
amifostine NN N
and CC N
control NN N
groups NNS N
, , N
respectively RB N
( ( N
P=0.09 NNP N
) ) N
With IN N
a DT N
median JJ N
follow-up NN N
of IN N
35 CD N
months NNS N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
median JJ N
progression-free NN N
or CC N
overall JJ N
survival NN N
times NNS N
for IN N
the DT N
two CD N
groups NNS N
We PRP N
conclude VBP N
that IN N
amifostine NN N
can MD N
be VB N
safely RB N
administered VBN N
prior RB N
to TO N
high-dose JJ N
melphalan NN N
and CC N
significantly RB N
reduces VBZ N
the DT N
frequency NN N
and CC N
severity NN N
of IN N
therapy-induced JJ N
oral JJ N
mucositis NN N
-DOCSTART- -X- O O 24630545

A DT N
blinded VBN N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
assessing VBG N
conservative JJ N
management NN N
strategies NNS N
for IN N
frozen JJ 4_p
shoulder NN 4_p
BACKGROUND NNP N
There EX N
is VBZ N
little JJ N
evidence NN N
for IN N
the DT N
optimal JJ N
form NN N
of IN N
nonoperative JJ N
treatment NN N
in IN N
the DT N
management NN N
of IN N
frozen JJ 4_p
shoulder NN 4_p
This DT N
study NN N
assesses VBZ N
the DT N
efficacy NN N
of IN N
current JJ N
physiotherapy NN N
strategies NNS N
METHODS NNP N
All DT N
primary JJ N
care NN N
referrals NNS N
of IN N
frozen JJ 4_p
shoulder NN 4_p
to TO N
our PRP$ N
physiotherapy NN N
department NN N
were VBD N
included VBN N
during IN N
a DT N
12-month JJ N
period NN N
Of IN N
these DT N
referrals NNS N
, , N
17 CD N
% NN N
met VBD N
the DT N
inclusion NN N
criteria NNS N
for IN N
primary JJ 4_p
idiopathic JJ 4_p
frozen JJ 4_p
shoulder NN 4_p
The DT N
75 CD 3_p
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
: : N
group NN N
exercise NN N
class NN N
, , N
individual JJ N
physiotherapy NN N
, , N
and CC N
home NN N
exercises NNS N
alone RB N
A DT N
single JJ N
independent JJ N
physiotherapist NN N
, , N
who WP N
was VBD N
blinded VBN N
to TO N
the DT N
treatment NN N
groups NNS N
, , N
made VBD N
all DT N
assessments NNS N
Range NNP N
of IN N
motion NN N
, , N
Constant NNP N
score NN N
, , N
Oxford NNP N
Shoulder NNP N
Score NNP N
, , N
Short NNP N
Form NNP N
36 CD N
, , N
and CC N
Hospital NNP N
Anxiety NNP N
and CC N
Disability NNP N
Scale NNP N
( ( N
HADS NNP N
) ) N
outcome NN N
measures NNS N
were VBD N
performed VBN N
at IN N
baseline NN N
, , N
6 CD N
weeks NNS N
, , N
6 CD N
months NNS N
, , N
and CC N
1 CD N
year NN N
RESULTS VB N
The DT N
exercise NN N
class NN N
group NN N
improved VBD N
from IN N
a DT N
mean JJ N
Constant NNP N
score NN N
of IN N
39.8 CD N
at IN N
baseline NN N
to TO N
71.4 CD N
at IN N
6 CD N
weeks NNS N
and CC N
88.1 CD N
at IN N
1 CD N
year NN N
There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
shoulder NN N
symptoms NNS N
on IN N
Oxford NNP N
and CC N
Constant NNP N
scores NNS N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
This DT N
improvement NN N
was VBD N
greater JJR N
than IN N
with IN N
individual JJ N
physiotherapy NN N
or CC N
home NN N
exercises NNS N
alone RB N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
The DT N
improvement NN N
in IN N
range NN N
of IN N
motion NN N
was VBD N
significantly RB N
greater JJR N
in IN N
both DT N
physiotherapy NN N
groups NNS N
over IN N
home NN N
exercises NNS N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
HADS NNP N
scores VBZ N
significantly RB N
improved VBN N
during IN N
the DT N
course NN N
of IN N
treatment NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
The DT N
improvement NN N
in IN N
HADS NNP N
anxiety NN N
score NN N
was VBD N
significantly RB N
greater JJR N
in IN N
both DT N
physiotherapy JJ N
intervention NN N
groups NNS N
than IN N
in IN N
home NN N
exercises NNS N
alone RB N
CONCLUSIONS VB N
A DT N
hospital-based JJ N
exercise NN N
class NN N
can MD N
produce VB N
a DT N
rapid JJ N
recovery NN N
from IN N
a DT N
frozen JJ 4_p
shoulder NN 4_p
with IN N
a DT N
minimum JJ N
number NN N
of IN N
visits NNS N
to TO N
the DT N
hospital NN N
and CC N
is VBZ N
more RBR N
effective JJ N
than IN N
individual JJ N
physiotherapy NN N
or CC N
a DT N
home NN N
exercise NN N
program NN N
-DOCSTART- -X- O O 3156347

[ JJ N
Trial NNP N
of IN N
a DT N
calcium NN N
antagonist NN N
in IN N
dysmenorrhea NN 4_p
] NN 4_p
-DOCSTART- -X- O O 19833610

Long-term JJ N
results NNS N
after IN N
intracoronary JJ N
injection NN N
of IN N
autologous JJ N
mononuclear JJ N
bone NN N
marrow NN N
cells NNS N
in IN N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
: : 4_p
the DT N
ASTAMI NNP 4_p
randomised VBD N
, , N
controlled VBD N
study NN N
OBJECTIVE NNP N
To TO N
investigate VB N
long-term JJ N
safety NN N
and CC N
efficacy NN N
after IN N
intracoronary JJ N
injection NN N
of IN N
autologous JJ N
mononuclear JJ N
bone NN N
marrow NN N
cells NNS N
( ( N
mBMCs NN N
) ) N
in IN N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
( ( 4_p
AMI NNP 4_p
) ) 4_p
DESIGN NNP N
Randomised VBD N
, , N
controlled VBD N
trial NN N
SETTING NN N
Two CD N
university NN N
hospitals NNS N
in IN N
Oslo NNP N
, , N
Norway NNP N
PATIENTS NNP N
Patients NNPS N
from IN N
the DT N
Autologous NNP N
Stem NNP N
cell NN N
Transplantation NNP N
in IN N
Acute NNP 4_p
Myocardial NNP 4_p
Infarction NNP 4_p
( ( 4_p
ASTAMI NNP 4_p
) ) 4_p
study NN N
were VBD N
re-assessed JJ N
3 CD N
years NNS N
after IN N
inclusion NN N
INTERVENTIONS NNP N
100 CD 3_p
patients NNS N
with IN N
anterior JJ N
wall NN N
ST-elevation NNP 4_p
myocardial JJ 4_p
infarction NN 4_p
treated VBN N
with IN N
acute JJ N
percutaneous JJ 4_p
coronary JJ 4_p
intervention NN 4_p
( ( 4_p
PCI NNP 4_p
) ) 4_p
were VBD N
randomised VBN N
to TO N
receive VB N
intracoronary JJ N
injection NN N
of IN N
mBMCs NN N
( ( N
n JJ N
= NNP N
50 CD N
) ) N
or CC N
not RB N
( ( N
n JJ N
= NNP N
50 CD N
) ) N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Change NNP N
in IN N
left JJ N
ventricular NN N
( ( N
LV NNP N
) ) N
ejection NN N
fraction NN N
( ( N
primary JJ N
) ) N
Change NN N
in IN N
exercise NN N
capacity NN N
( ( N
peak JJ N
VO NNP N
( ( N
2 CD N
) ) N
) ) N
and CC N
quality NN N
of IN N
life NN N
( ( N
secondary JJ N
) ) N
Infarct NNP N
size NN N
( ( N
additional JJ N
aim NN N
) ) N
, , N
and CC N
safety NN N
RESULTS VB N
The DT N
rates NNS N
of IN N
adverse JJ N
clinical JJ N
events NNS N
in IN N
the DT N
groups NNS N
were VBD N
low JJ N
and CC N
equal JJ N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
change NN N
of IN N
global JJ N
LV NNP N
systolic JJ N
function NN N
by IN N
echocardiography NN N
or CC N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
MRI NNP N
) ) N
during IN N
the DT N
follow-up JJ N
On IN N
exercise NN N
testing NN N
, , N
the DT N
mBMC-treated JJ N
patients NNS N
had VBD N
larger JJR N
improvement NN N
in IN N
exercise NN N
time NN N
from IN N
2-3 JJ N
weeks NNS N
to TO N
3 CD N
years NNS N
( ( N
1.5 CD N
minutes NNS N
vs VBP N
0.6 CD N
minutes NNS N
, , N
p VBP N
= RB N
0.05 CD N
) ) N
, , N
but CC N
the DT N
change NN N
in IN N
peak NN N
oxygen NN N
consumption NN N
did VBD N
not RB N
differ VB N
( ( N
3.0 CD N
ml/kg/min NN N
vs NN N
3.1 CD N
ml/kg/min NN N
, , N
p NN N
= NNP N
0.75 CD N
) ) N
CONCLUSION VB N
The DT N
results NNS N
indicate VBP N
that IN N
intracoronary JJ N
mBMC NN N
treatment NN N
in IN N
AMI NNP N
is VBZ N
safe JJ N
in IN N
the DT N
long JJ N
term NN N
A DT N
small JJ N
improvement NN N
in IN N
exercise NN N
time NN N
in IN N
the DT N
mBMC NN N
group NN N
was VBD N
found VBN N
, , N
but CC N
no DT N
other JJ N
effects NNS N
of IN N
treatment NN N
could MD N
be VB N
identified VBN N
3 CD N
years NNS N
after IN N
cell NN N
therapy NN N
-DOCSTART- -X- O O 17884602

Continuous JJ N
event NN N
recorders NNS N
did VBD N
not RB N
affect VB N
anxiety NN N
or CC N
quality NN N
of IN N
life NN N
in IN N
patients NNS N
with IN N
palpitations NNS 4_p
OBJECTIVES NNP N
Palpitations NNPS N
can MD N
generate VB N
feelings NNS N
of IN N
anxiety NN N
and CC N
decrease NN N
quality NN N
of IN N
life NN N
( ( N
QoL NNP N
) ) N
due JJ N
to TO N
fear VB N
of IN N
a DT N
cardiac JJ N
abnormality NN N
Continuous JJ N
event NN N
recorders NNS N
( ( N
CERs NNP N
) ) N
have VBP N
proven VBN N
to TO N
be VB N
successful JJ N
in IN N
diagnosing VBG N
causes NNS N
of IN N
palpitations NNS N
but CC N
may MD N
affect VB N
patient NN N
QoL NNP N
and CC N
anxiety NN N
The DT N
aim NN N
is VBZ N
to TO N
determine VB N
anxiety NN N
and CC N
health-related JJ N
( ( N
HR NNP N
) ) N
-QoL NN N
and CC N
evaluate VB N
the DT N
burden NN N
of IN N
carrying VBG N
a DT N
CER NNP N
in IN N
general JJ N
practice NN N
populations NNS N
STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
Patients NNP N
( ( N
n=244 JJ 3_p
) ) N
participated VBD N
in IN N
a DT N
randomized JJ N
trial NN N
One CD N
group NN N
( ( N
n=127 RB N
) ) N
carried VBD N
a DT N
CER NNP N
during IN N
4 CD N
weeks NNS N
One CD 3_p
hundred CD 3_p
and CC 3_p
seventeen JJ 3_p
patients NNS N
formed VBD N
the DT N
usual JJ N
care NN N
( ( N
UC NNP N
) ) N
group NN N
State-Trait NNP N
Anxiety NNP N
Inventory NNP N
( ( N
STAI NNP N
) ) N
and CC N
the DT N
Short NNP N
Form-36 NNP N
( ( N
SF-36 NNP N
) ) N
were VBD N
administered VBN N
at IN N
study NN N
inclusion NN N
, , N
after IN N
1 CD N
, , N
6 CD N
months NNS N
RESULTS NNP N
At IN N
baseline NN N
, , N
patients NNS N
reported VBD N
greater JJR N
anxiety NN N
and CC N
lower JJR N
QoL NNP N
than IN N
healthy JJ N
populations NNS N
The DT N
CER NNP N
group NN N
had VBD N
three CD N
times NNS N
more RBR N
cardiac JJ N
diagnoses NNS N
than IN N
the DT N
UC NNP N
group NN N
No DT N
differences NNS N
were VBD N
found VBN N
between IN N
CER NNP N
group NN N
and CC N
UC NNP N
group NN N
at IN N
6 CD N
weeks NNS N
At IN N
6 CD N
months NNS N
, , N
the DT N
UC NNP N
group NN N
showed VBD N
QoL NNP N
improvement NN N
and CC N
less JJR N
anxiety NN N
compared VBN N
to TO N
the DT N
CER NNP N
group NN N
Type NN N
of IN N
diagnosis NN N
had VBD N
influence NN N
, , N
but CC N
did VBD N
not RB N
fully RB N
explain VB N
these DT N
differences NNS N
CONCLUSION VB N
A DT N
CER NNP N
does VBZ N
not RB N
negatively RB N
influence JJ N
anxiety NN N
or CC N
QoL NNP N
Better NNP N
outcomes VBZ N
in IN N
the DT N
UC NNP N
group NN N
might MD N
be VB N
attributed VBN N
to TO N
less JJR N
cardiac JJ N
diagnosis NN N
and CC N
more JJR N
emphasis NN N
on IN N
psychological JJ N
well-being NN N
-DOCSTART- -X- O O 19436938

Osteoporosis NN N
and CC N
gait NN N
and CC N
balance NN N
disturbances NNS N
in IN N
older JJR N
sarcopenic JJ N
obese JJ N
New NNP N
Zealanders NNP N
UNLABELLED NNP N
Bone NNP N
, , N
muscle NN N
, , N
and CC N
fat NN N
may MD N
affect VB N
gait NN N
and CC N
balance NN N
in IN N
older JJR N
adults NNS N
Osteoporosis NN 4_p
was VBD N
prevalent JJ N
in IN N
low JJ N
muscle NN N
mass NN N
participants NNS N
and CC N
related VBN N
to TO N
gait VB N
and CC N
balance VB N
deficits NNS N
Low JJ N
muscle NN N
combined VBN N
with IN N
high JJ N
fat JJ N
mass NN N
had VBD N
more RBR N
functional JJ N
deficits NNS N
and CC N
poorer JJR N
bone NN N
health NN N
, , N
which WDT N
has VBZ N
implications NNS N
for IN N
falls NNS N
risk NN N
and CC N
fractures NNS N
INTRODUCTION NNP N
Decreasing VBG N
bone NN N
density NN N
and CC N
muscle NN N
mass NN N
and CC N
increasing VBG N
fat JJ N
mass NN N
may MD N
act VB N
synergistically RB N
to TO N
affect VB N
gait NN N
and CC N
balance NN N
in IN N
older JJR N
adults NNS N
METHODS NNP N
One CD 3_p
hundred VBD 3_p
eighty-three JJ 3_p
older NN 3_p
adults NNS 3_p
( ( N
age NN N
72.7 CD N
+/- JJ N
6 CD N
years NNS N
, , N
range VBP N
56-93 JJ N
; : N
body NN N
mass NN N
index NN N
28.2 CD N
+/- JJ N
4.9 CD N
, , N
range VBP N
16.6-46.0 JJ N
) ) N
were VBD N
recruited VBN N
from IN N
a DT N
New NNP N
Zealand NNP N
falls VBZ N
prevention NN N
intervention NN N
trial NN N
Total JJ 4_p
and CC 4_p
appendicular JJ 4_p
skeletal JJ 4_p
muscle NN 4_p
mass NN 4_p
( ( N
ASM NNP 4_p
) ) N
, , N
percent JJ N
fat NN N
, , N
and CC N
bone NN N
mineralization NN N
were VBD N
assessed VBN N
by IN N
dual JJ N
energy NN N
X-ray JJ N
absorptiometry NN N
and CC N
used VBD N
to TO N
characterize VB N
normal JJ N
lean JJ N
( ( N
NL NNP N
, , N
n JJ N
= NNP N
51 CD N
) ) N
, , N
sarcopenic JJ N
( ( N
SS NNP N
, , N
n JJ N
= NNP N
18 CD N
) ) N
, , N
sarcopenic JJ N
obese NN N
( ( N
SO NNP N
, , N
n JJ N
= NNP N
29 CD N
) ) N
, , N
and CC N
obese JJ N
( ( N
OO NNP N
, , N
n JJ N
= NNP N
85 CD N
) ) N
phenotypes NNS N
Functional JJ N
performance NN N
was VBD N
assessed VBN N
using VBG N
timed VBN N
up RP N
and CC N
go VB N
, , N
chair NN N
stand NN N
, , N
single JJ N
leg NN N
stand NN N
, , N
and CC N
step VB N
test NN N
Regression NN N
models NNS N
were VBD N
adjusted VBN N
for IN N
age NN N
, , N
sex NN N
, , N
medications NNS N
, , N
and CC N
physical JJ N
activity NN N
RESULTS NNP N
Femoral NNP N
neck NN N
osteoporosis NN N
was VBD N
present JJ N
in IN N
22 CD N
% NN N
SS NNP N
, , N
17 CD N
% NN N
SO NNP N
, , N
12 CD N
% NN N
NL NNP N
, , N
and CC N
7 CD N
% NN N
OO NNP N
Femoral NNP N
neck NN N
osteoporosis NN N
with IN N
low JJ N
ASM NNP N
predicted VBD N
poor JJ N
chair NN N
stand VBP N
performance NN N
( ( N
beta JJ N
-3.3 NNP N
, , N
standard JJ N
error NN N
1.6 CD N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
SO RB N
scored JJ N
lowest NN N
on IN N
the DT N
chair NN N
stand NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
and CC N
step JJ N
test NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
Higher JJR N
ASM NNP N
predicted VBD N
faster RBR N
timed VBN N
up RP N
and CC N
go VB N
performance NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
CONCLUSIONS NNP N
Osteoporosis NNP N
was VBD N
prevalent VBN N
in IN N
low JJ N
ASM NNP N
groups NNS N
( ( N
SS NNP N
and CC N
SO NNP N
) ) N
and CC N
related VBN N
to TO N
gait VB N
and CC N
balance VB N
deficits NNS N
, , N
particularly RB N
in IN N
the DT N
SO NNP N
This DT N
has VBZ N
implications NNS N
for IN N
falls NNS N
risk NN N
, , N
fractures NNS N
, , N
and CC N
interventions NNS N
-DOCSTART- -X- O O 11013281

Treatment NN N
of IN N
brain NN N
metastases NNS N
of IN N
small-cell JJ N
lung NN N
cancer NN N
: : N
comparing NN N
teniposide NN N
and CC N
teniposide NN N
with IN N
whole-brain JJ N
radiotherapy NN N
-- : N
a DT N
phase NN N
III NNP N
study NN N
of IN N
the DT N
European JJ N
Organization NNP N
for IN N
the DT N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
Lung NNP N
Cancer NNP N
Cooperative NNP N
Group NNP N
PURPOSE NNP N
Approximately RB N
60 CD N
% NN N
of IN N
patients NNS 4_p
with IN 4_p
small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
( ( 4_p
SCLC NNP 4_p
) ) 4_p
develop VB N
brain NN N
metastases NNS N
Whole-brain JJ N
radiotherapy NN N
( ( N
WBRT NNP N
) ) N
gives VBZ N
symptomatic JJ N
improvement NN N
in IN N
more JJR N
than IN N
50 CD N
% NN N
of IN N
these DT N
patients NNS N
Because IN N
brain NN N
metastases NNS N
are VBP N
a DT N
sign NN N
of IN N
systemic JJ N
progression NN N
, , N
and CC N
chemotherapy NN N
was VBD N
found VBN N
to TO N
be VB N
effective JJ N
as IN N
well RB N
, , N
it PRP N
becomes VBZ N
questionable JJ N
whether IN N
WBRT NNP N
is VBZ N
the DT N
only JJ N
appropriate JJ N
therapy NN N
in IN N
this DT N
situation NN N
PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
phase NN N
III NNP N
study NN N
, , N
SCLC NNP N
patients NNS N
with IN N
brain NN N
metastases NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
teniposide NN N
with IN N
or CC N
without IN N
WBRT NNP N
Teniposide NNP N
120 CD N
mg/m NN N
( ( N
2 CD N
) ) N
was VBD N
given VBN N
intravenously RB N
three CD N
times NNS N
a DT N
week NN N
, , N
every DT N
3 CD N
weeks NNS N
WBRT NNP N
( ( N
10 CD N
fractions NNS N
of IN N
3 CD N
Gy NNP N
) ) N
had VBD N
to TO N
start VB N
within IN N
3 CD N
weeks NNS N
from IN N
the DT N
start NN N
of IN N
chemotherapy NN N
Response NNP N
was VBD N
measured VBN N
clinically RB N
and CC N
by IN N
computed JJ N
tomography NN N
of IN N
the DT N
brain NN N
RESULTS NNP N
One CD 4_p
hundred VBD 4_p
twenty NN 4_p
eligible JJ 4_p
patients NNS 4_p
were VBD N
randomized VBN N
A DT N
57 CD N
% NN N
response NN N
rate NN N
was VBD N
seen VBN N
in IN N
the DT N
combined-modality NN N
arm NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
43 CD N
% NN N
to TO N
69 CD N
% NN N
) ) N
, , N
and CC N
a DT N
22 CD N
% NN N
response NN N
rate NN N
was VBD N
seen VBN N
in IN N
the DT N
teniposide-alone JJ N
arm NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
12 CD N
% NN N
to TO N
34 CD N
% NN N
) ) N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
Time NN N
to TO N
progression NN N
in IN N
the DT N
brain NN N
was VBD N
longer RBR N
in IN N
the DT N
combined-modality NN N
group NN N
( ( N
P=.005 NNP N
) ) N
Clinical JJ N
response NN N
and CC N
response NN N
outside IN N
the DT N
brain NN N
were VBD N
not RB N
different JJ N
The DT N
median JJ N
survival NN N
time NN N
was VBD N
3.5 CD N
months NNS N
in IN N
the DT N
combined-modality NN N
arm NN N
and CC N
3.2 CD N
months NNS N
in IN N
the DT N
teniposide-alone JJ N
arm NN N
Overall JJ N
survival NN N
in IN N
both DT N
groups NNS N
was VBD N
not RB N
different JJ N
( ( N
P=.087 NNP N
) ) N
CONCLUSION NNP N
Adding NNP N
WBRT NNP N
to TO N
teniposide VB N
results NNS N
in IN N
a DT N
much RB N
higher JJR N
response NN N
rate NN N
of IN N
brain NN N
metastases NNS N
and CC N
in IN N
a DT N
longer JJR N
time NN N
to TO N
progression NN N
of IN N
brain NN N
metastases NNS N
than IN N
teniposide RB N
alone JJ N
Survival NNP N
was VBD N
poor JJ N
in IN N
both DT N
groups NNS N
and CC N
not RB N
significantly RB N
different JJ N
-DOCSTART- -X- O O 3306431

Alpha NNP N
interferon NN N
clinical JJ N
trial NN N
for IN N
multiple JJ 4_p
sclerosis NN 4_p
: : N
design NN N
considerations NNS N
The DT N
design NN N
and CC N
course NN N
of IN N
a DT N
placebo-controlled JJ N
alpha-2 JJ N
interferon NN N
trial NN N
in IN N
MS NNP 4_p
patients NNS N
are VBP N
described VBN N
No DT N
beneficial JJ N
effect NN N
of IN N
the DT N
interferon NN N
on IN N
the DT N
course NN N
of IN N
MS NNP N
could MD N
be VB N
shown VBN N
-DOCSTART- -X- O O 11208371

Effect NN N
of IN N
surgical JJ N
technique NN N
in IN N
subtotal JJ N
and CC N
bilateral JJ N
thyroidectomy NN N
on IN N
risk NN N
of IN N
postoperative JJ N
parathyroid NN N
insufficiency NN N
development NN N
-- : N
our PRP$ N
experience NN N
One CD N
of IN N
the DT N
postoperative JJ N
complications NNS N
after IN N
strumectomy NN N
is VBZ N
hypoparathyroidism NN N
Therefore RB N
, , N
the DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
surgical JJ N
technique NN N
on IN N
the DT N
development NN N
of IN N
parathyroid JJ 4_p
gland NN 4_p
insufficiency NN 4_p
in IN N
our PRP$ N
group NN N
of IN N
patients NNS N
Subtotal NNP N
, , N
bilateral JJ N
strumectomies NNS N
were VBD N
performed VBN N
according VBG N
to TO N
Rothmund NNP N
's POS N
suggestions NNS N
Randomized NNP N
controlled VBD N
trial NN N
was VBD N
performed VBN N
in IN N
two CD N
groups NNS N
In IN N
the DT N
first JJ N
group NN N
of IN N
19 CD 3_p
patients NNS 3_p
, , N
main JJ N
trunk NN N
of IN N
the DT N
inferior JJ N
thyroid JJ N
artery NN N
was VBD N
ligated VBN N
and CC N
in IN N
the DT N
second JJ N
one CD N
consisting NN N
of IN N
18 CD 3_p
patients NNS 3_p
, , N
only RB N
the DT N
branches NNS N
of IN N
this DT N
artery NN N
were VBD N
ligated VBN N
Total JJ N
calcium NN N
and CC N
PTH NNP N
levels NNS N
were VBD N
evaluated VBN N
pre- JJ N
and CC N
postoperatively RB N
Based VBN N
on IN N
the DT N
biochemical JJ N
and CC N
clinical JJ N
data NNS N
, , N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
development NN N
of IN N
postoperative JJ N
hypoparathyroidism NN N
in IN N
relation NN N
to TO N
performed VB N
surgical JJ N
techniques NNS N
were VBD N
observed VBN N
-DOCSTART- -X- O O 22513516

Efficacy NN N
and CC N
safety NN N
of IN N
10 CD N
% NN N
HES NNP N
130/0.4 CD N
versus NN N
10 CD N
% NN N
HES NNP N
200/0.5 CD N
for IN N
plasma NN N
volume NN N
expansion NN N
in IN N
cardiac JJ N
surgery NN N
patients NNS N
AIM NNP N
Hydroxyethyl NNP N
starch NN N
( ( N
HES NNP N
) ) N
solutions NNS N
are VBP N
frequently RB N
used VBN N
for IN N
perioperative JJ N
volume NN N
replacement NN N
Whereas NNP N
older JJR N
HES NNP N
specimen NNS N
tended VBD N
to TO N
accumulate VB N
in IN N
the DT N
plasma NN N
and CC N
to TO N
cause VB N
negative JJ N
effects NNS N
on IN N
hemostasis NN N
, , N
more RBR N
recent JJ N
products NNS N
, , N
e.g. NN N
, , N
HES NNP N
130/0.4 CD N
, , N
are VBP N
characterised VBN N
by IN N
improved JJ N
pharmacological JJ N
properties NNS N
The DT N
present JJ N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
10 CD N
% NN N
HES NNP N
130/0.4 CD N
and CC N
10 CD N
% NN N
HES NNP N
200/0.5 CD N
METHODS NN N
In IN N
this DT N
post-hoc JJ N
analysis NN N
of IN N
a DT N
prospective JJ N
, , N
randomised JJ N
, , N
double-blind JJ N
, , N
multi-center JJ N
therapeutic JJ N
equivalence NN N
trial NN N
, , N
76 CD N
patients NNS N
undergoing JJ N
elective JJ N
on-pump JJ N
cardiac NN N
surgery NN N
received VBD N
perioperative JJ N
volume NN N
replacement NN N
using VBG N
either CC N
10 CD N
% NN N
HES NNP N
130/0.4 CD N
( ( N
N.=37 NNP N
) ) N
or CC N
10 CD N
% NN N
HES NNP N
200/0.5 CD N
( ( N
N.=39 NNP N
) ) N
up RB N
to TO N
a DT N
maximum JJ N
dose NN N
of IN N
20 CD N
mL JJ N
kg-1 NN N
RESULTS NNP N
Equivalent NNP N
volumes NNS N
of IN N
investigational JJ N
medication NN N
were VBD N
infused VBN N
until IN N
24 CD N
hours NNS N
after IN N
the DT N
first JJ N
administration NN N
( ( N
1577 CD N
vs. IN N
1540 CD N
mL NN N
; : N
treatment NN N
difference NN N
37 CD N
[ JJ N
-150 NN N
; : N
223 CD N
] NNP N
mL NN N
; : N
P NNP N
< VBZ N
0.0001 CD N
for IN N
equivalence NN N
) ) N
Whereas NNP N
standard JJ N
laboratory NN N
tests NNS N
of IN N
coagulation NN N
were VBD N
comparable JJ N
between IN N
groups NNS N
, , N
von FW N
Willebrand NNP N
factor NN N
activity NN N
on IN N
the DT N
first JJ N
postoperative JJ N
morning NN N
tended VBD N
to TO N
be VB N
higher JJR N
following VBG N
treatment NN N
with IN N
10 CD N
% NN N
HES NNP N
130/0.4 CD N
as IN N
compared VBN N
to TO N
10 CD N
% NN N
HES NNP N
200/0.5 CD N
( ( N
P=0.025 NNP N
) ) N
with IN N
this DT N
difference NN N
being VBG N
statistically RB N
significant JJ N
only RB N
in IN N
the DT N
per-protocol JJ N
analysis NN N
( ( N
P=0.02 NNP N
) ) N
Treatment JJ N
groups NNS N
were VBD N
comparable JJ N
concerning VBG N
other JJ N
safety NN N
parameters NNS N
and CC N
the DT N
incidence NN N
of IN N
adverse JJ N
drug NN N
reactions NNS N
In IN N
particular JJ N
, , N
renal JJ N
function NN N
was VBD N
well RB N
preserved VBN N
in IN N
both DT N
groups NNS N
CONCLUSION NNP N
Ten CD N
percent NN N
HES NNP N
130/0.4 CD N
was VBD N
equally RB N
effective JJ N
and CC N
safe JJ N
as IN N
compared VBN N
to TO N
10 CD N
% NN N
HES NNP N
200/0.5 CD N
for IN N
volume NN N
therapy NN N
in IN N
patients NNS N
undergoing VBG N
cardiovascular JJ N
surgery NN N
Postoperative JJ N
coagulation NN N
and CC N
renal JJ N
function NN N
, , N
as IN N
measured VBN N
by IN N
standard JJ N
laboratory NN N
tests NNS N
, , N
were VBD N
similar JJ N
among IN N
groups NNS N
-DOCSTART- -X- O O 16571852

Web-based JJ N
weight NN N
management NN N
programs NNS N
in IN N
an DT N
integrated JJ N
health NN N
care NN N
setting NN N
: : N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
OBJECTIVE UH N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
a DT N
Web-based JJ N
tailored JJ N
behavioral JJ N
weight JJ N
management NN N
program NN N
compared VBN N
with IN N
Web-based JJ N
information-only JJ N
weight NN N
management NN N
materials NNS N
RESEARCH NNP N
METHODS NNP N
AND NNP N
PROCEDURES NNP N
Participants NNP N
, , N
2862 CD 3_p
eligible JJ N
overweight NN 4_p
and CC 4_p
obese JJ 4_p
( ( 4_p
BMI NNP 4_p
= VBZ 4_p
27 CD 4_p
to TO 4_p
40 CD 4_p
kg/m2 NNS 4_p
) ) 4_p
members NNS N
from IN N
four CD N
regions NNS N
of IN N
Kaiser NNP N
Permanente NNP N
's POS N
integrated JJ N
health NN N
care NN N
delivery NN N
system NN N
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
a DT N
tailored VBN N
expert NN N
system NN N
or CC N
information-only JJ N
Web-based JJ N
weight NN N
management NN N
materials NNS N
Weight NNP N
change NN N
and CC N
program NN N
satisfaction NN N
were VBD N
assessed VBN N
by IN N
self-report NN N
through IN N
an DT N
Internet-based JJ N
survey NN N
at IN N
3- JJ N
and CC N
6-month JJ N
follow-up JJ N
periods NNS N
RESULTS NNP N
Significantly NNP N
greater JJR N
weight JJ N
loss NN N
at IN N
follow-up NN N
was VBD N
found VBN N
among IN N
participants NNS N
assigned VBN N
to TO N
the DT N
tailored VBN N
expert NN N
system NN N
than IN N
among IN N
those DT N
assigned VBN N
to TO N
the DT N
information-only JJ N
condition NN N
Subjects NNS N
in IN N
the DT N
tailored VBN N
expert NN N
system NN N
lost VBD N
a DT N
mean NN N
of IN N
3 CD N
+/- JJ N
0.3 CD N
% NN N
of IN N
their PRP$ N
baseline NN N
weight NN N
, , N
whereas JJ N
subjects NNS N
in IN N
the DT N
information-only JJ N
condition NN N
lost VBD N
a DT N
mean NN N
of IN N
1.2 CD N
+/- JJ N
0.4 CD N
% NN N
( ( N
p JJ N
< NNP N
0.0004 CD N
) ) N
Participants NNS N
were VBD N
also RB N
more RBR N
likely JJ N
to TO N
report VB N
that IN N
the DT N
tailored VBN N
expert NN N
system NN N
was VBD N
personally RB N
relevant JJ N
, , N
helpful JJ N
, , N
and CC N
easy JJ N
to TO N
understand VB N
Notably RB N
, , N
36 CD N
% NN N
of IN N
enrollees NNS N
were VBD N
African-American JJ N
, , N
with IN N
enrollment NN N
rates NNS N
higher RBR N
than IN N
the DT N
general JJ N
proportion NN N
of IN N
African JJ N
Americans NNPS N
in IN N
any DT N
of IN N
the DT N
study NN N
regions NNS N
DISCUSSION NNP N
The DT N
results NNS N
of IN N
this DT N
large JJ N
, , N
randomized VBD N
control NN N
trial NN N
show VBP N
the DT N
potential JJ N
benefit NN N
of IN N
the DT N
Web-based JJ N
tailored VBN N
expert NN N
system NN N
for IN N
weight JJ N
management NN N
compared VBN N
with IN N
a DT N
Web-based JJ N
information-only JJ N
weight JJ N
management NN N
program NN N
-DOCSTART- -X- O O 24435893

Early JJ N
psychosocial JJ N
intervention NN N
in IN N
Alzheimer NNP 4_p
's POS 4_p
disease NN 4_p
: : 4_p
cost NN N
utility NN N
evaluation NN N
alongside IN N
the DT N
Danish NNP N
Alzheimer NNP N
's POS N
Intervention NNP N
Study NNP N
( ( N
DAISY NNP N
) ) N
OBJECTIVE UH N
To TO N
assess VB N
the DT N
cost NN N
utility NN N
of IN N
early JJ N
psychosocial JJ N
intervention NN N
for IN N
patients NNS 4_p
with IN 4_p
Alzheimer NNP 4_p
's POS 4_p
disease NN 4_p
and CC 4_p
their PRP$ 4_p
primary JJ 4_p
caregivers NNS 4_p
DESIGN NN N
Cost NNP N
utility NN N
evaluation NN N
alongside IN N
a DT N
multicentre NN N
, , N
randomised VBD N
controlled VBN N
trial NN N
with IN N
3 CD N
years NNS N
of IN N
follow-up NN N
SETTING NN N
Primary NNP N
care NN N
and CC N
memory NN N
clinics NNS N
in IN N
five CD N
Danish JJ N
districts NNS N
PARTICIPANTS VB N
330 CD 3_p
community-dwelling JJ N
patients NNS N
and CC N
their PRP$ N
primary JJ N
caregivers NNS N
INTERVENTION NNP N
Psychosocial NNP N
counselling NN N
and CC N
support NN N
lasting VBG N
8-12 JJ N
months NNS N
after IN N
diagnosis NN N
and CC N
follow-up NN N
at IN N
3 CD N
, , N
6 CD N
, , N
12 CD N
and CC N
36 CD N
months NNS N
in IN N
the DT N
intervention NN N
group NN N
or CC N
follow-up NN N
only RB N
in IN N
the DT N
control NN N
group NN N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
cost NN N
of IN N
additional JJ N
quality-adjusted JJ N
life NN N
years NNS N
( ( N
QALYs NNP N
) ) N
Costs NNS N
were VBD N
measured VBN N
from IN N
a DT N
societal JJ N
perspective NN N
, , N
including VBG N
the DT N
costs NNS N
of IN N
healthcare NN N
, , N
social JJ N
care NN N
, , N
informal JJ N
care NN N
and CC N
production NN N
loss NN N
QALYs NNP N
were VBD N
estimated VBN N
separately RB N
for IN N
the DT N
patient NN N
and CC N
the DT N
caregiver NN N
before IN N
aggregation NN N
for IN N
the DT N
main JJ N
analysis NN N
RESULTS NNP N
None NN N
of IN N
the DT N
observed JJ N
cost NN N
and CC N
QALY NNP N
measures NNS N
were VBD N
significantly RB N
different JJ N
between IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
, , N
although IN N
a DT N
tendency NN N
was VBD N
noted VBN N
for IN N
psychosocial JJ N
care NN N
leading VBG N
to TO N
cost NN N
increases NNS N
with IN N
informal JJ N
care NN N
that WDT N
was VBD N
not RB N
outweighed VBN N
by IN N
the DT N
tendency NN N
for IN N
cost NN N
savings NNS N
with IN N
formal JJ N
care NN N
The DT N
probability NN N
of IN N
psychosocial JJ N
intervention NN N
being VBG N
cost-effective JJ N
did VBD N
not RB N
exceed VB N
36 CD N
% NN N
for IN N
any DT N
threshold JJ N
value NN N
The DT N
alternative JJ N
scenario NN N
analysis NN N
showed VBD N
that IN N
the DT N
probability NN N
of IN N
cost-effectiveness NN N
increased VBN N
over IN N
the DT N
range NN N
of IN N
threshold NN N
values NNS N
used VBN N
if IN N
the DT N
cost NN N
perspective NN N
was VBD N
restricted VBN N
to TO N
formal JJ N
healthcare NN N
CONCLUSIONS VB N
A NNP N
multifaceted JJ N
, , N
psychosocial JJ N
intervention NN N
programme NN N
was VBD N
found VBN N
unlikely RB N
to TO N
be VB N
cost-effective JJ N
from IN N
a DT N
societal JJ N
perspective NN N
The DT N
recommendation NN N
for IN N
practice NN N
in IN N
settings NNS N
that WDT N
are VBP N
similar JJ N
to TO N
the DT N
Danish JJ N
setting NN N
is VBZ N
to TO N
provide VB N
follow-up JJ N
with IN N
referral JJ N
to TO N
available JJ N
local JJ N
support NN N
programmes NNS N
when WRB N
needed VBN N
, , N
and CC N
to TO N
restrict VB N
large JJ N
multifaceted VBN N
intervention NN N
programmes NNS N
to TO N
patients NNS N
and CC N
caregivers NNS N
with IN N
special JJ N
needs NNS N
until IN N
further JJ N
evidence NN N
for IN N
cost-effectiveness JJ N
emerges NNS N
TRIAL NNP N
REGISTRATION NNP N
The DT N
study NN N
was VBD N
registered VBN N
in IN N
the DT N
Clinical JJ N
Trial NNP N
Database NNP N
as IN N
ISRCTN74848736 NNP N
-DOCSTART- -X- O O 18080171

Risperidone NNP N
versus NN N
haloperidol NN N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
AD NNP N
: : N
a DT N
randomized NN N
, , N
controlled VBN N
, , N
double-blind JJ N
trial NN N
OBJECTIVE CC N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
safety NN N
, , N
efficacy NN N
and CC N
tolerability NN N
of IN N
risperidone NN N
with IN N
haloperidol NN N
in IN N
the DT N
treatment NN N
of IN N
Autistic JJ N
Disorder NNP N
( ( N
AD NNP N
) ) N
METHOD NNP N
This DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
double-blind NN N
, , N
prospective JJ N
, , N
for IN N
a DT N
12-week JJ N
period NN N
A DT N
total NN N
of IN N
30 CD N
subjects NNS N
, , N
between IN N
the DT N
ages NNS N
of IN N
8 CD N
and CC N
18 CD N
with IN N
AD NNP N
based VBN N
on IN N
DSM NNP N
IV NNP N
criteria NNS N
, , N
were VBD N
included VBN N
in IN N
the DT N
study NN N
Behavioral NNP N
Rating VBG N
Scales NNS N
were VBD N
performed VBN N
by IN N
the DT N
investigators NNS N
and CC N
the DT N
parents NNS N
Safety NNP N
assessment NN N
included VBD N
vital JJ N
signs NNS N
, , N
electrocardiogram NN N
, , N
electroencephalogram NN N
, , N
adverse JJ N
events NNS N
, , N
laboratory NN N
tests NNS N
, , N
extrapyramidal NN N
symptoms NNS N
and CC N
the DT N
side NN N
effects NNS N
Both DT N
treatments NNS N
were VBD N
applied VBN N
in IN N
a DT N
once RB N
daily JJ N
dosage NN N
regimen NNS N
of IN N
0.01-0.08 JJ N
mg/kg/day NN N
RESULTS VB N
The DT N
reduction NN N
from IN N
baseline NN N
in IN N
Ritvo-Freeman NNP N
Real NNP N
Life NNP N
Rating NNP N
Scale NNP N
( ( N
RF-RLRS NNP N
) ) N
, , N
sensory JJ N
motor NN N
( ( N
subscale JJ N
I PRP N
) ) N
and CC N
language NN N
( ( N
subscale JJ N
V NNP N
) ) N
scores NNS N
were VBD N
significant JJ N
in IN N
risperidone NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
Compared VBN N
to TO N
haloperidol VB N
, , N
risperidone NN N
led VBD N
to TO N
a DT N
significantly RB N
greater JJR N
reduction NN N
in IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
( ( N
ABC NNP N
) ) N
and CC N
Turgay NNP N
DSM-IV NNP N
Pervasive NNP N
Developmental NNP N
Disorder NNP N
( ( N
PDD NNP N
) ) N
scale NN N
scores NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
and CC N
P NNP N
< NNP N
0.01 CD N
) ) N
There EX N
was VBD N
a DT N
greater JJR N
increase NN N
of IN N
prolactin NN N
in IN N
the DT N
risperidone NN N
group NN N
, , N
while IN N
alanine JJ N
amino NN N
transferase NN N
( ( N
ALT NNP N
) ) N
had VBD N
further RBR N
increased VBN N
in IN N
the DT N
haloperidol NN N
group NN N
Sensory NNP N
motor NN N
behaviors NNS N
( ( N
subscale JJ N
I PRP N
) ) N
and CC N
language NN N
at IN N
the DT N
end NN N
of IN N
the DT N
12th CD N
week NN N
, , N
RF-RLRS NNP N
sensory NN N
motor NN N
and CC N
language NN N
subscale JJ N
scores NNS N
decreased VBN N
in IN N
the DT N
risperidone NN N
group NN N
further RBR N
than IN N
the DT N
other JJ N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
CONCLUSIONS NNP N
Risperidone NNP N
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
haloperidol NN N
in IN N
the DT N
treatment NN N
of IN N
behavioral JJ N
symptoms NNS N
, , N
impulsivity NN N
, , N
language NN N
skills NNS N
, , N
and CC N
impaired JJ N
social JJ N
relations NNS N
in IN N
children NNS N
with IN N
AD NNP N
These DT N
results NNS N
demonstrated VBD N
that IN N
both DT N
drugs NNS N
were VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
treatment NN N
of IN N
AD NNP N
-DOCSTART- -X- O O 16939848

Preventing VBG N
paclitaxel-induced JJ N
peripheral JJ N
neuropathy NN N
: : N
a DT N
phase NN N
II NNP N
trial NN N
of IN N
vitamin NN N
E NNP N
supplementation NN N
A DT N
randomized JJ N
, , N
controlled VBD N
trial NN N
was VBD N
performed VBN N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
vitamin NN N
E NNP N
supplementation NN N
for IN N
prophylaxis NN N
against IN N
paclitaxel-induced JJ N
peripheral JJ N
neuropathy NN N
( ( N
PIPN NNP N
) ) N
Thirty-two JJ 3_p
patients NNS N
undergoing VBG N
six CD N
courses NNS N
of IN N
paclitaxel-based JJ N
chemotherapy NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
chemotherapy NN N
with IN N
vitamin NN N
E NNP N
( ( N
300 CD N
mg NN N
twice RB N
a DT N
day NN N
, , N
Group NNP N
I PRP N
) ) N
or CC N
chemotherapy NN N
without IN N
vitamin NN N
E NNP N
supplementation NN N
( ( N
Group NNP N
II NNP N
) ) N
A DT N
detailed JJ N
neurological JJ N
examination NN N
and CC N
electrophysiological JJ N
study NN N
was VBD N
performed VBN N
during IN N
and CC N
3 CD N
months NNS N
after IN N
chemotherapy NN N
The DT N
severity NN N
of IN N
PIPN NNP N
was VBD N
summarized VBN N
by IN N
means NNS N
of IN N
a DT N
modified JJ N
Peripheral NNP N
Neuropathy NNP N
( ( N
PNP NNP N
) ) N
score NN N
The DT N
incidence NN N
of IN N
neurotoxicity NN N
differed VBN N
significantly RB N
between IN N
groups NNS N
, , N
occurring VBG N
in IN N
3/16 CD N
( ( N
18.7 CD N
% NN N
) ) N
patients NNS N
assigned VBN N
to TO N
the DT N
vitamin NN N
E NNP N
supplementation NN N
group NN N
and CC N
in IN N
10/16 CD N
( ( N
62.5 CD N
% NN N
) ) N
controls VBZ N
( ( N
P=0.03 NNP N
) ) N
The DT N
relative JJ N
risk NN N
( ( N
RR NNP N
) ) N
of IN N
developing VBG N
PIPN NNP N
was VBD N
significantly RB N
higher JJR N
in IN N
controls NNS N
than IN N
in IN N
vitamin JJ N
E NNP N
group NN N
patients NNS N
( ( N
RR=0.3 NNP N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
=0.1-0.9 NN N
) ) N
Mean JJ N
PNP NNP N
scores NNS N
were VBD N
2.25+/-5.1 CD N
( ( N
range VB N
0-15 NNP N
) ) N
for IN N
patients NNS N
in IN N
Group NNP N
I PRP N
and CC N
11+/-11.63 JJ N
( ( N
range VB N
0-32 NN N
) ) N
for IN N
those DT N
in IN N
Group NNP N
II NNP N
( ( N
P=0.01 NNP N
) ) N
Vitamin NNP N
E NNP N
supplementation NN N
was VBD N
well RB N
tolerated VBN N
and CC N
showed VBD N
an DT N
excellent JJ N
safety NN N
profile NN N
This DT N
study NN N
shows VBZ N
that IN N
vitamin NN N
E NNP N
effectively RB N
and CC N
safely RB N
protects VBZ N
patients NNS N
with IN N
cancer NN 4_p
from IN N
the DT N
occurrence NN N
of IN N
paclitaxel-induced JJ N
peripheral JJ N
nerve NN N
damage NN N
A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
is VBZ N
needed VBN N
to TO N
confirm VB N
these DT N
results NNS N
-DOCSTART- -X- O O 21429223

A DT N
randomised JJ N
non-inferiority NN N
controlled VBD N
trial NN N
of IN N
a DT N
single JJ N
versus NN N
a DT N
four CD N
intradermal NN N
sterile JJ N
water NN N
injection NN N
technique NN N
for IN N
relief NN N
of IN N
continuous JJ N
lower JJR N
back RB N
pain NN N
during IN N
labour NN N
BACKGROUND NNP N
Almost NNP N
one CD N
third NN N
of IN N
women NNS 2_p
suffer VBP N
continuous JJ N
lower JJR N
back RB N
pain NN N
during IN N
labour NN N
Evidence NN N
from IN N
three CD N
systematic JJ N
reviews NNS N
demonstrates VBZ N
that IN N
sterile JJ N
water NN N
injections NNS N
( ( N
SWI NNP N
) ) N
provide VBP N
statistically RB N
and CC N
clinically RB N
significant JJ N
pain NN N
relief NN N
in IN N
women NNS N
experiencing VBG N
continuous JJ N
lower JJR N
back RB N
pain NN N
during IN N
labour NN N
The DT N
most RBS N
effective JJ N
technique NN N
to TO N
administer VB N
SWI NNP N
is VBZ N
yet RB N
to TO N
be VB N
determined VBN N
Therefore RB N
, , N
the DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
determine VB N
if IN N
the DT N
single JJ N
injection NN N
SWI NNP N
technique NN N
is VBZ N
no DT N
less RBR N
effective JJ N
than IN N
the DT N
routinely RB N
used VBN N
four CD N
injection NN N
SWI NNP N
method NN N
in IN N
reducing VBG N
continuous JJ N
lower JJR N
back RB N
pain NN N
during IN N
labour NN N
METHODS/DESIGN NNP N
The DT N
trial NN N
protocol NN N
was VBD N
developed VBN N
in IN N
consultation NN N
with IN N
an DT N
interdisciplinary JJ N
team NN N
of IN N
clinical JJ N
researchers NNS N
We PRP N
aim VBP N
to TO N
recruit VB N
319 CD 3_p
women NNS 2_p
presenting VBG N
at IN N
term NN N
, , N
seeking VBG N
analgesia NN 4_p
for IN 4_p
continuous JJ 4_p
severe JJ 4_p
lower JJR 4_p
back RB 4_p
pain NN 4_p
during IN 4_p
labour NN 4_p
Participants NNS N
will MD N
be VB N
recruited VBN N
from IN N
two CD N
major JJ N
maternity NN N
hospitals NNS N
in IN N
Australia NNP N
Randomised VBN N
participants NNS N
are VBP N
allocated VBN N
to TO N
receive VB N
a DT N
four CD N
or CC N
single JJ N
intradermal JJ N
needle JJ N
SWI NNP N
technique NN N
The DT N
primary JJ N
outcome NN N
is VBZ N
the DT N
change NN N
in IN N
self-reported JJ N
pain NN N
measured VBN N
by IN N
visual JJ N
analogue NN N
scale NN N
at IN N
baseline NN N
and CC N
thirty NN N
minutes NNS N
post VBP N
intervention NN N
Secondary JJ N
outcomes NNS N
include VBP N
VAS NNP N
change NN N
scores NNS N
at IN N
10 CD N
, , N
60 CD N
, , N
90 CD N
and CC N
120 CD N
min NN N
, , N
analgesia NN N
use NN N
, , N
mode NN N
of IN N
birth NN N
and CC N
maternal JJ N
satisfaction NN N
STATISTICAL JJ N
ANALYSIS NNP N
Sample NNP N
size NN N
was VBD N
calculated VBN N
to TO N
achieve VB N
90 CD N
% NN N
power NN N
at IN N
an DT N
alpha NN N
of IN N
0.025 CD N
to TO N
detect VB N
a DT N
non-inferiority JJ N
margin NN N
of IN N
≤1 NNP N
cm NN N
on IN N
the DT N
VAS NNP N
, , N
using VBG N
a DT N
one-sided JJ N
, , N
two-sample JJ N
t-test NN N
Baseline NNP N
demographic JJ N
and CC N
clinical JJ N
characteristics NNS N
will MD N
be VB N
analysed VBN N
for IN N
comparability NN N
between IN N
groups NNS N
Differences NNS N
in IN N
primary JJ N
( ( N
VAS NNP N
pain RB N
score RB N
) ) N
and CC N
secondary JJ N
outcomes NNS N
between IN N
groups NNS N
will MD N
be VB N
analysed VBN N
by IN N
intention NN N
to TO N
treat VB N
and CC N
per IN N
protocol NN N
analysis NN N
using VBG N
Student NNP N
's POS N
t-test NN N
and CC N
ANOVA NNP N
CONCLUSION NNP N
This DT N
study NN N
will MD N
determine VB N
if IN N
a DT N
single JJ N
intradermal JJ N
SWI NNP N
technique NN N
is VBZ N
no DT N
less RBR N
effective JJ N
than IN N
the DT N
routinely RB N
used VBN N
four CD N
injection NN N
technique NN N
for IN N
lower JJR N
back NN N
pain NN N
during IN N
labour NN N
The DT N
findings NNS N
will MD N
allow VB N
midwives NNS N
to TO N
offer VB N
women NNS N
requesting VBG N
SWI NNP N
during IN N
labour PRP$ N
an DT N
evidence-based JJ N
alternative NN N
technique NN N
more RBR N
easily RB N
administered VBN N
by IN N
staff NN N
and CC N
accepted VBN N
by IN N
labouring VBG N
women NNS N
TRIAL NNP N
REGISTRATION NNP N
ACTRN12609000964213 NNP N
-DOCSTART- -X- O O 22146934

Brief JJ N
report NN N
: : N
effect NN N
of IN N
a DT N
focused JJ N
imitation NN N
intervention NN N
on IN N
social JJ N
functioning NN N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
Imitation NNP N
is VBZ N
an DT N
early JJ N
skill NN N
thought VBN N
to TO N
play VB N
a DT N
role NN N
in IN N
social JJ N
development NN N
, , N
leading VBG N
some DT N
to TO N
suggest VB N
that IN N
teaching VBG N
imitation NN N
to TO N
children NNS 1_p
with IN N
autism NN 4_p
should MD N
lead VB N
to TO N
improvements NNS N
in IN N
social JJ N
functioning NN N
This DT N
study NN N
used VBD N
a DT N
randomized JJ N
controlled VBN N
trial NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
focused JJ N
imitation NN N
intervention NN N
on IN N
initiation NN N
of IN N
joint JJ N
attention NN N
and CC N
social-emotional JJ N
functioning NN N
in IN N
27 CD 3_p
young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
Results NNS N
indicated VBD N
the DT N
treatment NN N
group NN N
made VBD N
significantly RB N
more RBR N
gains NNS N
in IN N
joint JJ N
attention NN N
initiations NNS N
at IN N
post-treatment JJ N
and CC N
follow-up JJ N
and CC N
social-emotional JJ N
functioning NN N
at IN N
follow-up NN N
than IN N
the DT N
control NN N
group NN N
Although IN N
gains NNS N
in IN N
social JJ N
functioning NN N
were VBD N
associated VBN N
with IN N
treatment NN N
, , N
a DT N
mediation NN N
analysis NN N
did VBD N
not RB N
support VB N
imitation NN N
as IN N
the DT N
mechanism NN N
of IN N
action NN N
These DT N
findings NNS N
suggest VBP N
the DT N
intervention NN N
improves VBZ N
social JJ N
functioning NN N
in IN N
children NNS 1_p
with IN N
ASD NNP 4_p
-DOCSTART- -X- O O 7006663

Report NN N
on IN N
the DT N
second JJ N
myelomatosis NN N
trial NN N
after IN N
five CD N
years NNS N
of IN N
follow-up NN N
Medical NNP N
Research NNP N
Council NNP N
's POS N
Working NNP N
Party NNP N
on IN N
Leukaemia NNP 4_p
in IN N
Adults NNP 1_p
Three CD 3_p
hundred VBD 3_p
and CC 3_p
seventy-two JJ 3_p
patients NNS N
were VBD N
randomized VBN N
between IN N
3 CD N
regimens NNS N
of IN N
chemotherapy NN N
: : N
cyclophosphamide NN N
, , N
intermittent NN N
melphalan NN N
, , N
and CC N
melphalan NN N
with IN N
prednisone NN N
, , N
and CC N
were VBD N
followed VBN N
up RP N
to TO N
death NN N
or CC N
for IN N
at IN N
least JJS N
5 CD N
years NNS N
There EX N
was VBD N
no DT N
difference NN N
in IN N
survival NN N
between IN N
the DT N
treatments NNS N
, , N
either RB N
overall JJ N
or CC N
in IN N
any DT N
subgroup NN N
of IN N
patients NNS N
Therefore RB N
, , N
the DT N
choice NN N
among IN N
these DT N
3 CD N
treatments NNS N
should MD N
be VB N
guided VBN N
by IN N
the DT N
patient NN N
's POS N
comfort NN N
and CC N
convenience NN N
The DT N
most RBS N
important JJ N
prognostic JJ N
feature NN N
at IN N
presentation NN N
was VBD N
the DT N
quality NN N
of IN N
renal JJ N
function NN N
It PRP N
was VBD N
possible JJ N
to TO N
define VB N
good JJ 4_p
, , N
intermediate JJ 4_p
and CC N
poor JJ 4_p
renal-function NN N
groups NNS N
which WDT N
were VBD N
highly RB N
correlated VBN N
with IN N
prognosis NN N
( ( N
X2 NNP N
for IN N
trend NN N
= NNP N
62.6 CD N
) ) N
The DT N
haemoglobin JJ N
level NN N
at IN N
presentation NN N
was VBD N
strongly RB N
correlated VBN N
with IN N
prognosis NN N
among IN N
patients NNS N
in IN N
the DT N
good JJ 4_p
renal-function NN 4_p
group NN N
Among IN N
107 CD 3_p
patients NNS N
who WP N
presented VBD N
with IN N
good JJ 4_p
renal JJ 4_p
function NN 4_p
and CC N
with IN N
haemoglobin NNS N
above IN N
100 CD N
g/l NN N
, , N
the DT N
5-year JJ N
survival NN N
was VBD N
43 CD N
% NN N
Other JJ N
prognostic JJ N
features NNS N
were VBD N
much RB N
less RBR N
important JJ N
when WRB N
account NN N
was VBD N
taken VBN N
of IN N
renal JJ N
function NN N
and CC N
haemoglobin JJ N
level NN N
-DOCSTART- -X- O O 7410734

Scaling VBG N
clinical JJ N
judgments NNS N
of IN N
symptom JJ N
pathology NN N
by IN N
means NNS N
of IN N
the DT N
psychophysiological JJ N
method NN N
of IN N
magnitude NN N
estimation NN N
Summing VBG N
scores NNS N
across IN N
heterogeneous JJ N
symptom NN N
items NNS N
without IN N
consideration NN N
of IN N
their PRP$ N
differing JJ N
psychopathological JJ N
significance NN N
has VBZ N
been VBN N
criticized VBN N
as IN N
producing VBG N
an DT N
inadequate JJ N
picture NN N
of IN N
an DT N
individual NN N
's POS N
clinical JJ N
status NN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
derive JJ N
symptom JJ N
item NN N
weights NNS N
representing VBG N
clinically RB N
judged VBN N
seriousness NN N
of IN N
each DT N
symptom NN N
through IN N
the DT N
application NN N
of IN N
Steven NNP N
's POS N
psychophysical JJ N
method NN N
of IN N
magnitude NN N
estimation NN N
A DT N
nationwide JJ N
sample NN N
of IN N
129 CD N
clinicians NNS N
rated VBD N
the DT N
pathological JJ N
significance NN N
of IN N
221 CD N
symptom JJ N
items NNS N
in IN N
a DT N
design NN N
such JJ N
that IN N
every DT N
rater NN N
rated VBD N
121 CD N
items NNS N
, , N
21 CD N
of IN N
which WDT N
were VBD N
rated VBN N
by IN N
all DT N
raters NNS N
and CC N
100 CD N
of IN N
which WDT N
were VBD N
rated VBN N
only RB N
by IN N
the DT N
A NNP N
or CC N
B NNP N
subgroup NN N
to TO N
which WDT N
each DT N
rater NN N
was VBD N
randomly RB N
assigned VBN N
Each DT N
item NN N
was VBD N
rated VBN N
as IN N
to TO N
the DT N
seriousness NN N
of IN N
the DT N
pathology NN N
it PRP N
would MD N
represent VB N
if IN N
manifested VBN N
by IN N
either CC N
a DT N
boy NN N
child NN N
, , N
girl JJ N
child NN N
, , N
boy JJ N
adolescent NN N
, , N
or CC N
girl JJ N
adolescent NN N
, , N
with IN N
one-fourth NN N
of IN N
the DT N
raters NNS N
assigned VBD N
to TO N
each DT N
condition NN N
The DT N
results NNS N
of IN N
211 CD N
two-way JJ N
analyses NNS N
of IN N
variance NN N
revealed VBD N
that IN N
age NN N
and CC N
age NN N
and CC N
sex NN N
in IN N
interaction NN N
, , N
but CC N
not RB N
sex VB N
alone RB N
, , N
significantly RB N
influenced VBD N
the DT N
clinical JJ N
ratings NNS N
The DT N
resulting VBG N
magnitude JJ N
estimation NN N
ratings NNS N
of IN N
symptom JJ N
pathology NN N
ranged VBD N
from IN N
1.0 CD N
to TO N
9.9 CD N
They PRP N
were VBD N
demonstrated VBN N
to TO N
have VB N
satisfactoy VBN N
reliability NN N
and CC N
convergent NN N
validity NN N
and CC N
to TO N
have VB N
the DT N
psychophysical JJ N
characteristics NNS N
of IN N
a DT N
prothetic JJ N
continuum NN N
-DOCSTART- -X- O O 15358853

Peripheral JJ N
arterial JJ N
disease NN N
: : N
therapeutic JJ N
confidence NN N
of IN N
CT NNP N
versus NNP N
digital JJ N
subtraction NN N
angiography NN N
and CC N
effects NNS N
on IN N
additional JJ N
imaging NN N
recommendations NNS N
PURPOSE NNP N
To TO N
compare VB N
multi-detector JJ N
row NN N
computed VBN N
tomographic JJ N
( ( N
CT NNP N
) ) N
angiography NN N
and CC N
digital JJ N
subtraction NN N
angiography NN N
( ( N
DSA NNP N
) ) N
prior RB N
to TO N
revascularization NN N
in IN N
patients NNS 4_p
with IN 4_p
symptomatic JJ 4_p
peripheral JJ 4_p
arterial JJ 4_p
disease NN 4_p
for IN N
the DT N
purpose NN N
of IN N
assessing VBG N
recommendations NNS N
for IN N
additional JJ N
imaging NN N
and CC N
physician JJ N
confidence NN N
ratings NNS N
for IN N
chosen NN N
therapy NN N
MATERIALS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
73 CD 3_p
patients NNS 3_p
were VBD 4_p
assigned VBN 4_p
to TO 4_p
CT NNP 4_p
angiography NN 4_p
, , 4_p
and CC 4_p
72 CD 3_p
were VBD 4_p
assigned VBN 4_p
to TO 4_p
DSA NNP 4_p
Physician JJ N
confidence NN N
in IN N
the DT N
treatment NN N
decision NN N
was VBD N
measured VBN N
as IN N
a DT N
continuous JJ N
outcome NN N
on IN N
a DT N
scale NN N
of IN N
0-10 NNP N
( ( N
uncertain JJ N
to TO N
certain JJ N
) ) N
and CC N
as IN N
a DT N
dichotomous JJ N
outcome NN N
( ( N
further JJ N
imaging NN N
recommended VBD N
, , N
yes UH N
or CC N
no DT N
) ) N
Mean JJ N
confidence NN N
scores NNS N
and CC N
additional JJ N
imaging NN N
recommendations NNS N
were VBD N
compared VBN N
between IN N
CT NNP N
and CC N
DSA NNP N
groups NNS N
in IN N
an DT N
intention-to-diagnose-and-treat JJ N
analysis NN N
To TO N
detect VB N
trends NNS N
in IN N
confidence NN N
, , N
confidence NN N
scores NNS N
were VBD N
plotted VBN N
over IN N
time NN N
, , N
and CC N
multiple JJ N
linear JJ N
regression NN N
analysis NN N
was VBD N
performed VBN N
To TO N
detect VB N
trends NNS N
in IN N
additional JJ N
imaging NN N
recommendations NNS N
, , N
logistic JJ N
regression NN N
analysis NN N
was VBD N
used VBN N
Data NNS N
from IN N
eligible JJ N
nonrandomized JJ N
patients NNS N
were VBD N
analyzed VBN N
separately RB N
RESULTS NNP N
No NNP N
statistically RB N
significant JJ N
difference NN N
in IN N
baseline NN N
characteristics NNS N
between IN N
randomized VBN N
groups NNS N
was VBD N
found VBN N
CT NNP N
had VBD N
a DT N
lower JJR N
confidence NN N
score JJR N
than IN N
did VBD N
DSA NNP N
( ( N
7.2 CD N
vs NN N
8.2 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
Further JJ N
imaging NN N
was VBD N
recommended VBN N
more RBR N
often RB N
after IN N
CT NNP N
( ( N
25 CD N
of IN N
71 CD N
patients NNS N
, , N
35 CD N
% NN N
) ) N
than IN N
after IN N
DSA NNP N
( ( N
nine CD N
of IN N
66 CD N
patients NNS N
, , N
14 CD N
% NN N
; : N
P NNP N
= NNP N
.003 NNP N
) ) N
Analysis NN N
of IN N
trends NNS N
demonstrated VBN N
increasing VBG N
( ( N
but CC N
not RB N
statistically RB N
significant JJ N
) ) N
confidence NN N
in IN N
CT NNP N
and CC N
stable JJ N
confidence NN N
in IN N
DSA NNP N
No NNP N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
baseline NN N
characteristics NNS N
between IN N
randomized VBN N
and CC N
nonrandomized JJ N
patients NNS N
Among IN N
nonrandomized JJ N
patients NNS N
, , N
no DT N
significant JJ N
difference NN N
in IN N
mean JJ N
confidence NN N
score NN N
( ( N
8.2 CD N
vs NN N
8.3 CD N
, , N
P NNP N
= NNP N
.26 NNP N
) ) N
was VBD N
found VBN N
between IN N
CT NNP N
( ( N
n JJ N
= NNP N
24 CD N
) ) N
and CC N
DSA NNP N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
CONCLUSION NN N
With IN N
CT NNP N
angiography NN N
, , N
physician JJ N
confidence NN N
decreases NNS N
with IN N
an DT N
associated JJ N
increase NN N
in IN N
additional JJ N
imaging NN N
prior RB N
to TO N
revascularization NN N
in IN N
patients NNS N
with IN N
symptomatic JJ N
peripheral JJ N
arterial JJ N
disease NN N
Given VBN N
that IN N
CT NNP N
is VBZ N
less RBR N
invasive JJ N
than IN N
DSA NNP N
, , N
results NNS N
suggest VBP N
that IN N
CT NNP N
may MD N
replace VB N
DSA NNP N
in IN N
selected VBN N
cases NNS N
-DOCSTART- -X- O O 12680863

A DT N
single JJ N
nasal NN N
allergen NN N
challenge NN N
increases NNS N
induced VBD N
sputum JJ N
inflammatory JJ N
markers NNS N
in IN N
non-asthmatic JJ 4_p
subjects NNS 4_p
with IN 4_p
seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
: : 4_p
correlation NN N
with IN N
plasma JJ N
interleukin-5 JJ N
BACKGROUND NNP N
Seasonal NNP N
allergic JJ N
rhinitis NN N
( ( N
SAR NNP N
) ) N
is VBZ N
a DT N
risk NN 4_p
factor NN 4_p
for IN 4_p
asthma NN 4_p
in IN 4_p
affected JJ 4_p
individuals NNS 4_p
Nasal NNP N
allergic JJ N
inflammation NN N
enhances VBZ N
bone-marrow JJ N
eosinophil NN N
production NN N
, , N
mainly RB N
via IN N
IL-5 NNP N
, , N
and CC N
rhinitis NN N
patients NNS N
have VBP N
increased VBN N
airway JJ N
inflammation NN N
during IN N
the DT N
pollen NN N
season NN N
OBJECTIVE UH N
To TO N
assess VB N
the DT N
impact NN N
of IN N
nasal NN N
allergy NN N
on IN N
sputum NN N
inflammatory NN N
markers NNS N
METHODS NNP N
In IN N
an DT N
open-labelled JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
cross-over NN N
study NN N
with IN N
16 CD 3_p
non-asthmatic JJ N
SAR NNP N
patients NNS N
( ( N
median JJ N
age NN N
25 CD N
years NNS N
, , N
56 CD 3_p
% NN 3_p
males NNS N
) ) N
, , N
the DT N
effect NN N
of IN N
a DT N
single JJ N
nasal NN N
allergen NN N
challenge NN N
performed VBD N
out IN N
of IN N
season NN N
on IN N
induced JJ N
sputum NN N
inflammatory NN N
parameters NNS N
was VBD N
evaluated VBN N
SAR JJ N
patients NNS N
were VBD N
identified VBN N
by IN N
history NN N
, , N
skin-prick JJ N
test NN N
and CC N
specific JJ N
IgE NNP N
All DT N
patients NNS N
had VBD N
normal JJ N
lung JJ N
function/bronchial JJ N
hyper-responsiveness NN N
out IN N
of IN N
season NN N
and CC N
a DT N
negative JJ N
asthma/wheezing NN N
history NN N
Sputum NNP N
cells NNS N
and CC N
supernatant JJ N
levels NNS N
of IN N
ECP NNP N
, , N
sICAM NN N
, , N
IL-5 NNP N
and CC N
IL-10 NNP N
, , N
and CC N
plasma NN N
levels NNS N
of IN N
IL-5 NNP N
and CC N
ECP NNP N
, , N
were VBD N
measured VBN N
before IN N
and CC N
24 CD N
h NN N
after IN N
nasal JJ N
allergen NN N
challenge NN N
After IN N
a DT N
washout JJ N
period NN N
of IN N
at IN N
least JJS N
4 CD N
weeks NNS N
, , N
the DT N
procedure NN N
was VBD N
repeated VBN N
with IN N
placebo NN N
challenge NN N
( ( N
diluent NN N
) ) N
RESULTS NNP N
Nasal NNP N
allergen VBZ N
challenge NN N
led VBD N
to TO N
an DT N
increase NN N
in IN N
sputum JJ N
ECP NNP N
( ( N
pre JJ N
= $ N
60 CD N
+/- JJ N
12 CD N
, , N
post NN N
= VBD N
212 CD N
+/- JJ N
63 CD N
micro NN N
g/L NN N
, , N
P NNP N
= VBZ N
0.02 CD N
vs. FW N
placebo NN N
) ) N
, , N
and CC N
sICAM NN N
( ( N
4.8 CD N
+/- JJ N
2.7 CD N
to TO N
6.5 CD N
+/- JJ N
2.9 CD N
ng/mL NN N
, , N
P NNP N
= VBZ N
0.02 CD N
vs. FW N
placebo NN N
) ) N
, , N
whereas JJ N
IL-10 NNP N
decreased VBD N
after IN N
provocation NN N
( ( N
44 CD N
+/- JJ N
11 CD N
to TO N
29 CD N
+/- JJ N
6 CD N
pg/mL NN N
, , N
P NNP N
= VBZ N
0.06 CD N
vs. FW N
placebo NN N
) ) N
Sputum NNP N
IL-5 NNP N
was VBD N
undetectable JJ N
in IN N
all DT N
patients NNS N
The DT N
absolute JJ N
number NN N
of IN N
blood NN N
and CC N
sputum NN N
eosinophils NNS N
did VBD N
not RB N
change VB N
significantly RB N
after IN N
allergen NN N
or CC N
placebo NN N
challenge NN N
( ( N
P NNP N
> NNP N
0.07 CD N
, , N
both DT N
comparisons NNS N
) ) N
Plasma NNP N
levels NNS N
of IN N
IL-5 NNP N
increased VBD N
after IN N
allergen NN N
challenge NN N
( ( N
8.7 CD N
+/- JJ N
2.9 CD N
to TO N
14.5 CD N
+/- JJ N
3.9 CD N
pg/mL NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
and CC N
the DT N
increase NN N
in IN N
plasma JJ N
IL-5 NNP N
was VBD N
positively RB N
correlated VBN N
with IN N
the DT N
rise NN N
in IN N
sputum NN N
ECP NNP N
in IN N
a DT N
subgroup NN N
of IN N
'responders NNS N
' POS N
( ( N
n JJ N
= NN N
12 CD N
, , N
r NN N
= VBD N
0.71 CD N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
CONCLUSIONS VB N
A DT N
single JJ N
nasal NN N
allergen NN N
challenge NN N
in IN N
SAR NNP N
patients NNS N
increased VBD N
markers NNS N
of IN N
allergic JJ N
inflammation NN N
in IN N
the DT N
lower JJR N
respiratory NN N
tract NN N
, , N
possibly RB N
via IN N
pronounced JJ N
activation NN N
of IN N
inflammatory NN N
cells NNS N
through IN N
circulating VBG N
immediate-type JJ N
reaction NN N
cytokines NNS N
like IN N
IL-5 NNP N
These DT N
findings NNS N
may MD N
provide VB N
additional JJ N
explanatory NN N
data NNS N
for IN N
the DT N
high JJ N
susceptibility NN N
of IN N
SAR NNP N
patients NNS N
to TO N
incident VB N
asthma NN N
